PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Bosch-Amate, X; Iranzo, P; Ivars, M; Galy, JMM; Espana, A				Bosch-Amate, Xavier; Iranzo, Pilar; Ivars, Marta; Mascaro Galy, Jose Manuel; Espana, Agustin			Anti-Desmocollin Autoantibodies in Autoimmune Blistering Diseases	FRONTIERS IN IMMUNOLOGY			English	Review						autoimmune blistering disease; pemphigus; desmocollin; desmoglein; systematic review; antibody	SUBCORNEAL PUSTULAR DERMATOSIS; IMMUNOGLOBULIN-G AUTOANTIBODIES; IGA PARANEOPLASTIC PEMPHIGUS; ATYPICAL PEMPHIGUS; DESMOGLEIN 3; BULLOUS DERMATOSIS; IGG/IGA PEMPHIGUS; IMMUNOBULLOUS DISEASE; CLINICAL-FEATURES; IGA/IGG PEMPHIGUS	The presence of anti-desmocollin (Dsc) antibodies is rarely described in autoimmune blistering diseases patients. Moreover, several clinical phenotypes of pemphigus may be associated with these antibodies. In this review we analyze clinicopathological, immunologic and outcome features of anti-Dsc autoimmune blistering diseases patients, to improve their diagnosis and management. We conducted a systematic search of PubMed and Embase (1990-present) for studies reporting cases of autoimmune blistering diseases with anti-Dsc antibodies. We classified the selected patients as patients with exclusively anti-Dsc autoantibodies, and patients with anti-Dsc and other autoantibodies. Of 93 cases with anti-Dsc autoantibodies included, 38 (41%) had exclusively these antibodies. Only 18% of patients presented with the typical clinicopathological phenotype of pemphigus vulgaris or pemphigus foliaceous. Mucosal involvement was seen in approximately half of the patients. Up to 18% of cases were associated with neoplasms. Acantholysis was described in 54% of cases with histopathological information. Treatments and outcomes vary in the different clinical phenotypes. The presence of anti-Dsc antibodies must be suspected mainly in those patients with either atypical pemphigus, in special with clinical pustules, or in cases showing intraepithelial or dermal neutrophilic/eosinophilic infiltrate on histological examination and dual pattern by direct immunofluorescence examination.	[Bosch-Amate, Xavier; Iranzo, Pilar; Mascaro Galy, Jose Manuel] Univ Barcelona, Hosp Clin Barcelona, Dematol Dept, Barcelona, Spain; [Ivars, Marta] Univ Navarra, Univ Clin Navarra, Dermatol Dept, Madrid, Spain; [Espana, Agustin] Univ Navarra, Univ Clin Navarra, Dermatol Dept, Pamplona, Spain	University of Barcelona; Hospital Clinic de Barcelona; University of Navarra; University of Navarra	Espana, A (corresponding author), Univ Navarra, Univ Clin Navarra, Dermatol Dept, Pamplona, Spain.	aespana@unav.es		Mascaro, Jose-Manuel/0000-0001-9327-2555; IVARS, MARTA/0000-0003-2500-3200				Ansai O, 2017, J DERMATOL, V44, P104, DOI 10.1111/1346-8138.13451; Anstey A, 2015, BRIT J DERMATOL, V173, pE23, DOI 10.1111/bjd.14162; Arai R, 2013, EUR J DERMATOL, V23, P362, DOI 10.1684/ejd.2013.2046; Asahina A, 2013, BRIT J DERMATOL, V168, P224, DOI 10.1111/j.1365-2133.2012.11127.x; Bolling MC, 2007, BRIT J DERMATOL, V157, P168, DOI 10.1111/j.1365-2133.2007.07920.x; Botella Estrada R., 2001, ACTAS DERMO SIFILIOG, V92, P283, DOI [10.1016/S0001-7310(01)76485-X, DOI 10.1016/S0001-7310(01)76485-X]; Bruckner AL, 2005, PEDIATR DERMATOL, V22, P321, DOI 10.1111/j.1525-1470.2005.22408.x; Carayannopoulos L, 1996, J EXP MED, V183, P1579, DOI 10.1084/jem.183.4.1579; Chernyavsky A, 2019, J BIOL CHEM, V294, P4520, DOI 10.1074/jbc.RA118.006743; CHORZELSKI TP, 1994, J AM ACAD DERMATOL, V31, P351, DOI 10.1016/S0190-9622(94)70171-7; &DDAG;Bosch-Amate X., IN PRESS; de Oliveira JP, 2003, J DERMATOL, V30, P886, DOI 10.1111/j.1346-8138.2003.tb00343.x; Didona D.T., 2021, J INVEST DERMATOL; Didona D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00779; Duker I, 2009, ARCH DERMATOL, V145, P1159, DOI 10.1001/archdermatol.2009.224; Endo Y, 2010, EUR J DERMATOL, V20, P620, DOI 10.1684/ejd.2010.1020; Gallo E, 2014, CLIN EXP DERMATOL, V39, P323, DOI 10.1111/ced.12296; Geller S, 2014, BRIT J DERMATOL, V171, P650, DOI 10.1111/bjd.12940; Geller S, 2016, PEDIATR DERMATOL, V33, pE10, DOI 10.1111/pde.12729; Gooptu C, 1999, BRIT J DERMATOL, V141, P882, DOI 10.1046/j.1365-2133.1999.03162.x; Gruss C, 2000, J AM ACAD DERMATOL, V43, P923, DOI 10.1067/mjd.2000.104002; Hashimoto Koji, 1994, Journal of Dermatological Science, V7, P100, DOI 10.1016/0923-1811(94)90083-3; Hashimoto T, 2002, CLIN EXP DERMATOL, V27, P636, DOI 10.1046/j.1365-2230.2002.01061.x; HASHIMOTO T, 1995, J INVEST DERMATOL, V104, P541, DOI 10.1111/1523-1747.ep12606050; Hashimoto T, 1997, J INVEST DERMATOL, V109, P127, DOI 10.1111/1523-1747.ep12319025; Hashimoto T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00994; Hatano Y, 2012, EUR J DERMATOL, V22, P560, DOI 10.1684/ejd.2012.1762; Heng A, 2006, BRIT J DERMATOL, V154, P1018, DOI 10.1111/j.1365-2133.2006.07226.x; Hong WJ, 2016, ANN DERMATOL, V28, P102, DOI 10.5021/ad.2016.28.1.102; Hosoda S, 2012, ACTA DERM-VENEREOL, V92, P164, DOI 10.2340/00015555-1258; Inoue-Nishimoto T, 2016, J EUR ACAD DERMATOL, V30, P1229, DOI 10.1111/jdv.13158; Iranzo P, 2019, AUSTRALAS J DERMATOL, V60, pE217, DOI 10.1111/ajd.12991; Ishii N, 2015, BRIT J DERMATOL, V173, P59, DOI 10.1111/bjd.13711; Ivars M, 2020, BRIT J DERMATOL, V182, P1194, DOI 10.1111/bjd.18382; Kalantari-Dehaghi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057587; Kamiya K, 2016, J DERMATOL, V43, P429, DOI 10.1111/1346-8138.13086; Kim J, 2013, J AM ACAD DERMATOL, V69, pE25, DOI 10.1016/j.jaad.2012.12.967; Kiritsi D, 2017, JAMA DERMATOL, V153, P921, DOI 10.1001/jamadermatol.2017.0901; Koga H, 2017, J DERMATOL, V44, P189, DOI 10.1111/1346-8138.13677; Kopp Tamara, 2006, J Dtsch Dermatol Ges, V4, P1045, DOI 10.1111/j.1610-0387.2006.06166.x; Kozlowska A, 2003, J AM ACAD DERMATOL, V48, P117, DOI 10.1067/mjd.2003.23; Kridin K, 2020, J AM ACAD DERMATOL, V82, P1386, DOI 10.1016/j.jaad.2019.11.059; Kurzen H, 2006, AUTOIMMUNITY, V39, P549, DOI 10.1080/08916930600971554; Leventhal JS, 2017, BRIT J DERMATOL, V177, pE226, DOI 10.1111/bjd.15954; Lim JM, 2017, ANN DERMATOL, V29, P219, DOI 10.5021/ad.2017.29.2.219; Lotti R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01387; Makino T, 2015, EUR J DERMATOL, V25, P619, DOI 10.1684/ejd.2015.2646; Mao XM, 2010, AM J PATHOL, V177, P2724, DOI 10.2353/ajpath.2010.100483; Matsukura S, 2014, INT J DERMATOL, V53, P1023, DOI 10.1111/j.1365-4632.2012.05725.x; Matsuyama K, 2018, CLIN EXP DERMATOL, V43, P917, DOI 10.1111/ced.13670; Mindorf S, 2017, EXP DERMATOL, V26, P1267, DOI 10.1111/exd.13409; Montagnon CM, 2021, J AM ACAD DERMATOL, V84, P1507, DOI 10.1016/j.jaad.2020.11.075; Muller R, 2009, CLIN EXP DERMATOL, V34, P898, DOI 10.1111/j.1365-2230.2009.03241.x; Nakamura Y, 2014, BRIT J DERMATOL, V171, P1588, DOI 10.1111/bjd.13088; Nguyen VT, 2001, ARCH DERMATOL, V137, P193; Ohata C, 2013, BRIT J DERMATOL, V168, P879, DOI 10.1111/bjd.12019; Ohata C, 2013, JAMA DERMATOL, V149, P502, DOI 10.1001/jamadermatol.2013.1916; On HR, 2015, BRIT J DERMATOL, V172, P1144, DOI 10.1111/bjd.13419; Otsuka Y, 2016, J DERMATOL, V43, P944, DOI 10.1111/1346-8138.13341; Preisz K, 2004, BRIT J DERMATOL, V150, P1018, DOI 10.1111/j.1365-2133.2004.05978.x; Rafei D, 2011, AM J PATHOL, V178, P718, DOI 10.1016/j.ajpath.2010.10.016; Ruiz-Genao DP, 2002, BRIT J DERMATOL, V147, P1040, DOI 10.1046/j.1365-2133.2002.504815.x; Saruta H, 2013, JAMA DERMATOL, V149, P1209, DOI 10.1001/jamadermatol.2013.5244; Shimokata-Isoe M, 2020, EUR J DERMATOL, V30, P417, DOI 10.1684/ejd.2020.3819; Solimani F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01413; Spindler V, 2018, J INVEST DERMATOL, V138, P32, DOI 10.1016/j.jid.2017.06.022; Sprecher E, 2015, BRIT J DERMATOL, V173, P1363, DOI 10.1111/bjd.14277; Taintor AR, 2007, J AM ACAD DERMATOL, V56, pS73, DOI 10.1016/j.jaad.2006.11.023; Tani N, 2018, EUR J DERMATOL, V28, P232, DOI 10.1684/ejd.2017.3202; Tateishi Chiharu, 2010, J Am Acad Dermatol, V63, pe8, DOI 10.1016/j.jaad.2009.09.016; Tay YE, 2018, CLIN EXP DERMATOL, V43, P360, DOI 10.1111/ced.13355; Toosi S, 2016, INT J DERMATOL, V55, pE184, DOI 10.1111/ijd.13025; Tsuchisaka A, 2015, BRIT J DERMATOL, V173, P268, DOI 10.1111/bjd.13617; Uchiyama R, 2014, ACTA DERM-VENEREOL, V94, P737, DOI 10.2340/00015555-1836; Ueda A, 2013, BRIT J DERMATOL, V169, P719, DOI 10.1111/bjd.12398; Ueda A, 2013, CLIN EXP DERMATOL, V38, P370, DOI 10.1111/ced.12050; WALLACH D, 1982, ANN DERMATOL VENER, V109, P959; Yamaguchi Y, 2018, BRIT J DERMATOL, V178, P294, DOI 10.1111/bjd.15834; Yashiro M, 2014, ACTA DERM-VENEREOL, V94, P235, DOI 10.2340/00015555-1660; Yasuda H, 2000, BRIT J DERMATOL, V143, P144, DOI 10.1046/j.1365-2133.2000.03604.x	80	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 10	2021	12								740820	10.3389/fimmu.2021.740820	http://dx.doi.org/10.3389/fimmu.2021.740820			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UU5GX	34567003	Green Published, gold			2022-12-18	WOS:000698829700001
J	Brunetta, E; Ramponi, G; Folci, M; De Santis, M; Morenghi, E; Vanni, E; Bredi, E; Furlan, R; Angelini, C; Selmi, C				Brunetta, Enrico; Ramponi, Giacomo; Folci, Marco; De Santis, Maria; Morenghi, Emanuela; Vanni, Elena; Bredi, Elena; Furlan, Raffaello; Angelini, Claudio; Selmi, Carlo			Serum ANCA and Overall Mortality: A 10-Year Retrospective Cohort Study on 1,024 Italian Subjects	FRONTIERS IN IMMUNOLOGY			English	Article						ANCA; retrospective; cohort; vasculitis; rheumatoid arthritis	ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; RHEUMATOID-ARTHRITIS; CLINICAL-SIGNIFICANCE; MYELOPEROXIDASE; AUTOANTIBODIES; NEUTROPHILS; PREVALENCE; VASCULITIS; GLOMERULONEPHRITIS; PROTEINASE-3	Background Antineutrophil cytoplasmic antibodies (ANCA) are primarily involved in the pathogenesis of ANCA-associated vasculitides (AAV). However, ANCA may also be present in healthy subjects and in patients with autoimmune disorders different from AAV. We hypothesized that serum ANCA are associated with a worse prognosis in disorders other than AAV. Objective We investigated the association between the overall survival and the presence of serum ANCA in 1,024 Italian subjects with various testing indications in a 10-year interval. Methods In this retrospective cohort study, a population of 6,285 patients (many of whom were subsequently excluded due to our criteria) who tested for ANCA at a single center in 10 years was considered, and life status and comorbidities of subjects were collected. We compared the overall survival of ANCA-positive and ANCA-negative patients by means of Kaplan-Meier curves, while a multivariable adjusted Cox regression was used to evaluate the association between the ANCA status and the outcome (death) in terms of hazard ratios (HR) with 95% confidence intervals (CI). Results The positivity of perinuclear ANCA (pANCA) increased significantly mortality (HR, 1.60; 95% CI, 1.10-2.32), while cytoplasmic ANCA (cANCA) positivity failed to show a significant association (HR, 1.43; 95% CI, 0.77-2.68). The increased mortality rate was observed for both pANCA and cANCA in patients suffering from rheumatic disorders. No association was found between mortality and anti-MPO (HR, 0.63; 95% CI, 0.20-2.00) or anti-PR3 (HR, 0.98; 95% CI, 0.24-3.96) after adjusting for confounders. Conclusions Serum pANCA and cANCA are independent negative prognostic factors in patients with concurrent autoimmune diseases.	[Brunetta, Enrico; Ramponi, Giacomo; Folci, Marco; Morenghi, Emanuela; Vanni, Elena; Bredi, Elena; Furlan, Raffaello; Angelini, Claudio] IRCCS Humanitas Res Hosp, Rozzano, Italy; [Brunetta, Enrico; Folci, Marco; De Santis, Maria; Morenghi, Emanuela; Vanni, Elena; Furlan, Raffaello; Angelini, Claudio; Selmi, Carlo] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, Italy; [De Santis, Maria; Selmi, Carlo] IRCCS Humanitas Res Hosp, Unit Rheumatol & Clin Immunol, Rozzano, Italy	Humanitas University	Brunetta, E (corresponding author), IRCCS Humanitas Res Hosp, Rozzano, Italy.; Brunetta, E (corresponding author), Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, Italy.	enrico.brunetta@humanitas.it	Selmi, Carlo/ABG-4899-2021	Selmi, Carlo/0000-0002-0323-0376; ANGELINI, CLAUDIO/0000-0002-4814-8712; Ramponi, Giacomo/0000-0001-6395-8994; Brunetta, Enrico/0000-0002-0676-1228; Morenghi, Emanuela/0000-0002-0254-3143				Berglin E, 2021, J AUTOIMMUN, V117, DOI 10.1016/j.jaut.2020.102579; Berthelot JM, 2017, JOINT BONE SPINE, V84, P255, DOI 10.1016/j.jbspin.2016.05.013; Bosch X, 2006, LANCET, V368, P404, DOI 10.1016/S0140-6736(06)69114-9; Chehroudi C, 2018, RHEUMATOL INT, V38, P641, DOI 10.1007/s00296-017-3905-0; Cui Z, 2010, KIDNEY INT, V78, P590, DOI 10.1038/ki.2010.198; Damoiseaux J, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis-2016-209507; Deshpande P, 2016, PATHOLOGY, V48, P483, DOI 10.1016/j.pathol.2016.03.014; Drooger J C, 2009, Open Rheumatol J, V3, P14, DOI 10.2174/1874312900903010014; Gomez-Puerta JA, 2009, AM J PATHOL, V175, P1790, DOI 10.2353/ajpath.2009.090533; Gregersen JW, 2019, RHEUMATOLOGY, V58, P1942, DOI 10.1093/rheumatology/kez111; Ho DE, 2011, J STAT SOFTW, V42; Holle JU, 2012, CLIN EXP RHEUMATOL, V30, pS66; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; Khandpur R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005580; Knol MJ, 2012, INT J EPIDEMIOL, V41, P514, DOI 10.1093/ije/dyr218; Lee KH, 2017, AUTOIMMUN REV, V16, P1160, DOI 10.1016/j.autrev.2017.09.012; Mahr A, 2014, ARTHRITIS RHEUMATOL, V66, P1672, DOI 10.1002/art.38389; Martin KR, 2017, J LEUKOCYTE BIOL, V102, P689, DOI 10.1189/jlb.3MR0217-069R; McLaren JS, 2001, QJM-INT J MED, V94, P615, DOI 10.1093/qjmed/94.11.615; Mustila A, 2000, ARTHRITIS RHEUM-US, V43, P1371, DOI 10.1002/1529-0131(200006)43:6<1371::AID-ANR22>3.0.CO;2-R; Mustila A, 1997, ARTHRITIS RHEUM, V40, P710, DOI 10.1002/art.1780400417; Peschel A, 2014, J AM SOC NEPHROL, V25, P455, DOI 10.1681/ASN.2013030320; Radford DJ, 2001, ARTHRITIS RHEUM, V44, P2851, DOI 10.1002/1529-0131(200112)44:12<2851::AID-ART473>3.0.CO;2-2; Radice A, 2013, CLIN CHEM LAB MED, V51, P2141, DOI 10.1515/cclm-2013-0308; Ramponi G, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102759; Robson J, 2019, RHEUMATOLOGY, V58, DOI [DOI 10.1093/RHEUMATOLOGY/KEZ058.050, 10.1093/rheumatology/kez058.050]; Roth AJ, 2013, J CLIN INVEST, V123, P1773, DOI 10.1172/JCI65292; Schonermarck U, 2001, RHEUMATOLOGY, V40, P178, DOI 10.1093/rheumatology/40.2.178; Schreiber A, 2013, PRESSE MED, V42, P520, DOI 10.1016/j.lpm.2013.01.010; Sinico RA, 2014, CLIN EXP RHEUMATOL, V32, pS112; Sinico RA, 2005, ARTHRITIS RHEUM, V52, P2926, DOI 10.1002/art.21250; Stone JH, 2000, ARTHRIT CARE RES, V13, P424, DOI 10.1002/1529-0131(200012)13:6<424::AID-ART14>3.0.CO;2-Q; Stone JH, 2010, NEW ENGL J MED, V363, P221, DOI 10.1056/NEJMoa0909905; Suwanchote S, 2018, CLIN RHEUMATOL, V37, P875, DOI 10.1007/s10067-018-4062-x; Tsiveriotis K, 2011, AUTOIMMUN DIS, V2011, DOI 10.4061/2011/626495; Tur BS, 2004, JOINT BONE SPINE, V71, P198, DOI 10.1016/j.jbspin.2003.04.002; Villanueva E, 2011, J IMMUNOL, V187, P538, DOI 10.4049/jimmunol.1100450; Vittecoq O, 2000, RHEUMATOLOGY, V39, P481, DOI 10.1093/rheumatology/39.5.481; Watts RA, 2001, ANN RHEUM DIS, V60, P1156; Xiao H, 2002, J CLIN INVEST, V110, P955, DOI 10.1172/JCI200215918; Xiao H, 2005, AM J PATHOL, V167, P39, DOI 10.1016/S0002-9440(10)62951-3; Xiao H, 2007, AM J PATHOL, V170, P52, DOI 10.2353/ajpath.2007.060573	42	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 10	2021	12								714174	10.3389/fimmu.2021.714174	http://dx.doi.org/10.3389/fimmu.2021.714174			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV7AC	34566970	Green Published, gold			2022-12-18	WOS:000717384200001
J	Carlier, Y; Truyens, C; Muraille, E				Carlier, Yves; Truyens, Carine; Muraille, Eric			Is Antibody-Dependent Enhancement of Trypanosoma cruzi Infection Contributing to Congenital/Neonatal Chagas Disease?	FRONTIERS IN IMMUNOLOGY			English	Article						Trypanosoma cruzi; chagas disease; congenital; neonatal infection; antibodies; FcR; antibody-dependent enhancement	INTERFERON-GAMMA; PREGNANT-WOMEN; IMMUNE CLEARANCE; CORD BLOOD; TRANSMISSION; MOTHERS; MICE; FC; PARASITEMIA; RECEPTORS	The newborns of women infected with the parasite Trypanosoma cruzi (the agent of Chagas disease) can be infected either before birth (congenitally), or after birth (as e.g., by vector route). Congenital Chagas disease can induce high levels of neonatal morbidity and mortality. Parasite-infected pregnant women transmit antibodies to their fetus. Antibodies, by opsonizing parasites, can promote phagocytosis and killing of T. cruzi by cells expressing Fc gamma R, on the mandatory condition that such cells are sufficiently activated in an inflammatory context. Antibody-dependent enhancement (ADE) is a mechanism well described in viral infections, by which antibodies enhance entry of infectious agents into host cells by exploiting the phagocytic Fc gamma R pathway. Previously reported Chagas disease studies highlighted a severe reduction of the maternal-fetal/neonatal inflammatory context in parasite-transmitting pregnant women and their congenitally infected newborns. Otherwise, experimental observations brought to light ADE of T. cruzi infection (involving Fc gamma R) in mouse pups displaying maternally transferred antibodies, out of an inflammatory context. Herein, based on such data, we discuss the previously unconsidered possibility of a role of ADE in the trans-placental parasite transmission, and/or the development of severe and mortal clinical forms of congenital/neonatal Chagas disease in newborns of T. cruzi-infected mothers.</p>	[Carlier, Yves; Truyens, Carine; Muraille, Eric] Univ Libre Bruxelles ULB, Fac Med, Lab Parasitol, Brussels, Belgium; [Carlier, Yves] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Trop Med, New Orleans, LA 70118 USA	Universite Libre de Bruxelles; Tulane University	Carlier, Y (corresponding author), Univ Libre Bruxelles ULB, Fac Med, Lab Parasitol, Brussels, Belgium.; Carlier, Y (corresponding author), Tulane Univ, Sch Publ Hlth & Trop Med, Dept Trop Med, New Orleans, LA 70118 USA.	yves.carlier@ulb.be	Mrl, Eric/ABC-5458-2021	Carlier, Yves/0000-0003-0199-6818				Alonso-Vega C, 2005, REV SOC BRAS MED TRO, V38, P101; [Anonymous], 2015, Wkly Epidemiol Rec, V90, P33; ARAUJOJORGE T, 1993, INFECT IMMUN, V61, P4925, DOI 10.1128/IAI.61.11.4925-4928.1993; Barrias ES, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00186; Batista MF, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00396; Bournazos S, 2020, NAT REV IMMUNOL, V20, P633, DOI 10.1038/s41577-020-00410-0; BRENIERE S F, 1983, Cahiers O.R.S.T.O.M. (Office de la Recherche Scientifique et Technique Outre-Mer) Serie Entomologie Medicale et Parasitologie, V21, P139; BRODSKYN CI, 1989, IMMUNOL CELL BIOL, V67, P343, DOI 10.1038/icb.1989.50; Bua J, 2012, T ROY SOC TROP MED H, V106, P623, DOI 10.1016/j.trstmh.2012.03.015; Burgener SS, 2021, J EXP MED, V218, DOI 10.1084/jem.20201738; Cardoni RL, 2004, ACTA TROP, V90, P65, DOI 10.1016/j.actatropica.2003.09.020; Carlier Y, 2017, AMERICAN TRYPANOSOMIASIS CHAGAS DISEASE: ONE HUNDRED YEARS OF RESEARCH, 2ND EDITION, P517, DOI 10.1016/B978-0-12-801029-7.00024-1; CARLIER Y, 1992, AM J TROP MED HYG, V46, P116, DOI 10.4269/ajtmh.1992.46.116; Carlier Y, 2020, CURR TROP MED REP, V7, P172, DOI 10.1007/s40475-020-00210-5; Carlier Y, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007694; Carlier Y, 2015, ACTA TROP, V151, P103, DOI 10.1016/j.actatropica.2015.07.016; Cencig S, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002271; Chippaux JP, 2010, TROP MED INT HEALTH, V15, P87, DOI 10.1111/j.1365-3156.2009.02431.x; Clements T, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01920; Danesi E, 2020, REV SOC BRAS MED TRO, V53, DOI 10.1590/0037-8682-0560-2019; Dauby N, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000571; DeAraujo SM, 1996, AM J TROP MED HYG, V54, P13, DOI 10.4269/ajtmh.1996.54.13; Dekel N, 2014, AM J REPROD IMMUNOL, V72, P141, DOI 10.1111/aji.12266; Didoli GL, 2000, INT J IMMUNOPHARMACO, V22, P45, DOI 10.1016/S0192-0561(99)00063-6; ELBOUHDIDI A, 1994, PARASITE IMMUNOL, V16, P69, DOI 10.1111/j.1365-3024.1994.tb00325.x; Garcia MM, 2008, AM J TROP MED HYG, V78, P499, DOI 10.4269/ajtmh.2008.78.499; Gascon J, 2010, ACTA TROP, V115, P22, DOI 10.1016/j.actatropica.2009.07.019; GAZZINELLI RT, 1991, PARASITE IMMUNOL, V13, P345, DOI 10.1111/j.1365-3024.1991.tb00288.x; HALSTEAD SB, 1970, YALE J BIOL MED, V42, P311; Hermann E, 2004, J INFECT DIS, V189, P1274, DOI 10.1086/382511; Hermann E, 2006, PEDIATR RES, V60, P38, DOI 10.1203/01.pdr.0000220335.05588.ea; Howard EJ, 2014, BJOG-INT J OBSTET GY, V121, P22, DOI 10.1111/1471-0528.12396; JORGE TA, 1993, PARASITE IMMUNOL, V15, P539, DOI 10.1111/j.1365-3024.1993.tb00642.x; Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836; KIPNIS TL, 1979, PARASITOLOGY, V78, P89, DOI 10.1017/S0031182000048617; Kolodny MH, 1939, AM J HYG, V30, P19, DOI 10.1093/oxfordjournals.aje.a118586; Krautz GM, 2000, PARASITOL TODAY, V16, P31, DOI 10.1016/S0169-4758(99)01581-1; Laucella SA, 2004, J INFECT DIS, V189, P909, DOI 10.1086/381682; LEGUIZAMON MS, 1994, J INFECT DIS, V170, P1570, DOI 10.1093/infdis/170.6.1570; Maidji E, 2006, AM J PATHOL, V168, P1210, DOI 10.2353/ajpath.2006.050482; Mayer JP, 2010, ANN TROP MED PARASIT, V104, P485, DOI 10.1179/136485910X12786389891362; METZ G, 1993, PARASITE IMMUNOL, V15, P693, DOI 10.1111/j.1365-3024.1993.tb00584.x; MILES MA, 1972, PARASITOLOGY, V65, P1, DOI 10.1017/S0031182000044188; MILES MA, 1975, T ROY SOC TROP MED H, V69, P286, DOI 10.1016/0035-9203(75)90171-6; Mjihdi A, 2004, EXP PARASITOL, V107, P58, DOI 10.1016/j.exppara.2004.03.016; Mjihdi A, 2002, AM J PATHOL, V161, P673, DOI 10.1016/S0002-9440(10)64223-X; Negrette OS, 2005, PEDIATRICS, V115, pE668, DOI 10.1542/peds.2004-1732; Pereira L, 2018, ANNU REV VIROL, V5, P273, DOI 10.1146/annurev-virology-092917-043236; Perez-Molina JA, 2018, LANCET, V391, P82, DOI 10.1016/S0140-6736(17)31612-4; Richter MY, 2004, INFECT IMMUN, V72, P187, DOI 10.1128/IAI.72.1.187-195.2004; RIVERA MT, 1995, INFECT IMMUN, V63, P591, DOI 10.1128/IAI.63.2.591-595.1995; Rodriguez P, 2005, REV SOC BRAS MED TRO, V38, P62; Rytter MJH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105017; SCOTT MT, 1982, CLIN EXP IMMUNOL, V48, P754; Simister NE, 2003, VACCINE, V21, P3365, DOI 10.1016/S0264-410X(03)00334-7; Sosa-Estani S, 2008, AM J TROP MED HYG, V79, P755, DOI 10.4269/ajtmh.2008.79.755; Torres VL, 2021, INFECT IMMUN, V89, DOI 10.1128/IAI.00054-21; Torrico F, 2004, AM J TROP MED HYG, V70, P201, DOI 10.4269/ajtmh.2004.70.201; Torrico MC, 2005, REV SOC BRAS MED TRO, V38, P58; Truyens C, 2005, REV SOC BRAS MED TRO, V38, P96; Truyens C, 2017, AMERICAN TRYPANOSOMIASIS CHAGAS DISEASE: ONE HUNDRED YEARS OF RESEARCH, 2ND EDITION, P579, DOI 10.1016/B978-0-12-801029-7.00026-5; UMEKITA LF, 1988, IMMUNOL LETT, V17, P85, DOI 10.1016/0165-2478(88)90106-X; Vekemans J, 2000, INFECT IMMUN, V68, P5430, DOI 10.1128/IAI.68.9.5430-5434.2000	63	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 10	2021	12								723516	10.3389/fimmu.2021.723516	http://dx.doi.org/10.3389/fimmu.2021.723516			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UU2KL	34566981	Green Published, gold			2022-12-18	WOS:000698630200001
J	Chen, CC; Hung, YM; Chiu, LT; Chou, MC; Chang, R; Wei, JCC				Chen, Chih-Chung; Hung, Yao-Min; Chiu, Lu-Ting; Chou, Mei-Chia; Chang, Renin; Wei, James Cheng-Chung			Association Between Severity of Leptospirosis and Subsequent Major Autoimmune Diseases: A Nationwide Observational Cohort Study	FRONTIERS IN IMMUNOLOGY			English	Article						leptospirosis; autoimmune diseases; cohort study; NHIRD; epidemiology	BLOOD MONONUCLEAR-CELLS; NATURAL-KILLER-CELLS; PULMONARY HEMORRHAGE; IMMUNOGLOBULIN; MODEL; COMPLEMENT; MECHANISMS; ANTIBODIES; DEPOSITION; CYTOKINES	Introduction Infections play a role in autoimmune diseases (AD). Leptospirosis has been linked to the trigger of systemic lupus erythematosus. Objective To investigate subsequent risk of major AD in hospitalized Taiwanese for Leptospirosis. Methods Retrospective observational cohort study was employed. The enrolled period was from 2000 to 2012. In the main model, we extracted 4026 inpatients with leptospirosis from the Taiwan National Health Insurance Research Database (NHIRD) and 16,104 participants without leptospirosis at a 1:4 ratio propensity-score matched (PSM) by age, gender, index year, and comorbidities. The follow-up period was defined as the time from the initial diagnosis of leptospirosis to major AD occurrence or 2013. This study was re-analyzed by frequency-matching as a sensitivity analysis for cross-validation. Univariable and multivariable Cox proportional hazards regression models were applied to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Results The adjusted HR (95% CI) of major ADs for the leptospirosis group was 4.45 (3.25-6.79) (p < 0.001) compared to the controls after full adjustment. The risk of major ADs was 5.52-fold (95% CI, 3.82-7.99) higher in leptospirosis patients hospitalized for seven days and above than the controls, while 2.80-fold (95% CI, 1.68-5.61) in those hospitalized less than seven days. The sensitivity analysis yields consistent findings. Stratified analysis revealed that the association between leptospirosis and major ADs was generalized in both genders, and all age groups. Conclusions Symptomatic leptospirosis is associated with increased rate of subsequent major ADs, and the risk seems to be higher in severe cases.	[Chen, Chih-Chung; Chang, Renin] Kaohsiung Vet Gen Hosp, Dept Emergency Med, Kaohsiung, Taiwan; [Hung, Yao-Min; Chang, Renin; Wei, James Cheng-Chung] Chung Shan Med Univ, Inst Med, Taichung, Taiwan; [Hung, Yao-Min] Meiho Univ, Coll Hlth & Nursing, Pingtung, Taiwan; [Hung, Yao-Min] Kaohsiung Municipal United Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Hung, Yao-Min] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan; [Chiu, Lu-Ting] China Med Univ Hosp, Management Off Hlth Data, Taichung, Taiwan; [Chou, Mei-Chia] Shu Zen Jr Coll Med & Management, Dept Phys Therapy, Kaohsiung, Taiwan; [Chou, Mei-Chia; Chang, Renin] Tajen Univ, Dept Recreat & Sports Management, Yanpu Township, Pingtung County, Taiwan; [Chou, Mei-Chia] Kaohsiung Vet Gen Hosp, Dept Phys Med & Rehabil, Pingtung Branch, Kaohsiung, Pingtung County, Taiwan; [Wei, James Cheng-Chung] Chung Shan Med Univ Hosp, Div Allergy Immunol & Rheumatol, Taichung, Taiwan; [Wei, James Cheng-Chung] China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan	Kaohsiung Veterans General Hospital; Chung Shan Medical University; National Yang Ming Chiao Tung University; China Medical University Taiwan; China Medical University Hospital - Taiwan; Kaohsiung Veterans General Hospital; Chung Shan Medical University; Chung Shan Medical University Hospital; China Medical University Taiwan	Chang, R (corresponding author), Kaohsiung Vet Gen Hosp, Dept Emergency Med, Kaohsiung, Taiwan.; Chang, R; Wei, JCC (corresponding author), Chung Shan Med Univ, Inst Med, Taichung, Taiwan.; Chou, MC (corresponding author), Shu Zen Jr Coll Med & Management, Dept Phys Therapy, Kaohsiung, Taiwan.; Chou, MC; Chang, R (corresponding author), Tajen Univ, Dept Recreat & Sports Management, Yanpu Township, Pingtung County, Taiwan.; Chou, MC (corresponding author), Kaohsiung Vet Gen Hosp, Dept Phys Med & Rehabil, Pingtung Branch, Kaohsiung, Pingtung County, Taiwan.; Wei, JCC (corresponding author), Chung Shan Med Univ Hosp, Div Allergy Immunol & Rheumatol, Taichung, Taiwan.; Wei, JCC (corresponding author), China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan.	meeichia@gmail.com; rhapsody1881@gmail.com; wei3228@gmail.com						American Autoimmune Related Diseases Association Inc, 2018, WOM AUT; Athanazio DA, 2008, ACTA TROP, V105, P176, DOI 10.1016/j.actatropica.2007.10.012; Athapattu TPJ, 2019, ACTA TROP, V195, P78, DOI 10.1016/j.actatropica.2019.04.029; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Bandara K, 2018, CAN J INFECT DIS MED, V2018, DOI 10.1155/2018/9704532; Bedoya SK, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/986789; Berzins SP, 2011, NAT REV IMMUNOL, V11, P131, DOI 10.1038/nri2904; Cooper GS, 2003, AUTOIMMUN REV, V2, P119, DOI 10.1016/S1568-9972(03)00006-5; Croda J, 2010, CLIN MICROBIOL INFEC, V16, P593, DOI 10.1111/j.1469-0691.2009.02916.x; Davidson A, 2001, NEW ENGL J MED, V345, P340, DOI 10.1056/NEJM200108023450506; Deng QC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00856; Desai MK, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00265; Gravano DM, 2013, J AUTOIMMUN, V45, P68, DOI 10.1016/j.jaut.2013.06.004; Guo YJ, 2010, MICROBES INFECT, V12, P364, DOI 10.1016/j.micinf.2010.01.010; Hauptmann M, 2017, INFECT IMMUN, V85, DOI [10.1128/IAI.00156-17, 10.1128/iai.00156-17]; Houen G, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.587380; Klimpel GR, 2003, J IMMUNOL, V171, P1447, DOI 10.4049/jimmunol.171.3.1447; Ko AI, 2009, NAT REV MICROBIOL, V7, P736, DOI 10.1038/nrmicro2208; Lee J, 2019, J RHEUMAT DIS, V26, P79, DOI 10.4078/jrd.2019.26.1.79; Lerner A, 2015, INT J CELIAC DIS, V3, P151, DOI [10.12691/ijcd-3-4-8, DOI 10.12691/IJCD-3-4-8]; Li SJ, 2010, INNATE IMMUN-LONDON, V16, P80, DOI 10.1177/1753425909105580; Lunemann A, 2009, MOL MED, V15, P352, DOI 10.2119/molmed.2009.00035; Mengesha BG, 2017, J FUNGI, V3, DOI 10.3390/jof3040052; Moderzynski K, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005404; Nally JE, 2004, AM J PATHOL, V164, P1115, DOI 10.1016/S0002-9440(10)63198-7; Oliveira TL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142821; Ouyang WJ, 2008, IMMUNITY, V28, P454, DOI 10.1016/j.immuni.2008.03.004; Pappas G, 2003, CLIN RHEUMATOL, V22, P343, DOI 10.1007/s10067-003-0730-5; Poggi A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00027; Radstake TRDJ, 2004, ARTHRITIS RHEUM-US, V50, P3856, DOI 10.1002/art.20678; Reis EAG, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002457; Rosenblum MD, 2015, J CLIN INVEST, V125, P2228, DOI 10.1172/JCI78088; RUGMAN FP, 1991, J CLIN PATHOL, V44, P517, DOI 10.1136/jcp.44.6.517; Sanchez B, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00594; Santecchia I, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007811; See LC, 2013, SEMIN ARTHRITIS RHEU, V43, P381, DOI 10.1016/j.semarthrit.2013.06.001; Shi GX, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/183591; Silva EF, 2007, VACCINE, V25, P6277, DOI 10.1016/j.vaccine.2007.05.053; Smyk D, 2012, CLIN REV ALLERG IMMU, V42, P199, DOI 10.1007/s12016-011-8259-x; Teh SH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60267-0; Tsao JT, 2012, CLIN EXP MED, V12, P153, DOI 10.1007/s10238-011-0161-6; Tuero I, 2010, J INFECT DIS, V201, P420, DOI 10.1086/650300; Verma A, 2008, CLIN VACCINE IMMUNOL, V15, P1019, DOI 10.1128/CVI.00203-07; Walsh SJ, 2000, AM J PUBLIC HEALTH, V90, P1463, DOI 10.2105/AJPH.90.9.1463; Wang H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042266; Werts C, 2001, NAT IMMUNOL, V2, P346, DOI 10.1038/86354; Yang CW, 2006, KIDNEY INT, V69, P815, DOI 10.1038/sj.ki.5000119; Zakka LR, 2012, AUTOIMMUNITY, V45, P44, DOI 10.3109/08916934.2011.606446; Zhang C, 2006, CELL MOL IMMUNOL, V3, P241	49	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 10	2021	12								721752	10.3389/fimmu.2021.721752	http://dx.doi.org/10.3389/fimmu.2021.721752			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WA9ZU	34566978	gold, Green Published			2022-12-18	WOS:000703242100001
J	Qin, YF; Kong, DJ; Qin, H; Zhu, YL; Li, GM; Sun, CL; Zhao, YM; Wang, HD; Hao, JP; Wang, H				Qin, Ya-fei; Kong, De-jun; Qin, Hong; Zhu, Yang-lin; Li, Guang-ming; Sun, Cheng-lu; Zhao, Yi-ming; Wang, Hong-da; Hao, Jing-peng; Wang, Hao			Melatonin Synergizes With Mesenchymal Stromal Cells Attenuates Chronic Allograft Vasculopathy	FRONTIERS IN IMMUNOLOGY			English	Correction						chronic allograft vasculopathy; melatonin; mesenchymal stromal cells; aorta transplantation; mice			[Qin, Ya-fei; Kong, De-jun; Qin, Hong; Zhu, Yang-lin; Li, Guang-ming; Sun, Cheng-lu; Zhao, Yi-ming; Wang, Hong-da; Wang, Hao] Tianjin Med Univ, Dept Gen Surg, Gen Hosp, Tianjin, Peoples R China; [Qin, Ya-fei; Kong, De-jun; Qin, Hong; Zhu, Yang-lin; Li, Guang-ming; Sun, Cheng-lu; Zhao, Yi-ming; Wang, Hong-da; Wang, Hao] Tianjin Med Univ, Tianjin Gen Surg Inst, Gen Hosp, Tianjin, Peoples R China; [Hao, Jing-peng] Tianjin Med Univ, Dept Anorectal Surg, Hosp 2, Tianjin, Peoples R China	Tianjin Medical University; Tianjin Medical University; Tianjin Medical University	Wang, H (corresponding author), Tianjin Med Univ, Dept Gen Surg, Gen Hosp, Tianjin, Peoples R China.; Wang, H (corresponding author), Tianjin Med Univ, Tianjin Gen Surg Inst, Gen Hosp, Tianjin, Peoples R China.	hwangca272@hotmail.com							0	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 10	2021	12								741234	10.3389/fimmu.2021.741234	http://dx.doi.org/10.3389/fimmu.2021.741234			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UU5BB	34567004	Green Published, gold			2022-12-18	WOS:000698814500001
J	Goplen, NP; Takamura, S; Nakayama, T; Sun, J				Goplen, Nick P.; Takamura, Shiki; Nakayama, Toshinori; Sun, Jie			Editorial: Resident Memory T Cells - Guardians of the Balance Between Local Immunity and Pathology - The Minority Report	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						resident memory T (Trm); differentiation; maintenance; immune protection; pathology			[Goplen, Nick P.; Sun, Jie] Mayo Clin, Thorac Dis Res Unit, Dept Med, Div Pulm & Crit Med, Rochester, MN USA; [Goplen, Nick P.; Sun, Jie] Mayo Clin, Robert & Arlene Kogod Ctr Aging, Rochester, MN USA; [Goplen, Nick P.; Sun, Jie] Mayo Clin, Dept Immunol, Rochester, MN USA; [Takamura, Shiki] Kindai Univ, Fac Med, Dept Immunol, Osaka, Japan; [Nakayama, Toshinori] Chiba Univ, Dept Immunol, Chiba, Japan; [Nakayama, Toshinori] Japan Agcy Med Res & Dev, Adv Res & Dev Programs Med Innovat CREST AMED CRE, Chiba, Japan	Mayo Clinic; Mayo Clinic; Mayo Clinic; Kindai University (Kinki University); Chiba University	Goplen, NP (corresponding author), Mayo Clin, Thorac Dis Res Unit, Dept Med, Div Pulm & Crit Med, Rochester, MN USA.; Goplen, NP (corresponding author), Mayo Clin, Robert & Arlene Kogod Ctr Aging, Rochester, MN USA.; Goplen, NP (corresponding author), Mayo Clin, Dept Immunol, Rochester, MN USA.	goplen.nicholas@mayo.edu	Takamura, Shiki/GXV-0595-2022						0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 9	2021	12								745256	10.3389/fimmu.2021.745256	http://dx.doi.org/10.3389/fimmu.2021.745256			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UU0SQ	34567011	gold, Green Published			2022-12-18	WOS:000698515600001
J	Misra, R; Mulligan, JK; Rowland-Jones, S; Zemlin, M				Misra, Ravi; Mulligan, Jennifer Konopa; Rowland-Jones, Sarah; Zemlin, Michael			Editorial: Autoimmunity and Chronic Inflammation in Early Life	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						autoimmunity; pediatrics; children; immune development and maturation; early life origin of disease; chronic inflammation			[Misra, Ravi] Univ Rochester, Med Ctr, Dept Pediat, Rochester, NY 14642 USA; [Mulligan, Jennifer Konopa] Univ Florida, Div Pulm Crit Care & Sleep Med, Gainesville, FL USA; [Rowland-Jones, Sarah] Nuffield Dept Med, Viral Immunol Unit, Oxford, England; [Zemlin, Michael] Saarland Univ, Dept Gen Pediat & Neonatol, Homburg, Germany	University of Rochester; State University System of Florida; University of Florida; University of Oxford; Universitatsklinikum des Saarlandes	Zemlin, M (corresponding author), Saarland Univ, Dept Gen Pediat & Neonatol, Homburg, Germany.	michael.zemlin@uks.eu		Mulligan, Jennifer/0000-0001-6880-6092	BMBF PRIMAL study [01GL1746D]	BMBF PRIMAL study(Federal Ministry of Education & Research (BMBF))	This study was supported by BMBF PRIMAL study (01GL1746D) to MZ.	Jian C, 2021, EBIOMEDICINE, V69, DOI 10.1016/j.ebiom.2021.103475; Sarkar A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10030459; Ubags NDJ, 2020, EUR RESPIR REV, V29, DOI 10.1183/16000617.0191-2020	3	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 9	2021	12								761160	10.3389/fimmu.2021.761160	http://dx.doi.org/10.3389/fimmu.2021.761160			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UU0FR	34567015	Green Published, gold			2022-12-18	WOS:000698481900001
J	Ronsard, L; Yousif, AS; Peabody, J; Okonkwo, V; Devant, P; Mogus, AT; Barnes, RM; Rohrer, D; Lonberg, N; Peabody, D; Chackerian, B; Lingwood, D				Ronsard, Larance; Yousif, Ashraf S.; Peabody, Julianne; Okonkwo, Vintus; Devant, Pascal; Mogus, Alemu Tekewe; Barnes, Ralston M.; Rohrer, Daniel; Lonberg, Nils; Peabody, David; Chackerian, Bryce; Lingwood, Daniel			Engineering an Antibody V Gene-Selective Vaccine	FRONTIERS IN IMMUNOLOGY			English	Article						antibody; B cell receptor; lineage; VLP; prime	VIRUS-LIKE PARTICLES; B-CELL RESPONSE; NEUTRALIZING ANTIBODIES; IMMUNOGENIC DISPLAY; DIVERSE PEPTIDES; HIV-1; BROAD; MATURATION; EPITOPE; IMMUNODOMINANCE	The ligand-binding surface of the B cell receptor (BCR) is formed by encoded and non-encoded antigen complementarity determining regions (CDRs). Genetically reproducible or 'public' antibodies can arise when the encoded CDRs play deterministic roles in antigen recognition, notably within human broadly neutralizing antibodies against HIV and influenza virus. We sought to exploit this by engineering virus-like-particle (VLP) vaccines that harbor multivalent affinity against gene-encoded moieties of the BCR antigen binding site. As proof of concept, we deployed a library of RNA bacteriophage VLPs displaying random peptides to identify a multivalent antigen that selectively triggered germline BCRs using the human V-H gene IGVH1-2*02. This VLP selectively primed IGHV1-2*02 BCRs that were present within a highly diversified germline antibody repertoire within humanized mice. Our approach thus provides methodology to generate antigens that engage specific BCR configurations of interest, in the absence of structure-based information.	[Ronsard, Larance; Yousif, Ashraf S.; Okonkwo, Vintus; Devant, Pascal; Lingwood, Daniel] MIT, Ragon Inst, Massachusetts Gen Hosp, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Ronsard, Larance; Yousif, Ashraf S.; Okonkwo, Vintus; Devant, Pascal; Lingwood, Daniel] Harvard Univ, Cambridge, MA 02138 USA; [Peabody, Julianne; Mogus, Alemu Tekewe; Peabody, David; Chackerian, Bryce] Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA; [Barnes, Ralston M.; Rohrer, Daniel; Lonberg, Nils] Bristol Myers Squibb, Redwood City, CA USA	Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Harvard University; University of New Mexico; Bristol-Myers Squibb	Lingwood, D (corresponding author), MIT, Ragon Inst, Massachusetts Gen Hosp, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Lingwood, D (corresponding author), Harvard Univ, Cambridge, MA 02138 USA.; Chackerian, B (corresponding author), Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA.	BChackenen@salud.unm.edu; dingwood@mgh.harvard.edu	Yousif, Ashraf Siddig/U-2876-2019	Yousif, Ashraf Siddig/0000-0001-9215-3853; Devant, Pascal/0000-0001-9743-6764	NIH [T32-AI007538, R01AI124378, R01AI137057, DP2DA042422, R01AI153098, R01AI155447]; Harvard University Milton Award; Gilead Research Scholars Program	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard University Milton Award; Gilead Research Scholars Program	This work was supported by NIH funding to D.L. and B.C. (R01AI124378, R01AI137057, DP2DA042422, R01AI153098, R01AI155447), the Harvard University Milton Award, and the Gilead Research Scholars Program. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. JP was supported by NIH grant T32-AI007538. We thank the members of the Lingwood and Chackerian labs for helpful discussion and technical assistance.	Abbott RK, 2020, IMMUNOL REV, V296, P120, DOI 10.1111/imr.12861; Abbott RK, 2018, IMMUNITY, V48, P133, DOI 10.1016/j.immuni.2017.11.023; Altman MO, 2018, VIRAL IMMUNOL, V31, P142, DOI 10.1089/vim.2017.0129; Amitai A, 2020, CELL SYST, V11, P573, DOI 10.1016/j.cels.2020.09.005; Andreano E, 2021, J EXP MED, V218, DOI 10.1084/jem.20210281; Avnir Y, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004103; Bonsignori M, 2018, IMMUNITY, V49, P1162, DOI 10.1016/j.immuni.2018.10.015; Briney B, 2019, NATURE, V566, P393, DOI 10.1038/s41586-019-0879-y; Briney B, 2016, CELL, V166, P1459, DOI 10.1016/j.cell.2016.08.005; Burton DR, 2015, NAT IMMUNOL, V16, P571, DOI 10.1038/ni.3158; Caldeira JD, 2010, VACCINE, V28, P4384, DOI 10.1016/j.vaccine.2010.04.049; Chackerian B, 2011, J MOL BIOL, V409, P225, DOI 10.1016/j.jmb.2011.03.072; Chen F, 2021, IMMUNITY, V54, P781, DOI 10.1016/j.immuni.2021.02.013; Chen XJ, 2021, IMMUNITY, V54, P324, DOI 10.1016/j.immuni.2020.12.014; Collar AL, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00654-20; Corbett KS, 2019, MBIO, V10, DOI 10.1128/mBio.02810-18; Crossey E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132560; Darricarrere N, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abe5449; Dosenovic P, 2019, J EXP MED, V216, P2316, DOI 10.1084/jem.20190446; Dosenovic P, 2018, P NATL ACAD SCI USA, V115, P4743, DOI 10.1073/pnas.1803457115; Duan HY, 2018, IMMUNITY, V49, P301, DOI 10.1016/j.immuni.2018.07.005; Ekiert DC, 2009, SCIENCE, V324, P246, DOI 10.1126/science.1171491; Ellebedy AH, 2016, NAT IMMUNOL, V17, P1226, DOI 10.1038/ni.3533; Escolano A, 2016, CELL, V166, P1445, DOI 10.1016/j.cell.2016.07.030; Flyak AI, 2018, CELL HOST MICROBE, V24, P703, DOI 10.1016/j.chom.2018.10.009; Frietze KM, 2020, METHODS MOL BIOL, V2070, P157, DOI 10.1007/978-1-4939-9853-1_9; Frietze KM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171511; Frietze KM, 2016, CURR OPIN VIROL, V18, P44, DOI 10.1016/j.coviro.2016.03.001; Glanville J, 2009, P NATL ACAD SCI USA, V106, P20216, DOI 10.1073/pnas.0909775106; Gold MR, 2019, ANNU REV IMMUNOL, V37, P97, DOI 10.1146/annurev-immunol-042718-041704; Golsaz-Shirazi F, 2015, VIRAL IMMUNOL, V28, P425, DOI 10.1089/vim.2015.0023; Gristick HB, 2016, NAT STRUCT MOL BIOL, V23, P906, DOI 10.1038/nsmb.3291; Havenar-Daughton C, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat0381; Haynes BF, 2017, IMMUNOL REV, V275, P5, DOI 10.1111/imr.12517; Hehle V, 2020, J EXP MED, V217, DOI 10.1084/jem.20200840; Huang DL, 2020, P NATL ACAD SCI USA, V117, P22920, DOI 10.1073/pnas.2004489117; Hwang KK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090725; Imkeller K, 2018, SCIENCE, V360, P1358, DOI 10.1126/science.aar5304; Janitzek CM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41522-5; Jardine JG, 2016, SCIENCE, V351, P1458, DOI 10.1126/science.aad9195; Jardine JG, 2015, SCIENCE, V349, P156, DOI 10.1126/science.aac5894; Joyce MG, 2016, CELL, V166, P609, DOI 10.1016/j.cell.2016.06.043; Kanekiyo M, 2013, NATURE, V499, P102, DOI 10.1038/nature12202; Kato Y, 2020, IMMUNITY, V53, P548, DOI 10.1016/j.immuni.2020.08.001; Kirik U, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01433; Kuroda D, 2008, PROTEINS, V73, P608, DOI 10.1002/prot.22087; Kwak K, 2019, NAT IMMUNOL, V20, P963, DOI 10.1038/s41590-019-0427-9; LeBien TW, 2008, BLOOD, V112, P1570, DOI 10.1182/blood-2008-02-078071; Lerner RA, 2011, MOL BIOSYST, V7, P1004, DOI 10.1039/c0mb00310g; Lin YR, 2020, IMMUNITY, V53, P840, DOI 10.1016/j.immuni.2020.09.007; Lingwood D, 2012, NATURE, V489, P566, DOI 10.1038/nature11371; Marcandalli J, 2019, CELL, V176, P1420, DOI 10.1016/j.cell.2019.01.046; Martinez-Murillo P, 2017, IMMUNITY, V46, P804, DOI 10.1016/j.immuni.2017.04.021; McGuire AT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10618; Medina-Ramirez M, 2017, J EXP MED, V214, P2573, DOI 10.1084/jem.20161160; Murugan R, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aap8029; O'Rourke JP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111198; Ord RL, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-326; Pappas L, 2014, NATURE, V516, P418, DOI 10.1038/nature13764; Peabody DS, 2008, J MOL BIOL, V380, P252, DOI 10.1016/j.jmb.2008.04.049; Peterhoff D, 2017, CURR OPIN HIV AIDS, V12, P257, DOI 10.1097/COH.0000000000000356; Pracht K, 2017, EUR J IMMUNOL, V47, P1389, DOI 10.1002/eji.201747019; Robbiani Davide F, 2020, Nature, V584, P437, DOI [10.1101/2020.05.13.092619, 10.1038/s41586-020-2456-9]; Saada R, 2007, IMMUNOL CELL BIOL, V85, P323, DOI 10.1038/sj.icb.7100055; Sangesland M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020125; Sangesland M, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108065; Sangesland M, 2019, IMMUNITY, V51, P735, DOI 10.1016/j.immuni.2019.09.001; Saunders KO, 2019, SCIENCE, V366, P1215, DOI 10.1126/science.aay7199; Schroeder HW, 2010, J ALLERGY CLIN IMMUN, V125, pS41, DOI 10.1016/j.jaci.2009.09.046; Setliff I, 2019, CELL, V179, P1636, DOI 10.1016/j.cell.2019.11.003; Sok D, 2016, SCIENCE, V353, P1557, DOI 10.1126/science.aah3945; Steichen JM, 2019, SCIENCE, V366, P1216, DOI 10.1126/science.aax4380; Sui JH, 2009, NAT STRUCT MOL BIOL, V16, P265, DOI 10.1038/nsmb.1566; Tian M, 2016, CELL, V166, P1471, DOI 10.1016/j.cell.2016.07.029; Tokatlian T, 2019, SCIENCE, V363, P649, DOI 10.1126/science.aat9120; Tokatlian T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34853-2; Tzarum N, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav1882; Veneziano R, 2020, NAT NANOTECHNOL, V15, P716, DOI 10.1038/s41565-020-0719-0; Villar RF, 2016, SCI REP-UK, V6, DOI 10.1038/srep36298; Wang C, 2014, J IMMUNOL, V192, P603, DOI 10.4049/jimmunol.1301384; Weaver GC, 2016, NAT PROTOC, V11, P193, DOI 10.1038/nprot.2016.009; Wec AZ, 2020, P NATL ACAD SCI USA, V117, P6675, DOI 10.1073/pnas.1921388117; Willis JR, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003045; Wu XL, 2011, SCIENCE, V333, P1593, DOI 10.1126/science.1207532; Xu JL, 2000, IMMUNITY, V13, P37, DOI 10.1016/S1074-7613(00)00006-6; Yassine HM, 2015, NAT MED, V21, P1065, DOI 10.1038/nm.3927; Yousif AS, 2021, IMMUNITY, V54, P235, DOI 10.1016/j.immuni.2020.12.001; Yuan M, 2020, SCIENCE, V369, P1119, DOI 10.1126/science.abd2321; Zhou TQ, 2015, CELL, V161, P1280, DOI 10.1016/j.cell.2015.05.007; Zhou TQ, 2013, IMMUNITY, V39, P245, DOI 10.1016/j.immuni.2013.04.012; Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819	92	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 9	2021	12								730471	10.3389/fimmu.2021.730471	http://dx.doi.org/10.3389/fimmu.2021.730471			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV9FA	34566992	Green Published, gold			2022-12-18	WOS:000717533600001
J	Schurgers, E; Wraith, DC				Schurgers, Evelien; Wraith, David C.			Induction of Tolerance to Therapeutic Proteins With Antigen-Processing Independent T Cell Epitopes: Controlling Immune Responses to Biologics	FRONTIERS IN IMMUNOLOGY			English	Review						Immunological tolerance; haemophilia A; Tr1 cell; Treg cell; immunotherapy; hypersensitivity; synthetic peptide; T cell epitope	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; VIII INHIBITOR DEVELOPMENT; HEMOPHILIA-A; REGULATORY CELLS; ORAL TOLERANCE; FVIII; PEPTIDE; PREVENTION; MICE; DIFFERENTIATION	The immune response to exogenous proteins can overcome the therapeutic benefits of immunotherapies and hamper the treatment of protein replacement therapies. One clear example of this is haemophilia A resulting from deleterious mutations in the FVIII gene. Replacement with serum derived or recombinant FVIII protein can cause anti-drug antibodies in 20-50% of individuals treated. The resulting inhibitor antibodies override the benefit of treatment and, at best, make life unpredictable for those treated. The only way to overcome the inhibitor issue is to reinstate immunological tolerance to the administered protein. Here we compare the various approaches that have been tested and focus on the use of antigen-processing independent T cell epitopes (apitopes) for tolerance induction. Apitopes are readily designed from any protein whether this is derived from a clotting factor, enzyme replacement therapy, gene therapy or therapeutic antibody.	[Schurgers, Evelien] Apitope Int NV, Diepenbeek, Belgium; [Wraith, David C.] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England	University of Birmingham	Wraith, DC (corresponding author), Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England.	d.wraith@bham.ac.uk		Schurgers, Evelien/0000-0001-8397-3112				Anderton SM, 2002, NAT IMMUNOL, V3, P175, DOI 10.1038/ni756; Anderton SM, 1998, EUR J IMMUNOL, V28, P1251, DOI 10.1002/(SICI)1521-4141(199804)28:04<1251::AID-IMMU1251>3.0.CO;2-O; Anderton SM, 2001, J EXP MED, V193, P1, DOI 10.1084/jem.193.1.1; Bevington SL, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107748; Blumberg RS, 2018, BLOOD, V131, P2205, DOI 10.1182/blood-2017-12-822908; BRAY GL, 1993, AM J HEMATOL, V42, P375, DOI 10.1002/ajh.2830420408; Burkhart C, 1999, INT IMMUNOL, V11, P1625, DOI 10.1093/intimm/11.10.1625; Burton BR, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5741; Chataway J, 2018, NEUROLOGY, V90, pE955, DOI 10.1212/WNL.0000000000005118; Chihara N, 2018, NATURE, V558, P454, DOI 10.1038/s41586-018-0206-z; Clemente-Casares X, 2016, NATURE, V530, P434, DOI 10.1038/nature16962; De Souza ALS, 2018, NEUROL THER, V7, P103, DOI 10.1007/s40120-018-0094-z; Faria AMC, 1999, ADV IMMUNOL, V73, P153, DOI 10.1016/S0065-2776(08)60787-7; Gabrysova L, 2010, EUR J IMMUNOL, V40, P1386, DOI 10.1002/eji.200940151; Gabrysova L, 2009, J EXP MED, V206, P1755, DOI 10.1084/jem.20082118; Gaitonde P, 2013, J BIOL CHEM, V288, P17051, DOI 10.1074/jbc.C112.396325; Hausl C, 2004, BLOOD, V104, P115, DOI 10.1182/blood-2003-07-2456; Hawiger D, 2001, J EXP MED, V194, P769, DOI 10.1084/jem.194.6.769; Hay CRM, 2012, BLOOD, V119, P1335, DOI 10.1182/blood-2011-08-369132; Hay CRM, 1997, THROMB HAEMOSTASIS, V77, P234; Herzog RW, 2017, MOL THER, V25, P512, DOI 10.1016/j.ymthe.2016.11.009; Hofbauer CJ, 2015, BLOOD, V125, P1180, DOI 10.1182/blood-2014-09-598268; Jansson L, 2018, ENDOCRINOLOGY, V159, P3446, DOI 10.1210/en.2018-00306; Kim YC, 2015, BLOOD, V125, P1107, DOI 10.1182/blood-2014-04-566786; Krienke Christina, 2021, Science, V371, P145, DOI 10.1126/science.aay3638; Lacroix-Desmazes S, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02991; Metzler B, 1996, ANN NY ACAD SCI, V778, P228, DOI 10.1111/j.1749-6632.1996.tb21131.x; METZLER B, 1993, INT IMMUNOL, V5, P1159, DOI 10.1093/intimm/5.9.1159; Moghimi B, 2011, J THROMB HAEMOST, V9, P1524, DOI 10.1111/j.1538-7836.2011.04351.x; Nicolson KS, 2006, J IMMUNOL, V176, P5329, DOI 10.4049/jimmunol.176.9.5329; Pearce SHS, 2019, THYROID, V29, P1003, DOI 10.1089/thy.2019.0036; Peyvandi F, 2016, NEW ENGL J MED, V374, P2054, DOI 10.1056/NEJMoa1516437; Pletinckx K, 2022, BLOOD ADV, V6, P2069, DOI 10.1182/bloodadvances.2021004451; Qian JH, 2000, BLOOD, V95, P1324, DOI 10.1182/blood.V95.4.1324.004k25_1324_1329; Qian JJ, 1999, THROMB HAEMOSTASIS, V81, P240, DOI 10.1055/s-0037-1614450; Quistrebert J, 2019, SEMIN ARTHRITIS RHEU, V48, P967, DOI 10.1016/j.semarthrit.2018.10.006; RAGNI MV, 1989, TRANSFUSION, V29, P447, DOI 10.1046/j.1537-2995.1989.29589284147.x; Reipert BM, 2001, THROMB HAEMOSTASIS, V86, P1345, DOI 10.1055/s-0037-1616733; Schep SJ, 2018, BLOOD REV, V32, P326, DOI 10.1016/j.blre.2018.02.003; Shen CR, 2003, BLOOD, V102, P3800, DOI 10.1182/blood-2002-07-2125; Shepard ER, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.654201; Steinitz KN, 2012, BLOOD, V119, P4073, DOI 10.1182/blood-2011-08-374645; Streeter HB, 2021, CURR OPIN IMMUNOL, V70, P75, DOI 10.1016/j.coi.2021.03.019; Streeter HB, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000093; Sundstedt A, 2003, J IMMUNOL, V170, P1240, DOI 10.4049/jimmunol.170.3.1240; van Haren SD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080239; Varthaman A, 2019, HAEMATOLOGICA, V104, P236, DOI 10.3324/haematol.2018.206383; Waters B, 2009, BLOOD, V113, P193, DOI 10.1182/blood-2008-04-151597; Wraith DC, 2018, CURR OPIN CHEM ENG, V19, P35, DOI 10.1016/j.coche.2017.12.004; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0; Wroblewska A, 2013, J THROMB HAEMOST, V11, P47, DOI 10.1111/jth.12065; Yoon J, 2017, BLOOD, V129, P238, DOI 10.1182/blood-2016-07-727834; Zhang AH, 2016, CELL IMMUNOL, V301, P74, DOI 10.1016/j.cellimm.2015.11.004; Zhang AH, 2011, BLOOD, V117, P2223, DOI 10.1182/blood-2010-06-293324	54	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 9	2021	12								742695	10.3389/fimmu.2021.742695	http://dx.doi.org/10.3389/fimmu.2021.742695			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UT9RO	34567009	Green Published, gold			2022-12-18	WOS:000698445200001
J	Spatz, LA; Silverman, GJ; James, JA				Spatz, Linda A.; Silverman, Gregg J.; James, Judith A.			Editorial: Pathogens, Pathobionts, and Autoimmunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						autoimmunity; autoimmune diseases; pathogens; viruses; molecular mimicry; SLE; pathobionts and gut microbiome; dysbiosis	LUPUS; EBNA-1; MICE; EBV		[Spatz, Linda A.] CUNY, CUNY Sch Med, Dept Mol Cellular & Biomed Sci, New York, NY 10021 USA; [Silverman, Gregg J.] NYU, Dept Med, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA; [Silverman, Gregg J.] NYU, Dept Pathol, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA; [James, Judith A.] Oklahoma Med Res Fdn, Dept Arthrit & Clin Immunol, 825 NE 13th St, Oklahoma City, OK 73104 USA	City University of New York (CUNY) System; New York University; New York University; Oklahoma Medical Research Foundation	Spatz, LA (corresponding author), CUNY, CUNY Sch Med, Dept Mol Cellular & Biomed Sci, New York, NY 10021 USA.	lspatz@med.cuny.edu			Global Autoimmune Institute (GAI); NIH [U54GM104938, UM1144292, P30AR073750, P50 AR070591-01A1, R01 AI143313-01U, R01 LM012517]; Lupus Research Alliance	Global Autoimmune Institute (GAI); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lupus Research Alliance	LAS is supported by a grant from the Global Autoimmune Institute (GAI). GJS is supported by NIH grants, P50 AR070591-01A1, R01 AI143313-01U, R01 LM012517, and a grant from the Lupus Research Alliance. JAJ is supported by NIH grants U54GM104938, UM1144292, and P30AR073750.	Azzouz D, 2019, ANN RHEUM DIS, V78, P947, DOI 10.1136/annrheumdis-2018-214856; Cros J, 2010, IMMUNITY, V33, P375, DOI 10.1016/j.immuni.2010.08.012; Gross AJ, 2005, J IMMUNOL, V174, P6599, DOI 10.4049/jimmunol.174.11.6599; Harley JB, 2018, NAT GENET, V50, P699, DOI 10.1038/s41588-018-0102-3; James JA, 1997, ANN NY ACAD SCI, V815, P124, DOI 10.1111/j.1749-6632.1997.tb52054.x; Jog NR, 2019, ANN RHEUM DIS, V78, P1235, DOI 10.1136/annrheumdis-2019-215361; Jog NR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02198; Kang I, 2004, J IMMUNOL, V172, P1287, DOI 10.4049/jimmunol.172.2.1287; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Larsen M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002328; MIELANTS H, 1995, J RHEUMATOL, V22, P2266; Peters AL, 2010, J IMMUNOL, V185, P4053, DOI 10.4049/jimmunol.0904065; Poole BD, 2008, J AUTOIMMUN, V31, P362, DOI 10.1016/j.jaut.2008.08.007; Samanta M, 2006, EMBO J, V25, P4207, DOI 10.1038/sj.emboj.7601314; Stunz LL, 2004, IMMUNITY, V21, P255, DOI 10.1016/j.immuni.2004.07.008; Yadav P, 2016, IMMUN INFLAMM DIS, V4, P362, DOI 10.1002/iid3.119	16	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 8	2021	12								752980	10.3389/fimmu.2021.752980	http://dx.doi.org/10.3389/fimmu.2021.752980			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UU5DX	34567014	Green Published, gold			2022-12-18	WOS:000698821900001
J	Cosgrove, J; Alden, K; Stein, JV; Coles, MC; Timmis, J				Cosgrove, Jason; Alden, Kieran; Stein, Jens, V; Coles, Mark C.; Timmis, Jon			Simulating CXCR5 Dynamics in Complex Tissue Microenvironments	FRONTIERS IN IMMUNOLOGY			English	Article						B cells; chemokines; systems biology; G-protein coupled receptors; mathematical modelling	B-CELL MIGRATION; RECEPTOR DESENSITIZATION; CHEMOKINE RECEPTOR; PEPTIDE; RECRUITMENT; LYMPHOCYTE; LIGANDS; MODEL	To effectively navigate complex tissue microenvironments, immune cells sense molecular concentration gradients using G-protein coupled receptors. However, due to the complexity of receptor activity, and the multimodal nature of chemokine gradients in vivo, chemokine receptor activity in situ is poorly understood. To address this issue, we apply a modelling and simulation approach that permits analysis of the spatiotemporal dynamics of CXCR5 expression within an in silico B-follicle with single-cell resolution. Using this approach, we show that that in silico B-cell scanning is robust to changes in receptor numbers and changes in individual kinetic rates of receptor activity, but sensitive to global perturbations where multiple parameters are altered simultaneously. Through multi-objective optimization analysis we find that the rapid modulation of CXCR5 activity through receptor binding, desensitization and recycling is required for optimal antigen scanning rates. From these analyses we predict that chemokine receptor signaling dynamics regulate migration in complex tissue microenvironments to a greater extent than the total numbers of receptors on the cell surface.	[Cosgrove, Jason; Alden, Kieran] Univ York, Dept Elect Engn, York, N Yorkshire, England; [Cosgrove, Jason] Univ PSL, Inst Curie, Sorbonne Univ, CNRS,UMR168,Lab Phys Chim Curie, Paris, France; [Stein, Jens, V] Univ Fribourg, Dept Oncol Microbiol & Immunol, Fribourg, Switzerland; [Coles, Mark C.] Univ Oxford, Kennedy Inst Rheumatol, Oxford, England; [Timmis, Jon] Univ Sunderland, Sch Comp Sci, Sunderland, England	University of York - UK; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie; Universite Paris Cite; University of Fribourg; University of Oxford; University of Sunderland	Cosgrove, J (corresponding author), Univ York, Dept Elect Engn, York, N Yorkshire, England.; Cosgrove, J (corresponding author), Univ PSL, Inst Curie, Sorbonne Univ, CNRS,UMR168,Lab Phys Chim Curie, Paris, France.; Coles, MC (corresponding author), Univ Oxford, Kennedy Inst Rheumatol, Oxford, England.; Timmis, J (corresponding author), Univ Sunderland, Sch Comp Sci, Sunderland, England.	jason.cosgrove47@gmail.com; mark.coles2@kennedy.ox.ac.uk; jon.timmis@sunderland.ac.uk		Cosgrove, Jason/0000-0003-3121-2009; Stein, Jens V/0000-0002-8199-9586	Wellcome Trust Centre for Future Health grant [204829]; EPSRC [EP/K040820/1]; Wellcome Trust (Computational Approaches in Translational Science) [WT0905024MA]; HFSP [RGP0006/2009]; Medical Research Grants [MR/K021125/1, G0601156]; Kennedy Trust	Wellcome Trust Centre for Future Health grant(Wellcome Trust); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Wellcome Trust (Computational Approaches in Translational Science)(Wellcome Trust); HFSP(Human Frontier Science Program); Medical Research Grants; Kennedy Trust	KA was supported by Wellcome Trust Centre for Future Health grant (204829), JT by EPSRC grant EP/K040820/1. JC, JT, and MC were funded by Wellcome Trust (Computational Approaches in Translational Science WT0905024MA, HFSP (RGP0006/2009 MC) and Medical Research Grants MR/K021125/1 and G0601156. MC is funded by the Kennedy Trust.	Alden K, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2014.1059; Alden K, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002916; Andrews P., 2010, YCS2010453; Ansel KM, 2000, NATURE, V406, P309, DOI 10.1038/35018581; Aronin CEP, 2017, IMMUNITY, V47, P862, DOI 10.1016/j.immuni.2017.10.020; Barroso R, 2012, FASEB J, V26, P4841, DOI 10.1096/fj.12-208876; Bennett LD, 2011, IMMUNOLOGY, V134, P246, DOI 10.1111/j.1365-2567.2011.03485.x; Beyer T, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.021929; Beyer T, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.148102; Calebiro D, 2013, P NATL ACAD SCI USA, V110, P743, DOI 10.1073/pnas.1205798110; Chan C, 2013, B MATH BIOL, V75, P185, DOI 10.1007/s11538-012-9799-9; Coelho FM, 2013, BLOOD, V121, P4101, DOI 10.1182/blood-2012-10-465336; Cosgrove J, 2015, CPT-PHARMACOMET SYST, V4, P615, DOI 10.1002/psp4.12018; Cosgrove J., 2017, SPATIAL DISTRIBUTION, pE189; Cosgrove J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17135-2; Deb K, 2002, IEEE T EVOLUT COMPUT, V6, P182, DOI 10.1109/4235.996017; Eden E, 2011, SCIENCE, V331, P764, DOI 10.1126/science.1199784; Figge MT, 2008, J EXP MED, V205, P3019, DOI 10.1084/jem.20081160; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; Gunn MD, 1998, NATURE, V391, P799, DOI 10.1038/35876; Gutenkunst RN, 2007, PLOS COMPUT BIOL, V3, P1871, DOI 10.1371/journal.pcbi.0030189; Herzmark P, 2007, P NATL ACAD SCI USA, V104, P13349, DOI 10.1073/pnas.0705889104; Irla M, 2013, J IMMUNOL, V190, P586, DOI 10.4049/jimmunol.1200119; Kohout TA, 2004, J BIOL CHEM, V279, P23214, DOI 10.1074/jbc.M402125200; Kumar V, 2010, BLOOD, V115, P4725, DOI 10.1182/blood-2009-10-250118; Legler DF, 1998, J EXP MED, V187, P655, DOI 10.1084/jem.187.4.655; Lin F, 2008, J IMMUNOL, V181, P8335, DOI 10.4049/jimmunol.181.12.8335; Luke S, 2005, SIMUL-T SOC MOD SIM, V81, P517, DOI 10.1177/0037549705058073; Luther SA, 2002, J IMMUNOL, V169, P424, DOI 10.4049/jimmunol.169.1.424; Marino S, 2008, J THEOR BIOL, V254, P178, DOI 10.1016/j.jtbi.2008.04.011; Milo R., 2015, CELL BIOL NUMBERS; MONROE JG, 1983, J IMMUNOL METHODS, V63, P45, DOI 10.1016/0022-1759(83)90208-9; Onder L, 2017, IMMUNITY, V47, P80, DOI 10.1016/j.immuni.2017.05.008; Otero C, 2006, J IMMUNOL, V177, P2314, DOI 10.4049/jimmunol.177.4.2314; Pereira JP, 2010, INT IMMUNOL, V22, P413, DOI 10.1093/intimm/dxq047; Phair RD, 2001, NAT REV MOL CELL BIO, V2, P898, DOI 10.1038/35103000; Read MN., 2011, STAT MODELLING TECHN; Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543; Royston P., 1992, STAT COMPUT, V2, P117, DOI [10.1007/BF01891203, DOI 10.1007/BF01891203]; Saltelli A, 1998, COMPUT STAT DATA AN, V26, P445, DOI 10.1016/S0167-9473(97)00043-1; Saltelli A., 2008, SENSITIVITY ANAL, V494; Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098; Schwarz J, 2016, SCI REP-UK, V6, DOI 10.1038/srep36440; SKLAR LA, 1984, J BIOL CHEM, V259, P5661; Sommerville I., 2010, SOFTWARE ENG, V792; Vargha A, 2000, J EDUC BEHAV STAT, V25, P101, DOI 10.3102/10769986025002101; Wang Y, 2013, INTEGR BIOL-UK, V5, P481, DOI 10.1039/c3ib20249f; ZIGMOND SH, 1981, J CELL BIOL, V88, P644, DOI 10.1083/jcb.88.3.644; ZIGMOND SH, 1982, J CELL BIOL, V92, P34, DOI 10.1083/jcb.92.1.34	49	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 7	2021	12								703088	10.3389/fimmu.2021.703088	http://dx.doi.org/10.3389/fimmu.2021.703088			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	US4AW	34557191	Green Published, Green Accepted, gold			2022-12-18	WOS:000697375200001
J	Giles, ML; Davey, MA; Wallace, EM				Giles, Michelle L.; Davey, Mary-Ann; Wallace, Euan M.			Associations Between Maternal Immunisation and Reduced Rates of Preterm Birth and Stillbirth: A Population Based Retrospective Cohort Study	FRONTIERS IN IMMUNOLOGY			English	Article						immunisation; pregnancy; influenza; pertussis; preterm birth	INFLUENZA VACCINATION; PREGNANT-WOMEN; OUTCOMES; COUNTRIES	Stillbirth and preterm birth (PTB) remain two of the most important, unresolved challenges in modern pregnancy care. Approximately 10% of all births are preterm with nearly one million children dying each year due to PTB. It remains the most common cause of death among children under five years of age. The numbers for stillbirth are no less shocking with 2.6 million babies stillborn each year. With minimal impact on the rate of these adverse birth outcomes over the past decade there is an urgent need to identify more effective interventions to tackle these problems. In this retrospective cohort study, we used whole-of-population data, to determine if maternal immunization during pregnancy against influenza and/or pertussis, is associated with a lower risk of PTB, delivering a small-for-gestational age (SGA) infant, developing preeclampsia or stillbirth. Women with a singleton pregnancy at 28 or more weeks' gestation delivering in Victoria, Australia from July 2015 to December 2018 were included in the analysis. Log-binomial regression was used to measure the relationship between vaccination during pregnancy against influenza and against pertussis, with preterm birth, SGA, preeclampsia and stillbirth. Variables included in the adjusted model were maternal age, body mass index, first or subsequent birth, maternal Indigenous status, socio-economic quintile, smoking, public or private maternity care and metropolitan or rural location of the hospital. Women who received influenza vaccine were 75% less likely to have a stillbirth (aRR 025; 95% CI 0.20, 0.31), and 31% less likely to birth <37 weeks (aRR 0.69; 95% CI 0.66, 0.72). Women who received pertussis vaccine were 77% less likely to have a stillbirth (aOR 0.23; 95% CI 0.18, 0.28) and 32% less likely to birth <37 weeks gestation (aRR 0.68; 95% CI 0.66, 0.71). Vaccination also reduced the odds of small for gestational age by 13% and reduced the odds of pre-eclampsia when restricted to primiparous women. This association was seen over four different influenza seasons and independent of the time of year suggesting that any protective effect on obstetric outcomes afforded by maternal vaccination may not be due to a pathogen-specific response but rather due to pathogen-agnostic immune-modulatory effects.</p>	[Giles, Michelle L.; Davey, Mary-Ann; Wallace, Euan M.] Monash Univ, Ritchie Ctr, Dept Obstet & Gynaecol, Clayton, Vic, Australia	Monash University	Giles, ML (corresponding author), Monash Univ, Ritchie Ctr, Dept Obstet & Gynaecol, Clayton, Vic, Australia.	michelle.giles@monash.edu						Amirthalingam G, 2014, LANCET, V384, P1521, DOI 10.1016/S0140-6736(14)60686-3; [Anonymous], 2017, Wkly Epidemiol Rec, V92, P53; [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461; Arriola CS, 2017, VACCINE, V35, P3056, DOI 10.1016/j.vaccine.2017.04.045; Blencowe H, 2012, LANCET, V379, P2162, DOI 10.1016/S0140-6736(12)60820-4; Brook B, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax4517; Calvert A, 2017, CURR OPIN INFECT DIS, V30, P268, DOI 10.1097/QCO.0000000000000372; Chawanpaiboon S, 2019, LANCET GLOB HEALTH, V7, pE37, DOI 10.1016/S2214-109X(18)30451-0; Council NHMRC., 2015, AUSTR IMMUNISATION H; Flood MM, 2017, HEALTH INF MANAG J, V46, P113, DOI 10.1177/1833358316689688; Giles ML, 2020, VACCINE, V38, P5268, DOI 10.1016/j.vaccine.2020.05.084; Giles ML, 2019, HUM VACC IMMUNOTHER, V15, P687, DOI 10.1080/21645515.2018.1540807; Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4; Goodridge HS, 2016, NAT REV IMMUNOL, V16, P392, DOI 10.1038/nri.2016.43; Iams JD, 2008, LANCET, V371, P164, DOI 10.1016/S0140-6736(08)60108-7; Jeong S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220910; Kollmann TR, 2020, SCIENCE, V368, P612, DOI 10.1126/science.aaz9447; Lawn JE, 2016, LANCET, V387, P587, DOI 10.1016/S0140-6736(15)00837-5; Lawn JE, 2014, LANCET, V384, P189, DOI 10.1016/S0140-6736(14)60496-7; Munoz FM, 2012, AM J OBSTET GYNECOL, V207, pS33, DOI 10.1016/j.ajog.2012.06.072; Olsen SJ, 2016, CLIN INFECT DIS, V63, P487, DOI 10.1093/cid/ciw290; Omer SB, 2020, LANCET RESP MED, V8, P597, DOI 10.1016/S2213-2600(19)30479-5; Ortiz JR, 2016, VACCINE, V34, P5400, DOI 10.1016/j.vaccine.2016.07.045; Public Health England, 2015, IMMUNISATION INFECT; Redman CWG, 2003, PLACENTA, V24, pS21, DOI 10.1053/plac.2002.0930; Regan AK, 2016, CLIN INFECT DIS, V62, P1221, DOI 10.1093/cid/ciw082; Romero R, 2014, SCIENCE, V345, P760, DOI 10.1126/science.1251816; Sawyer M, 2013, MMWR-MORBID MORTAL W, V62, P131; Sibai B, 2005, LANCET, V365, P785, DOI 10.1016/S0140-6736(05)71003-5; Vazquez-Benitez G, 2016, AM J EPIDEMIOL, V184, P176, DOI 10.1093/aje/kww043; World Health Organization, 2019, PROT ALL TET GUID SU	31	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 7	2021	12								704254	10.3389/fimmu.2021.704254	http://dx.doi.org/10.3389/fimmu.2021.704254			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	US7CC	34557193	gold, Green Published			2022-12-18	WOS:000697582700001
J	Pinto, AK; Hassert, M; Han, XB; Barker, D; Carnelley, T; Branche, E; Steffen, TL; Stone, ET; Geerling, E; Viramontes, KM; Nykiforuk, C; Toth, D; Shresta, S; Kodihalli, S; Brien, JD				Pinto, Amelia K.; Hassert, Mariah; Han, Xiaobing; Barker, Douglas; Carnelley, Trevor; Branche, Emilie; Steffen, Tara L.; Stone, E. Taylor; Geerling, Elizabeth; Viramontes, Karla M.; Nykiforuk, Cory; Toth, Derek; Shresta, Sujan; Kodihalli, Shantha; Brien, James D.			The Ability of Zika virus Intravenous Immunoglobulin to Protect From or Enhance Zika Virus Disease	FRONTIERS IN IMMUNOLOGY			English	Article						Zika virus; dengue virus; hyperimmunoglobulin; antibody dependent enhancement; animal model	ANTIBODY-DEPENDENT ENHANCEMENT; DENGUE VIRUS; MEDIATED NEUTRALIZATION; ARBOVIRUS INFECTIONS; CROSS-REACTIVITY; FEVER; MODEL; CYTOMEGALOVIRUS; PROPHYLAXIS; OUTBREAK	The closely related flaviviruses, dengue and Zika, cause significant human disease throughout the world. While cross-reactive antibodies have been demonstrated to have the capacity to potentiate disease or mediate protection during flavivirus infection, the mechanisms responsible for this dichotomy are still poorly understood. To understand how the human polyclonal antibody response can protect against, and potentiate the disease in the context of dengue and Zika virus infection we used intravenous hyperimmunoglobulin (IVIG) preparations in a mouse model of the disease. Three IVIGs (ZIKV-IG, Control-Ig and Gamunex(R)) were evaluated for their ability to neutralize and/or enhance Zika, dengue 2 and 3 viruses in vitro. The balance between virus neutralization and enhancement provided by the in vitro neutralization data was used to predict the IVIG concentrations which could protect or enhance Zika, and dengue 2 disease in vivo. Using this approach, we were able to define the unique in vivo dynamics of complex polyclonal antibodies, allowing for both enhancement and protection from flavivirus infection. Our results provide a novel understanding of how polyclonal antibodies interact with viruses with implications for the use of polyclonal antibody therapeutics and the development and evaluation of the next generation flavivirus vaccines.	[Pinto, Amelia K.; Hassert, Mariah; Steffen, Tara L.; Stone, E. Taylor; Geerling, Elizabeth; Brien, James D.] St Louis Univ, Dept Mol Microbiol & Immunol, St Louis, MO 63103 USA; [Han, Xiaobing; Barker, Douglas; Carnelley, Trevor; Nykiforuk, Cory; Toth, Derek; Kodihalli, Shantha] Emergent BioSolut Canada Inc, Winnipeg, MB, Canada; [Branche, Emilie; Viramontes, Karla M.; Shresta, Sujan] La Jolla Inst Immunol, Ctr Infect Dis & Vaccine Res, La Jolla, CA USA	Saint Louis University; La Jolla Institute for Immunology	Pinto, AK; Brien, JD (corresponding author), St Louis Univ, Dept Mol Microbiol & Immunol, St Louis, MO 63103 USA.; Kodihalli, S (corresponding author), Emergent BioSolut Canada Inc, Winnipeg, MB, Canada.	pintoak@slu.edu; skodihalli@ebsi.com; brienj@slu.edu			Saint Louis University; Emergent BioSolutions; National Institutes of Health grant from the National Institute of Allergy and Infectious Diseases (NIAID) [F31 AI152460-01]; NIH grant from the NIAID [R0112781495]	Saint Louis University; Emergent BioSolutions; National Institutes of Health grant from the National Institute of Allergy and Infectious Diseases (NIAID); NIH grant from the NIAID	This research was funded by Saint Louis University startup funding and a research contract from Emergent BioSolutions to SK, SS, AP and JB. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. This work was also supported by National Institutes of Health grant F31 AI152460-01 from the National Institute of Allergy and Infectious Diseases (NIAID) awarded to MH, NIH grant R0112781495 from the NIAID awarded to AP and JB.	Andrade P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08845-3; [Anonymous], 2015, Wkly Epidemiol Rec, V90, P609; Austin SK, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002930; Balsitis SJ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000790; Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365; Benhnia MREI, 2009, J VIROL, V83, P1201, DOI 10.1128/JVI.01797-08; Bialas KM, 2015, CLIN PERINATOL, V42, P61, DOI 10.1016/j.clp.2014.10.006; Branche E, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46291-9; BRANDT WE, 1982, INFECT IMMUN, V36, P1036, DOI 10.1128/IAI.36.3.1036-1041.1982; Brien JD, 2019, JOVE-J VIS EXP, DOI 10.3791/59632; Brien JD, 2013, J VIROL, V87, P7747, DOI 10.1128/JVI.00327-13; Brien JD, 2010, J VIROL, V84, P10630, DOI 10.1128/JVI.01190-10; Brown JA, 2019, IMMUNITY, V50, P751, DOI 10.1016/j.immuni.2019.01.005; Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI [10.3201/eid2006.140138, 10.3201/eid2011.141380]; Chau Tran Nguyen Bich, 2008, J Infect Dis, V198, P516, DOI 10.1086/590117; Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515; Dejnirattisai W, 2015, NAT IMMUNOL, V16, P170, DOI 10.1038/ni.3058; DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4; Dowd KA, 2014, J VIROL, V88, P11726, DOI 10.1128/JVI.01140-14; Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715; DUPAN RM, 1972, J INFECT DIS, V126, P341, DOI 10.1093/infdis/126.3.341; Dussupt V, 2020, NAT MED, V26, P228, DOI 10.1038/s41591-019-0746-2; FAGBAMI A, 1977, TROP GEOGR MED, V29, P187; FAGBAMI AH, 1979, J HYG-CAMBRIDGE, V83, P213, DOI 10.1017/S0022172400025997; Fowler AM, 2018, CELL HOST MICROBE, V24, P743, DOI 10.1016/j.chom.2018.09.015; George J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10901-1; GESER A, 1970, Bulletin of the World Health Organization, V43, P539; Gharebaghi N, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05507-4; Gordon A, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002726; Gunawardana SA, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3572-0; Halstead SB, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.AID-0022-2014; Hassert M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01678; Hastings AK, 2017, YALE J BIOL MED, V90, P325; Heang V, 2012, EMERG INFECT DIS, V18, P349, DOI 10.3201/eid1802.111224; Hemming VG, 2001, CLIN DIAGN LAB IMMUN, V8, P859, DOI 10.1128/CDLI.8.5.859-863.2001; Hessert M, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007237; Huang HR, 2017, J VIROL, V91, DOI [10.1128/JVI.00900-17, 10.1128/jvi.00900-17]; JAN C, 1978, B SOC PATHOL EXOT, V71, P140; Joao C, 2018, J IMMUNOL, V200, P1957, DOI 10.4049/jimmunol.1701271; Jurado KA, 2018, NAT MICROBIOL, V3, P141, DOI 10.1038/s41564-017-0060-z; Katzelnick LC, 2020, SCIENCE, V369, P1123, DOI 10.1126/science.abb6143; KEMPE CH, 1956, PEDIATRICS, V18, P177; KLIKS SC, 1988, AM J TROP MED HYG, V38, P411, DOI 10.4269/ajtmh.1988.38.411; Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287; Langerak T, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007640; Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010; Lazear HM, 2016, J VIROL, V90, P4864, DOI 10.1128/JVI.00252-16; Li M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200478; LITTAUA R, 1990, J IMMUNOL, V144, P3183; Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396; MARCHETTE NJ, 1969, AM J TROP MED HYG, V18, P411, DOI 10.4269/ajtmh.1969.18.411; Martin-Acebes MA, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00044; McCracken MK, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006487; MCCRAE AWR, 1982, T ROY SOC TROP MED H, V76, P552, DOI 10.1016/0035-9203(82)90161-4; Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831; Montecillo-Aguado MR, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/7239347; Montoya M, 2018, J INFECT DIS, V218, P536, DOI 10.1093/infdis/jiy164; Murphy BR, 2011, ANNU REV IMMUNOL, V29, P587, DOI 10.1146/annurev-immunol-031210-101315; Ngono AE, 2017, CELL HOST MICROBE, V21, P35, DOI 10.1016/j.chom.2016.12.010; Nigro G, 2012, J MATERN-FETAL NEO M, V25, P2202, DOI 10.3109/14767058.2012.684111; Oehler E, 2014, EUROSURVEILLANCE, V19, P4; OLSON JG, 1981, T ROY SOC TROP MED H, V75, P389, DOI 10.1016/0035-9203(81)90100-0; Pantoja P, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15674; Pardy RD, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006184; Paz-Bailey G, 2018, NEW ENGL J MED, V379, P1234, DOI 10.1056/NEJMoa1613108; Petersen EE, 2016, MMWR-MORBID MORTAL W, V65, P30, DOI 10.15585/mmwr.mm6502e1; Pierson TC, 2008, CELL HOST MICROBE, V4, P229, DOI 10.1016/j.chom.2008.08.004; Pierson TC, 2007, CELL HOST MICROBE, V1, P135, DOI 10.1016/j.chom.2007.03.002; Pierson TC, 2020, NAT MICROBIOL, V5, P796, DOI 10.1038/s41564-020-0714-0; Pierson TC, 2012, CURR OPIN VIROL, V2, P168, DOI 10.1016/j.coviro.2012.02.011; Pinto AK, 2015, MBIO, V6, DOI 10.1128/mBio.01316-15; Planitzer CB, 2007, J INFECT DIS, V196, P435, DOI 10.1086/519392; Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113; RENAUDET J, 1978, B SOC PATHOL EXOT, V71, P131; Reynolds CJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18781-1; Riemersma KK, 2021, J VIROL, V95, DOI 10.1128/JVI.02218-20; Robin Y., 1975, Bulletin Soc Path Exot, V68, P249; RODHAIN F, 1989, T ROY SOC TROP MED H, V83, P851, DOI 10.1016/0035-9203(89)90352-0; Sarathy VV, 2015, J VIROL, V89, P1254, DOI 10.1128/JVI.01320-14; Shim BS, 2019, MBIO, V10, DOI 10.1128/mBio.00758-19; Shimoni Z, 2001, EMERG INFECT DIS, V7, P759; Shresta S, 2006, J VIROL, V80, P10208, DOI 10.1128/JVI.00062-06; SIMPSON D. I. H., 1964, TRANS ROY SOC TROP MED HYG, V58, P335, DOI 10.1016/0035-9203(64)90201-9; Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505; VanBlargan LA, 2016, MICROBIOL MOL BIOL R, V80, DOI 10.1128/MMBR.00024-15; Waggoner JJ, 2020, J INFECT DIS, V221, P1846, DOI 10.1093/infdis/jiz618; Ye Q, 2016, INFECT GENET EVOL, V43, P43, DOI 10.1016/j.meegid.2016.05.004; Zellweger RM, 2010, CELL HOST MICROBE, V7, P128, DOI 10.1016/j.chom.2010.01.004	88	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 6	2021	12								717425	10.3389/fimmu.2021.717425	http://dx.doi.org/10.3389/fimmu.2021.717425			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV8HV	34552587	Green Published, gold			2022-12-18	WOS:000717472400001
J	Aranburu, A; Camponeschi, A; Geissler, S; Visentini, M; Rosado, MM				Aranburu, Alaitz; Camponeschi, Alessandro; Geissler, Sven; Visentini, Marcella; Rosado, M. Manuela			Editorial: The B-Side of B Cells	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						B cells; IgM natural antibodies; marginal zone (MZ) B cells; IgA; tertiary lymphoid structure; bloodborne infections			[Aranburu, Alaitz; Camponeschi, Alessandro] Univ Gothenburg, Dept Rheumatol & Inflammat Res, Gothenburg, Sweden; [Geissler, Sven] Charite Univ Med Berlin, Berlin Brandenburg Ctr Regenerat Therapies, Berlin, Germany; [Geissler, Sven] Free Univ Berlin, Berlin, Germany; [Geissler, Sven] Humboldt Univ, Berlin, Germany; [Geissler, Sven] Berlin Inst Hlth, Berlin, Germany; [Visentini, Marcella] Sapienza Univ Rome, Dept Translat & Precis Med, Rome, Italy; [Rosado, M. Manuela] Sapienia Univ Rome, Dept Clin Internal Sci Anesthesiol Cardiovasc Sci, Rome, Italy	University of Gothenburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Sapienza University Rome	Rosado, MM (corresponding author), Sapienia Univ Rome, Dept Clin Internal Sci Anesthesiol Cardiovasc Sci, Rome, Italy.	mariamanuelamrosado@gmail.com	Geißler, Sven/J-7275-2013	Geißler, Sven/0000-0002-8750-6324	German Research Foundation (DFG) [RG2165 (GE2512/2-2), CRC1444]; German Federal Ministry of Education and Research (BMBF) [031L0234B]; European Union's Horizon 2020 research and innovation programme [779293]	German Research Foundation (DFG)(German Research Foundation (DFG)); German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); European Union's Horizon 2020 research and innovation programme	SG was supported by the German Research Foundation (DFG) through funding of the RG2165 (GE2512/2-2) and the CRC1444, the German Federal Ministry of Education and Research (BMBF, 031L0234B) and the European Union's Horizon 2020 research and innovation programme under grant No 779293 (HIPGEN).	Cancro MP, 2020, ANNU REV IMMUNOL, V38, P315, DOI 10.1146/annurev-immunol-092419-031130; Kreslaysky T, 2018, CURR OPIN IMMUNOL, V51, P24, DOI 10.1016/j.coi.2018.01.001; Kristiansen TA, 2018, CURR OPIN IMMUNOL, V51, P7, DOI 10.1016/j.coi.2017.12.005; Lund FE, 2008, CURR OPIN IMMUNOL, V20, P332, DOI 10.1016/j.coi.2008.03.003; Sage AP, 2019, NAT REV CARDIOL, V16, P180, DOI 10.1038/s41569-018-0106-9; Srikakulapu P, 2017, AM J PHYSIOL-HEART C, V312, pH1060, DOI 10.1152/ajpheart.00859.2016; Van Hees S, 2021, CELL IMMUNOL, V362, DOI 10.1016/j.cellimm.2021.104283; Vigano M, 2014, EXPERT OPIN BIOL TH, V14, P1019, DOI 10.1517/14712598.2014.912273	8	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 3	2021	12								758164	10.3389/fimmu.2021.758164	http://dx.doi.org/10.3389/fimmu.2021.758164			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XF8DA	34539680	gold, Green Published			2022-12-18	WOS:000724295800001
J	Hardy, MY; Agardh, D; Anderson, RP				Hardy, Melinda Y.; Agardh, Daniel; Anderson, Robert P.			Editorial: Lessons on T-Cells and Immune-Targeting Therapeutics in Coeliac Disease	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						autoimmunity; coeliac disease; dermatitis herpetiformis; prevention; T cells; transglutaminase; treatment	BLOOD		[Hardy, Melinda Y.] Walter & Eliza Hall Inst Med Res, Div Immunol, Parkville, Vic, Australia; [Hardy, Melinda Y.] Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia; [Agardh, Daniel] Lund Univ, Unit Diabet & Celiac Dis, Dept Clin Sci, Malmo, Sweden; [Anderson, Robert P.] Wesley Med Res Wesley Hosp, Auchenflower, Qld, Australia	Walter & Eliza Hall Institute; University of Melbourne; Lund University	Anderson, RP (corresponding author), Wesley Med Res Wesley Hosp, Auchenflower, Qld, Australia.	banderson99133@gmail.com						Christophersen A, 2014, UNITED EUR GASTROENT, V2, P268, DOI 10.1177/2050640614540154; Hardy MY, 2015, J AUTOIMMUN, V56, P56, DOI 10.1016/j.jaut.2014.10.003; Sarna VK, 2018, GASTROENTEROLOGY, V154, P886, DOI 10.1053/j.gastro.2017.11.006; Sollid LM, 2020, IMMUNOGENETICS, V72, P85, DOI 10.1007/s00251-019-01141-w; Tye-Din JA, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001012	5	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 3	2021	12								756087	10.3389/fimmu.2021.756087	http://dx.doi.org/10.3389/fimmu.2021.756087			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UR4MI	34539679	Green Published, gold			2022-12-18	WOS:000696725000001
J	Joalland, N; Ducoin, K; Cadiou, G; Rabu, C; Guillonneau, C				Joalland, Noemie; Ducoin, Kathleen; Cadiou, Gwenann; Rabu, Catherine; Guillonneau, Carole			24th "Nantes Actualites en Transplantation" and 4th "LabEx Immunotherapy-Graft-Oncology" NAT and IGO Joint Meeting "New Horizons in Immunotherapy"	FRONTIERS IN IMMUNOLOGY			English	Review						immunotherapy; transplantation; autoimmunity; cancer; meeting report	MESENCHYMAL STROMAL CELLS; PLEURAL MESOTHELIOMA; MACROPHAGES; SENSITIVITY; TISSUE	The 24th edition of the annual NAT conference (Nantes Actualites Transplantation) and the 4th edition of the biennial LabEx IGO meeting (Immunotherapy Graft Oncology) were held jointly around a common theme: "New horizons in immunotherapy", on May 31st and June 1st 2021 to highlight new findings in the fields of transplantation, autoimmunity and cancer.	[Joalland, Noemie; Guillonneau, Carole] Nantes Univ, CHU Nantes, INSERM, Ctr Rech Transplantat & Immunol,UMR 1064,ITUN, Nantes, France; [Ducoin, Kathleen; Cadiou, Gwenann; Rabu, Catherine] Univ Nantes, INSERM, CRCINA, Nantes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite	Guillonneau, C (corresponding author), Nantes Univ, CHU Nantes, INSERM, Ctr Rech Transplantat & Immunol,UMR 1064,ITUN, Nantes, France.	carole.guillonneau@univ-nantes.fr	Rabu, Catherine/K-7369-2015	Rabu, Catherine/0000-0001-8405-2809; JOALLAND, Noemie/0000-0002-1620-6658	Labex IGO project part of the Investissements dAvenir French Government program [ANR-11-LABX-0016-01]; Fondation Progreffe; Fondation ARSEP; SFR Francois Bonamy; Centre Hospitalier Universitaire Nantes; Inserm; Universite de Nantes; Universite Bretagne Loire; Astellas; Fluidigm; Novartis; OSE Immunotherapeutics; Institut Merieux; Promega; Sandoz; Stem Cell; Beckman-Coulter; Bristol-Myers-Squibb; Cytek; Nanostring; Myltenyi; Xenothera; Cellectis	Labex IGO project part of the Investissements dAvenir French Government program; Fondation Progreffe; Fondation ARSEP; SFR Francois Bonamy; Centre Hospitalier Universitaire Nantes; Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Universite de Nantes; Universite Bretagne Loire; Astellas(Astellas Pharmaceuticals); Fluidigm; Novartis(Novartis); OSE Immunotherapeutics; Institut Merieux; Promega; Sandoz(Novartis); Stem Cell; Beckman-Coulter; Bristol-Myers-Squibb(Bristol-Myers Squibb); Cytek; Nanostring; Myltenyi; Xenothera; Cellectis	This meeting was organized by the chairwoman Carole Guillonneau, together with an organizing and scientific committee with Catherine Rabu, Nathalie Labarriere, Ignacio Anegon, Jerome Martin, Sophie Brouard, Jean-Francois Fonteneau, Yves Delneste, Frederic Altare and Mikael Roussel. The committee thanks Pauline Vidocq, Celine Kerandell, Nina Skybyk and Laurence Wolff for support in the organization. This work was realized in the context of the Labex IGO project (number ANR-11-LABX-001601), which is part of the Investissements dAvenir French Government program managed by the ANR. All members of the local organizing committee thank both institutional (Fondation Progreffe, Fondation ARSEP, SFR Francois Bonamy, Centre Hospitalier Universitaire Nantes, Inserm, Universite de Nantes, Universite Bretagne Loire) and industry partners (Astellas, Fluidigm, Novartis, OSE Immunotherapeutics, Institut Merieux, Promega, Sandoz, Stem Cell, Beckman-Coulter, Bristol-Myers-Squibb, Cytek, Nanostring, Myltenyi, Xenothera, Cellectis) for their support. Finally, the scientific program committee wish to thank all the speakers and meeting attendees for their invaluable contribution.	Achard C, 2015, ONCOTARGET, V6, P44892, DOI 10.18632/oncotarget.6285; Blondy T, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000182; Borner K., 2021, ANATOMICAL STRUCTURE, DOI [10.1101/2021.05.31.446440, DOI 10.1101/2021.05.31.446440]; Boyman O, 2006, SCIENCE, V311, P1924, DOI 10.1126/science.1122927; Braza MS, 2018, IMMUNITY, V49, P819, DOI 10.1016/j.immuni.2018.09.008; Caudana P, 2019, CANCER IMMUNOL RES, V7, P443, DOI 10.1158/2326-6066.CIR-18-0697; Chandran SS., 2021, BIORXIV, DOI [10.1101/2021.04.08.439061, DOI 10.1101/2021.04.08.439061]; Chinnadurai R, 2018, CELL REP, V22, P2504, DOI 10.1016/j.celrep.2018.02.013; Chinnadurai R, 2016, STEM CELLS, V34, P2429, DOI 10.1002/stem.2415; Comi M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01260; Comi M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00682; Consonni FM, 2021, NAT IMMUNOL, V22, P595, DOI 10.1038/s41590-021-00921-5; Damond N, 2019, CELL METAB, V29, P755, DOI 10.1016/j.cmet.2018.11.014; Delaunay T, 2020, J THORAC ONCOL, V15, P827, DOI 10.1016/j.jtho.2019.12.128; Demaria O, 2019, NATURE, V574, P45, DOI 10.1038/s41586-019-1593-5; Dominguez CX, 2020, CANCER DISCOV, V10, P232, DOI 10.1158/2159-8290.CD-19-0644; Ferrant J, 2021, METHODS MOL BIOL, V2236, P57, DOI 10.1007/978-1-0716-1060-2_6; Gauthier L, 2019, CELL, V177, P1701, DOI 10.1016/j.cell.2019.04.041; Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109; Lazaridou MF, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1774323; Loisel S, 2017, STEM CELLS, V35, P1431, DOI 10.1002/stem.2580; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Menard C, 2020, STEM CELLS, V38, P146, DOI 10.1002/stem.3077; Mulder WJM, 2019, NAT REV DRUG DISCOV, V18, P553, DOI 10.1038/s41573-019-0025-4; Park JE, 2020, SCIENCE, V368, P600, DOI 10.1126/science.aaz9330; Pfirsch-Maisonnas S, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001309; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Purcell JW, 2018, CANCER RES, V78, P4059, DOI 10.1158/0008-5472.CAN-18-0327; Shifrut E, 2018, CELL, V175, P1958, DOI 10.1016/j.cell.2018.10.024; Strauss L, 2015, CANCER CELL, V28, P253, DOI 10.1016/j.ccell.2015.07.006; Travelli C, 2019, CANCER RES, V79, P1938, DOI 10.1158/0008-5472.CAN-18-1544; van Hall T, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0761-3; Veatch JR, 2019, CANCER IMMUNOL RES, V7, P910, DOI 10.1158/2326-6066.CIR-18-0402; Veatch JR, 2018, J CLIN INVEST, V128, P1563, DOI 10.1172/JCI98689; Wickenhauser C, 2021, CANCERS, V13, DOI 10.3390/cancers13040620; Zanotelli VRT, 2020, MOL SYST BIOL, V16, DOI 10.15252/msb.20209798	36	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 3	2021	12								738312	10.3389/fimmu.2021.738312	http://dx.doi.org/10.3389/fimmu.2021.738312			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UR4FB	34539674	Green Published, gold			2022-12-18	WOS:000696705500001
J	Kong, DJ; Du, CG; Wang, H				Kong, Dejun; Du, Caigan; Wang, Hao			Editorial: New Insights Into and Interventions of the Persistent Immune Responses in Chronic Graft Rejection	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						transplantation; chronic graft rejection; innate immunity; organ preservation; treatment	TRANSPLANTATION; CELLS		[Kong, Dejun; Wang, Hao] Tianjin Med Univ Gen Hosp, Dept Gen Surg, Tianjin, Peoples R China; [Kong, Dejun; Wang, Hao] Tianjin Gen Surg Inst, Tianjin, Peoples R China; [Kong, Dejun] Tianjin First Cent Hosp, Organ Transplantat Ctr, Tianjin, Peoples R China; [Kong, Dejun] Nankai Univ, Sch Med, Tianjin, Peoples R China; [Du, Caigan] Univ British Columbia, Dept Urol Sci, Vancouver, BC, Canada; [Du, Caigan] Vancouver Coastal Hlth Res Inst, Immun & Infect Res Ctr, Vancouver, BC, Canada	Tianjin Medical University; Tianjin Medical University; Nankai University; University of British Columbia; Vancouver Coastal Health Research Institute	Wang, H (corresponding author), Tianjin Med Univ Gen Hosp, Dept Gen Surg, Tianjin, Peoples R China.; Wang, H (corresponding author), Tianjin Gen Surg Inst, Tianjin, Peoples R China.	hwangca272@hotmail.com			National Natural Science Foundation of China [82071802]; Li Jieshou Intestinal Barrier Research Special Fund [LJS_ 201412]; Natural Science Foundation of Tianjin [18JCZDJC35800]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Li Jieshou Intestinal Barrier Research Special Fund; Natural Science Foundation of Tianjin(Natural Science Foundation of Tianjin)	This work was supported by grants to HW from National Natural Science Foundation of China (No. 82071802), Li Jieshou Intestinal Barrier Research Special Fund (No. LJS_ 201412), and Natural Science Foundation of Tianjin (No. 18JCZDJC35800)	Bleriot C, 2020, IMMUNITY, V52, P957, DOI 10.1016/j.immuni.2020.05.014; Casiraghi F, 2016, NAT REV NEPHROL, V12, P241, DOI 10.1038/nrneph.2016.7; Hart A, 2019, Am J Transplant, V19 Suppl 2, P19, DOI 10.1111/ajt.15274; Huang YL, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02524-1; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Poggio ED, 2021, AM J TRANSPLANT, V21, P2824, DOI 10.1111/ajt.16463; Quintini C, 2021, TRANSPLANTATION, V105, P1643, DOI 10.1097/TP.0000000000003877; van den Bosch TPP, 2017, AM J TRANSPLANT, V17, P2659, DOI 10.1111/ajt.14280	8	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 3	2021	12								759189	10.3389/fimmu.2021.759189	http://dx.doi.org/10.3389/fimmu.2021.759189			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	US0XC	34539682	Green Published, gold			2022-12-18	WOS:000697160000001
J	Liu, J; Zhou, J; Wu, M; Hu, CF; Yang, J; Li, D; Wu, P; Chen, Y; Chen, P; Lin, S; Cui, YX; Fu, SZ; Wu, JB				Liu, Jing; Zhou, Jie; Wu, Min; Hu, ChuanFei; Yang, Juan; Li, Dong; Wu, Peng; Chen, Yue; Chen, Ping; Lin, Sheng; Cui, YongXia; Fu, ShaoZhi; Wu, JingBo			Low-Dose Total Body Irradiation Can Enhance Systemic Immune Related Response Induced by Hypo-Fractionated Radiation (vol 10, 317, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						systemic immune related response; hypo-fractionated radiation therapy; low-dose total body irradiation; immune enhancement; immunosuppressive microenvironment			[Liu, Jing; Wu, Min; Hu, ChuanFei; Yang, Juan; Li, Dong; Wu, Peng; Chen, Ping; Lin, Sheng; Cui, YongXia; Fu, ShaoZhi; Wu, JingBo] Southwest Med Univ, Nucl Med & Mol Imaging Key Lab Sichuan Prov, Affiliated Hosp, Dept Oncol, Luzhou, Peoples R China; [Zhou, Jie] Univ Elect Sci & Technol China, Sichuan Canc Ctr, Sichuan Canc Hosp & Inst, Dept Radiat Oncol,Sch Med, Chengdu, Peoples R China; [Chen, Yue] Southwest Med Univ, Affiliated Hosp, Nucl Med & Mol Imaging Key Lab Sichuan Prov, Dept Nucl Med, Luzhou, Peoples R China	Southwest Medical University; University of Electronic Science & Technology of China; Southwest Medical University	Fu, SZ; Wu, JB (corresponding author), Southwest Med Univ, Nucl Med & Mol Imaging Key Lab Sichuan Prov, Affiliated Hosp, Dept Oncol, Luzhou, Peoples R China.	shaozhifu513@163.com; wjb6147@163.com	Wu, Jing/GZK-5063-2022						0	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 3	2021	12								745787	10.3389/fimmu.2021.745787	http://dx.doi.org/10.3389/fimmu.2021.745787			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	US0SX	34539676	gold, Green Published			2022-12-18	WOS:000697148300001
J	Qi, YM; Zhang, LM; Yang, XN; Tang, BA; Xiao, T				Qi, Yumeng; Zhang, Liming; Yang, Xiaonan; Tang, Biao; Xiao, Ting			Genome-Wide DNA Methylation Profile in Whole Blood of Patients With Chronic Spontaneous Urticaria	FRONTIERS IN IMMUNOLOGY			English	Article						chronic spontaneous urticaria; DNA methylation; epigenetics; autoimmune; whole blood	FOLLOW-UP; EXPRESSION; HYPOMETHYLATION; ASSOCIATION; DISEASES	Background Chronic spontaneous urticaria (CSU) is a common autoimmune skin disease. Little is known about the role of epigenetics in the pathogenesis of CSU. This study aimed to investigate genome-wide DNA methylation profile in whole blood of patients with CSU. Patients and Methods Genome-wide DNA methylation levels in whole blood samples of 95 Chinese Han ethnicity adult CSU patients and 95 ethnicity-, age- and sex-matched healthy controls were analyzed using Illumina 850K methylation chip. The differentially methylated genes (DMGs) were screened out and then functionally annotated by the gene ontology and the Kyoto encyclopedia of genes and genomes databases. Results A total of 439 differentially methylated positions (DMPs) (p < 0.01 and |Delta beta| >= 0.06) were identified with 380 hypomethylated and 59 hypermethylated. The average global DNA methylation levels of the 439 DMPs in the CSU patients were significantly lower than those in the healthy controls (p < 0.001). The distribution of the 439 DMPs was wide on chromosome 1 to 22 and chromosome X. Chromosome 6 embodied the largest number of DMPs (n = 51) and their annotated genes were predominantly related to autoimmunity. The 304 annotated DMGs were mainly enriched in autoimmune disease- and immune-related pathways. A total of 41 DMPs annotated to 28 DMGs were identified when p < 0.01 and |Delta beta| >= 0.1. Of the 28 DMGs, HLA-DPB2, HLA-DRB1, PPP2R5C, and LTF were associated with autoimmunity. CSU cases with elevated total IgE, positive anti-thyroid peroxidase IgG autoantibodies, positive anti-thyroglobulin IgG autoantibodies, angioedema, UASday > 4, or recurrent CSU showed phenotype-specific DMPs as compared with cases with normal total IgE, negative anti-thyroid peroxidase IgG autoantibodies, negative anti-thyroglobulin IgG autoantibodies, no angioedema, UASday <= 4, or non-recurrent CSU respectively. Conclusion This study shows a distinct genome-wide DNA methylation profile in Chinese Han ethnicity adult CSU patients and indicates a role of epigenetics in the pathogenesis of CSU. The predominant enrichment of the CSU-associated DMGs in immunological pathways provides supportive evidence for the immunopathogenesis of CSU. Future research on the CSU-associated DMPs and DMGs will help discover potential therapeutic targets for CSU.	[Qi, Yumeng; Zhang, Liming; Xiao, Ting] China Med Univ, Dept Dermatol, Natl Hlth Commiss Key Lab Immunodermatol, Key Lab Immunodermatol,Minist Educ,Hosp 1, Shenyang, Peoples R China; [Yang, Xiaonan; Tang, Biao] Sinotech Genom Co Ltd, Shanghai, Peoples R China	China Medical University	Xiao, T (corresponding author), China Med Univ, Dept Dermatol, Natl Hlth Commiss Key Lab Immunodermatol, Key Lab Immunodermatol,Minist Educ,Hosp 1, Shenyang, Peoples R China.	cmuxt@126.com			Basic Research Project from the Department of Education, Liaoning Province, China [LZ2015078]; National Key Clinical Specialist Subject Construction Project on Urticaria from National Health Commission [(2012)649]	Basic Research Project from the Department of Education, Liaoning Province, China; National Key Clinical Specialist Subject Construction Project on Urticaria from National Health Commission	This study was supported by the Basic Research Project from the Department of Education, Liaoning Province, China (LZ2015078) and the National Key Clinical Specialist Subject Construction Project on Urticaria from National Health Commission [(2012)649].	Akdogan N, 2019, DERMATOL THER, V32, DOI 10.1111/dth.12966; Altrichter S, 2021, ALLERGY ASTHMA IMMUN, V13, P206, DOI 10.4168/aair.2021.13.2.206; Altrichter S, 2020, J ALLERGY CLIN IMMUN, V145, P1510, DOI 10.1016/j.jaci.2020.03.005; Anaparti V, 2020, J RHEUMATOL, V47, P1614, DOI 10.3899/jrheum.190376; Annese V, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104892; Bracken SJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00627; Calle-Fabregat CD, 2020, GENES-BASEL, V11, DOI 10.3390/genes11010110; Chen Q, 2018, J EUR ACAD DERMATOL, V32, P441, DOI 10.1111/jdv.14541; Chen T, 2018, ANN ALLERG ASTHMA IM, V121, P503, DOI 10.1016/j.anai.2018.06.002; Cildir G, 2019, IMMUNITY, V51, P949, DOI 10.1016/j.immuni.2019.09.021; Desai A, 2016, J ALLERGY CLIN IMMUN, V137, P1863, DOI 10.1016/j.jaci.2015.09.059; Dionigi PCL, 2016, ALLERGOL IMMUNOPATH, V44, P286, DOI 10.1016/j.aller.2015.10.004; Dogan N, 2020, TURK J MED SCI, V50, P1231, DOI 10.3906/sag-1907-159; Dolcino M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01284; Fok JS, 2021, ALLERGY, V76, P2965, DOI 10.1111/all.14757; Grant SFA, 2006, NAT GENET, V38, P320, DOI 10.1038/ng1732; Grzanka R, 2019, ALLERGY ASTHMA CL IM, V15, DOI 10.1186/s13223-019-0332-7; Guo QL, 2018, THYROID, V28, P377, DOI 10.1089/thy.2017.0301; HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710; Holbrook JD, 2017, EPIGENOMICS-UK, V9, P1143, DOI 10.2217/epi-2017-0032; Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115; Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Kananen L, 2021, EPIGENET CHROMATIN, V14, DOI 10.1186/s13072-021-00407-6; Kindt ASD, 2018, J AUTOIMMUN, V89, P63, DOI 10.1016/j.jaut.2017.11.008; Klein K, 2015, CURR OPIN RHEUMATOL, V27, P76, DOI 10.1097/BOR.0000000000000128; Kolkhir P, 2021, ALLERGY ASTHMA IMMUN, V13, P545, DOI 10.4168/aair.2021.13.4.545; Kolkhir P, 2020, J ALLER CL IMM-PRACT, V8, P318, DOI 10.1016/j.jaip.2019.08.025; Kolkhir P, 2017, AUTOIMMUN REV, V16, P1196, DOI 10.1016/j.autrev.2017.10.003; Kulinski JM, 2016, EUR J PHARMACOL, V778, P56, DOI 10.1016/j.ejphar.2015.02.058; Li Y, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-89087-6; Maltby VE, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78809-x; Miller S, 2019, ANN RHEUM DIS, V78, P519, DOI 10.1136/annrheumdis-2018-214323; Moy AP, 2016, J CUTAN PATHOL, V43, P372, DOI 10.1111/cup.12673; Mungall AJ, 2003, NATURE, V425, P805, DOI 10.1038/nature02055; Murdaca G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235856; O'Donnell BF, 1999, BRIT J DERMATOL, V140, P853, DOI 10.1046/j.1365-2133.1999.02815.x; Poddighe D, 2020, CELL IMMUNOL, V358, DOI 10.1016/j.cellimm.2020.104215; Qi CC, 2020, CLIN TRANSL ALLERGY, V10, DOI 10.1186/s13601-020-00365-4; Rhead B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206511; Schauberger E, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0628-3; Schoepke N, 2019, ALLERGY, V74, P2427, DOI 10.1111/all.13949; Teschendorff AE, 2013, BIOINFORMATICS, V29, P189, DOI 10.1093/bioinformatics/bts680; Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007; Zhang LM, 2020, J ALLER CL IMM-PRACT, V8, P1733, DOI 10.1016/j.jaip.2019.12.006; Zhang LM, 2019, ACTA DERM-VENEREOL, V99, P571, DOI 10.2340/00015555-3149; Zhao JW, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108444; Zhu HL, 2010, J DERMATOL, V37, P441, DOI 10.1111/j.1346-8138.2010.00805.x; Zhu XY, 2016, ENVIRON HEALTH PERSP, V124, P966, DOI 10.1289/ehp.1509834; Zuberbier T, 2018, ALLERGY, V73, P1393, DOI 10.1111/all.13397; Zuberbier T, 2014, ALLERGY, V69, P868, DOI 10.1111/all.12313	51	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 3	2021	12								681714	10.3389/fimmu.2021.681714	http://dx.doi.org/10.3389/fimmu.2021.681714			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	US0TX	34539625	gold, Green Published			2022-12-18	WOS:000697150900001
J	Zeng, J; Zhong, Q; Feng, XB; Li, LD; Feng, SJ; Fan, Y; Song, TR; Huang, ZL; Wang, XD; Lin, T				Zeng, Jun; Zhong, Qiang; Feng, Xiaobing; Li, Linde; Feng, Shijian; Fan, Yu; Song, Turun; Huang, Zhongli; Wang, Xianding; Lin, Tao			Conversion From Calcineurin Inhibitors to Mammalian Target of Rapamycin Inhibitors in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials	FRONTIERS IN IMMUNOLOGY			English	Review						calcineurin inhibitor; mammalian-target-of-rapamycin inhibitor; kidney transplantation; conversion; meta-analysis	SIROLIMUS MAINTENANCE THERAPY; CHRONIC ALLOGRAFT NEPHROPATHY; RENAL-FUNCTION; IMMUNOSUPPRESSIVE REGIMENS; CYCLOSPORINE WITHDRAWAL; MTOR-INHIBITOR; EVEROLIMUS; TACROLIMUS; EFFICACY; SAFETY	BackgroundA systematic review and meta-analysis were performed to investigate the efficacy and safety of conversion from calcineurin inhibitors (CNIs) to mammalian target of rapamycin inhibitors (mTORi) in kidney transplant recipients (KTRs). MethodsMEDLINE, EMBASE, PubMed, and Cochrane Library were searched to identify randomized controlled trials (RCTs) that compared the continuation of CNI with conversion to mTORi therapy. ResultsTwenty-nine RCTs (5,747 KTRs) were included in our analysis. Meta-analysis of the glomerular filtration rate (SMD 0.20; 95%CI 0.10-0.31; P<0.01) and malignancy (RR 0.74; 95%CI 0.55-0.99; P=0.04) demonstrated a significant advantage of mTORi conversion over CNI continuation. However, the risk of acute rejection (RR 1.58; 95%CI 1.22-2.04; P<0.01), infection (RR 1.55; 95%CI 1.01-1.31; P=0.04), proteinuria (RR 1.87; 95%CI 1.34-2.59; P<0.01), leukopenia (RR 1.56; 95%CI 1.27-1.91; P<0.01), acne (RR 6.43; 95%CI 3.43-12.04; P<0.01), and mouth ulcer (RR 11.70; 95%CI 6.18-22.17; P<0.01) were higher in the mTORi group. More patients in the conversion group had to discontinue study medication (RR 2.52; 95%CI 1.75-3.63; P<0.01). There was no significant difference between the two groups with regard to death, graft loss, diabetes, chronic allograft nephropathy, and interstitial fibrosis/tubular atrophy. ConclusionsPosttransplant patients have a better graft function and lower incidence of malignancy after conversion from CNI to mTORi therapy. However, this conversion strategy may be prevented by the higher drug discontinuation rate due to mTORi-associated adverse events, such as more acute rejection, infection, proteinuria, leukopenia, acne, and mouth ulcer, indicating that conversion therapy may only be a treatment option in selected patients.	[Zeng, Jun; Zhong, Qiang; Feng, Xiaobing; Li, Linde; Feng, Shijian; Fan, Yu; Song, Turun; Huang, Zhongli; Wang, Xianding; Lin, Tao] Sichuan Univ, West China Hosp, Inst Urol, Dept Urol, Chengdu, Peoples R China; [Zeng, Jun; Zhong, Qiang; Feng, Xiaobing; Li, Linde; Feng, Shijian; Fan, Yu; Song, Turun; Huang, Zhongli; Wang, Xianding; Lin, Tao] Sichuan Univ, West China Hosp, Organ Transplantat Ctr, Chengdu, Peoples R China	Sichuan University; Sichuan University	Wang, XD; Lin, T (corresponding author), Sichuan Univ, West China Hosp, Inst Urol, Dept Urol, Chengdu, Peoples R China.; Wang, XD; Lin, T (corresponding author), Sichuan Univ, West China Hosp, Organ Transplantat Ctr, Chengdu, Peoples R China.	xiandingwang@outlook.com; kidney5@163.com			Sichuan Science and Technology Program [2019YJ0133]; Chengdu Science and Technology Program [2019-YF05-00084-SN]; 1.3.5 Project for Disciplines of Excellence-Clinical Research Incubation Project, West China Hospital, Sichuan University [2019-075, ZY2016104, 2021HXFH007]	Sichuan Science and Technology Program; Chengdu Science and Technology Program; 1.3.5 Project for Disciplines of Excellence-Clinical Research Incubation Project, West China Hospital, Sichuan University	Funding This study was supported by grants from the Sichuan Science and Technology Program [grant number 2019YJ0133]; Chengdu Science and Technology Program [grant number 2019-YF05-00084-SN]; and 1.3.5 Project for Disciplines of Excellence-Clinical Research Incubation Project, West China Hospital, Sichuan University [grant number 2019-075, ZY2016104, 2021HXFH007].	Bansal D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075591; Bemelman FJ, 2017, AM J TRANSPLANT, V17, P1020, DOI 10.1111/ajt.14048; Bemelman FJ, 2009, TRANSPLANTATION, V88, P421, DOI 10.1097/TP.0b013e3181af1df6; Bouamar R, 2018, NETH J MED, V76, P14; Brakemeier S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222730; Budde K, 2017, NEPHROL DIAL TRANSPL, V32, P1060, DOI 10.1093/ndt/gfx075; Budde K, 2015, CLIN NEPHROL, V83, P11, DOI 10.5414/CN108444; Budde K, 2011, LANCET, V377, P837, DOI 10.1016/S0140-6736(10)62318-5; Chaabane A, 2013, J CLIN PHARMACOL, V53, P925, DOI 10.1002/jcph.125; Chhabra D, 2013, AM J TRANSPLANT, V13, P2902, DOI 10.1111/ajt.12437; Claes K, 2012, NEPHROL DIAL TRANSPL, V27, P850, DOI 10.1093/ndt/gfr238; Cruzado JM, 2016, TRANSPL INT, V29, P1317, DOI 10.1111/tri.12862; de Fijter JW, 2017, AM J TRANSPLANT, V17, P1853, DOI 10.1111/ajt.14186; de Sandes-Freitas TV, 2015, TRANSPLANTATION, V99, P2372, DOI 10.1097/TP.0000000000000748; Ekberg H, 2010, NEPHROL DIAL TRANSPL, V25, P2004, DOI 10.1093/ndt/gfp778; Franz S, 2010, AM J KIDNEY DIS, V55, P335, DOI 10.1053/j.ajkd.2009.09.004; Gatault P, 2013, TRANSPLANT RES, V2, DOI 10.1186/2047-1440-2-S1-S3; Glover TE, 2016, TRANSPLANTATION, V100, P621, DOI 10.1097/TP.0000000000001006; Guba M, 2010, TRANSPLANTATION, V90, P175, DOI 10.1097/TP.0b013e3181e11798; Guerra G, 2011, J AM SOC NEPHROL, V22, P1758, DOI 10.1681/ASN.2011010006; Hamdy AF, 2008, J AM SOC NEPHROL, V19, P1225, DOI 10.1681/ASN.2007091001; Hart A, 2018, AM J TRANSPLANT, V18, P18, DOI 10.1111/ajt.14557; Haynes R, 2018, AM J TRANSPLANT, V18, P1424, DOI 10.1111/ajt.14619; Heilman RL, 2011, TRANSPLANTATION, V92, P767, DOI 10.1097/TP.0b013e31822805d7; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Holdaas H, 2011, TRANSPLANTATION, V92, P410, DOI 10.1097/TP.0b013e318224c12d; Lamb KE, 2011, AM J TRANSPLANT, V11, P450, DOI 10.1111/j.1600-6143.2010.03283.x; Lebranchu Y, 2009, AM J TRANSPLANT, V9, P1115, DOI 10.1111/j.1600-6143.2009.02615.x; Lim WH, 2014, AM J TRANSPLANT, V14, P2106, DOI 10.1111/ajt.12795; Liu M, 2007, TRANSPL P, V39, P1410, DOI 10.1016/j.transproceed.2007.03.072; Maluf DG, 2014, AM J TRANSPLANT, V14, P1152, DOI 10.1111/ajt.12696; Mjornstedt L, 2012, AM J TRANSPLANT, V12, P2744, DOI 10.1111/j.1600-6143.2012.04162.x; Mjornstedt L, 2015, TRANSPL INT, V28, P42, DOI 10.1111/tri.12437; Mohan S, 2013, TRANSPLANTATION, V95, P17, DOI 10.1097/TP.0b013e31827b3d70; Moher David, 2009, Ann Intern Med, V151, P264, DOI [10.1136/bmj.b2535, 10.1016/j.ijsu.2010.02.007]; Morath C, 2007, NEPHROL DIAL TRANSPL, V22, P61, DOI 10.1093/ndt/gfm652; Mourer JS, 2013, TRANSPLANTATION, V96, P49, DOI 10.1097/TP.0b013e3182958552; Mulay AV, 2006, TRANSPLANTATION, V82, P1153, DOI 10.1097/01.tp.0000237101.58974.43; Nashan B, 2012, TRANSPLANTATION, V94, P547, DOI 10.1097/TP.0b013e3182551021; Peddi VR, 2013, TRANSPLANT REV-ORLAN, V27, P97, DOI 10.1016/j.trre.2013.06.001; Felix MJP, 2016, PHARMACOTHERAPY, V36, P152, DOI 10.1002/phar.1692; Pretagostini R, 2016, TRANSPL P, V48, P326, DOI 10.1016/j.transproceed.2016.02.004; Rostaing L, 2015, AM J TRANSPLANT, V15, P1303, DOI 10.1111/ajt.13132; Russ G, 2005, TRANSPLANTATION, V80, P1204, DOI 10.1097/01.tp.0000178393.78084.9b; Sanchez-Escuredo A, 2016, TRANSPL INT, V29, P362, DOI 10.1111/tri.12732; Schena FP, 2009, TRANSPLANTATION, V87, P233, DOI 10.1097/TP.0b013e3181927a41; Sharif A, 2011, J AM SOC NEPHROL, V22, P2107, DOI 10.1681/ASN.2010111160; Silva HT, 2013, AM J TRANSPLANT, V13, P3155, DOI 10.1111/ajt.12481; Stallone G, 2005, J AM SOC NEPHROL, V16, P3755, DOI 10.1681/ASN.2005060635; Sutherland AI, 2014, AM J TRANSPLANT, V14, P677, DOI 10.1111/ajt.12572; Taber DJ, 2019, CLIN TRANSPLANT, V33, DOI 10.1111/ctr.13679; Thierry A, 2011, AM J TRANSPLANT, V11, P2153, DOI 10.1111/j.1600-6143.2011.03695.x; Tonshoff B, 2019, AM J TRANSPLANT, V19, P811, DOI 10.1111/ajt.15081; Vincenti F, 2012, KIDNEY INT, V82, P1054, DOI 10.1038/ki.2012.194; Webster AC, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004290.pub2; Webster AC, 2006, TRANSPLANTATION, V81, P1234, DOI 10.1097/01.tp.0000219703.39149.85; Weir MR, 2011, KIDNEY INT, V79, P897, DOI 10.1038/ki.2010.492; Wolf S, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13267; Wolf S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194975	59	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 3	2021	12								663602	10.3389/fimmu.2021.663602	http://dx.doi.org/10.3389/fimmu.2021.663602			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XF8CL	34539621	gold, Green Published			2022-12-18	WOS:000724294300001
J	Figueras, A; Marino, R; Melillo, D; Pinsino, A				Figueras, Antonio; Marino, Rita; Melillo, Daniela; Pinsino, Annalisa			Editorial: Immunity in Marine Invertebrates: Integrating Transcriptomics to Proteomics and Metabolomics	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						marine invertebrates; immune response; transcriptomics; proteomics; metabolomics			[Figueras, Antonio] Natl Res Council CSIC, Inst Marine Res IIM, Vigo, Spain; [Marino, Rita] Stazione Zool Anton Dohrn SZN, Biol & Evolut Marine Organisms BEOM, Naples, Italy; [Melillo, Daniela] Natl Res Council CNR, Inst Biochem & Cell Biol IBBC, Naples, Italy; [Pinsino, Annalisa] Natl Res Council CNR, Inst Biomed Res & Innovat IRIB, Palermo, Italy	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Marinas (IIM); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica e Biologia Cellulare (IBBC-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto Ricerca l'Innovazione Biomedica (IRIB-CNR)	Melillo, D (corresponding author), Natl Res Council CNR, Inst Biochem & Cell Biol IBBC, Naples, Italy.	daniela.melillo@ibbc.cnr.it	Pinsino, Annalisa/AAW-8010-2020	Pinsino, Annalisa/0000-0002-0021-3909				Oren M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01298; Zhang SM, 2004, SCIENCE, V305, P251, DOI 10.1126/science.1088069	2	0	0	20	43	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 1	2021	12								755839	10.3389/fimmu.2021.755839	http://dx.doi.org/10.3389/fimmu.2021.755839			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	US0LN	34539678	gold, Green Published			2022-12-18	WOS:000697129000001
J	Khan, N; Kaur, S; Knuth, CM; Jeschke, MG				Khan, Noorisah; Kaur, Supreet; Knuth, Carly M.; Jeschke, Marc G.			CNS-Spleen Axis - a Close Interplay in Mediating Inflammatory Responses in Burn Patients and a Key to Novel Burn Therapeutics	FRONTIERS IN IMMUNOLOGY			English	Review						trauma; CNS; spleen; burns; sepsis	NICOTINIC ACETYLCHOLINE-RECEPTOR; VAGUS NERVE; PROINFLAMMATORY CYTOKINES; SYSTEMIC INFLAMMATION; IMPROVES SURVIVAL; NMDA RECEPTOR; SEVERE SEPSIS; MAST-CELLS; INJURY; STIMULATION	Severe burn-induced inflammation and subsequent hypermetabolic response can lead to profound infection and sepsis, resulting in multiple organ failure and high mortality risk in patients. This represents an extremely challenging issue for clinicians as sepsis is the leading cause of mortality in burn patients. Since hyperinflammation and immune dysfunction are a result of an immune imbalance, restoring these conditions seem to have promising benefits for burn patients. A key network that modulates the immune balance is the central nervous system (CNS)-spleen axis, which coordinates multiple signaling pathways, including sympathetic and parasympathetic pathways. Modulating inflammation is a key strategy that researchers use to understand neuroimmunomodulation in other hyperinflammatory disease models and modulating the CNS-spleen axis has led to improved clinical outcomes in patients. As the immune balance is paramount for recovery in burn-induced sepsis and patients with hyperinflammatory conditions, it appears that severe burn injuries substantially alter this CNS-spleen axis. Therefore, it is essential to address and discuss the potential therapeutic techniques that target the CNS-spleen axis that aim to restore homeostasis in burn patients. To understand this in detail, we have conducted a systematic review to explore the role of the CNS-spleen axis and its impact on immunomodulation concerning the burn-induced hypermetabolic response and associated sepsis complications. Furthermore, this thorough review explores the role of the spleen, CNS-spleen axis in the ebb and flow phases following a severe burn, how this axis induces metabolic factors and immune dysfunction, and therapeutic techniques and chemical interventions that restore the immune balance via neuroimmunomodulation.	[Khan, Noorisah; Kaur, Supreet; Knuth, Carly M.; Jeschke, Marc G.] Sunnybrook Hlth Sci Ctr, Ross Tilley Burn Ctr, Toronto, ON, Canada; [Knuth, Carly M.; Jeschke, Marc G.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Jeschke, MG (corresponding author), Sunnybrook Hlth Sci Ctr, Ross Tilley Burn Ctr, Toronto, ON, Canada.; Jeschke, MG (corresponding author), Univ Toronto, Inst Med Sci, Toronto, ON, Canada.	marc.jeschke@sunnybrook.ca			national institute of health (NIH) [R01GM133961]	national institute of health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding The research work of this review article is supported by the national institute of health (NIH R01GM133961) grant.	Abdulkhaleq LA, 2018, VET WORLD, V11, P627, DOI 10.14202/vetworld.2018.627-635; Adrover JM, 2019, IMMUNITY, V50, P390, DOI 10.1016/j.immuni.2019.01.002; Bankova LG, 2014, J IMMUNOL, V192, P2812, DOI 10.4049/jimmunol.1301794; Barnes MA, 2015, CYTOKINE, V72, P210, DOI 10.1016/j.cyto.2015.01.008; Ben-Shaanan TL, 2016, NAT MED, V22, P940, DOI 10.1038/nm.4133; Bencherif M, 2011, CELL MOL LIFE SCI, V68, P931, DOI 10.1007/s00018-010-0525-1; Bianchi M, 1996, J EXP MED, V183, P927, DOI 10.1084/jem.183.3.927; Borges U, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223848; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Carnevale D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13035; Chen P, 2018, SURGERY, V163, P409, DOI 10.1016/j.surg.2017.08.010; Chiu IM, 2013, NATURE, V501, P52, DOI 10.1038/nature12479; Da Silva VJD, 2002, AM J PHYSIOL-REG I, V283, pR543, DOI 10.1152/ajpregu.00608.2001; de Jonge WJ, 2007, BRIT J PHARMACOL, V151, P915, DOI 10.1038/sj.bjp.0707264; Douaiher J, 2014, ADV IMMUNOL, V122, P211, DOI 10.1016/B978-0-12-800267-4.00006-7; FELTEN DL, 1987, J NEUROSCI RES, V18, P28, DOI 10.1002/jnr.490180107; FOOTE SL, 1983, PHYSIOL REV, V63, P844, DOI 10.1152/physrev.1983.63.3.844; Forjuoh SN, 2006, BURNS, V32, P529, DOI 10.1016/j.burns.2006.04.002; Garg BK, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214942; Geissmann F, 2008, IMMUNOL CELL BIOL, V86, P398, DOI 10.1038/icb.2008.19; Goebel MU, 2002, FASEB J, V16, P1869, DOI 10.1096/fj.02-0389com; GOOD RA, 1967, AM J DIS CHILD, V114, P477, DOI 10.1001/archpedi.1967.02090260065004; Greenhalgh DG, 2017, BURNS TRAUMA, V5, DOI 10.1186/s41038-017-0089-5; Guirao X, 1997, AM J PHYSIOL-ENDOC M, V273, pE1203, DOI 10.1152/ajpendo.1997.273.6.E1203; Hasan S, 2019, FRONT MED-LAUSANNE, V6, DOI 10.3389/fmed.2019.00260; Herisson F, 2018, NAT NEUROSCI, V21, P1209, DOI 10.1038/s41593-018-0213-2; Hey YY, 2017, BMC IMMUNOL, V18, DOI 10.1186/s12865-016-0186-4; Holmes CJ, 2017, SHOCK, V47, P175, DOI 10.1097/SHK.0000000000000752; Hoover DB, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01712; Hoover DB, 2017, PHARMACOL THERAPEUT, V179, P1, DOI 10.1016/j.pharmthera.2017.05.002; Howland Robert H, 2014, Curr Behav Neurosci Rep, V1, P64; Huang LF, 2011, CYTOKINE, V53, P29, DOI 10.1016/j.cyto.2010.09.010; Huston JM, 2007, CRIT CARE MED, V35, P2762, DOI 10.1097/01.CCM.0000288102.15975.BA; Huston JM, 2006, J EXP MED, V203, P1623, DOI 10.1084/jem.20052362; Huston JM, 2012, SURG INFECT, V13, P187, DOI 10.1089/sur.2012.126; Inra CN, 2015, NATURE, V527, P466, DOI 10.1038/nature15530; Jeremias IC, 2016, MOL NEUROBIOL, V53, P6635, DOI 10.1007/s12035-015-9538-y; Jeschke MG, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-0145-5; Jeschke MG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021245; Jouda J, 2012, ANN NY ACAD SCI, V1261, P18, DOI 10.1111/j.1749-6632.2012.06642.x; Jung WC, 2017, SEMIN CELL DEV BIOL, V61, P60, DOI 10.1016/j.semcdb.2016.08.010; Kumar M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14182-2; Lin XC, 2005, AM J PHYSIOL-LUNG C, V289, pL583, DOI 10.1152/ajplung.00091.2005; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; Loftus TJ, 2018, CURR OPIN HEMATOL, V25, P37, DOI 10.1097/MOH.0000000000000395; Lori A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061216; MADDEN KS, 1995, ANNU REV PHARMACOL, V35, P417, DOI 10.1146/annurev.pharmtox.35.1.417; Mostel Z, 2019, MOL MED, V26, DOI 10.1186/s10020-019-0132-z; Munford RS, 2002, MOL MED, V8, P437, DOI 10.1007/BF03402023; Niederbichler Andreas D, 2010, Eplasty, V10, pe45; Niederbichler AD, 2009, BURNS, V35, P783, DOI 10.1016/j.burns.2008.08.023; Noble BT, 2018, J NEUROIMMUNOL, V321, P1, DOI 10.1016/j.jneuroim.2018.05.007; Nolte MA, 2000, EUR J IMMUNOL, V30, P626; ORiordain MG, 1996, J SURG RES, V64, P95, DOI 10.1006/jsre.1996.0312; Pavlov VA, 2017, NAT NEUROSCI, V20, P156, DOI 10.1038/nn.4477; Rosas-Ballina M, 2009, J INTERN MED, V265, P663, DOI 10.1111/j.1365-2796.2009.02098.x; Santos FX, 2000, BURNS, V26, P145, DOI 10.1016/S0305-4179(99)00021-2; Scanzano A, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00171; Schaefer TJ., 2021, BURN RESUSCITATION M; SCHWEITZER P, 1985, AM J MED, V78, P645, DOI 10.1016/0002-9343(85)90408-5; Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653; Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110; Simsek T, 2014, TURK J SURG, V30, P153, DOI 10.5152/UCD.2014.2653; Song XM, 2010, BURNS, V36, P75, DOI 10.1016/j.burns.2009.02.002; Stahel PF, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-34; Straub RH, 2004, TRENDS PHARMACOL SCI, V25, P640, DOI 10.1016/j.tips.2004.10.007; Straub RH, 1997, J NEUROIMMUNOL, V80, P149, DOI 10.1016/S0165-5728(97)00150-1; Suhs KW, 2016, NEUROSCI LETT, V629, P227, DOI 10.1016/j.neulet.2016.07.016; Sunden-Cullberg J, 2005, CRIT CARE MED, V33, P564, DOI [10.1097/01.CCM.0000155991.88802.4D, 10.1097/01.ccm.0000155991.88802.4D]; Swirski FK, 2009, SCIENCE, V325, P612, DOI 10.1126/science.1175202; Syngle V, 2016, AUTON NEUROSCI-BASIC, V201, P54, DOI 10.1016/j.autneu.2016.07.008; Tarantino G, 2011, WORLD J GASTROENTERO, V17, P3776, DOI 10.3748/wjg.v17.i33.3776; TAYLOR RB, 1992, AM J PHYSIOL, V263, pH1026, DOI 10.1152/ajpheart.1992.263.4.H1026; Tesmer LA, 2008, IMMUNOL REV, V223, P87, DOI 10.1111/j.1600-065X.2008.00628.x; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; Ulloa L, 2002, P NATL ACAD SCI USA, V99, P12351, DOI 10.1073/pnas.192222999; Ulloa L, 2009, CRIT CARE, V13, DOI 10.1186/cc7758; Valdes-Ferrer SI, 2013, J INTERN MED, V274, P381, DOI 10.1111/joim.12104; Valdes-Ferrer SI, 2013, SHOCK, V40, P492, DOI 10.1097/SHK.0000000000000050; Vida G, 2011, J IMMUNOL, V186, P4340, DOI 10.4049/jimmunol.1003722; Viviani B, 2003, J NEUROSCI, V23, P8692; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Wang HC, 1999, SURGERY, V126, P389, DOI 10.1016/S0039-6060(99)70182-0; Wang HH, 2001, AM J RESP CRIT CARE, V164, P1768, DOI 10.1164/ajrccm.164.10.2106117; Williams FN, 2009, CLIN PLAST SURG, V36, P583, DOI 10.1016/j.cps.2009.05.001; Yaprak M., 2008, NEUROANATOMY, V7, P17	88	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 1	2021	12								720221	10.3389/fimmu.2021.720221	http://dx.doi.org/10.3389/fimmu.2021.720221			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XF8TA	34539655	gold, Green Published			2022-12-18	WOS:000724337600001
J	Myint, K; Jacobs, K; Myint, AM; Lam, SK; Lim, YA; Boey, CCM; Hoe, SZ; Guillemin, GJ				Myint, Kyaimon; Jacobs, Kelly; Myint, Aye-Mu; Lam, Sau Kuen; Lim, Yvonne Ai-Lian; Boey, Christopher Chiong-Meng; Hoe, See Ziau; Guillemin, Gilles J.			Psychological Stresses in Children Trigger Cytokine- and Kynurenine Metabolite-Mediated Abdominal Pain and Proinflammatory Changes	FRONTIERS IN IMMUNOLOGY			English	Article						recurrent abdominal pain; stress; neurotrophin; immune mediators; kynurenine pathway	MEDICALLY UNEXPLAINED SYMPTOMS; 3-HYDROXYANTHRANILIC ACID; NEUROTROPHIC FACTOR; QUINOLINIC ACID; INDOLEAMINE 2,3-DIOXYGENASE; DIFFICULTIES QUESTIONNAIRE; HUMAN MICROGLIA; BRAIN; PATHWAY; HYPOTHESIS	Recurrent abdominal pain (RAP) is a common medically unexplained symptom among children worldwide. However, the biological mechanisms behind the development of functional and behavioral symptoms and changes in blood markers have not been well explored. This study aimed to assess changes in the concentrations of inflammatory markers, including cytokines and tryptophan catabolites, in the serum of children with RAP compared to those with subclinical infections. Children with RAP but without organic diseases were included, and those with asymptomatic intestinal parasitic infections were used as a subclinical infection cohort. Blood samples were collected and used to measure the cytokine profile using Multiplex Immunoassay and tryptophan catabolites using high performance liquid chromatography. Children with RAP showed significantly higher concentrations of serum tumor necrotic factor-alpha, p<0.05, but lower concentrations of IL-10, p<0.001, IL-6, p<0.001 and brain-derived neurotrophic factors (BDNF) p<0.01. In addition, a significant increase in the metabolite of the kynurenine pathway, 3-hydroxyanthranilic acid (3-HAA) p<0.01, a significant decrease in the concentrations of anthranilic acid (AA) p<0.001, together with an increased ratio of serum 3-HAA to AA (3-HAA/AA) p<0.001, was found in this cohort. These findings indicate the significant activation of the immune system and presence of inflammation in children with RAP than those with subclinical parasitic infections. Moreover, children with RAP tested with the Strengths and Difficulties Questionnaire (SDQ), displayed high psychological problems though these SDQ scores were not statistically associated with measured cytokines and kynurenine metabolites. We however could hypothesize that the pro-inflammatory state together with concomitant low concentrations of BDNF in those children with RAP could play a role in psychological stress and experiencing medically unexplained symptoms.</p>	[Myint, Kyaimon; Hoe, See Ziau] Univ Malaya, Dept Physiol, Fac Med, Kuala Lumpur, Malaysia; [Jacobs, Kelly; Guillemin, Gilles J.] Macquarie Univ, Fac Med & Hlth Sci, Dept Biomed Sci, Neuroinflammat Grp, Sydney, NSW, Australia; [Myint, Aye-Mu] European Collaborat Project, Psychoneuroimmunol Res Grp, Munich, Germany; [Lam, Sau Kuen] Univ Tunku Abdul Rahman, Fac Med & Hlth Sci, Dept Preclin Sci, Bandar Sungai Long, Malaysia; [Lim, Yvonne Ai-Lian] Univ Malaya, Dept Parasitol, Fac Med, Kuala Lumpur, Malaysia; [Boey, Christopher Chiong-Meng] Univ Malaya, Dept Paediat, Fac Med, Kuala Lumpur, Malaysia	Universiti Malaya; Macquarie University; Universiti Malaya; Universiti Malaya	Hoe, SZ (corresponding author), Univ Malaya, Dept Physiol, Fac Med, Kuala Lumpur, Malaysia.; Guillemin, GJ (corresponding author), Macquarie Univ, Fac Med & Hlth Sci, Dept Biomed Sci, Neuroinflammat Grp, Sydney, NSW, Australia.	hoesz@ummc.edu.my; gilles.guillemin@mq.edu.au	KYAIMON, MYINT/B-8822-2010; HOE, SEE ZIAU/B-8637-2010; Guillemin, Gilles J/C-3878-2015; LIM, YVONNE AL/B-5276-2010	HOE, SEE ZIAU/0000-0001-6138-1271; Guillemin, Gilles J/0000-0001-8105-4470; LIM, YVONNE AL/0000-0003-4050-6332; Jacobs, Kelly/0000-0002-2595-6426	University of Malaya Research Grant [UMRG 489/12 HTM]; National Health and Medical Research Council (NHMRC); Australian Research Council (ARC); Macquarie University	University of Malaya Research Grant; National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council (ARC)(Australian Research Council); Macquarie University	The work of this study is fully funded by University of Malaya Research Grant, UMRG 489/12 HTM. GG is supported by the National Health and Medical Research Council (NHMRC), the Australian Research Council (ARC) and Macquarie University.	Al-Delaimy AK, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003074; Al-Harazi Talal, 2013, J Egypt Soc Parasitol, V43, P561; Algorta GP, 2016, EUR CHILD ADOLES PSY, V25, P949, DOI 10.1007/s00787-015-0815-0; Anderson G, 2013, PHARMACOL REP, V65, P1647, DOI 10.1016/S1734-1140(13)71526-3; Anuar TS, 2012, INT J PARASITOL, V42, P871, DOI 10.1016/j.ijpara.2012.07.003; APLEY J, 1958, ARCH DIS CHILD, V33, P165, DOI 10.1136/adc.33.168.165; Boey CCM, 2000, J PAEDIATR CHILD H, V36, P114, DOI 10.1046/j.1440-1754.2000.00465.x; Boey CCM, 2001, EUR J GASTROEN HEPAT, V13, P401, DOI 10.1097/00042737-200104000-00017; Calabrese F, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00430; Carlsson E, 2014, J IMMUNOL, V192, P2071, DOI 10.4049/jimmunol.1301713; Cervenka I, 2017, SCIENCE, V357, DOI 10.1126/science.aaf9794; Chen YQ, 2009, INT J TRYPTOPHAN RES, V2, P1; Cho HJ, 2012, BRAIN BEHAV IMMUN, V26, P859, DOI 10.1016/j.bbi.2012.04.005; Clark SM, 2019, CYTOKINE, V113, P256, DOI 10.1016/j.cyto.2018.07.015; Dann SM, 2008, J IMMUNOL, V180, P6816, DOI 10.4049/jimmunol.180.10.6816; Darlington LG, 2010, INT J TRYPTOPHAN RES, V3, P51, DOI 10.4137/IJTR.S4282; Duman RS, 2006, BIOL PSYCHIAT, V59, P1116, DOI 10.1016/j.biopsych.2006.02.013; Elenkov IJ, 2004, ANN NY ACAD SCI, V1024, P138, DOI 10.1196/annals.1321.010; Elenkov IJ, 2006, NEUROIMMUNOMODULAT, V13, P257, DOI 10.1159/000104853; Eminson DM, 2007, CLIN PSYCHOL REV, V27, P855, DOI 10.1016/j.cpr.2007.07.007; Erhardt S, 2013, NEUROPSYCHOPHARMACOL, V38, P743, DOI 10.1038/npp.2012.248; Fatokun AA, 2013, AMINO ACIDS, V45, P1319, DOI 10.1007/s00726-013-1602-1; FAULL C, 1986, J CHILD PSYCHOL PSYC, V27, P251; Forrest CM, 2004, FREE RADICAL RES, V38, P1167, DOI 10.1080/10715760400011437; Fujimura H, 2002, THROMB HAEMOSTASIS, V87, P728; GARBER J, 1990, J AM ACAD CHILD PSY, V29, P648, DOI 10.1097/00004583-199007000-00021; Goldstein LE, 2000, BIOCHEMISTRY-US, V39, P7266, DOI 10.1021/bi992997s; Goodman R, 1998, EUR CHILD ADOLES PSY, V7, P125, DOI 10.1007/s007870050057; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; Gouin JP, 2012, ANN BEHAV MED, V44, P287, DOI 10.1007/s12160-012-9386-1; Guillemin GJ, 2012, FEBS J, V279, P1355, DOI 10.1111/j.1742-4658.2012.08493.x; Guillemin GJ, 2005, GLIA, V49, P15, DOI 10.1002/glia.20090; Guillemin GJ, 2003, ADV EXP MED BIOL, V527, P105; Hartman TCO, 2013, BRIT J GEN PRACT, V63, P625, DOI 10.3399/bjgp13X675241; Heijmans M, 2011, FAM PRACT, V28, P444, DOI 10.1093/fampra/cmr004; Herman JP, 2016, COMPR PHYSIOL, V6, P603, DOI 10.1002/cphy.c150015; JHAMANDAS K, 1990, BRAIN RES, V529, P185, DOI 10.1016/0006-8993(90)90826-W; Jones SP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131389; Lim CK, 2017, PROG NEUROBIOL, V155, P76, DOI 10.1016/j.pneurobio.2015.12.009; Lopez AS, 2008, IMMUNOL LETT, V117, P91, DOI 10.1016/j.imlet.2008.01.001; Lovelace MD, 2017, NEUROPHARMACOLOGY, V112, P373, DOI 10.1016/j.neuropharm.2016.03.024; Lugo-Huitron R, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/104024; Maes M, 2011, PROG NEURO-PSYCHOPH, V35, P702, DOI 10.1016/j.pnpbp.2010.12.017; Maes M, 2011, PROG NEURO-PSYCHOPH, V35, P664, DOI 10.1016/j.pnpbp.2010.06.014; McSorley HJ, 2012, CLIN MICROBIOL REV, V25, P585, DOI 10.1128/CMR.05040-11; Miller GE, 2011, PSYCHOL BULL, V137, P959, DOI 10.1037/a0024768; Morita T, 2001, ANN CLIN BIOCHEM, V38, P242, DOI 10.1258/0004563011900461; Muller N, 2019, J AFFECT DISORDERS, V253, P270, DOI 10.1016/j.jad.2019.04.088; Muller N, 2011, NEUROTOX RES, V19, P308, DOI 10.1007/s12640-010-9210-2; Myint AM, 2005, J AFFECT DISORDERS, V88, P167, DOI 10.1016/j.jad.2005.07.008; Myint AM, 2003, MED HYPOTHESES, V61, P519, DOI 10.1016/S0306-9877(03)00207-X; Myint AM, 2014, PROG NEURO-PSYCHOPH, V48, P304, DOI 10.1016/j.pnpbp.2013.08.008; Myint K, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0252668; Notarangelo FM, 2014, SCHIZOPHR RES, V152, P261, DOI 10.1016/j.schres.2013.11.011; Numakawa T, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112312; O'Farrell K, 2017, NEUROPHARMACOLOGY, V112, P307, DOI 10.1016/j.neuropharm.2015.12.004; Oxenkrug GF, 2010, ISR J PSYCHIATR REL, V47, P56; Parrott JM, 2015, FRONT PSYCHIATRY, V6, DOI 10.3389/fpsyt.2015.00116; Phillips C, 2017, NEURAL PLAST, V2017, DOI 10.1155/2017/7260130; Quak SH, 2015, SINGAP MED J, V56, P125, DOI 10.11622/smedj.2015038; Redpath SA, 2014, PARASITE IMMUNOL, V36, P233, DOI 10.1111/pim.12113; Ruddick Jon P., 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406000068; Samant M, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.624009; Schwarcz R, 2012, NAT REV NEUROSCI, V13, P465, DOI 10.1038/nrn3257; Sen S, 2008, BIOL PSYCHIAT, V64, P527, DOI 10.1016/j.biopsych.2008.05.005; Slopen N, 2013, PSYCHONEUROENDOCRINO, V38, P188, DOI 10.1016/j.psyneuen.2012.05.013; Smith JR, 2016, DRUG DISCOV TODAY, V21, P315, DOI 10.1016/j.drudis.2015.11.001; SPECIALE C, 1993, J NEUROCHEM, V60, P212, DOI 10.1111/j.1471-4159.1993.tb05840.x; Steiner J, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-94; Steptoe A, 2007, BRAIN BEHAV IMMUN, V21, P901, DOI 10.1016/j.bbi.2007.03.011; Stone LL, 2010, CLIN CHILD FAM PSYCH, V13, P254, DOI 10.1007/s10567-010-0071-2; Sundaram G, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0204-5; Tyebji S, 2019, NEUROSCI BIOBEHAV R, V96, P72, DOI 10.1016/j.neubiorev.2018.11.012; WATANABE Y, 1980, BIOCHEM J, V189, P393, DOI 10.1042/bj1890393; WETMORE C, 1990, EXP NEUROL, V109, P141, DOI 10.1016/0014-4886(90)90068-4; Wichers MC, 2005, MOL PSYCHIATR, V10, P538, DOI 10.1038/sj.mp.4001600	76	0	0	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 1	2021	12								702301	10.3389/fimmu.2021.702301	http://dx.doi.org/10.3389/fimmu.2021.702301			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UR6AL	34539633	gold, Green Published			2022-12-18	WOS:000696829800001
J	Cardozo-Ojeda, EF; Perelson, AS				Cardozo-Ojeda, E. Fabian; Perelson, Alan S.			Modeling HIV-1 Within-Host Dynamics After Passive Infusion of the Broadly Neutralizing Antibody VRC01	FRONTIERS IN IMMUNOLOGY			English	Article						virus dynamics; HIV-1; VRC01; mathematical modeling; ODE	HUMAN MONOCLONAL-ANTIBODIES; MACROPHAGE PHAGOCYTOSIS; EFFECTOR FUNCTIONS; T-CELLS; VIRUS; CLEARANCE; DECAY; INFECTION; MECHANISM; LIFE	VRC01 is a broadly neutralizing antibody that targets the CD4 binding site of HIV-1 gp120. Passive administration of VRC01 in humans has assessed the safety and the effect on plasma viremia of this monoclonal antibody (mAb) in a phase 1 clinical trial. After VRC01 infusion, the plasma viral load in most of the participants was reduced but had particular dynamics not observed during antiretroviral therapy. In this paper, we introduce different mathematical models to explain the observed dynamics and fit them to the plasma viral load data. Based on the fitting results we argue that a model containing reversible Ab binding to virions and clearance of virus-VRC01 complexes by a two-step process that includes (1) saturable capture followed by (2) internalization/degradation by phagocytes, best explains the data. This model predicts that VRC01 may enhance the clearance of Ab-virus complexes, explaining the initial viral decay observed immediately after antibody infusion in some participants. Because Ab-virus complexes are assumed to be unable to infect cells, i.e., contain neutralized virus, the model predicts a longer-term viral decay consistent with that observed in the VRC01 treated participants. By assuming a homogeneous viral population sensitive to VRC01, the model provides good fits to all of the participant data. However, the fits are improved by assuming that there were two populations of virus, one more susceptible to antibody-mediated neutralization than the other.	[Cardozo-Ojeda, E. Fabian] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98104 USA; [Perelson, Alan S.] Los Alamos Natl Lab, Theoret Biol & Biophys, Los Alamos, NM 87544 USA	Fred Hutchinson Cancer Center; United States Department of Energy (DOE); Los Alamos National Laboratory	Perelson, AS (corresponding author), Los Alamos Natl Lab, Theoret Biol & Biophys, Los Alamos, NM 87544 USA.	asp@lanl.gov			U.S. Department of Energy [89233218CNA000001]; National Institutes of Health [R01 AI150500, R01 AI028433, R01 OD011095, P01 AI131365]	U.S. Department of Energy(United States Department of Energy (DOE)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Portions of this work were one under the auspices of the U.S. Department of Energy under contract 89233218CNA000001. This study was supported by grants from the National Institutes of Health, R01 AI150500 (EC) and R01 AI028433, R01 OD011095 and P01 AI131365 (AP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrade A, 2015, AIDS, V29, P2419, DOI 10.1097/QAD.0000000000000843; Barouch DH, 2013, NATURE, V503, P224, DOI 10.1038/nature12744; Bonhoeffer S, 2000, AIDS, V14, P2313, DOI 10.1097/00002030-200010200-00012; Bournazos S, 2014, CELL, V158, P1243, DOI 10.1016/j.cell.2014.08.023; Brandin E, 2006, J VIROL, V80, P9861, DOI 10.1128/JVI.00394-06; Burnham K.P., 2003, MODEL SELECTION MULT, P488; Callaway DS, 2002, B MATH BIOL, V64, P29, DOI 10.1006/bulm.2001.0266; Cardozo EF, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006478; Caskey M, 2017, NAT MED, V23, P185, DOI 10.1038/nm.4268; Caskey M, 2015, NATURE, V522, P487, DOI 10.1038/nature14411; Ciupe SM, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003730; Ciupe SM, 2011, J THEOR BIOL, V277, P55, DOI 10.1016/j.jtbi.2011.01.050; Collini P, 2010, CURR MOL MED, V10, P727, DOI 10.2174/156652410793384141; Conway JM, 2015, P NATL ACAD SCI USA, V112, P5467, DOI 10.1073/pnas.1419162112; Debaisieux S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7211; Di Mascio M, 2003, J VIROL, V77, P2271, DOI 10.1128/JVI.77.3.2271-2275.2003; Doitsh G, 2014, NATURE, V505, P509, DOI 10.1038/nature12940; Doitsh G, 2010, CELL, V143, P789, DOI 10.1016/j.cell.2010.11.001; Dugast AS, 2011, VIROLOGY, V415, P160, DOI 10.1016/j.virol.2011.03.012; Dumas A, 2015, J CELL BIOL, V211, P359, DOI 10.1083/jcb.201503124; Gabrielsson J., 2001, PHARMACOKINETIC PHAR; Gadhamsetty S, 2016, J VIROL, V90, P7066, DOI 10.1128/JVI.00306-16; Ganji R, 2016, CELL MICROBIOL, V18, P355, DOI 10.1111/cmi.12516; HAMPTON MB, 1994, J LEUKOCYTE BIOL, V55, P147, DOI 10.1002/jlb.55.2.147; Holl V, 2004, J IMMUNOL, V173, P6274, DOI 10.4049/jimmunol.173.10.6274; Holte SE, 2006, JAIDS-J ACQ IMM DEF, V41, P266, DOI 10.1097/01.qai.0000199233.69457.e4; Igarashi T, 1999, NAT MED, V5, P211, DOI 10.1038/5576; Jambo KC, 2014, MUCOSAL IMMUNOL, V7, P1116, DOI 10.1038/mi.2013.127; Janeway CA, 2001, IMMUNOBIOLOGY; Joos B, 2006, ANTIMICROB AGENTS CH, V50, P1773, DOI 10.1128/AAC.50.5.1773-1779.2006; Ledgerwood JE, 2015, CLIN EXP IMMUNOL, V182, P289, DOI 10.1111/cei.12692; Li YX, 2011, J VIROL, V85, P8954, DOI 10.1128/JVI.00754-11; Lu CL, 2016, SCIENCE, V352, P1001, DOI 10.1126/science.aaf1279; Luo RT, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0186; Luo RT, 2012, J CLIN MICROBIOL, V50, P3381, DOI 10.1128/JCM.01254-12; Luo RT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040198; Lynch RM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad5752; Markowitz M, 2003, J VIROL, V77, P5037, DOI 10.1128/JVI.77.8.5037-5038.2003; Mazzolini J, 2010, BLOOD, V115, P4226, DOI 10.1182/blood-2009-12-259473; McKinley SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100598; MELLMAN I, 1984, J CELL BIOL, V98, P1170, DOI 10.1083/jcb.98.4.1170; Miao HY, 2011, SIAM REV, V53, P3, DOI 10.1137/090757009; Mohri H, 2001, J EXP MED, V194, P1277, DOI 10.1084/jem.194.9.1277; Murray JM, 2011, J VIROL, V85, P10798, DOI 10.1128/JVI.05095-11; Perelson AS, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-96; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 2002, NAT REV IMMUNOL, V2, P28, DOI 10.1038/nri700; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Ramratnam B, 1999, LANCET, V354, P1782, DOI 10.1016/S0140-6736(99)02035-8; Rigden RC, 2002, IMMUNOLOGY, V106, P537, DOI 10.1046/j.1365-2567.2002.01460.x; Sips M, 2016, MUCOSAL IMMUNOL, V9, P1584, DOI 10.1038/mi.2016.12; Stafford MA, 2000, J THEOR BIOL, V203, P285, DOI 10.1006/jtbi.2000.1076; Tomaras GD, 2008, J VIROL, V82, P12449, DOI 10.1128/JVI.01708-08; Torre D, 2002, CLIN DIAGN LAB IMMUN, V9, P983, DOI 10.1128/CDLI.9.5.983-986.2002; Wieland A, 2015, IMMUNITY, V42, P367, DOI 10.1016/j.immuni.2015.01.009; Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659; Yamada DH, 2015, IMMUNITY, V42, P379, DOI 10.1016/j.immuni.2015.01.005; Zhou TQ, 2007, NATURE, V445, P732, DOI 10.1038/nature05580; Zhou TQ, 2013, IMMUNITY, V39, P245, DOI 10.1016/j.immuni.2013.04.012; Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819	61	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 31	2021	12								710012	10.3389/fimmu.2021.710012	http://dx.doi.org/10.3389/fimmu.2021.710012			20	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UU5CF	34531859	Green Submitted, Green Published, gold			2022-12-18	WOS:000698817500001
J	Orru, V; Steri, M; Cucca, F; Fiorillo, E				Orru, Valeria; Steri, Maristella; Cucca, Francesco; Fiorillo, Edoardo			Application of Genetic Studies to Flow Cytometry Data and Its Impact on Therapeutic Intervention for Autoimmune Disease	FRONTIERS IN IMMUNOLOGY			English	Review						drug development; immune profiling; autoimmune diseases; GWAS; flow cytometry	ANTIGEN-PRESENTING CELLS; BISPECIFIC ANTIBODY; IMMUNE-SYSTEM; ACTIVATION; ARCHITECTURE; DRIVEN; IXA	In recent years, systematic genome-wide association studies of quantitative immune cell traits, represented by circulating levels of cell subtypes established by flow cytometry, have revealed numerous association signals, a large fraction of which overlap perfectly with genetic signals associated with autoimmune diseases. By identifying further overlaps with association signals influencing gene expression and cell surface protein levels, it has also been possible, in several cases, to identify causal genes and infer candidate proteins affecting immune cell traits linked to autoimmune disease risk. Overall, these results provide a more detailed picture of how genetic variation affects the human immune system and autoimmune disease risk. They also highlight druggable proteins in the pathogenesis of autoimmune diseases; predict the efficacy and side effects of existing therapies; provide new indications for use for some of them; and optimize the research and development of new, more effective and safer treatments for autoimmune diseases. Here we review the genetic-driven approach that couples systematic multi-parametric flow cytometry with high-resolution genetics and transcriptomics to identify endophenotypes of autoimmune diseases for the development of new therapies.	[Orru, Valeria; Steri, Maristella; Cucca, Francesco; Fiorillo, Edoardo] Natl Res Council CNR, Inst Genet & Biomed Res, Sardinia, Italy; [Cucca, Francesco] Univ Sassari, Dept Biomed Sci, Sassari, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Ricerca Genetica e Biomedica (IRGB-CNR); University of Sassari	Orru, V (corresponding author), Natl Res Council CNR, Inst Genet & Biomed Res, Sardinia, Italy.	valeria.orru@irgb.cnr.it	Steri, Maristella/AAX-8760-2020	Steri, Maristella/0000-0001-5869-3872	National Institute on Aging, National Institutes of Health (NIH) [HHSN271201600005C]; Horizon 2020 Research and Innovation Program of the European Union [633964]; Fondazione di Sardegna [U1301.2015/AI.1157. BE Prat. 2015-1651]	National Institute on Aging, National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Horizon 2020 Research and Innovation Program of the European Union; Fondazione di Sardegna(Fondazione Banco di Sardegna)	The preparation of this manuscript was supported by the Intramural Research Program of the National Institute on Aging, National Institutes of Health (NIH) (contract HHSN271201600005C), the Horizon 2020 Research and Innovation Program of the European Union (grant 633964), and Fondazione di Sardegna (grant U1301.2015/AI.1157. BE Prat. 2015-1651).	Aguet F, 2020, SCIENCE, V369, P1318, DOI 10.1126/science.aaz1776; Aguirre-Gamboa R, 2016, CELL REP, V17, P2474, DOI 10.1016/j.celrep.2016.10.053; Akbari P., 2020, BIORXIV PREPRINT, DOI [10.1101/2020.01.30.927483, DOI 10.1101/2020.01.30.927483]; Amir ED, 2013, NAT BIOTECHNOL, V31, P545, DOI 10.1038/nbt.2594; Bandura DR, 2009, ANAL CHEM, V81, P6813, DOI 10.1021/ac901049w; Bargou R, 2008, SCIENCE, V321, P974, DOI 10.1126/science.1158545; Becher B, 2014, NAT IMMUNOL, V15, P1181, DOI 10.1038/ni.3006; Bendall SC, 2014, CELL, V157, P714, DOI 10.1016/j.cell.2014.04.005; Berney-Lang MA, 2013, PLATELETS, P581; Bosley K, 2017, NAT REV DRUG DISCOV, V16, P672, DOI 10.1038/nrd.2017.191; Boyle EA, 2017, CELL, V169, P1177, DOI 10.1016/j.cell.2017.05.038; Brinkmann U, 2017, MABS-AUSTIN, V9, P182, DOI 10.1080/19420862.2016.1268307; Broekema RV, 2020, OPEN BIOL, V10, DOI 10.1098/rsob.190221; Bruggner RV, 2014, P NATL ACAD SCI USA, V111, pE2770, DOI 10.1073/pnas.1408792111; Chan RCF, 2017, CYTOM PART B-CLIN CY, V92, P508, DOI 10.1002/cyto.b.21371; Cook D, 2014, NAT REV DRUG DISCOV, V13, P419, DOI 10.1038/nrd4309; Dahlen Eva, 2018, Ther Adv Vaccines Immunother, V6, P3, DOI 10.1177/2515135518763280; Davey Smith G, 2014, HUM MOL GENET, V23, pR89, DOI 10.1093/hmg/ddu328; Farh KKH, 2015, NATURE, V518, P337, DOI 10.1038/nature13835; Ferreira MAR, 2010, AM J HUM GENET, V86, P88, DOI 10.1016/j.ajhg.2009.12.008; Fung E, 2010, NAT PROTOC, V5, P357, DOI 10.1038/nprot.2009.246; Ganusov VV, 2007, TRENDS IMMUNOL, V28, P514, DOI 10.1016/j.it.2007.08.009; Giambartolomei C, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004383; Goddard GR, 2007, ANAL CHEM, V79, P8740, DOI 10.1021/ac071402t; Hunig T, 2016, FEBS J, V283, P3325, DOI 10.1111/febs.13754; Idda ML, 2018, NUCLEIC ACIDS RES, V46, P12040, DOI 10.1093/nar/gky866; Kadic E, 2017, BMC IMMUNOL, V18, DOI 10.1186/s12865-017-0192-1; Kitazawa T, 2012, NAT MED, V18, P1570, DOI 10.1038/nm.2942; Knight T, 2018, THER ADV HEMATOL, V9, P319, DOI 10.1177/2040620718799997; Lagou V, 2018, CELL REP, V25, P798, DOI 10.1016/j.celrep.2018.09.048; Lai AC, 2017, NAT REV DRUG DISCOV, V16, P101, DOI 10.1038/nrd.2016.211; Levine JH, 2015, CELL, V162, P184, DOI 10.1016/j.cell.2015.05.047; Liang F, 2017, MOL THER, V25, P2635, DOI 10.1016/j.ymthe.2017.08.006; Mair F, 2016, EUR J IMMUNOL, V46, P34, DOI 10.1002/eji.201545774; Mangino M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13850; Marti GE, 2005, BRIT J HAEMATOL, V130, P325, DOI 10.1111/j.1365-2141.2005.05550.x; Okada D, 2021, J HUM GENET, V66, P557, DOI 10.1038/s10038-020-00874-x; Orru V, 2020, NAT GENET, V52, P1266, DOI 10.1038/s41588-020-00718-6; Orru V, 2013, CELL, V155, P242, DOI 10.1016/j.cell.2013.08.041; Paaby AB, 2013, TRENDS GENET, V29, P66, DOI 10.1016/j.tig.2012.10.010; Paternoster L, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006944; Patin E, 2018, NAT IMMUNOL, V19, P302, DOI 10.1038/s41590-018-0049-7; Payne K, 2020, CYTOM PART A, V97, P777, DOI 10.1002/cyto.a.24018; Picot J, 2012, CYTOTECHNOLOGY, V64, P109, DOI 10.1007/s10616-011-9415-0; Pina-Vaz C, 2017, SER BIOENG, P153, DOI 10.1007/978-981-10-4499-1_7; Qiu P, 2011, NAT BIOTECHNOL, V29, P886, DOI 10.1038/nbt.1991; Roederer M., 2002, CURR PROTOC CYTOM, V22:Unit 1.14; Roederer M, 2015, CELL, V161, P387, DOI 10.1016/j.cell.2015.02.046; Sawant MS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207496; Schoenfelder S, 2018, JOVE-J VIS EXP, DOI 10.3791/57320; Schuh E, 2016, J IMMUNOL, V197, P1111, DOI 10.4049/jimmunol.1600089; Sebastian Martin, 2010, Cancer Manag Res, V2, P283, DOI 10.2147/CMR.S14115; Shekhar K, 2014, P NATL ACAD SCI USA, V111, P202, DOI 10.1073/pnas.1321405111; Slatkin M, 2008, NAT REV GENET, V9, P477, DOI 10.1038/nrg2361; Steri M, 2017, NEW ENGL J MED, V376, P1615, DOI 10.1056/NEJMoa1610528; Streeter I, 2017, NUCLEIC ACIDS RES, V45, pD691, DOI 10.1093/nar/gkw928; Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842; Tabares P, 2014, EUR J IMMUNOL, V44, P1225, DOI 10.1002/eji.201343967; van der Graaf A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18716-x; van der Maaten L, 2008, J MACH LEARN RES, V9, P2579; van Velzen JF, 2012, THROMB RES, V130, P92, DOI 10.1016/j.thromres.2012.02.041; Veri MC, 2010, ARTHRITIS RHEUM-US, V62, P1933, DOI 10.1002/art.27477; Wilkinson MG., 2015, FLOW CYTOMETRY MICRO, P230; Xu L, 2017, SCIENCE, V358, P85, DOI 10.1126/science.aan8630	64	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 31	2021	12								714461	10.3389/fimmu.2021.714461	http://dx.doi.org/10.3389/fimmu.2021.714461			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UU4WP	34531863	Green Published, gold			2022-12-18	WOS:000698802900001
J	Peng, JW; Dai, HL; Zhang, HD; Yu, SJ; Xie, XB; Peng, FH; Lan, GB; Hu, SB; Wang, Y; Tang, XT; Guo, Y; Gao, C; Fang, CH; Nie, MH; Yuan, XQ; Zhong, MD; Tang, ZQ; Li, TF; Sun, SY; Yao, HC; Hou, JF; Huang, RX; Peng, LK				Peng, Jiawei; Dai, Helong; Zhang, Hedong; Yu, Shaojie; Xie, Xubiao; Peng, Fenghua; Lan, Gongbin; Hu, Shanbiao; Wang, Yu; Tang, Xiaotian; Guo, Yong; Gao, Chen; Fang, Chunhua; Nie, Manhua; Yuan, Xiaoqiong; Zhong, Mingda; Tang, Zhouqi; Li, Tengfang; Sun, Siyu; Yao, Hengchang; Hou, Jianfei; Huang, Ruixue; Peng, Longkai			Comparison of Outcomes of Kidney Transplantation From Extremely Low Body Weight <= 5kg Versus Larger Body Weight Pediatric Donors	FRONTIERS IN IMMUNOLOGY			English	Article						center experience; kidney transplantation; extremely low body weight; pediatric donor; graft survival; utilization	EN-BLOC KIDNEY; COMPARABLE OUTCOMES; ADULT RECIPIENTS; RENAL-TRANSPLANT; GRAFT FUNCTION; LESS-THAN; SINGLE; SUPERIOR; DIALYSIS; KG	Background Kidney transplantation from donors who weigh <= 5 kg is performed at only a few transplant centers owing to the high complication and low graft survival rates associated with this approach. Methods We retrospectively compared the results of kidney transplantation at our center between January 2015 and December 2019 based on the following pediatric donor criteria: donor body weight <= 5 kg (n=32), 5 kg< donor weight <= 20 kg (n=143), and donor weight >20 kg (n=110). We also perform subgroup analysis of kidney transplantation outcomes from <= 5 kg donors, using conventional (dual separate and classic en-bloc KTx)/novel (en-bloc KTx with outflow tract) surgical methods and allocating to adult/pediatric recipients. Results The death-censored graft survival rates from extremely low body weight <= 5kg at 1 month, and 1, 3, and 5 years were 90.6%, 80.9%, 77.5%, and 73.9%, respectively, which were significantly lower than that from larger body weight pediatric donors. However, the 3-, and 5-year post-transplantation eGFRs were not significantly different between the pediatric and adult recipient group. The thrombosis (18.8%) and urinary leakage (18.8%) rates were significantly higher in the donor weight <= 5 kg group. Compared with 5 kg< donor weight <= 20 kg group, donor weight <= 5kg group was at elevated risk of graft loss due to thrombosis (OR: 13.4) and acute rejection (OR: 6.7). No significant difference on the outcomes of extremely low body weight donor kidney transplantation was observed between adults and pediatric recipients. Urinary leakage rate is significantly lower in the novel operation (8.7%) than in the conventional operation group (44.4%). Conclusions Although the outcomes of donor body weight <= 5kg kidney transplantation is inferior to that from donors with large body weight, it can be improved through technical improvement. Donors with body weight <= 5 kg can be considered as an useful source to expand the donor pool.	[Peng, Jiawei; Dai, Helong; Zhang, Hedong; Yu, Shaojie; Xie, Xubiao; Peng, Fenghua; Lan, Gongbin; Hu, Shanbiao; Wang, Yu; Tang, Xiaotian; Guo, Yong; Gao, Chen; Fang, Chunhua; Nie, Manhua; Yuan, Xiaoqiong; Zhong, Mingda; Tang, Zhouqi; Li, Tengfang; Sun, Siyu; Yao, Hengchang; Hou, Jianfei; Peng, Longkai] Cent South Univ, Xiangya Hosp 2, Dept Kidney Transplantat, Changsha, Peoples R China; [Peng, Jiawei; Dai, Helong; Zhang, Hedong; Yu, Shaojie; Xie, Xubiao; Peng, Fenghua; Lan, Gongbin; Hu, Shanbiao; Wang, Yu; Tang, Xiaotian; Guo, Yong; Gao, Chen; Fang, Chunhua; Nie, Manhua; Yuan, Xiaoqiong; Zhong, Mingda; Tang, Zhouqi; Li, Tengfang; Sun, Siyu; Yao, Hengchang; Hou, Jianfei; Peng, Longkai] Clin Res Ctr Organ Transplantat Hunan Prov, Changsha, Peoples R China; [Dai, Helong; Peng, Longkai] Cent South Univ, Clin Immunol Ctr, Changsha, Peoples R China; [Huang, Ruixue] Cent South Univ, Xiangya Sch Publ Hlth, Dept Occupat & Environm Hlth, Changsha, Peoples R China	Central South University; Central South University; Central South University	Peng, LK (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Kidney Transplantat, Changsha, Peoples R China.; Peng, LK (corresponding author), Clin Res Ctr Organ Transplantat Hunan Prov, Changsha, Peoples R China.; Peng, LK (corresponding author), Cent South Univ, Clin Immunol Ctr, Changsha, Peoples R China.	penglongkai@csu.edu.cn			National Science Foundation of China [82070776, 81900370, 81800664, 81970655]; Excellent Youth Foundation of Hunan Province of China [2021JJ10076]; Huxiang Young Talents of Hunan Province [2019RS2013]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Excellent Youth Foundation of Hunan Province of China; Huxiang Young Talents of Hunan Province	This work is supported by the National Science Foundation of China (82070776, 81900370, 81800664 and 81970655), Excellent Youth Foundation of Hunan Province of China (2021JJ10076) and Huxiang Young Talents of Hunan Province (2019RS2013).	Afanetti M, 2012, PEDIATR TRANSPLANT, V16, P183, DOI 10.1111/j.1399-3046.2012.01654.x; Balachandran VP, 2010, TRANSPLANTATION, V90, P518, DOI 10.1097/TP.0b013e3181e98d35; Bent C, 2015, AM J TRANSPLANT, V15, P2940, DOI 10.1111/ajt.13365; Dai HL, 2018, AM J TRANSPLANT, V18, P2200, DOI 10.1111/ajt.14692; Dharnidharka VR, 2014, NEW ENGL J MED, V371, P549, DOI 10.1056/NEJMra1314376; Dubourg L, 2002, KIDNEY INT, V62, P1454, DOI 10.1111/j.1523-1755.2002.kid576.x; El-Sheikh MFA, 2003, TRANSPLANT P, V35, P786, DOI 10.1016/S0041-1345(03)00044-7; Eng M, 2011, CLIN TRANSPLANT, V25, P292, DOI 10.1111/j.1399-0012.2010.01293.x; Fananapazir G, 2020, AM J TRANSPLANT, V20, P2126, DOI 10.1111/ajt.15792; Fananapazir G, 2016, RADIOLOGY, V279, P935, DOI 10.1148/radiol.2015150430; HINCHLIFFE SA, 1991, LAB INVEST, V64, P777; Kayler LK, 2009, AM J TRANSPLANT, V9, P2745, DOI 10.1111/j.1600-6143.2009.02809.x; Maluf DG, 2013, AM J TRANSPLANT, V13, P2703, DOI 10.1111/ajt.12410; Merkel FK, 2001, TRANSPLANT P, V33, P1168, DOI 10.1016/S0041-1345(00)02446-5; Mitrou N, 2018, AM J TRANSPLANT, V18, P2689, DOI 10.1111/ajt.14946; Mohanka R, 2008, TRANSPLANTATION, V86, P264, DOI 10.1097/TP.0b013e318177894e; Ozcan H, 2015, TRANSPL P, V47, P1348, DOI 10.1016/j.transproceed.2015.04.032; Pape L, 2006, NEPHROL DIAL TRANSPL, V21, P2596, DOI 10.1093/ndt/gfl119; Pelletier SJ, 2006, AM J TRANSPLANT, V6, P1646, DOI 10.1111/j.1600-6143.2006.01353.x; Peng Fenghua, 2014, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V39, P204, DOI 10.11817/j.issn.1672-7347.2014.02.017; Sanchez-Fructuoso AI, 2003, TRANSPLANTATION, V76, P1180, DOI 10.1097/01.TP.0000090395.98045.09; Sharma A, 2013, TRANSPLANTATION, V95, P1354, DOI 10.1097/TP.0b013e31828a9493; Sharma A, 2011, TRANSPLANTATION, V92, P564, DOI 10.1097/TP.0b013e3182279107; Singh A, 1997, TRANSPLANTATION, V63, P1263, DOI 10.1097/00007890-199705150-00012; Sui MX, 2016, PEDIATR TRANSPLANT, V20, P39, DOI 10.1111/petr.12645; Sureshkumar KK, 2006, TRANSPLANTATION, V82, P348, DOI 10.1097/01.tp.0000228872.89572.d3; Thomusch O, 2009, TRANSPLANTATION, V88, P920, DOI 10.1097/TP.0b013e3181b74e84; Uemura T, 2010, TRANSPLANTATION, V89, P710, DOI 10.1097/TP.0b013e3181c90226; Wang HY, 2017, PEDIATR TRANSPLANT, V21, DOI 10.1111/petr.12845; Wang YM, 2015, EXP CLIN TRANSPLANT, V13, P239, DOI 10.6002/ect.2014.0177; Wijetunga I, 2018, AM J TRANSPLANT, V18, P2679, DOI 10.1111/ajt.15006; Xu YH, 2014, MED SCI MONITOR, V20, P379, DOI 10.12659/MSM.890204; Yoo KD, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004352; Yu SJ, 2015, TRANSPL P, V47, P1727, DOI 10.1016/j.transproceed.2015.04.100; Zhang Y, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17197318; Zhao WY, 2014, TRANSPLANTATION, V97, P555, DOI 10.1097/01.tp.0000437174.55798.0b; Zhu L, 2019, TRANSPLANTATION, V103, P2388, DOI 10.1097/TP.0000000000002618	37	0	0	2	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 31	2021	12								738749	10.3389/fimmu.2021.738749	http://dx.doi.org/10.3389/fimmu.2021.738749			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UT2PW	34531876	Green Published, gold			2022-12-18	WOS:000697964000001
J	Wei, BJ; Yu, M; Yao, JH; Jiang, MZ; An, J; Yang, JP; Lin, JX; Zhao, YK; Zhu, YY				Wei, Baojun; Yu, Meng; Yao, Jihang; Jiang, Mingzhe; An, Jun; Yang, Jieping; Lin, Jiaxing; Zhao, Yongkang; Zhu, Yuyan			Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						renal papillary cell carcinoma; CD8+T-cell exhaustion; CCL5; FASLG; immunotherapy response subtypes	FAS LIGAND; CANCER; NIVOLUMAB; EXPRESSION; APOPTOSIS; INFLAMMATION; PRIVILEGE; CYTOKINES; BLOCKADE	Kidney renal papillary cell carcinoma (KIRP), the second most common subtype of renal cell carcinoma, still lacks effective treatment regimens for individualized immunotherapy because of the heterogeneity of its elusive immune microenvironment. Therefore, we aimed to comprehensively evaluate the immune microenvironment of KIRP by using the computational biology strategy to analyze the expression profile data of 289 KIRP patients obtained from The Cancer Genome Atlas database. Based on multidimensional, multi-omics bioinformatics analysis, we found that the tumor of patients with KIRP exhibited "hot" tumor characteristics but the CD8+ T cells in the tumor tissues did not limit tumor progression. Thus, patients with KIRP may realize higher clinical benefits by receiving treatment that can reverse CD8+ T-cell exhaustion. Among them, C1 and C3 immune subtypes could realize the best efficacy of reversing CD8+ T-cell exhaustion. Moreover, CCL5 and FASLG expression may be related to the formation of the immunosuppressive microenvironment in the tumors of patients with KIRP. In conclusion, the immune microenvironment landscape presented in this study provides a novel insight for further experimental and clinical exploration of tailored immunotherapy for patients with KIRP.</p>	[Wei, Baojun; Jiang, Mingzhe; An, Jun; Yang, Jieping; Lin, Jiaxing; Zhu, Yuyan] China Med Univ, Dept Urol, Hosp 1, Shenyang, Peoples R China; [Yu, Meng] China Med Univ, Dept Lab Aninal Sci, Shenyang, Peoples R China; [Yu, Meng] China Med Univ, Key Lab Transgen Anim Res, Shenyang, Peoples R China; [Yao, Jihang] China Med Univ, Dept Gynecol, Hosp 1, Shenyang, Peoples R China; [Zhao, Yongkang] China Med Univ, Natl Inst Hlth & Med Big Data, Shenyang, Peoples R China; [Zhao, Yongkang; Zhu, Yuyan] Northeastern Univ, Joint Lab Artificial Intelligence & Precis Med Ch, Shenyang, Peoples R China	China Medical University; China Medical University; China Medical University; China Medical University; China Medical University; Northeastern University - China	Zhu, YY (corresponding author), China Med Univ, Dept Urol, Hosp 1, Shenyang, Peoples R China.; Zhu, YY (corresponding author), Northeastern Univ, Joint Lab Artificial Intelligence & Precis Med Ch, Shenyang, Peoples R China.	yyzhu@cmu.edu.cn	Zhu, Yuyan/ABE-4176-2021	Zhu, Yuyan/0000-0003-0479-3151	national natural science foundation of China [81672523, 81472404, 81472403, 81272834, 31000572]; plan for innovative talents in colleges and universities of Liaoning province; Liaoning province [33013]; Key R&D projects of Shenyang [19-112-4-102]	national natural science foundation of China(National Natural Science Foundation of China (NSFC)); plan for innovative talents in colleges and universities of Liaoning province; Liaoning province(Natural Science Foundation of Liaoning Province); Key R&D projects of Shenyang	This work was supported by the national natural science foundation of China (grants 81672523, 81472404, 81472403, 81272834, and 31000572); the 2018 support plan for innovative talents in colleges and universities of Liaoning province; the 2018 "million talents project" funded project of Liaoning province (grant 33013); and the 2019 Key R&D projects of Shenyang (grant 19-112-4-102).	Herrera DA, 2017, INVEST NEW DRUG, V35, P665, DOI 10.1007/s10637-017-0469-5; Albers AE, 2005, CANCER IMMUNOL IMMUN, V54, P1072, DOI 10.1007/s00262-005-0670-9; Aldinucci D, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/292376; Allen JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029348; Andreola G, 2002, J EXP MED, V195, P1303, DOI 10.1084/jem.20011624; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Barashi N, 2013, HEPATOLOGY, V58, P1021, DOI 10.1002/hep.26403; Barata PC, 2017, CA-CANCER J CLIN, V67, P507, DOI 10.3322/caac.21411; BIERER BE, 1988, J EXP MED, V168, P1145, DOI 10.1084/jem.168.3.1145; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Butte MJ, 2007, IMMUNITY, V27, P111, DOI 10.1016/j.immuni.2007.05.016; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chen H, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-35; Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-S4-S11; Courthod G, 2015, CRIT REV ONCOL HEMAT, V96, P100, DOI 10.1016/j.critrevonc.2015.05.008; Cullen SP, 2010, CELL DEATH DIFFER, V17, P616, DOI 10.1038/cdd.2009.206; Delahunt B, 1997, MODERN PATHOL, V10, P537; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Fife BT, 2008, IMMUNOL REV, V224, P166, DOI 10.1111/j.1600-065X.2008.00662.x; Fourcade J, 2010, J EXP MED, V207, P2175, DOI 10.1084/jem.20100637; Garcia JA, 2007, CA-CANCER J CLIN, V57, P112, DOI 10.3322/canjclin.57.2.112; Gordon SM, 2012, IMMUNITY, V36, P55, DOI 10.1016/j.immuni.2011.11.016; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Jiang P, 2018, NAT MED, V24, P1550, DOI 10.1038/s41591-018-0136-1; Kim JW, 2005, CLIN CANCER RES, V11, P1010; Kim R, 2004, CANCER-AM CANCER SOC, V100, P2281, DOI 10.1002/cncr.20270; Korman AJ, 2006, ADV IMMUNOL, V90, P297, DOI 10.1016/S0065-2776(06)90008-X; Lahn M, 1999, EUR UROL, V35, P70, DOI 10.1159/000019821; Langfelder P, 2008, BIOINFORMATICS, V24, P719, DOI 10.1093/bioinformatics/btm563; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Leong SR, 2017, BLOOD, V129, P609, DOI 10.1182/blood-2016-08-735365; Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307; Linehan WM, 2016, NEW ENGL J MED, V374, P135, DOI 10.1056/NEJMoa1505917; Liou GY, 2013, J CELL BIOL, V202, P563, DOI 10.1083/jcb.201301001; Liu ZP, 2016, BIOMARK MED, V10, P633, DOI 10.2217/bmm-2015-0035; Ljungberg B, 2015, EUR UROL, V67, P913, DOI 10.1016/j.eururo.2015.01.005; Melero I, 2007, NAT REV CANCER, V7, P95, DOI 10.1038/nrc2051; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Nakano O, 2001, CANCER RES, V61, P5132; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Pearce EL, 2003, SCIENCE, V302, P1041, DOI 10.1126/science.1090148; ROSENSTEIN Y, 1989, J EXP MED, V169, P149, DOI 10.1084/jem.169.1.149; Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324; Yamamoto TN, 2019, J CLIN INVEST, V129, P1551, DOI 10.1172/JCI121491; You Y, 2018, CLIN EXP IMMUNOL, V191, P60, DOI 10.1111/cei.13044	48	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 31	2021	12								657951	10.3389/fimmu.2021.657951	http://dx.doi.org/10.3389/fimmu.2021.657951			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UU0WT	34531849	Green Published, gold			2022-12-18	WOS:000698526300001
J	Xia, AH; Li, X; Quan, JJ; Chen, X; Xu, ZZ; Jiao, XA				Xia, Aihong; Li, Xin; Quan, Juanjuan; Chen, Xiang; Xu, Zhengzhong; Jiao, Xinan			Mycobacterium tuberculosis Rv0927c Inhibits NF-kappa B Pathway by Downregulating the Phosphorylation Level of I kappa B alpha and Enhances Mycobacterial Survival	FRONTIERS IN IMMUNOLOGY			English	Article						Rv0927c; Mycobacterium tuberculosis; proinflammatory cytokine; NF-kappa B pathway; mycobacterial survival	INNATE IMMUNITY; HOST-DEFENSE; KINASE TAK1; INFECTION; MACROPHAGES; ACTIVATE; MUTANT; TNF	Through long-term coevolution with its host, Mycobacterium tuberculosis (M. tuberculosis) uses multiple strategies to escape host defenses. The M. tuberculosis Rv0927c protein is predicted to be a short-chain dehydrogenase/reductase related to bacterial metabolism. However, the role of Rv0927c during M. tuberculosis infection remains unclear. Here, we observed that Rv0927c inhibited the expression of IL-6, TNF-alpha, and IL-1 beta, an effect dependent on NF-kappa B and p38 pathways. Western blot analysis of macrophages infected with recombinant Mycobacterium smegmatis strains showed that Rv0927c attenuated NF-kappa B activation by downregulating the phosphorylation of I kappa B alpha. Additionally, Rv0927c enhanced intracellular survival of M. smegmatis and pathological effects in mice. In conclusion, our findings demonstrate that Rv0927c functions as a regulator of inflammatory genes and enhances the survival of M. smegmatis.</p>	[Xia, Aihong; Quan, Juanjuan; Chen, Xiang; Xu, Zhengzhong; Jiao, Xinan] Yangzhou Univ, Jiangsu Key Lab Zoonosis Jiangsu Coinnovat Ctr Pr, Yangzhou, Jiangsu, Peoples R China; [Li, Xin; Chen, Xiang; Xu, Zhengzhong; Jiao, Xinan] Yangzhou Univ, Key Lab Prevent & Control Biol Hazard Factors Ani, Minist Agr & Rural Affairs, Yangzhou, Jiangsu, Peoples R China	Yangzhou University; Ministry of Agriculture & Rural Affairs; Yangzhou University	Xu, ZZ; Jiao, XA (corresponding author), Yangzhou Univ, Jiangsu Key Lab Zoonosis Jiangsu Coinnovat Ctr Pr, Yangzhou, Jiangsu, Peoples R China.; Xu, ZZ; Jiao, XA (corresponding author), Yangzhou Univ, Key Lab Prevent & Control Biol Hazard Factors Ani, Minist Agr & Rural Affairs, Yangzhou, Jiangsu, Peoples R China.	zzxu@yzu.edu.cn; jiao@yzu.edu.cn		/0000-0002-9736-8180	Science and Technology Program of Jiangsu [BK20201432]; Science and Technology Innovation Cultivation Program of Yangzhou University [2019CXJ158]; independent program of Jiangsu Key Laboratory of Zoonosis [RZZ202003]; Priority Academic Development Program of Jiangsu Higher Education Institutions (PADP); Qinglan Project	Science and Technology Program of Jiangsu; Science and Technology Innovation Cultivation Program of Yangzhou University; independent program of Jiangsu Key Laboratory of Zoonosis; Priority Academic Development Program of Jiangsu Higher Education Institutions (PADP); Qinglan Project(Jiangsu Polytech Institute)	This work was supported by the Science and Technology Program of Jiangsu (BK20201432), the Science and Technology Innovation Cultivation Program of Yangzhou University (2019CXJ158), the independent program of Jiangsu Key Laboratory of Zoonosis (RZZ202003) and the Qinglan Project and Priority Academic Development Program of Jiangsu Higher Education Institutions (PADP).	Andreu N, 2017, SCI REP-UK, V7, DOI 10.1038/srep42225; Beaulieu AM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015120; Bourigault ML, 2013, IMMUN INFLAMM DIS, V1, P47, DOI 10.1002/iid3.9; Cambier CJ, 2014, CELL, V159, P1497, DOI 10.1016/j.cell.2014.11.024; Chai QY, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00158; de Souza GA, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002527; Deng WY, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00613; Djelouadji Z, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000253; Djelouadji Zoheira, 2009, BMC Res Notes, V2, P239, DOI 10.1186/1756-0500-2-239; Domingo-Gonzalez R, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.TBTB2-0018-2016; Fan LB, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00171; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Holscher C, 2001, J IMMUNOL, V167, P6957, DOI 10.4049/jimmunol.167.12.6957; Jiang X, 2007, MICROBES INFECT, V9, P241, DOI 10.1016/j.micinf.2006.11.012; Jiang X, 2009, MICROBES INFECT, V11, P419, DOI 10.1016/j.micinf.2009.01.008; Juffermans NP, 2000, J INFECT DIS, V182, P902, DOI 10.1086/315771; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Kawai T, 2011, IMMUNITY, V34, P637, DOI 10.1016/j.immuni.2011.05.006; Kim SY, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012497; Kumar M, 2015, CELL HOST MICROBE, V17, P345, DOI 10.1016/j.chom.2015.01.007; Ladel CH, 1997, INFECT IMMUN, V65, P4843, DOI 10.1128/IAI.65.11.4843-4849.1997; Leung ETY, 2011, J CLIN MICROBIOL, V49, P2509, DOI 10.1128/JCM.00108-11; Li FG, 2018, TUBERCULOSIS, V111, P57, DOI 10.1016/j.tube.2018.05.007; Li J, 2015, J IMMUNOL, V194, P3756, DOI 10.4049/jimmunol.1402679; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Liu CH, 2017, CELL MOL IMMUNOL, V14, P963, DOI 10.1038/cmi.2017.88; Liu Y, 2016, CELL MOL IMMUNOL, V13, P729, DOI 10.1038/cmi.2015.58; Lu Q, 2020, MOL IMMUNOL, V127, P47, DOI 10.1016/j.molimm.2020.08.005; Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006; Mi YJ, 2017, RES MICROBIOL, V168, P234, DOI 10.1016/j.resmic.2016.06.004; Nandi B, 2011, J EXP MED, V208, P2251, DOI 10.1084/jem.20110919; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Qiang LH, 2019, CELL MOL IMMUNOL, V16, P380, DOI 10.1038/s41423-018-0016-0; Roach DR, 2002, J IMMUNOL, V168, P4620, DOI 10.4049/jimmunol.168.9.4620; Roach JC, 2005, P NATL ACAD SCI USA, V102, P9577, DOI 10.1073/pnas.0502272102; Sia JK, 2019, MICROBIOL SPECTR, V7, DOI 10.1128/microbiolspec.GPP3-0022-2018; Thiefes A, 2005, J BIOL CHEM, V280, P27728, DOI 10.1074/jbc.M411657200; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang J, 2015, NAT IMMUNOL, V16, P237, DOI 10.1038/ni.3096; Wang L, 2020, NATURE, V577, P682, DOI 10.1038/s41586-019-1915-7; West AP, 2006, ANNU REV CELL DEV BI, V22, P409, DOI 10.1146/annurev.cellbio.21.122303.115827; WHO, 2021, TUBERCULOSIS; Yang H, 2019, ARCH BIOCHEM BIOPHYS, V667, P49, DOI 10.1016/j.abb.2019.04.006; Zheng RJ, 2018, J INFECT DIS, V218, P312, DOI 10.1093/infdis/jix636	45	0	0	2	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 31	2021	12								721370	10.3389/fimmu.2021.721370	http://dx.doi.org/10.3389/fimmu.2021.721370			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	US6UG	34531869	Green Published, gold			2022-12-18	WOS:000697561100001
J	Shaw, BI; Ord, JR; Nobuhara, C; Luo, XR				Shaw, Brian, I; Ord, Jeffrey R.; Nobuhara, Chloe; Luo, Xunrong			Cellular Therapies in Solid Organ Allotransplantation: Promise and Pitfalls	FRONTIERS IN IMMUNOLOGY			English	Review						allotransplantation; donor specific transfusion (DST); donor specific antibodies; mesenchymal stem cell; sensitization; allosensitization; tolerance	MESENCHYMAL STROMAL CELLS; DONOR-SPECIFIC TRANSFUSION; STEM-CELLS; RENAL-TRANSPLANTATION; KIDNEY-TRANSPLANTATION; ALLOGRAFT TOLERANCE; BLOOD-TRANSFUSION; BONE-MARROW; T-CELLS; GRAFT-SURVIVAL	Donor specific transfusions have been the basis of tolerance inducing protocols since Peter Medawar showed that it was experimentally feasible in the 1950s. Though trials of cellular therapies have become increasingly common in solid organ transplantation, they have not become standard practice. Additionally, whereas some protocols have focused on cellular therapies as a method for donor antigen delivery-thought to promote tolerance in and of itself in the correct immunologic context-other approaches have alternatively focused on the intrinsic immunosuppressive properties of the certain cell types with less emphasis on their origin, including mesenchymal stem cells, regulatory T cells, and regulatory dendritic cells. Regardless of intent, all cellular therapies must contend with the potential that introducing donor antigen in a new context will lead to sensitization. In this review, we focus on the variety of cellular therapies that have been applied in human trials and non-human primate models, describe their efficacy, highlight data regarding their potential for sensitization, and discuss opportunities for cellular therapies within our current understanding of the immune landscape.	[Shaw, Brian, I] Duke Univ, Dept Surg, Durham, NC USA; [Ord, Jeffrey R.; Nobuhara, Chloe] Duke Univ, Sch Med, Durham, NC USA; [Luo, Xunrong] Duke Univ, Dept Med, Div Nephrol, Durham, NC 27708 USA	Duke University; Duke University; Duke University	Luo, XR (corresponding author), Duke Univ, Dept Med, Div Nephrol, Durham, NC 27708 USA.	Xunrong.Luo@duke.edu			NIH [R38 AI140297]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	BS was supported by NIH grant R38 AI140297.	Arandjelovic S, 2015, NAT IMMUNOL, V16, P907, DOI 10.1038/ni.3253; Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301-472X(01)00769-X; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; Bryant J, 2014, J IMMUNOL, V192, P6092, DOI 10.4049/jimmunol.1302771; Calne R, 1998, LANCET, V351, P1701, DOI 10.1016/S0140-6736(05)77739-4; Caplan H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01645; Casiraghi F, 2012, AM J TRANSPLANT, V12, P2373, DOI 10.1111/j.1600-6143.2012.04115.x; Casiraghi F, 2008, J IMMUNOL, V181, P3933, DOI 10.4049/jimmunol.181.6.3933; Chen G, 2012, AM J TRANSPLANT, V12, P2920, DOI 10.1111/j.1600-6143.2012.04203.x; Chinnadurai R, 2016, STEM CELLS, V34, P2429, DOI 10.1002/stem.2415; Coemans M, 2018, KIDNEY INT, V94, P964, DOI 10.1016/j.kint.2018.05.018; Cornell LD, 2008, ANNU REV PATHOL-MECH, V3, P189, DOI 10.1146/annurev.pathmechdis.3.121806.151508; Cowan JE, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00897; Dangi A, 2020, AM J TRANSPLANT, V20, P2728, DOI 10.1111/ajt.15878; Deng YA, 2016, SCI REP-UK, V6, DOI 10.1038/srep37566; Detry O, 2017, J HEPATOL, V67, P47, DOI 10.1016/j.jhep.2017.03.001; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Dreyer GJ, 2020, AM J TRANSPLANT, V20, P2905, DOI 10.1111/ajt.15910; Erpicum P, 2019, KIDNEY INT, V95, P693, DOI 10.1016/j.kint.2018.08.046; Fudaba Y, 2006, AM J TRANSPLANT, V6, P2121, DOI 10.1111/j.1600-6143.2006.01434.x; HALASZ NA, 1964, TRANSPLANTATION, V2, P453, DOI 10.1097/00007890-196407000-00001; Hancock WW, 1996, P NATL ACAD SCI USA, V93, P13967, DOI 10.1073/pnas.93.24.13967; Hart A, 2021, AM J TRANSPLANT, V21, P21, DOI 10.1111/ajt.16502; Hickson LJ, 2021, KIDNEY360, V2, P542, DOI [10.34067/KID.0005692020, 10.34067/kid.0005692020]; HORI S, 1989, J IMMUNOL, V143, P1447; HOURMANT M, 1979, TRANSPLANTATION, V28, P40, DOI 10.1097/00007890-197907000-00009; Iwakoshi NN, 2000, J IMMUNOL, V164, P512, DOI 10.4049/jimmunol.164.1.512; Jiang XX, 2005, BLOOD, V105, P4120, DOI 10.1182/blood-2004-02-0586; Jiga LP, 2004, TRANSPLANTATION, V77, P1761, DOI 10.1097/01.TP.0000131165.37177.6E; Jiga LP, 2007, TRANSPLANTATION, V83, P347, DOI 10.1097/01.tp.0000248854.30016.11; Kawai T, 1999, TRANSPLANTATION, V68, P1767, DOI 10.1097/00007890-199912150-00022; KAWAI T, 1995, TRANSPLANTATION, V59, P256, DOI 10.1097/00007890-199501270-00018; Kawai T, 2008, NEW ENGL J MED, V358, P353, DOI 10.1056/NEJMoa071074; Keller CA, 2018, STEM CELL TRANSL MED, V7, P161, DOI 10.1002/sctm.17-0198; Kirk AD, 2014, AM J TRANSPLANT, V14, P1142, DOI 10.1111/ajt.12712; Kishimoto K, 2004, J AM SOC NEPHROL, V15, P2423, DOI 10.1097/01.ASN.0000137883.20961.2D; Kleist C, 2015, CLIN SCI, V128, P593, DOI 10.1042/CS20140258; Lamb KE, 2011, AM J TRANSPLANT, V11, P450, DOI 10.1111/j.1600-6143.2010.03283.x; Lazarus HM, 2005, BIOL BLOOD MARROW TR, V11, P389, DOI 10.1016/j.bbmt.2005.02.001; LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140-6736(08)60690-X; Lee SJ, 2007, BLOOD, V110, P4576, DOI 10.1182/blood-2007-06-097386; Leventhal J, 2013, TRANSPLANTATION, V95, P169, DOI 10.1097/TP.0b013e3182782fc1; Leventhal J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003509; Leventhal JR, 2018, HUM IMMUNOL, V79, P277, DOI 10.1016/j.humimm.2018.01.010; Lohan P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02666; Luo XR, 2008, P NATL ACAD SCI USA, V105, P14527, DOI 10.1073/pnas.0805204105; Mackie F, 2010, NEPHROLOGY, V15, pS101, DOI 10.1111/j.1440-1797.2009.01217.x; Melief SM, 2013, STEM CELLS, V31, P1980, DOI 10.1002/stem.1432; Moll G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01091; Moll G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00243; Moll G, 2019, TRENDS MOL MED, V25, P149, DOI 10.1016/j.molmed.2018.12.006; Moll G, 2012, STEM CELLS, V30, P1565, DOI 10.1002/stem.1111; Morath C, 2020, J CLIN INVEST, V130, P2364, DOI 10.1172/JCI133595; Mudrabettu C, 2015, NEPHROLOGY, V20, P25, DOI 10.1111/nep.12338; Naesens M, 2009, CLIN J AM SOC NEPHRO, V4, P481, DOI 10.2215/CJN.04800908; OKAZAKI H, 1980, TRANSPLANTATION, V30, P421, DOI 10.1097/00007890-198012000-00007; OWEN RD, 1945, SCIENCE, V102, P400, DOI 10.1126/science.102.2651.400; Pal R, 2009, CYTOTHERAPY, V11, P897, DOI 10.3109/14653240903253857; Pan GH, 2016, ONCOTARGET, V7, P12089, DOI 10.18632/oncotarget.7725; PARKER DC, 1995, P NATL ACAD SCI USA, V92, P9560, DOI 10.1073/pnas.92.21.9560; Pearl JP, 2007, TRANSPLANTATION, V83, P1219, DOI 10.1097/01.tp.0000259929.04596.d5; Pearl JP, 2005, AM J TRANSPLANT, V5, P465, DOI 10.1111/j.1600-6143.2005.00759.x; Peng YW, 2013, TRANSPLANTATION, V95, P161, DOI 10.1097/TP.0b013e3182754c53; Perico N, 2011, CLIN J AM SOC NEPHRO, V6, P412, DOI 10.2215/CJN.04950610; Preston EH, 2005, AM J TRANSPLANT, V5, P1032, DOI 10.1111/j.1600-6143.2005.00796.x; Quezada SA, 2003, BLOOD, V102, P1920, DOI 10.1182/blood-2003-02-0586; Radu CA, 2018, LANGENBECK ARCH SURG, V403, P83, DOI 10.1007/s00423-017-1616-3; Ramasamy R, 2007, TRANSPLANTATION, V83, P71, DOI 10.1097/01.tp.0000244572.24780.54; Rana A, 2019, ANN SURG, V269, P20, DOI 10.1097/SLA.0000000000002650; Reinders MEJ, 2013, STEM CELL TRANSL MED, V2, P107, DOI 10.5966/sctm.2012-0114; Roemhild A, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3734; SALVATIERRA O, 1980, ANN SURG, V192, P543, DOI 10.1097/00000658-198010000-00012; SANFILIPPO F, 1990, TRANSPLANTATION, V49, P25, DOI 10.1097/00007890-199001000-00006; Sawitzki B, 2020, LANCET, V395, P1627, DOI 10.1016/S0140-6736(20)30167-7; Sayegh MH, 1997, TRANSPLANTATION, V64, P1646, DOI 10.1097/00007890-199712270-00003; Scandling JD, 2015, AM J TRANSPLANT, V15, P695, DOI 10.1111/ajt.13091; Scandling JD, 2012, AM J TRANSPLANT, V12, P1133, DOI 10.1111/j.1600-6143.2012.03992.x; Scandling JD, 2008, NEW ENGL J MED, V358, P362, DOI 10.1056/NEJMoa074191; Schmitz R, 2020, AM J TRANSPLANT, V20, P3609, DOI 10.1111/ajt.16121; SHARABI Y, 1989, J EXP MED, V169, P493, DOI 10.1084/jem.169.2.493; Singh A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11338-y; Soeder Y, 2015, STEM CELL TRANSL MED, V4, P899, DOI 10.5966/sctm.2015-0002; Spitzer TR, 2011, TRANSPLANTATION, V91, P672, DOI 10.1097/TP.0b013e31820a3068; Spitzer TR, 1999, TRANSPLANTATION, V68, P480, DOI 10.1097/00007890-199908270-00006; STILLER CR, 1978, LANCET, V1, P169; Stock P, 2011, AM J TRANSPLANT, V11, P1349, DOI 10.1111/j.1600-6143.2011.03543.x; Sun QP, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1422-x; Tan JM, 2012, JAMA-J AM MED ASSOC, V307, P1169, DOI 10.1001/jama.2012.316; Todd JL, 2017, J CLIN INVEST, V127, P2464, DOI 10.1172/JCI90594; VANROOD JJ, 1978, TRANSPLANTATION, V26, P275, DOI 10.1097/00007890-197811000-00001; VANTWUYVER E, 1991, NEW ENGL J MED, V325, P1210, DOI 10.1056/NEJM199110243251704; Vignes C, 2000, J IMMUNOL, V165, P96, DOI 10.4049/jimmunol.165.1.96; Vincenti F, 2010, AM J TRANSPLANT, V10, P535, DOI 10.1111/j.1600-6143.2009.03005.x; Vincenti F, 2005, NEW ENGL J MED, V353, P770, DOI 10.1056/NEJMoa050085; Vincenti F, 2016, NEW ENGL J MED, V374, P333, DOI 10.1056/NEJMoa1506027; Wang SS, 2015, CELL TRANSPLANT, V24, P1155, DOI 10.3727/096368914X681027; Wang Y, 2009, TRANSPL P, V41, P4352, DOI 10.1016/j.transproceed.2009.08.072; Webster AC, 2005, BMJ-BRIT MED J, V331, P810, DOI 10.1136/bmj.38569.471007.AE; Weiss ARR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01191; Xu H, 2003, J IMMUNOL, V170, P2776, DOI 10.4049/jimmunol.170.5.2776; Zhang L, 2019, AM J TRANSPLANT, V19, P674, DOI 10.1111/ajt.15087; Zhao LF, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02219-7	102	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 30	2021	12								714723	10.3389/fimmu.2021.714723	http://dx.doi.org/10.3389/fimmu.2021.714723			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UU0AT	34526991	gold, Green Published			2022-12-18	WOS:000698469100001
J	Yu, ZQ; Cao, WD; Gao, XC; Aleem, MT; Liu, JL; Luo, JX; Yan, RF; Xu, LX; Song, XK; Li, XR				Yu, Zhengqing; Cao, Wandi; Gao, Xuchen; Aleem, Muhammad Tahir; Liu, Junlong; Luo, Jianxun; Yan, Ruofeng; Xu, Lixin; Song, Xiaokai; Li, Xiangrui			With Chitosan and PLGA as the Delivery Vehicle, Toxoplasma gondii Oxidoreductase-Based DNA Vaccines Decrease Parasite Burdens in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						Toxoplasma gondii; oxidoreductase; chitosan; PLGA; immune protection; mouse	SHORT-CHAIN DEHYDROGENASE/REDUCTASE; HOST IMMUNE-RESPONSES; DENDRITIC CELLS; FUNCTIONAL ASSIGNMENTS; MOLECULAR-MECHANISMS; PROTECTIVE IMMUNITY; IFN-GAMMA; CLASS-I; NANOPARTICLES; ANTIGEN	Toxoplasma gondii (T. gondii) is an intracellular parasitic protozoan that can cause serious public health problems. However, there is no effectively preventive or therapeutic strategy available for human and animals. In the present study, we developed a DNA vaccine encoding T. gondii oxidoreductase from short-chain dehydrogenase/reductase family (TgSDRO-pVAX1) and then entrapped in chitosan and poly lactic-co-glycolic acid (PLGA) to improve the efficacy. When encapsulated in chitosan (TgSDRO-pVAX1/CS nanospheres) and PLGA (TgSDRO-pVAX1/PLGA nanospheres), adequate plasmids were loaded and released stably. Before animal immunizations, the DNA vaccine was transfected into HEK 293-T cells and examined by western blotting and laser confocal microscopy. Th1/Th2 cellular and humoral immunity was induced in immunized mice, accompanied by modulated secretion of antibodies and cytokines, promoted the maturation and MHC expression of dendritic cells, and enhanced the percentages of CD4(+) and CD8(+) T lymphocytes. Immunization with TgSDRO-pVAX1/CS and TgSDRO-pVAX1/PLGA nanospheres conferred significant immunity with lower parasite burden in the mice model of acute toxoplasmosis. Furthermore, our results also lent credit to the idea that TgSDRO-pVAX1/CS and TgSDRO-pVAX1/PLGA nanospheres are substitutes for each other. In general, the current study proposed that TgSDRO-pVAX1 with chitosan or PLGA as the delivery vehicle is a promising vaccine candidate against acute toxoplasmosis.	[Yu, Zhengqing; Cao, Wandi; Gao, Xuchen; Aleem, Muhammad Tahir; Yan, Ruofeng; Xu, Lixin; Song, Xiaokai; Li, Xiangrui] Nanjing Agr Univ, Coll Vet Med, MOE Joint Int Res Lab Anim Hlth & Food Safety, Minist Educ, Nanjing, Peoples R China; [Liu, Junlong; Luo, Jianxun] Chinese Acad Agr Sci, Lanzhou Vet Res Inst, State Key Lab Vet Etiol Biol, Key Lab Vet Parasitol Gansu Prov, Lanzhou, Peoples R China	Nanjing Agricultural University; Chinese Academy of Agricultural Sciences; Lanzhou Veterinary Research Institute, CAAS	Li, XR (corresponding author), Nanjing Agr Univ, Coll Vet Med, MOE Joint Int Res Lab Anim Hlth & Food Safety, Minist Educ, Nanjing, Peoples R China.	lixiangrui@njau.edu.cn	Luo, jian/HGE-7331-2022		Key Scientific and Technological Project of XPCC [2020AB025]; College Students' innovation and entrepreneurship training program [202010307099]; State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences	Key Scientific and Technological Project of XPCC; College Students' innovation and entrepreneurship training program; State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences	This research was supported by Key Scientific and Technological Project of XPCC (2020AB025), College Students' innovation and entrepreneurship training program (202010307099), and State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences.	Aguirre AA, 2019, ECOHEALTH, V16, P378, DOI 10.1007/s10393-019-01405-7; Algaba IG, 2018, INT J PARASITOL, V48, P555, DOI 10.1016/j.ijpara.2017.12.009; AMCSF, 2012, RISK PROF REL TOX FO; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Beck KR, 2017, J STEROID BIOCHEM, V171, P157, DOI 10.1016/j.jsbmb.2017.03.008; Bessieres MH, 1997, J EUKARYOT MICROBIOL, V44, p87S, DOI 10.1111/j.1550-7408.1997.tb05800.x; Bowman K, 2006, INT J NANOMED, V1, P117, DOI 10.2147/nano.2006.1.2.117; Buschmann MD, 2013, ADV DRUG DELIVER REV, V65, P1234, DOI 10.1016/j.addr.2013.07.005; BUXTON D, 1995, PARASITOLOGY, V110, pS11, DOI 10.1017/S003118200000144X; Carroll EC, 2016, IMMUNITY, V44, P597, DOI 10.1016/j.immuni.2016.02.004; Cebrian V, 2011, ACTA BIOMATER, V7, P3645, DOI 10.1016/j.actbio.2011.06.018; Chereddy KK, 2016, WOUND REPAIR REGEN, V24, P223, DOI 10.1111/wrr.12404; Ching XT, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00609; De Temmerman ML, 2011, DRUG DISCOV TODAY, V16, P569, DOI 10.1016/j.drudis.2011.04.006; Dittmar AJ, 2016, MSPHERE, V1, DOI 10.1128/mSphere.00042-15; Dubey JP, 2014, PARASITOLOGY, V141, P311, DOI 10.1017/S0031182013001509; Dubois DJ, 2019, CELL MICROBIOL, V21, DOI 10.1111/cmi.13018; Dupont CD, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004047; Dupont CD, 2012, SEMIN IMMUNOPATHOL, V34, P793, DOI 10.1007/s00281-012-0339-3; Fan W, 2012, COLLOID SURFACE B, V90, P21, DOI 10.1016/j.colsurfb.2011.09.042; Fonte P, 2015, INT J PHARMACEUT, V496, P850, DOI 10.1016/j.ijpharm.2015.10.032; Fredriksen AB, 2006, MOL THER, V13, P776, DOI 10.1016/j.ymthe.2005.10.019; GERMANN T, 1995, EUR J IMMUNOL, V25, P823, DOI 10.1002/eji.1830250329; Gigley JP, 2009, J IMMUNOL, V182, P1069, DOI 10.4049/jimmunol.182.2.1069; Gratton SEA, 2008, P NATL ACAD SCI USA, V105, P11613, DOI 10.1073/pnas.0801763105; Grodeland G, 2013, J IMMUNOL, V191, P3221, DOI 10.4049/jimmunol.1300504; Grosche L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00721; Guiton R, 2010, J INFECT DIS, V202, P427, DOI 10.1086/653738; Hady WEA, 2019, INT J NANOMED, V14, P7191, DOI 10.2147/IJN.S213836; Hajissa K, 2019, J ADV VET ANIM RES, V6, P174, DOI 10.5455/javar.2019.f329; Hamdy S, 2011, ADV DRUG DELIVER REV, V63, P943, DOI 10.1016/j.addr.2011.05.021; Hassan IA, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-431; Hernandez-Cortazar IB, 2017, FOODBORNE PATHOG DIS, V14, P288, DOI 10.1089/fpd.2016.2224; Homan WL, 2000, INT J PARASITOL, V30, P69, DOI 10.1016/S0020-7519(99)00170-8; Howard C. J., 2004, Animal Health Research Reviews, V5, P1, DOI [10.1079/AHRR200464, 10.1079/AHR200468]; Illum L, 1998, PHARM RES-DORDR, V15, P1326; Innes EA, 2009, PARASITOLOGY, V136, P1887, DOI 10.1017/S0031182009991636; Islam MA, 2012, INT J NANOMED, V7, P6077, DOI 10.2147/IJN.S38330; Jreyssaty Christian, 2012, ISRN Pharm, V2012, P369270, DOI 10.5402/2012/369270; Jurankova J, 2014, FOOD MICROBIOL, V38, P167, DOI 10.1016/j.fm.2013.08.011; Kallberg Y, 2002, EUR J BIOCHEM, V269, P4409, DOI 10.1046/j.1432-1033.2002.03130.x; Kelly MN, 2005, INFECT IMMUN, V73, P617, DOI 10.1128/IAI.73.1.617-621.2005; Kemball CC, 2007, J IMMUNOL, V179, P1113, DOI 10.4049/jimmunol.179.2.1113; Koppolu BP, 2014, BIOMATERIALS, V35, P4382, DOI 10.1016/j.biomaterials.2014.01.078; Kumar MNVR, 2000, REACT FUNCT POLYM, V46, P1; Laidlaw BJ, 2016, NAT REV IMMUNOL, V16, P102, DOI 10.1038/nri.2015.10; Lakhrif Z, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00317; Leya T, 2020, INT J BIOL MACROMOL, V156, P928, DOI 10.1016/j.ijbiomac.2020.04.048; Li L, 2016, EXPERT REV VACCINES, V15, P313, DOI 10.1586/14760584.2016.1124762; Li YW, 2018, EXPERT OPIN BIOL TH, V18, P273, DOI 10.1080/14712598.2018.1413086; Lim M, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12010030; Liu Y, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2507-5; Lu G, 2018, PARASITE IMMUNOL, V40, DOI 10.1111/pim.12578; Luo L, 2017, DRUG DELIV, V24, P1099, DOI 10.1080/10717544.2017.1359861; Lyons RE, 2002, TRENDS PARASITOL, V18, P198, DOI 10.1016/S1471-4922(02)02248-1; Lyons RE, 2001, INFECT IMMUN, V69, P2589, DOI 10.1128/IAI.69.4.2589-2595.2001; Marques CS, 2020, PARASITE VECTOR, V13, DOI 10.1186/s13071-020-04040-2; Martini M, 2010, VACCINE, V28, P3548, DOI 10.1016/j.vaccine.2010.03.007; Matsumoto K, 2013, APPL ENVIRON MICROB, V79, P6134, DOI 10.1128/AEM.01768-13; Mellman I, 2013, CANCER IMMUNOL RES, V1, P145, DOI 10.1158/2326-6066.CIR-13-0102; Montazeri N, 2017, FRONT MICROBIOL, V8, DOI [10.3389/fmicb.2017.01031, 10.3389/fmicb.2017.00025]; Montoya JG, 2004, LANCET, V363, P1965, DOI 10.1016/S0140-6736(04)16412-X; O'Hagan DT, 2006, METHODS, V40, P10, DOI 10.1016/j.ymeth.2006.05.017; Opsteegh M, 2010, INT J FOOD MICROBIOL, V139, P193, DOI 10.1016/j.ijfoodmicro.2010.02.027; Persson B, 2003, CHEM-BIOL INTERACT, V143, P271, DOI 10.1016/S0009-2797(02)00223-5; Persson B, 2009, CHEM-BIOL INTERACT, V178, P94, DOI 10.1016/j.cbi.2008.10.040; Pifer R, 2011, TRENDS PARASITOL, V27, P388, DOI 10.1016/j.pt.2011.03.009; Prabha S, 2016, ARTIF CELL NANOMED B, V44, P83, DOI 10.3109/21691401.2014.913054; Rajapakse S, 2017, PATHOG GLOB HEALTH, V111, P333, DOI 10.1080/20477724.2017.1370528; Ramamoorth M, 2015, J CLIN DIAGN RES, V9, pGE1, DOI 10.7860/JCDR/2015/10443.5394; Rezaei F, 2019, MICROB PATHOGENESIS, V126, P172, DOI 10.1016/j.micpath.2018.11.003; Saade F, 2012, EXPERT REV VACCINES, V11, P189, DOI [10.1586/ERV.11.188, 10.1586/erv.11.188]; Salari F, 2015, INT IMMUNOPHARMACOL, V29, P672, DOI 10.1016/j.intimp.2015.09.011; Sasai M, 2018, INT IMMUNOL, V30, P113, DOI 10.1093/intimm/dxy004; Schlosser PM, 2015, ENVIRON HEALTH PERSP, V123, P114, DOI 10.1289/ehp.1308030; Silva AL, 2016, HUM VACC IMMUNOTHER, V12, P1056, DOI 10.1080/21645515.2015.1117714; Skop NB, 2013, ACTA BIOMATER, V9, P6834, DOI 10.1016/j.actbio.2013.02.043; Sonaimuthu P, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00808; Song XY, 2014, ADV EXP MED BIOL, V841, P99, DOI 10.1007/978-94-017-9487-9_5; Sousa CRE, 2004, CURR OPIN IMMUNOL, V16, P21, DOI 10.1016/j.coi.2003.11.007; Sroka J, 2019, FOODBORNE PATHOG DIS, V16, P195, DOI 10.1089/fpd.2018.2537; Sun H, 2020, MICROB PATHOGENESIS, V147, DOI 10.1016/j.micpath.2020.104441; Tacken PJ, 2011, BLOOD, V118, P6836, DOI 10.1182/blood-2011-07-367615; Tan F, 2011, VACCINE, V29, P2742, DOI 10.1016/j.vaccine.2011.01.089; Tang XM, 2016, SCI REP-UK, V6, DOI 10.1038/srep29379; Tao Q, 2013, PARASITOL RES, V112, P2871, DOI 10.1007/s00436-013-3458-4; Thiebaut R, 2007, LANCET, V369, P115, DOI 10.1016/S0140-6736(07)60072-5; Tomova C, 2009, TRAFFIC, V10, P1471, DOI 10.1111/j.1600-0854.2009.00954.x; Trombetta ES, 2005, ANNU REV IMMUNOL, V23, P975, DOI 10.1146/annurev.immunol.22.012703.104538; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Walseng E, 2010, J BIOL CHEM, V285, P41749, DOI 10.1074/jbc.M110.157586; Wang JL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00730; Wang S, 2013, TRANSPL P, V45, P677, DOI 10.1016/j.transproceed.2012.02.036; Wang S, 2014, AVIAN PATHOL, V43, P91, DOI 10.1080/03079457.2013.874007; Wang W, 2000, INT J PHARMACEUT, V203, P1, DOI 10.1016/S0378-5173(00)00423-3; Wang WQ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020487; Wedmore I, 2006, J TRAUMA, V60, P655, DOI 10.1097/01.ta.0000199392.91772.44; Weiss LM, 2009, INT J PARASITOL, V39, P895, DOI 10.1016/j.ijpara.2009.02.004; Yarovinsky F, 2014, NAT REV IMMUNOL, V14, P109, DOI 10.1038/nri3598; Yoshida N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01703; Zhang M, 2014, VET PARASITOL, V200, P85, DOI 10.1016/j.vetpar.2013.10.022; Zhang NZ, 2015, EXPERT REV VACCINES, V14, P1609, DOI 10.1586/14760584.2015.1098539; Zhao GH, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-175; Zheng B, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00734; Zheng B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00418; Zheng FR, 2016, AQUACULTURE, V452, P263, DOI 10.1016/j.aquaculture.2015.11.013; Zhou F, 2009, INT REV IMMUNOL, V28, P239, DOI 10.1080/08830180902978120	108	0	1	3	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 27	2021	12								726615	10.3389/fimmu.2021.726615	http://dx.doi.org/10.3389/fimmu.2021.726615			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV9NW	34512659	gold, Green Published			2022-12-18	WOS:000717557000001
J	Bouvier, S; Kaspi, E; Joshkon, A; Paulmyer-Lacroix, O; Piercecchi-Marti, MD; Sharma, A; Leroyer, AS; Bertaud, A; Gris, JC; Dignat-George, F; Blot-Chabaud, M; Bardin, N				Bouvier, Sylvie; Kaspi, Elise; Joshkon, Ahmad; Paulmyer-Lacroix, Odile; Piercecchi-Marti, Marie-Dominique; Sharma, Akshita; Leroyer, Aurelie S.; Bertaud, Alexandrine; Gris, Jean-Christophe; Dignat-George, Francoise; Blot-Chabaud, Marcel; Bardin, Nathalie			The Role of the Adhesion Receptor CD146 and Its Soluble Form in Human Embryo Implantation and Pregnancy	FRONTIERS IN IMMUNOLOGY			English	Review						biomarker; CD146; sCD146; fertility; implantation; pregnancy; preeclampsia	POTENTIAL ROLE; MOLECULE; EXPRESSION; MARKER; IDENTIFICATION; MIGRATION; MEMBRANE; FAILURE; GROWTH; CELLS	CD146 is an adhesion molecule essentially located in the vascular system, which has been described to play an important role in angiogenesis. A soluble form of CD146, called sCD146, is detected in the bloodstream and is known as an angiogenic factor. During placental development, CD146 is selectively expressed in extravillous trophoblasts. A growing body of evidence shows that CD146 and, in particular, sCD146, regulate extravillous trophoblasts migration and invasion both in vitro and in vivo. Hereby, we review expression and functions of CD146/sCD146 in the obstetrical field, mainly in pregnancy and in embryo implantation. We emphasized the relevance of quantifying sCD146 in the plasma of pregnant women or in embryo supernatant in the case of in vitro fertilization (IVF) to predict pathological pregnancy such as preeclampsia or implantation defect. This review will also shed light on some major results that led us to define CD146/sCD146 as a biomarker of placental development and paves the way toward identification of new therapeutic targets during implantation and pregnancy.	[Bouvier, Sylvie; Gris, Jean-Christophe] Nimes Univ Hosp, Dept Hematol, Nimes, France; [Bouvier, Sylvie; Gris, Jean-Christophe] Univ Montpellier, Fac Pharmaceut & Biol Sci, Montpellier, France; [Bouvier, Sylvie; Gris, Jean-Christophe] Univ Montpellier, UA11 Inst Desbrest Epidemiol & Publ Hlth, INSERM, Montpellier, France; [Kaspi, Elise] Aix Marseille Univ, Hop la Timone, AP HM, MMG,Serv Biol Cellulaire,INSERM, Marseille, France; [Joshkon, Ahmad; Leroyer, Aurelie S.; Bertaud, Alexandrine; Blot-Chabaud, Marcel] Aix Marseille Univ, C2VN, INRAE, INSERM, Marseille, France; [Paulmyer-Lacroix, Odile] Aix Marseille Univ, Hop Concept, AP HM, Lab Histol Embryol Biol Reprod, Marseille, France; [Piercecchi-Marti, Marie-Dominique] Aix Marseille Univ, Hop La Timone, AP HM, CNRS,EFS,ADES,Forens Dept, Marseille, France; [Sharma, Akshita] DY Patil Univ, Ctr Interdisciplinary Res, Dept Stem Cell & Regenerat Med, Kolhapur, Maharashtra, India; [Gris, Jean-Christophe] IM Sechenov First Moscow State Med Univ, Moscow, Russia; [Dignat-George, Francoise] Aix Marseille Univ, Hop Concept, AP HM, INSERM,INRAE,C2VN,Lab Hematol, Marseille, France; [Bardin, Nathalie] Aix Marseille Univ, Hop Concept, AP HM, INSEAM,INRAE,C2VN,Lab Immunol, Marseille, France	Universite de Montpellier; CHU de Nimes; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centre National de la Recherche Scientifique (CNRS); Universite Bordeaux-Montaigne; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sechenov First Moscow State Medical University; INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; INRAE; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Bardin, N (corresponding author), Aix Marseille Univ, Hop Concept, AP HM, INSEAM,INRAE,C2VN,Lab Immunol, Marseille, France.	nathalie.bardin@univ-amu.fr	DIGNAT-GEORGE, Françoise/R-1129-2016; Joshkon, Ahmad/AFR-7901-2022; sharma, akshita/GXA-0011-2022; Kaspi, Elise/I-4936-2016; Bardin, Nathalie/AAL-3663-2020	DIGNAT-GEORGE, Françoise/0000-0001-7006-4462; Joshkon, Ahmad/0000-0003-2124-1914; Kaspi, Elise/0000-0003-0458-5109; Bardin, Nathalie/0000-0003-3680-082X	Nimes University Hospital	Nimes University Hospital	We thank the research team at the "Direction de la Recherche Clinique et de l'Innovation" at Nimes University hospital: S. Cle ' ment, C. Meyzonnier, N. Best, A. Megzari, E. Dupeyron, S. Granier, B. Lafont, C. Masseguin, O. Albert, S. Doulay, M. Hnida, S.de Bouard, P. Rataboul, and M. P. Francheschi. We are also grateful to Teresa Sawyers, Medical Writer at the B.E.S.P.I.M, Nimes University Hospital, for revising and editing this article. Our thanks also go to the Department of Gynecology and Obstetrics at Nimes University Hospital, particularly Prof. Vincent Letouzey and Dr Eve Mousty. We are also most grateful to Nimes University Hospital for its structural, human, and financial support.	Bardin N, 1998, FEBS LETT, V421, P12, DOI 10.1016/S0014-5793(97)01455-5; Bardin N, 2001, BLOOD, V98, P3677, DOI 10.1182/blood.V98.13.3677; Boneberg EM, 2009, MICROVASC RES, V78, P325, DOI 10.1016/j.mvr.2009.06.012; Bouvier S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173724; Cierna Z, 2016, ANN ANAT, V204, P45, DOI 10.1016/j.aanat.2015.10.003; Dagur PK, 2011, J AUTOIMMUN, V37, P319, DOI 10.1016/j.jaut.2011.09.003; Dey SK, 2004, ENDOCR REV, V25, P341, DOI 10.1210/er.2003-0020; Fisher S J, 1993, Semin Cell Biol, V4, P183, DOI 10.1006/scel.1993.1022; Guezguez B, 2006, FEBS LETT, V580, P3649, DOI 10.1016/j.febslet.2006.05.048; Higuchi T, 2003, MOL HUM REPROD, V9, P359, DOI 10.1093/molehr/gag044; Huppertz Berthold, 2005, Angiogenesis, V8, P157, DOI 10.1007/s10456-005-9007-8; Joshkon A, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8120633; Kamiyama T, 2012, J DERMATOL, V39, P838, DOI 10.1111/j.1346-8138.2012.01544.x; Kaspi E, 2013, ANGIOGENESIS, V16, P329, DOI 10.1007/s10456-012-9317-6; Kim YM, 2017, AM J PHYSIOL-CELL PH, V312, pC749, DOI 10.1152/ajpcell.00346.2016; Knofler M, 2010, INT J DEV BIOL, V54, P269, DOI 10.1387/ijdb.082769mk; Kolundzic N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028514; Lee Y, 2007, HUM PATHOL, V38, P1003, DOI 10.1016/j.humpath.2006.12.012; Liu Q, 2004, LAB INVEST, V84, P221, DOI 10.1038/labinvest.3700033; Liu Q, 2008, J CELL PHYSIOL, V215, P621, DOI 10.1002/jcp.21341; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; Mills L, 2002, CANCER RES, V62, P5106; Oka S, 2012, ANTICANCER RES, V32, P861; Onogi A, 2011, PLACENTA, V32, P665, DOI 10.1016/j.placenta.2011.06.023; Pasquier E, 2013, FERTIL STERIL, V100, P1013, DOI 10.1016/j.fertnstert.2013.06.008; Pollheimer J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02597; SERS C, 1994, CANCER RES, V54, P5689; Shih IM, 1998, J CELL SCI, V111, P2655; Shih IM, 1996, LAB INVEST, V75, P377; Wang H., 2008, J REPROD CONTRACEPT, V19, P7, DOI [10.1016/S1001-7844(08)60003-6, DOI 10.1016/S1001-7844(08)60003-6]; Wu GJ, 2011, J UROLOGY, V185, P1504, DOI 10.1016/j.juro.2010.11.052; Zabouo G, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2215	32	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 26	2021	12								711394	10.3389/fimmu.2021.711394	http://dx.doi.org/10.3389/fimmu.2021.711394			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UU2PG	34512633	gold, Green Published			2022-12-18	WOS:000698642700001
J	Li, B; Lian, M; Li, YK; Qian, QW; Zhang, J; Liu, QY; Tang, RQ; Ma, X				Li, Bo; Lian, Min; Li, Yikang; Qian, Qiwei; Zhang, Jun; Liu, Qiaoyan; Tang, Ruqi; Ma, Xiong			Myeloid-Derived Suppressive Cells Deficient in Liver X Receptor alpha Protected From Autoimmune Hepatitis	FRONTIERS IN IMMUNOLOGY			English	Article						liver X receptor alpha; myeloid-derived suppressor cells; autoimmune hepatitis; interferon regulatory factor 8; immune-mediated hepatitis	DENDRITIC CELLS; ACTIVATION; MECHANISMS; MACROPHAGES; RESPONSES	Myeloid-derived suppressor cells (MDSCs) emerge as a promising candidate for the immunotherapy of autoimmune hepatitis (AIH). However, targets for modulating MDSC in AIH are still being searched. Liver X receptors (LXRs) are important nuclear receptors linking lipid metabolism and immune responses. Despite the extensive studies of LXR in myeloid compartment, its role in MDSCs is currently less understood. Herein, expression of LXR alpha was found to be upregulated in AIH patients and colocalized with hepatic MDSCs. In ConA-induced hepatitis, deletion of LXR alpha led to increased expansion of MDSCs in the liver and alleviated the hepatic injury. MDSCs in LXR alpha(-/-) mice exhibited enhanced proliferation and survival comparing with WT mice. T-cell proliferation assay and adoptive cell transfer experiment validated the potent immunoregulatory role of MDSCs in vitro and in vivo. Mechanistically, MDSCs from LXR alpha(-/-) mice possessed significantly lower expression of interferon regulatory factor 8 (IRF-8), a key negative regulator of MDSC differentiation. Transcriptional activation of IRF-8 by LXR alpha was further demonstrated ConclusionWe reported that abrogation of LXR alpha facilitated the expansion of MDSCs via downregulating IRF-8, and thereby ameliorated hepatic immune injury profoundly. Our work highlights the therapeutic potential of targeting LXR alpha in AIH.	[Li, Bo; Lian, Min; Li, Yikang; Qian, Qiwei; Zhang, Jun; Liu, Qiaoyan; Tang, Ruqi; Ma, Xiong] Shanghai Jiao Tong Univ, Shanghai Inst Digest Dis, Div Gastroenterol & Hepatol,Renji Hosp,Sch Med,Mi, Key Lab Gastroenterol & Hepatol,State Key Lab Onc, Shanghai, Peoples R China	Shanghai Jiao Tong University	Tang, RQ; Ma, X (corresponding author), Shanghai Jiao Tong Univ, Shanghai Inst Digest Dis, Div Gastroenterol & Hepatol,Renji Hosp,Sch Med,Mi, Key Lab Gastroenterol & Hepatol,State Key Lab Onc, Shanghai, Peoples R China.	ruqi.tang@gmail.com; maxiongmd@hotmail.com		Ma, Xiong/0000-0001-9616-4672	National Natural Science Foundation of China [81830016, 81771732, 81620108002, 81922010, 81873561, 81570469, 81800504]; Shanghai Sailing Program [18YF1412900]; "Chen Guang" project - Shanghai Municipal Education Commission; Shanghai Education Development Foundation [19CG16]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Sailing Program; "Chen Guang" project - Shanghai Municipal Education Commission; Shanghai Education Development Foundation	This work was supported by the National Natural Science Foundation of China grants (#81830016, 81771732, and 81620108002 to XM; #81922010, 81873561, and 81570469 to RT; #81800504 to ML), Shanghai Sailing Program (No. 18YF1412900 to ML), and "Chen Guang" project supported by Shanghai Municipal Education Commission and Shanghai Education Development Foundation (No. 19CG16).	Bensinger SJ, 2008, CELL, V134, P97, DOI 10.1016/j.cell.2008.04.052; Bilotta MT, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.584303; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Crick PJ, 2017, MOL NEUROBIOL, V54, P8009, DOI 10.1007/s12035-016-0281-9; Cui GL, 2011, J CLIN INVEST, V121, P658, DOI 10.1172/JCI42974; Diao WL, 2014, PROTEIN CELL, V5, P714, DOI 10.1007/s13238-014-0069-5; Diczfalusy U, 2009, J LIPID RES, V50, P2258, DOI 10.1194/jlr.M900107-JLR200; Duc D, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184522; Endo-Umeda K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205045; Endo-Umeda K, 2018, ENDOCRINOLOGY, V159, P1419, DOI 10.1210/en.2017-03141; Fontaine C, 2007, CIRC RES, V101, P40, DOI 10.1161/CIRCRESAHA.106.135814; Gao L, 2020, HEPATOL COMMUN, V4, P1664, DOI 10.1002/hep4.1584; Glaria E, 2020, CURR OPIN PHARMACOL, V53, P55, DOI 10.1016/j.coph.2020.05.001; Guillemot-Legris O, 2019, J CROHNS COLITIS, V13, P218, DOI 10.1093/ecco-jcc/jjy157; Hammerich L, 2015, HEPATOLOGY, V61, P990, DOI 10.1002/hep.27571; Hennes EM, 2008, HEPATOLOGY, V48, P169, DOI 10.1002/hep.22322; Herold M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184985; Hu XL, 2013, J BIOL CHEM, V288, P19103, DOI 10.1074/jbc.M112.434530; Kaffe ET, 2015, REDOX REP, V20, DOI 10.1179/1351000214Y.0000000101; Laffitte BA, 2001, MOL CELL BIOL, V21, P7558, DOI 10.1128/MCB.21.22.7558-7568.2001; Li HW, 2015, MOL MED REP, V12, P3667, DOI 10.3892/mmr.2015.3791; Lian M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02577; Ma LQ, 2020, CANCER LETT, V493, P266, DOI 10.1016/j.canlet.2020.08.020; Menegaut L, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107665; Nagy L, 2012, PHYSIOL REV, V92, P739, DOI 10.1152/physrev.00004.2011; Netherby CS, 2017, J IMMUNOL, V198, P4129, DOI 10.4049/jimmunol.1601722; Park K, 2010, J LEUKOCYTE BIOL, V88, P1081, DOI 10.1189/jlb.0610318; Pascual-Garcia M, 2013, J IMMUNOL, V190, P6520, DOI 10.4049/jimmunol.1201393; Pourcet B, 2011, CIRC RES, V109, P492, DOI 10.1161/CIRCRESAHA.111.241810; Ramachandran P, 2019, NATURE, V575, P512, DOI 10.1038/s41586-019-1631-3; Ramon-Vazquez A, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00376-18; Raselli T, 2019, J CROHNS COLITIS, V13, P1186, DOI 10.1093/ecco-jcc/jjz039; Raselli T, 2019, J LIPID RES, V60, P1270, DOI 10.1194/jlr.M093229; Sarra M, 2013, HEPATOLOGY, V58, P1436, DOI 10.1002/hep.26446; Souto FO, 2020, J INFECT DIS, V221, P1542, DOI 10.1093/infdis/jiz635; Tavazoie MF, 2018, CELL, V172, P825, DOI 10.1016/j.cell.2017.12.026; Torocsik D, 2010, J IMMUNOL, V184, P5456, DOI 10.4049/jimmunol.0902399; Veglia F, 2018, NAT IMMUNOL, V19, P108, DOI 10.1038/s41590-017-0022-x; Villablanca EJ, 2010, NAT MED, V16, P98, DOI 10.1038/nm.2074; Waight JD, 2013, J CLIN INVEST, V123, P4464, DOI 10.1172/JCI68189; Wang HX, 2012, WORLD J GASTROENTERO, V18, P119, DOI 10.3748/wjg.v18.i2.119; Webb GJ, 2018, ANNU REV PATHOL-MECH, V13, P247, DOI 10.1146/annurev-pathol-020117-043534; Zhang HY, 2018, HEPATOLOGY, V67, P232, DOI 10.1002/hep.29418; Zhang HY, 2014, J AUTOIMMUN, V53, P55, DOI 10.1016/j.jaut.2014.02.010; Zhang XX, 2019, NUCLEIC ACIDS RES, V47, pD721, DOI 10.1093/nar/gky900; Zhong LM, 2014, MOL IMMUNOL, V60, P32, DOI 10.1016/j.molimm.2014.03.006	46	0	0	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 26	2021	12								732102	10.3389/fimmu.2021.732102	http://dx.doi.org/10.3389/fimmu.2021.732102			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XN1YO	34512667	Green Published, gold			2022-12-18	WOS:000729308400001
J	Moser, T; Seiberl, M; Feige, J; Bieler, L; Radlberger, RF; O'Sullivan, C; Pilz, G; Harrer, A; Schwenker, K; Haschke-Becher, E; Machegger, L; Grimm, J; Redlberger-Fritz, M; Buchmann, A; Khalil, M; Kvas, E; Trinka, E; Wipfler, P				Moser, Tobias; Seiberl, Michael; Feige, Julia; Bieler, Lara; Radlberger, Richard F.; O'Sullivan, Ciara; Pilz, Georg; Harrer, Andrea; Schwenker, Kerstin; Haschke-Becher, Elisabeth; Machegger, Lukas; Grimm, Jochen; Redlberger-Fritz, Monika; Buchmann, Arabella; Khalil, Michael; Kvas, Erich; Trinka, Eugen; Wipfler, Peter			Tetravalent Influenza Vaccine Is Not Associated With Neuroaxonal Damage in Multiple Sclerosis Patients	FRONTIERS IN IMMUNOLOGY			English	Article						vaccination; immunization; NfL; titers; influenza; COVID-19; antibody response	SERUM NEUROFILAMENT LIGHT; RISK; BIOMARKER; TRIAL	Background Efficacy of vaccines and disease activity linked to immunization are major concerns among people with multiple sclerosis (pwMS). Objective To assess antibody responses to seasonal influenza antigens and vaccine-associated neuroaxonal damage utilizing serum neurofilament light chain (sNfL) in pwMS receiving dimethyl fumarate (DMF). Methods In this prospective study, the 2020/2021 seasonal tetravalent influenza vaccine was administered to 20 pwMS treated with DMF and 15 healthy controls (HCs). The primary endpoints were responder rate of strain-specific antibody production (seroconversion or significant (4-fold) increase in influenza-antibody titers for >= 2/4 strains) at 30 days post-vaccination and changes in sNfL levels. Results All patients treated with DMF fulfilled the responder criteria for immunization compared with 53% of the controls. However, higher proportions of HCs already had influenza-antibody titers >= 1:40 at baseline (53% vs. 41%, p = 0.174). sNfL levels were comparable among both groups at baseline and did not increase 34 days after vaccination. In addition, no clinical or radiological disease reactivation was found. Conclusion DMF-treated patients mount an adequate humoral immune response to influenza vaccines. Within the limits of the small cohort investigated, our data suggest that influenza immunization is not associated with clinical or subclinical disease reactivation.	[Moser, Tobias; Seiberl, Michael; Feige, Julia; Bieler, Lara; Radlberger, Richard F.; O'Sullivan, Ciara; Pilz, Georg; Harrer, Andrea; Schwenker, Kerstin; Trinka, Eugen; Wipfler, Peter] Paracelsus Med Univ, Christian Doppler Univ Hosp, Dept Neurol, Salzburg, Austria; [Moser, Tobias; Seiberl, Michael; Feige, Julia; Bieler, Lara; Radlberger, Richard F.; O'Sullivan, Ciara; Pilz, Georg; Harrer, Andrea; Schwenker, Kerstin; Trinka, Eugen; Wipfler, Peter] Ctr Cognit Neurosci, Salzburg, Austria; [Haschke-Becher, Elisabeth] Paracelsus Med Ctr, Dept Lab Med, Salzburg, Austria; [Machegger, Lukas; Grimm, Jochen] Paracelsus Med Univ, Christian Doppler Univ Hosp, Dept Neuroradiol, Salzburg, Austria; [Redlberger-Fritz, Monika] Med Univ Vienna, Ctr Virol, Vienna, Austria; [Buchmann, Arabella; Khalil, Michael] Med Univ Graz, Dept Neurol, Graz, Austria; [Kvas, Erich] Hermesoft, Stat, Graz, Austria; [Trinka, Eugen] Paracelsus Med Univ, Christian Doppler Univ Hosp, Neurosci Inst, Salzburg, Austria	Paracelsus Private Medical University; Paracelsus Private Medical University; Medical University of Vienna; Medical University of Graz; Paracelsus Private Medical University	Moser, T (corresponding author), Paracelsus Med Univ, Christian Doppler Univ Hosp, Dept Neurol, Salzburg, Austria.; Moser, T (corresponding author), Ctr Cognit Neurosci, Salzburg, Austria.	t.moser@salk.at	Machegger, Lukas/GRE-6020-2022; Grimm, Jochen M/H-8237-2019	Grimm, Jochen M/0000-0003-0037-6924; Moser, Tobias/0000-0002-5397-5595; Buchmann, Arabella/0000-0002-7381-2427; Wipfler, Peter/0000-0003-4982-4855; Redlberger-Fritz, Monika/0000-0001-6265-557X; Machegger, Lukas/0000-0002-7437-8992	Biogen	Biogen(Biogen)	Funding This study was financially supported by Biogen. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	Aamodt AH, 2021, J NEUROL, V268, P3574, DOI 10.1007/s00415-021-10517-6; Ameres M, 2020, J NEUROL, V267, P3476, DOI 10.1007/s00415-020-10050-y; BAMFORD CR, 1978, ARCH NEUROL-CHICAGO, V35, P242, DOI 10.1001/archneur.1978.00500280060012; Bar-Or A, 2020, NEUROLOGY, V95, pE1999, DOI 10.1212/WNL.0000000000010380; Ciotti JR, 2020, MULT SCLER RELAT DIS, V45, DOI 10.1016/j.msard.2020.102439; Correale J, 2006, NEUROLOGY, V67, P652, DOI 10.1212/01.wnl.0000233834.09743.3b; De Keyser J, 1998, J NEUROL SCI, V159, P51, DOI 10.1016/S0022-510X(98)00139-7; Disanto G, 2017, ANN NEUROL, V81, P857, DOI 10.1002/ana.24954; European Agency for the Evaluation of Medicinal Products, 1997, COMM PROPR MED PROD; Farez MF, 2019, NEUROLOGY, V93, P584, DOI 10.1212/WNL.0000000000008157; Farez MF, 2012, MULT SCLER J, V18, P254, DOI 10.1177/1352458511417253; Gattringer T, 2017, NEUROLOGY, V89, P2108, DOI 10.1212/WNL.0000000000004645; Gold R, 2020, THER ADV NEUROL DISO, V13, DOI 10.1177/1756286420915005; Gold R, 2012, NEW ENGL J MED, V367, P1098, DOI 10.1056/NEJMoa1114287; Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433; Kappos L, 2015, NEUROLOGY, V84, P872, DOI 10.1212/WNL.0000000000001302; Kern DM, 2020, BMC NEUROL, V20, DOI 10.1186/s12883-020-01882-2; Khalil M, 2018, NAT REV NEUROL, V14, P577, DOI 10.1038/s41582-018-0058-z; Kremer S, 2020, RADIOLOGY, V297, pE242, DOI [10.1148/radiol.2020202222, 10.1148/radiol.202020222]; Lapostolle F, 2020, INTERN EMERG MED, V15, P813, DOI 10.1007/s11739-020-02379-z; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Marrodan M, 2019, MULT SCLER J, V25, P891, DOI 10.1177/1352458518823940; McDonald SJ, 2021, BIOMARK RES, V9, DOI 10.1186/s40364-020-00256-7; McNicholas N, 2011, J NEUROL, V258, P1545, DOI 10.1007/s00415-011-5944-x; Miller AE, 1997, NEUROLOGY, V48, P312, DOI 10.1212/WNL.48.2.312; Moser T, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102647; MYERS LW, 1977, J INFECT DIS, V136, pS546, DOI 10.1093/infdis/136.Supplement_3.S546; Nauta JJP, 2009, BIOLOGICALS, V37, P216, DOI 10.1016/j.biologicals.2009.02.002; Olberg HK, 2014, MULT SCLER J, V20, P1074, DOI 10.1177/1352458513513970; Pajo AT, 2021, NEUROL SCI, V42, P1255, DOI 10.1007/s10072-021-05068-7; SALVETTI M, 1995, J NEUROL, V242, P143, DOI 10.1007/BF00936886; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Siller N, 2019, MULT SCLER J, V25, P678, DOI 10.1177/1352458518765666; Sutter R, 2021, ANN NEUROL, V89, P610, DOI 10.1002/ana.26004; Thompson AJ, 2018, LANCET NEUROL, V17, P162, DOI 10.1016/S1474-4422(17)30470-2; Varhaug KN, 2018, NEUROL-NEUROIMMUNOL, V5, DOI 10.1212/NXI.0000000000000422; von Hehn C, 2018, NEUROL-NEUROIMMUNOL, V5, DOI 10.1212/NXI.0000000000000409; Williamson EM, 2015, CNS DRUGS, V29, P229, DOI 10.1007/s40263-015-0226-2; Wingerchuk DM, 2014, MAYO CLIN PROC, V89, P225, DOI 10.1016/j.mayocp.2013.11.002; Wirsching A, 2019, J NEUROTRAUM, V36, P548, DOI 10.1089/neu.2018.5836; World Health Organization, 2014, REP SAG WORK GROUP V	41	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 26	2021	12								718895	10.3389/fimmu.2021.718895	http://dx.doi.org/10.3389/fimmu.2021.718895			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV8ME	34512642	gold, Green Published			2022-12-18	WOS:000717483800001
J	Pers, YM; Jorgensen, C; Khoury, M				Pers, Yves-Marie; Jorgensen, Christian; Khoury, Maroun			Editorial: The Role of Metabolism in MSC-Mediated Immunomodulation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						MSC; metabolism; immunomodulation; extracellular vesicles (EV); miR (microRNA); macrophages; glycolytic activity; mitochondria transfer	MESENCHYMAL STEM-CELLS; DISEASE		[Pers, Yves-Marie; Jorgensen, Christian] Univ Montpellier, IRMB, INSERM, CHU Montpellier, Montpellier, France; [Pers, Yves-Marie; Jorgensen, Christian] Lapeyronie Univ Hosp, Dept Rheumatol, Clin Immunol & Osteoarticular Dis Therapeut Unit, Montpellier, France; [Khoury, Maroun] Univ Andes, Lab Nanoregenerat Med, Fac Med, Santiago, Chile; [Khoury, Maroun] Chilean Consortium Regenerat Med, Cells Cells & REGENERO, Santiago, Chile	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; Universidad de los Andes - Chile	Pers, YM (corresponding author), Univ Montpellier, IRMB, INSERM, CHU Montpellier, Montpellier, France.; Pers, YM (corresponding author), Lapeyronie Univ Hosp, Dept Rheumatol, Clin Immunol & Osteoarticular Dis Therapeut Unit, Montpellier, France.	ym-pers@chu-montpellier.fr						Andrejeva G, 2017, CELL METAB, V26, P49, DOI 10.1016/j.cmet.2017.06.004; Fitzsimmons REB, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/8031718; Hu ZL, 2018, FRONT MED-PRC, V12, P463, DOI 10.1007/s11684-018-0668-2; Joswig AJ, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0503-8; LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140-6736(08)60690-X; Lohan P, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01626; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Panes J, 2016, LANCET, V388, P1281, DOI 10.1016/S0140-6736(16)31203-X; Pers YM, 2018, BIOCHIMIE, V155, P109, DOI 10.1016/j.biochi.2018.07.001; Shi YF, 2018, NAT REV NEPHROL, V14, P493, DOI 10.1038/s41581-018-0023-5	10	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 26	2021	12								751865	10.3389/fimmu.2021.751865	http://dx.doi.org/10.3389/fimmu.2021.751865			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	US0HS	34512675	Green Published, gold			2022-12-18	WOS:000697119100001
J	Xu, GZ; Jiang, L; Ye, C; Qin, GZ; Luo, ZX; Mo, YZ; Chen, J				Xu, Guozeng; Jiang, Lei; Ye, Cheng; Qin, Guizhen; Luo, Zhanxiong; Mo, Yuzhen; Chen, Jian			The Ratio of CD86+/CD163+Macrophages Predicts Postoperative Recurrence in Stage II-III Colorectal Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						CD86; CD163; ratio; recurrence; colorectal cancer; macrophage	COLON-CANCER; ADJUVANT TREATMENT; INVASIVE FRONT; OXALIPLATIN; SURVIVAL; FLUOROURACIL; CHEMOTHERAPY; MACROPHAGES; LEUCOVORIN; PROGNOSIS	Tumor-associated macrophages (TAMs) are pivotal for tumor progression and metastasis. We investigated the stromal CD86+TAM/CD163+TAM (CD86/CD163) ratio as a novel prognostic biomarker for stage II-III colorectal cancer (CRC). Two independently clinical cohorts of stage II-III CRC were retrospectively enrolled in this study. TAMs were detected using immunohistochemical staining for CD86 and CD163. The stromal CD86/CD163 ratio was calculated as a prognostic biomarker for recurrence-free survival (RFS) and overall survival (OS). Patients with a low CD86/CD163 ratio had shorter RFS (HR=0.193, p<0.001) and OS (HR=0.180, p<0.001) than patients with a high CD86/CD163 ratio in the training cohort. CD86/CD163 ratio may be an independent predictor for RFS (HR=0.233, p<0.001) and OS (HR=0.224, p<0.001) in the training cohort. We obtained equivalent results in the validation cohort. The CD86/CD163 ratio tends to have better predictive values than tumor stage in the training (AUC: 0.682 vs 0.654, p=0.538) and validation (AUC: 0.697 vs 0.659, p=0.586) cohorts. CD86/CD163 ratio effectively predicts RFS for stage II (HR=0.203, p<0.001) and stage III CRC (HR=0.302, p<0.001). CD86/CD163 ratio also effectively predicts RFS in CRC patients with adjutant chemotherapy (HR=0.258, p<0.001) and without adjutant chemotherapy (HR=0.205, p<0.001). The stromal CD86/CD163 ratio could be used for individual risk assessment of recurrence and mortality for stage II-III CRC. Together with tumor stage, this ratio will aid in the personal treatment.	[Xu, Guozeng; Qin, Guizhen; Luo, Zhanxiong] Guangxi Med Univ, Dept Oncol, Liuzhou People Hosp, Liuzhou, Peoples R China; [Jiang, Lei] Qingdao Univ, Yantai Yuhuangding Hosp, Dept Pathol, Yantai, Peoples R China; [Ye, Cheng] Guangxi Med Univ, Liuzhou People Hosp, Dept Pathol, Liuzhou, Peoples R China; [Mo, Yuzhen] Jinan Univ, Guangzhou Red Cross Hosp, Dept Radiat Oncol, Guangzhou, Peoples R China; [Chen, Jian] Qingdao Univ, Dept Med Oncol, Yantai Yuhuangding Hosp, Yantai, Peoples R China	Guangxi Medical University; Qingdao University; Guangxi Medical University; Jinan University; Qingdao University	Luo, ZX (corresponding author), Guangxi Med Univ, Dept Oncol, Liuzhou People Hosp, Liuzhou, Peoples R China.; Mo, YZ (corresponding author), Jinan Univ, Guangzhou Red Cross Hosp, Dept Radiat Oncol, Guangzhou, Peoples R China.; Chen, J (corresponding author), Qingdao Univ, Dept Med Oncol, Yantai Yuhuangding Hosp, Yantai, Peoples R China.	lzrmyylzx@163.com; gzmyz2016@126.com; chenjianyt@163.com			High-level Talents Project of Liuzhou People Hospital [lrygcc202106]; Basic Research Ability Improvement Project of Young and Middle-aged Teachers from Guangxi colleges [2021KY0111]; Self-funded project of Health Committee of Guangxi Zhuang Autonomous Region [Z20190901]	High-level Talents Project of Liuzhou People Hospital; Basic Research Ability Improvement Project of Young and Middle-aged Teachers from Guangxi colleges; Self-funded project of Health Committee of Guangxi Zhuang Autonomous Region	This study protocol was supported by the High-level Talents Project of Liuzhou People Hospital (No. lrygcc202106), the Basic Research Ability Improvement Project of Young and Middle-aged Teachers from Guangxi colleges (No. 2021KY0111), and Self-funded project of Health Committee of Guangxi Zhuang Autonomous Region (Z20190901).	Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Andre T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771; Angel H, 2013, CURR OPIN IMMUNOL, V25, P261, DOI 10.1016/j.coi.2013.03.004; Barbera-Guillem E, 2002, CANCER RES, V62, P7042; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cooks T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03224-w; Giraldez MD, 2013, INT J CANCER, V132, P1090, DOI 10.1002/ijc.27747; Feng QY, 2019, CLIN CANCER RES, V25, P3896, DOI 10.1158/1078-0432.CCR-18-2076; Gallo G, 2021, J CLIN MED, V10, DOI 10.3390/jcm10112295; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Galon J, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-205; Galon J, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-1; Grothey A, 2018, NEW ENGL J MED, V378, P1177, DOI 10.1056/NEJMoa1713709; Haller DG, 2011, J CLIN ONCOL, V29, P1465, DOI 10.1200/JCO.2010.33.6297; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Hernandez C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098458; Herrera M, 2013, CANCER SCI, V104, P437, DOI 10.1111/cas.12096; Iasonos A, 2008, J CLIN ONCOL, V26, P1364, DOI 10.1200/JCO.2007.12.9791; Jayasingam SD, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01512; Kinouchi M, 2011, HEPATO-GASTROENTEROL, V58, P352; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; O'Connell MJ, 2008, J CLIN ONCOL, V26, P2336, DOI 10.1200/JCO.2007.15.8261; O'Connor ES, 2011, J CLIN ONCOL, V29, P3381, DOI 10.1200/JCO.2010.34.3426; Ogluszka M, 2019, COMPUT METH PROG BIO, V177, P133, DOI 10.1016/j.cmpb.2019.05.023; Olsson A, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0098-5; Qin LX, 2012, CANCER MICROENVIRON, V5, P203, DOI 10.1007/s12307-012-0111-1; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Schmieder A, 2012, SEMIN CANCER BIOL, V22, P289, DOI 10.1016/j.semcancer.2012.02.002; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Tan HY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.271; Twelves C, 2005, NEW ENGL J MED, V352, P2696, DOI 10.1056/NEJMoa043116; von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013; Yahaya MAF, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/2368249; Yang CG, 2019, INT J BIOL SCI, V15, P984, DOI 10.7150/ijbs.29836; Yothers G, 2011, J CLIN ONCOL, V29, P3768, DOI 10.1200/JCO.2011.36.4539	37	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 26	2021	12								724429	10.3389/fimmu.2021.724429	http://dx.doi.org/10.3389/fimmu.2021.724429			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6I0PI	34512652	gold, Green Published			2022-12-18	WOS:000885829700001
J	Zhang, P; Liu, ZJ; Wang, DC; Li, YX; Xing, YF; Xiao, YJ				Zhang, Pu; Liu, Zijian; Wang, Decai; Li, Yunxue; Xing, Yifei; Xiao, Yajun			Scoring System Based on RNA Modification Writer-Related Genes to Predict Overall Survival and Therapeutic Response in Bladder Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						RNA modification "writer"; bladder cancer; tumor microenvironment; tumor mutation burden; immunotherapy	EXPRESSION SIGNATURE; POLYADENYLATION; IDENTIFICATION; BIOMARKER; NOMOGRAM	Introduction It's widely reported the "writer" enzymes mediated RNA adenosine modifications which is known as a crucial mechanism of epigenetic regulation in development of tumor and the immunologic response in many kinds of cancers. However, the potential roles of these writer genes in the progression of bladder cancer (BLCA) remain unclear. Materials and Methods We comprehensively described the alterations of 26 RNA modification writer genes in BLCA from the genetic and transcriptional fields and identified writer-related genes from four independent datasets. Utilizing least absolute shrinkage and selection operator (LASSO) regression and multivariate Cox regression, we constructed a ten writer-related gene signature. After that, we confirmed the predictive and prognostic value of this signature on another six independent datasets and established a nomogram to forecast the overall survival (OS) and mortality odds of BLCA patients clinically. Results The writer-related genes signature showed good performance in predicting the OS for BLCA patients. Moreover, the writer-related gene signature was related to EMT-related pathways and immune characteristics. Furthermore, the immune cell infiltration levels of CD8 T cells, cytotoxic cells, M1/2 macrophage cells and tumor mutation burden might be able to predict which patients will benefit from immunotherapy. This could also be reflected by the writer-related gene signature. Conclusions This signature might play an important role in precision individualized immunotherapy. The present work highlights the crucial clinical implications of RNA modifications and may help developing individualized therapeutic strategies for patients with BLCA.	[Zhang, Pu; Li, Yunxue; Xing, Yifei; Xiao, Yajun] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Urol Surg, Wuhan, Peoples R China; [Liu, Zijian] Sichuan Univ, West China Hosp, Dept Head & Neck Oncol, Chengdu, Peoples R China; [Liu, Zijian] Sichuan Univ, West China Hosp, Dept Radiat Oncol, Canc Ctr, Chengdu, Peoples R China; [Liu, Zijian] Sichuan Univ, West China Hosp, Stale Key Lab Biotherapy, Chengdu, Peoples R China; [Wang, Decai] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Emergency Surg, Wuhan, Peoples R China	Huazhong University of Science & Technology; Sichuan University; Sichuan University; Sichuan University; Huazhong University of Science & Technology	Xing, YF; Xiao, YJ (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Urol Surg, Wuhan, Peoples R China.	Yifei_Xing@163.com; 1984XH0663@hust.edu.cn			National Natural Science Foundation of China [000004608, 900002627]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The study was supported by National Natural Science Foundation of China (Grants No. 000004608 and 900002627).	Nieto MA, 2009, INT J DEV BIOL, V53, P1541, DOI 10.1387/ijdb.072410mn; Antoni S, 2017, EUR UROL, V71, P96, DOI 10.1016/j.eururo.2016.06.010; Baysal BE, 2017, CANCER RES, V77, P3733, DOI 10.1158/0008-5472.CAN-17-0520; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003; Braun DA, 2016, CLIN CANCER RES, V22, P5642, DOI 10.1158/1078-0432.CCR-16-0066; Cao R, 2020, J CELL MOL MED, V24, P605, DOI 10.1111/jcmm.14767; Chen HF, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01322-w; Cheng YL, 2012, LAB INVEST, V92, P1013, DOI 10.1038/labinvest.2012.59; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Colaprico A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1507; Dominissini D, 2016, NATURE, V530, P441, DOI 10.1038/nature16998; Dudley JC, 2016, CLIN CANCER RES, V22, P813, DOI 10.1158/1078-0432.CCR-15-1678; Elkon R, 2013, NAT REV GENET, V14, P496, DOI 10.1038/nrg3482; Geeleher P, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-3-r47; Ghatalia P, 2019, NAT MED, V25, P1650, DOI 10.1038/s41591-019-0645-6; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Han J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1036-9; Han YY, 2020, WORLD J SURG ONCOL, V18, DOI 10.1186/s12957-020-02084-3; Hume DA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00370; Ichinose J, 2014, CANCER SCI, V105, P1135, DOI 10.1111/cas.12472; Ji XD, 2014, ELIFE, V3, DOI 10.7554/eLife.02907; Jiang MZ, 2020, PEERJ, V8, DOI 10.7717/peerj.9453; Jiang P, 2018, NAT MED, V24, P1550, DOI 10.1038/s41591-018-0136-1; Jiang Z, 2020, AM J TRANSL RES, V12, P3858; Kietrys AM, 2016, NATURE, V530, P423, DOI 10.1038/530423a; Laurin C, 2016, STAT APPL GENET MOL, V15, P305, DOI 10.1515/sagmb-2015-0043; Lee JS, 2010, J CLIN ONCOL, V28, P2660, DOI 10.1200/JCO.2009.25.0977; Li PJ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.646982; Lian PH, 2019, AGING-US, V11, P6930, DOI 10.18632/aging.102225; Lindgren D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038863; Luo YW, 2020, J CELL MOL MED, V24, P13370, DOI 10.1111/jcmm.15960; McConkey DJ, 2016, EUR UROL, V69, P855, DOI 10.1016/j.eururo.2015.08.034; Montironi R, 2016, EUR UROL, V70, P120, DOI 10.1016/j.eururo.2016.03.011; Motorin Y, 2011, WIRES RNA, V2, P611, DOI 10.1002/wrna.79; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Qiu HD, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00012; Ramanathan A, 2016, NUCLEIC ACIDS RES, V44, P7511, DOI 10.1093/nar/gkw551; Riester M, 2012, CLIN CANCER RES, V18, P1323, DOI 10.1158/1078-0432.CCR-11-2271; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21590, 10.3322/caac.21601]; Sjodahl G, 2012, CLIN CANCER RES, V18, P3377, DOI 10.1158/1078-0432.CCR-12-0077-T; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Song YX, 2020, AGING-US, V12, P12051, DOI 10.18632/aging.103369; van Rhijn BWG, 2020, EUR UROL, V78, P682, DOI 10.1016/j.eururo.2020.07.002; Wang GP, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.627706; Wang XF, 2018, CANCER RES, V78, P4586, DOI 10.1158/0008-5472.CAN-17-3841; Xiao P, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1440166; Zhang CX, 2017, NATURE, V549, P273, DOI 10.1038/nature23883; Zhang XY, 2015, CELL BIOCHEM BIOPHYS, V73, P65, DOI 10.1007/s12013-015-0574-z; Zheng B, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20204456	50	0	0	3	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 26	2021	12								724541	10.3389/fimmu.2021.724541	http://dx.doi.org/10.3389/fimmu.2021.724541			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UU0GG	34512654	Green Published, gold			2022-12-18	WOS:000698483400001
J	Martinez-Blanco, A; Dominguez-Pantoja, M; Botia-Sanchez, M; Perez-Cabrera, S; Bello-Iglesias, N; Carrillo-Rodriguez, P; Martin-Morales, N; Lario-Simon, A; Perez-Sanchez-Canete, MM; Montosa-Hidalgo, L; Guerrero-Fernandez, S; Longobardo-Polanco, VM; Redondo-Sanchez, S; Cornet-Gomez, A; Torres-Saez, M; Fernandez-Ibanez, A; Terron-Camero, L; Andres-Leon, E; O'Valle, F; Merino, R; Zubiaur, M; Sancho, J				Martinez-Blanco, Africa; Dominguez-Pantoja, Marilu; Botia-Sanchez, Maria; Perez-Cabrera, Sonia; Bello-Iglesias, Nerea; Carrillo-Rodriguez, Paula; Martin-Morales, Natividad; Lario-Simon, Antonio; Perez-Sanchez-Canete, Maria M.; Montosa-Hidalgo, Laura; Guerrero-Fernandez, Salvador; Longobardo-Polanco, Victoria M.; Redondo-Sanchez, Sandra; Cornet-Gomez, Alberto; Torres-Saez, Maria; Fernandez-Ibanez, Ana; Terron-Camero, Laura; Andres-Leon, Eduardo; O'Valle, Francisco; Merino, Ramon; Zubiaur, Mercedes; Sancho, Jaime			CD38 Deficiency Ameliorates Chronic Graft-Versus-Host Disease Murine Lupus via a B-Cell-Dependent Mechanism	FRONTIERS IN IMMUNOLOGY			English	Article						CD38; cGVHD lupus-like; T-bet(+) B cells; anti-ssDNA antibodies; GC B cells; STAT1; type I IFN-signature; inflammation	SOLUBLE CD40 LIGAND; T-CELLS; AUTOANTIBODY PRODUCTION; ERYTHEMATOSUS; EXPRESSION; INDUCTION; CYTOSCAPE; INSIGHTS; PROTEIN; DEATH	The absence of the mouse cell surface receptor CD38 in Cd38(-/-) mice suggests that this receptor acts as a positive regulator of inflammatory and autoimmune responses. Here, we report that, in the context of the chronic graft-versus-host disease (cGVHD) lupus inducible model, the transfer of B6.C-H2bm12/KhEg(bm12) spleen cells into co-isogenic Cd38(-/-) B6 mice causes milder lupus-like autoimmunity with lower levels of anti-ssDNA autoantibodies than the transfer of bm12 spleen cells into WT B6 mice. In addition, significantly lower percentages of Tfh cells, as well as GC B cells, plasma cells, and T-bet(+)CD11c(hi) B cells, were observed in Cd38(-/-) mice than in WT mice, while the expansion of Treg cells and Tfr cells was normal, suggesting that the ability of Cd38(-/-) B cells to respond to allogeneic help from bm12 CD4(+) T cells is greatly diminished. The frequencies of T-bet(+)CD11c(hi) B cells, which are considered the precursors of the autoantibody-secreting cells, correlate with anti-ssDNA autoantibody serum levels, IL-27, and sCD40L. Proteomics profiling of the spleens from WT cGVHD mice reflects a STAT1-driven type I IFN signature, which is absent in Cd38(-/-) cGVHD mice. Kidney, spleen, and liver inflammation was mild and resolved faster in Cd38(-/-) cGVHD mice than in WT cGVHD mice. We conclude that CD38 in B cells functions as a modulator receptor that controls autoimmune responses.	[Martinez-Blanco, Africa; Dominguez-Pantoja, Marilu; Botia-Sanchez, Maria; Perez-Cabrera, Sonia; Bello-Iglesias, Nerea; Carrillo-Rodriguez, Paula; Cornet-Gomez, Alberto; Torres-Saez, Maria; Zubiaur, Mercedes; Sancho, Jaime] CSIC, Dept Cellular Biol & Immunol, Inst Parasitol & Biomed Lopez Neyra IPBLN, Granada, Spain; [Martin-Morales, Natividad; O'Valle, Francisco] Univ Granada UGR, Fac Med, Dept Pathol, Granada, Spain; [Lario-Simon, Antonio; Longobardo-Polanco, Victoria M.] CSIC, Prote Unit, IPBLN, Granada, Spain; [Perez-Sanchez-Canete, Maria M.; Guerrero-Fernandez, Salvador; Redondo-Sanchez, Sandra] CSIC, Flow Cytometry Unit, IPBLN, Granada, Spain; [Montosa-Hidalgo, Laura] CSIC, Microscopy Unit, IPBLN, Granada, Spain; [Fernandez-Ibanez, Ana] UGR, Sci Instrumentat Ctr CIC, Granada, Spain; [Terron-Camero, Laura; Andres-Leon, Eduardo] CSIC, Bioinformat Unit, IPBLN, Granada, Spain; [Merino, Ramon] Univ Cantabria, Inst Biomed & Biotecnol Cantabria IBBTEC, Dept Mol & Cellular Signalling, CSIC,UC, Santander, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); University of Granada; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); University of Granada; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC)	Zubiaur, M; Sancho, J (corresponding author), CSIC, Dept Cellular Biol & Immunol, Inst Parasitol & Biomed Lopez Neyra IPBLN, Granada, Spain.	mzubiaur@ipb.csic.es; granada@ipb.csic.es	Andrés-León., Eduardo/K-8944-2014; Sancho, Jaime/O-3228-2013; Terron Camero, Laura Carmen/E-1695-2016	Andrés-León., Eduardo/0000-0002-0621-9914; Sancho, Jaime/0000-0003-3852-7951; Cornet-Gomez, Alberto/0000-0001-9378-8594; Carrillo Rodriguez, Paula/0000-0002-0096-2846; Martin-Morales, Natividad/0000-0003-3540-1085; Terron Camero, Laura Carmen/0000-0002-9746-8800; Redondo, Sandra/0000-0001-5805-1044	Proyecto del Plan Estatal [SAF2017-89801-R]; IPBLN-CSIC Proteomics Unit belonged to ProteoRed-ISCIII [PRB2, PRB3]; CIB-CSIC; IPBLN-CSIC [PT17/0019/0010]; JAE-Intro (CSIC); Consejo Nacional de Ciencia y Tecnologia (CONACYT) of Mexico [502492]; Andalusian Government; IPBLN-CSIC [PT13/0001/0011];  [SAF2017-82905-R]	Proyecto del Plan Estatal; IPBLN-CSIC Proteomics Unit belonged to ProteoRed-ISCIII; CIB-CSIC; IPBLN-CSIC; JAE-Intro (CSIC); Consejo Nacional de Ciencia y Tecnologia (CONACYT) of Mexico(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Andalusian Government; IPBLN-CSIC; 	JS and MZ received financial support through "Proyecto del Plan Estatal": SAF2017-89801-R. The IPBLN-CSIC Proteomics Unit belonged to ProteoRed-ISCIII (PRB2; PRB3) and was supported by grants PT13/0001/0011 (IPBLN-CSIC) and PT17/0019/0010 (CIB-CSIC; IPBLN-CSIC). RM: Project: SAF2017-82905-R. FO'V: Ca ' tedra MIS IMPLANT-UGR. The stay of AC-G in Sancho's lab was supported by a fellowship-contract JAE-Intro (CSIC). The stay of MD-P in Sancho's lab was supported by a 1-year postdoctoral fellowship (Reference No. 502492) from the Consejo Nacional de Ciencia y Tecnologia (CONACYT) of Mexico. EA-L was recipient of a postdoctoral fellowship from the regional Andalusian Government.	Banchereau R, 2016, CELL, V165, P551, DOI 10.1016/j.cell.2016.03.008; Baumjohann D, 2013, IMMUNITY, V38, P596, DOI 10.1016/j.immuni.2012.11.020; Bindea G, 2013, BIOINFORMATICS, V29, P661, DOI 10.1093/bioinformatics/btt019; Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101; Bradley SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141171; Burlock B, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102906; Chatterjee S, 2019, AGING-US, V11, P8743, DOI 10.18632/aging.102385; Chatterjee S, 2018, CELL METAB, V27, P85, DOI 10.1016/j.cmet.2017.10.006; Chen J, 2006, J IMMUNOL, V176, P4590, DOI 10.4049/jimmunol.176.8.4590; Chen LM, 2018, CANCER DISCOV, V8, P1156, DOI 10.1158/2159-8290.CD-17-1033; Cole S, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1578-z; Dominguez-Pantoja M, 2018, SCAND J IMMUNOL, V87, DOI 10.1111/sji.12664; du Sert NP, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000410; Eisenberg RA, 2012, J AUTOIMMUN, V39, P240, DOI 10.1016/j.jaut.2012.05.017; Facciotti F, 2020, P NATL ACAD SCI USA, V117, P7305, DOI 10.1073/pnas.1917834117; Fliegert R, 2019, BIOCHEM SOC T, V47, P329, DOI 10.1042/BST20180419; Fumey W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14112-6; Garcia-Rodriguez S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21337-6; Hogan KA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01187; Horikoshi M., 2018, **DATA OBJECT**; Ishihama Y, 2005, MOL CELL PROTEOMICS, V4, P1265, DOI 10.1074/mcp.M500061-MCP200; Jenks SA, 2018, IMMUNITY, V49, P725, DOI 10.1016/j.immuni.2018.08.015; Kassambara AM F., 2017, **DATA OBJECT**; Kato K, 1999, J CLIN INVEST, V104, P947, DOI 10.1172/JCI7014; Katsuyama E, 2020, CELL REP, V30, P112, DOI 10.1016/j.celrep.2019.12.014; Kerfoot SM, 2011, IMMUNITY, V34, P947, DOI 10.1016/j.immuni.2011.03.024; Klarquist Jared, 2020, Immunohorizons, V4, P140, DOI 10.4049/immunohorizons.2000005; Klarquist J, 2015, JOVE-J VIS EXP, DOI 10.3791/53319; Knode LMR, 2017, J IMMUNOL, V198, P1921, DOI 10.4049/jimmunol.1601106; Lee MH, 2019, J LEUKOCYTE BIOL, V106, P967, DOI 10.1002/JLB.3AB0518-180RR; Liu Y, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1438-2; LopezHoyos M, 1996, J EXP MED, V183, P2523, DOI 10.1084/jem.183.6.2523; Maechler M., 2021, CLUSTER FINDING GROU; Manna A, 2019, CLIN CANCER RES, V25, P3974, DOI 10.1158/1078-0432.CCR-18-3412; Marquina R, 2004, J IMMUNOL, V172, P7177, DOI 10.4049/jimmunol.172.11.7177; Morandi F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02722; MORRIS SC, 1990, CLIN IMMUNOL IMMUNOP, V57, P263, DOI 10.1016/0090-1229(90)90040-W; MORRIS SC, 1990, J EXP MED, V171, P503, DOI 10.1084/jem.171.2.503; MORRIS SC, 1990, J IMMUNOL, V144, P916; Mountz JD, 2019, J IMMUNOL, V202, P1649, DOI 10.4049/jimmunol.1801150; Myles A, 2019, CURR OPIN IMMUNOL, V57, P40, DOI 10.1016/j.coi.2019.01.002; Ostendorf L, 2020, NEW ENGL J MED, V383, P1149, DOI 10.1056/NEJMoa2023325; Pavon EJ, 2013, CYTOKINE, V62, P232, DOI 10.1016/j.cyto.2013.02.023; Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106; Postigo J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033534; Prive F, 2020, BIOINFORMATICS, V36, P4449, DOI 10.1093/bioinformatics/btaa520; Ridderstad A, 1998, J IMMUNOL, V160, P4688; Rissiek B, 2015, CURR TOP MICROBIOL, V384, P107, DOI 10.1007/82_2014_420; Rosal-Vela A, 2016, J PROTEOMICS, V134, P127, DOI 10.1016/j.jprot.2015.11.023; Rubtsova K, 2017, J CLIN INVEST, V127, P1392, DOI 10.1172/JCI91250; Sage PT, 2016, IMMUNOL REV, V271, P246, DOI 10.1111/imr.12411; Sage PT, 2015, CELL REP, V12, P163, DOI 10.1016/j.celrep.2015.06.015; Sage PT, 2015, TRENDS IMMUNOL, V36, P410, DOI 10.1016/j.it.2015.05.005; Schneider M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126007; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; SHIH W, 1988, KIDNEY INT, V33, P1113, DOI 10.1038/ki.1988.119; Sivakumar R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01053; Stebegg M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02469; Thibault DL, 2008, J CLIN INVEST, V118, P1417, DOI 10.1172/JCI30065; Thibault DL, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2771; Tsokos GC, 2016, NAT REV RHEUMATOL, V12, P716, DOI 10.1038/nrrheum.2016.186; Vakkalanka RK, 1999, ARTHRITIS RHEUM, V42, P871, DOI 10.1002/1529-0131(199905)42:5<871::AID-ANR5>3.0.CO;2-J; Viegas MS, 2011, RHEUMATOLOGY, V50, P1569, DOI 10.1093/rheumatology/ker178; Yoshimoto T, 2004, J IMMUNOL, V173, P2479, DOI 10.4049/jimmunol.173.4.2479; Zhang WQ, 2019, P NATL ACAD SCI USA, V116, P18550, DOI 10.1073/pnas.1901340116; Zhuang HY, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00291; Zubiaur M, 1997, J IMMUNOL, V159, P193; Zumaquero E, 2019, ELIFE, V8, DOI 10.7554/eLife.41641; Zumaquero E, 2010, EXP CELL RES, V316, P2692, DOI 10.1016/j.yexcr.2010.05.032	69	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 24	2021	12									10.3389/fimmu.2021.713697	http://dx.doi.org/10.3389/fimmu.2021.713697			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UQ3OO	34504495	gold, Green Published			2022-12-18	WOS:000695976900001
J	De Rienzo, M; Foddai, ML; Conti, L; Mandoj, C; Iaboni, S; Saladini, I; Castilletti, C; Matusali, G; Donno, DR; Marchioni, L; Ianniello, S; Corpolongo, A; Palange, M; Ciliberto, G; Piaggio, G; De Marco, F				De Rienzo, Mafalda; Foddai, Maria Laura; Conti, Laura; Mandoj, Chiara; Iaboni, Stefano; Saladini, Ilenia; Castilletti, Concetta; Matusali, Giulia; Donno, Davide Roberto; Marchioni, Luisa; Ianniello, Stefania; Corpolongo, Angela; Palange, Maria; Ciliberto, Gennaro; Piaggio, Giulia; De Marco, Federico			Long-Term Persistence and Relevant Therapeutic Impact of High-Titer Viral-Neutralizing Antibody in a Convalescent COVID-19 Plasma Super-Donor: A Case Report	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; neutralizing antibodies; hyperimmune plasma; IgA; RBD/ACE2-binding inhibition test; case report		A convalescent, non-severe, patient with COVID-19 was enrolled as a hyper-immune plasma voluntary donor by the Immuno-Hematology and Transfusion Unit of the Regina Elena National Cancer Institute in Rome, under the TSUNAMI national study criteria. During a nearly 6-month period (May-October 2020), the patient was closely monitored and underwent four hyperimmune plasma collections. Serum SARS-CoV-2 (anti-S + anti-N) IgG and IgM, anti-S1 IgA, and neutralizing titers (NTs) were measured. Anti-SARS-CoV-2 antibody levels steadily decreased. No correlation was found between anti-S/anti-N IgG and IgM levels and viral NT, measured by either a microneutralization test or the surrogate RBD/ACE2-binding inhibition test. Conversely, NTs directly correlated with anti-S1 IgA levels. Hyperimmune donor plasma, administered to five SARS-CoV-2 patients with persistent, severe COVID-19 symptoms, induced short-term clinical and pathological improvement. Reported data suggest that high NTs can persist longer than expected, thus widening hyperimmune plasma source, availability, and potential use. In vitro RBD/ACE2-binding inhibition test is confirmed as a convenient surrogate index for neutralizing activity and patients' follow-up, suitable for clinical settings where biosafety level 3 facilities are not available. IgA levels may correlate with serum neutralizing activity and represent a further independent index for patient evaluation.	[De Rienzo, Mafalda; Foddai, Maria Laura; Iaboni, Stefano; Saladini, Ilenia] Regina Elena Natl Canc Inst IRCCS, Immunohematol & Transfus Med Unit, Rome, Italy; [Conti, Laura; Mandoj, Chiara] Regina Elena Natl Canc Inst IRCCS, Clin Pathol Unit & Canc Biobank, Rome, Italy; [Castilletti, Concetta; Matusali, Giulia] Natl Inst Infect Dis Lazzaro Spallanzani IRCCS, Virol & Biosecur Labs, Rome, Italy; [Donno, Davide Roberto; Marchioni, Luisa; Corpolongo, Angela] Lazzaro Spallanzani IRCCS, Natl Inst Infect Dis, Dept Infect Dis, Rome, Italy; [Ianniello, Stefania] Natl Inst Infect Dis Lazzaro Spallanzani IRCCS, Dept Radiol, Rome, Italy; [Palange, Maria] San Camillo Forlanini Hosp, Immunohematol & Transfus Med Unit, Rome, Italy; [Ciliberto, Gennaro] Regina Elena Natl Canc Inst IRCCS, Rome, Italy; [Piaggio, Giulia; De Marco, Federico] Regina Elena Natl Canc Inst IRCCS, Dept Res, Technol Innovat Adv Diagnost, Rome, Italy	IRCCS Lazzaro Spallanzani; IRCCS Lazzaro Spallanzani; IRCCS Lazzaro Spallanzani; Azienda Ospedaliera San Camillo-Forlanini	De Rienzo, M (corresponding author), Regina Elena Natl Canc Inst IRCCS, Immunohematol & Transfus Med Unit, Rome, Italy.	mafalda.derienzo@ifo.gov.it	Piaggio, Giulia/AAD-7336-2022; Marchioni, Luisa/AGK-4889-2022; Ciliberto, Gennaro/J-4131-2017	Marchioni, Luisa/0000-0003-3273-7309; Ciliberto, Gennaro/0000-0003-2851-8605; De Marco, Federico/0000-0002-1173-2843	Italian Ministry of Health	Italian Ministry of Health(Ministry of Health, Italy)	The study was supported by funds from the Italian Ministry of Health, Ricerca Corrente.	Baum A, 2020, SCIENCE, V370, P1110, DOI 10.1126/science.abe2402; Cento V, 2020, J INFECTION, V81, pE90, DOI 10.1016/j.jinf.2020.06.024; Corti D, 2021, CELL, V184, P3086, DOI [10.1016/j.cell.2021.07.027, 10.1016/j.cell.2021.05.005]; Dogan M, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-01649-6; Esmaeilzadeh A, 2021, J CELL BIOCHEM, V122, P1389, DOI 10.1002/jcb.30017; European Commission, 2020, EU PROGR COVID 19 CO; Klein S, 2020, J CLIN INVEST, V130, P6141, DOI 10.1172/JCI142004; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Lee CYP, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00879; Ministero della Salute, 2015, GU SER GEN; Muller L, 2021, EUR J CLIN MICROBIOL, V40, P1063, DOI 10.1007/s10096-021-04169-7; Patel EU, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.02257-20; Pieri M, 2021, J MED VIROL, V93, P2523, DOI 10.1002/jmv.26809; Rees-Spear C, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108890; Scholer L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.573526; Serre-Miranda C, 2021, INT J INFECT DIS, V104, P661, DOI 10.1016/j.ijid.2021.01.038; Sherina N, 2021, MED-CAMBRIDGE, V2, P281, DOI 10.1016/j.medj.2021.02.001; To KKW, 2020, CLIN INFECT DIS, V71, P841, DOI 10.1093/cid/ciaa149; Valk SJ, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013600; Wajnberg A, 2020, LANCET MICROBE, V1, pE283, DOI 10.1016/S2666-5247(20)30120-8; Wang YQ, 2020, J CLIN INVEST, V130, P5235, DOI [10.1172/JCI138759, 10.1172/JCI138759.]; Weinreich DM, 2021, NEW ENGL J MED, V384, P238, DOI 10.1056/NEJMoa2035002; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Zeng WH, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00478-7; Zhang XY, 2020, VIROL SIN, V35, P820, DOI 10.1007/s12250-020-00329-9	25	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 23	2021	12								690322	10.3389/fimmu.2021.690322	http://dx.doi.org/10.3389/fimmu.2021.690322			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UM1KZ	34497602	gold, Green Published			2022-12-18	WOS:000693098600001
J	Szumilas, N; Corneth, OBJ; Lehmann, CHK; Schmitt, H; Cunz, S; Cullen, JG; Chu, T; Marosan, A; Mocsai, A; Benes, V; Zehn, D; Dudziak, D; Hendriks, RW; Nitschke, L				Szumilas, Nadine; Corneth, Odilia B. J.; Lehmann, Christian H. K.; Schmitt, Heike; Cunz, Svenia; Cullen, Jolie G.; Chu, Talyn; Marosan, Anita; Mocsai, Attila; Benes, Vladimir; Zehn, Dietmar; Dudziak, Diana; Hendriks, Rudi W.; Nitschke, Lars			Siglec-H-Deficient Mice Show Enhanced Type I IFN Responses, but Do Not Develop Autoimmunity After Influenza or LCMV Infections	FRONTIERS IN IMMUNOLOGY			English	Article						plasmacytoid dendritic cells; Interferon-alpha; Siglec; TLR9; SLE	PLASMACYTOID DENDRITIC CELLS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; TOLL-LIKE RECEPTORS; FAMILY KINASES HCK; LUPUS; INTERFERON; RECOGNITION; FGR; LYN; IPC	Siglec-H is a DAP12-associated receptor on plasmacytoid dendritic cells (pDCs) and microglia. Siglec-H inhibits TLR9-induced IFN-alpha production by pDCs. Previously, it was found that Siglec-H-deficient mice develop a lupus-like severe autoimmune disease after persistent murine cytomegalovirus (mCMV) infection. This was due to enhanced type I interferon responses, including IFN-alpha. Here we examined, whether other virus infections can also induce autoimmunity in Siglec-H-deficient mice. To this end we infected Siglec-H-deficient mice with influenza virus or with Lymphocytic Choriomeningitis virus (LCMV) clone 13. With both types of viruses we did not observe induction of autoimmune disease in Siglec-H-deficient mice. This can be explained by the fact that both types of viruses are ssRNA viruses that engage TLR7, rather than TLR9. Also, Influenza causes an acute infection that is rapidly cleared and the chronicity of LCMV clone 13 may not be sufficient and may rather suppress pDC functions. Siglec-H inhibited exclusively TLR-9 driven type I interferon responses, but did not affect type II or type III interferon production by pDCs. Siglec-H-deficient pDCs showed impaired Hck expression, which is a Src-family kinase expressed in myeloid cells, and downmodulation of the chemokine receptor CCR9, that has important functions for pDCs. Accordingly, Siglec-H-deficient pDCs showed impaired migration towards the CCR9 ligand CCL25. Furthermore, autoimmune-related genes such as Klk1 and DNase1l3 are downregulated in Siglec-H-deficient pDCs as well. From these findings we conclude that Siglec-H controls TLR-9-dependent, but not TLR-7 dependent inflammatory responses after virus infections and regulates chemokine responsiveness of pDCs.	[Szumilas, Nadine; Cunz, Svenia; Nitschke, Lars] Univ Erlangen Nurnberg, Dept Biol, Div Genet, Erlangen, Germany; [Corneth, Odilia B. J.; Hendriks, Rudi W.] Univ Med Ctr, Dept Pulm Med, Erasmus MC, Rotterdam, Netherlands; [Lehmann, Christian H. K.; Dudziak, Diana] Univ Hosp Erlangen, Dept Dermatol, Lab Dendrit Cell Biol, Erlangen, Germany; [Lehmann, Christian H. K.; Dudziak, Diana] Univ Erlangen Nurnberg, Univ Hosp Erlangen, Deutsch Zentrum Immuntherapie DZI, Erlangen, Germany; [Lehmann, Christian H. K.; Dudziak, Diana; Nitschke, Lars] Univ Erlangen Nurnberg, Med Immunol Campus Erlangen MICE, Erlangen, Germany; [Schmitt, Heike] Univ Hosp Erlangen, Dept Med 1, Erlangen, Germany; [Cullen, Jolie G.; Chu, Talyn; Zehn, Dietmar] Tech Univ Munich, Sch Life Sci Weihenstephan, Div Anim Physiol & Immunol, Freising Weihenstephan, Germany; [Marosan, Anita] Univ Hosp Erlangen, Dept Immune Modulat, Erlangen, Germany; [Mocsai, Attila] Semmelweis Univ, Sch Med, Budapest, Hungary; [Benes, Vladimir] EMBL Heidelberg, Genom Core Facil, Heidelberg, Germany	University of Erlangen Nuremberg; Erasmus University Rotterdam; Erasmus MC; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg; Technical University of Munich; University of Erlangen Nuremberg; Semmelweis University; European Molecular Biology Laboratory (EMBL)	Nitschke, L (corresponding author), Univ Erlangen Nurnberg, Dept Biol, Div Genet, Erlangen, Germany.; Nitschke, L (corresponding author), Univ Erlangen Nurnberg, Med Immunol Campus Erlangen MICE, Erlangen, Germany.	lars.nitschke@fau.de		Knott, Heike/0000-0001-5638-9471	Y	Y	Funding This work was supported by the DFG through CRC1181 (project B06 to LN and A07 to DD) and RTG2504 (project B02 to CL and DD), Dutch Arthritis Association to RH and an ERC grant (ERC-2017-CoG - 772473 ToCCaTa) to DZ.	AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521; Al-Mayouf SM, 2011, NAT GENET, V43, P1186, DOI 10.1038/ng.975; Baechler EC, 2003, P NATL ACAD SCI USA, V100, P2610, DOI 10.1073/pnas.0337679100; Baumann I, 2002, ARTHRITIS RHEUM-US, V46, P191, DOI 10.1002/1529-0131(200201)46:1<191::AID-ART10027>3.0.CO;2-K; Bennett L, 2003, J EXP MED, V197, P711, DOI 10.1084/jem.20021553; Bergthaler A, 2010, P NATL ACAD SCI USA, V107, P21641, DOI 10.1073/pnas.1011998107; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Blank CU, 2019, NAT REV IMMUNOL, V19, P665, DOI 10.1038/s41577-019-0221-9; Blasius AL, 2006, BLOOD, V107, P2474, DOI 10.1182/blood-2005-09-3746; Blasius AL, 2006, TRENDS IMMUNOL, V27, P255, DOI 10.1016/j.it.2006.04.005; Cannon MJ, 2011, REV MED VIROL, V21, P240, DOI 10.1002/rmv.695; Chan VWF, 1998, CURR BIOL, V8, P545, DOI 10.1016/S0960-9822(98)70223-4; Colonna M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/ni1141; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Finotti G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01015; GeurtsvanKessel CH, 2009, J EXP MED, V206, P2339, DOI 10.1084/jem.20090410; Hadeiba H, 2008, NAT IMMUNOL, V9, P1253, DOI 10.1038/ni.1658; Hamerman JA, 2005, NAT IMMUNOL, V6, P579, DOI 10.1038/ni1204; Handa-Narumi M, 2018, CELL STRUCT FUNCT, V43, P141, DOI 10.1247/csf.18009; Hansen KE, 1998, SEMIN ARTHRITIS RHEU, V27, P263, DOI 10.1016/S0049-0172(98)80047-4; Harley ITW, 2009, NAT REV GENET, V10, P285, DOI 10.1038/nrg2571; Harley JB, 2006, BULL HOSP JT DIS, V64, P45; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; Jacobi AM, 2005, J EXP MED, V202, P341, DOI 10.1084/jem.20050221; Jeske S, 2013, NUCLEIC ACID THER, V23, P118, DOI 10.1089/nat.2012.0384; Kopatz J, 2013, GLIA, V61, P1122, DOI 10.1002/glia.22501; Kovacs M, 2014, J EXP MED, V211, P1993, DOI 10.1084/jem.20132496; Krug A, 2004, IMMUNITY, V21, P107, DOI 10.1016/j.immuni.2004.06.007; Levy DE, 2011, CURR OPIN VIROL, V1, P476, DOI 10.1016/j.coviro.2011.11.001; Liu K, 2009, J CLIN INVEST, V119, P911, DOI 10.1172/JCI36728; Liu YJ, 2005, ANNU REV IMMUNOL, V23, P275, DOI 10.1146/annurev.immunol.23.021704.115633; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; Macal M, 2018, IMMUNITY, V48, P730, DOI 10.1016/j.immuni.2018.03.020; Macal M, 2012, CELL HOST MICROBE, V11, P617, DOI 10.1016/j.chom.2012.04.017; Marshak-Rothstein A, 2007, ANNU REV IMMUNOL, V25, P419, DOI 10.1146/annurev.immunol.22.012703.104514; Marshak-Rothstein A, 2006, NAT REV IMMUNOL, V6, P823, DOI 10.1038/nri1957; MCFARLANE BM, 1995, EUR J GASTROEN HEPAT, V7, P615; Moser KL, 2009, GENES IMMUN, V10, P373, DOI 10.1038/gene.2009.39; Orr SL, 2013, GLYCOBIOLOGY, V23, P363, DOI 10.1093/glycob/cws150; Puttur F, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003648; Rahman A, 2008, NEW ENGL J MED, V358, P929, DOI 10.1056/NEJMra071297; Schlitzer A, 2011, BLOOD, V117, P6562, DOI 10.1182/blood-2010-12-326678; Schmitt H, 2016, J EXP MED, V213, P1627, DOI 10.1084/jem.20160189; Seliga A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00156; Sjolin H, 2006, J IMMUNOL, V177, P2908, DOI 10.4049/jimmunol.177.5.2908; SMITH AL, 1993, J WILDLIFE DIS, V29, P219, DOI 10.7589/0090-3558-29.2.219; Smith KGC, 1998, J EXP MED, V187, P807, DOI 10.1084/jem.187.5.807; Speiser DE, 2014, NAT REV IMMUNOL, V14, P768, DOI 10.1038/nri3740; Sullivan BM, 2011, P NATL ACAD SCI USA, V108, P2969, DOI 10.1073/pnas.1019304108; Swiecki M, 2010, IMMUNITY, V33, P955, DOI 10.1016/j.immuni.2010.11.020; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; Takagi H, 2011, IMMUNITY, V35, P958, DOI 10.1016/j.immuni.2011.10.014; Thangavel RR, 2014, J IMMUNOL METHODS, V410, P60, DOI 10.1016/j.jim.2014.03.023; Turnbull IR, 2007, NAT REV IMMUNOL, V7, P155, DOI 10.1038/nri2014; Utzschneider DT, 2016, J EXP MED, V213, P1819, DOI 10.1084/jem.20150598; Weisenburger T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01551; Wendland M, 2007, P NATL ACAD SCI USA, V104, P6347, DOI 10.1073/pnas.0609180104; Wu Q, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3363; Zhang H, 2005, IMMUNITY, V22, P235, DOI 10.1016/j.immuni.2005.01.004; Zhang JQ, 2006, BLOOD, V107, P3600, DOI 10.1182/blood-2005-09-3842; Zickert A, 2016, LUPUS SCI MED, V3, DOI 10.1136/lupus-2016-000170; Zucchini N, 2008, INT IMMUNOL, V20, P45, DOI 10.1093/intimm/dxm119	62	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 23	2021	12								698420	10.3389/fimmu.2021.698420	http://dx.doi.org/10.3389/fimmu.2021.698420			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV7YG	34497606	gold, Green Submitted, Green Published			2022-12-18	WOS:000717447200001
J	Feng, ZH; Li, SQ; Zhang, JX; Ni, B; Bai, XR; Xu, JH; Liu, ZB; Xin, WW; Kang, L; Gao, S; Wang, J; Li, YW; Li, JX; Yuan, Y; Wang, JL				Feng, Zi-Han; Li, Shi-Qing; Zhang, Jia-Xin; Ni, Bin; Bai, Xin-Ru; Xu, Jian-Hao; Liu, Zhen-Bo; Xin, Wen-Wen; Kang, Lin; Gao, Shan; Wang, Jing; Li, Yan-Wei; Li, Jia-Xin; Yuan, Yuan; Wang, Jing-Lin			Analysis of Gene Expression Profiles, Cytokines, and Bacterial Loads Relevant to Alcoholic Liver Disease Mice Infected With V. vulnificus	FRONTIERS IN IMMUNOLOGY			English	Article						Vibrio vulnificus; alcoholic liver disease; RNA-seq; cytokines; bacterial loads	VIBRIO-VULNIFICUS; UNITED-STATES; HUMAN SERUM; PARAHAEMOLYTICUS; NEUTROPHILS; APOPTOSIS; SURVIVAL; MODEL; IRON	Patients with liver disease are susceptible to infection with Vibrio vulnificus (V. vulnificus), but the specific reasons remain elusive. Through RNA-seq, we found that when mice with alcoholic liver disease (ALD) were infected with V. vulnificus by gavage, compared with the Pair group, the small intestinal genes affecting intestinal permeability were upregulated; and the number of differentially expressed genes related to immune functions (e.g., such as cell chemotaxis, leukocyte differentiation, and neutrophil degranulation) decreased in the liver, spleen, and blood. Further analysis showed that the number of white blood cells decreased in the Pair group, whereas those in the ALD mice did not change significantly. Interestingly, the blood bacterial load in the ALD mice was about 100 times higher than that of the Pair group. After the ALD mice were infected with V. vulnificus, the concentrations of T cell proliferation-promoting cytokines (IL-2, IL-23) decreased. Therefore, unlike the Pair group, ALD mice had weaker immune responses, lower T cell proliferation-promoting cytokines, and higher bacterial loads post-infection, possibly increasing their susceptibility to V. vulnificus infection. These new findings we presented here may help to advance the current understanding of the reasons why patients with liver disease are susceptible to V. vulnificus infection and provides potential targets for further investigation in the context of treatment options for V. vulnificus sepsis in liver disease patient.	[Feng, Zi-Han; Li, Shi-Qing; Zhang, Jia-Xin; Bai, Xin-Ru; Xu, Jian-Hao; Xin, Wen-Wen; Kang, Lin; Gao, Shan; Wang, Jing; Li, Yan-Wei; Li, Jia-Xin; Yuan, Yuan; Wang, Jing-Lin] Acad Mil Med Sci AMMS, Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China; [Ni, Bin] Jiangsu Univ, Sch Med, Zhenjiang, Jiangsu, Peoples R China; [Bai, Xin-Ru] Hebei Normal Univ, Coll Life Sci, Shijiazhuang, Hebei, Peoples R China; [Xu, Jian-Hao] Fujian Agr & Forestry Univ, Sch Life Sci, Fuzhou, Peoples R China; [Liu, Zhen-Bo] Rong Cheng Customs, Rongcheng Int Travel Hlth Care Ctr, Rongcheng, Peoples R China	Beijing Institute of Microbiology & Epidemiology; Jiangsu University; Hebei Normal University; Fujian Agriculture & Forestry University	Yuan, Y; Wang, JL (corresponding author), Acad Mil Med Sci AMMS, Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China.	miniminiyuan@163.com; wangjlin@bmi.ac.cn	li, yan/GTI-4638-2022					Abbas AK, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aat1482; Baker-Austin C, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0005-8; Baker-Austin C, 2018, ENVIRON MICROBIOL, V20, P423, DOI 10.1111/1462-2920.13955; Baker-Austin C, 2010, ENV MICROBIOL REP, V2, P7, DOI 10.1111/j.1758-2229.2009.00096.x; Bertola A, 2013, NAT PROTOC, V8, P627, DOI 10.1038/nprot.2013.032; Bettelli E, 2007, NAT IMMUNOL, V8, P345, DOI 10.1038/ni0407-345; Boettner B, 2009, CURR OPIN CELL BIOL, V21, P684, DOI 10.1016/j.ceb.2009.06.004; Bogard RW, 2007, APPL ENVIRON MICROB, V73, P7501, DOI 10.1128/AEM.01551-07; Bross MH, 2007, AM FAM PHYSICIAN, V76, P539; Caughey GH, 2016, EUR J PHARMACOL, V778, P44, DOI 10.1016/j.ejphar.2015.04.045; Chen CY, 2003, GENOME RES, V13, P2577, DOI 10.1101/gr.1295503; Hor LI, 1999, J INFECT DIS, V179, P275, DOI 10.1086/314554; Huang XH, 2021, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.596609; Huang XH, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.587961; Jeong HG, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007895; Jones MK, 2009, INFECT IMMUN, V77, P1723, DOI 10.1128/IAI.01046-08; Junttila IS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00888; Kashimoto T, 2005, J MED MICROBIOL, V54, P15, DOI 10.1099/jmm.0.45861-0; Kashimoto T, 2003, INFECT IMMUN, V71, P533, DOI 10.1128/IAI.71.1.533-535.2003; Kim AC, 2012, CLIN LIVER DIS, V16, P783, DOI 10.1016/j.cld.2012.08.008; Kim D, 2019, NAT BIOTECHNOL, V37, P907, DOI 10.1038/s41587-019-0201-4; Kim HY, 2014, FOODBORNE PATHOG DIS, V11, P119, DOI 10.1089/fpd.2013.1581; Lee SE, 2006, INFECT IMMUN, V74, P694, DOI 10.1128/IAI.74.1.694-702.2006; Li TW, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/9254087; Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214; Liu WM, 2016, ARCH IMMUNOL THER EX, V64, P371, DOI 10.1007/s00005-016-0395-9; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Luo G, 2020, ENVIRON MICROBIOL, V22, P677, DOI 10.1111/1462-2920.14884; Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046-08; Mossahebi-Mohammadi M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00079; Newton A, 2012, CLIN INFECT DIS, V54, pS391, DOI 10.1093/cid/cis243; Osaka K, 2004, EPIDEMIOL INFECT, V132, P993, DOI 10.1017/S0950268804002407; Parkin J, 2001, LANCET, V357, P1777, DOI 10.1016/S0140-6736(00)04904-7; Phillips KE, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006053; Pietrangelo A, 2016, LIVER INT, V36, P116, DOI 10.1111/liv.13020; Raszl SM, 2016, J APPL MICROBIOL, V121, P1201, DOI 10.1111/jam.13246; Sang LX, 2021, INT IMMUNOPHARMACOL, V96, DOI 10.1016/j.intimp.2021.107572; Shapiro RL, 1998, J INFECT DIS, V178, P752, DOI 10.1086/515367; Thiaville PC, 2011, INFECT IMMUN, V79, P1194, DOI 10.1128/IAI.01031-10; Tiberio L, 2018, CELL MOL IMMUNOL, V15, P346, DOI 10.1038/s41423-018-0005-3; Toma C, 2010, J IMMUNOL, V184, P5287, DOI 10.4049/jimmunol.0903536; Tukaj S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155298; van Rees DJ, 2016, SEMIN IMMUNOL, V28, P94, DOI 10.1016/j.smim.2016.02.004; Xie DL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181454; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yu MJ, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-6351-4; Zhao H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136019; Zhu JF, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a030338	48	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 20	2021	12									10.3389/fimmu.2021.695491	http://dx.doi.org/10.3389/fimmu.2021.695491			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UN2PC	34489943	Green Published, gold			2022-12-18	WOS:000693860700001
J	Hernandez-Davies, JE; Felgner, J; Strohmeier, S; Pone, EJ; Jain, A; Jan, S; Nakajima, R; Jasinskas, A; Strahsburger, E; Krammer, F; Felgner, PL; Davies, DH				Hernandez-Davies, J. E.; Felgner, J.; Strohmeier, S.; Pone, E. J.; Jain, A.; Jan, S.; Nakajima, R.; Jasinskas, A.; Strahsburger, E.; Krammer, F.; Felgner, P. L.; Davies, D. H.			Administration of Multivalent Influenza Virus Recombinant Hemagglutinin Vaccine in Combination-Adjuvant Elicits Broad Reactivity Beyond the Vaccine Components (vol 12, 692151, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						vaccine; influenza; adjuvant; CpG; MPLA; ADDAVAX((R)); hemagglutinin												Hernandez-Davies JE, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.692151	1	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 20	2021	12								754535	10.3389/fimmu.2021.754535	http://dx.doi.org/10.3389/fimmu.2021.754535			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6I0PD		gold, Green Published			2022-12-18	WOS:000885829200001
J	Wu, SW; Peng, CK; Wu, SY; Wang, Y; Yang, SS; Tang, SE; Huang, KL				Wu, Shih-Wei; Peng, Chung-Kan; Wu, Shu-Yu; Wang, Yu; Yang, Sung-Sen; Tang, Shih-En; Huang, Kun-Lun			Obesity Attenuates Ventilator-Induced Lung Injury by Modulating the STAT3-SOCS3 Pathway	FRONTIERS IN IMMUNOLOGY			English	Article						obesity; ventilator-induced lung injury (VILI); suppressor of cytokine signaling 3 (SOCS3); hesperetin; WNK lysine deficient protein kinase 4 (WNK4); alveolar fluid clearance (AFC)	ALVEOLAR FLUID CLEARANCE; INHIBITION; KINASE; RATS; EXPRESSION; MODEL	Background Ventilator-induced lung injury (VILI) is characterized by vascular barrier dysfunction and suppression of alveolar fluid clearance (AFC). Obesity itself leads to chronic inflammation, which may initiate an injurious cascade to the lungs and simultaneously induce a protective feedback. In this study, we investigated the protective mechanism of obesity on VILI in a mouse model. Methods The VILI model was set up via 6-h mechanical ventilation with a high tidal volume. Parameters including lung injury score, STAT3/NF kappa B pathway, and AFC were assessed. Mice with diet-induced obesity were obtained by allowing free access to a high-fat diet since the age of 3 weeks. After a 9-week diet intervention, these mice were sacrificed at the age of 12 weeks. The manipulation of SOCS3 protein was achieved by siRNA knockdown and pharmaceutical stimulation using hesperetin. WNK4 knockin and knockout obese mice were used to clarify the pathway of AFC modulation. Results Obesity itself attenuated VILI. Knockdown of SOCS3 in obese mice offset the protection against VILI afforded by obesity. Hesperetin stimulated SOCS3 upregulation in nonobese mice and provided protection against VILI. In obese mice, the WNK4 axis was upregulated at the baseline, but was significantly attenuated after VILI compared with nonobese mice. At the baseline, the manipulation of SOCS3 by siRNA and hesperetin also led to the corresponding alteration of WNK4, albeit to a lesser extent. After VILI, WNK4 expression correlated with STAT3/NF kappa B activation, regardless of SOCS3 status. Obese mice carrying WNK4 knockout had VILI with a severity similar to that of wild-type obese mice. The severity of VILI in WNK4-knockin obese mice was counteracted by obesity, similar to that of wild-type nonobese mice only. Conclusions Obesity protects lungs from VILI by upregulating SOCS3, thus suppressing the STAT3/NF kappa B inflammatory pathway and enhancing WNK4-related AFC. However, WNK4 activation is mainly from direct NF kappa B downstreaming, and less from SOCS3 upregulation. Moreover, JAK2-STAT3/NF kappa B signaling predominates the pathogenesis of VILI. Nevertheless, the interaction between SOCS3 and WNK4 in modulating VILI in obesity warrants further investigation.	[Wu, Shih-Wei; Peng, Chung-Kan; Tang, Shih-En; Huang, Kun-Lun] Triserv Gen Hosp, Dept Internal Med, Div Pulm & Crit Care, Taipei, Taiwan; [Wu, Shih-Wei; Yang, Sung-Sen; Huang, Kun-Lun] Natl Def Med Ctr, Grad Inst Med Sci, Taipei, Taiwan; [Peng, Chung-Kan; Wu, Shu-Yu; Wang, Yu; Tang, Shih-En; Huang, Kun-Lun] Natl Def Med Ctr, Inst Aerosp & Undersea Med, Taipei, Taiwan; [Yang, Sung-Sen] Triserv Gen Hosp, Natl Def Med Ctr, Div Nephrol, Taipei, Taiwan	Tri-Service General Hospital; National Defense Medical Center; National Defense Medical Center; National Defense Medical Center; Tri-Service General Hospital	Tang, SE; Huang, KL (corresponding author), Triserv Gen Hosp, Dept Internal Med, Div Pulm & Crit Care, Taipei, Taiwan.; Huang, KL (corresponding author), Natl Def Med Ctr, Grad Inst Med Sci, Taipei, Taiwan.; Tang, SE; Huang, KL (corresponding author), Natl Def Med Ctr, Inst Aerosp & Undersea Med, Taipei, Taiwan.	msetang@gmail.com; kun@mail.ndmctsgh.edu.tw			Ministry of Science and Technology [MOST 109-2314-B-016-029MY3]; Tri-Service General Hospital [TSGHC103-087, TSGH-C105-086, TSGH-C107-076, TSGH-C108105]; Ministry of National Defense-Medical Affairs Bureau [MAB-106-014, MAB-107-038]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Tri-Service General Hospital; Ministry of National Defense-Medical Affairs Bureau	This study was supported by grants from Ministry of Science and Technology (Award numbers: MOST 109-2314-B-016-029MY3), Tri-Service General Hospital (Award numbers: TSGHC103-087, TSGH-C105-086, TSGH-C107-076, TSGH-C108105); and Ministry of National Defense-Medical Affairs Bureau (Award numbers: MAB-106-014, MAB-107-038).	Abdelaal M, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.03.107; Ba F, 2019, J THORAC DIS, V11, P3599, DOI 10.21037/jtd.2019.08.86; Ball L, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1682-5; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Castaneda-Bueno M, 2017, P NATL ACAD SCI USA, V114, pE879, DOI 10.1073/pnas.1620315114; Checkley W, 2008, AM J RESP CRIT CARE, V177, P1215, DOI 10.1164/rccm.200709-1424OC; Chen L, 2018, CHINESE MED J-PEKING, V131, P1225, DOI 10.4103/0366-6999.226840; Chen XX, 2020, INFLAMM RES, V69, P883, DOI 10.1007/s00011-020-01378-2; Engin A, 2017, ADV EXP MED BIOL, V960, P381, DOI 10.1007/978-3-319-48382-5_16; Fang XZ, 2016, INT IMMUNOPHARMACOL, V31, P66, DOI 10.1016/j.intimp.2015.12.017; Garat C, 1998, J APPL PHYSIOL, V84, P1763, DOI 10.1152/jappl.1998.84.5.1763; Gattinoni L, 2010, CRIT CARE MED, V38, pS539, DOI 10.1097/CCM.0b013e3181f1fcf7; Gong MN, 2010, THORAX, V65, P44, DOI 10.1136/thx.2009.117572; Guh DP, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-88; Hoegl S, 2011, AM J RESP CELL MOL, V44, P369, DOI 10.1165/rcmb.2009-0440OC; Hou YP, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00012; Huang CY, 2017, INT J MOL MED, V39, P693, DOI 10.3892/ijmm.2017.2873; Hung CM, 2020, BIOCHEM PHARMACOL, V171, DOI 10.1016/j.bcp.2019.113738; Huppert LA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00371; Jo D, 2005, NAT MED, V11, P892, DOI 10.1038/nm1269; Karampela I, 2020, CURR OBES REP, V9, P231, DOI 10.1007/s13679-020-00394-x; Katira BH, 2019, RESP CARE, V64, P629, DOI 10.4187/respcare.07055; Lan CC, 2017, J THORAC CARDIOV SUR, V153, P206, DOI 10.1016/j.jtcvs.2016.09.068; Lavie CJ, 2016, PROG CARDIOVASC DIS, V58, P537, DOI 10.1016/j.pcad.2016.01.008; Li SX, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.9728; Li YH, 2021, INT J MOL MED, V47, DOI 10.3892/ijmm.2021.4919; Lin HJ, 2015, CRIT CARE MED, V43, pE412, DOI 10.1097/CCM.0000000000001144; Luo YY, 2020, MOL MED REP, V21, P429, DOI 10.3892/mmr.2019.10821; Ma HZ, 2015, EUR J PHARMACOL, V769, P333, DOI 10.1016/j.ejphar.2015.11.038; Maia LD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01215; Malhotra A, 2007, NEW ENGL J MED, V357, P1113, DOI 10.1056/NEJMct074213; Morty RE, 2007, INTENS CARE MED, V33, P1229, DOI 10.1007/s00134-007-0662-7; Ni YN, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1615-3; Ozeke O, 2011, MED HYPOTHESES, V76, P61, DOI 10.1016/j.mehy.2010.08.030; Petrucci N, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003844.pub4; Planes C, 2005, AM J PHYSIOL-LUNG C, V288, pL1099, DOI 10.1152/ajplung.00332.2004; Plataki Maria, 2010, Expert Rev Respir Med, V4, P373, DOI 10.1586/ers.10.28; Richardson C, 2008, J CELL SCI, V121, P3293, DOI 10.1242/jcs.029223; Salie R, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/s12933-014-0109-8; Schetz M, 2019, INTENS CARE MED, V45, P757, DOI 10.1007/s00134-019-05594-1; Shen CH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02049; Thompson BT, 2017, NEW ENGL J MED, V377, P562, DOI [10.1056/NEJMra1608077, 10.1056/NEJMc1711824]; Tremblay LN, 2006, INTENS CARE MED, V32, P24, DOI 10.1007/s00134-005-2817-8; Visscher TLS, 2001, ANNU REV PUBL HEALTH, V22, P355, DOI 10.1146/annurev.publhealth.22.1.355; Wang L, 2019, INT IMMUNOPHARMACOL, V75, DOI 10.1016/j.intimp.2019.105795; Wang NG, 2019, ARCH PHARM RES, V42, P1063, DOI 10.1007/s12272-019-01200-6; Wang Q, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/6705985; Wang ZF, 2014, NEUROSCIENCE, V273, P65, DOI 10.1016/j.neuroscience.2014.04.052; Wei K, 2020, DIABET METAB SYND OB, V13, P4179, DOI 10.2147/DMSO.S278684; Wiejak J, 2013, BIOCHEM J, V454, P283, DOI 10.1042/BJ20130481; Wilson MR, 2017, CRIT CARE MED, V45, pE831, DOI 10.1097/CCM.0000000000002403; Wunderlich Claudia M, 2013, JAKSTAT, V2, pe23878, DOI 10.4161/jkst.23878; Yan YT, 2008, WORLD J GASTROENTERO, V14, P6115, DOI 10.3748/wjg.14.6115; Yang SS, 2007, CELL METAB, V5, P331, DOI 10.1016/j.cmet.2007.03.009; Yang SS, 2010, ENDOCRINOLOGY, V151, P1829, DOI 10.1210/en.2009-0951; Ye JY, 2019, EUR J PHARMACOL, V852, P151, DOI 10.1016/j.ejphar.2019.02.042; Zhao Yonghua, 2018, PLoS One, V13, pe0198669, DOI 10.1371/journal.pone.0198669	57	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 20	2021	12									10.3389/fimmu.2021.720844	http://dx.doi.org/10.3389/fimmu.2021.720844			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UR2JK	34489970	gold, Green Published			2022-12-18	WOS:000696580200001
J	Zhai, X; Kong, WG; Cheng, GF; Cao, JF; Dong, F; Han, GK; Song, YL; Qin, CJ; Xu, Z				Zhai, Xue; Kong, Wei-Guang; Cheng, Gao-Feng; Cao, Jia-Feng; Dong, Fen; Han, Guang-Kun; Song, Yan-Ling; Qin, Chuan-Jie; Xu, Zhen			Molecular Characterization and Expression Analysis of Intercellular Adhesion Molecule-1 (ICAM-1) Genes in Rainbow Trout (Oncorhynchus mykiss) in Response to Viral, Bacterial and Parasitic Challenge	FRONTIERS IN IMMUNOLOGY			English	Article						intercellular adhesion molecule-1; rainbow trout; infectious hematopoietic necrosis virus; Flavobacterium columnare G(4); Ichthyophthirius multifiliis; mucosal immune response	EPITHELIAL-CELLS; VIRUS; ACTIVATION; CLONING; LIGAND; MICE; RESISTANCE; INDUCTION; INFECTION; SEQUENCE	The intercellular adhesion molecule-1 (ICAM-1), known as CD54, is a transmembrane cell surface glycoprotein that interacts with two integrins (i.e., LFA-1 and Mac-l) important for trans-endothelial migration of leukocytes. The level of ICAM-1 expression is upregulated in response to some inflammatory stimulations, including pathogen infection and proinflammatory cytokines. Yet, to date, our knowledge regarding the functional role of ICAM-1 in teleost fish remains largely unknown. In this study, we cloned and characterized the sequence of ICAM-1 in rainbow trout (Oncorhynchus mykiss) for the first time, which exhibited that the molecular features of ICAM-1 in fishes were relatively conserved compared with human ICAM-1. The transcriptional level of ICAM-1 was detected in 12 different tissues, and we found high expression of this gene in the head kidney, spleen, gills, skin, nose, and pharynx. Moreover, upon stimulation with infectious hematopoietic necrosis virus (IHNV), Flavobacterium columnare G(4) (F. columnare), and Ichthyophthirius multifiliis (Ich) in rainbow trout, the morphological changes were observed in the skin and gills, and enhanced expression of ICAM-1 mRNA was detected both in the systemic and mucosal tissues. These results indicate that ICAM-1 may be implicated in the mucosal immune responses to viral, bacterial, and parasitic infections in teleost fish, meaning that ICAM-1 emerges as a master regulator of mucosal immune responses against pathogen infections in teleost fish.	[Zhai, Xue; Cheng, Gao-Feng; Cao, Jia-Feng; Dong, Fen; Han, Guang-Kun; Song, Yan-Ling] Huazhong Agr Univ, Coll Fisheries, Dept Aquat Anim Med, Wuhan, Peoples R China; [Kong, Wei-Guang; Xu, Zhen] Chinese Acad Sci, Inst Hydrobiol, Ctr Fish Biol & Fishery Biotechnol, State Key Lab Freshwater Ecol & Biotechnol, Wuhan, Peoples R China; [Qin, Chuan-Jie] Neijiang Normal Univ, Key Lab Sichuan Prov Conservat & Utilizat Fishes, Dept Life Sci, Neijiang, Peoples R China	Huazhong Agricultural University; Chinese Academy of Sciences; Institute of Hydrobiology, CAS; Neijiang Normal University	Xu, Z (corresponding author), Chinese Acad Sci, Inst Hydrobiol, Ctr Fish Biol & Fishery Biotechnol, State Key Lab Freshwater Ecol & Biotechnol, Wuhan, Peoples R China.	zhenxu@ihb.ac.cn						Alkhamesi NA, 2007, BIOMARK INSIGHTS, V2, P377; Bastiani L, 1997, J VIROL, V71, P3444, DOI 10.1128/JVI.71.5.3444-3450.1997; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BINNERTS ME, 1994, EUR J IMMUNOL, V24, P2155, DOI 10.1002/eji.1830240933; Bui TM, 2020, J LEUKOCYTE BIOL, V108, P787, DOI 10.1002/JLB.2MR0220-549R; Cunningham DA, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1834-8; de Paula RR, 2017, MICROBES INFECT, V19, P527, DOI 10.1016/j.micinf.2017.09.005; Dixon P, 2016, VET RES, V47, DOI 10.1186/s13567-016-0341-1; DUSTIN ML, 1986, J IMMUNOL, V137, P245; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; Frick C, 2005, EUR J IMMUNOL, V35, P3610, DOI 10.1002/eji.200425914; Gaglia JL, 2000, J IMMUNOL, V165, P6091, DOI 10.4049/jimmunol.165.11.6091; Gay AN, 2011, J SURG RES, V171, pE1, DOI 10.1016/j.jss.2011.06.053; Gu RP, 2017, INVEST OPHTH VIS SCI, V58, P631, DOI 10.1167/iovs.16-20933; Holland J, 1997, J BIOL CHEM, V272, P9108; Hubbard AK, 2000, FREE RADICAL BIO MED, V28, P1379, DOI 10.1016/S0891-5849(00)00223-9; Humlicek AL, 2004, AM J PHYSIOL-LUNG C, V287, pL598, DOI 10.1152/ajplung.00073.2004; Karber G, 1931, N-S ARCH EX PATH PH, V162, P480, DOI 10.1007/BF01863914; KITA Y, 1992, BIOCHIM BIOPHYS ACTA, V1131, P108, DOI 10.1016/0167-4781(92)90107-B; Lawson C, 2009, PHARMACOL REP, V61, P22, DOI 10.1016/S1734-1140(09)70004-0; MANNING AM, 1995, GENE, V156, P291, DOI 10.1016/0378-1119(95)00045-8; Othumpangat S, 2016, VIROLOGY, V487, P85, DOI 10.1016/j.virol.2015.10.005; Owens RM, 2010, J BIOL CHEM, V285, P15906, DOI 10.1074/jbc.M110.104349; Park GS, 2015, MOL CELLS, V38, P821, DOI 10.14348/molcells.2015.0174; Pastre MJ, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108797; Ramaswamy K, 1997, EXP PARASITOL, V86, P118, DOI 10.1006/expr.1997.4178; SCHEYNIUS A, 1991, SCAND J IMMUNOL, V33, P237, DOI 10.1111/j.1365-3083.1991.tb03755.x; Schneider LE, 2019, EXP DERMATOL, V28, P142, DOI 10.1111/exd.13861; SIU G, 1989, J IMMUNOL, V143, P3813; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; Sumagin R, 2016, MUCOSAL IMMUNOL, V9, P1151, DOI 10.1038/mi.2015.135; Suzuki K, 2019, INT J MOL MED, V44, P1187, DOI 10.3892/ijmm.2019.4294; van den Engel NK, 2000, BLOOD, V95, P1350, DOI 10.1182/blood.V95.4.1350.004k07_1350_1355; vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069; Velazquez FE, 2019, IMMUNOLOGY, V157, P52, DOI 10.1111/imm.13047; Walling BL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00952; Walter NAR, 2005, J THEOR BIOL, V232, P339, DOI 10.1016/j.jtbi.2004.08.024; Wang JH, 2009, J VIROL, V83, P4195, DOI 10.1128/JVI.00006-09; Wei H, 2018, FISH SHELLFISH IMMUN, V81, P67, DOI 10.1016/j.fsi.2018.07.011; Xiao CA, 2005, STRUCTURE, V13, P1019, DOI 10.1016/j.str.2005.04.011; XU H, 1994, J EXP MED, V180, P95, DOI 10.1084/jem.180.1.95; XU H, 2020, FRONT IMMUNOL, V11, DOI DOI 10.3389/FIMMU; Xu Z, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aay3254; Xu Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10728; Yu YY, 2019, ISCIENCE, V19, P821, DOI 10.1016/j.isci.2019.08.034; Yu YY, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007251; Zhang XT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02972; Zheng Y, 2013, LEUKEMIA, V27, P702, DOI 10.1038/leu.2012.272	50	0	0	2	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 20	2021	12								704224	10.3389/fimmu.2021.704224	http://dx.doi.org/10.3389/fimmu.2021.704224			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XM5AS	34489953	gold, Green Published			2022-12-18	WOS:000728840400001
J	Yang, SX; Zhao, WJ; Zhu, MC; Hu, HJ; Wang, WJ; Zang, ZS; Jin, ML; Bi, JC; Huang, JD; Liu, CL; Li, XF; Yin, P; Li, N				Yang, Shuxin; Zhao, Wenjuan; Zhu, Muchun; Hu, Huijuan; Wang, Weijie; Zang, Zhongsheng; Jin, Meiling; Bi, Jiacheng; Huang, Jiandong; Liu, Chenli; Li, Xuefei; Yin, Peng; Li, Nan			Tumor Temporal Proteome Profiling Reveals the Immunological Triple Offensive Induced by Synthetic Anti-Cancer Salmonella	FRONTIERS IN IMMUNOLOGY			English	Article						quantitative proteomics; cancer immunotherapy; engineered Salmonella; blood coagulation; phagocytosis; antitumor T cell response	BACILLUS-CALMETTE-GUERIN; MEDIATED CANCER-THERAPY; POLARIZATION; TYPHIMURIUM; METASTASIS; ACTIVATION; MECHANISM; GROWTH; ROLES	The engineered "obligate" anaerobic Salmonella typhimurium strain YB1 shows a prominent ability to repress tumor growth and metastasis, which has great potential as a novel cancer immunotherapy. However, the antitumor mechanism of YB1 remains unelucidated. To resolve the proteome dynamics induced by the engineered bacteria, we applied tumor temporal proteome profiling on murine bladder tumors after intravenous injection of either YB1 or PBS as a negative control. Our data suggests that during the two weeks treatment of YB1 injections, the cured tumors experienced three distinct phases of the immune response. Two days after injection, the innate immune response was activated, particularly the complement and blood coagulation pathways. In the meantime, the phagocytosis was initiated. The professional phagocytes such as macrophages and neutrophils were recruited, especially the infiltration of iNOS(+) and CD68(+) cells was enhanced. Seven days after injection, substantial amount of T cells was observed at the invasion margin of the tumor. As a result, the tumor shrunk significantly. Overall, the temporal proteome profiling can systematically reveal the YB1 induced immune responses in tumor, showing great promise for elucidating the mechanism of bacteria-mediated cancer immunotherapy.	[Yang, Shuxin; Zhao, Wenjuan; Hu, Huijuan; Wang, Weijie; Zang, Zhongsheng; Jin, Meiling; Bi, Jiacheng; Huang, Jiandong; Liu, Chenli; Li, Xuefei; Li, Nan] Chinese Acad Sci, Shenzhen Inst Adv Technol, Shenzhen Inst Synthet Biol, Key Lab Quantitat Engn Biol, Shenzhen, Peoples R China; [Zhu, Muchun; Yin, Peng] Chinese Acad Sci, Shenzhen Inst Adv Technol, Guangdong Hong Kong Macao Joint Lab Human Machine, Shenzhen, Peoples R China	Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology, CAS; Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology, CAS	Li, N (corresponding author), Chinese Acad Sci, Shenzhen Inst Adv Technol, Shenzhen Inst Synthet Biol, Key Lab Quantitat Engn Biol, Shenzhen, Peoples R China.	nan.li@siat.ac.cn						Allendorf DJ, 2005, J IMMUNOL, V174, P7050, DOI 10.4049/jimmunol.174.11.7050; Avogadri F, 2005, CANCER RES, V65, P3920, DOI 10.1158/0008-5472.CAN-04-3002; Benoit ME, 2012, J IMMUNOL, V188, P5682, DOI 10.4049/jimmunol.1103760; Boutte AM, 2011, FASEB J, V25, P2626, DOI 10.1096/fj.10-180604; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Chen FM, 2019, BIOMATERIALS, V214, DOI 10.1016/j.biomaterials.2019.119226; Chen YB, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0568-z; Coley W. B., 1910, P ROY SOC MED, V3, P1, DOI DOI 10.1177/003591571000301601; Connell HC, 1935, CAN MED ASSOC J, V33, P364; Connelly L, 2001, J IMMUNOL, V166, P3873, DOI 10.4049/jimmunol.166.6.3873; Din MO, 2016, NATURE, V536, P81, DOI 10.1038/nature18930; Dunkelberger JR, 2010, CELL RES, V20, P34, DOI 10.1038/cr.2009.139; Gangloff SC, 2005, J IMMUNOL, V175, P3940, DOI 10.4049/jimmunol.175.6.3940; Guo ZL, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0196-3; Ho CL, 2018, NAT BIOMED ENG, V2, P27, DOI 10.1038/s41551-017-0181-y; Jaramillo M, 2003, J IMMUNOL, V171, P4243, DOI 10.4049/jimmunol.171.8.4243; Jeannin P, 2018, FEBS J, V285, P680, DOI 10.1111/febs.14343; Karagiannis GS, 2012, ONCOTARGET, V3, P267, DOI 10.18632/oncotarget.451; Lardner A, 2001, J LEUKOCYTE BIOL, V69, P522; Li CX, 2017, ONCOL LETT, V13, P177, DOI 10.3892/ol.2016.5453; Lin QB, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22755-3; Liu J, 2018, DISCOV MED, V25, P211; Lou XY, 2021, NANO-MICRO LETT, V13, DOI 10.1007/s40820-020-00560-9; Low KB, 1999, NAT BIOTECHNOL, V17, P37, DOI 10.1038/5205; Ma Y, 2013, J CANCER, V4, P36, DOI 10.7150/jca.5046; Maechler M, 2013, CLUSTER ANAL EXTENDE; Duong MTQ, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0297-0; McCarthy Edward F, 2006, Iowa Orthop J, V26, P154; Mi Z, 2019, J CANCER, V10, P4765, DOI 10.7150/jca.32650; Minton NP, 2003, NAT REV MICROBIOL, V1, P237, DOI 10.1038/nrmicro777; Mo YZ, 2019, J CANCER, V10, P2342, DOI 10.7150/jca.30454; MORALES A, 1976, J UROLOGY, V116, P180, DOI 10.1016/S0022-5347(17)58737-6; Munoz-Erazo L, 2020, CELL MOL IMMUNOL, V17, P570, DOI 10.1038/s41423-020-0457-0; Muraoka D, 2019, J CLIN INVEST, V129, P1278, DOI 10.1172/JCI97642; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Ning BT, 2017, J CANCER, V8, P1609, DOI 10.7150/jca.18776; Nissen NI, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1110-6; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Orecchioni M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00234; Pages F, 2018, LANCET, V391, P2128, DOI 10.1016/S0140-6736(18)30789-X; Pham NA, 2007, DIAGN PATHOL, V2, DOI 10.1186/1746-1596-2-8; Saini R, 2006, J LEUKOCYTE BIOL, V79, P519, DOI 10.1189/jlb.0605320; Selkrig J, 2020, NAT MICROBIOL, V5, P1119, DOI 10.1038/s41564-020-0736-7; Shintani Y, 2007, INT J UROL, V14, P140, DOI 10.1111/j.1442-2042.2007.01696.x; Sonar SA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00710; Toso JF, 2002, J CLIN ONCOL, V20, P142, DOI 10.1200/JCO.2002.20.1.142; Nguyen VH, 2017, NUCL MED MOLEC IMAG, V51, P118, DOI 10.1007/s13139-016-0415-z; Wall DM, 2010, ONCOTARGET, V1, P721; Wang Y., 2008, METAL BASED DRUGS, Vp, P716329, DOI [10. 1155/2008/716329., DOI 10.1155/2008/716329, 10.1155/2008/716329]; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Xie Q, 2015, PROTEIN CELL, V6, P117, DOI 10.1007/s13238-014-0109-1; Yi X, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba3546; Yu B, 2012, SCI REP-UK, V2, DOI 10.1038/srep00436; Zhang KH, 2010, IMAGE VISION COMPUT, V28, P668, DOI 10.1016/j.imavis.2009.10.009; Zhang RH, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-1027-3; Zheng JH, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aak9537; Zhou SB, 2018, NAT REV CANCER, V18, P727, DOI 10.1038/s41568-018-0070-z	57	0	0	6	21	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 19	2021	12									10.3389/fimmu.2021.712936	http://dx.doi.org/10.3389/fimmu.2021.712936			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UM7NQ	34489962	Green Published, gold			2022-12-18	WOS:000693515400001
J	Zhou, ZC; You, YJ; Wang, F; Sun, Y; Teng, JL; Liu, HL; Cheng, XB; Su, YT; Shi, H; Hu, QY; Chi, HH; Jia, JC; Wan, LY; Liu, TT; Wang, MY; Shi, C; Yang, CD; Ye, JN				Zhou, Zhuochao; You, Yijun; Wang, Fan; Sun, Yue; Teng, Jialin; Liu, Honglei; Cheng, Xiaobing; Su, Yutong; Shi, Hui; Hu, Qiongyi; Chi, Huihui; Jia, Jinchao; Wan, Liyan; Liu, Tingting; Wang, Mengyan; Shi, Ce; Yang, Chengde; Ye, Junna			Urine Proteomics Differentiate Primary Thrombotic Antiphospholipid Syndrome From Obstetric Antiphospholipid Syndrome	FRONTIERS IN IMMUNOLOGY			English	Article						thrombotic antiphospholipid syndrome; obstetric antiphospholipid syndrome; CXCL12; PDGFB; urine proteomics	CLASSIFICATION CRITERIA; LUPUS NEPHRITIS; DISEASE; PATTERNS	Antiphospholipid syndrome (APS) is a multisystem disorder characterized by thrombosis and/or recurrent fetal loss. This clinical phenotype heterogeneity may result in differences in response to treatment and prognosis. In this study, we aimed to identify primary thrombotic APS (TAPS) from primary obstetric APS (OAPS) using urine proteomics as a non-invasive method. Only patients with primary APS were enrolled in this study from 2016 to 2018 at a single clinical center in Shanghai. Urine samples from 15 patients with TAPS, 9 patients with OAPS, and 15 healthy controls (HCs) were collected and analyzed using isobaric tags for relative and absolute quantification (iTRAQ) labeling combined with liquid chromatography-tandem mass spectrometry analysis to identify differentially expressed proteins. Cluster analysis of urine proteomics identified differentiated proteins among the TAPS, OAPS, and HC groups. Urinary proteins were enriched in cytokine and cytokine receptor pathways. Representative secreted cytokines screened out (fold change >1.20, or <0.83, p<0.05) in these differentiated proteins were measured by enzyme-linked immunosorbent assay in a validation cohort. The results showed that the levels of C-X-C motif chemokine ligand 12 (CXCL12) were higher in the urine of patients with TAPS than in those with OAPS (p=0.035), while the levels of platelet-derived growth factor subunit B (PDGFB) were lower in patients with TAPS than in those with OAPS (p=0.041). In addition, correlation analysis showed that CXCL12 levels were positively correlated with immunoglobulin G anti-beta 2-glycoprotein I antibody (r=0.617, p=0.016). Our results demonstrated that urinary CXCL12 and PDGFB might serve as potential non-invasive markers to differentiate primary TAPS from primary OAPS.	[Zhou, Zhuochao; You, Yijun; Wang, Fan; Sun, Yue; Teng, Jialin; Liu, Honglei; Cheng, Xiaobing; Su, Yutong; Shi, Hui; Hu, Qiongyi; Chi, Huihui; Jia, Jinchao; Wan, Liyan; Liu, Tingting; Wang, Mengyan; Yang, Chengde; Ye, Junna] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Rheumatol & Immunol, Sch Med, Shanghai, Peoples R China; [Shi, Ce] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Lab Med, Sch Med, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Yang, CD; Ye, JN (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Rheumatol & Immunol, Sch Med, Shanghai, Peoples R China.; Shi, C (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Lab Med, Sch Med, Shanghai, Peoples R China.	shice1602@163.com; yangchengde@sina.com; yjn0912@qq.com	liu, ting/GZM-3326-2022; Chi, Huihui/AAW-2346-2021; chi, huihui/GRX-6820-2022	Chi, Huihui/0000-0001-9587-1180; 				Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI 10.1002/art.27584; Alvarez Angela M, 2017, J Hum Reprod Sci, V10, P10, DOI 10.4103/0974-1208.204018; Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Cheng QY, 2018, EUR J IMMUNOL, V48, P1020, DOI 10.1002/eji.201747023; Davis LS, 2017, RHEUMATOLOGY, V56, P100, DOI 10.1093/rheumatology/kew417; de Jesus GR, 2019, BJOG-INT J OBSTET GY, V126, P656, DOI 10.1111/1471-0528.15469; Devarapu SK, 2016, CLIN IMMUNOL, V169, P139, DOI 10.1016/j.clim.2016.07.003; El Shahawy MS, 2018, SCAND J CLIN LAB INV, V78, P264, DOI 10.1080/00365513.2018.1449242; Galli M, 1999, BLOOD, V93, P2149, DOI 10.1182/blood.V93.7.2149.407a33_2149_2157; Gerli G, 2005, CLIN CHEM, V51, P2411, DOI 10.1373/clinchem.2005.057802; Giannakopoulos B, 2009, BLOOD, V113, P985, DOI 10.1182/blood-2007-12-129627; Go DJ, 2018, LUPUS, V27, P1600, DOI 10.1177/0961203318778774; Gupta R, 2016, CLIN RHEUMATOL, V35, P2707, DOI 10.1007/s10067-016-3404-9; Janssens R, 2018, CELL MOL IMMUNOL, V15, P299, DOI 10.1038/cmi.2017.107; Jog NR, 2016, LUPUS, V25, P1551, DOI 10.1177/0961203316644331; Kang MJ, 2014, J PROTEOME RES, V13, P5206, DOI 10.1021/pr500467d; Kentsis A, 2009, PROTEOM CLIN APPL, V3, P1052, DOI 10.1002/prca.200900008; Kitagori K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167141; Lima G, 2007, HUM IMMUNOL, V68, P980, DOI 10.1016/j.humimm.2007.10.007; Lopez-Pedrera C, 2008, LUPUS, V17, P904, DOI 10.1177/0961203308095285; Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x; Pacheco Y, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1345-y; Petri M, 2020, TRANSL RES, V225, P70, DOI 10.1016/j.trsl.2020.04.006; Petri M, 2012, ARTHRITIS RHEUM-US, V64, P2677, DOI 10.1002/art.34473; Potti A, 2006, BLOOD, V107, P1391, DOI 10.1182/blood-2005-07-2669; Ripoll VM, 2018, J AUTOIMMUN, V93, P114, DOI 10.1016/j.jaut.2018.07.002; Ripoll VM, 2014, BLOOD, V124, P3808, DOI 10.1182/blood-2014-05-577569; Smadja DM, 2010, LUPUS, V19, P837, DOI 10.1177/0961203309360985; Soliman S, 2017, INT J RHEUM DIS, V20, P1714, DOI 10.1111/1756-185X.13197; Sun Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02112; Tektonidou MG, 2019, RMD OPEN, V5, DOI 10.1136/rmdopen-2019-000924; Weber C, 2004, ARTERIOSCL THROM VAS, V24, P1997, DOI 10.1161/01.ATV.0000142812.03840.6f; Yelnik CM, 2016, LUPUS SCI MED, V3, DOI 10.1136/lupus-2015-000131; Yuan Y, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1238-8	34	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 19	2021	12									10.3389/fimmu.2021.702425	http://dx.doi.org/10.3389/fimmu.2021.702425			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UM7OI	34489952	Green Published, gold			2022-12-18	WOS:000693517200001
J	Sturm, N; Quinterot, M; Guyot, JP; Righini, C; Daamen, WF; van Kuppevelt, TH; Huard, B				Sturm, Nathalie; Quinterot, Melanie; Guyot, Jean-Philippe; Righini, Christian; Daamen, Willeke F.; van Kuppevelt, Toin H.; Huard, Bertrand			Polarized Secretion of APRIL by the Tonsil Epithelium Upon Toll-Like Receptor Stimulation	FRONTIERS IN IMMUNOLOGY			English	Article						mucosa; plasmocytes; survival; epithelium; APRIL	PROTEOGLYCANS; LIGAND; CELLS; TRANSCYTOSIS; LESIONS	In mucosa such as tonsil, antibody-producing plasmocytes (PCs) lie in sub-epithelium space, which is thought to provide a suitable environment for their survival. A proliferation inducing ligand (APRIL) is one key survival factor for PCs present in this area. According to in situ staining, apical epithelial cells produced APRIL, and the secreted product had to migrate all through the stratified surface epithelium to reach basal cells. A similar process also occurred in the less-organized crypt epithelium. Tonsil epithelial cells captured secreted APRIL, thanks to their surface expression of the APRIL coreceptor, either syndecan-1 or -4 depending on their differentiation stage. In the most basal epithelial cells, secreted APRIL accumulated inside secretory lamp-1(+) vesicles in a polarized manner, facing the sub-epithelium. The tonsil epithelium upregulated APRIL production by apical cells and secretion by basal cells upon Toll-like receptor stimulation. Furthermore, LPS-stimulated epithelial cells sustained in vitro PC survival in a secreted APRIL-dependent manner. Taken together, our study shows that the tonsil epithelium responds to pathogen sensing by a polarized secretion of APRIL in the sub-epithelial space, wherein PCs reside.	[Sturm, Nathalie] Univ Hosp, Dept Pathol, Grenoble, France; [Sturm, Nathalie; Quinterot, Melanie; Huard, Bertrand] CNRS, Translat Innovat Med & Complex, UMR5525, La Tronche, France; [Guyot, Jean-Philippe] Univ Hosp, Otorhinolaryngol Unit, Geneva, Switzerland; [Righini, Christian] Univ Hosp, Head & Neck Dept, Grenoble, France; [Daamen, Willeke F.; van Kuppevelt, Toin H.] Univ Med Ctr, Radboud Inst Mol Life Sci, Dept Biochem, Nijmegen, Netherlands	CHU Grenoble Alpes; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); University of Geneva; CHU Grenoble Alpes; Radboud University Nijmegen	Huard, B (corresponding author), CNRS, Translat Innovat Med & Complex, UMR5525, La Tronche, France.	bertrand.huard@univ-grenoble-alpes.fr	Daamen, Willeke F./D-5854-2015; huard, bertrand/L-8011-2013	Daamen, Willeke F./0000-0003-3155-3030; huard, bertrand/0000-0003-1358-6576	FINOVI foundation; AFEF	FINOVI foundation; AFEF	This work was supported by a grant from the FINOVI foundation to BH and the AFEF to NS.	Baert L, 2018, J AUTOIMMUN, V95, P179, DOI 10.1016/j.jaut.2018.10.016; Bobardt MD, 2007, J VIROL, V81, P395, DOI 10.1128/JVI.01303-06; Buckley A, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a029314; Candela P, 2008, ENDOTHELIUM-J ENDOTH, V15, P254, DOI 10.1080/10623320802487759; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; Fung KYY, 2018, TRAFFIC, V19, P5, DOI 10.1111/tra.12533; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; He B, 2007, IMMUNITY, V26, P812, DOI 10.1016/j.immuni.2007.04.014; Hendriks J, 2005, CELL DEATH DIFFER, V12, P637, DOI 10.1038/sj.cdd.4401647; Huard B, 2008, J CLIN INVEST, V118, P2887, DOI 10.1172/JCI33760; Ingold K, 2005, J EXP MED, V201, P1375, DOI 10.1084/jem.20042309; Kurup S, 2007, J BIOL CHEM, V282, P21032, DOI 10.1074/jbc.M702073200; Kusche-Gullberg M, 2003, CURR OPIN STRUC BIOL, V13, P605, DOI 10.1016/j.sbi.2003.08.002; Lange MJ, 2009, INT J PEDIATR OTORHI, V73, P613, DOI 10.1016/j.ijporl.2008.12.013; Leteux C, 2001, J BIOL CHEM, V276, P12539, DOI 10.1074/jbc.M010291200; Lopez-Fraga M, 2001, EMBO REP, V2, P945, DOI 10.1093/embo-reports/kve198; Manfroi B, 2017, CANCER RES, V77, P1097, DOI 10.1158/0008-5472.CAN-16-0786; Matthes T, 2011, BLOOD, V118, P1838, DOI 10.1182/blood-2011-01-332940; Radbruch A, 2006, NAT REV IMMUNOL, V6, P741, DOI 10.1038/nri1886; SCHMOLDT A, 1975, BIOCHEM PHARMACOL, V24, P1639, DOI 10.1016/0006-2952(75)90094-5; Schwaller J, 2007, BLOOD, V109, P331, DOI 10.1182/blood-2006-02-001800; Vincent FB, 2013, CYTOKINE GROWTH F R, V24, P203, DOI 10.1016/j.cytogfr.2013.04.003; Wijnhoven TJM, 2006, AM J KIDNEY DIS, V48, P250, DOI 10.1053/j.ajkd.2006.05.003	23	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 18	2021	12									10.3389/fimmu.2021.715724	http://dx.doi.org/10.3389/fimmu.2021.715724			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UQ2LA	34484218	Green Published, gold			2022-12-18	WOS:000695899800001
J	Chang, YJ; Ding, Q; Hwang, WYK; Sahoo, RK				Chang, Ying-Jun; Ding, Qing; Hwang, William Ying Khee; Sahoo, Ranjit Kumar			Editorial: Recent Developments in Haploidentical Hematopoietic Cell Transplantation: Therapy and Complications	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						stem cell transplantation; graft-versus-host disease; graft failure; graft-versus-leukemia effect; car-t; infection			[Chang, Ying-Jun] Peking Univ, Peoples Hosp, Beijing, Peoples R China; [Chang, Ying-Jun] Peking Univ, Inst Hematol, Natl Clin Res Ctr Hematol Dis, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing, Peoples R China; [Ding, Qing] Univ Pittsburgh, Thomas E Starzl Transplantat Inst, Pittsburgh, PA USA; [Hwang, William Ying Khee] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore; [Sahoo, Ranjit Kumar] All India Inst Med Sci, Dept Med Oncol, New Delhi, India	Peking University; Peking University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Cancer Centre Singapore (NCCS); All India Institute of Medical Sciences (AIIMS) New Delhi	Chang, YJ (corresponding author), Peking Univ, Peoples Hosp, Beijing, Peoples R China.; Chang, YJ (corresponding author), Peking Univ, Inst Hematol, Natl Clin Res Ctr Hematol Dis, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing, Peoples R China.	rmcyj@bjmu.edu.cn	Hwang, William/AAX-8452-2021	Hwang, William Ying Khee/0000-0003-0143-6263					0	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 17	2021	12								746221	10.3389/fimmu.2021.746221	http://dx.doi.org/10.3389/fimmu.2021.746221			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UL5NZ	34484249	Green Published, gold			2022-12-18	WOS:000692699000001
J	Zhao, RP; Zhou, XD; Khan, ES; Alansary, D; Friedmann, KS; Yang, WJ; Schwarz, EC; del Campo, A; Hoth, M; Qu, B				Zhao, Renping; Zhou, Xiangda; Khan, Essak S.; Alansary, Dalia; Friedmann, Kim S.; Yang, Wenjuan; Schwarz, Eva C.; del Campo, Aranzazu; Hoth, Markus; Qu, Bin			Targeting the Microtubule-Network Rescues CTL Killing Efficiency in Dense 3D Matrices	FRONTIERS IN IMMUNOLOGY			English	Article						CTLs; collagen; dense matrices; microtubules; migration; nuclear deformation; 3D killing	CYTOTOXIC T-LYMPHOCYTES; IMMUNOLOGICAL SYNAPSE; CELL-MIGRATION; COLLAGEN; ACTIVATION; STIFFNESS; FILAMENTS; GRANULES	Efficacy of cytotoxic T lymphocyte (CTL)-based immunotherapy is still unsatisfactory against solid tumors, which are frequently characterized by condensed extracellular matrix. Here, using a unique 3D killing assay, we identify that the killing efficiency of primary human CTLs is substantially impaired in dense collagen matrices. Although the expression of cytotoxic proteins in CTLs remained intact in dense collagen, CTL motility was largely compromised. Using light-sheet microscopy, we found that persistence and velocity of CTL migration was influenced by the stiffness and porosity of the 3D matrix. Notably, 3D CTL velocity was strongly correlated with their nuclear deformability, which was enhanced by disruption of the microtubule network especially in dense matrices. Concomitantly, CTL migration, search efficiency, and killing efficiency in dense collagen were significantly increased in microtubule-perturbed CTLs. In addition, the chemotherapeutically used microtubule inhibitor vinblastine drastically enhanced CTL killing efficiency in dense collagen. Together, our findings suggest targeting the microtubule network as a promising strategy to enhance efficacy of CTL-based immunotherapy against solid tumors, especially stiff solid tumors.	[Zhao, Renping; Zhou, Xiangda; Friedmann, Kim S.; Yang, Wenjuan; Schwarz, Eva C.; Hoth, Markus; Qu, Bin] Saarland Univ, Sch Med, Ctr Integrat Physiol & Mol Med CIPMM, Biophys, Homburg, Germany; [Khan, Essak S.; del Campo, Aranzazu; Qu, Bin] INM Leibniz Inst New Mat, Saarbrucken, Germany; [Alansary, Dalia] Saarland Univ, Sch Med, CIPMM, Mol Biophys, Homburg, Germany	Universitatsklinikum des Saarlandes; Leibniz Institut fur Neue Materialien (INM); Universitatsklinikum des Saarlandes	Qu, B (corresponding author), Saarland Univ, Sch Med, Ctr Integrat Physiol & Mol Med CIPMM, Biophys, Homburg, Germany.; Qu, B (corresponding author), INM Leibniz Inst New Mat, Saarbrucken, Germany.	bin.qu@uks.eu	Qu, Bin/AAK-2260-2021	Qu, Bin/0000-0002-9382-3203; Alansary, Dalia/0000-0002-7541-6057; Khan, Essak/0000-0001-5691-4854	Deutsche Forschungsgemeinschaft [SFB 1027, GZ: INST 256/419-1 FUGG, GZ: INST 256/423-1 FUGG, GZ: INST 256/429-1 FUGB]; Bundesministeriumfur Bildung und Forschung (BMBF) [031L0133]; University of Saarland HOMFORexzellent grant; Leibniz-Gemeinschaft	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Bundesministeriumfur Bildung und Forschung (BMBF)(Federal Ministry of Education & Research (BMBF)); University of Saarland HOMFORexzellent grant; Leibniz-Gemeinschaft	This project was funded by the Deutsche Forschungsgemeinschaft (SFB 1027; Forschungsgrossgerate (GZ: INST 256/419-1 FUGG for the light-sheet microscope, GZ: INST 256/423-1 FUGG for the flow cytometer, and GZ: INST 256/429-1 FUGB for ImageXpress), Bundesministeriumfur Bildung und Forschung (BMBF, 031L0133 to MH), University of Saarland HOMFORexzellent grant (to RZ), and by the Leibniz-Gemeinschaft (INM Fellow to BQ).	Acton SE, 2014, NATURE, V514, P498, DOI 10.1038/nature13814; Acuto O, 2000, ANNU REV IMMUNOL, V18, P165, DOI 10.1146/annurev.immunol.18.1.165; Alisafaei F, 2019, P NATL ACAD SCI USA, V116, P13200, DOI 10.1073/pnas.1902035116; Artyomov MN, 2010, P NATL ACAD SCI USA, V107, P16916, DOI 10.1073/pnas.1010568107; Backes CS, 2018, J BIOL CHEM, V293, P16348, DOI 10.1074/jbc.RA118.004549; Barry M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/nri819; Basu R, 2016, CELL, V165, P100, DOI 10.1016/j.cell.2016.01.021; Billadeau DD, 2007, NAT REV IMMUNOL, V7, P131, DOI 10.1038/nri2021; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Denais CM, 2016, SCIENCE, V352, P353, DOI 10.1126/science.aad7297; Deptula P, 2020, ACS BIOMATER SCI ENG, V6, P5620, DOI 10.1021/acsbiomaterials.0c00975; Dieckmann NMG, 2016, J CELL SCI, V129, P2881, DOI 10.1242/jcs.186205; Dupre L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00586; Dustin ML, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002311; Feng Q, 2018, J CELL SCI, V131, DOI 10.1242/jcs.218479; Friedmann KS., 2020, COMBINED CTL NK CELL, DOI [10.1101/2020.06.14.150672, DOI 10.1101/2020.06.14.150672]; Garteiser P, 2012, EUR RADIOL, V22, P2169, DOI 10.1007/s00330-012-2474-6; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Goldberg MW, 2008, J CELL SCI, V121, P215, DOI 10.1242/jcs.022020; Halle S, 2017, TRENDS IMMUNOL, V38, P432, DOI 10.1016/j.it.2017.04.002; Hetmanski JHR, 2019, DEV CELL, V51, P460, DOI 10.1016/j.devcel.2019.09.006; Hons M, 2018, NAT IMMUNOL, V19, P606, DOI 10.1038/s41590-018-0109-z; Hua SX, 2020, EUR J MED CHEM, V189, DOI 10.1016/j.ejmech.2020.112041; Huang J, 2007, J IMMUNOL, V179, P7653, DOI 10.4049/jimmunol.179.11.7653; Jacobelli J, 2010, NAT IMMUNOL, V11, P953, DOI 10.1038/ni.1936; Kim DH, 2015, J CELL SCI, V128, P3375, DOI 10.1242/jcs.166330; Kim DH, 2014, J CELL SCI, V127, P2528, DOI 10.1242/jcs.144345; Knorck A., 2021, CYTOTOXIC EFFICIENCY, DOI [10.1101/2021.03.15.435339, DOI 10.1101/2021.03.15.435339]; Kopf A, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201907154; Krause M, 2019, PHILOS T R SOC B, V374, DOI 10.1098/rstb.2018.0225; Krummel MF, 2016, NAT REV IMMUNOL, V16, P193, DOI 10.1038/nri.2015.16; Kuczek DE, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0556-6; Kummerow C, 2014, EUR J IMMUNOL, V44, P1870, DOI 10.1002/eji.201444518; Lammermann T, 2008, NATURE, V453, P51, DOI 10.1038/nature06887; Lammerding J, 2011, COMPR PHYSIOL, V1, P783, DOI 10.1002/cphy.c100038; Lang NR, 2015, ACTA BIOMATER, V13, P61, DOI 10.1016/j.actbio.2014.11.003; Leikina E, 2002, P NATL ACAD SCI USA, V99, P1314, DOI 10.1073/pnas.032307099; Li YL, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00206; Lyubchenko TA, 2003, J PHYSIOL-LONDON, V547, P835, DOI 10.1113/jphysiol.2002.033522; Madsen CD, 2017, BIO-PROTOCOL, V7, DOI 10.21769/BioProtoc.2265; Mason BN, 2013, ACTA BIOMATER, V9, P4635, DOI 10.1016/j.actbio.2012.08.007; Park H, 2015, BIOMED ENG LETT, V5, P188, DOI 10.1007/s13534-015-0197-8; Peng DH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18298-8; PETERS PJ, 1991, J EXP MED, V173, P1099, DOI 10.1084/jem.173.5.1099; Qu B, 2011, J IMMUNOL, V186, P6894, DOI 10.4049/jimmunol.1003471; Ratner S, 1997, J IMMUNOL, V159, P1063; Ren XD, 2004, J CELL SCI, V117, P3511, DOI 10.1242/jcs.01205; Renkawitz J, 2019, NATURE, V568, P546, DOI 10.1038/s41586-019-1087-5; Ritter AT, 2017, P NATL ACAD SCI USA, V114, pE6585, DOI 10.1073/pnas.1710751114; Rocha-Perugini V, 2014, NUCLEUS-PHILA, V5, P396, DOI 10.4161/nucl.36361; Sadjadi Z, 2020, BIOPHYS J, V119, P2141, DOI 10.1016/j.bpj.2020.10.020; Salmon H, 2012, J CLIN INVEST, V122, P899, DOI 10.1172/JCI45817; Schoppmeyer R, 2018, JOVE-J VIS EXP, DOI 10.3791/57651; Schoppmeyer R, 2017, EUR J IMMUNOL, V47, P1562, DOI 10.1002/eji.201747124; Serrador JM, 1999, TRENDS CELL BIOL, V9, P228, DOI 10.1016/S0962-8924(99)01553-6; Shannon GS, 2015, RSC ADV, V5, P2113, DOI 10.1039/c4ra11480a; Sinkus R, 2007, MAGN RESON MED, V58, P1135, DOI 10.1002/mrm.21404; Stinchcombe JC, 2001, IMMUNITY, V15, P751, DOI 10.1016/S1074-7613(01)00234-5; Sugita S, 1996, INT IMMUNOL, V8, P799, DOI 10.1093/intimm/8.5.799; Tabdanov ED, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22985-5; Tamzali Y., 2015, CLIN EQUINE ONCOLOGY; Tariq Z, 2017, NUCLEUS-PHILA, V8, P433, DOI 10.1080/19491034.2017.1320460; Thiam HR, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10997; Wolf K, 2013, J CELL BIOL, V201, P1069, DOI 10.1083/jcb.201210152; Yi JS, 2013, J CELL BIOL, V202, P779, DOI 10.1083/jcb.201301004; Yue Beatrice, 2014, J Glaucoma, V23, pS20, DOI 10.1097/IJG.0000000000000108; Zhang N, 2011, IMMUNITY, V35, P161, DOI 10.1016/j.immuni.2011.07.010; Zhu JL, 2014, BIOPHYS J, V106, P1822, DOI 10.1016/j.bpj.2014.03.011	68	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 17	2021	12									10.3389/fimmu.2021.729820	http://dx.doi.org/10.3389/fimmu.2021.729820			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UM8YQ	34484240	gold, Green Published			2022-12-18	WOS:000693611700001
J	Huang, ZQ; Yang, P; Wang, F				Huang, Zhiqi; Yang, Peng; Wang, Fan			Shrimp Plasma CREG Is a Hemocyte Activation Factor	FRONTIERS IN IMMUNOLOGY			English	Article						Penaeus vannamei; CREG; phagocytosis; transcriptome; hemocyte activation	E1A-STIMULATED GENES; CELLULAR REPRESSOR; DIFFERENTIATION; INFLAMMATION; PROTEINS; GROWTH; SERUM	Cytokines are a class of immunoregulatory proteins that are secreted by cells. Although vertebrate cytokine, especially mammalian cytokine has been well studied for the past decades. Much less attention has been paid to invertebrate so that only some cytokines have been identified in invertebrates. We have chosen Peaneus vannamei as a model to explore novel invertebrate cytokines. To achieve this, we previously purified shrimp plasma low abundance proteins and identified more than 400 proteins with proteomics analyses. In this study, a cellular repressor of E1A-stimulated gene (CREG)-like protein, which is highly conserved from Drosophila melanogaster to Homo sapiens, was further characterized in shrimp plasma. We found that shrimp plasma CREG was a glycoprotein which was strongly induced in hemolymph at 8 h post-LPS injection. Further function experiment unveiled that recombinant shrimp CREG protein injection significantly increased phagocytic hemocyte and lysosome-high hemocyte proportion in hemolymph. After that, hemocytes from rEGFP- and rCREG-protein injected shrimps were subjected to transcriptome analyses, which revealed that shrimp CREG protein could comprehensively promote hemocyte maturation and activation. Taken together, our data clearly indicated that shrimp plasma CREG protein is a novel hemocyte activation factor, which is probably a conserved myeloid cell lineage activation factor from invertebrate to vertebrate.	[Huang, Zhiqi; Wang, Fan] Shantou Univ, Dept Biol, Coll Sci, Shantou, Peoples R China; [Yang, Peng; Wang, Fan] Shantou Univ, Inst Marine Sci, Shantou, Peoples R China; [Yang, Peng; Wang, Fan] Shantou Univ, Guangdong Prov Key Lab Marine Biotechnol, Shantou, Peoples R China; [Wang, Fan] Shantou Univ, STU UMT Joint Shellfish Res Lab, Shantou, Peoples R China	Shantou University; Shantou University; Shantou University; Shantou University	Wang, F (corresponding author), Shantou Univ, Dept Biol, Coll Sci, Shantou, Peoples R China.; Wang, F (corresponding author), Shantou Univ, Inst Marine Sci, Shantou, Peoples R China.; Wang, F (corresponding author), Shantou Univ, Guangdong Prov Key Lab Marine Biotechnol, Shantou, Peoples R China.; Wang, F (corresponding author), Shantou Univ, STU UMT Joint Shellfish Res Lab, Shantou, Peoples R China.			yang, peng/0000-0002-8298-8926; Wang, Fan/0000-0002-6059-6956	National Natural Science Foundation of China [41976123]; Sail Plan Program for the Introduction of Outstanding Talents of Guangdong Province of China [14600703]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Sail Plan Program for the Introduction of Outstanding Talents of Guangdong Province of China	Funding This work was sponsored by the National Natural Science Foundation of China (No. 41976123) and the Sail Plan Program for the Introduction of Outstanding Talents of Guangdong Province of China (No. 14600703).	Alenton RR, 2019, J IMMUNOL, V203, P2310, DOI 10.4049/jimmunol.1900156; Barletta ABF, 2019, ISCIENCE, V19, P54, DOI 10.1016/j.isci.2019.07.012; Csordas G, 2021, DEV BIOL, V469, P135, DOI 10.1016/j.ydbio.2020.10.006; Dedkhad W, 2019, TROP BIOMED, V36, P505; Di Bacco A, 2003, ONCOGENE, V22, P5436, DOI 10.1038/sj.onc.1206670; Gao JF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.593987; Ghobrial G, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00136; Kowalewski-Nimmerfall E, 2014, BBA-MOL CELL RES, V1843, P2900, DOI 10.1016/j.bbamcr.2014.08.012; Liu J, 2021, AUTOPHAGY, V17, P4249, DOI 10.1080/15548627.2021.1909997; Liu J, 2016, STEM CELLS, V34, P2648, DOI 10.1002/stem.2434; Loke I, 2016, MOL ASPECTS MED, V51, P31, DOI 10.1016/j.mam.2016.04.004; Lundgren-Akerlund E, 2014, ADV EXP MED BIOL, V819, P61, DOI 10.1007/978-94-017-9153-3_4; Morris KE, 2006, J BIOL CHEM, V281, P9297, DOI 10.1074/jbc.M511710200; Mortha A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00191; Ning P, 2018, DEV COMP IMMUNOL, V81, P74, DOI 10.1016/j.dci.2017.11.010; Soto JO, 2021, WORLD J MICROB BIOT, V37, DOI 10.1007/s11274-020-02987-z; Park MH, 2019, REPROD DOMEST ANIM, V54, P1497, DOI 10.1111/rda.13555; Peach CJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041264; Qian MQ, 2008, MOL CELL PROTEOMICS, V7, P58, DOI 10.1074/mcp.M700217-MCP200; Raddi G, 2020, SCIENCE, V369, P1128, DOI 10.1126/science.abc0322; Reichelt P, 2006, PROTEIN EXPRES PURIF, V46, P483, DOI 10.1016/j.pep.2005.09.027; Rodrigues J, 2010, SCIENCE, V329, P1353, DOI 10.1126/science.1190689; Sacher M, 2005, P NATL ACAD SCI USA, V102, P18326, DOI 10.1073/pnas.0505071102; Soderhall I, 2016, DEV COMP IMMUNOL, V58, P129, DOI 10.1016/j.dci.2015.12.009; Tao MY, 2020, MOL IMMUNOL, V120, P113, DOI 10.1016/j.molimm.2020.02.007; Tao MY, 2019, DEV COMP IMMUNOL, V93, P89, DOI 10.1016/j.dci.2019.01.003; Tattikota SG, 2020, ELIFE, V9, DOI 10.7554/eLife.54818; Thornber K, 2020, REV AQUACULT, V12, P966, DOI 10.1111/raq.12367; Van den Steen P, 1998, ADV EXP MED BIOL, V435, P133; Veal E, 1998, MOL CELL BIOL, V18, P5032, DOI 10.1128/MCB.18.9.5032; Veal E, 2000, ONCOGENE, V19, P2120, DOI 10.1038/sj.onc.1203529; Voisset E, 2020, CANCERS, V12, DOI 10.3390/cancers12071996; Yu Y, 2016, J INVERTEBR PATHOL, V139, P19, DOI 10.1016/j.jip.2016.06.009; Zhang XJ, 2019, NAT COMMUN, V10, DOI [10.1038/s41467-018-08197-4, 10.1038/s41467-019-13333-9]; Zhang YL, 2018, FISH SHELLFISH IMMUN, V76, P187, DOI 10.1016/j.fsi.2018.03.002; Zhang YZ, 2005, J CLIN INVEST, V115, P2870, DOI 10.1172/JCI25327	36	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 16	2021	12								707770	10.3389/fimmu.2021.707770	http://dx.doi.org/10.3389/fimmu.2021.707770			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XF5WN	34484206	gold, Green Published			2022-12-18	WOS:000724141000001
J	Righi, I; Vaira, V; Morlacchi, LC; Croci, GA; Rossetti, V; Blasi, F; Ferrero, S; Nosotti, M; Rosso, L; Clerici, M				Righi, Ilaria; Vaira, Valentina; Morlacchi, Letizia Corinna; Croci, Giorgio Alberto; Rossetti, Valeria; Blasi, Francesco; Ferrero, Stefano; Nosotti, Mario; Rosso, Lorenzo; Clerici, Mario			Immune Checkpoints Expression in Chronic Lung Allograft Rejection	FRONTIERS IN IMMUNOLOGY			English	Article						lung transplant; chronic rejection; immunology; Treg lymphocytes; PD-1 and PD-L1; FoxP3	PD-1; B7-H1; TRANSPLANTATION; EXHAUSTION; ENGAGEMENT; INSIGHTS; RECEPTOR; PATHWAY; MEMBER; CELLS	Chronic lung allograft dysfunction (CLAD) is the main cause of poor survival and low quality of life of lung transplanted patients. Several studies have addressed the role of dendritic cells, macrophages, T cells, donor specific as well as anti-HLA antibodies, and interleukins in CLAD, but the expression and function of immune checkpoint molecules has not yet been analyzed, especially in the two CLAD subtypes: BOS (bronchiolitis obliterans syndrome) and RAS (restrictive allograft syndrome). To shed light on this topic, we conducted an observational study on eight consecutive grafts explanted from patients who received lung re-transplantation for CLAD. The expression of a panel of immune molecules (PD1/CD279, PDL1/CD274, CTLA4/CD152, CD4, CD8, hFoxp3, TIGIT, TOX, B-Cell-Specific Activator Protein) was analyzed by immunohistochemistry in these grafts and in six control lungs. Results showed that RAS compared to BOS grafts were characterized by 1) the inversion of the CD4/CD8 ratio; 2) a higher percentage of T lymphocytes expressing the PD-1, PD-L1, and CTLA4 checkpoint molecules; and 3) a significant reduction of exhausted PD-1-expressing T lymphocytes (PD-1(pos)/TOXpos) and of exhausted Treg (PD-1(pos)/FOXP3(pos)) T lymphocytes. Results herein, although being based on a limited number of cases, suggest a role for checkpoint molecules in the development of graft rejection and offer a possible immunological explanation for the worst prognosis of RAS. Our data, which will need to be validated in ampler cohorts of patients, raise the possibility that the evaluation of immune checkpoints during follow-up offers a prognostic advantage in monitoring the onset of rejection, and suggest that the use of compounds that modulate the function of checkpoint molecules could be evaluated in the management of chronic rejection in LTx patients.	[Righi, Ilaria; Nosotti, Mario; Rosso, Lorenzo] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Thorac Surg & Lung Transplantat Unit, Milan, Italy; [Vaira, Valentina; Croci, Giorgio Alberto; Ferrero, Stefano] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Pathol, Milan, Italy; [Vaira, Valentina; Croci, Giorgio Alberto; Blasi, Francesco; Nosotti, Mario; Rosso, Lorenzo; Clerici, Mario] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy; [Morlacchi, Letizia Corinna; Rossetti, Valeria; Blasi, Francesco] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Resp Unit, Milan, Italy; [Morlacchi, Letizia Corinna; Rossetti, Valeria; Blasi, Francesco] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Adult Cyst Fibrosis Ctr, Internal Med Dept, Milan, Italy; [Ferrero, Stefano] Univ Milan, Dept Biomed Surg & Dent Sci, Milan, Italy; [Clerici, Mario] IRCCS, Don C Gnocchi Fdn, Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS Fondazione Don Carlo Gnocchi Onlus	Rosso, L (corresponding author), Fdn IRCCS Ca Granda Osped Maggiore Policlin, Thorac Surg & Lung Transplantat Unit, Milan, Italy.; Rosso, L; Clerici, M (corresponding author), Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy.; Clerici, M (corresponding author), IRCCS, Don C Gnocchi Fdn, Milan, Italy.	lorenzo.rosso@unimi.it; mario.clerici@unimi.it	Morlacchi, Letizia Corinna/K-7336-2018; Nosotti, Mario/K-7389-2016; Rossetti, Valeria/AAC-7279-2022; Nosotti, Mario/AAA-5976-2022; Vaira, Valentina/K-6499-2016; Rosso, Lorenzo/J-6815-2015; Blasi, Francesco/O-5885-2017	Morlacchi, Letizia Corinna/0000-0002-4661-6471; Nosotti, Mario/0000-0002-8571-121X; Nosotti, Mario/0000-0002-8571-121X; Vaira, Valentina/0000-0003-4416-6216; Rosso, Lorenzo/0000-0002-9809-7140; Blasi, Francesco/0000-0002-2285-9970				Blazar BR, 2003, J IMMUNOL, V171, P1272, DOI 10.4049/jimmunol.171.3.1272; Creemers P, 2002, TRANSPL IMMUNOL, V10, P285, DOI 10.1016/S0966-3274(02)00072-2; Croci GA, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10030611; Daud A, 2020, J HEART LUNG TRANSPL, V39, P604, DOI 10.1016/j.healun.2020.02.015; Dong HD, 2003, J MOL MED, V81, P281, DOI 10.1007/s00109-003-0430-2; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Fribourg M, 2019, KIDNEY INT, V96, P436, DOI 10.1016/j.kint.2019.01.040; Gelman AE, 2009, J IMMUNOL, V182, P3969, DOI 10.4049/jimmunol.0803514; Glanville AR, 2019, J HEART LUNG TRANSPL, V38, P483, DOI 10.1016/j.healun.2019.03.008; Gregson AL, 2008, TRANSPLANTATION, V85, P1056, DOI 10.1097/TP.0b013e318169bd85; Gunasinghe SD, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.600829; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Khush KK, 2019, J HEART LUNG TRANSPL, V38, P1056, DOI 10.1016/j.healun.2019.08.004; Kotecha S, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.01.05; Krupnick AS, 2014, J CLIN INVEST, V124, P1130, DOI 10.1172/JCI71359; Mazanet MM, 2002, J IMMUNOL, V169, P3581, DOI 10.4049/jimmunol.169.7.3581; Nishimura H, 2001, TRENDS IMMUNOL, V22, P265, DOI 10.1016/S1471-4906(01)01888-9; Petroff MG, 2003, BIOL REPROD, V68, P1496, DOI 10.1095/biolreprod.102.010058; Peyster EG, 2020, JACC-BASIC TRANSL SC, V5, P328, DOI 10.1016/j.jacbts.2020.01.015; Sacreas A, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.00847-2019; Salama AD, 2003, J EXP MED, V198, P71, DOI 10.1084/jem.20022119; Sanchez-Fueyo A, 2016, AM J TRANSPLANT, V16, P1953, DOI 10.1111/ajt.13702; Shastri N, 2015, CURR OPIN IMMUNOL, V34, pV, DOI 10.1016/j.coi.2015.04.004; Stewart S, 2007, J HEART LUNG TRANSPL, V26, P1229, DOI 10.1016/j.healun.2007.10.017; Takahashi T, 2018, AM J TRANSPLANT, V18, P216, DOI 10.1111/ajt.14437; Thorp EB, 2015, CURR OPIN ORGAN TRAN, V20, P37, DOI 10.1097/MOT.0000000000000153; Tiriveedhi V, 2012, CLIN EXP IMMUNOL, V167, P158, DOI 10.1111/j.1365-2249.2011.04486.x; Trabattoni D, 2009, J IMMUNOL, V183, P4984, DOI 10.4049/jimmunol.0901038; Vaira V, 2020, CLIN SCI, V134, P1151, DOI 10.1042/CS20200032; Verleden SE, 2020, CLIN TRANSPLANT, V34, DOI 10.1111/ctr.13781; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Zhang XW, 2004, IMMUNITY, V20, P337, DOI 10.1016/S1074-7613(04)00051-2	33	0	0	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 13	2021	12									10.3389/fimmu.2021.714132	http://dx.doi.org/10.3389/fimmu.2021.714132			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UM6SG	34489963	Green Published, gold			2022-12-18	WOS:000693459800001
J	Rijkers, GTT; Riccardi, C; Kroese, FGM				Rijkers, Ger T. T.; Riccardi, Carlo; Kroese, Frans G. M.			Editorial: Defects in Regulation: How, Where and When the Immune System Can Go Wrong	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						immunoregulation; autoinflammation; autoimmunity; AIRE; glucocorticoids; TNF-blockade; addison; SLE			[Rijkers, Ger T. T.] Univ Coll Roosevelt, Dept Sci, Middelburg, Netherlands; [Rijkers, Ger T. T.] St Elizabeth Hosp, Microvida Lab Med Microbiol & Immunol, Middelburg, Netherlands; [Riccardi, Carlo] Univ Perugia, Dept Med, Perugia, Italy; [Kroese, Frans G. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Rheumatol & Clin Immunol, Groningen, Netherlands	University of Perugia; University of Groningen	Rijkers, GTT (corresponding author), Univ Coll Roosevelt, Dept Sci, Middelburg, Netherlands.; Rijkers, GTT (corresponding author), St Elizabeth Hosp, Microvida Lab Med Microbiol & Immunol, Middelburg, Netherlands.	g.rijkers@ucr.nl		Riccardi, Carlo/0000-0001-9257-3997					0	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 13	2021	12								746418	10.3389/fimmu.2021.746418	http://dx.doi.org/10.3389/fimmu.2021.746418			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UL4WF	34484250	gold, Green Published			2022-12-18	WOS:000692652300001
J	Munoz, C; Gonzalez-Lorca, J; Parra, M; Soto, S; Valdes, N; Sandino, AM; Vargas, R; Gonzalez, A; Tello, M				Munoz, Carlos; Gonzalez-Lorca, Josue; Parra, Mick; Soto, Sarita; Valdes, Natalia; Maria Sandino, Ana; Vargas, Rodrigo; Gonzalez, Alex; Tello, Mario			Lactococcus lactis Expressing Type I Interferon From Atlantic Salmon Enhances the Innate Antiviral Immune Response In Vivo and In Vitro	FRONTIERS IN IMMUNOLOGY			English	Article						interferon Ia; Lactococcus lactis; antiviral; IPNV; Atlantic salmon	INFECTIOUS PANCREATIC NECROSIS; ANTIINFLAMMATORY CYTOKINE EXPRESSION; ORAL IMMUNIZATION; LACTOBACILLUS-CASEI; SPRING VIREMIA; ANEMIA-VIRUS; ALPHA-INTERFERON; VIRAL DISEASES; COMMON CARP; G-PROTEIN	In salmon farming, viruses are responsible for outbreaks that produce significant economic losses for which there is a lack of control tools other than vaccines. Type I interferon has been successfully used for treating some chronic viral infections in humans. However, its application in salmonids depends on the proper design of a vehicle that allows its massive administration, ideally orally. In mammals, administration of recombinant probiotics capable of expressing cytokines has shown local and systemic therapeutic effects. In this work, we evaluate the use of Lactococcus lactis as a type I Interferon expression system in Atlantic salmon, and we analyze its ability to stimulate the antiviral immune response against IPNV, in vivo and in vitro. The interferon expressed in L. lactis, even though it was located mainly in the bacterial cytoplasm, was functional, stimulating Mx and PKR expression in CHSE-214 cells, and reducing the IPNV viral load in SHK-1 cells. In vivo, the oral administration of this L. lactis producer of Interferon I increases Mx and PKR expression, mainly in the spleen, and to a lesser extent, in the head kidney. The oral administration of this strain also reduces the IPNV viral load in Atlantic salmon specimens challenged with this pathogen. Our results show that oral administration of L. lactis producing Interferon I induces systemic effects in Atlantic salmon, allowing to stimulate the antiviral immune response. This probiotic could have effects against a wide variety of viruses that infect Atlantic salmon and also be effective in other salmonids due to the high identity among their type I interferons.	[Munoz, Carlos; Gonzalez-Lorca, Josue; Parra, Mick; Soto, Sarita; Valdes, Natalia; Vargas, Rodrigo; Tello, Mario] Univ Santiago Chile, Fac Quim & Biol, Ctr Biotecnol Acuicola, Lab Metagenom Bacteriana,Dept Biol, Santiago, Chile; [Maria Sandino, Ana] Univ Santiago Chile, Fac Quim & Biol, Ctr Biotecnol Acuicola, Lab Virol,Dept Biol, Santiago, Chile; [Maria Sandino, Ana] ActivaQ SA, Santiago, Chile; [Gonzalez, Alex] Univ Lagos, Dept Ciencias Biol & Biodiversidad, Lab Microbiol Ambiental & Extremofilos, Osorno, Chile; [Tello, Mario] IctioBiot SpA, Santiago, Chile	Universidad de Santiago de Chile; Universidad de Santiago de Chile; Universidad de Los Lagos	Tello, M (corresponding author), Univ Santiago Chile, Fac Quim & Biol, Ctr Biotecnol Acuicola, Lab Metagenom Bacteriana,Dept Biol, Santiago, Chile.; Gonzalez, A (corresponding author), Univ Lagos, Dept Ciencias Biol & Biodiversidad, Lab Microbiol Ambiental & Extremofilos, Osorno, Chile.; Tello, M (corresponding author), IctioBiot SpA, Santiago, Chile.	alex.gonzalez@ulagos.cl; mario.tello@usach.cl	González, Alex/GYU-3220-2022; Tello, Mario/N-4198-2019	Tello, Mario/0000-0003-4573-6460; Gonzalez, Alex/0000-0001-9968-8623	Fundacion Innovacion Agraria (FIA) [PYT 2012-0056]	Fundacion Innovacion Agraria (FIA)	This research was funded by Fundacion Innovacion Agraria (FIA), grant number PYT 2012-0056 to MT. The funder was not involved in the study design, collection, analysis, and interpretation of data, the writing of this article or the decision to submit it for publication.	Abid A, 2013, FISH SHELLFISH IMMUN, V35, P1948, DOI 10.1016/j.fsi.2013.09.039; Bain N, 2008, J FISH DIS, V31, P37, DOI 10.1111/j.1365-2761.2007.00864.x; Bayat O, 2014, BIOTECHNOL LETT, V36, P581, DOI 10.1007/s10529-013-1390-4; Belcaid M, 2019, P NATL ACAD SCI USA, V116, P3030, DOI 10.1073/pnas.1817322116; Bergmann SM, 2020, J APPL MICROBIOL, V129, P98, DOI 10.1111/jam.14616; Bermudez-Humaran LG, 2003, INFECT IMMUN, V71, P1887, DOI 10.1128/IAI.71.4.1887-1896.2003; Bermudez-Humaran LG, 2013, CURR OPIN MICROBIOL, V16, P278, DOI 10.1016/j.mib.2013.06.002; Bjorgen H, 2021, IMMUNOGENETICS, V73, P53, DOI 10.1007/s00251-020-01196-0; Chang CJ, 2016, FISH SHELLFISH IMMUN, V57, P35, DOI 10.1016/j.fsi.2016.08.020; Chang CJ, 2015, VACCINE, V33, P2442, DOI 10.1016/j.vaccine.2015.03.093; Chang CJ, 2014, VACCINE, V32, P4695, DOI 10.1016/j.vaccine.2014.05.059; Chen YP, 2020, FISH SHELLFISH IMMUN, V100, P18, DOI 10.1016/j.fsi.2020.03.001; Cui LC, 2015, VACCINE, V33, P3092, DOI 10.1016/j.vaccine.2015.05.002; Dar AC, 2005, CELL, V122, P887, DOI 10.1016/j.cell.2005.06.044; Das BK, 2009, FISH SHELLFISH IMMUN, V26, P40, DOI 10.1016/j.fsi.2008.03.009; Davarpanah E, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0007939; de Andres J, 2018, NUTRIENTS, V10, DOI 10.3390/nu10010014; Deperasinska I, 2018, J VET RES, V62, P1, DOI 10.2478/jvetres-2018-0001; Dick A, 2015, J BIOL CHEM, V290, P12779, DOI 10.1074/jbc.M115.650325; Duan KX, 2018, FISH SHELLFISH IMMUN, V83, P223, DOI 10.1016/j.fsi.2018.09.034; Eriksson-Kallio AM, 2020, DIS AQUAT ORGAN, V141, P103, DOI 10.3354/dao03512; Evensen O, 2013, FISH SHELLFISH IMMUN, V35, P1751, DOI 10.1016/j.fsi.2013.10.021; FAO, 2018, SOFIA 2018 STATE FIS; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Flores-Kossack C, 2020, FISH SHELLFISH IMMUN, V98, P52, DOI 10.1016/j.fsi.2019.12.093; Francois C, 2005, ANTIMICROB AGENTS CH, V49, P3770, DOI 10.1128/AAC.49.9.3770-3775.2005; Freed LL, 2019, FEMS MICROBIOL ECOL, V95, DOI 10.1093/femsec/fiz146; Gorain C, 2020, VACCINE, V38, P1630, DOI 10.1016/j.vaccine.2019.12.064; Hinzke T, 2019, MBIO, V10, DOI 10.1128/mBio.02243-19; Hua XJ, 2021, AQUACULTURE, V535, DOI 10.1016/j.aquaculture.2021.736425; Jacouton E, 2019, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03355; Jensen I, 2002, FISH SHELLFISH IMMUN, V13, P221, DOI 10.1006/fsim.2001.0397; Jia S, 2020, FISH SHELLFISH IMMUN, V105, P327, DOI 10.1016/j.fsi.2020.07.052; Katla S, 2019, ENZYME MICROB TECH, V128, P49, DOI 10.1016/j.enzmictec.2019.05.007; Kelly C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00559; Kibenge FSB, 2016, AQUACULTURE VIROLOGY, P95, DOI 10.1016/B978-0-12-801573-5.00006-1; Kibenge FSB, 2019, CURR OPIN VIROL, V34, P97, DOI 10.1016/j.coviro.2018.12.008; Kibenge FSB, 2012, ANTIVIR RES, V95, P257, DOI 10.1016/j.antiviral.2012.06.003; Kileng O, 2008, FISH SHELLFISH IMMUN, V24, P514, DOI 10.1016/j.fsi.2007.10.005; Kileng O, 2007, FISH SHELLFISH IMMUN, V23, P378, DOI 10.1016/j.fsi.2006.11.011; Kotob MH, 2016, VET RES, V47, DOI 10.1186/s13567-016-0383-4; Langevin C, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030302; Levican J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03036-w; Levican-Asenjo J, 2019, J FISH DIS, V42, P1035, DOI 10.1111/jfd.13009; Li YX, 2021, ANIM MICROBIOME, V3, DOI 10.1186/s42523-020-00071-3; Lilkova E, 2019, J MOL MODEL, V25, DOI 10.1007/s00894-019-4013-8; Lin-Zhao Z, 2021, MICROB PATHOGENESIS, V156, DOI 10.1016/j.micpath.2021.104827; Liu FG, 2020, FISH SHELLFISH IMMUN, V98, P564, DOI 10.1016/j.fsi.2020.01.039; Liu M, 2012, FISH SHELLFISH IMMUN, V32, P196, DOI 10.1016/j.fsi.2011.11.015; Madhun AS, 2016, DIS AQUAT ORGAN, V120, P109, DOI 10.3354/dao03009; Maradonna F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083155; Martin SAM, 2007, PHYSIOL GENOMICS, V32, P33, DOI 10.1152/physiolgenomics.00064.2007; McPherson AC, 2021, TRENDS IMMUNOL, V42, P137, DOI 10.1016/j.it.2020.12.005; Meron D, 2020, MICROB BIOTECHNOL, V13, P770, DOI 10.1111/1751-7915.13537; Mirpuri J, 2010, J IMMUNOL, V184, P7186, DOI 10.4049/jimmunol.0903116; Mobitec GmbH, 2015, NICE EXPR SYST LACT; Naderi-Samani M, 2020, FISH SHELLFISH IMMUN, V105, P62, DOI 10.1016/j.fsi.2020.07.007; Nicolas GR, 2019, TRENDS PHARMACOL SCI, V40, P430, DOI 10.1016/j.tips.2019.04.006; Ooi EL, 2008, DEV COMP IMMUNOL, V32, P1211, DOI 10.1016/j.dci.2008.03.010; Ooi EL, 2008, FISH SHELLFISH IMMUN, V24, P506, DOI 10.1016/j.fsi.2007.10.004; Opazo R, 2016, GENOME ANNOUNCEMENTS, V4, DOI 10.1128/genomeA.00881-16; Parra M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8091320; Pasolli E, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16438-8; Peng XY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24879-x; Perdiguero P, 2019, CELL REP, V29, P4223, DOI 10.1016/j.celrep.2019.11.101; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Phelps D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10517-5; Rawls JF, 2004, P NATL ACAD SCI USA, V101, P4596, DOI 10.1073/pnas.0400706101; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Reyes-Cerpa S, 2014, FISH SHELLFISH IMMUN, V41, P172, DOI 10.1016/j.fsi.2014.08.029; Reyes-Cerpa S, 2012, FISH SHELLFISH IMMUN, V32, P291, DOI 10.1016/j.fsi.2011.11.018; Rimstad E, 2020, J APPL MICROBIOL, V129, P85, DOI 10.1111/jam.14567; Robertsen B, 2003, J INTERF CYTOK RES, V23, P601, DOI 10.1089/107999003322485107; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Schoggins JW, 2011, CURR OPIN VIROL, V1, P519, DOI 10.1016/j.coviro.2011.10.008; Semova I, 2012, CELL HOST MICROBE, V12, P277, DOI 10.1016/j.chom.2012.08.003; Smirne C, 2012, PERITON DIALYSIS INT, V32, P664, DOI 10.3747/pdi.2011.00307; Song AAL, 2017, MICROB CELL FACT, V16, DOI 10.1186/s12934-017-0669-x; Srivastava P, 2005, PROTEIN EXPRES PURIF, V41, P313, DOI 10.1016/j.pep.2004.12.018; Stecher G, 2020, MOL BIOL EVOL, V37, P1237, DOI 10.1093/molbev/msz312; Steidler L, 2000, SCIENCE, V289, P1352, DOI 10.1126/science.289.5483.1352; Stressmann FA, 2021, ISME J, V15, P702, DOI 10.1038/s41396-020-00807-8; Sun B, 2014, DEV COMP IMMUNOL, V47, P275, DOI 10.1016/j.dci.2014.08.007; Surachetpong W, 2020, J FISH DIS, V43, P1115, DOI 10.1111/jfd.13237; Svingerud T, 2013, VIRUS RES, V177, P163, DOI 10.1016/j.virusres.2013.08.004; Svingerud T, 2012, J IMMUNOL, V189, P5912, DOI 10.4049/jimmunol.1201188; Taghinezhad-S S, 2019, MOL THER-METH CLIN D, V15, P40, DOI 10.1016/j.omtm.2019.08.005; Verma AK, 2017, FISH SHELLFISH IMMUN, V67, P141, DOI 10.1016/j.fsi.2017.06.007; Wang JY, 2019, APPL MICROBIOL BIOT, V103, P7931, DOI 10.1007/s00253-019-10094-9; Wang J, 2021, ANIM MICROBIOME, V3, DOI 10.1186/s42523-021-00075-7; Wu ZL, 2005, TOXICON, V46, P471, DOI 10.1016/j.toxicon.2005.06.002; Xu C, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1302-1; Xu C, 2010, J VIROL, V84, P8903, DOI 10.1128/JVI.00851-10; Xu Z, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aay3254; Yao JY, 2016, FISH SHELLFISH IMMUN, V58, P302, DOI 10.1016/j.fsi.2016.09.037; Zhang C, 2020, FISH SHELLFISH IMMUN, V104, P262, DOI 10.1016/j.fsi.2020.06.021; Zhang DX, 2018, FISH SHELLFISH IMMUN, V72, P552, DOI 10.1016/j.fsi.2017.10.043; Zhang L, 2019, MICROB PATHOGENESIS, V133, DOI 10.1016/j.micpath.2019.103552; Zhang QX, 2010, BIOTECHNOL LETT, V32, P1271, DOI 10.1007/s10529-010-0285-x; Zhao LL, 2012, VACCINE, V30, P1823, DOI 10.1016/j.vaccine.2011.12.132; Zhao LN, 2019, MICROB CELL FACT, V18, DOI 10.1186/s12934-019-1195-9; Zheng DP, 2020, CELL RES, V30, P492, DOI 10.1038/s41422-020-0332-7; Zorriehzahra MJ, 2016, VET QUART, V36, P228, DOI 10.1080/01652176.2016.1172132; ZUCKERKANDL EMILE, 1965, P97	104	0	0	3	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 12	2021	12									10.3389/fimmu.2021.696781	http://dx.doi.org/10.3389/fimmu.2021.696781			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UN2GL	34475871	gold, Green Published			2022-12-18	WOS:000693838200001
J	Rahmel, T; Nowak, H; Frisenda, S; Rump, K; Koos, B; Schenker, P; Viebahn, R; Adamzik, M; Bergmann, L				Rahmel, Tim; Nowak, Hartmuth; Frisenda, Sandra; Rump, Katharina; Koos, Bjoern; Schenker, Peter; Viebahn, Richard; Adamzik, Michael; Bergmann, Lars			The Aquaporin 5 -1364A/C Promoter Polymorphism Is Associated With Cytomegalovirus Infection Risk in Kidney Transplant Recipients (vol 10, 2871, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						AQP5; single nucleotide polymorphism (SNP); cytomegalovirus; immunosuppression; infection risk; kidney transplantation			[Rahmel, Tim; Nowak, Hartmuth; Frisenda, Sandra; Rump, Katharina; Koos, Bjoern; Adamzik, Michael; Bergmann, Lars] Univ Knappschaftskrankenhaus Bochum, Klin Anasthesiol Intensivmed & Schmerztherapi, Bochum, Germany; [Schenker, Peter; Viebahn, Richard] Univ Knappschaftskrankenhaus Bochum, Chirurg Klin, Bochum, Germany	Ruhr University Bochum; Ruhr University Bochum	Rahmel, T (corresponding author), Univ Knappschaftskrankenhaus Bochum, Klin Anasthesiol Intensivmed & Schmerztherapi, Bochum, Germany.	Tim.Rahmel@ruhr-uni-bochum.de	Adamzik, Michael/HGE-9286-2022; Rump, Katharina/AAJ-9090-2020	Rump, Katharina/0000-0003-2220-519X				Rahmel T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02871	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 12	2021	12								739229	10.3389/fimmu.2021.739229	http://dx.doi.org/10.3389/fimmu.2021.739229			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UJ6VU	34475876	gold, Green Published			2022-12-18	WOS:000691421900001
J	Xie, SA; Wei, HX; Peng, AP; Xie, AQ; Li, JJ; Fang, C; Shi, FH; Yang, Q; Huang, H; Xie, HY; Pan, XF; Tian, X; Huang, J				Xie, Shihao; Wei, Haixia; Peng, Anping; Xie, Anqi; Li, Jiajie; Fang, Chao; Shi, Feihu; Yang, Quan; Huang, He; Xie, Hongyan; Pan, Xingfei; Tian, Xu; Huang, Jun			Ikzf2 Regulates the Development of ICOS+ Th Cells to Mediate Immune Response in the Spleen of S. japonicum-Infected C57BL/6 Mice	FRONTIERS IN IMMUNOLOGY			English	Article						Schistosoma japonicum; spleen; CD4(+) T cells; ICOS; Ikzf2(Helios)	IFN-GAMMA; PROMOTES; IL-4; EXPRESSION; FAMILY; METHYLATION; BRAIN	Background Th cells (helper T cells) have multiple functions in Schistosoma japonicum (S. japonicum) infection. Inducible co-stimulator (ICOS) is induced and expressed in activated T lymphocytes, which enhances the development of B cells and antibody production through the ICOS/ICOSL pathway. It remains unclear about the role and possible regulating mechanism of ICOS+ Th cells in the spleen of S. japonicum-infected C57BL/6 mice. Methods C57BL/6 mice were infected with cercariae of S. japonicum through the abdomen. The expression of ICOS, activation markers, and the cytokine production on CD4(+) ICOS+ Th cells were detected by flow cytometry (FCM) and quantitative real-time PCR (qRT-PCR). Moreover, the differentially expressed gene data of ICOS+ and ICOS- Th cells from the spleen of infected mice were obtained by mRNA sequencing. Besides, Western blot and chromatin immunoprecipitation (ChIP) were used to explore the role of Ikzf2 on ICOS expression. Results After S. japonicum infection, the expression of ICOS molecules gradually increased in splenic lymphocytes, especially in Th cells (P < 0.01). Compared with ICOS- Th cells, more ICOS+ Th cells expressed CD69, CD25, CXCR5, and CD40L (P < 0.05), while less of them expressed CD62L (P < 0.05). Also, ICOS+ Th cells expressed more cytokines, such as IFN-gamma, IL-4, IL-10, IL-2, and IL-21 (P < 0.05). RNA sequencing results showed that many transcription factors were increased significantly in ICOS+ Th cells, especially Ikzf2 (P < 0.05). And then, the expression of Ikzf2 was verified to be significantly increased and mainly located in the nuclear of ICOS+ Th cells. Finally, ChIP experiments and dual-luciferase reporter assay confirmed that Ikzf2 could directly bind to the ICOS promoter in Th cells. Conclusion In this study, ICOS+ Th cells were found to play an important role in S. japonicum infection to induce immune response in the spleen of C57BL/6 mice. Additionally, Ikzf2 was found to be one important transcription factor that could regulate the expression of ICOS in the spleen of S. japonicum-infected C57BL/6 mice.	[Xie, Shihao; Fang, Chao; Shi, Feihu; Pan, Xingfei] Guangzhou Med Univ, Dept Infect Dis, Key Lab Major Obster Dis Guangdong Prov, Affiliated Hosp 3, Guangzhou, Peoples R China; [Wei, Haixia; Xie, Anqi; Li, Jiajie; Yang, Quan; Huang, He; Xie, Hongyan; Tian, Xu; Huang, Jun] Guangzhou Med Univ, State Key Lab Resp Dis, Guangzhou Inst Resp Hlth, Affiliated Hosp 1, Guangzhou, Peoples R China; [Peng, Anping] Guangzhou Univ Chinese Med, Biol Resource Ctr, Affiliated Hosp 2, Guangzhou, Peoples R China; [Tian, Xu] Guangzhou Med Univ, Coll Pharm, Guangzhou, Peoples R China; [Huang, Jun] Guangzhou Med Univ, Sino French Hoffmann Inst, Key Lab Immunol, Guangzhou, Peoples R China	Guangzhou Medical University; Guangzhou Medical University; State Key Laboratory of Respiratory Disease; Guangzhou University of Chinese Medicine; Guangzhou Medical University; Guangzhou Medical University	Pan, XF (corresponding author), Guangzhou Med Univ, Dept Infect Dis, Key Lab Major Obster Dis Guangdong Prov, Affiliated Hosp 3, Guangzhou, Peoples R China.; Tian, X; Huang, J (corresponding author), Guangzhou Med Univ, State Key Lab Resp Dis, Guangzhou Inst Resp Hlth, Affiliated Hosp 1, Guangzhou, Peoples R China.; Tian, X (corresponding author), Guangzhou Med Univ, Coll Pharm, Guangzhou, Peoples R China.; Huang, J (corresponding author), Guangzhou Med Univ, Sino French Hoffmann Inst, Key Lab Immunol, Guangzhou, Peoples R China.	panxf0125@163.com; xtian@gzhmu.edu.cn; hj165@sina.com			Natural Science Foundation of China [81771696, 81802024]; Natural Science Foundation of Guangdong Province [2020A1515010251, 2021A1515011032, 2018A030313217]; Guangzhou Science and Technology Project [202002030082]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Guangzhou Science and Technology Project	Funding This research was supported by grants from the Natural Science Foundation of China (81771696, 81802024), the Natural Science Foundation of Guangdong Province (2020A1515010251, 2021A1515011032, 2018A030313217), and Guangzhou Science and Technology Project (202002030082).	Amatore F, 2020, EXPERT OPIN BIOL TH, V20, P141, DOI 10.1080/14712598.2020.1693540; Beischlag TV, 2018, METHODS MOL BIOL, V1689, P103, DOI 10.1007/978-1-4939-7380-4_9; Burke ML, 2009, PARASITE IMMUNOL, V31, P163, DOI 10.1111/j.1365-3024.2009.01098.x; Cai MS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00549; Cha HF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01045; Chen DH, 2016, IMMUNOLOGY, V149, P25, DOI 10.1111/imm.12623; Chen X., 2020, XI BAO YU FEN ZI MIA, V36, P1102, DOI [10.13423/j.cnki.cjcmi.009116, DOI 10.13423/J.CNKI.CJCMI.009116]; Choi JY, 2020, NAT IMMUNOL, V21, P777, DOI 10.1038/s41590-020-0706-5; Cippitelli M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031103; Ding S, 2020, CELL MOL IMMUNOL, V17, P474, DOI 10.1038/s41423-019-0268-3; Gadani SP, 2012, J IMMUNOL, V189, P4213, DOI 10.4049/jimmunol.1202246; Guo YX, 2017, J IMMUNOL, V198, P4490, DOI 10.4049/jimmunol.1601988; Heim L, 2018, CANCER RES, V78, P3619, DOI 10.1158/0008-5472.CAN-17-3297; Heizmann B, 2018, CURR OPIN IMMUNOL, V51, P14, DOI 10.1016/j.coi.2017.11.005; Ho IC, 2016, ADV EXP MED BIOL, V941, P31, DOI 10.1007/978-94-024-0921-5_3; Hoshi Y, 2016, FEBS LETT, V590, P270, DOI 10.1002/1873-3468.12042; Huang YK, 2019, J BIOL CHEM, V294, P16152, DOI 10.1074/jbc.RA119.009883; John LB, 2011, MOL IMMUNOL, V48, P1272, DOI 10.1016/j.molimm.2011.03.006; Kak Gunjan, 2018, BioMolecular Concepts, V9, P64, DOI 10.1515/bmc-2018-0007; Kimura MY, 2019, SEMIN IMMUNOPATHOL, V41, P349, DOI 10.1007/s00281-019-00734-7; Kroenke MA, 2012, J IMMUNOL, V188, P3734, DOI 10.4049/jimmunol.1103246; Langenberg MCC, 2020, NAT MED, V26, P326, DOI 10.1038/s41591-020-0759-x; Le KS, 2018, BLOOD ADV, V2, P1889, DOI 10.1182/bloodadvances.2018017244; Li LT, 2019, CANCER MANAG RES, V11, P9749, DOI 10.2147/CMAR.S213769; Li L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02422-8; Metzger TC, 2016, CANCER RES, V76, P3684, DOI 10.1158/0008-5472.CAN-15-3412; Ng MSF, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aav5947; Nouailles G, 2011, EUR J IMMUNOL, V41, P981, DOI 10.1002/eji.201040608; Parker MH, 2021, TRANSPLANTATION, V105, P1008, DOI 10.1097/TP.0000000000003489; Powell MD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01299; Rivas MN, 2016, J ALLERGY CLIN IMMUN, V138, P801, DOI 10.1016/j.jaci.2016.02.030; Scales HE, 2004, EUR J IMMUNOL, V34, P2854, DOI 10.1002/eji.200324364; Shen J, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.02092; Shi WW, 2020, INT IMMUNOPHARMACOL, V82, DOI 10.1016/j.intimp.2020.106295; Sonar SA, 2017, IMMUNOL CELL BIOL, V95, P843, DOI 10.1038/icb.2017.56; Sun YL, 2021, ANAL BIOCHEM, V612, DOI 10.1016/j.ab.2020.114021; Suurvali J, 2015, SCAND J IMMUNOL, V81, P23, DOI 10.1111/sji.12250; Thornton AM, 2019, IMMUNOLOGY, V158, P161, DOI 10.1111/imm.13115; van der Vlugt LEPM, 2017, INT J PARASITOL, V47, P545, DOI 10.1016/j.ijpara.2017.02.002; Wang MM, 2018, J INTERF CYTOK RES, V38, P86, DOI 10.1089/jir.2017.0031; Watatani Y, 2019, LEUKEMIA, V33, P2867, DOI 10.1038/s41375-019-0473-1; Werner JM, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/8175810; Wikenheiser DJ, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00304; Xia TQ, 2020, PARASITE VECTOR, V13, DOI 10.1186/s13071-020-04457-9; Xiao JL, 2020, PARASITE VECTOR, V13, DOI 10.1186/s13071-020-04015-3; Yang Q, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02154; Ye MJ, 2020, ONCOL LETT, V20, DOI 10.3892/ol.2020.11862; Zheng B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00061; Zhu X, 2020, NUCLEIC ACIDS RES, V48, P6563, DOI 10.1093/nar/gkaa441; Zhu YY, 2019, J EXP MED, V216, P1664, DOI 10.1084/jem.20190337	50	0	0	5	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 12	2021	12									10.3389/fimmu.2021.687919	http://dx.doi.org/10.3389/fimmu.2021.687919			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UN2IJ	34475870	gold, Green Published			2022-12-18	WOS:000693843200001
J	McQuiston, A; Emtiazjoo, A; Angel, P; Machuca, T; Christie, J; Atkinson, C				McQuiston, Alexander; Emtiazjoo, Amir; Angel, Peggi; Machuca, Tiago; Christie, Jason; Atkinson, Carl			Set Up for Failure: Pre-Existing Autoantibodies in Lung Transplant	FRONTIERS IN IMMUNOLOGY			English	Review						lung transplant; complement; Autoantibodies; primary graft dysfunction; chronic lung allograft dysfunction; glycans	PRIMARY GRAFT DYSFUNCTION; II TYPE-1 RECEPTOR; BRONCHIOLITIS OBLITERANS SYNDROME; IDIOPATHIC PULMONARY-FIBROSIS; LEUKOCYTE ANTIGEN ANTIBODIES; HLA ANTIBODIES; GENE 5; PRETRANSPLANT ANTIBODIES; ANTIVIMENTIN ANTIBODIES; ACTIVATING ANTIBODIES	Lung transplant patients have the lowest long-term survival rates compared to other solid organ transplants. The complications after lung transplantation such as primary graft dysfunction (PGD) and ultimately chronic lung allograft dysfunction (CLAD) are the main reasons for this limited survival. In recent years, lung-specific autoantibodies that recognize non-HLA antigens have been hypothesized to contribute to graft injury and have been correlated with PGD, CLAD, and survival. Mounting evidence suggests that autoantibodies can develop during pulmonary disease progression before lung transplant, termed pre-existing autoantibodies, and may participate in allograft injury after transplantation. In this review, we summarize what is known about pulmonary disease autoantibodies, the relationship between pre-existing autoantibodies and lung transplantation, and potential mechanisms through which pre-existing autoantibodies contribute to graft injury and rejection.	[McQuiston, Alexander] Med Univ South Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA; [McQuiston, Alexander; Emtiazjoo, Amir; Atkinson, Carl] Univ Florida, Div Pulm Crit Care & Sleep Med, Gainesville, FL 32611 USA; [Angel, Peggi] Med Univ South Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA; [Machuca, Tiago] Univ Florida, Dept Surg, Gainesville, FL USA; [Christie, Jason] Univ Penn, Dept Med, Philadelphia, PA 19104 USA	Medical University of South Carolina; State University System of Florida; University of Florida; Medical University of South Carolina; State University System of Florida; University of Florida; University of Pennsylvania	Atkinson, C (corresponding author), Univ Florida, Div Pulm Crit Care & Sleep Med, Gainesville, FL 32611 USA.	carl.atkinson@medicine.ufl.edu			NIH [NHLBI R1R01HL 140470-01A1, NHLBI 3RO1HL140470-03S1, NIAID U01 AI132894-01, TL1 TR001451, U01CA242096, NHLBI K24-HL115354, NHLBI R01HL087115, NHLBI U01-HL145435]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	These studies were supported by grants from the NIH (NHLBI R1R01HL 140470-01A1, NHLBI 3RO1HL140470-03S1 and NIAID U01 AI132894-01 to CA), TL1 TR001451 to AM, U01CA242096 to PMA (multi-PI), (NHLBI K24-HL115354, NHLBI R01HL087115, and NHLBI U01-HL145435 to JC).	Aleyd E, 2015, IMMUNOL REV, V268, P123, DOI 10.1111/imr.12337; Allenbach Y, 2016, AM J PATHOL, V186, P691, DOI 10.1016/j.ajpath.2015.11.010; Altun GT, 2015, TURK J ANAESTHESIOL, V43, P418, DOI 10.5152/TJAR.2015.16443; Arnold JN, 2007, ANNU REV IMMUNOL, V25, P21, DOI 10.1146/annurev.immunol.25.022106.141702; Arnold ML, 2014, TRANSPL INT, V27, P253, DOI 10.1111/tri.12206; Atkinson C, 2015, CIRCULATION, V131, P1171, DOI 10.1161/CIRCULATIONAHA.114.010482; Avrameas S, 2013, J AUTOIMMUN, V41, P46, DOI 10.1016/j.jaut.2013.01.006; Bauhammer J, 2016, J RHEUMATOL, V43, P1566, DOI 10.3899/jrheum.150844; Benfaremo D, 2020, EUR J RHEUMATOL, V7, pS181, DOI 10.5152/eurjrheum.2020.19131; Bharat A, 2016, AM J RESP CELL MOL, V55, P532, DOI 10.1165/rcmb.2016-0077OC; Bharat A, 2010, ANN THORAC SURG, V90, P1094, DOI 10.1016/j.athoracsur.2010.06.009; Bon J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105066; Bondt A, 2014, MOL CELL PROTEOMICS, V13, P3029, DOI 10.1074/mcp.M114.039537; Breedveld A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00553; Budding K, 2015, J CYST FIBROS, V14, P42, DOI 10.1016/j.jcf.2014.07.007; Burton CM, 2007, EUR J CARDIO-THORAC, V31, P75, DOI 10.1016/j.ejcts.2006.10.024; Byrne R, 2019, IMMUNOL LETT, V214, P8, DOI 10.1016/j.imlet.2019.08.007; Cao H, 2012, ARTHRIT CARE RES, V64, P1602, DOI 10.1002/acr.21728; Cardinal H, 2017, J AM SOC NEPHROL, V28, P400, DOI 10.1681/ASN.2016070756; Chaisson NF, 2012, MEDICINE, V91, P220, DOI 10.1097/MD.0b013e3182606f0b; Chambers DC, 2017, J HEART LUNG TRANSPL, V36, P1047, DOI 10.1016/j.healun.2017.07.016; Cheng GL, 2016, CLIN LAB, V62, P1101, DOI 10.7754/Clin.Lab.2015.151020; Cobb BA, 2020, GLYCOBIOLOGY, V30, P202, DOI 10.1093/glycob/cwz065; Cojocaru Manole, 2011, Maedica (Bucur), V6, P224; Rocha-Munoz AD, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/151626; de Haan N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01238; Dekkers G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00553; Dekkers G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00877; Diamond JM, 2013, AM J RESP CRIT CARE, V187, P527, DOI 10.1164/rccm.201210-1865OC; Dragun D, 2005, NEW ENGL J MED, V352, P558, DOI 10.1056/NEJMoa035717; Duncan SR, 2012, NATURE, V489, pS15, DOI 10.1038/489S15a; Elkon K, 2008, NAT CLIN PRACT RHEUM, V4, P491, DOI 10.1038/ncprheum0895; Elvington A, 2012, J IMMUNOL, V188, P1460, DOI 10.4049/jimmunol.1102132; Feghali-Bostwick CA, 2008, AM J RESP CRIT CARE, V177, P156, DOI 10.1164/rccm.200701-014OC; Feghali-Bostwick CA, 2011, AM J RESP CRIT CARE, V183, P692, DOI 10.1164/rccm.201010-1727ED; Fischer A, 2015, EUR RESPIR J, V46, P976, DOI 10.1183/13993003.00150-2015; Fuss A, 2015, NEPHROLOGY, V20, P467, DOI 10.1111/nep.12441; Giles JT, 2014, ANN RHEUM DIS, V73, P1487, DOI 10.1136/annrheumdis-2012-203160; Giral M, 2013, AM J TRANSPLANT, V13, P2567, DOI 10.1111/ajt.12397; Giwa S, 2017, NAT BIOTECHNOL, V35, P530, DOI 10.1038/nbt.3889; Glanville AR, 2019, J HEART LUNG TRANSPL, V38, P483, DOI 10.1016/j.healun.2019.03.008; Goers TA, 2008, J IMMUNOL, V180, P4487, DOI 10.4049/jimmunol.180.7.4487; Gonzalez-Almada A, 2019, TRANSPL IMMUNOL, V54, P1, DOI 10.1016/j.trim.2018.10.003; Gouda TM, 2014, EGYPT J CHEST DIS TU, V63, P49, DOI 10.1016/j.ejcdt.2013.11.001; Goulabchand R, 2014, AUTOIMMUN REV, V13, P742, DOI 10.1016/j.autrev.2014.02.005; Gudelja I, 2018, CELL IMMUNOL, V333, P65, DOI 10.1016/j.cellimm.2018.07.009; Gunther J, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4503; Hachem RR, 2010, J HEART LUNG TRANSPL, V29, P973, DOI 10.1016/j.healun.2010.05.006; Hagedorn PH, 2011, IMMUNOLOGY, V132, P394, DOI 10.1111/j.1365-2567.2010.03373.x; Hagedorn PH, 2010, IMMUNOLOGY, V130, P427, DOI 10.1111/j.1365-2567.2010.03246.x; Halloran K, 2020, AM J TRANSPLANT, V20, P954, DOI 10.1111/ajt.15685; Hansen IS, 2019, CELL MOL LIFE SCI, V76, P1041, DOI 10.1007/s00018-018-2976-8; Ederveen ALH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207635; Honger G, 2011, TRANSPLANTATION, V92, P41, DOI 10.1097/TP.0b013e31821cdf0d; Hu JY., 2017, SCI REP-UK, V7, P1, DOI [10.1038/srep43962, DOI 10.1038/SREP43962]; Iwata T, 2008, J IMMUNOL, V181, P5738, DOI 10.4049/jimmunol.181.8.5738; Jee AS, 2017, J CLIN MED, V6, DOI 10.3390/jcm6050051; Kaneku H, 2012, LIVER TRANSPLANT, V18, P984, DOI 10.1002/lt.23451; Kawai T, 2017, PHARMACOL RES, V125, P4, DOI 10.1016/j.phrs.2017.05.008; Kaza V, 2021, HUM IMMUNOL, V82, P25, DOI 10.1016/j.humimm.2020.10.006; Kaza V, 2020, TRANSPL IMMUNOL, V59, DOI 10.1016/j.trim.2020.101271; Kheradmand F, 2012, EXPERT REV CLIN IMMU, V8, P285, DOI [10.1586/ECI.12.7, 10.1586/eci.12.7]; Kirkham PA, 2011, AM J RESP CRIT CARE, V184, P796, DOI 10.1164/rccm.201010-1605OC; Koneczny I, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00097; Krapp S, 2003, J MOL BIOL, V325, P979, DOI 10.1016/S0022-2836(02)01250-0; Kulik L, 2009, J IMMUNOL, V182, P5363, DOI 10.4049/jimmunol.0803980; Kuo YB, 2010, IMMUNOL LETT, V128, P131, DOI 10.1016/j.imlet.2009.12.017; Lee SH, 2007, NAT MED, V13, P567, DOI 10.1038/nm1583; Lefaucheur C, 2019, KIDNEY INT, V96, P189, DOI 10.1016/j.kint.2019.01.030; Li FJ, 2017, J IMMUNOL, V199, P1596, DOI 10.4049/jimmunol.1700473; Lopez-Soler RI, 2016, TRANSPL P, V48, P2023, DOI 10.1016/j.transproceed.2016.04.009; Lukitsch I, 2012, TRANSPLANTATION, V94, P8, DOI 10.1097/TP.0b013e3182529bb7; Luo XM, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.57; Ma AP, 2020, INT J CHRONIC OBSTR, V15, P189, DOI 10.2147/COPD.S235903; Majo J, 2001, EUR RESPIR J, V17, P946, DOI 10.1183/09031936.01.17509460; Maverakis E, 2015, J AUTOIMMUN, V57, P1, DOI 10.1016/j.jaut.2014.12.002; Morissette MC, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-49; Morrell MR, 2014, J HEART LUNG TRANSPL, V33, P1288, DOI 10.1016/j.healun.2014.07.018; Murthy SC, 2018, J THORAC CARDIOV SUR, V156, P882, DOI 10.1016/j.jtcvs.2018.03.165; Nagele EP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060726; Noro D, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081731; NOSE M, 1983, P NATL ACAD SCI-BIOL, V80, P6632, DOI 10.1073/pnas.80.21.6632; Nunez B, 2011, AM J RESP CRIT CARE, V183, P1025, DOI 10.1164/rccm.201001-0029OC; Nunoda S, 2019, CURR OPIN ORGAN TRAN, V24, P220, DOI 10.1097/MOT.0000000000000629; PAREKH RB, 1985, NATURE, V316, P452, DOI 10.1038/316452a0; Patel KJ, 2019, AM J RESP CELL MOL, V60, P678, DOI 10.1165/rcmb.2018-0224OC; Pavic T, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1695-0; Pearl MH, 2020, KIDNEY INT REP, V5, P1925, DOI 10.1016/j.ekir.2020.09.004; Peschke B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00646; Petrenko A, 2019, TRANSFUS MED HEMOTH, V46, P151, DOI 10.1159/000499610; Plomp R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12495-0; Rao U, 2019, TRANSPL IMMUNOL, V54, P65, DOI 10.1016/j.trim.2019.02.006; Rasheed N, 2019, INT J HEALTH SCI-IJH, V13, P1; Reily C, 2019, NAT REV NEPHROL, V15, P346, DOI 10.1038/s41581-019-0129-4; Reinsmoen NL, 2013, HUM IMMUNOL, V74, P1474, DOI 10.1016/j.humimm.2013.06.034; Reinsmoen NL, 2010, TRANSPLANTATION, V90, P1473, DOI 10.1097/TP.0b013e3181fd97f1; Rinaldi M, 2012, THORAX, V67, P694, DOI 10.1136/thoraxjnl-2011-200690; Rose ML, 2013, HUM IMMUNOL, V74, P1459, DOI 10.1016/j.humimm.2013.06.006; Safavi S, 2014, J HEART LUNG TRANSPL, V33, P1273, DOI 10.1016/j.healun.2014.07.012; Sato S, 2009, ARTHRITIS RHEUM-US, V60, P2193, DOI 10.1002/art.24621; Schroeder HW, 2010, J ALLERGY CLIN IMMUN, V125, pS41, DOI 10.1016/j.jaci.2009.09.046; Sontheimer RD, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.03.94; Sorohan BM, 2020, TRANSPLANT REV-ORLAN, V34, DOI 10.1016/j.trre.2020.100573; Strzelak A, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15051033; Sureshbabu A, 2020, TRANSPL INT, V33, P41, DOI 10.1111/tri.13487; Susal C, 2000, TRANSPLANTATION, V69, P1337; Suzuki Y, 2013, SEMIN RESP CRIT CARE, V34, P305, DOI 10.1055/s-0033-1348474; Taille C, 2011, AM J RESP CRIT CARE, V183, P759, DOI 10.1164/rccm.201001-0076OC; Thabut G, 2017, J THORAC DIS, V9, P2684, DOI 10.21037/jtd.2017.07.85; Thomas KA, 2015, TRENDS MOL MED, V21, P319, DOI 10.1016/j.molmed.2015.02.004; Tiriveedhi V, 2013, J HEART LUNG TRANSPL, V32, P807, DOI 10.1016/j.healun.2013.06.003; Valenzuela NM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00433; Verhelst X, 2019, ACTA GASTRO-ENT BELG, V82, P309; Verhelst X, 2020, GASTROENTEROLOGY, V158, P95, DOI 10.1053/j.gastro.2019.08.060; Verhelst X, 2018, GASTROENTEROLOGY, V154, P1361, DOI 10.1053/j.gastro.2017.12.027; Verleden GM, 2019, J HEART LUNG TRANSPL, V38, P493, DOI 10.1016/j.healun.2019.03.009; Vinson AD, 2018, OCHSNER J, V18, P260, DOI 10.31486/toj.17.0068; Wada R, 2019, MABS-AUSTIN, V11, P350, DOI 10.1080/19420862.2018.1551044; Watts RP, 2013, J TRANSPLANT, V2013, DOI 10.1155/2013/521369; Weigold F, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1545-8; Weigt SS, 2013, SEMIN RESP CRIT CARE, V34, P336, DOI 10.1055/s-0033-1348467; Wen LF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00066; Willemse BWM, 2004, EUR RESPIR J, V23, P464, DOI 10.1183/09031936.04.00012704; Wuhrer M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0450-1; Xiao ZX, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2020.102743; Xiong Y, 2017, ARCH MED RES, V48, P79, DOI 10.1016/j.arcmed.2017.01.007; Yamaguchi Y, 2006, BBA-GEN SUBJECTS, V1760, P693, DOI 10.1016/j.bbagen.2005.10.002; Yang ML, 2018, ANTIOXID REDOX SIGN, V29, P1415, DOI 10.1089/ars.2017.7382; Yang Y, 2002, CLIN EXP IMMUNOL, V128, P169, DOI 10.1046/j.1365-2249.2002.01811.x; Yoshida S, 2006, AM J TRANSPLANT, V6, P724, DOI 10.1111/j.1600-6143.2006.01236.x; Zaffiri L, 2019, TRANSPL IMMUNOL, V56, DOI 10.1016/j.trim.2019.101224; Zhang M, 2006, J EXP MED, V203, P141, DOI 10.1084/jem.20050390; Zhang M, 2004, P NATL ACAD SCI USA, V101, P3886, DOI 10.1073/pnas.0400347101; Zhang M, 2008, MOL IMMUNOL, V45, P4036, DOI 10.1016/j.molimm.2008.06.013; Zhang XH, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00434; Zhou X, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102804	136	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 11	2021	12									10.3389/fimmu.2021.711102	http://dx.doi.org/10.3389/fimmu.2021.711102			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UN2JF	34456920	Green Published, gold			2022-12-18	WOS:000693845400001
J	Yi, HA; Jiang, WY; Yang, F; Li, F; Li, YR; Zhu, WJ; Li, Q; Fakhar, SH; Cao, YM; Luo, L; Zhang, W; He, YS				Yi, Haoan; Jiang, Weiyang; Yang, Fang; Li, Fan; Li, Yirong; Zhu, Wenjing; Li, Qing; Fakhar, Syed Hassam; Cao, Yaming; Luo, Lan; Zhang, Wen; He, Yongshu			G6pd-Deficient Mice Are Protected From Experimental Cerebral Malaria and Liver Injury by Suppressing Proinflammatory Response in the Early Stage of Plasmodium berghei Infection	FRONTIERS IN IMMUNOLOGY			English	Article						G6PD deficiency; Plasmodium berghei; proinflammatory response; experimental cerebral malaria; acute liver injury	CD8(+) T-CELLS; HEME OXYGENASE-1; SEQUESTRATION; DEFICIENCY; RECEPTOR; BRAIN; BETA	Epidemiological studies provide compelling evidence that glucose-6-phosphate dehydrogenase (G6PD) deficiency individuals are relatively protected against Plasmodium parasite infection. However, the animal model studies on this subject are lacking. Plus, the underlying mechanism in vivo is poorly known. In this study, we used a G6pd-deficient mice infected with the rodent parasite Plasmodium berghei (P.berghei) to set up a malaria model in mice. We analyzed the pathological progression of experimental cerebral malaria (ECM) and acute liver injury in mice with different G6pd activity infected with P.berghei. We performed dual RNA-seq for host-parasite transcriptomics and validated the changes of proinflammatory response in the murine model. G6pd-deficient mice exhibited a survival advantage, less severe ECM and mild liver injury compared to the wild type mice. Analysis based on dual RNA-seq suggests that G6pd-deficient mice are protected from ECM and acute liver injury were related to proinflammatory responses. Th1 differentiation and dendritic cell maturation in the liver and spleen were inhibited in G6pd-deficient mice. The levels of proinflammatory cytokines were reduced, chemokines and vascular adhesion molecules in the brain were significantly down-regulated, these led to decreased cerebral microvascular obstruction in G6pd-deficient mice. We generated the result that G6pd-deficiency mediated protection against ECM and acute liver injury were driven by the regulatory proinflammatory responses. Furthermore, bioinformatics analyses showed that P.berghei might occur ribosome loss in G6pd-deficient mice. Our findings provide a novel perspective of the underlying mechanism of G6PD deficiency mediated protection against malaria in vivo.	[Yi, Haoan; Jiang, Weiyang; Yang, Fang; Li, Qing; Luo, Lan; Zhang, Wen; He, Yongshu] Kunming Med Univ, Dept Cell Biol & Med Genet, Kunming, Yunnan, Peoples R China; [Li, Fan] Kunming Med Univ, Dept Pathol & Pathophysiol, Kunming, Yunnan, Peoples R China; [Li, Yirong] Kunming Med Univ, Sch Pharmaceut Sci, Kunming, Yunnan, Peoples R China; [Li, Yirong] Kunming Med Univ, Yunnan Key Lab Pharmacol Nat Prod, Kunming, Yunnan, Peoples R China; [Zhu, Wenjing] Kunming Med Univ, Sch Basic Med, Dept Human Anat Histol & Embryol, Kunming, Yunnan, Peoples R China; [Fakhar, Syed Hassam] Kunming Med Univ, Sch Publ Hlth, Kunming, Yunnan, Peoples R China; [Cao, Yaming] China Med Univ, Coll Basic Med Sci, Dept Immunol, Shenyang, Peoples R China	Kunming Medical University; Kunming Medical University; Kunming Medical University; Kunming Medical University; Kunming Medical University; Kunming Medical University; China Medical University	He, YS (corresponding author), Kunming Med Univ, Dept Cell Biol & Med Genet, Kunming, Yunnan, Peoples R China.	heyongshu@kmmu.edu.cn			National Natural Science Foundation of China [31760308]; Graduate Innovation Foundation of Kunming Medical University [2021D03]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Graduate Innovation Foundation of Kunming Medical University	This work was supported by the National Natural Science Foundation of China (#31760308) and Graduate Innovation Foundation of Kunming Medical University (2021D03).	Adachi K, 2001, J IMMUNOL, V167, P5928, DOI 10.4049/jimmunol.167.10.5928; Ayi K, 2004, BLOOD, V104, P3364, DOI 10.1182/blood-2003-11-3820; Belnoue E, 2002, J IMMUNOL, V169, P6369, DOI 10.4049/jimmunol.169.11.6369; Campanella GSV, 2008, P NATL ACAD SCI USA, V105, P4814, DOI 10.1073/pnas.0801544105; Cappadoro M, 1998, BLOOD, V92, P2527, DOI 10.1182/blood.V92.7.2527.2527_2527_2534; Chen X, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j4263; Chu CS, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2248-y; Clarke GM, 2017, ELIFE, V6, DOI [10.7554/elife.15085, 10.7554/eLIFE.15085, 10.7554/eLife.15085]; Cunningham DA, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1834-8; Deng ZS, 2018, J INFECTION, V77, P435, DOI 10.1016/j.jinf.2018.06.005; Dey S, 2012, J BIOL CHEM, V287, P26630, DOI 10.1074/jbc.M112.341255; Diouf I, 2007, J REPROD IMMUNOL, V74, P152, DOI 10.1016/j.jri.2006.10.001; Dobano C, 2019, CLIN INFECT DIS, V69, P820, DOI 10.1093/cid/ciy934; Dunst J, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00324; Ferreira A, 2011, CELL, V145, P398, DOI 10.1016/j.cell.2011.03.049; Franke-Fayard B, 2005, P NATL ACAD SCI USA, V102, P11468, DOI 10.1073/pnas.0503386102; Frevert U, 2014, PARASITOL INT, V63, P171, DOI 10.1016/j.parint.2013.09.013; Ghergurovich JM, 2020, NAT CHEM BIOL, V16, P731, DOI 10.1038/s41589-020-0533-x; Gowda DC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03006; Haque A, 2011, J IMMUNOL, V186, P6148, DOI 10.4049/jimmunol.1003955; Joste V, 2020, MBIO, V11, DOI 10.1128/mBio.02103-20; Kariuki SN, 2020, HUM GENET, V139, P801, DOI 10.1007/s00439-020-02142-6; Keswani T, 2016, CYTOKINE, V88, P154, DOI 10.1016/j.cyto.2016.08.034; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kinra P, 2013, TROP BIOMED, V30, P645; Kochar D K, 2003, J Assoc Physicians India, V51, P1069; Kurup SP, 2019, NAT REV IMMUNOL, V19, P457, DOI 10.1038/s41577-019-0158-z; Loevenich K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00152; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Luzolo AL, 2019, BRAIN RES BULL, V145, P53, DOI 10.1016/j.brainresbull.2019.01.010; Luzzatto L, 2020, BLOOD, V136, P1225, DOI 10.1182/blood.2019000944; Luzzatto L, 2014, BRIT J HAEMATOL, V164, P469, DOI 10.1111/bjh.12665; Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551; McQuillan JA, 2011, INT J PARASITOL, V41, P155, DOI 10.1016/j.ijpara.2010.08.003; Moore BR, 2018, EBIOMEDICINE, V37, P15, DOI 10.1016/j.ebiom.2018.10.023; Nautiyal Amit, 2005, MedGenMed, V7, P8; Netea MG, 2000, CLIN INFECT DIS, V31, pS178, DOI 10.1086/317513; Pais TF, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03100; Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586; PRETSCH W, 1988, BIOCHEM GENET, V26, P89, DOI 10.1007/BF00555491; Ramos S, 2019, P NATL ACAD SCI USA, V116, P5681, DOI 10.1073/pnas.1822024116; Sahu PK, 2015, FRONT CELL INFECT MI, V5, DOI 10.3389/fcimb.2015.00075; Schmid U, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00027; Sebina I, 2018, IMMUNOLOGY, V155, P176, DOI 10.1111/imm.12971; Seixas E, 2009, P NATL ACAD SCI USA, V106, P15837, DOI 10.1073/pnas.0903419106; Shan Y, 2013, KOREAN J PARASITOL, V51, P289, DOI 10.3347/kjp.2013.51.3.289; Shelton P, 2013, FASEB J, V27, P414, DOI 10.1096/fj.12-217257; Sorensen EW, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98911; van der Heyde HC, 2006, TRENDS PARASITOL, V22, P503, DOI 10.1016/j.pt.2006.09.002; Westermann AJ, 2012, NAT REV MICROBIOL, V10, P618, DOI 10.1038/nrmicro2852; Wunderlich F, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00559; Yang HC, 2016, FREE RADICAL RES, V50, P1047, DOI 10.1080/10715762.2016.1223296; Yang Z, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7151; Yi HA, 2019, INFECT GENET EVOL, V75, DOI 10.1016/j.meegid.2019.103980	54	0	0	2	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 11	2021	12								719189	10.3389/fimmu.2021.719189	http://dx.doi.org/10.3389/fimmu.2021.719189			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UE6TB	34456927	Green Published, gold			2022-12-18	WOS:000688017200001
J	Charab, W; Rosenberger, MG; Shivram, H; Mirazee, JM; Donkor, M; Shekhar, SR; Gjuka, D; Khoo, KH; Kim, JE; Iyer, VR; Georgiou, G				Charab, Wissam; Rosenberger, Matthew G.; Shivram, Haridha; Mirazee, Justin M.; Donkor, Moses; Shekhar, Soumya R.; Gjuka, Donjeta; Khoo, Kimberly H.; Kim, Jin Eyun; Iyer, Vishwanath R.; Georgiou, George			IgG Immune Complexes Inhibit Naive T Cell Proliferation and Suppress Effector Function in Cytotoxic T Cells	FRONTIERS IN IMMUNOLOGY			English	Article						T cell activation proliferation and inhibition; Naive and memory T cells; T cell Fc Gamma Receptors (FcgR); T cell antibody receptors; IgG Immune Complexes (ICs); T cell non-canonical Fc Receptors; Antigen and Antibody Immune Complexes; T cell Fc Receptors	FC-GAMMA-RIIB; KAPPA-B ACTIVATION; MEMORY; EXPRESSION; RECEPTORS; IDENTIFICATION; CATENIN; MOUSE; LYMPHOCYTES; DEPOSITION	Elevated levels of circulating immune complexes are associated with autoimmunity and with worse prognoses in cancer. Here, we examined the effects of well-defined, soluble immune complexes (ICs) on human peripheral T cells. We demonstrate that IgG-ICs inhibit the proliferation and differentiation of a subset of naive T cells but stimulate the division of another naive-like T cell subset. Phenotypic analysis by multi-parameter flow cytometry and RNA-Seq were used to characterize the inhibited and stimulated T cells revealing that the inhibited subset presented immature features resembling those of recent thymic emigrants and non-activated naive T cells, whereas the stimulated subset exhibited transcriptional features indicative of a more differentiated, early memory progenitor with a naive-like phenotype. Furthermore, we show that while IgG1 -ICs do not profoundly inhibit the proliferation of memory T cells, IgG1-ICs suppress the production of granzyme-ii and perforin in cytotoxic memory T cells. Our findings reveal how ICs can link humoral immunity and T cell function.	[Charab, Wissam; Georgiou, George] Univ Texas Austin, Dept Chem Engn, Austin, TX 78712 USA; [Rosenberger, Matthew G.; Kim, Jin Eyun; Georgiou, George] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA; [Shivram, Haridha; Mirazee, Justin M.; Donkor, Moses; Shekhar, Soumya R.; Gjuka, Donjeta; Khoo, Kimberly H.; Iyer, Vishwanath R.; Georgiou, George] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Georgiou, G (corresponding author), Univ Texas Austin, Dept Chem Engn, Austin, TX 78712 USA.; Georgiou, G (corresponding author), Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA.; Georgiou, G (corresponding author), Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA.	gg@che.utexas.edu		Kim, Jin Eyun/0000-0002-6297-3292; Rosenberger, Matthew/0000-0002-0595-5338	Clayton Foundation; National Institute of Health [NIH U01AI148118]; University of Texas at Austin	Clayton Foundation; National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Texas at Austin	This work was supported by grants from the Clayton Foundation, the National Institute of Health (NIH U01AI148118), and The University of Texas at Austin.	Acuto O, 2003, NAT REV IMMUNOL, V3, P939, DOI 10.1038/nri1248; Alvarez RV, 2019, BIOINFORMATICS, V35, P1960, DOI 10.1093/bioinformatics/bty896; Blank CU, 2019, NAT REV IMMUNOL, V19, P665, DOI 10.1038/s41577-019-0221-9; Bluestone JA, 2008, NAT MED, V14, P118, DOI 10.1038/nm0208-118; Bruhns P, 2015, IMMUNOL REV, V268, P25, DOI 10.1111/imr.12350; Chauhan AK, 2015, J BIOL CHEM, V290, P5127, DOI 10.1074/jbc.M114.599266; Chen X, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00292; Chenoweth AM, 2020, IMMUNOL CELL BIOL, V98, P287, DOI 10.1111/imcb.12326; Chi H, 2012, NAT REV IMMUNOL, V12, P325, DOI 10.1038/nri3198; Chukwudi Ezeani M, 2017, INT J GENET GENOMICS, V5, P1, DOI [10.11648/j.ijgg.20170501.11, DOI 10.11648/J.IJGG.20170501.11]; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; De Simone G, 2019, J IMMUNOL, V203, P3179, DOI 10.4049/jimmunol.1901072; Delpoux A, 2018, J EXP MED, V215, P575, DOI 10.1084/jem.20170697; Descours B, 2017, NATURE, V543, P564, DOI 10.1038/nature21710; Ding Y, 2008, NAT MED, V14, P162, DOI 10.1038/nm1707; Ewels P, 2016, BIOINFORMATICS, V32, P3047, DOI 10.1093/bioinformatics/btw354; Farber DL, 2014, NAT REV IMMUNOL, V14, P24, DOI 10.1038/nri3567; Faria TV, 2010, RENAL FAILURE, V32, P1223, DOI 10.3109/0886022X.2010.516852; Finney OC, 2019, J CLIN INVEST, V129, P2123, DOI 10.1172/JCI125423; Fiorentini S, 2001, J IMMUNOL, V166, P900, DOI 10.4049/jimmunol.166.2.900; Gamberale R, 2002, LEUKEMIA LYMPHOMA, V43, P251, DOI 10.1080/10428190290006008; Ganesan LP, 2012, J IMMUNOL, V189, P4981, DOI 10.4049/jimmunol.1202017; Gruber T, 2010, IMMUNOL LETT, V132, P6, DOI 10.1016/j.imlet.2010.04.008; HEIER HE, 1977, INT J CANCER, V20, P887, DOI 10.1002/ijc.2910200611; Hogarth PM, 2012, NAT REV DRUG DISCOV, V11, P311, DOI 10.1038/nrd2909; Intlekofer AM, 2005, NAT IMMUNOL, V6, P1236, DOI 10.1038/ni1268; Jameson SC, 2018, IMMUNITY, V48, P214, DOI 10.1016/j.immuni.2018.02.010; Jung ST, 2010, P NATL ACAD SCI USA, V107, P604, DOI 10.1073/pnas.0908590107; Kang S, 2017, J IMMUNOL, V198, P2602, DOI 10.4049/jimmunol.1600281; Kao D, 2015, CELL REP, V13, P2376, DOI 10.1016/j.celrep.2015.11.027; Karsten CM, 2012, NAT MED, V18, P1401, DOI 10.1038/nm.2862; Kerntke C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00118; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kim EH, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00020; Larbi A, 2014, CYTOM PART A, V85A, P25, DOI 10.1002/cyto.a.22351; Levin D, 2015, TRENDS BIOTECHNOL, V33, P27, DOI 10.1016/j.tibtech.2014.11.001; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lux A, 2013, J IMMUNOL, V190, P4315, DOI 10.4049/jimmunol.1200501; Ma B, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00378; Maecker HT, 2012, NAT REV IMMUNOL, V12, P471, DOI [10.1038/nri3229, DOI 10.1038/NRI3229]; Martin M., 2011, EMBNET J, V17, P10, DOI [10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]; Martinez GJ, 2015, IMMUNITY, V42, P265, DOI 10.1016/j.immuni.2015.01.006; Masopust D, 2012, J IMMUNOL, V188, P5811, DOI 10.4049/jimmunol.1102695; Matias D, 2017, BBA-REV CANCER, V1868, P333, DOI 10.1016/j.bbcan.2017.05.007; McFarland RD, 2000, P NATL ACAD SCI USA, V97, P4215, DOI 10.1073/pnas.070061597; Morris AB, 2020, IMMUNITY, V52, P136, DOI 10.1016/j.immuni.2019.12.006; Mota G, 2003, EUR J IMMUNOL, V33, P2197, DOI 10.1002/eji.200323534; Naluyima P, 2019, J IMMUNOL, V203, P2210, DOI 10.4049/jimmunol.1900422; Namekar M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045851; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Nimmerjahn F, 2020, IMMUNITY, V52, P9, DOI 10.1016/j.immuni.2019.12.012; Pekalski ML, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93739; Pennock ND, 2013, ADV PHYSIOL EDUC, V37, P273, DOI 10.1152/advan.00066.2013; Perez D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02644; Pincetic A, 2014, NAT IMMUNOL, V15, P707, DOI 10.1038/ni.2939; Pulko V, 2016, NAT IMMUNOL, V17, P966, DOI 10.1038/ni.3483; Rahimpour A, 2015, J EXP MED, V212, P1095, DOI 10.1084/jem.20142110; Ramakrishna C, 2014, J ALLERGY CLIN IMMUN, V134, P1469, DOI 10.1016/j.jaci.2014.08.049; Ranzani V, 2015, NAT IMMUNOL, V16, P318, DOI 10.1038/ni.3093; Rasoulouniriana D, 2019, J CLIN INVEST, V129, P4151, DOI 10.1172/JCI127590; Reiser J, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/8941260; Roederer M, 2011, CYTOM PART A, V79A, P95, DOI 10.1002/cyto.a.21010; Rojko JL, 2014, TOXICOL PATHOL, V42, P725, DOI 10.1177/0192623314526475; Rudd CE, 2009, IMMUNOL REV, V229, P12, DOI 10.1111/j.1600-065X.2009.00770.x; Rueda D, 2005, IMMUNITY, V23, P551, DOI 10.1016/j.immuni.2005.11.007; Saeys Y, 2016, NAT REV IMMUNOL, V16, P449, DOI 10.1038/nri.2016.56; Schmitz ML, 2006, CELL DEATH DIFFER, V13, P834, DOI 10.1038/sj.cdd.4401845; Sean D, 2007, BIOINFORMATICS, V23, P1846, DOI 10.1093/bioinformatics/btm254; Sharpe AH, 2018, NAT REV IMMUNOL, V18, P153, DOI 10.1038/nri.2017.108; Singer M, 2016, CELL, V166, P1500, DOI 10.1016/j.cell.2016.08.052; Smith KGC, 2010, NAT REV IMMUNOL, V10, P328, DOI 10.1038/nri2762; Smith NL, 2018, CELL, V174, P117, DOI 10.1016/j.cell.2018.05.029; Starbeck-Miller GR, 2014, J IMMUNOL, V192, P35, DOI 10.4049/jimmunol.1302232; Strohl WR, 2018, PROTEIN CELL, V9, P86, DOI 10.1007/s13238-017-0457-8; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tyagarajan S, 2020, MOL THER-METH CLIN D, V16, P136, DOI 10.1016/j.omtm.2019.11.018; van den Broek T, 2018, NAT REV IMMUNOL, V18, P363, DOI 10.1038/s41577-018-0001-y; van Egmond M, 2001, TRENDS IMMUNOL, V22, P205, DOI 10.1016/S1471-4906(01)01873-7; van Stijn A, 2008, J IMMUNOL, V180, P4550, DOI 10.4049/jimmunol.180.7.4550; Veri MC, 2007, IMMUNOLOGY, V121, P392, DOI 10.1111/j.1365-2567.2007.02588.x; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Xiang DM, 2017, HEPATOLOGY, V65, P1566, DOI 10.1002/hep.28919; Youngblood B, 2017, NATURE, V552, P404, DOI 10.1038/nature25144; Zheng CH, 2017, CELL, V169, P1342, DOI 10.1016/j.cell.2017.05.035	86	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 10	2021	12								713704	10.3389/fimmu.2021.713704	http://dx.doi.org/10.3389/fimmu.2021.713704			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6I0OR	34447380	Green Published, gold			2022-12-18	WOS:000885828000001
J	Pastar, I; O'Neill, K; Padula, L; Head, CR; Burgess, JL; Chen, V; Garcia, D; Stojadinovic, O; Hower, S; Plano, GV; Thaller, SR; Tomic-Canic, M; Strbo, N				Pastar, Irena; O'Neill, Katelyn; Padula, Laura; Head, Cheyanne R.; Burgess, Jamie L.; Chen, Vivien; Garcia, Denisse; Stojadinovic, Olivera; Hower, Suzanne; Plano, Gregory V.; Thaller, Seth R.; Tomic-Canic, Marjana; Strbo, Natasa			Staphylococcus epidermidis Boosts Innate Immune Response by Activation of Gamma Delta T Cells and Induction of Perforin-2 in Human Skin (vol 11, 550946, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						perforin-2/mpeg-1; human skin; innate immunity; Staphylococcus epidermidis; gamma delta T cells; cytotoxicity			[Pastar, Irena; Head, Cheyanne R.; Burgess, Jamie L.; Chen, Vivien; Stojadinovic, Olivera; Tomic-Canic, Marjana] Univ Miami, Miller Sch Med, Wound Healing & Regenerat Med Res Program, Dr Phillip Frost Dept Dermatol & Cutaneous Surg, Miami, FL 33136 USA; [O'Neill, Katelyn; Padula, Laura; Garcia, Denisse; Hower, Suzanne; Plano, Gregory V.; Strbo, Natasa] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA; [Thaller, Seth R.] Univ Miami, Miller Sch Med, Dept Surg, Div Plast Surg Dewitt Daughtry, Miami, FL 33136 USA	University of Miami; University of Miami; University of Miami	Tomic-Canic, M (corresponding author), Univ Miami, Miller Sch Med, Wound Healing & Regenerat Med Res Program, Dr Phillip Frost Dept Dermatol & Cutaneous Surg, Miami, FL 33136 USA.; Strbo, N (corresponding author), Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA.	MTcanic@med.miami.edu; nstrbo@med.miami.edu						Pastar I, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.550946	1	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 10	2021	12								741437	10.3389/fimmu.2021.741437	http://dx.doi.org/10.3389/fimmu.2021.741437			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UF1GS	34447392	Green Published, gold			2022-12-18	WOS:000688330400001
J	Petruccioli, E; Petrone, L; Chiacchio, T; Farroni, C; Cuzzi, G; Navarra, A; Vanini, V; Massafra, U; Lo Pizzo, M; Guggino, G; Caccamo, N; Cantini, F; Palmieri, F; Goletti, D				Petruccioli, Elisa; Petrone, Linda; Chiacchio, Teresa; Farroni, Chiara; Cuzzi, Gilda; Navarra, Assunta; Vanini, Valentina; Massafra, Umberto; Lo Pizzo, Marianna; Guggino, Giuliana; Caccamo, Nadia; Cantini, Fabrizio; Palmieri, Fabrizio; Goletti, Delia			Mycobacterium tuberculosis Immune Response in Patients With Immune-Mediated Inflammatory Disease	FRONTIERS IN IMMUNOLOGY			English	Article						tuberculosis; immune-mediated inflammatory disease; M. tuberculosis; IFN-gamma; CD27	EFFECTOR MEMORY PHENOTYPE; T-CELL RESPONSES; ACTIVE TUBERCULOSIS; HLA-E; RISK; BIOMARKERS; INFECTION; ASSAY; PROGRESSION; BIOLOGICS	Subjects with immune-mediated inflammatory diseases (IMID), such as rheumatoid arthritis (RA), have an intrinsic higher probability to develop active-tuberculosis (TB) compared to the general population. The risk ranges from 2.0 to 8.9 in RA patients not receiving therapies. According to the WHO, the RA prevalence varies between 0.3% and 1% and is more common in women and in developed countries. Therefore, the identification and treatment of TB infection (TBI) in this fragile population is important to propose the TB preventive therapy. We aimed to study the M. tuberculosis (Mtb) specific T-cell response to find immune biomarkers of Mtb burden or Mtb clearance in patients with different TB status and different risk to develop active-TB disease. We enrolled TBI subjects as example of Mtb-containment, the active-TB as example of a replicating Mtb status, and the TBI-IMID as fragile population. To study the Mtb-specific response in a condition of possible Mtb sterilization, we longitudinally enrolled TBI subjects and active-TB patients before and after TB therapy. Peripheral blood mononuclear cells were stimulated overnight with Mtb peptides contained in TB1- and TB2-tubes of the Quantiferon-Plus kit. Then, we characterized by cytometry the Mtb-specific CD4 and CD8 T cells. In TBI-IMID, the TB therapy did not affect the ability of CD4 T cells to produce interferon-gamma, tumor necrosis factor-alpha, and interleukin-2, their functional status, and their phenotype. The TB therapy determined a contraction of the triple functional CD4 T cells of the TBI subjects and active-TB patients. The CD45RA(-) CD27(+) T cells stood out as a main subset of the Mtb-specific response in all groups. Before the TB-preventive therapy, the TBI subjects had higher proportion of Mtb-specific CD45RA(-)CD27(+)CD4(+) T cells and the active-TB subjects had higher proportion of Mtb-specific CD45RA(-)CD27(-)CD4(+) T cells compared to other groups. The TBI-IMID patients showed a phenotype similar to TBI, suggesting that the type of IMID and the IMID therapy did not affect the activation status of Mtb-specific CD4 T cells. Future studies on a larger and better-stratified TBI-IMID population will help to understand the change of the Mtb-specific immune response over time and to identify possible immune biomarkers of Mtb-containment or active replication.	[Petruccioli, Elisa; Petrone, Linda; Chiacchio, Teresa; Farroni, Chiara; Cuzzi, Gilda; Vanini, Valentina; Goletti, Delia] Natl Inst Infect Dis Lazzaro Spallazani IRCCS, Translat Res Unit, Rome, Italy; [Navarra, Assunta] Natl Inst Infect Dis Lazzaro Spallanzani IRCCS, Clin Epidemiol Unit, Rome, Italy; [Vanini, Valentina] Natl Inst Infect Dis Lazzaro Spallanzani IRCCS, UOS Profess Sanit Tecn, Rome, Italy; [Massafra, Umberto] S Pietro Fatebenefratelli Hosp, Dept Internal Med, Rome, Italy; [Lo Pizzo, Marianna; Guggino, Giuliana] Univ Palermo, Dept Hlth Promot Mother & Child Care, Internal Med & Med Specialties, Rheumatol Sect, Palermo, Italy; [Caccamo, Nadia] Univ Palermo, Cent Lab Adv Diag & Biomed Res, Palermo, Italy; [Caccamo, Nadia] Univ Palermo, Dept Biomed Neurosci & Adv Diagnost, Palermo, Italy; [Cantini, Fabrizio] Hosp Prato, Azienda USL Toscana Ctr, Rheumatol Dept, Prato, Italy; [Palmieri, Fabrizio] Natl Inst Infect Dis Lazzaro Spallanzani IRCCS, Resp Infect Dis Unit, Rome, Italy	IRCCS Lazzaro Spallanzani; IRCCS Lazzaro Spallanzani; University of Palermo; University of Palermo; University of Palermo; Prato Hospital; IRCCS Lazzaro Spallanzani	Goletti, D (corresponding author), Natl Inst Infect Dis Lazzaro Spallazani IRCCS, Translat Res Unit, Rome, Italy.	delia.goletti@inmi.it	FARRONI, CHIARA/AAC-3567-2022; Petrone, Linda/K-3947-2016; Caccamo, Nadia/J-6808-2018; LO PIZZO, MARIANNA/AHE-7328-2022	FARRONI, CHIARA/0000-0002-2425-9936; Petrone, Linda/0000-0002-2593-3478; Goletti, Delia/0000-0001-8360-4376	Italian Ministry of Health [GR-2018-12367178]	Italian Ministry of Health(Ministry of Health, Italy)	This study was funded by GR-2018-12367178 and Ricerca Corrente by Line four, all funded by Italian Ministry of Health.	Abubakar I, 2018, LANCET INFECT DIS, V18, P1077, DOI 10.1016/S1473-3099(18)30355-4; Adekambi T, 2015, J CLIN INVEST, V125, P1827, DOI 10.1172/JCI77990; Andrews JR, 2012, CLIN INFECT DIS, V54, P784, DOI 10.1093/cid/cir951; [Anonymous], 2002, Bull World Health Organ, V80, P983; Behr MA, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k2738; Caccamo N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02832; Caccamo N, 2022, EUR J IMMUNOL, DOI 10.1002/eji.201445193; Cantini F, 2020, EXPERT OPIN DRUG SAF, V19, P861, DOI 10.1080/14740338.2020.1774550; Cantini F, 2019, EXPERT OPIN DRUG SAF, V18, P415, DOI 10.1080/14740338.2019.1612872; Cantini F, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/8909834; Cantini F, 2015, AUTOIMMUN REV, V14, P503, DOI 10.1016/j.autrev.2015.01.011; Cantini F, 2014, J RHEUMATOL, V41, P56, DOI 10.3899/jrheum.140103; Chiacchio T, 2019, J INFECTION, V79, P15, DOI 10.1016/j.jinf.2019.04.010; Chiacchio T, 2018, IMMUNOL LETT, V198, P33, DOI 10.1016/j.imlet.2018.04.001; Chiacchio T, 2014, J INFECTION, V69, P533, DOI 10.1016/j.jinf.2014.06.009; Day CL, 2011, J IMMUNOL, V187, P2222, DOI 10.4049/jimmunol.1101122; Du Bruyn E, 2021, MUCOSAL IMMUNOL, V14, P491, DOI 10.1038/s41385-020-0322-6; Geldmacher C, 2010, J EXP MED, V207, P2869, DOI 10.1084/jem.20100090; Goletti D, 2006, CLIN MICROBIOL INFEC, V12, P544, DOI 10.1111/j.1469-0691.2006.01391.x; Goletti D, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-5; Goletti D, 2020, INT J INFECT DIS, V92, P62, DOI 10.1016/j.ijid.2019.12.031; Goletti D, 2018, EXPERT REV ANTI-INFE, V16, P501, DOI 10.1080/14787210.2018.1483238; Goletti D, 2018, RESPIROLOGY, V23, P455, DOI 10.1111/resp.13272; Goletti D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003417; Horton KC, 2016, PLOS MED, V13, DOI [10.1371/journal.pmed.1002152, 10.1371/journal.pmed.1002119]; Igari H, 2018, J INFECT CHEMOTHER, V24, P110, DOI 10.1016/j.jiac.2017.09.012; Kik SV, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00946-2018; La Manna MP, 2020, AM J RESP CELL MOL, V62, P430, DOI 10.1165/rcmb.2019-0261OC; La Manna MP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171358; Lyadova I, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00972; Moguche AO, 2017, CELL HOST MICROBE, V21, P695, DOI 10.1016/j.chom.2017.05.012; Mpande CAM, 2021, EBIOMEDICINE, V64, DOI 10.1016/j.ebiom.2021.103233; Mpande CAM, 2021, AM J RESP CRIT CARE, V203, P1556, DOI [10.1164/rccm.202007-2686OC, 10.25375/uct.14761596]; Musvosvi M, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.00153-2018; Nash P, 2021, ANN RHEUM DIS, V80, P71, DOI 10.1136/annrheumdis-2020-218398; Nemes E, 2017, AM J RESP CRIT CARE, V196, P638, DOI 10.1164/rccm.201704-0817OC; Nikitina IY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043733; Petruccioli E, 2017, TUBERCULOSIS, V106, P38, DOI 10.1016/j.tube.2017.06.002; Petruccioli E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33825-w; Petruccioli E, 2016, EUR RESPIR J, V48, P1751, DOI 10.1183/13993003.01012-2016; Petruccioli E, 2016, J INFECTION, V73, P588, DOI 10.1016/j.jinf.2016.09.008; Petruccioli E, 2016, DIAGN MICR INFEC DIS, V86, P169, DOI 10.1016/j.diagmicrobio.2016.06.007; Petruccioli E, 2015, J INFECTION, V71, P526, DOI 10.1016/j.jinf.2015.07.009; Petruccioli E, 2013, J INFECTION, V66, P475, DOI 10.1016/j.jinf.2013.02.004; Portevin D, 2014, LANCET INFECT DIS, V14, P931, DOI 10.1016/S1473-3099(14)70884-9; Prezzemolo T, 2018, EUR J IMMUNOL, V48, P293, DOI 10.1002/eji.201747184; Prezzemolo T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00180; QIAGEN, 2021, QTF PLUS; Riou C, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1176; Riou C, 2017, FRONT IMMUNOL, V8, P1, DOI 10.3389/fimmu.2017.00968; Riou C, 2015, J IMMUNOL, V195, P2273, DOI 10.4049/jimmunol.1500803; Rozot V, 2013, EUR J IMMUNOL, V43, P1568, DOI 10.1002/eji.201243262; Saliu OY, 2006, J INFECT DIS, V194, P486, DOI 10.1086/505430; Sallin MA, 2018, NAT MICROBIOL, V3, P1198, DOI 10.1038/s41564-018-0231-6; SANSONI P, 1993, BLOOD, V82, P2767; Sauzullo I, 2014, CLIN EXP IMMUNOL, V176, P410, DOI 10.1111/cei.12290; Savolainen LE, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00239; Trauer JM, 2016, CHEST, V149, P516, DOI 10.1016/j.chest.2015.11.017; Wang XJ, 2010, J INFECTION, V60, P133, DOI 10.1016/j.jinf.2009.10.048; Wong SH, 2016, THORAX, V71, P64, DOI 10.1136/thoraxjnl-2015-207811; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053	61	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 10	2021	12								716857	10.3389/fimmu.2021.716857	http://dx.doi.org/10.3389/fimmu.2021.716857			20	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UE7ST	34447382	gold, Green Published			2022-12-18	WOS:000688084300001
J	Staels, F; Betrains, A; Woei-A-Jin, FJSH; Boeckx, N; Beckers, M; Bervoets, A; Willemsen, M; Neerinckx, B; Humblet-Baron, S; Blockmans, DE; Vanderschueren, S; Schrijvers, R				Staels, F.; Betrains, A.; Woei-A-Jin, F. J. S. H.; Boeckx, N.; Beckers, M.; Bervoets, A.; Willemsen, M.; Neerinckx, B.; Humblet-Baron, S.; Blockmans, D. E.; Vanderschueren, S.; Schrijvers, R.			Case Report: VEXAS Syndrome: From Mild Symptoms to Life-Threatening Macrophage Activation Syndrome (vol 12, 678927, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						primary immunodeficiencies; autoinflammation; treatment reactions; myelodysplasia; ubiquitination												Staels F, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.678927	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 10	2021	12								748756	10.3389/fimmu.2021.748756	http://dx.doi.org/10.3389/fimmu.2021.748756			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6C3KD		Green Published, gold			2022-12-18	WOS:000881916800001
J	Raffetseder, J; Lindau, R; van der Veen, S; Berg, G; Larsson, M; Ernerudh, J				Raffetseder, Johanna; Lindau, Robert; van der Veen, Sigrid; Berg, Goran; Larsson, Marie; Ernerudh, Jan			MAIT Cells Balance the Requirements for Immune Tolerance and Anti-Microbial Defense During Pregnancy	FRONTIERS IN IMMUNOLOGY			English	Article						mucosal-associated invariant T (MAIT) cells; pregnancy; innate-like T cells; decidua; T cells; immune tolerance; anti-microbial response; immunomodulation	MUCOSAL-ASSOCIATED INVARIANT; TRACT INNATE IMMUNITY; INFLUENZA-A VIRUS; T-CELLS; ACTIVATION; RESPONSES; EXPRESSION; INTERFACE; PHENOTYPE; PROMOTES	Mucosal-associated invariant T (MAIT) cells are an innate-like T cell subset with proinflammatory and cytotoxic effector functions. During pregnancy, modulation of the maternal immune system, both at the fetal-maternal interface and systemically, is crucial for a successful outcome and manifests through controlled enhancement of innate and dampening of adaptive responses. Still, immune defenses need to efficiently protect both the mother and the fetus from infection. So far, it is unknown whether MAIT cells are subjected to immunomodulation during pregnancy, and characterization of decidual MAIT cells as well as their functional responses during pregnancy are mainly lacking. We here characterized the presence and phenotype of V alpha 7.2(+)CD161(+) MAIT cells in blood and decidua (the uterine endometrium during pregnancy) from women pregnant in the 1(st) trimester, i.e., the time point when local immune tolerance develops. We also assessed the phenotype and functional responses of MAIT cells in blood of women pregnant in the 3(rd) trimester, i.e., when systemic immunomodulation is most pronounced. Multi-color flow cytometry panels included markers for MAIT subsets, and markers of activation (CD69, HLA-DR, Granzyme B) and immunoregulation (PD-1, CTLA-4). MAIT cells were numerically decreased at the fetal-maternal interface and showed, similar to other T cells in the decidua, increased expression of immune checkpoint markers compared with MAIT cells in blood. During the 3(rd) trimester, circulating MAIT cells showed a higher expression of CD69 and CD56, and their functional responses to inflammatory (activating anti-CD3/CD28 antibodies, and IL-12 and IL-18) and microbial stimuli (Escherichia coli, group B streptococci and influenza A virus) were generally increased compared with MAIT cells from non-pregnant women, indicating enhanced antimicrobial defenses during pregnancy. Taken together, our findings indicate dual roles for MAIT cells during pregnancy, with an evidently well-adapted ability to balance the requirements of immune tolerance in parallel with maintained antimicrobial defenses. Since MAIT cells are easily activated, they need to be strictly regulated during pregnancy, and failure to do so could contribute to pregnancy complications.	[Raffetseder, Johanna; Lindau, Robert; van der Veen, Sigrid] Linkoping Univ, Dept Biomed & Clin Sci BKV, Div Inflammat & Infect 2, Linkoping, Sweden; [Berg, Goran] Linkoping Univ, Div Obstet & Gynecol, Linkoping, Sweden; [Berg, Goran] Linkoping Univ, Dept Biomed & Clin Sci BKV, Linkoping, Sweden; [Larsson, Marie] Linkoping Univ, Dept Biomed & Clin Sci BKV, Div Mol Med & Virol MMV, Linkoping, Sweden; [Ernerudh, Jan] Linkoping Univ, Dept Clin Immunol & Transfus Med, Linkoping, Sweden; [Ernerudh, Jan] Linkoping Univ, Dept Biomed & Clin Sci, Linkoping, Sweden	Linkoping University; Linkoping University; Linkoping University; Linkoping University; Linkoping University; Linkoping University	Raffetseder, J (corresponding author), Linkoping Univ, Dept Biomed & Clin Sci BKV, Div Inflammat & Infect 2, Linkoping, Sweden.	johanna.raffetseder@liu.se	Lindau, Robert/AAC-1260-2020	Lindau, Robert/0000-0002-1255-7098; Larsson, Marie/0000-0002-4524-0177; van der Veen, Sigrid/0000-0001-8300-0812; Raffetseder, Johanna/0000-0001-8871-2560	MIIC (Medical Infection and Inflammation Center, Linkoping University and Region Ostergotland) seed grant; MIIC postdoc grant; FORSS (Medical Research Council of Southeast Sweden) [FORSS-657691, FORSS-751571, FORSS-85007]; Swedish Research Council [2017-01091, 2018-02776]; Linkoping University Hospital Research Fund	MIIC (Medical Infection and Inflammation Center, Linkoping University and Region Ostergotland) seed grant; MIIC postdoc grant; FORSS (Medical Research Council of Southeast Sweden); Swedish Research Council(Swedish Research CouncilEuropean Commission); Linkoping University Hospital Research Fund	This work has been supported by: MIIC (Medical Infection and Inflammation Center, Linkoping University and Region Ostergotland) seed grant (ML and JE) and MIIC postdoc grant (JE), FORSS (Medical Research Council of Southeast Sweden, ML FORSS-657691, FORSS-751571 and FORSS-850071), the Swedish Research Council (ML 2017-01091, JE 2018-02776) and Linkoping University Hospital Research Fund (ML and JE).	Abu-Raya B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.575197; Aronoff DM, 2008, J IMMUNOL, V180, P8222, DOI 10.4049/jimmunol.180.12.8222; Bister J, 2021, MUCOSAL IMMUNOL, V14, P357, DOI 10.1038/s41385-020-0331-5; Bulmer JN, 2010, INT J DEV BIOL, V54, P281, DOI 10.1387/ijdb.082763jb; Confavreux C, 1998, NEW ENGL J MED, V339, P285, DOI 10.1056/NEJM199807303390501; Corbett AJ, 2014, NATURE, V509, P361, DOI 10.1038/nature13160; Dias J, 2018, P NATL ACAD SCI USA, V115, pE11513, DOI 10.1073/pnas.1812273115; Dias J, 2017, P NATL ACAD SCI USA, V114, pE5434, DOI 10.1073/pnas.1705759114; Engels G, 2017, CELL HOST MICROBE, V21, P321, DOI 10.1016/j.chom.2017.02.020; Favreau M, 2017, HAEMATOLOGICA, V102, pE266, DOI 10.3324/haematol.2017.163758; Flament H, 2021, EUR J IMMUNOL, V51, P298, DOI 10.1038/s41590-021-00870-z; Forbes RL, 2012, J INFECT DIS, V206, P646, DOI 10.1093/infdis/jis377; Gherardin NA, 2018, IMMUNOL CELL BIOL, V96, P507, DOI 10.1111/imcb.12021; Gibbs A, 2017, MUCOSAL IMMUNOL, V10, P35, DOI 10.1038/mi.2016.30; Gustafsson C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002078; Hapshy Vera, 2021, SN Compr Clin Med, V3, P1477, DOI 10.1007/s42399-021-00915-2; Hinks TSC, 2019, CELL REP, V28, P3249, DOI 10.1016/j.celrep.2019.07.039; Kaipe H, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01788; Kalams SA, 2016, EUR J CONTRACEP REPR, V21, P436, DOI 10.1080/13625187.2016.1229765; Kay AW, 2014, P NATL ACAD SCI USA, V111, P14506, DOI 10.1073/pnas.1416569111; Kieffer TEC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00625; Kjer-Nielsen L, 2012, NATURE, V491, P717, DOI 10.1038/nature11605; Kourtis AP, 2014, NEW ENGL J MED, V370, P2211, DOI 10.1056/NEJMra1213566; Kraus TA, 2012, J CLIN IMMUNOL, V32, P300, DOI 10.1007/s10875-011-9627-2; Kurioka A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01031; Lee OJ, 2014, EXP GERONTOL, V49, P47, DOI 10.1016/j.exger.2013.11.003; Lindau R, 2021, J REPROD IMMUNOL, V146, DOI 10.1016/j.jri.2021.103330; Liuzzi AR, 2015, CURR OPIN IMMUNOL, V36, P31, DOI 10.1016/j.coi.2015.06.002; Manaster I, 2008, J IMMUNOL, V181, P1869, DOI 10.4049/jimmunol.181.3.1869; Meggyes M, 2018, AM J REPROD IMMUNOL, V79, DOI 10.1111/aji.12805; MINCHEVANILSSON L, 1994, J IMMUNOL, V152, P2020; Mor G, 2010, AM J REPROD IMMUNOL, V63, P425, DOI 10.1111/j.1600-0897.2010.00836.x; Nel I, 2021, MUCOSAL IMMUNOL, V14, P803, DOI 10.1038/s41385-021-00391-w; Novak J, 2014, SCAND J IMMUNOL, V80, P271, DOI 10.1111/sji.12193; Ostensen M, 2007, SEMIN IMMUNOPATHOL, V29, P185, DOI 10.1007/s00281-007-0072-5; Parrot T, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe1670; PORCELLI S, 1993, J EXP MED, V178, P1, DOI 10.1084/jem.178.1.1; Ravi K, 2020, AM J REPROD IMMUNOL, V83, DOI 10.1111/aji.13240; Rieger L, 2009, REPROD BIOL ENDOCRIN, V7, DOI 10.1186/1477-7827-7-132; Riegert P, 1998, J IMMUNOL, V161, P4066; Saito S, 1999, CLIN EXP IMMUNOL, V117, P550; Schmaler M, 2018, MUCOSAL IMMUNOL, V11, P1060, DOI 10.1038/s41385-018-0020-9; Shannon C, 2008, J IMMUNOL, V181, P2263, DOI 10.4049/jimmunol.181.4.2263; Sobkowiak MJ, 2019, EUR J IMMUNOL, V49, P133, DOI 10.1002/eji.201847759; Solders M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01300; Solders M, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/8010961; Solders M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06430-6; Svensson J, 2011, J IMMUNOL, V187, P3671, DOI 10.4049/jimmunol.1100130; Svensson-Arvelund J, 2015, J IMMUNOL, V194, P1534, DOI 10.4049/jimmunol.1401536; Svensson-Arvelund J, 2014, TOXICOL PATHOL, V42, P327, DOI 10.1177/0192623313482205; Treiner E, 2003, NATURE, V422, P164, DOI 10.1038/nature01433; Ussher JE, 2014, EUR J IMMUNOL, V44, P195, DOI 10.1002/eji.201343509; Van Rhijn I, 2013, NAT IMMUNOL, V14, P706, DOI 10.1038/ni.2630; van Wilgenburg B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07207-9; van Wilgenburg B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11653; Vento-Tormo R, 2018, NATURE, V563, P347, DOI 10.1038/s41586-018-0698-6; Vornhagen J, 2017, TRENDS MICROBIOL, V25, P919, DOI 10.1016/j.tim.2017.05.013; Walker LJ, 2014, SCAND J IMMUNOL, V80, P462, DOI 10.1111/sji.12237	58	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 9	2021	12									10.3389/fimmu.2021.718168	http://dx.doi.org/10.3389/fimmu.2021.718168			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UQ1UB	34497611	Green Published, gold			2022-12-18	WOS:000695855000001
J	Sachar, C; Kam, LC				Sachar, Chirag; Kam, Lance C.			Probing T Cell 3D Mechanosensing With Magnetically-Actuated Structures	FRONTIERS IN IMMUNOLOGY			English	Article						mechanobiology; CD4(+) T cell; magnetic; micropillar; activation	EPITHELIAL-CELLS; FORCE; TCR; ACTIVATION	The ability of cells to recognize and respond to the mechanical properties of their environment is of increasing importance in T cell physiology. However, initial studies in this direction focused on planar hydrogel and elastomer surfaces, presenting several challenges in interpretation including difficulties in separating mechanical stiffness from changes in chemistry needed to modulate this property. We introduce here the use of magnetic fields to change the structural rigidity of microscale elastomer pillars loaded with superparamagnetic nanoparticles, independent of substrate chemistry. This magnetic modulation of rigidity, embodied as the pillar spring constant, changed the interaction of mouse naive CD4(+) T cells from a contractile morphology to one involving deep embedding into the array. Furthermore, increasing spring constant was associated with higher IL-2 secretion, showing a functional impact on mechanosensing. The system introduced here thus separates local substrate stiffness and long-range structural rigidity, revealing new facets of T cell interaction with their environment.	[Sachar, Chirag; Kam, Lance C.] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA	Columbia University	Kam, LC (corresponding author), Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA.	lance.kam@columbia.edu			National Institutes of Health [R21AI119953, R01AI110593]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported in part by the National Institutes of Health (R21AI119953 and R01AI110593 to LK).	Bashour KT, 2014, P NATL ACAD SCI USA, V111, P2241, DOI 10.1073/pnas.1315606111; Basu R, 2016, CELL, V165, P100, DOI 10.1016/j.cell.2016.01.021; Chaudhuri PK, 2020, ADV BIOSYST, V4, DOI 10.1002/adbi.202000143; Dang AP, 2018, ADV BIOSYST, V2, DOI 10.1002/adbi.201700167; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Fu JP, 2010, NAT METHODS, V7, P733, DOI 10.1038/nmeth.1487; Hong JS, 2018, NAT IMMUNOL, V19, P1379, DOI 10.1038/s41590-018-0259-z; Hong JS, 2015, J IMMUNOL, V195, P3557, DOI 10.4049/jimmunol.1501407; Hu KH, 2016, J CELL BIOL, V213, P535, DOI 10.1083/jcb.201511053; Jin WY, 2019, P NATL ACAD SCI USA, V116, P19835, DOI 10.1073/pnas.1906986116; Judokusumo E, 2012, BIOPHYS J, V102, pL5, DOI 10.1016/j.bpj.2011.12.011; Kim ST, 2009, J BIOL CHEM, V284, P31028, DOI 10.1074/jbc.M109.052712; Lambert LH, 2017, NANO LETT, V17, P821, DOI 10.1021/acs.nanolett.6b04071; le Digabel J, 2011, LAB CHIP, V11, P2630, DOI 10.1039/c1lc20263d; Li YC, 2010, J IMMUNOL, V184, P5959, DOI 10.4049/jimmunol.0900775; Liu BY, 2014, CELL, V157, P357, DOI 10.1016/j.cell.2014.02.053; Liu Y, 2016, P NATL ACAD SCI USA, V113, P5610, DOI 10.1073/pnas.1600163113; O'Connor RS, 2012, J IMMUNOL, V189, P1330, DOI 10.4049/jimmunol.1102757; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; Saez A, 2005, BIOPHYS J, V89, pL52, DOI 10.1529/biophysj.105.071217; Saez A, 2007, P NATL ACAD SCI USA, V104, P8281, DOI 10.1073/pnas.0702259104; Sage D, 2017, METHODS, V115, P28, DOI 10.1016/j.ymeth.2016.12.015; Sage PT, 2012, J IMMUNOL, V188, P3686, DOI 10.4049/jimmunol.1102594; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Shen K, 2008, P NATL ACAD SCI USA, V105, P7791, DOI 10.1073/pnas.0710295105; Sims TN, 2007, CELL, V129, P773, DOI 10.1016/j.cell.2007.03.037; Sniadecki NJ, 2007, P NATL ACAD SCI USA, V104, P14553, DOI 10.1073/pnas.0611613104; Sniadecki NJ, 2008, REV SCI INSTRUM, V79, DOI 10.1063/1.2906228; Tamzalit F, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aav5445; Tan JL, 2003, P NATL ACAD SCI USA, V100, P1484, DOI 10.1073/pnas.0235407100; Trappmann B, 2012, NAT MATER, V11, P642, DOI [10.1038/NMAT3339, 10.1038/nmat3339]; Ueda H, 2011, P NATL ACAD SCI USA, V108, P17099, DOI 10.1073/pnas.1113703108; von Lockette P, 2011, SMART MATER STRUCT, V20, DOI 10.1088/0964-1726/20/10/105022; Wahl A, 2019, P NATL ACAD SCI USA, V116, P5908, DOI 10.1073/pnas.1811516116; Wang Y, 2013, LAB CHIP, V13, P3360, DOI 10.1039/c3lc50458a	35	0	0	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 9	2021	12								704693	10.3389/fimmu.2021.704693	http://dx.doi.org/10.3389/fimmu.2021.704693			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UU0GR	34566962	Green Published, gold			2022-12-18	WOS:000698484500001
J	Hao, JH; Shen, CC; Wei, NN; Yan, MH; Zhang, XG; Xu, GW; Zhang, DJ; Hou, J; Cao, WJ; Jin, Y; Zhang, KS; Zheng, HX; Liu, XT				Hao, Junhong; Shen, Chaochao; Wei, Nannan; Yan, Minghao; Zhang, Xuegang; Xu, Guowei; Zhang, Dajun; Hou, Jing; Cao, Weijun; Jin, Ye; Zhang, Keshan; Zheng, Haixue; Liu, Xiangtao			Foot-and-Mouth Disease Virus Capsid Protein VP1 Antagonizes TPL2-Mediated Activation of the IRF3/IFN-beta Signaling Pathway to Facilitate the Virus Replication (vol 11, 580334, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						foot-and-mouth disease virus; viral protein 1; tumor progression locus 2; immune escape; interferon regulatory factor 3/interferon-beta; immune escape			[Hao, Junhong; Shen, Chaochao; Wei, Nannan; Yan, Minghao; Zhang, Xuegang; Xu, Guowei; Zhang, Dajun; Hou, Jing; Cao, Weijun; Jin, Ye; Zhang, Keshan; Zheng, Haixue; Liu, Xiangtao] Chinese Acad Agr Sci, Lanzhou Vet Res Inst, Natl Foot & Mouth Dis Reference Lab, State Key Lab Vet Etiol Biol, Lanzhou, Peoples R China	Chinese Academy of Agricultural Sciences; Lanzhou Veterinary Research Institute, CAAS	Zhang, KS; Zheng, HX (corresponding author), Chinese Acad Agr Sci, Lanzhou Vet Res Inst, Natl Foot & Mouth Dis Reference Lab, State Key Lab Vet Etiol Biol, Lanzhou, Peoples R China.	vetzks009@163.com; zhenghaixue@caas.cn						Hao JH, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.580334	1	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 6	2021	12								686494	10.3389/fimmu.2021.686494	http://dx.doi.org/10.3389/fimmu.2021.686494			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UF2AK	34421898	gold, Green Published			2022-12-18	WOS:000688381600001
J	Ichinose, K; Hedrich, CM; Moulton, VR; Mizui, M				Ichinose, Kunihiro; Hedrich, Christian Michael; Moulton, Vaishali R.; Mizui, Masayuki			Editorial: Focusing on T-Cells for Novel Treatments of Systemic Lupus Erythematosus	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						lupus T-cells; immunometabolism; innate lymphocytes; post-transcriptional regulation; Th17/Treg balance			[Ichinose, Kunihiro] Nagasaki Univ, Grad Sch Biomed Sci, Div Adv Prevent Med Sci, Dept Immunol & Rheumatol, Nagasaki, Japan; [Hedrich, Christian Michael] Univ Liverpool, Inst Life Course & Med Sci, Dept Womens & Childrens Hlth, Liverpool, Merseyside, England; [Hedrich, Christian Michael] Alder Hey Childrens NHS Fdn Trust Hosp, Div Rheumatol & Clin Immunol, Liverpool, Merseyside, England; [Moulton, Vaishali R.] Beth Israel Deaconess Med Ctr, Dept Med, Div Rheumatol & Clin Immunol, Boston, MA USA; [Moulton, Vaishali R.] Harvard Med Sch, Boston, MA 02115 USA; [Mizui, Masayuki] Osaka Univ, Grad Sch Med, Dept Nephrol, Suita, Osaka, Japan	Nagasaki University; University of Liverpool; Alder Hey Children's NHS Foundation Trust; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Osaka University	Mizui, M (corresponding author), Osaka Univ, Grad Sch Med, Dept Nephrol, Suita, Osaka, Japan.	mmizui@kid.med.osaka-u.ac.jp	Ichinose, Kunihiro/I-2126-2019; Mizui, Masayuki/AAD-1432-2019	Ichinose, Kunihiro/0000-0001-8794-7106; Mizui, Masayuki/0000-0003-2543-8108				Brandt D, 2018, AUTOIMMUN REV, V17, P422, DOI 10.1016/j.autrev.2018.02.001; Herrada AA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00772; Katsuyama T, 2019, J CLIN INVEST, V129, P5411, DOI 10.1172/JCI127949; Li H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16636-4; Omenetti S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00639; Ostendorf L, 2020, NEW ENGL J MED, V383, P1149, DOI 10.1056/NEJMoa2023325; Perl A, 2016, NAT REV RHEUMATOL, V12, P169, DOI 10.1038/nrrheum.2015.172; Rovin BH, 2021, LANCET, V397, P2070, DOI 10.1016/S0140-6736(21)00578-X; Schmidt T, 2015, ARTHRITIS RHEUMATOL, V67, P475, DOI 10.1002/art.38955; Tsai CY, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10121641; Yoh K, 2001, KIDNEY INT, V60, P1343, DOI 10.1046/j.1523-1755.2001.00939.x; Zhao M, 2016, SCI REP-UK, V6, DOI 10.1038/srep38619	12	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 6	2021	12								744866	10.3389/fimmu.2021.744866	http://dx.doi.org/10.3389/fimmu.2021.744866			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UD7GC	34421933	Green Published, gold			2022-12-18	WOS:000687372600001
J	Jubel, JM; Randau, TM; Becker-Gotot, J; Scheidt, S; Wimmer, MD; Kohlhof, H; Burger, C; Wirtz, DC; Schildberg, FA				Jubel, Jil M.; Randau, Thomas M.; Becker-Gotot, Janine; Scheidt, Sebastian; Wimmer, Matthias D.; Kohlhof, Hendrik; Burger, Christof; Wirtz, Dieter C.; Schildberg, Frank A.			sCD28, sCD80, sCTLA-4, and sBTLA Are Promising Markers in Diagnostic and Therapeutic Approaches for Aseptic Loosening and Periprosthetic Joint Infection	FRONTIERS IN IMMUNOLOGY			English	Article						aseptic loosening; periprosthetic joint infection; immunoregulatory markers; sCD28; sCD80; sCTLA-4; sBTLA; osteoimmunology	T-CELL-ACTIVATION; SOLUBLE COSTIMULATORY MOLECULES; KNEE ARTHROPLASTY; TOTAL HIP; COINHIBITORY PATHWAYS; INCREASED EXPRESSION; ANTITUMOR IMMUNITY; PD-1 EXPRESSION; CTLA-4; CD28	Aseptic prosthetic loosening and periprosthetic joint infections (PJI) are among the most frequent complications after total knee/hip joint arthroplasty (TJA). Current research efforts focus on understanding the involvement of the immune system in these frequent complications. Different immune cell types have already been implicated in aseptic prosthetic loosening and PJI. The aim of this study was to systematically analyze aspirates from knee and hip joints, evaluating the qualitative and quantitative composition of soluble immunoregulatory markers, with a focus on co-inhibitory and co-stimulatory markers. It has been shown that these molecules play important roles in immune regulation in cancer and chronic infectious diseases, but they have not been investigated in the context of joint replacement. For this purpose, aspirates from control joints (i.e., native joints without implanted prostheses), joints with TJA (no signs of infection or aseptic loosening), joints with aseptic implant failure (AIF; i.e., aseptic loosening), and joints with PJI were collected. Fourteen soluble immunoregulatory markers were assessed using bead-based multiplex assays. In this study, it could be shown that the concentrations of the analyzed immunoregulatory molecules vary between control, TJA, AIF, and PJI joints. Comparing TJA patients to CO patients, sCD80 was significantly elevated. The marker sBTLA was significantly elevated in AIF joints compared to TJA joints. In addition, a significant difference for eight markers could be shown when comparing the AIF and CO groups (sCD27, sCTLA-4, sCD137, sCD80, sCD28, sTIM-3, sPD-1, sBTLA). A significant difference was also reached for nine soluble markers when the PJI and CO groups were compared (sLAG-3, sCTLA-4, sCD27, sCD80, sCD28, sTIM-3, sPD-1, IDO, sBTLA). In summary, the analyzed immunoregulatory markers could be useful for diagnostic purposes as well as to develop new therapeutic approaches for AIF and PJI.	[Jubel, Jil M.; Randau, Thomas M.; Scheidt, Sebastian; Wimmer, Matthias D.; Kohlhof, Hendrik; Burger, Christof; Wirtz, Dieter C.; Schildberg, Frank A.] Univ Hosp Bonn, Clin Orthoped & Trauma Surg, Bonn, Germany; [Becker-Gotot, Janine] Univ Hosp Bonn, Inst Expt Immunol, Bonn, Germany	University of Bonn; University of Bonn	Schildberg, FA (corresponding author), Univ Hosp Bonn, Clin Orthoped & Trauma Surg, Bonn, Germany.	frank.schildberg@ukbonn.de	Randau, Thomas/AAY-8690-2021; Randau, Thomas Martin/AEP-9749-2022; Kohlhof, Hendrik/ABA-6232-2021	Randau, Thomas Martin/0000-0002-5224-9639; 	National Multiple Sclerosis Society [RG 1809-32591]	National Multiple Sclerosis Society(National Multiple Sclerosis Society)	This work was supported by a grant from the National Multiple Sclerosis Society (RG 1809-32591 to FS).	Akindolire J, 2020, CAN J SURG, V63, pE52, DOI [10.1503.cjs.004219, 10.1503/cjs.004219]; Anderson KM, 2006, J IMMUNOL, V176, P5306, DOI 10.4049/jimmunol.176.9.5306; Attanasio J, 2016, IMMUNITY, V44, P1052, DOI 10.1016/j.immuni.2016.04.022; Baumeister SH, 2016, ANNU REV IMMUNOL, V34, P539, DOI 10.1146/annurev-immunol-032414-112049; Berbari EF, 2007, CLIN INFECT DIS, V45, P1113, DOI 10.1086/522184; Bian B, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1561120; Blanco JF, 2020, ARCH ORTHOP TRAUM SU, V140, P239, DOI 10.1007/s00402-019-03304-6; Bonilla FA, 2010, J ALLERGY CLIN IMMUN, V125, pS33, DOI 10.1016/j.jaci.2009.09.017; Cao J, 2012, INT IMMUNOPHARMACOL, V14, P585, DOI 10.1016/j.intimp.2012.08.004; Chakrabarti R, 2019, CANCER REP-US, V2, DOI 10.1002/cnr2.1160; Chauvin JM, 2015, J CLIN INVEST, V125, P2046, DOI 10.1172/JCI80445; Cheng HY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095870; Cherian JJ, 2015, CLIN ORTHOP RELAT R, V473, P2700, DOI 10.1007/s11999-015-4220-2; Cortes KC, 2019, J VIRAL HEPATITIS, V26, P942, DOI 10.1111/jvh.13108; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; Del Pozo JL, 2009, NEW ENGL J MED, V361, P787, DOI 10.1056/NEJMcp0905029; Dong MP, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60440-5; Dong YJ, 2019, BMC IMMUNOL, V20, DOI 10.1186/s12865-019-0309-9; Dustin ML, 2009, IMMUNITY, V30, P482, DOI 10.1016/j.immuni.2009.03.010; Erfani N, 2010, CANCER INVEST, V28, P828, DOI 10.3109/07357901003630934; Francisco LM, 2009, J EXP MED, V206, P3015, DOI 10.1084/jem.20090847; Gehrke T, 2015, BONE JOINT J, V97B, P20, DOI 10.1302/0301-620X.97B10.36475; Gomez-Urena EO, 2017, INFECT DIS CLIN N AM, V31, P219, DOI 10.1016/j.idc.2017.01.008; Gorgulho J, 2021, INT J CANCER, V149, P1189, DOI 10.1002/ijc.33610; Gu DQ, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0449-0; GUERDER S, 1995, CURR BIOL, V5, P866, DOI 10.1016/S0960-9822(95)00175-8; Haile ST, 2014, CANCER IMMUNOL RES, V2, P610, DOI 10.1158/2326-6066.CIR-13-0204; Haile ST, 2013, J IMMUNOL, V191, P2829, DOI 10.4049/jimmunol.1202777; Hebbar M, 2004, CLIN EXP IMMUNOL, V136, P388, DOI 10.1111/j.1365-2249.2004.02427.x; Helwig P, 2014, INT ORTHOP, V38, P1077, DOI 10.1007/s00264-013-2265-y; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Huang X, 2009, P NATL ACAD SCI USA, V106, P6303, DOI 10.1073/pnas.0809422106; Ip WK, 2005, INT ARCH ALLERGY IMM, V137, P45, DOI 10.1159/000084612; Irvine DJ, 2002, NATURE, V419, P845, DOI 10.1038/nature01076; Izakovicova P, 2019, EFORT OPEN REV, V4, P482, DOI 10.1302/2058-5241.4.180092; JENKINS MK, 1991, J IMMUNOL, V147, P2461; Jubel JM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00487; Kakoulidou M, 2007, SCAND J IMMUNOL, V66, P529, DOI 10.1111/j.1365-3083.2007.02009.x; Koh CK, 2017, CLIN ORTHOP RELAT R, V475, P2194, DOI 10.1007/s11999-017-5396-4; Kremers HM, 2015, J BONE JOINT SURG AM, V97A, P1386, DOI 10.2106/JBJS.N.01141; Kunutsor SK, 2016, PLOS ONE, V11, DOI [10.1371/journal.pone.0150866, 10.1371/journal.pone.0151537]; Kurtz S, 2007, J BONE JOINT SURG AM, V89A, P780, DOI 10.2106/JBJS.F.00222; Kurtz SM, 2012, J ARTHROPLASTY, V27, P61, DOI 10.1016/j.arth.2012.02.022; Landgraeber S, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/185150; Lange A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169176; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Li C, 2020, INT ORTHOP, V44, P3, DOI 10.1007/s00264-019-04426-7; Liu MF, 2003, SCAND J IMMUNOL, V57, P568, DOI 10.1046/j.1365-3083.2003.01232.x; Liu QQ, 2017, ONCOTARGETS THER, V10, P2147, DOI 10.2147/OTT.S128451; Mansour A, 2014, LEUKEMIA LYMPHOMA, V55, P2120, DOI 10.3109/10428194.2013.869328; Monaghan SF, 2018, MOL MED, V24, P1, DOI 10.1186/s10020-018-0036-3; Namba RS, 2005, J ARTHROPLASTY, V20, P46, DOI 10.1016/j.arth.2005.04.023; Natarajan K, 1999, Rev Immunogenet, V1, P32; Oaks MK, 2000, J IMMUNOL, V164, P5015, DOI 10.4049/jimmunol.164.10.5015; Orfanos AV, 2020, KNEE, V27, P1101, DOI 10.1016/j.knee.2019.10.007; Ostrand-Rosenberg S, 2015, CANCER IMMUNOL IMMUN, V64, P1287, DOI 10.1007/s00262-015-1677-5; Palan J, 2019, EFORT OPEN REV, V4, P585, DOI 10.1302/2058-5241.4.180067; Parry RV, 2005, MOL CELL BIOL, V25, P9543, DOI 10.1128/MCB.25.21.9543-9553.2005; Parvizi J, 2018, J ARTHROPLASTY, V33, P1309, DOI 10.1016/j.arth.2018.02.078; Patsoukis N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7692; Saverino D, 2007, CLIN IMMUNOL, V123, P190, DOI 10.1016/j.clim.2007.01.003; Schildberg FA, 2016, IMMUNITY, V44, P955, DOI 10.1016/j.immuni.2016.05.002; Simone R, 2009, INT IMMUNOL, V21, P1037, DOI 10.1093/intimm/dxp069; Tang ZS, 2016, MOL MED REP, V14, P1107, DOI 10.3892/mmr.2016.5396; Uede T, 1995, Nihon Rinsho, V53, P2597; van der Kraan PM, 2019, TISSUE ENG REGEN MED, V16, P327, DOI 10.1007/s13770-019-00204-z; Wan B, 2006, J IMMUNOL, V177, P8844, DOI 10.4049/jimmunol.177.12.8844; Wang QC, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0810-y; Wang XB, 2002, J NEUROIMMUNOL, V130, P224, DOI 10.1016/S0165-5728(02)00228-X; Ward FJ, 2014, IMMUNOTHERAPY-UK, V6, P1073, DOI [10.2217/IMT.14.73, 10.2217/imt.14.73]; Ward FJ, 2013, EUR J IMMUNOL, V43, P1274, DOI 10.1002/eji.201242529; Wengler A, 2014, DTSCH ARZTEBL INT, V111, P407, DOI 10.3238/arztebl.2014.0407; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Wong CK, 2005, RHEUMATOLOGY, V44, P989, DOI 10.1093/rheumatology/keh663; Woo SR, 2012, CANCER RES, V72, P917, DOI 10.1158/0008-5472.CAN-11-1620; Wooley PH, 2004, GENE THER, V11, P402, DOI 10.1038/sj.gt.3302202; Yang F, 2011, BIOMATERIALS, V32, P9159, DOI 10.1016/j.biomaterials.2011.08.039; YANG SY, 1988, J EXP MED, V168, P1457, DOI 10.1084/jem.168.4.1457; Zhou L, 2019, J VIRAL HEPATITIS, V26, P795, DOI 10.1111/jvh.13055	79	0	1	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 6	2021	12								687065	10.3389/fimmu.2021.687065	http://dx.doi.org/10.3389/fimmu.2021.687065			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UD2QX	34421900	Green Published, gold			2022-12-18	WOS:000687058200001
J	Li, SJ; Qiu, YC; Tang, L; Wang, ZJ; Cao, WJ; Zhou, XT; Sun, XH				Li, Shengjie; Qiu, Yichao; Tang, Li; Wang, Zhujian; Cao, Wenjun; Zhou, Xingtao; Sun, Xinghuai			Association of Ocular Surface Diseases With SARS-CoV-2 Infection in Six Districts of China: An Observational Cohort Study	FRONTIERS IN IMMUNOLOGY			English	Article						SARS- CoV-2; immunoglobulin G; immunoglobulin M; ocular surface diseases; cross-sectional study; seroprevalence; COVID-19		The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viruses is mainly transmitted through respiratory droplets. Notably, some coronavirus disease 2019 (COVID-19) patients have ocular manifestations, including conjunctival hyperaemia, chemosis, epiphora, and increased secretions. However, the association between SARS-CoV-2 and ocular surface diseases is poorly described. Between May 2020 and March 2021, a total of 2, 0157 participants from six districts of China were enrolled. Serum samples were tested for immunoglobulin G and M (IgG and IgM) antibodies against the SARS-CoV-2 spike protein and nucleoprotein using magnetic chemiluminescence enzyme immunoassays. Throat swabs were tested for SARS-CoV-2 RNA using RT-PCR assays in a designated virology laboratory. Fisher exact, chi(2) test, and logistic regression analysis were performed. Of 2, 0157 serum samples tested, 1, 755 (8.71%) were from ocular surface diseases, 1, 2550 (62.26%) from no-ocular surface diseases (ocular diseases except ocular surface diseases), 5, 852 (29.03%) from no-ocular diseases. SARS-CoV-2 prevalence for the combined measure was 0.90% (182/2, 0157). Seroprevalence of SARS-CoV-2 was significantly (p<0.05) higher in the population with ocular surface diseases (2.28%, 40/1755) compared with no-ocular surface diseases (0.70%, 88/1, 2550), and no-ocular diseases (0.92%, 54/5, 852). Similar results were also observed with respect to sex, age, time, and districts. Logistic regression analyses revealed that ocular surface diseases [ocular surface diseases vs. no-ocular diseases (p=0.001, OR =1.467, 95% CI=1.174-1.834); ocular surface diseases vs. no-ocular surface diseases (p<0.001, OR =2.170, 95% CI=1.434-3.284)] were associated with increased risk of susceptible to SARS-CoV-2 infection. In a word, there was a significant association between ocular surface disease and SARS-CoV-2 infection. Therefore, increasing awareness of eye protection during the pandemic is necessary, especially for individuals with ocular surface diseases.	[Li, Shengjie; Qiu, Yichao; Tang, Li; Wang, Zhujian; Cao, Wenjun] Fudan Univ, Eye & ENT Hosp, Clin Lab, Shanghai, Peoples R China; [Li, Shengjie; Cao, Wenjun; Zhou, Xingtao; Sun, Xinghuai] Fudan Univ, Eye & ENT Hosp, Eye Inst, Shanghai, Peoples R China; [Li, Shengjie; Cao, Wenjun; Zhou, Xingtao] Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, Shanghai, Peoples R China; [Cao, Wenjun; Zhou, Xingtao; Sun, Xinghuai] Fudan Univ, Chinese Acad Med Sci, NHC Key Lab Myopia, Key Lab Myopia, Shanghai, Peoples R China; [Cao, Wenjun; Zhou, Xingtao; Sun, Xinghuai] Shanghai Key Lab Visual Impairment & Restorat, Shanghai, Peoples R China; [Zhou, Xingtao] Shanghai Res Ctr Ophthalmol & Optometry, Shanghai, Peoples R China; [Zhou, Xingtao] Shanghai Engn Res Ctr Laser & Autostereoscop 3D V, Shanghai, Peoples R China	Fudan University; Fudan University; Fudan University; Chinese Academy of Medical Sciences - Peking Union Medical College; Fudan University	Cao, WJ (corresponding author), Fudan Univ, Eye & ENT Hosp, Clin Lab, Shanghai, Peoples R China.; Cao, WJ; Zhou, XT (corresponding author), Fudan Univ, Eye & ENT Hosp, Eye Inst, Shanghai, Peoples R China.; Cao, WJ; Zhou, XT (corresponding author), Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, Shanghai, Peoples R China.; Cao, WJ; Zhou, XT (corresponding author), Fudan Univ, Chinese Acad Med Sci, NHC Key Lab Myopia, Key Lab Myopia, Shanghai, Peoples R China.; Cao, WJ; Zhou, XT (corresponding author), Shanghai Key Lab Visual Impairment & Restorat, Shanghai, Peoples R China.; Zhou, XT (corresponding author), Shanghai Res Ctr Ophthalmol & Optometry, Shanghai, Peoples R China.; Zhou, XT (corresponding author), Shanghai Engn Res Ctr Laser & Autostereoscop 3D V, Shanghai, Peoples R China.	wgkjyk@aliyun.com; doctzhouxingtao@163.com	zhou, xing/GQP-4516-2022; zhou, xt/GWZ-9212-2022		Shanghai Municipal Commission of Health and Family Planning [20174Y0169, 201840050]; State Key Program of National Natural Science Foundation of China [81430007]; National Natural Science Foundation of China [81770955, 81790641]; Shanghai Committee of Science and Technology of China [17410712500]; top priority of clinical medicine center of Shanghai [2017ZZ01020]; Shanghai Science and Technology Committee Foundation [19411964600]; Project of Shanghai Science and Technology [20410710100]; Clinical Research Plan of SHDC [SHDC2020CR1043B]; Project of Shanghai Xuhui District Science and Technology [2020-015]; Joint research project of new frontier technology in municipal hospitals [SHDC12018103]	Shanghai Municipal Commission of Health and Family Planning; State Key Program of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Committee of Science and Technology of China; top priority of clinical medicine center of Shanghai; Shanghai Science and Technology Committee Foundation(Shanghai Science & Technology Committee); Project of Shanghai Science and Technology; Clinical Research Plan of SHDC; Project of Shanghai Xuhui District Science and Technology; Joint research project of new frontier technology in municipal hospitals	This work was supported by the Shanghai Municipal Commission of Health and Family Planning (20174Y0169 and 201840050), the State Key Program of National Natural Science Foundation of China (81430007), the subject of major projects of National Natural Science Foundation of China (81790641), the Shanghai Committee of Science and Technology of China (17410712500), and the top priority of clinical medicine center of Shanghai (2017ZZ01020) and Shanghai Science and Technology Committee Foundation grant (19411964600), National Natural Science Foundation of China (Grant No. 81770955), Joint research project of new frontier technology in municipal hospitals (SHDC12018103), Project of Shanghai Science and Technology (Grant No.20410710100), Clinical Research Plan of SHDC (SHDC2020CR1043B), Project of Shanghai Xuhui District Science and Technology (2020-015).	Chen XH, 2021, LANCET GLOB HEALTH, V9, pE598, DOI [10.1016/S2214-109X(21)00026-7, 10.1101/2020.09.11.20192773]; Collin J, 2021, OCUL SURF, V19, P190, DOI 10.1016/j.jtos.2020.05.013; Deiner MS, 2021, OPHTHALMOLOGY, V128, P167, DOI 10.1016/j.ophtha.2020.06.026; Deng W, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18149-6; Duan SH, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0008975; Gangaputra SS, 2020, OPHTHALMOLOGY, V127, P1425, DOI 10.1016/j.ophtha.2020.06.037; Gudbjartsson DF, 2020, NEW ENGL J MED, V383, P1724, DOI 10.1056/NEJMoa2026116; Havers FP, 2020, JAMA INTERN MED, V180, P1576, DOI 10.1001/jamainternmed.2020.4130; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Li SJ, 2021, OCUL SURF, V19, P249, DOI 10.1016/j.jtos.2020.09.010; Lu CW, 2020, LANCET, V395, pE39, DOI 10.1016/S0140-6736(20)30313-5; Moscola J, 2020, JAMA-J AM MED ASSOC, V324, P893, DOI 10.1001/jama.2020.14765; Murhekar MV, 2020, INDIAN J MED RES, V152, P48, DOI 10.4103/ijmr.IJMR_3290_20; Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002; Wu P, 2020, JAMA OPHTHALMOL, V138, P575, DOI 10.1001/jamaophthalmol.2020.1291; Xie HT, 2020, EYE VISION, V7, DOI 10.1186/s40662-020-00189-0; Zhang X, 2020, OCUL SURF, V18, P360, DOI 10.1016/j.jtos.2020.03.010; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344; Zhou Lingli, 2020, bioRxiv, DOI 10.1101/2020.05.09.086165; Zhou YY, 2020, OPHTHALMOLOGY, V127, P982, DOI 10.1016/j.ophtha.2020.04.028	21	0	0	0	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 6	2021	12								695428	10.3389/fimmu.2021.695428	http://dx.doi.org/10.3389/fimmu.2021.695428			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UE0MC	34421905	gold, Green Published			2022-12-18	WOS:000687591600001
J	Lu, JL; Liang, Y; Meng, HY; Zhang, AL; Zhao, JJ; Zhang, CL				Lu, Jingli; Liang, Yan; Meng, Haiyang; Zhang, Ailing; Zhao, Junjie; Zhang, Chengliang			Metabolic Controls on Epigenetic Reprogramming in Regulatory T Cells	FRONTIERS IN IMMUNOLOGY			English	Review						regulatory T cells; metabolism; epigenetics; immune suppression; metabolites	PROTEIN O-GLCNACYLATION; FOXP3 EXPRESSION; DNA-METHYLATION; TRANSCRIPTION FACTOR; MITOCHONDRIAL BIOGENESIS; BETA-HYDROXYBUTYRATE; CELLULAR-METABOLISM; ACETYL-COENZYME; KEY DETERMINANT; HISTONE	Forkhead box protein 3 (Foxp3(+))-expressing regulatory T (Treg) cells are a unique CD4(+)T cell subset that suppresses excessive immune responses. The epigenetic plasticity and metabolic traits of Treg cells are crucial for the acquisition of their phenotypic and functional characteristics. Therefore, alterations to the epigenetics and metabolism affect Treg cell development and function. Recent evidence reveals that altering the metabolic pathways and generation of metabolites can regulate the epigenetics of Treg cells. Specifically, some intermediates of cell metabolism can directly act as substrates or cofactors of epigenetic-modifying enzymes. Here, we describe the metabolic and epigenetic features during Treg cell development, and discuss how metabolites can contribute to epigenetic alterations of Treg cells, which affects Treg cell activation, differentiation, and function.	[Lu, Jingli; Liang, Yan; Meng, Haiyang; Zhang, Ailing; Zhao, Junjie] Zhengzhou Univ, Affiliated Hosp 1, Dept Pharm, Zhengzhou, Peoples R China; [Lu, Jingli; Liang, Yan; Meng, Haiyang; Zhang, Ailing; Zhao, Junjie] Henan Engn Res Ctr Clin Mass Spectrometry Precis, Zhengzhou, Peoples R China; [Lu, Jingli; Liang, Yan; Meng, Haiyang; Zhang, Ailing; Zhao, Junjie] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou Key Lab Clin Mass Spectrometry, Zhengzhou, Peoples R China; [Zhang, Chengliang] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Pharm, Wuhan, Peoples R China	Zhengzhou University; Zhengzhou University; Huazhong University of Science & Technology	Lu, JL (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Pharm, Zhengzhou, Peoples R China.; Lu, JL (corresponding author), Henan Engn Res Ctr Clin Mass Spectrometry Precis, Zhengzhou, Peoples R China.; Lu, JL (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou Key Lab Clin Mass Spectrometry, Zhengzhou, Peoples R China.; Zhang, CL (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Pharm, Wuhan, Peoples R China.	lujingli123@163.com; clzhang@tjh.tjmu.edu.cn	Zhang, Cheng/GRS-8698-2022		National Natural Science Foundation of China [82073860]; Young Elite Scientist Sponsorship Program of Henan Association for Science and Technology [2021HYTP048]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Young Elite Scientist Sponsorship Program of Henan Association for Science and Technology	This work was supported by the National Natural Science Foundation of China (grant number 82073860) and the Young Elite Scientist Sponsorship Program of Henan Association for Science and Technology (grant number 2021HYTP048).	Aik W, 2013, J MED CHEM, V56, P3680, DOI 10.1021/jm400193d; Angelin A, 2017, CELL METAB, V25, P1282, DOI 10.1016/j.cmet.2016.12.018; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Arvey A, 2015, ELIFE, V4, DOI 10.7554/eLife.07571; Arvey A, 2014, NAT IMMUNOL, V15, P580, DOI 10.1038/ni.2868; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Beier UH, 2011, MOL CELL BIOL, V31, P1022, DOI 10.1128/MCB.01206-10; Berod L, 2014, NAT MED, V20, P1327, DOI 10.1038/nm.3704; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Burzyn D, 2013, NAT IMMUNOL, V14, P1007, DOI 10.1038/ni.2683; Cai L, 2011, MOL CELL, V42, P426, DOI 10.1016/j.molcel.2011.05.004; Carey BW, 2015, NATURE, V518, P413, DOI 10.1038/nature13981; Castillo J, 2019, CANCER RES, V79, P3916, DOI 10.1158/0008-5472.CAN-18-3622; Cavalli G, 2019, NATURE, V571, P489, DOI 10.1038/s41586-019-1411-0; Chalkiadaki A, 2012, NAT REV ENDOCRINOL, V8, P287, DOI 10.1038/nrendo.2011.225; Chan MWY, 2014, MOL MED, V20, P248, DOI 10.2119/molmed.2013.00159; Chisolm DA, 2018, ANNU REV IMMUNOL, V36, P221, DOI 10.1146/annurev-immunol-042617-053127; Chou WC, 2021, NATURE, V591, P300, DOI 10.1038/s41586-021-03231-w; Cluntun AA, 2015, CANCER METAB, V3, DOI 10.1186/s40170-015-0135-3; de Jesus TJ, 2021, GLYCOBIOLOGY, V31, P812, DOI 10.1093/glycob/cwab001; De Rosa V, 2015, NAT IMMUNOL, V16, P1174, DOI 10.1038/ni.3269; Delacher M, 2021, IMMUNITY, V54, P702, DOI 10.1016/j.immuni.2021.03.007; Delacher M, 2020, IMMUNITY, V52, P295, DOI 10.1016/j.immuni.2019.12.002; Delacher M, 2017, NAT IMMUNOL, V18, P1160, DOI 10.1038/ni.3799; Dominguez-Villar M, 2018, NAT IMMUNOL, V19, P665, DOI 10.1038/s41590-018-0120-4; Ducker GS, 2017, CELL METAB, V25, P27, DOI 10.1016/j.cmet.2016.08.009; Elkhal A, 2016, SCI REP-UK, V6, DOI 10.1038/srep22325; Fallarino F, 2006, J IMMUNOL, V176, P6752, DOI 10.4049/jimmunol.176.11.6752; Feng YQ, 2015, NATURE, V528, P132, DOI 10.1038/nature16141; Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038; Fu Z, 2019, CELL REP, V28, P159, DOI 10.1016/j.celrep.2019.06.024; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Gerken T, 2007, SCIENCE, V318, P1469, DOI 10.1126/science.1151710; Gerriets VA, 2016, NAT IMMUNOL, V17, P1459, DOI 10.1038/ni.3577; Gerriets VA, 2015, J CLIN INVEST, V125, P194, DOI 10.1172/JCI76012; Golovina TN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015868; Hang SY, 2019, NATURE, V576, P143, DOI 10.1038/s41586-019-1785-z; Hayatsu N, 2017, IMMUNITY, V47, P268, DOI 10.1016/j.immuni.2017.07.008; He HQ, 2014, IMMUNOLOGY, V141, P362, DOI 10.1111/imm.12198; Helmin KA, 2020, J CLIN INVEST, V130, P6571, DOI 10.1172/JCI137712; Hosios AM, 2016, DEV CELL, V36, P540, DOI 10.1016/j.devcel.2016.02.012; Ikeda K, 2017, CELL REP, V21, P1824, DOI 10.1016/j.celrep.2017.10.082; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Kawakami R, 2021, IMMUNITY, V54, P947, DOI 10.1016/j.immuni.2021.04.005; Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109; Kinnaird A, 2016, NAT REV CANCER, V16, P694, DOI 10.1038/nrc.2016.82; Kitagawa Y, 2017, NAT IMMUNOL, V18, P173, DOI 10.1038/ni.3646; Klysz D, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab2610; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kurniawan H, 2020, CELL METAB, V31, P920, DOI 10.1016/j.cmet.2020.03.004; Latham T, 2012, NUCLEIC ACIDS RES, V40, P4794, DOI 10.1093/nar/gks066; Li HB, 2017, NATURE, V548, P338, DOI 10.1038/nature23450; Li QT, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6780; Lim SA, 2021, NATURE, V591, P306, DOI 10.1038/s41586-021-03235-6; Liu B, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08300-3; Liu X, 2017, NAT CELL BIOL, V19, P626, DOI 10.1038/ncb3527; Liu YJ, 2013, NAT MED, V19, P1173, DOI 10.1038/nm.3286; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Lu CH, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00488; Lu L, 2017, NAT REV IMMUNOL, V17, P703, DOI 10.1038/nri.2017.75; Lu L, 2014, P NATL ACAD SCI USA, V111, pE3432, DOI 10.1073/pnas.1408780111; Lu TX, 2020, CELL MOL GASTROENTER, V10, P747, DOI 10.1016/j.jcmgh.2020.07.001; Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237; Ma JF, 2021, CHEM REV, V121, P1513, DOI 10.1021/acs.chemrev.0c00884; Marcel N, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah4679; Martinez-Reyes I, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13668-3; McDonnell E, 2016, CELL REP, V17, P1463, DOI 10.1016/j.celrep.2016.10.012; Meier JL, 2013, ACS CHEM BIOL, V8, P2607, DOI 10.1021/cb400689r; Melkonian, 2021, STATPEARLS; Mentch SJ, 2015, CELL METAB, V22, P861, DOI 10.1016/j.cmet.2015.08.024; Metzler B, 2016, J IMMUNOL, V196, P3618, DOI 10.4049/jimmunol.1501756; Mezrich JD, 2010, J IMMUNOL, V185, P3190, DOI 10.4049/jimmunol.0903670; Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613; Mijnheer G, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22975-7; Mikami N, 2020, P NATL ACAD SCI USA, V117, P12258, DOI [10.1073/pnas.1922600117/-/DCSupplemental, 10.1073/pnas.1922600117]; Miska J, 2019, CELL REP, V27, P226, DOI 10.1016/j.celrep.2019.03.029; Montgomery DC, 2015, CHEM BIOL, V22, P1030, DOI 10.1016/j.chembiol.2015.06.015; Moore JR, 2018, J NEUROIMMUNOL, V324, P100, DOI 10.1016/j.jneuroim.2018.09.008; Morales-Nebreda L, 2019, TRANSL RES, V204, P1, DOI 10.1016/j.trsl.2018.08.001; Morikawa H, 2014, P NATL ACAD SCI USA, V111, P5289, DOI 10.1073/pnas.1312717110; Nakaya M, 2014, IMMUNITY, V40, P692, DOI 10.1016/j.immuni.2014.04.007; Newman JC, 2014, DIABETES RES CLIN PR, V106, P173, DOI 10.1016/j.diabres.2014.08.009; Newton R, 2016, NAT IMMUNOL, V17, P618, DOI 10.1038/ni.3466; Obata Y, 2014, NAT IMMUNOL, V15, P571, DOI 10.1038/ni.2886; Ohkura N, 2020, IMMUNITY, V52, P1119, DOI 10.1016/j.immuni.2020.04.006; Ohkura N, 2020, CELL RES, V30, P465, DOI 10.1038/s41422-020-0324-7; Ohkura N, 2012, IMMUNITY, V37, P785, DOI 10.1016/j.immuni.2012.09.010; Ohnmacht C, 2015, SCIENCE, V349, P989, DOI 10.1126/science.aac4263; Pendleton KE, 2017, CELL, V169, P824, DOI 10.1016/j.cell.2017.05.003; Peng M, 2016, SCIENCE, V354, P481, DOI 10.1126/science.aaf6284; Pfalzer AC, 2014, PHYSIOL GENOMICS, V46, P617, DOI 10.1152/physiolgenomics.00056.2014; Picca A, 2015, MITOCHONDRION, V25, P67, DOI 10.1016/j.mito.2015.10.001; Pietrocola F, 2015, CELL METAB, V21, P805, DOI 10.1016/j.cmet.2015.05.014; Polansky JK, 2008, EUR J IMMUNOL, V38, P1654, DOI 10.1002/eji.200838105; Pompura SL, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI138519; Procaccini C, 2021, IMMUNITY, V54, P1543, DOI 10.1016/j.immuni.2021.04.014; Procaccini C, 2016, IMMUNITY, V44, P406, DOI 10.1016/j.immuni.2016.01.028; Reid MA, 2017, NAT CELL BIOL, V19, P1298, DOI 10.1038/ncb3629; Ryall JG, 2015, CELL STEM CELL, V16, P171, DOI 10.1016/j.stem.2014.12.004; Sabari BR, 2015, MOL CELL, V58, P203, DOI 10.1016/j.molcel.2015.02.029; Saravia J, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaw6443; Sebastian C, 2012, J BIOL CHEM, V287, P42444, DOI 10.1074/jbc.R112.402768; Sefik E, 2015, SCIENCE, V349, P993, DOI 10.1126/science.aaa9420; Shi H, 2019, IMMUNITY, V51, P1012, DOI 10.1016/j.immuni.2019.10.001; Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278; Sinclair LV, 2013, NAT IMMUNOL, V14, P500, DOI 10.1038/ni.2556; Singer BD, 2015, AM J RESP CELL MOL, V52, P641, DOI 10.1165/rcmb.2014-0327OC; Song XY, 2020, NATURE, V577, P410, DOI 10.1038/s41586-019-1865-0; Sun IH, 2018, J IMMUNOL, V201, P481, DOI 10.4049/jimmunol.1701477; Swamy M, 2016, NAT IMMUNOL, V17, P712, DOI 10.1038/ni.3439; Takahashi H, 2006, MOL CELL, V23, P207, DOI 10.1016/j.molcel.2006.05.040; Tao R, 2007, NAT MED, V13, P1299, DOI 10.1038/nm1652; Tong JY, 2018, CELL RES, V28, P253, DOI 10.1038/cr.2018.7; van Loosdregt J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019047; Vasanthakumar A, 2020, NATURE, V579, P581, DOI 10.1038/s41586-020-2040-3; Wang HP, 2020, NAT IMMUNOL, V21, P298, DOI 10.1038/s41590-019-0589-5; Wang LQ, 2016, EBIOMEDICINE, V13, P99, DOI 10.1016/j.ebiom.2016.10.018; Wapenaar H, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0225-2; Watson MJ, 2021, NATURE, V591, P645, DOI 10.1038/s41586-020-03045-2; Wei G, 2009, IMMUNITY, V30, P155, DOI 10.1016/j.immuni.2008.12.009; Weinberg SE, 2019, NATURE, V565, P495, DOI 10.1038/s41586-018-0846-z; Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097; Xiao MT, 2012, GENE DEV, V26, P1326, DOI 10.1101/gad.191056.112; Xiao Y, 2014, CELL REP, V7, P1471, DOI 10.1016/j.celrep.2014.04.021; Xu T, 2017, NATURE, V548, P228, DOI 10.1038/nature23475; Yang M, 2016, NAT REV CANCER, V16, P650, DOI 10.1038/nrc.2016.81; Yang RL, 2015, IMMUNITY, V43, P251, DOI 10.1016/j.immuni.2015.07.017; Yang XY, 2017, NAT REV MOL CELL BIO, V18, P452, DOI 10.1038/nrm.2017.22; Zappasodi R, 2021, NATURE, V591, P652, DOI 10.1038/s41586-021-03326-4; Zhang HF, 2020, NAT CELL BIOL, V22, P18, DOI 10.1038/s41556-019-0440-0; Zhang Q, 2019, NAT REV IMMUNOL, V19, P417, DOI 10.1038/s41577-019-0151-6; Zhang XL, 2018, CELL REP, V24, P607, DOI 10.1016/j.celrep.2018.06.052; Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750	133	0	0	4	24	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 5	2021	12								728783	10.3389/fimmu.2021.728783	http://dx.doi.org/10.3389/fimmu.2021.728783			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UD6AR	34421930	gold, Green Published			2022-12-18	WOS:000687288000001
J	Pereira, M; Lee, NT; Noonan, J; Willcox, AEH; Calvello, I; Georgy, SR; Selan, C; Chia, JS; Hauw, W; Wang, XW; Peter, K; Robson, SC; Nandurkar, HH; Sashindranath, M				Pereira, Melrine; Lee, Natasha Ting; Noonan, Jonathan; Willcox, Abbey E. H.; Calvello, Ilaria; Georgy, Smitha Rose; Selan, Carly; Chia, Joanne S.; Hauw, Wayne; Wang, Xiaowei; Peter, Karlheinz; Robson, Simon C.; Nandurkar, Harshal H.; Sashindranath, Maithili			Early Endothelial Activation in a Mouse Model of Graft vs Host Disease Following Chemotherapy	FRONTIERS IN IMMUNOLOGY			English	Article						graft vs host disease; endothelial cell dysfunction; chemotherapy; mouse model; allogeneic haematopoietic stem cell transplant; allo-HSCT; monocrotaline; sinusoldal obstruction syndrome	BONE-MARROW-TRANSPLANTATION; GROWTH-FACTOR; MURINE MODEL; INJURY; CELLS; GVHD; COMPLICATIONS; DYSFUNCTION; EXPRESSION; TARGET	Allogenic hematopoietic stem cell transplant (allo-HSCT) can lead to sinusoidal obstruction syndrome (SOS) and graft-versus-host disease (GvHD) in some individuals. GvHD is characterised by an immune triggered response that arises due to donor T cells recognizing the recipient tissue as "foreign". SOS results in impaired liver function due to microvascular thrombosis and consequent obstruction of liver sinusoids. Endothelial damage occurs following chemotherapy and allo-HSCT and is strongly associated with GvHD onset as well as hepatic SOS. Animal models of GvHD are rarely clinically relevant, and endothelial dysfunction remains uncharacterised. Here we established and characterised a clinically relevant model of GvHD wherein Balb/C mice were subjected to myeloablative chemotherapy followed by transplantation of bone marrow (BM) cells +/- splenic T-cells from C57Bl6 mice, resulting in a mismatch of major histocompatibility complexes (MHC). Onset of disease indicated by weight loss and apoptosis in the liver and intestine was discovered at day 6 post-transplant in mice receiving BM+T-cells, with established GvHD detectable by histology of the liver within 3 weeks. Together with significant increases in pro-inflammatory cytokine gene expression in the liver and intestine, histopathological signs of GvHD and a significant increase in CD4+ and CD8+ effector and memory T-cells were seen. Endothelial activation including upregulation of vascular cell adhesion molecule (VCAM)- 1 and downregulation of endothelial nitric oxide synthase (eNOS) as well as thrombosis in the liver indicated concomitant hepatic SOS. Our findings confirm that endothelial activation is an early sign of acute GvHD and SOS in a clinically relevant mouse model of GvHD based on myeloablative chemotherapy. Preventing endothelial activation may be a viable therapeutic strategy to prevent GvHD.	[Pereira, Melrine; Lee, Natasha Ting; Willcox, Abbey E. H.; Calvello, Ilaria; Selan, Carly; Chia, Joanne S.; Hauw, Wayne; Nandurkar, Harshal H.; Sashindranath, Maithili] Monash Univ, Alfred Hosp, Australian Ctr Blood Dis, Cent Clin Sch, Melbourne, Vic, Australia; [Noonan, Jonathan; Wang, Xiaowei; Peter, Karlheinz] Baker Heart & Diabet Inst, Atherothrombosis & Vasc Biol Lab, Melbourne, Vic, Australia; [Noonan, Jonathan; Wang, Xiaowei; Peter, Karlheinz] Univ Melbourne, Dept Cardiometab Hlth, Melbourne, Vic, Australia; [Noonan, Jonathan] Monash Univ, Dept Immunol, Melbourne, Vic, Australia; [Georgy, Smitha Rose] Univ Melbourne, Melbourne Vet Sch, Dept Anat Pathol, Fac Vet & Agr Sci, Werribee, Vic, Australia; [Robson, Simon C.] Harvard Med Sch, Dept Med, Div Gastroenterol, Boston, MA 02115 USA	Florey Institute of Neuroscience & Mental Health; Monash University; University of Melbourne; Monash University; University of Melbourne; Harvard University; Harvard Medical School	Sashindranath, M (corresponding author), Monash Univ, Alfred Hosp, Australian Ctr Blood Dis, Cent Clin Sch, Melbourne, Vic, Australia.	maithili.sashindranath@monash.edu		Noonan, Jonathan/0000-0001-9173-0903; Wang, Xiaowei/0000-0001-8658-7399	NHMRC Project [APP1141046]	NHMRC Project(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by NHMRC Project grant APP1141046 awarded to HN.	Al-Hashmi S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030897; Biedermann BC, 2002, LANCET, V359, P2078, DOI 10.1016/S0140-6736(02)08907-9; Blix ES, 2016, LEUKEMIA LYMPHOMA, V57, P2752, DOI 10.1080/10428194.2016.1201566; Buser TA, 2019, EUR J HAEMATOL, V103, P472, DOI 10.1111/ejh.13310; Carreras E, 2011, BONE MARROW TRANSPL, V46, P1495, DOI 10.1038/bmt.2011.65; Cooke KR, 2008, BIOL BLOOD MARROW TR, V14, P23, DOI 10.1016/j.bbmt.2007.10.008; Daglas M, 2019, CELL REP, V29, P1178, DOI 10.1016/j.celrep.2019.09.046; Deschaumes C, 2007, LAB INVEST, V87, P417, DOI 10.1038/labinvest.3700541; Dietrich S, 2013, BIOL BLOOD MARROW TR, V19, P22, DOI 10.1016/j.bbmt.2012.09.018; Eyrich M, 2005, BIOL BLOOD MARROW TR, V11, P371, DOI 10.1016/j.bbmt.2005.02.002; Garcia-Bernal D, 2020, J CELL MOL MED, V24, P8031, DOI 10.1111/jcmm.15434; Ghimire S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00079; Henden AS, 2015, J IMMUNOL, V194, P4604, DOI 10.4049/jimmunol.1500117; Hildebrandt GC, 2020, BRIT J HAEMATOL, V190, P508, DOI 10.1111/bjh.16621; Ikezoe T, 2017, BONE MARROW TRANSPL, V52, P73, DOI 10.1038/bmt.2016.195; Kroger N, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01756; Lee NT, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75034-4; Martinez-Sanchez J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02339; Matsukuma KE, 2016, J GASTROINTEST ONCOL, V7, pS21, DOI 10.3978/j.issn.2078-6891.2015.036; Medinger M, 2013, BONE MARROW TRANSPL, V48, P715, DOI 10.1038/bmt.2012.200; Pagliuca S, 2019, BLOOD ADV, V3, P2424, DOI 10.1182/bloodadvances.2019000143; Pober JS, 2007, NAT REV IMMUNOL, V7, P803, DOI 10.1038/nri2171; Qiao JL, 2015, EXP MOL PATHOL, V98, P73, DOI 10.1016/j.yexmp.2014.12.008; Richard S, 1996, BONE MARROW TRANSPL, V18, P955; Riesner K, 2016, BONE MARROW TRANSPL, V51, P410, DOI 10.1038/bmt.2015.279; Riesner K, 2017, BLOOD, V129, P2021, DOI 10.1182/blood-2016-08-736314; Sadeghi B, 2008, BONE MARROW TRANSPL, V42, P807, DOI 10.1038/bmt.2008.261; Sadeghi B, 2010, CLIN DEV IMMUNOL, DOI 10.1155/2010/142943; Sakai M, 2009, BONE MARROW TRANSPL, V44, P441, DOI 10.1038/bmt.2009.56; Salat C, 1997, BONE MARROW TRANSPL, V19, P909, DOI 10.1038/sj.bmt.1700767; Sashindranath M, 2019, RES PRACT THROMB HAE, V3, P197, DOI 10.1002/rth2.12184; Sashindranath M, 2012, BRAIN, V135, P3251, DOI 10.1093/brain/aws178; Schmid PM, 2014, BIOL BLOOD MARROW TR, V20, P1493, DOI 10.1016/j.bbmt.2014.05.002; Schroeder MA, 2011, DIS MODEL MECH, V4, P318, DOI 10.1242/dmm.006668; Socie G, 2009, BLOOD, V114, P4327, DOI 10.1182/blood-2009-06-204669; Tichelli A, 2008, BEST PRACT RES CL HA, V21, P139, DOI 10.1016/j.beha.2008.02.002; van Leeuwen L, 2002, BONE MARROW TRANSPL, V29, P151, DOI 10.1038/sj.bmt.1703328; Vion AC, 2015, SEMIN THROMB HEMOST, V41, P629, DOI 10.1055/s-0035-1556728; Zeng LY, 2012, CELL BIOCHEM BIOPHYS, V64, P213, DOI 10.1007/s12013-012-9387-5	39	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 5	2021	12								708554	10.3389/fimmu.2021.708554	http://dx.doi.org/10.3389/fimmu.2021.708554			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UE0UU	34421913	Green Published, gold			2022-12-18	WOS:000687614300001
J	Pisetsky, DS; Voll, R; Buzas, EI				Pisetsky, David S.; Voll, Reinhard; Buzas, Edit I.			Editorial: The Role of Nuclear Molecules in the Pathogenesis of Autoimmune Disease	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						DNA; HMGB1; NETosis; autoimmunity; systemic lupus; extracellular vesicles			[Pisetsky, David S.] Duke Univ, Med Ctr, Dept Med & Immunol, Durham, NC 27708 USA; [Pisetsky, David S.] Durham Vet Adm Med Ctr, Med Res Serv, Durham, NC 27705 USA; [Voll, Reinhard] Univ Freiburg, Dept Rheumatol & Clin Immunol, Med Ctr, Fac Med, Freiburg, Germany; [Buzas, Edit I.] Semmelweis Univ, HCEMM SU & ELKH SE Immune Proteogen Res Extracell, Budapest, Hungary	Duke University; University of Freiburg; Eotvos Lorand Research Network; Office for Supported Research Groups (ELKH); Semmelweis University	Pisetsky, DS (corresponding author), Duke Univ, Med Ctr, Dept Med & Immunol, Durham, NC 27708 USA.; Pisetsky, DS (corresponding author), Durham Vet Adm Med Ctr, Med Res Serv, Durham, NC 27705 USA.	David.Pisetsky@duke.edu			VA Merit Review grant; NIH [1RO1AR073935]	VA Merit Review grant(US Department of Veterans Affairs); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	DSP is supported by a VA Merit Review grant as well as an NIH grant (1RO1AR073935).		0	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 5	2021	12								737923	10.3389/fimmu.2021.737923	http://dx.doi.org/10.3389/fimmu.2021.737923			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UE1AZ	34421932	Green Published, gold			2022-12-18	WOS:000687630400001
J	Domaszewska, T; Zyla, J; Otto, R; Kaufmann, SHE; Weiner, J				Domaszewska, Teresa; Zyla, Joanna; Otto, Raik; Kaufmann, Stefan H. E.; Weiner, January			Gene Set Enrichment Analysis Reveals Individual Variability in Host Responses in Tuberculosis Patients	FRONTIERS IN IMMUNOLOGY			English	Article						tuberculosis; endotypes; individual variability in host response; interferon; immune response; gene set enrichment analysis	TRANSCRIPTIONAL SIGNATURE; ACTIVE TUBERCULOSIS; EXPRESSION OMNIBUS; MONONUCLEAR-CELLS; IMMUNE-RESPONSE; BLOOD; KEGG	Group-aggregated responses to tuberculosis (TB) have been well characterized on a molecular level. However, human beings differ and individual responses to infection vary. We have combined a novel approach to individual gene set analysis (GSA) with the clustering of transcriptomic profiles of TB patients from seven datasets in order to identify individual molecular endotypes of transcriptomic responses to TB. We found that TB patients differ with respect to the intensity of their hallmark interferon (IFN) responses, but they also show variability in their complement system, metabolic responses and multiple other pathways. This variability cannot be sufficiently explained with covariates such as gender or age, and the molecular endotypes are found across studies and populations. Using datasets from a Cynomolgus macaque model of TB, we revealed that transcriptional signatures of different molecular TB endotypes did not depend on TB progression post-infection. Moreover, we provide evidence that patients with molecular endotypes characterized by high levels of IFN responses (IFN-rich), suffered from more severe lung pathology than those with lower levels of IFN responses (IFN-low). Harnessing machine learning (ML) models, we derived gene signatures classifying IFN-rich and IFN-low TB endotypes and revealed that the IFN-low signature allowed slightly more reliable overall classification of TB patients from non-TB patients than the IFN-rich one. Using the paradigm of molecular endotypes and the ML-based predictions allows more precisely tailored treatment regimens, predicting treatment-outcome with higher accuracy and therefore bridging the gap between conventional treatment and precision medicine.	[Domaszewska, Teresa; Kaufmann, Stefan H. E.; Weiner, January] Max Planck Inst Infect Biol, Dept Immunol, Berlin, Germany; [Domaszewska, Teresa] Robert Koch Inst, Dept Infect Dis Epidemiol, Berlin, Germany; [Zyla, Joanna] Silesian Tech Univ, Dept Data Sci & Engn, Gliwice, Poland; [Otto, Raik] Humboldt Univ, Inst Comp Sci, Knowledge Management Bioinformat, Berlin, Germany; [Kaufmann, Stefan H. E.] Max Planck Inst Biophys Chem, Emeritus Grp Syst Immunol, Gottingen, Germany; [Kaufmann, Stefan H. E.] Texas A&M Univ, Hagler Inst Adv Study, College Stn, TX USA	Max Planck Society; Robert Koch Institute; Silesian University of Technology; Humboldt University of Berlin; Max Planck Society; Texas A&M University System; Texas A&M University College Station	Weiner, J (corresponding author), Max Planck Inst Infect Biol, Dept Immunol, Berlin, Germany.	january.weiner@bihealth.de		Zyla, Joanna/0000-0002-2895-7969; Weiner, January/0000-0003-1438-7819	Max Planck Society; Silesian University of Technology	Max Planck Society(Max Planck SocietyFoundation CELLEX); Silesian University of Technology	This work received intramural funding from the Max Planck Society to SK. This work was partially supported by the Silesian University of Technology grant for Support and Development of Research Potential (JZ).	Anderson ST, 2014, NEW ENGL J MED, V370, P1712, DOI 10.1056/NEJMoa1303657; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berry MPR, 2010, NATURE, V466, P973, DOI 10.1038/nature09247; Blankley S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162220; Blankley S, 2016, EUR RESPIR J, V47, P1873, DOI 10.1183/13993003.02121-2015; Bloom CI, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070630; Borah K, 2019, CELL REP, V29, P3580, DOI 10.1016/j.celrep.2019.11.037; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Cai Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092340; Chaussabel D, 2008, IMMUNITY, V29, P150, DOI 10.1016/j.immuni.2008.05.012; Cliff JM, 2015, IMMUNOL REV, V264, P88, DOI 10.1111/imr.12269; Cliff JM, 2013, J INFECT DIS, V207, P18, DOI 10.1093/infdis/jis499; Coleman MT, 2014, INFECT IMMUN, V82, P2400, DOI 10.1128/IAI.01599-13; Dawany N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089925; Diel R, 2010, CHEST, V137, P952, DOI 10.1378/chest.09-2350; DiNardo AR, 2021, MED-CAMBRIDGE, V2, P217, DOI 10.1016/j.medj.2020.11.003; Durinck S, 2005, BIOINFORMATICS, V21, P3439, DOI 10.1093/bioinformatics/bti525; Durinck S, 2009, NAT PROTOC, V4, P1184, DOI 10.1038/nprot.2009.97; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Gideon HP, 2016, J IMMUNOL, V197, P4817, DOI 10.4049/jimmunol.1601138; Guler R, 2019, MUCOSAL IMMUNOL, V12, P390, DOI 10.1038/s41385-018-0108-2; Hemann EA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01707; James Melville, 2020, Arxiv, DOI arXiv:1802.03426; Kaforou M, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001538; Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092; Kanehisa M, 2016, NUCLEIC ACIDS RES, V44, pD457, DOI 10.1093/nar/gkv1070; Kaufmann SHE, 2018, NAT REV DRUG DISCOV, V17, P35, DOI 10.1038/nrd.2017.162; Kuhn M, 2008, J STAT SOFTW, V28, P1, DOI 10.18637/jss.v028.i05; Li S, 2014, NAT IMMUNOL, V15, P195, DOI 10.1038/ni.2789; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Maertzdorf J, 2016, EMBO MOL MED, V8, P86, DOI 10.15252/emmm.201505790; Maertzdorf J, 2012, P NATL ACAD SCI USA, V109, P7853, DOI 10.1073/pnas.1121072109; Maertzdorf Jeroen, 2011, PLoS One, V6, pe26938, DOI 10.1371/journal.pone.0026938; O'Garra A, 2013, ANNU REV IMMUNOL, V31, P475, DOI 10.1146/annurev-immunol-032712-095939; Philips L, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2657-5; R Core Team, 2021, R LANG ENV STAT COMP; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Roe JK, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87238; Rusinova I, 2013, NUCLEIC ACIDS RES, V41, pD1040, DOI 10.1093/nar/gks1215; Scheuermann L, 2020, AM J RESP CRIT CARE, V202, P730, DOI 10.1164/rccm.201910-2063OC; Sean D, 2007, BIOINFORMATICS, V23, P1846, DOI 10.1093/bioinformatics/btm254; Singhania A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04579-w; Suliman S, 2018, AM J RESP CRIT CARE, V197, P1198, DOI 10.1164/rccm.201711-2340OC; Sutherland A, 2011, CRIT CARE, V15, DOI 10.1186/cc10274; Tang BMP, 2009, CRIT CARE MED, V37, P882, DOI 10.1097/CCM.0b013e31819b52fd; Trimble WS, 2007, CELL, V130, P12, DOI 10.1016/j.cell.2007.06.039; Verhagen LM, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-74; Walter ND, 2016, J CLIN MICROBIOL, V54, P274, DOI 10.1128/JCM.01990-15; Weiner J., 2017, TMOD MODULE ENRICHME; Weiner J, 2016, PEERJ PREPRINTS, V4, DOI 10.7287/peerj.preprints.2420v1; Weiner J., 2020, pca3D: Three Dimensional PCA Plots. R Package Version 0.10.2 from.; WHO, 2021, TUBERCULOSIS; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wong HR, 2009, CRIT CARE MED, V37, P1558, DOI 10.1097/CCM.0b013e31819fcc08; Yamaguchi KD, 2008, J NEUROIMMUNOL, V195, P116, DOI 10.1016/j.jneuroim.2007.12.007; Zak DE, 2016, LANCET, V387, P2312, DOI 10.1016/S0140-6736(15)01316-1; Zyla J, 2019, BIOINFORMATICS, V35, P5146, DOI 10.1093/bioinformatics/btz447	58	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 4	2021	12								694680	10.3389/fimmu.2021.694680	http://dx.doi.org/10.3389/fimmu.2021.694680			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UF2AX	34421903	Green Published, gold			2022-12-18	WOS:000688382900001
J	Gies, V; Dieudonne, Y; Morel, F; Sougakoff, W; Carapito, R; Martin, A; Weingertner, N; Jacquel, L; Hubele, F; Kuhnert, C; Jung, S; Schramm, F; Boyer, P; Hansmann, Y; Danion, F; Korganow, AS; Guffroy, A				Gies, Vincent; Dieudonne, Yannick; Morel, Florence; Sougakoff, Wladimir; Carapito, Raphael; Martin, Aurelie; Weingertner, Noelle; Jacquel, Lea; Hubele, Fabrice; Kuhnert, Cornelia; Jung, Sophie; Schramm, Frederic; Boyer, Pierre; Hansmann, Yves; Danion, Francois; Korganow, Anne-Sophie; Guffroy, Aurelien			Case Report: Acquired Disseminated BCG in the Context of a Delayed Immune Reconstitution After Hematological Malignancy	FRONTIERS IN IMMUNOLOGY			English	Article						BCG; BCGosis-susceptible PIDs; Immunodeficiency; hematological malignancies; contamination; case report	BACILLE CALMETTE-GUERIN; MENDELIAN SUSCEPTIBILITY; MYCOBACTERIAL DISEASE; AUTOANTIBODIES; THERAPY	Context Disseminated infections due to Mycobacterium bovis Bacillus Calmette-Guerin (BCG) are unusual and occur mostly in patients with inborn error of immunity (IEI) or acquired immunodeficiency. However, cases of secondary BCGosis due to intravesical BCG instillation have been described. Herein, we present a case of severe BCGosis occurring in an unusual situation. C ase Description We report one case of severe disseminated BCG disease occurring after hematological malignancy in a 48-year-old man without BCG instillation and previously vaccinated in infancy with no complication. Laboratory investigations demonstrated that he was not affected by any known or candidate gene of IEI or intrinsic cellular defect involving IFN gamma pathway. Whole genome sequencing of the BCG strain showed that it was most closely related to the M. bovis BCG Tice strain, suggesting an unexpected relationship between the secondary immunodeficiency of the patient and the acquired BCG infection. Conclusion This case highlights the fact that, in addition to the IEI, physicians, as well as microbiologists and pharmacists should be aware of possible acquired disseminated BCG disease in secondary immunocompromised patients treated in centers that administrate BCG for bladder cancers.	[Gies, Vincent; Dieudonne, Yannick; Jacquel, Lea; Korganow, Anne-Sophie; Guffroy, Aurelien] Strasbourg Univ Hosp, Natl Reference Ctr Syst Autoimmune Dis CNR RESO, Tertiary Ctr Primary Immunodeficiency, Dept Clin Immunol & Internal Med, Strasbourg, France; [Gies, Vincent; Dieudonne, Yannick; Carapito, Raphael; Jacquel, Lea; Jung, Sophie; Korganow, Anne-Sophie; Guffroy, Aurelien] Univ Strasbourg, Federat Hosp Univ OMICARE,Fac Med, Federat Med Translationnelle Strasbourg FMTS,Tran, INSERM UMR S1109,Inst Themat Interdisciplinaire I, Strasbourg, France; [Gies, Vincent] Univ Strasbourg, Fac Pharm, Illkirch Graffenstaden, France; [Morel, Florence; Sougakoff, Wladimir] Sorbonne Univ, Hop Pitie Salpetriere, AP HP, Lab Bacteriol Hyg,Ctr Natl Reference Mycobacterie, Paris, France; [Morel, Florence; Sougakoff, Wladimir] Sorbonne Univ, Ctr Immunol & Malad Infect Cimi Paris, INSERM, UMR 1135, Paris, France; [Carapito, Raphael] Strasbourg Univ Hosp, Immunol Lab, Strasbourg, France; [Martin, Aurelie; Hansmann, Yves; Danion, Francois] Strasbourg Univ Hosp, Dept Infectiol, Strasbourg, France; [Weingertner, Noelle] Strasbourg Univ Hosp, Dept Pathol, Strasbourg, France; [Hubele, Fabrice] Univ Hosp Strasbourg, Dept Nucl Med & Mol Imaging, ICANS, Strasbourg, France; [Kuhnert, Cornelia] Strasbourg Univ Hosp, Dept Internal Med, Strasbourg, France; [Jung, Sophie] Hop Univ Strasbourg, Ctr Reference Malad Rares Orales & Dent O Rares, Pole Med & Chirurg Bucco Dent, Strasbourg, France; [Schramm, Frederic; Boyer, Pierre] Strasbourg Univ Hosp, Inst Bacteriol, Lab Bacteriol, FMTS CHRU Strasbourg,Virulence Bacterienne Precoc, Strasbourg, France	CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Guffroy, A (corresponding author), Strasbourg Univ Hosp, Natl Reference Ctr Syst Autoimmune Dis CNR RESO, Tertiary Ctr Primary Immunodeficiency, Dept Clin Immunol & Internal Med, Strasbourg, France.; Guffroy, A (corresponding author), Univ Strasbourg, Federat Hosp Univ OMICARE,Fac Med, Federat Med Translationnelle Strasbourg FMTS,Tran, INSERM UMR S1109,Inst Themat Interdisciplinaire I, Strasbourg, France.	aurelien.guffroy@chru-strasbourg.fr	BOYER, Pierre/AAL-6569-2020; Jung, Sophie/AAA-5556-2021; Morel, Florence/ABC-4872-2020; SOUGAKOFF, Wladimir/O-9754-2017; Carapito, Raphael/O-5317-2016; Schramm, Frederic/M-8166-2015; Danion, Francois/Q-2764-2017	Jung, Sophie/0000-0002-7925-1077; Morel, Florence/0000-0003-0848-1198; SOUGAKOFF, Wladimir/0000-0002-2447-517X; Carapito, Raphael/0000-0002-7036-442X; Schramm, Frederic/0000-0002-6889-515X; Gies, Vincent/0000-0002-8658-8604; Guffroy, Aurelien/0000-0003-0615-5305; Danion, Francois/0000-0003-3907-0658; Korganow, Anne-Sophie/0000-0002-1664-6311	European regional development fund (ERDF); Hopitaux Universitaires de Strasbourg	European regional development fund (ERDF)(European Commission); Hopitaux Universitaires de Strasbourg	We thank the physicians who helped us to take care of the patient reported in themanuscript. We thank the "Hopitaux Universitaires de Strasbourg" for their support; the ERNs (European Reference Networks for rare disease), RITA (Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases), and ReCONNET (European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases); and the INTERREG V program [PERSONALIS project, co-financed by the European regional development fund (ERDF)].	Al-Muhsen S, 2008, J ALLERGY CLIN IMMUN, V122, P1043, DOI 10.1016/j.jaci.2008.10.037; Boisson-Dupuis S, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aau8714; Bousfiha A, 2020, J CLIN IMMUNOL, V40, P66, DOI 10.1007/s10875-020-00758-x; Browne SK, 2010, LANCET INFECT DIS, V10, P875, DOI 10.1016/S1473-3099(10)70196-1; Bustamante J, 2014, SEMIN IMMUNOL, V26, P454, DOI 10.1016/j.smim.2014.09.008; COPPES MJ, 1992, CLIN INFECT DIS, V14, P662, DOI 10.1093/clinids/14.3.662; Costagliola D, 2005, CLIN INFECT DIS, V41, P1772, DOI 10.1086/498315; Fekrvand S, 2020, J ALLER CL IMM-PRACT, V8, P1371, DOI 10.1016/j.jaip.2020.01.038; Kampmann B, 2005, J CLIN INVEST, V115, P2480, DOI 10.1172/JCI19316; Levi LI, 2019, MED MALADIES INFECT, V49, P350, DOI 10.1016/j.medmal.2018.11.014; Liew WK, 2019, J CLIN IMMUNOL, V39, P512, DOI 10.1007/s10875-019-00652-1; Lukacs S, 2013, Case Rep Urol, V2013, P821526, DOI 10.1155/2013/821526; Meije Y, 2017, CLIN INFECT DIS, V65, P1136, DOI 10.1093/cid/cix496; Oladiran O, 2020, J COMMUNITY HOSP INT, V10, P168, DOI 10.1080/20009666.2020.1742475; Asin MAPJ, 2014, MEDICINE, V93, P236, DOI 10.1097/MD.0000000000000119; Saharia KK, 2013, CELL, V155, P505, DOI 10.1016/j.cell.2013.09.045; STONE MM, 1995, NEW ENGL J MED, V333, P561, DOI 10.1056/NEJM199508313330905; To U, 2014, CASE REP MED, V2014, DOI 10.1155/2014/362845; Uchida K, 2007, NEW ENGL J MED, V356, P567, DOI 10.1056/NEJMoa062505; Vos MC, 2003, J INFECT DIS, V188, P1332, DOI 10.1086/379034; Waecker NJ, 2000, CLIN INFECT DIS, V30, P356, DOI 10.1086/313652; Westhovens Ine M, 2016, BMJ Case Rep, V2016, DOI 10.1136/bcr-2016-215599	22	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 3	2021	12								696268	10.3389/fimmu.2021.696268	http://dx.doi.org/10.3389/fimmu.2021.696268			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UO8LT	34413849	Green Published, gold			2022-12-18	WOS:000694943600001
J	Marinescu, CI; Preda, MB; Neculachi, CA; Rusu, EG; Popescu, S; Burlacu, A				Marinescu, Catalina-Iolanda; Preda, Mihai Bogdan; Neculachi, Carmen Alexandra; Rusu, Evelyn Gabriela; Popescu, Sinziana; Burlacu, Alexandrina			Identification of a Hematopoietic Cell Population Emerging From Mouse Bone Marrow With Proliferative Potential In Vitro and Immunomodulatory Capacity	FRONTIERS IN IMMUNOLOGY			English	Article						mesenchymal stromal cells; Ly-6C; bone marrow-derived proliferating hematopoietic cells; CCL-6; immunomodulation	MESENCHYMAL STEM-CELLS; STROMAL CELLS; SUPPRESSOR-CELLS; THERAPY; GROWTH; CCL6; TRANSPLANTATION; TUMORIGENESIS; ACTIVATION; AUTOIMMUNE	There is continuing interest in therapeutic applications of bone marrow-derived mesenchymal stromal cells (MSC). Unlike human counterparts, mouse MSC are difficult to propagate in vitro due to their contamination with adherent hematopoietic cells that overgrow the cultures. Here we investigated the properties of these contaminating cells, referred to as bone marrow-derived proliferating hematopoietic cells (BM-PHC). The results showed that both BM-PHC and MSC had strong immunomodulatory properties on T cells in vitro, with PGE2 and NO involved in this mechanism. However, BM-PHC were stronger immunomodulators than MSC, with CCL-6 identified as putative molecule responsible for superior effects. In vivo studies showed that, in contrast to BM-PHC, MSC endorsed a more rapid xenograft tumor rejection, thus indicating a particular context in which only MSC therapy would produce positive outcomes. In conclusion, bone marrow contains two cell populations with immunomodulatory properties, which are valuable sources for therapeutic studies in specific disease-relevant contexts.	[Marinescu, Catalina-Iolanda; Preda, Mihai Bogdan; Neculachi, Carmen Alexandra; Rusu, Evelyn Gabriela; Popescu, Sinziana; Burlacu, Alexandrina] Inst Cellular Biol & Pathol Nicolae Simionescu, Lab Stem Cell Biol, Dept Regenerat Med, Bucharest, Romania	Romanian Academy of Sciences; Nicolae Simionescu Institute of Cellular Biology & Pathology	Burlacu, A (corresponding author), Inst Cellular Biol & Pathol Nicolae Simionescu, Lab Stem Cell Biol, Dept Regenerat Med, Bucharest, Romania.	sanda.burlacu@icbp.ro	Marinescu, Cătălina Iolanda/HGE-5327-2022; Nastase-Rusu, Evelyn Gabriela/AAD-2524-2022; Preda, Mihai Bogdan/C-1646-2013	Marinescu, Cătălina Iolanda/0000-0003-0727-3645; Nastase-Rusu, Evelyn Gabriela/0000-0001-7857-4117; Preda, Mihai Bogdan/0000-0003-2500-4078	European Regional Development Fund through the Competitiveness Operational Program 2014-2020 (POC-A.1A.1.1.4-E-2015) [P 37 668]; Romanian Ministry of Education [PN-III-P1-1.1-PD-20161903, 133PD/2018, PN-III-P4-ID-PCE-20201340, 122/2021]	European Regional Development Fund through the Competitiveness Operational Program 2014-2020 (POC-A.1A.1.1.4-E-2015); Romanian Ministry of Education(Ministry of Education and Research - Romania)	This work was supported by a project co-financed by the European Regional Development Fund through the Competitiveness Operational Program 2014-2020 (POC-A.1A.1.1.4-E-2015, ID: P 37 668, acronym DIABETER) and Romanian Ministry of Education (PN-III-P1-1.1-PD-20161903, contract no 133PD/2018 and PN-III-P4-ID-PCE-20201340-contract 122/2021).	Abdi R, 2008, DIABETES, V57, P1759, DOI 10.2337/db08-0180; Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Balaji S, 2012, ADV WOUND CARE, V1, P159, DOI 10.1089/wound.2012.0361; Ben Nasr M, 2015, ACTA DIABETOL, V52, P917, DOI 10.1007/s00592-015-0735-y; Bianchi G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048654; Bloom DD, 2015, CYTOTHERAPY, V17, P140, DOI 10.1016/j.jcyt.2014.10.002; Boregowda SV, 2016, METHODS MOL BIOL, V1416, P205, DOI 10.1007/978-1-4939-3584-0_11; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Burlacu A, 2013, STEM CELLS DEV, V22, P643, DOI 10.1089/scd.2012.0273; Bushkin Y, 2015, J IMMUNOL, V194, P836, DOI 10.4049/jimmunol.1401515; Caplan H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01645; Caroti CM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13477-y; Chen X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.537; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Coelho AL, 2007, J IMMUNOL, V179, P5474, DOI 10.4049/jimmunol.179.8.5474; De Miguel MP, 2012, CURR MOL MED, V12, P574; Dezawa M, 2005, SCIENCE, V309, P314, DOI 10.1126/science.1110364; Fang ZX, 2017, ONCOTARGET, V8, P54173, DOI 10.18632/oncotarget.17013; Fiorina P, 2009, J IMMUNOL, V183, P993, DOI 10.4049/jimmunol.0900803; Galipeau J, 2016, CYTOTHERAPY, V18, P151, DOI 10.1016/j.jcyt.2015.11.008; Harman RM, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.654885; Harris SG, 2002, TRENDS IMMUNOL, V23, P144, DOI 10.1016/S1471-4906(01)02154-8; Hathcock KS., 1999, CURR PROTOC IMMUNOL, V30, P321, DOI [10.1002/0471142735.im0302s30, DOI 10.1002/0471142735.IM0302S30]; Ho IAW, 2013, STEM CELLS, V31, P146, DOI 10.1002/stem.1247; Hu YX, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/6704583; Hubel J, 2015, BIOMEDICINES, V3, P138, DOI 10.3390/biomedicines3010138; Ilangumaran S, 2016, CYTOKINE, V82, P125, DOI 10.1016/j.cyto.2015.12.013; Jones BA, 2010, MOL INTERV, V10, P263, DOI 10.1124/mi.10.5.3; Jung YH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2766; Kabashima-Niibe A, 2013, CANCER SCI, V104, P157, DOI 10.1111/cas.12059; Kwak M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74996-9; Lee HY, 2017, CANCER SCI, V108, P1939, DOI 10.1111/cas.13334; Lee HJ, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.136059; Lee TM, 2019, REDOX BIOL, V27, DOI 10.1016/j.redox.2019.101170; Ling XY, 2010, CANCER MICROENVIRON, V3, P83, DOI 10.1007/s12307-010-0041-8; Liu JL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01843; Marinescu CI, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02344-3; Mendez-Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262; Miura Y, 2006, STEM CELLS, V24, P2428, DOI 10.1634/stemcells.2006-0089; Moll G, 2019, TRENDS MOL MED, V25, P149, DOI 10.1016/j.molmed.2018.12.006; Nakiboneka R, 2019, VACCINE, V37, P113, DOI 10.1016/j.vaccine.2018.11.024; Nardi V, 2009, BLOOD, V113, P3813, DOI 10.1182/blood-2008-07-167189; Nino JLG, 2020, ELIFE, V9, DOI 10.7554/eLife.56554; Odent G, 2015, BIOMATERIALS, V60, P72, DOI 10.1016/j.biomaterials.2015.05.002; Ohlsson LB, 2003, EXP MOL PATHOL, V75, P248, DOI 10.1016/j.yexmp.2003.06.001; Ortiz LA, 2007, P NATL ACAD SCI USA, V104, P11002, DOI 10.1073/pnas.0704421104; Papaccio F, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113595; Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood-2003-09-3070; Preda MB, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03839-w; Preda MB, 2020, J CELL MOL MED, V24, P10889, DOI 10.1111/jcmm.15717; Preda MB, 2014, STEM CELLS, V32, P2123, DOI 10.1002/stem.1687; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Raphael I, 2015, CYTOKINE, V74, P5, DOI 10.1016/j.cyto.2014.09.011; Regmi S, 2019, EUR J CELL BIOL, V98, DOI 10.1016/j.ejcb.2019.04.002; Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014; Rodini Carolina Oliveira, 2018, Oncotarget, V9, P24766, DOI 10.18632/oncotarget.25346; Rodriguez PC, 2005, J EXP MED, V202, P931, DOI 10.1084/jem.20050715; Rodriguez R, 2009, NEOPLASIA, V11, P397, DOI 10.1593/neo.81620; Rosca AM, 2011, STEM CELLS DEV, V20, P1213, DOI 10.1089/scd.2010.0433; Roux C, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01991; Sagi Z, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00517; Sasaki M, 2008, J IMMUNOL, V180, P2581, DOI 10.4049/jimmunol.180.4.2581; Sato K, 2007, BLOOD, V109, P228, DOI 10.1182/blood-2006-02-002246; Schmid M, 2014, EUR J IMMUNOL, V44, P3295, DOI 10.1002/eji.201344335; Semenkow S, 2017, ONCOTARGET, V8, P61072, DOI 10.18632/oncotarget.17851; Shabbir A, 2009, AM J PHYSIOL-HEART C, V296, pH1888, DOI 10.1152/ajpheart.00186.2009; Shi YF, 2018, NAT REV NEPHROL, V14, P493, DOI 10.1038/s41581-018-0023-5; Shou P, 2016, ONCOGENE, V35, P5953, DOI 10.1038/onc.2016.128; Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221; Stevens HY, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.600160; Takizawa N, 2017, EXP CELL RES, V358, P411, DOI 10.1016/j.yexcr.2017.07.014; Tropel P, 2004, EXP CELL RES, V295, P395, DOI 10.1016/j.yexcr.2003.12.030; Trounson A, 2015, CELL STEM CELL, V17, P11, DOI 10.1016/j.stem.2015.06.007; Viswanathan S, 2019, CYTOTHERAPY, V21, P1019, DOI 10.1016/j.jcyt.2019.08.002; Wang HH, 2016, CANCER LETT, V375, P349, DOI 10.1016/j.canlet.2016.02.033; Wei QZ, 2018, IMMUNITY, V48, P632, DOI 10.1016/j.immuni.2018.03.024; Weiss ARR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01191; Yi FH, 2003, CANCER RES, V63, P2923; Yin JQ, 2019, NAT BIOMED ENG, V3, P90, DOI 10.1038/s41551-018-0325-8; Youn JI, 2010, EUR J IMMUNOL, V40, P2969, DOI 10.1002/eji.201040895; Zhang M, 2007, FASEB J, V21, P3197, DOI 10.1096/fj.06-6558com	81	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 3	2021	12								698070	10.3389/fimmu.2021.698070	http://dx.doi.org/10.3389/fimmu.2021.698070			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UA9UG	34413852	gold, Green Published			2022-12-18	WOS:000685498600001
J	Schwarzer, M; Tlaskalova-Hogenova, H; Leulier, F; Schabussova, I				Schwarzer, Martin; Tlaskalova-Hogenova, Helena; Leulier, Francois; Schabussova, Irma			Editorial: Employing Experimental Gnotobiotic Models to Decipher the Host-Microbiota Cross-Talk in Health and Disease	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						germ-free; host-bacteria interactions; microbiota; gnotobiology; immune system	GERM-FREE		[Schwarzer, Martin] Czech Acad Sci, Inst Microbiol, Lab Gnotobiol, Novy Hradek, Czech Republic; [Tlaskalova-Hogenova, Helena] Czech Acad Sci, Lab Cellular & Mol Immunol, Prague, Czech Republic; [Leulier, Francois] Univ Claude Bernard Lyon 1, CNRS, Inst Genom Fonct Lyon, Ecole Normale Super Lyon,Unite Mixte Rech 5242, Lyon, France; [Schabussova, Irma] Med Univ Vienna, Inst Specif Prophylaxis & Trop Med, Vienna, Austria	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; Czech Academy of Sciences; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Ecole Normale Superieure de Lyon (ENS de LYON); Medical University of Vienna	Schwarzer, M (corresponding author), Czech Acad Sci, Inst Microbiol, Lab Gnotobiol, Novy Hradek, Czech Republic.	schwarzer@biomed.cas.cz	; Schwarzer, Martin/P-9871-2017	Schabussova, Irma/0000-0002-2109-2640; Schwarzer, Martin/0000-0002-1401-6578; Leulier, Francois/0000-0002-4542-3053	Czech Science Foundation [18-07015Y]; EMBO Installation grant; Czech Health Research Council grant [NV19-03-00179]; Government of Lower Austria	Czech Science Foundation(Grant Agency of the Czech Republic); EMBO Installation grant; Czech Health Research Council grant; Government of Lower Austria	This work was supported by grant 18-07015Y from the Czech Science Foundation and EMBO Installation grant to MS, The Danube-ARC funded by the Government of Lower Austria to IS and Czech Health Research Council grant NV19-03-00179 to HT-H.	Cahenzli J, 2013, CELL HOST MICROBE, V14, P559, DOI 10.1016/j.chom.2013.10.004; Darnaud M, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26963-9; Heintz-Buschart A, 2018, TRENDS MICROBIOL, V26, P563, DOI 10.1016/j.tim.2017.11.002; Hong SW, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw1507; Leulier F, 2017, CELL METAB, V25, P522, DOI 10.1016/j.cmet.2017.02.001; Macpherson AJ, 2015, IMMUNITY, V43, P416, DOI 10.1016/j.immuni.2015.08.024; Oka A, 2020, DIGEST DIS SCI, V65, P757, DOI 10.1007/s10620-020-06090-z; Rodriguez B, 2011, FEMS MICROBIOL ECOL, V76, P133, DOI 10.1111/j.1574-6941.2010.01035.x; Tlaskalova-Hogenova H, 2011, CELL MOL IMMUNOL, V8, P110, DOI 10.1038/cmi.2010.67; TLASKALOVAHOGENOVA H, 1983, ANN NY ACAD SCI, V409, P96, DOI 10.1111/j.1749-6632.1983.tb26862.x	10	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 3	2021	12								729052	10.3389/fimmu.2021.729052	http://dx.doi.org/10.3389/fimmu.2021.729052			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UK2ZD	34413863	Green Published, gold			2022-12-18	WOS:000691842200001
J	Li, GY; Kolan, SS; Guo, S; Marciniak, K; Kolan, P; Malachin, G; Grimolizzi, F; Haraldsen, G; Skalhegg, BS				Li, Gaoyang; Kolan, Shrikant Shantilal; Guo, Shuai; Marciniak, Katarzyna; Kolan, Pratibha; Malachin, Giulia; Grimolizzi, Franco; Haraldsen, Guttorm; Skalhegg, Bjorn Steen			Activated, Pro-Inflammatory Th1, Th17, and Memory CD4+T Cells and B Cells Are Involved in Delayed-Type Hypersensitivity Arthritis (DTHA) Inflammation and Paw Swelling in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						CD4+T cell; methotrexate; rheumatoid arthritis; DTHA mouse model; dexamethasone	COLLAGEN-INDUCED ARTHRITIS; CHEMOKINE RECEPTOR EXPRESSION; REGULATORY T-CELLS; RHEUMATOID-ARTHRITIS; AUTOIMMUNE ARTHRITIS; METHOTREXATE; LYMPHOCYTES; EFFECTOR; CYTOKINE; JOINTS	Delayed-type hypersensitivity arthritis (DTHA) is a recently established experimental model of rheumatoid arthritis (RA) in mice with pharmacological values. Despite an indispensable role of CD4+ T cells in inducing DTHA, a potential role for CD4+ T cell subsets is lacking. Here we have quantified CD4+ subsets during DTHA development and found that levels of activated, pro-inflammatory Th1, Th17, and memory CD4+ T cells in draining lymph nodes were increased with differential dynamic patterns after DTHA induction. Moreover, according to B-cell depletion experiments, it has been suggested that this cell type is not involved in DTHA. We show that DTHA is associated with increased levels of B cells in draining lymph nodes accompanied by increased levels of circulating IgG. Finally, using the anti-rheumatoid agents, methotrexate (MTX) and the anti-inflammatory drug dexamethasone (DEX), we show that MTX and DEX differentially suppressed DTHA-induced paw swelling and inflammation. The effects of MTX and DEX coincided with differential regulation of levels of Th1, Th17, and memory T cells as well as B cells. Our results implicate Th1, Th17, and memory T cells, together with activated B cells, to be involved and required for DTHA-induced paw swelling and inflammation.	[Li, Gaoyang; Kolan, Shrikant Shantilal; Guo, Shuai; Kolan, Pratibha; Malachin, Giulia; Grimolizzi, Franco; Skalhegg, Bjorn Steen] Univ Oslo, Inst Basic Med Sci, Dept Nutr, Oslo, Norway; [Marciniak, Katarzyna; Haraldsen, Guttorm] Oslo Univ Hosp, Dept Pathol, Oslo, Norway; [Marciniak, Katarzyna; Haraldsen, Guttorm] Univ Oslo, Oslo, Norway	University of Oslo; University of Oslo; University of Oslo	Skalhegg, BS (corresponding author), Univ Oslo, Inst Basic Med Sci, Dept Nutr, Oslo, Norway.	b.s.skalhegg@medisin.uio.no	Skålhegg, Bjørn Steen/AAZ-2976-2021	Skålhegg, Bjørn Steen/0000-0002-3481-8084; Marciniak, Katarzyna/0000-0002-0020-6223	UiO-MED; UiO-IMB; Norwegian Research Council [ES612356]; Throne Holst Foundation [BSS2019/2021]	UiO-MED; UiO-IMB; Norwegian Research Council(Research Council of NorwayEuropean Commission); Throne Holst Foundation	This work was supported by the UiO-MED and UiO-IMB, Grants to GL, SG, and BSS, The Norwegian Research Council, grant #ES612356, and Throne Holst Foundation, grant #BSS2019/2021. Principal funding recipient is BSS.	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Atkinson SM, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3867; Atkinson SM, 2016, DIS MODEL MECH, V9, P427, DOI 10.1242/dmm.022905; Baaten BJG, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00023; Bending D, 2009, J CLIN INVEST, V119, P565, DOI 10.1172/JCI37865; Black C A, 1999, Dermatol Online J, V5, P7; BOKKERINK JPM, 1988, BIOCHEM PHARMACOL, V37, P2329, DOI 10.1016/0006-2952(88)90359-0; BRACKERTZ D, 1977, ARTHRITIS RHEUM, V20, P841, DOI 10.1002/art.1780200314; Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173; Brown PM, 2016, NAT REV RHEUMATOL, V12, P731, DOI 10.1038/nrrheum.2016.175; Caruso A, 1997, CYTOMETRY, V27, P71, DOI 10.1002/(SICI)1097-0320(19970101)27:1<71::AID-CYTO9>3.0.CO;2-O; Chemin K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00353; Choy E, 2012, RHEUMATOLOGY, V51, pV3, DOI 10.1093/rheumatology/kes113; Cronstein BN, 2005, PHARMACOL REV, V57, P163, DOI 10.1124/pr.57.2.3; Cutolo M, 2001, ANN RHEUM DIS, V60, P729, DOI 10.1136/ard.60.8.729; Deane KD, 2017, BEST PRACT RES CL RH, V31, P3, DOI 10.1016/j.berh.2017.08.003; Dolhain RJEM, 1996, ARTHRITIS RHEUM-US, V39, P1961, DOI 10.1002/art.1780391204; Fairbanks LD, 1999, BIOCHEM J, V342, P143, DOI 10.1042/0264-6021:3420143; Garcia S, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1865; Gasper DJ, 2014, CRIT REV IMMUNOL, V34, P121, DOI 10.1615/CritRevImmunol.2014010373; Genestier L, 1998, J CLIN INVEST, V102, P322, DOI 10.1172/JCI2676; Ghani S, 2009, IMMUNOLOGY, V128, pe870, DOI 10.1111/j.1365-2567.2009.03096.x; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; Guo Q, 2018, BONE RES, V6, DOI 10.1038/s41413-018-0016-9; Herman S, 2008, CLIN EXP RHEUMATOL, V26, P317; Hirota K, 2007, J EXP MED, V204, P2803, DOI 10.1084/jem.20071397; Hoes JN, 2010, NAT REV RHEUMATOL, V6, P693, DOI 10.1038/nrrheum.2010.179; Inglis JJ, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2319; James EA, 2014, ARTHRITIS RHEUMATOL, V66, P1712, DOI 10.1002/art.38637; Jeffery R. C., 2014, MEDICINE, V42, P231, DOI DOI 10.1016/J.MPMED.2014.02.011; Khanolkar A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065234; KIRWAN JR, 1995, NEW ENGL J MED, V333, P142, DOI 10.1056/NEJM199507203330302; Kobayashi K, 2001, MICROSC RES TECHNIQ, V53, P241, DOI 10.1002/jemt.1090; Kocijan R, 2013, CURR RHEUMATOL REP, V15, DOI 10.1007/s11926-013-0366-7; Kotake S, 2017, J CLIN MED, V6, DOI 10.3390/jcm6070067; Kraan MC, 2000, ARTHRITIS RHEUM, V43, P1488, DOI 10.1002/1529-0131(200007)43:7<1488::AID-ANR11>3.0.CO;2-G; Lange F, 2005, ANN RHEUM DIS, V64, P599, DOI 10.1136/ard.2004.026120; Lee YK, 2009, IMMUNITY, V30, P92, DOI 10.1016/j.immuni.2008.11.005; Leipe J, 2010, ARTHRITIS RHEUM-US, V62, P2876, DOI 10.1002/art.27622; Luo Y, 2001, Curr Protoc Immunol, VChapter 4, DOI 10.1002/0471142735.im0405s55; MacLeod MKL, 2009, SEMIN IMMUNOL, V21, P53, DOI 10.1016/j.smim.2009.02.006; Matheu MP, 2008, IMMUNITY, V29, P602, DOI 10.1016/j.immuni.2008.07.015; MILTENBURG AMM, 1992, SCAND J IMMUNOL, V35, P603, DOI 10.1111/j.1365-3083.1992.tb03260.x; Montesinos MC, 2003, ARTHRITIS RHEUM-US, V48, P240, DOI 10.1002/art.10712; Muranski P, 2013, BLOOD, V121, P2402, DOI 10.1182/blood-2012-09-378653; Nakae S, 2003, J IMMUNOL, V171, P6173, DOI 10.4049/jimmunol.171.11.6173; Nakajima A, 1996, ANN RHEUM DIS, V55, P237, DOI 10.1136/ard.55.4.237; Nandakumar KS, 2005, J IMMUNOL METHODS, V304, P126, DOI 10.1016/j.jim.2005.06.017; Nanki T, 2000, ARTHRITIS RES, V2, P415, DOI 10.1186/ar120; Neurath MF, 1999, CLIN EXP IMMUNOL, V115, P42; Nistala K, 2010, P NATL ACAD SCI USA, V107, P14751, DOI 10.1073/pnas.1003852107; Ohshima S, 1998, P NATL ACAD SCI USA, V95, P8222, DOI 10.1073/pnas.95.14.8222; Pepper M, 2011, NAT IMMUNOL, V12, P467, DOI 10.1038/ni.2038; Peres RS, 2015, P NATL ACAD SCI USA, V112, P2509, DOI 10.1073/pnas.1424792112; Priyadarssini M, 2019, CLIN EXP DERMATOL, V44, P491, DOI 10.1111/ced.13795; Rao DA, 2017, NATURE, V542, P110, DOI 10.1038/nature20810; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Sarkar S, 2010, RHEUM DIS CLIN N AM, V36, P345, DOI 10.1016/j.rdc.2010.02.006; Sido JM, 2018, METHODS MOL BIOL, V1803, P95, DOI 10.1007/978-1-4939-8549-4_7; Silverman GJ, 2003, ARTHRITIS RES THER, V5, pS1, DOI 10.1186/ar1010; Steffen U, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01483; Tanaka D, 2007, CLIN EXP IMMUNOL, V148, P360, DOI 10.1111/j.1365-2249.2007.03354.x; Taylor PC, 2019, J CLIN MED, V8, DOI 10.3390/jcm8040515; THOMAS R, 1992, ARTHRITIS RHEUM-US, V35, P1455, DOI 10.1002/art.1780351209; Van Laethem F, 2001, J EXP MED, V193, P803, DOI 10.1084/jem.193.7.803; WASCHER TC, 1994, CLIN INVESTIGATOR, V72, P535; Weinblatt Michael E, 2013, Trans Am Clin Climatol Assoc, V124, P16; WOOLEY PH, 1988, METHOD ENZYMOL, V162, P361; Xing KL, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0103-2; Yamada H, 2008, ANN RHEUM DIS, V67, P1299, DOI 10.1136/ard.2007.080341; Yamaki K, 2003, J PHARM PHARMACOL, V55, P1661, DOI 10.1211/0022357022269; Yang S, 2013, BIOL PROCED ONLINE, V15, DOI 10.1186/1480-9222-15-8; Yap HY, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7100161	74	0	1	0	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 2	2021	12								689057	10.3389/fimmu.2021.689057	http://dx.doi.org/10.3389/fimmu.2021.689057			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UI9RK	34408746	gold, Green Published			2022-12-18	WOS:000690934300001
J	Wang, CQ; Ruan, LW; Shi, H; Lin, WY; Liu, LM; Li, SJ				Wang, Chuanqi; Ruan, Lingwei; Shi, Hong; Lin, Wenyang; Liu, Linmin; Li, Sujie			Phosphorylation of Shrimp Tcf by a Viral Protein Kinase WSV083 Suppresses Its Antiviral Effect	FRONTIERS IN IMMUNOLOGY			English	Article						Wnt signaling pathway; LvTcf; LvVago1; WSV083; phosphorylation; ubiquitin-proteasome pathway	IMMEDIATE-EARLY PROTEIN; BETA-CATENIN HOMOLOG; MOLECULAR CHARACTERIZATION; LITOPENAEUS-VANNAMEI; E3 LIGASE; WHITE; TRANSCRIPTION; DEGRADATION; INNATE; STAT	Nuclear DNA-binding TCF proteins, which act as the main downstream effectors of Wnt signaling, are essential for the regulation of cell fate and innate immunity. However, their role during viral infection in shrimp remains unknown. Herein, we demonstrated that Litopenaeus vannamei TCF (LvTcf) acts independently of Lv beta-catenin to promote interferon-like protein LvVago1 production, thus mounting the response to WSSV infection. Further, we observed that WSV083, a WSSV serine/threonine protein kinase, bound to LvTcf and phosphorylated it. Phosphorylated LvTcf was then recognized and degraded via the ubiquitin-proteasome pathway. Moreover, mass spectrometry analyses indicated that the T39 and T104 residues of LvTcf were target sites phosphorylated by WSV083. Point mutation analyses suggested that additional sites of LvTcf may undergo phosphorylation via WSV083. Taken together, the current work provides valuable insights into host immunity and viral pathogenesis. LvTcf is not only a modulator of shrimp innate immunity but is also an important target for WSSV immune evasion. Thus, the current findings will help improve disease control in shrimps.	[Wang, Chuanqi; Ruan, Lingwei; Shi, Hong; Lin, Wenyang; Liu, Linmin; Li, Sujie] Minist Nat Resources, Fujian Key Lab Marine Genet Resources, State Key Lab Breeding Base Marine Genet Resource, Key Lab Marine Genet Resources,Inst Oceanog 3, Xiamen, Peoples R China; [Wang, Chuanqi; Lin, Wenyang] Xiamen Univ, Sch Life Sci, Xiamen, Peoples R China	Ministry of Natural Resources of the People's Republic of China; Xiamen University	Ruan, LW (corresponding author), Minist Nat Resources, Fujian Key Lab Marine Genet Resources, State Key Lab Breeding Base Marine Genet Resource, Key Lab Marine Genet Resources,Inst Oceanog 3, Xiamen, Peoples R China.	ruanlingwei@tio.org.cn		Lin, Wenyang/0000-0003-2992-7021	Natural Science Foundation of Fujian Province of China [2020J06031]; National Natural Science Foundation of China [31972816]; China Agriculture Research System of MOF and MARA [CARS-48]	Natural Science Foundation of Fujian Province of China(Natural Science Foundation of Fujian Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Agriculture Research System of MOF and MARA(Ministry of Oceans & Fisheries (MOF), Republic of Korea)	This work was funded by Natural Science Foundation of Fujian Province of China (2020J06031), National Natural Science Foundation of China (No. 31972816) and China Agriculture Research System of MOF and MARA (CARS-48).	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Atcha FA, 2007, MOL CELL BIOL, V27, P8352, DOI 10.1128/MCB.02132-06; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Cadigan KM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007906; Chen IT, 2016, SCI REP-UK, V6, DOI 10.1038/srep27732; Chen IT, 2011, J VIROL, V85, P12919, DOI 10.1128/JVI.05385-11; Chen K, 2016, MOL MED REP, V13, P2439, DOI 10.3892/mmr.2016.4869; Chen XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073218; Chen YH, 2011, DEV COMP IMMUNOL, V35, P661, DOI 10.1016/j.dci.2011.01.010; De Obaldia ME, 2015, ANNU REV IMMUNOL, V33, P607, DOI 10.1146/annurev-immunol-032414-112032; Deepika A, 2014, FISH SHELLFISH IMMUN, V41, P441, DOI 10.1016/j.fsi.2014.09.026; Doumpas N, 2019, EMBO J, V38, DOI 10.15252/embj.201798873; Du JL, 2018, FISH SHELLFISH IMMUN, V77, P233, DOI 10.1016/j.fsi.2018.03.034; Escobedo-Bonilla CM, 2008, J FISH DIS, V31, P1, DOI 10.1111/j.1365-2761.2007.00877.x; Freese JL, 2010, NEUROBIOL DIS, V38, P148, DOI 10.1016/j.nbd.2009.09.003; Gantner BN, 2012, J IMMUNOL, V189, P3104, DOI 10.4049/jimmunol.1201669; Harmon B, 2016, J VIROL, V90, P7084, DOI 10.1128/JVI.00543-16; He F, 2006, J VIROL, V80, P3884, DOI 10.1128/JVI.80.8.3884-3892.2006; He F, 2009, VIROL J, V5, DOI 10.1186/1743-422X-5-151; He F, 2009, J GEN VIROL, V90, P1483, DOI 10.1099/vir.0.008912-0; Hikasa H, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.185280; Hrckulak D, 2016, CANCERS, V8, DOI 10.3390/cancers8070070; Huang PH, 2017, J VIROL, V91, DOI [10.1128/JVI.02314-16, 10.1128/jvi.02314-16]; Huang XD, 2010, VIROLOGY, V406, P176, DOI 10.1016/j.virol.2010.06.046; Isaacson MK, 2009, CELL HOST MICROBE, V5, P559, DOI 10.1016/j.chom.2009.05.012; Komiya Yuko, 2008, Organogenesis, V4, P68; Li CZ, 2019, FISH SHELLFISH IMMUN, V84, P558, DOI 10.1016/j.fsi.2018.10.043; Li CZ, 2015, SCI REP-UK, V5, DOI 10.1038/srep15078; Li FH, 2013, FISH SHELLFISH IMMUN, V34, P973, DOI 10.1016/j.fsi.2012.08.023; Li P, 2017, NATURE, V551, P378, DOI 10.1038/nature24467; Liu WJ, 2007, J VIROL, V81, P1461, DOI 10.1128/JVI.01880-06; Ljungberg JK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02521; Lu HS, 2011, VIROLOGY, V419, P84, DOI 10.1016/j.virol.2011.07.021; Maiti G, 2012, P NATL ACAD SCI USA, V109, P16600, DOI 10.1073/pnas.1207789109; Marcato V, 2016, MOL CELL BIOL, V36, P13, DOI 10.1128/MCB.00641-15; Raghu D, 2019, TRENDS IMMUNOL, V40, P1149, DOI 10.1016/j.it.2019.10.006; Ran XZ, 2013, J VIROL, V87, P12576, DOI 10.1128/JVI.01551-13; Ren Q, 2015, SCI REP-UK, V5, DOI 10.1038/srep18384; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Ruan LW, 2018, FISH SHELLFISH IMMUN, V78, P114, DOI 10.1016/j.fsi.2018.04.039; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sanchez-Paz A, 2010, VET RES, V41, DOI 10.1051/vetres/2010015; Sedeh FM, 2012, IRAN J FISH SCI, V11, P145; Shi H, 2012, DEV COMP IMMUNOL, V37, P421, DOI 10.1016/j.dci.2012.03.002; Su MA, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004196; Sun JZ, 2017, DEV COMP IMMUNOL, V76, P412, DOI 10.1016/j.dci.2017.07.003; Tassanakajon A, 2013, FISH SHELLFISH IMMUN, V34, P954, DOI 10.1016/j.fsi.2012.09.021; van Beest M, 2000, J BIOL CHEM, V275, P27266; van Zuylen WJ, 2016, REV MED VIROL, V26, P340, DOI 10.1002/rmv.1892; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Wang S, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2019.100752; Wang ZL, 2005, J VIROL, V79, P8764, DOI 10.1128/JVI.79.14.8764-8772.2005; Wen R, 2014, FISH SHELLFISH IMMUN, V38, P354, DOI 10.1016/j.fsi.2014.04.002; Willems AR, 1999, PHILOS T ROY SOC B, V354, P1533, DOI 10.1098/rstb.1999.0497; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Xie XX, 2005, VIRUS RES, V108, P63, DOI 10.1016/j.virusres.2004.08.002; Xu LF, 2015, NAT IMMUNOL, V16, P991, DOI 10.1038/ni.3229; Yamada M, 2006, J BIOL CHEM, V281, P20749, DOI 10.1074/jbc.M602089200; Yamamoto H, 2003, EMBO J, V22, P2047, DOI 10.1093/emboj/cdg204; Yang F, 2001, J VIROL, V75, P11811, DOI 10.1128/JVI.75.23.11811-11820.2001; Yang LW, 2019, FISH SHELLFISH IMMUN, V89, P555, DOI 10.1016/j.fsi.2019.04.046; Yao DF, 2016, FISH SHELLFISH IMMUN, V59, P268, DOI 10.1016/j.fsi.2016.10.051; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zhang S, 2016, FISH SHELLFISH IMMUN, V54, P445, DOI 10.1016/j.fsi.2016.04.028; Zhang S, 2016, FISH SHELLFISH IMMUN, V54, P411, DOI 10.1016/j.fsi.2016.03.162; Zhao QL, 2015, J VIROL, V89, P415, DOI 10.1128/JVI.02591-14; Zhao WT, 2015, INFLAMMATION, V38, P1700, DOI 10.1007/s10753-015-0147-8; Zhou Q, 2007, J VIROL METHODS, V146, P288, DOI 10.1016/j.jviromet.2007.07.007; Zhu F, 2013, SCI REP-UK, V3, DOI 10.1038/srep02069; Zhu LL, 2021, DEV COMP IMMUNOL, V119, DOI 10.1016/j.dci.2021.104041; Zwezdaryk Kevin J, 2016, World J Virol, V5, P144	71	0	0	2	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 2	2021	12								698697	10.3389/fimmu.2021.698697	http://dx.doi.org/10.3389/fimmu.2021.698697			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UA6SU	34408747	Green Published, gold			2022-12-18	WOS:000685291000001
J	Arnaud, M; Bobisse, S; Chiffelle, J; Harari, A				Arnaud, Marion; Bobisse, Sara; Chiffelle, Johanna; Harari, Alexandre			The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients	FRONTIERS IN IMMUNOLOGY			English	Review						cancer immunotherapy; T cell receptor; gene transfer therapy; adoptive cell transfer; cell engineering; T cells	TUMOR-INFILTRATING LYMPHOCYTES; TERM-FOLLOW-UP; T-CELLS; METASTATIC MELANOMA; COMPLETE RESPONSES; ANTIGEN DISCOVERY; GENE-THERAPY; RECEPTORS; REGRESSION; MEMORY	Mutation-derived neoantigens are now established as attractive targets for cancer immunotherapy. The field of adoptive T cell transfer (ACT) therapy was significantly reshaped by tumor neoantigens and is now moving towards the genetic engineering of T cells with neoantigen-specific T cell receptors (TCRs). Yet, the identification of neoantigen-reactive TCRs remains challenging and the process needs to be adapted to clinical timelines. In addition, the state of recipient T cells for TCR transduction is critical and can affect TCR-ACT efficacy. Here we provide an overview of the main strategies for TCR-engineering, describe the selection and expansion of optimal carrier cells for TCR-ACT and discuss the next-generation methods for rapid identification of relevant TCR candidates for gene transfer therapy.	[Arnaud, Marion; Bobisse, Sara; Chiffelle, Johanna; Harari, Alexandre] Lausanne Univ Hosp CHUV, Ludwig Inst Canc Res Lausanne, Dept Oncol, Lausanne, Switzerland; [Arnaud, Marion; Bobisse, Sara; Chiffelle, Johanna; Harari, Alexandre] Univ Lausanne UNIL, Lausanne, Switzerland; [Arnaud, Marion; Bobisse, Sara; Chiffelle, Johanna; Harari, Alexandre] Lausanne Univ Hosp CHUV, Ctr Expt Therapeut, Dept Oncol, Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Arnaud, M; Harari, A (corresponding author), Lausanne Univ Hosp CHUV, Ludwig Inst Canc Res Lausanne, Dept Oncol, Lausanne, Switzerland.; Arnaud, M; Harari, A (corresponding author), Univ Lausanne UNIL, Lausanne, Switzerland.; Arnaud, M; Harari, A (corresponding author), Lausanne Univ Hosp CHUV, Ctr Expt Therapeut, Dept Oncol, Lausanne, Switzerland.	marion.arnaud@unil.ch; alexandre.harari@chuv.ch		Harari, Alexandre/0000-0002-1055-2090; Chiffelle, Johanna/0000-0002-8312-2681	Ludwig Institute for Cancer Research [310030_182384]; Swiss National Science Foundation	Ludwig Institute for Cancer Research; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	This research was supported by the Ludwig Institute for Cancer Research and grant 310030_182384 from the Swiss National Science Foundation (A.H.).	Ali M, 2019, NAT PROTOC, V14, P1926, DOI 10.1038/s41596-019-0170-6; Alspach E, 2019, NATURE, V574, P696, DOI 10.1038/s41586-019-1671-8; Andersen R, 2018, CANCER IMMUNOL RES, V6, P222, DOI 10.1158/2326-6066.CIR-17-0467; Andersen R, 2016, CLIN CANCER RES, V22, P3734, DOI 10.1158/1078-0432.CCR-15-1879; Andersen RS, 2012, CANCER RES, V72, P1642, DOI 10.1158/0008-5472.CAN-11-2614; Arnaud M, 2020, CURR OPIN BIOTECH, V65, P52, DOI 10.1016/j.copbio.2019.12.014; Azizi E, 2018, CELL, V174, P1293, DOI 10.1016/j.cell.2018.05.060; Backstrom BT, 1996, IMMUNITY, V5, P437, DOI 10.1016/S1074-7613(00)80500-2; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Bentzen AK, 2017, CANCER IMMUNOL IMMUN, V66, P657, DOI 10.1007/s00262-017-1971-5; Bentzen AK, 2016, NAT BIOTECHNOL, V34, P1037, DOI 10.1038/nbt.3662; Berdien B, 2014, GENE THER, V21, P539, DOI 10.1038/gt.2014.26; Berger C, 2008, J CLIN INVEST, V118, P294, DOI 10.1172/JCI32103; Bethune MT, 2017, CURR OPIN BIOTECH, V48, P142, DOI 10.1016/j.copbio.2017.03.024; Bianchi V, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01215; Bobisse S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03301-0; Bobisse S, 2009, CANCER RES, V69, P9385, DOI 10.1158/0008-5472.CAN-09-0494; Bunse M, 2014, MOL THER, V22, P1983, DOI 10.1038/mt.2014.142; Busch DH, 2016, SEMIN IMMUNOL, V28, P28, DOI 10.1016/j.smim.2016.02.001; Cachot A, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe3348; Cafri G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08304-z; Cain AK, 2020, NAT REV GENET, V21, P526, DOI 10.1038/s41576-020-0244-x; Chen FJ, 2019, J CLIN INVEST, V129, P2056, DOI 10.1172/JCI99538; Cohen CJ, 2015, J CLIN INVEST, V125, P3981, DOI 10.1172/JCI82416; Crowther MD, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071588; D'Angelo SP, 2018, CANCER DISCOV, V8, P944, DOI 10.1158/2159-8290.CD-17-1417; Dafni U, 2019, ANN ONCOL, V30, P1902, DOI 10.1093/annonc/mdz398; Deniger DC, 2018, CLIN CANCER RES, V24, P5562, DOI 10.1158/1078-0432.CCR-18-0573; Dong D, 2019, NATURE, V573, P546, DOI 10.1038/s41586-019-1537-0; Doudna JA, 2014, SCIENCE, V346, P1077, DOI 10.1126/science.1258096; Duhen T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05072-0; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Ellis J, 2005, HUM GENE THER, V16, P1241, DOI 10.1089/hum.2005.16.1241; Emerson RO, 2013, J PATHOL, V231, P433, DOI 10.1002/path.4260; Freeman JD, 2009, GENOME RES, V19, P1817, DOI 10.1101/gr.092924.109; Friedensohn S, 2017, TRENDS BIOTECHNOL, V35, P203, DOI 10.1016/j.tibtech.2016.09.010; Gaissmaier L, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9092095; Gattinoni L, 2005, J CLIN INVEST, V115, P1616, DOI 10.1172/JCI24480; Gattinoni L, 2012, NAT REV CANCER, V12, P671, DOI 10.1038/nrc3322; Gejman RS, 2020, CANCER IMMUNOL RES, V8, P672, DOI 10.1158/2326-6066.CIR-19-0745; Gokuldass A, 2020, CANCERS, V12, DOI 10.3390/cancers12113344; Graef P, 2014, IMMUNITY, V41, P116, DOI 10.1016/j.immuni.2014.05.018; Gros A, 2019, J CLIN INVEST, V129, P4992, DOI 10.1172/JCI127967; Hacker UT, 2020, CANCERS, V12, DOI 10.3390/cancers12071889; Hackett PB, 2010, MOL THER, V18, P674, DOI 10.1038/mt.2010.2; Han A, 2014, NAT BIOTECHNOL, V32, P684, DOI 10.1038/nbt.2938; Hilf N, 2019, NATURE, V565, P240, DOI 10.1038/s41586-018-0810-y; Hinrichs CS, 2011, BLOOD, V117, P808, DOI 10.1182/blood-2010-05-286286; Hirakawa MP, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20200127; Howe SJ, 2008, J CLIN INVEST, V118, P3143, DOI 10.1172/JCI35798; Howie B, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5624; Joglekar AV, 2019, NAT METHODS, V16, P191, DOI 10.1038/s41592-018-0304-8; Johnson LA, 2009, BLOOD, V114, P535, DOI 10.1182/blood-2009-03-211714; Kaneko S, 2009, BLOOD, V113, P1006, DOI 10.1182/blood-2008-05-156059; Kim SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037338; Krangel MS, 2009, CURR OPIN IMMUNOL, V21, P133, DOI 10.1016/j.coi.2009.03.009; Kreiter S, 2015, NATURE, V520, P692, DOI 10.1038/nature14426; Krishna S, 2020, SCIENCE, V370, P1328, DOI 10.1126/science.abb9847; Kumar BV, 2018, IMMUNITY, V48, P202, DOI 10.1016/j.immuni.2018.01.007; Lauss M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01460-0; Li CW, 2020, NAT REV GENET, V21, P255, DOI 10.1038/s41576-019-0205-4; Li GD, 2019, NAT METHODS, V16, P183, DOI 10.1038/s41592-018-0305-7; Linette GP, 2017, TRENDS MOL MED, V23, P869, DOI 10.1016/j.molmed.2017.08.007; Linnemann C, 2013, NAT MED, V19, P1534, DOI 10.1038/nm.3359; Lino CA, 2018, DRUG DELIV, V25, P1234, DOI 10.1080/10717544.2018.1474964; Lo W, 2019, CANCER IMMUNOL RES, V7, P534, DOI 10.1158/2326-6066.CIR-18-0686; Loew R, 2010, GENE THER, V17, P272, DOI 10.1038/gt.2009.134; Lu YC, 2019, CANCER IMMUNOL RES, V7, P1824, DOI 10.1158/2326-6066.CIR-19-0299; Lu Y, 2020, NAT MED, V26, P732, DOI 10.1038/s41591-020-0840-5; Lythe G, 2016, J THEOR BIOL, V389, P214, DOI 10.1016/j.jtbi.2015.10.016; Malekzadeh P, 2020, CLIN CANCER RES, V26, P1267, DOI 10.1158/1078-0432.CCR-19-1874; Manfredi F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01689; Marcucci KT, 2018, MOL THER, V26, P269, DOI 10.1016/j.ymthe.2017.10.012; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; McLellan AD, 2019, IMMUNOL CELL BIOL, V97, P664, DOI 10.1111/imcb.12254; Mensali N, 2019, EBIOMEDICINE, V40, P106, DOI 10.1016/j.ebiom.2019.01.031; Merlo A, 2010, J IMMUNOL, V184, P5895, DOI 10.4049/jimmunol.0902850; Minagawa A, 2018, CELL STEM CELL, V23, P850, DOI 10.1016/j.stem.2018.10.005; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; Morgan RA, 2013, J IMMUNOTHER, V36, P133, DOI 10.1097/CJI.0b013e3182829903; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Ng AHC, 2019, LAB CHIP, V19, P3011, DOI 10.1039/c9lc00538b; Nishimura T, 2013, CELL STEM CELL, V12, P114, DOI 10.1016/j.stem.2012.11.002; Od Z., 2020, MDPI, V12, P1704, DOI [10.3390/cancers12061704, DOI 10.3390/CANCERS12061704]; Oh DY, 2020, CELL, V181, P1612, DOI 10.1016/j.cell.2020.05.017; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Palmer DC., 2020, INTERNAL CHECKPOINT, DOI [10.1101/2020.09.24.306571, DOI 10.1101/2020.09.24.306571]; Paria BC, 2021, J IMMUNOTHER, V44, P1, DOI 10.1097/CJI.0000000000000342; Park JH, 2018, NEW ENGL J MED, V378, P449, DOI 10.1056/NEJMoa1709919; Parkhurst M, 2017, CLIN CANCER RES, V23, P2491, DOI 10.1158/1078-0432.CCR-16-2680; Parkhurst MR, 2019, CANCER DISCOV, V9, P1022, DOI 10.1158/2159-8290.CD-18-1494; Parlar A, 2019, EUR J IMMUNOL, V49, P1278, DOI 10.1002/eji.201948140; Pasetto A, 2016, CANCER IMMUNOL RES, V4, P734, DOI 10.1158/2326-6066.CIR-16-0001; Peng SM, 2019, CELL REP, V28, P2728, DOI 10.1016/j.celrep.2019.07.106; Pickar-Oliver A, 2019, NAT REV MOL CELL BIO, V20, P490, DOI 10.1038/s41580-019-0131-5; Pistello Mauro, 2007, Genet Vaccines Ther, V5, P8, DOI 10.1186/1479-0556-5-8; Polz MF, 1998, APPL ENVIRON MICROB, V64, P3724; Poran A, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100141; Poschke IC, 2020, CLIN CANCER RES, V26, P4289, DOI 10.1158/1078-0432.CCR-19-3845; Prickett TD, 2016, CANCER IMMUNOL RES, V4, P669, DOI 10.1158/2326-6066.CIR-15-0215; Prieto PA, 2010, J IMMUNOTHER, V33, P547, DOI 10.1097/CJI.0b013e3181d367bd; Provasi E, 2012, NAT MED, V18, P807, DOI 10.1038/nm.2700; Qasim W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaj2013; Racle J, 2019, NAT BIOTECHNOL, V37, P1283, DOI 10.1038/s41587-019-0289-6; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robbins PF, 2015, CLIN CANCER RES, V21, P1019, DOI 10.1158/1078-0432.CCR-14-2708; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; Rockinger GA, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000435; Rosati E, 2017, BMC BIOTECHNOL, V17, DOI 10.1186/s12896-017-0379-9; Rosenberg SA, 2015, SCIENCE, V348, P62, DOI 10.1126/science.aaa4967; Rosenberg SA, 2011, CLIN CANCER RES, V17, P4550, DOI 10.1158/1078-0432.CCR-11-0116; Ruggiero E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9081; Rui Y, 2019, TRENDS BIOTECHNOL, V37, P281, DOI 10.1016/j.tibtech.2018.08.010; Sadelain M, 2017, NATURE, V545, P423, DOI 10.1038/nature22395; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Sarkar S., 2015, J CLIN CELL IMMUNOL, V176, P139, DOI [10.1016/j.physbeh.2017.03.040, DOI 10.1016/J.PHYSBEH.2017.03.040]; Scheper W, 2019, NAT MED, V25, P89, DOI 10.1038/s41591-018-0266-5; Segaliny AI, 2018, LAB CHIP, V18, P3733, DOI 10.1039/c8lc00818c; Seliktar-Ofir S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01211; Sewell AK, 2012, NAT REV IMMUNOL, V12, P668, DOI 10.1038/nri3279; Sharma G, 2021, MOL THER, V29, P571, DOI 10.1016/j.ymthe.2020.09.028; Sheih A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13880-1; Simoni Y, 2018, NATURE, V557, P575, DOI 10.1038/s41586-018-0130-2; Stadtmauer EA, 2020, SCIENCE, V367, P1001, DOI 10.1126/science.aba7365; Sterner RC, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00459-7; Stevanovic S, 2015, J CLIN ONCOL, V33, P1543, DOI 10.1200/JCO.2014.58.9093; Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; van den Berg JH, 2015, MOL THER, V23, P1541, DOI 10.1038/mt.2015.60; van der Leun AM, 2020, NAT REV CANCER, V20, P218, DOI 10.1038/s41568-019-0235-4; van der Veken LT, 2006, CANCER RES, V66, P3331, DOI 10.1158/0008-5472.CAN-05-4190; Waldman AD, 2020, NAT REV IMMUNOL, V20, P651, DOI 10.1038/s41577-020-0306-5; Wood AJ, 2011, SCIENCE, V333, P307, DOI 10.1126/science.1207773; Wu D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01366; Xu Y, 2014, BLOOD, V123, P3750, DOI 10.1182/blood-2014-01-552174; Yang W, 2019, NAT MED, V25, P767, DOI 10.1038/s41591-019-0434-2; Yossef R, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122467; Yost KE, 2019, NAT MED, V25, P1251, DOI 10.1038/s41591-019-0522-3; Zacharakis N, 2018, NAT MED, V24, P724, DOI 10.1038/s41591-018-0040-8; Zhao YB, 2010, CANCER RES, V70, P9053, DOI 10.1158/0008-5472.CAN-10-2880; Zhao YB, 2006, MOL THER, V13, P151, DOI 10.1016/j.ymthe.2005.07.688; Zhou JX, 2019, PROTEIN CELL, V10, P764, DOI 10.1007/s13238-019-0643-y	142	0	0	2	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 30	2021	12								701636	10.3389/fimmu.2021.701636	http://dx.doi.org/10.3389/fimmu.2021.701636			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UD7NZ	34394096	Green Published, gold			2022-12-18	WOS:000687393100001
J	Kumar, V; Locke, JE				Kumar, Vineeta; Locke, Jayme E.			New Perspectives on Desensitization in the Current Era - An Overview	FRONTIERS IN IMMUNOLOGY			English	Review						kidney; desensitization; kidney paired donation; novel therapeutic agents; allocation	DONOR KIDNEY-TRANSPLANTATION; OUTCOMES; TRIAL	Blood group and tissue incompatibilities remain significant barriers to achieving transplantation. Although no patient should be labeled "un-transplantable" due to blood group or tissue incompatibility, all candidates should be provided with individualized and realistic counseling regarding their anticipated wait times for deceased donor or kidney paired donation matching, with early referral to expert centers for desensitization when needed. Vital is the careful selection of patients whose health status is such that desensitizing treatment is less likely to cause serious harm and whose anti-HLA antibody status is such that treatment is likely to accomplish the goal of increasing organ offers with an acceptable final crossmatch. Exciting new developments have re-energized the interest and scope of desensitization in the times ahead.	[Kumar, Vineeta; Locke, Jayme E.] Univ Alabama Birmingham, Comprehens Transplant Inst, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Locke, JE (corresponding author), Univ Alabama Birmingham, Comprehens Transplant Inst, Birmingham, AL 35294 USA.	jlocke@uabmc.edu	Kumar, Vineeta/AED-7155-2022	Locke, Jayme/0000-0002-0220-8716				Bentall A, 2013, AM J TRANSPLANT, V13, P76, DOI 10.1111/j.1600-6143.2012.04291.x; Gonzales MAM, 2017, TRANSPLANTATION, V101, P1222, DOI 10.1097/TP.0000000000001330; Jeyakanthan M, 2016, AM J TRANSPLANT, V16, P1548, DOI 10.1111/ajt.13625; Jordan SC, 2017, NEW ENGL J MED, V377, P442, DOI 10.1056/NEJMoa1612567; Massie AB, 2020, AM J KIDNEY DIS, V76, P616, DOI 10.1053/j.ajkd.2020.03.029; Mustian MN, 2019, ANN SURG, V270, P639, DOI 10.1097/SLA.0000000000003484; Opelz G, 2015, TRANSPLANTATION, V99, P400, DOI 10.1097/TP.0000000000000312; Orandi BJ, 2016, NEW ENGL J MED, V374, P940, DOI 10.1056/NEJMoa1508380; Schinstock CA, 2019, CLIN TRANSPLANT, V33, DOI 10.1111/ctr.13751; Slaney AM, 2016, BIOCONJUGATE CHEM, V27, P705, DOI 10.1021/acs.bioconjchem.5b00672; Stewart DE, 2016, AM J TRANSPLANT, V16, P1834, DOI 10.1111/ajt.13770; Susal C, 2016, EBIOMEDICINE, V9, P366, DOI 10.1016/j.ebiom.2016.06.006; Tremblay S, 2020, AM J TRANSPLANT, V20, P411, DOI 10.1111/ajt.15613; Vo AA, 2015, TRANSPLANTATION, V99, P2356, DOI 10.1097/TP.0000000000000741; Wiebe C, 2019, AM J TRANSPLANT, V19, P1708, DOI 10.1111/ajt.15177; Wiebe C, 2017, J AM SOC NEPHROL, V28, P3353, DOI 10.1681/ASN.2017030287; Woodle ES, 2015, AM J TRANSPLANT, V15, P101, DOI 10.1111/ajt.13050; Zachary AA, 2014, IMMUNOL REV, V258, P183, DOI 10.1111/imr.12150	18	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 30	2021	12								696467	10.3389/fimmu.2021.696467	http://dx.doi.org/10.3389/fimmu.2021.696467			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UA4KT	34394089	gold, Green Published			2022-12-18	WOS:000685130400001
J	Rossouw, TM; Feldman, C				Rossouw, Theresa M.; Feldman, Charles			Editorial: The Role of Platelet Activation in the Pathophysiology of HIV, Tuberculosis and Pneumococcal Disease	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						platelet activation; HIV; tuberculosis; pneumococcus (Streptococcus pneumoniae); platelet aggregation			[Rossouw, Theresa M.] Univ Pretoria, Fac Hlth Sci, Dept Immunol, Pretoria, South Africa; [Feldman, Charles] Univ Witwatersrand, Fac Hlth Sci, Dept Internal Med, Johannesburg, South Africa	University of Pretoria; University of Witwatersrand	Rossouw, TM (corresponding author), Univ Pretoria, Fac Hlth Sci, Dept Immunol, Pretoria, South Africa.	Theresa.Rossouw@up.ac.za						Portier I, 2021, ARTERIOSCL THROM VAS, V41, P70, DOI 10.1161/ATVBAHA.120.314645	1	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 30	2021	12								737016	10.3389/fimmu.2021.737016	http://dx.doi.org/10.3389/fimmu.2021.737016			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UB0GA	34400911	gold, Green Published			2022-12-18	WOS:000685530200001
J	Taavela, J; Viiri, K; Valimaki, A; Sarin, J; Salonoja, K; Maki, M; Isola, J				Taavela, Juha; Viiri, Keijo; Valimaki, Anna; Sarin, Jani; Salonoja, Kristiina; Maki, Markku; Isola, Jorma			Apolipoprotein A4 Defines the Villus-Crypt Border in Duodenal Specimens for Celiac Disease Morphometry	FRONTIERS IN IMMUNOLOGY			English	Article						celiac disease; morphometry; duodenal biopsy; histology; gluten challenge; apolipoprotein A4; digital pathology; clinical trial	SMALL-BOWEL; VILLOUS ATROPHY; IV; DIAGNOSIS; SYMPTOMS; GLUTEN; REPRODUCIBILITY; HISTOPATHOLOGY; PEOPLE; MARKER	Histological evaluation of the small intestinal mucosa is the cornerstone of celiac disease diagnostics and an important outcome in scientific studies. Gluten-dependent injury can be evaluated either with quantitative morphometry or grouped classifications. A drawback of mucosal readings is the subjective assessment of the border where the crypt epithelium changes to the differentiated villus epithelium. We studied potential immunohistochemical markers for the detection of the villus-crypt border: apolipoprotein A4 (APOA4), Ki-67, glucose transporter 2, keratin 20, cytochrome P450 3A4 and intestinal fatty-acid binding protein. Among these, villus-specific APOA4 was chosen as the best candidate for further studies. Hematoxylin-eosin (H&E)- and APOA4 stained duodenal biopsy specimens from 74 adult patients were evaluated by five observers to determine the villus-to-crypt ratio (VH : CrD). APOA4 delineated the villus to crypt epithelium transition clearly, and the correlation coefficient of VH : CrD values between APOA4 and H&E was excellent (r=0.962). The VH : CrD values were lower in APOA4 staining (p < 0.001) and a conversion factor of 0.2 in VH : CrD measurements was observed to make the two methods comparable to each other. In the intraobserver analysis, the doubled standard deviations, representing the error ranges, were 0.528 for H&E and 0.388 for APOA4 staining, and the ICCs were 0.980 and 0.971, respectively. In the interobserver analysis, the average error ranges were 1.017 for H&E and 0.847 for APOA4 staining, and the ICCs were better for APOA4 than for H&E staining in all analyses. In conclusion, the reliability and reproducibility of morphometrical VH : CrD readings are improved with the use of APOA4 staining.	[Taavela, Juha] Cent Finland Cent Hosp, Jyvaskyla, Finland; [Taavela, Juha; Viiri, Keijo; Maki, Markku] Tampere Univ, Fac Med & Hlth Technol, Celiac Dis Res Ctr, Tampere, Finland; [Valimaki, Anna] Fimlab Labs Inc, Tampere, Finland; [Valimaki, Anna; Sarin, Jani; Salonoja, Kristiina; Isola, Jorma] Jilab Inc, Tampere, Finland; [Maki, Markku] Tampere Univ Hosp, Tampere, Finland; [Isola, Jorma] Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland	Central Finland Central Hospital; Tampere University; Tampere University; Tampere University Hospital; Tampere University	Taavela, J (corresponding author), Cent Finland Cent Hosp, Jyvaskyla, Finland.; Taavela, J (corresponding author), Tampere Univ, Fac Med & Hlth Technol, Celiac Dis Res Ctr, Tampere, Finland.	juha.taavela@tuni.fi	Taavela, Juha/AAI-4415-2021	Taavela, Juha/0000-0003-3948-9555; Viiri, Keijo/0000-0002-7167-5094; Valimaki, Anna/0000-0002-0364-3365	Competitive State Research Financing of the Expert Responsibility Area of Kuopio University Hospital [B2009]; Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital [9X035, 9AB048]; Emil Aaltonen Foundation; Finnish Medical Foundation	Competitive State Research Financing of the Expert Responsibility Area of Kuopio University Hospital; Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital; Emil Aaltonen Foundation; Finnish Medical Foundation	This work was supported by grants from the Competitive State Research Financing of the Expert Responsibility Area of Kuopio University Hospital (B2009), Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (9X035 and 9AB048), Emil Aaltonen Foundation and the Finnish Medical Foundation.	Adelman DC, 2018, AM J GASTROENTEROL, V113, P339, DOI 10.1038/ajg.2017.480; Adriaanse MPM, 2016, AM J GASTROENTEROL, V111, P1014, DOI 10.1038/ajg.2016.162; Alina P, 2021, DIGEST DIS SCI, V66, P3352, DOI 10.1007/s10620-020-06680-x; [Anonymous], 2020, HUMAN PROTEIN ATLAS; Arguelles-Grande C, 2012, J CLIN PATHOL, V65, P242, DOI 10.1136/jclinpath-2011-200372; BARTKO JJ, 1966, PSYCHOL REP, V19, P3, DOI 10.2466/pr0.1966.19.1.3; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Corazza GR, 2007, CLIN GASTROENTEROL H, V5, P838, DOI 10.1016/j.cgh.2007.03.019; Corazza GR, 2005, J CLIN PATHOL, V58, P573, DOI 10.1136/jcp.2004.023978; Daveson AJM., 2020, GASTROHEP, V2, P22, DOI DOI 10.1002/YGH2.380; Dotsenko V, 2021, CELL MOL GASTROENTER, V11, P13, DOI 10.1016/j.jcmgh.2020.07.010; Gehart H, 2019, NAT REV GASTRO HEPAT, V16, P19, DOI 10.1038/s41575-018-0081-y; Hanniman EA, 2006, J LIPID RES, V47, P2503, DOI 10.1194/jlr.M600303-JLR200; KALOGERIS TJ, 1994, J LIPID RES, V35, P1141; Kaukinen K, 2007, ALIMENT PHARM THER, V25, P1237, DOI 10.1111/j.1365-2036.2007.03311.x; Kivela L, 2021, NAT REV GASTRO HEPAT, V18, P181, DOI 10.1038/s41575-020-00378-1; Kronenberg F, 2000, J AM COLL CARDIOL, V36, P751, DOI 10.1016/S0735-1097(00)00775-0; KUITUNEN P, 1982, J PEDIATR GASTR NUTR, V1, P525, DOI 10.1097/00005176-198212000-00012; Lahdeaho ML, 2019, LANCET GASTROENTEROL, V4, P948, DOI 10.1016/S2468-1253(19)30264-X; Larussa T, 2017, NUTRIENTS, V9, DOI 10.3390/nu9020098; Loberman-Nachum N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52733-1; Ludvigsson JF, 2018, GUT, V67, P1410, DOI 10.1136/gutjnl-2017-314853; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P; Moron B, 2013, AM J GASTROENTEROL, V108, P1344, DOI 10.1038/ajg.2013.151; Mubarak A, 2011, SCAND J GASTROENTERO, V46, P1065, DOI 10.3109/00365521.2011.589471; Murray JA, 2017, GASTROENTEROLOGY, V152, P787, DOI 10.1053/j.gastro.2016.11.004; N Marsh Michael, 2015, Gastroenterol Hepatol Bed Bench, V8, P99; Oberhuber G, 1999, EUR J GASTROEN HEPAT, V11, P1185, DOI 10.1097/00042737-199910000-00019; Picarelli A, 2014, SCAND J GASTROENTERO, V49, P1318, DOI 10.3109/00365521.2014.948052; Roos S, 2019, GASTROENTEROL NURS, V42, P496, DOI 10.1097/SGA.0000000000000377; Schneider MR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014325; Schober P, 2018, ANESTH ANALG, V126, P1763, DOI 10.1213/ANE.0000000000002864; Shalimar, 2013, ARCH PATHOL LAB MED, V137, P1262, DOI 10.5858/arpa.2012-0354-OA; STAELS B, 1990, ENDOCRINOLOGY, V126, P2153; Taavela J, 2019, BMC GASTROENTEROL, V19, DOI 10.1186/s12876-019-1089-7; Taavela J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076163; Taavela J, 2013, CLIN GASTROENTEROL H, V11, P166, DOI 10.1016/j.cgh.2012.09.030; Verges B, 2001, J LIPID RES, V42, P2021; Virta J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69487-w; Vowinkel T, 2004, J CLIN INVEST, V114, P260, DOI 10.1172/JCI200421233; Wang F, 2012, P NATL ACAD SCI USA, V109, P9641, DOI 10.1073/pnas.1201433109; Weinberg RB, 2012, J LIPID RES, V53, P736, DOI 10.1194/jlr.M019992; Weinstock PH, 1997, J LIPID RES, V38, P1782; Werkstetter KJ, 2017, GASTROENTEROLOGY, V153, P924, DOI 10.1053/j.gastro.2017.06.002; West J, 2004, BRIT MED J, V329, P716, DOI 10.1136/bmj.38169.486701.7C	45	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 29	2021	12								713854	10.3389/fimmu.2021.713854	http://dx.doi.org/10.3389/fimmu.2021.713854			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UI9QB	34394117	gold, Green Published			2022-12-18	WOS:000690930800001
J	Xu, QQ; Li, QJ; Huang, CL; Cai, MY; Zhang, MF; Yin, SH; Lu, LX; Chen, L				Xu, Qing-Qing; Li, Qing-Jie; Huang, Cheng-Long; Cai, Mu-Yan; Zhang, Mei-Fang; Yin, Shao-Han; Lu, Li-Xia; Chen, Lei			Prognostic Value of an Immunohistochemical Signature in Patients With Head and Neck Mucosal Melanoma	FRONTIERS IN IMMUNOLOGY			English	Article						head and neck mucosal melanoma; immunohistochemistry; nomogram; prognosis; signature	PHASE-II; IPILIMUMAB; EXPRESSION; HMB-45; CARBOPLATIN; COMBINATION; PACLITAXEL; NIVOLUMAB; EFFICACY; BENIGN	Purpose: We aimed to develop a prognostic immunohistochemistry (IHC) signature for patients with head and neck mucosal melanoma (MMHN). Methods: In total, 190 patients with nonmetastatic MMHN with complete clinical and pathological data before treatment were included in our retrospective study. Results: We extracted five IHC markers associated with overall survival (OS) and then constructed a signature in the training set (n=116) with the least absolute shrinkage and selection operator (LASSO) regression model. The validation set (n=74) was further built to confirm the prognostic significance of this classifier. We then divided patients into high- and low-risk groups according to the IHC score. In the training set, the 5-year OS rate was 22.0% (95% confidence interval [CI]: 11.2%- 43.2%) for the high-risk group and 54.1% (95% CI: 41.8%-69.9%) for the low-risk group (P<0.001), and in the validation set, the 5-year OS rate was 38.1% (95% CI: 17.9%-81.1%) for the high-risk group and 43.1% (95% CI: 30.0%-61.9%) for the low-risk group (P=0.26). Multivariable analysis revealed that IHC score, T stage, and primary tumor site were independent variables for predicting OS (all P<0.05). We developed a nomogram incorporating clinicopathological risk factors (primary site and T stage) and the IHC score to predict 3-, 5-, and 10-year OS. Conclusions: A nomogram was generated and confirmed to be of clinical value. Our IHC classifier integrating five IHC markers could help clinicians make decisions and determine optimal treatments for patients with MMHN.	[Xu, Qing-Qing; Li, Qing-Jie; Huang, Cheng-Long; Lu, Li-Xia; Chen, Lei] Sun Yat Sen Univ, Dept Radiat Oncol, Ctr Canc,Guangdong Key Lab Nasopharyngeal Carcino, State Key Lab Oncol South China,Collaborat Innova, Guangzhou, Peoples R China; [Cai, Mu-Yan; Zhang, Mei-Fang] Sun Yat Sen Univ, Dept Pathol, Ctr Canc, Guangzhou, Peoples R China; [Yin, Shao-Han] Sun Yat Sen Univ, Imaging Diag & Intervent Ctr, Ctr Canc, State Key Lab Oncol Southern China,Collaborat Inn, Guangzhou, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University	Lu, LX; Chen, L (corresponding author), Sun Yat Sen Univ, Dept Radiat Oncol, Ctr Canc,Guangdong Key Lab Nasopharyngeal Carcino, State Key Lab Oncol South China,Collaborat Innova, Guangzhou, Peoples R China.	lulx@sysucc.org.cn; chenlei@sysucc.org.cn			Planned Science and Technology Project of Guangdong Province [2016A020215085, 201707010087]; 308 Clinical Research Funding of Sun Yat-Sen University Cancer Center [308-2015-011]	Planned Science and Technology Project of Guangdong Province; 308 Clinical Research Funding of Sun Yat-Sen University Cancer Center	This study was funded by the Planned Science and Technology Project of Guangdong Province (No 2016A020215085, 201707010087) and the 308 Clinical Research Funding of Sun Yat-Sen University Cancer Center (No 308-2015-011). These funding sources had no role in the study design, data collection, data analysis, interpretation, and writing of the report.	Bai X, 2017, NEOPLASMA, V64, P626, DOI 10.4149/neo_2017_419; Chang AE, 1998, CANCER, V83, P1664, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G; Chi ZH, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-85; COLOMBARI R, 1988, VIRCHOWS ARCH A, V413, P17, DOI 10.1007/BF00844277; D'Angelo SP, 2017, J CLIN ONCOL, V35, P226, DOI 10.1200/JCO.2016.67.9258; Dean DN, 2020, P NATL ACAD SCI USA, V117, P22671, DOI 10.1073/pnas.2009702117; Del Vecchio M, 2014, EUR J CANCER, V50, P121, DOI 10.1016/j.ejca.2013.09.007; Guo J, 2011, J CLIN ONCOL, V29, P2904, DOI 10.1200/JCO.2010.33.9275; Hamid O, 2018, BRIT J CANCER, V119, P670, DOI 10.1038/s41416-018-0207-6; Hodi FS, 2002, AM J CLIN ONCOL-CANC, V25, P283, DOI 10.1097/00000421-200206000-00016; Jethanamest D, 2011, ANN SURG ONCOL, V18, P2748, DOI 10.1245/s10434-011-1685-4; Kim KB, 2012, J CLIN ONCOL, V30, P34, DOI 10.1200/JCO.2011.34.6270; Korabiowska M, 2005, ANTICANCER RES, V25, P2789; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; LEE SP, 1994, LARYNGOSCOPE, V104, P121; Li RY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094855; Lian B, 2017, ANN ONCOL, V28, P868, DOI 10.1093/annonc/mdw694; Long GV, 2015, LANCET, V386, P444, DOI 10.1016/S0140-6736(15)60898-4; Lourenco SV, 2009, AM J DERMATOPATH, V31, P323, DOI 10.1097/DAD.0b013e3181a0d37c; Mignard C, 2018, J ONCOL, V2018, DOI 10.1155/2018/1908065; Oguri H, 2004, J CLIN PATHOL, V57, P986, DOI 10.1136/jcp.2004.016220; Prasad ML, 2004, CANCER, V100, P1657, DOI 10.1002/cncr.20201; Sato S, 2020, J DERMATOL, V47, P1141, DOI 10.1111/1346-8138.15502; Shimada H, 2002, BRIT J CANCER, V86, P552, DOI 10.1038/sj.bjc.6600129; Siref AB, 2019, J CUTAN PATHOL, V46, P261, DOI 10.1111/cup.13412; Wang O, 2012, CHINESE MED J-PEKING, V125, P2895, DOI 10.3760/cma.j.issn.0366-6999.2012.16.018; Xu YP, 2016, J CANCER, V7, P587, DOI 10.7150/jca.13687; Yan XQ, 2021, J CLIN ONCOL, V39, P881, DOI 10.1200/JCO.20.00902; Yu CH, 2005, J ORAL PATHOL MED, V34, P540, DOI 10.1111/j.1600-0714.2005.00340.x; Zhu MY, 2019, CANCER MANAG RES, V11, P4577, DOI 10.2147/CMAR.S203010	30	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 29	2021	12								708293	10.3389/fimmu.2021.708293	http://dx.doi.org/10.3389/fimmu.2021.708293			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UA6FX	34394109	Green Published, gold			2022-12-18	WOS:000685256900001
J	Hernandez, J; Li, YL; Mateu, E				Hernandez, Jesus; Li, Yanli; Mateu, Enric			Swine Dendritic Cell Response to Porcine Reproductive and Respiratory Syndrome Virus: An Update	FRONTIERS IN IMMUNOLOGY			English	Review						PRRSV; dendritic cell; cDC1; cCD2; pDCs; bmDCs; moDCs	REGULATORY T-CELLS; NONSTRUCTURAL PROTEINS; NUCLEOCAPSID PROTEIN; IMMUNE-RESPONSES; INDUCTION; INTERLEUKIN-10; INFECTION; TYPE-2; IDENTIFICATION; MODULATION	Dendritic cells (DCs) are the most potent antigen-presenting cells, unique to initiate and coordinate the adaptive immune response. In pigs, conventional DCs (cDCs), plasmacytoid DCs (pDCs), and monocyte-derived DCs (moDCs) have been described in blood and tissues. Different pathogens, such as viruses, could infect these cells, and in some cases, compromise their response. The understanding of the interaction between DCs and viruses is critical to comprehend viral immunopathological responses. Porcine reproductive and respiratory syndrome virus (PRRSV) is the most important respiratory pathogen in the global pig population. Different reports support the notion that PRRSV modulates pig immune response in addition to their genetic and antigenic variability. The interaction of PRRSV with DCs is a mostly unexplored area with conflicting results and lots of uncertainties. Among the scarce certainties, cDCs and pDCs are refractory to PRRSV infection in contrast to moDCs. Additionally, response of DCs to PRRSV can be different depending on the type of DCs and maybe is related to the virulence of the viral isolate. The precise impact of this virus-DC interaction upon the development of the specific immune response is not fully elucidated. The present review briefly summarizes and discusses the previous studies on the interaction of in vitro derived bone marrow (bm)- and moDCs, and in vivo isolated cDCs, pDCs, and moDCs with PRRSV1 and 2.	[Hernandez, Jesus] Ctr Invest Alimentacio & Desarrollo, Lab Inmunol, Hermosillo, Sonora, Mexico; [Li, Yanli; Mateu, Enric] Univ Autonoma Barcelona, Fac Vet, Dept Sanitat & Anat Anim, Cerdanyola Del Valles, Spain; [Mateu, Enric] UAB, IRTA, CReSA, IRTA,Ctr Recerca Sanit Anim, Cerdanyola Del Valles, Spain	CIAD - Centro de Investigacion en Alimentacion y Desarrollo; Autonomous University of Barcelona; Autonomous University of Barcelona; IRTA	Hernandez, J (corresponding author), Ctr Invest Alimentacio & Desarrollo, Lab Inmunol, Hermosillo, Sonora, Mexico.	jhdez@ciad.mx	Hernandez, Jesus/G-2984-2012	Hernandez, Jesus/0000-0002-5131-3600	Consejo Nacional de Ciencia y Tecnologia (CONACyT) [222973]	Consejo Nacional de Ciencia y Tecnologia (CONACyT)(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	This work was supported by the Consejo Nacional de Ciencia y Tecnologia (CONACyT), grant number 222973.	Adams MJ, 2017, ARCH VIROL, V162, P2505, DOI 10.1007/s00705-017-3358-5; Alvarez B, 2013, DEV COMP IMMUNOL, V41, P153, DOI 10.1016/j.dci.2013.04.021; Auray G, 2016, J IMMUNOL, V197, P4791, DOI 10.4049/jimmunol.1600672; Auray G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156019; Baumann A, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-33; Bordet E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02299; Brooks DG, 2006, NAT MED, V12, P1301, DOI 10.1038/nm1492; Burgara-Estrella A, 2013, VIRUSES-BASEL, V5, P663, DOI 10.3390/v5020663; Bustamante-Cordova L, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020043; Calzada-Nova G, 2010, VET IMMUNOL IMMUNOP, V135, P20, DOI 10.1016/j.vetimm.2009.10.026; Cecere TE, 2012, VET MICROBIOL, V160, P233, DOI 10.1016/j.vetmic.2012.04.040; Chang HC, 2008, VET MICROBIOL, V129, P281, DOI 10.1016/j.vetmic.2007.12.002; Chaung HC, 2010, COMP IMMUNOL MICROB, V33, P197, DOI 10.1016/j.cimid.2008.10.001; Chen WY, 2018, J VIROL, V92, DOI 10.1128/JVI.01251-17; COLLINS JE, 1992, J VET DIAGN INVEST, V4, P117, DOI 10.1177/104063879200400201; Crisci E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.588411; Diaz I, 2005, J GEN VIROL, V86, P1943, DOI 10.1099/vir.0.80959-0; Edwards JC, 2017, SCI REP-UK, V7, DOI 10.1038/srep40942; Fan BC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138772; Fernandez A, 2014, HUM VACC IMMUNOTHER, V10, P3251, DOI 10.4161/hv.29847; Flores-Mendoza L, 2008, CLIN VACCINE IMMUNOL, V15, P720, DOI 10.1128/CVI.00224-07; Franzoni G, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11050445; Garcia-Nicolas O, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00771; Gimeno M, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-9; Gomez-Laguna J, 2010, J COMP PATHOL, V142, P51, DOI 10.1016/j.jcpa.2009.07.004; Guilliams M, 2016, IMMUNITY, V45, P669, DOI 10.1016/j.immuni.2016.08.015; Haniffa M, 2012, IMMUNITY, V37, P60, DOI 10.1016/j.immuni.2012.04.012; Holtkamp DJ, 2013, J SWINE HEALTH PROD, V21, P72; Hu Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep23977; Lechmann M, 2002, TRENDS IMMUNOL, V23, P273, DOI 10.1016/S1471-4906(02)02214-7; Li YL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.674185; Liu JL, 2016, DEV COMP IMMUNOL, V65, P245, DOI 10.1016/j.dci.2016.07.012; Liu X, 2015, J GEN VIROL, V96, P1276, DOI 10.1099/vir.0.000061; Loving CL, 2007, IMMUNOLOGY, V120, P217, DOI 10.1111/j.1365-2567.2006.02493.x; Loving CL, 2015, VET IMMUNOL IMMUNOP, V167, P1, DOI 10.1016/j.vetimm.2015.07.003; Maisonnasse P, 2016, MUCOSAL IMMUNOL, V9, P835, DOI 10.1038/mi.2015.105; Maizels RM, 2011, ADV IMMUNOL, V112, P73, DOI 10.1016/B978-0-12-387827-4.00003-6; Marquet F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016320; Meier WA, 2003, VIROLOGY, V309, P18, DOI 10.1016/S0042-6822(03)00009-6; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Mizuno R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00630; Nedumpun T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00579; Nedumpun T, 2018, VET MICROBIOL, V216, P13, DOI 10.1016/j.vetmic.2018.01.014; Nedumpun T, 2017, J GEN VIROL, V98, P77, DOI 10.1099/jgv.0.000665; Parida R, 2012, VIRUS RES, V169, P13, DOI 10.1016/j.virusres.2012.06.024; Park JY, 2008, J MICROBIOL BIOTECHN, V18, P1709; Parra-Sanchez H, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11111001; Parra-Sanchez H, 2018, MOL IMMUNOL, V96, P1, DOI 10.1016/j.molimm.2018.02.003; Peng YT, 2009, VET MICROBIOL, V136, P359, DOI 10.1016/j.vetmic.2008.11.013; Proll MJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187735; Puebla-Clark L, 2019, VIROLOGY, V529, P65, DOI 10.1016/j.virol.2019.01.012; Qu CF, 2014, INT J INFECT DIS, V19, P1, DOI 10.1016/j.ijid.2013.09.023; Rascon-Castelo E, 2015, VIRUSES-BASEL, V7, P873, DOI 10.3390/v7030873; Resendiz M, 2018, VET MICROBIOL, V223, P27, DOI 10.1016/j.vetmic.2018.07.012; Richmond O, 2015, VET MICROBIOL, V180, P223, DOI 10.1016/j.vetmic.2015.09.014; Rodriguez-Gomez IM, 2015, VET RES, V46, DOI 10.1186/s13567-015-0186-z; Sang YM, 2014, J VIROL, V88, P11395, DOI 10.1128/JVI.01714-14; Schlitzer A, 2015, SEMIN CELL DEV BIOL, V41, P9, DOI 10.1016/j.semcdb.2015.03.011; Schlitzer A, 2015, NAT IMMUNOL, V16, P718, DOI 10.1038/ni.3200; Schlitzer A, 2014, CURR OPIN IMMUNOL, V26, P90, DOI 10.1016/j.coi.2013.11.002; Silva-Campa E, 2012, VIROLOGY, V430, P73, DOI 10.1016/j.virol.2012.04.009; Silva-Campa E, 2010, VIROLOGY, V396, P264, DOI 10.1016/j.virol.2009.10.024; Silva-Campa E, 2009, VIROLOGY, V387, P373, DOI 10.1016/j.virol.2009.02.033; Singleton H, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00832; Snijder EJ, 2013, J GEN VIROL, V94, P2141, DOI 10.1099/vir.0.056341-0; Soldevila F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01800; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; Subramaniam S, 2017, VET IMMUNOL IMMUNOP, V190, P18, DOI 10.1016/j.vetimm.2017.07.003; Subramaniam S, 2011, VIRUS RES, V155, P415, DOI 10.1016/j.virusres.2010.11.010; Taylor A, 2006, IMMUNOLOGY, V117, P433, DOI 10.1111/j.1365-2567.2006.02321.x; Van Breedam W, 2010, J GEN VIROL, V91, P1659, DOI 10.1099/vir.0.020503-0; Villadangos JA, 2008, IMMUNITY, V29, P352, DOI 10.1016/j.immuni.2008.09.002; Wang X, 2007, ARCH VIROL, V152, P289, DOI 10.1007/s00705-006-0857-1; Wang YX, 2011, VIRUS RES, V158, P108, DOI 10.1016/j.virusres.2011.03.018; Weesendorp E, 2013, VET MICROBIOL, V167, P638, DOI 10.1016/j.vetmic.2013.09.021; Wongyanin P, 2010, VET IMMUNOL IMMUNOP, V133, P170, DOI 10.1016/j.vetimm.2009.07.012; Wongyanin P, 2012, J GEN VIROL, V93, P1236, DOI 10.1099/vir.0.040287-0; Zhao H, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01578	78	0	0	2	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 28	2021	12								712109	10.3389/fimmu.2021.712109	http://dx.doi.org/10.3389/fimmu.2021.712109			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TY5QI	34394113	gold, Green Published			2022-12-18	WOS:000683838500001
J	Kavian, N; Mehlal, S; Jeljeli, M; Saidu, NEB; Nicco, C; Cerles, O; Chouzenoux, S; Cauvet, A; Camus, C; Ait-Djoudi, M; Chereau, C; Kerdine-Romer, S; Allanore, Y; Batteux, F				Kavian, Niloufar; Mehlal, Souad; Jeljeli, Mohamed; Saidu, Nathaniel Edward Bennett; Nicco, Carole; Cerles, Olivier; Chouzenoux, Sandrine; Cauvet, Anne; Camus, Claire; Ait-Djoudi, Mehdi; Chereau, Christiane; Kerdine-Romer, Saadia; Allanore, Yannick; Batteux, Frederic			The Nrf2-Antioxidant Response Element Signaling Pathway Controls Fibrosis and Autoimmunity in Scleroderma (vol 9, 1896, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						systemic sclerosis; oxidative stress; fibrosis; inflammation; Nrf2			[Kavian, Niloufar; Mehlal, Souad; Jeljeli, Mohamed; Batteux, Frederic] Hop Cochin, Lab Immunol, Paris, France; [Kavian, Niloufar; Mehlal, Souad; Jeljeli, Mohamed; Saidu, Nathaniel Edward Bennett; Nicco, Carole; Cerles, Olivier; Chouzenoux, Sandrine; Cauvet, Anne; Camus, Claire; Ait-Djoudi, Mehdi; Chereau, Christiane; Allanore, Yannick; Batteux, Frederic] Inst Cochin, INSERM U1016, Paris, France; [Kerdine-Romer, Saadia] Univ Paris Saclay, Univ Paris Sud, INSERM, UMR996 Inflammat Chemokines & Immunopathol, Chatenay Malabry, France; [Allanore, Yannick] Hop Cochin, Serv Rhumatol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Batteux, F (corresponding author), Hop Cochin, Lab Immunol, Paris, France.; Batteux, F (corresponding author), Inst Cochin, INSERM U1016, Paris, France.	frederic.batteux@aphp.fr	Nicco, Carole/X-6726-2019; Nicco, Carole/O-8169-2017	Nicco, Carole/0000-0001-8211-2556; Nicco, Carole/0000-0001-8211-2556				Kavian N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01896	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 27	2021	12								737303	10.3389/fimmu.2021.737303	http://dx.doi.org/10.3389/fimmu.2021.737303			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TY0KJ	34386019	gold, Green Published			2022-12-18	WOS:000683472900001
J	Latysheva, E; Nazarova, E; Latysheva, T; Ilina, N				Latysheva, Elena; Nazarova, Evgeniya; Latysheva, Tatiana; Ilina, Natalia			Case Report: Safe and Effective Sublingual Birch Allergen Immunotherapy in Two HIV-Positive Patients	FRONTIERS IN IMMUNOLOGY			English	Article						allergen immunotherapy; HIV positive; birch allergen; case report; sublingual		Allergen-specific immunotherapy (AIT) is a safe, effective treatment for respiratory allergies (such as moderate-to-severe allergic rhinoconjunctivitis) that are not controlled by symptomatic medications. The indications and contraindications for AIT have been defined in international guidelines and consensus statements. However, some of these contraindications are not evidenced- based but have been deduced from the theoretical risk of an interaction between AIT disease-modifying effect and immune or inflammatory comorbidities. In the absence of clinical trial evidence, the accumulation of experience as case reports can narrow the spectrum of absolute contraindications. The majority of international guidelines list HIV infection as a contraindication to AIT. Here, we describe two cases of safe, effective sublingual birch pollen AIT in HIV-positive patients undergoing concomitant antiretroviral therapy. A 32-year-old female and a 63-year-old male sensitized to tree pollen and with clinically confirmed birch pollen allergy underwent pre- and co-seasonal sublingual birch pollen AIT for three and two pollen seasons, respectively. The therapy was associated with a marked reduction in the frequency and intensity of allergic symptoms, and the reduced use of (symptomatic) rescue medication. Mild, local, treatment-emergent adverse events were noted throughout the course of treatment but resolved spontaneously. No serious adverse events were reported. In particular, there were no obvious harmful effects on the patients' immune status or viral load. Hence, sublingual birch pollen AIT proved to be effective and safe in two HIV-positive patients.	[Latysheva, Elena; Nazarova, Evgeniya; Latysheva, Tatiana; Ilina, Natalia] Inst Immunol Fed Biomed Agcy, Inst Immunol, Natl Res Ctr, Moscow, Russia	NRC Institute of Immunology FMBA of Russia	Latysheva, E (corresponding author), Inst Immunol Fed Biomed Agcy, Inst Immunol, Natl Res Ctr, Moscow, Russia.	ealat@mail.ru			Stallergenes Greer	Stallergenes Greer	The authors declare that this study received funding from Stallergenes Greer. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	Alvaro-Lozano M, 2020, PEDIAT ALLERG IMM-UK, V31, P1, DOI 10.1111/pai.13189; Fodeman J, 2010, ANN ALLERG ASTHMA IM, V105, P320, DOI 10.1016/j.anai.2010.06.017; Iemoli E, 2016, ALLERGY, V71, P412, DOI 10.1111/all.12713; James C, 2017, CURR OPIN ALLERGY CL, V17, P55, DOI 10.1097/ACI.0000000000000335; [Курбачева Оксана Михайловна Kurbacheva O.M.], 2016, [Российский аллергологический журнал, Rossiiskii allergologicheskii zhurnal], P55; Larenas-Linnemann DES, 2016, ALLERGY ASTHMA PROC, V37, pE112, DOI 10.2500/aap.2016.37.3981; Linhar LS, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-35; Marshall GD, 1999, ALLERGY ASTHMA PROC, V20, P301, DOI 10.2500/108854199778251979; Musarra A, 2014, EUR ANN ALLERGY CLIN, V45, pS17; Panel on Opportunistic Infections in Adults and Adolescents With HIV, 2019, GUIDELINES PREVENTIO; Pfaar Oliver, 2014, Allergo J Int, V23, P282; Pitsios C, 2019, CLIN TRANSL ALLERGY, V9, DOI 10.1186/s13601-019-0285-4; Pitsios C, 2015, ALLERGY, V70, P897, DOI 10.1111/all.12638; Ramesh M, 2018, HUM VACC IMMUNOTHER, V14, P2848, DOI 10.1080/21645515.2018.1502126; Randhawa IS, 2007, ANN ALLERG ASTHMA IM, V98, P495, DOI 10.1016/S1081-1206(10)60767-3; Stokes SC, 2011, ANN ALLERG ASTHMA IM, V107, P1, DOI 10.1016/j.anai.2011.05.004; Walker SM, 2011, CLIN EXP ALLERGY, V41, P1177, DOI 10.1111/j.1365-2222.2011.03794.x	17	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 27	2021	12								599955	10.3389/fimmu.2021.599955	http://dx.doi.org/10.3389/fimmu.2021.599955			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TX7UZ	34385997	gold, Green Published			2022-12-18	WOS:000683295000001
J	Liu, YQ; Wang, XL; Zhou, JF; Shi, SB; Shen, TF; Chen, LL; Zhang, M; Liao, CS; Wang, C				Liu, Yongqing; Wang, Xiaoli; Zhou, Jiangfei; Shi, Shuaibing; Shen, Tengfei; Chen, Liangliang; Zhang, Min; Liao, Chengshui; Wang, Chen			Development of PDA Nanoparticles for H9N2 Avian Influenza BPP-V/BP-IV Epitope Peptide Vaccines: Immunogenicity and Delivery Efficiency Improvement	FRONTIERS IN IMMUNOLOGY			English	Article						polydopamine; nanoconjugates; nano BPP-V epitope vaccine; nano BP-IV epitope vaccine	MEDIATED IMMUNE-RESPONSES; VIRUS; POLYDOPAMINE; VACCINATION; DISEASE; BURSA; LUNG; MICE	The protection of current influenza vaccines is limited due to the viral antigenic shifts and antigenic drifts. The universal influenza vaccine is a new hotspot in vaccine research that aims to overcome these problems. Polydopamine (PDA), a versatile biomaterial, has the advantages of an excellent biocompatibility, controllable particle size, and distinctive drug loading approach in drug delivery systems. To enhance the immunogenicities and delivery efficiencies of H9N2 avian influenza virus (AIV) epitope peptide vaccines, PDA nanoparticles conjugated with the BPP-V and BP-IV epitope peptides were used to prepare the nano BPP-V and BP-IV epitope peptide vaccines, respectively. The characteristics of the newly developed epitope peptide vaccines were then evaluated, revealing particle sizes ranging from approximately 240 to 290 nm (PDI<0.3), indicating that the synthesized nanoparticles were stable. Simultaneously, the immunoprotective effects of nano BPP-V and BP-IV epitope peptide vaccines were assessed. The nano BPP-V and BP-IV epitope vaccines, especially nano BP-IV epitope vaccine, quickly induced anti-hemagglutinin (HA) antibody production and a sustained immune response, significantly promoted humoral and cellular immune responses, reduced viral lung damage and provided effective protection against AIV viral infection. Together, these results reveal that PDA, as a delivery carrier, can improve the immunogenicities and delivery efficiencies of H9N2 AIV nano epitope vaccines, thereby providing a theoretical basis for the design and development of PDA as a carrier of new universal influenza vaccines.	[Liu, Yongqing; Zhou, Jiangfei; Shi, Shuaibing; Shen, Tengfei; Chen, Liangliang; Zhang, Min; Liao, Chengshui; Wang, Chen] Henan Univ Sci & Technol, Key Lab Vet Biol Prod, Luoyang, Peoples R China; [Wang, Xiaoli] Henan Univ Sci & Technol, Sch Basic Med Sci, Luoyang, Peoples R China	Henan University of Science & Technology; Henan University of Science & Technology	Liao, CS; Wang, C (corresponding author), Henan Univ Sci & Technol, Key Lab Vet Biol Prod, Luoyang, Peoples R China.	liaochengshui33@163.com; wangchen2001@126.com			National Natural Science Foundation of China [U2004151, 31802159]; PhD Start-up Fund of Henan University of Science and Technology [13480071]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); PhD Start-up Fund of Henan University of Science and Technology	The whole study was supported from the financial support from the National Natural Science Foundation of China (grant number U2004151 and 31802159) and PhD Start-up Fund of Henan University of Science and Technology (13480071).	Alexander DJ, 2000, VET MICROBIOL, V74, P3, DOI 10.1016/S0378-1135(00)00160-7; Astill J, 2018, VACCINE, V36, P3908, DOI 10.1016/j.vaccine.2018.05.093; Benne CA, 1997, VACCINE, V15, P1039, DOI 10.1016/S0264-410X(96)00287-3; Bradley LM, 1996, J IMMUNOL, V157, P1350; Cappellano G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010204; Chen JR, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-0626-6; Chen Y, 2016, BIOMATERIALS, V77, P198, DOI 10.1016/j.biomaterials.2015.11.010; Coughlan L, 2018, CELL HOST MICROBE, V24, P18, DOI 10.1016/j.chom.2018.06.016; Deng L, 2018, ACS INFECT DIS, V4, P1656, DOI 10.1021/acsinfecdis.8b00206; Duran V, 2019, NANOMED-NANOTECHNOL, V21, DOI 10.1016/j.nano.2019.102073; Hayward AC, 2015, AM J RESP CRIT CARE, V191, P1422, DOI 10.1164/rccm.201411-1988OC; Herrmann VL, 2015, J CONTROL RELEASE, V216, P121, DOI 10.1016/j.jconrel.2015.08.019; Hiremath J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151922; Jabr-Milane LS, 2008, CANCER TREAT REV, V34, P592, DOI 10.1016/j.ctrv.2008.04.003; Jiang WM, 2006, VET IMMUNOL IMMUNOP, V113, P169, DOI 10.1016/j.vetimm.2006.05.001; Jin AT, 2020, BIOACT MATER, V5, P522, DOI 10.1016/j.bioactmat.2020.04.003; Ju KY, 2011, BIOMACROMOLECULES, V12, P625, DOI 10.1021/bm101281b; Kang TY, 2018, INT J NANOMED, V13, P3251, DOI 10.2147/IJN.S156346; Khalaj-Hedayati A, 2020, INFLUENZA OTHER RESP, V14, P92, DOI 10.1111/irv.12697; Krammer F, 2015, NAT REV DRUG DISCOV, V14, P167, DOI 10.1038/nrd4529; Li DY, 2011, AMINO ACIDS, V40, P505, DOI 10.1007/s00726-010-0663-7; Li DY, 2011, CLIN VACCINE IMMUNOL, V18, P1497, DOI 10.1128/CVI.05133-11; Li YT, 2019, BRIT MED BULL, V132, P81, DOI 10.1093/bmb/ldz036; Lu J, 2014, J VIROL, V88, P8297, DOI 10.1128/JVI.00630-14; Markman JL, 2013, ADV DRUG DELIVER REV, V65, P1866, DOI 10.1016/j.addr.2013.09.019; Neirynck S, 1999, NAT MED, V5, P1157, DOI 10.1038/13484; Le QV, 2019, ACS NANO, V13, P7442, DOI 10.1021/acsnano.9b02071; Reed SG, 2009, TRENDS IMMUNOL, V30, P23, DOI 10.1016/j.it.2008.09.006; Sano K, 2017, VACCINE, V35, P5388, DOI 10.1016/j.vaccine.2017.08.034; Sautto GA, 2018, VIROL J, V15, DOI 10.1186/s12985-017-0918-y; Shirai S, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03018; Sims LD, 2020, AVIAN PATHOL, V49, P529, DOI 10.1080/03079457.2020.1796139; Singh I, 2020, MAT SCI ENG C-MATER, V107, DOI 10.1016/j.msec.2019.110284; Singh SM, 2016, VIRAL IMMUNOL, V29, P269, DOI 10.1089/vim.2015.0144; Song YF, 2015, J VIROL, V89, P7841, DOI 10.1128/JVI.00976-15; SWAIN SL, 1990, J IMMUNOL, V145, P3796; Swayne DE, 2008, IMMUNOL REV, V225, P314, DOI 10.1111/j.1600-065X.2008.00668.x; Ulmer JB, 1998, J VIROL, V72, P5648, DOI 10.1128/JVI.72.7.5648-5653.1998; van Dijk JGB, 2018, CURR OPIN VIROL, V28, P26, DOI 10.1016/j.coviro.2017.10.006; Wang C, 2015, CLIN VACCINE IMMUNOL, V22, P56, DOI 10.1128/CVI.00636-14; Wang C, 2014, CELL IMMUNOL, V292, P57, DOI 10.1016/j.cellimm.2014.09.003; Wang WJ, 2020, NAT NANOTECHNOL, V15, P406, DOI 10.1038/s41565-020-0648-y; Wang X, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02019-1; Wang XL, 2019, BIOMATER SCI-UK, V7, P3062, DOI 10.1039/c9bm00010k; Wang XY, 2016, BIOMATERIALS, V81, P114, DOI 10.1016/j.biomaterials.2015.11.037; Wang Y, 2018, EXPERT REV VACCINES, V17, P967, DOI 10.1080/14760584.2018.1541408; Wang Z, 2018, J CONTROL RELEASE, V290, P56, DOI 10.1016/j.jconrel.2018.10.009; Wong TM, 2016, HUM VACC IMMUNOTHER, V12, P2096, DOI 10.1080/21645515.2016.1162931; Zhang C, 2018, J VET SCI, V19, P817, DOI 10.4142/jvs.2018.19.6.817; Zheng MB, 2013, ACS NANO, V7, P2056, DOI 10.1021/nn400334y; Zheng WC, 2015, LANGMUIR, V31, P11671, DOI 10.1021/acs.langmuir.5b02757; Zhou JF, 2018, PROTEIN PEPTIDE LETT, V25, P757, DOI 10.2174/0929866525666180806110928	52	0	0	4	22	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 27	2021	12								693972	10.3389/fimmu.2021.693972	http://dx.doi.org/10.3389/fimmu.2021.693972			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TX7YN	34386005	gold, Green Published			2022-12-18	WOS:000683304300001
J	Vittoraki, AG; Fylaktou, A; Tarassi, K; Tsinaris, Z; Siorenta, A; Petasis, GC; Gerogiannis, D; Lehmann, C; Carmagnat, M; Doxiadis, I; Iniotaki, AG; Theodorou, I				Vittoraki, Angeliki G.; Fylaktou, Asimina; Tarassi, Katerina; Tsinaris, Zafeiris; Siorenta, Alexandra; Petasis, George Ch; Gerogiannis, Demetris; Lehmann, Claudia; Carmagnat, Maryvonnick; Doxiadis, Ilias; Iniotaki, Aliki G.; Theodorou, Ioannis			Hidden Patterns of Anti-HLA Class I Alloreactivity Revealed Through Machine Learning	FRONTIERS IN IMMUNOLOGY			English	Article						machine learning; antigenic epitopes; alloimmune response; translational research; sensitization; bead array test; anti-HLA alloantibodies	ANTIBODIES; EPITOPES; HLAMATCHMAKER; SEQUENCE; REACTIVITY; PREDICTS; PROGRAM; DQ	Detection of alloreactive anti-HLA antibodies is a frequent and mandatory test before and after organ transplantation to determine the antigenic targets of the antibodies. Nowadays, this test involves the measurement of fluorescent signals generated through antibody-antigen reactions on multi-beads flow cytometers. In this study, in a cohort of 1,066 patients from one country, anti-HLA class I responses were analyzed on a panel of 98 different antigens. Knowing that the immune system responds typically to "shared" antigenic targets, we studied the clustering patterns of antibody responses against HLA class I antigens without any a priori hypothesis, applying two unsupervised machine learning approaches. At first, the principal component analysis (PCA) projections of intra-locus specific responses showed that anti-HLA-A and anti-HLA-C were the most distantly projected responses in the population with the anti-HLA-B responses to be projected between them. When PCA was applied on the responses against antigens belonging to a single locus, some already known groupings were confirmed while several new cross-reactive patterns of alloreactivity were detected. Anti-HLA-A responses projected through PCA suggested that three cross-reactive groups accounted for about 70% of the variance observed in the population, while anti-HLA-B responses were mainly characterized by a distinction between previously described Bw4 and Bw6 cross-reactive groups followed by several yet undocumented or poorly described ones. Furthermore, anti-HLA-C responses could be explained by two major cross-reactive groups completely overlapping with previously described C1 and C2 allelic groups. A second feature-based analysis of all antigenic specificities, projected as a dendrogram, generated a robust measure of allelic antigenic distances depicting bead-array defined cross reactive groups. Finally, amino acid combinations explaining major population specific cross-reactive groups were described. The interpretation of the results was based on the current knowledge of the antigenic targets of the antibodies as they have been characterized either experimentally or computationally and appear at the HLA epitope registry.	[Vittoraki, Angeliki G.; Siorenta, Alexandra] Gen Hosp Athens G Gennimatas, Immunol Dept, Athens, Greece; [Vittoraki, Angeliki G.; Siorenta, Alexandra] Gen Hosp Athens G Gennimatas, Natl Tissue Typing Ctr, Athens, Greece; [Fylaktou, Asimina; Tsinaris, Zafeiris; Petasis, George Ch] Hippokrateion Hosp, Immunol Dept, Natl Peripheral Histocompatibil Ctr, Thessaloniki, Greece; [Tarassi, Katerina] Evangelismos Gen Hosp, Immunol Histocompatibil Dept, Athens, Greece; [Gerogiannis, Demetris] Univ Ioannina, Dept Comp Sci & Engn, Ioannina, Greece; [Lehmann, Claudia; Doxiadis, Ilias] Univ Hosp Leipzig, Inst Transfus Med, Lab Transplantat Immunol, Leipzig, Germany; [Carmagnat, Maryvonnick; Theodorou, Ioannis] Hop St Louis, Lab Immunol, Paris, France; [Iniotaki, Aliki G.] Laikon Gen Hosp, Med Sch Athens, Nephrol & Transplantat Unit, Athens, Greece; [Theodorou, Ioannis] UPMC UMRS CR7 Inserm U1135 CNRS ERL, Ctr Immunol & Malad Infect, Paris, France	Evangelismos Hospital; University of Ioannina; Leipzig University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Laiko General Hospital; National & Kapodistrian University of Athens	Vittoraki, AG (corresponding author), Gen Hosp Athens G Gennimatas, Immunol Dept, Athens, Greece.; Vittoraki, AG (corresponding author), Gen Hosp Athens G Gennimatas, Natl Tissue Typing Ctr, Athens, Greece.	avittor2@yahoo.com	Doxiadis, ilias/AAH-9875-2020		Hellenic Society for Immunology [9/29.01.2019]	Hellenic Society for Immunology	The Hellenic Society for Immunology (HSI Ref: 9/29.01.2019).	[Anonymous], 2020, **DATA OBJECT**; Claas FHJ, 2004, TRANSPLANTATION, V78, P190, DOI 10.1097/01.tp.0000129260.86766.67; Duquesnoy RJ, 2019, HUM IMMUNOL, V80, P103, DOI 10.1016/j.humimm.2018.11.007; Duquesnoy RJ, 2009, TISSUE ANTIGENS, V74, P117, DOI 10.1111/j.1399-0039.2009.01271.x; Duquesnoy RJ, 2007, HUM IMMUNOL, V68, P12, DOI 10.1016/j.humimm.2006.10.003; Duquesnoy RJ, 2017, HUM IMMUNOL, V78, P481, DOI 10.1016/j.humimm.2017.03.005; Duquesnoy RJ, 2004, TRANSPL INT, V17, P22, DOI 10.1111/j.1432-2277.2004.tb00379.x; El-Awar N, 2007, HUM IMMUNOL, V68, P170, DOI 10.1016/j.humimm.2006.11.006; El-Awar N, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/3406230; El-Awar NR, 2007, TRANSPLANTATION, V84, P532, DOI 10.1097/01.tp.0000278721.97037.1e; Geneugelijk K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00321; Giuliani A, 2017, DRUG DISCOV TODAY, V22, P1069, DOI 10.1016/j.drudis.2017.01.005; Hilton HG, 2017, IMMUNOGENETICS, V69, P567, DOI 10.1007/s00251-017-1001-y; Hilton HG, 2017, CELL REP, V19, P1394, DOI 10.1016/j.celrep.2017.04.059; Hilton HG, 2012, J IMMUNOL, V189, P1418, DOI 10.4049/jimmunol.1100431; Klausen MS, 2019, PROTEINS, V87, P520, DOI 10.1002/prot.25674; Kosmoliaptsis V, 2016, AM J TRANSPLANT, V16, P2139, DOI 10.1111/ajt.13707; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lachmann N, 2017, AM J TRANSPLANT, V17, P3076, DOI 10.1111/ajt.14393; Le S, 2008, J STAT SOFTW, V25, P1, DOI 10.18637/jss.v025.i01; Lucas DP, 2015, TRANSPLANTATION, V99, P77, DOI 10.1097/TP.0000000000000355; Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514; Pontrelli P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01454; Ramsuran V, 2017, J IMMUNOL, V198, P2320, DOI 10.4049/jimmunol.1601679; Ravindranath MH, 2010, J IMMUNOL, V185, P1935, DOI 10.4049/jimmunol.1000424; RODEY GE, 1994, HUM IMMUNOL, V39, P272, DOI 10.1016/0198-8859(94)90270-4; Schnaidt M, 2011, TRANSPLANTATION, V92, P510, DOI 10.1097/TP.0b013e31822872dd; Tambur AR, 2020, AM J TRANSPLANT, V20, P2652, DOI 10.1111/ajt.15937; Tambur AR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02010; VANROOD JJ, 1963, J CLIN INVEST, V42, P1382; Vittoraki AG, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01667; WAN AM, 1986, J IMMUNOL, V137, P3671; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967; Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033; Wilkinson L, 2009, AM STAT, V63, P179, DOI 10.1198/tas.2009.0033; Willicombe M, 2018, TRANSPLANTATION, V102, P127, DOI 10.1097/TP.0000000000001887; Zhu L, 2018, TRANSPL IMMUNOL, V49, P59, DOI 10.1016/j.trim.2018.04.005	37	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 27	2021	12								670956	10.3389/fimmu.2021.670956	http://dx.doi.org/10.3389/fimmu.2021.670956			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TX8BX	34386000	Green Published, gold			2022-12-18	WOS:000683313200001
J	Zhang, YF; Wu, YY; Wang, W; Liu, F; Zhang, YW; Yang, C; Liu, AF; Wu, J; Zhu, TY; Nicholson, ML; Fan, YP; Yang, B				Zhang, Yufang; Wu, Yuanyuan; Wang, Wei; Liu, Feng; Zhang, Yiwen; Yang, Cheng; Liu, Aifen; Wu, Jing; Zhu, Tongyu; Nicholson, Michael L.; Fan, Yaping; Yang, Bin			Long-Term Protection of CHBP Against Combinational Renal Injury Induced by Both Ischemia-Reperfusion and Cyclosporine A in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						apoptosis; CASP-3; cyclic helix B peptide; cyclosporine A; ischemia-reperfusion injury	B SURFACE PEPTIDE; ISCHEMIA/REPERFUSION INJURY; CASPASE-3 SIRNA; ERYTHROPOIETIN; APOPTOSIS; CELLS; INFLAMMATION; ACTIVATION; PROSPECTS; FIBROSIS	Renal ischemia-reperfusion (IR) injury and cyclosporine A (CsA) nephrotoxicity affect allograft function and survival. The prolonged effects and underlying mechanisms of erythropoietin derived cyclic helix B peptide (CHBP) and/or caspase-3 small interfering RNA (CASP-3siRNA) were investigated in mouse kidneys, as well as kidney epithelial cells (TCMK-1), subjected to transplant-related injuries. Bilateral renal pedicles were clamped for 30 min followed by reperfusion for 2 and 8 weeks, with/without 35 mg/kg CsA gavage daily and/or 24 nmol/kg CHBP intraperitoneal injection every 3 days. The ratio of urinary albumin to creatinine was raised by IR injury, further increased by CsA and lowered by CHBP at 2, 4, 6 and 8 weeks, whereas the level of SCr was not significantly affected. Similar change trends were revealed in tubulointerstitial damage and fibrosis, HMGB1 and active CASP-3 protein. Increased apoptotic cells in IR kidneys were decreased by CsA and CHBP at 2 and/or 8 weeks. p70 S6 kinase and mTOR were reduced by CsA with/without CHBP at 2 weeks, so were S6 ribosomal protein and GSK-3 beta at 8 weeks, with reduced CASP-3 at both time points. CASP-3 was further decreased by CHBP in IR or IR + CsA kidneys at 2 or 8 weeks. Furthermore, in TCMK-1 cells CsA induced apoptosis was decreased by CHBP and/or CASP-3siRNA treatment. Taken together, CHBP predominantly protects kidneys against IR injury at 2 weeks and/or CsA nephrotoxicity at 8 weeks, with different underlying mechanisms. Urinary albumin/creatinine is a good biomarker in monitoring the progression of transplant-related injuries. CsA divergently affects apoptosis in kidneys and cultured kidney epithelial cells, in which CHBP and/or CASP-3siRNA reduces inflammation and apoptosis.	[Zhang, Yufang; Wu, Yuanyuan; Liu, Aifen; Yang, Bin] Nantong Univ, Med Coll, Basic Med Res Ctr, Renal Grp, Nantong, Peoples R China; [Wu, Yuanyuan; Wang, Wei; Liu, Feng; Zhang, Yiwen; Wu, Jing; Fan, Yaping; Yang, Bin] Nantong Univ, Affiliated Hosp, Dept Nephrol, Nantong Leicester Joint Inst Kidney Sci, Nantong, Peoples R China; [Yang, Cheng; Zhu, Tongyu] Fudan Univ, Zhongshan Hosp, Shanghai Key Lab Organ Transplantat, Dept Urol, Shanghai, Peoples R China; [Nicholson, Michael L.; Yang, Bin] Univ Leicester, Univ Hosp Leicester, Dept Cardiovasc Sci, Leicester, Leics, England; [Nicholson, Michael L.] Univ Cambridge, Addenbrookes Hosp, Dept Surg, Cambridge, England	Nantong University; Nantong University; Fudan University; University Hospitals of Leicester NHS Trust; University of Leicester; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Yang, B (corresponding author), Nantong Univ, Med Coll, Basic Med Res Ctr, Renal Grp, Nantong, Peoples R China.; Yang, B (corresponding author), Nantong Univ, Affiliated Hosp, Dept Nephrol, Nantong Leicester Joint Inst Kidney Sci, Nantong, Peoples R China.; Yang, B (corresponding author), Univ Leicester, Univ Hosp Leicester, Dept Cardiovasc Sci, Leicester, Leics, England.	by5@le.ac.uk			Basic Medical Research Centre of Nantong University; Comparative Medicine Institute of Nantong University	Basic Medical Research Centre of Nantong University; Comparative Medicine Institute of Nantong University	We acknowledge the Basic Medical Research Centre of Nantong University and the Comparative Medicine Institute of Nantong University for providing all facilities. We thank Professor Yaqiu Long (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) for providing CHBP. We also thank Tian Zhao, Zitong Zhao and Long Li (Urology, Zhongshan Hospital, Fudan University) for helping surgically established the animal model.	Aigner A, 2007, APPL MICROBIOL BIOT, V76, P9, DOI 10.1007/s00253-007-0984-y; Bhavsar D, 2012, CURR GENE THER, V12, P315, DOI 10.2174/156652312802083611; Brines M, 2008, P NATL ACAD SCI USA, V105, P10925, DOI 10.1073/pnas.0805594105; Cheng MC, 2015, AM J NEPHROL, V41, P257, DOI 10.1159/000381464; Fogarty CE, 2015, CURR TOP DEV BIOL, V114, P241, DOI 10.1016/bs.ctdb.2015.07.013; Hesketh EE, 2014, J INFLAMM-LOND, V11, DOI 10.1186/s12950-014-0031-6; Hu C, 2018, J IMMUNOL, V201, P3717, DOI 10.4049/jimmunol.1800987; Hu LK, 2012, J SURG RES, V176, P260, DOI 10.1016/j.jss.2011.06.035; Jansen MPB, 2017, KIDNEY INT, V91, P352, DOI 10.1016/j.kint.2016.08.006; Koop K, 2004, KIDNEY INT, V66, P2038, DOI 10.1111/j.1523-1755.2004.00976.x; Kusaba T, 2014, P NATL ACAD SCI USA, V111, P1527, DOI 10.1073/pnas.1310653110; Li JH, 2011, NEPHROL DIAL TRANSPL, V26, P469, DOI 10.1093/ndt/gfq466; Liu AF, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22852-2; Liu BC, 2018, KIDNEY INT, V93, P568, DOI 10.1016/j.kint.2017.09.033; Liu WJ, 2018, THERANOSTICS, V8, P5575, DOI 10.7150/thno.27372; Lynch J, 2010, AM J NEPHROL, V32, P590, DOI 10.1159/000320485; Olukman M, 2019, ADV CLIN EXP MED, V28, P1393, DOI 10.17219/acem/104544; Palmer SC, 2010, ANN INTERN MED, V153, P23, DOI 10.7326/0003-4819-153-1-201007060-00252; Papazova DA, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.035030; Qi RC, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.02.12; Shi MJ, 2018, AM J PHYSIOL-RENAL, V314, pF501, DOI 10.1152/ajprenal.00306.2017; Vazquez-Mendez E, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/8937657; Wu YY, 2020, J PHARMACOL EXP THER, V375, P92, DOI 10.1124/jpet.120.000092; Wu YY, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/758159; Yang B, 2005, KIDNEY INT, V68, P2050, DOI 10.1111/j.1523-1755.2005.00662.x; Yang B, 2001, KIDNEY INT, V60, P1765, DOI 10.1046/j.1523-1755.2001.00013.x; Yang B, 2006, TRANSPLANTATION, V81, P1442, DOI 10.1097/01.tp.0000209412.77312.69; Yang B, 2012, EXP BIOL MED, V237, P1462, DOI 10.1258/ebm.2012.012050; Yang B, 2011, EUR J PHARMACOL, V660, P420, DOI 10.1016/j.ejphar.2011.03.044; Yang C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.338; Yang C, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0161-y; Yang C, 2015, TRANSPLANT DIRECT, V1, DOI 10.1097/TXD.0000000000000515; Yang C, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0699-2; Yang C, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0387-2; Yang C, 2014, MOL THER, V22, P1817, DOI 10.1038/mt.2014.111; Yang C, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-210; YOUNG BA, 1995, KIDNEY INT, V48, P439, DOI 10.1038/ki.1995.312; Zeng YG, 2017, BIOMED PHARMACOTHER, V94, P1167, DOI 10.1016/j.biopha.2017.07.131; Zhang XP, 2020, INT IMMUNOPHARMACOL, V88, DOI 10.1016/j.intimp.2020.106849; Zhang YF, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00005; Zhang YF, 2017, CURR PROTEIN PEPT SC, V18, P1183, DOI 10.2174/1389203717666160909144436; Zhao HL, 2018, EBIOMEDICINE, V28, P31, DOI 10.1016/j.ebiom.2018.01.025	42	0	2	3	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 26	2021	12								697751	10.3389/fimmu.2021.697751	http://dx.doi.org/10.3389/fimmu.2021.697751			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TX3ID	34381450	Green Submitted, gold, Green Published			2022-12-18	WOS:000682982200001
J	Egger, EK; Ralser, DJ; Lindner, K; Recker, F; Marinova, M; Savchenko, O; Lau, JF; Mustea, A				Egger, Eva Katharina; Ralser, Damian J.; Lindner, Kira; Recker, Florian; Marinova, Milka; Savchenko, Oleksandre; Lau, Jan-Frederic; Mustea, Alexander			Diagnostic and Therapeutic Approach in a Metastatic Vaginal Adenocarcinoma: A Case Report	FRONTIERS IN IMMUNOLOGY			English	Article						immune checkpoint blockade; vaginal adenocarcinoma; trastuzumab; abscopal effect; mutational burden	CANCER; CHEMOTHERAPY	Background Vaginal adenocarcinomas (VAC) are most often reported after intrauterine exposition to diethylstilbestrol (DES). Rarely, VACs are reported as a malignant transformation of vaginal adenosis or endometriosis, in the context of chromosomal abnormalities or malformations of the uterus or the vagina. VACs without DES exposition have a poor prognosis and a significantly worse outcome compared to vaginal squamous cell carcinomas or DES-associated VACs. Objective Here, we report the case of a primarily metastatic VAC, treated successfully with different lines of chemo-, antiangiogenic, antibody, and immunotherapy. Case The 49-year-old patient presented in 5/2018 with a primarily pulmonary metastatic VAC. Significant tumor reduction was seen after six cycles of carboplatin AUC5/paclitaxel 175 mg/m(2)/bevacizumab 15 mg/kg q3w. Bevacizumab maintenance therapy and later cisplatin mono 50 mg/m(2) q2w led to local and distant tumor progression. To identify a potential targeted therapy, new tumor biopsies were obtained. Immunohistochemistry revealed ERBB2 expression, and paclitaxel 80 mg/m(2) weekly plus trastuzumab 4 mg/m(2) respectively 2 mg/m(2) q3w was administered. Due to local and pulmonal tumor progression after 6 months and persistent ERBB2 positivity, the therapy was adjusted to trastuzumab emtansine (T-DM1) 3.6 mg/kg q3w; however, the patient remained locally progressive after three cycles of T-DM1 and additionally showed a new bone metastasis. The new tumor biopsies revealed a combined positive score (CPS) of 2 regarding PD-L1, and pembrolizumab 200 mg q3w was initiated. The bone metastasis was radiated and treated with denosumab 120 mg q4w. Extreme tumor regression followed by stable disease was maintained for 9 months. Due to a slow locoregional progress only with new inguinal lymph node and pararectal lymph node metastases, a new tumor biopsy was taken. Molecular profiling showed an ARID1A mutation, a mutational burden of 5.1 mutations per megabase, and no genfusions. Based on these findings, therapy with PD-L1 antibodies, PD-1 antibodies, gemcitabine, or dasatinib was suggested. Therefore, administration of pembrolizumab was continued and local radiation therapy was performed. This led to a decrease in local tumor manifestations and a stable systemic disease. Conclusion Our case demonstrates the diagnostic and therapeutic approach in a patient with primary metastatic vaginal adenocarcinoma. By tumorgenetic profiling, different lines of systemic therapy, namely, antiangiogenic therapy, monoclonal antibody therapy, immunotherapy, and local radiation therapy, were identified and successfully administered.	[Egger, Eva Katharina; Ralser, Damian J.; Lindner, Kira; Recker, Florian; Mustea, Alexander] Univ Hosp Bonn, Dept Gynecol & Gynecol Oncol, Bonn, Germany; [Marinova, Milka; Savchenko, Oleksandre] Univ Hosp Bonn, Dept Diagnost & Intervent Radiol, Bonn, Germany; [Lau, Jan-Frederic] Univ Hosp Bonn, Dept Pathol, Bonn, Germany	University of Bonn; University of Bonn; University of Bonn	Egger, EK (corresponding author), Univ Hosp Bonn, Dept Gynecol & Gynecol Oncol, Bonn, Germany.	eva-katharina.egger@ukbonn.de	Egger, Eva/GSE-1447-2022; Recker, Florian/ABP-4557-2022	Egger, Eva/0000-0002-9891-3996; Recker, Florian/0000-0001-9135-4338				Berretta M, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9121182; Bredin P, 2020, SEMIN ONCOL, V47, P259, DOI 10.1053/j.seminoncol.2020.07.008; Chung HC, 2019, J CLIN ONCOL, V37, P1470, DOI 10.1200/JCO.18.01265; Cocetta V, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042049; Cousin S, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0630-4; Frank SJ, 2007, GYNECOL ONCOL, V105, P470, DOI 10.1016/j.ygyno.2007.01.005; Hacker NF, 2015, INT J GYNECOL OBSTET, V131, pS84, DOI 10.1016/j.ijgo.2015.06.003; Halle MK, 2017, AM J OBSTET GYNECOL, V217, DOI 10.1016/j.ajog.2017.05.068; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; Liu Y, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0647-8; Lorusso D, 2014, GYNECOL ONCOL, V133, P117, DOI 10.1016/j.ygyno.2014.01.042; Marabelle A, 2020, LANCET ONCOL, V21, P1353, DOI 10.1016/S1470-2045(20)30445-9; Naumann RW, 2019, J CLIN ONCOL, V37, P2825, DOI 10.1200/JCO.19.00739; Oh DY, 2015, ONCOTARGET, V6, P36219, DOI 10.18632/oncotarget.5283; Ojesina AI, 2014, NATURE, V506, P371, DOI 10.1038/nature12881; Pang LH, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6026-1; Quagliariello V, 2017, ONCOTARGET, V8, P30606, DOI 10.18632/oncotarget.16725; SANDER R, 1986, INT J GYNECOL PATHOL, V5, P362, DOI 10.1097/00004347-198612000-00008; Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943; TANAKA H, 1994, GYNECOL ONCOL, V55, P259, DOI 10.1006/gyno.1994.1287; Tewari KS, 2017, LANCET, V390, P1654, DOI 10.1016/S0140-6736(17)31607-0; Tewari KS, 2015, CLIN CANCER RES, V21, P5480, DOI 10.1158/1078-0432.CCR-15-1346; Zhou WL, 2020, ARCH GYNECOL OBSTET, V302, P1429, DOI 10.1007/s00404-020-05737-6	23	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 23	2021	12								686879	10.3389/fimmu.2021.686879	http://dx.doi.org/10.3389/fimmu.2021.686879			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TV3KP	34367146	gold, Green Published			2022-12-18	WOS:000681622400001
J	He, Y; Hung, SW; Liang, B; Zhang, RZ; Gao, YT; Chu, CY; Zhang, T; Xu, H; Chung, JPW; Wang, CC				He, Ying; Hung, Sze Wan; Liang, Bo; Zhang, Ruizhe; Gao, Yating; Chu, Ching Yan; Zhang, Tao; Xu, Hui; Chung, Jacqueline Pui Wah; Wang, Chi Chiu			Receptor Tyrosine Kinase Inhibitor Sunitinib as Novel Immunotherapy to Inhibit Myeloid-Derived Suppressor Cells for Treatment of Endometriosis	FRONTIERS IN IMMUNOLOGY			English	Article						endometriosis; myeloid-derived suppressor cells; Sunitinib; immunosuppression; gene expressions	TRANSCRIPTION FACTORS; DIFFERENTIATION; POLARIZATION; ALPHA; MDSC	Endometriosis is a common, benign, and hormone-dependent gynaecological disorder that displays altered immunoinflammatory profiles. Myeloid-derived suppressor cells (MDSCs) suppressed immunosurveillance in endometriosis in human and mouse model. Receptor tyrosine kinase inhibitor Sunitinib can induce MDSC apoptosis and suppress the progression of cancer. However, the effects of Sunitinib on MDSCs in endometriosis and the underlying mechanism are not clear. In this study, we employed an animal study of the endometriosis model in mice for treatment of Sunitinib. After syngeneic endometrium transplantation and treatment, endometriotic lesion volume, weight, and histology were compared. Peritoneal fluid, peripheral blood, and bone marrow MDSC subsets and their molecular signaling were monitored by flow cytometry. Peritoneal cytokines were assayed by ELISA. The gene expression profiles of isolated CD11b+Ly6G+Ly6C(lo) cells were studied by RNA sequencing. We found that Sunitinib significantly decreased the endometriotic lesion size and weight after 1 and 3 weeks, and decreased p-STAT3 activation in MDSCs after 1 week of treatment. In the first week, Sunitinib specifically increased the G-MDSC population in peritoneal fluid but the isolated CD11b+Ly6G+Ly6C(lo) MDSCs after Sunitinib treatment were presented as mature polynuclear MDSCs, while the control group had immature mononuclear MDSCs. Importantly, we found Sunitinib differentially suppressed gene expressions of immunosuppressive function and differentiation in peritoneal G-MDSCs. Apelin signaling pathway associated genes and inflammation related genes were upregulated, and amino acid metabolism regulator genes were downregulated in bone marrow G-MDSCs. For endometriotic lesions, the PPARG gene governing glucose metabolism and fatty acid storage, which is important for the development of endometriosis was upregulated. In conclusion, Sunitinib inhibited endometriotic lesions, by promoting peritoneal fluid MDSCs maturation and inhibiting the immunosuppressive function. These findings suggest that Sunitinib changed the immune microenvironment and inhibited the development of endometriosis, which has potential therapeutic effects as novel immunotherapy to promote MDSCs maturation, differentiation, and metabolism for the treatment of endometriosis.	[He, Ying; Hung, Sze Wan; Liang, Bo; Zhang, Ruizhe; Gao, Yating; Chu, Ching Yan; Zhang, Tao; Xu, Hui; Chung, Jacqueline Pui Wah; Wang, Chi Chiu] Chinese Univ Hong Kong, Dept Obstet & Gynaecol, Hong Kong, Peoples R China; [Wang, Chi Chiu] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China; [Wang, Chi Chiu] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China; [Wang, Chi Chiu] Chinese Univ Hong Kong, Chinese Univ Hong Kong Sichuan Univ Joint Lab Rep, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	Wang, CC (corresponding author), Chinese Univ Hong Kong, Dept Obstet & Gynaecol, Hong Kong, Peoples R China.; Wang, CC (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China.; Wang, CC (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China.; Wang, CC (corresponding author), Chinese Univ Hong Kong, Chinese Univ Hong Kong Sichuan Univ Joint Lab Rep, Hong Kong, Peoples R China.	ccwang@cuhk.edu.hk	Zhang, Tao/ADM-1606-2022	Zhang, Tao/0000-0002-8644-8468; Hung, Sze Wan/0000-0003-0576-4707; HE, Ying/0000-0002-9881-8155; Chung, Jacqueline/0000-0002-9742-578X	Health & Medical Research Fund from Food and Health Buerau [08190886]; Hong Kong Obstetrical & Gynaecological Trust Fund 2019 from Hong Kong Society of Obstericians and Gynaecologists; Chinese University of Hong Kong [3029876, 2017.044]	Health & Medical Research Fund from Food and Health Buerau; Hong Kong Obstetrical & Gynaecological Trust Fund 2019 from Hong Kong Society of Obstericians and Gynaecologists; Chinese University of Hong Kong(Chinese University of Hong Kong)	This research was supported by Health & Medical Research Fund (08190886) from Food and Health Buerau; The Hong Kong Obstetrical & Gynaecological Trust Fund 2019 from Hong Kong Society of Obstericians and Gynaecologists; Academic Equipment Grant (3029876); and Direct Grant (2017.044) from The Chinese University of Hong Kong.	Abbas MA, 2013, EUR J PHARM SCI, V49, P732, DOI 10.1016/j.ejps.2013.05.021; Ahn SH, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/795976; Belfiore A, 2009, PPAR RES, V2009, DOI 10.1155/2009/830501; Benoit M, 2008, J IMMUNOL, V181, P3733, DOI 10.4049/jimmunol.181.6.3733; Bjerregaard MD, 2003, BLOOD, V101, P4322, DOI 10.1182/blood-2002-03-0835; Borregaard N, 2001, CURR OPIN HEMATOL, V8, P23, DOI 10.1097/00062752-200101000-00005; Chu TF, 2007, LANCET, V370, P2011, DOI 10.1016/S0140-6736(07)61865-0; Condamine T, 2011, TRENDS IMMUNOL, V32, P19, DOI 10.1016/j.it.2010.10.002; Cummings AM, 1997, CRIT REV TOXICOL, V27, P367, DOI 10.3109/10408449709089899; Cumurciuc R, 2008, REV NEUROL-FRANCE, V164, P605, DOI 10.1016/j.neurol.2008.03.007; Demirturk F, 2006, J SOC GYNECOL INVEST, V13, P58, DOI 10.1016/j.jsgi.2005.10.002; Elkabets M, 2010, EUR J IMMUNOL, V40, P3347, DOI 10.1002/eji.201041037; Eskenazi B, 1997, OBSTET GYN CLIN N AM, V24, P235, DOI 10.1016/S0889-8545(05)70302-8; Faivre S, 2007, NAT REV DRUG DISCOV, V6, P734, DOI 10.1038/nrd2380; Finke J, 2011, INT IMMUNOPHARMACOL, V11, P856, DOI 10.1016/j.intimp.2011.01.030; Finke JH, 2008, CLIN CANCER RES, V14, P6674, DOI 10.1158/1078-0432.CCR-07-5212; Fischer Andrew H, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot4986; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Groth C, 2019, BRIT J CANCER, V120, P16, DOI 10.1038/s41416-018-0333-1; Holoch KJ, 2010, CLIN OBSTET GYNECOL, V53, P429, DOI 10.1097/GRF.0b013e3181db7d71; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Ko JS, 2009, CLIN CANCER RES, V15, P2148, DOI 10.1158/1078-0432.CCR-08-1332; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Liang B, 2018, REPROD BIOL ENDOCRIN, V16, DOI 10.1186/s12958-018-0347-9; Liechtenstein T, 2014, ONCOTARGET, V5, P7843, DOI 10.18632/oncotarget.2279; Liu CR, 2007, BLOOD, V109, P4336, DOI 10.1182/blood-2006-09-046201; Macer ML, 2012, OBSTET GYN CLIN N AM, V39, P535, DOI 10.1016/j.ogc.2012.10.002; Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293; Mueller EW, 2008, PHARMACOTHERAPY, V28, P1066, DOI 10.1592/phco.28.8.1066; Nagaraj S, 2010, J IMMUNOL, V184, P3106, DOI 10.4049/jimmunol.0902661; Nerlov C, 2007, TRENDS CELL BIOL, V17, P318, DOI 10.1016/j.tcb.2007.07.004; Ostrand-Rosenberg S, 2012, SEMIN CANCER BIOL, V22, P275, DOI 10.1016/j.semcancer.2012.01.011; Pala HG, 2015, J OBSTET GYNAECOL, V35, P183, DOI 10.3109/01443615.2014.941345; Pelch KE, 2012, JOVE-J VIS EXP, DOI 10.3791/3396; Peranzoni E, 2010, CURR OPIN IMMUNOL, V22, P238, DOI 10.1016/j.coi.2010.01.021; Ray Avijit, 2010, J Vis Exp, DOI 10.3791/1488; Roberts AW, 2005, GROWTH FACTORS, V23, P33, DOI 10.1080/08977190500055836; Tomida C, 2017, J MED INVESTIG, V64, P250, DOI 10.2152/jmi.64.250; Weischenfeldt Joachim, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot5080; Xin H, 2009, CANCER RES, V69, P2506, DOI 10.1158/0008-5472.CAN-08-4323; Youn JI, 2012, J LEUKOCYTE BIOL, V91, P167, DOI 10.1189/jlb.0311177; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang T, 2018, EUR J IMMUNOL, V48, P1059, DOI 10.1002/eji.201747417	46	0	0	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 22	2021	12								641206	10.3389/fimmu.2021.641206	http://dx.doi.org/10.3389/fimmu.2021.641206			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UF2QQ	34367125	gold, Green Published			2022-12-18	WOS:000688423900001
J	Malheiro, A; Ramasawmy, R; Courtin, D; Donadi, EA				Malheiro, Adriana; Ramasawmy, Rajendranath; Courtin, David; Donadi, Eduardo Antonio			Editorial: The Role of Gene Polymorphisms in Modulating the Immune Responses Against Tropical Infectious Diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						infectious diseases; HLA; immune response; gene polymorphism; tropical diseases			[Malheiro, Adriana] Univ Fed Amazonas, Dept Parasitol, Programa Posgrad Imunol Basica & Aplicada, Manaus, Amazonas, Brazil; [Malheiro, Adriana] Fundacao Hosp Hematol & Hemoterapia Amazonas, Lab Genom Rede Regesam, Manaus, Amazonas, Brazil; [Ramasawmy, Rajendranath] Univ Nilton Lins, Fac Med, Manaus, Amazonas, Brazil; [Ramasawmy, Rajendranath] Fundacao Med Trop Doutor Heitor Vieira Doura, Manaus, Amazonas, Brazil; [Courtin, David] Univ Paris, Inst Rech Dev IRD, UMR MERIT 261, Paris, France; [Donadi, Eduardo Antonio] Univ Sao Paulo, Ribeirao Preto Med Sch, Div Clin Immunol, Dept Med, Ribeirao Preto, Brazil	Universidade Federal de Amazonas; Centro Universitario Nilton Lins; Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Universite Paris Cite; Universidade de Sao Paulo	Malheiro, A (corresponding author), Univ Fed Amazonas, Dept Parasitol, Programa Posgrad Imunol Basica & Aplicada, Manaus, Amazonas, Brazil.; Malheiro, A (corresponding author), Fundacao Hosp Hematol & Hemoterapia Amazonas, Lab Genom Rede Regesam, Manaus, Amazonas, Brazil.	malheiroadriana@yahoo.com.br	courtin, david/A-1584-2017	courtin, david/0000-0002-5263-4430					0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 22	2021	12								714237	10.3389/fimmu.2021.714237	http://dx.doi.org/10.3389/fimmu.2021.714237			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TY2MH	34367183	gold, Green Published			2022-12-18	WOS:000683618700001
J	Chen, B; Qin, C; Chen, M; Yu, HH; Tao, R; Chu, YH; Bu, BT; Tian, DS				Chen, Bo; Qin, Chuan; Chen, Man; Yu, Hai-Han; Tao, Ran; Chu, Yun-Hui; Bu, Bi-Tao; Tian, Dai-Shi			Dynamic Changes in AQP4-IgG Level and Immunological Markers During Protein-A Immunoadsorption Therapy for NMOSD: A Case Report and Literature Review	FRONTIERS IN IMMUNOLOGY			English	Review						protein-A immunoadsorption; rescue therapy; AQP4-IgG; neuromyelitis optica spectrum disorder; case report	ACTIVATION; EXPRESSION; ANTIBODY; CELLS	The changes in the serum levels of aquaporin-4-IgG (AQP4-IgG), immunoglobulins, and inflammatory mediators in neuromyelitis optica spectrum disorder (NMOSD) cases treated with immunoadsorption have been rarely described in detail. Here we report a 29-year-old steroid-resistant NMOSD female with a severe disability (bilateral blindness and paraplegia) who received protein-A immunoadsorption as a rescue treatment. During the total 5 sessions, the circulating level of AQP4-IgG, immunoglobulins, and complement proteins (C3 and C4) showed a rapid and sawtooth-like decrease, and the serum AQP4-IgG titer declined from 1:320 to below the detectable limit at the end of the 3rd procedure. Of all the antibodies, IgG had the biggest removal rate (>96.1%), followed by IgM (>66.7%) and IgA (53%), while complement C3 and C4 also dropped by 73% and 65%, respectively. The reduced pro-inflammatory cytokines (interleukin-8 and tumor necrosis factor-alpha) and marked increased lymphocyte (T and B cell) counts were also observed. The improvement of symptoms initiated after the last session, with a low AQP4-IgG titer (1:32) persisting thereafter. Accordingly, protein-A immunoadsorption treatment could be one of the potential rescue therapies for steroid-resistant NMOSD patients with a severe disability.	[Chen, Bo; Qin, Chuan; Chen, Man; Yu, Hai-Han; Tao, Ran; Chu, Yun-Hui; Bu, Bi-Tao; Tian, Dai-Shi] Huazhong Univ Sci & Technol, Dept Neurol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China	Huazhong University of Science & Technology	Bu, BT; Tian, DS (corresponding author), Huazhong Univ Sci & Technol, Dept Neurol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China.	bubitao@tjh.tjmu.edu.cn; tiands@tjh.tjmu.edu.cn		Tian, Dai-shi/0000-0002-7627-0811	National Natural Science Foundation of China [82071380, 81873743]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The study was supported by National Natural Science Foundation of China (Grants: 82071380, 81873743).	Bulut D, 2013, SCAND J IMMUNOL, V77, P54, DOI 10.1111/sji.12000; Defendi F, 2019, TRANSPL INT, V32, P876, DOI 10.1111/tri.13431; Ding J, 2020, J CLIN NEUROSCI, V71, P9, DOI 10.1016/j.jocn.2019.11.022; Fujihara K, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000841; Heine J, 2016, J NEUROL, V263, P2395, DOI 10.1007/s00415-016-8277-y; HOWE RB, 1994, J CLIN APHERESIS, V9, P31, DOI 10.1002/jca.2920090109; Jarius S, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-14; Jarius S, 2010, NAT REV NEUROL, V6, P383, DOI 10.1038/nrneurol.2010.72; Kleiter I, 2018, NEUROL-NEUROIMMUNOL, V5, DOI 10.1212/NXI.0000000000000504; Kleiter I, 2016, ANN NEUROL, V79, P206, DOI 10.1002/ana.24554; Klingel R, 2013, ATHEROSCLEROSIS SUPP, V14, P161, DOI 10.1016/j.atherosclerosissup.2012.10.024; Kobayashi M, 2015, J CLIN APHERESIS, V30, P43, DOI 10.1002/jca.21324; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; Ling M, 2019, CLIN LAB MED, V39, P579, DOI 10.1016/j.cll.2019.07.006; Naganuma T, 2021, TRANSFUS APHER SCI, V60, DOI 10.1016/j.transci.2020.102969; Nishimura H, 2018, J ARTIF ORGANS, V21, P378, DOI 10.1007/s10047-018-1044-3; Nishiyama S, 2009, NEUROLOGY, V72, P1960, DOI 10.1212/WNL.0b013e3181a82621; Nytrova P, 2014, J NEUROIMMUNOL, V274, P185, DOI 10.1016/j.jneuroim.2014.07.001; Oji S, 2017, TRANSFUS APHER SCI, V56, P671, DOI 10.1016/j.transci.2017.08.013; Onugoren MD, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000207; Papadopoulos MC, 2012, LANCET NEUROL, V11, P535, DOI 10.1016/S1474-4422(12)70133-3; Pittock SJ, 2019, NEW ENGL J MED, V381, P614, DOI 10.1056/NEJMoa1900866; Tantisira KG, 2011, NEW ENGL J MED, V365, P1173, DOI 10.1056/NEJMoa0911353; Uzawa A, 2010, MULT SCLER J, V16, P1443, DOI 10.1177/1352458510379247; Veszeli N, 2014, MOL IMMUNOL, V57, P200, DOI 10.1016/j.molimm.2013.09.010; Weinshenker BG, 2006, ANN NEUROL, V59, P566, DOI 10.1002/ana.20770; Wingerchuk DM, 2015, NEUROLOGY, V85, P177, DOI 10.1212/WNL.0000000000001729; Yandamuri SS, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000852	28	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 21	2021	12								650782	10.3389/fimmu.2021.650782	http://dx.doi.org/10.3389/fimmu.2021.650782			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TU5RN	34367127	Green Published			2022-12-18	WOS:000681093500001
J	Nakano, M; Ayano, M; Kushimoto, K; Kawano, S; Higashioka, K; Inokuchi, S; Mitoma, H; Kimoto, Y; Akahoshi, M; Ono, N; Arinobu, Y; Akashi, K; Horiuchi, T; Niiro, H				Nakano, Miki; Ayano, Masahiro; Kushimoto, Kazuo; Kawano, Shotaro; Higashioka, Kazuhiko; Inokuchi, Shoichiro; Mitoma, Hiroki; Kimoto, Yasutaka; Akahoshi, Mitsuteru; Ono, Nobuyuki; Arinobu, Yojiro; Akashi, Koichi; Horiuchi, Takahiko; Niiro, Hiroaki			Increased Proportion of CD226(+) B Cells Is Associated With the Disease Activity and Prognosis of Systemic Lupus Erythematosus	FRONTIERS IN IMMUNOLOGY			English	Article						systemic lupus erythematosus; CD226; B cells; lupus low disease activity; lupus nephritis	TOLL-LIKE RECEPTORS; ACTIVITY STATE; T-CELLS; INSIGHTS; SLE; SUSCEPTIBILITY; PATHOGENESIS; EXPRESSION; SECRETION; IMMUNITY	Background: CD226, an activating receptor expressed on the surface of natural killer (NK) cells and T cells, is also seen on B cells and CD226 polymorphism is associated with systemic lupus erythematosus (SLE). Because the specific roles of CD226(+) B cells in SLE are still unknown, we investigated the association of CD226(+) B cells with SLE. Methods: We measured CD226 expression on B cells and its subsets using flow cytometry in 48 SLE patients and 24 healthy controls (HCs). We assessed the relationships between CD226+ B cells and SLE Disease Activity Index 2000 (SLEDAI2K), clinical manifestations, laboratory data, and prognosis after 12 months. Results: The proportions of CD226(+) cells in whole B cells and all its subsets were significantly higher in SLE patients than HCs. In SLE patients, the proportions of CD226(+) B cells and CD226(+) switched-memory (SM) B cells were significantly correlated with SLEDAI-2K scores and anti-dsDNA antibody titers, and negatively correlated with serum complement levels. Moreover, basal percentages of CD226(+) B cells and CD226(+) SM B cells were low in patients who were in Lupus Low Disease Activity State after 12 months. In patients with renal involvement, the proportion of CD226(+) B cells increased. Additionally, the proportion of CD226(+) B cells was higher in patients who were not in complete renal remission after 12 months. Conclusions: Increased proportion of CD226(+) B cells was associated with disease activity and prognosis of SLE. CD226(+) B cells may be a useful biomarker for the management of SLE.	[Nakano, Miki; Ayano, Masahiro; Kushimoto, Kazuo; Kawano, Shotaro; Higashioka, Kazuhiko; Inokuchi, Shoichiro; Mitoma, Hiroki; Akahoshi, Mitsuteru; Ono, Nobuyuki; Arinobu, Yojiro; Akashi, Koichi] Kyushu Univ, Grad Sch Med Sci, Dept Med & Biosyst Sci, Fukuoka, Japan; [Ayano, Masahiro] Kyushu Univ, Grad Sch Med Sci, Dept Canc Stem Cell Res, Fukuoka, Japan; [Kimoto, Yasutaka; Horiuchi, Takahiko] Kyushu Univ, Beppu Hosp, Dept Internal Med, Beppu, Oita, Japan; [Niiro, Hiroaki] Kyushu Univ, Dept Med Educ, Grad Sch Med Sci, Fukuoka, Japan; [Nakano, Miki] Fukuoka Natl Hosp, Dept Rheumatol, Fukuoka, Japan; [Higashioka, Kazuhiko] Iizuka Hosp, Ctr Rheumatol, Fukuoka, Japan; [Ayano, Masahiro; Akahoshi, Mitsuteru] Saga Univ Hosp, Dept Rheumatol, Saga, Japan	Kyushu University; Kyushu University; Kyushu University; Kyushu University; Saga University	Ayano, M (corresponding author), Saga Univ Hosp, Dept Rheumatol, Saga, Japan.	ayano.masahiro.811@m.kyushu-u.ac.jp	Horiuchi, Takahiko/ABH-1481-2021; Ayano, Masahiro/GSE-5333-2022	Horiuchi, Takahiko/0000-0002-1770-1087; inokuchi, shoichiro/0000-0002-5501-8852	Japan Society for the Promotion of Science (JSPS KAKENHI) [19K17887]	Japan Society for the Promotion of Science (JSPS KAKENHI)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Japan Society for the Promotion of Science [grant number JSPS KAKENHI 19K17887].	Alegria GC, 2017, CLIN REV ALLERG IMMU, V53, P219, DOI 10.1007/s12016-017-8608-5; Arriens C, 2017, RHEUMATOLOGY, V56, P32, DOI 10.1093/rheumatology/kew407; Ayano M, 2015, J IMMUNOL, V195, P892, DOI 10.4049/jimmunol.1403046; Bentham J, 2015, NAT GENET, V47, P1457, DOI 10.1038/ng.3434; Bernasconi NL, 2003, BLOOD, V101, P4500, DOI 10.1182/blood-2002-11-3569; Capecchi R, 2020, RHEUMATOLOGY, V59, P12, DOI 10.1093/rheumatology/keaa484; Cook RJ, 2000, J RHEUMATOL, V27, P1892; Cyster JG, 2019, CELL, V177, P524, DOI 10.1016/j.cell.2019.03.016; Dall'Era M, 2015, ARTHRITIS RHEUMATOL, V67, P1305, DOI 10.1002/art.39026; Dorner T, 2016, NAT REV RHEUMATOL, V12, P645, DOI 10.1038/nrrheum.2016.158; Fanouriakis A, 2020, ANN RHEUM DIS, V79, P713, DOI 10.1136/annrheumdis-2020-216924; Fanouriakis A, 2019, ANN RHEUM DIS, V78, P736, DOI 10.1136/annrheumdis-2019-215089; Fasth AER, 2010, EUR J IMMUNOL, V40, P378, DOI 10.1002/eji.200939399; Franklyn K, 2016, ANN RHEUM DIS, V75, P1615, DOI 10.1136/annrheumdis-2015-207726; Gatto M, 2019, NAT REV RHEUMATOL, V15, P30, DOI 10.1038/s41584-018-0133-2; Gladman DD, 2002, J RHEUMATOL, V29, P288; Hanaoka M, 2013, RHEUMATOLOGY, V52, P2149, DOI 10.1093/rheumatology/ket108; Hanly JG, 2016, RHEUMATOLOGY, V55, P252, DOI 10.1093/rheumatology/kev311; Harley ITW, 2009, NAT REV GENET, V10, P285, DOI 10.1038/nrg2571; Hiepe F, 2016, NAT REV NEPHROL, V12, P232, DOI 10.1038/nrneph.2016.20; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; Huang Z, 2011, J IMMUNOL, V186, P3421, DOI 10.4049/jimmunol.1000569; Huang ZY, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00564; Iwata S, 2016, LUPUS, V25, P850, DOI 10.1177/0961203316643172; Jin WL, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/9518137; Kosalka J, 2016, FOLIA HISTOCHEM CYTO, V54, P32, DOI 10.5603/FHC.a2016.0005; Kurosaki T, 2015, NAT REV IMMUNOL, V15, P149, DOI 10.1038/nri3802; Liu SW, 2019, CLIN IMMUNOL, V203, P72, DOI 10.1016/j.clim.2019.04.007; Llorente L, 2000, ARTHRITIS RHEUM, V43, P1790, DOI 10.1002/1529-0131(200008)43:8<1790::AID-ANR15>3.0.CO;2-2; Maecker HT, 2012, NAT REV IMMUNOL, V12, P191, DOI 10.1038/nri3158; Maiti AK, 2010, RHEUMATOLOGY, V49, P1239, DOI 10.1093/rheumatology/kep470; Marshak-Rothstein A, 2006, NAT REV IMMUNOL, V6, P823, DOI 10.1038/nri1957; Martinet L, 2015, NAT REV IMMUNOL, V15, P243, DOI 10.1038/nri3799; Nagayama-Hasegawa Y, 2020, CYTOM PART B-CLIN CY, V98, P368, DOI 10.1002/cyto.b.21859; Nakano S, 2008, RHEUMATOLOGY, V47, P145, DOI 10.1093/rheumatology/kem327; Nie DQ, 2016, RHEUMATOL INT, V36, P1657, DOI 10.1007/s00296-016-3570-8; Odendahl M, 2000, J IMMUNOL, V165, P5970, DOI 10.4049/jimmunol.165.10.5970; Papadimitraki ED, 2006, ARTHRITIS RHEUM-US, V54, P3601, DOI 10.1002/art.22197; Peng H, 2013, CLIN RHEUMATOL, V32, P1255, DOI 10.1007/s10067-013-2294-3; Petri M, 2018, ARTHRITIS RHEUMATOL, V70, P1790, DOI 10.1002/art.40571; Sanz I, 2010, NAT REV RHEUMATOL, V6, P326, DOI 10.1038/nrrheum.2010.68; Shibuya A, 1996, IMMUNITY, V4, P573, DOI 10.1016/S1074-7613(00)70060-4; Stanietsky N, 2009, P NATL ACAD SCI USA, V106, P17858, DOI 10.1073/pnas.0903474106; Sun C, 2016, NAT GENET, V48, P323, DOI 10.1038/ng.3496; Tanaka Y, 2018, CLIN IMMUNOL, V186, P21, DOI 10.1016/j.clim.2017.07.010; Tsokos GC, 2020, NAT IMMUNOL, V21, P605, DOI 10.1038/s41590-020-0677-6; Tsokos GC, 2016, NAT REV RHEUMATOL, V12, P716, DOI 10.1038/nrrheum.2016.186; Tsokos GC, 2011, NEW ENGL J MED, V365, P2110, DOI 10.1056/NEJMra1100359; Uribe AG, 2004, J RHEUMATOL, V31, P1934; van Vollenhoven RF, 2014, ANN RHEUM DIS, V73, P958, DOI 10.1136/annrheumdis-2013-205139; Wang YF, 2018, ANN RHEUM DIS, V77, P1078, DOI 10.1136/annrheumdis-2018-213093; Xu ZW, 2010, CELL MOL IMMUNOL, V7, P11, DOI 10.1038/cmi.2009.108; Yu X, 2009, NAT IMMUNOL, V10, P48, DOI 10.1038/ni.1674; Yuan Y, 2019, EXP THER MED, V17, P3247, DOI 10.3892/etm.2019.7290; Zen M, 2018, ANN RHEUM DIS, V77, P104, DOI 10.1136/annrheumdis-2017-211613	55	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 21	2021	12								713225	10.3389/fimmu.2021.713225	http://dx.doi.org/10.3389/fimmu.2021.713225			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TU6BX	34367178	gold, Green Published			2022-12-18	WOS:000681120600001
J	Nie, H; Chen, T; He, KF; Liang, CJ; Guo, W; Shi, XY				Nie, Hao; Chen, Ting; He, Kefei; Liang, Chanjin; Guo, Wei; Shi, Xingyuan			Immunotherapy-Based Therapeutic Strategies for Recurrent Advanced Squamous Cell Carcinoma of the Head and Neck: A Case Report and Literature Review	FRONTIERS IN IMMUNOLOGY			English	Review						case report; locoregionally advanced squamous cell carcinoma of head and neck; targeted therapy; immunotherapy; radiotherapy	OPEN-LABEL; R/M HEAD; CETUXIMAB; PEMBROLIZUMAB; NIVOLUMAB; CANCER; SAFETY	We present a patient with locoregionally advanced laryngeal carcinoma, who experienced recurrence 2 months after surgery. We exploratively treated this patient with immunotherapy combined with targeted therapy with or without radiation therapy. The patient exhibited a significant and durable response. Thus far, there are no standard or effective second-line therapeutic modalities for recurrent locoregionally advanced laryngeal carcinoma. The efficacy of conventional chemotherapy with anti-epidermal growth factor receptor (anti-EGFR) remains unsatisfactory. The addition of immunotherapy resulted in substantial improvement in the progression-free survival (PFS) and overall survival (OS) of this patient. In this case, immunotherapy combined with anti-EFGR was administered, leading to good tumor response; based on this observation, radiotherapy was added to further intensify tumor control. This therapeutic strategy may be a novel option for recurrent locoregionally advanced squamous cell carcinoma of the head and neck.	[Nie, Hao; Chen, Ting; He, Kefei; Liang, Chanjin; Guo, Wei; Shi, Xingyuan] Guangzhou Med Univ, Dept Radiat Oncol, Affiliated Hosp 1, Guangzhou, Peoples R China	Guangzhou Medical University	Shi, XY (corresponding author), Guangzhou Med Univ, Dept Radiat Oncol, Affiliated Hosp 1, Guangzhou, Peoples R China.	18549183@qq.com	Chen, Tingtao/ABA-6138-2021	Chen, Tingtao/0000-0002-0506-8536				Argiris A, 2008, LANCET, V371, P1695, DOI 10.1016/S0140-6736(08)60728-X; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Burugu S, 2018, SEMIN CANCER BIOL, V52, P39, DOI 10.1016/j.semcancer.2017.10.001; Chung CH., 2020, J CLIN ONCOL, V38, P6515, DOI [10.1200/JCO.2020.38.15_suppl.6515, DOI 10.1200/JCO.2020.38.15_SUPPL.6515]; Ferris R, 2017, NEW ENGL J MED, V376, P596, DOI 10.1056/NEJMc1615565; Kershaw MH, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.25962; Lattanzio L, 2017, CANCER IMMUNOL IMMUN, V66, P573, DOI 10.1007/s00262-017-1960-8; Laubli H, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1386362; Linares J, 2016, ORAL ONCOL, V55, pE4, DOI 10.1016/j.oraloncology.2016.02.006; Mazorra Z, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00382; Sacco AG, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.6037; Seiwert TY, 2016, LANCET ONCOL, V17, P956, DOI 10.1016/S1470-2045(16)30066-3; Thibult ML, 2013, INT IMMUNOL, V25, P129, DOI 10.1093/intimm/dxs098; Vanpouille-Box C, 2018, CLIN CANCER RES, V24, P259, DOI 10.1158/1078-0432.CCR-16-0037; Zhou XX, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01549-2	15	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 21	2021	12								680327	10.3389/fimmu.2021.680327	http://dx.doi.org/10.3389/fimmu.2021.680327			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TU5RU	34367140	Green Published			2022-12-18	WOS:000681094200001
J	Harrison, M; Brice, N; Scott, C				Harrison, Michael J.; Brice, Nicola; Scott, Christiaan			Clinical Features of HIV Arthropathy in Children: A Case Series and Literature Review	FRONTIERS IN IMMUNOLOGY			English	Review						paediatric HIV; inflammatory arthritis; Africa; autoimmunity; non-communicable disease; musculoskeletal manifestations	IMMUNODEFICIENCY-VIRUS-INFECTION; ACTIVE ANTIRETROVIRAL THERAPY; RHEUMATIC HEART-DISEASE; RHEUMATOLOGIC MANIFESTATIONS; CHANGING SPECTRUM; SEX-DIFFERENCES; PSORIATIC-ARTHRITIS; REITERS-SYNDROME; DENDRITIC CELLS; VIRAL LOAD	Background HIV infection has been associated with a non-erosive inflammatory arthritis in children, although few published reports exist. This study describes the clinical, laboratory and imaging features of this noncommunicable disease in a series of HIV-infected children in South Africa. Methods A database search was conducted to identify HIV-infected children enrolled in a Paediatric Rheumatology service in Cape Town, South Africa between 1 January 2010 and 31 December 2020. Retrospective data were collected from individuals classified with HIV arthropathy, based on a predefined checklist. Demographic, clinical, laboratory, sonographic, therapeutic, and outcomes data were extracted by chart review. Descriptive statistical analysis was performed using R (v4.0.3). Results Eleven cases of HIV arthropathy were included in the analysis. Cases predominantly presented in older boys with low CD4+ counts. Median age at arthritis onset was 10.3 years (IQR 6.9 - 11.6) and the male-female ratio was 3.0. The median absolute CD4+ count was 389 cells/uL (IQR 322 - 449). The clinical presentation was variable, with both oligoarthritis and polyarthritis being common. Elevated acute phase reactants were the most consistent laboratory feature, with a median ESR of 126 mL/h (IQR 67 - 136) and median CRP of 36 mg/L (IQR 25 - 68). Ultrasonography demonstrated joint effusions and synovial hypertrophy. Response to therapy was slower than has generally been described in adults, with almost all cases requiring more than one immunosuppressive agent. Five children were discharged in established remission after discontinuing immunotherapy, however outcomes data were incomplete for the remaining six cases. Conclusions In this case series, HIV arthropathy was associated with advanced immunosuppression. Therapeutic modalities included immunomodulators and antiretroviral therapy, which consistently induced disease remission although data were limited by a high rate of attrition. Prospective studies are needed to define and understand this HIV-associated noncommunicable disease.	[Harrison, Michael J.] Ft Beaufort Prov Hosp, Ft Beaufort, Eastern Cape, South Africa; [Brice, Nicola; Scott, Christiaan] Red Cross War Mem Childrens Hosp, Div Paediat Rheumatol, Dept Paediat & Child Hlth, Cape Town, South Africa; [Brice, Nicola; Scott, Christiaan] Univ Cape Town, Cape Town, South Africa	University of Cape Town	Harrison, M (corresponding author), Ft Beaufort Prov Hosp, Ft Beaufort, Eastern Cape, South Africa.	michael.john.thomas.harrison@gmail.com	Scott, Chris/I-4442-2019	Scott, Chris/0000-0003-3874-1704				Abuogi LL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156506; Adizie T, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1389-2; Aimes S., 2016, MANAGEMENT INFLAMMAT; Allroggen A, 2005, EUR J MED RES, V10, P305; Arrive E, 2008, JAIDS-J ACQ IMM DEF, V49, P523, DOI 10.1097/QAI.0b013e31818aadce; Azeroual Asmae, 2008, Eur J Intern Med, V19, pe34, DOI 10.1016/j.ejim.2007.09.020; Babiker A, 2000, LANCET, V355, P1131, DOI 10.1016/S0140-6736(00)02061-4; BERMAN A, 1991, J RHEUMATOL, V18, P1564; BERMAN A, 1988, AM J MED, V85, P59, DOI 10.1016/0002-9343(88)90503-7; Berman A, 1999, J RHEUMATOL, V26, P1158; BIJLSMA JWJ, 1988, ANN RHEUM DIS, V47, P350, DOI 10.1136/ard.47.4.350-b; Bileckot R, 1998, REV RHUM, V65, P549; Birhan TY, 2020, TROP MED HEALTH, V48, DOI 10.1186/s41182-020-00224-9; BLANCHE P, 1993, J RHEUMATOL, V20, P2123; BUSKILA D, 1990, CLIN EXP RHEUMATOL, V8, P567; Calabrese LH, 2005, SEMIN ARTHRITIS RHEU, V35, P166, DOI 10.1016/j.semarthrit.2005.03.007; Carlucci JG, 2019, AIDS, V33, P2375, DOI 10.1097/QAD.0000000000002366; Chakladar D, 2019, EUR J RHEUMATOL, V6, P7, DOI 10.5152/eurjrheum.2018.18045; Chang JJ, 2013, J INFECT DIS, V208, P830, DOI 10.1093/infdis/jit262; Chen HY, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002514; Chinniah K, 2005, RHEUMATOLOGY, V44, P915, DOI 10.1093/rheumatology/keh636; Chipeta J, 2013, PEDIATR RHEUMATOL, V11, DOI 10.1186/1546-0096-11-33; Crowell TA, 2015, J INFECT DIS, V211, P1692, DOI 10.1093/infdis/jiu809; de Azevedo SSD, 2017, RETROVIROLOGY, V14, DOI 10.1186/s12977-017-0354-5; den Uyl D, 2004, AIDS REV, V6, P89; Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938; Diaz-Pena R, 2012, TISSUE ANTIGENS, V80, P14, DOI 10.1111/j.1399-0039.2012.01879.x; Eggena MP, 2005, J IMMUNOL, V174, P4407, DOI 10.4049/jimmunol.174.7.4407; Ekwom P E, 2010, East Afr Med J, V87, P408; ESPINOZA LR, 1990, J RHEUMATOL, V17, P1195; Evans JS, 1997, J INFECT DIS, V175, P795, DOI 10.1086/513973; Farzadegan H, 1998, LANCET, V352, P1510, DOI 10.1016/S0140-6736(98)02372-1; FERNANDEZ SM, 1991, SEMIN ARTHRITIS RHEU, V21, P30, DOI 10.1016/0049-0172(91)90054-4; Ferrand RA, 2007, CLIN INFECT DIS, V44, P874, DOI 10.1086/511878; Fox C, 2015, BEST PRACT RES CL RH, V29, P244, DOI 10.1016/j.berh.2015.04.019; Fox MP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110252; Gleason B, 2016, JAIDS-J ACQ IMM DEF, V71, P196, DOI 10.1097/QAI.0000000000000827; Goulder PJ, 2016, NAT REV IMMUNOL, V16, P259, DOI 10.1038/nri.2016.19; Hall K., 2018, DEMOGRAPHY S AFRICAS; HOCHBERG MC, 1990, AIDS, V4, P1149, DOI 10.1097/00002030-199011000-00016; Hovis IW, 2019, PEDIATR INFECT DIS J, V38, P406, DOI 10.1097/INF.0000000000002161; Huang YM, 2016, IMMUNOL RES, V64, P641, DOI 10.1007/s12026-015-8767-5; HUGHES RA, 1990, BRIT J RHEUMATOL, V29, P166; Iordache L, 2014, AUTOIMMUN REV, V13, P850, DOI 10.1016/j.autrev.2014.04.005; Jean SS, 1999, PEDIATR INFECT DIS J, V18, P58, DOI 10.1097/00006454-199901000-00014; Johnson LF, 2017, S AFR J HIV MED, V18, DOI 10.4102/sajhivmed.v18i1.694; Kranzer K, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21737; Kumar P, 2013, INDIAN J MED RES, V138, P291; Kumar Raman, 2016, J Family Med Prim Care, V5, P3, DOI 10.4103/2249-4863.184615; Lamb MR, 2014, AIDS, V28, P559, DOI 10.1097/QAD.0000000000000054; Lau CS, 2017, NAT REV RHEUMATOL, V13, P8, DOI 10.1038/nrrheum.2016.196; Lawson E, 2012, BRIT MED BULL, V103, P203, DOI 10.1093/bmb/lds022; Li ZD, 2005, BLOOD, V106, P572, DOI 10.1182/blood-2005-01-0243; Limou S, 2009, J INFECT DIS, V199, P419, DOI 10.1086/596067; Little K, 2007, CURR HIV RES, V5, P139, DOI 10.2174/157016207780077002; Lopez-Larrea C, 2005, ARTHRITIS RHEUM-US, V52, P275, DOI 10.1002/art.20722; Madec Y, 2005, AIDS, V19, P2001, DOI 10.1097/01.aids.0000194134.28135.cd; Maganti RM, 2008, NAT CLIN PRACT RHEUM, V4, P428, DOI 10.1038/ncprheum0836; Mahajan A., 2006, J INDIAN ACAD CLIN M, V7, P136; Mahtab S., 2018, PROC 25 EUR PAEDIAT, V16, P50, DOI [10.1186/s12969-018-0265-6, DOI 10.1186/S12969-018-0265-6]; Marquez J, 2004, J RHEUMATOL, V31, P741; Martinez-Rojano H, 2001, AIDS PATIENT CARE ST, V15, P519, DOI 10.1089/108729101753205685; Medina F, 2006, INFECT DIS CLIN N AM, V20, P891, DOI 10.1016/j.idc.2006.09.002; MEDINARODRIGUEZ F, 1993, J RHEUMATOL, V20, P1880; Meier A, 2009, NAT MED, V15, P955, DOI 10.1038/nm.2004; Mody G., 2011, CME, V29, P320, DOI [10.1007/978-0-387-79061-9_5137, DOI 10.1007/978-0-387-79061-9_5137]; Mody GM, 2003, BEST PRACT RES CL RH, V17, P265, DOI 10.1016/S1521-6942(03)00003-2; Ndirangu J, 2010, AIDS, V24, P593, DOI 10.1097/QAD.0b013e328335cff5; Neumann-Haefelin C, 2013, CURR OPIN RHEUMATOL, V25, P426, DOI 10.1097/BOR.0b013e328362018f; Newell ML, 2004, LANCET, V364, P1236, DOI 10.1016/S0140-6736(04)17140-7; Nguyen BY, 2009, CURR OPIN RHEUMATOL, V21, P404, DOI 10.1097/BOR.0b013e32832c9d04; Njobvu P, 1998, J RHEUMATOL, V25, P1553; Njobvu P, 2000, J RHEUMATOL, V27, P1699; Ouedraogo DD, 2014, CLIN RHEUMATOL, V33, P385, DOI 10.1007/s10067-013-2455-4; Patel N, 2009, RHEUM DIS CLIN N AM, V35, P139, DOI 10.1016/j.rdc.2009.03.007; Paul ME, 2005, J ALLERGY CLIN IMMUN, V115, P848, DOI 10.1016/j.jaci.2004.11.054; Plate Ann-Marie, 2003, AIDS Read, V13, P69; Raghavan A, 2017, CURR HIV-AIDS REP, V14, P220, DOI 10.1007/s11904-017-0366-8; Restrepo CS, 2004, RADIOGRAPHICS, V24, P1029, DOI 10.1148/rg.244035151; REVEILLE JD, 1990, ARTHRITIS RHEUM, V33, P1574, DOI 10.1002/art.1780331016; Reveille JD, 2006, BEST PRACT RES CL RH, V20, P1159, DOI 10.1016/j.berh.2006.08.015; Romanelli F, 2004, CURR PHARM DESIGN, V10, P2643, DOI 10.2174/1381612043383791; ROSENBERG ZS, 1989, RADIOLOGY, V173, P171, DOI 10.1148/radiology.173.1.2781004; RYNES RI, 1988, AM J MED, V84, P810, DOI 10.1016/0002-9343(88)90057-5; Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5; SCHUVAL SJ, 1993, J RHEUMATOL, V20, P1578; Scully EP, 2018, CURR HIV-AIDS REP, V15, P136, DOI 10.1007/s11904-018-0383-2; Sekigawa I, 2001, INTERNAL MED, V40, P80, DOI 10.2169/internalmedicine.40.80; Spira R, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.5.e56; Stein CM, 1996, J RHEUMATOL, V23, P506; Suri D, 2016, INT J RHEUM DIS, V19, P1018, DOI 10.1111/1756-185X.12947; Tikly M, 2014, CURR RHEUMATOL REP, V16, DOI 10.1007/s11926-014-0421-z; Touloumi G, 2004, AIDS, V18, P1697, DOI 10.1097/01.aids.0000131395.14339.f5; Tshabalala M, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/746151; United Nations Joint Programme on HIV/AIDS, 2019, UNAIDS DAT 2019, P62; United Nations Joint Programme on HIV/AIDS, 2020, UNAIDS DAT 2020, P80; Vieira VA, 2019, AIDS, V33, P67, DOI 10.1097/QAD.0000000000002043; Violari A, 2008, NEW ENGL J MED, V359, P2233, DOI 10.1056/NEJMoa0800971; WEYAND CM, 1992, Z RHEUMATOL, V51, P55; Yao Q, 2008, CLIN EXP RHEUMATOL, V26, P799; Zaborowski AG, 2008, J AAPOS, V12, P608, DOI 10.1016/j.jaapos.2008.04.011; Zaki SA, 2009, J INFECTION, V58, P391, DOI 10.1016/j.jinf.2009.03.002; Zandman-Goddard Gisele, 2002, Autoimmunity Reviews, V1, P329, DOI 10.1016/S1568-9972(02)00086-1; Zanoni BC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022706; Zhang X, 2007, J RHEUMATOL, V34, P1760	105	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 20	2021	12								677984	10.3389/fimmu.2021.677984	http://dx.doi.org/10.3389/fimmu.2021.677984			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5X8CQ	34354702	gold, Green Published			2022-12-18	WOS:000878825400001
J	Hayashi, RJJ				Hayashi, Robert J. J.			Editorial: Immunological Challenges Following Pediatric Hematopoietic Transplantation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						hematopoietic stem cell transplantation; immunology; pediatrics; non-malignant disease; regulation			[Hayashi, Robert J. J.] Washington Univ, St Louis Childrens Hosp, Sch Med, Div Pediat Hematol Oncol, St Louis, MO 63110 USA	St. Louis Children's Hospital; Washington University (WUSTL)	Hayashi, RJJ (corresponding author), Washington Univ, St Louis Childrens Hosp, Sch Med, Div Pediat Hematol Oncol, St Louis, MO 63110 USA.	hayashi_r@wustl.edu	hayashi, robert james/AAH-2077-2019	hayashi, robert james/0000-0002-1140-1139					0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 20	2021	12								732261	10.3389/fimmu.2021.732261	http://dx.doi.org/10.3389/fimmu.2021.732261			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TT5KF	34354715	Green Published, gold			2022-12-18	WOS:000680386000001
J	Wijngaarden, LH; van der Harst, E; Klaassen, RA; Dunkelgrun, M; Kuijper, TM; Klepper, M; Ambagtsheer, G; IJzermans, JNM; de Bruin, RWF; Litjens, NHR				Wijngaarden, Leontine H.; van der Harst, Erwin; Klaassen, Rene A.; Dunkelgrun, Martin; Kuijper, T. Martijn; Klepper, Mariska; Ambagtsheer, Gisela; IJzermans, Jan N. M.; de Bruin, Ron W. F.; Litjens, Nicolle H. R.			Effects of Morbid Obesity and Metabolic Syndrome on the Composition of Circulating Immune Subsets	FRONTIERS IN IMMUNOLOGY			English	Article						T cells; B cells; NK cells; metabolic syndrome; morbid obesity; monocytes; metaflammation	T-CELLS; PERIPHERAL-BLOOD; WEIGHT; NK	Morbid obesity is characterized by chronic, low-grade inflammation, which is associated with 'inflamm-aging'. The presence of metabolic syndrome (MetS) might accelerate this phenomenon of metaflammation. In this study, we assessed the effects of morbid obesity and MetS on the composition of a broad spectrum of immune cells present within the circulation. A total of 117 morbidly obese patients (MOP) without MetS (MetS-), 127 MOP with MetS (MetS+) and 55 lean controls (LC) were included in this study. Absolute numbers of T cell, B cell, NK cell and monocyte subsets were assessed within peripheral blood using flow cytometry. Both absolute cell numbers and proportion of cells were evaluated correcting for covariates age, body mass index and cytomegalovirus serostatus. Although the absolute number of circulating CD4+ T cells was increased in the MetS+ group, the CD4+ T cell composition was not influenced by MetS. The CD8+ T cell and B cell compartment contained more differentiated cells in the MOP, but was not affected by MetS. Even though the absolute numbers of NK cells and monocytes were increased in the MOP as compared to LC, there was no difference in proportions of NK and monocyte subsets between the three study groups. In conclusion, although absolute numbers of CD4+ and CD8+ T cells, B cells, NK cells and monocytes are increased in MOP, obesity-induced effects of the composition of the immune system are confined to a more differentiated phenotype of CD8+ T cells and B cells. These results were not affected by MetS.	[Wijngaarden, Leontine H.; van der Harst, Erwin; Klaassen, Rene A.] Maasstad Hosp, Dept Surg, Rotterdam, Netherlands; [Wijngaarden, Leontine H.; Ambagtsheer, Gisela; IJzermans, Jan N. M.; de Bruin, Ron W. F.] Univ Med Ctr Rotterdam, Dept Surg, Erasmus MC, Rotterdam, Netherlands; [Dunkelgrun, Martin] Franciscus Gasthuis & Vlietland, Dept Surg, Rotterdam, Netherlands; [Kuijper, T. Martijn] Maasstad Hosp, Maasstad Acad, Rotterdam, Netherlands; [Klepper, Mariska; Litjens, Nicolle H. R.] Univ Med Ctr Rotterdam, Dept Internal Med, Sect Nephrol & Transplantat, Erasmus MC, Rotterdam, Netherlands	Maasstad Hospital; Erasmus University Rotterdam; Erasmus MC; Franciscus Gasthuis; Maasstad Hospital; Erasmus University Rotterdam; Erasmus MC	de Bruin, RWF (corresponding author), Univ Med Ctr Rotterdam, Dept Surg, Erasmus MC, Rotterdam, Netherlands.	r.w.f.debruin@erasmusmc.nl	Kuijper, T. Martijn/AAB-2627-2021	Kuijper, T. Martijn/0000-0002-2834-5727	Medtronic, Netherlands; Maasstad Hospital Science Fund	Medtronic, Netherlands; Maasstad Hospital Science Fund	The materials for immune cell phenotyping were funded by Medtronic, Netherlands. The publication fee was funded by the Maasstad Hospital Science Fund.	Antony AK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02945; Apostolopoulos V, 2016, MOL NUTR FOOD RES, V60, P43, DOI 10.1002/mnfr.201500272; Aw D, 2007, IMMUNOLOGY, V120, P435, DOI 10.1111/j.1365-2567.2007.02555.x; Bahr I, 2018, IMMUNOL RES, V66, P234, DOI 10.1007/s12026-018-8989-4; Borrego F, 1999, EXP GERONTOL, V34, P253, DOI 10.1016/S0531-5565(98)00076-X; Bray GA, 2004, J CLIN ENDOCR METAB, V89, P2583, DOI 10.1210/jc.2004-0535; Cao HM, 2014, J ENDOCRINOL, V220, pT47, DOI 10.1530/JOE-13-0339; Choromanska B, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9111087; Choromanska B, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1057570; Choromanska B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9040976; Colonna-Romano G, 2009, MECH AGEING DEV, V130, P681, DOI 10.1016/j.mad.2009.08.003; Dalmas E, 2011, AM J CLIN NUTR, V94, P450, DOI 10.3945/ajcn.111.013771; De Martinis M, 2005, FEBS LETT, V579, P2035, DOI 10.1016/j.febslet.2005.02.055; Fagnoni FF, 2000, BLOOD, V95, P2860, DOI 10.1182/blood.V95.9.2860.009k35_2860_2868; Franceschi C, 2000, ANN NY ACAD SCI, V908, P244; Frasca D, 2018, EXP GERONTOL, V107, P55, DOI 10.1016/j.exger.2017.07.002; Frasca D, 2016, OBESITY, V24, P615, DOI 10.1002/oby.21383; Grundy SM, 2016, TRENDS CARDIOVAS MED, V26, P364, DOI 10.1016/j.tcm.2015.10.004; IFSO, 2021, AR YOU CAND INT FED AR YOU CAND INT FED; Jongbloed F, 2019, INT J OBESITY, V43, P2189, DOI 10.1038/s41366-019-0351-y; Kim Mi Jung, 2008, Int J Stem Cells, V1, P55; Litjens NHR, 2011, IMMUN AGEING, V8, DOI 10.1186/1742-4933-8-2; Lumeng CN, 2011, J IMMUNOL, V187, P6208, DOI 10.4049/jimmunol.1102188; Lynch L, 2009, EUR J IMMUNOL, V39, P1893, DOI 10.1002/eji.200939349; Martin I, 2019, STAT MED, V38, P2248, DOI 10.1002/sim.8101; Mattos RT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168610; Monteiro R, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/289645; Morbach H, 2010, CLIN EXP IMMUNOL, V162, P271, DOI 10.1111/j.1365-2249.2010.04206.x; O'Rourke RW, 2005, OBES SURG, V15, P1463, DOI 10.1381/096089205774859308; Painter SD, 2015, VACCINE, V33, P4422, DOI 10.1016/j.vaccine.2015.06.101; Pawelec G, 2002, FRONT BIOSCI-LANDMRK, V7, pD1056; Poitou C, 2011, ARTERIOSCL THROM VAS, V31, P2322, DOI 10.1161/ATVBAHA.111.230979; Qin OY, 2003, J CLIN IMMUNOL, V23, P247, DOI 10.1023/A:1024580531705; Rogacev KS, 2010, EUR HEART J, V31, P369, DOI 10.1093/eurheartj/ehp308; Seidler S, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-30; Sokka T, 2008, CLIN EXP RHEUMATOL, V26, pS35, DOI 10.1161/CIRCULATIONAHA.109.192644; Solana R, 2000, VACCINE, V18, P1613, DOI 10.1016/S0264-410X(99)00495-8; Tobin LM, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94939; Trim W, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00169; van der Weerd K, 2012, DIABETES, V61, P401, DOI 10.2337/db11-1065; Viel S, 2017, CLIN IMMUNOL, V177, P12, DOI 10.1016/j.clim.2016.01.007; Wikby A, 2008, BIOGERONTOLOGY, V9, P299, DOI 10.1007/s10522-008-9138-6; Xia SJ, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/8426874	43	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 20	2021	12								675018	10.3389/fimmu.2021.675018	http://dx.doi.org/10.3389/fimmu.2021.675018			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TT9HT	34354700	Green Published, gold			2022-12-18	WOS:000680653100001
J	Lara, PG; Esteves, E; Sales-Campos, H; Assis, JB; Henrique, MO; Barros, MS; Neto, LS; Silva, PI; Martins, JO; Cardoso, CRB; Ribeiro, JMC; Sa-Nunes, A				Lara, Priscila G.; Esteves, Eliane; Sales-Campos, Helioswilton; Assis, Josiane B.; Henrique, Maressa O.; Barros, Michele S.; Neto, Leila S.; Silva, Pedro, I; Martins, Joilson O.; Cardoso, Cristina R. B.; Ribeiro, Jose M. C.; Sa-Nunes, Anderson			AeMOPE-1, a Novel Salivary Peptide From Aedes aegypti, Selectively Modulates Activation of Murine Macrophages and Ameliorates Experimental Colitis	FRONTIERS IN IMMUNOLOGY			English	Article						Aedes aegypti; AeMOPE-1; macrophages; immunomodulation; experimental colitis	YELLOW-FEVER MOSQUITO; DENGUE-VIRUS-INFECTION; FEMALE MOSQUITO; GLAND EXTRACT; DIFFERENTIAL MODULATION; IMMUNE-RESPONSE; DENDRITIC CELLS; SIALOSTATIN L; PROTEIN; INHIBITOR	The sialotranscriptomes of Aedes aegypti revealed a transcript overexpressed in female salivary glands that codes a mature 7.8 kDa peptide. The peptide, specific to the Aedes genus, has a unique sequence, presents a putative secretory nature and its function is unknown. Here, we confirmed that the peptide is highly expressed in the salivary glands of female mosquitoes when compared to the salivary glands of males, and its secretion in mosquito saliva is able to sensitize the vertebrate host by inducing the production of specific antibodies. The synthetic version of the peptide downmodulated nitric oxide production by activated peritoneal murine macrophages. The fractionation of a Ae. aegypti salivary preparation revealed that the fractions containing the naturally secreted peptide reproduced the nitric oxide downmodulation. The synthetic peptide also selectively interfered with cytokine production by murine macrophages, inhibiting the production of IL-6, IL-12p40 and CCL2 without affecting TNF-alpha or IL-10 production. Likewise, intracellular proteins associated with macrophage activation were also distinctively modulated: while iNOS and NF-kappa B p65 expression were diminished, I kappa B alpha and p38 MAPK expression did not change in the presence of the peptide. The anti-inflammatory properties of the synthetic peptide were tested in vivo on a dextran sulfate sodium-induced colitis model. The therapeutic administration of the Ae. aegypti peptide reduced the leukocytosis, macrophage activity and nitric oxide levels in the gut, as well as the expression of cytokines associated with the disease, resulting in amelioration of its clinical signs. Given its biological properties in vitro and in vivo, the molecule was termed Aedes-specific MOdulatory PEptide (AeMOPE-1). Thus, AeMOPE-1 is a novel mosquito-derived immunobiologic with potential to treat immune-mediated disorders.	[Lara, Priscila G.; Esteves, Eliane; Assis, Josiane B.; Henrique, Maressa O.; Barros, Michele S.; Neto, Leila S.; Sa-Nunes, Anderson] Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Sao Paulo, Brazil; [Sales-Campos, Helioswilton; Cardoso, Cristina R. B.] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Anal Toxicol & Food Sci, Ribeirao Preto, Brazil; [Silva, Pedro, I] Butantan Inst, Lab Appl Toxinol, Sao Paulo, Brazil; [Martins, Joilson O.] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, Sao Paulo, Brazil; [Ribeiro, Jose M. C.] NIAID, Sect Vector Biol, Lab Malaria & Vector Res, NIH, Rockville, MD USA; [Sa-Nunes, Anderson] Natl Council Sci & Technol Dev INCT EM CNPq, Natl Inst Sci & Technol Mol Entomol, Rio De Janeiro, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Instituto Butantan; Universidade de Sao Paulo; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Sa-Nunes, A (corresponding author), Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Sao Paulo, Brazil.; Sa-Nunes, A (corresponding author), Natl Council Sci & Technol Dev INCT EM CNPq, Natl Inst Sci & Technol Mol Entomol, Rio De Janeiro, Brazil.	sanunes@usp.br	Esteves, Eliane/H-9508-2013; Sales-Campos, Helioswilton/O-5367-2017; Sa-Nunes, Anderson/M-5654-2019; Martins, Joilson O./G-4367-2011; Instituto Butantan, Center of Toxins Immune Response and Cell Signaling CeTICS/J-5731-2015	Sales-Campos, Helioswilton/0000-0003-3252-2834; Sa-Nunes, Anderson/0000-0002-1859-4973; Martins, Joilson O./0000-0003-2630-7038; Esteves, Eliane/0000-0002-4347-798X; Henrique, Maressa de Oliveira/0000-0001-7914-3116	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2009/09892-6, 2015/22934-0, 2013/07467-1, 2020/03175-0, 2013/00740-4]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [465678/2014-9, 310174/2016-3, 311204/2018-0, 472744/2012-7, 310993/2020-2, 309583/2019-5]; Nucleo de Pesquisa em Moleculas Bioativas de Artropodes Vetores, University of Sao Paulo (NAP-MOBIARVE/USP) [12.1.17661.1.7]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [001]; Intramural Research Program of the National Institute of Allergy and Infectious Diseases (Vector-Borne Diseases: Biology of Vector-Host Relationship) [Z01 AI000810-20]	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Nucleo de Pesquisa em Moleculas Bioativas de Artropodes Vetores, University of Sao Paulo (NAP-MOBIARVE/USP); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Intramural Research Program of the National Institute of Allergy and Infectious Diseases (Vector-Borne Diseases: Biology of Vector-Host Relationship)	This work was supported by funds from the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) grant #2009/09892-6 (to AS-N), 2015/22934-0 (to AS-N), 2013/07467-1 (to PSJ) 2020/03175-0 (to JM) and 2013/00740-4 (to PL), Conselho Nacional de Desenvolvimento Cienti ' fico e Tecnolo ' gico (CNPq) grant #465678/2014-9 (to AS-N), 310174/2016-3 (to CC), 311204/2018-0 (to AS-N), 472744/2012-7 (to PSJ), 310993/2020-2 (to JM) and 309583/2019-5 (to CC), Nucleo de Pesquisa em Moleculas Bioativas de Artropodes Vetores, University of Sao Paulo (NAP-MOBIARVE/USP) grant #12.1.17661.1.7 (to AS-N), Coordenacao de Aperfeicoamento de Pessoal de Ni ' vel Superior (CAPES; Finance Code 001), and Intramural Research Program of the National Institute of Allergy and Infectious Diseases Vector-Borne Diseases: Biology of Vector-Host Relationship) grant #Z01 AI000810-20 (to JR).	Ader DB, 2004, VIRAL IMMUNOL, V17, P252, DOI 10.1089/0882824041310496; Arca B, 2007, INSECT BIOCHEM MOLEC, V37, P107, DOI 10.1016/j.ibmb.2006.10.007; Assis JB, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245788; Barros MS, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3487-7; Barros MS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155454; Bento AF, 2008, J LEUKOCYTE BIOL, V84, P1213, DOI 10.1189/jlb.0408231; BISSONNETTE EY, 1993, PARASITE IMMUNOL, V15, P27, DOI 10.1111/j.1365-3024.1993.tb00569.x; Bizzarro B, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-329; Breijo M, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-3017-z; Calvo E, 2007, J BIOL CHEM, V282, P26928, DOI 10.1074/jbc.M705669200; Cantillo JF, 2014, INT ARCH ALLERGY IMM, V165, P271, DOI 10.1159/000371349; Carregaro V, 2011, J IMMUNOL, V187, P4347, DOI 10.4049/jimmunol.1003404; Chagas AC, 2014, P NATL ACAD SCI USA, V111, P6946, DOI 10.1073/pnas.1404179111; CHAMPAGNE DE, 1994, P NATL ACAD SCI USA, V91, P138, DOI 10.1073/pnas.91.1.138; CHAMPAGNE DE, 1995, P NATL ACAD SCI USA, V92, P694, DOI 10.1073/pnas.92.3.694; Cherniack EP, 2011, ALTERN MED REV, V16, P50; Chudzinski-Tavassi AM, 2016, BIOMED PHARMACOTHER, V77, P14, DOI 10.1016/j.biopha.2015.11.003; Conway MJ, 2014, J VIROL, V88, P164, DOI 10.1128/JVI.02235-13; CROSS ML, 1994, AM J TROP MED HYG, V51, P690, DOI 10.4269/ajtmh.1994.51.690; Dave SH, 2007, J IMMUNOL, V179, P7852, DOI 10.4049/jimmunol.179.11.7852; de Souza JG, 2016, ONCOTARGET, V7, P62255, DOI 10.18632/oncotarget.11555; Deruaz M, 2008, J EXP MED, V205, P2019, DOI 10.1084/jem.20072689; Esteves E, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00476; Gomes RD, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7110182; Grespan R, 2012, INT IMMUNOPHARMACOL, V12, P603, DOI 10.1016/j.intimp.2012.02.004; Gulia-Nuss M, 2015, J INSECT PHYSIOL, V82, P8, DOI 10.1016/j.jinsphys.2015.08.001; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; Horka H, 2012, J IMMUNOL, V188, P2669, DOI 10.4049/jimmunol.1100529; JAMES AA, 1991, MOL BIOCHEM PARASIT, V44, P245, DOI 10.1016/0166-6851(91)90010-4; Jin L, 2018, NAT IMMUNOL, V19, P342, DOI 10.1038/s41590-018-0063-9; Juhn J, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-1; Juvekar A, 2011, MOL CANCER RES, V9, P183, DOI 10.1158/1541-7786.MCR-10-0368; Kamalian A, 2020, WORLD J GASTROENTERO, V26, P3365, DOI 10.3748/wjg.v26.i24.3365; Kenneth KR, 1998, J BIOL CHEM, V273, P20802, DOI 10.1074/jbc.273.33.20802; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maciel C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110551; Maria DA, 2019, TOXICOL REP, V6, P51, DOI 10.1016/j.toxrep.2018.11.014; McCafferty DM, 1997, GASTROENTEROLOGY, V112, P1022, DOI 10.1053/gast.1997.v112.pm9041266; McCracken MK, 2014, VIROLOGY, V468, P133, DOI 10.1016/j.virol.2014.07.019; Na YR, 2019, NAT REV GASTRO HEPAT, V16, P531, DOI 10.1038/s41575-019-0172-4; Nenci A, 2007, NATURE, V446, P557, DOI 10.1038/nature05698; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Paveglio SA, 2007, J IMMUNOL, V178, P7064, DOI 10.4049/jimmunol.178.11.7064; Peng ZK, 2007, CURR OPIN ALLERGY CL, V7, P350, DOI 10.1097/ACI.0b013e328259c313; Rampersad SN, 2012, SENSORS-BASEL, V12, P12347, DOI 10.3390/s120912347; RIBEIRO JMC, 1992, J EXP BIOL, V165, P61; Ribeiro JMC, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-6; Ribeiro JMC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151400; Roy S, 2018, ANNU REV ENTOMOL, V63, P489, DOI 10.1146/annurev-ento-020117-043258; Sa-Nunes A, 2007, MICROBES INFECT, V9, P1393, DOI 10.1016/j.micinf.2006.10.007; Sa-Nunes A, 2009, J IMMUNOL, V182, P7422, DOI 10.4049/jimmunol.0900075; Sales-Campos H, 2017, IMMUNOLOGY, V150, P115, DOI 10.1111/imm.12672; Sales-Campos H, 2015, INT IMMUNOPHARMACOL, V26, P13, DOI 10.1016/j.intimp.2015.03.002; Schmid MA, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005676; Schneider BS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011704; Shibata W, 2007, J IMMUNOL, V179, P2681, DOI 10.4049/jimmunol.179.5.2681; Stibraniova I, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00830; Sun P, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14115-z; Sun T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01245; Surasombatpattana P, 2012, J INVEST DERMATOL, V132, P2103, DOI 10.1038/jid.2012.76; Tomas-Cortazar J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11354-2; Valenzuela JG, 2002, INSECT BIOCHEM MOLEC, V32, P1101, DOI 10.1016/S0965-1748(02)00047-4; Vieira AT, 2009, AM J PATHOL, V175, P2382, DOI 10.2353/ajpath.2009.090093; Vogel KJ, 2015, P NATL ACAD SCI USA, V112, P5057, DOI 10.1073/pnas.1501814112; Wanasen N, 2004, MED VET ENTOMOL, V18, P191, DOI 10.1111/j.1365-2915.2004.00498.x; Wasserman HA, 2004, PARASITE IMMUNOL, V26, P295, DOI 10.1111/j.0141-9838.2004.00712.x; Watanabe RMO, 2010, BIOCHIMIE, V92, P933, DOI 10.1016/j.biochi.2010.03.024; Wei L, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-3000-8; Wei L, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1149-y; Wu J, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1176-8; Yang JJ, 2013, J EXP MED, V210, P1447, DOI 10.1084/jem.20122494; Yang YB, 2021, GUT, V70, P1495, DOI 10.1136/gutjnl-2020-320777	72	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 19	2021	12								681671	10.3389/fimmu.2021.681671	http://dx.doi.org/10.3389/fimmu.2021.681671			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	0L6RW	34349757	gold, Green Published			2022-12-18	WOS:000781600800001
J	Taheri, M; Sangseifid, S; Shahani, P; Eftekharian, MM; Arsang-Jang, S; Ghafouri-Fard, S				Taheri, Mohammad; Sangseifid, Somayeh; Shahani, Pariya; Eftekharian, Mohammad Mahdi; Arsang-Jang, Shahram; Ghafouri-Fard, Soudeh			Assessment of Expression of SOCS Genes in Acquired Immune-Mediated Polyneuropathies	FRONTIERS IN IMMUNOLOGY			English	Article						acquired immune-mediated polyneuropathies; Guillain-Barre syndrome; CIDP; AIDP; suppressor of cytokine signaling	GUILLAIN-BARRE-SYNDROME; CYTOKINE SIGNALING-1; SUPPRESSOR; PROTEINS; FAMILY; STAT3	Acquired immune-mediated polyneuropathies are classified to some subtypes among them are acute and chronic inflammatory demyelinating polyradiculoneuropathies (AIDP and CIDP). These two conditions share some common signs and underlying mechanisms. Based on the roles of Suppressor of cytokine signaling (SOCS) genes in the modulation of immune system reactions, these genes might be involved in the pathogenesis of these conditions. We evaluated expression of SOCS1-3 and SOCS5 genes in the leukocytes of 32 cases of CIDP, 19 cases of AIDP and 40 age- and sex-matched controls using real time PCR method. The Bayesian regression model was used to estimate differences in mean values of genes expressions between cases and control group. Expression levels of SOCS1 and SOCS2 were significantly lower in male patients compared with controls. This sex-specific pattern was also observed for SOCS3 down-regulation. Based on the area under curve values in Receiver Operating Characteristics (ROC) curve, diagnostic powers of SOCS1, SOCS2, SOCS3 and SOCS5 genes in the mentioned disorder were 0.61, 0.73, 0.68 and 0.58, respectively. Expression of none of genes was correlated with age of enrolled cases. The current study shows evidences for participation of SOCS genes in the pathophysiology of acquired immune-mediated polyneuropathies.	[Taheri, Mohammad] Shahid Beheshti Univ Med Sci, Loghman Hakim Hosp, Skull Base Res Ctr, Tehran, Iran; [Sangseifid, Somayeh] Hamadan Univ Med Sci, Sch Med, Dept Immunol, Hamadan, Iran; [Shahani, Pariya] Islamic Azad Univ, Fac New Sci, Med Tehran Branch, Dept Cellular Mol Biol, Tehran, Iran; [Eftekharian, Mohammad Mahdi] Hamadan Univ Med Sci, Neurophysiol Res Ctr, Hamadan, Iran; [Arsang-Jang, Shahram] Zanjan Univ Med Sci, Canc Gene Therapy Res Ctr, Zanjan, Iran; [Ghafouri-Fard, Soudeh] Shahid Beheshti Univ Med Sci, Sch Med, Dept Med Genet, Tehran, Iran	Shahid Beheshti University Medical Sciences; Islamic Azad University; Shahid Beheshti University Medical Sciences	Ghafouri-Fard, S (corresponding author), Shahid Beheshti Univ Med Sci, Sch Med, Dept Med Genet, Tehran, Iran.	s.ghafourifard@sbmu.ac.ir	Taheri, Mohammad/AAC-7307-2019	Taheri, Mohammad/0000-0001-8381-0591	Shahid Beheshti University of Medical Sciences	Shahid Beheshti University of Medical Sciences	The current study was supported by a grant from Shahid Beheshti University of Medical Sciences.	Ali ZPM, 2020, J MOL NEUROSCI, V70, P945, DOI 10.1007/s12031-020-01494-y; Basrai HS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153418; Egan PJ, 2003, J CLIN INVEST, V111, P915, DOI 10.1172/JCI200316156; Ghafouri-Fard S, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1529-9; Gisselbrecht S, 1999, EUR CYTOKINE NETW, V10, P463; Haber P, 2004, JAMA-J AM MED ASSOC, V292, P2478, DOI 10.1001/jama.292.20.2478; Hadden RDM, 1998, ANN NEUROL, V44, P780, DOI 10.1002/ana.410440512; Horste GMZ, 2007, NAT CLIN PRACT NEURO, V3, P198, DOI 10.1038/ncpneuro0452; Hu XY, 2007, J LEUKOCYTE BIOL, V82, P237, DOI 10.1189/jlb.1206763; Jander S, 2001, J NEUROIMMUNOL, V114, P253, DOI 10.1016/S0165-5728(00)00460-4; Keshavarzi A, 2019, BMC PSYCHIATRY, V19, DOI 10.1186/s12888-019-2396-9; Kieseier BC, 2004, MUSCLE NERVE, V30, P131, DOI 10.1002/mus.20076; Koller H, 2005, NEW ENGL J MED, V352, P1343, DOI 10.1056/nejmra041347; Lehmann HC, 2007, J NEUROPATH EXP NEUR, V66, P305, DOI 10.1097/nen.0b013e3180408daa; Lehmann Helmar C, 2009, Ther Adv Neurol Disord, V2, P261, DOI 10.1177/1756285609104792; Leonhard SE, 2019, NAT REV NEUROL, V15, P671, DOI 10.1038/s41582-019-0250-9; Leung KC, 2003, P NATL ACAD SCI USA, V100, P1016, DOI 10.1073/pnas.0337600100; Li P, 2018, EXP THER MED, V15, P5177, DOI 10.3892/etm.2018.6117; Mahdi-Rogers M, 2010, BIOL-TARGETS THER, V4, P45; Piessevaux J, 2006, J BIOL CHEM, V281, P32953, DOI 10.1074/jbc.M600776200; Rajabally YA, 2015, J NEUROL NEUROSUR PS, V86, P115, DOI 10.1136/jnnp-2014-307815; Safa A, 2021, J MOL NEUROSCI, V71, P902, DOI 10.1007/s12031-020-01720-7; Seki Y, 2003, NAT MED, V9, P1047, DOI 10.1038/nm896; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Tannahill GM, 2005, MOL CELL BIOL, V25, P9115, DOI 10.1128/MCB.25.20.9115-9126.2005; Toghi M, 2017, J NEUROL SCI, V375, P481, DOI 10.1016/j.jns.2017.02.015; Trengove MC, 2013, AM J CLIN EXP IMMUNO, V2, P1; Van den Bergh PYK, 2010, EUR J NEUROL, V17, P356, DOI 10.1111/j.1468-1331.2009.02930.x; Wang Y, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/564098; Yamana J, 2004, ARTHRITIS RES THER, V6, pR567, DOI 10.1186/ar1445; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Zhang HL, 2013, CYTOKINE GROWTH F R, V24, P443, DOI 10.1016/j.cytogfr.2013.05.005; Zhou DX, 2017, ONCOTARGET, V8, P60710, DOI 10.18632/oncotarget.19940	34	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 19	2021	12								712859	10.3389/fimmu.2021.712859	http://dx.doi.org/10.3389/fimmu.2021.712859			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TT2NG	34349769	Green Published, gold			2022-12-18	WOS:000680186400001
J	Jiang, H; Li, ZH; Yu, L; Zhang, Y; Zhou, L; Wu, JH; Yuan, J; Han, MY; Xu, T; He, JW; Wang, S; Yu, CF; Pan, S; Wu, M; Liu, HY; Zeng, HH; Song, Z; Wang, QQ; Qu, S; Zhang, JW; Huang, YF; Han, JY				Jiang, Han; Li, Zhaohui; Yu, Long; Zhang, Ying; Zhou, Li; Wu, Jianhua; Yuan, Jing; Han, Mengyao; Xu, Tao; He, Junwen; Wang, Shan; Yu, Chengfeng; Pan, Sha; Wu, Min; Liu, Hangyu; Zeng, Haihong; Song, Zhu; Wang, Qiangqiang; Qu, Shen; Zhang, Junwei; Huang, Yafei; Han, Junyan			Immune Phenotyping of Patients With Acute Vogt-Koyanagi-Harada Syndrome Before and After Glucocorticoids Therapy (vol 12,659150, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						immunopathogenesis; lymphocyte subsets; monocytes; VKH; autoimmunity; cytokine			[Jiang, Han; Wu, Min; Liu, Hangyu; Song, Zhu; Wang, Qiangqiang; Zhang, Junwei; Han, Junyan] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Immunol, Wuhan, Hubei, Peoples R China; [Li, Zhaohui; Wu, Jianhua; Yuan, Jing; Han, Mengyao; Xu, Tao; He, Junwen; Yu, Chengfeng; Pan, Sha] Wuhan Univ, Wuhan Aier Eye Hosp, Retinal & Vitreous Dis Dept, Wuhan, Hubei, Peoples R China; [Yu, Long; Zeng, Haihong; Qu, Shen; Huang, Yafei] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Pathogen Biol, Wuhan, Hubei, Peoples R China; [Zhang, Ying; Wang, Shan] Wuhan Univ, Wuhan Aier Eye Hosp, Ophthalm Imaging Dept, Wuhan, Hubei, Peoples R China; [Zhou, Li] Wuhan Univ, Wuhan Aier Eye Hosp, Cataract Dept, Wuhan, Hubei, Peoples R China	Huazhong University of Science & Technology; Wuhan University; Huazhong University of Science & Technology; Wuhan University; Wuhan University	Han, JY (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Immunol, Wuhan, Hubei, Peoples R China.; Li, ZH (corresponding author), Wuhan Univ, Wuhan Aier Eye Hosp, Retinal & Vitreous Dis Dept, Wuhan, Hubei, Peoples R China.; Huang, YF (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Pathogen Biol, Wuhan, Hubei, Peoples R China.	lizhaohui@whu.edu.cn; huangy2018@hust.edu.cn; hanj2014@hust.edu.cn						Jiang H, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.659150	1	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 16	2021	12								731824	10.3389/fimmu.2021.731824	http://dx.doi.org/10.3389/fimmu.2021.731824			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TU0AJ	34335636	gold, Green Published			2022-12-18	WOS:000680704100001
J	Leceta, J; Garin, MI; Conde, C				Leceta, Javier; Garin, Marina, I; Conde, Carmen			Mechanism of Immunoregulatory Properties of Vasoactive Intestinal Peptide in the K/BxN Mice Model of Autoimmune Arthritis	FRONTIERS IN IMMUNOLOGY			English	Article						neuroimmunology; VIP; T cell plasticity; follicular regulatory T cells (Tfr); nonclassic Th1 cells	REGULATORY T-CELLS; IMMUNE-SYSTEM; TH17 CELLS; HELPER T; VIP; DIFFERENTIATION; MICROBIOTA; ENCEPHALOMYELITIS; EXPRESSION; INDUCTION	The K/BxN mouse model of rheumatoid arthritis (RA) closely resembles the human disease. In this model, arthritis results from activation of autoreactive KRN T cells recognizing the glycolytic enzyme glucose-6-phosphate isomerase (GPI) autoantigen, which provides help to GPI-specific B cells, resulting in the production of pathogenic anti-GPI antibodies that ultimately leads to arthritis symptoms from 4 weeks of age. Vasoactive intestinal peptide (VIP) is a neuropeptide broadly distributed in the central and peripheral nervous system that is also expressed in lymphocytes and other immune cell types. VIP is a modulator of innate and adaptive immunity, showing anti-inflammatory and immunoregulatory properties. Basically, this neuropeptide promotes a shift in the Th1/Th2 balance and enhances dedifferentiation of T regulatory cells (Treg). It has demonstrated its therapeutic effects on the collagen-induced arthritis (CIA) mouse model of RA. In the present hypothesis and theory article, we propose that the immunoregulatory properties of VIP may be due likely to the inhibition of T cell plasticity toward non-classic Th1 cells and an enhanced follicular regulatory T cells (Tfr) activity. The consequences of these regulatory properties are the reduction of systemic pathogenic antibody titers.	[Leceta, Javier] Univ Complutense Madrid, Fac Biol, Dept Cell Biol, Madrid, Spain; [Garin, Marina, I] Ctr Invest Energet Medioambientales & Tecnol CIEM, Div Hematopoiet Innovat Therapies, Madrid, Spain; [Garin, Marina, I] Ctr Invest Biomed Red Enfermedades Raras CIBER ER, Madrid, Spain; [Garin, Marina, I] Fdn Jimenez Diaz IIS FJD UAM, Adv Therapy Unit, Inst Invest Sanitaria, Madrid, Spain; [Conde, Carmen] Hosp Clin Univ Santiago de Compostela CHUS, Inst Invest Sanitaria Santiago IDIS, Lab Reumatol Expt & Observac, SERGAS, Santiago De Compostela, Spain	Complutense University of Madrid; Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Fundacion Jimenez Diaz; Complexo Hospitalario Universitario de Santiago de Compostela	Leceta, J (corresponding author), Univ Complutense Madrid, Fac Biol, Dept Cell Biol, Madrid, Spain.	jleceta@bio.ucm.es	Conde, Carmen/ABA-2396-2021; Garin, Marina I/C-5094-2014	Garin, Marina I/0000-0001-7956-6792	Instituto de Salud Carlos III [PI17/01161, ISCIII/PI1701660]; European Regional Development Fund (ERDF); FEDER	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); European Regional Development Fund (ERDF)(European Commission); FEDER(European Commission)	! This work was supported by Instituto de Salud Carlos III grant (PI17/01161), and cofunded by the European Regional Development Fund (ERDF) and by Instituto de Salud Carlos III-ISCIII/PI1701660/Cofinanciado FEDER.	Arranz A, 2008, NEUROIMMUNOMODULAT, V15, P46, DOI 10.1159/000135623; Basdeo SA, 2017, J IMMUNOL, V198, P2249, DOI 10.4049/jimmunol.1600737; Bates NA, 2021, J IMMUNOL, V206, P941, DOI 10.4049/jimmunol.2000663; Bending D, 2009, J CLIN INVEST, V119, P565, DOI 10.1172/JCI37865; Block KE, 2016, J IMMUNOL, V196, P1550, DOI 10.4049/jimmunol.1501904; Chen VL, 2014, GUT MICROBES, V5, P129, DOI 10.4161/gmic.27289; Cheng HY, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7120583; Chesne J, 2019, MUCOSAL IMMUNOL, V12, P10, DOI 10.1038/s41385-018-0063-y; Couvineau A, 2012, BRIT J PHARMACOL, V166, P42, DOI 10.1111/j.1476-5381.2011.01676.x; Delgado M, 1996, J NEUROIMMUNOL, V68, P27, DOI 10.1016/0165-5728(96)00063-X; Delgado M, 2005, J LEUKOCYTE BIOL, V78, P1327, DOI 10.1189/jlb.0605299; Delgado M, 1999, J NEUROIMMUNOL, V96, P167, DOI 10.1016/S0165-5728(99)00023-5; Delgado M, 2001, NAT MED, V7, P563, DOI 10.1038/87887; Delgado M, 1999, J IMMUNOL, V163, P3629; Ditzel HJ, 2004, TRENDS MOL MED, V10, P40, DOI 10.1016/j.molmed.2003.11.004; Esplugues E, 2011, NATURE, V475, P514, DOI 10.1038/nature10228; Gomariz RP, 2007, PEPTIDES, V28, P1825, DOI 10.1016/j.peptides.2007.07.005; Gonzalez-Rey E, 2007, TRENDS MOL MED, V13, P241, DOI 10.1016/j.molmed.2007.04.003; Hickman-Brecks CL, 2011, J AUTOIMMUN, V36, P65, DOI 10.1016/j.jaut.2010.10.007; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; Jacobson A, 2021, MUCOSAL IMMUNOL, V14, P555, DOI 10.1038/s41385-020-00368-1; Ji H, 2002, IMMUNITY, V16, P157, DOI 10.1016/S1074-7613(02)00275-3; Jimeno R, 2015, J LEUKOCYTE BIOL, V98, P257, DOI 10.1189/jlb.3A0714-327R; Jimeno R, 2015, J MOL MED, V93, P457, DOI 10.1007/s00109-014-1232-4; Jimeno R, 2012, IMMUNOL CELL BIOL, V90, P178, DOI 10.1038/icb.2011.23; Jimeno R, 2010, IMMUNOL CELL BIOL, V88, P734, DOI 10.1038/icb.2010.29; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Juarranz Y, 2005, ARTHRITIS RES THER, V7, pR1034, DOI 10.1186/ar1779; Kanamori M, 2016, TRENDS IMMUNOL, V37, P803, DOI 10.1016/j.it.2016.08.012; Kim HJ, 2015, SCIENCE, V350, P334, DOI 10.1126/science.aad0616; Klose CSN, 2020, CELL RES, V30, P475, DOI 10.1038/s41422-020-0323-8; Korganow AS, 1999, IMMUNITY, V10, P451, DOI 10.1016/S1074-7613(00)80045-X; Kotake S, 2017, J CLIN MED, V6, DOI 10.3390/jcm6070067; Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092-8674(00)81989-3; Krantic S, 2000, PEPTIDES, V21, P1941, DOI 10.1016/S0196-9781(00)00347-8; Kulkarni N., 2017, IJIR, V1, pR2, DOI [10.15305/ijir/v1i1/258, DOI 10.15305/IJIR/V1I1/258]; Leceta J, 2007, NEUROIMMUNOMODULAT, V14, P134, DOI 10.1159/000110636; Li HY, 2006, J CLIN IMMUNOL, V26, P430, DOI 10.1007/s10875-006-9042-2; Linterman MA, 2011, NAT MED, V17, P975, DOI 10.1038/nm.2425; Maccioni M, 2002, J EXP MED, V195, P1071, DOI 10.1084/jem.20011941; Matsumoto I, 1999, SCIENCE, V286, P1732, DOI 10.1126/science.286.5445.1732; McCarron MJ, 2014, J CLIN INVEST, V124, P4375, DOI 10.1172/JCI76179; Nistala K, 2010, P NATL ACAD SCI USA, V107, P14751, DOI 10.1073/pnas.1003852107; Ohmura K, 2005, ARTHRITIS RHEUM-US, V52, P1866, DOI 10.1002/art.21104; Pigott E, 2014, AUTOIMMUNITY, V47, P409, DOI 10.3109/08916934.2014.914507; Prasse A, 2010, AM J RESP CRIT CARE, V182, P540, DOI 10.1164/rccm.200909-1451OC; Rankin LC, 2018, CELL, V173, P554, DOI 10.1016/j.cell.2018.03.013; Sage PT, 2016, NAT IMMUNOL, V17, P1436, DOI 10.1038/ni.3578; Sage PT, 2015, TRENDS IMMUNOL, V36, P410, DOI 10.1016/j.it.2015.05.005; SAID SI, 1984, PEPTIDES, V5, P143, DOI 10.1016/0196-9781(84)90197-9; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Tan YV, 2015, BRAIN BEHAV IMMUN, V44, P167, DOI 10.1016/j.bbi.2014.09.020; Teng F, 2016, IMMUNITY, V44, P875, DOI 10.1016/j.immuni.2016.03.013; Thornton AM, 2010, J IMMUNOL, V184, P3433, DOI 10.4049/jimmunol.0904028; Verbruggen G, 2005, ANN RHEUM DIS, V64, P1075, DOI 10.1136/ard.2004.030049; Villanueva-Romero R, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6043710; Wu HJ, 2010, IMMUNITY, V32, P815, DOI 10.1016/j.immuni.2010.06.001; Yadav M, 2008, J IMMUNOL, V180, P2772, DOI 10.4049/jimmunol.180.5.2772; Yoo BB, 2017, IMMUNITY, V46, P910, DOI 10.1016/j.immuni.2017.05.011	59	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 16	2021	12								701862	10.3389/fimmu.2021.701862	http://dx.doi.org/10.3389/fimmu.2021.701862			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TS8LH	34335612	Green Accepted, gold, Green Published			2022-12-18	WOS:000679898000001
J	Rawat, K; Pal, A; Banerjee, S; Pal, A; Mandal, SC; Batabyal, S				Rawat, Kavita; Pal, Aruna; Banerjee, Samiddha; Pal, Abantika; Mandal, Subhas Chandra; Batabyal, Subhasis			Ovine CD14-an Immune Response Gene Has a Role Against Gastrointestinal Nematode Haemonchus contortus-A Novel Report	FRONTIERS IN IMMUNOLOGY			English	Article						CD14 molecule; in silico analysis; Haemonchus contortus; sheep; differential mRNA expression analysis; molecular docking; molecular phylogeny	LIPOPOLYSACCHARIDE-BINDING-PROTEIN; MONOCYTE DIFFERENTIATION ANTIGEN; GRAM-NEGATIVE BACTERIA; MONOMERIC ENDOTOXIN; CRYSTAL-STRUCTURE; DOMAIN LINKERS; RECEPTOR; RECOGNITION; ACTIVATION; MEMBRANE	CD14 (also known as the monocyte differentiation antigen) is an important immune response gene known to be primarily responsible for innate immunity against bacterial pathogens, and as a pattern recognition receptor (PRR), binds with LPS (endotoxin), lipoproteins, and lipotechoic acid of bacteria. So far very limited work has been conducted in parasitic immunology. In the current study, we reported the role of CD14 in parasitic immunology in livestock species (sheep) for the first time. Ovine CD14 is characterized as a horse-shoe shaped bent solenoid with a hydrophobic amino-terminal pocket for CD14 along with domains. High mutation frequency was observed, out of total 41 mutations identified, 23 mutations were observed to be thermodynamically unstable and 11 mutations were deleterious in nature, causing major functional alteration of important domains of CD14, an indication of variations in individual susceptibility for sheep against Haemonchus contortus infestations. In silico studies with molecular docking reveal a role of immune response against Haemonchus contortus in sheep, which is later confirmed with experimental evidence through differential mRNA expression analysis for sheep, which revealed better expression of CD14 in Haemonchus contortus infected sheep compared to that of non-infected sheep. We confirmed the above findings with supportive evidence through haematological and biochemical analyses. Phylogenetic analysis was conducted to assess the evolutionary relationship with respect to humans and it was observed that sheep may well be used as model organisms due to better genetic closeness compared to that of mice.	[Rawat, Kavita; Batabyal, Subhasis] West Bengal Univ Anim & Fishery Sci, Dept Biochem, Kolkata, India; [Pal, Aruna] West Bengal Univ Anim & Fishery Sci, Dept LFC, Kolkata, India; [Banerjee, Samiddha] Visva Bharati Univ, Dept Anim Sci, Bolpur, India; [Pal, Abantika] Indian Inst Technol, Dept Comp Sci, Kharagpur, W Bengal, India; [Mandal, Subhas Chandra] West Bengal Univ Anim & Fishery Sci, Dept Parasitol, Kolkata, India	West Bengal University of Animal & Fishery Sciences; West Bengal University of Animal & Fishery Sciences; Visva Bharati University; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Kharagpur; West Bengal University of Animal & Fishery Sciences	Pal, A (corresponding author), West Bengal Univ Anim & Fishery Sci, Dept LFC, Kolkata, India.	arunachatterjee@gmail.com			Department of Biotechnology, Ministry of Science and Technology [BT/Bio-CARe/04/10100/2013-14]	Department of Biotechnology, Ministry of Science and Technology	The authors would like to thank Department of Biotechnology, Ministry of Science and Technology, Govt. of India for providing the financial support for carrying out the research work (Grant No. BT/Bio-CARe/04/10100/2013-14). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors are equally thankful to West Bengal University of Animal and Fishery Sciences and Indian Veterinary Research Institute for carrying out the work.	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Antonelli LRV, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004393; Passos LSA, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2366-0; BAZIL V, 1986, EUR J IMMUNOL, V16, P1583, DOI 10.1002/eji.1830161218; Benjamin M.M.., 1985, OUTLINE VET CLIN PAT, V3, P233; Capriotti E, 2005, NUCLEIC ACIDS RES, V33, pW306, DOI 10.1093/nar/gki375; Choi Y, 2015, BIOINFORMATICS, V31, P2745, DOI 10.1093/bioinformatics/btv195; Cunningham MD, 2000, J IMMUNOL, V164, P3255, DOI 10.4049/jimmunol.164.6.3255; Das M., 2017, ARCH PARASITOL, V1, P107; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; Ebina T, 2009, BIOPOLYMERS, V92, P1, DOI 10.1002/bip.21105; Elass E, 2007, FEBS LETT, V581, P1383, DOI 10.1016/j.febslet.2007.02.056; Engel P, 2015, J IMMUNOL, V195, P4555, DOI 10.4049/jimmunol.1502033; Fan XL, 1999, INFECT IMMUN, V67, P2964, DOI 10.1128/IAI.67.6.2964-2968.1999; Filipp D, 2001, P NATL ACAD SCI USA, V98, P603, DOI 10.1073/pnas.98.2.603; Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094; George RA, 2002, PROTEIN ENG, V15, P871, DOI 10.1093/protein/15.11.871; Gioannini TL, 2004, P NATL ACAD SCI USA, V101, P4186, DOI 10.1073/pnas.0306906101; Glick D.M., 1977, GLOSSARY BIOCH MOL B, VRevised; Goldsby RA, 2000, KUBY IMMUNOLOGY; GOYERT SM, 1988, SCIENCE, V239, P497, DOI 10.1126/science.2448876; Grunwald U, 1996, J IMMUNOL, V157, P4119; Gupta D, 1996, J BIOL CHEM, V271, P23310, DOI 10.1074/jbc.271.38.23310; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; Hawk PB., 1965, HAWAKS PHYSIOLOGICAL, V14th; HAZIOT A, 1988, J IMMUNOL, V141, P547; Hirako IC, 2015, MBIO, V6, DOI 10.1128/mBio.01605-15; HIXSON JE, 1986, MOL BIOL EVOL, V3, P1; Inohara N, 2002, TRENDS BIOCHEM SCI, V27, P219, DOI 10.1016/S0968-0004(02)02084-4; JACK RS, 1995, EUR J IMMUNOL, V25, P1436, DOI 10.1002/eji.1830250545; Jain NC., 1986, ESSENTIALS VET HAEMA, P57; Janeway C.A., 2004, IMMUNOBIOLOGY IMMUNE; Katoh K, 2016, BIOINFORMATICS, V32, P1933, DOI 10.1093/bioinformatics/btw108; Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053; Kelley SL, 2013, J IMMUNOL, V190, P1304, DOI 10.4049/jimmunol.1202446; Kiefer Florian, 2009, Nucleic Acids Res, V37, pD387, DOI 10.1093/nar/gkn750; Kim JI, 2005, J BIOL CHEM, V280, P11347, DOI 10.1074/jbc.M414607200; Klein J, 1998, ANNU REV ECOL SYST, V29, P1, DOI 10.1146/annurev.ecolsys.29.1.1; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lee JW, 2003, INFECT IMMUN, V71, P4034, DOI 10.1128/IAI.71.7.4034-4039.2003; Li L, 2011, J MOL EVOL, V72, P474, DOI 10.1007/s00239-011-9446-3; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; Maizels Rick M., 2009, Journal of Biology (London), V8, P62, DOI 10.1186/jbiol166; Meng J, 2008, J BIOL CHEM, V283, P3376, DOI 10.1074/jbc.M707640200; Miguel RN, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000788; Muroi M, 2002, J BIOL CHEM, V277, P42372, DOI 10.1074/jbc.M205966200; Nakata T, 2006, CELL MICROBIOL, V8, P1899, DOI 10.1111/j.1462-5822.2006.00756.x; Oakley MS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006793; Ohto U, 2007, SCIENCE, V316, P1632, DOI 10.1126/science.1139111; Ohto U, 2012, P NATL ACAD SCI USA, V109, P7421, DOI 10.1073/pnas.1201193109; Opal SM, 1999, CRIT CARE MED, V27, P1608, DOI 10.1097/00003246-199908000-00039; Paape MJ, 1996, AM J VET RES, V57, P477; Pal Aruna, 2011, Mol Biol Int, V2011, P507346, DOI 10.4061/2011/507346; Pal A, 2013, INDIAN J ANIM SCI, V83, P1062; Pal A, 2013, BUFFALO BULL, V32, P138; Pal A, 2009, SMALL RUMINANT RES, V82, P84, DOI 10.1016/j.smallrumres.2008.11.016; Parija Subhash Chandra, 2011, Trop Parasitol, V1, P49, DOI 10.4103/2229-5070.86918; Petersen B, 2009, BMC STRUCT BIOL, V9, DOI 10.1186/1472-6807-9-51; Prohinar P, 2007, J BIOL CHEM, V282, P1010, DOI 10.1074/jbc.M609400200; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; Rietschel E T, 1985, Prog Clin Biol Res, V189, P31; Salomao R, 2012, SHOCK, V38, P227, DOI 10.1097/SHK.0b013e318262c4b0; Sambrook JF, 2001, MOL CLONING LAB MANU, V1-3; Savedra R, 1996, J IMMUNOL, V157, P2549; Schiff DE, 1997, J LEUKOCYTE BIOL, V62, P786, DOI 10.1002/jlb.62.6.786; Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481; Schroder NWJ, 2000, J IMMUNOL, V165, P2683, DOI 10.4049/jimmunol.165.5.2683; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SETOGUCHI M, 1989, BIOCHIM BIOPHYS ACTA, V1008, P213, DOI 10.1016/0167-4781(80)90012-3; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; SIMMONS DL, 1989, BLOOD, V73, P284; Skrzeczynska-Moncznik J, 2008, SCAND J IMMUNOL, V67, P152, DOI 10.1111/j.1365-3083.2007.02051.x; Smarda P, 2014, P NATL ACAD SCI USA, V111, pE4096, DOI 10.1073/pnas.1321152111; Stelter F, 1997, EUR J BIOCHEM, V243, P100, DOI 10.1111/j.1432-1033.1997.00100.x; Takai N, 1997, J LEUKOCYTE BIOL, V61, P736, DOI 10.1002/jlb.61.6.736; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Teghanemt A, 2008, J BIOL CHEM, V283, P21881, DOI 10.1074/jbc.M800672200; Teghanemt A, 2007, J BIOL CHEM, V282, P36250, DOI 10.1074/jbc.M705995200; Tizard I., 1992, Veterinary immunology. An introduction.; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; Tundup S, 2014, INFECT IMMUN, V82, P3240, DOI 10.1128/IAI.01780-14; Turner JD, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002817; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; Vinogradov AE, 2003, NUCLEIC ACIDS RES, V31, P1838, DOI 10.1093/nar/gkg296; Wang PY, 1998, J BIOL CHEM, V273, P24309, DOI 10.1074/jbc.273.38.24309; Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290; WRIGHT SD, 1991, J EXP MED, V173, P1281, DOI 10.1084/jem.173.5.1281; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Wu ZG, 2009, DEV COMP IMMUNOL, V33, P97, DOI 10.1016/j.dci.2008.07.008; Wurfel MM, 1997, J IMMUNOL, V158, P3925; Yoon HJ, 2003, J MED GENET, V40, P104, DOI 10.1136/jmg.40.2.104; Yu B, 1997, J CLIN INVEST, V99, P315, DOI 10.1172/JCI119160; Yu B, 1996, J BIOL CHEM, V271, P4100; Yu WM, 1998, J IMMUNOL, V161, P4244; Zhang Y, 2005, NUCLEIC ACIDS RES, V33, P2302, DOI 10.1093/nar/gki524	97	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 16	2021	12								664877	10.3389/fimmu.2021.664877	http://dx.doi.org/10.3389/fimmu.2021.664877			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TS9ML	34335567	Green Published, gold, Green Submitted			2022-12-18	WOS:000679973500001
J	Visser, MJE; Tarr, G; Pretorius, E				Visser, Maria J. E.; Tarr, Gareth; Pretorius, Etheresia			Thrombosis in Psoriasis: Cutaneous Cytokine Production as a Potential Driving Force of Haemostatic Dysregulation and Subsequent Cardiovascular Risk	FRONTIERS IN IMMUNOLOGY			English	Review						cardiovascular disease; endothelium; hypercoagulability; platelets; psoriasis; systemic inflammation	TUMOR-NECROSIS-FACTOR; VASCULAR ENDOTHELIAL-CELLS; PLATELET-ACTIVATING-FACTOR; POPULATION-BASED-COHORT; CHRONIC KIDNEY-DISEASE; TISSUE FACTOR PATHWAY; NF-KAPPA-B; FACTOR-ALPHA; TNF-ALPHA; DENDRITIC CELLS	Psoriasis (PsO) is a common T cell-mediated inflammatory disorder of the skin with an estimated prevalence of 2%. The condition manifests most commonly as erythematous plaques covered with scales. The aetiology of PsO is multifactorial and disease initiation involves interactions between environmental factors, susceptibility genes, and innate and adaptive immune responses. The underlying pathology is mainly driven by interleukin-17. In addition, various inflammatory mediators from specific T helper (T-H) cell subsets, namely T(H)1, T(H)17, and T(H)22, are overexpressed in cutaneous lesions and may also be detected in the peripheral blood of psoriatic patients. Moreover, these individuals are also at greater risk, compared to the general population, of developing multiple comorbid conditions. Cardiovascular disease (CVD) has been recognised as a prominent comorbidity of PsO. A potential mechanism contributing to this association may be the presence of a hypercoagulable state in these individuals. Inflammation and coagulation are closely related. The presence of chronic, low-grade systemic inflammation may promote thrombosis - one of the major determinants of CVD. A pro-inflammatory milieu may induce the expression of tissue factor, augment platelet activity, and perturb the vascular endothelium. Altogether, these changes will result in a prothrombotic state. In this review, we describe the aetiology of PsO, as well as the pathophysiology of the condition. We also consider its relationship to CVD. Given the systemic inflammatory nature of PsO, we evaluate the potential contribution of prominent inflammatory mediators (implicated in PsO pathogenesis) to establishing a prothrombotic state in psoriatic patients.	[Visser, Maria J. E.; Tarr, Gareth; Pretorius, Etheresia] Stellenbosch Univ, Fac Sci, Dept Physiol Sci, Stellenbosch, South Africa; [Tarr, Gareth] Winelands Mediclin Orthopaed Hosp, Inst Orthopaed & Rheumatol, Div Rheumatol, Stellenbosch, South Africa	Stellenbosch University	Pretorius, E (corresponding author), Stellenbosch Univ, Fac Sci, Dept Physiol Sci, Stellenbosch, South Africa.	rasiap@sun.ac.za			National Research Foundation (NRF) of South Africa [117473, 132825]	National Research Foundation (NRF) of South Africa(National Research Foundation - South Africa)	This work is based on the research supported in part by the National Research Foundation (NRF) of South Africa (Grant Numbers: 117473 and 132825). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABELE DC, 1963, ARCH DERMATOL, V88, P38, DOI 10.1001/archderm.1963.01590190044005; Abeyama K, 2005, J CLIN INVEST, V115, P1267, DOI 10.1172/JCI200522782; Abuabara K, 2010, BRIT J DERMATOL, V163, P586, DOI 10.1111/j.1365-2133.2010.09941.x; Ahlehoff O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018125; Aksentijevich M, 2020, TRENDS CARDIOVAS MED, V30, P472, DOI 10.1016/j.tcm.2019.11.001; Alabbas SY, 2018, CLIN TRANSL IMMUNOL, V7, DOI 10.1002/cti2.1017; Alekseyenko AV, 2013, MICROBIOME, V1, DOI 10.1186/2049-2618-1-31; Arican O, 2005, MEDIAT INFLAMM, P273, DOI 10.1155/MI.2005.273; Armstrong AW, 2014, BRIT J DERMATOL, V170, P304, DOI 10.1111/bjd.12670; Armstrong AW, 2011, BRIT J DERMATOL, V165, P1162, DOI 10.1111/j.1365-2133.2011.10526.x; Armstrong AW, 2020, JAMA-J AM MED ASSOC, V323, P1945, DOI 10.1001/jama.2020.4006; Armstrong AW, 2013, JAMA DERMATOL, V149, P84, DOI 10.1001/2013.jamadermatol.406; Armstrong AW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052935; Armstrong EJ, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000062; Arnett DK, 2019, CIRCULATION, V140, pE596, DOI [10.1161/CIR.0000000000000678, 10.1016/j.jacc.2019.03.010, 10.1161/CIR.0000000000000677, 10.1016/j.jacc.2019.03.009]; Attwa E, 2011, J EUR ACAD DERMATOL, V25, P782, DOI 10.1111/j.1468-3083.2010.03860.x; Austin LM, 1999, J INVEST DERMATOL, V113, P752, DOI 10.1046/j.1523-1747.1999.00749.x; Azfar RS, 2008, CURR OPIN RHEUMATOL, V20, P416, DOI 10.1097/BOR.0b013e3283031c99; Bai F, 2018, ONCOTARGET, V9, P1266, DOI 10.18632/oncotarget.22260; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bernardo A, 2004, BLOOD, V104, P100, DOI 10.1182/blood-2004-01-0107; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; Blann AD, 2006, BMJ-BRIT MED J, V332, P215, DOI 10.1136/bmj.332.7535.215; Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695; Bonifati C, 1999, INT J DERMATOL, V38, P241, DOI 10.1046/j.1365-4362.1999.00622.x; Boyman O, 2004, J EXP MED, V199, P731, DOI 10.1084/jem.20031482; Brauchli YB, 2009, J INVEST DERMATOL, V129, P2604, DOI 10.1038/jid.2009.113; Brembilla NC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01682; BUSSOLINO F, 1988, J BIOL CHEM, V263, P11856; Cai YH, 2011, IMMUNITY, V35, P596, DOI 10.1016/j.immuni.2011.08.001; Cambien B, 2003, J CLIN INVEST, V112, P1589, DOI 10.1172/JCI200319284; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Camerer E, 2002, J BIOL CHEM, V277, P16081, DOI 10.1074/jbc.M108555200; CAMUSSI G, 1990, CLIN IMMUNOL IMMUNOP, V57, P331, DOI 10.1016/0090-1229(90)90108-3; CAMUSSI G, 1987, J EXP MED, V166, P1390, DOI 10.1084/jem.166.5.1390; Candia R, 2015, J EUR ACAD DERMATOL, V29, P656, DOI 10.1111/jdv.12847; Cargill M, 2007, AM J HUM GENET, V80, P273, DOI 10.1086/511051; Cataldi C, 2019, INFLAMM RES, V68, P557, DOI 10.1007/s00011-019-01238-8; Chen GY, 2008, J FORMOS MED ASSOC, V107, P21, DOI 10.1016/S0929-6646(08)60004-2; Chen YX, 2009, FEBS LETT, V583, P2811, DOI 10.1016/j.febslet.2009.07.037; Chi CC, 2015, J DERMATOL SCI, V78, P232, DOI 10.1016/j.jdermsci.2015.03.012; CHIGNARD M, 1979, NATURE, V279, P799, DOI 10.1038/279799a0; Chiricozzi A, 2011, J INVEST DERMATOL, V131, P677, DOI 10.1038/jid.2010.340; Chiu HY, 2015, BRIT J DERMATOL, V173, P146, DOI 10.1111/bjd.13599; Codoner FM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22125-y; Cohen AD, 2008, J EUR ACAD DERMATOL, V22, P585, DOI 10.1111/j.1468-3083.2008.02636.x; Cohen AD, 2008, DERMATOLOGY, V216, P152, DOI 10.1159/000111512; Cohen AD, 2009, J EUR ACAD DERMATOL, V23, P561, DOI 10.1111/j.1468-3083.2008.03031.x; Cohen AD, 2007, ACTA DERM-VENEREOL, V87, P506, DOI 10.2340/00015555-0297; CONWAY EM, 1989, THROMB RES, V53, P231, DOI 10.1016/0049-3848(89)90098-4; CONWAY EM, 1988, MOL CELL BIOL, V8, P5588, DOI 10.1128/MCB.8.12.5588; Danielsen K, 2013, BRIT J DERMATOL, V168, P1303, DOI 10.1111/bjd.12230; Davidovici BB, 2010, J INVEST DERMATOL, V130, P1785, DOI 10.1038/jid.2010.103; de Jonge E, 2003, CLIN DIAGN LAB IMMUN, V10, P495, DOI 10.1128/CDLI.10.3.495-497.2003; Demetz G, 2012, INT J INFLAMM, V2012, DOI 10.1155/2012/860301; Di Cesare A, 2009, J INVEST DERMATOL, V129, P1339, DOI 10.1038/jid.2009.59; Ding PW, 2018, INT IMMUNOPHARMACOL, V57, P132, DOI 10.1016/j.intimp.2018.02.006; Dowlatshahi EA, 2014, J INVEST DERMATOL, V134, P1542, DOI 10.1038/jid.2013.508; Duarte GV, 2013, INT J DERMATOL, V52, P177, DOI 10.1111/j.1365-4632.2011.05270.x; Duffin KC, 2008, J RHEUMATOL, V35, P1449; DUFFY DL, 1993, J AM ACAD DERMATOL, V29, P428, DOI 10.1016/0190-9622(93)70206-9; Egeberg A, 2016, BRIT J DERMATOL, V175, P487, DOI 10.1111/bjd.14528; Egeberg A, 2016, J EUR ACAD DERMATOL, V30, P1349, DOI 10.1111/jdv.13619; Elmets CA, 2021, J AM ACAD DERMATOL, V84, P432, DOI 10.1016/j.jaad.2020.07.087; Eppinga H, 2016, J CROHNS COLITIS, V10, P1067, DOI 10.1093/ecco-jcc/jjw070; Erbel C, 2009, J IMMUNOL, V183, P8167, DOI 10.4049/jimmunol.0901126; Esmon CT, 2005, BRIT J HAEMATOL, V131, P417, DOI 10.1111/j.1365-2141.2005.05753.x; ETTEHADI P, 1994, CLIN EXP IMMUNOL, V96, P146, DOI 10.1111/j.1365-2249.1994.tb06244.x; Evers AWM, 2010, BRIT J DERMATOL, V163, P986, DOI 10.1111/j.1365-2133.2010.09984.x; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023; FARBER EM, 1974, ARCH DERMATOL, V109, P207, DOI 10.1001/archderm.109.2.207; Foley JH, 2016, CIRC RES, V118, P1392, DOI 10.1161/CIRCRESAHA.116.306853; Gaeta M, 2013, INT J CARDIOL, V168, P2282, DOI 10.1016/j.ijcard.2013.01.197; Ganguly D, 2009, J EXP MED, V206, P1983, DOI 10.1084/jem.20090480; Gao Z, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002719; Gelfand JM, 2007, ARCH DERMATOL, V143, P1493, DOI 10.1001/archderm.143.12.1493; Gelfand JM, 2006, JAMA-J AM MED ASSOC, V296, P1735, DOI 10.1001/jama.296.14.1735; Gelfand JM, 2009, J INVEST DERMATOL, V129, P2411, DOI 10.1038/jid.2009.112; Gerdes S, 2011, EXP DERMATOL, V20, P81, DOI 10.1111/j.1600-0625.2010.01210.x; Gillitzer R, 1996, J INVEST DERMATOL, V107, P778, DOI 10.1111/1523-1747.ep12371803; Gisondi P, 2018, CLIN DERMATOL, V36, P21, DOI 10.1016/j.clindermatol.2017.09.005; Gisondi P, 2009, J HEPATOL, V51, P758, DOI 10.1016/j.jhep.2009.04.020; Goldstein JD, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.202000688; Golia E, 2014, CURR ATHEROSCLER REP, V16, DOI 10.1007/s11883-014-0435-z; Goodman WA, 2009, J IMMUNOL, V183, P3170, DOI 10.4049/jimmunol.0803721; Griffiths CEM, 2021, LANCET, V397, P1301, DOI 10.1016/S0140-6736(20)32549-6; Grine L, 2015, CYTOKINE GROWTH F R, V26, P25, DOI 10.1016/j.cytogfr.2014.10.009; Grjibovski AM, 2007, J EUR ACAD DERMATOL, V21, P1337, DOI 10.1111/j.1468-3083.2007.02268.x; Gros A, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00678; Grozdev I, 2014, CLIN DERMATOL, V32, P343, DOI 10.1016/j.clindermatol.2013.11.001; Gudjonsson JE, 2003, BRIT J DERMATOL, V149, P530, DOI 10.1046/j.1365-2133.2003.05552.x; Hao JQ, 2014, INFLAMMATION, V37, P94, DOI 10.1007/s10753-013-9715-y; Harper EG, 2009, J INVEST DERMATOL, V129, P2175, DOI 10.1038/jid.2009.65; Hartupee J, 2007, J IMMUNOL, V179, P4135, DOI 10.4049/jimmunol.179.6.4135; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; Hernandez-Santana YE, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.201900586; Hiippala K, 2018, NUTRIENTS, V10, DOI 10.3390/nu10080988; Homey B, 2000, J IMMUNOL, V164, P6621, DOI 10.4049/jimmunol.164.12.6621; Hot A, 2012, ANN RHEUM DIS, V71, P768, DOI 10.1136/annrheumdis-2011-200468; Hou BD, 2004, J BIOL CHEM, V279, P18127, DOI 10.1074/jbc.M310438200; Hwang ST, 2017, J INVEST DERMATOL, V137, P550, DOI 10.1016/j.jid.2016.11.007; Iwaki T, 2005, BLOOD, V105, P2364, DOI 10.1182/blood-2004-06-2456; Jin W, 2013, EMERG MICROBES INFEC, V2, DOI 10.1038/emi.2013.58; Johansen C, 2009, BRIT J DERMATOL, V160, P319, DOI 10.1111/j.1365-2133.2008.08902.x; Johnson-Huang LM, 2012, J INVEST DERMATOL, V132, P1177, DOI 10.1038/jid.2011.458; Johnston A, 2008, BRIT J DERMATOL, V159, P342, DOI 10.1111/j.1365-2133.2008.08655.x; Kablak-Ziembicka A, 2011, ATHEROSCLEROSIS, V214, P185, DOI 10.1016/j.atherosclerosis.2010.10.017; Kaushik SB, 2019, INT J DERMATOL, V58, P649, DOI 10.1111/ijd.14246; Khalid U, 2013, DIABETES CARE, V36, P2402, DOI 10.2337/dc12-2330; KIRCHHOFER D, 1994, J CLIN INVEST, V93, P2073, DOI 10.1172/JCI117202; Kofler S, 2005, CLIN SCI, V108, P205, DOI 10.1042/CS20040174; Kolbinger F, 2017, J ALLERGY CLIN IMMUN, V139, P923, DOI 10.1016/j.jaci.2016.06.038; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Korman NJ, 2020, BRIT J DERMATOL, V182, P840, DOI 10.1111/bjd.18245; Koupenova M, 2017, EUR HEART J, V38, P785, DOI 10.1093/eurheartj/ehw550; Kurd SK, 2010, ARCH DERMATOL, V146, P891, DOI 10.1001/archdermatol.2010.186; Kyriakou A, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/467541; Lande R, 2007, NATURE, V449, P564, DOI 10.1038/nature06116; Langan SM, 2012, J INVEST DERMATOL, V132, P556, DOI 10.1038/jid.2011.365; Levi M, 2005, TRENDS CARDIOVAS MED, V15, P254, DOI 10.1016/j.tcm.2005.07.004; Li WQ, 2013, ANN RHEUM DIS, V72, P1200, DOI 10.1136/annrheumdis-2012-202143; Li WQ, 2012, AM J EPIDEMIOL, V175, P402, DOI 10.1093/aje/kwr325; Li YM, 2018, J INVEST DERMATOL, V138, P310, DOI 10.1016/j.jid.2017.09.021; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Lin AM, 2011, J IMMUNOL, V187, P490, DOI 10.4049/jimmunol.1100123; Love TJ, 2011, ARCH DERMATOL, V147, P419, DOI 10.1001/archdermatol.2010.370; Lowes MA, 2005, P NATL ACAD SCI USA, V102, P19057, DOI 10.1073/pnas.0509736102; Lozano R, 2013, LANCET, V381, P991, DOI 10.1016/S0140-6736(13)60704-7; Machlus KR, 2011, BLOOD, V117, P4953, DOI 10.1182/blood-2010-11-316885; Mackman N, 2012, J CLIN INVEST, V122, P2331, DOI 10.1172/JCI60229; Maione F, 2014, INT J INFLAMM, V2014, DOI 10.1155/2014/247503; Maione F, 2011, BIOCHEM BIOPH RES CO, V408, P658, DOI 10.1016/j.bbrc.2011.04.080; Mallbris L, 2004, EUR J EPIDEMIOL, V19, P225, DOI 10.1023/B:EJEP.0000020447.59150.f9; Manolis AA, 2019, INT REV IMMUNOL, V38, P33, DOI 10.1080/08830185.2018.1539084; Marcovina SM, 2007, J INTERN MED, V261, P214, DOI 10.1111/j.1365-2796.2006.01734.x; Marino M, 2013, J BIOL REG HOMEOS AG, V27, P841; Marta RF, 2005, CYTOKINE, V29, P13, DOI 10.1016/j.cyto.2004.09.003; Mehta NN, 2011, ARCH DERMATOL, V147, P1031, DOI 10.1001/archdermatol.2011.119; Mehta NN, 2010, EUR HEART J, V31, P1000, DOI 10.1093/eurheartj/ehp567; Menter A, 2020, J AM ACAD DERMATOL, V82, P1445, DOI 10.1016/j.jaad.2020.02.044; Michalek IM, 2017, J EUR ACAD DERMATOL, V31, P205, DOI 10.1111/jdv.13854; Mosca A, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00455; Muromoto R, 2016, INT IMMUNOL, V28, P443, DOI 10.1093/intimm/dxw011; Nagareddy P, 2013, CURR OPIN HEMATOL, V20, P457, DOI 10.1097/MOH.0b013e328364219d; Nair RP, 2009, NAT GENET, V41, P199, DOI 10.1038/ng.311; Nair RP, 2006, AM J HUM GENET, V78, P827, DOI 10.1086/503821; Naldi L, 2005, J INVEST DERMATOL, V125, P61, DOI 10.1111/j.0022-202X.2005.23681.x; Naldi L, 2007, CLIN DERMATOL, V25, P510, DOI 10.1016/j.clindermatol.2007.08.003; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; Nestle FO, 2005, J EXP MED, V202, P135, DOI 10.1084/jem.20050500; NESTLE FO, 1994, J CLIN INVEST, V94, P202, DOI 10.1172/JCI117308; Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595; NEUNER P, 1991, J INVEST DERMATOL, V97, P27, DOI 10.1111/1523-1747.ep12477880; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Onishi RM, 2010, IMMUNOLOGY, V129, P311, DOI 10.1111/j.1365-2567.2009.03240.x; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Pignatelli P, 2005, BLOOD, V106, P1992, DOI 10.1182/blood-2005-03-1247; Pignatelli P, 2004, CIRCULATION, V110, P1326, DOI 10.1161/01.CIR.0000134963.77201.55; Pignatelli P, 2008, CARDIOVASC RES, V78, P515, DOI 10.1093/cvr/cvn040; Pircher J, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4064; Pouplard C, 2013, J EUR ACAD DERMATOL, V27, P36, DOI 10.1111/jdv.12165; Rashmi R, 2009, CLIN EXP DERMATOL, V34, P658, DOI 10.1111/j.1365-2230.2009.03410.x; Raskob GE, 2014, ARTERIOSCL THROM VAS, V34, P2363, DOI 10.1161/ATVBAHA.114.304488; Reich K, 2012, J EUR ACAD DERMATOL, V26, P3, DOI 10.1111/j.1468-3083.2011.04410.x; Reitsma PH, 2004, J THROMB HAEMOST, V2, P619, DOI 10.1111/j.1538-7836.2004.00689.x; Richards HL, 2005, BRIT J DERMATOL, V153, P1114, DOI 10.1111/j.1365-2133.2005.06817.x; Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914; Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646; Ridker PM, 2018, EUR HEART J, V39, P3499, DOI 10.1093/eurheartj/ehy310; Ridker PM, 2000, CIRCULATION, V101, P2149, DOI 10.1161/01.CIR.101.18.2149; Rizzo HL, 2011, J IMMUNOL, V186, P1495, DOI 10.4049/jimmunol.1001001; Roberts KK, 2015, ALIMENT PHARM THER, V41, P293, DOI 10.1111/apt.13042; Sa SM, 2007, J IMMUNOL, V178, P2229, DOI 10.4049/jimmunol.178.4.2229; de Oliveira PSS, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/819149; de Oliveira MDSP, 2015, AN BRAS DERMATOL, V90, P9, DOI 10.1590/abd1806-4841.20153038; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; Simon T, 2013, EUR HEART J, V34, P570, DOI 10.1093/eurheartj/ehs263; Singh TP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051752; Sommer DM, 2006, ARCH DERMATOL RES, V298, P321, DOI 10.1007/s00403-006-0703-z; Strange A, 2010, NAT GENET, V42, P985, DOI 10.1038/ng.694; Sun DX, 2011, NAT IMMUNOL, V12, P853, DOI 10.1038/ni.2081; Sun LD, 2010, NAT GENET, V42, P1005, DOI 10.1038/ng.690; Szotowski B, 2005, CIRC RES, V96, P1233, DOI 10.1161/01.RES.0000171805.24799.fa; Takahashi H, 2012, J DERMATOL, V39, P212, DOI 10.1111/j.1346-8138.2011.01408.x; Takeshita J, 2017, J AM ACAD DERMATOL, V76, P377, DOI 10.1016/j.jaad.2016.07.064; Takeshita J, 2015, J INVEST DERMATOL, V135, P2955, DOI 10.1038/jid.2015.296; Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295; Terajima S, 1998, ARCH DERMATOL RES, V290, P246, DOI 10.1007/s004030050299; Teunissen MBM, 2014, J INVEST DERMATOL, V134, P2898, DOI 10.1038/jid.2014.261; Tobin AM, 2010, J RHEUMATOL, V37, P1386, DOI 10.3899/jrheum.090822; Tohyama M, 2018, EUR J IMMUNOL, V48, P168, DOI 10.1002/eji.201747017; Tomi NS, 2005, J AM ACAD DERMATOL, V53, P67, DOI 10.1016/j.jaad.2005.02.034; Trembath RC, 1997, HUM MOL GENET, V6, P813, DOI 10.1093/hmg/6.5.813; Tsoi LC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15382; Tsoi LC, 2012, NAT GENET, V44, P1341, DOI 10.1038/ng.2467; van Aken BE, 2000, THROMB HAEMOSTASIS, V83, P536, DOI 10.1055/s-0037-1613858; van der Fits L, 2009, J IMMUNOL, V182, P5836, DOI 10.4049/jimmunol.0802999; Vestergaard C, 2004, ACTA DERM-VENEREOL, V84, P353, DOI 10.1080/00015550410034444; Villanova F, 2014, J INVEST DERMATOL, V134, P984, DOI 10.1038/jid.2013.477; Visser MJE, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00007; Vorlova S, 2017, THROMB HAEMOSTASIS, V117, P176, DOI 10.1160/TH16-06-0466; Wan J, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5961; Wang F, 2012, BRIT J DERMATOL, V167, P92, DOI 10.1111/j.1365-2133.2012.10961.x; Watanabe H, 2009, J INVEST DERMATOL, V129, P650, DOI 10.1038/jid.2008.294; Witte E, 2014, J INVEST DERMATOL, V134, P2757, DOI 10.1038/jid.2014.308; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503; Wolk K, 2009, J MOL MED, V87, P523, DOI 10.1007/s00109-009-0457-0; Yacoub D, 2010, ARTERIOSCL THROM VAS, V30, P2424, DOI 10.1161/ATVBAHA.110.216143; Yang YC, 2007, J EUR ACAD DERMATOL, V21, P643, DOI 10.1111/j.1468-3083.2006.02036.x; Young CN, 2008, J INVEST DERMATOL, V128, P2606, DOI 10.1038/jid.2008.122; Yuan J, 2015, J HUAZHONG U SCI-MED, V35, P679, DOI 10.1007/s11596-015-1489-z; Zaba LC, 2009, J INVEST DERMATOL, V129, P79, DOI 10.1038/jid.2008.194; Zelova H, 2013, INFLAMM RES, V62, P641, DOI 10.1007/s00011-013-0633-0; Zenewicz LA, 2011, INT IMMUNOL, V23, P159, DOI 10.1093/intimm/dxr001; Zeng FF, 2021, J INVEST DERMATOL, V141, P596, DOI 10.1016/j.jid.2020.07.027; Zeng JR, 2017, J DERMATOL, V44, P863, DOI 10.1111/1346-8138.13806; Zhang S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040641; Zhao Y, 2007, ARTERIOSCL THROM VAS, V27, P1645, DOI 10.1161/ATVBAHA.106.137455; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505; Zhu FL, 2011, CLIN IMMUNOL, V141, P152, DOI 10.1016/j.clim.2011.07.003	222	0	0	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 16	2021	12								688861	10.3389/fimmu.2021.688861	http://dx.doi.org/10.3389/fimmu.2021.688861			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TS7WC	34335591	Green Published, gold			2022-12-18	WOS:000679856600001
J	Blanco, FC; Gravisaco, MJ; Bigi, MM; Garcia, EA; Marquez, C; McNeil, M; Jackson, M; Bigi, F				Blanco, Federico Carlos; Gravisaco, Maria Jose; Bigi, Maria Mercedes; Garcia, Elizabeth Andrea; Marquez, Cecilia; McNeil, Mike; Jackson, Mary; Bigi, Fabiana			Identifying Bacterial and Host Factors Involved in the Interaction of Mycobacterium bovis with the Bovine Innate Immune Cells	FRONTIERS IN IMMUNOLOGY			English	Article						innate immune response; Mycobacterium bovis; NK cells; ESAT-6; bovine tuberculosis	DELTA T-CELLS; DELAYED-TYPE HYPERSENSITIVITY; PULMONARY TUBERCULOSIS; BCG; GAMMA; RESPONSES; VIRULENT; ANTIGEN; CATTLE; MACROPHAGES	Bovine tuberculosis is an important animal and zoonotic disease caused by Mycobacterium bovis. The innate immune response is the first line of defense against pathogens and is also crucial for the development of an efficient adaptive immune response. In this study we used an in vitro co-culture model of antigen presenting cells (APC) and autologous lymphocytes derived from peripheral blood mononuclear cells to identify the cell populations and immune mediators that participate in the development of an efficient innate response capable of controlling the intracellular replication of M. bovis. After M. bovis infection, bovine immune cell cultures displayed upregulated levels of iNOS, IL-22 and IFN-gamma and the induction of the innate immune response was dependent on the presence of differentiated APC. Among the analyzed M. bovis isolates, only a live virulent M. bovis isolate induced an efficient innate immune response, which was increased upon stimulation of cell co-cultures with the M. bovis culture supernatant. Moreover, we demonstrated that an allelic variation of the early secreted protein ESAT-6 (ESAT6 T63A) expressed in the virulent strain is involved in this increased innate immune response. These results highlight the relevance of the compounds secreted by live M. bovis as well as the variability among the assessed M. bovis strains to induce an efficient innate immune response.	[Blanco, Federico Carlos; Gravisaco, Maria Jose; Garcia, Elizabeth Andrea; Bigi, Fabiana] Inst Biotechnol, Natl Inst Agr Technol INTA, Inst Nacl Tecnol Agr, Inst Biotecnol, Buenos Aires, DF, Argentina; [Blanco, Federico Carlos; Bigi, Fabiana] Consejo Nacl Invest Cient & Tecn, Natl Sci & Tech Res Council, Consejo Nacl Invest Cient & Tecnol, Buenos Aires, DF, Argentina; [Bigi, Maria Mercedes] Univ Buenos Aires UBA, Univ Buenos Aires, Fac Agron, Sch Agron, Buenos Aires, DF, Argentina; [Marquez, Cecilia] High Technol Analyt Ctr, Buenos Aires, DF, Argentina; [McNeil, Mike; Jackson, Mary] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA	Instituto Nacional de Tecnologia Agropecuaria (INTA); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Colorado State University	Blanco, FC (corresponding author), Inst Biotechnol, Natl Inst Agr Technol INTA, Inst Nacl Tecnol Agr, Inst Biotecnol, Buenos Aires, DF, Argentina.; Blanco, FC (corresponding author), Consejo Nacl Invest Cient & Tecn, Natl Sci & Tech Res Council, Consejo Nacl Invest Cient & Tecnol, Buenos Aires, DF, Argentina.	blanco.federico@inta.gob.ar	Jackson, Mary/D-5345-2017	Jackson, Mary/0000-0002-9212-0258; BIGI, Maria Mercedes/0000-0001-8711-1413	ANCyPT [PICT-2018 01113, PICT 2017-1721, PICT 2017-2704]; INTA [I105, I102]	ANCyPT; INTA	This work was funded by ANCyPT Grants: PICT-2018 01113, PICT 2017-1721, PICT 2017-2704, INTA Grant I105 and I102. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Leon DA, 2009, CLIN EXP IMMUNOL, V157, P139, DOI 10.1111/j.1365-2249.2009.03923.x; Aldwell FE, 2001, TUBERCULOSIS, V81, P115, DOI 10.1054/tube.2000.0280; Aranday-Cortes E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030626; Azad AK, 1997, J BIOL CHEM, V272, P16741, DOI 10.1074/jbc.272.27.16741; Baldwin CL, 2015, MOL IMMUNOL, V66, P35, DOI 10.1016/j.molimm.2014.10.024; Bigi M, 2019, VET MICROBIOL, V239, DOI 10.1016/j.vetmic.2019.108482; Blanco FC, 2021, COMP IMMUNOL MICROB, V75, DOI 10.1016/j.cimid.2021.101615; Blanco FC, 2009, MICROBES INFECT, V11, P956, DOI 10.1016/j.micinf.2009.06.006; Bozzano F, 2009, INT IMMUNOL, V21, P779, DOI 10.1093/intimm/dxp046; BUDDLE BM, 1995, RES VET SCI, V59, P10, DOI 10.1016/0034-5288(95)90023-3; Caimi K, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/458278; Blanco FC, 2013, TUBERCULOSIS, V93, P363, DOI 10.1016/j.tube.2013.02.004; Blanco FC, 2011, TUBERCULOSIS, V91, P57, DOI 10.1016/j.tube.2010.11.007; Carpenter E, 1998, IMMUNOL CELL BIOL, V76, P363, DOI 10.1046/j.1440-1711.1998.00760.x; Carpenter E, 1997, IMMUNOL CELL BIOL, V75, P554, DOI 10.1038/icb.1997.86; Carroll MV, 2010, PROTEIN CELL, V1, P859, DOI 10.1007/s13238-010-0101-3; Collins RA, 1998, J LEUKOCYTE BIOL, V63, P707, DOI 10.1002/jlb.63.6.707; Cross ML, 1999, VET MICROBIOL, V66, P235, DOI 10.1016/S0378-1135(99)00011-5; Darwich L, 2009, IMMUNOLOGY, V126, P386, DOI 10.1111/j.1365-2567.2008.02905.x; Denis M, 2007, TUBERCULOSIS, V87, P53, DOI 10.1016/j.tube.2006.03.005; Encinas M, 2018, TUBERCULOSIS, V111, P143, DOI 10.1016/j.tube.2018.06.007; Endsley JJ, 2006, J LEUKOCYTE BIOL, V79, P71, DOI 10.1189/jlb.0505239; Esin S, 2004, IMMUNOLOGY, V112, P143, DOI 10.1111/j.1365-2567.2004.01858.x; Fikri Y, 2001, IMMUNOL LETT, V77, P87, DOI 10.1016/S0165-2478(01)00182-1; FLESCH IEA, 1993, IMMUNOBIOLOGY, V189, P316, DOI 10.1016/S0171-2985(11)80364-5; Fu XY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151721; Garcia JSY, 2020, VET MICROBIOL, V247, DOI 10.1016/j.vetmic.2020.108758; Goldberg MF, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.MGM2-0005-2013; Gonzalez-Zamnorano M, 2009, J PROTEOME RES, V8, P721, DOI 10.1021/pr800756a; Hamilton CA, 2016, VET RES, V47, DOI 10.1186/s13567-016-0367-4; Huang L, 2018, J EXP MED, V215, P1135, DOI 10.1084/jem.20172020; Ishikawa E, 2017, TRENDS IMMUNOL, V38, P66, DOI 10.1016/j.it.2016.10.009; Ito T, 2008, INT IMMUNOL, V20, P849, DOI 10.1093/intimm/dxn043; Jensen K, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00385-17; Jones GJ, 2010, INFECT IMMUN, V78, P1326, DOI 10.1128/IAI.01246-09; Karimova G, 1998, P NATL ACAD SCI USA, V95, P5752, DOI 10.1073/pnas.95.10.5752; Kennedy HE, 2003, VET IMMUNOL IMMUNOP, V93, P169, DOI 10.1016/S0165-2427(03)00070-9; Kennedy HE, 2002, INFECT IMMUN, V70, P1488, DOI 10.1128/IAI.70.3.1488-1500.2002; Keyser A, 2011, VACCINE, V29, P9308, DOI 10.1016/j.vaccine.2011.10.019; Kruse PH, 2014, IMMUNOL CELL BIOL, V92, P221, DOI 10.1038/icb.2013.98; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Leisching G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153079; Liebana E, 2000, IMMUNOLOGY, V99, P23, DOI 10.1046/j.1365-2567.2000.00930.x; Liu CH, 2017, CELL MOL IMMUNOL, V14, P963, DOI 10.1038/cmi.2017.88; Lugo-Villarino G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01123; Ly A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113985; Ma Y, 2016, MOL IMMUNOL, V71, P23, DOI 10.1016/j.molimm.2016.01.004; Magee DA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032034; Meikle V, 2011, BMC VET RES, V7, DOI 10.1186/1746-6148-7-37; Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098; Pagan AJ, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a018499; Pahari S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00906; Parlane NA, 2015, CURR CLIN MICROBIOL, V2, P44, DOI 10.1007/s40588-014-0009-4; Pathak SK, 2007, NAT IMMUNOL, V8, P610, DOI 10.1038/ni1468; Pecora ND, 2006, J IMMUNOL, V177, P422, DOI 10.4049/jimmunol.177.1.422; Pirson C, 2015, CLIN VACCINE IMMUNOL, V22, P178, DOI 10.1128/CVI.00638-14; Pirson C, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-54; Refai A, 2015, FEBS J, V282, P4114, DOI 10.1111/febs.13408; Renshaw PS, 2005, EMBO J, V24, P2491, DOI 10.1038/sj.emboj.7600732; Sartain MJ, 2011, J LIPID RES, V52, P861, DOI 10.1194/jlr.M010363; Schorey JS, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.TBTB2-0010-2016; Siddiqui N, 2013, EUR J IMMUNOL, V43, P159, DOI 10.1002/eji.201242736; Siddiqui N, 2012, COMP IMMUNOL MICROB, V35, P219, DOI 10.1016/j.cimid.2011.11.003; Stadthagen G, 2005, J BIOL CHEM, V280, P40699, DOI 10.1074/jbc.M508332200; Steinbach S, 2016, SCI REP-UK, V6, DOI 10.1038/srep29990; Szpakowski P, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/359153; Tailleux L., 2005, PLOS MED, V2, P410, DOI [10.1371/journal.pmed.0020410, DOI 10.1371/JOURNAL.PMED.0020410]; Telfer JC, 2015, CELL IMMUNOL, V296, P76, DOI 10.1016/j.cellimm.2015.05.003; Toka FN, 2011, J IMMUNOL, V186, P4853, DOI 10.4049/jimmunol.1003599; Turner J, 2018, PATHOG DIS, V76, DOI 10.1093/femspd/fty026; Vankayalapati R, 2002, J IMMUNOL, V168, P3451, DOI 10.4049/jimmunol.168.7.3451; Vannberg FO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001388; Verrall AJ, 2014, IMMUNOLOGY, V141, P506, DOI 10.1111/imm.12223; Wedlock DN, 1999, INFECT IMMUN, V67, P2172, DOI 10.1128/IAI.67.5.2172-2177.1999; Welsh MD, 2002, INFECT IMMUN, V70, P6114, DOI 10.1128/IAI.70.11.6114-6120.2002; Whelan AO, 2008, VACCINE, V26, P166, DOI 10.1016/j.vaccine.2007.11.005; Zhang X, 2013, MOL BIOL REP, V40, P5073, DOI 10.1007/s11033-013-2610-7; Zhang X, 2012, INT J BIOL SCI, V8, P375, DOI 10.7150/ijbs.4047; Zumarraga MJ, 1999, J CLIN MICROBIOL, V37, P296	79	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 15	2021	12								674643	10.3389/fimmu.2021.674643	http://dx.doi.org/10.3389/fimmu.2021.674643			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TS0UP	34335572	Green Published, gold			2022-12-18	WOS:000679373000001
J	Denisov, SS				Denisov, Stepan S.			CXCL17: The Black Sheep in the Chemokine Flock	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						chemokines; CXCL17; DMC; VCC-1; CXCL8			[Denisov, Stepan S.] Maastricht Univ, Cardiovasc Res Inst Maastricht CARIM, Dept Biochem, Maastricht, Netherlands	Maastricht University	Denisov, SS (corresponding author), Maastricht Univ, Cardiovasc Res Inst Maastricht CARIM, Dept Biochem, Maastricht, Netherlands.	s.denisov@maastrichtuniversity.nl		Denisov, Stepan S./0000-0001-5460-940X	Maastricht Universitair Medisch Centrum	Maastricht Universitair Medisch Centrum	This work was supported by the Maastricht Universitair Medisch Centrum.	Clark HF, 2003, GENOME RES, V13, P2265, DOI 10.1101/gr.1293003; Hughes CE, 2018, FEBS J, V285, P2944, DOI 10.1111/febs.14466; King RD, 1996, PROTEIN SCI, V5, P2298, DOI 10.1002/pro.5560051116; Lee WY, 2013, AM J PHYSIOL-ENDOC M, V304, pE32, DOI 10.1152/ajpendo.00083.2012; Miller MC, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102088; Nordsieck K, 2018, BIOPOLYMERS, V109, DOI 10.1002/bip.23103; Pisabarro MT, 2006, J IMMUNOL, V176, P2069, DOI 10.4049/jimmunol.176.4.2069; Sun CJ, 2021, BIOCHEM PHARMACOL, V188, DOI 10.1016/j.bcp.2021.114586; von Hundelshausen P, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah6650; Wang X, 2011, STRUCTURE, V19, P1138, DOI 10.1016/j.str.2011.06.001; Weinstein EJ, 2006, BIOCHEM BIOPH RES CO, V350, P74, DOI 10.1016/j.bbrc.2006.08.194; Xiao SY, 2021, SCAND J IMMUNOL, V93, DOI 10.1111/sji.12965	12	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 15	2021	12								712897	10.3389/fimmu.2021.712897	http://dx.doi.org/10.3389/fimmu.2021.712897			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TR9AV	34335630	Green Published, gold			2022-12-18	WOS:000679252100001
J	Haller, M; Bonczarowska, JH; Rieger, D; Lenz, TL; Nebel, A; Krause-Kyora, B				Haller, Magdalena; Bonczarowska, Joanna H.; Rieger, Dirk; Lenz, Tobias L.; Nebel, Almut; Krause-Kyora, Ben			Ancient DNA Study in Medieval Europeans Shows an Association Between HLA-DRB1*03 and Paratyphoid Fever	FRONTIERS IN IMMUNOLOGY			English	Article						Salmonella enterica Paratyphi C; enteric fever; human leukocyte antigen; trade-off; antigen binding prediction	SYSTEMIC-LUPUS-ERYTHEMATOSUS; CLASS-II; GENOME-WIDE; MHC; SUSCEPTIBILITY; RESISTANCE; ALLELES; GENES; RISK; GENOTYPES	Outbreaks of infectious diseases repeatedly affected medieval Europe, leaving behind a large number of dead often inhumed in mass graves. Human remains interred in two burial pits from 14(th) century CE Germany exhibited molecular evidence of Salmonella enterica Paratyphi C (S. Paratyphi C) infection. The pathogen is responsible for paratyphoid fever, which was likely the cause of death for the buried individuals. This finding presented the unique opportunity to conduct a paratyphoid fever association study in a European population. We focused on HLA-DRB1*03:01 that is a known risk allele for enteric fever in present-day South Asians. We generated HLA profiles for 29 medieval S. Paratyphi C cases and 24 contemporaneous controls and compared these to a modern German population. The frequency of the risk allele was higher in the medieval cases (29.6%) compared to the contemporaneous controls (13%; p = 0.189), albeit not significantly so, possibly because of small sample sizes. Indeed, in comparison with the modern controls (n = 39,689; 10.2%; p = 0.005) the frequency difference became statistically significant. This comparison also suggested a slight decrease in the allele's prevalence between the medieval and modern controls. Up to now, this is the first study on the genetic predisposition to Salmonella infection in Europeans and the only association analysis on paratyphoid fever C. Functional investigation using computational binding prediction between HLA variants and S. Paratyphi and S. Typhi peptides supported a reduced recognition capacity of bacterial proteins by DRB1*03:01 relative to other common DRB1 variants. This pattern could potentially explain the disease association. Our results suggest a slightly reduced predisposition to paratyphoid fever in modern Europeans. The causative allele, however, is still common today, which can be explained by a trade-off, as DRB1*03:01 is protective against infectious respiratory diseases such as severe respiratory syndrome (SARS). It is thus possible that the allele also provided resistance to corona-like viruses in the past.	[Haller, Magdalena; Bonczarowska, Joanna H.; Nebel, Almut; Krause-Kyora, Ben] Univ Kiel, Inst Clin Mol Biol, Kiel, Germany; [Rieger, Dirk] Hanseat City Lubeck Hist Monuments Protect Author, Dept Archaeol, Lubeck, Germany; [Lenz, Tobias L.] Max Planck Inst Evolutionary Biol, Res Grp Evolutionary Immunogenom, Plon, Germany; [Lenz, Tobias L.] Univ Hamburg, Dept Biol, Res Unit Evolutionary Immunogenom, Hamburg, Germany	University of Kiel; Max Planck Society; University of Hamburg	Krause-Kyora, B (corresponding author), Univ Kiel, Inst Clin Mol Biol, Kiel, Germany.	b.krause-kyora@ikmb.uni-kiel.de	Bonczarowska, Joanna H./AAO-4604-2021; Lenz, Tobias L/D-1387-2009; Nebel, Almut/E-4196-2010; Krause-Kyora, Ben/C-3341-2013	Bonczarowska, Joanna H./0000-0003-0761-9597; Lenz, Tobias L/0000-0002-7203-0044; Krause-Kyora, Ben/0000-0001-9435-2872; Haller, Magdalena/0000-0003-3677-1504	Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [2901391021, CRC 1266, 437857095]; Germany's Excellence Strategy [EXC2167-390884018]; International Max Planck Research School for Evolutionary Biology	Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)(German Research Foundation (DFG)); Germany's Excellence Strategy; International Max Planck Research School for Evolutionary Biology	This study was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) through the projects 2901391021 (CRC 1266), 437857095 and Germany's Excellence Strategy EXC2167-390884018. JB was funded by the International Max Planck Research School for Evolutionary Biology.	Achtman M, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002776; Ali S, 2006, CLIN EXP IMMUNOL, V144, P425, DOI 10.1111/j.1365-2249.2006.03087.x; Alicia SM, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20248; Alvarez MI, 2017, P NATL ACAD SCI USA, V114, pE7746, DOI 10.1073/pnas.1706070114; Appiah GD., 2020, CDC YELLOW BOOK 2020; Arora J, 2020, MOL BIOL EVOL, V37, P639, DOI 10.1093/molbev/msz249; Asti M, 1999, HEPATOLOGY, V29, P1272, DOI 10.1002/hep.510290445; Boldsen JL, 2005, AM J PHYS ANTHROPOL, V126, P159, DOI 10.1002/ajpa.20085; Chen QY, 1999, J CLIN ENDOCR METAB, V84, P3182, DOI 10.1210/jc.84.9.3182; Crump JA, 2010, CLIN INFECT DIS, V50, P241, DOI 10.1086/649541; Cruz-Tapias P, 2012, AUTOIMMUN DIS, V2012, DOI 10.1155/2012/569728; Dabney J, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012567; Dimitrov I, 2016, INT ARCH ALLERGY IMM, V169, P33, DOI 10.1159/000444172; Dunstan SJ, 2014, NAT GENET, V46, P1333, DOI 10.1038/ng.3143; Dunstan SJ, 2001, J INFECT DIS, V183, P261, DOI 10.1086/317940; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Fehren-Schmitz L, 2010, AM J PHYS ANTHROPOL, V141, P208, DOI 10.1002/ajpa.21135; Fernando MMA, 2007, PLOS GENET, V3, P2109, DOI 10.1371/journal.pgen.0030192; Field Y, 2016, SCIENCE, V354, P760, DOI 10.1126/science.aag0776; Fumagalli M, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002355; Gonzalez-Galarza FF, 2020, NUCLEIC ACIDS RES, V48, pD783, DOI 10.1093/nar/gkz1029; Haller M, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102419; Hopkins DR., 2002, GREATEST KILLER SMAL; Hu JM, 2012, CANCER IMMUNOL IMMUN, V61, P2135, DOI 10.1007/s00262-012-1281-x; Immel A, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-020-01627-4; Koppmann K., 1899, CHRONIKEN NIEDERS CH; Krause-Kyora B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03857-x; Kwon OJ, 1999, ARCH NEUROL-CHICAGO, V56, P555, DOI 10.1001/archneur.56.5.555; Lutgert SA., 2002, LUBECKER SCHRIFFEN A, P139; Malkova A, 2020, ERJ OPEN RES, V6, DOI 10.1183/23120541.00155-2020; Mbarek H, 2011, HUM MOL GENET, V20, P3884, DOI 10.1093/hmg/ddr301; Morris DL, 2012, AM J HUM GENET, V91, P778, DOI 10.1016/j.ajhg.2012.08.026; Muhlemann B, 2020, SCIENCE, V369, P391, DOI 10.1126/science.aaw8977; Nakken B, 2001, SCAND J IMMUNOL, V54, P428, DOI 10.1046/j.1365-3083.2001.00993.x; Ng MHL, 2004, J INFECT DIS, V190, P515, DOI 10.1086/421523; Ogrodowczyk AM, 2021, FOODS, V10, DOI 10.3390/foods10010163; Pedersen DD, 2019, INT J PALEOPATHOL, V27, P101, DOI 10.1016/j.ijpp.2018.11.003; Penn DJ, 2002, P NATL ACAD SCI USA, V99, P11260, DOI 10.1073/pnas.162006499; Pierini F, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64312-w; Prechel M., 2002, LUBECKER SCHRIFTEN A, P245; Prechel M., 1996, LUBECKER SCHRIFTEN A, P323; Reynisson B, 2020, NUCLEIC ACIDS RES, V48, pW449, DOI 10.1093/nar/gkaa379; Schuenemann VJ, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006997; Shankarkumar U, 2003, ANN RHEUM DIS, V62, P92, DOI 10.1136/ard.62.1.92; Spyrou MA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12154-0; Sveinbjornsson G, 2016, NAT GENET, V48, P318, DOI 10.1038/ng.3498; Szolek A, 2014, BIOINFORMATICS, V30, P3310, DOI 10.1093/bioinformatics/btu548; Uzzau S, 2000, EPIDEMIOL INFECT, V125, P229, DOI 10.1017/S0950268899004379; Vagene AJ, 2018, NAT ECOL EVOL, V2, P520, DOI 10.1038/s41559-017-0446-6; van Gerven NMF, 2015, GENES IMMUN, V16, P247, DOI 10.1038/gene.2014.82; Wang SF, 2011, VIRAL IMMUNOL, V24, P421, DOI 10.1089/vim.2011.0024; Willmott H, 2020, ANTIQUITY, V94, P179, DOI 10.15184/aqy.2019.213; Zhang FR, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-133; Zhang R, 2019, BLOOD ADV, V3, P3136, DOI 10.1182/bloodadvances.2019000311; Zhou ZM, 2018, CURR BIOL, V28, P2420, DOI 10.1016/j.cub.2018.05.058	55	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 15	2021	12								691475	10.3389/fimmu.2021.691475	http://dx.doi.org/10.3389/fimmu.2021.691475			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology	TR7TH	34335597	Green Published, gold			2022-12-18	WOS:000679163500001
J	Kumar, V; Kiran, S; Shamran, HA; Singh, UP				Kumar, Vijay; Kiran, Sonia; Shamran, Haidar A.; Singh, Udai P.			Differential Expression of microRNAs Correlates With the Severity of Experimental Autoimmune Cystitis	FRONTIERS IN IMMUNOLOGY			English	Article						microRNAs; autoimmune cystitis; inflammation; urinary bladder; cytokine	EXPERIMENTAL COLITIS; MAST-CELLS; MIGRATION; DISEASE; MODEL; MICE	Interstitial cystitis (IC)/bladder pain syndrome (BPS) primarily affects women. It varies in its severity and currently has no effective treatment. The symptoms of IC include pelvic pain, urgency and frequency of urination, and discomfort or pain in the bladder and lower abdomen. The bladders of IC patients exhibit infiltration by immune cells, which lends credence to the hypothesis that immune mechanisms also play a role in the etiology and pathophysiology of IC. The Differentially expressed microRNAs (miRs) in immune cells may serve as crucial immunoregulators in the IC. Therefore, we sought to determine whether miRs might play a regulatory role in the progression and pathogenesis of IC, using experimental autoimmune cystitis (EAC) model. In the present study, we observed differential expression of a specific subset of miRs in iliac lymph nodes (ILNs) and urinary bladders (UB) of IC mice compared to that in control mice. Microarray analysis of 96 miRs from the bladder and 135 miRs from ILNs allowed us to identify 50 that exhibited at least a 1.5-fold greater difference in expression in EAC mice compared to control mice. Hierarchical cluster analysis of the microarray data was used to search available databases to predict molecular pathways with which the miRs might interact. Four miRs from each organ that exhibited altered expression in EAC mice and that were predicted to have roles in inflammation (miR-146a, -181, -1931, and -5112) were selected for further analysis by reverse transcription-polymerase chain reaction (RT-PCR). All were confirmed to be elevated in EAC mice. Histological inflammatory scores, systemic chemokines, and cytokines expressed by T helper type 1 (Th1) lymphocytes were also elevated in EAC mice as compared to control animals. We hypothesize that the mechanism of EAC induction might involve the modulation of specific miRs that increase local and systemic levels of chemokines and cytokines. The present study identifies novel miRs expressed in UB and ILNs that will allow us to highlight mechanisms of EAC pathogenesis and may provide potential biomarkers and/or serve as the basis of new therapies for the treatment of IC.	[Kumar, Vijay; Kiran, Sonia; Singh, Udai P.] Univ Tennessee, Ctr Hlth Sci, Coll Pharm, Dept Pharmaceut Sci, Memphis, TN 38163 USA; [Shamran, Haidar A.] Univ South Carolina, Sch Med, Pathol Microbiol & Immunol, Columbia, SC 29208 USA	University of Tennessee System; University of Tennessee Health Science Center; University of South Carolina System; University of South Carolina Columbia	Singh, UP (corresponding author), Univ Tennessee, Ctr Hlth Sci, Coll Pharm, Dept Pharmaceut Sci, Memphis, TN 38163 USA.	usingh1@uthsc.edu	Kumar, Vijay/O-6315-2014	Kumar, Vijay/0000-0001-9741-3597; Kiran, Sonia/0000-0002-1902-3451	NIAID at UTHSC in Memphis, TN [R01 AI140405]	NIAID at UTHSC in Memphis, TN	This study was supported in part by grants from NIAID R01 AI140405 to US, at UTHSC in Memphis, TN.	Abou-Zeid A, 2011, GENET TEST MOL BIOMA, V15, P807, DOI 10.1089/gtmb.2011.0026; Altuntas CZ, 2006, J IMMUNOL, V177, P1988, DOI 10.4049/jimmunol.177.3.1988; Altuntas CZ, 2012, EUR UROL, V61, P193, DOI 10.1016/j.eururo.2011.06.028; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; Droupy Stephane, 2017, Urologia, V84, P8, DOI 10.5301/uj.5000262; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Gamper M, 2013, INT UROGYNECOL J, V24, P2049, DOI 10.1007/s00192-013-2112-0; Gonzalez-Martin A, 2016, NAT IMMUNOL, V17, P433, DOI 10.1038/ni.3385; Groppo R, 2011, MOL CELL BIOL, V31, P2707, DOI 10.1128/MCB.05133-11; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; House IG, 2020, CLIN CANCER RES, V26, P487, DOI 10.1158/1078-0432.CCR-19-1868; Huang XM, 2016, ONCOTARGET, V7, P59273, DOI 10.18632/oncotarget.11150; Ivshina M, 2015, MOL CELL BIOL, V35, P610, DOI 10.1128/MCB.00800-14; Jaini R, 2006, MOL THER, V14, P416, DOI 10.1016/j.ymthe.2006.04.009; Jane-Wit D, 2002, J IMMUNOL, V169, P6507, DOI 10.4049/jimmunol.169.11.6507; Kramer S, 2019, NEUROL-NEUROIMMUNOL, V6, DOI 10.1212/NXI.0000000000000623; Lee JH, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1353-6; Lin TJ, 2002, J IMMUNOL, V169, P4522, DOI 10.4049/jimmunol.169.8.4522; Lin YH, 2008, BJU INT, V102, P1724, DOI 10.1111/j.1464-410X.2008.07891.x; Loos T, 2006, LAB INVEST, V86, P902, DOI 10.1038/labinvest.3700453; Malik ST, 2018, J CLIN PATHOL, V71, P840, DOI 10.1136/jclinpath-2017-204881; Muljo SA, 2005, J EXP MED, V202, P261, DOI 10.1084/jem.20050678; Nakasa T, 2008, ARTHRITIS RHEUM-US, V58, P1284, DOI 10.1002/art.23429; Nordling J, 2012, WORLD J UROL, V30, P457, DOI 10.1007/s00345-011-0785-x; O'Connell RM, 2012, ANNU REV IMMUNOL, V30, P295, DOI 10.1146/annurev-immunol-020711-075013; Ralfkiaer U, 2011, BLOOD, V118, P5891, DOI 10.1182/blood-2011-06-358382; Sakthivel Senthilkumar K, 2008, J Immune Based Ther Vaccines, V6, P6, DOI 10.1186/1476-8518-6-6; Shamran H, 2017, BRAIN BEHAV IMMUN, V59, P10, DOI 10.1016/j.bbi.2016.06.008; Singh UP, 2014, IMMUNOLOGY, V143, P478, DOI 10.1111/imm.12328; Singh UP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079751; Su R, 2015, ONCOGENE, V34, P3226, DOI 10.1038/onc.2014.274; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Vincent-Schneider H, 2001, J CELL SCI, V114, P323; Wang S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7913418; Wu F, 2008, GASTROENTEROLOGY, V135, P1624, DOI 10.1053/j.gastro.2008.07.068; Xia P, 2012, IMMUNOL LETT, V148, P151, DOI 10.1016/j.imlet.2012.09.004; Xu LL, 1996, J LEUKOCYTE BIOL, V60, P365, DOI 10.1002/jlb.60.3.365; Xue Q, 2011, MOL IMMUNOL, V48, P592, DOI 10.1016/j.molimm.2010.10.021	39	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 14	2021	12								716564	10.3389/fimmu.2021.716564	http://dx.doi.org/10.3389/fimmu.2021.716564			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TS0RI	34335632	Green Published, gold			2022-12-18	WOS:000679363500001
J	Mamontov, A; Losev, I; Korzhevskii, D; Guselnikova, V; Polevshchikov, A; Desheva, Y				Mamontov, Andrey; Losev, Igor; Korzhevskii, Dmitrii; Guselnikova, Valeriia; Polevshchikov, Alexander; Desheva, Yulia			Study of Antibody-Dependent Reactions of Mast Cells In Vitro and in a Model of Severe Influenza Infection in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						mast cells; influenza infection; vaccination; IgG antibodies; immune complexes	INACTIVATED VACCINES; ENHANCEMENT; VIRUSES; RECEPTORS; RESPONSES; IMMUNITY	We investigated the reaction of mouse peritoneal mast cells (MCs) in vitro after IgG-containing immune complex introduction using A/H5N1 and A/H1N1pdm09 influenza viruses as antigens. The sera of immune mice served as a source of IgG antibodies. The concentration of histamine in the supernatants was determined at 4 hours after incubation with antisera and virus. We compared the contribution of MCs to the pathogenesis of post-immunization influenza infection with A/H5N1 and A/H1N1 influenza viruses in mice. The mice were immunized parenterally with inactivated viruses and challenged with lethal doses of drift A/H5N1 and A/H1N1 influenza viruses on the 14(th) day after immunization. Simultaneously, half of the mice were injected intraperitoneally with a mixture of histamine receptor blockers (chloropyramine and quamatel). In in vitro experiments, the immune complex formed by A/H5N1 virus and antiserum caused a significant increase in the histamine release compared to immune serum or the virus alone. With regard to the A/H1N1 virus, such an increase was not significant. A/H1N1 immunization caused detectable HI response in mice at 12(th) day after immunization, in contrast to the A/H5N1 virus. After challenge of A/H5N1-immunized mice, administration of antihistamines increased the survival rate by up to 90%. When infecting the A/H1N1-immunized mice, 90% of the animals were already protected from lethal infection by day 14; the administration of histamine receptor blockers did not increase survival. Histological examination of the lungs has shown that toluidine blue staining allows to estimate the degree of MC degranulation. The possibility of in vitro activation of murine MCs by IgG-containing immune complexes has been shown. In a model of influenza infection, it was shown that the administration of histamine receptor blockers increased survival. When the protection was formed faster due to the earlier production of HI antibodies, the administration of histamine receptor blockers did not significantly affect the course of the infection. These data allow to propose that even if there are antibody-dependent MC reactions, they can be easily stopped by the administration of histamine receptor blockers.	[Mamontov, Andrey; Polevshchikov, Alexander] Fed State Budgetary Sci Inst, Inst Expt Med, Dept Immunol, St Petersburg, Russia; [Losev, Igor; Desheva, Yulia] Fed State Budgetary Sci Inst, Inst Expt Med, Dept Virol, St Petersburg, Russia; [Korzhevskii, Dmitrii; Guselnikova, Valeriia] Fed State Budgetary Sci Inst, Inst Expt Med, Dept Gen & Special Morphol, St Petersburg, Russia	Institute of Experimental Medicine; Institute of Experimental Medicine; Institute of Experimental Medicine	Desheva, Y (corresponding author), Fed State Budgetary Sci Inst, Inst Expt Med, Dept Virol, St Petersburg, Russia.	desheva@mail.ru	Desheva, Yulia/I-1493-2013; Guselnikova, Valeriia/F-6019-2017	Desheva, Yulia/0000-0001-9794-3520; Guselnikova, Valeriia/0000-0002-9499-8275; Mamontov, Andrey/0000-0002-5901-6942	Federal State Budgetary Scientific Institution "Institute of Experimental Medicine"	Federal State Budgetary Scientific Institution "Institute of Experimental Medicine"	This work was supported by the Federal State Budgetary Scientific Institution "Institute of Experimental Medicine"	Adlhoch C, 2021, EFSA J, V19, DOI 10.2903/j.efsa.2021.6497; Baudino L, 2008, J IMMUNOL, V180, P1948, DOI 10.4049/jimmunol.180.3.1948; Bodewes R, 2012, VACCINE, V30, P7407, DOI 10.1016/j.vaccine.2012.04.086; Boonnak K, 2008, J VIROL, V82, P3939, DOI 10.1128/JVI.02484-07; Bournazos S, 2017, MYELOID CELLS IN HEALTH AND DISEASE, P407, DOI 10.1128/microbiolspec.MCHD-0045-2016; Braber S, 2010, AM J PHYSIOL-LUNG C, V299, pL843, DOI 10.1152/ajplung.00192.2010; Bruhns P, 2012, BLOOD, V119, P5640, DOI 10.1182/blood-2012-01-380121; Church MK, 1997, J ALLERGY CLIN IMMUN, V99, P155, DOI 10.1016/S0091-6749(97)70089-7; Monsalvo AC, 2011, NAT MED, V17, P195, DOI 10.1038/nm.2262; Couch RB, 2013, J INFECT DIS, V207, P974, DOI 10.1093/infdis/jis935; Desheva JA, 2006, VACCINE, V24, P6859, DOI 10.1016/j.vaccine.2006.06.023; Desheva Y, 2020, LIFE SCI, V258, DOI 10.1016/j.lfs.2020.118230; Du LY, 2010, MICROBES INFECT, V12, P280, DOI 10.1016/j.micinf.2010.01.001; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Gupta V, 2006, VACCINE, V24, P3881, DOI 10.1016/j.vaccine.2006.01.010; Huo CY, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00595; Lu XH, 2006, VACCINE, V24, P6588, DOI 10.1016/j.vaccine.2006.05.039; da Silva EZM, 2014, J HISTOCHEM CYTOCHEM, V62, P698, DOI 10.1369/0022155414545334; OCHIAI H, 1992, J MED VIROL, V36, P217, DOI 10.1002/jmv.1890360312; OCHIAI H, 1990, J MED VIROL, V30, P258, DOI 10.1002/jmv.1890300406; Patel SM, 2010, VACCINE, V28, P3025, DOI 10.1016/j.vaccine.2009.10.152; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Shore PA, 1971, METHODS BIOCH ANAL S, P89, DOI [10.1002/9780470110409.ch3, DOI 10.1002/9780470110409.CH3]; Skowronski DM, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000258; Subbarao K, 1998, SCIENCE, V279, P393, DOI 10.1126/science.279.5349.393; TAMURA M, 1991, VIROLOGY, V182, P211, DOI 10.1016/0042-6822(91)90664-W; TAMURA M, 1994, J VIROL, V68, P3499, DOI 10.1128/JVI.68.6.3499-3504.1994; Theoharides TC, 2017, EXP DERMATOL, V26, P751, DOI 10.1111/exd.13288; Treanor JJ, 2006, NEW ENGL J MED, V354, P1343, DOI 10.1056/NEJMoa055778; Walker ME, 2012, BBA-MOL BASIS DIS, V1822, P57, DOI 10.1016/j.bbadis.2011.02.009; Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090; Wang S, 2014, HUM VACC IMMUNOTHER, V10, P461, DOI 10.4161/hv.27165; Xiao WB, 2005, J IMMUNOL, V175, P6885, DOI 10.4049/jimmunol.175.10.6885	35	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 14	2021	12								689436	10.3389/fimmu.2021.689436	http://dx.doi.org/10.3389/fimmu.2021.689436			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TQ7SA	34335593	gold, Green Published			2022-12-18	WOS:000678479100001
J	Nudelman, I; Kudrin, D; Nudelman, G; Deshpande, R; Hartmann, BMM; Kleinstein, SH; Myers, CLL; Sealfon, SCC; Zaslavsky, E				Nudelman, Irina; Kudrin, Daniil; Nudelman, German; Deshpande, Raamesh; Hartmann, Boris M. M.; Kleinstein, Steven H.; Myers, Chad L. L.; Sealfon, Stuart C. C.; Zaslavsky, Elena			Comparing Host Module Activation Patterns and Temporal Dynamics in Infection by Influenza H1N1 Viruses	FRONTIERS IN IMMUNOLOGY			English	Article						transcriptional profile; temporal dynamics; module discovery; conserved and differential modules; differential regulation; functional network; virus infection; Influenza H1N1	A VIRUS; GENOMIC ANALYSIS; CELL RESPONSE; TIME-SERIES; INTERFERON; IMMUNE; INDUCTION; MACAQUES; RESOURCE; TOOL	Influenza is a serious global health threat that shows varying pathogenicity among different virus strains. Understanding similarities and differences among activated functional pathways in the host responses can help elucidate therapeutic targets responsible for pathogenesis. To compare the types and timing of functional modules activated in host cells by four influenza viruses of varying pathogenicity, we developed a new DYNAmic MOdule (DYNAMO) method that addresses the need to compare functional module utilization over time. This integrative approach overlays whole genome time series expression data onto an immune-specific functional network, and extracts conserved modules exhibiting either different temporal patterns or overall transcriptional activity. We identified a common core response to influenza virus infection that is temporally shifted for different viruses. We also identified differentially regulated functional modules that reveal unique elements of responses to different virus strains. Our work highlights the usefulness of combining time series gene expression data with a functional interaction map to capture temporal dynamics of the same cellular pathways under different conditions. Our results help elucidate conservation of the immune response both globally and at a granular level, and provide mechanistic insight into the differences in the host response to infection by influenza strains of varying pathogenicity.	[Nudelman, Irina; Kudrin, Daniil; Nudelman, German; Hartmann, Boris M. M.; Sealfon, Stuart C. C.; Zaslavsky, Elena] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [Nudelman, Irina] NYU Langone Med Ctr, Div Gen Internal Med, New York, NY USA; [Deshpande, Raamesh; Myers, Chad L. L.] Univ Minnesota Twin Cities, Dept Comp Sci & Engn, Minneapolis, MN USA; [Hartmann, Boris M. M.; Sealfon, Stuart C. C.; Zaslavsky, Elena] Icahn Sch Med Mt Sinai, Ctr Adv Res Diagnost Assays CARDA, New York, NY 10029 USA; [Kleinstein, Steven H.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Myers, Chad L. L.] Univ Minnesota Twin Cities, Program Biomed Informat & Computat Biol, Minneapolis, MN USA	Icahn School of Medicine at Mount Sinai; NYU Langone Medical Center; University of Minnesota System; University of Minnesota Twin Cities; Icahn School of Medicine at Mount Sinai; Yale University; University of Minnesota System; University of Minnesota Twin Cities	Zaslavsky, E (corresponding author), Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA.; Zaslavsky, E (corresponding author), Icahn Sch Med Mt Sinai, Ctr Adv Res Diagnost Assays CARDA, New York, NY 10029 USA.	elena.zaslavsky@mssm.edu	Hartmann, Boris M./A-6121-2010	Hartmann, Boris M./0000-0002-5649-6776; Zaslavsky, Elena/0000-0002-4828-7771	National Institutes of Health [HHSN272201000054C, 1U19AI117873]; Graduate School of Arts and Science, New York University	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Graduate School of Arts and Science, New York University	This work was supported by National Institutes of Health contract HHSN272201000054C and Grant 1U19AI117873. IN was supported by the Graduate School of Arts and Science, New York University.	Aach J, 2001, BIOINFORMATICS, V17, P495, DOI 10.1093/bioinformatics/17.6.495; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bar-Joseph Z, 2012, NAT REV GENET, V13, P552, DOI 10.1038/nrg3244; Baskin CR, 2004, J VIROL, V78, P10420, DOI 10.1128/JVI.78.19.10420-10432.2004; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Cilloniz C, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000604; Deshpande R, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1001028; Diamond MS, 2013, NAT REV IMMUNOL, V13, P46, DOI 10.1038/nri3344; Dienz O, 2012, MUCOSAL IMMUNOL, V5, P258, DOI 10.1038/mi.2012.2; Eddy JA, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000792; Gao SG, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S9-S5; Gao SG, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-167; Garcia-Sastre A, 1998, J VIROL, V72, P8550; Geiss GK, 2002, P NATL ACAD SCI USA, V99, P10736, DOI 10.1073/pnas.112338099; Gill R, 2010, BMC BIOINFORMATICS, V11, DOI [10.1186/1471-2105-11-95, 10.1186/1471-2105-11-427]; Gorenshteyn D, 2015, IMMUNITY, V43, P605, DOI 10.1016/j.immuni.2015.08.014; Guan YF, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000165; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Haller O, 2006, VIROLOGY, V344, P119, DOI 10.1016/j.virol.2005.09.024; Hartmann BM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02035-9; Hartmann BM, 2015, J VIROL, V89, P10190, DOI 10.1128/JVI.01523-15; Hufford MM, 2015, CURR TOP MICROBIOL, V386, P423, DOI 10.1007/82_2014_397; Huttenhower C, 2009, GENOME RES, V19, P1093, DOI 10.1101/gr.082214.108; Ideker Trey, 2002, Bioinformatics, V18 Suppl 1, pS233; Jin RM, 2009, PACIFIC SYMPOSIUM ON BIOCOMPUTING 2009, P203; Josset L, 2012, J VIROL, V86, P7192, DOI 10.1128/JVI.00563-12; Kanehisa M, 2004, NUCLEIC ACIDS RES, V32, pD277, DOI 10.1093/nar/gkh063; Kash JC, 2006, NATURE, V443, P578, DOI 10.1038/nature05181; Kobasa D, 2007, NATURE, V445, P319, DOI 10.1038/nature05495; Korth MJ, 2013, SEMIN IMMUNOL, V25, P228, DOI 10.1016/j.smim.2012.11.001; Lan A, 2011, NUCLEIC ACIDS RES, V39, pW424, DOI 10.1093/nar/gkr359; Lee SMY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008072; Leiserson MDM, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003054; Luscombe NM, 2004, NATURE, V431, P308, DOI 10.1038/nature02782; Maduranga D. A. K., 2013, Pattern Recognition in Bioinformatics. 8th IAPR International Conference, PRIB 2013. Proceedings: LNCS 7986, P13, DOI 10.1007/978-3-642-39159-0_2; Melchjorsen J, 2009, J INTERF CYTOK RES, V29, P199, DOI 10.1089/jir.2008.0050; Michaelis M, 2009, MED MICROBIOL IMMUN, V198, P175, DOI 10.1007/s00430-009-0118-5; Mitra K, 2013, NAT REV GENET, V14, P719, DOI 10.1038/nrg3552; Myers CL, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-13-r114; PAVLOVIC J, 1992, J VIROL, V66, P2564, DOI 10.1128/JVI.66.4.2564-2569.1992; PITOSSI F, 1993, J VIROL, V67, P6726, DOI 10.1128/JVI.67.11.6726-6732.1993; Przytycka TM, 2010, BRIEF BIOINFORM, V11, P15, DOI 10.1093/bib/bbp057; Reiss DJ, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-280; Schultz-Cherry S, 1998, SEMIN VIROL, V8, P491, DOI 10.1006/smvy.1998.0153; Smed-Sorensen A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002572; Valcarcel B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024702; Waltman P, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-9-r96; Watanabe T, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001218; Zhang B, 2011, BIOINFORMATICS, V27, P1036, DOI 10.1093/bioinformatics/btr052; Zinman GE, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1224; Zoppoli P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-154	52	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 14	2021	12								691758	10.3389/fimmu.2021.691758	http://dx.doi.org/10.3389/fimmu.2021.691758			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TQ7VV	34335598	Green Published, gold, Green Submitted			2022-12-18	WOS:000678489000001
J	Prenc, E; Pulanic, D; Pucic-Bakovic, M; Ugrina, I; Desnica, L; Milosevic, M; Pirsl, F; Mitchell, S; Rose, J; Vrhovac, R; Nemet, D; Lauc, G; Pavletic, SZ				Prenc, Ema; Pulanic, Drazen; Pucic-Bakovic, Maja; Ugrina, Ivo; Desnica, Lana; Milosevic, Milan; Pirsl, Filip; Mitchell, Sandra; Rose, Jeremy; Vrhovac, Radovan; Nemet, Damir; Lauc, Gordan; Pavletic, Steven Z.			Significant Associations of IgG Glycan Structures With Chronic Graft-Versus-Host Disease Manifestations: Results of the Cross-Sectional NIH Cohort Study	FRONTIERS IN IMMUNOLOGY			English	Article						allogeneic hematopoietic stem cell transplantation; chronic graft-versus-host disease; immunoglobulin G; glycans; biomarker	CONSENSUS DEVELOPMENT PROJECT; RHEUMATOID-ARTHRITIS; CLINICAL-TRIALS; LABORATORY MARKERS; GLYCOSYLATION; FC; CRITERIA; GALACTOSYLATION; ANTIBODIES; DIAGNOSIS	Chronic graft-versus-host disease (cGvHD) is a systemic alloimmune and autoimmune disorder and a major late complication of allogeneic hematopoietic stem cell transplantation (alloHSCT). The disease is characterized by an altered homeostasis of the humoral immune response. Immunoglobulin G (IgG) glycoprotein is the main effector molecule of the humoral immune response. Changes in IgG glycosylation are associated with a number of autoimmune diseases. IgG glycosylation analysis was done by the means of liquid chromatography in the National Institutes of Health (NIH) cohort of 213 cGvHD patients. The results showed statistically significant differences with regards to cGvHD NIH joint/fascia and skin score, disease activity and intensity of systemic immunosuppression. ROC analysis confirmed that IgG glycosylation increases specificity and sensitivity of models using laboratory parameters and markers of inflammation associated with cGvHD (eosinophil count, complement components C3 and C4 and inflammation markers: albumin, CRP and thrombocyte count). This research shows that IgG glycosylation may play a significant role in cGvHD pathology. Further research could contribute to the understanding of the disease biology and lead to the clinical biomarker development to allow personalized approaches to chronic GvHD therapy.	[Prenc, Ema] Fidelta Ltd, Translat Res & Alliances, Zagreb, Croatia; [Prenc, Ema; Pulanic, Drazen; Milosevic, Milan; Vrhovac, Radovan; Nemet, Damir] Univ Zagreb, Sch Med, Zagreb, Croatia; [Pulanic, Drazen; Desnica, Lana; Vrhovac, Radovan; Nemet, Damir] Univ Hosp Ctr Zagreb, Dept Internal Med, Div Hematol, Zagreb, Croatia; [Pucic-Bakovic, Maja; Ugrina, Ivo; Lauc, Gordan] Genos Ltd, Zagreb, Croatia; [Ugrina, Ivo] Univ Split, Fac Sci, Split, Croatia; [Milosevic, Milan] Andrija Stampar Teaching Inst Publ Hlth, Dept Environm & Occupat Hlth & Sports, Zagreb, Croatia; [Pirsl, Filip; Rose, Jeremy; Pavletic, Steven Z.] NIH, NCI, Ctr Canc Res, Bldg 10, Bethesda, MD 20892 USA; [Mitchell, Sandra] NIH, NCI, Div Canc Control & Populat Sci, Bldg 10, Bethesda, MD 20892 USA	University of Zagreb; University of Zagreb; University of Split; University of Zagreb; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pulanic, D (corresponding author), Univ Zagreb, Sch Med, Zagreb, Croatia.; Pulanic, D (corresponding author), Univ Hosp Ctr Zagreb, Dept Internal Med, Div Hematol, Zagreb, Croatia.	drazen.pulanic@kbc-zagreb.hr	Lauc, Gordan/K-5864-2012	Lauc, Gordan/0000-0003-1840-9560; Pucic-Bakovic, Maja/0000-0003-0866-623X	Unity Through Knowledge Fund; Croatian Science Foundation [IP-2016-06-8046]; Center for Cancer Research, Intramural Research Program of the National Cancer Institute, National Institutes of Health, USA	Unity Through Knowledge Fund; Croatian Science Foundation; Center for Cancer Research, Intramural Research Program of the National Cancer Institute, National Institutes of Health, USA	This work is supported by the Unity Through Knowledge Fund project entitled "Clinical and Biological Factors Determining Severity and Activity of Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation", and also,in part, by the Croatian Science Foundation project IP-2016-06-8046 entitled "New biomarkers for chronic Graft-versus-Hostdisease". This work is supported by the Center for Cancer Research, Intramural Research Program of the National Cancer Institute, National Institutes of Health, USA. The opinions expressed here are those of the authors and do not represent the official position of the National Institutes of Health or the US Government.	Bakovic MP, 2013, J PROTEOME RES, V12, P821, DOI 10.1021/pr300887z; Davies J, 2001, BIOTECHNOL BIOENG, V74, P288, DOI 10.1002/bit.1119.abs; de Haan N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01238; de Jong SE, 2016, SCI REP-UK, V6, DOI 10.1038/srep28207; Ercan A, 2010, ARTHRITIS RHEUM-US, V62, P2239, DOI 10.1002/art.27533; Ferrara C, 2011, P NATL ACAD SCI USA, V108, P12669, DOI 10.1073/pnas.1108455108; Filipovich AH, 2008, BEST PRACT RES CL HA, V21, P251, DOI 10.1016/j.beha.2008.02.008; Gindzienska-Sieskiewicz E, 2016, ADV MED SCI-POLAND, V61, P193, DOI 10.1016/j.advms.2015.12.009; Gornik O, 2008, DIS MARKERS, V25, P267, DOI 10.1155/2008/493289; Grkovic L, 2012, LEUKEMIA, V26, P633, DOI 10.1038/leu.2011.254; Gudelj I, 2018, BBA-MOL BASIS DIS, V1864, P2034, DOI 10.1016/j.bbadis.2018.03.018; Holland M, 2006, BBA-GEN SUBJECTS, V1760, P669, DOI 10.1016/j.bbagen.2005.11.021; Inamoto Y, 2014, ARTHRITIS RHEUMATOL, V66, P1044, DOI 10.1002/art.38293; Jagasia MH, 2015, BIOL BLOOD MARROW TR, V21, P389, DOI 10.1016/j.bbmt.2014.12.001; Jefferis R, 2009, NAT REV DRUG DISCOV, V8, P226, DOI 10.1038/nrd2804; Lauc G, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003225; MALHOTRA R, 1995, NAT MED, V1, P237, DOI 10.1038/nm0395-237; Martires KJ, 2011, BLOOD, V118, P4250, DOI 10.1182/blood-2011-04-350249; National Association for the Education of Young Children & Fred Rogers Center for Early Learning and Children's Media, 2012, TRANSF CRIT BLEED MA, P1; Paczesny S, 2015, BIOL BLOOD MARROW TR, V21, P780, DOI 10.1016/j.bbmt.2015.01.003; PAREKH RB, 1988, LANCET, V1, P966; Plomp R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12495-0; Prenc E., THESIS U ZAGREB SCH; Prenc E, 2016, BBA-GEN SUBJECTS, V1860, P1615, DOI 10.1016/j.bbagen.2016.02.015; Pucic M, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.010090; Schultz KR, 2006, BIOL BLOOD MARROW TR, V12, P126, DOI 10.1016/j.bbmt.2005.11.010; Shinzaki S, 2008, AM J GASTROENTEROL, V103, P1173, DOI 10.1111/j.1572-0241.2007.01699.x; Sondermann P, 2013, P NATL ACAD SCI USA, V110, P9868, DOI 10.1073/pnas.1307864110; van de Bovenkamp FS, 2016, J IMMUNOL, V196, P1435, DOI 10.4049/jimmunol.1502136; Varki A., 2015, ESSENTIALS GLYCOBIOL; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Vuckovic F, 2015, ARTHRITIS RHEUMATOL, V67, P2978, DOI 10.1002/art.39273; Vukic T, 2016, CROAT MED J, V57, P266, DOI 10.3325/cmj.2016.57.266; Zeiser R, 2017, NEW ENGL J MED, V377, P2565, DOI 10.1056/NEJMra1703472	34	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 14	2021	12								633214	10.3389/fimmu.2021.633214	http://dx.doi.org/10.3389/fimmu.2021.633214			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TR0PX	34335560	Green Published, gold			2022-12-18	WOS:000678676500001
J	Bieberich, F; Vazquez-Lombardi, R; Yermanos, A; Ehling, RA; Mason, DM; Wagner, B; Kapetanovic, E; Di Roberto, RB; Weber, CR; Savic, M; Rudolf, F; Reddy, ST				Bieberich, Florian; Vazquez-Lombardi, Rodrigo; Yermanos, Alexander; Ehling, Roy A.; Mason, Derek M.; Wagner, Bastian; Kapetanovic, Edo; Di Roberto, Raphael Brisset; Weber, Cedric R.; Savic, Miodrag; Rudolf, Fabian; Reddy, Sai T.			A single-cell atlas of lymphocyte adaptive immune repertoires and transcriptomes reveals age-related differences in convalescent COVID-19 patients	FRONTIERS IN IMMUNOLOGY			English	Article							PLASMA-CELL; B-CELLS; DIFFERENTIATION; HOMEOSTASIS; INFERENCE; DYNAMICS; HEAVY; FATE; GENE	COVID-19 disease outcome is highly dependent on adaptive immunity from T and B lymphocytes, which play a critical role in the control, clearance and long-term protection against SARS-CoV-2. To date, there is limited knowledge on the composition of the T and B cell immune receptor repertoires [T cell receptors (TCRs) and B cell receptors (BCRs)] and transcriptomes in convalescent COVID-19 patients of different age groups. Here, we utilize single-cell sequencing (scSeq) of lymphocyte immune repertoires and transcriptomes to quantitatively profile the adaptive immune response in COVID-19 patients of varying age. We discovered highly expanded T and B cells in multiple patients, with the most expanded clonotypes coming from the effector CD8(+) T cell population. Highly expanded CD8(+) and CD4(+) T cell clones show elevated markers of cytotoxicity (CD8: PRF1, GZMH, GNLY; CD4: GZMA), whereas clonally expanded B cells show markers of transition into the plasma cell state and activation across patients. By comparing young and old convalescent COVID-19 patients (mean ages = 31 and 66.8 years, respectively), we found that clonally expanded B cells in young patients were predominantly of the IgA isotype and their BCRs had incurred higher levels of somatic hypermutation than elderly patients. In conclusion, our scSeq analysis defines the adaptive immune repertoire and transcriptome in convalescent COVID-19 patients and shows important age-related differences implicated in immunity against SARS-CoV-2.	[Bieberich, Florian; Vazquez-Lombardi, Rodrigo; Yermanos, Alexander; Ehling, Roy A.; Mason, Derek M.; Wagner, Bastian; Kapetanovic, Edo; Di Roberto, Raphael Brisset; Weber, Cedric R.; Rudolf, Fabian; Reddy, Sai T.] Swiss Fed Inst Technol, Dept Biosyst Sci & Engn, Basel, Switzerland; [Yermanos, Alexander] Swiss Fed Inst Technol, Dept Biol, Inst Microbiol & Immunol, Zurich, Switzerland; [Yermanos, Alexander] Univ Geneva, Dept Pathol & Immunol, Geneva, Switzerland; [Yermanos, Alexander; Reddy, Sai T.] Botnar Res Ctr Child Hlth, Basel, Switzerland; [Mason, Derek M.; Weber, Cedric R.; Savic, Miodrag] deepCDR Biol AG, Basel, Switzerland; [Mason, Derek M.; Weber, Cedric R.; Savic, Miodrag] Univ Basel, Dept Biomed Engn, Allschwil, Switzerland; [Savic, Miodrag] Univ Hosp Basel, Dept Surg Oral & Cranio Maxillofacial Surg, Basel, Switzerland; [Savic, Miodrag] Dept Hlth Econ & Hlth Directorate, Canton Basel Landschaft, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Geneva; University of Basel; University of Basel	Reddy, ST (corresponding author), Swiss Fed Inst Technol, Dept Biosyst Sci & Engn, Basel, Switzerland.; Reddy, ST (corresponding author), Botnar Res Ctr Child Hlth, Basel, Switzerland.	sai.reddy@ethz.ch		Bieberich, Florian/0000-0002-6678-5985; Ehling, Roy A./0000-0002-4879-8168				Altmann Daniel M, 2020, Oxf Open Immunol, V1, piqaa003, DOI 10.1093/oxfimm/iqaa003; Becht E, 2019, NAT BIOTECHNOL, V37, P38, DOI 10.1038/nbt.4314; Briney B, 2019, NATURE, V566, P393, DOI 10.1038/s41586-019-0879-y; Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902; Brummelman J, 2018, J EXP MED, V215, P2520, DOI 10.1084/jem.20180684; Chen J, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-02064-6; Cohn LB, 2018, NAT MED, V24, P604, DOI 10.1038/s41591-018-0017-7; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Davies NG, 2020, NAT MED, V26, P1205, DOI 10.1038/s41591-020-0962-9; DeKosky BJ, 2015, NAT MED, V21, P86, DOI 10.1038/nm.3743; DeKosky BJ, 2013, NAT BIOTECHNOL, V31, P166, DOI 10.1038/nbt.2492; Dewitt WS, 2018, ELIFE, V7, DOI 10.7554/eLife.38358; Egorov ES, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01618; Emerson RO, 2017, NAT GENET, V49, P659, DOI 10.1038/ng.3822; Ferretti AP, 2020, IMMUNITY, V53, P1095, DOI 10.1016/j.immuni.2020.10.006; Friedensohn S, 2017, TRENDS BIOTECHNOL, V35, P203, DOI 10.1016/j.tibtech.2016.09.010; Gaebler C, 2021, NATURE, V591, P639, DOI [10.1038/s41586-021-03207-w, 10.1101/2020.11.03.367391]; Galson JD, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.605170; Galson JD, 2015, EBIOMEDICINE, V2, P2070, DOI 10.1016/j.ebiom.2015.11.034; Gass JN, 2004, TRENDS IMMUNOL, V25, P17, DOI 10.1016/j.it.2003.11.004; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Han A, 2015, NAT BIOTECHNOL, V33, P210, DOI 10.1038/nbt0215-210c; Han XP, 2018, CELL, V173, P1307, DOI 10.1016/j.cell.2018.05.012; Howie B, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5624; Huang H, 2020, NAT BIOTECHNOL, V38, P1194, DOI 10.1038/s41587-020-0505-4; Juno JA, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0995-0; Kaltenbach H.-M., INITIAL CHARACTERISA, DOI [10.1101/2020.07.05.20145888, DOI 10.1101/2020.07.05.20145888]; Korsunsky I, 2019, NAT METHODS, V16, P1289, DOI 10.1038/s41592-019-0619-0; Laidlaw BJ, 2021, NAT REV IMMUNOL, V21, P209, DOI 10.1038/s41577-020-00446-2; Lank SM, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-378; Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9; Liu LH, 2020, NATURE, V584, P450, DOI 10.1038/s41586-020-2571-7; Lonnberg Tapio, 2017, Sci Immunol, V2, DOI 10.1126/sciimmunol.aal2192; Luecken MD, 2019, MOL SYST BIOL, V15, DOI 10.15252/msb.20188746; Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002; McInnes L., 2018, J OPEN SOURCE SOFTW, DOI [DOI 10.21105/JOSS.00861, 10.21105/joss.00861]; Niu XF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.582010; Peng YC, 2020, NAT IMMUNOL, V21, P1336, DOI [10.1038/s41590-020-0782-6, 10.1101/2020.06.05.134551]; Reddy ST, 2010, NAT BIOTECHNOL, V28, P965, DOI 10.1038/nbt.1673; Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9; Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520; ROSA FM, 1988, J IMMUNOL, V140, P1660; Rosati E, 2017, BMC BIOTECHNOL, V17, DOI 10.1186/s12896-017-0379-9; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Setliff I, 2019, CELL, V179, P1636, DOI 10.1016/j.cell.2019.11.003; Shaffer AL, 2004, IMMUNITY, V21, P81, DOI 10.1016/j.immuni.2004.06.010; Shimoda M, 2006, J IMMUNOL, V176, P2122, DOI 10.4049/jimmunol.176.4.2122; Shomuradova AS, 2020, IMMUNITY, V53, P1245, DOI 10.1016/j.immuni.2020.11.004; Shoukat MS, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100192; Singer M, 2017, CELL, V171, P1221, DOI 10.1016/j.cell.2017.11.006; Soto C, 2019, NATURE, V566, P398, DOI 10.1038/s41586-019-0934-8; Stoeckius M, 2017, NAT METHODS, V14, P865, DOI [10.1038/NMETH.4380, 10.1038/nmeth.4380]; Street K, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-4772-0; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Stubbington MJT, 2016, NAT METHODS, V13, P329, DOI [10.1038/NMETH.3800, 10.1038/nmeth.3800]; Su YP, 2020, CELL, V183, P1479, DOI 10.1016/j.cell.2020.10.037; Suan D, 2017, CURR OPIN IMMUNOL, V45, P97, DOI 10.1016/j.coi.2017.03.006; Tarke A, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100204; Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859; Tsui C, 2018, LIFE SCI ALLIANCE, V1, DOI 10.26508/lsa.201800060; Upadhyay V, 2013, NAT REV IMMUNOL, V13, P270, DOI 10.1038/nri3406; van der Maaten L, 2012, MACH LEARN, V87, P33, DOI 10.1007/s10994-011-5273-4; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Vollmers C, 2013, P NATL ACAD SCI USA, V110, P13463, DOI 10.1073/pnas.1312146110; Wabl M, 1996, CURR OPIN IMMUNOL, V8, P89, DOI 10.1016/S0952-7915(96)80110-5; Xu G, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-00225-2; Yan Jun, 2010, Immun Ageing, V7, P4, DOI 10.1186/1742-4933-7-4; Zhang JY, 2020, NAT IMMUNOL, V21, P1107, DOI 10.1038/s41590-020-0762-x	70	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 12	2021	12									10.1101/2021.02.12.430907	http://dx.doi.org/10.1101/2021.02.12.430907			31	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6G9NM		Green Submitted, Green Published			2022-12-18	WOS:000885077500001
J							Frontiers Prod Off	Detailed Multiplex Analysis of SARS-CoV-2 Specific Antibodies in COVID-19 Disease (vol 12, 695230, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						COVID-19; SARS-CoV-2; antibodies; multiplex; IgG; IgA; IgM			[Frontiers Prod Off] Frontiers Media SA, Lausanne, Switzerland		Frontiers Media SA, Lausanne, Switzerland.							Brynjolfsson SF, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.695230	1	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 12	2021	12								733897	10.3389/fimmu.2021.733897	http://dx.doi.org/10.3389/fimmu.2021.733897			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TR5AV	34326851	gold, Green Published			2022-12-18	WOS:000678977700001
J	Zhang, ZY; Liu, JQ; Wang, JY; Wang, YS				Zhang, Zhiyu; Liu, Junqian; Wang, Jingyue; Wang, Yushi			Hemophagocytic Lymphohistiocytosis Associated to Klebsiella pneumoniae Infection: A Case Report	FRONTIERS IN IMMUNOLOGY			English	Article						hemophagocytic lymphohistiocytosis; hemophagocytic syndrome; Klebsiella pneumoniae; hyperferritinemia; ferritin; intensive care unit	SECONDARY; CELLS	This is a case analysis of a 73-year-old Chinese man admitted to the cardiac intensive care unit (ICU) with fever and general pain. Based on the patient's initial condition of multi-organ function impairment and increased serum ferritin, and after a series of examinations, the patient was diagnosed with Klebsiella pneumonia-induced hemophagocytic lymphohistiocytosis (HLH). Meropenem and dexamethasone were used in combination to treat the patient, and the results were very successful. In this case report, it is further suggested that Klebsiella pneumoniae is a possible trigger of HLH, and a combination of antibiotics and corticosteroids can be effective in treating HLH. It is also recommended that doctors in the ICU of each department should pay attention to the role of hyperferritinemia in the diagnosis of HLH, and ICU admission teams should include ferritin in their monitoring.	[Zhang, Zhiyu; Liu, Junqian; Wang, Jingyue; Wang, Yushi] First Hosp Jilin Univ, Dept Cardiol, Changchun, Peoples R China	Jilin University	Wang, YS (corresponding author), First Hosp Jilin Univ, Dept Cardiol, Changchun, Peoples R China.	yushi@jlu.edu.cn		, Jingyue/0000-0001-8796-9612				Ahmed A, 2019, LANCET HAEMATOL, V6, pE630, DOI 10.1016/S2352-3026(19)30156-5; Birndt S, 2020, J CANCER RES CLIN, V146, P1065, DOI 10.1007/s00432-020-03139-4; Chen CW, 2002, J FORMOS MED ASSOC, V101, P144; Chen M, 2012, BLOOD, V119, P127, DOI 10.1182/blood-2011-06-363994; Filipovich A, 2010, BIOL BLOOD MARROW TR, V16, pS82, DOI 10.1016/j.bbmt.2009.11.014; George MR, 2014, J BLOOD MED, V5, P69, DOI 10.2147/JBM.S46255; Gill H, 2013, AM J HEMATOL, V88, P626, DOI 10.1002/ajh.23437; Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039; HENTER JI, 1991, BLOOD, V78, P2918, DOI 10.1182/blood.V78.11.2918.2918; Hibino M, 2014, INTERNAL MED, V53, P1679, DOI 10.2169/internalmedicine.53.2089; Jordan MB, 2004, BLOOD, V104, P735, DOI 10.1182/blood-2003-10-3413; Jordan MB, 2011, BLOOD, V118, P4041, DOI 10.1182/blood-2011-03-278127; Kangwanprasert Monsicha, 2005, Hawaii Med J, V64, P216; Knaak C, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02941-3; Morimoto A, 2016, PEDIATR INT, V58, P817, DOI 10.1111/ped.13064; Osugi Y, 1997, BLOOD, V89, P4100, DOI 10.1182/blood.V89.11.4100; Rajadhyaksha Anjali, 2014, J Assoc Physicians India, V62, P637; Rajajee S, 2014, INDIAN J PEDIATR, V81, P1337, DOI 10.1007/s12098-014-1461-0; Ramos-Casals M, 2014, LANCET, V383, P1503, DOI 10.1016/S0140-6736(13)61048-X; Schaffner Meredith, 2017, Am J Med Sci, V354, P152, DOI 10.1016/j.amjms.2017.04.016; Schram AM, 2015, BLOOD, V125, P2908, DOI 10.1182/blood-2015-01-551622; Tang YM, 2008, BRIT J HAEMATOL, V143, P84, DOI 10.1111/j.1365-2141.2008.07298.x; Trottestam H, 2011, BLOOD, V118, P4577, DOI 10.1182/blood-2011-06-356261; Vallurupalli M, 2019, BLOOD, V134, P1783, DOI 10.1182/blood.2019002289; Zhao YC, 2019, HEMATOLOGY, V24, P606, DOI 10.1080/16078454.2019.1660458; Zoller EE, 2011, J EXP MED, V208, P1203, DOI 10.1084/jem.20102538	26	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 12	2021	12								684805	10.3389/fimmu.2021.684805	http://dx.doi.org/10.3389/fimmu.2021.684805			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TR6MB	34335586	gold, Green Published			2022-12-18	WOS:000679075600001
J	Bos, AV; Erkelens, MN; Koenders, STA; van der Stelt, M; van Egmond, M; Mebius, RE				Bos, Amelie V.; Erkelens, Martje N.; Koenders, Sebastiaan T. A.; van der Stelt, Mario; van Egmond, Marjolein; Mebius, Reina E.			Clickable Vitamins as a New Tool to Track Vitamin A and Retinoic Acid in Immune Cells	FRONTIERS IN IMMUNOLOGY			English	Article						copper-facilitated click chemistry; retinoid probes; retinoic acid; vitamin A metabolism; CD38	CD103(+) DENDRITIC CELLS; CELLULAR UPTAKE; LAMINA PROPRIA; ALKYNE LIPIDS; T-CELLS; B-CELLS; METABOLISM; RECEPTOR; TISSUE; GENERATION	The vitamin A derivative, retinoid acid (RA) is key player in guiding adaptive mucosal immune responses. However, data on the uptake and metabolism of vitamin A within human immune cells has remained largely elusive because retinoids are small, lipophilic molecules which are difficult to detect. To overcome this problem and to be able to study the effect of vitamin A metabolism in human immune cell subsets, we have synthesized novel bio-orthogonal retinoid-based probes (clickable probes), which are structurally and functionally indistinguishable from vitamin A. The probes contain a functional group (an alkyne) to conjugate to a fluorogenic dye to monitor retinoid molecules in real-time in immune cells. We demonstrate, by using flow cytometry and microscopy, that multiple immune cells have the capacity to internalize retinoids to varying degrees, including human monocyte-derived dendritic cells (DCs) and naive B lymphocytes. We observed that naive B cells lack the enzymatic machinery to produce RA, but use exogenous retinoic acid to enhance CD38 expression. Furthermore, we showed that human DCs metabolize retinal into retinoic acid, which in co-culture with naive B cells led to of the induction of CD38 expression. These data demonstrate that in humans, DCs can serve as an exogenous source of RA for naive B cells. Taken together, through the use of clickable vitamins our data provide valuable insight in the mechanism of vitamin A metabolism and its importance for human adaptive immunity.	[Bos, Amelie V.; Erkelens, Martje N.; van Egmond, Marjolein; Mebius, Reina E.] Amsterdam Univ Med Ctr, Dept Mol Cell Biol & Immunol, Locat VUmc, Amsterdam, Netherlands; [Koenders, Sebastiaan T. A.; van der Stelt, Mario] Leiden Univ, Leiden Inst Chem, Dept Mol Physiol, Leiden, Netherlands; [van Egmond, Marjolein] Amsterdam Univ Med Ctr, Dept Surg, Locat VUmc, Amsterdam, Netherlands	Leiden University; Leiden University - Excl LUMC	Mebius, RE (corresponding author), Amsterdam Univ Med Ctr, Dept Mol Cell Biol & Immunol, Locat VUmc, Amsterdam, Netherlands.	r.mebius@amsterdamumc.nl		Mebius, Reina/0000-0003-0451-7464; Koenders, Sebastiaan/0000-0002-8486-4476	Institute for Chemical Immunology (ICI); Oncode Institute	Institute for Chemical Immunology (ICI); Oncode Institute	This project received funding from the Institute for Chemical Immunology (ICI) and Oncode Institute.	Agace WW, 2012, TRENDS IMMUNOL, V33, P42, DOI 10.1016/j.it.2011.10.001; Aibana O, 2017, CLIN INFECT DIS, V65, P900, DOI 10.1093/cid/cix476; BABLER JH, 1979, J ORG CHEM, V44, P1716, DOI 10.1021/jo01324a030; Bakdash G, 2015, MUCOSAL IMMUNOL, V8, P265, DOI 10.1038/mi.2014.64; Barua AB, 1998, MOL BIOTECHNOL, V10, P167, DOI 10.1007/BF02760863; BLOMHOFF R, 1994, NUTR REV, V52, P13; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Duester G, 2003, CHEM-BIOL INTERACT, V143, P201, DOI 10.1016/S0009-2797(02)00204-1; Fincher JA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53938-0; Gaebler A, 2016, J LIPID RES, V57, P1934, DOI 10.1194/jlr.D070565; Gaebler A, 2013, J LIPID RES, V54, P2282, DOI 10.1194/jlr.D038653; Gerco den Hartog TvO, 2018, EUR J IMMUNOL, V48, P483; Golczak M, 2008, J BIOL CHEM, V283, P9543, DOI 10.1074/jbc.M708982200; GOODMAN DS, 1965, J LIPID RES, V6, P390; Goverse G, 2015, EUR J IMMUNOL, V45, P89, DOI 10.1002/eji.201343340; Hammerschmidt SI, 2008, J EXP MED, V205, P2483, DOI 10.1084/jem.20080039; Hannoush RN, 2009, ACS CHEM BIOL, V4, P581, DOI 10.1021/cb900085z; Harrison EH, 2012, BBA-MOL CELL BIOL L, V1821, P70, DOI 10.1016/j.bbalip.2011.06.002; Huang ZY, 2018, J CLIN MED, V7, DOI 10.3390/jcm7090258; Iliev ID, 2009, GUT, V58, P1481, DOI 10.1136/gut.2008.175166; Iwata M, 2004, IMMUNITY, V21, P527, DOI 10.1016/j.immuni.2004.08.011; Jaensson E, 2008, J EXP MED, V205, P2139, DOI 10.1084/jem.20080414; Jang MH, 2006, J IMMUNOL, V176, P803, DOI 10.4049/jimmunol.176.2.803; Jijon HB, 2018, MUCOSAL IMMUNOL, V11, P703, DOI 10.1038/mi.2017.91; Jing J, 2017, J PHARMACOL EXP THER, V361, P246, DOI 10.1124/jpet.117.240523; Johansson-Lindbom B, 2005, J EXP MED, V202, P1063, DOI 10.1084/jem.20051100; Kawaguchi R, 2007, SCIENCE, V315, P820, DOI 10.1126/science.1136244; Kawaguchi R, 2015, MEMBRANES, V5, P425, DOI 10.3390/membranes5030425; Kawaguchi R, 2011, ACS CHEM BIOL, V6, P1041, DOI 10.1021/cb200178w; Kim MJ, 2014, J PERIODONTAL IMPLAN, V44, P235, DOI 10.5051/jpis.2014.44.5.235; Koenders STA, 2019, ACS CENTRAL SCI, V5, P1965, DOI 10.1021/acscentsci.9b01022; Lambertin F, 1999, EUR J ORG CHEM, V1999, P1489, DOI 10.1002/(SICI)1099-0690(199906)1999:6<1489::AID-EJOC1489>3.0.CO;2-1; Lee JM, 2016, CELL MOL IMMUNOL, V13, P862, DOI 10.1038/cmi.2015.73; Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200; Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200; Magnusson MK, 2016, MUCOSAL IMMUNOL, V9, P171, DOI 10.1038/mi.2015.48; McDonald KG, 2012, AM J PATHOL, V180, P984, DOI 10.1016/j.ajpath.2011.11.009; Molenaar R, 2011, J IMMUNOL, V186, P1934, DOI 10.4049/jimmunol.1001672; Molenaar R, 2009, J IMMUNOL, V183, P6395, DOI 10.4049/jimmunol.0900311; Mora JR, 2006, SCIENCE, V314, P1157, DOI 10.1126/science.1132742; Morikawa K, 2005, INT IMMUNOPHARMACOL, V5, P1830, DOI 10.1016/j.intimp.2005.06.002; Pantazi E, 2015, J IMMUNOL, V195, P1368, DOI 10.4049/jimmunol.1500989; Robichaud PP, 2016, J LIPID RES, V57, P1821, DOI 10.1194/jlr.M067637; Roe MM, 2017, J LEUKOCYTE BIOL, V101, P1169, DOI 10.1189/jlb.1MA0316-131R; Bono MR, 2016, NUTRIENTS, V8, DOI 10.3390/nu8060349; Ross AC, 2011, VITAM HORM, V86, P103, DOI 10.1016/B978-0-12-386960-9.00005-8; Roy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082121; Sandell LL, 2007, GENE DEV, V21, P1113, DOI 10.1101/gad.1533407; Seo GY, 2014, HUM IMMUNOL, V75, P923, DOI 10.1016/j.humimm.2014.06.021; Seo GY, 2013, J LEUKOCYTE BIOL, V94, P325, DOI 10.1189/jlb.0313128; Soethoudt M, 2018, J AM CHEM SOC, V140, P6067, DOI 10.1021/jacs.7b11281; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Svensson M, 2008, MUCOSAL IMMUNOL, V1, P38, DOI 10.1038/mi.2007.4; Thiele C, 2012, ACS CHEM BIOL, V7, P2004, DOI 10.1021/cb300414v; Thomas S, 2005, BRIT J NUTR, V93, P59, DOI 10.1079/BJN20041306; Thorne-Lyman A, 2012, NESTLE NUTR WORKS SE, V70, P79, DOI 10.1159/000337445; Tobias F, 2018, J LIPID RES, V59, P2446, DOI 10.1194/jlr.D086090; Villablanca EJ, 2011, GASTROENTEROLOGY, V141, P176, DOI 10.1053/j.gastro.2011.04.010; Vsianska P, 2017, EUR J HAEMATOL, V98, P19, DOI 10.1111/ejh.12779; Watchmaker PB, 2014, NAT IMMUNOL, V15, P98, DOI 10.1038/ni.2768	60	0	0	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 8	2021	12								671283	10.3389/fimmu.2021.671283	http://dx.doi.org/10.3389/fimmu.2021.671283			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TM5KZ	34305901	gold, Green Published			2022-12-18	WOS:000675589800001
J	Dai, RX; Lv, G; Li, WY; Tang, WJ; Chen, JJ; Liu, Q; Yang, L; Zhang, M; Tian, ZR; Zhou, LN; Yan, X; Wang, YT; Ding, Y; An, YF; Zhang, ZY; Tang, XM; Zhao, XD				Dai, Rongxin; Lv, Ge; Li, Wenyan; Tang, Wenjing; Chen, Junjie; Liu, Qiao; Yang, Lu; Zhang, Min; Tian, Zhirui; Zhou, Lina; Yan, Xin; Wang, Yating; Ding, Yuan; An, Yunfei; Zhang, Zhiyong; Tang, Xuemei; Zhao, Xiaodong			Altered Functions of Neutrophils in Two Chinese Patients With Severe Congenital Neutropenia Type 4 Caused by G6PC3 Mutations	FRONTIERS IN IMMUNOLOGY			English	Article						G6PC3; neutrophils; severe congenital neutropenia; NETs; G-CSF treatment; apoptosis	EXTRACELLULAR TRAPS; CELL-DEATH; APOPTOSIS; ACTIVATION; MITOCHONDRIA; RECRUITMENT; DYSFUNCTION; DEFICIENCY; ELASTASE; RELEASE	Background SCN4 is an autosomal recessive disease caused by mutations in the G6PC3 gene. The clinical, molecular, and immunological features; function of neutrophils; and prognosis of patients with SCN4 have not been fully elucidated. Methods Two Chinese pediatric patients with G6PC3 mutations were enrolled in this study. Clinical data, genetic and immunologic characteristics, and neutrophil function were evaluated in patients and controls before and after granulocyte colony-stimulating factor (G-CSF) treatment. Results Both patients had histories of pneumonia, inguinal hernia, cryptorchidism, and recurrent oral ulcers. Patient 1 also had asthma and otitis media, and patient 2 presented with prominent ectatic superficial veins and inflammatory bowel disease. DNA sequencing demonstrated that both patients harbored heterozygous G6PC3 gene mutations. Spontaneous and FAS-induced neutrophil apoptosis were significantly increased in patients, and improved only slightly after G-CSF treatment, while neutrophil respiratory burst and neutrophil extracellular traps production remained impaired in patients after G-CSF treatment. Conclusion G-CSF treatment is insufficient for patients with SCN4 patients, who remain at risk of infection. Where possible, regular G-CSF treatment, long-term prevention of infection, are the optimal methods for cure of SCN4 patients. It is important to monitor closely for signs of leukemia in SCN4 patients. Once leukemia occurs in SCN4 patients, hematopoietic stem cell transplantation is the most important choice of treatment.	[Dai, Rongxin; Tang, Wenjing; Yan, Xin; Wang, Yating; An, Yunfei; Zhang, Zhiyong; Tang, Xuemei] Chongqing Med Univ, Childrens Hosp, Dept Rheumatol & Immunol, Chongqing, Peoples R China; [Dai, Rongxin; Lv, Ge; Li, Wenyan; Tang, Wenjing; Chen, Junjie; Liu, Qiao; Yang, Lu; Zhang, Min; Tian, Zhirui; Zhou, Lina; Yan, Xin; Wang, Yating; Ding, Yuan; An, Yunfei; Zhang, Zhiyong; Tang, Xuemei; Zhao, Xiaodong] Chongqing Med Univ, Childrens Hosp, Natl Clin Res Ctr Child Hlth & Disorders, Chongqing, Peoples R China; [Dai, Rongxin; Lv, Ge; Li, Wenyan; Tang, Wenjing; Chen, Junjie; Liu, Qiao; Yang, Lu; Zhang, Min; Tian, Zhirui; Zhou, Lina; Yan, Xin; Wang, Yating; Ding, Yuan; An, Yunfei; Zhang, Zhiyong; Tang, Xuemei; Zhao, Xiaodong] Chongqing Med Univ, Childrens Hosp, Key Lab Child Dev & Disorders, Minist Educ, Chongqing, Peoples R China; [Dai, Rongxin; Lv, Ge; Li, Wenyan; Tang, Wenjing; Chen, Junjie; Liu, Qiao; Yang, Lu; Zhang, Min; Tian, Zhirui; Zhou, Lina; Yan, Xin; Wang, Yating; Ding, Yuan; An, Yunfei; Zhang, Zhiyong; Tang, Xuemei; Zhao, Xiaodong] Chongqing Med Univ, Childrens Hosp, Chongqing Key Lab Child Infect & Immun, Chongqing, Peoples R China	Chongqing Medical University; Chongqing Medical University; Chongqing Medical University; Chongqing Medical University	Li, WY; Zhao, XD (corresponding author), Chongqing Med Univ, Childrens Hosp, Natl Clin Res Ctr Child Hlth & Disorders, Chongqing, Peoples R China.; Li, WY; Zhao, XD (corresponding author), Chongqing Med Univ, Childrens Hosp, Key Lab Child Dev & Disorders, Minist Educ, Chongqing, Peoples R China.; Li, WY; Zhao, XD (corresponding author), Chongqing Med Univ, Childrens Hosp, Chongqing Key Lab Child Infect & Immun, Chongqing, Peoples R China.	liwenyan32@126.com; zhaoxd530@aliyun.com		An, Yunfei/0000-0001-9664-1256	National Natural Science Foundation of China [81801637, 81620108014]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (81801637, 81620108014).	Alizadeh Z, 2011, IRAN J ALLERGY ASTHM, V10, P227, DOI 010.03/ijaai.227230; Aytekin C, 2013, J PEDIAT HEMATOL ONC, V35, pE81, DOI 10.1097/MPH.0b013e3182679000; Banka S, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-84; Banka S, 2010, AM J MED GENET A, V152A, P2609, DOI 10.1002/ajmg.a.33615; Begin P, 2013, J CLIN IMMUNOL, V33, P520, DOI 10.1007/s10875-012-9833-6; Bjornsdottir H, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00257; Bjornsdottir H, 2015, FREE RADICAL BIO MED, V89, P1024, DOI 10.1016/j.freeradbiomed.2015.10.398; Borregaard N, 2010, IMMUNITY, V33, P657, DOI 10.1016/j.immuni.2010.11.011; Boztug K, 2012, J PEDIATR-US, V160, P679, DOI 10.1016/j.jpeds.2011.09.019; Boztug K, 2009, NEW ENGL J MED, V360, P32, DOI 10.1056/NEJMoa0805051; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Cheung YY, 2007, J CLIN INVEST, V117, P784, DOI 10.1172/JCI30443; DANCEY JT, 1976, J CLIN INVEST, V58, P705, DOI 10.1172/JCI108517; Demers M, 2012, P NATL ACAD SCI USA, V109, P13076, DOI 10.1073/pnas.1200419109; Desplantes C, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023-014-0183-8; Fernandez BA, 2012, BMC MED GENET, V13, DOI 10.1186/1471-2350-13-111; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Guionie O, 2003, FEBS LETT, V551, P159, DOI 10.1016/S0014-5793(03)00903-7; Hampson P, 2013, CURR OPIN HEMATOL, V20, P10, DOI 10.1097/MOH.0b013e32835b06be; Hayee B, 2011, GLYCOBIOLOGY, V21, P914, DOI 10.1093/glycob/cwr023; Hoffmann D, 2020, GENE THER, V27, P297, DOI 10.1038/s41434-020-0127-y; Jun HS, 2011, BLOOD, V117, P3881, DOI 10.1182/blood-2010-08-302059; Jun HS, 2010, BLOOD, V116, P2783, DOI 10.1182/blood-2009-12-258491; Kim SY, 2008, BLOOD, V111, P5704, DOI 10.1182/blood-2007-12-129114; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Kotone-Miyahara Y, 2004, J LEUKOCYTE BIOL, V76, P1047, DOI 10.1189/jlb.0104048; Liu Q, 2019, BMC PEDIATR, V19, DOI 10.1186/s12887-019-1556-x; Maianski NA, 2004, J IMMUNOL, V172, P7024, DOI 10.4049/jimmunol.172.11.7024; Maianski NA, 2002, BLOOD, V99, P672, DOI 10.1182/blood.V99.2.672; Mantovani A, 2011, NAT REV IMMUNOL, V11, P519, DOI 10.1038/nri3024; Marin-Esteban V, 2012, INFECT IMMUN, V80, P1891, DOI 10.1128/IAI.00050-12; McDermott DH, 2010, BLOOD, V116, P2793, DOI 10.1182/blood-2010-01-265942; Metzler KD, 2014, CELL REP, V8, P883, DOI 10.1016/j.celrep.2014.06.044; Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052; Rodriguez-Espinosa O, 2015, IMMUNOLOGY, V145, P213, DOI 10.1111/imm.12437; Rosenberg PS, 2010, BRIT J HAEMATOL, V150, P196, DOI 10.1111/j.1365-2141.2010.08216.x; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scheel-Toellner D, 2004, BLOOD, V104, P2557, DOI 10.1182/blood-2004-01-0191	39	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 8	2021	12								699743	10.3389/fimmu.2021.699743	http://dx.doi.org/10.3389/fimmu.2021.699743			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TM4PZ	34305938	gold, Green Published			2022-12-18	WOS:000675534400001
J	Fevang, B; Warnatz, K; Hurst, JR				Fevang, Borre; Warnatz, Klaus; Hurst, John R.			Editorial: Interstitial Lung Disease in Primary Immunodeficiencies	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						interstitial lung disease (ILD); primary immunodeficencies (PID); common variable immune deficiency (CVID); granulomatous lymphocytic interstitial lung disease (GLILD); APECED; Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy			[Fevang, Borre] Oslo Univ Hosp, Sect Clin Immunol & Infect Dis, Oslo, Norway; [Fevang, Borre] Oslo Univ Hosp, Internal Med Res Inst, Oslo, Norway; [Fevang, Borre] Oslo Univ Hosp, Ctr Rare Dis, Oslo, Norway; [Warnatz, Klaus] Univ Freiburg, Med Ctr, Dept Rheumatol & Clin Immunol, Fac Med, Freiburg, Germany; [Warnatz, Klaus] Univ Freiburg, Fac Med, Med Ctr, Ctr Chron Immunodeficiency, Freiburg, Germany; [Hurst, John R.] UCL, UCL Resp, London, England	University of Oslo; University of Oslo; University of Oslo; University of Freiburg; University of Freiburg; University of London; University College London	Fevang, B (corresponding author), Oslo Univ Hosp, Sect Clin Immunol & Infect Dis, Oslo, Norway.; Fevang, B (corresponding author), Oslo Univ Hosp, Internal Med Res Inst, Oslo, Norway.; Fevang, B (corresponding author), Oslo Univ Hosp, Ctr Rare Dis, Oslo, Norway.	borre.fevang@medisin.uio.no	Warnatz, Klaus/AAD-3464-2022	Hurst, John/0000-0002-7246-6040				Bates CA, 2004, J ALLERGY CLIN IMMUN, V114, P415, DOI 10.1016/j.jaci.2004.05.057; Chase NM, 2013, J CLIN IMMUNOL, V33, P30, DOI 10.1007/s10875-012-9755-3; Ho HE, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00149; Hurst JR, 2017, J ALLER CL IMM-PRACT, V5, P938, DOI 10.1016/j.jaip.2017.01.021	4	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 8	2021	12								699126	10.3389/fimmu.2021.699126	http://dx.doi.org/10.3389/fimmu.2021.699126			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TS0DE	34305936	gold, Green Published			2022-12-18	WOS:000679326200001
J	Kostinov, MP; Akhmatova, NK; Karpocheva, SV; Vlasenko, AE; Polishchuk, VB; Kostinov, AM				Kostinov, Mikhail Petrovich; Akhmatova, Nelli Kimovna; Karpocheva, Svetlana Victorovna; Vlasenko, Anna Egorovna; Polishchuk, Valentina Borisovna; Kostinov, Anton Mikhailovich			Vaccination Against Diphtheria and Tetanus as a Way to Activate Adaptive Immunity in Children with Solid Tumors	FRONTIERS IN IMMUNOLOGY			English	Article						solid tumors; vaccination in children; diphtheria and tetanus toxoid; T-lymphocytes; post-vaccination antibodies	BONE-MARROW-TRANSPLANTATION; LYMPHOCYTE RECOVERY; MYELOID-LEUKEMIA; CELL; IMMUNIZATION; SURVIVAL	Early studies on vaccination of children with oncological diseases were only dedicated to the assessment of safety and immunogenicity of the drug. Mechanisms of the post-vaccination immune response were not investigated. This study involved 41 patients aged 7-15 years who were treated for solid tumors two or more years ago. Of these, 26 were vaccinated against diphtheria and tetanus with ADS-m toxoid. Fifteen children (i.e., controls) were not vaccinated. The vaccination tolerability and clinical characteristics of the underlying disease remission ware assessed. Lymphocyte subpopulations were investigated over time by flow cytometry at 1, 6, and 12 months. IgG anti-diphtheria and anti-tetanus toxoids levels were assessed by ELISA. Within the first day of the post-vaccination period, two (7.7%) children demonstrated moderate local reactions and increased body temperature (up to 38.0 degrees C). Relapse and metastasis were not mentioned within a year after immunization. An increase in concentration of IgG antibodies, maintained for 12 months, were noted [2.1 (1.3-3.4) IU/ml against diphtheria (p <0.001), 6.4 (2.3-9.7) IU/ml against tetanus (p <0.001)]. In contrast to healthy children, those with a history of cancer demonstrated a decrease in the relative number of mature T lymphocytes, as well as in absolute number of cytotoxic T cells and B lymphocytes. In a month after the revaccination, a significant increase in absolute (p = 0.04) and relative (p = 0.007) numbers of T lymphocytes and T helpers was revealed. In a year, these values decreased to baseline levels. As for helpers, they decreased below baseline and control values (p = 0.004). In a year after the vaccination, there was a significant (p = 0.05) increase in lymphocyte level with a decrease in the number of NK cells and B cells as compared with controls. Revaccination against diphtheria and tetanus promoted proliferation of a total lymphocytic cell pool along with restoration of the T lymphocyte subpopulation in children with a history of solid tumors. The ADS-m toxoid has a certain nonspecific immunomodulatory effect. These findings are important, also in the midst of the coronavirus pandemic.	[Kostinov, Mikhail Petrovich; Karpocheva, Svetlana Victorovna; Polishchuk, Valentina Borisovna; Kostinov, Anton Mikhailovich] II Mechnikov Res Inst Vaccines & Sera, Dept Allergol, Moscow, Russia; [Kostinov, Mikhail Petrovich] Sechenov First Moscow State Med Univ, Dept Epidemiol & Modern Vaccinat Technol, Moscow, Russia; [Akhmatova, Nelli Kimovna] II Mechnikov Res Inst Vaccines & Sera, Dept Immunol, Moscow, Russia; [Vlasenko, Anna Egorovna] Russian Med Acad Continuous Profess Educ, Novokuznetsk State Inst Adv Training Phys, Dept Med Cybernet & Comp Sci, Branch Campus, Novokuznetsk, Russia	Russian Academy of Medical Sciences; Research Institute of Vaccines and Sera Mechnikov, RAMS; Sechenov First Moscow State Medical University; Russian Academy of Medical Sciences; Research Institute of Vaccines and Sera Mechnikov, RAMS	Kostinov, AM (corresponding author), II Mechnikov Res Inst Vaccines & Sera, Dept Allergol, Moscow, Russia.	amkostinov@gmail.com	Polishchuk, Valentina/AAH-4625-2021; Kostinov, Mikhail P/J-8296-2018; Vlasenko, Anna/S-7260-2016	Vlasenko, Anna/0000-0001-6454-4216				Admiraal R, 2016, BONE MARROW TRANSPL, V51, P1376, DOI 10.1038/bmt.2016.116; Apostolico JD, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/1459394; Awate S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00114; Chuchalin AG., 2015, CLIN GUIDELINES PU S CLIN GUIDELINES PU S, V2, P1; Fedele R, 2012, BLOOD TRANSFUS-ITALY, V10, P174, DOI 10.2450/2012.0034-11; Goldberg JD, 2017, LEUKEMIA LYMPHOMA, V58, P1859, DOI 10.1080/10428194.2016.1265113; Kostinov MP., 2004, CLIN IMMUNE EFFECTIV, V256; Kostinov MP, 2013, VACCINATION CHILDREN, V4th, P432; Kostinov MP, 1996, VACCINATION CHILDREN, V78; Kostinov MP., 1997, NEW CLIN DIAGNOSTICS, V110; KUNG FH, 1984, PEDIATRICS, V74, P86; Kwon HJ, 2012, J KOREAN MED SCI, V27, P78, DOI 10.3346/jkms.2012.27.1.78; Larenas-Linnemann D, 2020, WORLD ALLERGY ORGAN, V13, DOI 10.1016/j.waojou.2020.100476; Le Blanc K, 2009, BIOL BLOOD MARROW TR, V15, P1108, DOI 10.1016/j.bbmt.2009.05.015; Maury S, 2001, BRIT J HAEMATOL, V115, P630, DOI 10.1046/j.1365-2141.2001.03135.x; Nixon AB, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0799-2; Powles R, 1998, BLOOD, V91, P3481, DOI 10.1182/blood.V91.9.3481.3481_3481_3486; Remund Kaspar F, 2009, Proc Am Thorac Soc, V6, P94, DOI 10.1513/pats.200809-113GO; RIDGWAY D, 1993, LEUKEMIA LYMPHOMA, V9, P177, DOI 10.3109/10428199309147369; Rubin LG, 2014, CLIN INFECT DIS, V58, P309, DOI [10.1093/cid/cit684, 10.1093/cid/cit816]; Small TN, 1999, BLOOD, V93, P467, DOI 10.1182/blood.V93.2.467.402k22_467_480; Storek J, 1997, AM J HEMATOL, V54, P131, DOI 10.1002/(SICI)1096-8652(199702)54:2<131::AID-AJH6>3.0.CO;2-Y; Takahama Y, 2006, NAT REV IMMUNOL, V6, P127, DOI 10.1038/nri1781; van Tilburg CM, 2011, BRIT J HAEMATOL, V152, P201, DOI 10.1111/j.1365-2141.2010.08478.x; Velardi E, 2021, NAT REV IMMUNOL, V21, P277, DOI 10.1038/s41577-020-00457-z	25	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 8	2021	12								696816	10.3389/fimmu.2021.696816	http://dx.doi.org/10.3389/fimmu.2021.696816			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TM4DZ	34305933	gold, Green Published			2022-12-18	WOS:000675502800001
J	Perez, EE; Hebert, J; Ellis, AK; Alpan, O; Lumry, WR; Shapiro, R; Suez, D; Mandujano, JF; Wasserman, RL				Perez, Elena E.; Hebert, Jacques; Ellis, Anne K.; Alpan, Oral; Lumry, William R.; Shapiro, Ralph; Suez, Daniel; Mandujano, J. Fernando; Wasserman, Richard L.			Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies	FRONTIERS IN IMMUNOLOGY			English	Article						primary immunodeficiency disease; inborn errors of immunity; immune globulin intravenous; intravenous immune globulin; immunoglobulin replacement therapy; IVIG; IgG; GC5107	LIQUID; PHARMACOKINETICS; DISEASES; MULTICENTER; 5-PERCENT; PRODUCT	We report here the results of a phase 3 study to assess the efficacy, safety, and tolerability of GC5107, a new 10% liquid intravenous immunoglobulin (IVIG) in preventing serious bacterial infections in patients with primary immunodeficiency (ClinicalTrials.gov: NCT02783482). Over a 12-month study period, 49 patients aged 3 to 70 years with a confirmed diagnosis of primary immunodeficiency received GC5107 at doses ranging from 319 to 881 mg/kg body weight every 21 or 28 days, according to their previous IVIG maintenance therapy. A total of 667 infusions of GC5107 were administered comprising a total of 45.86 patient-years of treatment. A single acute serious bacterial infection occurred during the study, resulting in an incidence of 0.02 events per patient-year (upper 99% one-sided confidence interval limit: 0.21), meeting the prespecified primary efficacy endpoint. The mean incidence of infections other than acute serious bacterial infections was 2.9 infections per patient-year. Efficacy was also demonstrated by the low mean annualized rate of hospitalizations due to infection (0.1 day) and the mean annualized duration of hospitalizations (0.1 day). The mean rate of intravenous and oral antibiotic use was 0.1 day and 13.2 days, respectively. There was a mean of 7.1 days of missed work, school, or daycare days. The proportion of infusions with temporally associated adverse events (TAAEs) occurring during or within 72 hours after GC5107 infusion was 0.24 (upper 95% one-sided confidence interval limit: 0.31), meeting the pre-specified primary safety endpoint. Overall, 149 of 667 infusions (22%) were associated with TAAEs. The most common TAAE was headache, reported by 49% of patients. More than 98% (731/743) of all adverse events that occurred throughout the 12-month study period were mild or moderate. More than 98% of infusions were completed without discontinuation, interruption or rate reduction. There were no treatment-emergent serious adverse events related to GC5107 or study discontinuations due to an adverse event. Overall, pharmacokinetic parameters for GC5107 were within the range of those reported in studies of other marketed IVIG products. Results of the present study demonstrate that GC5107 is an effective, safe and well-tolerated treatment for patients with primary immunodeficiency.	[Perez, Elena E.] Allergy Associates Palm Beaches, North Palm Beach, FL USA; [Hebert, Jacques] Laval Univ, Dept Med, Quebec City, PQ, Canada; [Ellis, Anne K.] Queens Univ, Div Allergy & Immunol, Dept Med, Kingston, ON, Canada; [Alpan, Oral] O&O Alpan, Sect Immunopathogenesis, Fairfax, VA USA; [Lumry, William R.] Allergy & Asthma Res Associates Res Ctr, Dallas, TX USA; [Shapiro, Ralph] Midwest Immunol Clin, Dept Immunol, Plymouth, MN USA; [Suez, Daniel] Allergy Asthma & Immunol Clin PA, Irving, TX USA; [Mandujano, J. Fernando] Pediat Pulm Associates North Texas, Frisco, TX USA; [Wasserman, Richard L.] Allergy Partners North Texas Res, Dallas, TX 75230 USA	Laval University; Queens University - Canada	Wasserman, RL (corresponding author), Allergy Partners North Texas Res, Dallas, TX 75230 USA.	drrichwasserman@gmail.com			GC Pharma, Korea	GC Pharma, Korea	This study was funded by GC Pharma, Korea.	Berger M, 2007, J CLIN IMMUNOL, V27, P628, DOI 10.1007/s10875-007-9107-x; Berger M, 2010, J CLIN IMMUNOL, V30, P321, DOI 10.1007/s10875-009-9348-y; Borte M, 2017, J CLIN IMMUNOL, V37, P603, DOI 10.1007/s10875-017-0424-4; Bousfiha A, 2020, J CLIN IMMUNOL, V40, P66, DOI 10.1007/s10875-020-00758-x; Chinn IK, 2020, J ALLERGY CLIN IMMUN, V145, P46, DOI 10.1016/j.jaci.2019.09.009; Church JA, 2006, J CLIN IMMUNOL, V26, P388, DOI 10.1007/s10875-006-9025-3; Edington HJ, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28260; Hagan JB, 2010, J CLIN IMMUNOL, V30, P734, DOI 10.1007/s10875-010-9423-4; Hartmann J, 2020, TRANSFUSION, V60, P2748, DOI 10.1111/trf.16078; Kobayashi RH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00040; McCusker C, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223-018-0290-5; Milgrom H, 1998, ANN ALLERG ASTHMA IM, V81, P97, DOI 10.1016/S1081-1206(10)62792-5; Moy JN, 2010, CLIN EXP IMMUNOL, V162, P510, DOI 10.1111/j.1365-2249.2010.04247.x; Ochs HD, 2006, J CLIN IMMUNOL, V26, P265, DOI 10.1007/s10875-006-9021-7; Ochs HD, 2004, J CLIN IMMUNOL, V24, P309, DOI 10.1023/B:JOCI.0000025453.23817.3f; Park DH, 2017, BIOLOGICALS, V45, P1, DOI 10.1016/j.biologicals.2016.11.002; Perez EE, 2017, J ALLERGY CLIN IMMUN, V139, pS1, DOI 10.1016/j.jaci.2016.09.023; Schroeder HW, 2012, INFECTION, V40, P601, DOI 10.1007/s15010-012-0323-9; Stein MR, 2009, J CLIN IMMUNOL, V29, P137, DOI 10.1007/s10875-008-9231-2; Suez D, 2016, J CLIN IMMUNOL, V36, P700, DOI 10.1007/s10875-016-0327-9; Tangye SG, 2020, J CLIN IMMUNOL, V40, P24, DOI 10.1007/s10875-019-00737-x; *US FDA, 2008, GUID IND SAF EFF PHA; Wasserman R, 2016, J CLIN IMMUNOL, V36, P590, DOI 10.1007/s10875-016-0308-z; Wasserman RL, 2012, J CLIN IMMUNOL, V32, P663, DOI 10.1007/s10875-012-9656-5; Wasserman RL, 2011, J CLIN IMMUNOL, V31, P323, DOI 10.1007/s10875-011-9512-z; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	26	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 8	2021	12								707463	10.3389/fimmu.2021.707463	http://dx.doi.org/10.3389/fimmu.2021.707463			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TM5HK	34305948	Green Published, gold			2022-12-18	WOS:000675580400001
J	Svanberg, C; Ellegard, R; Crisci, E; Khalid, M; Wodlin, NB; Svenvik, M; Nystrom, S; Birse, K; Burgener, A; Shankar, EM; Larsson, M				Svanberg, Cecilia; Ellegard, Rada; Crisci, Elisa; Khalid, Mohammad; Wodlin, Ninnie Borendal; Svenvik, Maria; Nystrom, Sofia; Birse, Kenzie; Burgener, Adam; Shankar, Esaki M.; Larsson, Marie			Complement-Opsonized HIV Modulates Pathways Involved in Infection of Cervical Mucosal Tissues: A Transcriptomic and Proteomic Study (vol 12, 625649, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						cervical tissue; complement opsonized HIV-1; innate immunity; primary infection; proteomics; transcriptomics; HIV-human immunodeficiency virus			[Svanberg, Cecilia; Ellegard, Rada; Crisci, Elisa; Khalid, Mohammad; Nystrom, Sofia; Larsson, Marie] Linkoping Univ, Dept Biomed & Clin Sci, Div Mol Med & Virol, Linkoping, Sweden; [Wodlin, Ninnie Borendal] Univ Hosp, Dept Obstet & Gynecol, Linkoping, Sweden; [Svenvik, Maria] Dept Obstet & Gynecol, Kalmar, Region Kalmar C, Sweden; [Svenvik, Maria; Nystrom, Sofia] Linkoping Univ, Dept Biomed & Clin Sci, Linkoping, Sweden; [Nystrom, Sofia] Linkoping Univ, Dept Clin Immunol & Transfus Med, Linkoping, Sweden; [Birse, Kenzie] Publ Hlth Agcy Canada, JC Wilt Infect Dis Res Ctr, Natl HIV & Retrovirol Labs, Winnipeg, MB, Canada; [Burgener, Adam] Case Western Reserve Univ, Sch Med, Ctr Global Hlth & Dis, Cleveland, OH USA; [Shankar, Esaki M.] Cent Univ Tamil Nadu, Dept Life Sci, Infect Biol, Thiruvarur, India	Linkoping University; Linkoping University; Linkoping University; Public Health Agency of Canada; Case Western Reserve University; Central University of Tamil Nadu	Larsson, M (corresponding author), Linkoping Univ, Dept Biomed & Clin Sci, Div Mol Med & Virol, Linkoping, Sweden.	marie.larsson@liu.se	NystrÃm, Sofia/GYQ-5893-2022; Crisci, Elisa/AAF-9263-2020	Crisci, Elisa/0000-0002-4235-8508				Svanberg C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.625649	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 8	2021	12								730130	10.3389/fimmu.2021.730130	http://dx.doi.org/10.3389/fimmu.2021.730130			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TM5KD	34305955	Green Published, gold			2022-12-18	WOS:000675587600001
J	Hottler, A; Marz, L; Lubke, M; Rammensee, HG; Stevanovic, S				Hoettler, Alexander; Maerz, Leo; Luebke, Maren; Rammensee, Hans-Georg; Stevanovic, Stefan			Broad and Efficient Activation of Memory CD4(+) T Cells by Novel HAdV- and HCMV-Derived Peptide Pools	FRONTIERS IN IMMUNOLOGY			English	Article						promiscuous CD4(+) T-cell epitopes; epitope prediction; antiviral T cells; HCMV (human cytomegalovirus); HAdV (human adenovirus); peptide pools; adoptive T-Cell therapy; HLA class II	EXTENSIVE CROSS-REACTIVITY; ADENOVIRUS-SPECIFIC CD4(+); HUMAN CYTOMEGALOVIRUS; STEM-CELL; PROTEIN PP65; HLA-DR; ADOPTIVE TRANSFER; 3RD-PARTY DONORS; CMV INFECTION; UNITED-STATES	Reactivation of Human Cytomegalovirus (HCMV) and Human Adenovirus (HAdV) in immunocompromised patients following stem cell transplantation (SCT) or solid organ transplantation (SOT) is associated with high morbidity and mortality. The adoptive transfer of virus-specific CD8(+) and CD4(+) T cells has been shown to re-establish the antiviral T-cell response and improve clinical outcome. The viral load in immunocompromised patients can efficiently be reduced solely by the infusion of virus-specific CD4(+) T cells. The identification of CD4(+) T-cell epitopes has mainly focused on a limited number of viral proteins that were characterized as immunodominant. Here, we used in silico prediction to determine promiscuous CD4(+) T-cell epitopes from the entire proteomes of HCMV and HAdV. Immunogenicity testing with enzyme-linked immuno spot (ELISpot) assays and intracellular cytokine staining (ICS) revealed numerous novel CD4(+) T-cell epitopes derived from a broad spectrum of viral antigens. We identified 17 novel HCMV-derived and seven novel HAdV-derived CD4(+) T-cell epitopes that were recognized by > 50% of the assessed peripheral blood mononuclear cell (PBMC) samples. The newly identified epitopes were pooled with previously published, retested epitopes to stimulate virus-specific memory T cells in PBMCs from numerous randomly selected blood donors. Our peptide pools induced strong IFN gamma secretion in 46 out of 48 (HCMV) and 31 out of 31 (HAdV) PBMC cultures. In conclusion, we applied an efficient method to screen large viral proteomes for promiscuous CD4(+) T-cell epitopes to improve the detection and isolation of virus-specific T cells in a clinical setting.	[Hoettler, Alexander; Maerz, Leo; Luebke, Maren; Rammensee, Hans-Georg; Stevanovic, Stefan] Univ Tubingen, Dept Immunol, Inst Cell Biol, Tubingen, Germany; [Rammensee, Hans-Georg; Stevanovic, Stefan] German Canc Res Ctr, Partner Site Tubingen, Tubingen, Germany; [Rammensee, Hans-Georg; Stevanovic, Stefan] German Canc Consortium DKTK, Partner Site Tubingen, Tubingen, Germany; [Rammensee, Hans-Georg; Stevanovic, Stefan] Univ Tubingen, Cluster Excellence iFIT Image Guided & Funct Inst, Tubingen, Germany; [Stevanovic, Stefan] German Ctr Infect Res DZIF, Partner Site Tubingen, Tubingen, Germany	Eberhard Karls University of Tubingen; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Eberhard Karls University of Tubingen; German Center for Infection Research	Marz, L (corresponding author), Univ Tubingen, Dept Immunol, Inst Cell Biol, Tubingen, Germany.	leo.maerz@gmx.de			IZKF Promotionskolleg of the Faculty of Medicine Tubingen [2018-2]; Integrated Research Training Group [SFB 685]; National Center for Infection Research (DZIF); University of Tubingen	IZKF Promotionskolleg of the Faculty of Medicine Tubingen; Integrated Research Training Group; National Center for Infection Research (DZIF); University of Tubingen	AH was supported by the IZKF Promotionskolleg of the Faculty of Medicine Tubingen (2018-2). LM was supported by the Integrated Research Training Group SFB 685. Part of this work was supported by the National Center for Infection Research (DZIF), partner site Tubingen. We acknowledge support by the Open Access Publishing Fund of the University of Tubingen.	Akter P, 2003, J GEN VIROL, V84, P1117, DOI 10.1099/vir.0.18952-0; Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049; Binder AM, 2017, MMWR-MORBID MORTAL W, V66, P1039, DOI 10.15585/mmwr.mm6639a2; Bitmansour AD, 2001, J IMMUNOL, V167, P1151, DOI 10.4049/jimmunol.167.3.1151; Cha TA, 1996, J VIROL, V70, P78, DOI 10.1128/JVI.70.1.78-83.1996; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; Crumpacker CS, 1996, NEW ENGL J MED, V335, P721, DOI 10.1056/NEJM199609053351007; Cwynarski K, 2001, BLOOD, V97, P1232, DOI 10.1182/blood.V97.5.1232; Dargan DJ, 2010, J GEN VIROL, V91, P1535, DOI 10.1099/vir.0.018994-0; Echavarria M, 2008, CLIN MICROBIOL REV, V21, P704, DOI 10.1128/CMR.00052-07; Einsele H, 2002, BLOOD, V99, P3916, DOI 10.1182/blood.V99.11.3916; Elkington R, 2003, J VIROL, V77, P5226, DOI 10.1128/JVI.77.9.5226-5240.2003; (EMBL-EBI) EBI, 2019, BIOINF TOOLS FAQ BIOINF TOOLS FAQ; FALK K, 1994, IMMUNOGENETICS, V39, P230; Feucht J, 2015, BLOOD, V125, P1986, DOI 10.1182/blood-2014-06-573725; Feuchtinger T, 2006, BRIT J HAEMATOL, V134, P64, DOI 10.1111/j.1365-2141.2006.06108.x; Feuchtinger T, 2005, BRIT J HAEMATOL, V128, P503, DOI 10.1111/j.1365-2141.2004.05331.x; Feuchtinger T, 2004, EXP HEMATOL, V32, P282, DOI 10.1016/j.exphem.2003.12.009; Feuchtinger T, 2010, BLOOD, V116, P4360, DOI 10.1182/blood-2010-01-262089; FLOMENBERG P, 1995, J INFECT DIS, V171, P1090, DOI 10.1093/infdis/171.5.1090; Gonzalez-Galarza FF, 2015, NUCLEIC ACIDS RES, V43, pD784, DOI 10.1093/nar/gku1166; Heemskerk B, 2003, J VIROL, V77, P6562, DOI 10.1128/JVI.77.11.6562-6566.2003; Hoeben RC, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a013003; Hutnick NA, 2010, VACCINE, V28, P1932, DOI 10.1016/j.vaccine.2009.10.091; Jacobson MA, 2004, J INFECT DIS, V189, P1362, DOI 10.1086/382964; JONJIC S, 1990, J VIROL, V64, P5457; Kern F, 1999, J VIROL, V73, P8179, DOI 10.1128/JVI.73.10.8179-8184.1999; Kern F, 2002, J INFECT DIS, V185, P1709, DOI 10.1086/340637; Kumar D, 2017, AM J TRANSPLANT, V17, P2468, DOI 10.1111/ajt.14347; Lauer KP, 2004, J GEN VIROL, V85, P2615, DOI 10.1099/vir.0.80118-0; Leen AM, 2008, J VIROL, V82, P546, DOI 10.1128/JVI.01689-07; Lilleri D, 2007, AM J TRANSPLANT, V7, P1997, DOI 10.1111/j.1600-6143.2007.01890.x; Lim EY, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00202; Lubke M, 2020, J EXP MED, V217, DOI 10.1084/jem.20191164; Lynch JP, 2016, SEMIN RESP CRIT CARE, V37, P586, DOI 10.1055/s-0036-1584923; Madeira F, 2019, NUCLEIC ACIDS RES, V47, pW636, DOI 10.1093/nar/gkz268; MCLAUGHLINTAYLOR E, 1994, J MED VIROL, V43, P103, DOI 10.1002/jmv.1890430119; Nastke MD, 2005, CELL MOL LIFE SCI, V62, P77, DOI 10.1007/s00018-004-4363-x; Neuenhahn M, 2017, LEUKEMIA, V31, P2161, DOI 10.1038/leu.2017.16; Nielsen Morten, 2010, Immunome Res, V6, P9, DOI 10.1186/1745-7580-6-9; Nielsen M, 2010, IMMUNOLOGY, V130, P319, DOI 10.1111/j.1365-2567.2010.03268.x; Olive M, 2002, HUM GENE THER, V13, P1167, DOI 10.1089/104303402320138952; Peper JK, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1065369; Pira GL, 2004, INT IMMUNOL, V16, P635, DOI 10.1093/intimm/dxh065; Provenzano M, 2009, J CELL MOL MED, V13, P2131, DOI 10.1111/j.1582-4934.2008.00531.x; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; RIDDELL SR, 1992, SCIENCE, V257, P238; Russell WC, 2000, J GEN VIROL, V81, P2573, DOI 10.1099/0022-1317-81-11-2573; Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274; Serangeli C, 2010, VIROLOGY, V397, P277, DOI 10.1016/j.virol.2009.10.049; Smith CA, 1998, HUM GENE THER, V9, P1419, DOI 10.1089/hum.1998.9.10-1419; Staras SAS, 2006, CLIN INFECT DIS, V43, P1143, DOI 10.1086/508173; Sukdolak C, 2013, BIOL BLOOD MARROW TR, V19, P1480, DOI 10.1016/j.bbmt.2013.07.015; Swain SL, 2012, NAT REV IMMUNOL, V12, P136, DOI 10.1038/nri3152; Sylwester AW, 2005, J EXP MED, V202, P673, DOI 10.1084/jem.20050882; SYMINGTON JS, 1986, J VIROL, V57, P848, DOI 10.1128/JVI.57.3.848-856.1986; Tang J, 2004, GENE THER, V11, P1408, DOI 10.1038/sj.gt.3302316; TRIBOULEY C, 1994, J VIROL, V68, P4450, DOI 10.1128/JVI.68.7.4450-4457.1994; Weekes MP, 2014, CELL, V157, P1460, DOI 10.1016/j.cell.2014.04.028; Wills MR, 1996, J VIROL, V70, P7569, DOI 10.1128/JVI.70.11.7569-7579.1996	61	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 7	2021	12								700438	10.3389/fimmu.2021.700438	http://dx.doi.org/10.3389/fimmu.2021.700438			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TR5FA	34322126	gold, Green Published			2022-12-18	WOS:000678988600001
J	Lassiter, R; Merchen, TD; Fang, XX; Wang, YL				Lassiter, Randi; Merchen, Todd D.; Fang, Xuexiu; Wang, Youli			Protective Role of Kynurenine 3-Monooxygenase in Allograft Rejection and Tubular Injury in Kidney Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						kidney transplantation; kynurenine 3-monooxygenase; allograft rejection; kynurenine metabolism; immunosuppresant	PORCINE ENDOGENOUS RETROVIRUSES; MYELOID DENDRITIC CELLS; INDOLEAMINE 2,3-DIOXYGENASE; T-CELL; EPITHELIAL-CELLS; RENAL-FUNCTION; COLD ISCHEMIA; STING ADAPTER; GENE-THERAPY; EXPRESSION	Renal tubular epithelial cells (TECs) are the primary targets of ischemia-reperfusion injury (IRI) and rejection by the recipient's immune response in kidney transplantation (KTx). However, the molecular mechanism of rejection and IRI remains to be identified. Our previous study demonstrated that kynurenine 3-monooxygenase (KMO) and kynureninase were reduced in ischemia-reperfusion procedure and further decreased in rejection allografts among mismatched pig KTx. Herein, we reveal that TEC injury in acutely rejection allografts is associated with alterations of Bcl2 family proteins, reduction of tight junction protein 1 (TJP1), and TEC-specific KMO. Three cytokines, IFN gamma , TNF alpha, and IL1 beta, reported in our previous investigation were identified as triggers of TEC injury by altering the expression of Bcl2, BID, and TJP1. Allograft rejection and TEC injury were always associated with a dramatic reduction of KMO. 3HK and 3HAA, as direct and downstream products of KMO, effectively protected TEC from injury via increasing expression of Bcl-xL and TJP1. Both 3HK and 3HAA further prevented allograft rejection by inhibiting T cell proliferation and up-regulating aryl hydrocarbon receptor expression. Pig KTx with the administration of DNA nanoparticles (DNP) that induce expression of indoleamine 2,3-dioxygenase (IDO) and KMO to increase 3HK/3HAA showed an improvement of allograft rejection as well as murine skin transplant in IDO knockout mice with the injection of 3HK indicated a dramatic reduction of allograft rejection. Taken together, our data provide strong evidence that reduction of KMO in the graft is a key mediator of allograft rejection and loss. KMO can effectively improve allograft outcome by attenuating allograft rejection and maintaining graft barrier function.	[Lassiter, Randi; Merchen, Todd D.] Augusta Univ, Med Coll Georgia, Dept Surg, Augusta, GA USA; [Fang, Xuexiu; Wang, Youli] Augusta Univ, Dept Med, Div Nephrol, Med Coll Georgia, Augusta, GA 30906 USA; [Lassiter, Randi] Nicklaus Childrens Hlth Syst, Miami, FL USA; [Merchen, Todd D.] Res Med Ctr, Transplant Inst, Kansas City, MO USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Wang, YL (corresponding author), Augusta Univ, Dept Med, Div Nephrol, Med Coll Georgia, Augusta, GA 30906 USA.	ywang2@augusta.edu			Carlos and Marquerite Mason Charitable Trust; Dialysis Clinic. Inc. [S-2444]	Carlos and Marquerite Mason Charitable Trust; Dialysis Clinic. Inc.	This work was supported in part by grants from the Carlos and Marquerite Mason Charitable Trust and Reserve Research grant fund #S-2444 from Dialysis Clinic. Inc.	Anders HJ, 2016, J AM SOC NEPHROL, V27, P2564, DOI 10.1681/ASN.2016020177; Badawy AAB, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150197; Bauer TM, 2005, TRANSPL INT, V18, P95, DOI 10.1111/j.1432-2277.2004.00031.x; Belladonna ML, 2006, J IMMUNOL, V177, P130, DOI 10.4049/jimmunol.177.1.130; Beutelspacher SC, 2006, AM J TRANSPLANT, V6, P1320, DOI 10.1111/j.1600-6143.2006.01324.x; BILLINGHAM RE, 1976, J INVEST DERMATOL, V67, P149, DOI 10.1111/1523-1747.ep12513006; Blusch JH, 2000, TRANSPLANTATION, V69, P2167, DOI 10.1097/00007890-200005270-00036; Brewer L, 2003, XENOTRANSPLANTATION, V10, P569, DOI 10.1034/j.1399-3089.2003.00058.x; BUSCH GJ, 1971, HUM PATHOL, V2, P253, DOI 10.1016/S0046-8177(71)80037-0; Campbell BM, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00012; Cheng CH, 2017, JOVE-J VIS EXP, DOI 10.3791/55105; Chung BH, 2012, IMMUNOLOGY, V136, P344, DOI 10.1111/j.1365-2567.2012.03588.x; Chung BH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145258; Ciliao HL, 2016, MUTAT RES-GEN TOX EN, V806, P47, DOI 10.1016/j.mrgentox.2016.07.001; Coombes JD, 2005, KIDNEY INT, V68, P2599, DOI 10.1111/j.1523-1755.2005.00732.x; Cooper DKC, 2018, BLOOD PURIFICAT, V45, P254, DOI 10.1159/000485163; Cooper DKC, 2017, TRANSPLANTATION, V101, P1766, DOI 10.1097/TP.0000000000001683; Crane AT, 2019, CELL TRANSPLANT, V28, P1091, DOI 10.1177/0963689719845351; Dai XC, 2009, EUR J PHARMACOL, V606, P225, DOI 10.1016/j.ejphar.2008.12.053; De Serres SA, 2012, CLIN J AM SOC NEPHRO, V7, P1018, DOI 10.2215/CJN.11051011; Debout A, 2015, KIDNEY INT, V87, P343, DOI 10.1038/ki.2014.304; Demmers MWHJ, 2015, CLIN EXP IMMUNOL, V179, P509, DOI 10.1111/cei.12469; Denner J, 2008, ANN TRANSPL, V13, P20; Denner J, 2016, ANN TRANSPL, V21, P717, DOI 10.12659/AOT.900531; Du CG, 2004, AM J TRANSPLANT, V4, P1583, DOI 10.1111/j.1600-6143.2004.00552.x; Ebrahimi A, 2016, GENE, V576, P412, DOI 10.1016/j.gene.2015.10.054; Fallarino F, 2003, ADV EXP MED BIOL, V527, P183; Fallarino I, 2002, CELL DEATH DIFFER, V9, P1069, DOI 10.1038/sj.cdd.4401073; Fiebig U, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020066; Fishman JA, 2018, XENOTRANSPLANTATION, V25, DOI 10.1111/xen.12395; Freitas MCS, 2011, TRANSPLANTATION, V92, P131, DOI 10.1097/TP.0b013e318220586e; Frumento G, 2002, J EXP MED, V196, P459, DOI 10.1084/jem.20020121; GUTTMANN RD, 1964, NATURE, V203, P196, DOI 10.1038/203196a0; He Y, 2015, TRANSPLANTATION, V99, P1829, DOI 10.1097/TP.0000000000000856; Heidt S, 2010, CURR OPIN ORGAN TRAN, V15, P456, DOI 10.1097/MOT.0b013e32833b9bfb; Heo Y, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090801; Hertig A, 2006, AM J TRANSPLANT, V6, P2937, DOI 10.1111/j.1600-6143.2006.01559.x; Huang L, 2013, J IMMUNOL, V191, P3509, DOI 10.4049/jimmunol.1301419; Jia LN, 2009, TRANSPL IMMUNOL, V21, P18, DOI 10.1016/j.trim.2009.01.004; Jordan SC, 2017, TRANSPLANTATION, V101, P32, DOI 10.1097/TP.0000000000001452; Kimsa MC, 2014, VIRUSES-BASEL, V6, P2062, DOI 10.3390/v6052062; Kobayashi E, 2016, CELL MED, V9, P9, DOI 10.3727/215517916X693113; Korstanje R, 2016, J AM SOC NEPHROL, V27, P3271, DOI 10.1681/ASN.2015070835; Kwan T, 2015, AM J TRANSPLANT, V15, P1555, DOI 10.1111/ajt.13140; Lahdou I, 2010, HUM IMMUNOL, V71, P1067, DOI 10.1016/j.humimm.2010.08.013; Lassiter R, 2017, TRANSPL IMMUNOL, V42, P40, DOI 10.1016/j.trim.2017.05.001; Colin-Gonzalez AL, 2013, NEUROTOXICOLOGY, V34, P189, DOI 10.1016/j.neuro.2012.11.007; Laurence JM, 2008, TRANSPLANTATION, V85, P1357, DOI 10.1097/TP.0b013e31816fc27f; Lemos H, 2014, J IMMUNOL, V192, P5571, DOI 10.4049/jimmunol.1303258; Li C, 2016, INT IMMUNOPHARMACOL, V36, P31, DOI 10.1016/j.intimp.2016.03.048; LIN Y, 1993, CLIN EXP IMMUNOL, V92, P145; Liu C, 2018, EUR CYTOKINE NETW, V29, P48, DOI 10.1684/ecn.2018.0410; Loverre A, 2011, AM J TRANSPLANT, V11, P1248, DOI 10.1111/j.1600-6143.2011.03529.x; Martin U, 2002, TRANSPL INT, V15, P361, DOI 10.1111/j.1432-2277.2002.tb00179.x; Mbongue JC, 2015, VACCINES-BASEL, V3, P703, DOI 10.3390/vaccines3030703; Mikhalski D, 2008, TRANSPLANTATION, V85, pS3, DOI 10.1097/TP.0b013e318169c29e; Millan O, 2014, CLIN IMMUNOL, V154, P141, DOI 10.1016/j.clim.2014.07.007; Mole DJ, 2016, NAT MED, V22, P202, DOI 10.1038/nm.4020; Moscoso I, 2005, TRANSPLANTATION, V79, P777, DOI 10.1097/01.TP.0000152662.55720.83; Mulley WR, 2008, XENOTRANSPLANTATION, V15, P174, DOI 10.1111/j.1399-3089.2008.00472.x; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Na N, 2016, MOL IMMUNOL, V79, P22, DOI 10.1016/j.molimm.2016.09.005; Nagashima H, 2016, THERIOGENOLOGY, V86, P422, DOI 10.1016/j.theriogenology.2016.04.056; Nguan Christopher Y C, 2009, Transplant Rev (Orlando), V23, P129, DOI 10.1016/j.trre.2009.02.003; Niu D, 2017, SCIENCE, V357, P1303, DOI 10.1126/science.aan4187; Oberbauer R, 1999, J AM SOC NEPHROL, V10, P2006; Oyouni AAA, 2018, TOXICOL REP, V5, P687, DOI 10.1016/j.toxrep.2018.06.003; Parrott JM, 2015, FRONT PSYCHIATRY, V6, DOI 10.3389/fpsyt.2015.00116; Ponticelli C, 2019, J NEPHROL, V32, P851, DOI 10.1007/s40620-019-00602-5; Robertson H, 2003, AM J TRANSPLANT, V3, P3, DOI 10.1034/j.1600-6143.2003.30102.x; Salahudeen AK, 2001, TRANSPLANTATION, V72, P798, DOI 10.1097/00007890-200109150-00010; Samsonov D, 2012, TRANSPLANT RES, V1, DOI 10.1186/2047-1440-1-4; Skouras C, 2016, SCI REP-UK, V6, DOI 10.1038/srep33951; Smith SF, 2019, KIDNEY INT, V95, P50, DOI 10.1016/j.kint.2018.10.009; Sucher R, 2012, J IMMUNOL, V188, P37, DOI 10.4049/jimmunol.1002777; Ting YT, 2012, NEPHROLOGY, V17, P11, DOI 10.1111/j.1440-1797.2011.01536.x; Uehara M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20858-4; Urbanics R, 2015, EUR J NANOMED, V7, P219, DOI 10.1515/ejnm-2015-0011; VALENZUELA R, 1980, HUM PATHOL, V11, P187, DOI 10.1016/S0046-8177(80)80143-2; Vavrincova-Yaghi D, 2016, GENE THER, V23, P797, DOI 10.1038/gt.2016.59; Vavrincova-Yaghi D, 2015, TRANSPLANTATION, V99, pE97, DOI 10.1097/TP.0000000000000603; Vavrincova-Yaghi D, 2011, J GENE MED, V13, P373, DOI 10.1002/jgm.1584; Wang Y, 2006, KIDNEY INT, V70, P882, DOI 10.1038/sj.ki.5001624; Wang YL, 2007, BIOCHEM BIOPH RES CO, V361, P1006, DOI 10.1016/j.bbrc.2007.07.122; Wang YL, 2018, J INVEST MED, V66, P1109, DOI 10.1136/jim-2018-000742; Wiseman AC, 2016, CLIN J AM SOC NEPHRO, V11, P332, DOI 10.2215/CJN.08570814; Woltman AM, 2000, J AM SOC NEPHROL, V11, P2044, DOI 10.1681/ASN.V11112044; Wyburn K, 2006, AM J TRANSPLANT, V6, P2612, DOI 10.1111/j.1600-6143.2006.01536.x; Yang LH, 2015, SCIENCE, V350, P1101, DOI 10.1126/science.aad1191; Yu G, 2008, J GENE MED, V10, P754, DOI 10.1002/jgm.1201; Zaher SS, 2011, INVEST OPHTH VIS SCI, V52, P2640, DOI 10.1167/iovs.10-5793; Zhao YL, 2019, XENOTRANSPLANTATION, V26, DOI 10.1111/xen.12502; Zoso A, 2014, EUR J IMMUNOL, V44, P3307, DOI 10.1002/eji.201444522; Zuidwijk K, 2012, KIDNEY INT, V81, P64, DOI 10.1038/ki.2011.289	94	0	0	4	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 7	2021	12								671025	10.3389/fimmu.2021.671025	http://dx.doi.org/10.3389/fimmu.2021.671025			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TL6FG	34305900	gold, Green Published			2022-12-18	WOS:000674954400001
J	Nguyen, LS; Salem, JE; Bories, MC; Coutance, G; Amour, J; Bougle, A; Suberbielle, C; Kheav, VD; Carmagnat, M; Rouvier, P; Kirsch, M; Varnous, S; Leprince, P; Saheb, S				Nguyen, Lee S.; Salem, Joe-Elie; Bories, Marie-Cecile; Coutance, Guillaume; Amour, Julien; Bougle, Adrien; Suberbielle, Caroline; Kheav, Vissal-David; Carmagnat, Maryvonnick; Rouvier, Philippe; Kirsch, Matthias; Varnous, Shaida; Leprince, Pascal; Saheb, Samir			Impact of Sex in the Efficacy of Perioperative Desensitization Procedures in Heart Transplantation: A Retrospective Cohort Study	FRONTIERS IN IMMUNOLOGY			English	Article						heart transplant; antibody mediated allograft rejection; desensitization; sex influence; gender inequalities	ANTIBODY-MEDIATED REJECTION; HLA ANTIBODIES	Background: Sensitized patients, i.e. recipients with preformed donor-specific HLA antibodies (pfDSA), are at high-risk of developing antibody-mediated rejections (AMR) and dying after heart transplantation (HTx). Perioperative desensitization procedures are associated with better outcomes but can cause sensitization, which may influence their efficacy. Methods : In sensitized patients (pfDSA > 1000 mean immunofluorescence (MFI) units), we assessed the effect of perioperative desensitization by comparing treated patients to a historical control cohort. Multivariable survival analyses were performed on the time to main outcome, a composite of death and biopsy-proven AMR with 5-year follow-up. Results: The study included 68 patients: 31 control and 37 treated patients. There was no difference in preoperative variables between the two groups, including cumulative pfDSA [4026 (1788;8725) vs 4560 (3162;13392) MFI units, p=0.28]. The cause of sensitization was pregnancy in 24/68, 35.3%, transfusion in 61/68, 89.7%, and previous HTx in 4/68, 5.9% patients. Multivariable analysis yielded significant protective association between desensitization and events (adjusted (adj.) hazard ratio (HR)=0.44 (95% confidence interval (95CI)=0.25-0.79), p=0.006) and deleterious association between cumulative pfDSA and events [per 1000-MFI increase, adj.HR=1.028 (1.002-1.053), p=0.031]. There was a sex-difference in the efficacy of desensitization: in men (n=35), the benefit was significant [unadj.HR=0.33 (95CI=0.14-0.78); p=0.01], but not in women (n=33) [unadj.HR=0.52 (0.23-1.17), p=0.11]. In terms of the number of patients treated, in men, 2.1 of patients that were treated prevented 1 event, while in women, 3.1 required treatment to prevent 1 event. Conclusion: Perioperative desensitization was associated with fewer AMR and deaths after HTx, and efficacy was more pronounced in men than women.	[Nguyen, Lee S.; Bories, Marie-Cecile; Coutance, Guillaume; Varnous, Shaida; Leprince, Pascal] Sorbonne Univ, AP HP 6 Pitie Salpetriere, Dept Cardiothorac Surg, Paris, France; [Nguyen, Lee S.] CMC Ambroise Pare, Res & Innovat, RICAP, Neuilly Sur Seine, France; [Nguyen, Lee S.; Salem, Joe-Elie] Sorbonne Univ, AP HP 6, INSERM, Clin Invest Ctr, Paris, France; [Amour, Julien] Jacques Cartier Private Hosp, Dept Cardiothorac Surg, Massy, France; [Bougle, Adrien] Sorbonne Univ, Dept Anesthesiol, AP HP 6 Pitie Salpetriere, Paris, France; [Suberbielle, Caroline; Kheav, Vissal-David; Carmagnat, Maryvonnick] St Louis Hosp, Immunol Dept, Paris, France; [Rouvier, Philippe] Sorbonne Univ, AP HP 6 Pitie Salpetriere, Dept Anatomopathol, Paris, France; [Kirsch, Matthias] Univ Hosp, Dept Cardiovasc Surg, Lausanne, Switzerland; [Saheb, Samir] Sorbonne Univ, AP HP 6 Pitie Salpetriere, Serv Hemobiol, Paris, France	UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Jacques Cartier Private Hospital; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); UDICE-French Research Universities; Sorbonne Universite	Nguyen, LS (corresponding author), Sorbonne Univ, AP HP 6 Pitie Salpetriere, Dept Cardiothorac Surg, Paris, France.; Nguyen, LS (corresponding author), CMC Ambroise Pare, Res & Innovat, RICAP, Neuilly Sur Seine, France.; Nguyen, LS (corresponding author), Sorbonne Univ, AP HP 6, INSERM, Clin Invest Ctr, Paris, France.	nguyen.lee@icloud.com		Saheb, Samir/0000-0002-7764-6016; Salem, Joe-Elie/0000-0002-0331-3307	LFB laboratories (Les Ulis, France)	LFB laboratories (Les Ulis, France)	Funding was granted by LFB laboratories (Les Ulis, France).	Berry GJ, 2013, J HEART LUNG TRANSPL, V32, P1147, DOI 10.1016/j.healun.2013.08.011; Clerkin KJ, 2017, J HEART LUNG TRANSPL, V36, P540, DOI 10.1016/j.healun.2016.10.016; Colvin MM, 2019, CIRCULATION, V139, pE553, DOI 10.1161/CIR.0000000000000598; Coutance G, 2019, TRANSPLANTATION, V103, P1439, DOI 10.1097/TP.0000000000002503; Grafals M, 2009, AM J KIDNEY DIS, V53, P370, DOI 10.1053/j.ajkd.2009.01.012; Hyun J, 2012, TRANSPL P, V44, P222, DOI 10.1016/j.transproceed.2011.12.049; Jennings DL, 2018, INT J CARDIOL, V265, P71, DOI 10.1016/j.ijcard.2018.03.111; Kobashigawa J, 2011, J HEART LUNG TRANSPL, V30, P252, DOI 10.1016/j.healun.2010.11.003; Lefaucheur C, 2010, J AM SOC NEPHROL, V21, P1398, DOI 10.1681/ASN.2009101065; Lindemann M, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030084; Margreiter R, 2002, LANCET, V359, P741, DOI 10.1016/S0140-6736(02)07875-3; Michaels PJ, 2003, J HEART LUNG TRANSPL, V22, P58, DOI 10.1016/S1053-2498(02)00472-2; Nguyen LS, 2020, AM J TRANSPLANT, V20, P2791, DOI 10.1111/ajt.15849; Nguyen LS, 2019, AM J TRANSPLANT, V19, P1160, DOI 10.1111/ajt.15133; Puoti F, 2016, BIOL SEX DIFFER, V7, DOI 10.1186/s13293-016-0088-4; Reed EF, 2006, J HEART LUNG TRANSPL, V25, P153, DOI 10.1016/j.healun.2005.09.003; Seferovic PM, 2019, EUR J HEART FAIL, V21, P1169, DOI 10.1002/ejhf.1531; Sethi S, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/6804678; Stehlik J, 2018, CIRCULATION, V137, P71, DOI 10.1161/CIRCULATIONAHA.117.029753; Zhang RB, 2018, CLIN J AM SOC NEPHRO, V13, P182, DOI 10.2215/CJN.00700117	20	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 7	2021	12								659303	10.3389/fimmu.2021.659303	http://dx.doi.org/10.3389/fimmu.2021.659303			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TQ2RB	34305891	Green Published, gold			2022-12-18	WOS:000678131500001
J	Talantsev, AD; Bahmetiev, MV; Morgunov, RB				Talantsev, A. D.; Bahmetiev, M., V; Morgunov, R. B.			Robust evaluation of coercivity in exchange biased films	FRONTIERS IN IMMUNOLOGY			English	Article						Exchange bias; Uniaxial anisotropy; Stoner-Wohlfarth model	MAGNETIC-PROPERTIES; THERMAL-STABILITY; THICKNESS; IRMN; INTERFACE; REVERSAL; NIFE	Exact measurement of coercivity in thin magnetic films is of high importance for sensor industry. In exchange biased multilayers, incorporated in magnetoresistive sensors, coercivity of the coupled ferromagnetic layers strongly depends on the orientation of easy axis in respect to field. We show, that in NiFe/IrMn films with high H-B/H-C ratio, field misalignment similar to 2 degrees results in similar to 50 % change in coercivity. Inhomogeneous magnetic field in a film deposition device as well as manual installation of the sample in magnetometers result in large error in coercivity. In this work, we propose measurement and analysis protocol to avoid this uncertainty and to evaluate easy axis coercivity values from tilted angle measurements in a wide temperature range using just one reference value of easy axis coercive field, measured at room temperature.	[Talantsev, A. D.; Bahmetiev, M., V; Morgunov, R. B.] Russian Acad Sci, Fed Res Ctr Problems Chem Phys & Med Chem, Moscow 142432, Russia; [Morgunov, R. B.] IM Sechenov First Moscow State Med Univ, Moscow 119991, Russia; [Morgunov, R. B.] Immanuel Kant Baltic Fed Univ, Kaliningrad 236016, Russia	Russian Academy of Sciences; Sechenov First Moscow State Medical University; Immanuel Kant Baltic Federal University	Talantsev, AD (corresponding author), Russian Acad Sci, Fed Res Ctr Problems Chem Phys & Med Chem, Moscow 142432, Russia.	adt@icp.ac.ru			Kaliningrad Region [06-C/2022]; government task of the Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry [AAAA-A19-119092390079-8]; Russian Science Foundation [22-19-20157]	Kaliningrad Region; government task of the Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry; Russian Science Foundation(Russian Science Foundation (RSF))	The research was carried out at the expense of the grant of the Russian Science Foundation No. 22-19-20157, https://rscf.ru/project/ 22-19-20157/, and the grant in the form of a subsidy from the budget of the Kaliningrad Region No. 06-C/2022. A.D.T. was supported by the AAAA-A19-119092390079-8 government task of the Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry.	Albisetti E, 2016, NAT NANOTECHNOL, V11, P545, DOI [10.1038/nnano.2016.25, 10.1038/NNANO.2016.25]; Albisetti E, 2018, APPL PHYS LETT, V113, DOI 10.1063/1.5047222; Bakhmetiev M, 2022, J PHYS D APPL PHYS, V55, DOI 10.1088/1361-6463/ac3ce7; Baltz V, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.104419; Baltz V, 2018, REV MOD PHYS, V90, DOI 10.1103/RevModPhys.90.015005; Baltz V, 2004, APPL PHYS LETT, V84, P4923, DOI 10.1063/1.1757646; Blachowicz T., 2021, COATINGS, V11, P122, DOI [10.3390/coatings11020122, DOI 10.3390/C0ATINGS11020122]; Borisov P, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.117203; Buchner M, 2018, J APPL PHYS, V124, DOI 10.1063/1.5045299; Camarero J, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.057204; Chen H, 2014, PHYS REV LETT, V112, DOI 10.1103/PhysRevLett.112.017205; da Silva RB, 2014, APPL PHYS LETT, V104, DOI 10.1063/1.4867973; Damsgaard CD, 2008, J APPL PHYS, V103, DOI 10.1063/1.2830008; Del Bianco L, 2008, J PHYS D APPL PHYS, V41, DOI 10.1088/0022-3727/41/13/134008; Dimitrov DV, 1998, PHYS REV B, V58, P12090, DOI 10.1103/PhysRevB.58.12090; Donolato M, 2011, J APPL PHYS, V109, DOI 10.1063/1.3561364; Dufour C, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.064420; Dunz M, 2018, J APPL PHYS, V124, DOI 10.1063/1.5051584; Garcia C, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3446894; Geshev J, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.134432; Geshev J, 2000, PHYS REV B, V62, P5627, DOI 10.1103/PhysRevB.62.5627; Giri S, 2011, J PHYS-CONDENS MAT, V23, DOI 10.1088/0953-8984/23/7/073201; Gogol P, 2002, J APPL PHYS, V92, P1458, DOI 10.1063/1.1489494; Gong WJ, 2012, APPL PHYS LETT, V101, DOI 10.1063/1.4733341; Goswami S, 2020, APL MATER, V8, DOI 10.1063/5.0015339; Gritsenko C, 2019, J MAGN MAGN MATER, V475, P763, DOI 10.1016/j.jmmm.2018.10.013; Grollier J, 2020, NAT ELECTRON, V3, P360, DOI 10.1038/s41928-019-0360-9; Guo Y, 2017, IEEE SENS J, V17, P3309, DOI 10.1109/JSEN.2017.2695238; Hao RR, 2019, CHINESE PHYS B, V28, DOI 10.1088/1674-1056/28/3/037202; Hashimoto S, 2009, PHYS MED BIOL, V54, P2571, DOI 10.1088/0031-9155/54/8/021; Henriksen AD, 2015, J MAGN MAGN MATER, V380, P209, DOI 10.1016/j.jmmm.2014.09.056; Ingvarsson S, 2002, J MAGN MAGN MATER, V251, P202, DOI 10.1016/S0304-8853(02)00577-2; Jenkins S, 2021, PHYS REV B, V103, DOI 10.1103/PhysRevB.103.014424; Jungfleisch MB, 2018, PHYS LETT A, V382, P865, DOI 10.1016/j.physleta.2018.01.008; Kang J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26678-x; King JP, 2001, J PHYS D APPL PHYS, V34, P528, DOI 10.1088/0022-3727/34/4/315; Kiwi M, 2001, J MAGN MAGN MATER, V234, P584, DOI 10.1016/S0304-8853(01)00421-8; Kocaman B, 2021, J MAGN MAGN MATER, V530, DOI 10.1016/j.jmmm.2021.167926; Lage E, 2014, APPL PHYS LETT, V104, DOI 10.1063/1.4870511; Leighton C, 2000, PHYS REV LETT, V84, P3466, DOI 10.1103/PhysRevLett.84.3466; Lhoutellier G, 2016, J APPL PHYS, V120, DOI 10.1063/1.4967829; Lund MS, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.054422; Luo C, 2015, J MAGN MAGN MATER, V374, P711, DOI 10.1016/j.jmmm.2014.09.014; Ma TY, 2020, PHYS REV B, V101, DOI 10.1103/PhysRevB.101.134417; Makarov D, 2022, ADV MATER, V34, DOI 10.1002/adma.202101758; Manna PK, 2014, PHYS REP, V535, P61, DOI 10.1016/j.physrep.2013.10.002; Marti X, 2015, IEEE T MAGN, V51, DOI 10.1109/TMAG.2014.2358939; McCord J, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.094420; McCord J, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.094419; MEIKLEJOHN WH, 1957, PHYS REV, V105, P904, DOI 10.1103/PhysRev.105.904; Mendes JBS, 2014, PHYS REV B, V89, DOI 10.1103/PhysRevB.89.140406; Mishra SK, 2019, J MAGN MAGN MATER, V488, DOI 10.1016/j.jmmm.2019.165374; Morrison G, 2015, J SOLID STATE CHEM, V221, P334, DOI 10.1016/j.jssc.2014.10.026; Nemec P, 2018, NAT PHYS, V14, P229, DOI 10.1038/s41567-018-0051-x; Nogues J, 1999, J MAGN MAGN MATER, V192, P203, DOI 10.1016/S0304-8853(98)00266-2; Nogues J, 2005, PHYS REP, V422, P65, DOI 10.1016/j.physrep.2005.08.004; O'Grady K, 2010, J MAGN MAGN MATER, V322, P883, DOI 10.1016/j.jmmm.2009.12.011; Oksuzoglu RM, 2011, J MAGN MAGN MATER, V323, P1827, DOI 10.1016/j.jmmm.2011.02.021; Panchal G, 2019, J ALLOY COMPD, V796, P196, DOI 10.1016/j.jallcom.2019.05.033; Radu F, 2008, SPRINGER TRAC MOD PH, V227, P97, DOI 10.1007/978-3-540-73462-8; Raut S, 2022, J MAGN MAGN MATER, V563, DOI 10.1016/j.jmmm.2022.169950; Raviolo S, 2018, MATER RES EXPRESS, V5, DOI 10.1088/2053-1591/aaa537; Saglam H, 2018, PHYS REV B, V98, DOI 10.1103/PhysRevB.98.094407; Samant MG, 2000, APPL PHYS LETT, V76, P3097, DOI 10.1063/1.126535; Seidel R, 2002, IEEE T MAGN, V38, P2776, DOI 10.1109/TMAG.2002.803157; Sharma PP, 2016, SENSORS-BASEL, V16, DOI 10.3390/s16071030; Sinclair J, 2019, J MAGN MAGN MATER, V476, P278, DOI 10.1016/j.jmmm.2018.12.018; Song C, 2018, NANOTECHNOLOGY, V29, DOI 10.1088/1361-6528/aaa812; Spetzler B, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84415-2; Spizzo F, 2015, PHYS REV B, V91, DOI 10.1103/PhysRevB.91.064410; Spizzo F, 2013, J PHYS-CONDENS MAT, V25, DOI 10.1088/0953-8984/25/38/386001; Stamps RL, 2000, J PHYS D APPL PHYS, V33, pR247, DOI 10.1088/0022-3727/33/23/201; Stiles MD, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.064405; Talantsev A, 2022, J PHYS D APPL PHYS, V55, DOI 10.1088/1361-6463/ac6e13; Thole F, 2020, J APPL PHYS, V127, DOI 10.1063/5.0006071; Thomas L, 2000, J APPL PHYS, V87, P5061, DOI 10.1063/1.373248; Tian FH, 2021, APL MATER, V9, DOI 10.1063/5.0036910; Tsai H, 2020, NATURE, V580, P608, DOI 10.1038/s41586-020-2211-2; Luong VS, 2018, MEASUREMENT, V115, P173, DOI 10.1016/j.measurement.2017.10.038; Wang Z, 2020, J MAGN MAGN MATER, V513, DOI 10.1016/j.jmmm.2020.167126; Wu H, 2017, J MAGN MAGN MATER, V441, P149, DOI 10.1016/j.jmmm.2017.05.031; Wu SM, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.067202; Xi HW, 2000, PHYS REV B, V61, P80, DOI 10.1103/PhysRevB.61.80; Xiong DR, 2022, FUND RES-CHINA, V2, P522, DOI 10.1016/j.fmre.2022.03.016; Xu F, 2011, IEEE T MAGN, V47, P3486, DOI 10.1109/TMAG.2011.2159486; Youssef A, 2008, IEEE T APPL SUPERCON, V18, P1589, DOI 10.1109/TASC.2008.922391; Yu J, 2000, J APPL PHYS, V87, P5049, DOI 10.1063/1.373244; Yuan FT, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3399780; Zelezny J, 2018, NAT PHYS, V14, P220, DOI 10.1038/s41567-018-0062-7; Zhang CY, 2021, PHYS REV B, V103, DOI 10.1103/PhysRevB.103.014445; Zhang W, 2016, MAT SCI ENG R, V105, P1, DOI 10.1016/j.mser.2016.04.001; Zhang W, 2014, PHYS REV LETT, V113, DOI 10.1103/PhysRevLett.113.196602; Zhao ZD, 2015, APPL SURF SCI, V332, P710, DOI 10.1016/j.apsusc.2015.01.111; Zhu J, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.027004	94	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 7	2021	12								112074	10.1016/j.measurement.2022.112074	http://dx.doi.org/10.1016/j.measurement.2022.112074			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5X8BP					2022-12-18	WOS:000878822700002
J	Zhang, Y; Li, MW; Li, GX; Li, JS; Zheng, LH; Zhang, M; Wang, MJ				Zhang, Yu; Li, Maowei; Li, GuiXin; Li, Jinsong; Zheng, Lihua; Zhang, Man; Wang, Minjuan			Multi-phenotypic parameters extraction and biomass estimation for lettuce based on point clouds	FRONTIERS IN IMMUNOLOGY			English	Article						Plant phenotypic parameter; Point cloud; Lettuce; Biomass Estimation	PLANT; SEGMENTATION; HULL	Traditional phenotypic measurements were destructive, time-consuming and laborious. 3D computer vision technology collects plant information in a non-destructive manner and can work continuously. The purpose of this paper is to measure lettuce multi-phenotypic parameters and estimate biomass by point clouds. The result shows: (1) RGB information improved the segmentation effect of the point cloud. (2) The point cloud segmentation method proposed in this paper has a high accuracy (accuracy = 98.7 %) and keeps high spatial resolution. (3) On the test set, the R-2 of height, diameter, leaf area, fresh weight and dry weight are 0.935, 0.905, 0.969, 0.966 and 0.968, respectively, the cumulative NMSE is as low as 0.069. The Totaiscore is 15 % better than the 1st of the online challenge held based on this data set. The results showed that the plant phenotypic extraction method proposed in this paper was accurate and efficient, and could be applied for high-throughput phenotyping.	[Zhang, Yu; Li, Maowei; Li, GuiXin; Li, Jinsong; Zheng, Lihua; Zhang, Man; Wang, Minjuan] China Agr Univ, Key Lab Smart Agr Syst, Minist Educ, Beijing 100083, Peoples R China; [Zheng, Lihua; Zhang, Man; Wang, Minjuan] China Agr Univ, Yantai Inst, Yantai 264670, Peoples R China; [Wang, Minjuan] Beihang Univ, State Key Lab Virtual Real Technol & Syst, Beijing 100191, Peoples R China; [Zhang, Yu; Li, Maowei; Li, GuiXin; Li, Jinsong; Zheng, Lihua; Zhang, Man] China Agr Univ, Coll Informat & Elect Engn, Beijing 100083, Peoples R China	China Agricultural University; China Agricultural University; Beihang University; China Agricultural University	Wang, MJ (corresponding author), China Agr Univ, Key Lab Smart Agr Syst, Minist Educ, Beijing 100083, Peoples R China.	minjuan@cau.edu.cn			National Natural Science Foundation of China [32201654]; Natural Science Foundation of Shandong Province [ZR2021MC021]; Open Project Program of State Key Laboratory of Virtual Reality Technology and Systems, Beihang University [VRLAB2021A02]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Open Project Program of State Key Laboratory of Virtual Reality Technology and Systems, Beihang University	This work was supported in part by National Natural Science Foundation of China (32201654), the Natural Science Foundation of Shandong Province (ZR2021MC021) and the Open Project Program of State Key Laboratory of Virtual Reality Technology and Systems, Beihang University (No. VRLAB2021A02).	Phan AV, 2018, NEURAL NETWORKS, V108, P533, DOI 10.1016/j.neunet.2018.09.001; Asaeedi S, 2017, THEOR COMPUT SCI, V702, P48, DOI 10.1016/j.tcs.2017.08.014; Bello SA, 2020, REMOTE SENS-BASEL, V12, DOI 10.3390/rs12111729; BESL PJ, 1988, IEEE T PATTERN ANAL, V10, P167, DOI 10.1109/34.3881; Bloice M.D., 2017, ARXIV170804680, DOI DOI 10.21105/J0SS.00432; Breure TS, 2021, PRECIS AGRIC, V22, P226, DOI 10.1007/s11119-020-09739-x; Campbell G. S., 1989, Plant Canopies: their growth, form and function., P1, DOI 10.1017/CBO9780511752308.002; Dai A, 2017, PROC CVPR IEEE, P6545, DOI 10.1109/CVPR.2017.693; Dube N, 2020, AGRON J, V112, P4976, DOI 10.1002/agj2.20412; Gelard W, 2017, PROCEEDINGS OF THE 12TH INTERNATIONAL JOINT CONFERENCE ON COMPUTER VISION, IMAGING AND COMPUTER GRAPHICS THEORY AND APPLICATIONS (VISIGRAPP 2017), VOL 4, P459, DOI 10.5220/0006126404590467; Girardeau-Montaut D., 2016, CLOUDCOMPARE, P11; GRAHAM RL, 1983, J ALGORITHM, V4, P324, DOI 10.1016/0196-6774(83)90013-5; Hartmann A, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-148; He YB, 2021, REMOTE SENS-BASEL, V13, DOI 10.3390/rs13173417; Ishikawa T., 2018, INT ARCH PHOTOGRAMME, V42, P463, DOI DOI 10.5194/ISPRS-ARCHIVES-XLII-2-463-2018; Iyer-Pascuzzi AS, 2010, PLANT PHYSIOL, V152, P1148, DOI 10.1104/pp.109.150748; Medina-Lozano I, 2021, FOOD CHEM, V359, DOI 10.1016/j.foodchem.2021.129864; Ohashi Y, 2020, SENSORS-BASEL, V20, DOI 10.3390/s20185270; Qi C.R., 2017, C NEUR INF PROC SYST, V5, P7; Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28; Sallem NK, 2013, LECT NOTES COMPUT SC, V8192, P354, DOI 10.1007/978-3-319-02895-8_32; Shi WN, 2019, BIOSYST ENG, V187, P81, DOI 10.1016/j.biosystemseng.2019.08.014; Song Y, 2019, REMOTE SENS-BASEL, V11, DOI 10.3390/rs11101239; Story D., 2011, ACTA HORTIC; Tahir R., 2006, INT ARCH PHOTOGRAMM, V36, P248, DOI DOI 10.1111/1750-3841.12802; Torralba A, 2010, P IEEE, V98, P1467, DOI 10.1109/JPROC.2010.2050290; Vazquez-Arellano M, 2018, COMPUT ELECTRON AGR, V154, P276, DOI 10.1016/j.compag.2018.09.006; Watt M, 2020, ANNU REV PLANT BIOL, V71, P689, DOI 10.1146/annurev-arplant-042916-041124; Weisberg S, 2014, APPL LINEAR REGRESSI, V4, DOI DOI 10.1002/0471704091; Yang WN, 2011, REV SCI INSTRUM, V82, DOI 10.1063/1.3531980; Yao YD, 2016, INT CONF AGRO-GEOINF, P187; Zhang C, 2001, 2001 INTERNATIONAL CONFERENCE ON IMAGE PROCESSING, VOL III, PROCEEDINGS, P935, DOI 10.1109/ICIP.2001.958278; Zhang L, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02445-9; Zhao HS, 2019, PROC CVPR IEEE, P5550, DOI 10.1109/CVPR.2019.00571	35	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 7	2021	12								112094	10.1016/j.measurement.2022.112094	http://dx.doi.org/10.1016/j.measurement.2022.112094			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5X8BP					2022-12-18	WOS:000878822700001
J	Zhang, Z; Zhang, WT; Yang, K; Zhang, SJ				Zhang, Zhen; Zhang, Wentao; Yang, Kuo; Zhang, Shujing			Remaining useful life prediction of lithium-ion batteries based on attention mechanism and bidirectional long short-term memory network	FRONTIERS IN IMMUNOLOGY			English	Article						Remaining useful life; Lithium-ion battery; Attention mechanism; Bidirectional long short-term memory		Accurate prediction of the remaining useful life of lithium-ion batteries is beneficial to prolong the battery's life and increase safety. However, there is insufficient historical data available because of the limitation of charge and discharge cycles of lithium-ion batteries. To enhance the prediction accuracy, a hybrid model based on an attention mechanism and a bidirectional long short-term memory network is proposed, which can acquire good prediction results with early data of the target battery. Multiple temporal features, which strongly correlate with the capacity considered the main feature of battery health, are used as input to train and test the proposed model. The attention mechanism is added in the bidirectional long short-term memory network to precisely decide the attention distribution of multiple features to extract useful information. It helps the bidirectional long short-term memory networks to make a better prognosis and overcome the vanishing and exploding gradient problems. The experimental results show that the proposed framework can decrease the uncertainty for multi-step prediction and outperforms other machine learning models in prediction accuracy.	[Zhang, Zhen; Zhang, Wentao; Yang, Kuo] Shanghai Univ, Sch Mechatron Engn & Automat, Shanghai, Peoples R China; [Zhang, Shujing] State Grid Intelligence Technol Co Ltd, Jinan, Shandong, Peoples R China	Shanghai University	Zhang, Z (corresponding author), Shanghai Univ, Sch Mechatron Engn & Automat, Shanghai, Peoples R China.	zhangzhen_ta@shu.edu.cn						Cheng G, 2021, ENERGY, V232, DOI 10.1016/j.energy.2021.121022; Ding P, 2021, RENEW SUST ENERG REV, V148, DOI 10.1016/j.rser.2021.111287; Dong GZ, 2020, IEEE T IND INFORM, V16, P4736, DOI 10.1109/TII.2019.2948018; Ge MF, 2021, MEASUREMENT, V174, DOI 10.1016/j.measurement.2021.109057; Hong J, 2020, APPL ENERG, V278, DOI 10.1016/j.apenergy.2020.115646; Jiao RH, 2020, IEEE T INSTRUM MEAS, V69, P8831, DOI 10.1109/TIM.2020.2996004; Li PH, 2020, J POWER SOURCES, V459, DOI 10.1016/j.jpowsour.2020.228069; Li S, 2021, RELIAB ENG SYST SAFE, V210, DOI 10.1016/j.ress.2021.107542; Li TF, 2021, RELIAB ENG SYST SAFE, V215, DOI 10.1016/j.ress.2021.107878; Lin CP, 2020, APPL ENERG, V275, DOI 10.1016/j.apenergy.2020.115338; Liu KL, 2021, IEEE T IND ELECTRON, V68, P3170, DOI 10.1109/TIE.2020.2973876; Ma GJ, 2019, APPL ENERG, V253, DOI 10.1016/j.apenergy.2019.113626; Ma J, 2021, APPL ENERG, V282, DOI 10.1016/j.apenergy.2020.116167; Patil MA, 2015, APPL ENERG, V159, P285, DOI 10.1016/j.apenergy.2015.08.119; Roman D, 2021, NAT MACH INTELL, V3, P447, DOI 10.1038/s42256-021-00312-3; Tang YG, 2022, MEASUREMENT, V199, DOI 10.1016/j.measurement.2022.111530; Tang YG, 2022, RENEW SUST ENERG REV, V162, DOI 10.1016/j.rser.2022.112473; VASWANI A, 2017, SYSTEMS, V30, DOI DOI 10.48550/ARXIV.1706.03762; Wang FK, 2018, J POWER SOURCES, V401, P49, DOI 10.1016/j.jpowsour.2018.08.073; Wang SL, 2021, ENERGY REP, V7, P5562, DOI 10.1016/j.egyr.2021.08.182; Wei JW, 2018, IEEE T IND ELECTRON, V65, P5634, DOI 10.1109/TIE.2017.2782224; Wu J, 2016, APPL ENERG, V173, P134, DOI 10.1016/j.apenergy.2016.04.057; Xia J, 2021, ENG FAIL ANAL, V125, DOI 10.1016/j.engfailanal.2021.105385; Xia TB, 2020, COMPUT IND, V115, DOI 10.1016/j.compind.2019.103182; Xu F, 2021, RELIAB ENG SYST SAFE, V208, DOI 10.1016/j.ress.2020.107396; Xue ZW, 2020, NEUROCOMPUTING, V376, P95, DOI 10.1016/j.neucom.2019.09.074; Yang K, 2022, ENERGY, V244, DOI 10.1016/j.energy.2022.123233; Yang K, 2021, ENERGIES, V14, DOI 10.3390/en14041054; Yao F, 2022, ENERGY, V248, DOI 10.1016/j.energy.2022.123622; Yu W, 2021, MEASUREMENT, V177, DOI 10.1016/j.measurement.2021.109310; Zhang QS, 2022, ENERGY, V241, DOI 10.1016/j.energy.2021.122716; Zhang YZ, 2018, IEEE T VEH TECHNOL, V67, P5695, DOI 10.1109/TVT.2018.2805189; Zhang Y, 2021, ENERGY, V221, DOI 10.1016/j.energy.2021.119901; Zhang Z, 2022, APPL SOFT COMPUT, V118, DOI 10.1016/j.asoc.2022.108469; Zhang Z, 2022, ADV MANUF, V10, P114, DOI 10.1007/s40436-021-00366-x	35	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 7	2021	12								112093	10.1016/j.measurement.2022.112093	http://dx.doi.org/10.1016/j.measurement.2022.112093			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5X8BP					2022-12-18	WOS:000878822700003
J	Han, Q; Zheng, ZH; Liang, Q; Zhang, K; Yang, FF; Fu, XH; Luo, X; Ding, J; Xie, RH; Zhu, WX; Zhu, P				Han, Qing; Zheng, ZhaoHui; Liang, Qiang; Zhang, Kui; Yang, FengFan; Fu, XiangHui; Luo, Xing; Ding, Jin; Xie, Ronghua; Zhu, WenXiao; Zhu, Ping			Testing if Micro-CT Is Capable of Quantitating the Extent of Proteoglycan-Aggrecan Induced Axial Spondyloarthritis in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						spondyloarthritis; proteoglycan; aggrecan; BALB; c; animal models	ANKYLOSING-SPONDYLITIS; BALB/C MICE	Objective Injections of proteoglycan aggrecan (PGA) have been reported to induce axial spondyloarthritis (ax-SpA) in BALB/c mice. It is considered to be a model for radiographic ax-SpA. However, evaluation of the extent of axial disease by histopathological assessment of every intervertebral space is labor-intensive. The objective of our paper is to test the feasibility of Micro Computed Tomography (Micro-CT) in rapidly enumerating the number of intervertebral spaces affected in each mouse. Methods Arthritis was induced in BALB/c mice by intraperitoneal injections of PGA. Involvement of several spinal segments, and selected sacroiliac and hip joints were evaluated by histopathology. The involvement of all intervertebral spaces, sacroiliac and hip joints was evaluated by Micro-CT. Results BALB/c mice injected with PGA developed histopathology of SpA-like axial lesions, including spondylitis, sacroiliac joint arthritis and hip joint arthritis. Micro-CT allowed us to clearly enumerate the number of lesions in each mouse. Conclusion Micro-CT allows quantitative assessment of the extent of axial involvement in PGA-induced mouse spondylitis. This can be a useful tool in assessing therapeutic interventions.	[Han, Qing; Zheng, ZhaoHui; Liang, Qiang; Zhang, Kui; Yang, FengFan; Fu, XiangHui; Luo, Xing; Ding, Jin; Xie, Ronghua; Zhu, WenXiao; Zhu, Ping] Fourth Mil Med Univ, PLA Specialized Res Inst Rheumatol & Immunol, Xijing Hosp, Dept Clin Immunol, Xian, Peoples R China; [Han, Qing; Zheng, ZhaoHui; Liang, Qiang; Zhang, Kui; Yang, FengFan; Fu, XiangHui; Luo, Xing; Ding, Jin; Xie, Ronghua; Zhu, WenXiao; Zhu, Ping] Natl Translat Sci Ctr Mol Med, Xian, Peoples R China	Air Force Military Medical University	Zhu, P (corresponding author), Fourth Mil Med Univ, PLA Specialized Res Inst Rheumatol & Immunol, Xijing Hosp, Dept Clin Immunol, Xian, Peoples R China.; Zhu, P (corresponding author), Natl Translat Sci Ctr Mol Med, Xian, Peoples R China.	zhuping@fmmu.edu.cn			National Basic Research Program of China [2015CB553704]; National Nature Science Foundation Key Research Project of China [2017YFC0909002]	National Basic Research Program of China(National Basic Research Program of China); National Nature Science Foundation Key Research Project of China	This study was funded by the National Basic Research Program of China (2015CB553704) and the National Nature Science Foundation Key Research Project of China (2017YFC0909002).	Bardos T, 2005, ANN RHEUM DIS, V64, P981, DOI 10.1136/ard.2004.029710; Coates LC, 2021, ARTHRIT CARE RES, V73, P856, DOI 10.1002/acr.24174; Farkas B, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2613; Giant TT, 2004, METH MOLEC MED, V102, P313; Ivanova M, 2019, RHEUMATOL INT, V39, P111, DOI 10.1007/s00296-018-4204-0; Lee SH, 2013, RHEUMATOL INT, V33, P1689, DOI 10.1007/s00296-012-2624-9; MIKECZ K, 1987, ARTHRITIS RHEUM, V30, P306, DOI 10.1002/art.1780300310; Sode J, 2018, BMC MED GENET, V19, DOI 10.1186/s12881-018-0680-z; Szabo Z, 2005, ARTHRITIS RHEUM-US, V52, P2452, DOI 10.1002/art.21193; Tseng HW, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-015-0805-0; Wang CH, 2015, CLIN RHEUMATOL, V34, P1073, DOI 10.1007/s10067-015-2939-5; Wang R, 2018, CURR OPIN RHEUMATOL, V30, P137, DOI 10.1097/BOR.0000000000000475	12	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 5	2021	12								681217	10.3389/fimmu.2021.681217	http://dx.doi.org/10.3389/fimmu.2021.681217			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TK6MD	34290703	gold, Green Published			2022-12-18	WOS:000674269300001
J	Kang, SJ; Park, KJ; Jin, HM; Cho, YN; Oh, TH; Kim, SE; Kim, UJ; Park, KH; Jung, SI; Kim, TO; Kim, HS; Jo, YG; Ju, JK; Kee, SJ; Park, YW				Kang, Seung-Ji; Park, Ki-Jeong; Jin, Hye-Mi; Cho, Young-Nan; Oh, Tae Hoon; Kim, Seong Eun; Kim, Uh Jin; Park, Kyung-Hwa; Jung, Sook-In; Kim, Tae-Ok; Kim, Hyo Shin; Jo, Young-Goun; Ju, Jae Kyun; Kee, Seung-Jung; Park, Yong-Wook			Circulating Plasmacytoid and Conventional Dendritic Cells Are Numerically and Functionally Deficient in Patients With Scrub Typhus	FRONTIERS IN IMMUNOLOGY			English	Article						cytokine; Orientia tsutsugamushi; plasmacytoid dendritic cells; scrub typhus; conventional dendritic cells	TUMOR-NECROSIS-FACTOR; RICKETTSIA-TSUTSUGAMUSHI; ORIENTIA-TSUTSUGAMUSHI; HOST-DEFENSE; OLIGONUCLEOTIDES; ACTIVATION; INDUCTION; SUBSETS	Background Dendritic cells (DCs) are specialized antigen-presenting cells known to bridge innate and adaptive immune reactions. However, the relationship between circulating DCs and Orientia tsutsugamushi infection is unclear. Therefore, this study aimed to examine the level and function of plasmacytoid DCs (pDCs) and conventional DCs (cDCs), two subsets of circulating DCs, in scrub typhus patients. Methods The study included 35 scrub typhus patients and 35 healthy controls (HCs). pDC and cDC levels, CD86 and CD274 expression, and cytokine levels were measured using flow cytometry. Results Circulating pDC and cDC levels were found to be significantly reduced in scrub typhus patients, which were correlated with disease severity. The patients displayed increased percentages of CD86(+) pDCs, CD274(+) pDCs, and CD274(+) cDCs in the peripheral blood. The alterations in the levels and surface phenotypes of pDCs and cDCs were recovered in the remission state. In addition, the production of interferon (IFN)-alpha and tumor necrosis factor (TNF)-alpha by circulating pDCs, and interleukin (IL)-12 and TNF-alpha by circulating cDCs was reduced in scrub typhus patients. Interestingly, our in vitro experiments showed that the percentages of CD86(+) pDCs, CD274(+) pDCs, and CD274(+) cDCs were increased in cultures treated with cytokines including IFN-gamma, IL-12, and TNF-alpha. Conclusions This study demonstrates that circulating pDCs and cDCs are numerically deficient and functionally impaired in scrub typhus patients. In addition, alterations in the expression levels of surface phenotypes of pDCs and cDCs could be affected by pro-inflammatory cytokines.	[Kang, Seung-Ji; Oh, Tae Hoon; Kim, Seong Eun; Kim, Uh Jin; Park, Kyung-Hwa; Jung, Sook-In] Chonnam Natl Univ, Sch Med, Hosp, Dept Infect Dis, Gwangju, South Korea; [Park, Ki-Jeong; Jin, Hye-Mi; Cho, Young-Nan; Park, Yong-Wook] Chonnam Natl Univ Med Sch & Hosp, Dept Rheumatol, Gwangju, South Korea; [Kim, Tae-Ok] Chonnam Natl Univ Med Sch & Hosp, Dept Pulmonol, Gwangju, South Korea; [Kim, Hyo Shin; Jo, Young-Goun; Ju, Jae Kyun] Chonnam Natl Univ Med Sch & Hosp, Dept Surg, Gwangju, South Korea; [Kee, Seung-Jung] Chonnam Natl Univ Med Sch & Hosp, Dept Lab Med, Gwangju, South Korea	Chonnam National University; Chonnam National University; Chonnam National University Hospital; Chonnam National University; Chonnam National University Hospital; Chonnam National University; Chonnam National University Hospital; Chonnam National University; Chonnam National University Hospital	Park, YW (corresponding author), Chonnam Natl Univ Med Sch & Hosp, Dept Rheumatol, Gwangju, South Korea.; Kee, SJ (corresponding author), Chonnam Natl Univ Med Sch & Hosp, Dept Lab Med, Gwangju, South Korea.	sjkee@jnu.ac.kr; parkyw@jnu.ac.kr		gi, seungjeong/0000-0001-9708-5837	National Research Foundation of Korea [2019R1A2C1003238, 2019R1I1A1A01040762]; Korea Health Technology R&D Project through the Korea Health Industry Development Institute - Ministry of Health & Welfare, Republic of Korea [HI20C0079]; Chonnam National University Hospital Biomedical Research Institute [CRI18042-21]	National Research Foundation of Korea(National Research Foundation of Korea); Korea Health Technology R&D Project through the Korea Health Industry Development Institute - Ministry of Health & Welfare, Republic of Korea; Chonnam National University Hospital Biomedical Research Institute	This work was supported by the National Research Foundation of Korea (2019R1A2C1003238, 2019R1I1A1A01040762), the Korea Health Technology R&D Project through the Korea Health Industry Development Institute funded by the Ministry of Health & Welfare, Republic of Korea (HI20C0079) and the Chonnam National University Hospital Biomedical Research Institute (CRI18042-21).	Astrup E, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002648; Bakdash G, 2014, EXPERT REV CLIN IMMU, V10, P915, DOI 10.1586/1744666X.2014.912561; Balan S, 2019, INT REV CEL MOL BIO, V348, P1, DOI 10.1016/bs.ircmb.2019.07.004; Cavaleiro R, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000667; Choi JH, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0001981; Chu H, 2013, J MICROBIOL BIOTECHN, V23, P1159, DOI 10.4014/jmb.1303.03019; Collin M, 2018, IMMUNOLOGY, V154, P3, DOI 10.1111/imm.12888; Diaz FE, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00076-17; GENG PG, 1994, MICROBIOL IMMUNOL, V38, P703, DOI 10.1111/j.1348-0421.1994.tb01845.x; Grimaldi D, 2011, INTENS CARE MED, V37, P1438, DOI 10.1007/s00134-011-2306-1; Guisset O, 2007, INTENS CARE MED, V33, P148, DOI 10.1007/s00134-006-0436-7; Hartmann G, 2003, EUR J IMMUNOL, V33, P1633, DOI 10.1002/eji.200323813; Huang JH, 2011, J INFECT DIS, V204, P1557, DOI 10.1093/infdis/jir616; Huang MH, 2018, INT J INFECT DIS, V77, P5, DOI 10.1016/j.ijid.2018.09.015; JERRELLS TR, 1994, MICROBIOL IMMUNOL, V38, P713, DOI 10.1111/j.1348-0421.1994.tb01846.x; Kang SJ, 2018, J INFECT DIS, V218, P1813, DOI 10.1093/infdis/jiy402; Kang SJ, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005815; Kang SJ, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004832; KIM IS, 1993, J CLIN MICROBIOL, V31, P2057, DOI 10.1128/JCM.31.8.2057-2060.1993; Krug A, 2003, J IMMUNOL, V170, P3468, DOI 10.4049/jimmunol.170.7.3468; Lertjuthaporn S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200564; Marin E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00274; Min CK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02022; Moron CG, 2001, MODERN PATHOL, V14, P752, DOI 10.1038/modpathol.3880385; Pacanowski J, 2001, BLOOD, V98, P3016, DOI 10.1182/blood.V98.10.3016; Paris DH, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001466; Park SW, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003814; Rahman T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00608; Rhodes JW, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01088; Scumpia PO, 2005, J IMMUNOL, V175, P3282, DOI 10.4049/jimmunol.175.5.3282; Shen T, 2010, J MED VIROL, V82, P1152, DOI 10.1002/jmv.21809; Soong L, 2018, J IMMUNOL, V200, P1233, DOI 10.4049/jimmunol.1701219; Swiecki M, 2015, NAT REV IMMUNOL, V15, P471, DOI 10.1038/nri3865; Taylor AJ, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003971; Villani AC, 2017, SCIENCE, V356, DOI 10.1126/science.aah4573; Wculek SK, 2020, NAT REV IMMUNOL, V20, P7, DOI 10.1038/s41577-019-0210-z; Xu G, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006062; Zhang WJ, 2017, INT J INFECT DIS, V54, P113, DOI 10.1016/j.ijid.2016.11.418	38	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 1	2021	12								700755	10.3389/fimmu.2021.700755	http://dx.doi.org/10.3389/fimmu.2021.700755			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TJ8BR	34276693	gold, Green Published			2022-12-18	WOS:000673700600001
J	Paiva, MB; Ribeiro-Romao, RP; Resende-Vieira, L; Braga-Gomes, T; Oliveira, MP; Saavedra, AF; Silva-Couto, L; Albuquerque, HG; Moreira, OC; Pinto, EF; Da-Cruz, AM; Gomes-Silva, A				Paiva, Milla B.; Ribeiro-Romao, Raquel Peralva; Resende-Vieira, Larissa; Braga-Gomes, Thais; Oliveira, Marcia P.; Saavedra, Andrea F.; Silva-Couto, Luzinei; Albuquerque, Hermano G.; Moreira, Otacilio C.; Pinto, Eduardo Fonseca; Da-Cruz, Alda Maria; Gomes-Silva, Adriano			A Cytokine Network Balance Influences the Fate of Leishmania (Viannia) braziliensis Infection in a Cutaneous Leishmaniasis Hamster Model	FRONTIERS IN IMMUNOLOGY			English	Article						cytokines; cutaneous lesions; parasite load; disease control; Leishmania (Viannia) braziliensis; iNOS; arginase; immune-regulation; hamster model	CD4(+) T-CELLS; AMERICAN TEGUMENTARY LEISHMANIASIS; GROWTH-FACTOR-BETA; IL-4 PRODUCTION; SUSCEPTIBLE MICE; PARASITE LOAD; RESPONSES; EXPRESSION; INSTRUCTS; SKIN	The golden hamster is a suitable model for studying cutaneous leishmaniasis (CL) due to Leishmania (Viannia) braziliensis. Immunopathological mechanisms are well established in the L. (L.) major-mouse model, in which IL-4 instructs a Th2 response towards progressive infection. In the present study, we evaluated the natural history of L. braziliensis infection from its first stages up to lesion establishment, with the aim of identifying immunological parameters associated with the disease outcome and parasitism fate. To this end, hamsters infected with 10(4), 10(5), or 10(6) promastigotes were monitored during the first hours (4h, 24h), early (15 days, 30 days) and late (50 days) post-infection (pi) phases. Cytokines, iNOS and arginase gene expression were quantified in the established lesions by reverse transcription-quantitative PCR. Compared to the 10(5) or 10(6) groups, 10(4) animals presented lower lesions sizes, less tissue damage, and lower IgG levels. Basal gene expression in normal skin was high for TGF-beta, and intermediary for TNF, IL-6, and IL-4. At 4hpi, no cytokine induction was observed in the 10(4) group, while an upregulation of IL-6, IL-10, and IL-4 was observed in the 10(6) group. At 15dpi, lesion appearance was accompanied by an increased expression of all assessed cytokines, markedly in the 10(5) and 10(6) groups. Upregulation of all investigated cytokines was observed in the late phase, although less expressive in the 10(4) group. IFN-gamma was the depending variable influencing tissue damage, while IL-6 was associated to parasite load. The network correlating gene expression and clinical and laboratorial parameters indicated inoculum-independent associations at 15 and 30dpi. A strong positive network correlation was observed in the 10(4) group, but not in the 10(5) or 10(6) groups. In conclusion, IL-4, IL-6, IL-10, and TGF-beta are linked o L. braziliensis progression. However, a balanced cytokine network is the key for an immune response able to reduce the ongoing infection and reduce pathological damage.	[Paiva, Milla B.; Ribeiro-Romao, Raquel Peralva; Resende-Vieira, Larissa; Braga-Gomes, Thais; Oliveira, Marcia P.; Saavedra, Andrea F.; Silva-Couto, Luzinei; Pinto, Eduardo Fonseca; Da-Cruz, Alda Maria; Gomes-Silva, Adriano] Fiocruz MS, Inst Oswaldo Cruz, Lab Interdisciplinar Pesquisas Med, Rio De Janeiro, Brazil; [Albuquerque, Hermano G.] Fiocruz MS, Inst Oswaldo Cruz, Lab Transmissores Hematozoarios, Rio De Janeiro, Brazil; [Moreira, Otacilio C.] Fiocruz MS, Inst Oswaldo Cruz, Lab Biol Mol & Doencas Endem, Rio De Janeiro, Brazil; [Pinto, Eduardo Fonseca; Da-Cruz, Alda Maria] Rede Pesquisas Saude Estado Rio de Janeiro FAPERJ, Rio De Janeiro, Brazil; [Da-Cruz, Alda Maria] Univ Estado Rio De Janeiro, Fac Ciencias Med, Disciplina Parasitol MIP, Rio De Janeiro, Brazil; [Da-Cruz, Alda Maria] Natl Inst Sci & Technol Neuroimmunomodulat INCT N, Rio De Janeiro, Brazil; [Gomes-Silva, Adriano] Fiocruz MS, Inst Nacl Infectol Evandro Chagas, Lab Pesquisa Clin Micobacterioses, Rio De Janeiro, Brazil	Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; Universidade do Estado do Rio de Janeiro; Fundacao Oswaldo Cruz	Da-Cruz, AM (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Interdisciplinar Pesquisas Med, Rio De Janeiro, Brazil.; Da-Cruz, AM (corresponding author), Rede Pesquisas Saude Estado Rio de Janeiro FAPERJ, Rio De Janeiro, Brazil.; Da-Cruz, AM (corresponding author), Univ Estado Rio De Janeiro, Fac Ciencias Med, Disciplina Parasitol MIP, Rio De Janeiro, Brazil.; Da-Cruz, AM (corresponding author), Natl Inst Sci & Technol Neuroimmunomodulat INCT N, Rio De Janeiro, Brazil.; Gomes-Silva, A (corresponding author), Fiocruz MS, Inst Nacl Infectol Evandro Chagas, Lab Pesquisa Clin Micobacterioses, Rio De Janeiro, Brazil.	alda@ioc.fiocruz.br; adriano.gomes@ini.fiocruz.br			CNPq (Universal) [311459/2018-8]; Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro [E26/2002.944/2016]; IOC/FIOCRUZ-PAEF [IOC-023FIO-18-53]	CNPq (Universal)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); IOC/FIOCRUZ-PAEF	This work was supported by CNPq (Universal) -311459/2018-8, Fundacao de Amparo aPesquisa do Estado do Rio de Janeiro: E26/2002.944/2016 and IOC/FIOCRUZ-PAEF IOC-023FIO-18-53.	Akhoundi M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004349; Andrade-Narvaez FJ, 2016, MEM I OSWALDO CRUZ, V111, P599, DOI 10.1590/0074-02760160138; BARRAL A, 1995, AM J TROP MED HYG, V53, P256, DOI 10.4269/ajtmh.1995.53.256; BARRAL A, 1993, P NATL ACAD SCI USA, V90, P3442, DOI 10.1073/pnas.90.8.3442; Belkaid Y, 2000, J IMMUNOL, V165, P969, DOI 10.4049/jimmunol.165.2.969; Biedermann T, 2001, NAT IMMUNOL, V2, P1054, DOI 10.1038/ni725; Bittar RC, 2007, MEM I OSWALDO CRUZ, V102, P625, DOI 10.1590/S0074-02762007005000069; Bourreau E, 2009, INFECT IMMUN, V77, P1465, DOI 10.1128/IAI.01398-08; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; Costa RS, 2018, J INFECT DIS, V217, P840, DOI 10.1093/infdis/jix627; Covre LP, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03001; Cupolillo E, 2003, J CLIN MICROBIOL, V41, P3126, DOI 10.1128/JCM.41.7.3126-3132.2003; Guerra JAD, 2015, REV SOC BRAS MED TRO, V48, P12, DOI 10.1590/0037-8682-0268-2013; Guerra JAD, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000980; Mendes-Aguiar CD, 2016, CLIN EXP IMMUNOL, V185, P202, DOI 10.1111/cei.12798; de Oliveira MP, 2005, EXP PARASITOL, V109, P72, DOI 10.1016/j.exppara.2004.11.011; de Oliveira-Neto MP, 2000, INT J DERMATOL, V39, P506, DOI 10.1046/j.1365-4362.2000.00969.x; Descatoire M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01265; Ehrchen JM, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000871; Follador I, 2002, CLIN INFECT DIS, V34, pE54, DOI 10.1086/340261; Giraud E, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0323-8; Gomes CM, 2014, PARASITE IMMUNOL, V36, P225, DOI 10.1111/pim.12109; Gomes-Silva A, 2008, REV SOC BRAS MED TRO, V41, P135, DOI 10.1590/S0037-86822008000200001; Govender M, 2018, INFECT IMMUN, V86, DOI [10.1128/IAI.00710-18, 10.1128/iai.00710-18]; Himmelrich H, 2000, J IMMUNOL, V164, P4819, DOI 10.4049/jimmunol.164.9.4819; Hurdayal R, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003699; Jirmanus L, 2012, AM J TROP MED HYG, V86, P426, DOI 10.4269/ajtmh.2012.11-0378; Kimblin N, 2008, P NATL ACAD SCI USA, V105, P10125, DOI 10.1073/pnas.0802331105; Launois P, 1997, IMMUNITY, V6, P541, DOI 10.1016/S1074-7613(00)80342-8; Launois P, 1995, EUR J IMMUNOL, V25, P3298, DOI 10.1002/eji.1830251215; Launois P, 2002, J IMMUNOL, V168, P4628, DOI 10.4049/jimmunol.168.9.4628; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LOPEZ M, 1993, AM J TROP MED HYG, V49, P348, DOI 10.4269/ajtmh.1993.49.348; Machado P, 2002, CLIN INFECT DIS, V34, pE69, DOI 10.1086/340526; Maucher M, 2011, BIOINFORMATICS, V27, P1529, DOI 10.1093/bioinformatics/btr166; Montoya A, 2019, PEERJ, V6, DOI 10.7717/peerj.6228; Montoya A, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00350; Morgado FN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21277-1; Oliveira WN, 2014, CYTOKINE, V66, P127, DOI 10.1016/j.cyto.2013.12.016; Osorio Y, 2003, PARASITE IMMUNOL, V25, P139, DOI 10.1046/j.1365-3024.2003.00615.x; Peniche AG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179084; Pessenda G, 2020, PARASITE IMMUNOL, V42, DOI 10.1111/pim.12722; Pereira LDR, 2017, INT J INFECT DIS, V57, P132, DOI 10.1016/j.ijid.2017.01.036; Rego FD, 2019, MOL IMMUNOL, V106, P36, DOI 10.1016/j.molimm.2018.12.013; Rego FD, 2018, PARASITOL RES, V117, P3157, DOI 10.1007/s00436-018-6014-4; Ribeiro-Gomes FL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002536; Ribeiro-Romao RP, 2014, INFECT IMMUN, V82, P5203, DOI 10.1128/IAI.02083-14; Ribeiro-Romao RP, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1647-6; Roma EH, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1472-y; Romero Gustavo A. S., 2001, Clinical Infectious Diseases, V32, P1304, DOI 10.1086/319990; Saldanha MG, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00355; Saldanha MG, 2017, AM J TROP MED HYG, V96, P645, DOI 10.4269/ajtmh.16-0539; Schaper F, 2015, CYTOKINE GROWTH F R, V26, P475, DOI 10.1016/j.cytogfr.2015.07.004; SCOTT P, 1991, J IMMUNOL, V147, P3149; Shaw J, 2019, T ROY SOC TROP MED H, V113, P108, DOI 10.1093/trstmh/try090; Silveira FT, 2004, MEM I OSWALDO CRUZ, V99, P239, DOI 10.1590/S0074-02762004000300001; Sousa R, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02464; Vinhaes CL, 2019, CYTOKINE, V123, DOI 10.1016/j.cyto.2019.154759; World Health Organization, LEISHMANIASIS; ZAJTCHUK JT, 1989, LARYNGOSCOPE, V99, P925, DOI 10.1288/00005537-198909000-00006	60	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 1	2021	12								656919	10.3389/fimmu.2021.656919	http://dx.doi.org/10.3389/fimmu.2021.656919			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TI4UY	34276650	gold, Green Published, Green Submitted			2022-12-18	WOS:000672797700001
J	Roe, D; Vierra-Green, C; Pyo, CW; Geraghty, DE; Spellman, SR; Maiers, M; Kuang, R				Roe, David; Vierra-Green, Cynthia; Pyo, Chul-Woo; Geraghty, Daniel E.; Spellman, Stephen R.; Maiers, Martin; Kuang, Rui			Corrigendum: A Detailed View of KIR Haplotype Structures and Gene Families as Provided by a New Motif-Based Multiple Sequence Alignment (vol 11, 585731, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						killer-cell immunoglobulin-like receptors (KIR); alignment; DNA; haplotype; nomenclature; natural killer			[Roe, David; Kuang, Rui] Univ Minnesota, Bioinformat & Computat Biol, Rochester, MN 55904 USA; [Vierra-Green, Cynthia; Spellman, Stephen R.; Maiers, Martin] Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA; [Pyo, Chul-Woo; Geraghty, Daniel E.] Fred Hutchinson Canc Res, Div Clin Res, Seattle, WA USA; [Kuang, Rui] Univ Minnesota, Dept Comp Sci & Engn, Minneapolis, MN USA	University of Minnesota System; University of Minnesota Rochester; Center for International Blood & Marrow Transplant Research; Fred Hutchinson Cancer Center; University of Minnesota System; University of Minnesota Twin Cities	Roe, D (corresponding author), Univ Minnesota, Bioinformat & Computat Biol, Rochester, MN 55904 USA.	roex0050@umn.edu						Roe D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585731	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 1	2021	12								724357	10.3389/fimmu.2021.724357	http://dx.doi.org/10.3389/fimmu.2021.724357			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TJ9FY	34276710	gold, Green Published			2022-12-18	WOS:000673779300001
J	Ding, XN; Mei, Y; Mao, Z; Long, LL; Han, QX; You, YQ; Zhu, HY				Ding, Xiaonan; Mei, Yan; Mao, Zhi; Long, Lingling; Han, Qiuxia; You, Yanqin; Zhu, Hanyu			Association of Immune and Inflammatory Gene Polymorphism With the Risk of IgA Nephropathy: A Systematic Review and Meta-Analysis of 45 Studies	FRONTIERS IN IMMUNOLOGY			English	Review						IgA nephropathy; susceptibility; inflammatory molecules; immune pathway; single-nucleotide polymorphism; meta-analysis	TRANSFORMING GROWTH-FACTOR-BETA-1 GENE; IMMUNOGLOBULIN-A NEPHROPATHY; GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY; VARIANTS; PATHOPHYSIOLOGY; ST6GALNAC2; EXPRESSION; PROMOTER; LOCI	IgA nephropathy is the most prevalent primary glomerulonephritis worldwide, with identical immunopathological characteristics caused by multiple etiologies as well as influenced by geographical and ethnical factors. To elucidate the role of immunologic and inflammatory mechanisms in the susceptibility to IgA nephropathy, we explored single nucleotide polymorphisms of related molecules in the immune pathways. We searched the PubMed database for studies that involved all gene variants of molecules in the 20 immunologic and inflammatory pathways selected from the Kyoto Encyclopedia of Genes and Genomes database. The odds ratios with their corresponding 95% confidence intervals in six genetic models (allele model, dominant model, homozygote model, heterozygote model, overdominant model, and recessive model) were summarized using fixed or random effect models. Subgroup analysis was conducted based on different ethnicities with generalized odds ratios. Heterogeneity was evaluated using the Q and I-2 tests. Begg's funnel plot and Egger's linear regression test were used to evaluating possible publication bias among the included studies, and sensitivity analysis was used to test the stability of the overall results. A total of 45 studies met our selection criteria and eight related genetic association studies were retrieved, including 320 single-nucleotide polymorphisms from 20 candidate pathways, ranging from 2000 to 2021. A total of 28,994 healthy people versus 20,600 IgA nephropathy patients were enrolled. Upon meta-analyzed results that TGFB1 (rs1800469, rs1982073, rs1800471), IL-1B (rs1143627), IL-18 (rs1946518), and TLR1 (rs5743557) showed effect with or without ethnicity difference. And 10 variants presented stable and robust related to IgA nephropathy. This research showed that genetic variants are related to the immunologic and inflammatory effects of IgA nephropathy pathogenesis. The meta-analysis results supported the previous researches, and may help deepen the understanding of pathogenesis and explore new targets for IgA nephropathy-specific immunotherapy.	[Ding, Xiaonan] Med Sch Chinese PLA, Beijing, Peoples R China; [Ding, Xiaonan; Mei, Yan; Long, Lingling; Han, Qiuxia; Zhu, Hanyu] Chinese Peoples Liberat Army Gen Hosp, Chinese PLA Inst Nephrol, Natl Clin Res Ctr Kidney Dis, Dept Nephrol,Med Ctr 1,State Key Lab Kidney Dis, Beijing, Peoples R China; [Mao, Zhi] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Crit Care Med, Beijing, Peoples R China; [You, Yanqin] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Obstet & Gynecol, Beijing, Peoples R China	Chinese People's Liberation Army General Hospital; Chinese People's Liberation Army General Hospital; Chinese People's Liberation Army General Hospital; Chinese People's Liberation Army General Hospital	Zhu, HY (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Chinese PLA Inst Nephrol, Natl Clin Res Ctr Kidney Dis, Dept Nephrol,Med Ctr 1,State Key Lab Kidney Dis, Beijing, Peoples R China.; You, YQ (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Obstet & Gynecol, Beijing, Peoples R China.	youyanqin76@163.com; hanyuzhu301@126.com			National Natural Science Foundation of China [61971441]; National Key R&D Program of China [2016YFC1305500]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China	This research was funded by The National Natural Science Foundation of China (Nos. 61971441) and the National Key R&D Program of China (Nos. 2016YFC1305500).	Brezzi B, 2009, J NEPHROL, V22, P747; Carturan S, 2004, J NEPHROL, V17, P786; Donadio JV, 2002, NEW ENGL J MED, V347, P738, DOI 10.1056/NEJMra020109; Feehally J, 2010, J AM SOC NEPHROL, V21, P1791, DOI 10.1681/ASN.2010010076; Feng Y, 2019, INT IMMUNOPHARMACOL, V71, P295, DOI 10.1016/j.intimp.2019.03.041; Fu DY, 2020, IMMUNOBIOLOGY, V225, DOI 10.1016/j.imbio.2020.151973; Gao J, 2017, KIDNEY BLOOD PRESS R, V42, P136, DOI 10.1159/000473889; Gao J, 2017, KIDNEY BLOOD PRESS R, V42, P89, DOI 10.1159/000471899; Gao J, 2016, ONCOTARGET, V7, P83031, DOI 10.18632/oncotarget.12965; Gharavi AG, 2011, NAT GENET, V43, P321, DOI 10.1038/ng.787; Giedraitis V, 2001, J NEUROIMMUNOL, V112, P146, DOI 10.1016/S0165-5728(00)00407-0; Gros P, 2008, NAT REV IMMUNOL, V8, P48, DOI 10.1038/nri2231; Hahn WH, 2009, PEDIATR NEPHROL, V24, P1329, DOI 10.1007/s00467-009-1146-5; He B, 2007, IMMUNITY, V26, P812, DOI 10.1016/j.immuni.2007.04.014; Hou Ling, 2009, Zhongguo Dang Dai Er Ke Za Zhi, V11, P113; Infante B, 2020, CLIN KIDNEY J, V13, P758, DOI 10.1093/ckj/sfaa060; Jacob M, 2018, KIDNEY BLOOD PRESS R, V43, P360, DOI 10.1159/000488069; Jancar S, 2005, TRENDS IMMUNOL, V26, P48, DOI 10.1016/j.it.2004.11.007; Jarrick S, 2019, J AM SOC NEPHROL, V30, P866, DOI 10.1681/ASN.2018101017; Jung HY, 2012, KIDNEY RES CLIN PRAC, V31, P234, DOI 10.1016/j.krcp.2012.09.006; Kim HJ, 2011, J GENET, V90, P151, DOI 10.1007/s12041-011-0042-5; Kiryluk K, 2014, NAT GENET, V46, P1187, DOI 10.1038/ng.3118; Kiryluk K, 2013, ANNU REV MED, V64, P339, DOI 10.1146/annurev-med-041811-142014; Kiryluk K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002765; Lai KN, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.1; Lee JS, 2011, INT J IMMUNOGENET, V38, P133, DOI 10.1111/j.1744-313X.2010.00978.x; Lewis Cathryn M, 2012, Cold Spring Harb Protoc, V2012, P297, DOI 10.1101/pdb.top068163; Li GS, 2007, HUM MUTAT, V28, P950, DOI 10.1002/humu.20543; Li M, 2020, J AM SOC NEPHROL, V31, P2949, DOI 10.1681/ASN.2019080799; Li M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8270; Lim CS, 2005, CLIN NEPHROL, V63, P61; Liu XQ, 2008, J AM SOC NEPHROL, V19, P1025, DOI 10.1681/ASN.2007091013; Lu C, 2015, EXP THER MED, V9, P2127, DOI 10.3892/etm.2015.2404; Mai TV, 2009, NEPHROL DIAL TRANSPL, V24, P3061, DOI 10.1093/ndt/gfp079; Minelli C, 2005, INT J EPIDEMIOL, V34, P1319, DOI 10.1093/ije/dyi169; Novak J, 2011, NEPHROL DIAL TRANSPL, V26, P3451, DOI 10.1093/ndt/gfr448; Pan M, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0658-7; Park SR, 2001, EUR J IMMUNOL, V31, P1706, DOI 10.1002/1521-4141(200106)31:6<1706::AID-IMMU1706>3.0.CO;2-Z; Rauta V, 2003, NEPHROL DIAL TRANSPL, V18, P1785, DOI 10.1093/ndt/gfg234; Roberts ISD, 2014, NAT REV NEPHROL, V10, P445, DOI 10.1038/nrneph.2014.92; Saka S, 2015, J HUM GENET, V60, P573, DOI 10.1038/jhg.2015.88; Sato F, 2004, TISSUE ANTIGENS, V64, P35, DOI 10.1111/j.1399-0039.2004.00256.x; Schena FP, 2018, SEMIN NEPHROL, V38, P435, DOI 10.1016/j.semnephrol.2018.05.013; Shi DC, 2020, J HUM GENET, V65, P241, DOI 10.1038/s10038-019-0699-9; Shi MM, 2021, KIDNEY INT REP, V6, P91, DOI 10.1016/j.ekir.2020.10.015; Smith KD, 2009, CURR OPIN NEPHROL HY, V18, P189, DOI 10.1097/MNH.0b013e32832a1d5f; Suzuki H, 2014, J BIOL CHEM, V289, P5330, DOI 10.1074/jbc.M113.512277; Suzuki H, 2011, J AM SOC NEPHROL, V22, P1795, DOI 10.1681/ASN.2011050464; Wang YN, 2021, J AM SOC NEPHROL, V32, P545, DOI 10.1681/ASN.2020060823; Wyatt RJ, 2013, NEW ENGL J MED, V368, P2402, DOI 10.1056/NEJMra1206793; Yang Bin, 2018, Oncotarget, V9, P7066, DOI 10.18632/oncotarget.23829; Yang B, 2017, APPL IMMUNOHISTO M M, V25, P725, DOI 10.1097/PAI.0000000000000364; Yu XQ, 2012, NAT GENET, V44, P178, DOI 10.1038/ng.1047; Zhang DF, 2017, ONCOTARGET, V8, P71750, DOI 10.18632/oncotarget.17603; Zhong Z, 2017, J GENE MED, V19, DOI 10.1002/jgm.2966; Zhou XJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061208; Zintzaras E, 2010, STAT APPL GENET MOL, V9, DOI 10.2202/1544-6115.1542	57	0	0	2	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 30	2021	12								683913	10.3389/fimmu.2021.683913	http://dx.doi.org/10.3389/fimmu.2021.683913			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TJ0ZF	34354705	gold, Green Published			2022-12-18	WOS:000673220300001
J	Vandooren, J; Pereira, RVS; Ugarte-Berzal, E; Rybakin, V; Noppen, S; Stas, MR; Bernaerts, E; Ganseman, E; Metzemaekers, M; Schols, D; Proost, P; Opdenakker, G				Vandooren, Jennifer; Pereira, Rafaela Vaz Sousa; Ugarte-Berzal, Estefania; Rybakin, Vasily; Noppen, Sam; Stas, Melissa R.; Bernaerts, Eline; Ganseman, Eva; Metzemaekers, Mieke; Schols, Dominique; Proost, Paul; Opdenakker, Ghislain			Internal Disulfide Bonding and Glycosylation of Interleukin-7 Protect Against Proteolytic Inactivation by Neutrophil Metalloproteinases and Serine Proteases	FRONTIERS IN IMMUNOLOGY			English	Article						IL-7; matrix metalloproteinase-9; proteolysis; signal transduction; proliferation; neutrophils	MULTIPLE-SCLEROSIS; CD127 EXPRESSION; REMNANT EPITOPES; IL-7; GELATINASE; CELLS; RECEPTOR; EXPANSION; NAIVE; PROLIFERATION	Interleukin 7 (IL-7) is a cell growth factor with a central role in normal T cell development, survival and differentiation. The lack of IL-7-IL-7 receptor(R)-mediated signaling compromises lymphoid development, whereas increased signaling activity contributes to the development of chronic inflammation, cancer and autoimmunity. Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading. Several IL-7-associated pathologies are also characterized by increased presence of matrix metalloproteinase-9 (MMP-9), due to neutrophil degranulation and its regulated production by other cell types. Since proteases secreted by neutrophils are known to modulate the activity of many cytokines, we investigated the interactions between IL-7, MMP-9 and several other neutrophil-derived proteases. We demonstrated that MMP-9 efficiently cleaved human IL-7 in the exposed loop between the alpha-helices C and D and that this process is delayed by IL-7 N-linked glycosylation. Functionally, the proteolytic cleavage of IL-7 did not influence IL-7R alpha binding and internalization nor the direct pro-proliferative effects of IL-7 on a T-ALL cell line (HPB-ALL) or in primary CD8(+) human peripheral blood mononuclear cells. A comparable effect was observed for the neutrophil serine proteases neutrophil elastase, proteinase 3 and combinations of neutrophil proteases. Hence, glycosylation and disulfide bonding as two posttranslational modifications influence IL-7 bioavailability in the human species: glycosylation protects against proteolysis, whereas internal cysteine bridging under physiological redox state keeps the IL-7 conformations as active proteoforms. Finally, we showed that mouse IL-7 does not contain the protease-sensitive loop and, consequently, was not cleaved by MMP-9. With the latter finding we discovered differences in IL-7 biology between the human and mouse species.	[Vandooren, Jennifer; Pereira, Rafaela Vaz Sousa; Ugarte-Berzal, Estefania; Rybakin, Vasily; Stas, Melissa R.; Bernaerts, Eline; Opdenakker, Ghislain] Katholieke Univ Leuven, Dept Microbiol Immunol & Transplantat, Lab Immunobiol, Rega Inst Med Res, Leuven, Belgium; [Noppen, Sam; Schols, Dominique] Katholieke Univ Leuven, Dept Microbiol Immunol & Transplantat, Lab Virol & Chemotherapy, Rega Inst Med Res, Leuven, Belgium; [Ganseman, Eva; Metzemaekers, Mieke; Proost, Paul] Katholieke Univ Leuven, Dept Microbiol, Rega Inst Med Res, Dept Microbiol Immunol & Transplantat, Leuven, Belgium	KU Leuven; KU Leuven; KU Leuven	Opdenakker, G (corresponding author), Katholieke Univ Leuven, Dept Microbiol Immunol & Transplantat, Lab Immunobiol, Rega Inst Med Res, Leuven, Belgium.	ghislain.opdenakker@kuleuven.be	Metzemaekers, Mieke/U-4989-2017; Noppen, Sam/F-8681-2018; Schols, Dominique/S-9057-2017; Vandooren, Jennifer/O-6424-2018; Opdenakker, Ghislain/Q-3130-2017; Proost, Paul/V-3052-2017	Metzemaekers, Mieke/0000-0002-8548-0124; Noppen, Sam/0000-0002-2831-5042; Schols, Dominique/0000-0003-3256-5850; Vandooren, Jennifer/0000-0002-7157-3370; Opdenakker, Ghislain/0000-0003-1714-2294; Ganseman, Eva/0000-0002-2305-7451; Proost, Paul/0000-0002-0133-5545	Research Foundation Flanders/FWO-Vlaanderen [G0A3820N]; KU Leuven [C16/17/010]; Belgian Charcot Foundation; Rega Foundation; L'Oreal-UNESCO-FWO; Research Foundation of Flanders (FWO Vlaanderen) [12Z0920N]	Research Foundation Flanders/FWO-Vlaanderen(FWO); KU Leuven(KU Leuven); Belgian Charcot Foundation; Rega Foundation; L'Oreal-UNESCO-FWO(L'Oreal Group); Research Foundation of Flanders (FWO Vlaanderen)(FWO)	This research was supported by the Research Foundation Flanders/FWO-Vlaanderen (G0A3820N), C1 funding of KU Leuven (C16/17/010), the Belgian Charcot Foundation (JV and GO), and the Rega Foundation (VR, JV). MM is supported by a predoctoral research fellowship "For Women in Science" of L'Oreal-UNESCO-FWO. There is no conflict of interest. JV is a postdoctoral fellow of the Research Foundation of Flanders (FWO Vlaanderen, mandate 12Z0920N).	Adrover JM, 2020, NAT IMMUNOL, V21, P135, DOI 10.1038/s41590-019-0571-2; Ardi VC, 2007, P NATL ACAD SCI USA, V104, P20262, DOI 10.1073/pnas.0706438104; Barata JT, 2019, NAT IMMUNOL, V20, P1584, DOI 10.1038/s41590-019-0479-x; Boudil A, 2015, NAT IMMUNOL, V16, P397, DOI 10.1038/ni.3122; Buffiere A, 2019, ONCOGENE, V38, P7357, DOI 10.1038/s41388-019-0921-4; Cauwe B, 2008, EXP CELL RES, V314, P2739, DOI 10.1016/j.yexcr.2008.07.008; Dai ZP, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abd1866; De Smedt R, 2020, BLOOD, V135, P1685, DOI 10.1182/blood.2019003880; Einarson TR, 2017, CURR MED RES OPIN, V33, P579, DOI 10.1080/03007995.2016.1276895; Fry TJ, 2005, J IMMUNOL, V174, P6571, DOI 10.4049/jimmunol.174.11.6571; GOODWIN RG, 1989, P NATL ACAD SCI USA, V86, P302, DOI 10.1073/pnas.86.1.302; Goth CK, 2018, TRENDS BIOCHEM SCI, V43, P269, DOI 10.1016/j.tibs.2018.02.005; Gregory SG, 2007, NAT GENET, V39, P1083, DOI 10.1038/ng2103; Henriques CM, 2010, BLOOD, V115, P3269, DOI 10.1182/blood-2009-10-246876; Hixon JA, 2020, LEUKEMIA, V34, P35, DOI 10.1038/s41375-019-0531-8; Horev L, 2015, J AM ACAD DERMATOL, V72, P1082, DOI 10.1016/j.jaad.2015.02.1118; Kamiguti AS, 2004, BRIT J HAEMATOL, V125, P128, DOI 10.1111/j.1365-2141.2004.04877.x; Kroemer RT, 1998, PROTEIN ENG, V11, P31, DOI 10.1093/protein/11.1.31; Leonard WJ, 2019, IMMUNITY, V50, P832, DOI 10.1016/j.immuni.2019.03.028; Levy Y, 2012, CLIN INFECT DIS, V55, P291, DOI 10.1093/cid/cis383; Levy Y, 2009, J CLIN INVEST, V119, P997, DOI 10.1172/JCI38052; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Liu Y, 2017, NAT GENET, V49, P1211, DOI 10.1038/ng.3909; Lundmark F, 2007, NAT GENET, V39, P1108, DOI 10.1038/ng2106; Mackall CL, 2011, NAT REV IMMUNOL, V11, P330, DOI 10.1038/nri2970; Martin CE, 2017, IMMUNITY, V47, P171, DOI 10.1016/j.immuni.2017.07.005; MASURE S, 1991, EUR J BIOCHEM, V198, P391, DOI 10.1111/j.1432-1033.1991.tb16027.x; Mazzucchelli R, 2007, NAT REV IMMUNOL, V7, P144, DOI 10.1038/nri2023; McElroy CA, 2009, STRUCTURE, V17, P54, DOI 10.1016/j.str.2008.10.019; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Nelissen I, 2003, BRAIN, V126, P1371, DOI 10.1093/brain/awg129; Nuti E, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071634; OPDENAKKER G, 1995, FASEB J, V9, P453, DOI 10.1096/fasebj.9.5.7896019; Opdenakker G, 1998, IMMUNOL TODAY, V19, P182, DOI 10.1016/S0167-5699(97)01243-7; Opdenakker G, 2020, TRENDS IMMUNOL, V41, P367, DOI 10.1016/j.it.2020.03.004; Patsopoulos NA, 2019, SCIENCE, V365, P1417, DOI 10.1126/science.aav7188; Perna SK, 2014, CLIN CANCER RES, V20, P131, DOI 10.1158/1078-0432.CCR-13-1016; RICH BE, 1993, J EXP MED, V177, P305, DOI 10.1084/jem.177.2.305; Rorvig S, 2013, J LEUKOCYTE BIOL, V94, P711, DOI 10.1189/jlb.1212619; Rosenberg SA, 2006, J IMMUNOTHER, V29, P313, DOI 10.1097/01.cji.0000210386.55951.c2; RUDD PM, 1994, BIOCHEMISTRY-US, V33, P17, DOI 10.1021/bi00167a003; Rybakin V, 2019, BIOCHEM J, V476, P2191, DOI 10.1042/BCJ20180382; Scarisbrick IA, 2008, CURR TOP MICROBIOL, V318, P133; Schluns KS, 2000, NAT IMMUNOL, V1, P426, DOI 10.1038/80868; Schonbeck U, 1998, J IMMUNOL, V161, P3340; Sheu BC, 2001, CANCER RES, V61, P237; Shitara S, 2013, J IMMUNOL, V190, P6173, DOI 10.4049/jimmunol.1202573; Song JN, 2019, BRIEF BIOINFORM, V20, P638, DOI 10.1093/bib/bby028; Sportes C, 2008, J EXP MED, V205, P1701, DOI 10.1084/jem.20071681; Tan JT, 2001, P NATL ACAD SCI USA, V98, P8732, DOI 10.1073/pnas.161126098; Van den Steen PE, 2004, BIOCHEMISTRY-US, V43, P10809, DOI 10.1021/bi0493665; Van den Steen PE, 2000, BLOOD, V96, P2673, DOI 10.1182/blood.V96.8.2673.h8002673_2673_2681; Van den Steen PE, 2006, J BIOL CHEM, V281, P18626, DOI 10.1074/jbc.M512308200; Vanden Bempt M, 2018, CANCER CELL, V34, P271, DOI 10.1016/j.ccell.2018.07.007; Vicente C, 2015, HAEMATOLOGICA, V100, P1301, DOI 10.3324/haematol.2015.130179; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Vranjkovic A, 2007, INT IMMUNOL, V19, P1329, DOI 10.1093/intimm/dxm102	57	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 30	2021	12								701739	10.3389/fimmu.2021.701739	http://dx.doi.org/10.3389/fimmu.2021.701739			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TK3WM	34276694	Green Published, gold			2022-12-18	WOS:000674092800001
J	Yang, AL; Zhou, Y; Kong, YA; Wei, XL; Ye, F; Zhang, LJ; Zhong, X; Li, MY; Lu, SL; An, X; Xiao, WK				Yang, Anli; Zhou, Ying; Kong, Yanan; Wei, Xiaoli; Ye, Feng; Zhang, Lijuan; Zhong, Xian; Li, Mingyue; Lu, Shilin; An, Xin; Xiao, Weikai			Identification and Validation of Immune-Related Methylation Clusters for Predicting Immune Activity and Prognosis in Breast Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						DNA methylation; IRMGs; immune infiltration; prognosis; breast cancer		The role of DNA methylation of breast cancer-infiltrating immune cells has not been fully explored. We conducted a cohort-based retrospective study analyzing the genome-wide immune-related DNA methylation of 1057 breast cancer patients from the TCGA cohort and GSE72308 cohort. Based on patients' overall survival (OS), a prognostic risk score system using 18 immune-related methylation genes (IRMGs) was established and further validated in an independent cohort. Kaplan-Meier analysis showed a clear separation of OS between the low- and high-risk groups. Patients in the low-risk group had a higher immune score and stromal score compared with the high-risk group. Moreover, the characteristics based on 18-IRMGs signature were related to the tumor immune microenvironment and affected the abundance of tumor-infiltrating immune cells. Consistently, the 18-IRMGs signatures showed similar influences on immune modulation and survival in another external validation cohort (GSE72308). In conclusion, the proposed 18-IRMGs signature could be a potential marker for breast cancer prognostication.	[Yang, Anli; Kong, Yanan; Ye, Feng; Zhang, Lijuan; Xiao, Weikai] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Breast Oncol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China; [Zhou, Ying] Haizhu Dist Ctr Dis Control & Prevent, Dept Infect Dis & Endem Dis Control, Guangzhou, Peoples R China; [Wei, Xiaoli; An, Xin] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Med Oncol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China; [Zhong, Xian] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Ultrasound, Guangzhou, Peoples R China; [Li, Mingyue] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Lu, Shilin] Sun Yat Sen Univ, Zhongshan Sch Med, Guangzhou, Peoples R China; [Xiao, Weikai] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Canc Ctr, Dept Breast Canc, Guangzhou, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; University of Pennsylvania; Pennsylvania Medicine; Sun Yat Sen University; Guangdong Academy of Medical Sciences & Guangdong General Hospital	Xiao, WK (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Breast Oncol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China.; An, X (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Med Oncol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China.; Xiao, WK (corresponding author), Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Canc Ctr, Dept Breast Canc, Guangzhou, Peoples R China.	anxin@sysucc.org.cn; xiaowk@sysucc.org.cn			National Natural Science Foundation of China [8203066]; Guangzhou basic and applied basic research project; special science and Technology Fund (Doctoral entrepreneurship project) of Guangdong People's Hospital; Guangdong Provincial Medical Research Fund [a2021080]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou basic and applied basic research project; special science and Technology Fund (Doctoral entrepreneurship project) of Guangdong People's Hospital; Guangdong Provincial Medical Research Fund	This research is funded by theNational Natural Science Foundation of China (approval No.: 8203066), Guangzhou basic and applied basic research project (approved in 2021), and special science and Technology Fund (Doctoral entrepreneurship project) of Guangdong People's Hospital and Guangdong Provincial Medical Research Fund (a2021080).	Ali HR, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002194; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Blanche P, 2013, STAT MED, V32, P5381, DOI 10.1002/sim.5958; Briand J, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0759-1; Capper D, 2018, NATURE, V555, P469, DOI 10.1038/nature26000; Das D, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0782-2; Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801; Ding SN, 2020, CANCER COMMUN, V40, P329, DOI 10.1002/cac2.12078; Duruisseaux M, 2018, LANCET RESP MED, V6, P771, DOI 10.1016/S2213-2600(18)30284-4; Feinberg AP, 2016, NAT REV GENET, V17, P284, DOI 10.1038/nrg.2016.13; Fleischer T, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00510-x; Fleischer T, 2014, GENOME BIOL, V15, DOI [10.1186/s13059-014-0435-x, 10.1186/PREACCEPT-2333349012841587]; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Gu L, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0178-7; Gu L, 2015, NAT GENET, V47, P22, DOI 10.1038/ng.3165; Guan XW, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-018-0346-4; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Harbeck N, 2017, LANCET, V389, P1134, DOI [10.1016/s0140-6736(16)31891-8, 10.1016/S0140-6736(16)31891-8]; Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590; Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86; Ibn Sina AA, 2019, TRENDS MOL MED, V25, P955, DOI 10.1016/j.molmed.2019.05.014; Jackson HW, 2020, NATURE, V578, P615, DOI 10.1038/s41586-019-1876-x; Jeschke J, 2017, J CLIN INVEST, V127, P3090, DOI 10.1172/JCI91095; Kamalakaran S, 2011, MOL ONCOL, V5, P77, DOI 10.1016/j.molonc.2010.11.002; Kim JY, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148-020-00907-4; Klughammer J, 2018, NAT MED, V24, P1611, DOI 10.1038/s41591-018-0156-x; Moss J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07466-6; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Shao F, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0401-9; Srivastava S, 2019, NAT REV CANCER, V19, P349, DOI 10.1038/s41568-019-0142-8; Tibshirani R, 1997, STAT MED, V16, P385, DOI 10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3; Wagner J, 2019, CELL, V177, P1330, DOI 10.1016/j.cell.2019.03.005; Waks AG, 2019, JAMA-J AM MED ASSOC, V321, P288, DOI 10.1001/jama.2018.19323; Wang Q, 2013, NAT PROTOC, V8, P2022, DOI 10.1038/nprot.2013.118; Yi LL, 2020, MOL THER-NUCL ACIDS, V21, P299, DOI 10.1016/j.omtn.2020.06.001; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zheng SQ, 2020, MOL ONCOL, V14, P2814, DOI 10.1002/1878-0261.12747; Zheng SQ, 2020, INT J CANCER, V147, P542, DOI 10.1002/ijc.33009	40	0	0	0	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 30	2021	12								704557	10.3389/fimmu.2021.704557	http://dx.doi.org/10.3389/fimmu.2021.704557			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TI9XG	34276701	gold, Green Published			2022-12-18	WOS:000673147200001
J	Duecker, RP; Gronau, L; Baer, PC; Zielen, S; Schubert, R				Duecker, Ruth Pia; Gronau, Lucia; Baer, Patrick C.; Zielen, Stefan; Schubert, Ralf			Survival and Functional Immune Reconstitution After Haploidentical Stem Cell Transplantation in Atm-Deficient Mice	FRONTIERS IN IMMUNOLOGY			English	Article						Ataxia-telangiectasia; HSCT; haploidentical; ATM; GvHD; T-lymphocytes	BONE-MARROW-TRANSPLANTATION; ATAXIA-TELANGIECTASIA GENE; VERSUS-HOST-DISEASE; FANCONI-ANEMIA; BLOOD; PARADIGM; LYMPHOMA	Hematopoietic stem cell transplantation (HSCT) has been proposed as a promising therapeutic opportunity to improve immunity and prevent hematologic malignancies in Ataxia-telangiectasia (A-T). However, experience in the transplantation strategy for A-T patients is still scarce. The aim of this study was to investigate whether different approaches of HSCT are feasible in regard to graft versus host response and sufficient concerning functional immune reconstitution. Atm-deficient mice were treated with a clinically relevant non-myeloablative host-conditioning regimen and transplanted with CD90.2-depleted, green fluorescent protein (GFP)-expressing, and ataxia telangiectasia mutated (ATM)-competent bone marrow donor cells in a syngeneic, haploidentical or allogeneic setting. Like syngeneic HSCT, haploidentical HSCT, but not allogeneic HSCT extended the lifespan of Atm-deficient mice through the reduction of thymic tumors and normalized T-cell numbers. Donor-derived splenocytes isolated from transplanted Atm-deficient mice filled the gap of cell loss in the naive T-cell population and raised CD4 cell functionality up to wild-type level. Interestingly, HSCT using heterozygous donor cells let to a significantly improved survival of Atm-deficient mice and increased CD4 cell numbers as well as CD4 cell functionality equivalent to HSCT using with wild-type donor cells. Our data provided evidence that haploidentical HSCT could be a feasible strategy for A-T, possibly even if the donor is heterozygous for ATM. However, this basic research cannot substitute any research in humans.	[Duecker, Ruth Pia; Gronau, Lucia; Zielen, Stefan; Schubert, Ralf] Goethe Univ, Dept Children & Adolescence, Div Allergy Pneumol & Cyst Fibrosis, Frankfurt, Germany; [Baer, Patrick C.] Goethe Univ, Div Nephrol, Dept Internal Med 3, Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt	Duecker, RP (corresponding author), Goethe Univ, Dept Children & Adolescence, Div Allergy Pneumol & Cyst Fibrosis, Frankfurt, Germany.	ruthpia.duecker@kgu.de			SPARKS Charity, Action for A-T (London, England) [14GOU01]	SPARKS Charity, Action for A-T (London, England)	This study was funded by the SPARKS Charity, Action for A-T (Grant Reference 14GOU01, London, England).	Albert MH, 2010, BONE MARROW TRANSPL, V45, P622, DOI 10.1038/bmt.2009.207; Apperley J, 2016, BIOL BLOOD MARROW TR, V22, P23, DOI 10.1016/j.bbmt.2015.11.001; Ayas M, 2012, BIOL BLOOD MARROW TR, V18, P627, DOI 10.1016/j.bbmt.2011.08.015; Bagley J, 2004, BLOOD, V104, P572, DOI 10.1182/blood-2003-12-4226; Bakhtiar S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02495; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BODER E, 1958, PEDIATRICS, V21, P526; Choo SY, 2007, YONSEI MED J, V48, P11, DOI 10.3349/ymj.2007.48.1.11; Cooke KR, 2017, BIOL BLOOD MARROW TR, V23, P211, DOI 10.1016/j.bbmt.2016.09.023; Cooke KR, 1996, BLOOD, V88, P3230, DOI 10.1182/blood.V88.8.3230.bloodjournal8883230; de Latour RP, 2013, BLOOD, V122, P4279, DOI 10.1182/blood-2013-01-479733; Di Siena S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0357-8; Driessen GJ, 2013, J ALLERGY CLIN IMMUN, V131, P1367, DOI 10.1016/j.jaci.2013.01.053; Duecker R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02785; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Fabricius William A, 2016, Adv Hematol, V2016, P5726132, DOI 10.1155/2016/5726132; Fuchs EJ, 2012, HEMATOL-AM SOC HEMAT, P230, DOI 10.1182/asheducation-2012.1.230; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; Ghosh S, 2018, J ALLERGY CLIN IMMUN, V142, P904, DOI 10.1016/j.jaci.2017.11.050; Gumy-Pause F, 2004, LEUKEMIA, V18, P238, DOI 10.1038/sj.leu.2403221; Hill GR, 2000, BLOOD, V95, P2754, DOI 10.1182/blood.V95.9.2754.009k25_2754_2759; Lavin MF, 2008, NAT REV MOL CELL BIO, V9, P759, DOI 10.1038/nrm2514; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; McGrath-Morrow SA, 2010, PEDIATR PULM, V45, P847, DOI 10.1002/ppul.21277; Micol R, 2011, J ALLERGY CLIN IMMUN, V128, P382, DOI 10.1016/j.jaci.2011.03.052; Montoro J, 2016, LEUKEMIA LYMPHOMA, V57, P1766, DOI 10.3109/10428194.2016.1167204; Nietfeld JJ, 2008, BIOL BLOOD MARROW TR, V14, P316, DOI 10.1016/j.bbmt.2007.12.493; Olsson RF, 2015, LEUKEMIA, V29, P1754, DOI 10.1038/leu.2015.75; Passweg JR, 2017, BONE MARROW TRANSPL, V52, P811, DOI 10.1038/bmt.2017.34; Piemontese S, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0394-2; Pietzner J, 2013, HUM MOL GENET, V22, P493, DOI 10.1093/hmg/dds448; PIGUET PF, 1987, J EXP MED, V166, P1280, DOI 10.1084/jem.166.5.1280; de Oliveira BSP, 2020, CANCERS, V12, DOI 10.3390/cancers12113207; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Schubert R, 2002, CLIN EXP IMMUNOL, V129, P125, DOI 10.1046/j.1365-2249.2002.01830.x; Shiloh Y, 2013, NAT REV MOL CELL BIO, V14, P197, DOI 10.1038/nrm3546; Slack J, 2018, J ALLERGY CLIN IMMUN, V141, P322, DOI 10.1016/j.jaci.2017.02.036; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Ussowicz M, 2018, BIOL BLOOD MARROW TR, V24, P2245, DOI 10.1016/j.bbmt.2018.07.001; Vacchio MS, 2007, P NATL ACAD SCI USA, V104, P6323, DOI 10.1073/pnas.0611222104; van Os NJH, 2016, CLIN GENET, V90, P105, DOI 10.1111/cge.12710	42	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 29	2021	12								693897	10.3389/fimmu.2021.693897	http://dx.doi.org/10.3389/fimmu.2021.693897			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TI0ZE	34267759	Green Published, gold			2022-12-18	WOS:000672511200001
J	Leibinger, EA; Pauler, G; Benedek, N; Berki, T; Jankovics, I; McNally, R; Ottoffy, G				Leibinger, Evelin A.; Pauler, Gabor; Benedek, Noemi; Berki, Timea; Jankovics, Istvan; McNally, Richard; Ottoffy, Gabor			Baseline CD3+CD56+(NKT-like) Cells and the Outcome of Influenza Vaccination in Children Undergoing Chemotherapy	FRONTIERS IN IMMUNOLOGY			English	Article						influenza vaccines; pediatrics; immunosuppression; natural killer T-cells; lymphocyte subsets; cellular immunity; CD4+T-cells	NKT CELLS; IMMUNE-RESPONSE; VIRUS; CHILDHOOD; LYMPHOCYTES; RECOVERY; BLOOD; IMMUNOGENICITY; THERAPY; INNATE	Background In children undergoing chemotherapy yearly influenza vaccination is recommended by treatment protocols. We investigated the relationship between cellular immunity and the antibody response to inactivated influenza vaccines. Methods 25 patients (age: 2-18 years) undergoing chemotherapy for different malignancies participated in our study. Flow cytometric detection of peripheral blood lymphocyte subpopulations together with hemagglutination inhibition antibody titers were measured before and 21-28 days after vaccination. We examined the ratio and total numbers of CD3+, CD4+, CD8+ T cells, activated helper (CD3+CD4+CD25(low)), regulatory (CD3+CD4+CD25(high)), naive (CD3+CD45RA+) and memory (CD3+CD45RO+) T cells, CD56+NK, and CD3+CD56+ (NKT-like) cells. Relationships between specific antibody responses (seroprotection, seroconversion, geometric mean titer (GMT), geometric mean fold increase (GMFI)) and the ratios and counts of lymphocyte subpopulations were evaluated using one-way ANOVA and the paired sample t test after dichotomization according to age-related reference values. Results Patients with CD4+ lymphocyte levels in the normal age-specific range showed significantly better response regarding postvaccination GMT elevation for H1N1 and H3N2 strains (97.52 vs. 19.2, p=0.019, 80 vs. 14.43, p=0.021, respectively). GMFI results were significant only against B strain (2.69-fold vs. 1.23-fold, p=0.046). Prevaccination CD3+CD56+ (NKT-like) cells above predicted values according to age showed significant associations both in postvaccination GMT elevation (H1N1: 75.11 vs. 14.14, p=0.010; H3N2: 62.18 vs. 11.22, p=0.012; B: 22.69 vs. 6.67, p=0.043) and GMFI against all three strains (H1N1: 3.76-fold vs. 1.06-fold, p=0.015; H3N2: 2.74-fold vs. 1, p=0.013; B: 2.57-fold vs. 1, p=0.008). By one-way ANOVA, we found a positive relation between absolute lymphocyte cell count above 1000/mu l and the postvaccination GMT elevation against H3N2 (12.81 vs. 56.56, p=0.032), and GMFI regarding H1N1 (1.22-fold vs. 3.48-fold, p=0.044). Conclusions In addition to verifying the predictive value of absolute lymphocyte count above 1000/mu l, our results suggest an association between NKT-like cell counts and the specific antibody response against all three investigated influenza strains in highly immunosuppressed patients. Furthermore, prevaccination CD4+ lymphocyte levels in the normal age-specific range may influence seroresponse.	[Leibinger, Evelin A.; Benedek, Noemi; Ottoffy, Gabor] Univ Pecs, Dept Pediat, Div Pediat Hematol & Oncol, Med Sch, Pecs, Hungary; [Pauler, Gabor] Univ Pecs, Inst Math & Informat, Pecs, Hungary; [Berki, Timea] Univ Pecs, Dept Immunol & Biotechnol, Med Sch, Pecs, Hungary; [Jankovics, Istvan] Natl Ctr Epidemiol, Dept Virol, Budapest, Hungary; [McNally, Richard] Newcastle Univ, Populat Hlth Sci Inst, Newcastle, NSW, Australia	University of Pecs; University of Pecs; University of Pecs; University of Newcastle	Leibinger, EA; Ottoffy, G (corresponding author), Univ Pecs, Dept Pediat, Div Pediat Hematol & Oncol, Med Sch, Pecs, Hungary.	leibinger.evelin@pte.hu; ottoffy.gabor@pte.hu	Ottóffy, Gábor/AAZ-1694-2021	Leibinger, Evelin Anna/0000-0001-6234-4050; McNally, Richard/0000-0001-6685-6467	Hungarian Government [2020-4.1.1-TKP2020]	Hungarian Government	Statistical work was partially financed by 2020-4.1.1-TKP2020, the Subprogram 3: "Innovation for sustainable life and environment" of "Scientific Field Excellence Program 2020" of the Hungarian Government.	ALANKO S, 1994, PEDIATR HEMAT ONCOL, V11, P281, DOI 10.3109/08880019409141671; ALANKO S, 1994, PEDIATR HEMAT ONCOL, V11, P33, DOI 10.3109/08880019409141899; Artiaga BL, 2016, SCI REP-UK, V6, DOI 10.1038/srep37999; Artiaga BL, 2016, SCI REP-UK, V6, DOI 10.1038/srep23593; Beyer WEP, 2004, VIRUS RES, V103, P125, DOI 10.1016/j.virusres.2004.02.024; Choi DK, 2016, PEDIATR BLOOD CANCER, V63, P2011, DOI 10.1002/pbc.26110; Csohan A., 2016, EPINFO; Doganis D, 2018, HUM VACC IMMUNOTHER, V14, P2310, DOI 10.1080/21645515.2018.1470734; Driver JP, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02172; Dwivedi V, 2016, VET MICROBIOL, V186, P157, DOI 10.1016/j.vetmic.2016.02.028; EMMI, 2017, EGESZSEGUGYI KOZLONY EGESZSEGUGYI KOZLONY, V66; Galli G, 2007, P NATL ACAD SCI USA, V104, P3984, DOI 10.1073/pnas.0700191104; Geerlinks AV, 2016, PEDIATR BLOOD CANCER, V63, P2046, DOI 10.1002/pbc.26108; Godfrey DI, 2004, NAT REV IMMUNOL, V4, P231, DOI 10.1038/nri1309; Ho LP, 2008, EUR J IMMUNOL, V38, P1913, DOI 10.1002/eji.200738017; Huenecke S, 2008, EUR J HAEMATOL, V80, P532, DOI 10.1111/j.1600-0609.2008.01052.x; Jurchott K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150812; Kantar M, 2003, J TROP PEDIATRICS, V49, P286, DOI 10.1093/tropej/49.5.286; Kersun LS, 2013, INFLUENZA OTHER RESP, V7, P1158, DOI 10.1111/irv.12058; Kersun LS, 2013, ONCOLOGIST, V18, P204, DOI 10.1634/theoncologist.2012-0401; Kosmidis S, 2008, PEDIATR BLOOD CANCER, V50, P528, DOI 10.1002/pbc.21327; Kotecha RS, 2016, CANCER MED-US, V5, P285, DOI 10.1002/cam4.596; Lang ML, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00305; Larsson AM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49943-y; Lee GE, 2015, J PEDIAT INF DIS SOC, V4, P290, DOI 10.1093/jpids/piu066; LOVAT PE, 1993, PEDIATR HEMAT ONCOL, V10, P129, DOI 10.3109/08880019309016546; Wong-Chew RM, 2012, ONCOL LETT, V4, P329, DOI 10.3892/ol.2012.721; Mavinkurve-Groothuis AMC, 2013, CLIN VACCINE IMMUNOL, V20, P118, DOI 10.1128/CVI.00585-12; Mazur B, 2006, LEUKEMIA RES, V30, P33, DOI 10.1016/j.leukres.2005.05.024; Ottoffy G, 2014, PEDIATR BLOOD CANCER, V61, P1013, DOI 10.1002/pbc.24893; Pawelec Graham, 2020, F1000Res, V9, DOI 10.12688/f1000research.22611.1; Reilly A, 2013, J PEDIAT HEMATOL ONC, V35, P46, DOI 10.1097/MPH.0b013e318266c0c8; Rico M. J., 2012, Experimental Oncology, V34, P38; Romero-Olmedo AJ, 2021, EUR J IMMUNOL, V51, P672, DOI 10.1002/eji.202048941; Slauenwhite D, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00255; Vajo Z, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030500; Van Acker HH, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00892; van Tilburg CM, 2011, BRIT J HAEMATOL, V152, P201, DOI 10.1111/j.1365-2141.2010.08478.x; World Health Organization, 2011, MAN LAB DIAGN VIR SU; Yen TY, 2011, PEDIATR BLOOD CANCER, V57, P1154, DOI 10.1002/pbc.23113; Zawitkowska J, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000022790; Zingaropoli MA, 2021, CLIN IMMUNOL, V222, DOI 10.1016/j.clim.2020.108630	42	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 29	2021	12								690940	10.3389/fimmu.2021.690940	http://dx.doi.org/10.3389/fimmu.2021.690940			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TI0XT	34267757	Green Published, gold			2022-12-18	WOS:000672507300001
J	Swartz, TH; Bradford, BJ; Mamedova, LK				Swartz, Turner H.; Bradford, Barry J.; Mamedova, Laman K.			Connecting Metabolism to Mastitis: Hyperketonemia Impaired Mammary Gland Defenses During a Streptococcus uberis Challenge in Dairy Cattle	FRONTIERS IN IMMUNOLOGY			English	Article						mastitis; ketosis; metabolism; inflammation; immune function	SUBCLINICAL KETOSIS; BETA-HYDROXYBUTYRATE; LIPOPOLYSACCHARIDE CHALLENGE; REPRODUCTIVE-PERFORMANCE; PERIPARTURIENT HOLSTEIN; INTRAMAMMARY INFECTIONS; GLUCOSE-METABOLISM; CLINICAL MASTITIS; MILK-PRODUCTION; KETONE-BODIES	beta-hydroxybutyrate (BHB) has been associated with disease incidence in early lactation dairy cattle, but such associations do not demonstrate causation. Therefore, the objective of this study was to examine the effects of BHB during an intramammary Streptococcus uberis challenge. A secondary objective was to elucidate the mechanisms behind BHB effects on cytokine transcript abundance using the RAW 264.7 cell line. Late lactation multiparous dairy cows (n = 12) were continuously infused intravenously with either BHB to induce hyperketonemia (target concentration: 1.8 mM) or with saline (CON) for 72 h during a S. uberis intramammary challenge. Body temperature, dry matter intake (DMI), milk production, and milk S. uberis cfu were measured daily until one week post-challenge. Blood samples were collected during infusion to assess changes in metabolism (glucose, insulin, glucagon, NEFA, and cortisol) and systemic inflammation (IL-1 beta and SAA). Mammary biopsies were conducted at 72 h post-challenge to assess transcript abundance of inflammation-associated genes. BHB-infused cows exhibited a delayed febrile response, noted by a lesser vaginal temperature during the final day of infusion, followed by a greater vaginal temperature 6 d post-challenge. Consequently, BHB-infused cows had greater S. uberis cfu on d 4, 6, and 7 as compared to CON. Accordingly, BHB-infused cows consumed less DM, produced less milk, had reduced blood glucose, and had increased cortisol concentrations, however, no effects were seen on other systemic parameters or transcript abundance of inflammation-related genes in mammary tissue. To elucidate mechanisms behind the impaired immune defenses, RAW 264.7 cells were transfected with a GPR109A siRNA for 24 h and then treated with or without 1.8 mM BHB and challenged or left unchallenged with S. uberis for an additional 3 h. Transfection with siRNA reduced Gpr109a by 75%. Although BHB treatment did not significantly increase Il10, GPR109A knockdown as compared to the scrambled control reduced Il10 by 90% in S. uberis challenged macrophages treated with BHB, suggesting that macrophage immune responses to S. uberis can be altered via a GPR109A-dependent mechanism. Taken together, these data suggest that BHB altered the immune response promoting tolerance toward S. uberis rather than resistance.	[Swartz, Turner H.; Bradford, Barry J.; Mamedova, Laman K.] Michigan State Univ, Dept Anim Sci, E Lansing, MI 48824 USA; [Swartz, Turner H.; Bradford, Barry J.; Mamedova, Laman K.] Kansas State Univ, Dept Anim Sci & Ind, Manhattan, KS 66506 USA	Michigan State University; Kansas State University	Swartz, TH (corresponding author), Michigan State Univ, Dept Anim Sci, E Lansing, MI 48824 USA.; Swartz, TH (corresponding author), Kansas State Univ, Dept Anim Sci & Ind, Manhattan, KS 66506 USA.	swartztu@msu.edu	Swartz, Turner/ABC-3078-2020; Bradford, Barry/B-7870-2010	Swartz, Turner/0000-0002-9457-2418; Bradford, Barry/0000-0002-6775-4961	USDA postdoctoral fellowship [2019-67012-29665]	USDA postdoctoral fellowship	This work and the primary author are financially supported by a USDA postdoctoral fellowship (2019-67012-29665).	Abuajamieh M, 2016, RES VET SCI, V109, P81, DOI 10.1016/j.rvsc.2016.09.015; Adkins P.R., 2017, LAB HDB BOVINE MASTI; Chen YL, 2018, J HEPATOL, V69, P687, DOI 10.1016/j.jhep.2018.04.004; Daley VL, 2018, JOVE-J VIS EXP, DOI 10.3791/58602; DOHOO IR, 1984, CAN J COMP MED, V48, P1; Dong JS, 2018, BMC VET RES, V14, DOI 10.1186/s12917-018-1360-0; Duffield TF, 2009, J DAIRY SCI, V92, P571, DOI 10.3168/jds.2008-1507; Duffield TF, 1998, J DAIRY SCI, V81, P2866, DOI 10.3168/jds.S0022-0302(98)75846-1; Farr VC, 1996, J DAIRY SCI, V79, P543, DOI 10.3168/jds.S0022-0302(96)76398-1; Feingold KR, 2014, J LIPID RES, V55, P2501, DOI 10.1194/jlr.M050955; Finch JM, 1997, VACCINE, V15, P1138, DOI 10.1016/S0264-410X(96)00307-6; FRANKLIN ST, 1991, J DAIRY SCI, V74, P2507, DOI 10.3168/jds.S0022-0302(91)78428-2; Grinberg N, 2008, INFECT IMMUN, V76, P2802, DOI 10.1128/IAI.00051-08; Gross JJ, 2015, J ANIM SCI, V93, P3395, DOI 10.2527/jas.2015-8903; Hammer JF, 2012, AUST VET J, V90, P167, DOI 10.1111/j.1751-0813.2012.00917.x; HERDT TH, 1992, VET CLIN N AM-FOOD A, V8, P91, DOI 10.1016/S0749-0720(15)30761-1; Hoeben D, 1997, VET IMMUNOL IMMUNOP, V58, P165, DOI 10.1016/S0165-2427(97)00031-7; Jayarao BM, 1999, J VET MED B, V46, P433, DOI 10.1046/j.1439-0450.1999.00254.x; Kester HJ, 2015, J DAIRY SCI, V98, P999, DOI 10.3168/jds.2014-8576; KLUCINSKI W, 1988, J VET MED A, V35, P632; KREMER WDJ, 1993, J DAIRY SCI, V76, P3428, DOI 10.3168/jds.S0022-0302(93)77681-X; Kuhla B., 2011, CENTRAL ADM BETAHYDR CENTRAL ADM BETAHYDR, P84; Kushibiki S, 2003, J DAIRY SCI, V86, P819, DOI 10.3168/jds.S0022-0302(03)73664-9; Kvidera SK, 2017, J DAIRY SCI, V100, P2360, DOI 10.3168/jds.2016-12001; McArt JAA, 2012, J DAIRY SCI, V95, P5056, DOI 10.3168/jds.2012-5443; Moyes KM, 2009, J DAIRY SCI, V92, P4301, DOI 10.3168/jds.2009-2170; Newman JC, 2014, TRENDS ENDOCRIN MET, V25, P42, DOI 10.1016/j.tem.2013.09.002; NONNECKE BJ, 1992, J DAIRY SCI, V75, P982, DOI 10.3168/jds.S0022-0302(92)77840-0; OLIVER SP, 1988, AM J VET RES, V49, P1789; OLTENACU PA, 1994, VET RES, V25, P208; Perkins KH, 2002, J DAIRY SCI, V85, P1724, DOI 10.3168/jds.S0022-0302(02)74246-X; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pires JAA, 2019, J DAIRY SCI, V102, P5347, DOI 10.3168/jds.2018-15446; Poindexter MB, 2020, J DAIRY SCI, V103, P805, DOI 10.3168/jds.2019-16999; Raboisson D, 2014, J DAIRY SCI, V97, P7547, DOI 10.3168/jds.2014-8237; Rezamand P, 2007, J DAIRY SCI, V90, P5097, DOI 10.3168/jds.2007-0035; RUEGG PL, 1995, J DAIRY SCI, V78, P552, DOI 10.3168/jds.S0022-0302(95)76666-8; Schlumbohm C, 2004, J DAIRY SCI, V87, P350, DOI 10.3168/jds.S0022-0302(04)73174-4; Swartz T H, 2021, JDS Commun, V2, P142, DOI 10.3168/jdsc.2020-0038; THOMAS LH, 1994, AM J VET RES, V55, P1723; Todhunter DA, 1995, J DAIRY SCI, V78, P2366, DOI 10.3168/jds.S0022-0302(95)76864-3; van den Borne BHP, 2010, PREV VET MED, V96, P49, DOI 10.1016/j.prevetmed.2010.05.010; van Straten M, 2009, J DAIRY SCI, V92, P4386, DOI 10.3168/jds.2009-2204; Vernay MCMB, 2012, J DAIRY SCI, V95, P2540, DOI 10.3168/jds.2011-5188; Yeager MP, 2011, DOSE-RESPONSE, V9, P332, DOI 10.2203/dose-response.10-013.Yeager; Yuan K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080316; Zarrin M, 2017, J DAIRY SCI, V100, P2323, DOI 10.3168/jds.2016-11714; Zarrin M, 2014, J DAIRY SCI, V97, P3531, DOI 10.3168/jds.2013-7480; Zarrin M, 2014, J DAIRY SCI, V97, P330, DOI 10.3168/jds.2013-7222; Zarrin M, 2013, J DAIRY SCI, V96, P2960, DOI 10.3168/jds.2012-6224	50	0	0	4	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 29	2021	12								700278	10.3389/fimmu.2021.700278	http://dx.doi.org/10.3389/fimmu.2021.700278			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TI0YL	34267762	Green Published, gold			2022-12-18	WOS:000672509200001
J	Teng, YKO; Pusey, CD; Vaglio, A; Mok, CC; van Kooten, C				Teng, Y. K. Onno; Pusey, Charles Dickson; Vaglio, Augusto; Mok, Chi Chui; van Kooten, Cees			Editorial: Immune Monitoring Responses in Renal Autoimmune Diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						Glomerulonefritis; renal autoimmune diseases; Lupus Nephritis; ANCA - associated vasculitis; membranoproliferative glomerulonephritis (MPGN)			[Teng, Y. K. Onno; van Kooten, Cees] Leiden Univ, Nephrol Sect, Dept Internal Med, Ctr Expertise Lupus Vasc & Complement Med,Med Ctr, Leiden, Netherlands; [Pusey, Charles Dickson] Hammersmith Hosp, Imperial Coll London, Dept Immunol & Inflammat, Ctr Inflammatory Dis, London, England; [Vaglio, Augusto] Univ Firenze, Dept Biomed Expt & Clin Sci Mario Serio, Florence, Italy; [Vaglio, Augusto] Meyer Childrens Hosp, Dialysis Unit, Florence, Italy; [Mok, Chi Chui] Tuen Mun Hosp, Dept Med, Div Rheumatol, Hong Kong, Peoples R China	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Imperial College London; University of Florence; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; Tuen Mun Hospital	Teng, YKO (corresponding author), Leiden Univ, Nephrol Sect, Dept Internal Med, Ctr Expertise Lupus Vasc & Complement Med,Med Ctr, Leiden, Netherlands.	y.k.o.teng@lumc.nl	Vaglio, Augusto/AHE-8117-2022; Teng, Yoe Kie Onno/S-1765-2019; van Kooten, Cees/E-5694-2018	Vaglio, Augusto/0000-0002-3814-9172; Teng, Yoe Kie Onno/0000-0001-9920-2195; van Kooten, Cees/0000-0002-6257-0899	Dutch Kidney Foundation [17OKG04]; Netherlands Scientific Organisation	Dutch Kidney Foundation; Netherlands Scientific Organisation	The work of YT is supported by the Dutch Kidney Foundation (17OKG04) and the Netherlands Scientific Organisation.	Furie R, 2020, NEW ENGL J MED, V383, P1117, DOI 10.1056/NEJMoa2001180; Jayne DRW, 2021, NEW ENGL J MED, V384, P599, DOI 10.1056/NEJMoa2023386; Rovin BH, 2021, LANCET, V397, P2070, DOI 10.1016/S0140-6736(21)00578-X	3	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 29	2021	12								722791	10.3389/fimmu.2021.722791	http://dx.doi.org/10.3389/fimmu.2021.722791			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TH8MF	34267765	Green Published, gold			2022-12-18	WOS:000672337100001
J	Hamie, M; Tawil, N; El Hajj, R; Najm, R; Moodad, S; Hleihel, R; Karam, M; El Sayyed, S; Besteiro, S; El-Sabban, M; Dubremetz, JF; Lebrun, M; El Hajj, H				Hamie, Maguy; Tawil, Nadim; El Hajj, Rana; Najm, Rania; Moodad, Sara; Hleihel, Rita; Karam, Martin; El Sayyed, Sana; Besteiro, Sebastien; El-Sabban, Marwan; Dubremetz, Jean-Francois; Lebrun, Maryse; El Hajj, Hiba			P18 (SRS35/TgSAG4) Plays a Role in the Invasion and Virulence of Toxoplasma gondii	FRONTIERS IN IMMUNOLOGY			English	Article						inflammation; neurotoxoplasmosis; murine toxoplasmosis; cysts; tachyzoites; bradyzoites	GAMMA-MEDIATED EXPRESSION; INDUCIBLE NITRIC-OXIDE; IMMUNE T-CELLS; IFN-GAMMA; DENDRITIC CELLS; CHRONIC INFECTION; INTERFERON-GAMMA; CEREBRAL INFECTION; SURFACE-ANTIGENS; HOST-RESISTANCE	Toxoplasmosis is a prevalent parasitic disease caused by Toxoplasma gondii (T. gondii). Under the control of the host immune system, T. gondii persists as latent bradyzoite cysts. Immunosuppression leads to their reactivation, a potentially life-threatening condition. Interferon-gamma (IFN-gamma) controls the different stages of toxoplasmosis. Here, we addressed the role of the parasite surface antigen P18, belonging to the Surface-Antigen 1 (SAG-1) Related Sequence (SRS) family, in a cyst-forming strain. Deletion of P18 gene (KO P18) impaired the invasion of parasites in macrophages and IFN-gamma-mediated activation of macrophages further reduced the invasion capacity of this KO, as compared to WT strain. Mice infected by KO P18, showed a marked decrease in virulence during acute toxoplasmosis. This was consequent to less parasitemia, accompanied by a substantial recruitment of dendritic cells, macrophages and natural killer cells (NK). Furthermore, KO P18 resulted in a higher number of bradyzoite cysts, and a stronger inflammatory response. A prolonged survival of mice was observed upon immunosuppression of KO P18 infected BALB/c mice or upon oral infection of Severe Combined Immunodeficiency (SCID) mice, with intact macrophages and natural killer (NK) cells. In stark contrast, oral infection of NSG (NOD/Shi-scid/IL-2R gamma null) mice, defective in macrophages and NK cells, with KO P18, was as lethal as that of the control strain showing that the conversion from bradyzoites to tachyzoites is intact and, suggesting a role of P18 in the response to host IFN-gamma. Collectively, these data demonstrate a role for P18 surface antigen in the invasion of macrophages and in the virulence of the parasite, during acute and chronic toxoplasmosis.	[Hamie, Maguy; Tawil, Nadim; Najm, Rania; Moodad, Sara; Hleihel, Rita; Karam, Martin; El Sayyed, Sana; El Hajj, Hiba] Amer Univ Beirut, Fac Med, Dept Expt Pathol Immunol & Microbiol, Beirut, Lebanon; [El Hajj, Rana] Beirut Arab Univ, Dept Biol Sci, Beirut, Lebanon; [Besteiro, Sebastien; Dubremetz, Jean-Francois; Lebrun, Maryse] Univ Montpellier, CNRS, LPHI UMR5235, Montpellier, France; [El-Sabban, Marwan] Amer Univ Beirut, Fac Med, Dept Anat Cell Biol & Physiol Sci, Beirut, Lebanon	American University of Beirut; Beirut Arab University; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; American University of Beirut	El Hajj, H (corresponding author), Amer Univ Beirut, Fac Med, Dept Expt Pathol Immunol & Microbiol, Beirut, Lebanon.	he21@aub.edu.lb	Besteiro, Sébastien/F-3622-2014	Besteiro, Sébastien/0000-0003-1853-1494; Najm, Rania/0000-0002-7685-0760; TAWIL, NADIM/0000-0003-2396-6679; Lebrun, Maryse/0000-0002-0962-0156	Medical Practice Plan (Faculty of Medicine, American University of Beirut); American University of Beirut and the Centre National de Recherche Scientifique Libanais (AUB-CNRS-L GRP) funds	Medical Practice Plan (Faculty of Medicine, American University of Beirut); American University of Beirut and the Centre National de Recherche Scientifique Libanais (AUB-CNRS-L GRP) funds	This work was made possible through core support from the Medical Practice Plan (Faculty of Medicine, American University of Beirut) and the American University of Beirut and the Centre National de Recherche Scientifique Libanais (AUB-CNRS-L GRP) funds.	Bannoura S, 2018, IDCases, V13, DOI 10.1016/j.idcr.2018.e00434; Basavaraju Anuradha, 2016, Trop Parasitol, V6, P129; Blader IJ, 2009, APMIS, V117, P458, DOI 10.1111/j.1600-0463.2009.02453.x; Blanchard N, 2015, PARASITE IMMUNOL, V37, P150, DOI 10.1111/pim.12173; Boothroyd JC, 1998, INT J PARASITOL, V28, P3, DOI 10.1016/S0020-7519(97)00182-3; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; Bossi P, 2004, LANCET, V364, P579, DOI 10.1016/S0140-6736(04)16841-4; Bouhamdan Sarah F, 2010, J Med Liban, V58, P8; Boulanger MJ, 2010, CURR OPIN STRUC BIOL, V20, P551, DOI 10.1016/j.sbi.2010.08.003; CHAO CC, 1994, J IMMUNOL, V152, P1246; Chapuis A, 2016, INT J INFECT DIS, V46, P79, DOI 10.1016/j.ijid.2016.04.002; Collantes-Fernandez E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032123; Daher W, 2012, EUKARYOT CELL, V11, P343, DOI 10.1128/EC.05192-11; DENKERS EY, 1993, J EXP MED, V178, P1465, DOI 10.1084/jem.178.5.1465; Diana J, 2004, FEMS IMMUNOL MED MIC, V42, P321, DOI 10.1016/j.femsim.2004.06.021; Dincel GC, 2015, EXP PARASITOL, V156, P104, DOI 10.1016/j.exppara.2015.06.009; ERLICH HA, 1983, INFECT IMMUN, V41, P683, DOI 10.1128/IAI.41.2.683-690.1983; Fischer HG, 2000, J IMMUNOL, V164, P4826, DOI 10.4049/jimmunol.164.9.4826; Fox BA, 2009, EUKARYOT CELL, V8, P520, DOI 10.1128/EC.00357-08; Gaskell EA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004801; GAZZINELLI RT, 1993, INFECT AGENT DIS, V2, P139; Goldszmid RS, 2012, IMMUNITY, V36, P1047, DOI 10.1016/j.immuni.2012.03.026; Hakimi MA, 2017, CLIN MICROBIOL REV, V30, P615, DOI 10.1128/CMR.00005-17; He XL, 2002, NAT STRUCT BIOL, V9, P606, DOI 10.1038/nsb819; Huynh MH, 2006, PLOS PATHOG, V2, P753, DOI 10.1371/journal.ppat.0020084; Huynh MH, 2009, EUKARYOT CELL, V8, P530, DOI 10.1128/EC.00358-08; Kang H, 2001, INFECT IMMUN, V69, P2920, DOI 10.1128/IAI.69.5.2920-2927.2001; Kim SK, 2007, INFECT IMMUN, V75, P1626, DOI 10.1128/IAI.01862-06; Knoll LJ, 1998, MOL CELL BIOL, V18, P807, DOI 10.1128/MCB.18.2.807; Kodym P, 2015, EPIDEMIOL INFECT, V143, P600, DOI 10.1017/S0950268814001253; Lachenmaier SM, 2011, J NEUROIMMUNOL, V232, P119, DOI 10.1016/j.jneuroim.2010.10.029; Lambert H, 2006, CELL MICROBIOL, V8, P1611, DOI 10.1111/j.1462-5822.2006.00735.x; Lambert H, 2009, INFECT IMMUN, V77, P1679, DOI 10.1128/IAI.01289-08; LANGERMANS JAM, 1992, INFECT IMMUN, V60, P5107, DOI 10.1128/IAI.60.12.5107-5112.1992; LANGERMANS JAM, 1992, J IMMUNOL, V148, P568; Leal-Sena JA, 2018, APPL MICROBIOL BIOT, V102, P2235, DOI 10.1007/s00253-018-8759-1; Lekutis C, 2001, INT J PARASITOL, V31, P1285, DOI 10.1016/S0020-7519(01)00261-2; Lentini G, 2015, CELL MICROBIOL, V17, P62, DOI 10.1111/cmi.12337; LIEW FY, 1991, IMMUNOPARASITOL TOD, pA17, DOI 10.1016/S0167-5699(05)80006-4; Manger ID, 1998, INFECT IMMUN, V66, P1632, DOI 10.1128/IAI.66.4.1632-1637.1998; Manger ID, 1998, INFECT IMMUN, V66, P2237, DOI 10.1128/IAI.66.5.2237-2244.1998; Mashayekhi M, 2011, IMMUNITY, V35, P249, DOI 10.1016/j.immuni.2011.08.008; MINEO JR, 1993, J IMMUNOL, V150, P3951; Montoya JG, 2004, LANCET, V363, P1965, DOI 10.1016/S0140-6736(04)16412-X; Nahouli H, 2017, VECTOR-BORNE ZOONOT, V17, P785, DOI 10.1089/vbz.2016.2092; Ochiai E, 2015, AM J PATHOL, V185, P314, DOI 10.1016/j.ajpath.2014.10.003; OdbergFerragut C, 1996, MOL BIOCHEM PARASIT, V82, P237, DOI 10.1016/0166-6851(96)02740-5; Ohbo K, 1996, BLOOD, V87, P956, DOI 10.1182/blood.V87.3.956.bloodjournal873956; Park J, 2020, PARASITE IMMUNOL, V42, DOI 10.1111/pim.12712; Parlog A, 2014, DIS MODEL MECH, V7, P459, DOI 10.1242/dmm.014183; PETERSON PK, 1995, J INFECT DIS, V171, P516, DOI 10.1093/infdis/171.2.516; Pollard AM, 2008, INFECT IMMUN, V76, P103, DOI 10.1128/IAI.01170-07; Rachinel N, 2004, J IMMUNOL, V173, P2725, DOI 10.4049/jimmunol.173.4.2725; Sa Q, 2015, J IMMUNOL, V195, P796, DOI 10.4049/jimmunol.1500814; Sa QL, 2014, INFECT IMMUN, V82, P2826, DOI 10.1128/IAI.01494-13; Sasai M, 2018, INT IMMUNOL, V30, P113, DOI 10.1093/intimm/dxy004; SchartonKersten T, 1996, EXP PARASITOL, V84, P102, DOI 10.1006/expr.1996.0096; SchartonKersten TM, 1997, J EXP MED, V185, P1261, DOI 10.1084/jem.185.7.1261; SchartonKersten TM, 1996, J IMMUNOL, V157, P4045; Schluter D, 1999, J IMMUNOL, V162, P3512; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Sher A, 2003, IMMUNOL RES, V27, P521, DOI 10.1385/IR:27:2-3:521; SHER A, 1993, J IMMUNOL, V150, P3982; SOETE M, 1993, EXP PARASITOL, V76, P259, DOI 10.1006/expr.1993.1031; Strack A, 2002, GLIA, V40, P372, DOI 10.1002/glia.10104; SUZUKI Y, 1988, SCIENCE, V240, P516, DOI 10.1126/science.3128869; Suzuki Y, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411002018; Suzuki Y, 2010, AM J PATHOL, V176, P1607, DOI 10.2353/ajpath.2010.090825; Tenter AM, 2000, INT J PARASITOL, V30, P1217, DOI 10.1016/S0020-7519(00)00124-7; TOMAVO S, 1991, INFECT IMMUN, V59, P3750, DOI 10.1128/IAI.59.10.3750-3753.1991; Tomita T, 2018, PARASITOL RES, V117, P2457, DOI 10.1007/s00436-018-5934-3; Tomita T, 2017, MBIO, V8, DOI [10.1128/mBio.02048-16, 10.1128/mbio.02048-16]; Tomita T, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003823; Tu V, 2019, MBIO, V10, DOI [10.1128/mBio.00469-19, 10.1128/mbio.00469-19]; Tussiwand R, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00634-20; Wang XS, 2007, J INTERF CYTOK RES, V27, P329, DOI 10.1089/jir.2006.0154; Wasmuth JD, 2012, MBIO, V3, DOI 10.1128/mBio.00321-12; Webster JP, 2010, FOLIA PARASIT, V57, P95, DOI 10.14411/fp.2010.012; Wen XS, 2010, J INTERF CYTOK RES, V30, P653, DOI 10.1089/jir.2009.0119; Yarovinsky F, 2014, NAT REV IMMUNOL, V14, P109, DOI 10.1038/nri3598; Zeiner GM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008742; Zhang J, 2017, PARASITOLOGY, V144, P1551, DOI [10.1017/s0031182017001111, 10.1017/S0031182017001111]	83	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 28	2021	12								643292	10.3389/fimmu.2021.643292	http://dx.doi.org/10.3389/fimmu.2021.643292			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TH1DK	34262559	Green Published, gold			2022-12-18	WOS:000671834500001
J	Lagasse, HAD; Hopkins, LB; Jankowski, W; Jacquemin, MG; Sauna, ZE; Golding, B				Lagasse, H. A. Daniel; Hopkins, Louis B.; Jankowski, Wojciech; Jacquemin, Marc G.; Sauna, Zuben E.; Golding, Basil			Factor VIII-Fc Activates Natural Killer Cells via Fc-Mediated Interactions With CD16	FRONTIERS IN IMMUNOLOGY			English	Article						Fc-fusion; immunogenicity; Fc gamma receptors; natural killer cells; antibody-dependent cellular cytotoxicity	IMMUNE TOLERANCE INDUCTION; SEVERE HEMOPHILIA-A; FUSION PROTEIN; MONOCLONAL-ANTIBODY; GAMMA RECEPTORS; HALF-LIFE; PROLONGED ACTIVITY; B-CELLS; RITUXIMAB; IGG	The most challenging complication associated with Factor VIII (FVIII) replacement therapy is the development of neutralizing anti-drug antibodies, or inhibitors, which occur in 23-35% of severe (FVIII level <1%) hemophilia A (HA) patients and are a serious hindrance to effective management of HA. Consequently, strategies that can either prevent anti-FVIII inhibitors from developing or "tolerize" individuals who develop such antibodies represent a clinically important unmet need. One intervention for patients with high-titer inhibitors is immune tolerance induction (ITI) therapy. Although ITI therapy is the only clinically proven strategy to eradicate anti-FVIII inhibitors, mechanisms of inhibitor reduction remain unknown. Factor VIII Fc-fusion (rFVIIIFc) is an enhanced half-life antihemophilic factor used in replacement therapy for HA. Fc-fusion is a successful protein bio-engineering platform technology. In addition to enhancement of plasma half-life via neonatal Fc receptor (FcRn) binding, other Fc-mediated interactions, including engagement with Fc gamma receptors (Fc gamma R), may have immunological consequences. Several case reports and retrospective analyses suggest that rFVIIIFc offers superior outcomes with respect to ITI compared to other FVIII products. Previously we and others demonstrated rFVIIIFc interactions with activating Fc gamma RIIIA/CD16. Here, we investigated if rFVIIIFc activates natural killer (NK) cells via CD16. We demonstrated rFVIIIFc signaling via CD16 independent of Von Willebrand Factor (VWF):FVIII complex formation. We established that rFVIIIFc potently activated NK cells in a CD16-dependent fashion resulting in IFN gamma secretion and cytolytic perforin and granzyme B release. We also demonstrated an association between rFVIIIFc-mediated NK cell IFN gamma secretion levels and the high-affinity (158V) CD16 genotype. Furthermore, we show that rFVIIIFc-activated CD16(+) NK cells were able to lyse a B-cell clone (BO2C11) bearing an anti-FVIII B-cell receptor in an antibody-dependent cellular cytotoxicity (ADCC) assay. These in vitro findings provide an underlying molecular mechanism that may help explain clinical case reports and retrospective studies suggesting rFVIIIFc may be more effective in tolerizing HA patients with anti-FVIII inhibitors compared to FVIII not linked to Fc. Our in vitro findings suggest a potential use of Fc-fusion proteins acting via NK cells to target antigen-specific B-cells, in the management of unwanted immune responses directed against immunogenic self-antigens or therapeutic protein products.	[Lagasse, H. A. Daniel; Hopkins, Louis B.; Jankowski, Wojciech; Sauna, Zuben E.; Golding, Basil] US FDA, Hemostasis Branch, Div Plasma Prot Therapeut, Off Tissues & Adv Therapies,Ctr Biol Evaluat & Re, Silver Spring, MD 20993 USA; [Jacquemin, Marc G.] Univ Leuven, Ctr Mol & Vasc Biol, Dept Cardiovasc Sci, Leuven, Belgium	US Food & Drug Administration (FDA); KU Leuven	Sauna, ZE (corresponding author), US FDA, Hemostasis Branch, Div Plasma Prot Therapeut, Off Tissues & Adv Therapies,Ctr Biol Evaluat & Re, Silver Spring, MD 20993 USA.	zuben.sauna@fda.hhs.gov	Hopkins, Louis/GXH-1278-2022	Hopkins, Louis/0000-0002-6751-6285	U.S. FDA	U.S. FDA(United States Department of Health & Human Services)	BG and ZS are funded by intramural grants from the U.S. FDA.	Beck A, 2011, MABS-AUSTIN, V3, P415, DOI 10.4161/mabs.3.5.17334; Bowles JA, 2005, J IMMUNOL METHODS, V304, P88, DOI 10.1016/j.jim.2005.06.018; Bruhns P, 2015, IMMUNOL REV, V268, P25, DOI 10.1111/imr.12350; Carcao M, 2006, HAEMOPHILIA, V12, P7, DOI 10.1111/j.1365-2516.2005.01170.x; Carcao M, 2018, HAEMOPHILIA, V24, P245, DOI 10.1111/hae.13413; Carter PJ, 2011, EXP CELL RES, V317, P1261, DOI 10.1016/j.yexcr.2011.02.013; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Coppola A, 2010, BRIT J HAEMATOL, V150, P515, DOI 10.1111/j.1365-2141.2010.08263.x; Dall'Ozzo S, 2004, CANCER RES, V64, P4664, DOI 10.1158/0008-5472.CAN-03-2862; DiMichele DM, 2006, J THROMB HAEMOST, V4, P2271, DOI 10.1111/j.1538-7836.2006.02127.x; Douglass EF, 2013, J AM CHEM SOC, V135, P6092, DOI 10.1021/ja311795d; Dumont JA, 2012, BLOOD, V119, P3024, DOI 10.1182/blood-2011-08-367813; Franchini M, 2014, BRIT J HAEMATOL, V165, P600, DOI 10.1111/bjh.12829; Georgescu MT, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00138; Gouw SC, 2012, BLOOD, V119, P2922, DOI 10.1182/blood-2011-09-379453; Groomes CL, 2016, PEDIATR BLOOD CANCER, V63, P922, DOI 10.1002/pbc.25874; Guilliams M, 2014, NAT REV IMMUNOL, V14, P94, DOI 10.1038/nri3582; Jacquemin MG, 1998, BLOOD, V92, P496, DOI 10.1182/blood.V92.2.496.414k16_496_506; Jafari R, 2017, CURR MED CHEM, V24, P1228, DOI 10.2174/0929867324666170113112759; Janbain M, 2016, HEMATOL-AM SOC HEMAT, P648, DOI 10.1182/asheducation-2016.1.648; Kannicht C, 2020, HEMASPHERE, V4, DOI 10.1097/HS9.0000000000000330; Kazi ZB, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94328; Kis-Toth K, 2018, BLOOD ADV, V2, P2904, DOI 10.1182/bloodadvances.2018024497; Koene HR, 1997, BLOOD, V90, P1109, DOI 10.1182/blood.V90.3.1109.1109_1109_1114; Kontermann RE, 2011, CURR OPIN BIOTECH, V22, P868, DOI 10.1016/j.copbio.2011.06.012; Krishnamoorthy S, 2016, CELL IMMUNOL, V301, P30, DOI 10.1016/j.cellimm.2015.12.008; Lagasse HAD, 2019, AAPS J, V21, DOI 10.1208/s12248-019-0336-8; Lai JD, 2017, INT J LAB HEMATOL, V39, P6, DOI 10.1111/ijlh.12659; Levin D, 2015, TRENDS BIOTECHNOL, V33, P27, DOI 10.1016/j.tibtech.2014.11.001; Malec LM, 2016, HAEMOPHILIA, V22, pE552, DOI 10.1111/hae.13064; Mossner E, 2010, BLOOD, V115, P4393, DOI 10.1182/blood-2009-06-225979; Mulgrew K, 2006, MOL CANCER THER, V5, P3122, DOI 10.1158/1535-7163.MCT-06-0356; Muntasell A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01544; NILSSON IM, 1988, NEW ENGL J MED, V318, P947, DOI 10.1056/NEJM198804143181503; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Nimmerjahn F, 2007, ADV IMMUNOL, V96, P179, DOI 10.1016/S0065-2776(07)96005-8; Nimmerjahn F, 2015, TRENDS IMMUNOL, V36, P325, DOI 10.1016/j.it.2015.04.005; Pincetic A, 2014, NAT IMMUNOL, V15, P707, DOI 10.1038/ni.2939; Pipe SW, 2016, BLOOD, V128, P2007, DOI 10.1182/blood-2016-04-713289; Powell JS, 2012, BLOOD, V119, P3031, DOI 10.1182/blood-2011-09-382846; Rath T, 2015, CRIT REV BIOTECHNOL, V35, P235, DOI 10.3109/07388551.2013.834293; REFF ME, 1994, BLOOD, V83, P435; Roopenian DC, 2007, NAT REV IMMUNOL, V7, P715, DOI 10.1038/nri2155; Shakya AK, 2018, TRENDS BIOTECHNOL, V36, P686, DOI 10.1016/j.tibtech.2018.02.008; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; Spiegel PC, 2001, BLOOD, V98, P13, DOI 10.1182/blood.V98.1.13; Stepanov AV, 2015, ACTA NATURAE, V7, P74, DOI 10.32607/20758251-2015-7-2-74-79; Stepanov AV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020991; Strohl WR, 2015, BIODRUGS, V29, P215, DOI 10.1007/s40259-015-0133-6; Terraube V, 2010, HAEMOPHILIA, V16, P3, DOI 10.1111/j.1365-2516.2009.02005.x; VLOT AJ, 1995, BLOOD, V85, P3150, DOI 10.1182/blood.V85.11.3150.bloodjournal85113150; Wang TT, 2019, J CLIN INVEST, V129, P3492, DOI 10.1172/JCI130029; Wang XH, 2018, PROTEIN CELL, V9, P63, DOI 10.1007/s13238-017-0473-8; Waters B, 2009, J THROMB HAEMOST, V7, P1446, DOI 10.1111/j.1538-7836.2009.03538.x; Weiner GJ, 2010, SEMIN HEMATOL, V47, P115, DOI 10.1053/j.seminhematol.2010.01.011; Zocher M, 2003, INT IMMUNOL, V15, P789, DOI 10.1093/intimm/dxg076	58	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 28	2021	12								692157	10.3389/fimmu.2021.692157	http://dx.doi.org/10.3389/fimmu.2021.692157			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TH0ZP	34262568	Green Published, gold			2022-12-18	WOS:000671824500001
J	Park, HE; Lee, W; Shin, MK; Shin, SJ				Park, Hyun-Eui; Lee, Wonsik; Shin, Min-Kyoung; Shin, Sung Jae			Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis?	FRONTIERS IN IMMUNOLOGY			English	Review						mycobacteria; tuberculosis; anti-TB drug; immune response; Mtb response	COLONY-STIMULATING FACTOR; ACTIVATED PROTEIN-KINASE; MYCOBACTERIUM-TUBERCULOSIS; HEME OXYGENASE-1; ADJUNCTIVE THERAPY; N-ACETYLCYSTEINE; GENE-EXPRESSION; ANTITUBERCULOSIS DRUGS; STAPHYLOCOCCUS-AUREUS; INHALABLE PARTICLES	Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb) infection, remains a global health threat despite recent advances and insights into host-pathogen interactions and the identification of diverse pathways that may be novel therapeutic targets for TB treatment. In addition, the emergence and spread of multidrug-resistant Mtb strains led to a low success rate of TB treatments. Thus, novel strategies involving the host immune system that boost the effectiveness of existing antibiotics have been recently suggested to better control TB. However, the lack of comprehensive understanding of the immunomodulatory effects of anti-TB drugs, including first-line drugs and newly introduced antibiotics, on bystander and effector immune cells curtailed the development of effective therapeutic strategies to combat Mtb infection. In this review, we focus on the influence of host immune-mediated stresses, such as lysosomal activation, metabolic changes, oxidative stress, mitochondrial damage, and immune mediators, on the activities of anti-TB drugs. In addition, we discuss how anti-TB drugs facilitate the generation of Mtb populations that are resistant to host immune response or disrupt host immunity. Thus, further understanding the interplay between anti-TB drugs and host immune responses may enhance effective host antimicrobial activities and prevent Mtb tolerance to antibiotic and immune attacks. Finally, this review highlights novel adjunctive therapeutic approaches against Mtb infection for better disease outcomes, shorter treatment duration, and improved treatment efficacy based on reciprocal interactions between current TB antibiotics and host immune cells.	[Park, Hyun-Eui; Shin, Min-Kyoung] Gyeongsang Natl Univ, Inst Hlth Sci, Dept Microbiol & Convergence Med Sci, Coll Med, Jinju, South Korea; [Lee, Wonsik] Sungkyunkwan Univ, Sch Pharm, Suwon, South Korea; [Shin, Sung Jae] Yonsei Univ, Grad Sch Med Sci, Coll Med, Dept Microbiol,Inst Immunol & Immunol Dis,Brain K, Seoul, South Korea	Gyeongsang National University; Sungkyunkwan University (SKKU); Yonsei University; Yonsei University Health System	Shin, MK (corresponding author), Gyeongsang Natl Univ, Inst Hlth Sci, Dept Microbiol & Convergence Med Sci, Coll Med, Jinju, South Korea.; Shin, SJ (corresponding author), Yonsei Univ, Grad Sch Med Sci, Coll Med, Dept Microbiol,Inst Immunol & Immunol Dis,Brain K, Seoul, South Korea.	mkshin@gnu.ac.kr; sjshin@yuhs.ac		Shin, Sung Jae/0000-0003-0854-4582	National Research Foundation of Korea (NRF) [NRF-2019R1A2C2003204, NRF2021R1C1C2012177]; Bio & Medical Technology Development Program of NRF - Korean Government (MSIT), Republic of Korea [NRF-2020M3A9H5104234]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Bio & Medical Technology Development Program of NRF - Korean Government (MSIT), Republic of Korea	This work was supported by the National Research Foundation of Korea (NRF) grant (NRF-2019R1A2C2003204 and NRF2021R1C1C2012177) and the Bio & Medical Technology Development Program of NRF (NRF-2020M3A9H5104234) funded by the Korean Government (MSIT), Republic of Korea. The funders had no role in study design, data collection and analysis, decision to publish, or manuscript preparation.	Ackart DF, 2014, PATHOG DIS, V70, P359, DOI 10.1111/2049-632X.12144; Mata-Espinosa DA, 2019, SCAND J IMMUNOL, V89, DOI 10.1111/sji.12743; Ahmad S, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008356; Amaral EP, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0872-7; Aminov RI, 2010, FRONT MICROBIOL, V1, DOI 10.3389/fmicb.2010.00134; Andersson AM, 2016, SCI REP-UK, V6, DOI 10.1038/srep28171; Andrade BB, 2015, J IMMUNOL, V195, P2763, DOI 10.4049/jimmunol.1500942; Andries K, 2005, SCIENCE, V307, P223, DOI 10.1126/science.1106753; Antonelli LRV, 2010, J CLIN INVEST, V120, P1674, DOI 10.1172/JCI40817; Arbues A, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008312; Asensio JG, 2006, J BIOL CHEM, V281, P1313, DOI 10.1074/jbc.C500388200; Avarbock A, 2005, BIOCHEMISTRY-US, V44, P9913, DOI 10.1021/bi0505316; Avarbock D, 1999, GENE, V233, P261, DOI 10.1016/S0378-1119(99)00114-6; Baek SH, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001065; Balaban NQ, 2019, NAT REV MICROBIOL, V17, P441, DOI 10.1038/s41579-019-0196-3; Baniasadi S, 2010, EUR J GASTROEN HEPAT, V22, P1235, DOI 10.1097/MEG.0b013e32833aa11b; Basaraba RJ, 2017, MICROBIOL SPECTR, V5, DOI 10.1128/microbiolspec.TBTB2-0024-2016; Beceiro A, 2013, CLIN MICROBIOL REV, V26, P185, DOI 10.1128/CMR.00059-12; Benmerzoug S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26984-3; Benoun JM, 2016, MBIO, V7, DOI [10.1128/mbio.01520-16, 10.1128/mBio.01520-16]; Berry MPR, 2010, NATURE, V466, P973, DOI 10.1038/nature09247; Berti A, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa302; Bhattacharya P, 2015, J INTERF CYTOK RES, V35, P585, DOI 10.1089/jir.2014.0149; Bi W, 2011, BRAIN RES, V1395, P12, DOI 10.1016/j.brainres.2011.04.019; Biraro IA, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1201-8; Bode C, 2014, INT IMMUNOPHARMACOL, V18, P27, DOI 10.1016/j.intimp.2013.10.025; Boshoff HIM, 2003, CELL, V113, P183, DOI 10.1016/S0092-8674(03)00270-8; Brauner A, 2016, NAT REV MICROBIOL, V14, P320, DOI 10.1038/nrmicro.2016.34; Brown DR, 2019, J BACTERIOL, V201, DOI 10.1128/JB.00622.18; Canesin G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00066; Cao RQ, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.01132-18; Carr AC, 2017, NUTRIENTS, V9, DOI 10.3390/nu9111211; CHAN J, 1992, J EXP MED, V175, P1111, DOI 10.1084/jem.175.4.1111; Chang SH, 2002, J BIOL CHEM, V277, P1933, DOI 10.1074/jbc.M108921200; Chen C, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.02107-17; Chinta KC, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10020177; Chinta KC, 2018, CELL REP, V25, P1938, DOI 10.1016/j.celrep.2018.10.073; Cholo MC, 2012, J ANTIMICROB CHEMOTH, V67, P290, DOI 10.1093/jac/dkr444; Choudhary E, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00070; Chuang YM, 2016, ANTIMICROB AGENTS CH, V60, P6460, DOI 10.1128/AAC.01139-16; Cimino M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042876; Correia FF, 2006, J BACTERIOL, V188, P8360, DOI 10.1128/JB.01237-06; Costa DL, 2021, MUCOSAL IMMUNOL, V14, P253, DOI 10.1038/s41385-020-00342-x; Costa DL, 2016, MBIO, V7, DOI 10.1128/mBio.01675-16; Dalebroux ZD, 2010, MICROBIOL MOL BIOL R, V74, P171, DOI 10.1128/MMBR.00046-09; Dawson R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006984; Deb C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006077; Degner NR, 2018, CLIN INFECT DIS, V66, P198, DOI 10.1093/cid/cix819; Guerra-De-Blas PD, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02097; Dhiman R, 2014, J INFECT DIS, V209, P578, DOI 10.1093/infdis/jit495; Domingo-Gonzalez R, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.TBTB2-0018-2016; Drenkard E, 2002, NATURE, V416, P740, DOI 10.1038/416740a; Dumont FJ, 1995, LIFE SCI, V58, P373, DOI 10.1016/0024-3205(95)02233-3; Dutta NK, 2020, J INFECT DIS, V221, P1079, DOI 10.1093/infdis/jiz517; Dutta NK, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav2104; Dutta NK, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.00652-17; Dutta NK, 2016, J ANTIMICROB CHEMOTH, V71, P1570, DOI 10.1093/jac/dkw014; Ejigu Dawit A, 2020, Tuberc Res Treat, V2020, P5907839, DOI 10.1155/2020/5907839; Esmail H, 2018, P NATL ACAD SCI USA, V115, pE964, DOI 10.1073/pnas.1711853115; Esteban J, 2018, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02651; Fauvart M, 2011, J MED MICROBIOL, V60, P699, DOI 10.1099/jmm.0.030932-0; Flentie K, 2016, J BACTERIOL, V198, P1360, DOI 10.1128/JB.00935-15; Floyd K, 2018, LANCET RESP MED, V6, P299, DOI 10.1016/S2213-2600(18)30057-2; Forrester SJ, 2018, CIRC RES, V122, P877, DOI 10.1161/CIRCRESAHA.117.311401; Francisco-Cruz A, 2013, CLIN EXP IMMUNOL, V171, P283, DOI 10.1111/cei.12015; Francisco-Cruz A, 2016, TUBERCULOSIS, V100, P5, DOI 10.1016/j.tube.2016.05.015; Frenkel JDH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73212-y; Fukutomi Y, 2011, ANTIMICROB AGENTS CH, V55, P4000, DOI 10.1128/AAC.00434-11; Galagan JE, 2013, NATURE, V499, P178, DOI 10.1038/nature12337; Giraud-Gatineau A, 2020, ELIFE, V9, DOI 10.7554/eLife.55692; Goossens SN, 2021, CLIN MICROBIOL REV, V34, DOI 10.1128/CMR.00141-20; Gopal R, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004099; Guerra C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028378; Gupta A, 2016, PHARM RES-DORDR, V33, P1899, DOI 10.1007/s11095-016-1926-0; Gupta A, 2014, MOL PHARMACEUT, V11, P1201, DOI 10.1021/mp4006563; GUPTA S, 1975, ANN INTERN MED, V82, P484, DOI 10.7326/0003-4819-82-4-484; Gupta S, 2014, ANTIMICROB AGENTS CH, V58, P574, DOI 10.1128/AAC.01462-13; Gupta S, 2013, AM J RESP CRIT CARE, V188, P600, DOI 10.1164/rccm.201304-0650OC; Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038; Hall CW, 2017, FEMS MICROBIOL REV, V41, P276, DOI [10.1093/femsre/fux010, 10.1093/femsre/f]; Hall-Stoodley L, 2004, NAT REV MICROBIOL, V2, P95, DOI 10.1038/nrmicro821; Happel KI, 2005, INFECT IMMUN, V73, P5782, DOI 10.1128/IAI.73.9.5782-5788.2005; Hardie DG, 2007, ANNU REV PHARMACOL, V47, P185, DOI 10.1146/annurev.pharmtox.47.120505.105304; Hedrich WD, 2016, ACTA PHARM SIN B, V6, P413, DOI 10.1016/j.apsb.2016.07.016; Helaine S, 2014, SCIENCE, V343, P204, DOI 10.1126/science.1244705; Hu YM, 2000, J BACTERIOL, V182, P6358, DOI 10.1128/JB.182.22.6358-6365.2000; Huang D, 2007, J INFECT DIS, V195, P55, DOI 10.1086/509895; Hudock TA, 2017, AM J RESP CELL MOL, V56, P637, DOI 10.1165/rcmb.2016-0239OC; Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581; Jagannath C, 2009, NAT MED, V15, P267, DOI 10.1038/nm.1928; Javid B, 2014, P NATL ACAD SCI USA, V111, P1132, DOI 10.1073/pnas.1317580111; Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161; Johnson B, 1998, NOVART FDN SYMP, V217, P99, DOI 10.1002/0470846526.ch7; Kaiser P, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001793; Kalghatgi S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006055; Kang KY, 2013, INT IMMUNOPHARMACOL, V16, P85, DOI 10.1016/j.intimp.2013.03.020; Kapoor N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053657; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; Keren I, 2011, MBIO, V2, DOI 10.1128/mBio.00100-11; Khader SA, 2005, J IMMUNOL, V175, P788, DOI 10.4049/jimmunol.175.2.788; Khameneh B, 2016, MICROB PATHOGENESIS, V93, P83, DOI 10.1016/j.micpath.2015.11.006; Khan Taj Ali, 2016, Chemother Res Pract, V2016, P7295390, DOI 10.1155/2016/7295390; Kilinc G, 2021, IMMUNOL REV, V301, P62, DOI 10.1111/imr.12951; Kim YS, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0290-7; Kocyigit I, 2015, EUR ARCH OTO-RHINO-L, V272, P2611, DOI 10.1007/s00405-014-3207-z; Kohanski MA, 2016, INT FORUM ALLERGY RH, V6, P191, DOI 10.1002/alr.21646; Koul A, 2007, NAT CHEM BIOL, V3, P323, DOI 10.1038/nchembio884; Lachmandas E, 2019, J INFECT DIS, V220, P139, DOI 10.1093/infdis/jiz064; Lamorte S, 2021, MOL ASPECTS MED, V78, DOI 10.1016/j.mam.2021.100942; Lamprecht DA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12393; Lee EH, 2020, CHEM-BIOL INTERACT, V315, DOI 10.1016/j.cbi.2019.108889; Lee JJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10975-7; Lee JS, 2008, CELL HOST MICROBE, V3, P97, DOI 10.1016/j.chom.2008.01.002; Lee W, 2013, J BIOL CHEM, V288, P6788, DOI 10.1074/jbc.M112.445056; Levin-Reisman I, 2019, P NATL ACAD SCI USA, V116, P14734, DOI 10.1073/pnas.1906169116; Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782; Li GL, 2015, J ANTIBIOT, V68, P431, DOI 10.1038/ja.2015.9; Liao KF, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00597; Nguyen L, 2016, ARCH TOXICOL, V90, P1585, DOI 10.1007/s00204-016-1727-6; Liu CH, 2017, CELL MOL IMMUNOL, V14, P963, DOI 10.1038/cmi.2017.88; Liu X, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02350; Liu YC, 2016, J EXP MED, V213, P809, DOI 10.1084/jem.20151248; Lobato LS, 2014, ANTIMICROB AGENTS CH, V58, P5766, DOI 10.1128/AAC.01826-13; Ma DZ, 2019, MBIO, V10, DOI 10.1128/mBio.01658-19; Ma YF, 2011, MICROBES INFECT, V13, P1099, DOI 10.1016/j.micinf.2011.06.012; Machado D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034538; MacMicking JD, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a018507; Mahakalkar Sunil M, 2017, Perspect Clin Res, V8, P132, DOI 10.4103/2229-3485.210450; Mambo G, 2003, INT IMMUNOPHARMACOL, V3, P513, DOI 10.1016/S1567-5769(03)00022-5; Manca C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074082; Mandal S, 2019, MICROBIOL-SGM, V165, P492, DOI 10.1099/mic.0.000760; Manina G, 2015, CELL HOST MICROBE, V17, P32, DOI 10.1016/j.chom.2014.11.016; Manzanillo PS, 2013, NATURE, V501, P512, DOI 10.1038/nature12566; Martin C, 2006, VACCINE, V24, P3408, DOI 10.1016/j.vaccine.2006.03.017; Mata-Espinosa DA, 2008, MOL THER, V16, P1065, DOI 10.1038/mt.2008.69; Matern WM, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00610; Mayer-Barber KD, 2014, NATURE, V511, P99, DOI 10.1038/nature13489; Memari B, 2015, J IMMUNOL, V195, P4479, DOI 10.4049/jimmunol.1501141; Menzel DB, 1998, BIOCHEM BIOPH RES CO, V250, P653, DOI 10.1006/bbrc.1998.9363; Meylan S, 2018, CELL, V172, P1228, DOI 10.1016/j.cell.2018.01.037; Mok WWK, 2018, P NATL ACAD SCI USA, V115, pE6301, DOI 10.1073/pnas.1804218115; Moreira-Teixeira L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19412-6; Moreira-Teixeira L, 2018, J EXP MED, V215, P1273, DOI 10.1084/jem.20180325; Moreira-Teixeira L, 2016, J IMMUNOL, V197, P4714, DOI 10.4049/jimmunol.1600584; Moura-Alves P, 2014, NATURE, V512, P387, DOI 10.1038/nature13684; Mourik BC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00294; Mouton JM, 2016, MICROBIOL-SGM, V162, P966, DOI 10.1099/mic.0.000288; Nandakumar M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5306; Nandi M, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-6190-3; Nasiri MJ, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00681; Neubauer JA, 2012, RESP PHYSIOL NEUROBI, V184, P178, DOI 10.1016/j.resp.2012.06.027; NILSSON BS, 1971, LANCET, V2, P374; Nolt D, 2004, INFECT IMMUN, V72, P2976, DOI 10.1128/IAI.72.5.2976-2988.2004; Oesterle A, 2017, CIRC RES, V120, P229, DOI 10.1161/CIRCRESAHA.116.308537; Oh S, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.611304; Pagan AJ, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a018499; Page R, 2016, NAT CHEM BIOL, V12, P208, DOI [10.1038/NCHEMBIO.2044, 10.1038/nchembio.2044]; Palanisamy GS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026254; Papotto PH, 2017, NAT IMMUNOL, V18, P604, DOI 10.1038/ni.3726; Parihar SP, 2014, J INFECT DIS, V209, P754, DOI 10.1093/infdis/jit550; Parish T, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.MGM2-0010-2013; Pasula R, 2015, J BIOL CHEM, V290, P7151, DOI 10.1074/jbc.M114.591891; Perez E, 2001, MOL MICROBIOL, V41, P179, DOI 10.1046/j.1365-2958.2001.02500.x; Pieterman ED, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.01354-18, 10.1128/aac.01354-18]; Pipkin ME, 2010, IMMUNITY, V32, P79, DOI 10.1016/j.immuni.2009.11.012; Pociask DA, 2013, AM J PATHOL, V182, P1286, DOI 10.1016/j.ajpath.2012.12.007; Podlesek Z, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01785; Primm TP, 2000, J BACTERIOL, V182, P4889, DOI 10.1128/JB.182.17.4889-4898.2000; Puyskens A, 2020, CELL HOST MICROBE, V27, P238, DOI 10.1016/j.chom.2019.12.005; Ramirez-Alejo N, 2014, J INTERF CYTOK RES, V34, P307, DOI 10.1089/jir.2013.0050; Ramos-Espinosa O, 2016, PATHOG DIS, V74, DOI 10.1093/femspd/ftw075; Richards JP, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.01213-19; Roach DR, 2002, J IMMUNOL, V168, P4620, DOI 10.4049/jimmunol.168.9.4620; Robinson RT, 2017, MBIO, V8, DOI 10.1128/mBio.02087-17; Rockwood N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00542; Rothchild AC, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw6693; Rothhammer V, 2019, NAT REV IMMUNOL, V19, P184, DOI 10.1038/s41577-019-0125-8; Rowe SE, 2020, NAT MICROBIOL, V5, P282, DOI 10.1038/s41564-019-0627-y; Saenwongsa W, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60213-0; Safe IP, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235381; Sambarey A, 2017, EBIOMEDICINE, V15, P112, DOI 10.1016/j.ebiom.2016.12.009; Santucci P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45164-5; Saunders RN, 2001, KIDNEY INT, V59, P3, DOI 10.1046/j.1523-1755.2001.00460.x; Schnappinger D, 2003, J EXP MED, V198, P693, DOI 10.1084/jem.20030846; Sebastian J, 2019, REDUCED PERMEABILITY, DOI [10.1101/624569, DOI 10.1101/624569]; Sebastian J, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.01343-16; Secor PR, 2018, P NATL ACAD SCI USA, V115, P10780, DOI 10.1073/pnas.1806005115; Sharma A, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.02037; Sharma V, 2000, NAT STRUCT BIOL, V7, P663, DOI 10.1038/77964; Shen H, 2015, ARCH MED SCI, V11, P584, DOI 10.5114/aoms.2015.52362; Shen HB, 2018, CELL MOL IMMUNOL, V15, P216, DOI 10.1038/cmi.2017.128; Shinde R, 2018, NAT IMMUNOL, V19, P571, DOI 10.1038/s41590-018-0107-1; Sikri K, 2018, REDOX BIOL, V15, P452, DOI 10.1016/j.redox.2017.12.020; Singh R, 2013, J BACTERIOL, V195, P2839, DOI 10.1128/JB.00038-13; Singhal A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009885; Skerry C, 2014, J ANTIMICROB CHEMOTH, V69, P2453, DOI 10.1093/jac/dku166; Slayden RA, 2018, PATHOG DIS, V76, DOI 10.1093/femspd/fty039; Smollett KL, 2012, J BIOL CHEM, V287, P22004, DOI 10.1074/jbc.M112.357715; Son HJ, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/973986; Stewart PS, 2001, LANCET, V358, P135, DOI 10.1016/S0140-6736(01)05321-1; Su VYF, 2017, CHEST, V152, P598, DOI 10.1016/j.chest.2017.04.170; Sun Q, 2020, BIOCHEM BIOPH RES CO, V531, P312, DOI 10.1016/j.bbrc.2020.07.026; Susanto L, 2018, IOP C SER EARTH ENV, V125, DOI 10.1088/1755-1315/125/1/012140; Suzuki T, 2015, FREE RADICAL BIO MED, V88, P93, DOI 10.1016/j.freeradbiomed.2015.06.006; Szeliga J, 2008, TUBERCULOSIS, V88, P7, DOI 10.1016/j.tube.2007.08.009; Tahir Faryal, 2020, Cureus, V12, pe7404, DOI 10.7759/cureus.7404; Talwar S, 2020, MSYSTEMS, V5, DOI 10.1128/mSystems.00855-20; Teskey G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02069; Tezera LB, 2020, ELIFE, V9, DOI 10.7554/eLife.52668; Titov AA, 2019, J IMMUNOL, V203, P338, DOI 10.4049/jimmunol.1801651; Torrey HL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155127; Tousif S, 2014, J BIOL CHEM, V289, P30190, DOI 10.1074/jbc.C114.598946; Trastoy R, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00023-18; Treerat P, 2017, MUCOSAL IMMUNOL, V10, P1069, DOI 10.1038/mi.2017.15; Tripathi P, 2020, INT J MED MICROBIOL, V310, DOI 10.1016/j.ijmm.2020.151402; Trivedi A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11392; Tsuchihashi S, 2005, TRANSPL P, V37, P1677, DOI 10.1016/j.transproceed.2005.03.080; Ubeda C, 2012, TRENDS IMMUNOL, V33, P459, DOI 10.1016/j.it.2012.05.003; Vatansever F, 2013, FEMS MICROBIOL REV, V37, P955, DOI 10.1111/1574-6976.12026; Vega NM, 2012, NAT CHEM BIOL, V8, P431, DOI [10.1038/NCHEMBIO.915, 10.1038/nchembio.915]; Venketaraman V, 2008, MICROB PATHOGENESIS, V44, P255, DOI 10.1016/j.micpath.2007.09.002; Verver S, 2005, AM J RESP CRIT CARE, V171, P1430, DOI 10.1164/rccm.200409-1200OC; Vilcheze C, 2021, ANTIMICROB AGENTS CH, V65, DOI 10.1128/AAC.01703-20; Vilcheze C, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.02165-17; Vilcheze C, 2017, P NATL ACAD SCI USA, V114, P4495, DOI 10.1073/pnas.1704376114; Vilcheze C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2898; Volzing KG, 2015, MBIO, V6, DOI 10.1128/mBio.00731-15; Vural A, 2018, PERITON DIALYSIS INT, V38, P57, DOI 10.3747/pdi.2017.00133; Walters SB, 2006, MOL MICROBIOL, V60, P312, DOI 10.1111/j.1365-2958.2006.05102.x; Wang LS, 2011, CHEM-BIOL INTERACT, V190, P129, DOI 10.1016/j.cbi.2011.02.001; Wang XX, 2021, TRENDS MICROBIOL, V29, P388, DOI 10.1016/j.tim.2020.12.001; West EE, 2013, J CLIN INVEST, V123, P2604, DOI 10.1172/JCI67008; WHO, 2021, TUBERCULOSIS; Willing BP, 2011, NAT REV MICROBIOL, V9, P233, DOI 10.1038/nrmicro2536; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Wu B, 2008, IMMUNOL LETT, V117, P57, DOI 10.1016/j.imlet.2007.11.018; Wu B, 2007, INFECT IMMUN, V75, P3658, DOI 10.1128/IAI.00244-07; Xu J, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.01692-17; Yan J, 2019, CELL HOST MICROBE, V26, P15, DOI 10.1016/j.chom.2019.06.002; Yang JH, 2017, CELL HOST MICROBE, V22, P757, DOI 10.1016/j.chom.2017.10.020; Yang TW, 2017, MEDICINE, V96, DOI [10.1097/MD.0000000000007482, 10.1097/md.0000000000007482]; Yee D, 2003, AM J RESP CRIT CARE, V167, P1472, DOI 10.1164/rccm.200206-626OC; Yoon GS, 2015, MOL PHARMACEUT, V12, P2517, DOI 10.1021/acs.molpharmaceut.5b00035; Yu X, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-0941-1; Zak DE, 2016, LANCET, V387, P2312, DOI 10.1016/S0140-6736(15)01316-1; Zhang L, 2021, J EXP MED, V218, DOI 10.1084/jem.20200887; Zhang Y, 2012, ANTIMICROB AGENTS CH, V56, P2223, DOI 10.1128/AAC.06288-11; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505; Zhu JH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06667-3; Ziglam HM, 2004, J CHEMOTHERAPY, V16, P357, DOI 10.1179/joc.2004.16.4.357; Zullo AJ, 2014, BMC BIOCHEM, V15, DOI 10.1186/1471-2091-15-4	251	0	0	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 28	2021	12								703060	10.3389/fimmu.2021.703060	http://dx.doi.org/10.3389/fimmu.2021.703060			23	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TH0ZD	34262571	Green Published, gold			2022-12-18	WOS:000671823300001
J	Plaza-Zabala, A; Sierra-Torre, V; Sierra, A				Plaza-Zabala, A.; Sierra-Torre, V; Sierra, A.			Assessing Autophagy in Microglia: A Two-Step Model to Determine Autophagosome Formation, Degradation, and Net Turnover (vol 11, 620602, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						autophagy; autophagosome; formation; degradation; LC3; microglia			[Plaza-Zabala, A.] Univ Basque Country, UPV EHU, Dept Pharmacol, Leioa, Spain; Achucarro Basque Ctr Neurosci, Glial Cell Biol Lab, Leioa, Spain; Univ Basque Country, UPV EHU, Dept Neurosci, Leioa, Spain	University of Basque Country; University of Basque Country	Plaza-Zabala, A (corresponding author), Univ Basque Country, UPV EHU, Dept Pharmacol, Leioa, Spain.							Plaza-Zabala A, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.620602	1	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 25	2021	12								724901	10.3389/fimmu.2021.724901	http://dx.doi.org/10.3389/fimmu.2021.724901			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TG4VE		gold, Green Published			2022-12-18	WOS:000671403500001
J	Vellozo, NS; Rigoni, TS; Lopes, MF				Vellozo, Natalia S.; Rigoni, Thais S.; Lopes, Marcela F.			New Therapeutic Tools to Shape Monocyte Functional Phenotypes in Leishmaniasis	FRONTIERS IN IMMUNOLOGY			English	Review						ATRA; Leishmania major; M1 and M2 macrophages; monocytes; nitric oxide; RANKL	TUMOR-NECROSIS-FACTOR; RETINOIC ACID; CUTANEOUS LEISHMANIASIS; MAJOR INFECTION; SUPPRESSOR-CELLS; FAMILY-MEMBER; MACROPHAGES; ACTIVATION; POLARIZATION; RECEPTOR	In the innate immunity to Leishmania infection tissue-resident macrophages and inflammatory monocytes accumulate host-cell, effector, and efferocytosis functions. In addition, neutrophils, as host, effector, and apoptotic cells, as well as tissue-resident and monocyte-derived dendritic cells (DCs) imprint innate and adaptive immunity to Leishmania parasites. Macrophages develop phenotypes ranging from antimicrobial M1 to parasite-permissive M2, depending on mouse strain, Leishmania species, and T-cell cytokines. The Th1 (IFN-gamma) and Th2 (IL-4) cytokines, which induce classically-activated (M1) or alternatively-activated (M2) macrophages, underlie resistance versus susceptibility to leishmaniasis. While macrophage phenotypes have been well discussed, new developments addressed the monocyte functional phenotypes in Leishmania infection. Here, we will emphasize the role of inflammatory monocytes to access how potential host-directed therapies for leishmaniasis, such as all-trans-retinoic acid (ATRA) and the ligand of Receptor Activator of Nuclear Factor-Kappa B (RANKL) might modulate immunity to Leishmania infection, by directly targeting monocytes to develop M1 or M2 phenotypes.	[Vellozo, Natalia S.; Rigoni, Thais S.; Lopes, Marcela F.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	Lopes, MF (corresponding author), Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Rio De Janeiro, Brazil.	marcelal@biof.ufrj.br	Lopes, Marcela Freitas/E-2201-2012	Lopes, Marcela Freitas/0000-0002-4508-0505	Brazilian National Research Council (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, CNPq); Rio de Janeiro State Science Foundation (Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro, FAPERJ); CNPq; FAPERJ; American Association of Immunologists	Brazilian National Research Council (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Rio de Janeiro State Science Foundation (Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro, FAPERJ)(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FAPERJ(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); American Association of Immunologists	This work was supported by the Brazilian National Research Council (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, CNPq) and the Rio de Janeiro State Science Foundation (Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro, FAPERJ). ML is a research fellow at CNPq, Brazil. We also received fellowships from CNPq (TR), FAPERJ (NV) and the American Association of Immunologists (NV and ML).	Alexander J, 2005, IMMUNOL LETT, V99, P17, DOI 10.1016/j.imlet.2005.01.009; Allman WR, 2015, P NATL ACAD SCI USA, V112, pE4094, DOI 10.1073/pnas.1421580112; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; BEIL WJ, 1992, J LEUKOCYTE BIOL, V52, P135, DOI 10.1002/jlb.52.2.135; BOGDAN C, 1991, EUR J IMMUNOL, V21, P327, DOI 10.1002/eji.1830210213; Bogdan Christian, 2020, Cytokine X, V2, P100041, DOI 10.1016/j.cytox.2020.100041; Bosurgi L, 2017, SCIENCE, V356, P1072, DOI 10.1126/science.aai8132; Broadhurst MJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002883; Cabanel M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132984; Cabral-Piccin MP, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.135; Carneiro MB, 2020, CELL HOST MICROBE, V27, P752, DOI 10.1016/j.chom.2020.03.011; Chaves MM, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008674; Chiba T, 2016, J AM SOC NEPHROL, V27, P495, DOI 10.1681/ASN.2014111108; Climaco-Arvizu S, 2016, LIFE SCI, V155, P76, DOI 10.1016/j.lfs.2016.05.001; Costa DL, 2016, J LEUKOCYTE BIOL, V100, P423, DOI 10.1189/jlb.4A0715-288R; Das S, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009343; Dorlo TPC, 2012, J ANTIMICROB CHEMOTH, V67, P2576, DOI 10.1093/jac/dks275; Fernandes AP, 2001, J INFECT DIS, V183, P1646, DOI 10.1086/320699; Freire-de-Lima CG, 2000, NATURE, V403, P199, DOI 10.1038/35003208; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gallina G, 2006, J CLIN INVEST, V116, P2777, DOI 10.1172/JCI28828; Garg R, 2004, PARASITOLOGY, V129, P685, DOI 10.1017/S0031182004006055; Giudice A, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-75; Goncalves R, 2011, J EXP MED, V208, P1253, DOI 10.1084/jem.20101751; Gundra UM, 2017, NAT IMMUNOL, V18, P642, DOI 10.1038/ni.3734; Hall JA, 2011, IMMUNITY, V35, P13, DOI 10.1016/j.immuni.2011.07.002; Heyde S, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007374; Hong K, 2014, IMMUNOL LETT, V162, P34, DOI 10.1016/j.imlet.2014.06.011; Huang R, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.19; Italiani P, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00514; Josien R, 2000, J EXP MED, V191, P495, DOI 10.1084/jem.191.3.495; Kaye P, 2011, NAT REV MICROBIOL, V9, P604, DOI 10.1038/nrmicro2608; Kip AE, 2015, ANTIMICROB AGENTS CH, V59, P1, DOI 10.1128/AAC.04298-14; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee B, 2016, NUCLEIC ACIDS RES, V44, P7568, DOI 10.1093/nar/gkw392; Lee SH, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aaz4415; Lee SH, 2018, J EXP MED, V215, P357, DOI 10.1084/jem.20171389; Locati M, 2020, ANNU REV PATHOL-MECH, V15, P123, DOI 10.1146/annurev-pathmechdis-012418-012718; Lopes MF, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/754965; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; McMahon-Pratt D, 2004, IMMUNOL REV, V201, P206, DOI 10.1111/j.0105-2896.2004.00190.x; Meng YH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.505; Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166; Miyahira Y, 2003, J IMMUNOL, V171, P6344, DOI 10.4049/jimmunol.171.12.6344; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; Nefedova Y, 2007, CANCER RES, V67, P11021, DOI 10.1158/0008-5472.CAN-07-2593; Novais FO, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.660183; Okwor I, 2016, AM J TROP MED HYG, V94, P489, DOI 10.4269/ajtmh.15-0408; Ouimet M, 2015, J CLIN INVEST, V125, P4334, DOI 10.1172/JCI81676; Padigel UM, 2003, J IMMUNOL, V171, P5437, DOI 10.4049/jimmunol.171.10.5437; Pereira WF, 2011, J LEUKOCYTE BIOL, V90, P1191, DOI 10.1189/jlb.1110608; Pereira-Manfro WF, 2014, J LEUKOCYTE BIOL, V95, P347, DOI 10.1189/jlb.0912463; Peters NC, 2008, SCIENCE, V321, P970, DOI 10.1126/science.1159194; Poon IKH, 2014, NAT REV IMMUNOL, V14, P166, DOI 10.1038/nri3607; Reverte M, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009422; Ribeiro-Gomes FL, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.351; Ribeiro-Gomes FL, 2004, J IMMUNOL, V172, P4454, DOI 10.4049/jimmunol.172.7.4454; Ribeiro-Gomes FL, 2014, INFECT IMMUN, V82, P2713, DOI 10.1128/IAI.01600-13; Ribeiro-Gomes FL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002536; Rigoni TS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00886; Rocha FJS, 2007, INFECT IMMUN, V75, P3823, DOI 10.1128/IAI.01335-06; Romano A, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006479; Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933; Schleicher U, 2016, CELL REP, V15, P1062, DOI 10.1016/j.celrep.2016.04.001; Schmid M, 2014, EUR J IMMUNOL, V44, P3295, DOI 10.1002/eji.201344335; SCOTT P, 1986, J IMMUNOL, V136, P1461; Scott P, 2016, NAT REV IMMUNOL, V16, P581, DOI 10.1038/nri.2016.72; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Steinbrink K, 2000, IMMUNOBIOLOGY, V202, P442, DOI 10.1016/S0171-2985(00)80103-5; SUNDERKOTTER C, 1993, J IMMUNOL, V151, P4891; Taslimi Y, 2020, CYTOKINE, V130, DOI 10.1016/j.cyto.2020.155056; Tomiotto-Pellissier F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02529; Vellozo NS, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01560; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075	77	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 25	2021	12								704429	10.3389/fimmu.2021.704429	http://dx.doi.org/10.3389/fimmu.2021.704429			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TG4KY	34249011	Green Published, gold			2022-12-18	WOS:000671376900001
J	Conde, R; Hernandez-Torres, E; Claudio-Piedras, F; Recio-Totoro, B; Maya-Maldonado, K; Cardoso-Jaime, V; Lanz-Mendoza, H				Conde, Renaud; Hernandez-Torres, Erika; Claudio-Piedras, Fabiola; Recio-Totoro, Benito; Maya-Maldonado, Krystal; Cardoso-Jaime, Victor; Lanz-Mendoza, Humberto			Heat Shock Causes Lower Plasmodium Infection Rates in Anopheles albimanus	FRONTIERS IN IMMUNOLOGY			English	Article						Anopheles albimanus; Plasmodium berghei; heat shock; immunity; infection resistance	GENES; IMMUNITY; BERGHEI; IDENTIFICATION; EXPRESSION; HEMOCYTES	The immune response of Anopheles mosquitoes to Plasmodium invasion has been extensively studied and shown to be mediated mainly by the nitric oxide synthase (NOS), dual oxidase (DUOX), phenoloxidase (PO), and antimicrobial peptides activity. Here, we studied the correlation between a heat shock insult, transcription of immune response genes, and subsequent susceptibility to Plasmodium berghei infection in Anopheles albimanus. We found that transcript levels of many immune genes were drastically affected by the thermal stress, either positively or negatively. Furthermore, the transcription of genes associated with modifications of nucleic acid methylation was affected, suggesting an increment in both DNA and RNA methylation. The heat shock increased PO and NOS activity in the hemolymph, as well as the transcription of several immune genes. As consequence, we observed that heat shock increased the resistance of mosquitoes to Plasmodium invasion. The data provided here could help the understanding of infection transmission under the ever more common heat waves.	[Conde, Renaud; Hernandez-Torres, Erika; Claudio-Piedras, Fabiola; Recio-Totoro, Benito; Maya-Maldonado, Krystal; Cardoso-Jaime, Victor; Lanz-Mendoza, Humberto] Inst Nacl Salud Publ, Ctr Invest Enfermedades Infecciosas, Cuernavaca, Morelos, Mexico; [Recio-Totoro, Benito] Univ Nacl Autonoma Mexico, Inst Biotecnol, Cuernavaca, Morelos, Mexico	Instituto Nacional de Salud Publica; Universidad Nacional Autonoma de Mexico	Lanz-Mendoza, H (corresponding author), Inst Nacl Salud Publ, Ctr Invest Enfermedades Infecciosas, Cuernavaca, Morelos, Mexico.	humberto@insp.mx	Lanz-Mendoza, Humberto/GLV-1737-2022	Maya-Maldonado, Krystal/0000-0001-7810-9741; Recio-Totoro, Benito/0000-0002-0449-2845; Cardoso Jaime, Victor Manuel Jonathan/0000-0003-4605-092X				AHMAD S, 1995, BIOCHEM SOC T, V23, pS110, DOI 10.1042/bst023110s; Altincicek B, 2008, DEV COMP IMMUNOL, V32, P585, DOI 10.1016/j.dci.2007.09.005; Benoit JB, 2011, P NATL ACAD SCI USA, V108, P8026, DOI 10.1073/pnas.1105195108; Bustin SA, 2005, J MOL ENDOCRINOL, V34, P597, DOI 10.1677/jme.1.01755; Claudio-Piedras F, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03025; COLLINS FH, 1986, SCIENCE, V234, P607, DOI 10.1126/science.3532325; Dai TM, 2018, INSECT MOL BIOL, V27, P123, DOI 10.1111/imb.12354; Dieme C, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00508; Eggert H, 2015, ECOL EVOL, V5, P1318, DOI 10.1002/ece3.1443; Feliciello I, 2013, EPIGENETICS-US, V8, P534, DOI 10.4161/epi.24507; Franke-Fayard B, 2004, MOL BIOCHEM PARASIT, V137, P23, DOI 10.1016/j.molbiopara.2004.04.007; Gonsalves SE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015934; Harvey JA, 2020, GLOBAL CHANGE BIOL, V26, P6685, DOI 10.1111/gcb.15377; Herrera-Ortiz A, 2004, INSECT BIOCHEM MOLEC, V34, P893, DOI 10.1016/j.ibmb.2004.05.007; Janeh M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50994-4; Jove V, 2020, JOVE-J VIS EXP, DOI 10.3791/61835; Kang S, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-136; Ko M, 2015, IMMUNOL REV, V263, P6, DOI 10.1111/imr.12239; Ko M, 2011, P NATL ACAD SCI USA, V108, P14566, DOI 10.1073/pnas.1112317108; Lambrechts L, 2006, P ROY SOC B-BIOL SCI, V273, P1501, DOI 10.1098/rspb.2006.3483; Li XQ, 2012, DEV COMP IMMUNOL, V36, P648, DOI 10.1016/j.dci.2011.11.005; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luckhart S, 1998, P NATL ACAD SCI USA, V95, P5700, DOI 10.1073/pnas.95.10.5700; Luna C, 2006, INSECT MOL BIOL, V15, P721, DOI 10.1111/j.1365-2583.2006.00661.x; Miranda KM, 2001, NITRIC OXIDE-BIOL CH, V5, P62, DOI 10.1006/niox.2000.0319; Momiuchi Y, 2015, J BIOL CHEM, V290, P23816, DOI 10.1074/jbc.M115.664193; Murdock CC, 2012, P ROY SOC B-BIOL SCI, V279, P3357, DOI 10.1098/rspb.2012.0638; NARANG S, 1983, BIOCHEM GENET, V21, P885, DOI 10.1007/BF00483947; Peterson TML, 2007, FREE RADICAL BIO MED, V42, P132, DOI 10.1016/j.freeradbiomed.2006.10.037; Peuss R, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2015.2041; Raddi G, 2020, SCIENCE, V369, P1128, DOI 10.1126/science.abc0322; Ramirez JL, 2014, J INNATE IMMUN, V6, P119, DOI 10.1159/000353765; Ribeiro C, 2006, J INSECT PHYSIOL, V52, P417, DOI 10.1016/j.jinsphys.2006.01.005; Ribeiro JMC, 2003, INSECT BIOCHEM MOLEC, V33, P865, DOI 10.1016/S0965-1748(03)00080-8; Rodriguez MC, 2002, EXP PARASITOL, V101, P73, DOI 10.1016/S0014-4894(02)00035-8; Schwartz A, 2002, J MED ENTOMOL, V39, P84, DOI 10.1603/0022-2585-39.1.84; Sim C, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-231; Simoes ML, 2017, MBIO, V8, DOI 10.1128/mBio.01631-17; Smith JA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00422; Suzuki J, 2019, AQUAT TOXICOL, V211, P66, DOI 10.1016/j.aquatox.2019.04.001; Vertyporokh L, 2015, J INVERTEBR PATHOL, V130, P42, DOI 10.1016/j.jip.2015.07.001; Vogel H, 2011, INSECT MOL BIOL, V20, P787, DOI 10.1111/j.1365-2583.2011.01109.x; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cb.11.110195.002301; Xiong WF, 2018, CELL STRESS CHAPERON, V23, P29, DOI 10.1007/s12192-017-0821-x; Zhao L, 2012, ISJ-INVERT SURVIV J, V9, P93	45	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 24	2021	12								584660	10.3389/fimmu.2021.584660	http://dx.doi.org/10.3389/fimmu.2021.584660			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TF2QT	34248924	Green Published, gold			2022-12-18	WOS:000670557400001
J	Guerra, PV; Andrade, CM; Nunes, IV; Gama, BC; Tiburcio, R; Santos, WLC; Azevedo, VA; Tavares, NM; Reboucas, JD; Maiolii, TU; Faria, AMC; Brodskyn, CI				Guerra, Priscila Valera; Andrade, Camila Mattos; Nunes, Ivaneia Valeriano; Gama, Brena Cardoso; Tiburcio, Rafael; Santos, Washington Luis Conrado; Azevedo, Vasco Ariston; Tavares, Natalia Machado; Reboucas, Juliana de Souza; Maiolii, Tatiani Uceli; Faria, Ana Maria Caetano; Brodskyn, Claudia Ida			Oral Tolerance Induced by Heat Shock Protein 65-Producing Lactococcus lactis Mitigates Inflammation in Leishmania braziliensis Infection	FRONTIERS IN IMMUNOLOGY			English	Article						Leishmania braziliensis; heat shock protein 65; Lactococcus lactis; oral tolerance; IL-10; TLR2; TGF-beta	REGULATORY T-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; LATENCY-ASSOCIATED PEPTIDE; MYELIN BASIC-PROTEIN; CUTANEOUS LEISHMANIASIS; EXPERIMENTAL-MODEL; IMMUNE-RESPONSES; IN-VITRO; SUPPRESSION; INDUCTION	Cutaneous leishmaniasis caused by L. braziliensis induces a pronounced Th1 inflammatory response characterized by IFN-gamma production. Even in the absence of parasites, lesions result from a severe inflammatory response in which inflammatory cytokines play an important role. Different approaches have been used to evaluate the therapeutic potential of orally administrated heat shock proteins (Hsp). These proteins are evolutionarily preserved from bacteria to humans, highly expressed under inflammatory conditions and described as immunodominant antigens. Tolerance induced by the oral administration of Hsp65 is capable of suppressing inflammation and inducing differentiation in regulatory cells, and has been successfully demonstrated in several experimental models of autoimmune and inflammatory diseases. We initially administered recombinant Lactococcus lactis (L. lactis) prior to infection as a proof of concept, in order to verify its immunomodulatory potential in the inflammatory response arising from L. braziliensis. Using this experimental approach, we demonstrated that the oral administration of a recombinant L. lactis strain, which produces and secretes Hsp65 from Mycobacterium leprae directly into the gut, mitigated the effects of inflammation caused by L. braziliensis infection in association or not with PAM 3CSK4 (N-alpha-Palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-L-cysteine, a TLR2 agonist). This was evidenced by the production of anti-inflammatory cytokines and the expansion of regulatory T cells in the draining lymph nodes of BALB/c mice. Our in vitro experimental results suggest that IL-10, TLR-2 and LAP are important immunomodulators in L. braziliensis infection. In addition, recombinant L. lactis administered 4 weeks after infection was observed to decrease lesion size, as well as the number of parasites, and produced a higher IL-10 production and decrease IFN-gamma secretion. Together, these results indicate that Hsp65-producing L. lactis can be considered as an alternative candidate for treatment in both autoimmune diseases, as well as in chronic infections that cause inflammatory disease.	[Guerra, Priscila Valera; Andrade, Camila Mattos; Nunes, Ivaneia Valeriano; Gama, Brena Cardoso; Tiburcio, Rafael; Tavares, Natalia Machado; Brodskyn, Claudia Ida] Inst Goncalo Moniz, Fundacao Oswaldo Cruz, Lab Interacao Parasita Hosp Epidemiol, Salvador, BA, Brazil; [Guerra, Priscila Valera] Ctr Univ Christus, Curso Med, Fortaleza, Ceara, Brazil; [Santos, Washington Luis Conrado] Inst Goncalo Moniz, Fundacao Oswaldo Cruz, Lab Patol Estrutural Mol LAP, Salvador, BA, Brazil; [Santos, Washington Luis Conrado] Univ Fed Bahia, Fac Med, Dept Patol & Med Legal, Salvador, BA, Brazil; [Azevedo, Vasco Ariston] Univ Fed Minais Gerais, Inst Ciencias Biomed, Dept Genet Ecol & Evolucao, Belo Horizonte, MG, Brazil; [Tavares, Natalia Machado; Brodskyn, Claudia Ida] Inst Nacl Ciencia Tecnol INCT, Inst Invest Imunol, Sao Paulo, Brazil; [Reboucas, Juliana de Souza] Univ Pernambuco, Programa Pos Grad Ciencias Sauda, Inst Ciencias Biol, Recife, PE, Brazil; [Maiolii, Tatiani Uceli] Univ Fed Minas Gerais, Escola Enfermagem, Dept Nutr, Belo Horizonte, MG, Brazil; [Faria, Ana Maria Caetano] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim Imunol, Belo Horizonte, MG, Brazil	Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; Universidade Federal da Bahia; Universidade Federal de Minas Gerais; Universidade de Pernambuco (UPE); Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais	Brodskyn, CI (corresponding author), Inst Goncalo Moniz, Fundacao Oswaldo Cruz, Lab Interacao Parasita Hosp Epidemiol, Salvador, BA, Brazil.; Brodskyn, CI (corresponding author), Inst Nacl Ciencia Tecnol INCT, Inst Invest Imunol, Sao Paulo, Brazil.	claudia.brodskyn@fiocruz.br	Azevedo, Vasco/B-1556-2019	Azevedo, Vasco/0000-0002-4775-2280; Faria, Ana Maria/0000-0002-0604-8510	CNPq [428371/2018-3, 304876/2019-4]; Fundacao Oswaldo Cruz, Programa Inova; Coordenacao de Aperfeicoamento de Pessoal de Nivel SUperior (CAPES)-Brazil [001]	CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao Oswaldo Cruz, Programa Inova; Coordenacao de Aperfeicoamento de Pessoal de Nivel SUperior (CAPES)-Brazil(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This study was supported by CNPq grants numbers 428371/2018-3 and 304876/2019-4. PVG received a pos-doc fellowship from Fundacao Oswaldo Cruz, Programa Inova. VAA, TUM, AMCF, and CIB are senior investigators of CNPq. This study is financed in part by the Coordenacao de Aperfeicoamento de Pessoal de Nivel ' SUperior (CAPES)-Brazil, Finance Code 001.	Ablamunits V, 1999, CLIN EXP IMMUNOL, V115, P260, DOI 10.1046/j.1365-2249.1999.00802.x; Alemayehu B., 2017, HLTH SCI J, V11, P519, DOI DOI 10.21767/1791-809X.1000519; Alexander J, 1999, J CELL SCI, V112, P2993; Allen JE, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002003; Belkaid Y, 1998, J EXP MED, V188, P1941, DOI 10.1084/jem.188.10.1941; Bilate AM, 2012, ANNU REV IMMUNOL, V30, P733, DOI 10.1146/annurev-immunol-020711-075043; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; Casadevall A, 1999, INFECT IMMUN, V67, P3703, DOI 10.1128/IAI.67.8.3703-3713.1999; Castellano LR, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/152741; Castro AB, 2012, CELL IMMUNOL, V280, P171, DOI 10.1016/j.cellimm.2012.12.004; Chandawarkar RY, 2004, INT IMMUNOL, V16, P615, DOI 10.1093/intimm/dxh063; Chen ML, 2008, J IMMUNOL, V180, P7327, DOI 10.4049/jimmunol.180.11.7327; Cobelens PM, 2002, RHEUMATOLOGY, V41, P775, DOI 10.1093/rheumatology/41.7.775; COHEN IR, 1991, IMMUNOL TODAY, V12, P105, DOI 10.1016/0167-5699(91)90093-9; CONVIT J, 1993, T ROY SOC TROP MED H, V87, P444, DOI 10.1016/0035-9203(93)90030-T; Costa J M, 1990, Rev Soc Bras Med Trop, V23, P205, DOI 10.1590/S0037-86821990000400004; de Azevedo MSP, 2012, GENET MOL RES, V11, P1146, DOI 10.4238/2012.April.27.14; de Faria AMC, 1998, MECH AGEING DEV, V102, P67, DOI 10.1016/S0047-6374(98)00024-4; de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005; DeKrey GK, 1998, INFECT IMMUN, V66, P827, DOI 10.1128/IAI.66.2.827-829.1998; Duthie MS, 2011, IMMUNOL REV, V239, P178, DOI 10.1111/j.1600-065X.2010.00978.x; ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576; Ellis R J, 1990, Semin Cell Biol, V1, P1; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; Faria AMC, 2003, J AUTOIMMUN, V20, P135, DOI 10.1016/S0896-8411(02)00112-9; Faria AMC, 2006, CLIN DEV IMMUNOL, V13, P143, DOI 10.1080/17402520600876804; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; Gause WC, 2013, NAT REV IMMUNOL, V13, P607, DOI 10.1038/nri3476; Gomes-Santos AC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00030; Gomes-Silva A, 2013, PARASITOLOGY, V140, P771, DOI 10.1017/S0031182012002156; Gusmao-Silva G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.562905; Harats D, 2002, J AM COLL CARDIOL, V40, P1333, DOI 10.1016/S0735-1097(02)02135-6; Hauet-Broere F, 2006, ANN RHEUM DIS, V65, P65, DOI 10.1136/ard.2006.058495; HERWALDT BL, 1992, J INFECT DIS, V165, P518, DOI 10.1093/infdis/165.3.518; HIGGINS PJ, 1988, J IMMUNOL, V140, P440; Hou J, 2011, VACCINE, V29, P4102, DOI 10.1016/j.vaccine.2011.03.105; Huang L, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003546; Kautz-Neu K, 2011, J EXP MED, V208, P885, DOI 10.1084/jem.20102318; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Maron R, 2002, CIRCULATION, V106, P1708, DOI 10.1161/01.CIR.0000029750.99462.30; MARSDEN PD, 1986, T ROY SOC TROP MED H, V80, P859, DOI 10.1016/0035-9203(86)90243-9; MARSDEN PD, 1984, T ROY SOC TROP MED H, V78, P561, DOI 10.1016/0035-9203(84)90087-7; Medzhitov R, 2012, SCIENCE, V335, P936, DOI 10.1126/science.1214935; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; Lessa Marcus Miranda, 2007, Rev. Bras. Otorrinolaringol., V73, P843, DOI [10.1590/S0034-72992007000600016, 10.1016/S1808-8694(15)31181-2]; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Oida T, 2003, J IMMUNOL, V170, P2516, DOI 10.4049/jimmunol.170.5.2516; Oliveira RP, 2015, J IMMUNOL METHODS, V421, P36, DOI 10.1016/j.jim.2015.02.005; Pasparakis M, 2014, NAT REV IMMUNOL, V14, P289, DOI 10.1038/nri3646; Pinto-da-Silva LH, 2002, INT J PARASITOL, V32, P1371, DOI 10.1016/S0020-7519(02)00137-6; Quintana FJ, 2011, TRENDS IMMUNOL, V32, P89, DOI 10.1016/j.it.2010.11.001; Quintana FJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004026; Raberg L, 2009, PHILOS T R SOC B, V364, P37, DOI 10.1098/rstb.2008.0184; Read AF, 2008, PLOS BIOL, V6, P2638, DOI 10.1371/journal.pbio.1000004; Rezende RM, 2013, J AUTOIMMUN, V40, P45, DOI 10.1016/j.jaut.2012.07.012; Ribeiro-de-Jesus A, 1998, BRAZ J MED BIOL RES, V31, P143, DOI 10.1590/S0100-879X1998000100020; Rottiers P, 2009, INT REV IMMUNOL, V28, P465, DOI 10.3109/08830180903197498; Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933; Sadeghian Giti, 2006, Dermatol Online J, V12, P3; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Schmid-Hempel P., 2013, Evolutionary Parasitology: The Integrated Study of Infections, Immunology, Ecology, and Genetics, P516, DOI 10.1093/acprof:oso/9780199229482.003.0008; Schneider DS, 2008, NAT REV IMMUNOL, V8, P889, DOI 10.1038/nri2432; Scorza B.M., 2017, INT J MOL SCI, V18, DOI [10.3390/ijms18061296., DOI 10.3390/ijms18061296]; Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010; Tsuji NM, 2001, IMMUNOLOGY, V103, P458, DOI 10.1046/j.1365-2567.2001.01265.x; van Puijvelde HM, 2007, ARTERIOSCL THROM VAS, V27, P2677, DOI 10.1161/ATVBAHA.107.151274; VANDENBROEK MF, 1989, J EXP MED, V170, P449, DOI 10.1084/jem.170.2.449; VAZ NM, 1977, J ALLERGY CLIN IMMUN, V60, P110, DOI 10.1016/0091-6749(77)90035-5; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Weiner HL, 2011, IMMUNOL REV, V241, P241, DOI 10.1111/j.1600-065X.2011.01017.x; Wieten L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004186; Zanin-Zhorov A, 2005, J IMMUNOL, V174, P3227, DOI 10.4049/jimmunol.174.6.3227; Zanin-Zhorov A, 2003, FASEB J, V17, P1567, DOI 10.1096/fj.02-1139fje; Zanin-Zhorov A, 2006, J CLIN INVEST, V116, P2022, DOI 10.1172/JCI28423; ZHANG ZJ, 1991, P NATL ACAD SCI USA, V88, P10252, DOI 10.1073/pnas.88.22.10252	75	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 24	2021	12								647987	10.3389/fimmu.2021.647987	http://dx.doi.org/10.3389/fimmu.2021.647987			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TF2SD	34248935	gold, Green Published			2022-12-18	WOS:000670561000001
J	Loevenich, S; Spahn, AS; Rian, K; Boyartchuk, V; Anthonsen, MW				Loevenich, Simon; Spahn, Alix S.; Rian, Kristin; Boyartchuk, Victor; Anthonsen, Marit Walbye			Human Metapneumovirus Induces IRF1 via TANK-Binding Kinase 1 and Type I IFN	FRONTIERS IN IMMUNOLOGY			English	Article						human macrophages; innate immune response; antiviral response; interferon; human metapneumovirus; interferon regulatory factor 1; nuclear factor-kB; TANK-binding kinase 1	NF-KAPPA-B; IKK-EPSILON; TRANSCRIPTION FACTORS; INTERFERON RESPONSE; GENE-EXPRESSION; DENDRITIC CELLS; NUCLEAR-FACTOR; ACTIVATION; TBK1; INFECTION	The innate immune and host-protective responses to viruses, such as the airway pathogen human metapneumovirus (HMPV), depend on interferons (IFNs) that is induced through TANK-binding kinase 1 (TBK1) and IFN regulatory factors (IRFs). The transcription factor IRF1 is important for host resistance against several viruses and has a key role in induction of IFN-lambda at mucosal surfaces. In most cell types IRF1 is expressed at very low levels, but its mRNA is rapidly induced when the demand for IRF1 activity arises. Despite general recognition of the importance of IRF1 to antiviral responses, the molecular mechanisms by which IRF1 is regulated during viral infections are not well understood. Here we identify the serine/threonine kinase TBK1 and IFN-beta as critical regulators of IRF1 mRNA and protein levels in human monocyte-derived macrophages. We find that inhibition of TBK1 activity either by the semi-selective TBK1/IKK epsilon inhibitor BX795 or by siRNA-mediated knockdown abrogates HMPV-induced expression of IRF1. Moreover, we show that canonical NF-kappa B signaling is involved in IRF1 induction and that the TBK1/IKK epsilon inhibitor BX795, but not siTBK1 treatment, impairs HMPV-induced phosphorylation of the NF-kappa B subunit p65. At later time-points of the infection, IRF1 expression depended heavily on IFN-beta-mediated signaling via the IFNAR-STAT1 pathway. Hence, our results suggest that TBK1 activation and TBK1/IKK epsilon-mediated phosphorylation of the NF-kappa B subunit p65 control transcription of IRF1. Our study identifies a novel mechanism for IRF1 induction in response to viral infection of human macrophages that could be relevant not only to defense against HMPV, but also to other viral, bacterial and fungal pathogens.	[Loevenich, Simon; Spahn, Alix S.; Rian, Kristin; Boyartchuk, Victor; Anthonsen, Marit Walbye] Norwegian Univ Sci & Technol NTNU, Dept Clin & Mol Med IKOM, Trondheim, Norway; [Boyartchuk, Victor] St Olav Hosp HF, Clin Surg, Trondheim, Norway; [Boyartchuk, Victor] Norwegian Univ Life Sci, Fac Biosci, Dept Anim & Aquacultural Sci, Ctr Integrat Genet, As, Norway	Norwegian University of Science & Technology (NTNU); Norwegian University of Life Sciences	Anthonsen, MW (corresponding author), Norwegian Univ Sci & Technol NTNU, Dept Clin & Mol Med IKOM, Trondheim, Norway.	marit.w.anthonsen@ntnu.no		Loevenich, Simon/0000-0001-5424-8755	Liaison Committee [46085000]; Faculty of Medicine at the Norwegian University of Science and Technology; Children's Clinic, St. Olavs Hospital Trondheim [16/9564-104/NISLIN]; MCSA ITN project "INITIATE" [813343]	Liaison Committee; Faculty of Medicine at the Norwegian University of Science and Technology; Children's Clinic, St. Olavs Hospital Trondheim; MCSA ITN project "INITIATE"	This work was supported by the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology (grant number 46085000), the Faculty of Medicine at the Norwegian University of Science and Technology, the Children's Clinic, St. Olavs Hospital Trondheim (grant number 16/9564-104/NISLIN), and the MCSA ITN project "INITIATE" (813343).	Abe T, 2014, J VIROL, V88, P5328, DOI 10.1128/JVI.00037-14; Adli M, 2006, J BIOL CHEM, V281, P26976, DOI 10.1074/jbc.M603133200; Ahmad L, 2016, TRENDS MOL MED, V22, P511, DOI 10.1016/j.molmed.2016.04.006; Ank N, 2006, J VIROL, V80, P4501, DOI 10.1128/JVI.80.9.4501-4509.2006; Balka KR, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.03.056; Banos-Lara MD, 2015, J VIROL, V89, P730, DOI 10.1128/JVI.02897-14; Bao X, 2007, VIROLOGY, V368, P91, DOI 10.1016/j.virol.2007.06.023; Bonelli M, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0267-6; Briard B, 2019, NAT MICROBIOL, V4, P316, DOI 10.1038/s41564-018-0298-0; Brien JD, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002230; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; Cespedes PF, 2016, CLIN MICROBIOL REV, V29, P795, DOI 10.1128/CMR.00081-15; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Cheon H, 2013, EMBO J, V32, P2751, DOI 10.1038/emboj.2013.203; Clark K, 2009, J BIOL CHEM, V284, P14136, DOI 10.1074/jbc.M109.000414; Durand JK, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7090139; Farlik M, 2012, MOL CELL BIOL, V32, P1032, DOI 10.1128/MCB.06021-11; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2011, J INTERF CYTOK RES, V31, P131, DOI 10.1089/jir.2010.0127; Forero A, 2019, IMMUNITY, V51, P451, DOI 10.1016/j.immuni.2019.07.007; Goutagny N, 2010, J IMMUNOL, V184, P1168, DOI 10.4049/jimmunol.0902750; Guerrero-Plata A, 2006, AM J RESP CELL MOL, V34, P320, DOI 10.1165/rcmb.2005-0287OC; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Harman AN, 2015, J VIROL, V89, P6575, DOI 10.1128/JVI.00889-15; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Honda K, 2006, NAT REV IMMUNOL, V6, P644, DOI 10.1038/nri1900; Jackson JD, 2016, MOL CANCER RES, V14, P482, DOI 10.1158/1541-7786.MCR-15-0427; Kalinowski A, 2018, MUCOSAL IMMUNOL, V11, P958, DOI 10.1038/mi.2017.120; Koetzler R, 2009, J ALLERGY CLIN IMMUN, V124, P551, DOI 10.1016/j.jaci.2009.04.041; Kolli D, 2014, AM J RESP CELL MOL, V51, P502, DOI 10.1165/rcmb.2013-0414OC; Kolli D, 2011, J IMMUNOL, V187, P47, DOI 10.4049/jimmunol.1002589; Kuriakose T, 2018, J IMMUNOL, V200, P1489, DOI 10.4049/jimmunol.1701538; Lazear HM, 2019, IMMUNITY, V50, P907, DOI 10.1016/j.immuni.2019.03.025; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Li XX, 1996, J BIOL CHEM, V271, P5790, DOI 10.1074/jbc.271.10.5790; Li YX, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19225-0; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loevenich S, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/4964239; Malmo J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155484; Man SM, 2015, NAT IMMUNOL, V16, P467, DOI 10.1038/ni.3118; Marvin SA, 2017, J VIROL, V91, DOI 10.1128/JVI.01417-16; Mattioli I, 2006, J BIOL CHEM, V281, P6175, DOI 10.1074/jbc.M508045200; Mills EL, 2018, NATURE, V556, P113, DOI 10.1038/nature25986; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Mordstein M, 2010, J VIROL, V84, P5670, DOI 10.1128/JVI.00272-10; Nakagawa K, 2000, EUR J BIOCHEM, V267, P1680, DOI 10.1046/j.1432-1327.2000.01163.x; Odendall C, 2014, NAT IMMUNOL, V15, P717, DOI 10.1038/ni.2915; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; Panda D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01019; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Quintas-Cardama A, 2010, BLOOD, V115, P3109, DOI 10.1182/blood-2009-04-214957; REIN T, 1994, NUCLEIC ACIDS RES, V22, P3033, DOI 10.1093/nar/22.15.3033; Remoli AL, 2016, MBIO, V7, DOI 10.1128/mBio.01528-16; Satoh JI, 2013, GENE REGUL SYST BIO, V7, P41, DOI 10.4137/GRSB.S11433; Sen N, 2018, J VIROL, V92, DOI 10.1128/JVI.01151-18; Sgarbanti M, 2002, J EXP MED, V195, P1359, DOI 10.1084/jem.20010753; Sivro A, 2013, AIDS RES HUM RETROV, V29, P1428, DOI [10.1089/aid.2013.0098, 10.1089/AID.2013.0098]; Takaoka A, 2008, CANCER SCI, V99, P467, DOI 10.1111/j.1349-7006.2007.00720.x; Tallam A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149050; Taniguchi T, 1997, BBA-REV CANCER, V1333, pM9, DOI 10.1016/S0304-419X(97)00014-0; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; tenOever BR, 2004, J VIROL, V78, P10636, DOI 10.1128/JVI.78.19.10636-10649.2004; Tian B, 2018, J VIROL, V92, DOI 10.1128/JVI.00441-18; Wang JM, 2010, J IMMUNOL, V185, P1720, DOI 10.4049/jimmunol.1000114; Wietek C, 2006, J BIOL CHEM, V281, P34973, DOI 10.1074/jbc.M607018200; Zaritsky LA, 2015, J VIROL, V89, P11534, DOI 10.1128/JVI.01727-15; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	68	0	0	1	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 24	2021	12								563336	10.3389/fimmu.2021.563336	http://dx.doi.org/10.3389/fimmu.2021.563336			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TF2ZX	34248923	Green Published, gold			2022-12-18	WOS:000670581600001
J	Pollack, S; Eisenstein, I; Mory, A; Paperna, T; Ofir, A; Baris-Feldman, H; Weiss, K; Veszeli, N; Csuka, D; Shemer, R; Glaser, F; Prohaszka, Z; Magen, D				Pollack, Shirley; Eisenstein, Israel; Mory, Adi; Paperna, Tamar; Ofir, Ayala; Baris-Feldman, Hagit; Weiss, Karin; Veszeli, Nora; Csuka, Dorottya; Shemer, Revital; Glaser, Fabian; Prohaszka, Zoltan; Magen, Daniella			A Novel Homozygous In-Frame Deletion in Complement Factor 3 Underlies Early-Onset Autosomal Recessive Atypical Hemolytic Uremic Syndrome-Case Report	FRONTIERS IN IMMUNOLOGY			English	Article						atypical hemolytic uremic syndrome (aHUS); complement factor C3; eculizumab; alternative complement pathway; homozygous deletion	FACTOR-H; STRUCTURAL INSIGHTS; MOLECULAR-BASIS; C3 CONVERTASE; COMPONENT C3; MUTATIONS; ASSOCIATION; VARIANTS; SEQUENCE; GAIN	Background and Objectives Atypical hemolytic uremic syndrome (aHUS) is mostly attributed to dysregulation of the alternative complement pathway (ACP) secondary to disease-causing variants in complement components or regulatory proteins. Hereditary aHUS due to C3 disruption is rare, usually caused by heterozygous activating mutations in the C3 gene, and transmitted as autosomal dominant traits. We studied the molecular basis of early-onset aHUS, associated with an unusual finding of a novel homozygous activating deletion in C3. Design, Setting, Participants, & Measurements A male neonate with eculizumab-responsive fulminant aHUS and C3 hypocomplementemia, and six of his healthy close relatives were investigated. Genetic analysis on genomic DNA was performed by exome sequencing of the patient, followed by targeted Sanger sequencing for variant detection in his close relatives. Complement components analysis using specific immunoassays was performed on frozen plasma samples from the patient and mother. Results Exome sequencing revealed a novel homozygous variant in exon 26 of C3 (c.3322_3333del, p.Ile1108_Lys1111del), within the highly conserved thioester-containing domain (TED), fully segregating with the familial disease phenotype, as compatible with autosomal recessive inheritance. Complement profiling of the patient showed decreased C3 and FB levels, with elevated levels of the terminal membrane attack complex, while his healthy heterozygous mother showed intermediate levels of C3 consumption. Conclusions Our findings represent the first description of aHUS secondary to a novel homozygous deletion in C3 with ensuing unbalanced C3 over-activation, highlighting a critical role for the disrupted C3-TED domain in the disease mechanism.	[Pollack, Shirley; Eisenstein, Israel; Magen, Daniella] Ruth Childrens Hosp, Pediat Nephrol Inst, Haifa, Israel; [Pollack, Shirley] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel; [Mory, Adi; Paperna, Tamar; Ofir, Ayala; Baris-Feldman, Hagit; Weiss, Karin] Genet Inst Inc, Haifa, Israel; [Veszeli, Nora; Csuka, Dorottya; Prohaszka, Zoltan] Hungarian Acad Sci, Res Lab, Dept Internal Med & Haematol, Budapest, Hungary; [Veszeli, Nora; Csuka, Dorottya; Prohaszka, Zoltan] Hungarian Acad Sci, MTA SE Res Grp Immunol & Hematol, Budapest, Hungary; [Veszeli, Nora; Csuka, Dorottya; Prohaszka, Zoltan] Semmelweis Univ, Budapest, Hungary; [Shemer, Revital; Magen, Daniella] Technion Israel Inst Technol, Mol Med Lab, Rappaport Fac Med, Haifa, Israel; [Glaser, Fabian] Technion Israel Inst Technol, Bioinformat Knowledge Unit, Lorry I Lokey Interdisciplinary Ctr Sci & Engn, Haifa, Israel	Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Hungarian Academy of Sciences; Hungarian Academy of Sciences; Semmelweis University; Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology	Pollack, S (corresponding author), Ruth Childrens Hosp, Pediat Nephrol Inst, Haifa, Israel.; Pollack, S (corresponding author), Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel.	s_pollack@rmc.gov.il			Premium Postdoctoral Fellowship Program of the Hungarian Academy of Sciences [PPD2018-016/2018]; Kaylie Kidney Research Center of Excellence at Rambam Medical Center	Premium Postdoctoral Fellowship Program of the Hungarian Academy of Sciences; Kaylie Kidney Research Center of Excellence at Rambam Medical Center	The study was supported by the Premium Postdoctoral Fellowship Program of the Hungarian Academy of Sciences (PPD2018-016/2018), and by the Kaylie Kidney Research Center of Excellence at Rambam Medical Center.	Bresin E, 2013, J AM SOC NEPHROL, V24, P475, DOI 10.1681/ASN.2012090884; Bu FX, 2014, J AM SOC NEPHROL, V25, P55, DOI 10.1681/ASN.2013050453; DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708; Dzik S, 2019, TRANSFUS MED REV, V33, P199, DOI 10.1016/j.tmrv.2019.08.004; Fakhouri F, 2018, SEMIN HEMATOL, V55, P150, DOI 10.1053/j.seminhematol.2018.04.009; Feitz WJC, 2018, MED GENET-BERLIN, V30, P400, DOI 10.1007/s11825-018-0216-0; Fremeaux-Bacchi V, 2013, CLIN J AM SOC NEPHRO, V8, P554, DOI 10.2215/CJN.04760512; Fremeaux-Bacchi V, 2008, BLOOD, V112, P4948, DOI 10.1182/blood-2008-01-133702; Janssen BJC, 2007, MOL IMMUNOL, V44, P3, DOI 10.1016/j.molimm.2006.06.017; Janssen BJC, 2006, NATURE, V444, P213, DOI 10.1038/nature05172; Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005; Lemaire M, 2013, NAT GENET, V45, P531, DOI 10.1038/ng.2590; Lhotta K, 2009, CLIN J AM SOC NEPHRO, V4, P1356, DOI 10.2215/CJN.06281208; Loirat C, 2016, PEDIATR NEPHROL, V31, P15, DOI 10.1007/s00467-015-3076-8; Lumbreras J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01348; Martinez-Barricarte R, 2015, MOL IMMUNOL, V66, P263, DOI 10.1016/j.molimm.2015.03.248; Moore I, 2010, BLOOD, V115, P379, DOI 10.1182/blood-2009-05-221549; Morgan HP, 2011, NAT STRUCT MOL BIOL, V18, P463, DOI 10.1038/nsmb.2018; Noris M, 2009, NEW ENGL J MED, V361, P1676, DOI 10.1056/NEJMra0902814; Okura Y, 2016, J ALLERGY CLIN IMMUN, V137, P640, DOI 10.1016/j.jaci.2015.08.017; Osborne AJ, 2018, J IMMUNOL, V200, P2464, DOI 10.4049/jimmunol.1701695; Persson BD, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001122; Pettersen EF, 2021, PROTEIN SCI, V30, P70, DOI 10.1002/pro.3943; Reis ES, 2006, SCAND J IMMUNOL, V63, P155, DOI 10.1111/j.1365-3083.2006.01729.x; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Rodriguez E, 2014, BIOSCIENCE REP, V34, P635, DOI 10.1042/BSR20140117; Rosell M, 2020, METHODS MOL BIOL, V2165, P175, DOI 10.1007/978-1-0716-0708-4_10; Roumenina LT, 2012, BLOOD, V119, P4182, DOI 10.1182/blood-2011-10-383281; Sansbury FH, 2014, J MED GENET, V51, P756, DOI 10.1136/jmedgenet-2014-102498; Sartz L, 2012, J IMMUNOL, V188, P2030, DOI 10.4049/jimmunol.1100319; Schaefer F, 2018, KIDNEY INT, V94, P408, DOI 10.1016/j.kint.2018.02.029; Schramm EC, 2015, BLOOD, V125, P2359, DOI 10.1182/blood-2014-10-609073; Valoti E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00853; Wu J, 2009, NAT IMMUNOL, V10, P728, DOI 10.1038/ni.1755; Yoshida Y, 2019, J ATHEROSCLER THROMB, V26, P99, DOI 10.5551/jat.RV17026	35	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 24	2021	12								608604	10.3389/fimmu.2021.608604	http://dx.doi.org/10.3389/fimmu.2021.608604			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TF3TD	34248927	gold, Green Published			2022-12-18	WOS:000670638700001
J	Pucca, MB; Fry, BG; Sartim, MA; Peigneur, S; Monteiro, WM				Pucca, Manuela B.; Fry, Bryan G.; Sartim, Marco A.; Peigneur, Steve; Monteiro, Wuelton M.			Editorial: Venoms and Toxins: At the Crossroads of Basic, Applied and Clinical Immunology	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						animal venoms; immunology; toxins; envenoming; drug development			[Pucca, Manuela B.] Univ Fed Roraima, Sch Med, Boa Vista, Parana, Brazil; [Fry, Bryan G.] Univ Queensland, Sch Biol Sci, Venom Evolut Lab, St Lucia, Qld, Australia; [Sartim, Marco A.; Monteiro, Wuelton M.] Dr Heitor Vieira Dourado Trop Med Fdn, Dept Res, Manaus, Amazonas, Brazil; [Sartim, Marco A.] Univ Fed Amazonas, Inst Biol Sci, Manaus, Amazonas, Brazil; [Peigneur, Steve] Katholieke Univ Leuven, Toxicol & Pharmacol, Leuven, Belgium; [Monteiro, Wuelton M.] Amazonas State Univ, Sch Hlth Sci, Manaus, Amazonas, Brazil	Universidade Federal de Roraima; University of Queensland; Universidade Federal de Amazonas; KU Leuven; Universidade do Estado do Amazonas	Pucca, MB (corresponding author), Univ Fed Roraima, Sch Med, Boa Vista, Parana, Brazil.; Monteiro, WM (corresponding author), Dr Heitor Vieira Dourado Trop Med Fdn, Dept Res, Manaus, Amazonas, Brazil.; Monteiro, WM (corresponding author), Amazonas State Univ, Sch Hlth Sci, Manaus, Amazonas, Brazil.	manu.pucca@ufrr.br; wueltonmm@gmail.com	Sartim, Marco/X-4086-2019	Sartim, Marco/0000-0003-4572-3109	Conselho Nacional de Desenvolvimento Cientofico e Tecnologico (CNPq) [307184/2020-0, 309207/2020-7]; Fundacao de Amparo a Pesquisa do Estado do Amazonas [PAPAC 005/2019]; Hamish Ogston Foundation -Global Snakebite Initiative	Conselho Nacional de Desenvolvimento Cientofico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao de Amparo a Pesquisa do Estado do Amazonas; Hamish Ogston Foundation -Global Snakebite Initiative	We thank Conselho Nacional de Desenvolvimento Cientofico e Tecnologico (CNPq, The National Council for Scientific and Technological Development, scholarship to MBP no. 307184/2020-0 and WMM n. 309207/2020-7). WMM acknowledges funding support from Fundacao de Amparo a Pesquisa do Estado do Amazonas (PAPAC 005/2019, PRO '-ESTADO, and Posgrad calls). MBP acknowledges funding support from Hamish Ogston Foundation -Global Snakebite Initiative.		0	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 24	2021	12								716508	10.3389/fimmu.2021.716508	http://dx.doi.org/10.3389/fimmu.2021.716508			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TF2UO	34249021	Green Published, gold			2022-12-18	WOS:000670567300001
J	Reali, E; Ferrando-Martinez, S; Catalfamo, M				Reali, Eva; Ferrando-Martinez, Sara; Catalfamo, Marta			Editorial: The Interplay Between Immune Activation and Cardiovascular Disease During Infection, Autoimmunity and Aging: The Role of T Cells	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						T cells; cardiovascular disease; infection; aging; autoimmunity			[Reali, Eva] Univ Milano Bicocca, Dept Biotechnol & Biosci, Milan, Italy; [Ferrando-Martinez, Sara] NeoImmuneTech Inc, Rockville, MD USA; [Catalfamo, Marta] Georgetown Univ, Sch Med, Dept Microbiol & Immunol, Washington, DC 20057 USA	University of Milano-Bicocca; Georgetown University	Reali, E (corresponding author), Univ Milano Bicocca, Dept Biotechnol & Biosci, Milan, Italy.; Catalfamo, M (corresponding author), Georgetown Univ, Sch Med, Dept Microbiol & Immunol, Washington, DC 20057 USA.	eva.reali@grupposandonato.it; mc2151@georgetown.edu			National Institute of Allergy and Infectious Diseases of the National Institutes of Health [NIH R01AI145549-02]; National Cancer Institute, NIH [HHSN261200800001E]; District of Columbia Center for AIDS Research, an NIH [P30AI117970]	National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Cancer Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); District of Columbia Center for AIDS Research, an NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	MC is supported by: The National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number NIH R01AI145549-02. Leidos Biomedical Research, Inc. has been funded in whole or in part with federal funds from the National Cancer Institute, NIH, under Contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. MC is supported in part by the District of Columbia Center for AIDS Research, an NIH funded program (P30AI117970). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Cochain C, 2016, BASIC RES CARDIOL, V111, DOI 10.1007/s00395-016-0589-7; Fernandez DM, 2019, NAT MED, V25, P1576, DOI 10.1038/s41591-019-0590-4; Furman D, 2019, NAT MED, V25, P1822, DOI 10.1038/s41591-019-0675-0; Saigusa R, 2020, NAT REV CARDIOL, V17, P387, DOI 10.1038/s41569-020-0352-5; Simons KH, 2019, NAT REV CARDIOL, V16, P325, DOI 10.1038/s41569-019-0164-7; Stark K, 2021, NAT REV CARDIOL, V18, P666, DOI 10.1038/s41569-021-00552-1; Triant VA, 2018, CIRCULATION, V137, P2203, DOI [10.1161/CIRCULATIONAHA.117.028975, 10.1161/circulationaha.117.028975]; Witztum JL, 2014, ANNU REV PATHOL-MECH, V9, P73, DOI 10.1146/annurev-pathol-020712-163936; Xu MM, 2019, AM J PHYSIOL-HEART C, V316, pH1354, DOI 10.1152/ajpheart.00148.2019	9	0	0	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 24	2021	12								719517	10.3389/fimmu.2021.719517	http://dx.doi.org/10.3389/fimmu.2021.719517			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TF3TO	34249022	Green Published, gold			2022-12-18	WOS:000670639800001
J	Seneschal, J; Harris, JE; Le Poole, IC; Passeron, T; Speeckaert, R; Boniface, K				Seneschal, Julien; Harris, John E.; Le Poole, I. Caroline; Passeron, Thierry; Speeckaert, Reinhart; Boniface, Katia			Editorial: Immunology of Vitiligo	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						vitiligo; melanocytes; innate immunity; adaptive immunity; oxidative stress; translational research; tolerance	T-CELLS; PATHOGENESIS		[Seneschal, Julien; Boniface, Katia] Univ Bordeaux, INSERM, BMGIC, U1035, Bordeaux, France; [Seneschal, Julien] Hop St Andre, Dept Dermatol & Pediat Dermatol, Natl Reference Ctr Rare Skin Disorders, Bordeaux, France; [Harris, John E.] Univ Massachusetts, Sch Med, Dept Dermatol, Worcester, MA USA; [Le Poole, I. Caroline] Northwestern Univ, Dept Dermatol, Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Le Poole, I. Caroline] Northwestern Univ, Dept Microbiol, Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Le Poole, I. Caroline] Northwestern Univ, Dept Immunol, Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Passeron, Thierry] Cote Azur Univ, INSERM U1065, Ctr Mediterraneen Med Mol C3M, Nice, France; [Passeron, Thierry] Cote Azur Univ, Dept Dermatol, CHU Nice, Nice, France; [Speeckaert, Reinhart] Ghent Univ Hosp, Dept Dermatol, Ghent, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; CHU Bordeaux; University of Massachusetts System; University of Massachusetts Worcester; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; Ghent University; Ghent University Hospital	Boniface, K (corresponding author), Univ Bordeaux, INSERM, BMGIC, U1035, Bordeaux, France.	katia.boniface@u-bordeaux.fr						Boniface K, 2019, EXP DERMATOL, V28, P656, DOI 10.1111/exd.13879; Boniface K, 2018, CLIN REV ALLERG IMMU, V54, P52, DOI 10.1007/s12016-017-8622-7; Dwivedi M, 2015, AUTOIMMUN REV, V14, P49, DOI 10.1016/j.autrev.2014.10.002; Ezzedine K, 2015, LANCET, V386, P74, DOI 10.1016/S0140-6736(14)60763-7; Frisoli ML, 2020, ANNU REV IMMUNOL, V38, P621, DOI 10.1146/annurev-immunol-100919-023531; Mukhatayev Z, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102761; Passeron T, 2020, LANCET, V396, P74, DOI 10.1016/S0140-6736(20)30747-9; Picardo M, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.11; Riding RL, 2019, J IMMUNOL, V203, P11, DOI 10.4049/jimmunol.1900027; Rosmarin D, 2020, LANCET, V396, P110, DOI 10.1016/S0140-6736(20)30609-7; Seneschal J, 2021, PIGM CELL MELANOMA R, V34, P236, DOI 10.1111/pcmr.12949; van Geel N, 2012, BRIT J DERMATOL, V166, P240, DOI 10.1111/j.1365-2133.2011.10650.x	12	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 24	2021	12								711080	10.3389/fimmu.2021.711080	http://dx.doi.org/10.3389/fimmu.2021.711080			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TF3TI	34249018	Green Published, gold			2022-12-18	WOS:000670639200001
J	Jamal, F; Singh, MK; Hansa, J; Pushpanjali; Ahmad, G; Dikhit, MR; Umar, MS; Bimal, S; Das, P; Mujeeb, AA; Singh, SK; Zubair, S; Owais, M				Jamal, F.; Singh, M. K.; Hansa, J.; Pushpanjali; Ahmad, G.; Dikhit, M. R.; Umar, M. S.; Bimal, S.; Das, P.; Mujeeb, A. A.; Singh, S. K.; Zubair, S.; Owais, M.			RETRACTION: Leishmania-Specific Promiscuous Membrane Protein Tubulin Folding Cofactor D Divulges Th-1/Th-2 Polarization in the Host via ERK-1/2 and p38 MAPK Signaling Cascade (Retraction of Vol 11, art no 2019, 2020)	FRONTIERS IN IMMUNOLOGY			English	Retraction																		Jamal F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02019	1	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 23	2021	12								724893	10.3389/fimmu.2021.724893	http://dx.doi.org/10.3389/fimmu.2021.724893			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TE9HD		gold, Green Published			2022-12-18	WOS:000670316300001
J	Jamal, F; Singh, MK; Hansa, J; Pushpanjali; Ahmad, G; Dikhit, MR; Umar, MS; Bimal, S; Das, P; Mujeeb, AA; Singh, SK; Zubair, S; Owais, M				Jamal, F.; Singh, M. K.; Hansa, J.; Pushpanjali; Ahmad, G.; Dikhit, M. R.; Umar, M. S.; Bimal, S.; Das, P.; Mujeeb, A. A.; Singh, S. K.; Zubair, S.; Owais, M.			RETRACTION: Leishmania-Specific Promiscuous Membrane Protein Tubulin Folding Cofactor D Divulges Th-1/Th-2 Polarization in the Host via ERK-1/2 and p38 MAPK Signaling Cascade (Retraction of Vol 11, art no 817, 2020)	FRONTIERS IN IMMUNOLOGY			English	Retraction																		Jamal F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00817	1	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 23	2021	12								724474	10.3389/fimmu.2021.724474	http://dx.doi.org/10.3389/fimmu.2021.724474			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TE9HF		gold, Green Published			2022-12-18	WOS:000670316500001
J	Liu, H; Lin, XX; Huang, XB; Huang, DH; Song, S; Chen, YJ; Tang, J; Tao, D; Yin, ZN; Mor, G; Liao, AH				Liu, H.; Lin, X-X; Huang, X-B; Huang, D-H; Song, S.; Chen, Y-J; Tang, J.; Tao, D.; Yin, Z-N; Mor, G.; Liao, A-H			Systemic Characterization of Novel Immune Cell Phenotypes in Recurrent Pregnancy Loss (vol 12, 657552, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						recurrent pregnancy loss; flow cytometry; peripheral T helper cell; immune cell; NK cell; gamma delta T cell	MEMBER											Brummelman J, 2018, INT REV CEL MOL BIO, V341, P63, DOI 10.1016/bs.ircmb.2018.05.007; Cai DL, 2019, J REPROD IMMUNOL, V131, P57, DOI 10.1016/j.jri.2019.01.003; Cantoni C, 1999, J EXP MED, V189, P787, DOI 10.1084/jem.189.5.787; Chen Y, 2018, PATHOL ONCOL RES, V24, P717, DOI 10.1007/s12253-017-0357-5; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Gattinoni L, 2011, NAT MED, V17, P1290, DOI 10.1038/nm.2446; Gordon CL, 2017, J EXP MED, V214, P651, DOI 10.1084/jem.20160758; Liu H, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.657552; Peters C, 2018, CELL MOL LIFE SCI, V75, P2125, DOI 10.1007/s00018-018-2788-x; Ribeiro S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00015; Simoes AE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00929; Sprent J, 2011, NAT IMMUNOL, V12, P478, DOI 10.1038/ni.2018; Uchida Y, 2020, J DERMATOL SCI, V100, P129, DOI 10.1016/j.jdermsci.2020.09.001; Weiskopf D, 2015, P NATL ACAD SCI USA, V112, pE4256, DOI 10.1073/pnas.1505956112; Xu B, 2011, P NATL ACAD SCI USA, V108, P2414, DOI 10.1073/pnas.1015433108	15	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 23	2021	12								722805	10.3389/fimmu.2021.722805	http://dx.doi.org/10.3389/fimmu.2021.722805			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TE9RE		gold, Green Published			2022-12-18	WOS:000670342600001
J	Snen, H; Kallel, A; Blibech, H; Jemel, S; Ben Salah, N; Marouen, S; Mehiri, N; Belhaj, S; Louzir, B; Kallel, K				Snen, Houda; Kallel, Aicha; Blibech, Hana; Jemel, Sana; Ben Salah, Nozha; Marouen, Sonia; Mehiri, Nadia; Belhaj, Slah; Louzir, Bechir; Kallel, Kalthoum			Case Report: Allergic Bronchopulmonary Aspergillosis Revealing Asthma	FRONTIERS IN IMMUNOLOGY			English	Article						allergic bronchopulmonary aspergillosis; Aspergillus fumigatus; antifungal therapy; drug toxicity; uncontrolled asthma	RANDOMIZED-TRIAL; FUMIGATUS; DIAGNOSIS; PHYSIOTHERAPY; SEVERITY; EFFICACY; SPECTRUM	Allergic bronchopulmonary aspergillosis (ABPA) is an immunological pulmonary disorder caused by hypersensitivity to Aspergillus which colonizes the airways of patients with asthma and cystic fibrosis. Its diagnosis could be difficult in some cases due to atypical presentations especially when there is no medical history of asthma. Treatment of ABPA is frequently associated to side effects but cumulated drug toxicity due to different molecules is rarely reported. An accurate choice among the different available molecules and effective on ABPA is crucial. We report a case of ABPA in a woman without a known history of asthma. She presented an acute bronchitis with wheezing dyspnea leading to an acute respiratory failure. She was hospitalized in the intensive care unit. The bronchoscopy revealed a complete obstruction of the left primary bronchus by a sticky greenish material. The culture of this material isolated Aspergillus fumigatus and that of bronchial aspiration fluid isolated Pseudomonas aeruginosa. The diagnosis of ABPA was based on elevated eosinophil count, the presence of specific IgE and IgG against Aspergillus fumigatus and left segmental collapse on chest computed tomography. The patient received an inhaled treatment for her asthma and a high dose of oral corticosteroids for ABPA. Her symptoms improved but during the decrease of corticosteroids, the patient presented a relapse. She received itraconazole in addition to corticosteroids. Four months later, she presented a drug-induced hepatitis due to itraconazole which was immediately stopped. During the monitoring of her asthma which was partially controlled, the patient presented an aseptic osteonecrosis of both femoral heads that required surgery. Nine months after itraconazole discontinuation, she presented a second relapse of her ABPA. She received voriconazole for nine months associated with a low dose of systemic corticosteroid therapy with an improvement of her symptoms. After discontinuation of antifungal treatment, there was no relapse for one year follow-up.	[Snen, Houda; Blibech, Hana; Ben Salah, Nozha; Mehiri, Nadia; Louzir, Bechir] Hosp Mongi Slim, Pulm Dept, La Marsa, Tunisia; [Snen, Houda; Kallel, Aicha; Blibech, Hana; Jemel, Sana; Ben Salah, Nozha; Mehiri, Nadia; Louzir, Bechir; Kallel, Kalthoum] Tunis El Manar Univ, Fac Med, Tunis, Tunisia; [Kallel, Aicha; Jemel, Sana; Marouen, Sonia; Belhaj, Slah; Kallel, Kalthoum] La Rabta Hosp, Parasitol & Mycol Dept, Tunis, Tunisia	Universite de Tunis-El-Manar; Hopital Mongi Slim; Universite de Tunis-El-Manar; Faculte de Medecine de Tunis (FMT); Universite de Tunis-El-Manar; Hopital La Rabta	Snen, H (corresponding author), Hosp Mongi Slim, Pulm Dept, La Marsa, Tunisia.; Snen, H; Kallel, A (corresponding author), Tunis El Manar Univ, Fac Med, Tunis, Tunisia.; Kallel, A (corresponding author), La Rabta Hosp, Parasitol & Mycol Dept, Tunis, Tunisia.	houda.snen@gmail.com; aicha.kallel@fmt.utm.tn						Abdolrasouli A, 2018, INT J ANTIMICROB AG, V52, P637, DOI 10.1016/j.ijantimicag.2018.08.004; Agarwal R, 2013, CLIN EXP ALLERGY, V43, P850, DOI 10.1111/cea.12141; Agarwal R, 2009, INT J TUBERC LUNG D, V13, P936; Agarwal R, 2020, INDIAN J MED RES, V151, P529, DOI 10.4103/ijmr.IJMR_1187_19; Agarwal R, 2017, MYCOSES, V60, P33, DOI 10.1111/myc.12541; Agarwal R, 2016, EXPERT REV RESP MED, V10, P1317, DOI 10.1080/17476348.2016.1249853; Agarwal R, 2016, EUR RESPIR J, V47, P490, DOI 10.1183/13993003.01475-2015; Agarwal Ritesh, 2011, Indian J Radiol Imaging, V21, P242, DOI 10.4103/0971-3026.90680; Agarwal Ritesh, 2011, J Infect Public Health, V4, P235, DOI 10.1016/j.jiph.2011.08.006; Agarwal R, 2009, CHEST, V135, P805, DOI 10.1378/chest.08-2586; Amin R, 2010, CHEST, V137, P171, DOI 10.1378/chest.09-1103; Ashu EE, 2017, MSPHERE, V2, DOI 10.1128/mSphere.00019-17; Casciaro R, 2015, J CHEMOTHERAPY, V27, P307, DOI 10.1179/1973947814Y.0000000194; Chatterjee P, 2020, J FUNGI, V6, DOI 10.3390/jof6020081; Chishimba L, 2015, J ASTHMA, V52, P289, DOI 10.3109/02770903.2014.958853; Chishimba L, 2012, J ASTHMA, V49, P423, DOI 10.3109/02770903.2012.662568; Denning DW, 2013, MED MYCOL, V51, P361, DOI 10.3109/13693786.2012.738312; Denning DW, 2011, CLIN INFECT DIS, V52, P1123, DOI 10.1093/cid/cir179; Fekih Leila, 2011, Tunis Med, V89, P491; Ghosh K, 2012, BMJ Case Rep, V2012, P1, DOI 10.1136/bcr.12.2011.5349; Hansen D, 2008, J HOSP INFECT, V70, P259, DOI 10.1016/j.jhin.2008.07.010; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; Kanj A, 2018, RESP MED, V141, P121, DOI 10.1016/j.rmed.2018.06.029; Kaur M, 2014, J CLIN DIAGN RES, V8, pRC5, DOI [10.7860/JCDR/2014/6901.4050, 10.7860/JCDR/2014/8255.4423]; Kellett F, 2005, RESP MED, V99, P27, DOI 10.1016/j.rmed.2004.05.006; Khalil KF, 2015, JCPSP-J COLL PHYSICI, V25, P359, DOI 05.2015/JCPSP.359362; Knutsen AP, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/843763; Kosmidis C, 2015, THORAX, V70, P270, DOI 10.1136/thoraxjnl-2014-206291; Kousha M, 2011, EUR RESPIR REV, V20, P156, DOI 10.1183/09059180.00001011; Kumar Raj, 2015, Pneumonol Alergol Pol, V83, P144, DOI 10.5603/PiAP.2015.0023; Lavergne RA, 2019, J ANTIMICROB CHEMOTH, V74, P1884, DOI 10.1093/jac/dkz144; Mahdavinia M, 2012, THER ADV RESPIR DIS, V6, P173, DOI 10.1177/1753465812443094; Murray MP, 2009, EUR RESPIR J, V34, P1086, DOI 10.1183/09031936.00055509; Oguma T, 2018, ALLERGOL INT, V67, P79, DOI 10.1016/j.alit.2017.04.011; PATTERSON R, 1968, University of Michigan Medical Center Journal, V34, P8; Phuyal S, 2016, CURR PROBL DIAGN RAD, V45, P168, DOI 10.1067/j.cpradiol.2015.07.006; Savi D, 2020, BMC PULM MED, V20, DOI 10.1186/s12890-020-01373-7; Shah A, 2014, EUR ANN ALLERGY CLIN, V46, P147; Shah A, 2016, ALLERGY ASTHMA IMMUN, V8, P282, DOI 10.4168/aair.2016.8.4.282; Shah A, 2014, EUR RESPIR REV, V23, P8, DOI 10.1183/09059180.00007413; SLAVIN RG, 1969, AM J MED, V47, P306, DOI 10.1016/0002-9343(69)90156-9; Stevens DA, 2000, NEW ENGL J MED, V342, P756, DOI 10.1056/NEJM200003163421102; Tashiro T, 2011, MED MYCOL, V49, P581, DOI 10.3109/13693786.2010.548084; VAUGHAN LM, 1993, CLIN PHARMACY, V12, P24; Vlahakis NE, 2001, MAYO CLIN PROC, V76, P930; Voskamp AL, 2015, J ALLER CL IMM-PRACT, V3, P192, DOI 10.1016/j.jaip.2014.12.008; Wark PAB, 2000, EUR RESPIR J, V16, P1095, DOI 10.1034/j.1399-3003.2000.16f13.x; Zhang Mingqiang, 2017, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V39, P352, DOI 10.3881/j.issn.1000-503X.2017.03.009	48	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 22	2021	12								695954	10.3389/fimmu.2021.695954	http://dx.doi.org/10.3389/fimmu.2021.695954			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TE4OV	34239516	Green Published, gold			2022-12-18	WOS:000669991600001
J	Zhou, XY; Lu, LF				Zhou, Xuyu; Lu, Li-Fan			Editorial: Regulators of a Regulator: Post-Transcriptional Regulation in Tregs	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						post-transcriptional and post-translational regulation; Treg; non-coding RNAs; RNA modification; Foxp3			[Zhou, Xuyu] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing, Peoples R China; [Zhou, Xuyu] Univ Chinese Acad Sci, Savaid Med Sch, Beijing, Peoples R China; [Lu, Li-Fan] Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA	Chinese Academy of Sciences; Institute of Microbiology, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; University of California System; University of California San Diego	Zhou, XY (corresponding author), Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing, Peoples R China.; Zhou, XY (corresponding author), Univ Chinese Acad Sci, Savaid Med Sch, Beijing, Peoples R China.; Lu, LF (corresponding author), Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA.	zhouxy@im.ac.cn; lifanlu@ucsd.edu	Zhou, Xuyu/L-7422-2019	Zhou, Xuyu/0000-0002-6626-0898					0	0	0	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 22	2021	12								699911	10.3389/fimmu.2021.699911	http://dx.doi.org/10.3389/fimmu.2021.699911			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TE4NW	34239517	gold, Green Published			2022-12-18	WOS:000669989100001
J	DiSimone, N; Barnea, ER; Mueller, M				DiSimone, Nicoletta; Barnea, Eytan Robert; Mueller, Martin			Editorial: Immunological Role of the Maternal Microbiome in Pregnancy	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						microbiota; immunity; pregnancy; implantation; preterm (birth); preterm; full term infants			[DiSimone, Nicoletta] Humanitas Univ, Dept Biomed Sci, Milan, Italy; [DiSimone, Nicoletta] IRCCS Humanitas Res Hosp, Milan, Italy; [Barnea, Eytan Robert] SIEP Soc Invest Early Pregnancy, New York, NY USA; [Mueller, Martin] Univ Bern, Univ Hosp Bern, Dept Obstet & Gynecol, Bern, Switzerland; [Mueller, Martin] Maastricht Univ, Med Ctr MUMC, Dept Pediat, Maastricht, Netherlands	Humanitas University; University of Bern; University Hospital of Bern; Maastricht University; Maastricht University Medical Centre (MUMC)	Mueller, M (corresponding author), Univ Bern, Univ Hosp Bern, Dept Obstet & Gynecol, Bern, Switzerland.; Mueller, M (corresponding author), Maastricht Univ, Med Ctr MUMC, Dept Pediat, Maastricht, Netherlands.	martin.mueller@insel.ch	Mueller, Martin/J-9682-2019	Mueller, Martin/0000-0001-5594-0532; DI SIMONE, NICOLETTA/0000-0003-1273-3335					0	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 21	2021	12								703009	10.3389/fimmu.2021.703009	http://dx.doi.org/10.3389/fimmu.2021.703009			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TD7EC	34234790	Green Published, gold			2022-12-18	WOS:000669484400001
J	Gu, SQ; Fu, X; Ye, GF; Chen, CC; Li, XY; Zhong, SH; Tang, LB; Chen, HT; Jiang, DK; Hou, JL; Li, YY				Gu, Shuqin; Fu, Xin; Ye, Guofu; Chen, Chengcong; Li, Xiaoyi; Zhong, Shihong; Tang, Libo; Chen, Haitao; Jiang, Deke; Hou, Jinlin; Li, Yongyin			High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection	FRONTIERS IN IMMUNOLOGY			English	Article						L-carnitine; hepatitis B virus; immunosuppression; immune cells; single-nucleotide polymorphism	METABOLIC-REGULATION; SEROCONVERSION; THERAPY; CELLS; IL-21	Persistent antigen exposure during chronic hepatitis B infection leads to exhausted immune responses, thus impeding viral control. In recent years, immunometabolism opens new therapeutic possibilities for the modulation of immune responses. Herein, we investigated the immunomodulatory effect of L-carnitine (L-Cn) on immune cells in chronic HBV infection. In this study, 141 treatment-naive patients with chronic HBV infection, 38 patients who achieved HBsAg loss following antiviral treatment, and 47 patients who suffered from HBV-related HCC from real-life clinical practice were recruited. The plasma L-Cn levels were measured by ELISA. RNA sequencing was conducted to define the transcriptional profiles of peripheral blood mononuclear cells after L-Cn stimulation. In vitro assays were performed to assess the effect of L-Cn on immune cells; the frequencies and function of immune cells were analyzed by flow cytometry. We found that compared with patients with HBsAg loss, patients with HBsAg positivity and patients who suffered from HBV-related HCC had higher levels of L-Cn, and the plasma levels of L-Cn in the HBeAg-positive chronic hepatitis patients who had elevated ALT were significantly higher than that of HBeAg-negative chronic infection and HBsAg loss groups. Moreover, a positive correlation between plasma levels of L-Cn and HBsAg levels was found. Additionally, RNA sequencing analysis demonstrated that L-Cn altered the transcriptional profiles related to immune response. In vitro assays revealed that L-Cn suppressed the proliferation of and IFN-gamma production by CD4(+) and CD8(+) T cells. It also down-regulated the proliferation and IgG production of B cells. Notably, L-Cn enhanced IL-10 secretion from regulatory T cells and up-regulated the expression of inhibitory receptors on T cells. Moreover, a variant in CPT2 (rs1799821) was confirmed to be associated with L-Cn levels as well as complete response in CHB patients following Peg-IFN alpha antiviral therapy. Taken together, the immunosuppressive properties of L-Cn may hinder the control of HBV in chronic HBV infection, implicating that L-Cn manipulation might influence the prognosis of patients with HBV infection.	[Gu, Shuqin; Fu, Xin; Ye, Guofu; Chen, Chengcong; Li, Xiaoyi; Zhong, Shihong; Tang, Libo; Chen, Haitao; Jiang, Deke; Hou, Jinlin; Li, Yongyin] Southern Med Univ, Nanfang Hosp, Guangdong Prov Key Lab Viral Hepatitis Res, State Key Lab Organ Failure Res,Dept Infect Dis, Guangzhou, Peoples R China	Southern Medical University - China	Li, YY (corresponding author), Southern Med Univ, Nanfang Hosp, Guangdong Prov Key Lab Viral Hepatitis Res, State Key Lab Organ Failure Res,Dept Infect Dis, Guangzhou, Peoples R China.	yongyinli@foxmail.com			National Natural Science Foundation of China [81971933, 81770592, 81671570]; National Science and Technology Major Project of China [2017ZX10202202-004, 2018ZX10301202]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Major Project of China	This work was supported by grants from the National Natural Science Foundation of China (81971933, 81770592, and 81671570), National Science and Technology Major Project of China (2017ZX10202202-004 and 2018ZX10301202).	Alesci S, 2003, FASEB J, V17, P1553, DOI 10.1096/fj.02-1024fje; Athanassakis I, 2001, INT IMMUNOPHARMACOL, V1, P1813, DOI 10.1016/S1567-5769(01)00105-9; Bengsch B, 2014, J HEPATOL, V61, P1212, DOI 10.1016/j.jhep.2014.07.005; Bertoletti A, 2016, J HEPATOL, V64, pS71, DOI 10.1016/j.jhep.2016.01.026; Boni C, 2007, J VIROL, V81, P4215, DOI 10.1128/JVI.02844-06; Buck MD, 2016, CELL, V166, P63, DOI 10.1016/j.cell.2016.05.035; Chen HT, 2020, CLIN GASTROENTEROL H, V18, P196, DOI 10.1016/j.cgh.2019.04.044; Chmurzynska A, 2018, NUTR RES, V56, P61, DOI 10.1016/j.nutres.2018.04.018; Chou HH, 2015, P NATL ACAD SCI USA, V112, P2175, DOI 10.1073/pnas.1424775112; Ecker J, 2010, P NATL ACAD SCI USA, V107, P7817, DOI 10.1073/pnas.0912059107; El-Hattab AW, 2015, MOL GENET METAB, V116, P107, DOI 10.1016/j.ymgme.2015.09.004; European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021; Fortin G, 2009, CLIN EXP IMMUNOL, V156, P161, DOI 10.1111/j.1365-2249.2009.03879.x; Gong ZG, 2017, ONCOTARGET, V8, P63890, DOI 10.18632/oncotarget.19173; Hiramatsu A, 2019, HEPATOL COMMUN, V3, P348, DOI 10.1002/hep4.1309; Jansen L, 2014, J HEPATOL, V61, P730, DOI 10.1016/j.jhep.2014.05.004; Jun DW, 2013, CLIN MOL HEPATOL, V19, P165, DOI 10.3350/cmh.2013.19.2.165; Khan HA, 2013, GENE, V523, P76, DOI 10.1016/j.gene.2013.03.086; Kishore M, 2017, IMMUNITY, V47, P875, DOI 10.1016/j.immuni.2017.10.017; Koeth RA, 2019, J CLIN INVEST, V129, P373, DOI 10.1172/JCI94601; Koeth RA, 2013, NAT MED, V19, P576, DOI 10.1038/nm.3145; Li L, 2013, SCAND J IMMUNOL, V78, P439, DOI 10.1111/sji.12099; Li YY, 2020, J HEPATOL, V72, P420, DOI 10.1016/j.jhep.2019.09.031; Li YY, 2013, HEPATOLOGY, V58, P1277, DOI 10.1002/hep.26489; Ma SW, 2012, J HEPATOL, V56, P775, DOI 10.1016/j.jhep.2011.10.020; MacIver NJ, 2013, ANNU REV IMMUNOL, V31, P259, DOI 10.1146/annurev-immunol-032712-095956; Norata GD, 2015, IMMUNITY, V43, P421, DOI 10.1016/j.immuni.2015.08.023; Pallett LJ, 2015, NAT MED, V21, P591, DOI 10.1038/nm.3856; Schurich A, 2011, HEPATOLOGY, V53, P1494, DOI 10.1002/hep.24249; Schweitzer A, 2015, LANCET, V386, P1546, DOI 10.1016/S0140-6736(15)61412-X; Shin SY, 2014, NAT GENET, V46, P543, DOI 10.1038/ng.2982; Sun J, 2016, J HEPATOL, V65, P674, DOI 10.1016/j.jhep.2016.05.024; Tajiri K, 2018, J NUTR SCI VITAMINOL, V64, P321, DOI 10.3177/jnsv.64.321; Tani J, 2021, EUR J GASTROEN HEPAT, V33, P288, DOI 10.1097/MEG.0000000000001748; Terrault NA, 2016, HEPATOLOGY, V63, P261, DOI 10.1002/hep.28156; Venkatakrishnan B, 2016, ANNU REV VIROL, V3, P429, DOI 10.1146/annurev-virology-110615-042238; Wang ZN, 2019, EUR HEART J, V40, P583, DOI [10.109, 10.1093/eurheartj/ehy799]; Xu D, 2015, EUR J CLIN MICROBIOL, V34, P2139, DOI 10.1007/s10096-015-2464-0; Yang RL, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/2361963	39	0	0	1	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 21	2021	12								649197	10.3389/fimmu.2021.649197	http://dx.doi.org/10.3389/fimmu.2021.649197			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TD6XU	34234772	Green Published, gold			2022-12-18	WOS:000669468000001
J	Pritzl, CJ; Daniels, MA; Teixeiro, E				Pritzl, Curtis J.; Daniels, Mark A.; Teixeiro, Emma			Interplay of Inflammatory, Antigen and Tissue-Derived Signals in the Development of Resident CD8 Memory T Cells	FRONTIERS IN IMMUNOLOGY			English	Review						resident memory; inflammation; antigenic stimulation; tissue-derived signals; memory differentiation	TGF-BETA; CUTTING EDGE; TRANSCRIPTION FACTORS; EFFECTOR FUNCTION; NONLYMPHOID TISSUES; DENDRITIC CELLS; LOCAL ANTIGEN; RM CELLS; DIFFERENTIATION; PROMOTES	CD8 positive, tissue resident memory T cells (T-RM) are a specialized subset of CD8 memory T cells that surveil tissues and provide critical first-line protection against tumors and pathogen re-infection. Recently, much effort has been dedicated to understanding the function, phenotype and development of T-RM. A myriad of signals is involved in the development and maintenance of resident memory T cells in tissue. Much of the initial research focused on the roles tissue-derived signals play in the development of T-RM, including TGFss and IL-33 which are critical for the upregulation of CD69 and CD103. However, more recent data suggest further roles for antigenic and pro-inflammatory cytokines. This review will focus on the interplay of pro-inflammatory, tissue and antigenic signals in the establishment of resident memory T cells.	[Pritzl, Curtis J.; Daniels, Mark A.; Teixeiro, Emma] Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, Columbia, MO 65212 USA	University of Missouri System; University of Missouri Columbia	Teixeiro, E (corresponding author), Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, Columbia, MO 65212 USA.	teixeiropernase@missouri.edu			National Institutes of Health [NIH AI110420-01A1, NCI CA244314]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by grants from the National Institutes of Health (NIH AI110420-01A1, NCI CA244314).	Adachi T, 2015, NAT MED, V21, P1272, DOI 10.1038/nm.3962; Arens R, 2010, IMMUNOL REV, V235, P190, DOI 10.1111/j.0105-2896.2010.00899.x; Ariotti S, 2014, SCIENCE, V346, P101, DOI 10.1126/science.1254803; Backer RA, 2014, NAT IMMUNOL, V15, P1143, DOI 10.1038/ni.3027; Badovinac VP, 2005, NAT MED, V11, P748, DOI 10.1038/nm1257; Banerjee A, 2010, J IMMUNOL, V185, P4988, DOI 10.4049/jimmunol.1002042; Becker TC, 2002, J EXP MED, V195, P1541, DOI 10.1084/jem.20020369; Behr FM, 2020, NAT IMMUNOL, V21, P1070, DOI 10.1038/s41590-020-0723-4; Behr FM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00400; Bergsbaken T, 2017, CELL REP, V19, P114, DOI 10.1016/j.celrep.2017.03.031; Beura LK, 2018, IMMUNITY, V48, P327, DOI 10.1016/j.immuni.2018.01.015; Bonilla WV, 2012, SCIENCE, V335, P984, DOI 10.1126/science.1215418; Braga FAV, 2015, EUR J IMMUNOL, V45, P2945, DOI 10.1002/eji.201545650; BRENNAN FM, 1989, LANCET, V2, P244; Bromley SK, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108085; Butler DM, 1995, EUR CYTOKINE NETW, V6, P225; Casey KA, 2012, J IMMUNOL, V188, P4866, DOI 10.4049/jimmunol.1200402; Chen Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02826; Cho OH, 2009, J IMMUNOL, V182, P3380, DOI 10.4049/jimmunol.0802598; Corgnac S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01904; Croft M, 2009, NAT REV IMMUNOL, V9, P271, DOI 10.1038/nri2526; Cruz-Guilloty F, 2009, J EXP MED, V206, P51, DOI 10.1084/jem.20081242; Cui WG, 2011, IMMUNITY, V35, P792, DOI 10.1016/j.immuni.2011.09.017; Cui W, 2009, VACCINE, V27, P2177, DOI 10.1016/j.vaccine.2009.01.088; Curtsinger JM, 2005, J IMMUNOL, V174, P4465, DOI 10.4049/jimmunol.174.8.4465; Curtsinger JM, 2010, CURR OPIN IMMUNOL, V22, P333, DOI 10.1016/j.coi.2010.02.013; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Derynck R, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aav5183; Desai P, 2018, J IMMUNOL, V200, P2894, DOI 10.4049/jimmunol.1701499; Dienz O, 2009, J EXP MED, V206, P69, DOI 10.1084/jem.20081571; Dunne Aisling, 2003, Sci STKE, V2003, pre3, DOI 10.1126/stke.2003.171.re3; Ebel ME, 2016, J IMMUNOL, V197, P2627, DOI 10.4049/jimmunol.1600723; El-Asady R, 2005, J EXP MED, V201, P1647, DOI 10.1084/jem.20041044; Fajgenbaum DC, 2020, NEW ENGL J MED, V383, P2255, DOI 10.1056/NEJMra2026131; Fernandez-Ruiz D, 2016, IMMUNITY, V45, P889, DOI 10.1016/j.immuni.2016.08.011; Ferreira C, 2020, NAT IMMUNOL, V21, P766, DOI 10.1038/s41590-020-0674-9; Fiege JK, 2019, J IMMUNOL, V203, P936, DOI 10.4049/jimmunol.1900093; Finlay DK, 2012, J EXP MED, V209, P2441, DOI 10.1084/jem.20112607; Fonseca R, 2020, NAT IMMUNOL, V21, P412, DOI 10.1038/s41590-020-0607-7; Frias AB, 2021, IMMUNOL REV, V300, P9, DOI 10.1111/imr.12943; Gagnon J, 2008, J IMMUNOL, V180, P7958, DOI 10.4049/jimmunol.180.12.7958; Gaide O, 2015, NAT MED, V21, P647, DOI 10.1038/nm.3860; Garbers C, 2018, NAT REV DRUG DISCOV, V17, P395, DOI 10.1038/nrd.2018.45; Gattinoni L, 2017, NAT MED, V23, P18, DOI 10.1038/nm.4241; Goldrath AW, 2002, J EXP MED, V195, P1515, DOI 10.1084/jem.20020033; Gong DP, 2007, J IMMUNOL, V178, P242, DOI 10.4049/jimmunol.178.1.242; Graham JB, 2014, J IMMUNOL, V192, P683, DOI 10.4049/jimmunol.1202153; Griesenauer B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00475; Haring JS, 2006, IMMUNITY, V25, P19, DOI 10.1016/j.immuni.2006.07.001; Heink S, 2017, NAT IMMUNOL, V18, P74, DOI 10.1038/ni.3632; Hendriks J, 2000, NAT IMMUNOL, V1, P433, DOI 10.1038/80877; Hirai T, 2021, IMMUNITY, V54, P84, DOI 10.1016/j.immuni.2020.10.022; Hirano T, 2021, INT IMMUNOL, V33, P127, DOI 10.1093/intimm/dxaa078; Hu YH, 2015, J IMMUNOL, V194, P2407, DOI 10.4049/jimmunol.1402369; Iborra S, 2016, IMMUNITY, V45, P847, DOI 10.1016/j.immuni.2016.08.019; Iijima N, 2014, SCIENCE, V346, P93, DOI 10.1126/science.1257530; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Jeannet G, 2010, P NATL ACAD SCI USA, V107, P9777, DOI 10.1073/pnas.0914127107; Jennings E, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108328; Jiang XD, 2012, NATURE, V483, P227, DOI 10.1038/nature10851; Joshi NS, 2008, J IMMUNOL, V180, P1309, DOI 10.4049/jimmunol.180.3.1309; Joshi NS, 2007, IMMUNITY, V27, P281, DOI 10.1016/j.immuni.2007.07.010; Khan TN, 2016, J EXP MED, V213, P951, DOI 10.1084/jem.20151855; Kim EY, 2006, J IMMUNOL, V176, P1026, DOI 10.4049/jimmunol.176.2.1026; Kim MV, 2013, IMMUNITY, V39, P286, DOI 10.1016/j.immuni.2013.07.013; Knudson KM, 2017, P NATL ACAD SCI USA, V114, pE1659, DOI 10.1073/pnas.1608448114; Knudson KM, 2013, J IMMUNOL, V191, P5797, DOI 10.4049/jimmunol.1300905; Knudson KM, 2013, CELL REP, V4, P554, DOI 10.1016/j.celrep.2013.07.008; Kok L, 2020, J EXP MED, V217, DOI 10.1084/jem.20191711; Kumar BV, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.123568; Kurd NS, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aaz6894; Laidlaw BJ, 2015, NAT IMMUNOL, V16, P871, DOI 10.1038/ni.3224; Laidlaw BJ, 2014, IMMUNITY, V41, P633, DOI 10.1016/j.immuni.2014.09.007; Lee N, 2014, AM J RESP CRIT CARE, V190, P1383, DOI 10.1164/rccm.201403-0601OC; Lee YJ, 2011, TRENDS IMMUNOL, V32, P50, DOI 10.1016/j.it.2010.12.004; Lee YT, 2011, J VIROL, V85, P4085, DOI 10.1128/JVI.02493-10; Leignadier J, 2008, P NATL ACAD SCI USA, V105, P20440, DOI 10.1073/pnas.0806289106; Li MO, 2008, CELL, V134, P392, DOI 10.1016/j.cell.2008.07.025; Liew FY, 2016, NAT REV IMMUNOL, V16, P676, DOI 10.1038/nri.2016.95; Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23; Loyal L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19002-6; Mackay LK, 2016, SCIENCE, V352, P459, DOI 10.1126/science.aad2035; Mackay LK, 2015, IMMUNITY, V43, P1101, DOI 10.1016/j.immuni.2015.11.008; Mackay LK, 2013, NAT IMMUNOL, V14, P1294, DOI 10.1038/ni.2744; Mackay LK, 2012, P NATL ACAD SCI USA, V109, P7037, DOI 10.1073/pnas.1202288109; Man K, 2017, IMMUNITY, V47, P1129, DOI 10.1016/j.immuni.2017.11.021; Man K, 2015, NAT REV IMMUNOL, V15, P574, DOI 10.1038/nri3874; Mani V, 2019, SCIENCE, V366, P202, DOI 10.1126/science.aav5728; Martin MD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02692; Masopust D, 2004, CURR OPIN IMMUNOL, V16, P217, DOI 10.1016/j.coi.2004.02.005; Masopust D, 2019, ANNU REV IMMUNOL, V37, P521, DOI 10.1146/annurev-immunol-042617-053214; McGill J, 2008, J EXP MED, V205, P1635, DOI 10.1084/jem.20080314; McLaren JE, 2019, J IMMUNOL, V202, P943, DOI 10.4049/jimmunol.1701757; McMaster SR, 2018, MUCOSAL IMMUNOL, V11, P1071, DOI 10.1038/s41385-018-0003-x; Mehta AK, 2018, CYTOKINE, V101, P14, DOI 10.1016/j.cyto.2016.08.003; Mescher MF, 2006, IMMUNOL REV, V211, P81, DOI 10.1111/j.0105-2896.2006.00382.x; Milner JJ, 2017, NATURE, V552, P253, DOI 10.1038/nature24993; Mukhopadhyay S, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-125; Murali-Krishna K, 1999, SCIENCE, V286, P1377, DOI 10.1126/science.286.5443.1377; Muschaweckh A, 2016, J EXP MED, V213, P3075, DOI 10.1084/jem.20160888; Nath AP, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210495; Nayar R, 2014, J IMMUNOL, V192, P5881, DOI 10.4049/jimmunol.1303187; Nowyhed HN, 2015, J IMMUNOL, V195, P3515, DOI 10.4049/jimmunol.1403027; O'Garra A, 2004, J CLIN INVEST, V114, P1372, DOI 10.1172/JCI200423215; Paik DH, 2021, CURR OPIN VIROL, V46, P20, DOI 10.1016/j.coviro.2020.09.006; Park SL, 2019, TRENDS IMMUNOL, V40, P735, DOI 10.1016/j.it.2019.06.002; Rao RR, 2012, IMMUNITY, V36, P374, DOI 10.1016/j.immuni.2012.01.015; Rao RR, 2010, IMMUNITY, V32, P67, DOI 10.1016/j.immuni.2009.10.010; Ren HTM, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186966; Richter MV, 2007, J IMMUNOL, V179, P5054, DOI 10.4049/jimmunol.179.8.5054; Rincon M, 2012, INT J BIOL SCI, V8, P1281, DOI 10.7150/ijbs.4874; Rochman I, 2005, J IMMUNOL, V174, P4761, DOI 10.4049/jimmunol.174.8.4761; Rosato PC, 2017, CURR OPIN VIROL, V22, P44, DOI 10.1016/j.coviro.2016.11.011; Roychoudhuri R, 2016, NAT IMMUNOL, V17, P851, DOI 10.1038/ni.3441; Salehi S, 2012, J IMMUNOL, V189, P5682, DOI 10.4049/jimmunol.1201966; Salek-Ardakani S, 2011, J VIROL, V85, P9051, DOI 10.1128/JVI.00619-11; Sandborn WJ, 2004, GUT, V53, P1485, DOI 10.1136/gut.2003.035253; Sanjabi S, 2009, IMMUNITY, V31, P131, DOI 10.1016/j.immuni.2009.04.020; Schenkel JM, 2016, J IMMUNOL, V196, P3920, DOI 10.4049/jimmunol.1502337; Schenkel JM, 2014, SCIENCE, V346, P98, DOI 10.1126/science.1254536; Schenkel JM, 2013, NAT IMMUNOL, V14, P509, DOI 10.1038/ni.2568; Schlickum S, 2008, BLOOD, V112, P619, DOI 10.1182/blood-2008-01-134833; Schluns KS, 2002, J IMMUNOL, V168, P4827, DOI 10.4049/jimmunol.168.10.4827; Schon MP, 1999, J IMMUNOL, V162, P6641; Senda T, 2019, MUCOSAL IMMUNOL, V12, P378, DOI 10.1038/s41385-018-0110-8; Sheridan BS, 2014, IMMUNITY, V40, P747, DOI 10.1016/j.immuni.2014.03.007; Shin YS, 2012, AM J RESP CELL MOL, V46, P488, DOI 10.1165/rcmb.2011-0190OC; Sidwell T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14112-2; Skon CN, 2013, NAT IMMUNOL, V14, P1285, DOI 10.1038/ni.2745; Slutter B, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aag2031; Smith LK, 2018, IMMUNITY, V48, P299, DOI 10.1016/j.immuni.2018.01.006; Solouki S, 2020, J IMMUNOL, V205, P1217, DOI 10.4049/jimmunol.1901167; Son YM, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abb6852; Sowell RT, 2017, J IMMUNOL, V199, P2536, DOI 10.4049/jimmunol.1501638; Sowell RT, 2014, J IMMUNOL, V193, P2067, DOI 10.4049/jimmunol.1400074; Stolley JM, 2020, J EXP MED, V217, DOI 10.1084/jem.20192197; Strutt TM, 2016, J IMMUNOL, V197, P3260, DOI 10.4049/jimmunol.1600033; Surh CD, 2008, IMMUNITY, V29, P848, DOI 10.1016/j.immuni.2008.11.002; Takamura S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00733; Takamura S, 2016, J EXP MED, V213, P3057, DOI 10.1084/jem.20160938; Takemoto N, 2006, J IMMUNOL, V177, P7515, DOI 10.4049/jimmunol.177.11.7515; Teixeiro E, 2009, SCIENCE, V323, P502, DOI 10.1126/science.1163612; Thome JJC, 2016, NAT MED, V22, P72, DOI 10.1038/nm.4008; Tian T, 2012, J INVEST DERMATOL, V132, P1425, DOI 10.1038/jid.2011.489; Travis MA, 2014, ANNU REV IMMUNOL, V32, P51, DOI 10.1146/annurev-immunol-032713-120257; Tzavlaki K, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030487; Utzschneider DT, 2018, CELL REP, V22, P3454, DOI 10.1016/j.celrep.2018.03.020; van der Windt GJW, 2012, IMMUNOL REV, V249, P27, DOI 10.1111/j.1600-065X.2012.01150.x; Wakim LM, 2015, MUCOSAL IMMUNOL, V8, P1060, DOI 10.1038/mi.2014.133; Wu JX, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.03.048; Xiao ZG, 2009, J IMMUNOL, V182, P2786, DOI 10.4049/jimmunol.0803484; Xin A, 2016, NAT IMMUNOL, V17, P422, DOI 10.1038/ni.3410; Xin G, 2015, CELL REP, V13, P1118, DOI 10.1016/j.celrep.2015.09.069; Xing SJ, 2016, NAT IMMUNOL, V17, P695, DOI 10.1038/ni.3456; Yang QT, 2011, EUR J IMMUNOL, V41, P3351, DOI 10.1002/eji.201141629; Yang R, 2016, J EXP MED, V213, P2281, DOI 10.1084/jem.20160417; Yu CI, 2013, IMMUNITY, V38, P818, DOI 10.1016/j.immuni.2013.03.004; Zehn D, 2009, NATURE, V458, P211, DOI 10.1038/nature07657; Zhang N, 2013, IMMUNITY, V39, P687, DOI 10.1016/j.immuni.2013.08.019; Zhou AC, 2017, MUCOSAL IMMUNOL, V10, P1294, DOI 10.1038/mi.2016.124; Zhou AC, 2019, J IMMUNOL, V202, P2482, DOI 10.4049/jimmunol.1800795; Zhou XY, 2010, IMMUNITY, V33, P229, DOI 10.1016/j.immuni.2010.08.002	162	0	0	2	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 21	2021	12								636240	10.3389/fimmu.2021.636240	http://dx.doi.org/10.3389/fimmu.2021.636240			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TD6TE	34234771	gold, Green Published			2022-12-18	WOS:000669456000001
J	de la Cruz, EV; Wang, LY; Bose, D; Gangadhara, S; Wilson, RL; Amara, RR; Kozlowski, PA; Aldovini, A				Velarde de la Cruz, Erandi; Wang, Lingyun; Bose, Deepanwita; Gangadhara, Sailaja; Wilson, Robert L.; Amara, Rama R.; Kozlowski, Pamela A.; Aldovini, Anna			Oral Vaccination Approaches for Anti-SHIV Immunity	FRONTIERS IN IMMUNOLOGY			English	Article						HIV; oral vaccine; poliovirus vector; mucosal immunity; AIDS; SHIV vaccine	HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELLS; RESIDENT MEMORY; NEUTRALIZING ANTIBODIES; MUCOSAL VACCINATION; VAGINAL CHALLENGE; RHESUS MACAQUES; SIV VACCINE; ALVAC-HIV; INFECTION	We modified a Sabin Oral Poliovirus Vaccine (OPV) vector to permit secretion of the antigens of interest with the goal of improving anti-HIV Env humoral responses in a SHIV mucosal immunization composed of DNA and recombinant OPVs. We evaluated stimulation of systemic and mucosal cell-mediated and humoral immunity in Rhesus macaques by two regimens, both involving a prime with a SHIV(BG505 )DNA construct producing non-infectious particles formulated in lipid nanoparticles, administered in the oral cavity, and two different viral vector boostings, administered in the oral cavity and intestinally. Group 1 was boosted with rMVA-SHIVBG505, expressing SIV Gag/Pol and HIVBG505 Env. Group 2 was boosted with a SHIVBG505-OPV vaccine including a non-secreting SIV(mac239)CA-p6-OPV, expressing Gag CA, NC and p6 proteins, and a HIV(BG505)C1-V2-OPV, secreting the C1-V2 fragment of HIV Env(BG505), recognized by the broadly neutralizing antibody PG16. A time course analysis of anti-SHIV Gag and Env CD4+ and CD8+ T-cell responses in PBMC and in lymph node, rectal, and vaginal MNC was carried out. Both regimens stimulated significant cell-mediated responses in all compartments, with SHIVBG505-OPV immunization stimulating more significant levels of responses than rMVA- SHIVBG505. Boolean analysis of these responses revealed predominantly monofunctional responses with multifunctional responses also present in all tissues. Stimulation of antibody responses was disappointing in both groups with negative anti-SHIV IgG in plasma, and IgA in salivary, rectal and vaginal secretions being restricted to a few animals. After repeated rectal challenge with SHIVBG505, two Group 1 animals remained uninfected at challenge termination. No significant differences were observed in post-infection viral loads between groups. After the acute phase decline, CD4+ T cell percentages returned to normal levels in vaccinated as well as control animals. However, when compared to controls, vaccinate groups had more significant preservation of PBMC and rectal MNC Th17/Treg ratios, considered the strongest surrogate marker of progression to AIDS. We conclude that the vaccine platforms used in this study are insufficient to stimulate significant humoral immunity at the tested doses and schedule but sufficient to stimulate significant mucosal and systemic cell-mediated immunity, impacting the preservation of key Th17 CD4+ T cells in blood and rectal mucosa.	[Velarde de la Cruz, Erandi; Wang, Lingyun; Bose, Deepanwita; Aldovini, Anna] Boston Childrens Hosp, Dept Med, Boston, MA 02115 USA; [Velarde de la Cruz, Erandi; Wang, Lingyun; Bose, Deepanwita; Aldovini, Anna] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [Gangadhara, Sailaja; Amara, Rama R.] Emory Univ, Yerkes Natl Primate Res Ctr, Emory Vaccine Ctr, Atlanta, GA 30322 USA; [Gangadhara, Sailaja; Amara, Rama R.] Emory Univ, Dept Microbiol & Immunol, Emory Sch Med, Atlanta, GA 30322 USA; [Wilson, Robert L.; Kozlowski, Pamela A.] Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol Immunol & Parasitol, New Orleans, LA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Emory University; Emory University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Aldovini, A (corresponding author), Boston Childrens Hosp, Dept Med, Boston, MA 02115 USA.; Aldovini, A (corresponding author), Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA.	anna.aldovini@childrens.harvard.edu	bose, deepanwita/ABG-6962-2020	bose, deepanwita/0000-0003-4164-6556	NIH [R01DE26325, UM1 AI124436]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by NIH grant R01DE26325 to AA and UM1 AI124436 to RA.	Akapirat S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196397; Alam SM, 2013, J VIROL, V87, P1554, DOI 10.1128/JVI.00718-12; Aldovini A, 2016, CURR HIV RES, V14, P247, DOI 10.2174/1570162X14999160224103025; Barouch DH, 2014, NAT REV MICROBIOL, V12, P765, DOI 10.1038/nrmicro3360; Barouch DH, 2013, CELL, V155, P531, DOI 10.1016/j.cell.2013.09.061; Barouch DH, 2012, NATURE, V482, P89, DOI 10.1038/nature10766; BEALE AJ, 1991, PEDIATR INFECT DIS J, V10, P970, DOI 10.1097/00006454-199112000-00029; Beura LK, 2018, NAT IMMUNOL, V19, P173, DOI 10.1038/s41590-017-0029-3; Billeskov R, 2019, HUM VACC IMMUNOTHER, V15, P407, DOI 10.1080/21645515.2018.1527496; Burrill Cecily P, 2013, Curr Protoc Microbiol, VChapter 15, DOI 10.1002/9780471729259.mc15h02s29; Chaudhary O, 2020, AIDS RES HUM RETROV, V36, P984, DOI [10.1089/aid.2020.0157, 10.1089/AID.2020.0157]; Chung NPY, 2014, RETROVIROLOGY, V11, DOI 10.1186/1742-4690-11-33; Cohen J, 2020, SCIENCE, V367, P611, DOI 10.1126/science.367.6478.611; Collins DR, 2020, NAT REV IMMUNOL, V20, P471, DOI 10.1038/s41577-020-0274-9; Crotty S, 2001, J VIROL, V75, P7435, DOI 10.1128/JVI.75.16.7435-7452.2001; Dandekar Satya, 2007, Curr HIV/AIDS Rep, V4, P10, DOI 10.1007/s11904-007-0002-0; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; Del Prete GQ, 2016, ANTIMICROB AGENTS CH, V60, P1560, DOI 10.1128/AAC.02625-15; Demberg T, 2009, INT REV IMMUNOL, V28, P20, DOI 10.1080/08830180802684331; Easterhoff D, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.131437; Easterhoff D, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006182; El Hed A, 2010, J INFECT DIS, V201, P843, DOI 10.1086/651021; Excler JL, 2014, CLIN VACCINE IMMUNOL, V21, P1023, DOI 10.1128/CVI.00230-14; Favre D, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000295; Fonseca R, 2020, NAT IMMUNOL, V21, P412, DOI 10.1038/s41590-020-0607-7; Freel SA, 2010, J VIROL, V84, P4998, DOI 10.1128/JVI.00138-10; Fruh K, 2017, CURR OPIN IMMUNOL, V47, P52, DOI 10.1016/j.coi.2017.06.010; Gaardbo JC, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/670957; Garces F, 2014, CELL, V159, P69, DOI 10.1016/j.cell.2014.09.009; Giri S, 2018, J INFECT DIS, V217, P1395, DOI 10.1093/infdis/jix687; Gottardo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075665; Gray GE, 2021, NEW ENGL J MED, V384, P1089, DOI 10.1056/NEJMoa2031499; Guadalupe M, 2003, J VIROL, V77, P11708, DOI 10.1128/JVI.77.21.11708-11717.2003; Haase AT, 2011, ANNU REV MED, V62, P127, DOI 10.1146/annurev-med-080709-124959; Hansen SG, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw2607; Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003; Hartigan-O'Connor DJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003941; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Hessell AJ, 2018, EXPERT REV VACCINES, V17, P127, DOI 10.1080/14760584.2018.1425619; Iyer SS, 2016, J VIROL, V90, P8842, DOI 10.1128/JVI.01163-16; Janes H, 2013, J INFECT DIS, V208, P1231, DOI 10.1093/infdis/jit322; Jardine JG, 2015, SCIENCE, V349, P156, DOI 10.1126/science.aac5894; Jiang XD, 2012, NATURE, V483, P227, DOI 10.1038/nature10851; Johansson EL, 2001, INFECT IMMUN, V69, P7481, DOI 10.1128/IAI.69.12.7481-7486.2001; Johnson RP, 1999, J VIROL, V73, P4952, DOI 10.1128/JVI.73.6.4952-4961.1999; Jones AT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08739-4; Kantele A, 1998, INFECT IMMUN, V66, P5630, DOI 10.1128/IAI.66.12.5630-5635.1998; Kepler TB, 2014, CELL HOST MICROBE, V16, P304, DOI 10.1016/j.chom.2014.08.006; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; Koff WC, 2006, NAT IMMUNOL, V7, P19, DOI 10.1038/ni1296; Kozlowski PA, 2000, J ACQ IMMUN DEF SYND, V24, P297; Kozlowski PA, 2002, J IMMUNOL, V169, P566, DOI 10.4049/jimmunol.169.1.566; Kozlowski Pamela A., 2019, Current Immunology Reviews, V15, P102, DOI 10.2174/1573395514666180605092054; Letvin NL, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002351; Li H, 2016, P NATL ACAD SCI USA, V113, pE3413, DOI 10.1073/pnas.1606636113; Liao HX, 2013, IMMUNITY, V38, P176, DOI 10.1016/j.immuni.2012.11.011; Lifson JD, 2001, J VIROL, V75, P10187, DOI 10.1128/JVI.75.21.10187-10199.2001; Lin L, 2015, NAT BIOTECHNOL, V33, P610, DOI 10.1038/nbt.3187; Liu ZQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02460-2; Magnus C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033441; Manrique M, 2009, MUCOSAL IMMUNOL, V2, P536, DOI 10.1038/mi.2009.103; Manrique M, 2008, AIDS RES HUM RETROV, V24, P505, DOI 10.1089/aid.2007.0191; Manrique M, 2014, J VIROL, V88, P212, DOI 10.1128/JVI.02523-13; Manrique M, 2013, J VIROL, V87, P4738, DOI 10.1128/JVI.03531-12; Manrique M, 2011, J IMMUNOL, V186, P3581, DOI 10.4049/jimmunol.1002594; Masopust D, 2019, ANNU REV IMMUNOL, V37, P521, DOI 10.1146/annurev-immunol-042617-053214; McMichael AJ, 2006, ANNU REV IMMUNOL, V24, P227, DOI 10.1146/annurev.immunol.24.021605.090605; MOLDOVEANU Z, 1995, ADV EXP MED BIOL, V371, P97; Moldoveanu Z, 1999, AIDS RES HUM RETROV, V15, P1469, DOI 10.1089/088922299309982; Nabi R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180245; O'Connor MA, 2019, AIDS RES HUM RETROV, V35, P295, DOI [10.1089/aid.2018.0184, 10.1089/AID.2018.0184]; Pauthner MG, 2019, IMMUNITY, V50, P241, DOI 10.1016/j.immuni.2018.11.011; Pitisuttithum P, 2020, LANCET HIV, V7, pE238, DOI 10.1016/S2352-3018(19)30406-0; Pugach P, 2015, J VIROL, V89, P3380, DOI 10.1128/JVI.03473-14; Rerks-Ngarm S, 2017, J INFECT DIS, V215, P1255, DOI 10.1093/infdis/jix099; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Ringe RP, 2015, J VIROL, V89, P12189, DOI 10.1128/JVI.01768-15; Ringe RP, 2013, P NATL ACAD SCI USA, V110, P18256, DOI 10.1073/pnas.1314351110; Robb ML, 2012, LANCET INFECT DIS, V12, P531, DOI 10.1016/S1473-3099(12)70088-9; Roederer M, 2014, NATURE, V505, P502, DOI 10.1038/nature12893; Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015; Rosato PC, 2017, CURR OPIN VIROL, V22, P44, DOI 10.1016/j.coviro.2016.11.011; Rudin A, 1999, INFECT IMMUN, V67, P2884, DOI 10.1128/IAI.67.6.2884-2890.1999; Ruprecht RM, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040194; Rybarczyk BJ, 2004, J VIROL, V78, P3561, DOI 10.1128/JVI.78.7.3561-3571.2004; Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618; Sathaliyawala T, 2013, IMMUNITY, V38, P187, DOI 10.1016/j.immuni.2012.09.020; Shen L, 2017, J VIROL, V91, DOI 10.1128/JVI.02310-16; Sholukh AM, 2015, VACCINE, V33, P2086, DOI 10.1016/j.vaccine.2015.02.020; Styles TM, 2019, J VIROL, V93, DOI 10.1128/JVI.00934-19; Sutton MS, 2016, J VIROL, V90, P5541, DOI 10.1128/JVI.00192-16; Tomaras GD, 2017, IMMUNOL REV, V275, P245, DOI 10.1111/imr.12514; Tomaras GD, 2014, VACCINES, V2, P15, DOI 10.3390/vaccines2010015; Valverde-Villegas JM, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/647916; W. H. Organization, 1995, WHO PUBL; Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746; Wang JY, 2011, APPL MICROBIOL BIOT, V91, P731, DOI 10.1007/s00253-011-3297-0; Watkins JD, 2013, AIDS, V27, pF13, DOI 10.1097/QAD.0b013e328360eac6; Wu XL, 2006, J VIROL, V80, P835, DOI 10.1128/JVI.80.2.835-844.2006; Yamamoto T, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3964; Yates NL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007730; Yeh Ming Te, 2020, Cell Host Microbe, V27, P736, DOI 10.1016/j.chom.2020.04.003; Zolla-Pazner S, 2019, CURR OPIN HIV AIDS, V14, P309, DOI 10.1097/COH.0000000000000551; Zolla-Pazner S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087572; Zolla-Pazner S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053629	105	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 21	2021	12								702705	10.3389/fimmu.2021.702705	http://dx.doi.org/10.3389/fimmu.2021.702705			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TD9CJ	34234789	gold, Green Published			2022-12-18	WOS:000669615200001
J	West, NP; Hughes, L; Ramsey, R; Zhang, P; Martoni, CJ; Leyer, GJ; Cripps, AW; Cox, AJ				West, Nicholas P.; Hughes, Lily; Ramsey, Rebecca; Zhang, Ping; Martoni, Christopher J.; Leyer, Gregory J.; Cripps, Allan W.; Cox, Amanda J.			Probiotics, Anticipation Stress, and the Acute Immune Response to Night Shift (vol 11, 599547, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						night shift; DDS-1; UABla-12; immunity; anticipatory stress			[West, Nicholas P.; Hughes, Lily; Ramsey, Rebecca; Cox, Amanda J.] Griffith Univ, Sch Med Sci, Gold Coast, Qld, Australia; [West, Nicholas P.; Hughes, Lily; Ramsey, Rebecca; Zhang, Ping; Cripps, Allan W.; Cox, Amanda J.] Griffith Univ, Menzies Hlth Inst QLD, Gold Coast, Qld, Australia; [Leyer, Gregory J.] UAS Labs, Windsor, WI USA; [Cripps, Allan W.] Griffith Univ, Sch Med, Nathan, Qld, Australia	Griffith University; Griffith University; Menzies Health Institute Queensland; Griffith University	West, NP (corresponding author), Griffith Univ, Sch Med Sci, Gold Coast, Qld, Australia.; West, NP (corresponding author), Griffith Univ, Menzies Hlth Inst QLD, Gold Coast, Qld, Australia.	n.west@griffith.edu.au	zhang, ping/L-3901-2017	zhang, ping/0000-0002-3907-1127; West, Nicholas/0000-0002-5482-4182				West NP, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.599547	1	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 21	2021	12								713237	10.3389/fimmu.2021.713237	http://dx.doi.org/10.3389/fimmu.2021.713237			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TE4NZ	34239518	gold, Green Published			2022-12-18	WOS:000669989400001
J	Adil, S; Paracha, RZ; Tariq, S; Nisar, M; Ijaz, S; Siddiqa, A; Hussain, Z; Amir, A				Adil, Sidra; Paracha, Rehan Zafar; Tariq, Salma; Nisar, Maryum; Ijaz, Sadaf; Siddiqa, Amnah; Hussain, Zamir; Amir, Afreenish			A Computational Systems Analyses to Identify Biomarkers and Mechanistic Link in Psoriasis and Cutaneous Squamous Cell Carcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						microarray data analysis; RNA-seq data analysis; psoriasis; cutaneous squamous cell carcinoma; pathway analysis; biomarkers; therapeutic target; differentially expressed genes	CHEMOKINE RECEPTORS; GENE-EXPRESSION; RISK-FACTORS; SKIN-CANCER; EPIDEMIOLOGY; STRINGTIE; DIAGNOSIS; BIOLOGY; TRENDS; HISAT	Psoriasis is the most common and chronic skin disease that affects individuals from every age group. The rate of psoriasis is increasing over the time in both developed and developing countries. Studies have revealed the possibility of association of psoriasis with skin cancers, particularly non-melanoma skin cancers (NMSC), which, include basal cell carcinoma and cutaneous squamous cell carcinoma (cSCC). There is a need to analyze the disease at molecular level to propose potential biomarkers and therapeutic targets in comparison to cSCC. Therefore, the second analyzed disease of this study is cSCC. It is the second most common prevalent skin cancer all over the world with the potential to metastasize and recur. There is an urge to validate the proposed biomarkers and discover new potential biomarkers as well. In order to achieve the goals and objectives of the study, microarray and RNA-sequencing data analyses were performed followed by network analysis. Afterwards, quantitative systems biology was implemented to analyze the results at a holistic level. The aim was to predict the molecular patterns that can lead psoriasis to cancer. The current study proposed potential biomarkers and therapeutic targets for psoriasis and cSCC. IL-17 signaling pathway is also identified as significant pathway in both diseases. Moreover, the current study proposed that autoimmune pathology, neutrophil recruitment, and immunity to extracellular pathogens are sensitive towards MAPKs (MAPK13 and MAPK14) and genes for AP-1 (FOSL1 and FOS). Therefore, these genes should be further studied in gene knock down based studies as they may play significant role in leading psoriasis towards cancer.	[Adil, Sidra; Paracha, Rehan Zafar; Tariq, Salma; Nisar, Maryum; Ijaz, Sadaf; Hussain, Zamir] Natl Univ Sci & Technol, Res Ctr Modeling & Simulat, Islamabad, Pakistan; [Siddiqa, Amnah] Jackson Lab Genom Med, Farmington, CT USA; [Amir, Afreenish] Natl Inst Hlth Pakistan, Islamabad, Pakistan	National University of Sciences & Technology - Pakistan; Jackson Laboratory	Paracha, RZ (corresponding author), Natl Univ Sci & Technol, Res Ctr Modeling & Simulat, Islamabad, Pakistan.	rehan@rcms.nust.edu.pk	Nisar, Maryum/AAZ-8470-2021					Asgari MM, 2017, J AM ACAD DERMATOL, V76, P632, DOI 10.1016/j.jaad.2016.10.006; Bernstein SC, 1996, DERMATOL SURG, V22, P243, DOI 10.1111/j.1524-4725.1996.tb00315.x; Blighe K., 2020, ENHANCEDVOLCANO PUBL, DOI DOI 10.1186/1471-2105-14-128; Brembilla NC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01682; Burton KA, 2016, AM J CLIN DERMATOL, V17, P491, DOI 10.1007/s40257-016-0207-3; Cassarino DS, 2006, J CUTAN PATHOL, V33, P261, DOI 10.1111/j.0303-6987.2006.00516.x; Chen SF, 2018, BIOINFORMATICS, V34, P884, DOI 10.1093/bioinformatics/bty560; Dreyer LN., 2012, NEW STATE DENT J, V33, P14, DOI [10.1111/j.0303-6987.2006.00516.x, DOI 10.1111/J.0303-6987.2006.00516.X]; Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485; Eckert RL, 2013, J SKIN CANCER, V2013, DOI 10.1155/2013/537028; Frazee A.C., 2014, NAT BIOTECHNOL, V33, P243, DOI [10.1038/nbt.3172, DOI 10.1155/2013/569751]; Gatfield J, 2000, PROTOPLASMA, V210, P99, DOI 10.1007/BF01276849; Giat E., 2019, MOSAIC AUTOIMMUN, V30, P453, DOI [10.1016/B978-0-12-814307-0.00041-4, DOI 10.1016/B978-0-12-814307-0.00041-4]; Gonzalez H, 2018, GENE DEV, V32, P1267, DOI 10.1101/gad.314617.118; Gorczynski RM, 2020, ADV EXP MED BIOL, V1240, P47, DOI 10.1007/978-3-030-38315-2_4; Gray DT, 1997, ARCH DERMATOL, V133, P735, DOI 10.1001/archderm.133.6.735; Griffiths CEM, 2017, DERMATOLOGY THER, V7, pS31, DOI 10.1007/s13555-016-0167-9; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Gupta Megha, 2013, Indian J Dermatol, V58, P151, DOI 10.4103/0019-5154.108065; Haase I, 2001, J CLIN INVEST, V108, P527, DOI 10.1172/JCI200112153; Haider AS, 2006, J INVEST DERMATOL, V126, P869, DOI 10.1038/sj.jid.5700157; Hawkes JE, 2018, J IMMUNOL, V201, P1605, DOI 10.4049/jimmunol.1800013; Hemminki K, 2003, BRIT J CANCER, V88, P1375, DOI 10.1038/sj.bjc.6600909; Hicks S.C., 2014, WHEN USE QUANTILE NO, P012203, DOI [10.1101/012203, DOI 10.1101/012203]; Hicks SC, 2018, BIOSTATISTICS, V19, P185, DOI 10.1093/biostatistics/kxx028; Housman TS, 2003, J AM ACAD DERMATOL, V48, P425, DOI 10.1067/mjd.2003.186; Icen M, 2009, J AM ACAD DERMATOL, V60, P394, DOI 10.1016/j.jaad.2008.10.062; Johansen C, 2004, BRIT J DERMATOL, V151, P600, DOI 10.1111/j.1365-2133.2004.06088.x; JOHNSON TM, 1992, J AM ACAD DERMATOL, V26, P467, DOI 10.1016/0190-9622(92)70074-P; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kim WB, 2017, CAN FAM PHYSICIAN, V63, P278; Klaus Bernd, 2016, F1000Res, V5, P1384, DOI 10.12688/f1000research.8967.1; KWA RE, 1992, J AM ACAD DERMATOL, V26, P1, DOI 10.1016/0190-9622(92)70001-V; Langley RGB, 2005, ANN RHEUM DIS, V64, P18, DOI 10.1136/ard.2004.033217; Lee CH, 2012, DERMATOL SIN, V30, P128, DOI 10.1016/j.dsi.2012.08.004; Lee EB, 2018, CUTIS, V102, P18; Lee Y, 2012, BIOCHEM BIOPH RES CO, V423, P647, DOI 10.1016/j.bbrc.2012.05.162; Linares MA, 2015, PRIMARY CARE, V42, P645, DOI 10.1016/j.pop.2015.07.006; Lopez-Romero PA, 2016, R PACKAGE VERSION, V2, P336, DOI [10.1049/iet-syb.2011.0015, DOI 10.1049/IET-SYB.2011.0015]; Mavropoulos A, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/569751; Mezentsev A, 2014, GENE, V540, P1, DOI 10.1016/j.gene.2014.01.068; Mullen JT, 2006, ANN SURG ONCOL, V13, P902, DOI 10.1245/ASO.2006.07.022; Nardinocchi L, 2015, EUR J IMMUNOL, V45, P922, DOI 10.1002/eji.201445052; National Cancer Institute N, 1988, NIH PUBL; Pariser DM, 2007, ARCH DERMATOL, V143, P239, DOI 10.1001/archderm.143.2.239; Parisi R, 2013, J INVEST DERMATOL, V133, P377, DOI 10.1038/jid.2012.339; Pertea M, 2016, NAT PROTOC, V11, P1650, DOI 10.1038/nprot.2016.095; Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122; Piruzian ES, 2007, MOL BIOL+, V41, P974, DOI 10.1134/S0026893307060143; Que SKT, 2018, J AM ACAD DERMATOL, V78, P237, DOI 10.1016/j.jaad.2017.08.059; Rahat MA, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/4375120; Raut AS, 2013, CRIT REV THER DRUG, V30, P183, DOI 10.1615/CritRevTherDrugCarrierSyst.2013005268; Rendon A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061475; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Schonthaler HB, 2013, IMMUNITY, V39, P1171, DOI 10.1016/j.immuni.2013.11.011; Singh TP, 2013, EXPERT OPIN THER TAR, V17, P1405, DOI 10.1517/14728222.2013.838220; Sun Y, 2016, ONCOL LETT, V11, P59, DOI 10.3892/ol.2015.3843; Takeda A, 2002, J INVEST DERMATOL, V118, P147, DOI 10.1046/j.0022-202x.2001.01610.x; Trakatelli M, 2007, BRIT J DERMATOL, V156, P1, DOI 10.1111/j.1365-2133.2007.07861.x; Uribe-Querol E, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/983698; Wang SW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01298; Wang X, 2008, ACTA PHARMACOL SIN, V29, P1275, DOI 10.1111/j.1745-7254.2008.00889.x; Xie SQ, 2014, INT J DERMATOL, V53, P1213, DOI 10.1111/ijd.12476; Xie Zhuorui, 2021, Curr Protoc, V1, pe90, DOI 10.1002/cpz1.90; Yin L, 2017, BIOMED RES-INDIA, V28, P2111; Zi Z, 2011, IET SYST BIOL, V5, P336, DOI 10.1049/iet-syb.2011.0015	66	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 18	2021	12								662528	10.3389/fimmu.2021.662528	http://dx.doi.org/10.3389/fimmu.2021.662528			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TI6IJ	34267747	gold, Green Published			2022-12-18	WOS:000672905600001
J	Bradley, LJ; Ward, A; Hsue, MCY; Liu, J; Copland, DA; Dick, AD; Nicholson, LB				Bradley, Lydia J.; Ward, Amy; Hsue, Madeleine C. Y.; Liu, Jian; Copland, David A.; Dick, Andrew D.; Nicholson, Lindsay B.			Quantitative Assessment of Experimental Ocular Inflammatory Disease	FRONTIERS IN IMMUNOLOGY			English	Review						uveitis; EAU; OCT; image processing; automated analysis	OPTICAL COHERENCE TOMOGRAPHY; EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; RETINAL LAYER SEGMENTATION; ENDOTOXIN-INDUCED UVEITIS; VESSEL SEGMENTATION; OCT-ANGIOGRAPHY; T-CELLS; CELLULAR INFILTRATE; ADOPTIVE TRANSFER; VITREOUS HAZE	Ocular inflammation imposes a high medical burden on patients and substantial costs on the health-care systems that mange these often chronic and debilitating diseases. Many clinical phenotypes are recognized and classifying the severity of inflammation in an eye with uveitis is an ongoing challenge. With the widespread application of optical coherence tomography in the clinic has come the impetus for more robust methods to compare disease between different patients and different treatment centers. Models can recapitulate many of the features seen in the clinic, but until recently the quality of imaging available has lagged that applied in humans. In the model experimental autoimmune uveitis (EAU), we highlight three linked clinical states that produce retinal vulnerability to inflammation, all different from healthy tissue, but distinct from each other. Deploying longitudinal, multimodal imaging approaches can be coupled to analysis in the tissue of changes in architecture, cell content and function. This can enrich our understanding of pathology, increase the sensitivity with which the impacts of therapeutic interventions are assessed and address questions of tissue regeneration and repair. Modern image processing, including the application of artificial intelligence, in the context of such models of disease can lay a foundation for new approaches to monitoring tissue health.	[Bradley, Lydia J.; Ward, Amy; Hsue, Madeleine C. Y.; Dick, Andrew D.; Nicholson, Lindsay B.] Univ Bristol, Sch Cellular & Mol Med, Bristol, Avon, England; [Liu, Jian; Copland, David A.; Dick, Andrew D.] Univ Bristol, Acad Unit Ophthalmol Translat Hlth Sci, Bristol, Avon, England; [Dick, Andrew D.] UCL, Inst Ophthalmol, London, England	University of Bristol; University of Bristol; University of London; University College London	Nicholson, LB (corresponding author), Univ Bristol, Sch Cellular & Mol Med, Bristol, Avon, England.	l.nicholson@bristol.ac.uk		Ward, Amy/0000-0002-4731-3333	National Eye Research Centre, Fight for Sight [5077/5078]; Underwood Trust	National Eye Research Centre, Fight for Sight; Underwood Trust	The authors gratefully acknowledge support of the National Eye Research Centre, Fight for Sight (5077/5078) and the Underwood Trust to research carried out in their laboratories.	Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567; Agarwal Rajeev K, 2012, Methods Mol Biol, V900, P443, DOI 10.1007/978-1-60761-720-4_22; Agarwal RK, 2004, METH MOLEC MED, V102, P395; Agrawal R, 2016, ACTA OPHTHALMOL, V94, pE135, DOI 10.1111/aos.12833; Alnawaiseh M, 2016, EXP EYE RES, V145, P417, DOI 10.1016/j.exer.2016.02.012; Anantrasirichai N, 2014, COMPUT MED IMAG GRAP, V38, P526, DOI 10.1016/j.compmedimag.2014.06.012; Bell OH, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03033; Berger A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096494; Boldison J, 2014, J IMMUNOL, V192, P4541, DOI 10.4049/jimmunol.1301390; Caspi RR, 2010, J CLIN INVEST, V120, P3073, DOI 10.1172/JCI42440; CASPI RR, 1988, J IMMUNOL, V140, P1490; Chen J, 2019, METHODS MOL BIOL, V1899, P211, DOI 10.1007/978-1-4939-8938-6_15; Chen J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063904; Chen M, 2012, AM J PATHOL, V180, P235, DOI 10.1016/j.ajpath.2011.09.020; Choi WJ, 2018, J BIOPHOTONICS, V11, DOI 10.1002/jbio.201800140; Chu CJ, 2016, DIS MODEL MECH, V9, P473, DOI 10.1242/dmm.022475; Chu CJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063002; Chu ZD, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.6.066008; Cingolani C, 2006, FREE RADICAL BIO MED, V40, P660, DOI 10.1016/j.freeradbiomed.2005.09.032; Copland DA, 2012, AM J PATHOL, V180, P672, DOI 10.1016/j.ajpath.2011.10.008; Copland DA, 2008, INVEST OPHTH VIS SCI, V49, P5458, DOI 10.1167/iovs.08-2348; Davis JL, 2010, AM J OPHTHALMOL, V150, P637, DOI 10.1016/j.ajo.2010.05.036; De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6; DEKOZAK Y, 1981, CURR EYE RES, V1, P327, DOI 10.3109/02713688108998359; Denniston AK, 2017, INVEST OPHTH VIS SCI, V58, pBIO131, DOI 10.1167/iovs.17-21788; Dick AD, 2016, OPHTHALMOLOGY, V123, P655, DOI 10.1016/j.ophtha.2015.10.028; Diedrichs-Mohring M, 2018, PROG RETIN EYE RES, V65, P107, DOI 10.1016/j.preteyeres.2018.02.003; Dingerkus VLS, 2019, J OPHTHALMIC INFLAMM, V9, DOI 10.1186/s12348-019-0176-9; Dogra A, 2017, PATTERN RECOGN LETT, V94, P189, DOI 10.1016/j.patrec.2017.03.002; Drexler W, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.7.071412; Dysli C, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.4.9; Epps SJ, 2020, EXP EYE RES, V191, DOI 10.1016/j.exer.2019.107901; Epps SJ, 2018, PROG RETIN EYE RES, V65, P93, DOI 10.1016/j.preteyeres.2018.03.001; Fischer MD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007507; Forrester JV, 2018, AM J OPHTHALMOL, V189, P77, DOI 10.1016/j.ajo.2018.02.019; FORRESTER JV, 1980, A GRAEF ARCH KLIN EX, V213, P221, DOI 10.1007/BF00417543; Gadjanski I, 2011, EXP EYE RES, V93, P82, DOI 10.1016/j.exer.2011.04.012; Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958; Gonzalez-Lopez A, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e01271; Gutowski MB, 2017, INVEST OPHTH VIS SCI, V58, P1521, DOI 10.1167/iovs.16-20824; Heng JS, 2019, P NATL ACAD SCI USA, V116, P26734, DOI 10.1073/pnas.1915571116; HOGAN MJ, 1959, AM J OPHTHALMOL, V47, P155, DOI 10.1016/S0002-9394(14)78239-X; Holland Gary N, 2007, Trans Am Ophthalmol Soc, V105, P344; Horai R, 2015, IMMUNITY, V43, P343, DOI 10.1016/j.immuni.2015.07.014; Hornbeak DM, 2014, OPHTHALMOLOGY, V121, P1643, DOI 10.1016/j.ophtha.2014.02.018; Hu ZH, 2012, IEEE T MED IMAGING, V31, P1900, DOI 10.1109/TMI.2012.2206822; HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169; Ishikawa H, 2005, INVEST OPHTH VIS SCI, V46, P2012, DOI 10.1167/iovs.04-0335; John S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68227-4; Jones GW, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00401; Kaburaki T, 2014, JPN J OPHTHALMOL, V58, P120, DOI 10.1007/s10384-013-0294-0; Kajic V, 2012, BIOMED OPT EXPRESS, V3, P86, DOI 10.1364/BOE.3.000086; Kajic V, 2010, OPT EXPRESS, V18, P14730, DOI 10.1364/OE.18.014730; Keane PA, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.5.4; Keane PA, 2014, OPHTHALMOLOGY, V121, P1706, DOI 10.1016/j.ophtha.2014.03.006; Kerr EC, 2008, PROG RETIN EYE RES, V27, P527, DOI 10.1016/j.preteyeres.2008.07.001; Kerr EC, 2008, J AUTOIMMUN, V31, P354, DOI 10.1016/j.jaut.2008.08.006; Kielczewski JL, 2016, J IMMUNOL, V196, P1013, DOI 10.4049/jimmunol.1501570; Kim AY, 2016, AM J OPHTHALMOL, V171, P101, DOI 10.1016/j.ajo.2016.08.035; KIMURA SJ, 1959, AM J OPHTHALMOL, V47, P171, DOI 10.1016/S0002-9394(14)78240-6; Lang A, 2013, BIOMED OPT EXPRESS, V4, P1133, DOI 10.1364/BOE.4.001133; Lee DJ, 2015, J LEUKOCYTE BIOL, V97, P1101, DOI 10.1189/jlb.3A1014-466RR; Lee RW, 2014, SEMIN IMMUNOPATHOL, V36, P581, DOI 10.1007/s00281-014-0433-9; Li A, 2017, BIOMED OPT EXPRESS, V8, P5604, DOI 10.1364/BOE.8.005604; Li J, 2017, INVEST OPHTH VIS SCI, V58, P4193, DOI 10.1167/iovs.17-22436; Lin HH, 2005, J EXP MED, V201, P1615, DOI 10.1084/jem.20042307; Liu XX, 2019, LANCET DIGIT HEALTH, V1, pE271, DOI 10.1016/S2589-7500(19)30123-2; Luger D, 2008, J EXP MED, V205, P799, DOI 10.1084/jem.20071258; Ma YH, 2021, IEEE T MED IMAGING, V40, P928, DOI 10.1109/TMI.2020.3042802; Marchese A, 2020, THER ADV OPHTHALMOL, V12, DOI 10.1177/2515841420917781; Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662; Mishra A, 2009, OPT EXPRESS, V17, P23719, DOI 10.1364/OE.17.023719; Mitchell HB, 2010, IMAGE FUSION: THEORIES, TECHNIQUES AND APPLICATIONS, P1, DOI 10.1007/978-3-642-11216-4; Moccia S, 2018, COMPUT METH PROG BIO, V158, P71, DOI 10.1016/j.cmpb.2018.02.001; MOCHIZUKI M, 1985, INVEST OPHTH VIS SCI, V26, P1; Montesano G, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20092-y; Mrejen S, 2013, SURV OPHTHALMOL, V58, P387, DOI 10.1016/j.survophthal.2012.12.001; Mujat M, 2005, OPT EXPRESS, V13, P9480, DOI 10.1364/OPEX.13.009480; NUSSENBLATT RB, 1980, INVEST OPHTH VIS SCI, V19, P686; Oh HM, 2011, J IMMUNOL, V187, P3338, DOI 10.4049/jimmunol.1004019; Paques M, 2007, INVEST OPHTH VIS SCI, V48, P2769, DOI 10.1167/iovs.06-1099; Passaglia CL, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.2.10; Pepple KL, 2016, INVEST OPHTH VIS SCI, V57, P3567, DOI 10.1167/iovs.16-19276; Pepple KL, 2015, INVEST OPHTH VIS SCI, V56, P8438, DOI 10.1167/iovs.15-17523; Radtke AJ, 2020, P NATL ACAD SCI USA, V117, P33455, DOI 10.1073/pnas.2018488117; Raveney BJE, 2009, J IMMUNOL, V183, P2321, DOI 10.4049/jimmunol.0901340; Ravin JG, 1999, ARCH OPHTHALMOL-CHIC, V117, P1634; Rodrigues P, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.12.126011; Ruggeri M, 2007, INVEST OPHTH VIS SCI, V48, P1808, DOI 10.1167/iovs.06-0815; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shao H, 2006, EXP EYE RES, V82, P323, DOI 10.1016/j.exer.2005.07.008; Silver P, 2015, J IMMUNOL, V194, P3011, DOI 10.4049/jimmunol.1402650; Smith R.S., 2002, SYSTEMATIC EVALUATIO; Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535; Srinivasan VJ, 2006, INVEST OPHTH VIS SCI, V47, P5522, DOI 10.1167/iovs.06-0195; Thurau SR, 2004, INT IMMUNOL, V16, P1573, DOI 10.1093/intimm/dxh158; Trusko B, 2013, METHOD INFORM MED, V52, P259, DOI 10.3414/ME12-01-0063; Venhuizen FG, 2017, BIOMED OPT EXPRESS, V8, P3292, DOI 10.1364/BOE.8.003292; Wang RX, 2014, NAT MED, V20, P633, DOI 10.1038/nm.3554; Weavers H, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.202004003; Xu HP, 2008, EXP EYE RES, V87, P319, DOI 10.1016/j.exer.2008.06.012; Yu CR, 2013, J IMMUNOL, V191, P5036, DOI 10.4049/jimmunol.1301132; Zarranz-Ventura J, 2016, AM J OPHTHALMOL, V161, P172, DOI 10.1016/j.ajo.2015.10.009; Zhong X, 2016, INVEST OPHTH VIS SCI, V57, P5558, DOI 10.1167/iovs.16-19965; Zhu QJ, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.3.57; Zinkernagel MS, 2013, AM J PATHOL, V182, P875, DOI 10.1016/j.ajpath.2012.11.031; Zinkernagel MS, 2012, IMMUNOL CELL BIOL, V90, P330, DOI 10.1038/icb.2011.43; Zinkernagel MS, 2009, J VIROL, V83, P159, DOI 10.1128/JVI.01211-08	108	0	0	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 18	2021	12								630022	10.3389/fimmu.2021.630022	http://dx.doi.org/10.3389/fimmu.2021.630022			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TC8VE	34220797	Green Submitted, Green Published, gold			2022-12-18	WOS:000668915600001
J	Ooi, JD; Deng, J; De Souza, AWS				Ooi, Joshua D.; Deng, Jun; De Souza, Alexandre W. S.			Editorial: Autoimmune Vasculitis-Advances in Pathogenesis and Therapies	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						systemic vasculitis; autoimmune disease; autoimmunity; autoantibodies; T cell targeting; autoepitopes			[Ooi, Joshua D.] Monash Univ, Monash Hlth, Sch Clin Sci, Clayton, Vic, Australia; [Deng, Jun] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, Sch Med,State Key Lab Oncogenes & Related Genes, Shanghai, Peoples R China; [De Souza, Alexandre W. S.] Univ Fed Sao Paulo, Dept Med, Rheumatol Div, Sao Paulo, Brazil	Monash University; Shanghai Jiao Tong University; Universidade Federal de Sao Paulo (UNIFESP)	Ooi, JD (corresponding author), Monash Univ, Monash Hlth, Sch Clin Sci, Clayton, Vic, Australia.	joshua.ooi@monash.edu			Al and Val Rosenstrauss Fellowship	Al and Val Rosenstrauss Fellowship	JDO is funded by an Al and Val Rosenstrauss Fellowship.		0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 18	2021	12								720257	10.3389/fimmu.2021.720257	http://dx.doi.org/10.3389/fimmu.2021.720257			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TC8TI	34220872	Green Published, gold			2022-12-18	WOS:000668910800001
J	Pinheiro, RGR; Alves, NL				Pinheiro, Ruben G. R.; Alves, Nuno L.			The Early Postnatal Life: A Dynamic Period in Thymic Epithelial Cell Differentiation	FRONTIERS IN IMMUNOLOGY			English	Review						thymus; thymic epithelial cells; tolerance; early postnatal life; aging	SELF-ANTIGEN EXPRESSION; DELTA-LIKE 4; STEM-CELLS; ANALYSIS REVEALS; GENE-EXPRESSION; CUTTING EDGE; CROSS-TALK; MEDULLARY; PROGENITOR; AIRE	The microenvironments formed by cortical (c) and medullary (m) thymic epithelial cells (TECs) play a non-redundant role in the generation of functionally diverse and self-tolerant T cells. The role of TECs during the first weeks of the murine postnatal life is particularly challenging due to the significant augment in T cell production. Here, we critically review recent studies centered on the timely coordination between the expansion and maturation of TECs during this period and their specialized role in T cell development and selection. We further discuss how aging impacts on the pool of TEC progenitors and maintenance of functionally thymic epithelial microenvironments, and the implications of these chances in the capacity of the thymus to sustain regular thymopoiesis throughout life.	[Pinheiro, Ruben G. R.; Alves, Nuno L.] Univ Porto, i3S Inst Invest & Inovacao Saude, Porto, Portugal; [Pinheiro, Ruben G. R.; Alves, Nuno L.] Univ Porto, IBMC Inst Biol Mol & Celutar, Porto, Portugal; [Pinheiro, Ruben G. R.] Univ Porto, Inst Ciencias Biomed, Doctoral Program Cell & Mol Biol, Porto, Portugal	Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto; Universidade do Porto; Universidade do Porto	Alves, NL (corresponding author), Univ Porto, i3S Inst Invest & Inovacao Saude, Porto, Portugal.; Alves, NL (corresponding author), Univ Porto, IBMC Inst Biol Mol & Celutar, Porto, Portugal.	nalves@ibmc.up.pt		pinheiro, ruben/0000-0002-5475-4719	European Research Council (ERC) [637843]; FEDER - Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020 - Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020; Portuguese funds through FCT - Fundacao para a Ciencia e a Tecnologia/Ministerio da Ciencia, Tecnologia e Ensino Superior [POCI-01-0145-FEDER-029129, PTDC/MED-IMU/29129/2017, PTDC/MED-IMU/1416/2020]; FCT program "Scientific Employment Stimulus"; FCT PhD fellowship	European Research Council (ERC)(European Research Council (ERC)European Commission); FEDER - Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020 - Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020; Portuguese funds through FCT - Fundacao para a Ciencia e a Tecnologia/Ministerio da Ciencia, Tecnologia e Ensino Superior(Portuguese Foundation for Science and Technology); FCT program "Scientific Employment Stimulus"; FCT PhD fellowship(Portuguese Foundation for Science and Technology)	This work was supported by a starting grant from the European Research Council (ERC) under the project 637843 and by FEDER -Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020 - Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through FCT -Fundacao para a Ciencia e a Tecnologia/Ministerio da Ciencia, Tecnologia e Ensino Superior in the framework of the project POCI-01-0145-FEDER-029129 (PTDC/MED-IMU/29129/2017) and PTDC/MED-IMU/1416/2020. NA is supported by the FCT program "Scientific Employment Stimulus" and RP by a FCT PhD fellowship.	Abramson J, 2017, ANNU REV IMMUNOL, V35, P85, DOI 10.1146/annurev-immunol-051116-052320; Akiyama N, 2016, J EXP MED, V213, P1441, DOI 10.1084/jem.20151780; Akiyama T, 2008, IMMUNITY, V29, P423, DOI 10.1016/j.immuni.2008.06.015; Alves NL, 2016, EUR J IMMUNOL, V46, P829, DOI 10.1002/eji.201646329; Alves NL, 2014, EUR J IMMUNOL, V44, P16, DOI 10.1002/eji.201344110; Alves NL, 2010, J IMMUNOL, V184, P5949, DOI 10.4049/jimmunol.1000601; Alves NL, 2009, TRENDS IMMUNOL, V30, P468, DOI 10.1016/j.it.2009.07.010; Alves NL, 2009, P NATL ACAD SCI USA, V106, P1512, DOI 10.1073/pnas.0809559106; Anderson G, 2012, TRENDS IMMUNOL, V33, P256, DOI 10.1016/j.it.2012.03.005; Baran-Gale J, 2020, ELIFE, V9, DOI 10.7554/eLife.56221; Bennett AR, 2002, IMMUNITY, V16, P803, DOI 10.1016/S1074-7613(02)00321-7; Boehm T, 2003, J EXP MED, V198, P757, DOI 10.1084/jem.20030794; Bornstein C, 2018, NATURE, V559, P622, DOI 10.1038/s41586-018-0346-1; Bredenkamp N, 2014, DEVELOPMENT, V141, P1627, DOI 10.1242/dev.103614; Brennecke P, 2015, NAT IMMUNOL, V16, P933, DOI 10.1038/ni.3246; Chen LZ, 2009, BLOOD, V113, P567, DOI 10.1182/blood-2008-05-156265; Cosway EJ, 2017, J EXP MED, V214, P3183, DOI 10.1084/jem.20171000; Cowan JE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13465-y; Dhalla F, 2020, EMBO J, V39, DOI 10.15252/embj.2019101828; Dumont-Lagace M, 2014, J IMMUNOL, V192, P2219, DOI 10.4049/jimmunol.1302961; Fiorini E, 2008, J IMMUNOL, V181, P8199, DOI 10.4049/jimmunol.181.12.8199; Gill J, 2002, NAT IMMUNOL, V3, P635, DOI 10.1038/ni812; Gordon J, 2001, MECH DEVELOP, V103, P141, DOI 10.1016/S0925-4773(01)00333-1; Gray D, 2007, J EXP MED, V204, P2521, DOI 10.1084/jem.20070795; Gray DHD, 2006, BLOOD, V108, P3777, DOI 10.1182/blood-2006-02-004531; Griffith AV, 2012, AGING CELL, V11, P169, DOI 10.1111/j.1474-9726.2011.00773.x; Guerau-De-Arellano M, 2009, J EXP MED, V206, P1245, DOI 10.1084/jem.20090300; Hamazaki Y, 2007, NAT IMMUNOL, V8, P304, DOI 10.1038/ni1438; Hamazaki Y, 2015, EUR J IMMUNOL, V45, P2985, DOI 10.1002/eji.201545844; Hikosaka Y, 2008, IMMUNITY, V29, P438, DOI 10.1016/j.immuni.2008.06.018; Hollander GA, 2010, CURR OPIN PHARMACOL, V10, P443, DOI 10.1016/j.coph.2010.04.008; Ishikawa T, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.621824; Jenkinson WE, 2008, J IMMUNOL, V181, P6101, DOI 10.4049/jimmunol.181.9.6101; Ki S, 2014, CELL REP, V9, P402, DOI 10.1016/j.celrep.2014.08.070; Koch U, 2008, J EXP MED, V205, P2515, DOI 10.1084/jem.20080829; Kozai M, 2017, J EXP MED, V214, P1925, DOI 10.1084/jem.20161864; Lkhagvasuren E, 2013, J IMMUNOL, V190, P5110, DOI 10.4049/jimmunol.1203203; Lynch HE, 2009, TRENDS IMMUNOL, V30, P366, DOI 10.1016/j.it.2009.04.003; Mayer CE, 2016, EUR J IMMUNOL, V46, P846, DOI 10.1002/eji.201545995; Meireles C, 2017, EUR J IMMUNOL, V47, P958, DOI 10.1002/eji.201746922; Meredith M, 2015, NAT IMMUNOL, V16, P942, DOI 10.1038/ni.3247; Metzger TC, 2013, CELL REP, V5, P166, DOI 10.1016/j.celrep.2013.08.038; Miller CN, 2018, NATURE, V559, P627, DOI 10.1038/s41586-018-0345-2; Nishikawa Y, 2014, J IMMUNOL, V192, P2585, DOI 10.4049/jimmunol.1302786; Nishikawa Y, 2010, J EXP MED, V207, P963, DOI 10.1084/jem.20092144; Ohigashi I, 2015, CELL REP, V13, P1432, DOI 10.1016/j.celrep.2015.10.012; Onder L, 2015, EUR J IMMUNOL, V45, P2218, DOI 10.1002/eji.201545677; Ribeiro AR, 2014, EUR J IMMUNOL, V44, P2918, DOI 10.1002/eji.201444585; Ribeiro AR, 2013, J IMMUNOL, V191, P1200, DOI 10.4049/jimmunol.1203042; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; Rode I, 2012, P NATL ACAD SCI USA, V109, P3463, DOI 10.1073/pnas.1118823109; Rodewald HR, 2008, ANNU REV IMMUNOL, V26, P355, DOI 10.1146/annurev.immunol.26.021607.090408; Rodrigues PM, 2018, J IMMUNOL, V200, P1389, DOI 10.4049/jimmunol.1701112; Rossi SW, 2006, NATURE, V441, P988, DOI 10.1038/nature04813; Sansom SN, 2014, GENOME RES, V24, P1918, DOI 10.1101/gr.171645.113; Sekai M, 2014, IMMUNITY, V41, P753, DOI 10.1016/j.immuni.2014.10.011; Sheridan JM, 2017, CELL REP, V21, P934, DOI 10.1016/j.celrep.2017.09.090; Takaba H, 2015, CELL, V163, P975, DOI 10.1016/j.cell.2015.10.013; Ucar A, 2014, IMMUNITY, V41, P257, DOI 10.1016/j.immuni.2014.07.005; Ulyanchenko S, 2016, CELL REP, V14, P2819, DOI 10.1016/j.celrep.2016.02.080; Wang XP, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00019; Wells KL, 2020, ELIFE, V9, DOI 10.7554/eLife.60188; Wong K, 2014, CELL REP, V8, P1198, DOI 10.1016/j.celrep.2014.07.029; Yang SY, 2015, SCIENCE, V348, P589, DOI 10.1126/science.aaa7017; Zook EC, 2011, BLOOD, V118, P5723, DOI 10.1182/blood-2011-03-342097; Zuklys S, 2016, NAT IMMUNOL, V17, P1206, DOI 10.1038/ni.3537	66	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 18	2021	12								668528	10.3389/fimmu.2021.668528	http://dx.doi.org/10.3389/fimmu.2021.668528			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TC8VO	34220815	gold, Green Published			2022-12-18	WOS:000668916600001
J	Davison, LM; Alberto, AA; Dand, HA; Keller, EJ; Patt, M; Khan, A; Dvorina, N; White, A; Sakurai, N; Liegl, LN; Vogl, T; Jorgensen, TN				Davison, Laura M.; Alberto, Andres A.; Dand, Hardik A.; Keller, Emma J.; Patt, Madeline; Khan, Ayesha; Dvorina, Nina; White, Alexandra; Sakurai, Nodoka; Liegl, Lauren N.; Vogl, Thomas; Jorgensen, Trine N.			S100a9 Protects Male Lupus-Prone NZBWF1 Mice From Disease Development	FRONTIERS IN IMMUNOLOGY			English	Article						lupus; MDSC; autoantibody; type I interferon; sex specific effects; mouse model; proteinuria	T-CELL RESPONSES; SUPPRESSOR-CELLS; AUTOIMMUNE-DISEASE; ERYTHEMATOSUS; NEUTROPHILS; EXPRESSION; SURVIVAL; GLOMERULONEPHRITIS; DIFFERENTIATION; INFLAMMATION	Systemic lupus erythematosus (SLE) is an autoimmune disorder disproportionally affecting women. A similar sex difference exists in the murine New Zealand Black/White hybrid model (NZBWF1) of SLE with all females, but only 30-40% of males, developing disease within the first year of life. Myeloid-derived suppressor cells (MDSCs) are prominent in NZBWF1 males and while depletion of these cells in males, but not females, promotes disease development, the mechanism of suppression remains unknown. S100a9, expressed by neutrophils and MDSCs, has previously been shown to exert immunosuppressive functions in cancer and inflammation. Here we investigated if S100a9 exerts immunosuppressive functions in NZBWF1 male and female mice. S100a9 (+/+), S100a9 (+/-) and S100a9 (-/-) NZBWF1 mice were followed for disease development for up to 8 months of age. Serum autoantibody levels, splenomegaly, lymphocyte activation, glomerulonephritis and proteinuria were measured longitudinally or at the time of harvest. In accordance with an immunosuppressive function of MDSCs in male mice, S100a9-deficient male NZBWF1 mice developed accelerated autoimmunity as indicated by increased numbers of differentiated effector B and T cells, elevated serum autoantibody levels, increased immune-complex deposition and renal inflammation, and accelerated development of proteinuria. In contrast, female mice showed either no response to S100a9-deficiency or even a slight reduction in disease symptoms. Furthermore, male, but not female, S100a9(-/-) NZBWF1 mice displayed an elevated type I interferon-induced gene signature, suggesting that S100a9 may dampen a pathogenic type I interferon signal in male mice. Taken together, S100a9 exerts an immunosuppressive function in male NZBWF1 mice effectively moderating lupus-like disease development via inhibition of type I interferon production, lymphocyte activation, autoantibody production and the development of renal disease.	[Davison, Laura M.; Keller, Emma J.] Case Western Reserve Univ, Dept Mol Med, Cleveland Clin Lerner Coll Med, Cleveland, OH 44106 USA; [Alberto, Andres A.; Dand, Hardik A.; Patt, Madeline; Khan, Ayesha; Dvorina, Nina; Sakurai, Nodoka; Liegl, Lauren N.; Jorgensen, Trine N.] Cleveland Clin Fdn, Lerner Res Inst, Dept Inflammat & Immun, NE40, 9500 Euclid Ave, Cleveland, OH 44195 USA; [White, Alexandra] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Cleveland, OH 44106 USA; [Vogl, Thomas] Univ Munster, Inst Immunol, Munster, Germany	Case Western Reserve University; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation; University of Munster	Jorgensen, TN (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Inflammat & Immun, NE40, 9500 Euclid Ave, Cleveland, OH 44195 USA.	jorgent@ccf.org		White, Alexandra/0000-0003-4704-6578; Keller, Emma/0000-0002-0368-4175	Department of Defense Grant [W81XWH-11-1-0667]	Department of Defense Grant(United States Department of Defense)	This study was supported in part by the Department of Defense Grant #W81XWH-11-1-0667 (TJ).	Alkhateeb Tuqa, 2020, J Clin Cell Immunol, V11; Aochi S, 2011, J AM ACAD DERMATOL, V64, P879, DOI 10.1016/j.jaad.2010.02.049; Atencio S, 2004, J IMMUNOL, V172, P4159, DOI 10.4049/jimmunol.172.7.4159; Bird AK, 2017, J IMMUNOL, V199, P458, DOI 10.4049/jimmunol.1700354; Blasius A, 2004, BLOOD, V103, P4201, DOI 10.1182/blood-2003-09-3108; Boso M, 2006, NEUROSCI LETT, V410, P169, DOI 10.1016/j.neulet.2006.08.092; BURNET M, 1965, NATURE, V207, P368, DOI 10.1038/207368a0; Bynote KK, 2008, GENES IMMUN, V9, P137, DOI 10.1038/sj.gene.6364458; Cesaro A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045478; Chakrabarti S, 2010, CARDIOVASC RES, V85, P796, DOI 10.1093/cvr/cvp368; Chen JQ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174585; Cheng PY, 2008, J EXP MED, V205, P2235, DOI 10.1084/jem.20080132; COHEN PL, 1977, J IMMUNOL, V119, P1534; Dai J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01565; Dai RJ, 2013, BIOL SEX DIFFER, V4, DOI 10.1186/2042-6410-4-19; De Filippo K, 2014, FASEB J, V28, P3600, DOI 10.1096/fj.13-247460; Denny MR, 2010, J IMMUNOL, V184, P3284, DOI 10.4049/jimmunol.0902199; Der E, 2014, J IMMUNOL, V192, P1570, DOI 10.4049/jimmunol.1302479; Dessing MC, 2015, KIDNEY INT, V87, P85, DOI 10.1038/ki.2014.216; DUBOIS EL, 1966, J AMER MED ASSOC, V195, P285, DOI 10.1001/jama.195.4.285; Frisancho-Kiss S, 2009, BRAIN BEHAV IMMUN, V23, P649, DOI 10.1016/j.bbi.2008.12.002; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gordon C, 2008, RHEUMATOLOGY, V47, P334, DOI 10.1093/rheumatology/kem342; Gubbles Bupp MR, 2008, GENES IMMUN, V9, P47, DOI 10.1038/sj.gene.6364447; Haas C, 1998, J IMMUNOL, V160, P3713; HESSIAN PA, 1993, J LEUKOCYTE BIOL, V53, P197, DOI 10.1002/jlb.53.2.197; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hiroshima Y, 2017, IMMUNOL CELL BIOL, V95, P461, DOI 10.1038/icb.2017.2; Hobbs JAR, 2003, MOL CELL BIOL, V23, P2564, DOI 10.1128/MCB.23.7.2564-2576.2003; Huang M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02243; Huang XF, 2015, CELL REP, V12, P1120, DOI 10.1016/j.celrep.2015.07.021; Jitschin R, 2014, BLOOD, V124, P750, DOI 10.1182/blood-2013-12-546416; Jones JM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01271; Jorgensen TN, 2007, GENES IMMUN, V8, P653, DOI 10.1038/sj.gene.6364430; Jung N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225699; KEISLER LW, 1991, BIOL REPROD, V44, P707, DOI 10.1095/biolreprod44.4.707; Kim HJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088924; Kotzin BL., 2001, CLIN IMMUNOLOGY PRIN, V2nd edn; LAHITA RG, 1992, J RHEUMATOL, V19, P547; Lapierre P, 2010, HEPATOLOGY, V51, P1789, DOI 10.1002/hep.23536; Lim SY, 2008, J IMMUNOL, V181, P5627, DOI 10.4049/jimmunol.181.8.5627; Lim SY, 2010, J BIOL CHEM, V285, P14377, DOI 10.1074/jbc.M109.075242; Liu Z, 2011, ARTHRITIS RHEUM-US, V63, P219, DOI 10.1002/art.30087; Ma WH, 2019, EXCLI J, V18, P21, DOI 10.17179/excli2018-1740; Mathian A, 2005, J IMMUNOL, V174, P2499, DOI 10.4049/jimmunol.174.5.2499; Mathis KW, 2017, PHARMACOL RES, V120, P252, DOI 10.1016/j.phrs.2017.04.005; Mellors R C, 1966, Int Rev Exp Pathol, V5, P217; Moline-Velazquez V, 2011, BRAIN PATHOL, V21, P678, DOI 10.1111/j.1750-3639.2011.00495.x; Ochoa AC, 2007, CLIN CANCER RES, V13, p721S, DOI 10.1158/1078-0432.CCR-06-2197; Pavon EJ, 2012, J PROTEOMICS, V75, P1778, DOI 10.1016/j.jprot.2011.12.020; Puga I, 2012, NAT IMMUNOL, V13, P170, DOI 10.1038/ni.2194; ROUBINIAN JR, 1979, J CLIN INVEST, V63, P902, DOI 10.1172/JCI109390; ROUBINIAN JR, 1977, J CLIN INVEST, V59, P1066, DOI 10.1172/JCI108729; ROUBINIAN JR, 1978, J EXP MED, V147, P1568, DOI 10.1084/jem.147.6.1568; Rupp MRG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00794; Santiago-Raber ML, 2003, J EXP MED, V197, P777, DOI 10.1084/jem.20021996; Schenten V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00447; Soyfoo MS, 2009, J RHEUMATOL, V36, P2190, DOI 10.3899/jrheum.081302; Stroncek DF, 2005, J TRANSL MED, V3, P1, DOI 10.1186/1479-5876-3-36; Su Yu-Jih, 2018, Oncotarget, V9, P27911, DOI 10.18632/oncotarget.25575; Tacke RS, 2012, HEPATOLOGY, V55, P343, DOI 10.1002/hep.24700; Trigunaite A, 2015, CELL IMMUNOL, V294, P87, DOI 10.1016/j.cellimm.2015.02.004; Trigunaite A, 2013, ARTHRITIS RHEUM-US, V65, P2392, DOI 10.1002/art.38048; van Vollenhoven Ronald F, 2002, Expert Opin Pharmacother, V3, P23, DOI 10.1517/14656566.3.1.23; Vlachou K, 2012, ANN RHEUM DIS, V71, DOI 10.1136/annrheumdis-2011-201238.29; Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638; Vogl T, 2018, J CLIN INVEST, V128, P1852, DOI 10.1172/JCI89867; Wache C, 2015, J INFECT DIS, V212, P247, DOI 10.1093/infdis/jiv028; Walecki M, 2015, MOL BIOL CELL, V26, P2845, DOI 10.1091/mbc.E14-08-1323; Yang Q, 2017, ONCOGENE, V36, P2969, DOI 10.1038/onc.2016.448; Zhang XM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01774; Zhu W, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1358-y	72	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 17	2021	12								681503	10.3389/fimmu.2021.681503	http://dx.doi.org/10.3389/fimmu.2021.681503			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TC5GY	34220829	Green Published, gold			2022-12-18	WOS:000668668500001
J	Makenga, G; Mtove, G; Yin, JK; Mziray, A; Bwana, VM; Kisinza, W; Mjema, J; Amos, B; Antony, L; Shingadia, D; Oftadeh, S; Booy, R				Makenga, Geofrey; Mtove, George; Yin, J. Kevin; Mziray, Abubakary; Bwana, Veneranda M.; Kisinza, William; Mjema, Julius; Amos, Ben; Antony, Laura; Shingadia, Delane; Oftadeh, Shahin; Booy, Robert			Immunogenicity and Efficacy of Pneumococcal Conjugate Vaccine (Prevenar13(R)) in Preventing Acquisition of Carriage of Pneumococcal Vaccine Serotypes in Tanzanian Children With HIV/AIDS	FRONTIERS IN IMMUNOLOGY			English	Article						immunogenicity; efficacy; Prevenar 13; carriage acquisition; immunocompromised children; prevention	IMMUNODEFICIENCY-VIRUS TYPE-1; STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL CARRIAGE; SAFETY; 13-VALENT; DISEASE; INFANTS; IMPACT; SERIES	In every year, up to one million children die due to pneumococcal disease. Children infected with Human Immunodeficiency Virus (HIV) are mostly affected, as they appear to have higher rates of pneumococcal carriage and invasive disease. Successful immunity is dependent on mounting a sufficient immune response to the vaccine. We conducted a double blinded crossover randomised controlled trial to determine the serum antibody response (>= 4-fold and geometric mean concentration) to pneumococcal vaccine (PCV13) serotypes at 3 months after second vaccination. We also determined the number and proportion of children carrying new (not present at baseline) vaccine serotypes of S. pneumoniae isolated from nasopharynx at 6 months post initial vaccination in recipients of Prevenar13(R) compared with those given Haemophilus influenzae-type b (Hib) vaccine (control). The study was conducted at St Augustine's also known as Teule Hospital in Muheza, Tanga Tanzania. 225 HIV infected children aged 1-14 years were enrolled from Jan 2013 to Nov 2013 and randomised to Prevenar13(R) or Hib vaccines each given at baseline and 2-3 months later. Nasopharyngeal and serum samples were collected at baseline and 4-6 months later. Serotyping was done by Quellung Reaction using Staten antisera. Serum antibodies were ELISA quantified. The study revealed a non-significant reduction in the acquisition of new vaccine serotypes of S. pneumoniae in the recipients of PCV13 by nearly a third compared to those who received Hib vaccine. The vaccine efficacy was 30.5% (95% confidence interval [CI(R) -6.4-54.6%, P = 0.100)(R). The antibody response was not enough to induce a 4-fold rise in GMC in 7 of the 13 vaccine serotypes. When combining the effects of preventing new acquisition and clearing existing vaccine type carriage, the overall efficacy was 31.5% (95% CI 1.5-52.4%, P = 0.045). In the PCV13 group, the proportion of participants carrying vaccine serotype was significantly lower after 2 doses of PCV13 (30%; 32/107), compared with the baseline proportion (48%; 51/107). The introduction of PCV13 targeting HIV-positive children in a setting similar to Tanzania is likely to be associated with appreciable decrease in the acquisition and carriage of pneumococci, which is an important marker of the likely effect of the vaccine on pneumococcal disease.	[Makenga, Geofrey; Mtove, George; Mziray, Abubakary; Bwana, Veneranda M.; Kisinza, William] Amani Res Ctr, Natl Inst Med Res NIMR, Muheza, Tanzania; [Yin, J. Kevin; Antony, Laura; Booy, Robert] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia; [Yin, J. Kevin; Booy, Robert] Univ Sydney, Natl Ctr Immunisat Res & Surveillance, Sydney, NSW, Australia; [Mjema, Julius; Amos, Ben] Hospitali Teule, Tanga, Tanzania; [Shingadia, Delane] Great Ormond St Hosp Sick Children, London, England; [Oftadeh, Shahin] Westmead Hosp, Inst Clin Pathol & Med Res, Ctr Infect Dis & Microbiol, NSW & ACT Pneumococcal Reference Lab, Westmead, NSW, Australia	National Institute of Medical Research; University of Sydney; University of Sydney; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Sydney	Makenga, G (corresponding author), Amani Res Ctr, Natl Inst Med Res NIMR, Muheza, Tanzania.	geofmacky@gmail.com	Amos, Ben/AAG-6934-2022; Amos, Ben/AFL-6820-2022	Amos, Ben/0000-0002-8569-1650; Amos, Ben/0000-0002-8569-1650; Bwana, Veneranda Masatu/0000-0002-4993-6390; Mtove, George/0000-0001-5173-0829; Makenga, Geofrey/0000-0001-5681-9785	Pfizer	Pfizer(Pfizer)	This was an investigator-initiated study sponsored by Pfizer to RB. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	Abzug MJ, 2006, PEDIATR INFECT DIS J, V25, P920, DOI 10.1097/01.inf.0000237830.33228.c3; Amos B, 2009, CLIN INFECT DIS, V48, pS162, DOI 10.1086/596496; [Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373; [Anonymous], 2007, Wkly Epidemiol Rec, V82, P93; Anthony L, 2012, INT J INFECT DIS, V16, pE753, DOI 10.1016/j.ijid.2012.05.1037; Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7; Bryant KA, 2010, PEDIATRICS, V125, P866, DOI 10.1542/peds.2009-1405; Cowgill Karen, 2007, Bull World Health Organ, V85, P0; Darboe MK, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-195; Duggan ST, 2010, DRUGS, V70, P1973, DOI 10.2165/11205110-000000000-00000; Esposito S, 2010, CLIN VACCINE IMMUNOL, V17, P1017, DOI 10.1128/CVI.00062-10; Goldblatt, 2002, TRAINING MANUAL ENZY, P1; Habib M, 2014, JOVE-J VIS EXP, DOI 10.3791/51208; Hausdorff WP, 2005, LANCET INFECT DIS, V5, P83, DOI 10.1016/S1473-3099(05)01280-6; Hill PC, 2006, CLIN INFECT DIS, V43, P673, DOI 10.1086/506941; Jefferies JMC, 2011, HUM VACCINES, V7, P1012, DOI 10.4161/hv.7.10.16794; Kieninger DM, 2010, VACCINE, V28, P4192, DOI 10.1016/j.vaccine.2010.04.008; Madhi SA, 2005, PEDIATR INFECT DIS J, V24, P410, DOI 10.1097/01.inf.0000160942.84169.14; Madhi SA, 2005, CLIN INFECT DIS, V40, P1511, DOI 10.1086/429828; Madhi SA, 2000, PEDIATR INFECT DIS J, V19, P1141, DOI 10.1097/00006454-200012000-00004; Nachman S, 2003, PEDIATRICS, V112, P66, DOI 10.1542/peds.112.1.66; O'Brien KL, 2003, PEDIATR INFECT DIS J, V22, P133, DOI [10.1097/00006454-200302000-00009, 10.1097/00006454-200302000-00010]; Oosterhuis-Kafeja F, 2007, VACCINE, V25, P2194, DOI 10.1016/j.vaccine.2006.11.032; Park DE, 2014, PEDIATR INFECT DIS J, V33, pS130, DOI 10.1097/INF.0000000000000081; Poolman J, 2011, CLIN VACCINE IMMUNOL, V18, P327, DOI 10.1128/CVI.00402-10; Selva L, 2012, J CLIN MICROBIOL, V50, P3451, DOI 10.1128/JCM.01368-12; SMITH T, 1993, EPIDEMIOL INFECT, V111, P27, DOI 10.1017/S0950268800056648; Snape MD, 2010, PEDIATR INFECT DIS J, V29, pE80, DOI 10.1097/INF.0b013e3181faa6be; Trotter CL, 2008, VACCINE, V26, P4434, DOI 10.1016/j.vaccine.2008.05.073; UNAIDS & WHO, 2007, AIDS EPIDEMIC UPDATE; von Gottberg A, 2013, VACCINE, V31, P4200, DOI 10.1016/j.vaccine.2013.04.077; WHO, 2013, EXP PROGR IMM; World Health Organization, 2005, World Health Organ Tech Rep Ser, V927, P1; World Health Organization, 2006, Wkly Epidemiol Rec, V81, P445; Yeh SH, 2010, PEDIATRICS, V126, pE493, DOI 10.1542/peds.2009-3027	35	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 17	2021	12								673392	10.3389/fimmu.2021.673392	http://dx.doi.org/10.3389/fimmu.2021.673392			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TC4YV	34220819	Green Published, gold			2022-12-18	WOS:000668646900001
J	Strubbe, S; De Bruyne, M; Pannicke, U; Beyls, E; Vandekerckhove, B; Leclercq, G; De Baere, E; Bordon, V; Vral, A; Schwarz, K; Haerynck, F; Taghon, T				Strubbe, Steven; De Bruyne, Marieke; Pannicke, Ulrich; Beyls, Elien; Vandekerckhove, Bart; Leclercq, Georges; De Baere, Elfride; Bordon, Victoria; Vral, Anne; Schwarz, Klaus; Haerynck, Filomeen; Taghon, Tom			A Novel Non-Coding Variant in DCLRE1C Results in Deregulated Splicing and Induces SCID Through the Generation of a Truncated ARTEMIS Protein That Fails to Support V(D)J Recombination and DNA Damage Repair	FRONTIERS IN IMMUNOLOGY			English	Article						SCID; NGS; ARTEMIS; V(D)J recombination; DNA damage repair	SEVERE COMBINED IMMUNODEFICIENCY; GENE-THERAPY; HOMOLOGOUS RECOMBINATION; INBORN-ERRORS; BREAK REPAIR; LIGASE IV; MUTATIONS; DEFICIENCY; RESECTION; MECHANISM	Severe Combined Immune Deficiency (SCID) is a primary deficiency of the immune system in which opportunistic and recurring infections are often fatal during neonatal or infant life. SCID is caused by an increasing number of genetic defects that induce an abrogation of T lymphocyte development or function in which B and NK cells might be affected as well. Because of the increased availability and usage of next-generation sequencing (NGS), many novel variants in SCID genes are being identified and cause a heterogeneous disease spectrum. However, the molecular and functional implications of these new variants, of which some are non-coding, are often not characterized in detail. Using targeted NGS, we identified a novel homozygous c.465-1G>C splice acceptor site variant in the DCLRE1C gene in a T-B-NK+ SCID patient and fully characterized the molecular and functional impact. By performing a minigene splicing reporter assay, we revealed deregulated splicing of the DCLRE1C transcript since a cryptic splice acceptor in exon 7 was employed. This induced a frameshift and the generation of a p.Arg155Serfs*15 premature termination codon (PTC) within all DCLRE1C splice variants, resulting in the absence of full-length ARTEMIS protein. Consistently, a V(D)J recombination assay and a G0 micronucleus assay demonstrated the inability of the predicted mutant ARTEMIS protein to perform V(D)J recombination and DNA damage repair, respectively. Together, these experiments molecularly and functionally clarify how a newly identified c.465-1G>C variant in the DCLRE1C gene is responsible for inducing SCID. In a clinical context, this demonstrates how the experimental validation of new gene variants, that are identified by NGS, can facilitate the diagnosis of SCID which can be vital for implementing appropriate therapies.	[Strubbe, Steven; Vandekerckhove, Bart; Leclercq, Georges; Taghon, Tom] Univ Ghent, Dept Diagnost Sci, Ghent, Belgium; [De Bruyne, Marieke; De Baere, Elfride] Ctr Med Genet Ghent CMGG, Ghent, Belgium; [Pannicke, Ulrich; Schwarz, Klaus] Univ Ulm, Inst Transfus Med, Ulm, Germany; [Beyls, Elien; Vral, Anne] Univ Ghent, Dept Human Struct & Repair, Ghent, Belgium; [Vandekerckhove, Bart; Leclercq, Georges; Taghon, Tom] Canc Res Inst Ghent CRIG, Ghent, Belgium; [De Baere, Elfride] Univ Ghent, Dept Biomol Med, Ghent, Belgium; [Bordon, Victoria] Ghent Univ Hosp, Dept Internal Med & Pediat, Div Pediat Hematooncol & Stem Cell Transplantat, Ghent, Belgium; [Schwarz, Klaus] Germa Red Cross Blood Serv Baden Wurttemberg Hess, Inst Clin Transfus Med & Immunogenet Ulm, Ulm, Germany; [Haerynck, Filomeen] Ghent Univ Hosp, Jeffrey Modell Diag & Res Ctr, Primary Immunodeficiency Res Lab, Ghent, Belgium; [Haerynck, Filomeen] Ghent Univ Hosp, Dept Internal Med & Pediat, Div Pediat Immunol & Pulmonol, Ghent, Belgium	Ghent University; Ulm University; Ghent University; Ghent University; Ghent University; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital	Taghon, T (corresponding author), Univ Ghent, Dept Diagnost Sci, Ghent, Belgium.; Taghon, T (corresponding author), Canc Res Inst Ghent CRIG, Ghent, Belgium.	Tom.Taghon@UGent.be	Haerynck, Filomeen/AAD-6761-2020; Leclercq, Georges/H-9659-2017	Haerynck, Filomeen/0000-0001-9161-7361; Leclercq, Georges/0000-0002-1691-5294; Strubbe, Steven/0000-0003-0361-2523	Fund for Scientific Research Flanders (FWO); Ghent University Research Fund	Fund for Scientific Research Flanders (FWO)(FWO); Ghent University Research Fund(Ghent University)	This work was supported by the Fund for Scientific Research Flanders (FWO, fellowship grant to SS) and grants from the Ghent University Research Fund (GOA and Starting Credit to TT).	Aiuti A, 2017, EMBO MOL MED, V9, P737, DOI 10.15252/emmm.201707573; Arcas-Garcia A, 2020, CLIN EXP IMMUNOL, V200, P61, DOI 10.1111/cei.13405; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Beucher A, 2009, EMBO J, V28, P3413, DOI 10.1038/emboj.2009.276; Biehs R, 2017, MOL CELL, V65, P671, DOI 10.1016/j.molcel.2016.12.016; Buck D, 2006, EUR J IMMUNOL, V36, P224, DOI 10.1002/eji.200535401; Chan A, 2007, J IMMUNOL, V179, P89, DOI 10.4049/jimmunol.179.1.89; Cicalese MP, 2018, MOL THER, V26, P917, DOI 10.1016/j.ymthe.2017.12.022; Cowan MJ, 2020, BIOL BLOOD MARROW TR, V26, pS88; de Bruin LMO, 2018, BLOOD, V132, P281, DOI 10.1182/blood-2017-12-820985; De Leeneer K, 2015, HUM MUTAT, V36, P379, DOI 10.1002/humu.22739; de Villartay JP, 2009, ADV EXP MED BIOL, V650, P46; de Villartay JP, 2005, J CLIN INVEST, V115, P3291, DOI 10.1172/JCI25178; Dobbs K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00798; Dvorak CC, 2010, IMMUNOL ALLERGY CLIN, V30, P125, DOI 10.1016/j.iac.2009.10.004; Ege M, 2005, BLOOD, V105, P4179, DOI 10.1182/blood-2004-12-4861; Felgentreff K, 2011, CLIN IMMUNOL, V141, P73, DOI 10.1016/j.clim.2011.05.007; Fenech M, 2007, NAT PROTOC, V2, P1084, DOI 10.1038/nprot.2007.77; Fischer A, 2000, CLIN EXP IMMUNOL, V122, P143, DOI 10.1046/j.1365-2249.2000.01359.x; Fischer A, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.61; Geng LY, 2007, MOL CELL BIOL, V27, P2625, DOI 10.1128/MCB.02072-06; Haddad E, 2018, BLOOD, V132, P1737, DOI 10.1182/blood-2018-03-840702; Houghton BC, 2021, HEMASPHERE, V5, DOI 10.1097/HS9.0000000000000509; Hustedt N, 2017, NAT CELL BIOL, V19, P1, DOI 10.1038/ncb3452; IJspeert H, 2011, GENES IMMUN, V12, P434, DOI 10.1038/gene.2011.16; Karo JM, 2014, CELL, V159, P94, DOI 10.1016/j.cell.2014.08.026; Kishore S, 2008, GENE, V427, P104, DOI 10.1016/j.gene.2008.09.021; Krumm N, 2012, GENOME RES, V22, P1525, DOI 10.1101/gr.138115.112; Kurosaki T, 2019, NAT REV MOL CELL BIO, V20, P406, DOI 10.1038/s41580-019-0126-2; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Li LY, 2002, J IMMUNOL, V168, P6323, DOI 10.4049/jimmunol.168.12.6323; Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131; Lobrich M, 2017, TRENDS BIOCHEM SCI, V42, P690, DOI 10.1016/j.tibs.2017.06.011; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Mace EM, 2017, J CLIN INVEST, V127, P306, DOI 10.1172/JCI86276; Maffucci P, 2018, J CLIN INVEST, V128, P5489, DOI 10.1172/JCI99629; Malu S, 2012, J EXP MED, V209, P955, DOI 10.1084/jem.20111437; Mamcarz E, 2019, NEW ENGL J MED, V380, P1525, DOI 10.1056/NEJMoa1815408; Meyts I, 2016, J ALLERGY CLIN IMMUN, V138, P957, DOI 10.1016/j.jaci.2016.08.003; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Nagy E, 1998, TRENDS BIOCHEM SCI, V23, P198, DOI 10.1016/S0968-0004(98)01208-0; Nahum A, 2020, CLIN IMMUNOL, V213, DOI 10.1016/j.clim.2020.108366; Neu-Yilik G, 2011, RNA, V17, P843, DOI 10.1261/rna.2401811; Nishana M, 2012, IMMUNOLOGY, V137, P271, DOI 10.1111/imm.12009; Notarangelo LD, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abb1662; Notarangelo LD, 2016, NAT REV IMMUNOL, V16, P234, DOI 10.1038/nri.2016.28; Notarangelo LD, 2010, J ALLERGY CLIN IMMUN, V125, pS182, DOI 10.1016/j.jaci.2009.07.053; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; Pannicke U, 2004, EMBO J, V23, P1987, DOI 10.1038/sj.emboj.7600206; Pannicke U, 2010, HUM MUTAT, V31, P197, DOI 10.1002/humu.21168; Pannunzio NR, 2018, J BIOL CHEM, V293, P10512, DOI 10.1074/jbc.TM117.000374; Picard C, 2014, EUR J IMMUNOL, V44, P2854, DOI 10.1002/eji.201444669; Poinsignon C, 2004, J EXP MED, V199, P315, DOI 10.1084/jem.20031142; Puck JM, 2019, IMMUNOL REV, V287, P241, DOI 10.1111/imr.12729; Raje N, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0468-y; Rohr J, 2010, J CLIN IMMUNOL, V30, P314, DOI 10.1007/s10875-009-9349-x; Schmitt EG, 2021, ANNU REV IMMUNOL, V39, P227, DOI 10.1146/annurev-immunol-093019-124513; Sheller R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.577853; Singh G, 2012, CELL, V151, P750, DOI 10.1016/j.cell.2012.10.007; Slonina D, 2007, RADIAT RES, V167, P251, DOI 10.1667/RR0649; Tangye SG, 2021, J CLIN IMMUNOL, V41, P666, DOI 10.1007/s10875-021-00980-1; Tangye SG, 2020, J CLIN IMMUNOL, V40, P24, DOI 10.1007/s10875-019-00737-x; Thaventhiran JED, 2020, NATURE, V583, P90, DOI 10.1038/s41586-020-2265-1; Thermann R, 1998, EMBO J, V17, P3484, DOI 10.1093/emboj/17.12.3484; van der Burg M, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00373; van der Burg M, 2009, J CLIN INVEST, V119, P91, DOI 10.1172/JCI37141; Wang JH, 2005, DNA REPAIR, V4, P556, DOI 10.1016/j.dnarep.2005.02.001; Woodbine L, 2013, J CLIN INVEST, V123, P2969, DOI 10.1172/JCI67349; Wu CF, 2014, CELL STEM CELL, V14, P486, DOI 10.1016/j.stem.2014.01.020; Zhang X, 2009, ONCOGENE, V28, P2196, DOI 10.1038/onc.2009.100; Zhang ZG, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-23	72	0	0	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 17	2021	12								674226	10.3389/fimmu.2021.674226	http://dx.doi.org/10.3389/fimmu.2021.674226			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TC5FD	34220820	Green Published, gold			2022-12-18	WOS:000668663800001
J	Chen, TYT; Chou, MC; Lai, JN; Chiu, LT; Chang, RN; Hung, YM; Wei, JCC				Chen, Thomas Yen-Ting; Chou, Mei-Chia; Lai, Jung-Nien; Chiu, Lu-Ting; Chang, Renin; Hung, Yao-Min; Wei, James Cheng-Chung			Non-Typhoidal Salmonella and the Risk of Kawasaki Disease: A Nationwide Population-Based Cohort Study	FRONTIERS IN IMMUNOLOGY			English	Article						Cohort study; Non-typhoidal Salmonella; Kawasaki disease; NHIRD; Taiwan	LONG-TERM MANAGEMENT; LYMPH-NODE SYNDROME; HEALTH-PROFESSIONALS; CORONARY ARTERITIS; UNITED-STATES; INFECTION; EPIDEMIOLOGY; PATHOGENESIS; DIAGNOSIS; CHILDREN	Objective The aim of this study was to investigate the relationship between non-typhoidal Salmonella (NTS) infection and the risk of Kawasaki disease (KD) by using a nationwide population-based data set in Taiwan. Methods In this retrospective cohort study, we enrolled 69,116 patients under 18 years of age, with NTS from January 1(st), 2000, to December 31(st), 2013, using the population-based National Health Insurance Research Database of Taiwan. A comparison group without NTS was matched (at a 1:4 ratio) by propensity score. The two cohorts were followed from the initial diagnosis of NTS until the date of KD development or December 31(st), 2013. Cox proportional hazard regression analysis was conducted to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) after adjusting for covariates. Also, we conducted sensitivity analyses to examine our findings. Results After adjusting for covariates, the risk of KD for the children with NTS was significantly higher than that of the comparison group (hazard ratio = 1.31; 95% confidence interval = 1.03-1.66; p < 0.01). Stratified analysis showed that the associated risk of the investigated outcome was significant in children aged <= 2 years (aHR= 1.31, 95% C.I. 1.02-1.69), in female patients (aHR= 1.46, 95% C.I. 1.03-2.08), and in those without allergic diseases. Conclusions NTS is associated with an increased risk of KD in Taiwanese children.	[Chen, Thomas Yen-Ting] Kaohsiung Vet Gen Hosp, Dept Med Res & Educ, Kaohsiung, Taiwan; [Chou, Mei-Chia] Tajen Univ, Dept Recreat & Sports Management, Pingtung, Taiwan; [Chou, Mei-Chia] Kaohsiung Vet Gen Hosp, Dept Phys Med & Rehabil, Pingtung Branch, Kaohsiung, Pingtung County, Taiwan; [Lai, Jung-Nien] China Med Univ, Coll Chinese Med, Sch Chinese Med, Taichung, Taiwan; [Lai, Jung-Nien] China Med Univ Hosp, Dept Chinese Med, Taichung, Taiwan; [Chiu, Lu-Ting] China Med Univ, Coll Med, Taichung, Taiwan; [Chiu, Lu-Ting] China Med Univ Hosp, Management Off Hlth Data, Taichung, Taiwan; [Chang, Renin] Kaohsiung Vet Gen Hosp, Dept Emergency Med, Kaohsiung, Taiwan; [Hung, Yao-Min; Wei, James Cheng-Chung] Chung Shan Med Univ, Inst Med, Taichung, Taiwan; [Hung, Yao-Min] Meiho Univ, Coll Nursing & Hlth, Pingtung, Taiwan; [Hung, Yao-Min] Kaohsiung Municipal United Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Hung, Yao-Min] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan; [Wei, James Cheng-Chung] Chung Shan Med Univ Hosp, Div Allergy Immunol & Rheumatol, Taichung, Taiwan; [Wei, James Cheng-Chung] China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan	Kaohsiung Veterans General Hospital; Kaohsiung Veterans General Hospital; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Kaohsiung Veterans General Hospital; Chung Shan Medical University; National Yang Ming Chiao Tung University; Chung Shan Medical University; Chung Shan Medical University Hospital; China Medical University Taiwan	Chang, RN (corresponding author), Kaohsiung Vet Gen Hosp, Dept Emergency Med, Kaohsiung, Taiwan.; Hung, YM; Wei, JCC (corresponding author), Chung Shan Med Univ, Inst Med, Taichung, Taiwan.; Hung, YM (corresponding author), Meiho Univ, Coll Nursing & Hlth, Pingtung, Taiwan.; Hung, YM (corresponding author), Kaohsiung Municipal United Hosp, Dept Internal Med, Kaohsiung, Taiwan.; Hung, YM (corresponding author), Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.; Wei, JCC (corresponding author), Chung Shan Med Univ Hosp, Div Allergy Immunol & Rheumatol, Taichung, Taiwan.; Wei, JCC (corresponding author), China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan.	rhapsody1881@gmail.com; ymhung1@gmail.com; wei3228@gmail.com			China Medical University Hospital [DMR-110-222]; Kaohsiung Veterans General Hospital [VGHKS107156]	China Medical University Hospital; Kaohsiung Veterans General Hospital	This study was supported in part by China Medical University Hospital (DMR-110-222) and Kaohsiung Veterans General Hospital (VGHKS107156). The funders had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript.	AKIYAMA T, 1993, EUR J PEDIATR, V152, P82, DOI 10.1007/BF02072479; Belizna CC, 2009, RHEUMATOLOGY, V48, P475, DOI 10.1093/rheumatology/kep026; Benseler SM, 2005, PEDIATRICS, V116, pE760, DOI 10.1542/peds.2005-0559; Burns JC, 2004, LANCET, V364, P533, DOI 10.1016/S0140-6736(04)16814-1; Chen PL, 2012, EPIDEMIOL INFECT, V140, P2256, DOI 10.1017/S0950268812000088; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; CURTIS N, 1995, ARCH DIS CHILD, V72, P308, DOI 10.1136/adc.72.4.308; Filiz S, 2014, PEDIATR DERMATOL, V31, P236, DOI 10.1111/j.1525-1470.2012.01856.x; GLYNN JR, 1992, AM J EPIDEMIOL, V136, P1369, DOI 10.1093/oxfordjournals.aje.a116449; Harnden A, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1514; Helaine S, 2014, SCIENCE, V343, P204, DOI 10.1126/science.1244705; Holman RC, 2003, PEDIATRICS, V112, P495, DOI 10.1542/peds.112.3.495; Huang WC, 2009, PEDIATRICS, V123, pe401, DOI 10.1542/peds.2008-2187; Huang YH, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00121; Jones TF, 2006, PEDIATRICS, V118, P2380, DOI 10.1542/peds.2006-1218; KATO H, 1983, LANCET, V2, P1383; KAWASAKI T, 1974, PEDIATRICS, V54, P271; LEHMAN TJA, 1988, CLIN IMMUNOL IMMUNOP, V48, P108, DOI 10.1016/0090-1229(88)90161-4; Leung DYM, 2002, J PEDIATR-US, V140, P742, DOI 10.1067/mpd.2002.123664; LEUNG DYM, 1993, LANCET, V342, P1385, DOI 10.1016/0140-6736(93)92752-F; Liang CD, 2009, AM HEART J, V157, P584, DOI 10.1016/j.ahj.2008.11.020; Majowicz SE, 2010, CLIN INFECT DIS, V50, P882, DOI 10.1086/650733; Mancia L, 1998, SCAND J IMMUNOL, V48, P443; McCrindle BW, 2017, CIRCULATION, V135, pE927, DOI 10.1161/CIR.0000000000000484; Meissner HC, 2000, PEDIATR INFECT DIS J, V19, P91, DOI 10.1097/00006454-200002000-00001; MELISH ME, 1976, AM J DIS CHILD, V130, P599, DOI 10.1001/archpedi.1976.02120070025006; Munoz-Grajales C, 2015, AUTOIMMUN DIS, V2015, DOI 10.1155/2015/286783; Nagi-Miura N, 2004, IMMUNOPHARM IMMUNOT, V26, P527, DOI 10.1081/IPH-200042295; Newburger JW, 2004, PEDIATRICS, V114, P1708, DOI 10.1542/peds.2004-2182; NIGRO G, 1994, LANCET, V343, P1260, DOI 10.1016/S0140-6736(94)92154-7; Olsen SJ, 2001, J INFECT DIS, V183, P753, DOI 10.1086/318832; Rabsch W, 2001, MICROBES INFECT, V3, P237, DOI 10.1016/S1286-4579(01)01375-2; Ravel A, 2010, FOODBORNE PATHOG DIS, V7, P785, DOI 10.1089/fpd.2009.0460; Root-Bernstein R, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-013-0407-3; ROWLEY AH, 1994, PEDIATR RES, V36, P567, DOI 10.1203/00006450-199411000-00003; Rowley AH, 2001, J IMMUNOL, V166, P1334, DOI 10.4049/jimmunol.166.2.1334; Shimoni Z, 1999, CLIN INFECT DIS, V28, P822, DOI 10.1086/515186; Sun YH, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000044; Takahashi K, 2011, CLIN EXP IMMUNOL, V164, P20, DOI 10.1111/j.1365-2249.2011.04361.x; Tavares Pedro Neves, 2020, Eur J Case Rep Intern Med, V7, P001403, DOI 10.12890/2020_001403; Tindall BJ, 2005, INT J SYST EVOL MICR, V55, P521, DOI 10.1099/ijs.0.63580-0; Tsai YJ, 2013, ALLERGY ASTHMA PROC, V34, P467, DOI 10.2500/aap.2013.34.3697; Tsolis RM, 2011, INFECT IMMUN, V79, P1806, DOI 10.1128/IAI.01369-10; Wang CL, 2005, PEDIATR INFECT DIS J, V24, P998, DOI 10.1097/01.inf.0000183786.70519.fa; Wei CC, 2014, ANN EPIDEMIOL, V24, P340, DOI 10.1016/j.annepidem.2014.02.003; Zhang SP, 2003, INFECT IMMUN, V71, P1, DOI 10.1128/IAI.71.1.1-12.2003	46	0	0	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 16	2021	12								701409	10.3389/fimmu.2021.701409	http://dx.doi.org/10.3389/fimmu.2021.701409			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TD0LH	34220865	gold, Green Published			2022-12-18	WOS:000669027200001
J	Horellou, P; de Chalus, A; Giorgi, L; Leroy, C; Chretien, P; Hacein-Bey-Abina, S; Bourgeois, C; Mariette, X; Serguera, C; Le Grand, R; Deiva, K				Horellou, Philippe; de Chalus, Alienor; Giorgi, Laetitia; Leroy, Carole; Chretien, Pascale; Hacein-Bey-Abina, Salima; Bourgeois, Christine; Mariette, Xavier; Serguera, Che; Le Grand, Roger; Deiva, Kumaran			Regulatory T Cells Increase After rh-MOG Stimulation in Non-Relapsing but Decrease in Relapsing MOG Antibody-Associated Disease at Onset in Children	FRONTIERS IN IMMUNOLOGY			English	Article						neuroinflammation; auto-immune diseases; acquired demyelinating syndromes (ADS); myelin oligodendrocyte glycoprotein; multiple sclerosis; regulatory T lymphocytes	MYELIN OLIGODENDROCYTE GLYCOPROTEIN; DEMYELINATING SYNDROMES; MULTIPLE-SCLEROSIS; ENCEPHALOMYELITIS; PHOSPHORYLATION; AUTOANTIGEN; COOPERATE; TRANSIENT; T(H)17	Background Myelin oligodendrocytes glycoprotein (MOG) antibody-associated disease (MOGAD) represent 25% of pediatric acquired demyelinating syndrome (ADS); 40% of them may relapse, mimicking multiple sclerosis (MS), a recurrent and neurodegenerative ADS, which is MOG-Abs negative. Aims To identify MOG antigenic immunological response differences between MOGAD, MS and control patients, and between relapsing versus non-relapsing subgroups of MOGAD. Methods Three groups of patients were selected: MOGAD (n=12 among which 5 relapsing (MOGR) and 7 non-relapsing (MOGNR)), MS (n=10) and control patients (n=7). Peripheral blood mononuclear cells (PBMC) collected at the time of the first demyelinating event were cultured for 48 h with recombinant human (rh)-MOG protein (10 mu g/ml) for a specific stimulation or without stimulation as a negative control. The T cells immunophenotypes were analyzed by flow cytometry. CD4(+) T cells, T helper (Th) cells including Th1, Th2, and Th17 were analyzed by intracellular staining of cytokines. Regulatory T cells (T-regs, Foxp3(+)), CD45RA(-)Foxp3(+) T-regs and subpopulation naive T-regs (CD45RA(+)Foxp3(int)), effector T-regs (CD45RA(-)Foxp3(high)) and non-suppressive T-regs (CD45RA(-)Foxp3(int)) proportions were determined. Results The mean onset age of each group, ranging from 9.9 to 13.8, and sex ratio, were similar between MOGR, MOGNR, MS and control patients as analyzed by one-way ANOVA and Chi-square test. When comparing unstimulated to rh-MOG stimulated T cells, a significant increase in the proportion of Th2 and Th17 cells was observed in MOGAD. Increase of Th17 cells was significant in MOGNR (means: 0.63 +/- 0.15 vs. 1.36 +/- 0.43; Wilcoxon-test p = 0.03) but not in MOGR. CD4(+) T-regs were significantly increased in MOGNR (means: 3.51 +/- 0.7 vs. 4.59 +/- 1.33; Wilcoxon-test p = 0.046) while they decreased in MOGR. CD45RA(-)Foxp3(+) T-regs were significantly decreased in MOGR (means: 2.37 +/- 0.23 vs. 1.99 +/- 0.17; paired t-test p = 0.021), but not in MOGNR. MOGR showed the highest ratio of effector T-regs/non suppressive-T-regs,T- which was significantly higher than in MOGNR. Conclusions Our findings suggest that CD4(+) Th2 and Th17 cells are involved in the pathophysiology of MOGAD in children. The opposite response of T-regs to rh-MOG in MOGNR, where CD4(+) T-regs increased, and in MOGR, where CD45RA(-)Foxp3(+) T-regs decreased, suggests a probable loss of tolerance toward MOG autoantigen in MOGR which may explain relapses in this recurrent pediatric autoimmune disease.	[Horellou, Philippe; de Chalus, Alienor; Giorgi, Laetitia; Leroy, Carole; Bourgeois, Christine; Mariette, Xavier; Le Grand, Roger; Deiva, Kumaran] Univ Paris Saclay, INSERM, CEA, UMR 1184, Le Kremlin Bicetre, France; [de Chalus, Alienor; Giorgi, Laetitia; Leroy, Carole; Deiva, Kumaran] Bicetre Hosp, Paris Saclay Univ Hosp, AP HP, Pediat Neurol Dept, Le Kremlin Bicetre, France; [Chretien, Pascale; Hacein-Bey-Abina, Salima] Hop Kremlin Bicetre, Grp Hosp Univ Paris Sud, AP HP, Clin Immunol Lab, Le Kremlin Bicetre, France; [Chretien, Pascale; Hacein-Bey-Abina, Salima] Univ Paris, Unite Technol Chim & Biol Sante, CNRS, INSERM, Paris, France; [Mariette, Xavier] Hop Bicetre, AP HP, Dept Rheumatol, Le Kremlin Bicetre, France; [Serguera, Che] Hop La Pitie Salpetriere, Inst Cerveau ICM, Paris, France; [Deiva, Kumaran] Hop Bicetre, AP HP, Pediat Neurol Dept, Natl Referral Ctr Rare Inflammatory & Autoimmune, Le Kremlin Bicetre, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay	Deiva, K (corresponding author), Univ Paris Saclay, INSERM, CEA, UMR 1184, Le Kremlin Bicetre, France.; Deiva, K (corresponding author), Bicetre Hosp, Paris Saclay Univ Hosp, AP HP, Pediat Neurol Dept, Le Kremlin Bicetre, France.; Deiva, K (corresponding author), Hop Bicetre, AP HP, Pediat Neurol Dept, Natl Referral Ctr Rare Inflammatory & Autoimmune, Le Kremlin Bicetre, France.	kumaran.deiva@aphp.fr	Horellou, Philippe/B-4290-2019; Bourgeois, Christine/L-5944-2018	Horellou, Philippe/0000-0003-2467-8177; Bourgeois, Christine/0000-0003-1146-6087; Serguera, Che/0000-0002-9210-0636	Institut National de la Santeet de la Recherche Medicale (INSERM); Assistance Publique-Hopitaux de Paris	Institut National de la Santeet de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Assistance Publique-Hopitaux de Paris	This work was supported by the Institut National de la Santeet de la Recherche Medicale (INSERM) and the Assistance Publique-Hopitaux de Paris.	Absoud M, 2013, MULT SCLER J, V19, P76, DOI 10.1177/1352458512445944; Badami E, 2019, P NATL ACAD SCI USA, V116, P26788, DOI 10.1073/pnas.1910281116; Berer K, 2011, NATURE, V479, P538, DOI 10.1038/nature10554; Bettelli E, 2003, J EXP MED, V197, P1073, DOI 10.1084/jem.20021603; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bettelli E, 2006, J CLIN INVEST, V116, P2393, DOI 10.1172/JCI28334; Brill L, 2019, MULT SCLER RELAT DIS, V30, P114, DOI 10.1016/j.msard.2019.01.047; Brilot F, 2009, ANN NEUROL, V66, P833, DOI 10.1002/ana.21916; Bronge M, 2019, J AUTOIMMUN, V102, P38, DOI 10.1016/j.jaut.2019.04.013; Brucklacher-Waldert V, 2009, BRAIN, V132, P3329, DOI 10.1093/brain/awp289; Charles N, 2010, NAT MED, V16, P701, DOI 10.1038/nm.2159; Costanza M, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/4204512; Dale RC, 2014, NEUROL-NEUROIMMUNOL, V1, DOI 10.1212/NXI.0000000000000012; de Mol CL, 2018, J NEUROL, V265, P1310, DOI 10.1007/s00415-018-8835-6; Fassett MS, 2012, P NATL ACAD SCI USA, V109, P3891, DOI 10.1073/pnas.1200090109; Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038; Fovet CM, 2019, EBIOMEDICINE, V47, P492, DOI 10.1016/j.ebiom.2019.08.052; GARDINIER MV, 1992, J NEUROSCI RES, V33, P177, DOI 10.1002/jnr.490330123; Genain CP, 1996, SCIENCE, V274, P2054, DOI 10.1126/science.274.5295.2054; Haak S, 2009, J CLIN INVEST, V119, P61, DOI 10.1172/JCI35997; Hacohen Y, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000081; Hochmeister S, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00031; Hohlfeld R, 2016, LANCET NEUROL, V15, P198, DOI 10.1016/S1474-4422(15)00334-8; Horellou P, 2015, J NEUROIMMUNOL, V289, P1, DOI 10.1016/j.jneuroim.2015.10.002; Iglesias A, 2001, GLIA, V36, P220, DOI 10.1002/glia.1111; Kebir H, 2009, ANN NEUROL, V66, P390, DOI 10.1002/ana.21748; Ketelslegers IA, 2015, MULT SCLER J, V21, P1513, DOI 10.1177/1352458514566666; Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432; Komiyama Y, 2006, J IMMUNOL, V177, P566, DOI 10.4049/jimmunol.177.1.566; Kothur K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149411; Krishnamoorthy G, 2006, J CLIN INVEST, V116, P2385, DOI 10.1172/JCI28330; Kroepfl JF, 1996, J NEUROCHEM, V67, P2219; Langer-Gould A, 2011, NEUROLOGY, V77, P1143, DOI 10.1212/WNL.0b013e31822facdd; LEBAR R, 1986, CLIN EXP IMMUNOL, V66, P423; Machado-Santos J, 2018, BRAIN, V141, P2066, DOI 10.1093/brain/awy151; Mader S, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-184; Marta CB, 2003, J NEUROSCI, V23, P5461; Mayer MC, 2012, THER ADV NEUROL DISO, V5, P147, DOI 10.1177/1756285611433772; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; Ngono AE, 2012, CLIN IMMUNOL, V144, P117, DOI 10.1016/j.clim.2012.05.009; Nie H, 2013, NAT MED, V19, P322, DOI 10.1038/nm.3085; Pedotti R, 2001, NAT IMMUNOL, V2, P216, DOI 10.1038/85266; Peschl P, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0984-5; PIDDLESDEN SJ, 1993, AM J PATHOL, V143, P555; Pillai V, 2007, CLIN IMMUNOL, V123, P18, DOI 10.1016/j.clim.2006.10.014; Pilli D, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00652; Polansky JK, 2008, EUR J IMMUNOL, V38, P1654, DOI 10.1002/eji.200838105; Probstel AK, 2011, NEUROLOGY, V77, P580, DOI 10.1212/WNL.0b013e318228c0b1; Serguera C, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1637-7; 't Hart Bert A, 2019, Primate Biol, V6, P17, DOI 10.5194/pb-6-17-2019; Taylor SRJ, 2007, J IMMUNOL, V178, P3474, DOI 10.4049/jimmunol.178.6.3474; Vargas-Lowy D, 2013, CLIN IMMUNOL, V146, P176, DOI 10.1016/j.clim.2012.12.008; Varrin-Doyer M, 2012, ANN NEUROL, V72, P53, DOI 10.1002/ana.23651; Waters P, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000089; Zaunders JJ, 2009, J IMMUNOL, V183, P2827, DOI 10.4049/jimmunol.0803548	55	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 16	2021	12								679770	10.3389/fimmu.2021.679770	http://dx.doi.org/10.3389/fimmu.2021.679770			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TB9EP	34220827	Green Published, gold			2022-12-18	WOS:000668247700001
J	McLean, ARD; Opi, DH; Stanisic, DI; Cutts, JC; Feng, GQ; Ura, A; Mueller, I; Rogerson, SJ; Beeson, JG; Fowkes, FJI				McLean, Alistair R. D.; Opi, D. Herbert; Stanisic, Danielle, I; Cutts, Julia C.; Feng, Gaoqian; Ura, Alice; Mueller, Ivo; Rogerson, Stephen J.; Beeson, James G.; Fowkes, Freya J., I			High Antibodies to VAR2CSA in Response to Malaria Infection Are Associated With Improved Birthweight in a Longitudinal Study of Pregnant Women	FRONTIERS IN IMMUNOLOGY			English	Article						VAR2CSA antibodies; birthweight; placental infection; Papua New Guinea; malaria in pregnancy (MiP); Plasmodium falciparum	VARIANT SURFACE-ANTIGENS; CHONDROITIN SULFATE-A; PLASMODIUM-FALCIPARUM; PLACENTAL MALARIA; VAR GENE; ERYTHROCYTES; PROTECTION; ADHESION; BINDING; OUTCOMES	Introduction Pregnant women have an increased risk of P. falciparum infection, which is associated with low birth weight and preterm delivery. VAR2CSA, a variant surface antigen expressed on the parasitized erythrocyte surface, enables sequestration in the placenta. Few studies have prospectively examined relationships between antibody responses during pregnancy and subsequent adverse birth outcomes, and there are limited data outside Africa. Methods Levels of IgG against VAR2CSA domains (DBL3; DBL5) and a VAR2CSA-expressing placental-binding P. falciparum isolate (PfCS2-IE) were measured in 301 women enrolled at their first visit to antenatal care which occurred mid-pregnancy (median = 26 weeks, lower and upper quartiles = 22, 28). Associations between antibody levels at enrolment and placental infection, birthweight and estimated gestational age at delivery were assessed by linear and logistic regression with adjustment for confounders. For all outcomes, effect modification by gravidity and peripheral blood P. falciparum infection at enrolment was assessed. Results Among women who had acquired P. falciparum infection at enrolment, those with higher levels of VAR2CSA antibodies (75(th) percentile) had infants with higher mean birthweight (estimates varied from +35g to +149g depending on antibody response) and reduced adjusted odds of placental infection (aOR estimates varied from 0.17 to 0.80), relative to women with lower levels (25(th) percentile) of VAR2CSA antibodies. However, among women who had not acquired an infection at enrolment, higher VAR2CSA antibodies were associated with increased odds of placental infection (aOR estimates varied from 1.10 to 2.24). Conclusions When infected by mid-pregnancy, a better immune response to VAR2CSA-expressing parasites may contribute to protecting against adverse pregnancy outcomes.	[McLean, Alistair R. D.; Opi, D. Herbert; Cutts, Julia C.; Feng, Gaoqian; Beeson, James G.; Fowkes, Freya J., I] Burnet Inst, Melbourne, Vic, Australia; [McLean, Alistair R. D.] Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Med, Oxford, England; [Opi, D. Herbert] Monash Univ, Dept Immunol & Pathol, Melbourne, Vic, Australia; [Opi, D. Herbert; Cutts, Julia C.; Feng, Gaoqian; Rogerson, Stephen J.; Beeson, James G.] Univ Melbourne, Dept Med, Doherty Inst, Melbourne, Vic, Australia; [Stanisic, Danielle, I; Ura, Alice; Mueller, Ivo] Papua New Guinea Inst Med Res, Madang, Papua N Guinea; [Stanisic, Danielle, I] Griffith Univ, Inst Glyc, Southport, Qld, Australia; [Mueller, Ivo] Walter & Eliza Hall Inst Med Res, Populat Hlth & Immun Div, Parkville, Vic, Australia; [Mueller, Ivo] Inst Pasteur, Dept Parasites & Insectes Vecteurs, Paris, France; [Beeson, James G.] Monash Univ, Dept Microbiol, Clayton, Vic, Australia; [Fowkes, Freya J., I] Monash Univ, Cent Clin Sch, Dept Infect Dis, Melbourne, Vic, Australia; [Fowkes, Freya J., I] Univ Melbourne, Ctr Epidemiol & Biostat, Melbourne, Vic, Australia; [Fowkes, Freya J., I] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia	Burnet Institute; University of Oxford; Monash University; University of Melbourne; PNG Institute Of Medical Research; Griffith University; Walter & Eliza Hall Institute; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Monash University; Monash University; University of Melbourne; Monash University	Beeson, JG; Fowkes, FJI (corresponding author), Burnet Inst, Melbourne, Vic, Australia.; Beeson, JG (corresponding author), Univ Melbourne, Dept Med, Doherty Inst, Melbourne, Vic, Australia.; Beeson, JG (corresponding author), Monash Univ, Dept Microbiol, Clayton, Vic, Australia.; Fowkes, FJI (corresponding author), Monash Univ, Cent Clin Sch, Dept Infect Dis, Melbourne, Vic, Australia.; Fowkes, FJI (corresponding author), Univ Melbourne, Ctr Epidemiol & Biostat, Melbourne, Vic, Australia.; Fowkes, FJI (corresponding author), Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia.	beeson@burnet.edu.au; freya.fowkes@burnet.edu.au		McLean, Alistair/0000-0003-3449-7142; Stanisic, Danielle/0000-0003-3908-7468	National Health and Medical Research Council [1166753, 575534, 1092789, 1173046]; NHMRC Independent Research Institutes Infrastructure Support Scheme; Victorian State Government Operational Infrastructure Support; NHMRC	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Independent Research Institutes Infrastructure Support Scheme(National Health and Medical Research Council (NHMRC) of Australia); Victorian State Government Operational Infrastructure Support; NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by the National Health and Medical Research Council (NHMRC: Research Fellowship 1166753 to FF, Project grant 575534, Program Grant 1092789 to JB. and SR, and Investigator Grant 1173046 to JB). Burnet Institute is supported by NHMRC Independent Research Institutes Infrastructure Support Scheme and the Victorian State Government Operational Infrastructure Support. JB, SR, IM, FF, HO, and JC are members of the NHMRC-funded Australian Centre for Research Excellence in Malaria Elimination.	Aitken EH, 2010, J INFECT DIS, V201, P1316, DOI 10.1086/651578; Andersen P, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040042; Ataide R, 2014, TRENDS PARASITOL, V30, P85, DOI 10.1016/j.pt.2013.12.007; Ataide R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022491; Ataide R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010807; Avril M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-143; Barfod L, 2010, J IMMUNOL, V185, P7553, DOI 10.4049/jimmunol.1002390; Beeson JG, 2007, AM J TROP MED HYG, V77, P22, DOI 10.4269/ajtmh.2007.77.22; Beeson JG, 2006, J INFECT DIS, V193, P721, DOI 10.1086/500145; Beeson JG, 2004, J INFECT DIS, V189, P169, DOI 10.1086/380975; Beeson JG, 2004, J INFECT DIS, V189, P540, DOI 10.1086/381186; Boyle MJ, 2015, IMMUNITY, V42, P580, DOI 10.1016/j.immuni.2015.02.012; BULMER JN, 1993, HISTOPATHOLOGY, V22, P211, DOI 10.1111/j.1365-2559.1993.tb00110.x; BULMER JN, 1993, HISTOPATHOLOGY, V22, P219, DOI 10.1111/j.1365-2559.1993.tb00111.x; Chan JA, 2014, CELL MOL LIFE SCI, V71, P3633, DOI 10.1007/s00018-014-1614-3; Chan JA, 2012, J CLIN INVEST, V122, P3227, DOI 10.1172/JCI62182; Chandrasiri UP, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1597-7; Chene A, 2019, EBIOMEDICINE, V42, P145, DOI 10.1016/j.ebiom.2019.03.010; Cutts JC, 2020, BMC MED, V18, DOI 10.1186/s12916-019-1467-6; Duffy MF, 2005, MOL MICROBIOL, V56, P774, DOI 10.1111/j.1365-2958.2005.04577.x; Duffy MF, 2006, INFECT IMMUN, V74, P4875, DOI 10.1128/IAI.01978-05; Duffy PE, 2003, INFECT IMMUN, V71, P6620, DOI 10.1128/IAI.71.11.6620-6623.2003; Elliott SR, 2005, INFECT IMMUN, V73, P5903, DOI 10.1128/IAI.73.9.5903-5907.2005; Feng GQ, 2009, J INFECT DIS, V200, P299, DOI 10.1086/599841; Fernandez P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012558; Fried M, 1998, J MOL MED-JMM, V76, P162, DOI 10.1007/s001090050205; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Fried M, 1998, NATURE, V395, P851, DOI 10.1038/27570; Hommel M, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2653-7; Hommel M, 2010, INFECT IMMUN, V78, P1963, DOI 10.1128/IAI.01365-09; Irani V, 2015, CLIN INFECT DIS, V61, P1244, DOI 10.1093/cid/civ525; Kinyanjui SM, 2004, J IMMUNOL METHODS, V288, P9, DOI 10.1016/j.jim.2004.01.022; Mayor A, 2013, J INFECT DIS, V207, P1664, DOI 10.1093/infdis/jit083; MCGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232, DOI 10.1016/0035-9203(83)90081-0; Mclean ARD, 2015, PARASITOLOGY, V142, P999, DOI 10.1017/S0031182015000074; Mordmuller B, 2019, CLIN INFECT DIS, V69, P1509, DOI 10.1093/cid/ciy1140; Ndam NGT, 2006, J INFECT DIS, V193, P713, DOI 10.1086/500146; Ndam NGT, 2005, J INFECT DIS, V192, P331, DOI 10.1086/430933; Ndam NT, 2015, EMERG INFECT DIS, V21, P813, DOI 10.3201/eid2105.141626; Oleinikov AV, 2008, J INFECT DIS, V197, P1119, DOI 10.1086/529526; Oleinikov AV, 2007, J INFECT DIS, V196, P155, DOI 10.1086/518513; Persson KEM, 2008, J CLIN INVEST, V118, P342, DOI 10.1172/JCI32138; Requena P, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00163; Ricke CH, 2000, J IMMUNOL, V165, P3309, DOI 10.4049/jimmunol.165.6.3309; Rijken MJ, 2012, LANCET INFECT DIS, V12, P75, DOI 10.1016/S1473-3099(11)70315-2; ROGERSON SJ, 1995, J EXP MED, V182, P15, DOI 10.1084/jem.182.1.15; Salanti A, 2004, J EXP MED, V200, P1197, DOI 10.1084/jem.20041579; Salanti A, 2003, MOL MICROBIOL, V49, P179, DOI 10.1046/j.1365-2958.2003.03570.x; Serra-Casas E, 2010, J INFECT DIS, V201, P123, DOI 10.1086/648595; Staalsoe T, 2004, LANCET, V363, P283, DOI 10.1016/S0140-6736(03)15386-X; Stanisic DI, 2015, T ROY SOC TROP MED H, V109, P313, DOI 10.1093/trstmh/trv019; Stanisic DI, 2009, INFECT IMMUN, V77, P1165, DOI 10.1128/IAI.01129-08; Tutterrow YL, 2012, INFECT IMMUN, V80, P1479, DOI 10.1128/IAI.00071-12; WALTER PR, 1982, AM J PATHOL, V109, P330; Williamson EJ, 2014, RESPIROLOGY, V19, P303, DOI 10.1111/resp.12238	55	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 16	2021	12								644563	10.3389/fimmu.2021.644563	http://dx.doi.org/10.3389/fimmu.2021.644563			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TB7FW	34220804	gold, Green Published			2022-12-18	WOS:000668111300001
J	Berkebile, ZW; Putri, DS; Abrahante, JE; Seelig, DM; Schleiss, MR; Bierle, CJ				Berkebile, Zachary W.; Putri, Dira S.; Abrahante, Juan E.; Seelig, Davis M.; Schleiss, Mark R.; Bierle, Craig J.			The Placental Response to Guinea Pig Cytomegalovirus Depends Upon the Timing of Maternal Infection	FRONTIERS IN IMMUNOLOGY			English	Article						cytomegalovirus; congenital infection; inflammation; placenta; fetal membranes; guinea pig	TROPHOBLAST PROGENITOR CELLS; EXPRESSION ANALYSIS; GENE-EXPRESSION; GLYCOPROTEIN-B; PREGNANCY; VIRUS; ANTIBODY; DISTINCT; GROWTH; MODEL	Human cytomegalovirus (HCMV) infects the placenta, and these placental infections can cause fetal injury and/or demise. The timing of maternal HCMV infection during pregnancy is a determinant of fetal outcomes, but how development affects the placenta's susceptibility to infection, the likelihood of placental injury post-infection, and the frequency of transplacental HCMV transmission remains unclear. In this study, guinea pig cytomegalovirus (GPCMV) was used to model primary maternal infection and compare the effects of infection at two different times on the placenta. When guinea pigs were infected with GPCMV at either 21- or 35-days gestation (dGA), maternal and placental viral loads, as determined by droplet digital PCR, were not significantly affected by the timing of maternal infection. However, when the transcriptomes of gestational age-matched GPCMV-infected and control placentas were compared, significant infection-associated changes in gene expression were only observed after maternal infection at 35 dGA. Notably, transcripts associated with immune activation (e.g. Cxcl10, Ido1, Tgtp1, and Tlr8) were upregulated in the infected placenta. A GPCMV-specific in situ hybridization assay detected rare infected cells in the main placenta after maternal infection at either time, and maternal infection at 35 dGA also caused large areas of GPCMV-infected cells in the junctional zone. As GPCMV infection after mid-gestation is known to cause high rates of stillbirth and/or fetal growth restriction, our results suggest that the placenta becomes sensitized to infection-associated injury late in gestation, conferring an increased risk of adverse pregnancy outcomes after cytomegalovirus infection.	[Berkebile, Zachary W.; Putri, Dira S.; Schleiss, Mark R.; Bierle, Craig J.] Univ Minnesota, Div Pediat Infect Dis, Dept Pediat, Minneapolis, MN USA; [Abrahante, Juan E.] Univ Minnesota, Inst Informat, Minneapolis, MN USA; [Seelig, Davis M.] Univ Minnesota, Dept Vet Clin Sci, Minneapolis, MN USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Bierle, CJ (corresponding author), Univ Minnesota, Div Pediat Infect Dis, Dept Pediat, Minneapolis, MN USA.	cjbierle@umn.edu		Abrahante, Juan/0000-0002-9074-4307; Bierle, Craig/0000-0002-7890-7409; Berkebile, Zachary/0000-0002-9318-7470	Minnesota Masonic Charities (Masonic Early Investigator Award); National Institutes of Health [R21HD087496, R01HD098866, UL1TR002494]	Minnesota Masonic Charities (Masonic Early Investigator Award); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This project was supported by grants from the Minnesota Masonic Charities (Masonic Early Investigator Award) and the National Institutes of Health (R21HD087496, R01HD098866, and UL1TR002494).	Auerbach MR, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004060; Bakaysa SL, 2014, MOL HUM REPROD, V20, P701, DOI 10.1093/molehr/gau028; Bierle CJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187720; Bodeus M, 1999, OBSTET GYNECOL, V93, P658, DOI 10.1016/S0029-7844(98)00538-9; Bodeus M, 2010, J CLIN VIROL, V47, P201, DOI 10.1016/j.jcv.2009.11.009; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Britt William J, 2010, Curr Protoc Microbiol, VChapter 14, DOI 10.1002/9780471729259.mc14e03s18; Butler H., 1987, ATLAS STAGING MAMMAL; Chatzakis C, 2020, AM J OBSTET GYNECOL, V223, P870, DOI 10.1016/j.ajog.2020.05.038; CHOI YC, 1978, J INFECT DIS, V138, P197, DOI 10.1093/infdis/138.2.197; Cross SN, 2017, J IMMUNOL, V199, P2885, DOI 10.4049/jimmunol.1700870; Davis NL, 2017, BIRTH DEFECTS RES, V109, P336, DOI 10.1002/bdra.23601; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Faure-Bardon V, 2019, CLIN INFECT DIS, V69, P1526, DOI 10.1093/cid/ciy1128; FONG CKY, 1983, LAB INVEST, V49, P183; Foulon I, 2008, J PEDIATR-US, V153, P84, DOI 10.1016/j.jpeds.2007.12.049; GARCIA AGP, 1989, PLACENTA, V10, P1; Gervasi MT, 2012, J MATERN-FETAL NEO M, V25, P2002, DOI 10.3109/14767058.2012.683899; Gervasi MT, 2012, J PERINAT MED, V40, P329, DOI 10.1515/jpm-2012-0034; Gibson CS, 2008, BJOG-INT J OBSTET GY, V115, P492, DOI 10.1111/j.1471-0528.2007.01653.x; Gindes L, 2008, BJOG-INT J OBSTET GY, V115, P830, DOI 10.1111/j.1471-0528.2007.01651.x; Goldstein JA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.531543; GRIFFITH BP, 1983, J INFECT DIS, V147, P990, DOI 10.1093/infdis/147.6.990; GRIFFITH BP, 1980, J INFECT DIS, V141, P787, DOI 10.1093/infdis/141.6.787; GRIFFITH BP, 1986, AM J PATHOL, V122, P112; GRIFFITH BP, 1982, PEDIATR RES, V16, P455, DOI 10.1203/00006450-198206000-00010; GRIFFITH BP, 1985, J VIROL, V55, P402, DOI 10.1128/JVI.55.2.402-409.1985; Harman MT, 1933, J MORPHOL, V54, P493, DOI 10.1002/jmor.1050540306; HARRISON CJ, 1995, J INFECT DIS, V172, P1212, DOI 10.1093/infdis/172.5.1212; HARRISON CJ, 1990, J MED VIROL, V31, P222, DOI 10.1002/jmv.1890310309; HARTLEY JW, 1957, P SOC EXP BIOL MED, V96, P281; Hoying JJ., 1975, SELECTION HISTOCHEMI; Iwasenko JM, 2011, J INFECT DIS, V203, P1526, DOI 10.1093/infdis/jir121; Kaufmann P, 1977, Adv Anat Embryol Cell Biol, V53, P5; Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199; Kenneson A, 2007, REV MED VIROL, V17, P253, DOI 10.1002/rmv.535; Kourtis AP, 2014, NEW ENGL J MED, V370, P2211, DOI 10.1056/NEJMra1213566; Kumar D, 2016, PLACENTA, V42, P59, DOI 10.1016/j.placenta.2016.03.015; KUMAR ML, 1983, AM J OBSTET GYNECOL, V145, P56, DOI 10.1016/0002-9378(83)90339-3; Lee J, 2013, PLACENTA, V34, P681, DOI 10.1016/j.placenta.2013.04.014; Lee J, 2013, AM J REPROD IMMUNOL, V70, P265, DOI 10.1111/aji.12142; Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214; Lipitz S, 2013, ULTRASOUND OBST GYN, V41, P508, DOI 10.1002/uog.12377; Lopez H, 2011, PLACENTA, V32, P522, DOI 10.1016/j.placenta.2011.04.016; Maidji E, 2010, AM J PATHOL, V177, P1298, DOI 10.2353/ajpath.2010.091210; McCarthy R, 2018, BIOL REPROD, V99, P922, DOI 10.1093/biolre/ioy109; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Mess A, 2007, PLACENTA, V28, P1234, DOI 10.1016/j.placenta.2007.08.003; Metsalu T, 2015, NUCLEIC ACIDS RES, V43, pW566, DOI 10.1093/nar/gkv468; Miller TE, 2021, J PEDIAT INF DIS SOC, V10, P562, DOI 10.1093/jpids/piaa154; Mocarski Jr E, 2013, FIELDS VIROLOGY, V2, P1960; Mor G, 2017, NAT REV IMMUNOL, V17, P469, DOI 10.1038/nri.2017.64; Morris JH, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-436; Morrison JL, 2018, J PHYSIOL-LONDON, V596, P5535, DOI 10.1113/JP274948; MUHLEMANN K, 1992, HUM PATHOL, V23, P1234, DOI 10.1016/0046-8177(92)90290-J; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Nozawa N, 2008, VIROLOGY, V379, P45, DOI 10.1016/j.virol.2008.06.018; Oesper L, 2011, SOURCE CODE BIOL MED, V6, DOI 10.1186/1751-0473-6-7; PANHANI S, 1994, SCAND J INFECT DIS, V26, P375, DOI 10.3109/00365549409008607; Pass RF, 2006, J CLIN VIROL, V35, P216, DOI 10.1016/j.jcv.2005.09.015; Pereira L, 2018, ANNU REV VIROL, V5, P273, DOI 10.1146/annurev-virology-092917-043236; Pereira L, 2014, J INFECT DIS, V209, P1573, DOI 10.1093/infdis/jiu019; Picone O, 2013, PRENATAL DIAG, V33, P751, DOI 10.1002/pd.4118; Potter JA, 2020, J REPROD IMMUNOL, V140, DOI 10.1016/j.jri.2020.103126; PREECE PM, 1983, ARCH DIS CHILD, V58, P970, DOI 10.1136/adc.58.12.970; Putri DS, 2020, VIROLOGY, V548, P93, DOI 10.1016/j.virol.2020.06.005; Raudvere U, 2019, NUCLEIC ACIDS RES, V47, pW191, DOI 10.1093/nar/gkz369; Reimand J, 2019, NAT PROTOC, V14, P482, DOI 10.1038/s41596-018-0103-9; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Romero R, 2007, SEMIN REPROD MED, V25, P21, DOI 10.1055/s-2006-956773; Romero R, 2017, AM J REPROD IMMUNOL, V78, DOI 10.1111/aji.12685; Schleiss MR, 2004, J INFECT DIS, V189, P1374, DOI 10.1086/382751; Scott GM, 2012, J INFECT DIS, V205, P1305, DOI 10.1093/infdis/jis186; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shi TL, 2018, J CLIN VIROL, V104, P48, DOI 10.1016/j.jcv.2018.04.016; SINZGER C, 1993, VIRCHOWS ARCH A, V423, P249, DOI 10.1007/BF01606887; Siren J, 2014, IEEE ACM T COMPUT BI, V11, P375, DOI 10.1109/TCBB.2013.2297101; Soncin F, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.156273; Tabata T, 2016, AM J PATHOL, V186, P2970, DOI 10.1016/j.ajpath.2016.07.016; Tabata T, 2016, CELL HOST MICROBE, V20, P155, DOI 10.1016/j.chom.2016.07.002; Tabata T, 2015, J VIROL, V89, P5134, DOI 10.1128/JVI.03674-14; Tabata T, 2012, AM J PATHOL, V181, P1540, DOI 10.1016/j.ajpath.2012.08.003; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Tsuge M, 2019, J PEDIATR-US, V206, P42, DOI 10.1016/j.jpeds.2018.10.003; Uenaka M, 2019, PLACENTA, V75, P62, DOI 10.1016/j.placenta.2019.01.003; Weisblum Y, 2017, J VIROL, V91, DOI [10.1128/JVI.01905-16, 10.1128/jvi.01905-16]; Weisblum Y, 2015, VIROLOGY, V485, P289, DOI 10.1016/j.virol.2015.06.023; Wright S., 1922, EFFECTS INBREEDING C; Yang DM, 2013, GENOME ANNOUNCEMENTS, V1, DOI 10.1128/genomeA.00054-13; Yockey LJ, 2020, SCIENCE, V368, P608, DOI 10.1126/science.aaz1960; Yockey LJ, 2018, IMMUNITY, V49, P397, DOI 10.1016/j.immuni.2018.07.017; Yoshimura K, 2005, J SOC GYNECOL INVEST, V12, P533, DOI 10.1016/j.jsgi.2005.06.006; Zydek M, 2014, VIRUSES-BASEL, V6, P1346, DOI 10.3390/v6031346	93	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 15	2021	12								686415	10.3389/fimmu.2021.686415	http://dx.doi.org/10.3389/fimmu.2021.686415			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TB1AF	34211475	Green Published, gold			2022-12-18	WOS:000667673800001
J	Chibssa, TR; Kangethe, RT; Berguido, FJ; Settypalli, TBK; Liu, Y; Grabherr, R; Loitsch, A; Sassu, EL; Pichler, R; Cattoli, G; Diallo, A; Wijewardana, V; Lamien, CE				Chibssa, Tesfaye Rufael; Kangethe, Richard Thiga; Berguido, Francisco J.; Settypalli, Tirumala Bharani K.; Liu, Yang; Grabherr, Reingard; Loitsch, Angelika; Sassu, Elena Lucia; Pichler, Rudolf; Cattoli, Giovanni; Diallo, Adama; Wijewardana, Viskam; Lamien, Charles Euloge			Innate Immune Responses to Wildtype and Attenuated Sheeppox Virus Mediated Through RIG-1 Sensing in PBMC In-Vitro	FRONTIERS IN IMMUNOLOGY			English	Article						gene expression; PRRs; cytokine; RIG-1; LAV; SPPV	EXPERIMENTAL-INFECTION; N1L PROTEIN; VACCINE; BLOOD; GOATS	Sheeppox (SPP) is a highly contagious disease of small ruminants caused by sheeppox virus (SPPV) and predominantly occurs in Asia and Africa with significant economic losses. SPPV is genetically and immunologically closely related to goatpox virus (GTPV) and lumpy skin disease virus (LSDV), which infect goats and cattle respectively. SPPV live attenuated vaccines (LAVs) are used for vaccination against SPP and goatpox (GTP). Mechanisms related to innate immunity elicited by SPPV are unknown. Although adaptive immunity is responsible for long-term immunity, it is the innate responses that prevent viral invasion and replication before LAVs generate specific long-term protection. We analyzed the relative expression of thirteen selected genes that included pattern recognition receptors (PRRs), Nuclear factor-kappa beta p65 (NF-kappa beta), and cytokines to understand better the interaction between SPPV and its host. The transcripts of targeted genes in sheep PBMC incubated with either wild type (WT) or LAV SPPV were analyzed using quantitative PCR. Among PRRs, we observed a significantly higher expression of RIG-1 in PBMC incubated with both WT and LAV, with the former producing the highest expression level. However, there was high inter-individual variability in cytokine transcripts levels among different donors, with the expression of TNF alpha, IL-15, and IL-10 all significantly higher in both PBMC infected with either WT or LAV compared to control PBMC. Correlation studies revealed a strong significant correlation between RIG-1 and IL-10, between TLR4, TNF alpha, and NF-kappa beta, between IL-18 and IL-15, and between NF-kappa beta and IL-10. There was also a significant negative correlation between RIG-1 and IFN gamma, between TLR3 and IL-1 beta, and between TLR4 and IL-15 (P< 0.05). This study identified RIG-1 as an important PRR in the signaling pathway of innate immune activation during SPPV infection, possibly through intermediate viral dsRNA. The role of immunomodulatory molecules produced by SPPV capable of inhibiting downstream signaling activation following RIG-1 upregulation is discussed. These findings advance our knowledge of the induction of immune responses by SPPV and will help develop safer and more potent vaccines against SPP and GTP.	[Chibssa, Tesfaye Rufael; Kangethe, Richard Thiga; Berguido, Francisco J.; Settypalli, Tirumala Bharani K.; Sassu, Elena Lucia; Pichler, Rudolf; Cattoli, Giovanni; Wijewardana, Viskam; Lamien, Charles Euloge] IAEA, Anim Prod & Hlth Lab, Joint FAO IAEA Agr & Biotechnol Lab, Div Nucl Tech Food & Agr,Dept Nucl Sci & Applicat, Vienna, Austria; [Chibssa, Tesfaye Rufael; Grabherr, Reingard] Univ Nat Resources & Life Sci BOKU, Inst Biotechnol, Vienna, Austria; [Chibssa, Tesfaye Rufael] Natl Anim Hlth Diagnost & Invest Ctr NAHDIC, Sebeta, Ethiopia; [Liu, Yang] Capital Med Univ, Beijing Tiantan Hosp, China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China; [Loitsch, Angelika] Austrian Agcy Hlth & Food Safety AGES, Vienna, Austria; [Sassu, Elena Lucia] Univ Vet Med, Univ Clin Swine, Dept Farm Anim & Vet Publ Hlth, Vienna, Austria; [Diallo, Adama] Inst Senegalais Rech Agr ISRA, Lab Natl Elevage & Rech Vet, Dakar, Senegal; [Diallo, Adama] UMR CIRAD INRA, Anim Sante Terr Risques & Ecosyst ASTRE, Montpellier, France	International Atomic Energy Agency; University of Natural Resources & Life Sciences, Vienna; Capital Medical University; University of Veterinary Medicine Vienna; CIRAD; INRAE	Kangethe, RT (corresponding author), IAEA, Anim Prod & Hlth Lab, Joint FAO IAEA Agr & Biotechnol Lab, Div Nucl Tech Food & Agr,Dept Nucl Sci & Applicat, Vienna, Austria.	R.T.Kangethe@iaea.org	Kangethe, Richard/GWZ-3122-2022	Liu, Yang/0000-0003-2108-3207; Kangethe, Richard/0000-0002-2598-9324; Rufael, Tesfaye/0000-0001-7865-4301				Abu-EL-Saad AAS, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-22; Babiuk S, 2008, TRANSBOUND EMERG DIS, V55, P263, DOI 10.1111/j.1865-1682.2008.01043.x; Bartlett N, 2002, J GEN VIROL, V83, P1965, DOI 10.1099/0022-1317-83-8-1965; Boshra H, 2015, ANTIVIR RES, V123, P39, DOI 10.1016/j.antiviral.2015.08.016; CARN VM, 1993, VACCINE, V11, P1275, DOI 10.1016/0264-410X(93)90094-E; Chibssa TR, 2018, VIROL J, V15, DOI 10.1186/s12985-018-0969-8; de Motes CM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002430; DiPerna G, 2004, J BIOL CHEM, V279, P36570, DOI 10.1074/jbc.M400567200; Dixit E, 2013, ADV IMMUNOL, V117, P99, DOI 10.1016/B978-0-12-410524-9.00004-9; Embury-Hyatt C, 2012, J COMP PATHOL, V146, P106, DOI 10.1016/j.jcpa.2011.12.001; Gulbahar MY, 2006, VET PATHOL, V43, P67, DOI 10.1354/vp.43-1-67; Hamdi J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65856-7; Iyer SS, 2012, CRIT REV IMMUNOL, V32, P23, DOI 10.1615/CritRevImmunol.v32.i1.30; Kangethe RT, 2018, VET IMMUNOL IMMUNOP, V197, P39, DOI 10.1016/j.vetimm.2018.01.009; Kitching R. P., 2003, VVolume 114, P161; Lamien CE, 2011, J VIROL METHODS, V171, P134, DOI 10.1016/j.jviromet.2010.10.014; McFadden G, 2005, NAT REV MICROBIOL, V3, P201, DOI 10.1038/nrmicro1099; Moss B, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a010199; Norian R., 2017, Research in Molecular Medicine, V5, P3, DOI 10.29252/rmm.5.2.3; Norian R., 2016, IRAN J VIROL, V10, P1, DOI [10.21859/isv.10.4.1, DOI 10.21859/ISV.10.4.1]; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; REED L. J., 1938, AMER JOUR HYG, V27, P493; Rubins KH, 2004, P NATL ACAD SCI USA, V101, P15190, DOI 10.1073/pnas.0405759101; Sassu EL, 2020, VET IMMUNOL IMMUNOP, V227, DOI 10.1016/j.vetimm.2020.110092; Settypalli TBK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153688; Smith GL, 2018, ADV VIRUS RES, V100, P355, DOI 10.1016/bs.aivir.2018.01.003; Takeuchi O, 2007, IMMUNOL REV, V220, P214, DOI 10.1111/j.1600-065X.2007.00562.x; Tulman ER, 2002, J VIROL, V76, P6054, DOI 10.1128/JVI.76.12.6054-6061.2002; Tuppurainen ESM, 2014, ANTIVIR RES, V109, P1, DOI 10.1016/j.antiviral.2014.06.009; Weber O, 2007, POXVIRUSES, P167; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wolff J, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12101098; Wong PS, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10120692; Yaqoob P, 1999, CYTOKINE, V11, P600, DOI 10.1006/cyto.1998.0471; Zhang ZN, 2005, ANN NY ACAD SCI, V1056, P69, DOI 10.1196/annals.1352.005	35	0	0	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 15	2021	12								666543	10.3389/fimmu.2021.666543	http://dx.doi.org/10.3389/fimmu.2021.666543			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TB2VX	34211465	Green Published, gold			2022-12-18	WOS:000667807900001
J	Li, XH; Lu, MY; Li, YJ; Liu, ZH; Yin, ZN; Liu, B; Wu, YZ				Li, Xiao-Hong; Lu, Mei-Yin; Li, Yi-jia; Liu, Zong-hua; Yin, Zhi-nan; Liu, Bin; Wu, Yang-zhe			Circulating PD1(+)V delta 1(+)gamma delta T Cell Predicts Fertility in Endometrial Polyp Patients of Reproductive-Age	FRONTIERS IN IMMUNOLOGY			English	Article						endometrial polyp; fertility; biomarker; gamma delta T cells; PD-1	PREGNANCY OUTCOMES; IMMUNE-SYSTEM; MECHANISMS	Clinically, immune cell function is correlated with pathogenesis of endometrial polyp (EP) and infertility of women of reproductive-age. However, the underlying immune cell hallmark in EP patients remains unclear. Here, we focused on analyzing circulating immune cells, and attempted to reveal the correlation between peripheral immune cell functional phenotypes and fertility in EP patients. Through comparison of circulating CD4(+)/CD8(+) T cells, NK cells, and gamma delta T cells between 64 EP patients and 68 healthy females, we found that gamma delta T cells, but not CD4(+)/CD8(+) T cells and NK cells, were immunologically correlated with conception rate and conception interval time. Specifically, total gamma delta T cells and the V delta 1(+)PD1(+) gamma delta T subpopulation decreased whereas the V delta 1/V delta 2 ratio increased in EP patients compared to healthy controls. Moreover, the patients with the higher V delta 1/V delta 2 ratio (median value equals 1.04) had a poorer fertility and longer interval time of conception (210 days versus 158 days for control). Meanwhile, higher V delta 1(+)PD1(+) gamma delta T cell proportion (median equals 15.7) was positively correlative with both higher conception rate and shortened median conception interval time (130 days for V delta 1(+)PD1(high) group versus 194 days for V delta 1(+)PD1(low) group). Notably, in healthy controls, both V delta 1/V delta 2 ratio and V delta 1(+)PD1(+) gamma delta T cell proportion correlated with pregnancy rate oppositely, comparing to EP patients. Together, our results suggested that imbalanced gamma delta T cell population occurred in EP patients, and that V delta 1/V delta 2 ratio and PD-1 expression of V delta 1(+) gamma delta T cells could be potentially developed into valuable predictors for fertility in EP patients.	[Li, Xiao-Hong] Jinan Univ, Shenzhen Baoan Womens & Childrens Hosp, Dept Obstet & Gynecol, Shenzhen, Peoples R China; [Lu, Mei-Yin; Liu, Bin] Jinan Univ, Shenzhen Baoan Womens & Childrens Hosp, Dept Biobank, Shenzhen, Peoples R China; [Li, Yi-jia; Yin, Zhi-nan; Wu, Yang-zhe] Jinan Univ, Zhuhai Hosp, Zhuhai Peoples Hosp, Zhuhai Inst Translat Med, Zhuhai, Peoples R China; [Li, Yi-jia; Liu, Zong-hua; Yin, Zhi-nan] Jinan Univ, Biomed Translat Res Inst, Fac Med Sci, Guangzhou, Peoples R China	Jinan University; Jinan University; Jinan University; Jinan University	Liu, B (corresponding author), Jinan Univ, Shenzhen Baoan Womens & Childrens Hosp, Dept Biobank, Shenzhen, Peoples R China.; Wu, YZ (corresponding author), Jinan Univ, Zhuhai Hosp, Zhuhai Peoples Hosp, Zhuhai Inst Translat Med, Zhuhai, Peoples R China.	gz12liubin@163.com; tyzwu@jnu.edu.cn	Liu, Bin/AAP-2376-2020	Liu, Bin/0000-0001-5785-2579; Lu, Mei-Yin/0000-0002-1358-8187	Research Foundation of Shenzhen Baoan Women's and Children's Hospital, Jinan University [BAFY 2020005]	Research Foundation of Shenzhen Baoan Women's and Children's Hospital, Jinan University	This work was supported by Research Foundation of Shenzhen Baoan Women's and Children's Hospital, Jinan University to BL (BAFY 2020005).	AAGL Advancing Minimally Invasive, 2012, J MINIM INVAS GYN, V19, P3, DOI 10.1016/j.jmig.2011.09.003; Bosteels J, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009461.pub4; Caccamo N, 2013, CELL MOL IMMUNOL, V10, P30, DOI 10.1038/cmi.2012.42; Chang RQ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1380-0; El-Hamarneh T, 2013, FERTIL STERIL, V100, P1364, DOI 10.1016/j.fertnstert.2013.06.050; Kabelitz D, 2013, INT IMMUNOPHARMACOL, V16, P382, DOI 10.1016/j.intimp.2013.01.022; Liu ZQ, 2019, J ONCOL, V2019, DOI 10.1155/2019/5935640; Lorincz J, 2019, ARCH GYNECOL OBSTET, V300, P217, DOI 10.1007/s00404-019-05155-3; McCarthy NE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00985; Mincheva-Nilsson Lucia, 2003, Reprod Biol Endocrinol, V1, P120, DOI 10.1186/1477-7827-1-120; Mor G, 2010, AM J REPROD IMMUNOL, V63, P425, DOI 10.1111/j.1600-0897.2010.00836.x; Munro MG, 2011, INT J GYNECOL OBSTET, V113, P3, DOI 10.1016/j.ijgo.2010.11.011; Peng G, 2007, IMMUNITY, V27, P334, DOI 10.1016/j.immuni.2007.05.020; PrabhuDas M, 2015, NAT IMMUNOL, V16, P328, DOI 10.1038/ni.3131; Racicot K, 2014, AM J REPROD IMMUNOL, V72, P107, DOI 10.1111/aji.12289; Romer T, 2006, GYNECOL ENDOCRINOL, V22, P140, DOI 10.1080/09513590600629068; Schatz F, 2016, HUM REPROD UPDATE, V22, P497, DOI 10.1093/humupd/dmw004; Silva-Santos B, 2019, NAT REV CANCER, V19, P392, DOI 10.1038/s41568-019-0153-5; Sun HY, 2019, CELL MOL IMMUNOL, V16, P205, DOI 10.1038/s41423-018-0192-y; Takahashi H, 2018, J PREGNANCY, V2018, DOI 10.1155/2018/4382084; Toth M, 2007, AM J REPROD IMMUNOL, V57, P361, DOI 10.1111/j.1600-0897.2007.00481.x; Vallve-Juanico J, 2019, HUM REPROD UPDATE, V25, P565, DOI 10.1093/humupd/dmz018; Wouk N, 2019, AM FAM PHYSICIAN, V99, P435; Ye J, 2013, J IMMUNOL, V190, P2403, DOI 10.4049/jimmunol.1202369; Zhang HX, 2019, J MINIM INVAS GYN, V26, P618, DOI 10.1016/j.jmig.2018.10.024; Zhu YL, 2018, CLIN EXP PHARMACOL P, V45, P1128, DOI 10.1111/1440-1681.12994; Zhu YL, 2018, CLIN EXP PHARMACOL P, V45, P507, DOI 10.1111/1440-1681.12913	27	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 15	2021	12								639221	10.3389/fimmu.2021.639221	http://dx.doi.org/10.3389/fimmu.2021.639221			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TB0UZ	34211457	Green Published, gold			2022-12-18	WOS:000667660100001
J	Wu, M; Liu, J; Seery, S; Meng, X; Yue, JB				Wu, Min; Liu, Jie; Seery, Samuel; Meng, Xue; Yue, Jinbo			Cytoreductive Nephrectomy Promoted Abscopal Effect of Camrelizumab Combined With Radiotherapy for Metastatic Renal Cell Carcinoma: A Case Report and Review of the Literature	FRONTIERS IN IMMUNOLOGY			English	Review						clear cell renal cell carcinoma; camrelizumab; abscopal effect; pseudoprogression; MLR	C-REACTIVE PROTEIN; IMMUNE-RELATED RESPONSE; CHECKPOINT BLOCKADE; RADIATION-THERAPY; IMPROVED SURVIVAL; SOLID TUMORS; CANCER; PATIENT; MACROPHAGES; RESISTANCE	There is little evidence around Camrelizumab combined with cytoreductive nephrectomy (CN) and radiotherapy (RT) as a treatment option for metastatic renal cell carcinoma (mRCC). The influence of CN on immune responses and the abscopal effect are not well understood. In this paper, we report a case of anti-programmed cell death-1 (PD-1) treated with combined RT once CN reduced the primary tumor burden (TB). This patient also encountered an increased response to targeted radiotherapy after immune resistance. We also observed a macrophage-to-lymphocyte ratio (MLR) peak, which may be correlated with subsequent pseudoprogression after thoracic radiotherapy. Consequently, even with the disease, this patient has remained stable. This peculiar instance suggests there is a need to investigate the underlying mechanisms of CN in promoting the abscopal effect during immunotherapy when combined with RT. It also suggests that there is a need for further investigation into the role of RT in overcoming immune resistance, and the value of MLR in predicting pseudoprogression. We hypothesize that a heavy tumor burden might suppress the abscopal effect, thereby ensuring that CN promotes it. However, radiotherapy may overcome immune resistance during oligoprogression.	[Wu, Min; Meng, Xue; Yue, Jinbo] Shandong Univ, Cheeloo Coll Med, Jinan, Peoples R China; [Wu, Min; Liu, Jie; Meng, Xue; Yue, Jinbo] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China; [Seery, Samuel] Univ Lancaster, Fac Hlth & Med, Hlth Res, Lancaster, England	Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; Lancaster University	Meng, X; Yue, JB (corresponding author), Shandong Univ, Cheeloo Coll Med, Jinan, Peoples R China.; Meng, X; Yue, JB (corresponding author), Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China.	mengxuesdzl@163.com; jbyue@sdfmu.edu.cn			National Natural Science Foundation of China [81871895]; Young Taishan Scholars and Academic Promotion Program of Shandong First Medical University [2019RC003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Young Taishan Scholars and Academic Promotion Program of Shandong First Medical University	This work was supported by the following grants: National Natural Science Foundation of China (Grant No. 81871895), Young Taishan Scholars and Academic Promotion Program of Shandong First Medical University (Grant No. 2019RC003).	Aben KKH, 2011, EUR J CANCER, V47, P2023, DOI 10.1016/j.ejca.2011.03.002; Atkins MB, 2018, LANCET ONCOL, V19, P405, DOI 10.1016/S1470-2045(18)30081-0; Barata PC, 2017, CA-CANCER J CLIN, V67, P507, DOI 10.3322/caac.21411; Ben Nasr M, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam7543; Borcoman E, 2019, ANN ONCOL, V30, P385, DOI 10.1093/annonc/mdz003; Cella D, 2019, LANCET ONCOL, V20, P297, DOI 10.1016/S1470-2045(18)30778-2; Champiat S, 2017, CLIN CANCER RES, V23, P1920, DOI 10.1158/1078-0432.CCR-16-1741; Chang LS, 2019, ENDOCR REV, V40, P17, DOI 10.1210/er.2018-00006; Chen D., 2020, INT J RADIAT ONCOL, V8, DOI [10.1016/j.ijrobp.2020.07.1687, DOI 10.1016/J.IJROBP.2020.07.1687]; Chiou VL, 2015, J CLIN ONCOL, V33, P3541, DOI 10.1200/JCO.2015.61.6870; Choueiri TK, 2016, CLIN CANCER RES, V22, P5461, DOI 10.1158/1078-0432.CCR-15-2839; Deloch L, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/3161750; DeNardo DG, 2019, NAT REV IMMUNOL, V19, P369, DOI 10.1038/s41577-019-0127-6; Deng LF, 2014, J CLIN INVEST, V124, P687, DOI 10.1172/JCI67313; Desai J, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000453; Di Giacomo AM, 2009, CANCER IMMUNOL IMMUN, V58, P1297, DOI 10.1007/s00262-008-0642-y; Ferrara R, 2018, JAMA ONCOL, V4, P1543, DOI 10.1001/jamaoncol.2018.3676; Flanigan RC, 2004, J UROLOGY, V171, P1071, DOI 10.1097/01.ju.0000110610.61545.ae; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Golden EB, 2015, LANCET ONCOL, V16, P795, DOI 10.1016/S1470-2045(15)00054-6; Grimaldi AM, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28780; Guo LP, 2020, J PATHOL, V251, P26, DOI 10.1002/path.5396; Hodi FS, 2018, J CLIN ONCOL, V36, P850, DOI 10.1200/JCO.2017.75.1644; Hughes J, 2015, DIABETES CARE, V38, pe55, DOI 10.2337/dc14-2349; Ishizuka JJ, 2019, NATURE, V565, P43, DOI 10.1038/s41586-018-0768-9; Ito H, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-337; Jia WX, 2019, CANCER BIOL MED, V16, P655, DOI 10.20892/j.issn.2095-3941.2019.0144; Kalogirou C, 2017, UROL INT, V99, P297, DOI 10.1159/000475932; Khene ZE, 2020, EUR UROL, V78, P288, DOI 10.1016/j.eururo.2020.04.002; Kim CG, 2019, ANN ONCOL, V30, P1104, DOI 10.1093/annonc/mdz123; Kim SH, 2020, J CANCER RES CLIN, V146, P3025, DOI 10.1007/s00432-020-03293-9; Klug F, 2013, CANCER CELL, V24, P589, DOI 10.1016/j.ccr.2013.09.014; Koller KM, 2017, CANCER BIOL THER, V18, P36, DOI 10.1080/15384047.2016.1264543; Lalani AKA, 2019, EUR UROL, V75, P100, DOI 10.1016/j.eururo.2018.10.010; Levitin M, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.566070; Liu Y, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0647-8; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Movahedi K, 2010, CANCER RES, V70, P5728, DOI 10.1158/0008-5472.CAN-09-4672; Ngwa W, 2018, NAT REV CANCER, V18, P313, DOI 10.1038/nrc.2018.6; Nishino M, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0134-0; Park HJ, 2020, RADIOLOGY, V297, P87, DOI 10.1148/radiol.2020200443; Rana R., 2014, EUR UROL, V23, P1, DOI [10.1016/j.eururo.2013.08.012.Impact, DOI 10.1016/J.EURURO.2013.08.012.IMPACT]; Sade-Feldman M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01062-w; Sakai I, 2014, INT J CLIN ONCOL, V19, P674, DOI 10.1007/s10147-013-0612-z; Schoenfeld AJ, 2020, J CLIN ONCOL, V38; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Singavi AK, 2017, ANN ONCOL, V28; Singla N, 2020, UROL ONCOL-SEMIN ORI, V38, DOI 10.1016/j.urolonc.2020.02.029; Stamatouli A, 2018, DIABETES, V67, P1471, DOI 10.2337/dbi18-0002; Tanaka N, 2014, EUR UROL, V65, P227, DOI 10.1016/j.eururo.2012.11.050; Tatokoro M, 2008, J UROLOGY, V180, P515, DOI 10.1016/j.juro.2008.04.025; Telo GH, 2017, ANN ONCOL, V28, P191, DOI 10.1093/annonc/mdw447; Terakawa T, 2013, UROL ONCOL-SEMIN ORI, V31, P493, DOI 10.1016/j.urolonc.2011.02.012; Thian Y, 2014, RADIOLOGY, V273, P452, DOI 10.1148/radiol.14132702; Van de Walle M, 2017, ACTA CLIN BELG, V72, P245, DOI 10.1080/17843286.2016.1201614; Wallington DG, 2020, ADV RADIAT ONCOL, V5, P503, DOI 10.1016/j.adro.2020.02.006; Wang XH, 2017, CANCER RES, V77, P839, DOI 10.1158/0008-5472.CAN-15-3142; Xie GZ, 2017, CANCER BIOL THER, V18, P547, DOI 10.1080/15384047.2017.1345389	58	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 15	2021	12								646085	10.3389/fimmu.2021.646085	http://dx.doi.org/10.3389/fimmu.2021.646085			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TB0TJ	34211459	gold, Green Published			2022-12-18	WOS:000667655700001
J	Fifita, JA; Fat, SCM; McCann, EP; Williams, KL; Twine, NA; Bauer, DC; Rowe, DB; Pamphlett, R; Kiernan, MC; Tan, VX; Blair, IP; Guillemin, GJ				Fifita, Jennifer A.; Chan Moi Fat, Sandrine; McCann, Emily P.; Williams, Kelly L.; Twine, Natalie A.; Bauer, Denis C.; Rowe, Dominic B.; Pamphlett, Roger; Kiernan, Matthew C.; Tan, Vanessa X.; Blair, Ian P.; Guillemin, Gilles J.			Genetic Analysis of Tryptophan Metabolism Genes in Sporadic Amyotrophic Lateral Sclerosis	FRONTIERS IN IMMUNOLOGY			English	Article						sporadic amyotrophic lateral sclerosis (SALS); whole-genome sequence (WGS); tryptophan; kynurenine pathway (KP); serotonin	KYNURENINE PATHWAY; QUINOLINIC ACID; WHOLE-GENOME; DISEASE; DEGENERATION; MECHANISMS; NEURONS; REVEL	The essential amino acid tryptophan (TRP) is the initiating metabolite of the kynurenine pathway (KP), which can be upregulated by inflammatory conditions in cells. Neuroinflammation-triggered activation of the KP and excessive production of the KP metabolite quinolinic acid are common features of multiple neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). In addition to its role in the KP, genes involved in TRP metabolism, including its incorporation into proteins, and synthesis of the neurotransmitter serotonin, have also been genetically and functionally linked to these diseases. ALS is a late onset neurodegenerative disease that is classified as familial or sporadic, depending on the presence or absence of a family history of the disease. Heritability estimates support a genetic basis for all ALS, including the sporadic form of the disease. However, the genetic basis of sporadic ALS (SALS) is complex, with the presence of multiple gene variants acting to increase disease susceptibility and is further complicated by interaction with potential environmental factors. We aimed to determine the genetic contribution of 18 genes involved in TRP metabolism, including protein synthesis, serotonin synthesis and the KP, by interrogating whole-genome sequencing data from 614 Australian sporadic ALS cases. Five genes in the KP (AFMID, CCBL1, GOT2, KYNU, HAAO) were found to have either novel protein-altering variants, and/or a burden of rare protein-altering variants in SALS cases compared to controls. Four genes involved in TRP metabolism for protein synthesis (WARS) and serotonin synthesis (TPH1, TPH2, MAOA) were also found to carry novel variants and/or gene burden. These variants may represent ALS risk factors that act to alter the KP and lead to neuroinflammation. These findings provide further evidence for the role of TRP metabolism, the KP and neuroinflammation in ALS disease pathobiology.	[Fifita, Jennifer A.; Chan Moi Fat, Sandrine; McCann, Emily P.; Williams, Kelly L.; Twine, Natalie A.; Rowe, Dominic B.; Tan, Vanessa X.; Blair, Ian P.; Guillemin, Gilles J.] Macquarie Univ, Fac Med Hlth & Human Sci, Ctr Motor Neuron Dis Res, Dept Biomed Sci, Sydney, NSW, Australia; [Twine, Natalie A.; Bauer, Denis C.] CSIRO, Hlth & Biosecur Flagship, Australian E Hlth Res Ctr, Sydney, NSW, Australia; [Bauer, Denis C.] Macquarie Univ, Fac Med Hlth & Human Sci, Dept Biomed Sci, Sydney, NSW, Australia; [Bauer, Denis C.] Macquarie Univ, Fac Sci & Engn, Appl BioSci, Sydney, NSW, Australia; [Rowe, Dominic B.] Macquarie Univ, Fac Med Hlth & Human Sci, Dept Clin Med, Sydney, NSW, Australia; [Pamphlett, Roger] Univ Sydney, Sch Med Sci, Discipline Pathol, Sydney, NSW, Australia; [Pamphlett, Roger] Royal Prince Alfred Hosp, Dept Neuropathol, Sydney, NSW, Australia; [Pamphlett, Roger; Kiernan, Matthew C.] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia; [Kiernan, Matthew C.] Royal Prince Alfred Hosp, Inst Clin Neurosci, Sydney, NSW, Australia	Macquarie University; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Macquarie University; Macquarie University; Macquarie University; University of Sydney; University of Sydney; University of Sydney; University of Sydney	Blair, IP (corresponding author), Macquarie Univ, Fac Med Hlth & Human Sci, Ctr Motor Neuron Dis Res, Dept Biomed Sci, Sydney, NSW, Australia.	ian.blair@mq.edu.au	Bauer, Denis/C-3903-2009; Guillemin, Gilles J/C-3878-2015; McCann, Emily/A-2563-2016; Rowe, Dominic/B-6661-2011; Williams, Kelly/A-5545-2010	Bauer, Denis/0000-0001-8033-9810; Guillemin, Gilles J/0000-0001-8105-4470; McCann, Emily/0000-0002-8200-3525; Chan Moi Fat, Sandrine/0000-0002-6304-0283; Tan, Vanessa/0000-0002-2945-2647; Rowe, Dominic/0000-0003-0912-2146; Fifita, Jennifer/0000-0002-0814-0118; Williams, Kelly/0000-0001-6319-9473; Twine, Natalie/0000-0002-2051-8275; Blair, Ian/0000-0003-3083-0075	Motor Neuron Disease Research Australia (Bill Gole Postdoctoral Research Fellowship); National Health and Medical Research Council of Australia [1092023, 1156093, 1176913, 1132524, 1153439, 1095215, 1176660]; Macquarie University	Motor Neuron Disease Research Australia (Bill Gole Postdoctoral Research Fellowship); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Macquarie University	This work was funded by Motor Neuron Disease Research Australia (Bill Gole Postdoctoral Research Fellowship), the National Health and Medical Research Council of Australia (1092023, 1156093, 1176913, 1132524, 1153439, 1095215, 1176660) and Macquarie University.	AI-Chalabi A, 2014, LANCET NEUROL, V13, P1108, DOI 10.1016/S1474-4422(14)70219-4; Al-Chalabi A, 2010, J NEUROL NEUROSUR PS, V81, P1324, DOI 10.1136/jnnp.2010.207464; Boros FA, 2018, MUTAT RES-REV MUTAT, V776, P32, DOI 10.1016/j.mrrev.2018.03.001; Brooks BR, 2000, AMYOTROPH LATERAL SC, V1, P293, DOI 10.1080/146608200300079536; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Chang CY, 2016, J BIOL CHEM, V291, P16567, DOI 10.1074/jbc.M116.730812; Chen YQ, 2010, NEUROTOX RES, V18, P132, DOI 10.1007/s12640-009-9129-7; Chio A, 2018, NEUROLOGY, V91, pE635, DOI 10.1212/WNL.0000000000005996; Cirulli ET, 2015, SCIENCE, V347, P1436, DOI 10.1126/science.aaa3650; Desmet FO, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp215; Dupuis L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013346; El Oussini H, 2017, ANN NEUROL, V82, P444, DOI 10.1002/ana.25030; Feng BJ, 2017, HUM MUTAT, V38, P243, DOI 10.1002/humu.23158; Gregory JM, 2020, CURR GENET MED REP, V8, P121, DOI 10.1007/s40142-020-00194-8; Guillemin GJ, 2005, NEURODEGENER DIS, V2, P166, DOI 10.1159/000089622; Guillemin GJ, 2012, FEBS J, V279, P1356, DOI 10.1111/j.1742-4658.2012.08485.x; Guillemin GJ, 2005, NEUROPATH APPL NEURO, V31, P395, DOI 10.1111/j.1365-2990.2005.00655.x; Guillemin GJ, 2001, J NEUROCHEM, V78, P842, DOI 10.1046/j.1471-4159.2001.00498.x; Ilzecka J, 2003, ACTA NEUROL SCAND, V107, P412, DOI 10.1034/j.1600-0404.2003.00076.x; Ioannidis NM, 2016, AM J HUM GENET, V99, P877, DOI 10.1016/j.ajhg.2016.08.016; Jacobs KR, 2018, NEURAL REGEN RES, V13, P2073, DOI 10.4103/1673-5374.241446; KALISCH BE, 1994, BRAIN RES, V668, P1, DOI 10.1016/0006-8993(94)90504-5; Lee JM, 2017, NEUROPHARMACOLOGY, V112, P346, DOI 10.1016/j.neuropharm.2016.05.011; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Lim CK, 2017, PROG NEUROBIOL, V155, P76, DOI 10.1016/j.pneurobio.2015.12.009; Lim CK, 2017, SCI REP-UK, V7, DOI 10.1038/srep41473; Liu XM, 2016, HUM MUTAT, V37, P235, DOI 10.1002/humu.22932; Lovelace MD, 2017, NEUROPHARMACOLOGY, V112, P373, DOI 10.1016/j.neuropharm.2016.03.024; Maddison DC, 2015, SEMIN CELL DEV BIOL, V40, P134, DOI 10.1016/j.semcdb.2015.03.002; Mathis S, 2019, J NEUROL SCI, V399, P217, DOI 10.1016/j.jns.2019.02.030; McCann EP, 2017, CLIN GENET, V92, P259, DOI 10.1111/cge.12973; McCann EP, 2021, J MED GENET, V58, P87, DOI 10.1136/jmedgenet-2020-106866; Myint AM, 2003, MED HYPOTHESES, V61, P519, DOI 10.1016/S0306-9877(03)00207-X; Pinese M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14079-0; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; RStudio Team, 2010, RSTUDIO INT DEV R; Ryan M, 2019, JAMA NEUROL, V76, P1367, DOI 10.1001/jamaneurol.2019.2044; Sandyk R, 2006, INT J NEUROSCI, V116, P775, DOI 10.1080/00207450600754087; Shefner JM, 2020, CLIN NEUROPHYSIOL, V131, P1975, DOI 10.1016/j.clinph.2020.04.005; Tan VX, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01013; Tian Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49224-8; Trost B, 2018, AM J HUM GENET, V102, P142, DOI 10.1016/j.ajhg.2017.12.007; Tsai PC, 2017, BRAIN, V140, P1252, DOI 10.1093/brain/awx058; Turner BJ, 2003, AMYOTROPH LATERAL SC, V4, P171, DOI 10.1080/14660820310009389; van Es MA, 2017, LANCET, V390, P2084, DOI 10.1016/S0140-6736(17)31287-4; Van Rheenen W, 2018, EUR J HUM GENET, V26, P1537, DOI 10.1038/s41431-018-0177-4; Wang BH, 2019, CLIN GENET, V96, P176, DOI 10.1111/cge.13563; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wingo TS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027985	49	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 14	2021	12								701550	10.3389/fimmu.2021.701550	http://dx.doi.org/10.3389/fimmu.2021.701550			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TA3YX	34194442	Green Published, gold			2022-12-18	WOS:000667187500001
J							Frontiers Editorial Off	RETRACTION: Akt2 Regulates the Differentiation and Function of NKT17 Cells via FoxO-1-ICOS Axis (Retraction of Vol 11, art no 589346, 2020)	FRONTIERS IN IMMUNOLOGY			English	Retraction																		Niu LL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.589346	1	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 14	2021	12								716458	10.3389/fimmu.2021.716458	http://dx.doi.org/10.3389/fimmu.2021.716458			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TA5FZ		gold, Green Published			2022-12-18	WOS:000667276000001
J	Smyth, M; Khamina, K; Popa, A; Gudipati, V; Agerer, B; Lercher, A; Kosack, L; Endler, L; Baazim, H; Viczenczova, C; Huppa, JB; Bergthaler, A				Smyth, Mark; Khamina, Kseniya; Popa, Alexandra; Gudipati, Venugopal; Agerer, Benedikt; Lercher, Alexander; Kosack, Lindsay; Endler, Lukas; Baazim, Hatoon; Viczenczova, Csilla; Huppa, Johannes B.; Bergthaler, Andreas			Characterization of CD8 T Cell-Mediated Mutations in the Immunodominant Epitope GP33-41 of Lymphocytic Choriomeningitis Virus	FRONTIERS IN IMMUNOLOGY			English	Article						viral infection; lymphocytic choriomeningitis (LCMV); CD8 T cell; immune evasion; mouse model; CTL escape mutation	VIRAL ESCAPE; DROSOPHILA-MELANOGASTER; CTL RESPONSE; VARIANTS; HIV; SELECTION; ANTIGEN; CYTOTOXICITY; DIVERSITY; INFECTION	Cytotoxic T lymphocytes (CTLs) represent key immune effectors of the host response against chronic viruses, due to their cytotoxic response to virus-infected cells. In response to this selection pressure, viruses may accumulate escape mutations that evade CTL-mediated control. To study the emergence of CTL escape mutations, we employed the murine chronic infection model of lymphocytic choriomeningitis virus (LCMV). We developed an amplicon-based next-generation sequencing pipeline to detect low frequency mutations in the viral genome and identified non-synonymous mutations in the immunodominant LCMV CTL epitope, GP33-41, in infected wildtype mice. Infected Rag2-deficient mice lacking CTLs did not contain such viral mutations. By using transgenic mice with T cell receptors specific to GP33-41, we characterized the emergence of viral mutations in this epitope under varying selection pressure. We investigated the two most abundant viral mutations by employing reverse genetically engineered viral mutants encoding the respective mutations. These experiments provided evidence that these mutations prevent activation and expansion of epitope-specific CD8 T cells. Our findings on the mutational dynamics of CTL escape mutations in a widely-studied viral infection model contributes to our understanding of how chronic viruses interact with their host and evade the immune response. This may guide the development of future treatments and vaccines against chronic infections.	[Smyth, Mark; Khamina, Kseniya; Popa, Alexandra; Agerer, Benedikt; Lercher, Alexander; Kosack, Lindsay; Endler, Lukas; Baazim, Hatoon; Viczenczova, Csilla; Bergthaler, Andreas] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria; [Gudipati, Venugopal; Huppa, Johannes B.] Med Univ Vienna, Inst Hyg & Appl Immunol, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria; [Lercher, Alexander] Rockefeller Univ, Lab Virol & Infect Dis, 1230 York Ave, New York, NY 10021 USA; [Kosack, Lindsay] Inst Gulbenkian Ciencias, Oeiras, Portugal; [Baazim, Hatoon] Harvard TH Chan Sch Publ Hlth, Dept Mol Metab, Boston, MA USA	Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; Medical University of Vienna; Rockefeller University; Instituto Gulbenkian de Ciencia; Harvard University; Harvard T.H. Chan School of Public Health	Bergthaler, A (corresponding author), Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria.	abergthaler@cemm.oeaw.ac.at	Bergthaler, Andreas/ABG-5047-2020; Lukas, Endler/ABD-2002-2021; Huppa, Johannes Bernhard/AAY-9471-2021	Bergthaler, Andreas/0000-0003-0597-1976; Lukas, Endler/0000-0002-9115-8756; Huppa, Johannes Bernhard/0000-0003-2634-8198; Gudipati, Venugopal/0000-0001-6647-0708; /0000-0003-4243-4950	DOC fellowships of the Austrian Academy of Sciences [24813, 24158, 24955]; Austrian Science Fund (FWF) [DK W1212]; Vienna Science and Technology Fund (WWTF) [LS14-031]	DOC fellowships of the Austrian Academy of Sciences; Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Vienna Science and Technology Fund (WWTF)	MS, KK, and AL were supported by DOC fellowships of the Austrian Academy of Sciences (No. 24813, No. 24158 and No. 24955 respectively). BA was supported by the Austrian Science Fund (FWF) DK W1212. VG and JH received support from the Vienna Science and Technology Fund (WWTF, LS14-031).	Agerer B, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abg6461; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; Bhattacharya A, 2015, IMMUNITY, V43, P974, DOI 10.1016/j.immuni.2015.10.013; Blaha DT, 2019, CANCER IMMUNOL RES, V7, P50, DOI 10.1158/2326-6066.CIR-18-0395; Blattman JN, 2009, J VIROL, V83, P4386, DOI 10.1128/JVI.02524-08; Blum JS, 2013, ANNU REV IMMUNOL, V31, P443, DOI 10.1146/annurev-immunol-032712-095910; Bowen DG, 2005, J EXP MED, V201, P1709, DOI 10.1084/jem.20050808; Carr IM, 2009, BIOINFORMATICS, V25, P3244, DOI 10.1093/bioinformatics/btp583; Chakradhar S, 2018, NAT MED, V24, P2, DOI 10.1038/nm0118-2; Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; Cingolani Pablo, 2012, Frontiers in Genetics, V3, P35, DOI 10.3389/fgene.2012.00035; de la Roche M, 2016, NAT REV IMMUNOL, V16, P421, DOI 10.1038/nri.2016.54; Deng K, 2015, NATURE, V517, P381, DOI 10.1038/nature14053; Erickson AL, 2001, IMMUNITY, V15, P883, DOI 10.1016/S1074-7613(01)00245-X; Fernandez CS, 2007, J VIROL, V81, P4137, DOI 10.1128/JVI.02193-06; Flatz L, 2006, P NATL ACAD SCI USA, V103, P4663, DOI 10.1073/pnas.0600652103; Ganusov VV, 2011, J VIROL, V85, P10518, DOI 10.1128/JVI.00655-11; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Goulder PJR, 2008, NAT REV IMMUNOL, V8, P619, DOI 10.1038/nri2357; Goulder PJR, 2004, NAT REV IMMUNOL, V4, P630, DOI 10.1038/nri1417; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Grotenbreg GM, 2008, P NATL ACAD SCI USA, V105, P3831, DOI 10.1073/pnas.0711504105; Haynes BF, 2016, CELL HOST MICROBE, V19, P292, DOI 10.1016/j.chom.2016.02.002; Johnson S, 2015, J IMMUNOL, V194, P1755, DOI 10.4049/jimmunol.1401771; Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Kotturi MF, 2007, J VIROL, V81, P4928, DOI 10.1128/JVI.02632-06; Lercher A, 2019, IMMUNITY, V51, P1074, DOI 10.1016/j.immuni.2019.10.014; Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992; Li H, 2011, BIOINFORMATICS, V27, P2987, DOI 10.1093/bioinformatics/btr509; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lord SJ, 2003, IMMUNOL REV, V193, P31, DOI 10.1034/j.1600-065X.2003.00044.x; Lucas M, 2001, INT J EXP PATHOL, V82, P269, DOI 10.1046/j.1365-2613.2001.00204.x; Martins MA, 2015, J VIROL, V89, P10802, DOI 10.1128/JVI.01440-15; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; PIRCHER H, 1987, EUR J IMMUNOL, V17, P1843, DOI 10.1002/eji.1830171226; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; Puglielli MT, 2001, J VIROL, V75, P5099, DOI 10.1128/JVI.75.11.5099-5107.2001; Schnell FJ, 2009, J IMMUNOL, V182, P1829, DOI 10.4049/jimmunol.0801798; Shorter SK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149582; Thimme R, 2021, J HEPATOL, V74, P220, DOI 10.1016/j.jhep.2020.09.022; Timm J, 2015, MED MICROBIOL IMMUN, V204, P29, DOI 10.1007/s00430-014-0372-z; Toebes M, 2006, NAT MED, V12, P246, DOI 10.1038/nm1360; van der Most RG, 2003, VIROLOGY, V315, P93, DOI 10.1016/j.virol.2003.07.001; Walker LJ, 2010, CLIN EXP IMMUNOL, V159, P245, DOI 10.1111/j.1365-2249.2009.04047.x; WEIDT G, 1995, J VIROL, V69, P7147, DOI 10.1128/JVI.69.11.7147-7151.1995; Wherry EJ, 2003, J VIROL, V77, P4911, DOI 10.1128/JVI.77.8.4911-4927.2003; Wilm A, 2012, NUCLEIC ACIDS RES, V40, P11189, DOI 10.1093/nar/gks918; Xu XN, 2001, IMMUNITY, V15, P867, DOI 10.1016/S1074-7613(01)00255-2; Zehn D, 2015, ADV EXP MED BIOL, V850, P137, DOI 10.1007/978-3-319-15774-0_10; Zhang N, 2011, IMMUNITY, V35, P161, DOI 10.1016/j.immuni.2011.07.010; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0; Zinkernagel RM, 2002, CURR TOP MICROBIOL, V263, P1	56	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 14	2021	12								638485	10.3389/fimmu.2021.638485	http://dx.doi.org/10.3389/fimmu.2021.638485			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TA4AD	34194424	gold, Green Published			2022-12-18	WOS:000667190700001
J	Zaini, A; Fulford, TS; Grumont, RJ; Runting, J; Rodrigues, G; Ng, J; Gerondakis, S; Zaph, C; Scheer, S				Zaini, Aidil; Fulford, Thomas S.; Grumont, Raelene J.; Runting, Jessica; Rodrigues, Grace; Ng, Judy; Gerondakis, Steve; Zaph, Colby; Scheer, Sebastian			c-Rel Is Required for IL-33-Dependent Activation of ILC2s	FRONTIERS IN IMMUNOLOGY			English	Article						ILC2; c-Rel; allergic lung inflammation; IL-33; papain	NF-KAPPA-B; INNATE LYMPHOID-CELLS; TRANSCRIPTION FACTOR GATA3; T-CELLS; AIRWAY HYPERRESPONSIVENESS; IL-33 PROMOTES; MICE LACKING; EXPRESSION; IMMUNITY; SURVIVAL	Group 2 innate lymphoid cells (ILC2s) are emerging as important cellular regulators of homeostatic and disease-associated immune processes. The cytokine interleukin-33 (IL-33) promotes ILC2-dependent inflammation and immunity, with IL-33 having been shown to activate NF-kappa B in a wide variety of cell types. However, it is currently unclear which NF-kappa B members play an important role in IL-33-dependent ILC2 biology. Here, we identify the NF-kappa B family member c-Rel as a critical component of the IL-33-dependent activation of ILC2s. Although c-Rel is dispensable for ILC2 development, it is critical for ILC2 function in the lung, with c-Rel-deficient (c-Rel(-/-) ) mice present a significantly reduced response to papain- and IL-33-induced lung inflammation. We also show that the absence of c-Rel reduces the IL-33-dependent expansion of ILC2 precursors and lower levels of IL-5 and IL-13 cytokine production by mature ILC2s in the lung. Together, these results identify the IL-33-c-Rel axis as a central control point of ILC2 activation and function.	[Zaini, Aidil; Grumont, Raelene J.; Runting, Jessica; Rodrigues, Grace; Ng, Judy; Gerondakis, Steve; Zaph, Colby; Scheer, Sebastian] Monash Biomed Discovery Inst, Infect & Immun Program, Clayton, Vic, Australia; [Zaini, Aidil; Grumont, Raelene J.; Runting, Jessica; Rodrigues, Grace; Ng, Judy; Gerondakis, Steve; Zaph, Colby; Scheer, Sebastian] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia; [Fulford, Thomas S.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia	Monash University; Monash University; University of Melbourne	Zaph, C; Scheer, S (corresponding author), Monash Biomed Discovery Inst, Infect & Immun Program, Clayton, Vic, Australia.; Zaph, C; Scheer, S (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia.	Colby.zaph@Monash.edu; Sebastian.scheer@Monash.edu		Zaph, Colby/0000-0002-9889-9848; Scheer, Sebastian/0000-0002-9716-5009	NHMRC [APP1104433, APP1104466]; Monash University Biomedicine Discovery Scholarship	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Monash University Biomedicine Discovery Scholarship	This work was supported by NHMRC project grants (APP1104433 and APP1104466 to CZ) and Monash University Biomedicine Discovery Scholarship (to AZ).	Antignano F, 2016, J EXP MED, V213, P1153, DOI 10.1084/jem.20151646; Ather JL, 2015, CLIN EXP ALLERGY, V45, P1245, DOI 10.1111/cea.12491; Barlow JL, 2013, J ALLERGY CLIN IMMUN, V132, P933, DOI 10.1016/j.jaci.2013.05.012; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bogdanova D, 2018, J IMMUNOL, V201, P3580, DOI 10.4049/jimmunol.1800539; Bunting K, 2007, J IMMUNOL, V178, P7097, DOI 10.4049/jimmunol.178.11.7097; Chenery AL, 2016, INFECT IMMUN, V84, P491, DOI 10.1128/IAI.01240-15; Christianson C, 2014, J ALLERGY CLIN IMMUN, V133, pAB170, DOI 10.1016/j.jaci.2013.12.610; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; Donovan CE, 1999, J IMMUNOL, V163, P6827; Gerlach K, 2014, NAT IMMUNOL, V15, P676, DOI 10.1038/ni.2920; Gerondakis S, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000182; Ghosh S, 2016, GENE, V581, P48, DOI 10.1016/j.gene.2016.01.025; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Gilmore Thomas D, 2011, Genes Cancer, V2, P695, DOI 10.1177/1947601911421925; Gorski SA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003615; Griesenauer B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00475; Grinberg-Bleyer Y, 2017, CELL, V170, P1096, DOI 10.1016/j.cell.2017.08.004; GRUMONT RJ, 1994, CELL GROWTH DIFFER, V5, P1321; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Halim TYF, 2012, IMMUNITY, V37, P463, DOI 10.1016/j.immuni.2012.06.012; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Huang YF, 2015, NAT IMMUNOL, V16, P161, DOI 10.1038/ni.3078; Humphreys NE, 2008, J IMMUNOL, V180, P2443, DOI 10.4049/jimmunol.180.4.2443; Hurrell BP, 2019, CELL REP, V29, P4509, DOI 10.1016/j.celrep.2019.11.102; Jones RG, 2005, J IMMUNOL, V175, P3790, DOI 10.4049/jimmunol.175.6.3790; Kearley J, 2015, IMMUNITY, V42, P566, DOI 10.1016/j.immuni.2015.02.011; Klose CSN, 2016, NAT IMMUNOL, V17, P765, DOI 10.1038/ni.3489; Kondo Y, 2008, INT IMMUNOL, V20, P791, DOI 10.1093/intimm/dxn037; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kurowska-Stolarska M, 2009, J IMMUNOL, V183, P6469, DOI 10.4049/jimmunol.0901575; Lao-Araya M, 2014, J ALLERGY CLIN IMMUN, V134, P1193, DOI 10.1016/j.jaci.2014.07.029; Liew FY, 2016, NAT REV IMMUNOL, V16, P676, DOI 10.1038/nri.2016.95; Lingel A, 2009, STRUCTURE, V17, P1398, DOI 10.1016/j.str.2009.08.009; Liu X, 2013, P NATL ACAD SCI USA, V110, P14918, DOI 10.1073/pnas.1308651110; Luthi AU, 2009, IMMUNITY, V31, P84, DOI 10.1016/j.immuni.2009.05.007; Matta BM, 2016, BLOOD, V128, P427, DOI 10.1182/blood-2015-12-684142; Mielke LA, 2013, J IMMUNOL, V191, P4383, DOI 10.4049/jimmunol.1301228; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moussion C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003331; Nagakumar P, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.01809-2018; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Oboki K, 2010, P NATL ACAD SCI USA, V107, P18581, DOI 10.1073/pnas.1003059107; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Ohne Y, 2016, NAT IMMUNOL, V17, P646, DOI 10.1038/ni.3447; Pichery M, 2012, J IMMUNOL, V188, P3488, DOI 10.4049/jimmunol.1101977; Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Rank MA, 2009, J ALLERGY CLIN IMMUN, V123, P1047, DOI 10.1016/j.jaci.2009.02.026; Rao S, 2003, J IMMUNOL, V170, P3724, DOI 10.4049/jimmunol.170.7.3724; Ruan QG, 2009, IMMUNITY, V31, P932, DOI 10.1016/j.immuni.2009.10.006; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Schiering C, 2014, NATURE, V513, P564, DOI 10.1038/nature13577; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shafiei-Jahani P, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18601-7; Shono Y, 2016, CANCER RES, V76, P377, DOI 10.1158/0008-5472.CAN-14-2814; Shono Y, 2014, CANCER DISCOV, V4, P578, DOI 10.1158/2159-8290.CD-13-0585; Spooner CJ, 2013, NAT IMMUNOL, V14, P1229, DOI 10.1038/ni.2743; Stadhouders R, 2018, J ALLERGY CLIN IMMUN, V142, P1793, DOI 10.1016/j.jaci.2017.12.1006; Stier MT, 2018, J EXP MED, V215, P263, DOI 10.1084/jem.20170449; Turnquist HR, 2008, J IMMUNOL, V181, P62, DOI 10.4049/jimmunol.181.1.62; Wang L, 2021, J EXP MED, V218, DOI 10.1084/jem.20191054; Wang WH, 1997, IMMUNITY, V6, P165, DOI 10.1016/S1074-7613(00)80423-9; Wolterink RGJK, 2013, P NATL ACAD SCI USA, V110, P10240, DOI 10.1073/pnas.1217158110; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Yang Q, 2013, IMMUNITY, V38, P694, DOI 10.1016/j.immuni.2012.12.003; Zaph C, 2007, NATURE, V446, P552, DOI 10.1038/nature05590; Zheng Y, 2003, J EXP MED, V197, P861, DOI 10.1084/jem.20021610; Zook EC, 2016, J EXP MED, V213, P687, DOI 10.1084/jem.20150851	72	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 14	2021	12								667922	10.3389/fimmu.2021.667922	http://dx.doi.org/10.3389/fimmu.2021.667922			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TA4GQ	34194431	gold, Green Published, Green Submitted			2022-12-18	WOS:000667207600001
J	Zhang, F; Yin, SF; Fan, Y; Song, TR; Huang, ZL; Liang, JY; Wu, JP; Yang, YM; Lin, T; Wang, XD				Zhang, Fan; Yin, Saifu; Fan, Yu; Song, Turun; Huang, Zhongli; Liang, Jiayu; Wu, Jiapei; Yang, Youmin; Lin, Tao; Wang, Xianding			Effect of Donor and Recipient ABH-Secretor Status on ABO-Incompatible Living Donor Kidney Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						kidney transplantation; ABO blood-group system; blood group incompatibility; graft function; accommodate	ANTIGEN-SPECIFIC IMMUNOADSORPTION; ANTIBODY-MEDIATED REJECTION; RENAL-TRANSPLANTATION; EXPRESSION; DONATION; OUTCOMES; IMPACT; LEWIS	Introduction ABO blood group antigens within grafts are continuously exposed to anti-A/B antibodies in the serum of recipients after ABO-incompatible (ABOi) kidney transplantation and are instrumental in antibody-mediated rejection. Some individuals secrete soluble blood group antigens into body fluids. In this study, we investigated the effect of donor and recipient secretor status on the outcomes of ABOi kidney transplantation. Methods Data of a total of 32 patients with ABOi living donor kidney transplantation were retrospectively collected between 2014 and 2020 in West China Hospital. The genotype and phenotype of both donors and recipients were examined and evaluated with post-transplantation anti-A/B titer changes, graft function, and rejection. Results Of the 32 recipients and 32 donors, 23 (71.9%) recipients and 27 (84.4%) donors had secretor genotypes, whereas 9 (28.1%) recipients and 5 (15.6%) donors did not. Anti-A/B titers after ABOi kidney transplantation were not significantly influenced by the secretor status of either donors or recipients. The post-transplantation serum creatinine (Scr) levels and estimated glomerular filtration rate (eGFR) was better in weak- or non-secretor recipients at day 30 (Scr P = 0.047, eGFR P = 0.008), day 90 (Scr P = 0.010, eGFR P = 0.005), and month 9 (eGFR P = 0.008), and recipients from secretor donors had a lower incidence of graft rejection in the first year after ABOi transplantation (P = 0.004). Conclusions A weak secretor status phenotype was found in both genotypes, i.e., individuals who secreted soluble antigens as well as those who did not. The recipient ABH-secretor status may have an influence on early posttransplant renal function, and the donor ABH-secretor status might affect the incidence of graft rejection.	[Zhang, Fan; Yin, Saifu; Fan, Yu; Song, Turun; Huang, Zhongli; Liang, Jiayu; Wu, Jiapei; Yang, Youmin; Lin, Tao; Wang, Xianding] Sichuan Univ, West China Hosp, Inst Urol, Dept Urol, Chengdu, Peoples R China; [Zhang, Fan; Yin, Saifu; Fan, Yu; Song, Turun; Huang, Zhongli; Liang, Jiayu; Wu, Jiapei; Yang, Youmin; Lin, Tao; Wang, Xianding] Sichuan Univ, West China Hosp, Organ Transplantat Ctr, Chengdu, Peoples R China	Sichuan University; Sichuan University	Lin, T; Wang, XD (corresponding author), Sichuan Univ, West China Hosp, Inst Urol, Dept Urol, Chengdu, Peoples R China.; Lin, T; Wang, XD (corresponding author), Sichuan Univ, West China Hosp, Organ Transplantat Ctr, Chengdu, Peoples R China.	kidney1234@163.com; xiandingwang@qq.com			National Natural Science Foundation of China [81870513]; Sichuan Science and Technology Program [2019YJ0133]; Chengdu Science and Technology Program [2019-YF05-00084-SN]; 1.3.5 Project for Disciplines of ExcellenceClinical Research Incubation Project, West China Hospital, Sichuan University [2018HXFH049, ZYJC18004, ZY2016104, 2021HXFH007]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Sichuan Science and Technology Program; Chengdu Science and Technology Program; 1.3.5 Project for Disciplines of ExcellenceClinical Research Incubation Project, West China Hospital, Sichuan University	This work was supported by grants from the National Natural Science Foundation of China [grant number 81870513], Sichuan Science and Technology Program [grant number 2019YJ0133], Chengdu Science and Technology Program [grant number 2019-YF05-00084-SN], and 1.3.5 Project for Disciplines of ExcellenceClinical Research Incubation Project, West China Hospital, Sichuan University [grant numbers 2018HXFH049, ZYJC18004, ZY2016104, 2021HXFH007]. The funders had no role in the study design, data collection or analysis, preparation of the manuscript, or the decision to publish.	ANDERSEN A, 1952, Acta Pathol Microbiol Scand, V31, P448; Bakhtiari S, 2020, SCIENTIFICA, V2020, DOI 10.1155/2020/2950856; Barbosa MGD, 2018, XENOTRANSPLANTATION, V25, DOI 10.1111/xen.12418; Breimer ME, 2006, TRANSPLANTATION, V82, P479, DOI 10.1097/01.tp.0000231697.15817.51; Drexler B, 2016, TRANSFUSION, V56, P2355, DOI 10.1111/trf.13711; FRYER JP, 1994, TRANSPLANTATION, V58, P723; Genberg H, 2008, TRANSPLANTATION, V85, P1745, DOI 10.1097/TP.0b013e3181726849; Grams ME, 2016, NEW ENGL J MED, V374, P411, DOI 10.1056/NEJMoa1510491; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; Kim J, 2017, ANN LAB MED, V37, P254, DOI 10.3343/alm.2017.37.3.254; Koo TY, 2015, KIDNEY RES CLIN PRAC, V34, P170, DOI 10.1016/j.krcp.2015.08.005; Lentine KL, 2019, CLIN J AM SOC NEPHRO, V14, P597, DOI 10.2215/CJN.11220918; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Linden S, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040002; Masterson R, 2014, AM J TRANSPLANT, V14, P2807, DOI 10.1111/ajt.12920; Montgomery RA, 2009, TRANSPLANTATION, V87, P1246, DOI 10.1097/TP.0b013e31819f2024; ORIOL R, 1980, TRANSPLANTATION, V29, P184, DOI 10.1097/00007890-198003000-00003; Park WD, 2003, AM J TRANSPLANT, V3, P952, DOI 10.1034/j.1600-6143.2003.00179.x; SARNESTO A, 1992, J BIOL CHEM, V267, P2745; Scurt FG, 2019, LANCET, V393, P2059, DOI 10.1016/S0140-6736(18)32091-9; Segev DL, 2005, JAMA-J AM MED ASSOC, V293, P1883, DOI 10.1001/jama.293.15.1883; Stussi G, 2005, BRIT J HAEMATOL, V130, P954, DOI 10.1111/j.1365-2141.2005.05705.x; Subramanian V, 2012, INT J IMMUNOGENET, V39, P282, DOI 10.1111/j.1744-313X.2012.01101.x; Takahashi K, 2004, AM J TRANSPLANT, V4, P1089, DOI 10.1111/j.1600-6143.2004.00464.x; Takahashi K, 2004, TRANSPL P, V36, p193S, DOI 10.1016/j.transproceed.2004.01.070; Toki D, 2009, AM J TRANSPLANT, V9, P567, DOI 10.1111/j.1600-6143.2008.02538.x; Tyden G, 2005, AM J TRANSPLANT, V5, P145, DOI 10.1111/j.1600-6143.2004.00653.x; Uchida J, 2020, INT J UROL, V27, P30, DOI 10.1111/iju.14109; Wang XD, 2020, ANN TRANSPL, V25, DOI 10.12659/AOT.920224	29	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 14	2021	12								671185	10.3389/fimmu.2021.671185	http://dx.doi.org/10.3389/fimmu.2021.671185			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TA4HF	34194432	gold, Green Published			2022-12-18	WOS:000667209100001
J	Ortolan, A; Lorenzin, M; Cosma, C; Cozzi, G; Padoan, A; Doria, A; Plebani, M; Ramonda, R				Ortolan, Augusta; Lorenzin, Mariagrazia; Cosma, Chiara; Cozzi, Giacomo; Padoan, Andrea; Doria, Andrea; Plebani, Mario; Ramonda, Roberta			SARS-CoV-2 Infection in Spondyloarthritis Patients Treated With Biotechnological Drugs: A Study on Serology	FRONTIERS IN IMMUNOLOGY			English	Article						spondyloarthritis; SARS-CoV-2; COVID-19; serology; immunosuppression	SOCIETY CLASSIFICATION CRITERIA; COVID-19; SEVERITY	Objective Serology could help to define the real extent of SARS-CoV-2 diffusion, especially in individuals considered at higher risk of COVID-19, such as spondyloarthritis (SpA) patients undergoing immunosuppressant. Our aim was to detect, by serology, previous SARS-CoV-2 contact in SpA, compared to health care workers (HCW), and healthy controls. Methods Sera from consecutive patients affected by SpA undergoing cytokine-targeted therapy, HCW and healthy controls from 2015 were analysed through chemiluminescent analytical system for the presence of IgG and IgM anti-SARS-CoV-2. Positive patients (IgM or IgG, or both) additionally underwent real-time Polymerase-Chain-Reaction (RT-PCR) to test for active infection. Serology was repeated at 3-months in SpA. Data across 3 groups were compared by Kruskal Wallis/Chi-square, and between 2 groups by Wilcoxon rank test/Chi-Square. P <= 0.05 were considered significant. Results 200 SpA, 95 HCW and 101 controls were recruited. Positive serology was found in 25(12.5%) SpA, 8(8.4%) HCW, 0(0%) controls (p=0.001). SpA patients with positive serology more frequently reported COVID-19-like symptoms than those with negative serology (20% vs. 4%, p=0.009) and 2 had COVID-19 as confirmed by RT-PCR, non severe. No HCW reported symptoms or had positive RT-PCR. In SpA patients, at 3 months, mean IgM titres decreased from 2.76 +/- 2.93 to 2.38 +/- 2.95 (p=0.001), while IgG titres from 0.89 +/- 3.25 to 0.31 +/- 0.87 (p=ns). Conclusions Serology revealed that exposure to SARS-CoV-2 in SpA patients and HCW was higher than expected based on reported symptoms. In SpA, anti-cytokine therapy could act as a protective factor for a severe disease course. However, a seroconversion was not observed at 3-months.	[Ortolan, Augusta; Lorenzin, Mariagrazia; Cozzi, Giacomo; Doria, Andrea; Ramonda, Roberta] Univ Padua, Dept Med DIMED, Rheumatol Unit, Padua, Italy; [Cosma, Chiara; Padoan, Andrea; Plebani, Mario] Univ Hosp Padova, Dept Lab Med, Padua, Italy; [Padoan, Andrea; Plebani, Mario] Univ Padua, Dept Med DIMED, Padua, Italy	University of Padua; University of Padua; Azienda Ospedaliera - Universita di Padova; University of Padua	Ramonda, R (corresponding author), Univ Padua, Dept Med DIMED, Rheumatol Unit, Padua, Italy.	roberta.ramonda@unipd.it	Padoan, Andrea/J-7869-2016	Padoan, Andrea/0000-0003-1284-7885; Doria, Andrea/0000-0003-0548-4983	Fondazione Cariparo [55813]	Fondazione Cariparo(Fondazione Cariparo)	This work was in part supported by a grant from Fondazione Cariparo (grant number 55813).	Amani L, 2020, BRIT J HOSP MED, V81, DOI 10.12968/hmed.2020.0284; Ambarus C, 2012, CURR OPIN RHEUMATOL, V24, P351, DOI 10.1097/BOR.0b013e3283534df4; Arleo T, 2021, CLIN RHEUMATOL, V40, P2633, DOI 10.1007/s10067-021-05578-x; Chen C, 2021, INT J INFECT DIS, V104, P458, DOI 10.1016/j.ijid.2021.01.017; Cheng MP, 2020, ANN INTERN MED, V173, P450, DOI 10.7326/M20-2854; Chi Y, 2020, J INFECT DIS, V222, P746, DOI 10.1093/infdis/jiaa363; Elefante E, 2020, CLIN EXP RHEUMATOL, V38, P577; Emmi G, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102575; Galipeau Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.610688; Jamilloux Y, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102567; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424; Padoan A, 2020, CLIN CHEM LAB MED, V58, P1081, DOI 10.1515/cclm-2020-0443; Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9; Rudwaleit M, 2011, ANN RHEUM DIS, V70, P25, DOI 10.1136/ard.2010.133645; Rudwaleit M, 2009, ANN RHEUM DIS, V68, P777, DOI 10.1136/ard.2009.108233; Sharmeen S, 2020, SEMIN ARTHRITIS RHEU, V50, P680, DOI 10.1016/j.semarthrit.2020.05.010; Wajnberg A, 2020, SCIENCE, V370, P1227, DOI 10.1126/science.abd7728; Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005; Yonas E, 2020, DIABETES METAB SYND, V14, P2219, DOI 10.1016/j.dsx.2020.11.011	20	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 11	2021	12								682850	10.3389/fimmu.2021.682850	http://dx.doi.org/10.3389/fimmu.2021.682850			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SY3JI	34177927	Green Published, gold			2022-12-18	WOS:000665786800001
J	Rahman, N; Miura, S; Okawa, M; Kibria, MG; Islam, MM; Kuroda, Y				Rahman, Nafsoon; Miura, Shiho; Okawa, Mami; Kibria, Md. Golam; Islam, Mohammad Monirul; Kuroda, Yutaka			Solubility Controlling Peptide Tags of Opposite Charges Generate a Bivalent Immune Response Against Dengue ED3 Serotypes 3 and 4	FRONTIERS IN IMMUNOLOGY			English	Article						SCP-tag (solubility controlling peptide tag); electrostatic interaction; sub-visible aggregates; dengue envelope protein domain 3 (ED3); immune response	NEUTRALIZING ANTIBODIES; IMMUNOGENICITY; PROTEINS; FLUORESCENCE; PARTICLES; ADJUVANTS; VACCINES; INNATE; FORM	We previously demonstrated that a protein's immunogenicity could be substantially increased by attaching a hydrophobic solubility controlling peptide tag (SCP-tag) producing small sub-visible aggregates. Here, we report the oligomerization of Dengue envelop protein domain 3 (ED3), and consequently, its immunogenicity increase by mixing ED3s attached with SCP-tags of opposite charges at equimolar concentration. We used ED3 of serotype 3 (D3ED3) and serotype 4 (D4ED3), which are, respectively, moderately and poorly immunogenic, and their SCP tagged variants constructed by attaching either a C-termini 5-Aspartic acid (C5D) or a 5-Lysine (C5K) tag. Light scattering indicated that the isolated tagged ED3s remained monomeric, but mixing the C5D and C5K tagged ED3s at equimolar concentration generated sub-visible aggregates or oligomers of similar to 500 nm through electrostatic interaction. In addition, the oligomerized ED3s remained in a native-like state, as assessed by fluorescence spectroscopy and circular dichroism. The in vivo immunogenicity of the D3ED3 and D4ED3 oligomers generated by the charged tags increased by 5 and 16 fold, respectively. Furthermore, injection of heterotypic ED3 oligomers (D3C5D+D4C5K) induced an immune response against both D3ED3 and D4ED3 in 3 of 4 responsive mice, and the IgG titer of the bivalent anti-D3C5D-D4C5K sera was over 100 times higher than that generated by co-injecting the untagged D3ED3 and D4ED3 (D3+D4). Altogether, these observations suggest that SCP-tags could be used as a platform for producing a long-sought tetravalent dengue vaccine.	[Rahman, Nafsoon; Miura, Shiho; Okawa, Mami; Kibria, Md. Golam; Kuroda, Yutaka] Univ Tokyo, Grad Sch Engn, Dept Biotechnol & Life Sci, Agr & Technol, Tokyo, Japan; [Islam, Mohammad Monirul] Univ Chittagong, Dept Biochem & Mol Biol, Chittagong, Bangladesh	University of Tokyo; University of Chittagong	Kuroda, Y (corresponding author), Univ Tokyo, Grad Sch Engn, Dept Biotechnol & Life Sci, Agr & Technol, Tokyo, Japan.	ykuroda@cc.tuat.ac.jp	Kuroda, Yutaka/G-1094-2013	Kuroda, Yutaka/0000-0002-3221-4295; Kibria, Md. Golam/0000-0001-9973-4933	JSPS (KAKENHI) [15H04359, 18H02385]; Japanese government (Monbukagakusho: MEXT)	JSPS (KAKENHI)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Japanese government (Monbukagakusho: MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was supported by a JSPS Grant-in-Aid for Scientific Research (KAKENHI-15H04359 and 18H02385) to YK, and a Japanese government (Monbukagakusho: MEXT) Ph.D. scholarship toNR.	Azevedo AS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020528; Bachmann MF, 1995, EUR J IMMUNOL, V25, P3445, DOI 10.1002/eji.1830251236; BUSHUEVA TL, 1978, BIOCHIM BIOPHYS ACTA, V534, P141, DOI 10.1016/0005-2795(78)90484-1; Chen HW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145717; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; Crill WD, 2001, J VIROL, V75, P7769, DOI 10.1128/JVI.75.16.7769-7773.2001; DeLano WL., 2016, ABSTRACTS PAPERS AM, V8, P82009, DOI [10.1007/s12551-016-0218-6, DOI 10.1007/S12551-016-0218-6]; den Engelsman J, 2011, PHARM RES-DORDR, V28, P920, DOI 10.1007/s11095-010-0297-1; Deng SQ, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010063; Elahi M, 2014, BBA-PROTEINS PROTEOM, V1844, P585, DOI 10.1016/j.bbapap.2013.12.013; Elahi M, 2013, PROTEINS, V81, P1090, DOI 10.1002/prot.24237; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fahimi H, 2018, APPL MICROBIOL BIOT, V102, P2977, DOI 10.1007/s00253-018-8822-y; Freitag AJ, 2015, PHARM RES-DORDR, V32, P430, DOI 10.1007/s11095-014-1472-6; Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018; GUPTA RK, 1995, VACCINE, V13, P1263, DOI 10.1016/0264-410X(95)00011-O; Hermeling S, 2005, PHARM RES-DORDR, V22, P1997, DOI 10.1007/s11095-005-8177-9; Holmes EC, 2003, INFECT GENET EVOL, V3, P19, DOI [10.1016/S1567-1348(03)00004-2, 10.1016/S1567-1348(02)00153-3]; Islam MM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00333; Islam MM, 2012, BBA-PROTEINS PROTEOM, V1824, P1144, DOI 10.1016/j.bbapap.2012.06.005; Joshi VB, 2013, HUM VACC IMMUNOTHER, V9, P2584, DOI 10.4161/hv.26136; Joubert MK, 2012, J BIOL CHEM, V287, P25266, DOI 10.1074/jbc.M111.330902; Kabir MG, 2018, BBA-PROTEINS PROTEOM, V1866, P366, DOI 10.1016/j.bbapap.2017.09.012; Karch CP, 2016, BIOCHEM PHARMACOL, V120, P1, DOI 10.1016/j.bcp.2016.05.001; Kato A, 2007, J MOL BIOL, V372, P737, DOI 10.1016/j.jmb.2007.06.066; Kato A, 2007, BIOPOLYMERS, V85, P12, DOI 10.1002/bip.20596; Khan MA, 2013, BBA-PROTEINS PROTEOM, V1834, P2107, DOI 10.1016/j.bbapap.2013.06.013; Khurana S, 2011, J VIROL, V85, P10945, DOI 10.1128/JVI.05406-11; Kibria MG, 2020, EUR J PHARM BIOPHARM, V152, P164, DOI 10.1016/j.ejpb.2020.05.006; Kulkarni MR, 2015, BBA-PROTEINS PROTEOM, V1854, P1438, DOI 10.1016/j.bbapap.2015.07.004; Kuroda Yutaka, 2018, Biophys Rev, V10, P473, DOI 10.1007/s12551-017-0342-y; Lawrence MS, 2007, J AM CHEM SOC, V129, P10110, DOI 10.1021/ja071641y; Lazo L, 2020, EXPERT REV VACCINES, V19, P807, DOI 10.1080/14760584.2020.1813578; Mannie MD, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00255; Masavuli MG, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01145; Metz SW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12677-6; Maeda DLNF, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01175; OSATOMI K, 1990, VIROLOGY, V176, P643, DOI 10.1016/0042-6822(90)90037-R; PAKULA AA, 1990, NATURE, V344, P363, DOI 10.1038/344363a0; Portillo AM, 2012, J PHYS-CONDENS MAT, V24, DOI 10.1088/0953-8984/24/16/164205; Rahman N, 2020, FEBS OPEN BIO, V10, P1947, DOI 10.1002/2211-5463.12941; Rahman N, 2020, MOL PHARMACEUT, V17, P1629, DOI 10.1021/acs.molpharmaceut.0c00071; RARITY JG, 1989, P ROY SOC LOND A MAT, V423, P89, DOI 10.1098/rspa.1989.0043; Ratanji KD, 2014, J IMMUNOTOXICOL, V11, P99, DOI 10.3109/1547691X.2013.821564; Rosenberg AS, 2006, AAPS J, V8, pE501, DOI 10.1208/aapsj080359; Saotome T, 2016, BIOCHEMISTRY-US, V55, P4469, DOI 10.1021/acs.biochem.6b00431; Sauerborn M, 2010, TRENDS PHARMACOL SCI, V31, P53, DOI 10.1016/j.tips.2009.11.001; Snapper CM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00598; Stetefeld Jorg, 2016, Biophys Rev, V8, P409, DOI 10.1007/s12551-016-0218-6; Telikepalli S, 2015, J PHARM SCI-US, V104, P1575, DOI 10.1002/jps.24379; Thomas SJ, 2019, HUM VACC IMMUNOTHER, V15, P2295, DOI 10.1080/21645515.2019.1658503; Wei YJ, 2018, J PHARM SCI-US, V107, P2325, DOI 10.1016/j.xphs.2018.05.019; Whitehead SS, 2007, NAT REV MICROBIOL, V5, P518, DOI 10.1038/nrmicro1690; Wilson KL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00331; Wu YM, 2015, VACCINE, V33, P7518, DOI 10.1016/j.vaccine.2015.09.097; Ying TL, 2012, J BIOL CHEM, V287, P19399, DOI 10.1074/jbc.M112.368647; ZHAO B, 1986, VIROLOGY, V155, P77, DOI 10.1016/0042-6822(86)90169-8	57	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 11	2021	12								671590	10.3389/fimmu.2021.671590	http://dx.doi.org/10.3389/fimmu.2021.671590			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SY3KC	34177912	gold, Green Published			2022-12-18	WOS:000665788900001
J	Zambonatto, RF; Teixeira, RN; Poma, SD; da Silva, EB; de Almeida, MM; Leite, GD; dos Santos, CMM; Alves, HHD; Gorjao, R; Pithon-Curi, TC; Carvalho, CRF; Curi, R; Levada-Pires, AC				Zambonatto, Raquel Freitas; Teixeira, Renata Nakata; Poma, Sarah de Oliveira; da Silva, Eliane Borges; de Almeida, Mariana Mendes; Leite, Gerson dos Santos; dos Santos, Cesar Miguel Momesso; Alves, Heloisa Helena de Oliveira; Gorjao, Renata; Pithon-Curi, Tania Cristina; Carvalho, Celso R. F.; Curi, Rui; Levada-Pires, Adriana Cristina			Features of Neutrophils From Atopic and Non-Atopic Elite Endurance Runners	FRONTIERS IN IMMUNOLOGY			English	Article						athletes; leukocytes; cytokines; lipopolysaccharide; allergy; IgE	CELL-DEATH; ALLERGIC RHINITIS; GENE-EXPRESSION; TNF-ALPHA; APOPTOSIS; ASTHMA; PREVALENCE; MECHANISMS; SYMPTOMS; CYTOKINE	We collected peripheral blood from thirty-nine elite male endurance runners at rest (24 hours after the last exercise session) and used the Allergy Questionnaire for Athletes score and plasma specific IgE level to separate them into atopic and non-atopic athletes. Neutrophils obtained from atopic and non-atopic athletes were subsequently stimulated in vitro with fMLP (N-formyl-methionyl-leucyl-phenylalanine), LPS (lipopolysaccharide), or PMA (phorbol 12-myristate 13-acetate). Neutrophils from non-atopic runners responded appropriately to LPS, as evidenced by the production of pro (IL-8, TNF-alpha, and IL-6) and anti-inflammatory (IL-10) cytokines. Neutrophils from atopic elite runners exhibited lower responses to LPS stimulus as indicated by no increase in IL-1 beta, TNF-alpha, and IL-6 production. Neutrophils from non-atopic and atopic runners responded similarly to fMLP stimulation, indicating that migration function remained unaltered. Both groups were unresponsive to PMA induced reactive oxygen species (ROS) production. Training hours and training volume were not associated with neutrophil IgE receptor gene expression or any evaluated neutrophil function. Since non-atopic runners normally responded to LPS stimulation, the reduced neutrophil response to the stimuli was most likely due to the atopic state and not exercise training. The findings reported are of clinical relevance because atopic runners exhibit a constant decline in competition performance and are more susceptible to invading microorganisms.	[Zambonatto, Raquel Freitas; Poma, Sarah de Oliveira; da Silva, Eliane Borges; de Almeida, Mariana Mendes; dos Santos, Cesar Miguel Momesso; Alves, Heloisa Helena de Oliveira; Gorjao, Renata; Pithon-Curi, Tania Cristina; Curi, Rui; Levada-Pires, Adriana Cristina] Univ Cruzeiro Sul, Inst Phys Act Sci & Sports, Interdisciplinary Postgrad Program Hlth Sci, Sao Paulo, Brazil; [Teixeira, Renata Nakata; Leite, Gerson dos Santos; Carvalho, Celso R. F.] Univ Sao Paulo, Sch Med, Dept Phys Therapy, Sao Paulo, Brazil	Universidade Cruzeiro do Sul; Universidade de Sao Paulo	Levada-Pires, AC (corresponding author), Univ Cruzeiro Sul, Inst Phys Act Sci & Sports, Interdisciplinary Postgrad Program Hlth Sci, Sao Paulo, Brazil.	adriana.pires@cruzeirodosul.edu.br	Pires, Adriana Cristina Levada/AAC-9783-2021; Momesso, Cesar Miguel/D-3281-2012	PITHON-CURI, TANIA CRISTINA/0000-0002-9714-9105; de Oliveira Alves, Heloisa Helena/0000-0002-5378-4510; Poma, Sarah/0000-0002-8482-8467; Momesso, Cesar Miguel/0000-0001-6448-6028	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [99999.006711/2015-04]	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This work is supported by research funding from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) (99999.006711/2015-04).	Amulic B, 2012, ANNU REV IMMUNOL, V30, P459, DOI 10.1146/annurev-immunol-020711-074942; Arebro J, 2017, SCI REP-UK, V7, DOI 10.1038/srep43568; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; Belotto MF, 2010, CLIN EXP IMMUNOL, V162, P237, DOI 10.1111/j.1365-2249.2010.04240.x; Bonini M, 2015, CURR OPIN ALLERGY CL, V15, P184, DOI 10.1097/ACI.0000000000000149; Bonini M, 2009, MED SCI SPORT EXER, V41, P1034, DOI 10.1249/MSS.0b013e318193c663; Borges L, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/1684013; Borges LD, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/846021; Boukemara H, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1411-7; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P9; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; Cassatella MA, 1999, ADV IMMUNOL, V73, P369, DOI 10.1016/S0065-2776(08)60791-9; Chinda D, 2003, LUMINESCENCE, V18, P324, DOI 10.1002/bio.744; Cury-Boaventura MF, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00202; Dinmezel S, 2005, ALLERGY ASTHMA PROC, V26, P403; Faniran AO, 1999, THORAX, V54, P606, DOI 10.1136/thx.54.7.606; Ghavami S, 2014, PROG NEUROBIOL, V112, P24, DOI 10.1016/j.pneurobio.2013.10.004; Hajeer AH, 2000, MICROSC RES TECHNIQ, V50, P216, DOI 10.1002/1097-0029(20000801)50:3<216::AID-JEMT5>3.0.CO;2-Q; Helenius IJ, 1998, J ALLERGY CLIN IMMUN, V101, P646, DOI 10.1016/S0091-6749(98)70173-3; Hidalgo MA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/120348; Hochdoerfer T, 2013, CELL SIGNAL, V25, P1339, DOI 10.1016/j.cellsig.2013.02.022; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; Hurme M, 1998, ANN MED, V30, P469, DOI 10.3109/07853899809002488; Ivanova D, 2016, CHINESE J CANCER RES, V28, P383, DOI 10.21147/j.issn.1000-9604.2016.04.01; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kroemer G, 1998, CELL DEATH DIFFER, V5, P547, DOI 10.1038/sj.cdd.4400387; Kuhns Douglas B, 2015, Curr Protoc Immunol, V111, DOI 10.1002/0471142735.im0723s111; Kurowski M, 2016, CLIN RESPIR J, V10, P231, DOI 10.1111/crj.12210; Lagranha CJ, 2007, CELL BIOCHEM FUNCT, V25, P563, DOI 10.1002/cbf.1421; Leliefeld PHC, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1250-4; Levada-Pires AC, 2008, MED SCI SPORT EXER, V40, P1447, DOI 10.1249/MSS.0b013e31816dc89e; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo HBR, 2008, AM J HEMATOL, V83, P288, DOI 10.1002/ajh.21078; Mayadas TN, 2014, ANNU REV PATHOL-MECH, V9, P181, DOI 10.1146/annurev-pathol-020712-164023; McDonald PP, 1997, BLOOD, V89, P3421, DOI 10.1182/blood.V89.9.3421; Moldoveanu AI, 2001, SPORTS MED, V31, P115, DOI 10.2165/00007256-200131020-00004; Monteseirin J, 2005, CLIN EXP ALLERGY, V35, P1204, DOI 10.1111/j.1365-2222.2005.02320.x; Monteseirin J, 2009, J INVEST ALLERG CLIN, V19, P340; Monteseirin J, 2004, J LEUKOCYTE BIOL, V76, P692, DOI 10.1189/jlb.0903441; Mooren FC, 2001, MED SCI SPORT EXER, V33, P242; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Owen WE, 2010, CLIN CHIM ACTA, V411, P1073, DOI 10.1016/j.cca.2010.03.041; Palanisamy V, 2012, J DENT RES, V91, P651, DOI 10.1177/0022034512437372; Panaro MA, 1999, IMMUNOPHARM IMMUNOT, V21, P397, DOI 10.3109/08923979909007117; Prasse A, 2007, J ALLERGY CLIN IMMUN, V119, P464, DOI 10.1016/j.jaci.2006.09.030; Robson-Ansley P, 2012, MED SCI SPORT EXER, V44, P999, DOI 10.1249/MSS.0b013e318243253d; Ryter SW, 2007, ANTIOXID REDOX SIGN, V9, P49, DOI 10.1089/ars.2007.9.49; Santos VC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166687; Santos VC, 2013, CELL BIOCHEM FUNCT, V31, P237, DOI 10.1002/cbf.2877; SIMON SI, 1992, J IMMUNOL, V149, P2765; Spence L, 2007, MED SCI SPORT EXER, V39, P577, DOI 10.1249/mss.0b013e31802e851a; Surda Pavol, 2017, Int J Otolaryngol, V2017, P8098426, DOI 10.1155/2017/8098426; Kuwabara WMT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116410; Tecchio C, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00508; Teixeira RN, 2018, CLIN J SPORT MED, V28, P268, DOI 10.1097/JSM.0000000000000444; Teixeira RN, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-7; Teixeira RN, 2018, INT J SPORTS MED, V39, P720, DOI 10.1055/a-0633-9001; Thomas Silke, 2010, Allergy Asthma Clin Immunol, V6, P31, DOI 10.1186/1710-1492-6-31; Todo-Bom A, 2007, J INVEST ALLERG CLIN, V17, P107; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vega A, 2006, J LEUKOCYTE BIOL, V80, P152, DOI 10.1189/jlb.0705411; Ventura I, 2014, PEDIAT ALLERG IMM-UK, V25, P129, DOI 10.1111/pai.12145; Vogeser M, 2017, CLIN CHEM LAB MED, V55, P826, DOI 10.1515/cclm-2016-0400; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zhang JM, 2007, INT ANESTHESIOL CLIN, V45, P27, DOI 10.1097/AIA.0b013e318034194e	67	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 11	2021	12								670763	10.3389/fimmu.2021.670763	http://dx.doi.org/10.3389/fimmu.2021.670763			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SY2ZM	34177910	gold, Green Published			2022-12-18	WOS:000665760900001
J	Olivera, A; Laky, K; Hogan, SP; Frischmeyer-Guerrerio, P				Olivera, Ana; Laky, Karen; Hogan, Simon Patrick; Frischmeyer-Guerrerio, Pamela			Editorial: Innate Cells in the Pathogenesis of Food Allergy	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						food allergy; eosinophilic esophagitis; innate cells; sensitization; cofactors; oral tolerance; microbiota	MAST-CELLS; MECHANISMS		[Olivera, Ana] NIAID, Mast Cell Biol Sect, Lab Allerg Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Laky, Karen; Frischmeyer-Guerrerio, Pamela] NIAID, Food Allergy Res Sect, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Hogan, Simon Patrick] Univ Michigan, Dept Pathol, Michigan Med, Mary H Weiser Food Allergy Ctr, Ann Arbor, MI 48109 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Michigan System; University of Michigan	Olivera, A (corresponding author), NIAID, Mast Cell Biol Sect, Lab Allerg Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	ana.olivera@nih.gov			National Institutes of Health [AI138177, AI140133, AI112626]; National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID); Mary H. Weiser Food Allergy Center (MHWFAC); MHWFAC	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Mary H. Weiser Food Allergy Center (MHWFAC); MHWFAC	This work was supported by the Intramural Research Program of the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (AO, KL and PF-G) and by the National Institutes of Health grants; AI138177, AI140133, AI112626; the Mary H. Weiser Food Allergy Center (MHWFAC) and the Ask with Endowment of the MHWFAC (SH).	Abdel-Gadir A, 2019, NAT MED, V25, P1164, DOI 10.1038/s41591-019-0461-z; Falduto GH, 2021, PHARMACOL THERAPEUT, V220, DOI 10.1016/j.pharmthera.2020.107718; Galli SJ, 2020, ANNU REV IMMUNOL, V38, P49, DOI 10.1146/annurev-immunol-071719-094903; Johnston LK, 2014, J IMMUNOL, V192, P2529, DOI 10.4049/jimmunol.1303026; Marshall JS, 2004, J ALLERGY CLIN IMMUN, V114, P21, DOI 10.1016/j.jaci.2004.04.045; Ohnmacht C, 2015, SCIENCE, V349, P989, DOI 10.1126/science.aac4263; Sampson HA, 2018, J ALLERGY CLIN IMMUN, V141, P11, DOI 10.1016/j.jaci.2017.11.005; Sicherer SH, 2018, J ALLERGY CLIN IMMUN, V141, P41, DOI 10.1016/j.jaci.2017.11.003; Tomar Sunil, 2020, F1000Res, V9, DOI 10.12688/f1000research.25638.1	9	0	0	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 10	2021	12								709991	10.3389/fimmu.2021.709991	http://dx.doi.org/10.3389/fimmu.2021.709991			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SX1DU	34177970	Green Published, gold			2022-12-18	WOS:000664952700001
J	Plaza-Rojas, L; Guevara-Patino, JA				Plaza-Rojas, Lourdes; Guevara-Patino, Jose A.			The Role of NKG2D in Vitiligo (vol 12, 644131, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						vitiligo; NKG2D; T cells; horror autotoxicus; Hsp70; oxidative stress			[Plaza-Rojas, Lourdes] Loyola Univ, Dept Canc Biol, Chicago, IL 60611 USA; [Guevara-Patino, Jose A.] Loyola Univ, Dept Surg, Chicago, IL 60611 USA	Loyola University Chicago; Loyola University Chicago	Guevara-Patino, JA (corresponding author), Loyola Univ, Dept Surg, Chicago, IL 60611 USA.	jaguevara@luc.edu						Plaza-Rojas L, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.624131	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 9	2021	12								714137	10.3389/fimmu.2021.714137	http://dx.doi.org/10.3389/fimmu.2021.714137			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SW6XR	34177971	Green Published, gold			2022-12-18	WOS:000664657700001
J	Wei, LW; Shang, YQ; Liu, X; Li, XH; Chen, GQ; Liang, SP; Zou, ZY; Ding, T; Hong, ZS; Minhao,; Xia, JY				Wei, Liwen; Shang, Yuqi; Liu, Xi; Li, Xinghua; Chen, Gongqi; Liang, Siping; Zou, Zhengyu; Ding, Tao; Hong, Zhongsi; Wu, Minhao; Xia, Jinyu			Antibody Responses and the Effects of Clinical Drugs in COVID-19 Patients	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; SARS-CoV-2; antibody; chloroquine; humoral response	SARS-COV-2	The coronavirus disease 2019 (COVID-19) emerged around December 2019 and have become a global epidemic disease currently. Specific antibodies against SAS-COV-2 could be detected in COVID-19 patients' serum or plasma, but the clinical values of these antibodies as well as the effects of clinical drugs on humoral responses have not been fully demonstrated. In this study, 112 plasma samples were collected from 36 patients diagnosed with laboratory-confirmed COVID-19 in the Fifth Affiliated Hospital of Sun Yat-sen University. The IgG and IgM antibodies against receptor binding domain (RBD) and spike protein subunit 1 (S1) of SAS-COV-2 were detected by ELISA. We found that COVID-19 patients generated specific antibodies against SARS-CoV-2 after infection, and the levels of anti-RBD IgG within 2 to 3 weeks from onset were negatively associated with the time of positive-to-negative conversion of SARS-CoV-2 nucleic acid. Patients with severe symptoms had higher levels of anti-RBD IgG in 2 to 3 weeks from onset. The use of chloroquine did not significantly influence the patients' antibody titer but reduced C-reaction protein (CRP) level. Using anti-viral drugs (lopinavir/ritonavir or arbidol) reduced antibody titer and peripheral lymphocyte count. While glucocorticoid therapy developed lower levels of peripheral lymphocyte count and higher levels of CRP, lactate dehydrogenase (LDH), alpha-Hydroxybutyrate dehydrogenase(alpha-HBDH), total bilirubin (TBIL), direct bilirubin (DBIL). From these results, we suggested that the anti-RBD IgG may provide an early protection of host humoral responses against SAS-COV-2 infection within 2 to 3 weeks from onset, and clinical treatment with different drugs displayed distinct roles in humoral and inflammatory responses.	[Wei, Liwen; Shang, Yuqi; Liu, Xi; Wu, Minhao; Xia, Jinyu] Sun Yat Sen Univ, Program Infect Dis, Affiliated Hosp 5, Zhongshan Sch Med, Guangzhou, Peoples R China; [Shang, Yuqi; Liu, Xi; Li, Xinghua; Chen, Gongqi; Hong, Zhongsi; Xia, Jinyu] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Infect Dis, Zhuhai, Peoples R China; [Wei, Liwen; Liang, Siping; Zou, Zhengyu; Ding, Tao; Wu, Minhao] Sun Yat Sen Univ, Minist Educ, Key Lab Trop Dis Control, Guangzhou, Peoples R China; [Wei, Liwen; Liang, Siping; Zou, Zhengyu; Ding, Tao; Wu, Minhao] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Immunol, Guangzhou, Peoples R China; [Wu, Minhao] Sun Yat Sen Univ, Zhongshan Sch Med, Biosafety Lab, Guangzhou, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Minhao,; Xia, JY (corresponding author), Sun Yat Sen Univ, Program Infect Dis, Affiliated Hosp 5, Zhongshan Sch Med, Guangzhou, Peoples R China.; Xia, JY (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Dept Infect Dis, Zhuhai, Peoples R China.; Minhao, (corresponding author), Sun Yat Sen Univ, Minist Educ, Key Lab Trop Dis Control, Guangzhou, Peoples R China.; Minhao, (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Immunol, Guangzhou, Peoples R China.; Minhao, (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Biosafety Lab, Guangzhou, Peoples R China.	wuminhao@mail.sysu.edu.cn; xiajinyu@mail.sysu.edu.cn			National Natural Science Foundation of China [31970893]; Guangdong Basic and Applied Basic Research Foundation [2020A1515010255]; Fundamental Research Funds for the Central Universities [19ykzd39, 19ykpy43]; 111 Project [B12003, B13037]; Open project of Key Laboratory of Tropical Disease Control (Sun Yat-sen University), Ministry of Education [2020kfkt08]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Basic and Applied Basic Research Foundation; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); 111 Project(Ministry of Education, China - 111 Project); Open project of Key Laboratory of Tropical Disease Control (Sun Yat-sen University), Ministry of Education	This work was supported by grants from National Natural Science Foundation of China [31970893], Guangdong Basic and Applied Basic Research Foundation [2020A1515010255], the Fundamental Research Funds for the Central Universities (19ykzd39; 19ykpy43), and the 111 Project [No. B12003, B13037], Open project of Key Laboratory of Tropical Disease Control (Sun Yat-sen University), Ministry of Education (2020kfkt08).	Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC; Cao B, 2016, CRIT CARE MED, V44, pE318, DOI 10.1097/CCM.0000000000001616; Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441; Deng LS, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.03.002; Duan Kai, 2020, Proc Natl Acad Sci U S A, V117, P9490, DOI 10.1073/pnas.2004168117; Huang Mingxing, 2020, Natl Sci Rev, V7, P1428, DOI 10.1093/nsr/nwaa113; Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007; Lane JCE, 2020, LANCET RHEUMATOL, V2, pE698, DOI 10.1016/S2665-9913(20)30276-9; Li YP, 2020, MED-CAMBRIDGE, V1, P105, DOI 10.1016/j.medj.2020.04.001; Li ZT, 2020, J MED VIROL, V92, P1518, DOI 10.1002/jmv.25727; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Lou B, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.00763-2020; Padoan A, 2020, CLIN CHEM LAB MED, V58, P1081, DOI 10.1515/cclm-2020-0443; Principi N, 2020, LANCET INFECT DIS, V20, P1118, DOI 10.1016/S1473-3099(20)30296-6; Roldan EQ, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104904; Roltgen K, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe0240; Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2; The National Institutes of Health, COR DIS 2019 COV 19; To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1; Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762; Vankadari N, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105998; Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0; WHO, COR DIS COV 19 DASHB; Wu F, 2020, SSRN ELECT, DOI [10.1101/2020.03.30.20047365, DOI 10.2139/SSRN.3566211, https://doi.org/10.1101/2020.03.30.20047365]; Wu F, 2020, NATURE, V580, pE7	25	0	0	1	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 9	2021	12								580989	10.3389/fimmu.2021.580989	http://dx.doi.org/10.3389/fimmu.2021.580989			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SW4UR	34177879	Green Published, gold			2022-12-18	WOS:000664512600001
J	Chen, YZ; Wen, SD; Xia, JW; Du, XY; Wu, Y; Pan, BZ; Zhu, W; Shen, B				Chen, Yuzhong; Wen, Shaodi; Xia, Jingwei; Du, Xiaoyue; Wu, Yuan; Pan, Banzhou; Zhu, Wei; Shen, Bo			Association of Dynamic Changes in Peripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer (vol 12, 672271, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						non-small cell lung cancer; PD-1 inhibitor; combination therapy; carcinoembryonic antigen; neutrophil-to-lymphocyte ratio; neuron-specific enolase			[Chen, Yuzhong; Wen, Shaodi; Xia, Jingwei; Du, Xiaoyue; Wu, Yuan; Pan, Banzhou; Shen, Bo] Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Canc Hosp, Nanjing, Peoples R China; [Chen, Yuzhong; Wen, Shaodi; Xia, Jingwei; Du, Xiaoyue; Wu, Yuan; Pan, Banzhou; Shen, Bo] Jiangsu Inst Canc Res, Nanjing, Peoples R China; [Zhu, Wei] Jiangsu Univ, Sch Med, Key Hematol Med Sci & Hematol Med Jiangsu Prov, Zhenjiang, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University; Jiangsu University	Shen, B (corresponding author), Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Canc Hosp, Nanjing, Peoples R China.; Shen, B (corresponding author), Jiangsu Inst Canc Res, Nanjing, Peoples R China.	shenbo987@126.com						Chen YZ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.672271	1	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 7	2021	12								713268	10.3389/fimmu.2021.713268	http://dx.doi.org/10.3389/fimmu.2021.713268			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SV4SL	34163493	Green Published, gold			2022-12-18	WOS:000663811700001
J	Jacque, E; Chottin, C; Laubreton, D; Nogre, M; Ferret, C; de Marcos, S; Baptista, L; Drajac, C; Mondon, P; De Romeuf, C; Rameix-Welti, MA; Eleouet, JF; Chtourou, S; Riffault, S; Perret, G; Descamps, D				Jacque, Emilie; Chottin, Claire; Laubreton, Daphne; Nogre, Michel; Ferret, Cecile; de Marcos, Sandrine; Baptista, Linda; Drajac, Carole; Mondon, Philippe; De Romeuf, Christophe; Rameix-Welti, Marie-Anne; Eleouet, Jean-Francois; Chtourou, Sami; Riffault, Sabine; Perret, Gerald; Descamps, Delphyne			Hyper-Enriched Anti-RSV Immunoglobulins Nasally Administered: A Promising Approach for Respiratory Syncytial Virus Prophylaxis	FRONTIERS IN IMMUNOLOGY			English	Article						concentration; nasal administration; bioprocess; human plasma; hyper-immune immunoglobulins; prophylactic strategy; neutralization; viral infection	INTRAVENOUS IMMUNOGLOBULIN; FUSION GLYCOPROTEIN; ANTIBODIES; INFECTION; ADULTS; CHILDREN; BURDEN; DISEASE; VACCINE	Respiratory syncytial virus (RSV) is a public health concern that causes acute lower respiratory tract infection. So far, no vaccine candidate under development has reached the market and the only licensed product to prevent RSV infection in at-risk infants and young children is a monoclonal antibody (Synagis(R)). Polyclonal human anti-RSV hyper-immune immunoglobulins (Igs) have also been used but were superseded by Synagis(R) owing to their low titer and large infused volume. Here we report a new drug class of immunoglobulins, derived from human non hyper-immune plasma that was generated by an innovative bioprocess, called Ig cracking, combining expertises in plasma-derived products and affinity chromatography. By using the RSV fusion protein (F protein) as ligand, the Ig cracking process provided a purified and concentrated product, designated hyper-enriched anti-RSV IgG, composed of at least 15-20% target-specific-antibodies from normal plasma. These anti-RSV Ig displayed a strong in vitro neutralization effect on RSV replication. Moreover, we described a novel prophylactic strategy based on local nasal administration of this unique hyper-enriched anti-RSV IgG solution using a mouse model of infection with bioluminescent RSV. Our results demonstrated that very low doses of hyper-enriched anti-RSV IgG can be administered locally to ensure rapid and efficient inhibition of virus infection. Thus, the general hyper-enriched Ig concept appeared a promising approach and might provide solutions to prevent and treat other infectious diseases. Importance Respiratory Syncytial Virus (RSV) is the major cause of acute lower respiratory infections in children, and is also recognized as a cause of morbidity in the elderly. There are still no vaccines and no efficient antiviral therapy against this virus. Here, we described an approach of passive immunization with a new class of hyper-enriched anti-RSV immunoglobulins (Ig) manufactured from human normal plasma. This new class of immunoglobulin plasma derived product is generated by an innovative bioprocess, called Ig cracking, which requires a combination of expertise in both plasma derived products and affinity chromatography. The strong efficacy in a small volume of these hyper-enriched anti-RSV IgG to inhibit the viral infection was demonstrated using a mouse model. This new class of immunoglobulin plasma-derived products could be applied to other pathogens to address specific therapeutic needs in the field of infectious diseases or even pandemics, such as COVID-19.	[Jacque, Emilie; Nogre, Michel; de Marcos, Sandrine; Baptista, Linda; Mondon, Philippe; De Romeuf, Christophe; Chtourou, Sami; Perret, Gerald] LFB Biotechnol, Les Ulis, France; [Chottin, Claire; Laubreton, Daphne; Ferret, Cecile; Drajac, Carole; Eleouet, Jean-Francois; Riffault, Sabine; Descamps, Delphyne] Univ Paris Saclay, VIM, INRAE, UVSQ, Jouy En Josas, France; [Rameix-Welti, Marie-Anne] Univ Paris Saclay, UVSQ, U1173, Infect & Inflammat,INSERM, Montigny Le Bretonneux, France; [Rameix-Welti, Marie-Anne] Hop Ambroise Pare, AP HP, Lab Microbiol, Boulogne, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP	Chtourou, S (corresponding author), LFB Biotechnol, Les Ulis, France.; Descamps, D (corresponding author), Univ Paris Saclay, VIM, INRAE, UVSQ, Jouy En Josas, France.	s.chtourou6@gmail.com; delphyne.descamps@inrae.fr	Laubreton, Daphne/GRT-0001-2022	Rameix-Welti, Marie-Anne/0000-0002-5901-3856; Mondon, Philippe/0000-0002-3538-2200	Ile de France region (SESAME)	Ile de France region (SESAME)(Region Ile-de-France)	We thank Dr. Isabelle Schwartz-Cornil (INRAE, Jouy-en-Josas) and Dr. Geraldine Taylor (The Pirbright Institute) for helpful discussion and critical reading of the manuscript. We thank all members from the Infectiology offishes and rodent facility unit (IERP, INRAE, 2018. doi: 10.15454/1.5572427140471238E12) for their support in the animal facilities. We thank the Emerg'in platform for access to the IVIS-200, which was financed by the Ile de France region (SESAME).	Backman K, 2014, ACTA PAEDIATR, V103, P850, DOI 10.1111/apa.12662; Bozzo J, 2017, EXPERT REV ANTI-INFE, V15, P585, DOI 10.1080/14787210.2017.1328278; Branche AR, 2015, DRUG AGING, V32, P261, DOI 10.1007/s40266-015-0258-9; Chatzis O, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3002-3; Collins PL, 2007, FIELDS VIROLOGY, P1601; Coultas JA, 2019, THORAX, V74, P986, DOI 10.1136/thoraxjnl-2018-212212; DEBRE M, 1993, LANCET, V342, P945, DOI 10.1016/0140-6736(93)92000-J; Dhainaut F, 2013, VOX SANG, V104, P115, DOI 10.1111/j.1423-0410.2012.01648.x; Eijkhout HW, 2001, ANN INTERN MED, V135, P165, DOI 10.7326/0003-4819-135-3-200108070-00008; Fleming DM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1218-z; Gilman MSA, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaj1879; Graham BS, 2017, CURR OPIN VIROL, V23, P107, DOI 10.1016/j.coviro.2017.03.012; GRAHAM BS, 1988, J MED VIROL, V26, P153, DOI 10.1002/jmv.1890260207; HEMMING VG, 1988, ANTIMICROB AGENTS CH, V32, P1269, DOI 10.1128/AAC.32.8.1269; Herve PL, 2016, J CONTROL RELEASE, V243, P146, DOI 10.1016/j.jconrel.2016.10.003; Kaur L, 2018, ARTIF CELL NANOMED B, V46, P452, DOI 10.1080/21691401.2017.1345927; Kazatchkine MD, 2001, NEW ENGL J MED, V345, P747, DOI 10.1056/NEJMra993360; Killikelly AM, 2016, SCI REP-UK, V6, DOI 10.1038/srep34108; McLellan JS, 2013, SCIENCE, V340, P1113, DOI 10.1126/science.1234914; McLellan JS, 2011, J VIROL, V85, P7788, DOI 10.1128/JVI.00555-11; Mouquet H, 2010, NATURE, V467, P591, DOI 10.1038/nature09385; O'Brien KL, 2019, LANCET, V394, P757, DOI 10.1016/S0140-6736(19)30721-4; Pelfrene E, 2019, CLIN MICROBIOL INFEC, V25, P60, DOI 10.1016/j.cmi.2018.04.024; PRINCE GA, 1987, J VIROL, V61, P1851, DOI 10.1128/JVI.61.6.1851-1854.1987; Rameix-Welti MA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6104; Rossey I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14158; Sesterhenn F, 2020, SCIENCE, V368, P730, DOI 10.1126/science.aay5051; Sesterhenn F, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000164; Shi T, 2017, LANCET, V390, P946, DOI [10.1016/s0140-6736(17)30938-8, 10.1016/S0140-6736(17)30938-8]; Vitiello G, 2019, INTERN EMERG MED, V14, P1041, DOI 10.1007/s11739-019-02150-z; Zhu Q, 2011, J INFECT DIS, V203, P674, DOI 10.1093/infdis/jiq100	31	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 7	2021	12								683902	10.3389/fimmu.2021.683902	http://dx.doi.org/10.3389/fimmu.2021.683902			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SV4WL	34163482	Green Published, gold			2022-12-18	WOS:000663822200001
J	Li, Y; Wang, JQ; Wu, LL; Li, XT; Zhang, XY; Zhang, GQ; Xu, SQ; Sun, SJ; Jiao, SC				Li, Ye; Wang, Jiaqian; Wu, Liangliang; Li, Xiaoting; Zhang, Xiaoyun; Zhang, Guoqing; Xu, Shengqiang; Sun, Shengjie; Jiao, Shunchang			Diversity of Dominant Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor Treatment in Advanced Cancers	FRONTIERS IN IMMUNOLOGY			English	Article						advanced cancer; immune checkpoint inhibitors; T cell repertoire; high-throughput sequencing; soluble checkpoint protein	GROWTH-FACTOR; BLOCKADE; EXPRESSION	Dynamic changes of the peripheral T cell receptor (TCR) and soluble receptors and ligands (sRLs) have the potential to be used as biomarkers to monitor the evolution of the immune system in tumor patients undergoing immunotherapy. These functional biomarkers could be used to predict immune response to treatment with immune checkpoint inhibitors (ICIs) and to provide high-value information on the immune function status of cancer patients, thereby helping physicians to make effective clinical decisions. We collected paired pre- and post-treatment peripheral blood samples from 31 solid tumor patients treated with ICIs. TCR and sRL status were investigated using next-generation sequencing and magnetic bead panels. We found that the diversity of the dominant TCR clone at baseline was correlated with durable clinical benefit in patients receiving single-agent treatment. The D50 index, the diversity from the cumulative 50% of the total complementary determinant region 3, was obtained during treatment. A significant difference in progression-free survival was demonstrated between the D50 high and D50 low groups. This result was validated in an independent cohort. A signature including soluble immune checkpoint proteins (sICPs) was identified. Upregulation of the signature during treatment was correlated with durable clinical benefit. All these results indicate that a novel biomarker based on peripheral TCR and sICPs has the potential to be used in prognostic prediction and for rapid determination of therapeutic outcomes in patients treated with immune checkpoint inhibitors.	[Li, Ye] Chinese Peoples Liberat Army Gen Hosp, Dept Radiotherapy, Med Ctr 1, Beijing, Peoples R China; [Li, Ye; Wu, Liangliang; Zhang, Xiaoyun; Jiao, Shunchang] Chinese Peoples Liberat Army Gen Hosp, Oncol Lab, Med Ctr 1, Beijing, Peoples R China; [Li, Ye] Med Sch Chinese PLA, Beijing, Peoples R China; [Wang, Jiaqian; Li, Xiaoting; Xu, Shengqiang] YuceBio, Shenzhen, Peoples R China; [Wang, Jiaqian; Li, Xiaoting; Xu, Shengqiang] YutaiAntigen, Shenzhen, Peoples R China; [Zhang, Guoqing; Sun, Shengjie; Jiao, Shunchang] Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, Med Ctr 1, Beijing, Peoples R China	Chinese People's Liberation Army General Hospital; Chinese People's Liberation Army General Hospital; Chinese People's Liberation Army General Hospital; Chinese People's Liberation Army General Hospital	Jiao, SC (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Oncol Lab, Med Ctr 1, Beijing, Peoples R China.; Sun, SJ; Jiao, SC (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, Med Ctr 1, Beijing, Peoples R China.	ssjdoctor@163.com; jiaosc@vip.sina.com	Wang, Jiaqian/AHA-3427-2022	Jiao, Shunchang/0000-0002-9120-5233				Ali Z, 2019, JCPSP-J COLL PHYSICI, V29, P235, DOI 10.29271/jcpsp.2019.03.235; Bolotin DA, 2015, NAT METHODS, V12, P380, DOI 10.1038/nmeth.3364; Chen F, 2016, J IMMUNOL METHODS, V434, P1, DOI 10.1016/j.jim.2016.03.005; Chen YX, 2017, GIGASCIENCE, V7, DOI 10.1093/gigascience/gix120; Crosby EJ, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1421891; Fairfax BP, 2020, NAT MED, V26, P193, DOI 10.1038/s41591-019-0734-6; Fluss R, 2005, BIOMETRICAL J, V47, P458, DOI 10.1002/bimj.200410135; Gordon A., 2010, FASTQA SHORT R UNPUB; Hogan SA, 2019, CANCER IMMUNOL RES, V7, P77, DOI 10.1158/2326-6066.CIR-18-0136; Hou DN, 2016, SCI REP-UK, V6, DOI 10.1038/srep33843; Jaccard P., 1912, NEW PHYTOL, V11, P37, DOI [DOI 10.1111/J.1469-8137.1912.TB05611.X, 10.1111/j.1469-8137.1912.tb05611.x]; James R., 2011, NUCLEIC ACIDS RES, DOI [10.1093/nar/gkz950, DOI 10.1093/NAR/GKZ950]; Kim KH, 2019, CLIN CANCER RES, V25, P2144, DOI 10.1158/1078-0432.CCR-18-1449; Liu D, 2019, NAT MED, V25, P1916, DOI 10.1038/s41591-019-0654-5; Msaouel P, 2017, ONCOTARGET, V8, P42149, DOI 10.18632/oncotarget.15011; Postow M., 2014, J IMMUNOTHERAPY CANC, V2, DOI [10.1186/2051-1426-2-s3-o8, DOI 10.1186/2051-1426-2-S3-O8]; Postow MA, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0070-4; Prat A, 2017, CANCER RES, V77, P3540, DOI 10.1158/0008-5472.CAN-16-3556; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Roh W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3560; Rosati E, 2017, BMC BIOTECHNOL, V17, DOI 10.1186/s12896-017-0379-9; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; Sharma P, 2015, CELL, V161, P205, DOI 10.1016/j.cell.2015.03.030; Takayama K, 2000, CANCER RES, V60, P2169; Turaj AH, 2017, CANCER CELL, V32, P777, DOI 10.1016/j.ccell.2017.11.001; van de Ven K, 2015, IMMUNOTHERAPY-UK, V7, P655, DOI [10.2217/IMT.15.32, 10.2217/imt.15.32]	26	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 7	2021	12								649343	10.3389/fimmu.2021.649343	http://dx.doi.org/10.3389/fimmu.2021.649343			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SV2DP	34163469	Green Published, gold			2022-12-18	WOS:000663635700001
J	Zhang, R; Cheung, CY; Seo, SU; Liu, H; Pardeshi, L; Wong, KH; Chow, LMC; Chau, MP; Wang, YX; Lee, AR; Kwon, WY; Chen, S; Chan, BKW; Wong, K; Choy, RKW; Ko, BB				Zhang, Rui; Cheung, Chris Y.; Seo, Sang-Uk; Liu, Hang; Pardeshi, Lakhansing; Wong, Koon Ho; Chow, Larry M. C.; Chau, Mary P.; Wang, Yixiang; Lee, Ah Ra; Kwon, Woon Yong; Chen, Sheng; Chan, Bill Kwan-wai; Wong, Kenneth; Choy, Richard K. W.; Ko, Ben C. B.			RUVBL1/2 Complex Regulates Pro-Inflammatory Responses in Macrophages via Regulating Histone H3K4 Trimethylation	FRONTIERS IN IMMUNOLOGY			English	Article						RUVBL1; 2; pro-inflammatory; macrophages; epigenetic modulation	CHROMATIN REMODELING COMPLEX; DEPENDENT BINDING; TRANSCRIPTION; METHYLTRANSFERASE; RECEPTOR; PROTEIN; TRANSFORMATION; EXPRESSION; RVB1/RVB2; COMPASS	Macrophages play an important role in the host defense mechanism. In response to infection, macrophages activate a genetic program of pro-inflammatory response to kill any invading pathogen, and initiate an adaptive immune response. We have identified RUVBL2 - an ATP-binding protein belonging to the AAA+ (ATPase associated with diverse cellular activities) superfamily of ATPases - as a novel regulator in pro-inflammatory response of macrophages. Gene knockdown of Ruvbl2, or pharmacological inhibition of RUVBL1/2 activity, compromises type-2 nitric oxide synthase (Nos2) gene expression, nitric oxide production and anti-bacterial activity of mouse macrophages in response to lipopolysaccharides (LPS). RUVBL1/2 inhibitor similarly inhibits pro-inflammatory response in human monocytes, suggesting functional conservation of RUVBL1/2 in humans. Transcriptome analysis further revealed that major LPS-induced pro-inflammatory pathways in macrophages are regulated in a RUVBL1/2-dependent manner. Furthermore, RUVBL1/2 inhibition significantly reduced the level of histone H3K4me3 at the promoter region of Nos2 and Il6, two prototypical pro-inflammatory genes, and diminished the recruitment of NF-kappaB to the corresponding enhancers. Our study reveals RUVBL1/2 as an integral component of macrophage pro-inflammatory responses through epigenetic regulations, and the therapeutic potentials of RUVBL1/2 inhibitors in the treatment of diseases caused by aberrant activation of pro-inflammatory pathways.	[Zhang, Rui; Cheung, Chris Y.; Chow, Larry M. C.; Chau, Mary P.; Wang, Yixiang; Chan, Bill Kwan-wai; Ko, Ben C. B.] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Peoples R China; [Zhang, Rui; Cheung, Chris Y.; Chow, Larry M. C.; Chau, Mary P.; Wang, Yixiang; Ko, Ben C. B.] Hong Kong Polytech Univ, State Key Lab Chem Biol & Drug Discovery, Hong Kong, Peoples R China; [Seo, Sang-Uk; Lee, Ah Ra] Catholic Univ Korea, Coll Med, Dept Microbiol, Dept Biomed & Hlth Sci, Seoul, South Korea; [Liu, Hang] Hong Kong Polytech Univ, Univ Res Facil Chem & Environm Anal, Hong Kong, Peoples R China; [Pardeshi, Lakhansing; Wong, Koon Ho] Univ Macau, Fac Hlth Sci, Ave Univ, Taipa, Macao, Peoples R China; [Pardeshi, Lakhansing] Univ Macau, Fac Hlth Sci, Genom & Bioinformat Core, Ave Univ, Taipa, Macao, Peoples R China; [Wong, Koon Ho] Univ Macau, Fac Hlth Sci, Inst Translat Med, Ave Univ, Taipa, Macao, Peoples R China; [Kwon, Woon Yong] Seoul Natl Univ, Dept Emergency Med, Coll Med, Seoul, South Korea; [Chen, Sheng] City Univ Hong Kong, Dept Infect Dis & Publ Hlth, Hong Kong, Peoples R China; [Wong, Kenneth; Choy, Richard K. W.] Chinese Univ Hong Kong, Dept Obstet & Gynaecol, Hong Kong, Peoples R China	Hong Kong Polytechnic University; Hong Kong Polytechnic University; Catholic University of Korea; Hong Kong Polytechnic University; University of Macau; University of Macau; University of Macau; Seoul National University (SNU); City University of Hong Kong; Chinese University of Hong Kong	Ko, BB (corresponding author), Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Peoples R China.; Ko, BB (corresponding author), Hong Kong Polytech Univ, State Key Lab Chem Biol & Drug Discovery, Hong Kong, Peoples R China.	ben.ko@polyu.edu.hk	Ko, Chi-bun/ACH-7514-2022	ZHANG, Rui/0000-0003-4343-8750; Chen, Sheng/0000-0003-3526-7808; Pardeshi, Lakhansing/0000-0003-0702-5465; Ko, Ben Chi Bun/0000-0003-2027-5899; Liu, Hang/0000-0003-3012-6061	RGC General Research Fund [15106417]; PolyU internal grant [P0009343]; Research Impact Funds [R5050-18 and R4015-19F]; Collaborative Research Fund Equipment Grant [C5012-15E]	RGC General Research Fund; PolyU internal grant; Research Impact Funds; Collaborative Research Fund Equipment Grant	This work was supported by RGC General Research Fund (15106417), PolyU internal grant (P0009343), Research Impact Funds (R5050-18 and R4015-19F), and Collaborative Research Fund Equipment Grant (C5012-15E).	Amor S, 2010, IMMUNOLOGY, V129, P154, DOI 10.1111/j.1365-2567.2009.03225.x; Angrisano T, 2012, MED MICROBIOL IMMUN, V201, P249, DOI 10.1007/s00430-011-0227-9; Arnold CN, 2012, P NATL ACAD SCI USA, V109, P12286, DOI 10.1073/pnas.1209134109; Assimon VA, 2019, ACS CHEM BIOL, V14, P236, DOI 10.1021/acschembio.8b00904; Austenaa L, 2012, IMMUNITY, V36, P572, DOI 10.1016/j.immuni.2012.02.016; Cai WW, 2020, INFLAMM RES, V69, P1087, DOI 10.1007/s00011-020-01391-5; Cho SG, 2001, MOL CELL BIOL, V21, P8398, DOI 10.1128/MCB.21.24.8398-8413.2001; Christensen J, 2007, CELL, V128, P1063, DOI 10.1016/j.cell.2007.02.003; Dauden MI, 2021, CURR OPIN STRUC BIOL, V67, P78, DOI 10.1016/j.sbi.2020.08.010; De Santa F, 2009, EMBO J, V28, P3341, DOI 10.1038/emboj.2009.271; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Feng Y, 2003, CANCER RES, V63, P8726; Gallant P, 2007, TRENDS CELL BIOL, V17, P187, DOI 10.1016/j.tcb.2007.02.005; Ghisletti S, 2009, GENE DEV, V23, P681, DOI 10.1101/gad.1773109; Gorynia S, 2011, J STRUCT BIOL, V176, P279, DOI 10.1016/j.jsb.2011.09.001; Grigoletto A, 2011, BBA-REV CANCER, V1815, P147, DOI 10.1016/j.bbcan.2010.11.002; Hargreaves DC, 2009, CELL, V138, P129, DOI 10.1016/j.cell.2009.05.047; Horejsi Z, 2010, MOL CELL, V39, P839, DOI 10.1016/j.molcel.2010.08.037; Hosokawa H, 2013, P NATL ACAD SCI USA, V110, P18626, DOI 10.1073/pnas.1311100110; Huen J, 2010, BIOCHEM CELL BIOL, V88, P29, DOI [10.1139/o09-122, 10.1139/O09-122]; Hyun K, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.11; Izumi N, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000468; Jantsch J, 2015, CELL METAB, V21, P493, DOI 10.1016/j.cmet.2015.02.003; Javary J, 2018, GUT, V67, P2192, DOI 10.1136/gutjnl-2017-314208; Jha S, 2013, MOL CELL BIOL, V33, P1164, DOI 10.1128/MCB.01567-12; Jha S, 2009, MOL CELL, V34, P521, DOI 10.1016/j.molcel.2009.05.016; Jin JY, 2005, J BIOL CHEM, V280, P41207, DOI 10.1074/jbc.M509128200; Kim D, 2019, NAT BIOTECHNOL, V37, P907, DOI 10.1038/s41587-019-0201-4; Kim SG, 2013, MOL CELL, V49, P172, DOI 10.1016/j.molcel.2012.10.003; Kleinert H, 2003, BIOL CHEM, V384, P1343, DOI 10.1515/BC.2003.152; Kouzarides T, 2007, CELL, V128, P802, DOI 10.1016/j.cell.2007.02.018; Leifer CA, 2016, J LEUKOCYTE BIOL, V100, P927, DOI 10.1189/jlb.2MR0316-117RR; Li Y, 2008, J BIOL CHEM, V283, P26771, DOI 10.1074/jbc.M802800200; Lonsdale DO, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.588863; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Ohdate H, 2003, J BIOL CHEM, V278, P14647, DOI 10.1074/jbc.M213220200; Palsson-McDermott EM, 2004, IMMUNOLOGY, V113, P153, DOI 10.1111/j.1365-2567.2004.01976.x; Parnas O, 2015, CELL, V162, P675, DOI 10.1016/j.cell.2015.06.059; Petukhov M, 2012, STRUCTURE, V20, P1321, DOI 10.1016/j.str.2012.05.012; Puri T, 2007, J MOL BIOL, V366, P179, DOI 10.1016/j.jmb.2006.11.030; Qiu H, 2015, FEBS LETT, V589, P1951, DOI 10.1016/j.febslet.2015.04.028; Rajendra E, 2014, NUCLEIC ACIDS RES, V42, P13736, DOI 10.1093/nar/gku1230; Ramirez-Carrozzi VR, 2009, CELL, V138, P114, DOI 10.1016/j.cell.2009.04.020; Rowe A, 2008, NEOPLASIA, V10, P1421, DOI 10.1593/neo.08850; Schneider J, 2005, MOL CELL, V19, P849, DOI 10.1016/j.molcel.2005.07.024; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Spellmon N, 2015, INT J MOL SCI, V16, P1406, DOI 10.3390/ijms16011406; Stender JD, 2012, MOL CELL, V48, P28, DOI 10.1016/j.molcel.2012.07.020; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Tarangelo A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10028; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Venteicher AS, 2008, CELL, V132, P945, DOI 10.1016/j.cell.2008.01.019; Wang X, 2012, J CELL SCI, V125, P4058, DOI 10.1242/jcs.103531; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Yu LM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00301-w; Zaarur N, 2015, EMBO J, V34, P2363, DOI 10.15252/embj.201591245; Zhang B, 2017, J PATHOL, V243, P418, DOI 10.1002/path.4976; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5; Zhou CY, 2017, CELL REP, V19, P2033, DOI 10.1016/j.celrep.2017.05.029	59	0	0	1	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 4	2021	12								679184	10.3389/fimmu.2021.679184	http://dx.doi.org/10.3389/fimmu.2021.679184			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SU2KB	34276666	gold, Green Published			2022-12-18	WOS:000662968600001
J	Da Silva, GH; Franqui, LS; Petry, R; Maia, MT; Fonseca, LC; Fazzio, A; Alves, OL; Martinez, DST				Da Silva, Gabriela H.; Franqui, Lidiane S.; Petry, Romana; Maia, Marcella T.; Fonseca, Leandro C.; Fazzio, Adalberto; Alves, Oswaldo L.; Martinez, Diego Stefani T.			Recent Advances in Immunosafety and Nanoinformatics of Two-Dimensional Materials Applied to Nano-imaging	FRONTIERS IN IMMUNOLOGY			English	Review						nanomaterials; bioimaging; immunotoxicity; nanobiotechnology; nanosafety	FUNCTIONALIZED GRAPHENE OXIDE; NANOPARTICLE PROTEIN CORONA; IN-VITRO; MOS2 NANOSHEETS; PRISTINE GRAPHENE; CARBON NITRIDE; SENSITIVE DETECTION; LATERAL DIMENSION; NANOMATERIALS; 2D	Two-dimensional (2D) materials have emerged as an important class of nanomaterials for technological innovation due to their remarkable physicochemical properties, including sheet-like morphology and minimal thickness, high surface area, tuneable chemical composition, and surface functionalization. These materials are being proposed for new applications in energy, health, and the environment; these are all strategic society sectors toward sustainable development. Specifically, 2D materials for nano-imaging have shown exciting opportunities in in vitro and in vivo models, providing novel molecular imaging techniques such as computed tomography, magnetic resonance imaging, fluorescence and luminescence optical imaging and others. Therefore, given the growing interest in 2D materials, it is mandatory to evaluate their impact on the immune system in a broader sense, because it is responsible for detecting and eliminating foreign agents in living organisms. This mini-review presents an overview on the frontier of research involving 2D materials applications, nano-imaging and their immunosafety aspects. Finally, we highlight the importance of nanoinformatics approaches and computational modeling for a deeper understanding of the links between nanomaterial physicochemical properties and biological responses (immunotoxicity/biocompatibility) towards enabling immunosafety-by-design 2D materials.	[Da Silva, Gabriela H.; Franqui, Lidiane S.; Petry, Romana; Maia, Marcella T.; Fazzio, Adalberto; Alves, Oswaldo L.; Martinez, Diego Stefani T.] Brazilian Ctr Res Energy & Mat CNPEM, Brazilian Nanotechnol Natl Lab LNNano, Campinas, Brazil; [Franqui, Lidiane S.; Martinez, Diego Stefani T.] Univ Campinas Unicamp, Sch Technol, Limeira, Brazil; [Petry, Romana; Fazzio, Adalberto] Fed Univ ABC UFABC, Ctr Nat & Human Sci, Santo Andre, Brazil; [Fonseca, Leandro C.; Alves, Oswaldo L.] Univ Campinas Unicamp, NanoBioss Lab & Solid State Chem Lab LQES, Inst Chem, Campinas, Brazil	Universidade Estadual de Campinas; Universidade Federal do ABC (UFABC); Universidade Estadual de Campinas	Martinez, DST (corresponding author), Brazilian Ctr Res Energy & Mat CNPEM, Brazilian Nanotechnol Natl Lab LNNano, Campinas, Brazil.; Martinez, DST (corresponding author), Univ Campinas Unicamp, Sch Technol, Limeira, Brazil.; Alves, OL (corresponding author), Univ Campinas Unicamp, NanoBioss Lab & Solid State Chem Lab LQES, Inst Chem, Campinas, Brazil.	izolas@unicamp.br; diego.martinez@lnnano.cnpem.br	Maia, Marcella/AAV-5963-2020; Fazzio, Adalberto/I-9933-2017	Maia, Marcella/0000-0001-9489-4129; 	Sao Paulo Research Foundation (FAPESP) [18/25103-0, 17/02317-2, 14/50906-9]; National Council for Scientific and Technological Development (CNPq) [315575/2020-4, 301358/2020-6]; Coordination for the Improvement of Higher Education Personnel (CAPES) [001]	Sao Paulo Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); National Council for Scientific and Technological Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordination for the Improvement of Higher Education Personnel (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This work was funded by the Sao Paulo Research Foundation (FAPESP, grant no. 18/25103-0; 17/02317-2; 14/50906-9), the National Council for Scientific and Technological Development (CNPq, grant no. 315575/2020-4; 301358/2020-6), and the Coordination for the Improvement of Higher Education Personnel (CAPES, Finance code 001).	Afantitis A, 2020, COMPUT STRUCT BIOTEC, V18, P583, DOI 10.1016/j.csbj.2020.02.023; Ahmad F, 2021, BIOMATER SCI-UK, V9, P1598, DOI 10.1039/d0bm01672a; Ahmad H, 2020, J HAZARD MATER, V384, DOI 10.1016/j.jhazmat.2019.121479; Alsharif SA, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10101967; Ares P, 2018, ADV MATER, V30, DOI 10.1002/adma.201703771; Baimanov D, 2020, ACS NANO, V14, P5529, DOI 10.1021/acsnano.9b09744; Ban Z, 2020, P NATL ACAD SCI USA, V117, P10492, DOI 10.1073/pnas.1919755117; Basei G, 2019, NANOIMPACT, V13, P76, DOI 10.1016/j.impact.2019.01.003; Bolotsky A, 2019, ACS NANO, V13, P9781, DOI 10.1021/acsnano.9b03632; Burello E, 2017, TOXICOL SCI, V159, P339, DOI 10.1093/toxsci/kfx136; Caglar M, 2020, ACS NANO, V14, P2729, DOI 10.1021/acsnano.9b08168; Cai XM, 2020, SMALL, V16, DOI 10.1002/smll.201907663; Cao MJ, 2021, NAT NANOTECHNOL, V16, P708, DOI 10.1038/s41565-021-00856-w; Chen CY, 2020, SMALL, V16, DOI 10.1002/smll.202002503; Chen L, 2018, ACS APPL MATER INTER, V10, P21137, DOI 10.1021/acsami.8b04807; Chen L, 2021, J MATER CHEM A, V9, P2018, DOI 10.1039/d0ta08649e; Chen M, 2017, NANO RES, V10, P1234, DOI 10.1007/s12274-016-1349-6; Chetwynd AJ, 2019, NANO TODAY, V28, DOI 10.1016/j.nantod.2019.06.004; Cho YC, 2016, SCI REP-UK, V6, DOI 10.1038/srep38884; Choi JS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24483-z; Cicuendez M, 2020, COLLOID SURFACE B, V186, DOI 10.1016/j.colsurfb.2019.110709; Corbo C, 2016, NANOMEDICINE-UK, V11, P81, DOI 10.2217/nnm.15.188; Cronin JG, 2020, CHEM RES TOXICOL, V33, P1061, DOI 10.1021/acs.chemrestox.0c00051; Cui Q, 2016, J PHYS CHEM B, V120, P7297, DOI 10.1021/acs.jpcb.6b03976; de Pablo JJ, 2014, CURR OPIN SOLID ST M, V18, P99, DOI 10.1016/j.cossms.2014.02.003; Deng DH, 2016, NAT NANOTECHNOL, V11, P218, DOI [10.1038/NNANO.2015.340, 10.1038/nnano.2015.340]; Deng HM, 2015, ANALYST, V140, P3210, DOI 10.1039/c4an02133a; Deng L, 2020, INT J NANOMED, V15, P2971, DOI 10.2147/IJN.S243537; Duan YK, 2020, NANOIMPACT, V17, DOI 10.1016/j.impact.2020.100207; Ede JD, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10061229; El-Reesh GYA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57519-4; Elumalai S, 2020, MICROCHIM ACTA, V187, DOI 10.1007/s00604-019-4018-0; Eom S, 2020, B CHEM SOC JPN, V93, P1, DOI 10.1246/bcsj.20190270; Fadeel B, 2018, ACS NANO, V12, P10582, DOI 10.1021/acsnano.8b04758; Fang XY, 2021, ADV SCI, V8, DOI 10.1002/advs.202003041; Feito MJ, 2014, J COLLOID INTERF SCI, V432, P221, DOI 10.1016/j.jcis.2014.07.004; Feng RH, 2021, BIOMATERIALS, V266, DOI 10.1016/j.biomaterials.2020.120469; Feng W, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201901942; Findlay MR, 2018, ENVIRON SCI-NANO, V5, P64, DOI [10.1039/c7en00466d, 10.1039/C7EN00466D]; Franqui LS, 2019, MAT SCI ENG C-MATER, V100, P363, DOI 10.1016/j.msec.2019.02.066; Fu YQ, 2020, MICROCHEM J, V159, DOI 10.1016/j.microc.2020.105454; Fu Y, 2021, MAT SCI ENG C-MATER, V118, DOI 10.1016/j.msec.2020.111367; Gajewicz A, 2018, NANOTOXICOLOGY, V12, P1, DOI 10.1080/17435390.2017.1415388; Ganguly P, 2018, ACS BIOMATER SCI ENG, V4, P2237, DOI 10.1021/acsbiomaterials.8b00068; Garcia-Gallastegui A, 2012, CHEM MATER, V24, P4531, DOI 10.1021/cm3018264; Gazzi A, 2020, J PHYS-MATER, V3, DOI 10.1088/2515-7639/ab9317; Giusti A, 2019, NANOIMPACT, V16, DOI 10.1016/j.impact.2019.100182; Gong F, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202002753; Gonzalez-Rodriguez R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217072; Grimaldi AM, 2017, NANOMEDICINE-UK, V12, P2349, DOI 10.2217/nnm-2017-0208; Gu ZL, 2019, NANOSCALE, V11, P22293, DOI 10.1039/c9nr04358f; Guo JJ, 2021, J MAGN MAGN MATER, V527, DOI 10.1016/j.jmmm.2020.167719; Guo XR, 2018, ACS APPL MATER INTER, V10, P26118, DOI 10.1021/acsami.8b10529; Gurunathan S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020247; Haase Klaessig, 2018, EU US ROADMAP NANOIN; Han MM, 2020, ACS APPL BIO MATER, V3, P4220, DOI 10.1021/acsabm.0c00306; Han QS, 2017, NANOSCALE, V9, P5927, DOI 10.1039/c7nr01460k; Hao JL, 2017, ADV SCI, V4, DOI 10.1002/advs.201600160; Hao SH, 2020, FRONT CHEM, V8, DOI 10.3389/fchem.2020.582146; Heiranian M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9616; Hernandez-Sanchez D, 2018, PHYS CHEM CHEM PHYS, V20, P1685, DOI 10.1039/c7cp04817c; Hu TT, 2019, SCI BULL, V64, P1707, DOI 10.1016/j.scib.2019.09.021; Hu XL, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201907906; Huang CM, 2014, NAT MATER, V13, P1096, DOI [10.1038/NMAT4064, 10.1038/nmat4064]; Huang HQ, 2014, CHEM COMMUN, V50, P15415, DOI 10.1039/c4cc06659f; Huang HY, 2020, OPEN CHEM, V18, P97, DOI 10.1515/chem-2020-0009; Huang Y, 2014, ACS NANO, V8, P10743, DOI 10.1021/nn504481r; Italiani P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.566309; Ji JJ, 2017, J AM CHEM SOC, V139, P11698, DOI 10.1021/jacs.7b06708; Ji XY, 2018, ADV MATER, V30, DOI 10.1002/adma.201803031; Feito MJ, 2019, COLLOID SURFACE B, V176, P96, DOI 10.1016/j.colsurfb.2018.12.063; Kamfer AAM, 2020, CHEM RES TOXICOL, V33, P1163, DOI 10.1021/acs.chemrestox.0c00079; Kang Y, 2020, J MATER CHEM B, V8, P4609, DOI 10.1039/d0tb00070a; Karcher S, 2018, NANOIMPACT, V9, P85, DOI 10.1016/j.impact.2017.11.002; Kinaret PAS, 2021, ADV SCI, V8, DOI 10.1002/advs.202004588; Kokulnathan T, 2020, ACS SUSTAIN CHEM ENG, V8, P12471, DOI 10.1021/acssuschemeng.0c03281; Kurapati R, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201605176; Le TC, 2016, SMALL, V12, P3568, DOI 10.1002/smll.201600597; Lebre F, 2020, NANOSCALE, V12, P11192, DOI 10.1039/c9nr09661b; Lee KT, 2016, ELECTROCHIM ACTA, V219, P241, DOI 10.1016/j.electacta.2016.10.003; Lei Y, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc4250; Li B, 2020, ACS APPL MATER INTER, V12, P9261, DOI 10.1021/acsami.9b20552; Li DO, 2020, J PHYS-MATER, V3, DOI 10.1088/2515-7639/ab7ab3; Li Q, 2014, LANGMUIR, V30, P8965, DOI 10.1021/la502033t; Li SW, 2021, ADV MATER, V33, DOI 10.1002/adma.202007480; Li Y, 2012, BIOMATERIALS, V33, P402, DOI 10.1016/j.biomaterials.2011.09.091; Lin H, 2019, ADV MATER, V31, DOI 10.1002/adma.201903013; Lin H, 2017, NANO LETT, V17, P384, DOI 10.1021/acs.nanolett.6b04339; Lin YF, 2020, NANO TODAY, V35, DOI 10.1016/j.nantod.2020.100922; Liu CS, 2020, NAT NANOTECHNOL, V15, P545, DOI 10.1038/s41565-020-0724-3; Liu GZ, 2018, J MEMBRANE SCI, V548, P548, DOI 10.1016/j.memsci.2017.11.065; Liu HM, 2021, BIOMATER SCI-UK, V9, P780, DOI 10.1039/d0bm01596b; Liu XL, 2020, ACS NANO, V14, P1936, DOI 10.1021/acsnano.9b08320; Liu XF, 2020, ACS BIOMATER SCI ENG, V6, P4653, DOI 10.1021/acsbiomaterials.0c00612; Liu ZG, 2020, ACS APPL MATER INTER, V12, P39014, DOI 10.1021/acsami.0c12078; Lynch I, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10122493; Lynch I, 2017, CHALL ADV COMPUT CHE, V24, P385, DOI 10.1007/978-3-319-56850-8_10; Ma BJ, 2020, CHEM SOC REV, V49, P6224, DOI 10.1039/c9cs00822e; Ma J, 2015, ACS NANO, V9, P10498, DOI 10.1021/acsnano.5b04751; Martinez DST, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10101936; Martins C, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16234718; Miernicki M, 2019, NAT NANOTECHNOL, V14, P208, DOI 10.1038/s41565-019-0396-z; Mikolajczyk A, 2018, ENVIRON SCI-NANO, V5, P1150, DOI 10.1039/c8en00085a; Milosevic A, 2020, SMALL, V16, DOI 10.1002/smll.201907650; Mo JB, 2020, NANOSCALE, V12, P1742, DOI 10.1039/c9nr08570j; Mo JB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04873-7; Moghzi F, 2020, ACS APPL MATER INTER, V12, P44499, DOI 10.1021/acsami.0c13166; Mohammadpour Z, 2020, ACS BIOMATER SCI ENG, V6, P1852, DOI 10.1021/acsbiomaterials.9b01894; Moore C, 2020, 2D MATER, V7, DOI 10.1088/2053-1583/ab5d98; Mukherjee SP, 2018, NANOSCALE, V10, P1180, DOI 10.1039/c7nr03552g; Muratov EN, 2020, CHEM SOC REV, V49, P3525, DOI 10.1039/d0cs00098a; Murugadoss S, 2021, ENVIRON SCI-NANO, V8, P580, DOI 10.1039/d0en01031f; Murugan C, 2019, J CONTROL RELEASE, V299, P1, DOI 10.1016/j.jconrel.2019.02.015; Naguib M, 2012, ACS NANO, V6, P1322, DOI 10.1021/nn204153h; Nicolosi V, 2013, SCIENCE, V340, P1420, DOI 10.1126/science.1226419; Noronha VT, 2019, MICRO NANO TECHNOL, P109, DOI 10.1016/B978-0-12-814829-7.00003-3; Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896; Och M, 2021, NANOSCALE, V13, P2157, DOI 10.1039/d0nr07867k; Oliveira NC, 2019, MICRO NANO TECHNOL, P227, DOI 10.1016/B978-0-12-814829-7.00006-9; Orecchioni M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01015-3; Orecchioni M, 2016, ADV DRUG DELIVER REV, V105, P163, DOI 10.1016/j.addr.2016.05.014; Orecchioni M, 2016, ADV HEALTHC MATER, V5, P276, DOI 10.1002/adhm.201500606; Ostadhossein A, 2019, COMMUN CHEM, V2, DOI 10.1038/s42004-019-0196-2; Ou JZ, 2014, NANO LETT, V14, P857, DOI 10.1021/nl4042356; Papadiamantis AG, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10102033; Papadiamantis AG, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10102017; Park EJ, 2017, J APPL TOXICOL, V37, P296, DOI 10.1002/jat.3361; Peng T, 2020, ENVIRON POLLUT, V267, DOI 10.1016/j.envpol.2020.115434; Peng YX, 2021, SENSORS-BASEL, V21, DOI 10.3390/s21020485; Pinsino A, 2020, ENVIRON SCI-NANO, V7, P3216, DOI 10.1039/d0en00732c; Purohit SD, 2020, FRONT MATER, V7, DOI 10.3389/fmats.2020.00250; Puzyn T, 2011, NAT NANOTECHNOL, V6, P175, DOI [10.1038/nnano.2011.10, 10.1038/NNANO.2011.10]; Qian XQ, 2017, MATER HORIZ, V4, P800, DOI 10.1039/c7mh00305f; Qian XX, 2015, NANOSCALE, V7, P6380, DOI 10.1039/c5nr00893j; Quan XB, 2019, CURR OPIN COLLOID IN, V41, P74, DOI 10.1016/j.cocis.2018.12.004; Rajan K., 2014, NANOTECHNOLOGY ENV H, P173; Ramalingam S, 2020, MICROCHIM ACTA, V187, DOI 10.1007/s00604-020-04589-w; Ramani D, 2014, CELLULOSE, V21, P3585, DOI 10.1007/s10570-014-0313-4; Raucci MG, 2019, ACS APPL MATER INTER, V11, P9333, DOI 10.1021/acsami.8b21592; Rohaizad N, 2021, CHEM SOC REV, V50, P619, DOI 10.1039/d0cs00150c; Safaei J, 2020, MATER TODAY ADV, V8, DOI 10.1016/j.mtadv.2020.100108; Samori P, 2020, NANOSCALE, V12, P24309, DOI 10.1039/d0nr90263b; Schinwald A, 2012, ACS NANO, V6, P736, DOI 10.1021/nn204229f; Schleder GR, 2019, J PHYS-MATER, V2, DOI 10.1088/2515-7639/ab084b; Schmidt J, 2019, NPJ COMPUT MATER, V5, DOI 10.1038/s41524-019-0221-0; Sekhon SS., 2021, NAT PARTN J 2D MAT A, V5, P1, DOI [10.1038/s41699-021-00202-7, DOI 10.1038/S41699-021-00202-7]; Serra A, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10040708; Shatkin JA, 2020, NANO LETT, V20, P1479, DOI 10.1021/acs.nanolett.0c00432; Shen JQ, 2021, APPL SURF SCI, V541, DOI 10.1016/j.apsusc.2020.148355; Shwetharani R, 2020, ACS APPL ENERG MATER, V3, P12682, DOI 10.1021/acsaem.0c02619; Singh AV, 2020, ADV INTELL SYST-GER, V2, DOI 10.1002/aisy.202000084; Singh AV, 2021, ACS APPL MATER INTER, V13, P1943, DOI 10.1021/acsami.0c18470; Singh AV, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.201901862; Singh C, 2018, SENSOR ACTUAT B-CHEM, V259, P1090, DOI 10.1016/j.snb.2017.12.094; Song SS, 2014, RSC ADV, V4, P42598, DOI 10.1039/c4ra05953k; Sturla SJ, 2014, CHEM RES TOXICOL, V27, P314, DOI 10.1021/tx400410s; Su YJ, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12121222; Su YJ, 2020, MATER HORIZ, V7, P574, DOI 10.1039/c9mh01068h; Tang WT, 2019, ACS NANO, V13, P284, DOI 10.1021/acsnano.8b05982; Tao W, 2018, ADV MATER, V30, DOI 10.1002/adma.201802061; Tao W, 2017, ADV MATER, V29, DOI 10.1002/adma.201603276; Trinh TX, 2018, ENVIRON SCI-NANO, V5, P1902, DOI 10.1039/c8en00061a; Ugeda MM, 2014, NAT MATER, V13, P1091, DOI [10.1038/NMAT4061, 10.1038/nmat4061]; Vaghasiya JV, 2020, ACS APPL MATER INTER, V12, P53039, DOI 10.1021/acsami.0c12879; Varsou DD, 2019, NANOSCALE ADV, V1, P706, DOI 10.1039/c8na00142a; de Luna LAV, 2019, NANOTOXICOLOGY, V13, P189, DOI 10.1080/17435390.2018.1537410; Wang CN, 2020, ACS APPL MATER INTER, V12, P51329, DOI 10.1021/acsami.0c12414; Wang H, 2014, NANO LETT, V14, P6424, DOI 10.1021/nl5029717; Wang L, 2013, SCI REP-UK, V3, DOI 10.1038/srep03568; Wang L, 2014, SMALL, V10, P1101, DOI 10.1002/smll.201302081; Wang QB, 2013, ANAL CHEM, V85, P12182, DOI 10.1021/ac403646n; Wang WY, 2017, ACS NANO, V11, P12641, DOI 10.1021/acsnano.7b07093; Wang X, 2015, SMALL, V11, P5079, DOI 10.1002/smll.201500906; Wang XW, 2019, NANOSCALE, V11, P15685, DOI 10.1039/c9nr04044g; Wang YS, 2014, ACS APPL MATER INTER, V6, P21798, DOI 10.1021/am501382y; Wang ZY, 2010, J AM CHEM SOC, V132, P13840, DOI 10.1021/ja1058026; Wang ZY, 2016, CHEM SOC REV, V45, P1750, DOI 10.1039/c5cs00914f; Warner JH, 2010, ACS NANO, V4, P1299, DOI 10.1021/nn901648q; Winkler DA, 2020, SMALL, V16, DOI 10.1002/smll.202001883; Winkler DA, 2016, TOXICOL APPL PHARM, V299, P96, DOI 10.1016/j.taap.2015.12.016; Worth A., 2017, NURSING LEGISLATION, DOI [10.2760/248139, DOI 10.2760/248139]; Xie HH, 2016, SMALL, V12, P4136, DOI 10.1002/smll.201601050; Xie ZJ, 2019, ACS APPL MATER INTER, V11, P22129, DOI 10.1021/acsami.9b04628; Xu M, 2016, ACS NANO, V10, P3267, DOI 10.1021/acsnano.6b00539; Xu ZX, 2020, J HAZARD MATER, V399, DOI 10.1016/j.jhazmat.2020.123057; Yan JY, 2017, COLLOID SURFACE B, V153, P300, DOI 10.1016/j.colsurfb.2017.02.036; Yang X, 2014, NANOSCALE, V6, P10126, DOI 10.1039/c4nr01965b; Yang XY, 2018, ACS APPL MATER INTER, V10, P12431, DOI 10.1021/acsami.8b00276; Ye SH, 2021, SEP PURIF TECHNOL, V266, DOI 10.1016/j.seppur.2021.118553; Yin WY, 2014, ACS NANO, V8, P6922, DOI 10.1021/nn501647j; Yue H, 2012, BIOMATERIALS, V33, P4013, DOI 10.1016/j.biomaterials.2012.02.021; Zhan YJ, 2017, TALANTA, V174, P365, DOI 10.1016/j.talanta.2017.06.032; Zhang N, 2020, THERANOSTICS, V10, P2791, DOI 10.7150/thno.42906; Zhao HN, 2020, CHEM ENG J, V394, DOI 10.1016/j.cej.2020.124314; Zhi X, 2013, BIOMATERIALS, V34, P5254, DOI 10.1016/j.biomaterials.2013.03.024; Zhou HJ, 2012, BIOMATERIALS, V33, P6933, DOI 10.1016/j.biomaterials.2012.06.064; Zhou XF, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00236; Zhu CZ, 2015, 2D MATER, V2, DOI 10.1088/2053-1583/2/3/032004	199	0	0	4	21	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 3	2021	12								689519	10.3389/fimmu.2021.689519	http://dx.doi.org/10.3389/fimmu.2021.689519			20	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ST2QW	34149731	gold, Green Published			2022-12-18	WOS:000662295600001
J	Zhou, JT; Xiao, ZH; Zhan, YL; Qu, XM; Mou, SS; Deng, C; Zhang, TX; Lan, X; Huang, SF; Li, YQ				Zhou, Jiatao; Xiao, Zhihui; Zhan, Yanli; Qu, Xuemei; Mou, Sisi; Deng, Chong; Zhang, Tianxiang; Lan, Xin; Huang, Shengfeng; Li, Yingqiu			Identification and Characterization of the Amphioxus Lck and Its Associated Tyrosine Phosphorylation-Dependent Inhibitory LRR Receptor	FRONTIERS IN IMMUNOLOGY			English	Article						amphioxus; lymphocyte-specific tyrosine kinase (Lck); tyrosine phosphorylation-dependent inhibitory immunoreceptor; leucine rich repeat receptor (LRR); amphioxus Lck associated LRR (BbLcLRR); tyrosine phosphorylation; immunoreceptor tyrosine-based inhibitory motif; TCR-mediated T cell activation	T-CELL-ACTIVATION; PROTEIN-KINASE; SH2 DOMAIN; EXPRESSION; P56(LCK); CD4; ICK	Amphioxus (e.g., Branchiostoma belcheri, Bb) has recently emerged as a new model for studying the origin and evolution of vertebrate immunity. Mammalian lymphocyte-specific tyrosine kinase (Lck) plays crucial roles in T cell activation, differentiation and homeostasis, and is reported to phosphorylate both the ITIM and ITSM of PD-1 to induce the recruitment of phosphatases and thus the inhibitory function of PD-1. Here, we identified and cloned the amphioxus homolog of human Lck. By generating and using an antibody against BbLck, we found that BbLck is expressed in the amphioxus gut and gill. Through overexpression of BbLck in Jurkat T cells, we found that upon TCR stimulation, BbLck was subjected to tyrosine phosphorylation and could partially rescue Lck-dependent tyrosine phosphorylation in Lck-knockdown T cells. Mass spectrometric analysis of BbLck immunoprecipitates from immunostimulants-treated amphioxus, revealed a BbLck-associated membrane-bound receptor LRR (BbLcLRR). By overexpressing BbLcLRR in Jurkat T cells, we demonstrated that BbLcLRR was tyrosine phosphorylated upon TCR stimulation, which was inhibited by Lck knockdown and was rescued by overexpression of BbLck. By mutating single tyrosine to phenylalanine (Y-F), we identified three tyrosine residues (Y539, Y655, and Y690) (3Y) of BbLcLRR as the major Lck phosphorylation sites. Reporter gene assays showed that overexpression of BbLcLRR but not the BbLcLRR-3YF mutant inhibited TCR-induced NF-kappa B activation. In Lck-knockdown T cells, the decline of TCR-induced IL-2 production was reversed by overexpression of BbLck, and this reversion was inhibited by co-expression of BbLcLRR but not the BbLcLRR-3YF mutant. Sequence analysis showed that the three tyrosine-containing sequences were conserved with the tyrosine-based inhibition motifs (ITIMs) or ITIM-like motifs. And TCR stimulation induced the association of BbLcLRR with tyrosine phosphatases SHIP1 and to a lesser extent with SHP1/2. Moreover, overexpression of wild-type BbLcLRR but not its 3YF mutant inhibited TCR-induced tyrosine phosphorylation of multiple signaling proteins probably via recruiting SHIP1. Thus, we identified a novel immunoreceptor BbLcLRR, which is phosphorylated by Lck and then exerts a phosphorylation-dependent inhibitory role in TCR-mediated T-cell activation, implying a mechanism for the maintenance of self-tolerance and homeostasis of amphioxus immune system and the evolutionary conservatism of Lck-regulated inhibitory receptor pathway.	[Zhou, Jiatao; Xiao, Zhihui; Zhan, Yanli; Qu, Xuemei; Mou, Sisi; Deng, Chong; Zhang, Tianxiang; Lan, Xin; Huang, Shengfeng; Li, Yingqiu] Sun Yat Sen Univ, Sch Life Sci, State Key Lab Biocontrol, Guangdong Prov Key Lab Pharmaceut Funct Genes, Guangzhou, Peoples R China	Sun Yat Sen University	Li, YQ (corresponding author), Sun Yat Sen Univ, Sch Life Sci, State Key Lab Biocontrol, Guangdong Prov Key Lab Pharmaceut Funct Genes, Guangzhou, Peoples R China.	lsslyq@mail.sysu.edu.cn			National Natural Science Foundation of China [31670893, 31370886]; Guangzhou Science and Technology Project [201904010445]; Guangdong Basic and Applied Basic Research Foundation [2021A1515010543]; Guangdong Science and Technology Department [2020B1212060031]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou Science and Technology Project; Guangdong Basic and Applied Basic Research Foundation; Guangdong Science and Technology Department	This study was supported by the National Natural Science Foundation of China (31670893, 31370886), the Guangzhou Science and Technology Project (201904010445), Guangdong Basic and Applied Basic Research Foundation (2021A1515010543) and Guangdong Science and Technology Department (2020B1212060031).	Abbas AK., 2021, CELLULAR MOL IMMUNOL, V10 th, P175; Abi-Rached L, 2002, NAT GENET, V31, P100, DOI 10.1038/ng855; Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Alder MN, 2005, SCIENCE, V310, P1970, DOI 10.1126/science.1119420; AlRamadi BK, 1996, J IMMUNOL, V157, P4751; Bougeret C, 1996, J BIOL CHEM, V271, P7465, DOI 10.1074/jbc.271.13.7465; Boussiotis VA, 2014, CANCER J, V20, P265, DOI 10.1097/PPO.0000000000000059; DOro U, 1997, IMMUNITY, V7, P619, DOI 10.1016/S1074-7613(00)80383-0; Dutta D, 2017, NAT IMMUNOL, V18, P196, DOI 10.1038/ni.3640; Eldar-Finkelman H, 2009, CURR PHARM DESIGN, V15, P2463, DOI 10.2174/138161209788682253; Gascoigne NRJ, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00072; Gaud G, 2018, NAT REV IMMUNOL, V18, P485, DOI 10.1038/s41577-018-0020-8; Hanamura K, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2002457; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; Hoberg AM, 2004, J MASS SPECTROM, V39, P38, DOI 10.1002/jms.547; Huang GH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000206; Huang SF, 2016, CELL, V166, P102, DOI 10.1016/j.cell.2016.05.032; Hui EF, 2017, SCIENCE, V355, P1428, DOI 10.1126/science.aaf1292; Hui EF, 2014, NAT STRUCT MOL BIOL, V21, P133, DOI 10.1038/nsmb.2762; Ladygina N, 2013, EUR J IMMUNOL, V43, P3183, DOI 10.1002/eji.201343812; Li JX, 2013, P NATL ACAD SCI USA, V110, P15013, DOI 10.1073/pnas.1314540110; Marti F, 1998, P NATL ACAD SCI USA, V95, P11810, DOI 10.1073/pnas.95.20.11810; McNeill L, 2007, IMMUNITY, V27, P425, DOI 10.1016/j.immuni.2007.07.015; Pancer Z, 2004, NATURE, V430, P174, DOI 10.1038/nature02740; Park I, 1995, P NATL ACAD SCI USA, V92, P12338, DOI 10.1073/pnas.92.26.12338; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; Rast JP, 2013, P NATL ACAD SCI USA, V110, P5746, DOI 10.1073/pnas.1303541110; Robertson LK, 2005, J IMMUNOL, V175, P8138, DOI 10.4049/jimmunol.175.12.8138; Rossy J, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00167; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; Rumpret M, 2020, NAT REV IMMUNOL, V20, P771, DOI 10.1038/s41577-020-0352-z; Schunk MK, 2005, ILAR J, V46, P241, DOI 10.1093/ilar.46.3.241; Stirnweiss A, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003607; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; Veillette A, 2002, ANNU REV IMMUNOL, V20, P669, DOI 10.1146/annurev.immunol.20.081501.130710; Wang QL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00314; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yu CL, 2005, J IMMUNOL, V174, P3493, DOI 10.4049/jimmunol.174.6.3493; Yuan SC, 2015, DEV COMP IMMUNOL, V48, P297, DOI 10.1016/j.dci.2014.05.004; Zhang YN, 2014, P NATL ACAD SCI USA, V111, P397, DOI 10.1073/pnas.1318843111; Zikherman J, 2010, IMMUNITY, V32, P342, DOI 10.1016/j.immuni.2010.03.006	43	0	0	2	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 3	2021	12								656366	10.3389/fimmu.2021.656366	http://dx.doi.org/10.3389/fimmu.2021.656366			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ST5GB	34149695	gold, Green Published			2022-12-18	WOS:000662470600001
J	Furesi, G; Fert, I; Beaufrere, M; Araujo, LM; Glatigny, S; Baschant, U; von Bonin, M; Hofbauer, LC; Horwood, NJ; Breban, M; Rauner, M				Furesi, Giulia; Fert, Ingrid; Beaufrere, Marie; Araujo, Luiza M.; Glatigny, Simon; Baschant, Ulrike; von Bonin, Malte; Hofbauer, Lorenz C.; Horwood, Nicole J.; Breban, Maxime; Rauner, Martina			Rodent Models of Spondyloarthritis Have Decreased White and Bone Marrow Adipose Tissue Depots	FRONTIERS IN IMMUNOLOGY			English	Article						spondyloarthritis; HLA-B27 transgenic rat; SKG mouse; bone marrow fat; IL-17	HLA-B27 TRANSGENIC RATS; RHEUMATOID-ARTHRITIS; DISEASE-ACTIVITY; NEUTROPHIL RECRUITMENT; INFLAMMATORY DISEASE; T-CELLS; PROFILE; IL-17; ALPHA; INTERLEUKIN-17	Bone marrow adipose tissue (BMAT) has recently been recognized as a distinct fat depot with endocrine functions. However, if and how it is regulated by chronic inflammation remains unknown. Here, we investigate the amount of white fat and BMAT in HLA-B27 transgenic rats and curdlan-challenged SKG mice, two well-established models of chronic inflammatory spondyloarthritis (SpA). Subcutaneous and gonadal white adipose tissue and BMAT was reduced by 65-70% and by up to 90% in both experimental models. Consistently, B27 rats had a 2-3-fold decrease in the serum concentrations of the adipocyte-derived cytokines adiponectin and leptin as well as a 2-fold lower concentration of triglycerides. The bone marrow of B27 rats was further characterized by higher numbers of neutrophils, lower numbers of erythroblast precursors, and higher numbers of IL-17 producing CD4(+) T cells. IL-17 concentration was also increased in the serum of B27 rats. Using a cell culture model, we show that high levels of IL-17 in the serum of B27 rats negatively impacted adipogenesis (-76%), an effect that was reversed in the presence of neutralizing anti-IL-17 antibody. In summary, these findings show BMAT is severely reduced in two experimental models of chronic inflammatory SpA and suggest that IL-17 is involved in this process.	[Furesi, Giulia; Baschant, Ulrike; Hofbauer, Lorenz C.; Rauner, Martina] Tech Univ Dresden, Dept Med 2, Dresden, Germany; [Furesi, Giulia; Baschant, Ulrike; Hofbauer, Lorenz C.; Rauner, Martina] Tech Univ Dresden, Ctr Hlth Aging, Dresden, Germany; [Fert, Ingrid; Beaufrere, Marie; Araujo, Luiza M.; Glatigny, Simon; Breban, Maxime] Univ Versailles St Quentin Paris Saclay, Lab Infect & Inflammat, UMR U1173 INSERM, Montigny Le Bretonneux, France; [Fert, Ingrid; Beaufrere, Marie; Araujo, Luiza M.; Glatigny, Simon; Breban, Maxime] Univ Paris 05, Lab Excellence Inflamex, Paris, France; [Fert, Ingrid; Beaufrere, Marie; Araujo, Luiza M.; Glatigny, Simon; Breban, Maxime] Hop Ambroise Pare, AP HP, Serv Rhumatol, Boulogne, France; [von Bonin, Malte] Tech Univ Dresden, Dept Med 1, Dresden, Germany; [Horwood, Nicole J.] Univ East Anglia, Norwich Med Sch, Norwich, Norfolk, England	Technische Universitat Dresden; Technische Universitat Dresden; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Technische Universitat Dresden; University of East Anglia	Rauner, M (corresponding author), Tech Univ Dresden, Dept Med 2, Dresden, Germany.; Rauner, M (corresponding author), Tech Univ Dresden, Ctr Hlth Aging, Dresden, Germany.	martina.rauner@ukdd.de	Glatigny, Simon/GRS-2887-2022	Horwood, Nicole/0000-0002-6344-1677; von Bonin, Malte/0000-0002-2995-3230	Deutsche Forschungsgemeinschaft; European Union [860898]; Versus Arthritis [20372]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); European Union(European Commission); Versus Arthritis(Versus Arthritis)	This work was supported by grants from the Deutsche Forschungsgemeinschaft and the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 860898 to MR and LH, as well as NH, supported by Versus Arthritis Grant No. 20372.	Ahmed M, 2013, CYTOKINE, V61, P898, DOI 10.1016/j.cyto.2012.12.007; BREBAN M, 1993, J EXP MED, V178, P1607, DOI 10.1084/jem.178.5.1607; Breban M, 1996, J IMMUNOL, V156, P794; Breban M, 2021, SEMIN IMMUNOPATHOL, V43, P207, DOI 10.1007/s00281-020-00832-x; Briot K, 2005, ANN RHEUM DIS, V64, P1137, DOI 10.1136/ard.2004.028670; Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168; Chen WS, 2012, J CHIN MED ASSOC, V75, P303, DOI 10.1016/j.jcma.2012.05.006; Fakhreldin S, 2020, EGYPT RHEUMATOL, V42, P297, DOI 10.1016/j.ejr.2020.07.009; Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023; Flannigan KL, 2017, MUCOSAL IMMUNOL, V10, P673, DOI 10.1038/mi.2016.80; Fragoulis GE, 2019, WORLD J GASTROENTERO, V25, P2162, DOI 10.3748/wjg.v25.i18.2162; Glatigny S, 2012, ARTHRITIS RHEUM-US, V64, P110, DOI 10.1002/art.33321; Griffin GK, 2012, J IMMUNOL, V188, P6287, DOI 10.4049/jimmunol.1200385; Gullick NJ, 2013, CLIN EXP IMMUNOL, V174, P292, DOI 10.1111/cei.12167; Jansen DTSL, 2015, RHEUMATOLOGY, V54, P728, DOI 10.1093/rheumatology/keu382; Jones SM, 2000, ANN RHEUM DIS, V59, P904, DOI 10.1136/ard.59.11.904; Keller KK, 2013, RHEUMATOL INT, V33, P1127, DOI 10.1007/s00296-012-2500-7; Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703; Krings A, 2012, BONE, V50, P546, DOI 10.1016/j.bone.2011.06.016; LAKATOS J, 1988, CLIN BIOCHEM, V21, P93, DOI 10.1016/S0009-9120(88)80094-8; Lee Y, 2013, BMB REP, V46, P479, DOI 10.5483/BMBRep.2013.46.10.141; Lubberts E, 2015, NAT REV RHEUMATOL, V11, P415, DOI 10.1038/nrrheum.2015.53; Miggitsch C, 2019, EBIOMEDICINE, V46, P387, DOI 10.1016/j.ebiom.2019.07.023; Myasoedova E, 2010, ANN RHEUM DIS, V69, P1310, DOI 10.1136/ard.2009.122374; Papagoras C, 2014, JOINT BONE SPINE, V81, P57, DOI 10.1016/j.jbspin.2013.03.019; Rauner M, 2015, BONE, V75, P183, DOI 10.1016/j.bone.2015.02.024; Rauner M, 2009, J RHEUMATOL, V36, P120, DOI 10.3899/jrheum.080475; Raychaudhuri SP, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1249-5; Regan-Komito D, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13853-4; Romero-Sanchez C, 2011, CLIN EXP RHEUMATOL, V29, P828; Ruutu M, 2012, ARTHRITIS RHEUM-US, V64, P2211, DOI 10.1002/art.34423; Scheller EL, 2016, TRENDS ENDOCRIN MET, V27, P392, DOI 10.1016/j.tem.2016.03.016; Shin JH, 2009, BIOCHEM PHARMACOL, V77, P1835, DOI 10.1016/j.bcp.2009.03.008; Sieper J, 2017, LANCET, V390, P73, DOI 10.1016/S0140-6736(16)31591-4; Suchacki KJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16878-2; Sulston RJ, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00128; Toussirot E, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00453; Tratwal J, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00065; van Halm VP, 2006, ANN RHEUM DIS, V65, P1473, DOI 10.1136/ard.2005.050443; Wang H, 2015, REV ENDOCR METAB DIS, V16, P47, DOI 10.1007/s11154-014-9306-8; Yin YF, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075-020-02208-w; Zhong LL, 2020, ELIFE, V9, DOI 10.7554/eLife.54695; Zou W, 2020, CELL METAB, V32, P801, DOI 10.1016/j.cmet.2020.09.011; Zuniga LA, 2010, J IMMUNOL, V185, P6947, DOI 10.4049/jimmunol.1001269	44	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2021	12								665208	10.3389/fimmu.2021.665208	http://dx.doi.org/10.3389/fimmu.2021.665208			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SS6HX	34149700	Green Published, gold, Green Accepted			2022-12-18	WOS:000661856400001
J	Manook, M; Flores, WJ; Schmitz, R; Fitch, Z; Yoon, J; Bae, Y; Shaw, B; Kirk, A; Harnois, M; Permar, S; Farris, AB; Magnani, DM; Kwun, J; Knechtle, S				Manook, Miriam; Flores, Walter J.; Schmitz, Robin; Fitch, Zachary; Yoon, Janghoon; Bae, Yeeun; Shaw, Brian; Kirk, Allan; Harnois, Melissa; Permar, Sallie; Farris, Alton B.; Magnani, Diogo M.; Kwun, Jean; Knechtle, Stuart			Measuring the Impact of Targeting FcRn-Mediated IgG Recycling on Donor-Specific Alloantibodies in a Sensitized NHP Model	FRONTIERS IN IMMUNOLOGY			English	Article						FcRn; IgG; alloantibody; sensitization; non-human primate (NHP)	NONHUMAN-PRIMATES; REJECTION; DESENSITIZATION; PLASMAPHERESIS; INHIBITOR; RECEPTOR	Background In transplantation, plasmapheresis and IVIg provide the mainstay of treatment directed at reducing or removing circulating donor-specific antibody (DSA), yet both have limitations. We sought to test the efficacy of targeting the IgG recycling mechanism of the neonatal Fc receptor (FcRn) using anti-FcRn mAb therapy in a sensitized non-human primate (NHP) model, as a pharmacological means of lowering DSA. Methods Six (6) rhesus macaque monkeys, previously sensitized by skin transplantation, received a single dose of 30mg/kg anti-RhFcRn IV, and effects on total IgG, as well as DSA IgG, were measured, in addition to IgM and protective immunity. Subsequently, 60mg/kg IV was given in the setting of kidney transplantation from skin graft donors. Kidney transplant recipients received RhATG, and tacrolimus, MMF, and steroid for maintenance immunosuppression. Results Circulating total IgG was reduced from a baseline 100% on D0 to 32.0% (mean, SD +/- 10.6) on d4 post infusion (p<0.05), while using a DSA assay. T-cell flow cross match (TFXM) was reduced to 40.6 +/- 12.5% of baseline, and B-cell FXCM to 52.2 +/- 19.3%. Circulating total IgM and DSA IgM were unaffected by treatment. Pathogen-specific antibodies (anti-gB and anti-tetanus toxin IgG) were significantly reduced for 14d post infusion. Post-transplant, circulating IgG responded to anti-FcRn mAb treatment, but DSA increased rapidly. Conclusion Targeting the FcRn-mediated recycling of IgG is an effective means of lowering circulating donor-specific IgG in the sensitized recipient, although in the setting of organ transplantation mechanisms of rapid antibody rise post-transplant remains unaffected.	[Manook, Miriam; Schmitz, Robin; Fitch, Zachary; Yoon, Janghoon; Bae, Yeeun; Shaw, Brian; Kirk, Allan; Kwun, Jean; Knechtle, Stuart] Duke Univ, Med Ctr, Dept Surg, Duke Transplant Ctr, Durham, NC 27710 USA; [Flores, Walter J.; Magnani, Diogo M.] Univ Massachusetts, Massbiol, Med Sch, Boston, MA 02125 USA; [Harnois, Melissa; Permar, Sallie] Duke Univ, Med Ctr, Human Vaccine Inst, Durham, NC USA; [Farris, Alton B.] Emory Sch Med, Dept Pathol, Atlanta, GA USA	Duke University; University of Massachusetts System; University of Massachusetts Boston; Duke University; Emory University	Kwun, J; Knechtle, S (corresponding author), Duke Univ, Med Ctr, Dept Surg, Duke Transplant Ctr, Durham, NC 27710 USA.	jean.kwun@duke.edu; stuart.knechtle@duke.edu	Schmitz, Robin/GQA-9389-2022; Kwun, Jean/F-2384-2018; Schmitz, Robin/AAW-8046-2021; Manook, Miriam/GZG-4089-2022	Kwun, Jean/0000-0002-8563-5472; Schmitz, Robin/0000-0003-1286-0457; Magnani, Diogo/0000-0002-1773-2406; Kirk, Allan/0000-0003-2004-5962; Harnois, Melissa/0000-0002-5910-6198	National Institute of Allergy and Infectious Diseases of the National Institutes of Health as part of the Nonhuman Primate Transplantation Tolerance Cooperative Study Group [U19AI131471]	National Institute of Allergy and Infectious Diseases of the National Institutes of Health as part of the Nonhuman Primate Transplantation Tolerance Cooperative Study Group	This work was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health as part of the Nonhuman Primate Transplantation Tolerance Cooperative Study Group under U19AI131471 (awarded to SK).	Baldwin WM, 2019, AM J TRANSPLANT, V19, P1881, DOI 10.1111/ajt.15366; Bentall A, 2014, TRANSPL INT, V27, P1235, DOI 10.1111/tri.12396; Burghuber CK, 2016, AM J TRANSPLANT, V16, P1726, DOI 10.1111/ajt.13688; Ezekian B, 2019, J AM SOC NEPHROL, V30, P2399, DOI 10.1681/ASN.2019030304; Haas M, 2018, AM J TRANSPLANT, V18, P293, DOI 10.1111/ajt.14625; Haas M, 2014, AM J TRANSPLANT, V14, P272, DOI 10.1111/ajt.12590; Ibrahim RB, 2007, PHARMACOTHERAPY, V27, P1529, DOI 10.1592/phco.27.11.1529; Jarnum S, 2015, J IMMUNOL, V195, P5592, DOI 10.4049/jimmunol.1501929; Jordan SC, 2017, NEW ENGL J MED, V377, P442, DOI 10.1056/NEJMoa1612567; Jordan SC, 2020, AM J TRANSPLANT, V20, P42, DOI 10.1111/ajt.15913; Jordan SC, 2020, TRANSPLANTATION, V104, P17, DOI 10.1097/TP.0000000000002912; Latvala S, 2017, J HISTOCHEM CYTOCHEM, V65, P321, DOI 10.1369/0022155417705095; Li T, 2019, J PHARM SCI-US, V108, P714, DOI 10.1016/j.xphs.2018.10.067; Ling LE, 2019, CLIN PHARMACOL THER, V105, P1031, DOI 10.1002/cpt.1276; Lonze BE, 2018, ANN SURG, V268, P488, DOI 10.1097/SLA.0000000000002924; Lorant T, 2018, AM J TRANSPLANT, V18, P2752, DOI 10.1111/ajt.14733; Loupy A, 2010, TRANSPLANTATION, V89, P1403, DOI 10.1097/TP.0b013e3181da1cc3; Marlu R, 2018, THROMB RES, V166, P113, DOI 10.1016/j.thromres.2018.04.018; Mengel M, 2012, AM J TRANSPLANT, V12, P563, DOI 10.1111/j.1600-6143.2011.03926.x; Montgomery RA, 2000, TRANSPLANTATION, V70, P887, DOI 10.1097/00007890-200009270-00006; Pol E, 2016, ANAL BIOCHEM, V510, P88, DOI 10.1016/j.ab.2016.07.009; Pyzik M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01540; Raghavan M, 1996, ANNU REV CELL DEV BI, V12, P181, DOI 10.1146/annurev.cellbio.12.1.181; Robak T, 2020, BLOOD ADV, V4, P4136, DOI 10.1182/bloodadvances.2020002003; Roufosse C, 2018, TRANSPLANTATION, V102, P1795, DOI 10.1097/TP.0000000000002366; Schroder PM, 2021, KIDNEY INT, V99, P161, DOI 10.1016/j.kint.2020.08.020; Sharif A, 2012, QJM-INT J MED, V105, P1141, DOI 10.1093/qjmed/hcs154; Sharif A, 2012, TRANSPLANTATION, V93, pE27, DOI 10.1097/TP.0b013e318249b10e; Shaw BI, 2021, CLIN TRANSPLANT, V35, DOI 10.1111/ctr.14369; Smith B, 2018, MABS-AUSTIN, V10, P1111, DOI 10.1080/19420862.2018.1505464; van Meer PJK, 2013, MABS-AUSTIN, V5, P810, DOI 10.4161/mabs.25234; Zhu XP, 2001, J IMMUNOL, V166, P3266, DOI 10.4049/jimmunol.166.5.3266	32	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2021	12								660900	10.3389/fimmu.2021.660900	http://dx.doi.org/10.3389/fimmu.2021.660900			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SS6BB	34149698	Green Published, gold			2022-12-18	WOS:000661838500001
J	Na, SY; Krishnamoorthy, G				Na, Shin-Young; Krishnamoorthy, Gurumoorthy			Targeted Expression of Myelin Autoantigen in the Periphery Induces Antigen-Specific T and B Cell Tolerance and Ameliorates Autoimmune Disease	FRONTIERS IN IMMUNOLOGY			English	Article						experimental autoimmue encephalomyelitis; tolerance; autoimmunity; multiple sclerosis (MS); MOG (myelin oligodendrocyte glycoprotein)	OLIGODENDROCYTE GLYCOPROTEIN; MULTIPLE-SCLEROSIS; SELF-ANTIGEN; NERVOUS-SYSTEM; ENCEPHALOMYELITIS; TRANSPLANTATION; LYMPHOCYTES; REPERTOIRE; ANTIBODIES; DELETION	There is a great interest in developing antigen-specific therapeutic approaches for the treatment of autoimmune diseases without compromising normal immune function. The key challenges are to control all antigen-specific lymphocyte populations that contribute to pathogenic inflammatory processes and to provide long-term protection from disease relapses. Here, we show that myelin oligodendrocyte glycoprotein (MOG)-specific tolerance can be established by ectopic expression of MOG in the immune organs. Using transgenic mice expressing MOG-specific CD4, CD8, and B cell receptors, we show that MOG expression in the bone marrow cells results in impaired development of MOG-specific lymphocytes. Ectopic MOG expression has also resulted in long-lasting protection from MOG-induced autoimmunity. This finding raises hope that transplantation of autoantigen-expressing bone marrow cells as a therapeutic strategy for specific autoantigen-driven autoimmune diseases.	[Na, Shin-Young; Krishnamoorthy, Gurumoorthy] Max Planck Inst Biochem, Res Grp Neuroinflammat & Mucosal Immunol, Martinsried, Germany	Max Planck Society	Krishnamoorthy, G (corresponding author), Max Planck Inst Biochem, Res Grp Neuroinflammat & Mucosal Immunol, Martinsried, Germany.	guru@biochem.mpg.de			Max Planck Society; European Research Council starting grant (GAMES) [635617]; German research foundation (DFG) [SFB TR-128]	Max Planck Society(Max Planck SocietyFoundation CELLEX); European Research Council starting grant (GAMES); German research foundation (DFG)(German Research Foundation (DFG))	This work was funded by the Max Planck Society. GK is further supported by the European Research Council starting grant (GAMES; 635617), German research foundation (DFG) SFB TR-128 (Project A1). None of the funding sources had an influence on the study design, data collection, analysis, interpretation, or the writing of the manuscript.	Ancau M, 2019, EXPERT OPIN BIOL TH, V19, P829, DOI 10.1080/14712598.2019.1611778; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Bettelli E, 2003, J EXP MED, V197, P1073, DOI 10.1084/jem.20021603; Bielekova B, 2000, NAT MED, V6, P1167, DOI 10.1038/80516; Burt R K, 1998, Curr Opin Hematol, V5, P472, DOI 10.1097/00062752-199811000-00020; Chan J, 2008, J IMMUNOL, V181, P7571, DOI 10.4049/jimmunol.181.11.7571; Chung JY, 2014, J IMMUNOL, V192, P2593, DOI 10.4049/jimmunol.1203563; Clemente-Casares X, 2016, NATURE, V530, P434, DOI 10.1038/nature16962; Fissolo N, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-139; Johns TG, 1999, J NEUROCHEM, V72, P1, DOI 10.1046/j.1471-4159.1999.0720001.x; Kappos L, 2000, NAT MED, V6, P1176, DOI 10.1038/80525; Kaushansky N, 2019, J NEUROIMMUNOL, V333, DOI 10.1016/j.jneuroim.2019.04.013; Kenison JE, 2020, P NATL ACAD SCI USA, V117, P32017, DOI 10.1073/pnas.2016451117; Klein L, 2000, NAT MED, V6, P56, DOI 10.1038/71540; Kleinschmidt-DeMasters BK, 2005, NEW ENGL J MED, V353, P369, DOI 10.1056/NEJMoa051782; Krienke Christina, 2021, Science, V371, P145, DOI 10.1126/science.aay3638; Krishnamoorthy G, 2009, EUR J IMMUNOL, V39, P2031, DOI 10.1002/eji.200939568; Krishnamoorthy G, 2009, NAT MED, V15, P626, DOI 10.1038/nm.1975; Kyewski B, 2004, NAT REV IMMUNOL, V4, P688, DOI 10.1038/nri1436; Kyewski B, 2006, ANNU REV IMMUNOL, V24, P571, DOI 10.1146/annurev.immunol.23.021704.115601; Lennon VA, 2005, J EXP MED, V202, P473, DOI 10.1084/jem.20050304; Litzenburger T, 2000, J IMMUNOL, V165, P5360, DOI 10.4049/jimmunol.165.9.5360; Litzenburger T, 1998, J EXP MED, V188, P169, DOI 10.1084/jem.188.1.169; Lobell A, 2003, J IMMUNOL, V170, P1806, DOI 10.4049/jimmunol.170.4.1806; Lucca LE, 2016, EUR J IMMUNOL, V46, P2247, DOI 10.1002/eji.201646416; Muraro PA, 2014, J CLIN INVEST, V124, P1168, DOI 10.1172/JCI71691; NEMAZEE D, 1991, IMMUNOL REV, V122, P117, DOI 10.1111/j.1600-065X.1991.tb00600.x; Pagany M, 2003, NEUROSCI LETT, V350, P165, DOI 10.1016/S0304-3940(03)00899-1; PIRCHER H, 1989, EMBO J, V8, P719, DOI 10.1002/j.1460-2075.1989.tb03431.x; Reindl M, 2019, NAT REV NEUROL, V15, P89, DOI 10.1038/s41582-018-0112-x; Rosenblum MD, 2015, J CLIN INVEST, V125, P2228, DOI 10.1172/JCI78088; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; Serra P, 2019, NAT BIOTECHNOL, V37, P238, DOI 10.1038/s41587-019-0015-4; Sospedra M, 2016, SEMIN NEUROL, V36, P115, DOI 10.1055/s-0036-1579739; Spadaro M, 2018, ANN NEUROL, V84, P315, DOI 10.1002/ana.25291; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; Wynford-Thomas R, 2019, J NEUROL, V266, P1280, DOI 10.1007/s00415-018-9122-2; Zhong MC, 2002, J CLIN INVEST, V110, P81, DOI 10.1172/JCI200215692	38	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2021	12								668487	10.3389/fimmu.2021.668487	http://dx.doi.org/10.3389/fimmu.2021.668487			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SS6JH	34149706	gold, Green Published			2022-12-18	WOS:000661860100001
J	Pisano, M; Cheng, Y; Sun, FM; Dhakal, B; D'Souza, A; Chhabra, S; Knight, JM; Rao, S; Zhan, FH; Hari, P; Janz, S				Pisano, Michael; Cheng, Yan; Sun, Fumou; Dhakal, Binod; D'Souza, Anita; Chhabra, Saurabh; Knight, Jennifer M.; Rao, Sridhar; Zhan, Fenghuang; Hari, Parameswaran; Janz, Siegfried			Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma	FRONTIERS IN IMMUNOLOGY			English	Review						genetically engineered mouse models of human cancer; auto- and xenografting; immune; immunodeficient mice models; immune pathogenesis; Myeloma	TRANSGENIC MOUSE MODEL; PLASMA-CELL NEOPLASMS; SCID-HU MICE; BCL-X-L; B-CELL; T-CELLS; MONOCLONAL GAMMOPATHY; ANTITUMOR-ACTIVITY; BONE-MARROW; MURINE MODEL	Mouse models of human cancer provide an important research tool for elucidating the natural history of neoplastic growth and developing new treatment and prevention approaches. This is particularly true for multiple myeloma (MM), a common and largely incurable neoplasm of post-germinal center, immunoglobulin-producing B lymphocytes, called plasma cells, that reside in the hematopoietic bone marrow (BM) and cause osteolytic lesions and kidney failure among other forms of end-organ damage. The most widely used mouse models used to aid drug and immunotherapy development rely on in vivo propagation of human myeloma cells in immunodeficient hosts (xenografting) or myeloma-like mouse plasma cells in immunocompetent hosts (autografting). Both strategies have made and continue to make valuable contributions to preclinical myeloma, including immune research, yet are ill-suited for studies on tumor development (oncogenesis). Genetically engineered mouse models (GEMMs), such as the widely known V kappa*MYC, may overcome this shortcoming because plasma cell tumors (PCTs) develop de novo (spontaneously) in a highly predictable fashion and accurately recapitulate many hallmarks of human myeloma. Moreover, PCTs arise in an intact organism able to mount a complete innate and adaptive immune response and tumor development reproduces the natural course of human myelomagenesis, beginning with monoclonal gammopathy of undetermined significance (MGUS), progressing to smoldering myeloma (SMM), and eventually transitioning to frank neoplasia. Here we review the utility of transplantation-based and transgenic mouse models of human MM for research on immunopathology and -therapy of plasma cell malignancies, discuss strengths and weaknesses of different experimental approaches, and outline opportunities for closing knowledge gaps, improving the outcome of patients with myeloma, and working towards a cure.	[Pisano, Michael; Cheng, Yan; Sun, Fumou; Dhakal, Binod; D'Souza, Anita; Chhabra, Saurabh; Hari, Parameswaran; Janz, Siegfried] Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI 53226 USA; [Pisano, Michael] Univ Iowa, Interdisciplinary Grad Program Immunol, Iowa City, IA USA; [Knight, Jennifer M.] Med Coll Wisconsin, Dept Psychiat, Milwaukee, WI 53226 USA; [Knight, Jennifer M.] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; [Knight, Jennifer M.] Med Coll Wisconsin, Dept Microbiol & Immunol, Milwaukee, WI 53226 USA; [Rao, Sridhar] Med Coll Wisconsin, Dept Pediat, Div Hematol Oncol & Marrow Transplant, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA; [Rao, Sridhar] Versiti Wisconsin, Blood Res Inst, Milwaukee, WI USA; [Zhan, Fenghuang] Univ Arkansas Med Sci, Myeloma Ctr, Dept Internal Med, Little Rock, AR 72205 USA; [Zhan, Fenghuang] Univ Arkansas Med Sci, Winthrop P Rockefeller Canc Inst, Little Rock, AR 72205 USA	Medical College of Wisconsin; University of Iowa; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Versiti Blood Center of Wisconsin; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Janz, S (corresponding author), Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI 53226 USA.	sjanz@mcw.edu	D'Souza, Anita/AGY-7436-2022		William G. Schuett, Jr., Multiple Myeloma Research Endowment; NCI [R01CA204231, R01CA236814, R01 CA151354]; DOD [CA180190]	William G. Schuett, Jr., Multiple Myeloma Research Endowment; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense)	This work was supported by the William G. Schuett, Jr., Multiple Myeloma Research Endowment. Additional support was provided by NCI R01CA204231 (to SR), NCI R01CA236814 and DOD CA180190 (to FZ) and NCI R01 CA151354 (to SJ).	Affer M, 2014, LEUKEMIA, V28, P1725, DOI 10.1038/leu.2014.70; Agirre X, 2015, GENOME RES, V25, P478, DOI 10.1101/gr.180240.114; Airoldi I, 2005, BLOOD, V106, P3846, DOI 10.1182/blood-2005-05-2034; Akhmetzyanova I, 2020, LEUKEMIA, V34, P245, DOI 10.1038/s41375-019-0519-4; Alici E, 2004, EXP HEMATOL, V32, P1064, DOI 10.1016/j.exphem.2004.07.019; Amend SR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127828; Amodio N, 2012, ONCOTARGET, V3, P1246; ANDERSON PN, 1969, NATURE, V222, P994, DOI 10.1038/222994a0; Asai T, 2016, SCI REP-UK, V6, DOI 10.1038/srep22760; Asimakopoulos F, 2018, BLOOD, V132, P1629, DOI 10.1182/blood-2018-08-864231; Avet-Loiseau H, 1999, CANCER RES, V59, P4546; Baghdadi M, 2019, BLOOD ADV, V3, P541, DOI 10.1182/bloodadvances.2018020008; Bailur JK, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127807; Barber A, 2011, GENE THER, V18, P509, DOI 10.1038/gt.2010.174; Barlogie B, 2002, SEMIN ONCOL, V29, P26, DOI 10.1053/sonc.2002.34074; Barlogie B, 2014, BLOOD, V124, P3043, DOI 10.1182/blood-2014-07-552059; Binsfeld M, 2016, ONCOTARGET, V7, P37931, DOI 10.18632/oncotarget.9270; Binsfeld M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113764; Bjorklund CC, 2020, LEUKEMIA, V34, P1197, DOI 10.1038/s41375-019-0620-8; Bliskovsky V, 2003, P NATL ACAD SCI USA, V100, P14982, DOI 10.1073/pnas.2431627100; Bogen B, 2019, CANCER IMMUNOL IMMUN, V68, P1865, DOI 10.1007/s00262-019-02374-0; Boylan KLM, 2007, CANCER RES, V67, P4069, DOI 10.1158/0008-5472.CAN-06-3699; Braathen R, 2020, MOL THER-METH CLIN D, V17, P378, DOI 10.1016/j.omtm.2020.01.007; BYRD LG, 1991, J IMMUNOL, V147, P3632; Calcinotto A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07305-8; Calimeri T, 2011, LEUKEMIA, V25, P707, DOI 10.1038/leu.2010.300; Capasso A, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0518-z; Carrasco DR, 2007, CANCER CELL, V11, P349, DOI 10.1016/j.ccr.2007.02.015; Chang LF, 2013, CELL REP, V3, P1389, DOI 10.1016/j.celrep.2013.03.040; Chauvin JM, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000957; Chesi M, 2008, CANCER CELL, V13, P167, DOI 10.1016/j.ccr.2008.01.007; Chesi M, 2016, NAT MED, V22, P1411, DOI 10.1038/nm.4229; Chesi M, 2012, BLOOD, V120, P376, DOI 10.1182/blood-2012-02-412783; Cheung WC, 2004, J CLIN INVEST, V113, P1763, DOI 10.1172/JCI200420369; Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343; Cohen AD, 2020, CLIN CANCER RES, V26, P1541, DOI 10.1158/1078-0432.CCR-19-2111; Cooke RE, 2019, J ONCOL, V2019, DOI 10.1155/2019/2186494; Cooke RE, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0994-6; Corre J, 2021, BLOOD, V137, P16, DOI 10.1182/blood.2019004309; Costa F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02204; CROESE JW, 1987, BRIT J CANCER, V56, P555, DOI 10.1038/bjc.1987.241; CROESE JW, 1991, NEOPLASMA, V38, P467; CROESE JW, 1991, NEOPLASMA, V38, P457; Dallas SL, 1999, BLOOD, V93, P1697, DOI 10.1182/blood.V93.5.1697.405a17_1697_1706; Daniels-Wells TR, 2020, J IMMUNOTHER, V43, P48, DOI 10.1097/CJI.0000000000000304; Das R, 2016, NAT MED, V22, P1351, DOI 10.1038/nm.4202; De Beck L, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1484981; De La Rochere P, 2018, TRENDS IMMUNOL, V39, P748, DOI 10.1016/j.it.2018.07.001; De Smedt E, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00566; de Weers M, 2011, J IMMUNOL, V186, P1840, DOI 10.4049/jimmunol.1003032; Dechow T, 2014, J CLIN INVEST, V124, P5263, DOI 10.1172/JCI69094; Di Martino MT, 2012, CLIN CANCER RES, V18, P6260, DOI 10.1158/1078-0432.CCR-12-1708; Dispenzieri A, 2020, HEMATOL-AM SOC HEMAT, P380, DOI 10.1182/hematology.2020000122; Epstein Joshua, 2005, V113, P183, DOI 10.1385/1-59259-916-8:183; Feyler S, 2009, BRIT J HAEMATOL, V144, P686, DOI 10.1111/j.1365-2141.2008.07530.x; Fowler JA, 2012, CANCER RES, V72, P2183, DOI 10.1158/0008-5472.CAN-11-2067; Fryer RA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057641; Galluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI 10.1038/nri.2016.107; Gemechu Y, 2018, P NATL ACAD SCI USA, V115, P11802, DOI 10.1073/pnas.1814446115; Goldstein RL, 2020, BLOOD ADV, V4, P4180, DOI 10.1182/bloodadvances.2020002565; Gooding S, 2016, CURR OPIN PHARMACOL, V28, P43, DOI 10.1016/j.coph.2016.02.013; Goyal G, 2019, LEUKEMIA, V33, P1273, DOI 10.1038/s41375-019-0419-7; Guillerey C, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125932; Guillerey C, 2018, BLOOD, V132, P1689, DOI 10.1182/blood-2018-01-825265; Guillerey C, 2015, J CLIN INVEST, V125, P2904, DOI 10.1172/JCI82646; Gulla A, 2020, HAEMATOLOGICA, V105, P2358, DOI 10.3324/haematol.2020.247015; Haabeth OA, 2016, LEUKEMIA, V30, P1216, DOI 10.1038/leu.2015.278; Haabeth OAW, 2020, BLOOD ADV, V4, P2595, DOI 10.1182/bloodadvances.2020001434; Hallett WHD, 2011, BIOL BLOOD MARROW TR, V17, P1133, DOI 10.1016/j.bbmt.2011.03.011; Hamouda MA, 2016, J EXP MED, V213, P1705, DOI 10.1084/jem.20150983; Hanazawa A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00152; Higgs JT, 2017, BLOOD ADV, V1, P2375, DOI 10.1182/bloodadvances.2017007310; Hofgaard PO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051892; Hong S, 2012, CLIN EXP IMMUNOL, V170, P167, DOI 10.1111/j.1365-2249.2012.04642.x; Hong SY, 2008, CANCER RES, V68, P8456, DOI 10.1158/0008-5472.CAN-08-2213; Hong SY, 2012, CANCER IMMUNOL IMMUN, V61, P561, DOI 10.1007/s00262-011-1123-2; Hu Y, 2015, LEUKEMIA, V29, P474, DOI 10.1038/leu.2014.202; Hu Y, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.53; Hunter KW, 2012, NAT REV CANCER, V12, P144, DOI 10.1038/nrc3206; Invrea F, 2020, CURR OPIN BIOTECH, V63, P151, DOI 10.1016/j.copbio.2020.01.003; Isidori A, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01439; Ito R, 2018, J CELL PHYSIOL, V233, P3723, DOI 10.1002/jcp.26045; Kararoudi MN, 2020, BLOOD, V136, P2416, DOI 10.1182/blood.2020006200; Kawano Y, 2018, J CLIN INVEST, V128, P2487, DOI 10.1172/JCI88169; Kearl TJ, 2013, J IMMUNOL, V190, P5620, DOI 10.4049/jimmunol.1202005; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kortum KM, 2016, BLOOD, V128, P1226, DOI 10.1182/blood-2016-02-698092; Kovalchuk AL, 2002, P NATL ACAD SCI USA, V99, P1509, DOI 10.1073/pnas.022643999; Kumar SK, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.46; Kyle RA, 2010, LEUKEMIA, V24, P1121, DOI 10.1038/leu.2010.60; KYLE RA, 1989, EUR J HAEMATOL, V43, P70; Kyle RA, 2006, BRIT J HAEMATOL, V134, P573, DOI 10.1111/j.1365-2141.2006.06235.x; KYOIZUMI S, 1992, BLOOD, V79, P1704; Lacy MQ, 2009, J CLIN ONCOL, V27, P5008, DOI 10.1200/JCO.2009.23.6802; Landgraf M, 2018, TRENDS BIOTECHNOL, V36, P242, DOI 10.1016/j.tibtech.2017.12.001; Laronne-Bar-On A, 2008, J IMMUNOL, V181, P3714, DOI 10.4049/jimmunol.181.5.3714; Leoh LS, 2018, J IMMUNOL, V200, P3485, DOI 10.4049/jimmunol.1700787; Li X, 2011, STEM CELLS, V29, P263, DOI 10.1002/stem.572; Lin L, 2021, LEUKEMIA, V35, P752, DOI 10.1038/s41375-020-0951-5; Linden M, 2004, BLOOD, V103, P2779, DOI 10.1182/blood-2003-10-3399; Linden MA, 2012, EXP HEMATOL, V40, P216, DOI 10.1016/j.exphem.2011.11.006; Liu H, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8949; Lomas Oliver C, 2020, Am Soc Clin Oncol Educ Book, V40, P1, DOI 10.1200/EDBK_278911; Lonial S, 2020, J CLIN ONCOL, V38, P1126, DOI 10.1200/JCO.19.01740; Lopez-Corral L, 2011, CLIN CANCER RES, V17, P1692, DOI 10.1158/1078-0432.CCR-10-1066; Lwin ST, 2016, BONEKEY REP, V5, DOI 10.1038/bonekey.2015.142; Maes K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33396-w; MANNING LS, 1992, BRIT J CANCER, V66, P1088, DOI 10.1038/bjc.1992.415; Marsh-Wakefield F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01596; Martin T, 2017, BLOOD, V129, P3294, DOI 10.1182/blood-2016-09-740787; McCarthy BA, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-203; MCINTIRE KR, 1969, IMMUNOLOGY, V17, P481; Minnie SA, 2020, J CLIN INVEST, V130, P1565, DOI 10.1172/JCI129205; Minnie SA, 2018, BLOOD, V132, P1675, DOI 10.1182/blood-2018-01-825240; Miyakawa Y, 2004, BIOCHEM BIOPH RES CO, V313, P258, DOI 10.1016/j.bbrc.2003.11.120; MOKYR MB, 1994, J IMMUNOL, V153, P3123; Moreaux J, 2011, HAEMATOL-HEMATOL J, V96, P574, DOI 10.3324/haematol.2010.033456; Morito N, 2011, CANCER RES, V71, P339, DOI 10.1158/0008-5472.CAN-10-1057; Muchtar E, 2018, LEUKEMIA LYMPHOMA, V59, P288, DOI 10.1080/10428194.2017.1334124; Murray ME, 2014, BLOOD, V123, P3770, DOI 10.1182/blood-2013-10-530964; Nadeem O, 2020, IMMUNOTARGETS THER, V9, P201, DOI 10.2147/ITT.S240886; Nakamura K, 2020, BLOOD, V136, P2731, DOI 10.1182/blood.2020006540; Nakamura K, 2018, CANCER CELL, V33, P634, DOI 10.1016/j.ccell.2018.02.007; Niiro H, 2002, NAT REV IMMUNOL, V2, P945, DOI 10.1038/nri955; Nikesitch N, 2016, J CLIN PATHOL, V69, P97, DOI 10.1136/jclinpath-2015-203414; Noble JN, 2019, CURR HEMATOL MALIG R, V14, P119, DOI 10.1007/s11899-019-00504-0; Nur H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065075; Ochoa MC, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1599636; Papadimitriou K, 2020, CANCERS, V12, DOI 10.3390/cancers12082006; Paton-Hough J, 2015, BONE, V77, P57, DOI 10.1016/j.bone.2015.04.004; Pearson JA, 2016, J AUTOIMMUN, V66, P76, DOI 10.1016/j.jaut.2015.08.019; Pennisi A, 2009, AM J HEMATOL, V84, P6, DOI 10.1002/ajh.21310; Phan TG, 2020, NAT REV CANCER, V20, P398, DOI 10.1038/s41568-020-0263-0; POTTER M, 1975, J NATL CANCER I, V54, P1413, DOI 10.1093/jnci/54.6.1413; Potter M, 2003, IMMUNOL REV, V194, P177, DOI 10.1034/j.1600-065X.2003.00061.x; POTTER M, 1962, NATURE, V193, P1086, DOI 10.1038/1931086a0; Radhakrishnan SV, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14619-z; RADL J, 1979, J IMMUNOL, V122, P609; RADL J, 1985, CANCER-AM CANCER SOC, V55, P1030, DOI 10.1002/1097-0142(19850301)55:5<1030::AID-CNCR2820550518>3.0.CO;2-Y; RADL J, 1988, AM J PATHOL, V132, P593; Rajkumar SV, 2019, HEMATOL ONCOL, V37, P62, DOI 10.1002/hon.2586; Rajkumar SV, 2014, LANCET ONCOL, V15, pE538, DOI 10.1016/S1470-2045(14)70442-5; Rasche L, 2020, BLOOD, V136, P2491, DOI 10.1182/blood.2019004176; Ray A, 2019, BLOOD CANCER J, V9, DOI 10.1038/s41408-019-0224-6; Robertson JD, 2000, BRIT J CANCER, V82, P1261, DOI 10.1054/bjoc.1999.1088; Rollig C, 2015, LANCET, V385, P2197, DOI 10.1016/S0140-6736(14)60493-1; Rongvaux A, 2014, NAT BIOTECHNOL, V32, P364, DOI 10.1038/nbt.2858; Rongvaux A, 2013, ANNU REV IMMUNOL, V31, P635, DOI 10.1146/annurev-immunol-032712-095921; Rosean TR, 2014, IMMUNOL RES, V59, P188, DOI 10.1007/s12026-014-8528-x; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; Rosenblatt J, 2019, CANCER J, V25, P38, DOI 10.1097/PPO.0000000000000356; Rosenblatt J, 2013, CLIN CANCER RES, V19, P3640, DOI 10.1158/1078-0432.CCR-13-0282; Rossi Marco, 2018, Oncotarget, V9, P20119, DOI 10.18632/oncotarget.24614; Rustad EH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15740-9; Rutsch S, 2010, BLOOD, V115, P1746, DOI 10.1182/blood-2009-08-237941; Sarin V, 2020, LEUKEMIA, V34, P2754, DOI 10.1038/s41375-020-0785-1; Savelyeva N, 2005, P NATL ACAD SCI USA, V102, P10987, DOI 10.1073/pnas.0505108102; Scherger AK, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.128435; Schueler J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079939; Schwarzer R, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.37; Sewastianik T, 2021, BLOOD, V137, P1905, DOI 10.1182/blood.2020009088; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; Shultz LD, 2019, MAMM GENOME, V30, P123, DOI 10.1007/s00335-019-09796-2; Silva S, 2003, CANCER RES, V63, P8656; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102; Soodgupta D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055841; Sorrig R, 2019, EUR J HAEMATOL, V102, P182, DOI 10.1111/ejh.13190; Stone MJ, 2001, CLIN LYMPHOMA, V2, P148, DOI 10.3816/CLM.2001.n.020; SUEMATSU S, 1992, P NATL ACAD SCI USA, V89, P232, DOI 10.1073/pnas.89.1.232; Sun FM, 2020, HAEMATOLOGICA, V105, DOI 10.3324/haematol.2019.221127; Tai YT, 2005, CANCER RES, V65, P11712, DOI 10.1158/0008-5472.CAN-05-1657; Tanaskovic O, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217345; Tassone P, 2005, CLIN CANCER RES, V11, P4251, DOI 10.1158/1078-0432.CCR-04-2611; Tentler JJ, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07500-1; Thirukkumaran CM, 2019, BLOOD ADV, V3, P797, DOI 10.1182/bloodadvances.2018025593; Tompkins VS, 2016, LEUKEMIA, V30, P962, DOI 10.1038/leu.2015.197; Trudel S, 2018, LANCET ONCOL, V19, P1641, DOI 10.1016/S1470-2045(18)30576-X; Ueda O, 2017, SCI REP-UK, V7, DOI 10.1038/srep45839; Urashima M, 1997, BLOOD, V90, P754, DOI 10.1182/blood.V90.2.754.754_754_765; van de Donk NWCJ, 2016, BLOOD, V127, P681, DOI 10.1182/blood-2015-10-646810; van Rhee F, 2009, MOL CANCER THER, V8, P2616, DOI 10.1158/1535-7163.MCT-09-0483; Vandenberg CJ, 2014, BLOOD, V124, P1099, DOI 10.1182/blood-2014-04-570770; Vanderkerken K, 1996, BRIT J CANCER, V73, P1463, DOI 10.1038/bjc.1996.277; Vicente-Duenas C, 2012, EMBO J, V31, P3704, DOI 10.1038/emboj.2012.227; Villa N, 2020, MOL THER-ONCOLYTICS, V18, P171, DOI 10.1016/j.omto.2020.06.011; Vlummens P, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00740; Vuckovic S, 2020, BLOOD ADV, V4, P4593, DOI 10.1182/bloodadvances.2020002237; Vuckovic S, 2019, J CLIN INVEST, V129, P106, DOI 10.1172/JCI98888; Wang D, 2017, LEUKEMIA, V31, P2114, DOI 10.1038/leu.2017.69; Wang SQ, 2006, BLOOD, V107, P2432, DOI 10.1182/blood-2005-06-2486; Weinhold N, 2016, BLOOD, V128, P1735, DOI 10.1182/blood-2016-06-723007; Weiss BM, 2009, BLOOD, V113, P5418, DOI 10.1182/blood-2008-12-195008; Wen Z, 2021, BLOOD, V137, P61, DOI 10.1182/blood.2020007156; Wong D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109018; Wong TW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070554; Yaccoby S, 2008, LEUKEMIA, V22, P406, DOI 10.1038/sj.leu.2405048; Yaccoby S, 1998, BLOOD, V92, P2908, DOI 10.1182/blood.V92.8.2908.420a32_2908_2913; Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood-2006-09-047712; Yado S, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0776-9; Yata K, 2004, LEUKEMIA, V18, P1891, DOI 10.1038/sj.leu.2403513; Zhan F, 2006, BLOOD, V108, P2020, DOI 10.1182/blood-2005-11-013458; Zhang BC, 2007, BLOOD, V110, P743, DOI 10.1182/blood-2006-11-058446; Zhang L, 2015, ONCOTARGET, V6, P36032, DOI 10.18632/oncotarget.5506; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001	204	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2021	12								667054	10.3389/fimmu.2021.667054	http://dx.doi.org/10.3389/fimmu.2021.667054			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SS6MA	34149703	Green Published, gold			2022-12-18	WOS:000661867600001
J	Ishihara, S; Sato, T; Sugioka, R; Miwa, R; Saito, H; Sato, R; Fukuyama, H; Nakajima, A; Sawai, S; Kotani, A; Katagiri, K				Ishihara, Sayaka; Sato, Tsuyoshi; Sugioka, Risa; Miwa, Ryota; Saito, Haruka; Sato, Ryota; Fukuyama, Hidehiro; Nakajima, Akihiko; Sawai, Satoshi; Kotani, Ai; Katagiri, Koko			Rap1 Is Essential for B-Cell Locomotion, Germinal Center Formation and Normal B-1a Cell Population	FRONTIERS IN IMMUNOLOGY			English	Article						B cells; Rap1; germinal center; B-1a; chemotactic factor	PYK2 TYROSINE PHOSPHORYLATION; T-CELL; FETAL LIVER; ANTIGEN; PROGENITORS; LYMPHOCYTE; ADHESION; DISTINCT; SIGNAL; ZONE	Integrin regulation by Rap1 is indispensable for lymphocyte recirculation. In mice having B-cell-specific Rap1a/b double knockouts (DKO), the number of B cells in lymph nodes decreased to approximately 4% of that of control mice, and B cells were present in the spleen and blood. Upon the immunization with NP-CGG, DKO mice demonstrated the defective GC formation in the spleen, and the reduced NP-specific antibody production. In vitro, Rap1 deficiency impaired the movement of activated B cells along the gradients of chemoattractants known to be critical for their localization in the follicles. Furthermore, B-1a cells were almost completely absent in the peritoneal cavity, spleen and blood of adult DKO mice, and the number of B-cell progenitor/precursor (B-p) were reduced in neonatal and fetal livers. However, DKO B-ps normally proliferated, and differentiated into IgM(+) cells in the presence of IL-7. CXCL12-dependent migration of B-ps on the VCAM-1 was severely impaired by Rap1 deficiency. Immunostaining study of fetal livers revealed defects in the co-localization of DKO B-ps and IL-7-producing stromal cells. This study proposes that the profound effects of Rap1-deficiency on humoral responses and B-1a cell generation may be due to or in part caused by impairments of the chemoattractant-dependent positioning and the contact with stromal cells.	[Ishihara, Sayaka; Sato, Tsuyoshi; Sugioka, Risa; Miwa, Ryota; Saito, Haruka; Katagiri, Koko] Kitasato Univ, Sch Sci, Dept Biosci, Sagamihara, Kanagawa, Japan; [Sato, Ryota; Fukuyama, Hidehiro] RIKEN, Lab Lymphocyte Differentiat, Ctr Integrat Med Sci IMS, Yokohama, Kanagawa, Japan; [Nakajima, Akihiko; Sawai, Satoshi] Univ Tokyo, Grad Sch Arts & Sci, Dept Basic Sci, Tokyo, Japan; [Kotani, Ai] Tokai Univ, Inst Med Sci, Dept Hematol Malignancy, Isehara, Kanagawa, Japan	Kitasato University; RIKEN; University of Tokyo; Tokai University	Katagiri, K (corresponding author), Kitasato Univ, Sch Sci, Dept Biosci, Sagamihara, Kanagawa, Japan.	katagirk@kitasato-u.ac.jp	Fukuyama, Hidehiro/AAY-6256-2021	Fukuyama, Hidehiro/0000-0002-6457-0630; Sawai, Satoshi/0000-0003-3764-219X	Japan Society for the Promotion of Science KAKENHI [20K16290, 19K07612]; Takeda Science Foundation; Naito Foundation; Kitasato University Research grant; Suzuken Memorial Foundation	Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Naito Foundation(Naito Memorial Foundation); Kitasato University Research grant; Suzuken Memorial Foundation	We would like to thank Ms. H. Onda for technical assistance. This work was supported by Japan Society for the Promotion of Science KAKENHI 20K16290 and 19K07612, Takeda Science Foundation, The Naito Foundation. Kitasato University Research grant for young researchers. Suzuken Memorial Foundation.	Allen CDC, 2004, NAT IMMUNOL, V5, P943, DOI 10.1038/ni1100; Allen CDC, 2007, IMMUNITY, V27, P190, DOI 10.1016/j.immuni.2007.07.009; Bannard O, 2013, IMMUNITY, V39, P912, DOI 10.1016/j.immuni.2013.08.038; Batista FD, 2009, NAT REV IMMUNOL, V9, P15, DOI 10.1038/nri2454; Batista FD, 2001, NATURE, V411, P489, DOI 10.1038/35078099; Beck TC, 2014, J EXP MED, V211, P2567, DOI 10.1084/jem.20140457; Carrasco YR, 2007, IMMUNITY, V27, P160, DOI 10.1016/j.immuni.2007.06.007; Chen JJ, 2018, CELL REP, V25, P3393, DOI 10.1016/j.celrep.2018.11.096; Chen YH, 2008, BLOOD, V111, P4627, DOI 10.1182/blood-2007-12-128140; Chu H, 2008, J IMMUNOL, V181, P3373, DOI 10.4049/jimmunol.181.5.3373; Dickinson GS, 2015, ANN NY ACAD SCI, V1362, P57, DOI 10.1111/nyas.12772; Duchniewicz M, 2006, MOL CELL BIOL, V26, P643, DOI 10.1128/MCB.26.2.643-653.2006; Durand CA, 2006, EUR J IMMUNOL, V36, P2235, DOI 10.1002/eji.200535004; Foote JB, 2009, J IMMUNOL, V183, P6359, DOI 10.4049/jimmunol.0902473; Fukujin F, 2016, J R SOC INTERFACE, V13, DOI 10.1098/rsif.2016.0233; Gatto D, 2013, TRENDS IMMUNOL, V34, P336, DOI 10.1016/j.it.2013.01.007; Ghosn EEB, 2016, STEM CELL REP, V6, P137, DOI 10.1016/j.stemcr.2015.11.011; Ghosn EEB, 2011, P NATL ACAD SCI USA, V108, P2879, DOI 10.1073/pnas.1019764108; Gloerich M, 2011, TRENDS CELL BIOL, V21, P615, DOI 10.1016/j.tcb.2011.07.001; HARDY RR, 1991, P NATL ACAD SCI USA, V88, P11550, DOI 10.1073/pnas.88.24.11550; Harwood NE, 2010, ANNU REV IMMUNOL, V28, P185, DOI 10.1146/annurev-immunol-030409-101216; HAYAKAWA K, 1985, J EXP MED, V161, P1554, DOI 10.1084/jem.161.6.1554; Hogg N, 2011, NAT REV IMMUNOL, V11, P416, DOI 10.1038/nri2986; Humphries JD, 2019, CURR OPIN CELL BIOL, V56, P14, DOI 10.1016/j.ceb.2018.08.004; Ishida D, 2006, IMMUNITY, V24, P417, DOI 10.1016/j.immuni.2006.02.007; Ishihara S, 2020, BMC BIOL, V18, DOI 10.1186/s12915-020-00809-0; Ishihara S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9982; Kajikhina K, 2016, ADV IMMUNOL, V132, P71, DOI 10.1016/bs.ai.2016.07.002; Kajikhina K, 2015, SCI REP-UK, V5, DOI 10.1038/srep12817; Katagiri K, 2002, MOL CELL BIOL, V22, P1001, DOI 10.1128/MCB.22.4.1001-1015.2002; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Katagiri K, 2004, NAT IMMUNOL, V5, P1045, DOI 10.1038/ni1111; Katagiri K, 2006, NAT IMMUNOL, V7, P919, DOI 10.1038/ni1374; Katagiri K, 2009, EMBO J, V28, P1319, DOI 10.1038/emboj.2009.82; Katayama Y, 2009, BLOOD, V114, P1768, DOI 10.1182/blood-2009-03-213371; Kobayashi M, 2014, P NATL ACAD SCI USA, V111, P12151, DOI 10.1073/pnas.1407370111; Li Y, 2007, J IMMUNOL, V179, P8322, DOI 10.4049/jimmunol.179.12.8322; Lu E, 2019, IMMUNOL REV, V289, P158, DOI 10.1111/imr.12743; McLeod SJ, 2004, J BIOL CHEM, V279, P12009, DOI 10.1074/jbc.M313098200; McLeod SJ, 2002, J IMMUNOL, V169, P1365, DOI 10.4049/jimmunol.169.3.1365; Montecino-Rodriguez E, 2006, NAT IMMUNOL, V7, P293, DOI 10.1038/ni1301; Montecino-Rodriguez E, 2012, IMMUNITY, V36, P13, DOI 10.1016/j.immuni.2011.11.017; Montecino-Rodriguez E, 2011, J IMMUNOL, V187, P5712, DOI 10.4049/jimmunol.1102416; Nakajima A, 2016, LAB CHIP, V16, P4382, DOI 10.1039/c6lc00898d; Pandya KD, 2018, J IMMUNOL, V200, P4078, DOI 10.4049/jimmunol.1701348; Pedersen GK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01738; Pedersen GK, 2014, P NATL ACAD SCI USA, V111, pE4119, DOI 10.1073/pnas.1415866111; Phan TG, 2007, NAT IMMUNOL, V8, P992, DOI 10.1038/ni1494; Sato R, 2020, INT IMMUNOL, V32, P499, DOI 10.1093/intimm/dxaa012; Shimonaka M, 2003, J CELL BIOL, V161, P417, DOI 10.1083/jcb.200301133; Song WX, 2014, BBA-BIOMEMBRANES, V1838, P569, DOI 10.1016/j.bbamem.2013.07.016; Tsuneto M, 2013, STEM CELLS, V31, P2800, DOI 10.1002/stem.1421; Wang Jia C, 2020, Small GTPases, V11, P402, DOI 10.1080/21541248.2018.1441626; Wang JC, 2017, J CELL SCI, V130, P1094, DOI 10.1242/jcs.191858; Yi TS, 2012, IMMUNITY, V37, P535, DOI 10.1016/j.immuni.2012.06.015; Yuseff MI, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00251	57	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 1	2021	12								624419	10.3389/fimmu.2021.624419	http://dx.doi.org/10.3389/fimmu.2021.624419			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SS0LR	34140948	gold, Green Published			2022-12-18	WOS:000661434400001
J	Chuang, GY; Shen, CH; Cheung, CS; Gorman, J; Creanga, A; Joyce, MG; Leung, K; Rawi, R; Wang, LS; Yang, ES; Yang, YP; Zhang, BS; Zhang, Y; Kanekiyo, M; Zhou, TQ; DeKosky, BJ; Graham, BS; Mascola, JR; Kwong, PD				Chuang, Gwo-Yu; Shen, Chen-Hsiang; Cheung, Crystal Sao-Fong; Gorman, Jason; Creanga, Adrian; Joyce, M. Gordon; Leung, Kwanyee; Rawi, Reda; Wang, Lingshu; Yang, Eun Sung; Yang, Yongping; Zhang, Baoshan; Zhang, Yi; Kanekiyo, Masaru; Zhou, Tongqing; DeKosky, Brandon J.; Graham, Barney S.; Mascola, John R.; Kwong, Peter D.			Sequence-Signature Optimization Enables Improved Identification of Human HV6-1-Derived Class Antibodies That Neutralize Diverse Influenza A Viruses	FRONTIERS IN IMMUNOLOGY			English	Article						antibody identification; hemagglutinin stem; influenza; iterative optimization; multidonor class antibody; neutralizing antibody; sequence signature	B-CELLS; MONOCLONAL-ANTIBODIES; MATURATION PATHWAY; HIV-1; GERMLINE; BINDING; BROAD; REVEALS; LINEAGE; IMMUNIZATION	Sequence signatures of multidonor broadly neutralizing influenza antibodies can be used to quantify the prevalence of B cells with virus-neutralizing potential to accelerate development of broadly protective vaccine strategies. Antibodies of the same class share similar recognition modes and developmental pathways, and several antibody classes have been identified that neutralize diverse group 1- and group 2-influenza A viruses and have been observed in multiple human donors. One such multidonor antibody class, the HV6-1-derived class, targets the stem region of hemagglutinin with extraordinary neutralization breadth. Here, we use an iterative process to combine informatics, biochemical, and structural analyses to delineate an improved sequence signature for HV6-1-class antibodies. Based on sequence and structure analyses of known HV6-1 class antibodies, we derived a more inclusive signature (version 1), which we used to search for matching B-cell transcripts from published next-generation sequencing datasets of influenza vaccination studies. We expressed selected antibodies, evaluated their function, and identified amino acid-level requirements from which to refine the sequence signature (version 2). The cryo-electron microscopy structure for one of the signature-identified antibodies in complex with hemagglutinin confirmed motif recognition to be similar to known HV6-1-class members, MEDI8852 and 56.a.09, despite differences in recognition-loop length. Threading indicated the refined signature to have increased accuracy, and signature-identified heavy chains, when paired with the light chain of MEDI8852, showed neutralization comparable to the most potent members of the class. Incorporating sequences of additional class members thus enables an improved sequence signature for HV6-1-class antibodies, which can identify class members with increased accuracy.	[Chuang, Gwo-Yu; Shen, Chen-Hsiang; Cheung, Crystal Sao-Fong; Gorman, Jason; Creanga, Adrian; Joyce, M. Gordon; Leung, Kwanyee; Rawi, Reda; Wang, Lingshu; Yang, Eun Sung; Yang, Yongping; Zhang, Baoshan; Zhang, Yi; Kanekiyo, Masaru; Zhou, Tongqing; Graham, Barney S.; Mascola, John R.; Kwong, Peter D.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [DeKosky, Brandon J.] Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66045 USA; [DeKosky, Brandon J.] Univ Kansas, Dept Chem Engn, Lawrence, KS 66045 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Kansas; University of Kansas	Kwong, PD (corresponding author), NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	pdkwong@nih.gov	Gorman, Jason/AGG-9417-2022	Wang, Lingshu/0000-0002-8404-4910	Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Simons Foundation [SF349247]; NYSTAR; NIH National Institute of General Medical Sciences [GM103310]	Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Simons Foundation; NYSTAR; NIH National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Support for this work was provided by the Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health. Some of this work was performed at the Simons Electron Microscopy Center and National Resource for Automated Molecular Microscopy located at the New York Structural Biology Center, supported by grants from the Simons Foundation (SF349247), NYSTAR, and the NIH National Institute of General Medical Sciences (GM103310).	Adams PD, 2004, J SYNCHROTRON RADIAT, V11, P53, DOI 10.1107/S0909049503024130; Avnir Y, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004103; Barad BA, 2015, NAT METHODS, V12, P943, DOI [10.1038/nmeth.3541, 10.1038/NMETH.3541]; Barnes CO, 2020, CELL, V182, P828, DOI [10.1016/j.cell.2020.06.025, 10.1101/2020.05.28.121533]; Bonsignori M, 2018, IMMUNITY, V49, P1162, DOI 10.1016/j.immuni.2018.10.015; Bonsignori M, 2016, CELL, V165, P449, DOI 10.1016/j.cell.2016.02.022; Bornholdt ZA, 2016, SCIENCE, V351, P1078, DOI 10.1126/science.aad5788; Briney B, 2016, CELL, V166, P1459, DOI 10.1016/j.cell.2016.08.005; Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902; Cagigi A, 2018, J INFECT DIS, V218, pS528, DOI 10.1093/infdis/jiy333; Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025; Chen XJ, 2021, IMMUNITY, V54, P324, DOI 10.1016/j.immuni.2020.12.014; Cheung CSF, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108088; Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952; Cho A, 2016, CURR OPIN VIROL, V17, P110, DOI 10.1016/j.coviro.2016.03.002; Creanga A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21954-2; Crowe JE, 2016, CELL, V166, P1360, DOI 10.1016/j.cell.2016.08.039; Davis CW, 2019, CELL, V177, P1566, DOI 10.1016/j.cell.2019.04.036; Davis IW, 2004, NUCLEIC ACIDS RES, V32, pW615, DOI 10.1093/nar/gkh398; DeKosky BJ, 2016, P NATL ACAD SCI USA, V113, pE2636, DOI 10.1073/pnas.1525510113; DeKosky BJ, 2015, NAT MED, V21, P86, DOI 10.1038/nm.3743; Doria-Rose NA, 2014, NATURE, V509, P55, DOI 10.1038/nature13036; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Escolano A, 2016, CELL, V166, P1445, DOI 10.1016/j.cell.2016.07.030; Frimpong A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02769; Fu LM, 2012, BIOINFORMATICS, V28, P3150, DOI 10.1093/bioinformatics/bts565; Gaudinski MR, 2019, LANCET, V393, P889, DOI 10.1016/S0140-6736(19)30036-4; Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827; Hastie KM, 2019, CELL, V178, P1004, DOI 10.1016/j.cell.2019.07.020; Huang JH, 2016, IMMUNITY, V45, P1108, DOI 10.1016/j.immuni.2016.10.027; Hurlburt NK, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19231-9; Jackson KJL, 2014, CELL HOST MICROBE, V16, P105, DOI 10.1016/j.chom.2014.05.013; Jardine JG, 2016, SCIENCE, V351, P1458, DOI 10.1126/science.aad9195; Jardine JG, 2015, SCIENCE, V349, P156, DOI 10.1126/science.aac5894; Joyce MG, 2016, CELL, V166, P609, DOI 10.1016/j.cell.2016.06.043; KOEHL P, 1995, NAT STRUCT BIOL, V2, P163, DOI 10.1038/nsb0295-163; Krebs SJ, 2019, IMMUNITY, V50, P677, DOI 10.1016/j.immuni.2019.02.008; Kwon YD, 2018, CELL REP, V22, P1798, DOI 10.1016/j.celrep.2018.01.023; Kwong PD, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101428; Kwong PD, 2018, IMMUNITY, V48, P855, DOI 10.1016/j.immuni.2018.04.029; Lagerman CE, 2019, J BIOSCI BIOENG, V128, P226, DOI 10.1016/j.jbiosc.2019.01.020; Lander GC, 2009, J STRUCT BIOL, V166, P95, DOI 10.1016/j.jsb.2009.01.002; Lanzavecchia A, 2016, CURR OPIN IMMUNOL, V41, P62, DOI 10.1016/j.coi.2016.06.001; Liu LH, 2020, NATURE, V584, P450, DOI 10.1038/s41586-020-2571-7; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Pappas L, 2014, NATURE, V516, P418, DOI 10.1038/nature13764; Parameswaran P, 2013, CELL HOST MICROBE, V13, P691, DOI 10.1016/j.chom.2013.05.008; Pettersen EF, 2021, PROTEIN SCI, V30, P70, DOI 10.1002/pro.3943; Pieper K, 2017, NATURE, V548, P597, DOI 10.1038/nature23670; Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]; Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520; Rohou A, 2015, J STRUCT BIOL, V192, P216, DOI 10.1016/j.jsb.2015.08.008; Scheres SHW, 2012, J STRUCT BIOL, V180, P519, DOI 10.1016/j.jsb.2012.09.006; Seydoux E, 2020, IMMUNITY, V53, P98, DOI 10.1016/j.immuni.2020.06.001; Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y; Soto C, 2019, NATURE, V566, P398, DOI 10.1038/s41586-019-0934-8; Stranges PB, 2013, PROTEIN SCI, V22, P74, DOI 10.1002/pro.2187; Sui JH, 2009, NAT STRUCT MOL BIOL, V16, P265, DOI 10.1038/nsmb.1566; Suloway C, 2005, J STRUCT BIOL, V151, P41, DOI 10.1016/j.jsb.2005.03.010; Tan J, 2018, NAT MED, V24, P401, DOI 10.1038/nm.4513; Tian M, 2016, CELL, V166, P1471, DOI 10.1016/j.cell.2016.07.029; Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017; Umotoy J, 2019, IMMUNITY, V51, P141, DOI 10.1016/j.immuni.2019.06.004; Voss NR, 2009, J STRUCT BIOL, V166, P205, DOI 10.1016/j.jsb.2009.01.004; West AP, 2012, P NATL ACAD SCI USA, V109, pE2083, DOI 10.1073/pnas.1208984109; Wheatley AK, 2015, J IMMUNOL, V195, P602, DOI 10.4049/jimmunol.1402835; Whittle JRR, 2014, J VIROL, V88, P4047, DOI 10.1128/JVI.03422-13; Wrammert J, 2011, J EXP MED, V208, P181, DOI 10.1084/jem.20101352; Wu NC, 2020, CELL HOST MICROBE, V28, P434, DOI 10.1016/j.chom.2020.06.003; Wu XL, 2015, CELL, V161, P470, DOI 10.1016/j.cell.2015.03.004; Wu XL, 2011, SCIENCE, V333, P1593, DOI 10.1126/science.1207532; Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659; Yang ZY, 2007, SCIENCE, V317, P825, DOI 10.1126/science.1135165; Ye J, 2013, NUCLEIC ACIDS RES, V41, pW34, DOI 10.1093/nar/gkt382; Yuan M, 2020, SCIENCE, V369, P1119, DOI 10.1126/science.abd2321; Zhang K, 2016, J STRUCT BIOL, V193, P1, DOI 10.1016/j.jsb.2015.11.003; Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193; Zhou TQ, 2015, CELL, V161, P1280, DOI 10.1016/j.cell.2015.05.007; Zhou TQ, 2013, IMMUNITY, V39, P245, DOI 10.1016/j.immuni.2013.04.012; Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819	82	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 31	2021	12								662909	10.3389/fimmu.2021.662909	http://dx.doi.org/10.3389/fimmu.2021.662909			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SR6JL	34135892	Green Published, gold			2022-12-18	WOS:000661149100001
J	Kelkka, T; Savola, P; Bhattacharya, D; Huuhtanen, J; Lonnberg, T; Kankainen, M; Paalanen, K; Tyster, M; Lepisto, M; Ellonen, P; Smolander, J; Eldfors, S; Yadav, B; Khan, S; Koivuniemi, R; Sjowall, C; Elo, LL; Lahdesmaki, H; Maeda, Y; Nishikawa, H; Leirisalo-Repo, M; Sokka-Isler, T; Mustjoki, S				Kelkka, Tiina; Savola, Paula; Bhattacharya, Dipabarna; Huuhtanen, Jani; Lonnberg, Tapio; Kankainen, Matti; Paalanen, Kirsi; Tyster, Mikko; Lepisto, Maija; Ellonen, Pekka; Smolander, Johannes; Eldfors, Samuli; Yadav, Bhagwan; Khan, Sofia; Koivuniemi, Riitta; Sjowall, Christopher; Elo, Laura L.; Lahdesmaki, Harri; Maeda, Yuka; Nishikawa, Hiroyoshi; Leirisalo-Repo, Marjatta; Sokka-Isler, Tuulikki; Mustjoki, Satu			Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature (vol 11, 578848, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						rheumatoid arthritis; seronegative; ACPA-negative; CD8+lymphocyte; T cell receptor; somatic mutation			[Kelkka, Tiina; Savola, Paula; Bhattacharya, Dipabarna; Huuhtanen, Jani; Kankainen, Matti; Tyster, Mikko; Yadav, Bhagwan; Mustjoki, Satu] Univ Helsinki, Hematol Res Unit Helsinki, Helsinki, Finland; [Kelkka, Tiina; Savola, Paula; Bhattacharya, Dipabarna; Huuhtanen, Jani; Kankainen, Matti; Tyster, Mikko; Yadav, Bhagwan; Mustjoki, Satu] Helsinki Univ Hosp, Dept Hematol, Ctr Comprehens Canc, Helsinki, Finland; [Kelkka, Tiina; Savola, Paula; Bhattacharya, Dipabarna; Huuhtanen, Jani; Tyster, Mikko; Yadav, Bhagwan; Mustjoki, Satu] Univ Helsinki, Dept Clin Chem & Hematol, Helsinki, Finland; [Kelkka, Tiina; Savola, Paula; Bhattacharya, Dipabarna; Huuhtanen, Jani; Kankainen, Matti; Tyster, Mikko; Yadav, Bhagwan; Mustjoki, Satu] Univ Helsinki, Translat Immunol Res Program, Helsinki, Finland; [Lonnberg, Tapio; Smolander, Johannes; Khan, Sofia; Elo, Laura L.] Univ Turku, Turku Biosci Ctr, Turku, Finland; [Lonnberg, Tapio; Smolander, Johannes; Khan, Sofia; Elo, Laura L.] Abo Akad Univ, Turku, Finland; [Paalanen, Kirsi; Sokka-Isler, Tuulikki] Jyvaskyla Cent Hosp, Rheumatol, Jyvaskyla, Finland; [Lepisto, Maija; Ellonen, Pekka; Eldfors, Samuli] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki Inst Life Sci HiLIFE, Helsinki, Finland; [Koivuniemi, Riitta; Leirisalo-Repo, Marjatta] Univ Helsinki, Helsinki Univ Hosp, Rheumatol, Helsinki, Finland; [Sjowall, Christopher] Linkoping Univ, Div Inflammat & Infect, Dept Biomed & Clin Sci, Linkoping, Sweden; [Elo, Laura L.] Univ Turku, Inst Biomed, Turku, Finland; [Lahdesmaki, Harri] Aalto Univ, Dept Comp Sci, Sch Sci, Espoo, Finland; [Maeda, Yuka; Nishikawa, Hiroyoshi] Natl Canc Ctr, Res Inst, Div Canc Immunol, Exploratory Oncol Res & Clin Trial Ctr EPOC, Tokyo, Japan; [Sokka-Isler, Tuulikki] Univ Eastern Finland, Fac Hlth Sci, Kuopio, Finland	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Helsinki; University of Turku; Abo Akademi University; Central Finland Central Hospital; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Linkoping University; University of Turku; Aalto University; National Cancer Center - Japan; University of Eastern Finland	Kelkka, T; Mustjoki, S (corresponding author), Univ Helsinki, Hematol Res Unit Helsinki, Helsinki, Finland.; Kelkka, T; Mustjoki, S (corresponding author), Helsinki Univ Hosp, Dept Hematol, Ctr Comprehens Canc, Helsinki, Finland.; Kelkka, T; Mustjoki, S (corresponding author), Univ Helsinki, Dept Clin Chem & Hematol, Helsinki, Finland.; Kelkka, T; Mustjoki, S (corresponding author), Univ Helsinki, Translat Immunol Res Program, Helsinki, Finland.	tiina.kelkka@helsinki.fi; satu.mustjoki@helsinki.fi	Mustjoki, Satu/AAD-9974-2020; Sjöwall, Christopher/C-9678-2009; Kelkka, Tiina/ABI-2952-2022	Mustjoki, Satu/0000-0002-0816-8241; Sjöwall, Christopher/0000-0003-0900-2048; Kelkka, Tiina/0000-0003-1085-6382				Kelkka T, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.578848	1	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 31	2021	12								710831	10.3389/fimmu.2021.710831	http://dx.doi.org/10.3389/fimmu.2021.710831			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SR6HC	34135915	Green Published, gold			2022-12-18	WOS:000661143000001
J	Sakaguchi, H; Mizuochi, T; Haruta, M; Takase, R; Yoshida, S; Yamashita, Y; Nishikomori, R				Sakaguchi, Hirotaka; Mizuochi, Tatsuki; Haruta, Masatoshi; Takase, Ryuta; Yoshida, Shigeo; Yamashita, Yushiro; Nishikomori, Ryuta			AIRE Gene Mutation Presenting at Age 2 Years With Autoimmune Retinopathy and Steroid-Responsive Acute Liver Failure: A Case Report and Literature Review	FRONTIERS IN IMMUNOLOGY			English	Review						AIRE; acute liver failure; autoimmune hepatitis; children; corticosteroid	POLYGLANDULAR SYNDROME TYPE-1; POLYENDOCRINOPATHY; CANDIDIASIS; HEPATITIS; CHILDREN	Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a rare monogenic autosomal recessive disorder caused by mutation in the autoimmune regulator (AIRE) gene. Patients usually are diagnosed at ages between 5 and 15 years when they show 3 or more manifestations, most typically mucocutaneous candidiasis, Addison's disease, and hypoparathyroidism. APECED-associated hepatitis (APAH) develops in only 10% to 40% of patients, with severity varying from subclinical chronic active hepatitis to potentially fatal acute liver failure (ALF). Ocular abnormalities are fairly common, most often keratopathy but sometimes retinopathy. Here we report a 2-year-old Japanese girl with an AIRE gene mutation who developed APAH with ALF, preceded by autoimmune retinopathy associated with anti-recoverin antibody before major symptoms suggested a diagnosis of APECED. Intravenous pulse methylprednisolone therapy followed by a corticosteroid combined with azathioprine treatment resolved ALF and achieved control of APAH. To our knowledge, our patient is the youngest reported to have ALF resulting from an AIRE gene mutation. Pulse methylprednisolone induction therapy followed by treatment with corticosteroid plus azathioprine may well be effective in other children with APAH and AIRE gene mutations.	[Sakaguchi, Hirotaka; Mizuochi, Tatsuki; Takase, Ryuta; Yamashita, Yushiro; Nishikomori, Ryuta] Kurume Univ, Dept Pediat & Child Hlth, Sch Med, Kurume, Fukuoka, Japan; [Haruta, Masatoshi; Yoshida, Shigeo] Kurume Univ, Dept Ophthalmol, Sch Med, Kurume, Fukuoka, Japan	Kurume University; Kurume University	Mizuochi, T (corresponding author), Kurume Univ, Dept Pediat & Child Hlth, Sch Med, Kurume, Fukuoka, Japan.	mizuochi_tatsuki@kurume-u.ac.jp	Nishikomori, Ryuta/AAM-5771-2020	Nishikomori, Ryuta/0000-0002-9407-6158				Adamus G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1577; AHONEN P, 1990, NEW ENGL J MED, V322, P1829, DOI 10.1056/NEJM199006283222601; Alvarez E, 1999, J HEPATOL, V31, P929, DOI 10.1016/S0168-8278(99)80297-9; Betterle C, 1998, J CLIN ENDOCR METAB, V83, P1049, DOI 10.1210/jc.83.4.1049; Borchers J, 2020, J CLIN ENDOCR METAB, V105, pE2207, DOI 10.1210/clinem/dgaa140; Bourgault S, 2015, BRIT J OPHTHALMOL, V99, P1536, DOI 10.1136/bjophthalmol-2014-305897; Chascsa DM, 2021, HEPATOLOGY, V73, P1088, DOI 10.1002/hep.31421; Couturier A, 2016, CURR OPIN OPHTHALMOL, V27, P505, DOI 10.1097/ICU.0000000000000306; Ferre EMN, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.88782; Guo CJ, 2018, AUTOIMMUN REV, V17, P78, DOI 10.1016/j.autrev.2017.11.012; Haruta M, 2021, OPHTHALMOL RETINA, V5, P9, DOI 10.1016/j.oret.2020.06.007; Husebye ES, 2018, NEW ENGL J MED, V378, P1132, DOI 10.1056/NEJMra1713301; Keltner JL, 1998, AM J OPHTHALMOL, V126, P296; Lankisch TO, 2009, J PEDIATR GASTR NUTR, V48, P498, DOI 10.1097/MPG.0b013e31818550de; Mieli-Vergani G, 2013, ARCH DIS CHILD, V98, P1012, DOI 10.1136/archdischild-2013-303848; Orlova EM, 2010, HORM RES PAEDIAT, V73, P449, DOI 10.1159/000313585; Sato K, 2002, ENDOCR J, V49, P625, DOI 10.1507/endocrj.49.625; Smith D, 2002, PEDIATR TRANSPLANT, V6, P166, DOI 10.1034/j.1399-3046.2002.01063.x; Sogo T, 2006, HEPATOL RES, V34, P187, DOI 10.1016/j.hepres.2005.12.002; Wolff ASB, 2007, J CLIN ENDOCR METAB, V92, P595, DOI 10.1210/jc.2006-1873; Yan Z, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000020000; Zachou K, 2019, HEPATOL RES, V49, P96, DOI 10.1111/hepr.13252	22	0	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 28	2021	12								687280	10.3389/fimmu.2021.687280	http://dx.doi.org/10.3389/fimmu.2021.687280			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SQ0NB	34122451	Green Published, gold			2022-12-18	WOS:000660057000001
J	Zhu, X; Li, F; Wang, MQ; Su, HB; Wu, XD; Qiu, HY; Zhou, W; Shan, CL; Wang, CC; Wei, L				Zhu, Xiang; Li, Feng; Wang, Miqun; Su, Huibin; Wu, Xuedong; Qiu, Haiyan; Zhou, Wang; Shan, Chunli; Wang, Cancan; Wei, Lei			Integrated Analysis of Omics Data Reveal AP-1 as a Potential Regulation Hub in the Inflammation-Induced Hyperalgesia Rat Model	FRONTIERS IN IMMUNOLOGY			English	Article						chronic pain; transcriptomic (RNA-Seq); DNA methylation; multi-omics; AP-1	CHRONIC PAIN; SPINAL-CORD; EXPRESSION; HYPERSENSITIVITY; POLYADENYLATION; MICRORNAS; PATHWAY	Inflammation-associated chronic pain is a global clinical problem, affecting millions of people worldwide. However, the underlying mechanisms that mediate inflammation-associated chronic pain remain unclear. A rat model of cutaneous inflammation induced by Complete Freund's Adjuvant (CFA) has been widely used as an inflammation-induced pain hypersensitivity model. We present the transcriptomics profile of CFA-induced inflammation in the rat dorsal root ganglion (DRG) via an approach that targets gene expression, DNA methylation, and post-transcriptional regulation. We identified 418 differentially expressed mRNAs, 120 differentially expressed microRNAs (miRNAs), and 2,670 differentially methylated regions (DMRs), which were all highly associated with multiple inflammation-related pathways, including nuclear factor kappa B (NF-kappa B) and interferon (IFN) signaling pathways. An integrated analysis further demonstrated that the activator protein 1 (AP-1) network, which may act as a regulator of the inflammatory response, is regulated at both the transcriptomic and epigenetic levels. We believe our data will not only provide drug screening targets for the treatment of chronic pain and inflammation but will also shed light on the molecular network associated with inflammation-induced hyperalgesia.	[Zhu, Xiang; Zhou, Wang; Shan, Chunli] Nantong Univ, Affiliated Hosp, Dept Anesthesiol, Nantong, Peoples R China; [Li, Feng] XuZhou Med Univ, Peoples Hosp Yancheng 1, Yancheng Clin Coll, Yancheng, Peoples R China; [Wang, Miqun] Qingdao Women & Childrens Hosp, Dept Anesthesiol, Qingdao, Peoples R China; [Su, Huibin; Wu, Xuedong; Wei, Lei] Nanjing Med Univ, Suzhou Municipal Hosp, Dept Anesthesiol, Suzhou, Peoples R China; [Qiu, Haiyan] First Peoples Hosp Yancheng, Dept Anesthesiol, Yancheng, Peoples R China; [Zhou, Wang; Shan, Chunli; Wang, Cancan] Nantong Univ, Grad Sch, Nantong, Peoples R China	Nantong University; Xuzhou Medical University; Nanjing Medical University; Nantong University	Zhu, X (corresponding author), Nantong Univ, Affiliated Hosp, Dept Anesthesiol, Nantong, Peoples R China.; Wei, L (corresponding author), Nanjing Med Univ, Suzhou Municipal Hosp, Dept Anesthesiol, Suzhou, Peoples R China.	bobofly8850@sina.com; 64624369@qq.com			National Natural Science Foundation of China [NSFC 81701105, 31872773]; Postdoctoral Research Funding Program of Jiangsu Province [2018K257C]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Postdoctoral Research Funding Program of Jiangsu Province	This study was supported by the National Natural Science Foundation of China [NSFC 81701105 and 31872773] and the Postdoctoral Research Funding Program of Jiangsu Province [2018K257C].	Bai G, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-15; Chen H, 2019, J TRADIT CHIN MED, V39, P566; Du JY, 2014, BRAIN RES BULL, V108, P27, DOI 10.1016/j.brainresbull.2014.06.004; Elkon R, 2013, NAT REV GENET, V14, P496, DOI 10.1038/nrg3482; Fayaz A, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010364; Fehrenbacher JC, 2012, CURR PROTOC PHARM, V05, P4, DOI DOI 10.1002/0471141755.PH0504S56; Gabay E, 2011, EUR J PAIN, V15, P242, DOI 10.1016/j.ejpain.2010.07.012; Hasin Y, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1215-1; He SQ, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-23; Juhling F, 2016, GENOME RES, V26, P256, DOI 10.1101/gr.196394.115; Ko SW, 2005, J PAIN, V6, P12, DOI 10.1016/j.jpain.2004.10.001; Kusuda R, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-17; Kynast KL, 2013, PAIN, V154, P368, DOI 10.1016/j.pain.2012.11.010; Li F, 2018, CNS NEUROSCI THER, V24, P947, DOI 10.1111/cns.12845; Li Q, 2019, GLIA, V67, P438, DOI 10.1002/glia.23552; Lindert U, 2009, MOL CELL BIOL, V29, P6283, DOI 10.1128/MCB.00847-09; Liu CC, 2017, EUR J NEUROSCI, V46, P2713, DOI 10.1111/ejn.13745; Mills SEE, 2019, BRIT J ANAESTH, V123, pE273, DOI 10.1016/j.bja.2019.03.023; Ni J, 2013, EUR J PAIN, V17, P313, DOI 10.1002/j.1532-2149.2012.00197.x; Pan ZQ, 2014, J NEUROSCI, V34, P9476, DOI 10.1523/JNEUROSCI.5346-13.2014; Park SJ, 2013, OSTEOARTHR CARTILAGE, V21, P981, DOI 10.1016/j.joca.2013.04.012; Reitsma ML, 2011, CHRON DIS INJ CAN, V31, P157; Rolbiecki Abigail, 2017, Traumatology (Tallahass Fla), V23, P89, DOI 10.1037/trm0000095; Sandhir R, 2011, NEUROCHEM RES, V36, P856, DOI 10.1007/s11064-011-0414-5; Schmidt J, 2008, GASTROENTEROLOGY, V135, P926, DOI 10.1053/j.gastro.2008.05.079; Sorge RE, 2015, NAT NEUROSCI, V18, P1081, DOI 10.1038/nn.4053; Sorge RE, 2011, J NEUROSCI, V31, P15450, DOI 10.1523/JNEUROSCI.3859-11.2011; Sun YV, 2016, ADV GENET, V93, P147, DOI 10.1016/bs.adgen.2015.11.004; Tam ST, 2011, CELL TISSUE RES, V346, P163, DOI 10.1007/s00441-011-1263-x; Tjitro R, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03110; van Hecke O, 2013, BRIT J ANAESTH, V111, P13, DOI 10.1093/bja/aet123; Voscopoulos C, 2010, BRIT J ANAESTH, V105, pI69, DOI 10.1093/bja/aeq323; Wang SX, 2009, PAIN, V141, P97, DOI 10.1016/j.pain.2008.10.021; Wang X, 2005, MOL THER, V12, P314, DOI 10.1016/j.ymthe.2005.03.032; Weighill D, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00874; Willemen HLDM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-143; Wu X, 2017, NUCLEIC ACIDS RES, V45, P12140, DOI 10.1093/nar/gkx999; Xia Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6274; Xiang HC, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1411-x; Xiang XN, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133248; Xu JF, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20492-7; Yang RR, 2020, INFLAMMATION, V43, P752, DOI 10.1007/s10753-019-01162-3; Yuan HJ, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-1711-1; Zhang MY, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01449	44	0	0	7	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 28	2021	12								672498	10.3389/fimmu.2021.672498	http://dx.doi.org/10.3389/fimmu.2021.672498			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SQ0IS	34122430	gold, Green Published			2022-12-18	WOS:000660045700001
J	Cui, KL; Hu, SX; Mei, XY; Cheng, M				Cui, Kele; Hu, Shouxin; Mei, Xinyu; Cheng, Min			Innate Immune Cells in the Esophageal Tumor Microenvironment (vol 12, 654731, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						innate immune cells; crosstalk; regulation; esophageal tumor microenvironment; immunotherapy strategy			[Cui, Kele] Univ Sci & Technol China, First Affiliated Hosp USTC, Dept Clin Lab, Div Life Sci & Med, Hefei, Peoples R China; [Hu, Shouxin; Cheng, Min] Univ Sci & Technol China, First Affiliated Hosp USTC, Gerontol Inst Anhui Prov, Dept Geriatr, Hefei, Peoples R China; [Cui, Kele; Hu, Shouxin; Cheng, Min] Anhui Prov Key Lab Tumor Immunotherapy & Nutr The, Hefei, Peoples R China; [Cui, Kele; Hu, Shouxin; Cheng, Min] Univ Sci & Technol China, First Affiliated Hosp USTC, Canc Immunotherapy Ctr, Div Life Sci & Med, Hefei, Peoples R China; [Mei, Xinyu] Univ Sci & Technol China, First Affiliated Hosp USTC, Dept Thorac Surg, Div Life Sci & Med, Hefei, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Cui, KL (corresponding author), Univ Sci & Technol China, First Affiliated Hosp USTC, Dept Clin Lab, Div Life Sci & Med, Hefei, Peoples R China.; Cheng, M (corresponding author), Univ Sci & Technol China, First Affiliated Hosp USTC, Gerontol Inst Anhui Prov, Dept Geriatr, Hefei, Peoples R China.; Cui, KL; Cheng, M (corresponding author), Anhui Prov Key Lab Tumor Immunotherapy & Nutr The, Hefei, Peoples R China.; Cui, KL; Cheng, M (corresponding author), Univ Sci & Technol China, First Affiliated Hosp USTC, Canc Immunotherapy Ctr, Div Life Sci & Med, Hefei, Peoples R China.	ckele@mail.ustc.edu.cn; chengmin@ustc.edu.cn						Cui KL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.654731	1	0	0	2	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 27	2021	12								708705	10.3389/fimmu.2021.708705	http://dx.doi.org/10.3389/fimmu.2021.708705			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SP2TX	34122459	Green Published, gold			2022-12-18	WOS:000659528100001
J	Page, L; Wallstabe, J; Lother, J; Bauser, M; Kniemeyer, O; Strobel, L; Voltersen, V; Teutschbein, J; Hortschansky, P; Morton, CO; Brakhage, AA; Topp, M; Einsele, H; Wurster, S; Loeffler, J				Page, Lukas; Wallstabe, Julia; Lother, Jasmin; Bauser, Maximilian; Kniemeyer, Olaf; Strobel, Lea; Voltersen, Vera; Teutschbein, Janka; Hortschansky, Peter; Morton, Charles Oliver; Brakhage, Axel A.; Topp, Max; Einsele, Hermann; Wurster, Sebastian; Loeffler, Juergen			CcpA- and Shm2-Pulsed Myeloid Dendritic Cells Induce T-Cell Activation and Enhance the Neutrophilic Oxidative Burst Response to Aspergillus fumigatus	FRONTIERS IN IMMUNOLOGY			English	Article						Aspergillus; antigens; dendritic cells; cytokines; host defense; immunotherapy	INVASIVE ASPERGILLOSIS; INTERFERON-GAMMA; IMMUNITY; GALACTOSAMINOGALACTAN; VACCINATION; INFECTIONS; ANTIGENS	Aspergillus fumigatus causes life-threatening opportunistic infections in immunocompromised patients. As therapeutic outcomes of invasive aspergillosis (IA) are often unsatisfactory, the development of targeted immunotherapy remains an important goal. Linking the innate and adaptive immune system, dendritic cells are pivotal in anti-Aspergillus defense and have generated interest as a potential immunotherapeutic approach in IA. While monocyte-derived dendritic cells (moDCs) require ex vivo differentiation, antigen-pulsed primary myeloid dendritic cells (mDCs) may present a more immediate platform for immunotherapy. To that end, we compared the response patterns and cellular interactions of human primary mDCs and moDCs pulsed with an A. fumigatus lysate and two A. fumigatus proteins (CcpA and Shm2) in a serum-free, GMP-compliant medium. CcpA and Shm2 triggered significant upregulation of maturation markers in mDCs and, to a lesser extent, moDCs. Furthermore, both A. fumigatus proteins elicited the release of an array of key pro-inflammatory cytokines including TNF-alpha, IL-1 beta, IL-6, IL-8, and CCL3 from both DC populations. Compared to moDCs, CcpA- and Shm2-pulsed mDCs exhibited greater expression of MHC class II antigens and stimulated stronger proliferation and IFN-gamma secretion from autologous CD4(+) and CD8(+) T-cells. Moreover, supernatants of CcpA- and Shm2-pulsed mDCs significantly enhanced the oxidative burst in allogeneic neutrophils co-cultured with A. fumigatus germ tubes. Taken together, our in vitro data suggest that ex vivo CcpA- and Shm2-pulsed primary mDCs have the potential to be developed into an immunotherapeutic approach to tackle IA.	[Page, Lukas; Wallstabe, Julia; Lother, Jasmin; Bauser, Maximilian; Strobel, Lea; Topp, Max; Einsele, Hermann; Loeffler, Juergen] Univ Hosp Wuerzburg, Dept Internal Med 2, Wurzburg, Germany; [Wallstabe, Julia] Univ Wurzburg, Inst Hyg & Microbiol, Wurzburg, Germany; [Lother, Jasmin] Otto von Guericke Univ, Ctr Image Guided Local Therapies, Magdeburg, Germany; [Kniemeyer, Olaf; Voltersen, Vera; Teutschbein, Janka; Hortschansky, Peter; Brakhage, Axel A.] Hans Knoell Inst, Leibniz Inst Nat Prod Res & Infect Biol, Jena, Germany; [Kniemeyer, Olaf; Voltersen, Vera; Teutschbein, Janka; Hortschansky, Peter; Brakhage, Axel A.] Friedrich Schiller Univ, Dept Mol & Appl Microbiol, Jena, Germany; [Morton, Charles Oliver] Western Sydney Univ, Sch Sci, Campbelltown, NSW, Australia; [Wurster, Sebastian] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis, Houston, TX 77030 USA	University of Wurzburg; University of Wurzburg; Otto von Guericke University; Hans Knoll Institute (HKI); Friedrich Schiller University of Jena; University of Sydney; Western Sydney University; University of Texas System; UTMD Anderson Cancer Center	Loeffler, J (corresponding author), Univ Hosp Wuerzburg, Dept Internal Med 2, Wurzburg, Germany.	loeffler_j@ukw.de		Morton, Charles Oliver/0000-0003-1702-0545; Page, Lukas/0000-0002-2729-9159	Deutsche Forschungsgemeinschaft (DFG) within the Collaborative Research Center CRC124 FungiNet "Pathogenic fungi and their human host: Networks of interaction", DFG [210879364]	Deutsche Forschungsgemeinschaft (DFG) within the Collaborative Research Center CRC124 FungiNet "Pathogenic fungi and their human host: Networks of interaction", DFG(German Research Foundation (DFG))	The study was supported by the Deutsche Forschungsgemeinschaft (DFG) within the Collaborative Research Center CRC124 FungiNet "Pathogenic fungi and their human host: Networks of interaction", DFG project number 210879364 (projects A1 to AB, A2 to HE and JLoe, A4 to MT, Z2 to OK, and travel support to CM and SW). We would like to thank the Department of Transfusion Medicine of the University Hospital of Wuerzburg for providing leukocyte reduction systems for PBMC isolation, and both Lydia Bussemer and Sylke Fricke for technical support.	Ackerman AL, 2005, NAT IMMUNOL, V6, P107, DOI 10.1038/ni1147; Armstrong-James D, 2010, AM J TRANSPLANT, V10, P1796, DOI 10.1111/j.1600-6143.2010.03094.x; Bacher P, 2014, J IMMUNOL, V193, P3332, DOI 10.4049/jimmunol.1400776; Bozza S, 2003, BLOOD, V102, P3807, DOI 10.1182/blood-2003-03-0748; Bozza S, 2002, MICROBES INFECT, V4, P1281, DOI 10.1016/S1286-4579(02)00007-2; Briard B, 2016, MYCOLOGIA, V108, P572, DOI 10.3852/15-312; Constantino J, 2016, TRANSL RES, V168, P74, DOI 10.1016/j.trsl.2015.07.008; Danion F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00038; Denning DW, 2000, LANCET, V355, P423, DOI 10.1016/S0140-6736(00)82003-6; Forster R, 2008, NAT REV IMMUNOL, V8, P362, DOI 10.1038/nri2297; Gressler M, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00365; Grosche L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00721; Gutjahr A, 2020, EBIOMEDICINE, V58, DOI 10.1016/j.ebiom.2020.102922; Humrich JY, 2006, IMMUNOLOGY, V117, P238, DOI 10.1111/j.1365-2567.2005.02292.x; Jia LJ, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00535-20; Kastanos EK, 1997, BIOCHEMISTRY-US, V36, P14956, DOI 10.1021/bi971610n; Kayraklioglu N, 2021, METHODS MOL BIOL, V2197, P51, DOI 10.1007/978-1-0716-0872-2_4; Kirtland ME, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.599083; Kumaresan PR, 2014, P NATL ACAD SCI USA, V111, P10660, DOI 10.1073/pnas.1312789111; Kumbhari A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.584680; Lauruschkat CD, 2018, J FUNGI, V4, DOI 10.3390/jof4040137; Lother J, 2014, INT J MED MICROBIOL, V304, P1160, DOI 10.1016/j.ijmm.2014.08.009; Lou YY, 2007, J IMMUNOL, V178, P1534, DOI 10.4049/jimmunol.178.3.1534; Morton CO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016016; Morton CO, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098279; Nanjappa SG, 2012, J CLIN INVEST, V122, P987, DOI 10.1172/JCI58762; Ramirez-Ortiz ZG, 2012, VIRULENCE, V3, P635, DOI 10.4161/viru.22295; Romani L, 2011, NAT REV IMMUNOL, V11, P275, DOI 10.1038/nri2939; Roy RM, 2012, CELL HOST MICROBE, V11, P436, DOI 10.1016/j.chom.2012.04.005; Sabado RL, 2017, CELL RES, V27, P74, DOI 10.1038/cr.2016.157; Safdar A, 2006, CANCER-AM CANCER SOC, V106, P2664, DOI 10.1002/cncr.21929; Schreibelt G, 2016, CLIN CANCER RES, V22, P2155, DOI 10.1158/1078-0432.CCR-15-2205; Stanzani M, 2005, BLOOD, V105, P2258, DOI 10.1182/blood-2004-09-3421; Stuehler C, 2015, J INFECT DIS, V211, P1251, DOI 10.1093/infdis/jiu607; Surenaud M, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008011; Teutschbein J, 2016, J PROTEOME RES, V15, P1580, DOI 10.1021/acs.jproteome.6b00042; Ueno K, 2019, MUCOSAL IMMUNOL, V12, P265, DOI 10.1038/s41385-018-0094-4; Voltersen V, 2018, MBIO, V9, DOI [10.1128/mBio.01557-18, 10.1128/mbio.01557-18]; Wurster S, 2020, J INFECT DIS, V222, P989, DOI 10.1093/infdis/jiaa264	39	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 27	2021	12								659752	10.3389/fimmu.2021.659752	http://dx.doi.org/10.3389/fimmu.2021.659752			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SP3CJ	34122417	Green Published, gold			2022-12-18	WOS:000659550100001
J	Wei, XB; Zhang, LL; Zhang, RJ; Wu, RJ; Petitte, JN; Hou, YF; Si, DY; Ahmad, B; Guo, HN; Zhang, MY; Cheng, Q; Tong, YC				Wei, Xubiao; Zhang, Lulu; Zhang, Rijun; Wu, Rujuan; Petitte, James N.; Hou, Yanfei; Si, Dayong; Ahmad, Baseer; Guo, Henan; Zhang, Manyi; Cheng, Qiang; Tong, Yucui			Targeting the TLR2 Receptor With a Novel Thymopentin-Derived Peptide Modulates Immune Responses	FRONTIERS IN IMMUNOLOGY			English	Article						TP5; immunopotentiating activity; physiological stability; molecular dynamics simulations; TLR2 cluster; NF-kappa B signaling	CYCLOPHOSPHAMIDE-INDUCED IMMUNOSUPPRESSION; ALPHA-1-THYMOPENTIN FUSION PEPTIDE; TOLL-LIKE RECEPTORS; POLYSACCHARIDE; RECOGNITION; LIPOPOLYSACCHARIDE; ANTIBACTERIAL; PENTAPEPTIDE; EXPRESSION; PATTERN	The innate and adaptive immune systems act in concert to protect us from infectious agents and other harmful substances. As a state of temporary or permanent immune dysfunction, immunosuppression can make an organism more susceptible to infection, organ injury, and cancer due to damage to the immune system. It takes a long time to develop new immunomodulatory agents to prevent and treat immunosuppressive diseases, with slow progress. Toll-like receptor 2 (TLR2) agonists have been reported as potential immunomodulatory candidates due to their effective activation of immune responses. It has been demonstrated that thymopentin (TP5) could modulate immunity by binding to the TLR2 receptor. However, the fairly short half-life of TP5 greatly reduces its pharmacological potential for immunosuppression therapy. Although peptide cathelicidin 2 (CATH2) has a long half-life, it shows poor immunomodulatory activity and severe cytotoxicity, which seriously hampers its clinical development. Peptide hybridization is an effective approach for the design and engineering of novel functional peptides because hybrid peptides combine the advantages and benefits of various native peptides. In this study, to overcome all these challenges faced by the parental peptides, six hybrid peptides (CaTP, CbTP, CcTP, TPCa, TPCb, and TPCc) were designed by combining the full-length TP5 with different active fragments of CATH2. CbTP, the most potent TLR2 agonist among the six hybrid peptides, was effectively screened through in silico analysis and in vitro experiments. The CbTP peptide exhibited lower cytotoxicity than either CATH2 or TP5. Furthermore, the immunomodulatory effects of CbTP were confirmed in a CTX-immunosuppressed mouse model, which showed that CbTP has increased immunopotentiating activity and physiological stability compared to the parental peptides. CbTP successfully inhibited immunosuppression and weight loss, increased immune organ indices, and improved CD4(+)/CD8(+) T lymphocyte subsets. In addition, CbTP significantly increased the production of the cytokine TNF-alpha and IL-6, and the immunoglobulins IgA, IgM, and IgG. The immunoenhancing effects of CbTP were attributed to its TLR2-binding activity, promoting the formation of the TLR2 cluster, the activation of the TLR2 receptor, and thus activation of the downstream MyD88-NF-kappa B signaling pathway.	[Wei, Xubiao; Zhang, Lulu; Zhang, Rijun; Wu, Rujuan; Si, Dayong; Ahmad, Baseer; Guo, Henan; Zhang, Manyi; Cheng, Qiang; Tong, Yucui] China Agr Univ, Coll Anim Sci & Technol, Lab Feed Biotechnol, State Key Lab Anim Nutr, Beijing, Peoples R China; [Petitte, James N.] North Carolina State Univ, Prestage Dept Poultry Sci, Coll Agr & Life Sci, Raleigh, NC USA; [Hou, Yanfei] Tsinghua Univ, Sch Pharmaceut Sci, Beijing, Peoples R China	China Agricultural University; University of North Carolina; North Carolina State University; Tsinghua University	Zhang, RJ (corresponding author), China Agr Univ, Coll Anim Sci & Technol, Lab Feed Biotechnol, State Key Lab Anim Nutr, Beijing, Peoples R China.	rjzhang@cau.edu.cn	zhang, lu/GRO-2969-2022; Ahmad, Baseer/ABG-5769-2021	Petitte, James/0000-0003-2764-6007; , Baseer/0000-0002-8177-0271	National Key Research and Development Program of China [2018YFD0500600]; National Natural Science Foundation of China [31572442, 31272476]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was funded by the National Key Research and Development Program of China (grant number 2018YFD0500600) and National Natural Science Foundation of China (grant numbers 31572442 and 31272476).	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Andreone L, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00229; Belikov AV, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0194-3; Berraondo P, 2019, BRIT J CANCER, V120, P6, DOI 10.1038/s41416-018-0328-y; Brzezinska-Blaszczyk E, 2010, POSTEP HIG MED DOSW, V64, P11; Coorens M, 2017, SCI REP-UK, V7, DOI 10.1038/srep40874; Corthesy B, 2007, J IMMUNOL, V178, P27, DOI 10.4049/jimmunol.178.1.27; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; DelaRosa O, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00182; Fan HJ, 2018, J ETHNOPHARMACOL, V222, P1, DOI 10.1016/j.jep.2018.04.032; Fan KJ, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/3849847; Fan YP, 2013, CELL IMMUNOL, V281, P37, DOI 10.1016/j.cellimm.2013.01.008; Fereig RM, 2019, VACCINE, V37, P937, DOI 10.1016/j.vaccine.2019.01.005; Gao DM, 2008, ARCH PHARM RES, V31, P1471, DOI 10.1007/s12272-001-2132-z; GOLDSTEIN G, 1979, SCIENCE, V204, P1309, DOI 10.1126/science.451537; Goldszmid RS, 2014, CELL HOST MICROBE, V15, P295, DOI 10.1016/j.chom.2014.02.003; Gong Y, 2015, INT J CLIN EXP MED, V8, P20631; Gonser S, 2004, MUTAT RES-GEN TOX EN, V558, P19, DOI 10.1016/j.mrgentox.2003.10.010; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hooper LV, 2012, SCIENCE, V336, P1268, DOI 10.1126/science.1223490; Hu X, 2016, J MATER CHEM B, V4, P1384, DOI 10.1039/c5tb01930c; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Li J, 2013, CANCER LETT, V337, P237, DOI 10.1016/j.canlet.2013.05.006; Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255; MASCARTLEMONE F, 1983, LANCET, V2, P735; Massova I, 2000, PERSPECT DRUG DISCOV, V18, P113, DOI 10.1023/A:1008763014207; Mei YX, 2013, INT J BIOL MACROMOL, V62, P330, DOI 10.1016/j.ijbiomac.2013.09.038; Molhoek EM, 2011, PEPTIDES, V32, P875, DOI 10.1016/j.peptides.2011.02.017; Molhoek EM, 2010, INT J ANTIMICROB AG, V36, P271, DOI 10.1016/j.ijantimicag.2010.06.001; Oliveira-Nascimento L, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00079; Park S, 2017, BIOMATERIALS, V126, P49, DOI 10.1016/j.biomaterials.2017.02.023; Pathak AK, 2019, J CHEM THEORY COMPUT, V15, P2706, DOI 10.1021/acs.jctc.9b00005; Peddireddy V, 2016, SCI REP-UK, V6, DOI 10.1038/srep24535; Pfeiffer A, 2001, EUR J IMMUNOL, V31, P3153, DOI 10.1002/1521-4141(200111)31:11<3153::AID-IMMU3153>3.0.CO;2-0; Ren Z, 2014, J ETHNOPHARMACOL, V155, P769, DOI 10.1016/j.jep.2014.06.021; Scheenstra MR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41246-6; Schroeder HW, 2010, J ALLERGY CLIN IMMUN, V125, pS41, DOI 10.1016/j.jaci.2009.09.046; Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372; Singh VK, 1998, IMMUNOL RES, V17, P345, DOI 10.1007/BF02786456; SUNDAL E, 1994, ARZNEIMITTEL-FORSCH, V44-2, P1145; Toskala E, 2014, INT FORUM ALLERGY RH, V4, pS21, DOI 10.1002/alr.21380; Triantafilou M, 2002, J CELL SCI, V115, P2603; van Dijk A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147919; van Dijk A, 2009, MOL IMMUNOL, V46, P2465, DOI 10.1016/j.molimm.2009.05.019; Waldmann TA, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028472; Wei XB, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17070983; Wei XB, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01361; Whitley NT, 2011, J SMALL ANIM PRACT, V52, P70, DOI 10.1111/j.1748-5827.2011.01024.x; Yu Q, 2014, INT J BIOL MACROMOL, V64, P395, DOI 10.1016/j.ijbiomac.2013.12.029; Yun LY, 2018, INT J BIOL MACROMOL, V118, P1267, DOI 10.1016/j.ijbiomac.2018.06.199; Zhang D, 2009, INT J COLORECTAL DIS, V24, P5, DOI 10.1007/s00384-008-0544-7; Zhang LL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01841; Zhang T, 2019, ACTA PHARMACOL SIN, V40, P514, DOI 10.1038/s41401-018-0085-8; Zhang YL, 2018, EUR J MED CHEM, V148, P291, DOI 10.1016/j.ejmech.2018.02.008	54	0	0	2	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 27	2021	12								620494	10.3389/fimmu.2021.620494	http://dx.doi.org/10.3389/fimmu.2021.620494			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SP2WL	34122400	Green Published, gold			2022-12-18	WOS:000659534700001
J	Devi-Marulkar, P; Moraes-Cabe, C; Campagne, P; Corre, B; Meghraoui-Kheddar, A; Bondet, V; Llibre, A; Duffy, D; Maillart, E; Papeix, C; Pellegrini, S; Michel, F				Devi-Marulkar, Priyanka; Moraes-Cabe, Carolina; Campagne, Pascal; Corre, Beatrice; Meghraoui-Kheddar, Aida; Bondet, Vincent; Llibre, Alba; Duffy, Darragh; Maillart, Elisabeth; Papeix, Caroline; Pellegrini, Sandra; Michel, Frederique			Altered Immune Phenotypes and HLA-DQB1 Gene Variation in Multiple Sclerosis Patients Failing Interferon beta Treatment	FRONTIERS IN IMMUNOLOGY			English	Article						multiple sclerosis; type I interferon; T cells; interferon-stimulated genes; HLA class II genes; immune phenotypes; blood biomarkers	REGULATORY T-CELLS; CENTRAL MEMORY; IFN-BETA; EXPRESSION; THERAPY; NAIVE; PREVALENCE; DISEASE; TYPE-1; DIFFERENTIATION	Background: Interferon beta (IFN beta) has been prescribed as a first-line disease-modifying therapy for relapsing-remitting multiple sclerosis (RRMS) for nearly three decades. However, there is still a lack of treatment response markers that correlate with the clinical outcome of patients. Aim: To determine a combination of cellular and molecular blood signatures associated with the efficacy of IFNO treatment using an integrated approach. Methods: The immune status of 40 RRMS patients, 15 of whom were untreated and 25 that received IFN beta 1a treatment (15 responders, 10 non-responders), was investigated by phenotyping regulatory CD4(+) T cells and naive/memory T cell subsets, by measurement of circulating IFN alpha/beta proteins with digital ELJSA (Simoa) and analysis of similar to 600 immune related genes including 159 interferon-stimulated genes (ISGs) with the Nanostring technology. The potential impact of HLA class II gene variation in treatment responsiveness was investigated by genotyping HLA-DRB1, -DRB3,4,5, -DOA1, and -DQB1 , using as a control population the Milieu Interieur cohort of 1,000 French healthy donors. Results: Clinical responders and non-responders displayed similar plasma levels of IFN beta and similar ISG profiles. However, non-responders mainly differed from other subject groups with reduced circulating naive regulatory T cells, enhanced terminally differentiated effector memory CD4(+) T-EMRA cells, and altered expression of at least six genes with immunoregulatory function. Moreover, non-responders were enriched for HLA-DQB1 genotypes encoding DQ8 and DQ2 serotypes. Interestingly, these two serotypes are associated with type 1 diabetes and celiac disease. Overall, the immune signatures of non-responders suggest an active disease that is resistant to therapeutic IFN beta, and in which CD4(+) T cells, likely restricted by DQ8 and/or DQ2, exert enhanced autoreactive and bystander inflammatory activities.	[Devi-Marulkar, Priyanka; Moraes-Cabe, Carolina; Corre, Beatrice; Meghraoui-Kheddar, Aida; Pellegrini, Sandra; Michel, Frederique] Inst Pasteur, Dept Immunol, Cytokine Signaling Unit, Paris, France; [Devi-Marulkar, Priyanka; Moraes-Cabe, Carolina; Corre, Beatrice; Meghraoui-Kheddar, Aida; Pellegrini, Sandra; Michel, Frederique] Inst Pasteur, Dept Immunol, INSERM, U1221, Paris, France; [Campagne, Pascal] Inst Pasteur, Ctr Bioinformat Biostat & Integrat Biol, Paris, France; [Bondet, Vincent; Llibre, Alba; Duffy, Darragh] Inst Pasteur, Dept Immunol, Translat Immunol Lab, Paris, France; [Maillart, Elisabeth; Papeix, Caroline] Hop La Pitie Salpetriere, Dept Neurol, Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Michel, F (corresponding author), Inst Pasteur, Dept Immunol, Cytokine Signaling Unit, Paris, France.; Michel, F (corresponding author), Inst Pasteur, Dept Immunol, INSERM, U1221, Paris, France.	frederique.michel@pasteur.fr	; Pellegrini, Sandra/G-5546-2015	Meghraoui-Kheddar, Aida/0000-0002-7440-5495; Moraes Cabe, Carolina/0000-0001-7718-159X; Pellegrini, Sandra/0000-0001-5837-7589; Devi-Marulkar, Priyanka/0000-0002-3755-423X	ARSEP (Aide a la Recherche sur la Sclerose En Plaques); FRM (Fondation pour la Recherche Medicale); INSERM; Milieu Interieur [ANR-10-LABX-6901]; Institut Pasteur, Paris	ARSEP (Aide a la Recherche sur la Sclerose En Plaques); FRM (Fondation pour la Recherche Medicale)(Fondation pour la Recherche Medicale); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Milieu Interieur; Institut Pasteur, Paris	This work was funded by the ARSEP (Aide a la Recherche sur la Scle ' rose En Plaques), FRM (Fondation pour la Recherche Medicale), INSERM, the Milieu Interieur ANR-10-LABX-6901, and the Institut Pasteur, Paris.	Astier AL, 2006, J CLIN INVEST, V116, P3252, DOI 10.1172/JCI29251; Axtell RC, 2010, NAT MED, V16, P406, DOI 10.1038/nm.2110; Bushnell SE, 2012, NEUROLOGY, V79, P531, DOI 10.1212/WNL.0b013e318259e123; Cao YH, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa8038; Chiarini M, 2012, MULT SCLER J, V18, P788, DOI 10.1177/1352458511427720; Chiarini M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02329-5; Comabella M, 2009, BRAIN, V132, P3353, DOI 10.1093/brain/awp228; Comi G, 2012, LANCET NEUROL, V11, P33, DOI 10.1016/S1474-4422(11)70262-9; Corre B, 2013, EUR J IMMUNOL, V43, P2730, DOI 10.1002/eji.201242977; Cossarizza A, 2019, EUR J IMMUNOL, V49, P1457, DOI 10.1002/eji.201970107; Creary LE, 2019, MULT SCLER J, V25, P772, DOI 10.1177/1352458518770019; D'Amico E, 2021, NEUROTHERAPEUTICS, V18, P905, DOI 10.1007/s13311-020-01001-6; D'Amico E, 2019, AUTOIMMUN REV, V18, P665, DOI 10.1016/j.autrev.2019.05.003; Dendrou CA, 2018, NAT REV IMMUNOL, V18, P325, DOI 10.1038/nri.2017.143; Dendrou CA, 2015, NAT REV IMMUNOL, V15, P545, DOI 10.1038/nri3871; Dominguez-Villar M, 2011, NAT MED, V17, P673, DOI 10.1038/nm.2389; Dooley J, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000240; Egholm C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02507; Fletcher JM, 2009, J IMMUNOL, V183, P7602, DOI 10.4049/jimmunol.0901881; Foulon S, 2017, J NEUROL, V264, P1185, DOI 10.1007/s00415-017-8513-0; Geginat J, 2001, J EXP MED, V194, P1711, DOI 10.1084/jem.194.12.1711; Geginat J, 2017, TRENDS IMMUNOL, V38, P498, DOI 10.1016/j.it.2017.04.006; Gneiss C, 2006, MULT SCLER J, V12, P731, DOI 10.1177/1352458506070941; Grossberg SE, 2011, J INTERF CYTOK RES, V31, P337, DOI 10.1089/jir.2010.0038; Guarda G, 2011, IMMUNITY, V34, P213, DOI 10.1016/j.immuni.2011.02.006; Haas J, 2007, J IMMUNOL, V179, P1322, DOI 10.4049/jimmunol.179.2.1322; Hauser SL, 2017, NEW ENGL J MED, V376, P221, DOI 10.1056/NEJMoa1601277; Herndon RM, 2005, MULT SCLER, V11, P409, DOI 10.1191/1352458505ms1209oa; Hesse D, 2010, NEUROLOGY, V74, P1455, DOI 10.1212/WNL.0b013e3181dc1a94; Hollenbach JA, 2015, J AUTOIMMUN, V64, P13, DOI 10.1016/j.jaut.2015.06.010; Housley WJ, 2015, CLIN IMMUNOL, V161, P51, DOI 10.1016/j.clim.2015.06.015; Hu D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01571-8; Hug A, 2003, J IMMUNOL, V171, P432, DOI 10.4049/jimmunol.171.1.432; Jakimovski D, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a032003; Jelcic I, 2018, CELL, V175, P85, DOI 10.1016/j.cell.2018.08.011; Kim H, 2018, J INTERF CYTOK RES, V38, P171, DOI 10.1089/jir.2017.0127; Kingwell E, 2019, BRAIN, V142, P1324, DOI 10.1093/brain/awz055; Kingwell E, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-128; Klitz W, 2003, TISSUE ANTIGENS, V62, P296, DOI 10.1034/j.1399-0039.2003.00103.x; Korporal M, 2008, ARCH NEUROL-CHICAGO, V65, P1434, DOI 10.1001/archneur.65.11.1434; Lassmann H, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a028936; Levings MK, 2001, J IMMUNOL, V166, P5530, DOI 10.4049/jimmunol.166.9.5530; Li R, 2018, NAT IMMUNOL, V19, P696, DOI 10.1038/s41590-018-0135-x; Llibre A, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00296; Malhotra S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023634; Malucchi S, 2008, NEUROLOGY, V70, P1119, DOI 10.1212/01.wnl.0000304040.29080.7b; Mantovani A, 2019, IMMUNITY, V50, P778, DOI 10.1016/j.immuni.2019.03.012; Markovic-Plese S, 2001, J CLIN INVEST, V108, P1185, DOI 10.1172/JCI200112516; Marsh SGE, 2010, TISSUE ANTIGENS, V75, P291, DOI 10.1111/j.1399-0039.2010.01466.x; Martin R, 2016, EUR J IMMUNOL, V46, P2078, DOI 10.1002/eji.201646485; Martire S, 2016, J NEUROIMMUNOL, V292, P34, DOI 10.1016/j.jneuroim.2016.01.010; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; Moutsianas L, 2015, NAT GENET, V47, P1107, DOI 10.1038/ng.3395; Nicol B, 2018, J AUTOIMMUN, V88, P61, DOI 10.1016/j.jaut.2017.10.005; Noble JA, 2015, J AUTOIMMUN, V64, P101, DOI 10.1016/j.jaut.2015.07.014; Olsson T, 2017, NAT REV NEUROL, V13, P25, DOI 10.1038/nrneurol.2016.187; Palace J, 2019, J NEUROL NEUROSUR PS, V90, P251, DOI 10.1136/jnnp-2018-318360; Paroni M, 2017, J ALLERGY CLIN IMMUN, V140, P797, DOI 10.1016/j.jaci.2016.11.045; Patin E, 2018, NAT IMMUNOL, V19, P302, DOI 10.1038/s41590-018-0049-7; Patsopoulos NA, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003926; Patsopoulos NA, 2019, SCIENCE, V365, P1417, DOI 10.1126/science.aav7188; Paul A, 2019, CSH PERSPECT MED, V9, DOI 10.1101/cshperspect.a029058; Peeters LM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01160; Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366; Ramgolam VS, 2009, J IMMUNOL, V183, P5418, DOI 10.4049/jimmunol.0803227; Reder AT, 2008, J INTERF CYTOK RES, V28, P317, DOI 10.1089/jir.2007.0131; Rieckmann P, 2004, DRUG SAFETY, V27, P745, DOI 10.2165/00002018-200427100-00005; Robinson J, 2020, NUCLEIC ACIDS RES, V48, pD948, DOI 10.1093/nar/gkz950; Rodero MP, 2017, J EXP MED, V214, P1547, DOI 10.1084/jem.20161451; Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251; Severa M, 2015, CYTOKINE GROWTH F R, V26, P229, DOI 10.1016/j.cytogfr.2014.11.005; Sollid LM, 2017, IMMUNOGENETICS, V69, P605, DOI 10.1007/s00251-017-0985-7; Teniente-Serra A, 2016, AUTOIMMUNITY, V49, P219, DOI 10.3109/08916934.2016.1138271; Thewissen M, 2007, J IMMUNOL, V179, P6514, DOI 10.4049/jimmunol.179.10.6514; Urrutia A, 2016, CELL REP, V16, P2777, DOI 10.1016/j.celrep.2016.08.011; van Baarsen LGM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001927; Venken K, 2008, J IMMUNOL, V180, P6411, DOI 10.4049/jimmunol.180.9.6411; Zula JA, 2011, P NATL ACAD SCI USA, V108, P19689, DOI 10.1073/pnas.1117347108	78	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2021	12								628375	10.3389/fimmu.2021.628375	http://dx.doi.org/10.3389/fimmu.2021.628375			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SO0MW	34113337	gold, Green Published			2022-12-18	WOS:000658676900001
J	Lemasson, Q; Akil, H; Feuillard, J; Vincent-Fabert, C				Lemasson, Quentin; Akil, Hussein; Feuillard, Jean; Vincent-Fabert, Christelle			Genetically Engineered Mouse Models Support a Major Role of Immune Checkpoint-Dependent Immunosurveillance Escape in B-Cell Lymphomas	FRONTIERS IN IMMUNOLOGY			English	Review						B-cell lymphoma; immune surveillance; PD-1; PD-L1; CTLA-4; MHC-II; NKG2D		These last 20 years, research on immune tumor microenvironment led to identify some critical recurrent mechanisms used in cancer to escape immune response. Through immune checkpoints, which are cell surface molecules involved in the immune system control, it is now established that tumor cells are able to shutdown the immune response. Due to the complexity and heterogeneity of Non Hodgkin B-cell Lymphomas (NHBLs), it is difficult to understand the precise mechanisms of immune escape and to explain the mitigated effect of immune checkpoints blockade for their treatment. Because genetically engineered mouse models are very reliable tools to improve our understanding of molecular mechanisms involved in B-cell transformation and, at the same time, can be useful preclinical models to predict immune response, we reviewed hereafter some of these models that highlight the immune escape mechanisms of NHBLs and open perspectives on future therapies.	[Lemasson, Quentin; Akil, Hussein; Feuillard, Jean; Vincent-Fabert, Christelle] Univ Limoges, CNRS, INSERM, U1262,UMR 7276,CRIBL, Limoges, France; [Lemasson, Quentin; Akil, Hussein; Feuillard, Jean; Vincent-Fabert, Christelle] CHU Limoges, Dupuytren Hosp Univ Ctr, Hematol Lab, Limoges, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Limoges; CHU Limoges	Vincent-Fabert, C (corresponding author), Univ Limoges, CNRS, INSERM, U1262,UMR 7276,CRIBL, Limoges, France.; Vincent-Fabert, C (corresponding author), CHU Limoges, Dupuytren Hosp Univ Ctr, Hematol Lab, Limoges, France.	christelle.vincent-fabert@unilim.fr	Vincent-Fabert, Christelle/AGZ-5883-2022	VINCENT-FABERT, Christelle/0000-0002-5799-980X; AKIL, Hussein/0000-0002-8177-6833	Ligue Nationale Contre le Cancer (Equipe labellise'e Ligue); Comite Orientation Recherche Cancer (CORC); France Lymphome Espoir association; Nouvelle Aquitaine Region; France Lymphome Espoir association of patients; Fondation pour la Recherche Medicale (FRM) [ECO202006011493]; HauteVienne committee of the Ligue Nationale Contre le Cancer; Correze committees of the Ligue Nationale Contre le Cancer	Ligue Nationale Contre le Cancer (Equipe labellise'e Ligue); Comite Orientation Recherche Cancer (CORC); France Lymphome Espoir association; Nouvelle Aquitaine Region; France Lymphome Espoir association of patients; Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); HauteVienne committee of the Ligue Nationale Contre le Cancer; Correze committees of the Ligue Nationale Contre le Cancer	The group of JF is supported by grants from the Ligue Nationale Contre le Cancer (Equipe labellise ' e Ligue), the Comite Orientation Recherche Cancer (CORC), the France Lymphome Espoir association, the Nouvelle Aquitaine Region and the HauteVienne and Correze committees of the Ligue Nationale Contre le Cancer. CVF was supported by the France Lymphome Espoir association of patients. QL was supported by the Fondation pour la Recherche Medicale (FRM, ECO202006011493).	Ansell SM, 2019, J CLIN ONCOL, V37, P481, DOI 10.1200/JCO.18.00766; Ansell SM, 2017, CLIN CANCER RES, V23, P1623, DOI 10.1158/1078-0432.CCR-16-1387; Auclair H, 2019, J IMMUNOL, V203, P1665, DOI 10.4049/jimmunol.1801420; Belting L, 2015, EUR J IMMUNOL, V45, P2593, DOI 10.1002/eji.201445375; Betzler AC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113949; Bichi R, 2002, P NATL ACAD SCI USA, V99, P6955, DOI 10.1073/pnas.102181599; Biram A, 2019, IMMUNOL REV, V288, P37, DOI 10.1111/imr.12737; Brenner CD, 2010, EUR J IMMUNOL, V40, P494, DOI 10.1002/eji.200939937; Brown PJ, 2016, LEUKEMIA, V30, P605, DOI 10.1038/leu.2015.299; Cerwenka A, 2000, IMMUNITY, V12, P721, DOI 10.1016/S1074-7613(00)80222-8; Chen BJ, 2013, CLIN CANCER RES, V19, P3462, DOI 10.1158/1078-0432.CCR-13-0855; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Cox MC, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.990773; David A, 2017, HAEMATOLOGICA, V102, P883, DOI 10.3324/haematol.2016.156281; Diefenbach A, 2000, NAT IMMUNOL, V1, P119, DOI 10.1038/77793; Do P, 2019, J IMMUNOL, V202, P2806, DOI 10.4049/jimmunol.1801359; Dong HD, 1999, NAT MED, V5, P1365; Flumann R, 2021, BLOOD CANCER DISCOV, V2, P70, DOI 10.1158/2643-3230.BCD-19-0059; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Godfrey J, 2019, BLOOD, V133, P2279, DOI 10.1182/blood-2018-10-879015; Groh V, 2002, NATURE, V419, P734, DOI 10.1038/nature01112; Guerra N, 2008, IMMUNITY, V28, P571, DOI 10.1016/j.immuni.2008.02.016; Hashwah H, 2017, P NATL ACAD SCI USA, V114, P9701, DOI 10.1073/pnas.1619555114; Herishanu Y, 2011, BLOOD, V117, P563, DOI 10.1182/blood-2010-05-284984; Herrmann A, 2017, CANCER RES, V77, P5118, DOI 10.1158/0008-5472.CAN-16-0342; Hilpert J, 2012, J IMMUNOL, V189, P1360, DOI 10.4049/jimmunol.1200796; Homig-Holzel C, 2008, J EXP MED, V205, P1317, DOI 10.1084/jem.20080238; Hofbauer JP, 2011, LEUKEMIA, V25, P1452, DOI 10.1038/leu.2011.111; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Khailaie S, 2018, BIOPHYS J, V115, P1330, DOI 10.1016/j.bpj.2018.08.020; Kleinstern G, 2020, HUM MOL GENET, V29, P70, DOI 10.1093/hmg/ddz228; Knittel G, 2016, BLOOD, V127, P2732, DOI [10.1182/blood-2015-11684183, 10.1182/blood-2015-11-684183]; Lenz G, 2008, P NATL ACAD SCI USA, V105, P13520, DOI 10.1073/pnas.0804295105; Lewinsky H, 2018, J CLIN INVEST, V128, P5465, DOI 10.1172/JCI96610; Li ZY, 2009, BLOOD, V114, P4158, DOI 10.1182/blood-2008-12-192583; Luckheeram RV, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/925135; Malarkannan S, 1998, J IMMUNOL, V161, P3501; Marom A, 2017, ONCOGENE, V36, P628, DOI 10.1038/onc.2016.238; McClanahan F, 2015, BLOOD, V126, P212, DOI 10.1182/blood-2015-02-626754; McClanahan F, 2015, BLOOD, V126, P203, DOI 10.1182/blood-2015-01-622936; Menter T, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00054; Menter T, 2016, HUM PATHOL, V54, P17, DOI 10.1016/j.humpath.2016.03.005; Moore CR, 2012, LEUKEMIA, V26, P1122, DOI 10.1038/leu.2011.309; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Nomura M, 1996, J BIOCHEM-TOKYO, V120, P987; Pascual M, 2019, BLOOD, V133, P2401, DOI 10.1182/blood.2018889931; Reimann M, 2021, BLOOD, V137, P2785, DOI 10.1182/blood.2020005244; Riemersma SA, 2000, BLOOD, V96, P3569, DOI 10.1182/blood.V96.10.3569.h8003569_3569_3577; Salih HR, 2003, BLOOD, V102, P1389, DOI 10.1182/blood-2003-01-0019; Spina V, 2016, SEMIN CANCER BIOL, V39, P61, DOI 10.1016/j.semcancer.2016.08.002; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Vincent-Fabert C, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0391-x; Vincent-Fabert C, 2019, CELL MOL IMMUNOL, V16, P621, DOI 10.1038/s41423-019-0228-y; Vincent-Fabert C, 2019, CELL MOL IMMUNOL, V16, P412, DOI 10.1038/s41423-018-0197-6; VOSE BM, 1985, SEMIN HEMATOL, V22, P27; Witkowska M, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/1982423; WORTZEL RD, 1983, NATURE, V304, P165, DOI 10.1038/304165a0; Wu J, 1999, SCIENCE, V285, P730, DOI 10.1126/science.285.5428.730; Xu-Monette ZY, 2018, BLOOD, V131, P68, DOI 10.1182/blood-2017-07-740993; Zhang BC, 2012, CELL, V148, P739, DOI 10.1016/j.cell.2011.12.031; Zhang J, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00351	61	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2021	12								669964	10.3389/fimmu.2021.669964	http://dx.doi.org/10.3389/fimmu.2021.669964			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SO0MS	34113345	Green Published, gold			2022-12-18	WOS:000658676500001
J	Torreggiani, E; Bononi, I; Pietrobon, S; Mazzoni, E; Guerra, G; Feo, C; Martini, F; Tognon, M				Torreggiani, Elena; Bononi, Ilaria; Pietrobon, Silvia; Mazzoni, Elisa; Guerra, Giovanni; Feo, Carlo; Martini, Fernanda; Tognon, Mauro			Colorectal Carcinoma Affected Patients Are Significantly Poor Responders Against the Oncogenic JC Polyomavirus	FRONTIERS IN IMMUNOLOGY			English	Article						colorectal carcinoma; polyomavirus; JCPyV; oncogenic; antigen; antibody; prevalence; mimotope	CAPSID PROTEIN MIMOTOPES; SERUM ANTIBODIES; BK VIRUSES; CANCER; SIMIAN-VIRUS-40; PREVALENCE; TUMOR; DNA; CELLS; RISK	Background Many investigations reported the association between human tumors and JCPyV, a polyomavirus with oncogenic potential. The association has been supported by studies that found JCPyV footprints in CRC and gliomas of different types. Indeed, JCPyV footprints including its nucleic acids and Tag oncoprotein have been revealed in CRC tissues. Methods Herein, sera from colorectal carcinoma (CRC) affected patients and healthy individuals (HS), employed as control, were analysed for immunoglobulin G (IgG) antibodies against specific JCPyV viral capsid protein 1 (VP1) antigens. The investigation was carried out employing an innovative immunological assay. Indeed, an indirect enzyme-linked immunosorbent assay (ELISA) with JCPyV VP1 mimotopes was used. JCPyV VP1 mimotopes consisted of synthetic peptides mimicking VP1 epitopes. Results Sera from CRC affected patients, evaluated using indirect ELISAs with synthetic mimotopes, showed a significant lower prevalence of IgG antibodies against JCPyV VP1 mimotopes (26%) compared to HS (51%), p<0.005. These data were confirmed by another method, the hemagglutination inhibition (HAI) assay. Altogether these results, i.e. the prevalence of serum IgG antibodies against JCPyV VP1 mimotopes from patients with CRC is approximately 50% lower than in HS, are of interest. Discussion Our data suggest that patients with CRC are significantly poor responders against JCPyV VP1 antigens. It is possible that CRC patients are affected by a specific immunological deregulation. This immunological dysfunction, revelled in CRC patients, may account for their predisposition to the colorectal carcinoma onset.	[Torreggiani, Elena; Pietrobon, Silvia; Mazzoni, Elisa; Feo, Carlo; Martini, Fernanda; Tognon, Mauro] Univ Ferrara, Sch Med, Dept Med Sci, Ferrara, Italy; [Bononi, Ilaria] Univ Ferrara, Sch Med, Dept Translat Med, Ferrara, Italy; [Guerra, Giovanni] Univ Hosp Ferrara, Clin Lab Anal, Ferrara, Italy	University of Ferrara; University of Ferrara; University of Ferrara; Arcispedale Sant'Anna	Martini, F; Tognon, M (corresponding author), Univ Ferrara, Sch Med, Dept Med Sci, Ferrara, Italy.	mrf@unife.it; tgm@unife.it	Mazzoni, Elisa/K-6313-2016	Mazzoni, Elisa/0000-0001-6829-8569	Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan [IG 21617]; University of Ferrara, Fondo di Ateneo per la Ricerca (FAR); Fondo di Incentivazione per la Ricerca (FIR)	Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan(Fondazione AIRC per la ricerca sul cancro); University of Ferrara, Fondo di Ateneo per la Ricerca (FAR); Fondo di Incentivazione per la Ricerca (FIR)	This research was funded by Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, grant number IG 21617 (to MT); University of Ferrara, Fondo di Ateneo per la Ricerca (FAR), grants 2019-2020 to MT, FM; Fondo di Incentivazione per la Ricerca (FIR), grant 2017 to FM, and grant 2020 to EM.	Arastefar A., 2015, J IMMUNOTHER CANCER, P379, DOI [10.1186/2051-1426-3-s2-p379, DOI 10.1186/2051-1426-3-S2-P379]; Assetta B, 2017, BIOL CHEM, V398, P839, DOI 10.1515/hsz-2016-0345; Barbanti-Brodano G, 2006, ADV EXP MED BIOL, V577, P319; Bononi I, 2018, J CELL PHYSIOL, V233, P5513, DOI 10.1002/jcp.26457; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen HD, 2015, INT J CANCER, V137, P12, DOI 10.1002/ijc.29180; Cherati AY, 2018, GASTROINTEST TUMORS, V5, P47, DOI 10.1159/000489928; Coelho TR, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-42; Coelho TR, 2013, J MED VIROL, V85, P2119, DOI 10.1002/jmv.23705; Corallini A, 2012, HUM IMMUNOL, V73, P502, DOI 10.1016/j.humimm.2012.02.009; Coursaget P, 2013, APMIS, V121, P755, DOI 10.1111/apm.12122; Croci DO, 2007, CANCER IMMUNOL IMMUN, V56, P1687, DOI 10.1007/s00262-007-0343-y; Del Valle L, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00711; Delbue S, 2017, INFECT AGENTS CANCER, V12, DOI 10.1186/s13027-017-0122-0; Egli A, 2009, J INFECT DIS, V199, P837, DOI 10.1086/597126; Engels EA, 2005, INT J CANCER, V117, P1013, DOI 10.1002/ijc.21277; Esmailzadeh N, 2020, GASTROINTEST TUMORS, V7, P30, DOI 10.1159/000504293; Guerrini R, 2010, MED RES REV, V30, P751, DOI 10.1002/med.20180; Hampras SS, 2014, CANCER EPIDEM BIOMAR, V23, P2591, DOI 10.1158/1055-9965.EPI-14-0370; Jarnicki AG, 2006, J IMMUNOL, V177, P896, DOI 10.4049/jimmunol.177.2.896; Kean JM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000363; Keum N, 2019, NAT REV GASTRO HEPAT, V16, P713, DOI 10.1038/s41575-019-0189-8; Kjaerheim K, 2007, INT J CANCER, V120, P2459, DOI 10.1002/ijc.22592; Ksiaa F, 2015, J BUON, V20, P762; Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65; Lasry A, 2016, NAT IMMUNOL, V17, P230, DOI 10.1038/ni.3384; Lundstig A, 2005, J GEN VIROL, V86, P1703, DOI 10.1099/vir.0.80783-0; Lundstig A, 2007, INT J CANCER, V121, P1098, DOI 10.1002/ijc.22770; Prado JCM, 2018, CLINICS, V73, DOI 10.6061/clinics/2018/e558s; Mazzoni E, 2020, J CELL PHYSIOL, V235, P5847, DOI 10.1002/jcp.29533; Mazzoni E, 2012, P NATL ACAD SCI USA, V109, P18066, DOI 10.1073/pnas.1213238109; McLean MH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015366; Mehrabani-Khasraghi Sahar, 2016, Iranian Biomedical Journal, V20, P302, DOI 10.22045/ibj.2016.08; Moens U, 2013, REV MED VIROL, V23, P250, DOI 10.1002/rmv.1747; Mou XZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035900; Newcomb PA, 2004, CANCER EPIDEM BIOMAR, V13, P662; Nishikawa H, 2014, CURR OPIN IMMUNOL, V27, P1, DOI 10.1016/j.coi.2013.12.005; Niv Y, 2010, J CLIN GASTROENTEROL, V44, P489, DOI 10.1097/MCG.0b013e3181d7a347; Ogino S, 2018, GUT, V67, P1168, DOI 10.1136/gutjnl-2017-315537; OuYang LY, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0410-7; Pietrobon S, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02059; Pietrobon S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00236; Pinto M, 2014, J INFECTION, V68, pS2, DOI 10.1016/j.jinf.2013.09.009; Ribeiro T, 2010, NEUROL SCI, V31, P517, DOI 10.1007/s10072-010-0353-y; Ricciardiello L, 2003, CANCER RES, V63, P7256; Rollison DE, 2009, CANCER EPIDEM BIOMAR, V18, P1515, DOI 10.1158/1055-9965.EPI-08-1119; Rotondo JC, 2017, J CELL PHYSIOL, V232, P982, DOI 10.1002/jcp.25686; Sakamoto K, 2009, CLIN CANCER RES, V15, P2248, DOI 10.1158/1078-0432.CCR-08-1383; Sarvari J, 2018, POL J MICROBIOL, V67, P73, DOI 10.5604/01.3001.0011.6146; Sheng J, 2020, INT J MED SCI, V17, P1095, DOI 10.7150/ijms.44439; Shi YH, 2015, IMMUNOBIOLOGY, V220, P1186, DOI 10.1016/j.imbio.2015.06.003; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Sinagra E, 2014, WORLD J GASTROENTERO, V20, P15745, DOI 10.3748/wjg.v20.i42.15745; Syrjanen K, 2013, SCAND J INFECT DIS, V45, P1, DOI 10.3109/00365548.2012.702281; Tagliapietra A, 2019, HUM REPROD, V34, P433, DOI 10.1093/humrep/dey375; Talmadge JE, 2013, NAT REV CANCER, V13, P739, DOI 10.1038/nrc3581; Tognon M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145720; Toumi W, 2017, NEW MICROBIOL, V40, P99; Touze A, 2010, J CLIN MICROBIOL, V48, P1767, DOI 10.1128/JCM.01691-09; Uleri E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235965; van der Geest LGM, 2015, CLIN EXP METASTAS, V32, P457, DOI 10.1007/s10585-015-9719-0; van Elsland D, 2018, EMBO REP, V19, DOI 10.15252/embr.201846632; Verzella D, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2399-y; Viscidi RP, 2003, CLIN DIAGN LAB IMMUN, V10, P278, DOI 10.1128/CDLI.10.2.278-285.2003; West NR, 2015, NAT REV IMMUNOL, V15, P615, DOI 10.1038/nri3896; White MK, 2009, J VIROL, V83, P10846, DOI 10.1128/JVI.00542-09; Xiong Y, 2019, NANOMED-NANOTECHNOL, V21, DOI 10.1016/j.nano.2019.102034; Yang T, 2019, INT J CANCER, V145, P2315, DOI 10.1002/ijc.32057; Zhang Y, 2020, CANCERS, V12, DOI 10.3390/cancers12123850	69	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2021	12								632129	10.3389/fimmu.2021.632129	http://dx.doi.org/10.3389/fimmu.2021.632129			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SO0ZV	34113338	Green Published, gold			2022-12-18	WOS:000658710600001
J	Cobb, J; Rawson, J; Gonzalez, N; Hensel, M; Kandeel, F; Husseiny, MI				Cobb, Jacob; Rawson, Jeffrey; Gonzalez, Nelson; Hensel, Michael; Kandeel, Fouad; Husseiny, Mohamed I.			Oral Salmonella msbB Mutant as a Carrier for a Salmonella-Based Vaccine for Prevention and Reversal of Type 1 Diabetes	FRONTIERS IN IMMUNOLOGY			English	Article						type 1 diabetes; autoantigens; immunotherapy; immunomodulator; Salmonella msbB mutant; oral vaccination; diabetes reversal and prevention	ANTIGEN DELIVERY; TYPHIMURIUM; ENTERICA; GENES; CONSTRUCTION; GENERATION; INDUCTION; VIRULENCE; RESPONSES; BACTERIAL	A therapy that includes an oral vaccine for type 1 diabetes (T1D) using live attenuated Salmonella MvP728 (Delta htrA/Delta purD), cytokines (IL10 and TGF beta) and preproinsulin (PPI) antigen in combination with a sub-therapeutic dose of anti-CD3 mAb was developed by our team. The vaccine combination therapy reduced insulitis and prevented and reversed diabetes in non-obese diabetic (NOD) mice. Here, we show the effectiveness of an alternative Salmonella mutant (Delta msbB) as a carrier strain, which is anticipated to have lower risks of an inflammatory response and septicemia as a result of modification in the lipopolysaccharide (LPS) via detoxification of lipid A. This mutant strain proved to have highly reduced pathogenic side effects. Salmonella strain Delta msbB expressed autoantigens and in combination with cytokines and anti-CD3 mAb, successfully prevented and reversed T1D to levels comparable to the previously used carrier strain Delta htrA/Delta purD. Additionally, the Salmonella msbB mutant resulted in higher rates of host cell infection. These results further demonstrate the potential of an oral Salmonella-based combined therapy in the treatment of early T1D.	[Cobb, Jacob; Rawson, Jeffrey; Gonzalez, Nelson; Kandeel, Fouad; Husseiny, Mohamed I.] City Hope Natl Med Ctr, Beckman Res Inst, Arthur Riggs Diabet & Metab Res Inst, Dept Translat Res & Cellular Therapeut, Duarte, CA 91010 USA; [Hensel, Michael] Univ Osnabruck, Div Microbiol, Osnabruck, Germany; [Husseiny, Mohamed I.] Zagazig Univ, Fac Pharm, Zagazig, Egypt	City of Hope; Beckman Research Institute of City of Hope; University Osnabruck; Egyptian Knowledge Bank (EKB); Zagazig University	Husseiny, MI (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Arthur Riggs Diabet & Metab Res Inst, Dept Translat Res & Cellular Therapeut, Duarte, CA 91010 USA.; Husseiny, MI (corresponding author), Zagazig Univ, Fac Pharm, Zagazig, Egypt.	melsayed@coh.org		Elsayed, Mohamed Ibrahim Husseiny/0000-0002-3470-2858; Hensel, Michael/0000-0001-6604-6253	Wanek Family Project to Cure Type 1 Diabetes	Wanek Family Project to Cure Type 1 Diabetes	This work was supported by the Wanek Family Project to Cure Type 1 Diabetes (award to MIH).	Abrahams GL, 2006, CELL MICROBIOL, V8, P728, DOI 10.1111/j.1462-5822.2006.00706.x; Cheminay C, 2008, INT J MED MICROBIOL, V298, P87, DOI 10.1016/j.ijmm.2007.08.006; Claes AK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113645; Coombes JL, 2008, NAT REV IMMUNOL, V8, P435, DOI 10.1038/nri2335; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Ellermeier CD, 2002, GENE, V290, P153, DOI 10.1016/S0378-1119(02)00551-6; Erova TE, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/famb.2016.00148; Evans DT, 2003, J VIROL, V77, P2400, DOI 10.1128/JVI.77.4.2400-2409.2003; Frahm M, 2015, MBIO, V6, DOI 10.1128/mBio.00254-15; Hensel M, 2000, MOL MICROBIOL, V36, P1015, DOI 10.1046/j.1365-2958.2000.01935.x; Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213; Husseiny MI, 2005, VACCINE, V23, P2580, DOI 10.1016/j.vaccine.2004.11.035; Husseiny MI, 2005, INFECT IMMUN, V73, P1598, DOI 10.1128/IAI.73.3.1598-1605.2005; Husseiny MI, 2008, MICROBIOL RES, V163, P605, DOI 10.1016/j.micres.2006.10.003; Husseiny MI, 2007, VACCINE, V25, P185, DOI 10.1016/j.vaccine.2005.11.020; Husseiny MI, 2018, VACCINE, V36, P8008, DOI 10.1016/j.vaccine.2018.10.101; Husseiny MI, 2014, VACCINE, V32, P2300, DOI 10.1016/j.vaccine.2014.02.070; Husseiny MI, 2009, VACCINE, V27, P3780, DOI 10.1016/j.vaccine.2009.03.053; Khan SA, 1998, MOL MICROBIOL, V29, P571, DOI 10.1046/j.1365-2958.1998.00952.x; Kong QK, 2011, INFECT IMMUN, V79, P5027, DOI 10.1128/IAI.05524-11; Kong QK, 2011, INFECT IMMUN, V79, P4227, DOI 10.1128/IAI.05398-11; Kong QK, 2011, J IMMUNOL, V187, P412, DOI 10.4049/jimmunol.1100339; Liu T, 2010, CANCER GENE THER, V17, P97, DOI 10.1038/cgt.2009.58; Low KB, 1999, NAT BIOTECHNOL, V17, P37, DOI 10.1038/5205; Low Kenneth Brooks, 2004, Methods Mol Med, V90, P47; Mbongue JC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00712; Mbongue JC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00320; Nishikawa H, 2006, J CLIN INVEST, V116, P1946, DOI 10.1172/JCI28045; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Toso JF, 2002, J CLIN ONCOL, V20, P142, DOI 10.1200/JCO.2002.20.1.142; Valdivia RH, 1997, SCIENCE, V277, P2007, DOI 10.1126/science.277.5334.2007; Weiner HL, 2011, IMMUNOL REV, V241, P241, DOI 10.1111/j.1600-065X.2011.01017.x; Xiong GS, 2010, INT J CANCER, V126, P2622, DOI 10.1002/ijc.24957; Xu X, 2010, INFECT IMMUN, V78, P4828, DOI 10.1128/IAI.00298-10; Yamada Y, 2014, MICROBIOL-SGM, V160, P2122, DOI 10.1099/mic.0.076562-0	35	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 24	2021	12								667897	10.3389/fimmu.2021.667897	http://dx.doi.org/10.3389/fimmu.2021.667897			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SN5EA	34108968	gold, Green Published			2022-12-18	WOS:000658311600001
J	Moraru, M; Perez-Portilla, A; Sanz, KA; Blazquez-Moreno, A; Arnaiz-Villena, A; Reyburn, HT; Vilches, C				Moraru, Manuela; Perez-Portilla, Adriana; Al-Akioui Sanz, Karima; Blazquez-Moreno, Alfonso; Arnaiz-Villena, Antonio; Reyburn, Hugh T.; Vilches, Carlos			FCGR Genetic Variation in Two Populations From Ecuador Highlands-Extensive Copy-Number Variation, Distinctive Distribution of Functional Polymorphisms, and a Novel, Locally Common, Chimeric FCGR3B/A (CD16B/A) Gene	FRONTIERS IN IMMUNOLOGY			English	Article						Fc gamma receptors; FCGR locus; CD16A; copy-number variation; copy number region; polymorphism; genetic variation; Ecuador	SYSTEMIC-LUPUS-ERYTHEMATOSUS; GAMMA RECEPTOR POLYMORPHISMS; LINKAGE DISEQUILIBRIUM; CLINICAL CONSEQUENCES; ALLELIC POLYMORPHISMS; PROMOTER HAPLOTYPE; ETHNIC VARIATION; SUSCEPTIBILITY; ASSOCIATION; LOCUS	Fc gamma receptors (Fc gamma R), cell-surface glycoproteins that bind antigen-IgG complexes, control both humoral and cellular immune responses. The FCGR locus on chromosome 1q23.3 comprises five homologous genes encoding low-affinity Fc gamma RII and Fc gamma RIII, and displays functionally relevant polymorphism that impacts on human health. Recurrent events of non-allelic homologous recombination across the FCGR locus result in copy-number variation of similar to 82.5 kbp-long fragments known as copy-number regions (CNR). Here, we characterize a recently described deletion that we name CNR5, which results in loss of FCGR3A, FCGR3B, and FCGR2C, and generation of a recombinant FCGR3B/A gene. We show that the CNR5 recombination spot lies at the beginning of the third FCGR3 intron. Although the FCGR3B/A-encoded hybrid protein CD16B/A reaches the plasma membrane in transfected cells, its possible natural expression, predictably restricted to neutrophils, could not be demonstrated in resting or interferon gamma-stimulated cells. As the CNR5-deletion was originally described in an Ecuadorian family from Llano Grande (an indigenous community in North-Eastern Quito), we characterized the FCGR genetic variation in two populations from the highlands of Ecuador. Our results reveal that CNR5-deletion is relatively frequent in Llano Grande (5 carriers out of 36 donors). Furthermore, we found a high frequency of two strong-phagocytosis variants: the FCGR3B-NA1 haplotype and the CNR1 duplication, which translates into an increased FCGR3B and FCGR2C copy-number. CNR1 duplication was particularly increased in Llano Grande, 77.8% of the studied sample carrying at least one such duplication. In contrast, an extended haplotype CD16A-176V - CD32C-ORF+2B.2 - CD32B-2B.4 including strong activating and inhibitory Fc gamma R variants was absent in Llano Grande found at a low frequency (8.6%) in Ecuador highlands. This particular distribution of FCGR polymorphism, possibly a result of selective pressures, further confirms the importance of a comprehensive, joint analysis of all genetic variations in the locus and warrants additional studies on their putative clinical impact. In conclusion, our study confirms important ethnic variation at the FCGR locus; it shows a distinctive FCGR polymorphism distribution in Ecuador highlands; provides a molecular characterization of a novel CNR5-deletion associated with CD16A and CD16B deficiency; and confirms its presence in that population.	[Moraru, Manuela; Al-Akioui Sanz, Karima; Vilches, Carlos] Inst Invest Sanitaria Puerta Hierro Segovia Arana, Immunogenet & Histocompatibil Lab, Majadahonda, Spain; [Perez-Portilla, Adriana; Blazquez-Moreno, Alfonso; Reyburn, Hugh T.] Natl Ctr Biotechnol CNB CSIC, Dept Immunol & Oncol, Madrid, Spain; [Arnaiz-Villena, Antonio] Univ Complutense, Sch Med, Dept Immunol, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Complutense University of Madrid	Moraru, M; Vilches, C (corresponding author), Inst Invest Sanitaria Puerta Hierro Segovia Arana, Immunogenet & Histocompatibil Lab, Majadahonda, Spain.; Reyburn, HT (corresponding author), Natl Ctr Biotechnol CNB CSIC, Dept Immunol & Oncol, Madrid, Spain.	manuelamoraru@yahoo.com; htreyburn@cnb.csic.es; carlos.vilches@yahoo.com	Vilches, Carlos/G-1471-2012	Vilches, Carlos/0000-0002-0300-9225; Moraru, Manuela/0000-0001-5394-4521	Spanish Ministerio de Ciencia e Innovacion (AEI/FEDER, EU) [SAF2016-80363-C2-2-R, SAF2014-58752-R, SAF2017-83265-R, PI-18-00720]; Consejeria de Sanidad de la Comunidad de Madrid; EU Youth Employment Initiative; Consejeria de Educacion, Juventud y Deporte de la Comunidad de Madrid; Asociacion Espanola contra el Cancer Foundation [GCB15152947MELE]; European Social Fund;  [PEJ-2017-AI/BMD-7377]	Spanish Ministerio de Ciencia e Innovacion (AEI/FEDER, EU); Consejeria de Sanidad de la Comunidad de Madrid; EU Youth Employment Initiative; Consejeria de Educacion, Juventud y Deporte de la Comunidad de Madrid; Asociacion Espanola contra el Cancer Foundation; European Social Fund(European Social Fund (ESF)); 	This work was funded by grant SAF2016-80363-C2-2-R to CV, grants SAF2014-58752-R and SAF2017-83265-R to HTR, and grant PI-18-00720 to AA-V from the Spanish Ministerio de Ciencia e Innovacion (AEI/FEDER, EU). Publication costs were defrayed by a nominative grant from Consejeria de Sanidad de la Comunidad de Madrid to support research in Fundacion de Investigacion Biomedica Puerta de Hierro. KA-S was supported by grant PEJ-2017-AI/BMD-7377, with cofinancing by EU Youth Employment Initiative, European Social Fund (91.89%), and Consejeria de Educacion, Juventud y Deporte de la Comunidad de Madrid. MM is supported by the Asociacion Espanola contra el Cancer Foundation grant GCB15152947MELE.	Anania JC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00464; Arnaiz-Villena A, 2018, HUM IMMUNOL, V79, P89, DOI 10.1016/j.humimm.2017.12.002; Asano K, 2009, NAT GENET, V41, P1325, DOI 10.1038/ng.482; Ashiru O, 2013, BIOCHEM J, V454, P295, DOI 10.1042/BJ20130194; Blank MC, 2005, HUM GENET, V117, P220, DOI 10.1007/s00439-005-1302-3; Blazquez-Moreno A, 2017, P NATL ACAD SCI USA, V114, pE5645, DOI 10.1073/pnas.1706483114; Bournazos S, 2009, CLIN EXP IMMUNOL, V157, P244, DOI 10.1111/j.1365-2249.2009.03980.x; Breunis WB, 2009, HUM MUTAT, V30, pE640, DOI 10.1002/humu.20997; BUTTRUM SM, 1993, BLOOD, V82, P1165; Clatworthy MR, 2007, P NATL ACAD SCI USA, V104, P7169, DOI 10.1073/pnas.0608889104; DEHAAS M, 1995, BLOOD, V86, P2403, DOI 10.1182/blood.V86.6.2403.bloodjournal8662403; den Dunnen JT, 2016, HUM MUTAT, V37, P564, DOI 10.1002/humu.22981; Elena CDDLV, 2008, TISSUE ANTIGENS, V71, P475, DOI 10.1111/j.1399-0039.2008.01034.x; Ernst LK, 2002, J MOL MED, V80, P248, DOI 10.1007/s00109-001-0294-2; Gillis C, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00254; Hargreaves CE, 2015, IMMUNOL REV, V268, P6, DOI 10.1111/imr.12341; Herrera Gioconda, 2015, Estud. Polit., P221, DOI 10.17533/udea.espo.n47a13; Hessner MJ, 1996, TRANSFUSION, V36, P895, DOI 10.1046/j.1537-2995.1996.361097017176.x; Hollox EJ, 2009, HUM MUTAT, V30, P477, DOI 10.1002/humu.20911; Koene HR, 1998, BLOOD, V91, P673, DOI 10.1182/blood.V91.2.673.673_673_679; Kuwano ST, 2000, TRANSFUSION, V40, P1388, DOI 10.1046/j.1537-2995.2000.40111388.x; Kyogoku C, 2002, ARTHRITIS RHEUM, V46, P1242, DOI 10.1002/art.10257; Lassauniere R, 2016, GENES IMMUN, V17, P93, DOI 10.1038/gene.2015.60; Lavu V, 2016, J PERIODONTOL, V87, P914, DOI 10.1902/jop.2016.150743; Lee YH, 2008, J RHEUMATOL, V35, P2129, DOI 10.3899/jrheum.080186; Lejeune J, 2012, MABS-AUSTIN, V4, P784, DOI 10.4161/mabs.22287; Li G, 2019, SCAND J IMMUNOL, V89, DOI 10.1111/sji.12758; Li XR, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007097; Machado LR, 2012, AM J HUM GENET, V90, P973, DOI 10.1016/j.ajhg.2012.04.018; Moraru M, 2015, J IMMUNOL, V195, P1676, DOI 10.4049/jimmunol.1500872; Moraru M, 2012, J IMMUNOL, V188, P4412, DOI 10.4049/jimmunol.1103434; Morris DL, 2010, EUR J HUM GENET, V18, P1027, DOI 10.1038/ejhg.2010.56; Mueller M, 2013, AM J HUM GENET, V92, P28, DOI 10.1016/j.ajhg.2012.11.013; NAGARAJAN S, 1995, J BIOL CHEM, V270, P25762, DOI 10.1074/jbc.270.43.25762; Nagelkerke SQ, 2015, GENES IMMUN, V16, P422, DOI 10.1038/gene.2015.25; Nagelkerke SQ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02237; Nagelkerke SQ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00185; Niederer HA, 2010, HUM MOL GENET, V19, P3282, DOI 10.1093/hmg/ddq216; Perez-Portilla A, 2020, J ALLERGY CLIN IMMUN, V145, P1288, DOI 10.1016/j.jaci.2019.11.049; Perez-Portilla A., 2019, THESIS U AUTONOMA MA; Rahbari R, 2017, HUM MUTAT, V38, P390, DOI 10.1002/humu.23159; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; SALMON JE, 1990, J CLIN INVEST, V85, P1287, DOI 10.1172/JCI114566; STAM NJ, 1986, J IMMUNOL, V137, P2299; Su KH, 2004, J IMMUNOL, V172, P7192, DOI 10.4049/jimmunol.172.11.7192; Su KH, 2004, J IMMUNOL, V172, P7186, DOI 10.4049/jimmunol.172.11.7186; Sved JA, 2018, GENETICS, V209, P629, DOI 10.1534/genetics.118.300642; Treffers LW, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03124; Tsang-A-Sjoe MWP, 2016, RHEUMATOLOGY, V55, P939, DOI 10.1093/rheumatology/kev433; Van den Berg L, 2001, IMMUNOLOGY, V104, P87, DOI 10.1046/j.1365-2567.2001.01284.x; van der Heijden J, 2012, J IMMUNOL, V188, P1318, DOI 10.4049/jimmunol.1003945; van Sorge NM, 2003, TISSUE ANTIGENS, V61, P189, DOI 10.1034/j.1399-0039.2003.00037.x; WARMERDAM PAM, 1990, J EXP MED, V172, P19, DOI 10.1084/jem.172.1.19; Willcocks LC, 2008, J EXP MED, V205, P1573, DOI 10.1084/jem.20072413; Willcocks LC, 2010, P NATL ACAD SCI USA, V107, P7881, DOI 10.1073/pnas.0915133107; Wineinger Nathan E., 2011, Frontiers in Genetics, V2, P17, DOI 10.3389/fgene.2011.00017; Zhu XW, 2016, SCI REP-UK, V6, DOI 10.1038/srep31617; Zuccherato LW, 2017, J R SOC INTERFACE, V14, DOI 10.1098/rsif.2017.0057	59	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 24	2021	12								615645	10.3389/fimmu.2021.615645	http://dx.doi.org/10.3389/fimmu.2021.615645			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SN6WP	34108956	gold, Green Published			2022-12-18	WOS:000658428500001
J	Merino-Wong, M; Niemeyer, BA; Alansary, D				Merino-Wong, Maylin; Niemeyer, Barbara A.; Alansary, Dalia			Plasma Membrane Calcium ATPase Regulates Stoichiometry of CD4(+) T-Cell Compartments	FRONTIERS IN IMMUNOLOGY			English	Article						Plasma Membrane Calcium ATPase; Yin Yang 1; CD4(+) compartments; calcium signaling; stoichiometry	EXPRESSION; CA2+; NEUROPLASTIN; COMPLEX	Immune responses involve mobilization of T cells within naive and memory compartments. Tightly regulated Ca2+ levels are essential for balanced immune outcomes. How Ca2+ contributes to regulating compartment stoichiometry is unknown. Here, we show that plasma membrane Ca2+ ATPase 4 (PMCA4) is differentially expressed in human CD4(+) T compartments yielding distinct store operated Ca2+ entry (SOCE) profiles. Modulation of PMCA4 yielded a more prominent increase of SOCE in memory than in naive CD4(+) T cell. Interestingly, downregulation of PMCA4 reduced the effector compartment fraction and led to accumulation of cells in the naive compartment. In silico analysis and chromatin immunoprecipitation point towards Ying Yang 1 (YY1) as a transcription factor regulating PMCA4 expression. Analyses of PMCA and YY1 expression patterns following activation and of PMCA promoter activity following downregulation of YY1 highlight repressive role of YY1 on PMCA expression. Our findings show that PMCA4 adapts Ca2+ levels to cellular requirements during effector and quiescent phases and thereby represent a potential target to intervene with the outcome of the immune response.	[Merino-Wong, Maylin; Niemeyer, Barbara A.; Alansary, Dalia] Saarland Univ, Mol Biophys, Homburg, Germany	Universitatsklinikum des Saarlandes	Alansary, D (corresponding author), Saarland Univ, Mol Biophys, Homburg, Germany.	dalia.alansary@uks.eu		Niemeyer, Barbara A./0000-0002-6963-0575; Alansary, Dalia/0000-0002-7541-6057	Deutsche Forschungsgemeinschaft DFG [FOR 2289-P6, TRR219-C09]; DFG [GZ: INST 256/423-1 FUGG]	Deutsche Forschungsgemeinschaft DFG(German Research Foundation (DFG)); DFG(German Research Foundation (DFG))	This work is supported by the Deutsche Forschungsgemeinschaft DFG (FOR 2289-P6) to BN and DA and (TRR219-C09) to BN. The FACSverse was funded by DFG (GZ: INST 256/423-1 FUGG).	Ahmed R, 2009, NAT REV IMMUNOL, V9, P662, DOI 10.1038/nri2619; Alansary D, 2020, J CELL SCI, V133, DOI 10.1242/jcs.240358; Ambrosini G, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3288-8; Austen M, 1998, ONCOGENE, V17, P511, DOI 10.1038/sj.onc.1201968; Bajnok A, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/8045161; Bautista DM, 2004, J PHYSIOL-LONDON, V556, P805, DOI 10.1113/jphysiol.2003.060004; Bautista DM, 2002, J PHYSIOL-LONDON, V541, P877, DOI 10.1113/jphysiol.2001.016154; Boczek T, 2017, BBA-GENE REGUL MECH, V1860, P502, DOI 10.1016/j.bbagrm.2017.01.012; Brini M, 2013, FEBS J, V280, P5385, DOI 10.1111/febs.12193; Caride AJ, 2001, CELL CALCIUM, V30, P49, DOI 10.1054/ceca.2001.0212; Christie D, 2014, CURR TOP MICROBIOL, V381, P125, DOI 10.1007/82_2014_372; Cibrian D, 2017, EUR J IMMUNOL, V47, P946, DOI 10.1002/eji.201646837; Daoussis D, 2004, CLIN DIAGN LAB IMMUN, V11, P635, DOI 10.1128/CDLI.11.4.635-641.2004; Durek P, 2016, IMMUNITY, V45, P1148, DOI 10.1016/j.immuni.2016.10.022; Eichmann M, 2020, J IMMUNOL, V204, P3129, DOI 10.4049/jimmunol.1901439; Farber DL, 2014, NAT REV IMMUNOL, V14, P24, DOI 10.1038/nri3567; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Fornes O, 2020, NUCLEIC ACIDS RES, V48, pD87, DOI 10.1093/nar/gkz1001; Go CK, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aaw2627; Gong DS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06075-7; Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080; Habib T, 2007, J CELL BIOL, V179, P717, DOI 10.1083/jcb.200704173; Henson SM, 2012, CURR OPIN IMMUNOL, V24, P476, DOI 10.1016/j.coi.2012.04.001; Ho PWL, 2015, BRAIN BEHAV, V5, DOI 10.1002/brb3.321; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Kiang JG, 2003, J CELL BIOCHEM, V89, P1030, DOI 10.1002/jcb.10564; Kircher S, 2018, BBA-MOL CELL RES, V1865, P932, DOI 10.1016/j.bbamcr.2018.04.001; Knorck A, 2018, TRANSFUSION, V58, P1516, DOI 10.1111/trf.14616; Korthals M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08519-4; Kulakovskiy IV, 2018, NUCLEIC ACIDS RES, V46, pD252, DOI 10.1093/nar/gkx1106; Launay S, 1997, J BIOL CHEM, V272, P10746; Lee BO, 2002, J EXP MED, V196, P693, DOI 10.1084/jem.20020845; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Mahnke YD, 2013, EUR J IMMUNOL, V43, P2797, DOI 10.1002/eji.201343751; Mayer SI, 2009, EUR J CELL BIOL, V88, P19, DOI 10.1016/j.ejcb.2008.07.002; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Neron S, 2007, TRANSFUSION, V47, P1042, DOI 10.1111/j.1537-2995.2007.01233.x; Oliveros J. C., 2015, VENNY INTERACTIVE TO; Pande Jyoti, 2011, World J Biol Chem, V2, P39, DOI 10.4331/wjbc.v2.i3.39; Priesner C, 2016, HUM GENE THER, V27, P860, DOI 10.1089/hum.2016.091; Ramesh G., 2021, CELL REP, V34, DOI [10.2139/ssrn.3707638, DOI 10.2139/SSRN.3707638]; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reddy M, 2004, J IMMUNOL METHODS, V293, P127, DOI 10.1016/j.jim.2004.07.006; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Ritchie MF, 2011, CELL CALCIUM, V49, P314, DOI 10.1016/j.ceca.2010.10.001; Ritchie MF, 2010, J BIOL CHEM, V285, P10591, DOI 10.1074/jbc.M109.083493; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; ROY M, 1993, J IMMUNOL, V151, P2497; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Sallusto F, 2009, EUR J IMMUNOL, V39, P2076, DOI 10.1002/eji.200939722; Samakai E, 2016, FASEB J, V30, P3878, DOI 10.1096/fj.201600532R; Savignac M, 2007, PFLUG ARCH EUR J PHY, V454, P523, DOI 10.1007/s00424-007-0238-y; Schmidt N, 2017, NEURON, V96, P827, DOI 10.1016/j.neuron.2017.09.038; Schoettler N, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0657-2; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; Stafford N, 2017, PHYSIOL REV, V97, P1089, DOI 10.1152/physrev.00028.2016; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Supper V, 2016, J IMMUNOL, V196, P1387, DOI 10.4049/jimmunol.1501889; Tian Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01728-5; Unsoeld H, 2005, J VIROL, V79, P4510, DOI 10.1128/JVI.79.7.4510-4513.2005; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Wu SF, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1393-y; Xie YL., 2013, J CLIN CELL IMMUNOL, V4, DOI [10.4172/2155-9899.1000181, DOI 10.4172/2155-9899.1000181]; Ximenes HM, 2003, J BIOL CHEM, V278, P22956, DOI 10.1074/jbc.M212339200; Zerbino DR, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0621-5; Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147	70	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 21	2021	12								687242	10.3389/fimmu.2021.687242	http://dx.doi.org/10.3389/fimmu.2021.687242			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SM5LT	34093590	gold, Green Published			2022-12-18	WOS:000657647500001
J	De Vlieger, L; Smolders, L; Nuyttens, L; Verelst, S; Breynaert, C; Vanuytsel, T; Hoffman, I; Bullens, DMA				De Vlieger, Liselot; Smolders, Lieselot; Nuyttens, Lisa; Verelst, Sophie; Breynaert, Christine; Vanuytsel, Tim; Hoffman, Ilse; Bullens, Dominique M. A.			A Clinical Perspective on the Dietary Therapies for Pediatric Eosinophilic Esophagitis: The Gap Between Research and Daily Practice	FRONTIERS IN IMMUNOLOGY			English	Review						eosinophilic esophagitis; pediatric; dietary therapy; elemental diet; elimination diet; allergy-test directed diet; reintroduction; child	ELIMINATION DIET; ADULT	Pediatric eosinophilic esophagitis (ped-EoE) is an immune-mediated pathology affecting 34 per 100.000 children. It is characterized by an esophageal inflammation caused by an immune response towards food antigens that come into contact with the esophageal lining. Depending on the age of the child, symptoms can vary from abdominal pain, vomiting and failure to thrive to dysphagia and food impaction. The diagnosis of this chronic disease is based on the symptoms of esophageal dysfunction combined with an infiltration of more than 15 eosinophils per high-power field and the exclusion of secondary causes. The treatment modalities include the 3Ds: Drugs, allergen avoidance by Diet and/or esophageal Dilation. In this review we focused on the efficacy of dietary approaches in ped-EoE, which currently include the elemental diet (amino acid-based diet), the empiric elimination diet and the allergy test-directed elimination diet. Although several reviews have summarized these dietary approaches, a lack of consistency between and within the elimination diets hampers its clinical use and differences in subsequent reintroduction phases present a barrier for dietary advice in daily clinical practice. We therefore conducted an analysis driven from a clinician's perspective on these dietary therapies in the management of ped-EoE, whereby we examined whether these variations within dietary approaches, yet considered to be similar, could result in significant differences in dietary counseling.	[De Vlieger, Liselot; Nuyttens, Lisa; Breynaert, Christine; Bullens, Dominique M. A.] Katholieke Univ Leuven, Dept Microbiol Immunol & Transplantat, Allergy & Immunol Res Grp, Leuven, Belgium; [Smolders, Lieselot; Breynaert, Christine] UZ Leuven, Dept Gen Internal Med, Leuven, Belgium; [Nuyttens, Lisa; Verelst, Sophie; Bullens, Dominique M. A.] UZ Leuven, Clin Div Pediat, Leuven, Belgium; [Vanuytsel, Tim] UZ Leuven, Gastroenterol & Hepatol, Leuven, Belgium; [Hoffman, Ilse] UZ Leuven, Pediat Gastroenterol Hepatol & Nutr, Leuven, Belgium	KU Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven	De Vlieger, L (corresponding author), Katholieke Univ Leuven, Dept Microbiol Immunol & Transplantat, Allergy & Immunol Res Grp, Leuven, Belgium.	liselot.devlieger@kuleuven.be	Breynaert, Christine/T-5611-2017; Vanuytsel, Tim/O-9972-2016	Breynaert, Christine/0000-0002-7368-1068; De Vlieger, Liselot/0000-0001-8356-0676; Vanuytsel, Tim/0000-0001-8728-0903				Al-Hussaini A, 2013, J GASTROENTEROL, V48, P1205, DOI 10.1007/s00535-012-0741-6; Atwal K, 2019, IMMUN INFLAMM DIS, V7, P292, DOI 10.1002/iid3.273; De Swert L, 2013, J ALLERGY CLIN IMMUN, V131, P600, DOI 10.1016/j.jaci.2012.10.057; Eke R, 2018, JGH OPEN, V2, P158, DOI 10.1002/jgh3.12059; Torrijos EG, 2019, J INVEST ALLERG CLIN, V29, P155, DOI 10.18176/jiaci.0358; Torrijos EG, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00247; Gomez-Aldana A, 2019, WORLD J GASTROENTERO, V25, P4598, DOI 10.3748/wjg.v25.i32.4598; Gonsalves N, 2013, GASTROENTEROLOGY, V144, pS154; Gutierrez-Junquera C, 2020, CURR OPIN CLIN NUTR, V23, P210, DOI 10.1097/MCO.0000000000000643; Henderson CJ, 2012, J ALLERGY CLIN IMMUN, V129, P1570, DOI 10.1016/j.jaci.2012.03.023; Kagalwalla AF, 2006, CLIN GASTROENTEROL H, V4, P1097, DOI 10.1016/j.cgh.2006.05.026; Kagalwalla AF, 2017, CLIN GASTROENTEROL H, V15, P1698, DOI 10.1016/j.cgh.2017.05.048; Kagalwalla AF, 2012, J PEDIATR GASTR NUTR, V55, P711, DOI 10.1097/MPG.0b013e318268da40; KELLY KJ, 1995, GASTROENTEROLOGY, V109, P1503, DOI 10.1016/0016-5085(95)90637-1; Kliewer K, 2019, GASTROENTEROLOGY, V156, pS172; Kliewer KL, 2018, CLIN REV ALLERG IMMU, V55, P70, DOI 10.1007/s12016-017-8660-1; Kruszewski PG, 2016, DIS ESOPHAGUS, V29, P377, DOI 10.1111/dote.12339; Leung J, 2015, J ALLER CL IMM-PRACT, V3, P951, DOI 10.1016/j.jaip.2015.06.024; Liacouras CA, 2005, CLIN GASTROENTEROL H, V3, P1198, DOI 10.1016/S1542-3565(05)00885-2; Lucendo AJ, 2017, UNITED EUR GASTROENT, V5, P335, DOI 10.1177/2050640616689525; Madison Jill M, 2020, Curr Gastroenterol Rep, V22, P25, DOI 10.1007/s11894-020-00758-2; Markowitz JE, 2003, AM J GASTROENTEROL, V98, P777, DOI 10.1111/j.1572-0241.2003.07390.x; Moawad Fouad J, 2018, Gastrointest Endosc Clin N Am, V28, P15, DOI 10.1016/j.giec.2017.07.001; Molina-Infante J, 2018, J ALLERGY CLIN IMMUN, V141, P1365, DOI 10.1016/j.jaci.2017.08.038; Muir R, 2010, GASTROENTEROLOGY, V138, pS177; Munoz-Persy M, 2018, EUR J PEDIATR, V177, P649, DOI 10.1007/s00431-018-3129-7; Navarro P, 2019, ALIMENT PHARM THER, V49, P1116, DOI 10.1111/apt.15231; Peters RL, 2012, PEDIAT ALLERG IMM-UK, V23, P347, DOI 10.1111/j.1399-3038.2011.01237.x; Reed CC, 2019, ANN ALLERG ASTHMA IM, V122, P296, DOI 10.1016/j.anai.2018.12.013; Reed CC, 2018, DIGEST DIS SCI, V63, P2381, DOI 10.1007/s10620-018-4931-9; Pascual JMR, 2011, J INVEST ALLERG CLIN, V21, P59; Simon D, 2016, ALLERGY, V71, P611, DOI 10.1111/all.12846; Spergel JM, 2002, J ALLERGY CLIN IMMUN, V109, P363, DOI 10.1067/mai.2002.121458; Spergel JM, 2012, J ALLERGY CLIN IMMUN, V130, P461, DOI 10.1016/j.jaci.2012.05.021; Storhaug CL, 2017, LANCET GASTROENTEROL, V2, P738, DOI 10.1016/S2468-1253(17)30154-1; Sugnanam KKN, 2007, ALLERGY, V62, P1257, DOI 10.1111/j.1398-9995.2007.01454.x; Teoh Timothy, 2019, J Can Assoc Gastroenterol, V2, P81, DOI 10.1093/jcag/gwy030; Vicario M, 2010, GUT, V59, P12, DOI 10.1136/gut.2009.178020; Warners MJ, 2018, GASTROENTEROLOGY, V154, P57, DOI 10.1053/j.gastro.2017.08.062; Wechsler JB, 2017, GASTROENTEROLOGY, V152, pS855, DOI 10.1016/S0016-5085(17)32944-X; Wong J, 2020, PEDIATR GASTROENTERO, V23, P79, DOI 10.5223/pghn.2020.23.1.79; Zhan TN, 2018, CLIN GASTROENTEROL H, V16, P1730, DOI 10.1016/j.cgh.2018.04.013	42	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2021	12								677859	10.3389/fimmu.2021.677859	http://dx.doi.org/10.3389/fimmu.2021.677859			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SL6ZG	34093578	Green Published, gold			2022-12-18	WOS:000657063200001
J	Moreira, J; Costelha, S; Saraiva, M; Saraiva, MJ				Moreira, Joao; Costelha, Susete; Saraiva, Margarida; Saraiva, Maria Joao			The Expression of Chemokines Is Downregulated in a Pre-Clinical Model of TTR V30M Amyloidosis	FRONTIERS IN IMMUNOLOGY			English	Article						transthyretin; chemokines; Schwann cell; immune regulation; familial amyloidotic polyneuropathy		Inflammation is a hallmark of several neurodegenerative disorders including hereditary amyloidogenic transthyretin amyloidosis (ATTRv). ATTRv is an autosomal dominant neurodegenerative disorder with extracellular deposition of mutant transthyretin (TTR) aggregates and fibrils, particularly in nerves and ganglia of the peripheral nervous system. Nerve biopsies from ATTRv patients show increased cytokine production, but interestingly no immune inflammatory cellular infiltrate is observed around TTR aggregates. Here we show that as compared to Wild Type (WT) animals, the expression of several chemokines is highly downregulated in the peripheral nervous system of a mouse model of the disease. Interestingly, we found that stimulation of mouse Schwann cells (SCs) with WT TTR results in the secretion of several chemokines, a process that is mediated by toll-like receptor 4 (TLR4). In contrast, the secretion of all tested chemokines is compromised upon stimulation of SCs with mutant TTR (V30M), suggesting that V30M TTR fails to activate TLR4 signaling. Altogether, our data shed light into a previously unappreciated mechanism linking TTR activation of SCs and possibly underlying the lack of inflammatory response observed in the peripheral nervous system of ATTRv patients.	[Moreira, Joao; Costelha, Susete; Saraiva, Margarida; Saraiva, Maria Joao] Univ Porto, i3S Inst Invest & Inovacao Saude, Porto, Portugal; [Moreira, Joao; Costelha, Susete; Saraiva, Margarida; Saraiva, Maria Joao] Univ Porto, IBMC Inst Biol Mol & Celular, Porto, Portugal; [Moreira, Joao] Univ Porto, ICBAS Inst Ciencias Biomed Abel Salazar, Porto, Portugal	Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto; Universidade do Porto; Universidade do Porto	Saraiva, MJ (corresponding author), Univ Porto, i3S Inst Invest & Inovacao Saude, Porto, Portugal.; Saraiva, MJ (corresponding author), Univ Porto, IBMC Inst Biol Mol & Celular, Porto, Portugal.	mjsaraiv@ibmc.up.pt	Saraiva, Maria Joao/K-3907-2013	Saraiva, Maria Joao/0000-0002-3360-6899; Moreira, Joao/0000-0001-7043-7230; Costelha, Susete/0000-0003-4203-2345	Porto Neurosciences and Neurologic Disease Research Initiative at I3S - Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (FEDER) [Norte-01-0145-FEDER-000008]; FCT [SFRH/BD/129345/2017]; FCT through Estimulo Individual ao Emprego Cientifico	Porto Neurosciences and Neurologic Disease Research Initiative at I3S - Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (FEDER); FCT(Portuguese Foundation for Science and TechnologyEuropean Commission); FCT through Estimulo Individual ao Emprego Cientifico(Portuguese Foundation for Science and Technology)	The work was funded by the project Norte-01-0145-FEDER-000008 - Porto Neurosciences and Neurologic Disease Research Initiative at I3S, supported by Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (FEDER). JM was supported by FCT with a PhD fellowship SFRH/BD/129345/2017. MS is funded by FCT through Estimulo Individual ao Emprego Cientifico.	Amor S, 2010, IMMUNOLOGY, V129, P154, DOI 10.1111/j.1365-2567.2009.03225.x; Ando Y, 2005, RINSHO SHINKEIGAKU, V45; ANDRADE C, 1952, BRAIN, V75, P408, DOI 10.1093/brain/75.3.408; Azevedo EP, 2019, BMC NEUROL, V19, DOI 10.1186/s12883-019-1369-4; Benson MD, 2007, MUSCLE NERVE, V36, P411, DOI 10.1002/mus.20821; Benson MD, 2018, AMYLOID, V25, P215, DOI 10.1080/13506129.2018.1549825; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campana WM, 2007, BRAIN BEHAV IMMUN, V21, P522, DOI 10.1016/j.bbi.2006.12.008; Chen ZL, 2007, ANNU REV NEUROSCI, V30, P209, DOI 10.1146/annurev.neuro.30.051606.094337; Cuenda A, 2017, TRENDS BIOCHEM SCI, V42, P431, DOI 10.1016/j.tibs.2017.02.008; Fleming CE, 2007, J NEUROCHEM, V103, P831, DOI 10.1111/j.1471-4159.2007.04828.x; Fleming CE, 2009, J NEUROSCI, V29, P3220, DOI 10.1523/JNEUROSCI.6012-08.2009; FURUYA H, 1991, BIOCHEMISTRY-US, V30, P2415, DOI 10.1021/bi00223a017; Goncalves NP, 2016, AM J PATHOL, V186, P1913, DOI 10.1016/j.ajpath.2016.02.020; Goncalves NP, 2014, AMYLOID, V21, P175, DOI 10.3109/13506129.2014.927759; Goncalves NP, 2014, EXP NEUROL, V257, P76, DOI 10.1016/j.expneurol.2014.04.030; Gupta J, 2015, FEBS J, V282, P1841, DOI 10.1111/febs.13250; Horste GMZ, 2008, MUSCLE NERVE, V37, P3, DOI 10.1002/mus.20893; JACOBSON DR, 1992, HUM GENET, V89, P353; Jessen KR, 2005, NAT REV NEUROSCI, V6, P671, DOI 10.1038/nrn1746; Kohno K, 1997, AM J PATHOL, V150, P1497; Kyriakis JM, 2012, PHYSIOL REV, V92, P689, DOI 10.1152/physrev.00028.2011; Merlini G, 2003, NEW ENGL J MED, V349, P583, DOI 10.1056/NEJMra023144; Misu K, 1999, BRAIN, V122, P1951, DOI 10.1093/brain/122.10.1951; Monteiro FA, 2006, FEBS LETT, V580, P3451, DOI 10.1016/j.febslet.2006.05.020; Murakami T, 2010, BRAIN RES, V1348, P222, DOI 10.1016/j.brainres.2010.06.017; Nyhlin N, 2000, J INTERN MED, V247, P485, DOI 10.1046/j.1365-2796.2000.00668.x; Pappa T, 2015, BEST PRACT RES CL EN, V29, P735, DOI 10.1016/j.beem.2015.09.002; Plante-Bordeneuve V, 2011, LANCET NEUROL, V10, P1086, DOI 10.1016/S1474-4422(11)70246-0; Richner M, 2014, MOL NEUROBIOL, V50, P945, DOI 10.1007/s12035-014-8706-9; Samara C, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00228; Santos SD, 2010, NEUROBIOL AGING, V31, P280, DOI 10.1016/j.neurobiolaging.2008.04.001; Saraiva MJ, 2012, CURR MED CHEM, V19, P2304; SARAIVA MJM, 1984, J CLIN INVEST, V74, P104, DOI 10.1172/JCI111390; Saraiva MJM, 2001, HUM MUTAT, V17, P493, DOI 10.1002/humu.1132; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Scholz J, 2007, NAT NEUROSCI, V10, P1361, DOI 10.1038/nn1992; Sipe JD, 2016, AMYLOID, V23, P209, DOI 10.1080/13506129.2016.1257986; SOPRANO DR, 1985, J BIOL CHEM, V260, P1793; Sousa MM, 2001, J NEUROSCI, V21, P7576, DOI 10.1523/JNEUROSCI.21-19-07576.2001; Sousa MM, 2000, LAB INVEST, V80, P1101, DOI 10.1038/labinvest.3780116; Stratton JA, 2016, EUR J NEUROSCI, V43, P365, DOI 10.1111/ejn.13006; Suenaga G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163944; Tsukuba T, 2009, J BIOCHEM, V145, P565, DOI 10.1093/jb/mvp016; van Zoelen MAD, 2009, SHOCK, V31, P280, DOI 10.1097/SHK.0b013e318186262d; Ydens E, 2013, NEUROBIOL DIS, V55, P95, DOI 10.1016/j.nbd.2013.03.005; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; Zhong HH, 2020, J IMMUNOL, V205, P767, DOI 10.4049/jimmunol.1900860	48	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2021	12								650269	10.3389/fimmu.2021.650269	http://dx.doi.org/10.3389/fimmu.2021.650269			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SL3TX	34093538	gold, Green Published			2022-12-18	WOS:000656842900001
J	Martirosyan, A; Poghosyan, D; Ghonyan, S; Mkrtchyan, N; Amaryan, G; Manukyan, G				Martirosyan, Anush; Poghosyan, David; Ghonyan, Susanna; Mkrtchyan, Nune; Amaryan, Gayane; Manukyan, Gayane			Transmigration of Neutrophils From Patients With Familial Mediterranean Fever Causes Increased Cell Activation	FRONTIERS IN IMMUNOLOGY			English	Article						Familial Mediterranean fever; neutrophils; fresh/aged neutrophils; transmigration; IL-1 beta; immunophenotype; Fc gamma Rs	EXPRESSION; PYRIN	Familial Mediterranean fever (FMF) is caused by pyrin-encoding MEFV gene mutations and characterized by the self-limiting periods of intense inflammation, which are mainly mediated by a massive influx of polymorphonuclear neutrophils (PMNs) into the inflamed sites. Perturbation of actin polymerization by different pathogens was shown to activate the pyrin inflammasome. Our aim was to test whether cytoskeletal dynamics in the absence of pathogens may cause abnormal activation of PMNs from FMF patients. We also aimed to characterize immunophenotypes of circulating neutrophils and their functional activity. Circulating PMNs displayed heterogeneity in terms of cell size, granularity and immunophenotypes. Particularly, PMNs from the patients in acute flares (FMF-A) exhibited a characteristic of aged/activated cells (small cell size and granularity, up-regulated CXCR4), while PMNs form the patients in remission period (FMF-R) displayed mixed fresh/aged cell characteristics (normal cell size and granularity, up-regulated CD11b, CD49d, CXCR4, and CD62L). The findings may suggest that sterile tissue-infiltrated PMNs undergo reverse migration back to bone marrow and may explain why these PMNs do not cause immune-mediated tissue damage. A multidirectional expression of Fc gamma Rs on neutrophils during acute flares was also noteworthy: up-regulation of Fc gamma RI and down-regulation of Fc gamma RII/Fc gamma RIII. We also observed spontaneous and fMPL-induced activation of PMNs from the patients after transmigration through inserts as seen by the increased expression of CD11b and intracellular expression of IL-1 beta. Our study suggests heightened sensitivity of mutated pyrin inflammasome towards cytoskeletal modifications in the absence of pathogens.	[Martirosyan, Anush; Poghosyan, David; Ghonyan, Susanna; Manukyan, Gayane] Natl Acad Sci Republ Armenia NAS RA, Lab Mol & Cellular Immunol, Inst Mol Biol, Yerevan, Armenia; [Mkrtchyan, Nune; Amaryan, Gayane] Natl Pediat Ctr Familial Mediterranean Fever Arab, Yerevan, Armenia; [Mkrtchyan, Nune; Amaryan, Gayane] Yerevan State Med Univ, Dept Pediat, Yerevan, Armenia	National Academy of Sciences of Armenia; Institute of Molecular Biology - NAS RA; Yerevan State Medical University	Manukyan, G (corresponding author), Natl Acad Sci Republ Armenia NAS RA, Lab Mol & Cellular Immunol, Inst Mol Biol, Yerevan, Armenia.	gaya.manukyan@gmail.com			State Committee Science MES RA [SCS 20RF-112]	State Committee Science MES RA	This work was supported by a State Committee Science MES RA, in frame of the research project no. SCS 20RF-112.	Adrover JM, 2016, TRENDS IMMUNOL, V37, P334, DOI 10.1016/j.it.2016.03.005; Aubert DF, 2016, CELL HOST MICROBE, V19, P664, DOI 10.1016/j.chom.2016.04.004; Biro M, 2014, BRIT J PHARMACOL, V171, P5491, DOI 10.1111/bph.12658; Bzowska M, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/284759; Casanova-Acebes M, 2013, CELL, V153, P1025, DOI 10.1016/j.cell.2013.04.040; Centola M, 2000, BLOOD, V95, P3223, DOI 10.1182/blood.V95.10.3223; Chae JJ, 2011, IMMUNITY, V34, P755, DOI 10.1016/j.immuni.2011.02.020; De Filippo K, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12949; Deniset JF, 2018, J LEUKOCYTE BIOL, V103, P829, DOI 10.1002/JLB.3RI0917-361R; Ekpenyong AE, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1602536; Gao WQ, 2016, P NATL ACAD SCI USA, V113, pE4857, DOI 10.1073/pnas.1601700113; Heilig R, 2018, EUR J IMMUNOL, V48, P230, DOI 10.1002/eji.201746947; Kim ML, 2015, J EXP MED, V212, P927, DOI 10.1084/jem.20142384; Komiya A, 2014, MOD RHEUMATOL, V24, P770, DOI 10.3109/14397595.2013.871108; Liston A, 2017, NAT REV IMMUNOL, V17, P208, DOI 10.1038/nri.2016.151; Livneh A, 1997, ARTHRITIS RHEUM-US, V40, P1879, DOI 10.1002/art.1780401023; Mansfield E, 2001, BLOOD, V98, P851, DOI 10.1182/blood.V98.3.851; Manukyan G, 2013, J BIOL REG HOMEOS AG, V27, P329; Manukyan G, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00456; Manukyan G, 2013, IMMUNOBIOLOGY, V218, P892, DOI 10.1016/j.imbio.2012.10.007; Matthews BD, 2006, J CELL SCI, V119, P508, DOI 10.1242/jcs.02760; Molad Y, 2004, J INVEST MED, V52, P58, DOI 10.1136/jim-52-01-28; Provenzano PP, 2011, J CELL SCI, V124, P1195, DOI 10.1242/jcs.067009; Ravelli RBG, 2004, NATURE, V428, P198, DOI 10.1038/nature02393; Schnappauf O, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01745; Stoler I, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00716; Stroka KM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061377; Sugiyama R, 2014, MOL BIOL REP, V41, P545, DOI 10.1007/s11033-013-2890-y; Taskiran EZ, 2012, J CELL BIOCHEM, V113, P3536, DOI 10.1002/jcb.24231; Tsuda Y, 2004, IMMUNITY, V21, P215, DOI 10.1016/j.immuni.2004.07.006; Uhl B, 2016, BLOOD, V128, P2327, DOI 10.1182/blood-2016-05-718999; Waite AL, 2009, EXP BIOL MED, V234, P40, DOI 10.3181/0806-RM-184; Wang J, 2017, SCIENCE, V358, P111, DOI 10.1126/science.aam9690; Wang Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01958; Wright HL, 2010, RHEUMATOLOGY, V49, P1618, DOI 10.1093/rheumatology/keq045; Xu H, 2014, NATURE, V513, P237, DOI 10.1038/nature13449; Yap B, 2005, J APPL PHYSIOL, V99, P2323, DOI 10.1152/japplphysiol.00503.2005; Zhang DC, 2015, NATURE, V525, P528, DOI 10.1038/nature15367	38	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 17	2021	12								672728	10.3389/fimmu.2021.672728	http://dx.doi.org/10.3389/fimmu.2021.672728			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SK3QF	34079554	Green Published, gold			2022-12-18	WOS:000656132700001
J	Nie, Z; Ao, YSQ; Wang, S; Shu, X; Li, MX; Zhan, XY; Yu, L; An, XM; Sun, YL; Guo, JY; Zhao, YN; He, L; Zhao, JL				Nie, Zheng; Ao, Yangsiqi; Wang, Sen; Shu, Xiang; Li, Muxiao; Zhan, Xueyan; Yu, Long; An, Xiaomeng; Sun, Yali; Guo, Jiaying; Zhao, Yangnan; He, Lan; Zhao, Junlong			Erythrocyte Adhesion of Merozoite Surface Antigen 2c1 Expressed During Extracellular Stages of Babesia orientalis	FRONTIERS IN IMMUNOLOGY			English	Article						invasion; adhesion; MSA-2c1; Babesia orientalis; merozoite surface antigen	PROTEIN; IDENTIFICATION	Babesia orientalis, a major infectious agent of water buffalo hemolytic babesiosis, is transmitted by Rhipicephalus haemaphysaloides. However, no effective vaccine is available. Essential antigens that are involved in parasite invasion of host red blood cells (RBCs) are potential vaccine candidates. Therefore, the identification and the conduction of functional studies of essential antigens are highly desirable. Here, we evaluated the function of B. orientalis merozoite surface antigen 2c1 (BoMSA-2c1), which belongs to the variable merozoite surface antigen (VMSA) family in B. orientalis. We developed a polyclonal antiserum against the purified recombinant (r)BoMSA-2c1 protein. Immunofluorescence staining results showed that BoMSA-2c1 was expressed only on extracellular merozoites, whereas the antigen was undetectable in intracellular parasites. RBC binding assays suggested that BoMSA-2c1 specifically bound to buffalo erythrocytes. Cytoadherence assays using a eukaryotic expression system in vitro further verified the binding and inhibitory ability of BoMSA-2c1. We found that BoMSA-2c1 with a GPI domain was expressed on the surface of HEK293T cells that bound to water buffalo RBCs, and that the anti-rBoMSA2c1 antibody inhibited this binding. These results indicated that BoMSA-2c1 was involved in mediating initial binding to host erythrocytes of B. orientalis. Identification of the occurrence of binding early in the invasion process may facilitate understanding of the growth characteristics, and may help in formulating strategies for the prevention and control of this parasite.	[Nie, Zheng; Ao, Yangsiqi; Wang, Sen; Shu, Xiang; Li, Muxiao; Zhan, Xueyan; Yu, Long; An, Xiaomeng; Sun, Yali; Guo, Jiaying; Zhao, Yangnan; He, Lan; Zhao, Junlong] Huazhong Agr Univ, Coll Vet Med, State Key Lab Agr Microbiol, Wuhan, Peoples R China; [Nie, Zheng; Ao, Yangsiqi; Wang, Sen; Shu, Xiang; Li, Muxiao; Zhan, Xueyan; Yu, Long; An, Xiaomeng; Sun, Yali; Guo, Jiaying; Zhao, Yangnan; He, Lan; Zhao, Junlong] Minist Agr Peoples Republ China, Key Lab Dev Vet Diagnost Prod, Wuhan, Peoples R China; [He, Lan; Zhao, Junlong] Cooperat Innovat Ctr Sustainable Pig Prod, Key Lab Prevent Vet Med Hubei Prov, Wuhan, Peoples R China	Huazhong Agricultural University; Ministry of Agriculture & Rural Affairs	Zhao, JL (corresponding author), Huazhong Agr Univ, Coll Vet Med, State Key Lab Agr Microbiol, Wuhan, Peoples R China.; Zhao, JL (corresponding author), Minist Agr Peoples Republ China, Key Lab Dev Vet Diagnost Prod, Wuhan, Peoples R China.; Zhao, JL (corresponding author), Cooperat Innovat Ctr Sustainable Pig Prod, Key Lab Prevent Vet Med Hubei Prov, Wuhan, Peoples R China.	zhaojunlong@mail.hzau.edu.cn	He, Lan/AFU-5817-2022		National Natural Science Foundation of China [31930108]; National Key Research and Development Program of China [2017YFD0501201]; Fundamental Research Funds for the Central Universities in China [2662020DKPY016]; Fundamental Research Funds for the Central University [2662019PY001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; Fundamental Research Funds for the Central Universities in China; Fundamental Research Funds for the Central University	This study was supported by the National Natural Science Foundation of China (Grant No. 31930108), the National Key Research and Development Program of China (Grant No. 2017YFD0501201), the Fundamental Research Funds for the Central Universities in China (Project: 2662020DKPY016) and the Fundamental Research Funds for the Central University (Grant No. 2662019PY001).	Asada M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035227; Beeson JG, 2016, FEMS MICROBIOL REV, V40, P343, DOI 10.1093/femsre/fuw001; Berens SJ, 2005, INFECT IMMUN, V73, P7180, DOI 10.1128/IAI.73.11.7180-7189.2005; Boyle MJ, 2014, INFECT IMMUN, V82, P924, DOI 10.1128/IAI.00866-13; Carcy B, 2006, VET PARASITOL, V138, P33, DOI 10.1016/j.vetpar.2006.01.038; Cowman AF, 2006, CELL, V124, P755, DOI 10.1016/j.cell.2006.02.006; Delbecq S, 2002, PARASITOLOGY, V125, P305, DOI 10.1017/S0031182002002160; Delbecq S, 2008, J MOL BIOL, V375, P409, DOI 10.1016/j.jmb.2007.08.019; Dluzewski AR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003085; Dominguez M, 2010, VET PARASITOL, V167, P216, DOI 10.1016/j.vetpar.2009.09.023; Dubremetz JF, 1998, INT J PARASITOL, V28, P1007, DOI 10.1016/S0020-7519(98)00076-9; Ejigiri I, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002725; Rodriguez AE, 2014, TICKS TICK-BORNE DIS, V5, P343, DOI 10.1016/j.ttbdis.2013.12.011; Rodriguez AE, 2010, VET PARASITOL, V167, P227, DOI 10.1016/j.vetpar.2009.09.024; Flores DA, 2020, VET PARASITOL, V287, DOI 10.1016/j.vetpar.2020.109275; Gallenti R, 2021, INT J PARASITOL, V51, P455, DOI 10.1016/j.ijpara.2020.10.010; Gohil S, 2010, TRENDS PARASITOL, V26, P591, DOI 10.1016/j.pt.2010.06.012; Guo JY, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-3018-y; He L, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-3038-7; He L, 2012, VET PARASITOL, V186, P490, DOI 10.1016/j.vetpar.2011.11.021; LeRoith T, 2006, INFECT IMMUN, V74, P3663, DOI 10.1128/IAI.00032-06; Lin CS, 2016, J BIOL CHEM, V291, P7703, DOI 10.1074/jbc.M115.698282; Liu Z., 1989, CHIN J VET SCI, V1, P61; Montero E, 2006, J BIOL CHEM, V281, P35717, DOI 10.1074/jbc.M604344200; Nie Z, 2020, PARASITOL RES, V119, P3639, DOI 10.1007/s00436-020-06877-z; Nikodem DP, 2000, MOL BIOCHEM PARASIT, V108, P79, DOI 10.1016/S0166-6851(00)00206-1; Schnittger L, 2012, INFECT GENET EVOL, V12, P1788, DOI 10.1016/j.meegid.2012.07.004; Shen B, 2014, MBIO, V5, DOI 10.1128/mBio.01795-14; Shu X, 2020, PARASITOL INT, V78, DOI 10.1016/j.parint.2020.102152; Singh SK, 2003, BIOCHEM J, V374, P193, DOI 10.1042/BJ20030622; Suarez CE, 2019, INT J PARASITOL, V49, P183, DOI 10.1016/j.ijpara.2018.11.002; Suarez CE, 2000, INFECT IMMUN, V68, P6865, DOI 10.1128/IAI.68.12.6865-6870.2000; Tattiyapong M, 2016, INFECT GENET EVOL, V41, P255, DOI 10.1016/j.meegid.2016.04.021; Tian Y, 2020, PARASITOL INT, V77, DOI 10.1016/j.parint.2020.102106; Woehlbier U, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-77; Wu MX, 2013, SCI REP-UK, V3, DOI 10.1038/srep03370; Yang YS, 2012, J BIOL CHEM, V287, P9495, DOI 10.1074/jbc.M111.260745; Zhan XY, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3457-0; Zimmer AJ., 2021, STATPEARLS	39	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 17	2021	12								623492	10.3389/fimmu.2021.623492	http://dx.doi.org/10.3389/fimmu.2021.623492			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SK3PQ	34079537	gold, Green Published			2022-12-18	WOS:000656131200001
J	Zhu, Z; Li, T; Chen, JY; Kumar, J; Kumar, P; Qin, J; Hadigan, C; Sereti, I; Baker, JV; Catalfamo, M				Zhu, Ziang; Li, Tong; Chen, Jinya; Kumar, Jai; Kumar, Princy; Qin, Jing; Hadigan, Colleen; Sereti, Irini; Baker, Jason V.; Catalfamo, Marta			The Role of Inflammation and Immune Activation on Circulating Endothelial Progenitor Cells in Chronic HIV Infection	FRONTIERS IN IMMUNOLOGY			English	Article						endothelial progenitor cells; HIV infection; endothelial inflammation; T cell activation; endothelial repair		Endothelial inflammation and damage are the main drivers of cardiovascular risk/disease. Endothelial repair is mediated in part by recruitment of bone marrow endothelial progenitor/endothelial colony forming cells (EPC/ECFC). People with HIV (PWH) have increased cardiovascular risk and the impact of infection in endothelial repair is not well defined. The low frequencies and challenges to in vitro isolation and differentiation of EPC/ECFC from PBMCs had made it difficult to study their role in this context. We hypothesized that HIV driven inflammation induces phenotypic changes that reflects the impact of infection. To test this hypothesis, we evaluated expression of markers of trafficking, endothelial differentiation, and angiogenesis, and study their association with biomarkers of inflammation in a cohort of PWH. In addition, we investigated the relationship of circulating endothelial progenitors and angiogenic T cells, a T cell subset with angiogenic function. Using a flow cytometry approach, we identified two subsets of circulating progenitors LIN4(-)CD45(-)CD34(+) and LIN4(-)CD45(dim)CD34(+) in PWH. We found that the phenotype but not frequencies were associated with biomarkers of inflammation. In addition, the percentage of LIN4(-)CD45(dim)CD34(+) was associated with serum levels of lipids. This data may provide a new tool to better address the impact of HIV infection in endothelial inflammation and repair.	[Zhu, Ziang; Li, Tong; Chen, Jinya; Catalfamo, Marta] Georgetown Univ, Sch Med, Dept Microbiol & Immunology, Washington, DC USA; [Kumar, Jai; Kumar, Princy] Georgetown Univ, Div Infect Dis & Trop Med, Sch Med, Washington, DC USA; [Qin, Jing] NIAID, Biostat Res Branch, Div Clin Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Hadigan, Colleen; Sereti, Irini] NIAID, Immunoregulat Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Baker, Jason V.] Univ Minnesota, Hennepin Healthcare Res Inst, Minneapolis, MN USA	Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Minnesota System; University of Minnesota Twin Cities	Catalfamo, M (corresponding author), Georgetown Univ, Sch Med, Dept Microbiol & Immunology, Washington, DC USA.	mc2151@georgetown.edu	Qin, Jing/J-9807-2016	Qin, Jing/0000-0002-7059-0929	National Institute of Allergy and Infectious Diseases of the National Institutes of Health [NIH R01AI145549-02]; Leidos Biomedical Research, Inc.; National Cancer Institute, NIH [HHSN261200800001E]; District of Columbia Center for AIDS Research, an NIH [P30AI117970]; NIH Co-Funding and Participating Institutes and Centers: NIAID; NCI; NICHD; NHLBI; NIDA; NIMH; NIA; NIDDK; NIMHD; NIDCR; NINR; FIC; OAR	National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Leidos Biomedical Research, Inc.; National Cancer Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); District of Columbia Center for AIDS Research, an NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Co-Funding and Participating Institutes and Centers: NIAID; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMHD; NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); FIC; OAR	Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number NIH R01AI145549-02. MC is supported in part by Leidos Biomedical Research, Inc. has been funded in whole or in part with federal funds from the National Cancer Institute, NIH, under Contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. MC is also supported in part by the District of Columbia Center for AIDS Research, an NIH funded program (P30AI117970), which is supported by the following NIH Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, NIDDK, NIMHD, NIDCR, NINR, FIC and OAR. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Baker J, 2010, HIV MED, V11, P608, DOI 10.1111/j.1468-1293.2010.00835.x; Baker JV, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx262; Baker JV, 2011, JAIDS-J ACQ IMM DEF, V56, P36, DOI 10.1097/QAI.0b013e3181f7f61a; Cimato TR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073861; Costiniuk CT, 2013, TRENDS CARDIOVAS MED, V23, P192, DOI 10.1016/j.tcm.2012.12.002; Costiniuk CT, 2012, J INFECT DIS, V205, P713, DOI 10.1093/infdis/jir836; Deeks SG, 2013, LANCET, V382, P1525, DOI 10.1016/S0140-6736(13)61809-7; Dong L, 2016, J AM SOC NEPHROL, V27, P1753, DOI 10.1681/ASN.2015050540; Echeverria P, 2017, J ANTIMICROB CHEMOTH, V72, P2049, DOI 10.1093/jac/dkx074; Estes ML, 2010, CYTOM PART A, V77A, P831, DOI 10.1002/cyto.a.20921; Fadini GP, 2012, CIRC RES, V110, P624, DOI 10.1161/CIRCRESAHA.111.243386; Freiberg MS, 2013, JAMA INTERN MED, V173, P614, DOI 10.1001/jamainternmed.2013.3728; Gomes AL, 2010, BLOOD, V115, P3886, DOI 10.1182/blood-2009-08-240580; Gomez-Garre D, 2012, JAIDS-J ACQ IMM DEF, V61, P545, DOI 10.1097/QAI.0b013e31826afbfc; Gupta SK, 2019, J INFECT DIS, V219, P1076, DOI 10.1093/infdis/jiy550; Guzik TJ, 2007, J EXP MED, V204, P2449, DOI 10.1084/jem.20070657; Hadigan C, 2017, JAMA CARDIOL, V2, P123, DOI 10.1001/jamacardio.2016.5177; Hays TR, 2015, JAIDS-J ACQ IMM DEF, V68, P550, DOI 10.1097/QAI.0000000000000506; Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287; Hirschi KK, 2008, ARTERIOSCL THROM VAS, V28, P1584, DOI 10.1161/ATVBAHA.107.155960; Hsue PY, 2012, J INFECT DIS, V205, pS375, DOI 10.1093/infdis/jis200; Hur J, 2007, CIRCULATION, V116, P1671, DOI 10.1161/CIRCULATIONAHA.107.694778; Ingram DA, 2005, BLOOD, V105, P2783, DOI 10.1182/blood-2004-08-3057; Ingram DA, 2004, BLOOD, V104, P2752, DOI 10.1182/blood-2004-04-1396; Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203; Lang JK, 2014, STEM CELL TRANSL MED, V3, P549, DOI 10.5966/sctm.2013-0205; Lopez M, 2012, J INFECT DIS, V206, P1479, DOI 10.1093/infdis/jis518; Lopez M, 2012, AIDS RES HUM RETROV, V28, P656, DOI [10.1089/aid.2011.0152, 10.1089/AID.2011.0152]; Medina RJ, 2017, STEM CELL TRANSL MED, V6, P1316, DOI 10.1002/sctm.16-0360; Mikolajczyk TP, 2019, CURR HYPERTENS REP, V21, DOI 10.1007/s11906-019-0971-6; Miller TL, 2010, JAIDS-J ACQ IMM DEF, V55, P182, DOI 10.1097/QAI.0b013e3181e222c9; Molina JM, 2018, LANCET HIV, V5, pE172, DOI 10.1016/S2352-3018(18)30003-1; Mudd JC, 2016, J INFECT DIS, V214, P1808, DOI 10.1093/infdis/jiw463; Mund JA, 2012, ARTERIOSCL THROM VAS, V32, P1045, DOI 10.1161/ATVBAHA.111.244210; Panigrahi S, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008885; Prasain N, 2014, NAT BIOTECHNOL, V32, P1151, DOI 10.1038/nbt.3048; Rennert RC, 2012, REGEN MED, V7, P833, DOI [10.2217/RME.12.82, 10.2217/rme.12.82]; Rossi F, 2010, MICROVASC RES, V80, P274, DOI 10.1016/j.mvr.2010.05.003; Schwarz TM, 2012, ARTERIOSCL THROM VAS, V32, pE13, DOI 10.1161/ATVBAHA.111.239822; Seang S, 2018, AIDS RES HUM RETROV, V34, P39, DOI [10.1089/aid.2017.0057, 10.1089/AID.2017.0057]; Shah ASV, 2018, CIRCULATION, V138, P1100, DOI 10.1161/CIRCULATIONAHA.117.033369; Teofili L, 2010, AIDS, V24, P2442, DOI 10.1097/QAD.0b013e32833ef79d; Triant VA, 2018, CIRCULATION, V137, P2203, DOI [10.1161/CIRCULATIONAHA.117.028975, 10.1161/circulationaha.117.028975]; Triant VA, 2013, CURR HIV-AIDS REP, V10, P199, DOI 10.1007/s11904-013-0168-6; Werner N, 2005, NEW ENGL J MED, V353, P999, DOI 10.1056/NEJMoa043814; Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471; Zhong DS, 2002, ARTERIOSCL THROM VAS, V22, P1560, DOI 10.1161/01.atv.0000034707.40046.02	48	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 17	2021	12								663412	10.3389/fimmu.2021.663412	http://dx.doi.org/10.3389/fimmu.2021.663412			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SK3OE	34079548	Green Published, gold			2022-12-18	WOS:000656127300001
J	Xiao, HT; Zhang, JS; Wang, K; Song, K; Zheng, HL; Yang, J; Li, KR; Yuan, RQ; Zhao, WY; Hui, Y				Xiao, Huiting; Zhang, Jiashuai; Wang, Kai; Song, Kai; Zheng, Hailong; Yang, Jing; Li, Keru; Yuan, Rongqiang; Zhao, Wenyuan; Hui, Yang			A Cancer-Specific Qualitative Method for Estimating the Proportion of Tumor-Infiltrating Immune Cells	FRONTIERS IN IMMUNOLOGY			English	Article						tumor microenvironment; relative expression orderings; signature genes; prognosis; immunotherapy	CONTEXTURE	Tumor-infiltrating immune cells are important components in the tumor microenvironment (TME) and different types of these cells exert different effects on tumor development and progression; these effects depend upon the type of cancer involved. Several methods have been developed for estimating the proportion of immune cells using bulk transcriptome data. However, there is a distinct lack of methods that are capable of predicting the immune contexture in specific types of cancer. Furthermore, the existing methods are based on absolute gene expression and are susceptible to experimental batch effects, thus resulting in incomparability across different datasets. In this study, we considered two common neoplasms as examples (colorectal cancer [CRC] and melanoma) and introduced the Tumor-infiltrating Immune Cell Proportion Estimator (TICPE), a cancer-specific qualitative method for estimating the proportion of tumor-infiltrating immune cells. The TICPE was based on the relative expression orderings (REOs) of gene pairs within a sample and is notably insensitive to batch effects. Performance evaluation using public expression data with mRNA mixtures, single-cell RNA-Seq (scRNA-Seq) data, immunohistochemistry data, and simulated bulk RNA-seq samples, indicated that the TICPE can estimate the proportion of immune cells with levels of accuracy that are clearly superior to other methods. Furthermore, we showed that the TICPE could effectively detect prognostic signals in patients with tumors and changes in the fractions of immune cells during immunotherapy in melanoma. In conclusion, our work presented a unique novel method, TICPE, to estimate the proportion of immune cells in specific cancer types and explore the effect of the infiltration of immune cells on the efficacy of immunotherapy and the prognosis of cancer. The source code for TICPE is available at https://github.com/huitingxiao/TICPE.	[Xiao, Huiting; Zhang, Jiashuai; Wang, Kai; Song, Kai; Zheng, Hailong; Yang, Jing; Li, Keru; Yuan, Rongqiang; Zhao, Wenyuan] Harbin Med Univ, Coll Bioinformat Sci & Technol, Dept Syst Biol, Harbin, Peoples R China; [Wang, Kai; Hui, Yang] Harbin Med Univ, Dept Biochem & Mol Biol, Harbin, Peoples R China	Harbin Medical University; Harbin Medical University	Zhao, WY (corresponding author), Harbin Med Univ, Coll Bioinformat Sci & Technol, Dept Syst Biol, Harbin, Peoples R China.; Hui, Y (corresponding author), Harbin Med Univ, Dept Biochem & Mol Biol, Harbin, Peoples R China.	zhaowenyuan@ems.hrbmu.edu.cn; huiyang79@126.com			National Natural Science Foundation of China [81872396]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China under Grant: 81872396.	Angelova M, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0620-6; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Aran D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9971; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Bland JM, 2004, BRIT MED J, V328, P1073, DOI 10.1136/bmj.328.7447.1073; Bruni D, 2020, NAT REV CANCER, V20, P662, DOI 10.1038/s41568-020-0285-7; Chen ZY, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbaa358; de Wolf C, 2018, CYTOTHERAPY, V20, P601, DOI 10.1016/j.jcyt.2018.01.011; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Eroglu Z, 2018, NATURE, V553, P347, DOI 10.1038/nature25187; Finotello F, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0638-6; Finotello F, 2018, CANCER IMMUNOL IMMUN, V67, P1031, DOI 10.1007/s00262-018-2150-z; Fridman WH, 2017, NAT REV CLIN ONCOL, V14, P717, DOI 10.1038/nrclinonc.2017.101; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Frishberg A, 2015, BIOINFORMATICS, V31, P3961, DOI 10.1093/bioinformatics/btv498; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Guo L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01052; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Korthauer K, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1716-1; Lan JQ, 2019, CANCER RES, V79, P146, DOI 10.1158/0008-5472.CAN-18-0014; Lazar C, 2013, BRIEF BIOINFORM, V14, P469, DOI 10.1093/bib/bbs037; Li B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1028-7; Maibach F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02105; Manoharan M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03017; Miao YR, 2020, ADV SCI, V7, DOI 10.1002/advs.201902880; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Nishikawa H, 2014, CURR OPIN IMMUNOL, V27, P1, DOI 10.1016/j.coi.2013.12.005; Oh S, 2008, P NATL ACAD SCI USA, V105, P5201, DOI 10.1073/pnas.0801003105; Patil P, 2015, BIOINFORMATICS, V31, P2318, DOI 10.1093/bioinformatics/btv157; Petitprez F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00784; Qi LS, 2017, MOL ONCOL, V11, P1630, DOI 10.1002/1878-0261.12137; Racle J, 2017, ELIFE, V6, DOI 10.7554/eLife.26476; Iraolagoitia XLR, 2016, J IMMUNOL, V197, P953, DOI 10.4049/jimmunol.1502291; Sideras K, 2018, J SURG ONCOL, V118, P68, DOI 10.1002/jso.25091; Sturm G, 2019, BIOINFORMATICS, V35, pI436, DOI 10.1093/bioinformatics/btz363; Subrahmanyam PB, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0328-8; Tang D, 2020, BIOINFORMATICS, V36, P1344, DOI 10.1093/bioinformatics/btz748; Tietze JK, 2017, EUR J CANCER, V75, P268, DOI 10.1016/j.ejca.2016.12.031; Wang HW, 2015, BIOINFORMATICS, V31, P62, DOI 10.1093/bioinformatics/btu522	39	0	0	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 14	2021	12								672031	10.3389/fimmu.2021.672031	http://dx.doi.org/10.3389/fimmu.2021.672031			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SJ6HM	34054849	gold, Green Published			2022-12-18	WOS:000655633800001
J	Aleman, OR; Mora, N; Rosales, C				Aleman, Omar Rafael; Mora, Nancy; Rosales, Carlos			The Antibody Receptor Fc Gamma Receptor IIIb Induces Calcium Entry via Transient Receptor Potential Melastatin 2 in Human Neutrophils	FRONTIERS IN IMMUNOLOGY			English	Article						neutrophil; Fc gamma receptor; calcium; reactive oxygen species; PKC (protein kinase C); TRPM2 cation channel	OXIDATIVE STRESS; ACTIVATION; MECHANISMS; CHANNELS; OXIDASE	Human neutrophils express two unique antibody receptors for IgG, the Fc gamma RIIa and the Fc gamma RIIIb. Fc gamma RIIa contains an immunoreceptor tyrosine-based activation motif (ITAM) sequence within its cytoplasmic tail, which is important for initiating signaling. In contrast, Fc gamma RIIIb is a glycosylphosphatidylinositol (GPI)-linked receptor with no cytoplasmic tail. Although, the initial signaling mechanism for Fc gamma RIIIb remains unknown, it is clear that both receptors are capable of initiating distinct neutrophil cellular functions. For example, Fc gamma RIIa is known to induce an increase in L-selectin expression and efficient phagocytosis, while Fc gamma RIIIb does not promote these responses. In contrast, Fc gamma RIIIb has been reported to induce actin polymerization, activation of beta 1 integrins, and formation of neutrophils extracellular traps (NET) much more efficiently than Fc gamma RIIa. Another function where these receptors seem to act differently is the increase of cytoplasmic calcium concentration. It has been known for a long time that Fc gamma RIIa induces production of inositol triphosphate (IP3) to release calcium from intracellular stores, while Fc gamma RIIIb does not use this phospholipid. Thus, the mechanism for Fc gamma RIIIb-mediated calcium rise remains unknown. Transient Receptor Potential Melastatin 2 (TRPM2) is a calcium permeable channel expressed in many cell types including vascular smooth cells, endothelial cells and leukocytes. TRPM2 can be activated by protein kinase C (PKC) and by oxidative stress. Because we previously found that Fc gamma RIIIb stimulation leading to NET formation involves PKC activation and reactive oxygen species (ROS) production, in this report we explored whether TRPM2 is activated via Fc gamma RIIIb and mediates calcium rise in human neutrophils. Calcium rise was monitored after Fc gamma receptors were stimulated by specific monoclonal antibodies in Fura-2-loaded neutrophils. The bacterial peptide fMLF and Fc gamma RIIa induced a calcium rise coming initially from internal pools. In contrast, Fc gamma RIIIb caused a calcium rise by inducing calcium entry from the extracellular medium. In addition, in the presence of 2-aminoethoxydiphenyl borate (2-APB) or of clotrimazole, two inhibitors of TRPM2, Fc gamma RIIIb-induced calcium rise was blocked. fMLF- or Fc gamma RIIa-induced calcium rise was not affected by these inhibitors. These data suggest for the first time that Fc gamma RIIIb aggregation activates TRPM2, to induce an increase in cytoplasmic calcium concentration through calcium internalization in human neutrophils.	[Aleman, Omar Rafael; Mora, Nancy; Rosales, Carlos] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Inmunol, Mexico City, DF, Mexico	Universidad Nacional Autonoma de Mexico	Rosales, C (corresponding author), Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Inmunol, Mexico City, DF, Mexico.	carosal@unam.mx		Aleman, Omar Rafael/0000-0001-5464-6171	Consejo Nacional de Ciencia y Tecnologia (CONACyT), Mexico [254434]; Direccion General de Asuntos del Personal Academico, Universidad Nacional Autonoma de Mexico (UNAM), Mexico [PAPIIT IN202520]	Consejo Nacional de Ciencia y Tecnologia (CONACyT), Mexico(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Direccion General de Asuntos del Personal Academico, Universidad Nacional Autonoma de Mexico (UNAM), Mexico	Research was supported by grant 254434 from Consejo Nacional de Ciencia y Tecnologi ' a (CONACyT), Mexico, and by grant PAPIIT IN202520 from Direccio ' n General de Asuntos del Personal Acade ' mico, Universidad Nacional Auto ' noma de Me ' xico (UNAM), Mexico.	Anderson R, 1997, CLIN EXP IMMUNOL, V110, P132, DOI 10.1046/j.1365-2249.1997.5051403.x; Asehnoune K, 2005, CELL SIGNAL, V17, P385, DOI 10.1016/j.cellsig.2004.08.005; Bagur R, 2017, MOL CELL, V66, P780, DOI 10.1016/j.molcel.2017.05.028; Balasubramanian N, 2002, LEUKEMIA RES, V26, P67, DOI 10.1016/S0145-2126(01)00098-4; Behnen M, 2014, J IMMUNOL, V193, P1954, DOI 10.4049/jimmunol.1400478; Borregaard N, 2010, IMMUNITY, V33, P657, DOI 10.1016/j.immuni.2010.11.011; Cai CQ, 2013, BIOCHEM BIOPH RES CO, V430, P816, DOI 10.1016/j.bbrc.2012.11.063; Chung MK, 2015, NEUROSCIENCE, V297, P160, DOI 10.1016/j.neuroscience.2015.03.067; Clemens RA, 2015, J LEUKOCYTE BIOL, V98, P497, DOI 10.1189/jlb.2MR1114-573R; Cruz-Torres I, 2020, MOL PHARMACOL, V97, P102, DOI 10.1124/mol.119.117549; DeHaven WI, 2009, J PHYSIOL-LONDON, V587, P2275, DOI 10.1113/jphysiol.2009.170431; Demaurex N, 2018, J PHYSIOL-LONDON, V596, P2699, DOI 10.1113/JP275639; Demaurex N, 2016, AM J PHYSIOL-CELL PH, V310, pC496, DOI 10.1152/ajpcell.00360.2015; Du JY, 2009, J GEN PHYSIOL, V134, P471, DOI 10.1085/jgp.200910254; Dupre-Crochet S, 2013, J LEUKOCYTE BIOL, V94, P657, DOI 10.1189/jlb.1012544; Edberg JC, 1998, J BIOL CHEM, V273, P8071, DOI 10.1074/jbc.273.14.8071; Eisfeld J., 2007, V179, P237; Fine N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.571085; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; Fliegert R, 2017, NAT CHEM BIOL, V13, P1036, DOI [10.1038/nchembio.2415, 10.1038/NCHEMBIO.2415]; Flockerzi V, 2014, HANDB EXP PHARMACOL, V222, P1, DOI 10.1007/978-3-642-54215-2_1; FRUMAN DA, 1991, AGENTS ACTIONS, V34, P16, DOI 10.1007/BF01993225; Futosi K, 2013, INT IMMUNOPHARMACOL, V17, P638, DOI 10.1016/j.intimp.2013.06.034; Gamberucci A, 2002, BIOCHEM J, V364, P245, DOI 10.1042/bj3640245; Garcia-Garcia E, 2013, JOVE-J VIS EXP, DOI 10.3791/50410; Garcia-Garcia E, 2009, J IMMUNOL, V182, P4547, DOI 10.4049/jimmunol.0801468; Gray RD, 2013, J INFLAMM-LOND, V10, DOI 10.1186/1476-9255-10-12; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Ham HY, 2012, TOXICOL APPL PHARM, V258, P82, DOI 10.1016/j.taap.2011.10.010; Hann J, 2020, J LEUKOCYTE BIOL, V107, P285, DOI 10.1002/JLB.3RU0719-241R; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Heiner I, 2003, CELL CALCIUM, V33, P533, DOI 10.1016/S0143-4160(03)00058-7; Heiner I, 2003, BIOCHEM J, V371, P1045, DOI 10.1042/BJ20021975; Hill K, 2004, N-S ARCH PHARMACOL, V370, P227, DOI 10.1007/s00210-004-0981-y; HUNDT M, 1992, EUR J IMMUNOL, V22, P811, DOI 10.1002/eji.1830220327; Immler R, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12964; Itagaki K, 2003, J BIOL CHEM, V278, P27540, DOI 10.1074/jbc.M301763200; Jakus Z, 2009, J EXP MED, V206, P577, DOI 10.1084/jem.20081859; Jimenez I, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9122604; Keshari RS, 2013, J CELL BIOCHEM, V114, P532, DOI 10.1002/jcb.24391; KIMBERLY RP, 1990, J EXP MED, V171, P1239, DOI 10.1084/jem.171.4.1239; Knowles H, 2011, P NATL ACAD SCI USA, V108, P11578, DOI 10.1073/pnas.1010678108; KRAUSE KH, 1985, J CLIN INVEST, V76, P1348, DOI 10.1172/JCI112109; Kuhn FJP, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186481; Lepannetier S, 2016, CELL CALCIUM, V60, P373, DOI 10.1016/j.ceca.2016.09.002; Li J, 2017, FRONT BIOSCI-LANDMRK, V22, P1427, DOI 10.2741/4551; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Liew PX, 2019, PHYSIOL REV, V99, P1223, DOI 10.1152/physrev.00012.2018; LOONEY RJ, 1986, J IMMUNOL, V136, P1641; Lopez JJ, 2020, ADV EXP MED BIOL, V1131, P445, DOI 10.1007/978-3-030-12457-1_17; Lunz V, 2019, CELL CALCIUM, V77, P29, DOI 10.1016/j.ceca.2018.11.009; Luo X, 2018, CHEM BIOL DRUG DES, V91, P552, DOI 10.1111/cbdd.13119; Ma HT, 2008, J IMMUNOL, V180, P2233, DOI 10.4049/jimmunol.180.4.2233; Marois L, 2011, J BIOL CHEM, V286, P3509, DOI 10.1074/jbc.M110.169516; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mayadas TN, 2014, ANNU REV PATHOL-MECH, V9, P181, DOI 10.1146/annurev-pathol-020712-164023; Mortadza SAS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00407; Najder K, 2018, PFLUG ARCH EUR J PHY, V470, P1017, DOI 10.1007/s00424-018-2146-8; Nauseef WM, 2014, J IMMUNOL, V193, P5357, DOI 10.4049/jimmunol.1402580; Nauseef WM, 2014, NAT IMMUNOL, V15, P602, DOI 10.1038/ni.2921; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; Naziroglu M, 2007, NEUROCHEM RES, V32, P1990, DOI 10.1007/s11064-007-9386-x; Naziroglu M, 2017, J MOL NEUROSCI, V61, P425, DOI 10.1007/s12031-017-0882-4; Naziroglu M, 2013, J BIOENERG BIOMEMBR, V45, P541, DOI 10.1007/s10863-013-9524-x; Naziroglu M, 2011, NEUROCHEM RES, V36, P355, DOI 10.1007/s11064-010-0347-4; Nguyen GT, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00373; Nishida M, 2006, MICROCIRCULATION, V13, P535, DOI 10.1080/10739680600885111; Nunes P, 2010, J LEUKOCYTE BIOL, V88, P57, DOI 10.1189/jlb.0110028; Ogawa N, 2016, CELL CALCIUM, V60, P115, DOI 10.1016/j.ceca.2016.02.009; Ortiz-Stern A, 2005, J LEUKOCYTE BIOL, V77, P787, DOI 10.1189/jlb.0504310; Ovey IS, 2015, NEUROSCIENCE, V284, P225, DOI 10.1016/j.neuroscience.2014.09.078; Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105; Perraud AL, 2005, J BIOL CHEM, V280, P6138, DOI 10.1074/jbc.M411446200; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Putney JW, 2017, BBA-MOL CELL RES, V1864, P900, DOI 10.1016/j.bbamcr.2016.11.028; Qian XW, 2018, INNATE IMMUN-LONDON, V24, P122, DOI 10.1177/1753425918759181; Aleman OR, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00277; Aleman OR, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/2908034; Rivas-Fuentes S, 2010, CELL IMMUNOL, V263, P114, DOI 10.1016/j.cellimm.2010.03.006; Roberge S, 2014, CARDIOVASC RES, V103, P90, DOI 10.1093/cvr/cvu112; ROSALES C, 1991, J IMMUNOL, V146, P3937; ROSALES C, 1992, J BIOL CHEM, V267, P1443; Rosales C, 2007, SIGNAL TRANSDUCTION, V7, P386, DOI DOI 10.1002/SITA.200700141; Rosales C., 2013, ADV BIOSCI BIOTECHNO, V4, P21, DOI [10.4236/abb.2013.44A004, DOI 10.4236/ABB.2013.44A004]; Rosales C., 1992, J BIOL CHEM, V267, DOI [10.1016/S0021-9258(18)42761-5, DOI 10.1016/S0021-9258(18)42761-5]; Rosales C, 2020, J LEUKOCYTE BIOL, V108, P377, DOI 10.1002/JLB.4MIR0220-574RR; Rosales C, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00113; Rosales C, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9042851; Rosales C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00280; Rosales Carlos, 2013, Current Immunology Reviews, V9, P44; Sakaguchi R, 2020, FREE RADICAL BIO MED, V146, P36, DOI 10.1016/j.freeradbiomed.2019.10.415; Salmon MD, 2011, INT IMMUNOPHARMACOL, V11, P145, DOI 10.1016/j.intimp.2010.11.006; Schepetkin IA, 2016, INT IMMUNOPHARMACOL, V37, P43, DOI 10.1016/j.intimp.2015.08.036; Scrimgeour N, 2009, J PHYSIOL-LONDON, V587, P2903, DOI 10.1113/jphysiol.2009.170662; Steinckwich N, 2011, J IMMUNOL, V186, P2182, DOI 10.4049/jimmunol.1001338; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; Sumoza-Toledo A, 2011, FASEB J, V25, P3529, DOI 10.1096/fj.10-178483; Sumoza-Toledo A, 2011, J PHYSIOL-LONDON, V589, P1515, DOI 10.1113/jphysiol.2010.201855; Togashi K, 2008, BRIT J PHARMACOL, V153, P1324, DOI 10.1038/sj.bjp.0707675; Tripathi JK, 2018, FASEB J, V32, P6848, DOI 10.1096/fj.201800605; Underhill DM, 2007, TRENDS IMMUNOL, V28, P66, DOI 10.1016/j.it.2006.12.004; Uribe-Querol E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01066; Varnai P, 2009, TRENDS PHARMACOL SCI, V30, P118, DOI 10.1016/j.tips.2008.11.005; VERHOEVEN AJ, 1993, J BIOL CHEM, V268, P18593; Wang G, 2016, DEV CELL, V38, P453, DOI 10.1016/j.devcel.2016.07.014; Wang LF, 2020, CURR OPIN IMMUNOL, V62, P131, DOI 10.1016/j.coi.2020.01.005; Xia SY, 2019, FEBS J, V286, P3333, DOI 10.1111/febs.14939; Yu PL, 2017, J GEN PHYSIOL, V149, P219, DOI 10.1085/jgp.201611675; Zeng MY, 2019, MOL ORAL MICROBIOL, V34, P27, DOI 10.1111/omi.12252; Zhang ZQ, 2017, ANESTHESIOLOGY, V126, P128, DOI 10.1097/ALN.0000000000001430; Zhong ZY, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2608	111	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 13	2021	12								657393	10.3389/fimmu.2021.657393	http://dx.doi.org/10.3389/fimmu.2021.657393			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SI7SY	34054821	Green Published, gold			2022-12-18	WOS:000655032100001
J	Choreno-Parra, JA; Jimenez-Alvarez, LA; Ramirez-Martinez, G; Sandoval-Vega, M; Salinas-Lara, C; Sanchez-Garibay, C; Luna-Rivero, C; Hernandez-Montiel, EM; Fernandez-Lopez, LA; Cabrera-Cornejo, MF; Choreno-Parra, EM; Cruz-Lagunas, A; Dominguez, A; Marquez-Garcia, E; Cabello-Gutierrez, C; Bolanos-Morales, FV; Mena-Hernandez, L; Delgado-Zaldivar, D; Rebolledo-Garcia, D; Guadarrama-Ortiz, P; Regino-Zamarripa, NE; Mendoza-Milla, C; Garcia-Latorre, EA; Rodriguez-Reyna, TS; Cervantes-Rosete, D; Hernandez-Cardenas, CM; Khader, SA; Zlotnik, A; Zuniga, J				Choreno-Parra, Jose Alberto; Jimenez-Alvarez, Luis Armando; Ramirez-Martinez, Gustavo; Sandoval-Vega, Montserrat; Salinas-Lara, Citlaltepetl; Sanchez-Garibay, Carlos; Luna-Rivero, Cesar; Hernandez-Montiel, Erika Mariana; Fernandez-Lopez, Luis Alejandro; Cabrera-Cornejo, Maria Fernanda; Choreno-Parra, Eduardo Misael; Cruz-Lagunas, Alfredo; Dominguez, Andrea; Marquez-Garcia, Eduardo; Cabello-Gutierrez, Carlos; Bolanos-Morales, Francina Valezka; Mena-Hernandez, Lourdes; Delgado-Zaldivar, Diego; Rebolledo-Garcia, Daniel; Guadarrama-Ortiz, Parmenides; Regino-Zamarripa, Nora E.; Mendoza-Milla, Criselda; Garcia-Latorre, Ethel A.; Rodriguez-Reyna, Tatiana Sofia; Cervantes-Rosete, Diana; Hernandez-Cardenas, Carmen M.; Khader, Shabaana A.; Zlotnik, Albert; Zuniga, Joaquin			CXCL17 Is a Specific Diagnostic Biomarker for Severe Pandemic Influenza A(H1N1) That Predicts Poor Clinical Outcome (vol 12, 633297, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						SARS-CoV-2; COVID-19; tuberculosis; chemokines; CXCL17			[Choreno-Parra, Jose Alberto; Fernandez-Lopez, Luis Alejandro; Regino-Zamarripa, Nora E.; Garcia-Latorre, Ethel A.] Inst Politecn Nacl, Escuela Nacl Ciencias Biol, Mexico City, DF, Mexico; [Choreno-Parra, Jose Alberto; Jimenez-Alvarez, Luis Armando; Ramirez-Martinez, Gustavo; Hernandez-Montiel, Erika Mariana; Fernandez-Lopez, Luis Alejandro; Cabrera-Cornejo, Maria Fernanda; Cruz-Lagunas, Alfredo; Dominguez, Andrea; Marquez-Garcia, Eduardo; Regino-Zamarripa, Nora E.; Zuniga, Joaquin] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Lab Inmunobiol & Genet, Mexico City, DF, Mexico; [Sandoval-Vega, Montserrat] Univ Nacl Autonoma Mexico, Fac Estudios Super Iztacala, Mexico City, DF, Mexico; [Salinas-Lara, Citlaltepetl; Sanchez-Garibay, Carlos] Inst Nacl Neurol & Neurocirugia Manuel Velasco Su, Dept Neuropatol, Mexico City, DF, Mexico; [Luna-Rivero, Cesar] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Dept Pathol, Mexico City, DF, Mexico; [Hernandez-Montiel, Erika Mariana; Cabrera-Cornejo, Maria Fernanda; Dominguez, Andrea; Regino-Zamarripa, Nora E.; Zuniga, Joaquin] Escuela Med & Ciencias Salud, Tecnol Monterrey, Mexico City, DF, Mexico; [Choreno-Parra, Eduardo Misael] Univ Nacl Autonoma Mexico, Posgrad Ciencias Biol, Mexico City, DF, Mexico; [Cabello-Gutierrez, Carlos] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Dept Virol, Mexico City, DF, Mexico; [Bolanos-Morales, Francina Valezka] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Subdirect Surg, Mexico City, DF, Mexico; [Mena-Hernandez, Lourdes; Delgado-Zaldivar, Diego; Rebolledo-Garcia, Daniel] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Dermatol, Mexico City, DF, Mexico; [Mena-Hernandez, Lourdes; Delgado-Zaldivar, Diego; Rebolledo-Garcia, Daniel] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Educ, Mexico City, DF, Mexico; [Guadarrama-Ortiz, Parmenides] Ctr Especializado Neurocirugia & Neurociencias Me, Mexico City, DF, Mexico; [Mendoza-Milla, Criselda] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Dept Fibrosis Pulm, Mexico City, DF, Mexico; [Rodriguez-Reyna, Tatiana Sofia; Cervantes-Rosete, Diana] Inst Ciencias Med & Nutr Salvador Zubiran, Dept Immunol & Rheumatol, Mexico City, DF, Mexico; [Hernandez-Cardenas, Carmen M.] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Resp Crit Care Unit, Mexico City, DF, Mexico; [Khader, Shabaana A.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; [Zlotnik, Albert] Univ Calif Irvine, Sch Med, Inst Immunol, Dept Physiol & Biophys, Irvine, CA 92717 USA	Instituto Politecnico Nacional - Mexico; Universidad Nacional Autonoma de Mexico; Tecnologico de Monterrey; Universidad Nacional Autonoma de Mexico; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Washington University (WUSTL); University of California System; University of California Irvine	Zuniga, J (corresponding author), Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Lab Inmunobiol & Genet, Mexico City, DF, Mexico.; Zuniga, J (corresponding author), Escuela Med & Ciencias Salud, Tecnol Monterrey, Mexico City, DF, Mexico.	joazu@yahoo.com	Choreño-Parra, José Alberto/ABB-2062-2021	A Khader, Shabaana/0000-0002-9545-4982; Sanchez-Garibay, Carlos/0000-0002-0637-5239; Fernandez-Lopez, Luis Alejandro/0000-0002-8680-1751				Choreno-Parra JA, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.633297	1	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 13	2021	12								700716	10.3389/fimmu.2021.700716	http://dx.doi.org/10.3389/fimmu.2021.700716			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SI9UK	34054884	Green Published, gold			2022-12-18	WOS:000655173600001
J	Mariani, E; Frasca, D				Mariani, Erminia; Frasca, Daniela			Editorial: Immunobiology of Osteoarticular Diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						rheumatic diseases; osteoarticular diseases; osteoarthritis; rheumatoid anhritis; osteoporosis; Inflammation; immunological mechanisms; diagnosis			[Mariani, Erminia] Ist Ortoped Rizzoli, Ist Ricovero & Cura Carattere Sci IRCCS, Lab Immunorheumatol & Tissue Regenerat, Bologna, Italy; [Mariani, Erminia] Alma Mater Studiorum Univ Bologna, Dept Med & Surg Sci, Bologna, Italy; [Frasca, Daniela] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA; [Frasca, Daniela] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA	Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Istituto Ortopedico Rizzoli; University of Bologna; University of Miami; University of Miami	Mariani, E (corresponding author), Ist Ortoped Rizzoli, Ist Ricovero & Cura Carattere Sci IRCCS, Lab Immunorheumatol & Tissue Regenerat, Bologna, Italy.; Mariani, E (corresponding author), Alma Mater Studiorum Univ Bologna, Dept Med & Surg Sci, Bologna, Italy.	erminia.mariani@unibo.it							0	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 13	2021	12								698992	10.3389/fimmu.2021.698992	http://dx.doi.org/10.3389/fimmu.2021.698992			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SI9UE	34054882	Green Published, gold			2022-12-18	WOS:000655173000001
J	Chen, TT; Cao, Q; Wang, RF; Zheng, GP; Azmi, F; Wang, J; Lee, VW; Wang, YM; Yu, H; Patel, M; P'ng, CH; Alexander, SI; Rogers, NM; Wang, YP; Harris, DCH				Chen, Titi; Cao, Qi; Wang, Ruifeng; Zheng, Guoping; Azmi, Farhana; Wang, Jeffery; Lee, Vincent W.; Wang, Yuan Min; Yu, Hong; Patel, Manish; P'ng, Chow Heok; Alexander, Stephen, I; Rogers, Natasha M.; Wang, Yiping; Harris, David C. H.			Conventional Type 1 Dendritic Cells (cDC1) in Human Kidney Diseases: Clinico-Pathological Correlations	FRONTIERS IN IMMUNOLOGY			English	Article						dendritic cells; CD141(+) DCs; conventional DCs; crescent; interstitial fibrosis; glomerulonephritis; acute tubular necrosis	TISSUE	Background cDC1 is a subset of conventional DCs, whose most recognized function is cross-presentation to CD8(+) T cells. We conducted this study to investigate the number and location of cDC1s in various human kidney diseases as well as their correlation with clinico-pathological features and CD8(+) T cells. Methods We analyzed 135 kidney biopsies samples. Kidney diseases included: acute tubular necrosis (ATN), acute interstitial nephritis (AIN), proliferative glomerulonephritis (GN) (IgA nephropathy, lupus nephritis, pauci-immune GN, anti-GBM disease), non-proliferative GN (minimal change disease, membranous nephropathy) and diabetic nephropathy. Indirect immunofluorescence staining was used to quantify cDC1s, CD1c(+) DCs, and CD8(+) T cells. Results cDC1s were rarely present in normal kidneys. Their number increased significantly in ATN and proliferative GN, proportionally much more than CD1c(+) DCs. cDC1s were mainly found in the interstitium, except in lupus nephritis, pauci-immune GN and anti-GBM disease, where they were prominent in glomeruli and peri-glomerular regions. The number of cDC1s correlated with disease severity in ATN, number of crescents in pauci-immune GN, interstitial fibrosis in IgA nephropathy and lupus nephritis, as well as prognosis in IgA nephropathy. The number of CD8(+) T cells also increased significantly in these conditions and cDC1 number correlated with CD8(+) T cell number in lupus nephritis and pauci-immune GN, with many of them closely co-localized. Conclusions cDC1 number correlated with various clinic-pathological features and prognosis reflecting a possible role in these conditions. Their association with CD8(+) T cells suggests a combined mechanism in keeping with the results in animal models.	[Chen, Titi; Cao, Qi; Zheng, Guoping; Azmi, Farhana; Wang, Jeffery; Lee, Vincent W.; Patel, Manish; Rogers, Natasha M.; Wang, Yiping; Harris, David C. H.] Univ Sydney, Sch Med, Camperdown, NSW, Australia; [Chen, Titi; Cao, Qi; Wang, Ruifeng; Zheng, Guoping; Azmi, Farhana; Wang, Jeffery; Lee, Vincent W.; Yu, Hong; Rogers, Natasha M.; Wang, Yiping; Harris, David C. H.] Westmead Inst Med Res, Ctr Transylant & Renal Res, Westmead, NSW, Australia; [Chen, Titi; Lee, Vincent W.; Rogers, Natasha M.; Harris, David C. H.] Westmead Hosp, Dept Renal Med, Westmead, NSW, Australia; [P'ng, Chow Heok] Westmead Hosp, Dept Anat Pathol, Westmead, NSW, Australia; [Patel, Manish] Westmead Hosp, Dept Urol, Westmead, NSW, Australia; [Wang, Yuan Min; Alexander, Stephen, I] Childrens Hosp Westmead, Ctr Kidney Res, Sydney, NSW, Australia	University of Sydney; University of Sydney; Westmead Institute for Medical Research; University of Sydney; University of Sydney; University of Sydney; University of Sydney	Chen, TT (corresponding author), Univ Sydney, Sch Med, Camperdown, NSW, Australia.; Chen, TT (corresponding author), Westmead Inst Med Res, Ctr Transylant & Renal Res, Westmead, NSW, Australia.; Chen, TT (corresponding author), Westmead Hosp, Dept Renal Med, Westmead, NSW, Australia.	titi.chen@sydney.edu.au	Lee, Vincent/H-6468-2019; Wang, Yixuan/GZK-6559-2022; wang, yi/GVT-8516-2022; Wang, Yin/HCI-9352-2022; Wang, Yu/GZL-9655-2022; Wang, Yijun/GXW-1763-2022; wangwangwang, yuanyaun/HHN-6432-2022; wang, yixuan/GXW-2866-2022	Lee, Vincent/0000-0002-9400-3696; Azmi, Farhana/0000-0003-2658-4609; zheng, guoping/0000-0002-5551-4522	National Health and Medical Research Council of Australia [APP1141330]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by the National Health and Medical Research Council of Australia (grant APP1141330).	Aasarod K, 2001, SCAND J UROL NEPHROL, V35, P401; Almaani S, 2017, CLIN J AM SOC NEPHRO, V12, P825, DOI 10.2215/CJN.05780616; Arazi A, 2019, NAT IMMUNOL, V20, P902, DOI 10.1038/s41590-019-0398-x; Atamas SP, 1999, ARTHRITIS RHEUM, V42, P1168, DOI 10.1002/1529-0131(199906)42:6<1168::AID-ANR13>3.0.CO;2-L; Bagavant H, 2009, CURR OPIN RHEUMATOL, V21, P489, DOI 10.1097/BOR.0b013e32832efff1; Blanco P, 2005, ARTHRITIS RHEUM, V52, P201, DOI 10.1002/art.20745; Bottcher JP, 2018, CELL, V172, P1022, DOI 10.1016/j.cell.2018.01.004; Brahler S, 2018, J AM SOC NEPHROL, V29, P138, DOI 10.1681/ASN.2017030270; Brodeur TY, 2015, J IMMUNOL, V195, P5251, DOI 10.4049/jimmunol.1500777; Cao Q, 2016, J AM SOC NEPHROL, V27, P1344, DOI 10.1681/ASN.2015030229; Chang J, 2017, J AM SOC NEPHROL, V28, P47, DOI 10.1681/ASN.2015121356; Chen AQ, 2020, NEPHROL DIAL TRANSPL, V35, P564, DOI 10.1093/ndt/gfz043; Chen AQ, 2018, J CLIN INVEST, V128, P3413, DOI 10.1172/JCI97879; Couzi L, 2007, ARTHRITIS RHEUM, V56, P2362, DOI 10.1002/art.22654; Crow MK, 2014, J IMMUNOL, V192, P5459, DOI 10.4049/jimmunol.1002795; Cunningham MA, 1999, J AM SOC NEPHROL, V10, P499; Daniil Z, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-81; Der E, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93009; Ding L, 2016, J IMMUNOL, V197, P303, DOI 10.4049/jimmunol.1502479; Dolff S, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4189; Dolff S, 2010, ANN RHEUM DIS, V69, P2034, DOI 10.1136/ard.2009.124636; Dong X, 2007, KIDNEY INT, V71, P619, DOI 10.1038/sj.ki.5002132; Evers BDG, 2016, J AM SOC NEPHROL, V27, P3368, DOI 10.1681/ASN.2015080873; Fiore N, 2008, MOL IMMUNOL, V45, P259, DOI 10.1016/j.molimm.2007.04.029; Guilliams M, 2016, IMMUNITY, V45, P669, DOI 10.1016/j.immuni.2016.08.015; Jongbloed SL, 2010, J EXP MED, V207, P1247, DOI 10.1084/jem.20092140; Kassianos AJ, 2013, AM J PHYSIOL-RENAL, V305, pF1391, DOI 10.1152/ajprenal.00318.2013; Kitching AR, 2018, J AM SOC NEPHROL, V29, P4, DOI 10.1681/ASN.2017101145; Kopetschke K, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0600-y; Lech M, 2009, J IMMUNOL, V183, P4109, DOI 10.4049/jimmunol.0900118; McKinney EF, 2010, NAT MED, V16, P586, DOI 10.1038/nm.2130; Merad M, 2013, ANNU REV IMMUNOL, V31, P563, DOI 10.1146/annurev-immunol-020711-074950; O'Sullivan KM, 2015, KIDNEY INT, V88, P1030, DOI 10.1038/ki.2015.202; Pakalniskyte D, 2017, ADV IMMUNOL, V134, P89, DOI 10.1016/bs.ai.2017.01.003; Segerer S, 2008, KIDNEY INT, V74, P37, DOI 10.1038/ki.2008.99; Snelgrove SL, 2017, TRANSPLANTATION, V101, P1013, DOI 10.1097/TP.0000000000001427; Suarez-Fueyo A, 2016, CURR OPIN IMMUNOL, V43, P32, DOI 10.1016/j.coi.2016.09.001; Tadagavadi RK, 2010, J AM SOC NEPHROL, V21, P53, DOI 10.1681/ASN.2009040407; van Es LA, 2008, KIDNEY INT, V73, P1426, DOI 10.1038/ki.2008.66; Villani AC, 2017, SCIENCE, V356, DOI 10.1126/science.aah4573; Wang RF, 2019, NEPHROL DIAL TRANSPL, V34, P1853, DOI 10.1093/ndt/gfy385; Weidner S, 2004, ARTHRITIS RHEUM-US, V50, P3651, DOI 10.1002/art.20607; Wilde B, 2009, NEPHROL DIAL TRANSPL, V24, P2151, DOI 10.1093/ndt/gfp019; Winchester R, 2012, ARTHRITIS RHEUM-US, V64, P1589, DOI 10.1002/art.33488; Woltman AM, 2007, KIDNEY INT, V71, P1001, DOI 10.1038/sj.ki.5002187; Ysebaert DK, 2000, NEPHROL DIAL TRANSPL, V15, P1562, DOI 10.1093/ndt/15.10.1562; Ysebaert DK, 2004, KIDNEY INT, V66, P491, DOI 10.1111/j.1523-1755.2004.761_4.x; Zickert A, 2016, LUPUS SCI MED, V3, DOI 10.1136/lupus-2016-000170	48	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2021	12								635212	10.3389/fimmu.2021.635212	http://dx.doi.org/10.3389/fimmu.2021.635212			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SH6DL	34054804	Green Published, gold			2022-12-18	WOS:000654225300001
J	Ghafouri-Fard, S; Hussen, BM; Nicknafs, F; Nazer, N; Sayad, A; Taheri, M				Ghafouri-Fard, Soudeh; Hussen, Bashdar Mahmud; Nicknafs, Fwad; Nazer, Naghme; Sayad, Arezou; Taheri, Mohammad			Expression Analysis of Protein Inhibitor of Activated STAT in Inflammatory Demyelinating Polyradiculoneuropathy	FRONTIERS IN IMMUNOLOGY			English	Article						protein inhibitor of activated STAT; PIAS; inflammatory demyelinating polyradiculoneuropathy; AIDP; CIDP	JAK/STAT PATHWAY; IMMUNE	Protein inhibitors of activated STAT (PIAS) are involved in the regulation of the JAK/STAT signaling pathway and have interactions with NF-kappa B, p73 and p53. These proteins regulate immune responses; therefore dysregulation in their expression leads to several immune-mediated disorders. In the present study, we examined expression of PIAS1-4 in peripheral blood of patients with acute/chronic inflammatory demyelinating polyradiculoneuropathy (AIDP/CIDP) compared with healthy subjects. We demonstrated down-regulation of all PIAS genes in both AIDP and CIDP cases compared with controls. Similarly, comparisons in gender-based groups revealed down-regulation of these gene0s in patients of each gender compared with gender-matched controls. There was no significant difference in expression of PIAS genes between AIDP and CIDP cases. Based on the area under the receiver operating characteristic curves, PIAS1-4 genes could distinguish between inflammatory demyelinating polyradiculoneuropathy and healthy status with accuracy values of 0.87, 0.87, 0.79 and 0.80, respectively. In differentiation between AIDP cases and healthy controls, these values were 0.92, 0.92, 0.83 and 0.86, respectively. Finally, PIAS1-4 genes could discriminate CIDP from healthy status with accuracy values of 0.82, 0.83, 0.75 and 0.75, respectively. The current study underscores the role of PIAS genes in the pathogenesis of inflammatory demyelinating polyradiculoneuropathy and their potential usage as biomarkers.	[Ghafouri-Fard, Soudeh; Nicknafs, Fwad; Sayad, Arezou] Shahid Beheshti Univ Med Sci, Dept Med Genet, Tehran, Iran; [Hussen, Bashdar Mahmud] Hawler Med Univ, Coll Pharm, Pharmacognosy Dept, Erbil, Iraq; [Nazer, Naghme] Sharif Univ Technol, Dept Elect Engn, Tehran, Iran; [Taheri, Mohammad] Shahid Beheshti Univ Med Sci, Loghman Hakim Hosp, Skull Base Res Ctr, Tehran, Iran	Shahid Beheshti University Medical Sciences; Hawler Medical University; Sharif University of Technology; Shahid Beheshti University Medical Sciences	Sayad, A (corresponding author), Shahid Beheshti Univ Med Sci, Dept Med Genet, Tehran, Iran.; Taheri, M (corresponding author), Shahid Beheshti Univ Med Sci, Loghman Hakim Hosp, Skull Base Res Ctr, Tehran, Iran.	ar.sayad@yahoo.com; Mohammad_823@yahoo.com	Sayad, Arezou/AAX-1349-2021; Taheri, Mohammad/AAC-7307-2019	Taheri, Mohammad/0000-0001-8381-0591	Shahid Beheshti University of Medical Sciences [18934]	Shahid Beheshti University of Medical Sciences	The current study was supported by a grant from Shahid Beheshti University of Medical Sciences (Grant number 18934).	Ali ZPM, 2020, J MOL NEUROSCI, V70, P945, DOI 10.1007/s12031-020-01494-y; Andorfer B, 2001, J NEUROIMMUNOL, V116, P226, DOI 10.1016/S0165-5728(01)00306-X; Arora T, 2003, J BIOL CHEM, V278, P21327, DOI 10.1074/jbc.C300119200; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; CORNBLATH DR, 1991, NEUROLOGY, V41, P617; Fornek JL, 2006, BLOOD, V107, P1085, DOI 10.1182/blood-2005-07-2871; Hayden MS, 2006, ONCOGENE, V25, P6758, DOI 10.1038/sj.onc.1209943; Huang P, 2020, J INT MED RES, V48, DOI 10.1177/0300060520904842; Li HYS, 2014, IMMUNOL REV, V261, P84, DOI 10.1111/imr.12198; Liu B, 2004, NAT IMMUNOL, V5, P891, DOI 10.1038/ni1104; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Malhotra N, 2013, IMMUNOLOGY, V139, P1, DOI 10.1111/imm.12076; Montoya MM, 2017, J IMMUNOL, V199, P559, DOI 10.4049/jimmunol.1700170; Nafar M, 2020, TRANSPL P, V52, P414, DOI 10.1016/j.transproceed.2019.10.006; Niu GJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02392; Nomair AM, 2019, EGYPTIAN J MED HUMAN, V20, DOI 10.1186/s43042-019-0021-6; O'Shea JJ, 2004, ANN RHEUM DIS, V63, P67, DOI 10.1136/ard.2004.028290; Peltier AC, 2012, SEMIN NEUROL, V32, P187, DOI 10.1055/s-0032-1329194; Sayad A, 2019, J CELL BIOCHEM, V120, P12937, DOI 10.1002/jcb.28564; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Shuai K, 2005, NAT REV IMMUNOL, V5, P593, DOI 10.1038/nri1667; Taheri M, 2018, J INFLAMM RES, V11, P457, DOI 10.2147/JIR.S187414; Ubogu EE, 2015, ACTA NEUROPATHOL, V130, P445, DOI 10.1007/s00401-015-1466-4; Van der Meche FGA, 2001, EUR NEUROL, V45, P133, DOI 10.1159/000052111; Welte T, 2003, P NATL ACAD SCI USA, V100, P1879, DOI 10.1073/PNAS.0237137100; Yagil Z, 2010, TRENDS IMMUNOL, V31, P199, DOI 10.1016/j.it.2010.01.005; Yang XXO, 2007, J BIOL CHEM, V282, P9358, DOI 10.1074/jbc.C600321200; Zhang L, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317719869; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	29	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2021	12								659038	10.3389/fimmu.2021.659038	http://dx.doi.org/10.3389/fimmu.2021.659038			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SH6CZ	34054823	gold, Green Published			2022-12-18	WOS:000654224000001
J	Goldberg-Murow, M; Cedillo-Pelaez, C; Concha-del-Rio, LE; Cheja-Kalb, R; Salgar-Henao, MJ; Orozco-Velasco, E; Luna-Pasten, H; Gomez-Chavez, F; Ibarra, A; Correa, D				Goldberg-Murow, Monica; Cedillo-Pelaez, Carlos; Elena Concha-del-Rio, Luz; Cheja-Kalb, Rashel; Jose Salgar-Henao, Maria; Orozco-Velasco, Eduardo; Luna-Pasten, Hector; Gomez-Chavez, Fernando; Ibarra, Antonio; Correa, Dolores			Autoantibodies Against Ubiquitous and Confined Antigens in Patients With Ocular, Neuro-Ophthalmic and Congenital Cerebral Toxoplasmosis	FRONTIERS IN IMMUNOLOGY			English	Article						Toxoplasma gondii; ocular toxoplasmosis; autoantibodies; HSP70; recoverin; hippocalcin; cerebral toxoplasmosis; cross-reactivity	RECOVERIN	Toxoplasma gondii infection can trigger autoreactivity by different mechanisms. In the case of ocular toxoplasmosis, disruption of the blood-retinal barrier may cause exposure of confined retinal antigens such as recoverin. Besides, cross-reactivity can be induced by molecular mimicry of parasite antigens like HSP70, which shares 76% identity with the human ortholog. Autoreactivity can be a determining factor of clinical manifestations in the eye and in the central nervous system. We performed a prospective observational study to determine the presence of autoantibodies against recoverin and HSP70 by indirect ELISA in the serum of 65 patients with ocular, neuro-ophthalmic and congenital cerebral toxoplasmosis. We found systemic autoantibodies against recoverin and HSP70 in 33.8% and 15.6% of individuals, respectively. The presence of autoantibodies in cases of OT may be related to the severity of clinical manifestations, while in cases with CNS involvement they may have a protective role. Unexpectedly, anti-recoverin antibodies were found in patients with cerebral involvement, without ocular toxoplasmosis; therefore, we analyzed and proved cross-reactivity between recoverin and a brain antigen, hippocalcin, so the immunological phenomenon occurring in one immune-privileged organ (e.g. the central nervous system) could affect the environment of another (egg. the eye).	[Goldberg-Murow, Monica; Cedillo-Pelaez, Carlos; Luna-Pasten, Hector; Gomez-Chavez, Fernando; Correa, Dolores] Inst Nacl Pediat, Lab Inmunol Expt, Cdmx, Mexico; [Goldberg-Murow, Monica; Ibarra, Antonio] Univ Anahuac, Ctr Invest Ciencias Salud, Huixquilucan, Mexico; [Elena Concha-del-Rio, Luz; Cheja-Kalb, Rashel; Jose Salgar-Henao, Maria; Orozco-Velasco, Eduardo] IAP, Assoc Evitar Ceguera Mexico, Clin Enfermedades Inflamatorias Oculares, Cdmx, Mexico; [Gomez-Chavez, Fernando] Inst Nacl Pediat, Catedras CONACyT, Cdmx, Mexico; [Gomez-Chavez, Fernando] ENMyH IPN, Dept Formac Basica Disciplinaria, Cdmx, Mexico; [Correa, Dolores] Univ Anahuac, Direcc Invest, Huixquilucan, Mexico	Universidad Anahuac; Universidad Anahuac	Correa, D (corresponding author), Inst Nacl Pediat, Lab Inmunol Expt, Cdmx, Mexico.; Ibarra, A (corresponding author), Univ Anahuac, Ctr Invest Ciencias Salud, Huixquilucan, Mexico.	jose.ibarra@anahuac.mx; mariadol@yahoo.com		Concha-del-Rio, Luz Elena/0000-0002-0081-7745	Centro de Investigacion en Ciencias de la Salud (CICSA), Mexic [201716]; FCS, Universidad Anahuac, Mexico; Instituto Nacional de Pediatria, Mexico [2016/034]	Centro de Investigacion en Ciencias de la Salud (CICSA), Mexic; FCS, Universidad Anahuac, Mexico; Instituto Nacional de Pediatria, Mexico	This work was partially financed by Centro de Investigacion en Ciencias de la Salud (CICSA) (project 201716), FCS, Universidad Anahuac and Instituto Nacional de Pediatria (project 2016/034), Mexico.	ABRAHAMS IW, 1982, AM J OPHTHALMOL, V93, P224, DOI 10.1016/0002-9394(82)90418-4; Aosai F, 2002, CELL STRESS CHAPERON, V7, P357, DOI 10.1379/1466-1268(2002)007<0357:TGDHSP>2.0.CO;2; Burgoyne RD, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a035154; Burnett AJ, 1998, OPHTHALMOLOGY, V105, P1032, DOI 10.1016/S0161-6420(98)96004-3; Butler NJ, 2013, CLIN EXP OPHTHALMOL, V41, P95, DOI 10.1111/j.1442-9071.2012.02838.x; Caballero-Ortega H, 2014, J INFECT DEV COUNTR, V8, P642, DOI 10.3855/jidc.3858; Canedo-Solares I, 2009, J PERINATOL, V29, P668, DOI 10.1038/jp.2009.79; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; Chen M, 2000, INFECT IMMUN, V68, P4893, DOI 10.1128/IAI.68.9.4893-4899.2000; Ciorba A, 2018, INT J IMMUNOPATH PH, V32, DOI 10.1177/2058738418808680; Correa D, 2007, PARASITE IMMUNOL, V29, P651, DOI 10.1111/j.1365-3024.2007.00982.x; Courret N, 2006, BLOOD, V107, P309, DOI 10.1182/blood-2005-02-0666; Daugaard M, 2007, FEBS LETT, V581, P3702, DOI [10.1016/j.febslet.2007.05.039, 10.1016/j.febsiet.2007.05.039]; Diaz-Coranguez M, 2017, VISION RES, V139, P123, DOI 10.1016/j.visres.2017.05.009; Dunn D, 1999, LANCET, V353, P1829, DOI 10.1016/S0140-6736(98)08220-8; Forthal DN, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.AID-0019-2014; Garweg JG, 2010, GRAEF ARCH CLIN EXP, V248, P573, DOI 10.1007/s00417-009-1242-z; Getts DR, 2020, AUTOIMMUNE DISEASES, 6TH EDITION, P363, DOI 10.1016/B978-0-12-812102-3.00021-X; Gomez-Toscano V, 2018, ACTA PEDIATR MEX, V39, P321, DOI 10.18233/APM39No6pp321-3331730; Kivity S, 2009, TRENDS IMMUNOL, V30, P409, DOI 10.1016/j.it.2009.05.005; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; Kodjikian L, 2006, GRAEF ARCH CLIN EXP, V244, P14, DOI 10.1007/s00417-005-1164-3; Kohl Thomas O, 2017, Cold Spring Harb Protoc, V2017, DOI 10.1101/pdb.prot093757; Konradt C, 2016, NAT MICROBIOL, V1, DOI [10.1038/nmicrobiol.2016.1, 10.1038/NMICROBIOL.2016.1]; LAMBRECHT HG, 1992, BIOCHIM BIOPHYS ACTA, V1160, P63, DOI 10.1016/0167-4838(92)90038-F; Li Y, 2018, INFECT IMMUN, V86, DOI [10.1128/IAI.00398-18, 10.1128/iai.00398-18]; McLeod R, 2006, CLIN INFECT DIS, V42, P1383, DOI 10.1086/501360; Montoya JG, 2004, LANCET, V363, P1965, DOI 10.1016/S0140-6736(04)16412-X; Muino JC, 1999, J CLIN IMMUNOL, V19, P215, DOI 10.1023/A:1020516029883; Niederkorn JY, 2006, NAT IMMUNOL, V7, P354, DOI 10.1038/ni1328; NUSSENBLATT RB, 1989, AM J OPHTHALMOL, V107, P632, DOI 10.1016/0002-9394(89)90260-2; Ohguro H, 1999, INVEST OPHTH VIS SCI, V40, P3160; Ohguro HN, 1999, INVEST OPHTH VIS SCI, V40, P82; Ortiz-Alegria LB, 2010, GENES IMMUN, V11, P363, DOI 10.1038/gene.2010.21; Rico-Torres CP, 2018, ACTA TROP, V178, P124, DOI 10.1016/j.actatropica.2017.11.008; Petersen E, 2012, OCUL IMMUNOL INFLAMM, V20, P68, DOI 10.3109/09273948.2012.661115; Pockley AG, 2003, LANCET, V362, P469, DOI 10.1016/S0140-6736(03)14075-5; Rico-Torres CP., 2016, SYSTEMATIC CRIT REV, V5, P1078, DOI [10.1007/s10096-016-2656-2, DOI 10.1007/S10096-016-2656-2]; Romero MD, 2006, INVEST OPHTH VIS SCI, V47, P1550, DOI 10.1167/iovs.05-1234; Rosenblum MD, 2015, J CLIN INVEST, V125, P2228, DOI 10.1172/JCI78088; Salviz M, 2013, OTOL NEUROTOL, V34, P1165, DOI 10.1097/MAO.0b013e31828297b6; Silosi I, 2016, ROM J MORPHOL EMBRYO, V57, P633; Smith Justine R, 2002, Curr Opin Ophthalmol, V13, P387, DOI 10.1097/00055735-200212000-00008; Suzuki Y., 2007, P567, DOI 10.1016/B978-012369542-0/50023-4; SUZUKI Y, 1988, SCIENCE, V240, P516, DOI 10.1126/science.3128869; Cursino SRT, 2010, CLINICS, V65, P1027, DOI 10.1590/S1807-59322010001000018; ten Berge JCEM, 2016, ACTA OPHTHALMOL, V94, P282, DOI 10.1111/aos.12939; Vallochi AL, 2005, J AUTOIMMUN, V24, P25, DOI 10.1016/j.jaut.2004.11.003; van Eden W, 2005, NAT REV IMMUNOL, V5, P318, DOI 10.1038/nri1593; Voigt V, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14618-z; Whittle RM, 1998, BRIT J OPHTHALMOL, V82, P1017, DOI 10.1136/bjo.82.9.1017; WYLER DJ, 1980, AM J TROP MED HYG, V29, P1181, DOI 10.4269/ajtmh.1980.29.1181; Yurttutan N., 2018, AUTOANTIBODIES CYTOK, V2, P437, DOI [10.5772/intechopen.76020, DOI 10.5772/INTECHOPEN.76020]	53	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2021	12								606963	10.3389/fimmu.2021.606963	http://dx.doi.org/10.3389/fimmu.2021.606963			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SH6BR	34054794	Green Published, gold			2022-12-18	WOS:000654220500001
J	Radzioch, D; Giera, M; De Sanctis, JB				Radzioch, Danuta; Giera, Martin; De Sanctis, Juan Bautista			Editorial: Quo Vadis Lipid Mediators - Lipid Mediators Implication in Inflammation and Chronic Inflammatory Diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						neutrophils; nuclear receptor corepressor 1; orsomucoid like 3; asthma; Alzheimer's disease; w 3 fatty acids; sebocytes; inflammation			[Radzioch, Danuta] McGill Univ, Ctr Hlth, Res Inst, Dept Expt Med, Montreal, PQ, Canada; [Radzioch, Danuta] McGill Univ, Ctr Hlth, Res Inst, Dept Genet, Montreal, PQ, Canada; [Giera, Martin] Leiden Univ, Med Ctr, Metabol Grp, Leiden, Netherlands; [De Sanctis, Juan Bautista] Palacky Univ, Fac Med & Dent, Inst Mol & Translat Med, Olomouc, Czech Republic	McGill University; McGill University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Palacky University Olomouc	De Sanctis, JB (corresponding author), Palacky Univ, Fac Med & Dent, Inst Mol & Translat Med, Olomouc, Czech Republic.	juanbautista.desanctis@upol.cz	De Sanctis, Juan B./H-5050-2019; Giera, Martin/Y-2413-2018	De Sanctis, Juan B./0000-0002-5480-4608; Giera, Martin/0000-0003-1684-1894	Ministry of Education, Youth and Sport, Czech Republic: Molecular and Cellular Clinical Approach to Healthy Ageing, ENOCH (European Regional Development Fund) [CZ.02.1.01/0.0/0.0/16_019/0000868, 869/V19]; Prostate Canada grant TAG2017 Movember Translation Acceleration grant entitled: Translational procedure and interventional platform development for optimal delivery of therapeutics to prostate cancer based on magnetotactic bacteria; Ministere de L' Economie et de l' Innovation: The enhancement of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) functional expression by Fenretinide (MESI) [2768, 3335]	Ministry of Education, Youth and Sport, Czech Republic: Molecular and Cellular Clinical Approach to Healthy Ageing, ENOCH (European Regional Development Fund); Prostate Canada grant TAG2017 Movember Translation Acceleration grant entitled: Translational procedure and interventional platform development for optimal delivery of therapeutics to prostate cancer based on magnetotactic bacteria; Ministere de L' Economie et de l' Innovation: The enhancement of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) functional expression by Fenretinide (MESI)	DR and JS are researchers funded by the grant from the Ministry of Education, Youth and Sport, Czech Republic: Molecular and Cellular Clinical Approach to Healthy Ageing, ENOCH (European Regional Development Fund Project No. CZ.02.1.01/0.0/0.0/16_019/0000868, IMTM #869/V19). DR is also funded by Prostate Canada grant TAG2017 Movember Translation Acceleration grant entitled: Translational procedure and interventional platform development for optimal delivery of therapeutics to prostate cancer based on magnetotactic bacteria; and grants from the Ministere de L' E ' conomie et de l' Innovation: The enhancement of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) functional expression by Fenretinide (MESI Accounts 2768 and 3335).		0	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2021	12								699276	10.3389/fimmu.2021.699276	http://dx.doi.org/10.3389/fimmu.2021.699276			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SH5YY	34054883	gold, Green Published			2022-12-18	WOS:000654213100001
J	Torrecillas, S; Terova, G; Makol, A; Serradell, A; Valdenegro-Vega, V; Izquierdo, M; Acosta, F; Montero, D				Torrecillas, Silvia; Terova, Genciana; Makol, Alex; Serradell, Antonio; Valdenegro-Vega, Victoria; Izquierdo, Marisol; Acosta, Felix; Montero, Daniel			Dietary Phytogenics and Galactomannan Oligosaccharides in Low Fish Meal and Fish Oil-Based Diets for European Sea Bass (Dicentrarchus labrax) Juveniles: Effects on Gill Structure and Health and Implications on Oxidative Stress Status	FRONTIERS IN IMMUNOLOGY			English	Article						European sea bass; gill morphology; oxidative stress; functional diets; prebiotics; phytogenics; low FM; FO diets	CARVACROL; ANTIOXIDANTS; RESPONSES; THYMOL; GROWTH	An effective replacement for fish meal (FM) and fish oil (FO) based on plant-based raw materials in the feed of marine fish species is necessary for the sustainability of the aquaculture sector. However, the use of plant-based raw materials to replace FM and FO has been associated with several negative health effects, some of which are related to oxidative stress processes that can induce functional and morphological alterations in mucosal tissues. This study aimed to evaluate the effects of dietary oligosaccharides of plant origin (5,000 ppm; galactomannan oligosaccharides, GMOS) and a phytogenic feed additive (200 ppm; garlic oil and labiatae plant extract mixture, PHYTO) on the oxidative stress status and mucosal health of the gills of juvenile European sea bass (Dicentrarchus labrax). The experimental diets, low FM and FO diets (10%FM/6%FO) were supplemented with GMOS from plant origin and PHYTO for 63 days. GMOS and PHYTO did not significantly affect feed utilization, fish growth, and survival. GMOS and PHYTO downregulated the expression of beta-act, sod, gpx, cat, and gr in the gills of the fish compared with that in fish fed the control diet. The expression of hsp70 and ocln was upregulated and downregulated, respectively, in the GMOS group compared with that in the control group, whereas the expression of zo-1 was downregulated in the PHYTO group compared with that in the GMOS group. The morphological, histopathological, immunohistochemical, and biochemical parameters of the fish gills were mostly unaffected by GMOS and PHYTO. However, the PHYTO group had lower incidence of lamellar fusion than did the control group after 63 days. Although the tissular distribution of goblet cells was unaffected by GMOS and PHYTO, goblet cell size showed a decreasing trend (-11%) in the GMOS group. GMOS and PHYTO significantly reduced the concentration of PCNA+ in the epithelium of the gills. The above findings indicated that GMOS and PHYTO in low FM/FO-based diets protected the gill epithelia of D. labrax from oxidative stress by modulating the expression of oxidative enzyme-related genes and reducing the density of PCNA+ cells in the gills of the fish.	[Torrecillas, Silvia; Serradell, Antonio; Izquierdo, Marisol; Acosta, Felix; Montero, Daniel] Univ Las Palmas Gran Canaria, IU ECOAQUA, Grp Invest Acuicultura GIA, Las Palmas Gran Canaria, Spain; [Terova, Genciana] Univ Insubria, Dept Biotechnol & Life Sci, Varese, Italy; [Makol, Alex] Delacon Biotech GmbH, Global Solut Aquaculture Unit, Engerwitzdorf, Austria; [Valdenegro-Vega, Victoria] BioMar AS, Global RD Hlth, Trondheim, Norway	Universidad de Las Palmas de Gran Canaria; University of Insubria	Torrecillas, S (corresponding author), Univ Las Palmas Gran Canaria, IU ECOAQUA, Grp Invest Acuicultura GIA, Las Palmas Gran Canaria, Spain.	silvia.torrecillas@giaqua.org	Torrecillas, Silvia/F-5378-2016; montero, daniel/O-7108-2015; montero, daniel/ABE-3894-2020; Terova, Genciana/G-1779-2010	Torrecillas, Silvia/0000-0003-2823-9999; montero, daniel/0000-0002-4358-2157; ACOSTA ARBELO, FELIX ANTONIO/0000-0002-1098-7529; Terova, Genciana/0000-0002-7532-7951; Marisol, Izquierdo/0000-0003-4297-210X	Spanish Ministry of Economy, Industry and Competitiveness [AGL2016-79725-P, IJCI2015-25748]; EU [818367]	Spanish Ministry of Economy, Industry and Competitiveness(Spanish Government); EU(European Commission)	This work was funded by the Spanish Ministry of Economy, Industry and Competitiveness ("Subprograma Estatal de Generacion de Conocimiento, en el marco del Plan Estatal de Investigacion Cientifica y Tecnica y de Innovacion 2013-2016") by the PROINMUNOIL PLUS (AGL2016-79725-P) project: "Functional diets for marine raw materials replacement: boosting the fish disease resistance through epithelial barriers reinforcement and immunization tools," in which DM, ST, FA, MI and AS were involved. GT was responsible for the gene expression analyses, which were funded by the EU Horizon 2020 AquaIMPACT (Genomic and nutritional innovations for genetically superior farmed fish to improve efficiency in European aquaculture), number: 818367. Besides, the Spanish Ministry of Economy, Industry, and Competitiveness funded ST research though the " Subprograma Juan de la CiervaIncorporacion, Convocatoria 2015, IJCI2015-25748.	Abdel-Moneim AM, 2012, J AQUAT ANIM HEALTH, V24, P148, DOI 10.1080/08997659.2012.675924; Al-Sagheer AA, 2018, AQUACULT NUTR, V24, P1006, DOI 10.1111/anu.12637; Almeida JA, 2009, NEOTROP ICHTHYOL, V7, P103, DOI 10.1590/S1679-62252009000100013; Amer SA, 2018, EGYPT J AQUATIC RES, V44, P251, DOI 10.1016/j.ejar.2018.07.004; Association of Official Analytical Chemists, 1990, OFFICIAL METHODS ANA; Augusti KT, 1996, EXPERIENTIA, V52, P115, DOI 10.1007/BF01923354; Awad E, 2015, FISH SHELLFISH IMMUN, V43, P43, DOI 10.1016/j.fsi.2014.12.009; Ballesteros ML, 2007, J ENVIRON SCI HEAL B, V42, P351, DOI 10.1080/03601230701309577; Bauerova K, 2008, NEUROENDOCRINOL LETT, V29, P691; Bello ARR, 2000, DIS AQUAT ORGAN, V42, P233, DOI 10.3354/dao042233; Bozin B, 2007, J AGR FOOD CHEM, V55, P7879, DOI 10.1021/jf0715323; Brunetti C, 2013, INT J MOL SCI, V14, P3540, DOI 10.3390/ijms14023540; Bui P, 2010, MOL CELL ENDOCRINOL, V317, P120, DOI 10.1016/j.mce.2009.12.002; Bunton TE, 2000, EXP TOXICOL PATHOL, V52, P209, DOI 10.1016/S0940-2993(00)80031-7; Carmona R, 2004, J FISH BIOL, V64, P553, DOI 10.1111/j.0022-1112.2004.00321.x; Chen C, 2005, TRENDS PHARMACOL SCI, V26, P318, DOI 10.1016/j.tips.2005.04.004; Dautremepuits C, 2003, FISH SHELLFISH IMMUN, V15, P467, DOI 10.1016/S1050-4648(03)00007-X; Dezfuli BS, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-198; Di Giulio Richard T., 2008, P273, DOI 10.1201/9780203647295.ch6; Edris AE, 2007, PHYTOTHER RES, V21, P308, DOI 10.1002/ptr.2072; Evans DH, 2005, PHYSIOL REV, V85, P97, DOI 10.1152/physrev.00050.2003; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fowler J., 1998, PRACTICAL STAT FIELD, P130; Giannenas I, 2012, AQUACULTURE, V350, P26, DOI 10.1016/j.aquaculture.2012.04.027; Gomaa AMS, 2018, CELL STRESS CHAPERON, V23, P913, DOI 10.1007/s12192-018-0898-x; Gomez D, 2013, FISH SHELLFISH IMMUN, V35, P1729, DOI 10.1016/j.fsi.2013.09.032; Goss GG, 1998, COMP BIOCHEM PHYS A, V119, P107, DOI 10.1016/S1095-6433(97)00401-7; Guardiola FA, 2017, FISH SHELLFISH IMMUN, V65, P169, DOI 10.1016/j.fsi.2017.04.014; Haramis APG, 2006, EMBO REP, V7, P444, DOI 10.1038/sj.embor.7400638; Hoffman E. O, 1983, LAB MED, V14, P779, DOI DOI 10.1093/LABMED/14.12.779; Hoseinifar SH, 2020, REV FISH SCI AQUAC, V28, P303, DOI 10.1080/23308249.2020.1731420; Hu R, 2004, NUTRITION, V20, P83, DOI 10.1016/j.nut.2003.09.015; Ighodaro OM, 2018, ALEX J MED, V54, P287, DOI 10.1016/j.ajme.2017.09.001; Ikwegbue PC, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11010002; Javed M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01749-6; KARNAKY KJ, 1976, J CELL BIOL, V70, P157, DOI 10.1083/jcb.70.1.157; Khatua TN, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00018; Kolosov D, 2014, J EXP BIOL, V217, P1667, DOI 10.1242/jeb.098731; Koppang E. O., 2015, MUCOSAL HLTH AQUACUL, P93, DOI [10.1016/b978-0-12-417186-2.00005-4, DOI 10.1016/B978-0-12-417186-2.00005-4]; Korkmaz N, 2009, ENVIRON TOXICOL PHAR, V28, P198, DOI 10.1016/j.etap.2009.04.004; Kurutas EB, 2016, NUTR J, V15, DOI 10.1186/s12937-016-0186-5; Kykkidou S, 2009, FOOD CHEM, V115, P169, DOI 10.1016/j.foodchem.2008.11.083; Lai KP, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-2271-0; Lazado CC, 2014, FISH SHELLFISH IMMUN, V39, P78, DOI 10.1016/j.fsi.2014.04.015; Li C, 2012, FISH SHELLFISH IMMUN, V32, P816, DOI 10.1016/j.fsi.2012.02.004; Lillehoj H, 2018, VET RES, V49, DOI 10.1186/s13567-018-0562-6; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Llana-Ruiz-Cabello M, 2015, TOXICOL IN VITRO, V29, P647, DOI 10.1016/j.tiv.2015.02.006; Louis XL, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-140; MANERA M, 1994, J FISH DIS, V17, P93, DOI 10.1111/j.1365-2761.1994.tb00349.x; Marcogliese DJ, 2005, DIS AQUAT ORGAN, V63, P77, DOI 10.3354/dao063077; Marcos-Lopez M, 2017, FISH SHELLFISH IMMUN, V66, P207, DOI 10.1016/j.fsi.2017.05.029; Martoja-Pierson M, 1970, T CNICAS HISTOLOG A; Merrifield DL., 2015, MUCOSAL HLTH AQUACUL, P273, DOI [10.1016/B978-0-12-417186-2.00010-8, DOI 10.1016/B978-0-12-417186-2.00010-8]; Metwally M.A.A., 2009, World Journal of Fish and Marine Sciences, V1, P56; Mironczuk-Chodakowska I, 2018, ADV MED SCI-POLAND, V63, P68, DOI 10.1016/j.advms.2017.05.005; Mohebbi A, 2012, AQUAC RES, V43, P1184, DOI 10.1111/j.1365-2109.2011.02922.x; Mosbah A, 2018, BIOL TRACE ELEM RES, V183, P370, DOI 10.1007/s12011-017-1146-4; Moussa Z., 2019, FREE RADICAL MED BIO, DOI [10.5772/intechopen.87778, DOI 10.5772/INTECHOPEN.87778]; Mozhdeganloo Z, 2014, J Parasit Dis, V38, P269, DOI 10.1007/s12639-013-0239-z; Nimse SB, 2015, RSC ADV, V5, P27986, DOI 10.1039/c4ra13315c; Nya EJ, 2011, FISH SHELLFISH IMMUN, V30, P845, DOI 10.1016/j.fsi.2011.01.008; Oksala NKJ, 2014, REDOX BIOL, V3, P25, DOI 10.1016/j.redox.2014.10.003; Oropesa AL, 2005, B ENVIRON CONTAM TOX, V74, P785, DOI 10.1007/s00128-005-0650-y; Oruc EO, 2007, ENVIRON TOXICOL PHAR, V23, P48, DOI 10.1016/j.etap.2006.06.005; Peatman E, 2015, TISSUE BARRIERS, V3, DOI 10.1080/21688370.2015.1068907; Perry SF, 1997, ANNU REV PHYSIOL, V59, P325, DOI 10.1146/annurev.physiol.59.1.325; Pietta PG, 2000, J NAT PROD, V63, P1035, DOI 10.1021/np9904509; Rimoldi S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231494; Rosety-Rodriguez M, 2002, ECOTOX ENVIRON SAFE, V51, P223, DOI 10.1006/eesa.2001.2148; Sales CF, 2017, FISH SHELLFISH IMMUN, V68, P10, DOI 10.1016/j.fsi.2017.07.001; Schepetkin IA, 2019, MOLECULES, V24, DOI 10.3390/molecules24091809; Serradell A, 2020, FISH SHELLFISH IMMUN, V100, P219, DOI 10.1016/j.fsi.2020.03.016; Slaninova A, 2009, NEUROENDOCRINOL LETT, V30, P2; Sokal R.R, 1995, INTRO BASIC STAT; Sonmez AY, 2015, FISH PHYSIOL BIOCHEM, V41, P165, DOI 10.1007/s10695-014-0014-9; Stumbo AD, 2012, PARASITOLOGY, V139, P1666, DOI 10.1017/S0031182012001023; Sun LY, 2015, COMP BIOCHEM PHYS D, V13, P60, DOI 10.1016/j.cbd.2015.01.002; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Torrecillas S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222063; Tovar-Ramirez D, 2010, AQUACULTURE, V300, P142, DOI 10.1016/j.aquaculture.2009.12.015; Volpatti D, 2013, AQUAC RES, V45, P31, DOI 10.1111/j.1365-2109.2012.03202.x; Wei HK, 2017, ANIMAL, V11, P193, DOI 10.1017/S1751731116001397; Wilson JM, 2000, J EXP BIOL, V203, P2279; Zhang JJ, 2012, ANN NY ACAD SCI, V1257, P193, DOI 10.1111/j.1749-6632.2012.06507.x; Zheng ZL, 2009, AQUACULTURE, V292, P214, DOI 10.1016/j.aquaculture.2009.04.025	86	0	1	4	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2021	12								663106	10.3389/fimmu.2021.663106	http://dx.doi.org/10.3389/fimmu.2021.663106			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SH6HB	34054829	gold, Green Published			2022-12-18	WOS:000654234900001
J	Zheng, L; Wang, XCA; Hu, LK; Gao, WJ; Zhang, WT; Zhang, XP; Hu, C; Rong, RM; Yang, C; Zhu, D				Zheng, Long; Wang, Xuanchuan; Hu, Linkun; Gao, Wenjun; Zhang, Weitao; Zhang, Xuepeng; Hu, Chao; Rong, Ruiming; Yang, Cheng; Zhu, Dong			Cyclic Helix B Peptide Prolongs Skin Allograft Survival via Inhibition of B Cell Immune Responses in a Murine Model	FRONTIERS IN IMMUNOLOGY			English	Article						cyclic helix B peptide; antibody-mediated rejection; plasma cells; germinal center B cells; Tfh cells; donor specific antibodies	FIBROSIS	Antibody-mediated rejection (AMR) represents a major cause of allograft dysfunction and results in allograft failure in solid organ transplantation. Cyclic helix B peptide (CHBP) is a novel erythropoietin-derived peptide that ameliorated renal allograft rejection in a renal transplantation model. However, its effect on AMR remains unknown. This study aimed to investigate the effect of CHBP on AMR using a secondary allogeneic skin transplantation model, which was created by transplanting skin from BALB/c mice to C57BL/6 mice with or without CHBP treatment. A secondary syngeneic skin transplantation model, involving transplantation from C57BL/6 mice to C57BL/6 mice, was also created to act as a control. Skin graft rejection, CD19(+) B cell infiltration in the skin allograft, the percentages of splenic plasma cells, germinal center (GC) B cells, and Tfh cells, the serum levels of donor specific antibodies (DSAs), and NF-kappa B signaling in splenocytes were analyzed. Skin allograft survival was significantly prolonged in the CHBP group compared to the allogeneic group. CHBP treatment also significantly reduced the CD19(+) B cell infiltration in the skin allograft, decreased the percentages of splenic plasma cells, GC B cells, and Tfh cells, and ameliorated the increase in the serum DSA level. At a molecular level, CHBP downregulated P100, RelB, and P52 in splenocytes. CHBP prolonged skin allograft survival by inhibiting AMR, which may be mediated by inhibition of NF-kappa B signaling to suppress B cell immune responses, thereby decreasing the DSA level.	[Zheng, Long; Wang, Xuanchuan; Gao, Wenjun; Zhang, Weitao; Hu, Chao; Rong, Ruiming; Yang, Cheng; Zhu, Dong] Fudan Univ, Zhongshan Hosp, Dept Urol, Shanghai, Peoples R China; [Zheng, Long; Wang, Xuanchuan; Gao, Wenjun; Zhang, Weitao; Hu, Chao; Yang, Cheng; Zhu, Dong] Shanghai Key Lab Organ Transplantat, Shanghai, Peoples R China; [Hu, Linkun] Soochow Univ, Dept Urol, Affiliated Hosp 1, Suzhou, Peoples R China; [Zhang, Xuepeng] Fudan Univ, Zhongshan Hosp, Dept Crit Care Med, Shanghai, Peoples R China; [Rong, Ruiming] Fudan Univ, Zhongshan Hosp, Dept Blood Transfus, Shanghai, Peoples R China; [Yang, Cheng] Fudan Univ, Zhangjiang Inst, Shanghai, Peoples R China	Fudan University; Soochow University - China; Fudan University; Fudan University; Fudan University	Rong, RM; Yang, C; Zhu, D (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Urol, Shanghai, Peoples R China.; Yang, C; Zhu, D (corresponding author), Shanghai Key Lab Organ Transplantat, Shanghai, Peoples R China.; Rong, RM (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Blood Transfus, Shanghai, Peoples R China.; Yang, C (corresponding author), Fudan Univ, Zhangjiang Inst, Shanghai, Peoples R China.	rong.ruiming@zs-hospital.sh.cn; yang.cheng1@zs-hospital.sh.cn; wgzd82@163.com	Li, Jiawei/GXM-4151-2022; Yang, Cheng/I-7166-2019	Yang, Cheng/0000-0003-4060-2746	National Natural Science Foundation of China [81500569, 81770747, 81770746, 81800659]; National Key R&D Program of China [2018YFA0107501, 2018YFA0107502]; Shanghai Rising-Star Program [19QA1406300]; Medical and Health Talents Training Plan for the Excellent Youth of Shanghai Municipal [2018YQ50]; Fujian Provincial Health and Health Career Training Project for Young and Middle-aged Talents [2020GGB058]; Shanghai Youth Talent Development Program	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China; Shanghai Rising-Star Program; Medical and Health Talents Training Plan for the Excellent Youth of Shanghai Municipal; Fujian Provincial Health and Health Career Training Project for Young and Middle-aged Talents; Shanghai Youth Talent Development Program	This study was supported by National Natural Science Foundation of China (81500569 to DZ, 81770747 to RR, 81770746 to CY, 81800659 to XW), National Key R&D Program of China (2018YFA0107501 to RR, 2018YFA0107502 to CY), Shanghai Rising-Star Program (19QA1406300 to CY), Medical and Health Talents Training Plan for the Excellent Youth of Shanghai Municipal (2018YQ50 to CY), 2019 Shanghai Youth Talent Development Program (to CY), and Fujian Provincial Health and Health Career Training Project for Young and Middle-aged Talents (2020GGB058 to DZ).	Bertrand D, 2020, TRANSPLANTATION, V104, P1726, DOI 10.1097/TP.0000000000003055; Chen C, 2019, J GEN VIROL, V100, P602, DOI 10.1099/jgv.0.001247; De Leo P, 2020, CLIN IMMUNOL, V210, DOI 10.1016/j.clim.2019.108309; De Silva NS, 2016, P NATL ACAD SCI USA, V113, P9063, DOI 10.1073/pnas.1602728113; De Silva NS, 2015, NAT REV IMMUNOL, V15, P137, DOI 10.1038/nri3804; Dijke EI, 2016, J HEART LUNG TRANSPL, V35, P704, DOI 10.1016/j.healun.2016.01.1232; DiLillo DJ, 2011, J IMMUNOL, V186, P2643, DOI 10.4049/jimmunol.1002983; Elsner RA, 2019, CELL REP, V29, P2796, DOI 10.1016/j.celrep.2019.10.069; Goetz CA, 2008, IMMUNOL RES, V41, P233, DOI 10.1007/s12026-008-8033-1; Hao YX, 2018, METHODS MOL BIOL, V1707, P15, DOI 10.1007/978-1-4939-7474-0_2; Harrison DK, 2021, TRANSPLANTATION, V105, P540, DOI 10.1097/TP.0000000000003442; Homig-Holzel C, 2008, J EXP MED, V205, P1317, DOI 10.1084/jem.20080238; Hu HB, 2011, P NATL ACAD SCI USA, V108, P12827, DOI 10.1073/pnas.1105774108; Imamura R, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9090733; Kenta I, 2021, NEPHRON, V144, P2, DOI 10.1159/000510747; Kerfoot SM, 2011, IMMUNITY, V34, P947, DOI 10.1016/j.immuni.2011.03.024; Liu AF, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22852-2; Pardi N, 2018, J EXP MED, V215, P1571, DOI 10.1084/jem.20171450; Qi RC, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.02.12; Silva-Cayetano A, 2020, CURR OPIN IMMUNOL, V64, P26, DOI 10.1016/j.coi.2020.03.007; Suchanek O, 2020, HLA, V96, P667, DOI 10.1111/tan.14092; Tavares RM, 2010, IMMUNITY, V33, P181, DOI 10.1016/j.immuni.2010.07.017; Walsh NC, 2015, EMBO REP, V16, P753, DOI 10.15252/embr.201439505; Xie P, 2007, IMMUNITY, V27, P253, DOI 10.1016/j.immuni.2007.07.012; Yang C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.338; Yang C, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0161-y; Yang C, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0699-2; Yang C, 2014, BBA-MOL BASIS DIS, V1842, P2306, DOI 10.1016/j.bbadis.2014.09.001; Zeng YG, 2017, BIOMED PHARMACOTHER, V94, P1167, DOI 10.1016/j.biopha.2017.07.131; Zhang C, 2017, CURR PROTEIN PEPT SC, V18, P1191, DOI 10.2174/1389203717666160909130006; Zhao DQ, 2018, AM J TRANSPLANT, V18, P1083, DOI 10.1111/ajt.14602	31	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2021	12								682749	10.3389/fimmu.2021.682749	http://dx.doi.org/10.3389/fimmu.2021.682749			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SH5ZY	34054874	Green Published, gold			2022-12-18	WOS:000654215700001
J	Silva, LBR; Taira, CL; Cleare, LG; Martins, M; Junqueira, M; Nosanchuk, JD; Taborda, CP				Silva, Leandro B. R.; Taira, Cleison L.; Cleare, Levi G.; Martins, Michele; Junqueira, Magno; Nosanchuk, Joshua D.; Taborda, Carlos P.			Identification of Potentially Therapeutic Immunogenic Peptides From Paracoccidioides lutzii Species	FRONTIERS IN IMMUNOLOGY			English	Article						paracoccidioidomycosis; vaccine; peptide; Paracoccidioides lutzii; PCM	REVEALS	Paracoccidioidomycosis (PCM) is an endemic mycosis in Latin America caused by the thermodimorphic fungi of the genus Paracoccidioides spp. Paracoccidioides lutzii (PL) is one of the 5 species that constitute the Paracoccidioides genus. PL expresses low amounts of glycoprotein (Gp) 43 (PLGp43) and PLGp43 displays few epitopes in common with the P. brasiliensis (PB) immunodominant antigen PBGp43, which is commonly used for serological diagnosis of PCM. This difference in structure between the glycoproteins markedly reduces the efficiency of serological diagnosis in patients infected with PL. We previously demonstrated that peptide 10 (P10) from the PBGp43 induces protective immune responses in in vitro and in vivo models of PB PCM. Since, P10 has proven to be a promising therapeutic to combat PB, we sought to identify peptides in PL that could similarly be applied for the treatment of PCM. PL yeast cell proteins were isolated from PL: dendritic cell co-cultures and subjected to immunoproteomics. This approach identified 18 PL peptides that demonstrated in silico predictions for immunogenicity. Eight of the most promising peptides were synthesized and applied to lymphocytes obtained from peptide-immunized or PL-infected mice as well as to in vitro cultures with peptides or dendritic cells pulsed the peptides. The peptides LBR5, LBR6 and LBR8 efficiently promoted CD4(+) and CD8(+) T cell proliferation and dendritic cells pulsed with LBR1, LBR3, LBR7 or LBR8 stimulated CD4(+) T cell proliferation. We observed increases of IFN-gamma in the supernatants from primed T cells for the conditions with peptides without or with dendritic cells, although IL-2 levels only increased in response to LBR8. These novel immunogenic peptides derived from PL will be employed to develop new peptide vaccine approaches and the proteins from which they are derived can be used to develop new diagnostic assays for PL and possibly other Paracoccidioides spp. These findings identify and characterize new peptides with a promising therapeutic profile for future against this important neglected systemic mycosis.	[Silva, Leandro B. R.; Taira, Cleison L.; Taborda, Carlos P.] Univ Sao Paulo, Dept Microbiol, Inst Ciencias Biomed, Sao Paulo, Brazil; [Silva, Leandro B. R.; Cleare, Levi G.; Nosanchuk, Joshua D.] Albert Einstein Coll Med, Dept Med, Div Infect Dis, New York, NY USA; [Silva, Leandro B. R.; Cleare, Levi G.; Nosanchuk, Joshua D.] Albert Einstein Coll Med, Dept Microbiol & Immunol, Div Infect Dis, New York, NY USA; [Martins, Michele; Junqueira, Magno] Fed Univ Rio Janeiro, Dept Biochem, Prote Unit, Inst Chem, Rio De Janeiro, Brazil; [Taborda, Carlos P.] Univ Sao Paulo, Inst Med Trop Sao Paulo, Fac Med, Dept Dermatol,Lab Micol Med LIM53, Sao Paulo, Brazil	Universidade de Sao Paulo; Yeshiva University; Yeshiva University; Universidade Federal do Rio de Janeiro; Universidade de Sao Paulo	Silva, LBR; Taborda, CP (corresponding author), Univ Sao Paulo, Dept Microbiol, Inst Ciencias Biomed, Sao Paulo, Brazil.; Silva, LBR (corresponding author), Albert Einstein Coll Med, Dept Med, Div Infect Dis, New York, NY USA.; Silva, LBR (corresponding author), Albert Einstein Coll Med, Dept Microbiol & Immunol, Div Infect Dis, New York, NY USA.; Taborda, CP (corresponding author), Univ Sao Paulo, Inst Med Trop Sao Paulo, Fac Med, Dept Dermatol,Lab Micol Med LIM53, Sao Paulo, Brazil.	leandrobr87@usp.br; taborda@usp.br	Junqueira, Magno/A-7495-2012; Nosanchuk, Joshua/AAS-7801-2021	Junqueira, Magno/0000-0002-7036-0728; /0000-0001-9197-1061	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2016/08730-6, 2018/25171-6, 2019/20622-2]; CNPq [420480/2018-8]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - CAPES	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This research was funded by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), grants number 2016/08730-6, 2018/25171-6 and 2019/20622-2. CNPq (grant number 420480/2018-8), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - CAPES.	Rosa SBA, 2020, J FUNGI, V6, DOI 10.3390/jof6040379; Arantes TD, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004606; Arantes TD, 2013, MED MYCOL, V51, P83, DOI 10.3109/13693786.2012.698444; Araujo DS, 2017, BBA-PROTEINS PROTEOM, V1865, P1304, DOI 10.1016/j.bbapap.2017.08.016; Batista J, 2010, MYCOSES, V53, P176, DOI 10.1111/j.1439-0507.2008.01687.x; Bisio LC, 2005, MED MYCOL, V43, P495, DOI 10.1080/13693780400029478; BRUMMER E, 1993, CLIN MICROBIOL REV, V6, P89, DOI 10.1128/CMR.6.2.89-117.1993; Bueno RA, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00074; Calich VLG, 1998, RES IMMUNOL, V149, P407, DOI 10.1016/S0923-2494(98)80764-5; CAMARGO ZP, 1994, J CLIN MICROBIOL, V32, P2377, DOI 10.1128/JCM.32.10.2377-2381.1994; Cunha DA, 2002, CLIN DIAGN LAB IMMUN, V9, P374, DOI 10.1128/CDLI.9.2.374-377.2002; Da Silva LBR, 2020, J FUNGI, V6, DOI 10.3390/jof6030119; da Silva RP, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070765; de Castro LF, 2013, J INFECTION, V67, P470, DOI 10.1016/j.jinf.2013.07.019; Diez S, 2002, J CLIN MICROBIOL, V40, P359, DOI 10.1128/JCM.40.2.359-365.2002; Moreira ALE, 2020, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02968; GOMEZ FJ, 1995, INFECT IMMUN, V63, P2587, DOI 10.1128/IAI.63.7.2587-2595.1995; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Izacc SMS, 2001, MED MYCOL, V39, P445, DOI 10.1080/714031053; Jobbins SE, 2010, J PROTEOME RES, V9, P3832, DOI 10.1021/pr100028t; Kursar M, 2007, J IMMUNOL, V178, P2661, DOI 10.4049/jimmunol.178.5.2661; Leitao NP, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003111; Li MO, 2007, IMMUNITY, V26, P579, DOI 10.1016/j.immuni.2007.03.014; Magalhaes A, 2012, CLIN VACCINE IMMUNOL, V19, P23, DOI 10.1128/CVI.05414-11; Martinez R, 2017, J FUNGI, V3, DOI 10.3390/jof3010001; Martinez R, 2015, REV INST MED TROP SP, V57, P11, DOI 10.1590/S0036-46652015000700004; Tristao FSM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00949; Mayorga O, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00154; Mendes Rinaldo Poncio, 2017, Open Microbiol J, V11, P224, DOI 10.2174/1874285801711010224; Munoz JE, 2014, MYCOPATHOLOGIA, V178, P177, DOI 10.1007/s11046-014-9801-1; Nosanchuk JD, 2003, J CLIN INVEST, V112, P1164, DOI [10.1172/JCI200319361, 10.1172/JCI19361]; PAPPAGIANIS D, 1975, AM J EPIDEMIOL, V102, P30, DOI 10.1093/oxfordjournals.aje.a112131; Parente-Rocha JA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137619; Pitarch A, 2016, J PROTEOMICS, V134, P144, DOI 10.1016/j.jprot.2015.10.022; PUCCIA R, 1991, J CLIN MICROBIOL, V29, P1610, DOI 10.1128/JCM.29.8.1610-1615.1991; Rappleye CA, 2006, ANNU REV MICROBIOL, V60, P281, DOI 10.1146/annurev.micro.59.030804.121055; Rodrigues AM, 2020, J FUNGI, V6, DOI 10.3390/jof6040357; Rodrigues AM, 2015, J PROTEOMICS, V115, P8, DOI 10.1016/j.jprot.2014.11.013; Dos Santos SR, 2020, J FUNGI, V6, DOI 10.3390/jof6030160; Shikanai-Yasuda MA, 2017, REV SOC BRAS MED TRO, V50, P715, DOI 10.1590/0037-8682-0230-2017; Silva LBR, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01727; Silva LBR, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01057; Souto JT, 2000, AM J PATHOL, V156, P1811, DOI 10.1016/S0002-9440(10)65053-5; Taborda CP, 1998, INFECT IMMUN, V66, P786, DOI 10.1128/IAI.66.2.786-793.1998; TABORDA CP, 1994, J CLIN MICROBIOL, V32, P554, DOI 10.1128/JCM.32.2.554-556.1994; Takayama A, 2010, MED MYCOL, V48, P64, DOI 10.3109/13693780902718065; Teixeira MD, 2013, EUKARYOT CELL, V12, P380, DOI 10.1128/EC.05052-11; Teixeira MM, 2009, MOL PHYLOGENET EVOL, V52, P273, DOI 10.1016/j.ympev.2009.04.005; Turissini DA, 2017, FUNGAL GENET BIOL, V106, P9, DOI 10.1016/j.fgb.2017.05.007; Vieira GD, 2014, REV SOC BRAS MED TRO, V47, P63, DOI 10.1590/0037-8682-0225-2013; Virginio ED, 2014, INT J MOL SCI, V15, P14505, DOI 10.3390/ijms150814505; Wang P, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000048; Zancope-Oliveira R.M., 2014, CURR TROP MED REP, V1, P111, DOI [10.1007/s40475-014-0022-y, DOI 10.1007/S40475-014-0022-Y]	53	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 11	2021	12								670992	10.3389/fimmu.2021.670992	http://dx.doi.org/10.3389/fimmu.2021.670992			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SG4XT	34046037	gold, Green Published			2022-12-18	WOS:000653445300001
J	Brennan, FH; Coulthard, LG; Alawieh, AM; Reiner, O; Pekna, M				Brennan, Faith H.; Coulthard, Liam G.; Alawieh, Ali M.; Reiner, Orly; Pekna, Marcela			Editorial: Complement in the Development and Regeneration of the Nervous System	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						innate immune system; opsonization and clearance; anaphylatoxin receptors; membrane attack complex; demyelination and neuronal damage; neurodegenerating diseases; central nervous system; visual system			[Brennan, Faith H.] Ohio State Univ, Dept Neurosci, Ctr Brain & Spinal Cord Repair, Wexner Med Ctr,Belford Ctr Spinal Cord Injury, Columbus, OH 43210 USA; [Coulthard, Liam G.] Royal Brisbane & Womens Hosp, Herston, Qld, Australia; [Coulthard, Liam G.] Univ Queensland, Fac Med, Herston, Qld, Australia; [Alawieh, Ali M.] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA USA; [Reiner, Orly] Weizmann Inst Sci, Dept Mol Genet, Rehovot, Israel; [Pekna, Marcela] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci, Gothenburg, Sweden	University System of Ohio; Ohio State University; Royal Brisbane & Women's Hospital; University of Queensland; Emory University; Weizmann Institute of Science; University of Gothenburg	Brennan, FH (corresponding author), Ohio State Univ, Dept Neurosci, Ctr Brain & Spinal Cord Repair, Wexner Med Ctr,Belford Ctr Spinal Cord Injury, Columbus, OH 43210 USA.; Coulthard, LG (corresponding author), Royal Brisbane & Womens Hosp, Herston, Qld, Australia.; Coulthard, LG (corresponding author), Univ Queensland, Fac Med, Herston, Qld, Australia.; Alawieh, AM (corresponding author), Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA USA.; Reiner, O (corresponding author), Weizmann Inst Sci, Dept Mol Genet, Rehovot, Israel.; Pekna, M (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci, Gothenburg, Sweden.	Faith.Brennan@osumc.edu; l.coulthard@uq.edu.au; aalawie@emory.edu; Orly.Reiner@weizmann.ac.il; marcela.pekna@neuro.gu.se	; Reiner, Orly/E-9455-2010	Brennan, Faith/0000-0002-9201-2476; Pekna, Marcela/0000-0003-2734-8237; Reiner, Orly/0000-0001-7560-9599	Wings for Life Spinal Research Foundation	Wings for Life Spinal Research Foundation	FB is supported by the Wings for Life Spinal Research Foundation.	Brennan FH, 2016, SEMIN IMMUNOL, V28, P292, DOI 10.1016/j.smim.2016.03.015; Brennan FH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-137; Coulthard LG, 2018, MOL IMMUNOL, V101, P176, DOI 10.1016/j.molimm.2018.06.271; Gorelik A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15096; Rahpeymai Y, 2006, EMBO J, V25, P1364, DOI 10.1038/sj.emboj.7601004; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036	7	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 10	2021	12								694810	10.3389/fimmu.2021.694810	http://dx.doi.org/10.3389/fimmu.2021.694810			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SF9JC	34040618	gold, Green Published			2022-12-18	WOS:000653061700001
J	Mika, T; Vangala, D; Eckhardt, M; La Rosee, P; Lange, C; Lehmberg, K; Wohlschlager, C; Biskup, S; Fuchs, I; Mann, J; Ehl, S; Warnatz, K; Schroers, R				Mika, Thomas; Vangala, Deepak; Eckhardt, Matthias; La Rosee, Paul; Lange, Christoph; Lehmberg, Kai; Wohlschlaeger, Charlotte; Biskup, Saskia; Fuchs, Ilka; Mann, Jasmin; Ehl, Stephan; Warnatz, Klaus; Schroers, Roland			Case Report: Hemophagocytic Lymphohistiocytosis and Non-Tuberculous Mycobacteriosis Caused by a Novel GATA2 Variant	FRONTIERS IN IMMUNOLOGY			English	Article						hemophagocytic lymphohistiocytosis; non-tuberculous mycobacteriosis; GATA2; CD107a; allogeneic hematopoietic stem cell transplantation		Hemophagocytic lymphohistiocytosis (HLH) is a disorder of uncontrolled immune activation with distinct clinical features including fever, cytopenia, splenomegaly, and sepsis-like symptoms. In a young adolescent patient a novel germline GATA2 variant (NM_032638.5 (GATA2): c.177C>G, p.Tyr59Ter) was discovered and had resulted in non-tuberculous mycobacterial (NTM) infection and aggressive HLH. Strikingly, impaired degranulation of cytotoxic T-lymphocytes (CTL) and natural killer (NK)-cells was detected in CD107a-analyses. The affected patient was treated with HLA-matched unrelated alloHSCT, and subsequently all hematologic and infectious abnormalities including HLH and NTM resolved. This case supports early alloHSCT in GATA2 deficiencies as curative approach regardless of active NTM infection. Future studies on GATA2 c.177C>G, p.Tyr59*Ter might unravel its potential role in cytotoxic effector cell function and its contribution to HLH pathogenesis.	[Mika, Thomas; Vangala, Deepak; Eckhardt, Matthias; Schroers, Roland] Ruhr Univ Bochum, Dept Hematol & Oncol, Knappschaftskankenhaus, Bochum, Germany; [La Rosee, Paul] Klin Innere Med II, Schwarzwald Baar Klinikum, Villingen Schwenningen, Germany; [Lange, Christoph] Res Ctr Borstel, Med Clin, Borstel, Germany; [Lange, Christoph] Univ Lubeck, Respiatoty Med & Int Hlth, Lubeck, Germany; [Lehmberg, Kai] Univ Med Ctr Eppendorf, Clin Pediat Hematol, Hamburg, Germany; [Wohlschlaeger, Charlotte] Hematopathol Lubeck, Lubeck, Germany; [Biskup, Saskia] CeGaT & Practice Human Genet, Tubingen, Germany; [Fuchs, Ilka; Mann, Jasmin; Ehl, Stephan] Univ Freiburg, Fac Med, Med Ctr, Ctr Chron Immunodeficiency,Inst Immunodeficiency, Freiburg, Germany; [Warnatz, Klaus] Univ Freiburg, Fac Med, Med Ctr, Dept Rheumatol & Clin Immunol, Freiburg, Germany; [Warnatz, Klaus] Univ Freiburg, Fac Med, Med Ctr, Ctr Chron Immunodeficiency, Freiburg, Germany	Ruhr University Bochum; Forschungszentrum Borstel; University of Lubeck; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Freiburg; University of Freiburg; University of Freiburg	Schroers, R (corresponding author), Ruhr Univ Bochum, Dept Hematol & Oncol, Knappschaftskankenhaus, Bochum, Germany.; Warnatz, K (corresponding author), Univ Freiburg, Fac Med, Med Ctr, Dept Rheumatol & Clin Immunol, Freiburg, Germany.; Warnatz, K (corresponding author), Univ Freiburg, Fac Med, Med Ctr, Ctr Chron Immunodeficiency, Freiburg, Germany.	Klaus.Warnatz@uniklinik-freiburg.de; Roland.Schroers@rub.de	Warnatz, Klaus/AAD-3464-2022; Vangala, Deepak/HHS-5988-2022; Vangala, Deepak/AAV-5780-2021	Vangala, Deepak/0000-0002-4175-5683; Mika, Thomas/0000-0003-3790-5826	DFG Open Access Publication Funds of the Ruhr-Universitat Bochum	DFG Open Access Publication Funds of the Ruhr-Universitat Bochum	We acknowledge support by the DFG Open Access Publication Funds of the Ruhr-Universitat Bochum.	Birndt S, 2020, J CANCER RES CLIN, V146, P1065, DOI 10.1007/s00432-020-03139-4; Bryceson YT, 2012, BLOOD, V119, P2754, DOI 10.1182/blood-2011-08-374199; Cohen JI, 2016, CLIN INFECT DIS, V63, P41, DOI 10.1093/cid/ciw160; Fardet L, 2014, ARTHRITIS RHEUMATOL, V66, P2613, DOI 10.1002/art.38690; Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039; Hsu AP, 2011, BLOOD, V118, P2653, DOI 10.1182/blood-2011-05-356352; La Rosee P, 2019, BLOOD, V133, P2465, DOI 10.1182/blood.2018894618; Mace EM, 2013, BLOOD, V121, P2669, DOI 10.1182/blood-2012-09-453969; Parta M, 2018, BIOL BLOOD MARROW TR, V24, P1250, DOI 10.1016/j.bbmt.2018.01.030; Rubin TS, 2017, BLOOD, V129, P2993, DOI 10.1182/blood-2016-12-753830; Shi W, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4061-9; Suzuki T, 2020, J INFECT CHEMOTHER, V26, P252, DOI 10.1016/j.jiac.2019.07.002; Vinh DC, 2010, BLOOD, V115, P1519, DOI 10.1182/blood-2009-03-208629; Wu UI, 2015, LANCET INFECT DIS, V15, P968, DOI 10.1016/S1473-3099(15)00089-4; Zhang KJ, 2011, BLOOD, V118, P5794, DOI 10.1182/blood-2011-07-370148	15	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 10	2021	12								682934	10.3389/fimmu.2021.682934	http://dx.doi.org/10.3389/fimmu.2021.682934			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SG2BO	34040617	gold, Green Published			2022-12-18	WOS:000653248300001
J	Ma, XX; Nakayamada, S; Wang, J				Ma, Xiaoxue; Nakayamada, Shingo; Wang, Jun			Multi-Source Pathways of T Follicular Helper Cell Differentiation (vol 12, 621105, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						T follicular helper cell; cytokine; signal transducer and activator of transcription; pathway; differentiation			[Ma, Xiaoxue] China Med Univ, Hosp 1, Dept Pediat, Shenyang, Peoples R China; [Ma, Xiaoxue; Wang, Jun] Dalhousie Univ, Dept Microbiol & Immunol & Pediat, Halifax, NS, Canada; [Ma, Xiaoxue; Wang, Jun] IWK Hlth Ctr, Canadian Ctr Vaccinol, Halifax, NS, Canada; [Nakayamada, Shingo] Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 1, Kitakyushu, Fukuoka, Japan	China Medical University; Dalhousie University; Dalhousie University; University of Occupational & Environmental Health - Japan	Ma, XX (corresponding author), China Med Univ, Hosp 1, Dept Pediat, Shenyang, Peoples R China.; Ma, XX (corresponding author), Dalhousie Univ, Dept Microbiol & Immunol & Pediat, Halifax, NS, Canada.; Ma, XX (corresponding author), IWK Hlth Ctr, Canadian Ctr Vaccinol, Halifax, NS, Canada.	snow1999521@126.com						Ma XX, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.621105	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 7	2021	12								690815	10.3389/fimmu.2021.690815	http://dx.doi.org/10.3389/fimmu.2021.690815			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SF3MG	34025687	Green Published, gold			2022-12-18	WOS:000652662800001
J	Tucker, KD; Schanen, BC; Phares, TW; Sassano, E; Terry, FE; Hindocha, P; Moise, L; Kotraiah, V; Martin, WD; De Groot, AS; Drake, DR; Gutierrez, GM; Noe, AR				Tucker, Kenneth D.; Schanen, Brian C.; Phares, Timothy W.; Sassano, Emily; Terry, Frances E.; Hindocha, Pooja; Moise, Leonard; Kotraiah, Vinayaka; Martin, William D.; De Groot, Anne S.; Drake, Donald R., III; Gutierrez, Gabriel M.; Noe, Amy R.			Identification, Selection and Immune Assessment of Liver Stage CD8 T Cell Epitopes From Plasmodium falciparum	FRONTIERS IN IMMUNOLOGY			English	Article						malaria; vaccine; epitopes; CSP; SPECT-2; MIMIC	MALARIA; PROTECTION; PROTEINS; REVEALS	Immunization with radiation-attenuated sporozoites (RAS) has been shown to protect against malaria infection, primarily through CD8 T cell responses, but protection is limited based on parasite strain. Therefore, while CD8 T cells are an ideal effector population target for liver stage malaria vaccine development strategies, such strategies must incorporate conserved epitopes that cover a large range of class I human leukocyte antigen (HLA) supertypes to elicit cross-strain immunity across the target population. This approach requires identifying and characterizing a wide range of CD8 T cell epitopes for incorporation into a vaccine such that coverage across a large range of class I HLA alleles is attained. Accordingly, we devised an experimental framework to identify CD8 T cell epitopes from novel and minimally characterized antigens found at the pre-erythrocytic stage of parasite development. Through in silico analysis we selected conserved P. falciparum proteins, using P. vivax orthologues to establish stringent conservation parameters, predicted to have a high number of T cell epitopes across a set of six class I HLA alleles representative of major supertypes. Using the decision framework, five proteins were selected based on the density and number of predicted epitopes. Selected epitopes were synthesized as peptides and evaluated for binding to the class I HLA alleles in vitro to verify in silico binding predictions, and subsequently for stimulation of human T cells using the Modular IMmune In-vitro Construct (MIMIC(R)) technology to verify immunogenicity. By combining the in silico tools with the ex vivo high throughput MIMIC platform, we identified 15 novel CD8 T cell epitopes capable of stimulating an immune response in alleles across the class I HLA panel. We recommend these epitopes should be evaluated in appropriate in vivo humanized immune system models to determine their protective efficacy for potential inclusion in future vaccines.	[Tucker, Kenneth D.; Phares, Timothy W.; Kotraiah, Vinayaka; Gutierrez, Gabriel M.; Noe, Amy R.] Leidos Inc, Leidos Life Sci, Frederick, MD 21703 USA; [Schanen, Brian C.; Sassano, Emily; Drake, Donald R., III] Sanofi Pasteur, Orlando, FL USA; [Terry, Frances E.; Hindocha, Pooja; Moise, Leonard; Martin, William D.; De Groot, Anne S.] EpiVax Inc, Providence, RI USA; [De Groot, Anne S.] Univ Georgia, Ctr Vaccines & Immunol, Athens, GA 30602 USA	Sanofi-Aventis; University System of Georgia; University of Georgia	Tucker, KD (corresponding author), Leidos Inc, Leidos Life Sci, Frederick, MD 21703 USA.	KENNETH.D.TUCKER-2@leidos.com	De Groot, Annie/B-6221-2013; Moise, Lenny/AAE-7448-2019	De Groot, Annie/0000-0001-5911-1459; Moise, Lenny/0000-0002-4410-865X	Office of Infectious Diseases, Bureau for Global Health, U.S. Agency for International Development [AID-OAA-C-15-00071]	Office of Infectious Diseases, Bureau for Global Health, U.S. Agency for International Development(United States Agency for International Development (USAID))	These studies were made possible through support provided by the Office of Infectious Diseases, Bureau for Global Health, U.S. Agency for International Development (https://www.usaid.gov), under the terms of the Malaria Vaccine Development Program (MVDP) Contract AID-OAA-C-15-00071, for which Leidos, Inc. is the prime contractor. The opinions expressed herein are those of the authors and do not necessarily reflect the views of the U.S. Agency for International Development. The funders approved study plans but had no direct role in development of study designs, data collection/analysis, or preparation of the manuscript.	Aguiar Joao C, 2015, PLoS One, V10, pe0136109, DOI 10.1371/journal.pone.0136109; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Arevalo-Herrera M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004563; Atcheson E, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00242-y; Aurrecoechea C, 2009, NUCLEIC ACIDS RES, V37, pD539, DOI 10.1093/nar/gkn814; Beeson JG, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau1458; Buchli R, 2005, BIOCHEMISTRY-US, V44, P12491, DOI 10.1021/bi050255v; Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153; Butler NS, 2011, CELL HOST MICROBE, V9, P451, DOI 10.1016/j.chom.2011.05.008; CLYDE DF, 1973, AM J MED SCI, V266, P169, DOI 10.1097/00000441-197309000-00002; Crompton PD, 2014, ANNU REV IMMUNOL, V32, P157, DOI 10.1146/annurev-immunol-032713-120220; Crompton PD, 2010, P NATL ACAD SCI USA, V107, P6958, DOI 10.1073/pnas.1001323107; Dauner A, 2017, VACCINE, V35, P5487, DOI 10.1016/j.vaccine.2017.03.099; De Groot AS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00442; Dent AE, 2015, J INFECT DIS, V212, P1429, DOI 10.1093/infdis/jiv224; Doolan DL, 2000, J IMMUNOL, V165, P1453, DOI 10.4049/jimmunol.165.3.1453; Doolan DL, 2003, P NATL ACAD SCI USA, V100, P9952, DOI 10.1073/pnas.1633254100; Doolan DL, 1997, IMMUNITY, V7, P97, DOI 10.1016/S1074-7613(00)80513-0; Duffy PE, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0196-3; Epstein JE, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89154; Ewer KJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3836; Feng YQ, 2015, NATURE, V528, P132, DOI 10.1038/nature16141; Frahm N, 2007, EUR J IMMUNOL, V37, P2419, DOI 10.1002/eji.200737365; Greenbaum J, 2011, IMMUNOGENETICS, V63, P325, DOI 10.1007/s00251-011-0513-0; Gwadz R W, 1979, Bull World Health Organ, V57 Suppl 1, P165; Higbee RG, 2009, ATLA-ALTERN LAB ANIM, V37, P19, DOI 10.1177/026119290903701S05; Hoffman SL, 2002, J INFECT DIS, V185, P1155, DOI 10.1086/339409; HOFFMAN SL, 1989, SCIENCE, V244, P1078, DOI 10.1126/science.2524877; Ishino T, 2005, CELL MICROBIOL, V7, P199, DOI 10.1111/j.1462-5822.2004.00447.x; Kaiser K, 2004, MOL MICROBIOL, V51, P1221, DOI 10.1046/j.1365-2958.2003.03909.x; Khan S, 2020, HUM VACC IMMUNOTHER, V16, P214, DOI 10.1080/21645515.2018.1560772; Khosh-Naucke M, 2018, INT J MED MICROBIOL, V308, P13, DOI 10.1016/j.ijmm.2017.07.007; Marques-da-Silva C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030400; Mauduit M, 2010, INFECT IMMUN, V78, P2182, DOI 10.1128/IAI.01415-09; McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881; Moise L, 2015, HUM VACC IMMUNOTHER, V11, P2312, DOI 10.1080/21645515.2015.1061159; Moise L, 2013, HUM VACC IMMUNOTHER, V9, P1577, DOI 10.4161/hv.24615; Molina-Franky J, 2020, MALARIA J, V19, DOI 10.1186/s12936-020-3141-z; Morse D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158174; NUSSENZWEIG RS, 1967, NATURE, V216, P160, DOI 10.1038/216160a0; Oehring SC, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-11-r108; Rao XY, 2011, IMMUNOGENETICS, V63, P691, DOI 10.1007/s00251-011-0552-6; RIECKMANN KH, 1974, T ROY SOC TROP MED H, V68, P258, DOI 10.1016/0035-9203(74)90129-1; RODRIGUES M, 1993, IMMUNOLOGY, V80, P1; SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0; Sette A, 1999, IMMUNOGENETICS, V50, P201, DOI 10.1007/s002510050594; SETTE A, 1994, J IMMUNOL, V153, P5586; Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1; Silvie O, 2002, PARASITE IMMUNOL, V24, P221, DOI 10.1046/j.1365-3024.2002.00450.x; Spearman P, 2016, VACCINE, V34, P5571, DOI 10.1016/j.vaccine.2016.09.041; Stone BC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153449; SUHRBIER A, 1990, INFECT IMMUN, V58, P2834, DOI 10.1128/IAI.58.9.2834-2839.1990; Tarun AS, 2008, P NATL ACAD SCI USA, V105, P305, DOI 10.1073/pnas.0710780104; Todryk SM, 2005, IMMUNOLOGY, V115, P163, DOI 10.1111/j.1365-2567.2005.02154.x; Tucker K, 2016, CURRENT TOPICS IN MALARIA, P335, DOI 10.5772/65592; Wang SF, 2016, IMMUNOL RES, V64, P908, DOI 10.1007/s12026-016-8795-9; Weiss WR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031247; WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573; Wolfl M, 2014, NAT PROTOC, V9, P950, DOI 10.1038/nprot.2014.064; Wu T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10661-8; Yang ASP, 2017, CELL REP, V18, P3105, DOI 10.1016/j.celrep.2017.03.017	61	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 7	2021	12								684116	10.3389/fimmu.2021.684116	http://dx.doi.org/10.3389/fimmu.2021.684116			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SF1BH	34025684	Green Published, gold			2022-12-18	WOS:000652497800001
J	Kamali, K; Schmelzle, M; Kamali, C; Brunnbauer, P; Splith, K; Leder, A; Berndt, N; Hillebrandt, KH; Raschzok, N; Feldbrugge, L; Felsenstein, M; Gassner, J; Ritschl, P; Lurje, G; Schoning, W; Benzing, C; Pratschke, J; Krenzien, F				Kamali, Kaan; Schmelzle, Moritz; Kamali, Can; Brunnbauer, Philipp; Splith, Katrin; Leder, Annekatrin; Berndt, Nadja; Hillebrandt, Karl-Herbert; Raschzok, Nathanael; Feldbruegge, Linda; Felsenstein, Matthaeus; Gassner, Joseph; Ritschl, Paul; Lurje, Georg; Schoening, Wenzel; Benzing, Christian; Pratschke, Johann; Krenzien, Felix			Sensing Acute Cellular Rejection in Liver Transplant Patients Using Liver-Derived Extracellular Particles: A Prospective, Observational Study	FRONTIERS IN IMMUNOLOGY			English	Article						acute cellular liver transplant rejection; extracellular particles (EP); FlowSOM; liver transplantation; liquid biopsy; t-SNE (t-Distributed Stochastic Neighbor Embedding); sensitivity and specificity	NECROSIS FACTOR-ALPHA; ASIALOGLYCOPROTEIN RECEPTOR; MICROPARTICLES; VISUALIZATION; INTERLEUKIN-6; INFLAMMATION; CONTRIBUTES; ACTIVATION; MECHANISMS; TARGET	Acute cellular rejection (ACR) after liver transplantation (LT) goes along with allograft dysfunction, which is diagnosed by liver biopsy and concomitant histological analysis, representing the gold standard in clinical practice. Yet, liver biopsies are invasive, costly, time-intensive and require expert knowledge. Herein we present substantial evidence that blood plasma residing peripheral liver-derived extracellular particles (EP) could be employed to diagnose ACR non-invasively. In vitro experiments showed organ-specific EP release from primary human hepatocytes under immunological stress. Secondly, analysis of consecutive LT patients (n=11) revealed significant heightened EP concentrations days before ACR. By conducting a diagnostic accuracy study (n = 69, DRKS00011631), we explored the viability of using EP as a liquid biopsy for diagnosing ACR following LT. Consequently, novel EP populations in samples were identified using visualization of t-distributed stochastic neighbor embedding (viSNE) and self-organizing maps (FlowSOM) algorithms. As a result, the ASGR1(+)CD130(+)Annexin V+ EP subpopulation exhibited the highest accuracy for predicting ACR (area under the curve: 0.80, 95% confidence interval [CI], 0.70-0.90), with diagnostic sensitivity and specificity of 100% (95% CI, 81.67-100.0%) and 68.5% (95% CI, 55.3-79.3%), respectively. In summary, this new EP subpopulation presented the highest diagnostic accuracy for detecting ACR in LT patients.	[Kamali, Kaan; Schmelzle, Moritz; Kamali, Can; Brunnbauer, Philipp; Splith, Katrin; Leder, Annekatrin; Berndt, Nadja; Hillebrandt, Karl-Herbert; Raschzok, Nathanael; Feldbruegge, Linda; Felsenstein, Matthaeus; Gassner, Joseph; Ritschl, Paul; Lurje, Georg; Schoening, Wenzel; Benzing, Christian; Pratschke, Johann; Krenzien, Felix] Humboldt Univ, Freie Univ Berlin, Charite Univ Med, Dept Surg,Berlin Inst Hlth, Berlin, Germany; [Hillebrandt, Karl-Herbert; Felsenstein, Matthaeus; Ritschl, Paul; Krenzien, Felix] Berlin Inst Hlth BIH, Berlin, Germany	Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health	Krenzien, F (corresponding author), Humboldt Univ, Freie Univ Berlin, Charite Univ Med, Dept Surg,Berlin Inst Hlth, Berlin, Germany.; Krenzien, F (corresponding author), Berlin Inst Hlth BIH, Berlin, Germany.	felix.krenzien@charite.de	Kamalı, Can/HGU-9071-2022	Kamalı, Can/0000-0003-1190-6775; /0000-0003-4610-1766; Raschzok, Nathanael/0000-0001-5074-7063; Lurje, Georg/0000-0001-9674-0756; Felsenstein, Matthaus/0000-0003-3146-8717; Splith, Katrin/0000-0002-1841-1495; Schoning, Wenzel/0000-0002-0446-5126; , Linda/0000-0002-3372-609X; Hillebrandt, Karl/0000-0002-5114-6590	German Research Foundation (DFG) [SCHM2661/3-1, SCHM2661/3-2]; Federal Ministry of Economics and Technology (BMWI) [F4245601SK6]	German Research Foundation (DFG)(German Research Foundation (DFG)); Federal Ministry of Economics and Technology (BMWI)(Federal Ministry for Economic Affairs and Energy (BMWi))	This work was supported by grants from the German Research Foundation (DFG, SCHM2661/3-1 and SCHM2661/3-2) and the Federal Ministry of Economics and Technology (BMWI, F4245601SK6).	Abdallah AN, 1997, EUR HEART J, V18, P1024; Amir ED, 2013, NAT BIOTECHNOL, V31, P545, DOI 10.1038/nbt.2594; Andreou A, 2015, HPB, V17, P168, DOI 10.1111/hpb.12345; Balasubramaniyan V, 2013, J HEPATOL, V58, P1194, DOI 10.1016/j.jhep.2013.01.023; Beggs KM, 2014, TOXICOL SCI, V137, P91, DOI 10.1093/toxsci/kft226; Bossuyt PM, 2015, BMJ-BRIT MED J, V351, DOI [10.1148/radiol.2015151516, 10.1136/bmj.h5527, 10.1373/clinchem.2015.246280]; Bradley JR, 2008, J PATHOL, V214, P149, DOI 10.1002/path.2287; BUBAK ME, 1991, HEPATOLOGY, V14, P1063, DOI 10.1002/hep.1840140619; BURGESS JB, 1992, HEPATOLOGY, V15, P702, DOI 10.1002/hep.1840150425; Chae MS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195262; Connor DE, 2010, THROMB HAEMOSTASIS, V103, P1044, DOI 10.1160/TH09-09-0644; Elferink RPJO, 2007, PFLUG ARCH EUR J PHY, V453, P601, DOI 10.1007/s00424-006-0062-9; Eugenin EA, 2007, CELL IMMUNOL, V247, P103, DOI 10.1016/j.cellimm.2007.08.001; Fingas CD, 2018, EXP CLIN TRANSPLANT, V16, P554, DOI 10.6002/ect.2017.0039; Fink K, 2011, CRIT CARE, V15, DOI 10.1186/cc10512; Horner R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43042-8; Jordan SC, 2017, TRANSPLANTATION, V101, P32, DOI 10.1097/TP.0000000000001452; Julich-Haertel H, 2017, J HEPATOL, V67, P282, DOI 10.1016/j.jhep.2017.02.024; Kim H, 1997, J BIOL CHEM, V272, P30741, DOI 10.1074/jbc.272.49.30741; Kim JY, 2017, TRANSPLANT DIRECT, V3, DOI 10.1097/TXD.0000000000000646; KITA Y, 1994, TRANSPLANTATION, V57, P1037, DOI 10.1097/00007890-199404150-00009; Kornek M, 2011, HEPATOLOGY, V53, P230, DOI 10.1002/hep.23999; Krenzien F, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051543; Krenzien F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00758; Krenzien F, 2015, TRANSPLANTATION, V99, P2258, DOI 10.1097/TP.0000000000000842; Liu R, 2009, EUR J HAEMATOL, V83, P220, DOI 10.1111/j.1600-0609.2009.01271.x; Lotvall J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.26913; Maes M, 2016, BBA-MOL BASIS DIS, V1862, P1111, DOI 10.1016/j.bbadis.2016.02.007; MAURY CPJ, 1987, J EXP MED, V166, P1132, DOI 10.1084/jem.166.4.1132; Morel O, 2008, J HEART LUNG TRANSPL, V27, P38, DOI 10.1016/j.healun.2007.09.031; Morel O, 2011, ARTERIOSCL THROM VAS, V31, P15, DOI 10.1161/ATVBAHA.109.200956; Morgul MH, 2018, BIOMARKERS, V23, P25, DOI 10.1080/1354750X.2017.1306754; NAKAYA R, 1994, J GASTROENTEROL, V29, P24, DOI 10.1007/BF01229069; Nielsen MH, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.20795; Olsen JA, 2020, NAT STRUCT MOL BIOL, V27, P62, DOI 10.1038/s41594-019-0354-3; Parida BK, 2015, THROMB RES, V135, P1000, DOI 10.1016/j.thromres.2015.02.011; Qamri Z, 2014, TRANSPL IMMUNOL, V31, P60, DOI 10.1016/j.trim.2014.06.006; Rebouissou S, 2009, NATURE, V457, P200, DOI 10.1038/nature07475; Robert S, 2012, ARTERIOSCL THROM VAS, V32, P1054, DOI 10.1161/ATVBAHA.111.244616; Rodriguez-Peralvarez M, 2016, TRANSPL INT, V29, P961, DOI 10.1111/tri.12737; Roggenbuck D, 2012, AUTOIMMUN HIGHLIGHTS, V3, P119, DOI 10.1007/s13317-012-0041-4; Roufosse C, 2018, TRANSPLANTATION, V102, P1795, DOI 10.1097/TP.0000000000002366; Schmelzle M, 2013, TRANSPLANTATION, V95, P63, DOI 10.1097/TP.0b013e318278d3cd; Shi B, 2013, J HISTOCHEM CYTOCHEM, V61, P901, DOI 10.1369/0022155413503662; Tacke F, 2016, LIVER TRANSPLANT, V22, P1136, DOI 10.1002/lt.24461; Trautwein C, 1996, GASTROENTEROLOGY, V110, P1854, DOI 10.1053/gast.1996.v110.pm8964411; Van Gassen S, 2015, CYTOM PART A, V87A, P636, DOI 10.1002/cyto.a.22625; Welsh JA, 2020, CYTOM PART A, V97, P592, DOI 10.1002/cyto.a.24029	48	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 5	2021	12								647900	10.3389/fimmu.2021.647900	http://dx.doi.org/10.3389/fimmu.2021.647900			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SD8CS	34025656	gold, Green Published			2022-12-18	WOS:000651603600001
J	Bacigalupo, A; Innocenti, I; Rossi, E; Sora, F; Galli, E; Autore, F; Metafuni, E; Chiusolo, P; Giammarco, S; Laurenti, L; Benintende, G; Sica, S; De Stefano, V				Bacigalupo, Andrea; Innocenti, Idanna; Rossi, Elena; Sora, Federica; Galli, Eugenio; Autore, Francesco; Metafuni, Elisabetta; Chiusolo, Patrizia; Giammarco, Sabrina; Laurenti, Luca; Benintende, Giulia; Sica, Simona; De Stefano, Valerio			Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021	FRONTIERS IN IMMUNOLOGY			English	Review						myelofibrosis; allogeneic transplantation; busulfan; thiotepa; fludarabine chimerism; splenectomy	SURVIVAL; RUXOLITINIB	The aim of this review is to update the current status of allogeneic hemopoietic stem cell transplants (HSCT) for patients with myelofibrosis (MF). We have first summarized the issue of an indication for allogeneic HSCT, discussing several prognostic scoring systems, developed to predict the outcome of MF, and therefore to identify patients who will benefit of an allogeneic HSCT. Patients with low risk MF are usually not selected for a transplant, whereas patients with intermediate or high risk MF are eligible. A separate issue, is how to predict the outcome of HSCT: we will outline a clinical molecular myelofibrosis transplant scoring system (MTSS), which predicts overall survival, ranging from 90% for low risk patients, to 20% for very high risk patients. We will also discuss transfusion burden and spleen size, as predictors of transplant outcome. The choice of a transplant platform including the conditioning regimen, the stem cell source and GvHD prophylaxis, are crucial for a successful program in MF, and will be outlined. Complications such as poor graft function, graft failure, GvHD and relapse of the disease, will also be reviewed. Finally we discuss monitoring the disease after HSCT with donor chimerism, driver mutations and hematologic data. We have made an effort to make this review as comprehensive and up to date as possible, and we hope it will provide some useful data for the clinicians.	[Bacigalupo, Andrea; Innocenti, Idanna; Rossi, Elena; Sora, Federica; Galli, Eugenio; Autore, Francesco; Metafuni, Elisabetta; Chiusolo, Patrizia; Giammarco, Sabrina; Laurenti, Luca; Sica, Simona; De Stefano, Valerio] Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Diagnost Immagini Radioterapia Oncol, Rome, Italy; [Bacigalupo, Andrea; Rossi, Elena; Sora, Federica; Chiusolo, Patrizia; Laurenti, Luca; Benintende, Giulia; Sica, Simona; De Stefano, Valerio] Univ Cattolica Sacro Cuore, Dipartimento Sci Radiol & Ematol, Sez Ematol, Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Bacigalupo, A (corresponding author), Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Diagnost Immagini Radioterapia Oncol, Rome, Italy.; Bacigalupo, A (corresponding author), Univ Cattolica Sacro Cuore, Dipartimento Sci Radiol & Ematol, Sez Ematol, Rome, Italy.	andrea.bacigalupo@unicatt.it	Metafuni, Elisabetta/AGG-8040-2022; CHIUSOLO, PATRIZIA/J-3003-2018	Metafuni, Elisabetta/0000-0002-4780-1273; CHIUSOLO, PATRIZIA/0000-0002-1355-1587; Galli, Eugenio/0000-0002-2839-916X; Benintende, Giulia/0000-0002-7826-5645	AIRC, Associazione Italiana Ricerca contro il Cancro	AIRC, Associazione Italiana Ricerca contro il Cancro	This study was partly funded by AIRC, Associazione Italiana Ricerca contro il Cancro; grant to AB.	Abd Kadir SSS, 2018, EUR J HAEMATOL, V101, P305, DOI 10.1111/ejh.13099; Abelsson J, 2012, BONE MARROW TRANSPL, V47, P380, DOI 10.1038/bmt.2011.91; Akpek G, 2013, BONE MARROW TRANSPL, V48, P825, DOI 10.1038/bmt.2012.249; Alchalby H, 2010, BONE MARROW TRANSPL, V45, P1404, DOI 10.1038/bmt.2009.367; Alchalby H, 2012, BRIT J HAEMATOL, V157, P75, DOI 10.1111/j.1365-2141.2011.09009.x; Alchalby H, 2010, BLOOD, V116, P3572, DOI 10.1182/blood-2009-12-260588; Bacigalupo A, 2010, BONE MARROW TRANSPL, V45, P458, DOI 10.1038/bmt.2009.188; Ballen KK, 2010, BIOL BLOOD MARROW TR, V16, P358, DOI 10.1016/j.bbmt.2009.10.025; Bannow BTS, 2018, BIOL BLOOD MARROW TR, V24, P386, DOI 10.1016/j.bbmt.2017.09.016; Barbuil T, 2018, LEUKEMIA, V32, P1057, DOI 10.1038/s41375-018-0077-1; Bouabdallah R, 2000, LEUKEMIA RES, V24, P491, DOI 10.1016/S0145-2126(00)00018-7; Bregante S, 2016, BIOL BLOOD MARROW TR, V22, P324, DOI 10.1016/j.bbmt.2015.09.028; Cervantes F, 2011, BLOOD CANCER J, V1, DOI 10.1038/bcj.2011.36; Cervantes F, 2009, BLOOD, V113, P2895, DOI 10.1182/blood-2008-07-170449; Chhabra S, 2020, BIOL BLOOD MARROW TR, V26, P893, DOI 10.1016/j.bbmt.2020.01.010; Chiusolo P, 2021, AM J HEMATOL, V96, P234, DOI 10.1002/ajh.26042; Ditschkowski M, 2006, BIOL BLOOD MARROW TR, V12, P1350, DOI 10.1016/j.bbmt.2006.07.010; Elliott MA, 1998, BRIT J HAEMATOL, V103, P505, DOI 10.1046/j.1365-2141.1998.00998.x; Gagelmann Nico, 2019, Biol Blood Marrow Transplant, V25, pe204, DOI 10.1016/j.bbmt.2019.03.024; Gagelmann N, 2019, BLOOD, V133, P2233, DOI 10.1182/blood-2018-12-890889; Gangat N, 2011, J CLIN ONCOL, V29, P392, DOI 10.1200/JCO.2010.32.2446; Guardiola P, 1999, BLOOD, V93, P2831; Guglielmelli P, 2018, J CLIN ONCOL, V36, P310, DOI 10.1200/JCO.2017.76.4886; Gupta V, 2009, BONE MARROW TRANSPL, V44, P317, DOI 10.1038/bmt.2009.10; Gupta V, 2019, BIOL BLOOD MARROW TR, V25, P256, DOI 10.1016/j.bbmt.2018.09.001; Gupta V, 2014, BIOL BLOOD MARROW TR, V20, P89, DOI 10.1016/j.bbmt.2013.10.018; Harrison C, 2012, NEW ENGL J MED, V366, P787, DOI 10.1056/NEJMoa1110556; Kalman NS, 2017, LEUKEMIA LYMPHOMA, V58, P2983, DOI 10.1080/10428194.2017.1321747; Kanate AS, 2020, BIOL BLOOD MARROW TR, V26, P1247, DOI 10.1016/j.bbmt.2020.03.002; Keyzner A, 2016, BIOL BLOOD MARROW TR, V22, P2180, DOI 10.1016/j.bbmt.2016.08.029; Klyuchnikov E, 2012, BRIT J HAEMATOL, V159, P172, DOI 10.1111/bjh.12013; Kroger N, 2018, BIOL BLOOD MARROW TR, V24, P2152, DOI 10.1016/j.bbmt.2018.05.023; Kroger N, 2017, BIOL BLOOD MARROW TR, V23, P1095, DOI 10.1016/j.bbmt.2017.03.034; Kroger N, 2015, BLOOD, V125, P3347, DOI 10.1182/blood-2014-10-608315; Kroger N, 2009, BLOOD, V114, P5264, DOI 10.1182/blood-2009-07-234880; Kroger N, 2005, BRIT J HAEMATOL, V128, P690, DOI 10.1111/j.1365-2141.2005.05373.x; Malato A, 2020, CL LYMPH MYELOM LEUK, V20, P588, DOI 10.1016/j.clml.2020.04.015; MARTINO R, 1994, ACTA HAEMATOL-BASEL, V92, P167; McLornan D, 2019, BIOL BLOOD MARROW TR, V25, P2167, DOI 10.1016/j.bbmt.2019.06.034; McLornan DP, 2019, HAEMATOLOGICA, V104, P659, DOI 10.3324/haematol.2018.206151; McLornan DP, 2018, BRIT J HAEMATOL, V182, P418, DOI 10.1111/bjh.15407; Morozova EV, 2021, ACTA HAEMATOL-BASEL, V144, P158, DOI 10.1159/000506758; Murata M, 2019, BIOL BLOOD MARROW TR, V25, P1536, DOI 10.1016/j.bbmt.2019.02.019; Olsson RF, 2015, LEUKEMIA, V29, P1754, DOI 10.1038/leu.2015.75; Panagiota V, 2014, LEUKEMIA, V28, P1552, DOI 10.1038/leu.2014.66; Passamonti F, 2010, BLOOD, V115, P1703, DOI 10.1182/blood-2009-09-245837; Patriarca F, 2008, HAEMATOL-HEMATOL J, V93, P1514, DOI 10.3324/haematol.12828; Patriarca F, 2019, BIOL BLOOD MARROW TR, V25, P932, DOI 10.1016/j.bbmt.2018.12.064; Raj K, 2019, BIOL BLOOD MARROW TR, V25, P522, DOI 10.1016/j.bbmt.2018.10.017; Robin M, 2019, HAEMATOLOGICA, V104, P1782, DOI 10.3324/haematol.2018.205211; Robin M, 2017, BIOL BLOOD MARROW TR, V23, P958, DOI 10.1016/j.bbmt.2017.03.002; Robin M, 2016, BIOL BLOOD MARROW TR, V22, P1206, DOI 10.1016/j.bbmt.2016.02.019; Robin M, 2014, BIOL BLOOD MARROW TR, V20, P1841, DOI 10.1016/j.bbmt.2014.06.011; Robin M, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.306.306; Robin M, 2011, BRIT J HAEMATOL, V152, P331, DOI 10.1111/j.1365-2141.2010.08417.x; Rondelli D, 2014, BLOOD, V124, P1183, DOI 10.1182/blood-2014-04-572545; Rumi E, 2010, BONE MARROW TRANSPL, V45, P798, DOI 10.1038/bmt.2009.231; Salas MQ, 2019, EUR J HAEMATOL, V103, P597, DOI 10.1111/ejh.13327; Santos FPS, 2014, LEUKEMIA LYMPHOMA, V55, P121, DOI 10.3109/10428194.2013.794269; Slot S, 2015, BONE MARROW TRANSPL, V50, P1424, DOI 10.1038/bmt.2015.172; Stasia A, 2014, BIOL BLOOD MARROW TR, V20, P1440, DOI 10.1016/j.bbmt.2014.05.016; Tefferi A, 2000, BLOOD, V95, P2226, DOI 10.1182/blood.V95.7.2226.007k19_2226_2233; Tefferi A, 2018, AM J HEMATOL, V93, P649, DOI 10.1002/ajh.25053; Tefferi A, 2018, AM J HEMATOL, V93, P348, DOI 10.1002/ajh.24978; Tefferi A, 2017, AM J HEMATOL, V92, P1187, DOI 10.1002/ajh.24881; Verstovsek S, 2012, NEW ENGL J MED, V366, P799, DOI 10.1056/NEJMoa1110557; VONBUELTZINGSLOEWEN A, 1994, BONE MARROW TRANSPL, V14, P339; Vyas OH, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.3170.3170; WAGNER H, 1986, CANCER, V58, P1204, DOI 10.1002/1097-0142(19860915)58:6<1204::AID-CNCR2820580605>3.0.CO;2-G; Wolschke C, 2017, BONE MARROW TRANSPL, V52, P1526, DOI 10.1038/bmt.2017.157	70	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 4	2021	12								637512	10.3389/fimmu.2021.637512	http://dx.doi.org/10.3389/fimmu.2021.637512			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SD5JU	34017327	gold, Green Published			2022-12-18	WOS:000651409700001
J	Paganini, J; Pontarotti, P				Paganini, Julien; Pontarotti, Pierre			Search for MHC/TCR-Like Systems in Living Organisms	FRONTIERS IN IMMUNOLOGY			English	Article						convergent evolution; kin recognition; vegetative incompatibility; self incompatibility; somatic diversification; adaptive immune system evolution	INCOMPATIBILITY; RECOGNITION; ALLORECOGNITION; EVOLUTION	Highly polymorphic loci evolved many times over the history of species. These polymorphic loci are involved in three types of functions: kind recognition, self-incompatibility, and the jawed vertebrate adaptive immune system (AIS). In the first part of this perspective, we reanalyzed and described some cases of polymorphic loci reported in the literature. There is a convergent evolution within each functional category and between functional categories, suggesting that the emergence of these self/non-self recognition loci has occurred multiple times throughout the evolutionary history. Most of the highly polymorphic loci are coding for proteins that have a homophilic interaction or heterophilic interaction between linked loci, leading to self or non-self-recognition. The highly polymorphic MHCs, which are involved in the AIS have a different functional mechanism, as they interact through presented self or non-self-peptides with T cell receptors, whose diversity is generated by somatic recombination. Here we propose a mechanism called "the capacity of recognition competition mechanism" that might contribute to the evolution of MHC polymorphism. We propose that the published cases corresponding to these three biological categories represent a small part of what can be found throughout the tree of life, and that similar mechanisms will be found many times, including the one where polymorphic loci interact with somatically generated loci.	[Paganini, Julien; Pontarotti, Pierre] XEGEN, Gemenos, France; [Pontarotti, Pierre] Aix Marseille Univ, IHU Mediterranee Infect, AP HM, IRD,MEPHI, Marseille, France; [Pontarotti, Pierre] SNC5039 CNRS, Marseille, France	Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Paganini, J; Pontarotti, P (corresponding author), XEGEN, Gemenos, France.; Pontarotti, P (corresponding author), Aix Marseille Univ, IHU Mediterranee Infect, AP HM, IRD,MEPHI, Marseille, France.; Pontarotti, P (corresponding author), SNC5039 CNRS, Marseille, France.	julien.paganini@xegen.fr; pierre.pontarotti@univ-amu.fr	, pontarotti/ABB-1753-2021		French Government under the "Investissements D'avenir" (Investments for the Future) programme [10-IAHU-03]; XEGEN RD company	French Government under the "Investissements D'avenir" (Investments for the Future) programme(French National Research Agency (ANR)); XEGEN RD company	This research was funded by the French Government under the "Investissements D'avenir" (Investments for the Future) programme managed by the Agence Nationale de la Recherche (ANR, fr: National Agency for Research), (reference: Me ' diterrane ' e Infection 10-IAHU-03) and XEGEN R&D company funding.	Abi-Rached L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206512; Arakawa H, 2002, SCIENCE, V295, P1301, DOI 10.1126/science.1067308; Aziz RK, 2010, NUCLEIC ACIDS RES, V38, P4207, DOI 10.1093/nar/gkq140; Benabentos R, 2009, CURR BIOL, V19, P567, DOI 10.1016/j.cub.2009.02.037; Bod'ova K, 2018, GENETICS, V209, P861, DOI 10.1534/genetics.118.300748; Boehm T, 2006, CELL, V125, P845, DOI 10.1016/j.cell.2006.05.017; Bradley P, 2019, ANNU REV IMMUNOL, V37, P547, DOI 10.1146/annurev-immunol-042718-041757; Cardarelli L, 2015, MBIO, V6, DOI 10.1128/mBio.00251-15; Carlon DB, 1999, TRENDS ECOL EVOL, V14, P491, DOI 10.1016/S0169-5347(99)01709-7; CHARLESWORTH D, 1987, ANNU REV ECOL SYST, V18, P237, DOI 10.1146/annurev.es.18.110187.001321; Espinosa A, 2014, EVOL ECOL, V28, P1019, DOI 10.1007/s10682-014-9721-z; Fugmann SD, 2010, SEMIN IMMUNOL, V22, P10, DOI 10.1016/j.smim.2009.11.004; Fujii S, 2016, NAT PLANTS, V2, DOI [10.1038/nplants.2016.130, 10.1038/NPLANTS.2016.130]; Gardner A, 2010, EVOLUTION, V64, P25, DOI 10.1111/j.1558-5646.2009.00842.x; Gloria-Soria A, 2012, MOL BIOL EVOL, V29, P3921, DOI 10.1093/molbev/mss197; GROSBERG RK, 1988, Q REV BIOL, V63, P377, DOI 10.1086/416026; Gruenheit N, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14171; Harada Y, 2008, SCIENCE, V320, P548, DOI 10.1126/science.1152488; Hattori D, 2008, ANNU REV CELL DEV BI, V24, P597, DOI 10.1146/annurev.cellbio.24.110707.175250; Heller J, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002431; Kaneko I, 2006, GENETICS, V172, P1545, DOI 10.1534/genetics.105.051490; KRAMER AP, 1985, J NEUROSCI, V5, P768; Kuaes U., 2011, EVOLUTION FUNGI FUNG, V14, DOI [10.1007/978-3-642-19974-5_6, DOI 10.1007/978-3-642-19974-5_6]; Maddison DR, 2007, ZOOTAXA, P19, DOI 10.11646/zootaxa.1668.1.4; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7; Nieuwenhuis BPS, 2013, HEREDITY, V111, P445, DOI 10.1038/hdy.2013.67; Niu SC, 2017, FRONT PLANT SCI, V8, DOI 10.3389/fpls.2017.01106; Norman PJ, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003938; Ostrowski EA, 2015, CURR BIOL, V25, P1661, DOI 10.1016/j.cub.2015.04.059; Paganini J, 2019, HLA, V93, P131, DOI 10.1111/tan.13455; Paoletti M, 2016, FUNGAL BIOL REV, V30, P152, DOI 10.1016/j.fbr.2016.08.002; Pontarotti P., 2018, ORIGIN EVOLUTION BIO, DOI [10.1007/978-3-319-95954-2_8, DOI 10.1007/978-3-319-95954-2_8]; Quinn JF., 1988, EVOLUTION ALLORECOGN, DOI [10.1007/978-1-4613-1053-2_12, DOI 10.1007/978-1-4613-1053-2_12]; Robinson J, 2020, NUCLEIC ACIDS RES, V48, pD948, DOI 10.1093/nar/gkz950; Rosengarten RD, 2011, MOL BIOL EVOL, V28, P933, DOI 10.1093/molbev/msq282; Rosental B, 2018, NATURE, V564, P425, DOI 10.1038/s41586-018-0783-x; Rossjohn J, 2015, ANNU REV IMMUNOL, V33, P169, DOI 10.1146/annurev-immunol-032414-112334; Saak CC, 2016, J BACTERIOL, V198, P3278, DOI 10.1128/JB.00402-16; Sandstrom A, 2014, IMMUNITY, V40, P490, DOI 10.1016/j.immuni.2014.03.003; Sarkizova S, 2020, NAT BIOTECHNOL, V38, P199, DOI 10.1038/s41587-019-0322-9; Saupe SJ, 2000, MICROBIOL MOL BIOL R, V64, P489, DOI 10.1128/MMBR.64.3.489-502.2000; Sawada H, 2014, BIOCHEM BIOPH RES CO, V450, P1142, DOI 10.1016/j.bbrc.2014.05.099; SCOFIELD VL, 1982, NATURE, V295, P499, DOI 10.1038/295499a0; Sewell AK, 2012, NAT REV IMMUNOL, V12, P668, DOI 10.1038/nri3279; Smith ML, 2000, GENETICS, V155, P1095; Speijer D, 2015, P NATL ACAD SCI USA, V112, P8827, DOI 10.1073/pnas.1501725112; Teng G, 2015, ADV IMMUNOL, V128, P1, DOI 10.1016/bs.ai.2015.07.002; Thu CA, 2014, CELL, V158, P1045, DOI 10.1016/j.cell.2014.07.012; Tsakou-Ngouafo L., 2020, DDE TRANSPOSON PUBLI, P337, DOI [10.1007/978-3-030-57246-4_14, DOI 10.1007/978-3-030-57246-4_14]; Tsakou-Ngouafo L, 2020, TRENDS IMMUNOL, V41, P561, DOI 10.1016/j.it.2020.05.002; Vassallo CM, 2017, ELIFE, V6, DOI 10.7554/eLife.29397; Vivier E, 2016, NAT IMMUNOL, V17, P790, DOI 10.1038/ni.3459; Voskoboynik A, 2013, SCIENCE, V341, P384, DOI 10.1126/science.1238036; Wall D, 2016, ANNU REV MICROBIOL, V70, P143, DOI 10.1146/annurev-micro-102215-095325; Wielgoss S, 2018, MOL ECOL, V27, P3146, DOI 10.1111/mec.14773; Wucherpfennig KW, 2007, SEMIN IMMUNOL, V19, P216, DOI 10.1016/j.smim.2007.02.012; Yang YY, 2019, IMMUNITY, V50, P1043, DOI 10.1016/j.immuni.2019.02.016; Zhang DP, 2012, BIOL DIRECT, V7, DOI 10.1186/1745-6150-7-18; Zhao JH, 2015, MOL BIOL EVOL, V32, P2417, DOI 10.1093/molbev/msv125	60	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 4	2021	12								635521	10.3389/fimmu.2021.635521	http://dx.doi.org/10.3389/fimmu.2021.635521			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SD2QI	34017326	Green Published, gold			2022-12-18	WOS:000651214300001
J	Kent, A; Longino, NV; Christians, A; Davila, E				Kent, Andrew; Longino, Natalie V.; Christians, Allison; Davila, Eduardo			Naturally Occurring Genetic Alterations in Proximal TCR Signaling and Implications for Cancer Immunotherapy	FRONTIERS IN IMMUNOLOGY			English	Review						T cell (antigen) receptor; cellular immunotherapy; cytokines; T cell signaling; cellular engineering	T-CELL-RECEPTOR; GAMMA-DELTA; FAMILY KINASES; LAT ADAPTER; LCK; ZAP-70; FYN; ACTIVATION; MUTATIONS; CD4	T cell-based immunotherapies including genetically engineered T cells, adoptive transfer of tumor-infiltrating lymphocytes, and immune checkpoint blockade highlight the impressive anti-tumor effects of T cells. These successes have provided new hope to many cancer patients with otherwise poor prognoses. However, only a fraction of patients demonstrates durable responses to these forms of therapies and many develop significant immune-mediated toxicity. These heterogeneous clinical responses suggest that underlying nuances in T cell genetics, phenotypes, and activation states likely modulate the therapeutic impact of these approaches. To better characterize known genetic variations that may impact T cell function, we 1) review the function of early T cell receptor-specific signaling mediators, 2) offer a synopsis of known mutations and genetic alterations within the associated molecules, 3) discuss the link between these mutations and human disease and 4) review therapeutic strategies under development or in clinical testing that target each of these molecules for enhancing anti-tumor T cell activity. Finally, we discuss novel engineering approaches that could be designed based on our understanding of the function of these molecules in health and disease.	[Kent, Andrew; Longino, Natalie V.; Christians, Allison; Davila, Eduardo] Univ Colorado, Dept Med, Div Med Oncol, Aurora, CO 80045 USA; [Kent, Andrew; Longino, Natalie V.; Christians, Allison; Davila, Eduardo] Univ Colorado, Human Immunol & Immunotherapy Initiat, Aurora, CO 80045 USA; [Kent, Andrew; Longino, Natalie V.; Christians, Allison; Davila, Eduardo] Univ Colorado, Comprehens Canc Ctr, Aurora, CO 80045 USA; [Davila, Eduardo] Univ Colorado, Dept Med, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Davila, E (corresponding author), Univ Colorado, Dept Med, Div Med Oncol, Aurora, CO 80045 USA.; Davila, E (corresponding author), Univ Colorado, Human Immunol & Immunotherapy Initiat, Aurora, CO 80045 USA.; Davila, E (corresponding author), Univ Colorado, Comprehens Canc Ctr, Aurora, CO 80045 USA.; Davila, E (corresponding author), Univ Colorado, Dept Med, Aurora, CO 80045 USA.	eduardo.davila@cuanschutz.edu		Christians, Allison/0000-0001-5881-3184	VA Merit Award [I01BX004935]; NCI [R01 CA207913, T32 CA23673402]; University of Colorado Comprehensive Cancer Center	VA Merit Award(US Department of Veterans Affairs); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of Colorado Comprehensive Cancer Center	VA Merit Award I01BX004935; NCI R01 CA207913; NCI T32 CA23673402; University of Colorado Comprehensive Cancer Center	Abate-Daga D, 2016, MOL THER-ONCOLYTICS, V3, DOI 10.1038/mto.2016.14; Acuto O, 2008, NAT REV IMMUNOL, V8, P699, DOI 10.1038/nri2397; Addobbati C, 2013, HUM IMMUNOL, V74, P1009, DOI 10.1016/j.humimm.2013.04.026; ADLER HT, 1992, ONCOGENE, V7, P1191; Aoki H, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03185; Arakawa A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01336; Arnaiz-Villena A, 1993, Immunodeficiency, V4, P121; ARNAIZVILLENA A, 1992, NEW ENGL J MED, V327, P529, DOI 10.1056/NEJM199208203270805; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; Arulraj T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206232; Athari SS, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392-019-0079-0; Au-Yeung BB, 2010, NAT IMMUNOL, V11, P1085, DOI 10.1038/ni.1955; Au-Yeung BB, 2009, IMMUNOL REV, V228, P41, DOI 10.1111/j.1600-065X.2008.00753.x; Bacchelli C, 2017, J ALLERGY CLIN IMMUN, V139, P634, DOI 10.1016/j.jaci.2016.05.036; Balagopalan L, 2015, J BIOL CHEM, V290, P26422, DOI 10.1074/jbc.R115.665869; Balagopalan L, 2011, P NATL ACAD SCI USA, V108, P2885, DOI 10.1073/pnas.1007098108; Barrett DM, 2015, J IMMUNOL, V195, P755, DOI 10.4049/jimmunol.1500751; Ben Mkaddem S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00294-0; Berg RE, 2006, CURR OPIN IMMUNOL, V18, P338, DOI 10.1016/j.coi.2006.03.010; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Bouzid D, 2013, GENET TEST MOL BIOMA, V17, P321, DOI 10.1089/gtmb.2012.0372; Bowers JS, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90772; Bradshaw JM, 2010, CELL SIGNAL, V22, P1175, DOI 10.1016/j.cellsig.2010.03.001; Brazin KN, 2018, IMMUNITY, V49, P829, DOI 10.1016/j.immuni.2018.09.007; Bridgeman JS, 2014, CLIN EXP IMMUNOL, V175, P258, DOI 10.1111/cei.12216; Brownlie R, 2009, IMMUNITY, V31, P174, DOI 10.1016/j.immuni.2009.08.002; Casas J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6624; Cerhan JR, 2012, CANCER EPIDEM BIOMAR, V21, P1799, DOI 10.1158/1055-9965.EPI-12-0696; Chakraborty AK, 2014, NAT IMMUNOL, V15, P798, DOI 10.1038/ni.2940; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; Chen LG, 2008, BLOOD, V111, P2685, DOI 10.1182/blood-2006-12-062265; Chen SY, 2016, CLIN RHEUMATOL, V35, P747, DOI 10.1007/s10067-015-3044-5; Cheroutre H, 2008, IMMUNITY, V28, P149, DOI 10.1016/j.immuni.2008.01.005; Chiang YJ, 2016, EUR J IMMUNOL, V46, P2401, DOI 10.1002/eji.201646440; Cohen CJ, 2007, CANCER RES, V67, P3898, DOI 10.1158/0008-5472.CAN-06-3986; Cohen CJ, 2006, CANCER RES, V66, P8878, DOI 10.1158/0008-5472.CAN-06-1450; Cole DK, 2012, IMMUNOLOGY, V137, P139, DOI 10.1111/j.1365-2567.2012.03625.x; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; Cordova A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049878; Courtney AH, 2018, TRENDS BIOCHEM SCI, V43, P108, DOI 10.1016/j.tibs.2017.11.008; Cui JH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02729; d'Amore F, 2010, BRIT J HAEMATOL, V150, P565, DOI 10.1111/j.1365-2141.2010.08298.x; Dadi HK, 2003, NEW ENGL J MED, V349, P1821, DOI 10.1056/NEJMoa031178; Daniels MA, 2001, IMMUNITY, V15, P1051, DOI 10.1016/S1074-7613(01)00252-7; Dar WA, 2007, IMMUNOLOGY, V120, P467, DOI 10.1111/j.1365-2567.2006.02534.x; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Davidson D, 2007, MOL CELL BIOL, V27, P1960, DOI 10.1128/MCB.01983-06; de Saint Basile G, 2004, J CLIN INVEST, V114, P1512, DOI 10.1172/JCI200422588; Decker CE, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56670-x; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Dobbins J, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf0626; Dong D, 2019, NATURE, V573, P546, DOI 10.1038/s41586-019-1537-0; Donia M, 2012, ONCOIMMUNOLOGY, V1, P1297, DOI 10.4161/onci.21659; Dopfer EP, 2014, CELL REP, V7, P1704, DOI 10.1016/j.celrep.2014.04.049; Elder ME, 1996, PEDIATR RES, V39, P743, DOI 10.1203/00006450-199605000-00001; Elder ME, 1998, SEMIN HEMATOL, V35, P310; Ellerman D, 2019, METHODS, V154, P102, DOI 10.1016/j.ymeth.2018.10.026; Enyedy EJ, 2001, ARTHRITIS RHEUM, V44, P1114, DOI 10.1002/1529-0131(200105)44:5<1114::AID-ANR192>3.0.CO;2-B; Ferjeni Z, 2015, IMMUNOL LETT, V163, P1, DOI 10.1016/j.imlet.2014.11.005; Feucht J, 2019, NAT MED, V25, P82, DOI 10.1038/s41591-018-0290-5; Filby A, 2007, J IMMUNOL, V179, P4635, DOI 10.4049/jimmunol.179.7.4635; Firtina S, 2017, IMMUNOGENETICS, V69, P653, DOI 10.1007/s00251-017-1005-7; Fischer A, 2005, CURR OPIN ALLERGY CL, V5, P491, DOI 10.1097/01.all.0000191886.12645.79; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GAJEWSKI TF, 1995, EUR J IMMUNOL, V25, P1836, DOI 10.1002/eji.1830250707; Garcillan B, 2014, J ALLERGY CLIN IMMUN, V133, P1205, DOI 10.1016/j.jaci.2013.10.002; Gascoigne NRJ, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00072; Gattinoni L, 2017, NAT MED, V23, P18, DOI 10.1038/nm.4241; Gaud G, 2018, NAT REV IMMUNOL, V18, P485, DOI 10.1038/s41577-018-0020-8; GELFAND EW, 1995, J EXP MED, V182, P1057, DOI 10.1084/jem.182.4.1057; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Genton C, 2006, J IMMUNOL, V177, P2285, DOI 10.4049/jimmunol.177.4.2285; Gerbec ZJ, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00472; Gil J, 2011, J CLIN INVEST, V121, P3872, DOI 10.1172/JCI44254; Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916; Goebeler ME, 2016, J CLIN ONCOL, V34, P1104, DOI 10.1200/JCO.2014.59.1586; Gokturk B, 2014, SCAND J IMMUNOL, V80, P354, DOI 10.1111/sji.12200; Goldman FD, 1998, J CLIN INVEST, V102, P421, DOI 10.1172/JCI3205; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; Golubovskaya V, 2016, CANCERS, V8, DOI 10.3390/cancers8030036; Golumba-Nagy V, 2018, MOL THER, V26, P2218, DOI 10.1016/j.ymthe.2018.07.005; Gooden MJM, 2011, BRIT J CANCER, V105, P93, DOI 10.1038/bjc.2011.189; Gorentla BK., 2012, CLIN CELL IMMUNOL, V2012, P5, DOI [10.4172/2155-9899.S12-005, DOI 10.4172/2155-9899.S12-005]; Gorman CL, 2008, J IMMUNOL, V180, P1060, DOI 10.4049/jimmunol.180.2.1060; Gruber C, 2004, BIOCHEM PHARMACOL, V67, P1859, DOI 10.1016/j.bcp.2004.01.026; Guittard G, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23549-2; Gulati P, 2018, CLIN CANCER RES, V24, P3981, DOI 10.1158/1078-0432.CCR-17-1788; Haga-Friedman A, 2012, J IMMUNOL, V188, P5538, DOI 10.4049/jimmunol.1103020; Hagberg H, 2005, MED ONCOL, V22, P191, DOI 10.1385/MO:22:2:191; Hauck F, 2012, J ALLERGY CLIN IMMUN, V130, P1144, DOI 10.1016/j.jaci.2012.07.029; Hayday AC, 2009, IMMUNITY, V31, P184, DOI 10.1016/j.immuni.2009.08.006; Hayes SM, 2006, J EXP MED, V203, P47, DOI 10.1084/jem.20051886; Haynes NM, 2001, J IMMUNOL, V166, P182, DOI 10.4049/jimmunol.166.1.182; He QH, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0812-8; He YN, 2015, J BIOL CHEM, V290, P19796, DOI 10.1074/jbc.M115.663799; Hogan SA, 2019, CANCER IMMUNOL RES, V7, P77, DOI 10.1158/2326-6066.CIR-18-0136; Holler PD, 2003, IMMUNITY, V18, P255, DOI 10.1016/S1074-7613(03)00019-0; Holst J, 2008, NAT IMMUNOL, V9, P658, DOI 10.1038/ni.1611; Hong KM, 2017, RHEUMATOLOGY, V56, P467, DOI 10.1093/rheumatology/kew405; Hopkins AC, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122092; Hsu LY, 2009, J EXP MED, V206, P2527, DOI 10.1084/jem.20082902; Irvine DJ, 2002, NATURE, V419, P845, DOI 10.1038/nature01076; Jeon HS, 2013, CLIN CANCER RES, V19, P4185, DOI 10.1158/1078-0432.CCR-12-2792; Jiang LL, 2012, DNA CELL BIOL, V31, P1480, DOI 10.1089/dna.2012.1706; Jiang N, 2011, IMMUNITY, V34, P13, DOI 10.1016/j.immuni.2010.12.017; Juraske C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01579; Kabouridis PS, 2011, MOL MEMBR BIOL, V28, P487, DOI 10.3109/09687688.2011.624990; Kaczanowska S, 2017, CANCER RES, V77, P7049, DOI 10.1158/0008-5472.CAN-17-0653; Kataoka K, 2015, NAT GENET, V47, P1304, DOI 10.1038/ng.3415; Katsuyama T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01088; Keller B, 2016, J EXP MED, V213, P1185, DOI 10.1084/jem.20151110; Kemp KL, 2010, J IMMUNOL, V184, P4178, DOI 10.4049/jimmunol.0901282; Kim YH, 2007, BLOOD, V109, P4655, DOI 10.1182/blood-2006-12-062877; Knox S, 1996, BLOOD, V87, P893, DOI 10.1182/blood.V87.3.893.bloodjournal873893; Knyazhitsky M, 2012, J BIOL CHEM, V287, P19725, DOI 10.1074/jbc.M111.309799; Kofler DM, 2011, MOL THER, V19, P760, DOI 10.1038/mt.2011.9; Koretzky GA, 2010, J IMMUNOL, V185, P2643, DOI 10.4049/jimmunol.1090076; Krangel MS, 2009, CURR OPIN IMMUNOL, V21, P133, DOI 10.1016/j.coi.2009.03.009; Kuball J, 2009, J EXP MED, V206, P463, DOI 10.1084/jem.20082487; Kuball J, 2007, BLOOD, V109, P2331, DOI 10.1182/blood-2006-05-023069; Kuen DS, 2020, IMMUNE NETW, V20, DOI 10.4110/in.2020.20.e6; Kuhns MS, 2006, IMMUNITY, V24, P133, DOI 10.1016/j.immuni.2006.01.006; Laidlaw BJ, 2016, NAT REV IMMUNOL, V16, P102, DOI 10.1038/nri.2015.10; LEDEIST F, 1991, EUR J IMMUNOL, V21, P1641, DOI 10.1002/eji.1830210709; Lee J, 2011, MOL CELL BIOL, V31, P3963, DOI 10.1128/MCB.05297-11; Lee SY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140216; Lee SH, 2011, ANN HUM GENET, V75, P359, DOI 10.1111/j.1469-1809.2010.00637.x; Legut M, 2015, CELL MOL IMMUNOL, V12, P656, DOI 10.1038/cmi.2015.28; Levin SE, 2008, J BIOL CHEM, V283, P15419, DOI 10.1074/jbc.M709000200; Li CY, 2015, EMBO MOL MED, V7, P754, DOI 10.15252/emmm.201404578; Li P, 2016, AUTOIMMUNITY, V49, P466, DOI 10.1080/08916934.2016.1174855; Li SL, 2016, BRIT J DERMATOL, V175, P1204, DOI 10.1111/bjd.14679; Li YL, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00206; Liang PI, 2014, INT J CLIN EXP PATHO, V7, P6097; Lin J, 2001, J BIOL CHEM, V276, P29588, DOI 10.1074/jbc.M102221200; Linka RM, 2012, LEUKEMIA, V26, P963, DOI 10.1038/leu.2011.371; Liu ZY, 2008, J IMMUNOL, V180, P6044, DOI 10.4049/jimmunol.180.9.6044; Lo WL, 2019, NAT IMMUNOL, V20, P1481, DOI 10.1038/s41590-019-0502-2; LUO KX, 1992, MOL CELL BIOL, V12, P4724, DOI 10.1128/MCB.12.10.4724; Malissen B, 2005, ADV IMMUNOL, V87, P1, DOI 10.1016/S0065-2776(05)87001-4; Malissen B, 2014, NAT IMMUNOL, V15, P790, DOI 10.1038/ni.2959; Mancebo E, 2008, MOL IMMUNOL, V45, P479, DOI 10.1016/j.molimm.2007.05.022; Manolios N, 2010, CELL ADHES MIGR, V4, P273, DOI 10.4161/cam.4.2.11909; Martin-Cofreces NB, 2006, J IMMUNOL, V176, P4201, DOI 10.4049/jimmunol.176.7.4201; Martinelli G, 2017, J CLIN ONCOL, V35, P1795, DOI 10.1200/JCO.2016.69.3531; Martinez-Florensa M, 2011, J LEUKOCYTE BIOL, V89, P63, DOI 10.1189/jlb.0509342; Martins M, 2015, GENES IMMUN, V16, P142, DOI 10.1038/gene.2014.73; Matsuda S, 1999, J BIOL CHEM, V274, P34515, DOI 10.1074/jbc.274.49.34515; Matsuda T, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1588085; Mingueneau M, 2009, IMMUNITY, V31, P197, DOI 10.1016/j.immuni.2009.05.013; Moody AM, 2001, CELL, V107, P501, DOI 10.1016/S0092-8674(01)00577-3; Moogk D, 2016, J IMMUNOL, V197, P644, DOI 10.4049/jimmunol.1600178; Morgan NV, 2011, J CLIN INVEST, V121, P695, DOI 10.1172/JCI41931; Moulton VR, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3251; Munoz-Ruiz M, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-3; Muranski P, 2008, BLOOD, V112, P362, DOI 10.1182/blood-2007-11-120998; Nambiar MP, 2003, J IMMUNOL, V170, P2871, DOI 10.4049/jimmunol.170.6.2871; Natarajan A, 2016, CELL REP, V14, P2833, DOI 10.1016/j.celrep.2016.02.081; Nicol AJ, 2011, BRIT J CANCER, V105, P778, DOI 10.1038/bjc.2011.293; Noraz N, 2000, J BIOL CHEM, V275, P15832, DOI 10.1074/jbc.M908568199; Nunez-Cruz S, 2003, NAT IMMUNOL, V4, P999, DOI 10.1038/ni977; Palacios EH, 2004, ONCOGENE, V23, P7990, DOI 10.1038/sj.onc.1208074; Pauza CD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01305; Paz PE, 2001, BIOCHEM J, V356, P461, DOI 10.1042/0264-6021:3560461; Peng XH, 2014, CELL IMMUNOL, V290, P131, DOI 10.1016/j.cellimm.2014.05.012; Pennock ND, 2013, ADV PHYSIOL EDUC, V37, P273, DOI 10.1152/advan.00066.2013; Pinz K, 2016, LEUKEMIA, V30, P701, DOI 10.1038/leu.2015.311; RAAB M, 1995, P NATL ACAD SCI USA, V92, P8891, DOI 10.1073/pnas.92.19.8891; Radvanyi LG, 2012, CLIN CANCER RES, V18, P6758, DOI 10.1158/1078-0432.CCR-12-1177; Rafiq S, 2020, NAT REV CLIN ONCOL, V17, P147, DOI 10.1038/s41571-019-0297-y; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; Rassenti LZ, 2004, NEW ENGL J MED, V351, P893, DOI 10.1056/NEJMoa040857; Recio MJ, 2007, J IMMUNOL, V178, P2556, DOI 10.4049/jimmunol.178.4.2556; Ren-Heidenreich L, 2002, CANCER IMMUNOL IMMUN, V51, P417, DOI 10.1007/s00262-002-0301-7; Rohaan MW, 2019, VIRCHOWS ARCH, V474, P449, DOI 10.1007/s00428-018-2484-0; Roncagalli R, 2014, NAT IMMUNOL, V15, P384, DOI 10.1038/ni.2843; Roncagalli R, 2010, TRENDS IMMUNOL, V31, P253, DOI 10.1016/j.it.2010.05.001; Rowe JH, 2018, BLOOD, V131, P2335, DOI 10.1182/blood-2018-02-835561; Rudolph J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02343; Saini M, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000702; Sakaguchi S, 2006, SEMIN IMMUNOL, V18, P199, DOI 10.1016/j.smim.2006.03.007; Salmikangas P, 2018, PHARM RES-DORDR, V35, DOI 10.1007/s11095-018-2436-z; Sawabe T, 2001, INT J MOL MED, V7, P609; Schaeuble K, 2011, J IMMUNOL, V187, P5645, DOI 10.4049/jimmunol.1101850; Serwas NK, 2014, BLOOD, V124, P655, DOI 10.1182/blood-2014-03-564930; Shalom B, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0091-1; Shen SD, 2009, J IMMUNOL, V182, P5596, DOI 10.4049/jimmunol.0803170; Sheng WW, 2014, EUR J HAEMATOL, V93, P214, DOI 10.1111/ejh.12327; Shitara K, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0677-y; Siggs OM, 2007, IMMUNITY, V27, P912, DOI 10.1016/j.immuni.2007.11.013; Simnica D, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1644110; Slaney CY, 2018, CANCER DISCOV, V8, P924, DOI 10.1158/2159-8290.CD-18-0297; Sledzinska A, 2020, IMMUNITY, V52, P151, DOI 10.1016/j.immuni.2019.12.007; Smith-Garvin JE, 2009, ANNU REV IMMUNOL, V27, P591, DOI 10.1146/annurev.immunol.021908.132706; Sommermeyer D, 2010, J IMMUNOL, V184, P6223, DOI 10.4049/jimmunol.0902055; Sommers CL, 2005, J EXP MED, V201, P1125, DOI 10.1084/jem.20041869; Sommers CL, 2002, SCIENCE, V296, P2040, DOI 10.1126/science.1069066; Sommers CL, 2001, J EXP MED, V194, P135, DOI 10.1084/jem.194.2.135; SOUDAIS C, 1993, NAT GENET, V3, P77, DOI 10.1038/ng0193-77; Stawczyk-Macieja M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163185; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Street SEA, 2004, J EXP MED, V199, P879, DOI 10.1084/jem.20031981; Suryadevara CM, 2019, CLIN CANCER RES, V25, P358, DOI 10.1158/1078-0432.CCR-18-1211; Susa M, 1996, BIOCHEM BIOPH RES CO, V220, P729, DOI 10.1006/bbrc.1996.0472; Takaba H, 2017, TRENDS IMMUNOL, V38, P805, DOI 10.1016/j.it.2017.07.010; Takeuchi T, 1998, INT IMMUNOL, V10, P911, DOI 10.1093/intimm/10.7.911; Tasher D, 2012, APPL CLIN GENET, V5, P67, DOI 10.2147/TACG.S18693; Teruel M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068295; Thakar MS, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01529; THOENES G, 1992, J BIOL CHEM, V267, P487; Tie GD, 2017, CANCER RES, V77, P2351, DOI 10.1158/0008-5472.CAN-16-1916; Toyabe S, 2001, IMMUNOLOGY, V103, P164, DOI 10.1046/j.1365-2567.2001.01246.x; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; Tsuzaka K, 2003, J IMMUNOL, V171, P2496, DOI 10.4049/jimmunol.171.5.2496; Tsuzaka K, 1998, J AUTOIMMUN, V11, P381, DOI 10.1006/jaut.1998.0223; TYCKO B, 1991, J EXP MED, V174, P867, DOI 10.1084/jem.174.4.867; Ueda A, 2012, J IMMUNOL, V188, P5247, DOI 10.4049/jimmunol.1102241; Ueha S, 2015, CANCER IMMUNOL RES, V3, P631, DOI 10.1158/2326-6066.CIR-14-0190; Utting O, 2001, J IMMUNOL, V166, P1540, DOI 10.4049/jimmunol.166.3.1540; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; Varma R, 2006, IMMUNITY, V25, P117, DOI 10.1016/j.immuni.2006.04.010; Walk SF, 1998, EUR J IMMUNOL, V28, P2265, DOI 10.1002/(SICI)1521-4141(199808)28:08<2265::AID-IMMU2265>3.0.CO;2-P; Wang HP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002279; Wang JH, 2001, P NATL ACAD SCI USA, V98, P10799, DOI 10.1073/pnas.191124098; Wang JH, 2012, IMMUNOL REV, V250, P102, DOI 10.1111/j.1600-065X.2012.01161.x; Wang R, 2009, J IMMUNOL, V183, P2554, DOI 10.4049/jimmunol.0901276; Wang XX, 2011, P NATL ACAD SCI USA, V108, P15960, DOI 10.1073/pnas.1109438108; Wang XL, 2016, BLOOD, V127, P2980, DOI 10.1182/blood-2015-12-686725; Wang YK, 2020, ANN RHEUM DIS, V79, P268, DOI 10.1136/annrheumdis-2019-215533; Watson ARO, 2012, CELL IMMUNOL, V276, P16, DOI 10.1016/j.cellimm.2012.02.003; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Wong NML, 2018, ACS SYNTH BIOL, V7, P969, DOI 10.1021/acssynbio.7b00394; Wu L, 2020, CELL MOL IMMUNOL, V17, P600, DOI 10.1038/s41423-020-0470-3; Wucherpfennig KW, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a005140; Wucherpfennig KW, 2009, CURR OPIN IMMUNOL, V21, P590, DOI 10.1016/j.coi.2009.07.008; Yamasaki S, 2003, MOL CELL BIOL, V23, P2515, DOI 10.1128/MCB.23.7.2515-2529.2003; Yan QR, 2013, MOL CELL BIOL, V33, P2188, DOI 10.1128/MCB.01637-12; Yu GP, 2011, PEDIATR TRANSPLANT, V15, P733, DOI 10.1111/j.1399-3046.2011.01563.x; Yu XZ, 2004, J IMMUNOL, V172, P1437, DOI 10.4049/jimmunol.172.3.1437; Zhang CM, 2018, PERS MED, V15, P167, DOI 10.2217/pme-2017-0071; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhu QW, 2019, PEDIATR RES, V86, P311, DOI 10.1038/s41390-019-0436-2	245	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 3	2021	12								658611	10.3389/fimmu.2021.658611	http://dx.doi.org/10.3389/fimmu.2021.658611			25	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SC9KZ	34012443	Green Published, gold			2022-12-18	WOS:000650983800001
J	Lafont, V; Lucas, S; Bonnefoy, N				Lafont, Virginie; Lucas, Sophie; Bonnefoy, Nathalie			Editorial: Novel Strategies for Cancer Immunotherapy: Targeting Immune-Mediated Suppressive Mechanisms	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						tumor environment; immunotherapy; immunosuppression; regulatory cells; tumor escape			[Lafont, Virginie; Bonnefoy, Nathalie] Univ Montpellier, Inst Rech Cancerol Montpellier IRCM, Inst Canc Montpellier ICM, Inserm,U1194, Montpellier, France; [Lucas, Sophie] UCLouvain, de Duve Inst, Brussels, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Universite Catholique Louvain	Lafont, V; Bonnefoy, N (corresponding author), Univ Montpellier, Inst Rech Cancerol Montpellier IRCM, Inst Canc Montpellier ICM, Inserm,U1194, Montpellier, France.; Lucas, S (corresponding author), UCLouvain, de Duve Inst, Brussels, Belgium.	virginie.lafont@inserm.fr; sophie.lucas@uclouvain.be; nathalie.bonnefoy@inserm.fr	Lafont, Virginie/R-9356-2017; Bonnefoy, Nathalie/J-2536-2012	Lafont, Virginie/0000-0001-9612-3934; Bonnefoy, Nathalie/0000-0003-4814-6722	French National Research Agency (ANR) as part of the "Investissements d'Avenir" program [ANR-10-LABX -53-01]; Institut National de la Santeet de la Recherche Medicale; University of Montpellier	French National Research Agency (ANR) as part of the "Investissements d'Avenir" program(French National Research Agency (ANR)); Institut National de la Santeet de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); University of Montpellier	NB and VL are supported by a public grant overseen by the French National Research Agency (ANR) as part of the "Investissements d'Avenir" program (reference: ANR-10-LABX -53-01), by the "Institut National de la Santeet de la Recherche Medicale" and by University of Montpellier.	Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013	1	0	0	4	22	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 3	2021	12								691899	10.3389/fimmu.2021.691899	http://dx.doi.org/10.3389/fimmu.2021.691899			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SD0LB	34012459	Green Published, gold			2022-12-18	WOS:000651053100001
J	Liang, YC; Xian, ZH; Fu, DH; Liu, S; Yao, Y; Jin, YB; Gao, C; Shen, L; Shi, GX; He, J				Liang, Yichen; Xian, Zhenhua; Fu, Dehua; Liu, Shuang; Yao, Yang; Jin, Yuebo; Gao, Chun; Shen, Long; Shi, Guixiu; He, Jing			IL-14 alpha as a Putative Biomarker for Stratification of Dry Eye in Primary Sjogren's Syndrome	FRONTIERS IN IMMUNOLOGY			English	Article						interleukin 14 &#945; Taxilin; biomarker; dry eye; Sj&#246; gren&#8217; s syndrome	RHEUMATOLOGY/EUROPEAN LEAGUE; CLASSIFICATION CRITERIA; MALIGNANT-LYMPHOMA; AMERICAN-COLLEGE; BAFF; PATHOGENESIS; AUTOANTIBODIES; LYMPHOTOXIN; DISORDERS; COHORT	Background Dry eye is often the first presenting manifestation of primary Sjogren's syndrome (pSS). Because of the high prevalence of dry eye disease in normal population, ophthalmologists urgently need a non-invasive and reliable screening test to diagnose dry eye associated SS patients, other than ocular symptoms and signs. Currently, there is no single test available. The correlation of serum IL-14 alpha with pSS has been found in pSS mouse model. Purpose To evaluate whether IL-14 alpha can serve as a biomarker to stratify dry eye in primary Sjogren's syndrome and its correlation to BAFF in a cohort of patients with non-SS dry eye (NSDE), pSS with dry eye disease, rheumatoid arthritis (RA), and healthy controls (HC). Methods Retrospective study based on serum levels of IL-14 alpha (defined by Western Blot) and BAFF (measured by ELISA) were evaluated among pSS with dry eye disease, NSDE, RA, and HC groups. Serum levels of SS related autoantibodies (Ro, La, SP1, PSP, and CA6) were also measured by ELISA. Results One hundred and eighty patients were included for the current study, patients were separated into four groups as defined by pSS (n=65), NSDE (n=20), RA (n=50) and HC (n=45). The level of serum IL-14 alpha in pSS was significantly higher compared to NSDE, RA, and HC (p=0.0011, p=0.0052 and p<0.0001, respectively). The levels of serum BAFF in pSS was significantly higher than in NSDE and HC (p=0.0148 and p<0.0001, respectively, whereas the levels of serum BAFF in RA was only significantly higher than in HC (p=0.001), but the level of BAFF was no significant difference between pSS and RA. In pSS, there was a decrease in the serum levels of IL-14 alpha associated with a longer duration of the disease. Also, there was a correlation between the serum levels of IL-14 alpha and SS related autoantibodies such as anti-SSA/Ro and anti-SSB/La in pSS patients. Conclusions This is the first paper to report both IL-14 alpha and BAFF could serve as a critical cytokine biomarker for the stratification of dry eye in primary Sjogren's syndrome. This may help ophthalmologists to develop non-invasive metrics for the diagnosis of dry eye associated pSS.	[Liang, Yichen; Shi, Guixiu] Xiamen Univ, Dept Rheumatol & Immunol, Affiliated Hosp 1, Xiamen, Peoples R China; [Xian, Zhenhua; Fu, Dehua; Liu, Shuang; Yao, Yang; Gao, Chun] Huazhong Univ Sci & Technol, Dept Gastrointestinal Surg, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China; [Jin, Yuebo; He, Jing] Peking Univ Peoples Hosp, Dept Rheumatol & Immunol, Beijing, Peoples R China; [Shen, Long] Northern Jiangsu Peoples Hosp, Dept Oncol, Yangzhou, Jiangsu, Peoples R China; [Shen, Long] Northern Jiangsu Peoples Hosp, Dept Oncol, Inst Canc, Yangzhou, Jiangsu, Peoples R China; [Shen, Long] Yangzhou Univ, Clin Med Coll, Yangzhou, Jiangsu, Peoples R China	Xiamen University; Huazhong University of Science & Technology; Peking University; Yangzhou University	Shi, GX (corresponding author), Xiamen Univ, Dept Rheumatol & Immunol, Affiliated Hosp 1, Xiamen, Peoples R China.; He, J (corresponding author), Peking Univ Peoples Hosp, Dept Rheumatol & Immunol, Beijing, Peoples R China.; Shen, L (corresponding author), Northern Jiangsu Peoples Hosp, Dept Oncol, Yangzhou, Jiangsu, Peoples R China.; Shen, L (corresponding author), Northern Jiangsu Peoples Hosp, Dept Oncol, Inst Canc, Yangzhou, Jiangsu, Peoples R China.; Shen, L (corresponding author), Yangzhou Univ, Clin Med Coll, Yangzhou, Jiangsu, Peoples R China.	shenl@buffalo.edu; Gshi@xmu.edu.cn; hejing1105@126.com		shi, guixiu/0000-0003-4044-3394	National Science funding of China [U1605223]; National Program on Key Basic Research Project (973 Program) [2014CB541903]	National Science funding of China; National Program on Key Basic Research Project (973 Program)(National Basic Research Program of China)	This research was partly supported by National Science funding of China (Grant No. U1605223) and National Program on Key Basic Research Project (973 Program, No. 2014CB541903) to GS.	Akpek EK, 2015, OPHTHALMOLOGY, V122, P56, DOI 10.1016/j.ophtha.2014.07.026; Akpek EK, 2009, CORNEA, V28, P493, DOI 10.1097/ICO.0b013e31818d3846; Aletaha D, 2010, ARTHRITIS RHEUM-US, V62, P2569, DOI 10.1002/art.27584; AMBRUS JL, 1985, J CLIN INVEST, V75, P732, DOI 10.1172/JCI111754; AMBRUS JL, 1990, J IMMUNOL, V145, P3949; Bunya VY, 2016, AM J OPHTHALMOL, V172, P87, DOI 10.1016/j.ajo.2016.09.013; Carubbi F, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4359; Delaleu N, 2005, EUR J ORAL SCI, V113, P101, DOI 10.1111/j.1600-0722.2004.00183.x; Fletcher CA, 2006, EUR J IMMUNOL, V36, P2504, DOI 10.1002/eji.200636270; FORD R, 1995, BLOOD, V86, P283, DOI 10.1182/blood.V86.1.283.bloodjournal861283; Ford RJ, 2007, BLOOD, V109, P4899, DOI 10.1182/blood-2006-08-038497; Fox RI, 2005, LANCET, V366, P321, DOI 10.1016/S0140-6736(05)66990-5; Le Pottier L, 2009, CLIN CHEM, V55, P1843, DOI 10.1373/clinchem.2009.129940; Liew M, 2012, BRIT J OPHTHALMOL, V96, P1498, DOI 10.1136/bjophthalmol-2012-301767; Mackay F, 1999, J EXP MED, V190, P1697, DOI 10.1084/jem.190.11.1697; Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152; Mariette X, 2003, ANN RHEUM DIS, V62, P168, DOI 10.1136/ard.62.2.168; Mariette X, 2010, CURR OPIN RHEUMATOL, V22, P471, DOI 10.1097/BOR.0b013e32833c36c5; Moutsopoulos H, 2010, HARRISONS RHEUMATOLO, P124; Nocturne G, 2015, BRIT J HAEMATOL, V168, P317, DOI 10.1111/bjh.13192; Peri Y, 2012, BEST PRACT RES CL RH, V26, P105, DOI 10.1016/j.berh.2012.01.012; Pers JO, 2005, ARTHRITIS RHEUM-US, V52, P2411, DOI 10.1002/art.21205; Quartuccio L, 2013, RHEUMATOLOGY, V52, P276, DOI 10.1093/rheumatology/kes180; Ramos-Casals M, 2012, BMJ-BRIT MED J, V344, DOI [10.1136/bmj.e3821, 10.1024/1661-8157/a001133]; Royer B, 1997, BLOOD, V90, P766, DOI 10.1182/blood.V90.2.766; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Shen L, 2006, J IMMUNOL, V177, P5676, DOI 10.4049/jimmunol.177.8.5676; Shen L, 2016, CLIN IMMUNOL, V168, P30, DOI 10.1016/j.clim.2016.04.008; Shen L, 2013, J IMMUNOL, V191, P608, DOI 10.4049/jimmunol.1203440; Shen L, 2012, CLIN IMMUNOL, V145, P251, DOI 10.1016/j.clim.2012.09.013; Shen L, 2010, J IMMUNOL, V185, P6355, DOI 10.4049/jimmunol.1001520; Shen L, 2009, CLIN IMMUNOL, V130, P304, DOI 10.1016/j.clim.2008.10.006; Shiboski CH, 2017, ANN RHEUM DIS, V76, P9, DOI [10.1136/annrheumdis-2016-210571, 10.1002/art.39859]; Thompson N, 2016, RHEUMATOLOGY, V55, P1548, DOI 10.1093/rheumatology/kev420; Tzioufas AG, 2012, J AUTOIMMUN, V39, P4, DOI 10.1016/j.jaut.2012.01.002; Voulgarelis M, 1999, ARTHRITIS RHEUM-US, V42, P1765, DOI 10.1002/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-V; Wolffsohn JS, 2017, OCUL SURF, V15, P539, DOI 10.1016/j.jtos.2017.05.001; Xian ZH, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/7627384; Youinou P, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3348; Zufferey P, 1995, SCAND J RHEUMATOL, V24, P342, DOI 10.3109/03009749509095178	40	0	0	3	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 3	2021	12								673658	10.3389/fimmu.2021.673658	http://dx.doi.org/10.3389/fimmu.2021.673658			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SD0LF	34012457	gold, Green Published			2022-12-18	WOS:000651053500001
J	Smaldini, PL; Trejo, FM; Rizzo, GP; Comerci, DJ; Kampinga, J; Docena, GH				Smaldini, Paola L.; Trejo, Fernando M.; Rizzo, Gaston P.; Comerci, Diego J.; Kampinga, Jaap; Docena, Guillermo H.			Mucosal Immunoregulatory Properties of Tsukamurella inchonensis to Reverse Experimental Food Allergy	FRONTIERS IN IMMUNOLOGY			English	Article						Tsukamurella inchonensis; Food hypersensitivity; Anti-inflammatory agents; Enterocytes; Intestinal mucosa		The intestinal mucosa is lined by epithelial cells, which are key cells to sustain gut homeostasis. Food allergy is an immune-mediated adverse reaction to food, likely due to defective regulatory circuits. Tsukamurella inchonensis is a non-pathogenic bacterium with immunomodulatory properties. We hypothesize that the anti-inflammatory effect of dead T. inchonensis on activated epithelial cells modulates milk allergy through the restoration of tolerance in a mouse model. Epithelial cells (Caco-2 and enterocytes from mouse gut) and macrophages were stimulated with T. inchonensis and induction of luciferase under the NF-kappa B promoter, ROS and cytokines production were studied. Balb/c mice were mucosally sensitized with cow ' s milk proteins plus cholera toxin and orally challenged with the allergen to evidence hypersensitivity symptoms. After that, mice were orally administered with heat-killed T. inchonensis as treatment and then challenged with the allergen. The therapeutic efficacy was in vivo (clinical score and cutaneous test) and in vitro (serum specific antibodies and cytokines-ELISA, and cell analysis-flow cytometry) evaluated. Heat-killed T. inchonensis modulated the induction of pro-inflammatory chemokines, with an increase in anti-inflammatory cytokines by intestinal epithelial cells and by macrophages with decreased OX40L expression. In vivo, oral administration of T. inchonensis increased the frequency of lamina propria CD4(+)CD25(+)FoxP3(+) T cells, and clinical signs were lower in T. inchonensis-treated mice compared with milk-sensitized animals. In vivo depletion of Tregs (anti-CD25) abrogated T. inchonensis immunomodulation. In conclusion, these bacteria suppressed the intestinal inflammatory immune response to reverse food allergy.	[Smaldini, Paola L.; Trejo, Fernando M.; Rizzo, Gaston P.; Docena, Guillermo H.] UNLP, Inst Estudios Inmunol & Fisiopatol IIFP, Dept Ciencias Biol, Fac Ciencias Exactas,CONICET,Asociado CIC PBA, La Plata, Argentina; [Comerci, Diego J.] Univ Nacl San Martin, Inst Invest Biotecnol, CONICET, Dr Rodolfo A Ugalde IIB INTECH, Buenos Aires, DF, Argentina; [Kampinga, Jaap] ActinoPharma Ltd, London, England	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of La Plata; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Docena, GH (corresponding author), UNLP, Inst Estudios Inmunol & Fisiopatol IIFP, Dept Ciencias Biol, Fac Ciencias Exactas,CONICET,Asociado CIC PBA, La Plata, Argentina.	guidoc@biol.unlp.edu.ar		Trejo, Fernando/0000-0001-5519-0970; Comerci, Diego J./0000-0003-1949-4226	Agencia Nacional de Promocion Cientifica y Tecnologica [PICT 2015-1648]; Consejo Nacional de Investigaciones Cientificas y Tecnicas [PIP 2013-189]	Agencia Nacional de Promocion Cientifica y Tecnologica(ANPCyT); Consejo Nacional de Investigaciones Cientificas y Tecnicas(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET))	This work was supported by the Agencia Nacional de Promocio ' n Cienti ' fica y Tecnolo ' gica (grant PICT 2015-1648) and the Consejo Nacional de Investigaciones Cienti ' ficas y Te ' cnicas (grant PIP 2013-189) to GD.	Akdis CA, 2009, J ALLERGY CLIN IMMUN, V123, P735, DOI 10.1016/j.jaci.2009.02.030; Bazzi S, 2017, INNATE IMMUN-LONDON, V23, P592, DOI 10.1177/1753425917727838; Bazzi S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01253; Bazzi S, 2015, IMMUNOBIOLOGY, V220, P1293, DOI 10.1016/j.imbio.2015.07.015; Brown JR, 2003, J LEUKOCYTE BIOL, V73, P591, DOI 10.1189/jlb.1202599; Chu DK, 2014, MUCOSAL IMMUNOL, V7, P1395, DOI 10.1038/mi.2014.29; Deng J, 2012, J IMMUNOL, V188, P5734, DOI 10.4049/jimmunol.1101323; Di Claudio F, 2017, J CELL PHYSIOL, V232, P2489, DOI 10.1002/jcp.25594; Ekkens MJ, 2003, J IMMUNOL, V170, P384, DOI 10.4049/jimmunol.170.1.384; Flom JD, 2019, NUTRIENTS, V11, DOI 10.3390/nu11051051; Halim TYF, 2018, IMMUNITY, V48, P1195, DOI 10.1016/j.immuni.2018.05.003; Jaffar Z, 2004, J IMMUNOL, V172, P3842, DOI 10.4049/jimmunol.172.6.3842; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Khare A, 2016, CELL REP, V15, P1700, DOI 10.1016/j.celrep.2016.04.060; Lewis G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02051; Li LZ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231865; Galdeano CM, 2019, ANN NUTR METAB, V74, P115, DOI 10.1159/000496426; Nempont C, 2008, J IMMUNOL, V181, P2036, DOI 10.4049/jimmunol.181.3.2036; Romani L, 2008, NATURE, V451, P211, DOI 10.1038/nature06471; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Smaldini PL, 2014, INNATE IMMUN-LONDON, V20, P626, DOI 10.1177/1753425913503577; Smaldini PL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141116; Trejo FM, 2013, J DAIRY RES, V80, P263, DOI 10.1017/S0022029913000216; van de Veerdonk FL, 2010, P NATL ACAD SCI USA, V107, P3030, DOI 10.1073/pnas.0914795107; Wang J, 2011, J CLIN INVEST, V121, P827, DOI [10.1172/JCI45434, 10.1186/1710-1492-7-S1-S7]; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; Yuan WH, 1998, J CELL PHYSIOL, V177, P174, DOI 10.1002/(SICI)1097-4652(199810)177:1<174::AID-JCP18>3.0.CO;2-D; Zavaglia AG, 1998, J FOOD PROTECT, V61, P865, DOI 10.4315/0362-028X-61.7.865; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	29	0	0	3	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 30	2021	12								641597	10.3389/fimmu.2021.641597	http://dx.doi.org/10.3389/fimmu.2021.641597			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SB5DJ	33995359	Green Published, gold			2022-12-18	WOS:000650014400001
J	Lemarie, M; Chatonnet, F; Caron, G; Fest, T				Lemarie, Maud; Chatonnet, Fabrice; Caron, Gersende; Fest, Thierry			Early Emergence of Adaptive Mechanisms Sustaining Ig Production: Application to Antibody Therapy	FRONTIERS IN IMMUNOLOGY			English	Review						UPR; ER stress; B cell differentiation; mAbs; RNA-seq	PLASMA-CELL DIFFERENTIATION; PROTEIN; SURVIVAL; PERK; SECRETION; BLIMP-1; IRE1; XBP1	Antibody therapy, where artificially-produced immunoglobulins (Ig) are used to treat pathological conditions such as auto-immune diseases and cancers, is a very innovative and competitive field. Although substantial efforts have been made in recent years to obtain specific and efficient antibodies, there is still room for improvement especially when considering a precise tissular targeting or increasing antigen affinity. A better understanding of the cellular and molecular steps of terminal B cell differentiation, in which an antigen-activated B cell becomes an antibody secreting cell, may improve antibody therapy. In this review, we use our recently published data about human B cell differentiation, to show that the mechanisms necessary to adapt a metamorphosing B cell to its new secretory function appear quite early in the differentiation process i.e., at the pre-plasmablast stage. After characterizing the molecular pathways appearing at this stage, we will focus on recent findings about two main processes involved in antibody production: unfolded protein response (UPR) and endoplasmic reticulum (ER) stress. We'll show that many genes coding for factors involved in UPR and ER stress are induced at the pre-plasmablast stage, sustaining our hypothesis. Finally, we propose to use this recently acquired knowledge to improve productivity of industrialized therapeutic antibodies.	[Lemarie, Maud; Chatonnet, Fabrice; Caron, Gersende; Fest, Thierry] Univ Rennes 1, INSERM, Etab Francais Sang Bretagne, UMR S1236, Rennes, France; [Chatonnet, Fabrice; Caron, Gersende; Fest, Thierry] Ctr Hosp Univ, Lab Hematol, Pole Biol, Rennes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; CHU Rennes	Fest, T (corresponding author), Univ Rennes 1, INSERM, Etab Francais Sang Bretagne, UMR S1236, Rennes, France.; Fest, T (corresponding author), Ctr Hosp Univ, Lab Hematol, Pole Biol, Rennes, France.	thierry.fest@univ-rennes1.fr	Chatonnet, Fabrice/AHI-8250-2022	Chatonnet, Fabrice/0000-0003-3639-6775	Agence Nationale de la Recherche (ANR) [ANR-19-CE15-0020-01]	Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR))	This study was funded by Agence Nationale de la Recherche (ANR) number: ANR-19-CE15-0020-01.	Acosta-Alvear D, 2007, MOL CELL, V27, P53, DOI 10.1016/j.molcel.2007.06.011; Alahari S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028863; Amin-Wetzel N, 2017, CELL, V171, P1625, DOI 10.1016/j.cell.2017.10.040; Behnke J, 2015, J MOL BIOL, V427, P1589, DOI 10.1016/j.jmb.2015.02.011; Belmont PJ, 2010, CIRC RES, V106, P307, DOI 10.1161/CIRCRESAHA.109.203901; Benhamron S, 2015, MOL CELL BIOL, V35, P153, DOI 10.1128/MCB.01187-14; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bhattacharya D, 2007, J IMMUNOL, V179, P6808, DOI 10.4049/jimmunol.179.10.6808; Borth N, 2005, BIOTECHNOL PROGR, V21, P106, DOI 10.1021/bp0498241; Braasch K, 2021, BIOTECHNOL BIOENG, V118, P1876, DOI 10.1002/bit.27703; Bracher A, 2015, FRONT MOL BIOSCI, V2, DOI 10.3389/fmolb.2015.00010; Brewer JW, 2005, NAT IMMUNOL, V6, P23, DOI 10.1038/ni1149; Capoccia BJ, 2011, PHYSIOL GENOMICS, V43, P174, DOI 10.1152/physiolgenomics.00084.2010; Capone V, 2018, BBA-MOL BASIS DIS, V1864, P3164, DOI 10.1016/j.bbadis.2018.07.003; Caron G, 2015, CELL REP, V13, P1059, DOI 10.1016/j.celrep.2015.09.051; Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200; Cocco M, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.202000654; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; Dalloul I, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1007721; Damasceno LM, 2007, APPL MICROBIOL BIOT, V74, P381, DOI 10.1007/s00253-006-0652-7; Dan H, 2008, BIOCHEM BIOPH RES CO, V365, P777, DOI 10.1016/j.bbrc.2007.11.040; De Silva NS, 2015, NAT REV IMMUNOL, V15, P137, DOI 10.1038/nri3804; Du ZM, 2013, BIOTECHNOL BIOENG, V110, P2184, DOI 10.1002/bit.24877; Gass JN, 2008, MOL IMMUNOL, V45, P1035, DOI 10.1016/j.molimm.2007.07.029; Gaudette BT, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14032-1; Ha TK, 2019, BIOTECHNOL J, V14, DOI 10.1002/biot.201900130; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hess DA, 2016, MOL CELL BIOL, V36, P2931, DOI 10.1128/MCB.00366-16; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hipp N, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01475-7; Hisanaga S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-19052-9; Huh WJ, 2010, GASTROENTEROLOGY, V139, P2038, DOI 10.1053/j.gastro.2010.08.050; Ichhaporia VP, 2015, MOL BIOL CELL, V26, P420, DOI 10.1091/mbc.E14-09-1392; Ishii Y, 2014, J BIOSCI BIOENG, V118, P223, DOI 10.1016/j.jbiosc.2014.01.013; Iwata TN, 2016, J IMMUNOL, V197, P2250, DOI 10.4049/jimmunol.1600492; Jones DD, 2016, J CLIN INVEST, V126, P4250, DOI 10.1172/JCI86504; Jourdan M, 2014, LEUKEMIA, V28, P1647, DOI 10.1038/leu.2014.61; Jourdan M, 2011, J IMMUNOL, V187, P3931, DOI 10.4049/jimmunol.1101230; Jung TW, 2018, MOL CELL BIOCHEM, V448, P335, DOI 10.1007/s11010-018-3392-y; Jung TW, 2018, J PHARMACOL EXP THER, V365, P485, DOI 10.1124/jpet.117.246686; Kassambara A, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004077; Kelly PS, 2018, CURR OPIN CHEM ENG, V22, P71, DOI 10.1016/j.coche.2018.08.009; Kityk R, 2018, MOL CELL, V69, P227, DOI 10.1016/j.molcel.2017.12.003; Kober L, 2012, BIOTECHNOL BIOENG, V109, P2599, DOI 10.1002/bit.24527; Koskela EV, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00255; Kowalik AS, 2007, AM J PHYSIOL-GASTR L, V292, pG1123, DOI 10.1152/ajpgi.00512.2006; Kusaczuk M, 2013, CURR PHARM DESIGN, V19, P2807, DOI 10.2174/1381612811319150016; Kuwabara K, 1996, J BIOL CHEM, V271, P5025; Laidlaw BJ, 2021, NAT REV IMMUNOL, V21, P209, DOI 10.1038/s41577-020-00446-2; Lam WY, 2018, TRENDS IMMUNOL, V39, P19, DOI 10.1016/j.it.2017.08.007; Lange PS, 2008, J EXP MED, V205, P1227, DOI 10.1084/jem.20071460; Le Gallou S, 2012, J IMMUNOL, V189, P161, DOI 10.4049/jimmunol.1200301; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee AH, 2005, EMBO J, V24, P4368, DOI 10.1038/sj.emboj.7600903; Lee AH, 2003, P NATL ACAD SCI USA, V100, P9946, DOI 10.1073/pnas.1334037100; Li BS, 2017, IMMUNOLOGY, V152, P276, DOI 10.1111/imm.12767; LIN HY, 1993, MOL BIOL CELL, V4, P1109, DOI 10.1091/mbc.4.11.1109; Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361; Lin JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004170; Linterman MA, 2010, J EXP MED, V207, P353, DOI 10.1084/jem.20091738; Liu J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14186; Lo HYG, 2017, GENE DEV, V31, P154, DOI 10.1101/gad.285684.116; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Ma YJ, 2010, CELL STRESS CHAPERON, V15, P281, DOI 10.1007/s12192-009-0142-9; Maldonado-Agurto R, 2018, BIOTECHNOL J, V13, DOI 10.1002/biot.201700429; Matucci A, 2016, CURR OPIN ALLERGY CL, V16, P576, DOI 10.1097/ACI.0000000000000315; McCarthy N, 2020, CANCER LETT, V490, P76, DOI 10.1016/j.canlet.2020.07.009; Metzler MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125153; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; Mohan C, 2007, BIOTECHNOL BIOENG, V98, P611, DOI 10.1002/bit.21453; Nakatani Y, 2005, J BIOL CHEM, V280, P847, DOI 10.1074/jbc.M411860200; Oda Y, 2006, J CELL BIOL, V172, P383, DOI 10.1083/jcb.200507057; Pieper LA, 2017, BIOTECHNOL BIOENG, V114, P1310, DOI 10.1002/bit.26263; Pignarre A, 2021, BLOOD, V137, P1166, DOI 10.1182/blood.2020005083; Poulain A, 2019, J BIOTECHNOL, V296, P32, DOI 10.1016/j.jbiotec.2019.03.009; Prashad K, 2015, CYTOTECHNOLOGY, V67, P237, DOI 10.1007/s10616-013-9678-8; Roobol A, 2015, BIOCHEM J, V465, P213, DOI 10.1042/BJ20140852; Roy G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183694; Sandadi S, 2005, BIOTECHNOL PROGR, V21, P1537, DOI 10.1021/bp0501266; Shaffer AL, 2004, IMMUNITY, V21, P81, DOI 10.1016/j.immuni.2004.06.010; Shaffer AL, 2002, IMMUNITY, V17, P51, DOI 10.1016/S1074-7613(02)00335-7; Shapiro-Shelef M, 2005, NAT REV IMMUNOL, V5, P230, DOI 10.1038/nri1572; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shen JS, 2004, J BIOL CHEM, V279, P43046, DOI 10.1074/jbc.M408466200; Shi ZH, 2020, BMC PULM MED, V20, DOI 10.1186/s12890-020-1123-0; Shimobayashi M, 2014, NAT REV MOL CELL BIO, V15, P155, DOI 10.1038/nrm3757; Sou SN, 2012, BIOCHEM BIOPH RES CO, V420, P473, DOI 10.1016/j.bbrc.2012.03.030; Sowers CR, 2018, J BIOL CHEM, V293, P5134, DOI 10.1074/jbc.M117.813790; Tagliavacca L, 2003, BIOL CHEM, V384, P1273, DOI 10.1515/BC.2003.141; Talbot NE, 2019, BIOTECHNOL J, V14, DOI 10.1002/biot.201900024; Tamatani M, 2001, NAT MED, V7, P317, DOI 10.1038/85463; Tellier J, 2016, NAT IMMUNOL, V17, P323, DOI 10.1038/ni.3348; Tigges M, 2006, METAB ENG, V8, P264, DOI 10.1016/j.ymben.2006.01.006; Todd DJ, 2008, NAT REV IMMUNOL, V8, P663, DOI 10.1038/nri2359; Tokutake Y, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010182; van Huizen R, 2003, J BIOL CHEM, V278, P15558, DOI 10.1074/jbc.M212074200; Victora GD, 2010, CELL, V143, P592, DOI 10.1016/j.cell.2010.10.032; Weitzmann A, 2006, FEBS LETT, V580, P5237, DOI 10.1016/j.febslet.2006.08.055; Wu J, 2007, DEV CELL, V13, P351, DOI 10.1016/j.devcel.2007.07.005; Yamamoto K, 2007, DEV CELL, V13, P365, DOI 10.1016/j.devcel.2007.07.018; Yan W, 2002, P NATL ACAD SCI USA, V99, P15920, DOI 10.1073/pnas.252341799; Yin BJ, 2018, BIOTECHNOL BIOENG, V115, P1531, DOI 10.1002/bit.26560; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zhang KZ, 2005, J CLIN INVEST, V115, P268, DOI 10.1172/JCI200521848; Zhang W, 2006, CELL METAB, V4, P491, DOI 10.1016/j.cmet.2006.11.002; Zhao LH, 2010, HUM MOL GENET, V19, P25, DOI 10.1093/hmg/ddp464; Zhou RY, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.602307; Zhu HB, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08908-5; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	111	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 29	2021	12								671998	10.3389/fimmu.2021.671998	http://dx.doi.org/10.3389/fimmu.2021.671998			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SB1LB	33995412	Green Published, gold			2022-12-18	WOS:000649762500001
J	Jami, R; Merour, E; Lamoureux, A; Bernard, J; Millet, JK; Biacchesi, S				Jami, Raphael; Merour, Emilie; Lamoureux, Annie; Bernard, Julie; Millet, Jean K.; Biacchesi, Stephane			Deciphering the Fine-Tuning of the Retinoic Acid-Inducible Gene-I Pathway in Teleost Fish and Beyond	FRONTIERS IN IMMUNOLOGY			English	Article						interferon; RIG-I-like receptors (RLRs); innate response; immune homeostasis; fish	INNATE IMMUNE-RESPONSE; (RIG-I)-LIKE RECEPTORS RLRS; RIG-I; RNA HELICASE; INTERFERON-PRODUCTION; LIGASE RIPLET; ZEBRAFISH; DEGRADATION; OPTINEURIN; TRIM25	Interferons are the first lines of defense against viral pathogen invasion during the early stages of infection. Their synthesis is tightly regulated to prevent excessive immune responses and possible deleterious effects on the host organism itself. The RIG-I-like receptor signaling cascade is one of the major pathways leading to the production of interferons. This pathway amplifies danger signals and mounts an appropriate innate response but also needs to be finely regulated to allow a rapid return to immune homeostasis. Recent advances have characterized different cellular factors involved in the control of the RIG-I pathway. This has been most extensively studied in mammalian species; however, some inconsistencies remain to be resolved. The IFN system is remarkably well conserved in vertebrates and teleost fish possess all functional orthologs of mammalian RIG-I-like receptors as well as most downstream signaling molecules. Orthologs of almost all mammalian regulatory components described to date exist in teleost fish, such as the widely used zebrafish, making fish attractive and powerful models to study in detail the regulation and evolution of the RIG-I pathway.	[Jami, Raphael; Merour, Emilie; Lamoureux, Annie; Bernard, Julie; Millet, Jean K.; Biacchesi, Stephane] Univ Paris Saclay, INRAE, UVSQ, VIM, Jouy En Josas, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay	Biacchesi, S (corresponding author), Univ Paris Saclay, INRAE, UVSQ, VIM, Jouy En Josas, France.	stephane.biacchesi@inrae.fr	Millet, Jean K./V-5479-2018; BIACCHESI, STEPHANE/A-6924-2010	Millet, Jean K./0000-0001-8373-3688; BIACCHESI, STEPHANE/0000-0002-7020-2391	INRAE	INRAE	We thank INRAE for its financial support. We thank Sandra Souto and Alain Le Coupanec for helpful discussions.	Altmann SM, 2003, J VIROL, V77, P1992, DOI 10.1128/JVI.77.3.1992-2002.2003; Ariumi Y, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00423; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; Barber MRW, 2010, P NATL ACAD SCI USA, V107, P5913, DOI 10.1073/pnas.1001755107; Biacchesi S, 2017, SCI REP-UK, V7, DOI 10.1038/srep44025; Biacchesi S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047737; Biacchesi S, 2009, J VIROL, V83, P7815, DOI 10.1128/JVI.00404-09; Boudinot P, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8110298; Cadena C, 2019, CELL, V177, P1187, DOI 10.1016/j.cell.2019.03.017; Cai Z, 2020, J EXP MED, V217, DOI 10.1084/jem.20191174; Castanier C, 2012, BMC BIOL, V10, DOI 10.1186/1741-7007-10-44; Chang MX, 2021, DEV COMP IMMUNOL, V119, DOI 10.1016/j.dci.2021.104038; Chang MX, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071530; Chang MX, 2011, J VIROL, V85, P8403, DOI 10.1128/JVI.00445-10; Chen SN, 2017, IMMUNOLOGY, V151, P16, DOI 10.1111/imm.12714; Clark TC, 2021, GENES-BASEL, V12, DOI 10.3390/genes12020238; Dahle MK, 2019, FISH SHELLFISH IMMUN, V87, P421, DOI 10.1016/j.fsi.2019.01.043; David RYS, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aar3993; Dehler CE, 2019, J IMMUNOL, V203, P465, DOI 10.4049/jimmunol.1801376; Esser-Nobis K, 2020, P NATL ACAD SCI USA, V117, P15778, DOI 10.1073/pnas.1921861117; Loureiro M, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007125; Feng H, 2011, FISH SHELLFISH IMMUN, V30, P1159, DOI 10.1016/j.fsi.2011.03.002; Feng H, 2016, J IMMUNOL, V197, P1893, DOI 10.4049/jimmunol.1600159; Fensterl V, 2009, BIOFACTORS, V35, P14, DOI 10.1002/biof.6; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Gabor KA, 2015, DEV COMP IMMUNOL, V51, P298, DOI 10.1016/j.dci.2015.01.006; Gack MU, 2007, NATURE, V446, P916, DOI 10.1038/nature05732; Gack MU, 2009, CELL HOST MICROBE, V5, P439, DOI 10.1016/j.chom.2009.04.006; Garcia-Moreno D, 2019, FISH SHELLFISH IMMUN, V90, P215, DOI 10.1016/j.fsi.2019.04.067; Ge R, 2015, J VIROL, V89, P7696, DOI 10.1128/JVI.01049-15; Genin P, 2015, PLOS PATHOG, V11, DOI [10.1371/journal.ppat.1004877, 10.1371/journal.ppat.1004971]; Genin P, 2009, CYTOKINE GROWTH F R, V20, P283, DOI 10.1016/j.cytogfr.2009.07.005; Gitlin L, 2006, P NATL ACAD SCI USA, V103, P8459, DOI 10.1073/pnas.0603082103; Gleason CE, 2011, J BIOL CHEM, V286, P35663, DOI 10.1074/jbc.M111.267567; Gu MD, 2014, CELL SIGNAL, V26, P2930, DOI 10.1016/j.cellsig.2014.09.007; Hayman TJ, 2019, IMMUNOL CELL BIOL, V97, P840, DOI 10.1111/imcb.12284; Holland JW, 2008, MOL IMMUNOL, V46, P269, DOI 10.1016/j.molimm.2008.08.265; Jahan AS, 2020, CELL REP, V30, P1570, DOI 10.1016/j.celrep.2020.01.015; Jin YL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02805; Jorgensen LV, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9080609; Kang DC, 2002, P NATL ACAD SCI USA, V99, P637, DOI 10.1073/pnas.022637199; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kim MS, 2018, FISH SHELLFISH IMMUN, V83, P443, DOI 10.1016/j.fsi.2018.09.025; Kok KH, 2011, CELL HOST MICROBE, V9, P299, DOI 10.1016/j.chom.2011.03.007; Kowalinski E, 2011, CELL, V147, P423, DOI 10.1016/j.cell.2011.09.039; Lai YX, 2019, FISH SHELLFISH IMMUN, V86, P474, DOI 10.1016/j.fsi.2018.11.070; Langevin C, 2013, J MOL BIOL, V425, P4904, DOI 10.1016/j.jmb.2013.09.033; Lauksund S, 2009, DEV COMP IMMUNOL, V33, P1196, DOI 10.1016/j.dci.2009.06.012; Levraud JP, 2019, J IMMUNOL, V203, P3361, DOI 10.4049/jimmunol.1900804; Levraud JP, 2014, TRENDS MICROBIOL, V22, P490, DOI 10.1016/j.tim.2014.04.014; Li WZ, 2021, FISH SHELLFISH IMMUN, V111, P83, DOI 10.1016/j.fsi.2021.01.006; Li Y, 2021, POULTRY SCI, V100, P9, DOI 10.1016/j.psj.2020.08.020; Li ZX, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004783; Lin RT, 2006, J BIOL CHEM, V281, P2095, DOI 10.1074/jbc.M510326200; Liu C, 2019, J IMMUNOL, V202, P2957, DOI 10.4049/jimmunol.1800656; Liu GQ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05745-w; Liu JX, 2017, FISH SHELLFISH IMMUN, V71, P95, DOI 10.1016/j.fsi.2017.09.068; Liu QX, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar2824; Liu SQ, 2015, SCIENCE, V347, P1217, DOI 10.1126/science.aaa2630; Lu HB, 2014, J IMMUNOL, V193, P1364, DOI 10.4049/jimmunol.1303322; Lu LF, 2019, J VIROL, V93, DOI 10.1128/JVI.01272-19; Lumb JH, 2017, CELL REP, V20, P819, DOI 10.1016/j.celrep.2017.06.085; Mankouri J, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000778; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Merour E, 2019, FISH SHELLFISH IMMUN, V84, P857, DOI 10.1016/j.fsi.2018.10.082; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Miyamoto M, 2017, BIOCHEM BIOPH RES CO, V494, P227, DOI 10.1016/j.bbrc.2017.10.048; Mojzesz M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197289; Mosallanejad K, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004841; Nonkwelo C, 1997, J VIROL, V71, P6887, DOI 10.1128/JVI.71.9.6887-6897.1997; Nunez RD, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19071877; O'Loughlin T, 2020, J CELL SCI, V133, DOI 10.1242/jcs.239822; Ohtani M, 2010, J IMMUNOL, V185, P7507, DOI 10.4049/jimmunol.1001850; Onomoto K, 2021, CELL MOL IMMUNOL, V18, P539, DOI 10.1038/s41423-020-00602-7; Oshiumi H, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003533; Oshiumi H, 2010, CELL HOST MICROBE, V8, P496, DOI 10.1016/j.chom.2010.11.008; Oshiumi H, 2010, EUR J IMMUNOL, V40, P940, DOI 10.1002/eji.200940203; Oshiumi H, 2009, J BIOL CHEM, V284, P807, DOI 10.1074/jbc.M804259200; Outlioua A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00853; Parisien JP, 2018, EMBO REP, V19, DOI 10.15252/embr.201745176; Pattabhi S, 2019, J INTERF CYTOK RES, V39, P331, DOI 10.1089/jir.2018.0163; Peng YY, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004041; Petro TM, 2020, J IMMUNOL, V205, P1981, DOI 10.4049/jimmunol.2000462; Pourcelot M, 2014, FEBS J, V281, P3791, DOI 10.1111/febs.12940; Poynter SJ, 2019, FISH SHELLFISH IMMUN, V93, P1056, DOI 10.1016/j.fsi.2019.07.054; Rao YL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00352; Rehwinkel J, 2020, NAT REV IMMUNOL, V20, P537, DOI 10.1038/s41577-020-0288-3; Robertsen B, 2018, DEV COMP IMMUNOL, V80, P41, DOI 10.1016/j.dci.2017.02.005; Rodriguez KR, 2014, J VIROL, V88, P8194, DOI 10.1128/JVI.00640-14; Rothenfusser S, 2005, J IMMUNOL, V175, P5260, DOI 10.4049/jimmunol.175.8.5260; Ruan J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02202; Saitoh T, 2005, J IMMUNOL, V174, P1507, DOI 10.4049/jimmunol.174.3.1507; Satoh T, 2010, P NATL ACAD SCI USA, V107, P1512, DOI 10.1073/pnas.0912986107; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shaw AE, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2004086; Sifuentes-Romero I, 2011, MUTAT RES-REV MUTAT, V728, P158, DOI 10.1016/j.mrrev.2011.09.001; Soulat D, 2008, EMBO J, V27, P2135, DOI 10.1038/emboj.2008.126; Stein C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-r251; Streicher F, 2019, TRENDS IMMUNOL, V40, P1134, DOI 10.1016/j.it.2019.10.009; Sun F, 2011, J IMMUNOL, V187, P2531, DOI 10.4049/jimmunol.1100642; Sun F, 2010, J IMMUNOL, V185, P7573, DOI 10.4049/jimmunol.1002401; Taschuk F, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020181; Varela M, 2017, ANTIVIR RES, V139, P59, DOI 10.1016/j.antiviral.2016.12.013; Vaughn LS, 2021, BIOCHEM J, V478, P493, DOI 10.1042/BCJ20200987; Venkataraman T, 2007, J IMMUNOL, V178, P6444, DOI 10.4049/jimmunol.178.10.6444; Vila IK, 2020, J MOL BIOL, V432, P5529, DOI 10.1016/j.jmb.2020.08.016; Vitour D, 2009, J BIOL CHEM, V284, P21797, DOI 10.1074/jbc.M109.018275; Wies E, 2013, IMMUNITY, V38, P437, DOI 10.1016/j.immuni.2012.11.018; Winton J, 2010, J FISH DIS, V33, P701, DOI 10.1111/j.1365-2761.2010.01165.x; Xiang WW, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501889; Xie MY, 2020, FEBS J, V287, P310, DOI 10.1111/febs.15035; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Xu L, 2016, P NATL ACAD SCI USA, V113, P10950, DOI 10.1073/pnas.1604939113; Yoneyama M, 2005, J IMMUNOL, V175, P2851, DOI 10.4049/jimmunol.175.5.2851; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Yoshinaka T, 2019, ISCIENCE, V19, P1065, DOI 10.1016/j.isci.2019.08.056; Zhang KL, 2019, CELL REP, V26, P1258, DOI 10.1016/j.celrep.2019.01.029; Zhang LT, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007067; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748; Zhang QM, 2018, J IMMUNOL, V200, P688, DOI 10.4049/jimmunol.1701388; Zhang YB, 2003, FISH SHELLFISH IMMUN, V15, P453, DOI 10.1016/S1050-4648(03)00025-1; Zhang ZM, 2020, J IMMUNOL, V204, P1904, DOI 10.4049/jimmunol.1900305; Zhang ZQ, 2011, J IMMUNOL, V187, P4501, DOI 10.4049/jimmunol.1101307; Zhao YL, 2012, CELL SIGNAL, V24, P2197, DOI 10.1016/j.cellsig.2012.06.017; Zheng N, 2017, ANNU REV BIOCHEM, V86, P129, DOI 10.1146/annurev-biochem-060815-014922; Zhou YL, 2017, EUR J IMMUNOL, V47, P1414, DOI 10.1002/eji.201746959; Zhu CL, 2015, J VIROL, V89, P6608, DOI 10.1128/JVI.00364-15; Zou J, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-85	130	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 28	2021	12								679242	10.3389/fimmu.2021.679242	http://dx.doi.org/10.3389/fimmu.2021.679242			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SA5HQ	33995423	gold, Green Published			2022-12-18	WOS:000649334000001
J	Chansard, A; Dubrulle, N; de Molliens, MP; Falanga, PB; Stephen, T; Hasan, M; van Zandbergen, G; Aulner, N; Shorte, SL; David-Watine, B				Chansard, Audrey; Dubrulle, Nelly; Poujol de Molliens, Mathilde; Falanga, Pierre B.; Stephen, Tharshana; Hasan, Milena; van Zandbergen, Ger; Aulner, Nathalie; Shorte, Spencer L.; David-Watine, Brigitte		Milieu Interieur Consortium	Unveiling Interindividual Variability of Human Fibroblast Innate Immune Response Using Robust Cell-Based Protocols (vol 11, 569331, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						immortalization; HSV-1; FACS; cytokines; human primary cells; NF-kB; TLR (Toll like receptors); innate immunity			[Chansard, Audrey; Dubrulle, Nelly; Poujol de Molliens, Mathilde; Falanga, Pierre B.; Aulner, Nathalie; Shorte, Spencer L.; David-Watine, Brigitte] Inst Pasteur, UTechS Photon BioImaging, C2RT, Paris, France; [Stephen, Tharshana; Hasan, Milena] Inst Pasteur, UTechS Cytometry & Biomarkers, CRT, Paris, France; [van Zandbergen, Ger] Paul Ehrlich Inst, Fed Inst Vaccines & Biomed, Div Immunol, Langen, Germany; [Shorte, Spencer L.] Inst Pasteur Korea, Pasteur Joint Int Res Unit Ai3D, Seongnam Si, South Korea; [David-Watine, Brigitte] Inst Pasteur, Unite INSERM U1223, Paris, France; [David-Watine, Brigitte] Inst Pasteur, Unite Biol & Genet Paroi Bacterienne, Paris, France; [David-Watine, Brigitte] CNRS, UMR2001, Paris, France; [David-Watine, Brigitte] INSERM, Equipe Avenir, Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Paul Ehrlich Institute; Institut Pasteur Korea; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Shorte, SL; David-Watine, B (corresponding author), Inst Pasteur, UTechS Photon BioImaging, C2RT, Paris, France.; Shorte, SL (corresponding author), Inst Pasteur Korea, Pasteur Joint Int Res Unit Ai3D, Seongnam Si, South Korea.; David-Watine, B (corresponding author), Inst Pasteur, Unite INSERM U1223, Paris, France.; David-Watine, B (corresponding author), Inst Pasteur, Unite Biol & Genet Paroi Bacterienne, Paris, France.; David-Watine, B (corresponding author), CNRS, UMR2001, Paris, France.; David-Watine, B (corresponding author), INSERM, Equipe Avenir, Paris, France.	spencer.shorte@pasteur.fr; brigitte.david-watine@pasteur.fr	David-Watine, Brigitte/ABF-5621-2020	David-Watine, Brigitte/0000-0002-3292-0042				Chansard A, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.569331	1	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 26	2021	12								685768	10.3389/fimmu.2021.685768	http://dx.doi.org/10.3389/fimmu.2021.685768			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RZ5UT	33981321				2022-12-18	WOS:000648662900001
J	Garau, J; Masnada, S; Dragoni, F; Sproviero, D; Fogolari, F; Gagliardi, S; Izzo, G; Varesio, C; Orcesi, S; Veggiotti, P; Zuccotti, GV; Pansarasa, O; Tonduti, D; Cereda, C				Garau, Jessica; Masnada, Silvia; Dragoni, Francesca; Sproviero, Daisy; Fogolari, Federico; Gagliardi, Stella; Izzo, Giana; Varesio, Costanza; Orcesi, Simona; Veggiotti, Pierangelo; Zuccotti, Gian Vincenzo; Pansarasa, Orietta; Tonduti, Davide; Cereda, Cristina			Case Report: Novel Compound Heterozygous RNASEH2B Mutations Cause Aicardi-Goutieres Syndrome	FRONTIERS IN IMMUNOLOGY			English	Article						Aicardi&#8211; Gouti&#232; res Syndrome; next generation sequencing; RNASEH2B; genetics; novel mutation		Aicardi-Goutieres Syndrome (AGS) is a rare disorder characterized by neurological and immunological signs. In this study we have described a child with a phenotype consistent with AGS carrying a novel compound heterozygous mutation in RNASEH2B gene. Next Generation Sequencing revealed two heterozygous variants in RNASEH2B gene. We also highlighted a reduction of RNase H2B transcript and protein levels in all the family members. Lower protein levels of RNase H2A have been observed in all the members of the family as well, whereas a deep depletion of RNase H2C has only been identified in the affected child. The structural analysis showed that both mutations remove many intramolecular contacts, possibly introducing conformational rearrangements with a decrease of the stability of RNase H2B and strongly destabilizing the RNase H2 complex. Taken together, these results highlight the importance of an integrated diagnostic approach which takes into consideration clinical, genetic, and molecular analyses.	[Garau, Jessica; Dragoni, Francesca; Sproviero, Daisy; Gagliardi, Stella; Pansarasa, Orietta; Cereda, Cristina] IRCCS Mondino Fdn, Genom & Postgen Unit, Pavia, Italy; [Masnada, Silvia; Veggiotti, Pierangelo; Tonduti, Davide] V Buzzi Childrens Hosp, Unit Pediat Neurol, Milan, Italy; [Masnada, Silvia; Izzo, Giana; Veggiotti, Pierangelo; Zuccotti, Gian Vincenzo; Tonduti, Davide] V Buzzi Childrens Hosp, COALA Ctr Diag & Treatment Leukodystrophies, Milan, Italy; [Dragoni, Francesca] Univ Pavia, Dept Biol & Biotechnol L Spallanzani, Pavia, Italy; [Fogolari, Federico] Univ Udine, Dept Math Comp Sci & Phys, Udine, Italy; [Izzo, Giana] V Buzzi Childrens Hosp, Dept Pediat Radiol & Neuroradiol, Milan, Italy; [Varesio, Costanza; Orcesi, Simona] IRCCS Mondino Fdn, Dept Child Neurol & Psychiat, Pavia, Italy; [Varesio, Costanza; Orcesi, Simona] Univ Pavia, Dept Brain & Behav Sci, Pavia, Italy; [Veggiotti, Pierangelo; Zuccotti, Gian Vincenzo] Univ Milan, Dept Biomed & Clin Sci L Sacco, Milan, Italy; [Zuccotti, Gian Vincenzo] V Buzzi Childrens Hosp, Dept Pediat, Milan, Italy	IRCCS Fondazione Casimiro Mondino; University of Pavia; University of Udine; IRCCS Fondazione Casimiro Mondino; University of Pavia; University of Milan; Luigi Sacco Hospital	Pansarasa, O (corresponding author), IRCCS Mondino Fdn, Genom & Postgen Unit, Pavia, Italy.	orietta.pansarasa@mondino.it	Varesio, Costanza/AAO-8013-2021; Sproviero, Daisy/AAB-8752-2019; Garau, Jessica/AAA-4959-2020; Dragoni, Francesca/AAB-8379-2022; Varesio, Costanza/AAB-8688-2019; CEREDA, CRISTINA/G-8208-2011; Sproviero, Daisy/GSN-0961-2022; Tonduti, Davide/K-1673-2016	Varesio, Costanza/0000-0001-5645-021X; Garau, Jessica/0000-0002-9885-1369; CEREDA, CRISTINA/0000-0001-9571-0862; Sproviero, Daisy/0000-0001-5061-683X; Tonduti, Davide/0000-0001-9371-7454	NIH [U01NS106845-01A1]; Italian Health Ministry grant RC 2017-2020	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Italian Health Ministry grant RC 2017-2020	This study was supported by NIH-funded grants (U01NS106845-01A1) (The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health) and by the Italian Health Ministry grant RC 2017-2020 to IRCCS Mondino Foundation, Pavia, Italy.	Ali M, 2006, J MED GENET, V43, P444, DOI 10.1136/jmg.2005.031880; Benitez-Guijarro M, 2018, EMBO J, V37, DOI 10.15252/embj.201798506; Crow YJ, 2015, AM J MED GENET A, V167, P296, DOI 10.1002/ajmg.a.36887; Figiel M, 2011, J BIOL CHEM, V286, P10540, DOI 10.1074/jbc.M110.181974; Garau J, 2019, J CLIN MED, V8, DOI 10.3390/jcm8050750; Hyjek M, 2019, DNA REPAIR, V84, DOI 10.1016/j.dnarep.2019.102672; Jeong HS, 2004, NUCLEIC ACIDS RES, V32, P407, DOI 10.1093/nar/gkh209; Mura E, 2021, METAB BRAIN DIS, V36, P859, DOI 10.1007/s11011-021-00716-5; Orcesi S, 2009, BRIT MED BULL, V89, P183, DOI 10.1093/bmb/ldn049; Pizzi S, 2015, HUM MOL GENET, V24, P649, DOI 10.1093/hmg/ddu485; Rabe B, 2013, J MOL MED, V91, P1235, DOI 10.1007/s00109-013-1061-x; Reijns MAM, 2011, J BIOL CHEM, V286, P10530, DOI 10.1074/jbc.M110.177394; Sase S, 2018, BRAIN PATHOL, V28, P399, DOI 10.1111/bpa.12600; Tonduti D, 2018, ORPHANET J RARE DIS, V13, DOI 10.1186/s13023-018-0854-y; Uggenti C, 2020, NAT GENET, V52, P1364, DOI 10.1038/s41588-020-00737-3	15	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 26	2021	12								672952	10.3389/fimmu.2021.672952	http://dx.doi.org/10.3389/fimmu.2021.672952			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RZ5AH	33981319	gold, Green Published			2022-12-18	WOS:000648608600001
J	Hasan, MZ; Walter, L				Hasan, Mohammad Zahidul; Walter, Lutz			Rhesus Macaque Activating Killer Immunoglobulin-Like Receptors Associate With Fc Receptor Gamma (FCER1G) and Not With DAP12 Adaptor Proteins Resulting in Stabilized Expression and Enabling Signal Transduction	FRONTIERS IN IMMUNOLOGY			English	Article						adaptor association; Co-immunoprecipitation (co-IP); rhesus macaque (Macaca mulatta); DAP12; FCER1G; activating KIR; Activating killer cell immunoglobulin-like receptors; NK cell	CELLS; INFECTION	Activating killer cell immunoglobulin-like receptors (KIR) in macaques are thought to be derived by genetic recombination of the region encoding the transmembrane and intracellular part of KIR2DL4 and a KIR3D gene. As a result, all macaque activating KIR possess a positively charged arginine residue in the transmembrane region. As human KIR2DL4 associates with the FCER1G (also called Fc receptor-gamma, FcR gamma) adaptor, we hypothesized that in contrast to human and great ape the activating KIRs of macaques associate with FcR gamma instead of DAP12. By applying co-immunoprecipitation of transfected as well as primary cells, we demonstrate that rhesus macaque KIR3DS05 indeed associates with FcR gamma and not with DAP12. This association with FcR gamma results in increased and substantially stabilized surface expression of KIR3DS05. In addition, we demonstrate that binding of specific ligands of KIR3DS05, Mamu-A1*001 and A1*011, resulted in signal transduction in the presence of FcR gamma in contrast to DAP12.	[Hasan, Mohammad Zahidul; Walter, Lutz] Leibniz Inst Primate Res, German Primate Ctr, Primate Genet Lab, Gottingen, Germany	Deutsches Primatenzentrum (DPZ)	Walter, L (corresponding author), Leibniz Inst Primate Res, German Primate Ctr, Primate Genet Lab, Gottingen, Germany.	walter@dpz.eu	Walter, Lutz/I-2606-2017	Walter, Lutz/0000-0001-9408-3131				Abi-Rached L, 2010, J IMMUNOL, V184, P1379, DOI 10.4049/jimmunol.0903016; Averdam A, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000688; Blokhuis JH, 2010, IMMUNOGENETICS, V62, P295, DOI 10.1007/s00251-010-0434-3; Blokhuis JH, 2009, MOL IMMUNOL, V46, P640, DOI 10.1016/j.molimm.2008.08.270; Bruijnesteijn J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.582804; Bruijnesteijn J, 2020, J IMMUNOL, V204, P1770, DOI 10.4049/jimmunol.1901140; Bruijnesteijn J, 2020, IMMUNOGENETICS, V72, P37, DOI 10.1007/s00251-019-01135-8; Bruijnesteijn J, 2018, J IMMUNOL, V200, P1692, DOI 10.4049/jimmunol.1701480; Cadavid LF, 2009, IMMUNOGENETICS, V61, P27, DOI 10.1007/s00251-008-0342-y; Call ME, 2007, NAT REV IMMUNOL, V7, P841, DOI 10.1038/nri2186; Campbell KS, 2004, J IMMUNOL, V172, P899, DOI 10.4049/jimmunol.172.2.899; Campbell KS, 1998, EUR J IMMUNOL, V28, P599, DOI 10.1002/(SICI)1521-4141(199802)28:02<599::AID-IMMU599>3.3.CO;2-6; Carr WH, 2007, J IMMUNOL, V178, P647, DOI 10.4049/jimmunol.178.2.647; Della Chiesa M, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00351; Garzon-Ospina D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079731; Hamerman JA, 2009, IMMUNOL REV, V232, P42, DOI 10.1111/j.1600-065X.2009.00841.x; Hermes M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064936; Hermes M, 2012, IMMUNOGENETICS, V64, P845, DOI 10.1007/s00251-012-0640-2; Hershberger KL, 2001, J IMMUNOL, V166, P4380, DOI 10.4049/jimmunol.166.7.4380; Hwang I, 2012, INT IMMUNOL, V24, P793, DOI 10.1093/intimm/dxs080; Kikuchi-Maki A, 2005, J IMMUNOL, V174, P3859, DOI 10.4049/jimmunol.174.7.3859; Kruse PH, 2010, IMMUNOGENETICS, V62, P281, DOI 10.1007/s00251-010-0433-4; Lanier LL, 2009, IMMUNOL REV, V227, P150, DOI 10.1111/j.1600-065X.2008.00720.x; Lanier LL, 1998, IMMUNITY, V8, P693, DOI 10.1016/S1074-7613(00)80574-9; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; Lee J, 2015, IMMUNITY, V42, P431, DOI 10.1016/j.immuni.2015.02.013; Liu WR, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101709; Mizuguchi H, 2000, MOL THER, V1, P376, DOI 10.1006/mthe.2000.0050; Moreland AJ, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-295; Mulrooney TJ, 2013, J LEUKOCYTE BIOL, V94, P301, DOI 10.1189/jlb.0213093; Muntasell A, 2016, J IMMUNOL, V196, P3818, DOI 10.4049/jimmunol.1502438; Muntasell A, 2013, EUR J IMMUNOL, V43, P1133, DOI 10.1002/eji.201243117; Nakajima H, 1999, J IMMUNOL, V162, P5; Olcese L, 1997, J IMMUNOL, V158, P5083; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P350, DOI 10.1073/pnas.88.2.350; Rosner C, 2011, J IMMUNOL, V186, P2156, DOI 10.4049/jimmunol.1002634; Rosner C, 2010, IMMUNOGENETICS, V62, P149, DOI 10.1007/s00251-010-0424-5; Sambrook JG, 2005, GENOME RES, V15, P25, DOI 10.1101/gr.2381205; Schlums H, 2015, IMMUNITY, V42, P443, DOI 10.1016/j.immuni.2015.02.008; Shah SV, 2018, CELL REP, V25, P2766, DOI 10.1016/j.celrep.2018.11.020; Truitt LL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02381; VIVIER E, 1991, J IMMUNOL, V147, P4263; Zhang TX, 2013, J IMMUNOL, V190, P1402, DOI 10.4049/jimmunol.1203034	44	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 23	2021	12								678964	10.3389/fimmu.2021.678964	http://dx.doi.org/10.3389/fimmu.2021.678964			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RY7QT	33968088	Green Published, gold			2022-12-18	WOS:000648102000001
J	Garcia, IE; Pando, RH; Ivanyi, J				Estrada Garcia, Iris; Hernandez Pando, Rogelio; Ivanyi, Juraj			Editorial: Advances in Immunotherapeutic Approaches to Tuberculosis	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						Tuberculosis; Intracellular infection; pulmonary infection disease; mycobacterial infections; Immunotherapies			[Estrada Garcia, Iris] ENCB IPN, Natl Sch Biol Sci, Dept Immunol, Mexico City, DF, Mexico; [Hernandez Pando, Rogelio] Natl Inst Med Sci & Nutr Salvador Zubiran, Dept Pathol, Expt Pathol Sect, Mexico City, DF, Mexico; [Ivanyi, Juraj] Guys Campus Kings Coll, Ctr Host Microbiome Interact, London, England	University of London; King's College London	Pando, RH (corresponding author), Natl Inst Med Sci & Nutr Salvador Zubiran, Dept Pathol, Expt Pathol Sect, Mexico City, DF, Mexico.	rhdezpando@hotmail.com	Ivanyi, Juraj/ABB-3326-2021						0	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 22	2021	12								684200	10.3389/fimmu.2021.684200	http://dx.doi.org/10.3389/fimmu.2021.684200			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RX7XK	33968090	Green Published			2022-12-18	WOS:000647433200001
J	Islam, MT; Bardaweel, SK; Mubarak, MS; Koch, W; Gawel-Beben, K; Antosiewicz, B; Sharifi-Rad, J				Islam, Muhammad Torequl; Bardaweel, Sanaa K.; Mubarak, Mohammad S.; Koch, Wojciech; Gawel-Beben, Katarzyna; Antosiewicz, Beata; Sharifi-Rad, Javad			Immunomodulatory Effects of Diterpenes and Their Derivatives Through NLRP3 Inflammasome Pathway: A Review (vol 11, 572136, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						diterpenes; inflammation; mitochondrial dysfunction; NLRP3; mechanism of action			[Islam, Muhammad Torequl] Ton Duc Thang Univ, Lab Theoret & Computat Biophys, Ho Chi Minh City, Vietnam; [Islam, Muhammad Torequl] Ton Duc Thang Univ, Fac Pharm, Ho Chi Minh City, Vietnam; [Bardaweel, Sanaa K.] Univ Jordan, Sch Pharm, Dept Pharmaceut Sci, Amman, Jordan; [Mubarak, Mohammad S.] Univ Jordan, Dept Chem, Amman, Jordan; [Koch, Wojciech] Med Univ Lublin, Chair & Dept Food & Nutr, Lublin, Poland; [Gawel-Beben, Katarzyna; Antosiewicz, Beata] Univ Informat Technol & Management Rzeszow, Dept Cosmetol, Rzeszow, Poland; [Sharifi-Rad, Javad] Zabol Univ Med Sci, Zabol Med Plants Res Ctr, Zabol, Iran	Ton Duc Thang University; Ton Duc Thang University; University of Jordan; University of Jordan; Medical University of Lublin; University of Information Technology & Management Rzeszow	Koch, W (corresponding author), Med Univ Lublin, Chair & Dept Food & Nutr, Lublin, Poland.; Sharifi-Rad, J (corresponding author), Zabol Univ Med Sci, Zabol Med Plants Res Ctr, Zabol, Iran.	kochw@interia.pl; javad.sharifirad@gmail.com	Gawel-Beben, Katarzyna Barbara/ABF-3672-2021; Islam, Muhammad Torequl/AFQ-8827-2022; Sharifi-Rad, Javad/D-5747-2016	Gawel-Beben, Katarzyna Barbara/0000-0001-5773-1849; Sharifi-Rad, Javad/0000-0002-7301-8151; Mubarak, Mohammad/0000-0002-9782-0835				Islam MT, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.572136	1	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 22	2021	12								692302	10.3389/fimmu.2021.692302	http://dx.doi.org/10.3389/fimmu.2021.692302			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RY0HK	33968092	Green Published, gold			2022-12-18	WOS:000647595400001
J	Matiaskova, K; Kavanova, L; Kulich, P; Gebauer, J; Nedbalcova, K; Kudlackova, H; Tesarik, R; Faldyna, M				Matiaskova, Katarina; Kavanova, Lenka; Kulich, Pavel; Gebauer, Jan; Nedbalcova, Katerina; Kudlackova, Hana; Tesarik, Radek; Faldyna, Martin			The Role of Antibodies Against the Crude Capsular Extract in the Immune Response of Porcine Alveolar Macrophages to In Vitro Infection of Various Serovars of Glaesserella (Haemophilus) parasuis	FRONTIERS IN IMMUNOLOGY			English	Article						Haemophilus parasuis; Glaesserela parasuis; capsule; antibodies; porcine alveolar macrophages; reactive oxygen species; catalase; antioxidants	INTERLEUKIN-1 RECEPTOR ANTAGONIST; RESPIRATORY SYNDROME VIRUS; CONCURRENT INFECTION	In Glasser's disease outbreaks, Glaesserella (Haemophilus) parasuis has to overcome the non-specific immune system in the lower respiratory tract, the alveolar macrophages. Here we showed that porcine alveolar macrophages (PAMs) were able to recognize and phagocyte G. parasuis with strain-to-strain variability despite the presence of the capsule in virulent (serovar 1, 5, 12) as well in avirulent strains (serovar 6 and 9). The capsule, outer membrane proteins, virulence-associated autotransporters, cytolethal distending toxins and many other proteins have been identified as virulence factors of this bacterium. Therefore, we immunized pigs with the crude capsular extract (cCE) from the virulent G. parasuis CAPM 6475 strain (serovar 5) and evaluated the role of the anti-cCE/post-vaccinal IgG in the immune response of PAMs to in vitro infection with various G. parasuis strains. We demonstrated the specific binding of the antibodies to the cCE by Western-blotting assay and immunoprecipitation as well as the specific binding to the strain CAPM 6475 in transmission electron microscopy. In the cCE, we identified several virulence-associated proteins that were immunoreactive with IgG isolated from sera of immunized pigs. Opsonization of G. parasuis strains by post-vaccinal IgG led to enhanced phagocytosis of G. parasuis by PAMs at the first two hours of infection. Moreover, opsonization increased the oxidative burst and expression/production of both pro- and anti-inflammatory cytokines. The neutralizing effects of these antibodies on the antioxidant mechanisms of G. parasuis may lead to attenuation of its virulence and pathogenicity in vivo. Together with opsonization of bacteria by these antibodies, the host may eliminate G. parasuis in the infection site more efficiently. Based on these results, the crude capsular extract is a vaccine candidate with immunogenic properties.	[Matiaskova, Katarina; Kavanova, Lenka; Gebauer, Jan; Nedbalcova, Katerina; Kudlackova, Hana; Tesarik, Radek; Faldyna, Martin] Vet Res Inst, Dept Infect Dis & Prevent Med, Brno, Czech Republic; [Kulich, Pavel] Vet Res Inst, Dept Pharmacol & Toxicol, Brno, Czech Republic; [Faldyna, Martin] Univ Vet Sci, Dept Infect Dis & Microbiol, Brno, Czech Republic	Czech Veterinary Research Institute; Czech Veterinary Research Institute; University of Veterinary Sciences Brno	Faldyna, M (corresponding author), Vet Res Inst, Dept Infect Dis & Prevent Med, Brno, Czech Republic.; Faldyna, M (corresponding author), Univ Vet Sci, Dept Infect Dis & Microbiol, Brno, Czech Republic.	faldyna@vri.cz	Gebauer, Jan/GPG-3682-2022		University of Veterinary and Pharmaceutical Sciences [IGA VFU Brno 123/2017/FVL]; Ministry of Agriculture of the Czech Republic [CZ.02.1.01/0.0/0.0/15_003/0000495, CZ.1.05/2.1.00/19.0385, RO 0518]	University of Veterinary and Pharmaceutical Sciences; Ministry of Agriculture of the Czech Republic(Ministry of Agriculture, Czech Republic)	The study was supported by the project IGA VFU Brno 123/2017/FVL of the University of Veterinary and Pharmaceutical Sciences, the projects of the Ministry of Education, Youth and Sports of the Czech Republic (CZ.02.1.01/0.0/0.0/15_003/0000495 and CZ.1.05/2.1.00/19.0385) and the project RO 0518 of the Ministry of Agriculture of the Czech Republic.	Aderem A, 2003, J INFECT DIS, V187, pS340, DOI 10.1086/374747; Aggarwal B., 2001, CYTOKINE REFERENCE C, V1, P413; AMANO H, 1994, J VET MED SCI, V56, P639, DOI 10.1292/jvms.56.639; BAGGIOLINI M, 1995, INT J IMMUNOPHARMACO, V17, P103, DOI 10.1016/0192-0561(94)00088-6; Barasuol BM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10627-0; Bedouhene S, 2017, AM J BLOOD RES, V7, P41; Brockmeier SL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103787; Celli J, 2002, TRENDS MICROBIOL, V10, P232, DOI 10.1016/S0966-842X(02)02343-0; Cerda-Cuellar M, 2008, VET J, V175, P384, DOI 10.1016/j.tvjl.2007.01.016; Chen YS, 2012, VET MICROBIOL, V160, P259, DOI 10.1016/j.vetmic.2012.05.021; Costa-Hurtado M, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-57; Dickerman A, 2020, INT J SYST EVOL MICR, V70, P180, DOI 10.1099/ijsem.0.003730; Ezraty B, 2017, NAT REV MICROBIOL, V15, P385, DOI 10.1038/nrmicro.2017.26; Foey AD, 1998, J IMMUNOL, V160, P920; Fu SL, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051307; Guo L, 2017, CAN J MICROBIOL, V63, P312, DOI 10.1139/cjm-2016-0671; Hau SJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220365; Howell KJ, 2013, J BACTERIOL, V195, P4264, DOI 10.1128/JB.00471-13; Huebner J, 1999, INFECT IMMUN, V67, P1213, DOI 10.1128/IAI.67.3.1213-1219.1999; JENKINS JK, 1994, LYMPHOKINE CYTOK RES, V13, P47; Kavanova L, 2017, VET RES, V48, DOI 10.1186/s13567-017-0433-6; Kavanova L, 2015, VET MICROBIOL, V180, P28, DOI 10.1016/j.vetmic.2015.08.026; KIELSTEIN P, 1992, J CLIN MICROBIOL, V30, P862, DOI 10.1128/JCM.30.4.862-865.1992; Kyrova K, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-115; Li G, 2017, J PROTEOMICS, V163, P111, DOI 10.1016/j.jprot.2017.05.014; Liu HS, 2016, VET IMMUNOL IMMUNOP, V180, P53, DOI 10.1016/j.vetimm.2016.09.002; Macedo N, 2015, VET RES, V46, DOI 10.1186/s13567-015-0263-3; de la Fuente AJM, 2009, RES VET SCI, V87, P47, DOI 10.1016/j.rvsc.2008.12.012; Matiaskova K, 2019, VET MED-CZECH, V64, P392, DOI 10.17221/71/2019-VETMED; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; Nedbalcova K, 2011, RES VET SCI, V91, P225, DOI 10.1016/j.rvsc.2010.12.008; Olvera A, 2010, VET RES, V41, DOI 10.1051/vetres/2009074; Olvera A, 2009, VET RES, V40, DOI 10.1051/vetres/2009007; Pavlova B, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-16; Perry MB, 2013, CARBOHYD RES, V378, P91, DOI 10.1016/j.carres.2013.04.023; Reddy J, 2000, VET IMMUNOL IMMUNOP, V74, P31, DOI 10.1016/S0165-2427(00)00164-1; Rosenberger CM, 2003, NAT REV MOL CELL BIO, V4, P385, DOI 10.1038/nrm1104; Segal BH, 2012, FREE RADICAL BIO MED, V53, P72, DOI 10.1016/j.freeradbiomed.2012.04.022; SIBILLE Y, 1990, AM REV RESPIR DIS, V141, P471, DOI 10.1164/ajrccm/141.2.471; ULICH TR, 1992, AM J PATHOL, V141, P61; VANNIER E, 1992, P NATL ACAD SCI USA, V89, P4076, DOI 10.1073/pnas.89.9.4076; Volf J, 2007, ZOONOSES PUBLIC HLTH, V54, P286, DOI 10.1111/j.1863-2378.2007.01064.x; Wen YP, 2018, GENE, V643, P107, DOI 10.1016/j.gene.2017.12.010; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]; Zelnickova P, 2008, NITRIC OXIDE-BIOL CH, V19, P36, DOI 10.1016/j.niox.2008.04.001; Zeng Z, 2017, MICROB PATHOGENESIS, V110, P380, DOI [10.1016/j.micPath.2017.06.035, 10.1016/j.micpath.2017.06.035]; Zhang B, 2014, VET MICROBIOL, V168, P1, DOI 10.1016/j.vetmic.2013.07.027; Zhang HF, 2018, LIFE SCI, V207, P296, DOI 10.1016/j.lfs.2018.06.015	48	0	0	5	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 22	2021	12								635097	10.3389/fimmu.2021.635097	http://dx.doi.org/10.3389/fimmu.2021.635097			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RX5WJ	33968026	Green Published			2022-12-18	WOS:000647293600001
J	Santa, P; Garreau, A; Serpas, L; Ferriere, A; Blanco, P; Soni, C; Sisirak, V				Santa, Pauline; Garreau, Anne; Serpas, Lee; Ferriere, Amandine; Blanco, Patrick; Soni, Chetna; Sisirak, Vanja			The Role of Nucleases and Nucleic Acid Editing Enzymes in the Regulation of Self-Nucleic Acid Sensing (vol 12, 629922, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						DNases; RNases; systemic lupus erythematosus; DNA sensing; RNA sensing; interferonopathies; aicardi goutieres syndrome; toll-like receptors			[Santa, Pauline; Garreau, Anne; Ferriere, Amandine; Blanco, Patrick; Sisirak, Vanja] Bordeaux Univ, CNRS UMR 5164, ImmunoConcEpT, Bordeaux, France; [Serpas, Lee; Soni, Chetna] NYU, Grossman Sch Med, Dept Pathol, New York, NY 10003 USA; [Blanco, Patrick] Bordeaux Univ Hosp, Immunol & Immunogenet Dept, Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; New York University; CHU Bordeaux	Sisirak, V (corresponding author), Bordeaux Univ, CNRS UMR 5164, ImmunoConcEpT, Bordeaux, France.; Soni, C (corresponding author), NYU, Grossman Sch Med, Dept Pathol, New York, NY 10003 USA.	chetna.soni@nyulangone.org; vsisirak@immuconcept.org	Sisirak, Vanja/GRJ-7805-2022; Sisirak, Vanja/O-9393-2016	Sisirak, Vanja/0000-0003-3070-6533				Santa P, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.629922	1	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 22	2021	12								690853	10.3389/fimmu.2021.690853	http://dx.doi.org/10.3389/fimmu.2021.690853			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RY0HQ	33968091	Green Published, gold			2022-12-18	WOS:000647596100001
J	Wei, Y; Gao, XJ; Zhao, F; Baimanov, D; Cong, YL; Jiang, YY; Hameed, S; Ouyang, YX; Gao, XF; Lin, XY; Wang, LM				Wei, Yang; Gao, Xuejiao; Zhao, Feng; Baimanov, Didar; Cong, Yalin; Jiang, Yingying; Hameed, Saima; Ouyang, Yixin; Gao, Xingfa; Lin, Xiaoying; Wang, Liming			Induced Autophagy of Macrophages and the Regulation of Inflammatory Effects by Perovskite Nanomaterial LaNiO3	FRONTIERS IN IMMUNOLOGY			English	Article						perovskite nanomaterials; LaNiO3; autophagy; dissolution; inflammation response	TNF-ALPHA; CELLS; APOPTOSIS	Perovskite nanomaterials (NMs) possess excellent physicochemical properties and have promising applications in light-emitting diodes (LEDs), lasers, photodetectors, and artificial synapse electronics. Potential exposure to these NMs happens in the manufacture and application of the perovskite-based products, however, the biological safety of these NMs is still unknown. Here, we used the LaNiO3 NM (LNO), a typical kind of perovskite nanostructures to study the interaction with macrophages (J774A.1) and to explore its biological effects at the cellular level. Firstly, we characterized the properties of LNO including the size, shape, and crystal structure using Transmission electronic microscope (TEM), Dynamic lighting scattering (DLS), and X-ray diffraction (XRD). Secondly, to gain a better understanding of the biological effect, we evaluated the effect of LNO on cell viability and found that LNO induced cell autophagy at a concentration of 5 mu g/ml and influenced the inflammatory response based on RT-PCR result. Finally, we demonstrated the mechanism that LNO causes cell autophagy and immune response is probably due to the metal ions released from LNO in acidic lysosomes, which triggered ROS and increased lysosomal membrane permeation. This study indicates the safety aspect of perovskite NMs and may guide the rational design of perovskite NMs with more biocompatibility during their manufacture and application.	[Wei, Yang; Gao, Xuejiao; Gao, Xingfa] Jiangxi Normal Univ, Coll Chem & Chem Engn, Nanchang, Jiangxi, Peoples R China; [Wei, Yang; Zhao, Feng; Baimanov, Didar; Cong, Yalin; Jiang, Yingying; Hameed, Saima; Ouyang, Yixin; Wang, Liming] Chinese Acad Sci, Inst High Energy Phys, CAS Key Lab Biol Effects Nanomat & Nanosafety, Beijing, Peoples R China; [Wei, Yang; Zhao, Feng; Baimanov, Didar; Cong, Yalin; Jiang, Yingying; Hameed, Saima; Ouyang, Yixin; Wang, Liming] Chinese Acad Sci, Inst High Energy Phys, CAS HKU Joint Lab Metall Hlth & Environm, Beijing, Peoples R China; [Wei, Yang; Zhao, Feng; Baimanov, Didar; Cong, Yalin; Jiang, Yingying; Hameed, Saima; Ouyang, Yixin; Wang, Liming] Chinese Acad Sci, Inst High Energy Phys, Beijing Metall Facil, Beijing, Peoples R China; [Baimanov, Didar; Cong, Yalin; Wang, Liming] Univ Chinese Acad Sci, Beijing, Peoples R China; [Cong, Yalin] Natl Ctr Nanosci & Technol, CAS Key Lab Biol Effects Nanomat & Nanosafety, Beijing, Peoples R China; [Jiang, Yingying] Qingdao Univ, Sch Publ Hlth, Qingdao, Peoples R China; [Ouyang, Yixin] Capital Med Univ, Sch Publ Hlth, Beijing, Peoples R China; [Lin, Xiaoying] Jilin Med Univ, Coll Pharm, Jilin, Jilin, Peoples R China	Jiangxi Normal University; Chinese Academy of Sciences; Institute of High Energy Physics, CAS; Chinese Academy of Sciences; Institute of High Energy Physics, CAS; Chinese Academy of Sciences; Institute of High Energy Physics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; National Center for Nanoscience & Technology - China; Qingdao University; Capital Medical University; Jilin Medical University	Gao, XF (corresponding author), Jiangxi Normal Univ, Coll Chem & Chem Engn, Nanchang, Jiangxi, Peoples R China.; Wang, LM (corresponding author), Chinese Acad Sci, Inst High Energy Phys, CAS Key Lab Biol Effects Nanomat & Nanosafety, Beijing, Peoples R China.; Wang, LM (corresponding author), Chinese Acad Sci, Inst High Energy Phys, CAS HKU Joint Lab Metall Hlth & Environm, Beijing, Peoples R China.; Wang, LM (corresponding author), Chinese Acad Sci, Inst High Energy Phys, Beijing Metall Facil, Beijing, Peoples R China.; Wang, LM (corresponding author), Univ Chinese Acad Sci, Beijing, Peoples R China.; Lin, XY (corresponding author), Jilin Med Univ, Coll Pharm, Jilin, Jilin, Peoples R China.	gaoxf@jxnu.edu.cn; linxytime@163.com; wangliming@ihep.ac.cn			Science and Technology Research Project of Jilin Province Education Department [JJKH20210496KJ]; National Basic Research Program of China [2016YFA0203200, 2020YFA0710702]; National Natural Science Foundation of China [31971322]; Users with Excellence Project of Hefei Science Center CAS [2018HSCUE004]; CAS President's International Fellowship Initiative (PIFI) [2021PM0059]; College Students' Science and Technology Innovation Project in IHEP [H95120P0U7]; College Students' Science and Technology Innovation Project in UCAS [H95120P0U7]; State Key Laboratory of Natural and Biomimetic Drugs, Peking University	Science and Technology Research Project of Jilin Province Education Department; National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Users with Excellence Project of Hefei Science Center CAS; CAS President's International Fellowship Initiative (PIFI); College Students' Science and Technology Innovation Project in IHEP; College Students' Science and Technology Innovation Project in UCAS; State Key Laboratory of Natural and Biomimetic Drugs, Peking University	We appreciated the funding from Science and Technology Research Project of Jilin Province Education Department (JJKH20210496KJ), the National Basic Research Program of China (2016YFA0203200, 2020YFA0710702), the National Natural Science Foundation of China (31971322), the Users with Excellence Project of Hefei Science Center CAS (2018HSCUE004), CAS President's International Fellowship Initiative (PIFI, 2021PM0059), and the College Students' Science and Technology Innovation Project in IHEP and UCAS (H95120P0U7). This work was partly supported by the State Key Laboratory of Natural and Biomimetic Drugs, Peking University.	Ahmad S., 2021, J HYBRID PEROVSKITE, DOI [10.1016/B978-0-12-819977-0.00005-6, DOI 10.1016/B978-0-12-819977-0.00005-6]; Chen MX, 2020, ADV SCI, V7, DOI 10.1002/advs.201901261; Chen RY, 2019, J AUTOIMMUN, V99, P39, DOI 10.1016/j.jaut.2019.01.010; Denaes T, 2016, SCI REP-UK, V6, DOI 10.1038/srep28806; Egorov VM, 2007, ANAL BIOANAL CHEM, V387, P2263, DOI 10.1007/s00216-006-1114-x; Ehrenstein MR, 2004, J EXP MED, V200, P277, DOI 10.1084/jem.20040165; Frissora F, 2003, EUR J IMMUNOL, V33, P907, DOI 10.1002/eji.200323657; Fujishiro Y, 1997, J ALLOY COMPD, V252, P103, DOI 10.1016/S0925-8388(96)02612-6; Greie JC, 2011, EUR J CELL BIOL, V90, P705, DOI 10.1016/j.ejcb.2011.04.011; Grekova S, 2010, CANCER BIOL THER, V10, P1280, DOI 10.4161/cbt.10.12.13455; Heidenau F, 2005, J MATER SCI-MATER M, V16, P883, DOI 10.1007/s10856-005-4422-3; Heo JH, 2017, J MATER CHEM A, V5, P21146, DOI 10.1039/c7ta06465a; Howard JM, 2020, ADV ENERGY MATER, V10, DOI 10.1002/aenm.201903161; Ichimura Y, 2010, SEMIN IMMUNOPATHOL, V32, P431, DOI 10.1007/s00281-010-0220-1; Into T, 2012, CELL SIGNAL, V24, P1150, DOI 10.1016/j.cellsig.2012.01.020; Jia GH, 2006, IMMUNOL CELL BIOL, V84, P448, DOI 10.1111/j.1440-1711.2006.01454.x; Jiang JK, 2009, J NANOPART RES, V11, P77, DOI 10.1007/s11051-008-9446-4; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Kumar P, 2016, INT J BIOCHEM CELL B, V73, P82, DOI 10.1016/j.biocel.2016.02.006; Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782; Li HY, 2020, ACS NANO, V14, P12854, DOI 10.1021/acsnano.0c03629; Li HY, 2020, NANOSCALE, V12, P6429, DOI 10.1039/c9nr08621h; Li RB, 2014, ACS NANO, V8, P10280, DOI 10.1021/nn505002w; Liu K, 2015, MED SCI MONIT BASIC, V21, P15, DOI 10.12659/MSMBR.893327; Lodder J, 2015, AUTOPHAGY, V11, P1280, DOI 10.1080/15548627.2015.1058473; Lukashevich IS, 1999, J MED VIROL, V59, P552, DOI 10.1002/(SICI)1096-9071(199912)59:4<552::AID-JMV21>3.3.CO;2-1; Luo MXM, 2015, J CELL PHYSIOL, V230, P2382, DOI 10.1002/jcp.24967; Maedler K, 2004, DIABETES, V53, P1706, DOI 10.2337/diabetes.53.7.1706; McCarthy JR, 2006, SMALL, V2, P983, DOI 10.1002/smll.200600139; Meissner F, 2010, P NATL ACAD SCI USA, V107, P13046, DOI 10.1073/pnas.1002396107; Mirshafiee V, 2018, ACS NANO, V12, P3836, DOI 10.1021/acsnano.8b01086; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Prokesch A, 2017, HISTOCHEM CELL BIOL, V147, P695, DOI 10.1007/s00418-016-1537-1; Racanelli AC, 2018, AUTOPHAGY, V14, P221, DOI 10.1080/15548627.2017.1389823; Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383; Saparov B, 2016, CHEM REV, V116, P4558, DOI 10.1021/acs.chemrev.5b00715; Scherz-Shouval R, 2011, TRENDS BIOCHEM SCI, V36, P30, DOI 10.1016/j.tibs.2010.07.007; Shen HM, 2014, TRENDS BIOCHEM SCI, V39, P61, DOI 10.1016/j.tibs.2013.12.001; Stoerzinger KA, 2017, CHEM MATER, V29, P9990, DOI 10.1021/acs.chemmater.7b03399; Stopford W, 2003, J ENVIRON MONITOR, V5, P675, DOI 10.1039/b302257a; Tan HY, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2795090; Tong L, 2020, ADV MATER, V32, DOI 10.1002/adma.202002251; Tsounis C, 2020, CATALYSTS, V10, DOI 10.3390/catal10040409; Virgin HW, 2009, NAT IMMUNOL, V10, P461, DOI 10.1038/ni.1726; Walkey CD, 2012, J AM CHEM SOC, V134, P2139, DOI 10.1021/ja2084338; Wang K, 2019, NANO ENERGY, V61, P352, DOI 10.1016/j.nanoen.2019.04.073; Wang K, 2020, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00397; Wang LM, 2015, ACS NANO, V9, P6532, DOI 10.1021/acsnano.5b02483; Wang LM, 2011, NANO LETT, V11, P772, DOI 10.1021/nl103992v; Wegrowski Y, 2006, CLIN EXP IMMUNOL, V144, P485, DOI 10.1111/j.1365-2249.2006.03059.x; Wu MY, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010070; Xiao B, 2013, BIOMATERIALS, V34, P7471, DOI 10.1016/j.biomaterials.2013.06.008; Xu K, 2015, INT J MOL MED, V36, P661, DOI 10.3892/ijmm.2015.2280; Yan L, 2019, ADV MATER, V31, DOI 10.1002/adma.201805391; Zhang H, 2017, AUTOPHAGY, V13, P627, DOI 10.1080/15548627.2016.1271516; Zhou CK, 2018, MATER RES LETT, V6, P552, DOI 10.1080/21663831.2018.1500951	57	0	0	4	28	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 22	2021	12								676773	10.3389/fimmu.2021.676773	http://dx.doi.org/10.3389/fimmu.2021.676773			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RX8FQ	33968087	Green Published			2022-12-18	WOS:000647454900001
J	Ma, QY; Grigorescu, M; Schreiber, A; Kettritz, R; Lindenmeyer, M; Anders, HJ; Steiger, S				Ma, Qiuyue; Grigorescu, Melissa; Schreiber, Adrian; Kettritz, Ralph; Lindenmeyer, Maja; Anders, Hans-Joachim; Steiger, Stefanie			Genetic Background but Not Intestinal Microbiota After Co-Housing Determines Hyperoxaluria-Related Nephrocalcinosis in Common Inbred Mouse Strains	FRONTIERS IN IMMUNOLOGY			English	Article						calcium oxalate; nephrocalcinosis; microbiota; mouse strains; uromodulin; kidney stone disease	CALCIUM-OXALATE CRYSTALLIZATION; GUT MICROBIOTA; KIDNEY	Calcium oxalate (CaOx) crystal formation, aggregation and growth is a common cause of kidney stone disease and nephrocalcinosis-related chronic kidney disease (CKD). Genetically modified mouse strains are frequently used as an experimental tool in this context but observed phenotypes may also relate to the genetic background or intestinal microbiota. We hypothesized that the genetic background or intestinal microbiota of mice determine CaOx crystal deposition and thus the outcome of nephrocalcinosis. Indeed, Casp1 (-/-), Cybb (-/-) or Casp1 (-/-)/Cybb (-/-) knockout mice on a 129/C57BL/6J (B6J) background that were fed an oxalate-rich diet for 14 days did neither encounter intrarenal CaOx crystal deposits nor nephrocalcinosis-related CKD. To test our assumption, we fed C57BL/6N (B6N), 129, B6J and Balb/c mice an oxalate-rich diet for 14 days. Only B6N mice displayed CaOx crystal deposits and developed CKD associated with tubular injury, inflammation and interstitial fibrosis. Intrarenal mRNA expression profiling of 64 known nephrocalcinosis-related genes revealed that healthy B6N mice had lower mRNA levels of uromodulin (Umod) compared to the other three strains. Feeding an oxalate-rich diet caused an increase in uromodulin protein expression and CaOx crystal deposition in the kidney as well as in urinary uromodulin excretion in B6N mice but not 129, B6J and Balb/c mice. However, backcrossing 129 mice on a B6N background resulted in a gradual increase in CaOx crystal deposits from F2 to F7, of which all B6N/129 mice from the 7(th) generation developed CaOx-related nephropathy similar to B6N mice. Co-housing experiments tested for a putative role of the intestinal microbiota but B6N co-housed with 129 mice or B6N/129 (3(rd) and 6(th) generation) mice did not affect nephrocalcinosis. In summary, genetic background but not the intestinal microbiome account for strain-specific crystal formation and, the levels of uromodulin secretion may contribute to this phenomenon. Our results imply that only littermate controls of the identical genetic background strain are appropriate when performing knockout mouse studies in this context, while co-housing is optional.	[Ma, Qiuyue; Grigorescu, Melissa; Anders, Hans-Joachim; Steiger, Stefanie] Ludwig Maximilians Univ Munchen, Univ Hosp, Div Nephrol, Dept Med 4, Munich, Germany; [Schreiber, Adrian; Kettritz, Ralph] Charite Univ Med Berlin, Dept Nephrol & Med Intens Care, Berlin, Germany; [Schreiber, Adrian; Kettritz, Ralph] Charite Univ Med Berlin, Expt & Clin Res Ctr, Berlin, Germany; [Schreiber, Adrian; Kettritz, Ralph] Helmholtz Assoc, Max Delbrueck Ctr Mol Med, Berlin, Germany; [Lindenmeyer, Maja] Univ Med Ctr Hamburg Eppendorf, Dept Med 3, Hamburg, Germany	University of Munich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Hamburg; University Medical Center Hamburg-Eppendorf	Steiger, S (corresponding author), Ludwig Maximilians Univ Munchen, Univ Hosp, Div Nephrol, Dept Med 4, Munich, Germany.	stefanie.steiger@med.uni-muenchen.de	Ma, Qiuyue/HHM-4226-2022; Schreiber, Adrian/ABC-4513-2021; Anders, Hans-Joachim/ABD-6247-2021	Ma, Qiuyue/0000-0001-8294-2488; Schreiber, Adrian/0000-0003-1244-6379; Kettritz, Ralph/0000-0001-5821-6718	Deutsche Forschungsgemeinschaft [STE2437/2-1, 2-2, AN372/16-2, 24-1, 27-1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The work was supported by grants from the Deutsche Forschungsgemeinschaft to SS (STE2437/2-1 and 2-2) and to H-JA (AN372/16-2, 24-1, 27-1).	Al-Wahsh I, 2012, UROL RES, V40, P191, DOI 10.1007/s00240-011-0421-7; Alexander AD, 2006, MAMM GENOME, V17, P1093, DOI 10.1007/s00335-006-0063-1; Anders HJ, 2018, KIDNEY INT, V93, P656, DOI 10.1016/j.kint.2017.09.022; Bates JM, 2004, KIDNEY INT, V65, P791, DOI 10.1111/j.1523-1755.2004.00452.x; Bourdi M, 2011, CHEM RES TOXICOL, V24, P794, DOI 10.1021/tx200143x; Breiderhoff T, 2012, P NATL ACAD SCI USA, V109, P14241, DOI 10.1073/pnas.1203834109; Campbell JH, 2012, ISME J, V6, P2033, DOI 10.1038/ismej.2012.54; Carvalho Mauricio, 2018, Braz. J. Nephrol., V40, P6, DOI [10.1590/1678-4685-jbn-2018-00010002, 10.1590/1678-4685-JBN-2018-00010002]; Coe FL, 2005, J CLIN INVEST, V115, P2598, DOI 10.1172/JCI26662; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Curhan GC, 1997, J AM SOC NEPHROL, V8, P1568; Denburg MR, 2020, J AM SOC NEPHROL, V31, P1358, DOI 10.1681/ASN.2019101131; Devuyst O, 2017, NAT REV NEPHROL, V13, P525, DOI 10.1038/nrneph.2017.101; Dobrowolski P, 2018, TRANSGENIC RES, V27, P265, DOI 10.1007/s11248-018-0073-2; Farkas C, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-5504-9; Faure E, 2016, NEW ENGL J MED, V375, DOI 10.1056/NEJMc1609332; Ferraro PM, 2019, AM J KIDNEY DIS, V74, P736, DOI 10.1053/j.ajkd.2019.06.005; Freeman D, 2006, CANCER RES, V66, P6492, DOI 10.1158/0008-5472.CAN-05-4143; Friswell MK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008584; Goldfarb DS, 2005, KIDNEY INT, V67, P1053, DOI 10.1111/j.1523-1755.2005.00170.x; Hatch M, 2006, KIDNEY INT, V69, P691, DOI 10.1038/sj.ki.5000162; Hatch M, 1999, J AM SOC NEPHROL, V10, pS324; Hatch M, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2016.12.70; Hildebrand F, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-1-r4; Howles SA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13145-x; Jiang ZR, 2006, NAT GENET, V38, P474, DOI 10.1038/ng1762; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; Kahle M, 2013, MOL METAB, V2, P435, DOI 10.1016/j.molmet.2013.07.009; Khan SR, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.8; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Klimesova K, 2015, UROLITHIASIS, V43, P107, DOI 10.1007/s00240-014-0728-2; Klinkhammer BM, 2020, J AM SOC NEPHROL, V31, P799, DOI 10.1681/ASN.2019080827; Knauf F, 2019, NAT REV NEPHROL, V15, P263, DOI 10.1038/s41581-019-0118-7; Knight J, 2013, UROLITHIASIS, V41, P187, DOI 10.1007/s00240-013-0566-7; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Kumar V, 2003, J AM SOC NEPHROL, V14, P289, DOI 10.1097/01.ASN.0000046030.24938.0A; Lim JP, 2012, BRAIN BEHAV, V2, P22, DOI 10.1002/brb3.29; Liu Y, 2010, AM J PHYSIOL-RENAL, V299, pF469, DOI 10.1152/ajprenal.00243.2010; Ma QY, 2017, PHYSIOL REP, V5, DOI 10.14814/phy2.13228; Manissorn J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01953-4; Marschner JA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02173; Maydan O, 2018, PHYSIOL REP, V6, DOI 10.14814/phy2.13654; McCoy Kathy D, 2017, Curr Protoc Immunol, V117, DOI 10.1002/cpim.25; Mehta M, 2016, INT J SURG, V36, P607, DOI 10.1016/j.ijsu.2016.11.024; Mekada K, 2021, EXP ANIM TOKYO, V70, P145, DOI 10.1538/expanim.20-0158; Mo L, 2004, KIDNEY INT, V66, P1159, DOI 10.1111/j.1523-1755.2004.00867.x; Mo L, 2004, AM J PHYSIOL-RENAL, V286, pF795, DOI 10.1152/ajprenal.00357.2003; Mulay SR, 2017, NAT REV NEPHROL, V13, P226, DOI 10.1038/nrneph.2017.10; Mulay SR, 2016, AM J PHYSIOL-RENAL, V310, pF785, DOI 10.1152/ajprenal.00488.2015; Mulay SR, 2013, J CLIN INVEST, V123, P236, DOI 10.1172/JCI63679; Nagy A, 2006, METHOD ENZYMOL, V418, P3, DOI 10.1016/S0076-6879(06)18001-5; Okada A, 2009, J BONE MINER RES, V24, P908, DOI [10.1359/JBMR.081245, 10.1359/jbmr.081245]; Platt RJ, 2014, CELL, V159, P440, DOI 10.1016/j.cell.2014.09.014; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; Rivera J, 2008, IMMUNITY, V28, P1, DOI 10.1016/j.immuni.2007.12.008; Robertson SJ, 2019, CELL REP, V27, P1910, DOI 10.1016/j.celrep.2019.04.023; Sayer JA, 2017, J AM SOC NEPHROL, V28, P748, DOI 10.1681/ASN.2016050576; Schreiber A, 2015, J AM SOC NEPHROL, V26, P411, DOI 10.1681/ASN.2013111177; Sellmayr M, 2020, J AM SOC NEPHROL, V31, P2773, DOI 10.1681/ASN.2020040523; Steiger S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00619; Stern JM, 2016, UROLITHIASIS, V44, P399, DOI 10.1007/s00240-016-0882-9; Sun L, 2018, KIDNEY BLOOD PRESS R, V43, P820, DOI 10.1159/000490136; Taguchi K, 2014, J AM SOC NEPHROL, V25, P1680, DOI 10.1681/ASN.2013060675; Tang RQ, 2018, UROLITHIASIS, V46, P503, DOI 10.1007/s00240-018-1037-y; Tasian GE, 2018, J AM SOC NEPHROL, V29, P1731, DOI 10.1681/ASN.2017111213; Thongboonkerd V, 2006, CLIN CHIM ACTA, V367, P120, DOI 10.1016/j.cca.2005.11.033; Ticinesi A, 2019, KIDNEY INT, V96, P25, DOI 10.1016/j.kint.2019.03.020; Ticinesi A, 2018, GUT, V67, P2097, DOI 10.1136/gutjnl-2017-315734; Turroni S, 2010, APPL ENVIRON MICROB, V76, P5609, DOI 10.1128/AEM.00844-10; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Usami M, 2018, UROLITHIASIS, V46, P515, DOI 10.1007/s00240-018-1040-3; Vanden Berghe T, 2015, IMMUNITY, V43, P200, DOI 10.1016/j.immuni.2015.06.011; Verkoelen CF, 2007, KIDNEY INT, V72, P13, DOI 10.1038/sj.ki.5002272; Vezzoli G, 2011, KIDNEY INT, V80, P587, DOI 10.1038/ki.2010.430	74	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 21	2021	12								673423	10.3389/fimmu.2021.673423	http://dx.doi.org/10.3389/fimmu.2021.673423			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RX5XN	33968083	gold, Green Accepted, Green Published			2022-12-18	WOS:000647296600001
J	Quinti, I; Spadaro, G; Jolles, S; Condino-Neto, A				Quinti, Isabella; Spadaro, Giuseppe; Jolles, Stephen; Condino-Neto, Antonio			Editorial: The Complexity of Primary Antibody Deficiencies	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						primary antibody deficiencies agammaglobulinemia; common variable immune deficiencies; chronic lung disease; liver diseases; endocrine diseases; T helper follicular cells; free light chains			[Quinti, Isabella] Sapienza Univ Rome, Dept Mol Med, Rome, Italy; [Spadaro, Giuseppe] Univ Naples Federico II, Dept Translat Med Sci, Naples, Italy; [Spadaro, Giuseppe] Univ Naples Federico II, Ctr Basic & Clin Immunol Res CISI, Naples, Italy; [Jolles, Stephen] Univ Hosp Wales, Immunodeficiency Ctr Wales, Cardiff, Wales; [Condino-Neto, Antonio] Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Sao Paulo, Brazil	Sapienza University Rome; University of Naples Federico II; University of Naples Federico II; Cardiff University; Universidade de Sao Paulo	Quinti, I (corresponding author), Sapienza Univ Rome, Dept Mol Med, Rome, Italy.	isabella.quinti@uniroma1.it	Condino-Neto, Antonio/D-4762-2012	Condino-Neto, Antonio/0000-0002-1069-3117; Ziyadullaev, Shukhrat/0000-0002-9309-3933	Jeffrey Modell Foundation; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [FAPESP 2016/22158-3]	Jeffrey Modell Foundation; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	AC-N is supported by a grant from the Jeffrey Modell Foundation and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP 2016/22158-3).	Bonilla FA, 2016, J ALLER CL IMM-PRACT, V4, P38, DOI 10.1016/j.jaip.2015.07.025; Conley ME, 2000, CLIN REV ALLERG IMMU, V19, P183, DOI 10.1385/CRIAI:19:2:183; Mahlaoui N, 2017, J CLIN IMMUNOL, V37, P452, DOI 10.1007/s10875-017-0401-y; Picard C, 2018, J CLIN IMMUNOL, V38, P96, DOI 10.1007/s10875-017-0464-9; Pulvirenti F, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/672458	5	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 21	2021	12								635482	10.3389/fimmu.2021.635482	http://dx.doi.org/10.3389/fimmu.2021.635482			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RX1TX	33968027	Green Accepted, gold, Green Published			2022-12-18	WOS:000647004700001
J	Steininger, J; Leiss-Piller, A; Geier, CB; Rossmanith, R; Elfeky, R; Bra, D; Pichler, H; Lawitschka, A; Zubarovskaya, N; Artacker, G; Matthes-Leodolter, S; Eibl, MM; Wolf, HM				Steininger, Jolanda; Leiss-Piller, Alexander; Geier, Christoph B.; Rossmanith, Raphael; Elfeky, Reem; Bra, David; Pichler, Herbert; Lawitschka, Anita; Zubarovskaya, Natascha; Artacker, Gottfried; Matthes-Leodolter, Susanne; Eibl, Martha M.; Wolf, Hermann M.			Case Report: A Novel IL2RG Frame-Restoring Rescue Mutation Mimics Early T Cell Engraftment Following Haploidentical Hematopoietic Stem Cell Transplantation in a Patient With X-SCID	FRONTIERS IN IMMUNOLOGY			English	Article						severe combined immunodeficiency; X-SCID; IL2RG; somatic mosaicism; early engraftment; second-site mutation; hematopoietic stem cell transplantation		Mutations of the interleukin 2 receptor gamma chain (IL2RG) result in the most common form of severe combined immunodeficiency (SCID), which is characterized by severe and persistent infections starting in early life with an absence of T cells and natural killer cells, normal or elevated B cell counts and hypogammaglobulinemia. SCID is commonly fatal within the first year of life, unless the immune system is reconstituted by hematopoietic stem cell transplantation (HSCT) or gene therapy. We herein describe a male infant with X-linked severe combined immunodeficiency (X-SCID) diagnosed at 5 months of age. Genetic testing revealed a novel C to G missense mutation in exon 1 resulting in a 3' splice site disruption with premature stop codon and aberrant IL2 receptor signaling. Following the diagnosis of X-SCID, the patient subsequently underwent a TCR alpha beta/CD19-depleted haploidentical HSCT. Post transplantation the patient presented with early CD8(+) T cell recovery with the majority of T cells (>99%) being non-donor T cells. Genetic analysis of CD4(+) and CD8(+) T cells revealed a spontaneous 14 nucleotide insertion at the mutation site resulting in a novel splice site and restoring the reading frame although defective IL2RG function was still demonstrated. In conclusion, our findings describe a spontaneous second-site mutation in IL2RG as a novel cause of somatic mosaicism and early T cell recovery following haploidentical HSCT.	[Steininger, Jolanda; Leiss-Piller, Alexander; Geier, Christoph B.; Rossmanith, Raphael; Bra, David; Eibl, Martha M.; Wolf, Hermann M.] Immunol Outpatient Clin, Vienna, Austria; [Elfeky, Reem] Royal Free Hosp, Dept Clin Immunol, London, England; [Pichler, Herbert; Lawitschka, Anita; Zubarovskaya, Natascha; Matthes-Leodolter, Susanne] Med Univ Vienna, St Anna Kinderspital, Dept Pediat, Vienna, Austria; [Artacker, Gottfried] Med Univ Vienna, Childrens Canc Res Inst, Vienna, Austria; [Eibl, Martha M.] Danube Hosp, Dept Paediat & Adolescent Med, Vienna, Austria; [Wolf, Hermann M.] Biomed Forsch GmbH, Vienna, Austria; Sigmund Freud Private Univ, Med Sch, Vienna, Austria	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Medical University of Vienna; Saint Anna Children's Hospital; Medical University of Vienna; Saint Anna Children's Hospital; Donauspital	Wolf, HM (corresponding author), Immunol Outpatient Clin, Vienna, Austria.; Wolf, HM (corresponding author), Biomed Forsch GmbH, Vienna, Austria.	hermann.wolf@itk.at						Admiraal R, 2017, J ALLERGY CLIN IMMUN, V140, P1643, DOI 10.1016/j.jaci.2016.12.992; Admiraal R, 2015, LANCET HAEMATOL, V2, pE194, DOI 10.1016/S2352-3026(15)00045-9; Al-Herz W, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00162; Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; Ariga T, 2001, BLOOD, V97, P2896, DOI 10.1182/blood.V97.9.2896; Ariga T, 2001, J IMMUNOL, V166, P5245, DOI 10.4049/jimmunol.166.8.5245; Arredondo-Vega FX, 2002, BLOOD, V99, P1005, DOI 10.1182/blood.V99.3.1005; Ban SA, 2014, J CLIN IMMUNOL, V34, P941, DOI 10.1007/s10875-014-0088-2; Bellamy GJ, 2000, CLIN LAB HAEMATOL, V22, P81, DOI 10.1046/j.1365-2257.2000.00288.x; Bertaina A, 2014, BLOOD, V124, P822, DOI 10.1182/blood-2014-03-563817; Bousso P, 2000, P NATL ACAD SCI USA, V97, P274, DOI 10.1073/pnas.97.1.274; Brettig T, 2019, J CLIN IMMUNOL, V39, P505, DOI 10.1007/s10875-019-00648-x; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Buckley RH, 1997, J PEDIATR-US, V130, P378, DOI 10.1016/S0022-3476(97)70199-9; Buckley RH, 2004, ANNU REV IMMUNOL, V22, P625, DOI 10.1146/annurev.immunol.22.012703.104614; Castagnoli R, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00295; Castillo N, 2017, BIOL BLOOD MARROW TR, V23, P491, DOI 10.1016/j.bbmt.2016.11.014; Chiesa R, 2012, BRIT J HAEMATOL, V156, P656, DOI 10.1111/j.1365-2141.2011.08994.x; DISANTO JP, 1994, P NATL ACAD SCI USA, V91, P9466, DOI 10.1073/pnas.91.20.9466; Elfeky R, 2019, EXPERT REV CLIN IMMU, V15, P735, DOI 10.1080/1744666X.2019.1612746; Elfeky R, 2019, J ALLERGY CLIN IMMUN, V144, P280, DOI 10.1016/j.jaci.2019.01.030; Fischer A, 2005, IMMUNOL REV, V203, P98, DOI 10.1111/j.0105-2896.2005.00223.x; Fischer A, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.61; GATTI RA, 1968, LANCET, V2, P1366; Gennery AR, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00381; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; Hacein-Bey-Abina S, 2002, INT J HEMATOL, V76, P295, DOI 10.1007/BF02982686; Haddad E, 2018, BLOOD, V132, P1737, DOI 10.1182/blood-2018-03-840702; HIRSCHHORN R, 1994, AM J HUM GENET, V55, P59; Hirschhorn R, 1996, NAT GENET, V13, P290, DOI 10.1038/ng0796-290; Kovanen PE, 2004, IMMUNOL REV, V202, P67, DOI 10.1111/j.0105-2896.2004.00203.x; Kwan A, 2014, JAMA-J AM MED ASSOC, V312, P729, DOI 10.1001/jama.2014.9132; Locatelli F, 2017, BLOOD, V130, P677, DOI 10.1182/blood-2017-04-779769; Mackall CL, 2001, BLOOD, V97, P1491, DOI 10.1182/blood.V97.5.1491; Manor U, 2019, IMMUNOL RES, V67, P166, DOI 10.1007/s12026-019-09081-z; Marsh RA, 2016, BLOOD, V127, P503, DOI 10.1182/blood-2015-07-659672; Miggelbrink AM, 2018, BLOOD, V131, P2967, DOI 10.1182/blood-2017-10-809822; Moncada-Velez M, 2011, SCAND J IMMUNOL, V74, P471, DOI 10.1111/j.1365-3083.2011.02593.x; Morelon E, 1996, BLOOD, V88, P1708; Mou WJ, 2017, IMMUNOGENETICS, V69, P29, DOI 10.1007/s00251-016-0949-3; Muller SM, 2001, BLOOD, V98, P1847, DOI 10.1182/blood.V98.6.1847; Nishikomori R, 2004, BLOOD, V103, P4565, DOI 10.1182/blood-2003-10-3655; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; Okuno Y, 2015, J CLIN IMMUNOL, V35, P610, DOI 10.1007/s10875-015-0202-0; Oshrine BR, 2013, BIOL BLOOD MARROW TR, V19, P1581, DOI 10.1016/j.bbmt.2013.08.003; Pai SY, 2014, NEW ENGL J MED, V371, P434, DOI 10.1056/NEJMoa1401177; Picard C, 2018, J CLIN IMMUNOL, V38, P96, DOI 10.1007/s10875-017-0464-9; SCHMALSTIEG FC, 1995, J CLIN INVEST, V95, P1169, DOI 10.1172/JCI117765; Shah RM, 2018, J ALLERGY CLIN IMMUN, V141, P1417, DOI 10.1016/j.jaci.2017.07.008; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Speckmann C, 2008, BLOOD, V112, P4090, DOI 10.1182/blood-2008-04-153361; STEPHAN JL, 1993, J PEDIATR-US, V123, P564, DOI 10.1016/S0022-3476(05)80951-5; Stephan V, 1996, NEW ENGL J MED, V335, P1563, DOI 10.1056/NEJM199611213352104; Stern L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01672; Wada T, 2005, BLOOD, V106, P2099, DOI 10.1182/blood-2005-03-0936; Wada T, 2008, BLOOD, V112, P1872, DOI 10.1182/blood-2008-04-149708; Wada T, 2008, CURR OPIN ALLERGY CL, V8, P510, DOI 10.1097/ACI.0b013e328314b651; Wahlstrom J, 2017, J ALLERGY CLIN IMMUN, V139, P628, DOI 10.1016/j.jaci.2016.04.049; Yang HX, 2020, AUTOPHAGY, V16, P271, DOI 10.1080/15548627.2019.1606647; Zhang ZY, 2020, GENES DIS, V7, P38, DOI 10.1016/j.gendis.2019.07.007	60	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 20	2021	12								644687	10.3389/fimmu.2021.644687	http://dx.doi.org/10.3389/fimmu.2021.644687			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RW6GY	33959125	Green Published, gold			2022-12-18	WOS:000646621700001
J	Trujillo-Ocampo, A; Cho, HW; Pareek, S; Ruiz-Vazquez, W; Clowers, M; Lee, SE; Im, JS				Trujillo-Ocampo, Abel; Cho, Hyun-Woo; Pareek, Sumedha; Ruiz-Vazquez, Wilfredo; Clowers, Michael; Lee, Sung-Eun; Im, Jin S.			IL-7 During Antigenic Stimulation Using Allogeneic Dendritic Cells Promotes Expansion of CD45RA(-)CD62L(+)CD4(+) Invariant NKT Cells With Th-2 Biased Cytokine Production Profile (vol 11, 567406, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						ex vivo expansion; human iNKT cells; Th2 polarization of expanded iNKT cells; IL-2; IL-7; IL-15; alpha GalCer; CD62L(+) iNKT cells			[Trujillo-Ocampo, Abel; Cho, Hyun-Woo; Pareek, Sumedha; Ruiz-Vazquez, Wilfredo; Clowers, Michael; Lee, Sung-Eun; Im, Jin S.] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA; [Lee, Sung-Eun] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Hematol, Seoul, South Korea	University of Texas System; UTMD Anderson Cancer Center; Catholic University of Korea; Seoul St. Mary's Hospital	Im, JS (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA.	jim@mdanderson.org						Trujillo-Ocampo A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.567406	1	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 20	2021	12								689959	10.3389/fimmu.2021.689959	http://dx.doi.org/10.3389/fimmu.2021.689959			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RW8EQ	33959134	Green Published, gold			2022-12-18	WOS:000646753000001
J	Britt, EA; Gitau, V; Saha, A; Williamson, AP				Britt, Emily A.; Gitau, Vanessa; Saha, Amara; Williamson, Adam P.			Modular Organization of Engulfment Receptors and Proximal Signaling Networks: Avenues to Reprogram Phagocytosis	FRONTIERS IN IMMUNOLOGY			English	Review						phagocytosis; engulfment; immune receptor; signal transduction; macrophage reprogramming; chimeric antigen receptor; immunotherapy		Transmembrane protein engulfment receptors expressed on the surface of phagocytes engage ligands on apoptotic cells and debris to initiate a sequence of events culminating in material internalization and immunologically beneficial outcomes. Engulfment receptors are modular, comprised of functionally independent extracellular ligation domains and cytosolic signaling motifs. Cognate kinases, adaptors, and phosphatases regulate engulfment by controlling the degree of receptor activation in phagocyte plasma membranes, thus acting as receptor-proximal signaling modules. Here, we review recent efforts to reprogram phagocytes using modular synthetic receptors composed of antibody-based extracellular domains fused to engulfment receptor signaling domains. To aid the development of new phagocyte reprogramming methods, we then define the kinases, adaptors, and phosphatases that regulate a conserved family of engulfment receptors. Finally, we discuss current challenges and opportunities for the field.	[Britt, Emily A.; Gitau, Vanessa; Saha, Amara; Williamson, Adam P.] Bryn Mawr Coll, Dept Biol, Bryn Mawr, PA 19010 USA	Bryn Mawr College	Williamson, AP (corresponding author), Bryn Mawr Coll, Dept Biol, Bryn Mawr, PA 19010 USA.	awilliams6@brynmawr.edu		Britt, Emily/0000-0003-3504-5914	Undergraduate Summer Science Research Funding, Bryn Mawr College; Research Startup Funds, Bryn Mawr College	Undergraduate Summer Science Research Funding, Bryn Mawr College; Research Startup Funds, Bryn Mawr College	EB, VG, AS - Undergraduate Summer Science Research Funding, Bryn Mawr College. AW - Research Startup Funds, Bryn Mawr College.	Callebaut I, 2003, BIOCHEM BIOPH RES CO, V300, P619, DOI 10.1016/S0006-291X(02)02904-2; Canton J, 2021, NAT IMMUNOL, V22, P140, DOI 10.1038/s41590-020-00824-x; Chung WS, 2013, NATURE, V504, P394, DOI 10.1038/nature12776; Davis SJ, 2006, NAT IMMUNOL, V7, P803, DOI 10.1038/ni1369; Deng ZH, 2015, NAT IMMUNOL, V16, P642, DOI 10.1038/ni.3155; Dong R, 2020, EMBO J, V39, DOI 10.15252/embj.2020104730; Etchegaray JI, 2012, DEVELOPMENT, V139, P4029, DOI 10.1242/dev.082776; Freeman SA, 2016, CELL, V164, P128, DOI 10.1016/j.cell.2015.11.048; Greenberg S, 1996, P NATL ACAD SCI USA, V93, P1103, DOI 10.1073/pnas.93.3.1103; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hashimoto Y, 2009, J IMMUNOL, V183, P7451, DOI 10.4049/jimmunol.0901032; Iram T, 2016, J NEUROSCI, V36, P5185, DOI 10.1523/JNEUROSCI.3850-15.2016; Jaumouille V, 2014, DEV CELL, V29, P534, DOI 10.1016/j.devcel.2014.04.031; Kay JN, 2012, NATURE, V483, P465, DOI 10.1038/nature10877; Kinchen JM, 2005, NATURE, V434, P93, DOI 10.1038/nature03263; Klichinsky M, 2020, NAT BIOTECHNOL, V38, P947, DOI 10.1038/s41587-020-0462-y; Kuraishi T, 2009, EMBO J, V28, P3868, DOI 10.1038/emboj.2009.343; Lim WA, 2017, CELL, V168, P724, DOI 10.1016/j.cell.2017.01.016; Lim WA, 2010, CELL, V142, P661, DOI 10.1016/j.cell.2010.08.023; Logan MA, 2012, NAT NEUROSCI, V15, P722, DOI 10.1038/nn.3066; MacDonald JM, 2006, NEURON, V50, P869, DOI 10.1016/j.neuron.2006.04.028; Morizawa YM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00037-1; Morrissey MA, 2018, ELIFE, V7, DOI 10.7554/eLife.36688; Mujal AM, 2019, SCIENCE, V364, P28, DOI 10.1126/science.aau8694; Niedergang F, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00018; Okada R, 2012, J BIOL CHEM, V287, P3138, DOI 10.1074/jbc.M111.277921; Ravichandran KS, 2010, J EXP MED, V207, P1807, DOI 10.1084/jem.20101157; Scheib JL, 2012, J NEUROSCI, V32, P13022, DOI 10.1523/JNEUROSCI.6350-11.2012; Singh TD, 2010, FEBS LETT, V584, P3936, DOI 10.1016/j.febslet.2010.08.050; Somogyi K, 2008, MOL BIOL EVOL, V25, P2337, DOI 10.1093/molbev/msn180; SONNENFELD MJ, 1995, J COMP NEUROL, V359, P644, DOI 10.1002/cne.903590410; Su HP, 2002, J BIOL CHEM, V277, P11772, DOI 10.1074/jbc.M109336200; Topfer K, 2015, J IMMUNOL, V194, P3201, DOI 10.4049/jimmunol.1400330; Tung TT, 2013, J BIOCHEM, V153, P483, DOI 10.1093/jb/mvt014; Wang XC, 2010, NAT CELL BIOL, V12, P655, DOI 10.1038/ncb2068; Williamson AP, 2018, J CELL BIOL, V217, P3977, DOI 10.1083/jcb.201711175; Wood W, 2017, DEV CELL, V40, P221, DOI 10.1016/j.devcel.2017.01.001; Wu HH, 2009, NAT NEUROSCI, V12, P1534, DOI 10.1038/nn.2446; Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI [10.1523/JNEUROSCI.1860-14.2014, 10.11772/j.issn.1001-9081.2014.07.1929]; Zhang YX, 2010, P NATL ACAD SCI USA, V107, P19332, DOI 10.1073/pnas.1008248107; Zhou Z, 2001, CELL, V104, P43, DOI 10.1016/S0092-8674(01)00190-8; Ziegenfuss JS, 2008, NATURE, V453, P935, DOI 10.1038/nature06901	43	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 19	2021	12								661974	10.3389/fimmu.2021.661974	http://dx.doi.org/10.3389/fimmu.2021.661974			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RV7YA	33953723	Green Published, gold			2022-12-18	WOS:000646043100001
J	Fuertes, T; Salgado, I; de Yebenes, VG				Fuertes, Teresa; Salgado, Irene; de Yebenes, Virginia G.			microRNA Fine-Tuning of the Germinal Center Response	FRONTIERS IN IMMUNOLOGY			English	Review						microRNA; germinal center; antibodies; autoimmunity; neoplasia		Germinal centers (GCs) are complex multicellular structures in which antigen-specific B cells undergo the molecular remodeling that enables the generation of high-affinity antibodies and the differentiation programs that lead to the generation of plasma-antibody-secreting cells and memory B cells. These reactions are tightly controlled by a variety of mechanisms, including the post-transcriptional control of gene expression by microRNAs (miRNAs). Through the development of animal models with B cell-specific modified miRNA expression, we have contributed to the understanding of the role of miRNAs in the regulation of GC responses and in B cell neoplasia. Here, we review recent advances in the understanding of the role of miRNAs in the regulation of B cell and T follicular helper physiology during the GC response and in the diseases associated to GC response dysregulation.	[Fuertes, Teresa] Ctr Nacl Invest Cardiovasc, B Lymphocyte Biol Lab, Madrid, Spain; [Salgado, Irene; de Yebenes, Virginia G.] Univ Complutense Madrid, Dept Immunol Ophthalmol & ENT, Sch Med, Madrid, Spain; [de Yebenes, Virginia G.] Hosp 12 Octubre Hlth Res Inst Imas12, Inmunol Linfocitaria Lab, Madrid, Spain	Centro Nacional de Investigaciones Cardiovasculares (CNIC); Complutense University of Madrid	de Yebenes, VG (corresponding author), Univ Complutense Madrid, Dept Immunol Ophthalmol & ENT, Sch Med, Madrid, Spain.; de Yebenes, VG (corresponding author), Hosp 12 Octubre Hlth Res Inst Imas12, Inmunol Linfocitaria Lab, Madrid, Spain.	vgarciay@ucm.es			Spanish Ministerio de Ciencia e Innovacion [PID2019-107551RB-I00]; Spanish Ministerio de Ciencia, Innovacion y Universidades [BES-2017-079759]; Universidad Complutense de Madrid; Ministerio de Educacion y Formacion Profesional	Spanish Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Spanish Ministerio de Ciencia, Innovacion y Universidades(Spanish Government); Universidad Complutense de Madrid; Ministerio de Educacion y Formacion Profesional(Spanish Government)	Our work is supported by the Spanish Ministerio de Ciencia e Innovacion (PID2019-107551RB-I00). TF is supported by a PhD fellowship from the Spanish Ministerio de Ciencia, Innovacion y Universidades (BES-2017-079759), VY by funding from the Universidad Complutense de Madrid, and IS by a student research grant from the Ministerio de Educacion y Formacion Profesional.	Alivernini S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12970; Arbore G, 2019, LIFE SCI ALLIANCE, V2, DOI 10.26508/lsa.201800244; Athanasopoulos V, 2010, FEBS J, V277, P2109, DOI 10.1111/j.1742-4658.2010.07628.x; Babar IA, 2012, P NATL ACAD SCI USA, V109, pE1695, DOI 10.1073/pnas.1201516109; Barnes NA, 2012, J IMMUNOL, V189, P253, DOI 10.4049/jimmunol.1101563; Bartolome-Izquierdo N, 2017, BLOOD, V129, P2408, DOI 10.1182/blood-2016-08-731166; Basso K, 2012, J EXP MED, V209, P2455, DOI 10.1084/jem.20121387; Basso K, 2012, IMMUNOL REV, V247, P172, DOI 10.1111/j.1600-065X.2012.01112.x; Basso K, 2009, IMMUNITY, V30, P744, DOI 10.1016/j.immuni.2009.03.017; Baumjohann D, 2013, NAT IMMUNOL, V14, P840, DOI 10.1038/ni.2642; Boldin MP, 2011, J EXP MED, V208, P1189, DOI 10.1084/jem.20101823; Bouamar H, 2015, MOL CELL BIOL, V35, P1329, DOI 10.1128/MCB.01446-14; Cannons JL, 2010, IMMUNITY, V32, P253, DOI 10.1016/j.immuni.2010.01.010; Casali P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00491; Chen J, 2015, ENDOCRINE, V49, P752, DOI 10.1007/s12020-015-0546-5; Cheng CJ, 2015, NATURE, V518, P107, DOI 10.1038/nature13905; Cho S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05196-3; Contreras JR, 2015, ONCOTARGET, V6, P11023, DOI 10.18632/oncotarget.3433; Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103; Costinean S, 2009, BLOOD, V114, P1374, DOI 10.1182/blood-2009-05-220814; de Yebenes VG, 2008, J EXP MED, V205, P2199, DOI 10.1084/jem.20080579; de Yebenes VG, 2014, BLOOD, V124, P229, DOI 10.1182/blood-2013-12-543611; Deenick EK, 2011, IMMUNOLOGY, V134, P361, DOI 10.1111/j.1365-2567.2011.03487.x; Dorsett Y, 2008, IMMUNITY, V28, P630, DOI 10.1016/j.immuni.2008.04.002; Elsner RA, 2020, IMMUNITY, V53, P1136, DOI 10.1016/j.immuni.2020.11.006; Essig K, 2017, IMMUNITY, V47, P1067, DOI 10.1016/j.immuni.2017.11.008; Fernandez-Messina L, 2020, EMBO REP, V21, DOI 10.15252/embr.201948925; Fuertes T, 2020, TRENDS IMMUNOL, V41, P932, DOI 10.1016/j.it.2020.08.006; Garchow BG, 2011, EMBO MOL MED, V3, P605, DOI 10.1002/emmm.201100171; Gebert LFR, 2019, NAT REV MOL CELL BIO, V20, P21, DOI 10.1038/s41580-018-0045-7; Gigoux M, 2009, P NATL ACAD SCI USA, V106, P20371, DOI 10.1073/pnas.0911573106; Go H, 2015, ONCOTARGET, V6, P15035, DOI 10.18632/oncotarget.3729; Gu L, 2013, ACTA HAEMATOL-BASEL, V130, P87, DOI 10.1159/000346441; Guo QY, 2013, BLOOD, V121, P4875, DOI 10.1182/blood-2012-08-452425; Guo WT, 2019, CELL MOL LIFE SCI, V76, P1697, DOI 10.1007/s00018-019-03020-9; Gururajan M, 2010, INT IMMUNOL, V22, P583, DOI 10.1093/intimm/dxq042; Hu RZ, 2014, IMMUNITY, V41, P605, DOI 10.1016/j.immuni.2014.09.015; Huang XP, 2012, INT J CANCER, V131, pE382, DOI 10.1002/ijc.26503; Iqbal J, 2015, BLOOD, V125, P1137, DOI 10.1182/blood-2014-04-566778; Jin HY, 2013, EMBO J, V32, P2377, DOI 10.1038/emboj.2013.178; Kang SG, 2013, NAT IMMUNOL, V14, P849, DOI 10.1038/ni.2648; Kashiwakuma D, 2010, J IMMUNOL, V185, P2730, DOI 10.4049/jimmunol.0903839; Kuchen S, 2010, IMMUNITY, V32, P828, DOI 10.1016/j.immuni.2010.05.009; Kuo G, 2019, J FORMOS MED ASSOC, V118, P2, DOI 10.1016/j.jfma.2018.04.013; Kurowska-Stolarska M, 2011, P NATL ACAD SCI USA, V108, P11193, DOI 10.1073/pnas.1019536108; Leng RX, 2011, CYTOKINE GROWTH F R, V22, P141, DOI 10.1016/j.cytogfr.2011.05.002; Leone E, 2013, CLIN CANCER RES, V19, P2096, DOI 10.1158/1078-0432.CCR-12-3325; Liu WH, 2016, J EXP MED, V213, P1901, DOI 10.1084/jem.20160204; Long H, 2018, CANCER LETT, V428, P90, DOI 10.1016/j.canlet.2018.04.016; Lu D, 2014, J EXP MED, V211, P2183, DOI 10.1084/jem.20140338; Malumbres R, 2009, BLOOD, V113, P3754, DOI 10.1182/blood-2008-10-184077; Medina PP, 2010, NATURE, V467, P86, DOI 10.1038/nature09284; Mesin L, 2016, IMMUNITY, V45, P471, DOI 10.1016/j.immuni.2016.09.001; Mitsumura T, 2018, BLOOD ADV, V2, P3483, DOI 10.1182/bloodadvances.2018017954; Mlynarczyk C, 2019, IMMUNOL REV, V288, P214, DOI 10.1111/imr.12755; Morelli E, 2015, LEUKEMIA, V29, P2173, DOI 10.1038/leu.2015.124; Moroney JB, 2020, CURR OPIN IMMUNOL, V67, P75, DOI 10.1016/j.coi.2020.09.004; Moroney JB, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19242-6; Nakagawa R, 2016, J CLIN INVEST, V126, P377, DOI 10.1172/JCI82914; Nie K, 2008, AM J PATHOL, V173, P242, DOI 10.2353/ajpath.2008.080009; Nie K, 2010, AM J PATHOL, V177, P1470, DOI 10.2353/ajpath.2010.091291; Park CY, 2010, HUM MOL GENET, V19, pR169, DOI 10.1093/hmg/ddq367; Pedersen IM, 2009, EMBO MOL MED, V1, P288, DOI 10.1002/emmm.200900028; Perez-Melgosa M, 1999, J IMMUNOL, V163, P1123; Phan RT, 2004, NATURE, V432, P635, DOI 10.1038/nature03147; Phan RT, 2007, NAT IMMUNOL, V8, P1132, DOI 10.1038/ni1508; Porstner M, 2015, EUR J IMMUNOL, V45, P1206, DOI 10.1002/eji.201444637; Pratama A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7436; Quezada SA, 2004, ANNU REV IMMUNOL, V22, P307, DOI 10.1146/annurev.immunol.22.012703.104533; Ripamonti A, 2017, P NATL ACAD SCI USA, V114, P12797, DOI 10.1073/pnas.1705364114; Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253; Rolf J, 2010, J IMMUNOL, V185, P4042, DOI 10.4049/jimmunol.1001730; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Santanam U, 2010, P NATL ACAD SCI USA, V107, P12210, DOI 10.1073/pnas.1007186107; Schneider C, 2014, P NATL ACAD SCI USA, V111, P8185, DOI 10.1073/pnas.1322466111; Shen T, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00627; Song S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02026; Stebegg M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02469; Su YL, 2020, BLOOD, V135, P167, DOI 10.1182/blood.2019002045; Takahashi H, 2012, NAT IMMUNOL, V13, P587, DOI 10.1038/ni.2286; Tam W, 2001, GENE, V274, P157, DOI 10.1016/S0378-1119(01)00612-6; Teng G, 2008, IMMUNITY, V28, P621, DOI 10.1016/j.immuni.2008.03.015; Thai TH, 2007, SCIENCE, V316, P604, DOI 10.1126/science.1141229; Thai TH, 2013, P NATL ACAD SCI USA, V110, P20194, DOI 10.1073/pnas.1317632110; Tsai DY, 2015, SCI REP-UK, V5, DOI 10.1038/srep17957; van Nieuwenhuijze A, 2017, CELL MOL LIFE SCI, V74, P2095, DOI 10.1007/s00018-017-2456-6; Victora GD, 2012, ANNU REV IMMUNOL, V30, P429, DOI 10.1146/annurev-immunol-020711-075032; Vigorito E, 2007, IMMUNITY, V27, P847, DOI 10.1016/j.immuni.2007.10.009; Vinuesa CG, 2016, ANNU REV IMMUNOL, V34, P335, DOI 10.1146/annurev-immunol-041015-055605; Vinuesa CG, 2009, NAT REV IMMUNOL, V9, P845, DOI 10.1038/nri2637; Wang HH, 2019, ONCOL LETT, V18, P5033, DOI 10.3892/ol.2019.10862; Wen ZK, 2013, J IMMUNOL, V190, P5411, DOI 10.4049/jimmunol.1203301; White CA, 2014, J IMMUNOL, V193, P5933, DOI 10.4049/jimmunol.1401702; Wu TQ, 2015, J IMMUNOL, V195, P2515, DOI 10.4049/jimmunol.1500317; Xiao CC, 2008, NAT IMMUNOL, V9, P405, DOI 10.1038/ni1575; Xin Q, 2015, J IMMUNOL, V194, P5437, DOI 10.4049/jimmunol.1403028; Xu HP, 2013, NATURE, V496, P523, DOI 10.1038/nature12058; Xu SL, 2012, BLOOD, V119, P767, DOI 10.1182/blood-2011-05-355412; Yan YL, 2017, ONCOL LETT, V13, P4734, DOI 10.3892/ol.2017.6039; Yu D, 2007, NATURE, V450, P299, DOI 10.1038/nature06253; Yu D, 2009, IMMUNITY, V31, P457, DOI 10.1016/j.immuni.2009.07.002; Zhang J, 2009, BLOOD, V113, P4586, DOI 10.1182/blood-2008-09-178186; Zhang JM, 2015, IMMUNOLOGY, V144, P56, DOI 10.1111/imm.12347; Zhang Y, 2012, BLOOD, V120, P1678, DOI 10.1182/blood-2012-02-410647; Zhao JL, 2011, P NATL ACAD SCI USA, V108, P9184, DOI 10.1073/pnas.1105398108; Zhu FQ, 2016, ONCOL RES, V24, P415, DOI 10.3727/096504016X14685034103473	106	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 19	2021	12								660450	10.3389/fimmu.2021.660450	http://dx.doi.org/10.3389/fimmu.2021.660450			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RV7YI	33953721	gold, Green Published			2022-12-18	WOS:000646043900001
J	Michael, M; McCormick, B; Anderson, KE; Karmakar, U; Vermeren, M; Schurmans, S; Amour, A; Vermeren, S				Michael, Melina; McCormick, Barry; Anderson, Karen E.; Karmakar, Utsa; Vermeren, Matthieu; Schurmans, Stephane; Amour, Augustin; Vermeren, Sonja			The 5-Phosphatase SHIP2 Promotes Neutrophil Chemotaxis and Recruitment	FRONTIERS IN IMMUNOLOGY			English	Article						neutrophil; chemotaxis; recruitment; PI3K; SHIP2; SHIP1; lipid second messenger		Neutrophils, the most abundant circulating leukocytes in humans have key roles in host defense and in the inflammatory response. Agonist-activated phosphoinositide 3-kinases (PI3Ks) are important regulators of many facets of neutrophil biology. PIP3 is subject to dephosphorylation by several 5' phosphatases, including SHIP family phosphatases, which convert the PI3K product and lipid second messenger phosphatidylinositol 3,4,5-trisphosphate (PIP3) into PI(3,4)P2, a lipid second messenger in its own right. In addition to the leukocyte restricted SHIP1, neutrophils express the ubiquitous SHIP2. This study analyzed mice and isolated neutrophils carrying a catalytically inactive SHIP2, identifying an important regulatory function in neutrophil chemotaxis and directionality in vitro and in neutrophil recruitment to sites of sterile inflammation in vivo, in the absence of major defects of any other neutrophil functions analyzed, including, phagocytosis and the formation of reactive oxygen species. Mechanistically, this is explained by a subtle effect on global 3-phosphorylated phosphoinositide species. This work identifies a non-redundant role for the hitherto overlooked SHIP2 in the regulation of neutrophils, and specifically, neutrophil chemotaxis/trafficking. It completes an emerging wider understanding of the complexity of PI3K signaling in the neutrophil, and the roles played by individual kinases and phosphatases within.	[Michael, Melina; McCormick, Barry; Karmakar, Utsa; Vermeren, Sonja] Univ Edinburgh, Ctr Inflammat Res, Inst Regenerat & Repair, Edinburgh, Midlothian, Scotland; [Anderson, Karen E.] Babrabam Inst, Signalling Programme, Cambridge, England; [Vermeren, Matthieu] Univ Edinburgh, Ctr Regenerat Med, Inst Regenerat & Repair, Edinburgh, Midlothian, Scotland; [Schurmans, Stephane] Univ Liege, Lab Funct Genet, GIGA Res Ctr, Liege, Belgium; [Amour, Augustin] GlaxoSmithKline, Adapt Immun Res Unit, Stevenage, Herts, England	University of Edinburgh; University of Edinburgh; University of Liege; GlaxoSmithKline	Vermeren, S (corresponding author), Univ Edinburgh, Ctr Inflammat Res, Inst Regenerat & Repair, Edinburgh, Midlothian, Scotland.	sonja.vermeren@ed.ac.uk		Vermeren, Sonja/0000-0002-8460-0884; Vermeren, Matthieu/0000-0003-3584-0387	BBSRC iCASE studentship; GSK [BB/R505651/1]; MRC [MR/M023060/1]; Versus Arthritis PhD scholarship [21577]	BBSRC iCASE studentship(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); GSK(GlaxoSmithKline); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Versus Arthritis PhD scholarship(Versus Arthritis)	MM was funded by a BBSRC iCASE studentship with GSK (BB/R505651/1). BM and SV were funded by the MRC (MR/M023060/1) and UK holds a Versus Arthritis PhD scholarship (21577).	Abdel-Latif D, 2004, BLOOD, V104, P832, DOI 10.1182/blood-2003-07-2624; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Boucrot E, 2015, NATURE, V517, P460, DOI 10.1038/nature14067; Clark J, 2011, NAT METHODS, V8, P267, DOI 10.1038/NMETH.1564; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dubois E, 2012, CELL SIGNAL, V24, P1971, DOI 10.1016/j.cellsig.2012.06.012; Ebner M, 2017, MOL CELL, V65, P416, DOI 10.1016/j.molcel.2016.12.028; Fergus GJ, 2007, NAT CELL BIOL, V9, P86, DOI 10.1038/ncb1517; Gambardella L, 2013, J LEUKOCYTE BIOL, V94, P603, DOI 10.1189/jlb.1112564; Gambardella L, 2011, BLOOD, V118, P1087, DOI 10.1182/blood-2010-10-312959; Gardai S, 2002, J BIOL CHEM, V277, P5236, DOI 10.1074/jbc.M110005200; Hak LCW, 2018, NAT CELL BIOL, V20, P1023, DOI 10.1038/s41556-018-0146-8; Hawkins PT, 2015, BBA-MOL CELL BIOL L, V1851, P882, DOI 10.1016/j.bbalip.2014.12.006; Hawkins PT, 2016, BIOCHEM SOC T, V44, P307, DOI 10.1042/BST20150248; Heit B, 2008, NAT IMMUNOL, V9, P743, DOI 10.1038/ni.1623; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Krugmann S, 2002, MOL CELL, V9, P95, DOI 10.1016/S1097-2765(02)00434-3; Lammermann T, 2008, NATURE, V453, P51, DOI 10.1038/nature06887; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Maekawa M, 2014, P NATL ACAD SCI USA, V111, pE978, DOI 10.1073/pnas.1311029111; Malawista SE, 1997, P NATL ACAD SCI USA, V94, P11577, DOI 10.1073/pnas.94.21.11577; Malek M, 2017, MOL CELL, V68, P566, DOI 10.1016/j.molcel.2017.09.024; McCormick B, 2019, J IMMUNOL, V203, P1579, DOI 10.4049/jimmunol.1900443; McQuin C, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005970; Mocsai A, 2002, IMMUNITY, V16, P547, DOI 10.1016/S1074-7613(02)00303-5; Mondal S, 2012, MOL BIOL CELL, V23, P1219, DOI 10.1091/mbc.E11-10-0889; Nauseef WM, 2014, NAT IMMUNOL, V15, P602, DOI 10.1038/ni.2921; Nishio M, 2007, NAT CELL BIOL, V9, P36, DOI 10.1038/ncb1515; Posor Y, 2013, NATURE, V499, P233, DOI 10.1038/nature12360; Puri KD, 2005, BLOOD, V106, P150, DOI 10.1182/blood-2005-01-0023; Ramos AR, 2019, J LIPID RES, V60, P276, DOI 10.1194/jlr.R087908; Rynkiewicz NK, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aaz4003; Sadhu C, 2003, J IMMUNOL, V170, P2647, DOI 10.4049/jimmunol.170.5.2647; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; SCHMALSTIEG FC, 1986, J LEUKOCYTE BIOL, V40, P677, DOI 10.1002/jlb.40.6.677; Sleeman MW, 2005, NAT MED, V11, P199, DOI 10.1038/nm1178; Smith DF, 2006, J LEUKOCYTE BIOL, V80, P1491, DOI 10.1189/jlb.0306227; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stephens L, 2008, CURR BIOL, V18, pR485, DOI 10.1016/j.cub.2008.04.048; Subramanian KK, 2007, BLOOD, V109, P4028, DOI 10.1182/blood-2006-10-055319; Vermeren S, 2016, J IMMUNOL, V197, P4771, DOI 10.4049/jimmunol.1600604; Wells Claire M, 2005, Methods Mol Biol, V294, P31; Zhang DC, 2019, BLOOD, V133, P2168, DOI 10.1182/blood-2018-11-844555; Zhu D, 2006, P NATL ACAD SCI USA, V103, P14836, DOI 10.1073/pnas.0605722103; ZICHA D, 1991, J CELL SCI, V99, P769	49	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 19	2021	12								671756	10.3389/fimmu.2021.671756	http://dx.doi.org/10.3389/fimmu.2021.671756			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RV7YU	33953730	gold, Green Published			2022-12-18	WOS:000646045100001
J	Patidar, M; Yadav, N; Dalai, SK				Patidar, Manoj; Yadav, Naveen; Dalai, Sarat K.			Development of Stable Chimeric IL-15 for Trans-Presentation by the Antigen Presenting Cells	FRONTIERS IN IMMUNOLOGY			English	Article						IL-15; bioavailability; immunotherapy; adjuvant; memory T cell		IL-15 is one of the important biologics considered for vaccine adjuvant and treatment of cancer. However, a short half-life and poor bioavailability limit its therapeutic potential. Herein, we have structured IL-15 into a chimeric protein to improve its half-life enabling greater bioavailability for longer periods. We have covalently linked IL-15 with IgG2 base to make the IL-15 a stable chimeric protein, which also increased its serum half-life by 40 fold. The dimeric structure of this kind of IgG based biologics has greater stability, resistance to proteolytic cleavage, and less frequent dosing schedule with minimum dosage for achieving the desired response compared to that of their monomeric forms. The structured chimeric IL-15 naturally forms a dimer, and retains its affinity for binding to its receptor, IL-15R beta. Moreover, with the focused action of the structured chimeric IL-15, antigen-presenting cells (APC) would transpresent chimeric IL-15 along with antigen to the T cell, that will help the generation of quantitatively and qualitatively better antigen-specific memory T cells. In vitro and in vivo studies demonstrate the biological activity of chimeric IL-15 with respect to its ability to induce IL-15 signaling and modulating CD8(+) T cell response in favor of memory generation. Thus, a longer half-life, dimeric nature, and anticipated focused transpresentation by APCs to the T cells will make chimeric IL-15 a super-agonist for memory CD8(+) T cell responses.	[Patidar, Manoj; Yadav, Naveen; Dalai, Sarat K.] Nirma Univ, Inst Sci, Ahmadabad, Gujarat, India; [Patidar, Manoj] Govt Coll Manawar, Dept Zool, Dhar, India; [Yadav, Naveen] Translat Hlth Sci & Technol Inst, NCR Biotech Sci Cluster, Faridabad, India	Nirma University; Department of Biotechnology (DBT) India; Translational Health Science & Technology Institute (THSTI)	Dalai, SK (corresponding author), Nirma Univ, Inst Sci, Ahmadabad, Gujarat, India.	sarat.dalai@nirmauni.ac.in			DBT (Department of Biotechnology), Govt. of India [BT/PR7857/BRB/10/1215/2013]; GSBTM (Gujarat State Biotechnology Mission), Govt. of Gujarat [GSBTM/JDRD/608/2020/455]; DBT & CSIR (Council of Scientific and Industrial Research); DST (Department of Science and Technology) Govt. of India for INSPIRE fellowship	DBT (Department of Biotechnology), Govt. of India(Department of Biotechnology (DBT) India); GSBTM (Gujarat State Biotechnology Mission), Govt. of Gujarat; DBT & CSIR (Council of Scientific and Industrial Research); DST (Department of Science and Technology) Govt. of India for INSPIRE fellowship	We acknowledge DBT (Department of Biotechnology), Govt. of India (BT/PR7857/BRB/10/1215/2013) and GSBTM (Gujarat State Biotechnology Mission), Govt. of Gujarat (GSBTM/JDR&D/608/2020/455) for research grants to SD; DBT & CSIR (Council of Scientific and Industrial Research) for fellowships to NY, and DST (Department of Science and Technology) Govt. of India for INSPIRE fellowship to MP. The authors also acknowledge the Department of Higher Education, Govt. of Madhya Pradesh and Govt. College Manawar. Thanks to Prof. Nilabh Shastri, UC Berkley for 10-2.16 cells (ATCC (R) TIB-93 (TM)) and Dr. Rajeev Tyagi, IMTECH, Chandigarh for critical reading and editing the manuscript.	Ali AK, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00355; Bannwart CF, 2007, J VENOM ANIM TOXINS, V13, P562, DOI 10.1590/S1678-91992007000300002; Bateman A, 2015, NUCLEIC ACIDS RES, V43, pD204, DOI 10.1093/nar/gku989; Becker TC, 2002, J EXP MED, V195, P1541, DOI 10.1084/jem.20020369; Benkert P, 2008, PROTEINS, V71, P261, DOI 10.1002/prot.21715; Benkert P, 2011, BIOINFORMATICS, V27, P343, DOI 10.1093/bioinformatics/btq662; Benkert P, 2009, NUCLEIC ACIDS RES, V37, pW510, DOI 10.1093/nar/gkp322; Berger C, 2009, BLOOD, V114, P2417, DOI 10.1182/blood-2008-12-189266; Cheever MAM, 2008, IMMUNOL REV, V222, P357, DOI 10.1111/j.1600-065X.2008.00604.x; Chen R, 2003, PROTEINS, V52, P80, DOI 10.1002/prot.10389; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; Chiu MH, 2011, J PHARM BIOALLIED SC, V3, P39, DOI 10.4103/0975-7406.76463; Cueto M, 2003, INT J PHARM, V252, P159, DOI 10.1016/S0378-5173(02)00627-0; Danilo Pagliari SF., 2013, INT TRENDS IMMUN, V1, P8; Dassault SystThmes BIOVIA, 2015, DISCOVERY STUDIO MOD; Dubois S, 2008, J IMMUNOL, V180, P2099, DOI 10.4049/jimmunol.180.4.2099; Eickhoff CS, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000983; Fawaz LM, 1999, J IMMUNOL, V163, P4473; Ferretti S, 2003, J IMMUNOL, V170, P2106, DOI 10.4049/jimmunol.170.4.2106; Ghetie MA, 1997, P NATL ACAD SCI USA, V94, P7509, DOI 10.1073/pnas.94.14.7509; Ghetie MA, 2001, BLOOD, V97, P1392, DOI 10.1182/blood.V97.5.1392; Guo Y, 2015, J IMMUNOL, V195, P2353, DOI 10.4049/jimmunol.1500300; Han KP, 2011, CYTOKINE, V56, P804, DOI 10.1016/j.cyto.2011.09.028; He X., 2013, J FOOD NUTR RES, V1, P30, DOI DOI 10.12691/JFNR-1-3-3; HOLM L, 1991, J MOL BIOL, V218, P183, DOI 10.1016/0022-2836(91)90883-8; Hospital A, 2012, BIOINFORMATICS, V28, P1278, DOI 10.1093/bioinformatics/bts139; Ing R, 2005, INFECT IMMUN, V73, P3172, DOI 10.1128/IAI.73.5.3172-3177.2005; Kokaji AI, 2008, J IMMUNOL, V180, P4391, DOI 10.4049/jimmunol.180.7.4391; Kota P, 2011, BIOINFORMATICS, V27, P2209, DOI 10.1093/bioinformatics/btr374; Kutzler MA, 2005, J IMMUNOL, V175, P112, DOI 10.4049/jimmunol.175.1.112; Li SR, 2010, CELL MOL IMMUNOL, V7, P491, DOI 10.1038/cmi.2010.44; Liu RB, 2013, P NATL ACAD SCI USA, V110, P8158, DOI 10.1073/pnas.1301022110; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Maiti R, 2004, NUCLEIC ACIDS RES, V32, pW590, DOI 10.1093/nar/gkh477; Meazza R, 2011, J BIOMED BIOTECHNOL, P1, DOI 10.1155/2011/861920; Moore BL, 2013, J COMPUT CHEM, V34, P1881, DOI 10.1002/jcc.23330; Mortier E, 2006, J BIOL CHEM, V281, P1612, DOI 10.1074/jbc.M508624200; Mukherjee S, 2011, STRUCTURE, V19, P955, DOI 10.1016/j.str.2011.04.006; Nicholas C, 2011, IMMUNOTHERAPY-UK, V3, P673, DOI [10.2217/IMT.11.45, 10.2217/imt.11.45]; Oh S, 2003, P NATL ACAD SCI USA, V100, P3392, DOI 10.1073/pnas.0630592100; Parasa VRR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037448; Patidar M, 2018, CURR PHARM DESIGN, V24, P1211, DOI 10.2174/1381612823666171018115206; Patidar M, 2016, CYTOKINE GROWTH F R, V31, P49, DOI 10.1016/j.cytogfr.2016.06.001; Perera PY, 2012, MICROBES INFECT, V14, P247, DOI 10.1016/j.micinf.2011.10.006; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Pilipow K, 2015, CANCER RES, V75, P5187, DOI 10.1158/0008-5472.CAN-15-1498; Ramachandran S, 2011, PROTEINS, V79, P261, DOI 10.1002/prot.22879; Rodrigues JPGLM, 2012, NUCLEIC ACIDS RES, V40, pW323, DOI 10.1093/nar/gks376; Rubinstein MP, 2006, P NATL ACAD SCI USA, V103, P9166, DOI 10.1073/pnas.0600240103; Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57; Sharpe M, 2015, DIS MODEL MECH, V8, P337, DOI 10.1242/dmm.018036; Stoklasek TA, 2006, J IMMUNOL, V177, P6072, DOI 10.4049/jimmunol.177.9.6072; Ugen KE, 2006, CANCER GENE THER, V13, P969, DOI 10.1038/sj.cgt.7700973; van der Windt GJW, 2012, IMMUNITY, V36, P68, DOI 10.1016/j.immuni.2011.12.007; Vangone A, 2015, ELIFE, V4, DOI 10.7554/eLife.07454; Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19; Ward A, 2009, PROTEIN EXPRES PURIF, V68, P42, DOI 10.1016/j.pep.2009.05.004; Webster S., 2013, PHARM TECHNOLOGY PRE, V37, P37; Weiss WF, 2016, J PHARM SCI-US, V105, P3465, DOI 10.1016/j.xphs.2016.09.003; Wilkins MR, 1999, METH MOL B, V112, P531; WOLFF EA, 1993, CANCER RES, V53, P2560; Xu D, 2011, BIOPHYS J, V101, P2525, DOI 10.1016/j.bpj.2011.10.024; Xu JR, 2010, BIOINFORMATICS, V26, P889, DOI 10.1093/bioinformatics/btq066; Xue LC, 2016, BIOINFORMATICS, V32, P3676, DOI 10.1093/bioinformatics/btw514; Yajima T, 2006, J IMMUNOL, V176, P507, DOI 10.4049/jimmunol.176.1.507; Zhang Y, 2004, PROTEINS, V57, P702, DOI 10.1002/prot.20264; Zhang Y, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-40; Zhang Y, 2010, COMPUT METH PROG BIO, V99, P306, DOI 10.1016/j.cmpb.2010.01.007; Zhu XY, 2009, J IMMUNOL, V183, P3598, DOI 10.4049/jimmunol.0901244	69	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 19	2021	12								646159	10.3389/fimmu.2021.646159	http://dx.doi.org/10.3389/fimmu.2021.646159			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RV7ZJ	33953717	gold, Green Published			2022-12-18	WOS:000646046600001
J	Swan, G; Geng, J; Park, E; Ding, QQ; Zhou, J; Walcott, C; Zhang, JJ; Huang, HI; Hammer, G; Wang, DH				Swan, Gregory; Geng, Jia; Park, Eunchong; Ding, Quanquan; Zhou, John; Walcott, Ciana; Zhang, Junyi J.; Huang, Hsin-I.; Hammer, Gianna; Wang, Donghai			A Requirement of Protein Geranylgeranylation for Chemokine Receptor Signaling and Th17 Cell Function in an Animal Model of Multiple Sclerosis (vol 12, 641188, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						protein geranylgeranylation; adaptive immune response; T cells; autoimmunity; lymphocyte migration			[Swan, Gregory; Geng, Jia; Ding, Quanquan; Zhou, John; Walcott, Ciana; Wang, Donghai] Duke Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Durham, NC 27706 USA; [Swan, Gregory; Park, Eunchong; Zhang, Junyi J.; Huang, Hsin-I.; Hammer, Gianna; Wang, Donghai] Duke Univ, Sch Med, Dept Immunol, Durham, NC 27710 USA	Duke University; Duke University	Wang, DH (corresponding author), Duke Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Durham, NC 27706 USA.; Wang, DH (corresponding author), Duke Univ, Sch Med, Dept Immunol, Durham, NC 27710 USA.	donghai.wang@duke.edu	Zhang, Junyi/HDN-7815-2022					Swan G, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.641188	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 19	2021	12								687135	10.3389/fimmu.2021.687135	http://dx.doi.org/10.3389/fimmu.2021.687135			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RW1QG	33953734	gold, Green Published			2022-12-18	WOS:000646297200001
J	Dorschner, BW; Wiedemuth, R; Funke, AC; Gentzel, M; Rogers, ML; Brenner, S; Thieme, S				Dorschner, Benjamin W.; Wiedemuth, Ralf; Funke, Ann-Christin; Gentzel, Marc; Rogers, Mary-Louise; Brenner, Sebastian; Thieme, Sebastian			Listening to the Whispers in Neuroimmune Crosstalk: A Comprehensive Workflow to Investigate Neurotrophin Receptor p75NTR Under Endogenous, Low Abundance Conditions	FRONTIERS IN IMMUNOLOGY			English	Article						p75NTR; CD271 (p75NTR); mass spectrometry; endogenous immunoprecipitation; protein-protein interaction; PMDC05; A375 (human melanoma) cell line; neuroimmune crosstalk	NERVE GROWTH-FACTOR; IDENTIFICATION; PURIFICATION; EXPRESSION; NGF	Inflammatory conditions are critically influenced by neuroimmune crosstalk. Cytokines and neurotrophic factors shape the responses of both nervous and immune systems. Although much progress has been made, most findings to date are based on expression of recombinant (tagged) proteins. The examination of receptor interactions by immunoprecipitation (IP) at endogenous levels provides further insight into the more subtle regulations of immune responses. Here, we present a comprehensive workflow and an optimized IP protocol that provide step-by-step instructions to investigate neurotrophin receptor p75NTR at endogenous, low abundance levels: from lysate preparation and confirmation of receptor expression to antibody validation and successful detection of protein-protein interactions. We employ human melanoma cell line A375 to validate specific antibodies and IP conditions, and apply these methods to explore p75NTR interactions in human leukemic plasmacytoid dendritic cell line PMDC05 detecting 14-3-3 epsilon:p75NTR interaction in this cell type. With p75NTR as an exemplary protein, our approach provides a strategy to detect specific interaction partners even under endogenous, low abundance expression conditions.	[Dorschner, Benjamin W.; Wiedemuth, Ralf; Funke, Ann-Christin; Brenner, Sebastian; Thieme, Sebastian] Univ Clin Carl Gustav Carus, Dept Pediat, Expt Hematol, Dresden, Germany; [Gentzel, Marc] Tech Univ Dresden, Mol Anal Mass Spectrometry, Ctr Mol & Cellular Bioengn CMCB, Dresden, Germany; [Rogers, Mary-Louise] Flinders Univ S Australia, Ctr Neurosci, Coll Med & Publ Hlth, Adelaide, SA, Australia	Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; Flinders University South Australia	Dorschner, BW (corresponding author), Univ Clin Carl Gustav Carus, Dept Pediat, Expt Hematol, Dresden, Germany.	benjamin.dorschner@ukdd.de		Rogers, Mary-Louise/0000-0002-3482-8741	Clinician Scientist program of Else Kroner Research College 'Phosphoproteome dynamics' at Technische Universitaet Dresden; Deutsche Forschungsgemeinschaft [WI 5006/2-1]; MeDDrive program of the Faculty of Medicine Carl Gustav Carus at Technische Universitaet Dresden; Saxon State Ministry for Science and the Arts; Dr. Robert Pfleger Foundation Bamberg; European Regional Development Fund (ERDF/EFRE) [100232736]; German Federal Ministry of Education and Research (BMBF) [03Z22EB1]; German Research Foundation (DFG) [INST 269/731-1 FUGG]	Clinician Scientist program of Else Kroner Research College 'Phosphoproteome dynamics' at Technische Universitaet Dresden; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); MeDDrive program of the Faculty of Medicine Carl Gustav Carus at Technische Universitaet Dresden; Saxon State Ministry for Science and the Arts; Dr. Robert Pfleger Foundation Bamberg; European Regional Development Fund (ERDF/EFRE); German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); German Research Foundation (DFG)(German Research Foundation (DFG))	This work was supported by the Clinician Scientist program of Else Kroner Research College 'Phosphoproteome dynamics' at Technische Universitaet Dresden (to BD), a grant from Deutsche Forschungsgemeinschaft (to RW, WI 5006/2-1), the MeDDrive program of the Faculty of Medicine Carl Gustav Carus at Technische Universitaet Dresden (to A-CF), the Saxon State Ministry for Science and the Arts (to ST), and the Dr. Robert Pfleger Foundation Bamberg (to SB and ST). The Facility `Molecular Analysis -Mass Spectrometry' at the CMCB was generously supported by grants of the European Regional Development Fund (ERDF/EFRE) (Contract #100232736), the German Federal Ministry of Education and Research (BMBF, 03Z22EB1) and the German Research Foundation (DFG, INST 269/731-1 FUGG).	Anastasia A, 2015, J NEUROSCI, V35, P11911, DOI 10.1523/JNEUROSCI.0591-15.2015; Bandola J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00981; BARKER PA, 1991, J BIOL CHEM, V266, P19113; Bonifacino J S, 2001, Curr Protoc Mol Biol, VChapter 10, DOI 10.1002/0471142727.mb1016s48; Butowt R, 2009, J NEUROSCI, V29, P10715, DOI 10.1523/JNEUROSCI.2512-09.2009; Chambers MC, 2012, NAT BIOTECHNOL, V30, P918, DOI 10.1038/nbt.2377; Chen Y, 2019, J PROTEOME RES, V18, P3715, DOI 10.1021/acs.jproteome.9b00427; Collin M, 2018, IMMUNOLOGY, V154, P3, DOI 10.1111/imm.12888; Cossarizza A, 2017, EUR J IMMUNOL, V47, P1584, DOI 10.1002/eji.201646632; DeCaprio James, 2020, Cold Spring Harb Protoc, V2020, DOI 10.1101/pdb.top098509; Deinhardt K, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002060; Delacour D, 2007, TRAFFIC, V8, P379, DOI 10.1111/j.1600-0854.2007.00539.x; DISTEFANO PS, 1991, ANN NEUROL, V29, P13, DOI 10.1002/ana.410290105; DISTEFANO PS, 1988, J NEUROSCI, V8, P231; Donaldson Julie G, 2015, Curr Protoc Cell Biol, V69, DOI 10.1002/0471143030.cb0403s69; Doppler W, 2001, MOL CELL BIOL, V21, P3266, DOI 10.1128/MCB.21.9.3266-3279.2001; Dubois C, 2018, METHODS MOL BIOL, V1843, P107, DOI 10.1007/978-1-4939-8704-7_9; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; Freund-Michel V, 2008, PHARMACOL THERAPEUT, V117, P52, DOI 10.1016/j.pharmthera.2007.07.003; Frossard N, 2004, EUR J PHARMACOL, V500, P453, DOI 10.1016/j.ejphar.2004.07.044; Gargano N, 1997, J NEUROSCI RES, V50, P1; GROB PM, 1985, J BIOL CHEM, V260, P8044; HERRMANN JL, 1993, MOL BIOL CELL, V4, P1205, DOI 10.1091/mbc.4.11.1205; HUBER LJ, 1995, J NEUROSCI RES, V40, P557, DOI 10.1002/jnr.490400415; Hubner NC, 2010, J CELL BIOL, V189, P739, DOI 10.1083/jcb.200911091; Jiang Y, 2007, J IMMUNOL, V179, P6297, DOI 10.4049/jimmunol.179.9.6297; Junqueira M, 2008, J PROTEOMICS, V71, P346, DOI 10.1016/j.jprot.2008.07.003; Kerschensteiner M, 2003, ANN NEUROL, V53, P292, DOI 10.1002/ana.10446; Kessner D, 2008, BIOINFORMATICS, V24, P2534, DOI 10.1093/bioinformatics/btn323; Kimura MT, 2001, J BIOL CHEM, V276, P17291, DOI 10.1074/jbc.M005453200; Langford D, 2002, J NEUROVIROL, V8, P625, DOI 10.1080/13550280290100996; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; Lee YR, 2016, METHODS MOL BIOL, V1390, P107, DOI 10.1007/978-1-4939-3335-8_7; Liao XF, 2016, JOVE-J VIS EXP, DOI 10.3791/54641; Lipinszki Z, 2014, METHODS MOL BIOL, V1170, P571, DOI 10.1007/978-1-4939-0888-2_33; Mak HC, 2012, NAT BIOTECHNOL, V30, P963, DOI 10.1038/nbt.2393; Marchetti D, 1998, ONCOGENE, V16, P3253, DOI 10.1038/sj.onc.1201877; Marmorstein AD, 1998, J CELL BIOL, V142, P697, DOI 10.1083/jcb.142.3.697; Minnone G, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051028; Mohammed H, 2013, MOL CANCER RES, V11, P1295, DOI 10.1158/1541-7786.MCR-13-0454; Monlauzeur L, 1998, J BIOL CHEM, V273, P30263, DOI 10.1074/jbc.273.46.30263; Narita M, 2008, ACTA HAEMATOL-BASEL, V120, P91, DOI 10.1159/000165510; Narita M, 2009, LEUKEMIA RES, V33, P1224, DOI 10.1016/j.leukres.2009.03.047; Nassenstein C, 2007, J ALLERGY CLIN IMMUN, V120, P1089, DOI 10.1016/j.jaci.2007.07.007; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; O'Leary NA, 2016, NUCLEIC ACIDS RES, V44, pD733, DOI 10.1093/nar/gkv1189; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Qin GC, 2017, SCI REP-UK, V7, DOI 10.1038/srep42943; Redmer T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092596; Rogers ML, 2006, J NEUROSCI METH, V158, P109, DOI 10.1016/j.jneumeth.2006.05.022; ROSS AH, 1984, P NATL ACAD SCI-BIOL, V81, P6681, DOI 10.1073/pnas.81.21.6681; Roux PP, 2002, PROG NEUROBIOL, V67, P203, DOI 10.1016/S0301-0082(02)00016-3; Ryu JY, 2019, LAB CHIP, V19, P1922, DOI 10.1039/c9lc00139e; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Searle BC, 2010, PROTEOMICS, V10, P1265, DOI 10.1002/pmic.200900437; Sennikov SV, 2019, INT ARCH ALLERGY IMM, V178, P182, DOI 10.1159/000494387; SHAN DE, 1990, J NEUROSCI RES, V27, P620, DOI 10.1002/jnr.490270423; Shepheard SR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087398; Siller-Farfan JA, 2018, IMMUNOL REV, V285, P194, DOI 10.1111/imr.12690; Skaper SD, 2017, IMMUNOLOGY, V151, P1, DOI 10.1111/imm.12717; Slaastad H, 2011, PROTEOMICS, V11, P4578, DOI 10.1002/pmic.201000744; Sousa MML, 2011, PROTEOME SCI, V9, DOI 10.1186/1477-5956-9-45; Stein BD, 2019, J PROTEOME RES, V18, P3703, DOI 10.1021/acs.jproteome.9b00378; Taniuchi M., 1985, J CELL BIOL, V101, DOI [10.1083/jcb.101.3.1100, DOI 10.1083/JCB.101.3.1100]; Tyner JW., 2013, BIOPROTOC, V3, pE904, DOI [10.21769/bioprotoc.904, DOI 10.21769/BIOPROTOC.904]; Valdo P, 2002, J NEUROPATH EXP NEUR, V61, P91, DOI 10.1093/jnen/61.1.91; Wiedemuth R, 2018, INT J BIOCHEM CELL B, V97, P78, DOI 10.1016/j.biocel.2018.02.004; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Zhang Y, 2008, ANAL CHEM, V80, P3144, DOI 10.1021/ac702081a; Zhou JY, 2012, ANAL CHEM, V84, P2862, DOI 10.1021/ac203394r; ZUPAN AA, 1989, J BIOL CHEM, V264, P11714	71	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 16	2021	12								648283	10.3389/fimmu.2021.648283	http://dx.doi.org/10.3389/fimmu.2021.648283			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RV0WL	33936068	Green Published, gold			2022-12-18	WOS:000645557900001
J	Ho, JCY; Cheung, SKF; Lui, ZY; Tang, IWH; Yang, WL; Ip, P; Lee, CK; Middleton, D; Kwok, JSY				Ho, Jenny Chung Yee; Cheung, Stephen Kwok Fan; Lui, Zhongyi; Tang, Ivan Wing Hong; Yang, Wanling; Ip, Patrick; Lee, Cheuk Kwong; Middleton, Derek; Kwok, Janette Siu Yin			Revisit of Optimal Donor Number Estimation in the Hong Kong Bone Marrow Donor Registry	FRONTIERS IN IMMUNOLOGY			English	Article						alleles; frequency haplotypes; HLA antigens; Chinese; matching probability		High resolution typing of the HLA-DPB1 locus for patient who requested for hematopoietic stem cell transplantation (HSCT) workup has recently become mandatory by the National Marrow Donor Program (NMDP) in order to facilitate matching between donors and recipients for better outcomes. The likelihood of identifying HLA matched donors in Hong Kong, on top of the existing HLA-A, -B, -C, and -DRB1 loci, is revisited in this study. HLA-A, -B, -C, -DRB1 and -DPB1 genotypes of 5,266 volunteer unrelated Chinese donors from the Hong Kong Bone Marrow Donor Registry (HKBMDR), were included in this study. Matching models were employed to determine the matching probabilities for 10/10(DPB1) and 9/10(DPB1) HLA match. The matching probabilities are 20% at 10/10(DPB1) HLA match and 55% at 9/10(DPB1) match, based on the existing 130,000 donors in the HKBMDR. The likelihoods of match become 27% and 65% respectively, by increasing the registry to 250,000. However, if DPB T-cell-epitope (TCE) model is considered in the matching, the probability will increase to 46% at 10/10 DPB1 permissive mismatching. Our findings provide vital information about the future planning on the targeted recruitment size, HLA typing and search strategies of the donor registry and arose the transplant physicians' acceptability to 9/10(DBP1) or 10/10(DBP1) HLA match. Nevertheless, the marrow donor registry has planned for increasing the registry size and bringing down the age of recruited donors which will ultimately enhance patient outcome.	[Ho, Jenny Chung Yee; Cheung, Stephen Kwok Fan; Tang, Ivan Wing Hong; Kwok, Janette Siu Yin] Queen Mary Hosp, Div Transplantat & Immunogenet, Hong Kong, Peoples R China; [Lui, Zhongyi; Yang, Wanling; Ip, Patrick] Univ Hong Kong, Dept Paediat & Adolescent Med, Hong Kong, Peoples R China; [Lee, Cheuk Kwong] Hong Kong Red Cross Blood Transfus Serv, Hong Kong, Peoples R China; [Middleton, Derek] Royal Liverpool Hosp, Transplant Immunol, Liverpool, Merseyside, England	University of Hong Kong; University of Hong Kong; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital	Kwok, JSY (corresponding author), Queen Mary Hosp, Div Transplantat & Immunogenet, Hong Kong, Peoples R China.	kwoksy@ha.org.hk	LEE, Cheuk Kwong/F-3950-2017	LEE, Cheuk Kwong/0000-0002-3939-564X				[Anonymous], 2019, WMDA GLOBAL TREND RE; Arrieta-Bolanos E, 2018, BLOOD ADV, V2, P1773, DOI 10.1182/bloodadvances.2018019620; Beatty PG, 2000, HUM IMMUNOL, V61, P834, DOI 10.1016/S0198-8859(00)00138-5; BEATTY PG, 1995, TRANSPLANTATION, V60, P778, DOI 10.1097/00007890-199510270-00003; Buck K, 2016, BIOL BLOOD MARROW TR, V22, P759, DOI 10.1016/j.bbmt.2015.12.012; Buhler S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041400; Burlingham WJ, 1998, NEW ENGL J MED, V339, P1657, DOI 10.1056/NEJM199812033392302; Crivello P, 2015, BIOL BLOOD MARROW TR, V21, P233, DOI 10.1016/j.bbmt.2014.10.017; CULLEN M, 1995, AM J HUM GENET, V56, P1350; Dehn J, 2015, BIOL BLOOD MARROW TR, V21, P137, DOI 10.1016/j.bbmt.2014.10.002; Excoffier L, 2010, MOL ECOL RESOUR, V10, P564, DOI 10.1111/j.1755-0998.2010.02847.x; Fleischhauer K, 2012, LANCET ONCOL, V13, P366, DOI 10.1016/S1470-2045(12)70004-9; Gaschet J, 1996, J CLIN INVEST, V98, P100, DOI 10.1172/JCI118753; Gaschet J, 1998, BONE MARROW TRANSPL, V22, P385, DOI 10.1038/sj.bmt.1701336; Gourraud PA, 2005, HUM IMMUNOL, V66, P563, DOI 10.1016/j.humimm.2005.01.011; Gragert L, 2014, NEW ENGL J MED, V371, P339, DOI 10.1056/NEJMsa1311707; Gragert L, 2013, HUM IMMUNOL, V74, P1313, DOI 10.1016/j.humimm.2013.06.025; GUO SW, 1992, BIOMETRICS, V48, P361, DOI 10.2307/2532296; Izumi K, 2019, ANN HEMATOL, V98, P2815, DOI 10.1007/s00277-019-03835-3; Johansen KA, 2008, TRANSFUSION MED, V18, P250, DOI 10.1111/j.1365-3148.2008.00865.x; Kollman C, 2007, HUM IMMUNOL, V68, P950, DOI 10.1016/j.humimm.2007.10.009; Kwok J, 2020, HUM IMMUNOL, V81, P577, DOI 10.1016/j.humimm.2020.08.005; Kwok J, 2017, HUM IMMUNOL, V78, P610, DOI 10.1016/j.humimm.2017.08.007; Kwok Janette, 2015, Ann Transplant, V20, P604, DOI 10.12659/AOT.894165; Laver JH, 2001, BIOL BLOOD MARROW TR, V7, P45, DOI 10.1053/bbmt.2001.v7.pm11215698; Lee SJ, 2007, BLOOD, V110, P4576, DOI 10.1182/blood-2007-06-097386; Linjama T, 2019, BIOL BLOOD MARROW TR, V25, P1956, DOI 10.1016/j.bbmt.2019.07.008; Linjama T, 2018, BIOL BLOOD MARROW TR, V24, P587, DOI 10.1016/j.bbmt.2017.10.010; Maiers M, 2007, HUM IMMUNOL, V68, P779, DOI 10.1016/j.humimm.2007.04.005; Marroni F, 2004, TISSUE ANTIGENS, V64, P478, DOI 10.1111/j.1399-0039.2004.00292.x; Mori M, 1996, Biol Blood Marrow Transplant, V2, P134; Mori M, 1997, TRANSPLANTATION, V64, P1017, DOI 10.1097/00007890-199710150-00014; Petersdorf Effie W, 2017, F1000Res, V6, P617, DOI 10.12688/f1000research.10990.1; Petersdorf EW, 2001, BLOOD, V98, P2922, DOI 10.1182/blood.V98.10.2922; Pidala J, 2014, BLOOD, V124, P2596, DOI 10.1182/blood-2014-05-576041; Pingel J, 2013, HUM IMMUNOL, V74, P330, DOI 10.1016/j.humimm.2012.10.029; Rendine S, 1998, TISSUE ANTIGENS, V52, P135, DOI 10.1111/j.1399-0039.1998.tb02277.x; Rutten CE, 2008, LEUKEMIA, V22, P1387, DOI 10.1038/leu.2008.90; Rutten CE, 2013, BIOL BLOOD MARROW TR, V19, P40, DOI 10.1016/j.bbmt.2012.07.020; Schmidt AH, 2008, BONE MARROW TRANSPL, V41, P605, DOI 10.1038/sj.bmt.1705950; Schmidt AH, 2007, BONE MARROW TRANSPL, V40, P823, DOI 10.1038/sj.bmt.1705832; Schmidt AH, 2010, TISSUE ANTIGENS, V76, P362, DOI 10.1111/j.1399-0039.2010.01520.x; Schmidt AH, 2009, BONE MARROW TRANSPL, V44, P405, DOI 10.1038/bmt.2009.55; Schmidt AH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086605; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Tram K, 2017, BIOL BLOOD MARROW TR, V23, P81, DOI 10.1016/j.bbmt.2016.10.021; Yamamoto H, 2019, INT J HEMATOL, V110, P39, DOI 10.1007/s12185-019-02672-4; Zino E, 2004, BLOOD, V103, P1417, DOI 10.1182/blood-2003-04-1279; Zino E, 2007, BIOL BLOOD MARROW TR, V13, P1031, DOI 10.1016/j.bbmt.2007.05.010	49	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 16	2021	12								638253	10.3389/fimmu.2021.638253	http://dx.doi.org/10.3389/fimmu.2021.638253			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RV0RH	33936051	Green Published, gold			2022-12-18	WOS:000645544500001
J	Liu, JC; Fei, Y; Zhou, T; Ji, H; Wu, J; Gu, XQ; Luo, Y; Zhu, JJ; Feng, MX; Wan, P; Qiu, BJ; Lu, YF; Yang, T; Deng, PF; Zhou, CP; Gong, DC; Deng, J; Xue, F; Xia, Q				Liu, Jinchuan; Fei, Yi; Zhou, Tao; Ji, Hao; Wu, Ji; Gu, Xiangqian; Luo, Yi; Zhu, Jianjun; Feng, Mingxuan; Wan, Ping; Qiu, Bijun; Lu, Yefeng; Yang, Tian; Deng, Pengfei; Zhou, Cuiping; Gong, Dongcheng; Deng, Jun; Xue, Feng; Xia, Qiang			Bile Acids Impair Vaccine Response in Children With Biliary Atresia	FRONTIERS IN IMMUNOLOGY			English	Article						bile acids; vaccine response; children; biliary atresia; B cells		Background Vaccination is the best way to protect children under 5 years from death or disability. Children with biliary atresia (BA), which is the most common pediatric cholestatic end-stage liver disease (PELD), are more vulnerable to infectious diseases. However, the vaccination coverage and factors modulating vaccine responses in children with BA are largely unknown. Methods In this study, 288 children (median age: 7 months) diagnosed with BA before liver transplantation were enrolled for the evaluation of vaccination status and the factors affecting the immune response to the hepatitis B (HBV) vaccine. Moreover, 49 BA children (median age: 4 months) were enrolled for flow cytometric analysis of CD4(+) T cells and CD19(+) B cell subsets and correlations with serum bile acid levels. Results Generally, these children had very low routine vaccination rates for the meningococcal serogroup AC (Men AC) (41.2%), measles-mumps-rubella (MMR) (31.3%), poliomyelitis (Polio) (25.3%), hepatitis A (HAV) (25.0%), Japanese encephalitis (JE) (15.0%), diphtheria-tetanus-pertussis (DTP) (14.2%), meningococcal serogroup A (Men A) (13.5%) and varicella (VAR) (10.8%) vaccines, but not for the HBV (96.2%) and bacillus Calmette-Guerin (BCG) (84.7%) vaccines. Remarkably, 19.8% (57/288) of the patients had HBV infection. Out of 220 patients vaccinated for HBV, 113 (51.4%), 85 (38.6%) and 22 (10%) had one, two or three doses of the HBV vaccine, respectively. Furthermore, logistic regression analysis revealed that the bile acid level was an independent factor associated with poor HBV vaccine response (p = 0.03; OR = 0.394; 95% CI = 0.170-0.969). Immunophenotyping showed that bile acids were only negatively correlated with the CD19(+)CD27(+)IgG(+) post-class-switched memory B cell ratio (p = 0.01). Conclusion This study reveals the overall vaccination rates of routine vaccines in Chinese BA children are very low and the poor HBV vaccine responses are associated with bile acids, possibly via the inhibition of CD19(+)CD27(+)IgG(+) post-class-switched memory B cell response.	[Liu, Jinchuan; Zhou, Tao; Ji, Hao; Wu, Ji; Gu, Xiangqian; Luo, Yi; Zhu, Jianjun; Feng, Mingxuan; Wan, Ping; Qiu, Bijun; Lu, Yefeng; Xue, Feng; Xia, Qiang] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Liver Surg & Liver Transplantat, Shanghai, Peoples R China; [Fei, Yi; Yang, Tian; Deng, Pengfei; Zhou, Cuiping] Shanghai Pudong Dist Ctr Dis Control & Prevent, Dept Immunol, Shanghai, Peoples R China; [Gong, Dongcheng; Deng, Jun] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Renji Hosp,Sch Med, Shanghai, Peoples R China; [Gong, Dongcheng; Deng, Jun] Shanghai Jiao Tong Univ, China Australia Ctr Personalized Immunol, Renji Hosp, Sch Med, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Center for Disease Control & Prevention; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Xue, F (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Liver Surg & Liver Transplantat, Shanghai, Peoples R China.; Deng, J (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Renji Hosp,Sch Med, Shanghai, Peoples R China.; Deng, J (corresponding author), Shanghai Jiao Tong Univ, China Australia Ctr Personalized Immunol, Renji Hosp, Sch Med, Shanghai, Peoples R China.	jund2347@163.com; liversurgery6108_rj@sjtu.edu.cn			National Natural Science Foundation of China [81670602, 82071816]; Shanghai Municipal Hospital Three-year-project for Clinical Skills' Promotion and Innovation [16CR1003A]; Renji Hospital Clinical Research Innovation Incubation Fund Plan, School of Medicine, Shanghai Jiao Tong University [PYI-17-002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Hospital Three-year-project for Clinical Skills' Promotion and Innovation; Renji Hospital Clinical Research Innovation Incubation Fund Plan, School of Medicine, Shanghai Jiao Tong University	This project was supported by the National Natural Science Foundation of China (81670602 to FX, 82071816 to JD), Shanghai Municipal Hospital Three-year-project for Clinical Skills' Promotion and Innovation (16CR1003A), and Renji Hospital Clinical Research Innovation Incubation Fund Plan (PYI-17-002), School of Medicine, Shanghai Jiao Tong University.	Akkaya M, 2020, NAT REV IMMUNOL, V20, P229, DOI 10.1038/s41577-019-0244-2; Anonymous, 2007, Morbidity and Mortality Weekly Report, V56, P441; BALISTRERI WF, 1983, J PEDIATR GASTR NUTR, V2, P346, DOI 10.1097/00005176-198305000-00025; Brouwer MC, 2010, CLIN MICROBIOL REV, V23, P467, DOI 10.1128/CMR.00070-09; Correia L, 2001, LIFE SCI, V69, P2337, DOI 10.1016/S0024-3205(01)01321-2; Cui FQ, 2017, EMERG INFECT DIS, V23, P765, DOI 10.3201/eid2305.161477; Dehghani SM, 2014, TURK J GASTROENTEROL, V25, P26, DOI 10.5152/tjg.2014.5139; Dehghani SM, 2009, PEDIATR TRANSPLANT, V13, P820, DOI 10.1111/j.1399-3046.2009.01177.x; Eguchi R, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2251-x; Fiorucci S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01853; Flanagan KL, 2017, ANNU REV CELL DEV BI, V33, P577, DOI 10.1146/annurev-cellbio-100616-060718; Greene SA, 2019, MMWR-MORBID MORTAL W, V68, P458, DOI 10.15585/mmwr.mm6820a3; Guo CS, 2016, IMMUNITY, V45, P802, DOI 10.1016/j.immuni.2016.09.008; Hang SY, 2019, NATURE, V576, P143, DOI 10.1038/s41586-019-1785-z; Hartley JL, 2009, LANCET, V374, P1704, DOI 10.1016/S0140-6736(09)60946-6; He J, 2016, NAT MED, V22, P991, DOI 10.1038/nm.4148; Jiang X, 2018, J AUTOIMMUN, V90, P64, DOI 10.1016/j.jaut.2018.01.007; Kasahara M, 2017, PEDIATR SURG INT, V33, P1289, DOI 10.1007/s00383-017-4173-5; Kikuchi K, 2009, HEPATOL RES, V39, P448, DOI 10.1111/j.1872-034X.2008.00474.x; Lefebvre P, 2009, PHYSIOL REV, V89, P147, DOI 10.1152/physrev.00010.2008; Li SX, 2019, LIVER INT, V39, P1755, DOI 10.1111/liv.14136; Liu J, 2007, LANCET, V369, P1582, DOI 10.1016/S0140-6736(07)60723-5; Liu J, 2019, B WORLD HEALTH ORGAN, V97, P230, DOI [10.2471/BLT.18.219469, 10.2471/blt.18.219469]; Mieli-Vergani G, 2009, SEMIN IMMUNOPATHOL, V31, P371, DOI 10.1007/s00281-009-0171-6; Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X; Peck M, 2019, MMWR-MORBID MORTAL W, V68, P937, DOI 10.15585/mmwr.mm6842a1; Piot P, 2019, NATURE, V575, P119, DOI 10.1038/s41586-019-1656-7; Pol S, 2015, NAT REV GASTRO HEPAT, V12, P190, DOI 10.1038/nrgastro.2015.28; Poland GA, 2018, VACCINE, V36, P5350, DOI 10.1016/j.vaccine.2017.07.062; Pols TWH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176715; Pulendran B, 2011, NAT IMMUNOL, V12, P509, DOI 10.1038/ni.2039; Qi XY, 2019, NAT MED, V25, P1225, DOI 10.1038/s41591-019-0509-0; Razavi-Shearer D, 2018, LANCET GASTROENTEROL, V3, P383, DOI 10.1016/S2468-1253(18)30056-6; Roden RBS, 2018, NAT REV CANCER, V18, P240, DOI 10.1038/nrc.2018.13; Rota PA, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.49; Santos Jorge L, 2010, Curr Gastroenterol Rep, V12, P30, DOI 10.1007/s11894-009-0081-8; Tang LB, 2017, J GASTROEN HEPATOL, V32, P659, DOI 10.1111/jgh.13534; Tarlinton D, 2013, SCIENCE, V341, P1205, DOI 10.1126/science.1241146; Ure BM, 2011, ANN SURG, V253, P826, DOI 10.1097/SLA.0b013e318211d7d8; Verkade HJ, 2016, J HEPATOL, V65, P631, DOI 10.1016/j.jhep.2016.04.032; World Health Organization, 2020, VACC PREV COMM DIS; World Health Organization, 2020, HEP B; Wu JF, 2008, PEDIATR RES, V64, P100, DOI 10.1203/PDR.0b013e3181732908; Wu JF, 2009, VACCINE, V27, P2812, DOI 10.1016/j.vaccine.2009.02.094; Yaghobi R, 2011, INDIAN J PEDIATR, V78, P478, DOI 10.1007/s12098-010-0309-5; You CR, 2014, WORLD J GASTROENTERO, V20, P13293, DOI 10.3748/wjg.v20.i37.13293; Zhou KJ, 2015, J PROTEOME RES, V14, P4844, DOI 10.1021/acs.jproteome.5b00676; Zimmermann P, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00084-18	48	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 16	2021	12								642546	10.3389/fimmu.2021.642546	http://dx.doi.org/10.3389/fimmu.2021.642546			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RV0SC	33936059	gold, Green Published			2022-12-18	WOS:000645546600001
J	Mrochen, DM; Trube, P; Jorde, I; Domanska, G; van den Brandt, C; Broker, BM				Mrochen, Daniel M.; Truebe, Patricia; Jorde, Ilka; Domanska, Grazyna; van den Brandt, Cindy; Broeker, Barbara M.			Immune Polarization Potential of the S. aureus Virulence Factors SplB and GlpQ and Modulation by Adjuvants	FRONTIERS IN IMMUNOLOGY			English	Article						Staphylococcus aureus; vaccine; adjuvants; SplB; GlpQ; immune polarization; mouse models; Th2		Protection against Staphylococcus aureus is determined by the polarization of the anti-bacterial immune effector mechanisms. Virulence factors of S. aureus can modulate these and induce differently polarized immune responses in a single individual. We proposed that this may be due to intrinsic properties of the bacterial proteins. To test this idea, we selected two virulence factors, the serine protease-like protein B (SplB) and the glycerophosphoryl diester phosphodiesterase (GlpQ). In humans naturally exposed to S. aureus, SplB induces a type 2-biased adaptive immune response, whereas GlpQ elicits type 1/type 3 immunity. We injected the recombinant bacterial antigens into the peritoneum of S. aureus-naive C57BL/6N mice and analyzed the immune response. This was skewed by SplB toward a Th2 profile including specific IgE, whereas GlpQ was weakly immunogenic. To elucidate the influence of adjuvants on the proteins' polarization potential, we studied Montanide ISA 71 VG and Imject (TM) Alum, which promote a Th1 and Th2 response, respectively. Alum strongly increased antibody production to the Th2-polarizing protein SplB, but did not affect the response to GlpQ. Montanide enhanced the antibody production to both S. aureus virulence factors. Montanide also augmented the inflammation in general, whereas Alum had little effect on the cellular immune response. The adjuvants did not override the polarization potential of the S. aureus proteins on the adaptive immune response.	[Mrochen, Daniel M.; Truebe, Patricia; Jorde, Ilka; Domanska, Grazyna; Broeker, Barbara M.] Univ Med Greifswald, Dept Immunol, Greifswald, Germany; [van den Brandt, Cindy] Univ Med Greifswald, Dept Med A, Greifswald, Germany; [Mrochen, Daniel M.] Leibniz Inst Plasma Sci & Technol eV INP, ZIK Plasmatis, Greifswald, Germany; [Truebe, Patricia] EUROIMMUN Med Labordiagnost AG, Dassow, Germany; [Jorde, Ilka] Otto von Guericke Univ, Expt Pneumol, Dept Pneumol, Univ Hosp Magdeburg,Med Fac,Hlth Campus Immunol I, Magdeburg, Germany	Greifswald Medical School; Greifswald Medical School; Leibniz Institut fur Plasmaforschung und Technologie; EUROIMMUN; Otto von Guericke University; University Hospital Magdeburg	Mrochen, DM (corresponding author), Univ Med Greifswald, Dept Immunol, Greifswald, Germany.; Mrochen, DM (corresponding author), Leibniz Inst Plasma Sci & Technol eV INP, ZIK Plasmatis, Greifswald, Germany.	mrochendaniel@gmail.com			Bundesministerium fur Bildung und Forschung [FKZ 03ZZ0806B]; Deutsche Forschungsgemeinschaft [BB FKZ CRC-TRR34, RTG 1870]; State of Mecklenburg Western Pomerania [FKZ ESF/14-BMA55-0004/16]	Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); State of Mecklenburg Western Pomerania	This work was supported by the Bundesministerium fur Bildung und Forschung (BB, DM, InfectControl2020, project InVAC, FKZ 03ZZ0806B, https://www.bmbf.de/), the Deutsche Forschungsgemeinschaft (PT, BB FKZ CRC-TRR34, RTG 1870, http://www.dfg.de/) and the State of Mecklenburg Western Pomerania (BB; ESF project KoInfekt, FKZ ESF/14-BMA55-0004/16).	Abdallah DSA, 2011, INT IMMUNOL, V23, P317, DOI 10.1093/intimm/dxr007; Aldinucci D, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/292376; Bekeredjian-Ding I, 2017, FUTURE MICROBIOL, V12, P1023, DOI 10.2217/fmb-2017-0138; Broker BM, 2016, PATHOGENS, V5, DOI 10.3390/pathogens5010031; Brown AF, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005226; Busse M, 2008, GUT, V57, P188, DOI 10.1136/gut.2007.121616; Cain DW, 2013, VACCINE, V31, P653, DOI 10.1016/j.vaccine.2012.11.044; CDC, 2013, ANT RES THREATS US; Cecil DL, 2014, CANCER RES, V74, P2710, DOI 10.1158/0008-5472.CAN-13-3286; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; Davoine F, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00570; De Jong NWM, 2019, MICROBIOL SPECTR, V7, DOI 10.1128/microbiolspec.GPP3-0061-2019; Di Genova G, 2010, EUR J IMMUNOL, V40, P976, DOI 10.1002/eji.200940017; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Ferraro A, 2019, HUM VACC IMMUNOTHER, V15, P2980, DOI 10.1080/21645515.2019.1613126; Firacative C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21039-z; Goerke C, 2004, INT J MED MICROBIOL, V294, P195, DOI 10.1016/j.ijmm.2004.06.013; Greenberg JA, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2025-x; He P, 2015, HUM VACC IMMUNOTHER, V11, P477, DOI 10.1080/21645515.2014.1004026; HogenEsch H, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0089-x; HogenEsch H, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00406; Jit M, 2020, BMC MED, V18, DOI 10.1186/s12916-020-1507-2; Johansson J, 2004, VACCINE, V22, P2873, DOI 10.1016/j.vaccine.2003.12.029; Jones HP, 2001, J IMMUNOL, V167, P4518, DOI 10.4049/jimmunol.167.8.4518; Joshi S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00288; Klimka A, 2015, SCAND J IMMUNOL, V81, P291, DOI 10.1111/sji.12279; Kolata J, 2011, PROTEOMICS, V11, P3914, DOI 10.1002/pmic.201000760; Kolata JB, 2015, J INFECT DIS, V212, P830, DOI 10.1093/infdis/jiv128; Korsholm KS, 2010, IMMUNOLOGY, V129, P75, DOI 10.1111/j.1365-2567.2009.03164.x; Leleux JA, 2017, CELL REP, V18, P700, DOI 10.1016/j.celrep.2016.12.073; Li B, 2015, SCI REP-UK, V5, DOI 10.1038/srep14793; Lin A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01781; Liu LY, 2007, J IMMUNOL, V179, P4840, DOI 10.4049/jimmunol.179.7.4840; Marchitto MC, 2019, P NATL ACAD SCI USA, V116, P10917, DOI 10.1073/pnas.1818256116; Martin RM, 1998, J IMMUNOL METHODS, V212, P187, DOI 10.1016/S0022-1759(98)00015-5; McNeely TB, 2014, HUM VACC IMMUNOTHER, V10, P3513, DOI 10.4161/hv.34407; Miller LS, 2020, FEMS MICROBIOL REV, V44, P123, DOI 10.1093/femsre/fuz030; Mrochen DM, 2018, INT J MED MICROBIOL, V308, P598, DOI 10.1016/j.ijmm.2017.11.006; Mulani MS, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00539; Proctor RA., 2019, GRAM POSITIVE PATHOG, P766; Proctor RA, 2019, MICROBIOL SPECTR, V7, DOI 10.1128/microbiolspec.GPP3-0037-2018; Pulendran B, 2004, IMMUNOL RES, V29, P187, DOI 10.1385/IR:29:1-3:187; Qian Feng, 2004, Cancer Immun, V4, P12; Rice LB, 2008, J INFECT DIS, V197, P1079, DOI 10.1086/533452; Ritchie SR, 2016, J INFECTION, V72, P295, DOI 10.1016/j.jinf.2015.12.010; Sakr A, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02419; Schmidt ST, 2016, J CONTROL RELEASE, V239, P107, DOI 10.1016/j.jconrel.2016.08.034; Schulz D, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00152; Stentzel S, 2017, J ALLERGY CLIN IMMUN, V139, P492, DOI 10.1016/j.jaci.2016.03.045; Stentzel S, 2015, J PROTEOMICS, V128, P1, DOI 10.1016/j.jprot.2015.06.018; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; Tacconelli E, 2018, LANCET INFECT DIS, V18, P318, DOI [10.1016/S1473-3099(17)30753-3, 10.1016/s1473-3099(17)30753-3]; Teufelberger AR, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.582044; Teufelberger AR, 2018, J ALLERGY CLIN IMMUN, V141, P549, DOI 10.1016/j.jaci.2017.05.004; Tong SYC, 2015, CLIN MICROBIOL REV, V28, P603, DOI 10.1128/CMR.00134-14; Palomino DCT, 2015, EINSTEIN-SAO PAULO, V13, P469, DOI 10.1590/S1679-45082015RB3438; Tsuzuki S, 2020, J INFECT CHEMOTHER, V26, P367, DOI 10.1016/j.jiac.2019.10.017; Uebele J, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006387; van Belkum A, 2009, J INFECT DIS, V199, P1820, DOI 10.1086/599119; Verkaik NJ, 2009, J INFECT DIS, V199, P625, DOI 10.1086/596743; Watt WC, 2017, SEMIN IMMUNOPATHOL, V39, P245, DOI 10.1007/s00281-016-0596-7; Wertheim HFL, 2005, LANCET INFECT DIS, V5, P751, DOI 10.1016/S1473-3099(05)70295-4; Zhang F, 2018, MBIO, V9, DOI 10.1128/mBio.01949-18; Zhen XM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60825-6; Zimmermann P, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00084-18	65	0	0	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 15	2021	12								642802	10.3389/fimmu.2021.642802	http://dx.doi.org/10.3389/fimmu.2021.642802			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RU4GN	33936060	Green Published, gold			2022-12-18	WOS:000645107000001
J	Khatri, I; Staal, FJT; van Dongen, JJM				Khatri, Indu; Staal, Frank J. T.; van Dongen, Jacques J. M.			Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2 Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity Antibodies: An Immune Perspective (vol 11, 2258, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						ACE2; SARS-CoV; interaction-synapse; antibody; binding-affinity; felines; interface			[Khatri, Indu; Staal, Frank J. T.; van Dongen, Jacques J. M.] Leiden Univ, Med Ctr, Dept Immunol, Leiden, Netherlands; [Khatri, Indu] Leiden Univ, Med Ctr, Leiden Computat Biol Ctr, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Khatri, I; van Dongen, JJM (corresponding author), Leiden Univ, Med Ctr, Dept Immunol, Leiden, Netherlands.; Khatri, I (corresponding author), Leiden Univ, Med Ctr, Leiden Computat Biol Ctr, Leiden, Netherlands.	i.khatri@lumc.nl; J.J.M.van_Dongen@lumc.nl	Khatri, Indu/Y-2429-2018	Khatri, Indu/0000-0002-7993-1953				Khatri I, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.570018	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2021	12								659375	10.3389/fimmu.2021.659375	http://dx.doi.org/10.3389/fimmu.2021.659375			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RU0PR	33936092	gold, Green Published			2022-12-18	WOS:000644854900001
J	Thudium, RF; Ringheim, H; Ronit, A; Hoel, H; Benfield, T; Mocroft, A; Gerstoft, J; Troseid, M; Borges, AH; Ostrowski, SR; Vestbo, J; Nielsen, SD				Thudium, Rebekka F.; Ringheim, Hedda; Ronit, Andreas; Hoel, Hedda; Benfield, Thomas; Mocroft, Amanda; Gerstoft, Jan; Troseid, Marius; Borges, Alvaro H.; Ostrowski, Sisse R.; Vestbo, Jorgen; Nielsen, Susanne D.			Independent Associations of Tumor Necrosis Factor-Alpha and Interleukin-1 Beta With Radiographic Emphysema in People Living With HIV	FRONTIERS IN IMMUNOLOGY			English	Article						HIV; emphysema; inflammation; non-AIDS comorbidity; interleukin-1 beta; cytokines		Background People living with HIV (PLWH) have increased systemic inflammation, and inflammation has been suggested to contribute to the pathogenesis of emphysema. We investigated whether elevated cytokine concentrations (interleukin (IL)-1 beta, IL-1 receptor antagonist (IL-1RA), IL-2, IL-4, IL-6, IL-10, IL-17A, tumor necrosis factor-alpha (TNF alpha), interferon-gamma (IFN gamma), soluble CD14 (sCD14) and sCD163 were independently associated with radiographic emphysema in PLWH. Methods We included PLWH from the Copenhagen Comorbidity in HIV Infection (COCOMO) Study without hepatitis B and C co-infection and with a plasma sample and a chest computed tomography scan available. Emphysema plus trace emphysema was defined as the percentage of low attenuation area under -950 Houndsfield Unit (%LAA-950) using a cut-off at 5%. Cytokine concentrations were measured by ELISA or Luminex immunoassays. An elevated cytokine concentration was defined as above the 75(th) percentile. Results Of 783 PLWH, 147 (18.8%) had emphysema. PLWH were predominantly male (86.0%) and 743 (94.9%) had undetectable viral replication. PLWH with emphysema had higher concentrations of TNF alpha (median (IQR): 8.2 (6.4-9.8) versus 7.1 (5.7-8.6) pg/ml, p<0.001), IL-1 beta (0.21 (0.1-0.4) versus 0.17 (0.1-0.3) pg/ml, p=0.004) and IL-6 (3.6 (2.6-4.9) versus 3.1 (2.0-4.3) pg/ml, p=0.023) than PLWH without. In a logistic regression model adjusted for age, sex, ethnicity, smoking status, BMI and CD4 nadir, elevated TNF alpha (adjusted odds ratio (aOR): 1.78 [95%CI: 1.14-2.76], p=0.011) and IL-1 beta (aOR: 1.81 [95%CI: 1.16-2.81], p=0.009) were independently associated with emphysema. The association between IL-1 beta and emphysema was modified by smoking (p-interaction=0.020) with a more pronounced association in never-smokers (aOR: 4.53 [95%CI: 2.05-9.98], p<0.001). Conclusion Two markers of systemic inflammation, TNF alpha and IL-1 beta, were independently associated with emphysema in PLWH and may contribute to the pathogenesis of emphysema. Importantly, the effect of IL-1 beta seems to be mediated through pathways that are independent of excessive smoking.	[Thudium, Rebekka F.; Ringheim, Hedda; Gerstoft, Jan; Nielsen, Susanne D.] Univ Copenhagen, Dept Infect Dis, Viro Immunol Res Unit, Rigshosp, Copenhagen, Denmark; [Ronit, Andreas; Benfield, Thomas] Copenhagen Univ Hosp, Dept Infect Dis, Amager & Hvidovre Hosp, Hvidovre, Denmark; [Hoel, Hedda; Troseid, Marius] Oslo Univ Hosp Rikshosp, Internal Med Res Inst, Oslo, Norway; [Benfield, Thomas; Gerstoft, Jan; Ostrowski, Sisse R.; Nielsen, Susanne D.] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark; [Mocroft, Amanda] UCL, Inst Global Hlth, Ctr Clin Res Epidemiol Modelling & Evaluat CREME, London, England; [Mocroft, Amanda] Univ Copenhagen, Sect 2100, Dept Infect Dis, Ctr Hlth & Infect Dis CHIP,Rigshosp, Copenhagen, Denmark; [Borges, Alvaro H.] Statens Serum Inst, Dept Infect Dis Immunol, Copenhagen, Denmark; [Ostrowski, Sisse R.] Univ Copenhagen, Dept Clin Immunol, Rigshosp, Copenhagen, Denmark; [Vestbo, Jorgen] Univ Manchester, Div Infect Immun & Resp Med, Manchester, Lancs, England; [Vestbo, Jorgen] Manchester Univ NHS Fdn Trust, Manchester, Lancs, England	Rigshospitalet; University of Copenhagen; University of Copenhagen; University of Oslo; National Hospital Norway; University of Copenhagen; University of London; University College London; Rigshospitalet; University of Copenhagen; Statens Serum Institut; Rigshospitalet; University of Copenhagen; University of Manchester	Nielsen, SD (corresponding author), Univ Copenhagen, Dept Infect Dis, Viro Immunol Res Unit, Rigshosp, Copenhagen, Denmark.; Nielsen, SD (corresponding author), Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark.	sdn@dadlnet.dk	Ostrowski, Sisse R/E-7423-2011; Borges, Alvaro Humberto/G-3231-2016	Ostrowski, Sisse R/0000-0001-5288-3851; Nielsen, Susanne Dam/0000-0001-6391-7455; Borges, Alvaro Humberto/0000-0003-2020-3828; Benfield, Thomas/0000-0003-0698-9385	Rigshospitalet Research Council; Novo Nordisk Foundation; NIHR Manchester BRC; Lundbeck Foundation [R219-2016-762]	Rigshospitalet Research Council; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); NIHR Manchester BRC; Lundbeck Foundation(Lundbeckfonden)	This work was supported by Rigshospitalet Research Council and The Novo Nordisk Foundation. JV is supported by the NIHR Manchester BRC. AB was supported by The Lundbeck Foundation during the conduct of this study (Grant R219-2016-762).	Attia EF, 2014, CHEST, V146, P1543, DOI 10.1378/chest.14-0543; Baker JV, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx262; Barr RG, 2012, COPD, V9, P151, DOI 10.3109/15412555.2012.654923; Besutti G, 2019, HIV MED, V20, P657, DOI 10.1111/hiv.12785; Borges AH, 2016, J INFECT DIS, V214, P408, DOI 10.1093/infdis/jiw173; Cavigli E, 2009, EUR RADIOL, V19, P1686, DOI 10.1007/s00330-009-1320-y; Coxson HO, 2013, LANCET RESP MED, V1, P129, DOI 10.1016/S2213-2600(13)70006-7; Cribbs SK, 2020, PHYSIOL REV, V100, P603, DOI 10.1152/physrev.00039.2018; Cribbs SK, 2015, AIDS RES HUM RETROV, V31, P64, DOI [10.1089/aid.2014.0133, 10.1089/AID.2014.0133]; Crothers K, 2006, CHEST, V130, P1326, DOI 10.1378/chest.130.5.1326; DIAZ PT, 1992, ANN INTERN MED, V116, P124, DOI 10.7326/0003-4819-116-2-124; Diaz PT, 2000, ANN INTERN MED, V132, P369, DOI 10.7326/0003-4819-132-5-200003070-00006; Duprez DA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044454; Fernandez-Botran R, 2020, CYTOKINE, V126, DOI 10.1016/j.cyto.2019.154874; Freeman ML, 2016, J INFECT DIS, V214, pS51, DOI 10.1093/infdis/jiw287; Guaraldi G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109027; Guaraldi G, 2011, CLIN INFECT DIS, V53, P1120, DOI 10.1093/cid/cir627; Hunt PW, 2012, CURR HIV-AIDS REP, V9, P139, DOI 10.1007/s11904-012-0118-8; Johannessen A, 2013, AM J RESP CRIT CARE, V187, P602, DOI 10.1164/rccm.201209-1722OC; Kaner RJ, 2009, J LEUKOCYTE BIOL, V86, P912, DOI 10.1189/jlb.0408240; Leader JK, 2016, JAIDS-J ACQ IMM DEF, V71, P420, DOI 10.1097/QAI.0000000000000894; Lynch DA, 2013, J THORAC IMAG, V28, P284, DOI 10.1097/RTI.0b013e318298733c; MacNee W, 2011, AM J RESP CRIT CARE, V184, P1327, DOI 10.1164/rccm.201110-1764ED; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Ronit A, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00296-2018; Ronit A, 2018, THORAX, V73, P431, DOI 10.1136/thoraxjnl-2017-211079; Ronit A, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02186-2016; Ronit A, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-2026-9; Sereti I, 2017, CLIN INFECT DIS, V64, P124, DOI 10.1093/cid/ciw683; Serrano-Villar S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085798; Triplette M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170857; Triplette M, 2017, JAIDS-J ACQ IMM DEF, V74, pE23, DOI 10.1097/QAI.0000000000001133; Zicari S, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030200	33	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2021	12								668113	10.3389/fimmu.2021.668113	http://dx.doi.org/10.3389/fimmu.2021.668113			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RU0MW	33936110	gold, Green Published			2022-12-18	WOS:000644847400001
J	Zhou, HY; Wang, LW; Liu, F				Zhou, Haiyan; Wang, Liwen; Liu, Feng			Immunological Impact of Intestinal T Cells on Metabolic Diseases (vol 12, 639902, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						obesity; intestine; T cells; microbiota; dietary signals			[Zhou, Haiyan; Wang, Liwen; Liu, Feng] Cent South Univ, Xiangya Hosp 2, Metab Syndrome Res Ctr, Natl Clin Res Ctr Metab Dis, Changsha, Peoples R China; [Zhou, Haiyan; Wang, Liwen; Liu, Feng] Cent South Univ, Xiangya Hosp 2, Dept Endocrinol & Metab, Changsha, Peoples R China; [Liu, Feng] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA	Central South University; Central South University; University of Texas System; University of Texas Health San Antonio	Zhou, HY; Liu, F (corresponding author), Cent South Univ, Xiangya Hosp 2, Metab Syndrome Res Ctr, Natl Clin Res Ctr Metab Dis, Changsha, Peoples R China.; Zhou, HY; Liu, F (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Endocrinol & Metab, Changsha, Peoples R China.; Liu, F (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA.	hyzhou02@csu.edu.cn; liuf@uthscsa.edu						Zhou HY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.639902	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2021	12								682376	10.3389/fimmu.2021.682376	http://dx.doi.org/10.3389/fimmu.2021.682376			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RU0IX	33936121	gold, Green Published			2022-12-18	WOS:000644836800001
J	Yu, J; Zhu, RR; Yu, KW; Wang, Y; Ding, Y; Zhong, YC; Zeng, QT				Yu, Jian; Zhu, Ruirui; Yu, Kunwu; Wang, Yue; Ding, Yan; Zhong, Yucheng; Zeng, Qiutang			Galectin-9: A Suppressor of Atherosclerosis? (vol 11, 604265, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						Galectin-9; atherosclerosis; T-cell immunoglobulin mucin 3; regulatory T cells; T helper cells			[Yu, Jian; Zhu, Ruirui; Yu, Kunwu; Wang, Yue; Ding, Yan; Zhong, Yucheng; Zeng, Qiutang] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Cardiol, Wuhan, Peoples R China	Huazhong University of Science & Technology	Zhong, YC; Zeng, QT (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Cardiol, Wuhan, Peoples R China.	zyc811029@126.com; zengqt139@sina.com						Yu J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.604265	1	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 13	2021	12								686592	10.3389/fimmu.2021.686592	http://dx.doi.org/10.3389/fimmu.2021.686592			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RT3UB	33927730	gold, Green Published			2022-12-18	WOS:000644386500001
J	Abbas, HA; Reville, PK; Jiang, XL; Yang, H; Reuben, A; Im, JS; Little, L; Sinson, JC; Chen, K; Futreal, A; Garcia-Manero, G				Abbas, Hussein A.; Reville, Patrick K.; Jiang, Xianli; Yang, Hui; Reuben, Alexandre; Im, Jin Seon; Little, Latasha; Sinson, Jefferson C.; Chen, Ken; Futreal, Andrew; Garcia-Manero, Guillermo			Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes	FRONTIERS IN IMMUNOLOGY			English	Article						myelodysplastic syndrome; T-cell repertoire; diversity; clonality; antigen recognition		Aberrant T-cell function is implicated in the pathogenesis of myelodysplastic syndrome (MDS). Monitoring the T-cell receptor (TCR) repertoire can provide insights into T-cell adaptive immunity. Previous studies found skewed TCR repertoires in MDS compared to healthy patients; however these studies that leverage mRNA-based spectratyping have limitations. Furthermore, evaluating the TCR repertoire in context of hypomethylating agents (HMAs) treatment can provide insights into the dynamics of T-cell mediated responses in MDS. We conducted immunosequencing of the CDR3 regions of TCR beta chains in bone marrows of 11 MDS patients prior to treatment (n=11 bone marrows prior to treatment), and in at least 2 timepoints for each patient following treatment (n=26 bone marrow aspirates post-treatment) with (HMA), alongside analyzing bone marrows from 4 healthy donors as controls. TCR repertoires in MDS patients were more clonal and less diverse than healthy donors. However, unlike previous reports, we did not observe significant skewness in CDR3 length or spectratyping. The global metrics of TCR profiling including richness, clonality, overlaps were not significantly changed in responders or non-responders following treatment with HMAs. However, we found an emergence of novel clonotypes in MDS patients who responded to treatment, while non-responders had a higher frequency of contracted clonotypes following treatment. By applying GLIPH2 for antigen prediction, we found rare TCR specificity clusters shared by TCR clonotypes from different patients at pre- or following treatment. Our data show clear differences in TCR repertoires of MDS compared with healthy patients and that novel TCR clonotype emergence in response to HMA therapy was correlated with response. This suggests that response to HMA therapy may be partially driven by T-cell mediated immunity and that the immune-based therapies, which target the adaptive immune system, may play a significant role in select patients with MDS.	[Abbas, Hussein A.; Reville, Patrick K.] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Med Oncol Fellowship, Houston, TX 77030 USA; [Jiang, Xianli; Chen, Ken] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Yang, Hui; Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Reuben, Alexandre] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Im, Jin Seon] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA; [Im, Jin Seon; Futreal, Andrew] Univ Texas MD Anderson Canc Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA; [Little, Latasha; Sinson, Jefferson C.; Futreal, Andrew] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Garcia-Manero, G (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.; Futreal, A (corresponding author), Univ Texas MD Anderson Canc Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA.; Futreal, A (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA.	afutreal@mdanderson.org; ggarciam@mdanderson.org	Chen, Ken/AAU-1432-2021	Chen, Ken/0000-0003-4013-5279	T32 NIH fellowship; Adaptive Biotechnology Young Investigator Award - T32 NIH grant	T32 NIH fellowship(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Adaptive Biotechnology Young Investigator Award - T32 NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The work was funded in part by T32 NIH fellowship and Adaptive Biotechnology Young Investigator Award to HA and PR (both were supported by T32 NIH grant).	Bagaev DV, 2020, NUCLEIC ACIDS RES, V48, pD1057, DOI 10.1093/nar/gkz874; Barennes P, 2021, NAT BIOTECHNOL, V39, DOI 10.1038/s41587-020-0656-3; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Cazzola M, 2020, NEW ENGL J MED, V383, P1358, DOI 10.1056/NEJMra1904794; Ciupe SM, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-35; Daver N, 2018, LEUKEMIA, V32, P1094, DOI 10.1038/s41375-018-0070-8; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; Emerson RO, 2017, NAT GENET, V49, P659, DOI 10.1038/ng.3822; Epperson DE, 2001, LEUKEMIA RES, V25, P1075, DOI 10.1016/S0145-2126(01)00083-2; Fozza C, 2015, LEUKEMIA RES, V39, P957, DOI 10.1016/j.leukres.2015.06.007; Fozza C, 2009, EXP HEMATOL, V37, P947, DOI 10.1016/j.exphem.2009.04.009; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Giannouli S, 2004, RHEUMATOLOGY, V43, P626, DOI 10.1093/rheumatology/keh136; Giovazzino A, 2019, BRIT J HAEMATOL, V185, P357, DOI 10.1111/bjh.15496; Glanville J, 2017, NATURE, V547, P94, DOI 10.1038/nature22976; Glenthoj A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060944; GORSKI J, 1994, J IMMUNOL, V152, P5109; Hou XL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00299; Huang H, 2020, NAT BIOTECHNOL, V38, P1194, DOI 10.1038/s41587-020-0505-4; Kepler TB, 2005, BIOINFORMATICS, V21, P3394, DOI 10.1093/bioinformatics/bti539; Killick SB, 2003, BRIT J HAEMATOL, V120, P679, DOI 10.1046/j.1365-2141.2003.04136.x; Malcovati L, 2013, BLOOD, V122, P2943, DOI 10.1182/blood-2013-03-492884; Nouaille S, 2017, NUCLEIC ACIDS RES, V45, P11711, DOI 10.1093/nar/gkx781; Page DB, 2016, CANCER IMMUNOL RES, V4, P835, DOI 10.1158/2326-6066.CIR-16-0013; Passweg JR, 2011, J CLIN ONCOL, V29, P303, DOI 10.1200/JCO.2010.31.2686; Reuben A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14273-0; Reuben A, 2017, CANCER DISCOV, V7, P1088, DOI 10.1158/2159-8290.CD-17-0256; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; SMITH MA, 1991, LEUKEMIA RES, V15, P597, DOI 10.1016/0145-2126(91)90028-R; Yazji S, 2003, LEUKEMIA, V17, P2101, DOI 10.1038/sj.leu.2403124	31	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 12	2021	12								659625	10.3389/fimmu.2021.659625	http://dx.doi.org/10.3389/fimmu.2021.659625			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RS6TR	33912187	Green Published, gold			2022-12-18	WOS:000643909600001
J	Jans, J; Unger, WW; Raeven, EAM; Simonetti, ER; Eleveld, MJ; de Groot, R; de Jonge, MI; Ferwerda, G				Jans, Jop; Unger, Wendy W.; Raeven, Elisabeth A. M.; Simonetti, Elles R.; Eleveld, Marc J.; de Groot, Ronald; de Jonge, Marion, I; Ferwerda, Gerben			Lack of Cell Cycle Inhibitor p21 and Low CD4(+) T Cell Suppression in Newborns After Exposure to IFN-beta	FRONTIERS IN IMMUNOLOGY			English	Article						interferon beta; respiratory syncytial virus; newborns; immunity; CD4 T cells; proliferation; cell cycle; cyclic-dependent kinase inhibitor; p21		Type I IFNs, such as interferon alpha and interferon beta, are key regulators of the adaptive immune response during infectious diseases. Type I IFNs are induced upon infection, bind interferon alpha/beta receptors on T-cells and activate intracellular pathways. The activating and inhibitory consequences of type I IFN-signaling are determined by cell type and cellular environment. The neonatal immune system is associated with increased vulnerability to infectious diseases which could partly be explained by an immature CD4(+) T-cell compartment. Here, we show low IFN-beta-mediated inhibition of CD4(+) T-cell proliferation, phosphorylation of retinoblastoma protein and cytokine production in human newborns compared to adults. In addition, both naive and total newborn CD4(+) T-cells are unable to induce the cell-cycle inhibitor p21 upon exposure to IFN-beta in contrast to adults. The distinct IFN-beta-signaling in newborns provides novel insights into T cell functionality and regulation of T cell-dependent inflammation during early life immune responses.	[Jans, Jop; Unger, Wendy W.] Erasmus MC Univ Med Ctr, Div Pedetr Infect Dis & Immunol, Lab Pediat, Sophia Chidrens Hosp, Rotterdam, Netherlands; [Jans, Jop; Raeven, Elisabeth A. M.; Simonetti, Elles R.; Eleveld, Marc J.; de Groot, Ronald; de Jonge, Marion, I; Ferwerda, Gerben] Radboud Univ Nijmegen Med Ctr, Radboud Inst Mol Life Sci, Dept Lab Med, Lab Med Immunol,Sect Pediat Infect Dis, Nijmegen, Netherlands; [Jans, Jop; Raeven, Elisabeth A. M.; Simonetti, Elles R.; Eleveld, Marc J.; de Groot, Ronald; de Jonge, Marion, I; Ferwerda, Gerben] Radboud Univ Nijmegen Med Ctr, Radboud Ctr Infect Dis, Nijmegen, Netherlands	Erasmus University Rotterdam; Erasmus MC; Radboud University Nijmegen; Radboud University Nijmegen	Jans, J (corresponding author), Erasmus MC Univ Med Ctr, Div Pedetr Infect Dis & Immunol, Lab Pediat, Sophia Chidrens Hosp, Rotterdam, Netherlands.; Jans, J (corresponding author), Radboud Univ Nijmegen Med Ctr, Radboud Inst Mol Life Sci, Dept Lab Med, Lab Med Immunol,Sect Pediat Infect Dis, Nijmegen, Netherlands.; Jans, J (corresponding author), Radboud Univ Nijmegen Med Ctr, Radboud Ctr Infect Dis, Nijmegen, Netherlands.	jjans@erasmusmc.nl	de Jonge, Marien I./P-5869-2015	de Jonge, Marien I./0000-0003-2812-5895; Eleveld, Marc/0000-0001-7454-018X				Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Chiantore MV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036909; Christiaansen AF, 2014, IMMUNOL RES, V59, P109, DOI 10.1007/s12026-014-8540-1; Daszkiewicz L, 2015, SCI REP-UK, V5, DOI 10.1038/srep07691; Di Stefano V, 2011, J BIOL CHEM, V286, P8644, DOI 10.1074/jbc.M110.184549; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gattinoni L, 2017, NAT MED, V23, P18, DOI 10.1038/nm.4241; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; Gibbons D, 2014, NAT MED, V20, P1206, DOI 10.1038/nm.3670; Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581; Jaitin DA, 2006, MOL CELL BIOL, V26, P1888, DOI 10.1128/MCB.26.5.1888-1897.2006; Jans J, 2017, J ALLERGY CLIN IMMUN, V139, P1997, DOI 10.1016/j.jaci.2016.10.032; Katayama T, 2007, INT J ONCOL, V31, P613; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Marshall HD, 2011, J VIROL, V85, P5929, DOI 10.1128/JVI.02516-10; Mateo MS, 1997, J CLIN PATHOL, V50, P645, DOI 10.1136/jcp.50.8.645; McNab F, 2015, NAT REV IMMUNOL, V15, P87, DOI 10.1038/nri3787; Olsson A, 2007, CELL DEATH DIFFER, V14, P1561, DOI 10.1038/sj.cdd.4402196; Piehler J, 2012, IMMUNOL REV, V250, P317, DOI 10.1111/imr.12001; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Rep MHG, 1996, J NEUROIMMUNOL, V67, P111; Rose S, 2006, EUR J IMMUNOL, V36, P1241, DOI 10.1002/eji.200535563; Runkel L, 1998, J BIOL CHEM, V273, P8003, DOI 10.1074/jbc.273.14.8003; Santiago-Raber ML, 2001, J IMMUNOL, V167, P4067, DOI 10.4049/jimmunol.167.7.4067; Schirmer SH, 2010, J BIOL CHEM, V285, P34677, DOI 10.1074/jbc.M110.164350; Taylor A, 2006, IMMUNOLOGY, V117, P433, DOI 10.1111/j.1365-2567.2006.02321.x; Vissers M, 2015, CYTOKINE, V76, P458, DOI 10.1016/j.cyto.2015.07.024; White GP, 2002, J IMMUNOL, V168, P2820, DOI 10.4049/jimmunol.168.6.2820; Zafranskaya M, 2007, IMMUNOLOGY, V121, P29, DOI 10.1111/j.1365-2567.2006.02518.x; Zhao M, 2016, SCI REP-UK, V6, DOI 10.1038/srep38411	31	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 12	2021	12								652965	10.3389/fimmu.2021.652965	http://dx.doi.org/10.3389/fimmu.2021.652965			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RS1OW	33912177	gold, Green Published			2022-12-18	WOS:000643554500001
J	Wang, DM; Su, S; Tan, MQ; Wu, YM; Wang, SN				Wang, Dongmei; Su, Shuang; Tan, Miaoqin; Wu, Yongming; Wang, Shengnan			Paroxysmal Sympathetic Hyperactivity in Severe Anti-N-Methyl-d-Aspartate Receptor Encephalitis: A Single Center Retrospective Observational Study	FRONTIERS IN IMMUNOLOGY			English	Article						anti-NMDA receptor encephalitis; paroxysmal sympathetic hyperactivity; autonomic dysfunction; neuro-intensive care unit; treatment		Background Paroxysmal sympathetic hyperactivity (PSH) is a disorder with excessive sympathetic activity commonly recognized in patients with acquired brain injury. Autonomic instability is frequent in anti-N-methyl-d-aspartate receptor encephalitis (anti-NMDARE). However, PSH in anti-NMDARE has gained little attention. Methods We retrospectively reviewed 24 patients diagnosed with severe anti-NMDARE in the neuro-intensive care unit (NICU) between 2014 and 2019. Patients were assessed with the PSH assessment measure (PSH-AM) scale, and categorized into "PSH+" group and "PSH-" group. The clinical characteristics, hospital mortality, and functional outcome by modified Rankin Scale (mRS) score at six months after discharge were compared between the two groups. Among patients with PSH+, the clinical features and pharmacotherapy of PSH were summarized and compared. Results Twenty-four patients were included in the study. Twelve of them (50%) were categorized as PSH+ based on PSH-AM scores. There were no significant differences in the demographic characteristic, GCS scores upon admission, incidence of status epilepticus, teratoma occurrence, hospital mortality, and 6-month mRS between PSH+ and PSH- groups. Patients with PSH+ had increased length of NICU stay, hospital stay and duration of mechanical ventilation. The most prominent clinical features of PSH in severe anti-NMDARE were tachycardia and hyperthermia, while posturing was the relatively mildest clinical feature. Propranolol and clonazepam were more commonly used than gabapentin in pharmacotherapy of PSH in severe anti-NMDARE. Conclusions The incidence of PSH in severe anti-NMDARE patients was as high as 50%. Patients with PSH demonstrated prolonged NICU stay, hospital stay and increased duration of mechanical ventilation, while no effect on hospital mortality and functional outcome. Clinicians should be aware of the distinctive characteristics and treatment options of PSH in severe anti-NMDARE.	[Wang, Dongmei; Tan, Miaoqin; Wu, Yongming; Wang, Shengnan] Southern Med Univ, Nanfang Hosp, Dept Neurol, Guangzhou, Peoples R China; [Su, Shuang] Southern Med Univ, Nanfang Hosp, Dept Geriatr, Guangzhou, Peoples R China	Southern Medical University - China; Southern Medical University - China	Wu, YM; Wang, SN (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Neurol, Guangzhou, Peoples R China.	13711530187@139.com; wsnpumc@smu.edu.cn			President Foundation of Nanfang Hospital, Southern Medical University [2020B006]	President Foundation of Nanfang Hospital, Southern Medical University	This study was supported by President Foundation of Nanfang Hospital, Southern Medical University (No.2020B006).	Baguley IJ, 2008, MED HYPOTHESES, V70, P26, DOI 10.1016/j.mehy.2007.04.037; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Baguley IJ, 2014, J NEUROTRAUM, V31, P1515, DOI 10.1089/neu.2013.3301; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Chen XP, 2016, NEUROL SCI, V37, P1993, DOI 10.1007/s10072-016-2702-y; Chia PL, 2013, PACE, V36, pe90, DOI 10.1111/j.1540-8159.2011.03154.x; Dolce G, 2021, J NEUROTRAUM, V38, P1441, DOI 10.1089/neu.2008.0536; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; Fernandez-Ortega JF, 2012, J NEUROTRAUM, V29, P1364, DOI 10.1089/neu.2011.2033; Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9; Hendricks HT, 2010, EUR J NEUROL, V17, P1172, DOI 10.1111/j.1468-1331.2010.02989.x; Hinson HE, 2017, J HEAD TRAUMA REHAB, V32, pE50, DOI 10.1097/HTR.0000000000000271; Hinson HE, 2015, BRAIN INJURY, V29, P455, DOI 10.3109/02699052.2014.995229; Hinson HE, 2013, CLIN AUTON RES, V23, P109, DOI 10.1007/s10286-012-0184-4; Huang QY, 2020, BRAIN RES, V1727, DOI 10.1016/j.brainres.2019.146549; Hughes EG, 2010, J NEUROSCI, V30, P5866, DOI 10.1523/JNEUROSCI.0167-10.2010; Lucca LF, 2019, J NEUROTRAUM, V36, P2430, DOI 10.1089/neu.2018.5963; Lv LQ, 2010, J NEUROTRAUM, V27, P1945, DOI 10.1089/neu.2010.1391; Mathew MJ, 2016, ACTA NEUROCHIR, V158, P2047, DOI 10.1007/s00701-016-2934-x; Mehr SR, 2016, CASE REP NEUROL MED, V2016, DOI 10.1155/2016/7967526; Meyfroidt G, 2017, LANCET NEUROL, V16, P721, DOI 10.1016/S1474-4422(17)30259-4; Perkes I, 2010, ANN NEUROL, V68, P126, DOI 10.1002/ana.22066; Pryzbylkowski PG, 2011, ANESTH ANALG, V113, P1188, DOI 10.1213/ANE.0b013e31822b8a7d; Rabinstein AA, 2008, CURR TREAT OPTION N, V10, P151, DOI 10.1007/s11940-008-0016-y; Samuel S, 2018, BRAIN INJURY, V32, P1115, DOI 10.1080/02699052.2018.1482002; Totikov A, 2019, BMC NEUROL, V19, DOI 10.1186/s12883-019-1399-y; van Eijck MM, 2019, J CRIT CARE, V49, P110, DOI 10.1016/j.jcrc.2018.10.018; Wang DM, 2020, J INT MED RES, V48, DOI 10.1177/0300060520925666	28	0	0	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 12	2021	12								665183	10.3389/fimmu.2021.665183	http://dx.doi.org/10.3389/fimmu.2021.665183			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RS3ZI	33912193	gold, Green Published			2022-12-18	WOS:000643719900001
J	Kishimoto, K; Wilder, CL; Buchanan, J; Nguyen, M; Okeke, C; Hoffmann, A; Cheng, QJ				Kishimoto, Kensei; Wilder, Catera L.; Buchanan, Justin; Nguyen, Minh; Okeke, Chidera; Hoffmann, Alexander; Cheng, Quen J.			High Dose IFN-beta Activates GAF to Enhance Expression of ISGF3 Target Genes in MLE12 Epithelial Cells	FRONTIERS IN IMMUNOLOGY			English	Article						interferon; JAK-STAT signaling pathway; signal transduction; gene regulation; ISGF3; GAF	I INTERFERONS	Interferon beta (IFN-beta) signaling activates the transcription factor complex ISGF3 to induce gene expression programs critical for antiviral defense and host immune responses. It has also been observed that IFN-beta activates a second transcription factor complex, gamma-activated factor (GAF), but the significance of this coordinated activation is unclear. We report that in murine lung epithelial cells (MLE12) high doses of IFN-beta indeed activate both ISGF3 and GAF, which bind to distinct genomic locations defined by their respective DNA sequence motifs. In contrast, low doses of IFN-beta preferentially activate ISGF3 but not GAF. Surprisingly, in MLE12 cells GAF binding does not induce nearby gene expression even when strongly bound to the promoter. Yet expression of interferon stimulated genes is enhanced when GAF and ISGF3 are both active compared to ISGF3 alone. We propose that GAF may function as a dose-sensitive amplifier of ISG expression to enhance antiviral immunity and establish pro-inflammatory states.	[Kishimoto, Kensei; Nguyen, Minh; Okeke, Chidera; Hoffmann, Alexander] Univ Calif Los Angeles, Inst Quantitat & Computat Biosci, Los Angeles, CA USA; [Kishimoto, Kensei] Univ Calif Los Angeles, Dept Chem & Biochem, 405 Hilgard Ave, Los Angeles, CA 90024 USA; [Wilder, Catera L.; Buchanan, Justin; Nguyen, Minh; Hoffmann, Alexander; Cheng, Quen J.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; [Okeke, Chidera] Fisk Univ, Dept Life & Phys Sci, Nashville, TN USA; [Cheng, Quen J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Infect Dis, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Fisk University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Cheng, QJ (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.; Cheng, QJ (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Infect Dis, Los Angeles, CA 90095 USA.	quencheng@ucla.edu			NIH [R01AI132835]; UCLA Bruins in Genomics Undergraduate Research Program; Ruth L. Kirschstein National Research Service Award [AI007323]; Chancellor's Postdoctoral Fellowship at UCLA; Irving and Jean Stone Foundation; Oppenheimer Award of the UCLA Undergraduate Research Fellows Program; UCLA Department of Medicine Specialty Training and Advanced Research Program	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UCLA Bruins in Genomics Undergraduate Research Program; Ruth L. Kirschstein National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Chancellor's Postdoctoral Fellowship at UCLA; Irving and Jean Stone Foundation; Oppenheimer Award of the UCLA Undergraduate Research Fellows Program; UCLA Department of Medicine Specialty Training and Advanced Research Program	The work was funded by NIH grant (to AH) R01AI132835. KK, MN, and CO were funded by the UCLA Bruins in Genomics Undergraduate Research Program. CW was supported by Ruth L. Kirschstein National Research Service Award AI007323 and the Chancellor's Postdoctoral Fellowship at UCLA. JB was supported by the Irving and Jean Stone Foundation and the Oppenheimer Award of the UCLA Undergraduate Research Fellows Program. QC was supported by the UCLA Department of Medicine Specialty Training and Advanced Research Program.	Aittomaki S, 2004, INT IMMUNOL, V16, P265, DOI 10.1093/intimm/dxh037; Barrat FJ, 2019, NAT IMMUNOL, V20, P1574, DOI 10.1038/s41590-019-0466-2; Begitt A, 2014, NAT IMMUNOL, V15, P168, DOI 10.1038/ni.2794; Bradley KC, 2019, CELL REP, V28, P245, DOI 10.1016/j.celrep.2019.05.105; Cheng Q, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40503-y; Chuquimia OD, 2013, INFECT IMMUN, V81, P381, DOI 10.1128/IAI.00950-12; Corces MR, 2018, SCIENCE, V362, P420, DOI 10.1126/science.aav1898; DECKER T, 1991, MOL CELL BIOL, V11, P5147, DOI 10.1128/MCB.11.10.5147; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Forero A, 2019, IMMUNITY, V51, P451, DOI 10.1016/j.immuni.2019.07.007; Fulco CP, 2019, NAT GENET, V51, P1664, DOI 10.1038/s41588-019-0538-0; Gough DJ, 2012, IMMUNITY, V36, P166, DOI 10.1016/j.immuni.2012.01.011; Hambleton S, 2013, P NATL ACAD SCI USA, V110, P3053, DOI 10.1073/pnas.1220098110; HAQUE SJ, 1994, J BIOL CHEM, V269, P19523; Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hoyos-Bachiloglu R, 2017, J CLIN INVEST, V127, P4415, DOI 10.1172/JCI93486; Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183; Ivashkiv LB, 2018, NAT REV IMMUNOL, V18, P545, DOI 10.1038/s41577-018-0029-z; Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581; Kolde R., 2019, **DATA OBJECT**; Langlais D, 2016, J EXP MED, V213, P585, DOI 10.1084/jem.20151764; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Leiva-Juarez MM, 2018, MUCOSAL IMMUNOL, V11, P21, DOI 10.1038/mi.2017.71; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Makris S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00259; Martin M., 2011, EMBNET J, V17, P10, DOI [10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]; McNab F, 2015, NAT REV IMMUNOL, V15, P87, DOI 10.1038/nri3787; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Ostuni R, 2013, CELL, V152, P157, DOI 10.1016/j.cell.2012.12.018; Ourthiague DR, 2015, J LEUKOCYTE BIOL, V98, P119, DOI 10.1189/jlb.4A1014-483RR; Platanitis E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10970-y; Platanitis E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02542; Qiao Y, 2013, IMMUNITY, V39, P454, DOI 10.1016/j.immuni.2013.08.009; Ramirez F, 2014, NUCLEIC ACIDS RES, V42, pW187, DOI 10.1093/nar/gku365; Ramirez-Carrozzi VR, 2009, CELL, V138, P114, DOI 10.1016/j.cell.2009.04.020; Ramsauer K, 2007, P NATL ACAD SCI USA, V104, P2849, DOI 10.1073/pnas.0610944104; Raza S, 2014, J LEUKOCYTE BIOL, V96, P167, DOI 10.1189/jlb.6HI0313-169R; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Ronnblom L, 2013, CURR OPIN RHEUMATOL, V25, P248, DOI 10.1097/BOR.0b013e32835c7e32; Sadzak I, 2008, P NATL ACAD SCI USA, V105, P8944, DOI 10.1073/pnas.0801794105; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; Schneider WM, 2014, ANNU REV IMMUNOL, V32, P513, DOI 10.1146/annurev-immunol-032713-120231; Schoenfelder S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06666-4; Semper C, 2014, MOL CELL BIOL, V34, P2235, DOI 10.1128/MCB.00295-14; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Smale ST, 2014, ANNU REV IMMUNOL, V32, P489, DOI 10.1146/annurev-immunol-031210-101303; Steed AL, 2017, SCIENCE, V357, P498, DOI 10.1126/science.aam5336; Stegemann-Koniszewski S, 2016, MBIO, V7, DOI 10.1128/mBio.00276-16; Taniguchi T, 2001, NAT REV MOL CELL BIO, V2, P378, DOI 10.1038/35073080; Thorley AJ, 2007, J IMMUNOL, V178, P463, DOI 10.4049/jimmunol.178.1.463; Vairo D, 2011, BLOOD, V118, P1806, DOI 10.1182/blood-2011-01-330571; Varinou L, 2003, IMMUNITY, V19, P793, DOI 10.1016/S1074-7613(03)00322-4; Waddell SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009753; Whitsett JA, 2015, NAT IMMUNOL, V16, P27, DOI 10.1038/ni.3045; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Zakharova N, 2003, J BIOL CHEM, V278, P43067, DOI 10.1074/jbc.M308166200; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	61	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 9	2021	12								651254	10.3389/fimmu.2021.651254	http://dx.doi.org/10.3389/fimmu.2021.651254			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RQ3EE	33897699	Green Published, gold			2022-12-18	WOS:000642304500001
J	Porritt, RA; Huizar, CC; Dick, EJ; Kumar, S; Escalona, R; Gomez, AC; Marek-Iannucci, S; Rivas, MN; Patterson, J; Forsthuber, TG; Arditi, M; Gorelik, M				Porritt, Rebecca A.; Chase Huizar, Carol; Dick, Edward J.; Kumar, Shyamesh; Escalona, Renee; Gomez, Angela C.; Marek-Iannucci, Stefani; Noval Rivas, Magali; Patterson, Jean; Forsthuber, Thomas G.; Arditi, Moshe; Gorelik, Mark			Inhibition of IL-6 in the LCWE Mouse Model of Kawasaki Disease Inhibits Acute Phase Reactant Serum Amyloid A but Fails to Attenuate Vasculitis	FRONTIERS IN IMMUNOLOGY			English	Article						Kawasaki disease; vasculitis; LCWE; magnetic and microwave proteomics; IL-6; STAT3; anakinra; IL-1		Objective Kawasaki disease (KD) is the most common cause of acquired pediatric heart disease in the developed world. 10% of KD patients are resistant to front-line therapy, and no interventions exist to address secondary complications such as myocardial fibrosis. We sought to identify proteins and pathways associated with disease and anti-IL-1 treatment in a mouse model of KD. Methods Vasculitis was induced via Lactobacillus casei cell wall extract (LCWE) injection in 5-week-old male mice. Groups of mice were injected with LCWE alone, LCWE and IL-1 receptor antagonist anakinra, or saline for controls. Upper heart tissue was assessed by quantitative mass spectrometry analysis. Expression and activation of STAT3 was assessed by immunohistochemistry, immunofluorescence and Western blot, and IL-6 expression by RNA-seq and ELISA. A STAT3 small molecular inhibitor and anti-IL-6R antibody were used to evaluate the role of STAT3 and IL-6 in disease development. Results STAT3 was highly expressed and phosphorylated in cardiac tissue of LCWE-injected mice, and reduced following anakinra treatment. Il6 and Stat3 gene expression was enhanced in abdominal aorta of LCWE-injected mice and reduced with Anakinra treatment. IL-6 serum levels were enhanced in LCWE-injected mice and normalized by anakinra. However, neither inhibition of STAT3 nor blockade of IL-6 altered disease development. Conclusion Proteomic analysis of cardiac tissues demonstrates differential protein expression between KD-like, control and anakinra treated cardiac tissue. STAT3 and IL-6 were highly upregulated with LCWE and normalized by anakinra treatment. However, both STAT3 and IL-6 were dispensable for disease development indicating they may be bystanders of inflammation.	[Porritt, Rebecca A.; Gomez, Angela C.; Marek-Iannucci, Stefani; Noval Rivas, Magali; Arditi, Moshe] Cedars Sinai Med Ctr, Dept Pediat, Div Pediat Infect Dis & Immunol, Los Angeles, CA 90048 USA; [Porritt, Rebecca A.; Gomez, Angela C.; Marek-Iannucci, Stefani; Noval Rivas, Magali; Arditi, Moshe] Cedars Sinai Med Ctr, Infect & Immunol Dis Res Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA; [Chase Huizar, Carol; Forsthuber, Thomas G.] Univ Texas San Antonio, Dept Biol, San Antonio, TX USA; [Dick, Edward J.; Kumar, Shyamesh; Escalona, Renee] Southwest Natl Primate Res Ctr, Texas Biomed Res Inst, San Antonio, TX USA; [Patterson, Jean] Texas Biomed Res Inst, San Antonio, TX USA; [Gorelik, Mark] Columbia Univ, Dept Pediat Allergy Immunol & Rheumatol, Med Ctr, New York, NY 10027 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; University of Texas System; University of Texas at San Antonio (UTSA); Texas Biomedical Research Institute; Texas Biomedical Research Institute; Columbia University	Gorelik, M (corresponding author), Columbia Univ, Dept Pediat Allergy Immunol & Rheumatol, Med Ctr, New York, NY 10027 USA.	mg4082@cumc.columbia.edu	Forsthuber, Thomas/AID-8080-2022		Max and Minnie Tomerlin Voelcker Young Investigator Award; San Antonio Medical Foundation 2018 Medical Research Award; American Heart Association Career Development Award; NIH [R01 HL139766, R01 AI072726]	Max and Minnie Tomerlin Voelcker Young Investigator Award; San Antonio Medical Foundation 2018 Medical Research Award; American Heart Association Career Development Award(American Heart Association); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	1) The work of MG was supported by The Max and Minnie Tomerlin Voelcker Young Investigator Award and The San Antonio Medical Foundation 2018 Medical Research Award. 2) The work of RP was supported by the American Heart Association Career Development Award. 3) The work of MA was supported by the NIH Grant R01 AI072726. 4) The work of MR was supported by the NIH grant R01 HL139766.	Antfolk D, 2017, P NATL ACAD SCI USA, V114, pE4574, DOI 10.1073/pnas.1703057114; Burns JC, 2017, ARTHRITIS RHEUMATOL, V69, P268, DOI 10.1002/art.39975; Chakraborty D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01236-6; Dietz SM, 2017, EUR J PEDIATR, V176, P995, DOI 10.1007/s00431-017-2937-5; Feldstein LR, 2020, NEW ENGL J MED, V383, P334, DOI 10.1056/NEJMoa2021680; Flanagan SE, 2014, NAT GENET, V46, P812, DOI 10.1038/ng.3040; Fu LY, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/4730507; Fuster JJ, 2014, EMBO J, V33, P1425, DOI 10.15252/embj.201488856; Gorelik M, 2019, CLIN EXP IMMUNOL, V198, P101, DOI 10.1111/cei.13314; Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9; Hashimoto Y, 2019, J NIPPON MED SCH, V86, P108, DOI 10.1272/jnms.JNMS.2019_86-206; Hillmer EJ, 2016, CYTOKINE GROWTH F R, V31, P1, DOI 10.1016/j.cytogfr.2016.05.001; Hoang LT, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0102-6; Hutchins AP, 2013, BRIEF FUNCT GENOMICS, V12, P489, DOI 10.1093/bfgp/elt028; Keser G, 2018, RHEUMATOLOGY, V57, P784, DOI 10.1093/rheumatology/kex333; Kibata T, 2016, INT J CARDIOL, V214, P209, DOI 10.1016/j.ijcard.2016.03.017; KIM D S, 1992, Yonsei Medical Journal, V33, P183; Kurdi M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03029; Lee Y, 2015, ARTERIOSCL THROM VAS, V35, P2605, DOI 10.1161/ATVBAHA.115.306475; Lee Y, 2012, CIRCULATION, V125, P1542, DOI 10.1161/CIRCULATIONAHA.111.072769; LEHMAN TJA, 1985, ARTHRITIS RHEUM, V28, P652, DOI 10.1002/art.1780280609; LEHMAN TJA, 1988, CLIN IMMUNOL IMMUNOP, V48, P108, DOI 10.1016/0090-1229(88)90161-4; Li J, 2013, INT J CARDIOL, V168, P2109, DOI 10.1016/j.ijcard.2013.01.006; Liebling EJ, 2019, ANN RHEUM DIS, V78, pE115, DOI 10.1136/annrheumdis-2018-214191; Lin IC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038635; LOPPNOW H, 1989, CELL IMMUNOL, V122, P493, DOI 10.1016/0008-8749(89)90095-6; LOPPNOW H, 1990, J CLIN INVEST, V85, P731, DOI 10.1172/JCI114498; MAURY CPJ, 1988, NEW ENGL J MED, V319, P1670; McCrindle BW, 2017, CIRCULATION, V135, pE927, DOI 10.1161/CIR.0000000000000484; Miyabe C, 2019, J CLIN INVEST, V129, P3610, DOI 10.1172/JCI123778; Monach PA, 2014, CURR OPIN RHEUMATOL, V26, P24, DOI 10.1097/BOR.0000000000000009; Nakaoka Y, 2018, ANN RHEUM DIS, V77, P348, DOI 10.1136/annrheumdis-2017-211878; NEWBURGER JW, 1991, NEW ENGL J MED, V324, P1633, DOI 10.1056/NEJM199106063242305; NEWBURGER JW, 1986, NEW ENGL J MED, V315, P341, DOI 10.1056/NEJM198608073150601; Nozawa T, 2017, NEW ENGL J MED, V377, P1894, DOI 10.1056/NEJMc1709609; Orenstein JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038998; Pedroza M, 2018, RHEUMATOLOGY, V57, P1838, DOI 10.1093/rheumatology/kex347; Pennanen C, 2014, J CELL SCI, V127, P2659, DOI 10.1242/jcs.139394; Pitter B, 2018, ARTERIOSCL THROM VAS, V38, P1147, DOI 10.1161/ATVBAHA.118.310840; Porritt RA, 2020, ARTERIOSCL THROM VAS, V40, P802, DOI 10.1161/ATVBAHA.119.313863; Raphael I, 2012, ELECTROPHORESIS, V33, P3810, DOI 10.1002/elps.201200200; Rifai N, 2006, NAT BIOTECHNOL, V24, P971, DOI 10.1038/nbt1235; Rivas MN, 2017, ARTHRITIS RHEUMATOL, V69, P410, DOI 10.1002/art.39939; Rosenkranz ME, 2005, CIRCULATION, V112, P2966, DOI 10.1161/CIRCULATIONAHA.105.537530; Sanchez-Alvarez C, 2020, ANN RHEUM DIS, V79, DOI 10.1136/annrheumdis-2018-214642; Scheller J, 2011, BBA-MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034; Scuccimarri R, 2012, PEDIATR CLIN N AM, V59, P425, DOI 10.1016/j.pcl.2012.03.009; Shimizu C, 2015, CARDIOVASC PATHOL, V24, P310, DOI 10.1016/j.carpath.2015.02.006; Shimizu C, 2013, HUM PATHOL, V44, P189, DOI 10.1016/j.humpath.2012.05.004; Stock AT, 2019, J IMMUNOL, V202, P3151, DOI 10.4049/jimmunol.1801593; Stone JH, 2017, NEW ENGL J MED, V377, P317, DOI 10.1056/NEJMoa1613849; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295; UENO Y, 1989, CLIN EXP IMMUNOL, V76, P337; Wakita D, 2016, ARTERIOSCL THROM VAS, V36, P886, DOI 10.1161/ATVBAHA.115.307072; Weng KP, 2010, CIRC J, V74, P544, DOI 10.1253/circj.CJ-09-0664; Yeung RSM, 2007, CLIN EXP RHEUMATOL, V25, pS69; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang Y, 2019, ADV CLIN CHEM, V90, P25, DOI 10.1016/bs.acc.2019.01.002	59	0	0	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 9	2021	12								630196	10.3389/fimmu.2021.630196	http://dx.doi.org/10.3389/fimmu.2021.630196			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RQ5CG	33897686	Green Published, gold			2022-12-18	WOS:000642434800001
J	Prasad, M; Wojciech, L; Brzostek, J; Hu, JF; Chua, YL; Tung, DWH; Yap, J; Rybakin, V; Gascoigne, NRJ				Prasad, Mukul; Wojciech, Lukasz; Brzostek, Joanna; Hu, Jianfang; Chua, Yen Leong; Tung, Desmond Wai Hon; Yap, Jiawei; Rybakin, Vasily; Gascoigne, Nicholas R. J.			Expansion of an Unusual Virtual Memory CD8(+) Subpopulation Bearing V alpha 3.2 TCR in Themis-Deficient Mice	FRONTIERS IN IMMUNOLOGY			English	Article						bystander activation; CD8 T cell; self-reactive; themis; T cell receptor		Deletion of the gene for Themis affects T cell selection in the thymus, which would be expected to affect the TCR repertoire. We found an increased proportion of cells expressing V alpha 3.2 (TRAV9N-3) in the peripheral CD8(+) T cell population in mice with germline Themis deficiency. Analysis of the TCR alpha repertoire indicated it was generally reduced in diversity in the absence of Themis, whereas the diversity of sequences using the TRAV9N-3 V-region element was increased. In wild type mice, V alpha 3.2(+) cells showed higher CD5, CD6 and CD44 expression than non-V alpha 3-expressing cells, and this was more marked in cells from Themis-deficient mice. This suggested a virtual memory phenotype, as well as a stronger response to self-pMHC. The V alpha 3.2(+) cells responded more strongly to IL-15, as well as showing bystander effector capability in a Listeria infection. Thus, the unusually large population of V alpha 3.2(+) CD8(+) T cells found in the periphery of Themis-deficient mice reflects not only altered thymic selection, but also allowed identification of a subset of bystander-competent cells that are also present in wild-type mice.	[Prasad, Mukul; Wojciech, Lukasz; Brzostek, Joanna; Chua, Yen Leong; Tung, Desmond Wai Hon; Yap, Jiawei; Gascoigne, Nicholas R. J.] Natl Univ Singapore, Yong Loo Lin Sch Med, Immunol Translat Res Programme, Singapore, Singapore; [Prasad, Mukul; Chua, Yen Leong; Gascoigne, Nicholas R. J.] Natl Univ Singapore, Life Sci Inst, Immunol Programme, Singapore, Singapore; [Prasad, Mukul; Wojciech, Lukasz; Brzostek, Joanna; Chua, Yen Leong; Tung, Desmond Wai Hon; Yap, Jiawei; Rybakin, Vasily; Gascoigne, Nicholas R. J.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol & Immunol, Singapore, Singapore; [Brzostek, Joanna; Hu, Jianfang; Rybakin, Vasily; Gascoigne, Nicholas R. J.] Scripps Res Inst, Dept Immunol & Microbiol, La Jolla, CA 92037 USA; [Brzostek, Joanna] Univ Freiburg, Biol 3, Freiburg, Germany; [Hu, Jianfang] Poseida San Diego, Proc Dev Dept, San Diego, CA USA; [Rybakin, Vasily] Repertoire Immune Med, Cambridge, MA USA	National University of Singapore; National University of Singapore; National University of Singapore; Scripps Research Institute; University of Freiburg	Gascoigne, NRJ (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Immunol Translat Res Programme, Singapore, Singapore.; Gascoigne, NRJ (corresponding author), Natl Univ Singapore, Life Sci Inst, Immunol Programme, Singapore, Singapore.; Gascoigne, NRJ (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol & Immunol, Singapore, Singapore.; Gascoigne, NRJ (corresponding author), Scripps Res Inst, Dept Immunol & Microbiol, La Jolla, CA 92037 USA.	micnrjg@nus.edu.sg		Tung, Desmond/0000-0001-9126-4519; Prasad, Mukul/0000-0002-3048-8540	Singapore Ministry of Health's National Medical Research Council [CBRG/0097/2015]; Singapore Ministry of Education [2014-T2-1-136]; NIH [AI073870, DK094173]	Singapore Ministry of Health's National Medical Research Council(National Medical Research Council, Singapore); Singapore Ministry of Education(Ministry of Education, Singapore); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This research was supported by the Singapore Ministry of Health's National Medical Research Council under its CBRG/0097/2015 and by the Singapore Ministry of Education's grant 2014-T2-1-136, to NG. Work performed at Scripps Research was supported by NIH grants AI073870 and DK094173 to NG.	Akue AD, 2012, J IMMUNOL, V188, P2516, DOI 10.4049/jimmunol.1102213; Azzam HS, 1998, J EXP MED, V188, P2301, DOI 10.1084/jem.188.12.2301; Bolotin DA, 2015, NAT METHODS, V12, P380, DOI 10.1038/nmeth.3364; Brzostek J, 2020, NAT IMMUNOL, V21, P186, DOI 10.1038/s41590-019-0570-3; Chen AM, 2005, J VIROL, V79, P4700, DOI 10.1128/JVI.79.8.4700-4708.2005; Cho BK, 2000, J EXP MED, V192, P549, DOI 10.1084/jem.192.4.549; Cho JH, 2010, IMMUNITY, V32, P214, DOI 10.1016/j.immuni.2009.11.014; Choi S, 2017, NAT IMMUNOL, V18, P433, DOI 10.1038/ni.3692; Chu T, 2013, CELL REP, V3, P701, DOI 10.1016/j.celrep.2013.02.020; Colwell RK, 2012, J PLANT ECOL, V5, P3, DOI 10.1093/jpe/rtr044; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; Drobek A, 2018, EMBO J, V37, DOI 10.15252/embj.201798518; Fohse L, 2011, EUR J IMMUNOL, V41, P3101, DOI 10.1002/eji.201141986; Freeman BE, 2012, P NATL ACAD SCI USA, V109, P9971, DOI 10.1073/pnas.1203543109; Fu G, 2013, NATURE, V504, P441, DOI 10.1038/nature12718; Fu G, 2009, NAT IMMUNOL, V10, P848, DOI 10.1038/ni.1766; Fulton RB, 2015, NAT IMMUNOL, V16, P107, DOI 10.1038/ni.3043; Garcia KC, 2009, NAT IMMUNOL, V10, P143, DOI 10.1038/ni.f.219; Gascoigne NRJ, 2016, ANNU REV CELL DEV BI, V32, P327, DOI 10.1146/annurev-cellbio-111315-125324; Gascoigne NRJ, 2011, CURR OPIN IMMUNOL, V23, P207, DOI 10.1016/j.coi.2010.12.017; Gimferrer I, 2003, J BIOL CHEM, V278, P8564, DOI 10.1074/jbc.M209591200; Goldrath AW, 1999, IMMUNITY, V11, P183, DOI 10.1016/S1074-7613(00)80093-X; Goldrath AW, 1999, NATURE, V402, P255, DOI 10.1038/35005508; Goplen NP, 2016, J IMMUNOL, V197, P2434, DOI 10.4049/jimmunol.1600037; Herndler-Brandstetter D, 2011, HUM IMMUNOL, V72, P627, DOI 10.1016/j.humimm.2011.03.028; Jameson SC, 2015, ADV IMMUNOL, V126, P173, DOI 10.1016/bs.ai.2014.12.001; Jin JH, 2020, CELL MOL IMMUNOL, V17, P1257, DOI 10.1038/s41423-020-0408-9; Johnson AL, 2009, NAT IMMUNOL, V10, P831, DOI 10.1038/ni.1769; Jordan MS, 2001, NAT IMMUNOL, V2, P301, DOI 10.1038/86302; Kassiotis G, 2003, J EXP MED, V197, P1007, DOI 10.1084/jem.20021812; Kieper WC, 2005, J IMMUNOL, V174, P3158, DOI 10.4049/jimmunol.174.6.3158; Kieper WC, 2004, J IMMUNOL, V172, P40, DOI 10.4049/jimmunol.172.1.40; Kieper WC, 1999, P NATL ACAD SCI USA, V96, P13306, DOI 10.1073/pnas.96.23.13306; Koschella M, 2004, J IMMUNOL, V172, P4804, DOI 10.4049/jimmunol.172.8.4804; Lee JY, 2013, P NATL ACAD SCI USA, V110, P13498, DOI 10.1073/pnas.1307572110; Lefranc MP, 2015, NUCLEIC ACIDS RES, V43, pD413, DOI 10.1093/nar/gku1056; Lesourne R, 2009, NAT IMMUNOL, V10, P840, DOI 10.1038/ni.1768; Leung MWL, 2009, J EXP MED, V206, P2121, DOI 10.1084/jem.20091033; Lin W, 2007, NAT IMMUNOL, V8, P359, DOI 10.1038/ni1445; Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511; Matz M, 1999, NUCLEIC ACIDS RES, V27, P1558, DOI 10.1093/nar/27.6.1558; Mehta M, 2018, P NATL ACAD SCI USA, V115, pE11331, DOI 10.1073/pnas.1720209115; Miller CH, 2020, NAT IMMUNOL, V21, P567, DOI 10.1038/s41590-020-0653-1; MITNACHT R, 1995, EUR J IMMUNOL, V25, P328, DOI 10.1002/eji.1830250204; Monjazeb AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102709; Orta-Mascaro M, 2016, J EXP MED, V213, P1387, DOI 10.1084/jem.20151785; Palmer MJ, 2011, IMMUNOL CELL BIOL, V89, P581, DOI 10.1038/icb.2011.5; Paster W, 2015, EMBO J, V34, P393, DOI 10.15252/embj.201387725; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Pope C, 2001, J IMMUNOL, V166, P3402, DOI 10.4049/jimmunol.166.5.3402; Prasad M, 2021, CELL MOL IMMUNOL, V18, P2249, DOI 10.1038/s41423-020-00578-4; Ritmahan W, 2020, IMMUNOGENETICS, V72, P109, DOI 10.1007/s00251-019-01134-9; Rivino L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa0526; Romagnoli P, 2002, J IMMUNOL, V168, P1644, DOI 10.4049/jimmunol.168.4.1644; Rybakin V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114320; Sckisel GD, 2014, CLIN EXP IMMUNOL, V175, P79, DOI 10.1111/cei.12186; Shugay M, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004503; Sim BC, 1998, J IMMUNOL, V160, P1204; Sim BC, 1998, IMMUNOL TODAY, V19, P276, DOI 10.1016/S0167-5699(98)01257-2; Sim BC, 1996, SCIENCE, V273, P963, DOI 10.1126/science.273.5277.963; Sim BC, 1998, CURR BIOL, V8, P701, DOI 10.1016/S0960-9822(98)70276-3; Simoni Y, 2018, NATURE, V557, P575, DOI 10.1038/s41586-018-0130-2; Sosinowski T, 2013, J IMMUNOL, V190, P1936, DOI 10.4049/jimmunol.1203149; Sprent J, 2011, NAT IMMUNOL, V12, P478, DOI 10.1038/ni.2018; Stadinski BD, 2016, NAT IMMUNOL, V17, P946, DOI 10.1038/ni.3491; Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601.141107; Surh CD, 2000, J EXP MED, V192, pF9, DOI 10.1084/jem.192.4.F9; Surh CD, 2008, IMMUNITY, V29, P848, DOI 10.1016/j.immuni.2008.11.002; Tan JT, 2001, P NATL ACAD SCI USA, V98, P8732, DOI 10.1073/pnas.161126098; TARAKHOVSKY A, 1995, SCIENCE, V269, P535, DOI 10.1126/science.7542801; Tough DF, 1996, SCIENCE, V272, P1947, DOI 10.1126/science.272.5270.1947; Walsh MC, 2014, J IMMUNOL, V193, P3992, DOI 10.4049/jimmunol.1400396; Wong J, 2007, J IMMUNOL, V178, P7032, DOI 10.4049/jimmunol.178.11.7032; Wong P, 2001, J EXP MED, V193, P1179, DOI 10.1084/jem.193.10.1179; Zhang XH, 1998, IMMUNITY, V8, P591, DOI 10.1016/S1074-7613(00)80564-6; Zvezdova E, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad1576	77	0	0	2	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 7	2021	12								644483	10.3389/fimmu.2021.644483	http://dx.doi.org/10.3389/fimmu.2021.644483			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RP2QB	33897691	Green Published, gold			2022-12-18	WOS:000641577500001
J	Peng, C; Liu, F; Su, KJ; Lin, X; Song, YQ; Shen, J; Hu, SD; Chen, QC; Yuan, HH; Li, WX; Zeng, CP; Deng, HW; Lou, HL				Peng, Cheng; Liu, Feng; Su, Kuan-Jui; Lin, Xu; Song, Yu-Qian; Shen, Jie; Hu, Shi-Di; Chen, Qiao-Cong; Yuan, Hui-Hui; Li, Wen-Xi; Zeng, Chun-Ping; Deng, Hong-Wen; Lou, Hui-Ling			Enhanced Identification of Novel Potential Variants for Appendicular Lean Mass by Leveraging Pleiotropy With Bone Mineral Density	FRONTIERS IN IMMUNOLOGY			English	Article						appendicular lean mass; bone mineral density; pleiotropy; genome wide association study; novel SNPs	GENOME-WIDE ASSOCIATION; METAANALYSIS	Strong relationships have been found between appendicular lean mass (ALM) and bone mineral density (BMD). It may be due to a shared genetic basis, termed pleiotropy. By leveraging the pleiotropy with BMD, the aim of this study was to detect more potential genetic variants for ALM. Using the conditional false discovery rate (cFDR) methodology, a combined analysis of the summary statistics of two large independent genome wide association studies (GWAS) of ALM (n = 73,420) and BMD (n = 10,414) was conducted. Strong pleiotropic enrichment and 26 novel potential pleiotropic SNPs were found for ALM and BMD. We identified 156 SNPs for ALM (cFDR <0.05), of which 74 were replicates of previous GWASs and 82 were novel SNPs potentially-associated with ALM. Eleven genes annotated by 31 novel SNPs (13 pleiotropic and 18 ALM specific) were partially validated in a gene expression assay. Functional enrichment analysis indicated that genes corresponding to the novel potential SNPs were enriched in GO terms and/or KEGG pathways that played important roles in muscle development and/or BMD metabolism (adjP <0.05). In protein-protein interaction analysis, rich interactions were demonstrated among the proteins produced by the corresponding genes. In conclusion, the present study, as in other recent studies we have conducted, demonstrated superior efficiency and reliability of the cFDR methodology for enhanced detection of trait-associated genetic variants. Our findings shed novel insight into the genetic variability of ALM in addition to the shared genetic basis underlying ALM and BMD.	[Peng, Cheng; Liu, Feng; Chen, Qiao-Cong; Yuan, Hui-Hui; Li, Wen-Xi; Lou, Hui-Ling] South China Univ Technol, Sch Med, Dept Geriatr, Guangzhou Peoples Hosp 1,Natl Key Clin Specialty, Guangzhou, Peoples R China; [Su, Kuan-Jui; Deng, Hong-Wen] Tulane Univ, Ctr Bioinformat & Genom, Dept Global Biostat & Data Sci, New Orleans, LA 70118 USA; [Lin, Xu; Shen, Jie] Southern Med Univ, Shunde Hosp, Peoples Hosp Shunde 1, Foshan, Peoples R China; [Song, Yu-Qian; Hu, Shi-Di] Southern Med Univ, Dept Endocrinol & Metab, Affiliated Hosp 3, Guangzhou, Peoples R China; [Zeng, Chun-Ping] Guangzhou Med Univ, Dept Endocrinol & Metab, Affiliated Hosp 5, Guangzhou, Peoples R China	South China University of Technology; Tulane University; Southern Medical University - China; Southern Medical University - China; Guangzhou Medical University	Lou, HL (corresponding author), South China Univ Technol, Sch Med, Dept Geriatr, Guangzhou Peoples Hosp 1,Natl Key Clin Specialty, Guangzhou, Peoples R China.	huilinglou@163.com			Guangzhou Planed Project of Science and Technology, Guangzhou, China [201903010091, 201704020105]; Medical Science and Technology Foundation of Guangdong Province (CN) [A2019005]; National Institutes of Health [AR069055, U19 AG055373, R01 MH104680, R01AR059781, P20GM109036]; Edward G. Schlieder Endowment Fund; China National Natural Scientific Foundation [81800794, 81770878]; Natural Science Foundation of Guangdong province doctor initiated (vertical collaboration) project [2017A030310390]	Guangzhou Planed Project of Science and Technology, Guangzhou, China; Medical Science and Technology Foundation of Guangdong Province (CN); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Edward G. Schlieder Endowment Fund; China National Natural Scientific Foundation(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong province doctor initiated (vertical collaboration) project	7H-LL, CP, and FL were supported by Guangzhou Planed Project of Science and Technology, Guangzhou, China [201903010091, 201704020105], and Medical Science and Technology Foundation of Guangdong Province (CN), [A2019005]. H-WD was partially supported by grants from the National Institutes of Health [AR069055, U19 AG055373, R01 MH104680, R01AR059781 and P20GM109036] and the Edward G. Schlieder Endowment Fund to Tulane University. S-DH and JS were supported by China National Natural Scientific Foundation [81800794, 81770878]] and Natural Science Foundation of Guangdong province doctor initiated (vertical collaboration) project [2017A030310390].	Amjadi-Moheb F, 2019, J CELL PHYSIOL, V234, P14641, DOI 10.1002/jcp.28207; Andreassen OA, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003455; Arden NK, 1997, J BONE MINER RES, V12, P2076, DOI 10.1359/jbmr.1997.12.12.2076; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Charette JR, 2017, MOL VIS, V23, P140; Girardi F, 2018, PROG MOL BIOL TRANSL, V153, P157, DOI 10.1016/bs.pmbts.2017.11.026; Greenbaum J, 2017, BONE, V99, P62, DOI 10.1016/j.bone.2017.03.052; Guo YF, 2013, HUM GENET, V132, P189, DOI 10.1007/s00439-012-1236-5; Hsu FC, 2005, OBES RES, V13, P312, DOI 10.1038/oby.2005.42; Janssen I, 2004, J AM GERIATR SOC, V52, P80, DOI 10.1111/j.1532-5415.2004.52014.x; Johnson AD, 2008, BIOINFORMATICS, V24, P2938, DOI 10.1093/bioinformatics/btn564; Karasik D, 2019, AM J CLIN NUTR, V109, P276, DOI 10.1093/ajcn/nqy272; Kawane T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31853-0; Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008; Kim IJ, 2017, CALCIFIED TISSUE INT, V101, P581, DOI 10.1007/s00223-017-0314-z; Kim SK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200785; Levasseur R, 2005, JOINT BONE SPINE, V72, P207, DOI 10.1016/j.jbspin.2004.10.008; Liu Da Zhi, 2015, J Neuromuscul Dis, V2, P387; Liu XG, 2009, AM J HUM GENET, V84, P418, DOI 10.1016/j.ajhg.2009.02.004; Medina-Gomez C, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00108-3; Minelli C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147388; Morley JE, 2017, CURR PHARM DESIGN, V23, P4484, DOI 10.2174/1381612823666161123150032; Paternoster L, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003247; Pei YF, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-01334-0; Peng C, 2017, BONE, V103, P70, DOI 10.1016/j.bone.2017.06.016; Ralston SH, 2010, ENDOCR REV, V31, P629, DOI 10.1210/er.2009-0044; Raue U, 2012, J APPL PHYSIOL, V112, P1625, DOI 10.1152/japplphysiol.00435.2011; Reppe S, 2010, BONE, V46, P604, DOI 10.1016/j.bone.2009.11.007; Rivadeneira F, 2009, NAT GENET, V41, P1199, DOI 10.1038/ng.446; Rizzoli R, 2010, BONE, V46, P294, DOI 10.1016/j.bone.2009.10.005; Rogers MB, 2015, J CELL BIOCHEM, V116, P2127, DOI 10.1002/jcb.25164; Schakman O, 2013, INT J BIOCHEM CELL B, V45, P2163, DOI 10.1016/j.biocel.2013.05.036; Singh H, 2017, J MUSCULOSKEL NEURON, V17, P50; Studenski SA, 2014, J GERONTOL A-BIOL, V69, P547, DOI 10.1093/gerona/glu010; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Suzuki A, 2015, MOL CELL BIOL, V35, P1763, DOI 10.1128/MCB.01180-14; Twells RCJ, 2001, GENOMICS, V72, P231, DOI 10.1006/geno.2000.6492; Urano T, 2014, AGING CELL, V13, P739, DOI 10.1111/acel.12228; Videman T, 2007, J BONE MINER RES, V22, P1455, DOI 10.1359/JBMR.070606; Wang J, 2013, NUCLEIC ACIDS RES, V41, pW77, DOI 10.1093/nar/gkt439; Wei JW, 2015, CELL, V161, P1576, DOI 10.1016/j.cell.2015.05.029; Zeng CP, 2017, J DIABETES, V9, P898, DOI 10.1111/1753-0407.12510; Ziembik MA, 2017, BIOCHEM SOC T, V45, P693, DOI 10.1042/BST20160169; Zillikens MC, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00031-7	44	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 6	2021	12								643894	10.3389/fimmu.2021.643894	http://dx.doi.org/10.3389/fimmu.2021.643894			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RO8AH	33889153	Green Published, gold			2022-12-18	WOS:000641262700001
J	Sabljic, AV; Bombicino, SS; Marfia, JI; Guerra, LL; Steinhardt, AP; Faccinetti, NI; Iacono, RF; Poskus, E; Trabucchi, A; Valdez, SN				Victoria Sabljic, Adriana; Sonia Bombicino, Silvina; Ignacio Marfia, Juan; Lucas Guerra, Luciano; Penas Steinhardt, Alberto; Ines Faccinetti, Natalia; Francisco Iacono, Ruben; Poskus, Edgardo; Trabucchi, Aldana; Noemi Valdez, Silvina			Novel Flow Cytometric Immunoassay for Detection of Proinsulin Autoantibodies in Diabetes Mellitus Employing a Recombinant Autoantigen Expressed in E. coli	FRONTIERS IN IMMUNOLOGY			English	Article						diabetes mellitus; autoimmunity; autoantibodies; proinsulin; flow cytometry; immunoassay		Introduction Insulin and proinsulin autoantibodies (IAA/PAA) are usually the first markers to appear in patients with type 1 Diabetes Mellitus (T1DM) and their prevalence ranges from 10 to 60% in the child-adolescent population. The reference method for IAA/PAA detection is the Radioligand Binding Assay (RBA), a highly specific and sensitive technique, but expensive and polluting. The aim of this work was to develop a novel flow cytometric microsphere-based immunoassay (FloCMIA) for PAA detection, employing recombinant human proinsulin (PI), as an alternative method to RBA, less expensive and harmful to the environment. Materials and Methods Human PI was expressed as Thioredoxin fusion protein (TrxPI) in E. coli and a fraction was biotinylated. A double paratope model was used in which samples were incubated with TrxPI-biotin and microspheres adsorbed with TrxPI. The immune complexes were revealed using Streptavidin-Phycoerythrin. The geometric mean of the signals was analyzed, and the results were expressed as Standard Deviation scores (SDs). Sera from 100 normal human control and from 111 type 1 diabetic patients were evaluated by FloCMIA. To correlate the novel assay with RBA, 51 diabetic patients were selected, spanning a wide range of PAA reactivity by RBA. Results The study of ROC curves allowed choosing a cut-off value of 3.0 SDs and the AUC was 0.705, indicating that FloCMIA has fair ability to distinguish between samples from each group. A prevalence of 50% for PAA was obtained in the population of diabetic patients studied. The specificity was 96% and the analytical sensitivity (percentage of patients RBA positive, also positive by FloCMIA) was 69%. There was a substantial agreement between methods (kappa statistic=0.700). Conclusions A novel immunoassay based on flow cytometry that uses easy-to produce recombinant PI was developed. This assay constitutes an innovative and cost-effective alternative to RBA for the determination of PAA in patients' sera. The method developed here, presents good performance and a wide dynamic range together with a small required sample volume. Furthermore, these results make it possible to develop multiplex immunoassays that allow the combined detection of autoantibodies present in T1DM and other related autoimmune diseases.	[Victoria Sabljic, Adriana; Sonia Bombicino, Silvina; Ignacio Marfia, Juan; Lucas Guerra, Luciano; Ines Faccinetti, Natalia; Francisco Iacono, Ruben; Poskus, Edgardo; Trabucchi, Aldana; Noemi Valdez, Silvina] Univ Buenos Aires UBA, Fac Farm & Bioquim, Dept Microbiol Inmunol Biotecnol & Genet, Catedra Inmunol, Buenos Aires, DF, Argentina; [Victoria Sabljic, Adriana; Sonia Bombicino, Silvina; Ignacio Marfia, Juan; Francisco Iacono, Ruben; Poskus, Edgardo; Trabucchi, Aldana; Noemi Valdez, Silvina] Univ Buenos Aires, Consejo Nacl Invest Cient & Tecn CONICET, Inst Estudios Inmuridad Humoral Prof Ricardo A M, Buenos Aires, DF, Argentina; [Penas Steinhardt, Alberto] Univ Nacl Lujan, Dept Ciencas Basicas, Lab Genom Computac, Buenos Aires, DF, Argentina	University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Universidad Nacional de Lujan	Valdez, SN (corresponding author), Univ Buenos Aires UBA, Fac Farm & Bioquim, Dept Microbiol Inmunol Biotecnol & Genet, Catedra Inmunol, Buenos Aires, DF, Argentina.; Valdez, SN (corresponding author), Univ Buenos Aires, Consejo Nacl Invest Cient & Tecn CONICET, Inst Estudios Inmuridad Humoral Prof Ricardo A M, Buenos Aires, DF, Argentina.	silval@ffyb.uba.ar			FONCYT Program of the National Agency for Science and Technology Promotion (ANPCYT) [PICT-2014-1928, PICT-20171436]; National Research Council (CONICET) [PIP 11220120100256CO, PUE 22920160100017CO]; University of Buenos Aires [UBA 20020150100115BA]	FONCYT Program of the National Agency for Science and Technology Promotion (ANPCYT); National Research Council (CONICET)(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); University of Buenos Aires(University of Buenos Aires)	This work was supported in part by grants from FONCYT Program of the National Agency for Science and Technology Promotion (ANPCYT) PICT-2014-1928 and PICT-20171436, National Research Council (CONICET) PIP 11220120100256CO and PUE 22920160100017CO and the University of Buenos Aires (UBA 20020150100115BA).	Achenbach P, 2004, DIABETES, V53, P384, DOI 10.2337/diabetes.53.2.384; [Anonymous], 1985, WHO TECH REP SER, P1; Atkinson MA, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007641; Betterle C, 2006, ACTA DIABETOL, V43, P79, DOI 10.1007/s00592-006-0217-3; BINGLEY P, 1997, DIABETES, V46; Bingley PJ, 2010, J CLIN ENDOCR METAB, V95, P25, DOI 10.1210/jc.2009-1365; Carter JV, 2016, SURGERY, V159, P1638, DOI 10.1016/j.surg.2015.12.029; CASTANO L, 1993, DIABETES, V42, P1202, DOI 10.2337/diabetes.42.8.1202; COHEN J, 1968, PSYCHOL BULL, V70; Eisenbarth GS, 2008, ARQ BRAS ENDOCRINOL, V52, P146, DOI 10.1590/S0004-27302008000200002; Faccinetti NI, 2017, MICROB CELL FACT, V16, DOI 10.1186/s12934-017-0816-4; GREENBAUM CJ, 1992, J CLIN ENDOCR METAB, V74, P1040, DOI 10.1210/jc.74.5.1040; GREENBAUM CJ, 1992, DIABETOLOGIA, V35, P798, DOI 10.1007/BF00429105; Gu Y, 2019, EBIOMEDICINE, V47, P365, DOI 10.1016/j.ebiom.2019.08.036; Guerra LL, 2014, ANALYST, V139, P3017, DOI 10.1039/c3an02243a; HOFFMAN RD, 1992, J BIOL CHEM, V267, P14005; Hummel M, 2004, ANN INTERN MED, V140, P882, DOI 10.7326/0003-4819-140-11-200406010-00009; Knip M, 2002, HORM RES, V57, P6, DOI 10.1159/000053305; Knip M, 2002, DIABETES CARE, V25, P623, DOI 10.2337/diacare.25.3.623; Knip M, 2008, AUTOIMMUN REV, V7, P550, DOI 10.1016/j.autrev.2008.04.008; KOCH G, 1977, BIOMETRICS, V33; Kong Young Hwa, 2013, Ann Pediatr Endocrinol Metab, V18, P65, DOI 10.6065/apem.2013.18.2.65; KURTZ AB, 1988, DIABETOLOGIA, V31, P395, DOI 10.1007/BF02341510; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Miao DM, 2015, DIABETES TECHNOL THE, V17, P119, DOI 10.1089/dia.2014.0186; PALMER J, 1983, SCIENCE, V222; PIHOKER C, 2005, DIABETES, V54; Schlosser M, 2010, DIABETOLOGIA, V53, P2611, DOI 10.1007/s00125-010-1915-5; STUMPO RD, 1994, J IMMUNOL METHODS, V169, P241; Torn C, 2008, DIABETOLOGIA, V51, P846, DOI 10.1007/s00125-008-0967-2; Trabucchi A, 2012, APPL MICROBIOL BIOT, V94, P1565, DOI 10.1007/s00253-011-3721-5; Valdez SN, 2003, J IMMUNOL METHODS, V279, P173, DOI 10.1016/S0022-1759(03)00197-2; VARDI P, 1988, DIABETES CARE, V11, P736, DOI 10.2337/diacare.11.9.736; WILLIAMS A, 1997, J AUTOIMMUN, V10; Yu LP, 2012, DIABETES, V61, P179, DOI 10.2337/db11-0670; ZIEGLER A, 1999, DIABETES, V48; Ziegler AG, 2010, IMMUNITY, V32, P468, DOI 10.1016/j.immuni.2010.03.018	37	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 6	2021	12								648021	10.3389/fimmu.2021.648021	http://dx.doi.org/10.3389/fimmu.2021.648021			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RP0PM	33889155	gold, Green Published			2022-12-18	WOS:000641438900001
J	Boluda-Navarro, M; Ibanez, M; Liquori, A; Franco-Jarava, C; Martinez-Gallo, M; Rodriguez-Vega, H; Teresa, J; Carreras, C; Such, E; Zuniga, A; Colobran, R; Cervera, JV				Boluda-Navarro, Mireia; Ibanez, Mariam; Liquori, Alessandro; Franco-Jarava, Clara; Martinez-Gallo, Monica; Rodriguez-Vega, Hector; Teresa, Jaijo; Carreras, Carmen; Such, Esperanza; Zuniga, Angel; Colobran, Roger; Cervera, Jose Vicente			Case Report: Partial Uniparental Disomy Unmasks a Novel Recessive Mutation in the LYST Gene in a Patient With a Severe Phenotype of Chediak-Higashi Syndrome	FRONTIERS IN IMMUNOLOGY			English	Article						Ch&#233; diak-Higashi syndrome; CHS; primary immunodeficiency; hemophagocytic lymphohistiocytosis; LYST; SNP-array; uniparental disomy; loss of heterozygosity		Chediak-Higashi syndrome (CHS) is a rare autosomal recessive (AR) immune disorder that has usually been associated to missense, nonsense or indels mutations in the LYST gene. In this study, we describe for the first time the case of a CHS patient carrying a homozygous mutation in the LYST gene inherited as a result of a partial uniparental isodisomy (UPiD) of maternal origin. Sanger sequencing of the LYST cDNA and single nucleotide polymorphism (SNP)-arrays were performed to identify the causative mutation and to explain the molecular mechanism of inheritance, respectively. Partial-UPiD leads to a copy neutral loss of heterozygosity (CN-LOH) of the telomeric region of chromosome 1 (1q41q44), unmasking the potential effect of the mutation detected. The mutation (c.8380dupT) is an insertion located in exon 32 of the LYST gene resulting in a premature stop codon and leading to the loss of all the conserved domains at the C-terminal of the LYST protein. This would account for the severe phenotype observed. We also reviewed the only two previously reported cases of CHS as a result of a uniparental disomy. In this study, we show that the combination of different strategies, including the use of SNP-arrays, is pivotal to fine-tune the diagnosis of rare AR disorders, such as CHS. Moreover, this case highlights the relevance of uniparental disomy as a potential mechanism of CHS expression in non-consanguineous families.	[Boluda-Navarro, Mireia; Ibanez, Mariam; Liquori, Alessandro] Inst Invest Sanitaria La Fe, Accredited Res Grp Hematol & Hemotherapy, Valencia, Spain; [Ibanez, Mariam; Such, Esperanza; Cervera, Jose Vicente] Hosp Univ & Politecn La Fe, Dept Hematol, Barcelona, Spain; [Ibanez, Mariam; Such, Esperanza] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain; [Ibanez, Mariam] Univ Valencia, Dept Med, Valencia, Spain; [Ibanez, Mariam] Univ CEU Cardenal Herrera, Fac Ciencias Salud, Dept Ciencias Biomed, Valencia, Spain; [Franco-Jarava, Clara; Martinez-Gallo, Monica; Colobran, Roger] Hosp Univ Vall dHebron HUVH, Div Immunol, Diagnost Immunol, Vall dHebron Res Inst VHIR, Barcelona, Spain; [Franco-Jarava, Clara; Martinez-Gallo, Monica; Colobran, Roger] Autonomous Univ Barcelona UAB, Dept Cell Biol Physiol & Immunol, Barcelona, Spain; [Rodriguez-Vega, Hector; Carreras, Carmen] Hosp Univ & Politecn La Fe, Pediat Hematol Unit, Valencia, Spain; [Teresa, Jaijo; Zuniga, Angel; Cervera, Jose Vicente] Hosp Univ & Politecn La Fe, Genet Unit, Valencia, Spain; [Colobran, Roger] Hosp Univ Vall dHebron HUVH, Dept Clin & Mol Genet, Barcelona, Spain	Hospital Universitari i Politecnic La Fe; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; University of Valencia; Universidad CEU Cardenal Herrera; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Autonomous University of Barcelona; Hospital Universitari i Politecnic La Fe; Hospital Universitari i Politecnic La Fe; Hospital Universitari Vall d'Hebron	Cervera, JV (corresponding author), Hosp Univ & Politecn La Fe, Dept Hematol, Barcelona, Spain.; Colobran, R (corresponding author), Hosp Univ Vall dHebron HUVH, Div Immunol, Diagnost Immunol, Vall dHebron Res Inst VHIR, Barcelona, Spain.; Colobran, R (corresponding author), Autonomous Univ Barcelona UAB, Dept Cell Biol Physiol & Immunol, Barcelona, Spain.; Cervera, JV (corresponding author), Hosp Univ & Politecn La Fe, Genet Unit, Valencia, Spain.; Colobran, R (corresponding author), Hosp Univ Vall dHebron HUVH, Dept Clin & Mol Genet, Barcelona, Spain.	rcolobran@vhebron.net; cervera_jos@gva.es	Cervera, Jose/ABF-2143-2020; Liquori, Alessandro/K-7934-2015; Colobran, Roger/HGB-6371-2022; IBAÑEZ COMPANY, MARIAM/AAW-9082-2021	Cervera, Jose/0000-0001-8252-1106; Liquori, Alessandro/0000-0002-4842-5986; IBAÑEZ COMPANY, MARIAM/0000-0002-7486-4659; Colobran, Roger/0000-0002-5964-536X; Martinez Gallo, Monica/0000-0002-7340-2161; Such, Esperanza/0000-0001-6892-403X; Franco-Jarava, Clara/0000-0002-9788-189X	FEDER funds (CIBERONC) [CB16/12/00284]; Instituto de Salud Carlos III [PI16/01113, PI17/00660, PI18/1472, PI19/00812]; European Regional Development Fund (ERDF); Conselleria de Educacion, Cultura y Deporte [GV/2019/084]; Asociacio'n Espanola Contra El Cancer; Fundacio'n Espanola de Hematologia y Hemoterapia	FEDER funds (CIBERONC); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); European Regional Development Fund (ERDF)(European Commission); Conselleria de Educacion, Cultura y Deporte; Asociacio'n Espanola Contra El Cancer; Fundacio'n Espanola de Hematologia y Hemoterapia	This study was supported by research funding from FEDER funds (CIBERONC, CB16/12/00284), Instituto de Salud Carlos III grants PI16/01113, PI17/00660, PI18/1472, PI19/00812 cofinanced by the European Regional Development Fund (ERDF); as well as from the "Conselleria de Educacion, Cultura y Deporte" GV/2019/084. MBN and AL are recipients of a fellowship from the "Asociacio ' n Espanola Contra El Cancer" and the "Fundacio ' n Espanola de Hematologia y Hemoterapia", respectively.	Arico M, 1996, LEUKEMIA, V10, P197; Bergsten E, 2017, BLOOD, V130, P2728, DOI 10.1182/blood-2017-06-788349; Conlin LK, 2010, HUM MOL GENET, V19, P1263, DOI 10.1093/hmg/ddq003; Cullinane AR, 2013, TRAFFIC, V14, P749, DOI 10.1111/tra.12069; del Gaudio D, 2020, GENET MED, V22, P1133, DOI 10.1038/s41436-020-0782-9; Dufourcq-Lagelouse R, 1999, EUR J HUM GENET, V7, P633, DOI 10.1038/sj.ejhg.5200355; Durchfort N, 2012, TRAFFIC, V13, P108, DOI 10.1111/j.1600-0854.2011.01300.x; Eggermann T, 2015, TRENDS MOL MED, V21, P77, DOI 10.1016/j.molmed.2014.11.010; ENGEL E, 1980, AM J MED GENET, V6, P137, DOI 10.1002/ajmg.1320060207; Gelb BD, 1998, AM J HUM GENET, V62, P848, DOI 10.1086/301795; GeneCards, HUM GEN GEN DAT GEN; Gudipati RK, 2012, MOL CELL, V48, P409, DOI 10.1016/j.molcel.2012.08.018; Hauck F, 2012, J ALLERGY CLIN IMMUN, V130, P1144, DOI 10.1016/j.jaci.2012.07.029; Henry I., 1993, European Journal of Human Genetics, V1, P19; Henter JI, 2002, BLOOD, V100, P2367, DOI 10.1182/blood-2002-01-0172; Jay JJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160519; Jessen B, 2011, BLOOD, V118, P4620, DOI 10.1182/blood-2011-05-356113; Karim MA, 2002, AM J MED GENET, V108, P16, DOI 10.1002/ajmg.10184; Keren B, 2013, EUR J MED GENET, V56, P546, DOI 10.1016/j.ejmg.2013.06.005; Landrum MJ, 2018, NUCLEIC ACIDS RES, V46, pD1062, DOI 10.1093/nar/gkx1153; Lapunzina P, 2011, BIOL CELL, V103, P303, DOI 10.1042/BC20110013; Makishima H, 2011, CLIN CANCER RES, V17, P3913, DOI 10.1158/1078-0432.CCR-10-2900; Mannurita SC, 2014, EUR J HUM GENET, V22, P197, DOI 10.1038/ejhg.2013.123; Manoli I, 2010, AM J MED GENET A, V152A, P1474, DOI 10.1002/ajmg.a.33389; Monk D, 2019, NAT REV GENET, V20, P235, DOI 10.1038/s41576-018-0092-0; Nagle DL, 1996, NAT GENET, V14, P307, DOI 10.1038/ng1196-307; Nakka P, 2019, AM J HUM GENET, V105, P921, DOI 10.1016/j.ajhg.2019.09.016; Niida Y, 2018, CYTOGENET GENOME RES, V154, P137, DOI 10.1159/000488572; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Roberts JL, 2012, P NATL ACAD SCI USA, V109, P10456, DOI 10.1073/pnas.1202249109; Robinson WP, 2000, BIOESSAYS, V22, P452; Sanchez-Guiu I, 2014, EUR J HAEMATOL, V92, P49, DOI 10.1111/ejh.12203; Scuffins J, 2021, GENET MED, V23, P1101, DOI 10.1038/s41436-020-01092-8; Soler-Palacin P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02397; Su JS, 2017, MOL CYTOGENET, V10, DOI 10.1186/s13039-017-0337-1; Travaglini L, 2017, BRAIN DEV-JPN, V39, P182, DOI 10.1016/j.braindev.2016.08.010; Turner CLS, 2007, AM J MED GENET A, V143A, P2172, DOI 10.1002/ajmg.a.31912; Wassink TH, 2005, HUM GENET, V117, P200, DOI 10.1007/s00439-005-1257-4; Yauy K, 2020, GENET MED, V22, P803, DOI 10.1038/s41436-019-0704-x; Zarzour W, 2005, MOL GENET METAB, V85, P125, DOI 10.1016/j.ymgme.2005.02.011	40	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 31	2021	12								625591	10.3389/fimmu.2021.625591	http://dx.doi.org/10.3389/fimmu.2021.625591			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RM7IW	33868243	Green Published, gold			2022-12-18	WOS:000639833700001
J	Niu, L; Xuan, X; Wang, J; Li, L; Yang, D; Jing, Y; Westerberg, LS; Liu, C				Niu, L.; Xuan, X.; Wang, J.; Li, L.; Yang, D.; Jing, Y.; Westerberg, L. S.; Liu, C.		Frontiers Editorial Off	RETRACTION: Retraction: Akt2 Regulates the Differentiation and Function of NKT17 Cells via FoxO-1-ICOS Axis (Retraction of Vol 9, art no 1940, 2018)	FRONTIERS IN IMMUNOLOGY			English	Retraction																		Niu LL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01940	1	0	0	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 31	2021	12								686304	10.3389/fimmu.2021.686304	http://dx.doi.org/10.3389/fimmu.2021.686304			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RM6ZS		gold, Green Published			2022-12-18	WOS:000639809800001
J	Purohit, S; Tran, PMH; Tran, LKH; Bin Satter, K; He, MF; Zhi, WB; Bai, S; Hopkins, D; Gardiner, M; Wakade, C; Bryant, J; Bernard, R; Morgan, J; Bode, B; Reed, JC; She, JX				Purohit, Sharad; Tran, Paul Minh Huy; Tran, Lynn Kim Hoang; Bin Satter, Khaled; He, Mingfang; Zhi, Wenbo; Bai, Shan; Hopkins, Diane; Gardiner, Melissa; Wakade, Chandramohan; Bryant, Jennifer; Bernard, Risa; Morgan, John; Bode, Bruce; Reed, John Chip; She, Jin-Xiong			Serum Levels of Inflammatory Proteins Are Associated With Peripheral Neuropathy in a Cross-Sectional Type-1 Diabetes Cohort	FRONTIERS IN IMMUNOLOGY			English	Article						autoimmunity; chronic inflammation; type-1 diabetes; cytokines; receptors; peripheral neuropathy	MICROVASCULAR COMPLICATIONS; TNF-ALPHA	Chronic low-grade inflammation is involved in the pathogenesis of type-1 diabetes (T1D) and its complications. In this cross-section study design, we investigated association between serum levels of soluble cytokine receptors with presence of peripheral neuropathy in 694 type-1 diabetes patients. Sex, age, blood pressure, smoking, alcohol intake, HbA1c and lipid profile, presence of DPN (peripheral and autonomic), retinopathy and nephropathy was obtained from patient's chart. Measurement of soluble cytokine receptors, markers of systemic and vascular inflammation was done using multiplex immunoassays. Serum levels were elevated in in DPN patients, independent of gender, age and duration of diabetes. Crude odds ratios were significantly associated with presence of DPN for 15/22 proteins. The Odds ratio (OR) remained unchanged for sTNFRI (1.72, p=0.00001), sTNFRII (1.45, p=0.0027), sIL2R alpha (1.40, p=0.0023), IGFBP6 (1.51, p=0.0032) and CRP (1.47, p=0.0046) after adjusting for confounding variables, HbA1C, hypertension and dyslipidemia. Further we showed risk of DPN is associated with increase in serum levels of sTNFRI (OR=11.2, p<10), sIL2R alpha (8.69, p<10(-15)), sNTFRII (4.8, p<10(-8)) and MMP2 (4.5, p<10(-5)). We combined the serum concentration using ridge regression, into a composite score, which can stratify the DPN patients into low, medium and high-risk groups. Our results here show activation of inflammatory pathway in DPN patients, and could be a potential clinical tool to identify T1D patients for therapeutic intervention of anti-inflammatory therapies.	[Purohit, Sharad; Tran, Paul Minh Huy; Tran, Lynn Kim Hoang; Bin Satter, Khaled; He, Mingfang; Zhi, Wenbo; Bai, Shan; Hopkins, Diane; Gardiner, Melissa; Wakade, Chandramohan; Bryant, Jennifer; Bernard, Risa; She, Jin-Xiong] Augusta Univ, Ctr Biotechnol & Genom Med, Augusta, GA 30912 USA; [Purohit, Sharad; She, Jin-Xiong] Augusta Univ, Dept Obstet & Gynecol, Med Coll Georgia, Augusta, GA 30912 USA; [Purohit, Sharad] Augusta Univ, Dept Undergrad Hlth Profess, Coll Allied Hlth Sci, Augusta, GA 30912 USA; [Morgan, John] Augusta Univ, Dept Neurol, Med Coll Georgia, Augusta, GA USA; [Bode, Bruce] Atlanta Diabet Associates, Atlanta, GA USA; [Reed, John Chip] Southeastern Endocrine & Diabet, Atlanta, GA USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Purohit, S; She, JX (corresponding author), Augusta Univ, Ctr Biotechnol & Genom Med, Augusta, GA 30912 USA.; Purohit, S; She, JX (corresponding author), Augusta Univ, Dept Obstet & Gynecol, Med Coll Georgia, Augusta, GA 30912 USA.; Purohit, S (corresponding author), Augusta Univ, Dept Undergrad Hlth Profess, Coll Allied Hlth Sci, Augusta, GA 30912 USA.	spurohit@augusta.edu; jshe@augusta.edu	Purohit, Sharad/ABA-8054-2021	Bin Satter, Khaled/0000-0002-2344-3002; Tran, Paul/0000-0003-2197-4376; Purohit, Sharad/0000-0003-0385-3829	National Institutes of Health [R21HD050196, R33HD050196, 2RO1HD37800]; JDRF [1-2004-661, 2-2011-153, 10-2006-792, 32004-195, 3-2009-275]; NIH/NIDDK fellowship [F30DK12146101A1]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); JDRF(Juvenile Diabetes Research Foundation); NIH/NIDDK fellowship	This work was supported by grants from the National Institutes of Health (R21HD050196, R33HD050196, and 2RO1HD37800) and JDRF (1-2004-661) to J-XS. SP (2-2011-153, 10-2006-792 and 32004-195) and WZ (3-2009-275) were supported by Postdoctoral Fellowship and Career Development Award from JDRF. PT was supported by NIH/NIDDK fellowship (F30DK12146101A1).	ADERKA D, 1992, J EXP MED, V175, P323, DOI 10.1084/jem.175.2.323; Aulich J, 2019, PEDIATR DIABETES, V20, P1118, DOI 10.1111/pedi.12913; Bongaerts BWC, 2013, DIABETES CARE, V36, P1141, DOI 10.2337/dc12-0744; Boulton AJM, 2004, DIABETES CARE, V27, P1458, DOI 10.2337/diacare.27.6.1458; Burrack AL, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00343; Christensen MMB, 2018, DIABETES TECHNOL THE, V20, P787, DOI 10.1089/dia.2018.0249; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Goldberg RB, 2009, J CLIN ENDOCR METAB, V94, P3171, DOI 10.1210/jc.2008-2534; Gonzalez-Clemente JM, 2005, CLIN ENDOCRINOL, V63, P525, DOI 10.1111/j.1365-2265.2005.02376.x; Herman WH, 2005, DIABETES CARE, V28, P1480, DOI 10.2337/diacare.28.6.1480; Jaiswal M, 2017, DIABETES CARE, V40, P1226, DOI 10.2337/dc17-0179; Jeyam A, 2020, DIABETES CARE, V43, P734, DOI 10.2337/dc19-1582; Jin HY, 2018, J DIABETES INVEST, V9, P1016, DOI 10.1111/jdi.12794; Laing SP, 2003, DIABETOLOGIA, V46, P760, DOI 10.1007/s00125-003-1116-6; Marcovecchio ML, 2010, BRIT MED BULL, V94, P145, DOI 10.1093/bmb/ldp053; Martin CL, 2014, DIABETES CARE, V37, P31, DOI 10.2337/dc13-2114; MASER RE, 1989, DIABETES, V38, P1456, DOI 10.2337/diabetes.38.11.1456; Mattila TK, 2010, DRUGS, V70, P2229, DOI 10.2165/11585220-000000000-00000; McCrimmon RJ, 2012, LANCET, V379, P2291, DOI 10.1016/S0140-6736(12)60360-2; Melendez-Ramirez LY, 2010, ENDOCRIN METAB CLIN, V39, P625, DOI 10.1016/j.ecl.2010.05.009; Mizokami-Stout KR, 2020, DIABETES CARE, V43, P806, DOI 10.2337/dc19-1583; Perkins BA, 2020, DIABETES CARE, V43, P695, DOI 10.2337/dci19-0076; Pop-Busui R, 2016, INT REV NEUROBIOL, V127, P9, DOI 10.1016/bs.irn.2016.02.020; Pop-Busui R, 2017, DIABETES CARE, V40, P136, DOI 10.2337/dc16-2042; Pop-Busui R, 2016, CURR DIABETES REP, V16, DOI 10.1007/s11892-016-0727-5; Purohit S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00154; Purohit S, 2015, J CLIN ENDOCR METAB, V100, pE1179, DOI 10.1210/JC.2015-1388; Reeh H, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0356-0; Satoh Jo, 2003, Exp Diabesity Res, V4, P65, DOI 10.1155/EDR.2003.65; Schram MT, 2005, DIABETOLOGIA, V48, P370, DOI 10.1007/s00125-004-1628-8; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Sharma A, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00002; Sharma S, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/279393; Su H, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00405; Tesfaye S, 1996, DIABETOLOGIA, V39, P1377, DOI 10.1007/s001250050586; Zhi WB, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.012203; Zoppini G, 2001, J CLIN ENDOCR METAB, V86, P3805, DOI 10.1210/jc.86.8.3805	37	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 31	2021	12								654233	10.3389/fimmu.2021.654233	http://dx.doi.org/10.3389/fimmu.2021.654233			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RM6ZV	33868296	Green Published, gold			2022-12-18	WOS:000639810100001
J	Han, JX; Zuniga-Pflucker, JC				Han, Jianxun; Zuniga-Pflucker, Juan Carlos			High-Oxygen Submersion Fetal Thymus Organ Cultures Enable FOXN1-Dependent and -Independent Support of T Lymphopoiesis	FRONTIERS IN IMMUNOLOGY			English	Article						FOXN1; Delta-like 4; T cell development; FTOC; oxygen; thymus epithelial cells		T cell development is effectively supported in fetal thymus organ cultures (FTOCs), which places thymus lobes atop an air-liquid interface (ALI) culture system. The direct exposure to air is critical for its success, as fetal thymus lobes placed in low oxygen submersion (LOS)-FTOCs fail to support thymocyte development. However, submersion cultures performed in the presence of high concentration of ambient oxygen (60 similar to 80%) allow for normal thymocyte development, but the underlying mechanism for this rescue has remained elusive. Here, we show that FOXN1 expression in thymic epithelial cells (TECs) from LOS-FTOCs was greatly reduced compared to conventional ALI-FTOCs. Consequently, the expression of important FOXN1 target genes, including Dll4 and Ccl25, in TECs was extinguished. The loss of DLL4 and CCL25 interrupted thymocyte differentiation and led to CD4(+)CD8(+) cells exiting the lobes, respectively. High oxygen submersion (HOS)-FTOCs restored the expression of FOXN1 and its target genes, as well as maintained high levels of MHCII expression in TECs. In addition, HOS-FTOCs promoted the self-renewal of CD4(-)CD8(-)CD44(-)CD25(+) cells, allowing for the continuous generation of later stage thymocytes. Forced FOXN1 expression in TECs rescued thymocyte developmental progression, but not cellularity, in LOS-FTOCs. Given that oxidative stress has been reported to accelerate the onset of age-associated thymic involution, we postulate that regulation of FOXN1 by oxygen and antioxidants may underpin this biological process.	[Han, Jianxun; Zuniga-Pflucker, Juan Carlos] Sunnybrook Res Inst, Dept Biol Sci, Toronto, ON, Canada; [Zuniga-Pflucker, Juan Carlos] Univ Toronto, Dept Immunol, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Zuniga-Pflucker, JC (corresponding author), Sunnybrook Res Inst, Dept Biol Sci, Toronto, ON, Canada.; Zuniga-Pflucker, JC (corresponding author), Univ Toronto, Dept Immunol, Toronto, ON, Canada.	jczp@sri.utoronto.ca			Natural Sciences and Engineering Research Council of Canada (NSERC) [RGPIN-2016-06592]; Canadian Institutes of Health Research (CHIR) [FND-154332]; Canada Research Chair in Developmental Immunology	Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canadian Institutes of Health Research (CHIR)(Canadian Institutes of Health Research (CIHR)); Canada Research Chair in Developmental Immunology(Canada Research Chairs)	This work was supported by grants from the Natural Sciences and Engineering Research Council of Canada (NSERC, RGPIN-2016-06592), and the Canadian Institutes of Health Research (CHIR, FND-154332). JCZ-P is supported by a Canada Research Chair in Developmental Immunology.	AUERBACH R, 1960, DEV BIOL, V2, P271, DOI 10.1016/0012-1606(60)90009-9; Belteki G, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni051; Boehm T, 2012, J EXP MED, V209, P1397, DOI 10.1084/jem.20121412; Bredenkamp N, 2014, DEVELOPMENT, V141, P1627, DOI 10.1242/dev.103614; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; CEREDIG R, 1989, J IMMUNOL, V142, P3353; Ciofani M, 2004, J IMMUNOL, V172, P5230, DOI 10.4049/jimmunol.172.9.5230; Ciofani M, 2005, NAT IMMUNOL, V6, P881, DOI 10.1038/ni1234; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; Gogate SS, 2011, ARTHRITIS RHEUM-US, V63, P1950, DOI 10.1002/art.30342; Gordon J, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-69; Griffith AV, 2015, CELL REP, V12, P1071, DOI 10.1016/j.celrep.2015.07.008; Hao ZY, 2001, J EXP MED, V194, P1151, DOI 10.1084/jem.194.8.1151; Hirakawa M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29460-0; Hozumi K, 2008, J EXP MED, V205, P2507, DOI 10.1084/jem.20080134; Joseph C, 2013, CELL STEM CELL, V13, P520, DOI 10.1016/j.stem.2013.10.010; Koch U, 2008, J EXP MED, V205, P2515, DOI 10.1084/jem.20080829; Liu CL, 2006, BLOOD, V108, P2531, DOI 10.1182/blood-2006-05-024190; MANDEL TE, 1978, IMMUNOLOGY, V35, P317; Martins VC, 2012, J EXP MED, V209, P1409, DOI 10.1084/jem.20120846; Mohtashami M, 2006, J IMMUNOL, V176, P730, DOI 10.4049/jimmunol.176.2.730; Peaudecerf L, 2012, J EXP MED, V209, P1401, DOI 10.1084/jem.20120845; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Place TL, 2017, FREE RADICAL BIO MED, V113, P311, DOI 10.1016/j.freeradbiomed.2017.10.003; Ridgway J, 2006, NATURE, V444, P1083, DOI 10.1038/nature05313; Rode I, 2015, J IMMUNOL, V195, P5678, DOI 10.4049/jimmunol.1502010; RODEWALD HR, 1995, IMMUNITY, V3, P313, DOI 10.1016/1074-7613(95)90116-7; Schodel J, 2011, BLOOD, V117, pE207, DOI 10.1182/blood-2010-10-314427; Shah DK, 2014, J IMMUNOL, V192, P4017, DOI 10.4049/jimmunol.1302259; Skubutyte R, 2010, ARTHRITIS RHEUM-US, V62, P2707, DOI 10.1002/art.27558; Takahama Y, 2006, NAT REV IMMUNOL, V6, P127, DOI 10.1038/nri1781; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; WATANABE Y, 1993, EUR J IMMUNOL, V23, P200, DOI 10.1002/eji.1830230131; WATSON JD, 1989, J IMMUNOL, V143, P1215; Zuklys S, 2016, NAT IMMUNOL, V17, P1206, DOI 10.1038/ni.3537	36	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 30	2021	12								652665	10.3389/fimmu.2021.652665	http://dx.doi.org/10.3389/fimmu.2021.652665			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RM3KI	33859647	Green Published			2022-12-18	WOS:000639561800001
J	Yang, SJ; Chen, YY; Hsu, CH; Hsu, CW; Chang, CY; Chang, JR; Dou, HY				Yang, Shiu-Ju; Chen, Yih-Yuan; Hsu, Chih-Hao; Hsu, Chia-Wei; Chang, Chun-Yu; Chang, Jia-Ru; Dou, Horng-Yunn			Activation of M1 Macrophages in Response to Recombinant TB Vaccines With Enhanced Antimycobacterial Activity (vol 11, 1298, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						recombinant Bacille Calmette-Guerin; Mycobacterium tuberculosis; innate immunity; macrophage; vaccine			[Yang, Shiu-Ju; Hsu, Chih-Hao; Hsu, Chia-Wei; Chang, Chun-Yu; Chang, Jia-Ru; Dou, Horng-Yunn] Natl Hlth Res Inst, Natl Inst Infect Dis & Vaccinol, Zhunan, Taiwan; [Chen, Yih-Yuan] Natl Chiayi Univ, Dept Biochem Sci & Technol, Chiayi, Taiwan	National Health Research Institutes - Taiwan; National Chiayi University	Dou, HY (corresponding author), Natl Hlth Res Inst, Natl Inst Infect Dis & Vaccinol, Zhunan, Taiwan.	hydou@nhri.edu.tw						Yang SJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01298	1	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 30	2021	12								669616	10.3389/fimmu.2021.669616	http://dx.doi.org/10.3389/fimmu.2021.669616			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RM3JP	33859654	Green Published, gold			2022-12-18	WOS:000639559900001
J	Hu, MY; Liu, SX; Lu, DL; Zhong, Y; Yu, DF; Qiu, W; Lu, ZQ; Zhang, BJ				Hu, Mengyan; Liu, Sanxin; Lu, Danli; Zhong, Yi; Yu, Dafan; Qiu, Wei; Lu, Zhengqi; Zhang, Bingjun			Case Report: Central Nervous System Immune Reconstitution Inflammatory Syndrome Related to Bacterial Meningitis	FRONTIERS IN IMMUNOLOGY			English	Article						immune reconstitution inflammatory syndrome; bacterial meningitis; Staphylococcus aureus; pregnancy; case report		Central nervous system immune reconstitution inflammatory syndrome (CNS-IRIS) describes clinical characteristics that may be observed in previously immunocompromised patients during rapid restoration of immunity function in the presence of a pathogen. There have been no reports about CNS-IRIS related to bacterial meningitis so far. Here, we report a 24-year-old pregnant female patient with bacterial meningitis. Her clinical and neuroradiological condition worsened after induced labor despite great effective anti-infective therapy. CNS-IRIS was considered. Corticosteroids were administered, and the patient gradually recovered. We present the first case of CNS-IRIS associated with bacterial meningitis.	[Hu, Mengyan; Liu, Sanxin; Lu, Danli; Yu, Dafan; Qiu, Wei; Lu, Zhengqi; Zhang, Bingjun] Sun Yat Sen Univ, Affiliated Hosp 3, Ctr Mental & Neurol Disorders & Dis, Dept Neurol, Guangzhou, Peoples R China; [Zhong, Yi] Guangzhou Women & Childrens Med Ctr, Dept Dermatol, Guangzhou, Peoples R China	Sun Yat Sen University	Zhang, BJ (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Ctr Mental & Neurol Disorders & Dis, Dept Neurol, Guangzhou, Peoples R China.	gdbingjun@163.com		Zhang, Bingjun/0000-0002-9641-2485	National Natural Science Foundation of China [81971110, 81671178]; Guangdong Basic and Applied Basic Research Foundation [2020A1515010056]; Third Affiliated Hospital of SunYat-SenUniversity, ClinicalResearch Program [QHJH201907]; Doctorial Starting Fund of GuangzhouWomen and Children's Medical Center [2018-293]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Basic and Applied Basic Research Foundation; Third Affiliated Hospital of SunYat-SenUniversity, ClinicalResearch Program; Doctorial Starting Fund of GuangzhouWomen and Children's Medical Center	This study was supported by the National Natural Science Foundation of China (81971110, 81671178); the Guangdong Basic and Applied Basic Research Foundation (2020A1515010056); the Third Affiliated Hospital of SunYat-SenUniversity, ClinicalResearch Program (QHJH201907); and the Doctorial Starting Fund of GuangzhouWomen and Children's Medical Center (2018-293).	Bahr N, 2013, CURR INFECT DIS REP, V15, P583, DOI 10.1007/s11908-013-0378-5; Barber DL, 2012, NAT REV MICROBIOL, V10, P150, DOI 10.1038/nrmicro2712; Bauer J, 2015, ACTA NEUROPATHOL, V130, P751, DOI 10.1007/s00401-015-1471-7; Beaman MH, 2018, MED J AUSTRALIA, V209, P449, DOI 10.5694/mja17.01073; Ecevit IZ, 2006, CLIN INFECT DIS, V42, P1443, DOI 10.1086/503570; Elsegeiny W, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00651; Haddow LJ, 2010, LANCET INFECT DIS, V10, P791, DOI 10.1016/S1473-3099(10)70170-5; Ishii K, 2019, BMC NEUROL, V19, DOI 10.1186/s12883-019-1493-1; McIntyre PB, 2012, LANCET, V380, P1703, DOI 10.1016/S0140-6736(12)61187-8; Pintado V, 2019, J HOSP INFECT, V102, P108, DOI 10.1016/j.jhin.2018.11.008; Pintado V, 2002, EUR J CLIN MICROBIOL, V21, P864, DOI 10.1007/s10096-002-0814-1; Sueki H, 2018, J DERMATOL, V45, P3, DOI 10.1111/1346-8138.14074; Tan CS, 2010, LANCET NEUROL, V9, P425, DOI 10.1016/S1474-4422(10)70040-5; van de Beek D, 2016, CLIN MICROBIOL INFEC, V22, pS37, DOI 10.1016/j.cmi.2016.01.007; Walker NF, 2018, CURR OPIN HIV AIDS, V13, P512, DOI [10.1097/COH.0000000000000502, 10.1097/coh.0000000000000502]; Wattjes MP, 2018, J NEUROL NEUROSUR PS, V89, P535, DOI 10.1136/jnnp-2017-316886	16	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 29	2021	12								585316	10.3389/fimmu.2021.585316	http://dx.doi.org/10.3389/fimmu.2021.585316			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RL5KM	33868222	gold, Green Published			2022-12-18	WOS:000639011900001
J	Herve, PL; Plaquet, C; Assoun, N; Oreal, N; Gaulme, L; Perrin, A; Bouzereau, A; Dhelft, V; Labernardiere, JL; Mondoulet, L; Sampson, HA				Herve, Pierre-Louis; Plaquet, Camille; Assoun, Noemie; Oreal, Nathalie; Gaulme, Laetitia; Perrin, Audrey; Bouzereau, Adeline; Dhelft, Veronique; Labernardiere, Jean-Louis; Mondoulet, Lucie; Sampson, Hugh A.			Pre-Existing Humoral Immunity Enhances Epicutaneously-Administered Allergen Capture by Skin DC and Their Migration to Local Lymph Nodes	FRONTIERS IN IMMUNOLOGY			English	Article						skin dendritic cells; epicutaneous delivery; allergen capture; Fc receptors (FcR); preexisting immunity	LANGERHANS CELLS; KERATINOCYTES; RECEPTORS	Due to its richness in antigen presenting cells, e.g., dendritic cells (DC), the skin has been identified as a promising route for immunotherapy and vaccination. Several years ago, a skin delivery system was developed based on epicutaneous patches allowing the administration of antigen through intact skin. Using mouse models, we have shown that epicutaneous allergen application leads to a rapid uptake and transport of allergen-positive cells to skin-draining lymph nodes (LN). This occurred primarily in animals previously sensitized to the same allergen. In that context, we sought to better understand the role of the specific preexisting immunity in allergen capture by skin DC and their subsequent migration to LN. Specifically, we investigated the role of humoral immunity induced by sensitization and the involvement of IgG Fc receptors (Fc gamma R). Epicutaneous patches containing fluorescently-labeled ovalbumin (OVA) were applied to naive mice that had previously received either sera or purified IgG isolated from OVA-sensitized mice. To investigate the involvement of Fc gamma R, animals received 2.4G2 (anti-Fc gamma RII/RIII) blocking antibody, 24 hours before patch application. Mice that received sera or purified IgG originating from OVA-sensitized mice showed an increase in the quantity of OVA-positive DC in skin and LN. Moreover, the blockade of Fc gamma R reduced the number of OVA-positive DC in LN to a level similar to that observed in naive animals. Overall, these results demonstrate that preexisting specific-IgG antibodies are involved in allergen capture by skin DC following EPIT through the involvement of antigen-specific IgG-Fc gamma R.	[Herve, Pierre-Louis; Plaquet, Camille; Assoun, Noemie; Oreal, Nathalie; Gaulme, Laetitia; Perrin, Audrey; Bouzereau, Adeline; Dhelft, Veronique; Labernardiere, Jean-Louis; Mondoulet, Lucie] DBV Technol, Res & Innovat, Montrouge, France; [Sampson, Hugh A.] DBV Technol, Res & Innovat, New York, NY USA		Herve, PL (corresponding author), DBV Technol, Res & Innovat, Montrouge, France.	pierre-louis.herve@dbv-technologies.com						BJERKE JR, 1994, ACTA DERM-VENEREOL, V74, P429; Campana R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10278-1; Cauza K, 2002, J INVEST DERMATOL, V119, P1074, DOI 10.1046/j.1523-1747.2002.19527.x; Clatworthy MR, 2014, NAT MED, V20, P1458, DOI 10.1038/nm.3709; Crowe JE, 2001, CLIN INFECT DIS, V33, P1720, DOI 10.1086/322971; de Aguero MG, 2012, J CLIN INVEST, V122, P1700, DOI 10.1172/JCI59725; Dioszeghy V, 2014, CLIN EXP ALLERGY, V44, P867, DOI 10.1111/cea.12312; Dioszeghy V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01951; Dioszeghy V, 2011, J IMMUNOL, V186, P5629, DOI 10.4049/jimmunol.1003134; Edwards KM, 2015, VACCINE, V33, P6469, DOI 10.1016/j.vaccine.2015.07.085; Gavillet BM, 2015, VACCINE, V33, P3450, DOI 10.1016/j.vaccine.2015.05.089; Guilliams M, 2016, IMMUNITY, V45, P669, DOI 10.1016/j.immuni.2016.08.015; Haut LH, 2011, J INFECT DIS, V203, P1073, DOI 10.1093/infdis/jiq161; Hayashi S, 1999, ARCH DERMATOL RES, V291, P241, DOI 10.1007/s004030050401; Henri S, 2010, IMMUNOL CELL BIOL, V88, P366, DOI 10.1038/icb.2010.34; Hertl M, 1996, J INVEST DERMATOL, V106, P221, DOI 10.1111/1523-1747.ep12340546; Herve PL, 2019, J CONTROL RELEASE, V298, P12, DOI 10.1016/j.jconrel.2019.02.004; Herve PL, 2016, J CONTROL RELEASE, V243, P146, DOI 10.1016/j.jconrel.2016.10.003; Herve PL, 2014, J VIROL, V88, P325, DOI 10.1128/JVI.01141-13; Kim D, 2011, BLOOD, V117, P6143, DOI 10.1182/blood-2010-11-320317; Laoubi L, 2019, J ALLERGY CLIN IMMUN, V143, pAB242, DOI 10.1016/j.jaci.2018.12.739; Malissen B, 2014, NAT REV IMMUNOL, V14, P417, DOI 10.1038/nri3683; Mondoulet L, 2010, CLIN EXP ALLERGY, V40, P659, DOI 10.1111/j.1365-2222.2009.03430.x; Mondoulet Lucie, 2012, ISRN Allergy, V2012, P375735, DOI 10.5402/2012/375735; Mondoulet L, 2015, J ALLERGY CLIN IMMUN, V135, P1546, DOI 10.1016/j.jaci.2014.11.028; Mondoulet Lucie, 2012, Clin Transl Allergy, V2, P22, DOI 10.1186/2045-7022-2-22; Pandey A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033428; Pichla-Gollon SL, 2009, J VIROL, V83, P5567, DOI 10.1128/JVI.00405-09; Sampson HA, 2017, JAMA-J AM MED ASSOC, V318, P1798, DOI 10.1001/jama.2017.16591; Saxena M, 2013, MICROBIOL-SGM, V159, P1, DOI 10.1099/mic.0.049601-0; Seneschal J, 2012, IMMUNITY, V36, P873, DOI 10.1016/j.immuni.2012.03.018; Sharquie IK, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-54; TIGALONOWA M, 1991, ACTA DERM-VENEREOL, V71, P99; TIGALONOWA M, 1990, ACTA DERM-VENEREOL, V70, P385; Zhang FH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157041	35	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 26	2021	12								609029	10.3389/fimmu.2021.609029	http://dx.doi.org/10.3389/fimmu.2021.609029			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RK3BM	33868229	gold, Green Published			2022-12-18	WOS:000638174800001
J	Kridin, K; Bieber, K; Sadik, CD; Schon, MP; Wang, G; Loser, K; Ludwig, RJ				Kridin, Khalaf; Bieber, Katja; Sadik, Christian D.; Schoen, Michael P.; Wang, Gang; Loser, Karin; Ludwig, Ralf J.			Editorial: Skin Autoimmunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						skin; autoimmunity; pemphigus; pemphigoid; psoriasis; alopecia aerata (AA)		YY	[Kridin, Khalaf; Bieber, Katja; Ludwig, Ralf J.] Univ Lubeck, Lubeck Inst Expt Dermatol, Lubeck, Germany; [Kridin, Khalaf; Bieber, Katja; Sadik, Christian D.; Ludwig, Ralf J.] Univ Lubeck, Ctr Res Inflammat Skin, Lubeck, Germany; [Kridin, Khalaf] Bar Ilan Univ, Azrieli Fac Med, Safed, Israel; [Sadik, Christian D.] Univ Lubeck, Dept Dermatol Allergy & Venereol, Lubeck, Germany; [Schoen, Michael P.] Univ Med Ctr Gottingen, Dept Dermatol Venereol & Allergol, Gottingen, Germany; [Schoen, Michael P.] Univ Med Ctr Gottingen, Lower Saxony Inst Occupat Dermatol, Gottingen, Germany; [Wang, Gang] Fourth Mil Med Univ, Xijing Hosp, Dept Dermatol, Xian, Peoples R China; [Loser, Karin] Carl von Ossietzky Univ Oldenburg, Inst Immunol, Oldenburg, Germany	University of Lubeck; University of Lubeck; Bar Ilan University; University of Lubeck; University of Gottingen; University of Gottingen; Air Force Military Medical University; Carl von Ossietzky Universitat Oldenburg	Ludwig, RJ (corresponding author), Univ Lubeck, Lubeck Inst Expt Dermatol, Lubeck, Germany.; Ludwig, RJ (corresponding author), Univ Lubeck, Ctr Res Inflammat Skin, Lubeck, Germany.	ralf.ludwig@uksh.de	Ludwig, Ralf/F-3996-2018; Sadik, Christian David/G-9593-2014	Ludwig, Ralf/0000-0002-1394-1737; Sadik, Christian David/0000-0001-6701-048X	Deutsche Forschungsgemeinschaft; Alexander von Humboldt Foundation	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Alexander von Humboldt Foundation(Alexander von Humboldt Foundation)	This work supported the Excellence Cluster "Precision Medicine in Chronic Inflammation" (EXC 2167) from the Deutsche Forschungsgemeinschaft. KK received support from the Alexander von Humboldt Foundation (Humboldt Research Fellowship for Postdoctoral Researchers).	Arakawa A, 2015, J EXP MED, V212, P2203, DOI 10.1084/jem.20151093; Arnold D.L., 2020, LICHEN PLANUS; Bieber K, 2020, ACTA DERM-VENEREOL, V100, P108, DOI 10.2340/00015555-3400; Chakievska L, 2019, J AUTOIMMUN, V96, P104, DOI 10.1016/j.jaut.2018.09.003; Dand N, 2017, HUM MOL GENET, V26, P4301, DOI 10.1093/hmg/ddx328; Edwards G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01477; Gelfand JM, 2006, JAMA-J AM MED ASSOC, V296, P1735, DOI 10.1001/jama.296.14.1735; Heratizadeh A, 2011, BRIT J DERMATOL, V164, P316, DOI 10.1111/j.1365-2133.2010.10090.x; Hirose M, 2016, MOL MED, V22, P918, DOI 10.2119/molmed.2015.00206; Jaster R, 2020, J CELL MOL MED, V24, P8862, DOI 10.1111/jcmm.15540; Joly P, 2002, NEW ENGL J MED, V346, P321, DOI 10.1056/NEJMoa011592; Joly P, 2017, LANCET, V389, P2031, DOI 10.1016/S0140-6736(17)30070-3; Kahler KC, 2020, J DTSCH DERMATOL GES, DOI 10.1111/ddg.14128; Kasperkiewicz M, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.26; Kridin K, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00220; Lande R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6621; Lauffer F, 2020, J DTSCH DERMATOL GES, DOI 10.1111/ddg.14124; Lee JM, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00306; Lin L, 2018, J INVEST DERMATOL, V138, P1032, DOI 10.1016/j.jid.2017.11.031; Ludwig RJ, 2007, BRIT J DERMATOL, V156, P271, DOI 10.1111/j.1365-2133.2006.07562.x; Ludwig RJ, 2009, GIORN ITAL DERMAT V, V144, P339; Ludwig RJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00603; MCDONALD CJ, 1973, NEW ENGL J MED, V288, P912; Messingham KN, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02331; Milani-Nejad N, 2017, EUR J DERMATOL, V27, P472, DOI 10.1684/ejd.2017.3066; Nemoto O, 2016, BRIT J DERMATOL, V174, P296, DOI 10.1111/bjd.14207; Oya K, 2019, EUR J DERMATOL, V29, P210, DOI 10.1684/ejd.2019.3497; Papakonstantinou E, 2019, J EUR ACAD DERMATOL, V33, P925, DOI 10.1111/jdv.15444; Papp K, 2017, LANCET, V390, P40, DOI 10.1016/S0140-6736(17)31189-3; ROSE NR, 1993, IMMUNOL TODAY, V14, P426, DOI 10.1016/0167-5699(93)90244-F; Sadeghi H, 2015, J IMMUNOL, V194, P3656, DOI 10.4049/jimmunol.1402688; Saschenbrecker S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01974; Schempp CM, 2019, J DTSCH DERMATOL GES, V17, P167, DOI 10.1111/ddg.13761; Schmidt E, 2019, LANCET, V394, P882, DOI 10.1016/S0140-6736(19)31778-7; Schmidt E, 2013, LANCET, V381, P320, DOI 10.1016/S0140-6736(12)61140-4; Schmidt T, 2018, J ALLERGY CLIN IMMUN, V142, P669, DOI 10.1016/j.jaci.2018.02.044; Schon MP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01323; Schroder L, 2012, HAUTARZT, V63, P558, DOI 10.1007/s00105-011-2319-2; Silverberg JI, 2020, J ALLERGY CLIN IMMUN, V145, P173, DOI 10.1016/j.jaci.2019.08.013; Sinha AA, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00218; Sondermann W, 2019, J DTSCH DERMATOL GES, V17, P1029, DOI [10.1111/ddg.13964_g, 10.1111/ddg.13964]; Teodoro WR, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-2052-2; Thaci D, 2016, LANCET, V387, P40, DOI 10.1016/S0140-6736(15)00388-8; Tuusa J, 2019, J INVEST DERMATOL, V139, P293, DOI 10.1016/j.jid.2018.09.010; Vorobyev A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11952-w; West J, 2017, CLIN EXP DERMATOL, V42, P651, DOI 10.1111/ced.13100; Witte M, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00296; Xing LZ, 2014, NAT MED, V20, P1043, DOI 10.1038/nm.3645	48	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 25	2021	12								627565	10.3389/fimmu.2021.627565	http://dx.doi.org/10.3389/fimmu.2021.627565			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RJ6ON	33841410	gold, Green Published			2022-12-18	WOS:000637719800001
J	Chen, DW; Song, XY; Wang, HY; Gao, ZW; Meng, WJ; Chen, SQ; Ma, YF; Wang, YD; Li, K; Yu, JM; Yue, JB				Chen, Dawei; Song, Xinyu; Wang, Haiyong; Gao, Zhenwu; Meng, Wenjuan; Chen, Shuquan; Ma, Yunfeng; Wang, Youda; Li, Kong; Yu, Jinming; Yue, Jinbo			Previous Radiotherapy Increases the Efficacy of IL-2 in Malignant Pleural Effusion: Potential Evidence of a Radio-Memory Effect? (vol 9, 2916, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						non-small-cell lung cancer (NSCLC); radiotherapy; radio-memory effect; immunotherapy; interleukin-2 (IL-2); malignant pleural effusion (MPE)			[Chen, Dawei; Li, Kong; Yu, Jinming; Yue, Jinbo] Shandong Univ, Dept Radiat Oncol, Shandong Canc Hosp, Jinan, Peoples R China; [Song, Xinyu; Wang, Haiyong] Shandong Univ, Dept Internal Med Oncol, Shandong Canc Hosp, Jinan, Peoples R China; [Song, Xinyu] Univ Jinan, Sch Med & Life Sci, Shandong Acad Med Sci, Jinan, Peoples R China; [Gao, Zhenwu] Weifang Med Univ, Dept Oncol, Affiliated Hosp, Weifang, Peoples R China; [Meng, Wenjuan] Weifang Peoples Hosp, Weifang, Peoples R China; [Chen, Shuquan] Laiwu Hosp Tradit Chinese Med, Laiwu, Peoples R China; [Ma, Yunfeng] Laiwu Peoples Hosp, Laiwu, Peoples R China; [Wang, Youda] Linyi City Peoples Hosp, Linyi, Shandong, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Jinan; Weifang Medical University	Yu, JM; Yue, JB (corresponding author), Shandong Univ, Dept Radiat Oncol, Shandong Canc Hosp, Jinan, Peoples R China.	sdyujinming@163.com; yuejinbo@hotmail.com						Chen DW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02916	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 23	2021	12								649620	10.3389/fimmu.2021.649620	http://dx.doi.org/10.3389/fimmu.2021.649620			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RI7NH	33833763	gold, Green Published			2022-12-18	WOS:000637093600001
J	Cao, W; Liu, XS; Hong, K; Ma, ZY; Zhang, YL; Lin, L; Han, Y; Xiong, Y; Liu, ZY; Ruan, LG; Li, TS				Cao, Wei; Liu, Xiaosheng; Hong, Ke; Ma, Zhiyong; Zhang, Yuelun; Lin, Ling; Han, Yang; Xiong, Yong; Liu, Zhengyin; Ruan, Lianguo; Li, Taisheng			High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China (vol 12, 627844, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						COVID-19; high-dose intravenous immunoglobulin; immunomodulation; 28-day mortality; inflammatory markers			[Cao, Wei; Liu, Xiaosheng; Lin, Ling; Han, Yang; Liu, Zhengyin; Li, Taisheng] Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Infect Dis, Beijing, Peoples R China; [Liu, Xiaosheng; Li, Taisheng] Tsinghua Univ, Sch Med, Dept Basic Med Sci, Beijing, Peoples R China; [Liu, Xiaosheng; Li, Taisheng] Tsinghua Peking Ctr Life Sci, Beijing, Peoples R China; [Hong, Ke; Ruan, Lianguo] JinYin tan Hosp, Dept Infect Dis, Wuhan, Peoples R China; [Ma, Zhiyong; Xiong, Yong] Wuhan Univ, Zhongnan Hosp, Dept Infect Dis, Wuhan, Peoples R China; [Zhang, Yuelun] Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, Medial Res Ctr, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Tsinghua University; Tsinghua University; Wuhan Jinyintan Hospital; Wuhan University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital	Li, TS (corresponding author), Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Infect Dis, Beijing, Peoples R China.; Li, TS (corresponding author), Tsinghua Univ, Sch Med, Dept Basic Med Sci, Beijing, Peoples R China.; Li, TS (corresponding author), Tsinghua Peking Ctr Life Sci, Beijing, Peoples R China.	litsh@263.net	han, yang/GRS-2388-2022					Cao W, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.627844	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 22	2021	12								671443	10.3389/fimmu.2021.671443	http://dx.doi.org/10.3389/fimmu.2021.671443			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RI3DN	33831136	gold, Green Published			2022-12-18	WOS:000636788200001
J	Comi, M; Amodio, G; Passeri, L; Fortunato, M; de Sio, FRS; Andolfi, G; Kajaste-Rudnitski, A; Russo, F; Cesana, L; Gregori, S				Comi, Michela; Amodio, Giada; Passeri, Laura; Fortunato, Marta; Santoni de Sio, Francesca Romana; Andolfi, Grazia; Kajaste-Rudnitski, Anna; Russo, Fabio; Cesana, Luca; Gregori, Silvia			Generation of Powerful Human Tolerogenic Dendritic Cells by Lentiviral-Mediated IL-10 Gene Transfer (vol 11, 1260, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						dendritic cells; IL-10; cell therapy; immune tolerance; allogeneic transplantation			[Comi, Michela; Amodio, Giada; Passeri, Laura; Fortunato, Marta; Santoni de Sio, Francesca Romana; Andolfi, Grazia; Kajaste-Rudnitski, Anna; Russo, Fabio; Cesana, Luca; Gregori, Silvia] San Raffaele Sci Inst IRCCS, San Raffaele Telethon Inst Gene Therapy SR TIGET, Milan, Italy	Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Gregori, S (corresponding author), San Raffaele Sci Inst IRCCS, San Raffaele Telethon Inst Gene Therapy SR TIGET, Milan, Italy.	gregori.silvia@hsr.it		Fortunato, Marta/0000-0002-3539-0307; Kajaste-Rudnitski, Anna/0000-0003-1549-2426				Comi M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01260	1	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 22	2021	12								672701	10.3389/fimmu.2021.672701	http://dx.doi.org/10.3389/fimmu.2021.672701			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RI3DP	33828568	gold, Green Published			2022-12-18	WOS:000636788400001
J	Stifano, G; De Palma, R				Stifano, Giuseppina; De Palma, Raffaele			Editorial: Etiopathogenesis of Systemic Sclerosis: An Update	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						systemic sclerosis (scleroderma); autoimmunity; vascular injury; fibrosis; immune response	CANCER		[Stifano, Giuseppina] Boston Univ, Sch Med, Arthrit Ctr, Boston, MA 02118 USA; [De Palma, Raffaele] Univ Genoa, Dipartimento Med Interna & Specialita Med DIMI, Genoa, Italy; [De Palma, Raffaele] IRCCS Osped Policlin San Martino IST Genova, Clin Immunol, Genoa, Italy	Boston University; University of Genoa	De Palma, R (corresponding author), Univ Genoa, Dipartimento Med Interna & Specialita Med DIMI, Genoa, Italy.; De Palma, R (corresponding author), IRCCS Osped Policlin San Martino IST Genova, Clin Immunol, Genoa, Italy.	depalma_raffaele@libero.it						Barnas JL, 2019, CURR OPIN IMMUNOL, V61, P92, DOI 10.1016/j.coi.2019.09.004; Frantz C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02356; Gabrielli A, 2009, NEW ENGL J MED, V360, P1989, DOI 10.1056/NEJMra0806188; Meng M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01861; Morry J, 2017, REDOX BIOL, V11, P240, DOI 10.1016/j.redox.2016.12.011; Murakami K, 2019, INTERNAL MED, V58, P5, DOI 10.2169/internalmedicine.1423-18; Schafer MKE, 2018, MATRIX BIOL, V68-69, P571, DOI 10.1016/j.matbio.2017.10.002; Servaas NH, 2021, J AUTOIMMUN, V117, DOI 10.1016/j.jaut.2020.102574; Shah AA, 2011, CURR OPIN RHEUMATOL, V23, P530, DOI 10.1097/BOR.0b013e32834a5081; Tang YY, 2020, J COMPUT BIOL, V27, P1519, DOI 10.1089/cmb.2019.0492	10	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 22	2021	12								663381	10.3389/fimmu.2021.663381	http://dx.doi.org/10.3389/fimmu.2021.663381			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RI1OD	33828566	gold, Green Published			2022-12-18	WOS:000636678100001
J	Alrashdi, B; Dawod, B; Tacke, S; Kuerten, S; Cote, PD; Marshall, JS				Alrashdi, Barakat; Dawod, Bassel; Tacke, Sabine; Kuerten, Stefanie; Cote, Patrice D.; Marshall, Jean S.			Mice Heterozygous for the Sodium Channel Scn8a (Nav1.6) Have Reduced Inflammatory Responses During EAE and Following LPS Challenge	FRONTIERS IN IMMUNOLOGY			English	Article						multiple sclerosis; inflammation; experimental autoimmune encephalomyelitis; sodium channel; lipopolysaccharide; mast cells		Voltage gated sodium (Nav) channels contribute to axonal damage following demyelination in experimental autoimmune encephalomyelitis (EAE), a rodent model of multiple sclerosis (MS). The Nav1.6 isoform has been implicated as a primary contributor in this process. However, the role of Nav1.6 in immune processes, critical to the pathology of both MS and EAE, has not been extensively studied. EAE was induced with myelin oligodendrocyte (MOG(35-55)) peptide in Scn8a(dmu/+) mice, which have reduced Nav1.6 levels. Scn8a(dmu/+) mice demonstrated improved motor capacity during the recovery and early chronic phases of EAE relative to wild-type animals. In the optic nerve, myeloid cell infiltration and the effects of EAE on the axonal ultrastructure were also significantly reduced in Scn8a(dmu/+) mice. Analysis of innate immune parameters revealed reduced plasma IL-6 levels and decreased percentages of Gr-1(high)/CD11b(+) and Gr-1(int)/CD11b(+) myeloid cells in the blood during the chronic phase of EAE in Scn8a(dmu/+) mice. Elevated levels of the anti-inflammatory cytokines IL-10, IL-13, and TGF-beta 1 were also observed in the brains of untreated Scn8a(dmu/+) mice. A lipopolysaccharide (LPS) model was used to further evaluate inflammatory responses. Scn8a(dmu/+) mice displayed reduced inflammation in response to LPS challenge. To further evaluate if this was an immune cell-intrinsic difference or the result of changes in the immune or hormonal environment, mast cells were derived from the bone marrow of Scn8a(dmu/+) mice. These mast cells also produced lower levels of IL-6, in response to LPS, compared with those from wild type mice. Our results demonstrate that in addition to its recognized impact on axonal damage, Nav1.6 impacts multiple aspects of the innate inflammatory response.	[Alrashdi, Barakat; Cote, Patrice D.] Dalhousie Univ, Dept Biol, Halifax, NS, Canada; [Dawod, Bassel; Marshall, Jean S.] Dalhousie Univ, Dept Pathol, Halifax, NS, Canada; [Tacke, Sabine; Kuerten, Stefanie] Friedrich Alexander Univ Erlangen Nuremberg FAU, Inst Anat, Dept Anat & Cell Biol, Erlangen, Germany; [Cote, Patrice D.] Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS, Canada; [Marshall, Jean S.] Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS, Canada	Dalhousie University; Dalhousie University; University of Erlangen Nuremberg; Dalhousie University; Dalhousie University	Cote, PD (corresponding author), Dalhousie Univ, Dept Biol, Halifax, NS, Canada.; Cote, PD (corresponding author), Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS, Canada.	patrice.cote@dal.ca		Cote, Patrice/0000-0002-4189-7526	Nova Scotia Research Foundation; Dalhousie Medical Research Foundation/Gillian's Hope MS Research Grant; Canadian Institutes of Health Research (CIHR) [THC-135230, MOP-93517]; Jouf University, Saudi Arabia; Saudi Cultural Bureau (Canada); Al Jouf University	Nova Scotia Research Foundation; Dalhousie Medical Research Foundation/Gillian's Hope MS Research Grant; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Jouf University, Saudi Arabia; Saudi Cultural Bureau (Canada); Al Jouf University	The Nova Scotia Research Foundation supported this work (to PC), the Dalhousie Medical Research Foundation/Gillian's Hope MS Research Grant (to PC), The Canadian Institutes of Health Research (CIHR) grant (to JM) grant number THC-135230 and MOP-93517, and Jouf University, Saudi Arabia (to BA). BA is a recipient of a postgraduate scholarship from the Saudi Cultural Bureau (Canada) and Al Jouf University.	Alrashdi B, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1622-1; Amor S, 2014, IMMUNOLOGY, V142, P151, DOI 10.1111/imm.12233; Aube B, 2014, J IMMUNOL, V193, P2438, DOI 10.4049/jimmunol.1400401; Barnett MH, 2006, MULT SCLER, V12, P121, DOI 10.1191/135248506ms1304rr; Bartholomaus I, 2009, NATURE, V462, P94, DOI 10.1038/nature08478; Benoit M, 2008, J IMMUNOL, V181, P3733, DOI 10.4049/jimmunol.181.6.3733; Besson P, 2015, BBA-BIOMEMBRANES, V1848, P2493, DOI 10.1016/j.bbamem.2015.04.013; Bitan M, 2010, MOL IMMUNOL, V47, P1890, DOI 10.1016/j.molimm.2010.03.014; Black JA, 2013, NEURON, V80, P280, DOI 10.1016/j.neuron.2013.09.012; Black JA, 2009, GLIA, V57, P1072, DOI 10.1002/glia.20830; Bouafia A, 2014, NEUROPATH APPL NEURO, V40, P579, DOI 10.1111/nan.12059; Bucher K, 2015, J LEUKOCYTE BIOL, V98, P365, DOI 10.1189/jlb.1AB1014-488RR; BURGESS DL, 1995, NAT GENET, V10, P461, DOI 10.1038/ng0895-461; de Oliveira LRC, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00161; Carrithers MD, 2009, J BIOL CHEM, V284, P8114, DOI 10.1074/jbc.M801892200; Catterall WA, 2005, PHARMACOL REV, V57, P397, DOI 10.1124/pr.57.4.4; Catterall WA, 2013, ENCY BIOL CHEM, DOI [10.1016/B978-0-12-378630-2.00208-5, DOI 10.1016/B978-0-12-378630-2.00208-5]; Chen WQ, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0847-0; Constantinescu CS, 2011, BRIT J PHARMACOL, V164, P1079, DOI 10.1111/j.1476-5381.2011.01302.x; Cote PD, 2005, J NEUROSCI, V25, P5046, DOI 10.1523/JNEUROSCI.4692-04.2005; Craner MJ, 2005, GLIA, V49, P220, DOI 10.1002/glia.20112; Craner MJ, 2004, P NATL ACAD SCI USA, V101, P8168, DOI 10.1073/pnas.0402765101; Craner MJ, 2004, BRAIN, V127, P294, DOI 10.1093/brain/awh032; Croxford JL, 2001, J IMMUNOL, V166, P4124, DOI 10.4049/jimmunol.166.6.4124; Daley JM, 2008, J LEUKOCYTE BIOL, V83, P64, DOI 10.1189/jlb.0407247; De Repentigny Y, 2001, HUM MOL GENET, V10, P1819, DOI 10.1093/hmg/10.17.1819; Dendrou CA, 2015, NAT REV IMMUNOL, V15, P545, DOI 10.1038/nri3871; Ding HH, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1421-8; Duffy SS, 2014, MULT SCLER INT, V2014, DOI 10.1155/2014/285245; Fillatreau S, 2002, NAT IMMUNOL, V3, P944, DOI 10.1038/ni833; FOSTER RE, 1980, SCIENCE, V210, P661, DOI 10.1126/science.6159685; Garcia-Vallejo JJ, 2014, J EXP MED, V211, P1457, DOI 10.1084/jem.20122192; GUY J, 1991, BRAIN, V114, P281; Horstmann L, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-120; Hossain MJ, 2015, ONCOTARGET, V6, P35131, DOI 10.18632/oncotarget.6031; Ignjatovic A, 2012, AMYOTROPH LATERAL SC, V13, P357, DOI 10.3109/17482968.2012.665929; Jacobsen M, 2002, BRAIN, V125, P538, DOI 10.1093/brain/awf059; Jurewicz A, 2005, BRAIN, V128, P2675, DOI 10.1093/brain/awh627; KORNER H, 1995, P NATL ACAD SCI USA, V92, P11066, DOI 10.1073/pnas.92.24.11066; Kuerten S, 2007, J NEUROIMMUNOL, V189, P31, DOI 10.1016/j.jneuroim.2007.06.016; Kumar V, 2010, MOL IMMUNOL, V48, P14, DOI 10.1016/j.molimm.2010.07.009; Kwilasz AJ, 2015, NEUROPHARMACOLOGY, V96, P55, DOI 10.1016/j.neuropharm.2014.10.020; Lo WL, 2012, NAT IMMUNOL, V13, P880, DOI 10.1038/ni.2379; McCurdy JD, 2001, J LEUKOCYTE BIOL, V70, P977; Meisler MH, 2004, GENETICA, V122, P37, DOI 10.1007/s10709-004-1441-9; Mohr DC, 2011, PSYCHOLOGICAL CO-MORBIDITIES OF PHYSICAL ILLNESS: A BEHAVIORAL MEDICINE PERSPECTIVE, P311, DOI 10.1007/978-1-4419-0029-6_8; Morsali D, 2013, BRAIN, V136, P1067, DOI 10.1093/brain/awt041; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; Pappalardo LW, 2016, GLIA, V64, P1628, DOI 10.1002/glia.22967; Patani R, 2007, NEUROPATH APPL NEURO, V33, P277, DOI 10.1111/j.1365-2990.2007.00805.x; Persson AK, 2014, GLIA, V62, P2080, DOI 10.1002/glia.22728; Pierson ER, 2014, J IMMUNOL, V192, P929, DOI 10.4049/jimmunol.1302171; Pinke KH, 2020, NEURAL REGEN RES, V15, P1995, DOI 10.4103/1673-5374.282238; Sagar D, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-245; Savio-Galimberti E, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00124; Shindler KS, 2008, EXP EYE RES, V87, P208, DOI 10.1016/j.exer.2008.05.017; Stadelmann C, 2011, BBA-MOL BASIS DIS, V1812, P275, DOI 10.1016/j.bbadis.2010.07.007; Stromnes IM, 2006, NAT PROTOC, V1, P1952, DOI 10.1038/nprot.2006.284; TERTIAN G, 1981, J IMMUNOL, V127, P788; Vaknin-Dembinsky AK, 2006, J IMMUNOL, V177, P2025, DOI 10.4049/jimmunol.177.3.2025-b; Van Wart A, 2006, J NEUROSCI, V26, P7172, DOI 10.1523/JNEUROSCI.1101-06.2006; Vega AV, 2008, NEUROSCI LETT, V442, P69, DOI 10.1016/j.neulet.2008.06.065; Waxman SG, 2006, NAT REV NEUROSCI, V7, P932, DOI 10.1038/nrn2023; Wojkowska DW, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/590409; Zhang MZ, 2017, KIDNEY INT, V91, P375, DOI 10.1016/j.kint.2016.08.020	65	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 19	2021	12								533423	10.3389/fimmu.2021.533423	http://dx.doi.org/10.3389/fimmu.2021.533423			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RG8OM	33815353	Green Published, gold			2022-12-18	WOS:000635792500001
J	Ma, Q; Pollard, KM; Brown, JM; Italiani, P; Moghimi, SM				Ma, Qiang; Pollard, Kenneth Michael; Brown, Jared M.; Italiani, Paola; Moghimi, Seyed Moein			Editorial: Immune Mechanisms in the Pathologic Response to Particles, Fibers, and Nanomaterials	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						particle; nanoparticle; nanomedicine; immune response; autoimmunity; allergy; inflammation; particle immunotoxicity			[Ma, Qiang] NIOSH, Hlth Effects Lab Div, Morgantown, WV 26505 USA; [Pollard, Kenneth Michael] Scripps Res Inst, Dept Mol Med, La Jolla, CA 92037 USA; [Brown, Jared M.] Univ Colorado Anschutz Med Campus, Skaggs Sch Pharm, Aurora, CO 80045 USA; [Italiani, Paola] Natl Res Council CNR, Inst Biochem & Cell Biol, Naples, Italy; [Moghimi, Seyed Moein] Newcastle Univ, Sch Pharm, Newcastle Upon Tyne, Tyne & Wear, England	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); Scripps Research Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; Newcastle University - UK	Ma, Q (corresponding author), NIOSH, Hlth Effects Lab Div, Morgantown, WV 26505 USA.; Pollard, KM (corresponding author), Scripps Res Inst, Dept Mol Med, La Jolla, CA 92037 USA.; Brown, JM (corresponding author), Univ Colorado Anschutz Med Campus, Skaggs Sch Pharm, Aurora, CO 80045 USA.; Italiani, P (corresponding author), Natl Res Council CNR, Inst Biochem & Cell Biol, Naples, Italy.; Moghimi, SM (corresponding author), Newcastle Univ, Sch Pharm, Newcastle Upon Tyne, Tyne & Wear, England.	qam1@cdc.gov; mpollard@scripps.edu; jared.brown@cuanschutz.edu; paola.italiani@ibbc.cnr.it; seyed.moghimi@newcastle.ac.uk	ma, qiang/HCI-1013-2022	Moghimi, Seyed Moein/0000-0003-0836-926X	Health Effects Laboratory Division at National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention [9390BMX]; National Institutes of Health [ES029581, ES031454, ES029263]; National Institute of Environmental Health Sciences [R01 ES019311]; European Commission H2020 grant ENDONANO [812661]; MUR-PRIN grant [20173ZECCM]; National Occupational Research Agenda Program at National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention [9390BMX]	Health Effects Laboratory Division at National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); European Commission H2020 grant ENDONANO; MUR-PRIN grant; National Occupational Research Agenda Program at National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention	QM was supported by grant 9390BMX from the Health Effects Laboratory Division and the National Occupational Research Agenda Program at National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention. KP was supported by grants ES029581, ES031454, and ES029263 from the National Institutes of Health. JB was supported by funding from the National Institute of Environmental Health Sciences R01 ES019311. PI was supported by funding from European Commission H2020 grant ENDONANO (GA 812661) and from MUR-PRIN grant (20173ZECCM).	Annunziato F, 2015, J ALLERGY CLIN IMMUN, V135, P626, DOI 10.1016/j.jaci.2014.11.001; Cullinan P, 2017, LANCET RESP MED, V5, P445, DOI [10.1016/S2213-2600(16)30424-6, 10.1016/s2213-2600(16)30424-6]; Donaldson K, 2012, PART FIBRE TOXICOL, V9, DOI 10.1186/1743-8977-9-13; Dong J, 2019, NANOTOXICOLOGY, V13, P1244, DOI 10.1080/17435390.2019.1651920; Dong J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01120; Huaux F, 2016, PART FIBRE TOXICOL, V13, DOI 10.1186/s12989-016-0158-0; Lusis AJ, 2008, NAT REV GENET, V9, P819, DOI 10.1038/nrg2468; Moghimi SM, 2012, ANNU REV PHARMACOL, V52, P481, DOI 10.1146/annurev-pharmtox-010611-134623; Moghimi SM, 2020, ADV DRUG DELIVER REV, V157, P83, DOI 10.1016/j.addr.2020.04.012; Moghimi SM, 2018, DRUG DISCOV TODAY, V23, P1034, DOI 10.1016/j.drudis.2017.11.006; Parks CG, 2002, ARTHRITIS RHEUM-US, V46, P1840, DOI 10.1002/art.10368; Pfau JC, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/782045; Pollard KM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00097; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Shtraichman O, 2015, OCCUP MED-OXFORD, V65, P444, DOI 10.1093/occmed/kqv073; United States Food and Drug Administration, 2019, FDA STRENGTHENS WARN; World Health Organization, 2021, PROJECTIONS MORTALIT	17	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 19	2021	12								665810	10.3389/fimmu.2021.665810	http://dx.doi.org/10.3389/fimmu.2021.665810			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RG8LX	33815427	Green Published, gold			2022-12-18	WOS:000635785800001
J	Mawa, PA; Hasso-Agopsowicz, M; Lubyayi, L; Nabakooza, G; Nakibuule, M; Blitz, R; Dun, L; Govind, A; Kaleebu, P; Webb, EL; Elliott, AM; Dockrell, HM; Cose, S; Smith, SG				Mawa, Patrice A.; Hasso-Agopsowicz, Mateusz; Lubyayi, Lawrence; Nabakooza, Grace; Nakibuule, Marjorie; Blitz, Rose; Dun, Li; Govind, Abha; Kaleebu, Pontiano; Webb, Emily L.; Elliott, Alison M.; Dockrell, Hazel M.; Cose, Stephen; Smith, Steven G.			Immune Responses Following BCG Immunization of Infants in Uganda and United Kingdom Are Similar for Purified Protein Derivative but Differ for Secretory Proteins of Mycobacterium tuberculosis	FRONTIERS IN IMMUNOLOGY			English	Article						BCG vaccine; cytokine responses; chemokine responses; mycobacterial antigens; latent Mycobacterium tuberculosis infection	CALMETTE-GUERIN VACCINATION; T-CELL RESPONSES; IN-VITRO; EFFICACY; ANTIGENS; UK; INHIBITION; PROTECTION; CHEMOKINES; INFECTION	Introduction: The immunogenicity of BCG vaccination in infants differs between populations. We hypothesized that prenatal exposure to mycobacterial antigens might explain the differences in immune responses to BCG seen in other studies of infants in Africa and the United Kingdom (UK) and we explored this in birth cohorts in Uganda and the UK. Materials and Methods: Blood samples were obtained from BCG-immunized infants of mothers with (n = 110) and without (n = 121) latent Mycobacterium tuberculosis infection (LTBI) in Uganda and BCG-immunized infants of mothers without LTBI (n = 25) in the UK at 10 and 52 weeks after birth. Cytokine and chemokine responses to PPD were measured to assess responses to BCG immunization, and to ESAT6/CFP10 to assess exposure to or infection with M. tuberculosis or non-tuberculous mycobacteria (NTM) in 6-day whole blood culture supernatants by a 17-plex Luminex assay. Median responses were compared between Ugandan infants (together, and separated by maternal LTBI status) and UK infants. Results: The IFN-gamma response to BCG vaccination was similar between Ugandan and UK infants at 10 and 52 weeks. At week 52, TNF production was marginally higher in Ugandan infants, but after adjusting for multiple comparisons this difference was not significant. At weeks 10 and 52, stimulation of blood with ESAT6/CFP10 produced significantly higher IFN-gamma, TNF, IL-12p40, IL-1 alpha, IL-1 beta, IL-1Ra, IP-10, MIP-1 alpha, MIP-1 beta, and GM-CSF in Ugandan compared to UK infants. Stimulation of blood with ESAT6/CFP10 produced significantly higher amounts of IL-8 (p = 0.0001), IL-10 (p = 0.0022), and IL-13 (p = 0.0020) in the UK than in Ugandan infants of mothers without LTBI at week 10, but not at week 52. Conclusions: Immune responses to mycobacterial antigens following BCG immunization are similar for PPD, but differ for ESAT6/CFP10, between infants in Uganda and the UK. Neither maternal LTBI nor infant exposure to or infection with mycobacteria impacts the response to BCG. The observed global differences in immune response to BCG immunization are likely to be due to other causes.	[Mawa, Patrice A.; Lubyayi, Lawrence; Nabakooza, Grace; Nakibuule, Marjorie; Kaleebu, Pontiano; Elliott, Alison M.; Cose, Stephen] Med Res Council Uganda Virus Res Inst, Immunomodulat & Vaccines Programme, Entebbe, Uganda; [Mawa, Patrice A.; Lubyayi, Lawrence; Nabakooza, Grace; Nakibuule, Marjorie; Kaleebu, Pontiano; Elliott, Alison M.; Cose, Stephen] London Sch Hyg & Trop Med Uganda Res Unit, Entebbe, Uganda; [Mawa, Patrice A.; Kaleebu, Pontiano] Uganda Virus Res Inst, Dept Immunol, Entebbe, Uganda; [Mawa, Patrice A.; Hasso-Agopsowicz, Mateusz; Blitz, Rose; Dockrell, Hazel M.; Smith, Steven G.] London Sch Hyg & Trop Med, Dept Infect Biol, London, England; [Lubyayi, Lawrence] Univ Witwatersrand, Dept Epidemiol & Biostat, Sch Publ Hlth, Johannesburg, South Africa; [Dun, Li; Govind, Abha] North Middlesex Univ Hosp Natl Hlth Serv Trust, Fetal Med Unit, Dept Obstet & Gynaecol, London, England; [Webb, Emily L.] London Sch Hyg & Trop Med, Med Res Council Trop Epidemiol Grp, Dept Infect Dis Epidemiol, London, England; [Elliott, Alison M.; Cose, Stephen] London Sch Hyg & Trop Med, Dept Clin Res, London, England; [Smith, Steven G.] Brunel Univ London, Ctr Inflammat Res & Translat Med, Coll Hlth Med & Life Sci, Uxbridge, Middx, England	Uganda Virus Research Institute; University of London; London School of Hygiene & Tropical Medicine; University of Witwatersrand; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; Brunel University	Mawa, PA (corresponding author), Med Res Council Uganda Virus Res Inst, Immunomodulat & Vaccines Programme, Entebbe, Uganda.; Mawa, PA (corresponding author), London Sch Hyg & Trop Med Uganda Res Unit, Entebbe, Uganda.; Mawa, PA (corresponding author), Uganda Virus Res Inst, Dept Immunol, Entebbe, Uganda.; Mawa, PA (corresponding author), London Sch Hyg & Trop Med, Dept Infect Biol, London, England.	patrice.mawa@lshtm.ac.uk		Elliott, Alison/0000-0003-2818-9549; Hasso-Agopsowicz, Mateusz/0000-0003-4137-4685; Mawa, Akusa Patrice/0000-0002-4819-8904; Smith, Steven/0000-0001-5623-7806	UK Medical Research Council [MR/K019708]; Commonwealth Scholarships Commission PhD scholarship [UGCS-2012-602]; DELTAS Africa Initiative SSACAB [107754]; DELTAS Initiative MUII-plus [107743]; New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency); Wellcome Trust [107754/Z/15/Z]; UK Government; EUHorizon 2020 programme (TBVAC2020) [643381]; MRC London Intercollegiate Doctoral Training Partnership studentship; MRC [MR/K012126/1]; UK Department for International Development (DFID); European Union; UK Medical Research Council (MRC)	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Commonwealth Scholarships Commission PhD scholarship; DELTAS Africa Initiative SSACAB; DELTAS Initiative MUII-plus; New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency); Wellcome Trust(Wellcome TrustEuropean Commission); UK Government; EUHorizon 2020 programme (TBVAC2020); MRC London Intercollegiate Doctoral Training Partnership studentship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Department for International Development (DFID); European Union(European Commission); UK Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by a project grant from the UK Medical Research Council, Grant Number MR/K019708. PM was supported by a Commonwealth Scholarships Commission PhD scholarship (UGCS-2012-602). LL was supported by a PhD fellowship through the DELTAS Africa Initiative SSACAB (Grant No. 107754). SC was supported by funds from the DELTAS Initiative MUII-plus (Grant No. 107743). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS) Alliance for Accelerating Excellence in Science in Africa (AESA) and was supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (Grant No. 107754/Z/15/Z) and the UK Government. The views expressed in this study are those of the authors and not necessarily those of the AAS, NEPAD Agency, Wellcome Trust or the UK Government. SS, MH-A, and HD received support fromthe EUHorizon 2020 programme (TBVAC2020, Agreement Number 643381) and MH-A was supported by an MRC London Intercollegiate Doctoral Training Partnership studentship. EW received funding from MRC Grant Reference MR/K012126/1; this grant and the MRC/UVRI and LSHTM Uganda Research Unit are jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement and are also part of the EDCTP2 programme supported by the European Union.	AABY P, 1990, J INFECT DIS, V162, P1043, DOI 10.1093/infdis/162.5.1043; Anderson EJ, 2012, VACCINE, V30, P2083, DOI 10.1016/j.vaccine.2012.01.053; Asiimwe BB, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-88; Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8; Black GF, 2001, J INFECT DIS, V184, P322, DOI 10.1086/322042; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; Brewer TF, 2000, CLIN INFECT DIS, V31, pS64, DOI 10.1086/314072; Burl S, 2010, J IMMUNOL, V185, P2620, DOI 10.4049/jimmunol.1000552; COLDITZ GA, 1995, PEDIATRICS, V96, P29; Djuardi Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014066; Elliott AM, 2010, VACCINE, V29, P247, DOI 10.1016/j.vaccine.2010.10.047; FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9; Fletcher HA, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0617-3; Gebreegziabiher D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093429; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; Gibbons D, 2014, NAT MED, V20, P1206, DOI 10.1038/nm.3670; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Harris RC, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0685-4; Holt PG, 2009, J EXP MED, V206, P2861, DOI 10.1084/jem.20092469; Hur YG, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-184; Jain A, 2017, J IMMUNOL, V198, P3791, DOI 10.4049/jimmunol.1602000; Kagina BMN, 2009, VACCINE, V27, P5488, DOI 10.1016/j.vaccine.2009.06.103; Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109; Lalor MK, 2011, J INFECT DIS, V204, P1075, DOI 10.1093/infdis/jir515; Lalor MK, 2010, VACCINE, V28, P1635, DOI 10.1016/j.vaccine.2009.11.004; Lalor MK, 2009, J INFECT DIS, V199, P795, DOI 10.1086/597069; Lubyayi L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00929; Luo Y, 2007, CLIN EXP IMMUNOL, V147, P370, DOI 10.1111/j.1365-2249.2006.03288.x; Lutwama F, 2014, J INFECT DIS, V209, P887, DOI 10.1093/infdis/jit570; Marchant A, 1999, J IMMUNOL, V163, P2249; Mawa PA, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0137; Mawa PA, 2017, VACCINE, V35, P273, DOI 10.1016/j.vaccine.2016.11.079; Mukaida N, 1998, CYTOKINE GROWTH F R, V9, P9, DOI 10.1016/S1359-6101(97)00022-1; Netea MG, 2011, CELL HOST MICROBE, V9, P355, DOI 10.1016/j.chom.2011.04.006; NOVATOSILVA E, 1992, SCAND J IMMUNOL, V35, P429, DOI 10.1111/j.1365-3083.1992.tb02878.x; O'Leary S, 2011, AM J RESP CELL MOL, V45, P172, DOI 10.1165/rcmb.2010-0319OC; Potian JA, 2011, J EXP MED, V208, P1863, DOI 10.1084/jem.20091473; Quach H, 2016, CELL, V167, P643, DOI 10.1016/j.cell.2016.09.024; Rahman MJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009699; Ritz N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037535; Rook GAW, 2007, CURR MOL MED, V7, P327; Smith SG, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00644; Smith SG, 2016, VACCINE, V34, P5298, DOI 10.1016/j.vaccine.2016.09.002; TAUB DD, 1995, J CLIN INVEST, V95, P1370, DOI 10.1172/JCI117788; Tena-Coki NG, 2010, AM J RESP CRIT CARE, V182, P120, DOI 10.1164/rccm.200912-1862OC; van Ingen J, 2009, J BACTERIOL, V191, P5865, DOI 10.1128/JB.00683-09; WILSON ME, 1995, CLIN INFECT DIS, V20, P982, DOI 10.1093/clinids/20.4.982; Zimmermann P, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00084-18	48	0	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 19	2021	12								637114	10.3389/fimmu.2021.637114	http://dx.doi.org/10.3389/fimmu.2021.637114			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RH0LQ	33815390	Green Published, gold			2022-12-18	WOS:000635920300001
J	Salinas, TP; Garrido, JL; Salazar, JR; Gonzalez, P; Zambrano, N; Fuentes-Villalobos, F; Bravo, F; Fica-Leon, V; Salas-Burgos, A; Calvo, M; Alvarez, R; Armien, B; Barria, MI				Salinas, Tybbysay P.; Garrido, Jose L.; Salazar, Jacqueline R.; Gonzalez, Publio; Zambrano, Nicole; Fuentes-Villalobos, Francisco; Bravo, Felipe; Fica-Leon, Victor; Salas-Burgos, Alexis; Calvo, Mario; Alvarez, Raymond; Armien, Blas; Barria, Maria Ines			Cytokine Profiles and Antibody Response Associated to Choclo Orthohantavirus Infection	FRONTIERS IN IMMUNOLOGY			English	Article						CHOV; HCPS; IL-4; IL-8; IL-10; IgG; neutralizing antibodies		Background New World Hantaviruses (NWHs) are the etiological agent underlying hantavirus cardiopulmonary syndrome (HCPS), a severe respiratory disease with high mortality rates in humans. In Panama, infections with Choclo Orthohantavirus (CHOV) cause a much milder illness characterized by higher seroprevalence and lower mortality rates. To date, the cytokine profiles and antibody responses associated with this milder form of HCPS have not been defined. Therefore, in this study, we examined immune serological profiles associated with CHOV infections. Methods For this retrospective study, sera from fifteen individuals with acute CHOV-induced HCPS, were analyzed alongside sera from fifteen convalescent phase individuals and thirty-three asymptomatic, CHOV-seropositive individuals. Cytokine profiles were analyzed by multiplex immunoassay. Antibody subclasses, binding, and neutralization against CHOV-glycoprotein (CHOV-GP) were evaluated by ELISA, and flow cytometry. Results High titers of IFN gamma, IL-4, IL-8, and IL-10 serum cytokines were found in the acute individuals. Elevated IL-4 serum levels were found in convalescent and asymptomatic seropositive individuals. High titers of IgG1 subclass were observed across the three cohorts analyzed. Neutralizing antibody response against CHOV-GP was detectable in few acute individuals but was strong in both convalescent and asymptomatic seropositive individuals. Conclusion A Th1/Th2 cytokine signature is characteristic during acute mild HCPS caused by CHOV infection. High expression of Th2 and IL-8 cytokines are correlated with clinical parameters in acute mild HCPS. In addition, a strong IL-4 signature is associated with different cohorts, including asymptomatic individuals. Furthermore, asymptomatic individuals presented high titers of neutralizing antibodies.	[Salinas, Tybbysay P.; Garrido, Jose L.; Zambrano, Nicole; Fuentes-Villalobos, Francisco; Bravo, Felipe; Barria, Maria Ines] Univ Concepcion, Fac Biol Sci, Biotechnol Ctr, Dept Microbiol, Concepcion, Chile; [Salinas, Tybbysay P.; Salazar, Jacqueline R.; Gonzalez, Publio; Armien, Blas] Gorgas Mem Inst Hlth Studies, Dept Res Emerging & Zoonot Dis, Panama City, Panama; [Garrido, Jose L.; Bravo, Felipe; Alvarez, Raymond] Ichor Biol LLC, New York, NY USA; [Fica-Leon, Victor; Salas-Burgos, Alexis] Univ Concepcion, Fac Biol Sci, Dept Pharmacol, Concepcion, Chile; [Calvo, Mario] Univ Austral Chile, Inst Med, Valdivia, Chile; [Armien, Blas] SENACYT, Sistema Nacl Invest SIN, Panama City, Panama	Universidad de Concepcion; Instituto Conmemorativo Gorgas de Estudios de la Salud; Universidad de Concepcion; Universidad Austral de Chile; Secretaria Nacional de Ciencia, Tecnologia e Innovacin (SENACYT)	Barria, MI (corresponding author), Univ Concepcion, Fac Biol Sci, Biotechnol Ctr, Dept Microbiol, Concepcion, Chile.; Armien, B (corresponding author), Gorgas Mem Inst Hlth Studies, Dept Res Emerging & Zoonot Dis, Panama City, Panama.; Armien, B (corresponding author), SENACYT, Sistema Nacl Invest SIN, Panama City, Panama.	barmien@gorgas.gob.pa; mbarriac@udec.cl	Salas Burgos, Alexis/GWC-2563-2022	Salas-Burgos, Alexis/0000-0002-6577-9970; Salazar Campo, Jacqueline R./0000-0002-4859-5862; Fuentes Villalobos, Francisco/0000-0003-3120-0198; Barria, Maria/0000-0001-6225-5971	Department of Research in Emergent and Zoonotic Diseases; Ministry of Economy and Finance of Panama [111130150.501.274]; SENACYT of Panama; IFARHU (Instituto para la Formacion y Aprovechamiento de Recursos Humanos) of Panama; Chilean National Agency for Research and Development (ANID)/FONDEQUIP [EQM150061]	Department of Research in Emergent and Zoonotic Diseases; Ministry of Economy and Finance of Panama; SENACYT of Panama; IFARHU (Instituto para la Formacion y Aprovechamiento de Recursos Humanos) of Panama; Chilean National Agency for Research and Development (ANID)/FONDEQUIP	The work was financed by the Department of Research in Emergent and Zoonotic Diseases and the Ministry of Economy and Finance of Panama [grant number 111130150.501.274]. BA is a member of the SNI (Sistema Nacional de Investigacion) from SENACYT (Secretaria Nacional de Ciencia y Tecnologia) of Panama. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Also, this work was funded by SENACYT and IFARHU (Instituto para la Formacion y Aprovechamiento de Recursos Humanos) of Panama to TS. This work was partially supported by the Chilean National Agency for Research and Development (ANID)/FONDEQUIP EQM150061.	Angulo J, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005757; [Anonymous], [No title captured]; Armien B, 2004, AM J TROP MED HYG, V70, P682, DOI 10.4269/ajtmh.2004.70.682; Armien B, 2011, EMERG INFECT DIS, V17, P1936, DOI 10.3201/eid1710.101717; Armien B, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004460; Armien B, 2013, AM J TROP MED HYG, V89, P489, DOI 10.4269/ajtmh.12-0334; Avsic-Zupanc T, 2019, CLIN MICROBIOL INFEC, V21, pE6, DOI 10.1111/1469-0691.12291; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; Bostik P, 2000, EMERG INFECT DIS, V6, P184, DOI 10.3201/eid0602.000213; Cohen L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01338; Dougan M, 2019, IMMUNITY, V50, P796, DOI 10.1016/j.immuni.2019.03.022; Garrido JL, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat6420; Halim L, 2017, CELL REP, V20, P757, DOI 10.1016/j.celrep.2017.06.079; HARADA A, 1994, J LEUKOCYTE BIOL, V56, P559, DOI 10.1002/jlb.56.5.559; Hepojoki J, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00727; HOLM S, 1979, SCAND J STAT, V6, P65; Jonsson CB, 2010, CLIN MICROBIOL REV, V23, P412, DOI 10.1128/CMR.00062-09; Junttila IS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00888; Khaiboullina SF, 2005, CURR MOL MED, V5, P773, DOI 10.2174/156652405774962317; Khaiboullina SF, 2002, VIRAL IMMUNOL, V15, P609, DOI 10.1089/088282402320914548; Khaiboullina SF, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00567; Koma T, 2014, J VIROL, V88, P7178, DOI 10.1128/JVI.00254-14; Krishnamoorthy N, 2012, NAT MED, V18, P1525, DOI 10.1038/nm.2896; Kruger DH, 2011, HUM VACCINES, V7, P685, DOI 10.4161/hv.7.6.15197; Llah ST, 2018, J MED VIROL, V90, P1003, DOI 10.1002/jmv.25054; MacNeil A, 2011, VIRUS RES, V162, P138, DOI 10.1016/j.virusres.2011.09.017; Maes P, 2018, ARCH VIROL, V163, P2295, DOI 10.1007/s00705-018-3843-5; Maleki KT, 2019, J INFECT DIS, V219, P1832, DOI 10.1093/infdis/jiz005; Ministerio de Salud Panama, 2016, QUIA MAN ENF HANT PA; Morzunov SP, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00432; Nelson R, 2010, J MED VIROL, V82, P1586, DOI 10.1002/jmv.21864; Pyle CJ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006640; Ratner B., 2009, J TARGET MEAS ANAL M, V17, P139, DOI [10.1057/jt.2009.5, DOI 10.1057/JT.2009.5]; Rouse BT, 2010, NAT REV IMMUNOL, V10, P514, DOI 10.1038/nri2802; Saavedra F, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00430; Strandin T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02098; Vaheri A, 2013, NAT REV MICROBIOL, V11, P539, DOI 10.1038/nrmicro3066; Valdivieso F, 2006, EMERG INFECT DIS, V12, P166, DOI 10.3201/eid1201.050930; Vallat R., 2018, J OPEN SOURCE SOFTW, V3, P1026, DOI [10.21105/joss.01026, DOI 10.21105/JOSS.01026]; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; WILCOX RR, 1994, PSYCHOMETRIKA, V59, P601, DOI 10.1007/BF02294395	41	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 19	2021	12								603228	10.3389/fimmu.2021.603228	http://dx.doi.org/10.3389/fimmu.2021.603228			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RG8OF	33815363	Green Published, gold			2022-12-18	WOS:000635791800001
J	Bijelic, D; Adzic, M; Peric, M; Jakovcevski, I; Forster, E; Schachner, M; Andjus, PR				Bijelic, Dunja; Adzic, Marija; Peric, Mina; Jakovcevski, Igor; Foerster, Eckart; Schachner, Melitta; Andjus, Pavle R.			Different Functions of Recombinantly Expressed Domains of Tenascin-C in Glial Scar Formation (vol 11, 3944, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						astrocyte; glial scar; microglia/macrophages; spinal cord injury; tenascin-C			[Bijelic, Dunja; Adzic, Marija; Peric, Mina; Andjus, Pavle R.] Univ Belgrade, Ctr Laser Microscopy, Fac Biol, Inst Physiol & Biochem Jean Giaja, Belgrade, Serbia; [Jakovcevski, Igor; Foerster, Eckart] Ruhr Univ Bochum, Inst Neuroanat & Mol Hirnforsch, Bochum, Germany; [Schachner, Melitta] Rutgers State Univ, Keck Ctr Collaborat Neurosci, Piscataway, NJ USA; [Schachner, Melitta] Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ USA	University of Belgrade; Ruhr University Bochum; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Andjus, PR (corresponding author), Univ Belgrade, Ctr Laser Microscopy, Fac Biol, Inst Physiol & Biochem Jean Giaja, Belgrade, Serbia.; Schachner, M (corresponding author), Rutgers State Univ, Keck Ctr Collaborat Neurosci, Piscataway, NJ USA.; Schachner, M (corresponding author), Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ USA.	schachner@dls.rutgers.edu; pandjus@bio.bg.ac.rs		Bijelic, Dunja/0000-0002-7479-0186; Peric, Mina/0000-0003-4050-5196				Bijelic D, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.624612	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 16	2021	12								672476	10.3389/fimmu.2021.672476	http://dx.doi.org/10.3389/fimmu.2021.672476			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RF5OQ	33796121	gold, Green Published			2022-12-18	WOS:000634888000001
J	Eswarappa, M; Cantarelli, C; Cravedi, P				Eswarappa, Meghana; Cantarelli, Chiara; Cravedi, Paolo			Erythropoietin in Lupus: Unanticipated Immune Modulating Effects of a Kidney Hormone	FRONTIERS IN IMMUNOLOGY			English	Review						erythropoietin; SLE; immunology; lupus; T cell; Treg		Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease with variable clinical presentation, typically characterized by a relapsing-remitting course. SLE has a multifactorial pathogenesis including genetic, environmental, and hormonal factors that lead to loss of tolerance against self-antigens and autoantibody production. Mortality in SLE patients remains significantly higher than in the general population, in part because of the limited efficacy of available treatments and the associated toxicities. Therefore, novel targeted therapies are urgently needed to improve the outcomes of affected individuals. Erythropoietin (EPO), a kidney-produced hormone that promotes red blood cell production in response to hypoxia, has lately been shown to also possess non-erythropoietic properties, including immunomodulatory effects. In various models of autoimmune diseases, EPO limits cell apoptosis and favors cell clearance, while reducing proinflammatory cytokines and promoting the induction of regulatory T cells. Notably, EPO has been shown to reduce autoimmune response and decrease disease severity in mouse models of SLE. Herein, we review EPO's non-erythropoietic effects, with a special focus on immune modulating effects in SLE and its potential clinical utility.	[Eswarappa, Meghana; Cravedi, Paolo] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA; [Cantarelli, Chiara] Azienda Osped Univ Parma, UO Nefrol, Parma, Italy	Icahn School of Medicine at Mount Sinai; University of Parma; University Hospital of Parma	Cravedi, P (corresponding author), Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.	paolo.cravedi@mssm.edu			National Institutes of Health (National Institute of Allergy and Infectious Diseases [NIAID]) [R01 0255A141]	National Institutes of Health (National Institute of Allergy and Infectious Diseases [NIAID])(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	PC was supported by the National Institutes of Health (National Institute of Allergy and Infectious Diseases [NIAID]) R01 0255A141. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Aghdam KA, 2016, J CURR OPHTHALMOL, V28, P5, DOI 10.1016/j.joco.2016.01.008; Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0; Alarcon GS, 2002, LUPUS, V11, P95, DOI 10.1191/0961203302lu155oa; Ali-Hassan-Sayegh S, 2015, CARDIOVASC REVASCULA, V16, P179, DOI 10.1016/j.carrev.2015.01.008; Bittorf T, 2000, CELL SIGNAL, V12, P23, DOI 10.1016/S0898-6568(99)00063-7; Bohlius J, 2019, J CLIN ONCOL, V37, P1336, DOI 10.1200/JCO.18.02142; Bohlius J, 2009, LANCET, V373, P1532, DOI 10.1016/S0140-6736(09)60502-X; Borhani-Haghighi A, 2012, NEUROSCIENCES, V17, P151; Brines M, 2006, KIDNEY INT, V70, P246, DOI 10.1038/sj.ki.5001546; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; Bunn HF, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a011619; Byts Nadiya, 2009, Exp Transl Stroke Med, V1, P4, DOI 10.1186/2040-7378-1-4; Cantarelli C, 2019, AM J TRANSPLANT, V19, P2407, DOI 10.1111/ajt.15369; Celhar T, 2015, P NATL ACAD SCI USA, V112, pE6195, DOI 10.1073/pnas.1507052112; Cervera R, 2003, MEDICINE, V82, P299, DOI 10.1097/01.md.0000091181.93122.55; Chateauvieux S, 2011, BIOCHEM PHARMACOL, V82, P1291, DOI 10.1016/j.bcp.2011.06.045; Chatterjee PK, 2005, LANCET, V365, P1890, DOI 10.1016/S0140-6736(05)66622-6; Choi D, 2010, J EXP MED, V207, P2831, DOI 10.1084/jem.20100665; Chun HY, 2007, J CLIN IMMUNOL, V27, P461, DOI 10.1007/s10875-007-9104-0; Contreras G, 2010, J AM SOC NEPHROL, V21, P1200, DOI 10.1681/ASN.2009101093; Cravedi P, 2014, J AM SOC NEPHROL, V25, P2003, DOI 10.1681/ASN.2013090945; Crispin JC, 2010, NAT REV RHEUMATOL, V6, P317, DOI 10.1038/nrrheum.2010.60; Crispin JC, 2008, J IMMUNOL, V181, P8761, DOI 10.4049/jimmunol.181.12.8761; Cuzzocrea S, 2005, ARTHRITIS RHEUM, V52, P940, DOI 10.1002/art.20875; Diem R, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010956; Dolff S, 2011, CLIN IMMUNOL, V141, P197, DOI 10.1016/j.clim.2011.08.005; Donadei C, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127428; Drueke TB, 2012, KIDNEY INT, V82, P952, DOI 10.1038/ki.2012.270; Ebert BL, 1999, BLOOD, V94, P1864; Ehrenreich H, 2009, STROKE, V40, pE647, DOI 10.1161/STROKEAHA.109.564872; Elliott S, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0438-4; Elliott S, 2012, BIOL-TARGETS THER, V6, P163, DOI 10.2147/BTT.S32281; Erbayraktar S, 2003, P NATL ACAD SCI USA, V100, P6741, DOI 10.1073/pnas.1031753100; Farkas L, 2001, AM J PATHOL, V159, P237, DOI 10.1016/S0002-9440(10)61689-6; Fiordaliso F, 2005, P NATL ACAD SCI USA, V102, P2046, DOI 10.1073/pnas.0409329102; Gomez-Puerta Jose A, 2013, J Clin Cell Immunol, V4, P179; Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723; Gulinello M, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/207504; Hand CC, 2011, J INVEST MED, V59, P1073, DOI 10.2310/JIM.0b013e3181ed30bf; Hara A, 2016, J RHEUMATOL, V43, P1328, DOI 10.3899/jrheum.151430; He Honghui, 2010, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V35, P1115, DOI 10.3969/j.issn.1672-7347.2010.11.001; Huang B, 2018, J CELL MOL MED, V22, P3330, DOI 10.1111/jcmm.13608; Iwata S, 2016, LUPUS, V25, P850, DOI 10.1177/0961203316643172; Jin O, 2008, LUPUS, V17, P654, DOI 10.1177/0961203308089410; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; Katavetin P, 2007, KIDNEY INT, V72, pS10, DOI 10.1038/sj.ki.5002482; Lech M, 2013, J AM SOC NEPHROL, V24, P1357, DOI 10.1681/ASN.2013010026; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Li J, 2015, AM J MED SCI, V350, P387, DOI 10.1097/MAJ.0000000000000569; Li W, 2017, CURR OPIN RHEUMATOL, V29, P434, DOI 10.1097/BOR.0000000000000412; Lifshitz L, 2009, MOL IMMUNOL, V46, P713, DOI 10.1016/j.molimm.2008.10.004; Lipsic E, 2006, J AM COLL CARDIOL, V48, P2161, DOI 10.1016/j.jacc.2006.08.031; Lipsky PE, 2001, NAT IMMUNOL, V2, P764, DOI 10.1038/ni0901-764; Lisowska KA, 2010, ARTIF ORGANS, V34, P654, DOI 10.1111/j.1525-1594.2009.00948.x; Liu YQ, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0090942, 10.1371/journal.pone.0085282]; Luo BW, 2016, IMMUNITY, V44, P287, DOI 10.1016/j.immuni.2016.01.002; Luo BW, 2013, BBA-MOL BASIS DIS, V1832, P1260, DOI 10.1016/j.bbadis.2013.04.015; Luo XY, 2013, LUPUS, V22, P121, DOI 10.1177/0961203312463980; Ma CY, 2019, CLIN IMMUNOL, V207, P1, DOI 10.1016/j.clim.2019.06.009; Ma JL, 2010, CLIN RHEUMATOL, V29, P1251, DOI 10.1007/s10067-010-1510-7; McGlasson S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01146; Miyara M, 2005, J IMMUNOL, V175, P8392, DOI 10.4049/jimmunol.175.12.8392; Moulton VR, 2017, TRENDS MOL MED, V23, P615, DOI 10.1016/j.molmed.2017.05.006; Munoz LE, 2010, NAT REV RHEUMATOL, V6, P280, DOI 10.1038/nrrheum.2010.46; Nairz M, 2011, IMMUNITY, V34, P61, DOI 10.1016/j.immuni.2011.01.002; Najjar SS, 2011, JAMA-J AM MED ASSOC, V305, P1863, DOI 10.1001/jama.2011.592; Nowling TK, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3528; Ott I, 2010, CIRC-CARDIOVASC INTE, V3, P408, DOI 10.1161/CIRCINTERVENTIONS.109.904425; Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845; Purroy C, 2017, J AM SOC NEPHROL, V28, P2377, DOI 10.1681/ASN.2016101100; Ren Y, 2003, ARTHRITIS RHEUM, V48, P2888, DOI 10.1002/art.11237; Ronnblom L, 2001, J EXP MED, V194, pF59, DOI 10.1084/jem.194.12.f59; Rowland SL, 2014, J EXP MED, V211, P1977, DOI 10.1084/jem.20132620; Santiago-Raber ML, 2004, AUTOIMMUN REV, V3, P33, DOI 10.1016/S1568-9972(03)00062-4; Schett G, 2001, RHEUMATOLOGY, V40, P424, DOI 10.1093/rheumatology/40.4.424; Shaban A, 2019, CURR NEUROL NEUROSCI, V19, DOI 10.1007/s11910-019-1012-1; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Taher TE, 2010, ARTHRITIS RHEUM-US, V62, P2412, DOI 10.1002/art.27505; Talaat RM, 2015, CYTOKINE, V72, P146, DOI 10.1016/j.cyto.2014.12.027; Tektonidou MG, 2016, ARTHRITIS RHEUMATOL, V68, P1432, DOI 10.1002/art.39594; Togel FE, 2016, J AM SOC NEPHROL, V27, P3394, DOI 10.1681/ASN.2015091059; Tonia T, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003407.pub5; Tsai TH, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0761-8; Tsokos GC, 2016, NAT REV RHEUMATOL, V12, P716, DOI 10.1038/nrrheum.2016.186; Tzioufas AG, 1997, ARTHRITIS RHEUM-US, V40, P2212, DOI 10.1002/art.1780401216; Villar J, 2020, TRENDS IMMUNOL, V41, P1062, DOI 10.1016/j.it.2020.10.002; Voulgarelis M, 2000, ANN RHEUM DIS, V59, P217, DOI 10.1136/ard.59.3.217; Wang F, 1997, LUPUS, V6, P248, DOI 10.1177/096120339700600306; Wei X, 2014, INFECT IMMUN, V82, P165, DOI 10.1128/IAI.00929-13; Westenfelder C, 1999, KIDNEY INT, V55, P808, DOI 10.1046/j.1523-1755.1999.055003808.x; Wiese L, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-3; Yang J, 2009, ARTHRITIS RHEUM-US, V60, P1472, DOI 10.1002/art.24499; Yuan RR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001924; Zhang ZM, 2018, INFLAMMATION, V41, P1888, DOI 10.1007/s10753-018-0832-5	94	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 16	2021	12								639370	10.3389/fimmu.2021.639370	http://dx.doi.org/10.3389/fimmu.2021.639370			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RF2VY	33796104	gold, Green Published			2022-12-18	WOS:000634702800001
J	Pedreno-Lopez, N; Rosen, BC; Flores, WJ; Gorman, MJ; Voigt, TB; Ricciardi, MJ; Crosno, K; Weisgrau, KL; Parks, CL; Lifson, JD; Alter, G; Rakasz, EG; Magnani, DM; Martins, MA; Watkins, DI				Pedreno-Lopez, Nuria; Rosen, Brandon C.; Flores, Walter J.; Gorman, Matthew J.; Voigt, Thomas B.; Ricciardi, Michael J.; Crosno, Kristin; Weisgrau, Kim L.; Parks, Christopher L.; Lifson, Jeffrey D.; Alter, Galit; Rakasz, Eva G.; Magnani, Diogo M.; Martins, Mauricio A.; Watkins, David I.			Non-neutralizing Antibodies May Contribute to Suppression of SIVmac239 Viremia in Indian Rhesus Macaques	FRONTIERS IN IMMUNOLOGY			English	Article						non-neutralizing antibodies; SIV; rhesus macaques (Macaca mulatta); immunoadsorption; anti-FcRn Ab; adoptive transfer; antibody depletion	INDUCED HUMORAL IMMUNITY; HIGHLY PATHOGENIC SIV; NEONATAL FC-RECEPTOR; THERAPEUTIC IMMUNOADSORPTION; PASSIVE TRANSFER; IGG HOMEOSTASIS; CELL DEPLETION; VACCINE; PROTECTION; NEUTRALIZATION	The antiviral properties of broadly neutralizing antibodies against HIV are well-documented but no vaccine is currently able to elicit protective titers of these responses in primates. While current vaccine modalities can readily induce non-neutralizing antibodies against simian immunodeficiency virus (SIV) and HIV, the ability of these responses to restrict lentivirus transmission and replication remains controversial. Here, we investigated the antiviral properties of non-neutralizing antibodies in a group of Indian rhesus macaques (RMs) that were vaccinated with vif, rev, tat, nef, and env, as part of a previous study conducted by our group. These animals manifested rapid and durable control of viral replication to below detection limits shortly after SIVmac239 infection. Although these animals had no serological neutralizing activity against SIVmac239 prior to infection, their pre-challenge titers of Env-binding antibodies correlated with control of viral replication. To assess the contribution of anti-Env humoral immune responses to virologic control in two of these animals, we transiently depleted their circulating antibodies via extracorporeal plasma immunoadsorption and inhibition of IgG recycling through antibody-mediated blockade of the neonatal Fc receptor. These procedures reduced Ig serum concentrations by up to 80% and temporarily induced SIVmac239 replication in these animals. Next, we transferred purified total Ig from the rapid controllers into six vaccinated RMs one day before intrarectal challenge with SIVmac239. Although recipients of the hyperimmune anti-SIV Ig fraction were not protected from infection, their peak and chronic phase viral loads were significantly lower than those in concurrent unvaccinated control animals. Together, our results suggest that non-neutralizing Abs may play a role in the suppression of SIVmac239 viremia.	[Pedreno-Lopez, Nuria; Voigt, Thomas B.; Ricciardi, Michael J.; Watkins, David I.] George Washington Univ, Dept Pathol, Washington, DC 20052 USA; [Rosen, Brandon C.] Univ Miami, Leonard M Miller Sch Med, Dept Pathol, Miami, FL USA; [Rosen, Brandon C.] Univ Miami, Leonard M Miller Sch Med, Med Scientist Training Program, Miami, FL USA; [Flores, Walter J.; Magnani, Diogo M.] Univ Massachusetts, Sch Med, Nonhuman Primate Reagent Resource, MassBiol, Boston, MA 02125 USA; [Gorman, Matthew J.; Alter, Galit] Ragon Inst MGH MIT & Harvard Univ, Cambridge, MA USA; [Crosno, Kristin; Weisgrau, Kim L.; Rakasz, Eva G.] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI USA; [Parks, Christopher L.] AIDS Vaccine Design & Dev Lab, Int AIDS Vaccine Initiat, Brooklyn, NY USA; [Lifson, Jeffrey D.] Leidos BioMed Res Inc, AIDS & Canc Virus Program, Frederick Natl Lab Canc Res, Frederick, MD USA; [Martins, Mauricio A.] Scripps Res, Dept Immunol & MicroBiol, Jupiter, FL USA	George Washington University; University of Miami; University of Miami; University of Massachusetts System; University of Massachusetts Boston; Harvard University; Harvard Medical School; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; University of Wisconsin System; University of Wisconsin Madison; International AIDS Vaccine Initiative; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pedreno-Lopez, N (corresponding author), George Washington Univ, Dept Pathol, Washington, DC 20052 USA.	npedreno@gwu.edu	Voigt, Thomas B/S-9736-2018	Voigt, Thomas B/0000-0003-2217-897X; Magnani, Diogo/0000-0002-1773-2406; Pedreno Lopez, Nuria/0000-0001-6927-2301	NIH [R01 AI052056, F30 AI147881, U24AI126683]; National Cancer Institute, National Institutes of Health [HHSN261200800001E, 75N91019D00024]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH Grant R01 AI052056, F30 AI147881, and U24AI126683, and in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract Nos. HHSN261200800001E and 75N91019D00024. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ackerman ME, 2011, J IMMUNOL METHODS, V366, P8, DOI 10.1016/j.jim.2010.12.016; Alter G, 2020, CELL, V183, P185, DOI 10.1016/j.cell.2020.08.033; Barouch DH, 2018, LANCET, V392, P232, DOI [10.1016/S0140-6736(18)31364-3, 10.1016/s0140-6736(18)31364-3]; Barouch DH, 2015, SCIENCE, V349, P320, DOI 10.1126/science.aab3886; Braun N, 1998, TRANSFUS SCI, V19, P65; Chaudhury C, 2003, J EXP MED, V197, P315, DOI 10.1084/jem.20021829; Chung AW, 2017, RETROVIROLOGY, V14, DOI 10.1186/s12977-017-0380-3; Chung AW, 2015, CELL, V163, P988, DOI 10.1016/j.cell.2015.10.027; Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669; D'Hooghe L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182695; DiLillo DJ, 2015, CELL, V161, P1035, DOI 10.1016/j.cell.2015.04.016; DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443; Gaufin T, 2009, J VIROL, V83, P10347, DOI 10.1128/JVI.00880-09; HALSTEAD SB, 1979, J INFECT DIS, V140, P527, DOI 10.1093/infdis/140.4.527; Hansen SG, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw2607; Hansen SG, 2013, NATURE, V502, P100, DOI 10.1038/nature12519; Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003; Hessell AJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000433; Huang KHG, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1100; Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836; Kim DK, 2015, ANN LAB MED, V35, P506, DOI 10.3343/alm.2015.35.5.506; Kim J, 2007, CLIN IMMUNOL, V122, P146, DOI 10.1016/j.clim.2006.09.001; KIPROV D D, 1987, Blood Purification, V5, P51, DOI 10.1159/000169456; Li H, 2016, P NATL ACAD SCI USA, V113, pE3413, DOI 10.1073/pnas.1606636113; Martins MA, 2018, J VIROL, V92, DOI 10.1128/JVI.00690-18; Martins MA, 2017, AIDS RES HUM RETROV, V33, P843, DOI [10.1089/aid.2017.0046, 10.1089/AID.2017.0046]; Martins MA, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006529; Martins MA, 2015, J VIROL, V89, P10802, DOI 10.1128/JVI.01440-15; Mascola JR, 1999, J VIROL, V73, P4009, DOI 10.1128/JVI.73.5.4009-4018.1999; Metzner KJ, 2000, J EXP MED, V191, P1921, DOI 10.1084/jem.191.11.1921; Micci L, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004467; Moldt B, 2012, P NATL ACAD SCI USA, V109, P18921, DOI 10.1073/pnas.1214785109; Montaudouin C, 2013, J IMMUNOL, V190, P106, DOI 10.4049/jimmunol.1200907; Montefiori David C., 2009, V485, P395, DOI 10.1007/978-1-59745-170-3_26; Ortiz AM, 2011, J CLIN INVEST, V121, P4433, DOI 10.1172/JCI46023; Pedreno-Lopez N, 2020, MOL THER-METH CLIN D, V16, P225, DOI 10.1016/j.omtm.2020.01.010; Poignard P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042209; RAGHAVAN M, 1995, BIOCHEMISTRY-US, V34, P14649, DOI 10.1021/bi00045a005; Richards JO, 2008, MOL CANCER THER, V7, P2517, DOI 10.1158/1535-7163.MCT-08-0201; Roopenian DC, 2003, J IMMUNOL, V170, P3528, DOI 10.4049/jimmunol.170.7.3528; Roopenian DC, 2007, NAT REV IMMUNOL, V7, P715, DOI 10.1038/nri2155; SATO H, 1989, J IMMUNOL METHODS, V118, P161, DOI 10.1016/0022-1759(89)90002-1; Sato T, 1988, Ann N Y Acad Sci, V540, P554, DOI 10.1111/j.1749-6632.1988.tb27170.x; Schmitz JE, 2005, J VIROL, V79, P8131, DOI 10.1128/JVI.79.13.8131-8141.2005; Schneider JR, 2017, J IMMUNOL METHODS, V450, P66, DOI 10.1016/j.jim.2017.07.009; Schneidewind JM, 1998, TRANSFUS SCI, V19, P59; Smith B, 2018, MABS-AUSTIN, V10, P1111, DOI 10.1080/19420862.2018.1505464; Sutton MS, 2019, J VIROL, V93, DOI 10.1128/JVI.00537-19; Tasca S, 2011, J VIROL, V85, P3086, DOI 10.1128/JVI.02150-10; Ward ES, 2003, INT IMMUNOL, V15, P187, DOI 10.1093/intimm/dxg018; Yant LJ, 2006, J VIROL, V80, P5074, DOI 10.1128/JVI.80.10.5074-5077.2006	53	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 16	2021	12								657424	10.3389/fimmu.2021.657424	http://dx.doi.org/10.3389/fimmu.2021.657424			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RF2YA	33796119	Green Published, gold			2022-12-18	WOS:000634708200001
J	Dreesman, A; Corbiere, V; Libin, M; Racape, J; Collart, P; Singh, M; Locht, C; Mascart, F; Dirix, V				Dreesman, Alexandra; Corbiere, Veronique; Libin, Myriam; Racape, Judith; Collart, Philippe; Singh, Mahavir; Locht, Camille; Mascart, Francoise; Dirix, Violette			Specific Host Signatures for the Detection of Tuberculosis Infection in Children in a Low TB Incidence Country	FRONTIERS IN IMMUNOLOGY			English	Article						tuberculosis; purified-protein derivative; culture-filtrate-protein-10; heparin-binding haemagglutinin; tumor-necrosis-factor-&#945; interferon-&#947; -induced protein 10; Interferon-&#947	ACTIVE TUBERCULOSIS; CELL RESPONSES; DIAGNOSIS; ASSAYS; LATENT	Diagnosis of tuberculosis (TB) in children remains challenging due to unspecific clinical presentation and low bacillary load. In low TB incidence countries, most cases are diagnosed by a contact screening strategy after exposure to an index TB case. Due to the severity of TB in young children, the priority is to determine whether a child is infected or not, whereas differential diagnosis between active TB (aTB) and latent TB constitutes a second step. In Belgium, a low TB incidence country, we prospectively included 47 children with a defined M. tuberculosis infection status (12 children with aTB, 18 with latent TB, and 17 uninfected) (exploratory cohort), and determined the optimal combinations of cytokines secreted by their peripheral blood mononuclear cells in response to a 5-days in vitro stimulation with four different mycobacterial antigens, in an attempt to classify the children according to their infectious status. Correct identification of all infected children was obtained by several combinations of two purified protein derivative (PPD)-induced cytokines (IFN-gamma and either GM-CSF, MIP-1 alpha, sCD40L or TNF-alpha), or by combining PPD-induced IFN-gamma with culture-filtrate protein-10 (CFP-10)-induced TNF-alpha. Alternatively, combining CFP-10-induced TNF-alpha and IP-10 with heparin-binding haemagglutinin (HBHA)-induced-IFN-gamma was more effective in testing recently BCG-vaccinated children or those suspected to be infected with non-tuberculous mycobacteria, providing a correct classification of 97% of the M. tuberculosis-infected children. This combination also correctly classified 98% of the children from a validation cohort comprising 40 M. tuberculosis infected children and 20 non-infected children. Further differentiation between aTB and children with latent TB was more difficult. Combining ESAT-6-induced MIP1-alpha and IP-10, CFP-10-induced MIG, and HBHA-induced MIG provided a correct classification of 77% of the children from the exploratory cohort but only of 57.5% of those from the validation cohort. We conclude that combining the measurement of 2-4 cytokines induced by three different mycobacterial antigens allows an excellent identification of M. tuberculosis-infected children, whereas differentiating children with aTB from those with latent TB remains far from perfect.	[Dreesman, Alexandra; Corbiere, Veronique; Libin, Myriam; Mascart, Francoise; Dirix, Violette] Univ Libre Bruxelles, Lab Vaccinol & Mucosal Immun, Brussels, Belgium; [Dreesman, Alexandra] Ctr Hosp Univ St Pierre, Pediat Dept, Brussels, Belgium; [Racape, Judith] Erasme Univ Hosp, Biomed Res Ctr, Brussels, Belgium; [Racape, Judith; Collart, Philippe] Univ Libre Bruxelles, Ctr Rech Epidemiol, Sch Publ Hlth, Rech Clin,Biostat, Brussels, Belgium; [Singh, Mahavir] Lionex Diagnost & Therapeut, Braunschweig, Germany; [Locht, Camille] Univ Lille, Inst Pasteur Lille, U1019 UMR9017,CIIL Ctr Infect & Immun Lille, CHU Lille,CNRS,Inserm, Lille, France	Universite Libre de Bruxelles; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Lionex Diagnostics & Therapeutics GmbH; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; CHU Lille; Universite de Lille	Mascart, F (corresponding author), Univ Libre Bruxelles, Lab Vaccinol & Mucosal Immun, Brussels, Belgium.	francoise.mascart@erasme.ulb.ac.be			Fond Van de Voorde from the Fondation Roi Baudouin; Fonds National de la Recherche Scientifique [FNRS-PDR T.0147.13]; European Community within the Seventh Framework Program (FP7) NEWTBVAC [HEALTH-2009-2.3.2-2]; Horizon2020 program TBVAC2020 [643381]; Fonds National de la Recherche Scientifique (FNRS); Innoviris	Fond Van de Voorde from the Fondation Roi Baudouin; Fonds National de la Recherche Scientifique(Fonds de la Recherche Scientifique - FNRS); European Community within the Seventh Framework Program (FP7) NEWTBVAC; Horizon2020 program TBVAC2020; Fonds National de la Recherche Scientifique (FNRS)(Fonds de la Recherche Scientifique - FNRS); Innoviris(Innoviris)	This work was supported by the grant Fond Van de Voorde from the Fondation Roi Baudouin, by the Fonds National de la Recherche Scientifique (FNRS-PDR T.0147.13), by the European Community within the Seventh Framework Program (FP7) NEWTBVAC (Grant HEALTH-2009-2.3.2-2), and within the Horizon2020 program TBVAC2020 (Grant agreement 643381), and by Innoviris. Brussels. VC was supported by a fellowship from the Fonds National de la Recherche Scientifique (FNRS).	[Anonymous], FONDS AFFECTIONS RES; Chiappini E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046041; Denkinger CM, 2015, J INFECT DIS, V211, pS29, DOI 10.1093/infdis/jiu821; Doan TN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188631; Dreesman A, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00311; Dreesman A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01059; Gourgouillon N, 2012, PEDIATR RES, V72, P370, DOI 10.1038/pr.2012.89; Hougardy JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000926; Kay AW, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-3918; Latorre I, 2014, J INFECTION, V69, P590, DOI 10.1016/j.jinf.2014.06.013; Mascart F, 2015, EXPERT REV VACCINES, V14, P1573, DOI 10.1586/14760584.2015.1102638; Masungi C, 2002, J INFECT DIS, V185, P513, DOI 10.1086/338833; Portevin D, 2014, LANCET INFECT DIS, V14, P931, DOI 10.1016/S1473-3099(14)70884-9; Schepers K, 2015, VACCINE, V33, P1077, DOI 10.1016/j.vaccine.2014.12.011; Schepers K, 2014, CLIN VACCINE IMMUNOL, V21, P111, DOI 10.1128/CVI.00525-13; Tebruegge M, 2016, PEDIATR INFECT DIS J, V35, P929, DOI 10.1097/INF.0000000000001195; Tebruegge M, 2015, PEDIATR INFECT DIS J, V34, P1014, DOI 10.1097/INF.0000000000000796; Tebruegge M, 2015, AM J RESP CRIT CARE, V192, P485, DOI 10.1164/rccm.201501-0059OC; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25; Whittaker E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003901; WHO, 2010, WORLD MALARIA REPORT 2010, P1; World Health Organization, 2018, ROADM END TB CHILDR, V2nd	22	0	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 15	2021	12								575519	10.3389/fimmu.2021.575519	http://dx.doi.org/10.3389/fimmu.2021.575519			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RE4BL	33790886	Green Published, gold			2022-12-18	WOS:000634101600001
J	Gerardo, CJ; Silvius, E; Schobel, S; Eppensteiner, JC; McGowan, LM; Elster, EA; Kirk, AD; Limkakeng, AT				Gerardo, Charles J.; Silvius, Elizabeth; Schobel, Seth; Eppensteiner, John C.; McGowan, Lauren M.; Elster, Eric A.; Kirk, Allan D.; Limkakeng, Alexander T.			Association of a Network of Immunologic Response and Clinical Features With the Functional Recovery From Crotalinae Snakebite Envenoming	FRONTIERS IN IMMUNOLOGY			English	Article						snake bite; antivenin; cytokine; prognostic model; predictive modeling; chemokine; Patient Specific Functional Scale	IMMUNE FAB ANTIVENOM; ENVENOMATION; BITES	Background The immunologic pathways activated during snakebite envenoming (SBE) are poorly described, and their association with recovery is unclear. The immunologic response in SBE could inform a prognostic model to predict recovery. The purpose of this study was to develop pre- and post-antivenom prognostic models comprised of clinical features and immunologic cytokine data that are associated with recovery from SBE. Materials and Methods We performed a prospective cohort study in an academic medical center emergency department. We enrolled consecutive patients with Crotalinae SBE and obtained serum samples based on previously described criteria for the Surgical Critical Care Initiative (SC2i)(ClinicalTrials.gov Identifier: NCT02182180). We assessed a standard set of clinical variables and measured 35 unique cytokines using Luminex Cytokine 35-Plex Human Panel pre- and post-antivenom administration. The Patient-Specific Functional Scale (PSFS), a well-validated patient-reported outcome of functional recovery, was assessed at 0, 7, 14, 21 and 28 days and the area under the patient curve (PSFS AUPC) determined. We performed Bayesian Belief Network (BBN) modeling to represent relationships with a diagram composed of nodes and arcs. Each node represents a cytokine or clinical feature and each arc represents a joint-probability distribution (JPD). Results Twenty-eight SBE patients were enrolled. Preliminary results from 24 patients with clinical data, 9 patients with pre-antivenom and 11 patients with post-antivenom cytokine data are presented. The group was mostly female (82%) with a mean age of 38.1 (SD +/- 9.8) years. In the pre-antivenom model, the variables most closely associated with the PSFS AUPC are predominantly clinical features. In the post-antivenom model, cytokines are more fully incorporated into the model. The variables most closely associated with the PSFS AUPC are age, antihistamines, white blood cell count (WBC), HGF, CCL5 and VEGF. The most influential variables are age, antihistamines and EGF. Both the pre- and post-antivenom models perform well with AUCs of 0.87 and 0.90 respectively. Discussion Pre- and post-antivenom networks of cytokines and clinical features were associated with functional recovery measured by the PSFS AUPC over 28 days. With additional data, we can identify prognostic models using immunologic and clinical variables to predict recovery from SBE.	[Gerardo, Charles J.; Eppensteiner, John C.; McGowan, Lauren M.; Kirk, Allan D.; Limkakeng, Alexander T.] Duke Univ, Dept Surg, Durham, NC USA; [Silvius, Elizabeth] DecisionQ, Arlington, VA USA; [Schobel, Seth; Elster, Eric A.] Uniformed Serv Univ Hlth Sci, Dept Surg, Bethesda, MD 20814 USA	Duke University; Uniformed Services University of the Health Sciences - USA	Gerardo, CJ (corresponding author), Duke Univ, Dept Surg, Durham, NC USA.	gerar001@mc.duke.edu	Elster, Eric/ABG-6091-2021	Kirk, Allan/0000-0003-2004-5962; Schobel, Seth/0000-0002-8967-257X	United States Department of Defense [USUHS HT9404-13-1-0032, USUHS HU001-15-2-0001]	United States Department of Defense(United States Department of Defense)	Grant funding for this research: United States Department of Defense. USUHS HT9404-13-1-0032 and USUHS HU001-15-2-0001.	Almeida MTD, 2020, TOXINS, V12, DOI 10.3390/toxins12020096; Anderson VE, 2019, CLIN TOXICOL, V57, P25, DOI 10.1080/15563650.2018.1491982; Belard A, 2018, MIL MED, V183, P487, DOI 10.1093/milmed/usx164; Bickler PE, 2020, TOXINS, V12, DOI 10.3390/toxins12020068; Borek HA, 2017, ANN EMERG MED, V70, P928, DOI 10.1016/j.annemergmed.2017.08.002; Bradley M, 2020, WORLD J SURG, V44, P2255, DOI 10.1007/s00268-019-05294-3; Brenes-Chacon H, 2019, ACTA TROP, V200, DOI 10.1016/j.actatropica.2019.105176; Bucaretch Fabio, 2001, Revista do Instituto de Medicina Tropical de Sao Paulo, V43, P329, DOI 10.1590/S0036-46652001000600006; BUCARETCHI Fábio, 2002, Rev. Inst. Med. trop. S. Paulo, V44, P133, DOI 10.1590/S0036-46652002000300004; Bush SP, 2015, CLIN TOXICOL, V53, P37, DOI 10.3109/15563650.2014.974263; Quintana-Castillo JC, 2020, CLINICOECONOMIC OUTC, V12, P547, DOI 10.2147/CEOR.S259426; Cezarette GN, 2020, INT J BIOL MACROMOL, V144, P296, DOI 10.1016/j.ijbiomac.2019.12.015; Chippaux JP, 1998, B WORLD HEALTH ORGAN, V76, P515; Chippaux JP, 2002, B SOC PATHOL EXOT, V95, P181; Clark RF, 2002, ANN EMERG MED, V39, P671, DOI 10.1067/mem.2002.123134; Dart RC, 1997, ANN EMERG MED, V30, P33, DOI 10.1016/S0196-0644(97)70107-0; Dart RC, 2001, ARCH INTERN MED, V161, P2030, DOI 10.1001/archinte.161.16.2030; de Silva HA, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000435; Dente CJ, 2017, J TRAUMA ACUTE CARE, V83, P609, DOI 10.1097/TA.0000000000001596; Freiermuth CE, 2019, WEST J EMERG MED, V20, P497, DOI 10.5811/westjem.2019.3.42693; Gelbard RB, 2019, J TRAUMA ACUTE CARE, V87, P1125, DOI 10.1097/TA.0000000000002486; Gerardo CJ, 2019, JAMA SURG, V154, P346, DOI 10.1001/jamasurg.2018.5069; Gerardo CJ, 2017, ANN EMERG MED, V70, P929, DOI 10.1016/j.annemergmed.2017.08.003; Gerardo CJ, 2017, ANN EMERG MED, V70, P233, DOI 10.1016/j.annemergmed.2017.04.034; Gerardo CJ, 2017, CLIN TOXICOL, V55, P109, DOI 10.1080/15563650.2016.1250275; Gerardo CJ, 2015, ACAD EMERG MED, V22, P308, DOI 10.1111/acem.12598; Gold BS, 2002, NEW ENGL J MED, V347, P347, DOI 10.1056/NEJMra013477; Habib AG, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008374; Habib AG, 2018, TOXICON, V150, P115, DOI 10.1016/j.toxicon.2018.05.009; Hamza M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004568; Harrison RA, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005969; Harrison RA, 2016, TOXINS, V8, DOI 10.3390/toxins8120351; Hasan SMK, 2012, TROP DOCT, V42, P41, DOI 10.1258/td.2011.110137; Kanaan NC, 2015, WILD ENVIRON MED, V26, P472, DOI 10.1016/j.wem.2015.05.007; Kasturiratne A, 2008, PLOS MED, V5, P1591, DOI 10.1371/journal.pmed.0050218; Kojima N, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1947-7; Kravitz J, 2006, CLIN TOXICOL, V44, P353, DOI 10.1080/15563650600584725; Lalloo DG, 2003, J TOXICOL-CLIN TOXIC, V41, P277, DOI 10.1081/CLT-120021113; Larson Bruce A, 2013, Cost Eff Resour Alloc, V11, P18, DOI 10.1186/1478-7547-11-18; Lavonas EJ, 2011, BMC EMERG MED, V11, DOI 10.1186/1471-227X-11-2; Lavonas EJ, 2020, CLIN TOXICOL, V58, P223, DOI 10.1080/15563650.2019.1641607; Lavonas EJ, 2019, CLIN TOXICOL, V57, P144, DOI 10.1080/15563650.2018.1502445; Lisboa FA, 2017, SURGERY, V161, P1164, DOI 10.1016/j.surg.2016.10.011; Liu Y, 2020, ANALYST, V145, P5027, DOI 10.1039/d0an00461h; Lomonte B, 2014, J PROTEOMICS, V96, P103, DOI 10.1016/j.jprot.2013.10.036; Lynch HE, 2014, J IMMUNOL METHODS, V409, P62, DOI 10.1016/j.jim.2014.04.011; Gutierez JM, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003960; Muema DM, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01529-6; Mullins ME, 2018, SOUTH MED J, V111, P716, DOI 10.14423/SMJ.0000000000000902; Nicoleti AF, 2010, REV SOC BRAS MED TRO, V43, P657, DOI 10.1590/S0037-86822010000600011; Nogueira FA, 2019, CURR TOP MED CHEM, V19, P2058, DOI 10.2174/1568026619666190809100319; Otero R, 2002, TOXICON, V40, P1107, DOI 10.1016/S0041-0101(02)00104-6; Pach S, 2020, ARCH DIS CHILD, V105, P1135, DOI 10.1136/archdischild-2020-319417; Patro ARK, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010034; Pham HX, 2018, CLIN TOXICOL, V56, P1121, DOI 10.1080/15563650.2018.1468447; Pinho FMO, 2005, KIDNEY INT, V67, P659, DOI 10.1111/j.1523-1755.2005.67122.x; Pucca MB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01598; Ren MH, 2019, LANCET GLOB HEALTH, V7, pE837, DOI 10.1016/S2214-109X(19)30225-6; Rex CJ, 2019, TOXICON, V164, P51, DOI 10.1016/j.toxicon.2019.03.027; Ribeiro LA, 2001, T ROY SOC TROP MED H, V95, P630, DOI 10.1016/S0035-9203(01)90101-4; Rokyta DR, 2015, TOXICON, V98, P34, DOI 10.1016/j.toxicon.2015.02.015; Ibiapina HNS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01882; Seifert SA, 2020, TOXICON, V184, P55, DOI 10.1016/j.toxicon.2020.05.026; Seifert SA, 2011, CLIN TOXICOL, V49, P324, DOI 10.3109/15563650.2011.566883; Shah KR, 2020, CLIN TOXICOL, V58, P222, DOI 10.1080/15563650.2019.1620263; Stone SF, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002326; Thomas L, 1998, T ROY SOC TROP MED H, V92, P542, DOI 10.1016/S0035-9203(98)90907-5; Vissoci JRN, 2020, TOXICON, V182, pS16; Ward KN., 2014, ANN EMERG MED, V64, pS141, DOI [10.1016/j.annemergmed.2014.07.424, DOI 10.1016/J.ANNEMERGMED.2014.07.424]; Wellmann IAM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01874; WHITE RR, 1991, ANN SURG, V213, P466, DOI 10.1097/00000658-199105000-00012; Williams DJ, 2007, TOXICON, V49, P780, DOI 10.1016/j.toxicon.2006.11.026; Williams DJ, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007059; Williams DJ, 2018, TOXICON, V150, P1, DOI 10.1016/j.toxicon.2018.05.001; Yin S, 2011, ACAD EMERG MED, V18, P46, DOI 10.1111/j.1553-2712.2010.00958.x	75	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 15	2021	12								628113	10.3389/fimmu.2021.628113	http://dx.doi.org/10.3389/fimmu.2021.628113			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RE6LZ	33790901	gold, Green Published			2022-12-18	WOS:000634264300001
J	Greco, R; Peccatori, J; Bonifazi, F; Snowden, JA; Ciceri, F				Greco, Raffaella; Peccatori, Jacopo; Bonifazi, Francesca; Snowden, John A.; Ciceri, Fabio			Editorial: Novel Immunological Biomarkers for Allogeneic HSCT Outcome	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						biomarkers; allogeneic transplantation; outcomes; graft-versus-host disease; transplant-related mortality; cytokines; immunological biomarkers; proteins			[Greco, Raffaella; Peccatori, Jacopo; Ciceri, Fabio] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Unit Hematol & Bone Marrow Transplantat, Milan, Italy; [Bonifazi, Francesca] Univ Bologna, IRCCS Azienda Osped, Hematol, Bologna, Italy; [Snowden, John A.] Sheffield Teaching Hosp NHS Fdn Trust, Dept Haematol, Sheffield, S Yorkshire, England; [Snowden, John A.] Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England; [Ciceri, Fabio] Univ Vita Salute San Raffaele, Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Bologna; University of Sheffield; University of Sheffield; Vita-Salute San Raffaele University	Greco, R (corresponding author), Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Unit Hematol & Bone Marrow Transplantat, Milan, Italy.	greco.raffaella@hsr.it	Greco, Raffaella/K-9499-2016; bonifazi, francesca/J-5643-2018	Greco, Raffaella/0000-0002-6117-5328; bonifazi, francesca/0000-0003-1544-9911; SNOWDEN, JOHN/0000-0001-6819-3476				Duarte RF, 2019, BONE MARROW TRANSPL, V54, P1525, DOI 10.1038/s41409-019-0516-2; Passweg JR, 2020, BONE MARROW TRANSPL, V55, P1604, DOI 10.1038/s41409-020-0826-4; Penack O, 2020, BLOOD ADV, V4, P6283, DOI 10.1182/bloodadvances.2020003418; Sorror ML, 2014, J CLIN ONCOL, V32, P3249, DOI 10.1200/JCO.2013.53.8157	4	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 12	2021	12								670822	10.3389/fimmu.2021.670822	http://dx.doi.org/10.3389/fimmu.2021.670822			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RC5ZK	33777058	Green Accepted, Green Published, gold			2022-12-18	WOS:000632878800001
J	Licciardi, PV; Frazer, IH; Garland, SM; Mulholland, K				Licciardi, Paul V.; Frazer, Ian H.; Garland, Suzanne M.; Mulholland, Kim			Editorial: Immunology of HPV Infection and Vaccination: Progress and Challenges	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						human papillomavirus; vaccination; immune response; HPV infection; protection			[Licciardi, Paul V.; Garland, Suzanne M.; Mulholland, Kim] Murdoch Childrens Res Inst, Infect & Immun, Melbourne, Vic, Australia; [Licciardi, Paul V.; Mulholland, Kim] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Frazer, Ian H.] Univ Queensland, Diamantina Inst, Brisbane, Qld, Australia; [Garland, Suzanne M.] Univ Melbourne, Dept Obstet & Gynecol, Melbourne, Vic, Australia; [Garland, Suzanne M.] Royal Womens Hosp, Ctr Womens Infect Dis Res, Melbourne, Vic, Australia; [Mulholland, Kim] London Sch Hyg & Trop Med, Dept Infect Dis Epidmiol, London, England	Murdoch Children's Research Institute; University of Melbourne; University of Queensland; University of Melbourne; University of London; London School of Hygiene & Tropical Medicine	Licciardi, PV (corresponding author), Murdoch Childrens Res Inst, Infect & Immun, Melbourne, Vic, Australia.; Licciardi, PV (corresponding author), Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia.	paul.licciardi@mcri.edu.au			Australian National Health and Medical Research Council Career Development Fellowship [GNT1146198]; Australian National Health and Medical Research Council [GNT1173927, GNT1197951]	Australian National Health and Medical Research Council Career Development Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	PVL is supported by an Australian National Health and Medical Research Council Career Development Fellowship Level 2 (GNT1146198). IHF is supported by an Australian National Health and Medical Research Council Investigator Grant (GNT1173927). SMG is supported by an Australian National Health and Medical Research Council Investigator Grant (GNT1197951).		0	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 12	2021	12								665463	10.3389/fimmu.2021.665463	http://dx.doi.org/10.3389/fimmu.2021.665463			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RC5SB	33777057	Green Published, gold			2022-12-18	WOS:000632859700001
J	Malengier-Devlies, B; Decaesteker, T; Dekoster, K; Vanstapel, A; Ahmadzadeh, K; Poosti, F; Mitera, T; Seldeslachts, L; Verbeken, E; Wouters, C; Vande Velde, G; Vanoirbeek, J; Matthys, P				Malengier-Devlies, Bert; Decaesteker, Tatjana; Dekoster, Kaat; Vanstapel, Arno; Ahmadzadeh, Kourosh; Poosti, Fariba; Mitera, Tania; Seldeslachts, Laura; Verbeken, Erik; Wouters, Carine; Vande Velde, Greetje; Vanoirbeek, Jeroen; Matthys, Patrick			Lung Functioning and Inflammation in a Mouse Model of Systemic Juvenile Idiopathic Arthritis	FRONTIERS IN IMMUNOLOGY			English	Article						lung inflammation; autoinflammation; mouse model; SJIA; IFN gamma		Systemic juvenile idiopathic arthritis (sJIA) is an immune disorder characterized by fever, skin rash, arthritis and splenomegaly. Recently, increasing number of sJIA patients were reported having lung disease. Here, we explored lung abnormalities in a mouse model for sJIA relying on injection of IFN-gamma deficient (IFN-gamma KO) mice with complete Freund's adjuvant (CFA). Monitoring of lung changes during development of sJIA using microcomputer tomography revealed a moderate enlargement of lungs, a decrease in aerated and increase in non-aerated lung density. When lung function and airway reactivity to methacholine was assessed, gender differences were seen. While male mice showed an increased tissue hysteresivity, female animals were characterized by an increased airway hyperactivity, mirroring ongoing inflammation. Histologically, lungs of sJIA-like mice showed subpleural and parenchymal cellular infiltrates and formation of small granulomas. Flow cytometric analysis identified immature and mature neutrophils, and activated macrophages as major cell infiltrates. Lung inflammation in sJIA-like mice was accompanied by augmented expression of IL-1 beta and IL-6, two target cytokines in the treatment of sJIA. The increased expression of granulocyte colony stimulating factor, a potent inducer of granulopoiesis, in lungs of mice was striking considering the observed neutrophilia in patients. We conclude that development of sJIA in a mouse model is associated with lung inflammation which is distinct to the lung manifestations seen in sJIA patients. Our observations however underscore the importance of monitoring lung disease during systemic inflammation and the model provides a tool to explore the underlying mechanism of lung pathology in an autoinflammatory disease context.	[Malengier-Devlies, Bert; Ahmadzadeh, Kourosh; Mitera, Tania; Wouters, Carine; Matthys, Patrick] Katholieke Univ Leuven, Dept Microbiol & Immunol, Lab Immunobiol, Leuven, Belgium; [Decaesteker, Tatjana; Vanstapel, Arno; Vanoirbeek, Jeroen] Katholieke Univ Leuven, Dept Chron Dis & Metab, Lab Resp Dis & Thorac Surg BREATHE, Leuven, Belgium; [Dekoster, Kaat; Seldeslachts, Laura; Vande Velde, Greetje] Katholieke Univ Leuven, Dept Imaging & Pathol, Biomed MRI, Leuven, Belgium; [Poosti, Fariba] Katholieke Univ Leuven, Dept Microbiol & Immunol, Lab Mol Immunol, Leuven, Belgium; [Verbeken, Erik] Univ Hosp Leuven, Morphol & Mol Pathol Sect, Leuven, Belgium; [Wouters, Carine] Univ Hosp Leuven, Div Pediat Rheumatol, Leuven, Belgium; [Wouters, Carine] Univ Hosp Leuven, European Reference Network Rare Immunodeficiency, Leuven, Belgium	KU Leuven; KU Leuven; KU Leuven; KU Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven	Matthys, P (corresponding author), Katholieke Univ Leuven, Dept Microbiol & Immunol, Lab Immunobiol, Leuven, Belgium.	patrick.matthys@kuleuven.be	Vanstapel, Arno/AAD-6103-2020; Malengier-Devlies, Bert/F-6523-2018; Matthys, Patrick/B-4813-2018; Vanoirbeek, Jeroen/D-5183-2016	Vanstapel, Arno/0000-0003-2412-8001; Wouters, Carine/0000-0002-6426-8845; Malengier-Devlies, Bert/0000-0003-3527-1145; Seldeslachts, Laura/0000-0002-9562-2923; Matthys, Patrick/0000-0002-9685-6836; Decaesteker, Tatjana/0000-0002-3268-9397; Vanoirbeek, Jeroen/0000-0001-5508-3518	Research Foundation Flanders (FWO) [G0A3218N]; C1 grants of the KU Leuven [C16/17/010, C24/17/061, STG/15/024]; FWO [1102020N, 1S75320N, 1186121N, 1S77319N];  [12V9218N]	Research Foundation Flanders (FWO)(FWO); C1 grants of the KU Leuven; FWO(FWO); 	This work was supported by grants from the Research Foundation Flanders (FWO, G0A3218N) and by C1 grants (C16/17/010, C24/17/061, and STG/15/024) of the KU Leuven. AV, KA, LS, and KD are FWO fellows (1102020N, 1S75320N, 1186121N, and 1S77319N). FP received a postdoctoral research fellowship (12V9218N).	Alamoudi OSB, 2015, RESPIROLOGY, V20, P474, DOI 10.1111/resp.12473; ATHREYA BH, 1980, CLIN CHEST MED, V1, P361; Avau A, 2015, CYTOKINE GROWTH F R, V26, P35, DOI 10.1016/j.cytogfr.2014.05.005; Avau A, 2014, ARTHRITIS RHEUMATOL, V66, P1340, DOI 10.1002/art.38359; Berghen N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53876-x; Chen ES, 2001, AM J RESP CELL MOL, V24, P545, DOI 10.1165/ajrcmb.24.5.4064; Chu CQ, 2007, ARTHRITIS RHEUM, V56, P1145, DOI 10.1002/art.22453; Cruz A, 2006, J IMMUNOL, V177, P1416, DOI 10.4049/jimmunol.177.3.1416; de Jager W, 2009, ARTHRITIS RHEUM-US, V60, P2782, DOI 10.1002/art.24750; Devos FC, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0610-1; FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249; Gerfaud-Valentin M, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004258; GILBERT S, 1993, AM REV RESPIR DIS, V148, P483, DOI 10.1164/ajrccm/148.2.483; Grevich S, 2017, ADOLESC HEALTH MED T, V8, P125, DOI 10.2147/AHMT.S109495; Grom AA, 2010, CURR OPIN RHEUMATOL, V22, P561, DOI 10.1097/01.bor.0000381996.69261.71; Guerrieri A, 2017, RESPIR MED CASE REP, V22, P91, DOI 10.1016/j.rmcr.2017.07.001; Iriguchi S, 2015, BLOOD, V125, P370, DOI 10.1182/blood-2014-05-575225; KAMIJO R, 1993, J EXP MED, V178, P1435, DOI 10.1084/jem.178.4.1435; Kelchtermans H, 2007, J LEUKOCYTE BIOL, V81, P1044, DOI 10.1189/jlb.0806486; Kessel C, 2017, ARTHRITIS RHEUMATOL, V69, P1480, DOI 10.1002/art.40099; Kessel C, 2013, CLIN IMMUNOL, V147, P229, DOI 10.1016/j.clim.2012.11.008; Kimura Y, 2013, ARTHRIT CARE RES, V65, P745, DOI 10.1002/acr.21889; Klotsche J, 2016, ARTHRITIS RHEUMATOL, V68, P3023, DOI 10.1002/art.39796; Macaubas C, 2010, CLIN IMMUNOL, V134, P206, DOI 10.1016/j.clim.2009.09.010; Matthys P, 1999, J IMMUNOL, V163, P3503; Mellins ED, 2011, NAT REV RHEUMATOL, V7, P416, DOI 10.1038/nrrheum.2011.68; Misharin AV, 2013, AM J RESP CELL MOL, V49, P503, DOI 10.1165/rcmb.2013-0086MA; Nigrovic PA, 2019, ARTHRITIS RHEUMATOL, V71, P1773, DOI 10.1002/art.41071; Ohshimo S, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0012-2017; Pascual V, 2005, J EXP MED, V201, P1479, DOI 10.1084/jem.20050473; Petty RE, 2004, J RHEUMATOL, V31, P390; Prakken B, 2011, LANCET, V377, P2138, DOI 10.1016/S0140-6736(11)60244-4; Prencipe G, 2019, CURR OPIN RHEUMATOL, V31, P421, DOI 10.1097/BOR.0000000000000634; Put K, 2017, ARTHRITIS RHEUMATOL, V69, P213, DOI 10.1002/art.39933; Ravelli A, 2015, HEMATOL ONCOL CLIN N, V29, P927, DOI 10.1016/j.hoc.2015.06.010; Ruperto N, 2012, NEW ENGL J MED, V367, P2396, DOI 10.1056/NEJMoa1205099; Saper VE, 2019, ANN RHEUM DIS, V78, P1722, DOI 10.1136/annrheumdis-2019-216040; Schulert GS, 2019, ARTHRITIS RHEUMATOL, V71, P1943, DOI 10.1002/art.41073; Schultz R, 2001, PEDIATR PULM, V32, P397, DOI 10.1002/ppul.1149; Schurgers E, 2012, EUR J IMMUNOL, V42, P3223, DOI 10.1002/eji.201242573; Solomon JJ, 2013, EUR RESPIR REV, V22, P6, DOI 10.1183/09059180.00005512; Takakuwa Y, 2019, CLIN EXP RHEUMATOL, V37, P23; Tarique AA, 2015, AM J RESP CELL MOL, V53, P676, DOI 10.1165/rcmb.2015-0012OC; Tomashefski JF., 2008, DAIL HAMMARS PULMONA, P316, DOI [10.1007/978-0-387-68792-6_9, DOI 10.1007/978-0-387-68792-6_9]; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Vande Velde G, 2016, DIS MODEL MECH, V9, P91, DOI 10.1242/dmm.020321; Vande Velde G, 2014, INVEST RADIOL, V49, P691, DOI 10.1097/RLI.0000000000000071; Woo P, 2006, NAT CLIN PRACT RHEUM, V2, P28, DOI 10.1038/ncprheum0084; Yokota S, 2008, LANCET, V371, P998, DOI 10.1016/S0140-6736(08)60454-7; Yunt ZX, 2015, RHEUM DIS CLIN N AM, V41, P225, DOI 10.1016/j.rdc.2014.12.004	50	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 12	2021	12								642778	10.3389/fimmu.2021.642778	http://dx.doi.org/10.3389/fimmu.2021.642778			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RC8IU	33777039	gold, Green Published			2022-12-18	WOS:000633038400001
J	Korb, E; Drinic, M; Wagner, A; Geissler, N; Inic-Kanada, A; Peschke, R; Joachim, A; Wiedermann, U; Schabussova, I				Korb, Elke; Drinic, Mirjana; Wagner, Angelika; Geissler, Nora; Inic-Kanada, Aleksandra; Peschke, Roman; Joachim, Anja; Wiedermann, Ursula; Schabussova, Irma			Reduction of Allergic Lung Disease by Mucosal Application of Toxoplasma gondii-Derived Molecules: Possible Role of Carbohydrates	FRONTIERS IN IMMUNOLOGY			English	Article						Toxoplasma gondii; tachyzoites lysate antigen; allergic airway inflammation; immunomodulation; deglycosylation; hygiene hypothesis; parasites; carbohydrates	ABILITY; ASTHMA	Background The hygiene hypothesis suggests a link between parasitic infections and immune disorders, such as allergic diseases. We previously showed that infection with Toxoplasma gondii or systemic application of T. gondii tachyzoites lysate antigen (TLA) in a prophylactic, but not therapeutic protocol, prevented allergic airway inflammation in mice. Here we tested the effect of prophylactic and therapeutic application of TLA via the mucosal route. Methods Mice were intranasally treated with TLA either i) prior to sensitization, ii) during sensitization and challenge, or iii) after sensitization with ovalbumin (OVA). Recruitment of inflammatory cells to the lung, cytokine levels in restimulated lung and spleen cell cultures as well as levels of OVA-specific antibodies in serum were measured. In parallel, the effect of native TLA, heat-inactivated (hiTLA) or deglycosylated TLA (dgTLA) on sensitized splenocytes was evaluated ex vivo. Results When applied together with OVA i) during systemic sensitization and local challenge or ii) exclusively during local challenge, TLA reduced infiltration of eosinophils into the lung, OVA-specific type 2 cytokines in restimulated lung cell cultures, and partially, type 2 cytokines in restimulated spleen cell cultures in comparison to allergic controls. No beneficial effect was observed when TLA was applied prior to the start of sensitization. Analysis of epitope sugars on TLA indicated a high abundance of mannose, fucose, N-acetylglucosamine, and N-acetylgalactosamine. Deglycosylation of TLA, but not heat-inactivation, abolished the potential of TLA to reduce type 2 responses ex vivo, suggesting a significant role of carbohydrates in immunomodulation. Conclusion We showed that mucosal application of TLA reduced the development of experimental allergy in mice. The beneficial effects depended on the timing of the application in relation to the time point of sensitization. Not only co-application, but also therapy in sensitized/allergic animals with native TLA reduced local allergic responses. Furthermore, we show that TLA is highly glycosylated and glycoconjugates seem to play a role in anti-allergic effects. In summary, given the powerful modulatory effect that TLA exhibits, understanding its exact mechanisms of action may lead to the development of novel immunomodulators in clinical application.	[Korb, Elke; Drinic, Mirjana; Wagner, Angelika; Geissler, Nora; Inic-Kanada, Aleksandra; Wiedermann, Ursula; Schabussova, Irma] Med Univ Vienna, Inst Specif Prophylaxis & Trop Med, Vienna, Austria; [Peschke, Roman; Joachim, Anja] Univ Vet Med Vienna, Inst Parasitol, Dept Pathobiol, Vienna, Austria	Medical University of Vienna; University of Veterinary Medicine Vienna	Schabussova, I (corresponding author), Med Univ Vienna, Inst Specif Prophylaxis & Trop Med, Vienna, Austria.	irma.schabussova@meduniwien.ac.at		Wiedermann, Ursula/0000-0002-1302-3223; Wagner, Angelika/0000-0002-5447-9534; Inic-Kanada, Aleksandra/0000-0001-7854-3812; Schabussova, Irma/0000-0002-2109-2640	Austrian Science Fund (FWF) [SFB F4612]; OeAD [CZ 17/2019, CZ 16/2019, SRB 20/2018, PL 04/2019]	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); OeAD	This work was supported by the Austrian Science Fund (FWF) grants SFB F4612 and the OeAD grants CZ 17/2019, CZ 16/2019, SRB 20/2018, and PL 04/2019 (to EK and IS).	Abramson MJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001186.pub2; Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Arroyo-Olarte RD, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002288; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bergeron A, 1997, BIOCHEM J, V321, P889, DOI 10.1042/bj3210889; Besteiro S, 2008, BIOCHEM J, V415, P87, DOI 10.1042/BJ20080795; Blader IJ, 2015, ANNU REV MICROBIOL, V69, P463, DOI 10.1146/annurev-micro-091014-104100; Calamita Z, 2006, ALLERGY, V61, P1162, DOI 10.1111/j.1398-9995.2006.01205.x; Cantani A, 2005, Eur Rev Med Pharmacol Sci, V9, P103; Carter NJ, 2011, DRUGS, V71, P1591, DOI 10.2165/11206860-000000000-00000; Chong BTY, 1998, J PHARMACOL TOXICOL, V39, P163, DOI 10.1016/S1056-8719(98)00021-5; Coppens I, 2020, TOXOPLASMA GONDII: THE MODEL APICOMPLEXAN-PERSPECTIVES AND METHODS, 3RD EDITION, P367, DOI 10.1016/B978-0-12-815041-2.00008-6; Coyle AJ, 1996, J IMMUNOL, V156, P2680; D'Amato G, 2014, MULTIDISCIP RESP MED, V9, DOI 10.1186/2049-6958-9-23; da Costa-Silva TA, 2012, EXP PARASITOL, V130, P463, DOI 10.1016/j.exppara.2012.01.005; Debierre-Grockiego F, 2007, INFECT IMMUN, V75, P2886, DOI 10.1128/IAI.01431-06; Demoly P, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0061-z; Donohue James F, 2004, Chest, V126, p125S, DOI 10.1378/chest.126.2_suppl_1.125S; Drinic M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15663-4; Droste JHJ, 2000, CLIN EXP ALLERGY, V30, P1547; Fauquenoy S, 2008, MOL CELL PROTEOMICS, V7, P891, DOI 10.1074/mcp.M700391-MCP200; Fenoy I, 2009, CLIN EXP IMMUNOL, V155, P275, DOI 10.1111/j.1365-2249.2008.03813.x; Fenoy IM, 2015, EXP PARASITOL, V154, P47, DOI 10.1016/j.exppara.2015.04.001; Fujita Hiroyuki, 2012, Clin Transl Allergy, V2, P2, DOI 10.1186/2045-7022-2-2; Garami A, 2001, MOL CELL BIOL, V21, P8168, DOI 10.1128/MCB.21.23.8168-8183.2001; Gas-Pascual E, 2019, J BIOL CHEM, V294, P1104, DOI 10.1074/jbc.RA118.006072; Greenwell P, 2008, INT J PARASITOL, V38, P749, DOI 10.1016/j.ijpara.2007.10.012; Hedlin G, 2012, THER ADV RESPIR DIS, V6, P137, DOI 10.1177/1753465812439793; Hill D, 2002, CLIN MICROBIOL INFEC, V8, P634, DOI 10.1046/j.1469-0691.2002.00485.x; Hill Dolores E., 2005, Animal Health Research Reviews, V6, P41, DOI 10.1079/AHR2005100; Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213; Homayun B, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11030129; HUGHES HPA, 1986, INT J PARASITOL, V16, P317, DOI 10.1016/0020-7519(86)90109-8; Kantelhardt SR, 2002, BIOCHEM J, V366, P217, DOI 10.1042/BJ20011678; Lajoie S, 2014, CLIN EXP ALLERGY, V44, P976, DOI 10.1111/cea.12341; LEVERY SB, 1992, J BIOL CHEM, V267, P5542; Mascanfroni ID, 2011, INT IMMUNOPHARMACOL, V11, P833, DOI 10.1016/j.intimp.2011.01.021; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; McSorley HJ, 2014, MUCOSAL IMMUNOL, V7, P1068, DOI 10.1038/mi.2013.123; McSorley HJ, 2012, CLIN MICROBIOL REV, V25, P585, DOI 10.1128/CMR.05040-11; Montoya JG, 2004, LANCET, V363, P1965, DOI 10.1016/S0140-6736(04)16412-X; Moran AP, 2008, CARBOHYD RES, V343, P1952, DOI 10.1016/j.carres.2007.12.012; Okano M, 2009, CLIN EXP IMMUNOL, V158, P164, DOI 10.1111/j.1365-2249.2009.04010.x; Piazza RMF, 1996, ACTA TROP, V61, P41, DOI 10.1016/0001-706X(95)00139-6; Possenti A, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-183; Repa A, 2003, VACCINE, V22, P87, DOI 10.1016/S0264-410X(03)00528-0; Russell M.W., 2015, MUCOSAL IMMUNOL, V4th ed., P1039, DOI [10.1016/b978-0-12-415847-4.00055-0, DOI 10.1016/B978-0-12-415847-4.00055-0]; Sarate PJ, 2019, MUCOSAL IMMUNOL, V12, P132, DOI 10.1038/s41385-018-0084-6; Sarmento B., 2014, MUCOSAL DELIV BIOPHA, P539, DOI [10.1007/978-1-4614-9524-6_25, DOI 10.1007/978-1-4614-9524-6_25]; Schabussova I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067544; Schabussova I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040271; Schabussova I, 2011, VACCINE, V29, P1981, DOI 10.1016/j.vaccine.2010.12.101; Schatz M, 2014, J ALLER CL IMM-PRACT, V2, P645, DOI 10.1016/j.jaip.2014.09.004; Skevaki C, 2018, J ALLERGY CLIN IMMUN, V142, P804, DOI 10.1016/j.jaci.2017.07.056; Smole U, 2017, SEMIN IMMUNOL, V30, P12, DOI 10.1016/j.smim.2017.07.007; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Sturge CR, 2014, INFECT IMMUN, V82, P3090, DOI 10.1128/IAI.01722-14; SUZUKI Y, 1988, SCIENCE, V240, P516, DOI 10.1126/science.3128869; Thompson R, 2011, ANAL BIOCHEM, V413, P114, DOI 10.1016/j.ab.2011.02.013; Valenta R, 2019, EBIOMEDICINE, V45, P17, DOI 10.1016/j.ebiom.2019.06.042; van den Berg LM, 2012, ANN NY ACAD SCI, V1253, P149, DOI 10.1111/j.1749-6632.2011.06392.x; von Mutius E, 2016, J ALLERGY CLIN IMMUN, V137, P680, DOI 10.1016/j.jaci.2015.12.1301; Wagner A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155081; Wagner A, 2009, INT J PARASITOL, V39, P465, DOI 10.1016/j.ijpara.2008.09.003; Wilson IBH, 2019, J BIOL CHEM, V294, P1126, DOI 10.1074/jbc.H118.007210; Yazdanbakhsh M, 2004, CLIN REV ALLERG IMMU, V26, P15, DOI 10.1385/CRIAI:26:1:15; Yukselen A, 2014, WORLD J CLIN CASES, V2, P859, DOI 10.12998/wjcc.v2.i12.859; Zaiss MM, 2015, IMMUNITY, V43, P998, DOI 10.1016/j.immuni.2015.09.012; Zhernov Y, 2019, CURR OPIN ALLERGY CL, V19, P402, DOI 10.1097/ACI.0000000000000536; Zwicker C, 2018, J ALLERGY CLIN IMMUN, V142, P1987, DOI 10.1016/j.jaci.2018.07.029	71	0	0	3	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 10	2021	11								612766	10.3389/fimmu.2020.612766	http://dx.doi.org/10.3389/fimmu.2020.612766			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RB1TT	33776987	Green Published, gold			2022-12-18	WOS:000631899500001
J	Bai, SY; Huang, BQ; Fu, S; Zhu, ML; Hu, LH; Zhu, LQ; Chen, MQ; Zhang, ZC; Tan, JP; Zhang, JP; Chen, H				Bai, Shiyu; Huang, Bingqian; Fu, Shuai; Zhu, Menglan; Hu, Lihao; Zhu, Liqiong; Chen, Manqi; Zhang, Zicheng; Tan, Jianping; Zhang, Jianping; Chen, Hui			Changes in the Distribution of Intrauterine Microbiota May Attribute to Immune Imbalance in the CBA/JxDBA/2 Abortion-Prone Mice Model	FRONTIERS IN IMMUNOLOGY			English	Article						microbiota; 16S rRNA sequencing; abortion-prone model; immune imbalance; maternal-fetal interface		Background: Female Genital Tract (FGT) is an important micro-ecological area of human body. Microbiota in the lower reproductive tract may subsequently invade the uterine cavity during embryo implantation and produce immune responses. CBA/JxDBA/2 mating combination has been widely used as an abortion-prone mice model but whether microbiota existed in their uterine cavity remains unclear. In this context, the role of the microbial communities in immune response deserves attention. Objective: To investigate the relationship between the distribution of microbiota in the uterine cavity of CBA/JxDBA/2 abortion-prone mouse model and the immune imbalance of the maternal-fetal interface. Methods: In this study, female CBA/J mice were paired with male DBA/2 mice to develop an abortion-prone model (BA group), and with male BALB/c mice to build a standard pregnancy model (BC group). The non-pregnant female mice were served as the control group (C group). Uterine flushing fluid and sera were collected on day 13.5 of pregnancy. 16S rRNA sequencing technology was used to analyze the distribution of intrauterine microbiota. Phylogenetic Investigation of Communities were conducted to predict the microbiota functions by Reconstruction of Unobserved States (PICRUST) and Kyoto Encyclopedia of Genes and Genomes (KEGG). The serum IL 10, INF-gamma, and TNF-alpha levels were examined using Enzyme-linked immunosorbent assay (ELISA) method. Results: All samples were detected with microbial communities. The alpha diversity (p = 0.00077) had significant differences among three groups. Proteobacteria was the most dominant phylum in C group (mean = 83.21%) and BA group (mean = 43.23%). Firmicutes was dominant in BC group (mean = 46.4%), as well as the second dominant one in C group (mean = 12.63%) and BA group (mean = 40.55%). Microbiota functions were associated with metabolism and immune response through the NOD-like receptor signaling pathway. The serum IL 10 level in BA group were significantly lower than that in BC group (10.14 +/- 1.90 pg/ml, n = 8; vs. 19.03 +/- 1.82 pg/ml, n = 10; p = 0.004). The serum TNF-alpha and INF-gamma level in BA group were also significantly higher than that in BC group (523.1 +/- 58.14 pg/ml, n = 8 vs. 310.3 +/- 28.51 pg/ml, n = 10, p = 0.0029; 69.22 +/- 5.38 pg/ml, n = 8 vs. 50.85 +/- 2.45 pg/ml, n = 10, p = 0.0042). Conclusion: Microbial communities were colonized in uterine cavity of CBA/J mice both at non-pregnant stage and pregnant stage when mated with both BALB/c and DBA/2 male mice. The differentially abundant microbiome may be attributed to the immune tolerance through binding to the NOD-like receptor.	[Bai, Shiyu; Huang, Bingqian; Fu, Shuai; Zhu, Menglan; Hu, Lihao; Zhu, Liqiong; Chen, Manqi; Tan, Jianping; Zhang, Jianping; Chen, Hui] Sun Yat Sen Univ, Dept Obstet & Gynecol, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China; [Bai, Shiyu; Huang, Bingqian; Fu, Shuai; Zhu, Menglan; Hu, Lihao; Zhu, Liqiong; Chen, Manqi; Tan, Jianping; Zhang, Jianping; Chen, Hui] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Ctr Reprod Genet & Reprod Med, Guangzhou, Peoples R China; [Zhang, Zicheng] Guangzhou Univ Chinese Med, Clin Med Coll 4, Dept Radiat Oncol, Shenzhen Tradit Chinese Med Hosp, Shenzhen, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Guangzhou University of Chinese Medicine	Tan, JP; Zhang, JP; Chen, H (corresponding author), Sun Yat Sen Univ, Dept Obstet & Gynecol, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China.; Tan, JP; Zhang, JP; Chen, H (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Ctr Reprod Genet & Reprod Med, Guangzhou, Peoples R China.	julietp2004@126.com; zhjianp@mail.sysu.edu.cn; chenhui9@mail.sysu.edu.cn			National Key Research and Development Program of China [2019YFA0801403]; National Nature Science Foundation of China [81771660, 81741017]; Science and Technology Planning Project of Guangdong Province [pdjh2020b0010, 2017A020214018, 2017A020214003]; Guangdong Natural Science Foundation [2018A030313023, 2018A030313162, 2018A030310162, 18zxxt56]; Science and Technology Planning Project of Guangzhou City Central Universities [201704020034]; 5010 projects at Sun Yat-Sen University [2012006]	National Key Research and Development Program of China; National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Planning Project of Guangdong Province; Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); Science and Technology Planning Project of Guangzhou City Central Universities; 5010 projects at Sun Yat-Sen University	This study was supported by the National Key Research and Development Program of China (2019YFA0801403), National Nature Science Foundation of China (Nos. 81771660 and 81741017), the Science and Technology Planning Project of Guangdong Province (2017A020214018 and 2017A020214003), Guangdong Natural Science Foundation (2018A030313023, 2018A030313162, 2018A030310162, and 18zxxt56), the Science and Technology Planning Project of Guangzhou City Central Universities (201704020034), 5010 projects at Sun Yat-Sen University (2012006), Science and Technology Planning Project of Guangdong Province (pdjh2020b0010).	Alijotas-Reig J, 2017, CLIN REV ALLERG IMMU, V53, P40, DOI 10.1007/s12016-016-8596-x; Antwis RE, 2019, MICROBIOME, V7, DOI 10.1186/s40168-019-0639-0; Bianchi E, 2016, ANNU REV GENET, V50, P93, DOI 10.1146/annurev-genet-121415-121834; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; De la Cruz-Barron M, 2017, MICROB ECOL, V73, P135, DOI 10.1007/s00248-016-0807-8; Douglas GM, 2018, METHODS MOL BIOL, V1849, P169, DOI 10.1007/978-1-4939-8728-3_11; Hoya M, 2018, AM J REPROD IMMUNOL, V79, DOI 10.1111/aji.12813; Jedrzejas MJ, 2003, CRIT REV BIOCHEM MOL, V38, P173, DOI 10.1080/713609234; Katagiri S, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00434; Mandal S, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0200-3; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Mongkolthanaruk W, 2012, J MICROBIOL BIOTECHN, V22, P1597, DOI 10.4014/jmb.1204.04013; Moreno I, 2016, AM J OBSTET GYNECOL, V215, P684, DOI 10.1016/j.ajog.2016.09.075; Nagaraj V, 2017, NPJ BIOFILMS MICROBI, V3, DOI 10.1038/s41522-017-0021-6; Proell M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002119; Rautava S, 2012, NAT REV GASTRO HEPAT, V9, P565, DOI 10.1038/nrgastro.2012.144; Renaud SJ, 2005, BIOL REPROD, V73, P237, DOI 10.1095/biolreprod.104.038000; Romero R, 2007, NUTR REV, V65, pS194, DOI [10.1111/j.1753-4887.2007.tb00362.x, 10.1301/nr.2007.dec.S194-S202]; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Tapiainen T, 2018, PEDIATR RES, V84, DOI 10.1038/pr.2018.29; Trowsdale J, 2006, NAT IMMUNOL, V7, P241, DOI 10.1038/ni1317; Walther-Antonio MRS, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0368-y; Wang Z, 2015, PLACENTA, V36, P652, DOI 10.1016/j.placenta.2015.03.004; Yang SZ, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01717	24	0	0	2	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 8	2021	12								641281	10.3389/fimmu.2021.641281	http://dx.doi.org/10.3389/fimmu.2021.641281			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QZ9SX	33763083	gold, Green Published			2022-12-18	WOS:000631060500001
J	Singh, K; Fang, H; Davies, G; Wright, B; Lockstone, H; Williams, RO; Cihakova, D; Knight, JC; Bhattacharya, S				Singh, Kamayani; Fang, Hai; Davies, Graham; Wright, Benjamin; Lockstone, Helen; Williams, Richard O.; Cihakova, Daniela; Knight, Julian C.; Bhattacharya, Shoumo			Transcriptomic Analysis of Inflammatory Cardiomyopathy Identifies Molecular Signatures of Disease and Informs in silico Prediction of a Network-Based Rationale for Therapy	FRONTIERS IN IMMUNOLOGY			English	Article						myocarditis; autoimmune; transcriptome; network; diagnosis; therapy		Inflammatory cardiomyopathy covers a group of diseases characterized by inflammation and dysfunction of the heart muscle. The immunosuppressive agents such as prednisolone, azathioprine and cyclosporine are modestly effective treatments, but a molecular rationale underpinning such therapy or the development of new therapeutic strategies is lacking. We aimed to develop a network-based approach to identify therapeutic targets for inflammatory cardiomyopathy from the evolving myocardial transcriptome in a mouse model of the disease. We performed bulk RNA sequencing of hearts at early, mid and late time points from mice with experimental autoimmune myocarditis. We identified a cascade of pathway-level events involving early activation of cytokine and chemokine-signaling pathways that precede leucocyte infiltration and are followed by innate immune, antigen-presentation, complement and cell-adhesion pathway activation. We integrated these pathway events into a network-like representation from which we further identified a 50-gene subnetwork that is predominantly induced during the course of autoimmune myocardial inflammation. We developed a combinatorial attack strategy where we quantify network tolerance to combinatorial node removal to determine target-specific therapeutic potential. We find that combinatorial attack of Traf2, Nfkb1, Rac1, and Vav1 disconnects 80% of nodes from the largest network component. Two of these nodes, Nfkb1 and Rac1, are directly targeted by prednisolone and azathioprine respectively, supporting the idea that the methodology developed here can identify valid therapeutic targets. Whereas Nfkb1 and Rac1 removal disconnects 56% of nodes, we show that additional removal of Btk and Pik3cd causes 72% node disconnection. In conclusion, transcriptome profiling, pathway integration, and network identification of autoimmune myocardial inflammation provide a molecular signature applicable to the diagnosis of inflammatory cardiomyopathy. Combinatorial attack provides a rationale for immunosuppressive therapy of inflammatory cardiomyopathy and provides an in silico prediction that the approved therapeutics, ibrutinib and idelalisib targeting Btk and Pik3cd respectively, could potentially be re-purposed as adjuncts to immunosuppression.	[Singh, Kamayani; Davies, Graham; Bhattacharya, Shoumo] Univ Oxford, RDM Cardiovasc Med, Oxford, England; [Singh, Kamayani; Fang, Hai; Davies, Graham; Wright, Benjamin; Lockstone, Helen; Knight, Julian C.; Bhattacharya, Shoumo] Univ Oxford, Wellcome Ctr Human Genet, Oxford, England; [Fang, Hai; Knight, Julian C.] Univ Oxford, Nuffield Dept Med, Oxford, England; [Williams, Richard O.] Univ Oxford, Kennedy Inst Rheumatol, Oxford, England; [Cihakova, Daniela] Johns Hopkins Univ, Sch Med, Dept Pathol, Div Immunol, Baltimore, MD 21205 USA	University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; University of Oxford; Johns Hopkins University	Bhattacharya, S (corresponding author), Univ Oxford, RDM Cardiovasc Med, Oxford, England.; Knight, JC; Bhattacharya, S (corresponding author), Univ Oxford, Wellcome Ctr Human Genet, Oxford, England.; Knight, JC (corresponding author), Univ Oxford, Nuffield Dept Med, Oxford, England.	julian.knight@well.ox.ac.uk; sbhattac@well.ox.ac.uk	Knight, Julian Charles/W-2399-2019	Knight, Julian Charles/0000-0002-0377-5536	British Heart Foundation Chair [CH/09/003/26631, PG/16/100/32632, RG/18/1/33351]; Oxford BHF Centre of Research Excellence [RE/13/1/30181]; Wellcome Trust Investigator Award [204969/Z/16/Z]; NIHR Oxford Biomedical Research Centre; EU/EFPIA Innovative Medicines Initiative [ULTRA-DD 115766]; Wellcome Trust [090532/Z/09/Z, 203141/Z/16/Z]	British Heart Foundation Chair(British Heart Foundation); Oxford BHF Centre of Research Excellence; Wellcome Trust Investigator Award(Wellcome Trust); NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); EU/EFPIA Innovative Medicines Initiative; Wellcome Trust(Wellcome TrustEuropean Commission)	This research was funded by British Heart Foundation Chair (CH/09/003/26631), Project Grant (PG/16/100/32632), Program Grant (RG/18/1/33351), and Oxford BHF Centre of Research Excellence (RE/13/1/30181) awards to SB. JK is supported by a Wellcome Trust Investigator Award (204969/Z/16/Z) and the NIHR Oxford Biomedical Research Centre. HF was supported by an EU/EFPIA Innovative Medicines Initiative (ULTRA-DD 115766). We thank theOxford Genomics Centre at theWellcome Centre for Human Genetics (funded by Wellcome Trust grant reference 203141/Z/16/Z) for the generation and initial processing of the sequencing data, and Dr. John Broxholme for running the RNA-Seq pipeline. Further support was received from Wellcome Trust Grant (090532/Z/09/Z) to core facilities at theWellcome Centre for Human Genetics.	Baldeviano GC, 2010, CIRC RES, V106, P1646, DOI 10.1161/CIRCRESAHA.109.213157; Blyszczuk P, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00064; Braunstein A, 2016, P NATL ACAD SCI USA, V113, P12368, DOI 10.1073/pnas.1605083113; Caforio ALP, 2013, EUR HEART J, V34, P2636, DOI 10.1093/eurheartj/eht210; Cheng FX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09186-x; Cihakova D., 2013, MANUAL RES TECHNIQUE, P197, DOI [10.1002/9781118495148.ch24, DOI 10.1002/9781118495148.CH24]; Colombel JF, 2010, NEW ENGL J MED, V362, P1383, DOI 10.1056/NEJMoa0904492; Conway JR, 2017, BIOINFORMATICS, V33, P2938, DOI 10.1093/bioinformatics/btx364; Diny NL, 2017, J EXP MED, V214, P943, DOI 10.1084/jem.20161702; Eriksson U, 2003, J EXP MED, V197, P323, DOI 10.1084/jem.20021788; Everaert C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01617-3; Fang H, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0384-y; Fang H, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0064-8; Fontes JA, 2017, IMMUN INFLAMM DIS, V5, P163, DOI 10.1002/iid3.155; Futamatsu H, 2006, J MOL CELL CARDIOL, V40, P853, DOI 10.1016/j.yjmcc.2006.03.432; Gansner ER, 2004, LECT NOTES COMPUT SC, V3383, P239; Goser S, 2005, CIRCULATION, V112, P3400, DOI 10.1161/CIRCULATIONAHA.105.572396; Graham GJ, 2019, TRENDS IMMUNOL, V40, P472, DOI 10.1016/j.it.2019.03.009; Guo XY, 2017, CIRCULATION, V136, P729, DOI 10.1161/CIRCULATIONAHA.116.026240; Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kaya Z, 2001, NAT IMMUNOL, V2, P739, DOI 10.1038/90686; Leuschner F, 2015, EUR HEART J, V36, P1478, DOI 10.1093/eurheartj/ehu225; Marty RR, 2006, CIRCULATION, V113, P258, DOI 10.1161/CIRCULATIONAHA.105.564294; Mendez D, 2019, NUCLEIC ACIDS RES, V47, pD930, DOI 10.1093/nar/gky1075; Meyer IS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02303; Myers Jennifer M, 2013, Curr Protoc Immunol, VChapter 15, DOI 10.1002/0471142735.im1514s101; Nabirotchkin S, 2020, CURR OPIN PHARMACOL, V51, P78, DOI 10.1016/j.coph.2019.12.004; O'Dell JR, 2013, NEW ENGL J MED, V369, P307, DOI 10.1056/NEJMoa1303006; Ong S, 2015, AM J PATHOL, V185, P847, DOI 10.1016/j.ajpath.2014.11.023; Poppe D, 2006, J IMMUNOL, V176, P640, DOI 10.4049/jimmunol.176.1.640; Pummerer CL, 1996, J CLIN INVEST, V97, P2057, DOI 10.1172/JCI118642; Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168; Shi JH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01849; SMITH SC, 1992, CIRC RES, V70, P856, DOI 10.1161/01.RES.70.4.856; Sonderegger I, 2008, J EXP MED, V205, P2281, DOI 10.1084/jem.20071119; Sonderegger I, 2006, EUR J IMMUNOL, V36, P2849, DOI 10.1002/eji.200636484; Stauffer D., 2018, INTRO PERCOLATION TH; Tiede I, 2003, J CLIN INVEST, V111, P1133, DOI 10.1172/JCI200316432; Trachtenberg BH, 2017, CIRC RES, V121, P803, DOI 10.1161/CIRCRESAHA.117.310221; Vanheule V, 2018, CYTOKINE, V109, P29, DOI 10.1016/j.cyto.2018.02.026; Wu L, 2016, EUR J IMMUNOL, V46, P582, DOI 10.1002/eji.201545924; Wu L, 2014, J EXP MED, V211, P1441, DOI 10.1084/jem.20132126; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914	44	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 5	2021	12								640837	10.3389/fimmu.2021.640837	http://dx.doi.org/10.3389/fimmu.2021.640837			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QY9GP	33746983	Green Published, gold			2022-12-18	WOS:000630344200001
J	Stoiber, H; Thielens, N; Wurzner, R; Reason, ID				Stoiber, Heribert; Thielens, Nicole; Wuerzner, Reinhard; De Messias Reason, Iara			Editorial: The Role of Complement in Microbial Infections	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						complement; pathogens; bacteria; viruses; fungi; parasites			[Stoiber, Heribert] Innsbruck Med Univ, Inst Virol, Innsbruck, Austria; [Thielens, Nicole] Univ Grenoble Alpes, CNRS, CEA, IBS, Grenoble, France; [Wuerzner, Reinhard] Innsbruck Med Univ, Inst Hyg & Med Microbiol, Innsbruck, Austria; [De Messias Reason, Iara] Univ Fed Parana, Lab Imunopatol Mol, Curitiba, Parana, Brazil	Medical University of Innsbruck; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Medical University of Innsbruck; Universidade Federal do Parana	Stoiber, H (corresponding author), Innsbruck Med Univ, Inst Virol, Innsbruck, Austria.	heribert.stoiber@i-med.ac.at	Thielens, Nicole M/F-2512-2013	Thielens, Nicole M/0000-0002-7354-0302; Jose de Messias Reason, Iara/0000-0002-5573-260X	FWF [W-1253 DK HOROS]	FWF(Austrian Science Fund (FWF))	RW and HS was supporting by the FWF (W-1253 DK HOROS).	Chen Y, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.608380	1	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 4	2021	12								640092	10.3389/fimmu.2021.640092	http://dx.doi.org/10.3389/fimmu.2021.640092			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QY3TN	33746982	gold, Green Published			2022-12-18	WOS:000629966100001
J	Yalamanoglu, A; Dubach, IL; Schulthess, N; Ingoglia, G; Swindle, DC; Humar, R; Schaer, DJ; Buehler, PW; Irwin, DC; Vallelian, F				Yalamanoglu, Ayla; Dubach, Irina L.; Schulthess, Nadja; Ingoglia, Giada; Swindle, Delaney C.; Humar, Rok; Schaer, Dominik J.; Buehler, Paul W.; Irwin, David C.; Vallelian, Florence			Agonistic Anti-CD40 Antibody Triggers an Acute Liver Crisis With Systemic Inflammation in Humanized Sickle Cell Disease Mice	FRONTIERS IN IMMUNOLOGY			English	Article						sickle cell anemia; CD40; macrophage; liver disease (Ld); vasoocclusive crisis		Sickle cell disease (SCD) is an inherited hemolytic disorder, defined by a point mutation in the beta-globin gene. Stress conditions such as infection, inflammation, dehydration, and hypoxia trigger erythrocyte sickling. Sickled red blood cells (RBCs) hemolyze more rapidly, show impaired deformability, and increased adhesive properties to the endothelium. In a proinflammatory, pro-coagulative environment with preexisting endothelial dysfunction, sickled RBCs promote vascular occlusion. Hepatobiliary involvement related to the sickling process, such as an acute sickle hepatic crisis, is observed in about 10% of acute sickle cell crisis incidents. In mice, ligation of CD40 with an agonistic antibody leads to a macrophage activation in the liver, triggering a sequence of systemic inflammation, endothelial cell activation, thrombosis, and focal ischemia. We found that anti-CD40 antibody injection in sickle cell mice induces a systemic inflammatory and hemodynamic response with accelerated hemolysis, extensive vaso-occlusion, and large ischemic infarctions in the liver mimicking an acute hepatic crisis. Administration of the tumor necrosis factor-alpha (TNF-alpha) blocker, etanercept, and the heme scavenger protein, hemopexin attenuated end-organ damage. These data collectively suggest that anti-CD40 administration offers a novel acute liver crisis model in humanized sickle mice, allowing for evaluation of therapeutic proof-of-concept.	[Yalamanoglu, Ayla; Dubach, Irina L.; Schulthess, Nadja; Ingoglia, Giada; Humar, Rok; Schaer, Dominik J.; Vallelian, Florence] Univ Zurich, Div Internal Med, Zurich, Switzerland; [Swindle, Delaney C.; Irwin, David C.] Univ Colorado Denver, Dept Med, Cardiovasc & Pulm Res Lab, Aurora, CO USA; [Buehler, Paul W.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Buehler, Paul W.] Univ Maryland, Sch Med, Dept Pediat, Ctr Blood Oxygen Transport & Hemostasis, Baltimore, MD 21201 USA	University of Zurich; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Vallelian, F (corresponding author), Univ Zurich, Div Internal Med, Zurich, Switzerland.	florence.vallelian@usz.ch	Yalamanoglu, Ayla/GYJ-1306-2022	Yalamanoglu, Ayla/0000-0002-0203-9297; Vallelian, Florence/0000-0001-9659-8278; Schulthess-Lutz, Nadja/0000-0002-2918-6262	Innosuisse [19300.1 PFLS-LS -1]; NIH/NHLBI [R01 HL125642-01]; Promedica Foundation; Olga Mayenfisch Stiftung; Novartis Foundation	Innosuisse; NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Promedica Foundation; Olga Mayenfisch Stiftung; Novartis Foundation(Novartis)	This study was supported by Innosuisse 19300.1 PFLS-LS -1 (to DJS), NIH/NHLBI -R01 HL125642-01 (to DCI), by the Promedica Foundation (to FV), the Olga Mayenfisch Stiftung (to FV), and the Novartis Foundation (to FV).	Banerjee S, 2001, HEPATOLOGY, V33, P1021, DOI 10.1053/jhep.2001.24114; Belcher JD, 2000, BLOOD, V96, P2451, DOI 10.1182/blood.V96.7.2451.h8002451_2451_2459; Belcher JD, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196455; Belcher JD, 2014, BLOOD, V123, P377, DOI 10.1182/blood-2013-04-495887; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Cabral F, 2018, JOVE-J VIS EXP, DOI 10.3791/56993; CARTER P, 1971, ANAL BIOCHEM, V40, P450, DOI 10.1016/0003-2697(71)90405-2; CASTRO O, 1994, BLOOD, V84, P643, DOI 10.1182/blood.V84.2.643.643; Chen G, 2014, BLOOD, V123, P3818, DOI 10.1182/blood-2013-10-529982; Deuel JW, 2015, FREE RADICAL BIO MED, V89, P931, DOI 10.1016/j.freeradbiomed.2015.09.016; Garrido VT, 2017, CYTOKINE, V97, P104, DOI 10.1016/j.cyto.2017.05.017; Gelderman MP, 2015, HAEMATOLOGICA, V100, P611, DOI 10.3324/haematol.2014.117325; Ghosh S, 2013, J CLIN INVEST, V123, P4809, DOI 10.1172/JCI64578; Hebbel RP, 2004, MICROCIRCULATION, V11, P129, DOI 10.1080/10739680490278402; HEBBEL RP, 1980, NEW ENGL J MED, V302, P992, DOI 10.1056/NEJM198005013021803; Holtzclaw JD, 2004, AM J RESP CRIT CARE, V169, P687, DOI 10.1164/rccm.200302-224OC; Ingoglia G, 2020, BLOOD ADV, V4, P2751, DOI 10.1182/bloodadvances.2020001624; INGRAM VM, 1957, NATURE, V180, P326, DOI 10.1038/180326a0; Jarvis B, 1999, DRUGS, V57, P945, DOI 10.2165/00003495-199957060-00014; Kaempfer T, 2011, J PROTEOME RES, V10, P2397, DOI 10.1021/pr101230y; Kato GJ, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.10; Kato GJ, 2017, J CLIN INVEST, V127, P750, DOI 10.1172/JCI89741; Kaul DK, 2000, J CLIN INVEST, V106, P411, DOI 10.1172/JCI9225; KONOTEYA.FI, 1974, ARCH INTERN MED, V133, P611, DOI 10.1001/archinte.133.4.611; Lee SP, 2007, BRIT J HAEMATOL, V139, P612, DOI 10.1111/j.1365-2141.2007.06787.x; Lee SP, 2006, ARTERIOSCL THROM VAS, V26, P1626, DOI 10.1161/01.ATV.0000220374.00602.a2; Manci EA, 2006, BLOOD, V107, P1651, DOI 10.1182/blood-2005-07-2839; Novelli EM, 2016, CHEST, V149, P1082, DOI 10.1016/j.chest.2015.12.016; Paszty C, 1997, SCIENCE, V278, P876, DOI 10.1126/science.278.5339.876; Perls M, 1867, VIRCHOW ARCH A, V39, P42, DOI DOI 10.1007/BF01878983; Pfefferle M, 2020, J CLIN INVEST, V130, P5576, DOI 10.1172/JCI137282; Piel FB, 2017, NEW ENGL J MED, V377, P305, DOI 10.1056/NEJMc1706325; Platt OS, 2000, J CLIN INVEST, V106, P337, DOI 10.1172/JCI10726; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; RUUTU R, 1975, CLIN CHIM ACTA, V61, P229, DOI 10.1016/0009-8981(75)90319-8; Schaer DJ, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00415; Schaer DJ, 2013, BLOOD, V121, P1276, DOI 10.1182/blood-2012-11-451229; Siciliano A, 2011, HAEMATOL-HEMATOL J, V96, P24, DOI 10.3324/haematol.2010.028506; Solovey A, 2004, BLOOD, V104, P840, DOI 10.1182/blood-2003-10-3719; Solovey A, 1997, NEW ENGL J MED, V337, P1584, DOI 10.1056/NEJM199711273372203; Solovey A, 2017, AM J HEMATOL, V92, P1119, DOI 10.1002/ajh.24856; Sundd P, 2019, ANNU REV PATHOL-MECH, V14, P263, DOI 10.1146/annurev-pathmechdis-012418-012838; Tello K, 2019, CIRC-HEART FAIL, V12, DOI 10.1161/CIRCHEARTFAILURE.118.005512; Theocharidou E, 2019, CLIN LIVER DIS, V23, P177, DOI 10.1016/j.cld.2018.12.002; Vallelian F, 2018, PHARMACOL RES PERSPE, V6, DOI 10.1002/prp2.392; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; Vercellotti GM, 2016, MOL MED, V22, P437, DOI 10.2119/molmed.2016.00063; Vonderheide RH, 2001, J CLIN ONCOL, V19, P3280, DOI 10.1200/JCO.2001.19.13.3280; Wallace KL, 2010, BLOOD, V116, P5010, DOI 10.1182/blood-2010-06-290643; Walter RB, 2003, BLOOD, V101, P3755, DOI 10.1182/blood-2002-11-3414; Williams TN, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a011692; Yalamanoglu A, 2018, AM J PHYSIOL-LUNG C, V315, pL765, DOI 10.1152/ajplung.00269.2018; Yale SH, 2000, AM FAM PHYSICIAN, V61, P1349	53	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 4	2021	12								627944	10.3389/fimmu.2021.627944	http://dx.doi.org/10.3389/fimmu.2021.627944			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QY3VR	33763072	Green Accepted, gold, Green Published			2022-12-18	WOS:000629971700001
J	Melamed, IR; Miranda, H; Heffron, M; Harper, JR				Melamed, Isaac R.; Miranda, Holly; Heffron, Melinda; Harper, Joseph R.			Recombinant Human C1 Esterase Inhibitor for the Management of Adverse Events Related to Intravenous Immunoglobulin Infusion in Patients With Common Variable Immunodeficiency or Polyneuropathy: A Pilot Open-Label Study	FRONTIERS IN IMMUNOLOGY			English	Article						angioedemas hereditary; complement C1 inhibitor protein; immunoglobulins intravenous; recombinant human C1 esterase inhibitor; Ruconest		It has been hypothesized that low levels of C1 esterase inhibitor (C1-INH), a key inhibitor of the complement pathway, may play a role in the occurrence of adverse events (AEs) associated with intravenous immunoglobulin (IVIG) therapy. This open-label pilot study evaluated C1-INH replacement, with recombinant human C1-INH (rhC1-INH), as a potential therapy for adults requiring IVIG and experiencing AEs. Patients received two rounds of IVIG infusion [pre-treatment phase (no rhC1-INH), 4-8 weeks] and then three rounds of one dose of intravenous rhC1-INH 50 U/kg (maximum, 4,200 U) with subsequent IVIG infusion (treatment phase, 6-12 weeks). Nineteen adults completed the study; all had an autoimmune condition linked to common variable immunodeficiency (CVID) or polyneuropathy, and 57.9% had low baseline C1-INH levels. Mean +/- SD total scores improved significantly with the Headache Impact Test (from 62.8 +/- 6.2 at pre-treatment to 57.7 +/- 9.1 after treatment; mean Delta, -5.0; p = 0.02) and Modified Fatigue Impact Scale (from 59.3 +/- 13.1 to 51.2 +/- 15.4; mean Delta, -8.1; p = 0.006). Significant improvements in the Migraine Disability Assessment were observed for three of five items (p <= 0.002). Mean +/- SD C1-INH level increased from 26.8 +/- 5.9 mg/dl after the second round of IVIG (pre-treatment) to 32.1 +/- 7.8 mg/dl after the third rhC1-INH treatment; functional C1-INH levels increased from 115.8 +/- 34.7% to 158.3 +/- 46.8%. Future research is warranted to explore the benefit of C1-INH therapy for reduction of IVIG-related AEs, as well as the role of C1-INH in patients with CVID and autoimmune disease.	[Melamed, Isaac R.; Miranda, Holly; Heffron, Melinda] IMMUNOe Res Ctr, Centennial, CO 80112 USA; [Harper, Joseph R.] Pharming Healthcare Inc, Warren, NJ USA		Melamed, IR (corresponding author), IMMUNOe Res Ctr, Centennial, CO 80112 USA.	melamedi@immunoe.com			Pharming Healthcare Inc.	Pharming Healthcare Inc.	Funding for this investigator-initiated pilot study was provided by Pharming Healthcare Inc. Pharming Healthcare Inc. provided recombinant human C1 esterase inhibitor and funding for statistical analyses, as well as interpreted the data.	Bernstein JA, 2018, AM J MANAG CARE, V24, pS292; Bonilla FA, 2016, J ALLER CL IMM-PRACT, V4, P38, DOI 10.1016/j.jaip.2015.07.025; Bork K, 2006, AM J MED, V119, P267, DOI 10.1016/j.amjmed.2005.09.064; Brennan VM, 2003, CLIN EXP IMMUNOL, V133, P247, DOI 10.1046/j.1365-2249.2003.02199.x; Cherin P, 2016, AUTOIMMUN REV, V15, P71, DOI 10.1016/j.autrev.2015.09.002; Chung JY, 2012, J KOREAN MED SCI, V27, P104, DOI 10.3346/jkms.2012.27.1.104; Dashti-Khavidaki S, 2009, J INVEST ALLERG CLIN, V19, P139; Deane S, 2009, INT ARCH ALLERGY IMM, V150, P311, DOI 10.1159/000226232; Farkas H, 2018, PEDIATR DRUGS, V20, P135, DOI 10.1007/s40272-017-0273-x; Guo Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01299; Kaveri SV, 2011, CLIN EXP IMMUNOL, V164, P2, DOI 10.1111/j.1365-2249.2011.04387.x; Kosinski M, 2003, QUAL LIFE RES, V12, P963, DOI 10.1023/A:1026119331193; Learmonth YC, 2013, J NEUROL SCI, V331, P102, DOI 10.1016/j.jns.2013.05.023; Li HH, 2015, J ALLER CL IMM-PRACT, V3, P417, DOI 10.1016/j.jaip.2014.12.013; Maarschalk-Ellerbroek LJ, 2011, INT J ANTIMICROB AG, V37, P396, DOI 10.1016/j.ijantimicag.2010.11.027; Melamed I., 2019, J CLIN CELL IMMUNOL, V10; Melamed IR, 2013, INT PRIM IMM C LISB; Melamed IR, 2015, ANN ALLERG ASTHMA IM, V115, P83, DOI 10.1016/j.anai.2015.04.023; Moldovan D, 2012, CLIN EXP ALLERGY, V42, P929, DOI 10.1111/j.1365-2222.2012.03984.x; Perez EE, 2017, J ALLERGY CLIN IMMUN, V139, pS1, DOI 10.1016/j.jaci.2016.09.023; Reshef A, 2019, PEDIAT ALLERG IMM-UK, V30, P562, DOI 10.1111/pai.13065; Riedl MA, 2014, ANN ALLERG ASTHMA IM, V112, P163, DOI 10.1016/j.anai.2013.12.004; Riedl MA, 2013, ANN ALLERG ASTHMA IM, V110, P295, DOI 10.1016/j.anai.2013.02.007; Ruconest, 2020, C1 EST INH REC INTR; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g7647; Stewart WF, 2001, NEUROLOGY, V56, pS20, DOI 10.1212/WNL.56.suppl_1.S20; van Doorn MBA, 2005, J ALLERGY CLIN IMMUN, V116, P876, DOI 10.1016/j.jaci.2005.05.019; Zuraw B, 2010, J ALLERGY CLIN IMMUN, V126, P821, DOI 10.1016/j.jaci.2010.07.021; Zuraw BL, 2008, NEW ENGL J MED, V359, P1027, DOI 10.1056/NEJMcp0803977	29	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 2	2021	12								632744	10.3389/fimmu.2021.632744	http://dx.doi.org/10.3389/fimmu.2021.632744			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QX3KO	33737935	Green Published, gold			2022-12-18	WOS:000629245100001
J	Gillis, A; Ben Yaacov, A; Agur, Z				Gillis, Avi; Ben Yaacov, Anat; Agur, Zvia			A New Method for Optimizing Sepsis Therapy by Nivolumab and Meropenem Combination: Importance of Early Intervention and CTL Reinvigoration Rate as a Response Marker	FRONTIERS IN IMMUNOLOGY			English	Article						inflammation; mathematical model; intensive care; immunosuppression; PD-1; fitness landscape; simulation; nivolumab		Background: Recently, there has been a growing interest in applying immune checkpoint blockers (ICBs), so far used to treat cancer, to patients with bacterial sepsis. We aimed to develop a method for predicting the personal benefit of potential treatments for sepsis, and to apply it to therapy by meropenem, an antibiotic drug, and nivolumab, a programmed cell death-1 (PD-1) pathway inhibitor. Methods: We defined an optimization problem as a concise framework of treatment aims and formulated a fitness function for grading sepsis treatments according to their success in accomplishing the pre-defined aims. We developed a mathematical model for the interactions between the pathogen, the cellular immune system and the drugs, whose simulations under diverse combined meropenem and nivolumab schedules, and calculation of the fitness function for each schedule served to plot the fitness landscapes for each set of treatments and personal patient parameters. Results: Results show that treatment by meropenem and nivolumab has maximum benefit if the interval between the onset of the two drugs does not exceed a dose-dependent threshold, beyond which the benefit drops sharply. However, a second nivolumab application, within 7-10 days after the first, can extinguish a pathogen which the first nivolumab application failed to remove. The utility of increasing nivolumab total dose above 6 mg/kg is contingent on the patient's personal immune attributes, notably, the reinvigoration rate of exhausted CTLs and the overall suppression rates of functional CTLs. A baseline pathogen load, higher than 5,000 CFU/mu L, precludes successful nivolumab and meropenem combination therapy, whereas when the initial load is lower than 3,000 CFU/mu L, meropenem monotherapy suffices for removing the pathogen. Discussion: Our study shows that early administration of nivolumab, 6 mg/kg, in combination with antibiotics, can alleviate bacterial sepsis in cases where antibiotics alone are insufficient and the initial pathogen load is not too high. The study pinpoints the role of precision medicine in sepsis, suggesting that personalized therapy by ICBs can improve pathogen elimination and dampen immunosuppression. Our results highlight the importance in using reliable markers for classifying patients according to their predicted response and provides a valuable tool in personalizing the drug regimens for patients with sepsis.	[Gillis, Avi; Ben Yaacov, Anat; Agur, Zvia] Inst Med Biomath IMBM, Bene Ataroth, Israel		Agur, Z (corresponding author), Inst Med Biomath IMBM, Bene Ataroth, Israel.	Agur@imbm.org		Agur, Zvia/0000-0001-5701-9149				Actor J., 2012, ELSEVIERS INTEGRATED, V2nd, P192; Adrie C, 2009, CRIT CARE, V13, DOI 10.1186/cc7881; Agrawal S, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0177-2; Agur Z., 2008, PRECLINICAL DEV HDB, P1229; Agur Z, 2006, OPER RES, V54, P829, DOI 10.1287/opre.1060.0320; Ahmad A, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0823-3; Alhashem F, 2017, WORLD J CLIN CASES, V5, P324, DOI 10.12998/wjcc.v5.i8.324; Angus DC, 2011, JAMA-J AM MED ASSOC, V306, P2614, DOI 10.1001/jama.2011.1853; [Anonymous], 2012, LIVERTOX CLIN RES IN; [Anonymous], 2018, HIGHL PRESCR INF; Bilgrami I, 2010, ANTIMICROB AGENTS CH, V54, P2974, DOI 10.1128/AAC.01582-09; Binkowska AM, 2015, CENT EUR J IMMUNOL, V40, P206, DOI 10.5114/ceji.2015.52835; Bomans K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02685; Boomer JS, 2011, JAMA-J AM MED ASSOC, V306, P2594, DOI 10.1001/jama.2011.1829; Brahmamdam P, 2010, J LEUKOCYTE BIOL, V88, P233, DOI 10.1189/jlb.0110037; Chatterjee A, 2018, LANCET INFECT DIS, V18, pE368, DOI 10.1016/S1473-3099(18)30296-2; Chen Y, 2019, BMC ANESTHESIOL, V19, DOI 10.1186/s12871-019-0849-9; Cortese I, 2019, NEW ENGL J MED, V380, P1597, DOI 10.1056/NEJMoa1815039; Cunnington AJ, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004563; Davies Roger, 2018, J Intensive Care Soc, V19, P326, DOI 10.1177/1751143718765407; Delano MJ, 2016, J CLIN INVEST, V126, P23, DOI 10.1172/JCI82224; Drewry AM, 2014, SHOCK, V42, P383, DOI 10.1097/SHK.0000000000000234; Food and Drug Administation (FDA), 2014, NIV OPD HIGH PRESCR; Gillis A, 2019, INTENS CARE MED EXP, V7, DOI 10.1186/s40635-019-0260-3; Girardot T, 2017, APOPTOSIS, V22, P295, DOI 10.1007/s10495-016-1325-3; Gomez JL., 2020, PRECISION PULMONARY, V1st, DOI [10.1007/978-3-030-31507-8, DOI 10.1007/978-3-030-31507-8]; Hashimoto M, 2018, ANNU REV MED, V69, P301, DOI 10.1146/annurev-med-012017-043208; Hotchkiss RS, 2019, INTENS CARE MED, V45, P1360, DOI 10.1007/s00134-019-05704-z; Hotchkiss RS, 2013, NAT REV IMMUNOL, V13, P862, DOI 10.1038/nri3552; Hotchkiss RS, 2013, LANCET INFECT DIS, V13, P260, DOI 10.1016/S1473-3099(13)70001-X; Hryniewicki AT, 2018, J EMERG MED, V55, P489, DOI 10.1016/j.jemermed.2018.07.005; Huang AC, 2017, NATURE, V545, P60, DOI 10.1038/nature22079; Jubel JM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00487; Kees MG, 2016, J CLIN PHARMACOL, V56, P307, DOI 10.1002/jcph.600; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Koralnik IJ, 2019, NEW ENGL J MED, V380, P1667, DOI 10.1056/NEJMe1904140; Kusadasi N, 2013, SHOCK, V40, P352, DOI 10.1097/SHK.0000000000000039; Lee LS, 2010, DIAGN MICR INFEC DIS, V68, P251, DOI 10.1016/j.diagmicrobio.2010.06.012; Lertwattanachai T, 2020, J INTENSIVE CARE, V8, DOI 10.1186/s40560-020-00442-7; Lewis SM, 2013, INT IMMUNOPHARMACOL, V17, P1226, DOI 10.1016/j.intimp.2013.10.002; Lin GL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02147; Manz MG, 2014, NAT REV IMMUNOL, V14, P302, DOI 10.1038/nri3660; Marciniak-Czochra A, 2009, STEM CELLS DEV, V18, P377, DOI 10.1089/scd.2008.0143; Martins F, 2019, NAT REV CLIN ONCOL, V16, P563, DOI 10.1038/s41571-019-0218-0; Muller-Sieburg CE, 2004, BLOOD, V103, P4111, DOI 10.1182/blood-2003-10-3448; Novelli A, 2005, CLIN PHARMACOKINET, V44, P539, DOI 10.2165/00003088-200544050-00007; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Park J, 2019, CLIN CANCER RES, V25, P2549, DOI 10.1158/1078-0432.CCR-18-2564; Patil NK, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112413; Pauken KE, 2016, SCIENCE, V354, P1160, DOI 10.1126/science.aaf2807; Perlstein D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226869; Rauer S, 2019, NEW ENGL J MED, V380, P1676, DOI 10.1056/NEJMc1817193; Regoes RR, 2004, ANTIMICROB AGENTS CH, V48, P3670, DOI 10.1128/AAC.48.10.3670-3676.2004; Rello J, 2018, CLIN MICROBIOL INFEC, V24, P1264, DOI 10.1016/j.cmi.2018.03.011; Roberts JA, 2009, J ANTIMICROB CHEMOTH, V64, P142, DOI 10.1093/jac/dkp139; Rudd KE, 2020, LANCET, V395, P200, DOI 10.1016/S0140-6736(19)32989-7; Shi ZZ, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/504259; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Summers C, 2010, TRENDS IMMUNOL, V31, P318, DOI 10.1016/j.it.2010.05.006; Trivedi MS, 2015, CLIN ADV HEMATOL ONC, V13, P858; Tsur N, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2081-2; Unsinger J, 2010, J IMMUNOL, V184, P6766, DOI 10.4049/jimmunol.0904054; Vainstein V, 2005, J THEOR BIOL, V234, P311, DOI 10.1016/j.jtbi.2004.11.026; van der Poll T, 2017, NAT REV IMMUNOL, V17, P407, DOI 10.1038/nri.2017.36; van Vught LA, 2016, JAMA-J AM MED ASSOC, V315, P1469, DOI 10.1001/jama.2016.2691; Verma V, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0442-7; Wang HZ, 2012, ANTIMICROB AGENTS CH, V56, P2683, DOI 10.1128/AAC.06486-11; Watanabe E, 2020, SHOCK, V53, P686, DOI 10.1097/SHK.0000000000001443; Weber JS, 2015, LANCET ONCOL, V16, P375, DOI 10.1016/S1470-2045(15)70076-8; Wei SC, 2018, CANCER DISCOV, V8, P1069, DOI 10.1158/2159-8290.CD-18-0367; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Winer A, 2018, J THORAC DIS, V10, pS480, DOI 10.21037/jtd.2018.01.111; Wu C. H. J., 2016, HEALTHCARE ANAL DATA, P221; Xia AL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01719	74	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 1	2021	12								616881	10.3389/fimmu.2021.616881	http://dx.doi.org/10.3389/fimmu.2021.616881			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QW6TZ	33732241	Green Published, gold			2022-12-18	WOS:000628781100001
J	Shankar, M; Uwamahoro, N; Backman, E; Holmberg, S; Niemiec, MJ; Roth, J; Vogl, T; Urban, CF				Shankar, Madhu; Uwamahoro, Nathalie; Backman, Emelie; Holmberg, Sandra; Niemiec, Maria Joanna; Roth, Johannes; Vogl, Thomas; Urban, Constantin F.			Immune Resolution Dilemma: Host Antimicrobial Factor S100A8/A9 Modulates Inflammatory Collateral Tissue Damage During Disseminated Fungal Peritonitis	FRONTIERS IN IMMUNOLOGY			English	Article						sepsis; host-pathogen interactions; peritonitis; Candida albicans; inflammation; A9 complex; host-targeted agents	CANDIDA-ALBICANS; MACROPHAGES; MRP14; INFECTIONS	Intra-abdominal infection (peritonitis) is a leading cause of severe disease in surgical intensive care units, as over 70% of patients diagnosed with peritonitis develop septic shock. A critical role of the immune system is to return to homeostasis after combating infection. S100A8/A9 (calprotectin) is an antimicrobial and pro-inflammatory protein complex used as a biomarker for diagnosis of numerous inflammatory disorders. Here we describe the role of S100A8/A9 in inflammatory collateral tissue damage (ICTD). Using a mouse model of disseminated intra-abdominal candidiasis (IAC) in wild-type and S100A8/A9-deficient mice in the presence or absence of S100A9 inhibitor paquinimod, the role of S100A8/A9 during ICTD and fungal clearance were investigated. S100A8/A9-deficient mice developed less ICTD than wild-type mice. Restoration of S100A8/A9 in knockout mice by injection of recombinant protein resulted in increased ICTD and fungal clearance comparable to wild-type levels. Treatment with paquinimod abolished ICTD and S100A9-deficient mice showed increased survival compared to wild-type littermates. The data indicates that S100A8/A9 controls ICTD levels and antimicrobial activity during IAC and that targeting of S100A8/A9 could serve as promising adjunct therapy against this challenging disease.	[Shankar, Madhu; Uwamahoro, Nathalie; Backman, Emelie; Niemiec, Maria Joanna; Urban, Constantin F.] Umea Univ, Dept Clin Microbiol, Umea Ctr Microbial Res UCMR, Umea, Sweden; [Shankar, Madhu; Uwamahoro, Nathalie; Backman, Emelie; Niemiec, Maria Joanna; Urban, Constantin F.] Umea Univ, Mol Infect Med Sweden MIMS, Umea, Sweden; [Holmberg, Sandra] Umea Univ, Dept Med Chem & Biophys, Umea, Sweden; [Roth, Johannes; Vogl, Thomas] Univ Munster, Univ Klinikum Munster, Inst Immunol, Munster, Germany; [Shankar, Madhu] Monash Biomed Discovery Inst, Dept Biochem & Mol Biol, Melbourne, Vic, Australia; [Niemiec, Maria Joanna] Hans Knoll Inst HKI, Leibniz Inst Nat Prod Res & Infect Biol, Jena, Germany; [Niemiec, Maria Joanna] Ctr Sepsis Control & Care, Jena, Germany	Umea University; Umea University; Umea University; University of Munster; Monash University; Hans Knoll Institute (HKI)	Urban, CF (corresponding author), Umea Univ, Dept Clin Microbiol, Umea Ctr Microbial Res UCMR, Umea, Sweden.; Urban, CF (corresponding author), Umea Univ, Mol Infect Med Sweden MIMS, Umea, Sweden.	constantin.urban@umu.se	Backman, Emelie/ABC-3154-2020	Backman, Emelie/0000-0002-2482-1458; Niemiec, Maria Joanna/0000-0001-5667-6032; Shankar, Madhu/0000-0002-3553-135X; Holmberg, Sandra/0000-0002-6290-2590	Swedish research council [VR-M 2014-02281, VR-M 2017-01681]; Kempe Foundation [SMK-1453]; Ake Wiberg Foundation [M14-0076, M15-0108]; Medical Faculty of Umea University [316-886-10]; UCMR; Interdisciplinary Center of Clinical Research at the University of Munster [Ro2/023/19, Vo2/011/19]; German Research Foundation [CRC 1009]	Swedish research council(Swedish Research CouncilEuropean Commission); Kempe Foundation; Ake Wiberg Foundation; Medical Faculty of Umea University; UCMR; Interdisciplinary Center of Clinical Research at the University of Munster; German Research Foundation(German Research Foundation (DFG))	We are grateful for funding provided to CU by the Swedish research council VR-M 2014-02281 and VR-M 2017-01681, the Kempe Foundation SMK-1453, the Ake Wiberg Foundation M14-0076 and M15-0108, and the Medical Faculty of Umea University 316-886-10. NU and MS held a postdoctoral fellowship received in competition from UCMR. JR and TV were funded by grants of the Interdisciplinary Center of Clinical Research at the University of Munster (Ro2/023/19 and Vo2/011/19) and the German Research Foundation CRC 1009 B08 (JR) and B09 (TV). The funders had no rule in study design nor analysis and interpretation of the results	Austermann J, 2014, CELL REP, V9, P2112, DOI 10.1016/j.celrep.2014.11.020; BAYER AS, 1981, ANTIMICROB AGENTS CH, V19, P179, DOI 10.1128/AAC.19.1.179; Bieghs V, 2010, PEDIATR RES, V68, P466, DOI 10.1203/PDR.0b013e3181f70eeb; Bjork P, 2009, PLOS BIOL, V7, P800, DOI 10.1371/journal.pbio.1000097; Casadevall A, 2003, NAT REV MICROBIOL, V1, P17, DOI 10.1038/nrmicro732; Chan JK, 2012, J CLIN INVEST, V122, P2711, DOI 10.1172/JCI62423; de Jong PR, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1458-3; Denning DW, 2017, EMERG INFECT DIS, V23, P177, DOI 10.3201/eid2302.152042; Ermert D, 2013, J LEUKOCYTE BIOL, V94, P223, DOI 10.1189/jlb.0213063; Fiore M, 2018, INFECT DRUG RESIST, V11, P177, DOI 10.2147/IDR.S152473; Fiore M, 2017, THER CLIN RISK MANAG, V13, P1409, DOI 10.2147/TCRM.S144262; Futami Junichiro, 2016, Biochem Biophys Rep, V6, P94, DOI 10.1016/j.bbrep.2016.03.009; Gouba N, 2015, MED MALADIES INFECT, V45, P9, DOI 10.1016/j.medmal.2015.01.007; Grainger JR, 2017, PFLUG ARCH EUR J PHY, V469, P527, DOI [10.1007/s00424-017-1958, 10.1007/s00424-017-1958-2]; Hall JC, 1998, GASTROENTEROLOGY, V114, P185, DOI 10.1016/S0016-5085(98)70646-8; Hamidzadeh K, 2017, ANNU REV PHYSIOL, V79, P567, DOI 10.1146/annurev-physiol-022516-034348; Hobbs JAR, 2003, MOL CELL BIOL, V23, P2564, DOI 10.1128/MCB.23.7.2564-2576.2003; Hohl TM, 2014, J IMMUNOL METHODS, V410, P100, DOI 10.1016/j.jim.2014.03.022; Hosseinzadeh A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00391; Kraakman MJ, 2017, J CLIN INVEST, V127, P2133, DOI 10.1172/JCI92450; Li XY, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00855; Lichtenstern C, 2007, DIGEST SURG, V24, P1, DOI 10.1159/000099009; Manitz MP, 2003, MOL CELL BIOL, V23, P1034, DOI 10.1128/MCB.23.3.1034-1043.2003; Masouris I, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0989-0; Netea MG, 2017, NAT IMMUNOL, V18, P826, DOI 10.1038/ni.3790; Paoli CJ, 2018, CRIT CARE MED, V46, P1889, DOI 10.1097/CCM.0000000000003342; Pettersson NF, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203228; Prieto D, 2016, FUTURE MICROBIOL, V11, P567, DOI 10.2217/fmb.16.1; Rello J, 2017, ADV THER, V34, P2393, DOI 10.1007/s12325-017-0622-8; Schelbergen RF, 2015, ANN RHEUM DIS, V74, P2254, DOI 10.1136/annrheumdis-2014-206517; Schwarz H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113840; Shankar M, 2020, BIORXIV, DOI [10.1101/2020.03.30.017491, DOI 10.1101/2020.03.30.017491]; Skipworth RJ, 2008, SURGERY, V26, P98, DOI [10.1016/j.mpsur.2008.01.004, DOI 10.1016/J.MPSUR.2008.01.004]; Sohnle PG, 2000, J INFECT DIS, V182, P1272, DOI 10.1086/315810; Urban CF, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000639; Uwamahoro N, 2014, MBIO, V5, DOI 10.1128/mBio.00003-14; van den Bosch MH, 2016, J RHEUMATOL, V43, P1874, DOI 10.3899/jrheum.160270; Vatsalya V., 2016, GASTROENT HEPAT-BARC, V4, P107; Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638; Vogl T, 2018, J CLIN INVEST, V128, P1852, DOI 10.1172/JCI89867; Wang SW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01298; Yao V, 2003, BRIT J SURG, V90, P1187, DOI 10.1002/bjs.4373; Yun J, 2018, INVEST OPHTH VIS SCI, V59, P1332, DOI 10.1167/iovs.17-23127; Zackular JP, 2015, J BIOL CHEM, V290, P18991, DOI 10.1074/jbc.R115.645085	44	0	0	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 26	2021	12								553911	10.3389/fimmu.2021.553911	http://dx.doi.org/10.3389/fimmu.2021.553911			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QV2AJ	33717058	gold, Green Published			2022-12-18	WOS:000627778800001
J	Tintinger, GR; Theron, AJ; Steel, HC; Cholo, MC; Nel, JG; Feldman, C; Anderson, R				Tintinger, Gregory R.; Theron, Annette J.; Steel, Helen C.; Cholo, Moloko C.; Nel, Jan G.; Feldman, Charles; Anderson, Ronald			Submission for Special Issue: The Role of Platelet Activation in the Pathophysiology of HIV, Tuberculosis, and Pneumococcal Disease. Bedaquiline Suppresses ADP-Mediated Activation of Human Platelets In Vitro via Interference With Phosphatidylinositol 3-Kinase	FRONTIERS IN IMMUNOLOGY			English	Article						adenosine-5&#8242; -triphosphate; bedaquiline; calcium fluxes; CD62P; phosphatidylinositol 3-kinase; platelets; wortmannin	DIARYLQUINOLINE TMC207; P2Y(12) RECEPTORS; AGGREGATION; INHIBITION; SECRETION; BINDING; AKT	Although bedaquiline has advanced the treatment of multidrug-resistant tuberculosis (TB), concerns remain about the cardiotoxic potential of this agent, albeit by unexplored mechanisms. Accordingly, we have investigated augmentation of the reactivity of human platelets in vitro as a potential mechanism of bedaquiline-mediated cardiotoxicity. Platelet-rich plasma (PRP) or isolated cells prepared from the blood of healthy, adult humans were treated with bedaquiline (0.625-10 mu g/ml), followed by activation with adenosine 5'-diphosphate (ADP), thrombin or the thromboxane A(2) receptor agonist (U46619). Expression of platelet CD62P (P-selectin), platelet aggregation, Ca2+ fluxes and phosphorylation of Akt1 were measured using flow cytometry, spectrophotometry, fluorescence spectrometry, and by ELISA procedures, respectively. Exposure to bedaquiline caused dose-related inhibition of ADP-activated, but not thrombin- or U46619-activated, expression of CD62P by platelets, achieving statistical significance at a threshold concentration of 5 mu g/ml and was paralleled by inhibition of aggregation and Ca2+ mobilization. These ADP-selective inhibitory effects of bedaquiline on platelet activation were mimicked by wortmannin, an inhibitor of phosphatidylinositol 3-kinase (PI3-K), implicating PI3-K as being a common target of both agents, a contention that was confirmed by the observed inhibitory effects of bedaquiline on the phosphorylation of Akt1 following activation of platelets with ADP. These apparent inhibitory effects of bedaquiline on the activity of PI3-K may result from the secondary cationic amphiphilic properties of this agent. If operative in vivo, these anti-platelet effects of bedaquiline may contribute to ameliorating the risk of TB-associated cardiovascular disease, but this remains to be explored in the clinical setting.	[Tintinger, Gregory R.] Univ Pretoria, Steve Biko Acad Hosp, Dept Internal Med, Pretoria, South Africa; [Tintinger, Gregory R.] Univ Pretoria, Fac Hlth Sci, Pretoria, South Africa; [Theron, Annette J.; Steel, Helen C.; Cholo, Moloko C.; Anderson, Ronald] Univ Pretoria, Dept Immunol, Fac Hlth Sci, Pretoria, South Africa; [Nel, Jan G.] Univ Pretoria, Dept Haematol, Fac Hlth Sci, Pretoria, South Africa; [Nel, Jan G.] Natl Hlth Lab Serv South Africa, Tshwane Acad Div, Pretoria, South Africa; [Feldman, Charles] Univ Witwatersrand, Dept Internal Med, Fac Hlth Sci, Johannesburg, South Africa	University of Pretoria; University of Pretoria; University of Pretoria; University of Pretoria; Tshwane University of Technology; University of Witwatersrand	Tintinger, GR (corresponding author), Univ Pretoria, Steve Biko Acad Hosp, Dept Internal Med, Pretoria, South Africa.; Tintinger, GR (corresponding author), Univ Pretoria, Fac Hlth Sci, Pretoria, South Africa.	grtintinger@gmail.com	Steel, Helen C./AAM-3129-2021; Nel, Jan/O-6370-2018	Nel, Jan/0000-0002-4693-1092; Steel, Helen/0000-0001-5899-4472	National Health Laboratory Research Trust of South Africa [004 94648]; National Research Foundation of South Africa	National Health Laboratory Research Trust of South Africa; National Research Foundation of South Africa(National Research Foundation - South Africa)	The study was supported from a grant awarded to MC Cholo by the National Health Laboratory Research Trust of South Africa (Grant: 004 94648), while C. Feldman is supported by the National Research Foundation of South Africa.	Abraham T, 2007, BBA-BIOMEMBRANES, V1768, P2089, DOI 10.1016/j.bbamem.2007.06.023; Al-Blewi FF, 2018, CHEM CENT J, V12, DOI 10.1186/s13065-018-0489-z; Barker SA, 1999, J LEUKOCYTE BIOL, V65, P321, DOI 10.1002/jlb.65.3.321; Cano-Muniz S, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00060-17; Cattaneo M, 2015, J THROMB HAEMOST, V13, pS10, DOI 10.1111/jth.12952; Chan MV, 2018, PLATELETS, V29, P650, DOI 10.1080/09537104.2018.1445838; Chen H, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01627; Cholo MC, 2017, J ANTIMICROB CHEMOTH, V72, P338, DOI 10.1093/jac/dkw426; Comin J, 2011, AM J NEURORADIOL, V32, P2002, DOI 10.3174/ajnr.A2913; Dangelmaier C, 2001, THROMB HAEMOSTASIS, V85, P341, DOI 10.1055/s-0037-1615690; de Jong JSSG, 2010, FRONT PHYSIOL, V1, DOI 10.3389/fphys.2010.00166; Diacon AH, 2009, NEW ENGL J MED, V360, P2397, DOI 10.1056/NEJMoa0808427; Dorsam RT, 2004, J CLIN INVEST, V113, P340, DOI 10.1172/JCI200420986; Fox GJ, 2013, INFECT DIS THER, V2, P123, DOI 10.1007/s40121-013-0009-3; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hardy AR, 2004, BLOOD, V104, P1745, DOI 10.1182/blood-2004-02-0534; Huaman MA, 2017, EPIDEMIOL INFECT, V145, P1363, DOI 10.1017/S0950268817000279; Jones J, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4197-7; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; Lauener RW, 1999, BBA-MOL CELL RES, V1452, P197, DOI 10.1016/S0167-4889(99)00125-1; Li SK, 2016, ORG BIOMOL CHEM, V14, P7563, DOI 10.1039/c6ob01060a; Lisman T, 2018, CELL TISSUE RES, V371, P567, DOI 10.1007/s00441-017-2727-4; Lopez-Izquierdo A, 2011, J CARDIOVASC PHARM, V57, P407, DOI 10.1097/FJC.0b013e31820b7c03; Moroi AJ, 2015, J THROMB HAEMOST, V13, P1139, DOI 10.1111/jth.12954; Nussio MR, 2007, CHEMMEDCHEM, V2, P366, DOI 10.1002/cmdc.200600252; O'Brien KA, 2011, BLOOD, V118, P4215, DOI 10.1182/blood-2010-12-323204; Osman S, 2016, SCI REP-UK, V6, DOI 10.1038/srep18536; Patel H, 2019, TUBERCULOSIS, V117, P79, DOI 10.1016/j.tube.2019.06.005; Pepper DJ, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-83; Poeckel D, 2005, BRIT J PHARMACOL, V146, P514, DOI 10.1038/sj.bjp.0706366; Pym AS, 2016, EUR RESPIR J, V47, P564, DOI 10.1183/13993003.00724-2015; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; Rustomjee R, 2008, ANTIMICROB AGENTS CH, V52, P2831, DOI 10.1128/AAC.01204-07; Sun DS, 2005, J BIOMED SCI, V12, P937, DOI 10.1007/s11373-005-9016-z; Tadolini M, 2016, EUR RESPIR J, V48, P1527, DOI 10.1183/13993003.01552-2016; US Food and Drug Administrations (FDA), 2012, 204384 US FDA NDA; Wagner DD, 2005, ARTERIOSCL THROM VAS, V25, P1321, DOI 10.1161/01.ATV.0000166521.90532.44; Wallis RS, 2016, EUR RESPIR J, V48, P1526, DOI 10.1183/13993003.01207-2016; Wonerow P, 2003, J BIOL CHEM, V278, P37520, DOI 10.1074/jbc.M305077200; Woulfe D, 2004, J CLIN INVEST, V113, P441, DOI 10.1172/JCI200420267; Woulfe DS, 2010, EXPERT REV HEMATOL, V3, P81, DOI 10.1586/EHM.09.75; Yang T, 2018, J PHARMACOL EXP THER, V365, P460, DOI 10.1124/jpet.117.246157; Zhabyeyev P, 2019, CHANNELS, V13, P520, DOI 10.1080/19336950.2019.1697127	43	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 26	2021	11								621148	10.3389/fimmu.2020.621148	http://dx.doi.org/10.3389/fimmu.2020.621148			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QV1QI	33717055	gold, Green Published			2022-12-18	WOS:000627752300001
J	Vanda, K; Bobbili, N; Matsunaga, M; Chen, JJ; Salanti, A; Leke, RFG; Taylor, DW				Vanda, Koko; Bobbili, Naveen; Matsunaga, Masako; Chen, John J.; Salanti, Ali; Leke, Rose F. G.; Taylor, Diane Wallace			The Development, Fine Specificity, and Importance of High-Avidity Antibodies to VAR2CSA in Pregnant Cameroonian Women Living in Yaounde, an Urban City	FRONTIERS IN IMMUNOLOGY			English	Article						Plasmodium falciparum; pregnant women; placental malaria; VAR2CSA; antibody avidity; urban cities	VARIANT SURFACE-ANTIGENS; MALARIA	Pregnant women infected with Plasmodium falciparum often produce antibodies (Abs) to VAR2CSA, a ligand that binds to placental chondroitin sulfate A causing placental malaria (PM). Antibodies to VAR2CSA are associated with improved pregnancy outcomes. Antibody avidity is a surrogate marker for the extent of maturation of the humoral immune response. Little is known about high avidity Abs to VAR2CSA for women living in urban African cities. Therefore, this study sought to determine: i) if high avidity Abs to full-length VAR2CSA (FV2) increase with gravidity in women in Yaounde, Cameroon exposed to similar to 0.3-1.1 infectious mosquito bites per month, ii) if high avidity Abs to FV2 are directed against a specific region of VAR2CSA, and iii) if having high avidity Abs to FV2 improve pregnancy outcomes. Plasma samples collected at delivery from 695 women who had Abs to FV2 were evaluated. Ab levels and the Avidity Index (AI), defined as the percent Abs remaining bound to FV2 after incubation with 3M NH4SCN, were determined. Similar Ab levels to FV2 were present in women of all gravidities (G1 through 6+; p=0.80), except significantly lower levels were detected in PM-negative (PM-) primigravidae (p<0.001). Median Ab avidities increased between gravidity 1 and 2 (p<0.001) and remained stable thereafter (G3-G6+: p=0.51). These results suggest that B cell clonal expansion began during the first pregnancy, with clonal selection primarily occurring during the second. However, the majority of women (84%) had AI <35, a level of high avidity Abs previously reported to be associated with improved pregnancy outcomes. When plasma from 107 Cameroonian women was tested against 8 different regions of FV2, high avidity Abs were predominately restricted to DBL5 with median AI of 50 compared to AI <25 for the other domains. The only significance influence of high avidity Abs on pregnancy outcome was that babies born to mothers with AI above the median were 104 g heavier than babies born to women with AI below the median (p=0.045). These results suggest that a vaccine that boosts maturation of the immune response to VAR2CSA may be beneficial for women residing in urban areas.	[Vanda, Koko; Bobbili, Naveen; Taylor, Diane Wallace] Univ Hawaii, John A Burns Sch Med, Dept Trop Med Med Microbiol & Pharmacol, Honolulu, HI 96822 USA; [Matsunaga, Masako; Chen, John J.] Univ Hawaii, John A Burns Sch Med, Dept Quantitat Hlth Sci, Honolulu, HI 96822 USA; [Salanti, Ali] Univ Copenhagen, Fac Hlth & Med Sci, Dept Immunol & Microbiol, Ctr Med Parasitol, Copenhagen, Denmark; [Salanti, Ali] Copenhagen Univ Hosp, Dept Infect Dis, Copenhagen, Denmark; [Leke, Rose F. G.] Univ Yaounde I, Biotechnol Ctr, Fac Med & Biomed Res, Yaounde, Cameroon	University of Hawaii System; University of Hawaii System; University of Copenhagen; University of Copenhagen; University of Yaounde I	Taylor, DW (corresponding author), Univ Hawaii, John A Burns Sch Med, Dept Trop Med Med Microbiol & Pharmacol, Honolulu, HI 96822 USA.	dwtaylor@hawaii.edu		Salanti, Ali/0000-0003-2207-5575	NIAID, NIH [UO1AI35839, 1R21AI105286]; Fogarty International Center, Global Infectious Diseases training grant [D43TW009074]; National Institute of Health (NIH) [U54MD007601]	NIAID, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Fogarty International Center, Global Infectious Diseases training grant; National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The study was funded by NIAID, NIH UO1AI35839 (sample, clinical information, and laboratory data collection) (DT). Laboratory studies by NIAID, 1R21AI105286 (JC and DT). KV was supported by the Fogarty International Center, Global Infectious Diseases training grant D43TW009074 (DT), and MM and JC were partially supported by U54MD007601 from the National Institute of Health (NIH).	Andersen P, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040042; Ataide R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022491; Ataide R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010807; Avril M, 2010, INFECT IMMUN, V78, P2248, DOI 10.1128/IAI.00410-09; Babakhanyan A, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-1023-6; Beeson JG, 2004, J INFECT DIS, V189, P540, DOI 10.1086/381186; Brabin BJ, 2004, PLACENTA, V25, P359, DOI 10.1016/j.placenta.2003.10.019; Clausen TM, 2012, J BIOL CHEM, V287, P23332, DOI 10.1074/jbc.M112.348839; Cutts JC, 2020, BMC MED, V18, DOI 10.1186/s12916-019-1467-6; Desai M, 2007, LANCET INFECT DIS, V7, P93, DOI 10.1016/S1473-3099(07)70021-X; Duffy PE, 2003, INFECT IMMUN, V71, P6620, DOI 10.1128/IAI.71.11.6620-6623.2003; Feng GQ, 2009, J INFECT DIS, V200, P299, DOI 10.1086/599841; FONDJO E, 1992, B SOC PATHOL EXOT, V85, P57; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Hedman K., 1993, REV MED MICROBIOL, V4, P123, DOI DOI 10.1097/00013542-199307000-00001; Hommel M, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2653-7; Hommel M, 2010, INFECT IMMUN, V78, P1963, DOI 10.1128/IAI.01365-09; Khattab A, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-21; Khunrae P, 2010, J MOL BIOL, V397, P826, DOI 10.1016/j.jmb.2010.01.040; Leke RFG, 2010, AM J TROP MED HYG, V83, P996, DOI 10.4269/ajtmh.2010.10-0249; Lloyd YM, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00166-18; Lo Tutterrow Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040049; Manga L., 1992, Memoires de la Societe Royale Belge d'Entomologie, V35, P155; Mayor A, 2013, J INFECT DIS, V207, P1664, DOI 10.1093/infdis/jit083; Mayor A, 2011, INFECT IMMUN, V79, P1654, DOI 10.1128/IAI.01000-10; Moore Kerryn A, 2017, Lancet Glob Health, V5, pe1101, DOI 10.1016/S2214-109X(17)30340-6; Ndam NT, 2015, EMERG INFECT DIS, V21, P813, DOI 10.3201/eid2105.141626; Nielsen MA, 2009, INFECT IMMUN, V77, P2482, DOI 10.1128/IAI.00159-09; Rogerson SJ, 2007, LANCET INFECT DIS, V7, P105, DOI 10.1016/S1473-3099(07)70022-1; Salanti A, 2004, J EXP MED, V200, P1197, DOI 10.1084/jem.20041579; Serra-Casas E, 2010, J INFECT DIS, V201, P123, DOI 10.1086/648595; Siriwardhana C, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-2041-3; Staalsoe T, 2004, LANCET, V363, P283, DOI 10.1016/S0140-6736(03)15386-X; Tako EA, 2005, AM J TROP MED HYG, V72, P236, DOI 10.4269/ajtmh.2005.72.236; Taylor DW, 2020, MALARIA J, V19, DOI 10.1186/s12936-020-03243-3; Tutterrow YL, 2012, INFECT IMMUN, V80, P1479, DOI 10.1128/IAI.00071-12; UNAID/WHO, 2004, CAMEROON EPIDEMIOLOG; WHO, 2010, WORLD MALARIA REPORT 2010, P1	38	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 26	2021	12								610108	10.3389/fimmu.2021.610108	http://dx.doi.org/10.3389/fimmu.2021.610108			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QV1OE	33717094	gold, Green Published			2022-12-18	WOS:000627746700001
J	Ding, MJ; He, YT; Zhang, SJ; Guo, WZ				Ding, Mingjie; He, Yuting; Zhang, Shuijun; Guo, Wenzhi			Recent Advances in Costimulatory Blockade to Induce Immune Tolerance in Liver Transplantation	FRONTIERS IN IMMUNOLOGY			English	Review						liver transplantation; immune tolerance; costimulatory; block; induce		Liver transplantation is an effective therapy for end-stage liver disease. However, most postoperative patients must take immunosuppressive drugs to prevent organ rejection. Interestingly, some transplant recipients have normal liver function and do not experience organ rejection after the withdrawal of immunosuppressive agents. This phenomenon, called immune tolerance, is the ultimate goal in clinical transplantation. Costimulatory molecules play important roles in T cell-mediated immune responses and the maintenance of T cell tolerance. Blocking costimulatory pathways can alter T cell responses and prolong graft survival. Better understanding of the roles of costimulatory molecules has facilitated the use of costimulatory blockade to effectively induce immune tolerance in animal transplantation models. In this article, we review the state of the art in costimulatory pathway blockade for the induction of immune tolerance in transplantation and its potential application prospects for liver transplantation.	[Ding, Mingjie; He, Yuting; Zhang, Shuijun; Guo, Wenzhi] Zhengzhou Univ, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Zhengzhou, Peoples R China; [Ding, Mingjie; He, Yuting; Zhang, Shuijun; Guo, Wenzhi] Open & Key Lab Hepatobiliary & Pancreat Surg & Di, Zhengzhou, Peoples R China; [Ding, Mingjie; Zhang, Shuijun; Guo, Wenzhi] Zhengzhou Key Lab Hepatobiliary & Pancreat Dis &, Zhengzhou, Peoples R China	Zhengzhou University	Guo, WZ (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Zhengzhou, Peoples R China.; Guo, WZ (corresponding author), Open & Key Lab Hepatobiliary & Pancreat Surg & Di, Zhengzhou, Peoples R China.; Guo, WZ (corresponding author), Zhengzhou Key Lab Hepatobiliary & Pancreat Dis &, Zhengzhou, Peoples R China.	guowz66@163.com			National Natural Science Foundation of China [81671958, U1604282]; Tackling Plan for Scientific and Technological in Medicine of Henan Province [SBGJ2018002]; Supporting Plan for Scientific and Technological Innovative Talents in Universities of Henan Province [19HASTIT003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tackling Plan for Scientific and Technological in Medicine of Henan Province; Supporting Plan for Scientific and Technological Innovative Talents in Universities of Henan Province	This work was supported by the National Natural Science Foundation of China (81671958 and U1604282) & the Tackling Plan for Scientific and Technological in Medicine of Henan Province (SBGJ2018002) and the Supporting Plan for Scientific and Technological Innovative Talents in Universities of Henan Province (19HASTIT003).	Alpdogan O, 2012, SEMIN ONCOL, V39, P629, DOI 10.1053/j.seminoncol.2012.10.001; Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Arai K, 1999, INT J PANCREATOL, V26, P23, DOI 10.1385/IJGC:26:1:23; Benitez C, 2013, HEPATOLOGY, V58, P1824, DOI 10.1002/hep.26426; Boenisch O, 2010, J IMMUNOL, V185, P5806, DOI 10.4049/jimmunol.0903435; Cai LJ, 2013, TRANSPLANTATION, V96, P379, DOI 10.1097/TP.0b013e31829b07b5; Cao W, 2011, IMMUNOLOGY, V133, P179, DOI 10.1111/j.1365-2567.2011.03424.x; Chatzigeorgiou A, 2009, BIOFACTORS, V35, P474, DOI 10.1002/biof.62; Chen LP, 2013, NAT REV IMMUNOL, V13, P227, DOI 10.1038/nri3405; Chen Y, 2009, AM J SURG, V198, P244, DOI 10.1016/j.amjsurg.2008.09.014; Chen ZH, 2018, TRANSPL IMMUNOL, V48, P32, DOI 10.1016/j.trim.2018.02.010; Chiba S, 2012, NAT IMMUNOL, V13, P832, DOI 10.1038/ni.2376; Cho HR, 2004, TRANSPL INT, V17, P351, DOI 10.1111/j.1432-2277.2004.tb00454.x; Croft M, 2009, IMMUNOL REV, V229, P173, DOI 10.1111/j.1600-065X.2009.00766.x; Cui B, 2019, ADV EXP MED BIOL, V1206, P595, DOI 10.1007/978-981-15-0602-4_27; Degauque N, 2008, J CLIN INVEST, V118, P735, DOI 10.1172/JCI32562; DEGAWA H, 1995, SURG TODAY, V25, P474, DOI 10.1007/BF00311833; Degawa H, 1996, TRANSPL P, V28, P1362; Demirci GI, 2004, J IMMUNOL, V172, P1691, DOI 10.4049/jimmunol.172.3.1691; Devlin J, 1998, HEPATOLOGY, V27, P926, DOI 10.1002/hep.510270406; Durrbach A, 2010, AM J TRANSPLANT, V10, P547, DOI 10.1111/j.1600-6143.2010.03016.x; Feng S, 2012, JAMA-J AM MED ASSOC, V307, P283, DOI 10.1001/jama.2011.2014; Freeman GJ, 2010, IMMUNOL REV, V235, P172, DOI 10.1111/j.0105-2896.2010.00903.x; Futagawa T, 2002, INT IMMUNOL, V14, P275, DOI 10.1093/intimm/14.3.275; de la Garza RG, 2013, LIVER TRANSPLANT, V19, P937, DOI 10.1002/lt.23686; Grazia TJ, 2005, J HEART LUNG TRANSPL, V24, P1410, DOI 10.1016/j.healun.2004.09.004; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Guo L, 2004, LIVER TRANSPLANT, V10, P743, DOI 10.1002/lt.20167; Guo L, 2002, TRANSPLANTATION, V73, P1027, DOI 10.1097/00007890-200204150-00003; Hancock WW, 1996, P NATL ACAD SCI USA, V93, P13967, DOI 10.1073/pnas.93.24.13967; Harada H, 2003, J CLIN INVEST, V112, P234, DOI 10.1172/JCI200317008; Hartigan CR, 2019, IMMUNOL REV, V292, P225, DOI 10.1111/imr.12824; He WT, 2009, TRANSPLANTATION, V88, P782, DOI 10.1097/TP.0b013e3181b47f25; Horst AK, 2016, CELL MOL IMMUNOL, V13, P277, DOI 10.1038/cmi.2015.112; Huang YH, 2016, NATURE, V536, P359, DOI 10.1038/nature17421; Isobe M, 1996, TRANSPLANTATION, V62, P411, DOI 10.1097/00007890-199608150-00019; Kinnear G, 2013, J IMMUNOL, V191, P1465, DOI 10.4049/jimmunol.1300553; Kinnear G, 2013, TRANSPLANTATION, V95, P527, DOI 10.1097/TP.0b013e31826d4672; Kirk AD, 1999, NAT MED, V5, P686, DOI 10.1038/9536; Klintmalm GB, 2014, AM J TRANSPLANT, V14, P1817, DOI 10.1111/ajt.12810; Kobayashi N, 2007, IMMUNITY, V27, P927, DOI 10.1016/j.immuni.2007.11.011; Kosuge H, 2003, TRANSPLANTATION, V75, P1374, DOI 10.1097/01.TP.0000061601.26325.82; Koyama I, 2004, TRANSPLANTATION, V77, P460, DOI 10.1097/01.TP.0000110291.29370.C0; Kwon BS, 1999, J BIOL CHEM, V274, P6056, DOI 10.1074/jbc.274.10.6056; LaMattina JC, 2014, TRANSPLANTATION, V97, P133, DOI 10.1097/01.TP.0000438635.44461.2e; Larsen CP, 2010, TRANSPLANTATION, V90, P1528, DOI 10.1097/TP.0b013e3181ff87cd; Larsen CP, 2005, AM J TRANSPLANT, V5, P443, DOI 10.1111/j.1600-6143.2005.00749.x; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; Lerut J, 2006, AM J TRANSPLANT, V6, P1774, DOI 10.1111/j.1600-6143.2006.01396.x; Li W, 2005, AM J TRANSPLANT, V5, P978, DOI 10.1111/j.1600-6143.2005.00823.x; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; Liu L, 2018, ARCH IMMUNOL THER EX, V66, P355, DOI 10.1007/s00005-018-0517-7; Mages HW, 2000, EUR J IMMUNOL, V30, P1040, DOI 10.1002/(SICI)1521-4141(200004)30:4<1040::AID-IMMU1040>3.0.CO;2-6; Mak TW, 2003, NAT IMMUNOL, V4, P765, DOI 10.1038/ni947; Malvezzi P, 2016, TRANSPLANTATION, V100, P2315, DOI 10.1097/TP.0000000000001344; McAdam AJ, 2000, J IMMUNOL, V165, P5035, DOI 10.4049/jimmunol.165.9.5035; Meyers JH, 2005, NAT IMMUNOL, V6, P455, DOI 10.1038/ni1185; Mizui M, 2008, INT IMMUNOL, V20, P695, DOI 10.1093/intimm/dxn029; Nurieva R, 2006, EMBO J, V25, P2623, DOI 10.1038/sj.emboj.7601146; Okimura K, 2014, AM J TRANSPLANT, V14, P1290, DOI 10.1111/ajt.12678; Oura T, 2012, AM J TRANSPLANT, V12, P1740, DOI 10.1111/j.1600-6143.2012.04014.x; Ozkaynak E, 2001, NAT IMMUNOL, V2, P591, DOI 10.1038/89731; Paterson AM, 2009, CELL, V137, P974, DOI 10.1016/j.cell.2009.05.015; Pestana JOM, 2012, AM J TRANSPLANT, V12, P630, DOI 10.1111/j.1600-6143.2011.03914.x; Pinelli DF, 2013, AM J TRANSPLANT, V13, P3021, DOI 10.1111/ajt.12417; Pinelli DF, 2015, IMMUNOTHERAPY-UK, V7, P399, DOI [10.2217/IMT.15.1, 10.2217/imt.15.1]; Qin L, 2010, CHINESE MED J-PEKING, V123, P212, DOI 10.3760/cma.j.issn.0366-6999.2010.02.017; Robles-Carrillo L, 2010, J IMMUNOL, V185, P1577, DOI 10.4049/jimmunol.0903888; Rodriguez-Manzanet R, 2008, J IMMUNOL, V180, P4706, DOI 10.4049/jimmunol.180.7.4706; Rodriguez-Manzanet R, 2009, IMMUNOL REV, V229, P259, DOI 10.1111/j.1600-065X.2009.00772.x; Schroder PM, 2019, CURR OPIN ORGAN TRAN, V24, P391, DOI 10.1097/MOT.0000000000000656; Schwarz C, 2015, CLIN TRANSPLANT, V29, P85, DOI 10.1111/ctr.12483; Shah JA, 2017, AM J TRANSPLANT, V17, P2178, DOI 10.1111/ajt.14341; Shi Y, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/192738; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Shuford WW, 1997, J EXP MED, V186, P47, DOI 10.1084/jem.186.1.47; Smith KM, 2003, J IMMUNOL, V170, P2310, DOI 10.4049/jimmunol.170.5.2310; Teschner D, 2011, SCAND J IMMUNOL, V74, P155, DOI 10.1111/j.1365-3083.2011.02564.x; Tone M, 2003, P NATL ACAD SCI USA, V100, P15059, DOI 10.1073/pnas.2334901100; Tseng M, 2016, AM J TRANSPLANT, V16, P1626, DOI 10.1111/ajt.13580; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; Uehara M, 2019, CLIN LAB MED, V39, P87, DOI 10.1016/j.cll.2018.10.009; Ueno T, 2008, J CLIN INVEST, V118, P742, DOI 10.1172/JCI32451; Umetsu SE, 2005, NAT IMMUNOL, V6, P447, DOI 10.1038/ni1186; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579; Vincenti F, 2012, AM J TRANSPLANT, V12, P210, DOI 10.1111/j.1600-6143.2011.03785.x; Vincenti F, 2010, AM J TRANSPLANT, V10, P535, DOI 10.1111/j.1600-6143.2009.03005.x; Walker LSK, 1999, J EXP MED, V190, P1115, DOI 10.1084/jem.190.8.1115; Wang F, 2008, TRANSPL IMMUNOL, V19, P12, DOI 10.1016/j.trim.2008.01.008; Webb GJ, 2016, CLIN REV ALLERG IMMU, V50, P312, DOI 10.1007/s12016-015-8498-3; Wei S, 2011, TRANSPL P, V43, P1971, DOI 10.1016/j.transproceed.2011.03.054; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Willoughby J, 2017, MOL IMMUNOL, V83, P13, DOI 10.1016/j.molimm.2017.01.006; Wu H, 2018, INT J MOL MED, V42, P346, DOI 10.3892/ijmm.2018.3606; Xiao ZY, 2020, CANCER RES, V80, P3023, DOI 10.1158/0008-5472.CAN-19-3265; Yamada A, 2002, TRANSPLANTATION, V73, pS36, DOI 10.1097/00007890-200201151-00012; Yeung MY, 2019, ADV EXP MED BIOL, V1189, P267, DOI 10.1007/978-981-32-9717-3_10; Yoshinaga SK, 1999, NATURE, V402, P827, DOI 10.1038/45582; Yuan XL, 2003, J IMMUNOL, V170, P2949, DOI 10.4049/jimmunol.170.6.2949; Zhu C, 2005, NAT IMMUNOL, V6, P1245, DOI 10.1038/ni1271; Zhu P, 2008, TRANSPL P, V40, P1618, DOI 10.1016/j.transproceed.2008.03.148; Zhuang Q, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12623	103	0	0	2	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 24	2021	12								537079	10.3389/fimmu.2021.537079	http://dx.doi.org/10.3389/fimmu.2021.537079			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QT9FT	33732228	Green Published, gold			2022-12-18	WOS:000626893400001
J	Okroj, M; Volokhina, E				Okroj, Marcin; Volokhina, Elena			Editorial: Complement and Immunotherapeutics	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						complement; immunotherapy; rituximab; eculizumab; factor H; antibodies			[Okroj, Marcin] Univ Gdansk, Intercollegiate Fac Biotechnol, Gdansk, Poland; [Okroj, Marcin] Med Univ Gdansk, Gdansk, Poland; [Volokhina, Elena] Amalia Childrens Hosp, Radboud Inst Mol Life Sci, Dept Pediat Nephrol, Nijmegen, Netherlands; [Volokhina, Elena] Radboud Univ Nijmegen, Med Ctr, Dept Lab Med, Nijmegen, Netherlands	Fahrenheit Universities; University of Gdansk; Fahrenheit Universities; Medical University Gdansk; Radboud University Nijmegen	Okroj, M (corresponding author), Univ Gdansk, Intercollegiate Fac Biotechnol, Gdansk, Poland.; Okroj, M (corresponding author), Med Univ Gdansk, Gdansk, Poland.; Volokhina, E (corresponding author), Amalia Childrens Hosp, Radboud Inst Mol Life Sci, Dept Pediat Nephrol, Nijmegen, Netherlands.; Volokhina, E (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Lab Med, Nijmegen, Netherlands.	marcin.okroj@gumed.edu.pl; elena.volokhina@radboudumc.nl	Volokhina, Elena/L-4725-2015	Volokhina, Elena/0000-0002-4294-8460				Gavriilaki E, 2020, J CLIN INVEST, V130, P2152, DOI 10.1172/JCI136094; Maloney DG, 1997, BLOOD, V90, P2188; Reis ES, 2018, NAT REV IMMUNOL, V18, P5, DOI 10.1038/nri.2017.97; Reis ES, 2015, CLIN IMMUNOL, V161, P225, DOI 10.1016/j.clim.2015.08.009; Ricklin D, 2018, NAT REV NEPHROL, V14, P26, DOI 10.1038/nrneph.2017.156; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Rother RP, 2007, NAT BIOTECHNOL, V25, P1256, DOI 10.1038/nbt1344	7	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 24	2021	12								663459	10.3389/fimmu.2021.663459	http://dx.doi.org/10.3389/fimmu.2021.663459			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QT9EV	33717205	Green Published, gold			2022-12-18	WOS:000626891000001
J	Harms, RZ; Ostlund, KR; Cabrera, M; Edwards, E; Smith, VB; Smith, LM; Sarvetnick, N				Harms, Robert Z.; Ostlund, Katie R.; Cabrera, Monina; Edwards, Earline; Smith, Victoria B.; Smith, Lynette M.; Sarvetnick, Nora			Frequencies of CD8 and DN MAIT Cells Among Children Diagnosed With Type 1 Diabetes Are Similar to Age-Matched Controls	FRONTIERS IN IMMUNOLOGY			English	Article						mucosal associated invariant T cells; type 1 diabetes; autoantibodies; vitamin D; human cytomegalovirus; interleukin 18; interleukin 7	INVARIANT T-CELLS; UP-REGULATION; ACTIVATION; AUTOANTIBODIES; MICROBIOME; CONTRIBUTE; EXPANSION; CORRELATE; DECREASE; MUCOSA	Mucosal-associated invariant T (MAIT) cells have been implicated in various forms of autoimmunity, including type 1 diabetes (T1D). Here, we tested the hypothesis that CD8 and double negative (DN) MAIT cell frequencies were altered among diagnosed T1D subjects compared to controls. To do this, we analyzed cryopreserved peripheral blood mononuclear cells (PBMCs) from age-matched T1D and control children using flow cytometry. We observed that CD8 and DN MAIT cell frequencies were similarly abundant between the two groups. We tested for associations between MAIT cell frequency and T1D-associated parameters, which could reveal a pathogenic role for MAIT cells in the absence of changes in frequency. We found no significant associations between CD8 and DN MAIT cell frequency and levels of islet cell autoantibodies (ICA), glutamate decarboxylase 65 (GAD65) autoantibodies, zinc transporter 8 (ZNT8) autoantibodies, and insulinoma antigen 2 (IA-2) autoantibodies. Furthermore, CD8 and DN MAIT cell frequencies were not significantly associated with time since diagnosis, c-peptide levels, HbA1c, and BMI. As we have examined this cohort for multiple soluble factors previously, we tested for associations between relevant factors and MAIT cell frequency. These could help to explain the broad range of MAIT frequencies we observed and/or indicate disease-associated processes. Although we found nothing disease-specific, we observed that levels of IL-7, IL-18, 25 (OH) vitamin D, and the ratio of vitamin D binding protein to 25 (OH) vitamin D were all associated with MAIT cell frequency. Finally, previous cytomegalovirus infection was associated with reduced CD8 and DN MAIT cells. From this evaluation, we found no connections between CD8 and DN MAIT cells and children with T1D. However, we did observe several intrinsic and extrinsic factors that could influence peripheral MAIT cell abundance among all children. These factors may be worth consideration in future experimental design.	[Harms, Robert Z.; Ostlund, Katie R.; Sarvetnick, Nora] Univ Nebraska Med Ctr, Dept Surg Transplant, Omaha, NE 68198 USA; [Cabrera, Monina; Edwards, Earline] Univ Nebraska Ctr, Pediat Endocrinol, Omaha, NE USA; [Cabrera, Monina; Edwards, Earline] Childrens Hosp & Med Ctr, Childrens Pediat Endocrinol, Omaha, NE USA; [Smith, Victoria B.] Univ Nebraska Med Ctr, Off Vice Chancellor Res, Omaha, NE USA; [Smith, Lynette M.] Univ Nebraska Med Ctr, Dept Biostat, Omaha, NE USA; [Sarvetnick, Nora] Univ Nebraska Med Ctr, Mary & Dick Holland Regenerat Med Program, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Harms, RZ (corresponding author), Univ Nebraska Med Ctr, Dept Surg Transplant, Omaha, NE 68198 USA.	rharms@unmc.edu			NIAID [UO1AI130841, UO1AI102012, RO1AI150274]; Juvenile Diabetes Research Foundation [2-SRA-2019-842-S-B, 2-SRA2016-288-S-B]; Leona M. and Harry B. Helmsley Charitable Trust [2016PG-T1D036]; J. W. Kieckhefer Foundation	NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); Leona M. and Harry B. Helmsley Charitable Trust; J. W. Kieckhefer Foundation	This work was supported by grants to NS from NIAID (UO1AI130841, UO1AI102012, and RO1AI150274), the Juvenile Diabetes Research Foundation (2-SRA-2019-842-S-B and 2-SRA2016-288-S-B), the Leona M. and Harry B. Helmsley Charitable Trust (2016PG-T1D036), and the J. W. Kieckhefer Foundation.	ARMITAGE RJ, 1990, J IMMUNOL, V144, P938; Bach JF, 2018, NAT REV IMMUNOL, V18, P105, DOI 10.1038/nri.2017.111; Barragan M, 2015, NUTRIENTS, V7, P8127, DOI 10.3390/nu7095383; Beam CA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-56951-5; Blum KS, 2007, IMMUNOL LETT, V108, P45, DOI 10.1016/j.imlet.2006.10.009; Brozova J, 2016, SCAND J IMMUNOL, V84, P245, DOI 10.1111/sji.12467; Chiba A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01333; Cosgrove C, 2013, BLOOD, V121, P951, DOI 10.1182/blood-2012-06-436436; Cui Y, 2015, J CLIN INVEST, V125, P4171, DOI 10.1172/JCI82424; Dias J, 2018, P NATL ACAD SCI USA, V115, pE11513, DOI 10.1073/pnas.1812273115; Dinarello CA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00289; Dunne JL, 2014, CLIN EXP IMMUNOL, V177, P30, DOI 10.1111/cei.12321; Dusseaux M, 2011, BLOOD, V117, P1250, DOI 10.1182/blood-2010-08-303339; Gazali AM, 2020, DIABETOLOGIA, V63, P2396, DOI 10.1007/s00125-020-05257-7; GENOVESE S, 1994, LANCET, V344, P756, DOI 10.1016/S0140-6736(94)92248-9; Gesualdo PD, 2016, PEDIATR DIABETES, V17, P441, DOI 10.1111/pedi.12301; Giongo A, 2011, ISME J, V5, P82, DOI 10.1038/ismej.2010.92; Gracey E, 2016, ANN RHEUM DIS, V75, P2124, DOI 10.1136/annrheumdis-2015-208902; Harjutsalo V, 2008, LANCET, V371, P1777, DOI 10.1016/S0140-6736(08)60765-5; Harms RZ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01922; Harms RZ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02332; Harms RZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117335; Havenith SHC, 2012, INT IMMUNOL, V24, P625, DOI 10.1093/intimm/dxs069; Hinks TSC, 2019, CELL REP, V28, P3249, DOI 10.1016/j.celrep.2019.07.039; Holodniy M, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0014764, 10.1371/journal.pone.0025792]; Huang WY, 2020, J VIRAL HEPATITIS, V27, P1096, DOI 10.1111/jvh.13341; Jiang J, 2016, SCI REP-UK, V6, DOI 10.1038/srep32320; Joseph RW, 2012, HUM IMMUNOL, V73, P693, DOI 10.1016/j.humimm.2012.04.019; Kjer-Nielsen L, 2012, NATURE, V491, P717, DOI 10.1038/nature11605; Korsgren S, 2012, AM J PATHOL, V181, P1735, DOI 10.1016/j.ajpath.2012.07.022; Kostic AD, 2015, CELL HOST MICROBE, V17, P260, DOI 10.1016/j.chom.2015.01.001; Kuric E, 2018, AM J PATHOL, V188, P1744, DOI 10.1016/j.ajpath.2018.04.009; Kurioka A, 2015, MUCOSAL IMMUNOL, V8, P429, DOI 10.1038/mi.2014.81; Le Bourhis L, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003681; Lee OJ, 2014, EXP GERONTOL, V49, P47, DOI 10.1016/j.exger.2013.11.003; Leeansyah E, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005072; Leeansyah E, 2013, BLOOD, V121, P1124, DOI 10.1182/blood-2012-07-445429; Lerner A, 2015, INT J CELIAC DIS, V3, P151, DOI [10.12691/ijcd-3-4-8, DOI 10.12691/IJCD-3-4-8]; Loh L, 2016, P NATL ACAD SCI USA, V113, P10133, DOI 10.1073/pnas.1610750113; Maclaren NK, 2003, DIABETOLOGIA, V46, P873, DOI 10.1007/s00125-003-1123-7; Magalhaes I, 2015, J CLIN INVEST, V125, P1752, DOI 10.1172/JCI78941; Myhr CB, 2013, J AUTOIMMUN, V44, P8, DOI 10.1016/j.jaut.2013.06.001; Paquin-Proulx D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175345; Patel O, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3142; Pellegrini S, 2017, J CLIN ENDOCR METAB, V102, P1468, DOI 10.1210/jc.2016-3222; Pincikova T, 2017, CLIN EXP IMMUNOL, V189, P359, DOI 10.1111/cei.12984; R Development Core Team, 2018, R LANG ENV STAT COMP; RIGBY WFC, 1990, BLOOD, V76, P189, DOI 10.1182/blood.V76.1.189.bloodjournal761189; Rosenberg SA, 2006, J IMMUNOTHER, V29, P313, DOI 10.1097/01.cji.0000210386.55951.c2; Rouxel O, 2017, NAT IMMUNOL, V18, P1321, DOI 10.1038/ni.3854; Sapone A, 2006, DIABETES, V55, P1443, DOI 10.2337/db05-1593; Sattler A, 2015, EUR J IMMUNOL, V45, P2286, DOI 10.1002/eji.201445313; Savilahti E, 1999, CLIN EXP IMMUNOL, V116, P70; Simmons KM, 2019, PEDIATR DIABETES, V20, P909, DOI 10.1111/pedi.12902; Sportes C, 2008, J EXP MED, V205, P1701, DOI 10.1084/jem.20071681; Tang XZ, 2013, J IMMUNOL, V190, P3142, DOI 10.4049/jimmunol.1203218; Ussher JE, 2014, EUR J IMMUNOL, V44, P195, DOI 10.1002/eji.201343509; van Wilgenburg B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11653; von Essen MR, 2010, NAT IMMUNOL, V11, P344, DOI 10.1038/ni.1851; Walikonis JE, 1998, MAYO CLIN PROC, V73, P1161, DOI 10.4065/73.12.1161; Walker LJ, 2014, SCAND J IMMUNOL, V80, P462, DOI 10.1111/sji.12237; Westerholm-Ormio M, 2003, DIABETES, V52, P2287, DOI 10.2337/diabetes.52.9.2287; Willing A, 2014, EUR J IMMUNOL, V44, P3119, DOI 10.1002/eji.201344160	63	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 23	2021	12								604157	10.3389/fimmu.2021.604157	http://dx.doi.org/10.3389/fimmu.2021.604157			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QT3GE	33708202	gold, Green Published			2022-12-18	WOS:000626477300001
J	Kakuda, N; Amiya, E; Hatano, M; Maki, H; Bujo, C; Tsuji, M; Narita, K; Fujita, K; Ishida, J; Ono, M; Komuro, I				Kakuda, Nobutaka; Amiya, Eisuke; Hatano, Masaru; Maki, Hisataka; Bujo, Chie; Tsuji, Masaki; Narita, Koichi; Fujita, Kanna; Ishida, Junichi; Ono, Minoru; Komuro, Issei			Case Report: A Case of Acute Cellular Rejection Due to Atopic Dermatitis Exacerbation 3 Years After Heart Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						atopic dermatitis; regulatory T cell; acute cellular rejection; heart transplantation; late rejection of graft		Background Little evidence has been presented about the association between previous atopic/allergic disease and graft rejection after solid organ transplantation. Thus, we present a case wherein acute cellular rejection (ACR) after heart transplantation (HTx) was noted along with exacerbation of atopic disease. Case Summary A 32-year-old man was admitted at our hospital for regular monitoring of graft rejection. He had undergone heart transplant 3 years prior due to dilated cardiomyopathy. Echocardiogram revealed good biventricular function, and no abnormal findings were found in blood sampling tests. However, biopsy showed moderate ACR [Grade 2R(ISHLT 2004)/3A(ISHLT 1990)], which required twice-repeated steroid pulses with intensified immunosuppression. Meanwhile, his atopic dermatitis, which was diagnosed before having heart failure, was getting worse for the past 6 months. The exacerbation of atopic dermatitis was presumed to be related to the development of the intractable cellular rejection. Discussion This case suggested the association of atopic disease and graft rejection after HTx. We examined 76 patients from a cohort of previous studies who underwent HTx at our hospital, which suggested that patients with atopic/allergic disorders such as atopic dermatitis and asthma tended to have a significantly higher frequency of moderate rejection than non-allergic patients. (p = 0.012; Fisher's exact test). Our case also suggests that exacerbation of atopic dermatitis might cause graft rejection of the transplanted organ, so that it is important to carefully evaluate the risk of graft rejection if there is a previous history of atopic/allergic disease.	[Kakuda, Nobutaka; Amiya, Eisuke; Hatano, Masaru; Bujo, Chie; Tsuji, Masaki; Narita, Koichi; Fujita, Kanna; Ishida, Junichi; Komuro, Issei] Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo, Japan; [Amiya, Eisuke; Hatano, Masaru] Univ Tokyo, Dept Therapeut Strategy Heart Failure, Tokyo, Japan; [Maki, Hisataka] Jichi Med Univ, Saitama Med Ctr, Dept Cardiovasc Med, Saitama, Japan; [Ono, Minoru] Univ Tokyo, Grad Sch Med, Dept Cardiac Surg, Tokyo, Japan	University of Tokyo; University of Tokyo; Jichi Medical University; University of Tokyo	Amiya, E (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo, Japan.; Amiya, E (corresponding author), Univ Tokyo, Dept Therapeut Strategy Heart Failure, Tokyo, Japan.	amiyae-tky@umin.ac.jp	Amiya, Eisuke/O-4981-2019	Amiya, Eisuke/0000-0003-2810-8040; , Junichi/0000-0001-9703-9419	Ministry of Education, Culture, Sports, Science and Technology of Japan [17K09488]	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan through Grant-in-Aid 17K09488 (to EA).	Braun MY, 2000, EUR J IMMUNOL, V30, P1290; Bujo C, 2021, HEART VESSELS, V36, P499, DOI 10.1007/s00380-020-01715-9; del Giudice MM, 2006, ALLERGY ASTHMA PROC, V27, P451, DOI 10.2500/aap.2006.27.2887; Dhar Sandipan, 2005, Indian J Dermatol Venereol Leprol, V71, P246; Dijke IE, 2009, TRANSPLANTATION, V87, P1191, DOI 10.1097/TP.0b013e31819ec2fb; Foley John F., 2012, SCI SIGNAL, V252, P302, DOI [10.1126/scisignal.2003810, DOI 10.1126/SCISIGNAL.2003810]; Goldman M, 2001, TRENDS IMMUNOL, V22, P247, DOI 10.1016/S1471-4906(01)01893-2; Joffre O, 2008, NAT MED, V14, P88, DOI 10.1038/nm1688; Kaes J, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112516; Kittleson MM, 2017, JACC-HEART FAIL, V5, P857, DOI 10.1016/j.jchf.2017.08.021; Marcus N, 2018, J PEDIATR-US, V196, P154, DOI 10.1016/j.jpeds.2017.11.026; Miura K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207480; Nguyen NX, 2009, GRAEF ARCH CLIN EXP, V247, P573, DOI 10.1007/s00417-008-0959-4; Niederkorn JY, 2009, AM J TRANSPLANT, V9, P1017, DOI 10.1111/j.1600-6143.2009.02603.x; Niederkorn JY, 2010, J IMMUNOL, V184, P6076, DOI 10.4049/jimmunol.0902300; Ozdemir O, 2006, PEDIATR TRANSPLANT, V10, P380, DOI 10.1111/j.1399-3046.2005.00474.x; Reyes NJ, 2013, AM J TRANSPLANT, V13, P1181, DOI 10.1111/ajt.12198; SEUNG LM, 1994, ARCH DERMATOL, V130, P584, DOI 10.1001/archderm.130.5.584	18	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 22	2021	12								630051	10.3389/fimmu.2021.630051	http://dx.doi.org/10.3389/fimmu.2021.630051			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QS6TY	33692803	Green Published, gold			2022-12-18	WOS:000626031500001
J	Stoiber, L; Schoenrath, F; Knosalla, C; Milting, H; Klingel, K; Tschope, C; Tanacli, R; Gebker, R; Berger, A; Pieske, B; Kelle, S				Stoiber, Lukas; Schoenrath, Felix; Knosalla, Christoph; Milting, Hendrik; Klingel, Karin; Tschope, Carsten; Tanacli, Radu; Gebker, Rolf; Berger, Alexander; Pieske, Burkert; Kelle, Sebastian			Case Report: Early Transplant Rejection of a Methanol-Intoxicated Donor Heart in a Young Female Patient. A Diagnostic Approach With CMR, Cardiac Biopsy, and Genetic Risk Assessment	FRONTIERS IN IMMUNOLOGY			English	Article						cardiac magnetic resonance imaging (CMR); heart transplantation; gene sequence; cardiomyopathy; mapping; magnetic resonance imaging		This case report describes the contributions of multimodality imaging, cardiac biopsy, and genetic sequencing to the diagnosis and management of heart transplant rejection in a 23-year old patient with dilated cardiomyopathy.	[Stoiber, Lukas; Schoenrath, Felix; Knosalla, Christoph] German Heart Ctr Berlin, Dept Cardiothorac & Vasc Surg, Berlin, Germany; [Stoiber, Lukas; Tanacli, Radu; Gebker, Rolf; Berger, Alexander; Pieske, Burkert; Kelle, Sebastian] German Heart Ctr Berlin, Dept Internal Med & Cardiol, Berlin, Germany; [Schoenrath, Felix; Knosalla, Christoph; Tschope, Carsten; Pieske, Burkert; Kelle, Sebastian] DZHK German Ctr Cardiovasc Res, Partner Site Berlin, Berlin, Germany; [Milting, Hendrik] Ruhr Univ Bochum, Erich & Hanna Klessmann Inst Cardiovasc Res & Dev, Heart & Diabet Ctr North Rine Westphalia NRW, Univ Hosp, Bad Oeynhausen, Germany; [Klingel, Karin] Univ Hosp Tubingen, Inst Pathol & Neuropathol, Cardiopathol, Tubingen, Germany; [Tschope, Carsten; Pieske, Burkert; Kelle, Sebastian] Charite Univ Med Berlin, Dept Internal Med & Cardiol, Berlin, Germany	German Heart Center Berlin; German Heart Center Berlin; German Centre for Cardiovascular Research; Ruhr University Bochum; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Stoiber, L (corresponding author), German Heart Ctr Berlin, Dept Cardiothorac & Vasc Surg, Berlin, Germany.; Stoiber, L (corresponding author), German Heart Ctr Berlin, Dept Internal Med & Cardiol, Berlin, Germany.	lukas.stoiber@gmx.at	; Pieske, Burkert/M-8089-2016	Tschope, Carsten/0000-0001-5243-8985; Pieske, Burkert/0000-0002-6466-5306; Kelle, Sebastian/0000-0001-8105-6599; Stoiber, Lukas/0000-0002-2368-0999; Knosalla, Christoph/0000-0002-8127-5019				Bentley MJ, 2001, ANN THORAC SURG, V71, P1194, DOI 10.1016/S0003-4975(01)02402-X; Berry GJ, 2013, J HEART LUNG TRANSPL, V32, P1147, DOI 10.1016/j.healun.2013.08.011; Braggion-Santos MF, 2014, EUR HEART J-CARD IMG, V15, P1125, DOI 10.1093/ehjci/jeu090; Bruneval P, 2017, AM J TRANSPLANT, V17, P42, DOI 10.1111/ajt.14112; CAVALLI A, 1987, POSTGRAD MED J, V63, P867, DOI 10.1136/pgmj.63.744.867; Dandel M, 2001, CIRCULATION, V104, pI184; HAMMOND EH, 1989, J HEART TRANSPLANT, V8, P430; Herman DS, 2012, NEW ENGL J MED, V366, P619, DOI 10.1056/NEJMoa1110186; Jaff Z, 2014, CARDIOL J, V21, P170, DOI 10.5603/CJ.a2013.0053; Kobashigawa J, 2011, J HEART LUNG TRANSPL, V30, P252, DOI 10.1016/j.healun.2010.11.003; Loupy A, 2018, NEW ENGL J MED, V379, P1150, DOI 10.1056/NEJMra1802677; Loupy A, 2017, CIRCULATION, V135, P917, DOI 10.1161/CIRCULATIONAHA.116.022907; Marie PY, 2001, J AM COLL CARDIOL, V37, P825, DOI 10.1016/S0735-1097(00)01196-7; Mengel M, 2010, AM J TRANSPLANT, V10, P2105, DOI 10.1111/j.1600-6143.2010.03182.x; Messroghli DR, 2017, J CARDIOVASC MAGN R, V19, DOI 10.1186/s12968-017-0389-8; Usman AA, 2012, CIRC-CARDIOVASC IMAG, V5, P782, DOI 10.1161/CIRCIMAGING.111.971101; Vermes E, 2018, J CARDIOVASC MAGN R, V20, DOI 10.1186/s12968-018-0480-9; Vlismas P, 2015, CIRC-HEART FAIL, V8, P836, DOI 10.1161/CIRCHEARTFAILURE.115.002307; Yusen RD, 2014, J HEART LUNG TRANSPL, V33, P1009, DOI 10.1016/j.healun.2014.08.004	19	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 22	2021	11								575635	10.3389/fimmu.2020.575635	http://dx.doi.org/10.3389/fimmu.2020.575635			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QS6XM	33692775	gold, Green Published			2022-12-18	WOS:000626040700001
J	Hofmann, M; Jandus, C; Lee, LN; Utzschneider, DT				Hofmann, Maike; Jandus, Camilla; Lee, Lian Ni; Utzschneider, Daniel T.			Editorial: Memory T Cells in Chronic Infections and Tumors	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						exhaustion; memory T cells; chronic infection; tumor; PD-1			[Hofmann, Maike] Univ Freiburg, Freiburg Univ, Gastroenterol Hepatol Endocrinol & Infect Dis, Clin Internal Med 2,Med Ctr, Freiburg, Germany; [Jandus, Camilla] Univ Geneva, Dept Pathol & Immunol, Fac Med, Geneva, Switzerland; [Jandus, Camilla] Ludwig Inst Canc Res, Lausanne, Switzerland; [Lee, Lian Ni] Univ Oxford, Nuffield Dept Med & Translat Gastroenterol Unit, Peter Medawar Bldg, Oxford, England; [Utzschneider, Daniel T.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia	University of Freiburg; University of Geneva; Ludwig Institute for Cancer Research; University of Oxford; University of Melbourne	Utzschneider, DT (corresponding author), Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia.	daniel.utzschneider@unimelb.edu.au	Utzschneider, Daniel/D-5855-2016	Utzschneider, Daniel/0000-0003-2205-9057	Emerson Collective; Cancer Research UK [A29991]	Emerson Collective; Cancer Research UK(Cancer Research UK)	LN is funded by the Emerson Collective and Cancer Research UK (Biotherapeutics Drug Discovery Project Award A29991).	Brummelman J, 2018, J EXP MED, V215, P2520, DOI 10.1084/jem.20180684; Hensel N, 2021, NAT IMMUNOL, V22, P229, DOI 10.1038/s41590-020-00817-w; Im SJ, 2016, NATURE, V537, P417, DOI 10.1038/nature19330; Jansen CS, 2019, NATURE, V576, P465, DOI 10.1038/s41586-019-1836-5; Kallies A, 2020, NAT REV IMMUNOL, V20, P128, DOI 10.1038/s41577-019-0223-7; Leong YA, 2016, NAT IMMUNOL, V17, P1187, DOI 10.1038/ni.3543; Miller BC, 2019, NAT IMMUNOL, V20, P326, DOI 10.1038/s41590-019-0312-6; Sekine T, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aba7918; Siddiqui I, 2019, IMMUNITY, V50, P195, DOI 10.1016/j.immuni.2018.12.021; Utzschneider DT, 2020, NAT IMMUNOL, V21, P1256, DOI 10.1038/s41590-020-0760-z; Utzschneider DT, 2016, IMMUNITY, V45, P415, DOI 10.1016/j.immuni.2016.07.021; Wieland D, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15050; Williams MA, 2007, ANNU REV IMMUNOL, V25, P171, DOI 10.1146/annurev.immunol.25.022106.141548	13	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 17	2021	12								656010	10.3389/fimmu.2021.656010	http://dx.doi.org/10.3389/fimmu.2021.656010			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QQ4GJ	33679814	Green Published, gold			2022-12-18	WOS:000624481100001
J	Takahashi, K; Takeuchi, H; Fukai, R; Nakamura, H; Morihara, K; Higashiyama, Y; Takahashi, T; Doi, H; Tanaka, F				Takahashi, Keita; Takeuchi, Hideyuki; Fukai, Ryoko; Nakamura, Haruko; Morihara, Keisuke; Higashiyama, Yuichi; Takahashi, Toshiyuki; Doi, Hiroshi; Tanaka, Fumiaki			Case Report: Anti-MOG Antibody Seroconversion Accompanied by Dimethyl Fumarate Treatment	FRONTIERS IN IMMUNOLOGY			English	Article						anti-myelin oligodendrocyte glycoprotein antibody-associated disease; dimethyl fumarate; fingolimod; multiple sclerosis; seroconversion		Here we report three cases of anti-myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) mimicking multiple sclerosis in which seropositivity for anti-MOG antibodies occurred during disease-modifying drug dimethyl fumarate (DMF) treatment. These patients developed relapses with anti-MOG antibody seroconversion after switching from fingolimod or steroid pulse therapy to DMF, which was associated with peripheral lymphocyte recovery. MOGAD is considered a humoral immune disease, and DMF reportedly enhances Th2-skewed humoral immune activity. Therefore, we suggest that DMF, but not fingolimod, may exacerbate humoral immune imbalance and enhance autoantibody production, leading to aggravation of MOGAD.	[Takahashi, Keita; Takeuchi, Hideyuki; Fukai, Ryoko; Nakamura, Haruko; Morihara, Keisuke; Higashiyama, Yuichi; Doi, Hiroshi; Tanaka, Fumiaki] Yokohama City Univ, Grad Sch Med, Dept Neurol & Stroke Med, Yokohama, Kanagawa, Japan; [Takahashi, Toshiyuki] Tohoku Univ, Grad Sch Med, Dept Neurol, Sendai, Miyagi, Japan	Yokohama City University; Tohoku University	Takeuchi, H; Tanaka, F (corresponding author), Yokohama City Univ, Grad Sch Med, Dept Neurol & Stroke Med, Yokohama, Kanagawa, Japan.	htake@yokohama-cu.ac.jp; ftanaka@yokohama-cu.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan; Ministry of Health, Labor and Welfare of Japan; Yokohama City University	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Yokohama City University	This study was supported partly by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, grants from the Ministry of Health, Labor and Welfare of Japan, and a grant for Strategic Research Promotion from Yokohama City University.	Fujihara K, 2018, CLIN EXP NEUROIMMUNO, V9, P48, DOI DOI 10.1111/CEN3.12434; Fukai R, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00763; Kira J, 2017, MULT SCLER J, V23, P1300, DOI 10.1177/1352458517703803; Narayan R, 2018, MULT SCLER RELAT DIS, V25, P66, DOI 10.1016/j.msard.2018.07.025; Pawlitzki M, 2020, MULT SCLER RELAT DIS, V37, DOI 10.1016/j.msard.2019.101420; Reindl M, 2019, NAT REV NEUROL, V15, P89, DOI 10.1038/s41582-018-0112-x; Rommer PS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01564; Sato DK, 2014, NEUROLOGY, V82, P474, DOI 10.1212/WNL.0000000000000101; Takahashi T, 2007, BRAIN, V130, P1235, DOI 10.1093/brain/awm062; Warabi Y, 2019, CUREUS, V11, DOI 10.7759/cureus.6040; Waters P, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000089; Yamout BI, 2017, MULT SCLER J, V23, P1297, DOI 10.1177/1352458517694086	12	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 15	2021	12								625465	10.3389/fimmu.2021.625465	http://dx.doi.org/10.3389/fimmu.2021.625465			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QO5SJ	33659007	Green Published, gold			2022-12-18	WOS:000623201700001
J	D'Aveni, M; Notarantonio, AB; Agbogan, VA; Bertrand, A; Fouquet, G; Gastineau, P; Garfa-Traore, M; De Carvalho, M; Hermine, O; Rubio, MT; Zavala, F				D'Aveni, Maud; Notarantonio, Anne-Beatrice; Agbogan, Viviane A.; Bertrand, Allan; Fouquet, Guillemette; Gastineau, Pauline; Garfa-Traore, Meriem; De Carvalho, Marcelo; Hermine, Olivier; Rubio, Marie-Therese; Zavala, Flora			Mobilized Multipotent Hematopoietic Progenitors Promote Expansion and Survival of Allogeneic Tregs and Protect Against Graft Versus Host Disease	FRONTIERS IN IMMUNOLOGY			English	Article						allogeneic HSCT; graft versus host disease; mobilization; multipotent progenitors; regulatory T cells; expansion; alloreactivity; mixed lymphocyte reaction		Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) is routinely performed with peripheral blood stem cells (PBSCs) mobilized by injection of G-CSF, a growth factor which not only modulates normal hematopoiesis but also induces diverse immature regulatory cells. Based on our previous evidence that G-CSF-mobilized multipotent hematopoietic progenitors (MPP) can increase survival and proliferation of natural regulatory T cells (Tregs) in autoimmune disorders, we addressed the question how these cells come into play in mice and humans in an alloimmune setting. Using a C57BL/6 mouse model, we demonstrate that mobilized MPP enhance the immunosuppressant effect exerted by Tregs, against alloreactive T lymphocytes, both in vitro and in vivo. They do so by migrating to sites of allopriming, interacting with donor Tregs and increasing their numbers, thus reducing the lethality of graft-versus-host disease (GVHD). Protection correlates likewise with increased allospecific Treg counts. Furthermore, we provide evidence for a phenotypically similar MPP population in humans, where it shares the capacity to promote selective Treg expansion in vitro. We postulate that G-CSF-mobilized MPPs might become a valuable cellular therapy to expand donor Tregs in vivo and prevent GVHD, thereby making allo-HSCT safer for the treatment of leukemia patients.	[D'Aveni, Maud; Notarantonio, Anne-Beatrice; Rubio, Marie-Therese] Univ Lorraine, CHRU Nancy, Hematol Dept, Nancy, France; [D'Aveni, Maud; Notarantonio, Anne-Beatrice; Bertrand, Allan; De Carvalho, Marcelo; Rubio, Marie-Therese] Univ Lorraine, UMR CNRS 7365, IMoPA, Nancy, France; [Agbogan, Viviane A.; Gastineau, Pauline; Zavala, Flora] Univ Paris, Dept Immunol Infectiol & Haematol, INSERM, U1151,CNRS UMR 8253,Inst Necker Enfants Malad INE, Paris, France; [Fouquet, Guillemette; Hermine, Olivier] Univ Paris, INSERM UMR 1163, Imagine Inst, Lab Cellular & Mol Mech Hematol Disorders & Thera, Paris, France; [Garfa-Traore, Meriem] Univ Paris, SFR Necker UMS 3633, US24 Struct Federat Rech Necker, Plateforme Imagerie Cellulaire, Paris, France; [De Carvalho, Marcelo] Univ Lorraine, CHRU Nancy, Immunol Dept, Nancy, France	CHU de Nancy; Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; CHU de Nancy; Universite de Lorraine	D'Aveni, M (corresponding author), Univ Lorraine, CHRU Nancy, Hematol Dept, Nancy, France.; D'Aveni, M (corresponding author), Univ Lorraine, UMR CNRS 7365, IMoPA, Nancy, France.; Zavala, F (corresponding author), Univ Paris, Dept Immunol Infectiol & Haematol, INSERM, U1151,CNRS UMR 8253,Inst Necker Enfants Malad INE, Paris, France.	m.daveni-piney@chru.nancy.fr; fiora.zavala@inserm.fr	Hermine, Olivier/Q-7072-2018; De Carvalho Bittencourt, Marcelo/E-9316-2012	De Carvalho Bittencourt, Marcelo/0000-0002-2698-2458; Zavala, Flora/0000-0002-2338-6802; GARFA TRAORE, Meriem/0000-0001-8597-6472	APHP (Assistance Publique des Hopitaux de Paris); Institut National du Cancer; Fondation ARC pour la Recherche contre le Cancer; The Secular Society (TSS); TSS	APHP (Assistance Publique des Hopitaux de Paris); Institut National du Cancer(Institut National du Cancer (INCA) France); Fondation ARC pour la Recherche contre le Cancer; The Secular Society (TSS); TSS	This work was supported by the APHP (Assistance Publique des Hopitaux de Paris), and the "Institut National du Cancer". FZ was supported by grants from Fondation ARC pour la Recherche contre le Cancer and from The Secular Society (TSS). VAA was recipient of a PhD fellowship from TSS.	Anderlini P, 1997, STEM CELLS, V15, P9, DOI 10.1002/stem.150009; Antin JH, 2002, BLOOD, V100, P3479, DOI 10.1182/blood-2002-03-0985; Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; Banerjee DK, 2006, BLOOD, V108, P2655, DOI 10.1182/blood-2006-03-011353; Bremm M, 2011, J IMMUNOL METHODS, V373, P36, DOI 10.1016/j.jim.2011.07.018; Brunstein CG, 2011, BLOOD, V117, P1061, DOI 10.1182/blood-2010-07-293795; Cohen JL, 2002, J EXP MED, V196, P401, DOI 10.1084/jem.20020090; D'Aveni M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00989; D'Aveni M, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010435; Ferreira LMR, 2019, NAT REV DRUG DISCOV, V18, P749, DOI 10.1038/s41573-019-0041-4; Ganesh BB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021949; Ganesh BB, 2009, INT IMMUNOL, V21, P269, DOI 10.1093/intimm/dxn147; Gao YY, 2015, P NATL ACAD SCI USA, V112, pE3246, DOI 10.1073/pnas.1421463112; Godfrey WR, 2005, BLOOD, V105, P750, DOI 10.1182/blood-2004-06-2467; Golovina TN, 2008, J IMMUNOL, V181, P2855, DOI 10.4049/jimmunol.181.4.2855; Hippen KL, 2008, BLOOD, V112, P2847, DOI 10.1182/blood-2008-01-132951; Hoffmann P, 2002, J EXP MED, V196, P389, DOI 10.1084/jem.20020399; Hoffmann P, 2006, BLOOD, V108, P4260, DOI 10.1182/blood-2006-06-027409; Jankovic D, 2013, J EXP MED, V210, P1899, DOI 10.1084/jem.20130084; Kared H, 2008, BLOOD, V112, P2575, DOI 10.1182/blood-2008-02-140681; Kared H, 2006, IMMUNITY, V25, P823, DOI 10.1016/j.immuni.2006.09.008; Koch MA, 2009, NAT IMMUNOL, V10, P595, DOI 10.1038/ni.1731; Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432; Koreth J, 2011, NEW ENGL J MED, V365, P2055, DOI 10.1056/NEJMoa1108188; Korniotis S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.607175; Lataillade JJ, 2005, J LEUKOCYTE BIOL, V77, P634, DOI 10.1189/jlb.0504273; Lee K, 2014, AM J TRANSPLANT, V14, P27, DOI 10.1111/ajt.12509; Li Q, 2010, LEUKEMIA RES, V34, P1158, DOI 10.1016/j.leukres.2010.03.017; Magenau JM, 2010, BIOL BLOOD MARROW TR, V16, P907, DOI 10.1016/j.bbmt.2010.02.026; Mercer F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008639; Putnam AL, 2013, AM J TRANSPLANT, V13, P3010, DOI 10.1111/ajt.12433; Su XH, 2020, CELL MOL IMMUNOL, V17, P483, DOI 10.1038/s41423-019-0312-3; Taylor PA, 2002, BLOOD, V99, P3493, DOI 10.1182/blood.V99.10.3493; Trenado A, 2006, J IMMUNOL, V176, P1266, DOI 10.4049/jimmunol.176.2.1266; Zhou XY, 2009, NAT IMMUNOL, V10, P1000, DOI 10.1038/ni.1774	35	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 12	2021	11								607180	10.3389/fimmu.2020.607180	http://dx.doi.org/10.3389/fimmu.2020.607180			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QM4WH	33643294	gold, Green Published			2022-12-18	WOS:000621780500001
J	Rama, TA; Martins, D; Gomes, N; Pinheiro, J; Nogueira, A; Delgado, L; Placido, JL; Coimbra, A				Rama, Tiago Azenha; Martins, Diana; Gomes, Nuno; Pinheiro, Jorge; Nogueira, Ana; Delgado, Luis; Placido, Jose Luis; Coimbra, Alice			Case Report: Mastocytosis: The Long Road to Diagnosis	FRONTIERS IN IMMUNOLOGY			English	Article						mastocytosis; anaphylaxis; flushing; food allergy; diagnostics		Mastocytosis is a heterogeneous group of disorders characterized by expansion and accumulation of clonal mast cells. Patients mainly present with either cutaneous lesions, anaphylaxis, or both. Its low prevalence and unusual features often hinder its diagnosis for several years. We report the case of an 18-year-old male who was referred to our department with a long-standing history of atypical skin lesions, allergic rhinitis, exercise-induced bronchoconstriction and what was believed to be food-related flushing and anaphylaxis, that was later diagnosed with mastocytosis. This case illustrates the need to consider investigating for mastocytosis when recurrent anaphylaxis is present, especially in the presence of atypical skin lesions, even if normal serum basal tryptase levels and allergic sensitization are present.	[Rama, Tiago Azenha; Delgado, Luis; Placido, Jose Luis; Coimbra, Alice] Ctr Hosp Univ Sao Joao, Serv Imunoalergol, Porto, Portugal; [Rama, Tiago Azenha; Delgado, Luis] Univ Porto, Fac Med, Dept Patol, Serv Imunol Basica & Clin, Porto, Portugal; [Martins, Diana; Pinheiro, Jorge] Ctr Hosp Univ Sao Joao, Serv Anat Patol, Porto, Portugal; [Gomes, Nuno; Nogueira, Ana] Ctr Hosp Univ Sao Joao, Serv Dermatovenereol, Porto, Portugal; [Delgado, Luis] Univ Porto, Fac Med, CINTESIS Ctr Invest Tecnol & Serv Saude, Porto, Portugal	Universidade do Porto; Universidade do Porto	Rama, TA (corresponding author), Ctr Hosp Univ Sao Joao, Serv Imunoalergol, Porto, Portugal.; Rama, TA (corresponding author), Univ Porto, Fac Med, Dept Patol, Serv Imunol Basica & Clin, Porto, Portugal.	tarama@med.up.pt	Placido, Jose/AGZ-3331-2022; Delgado, Luis/L-8035-2013; Rama, Tiago Azenha/AAN-7604-2020	Placido, Jose/0000-0001-8218-6280; Delgado, Luis/0000-0003-2375-9071; Rama, Tiago Azenha/0000-0003-0134-617X; Pinheiro, Jorge/0000-0003-3099-0984				Alvarez-Twose I., 2020, MASTOCYTOSIS, P93, DOI [10.1007/978-3-030-27820-5_6, DOI 10.1007/978-3-030-27820-5_6]; Alvarez-Twose I, 2016, J ALLERGY CLIN IMMUN, V137, P168, DOI 10.1016/j.jaci.2015.05.008; Andorf S, 2018, LANCET GASTROENTEROL, V3, P85, DOI 10.1016/S2468-1253(17)30392-8; Arock M, 2015, LEUKEMIA, V29, P1223, DOI 10.1038/leu.2015.24; Azana JM, 2016, ACTAS DERMO-SIFILOGR, V107, P5, DOI 10.1016/j.ad.2015.09.007; Balbino B, 2020, J CLIN INVEST, V130, P1330, DOI 10.1172/JCI129697; Brockow K, 2008, ALLERGY, V63, P226, DOI 10.1111/j.1398-9995.2007.01569.x; Broesby-Olsen S, 2018, ALLERGY, V73, P230, DOI 10.1111/all.13237; Brownell J, 2004, IMMUNOL ALLERGY CLIN, V24, P551, DOI 10.1016/j.iac.2004.06.002; Butterfield JH, 2006, IMMUNOL ALLERGY CLIN, V26, P487, DOI 10.1016/j.iac.2006.05.006; Carter MC, 2007, J ALLERGY CLIN IMMUN, V119, P1550, DOI 10.1016/j.jaci.2007.03.032; de Olano DG, 2007, CLIN EXP ALLERGY, V37, P1547, DOI 10.1111/j.1365-2222.2007.02804.x; Douglass JA, 2010, ALLERGY, V65, P926, DOI 10.1111/j.1398-9995.2009.02259.x; Hartmann K, 2016, J ALLERGY CLIN IMMUN, V137, P35, DOI 10.1016/j.jaci.2015.08.034; Hermans MAW, 2019, J EUR ACAD DERMATOL, V33, pE472, DOI 10.1111/jdv.15800; Hermans MAW, 2016, EUR J INTERN MED, V30, P25, DOI 10.1016/j.ejim.2016.01.005; Horny HP, 2017, WHO CLASSIFICATION T, V3, P61; Hughes JDM, 2018, CLIN EXP DERMATOL, V43, P573, DOI 10.1111/ced.13408; Jendoubi F, 2020, CLIN EXP ALLERGY, V50, P654, DOI 10.1111/cea.13592; Jennings S, 2014, J ALLER CL IMM-PRACT, V2, P70, DOI 10.1016/j.jaip.2013.09.004; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Lieberman PL, 2017, J ALLERGY CLIN IMMUN, V140, P1734, DOI 10.1016/j.jaci.2017.07.013; Limb SL, 2007, J ALLERGY CLIN IMMUN, V120, P1378, DOI 10.1016/j.jaci.2007.09.022; Matito A, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0450-8; Matito A, 2013, ANN ALLERG ASTHMA IM, V111, P425, DOI 10.1016/j.anai.2013.08.014; Morgado JM, 2013, HISTOPATHOLOGY, V63, P780, DOI 10.1111/his.12221; Morgado Jose Mario, 2020, Methods Mol Biol, V2163, P331, DOI 10.1007/978-1-0716-0696-4_27; Nadeau KC, 2011, J ALLERGY CLIN IMMUN, V127, P1622, DOI 10.1016/j.jaci.2011.04.009; Perino E, 2018, ANN ALLERG ASTHMA IM, V120, P664, DOI 10.1016/j.anai.2018.02.018; Sanchez-Munoz L, 2016, BRIT J HAEMATOL, V172, P56, DOI 10.1111/bjh.13789; Thomas Z-RM., 2020, MASTOCYTOSIS, V2020, P69, DOI [10.1007/978-3-030-27820-5_5, DOI 10.1007/978-3-030-27820-5_5]; Valent P, 2007, EUR J CLIN INVEST, V37, P435, DOI 10.1111/j.1365-2362.2007.01807.x; Valent P, 2014, ALLERGY, V69, P1267, DOI 10.1111/all.12436; Valent P, 2011, LEUKEMIA LYMPHOMA, V52, P740, DOI 10.3109/10428194.2010.550072; Wiechers T, 2015, J ALLERGY CLIN IMMUN, V136, P1581, DOI 10.1016/j.jaci.2015.05.034	35	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 12	2021	12								635909	10.3389/fimmu.2021.635909	http://dx.doi.org/10.3389/fimmu.2021.635909			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QM4TK	33643319	gold, Green Published			2022-12-18	WOS:000621772900001
J	Boldt, ABW; Oliveira-Tore, CD; Kretzschmar, GC; Mendes, HW; Stinghen, ST; Andrade, FA; Bumiller-Bini, V; Goncalves, LB; Braga, ACD; Stahlke, EVS; Velavan, TP; Thiel, S; de Messias-Reason, IJT				Boldt, Angelica Beate Winter; Oliveira-Tore, Camila de Freitas; Kretzschmar, Gabriela Canalli; Weinschutz Mendes, Hellen; Stinghen, Servio Tulio; Andrade, Fabiana Antunes; Bumiller-Bini, Valeria; Goncalves, Leticia Boslooper; Braga, Anna Carolina de Moraes; Seeling Stahlke, Ewalda von Rosen; Velavan, Thirumalaisamy P.; Thiel, Steffen; de Messias-Reason, Iara Jose Taborda			Hepatitis B Virus Infection Among Leprosy Patients: A Case for Polymorphisms Compromising Activation of the Lectin Pathway and Complement Receptors	FRONTIERS IN IMMUNOLOGY			English	Article						mannose-binding protein-associated serine proteases; mannose-binding lectin; ficolin; leprosy; complement 3b receptors; genetic polymorphisms; complement system proteins; Hepatitis B	MANNAN-BINDING LECTIN; ASSOCIATION	Thousands of leprosy patients not only suffer from physical deformities, but also either have or have had hepatitis B virus (HBV) coinfection. Polymorphisms of the complement system modulate susceptibility to leprosy, but genetic susceptibility to past or present HBV infection is unknown. We used sequencing and multiplex sequence-specific PCR to genotype 72 polymorphisms of seven genes (MBL2, FCN1, FCN2, FCN3, MASP1, MASP2, C3) encoding components of the lectin pathway, and two genes encoding complement receptors (CR1, VSIG4) in 190 patients, of which 74 were positive for HBsAg and/or anti-HBc (HBV+, 93.2% with a resolved infection) and 116 lepromatous patients, and 408 HBV-blood donors. In addition, we tested for levels of proteins of the lectin pathway. We found no difference between serum concentrations of mannan-binding lectin (MBL), MBL-associated serine proteins (MASP-1, MASP-2, MASP-3, MAp44), ficolin-3 (FCN-3), soluble complement receptor 1 (sCR1) and MBL mediated C4 activation, measured by ELISA or TRIFMA in up to 167 HBV+ and HBV- patients. Haplotypes lowering protein levels or encoding dysfunctional proteins increased susceptibility to HBV infection: MBL2*LYQC (OR = 3.4, p = 0.02), MASP1*AC_CC (OR = 4.0, p = 0.015) and MASP2*1C2-l (OR = 5.4, p = 0.03). Conversely, FCN1*3C2 haplotype, associated with higher gene expression, was protective (OR = 0.56, P = 0.033). Other haplotypes associated with HBV susceptibility were: MASP2*2B1-i (OR = 19.25, P = 0.003), CR1*3A (OR = 2.65, P = 0.011) and VSIG4*TGGRCG (OR = 12.55, P = 0.014). Some polymorphisms in ficolin genes associated with lower protein levels increased susceptibility to leprosy/HBV infection: FCN*1 (OR = 1.66, P = 0.029), FCN2*GGGCAC (OR = 6.73, P = 0.008), and FCN3*del_del_C (OR = 12.54, P = 0.037), and to lepromatous disease/HBV infection: FCN2*TA (OR = 2.5, P = 0.009), whereas FCN2*MAG was associated with increased FCN-2 expression and resistance against coinfection (OR = 0.29, P = 0.026). These associations were independent of demographic factors and did not increase susceptibility to leprosy per se, except MASP2*1C2-l. Associations for FCN2, FCN3, MASP1, MASP2, and VSIG4 variants were also independent of each other. In conclusion, polymorphisms compromising activation of the lectin pathway of complement increase susceptibility to HBV infection, with ficolin polymorphisms playing a major role in modulating the susceptibility among leprosy patients.	[Boldt, Angelica Beate Winter; Kretzschmar, Gabriela Canalli; Bumiller-Bini, Valeria] Univ Fed Parana, Postgrad Program Genet, Dept Genet, Lab Human Mol Genet, Curitiba, Parana, Brazil; [Boldt, Angelica Beate Winter; Oliveira-Tore, Camila de Freitas; Weinschutz Mendes, Hellen; Stinghen, Servio Tulio; Andrade, Fabiana Antunes; Goncalves, Leticia Boslooper; Braga, Anna Carolina de Moraes; de Messias-Reason, Iara Jose Taborda] Univ Fed Parana, Postgrad Program Internal Med & Hlth Sci, Lab Mol Immunopathol, Dept Clin Pathol,Hosp Clin, Curitiba, Parana, Brazil; [Seeling Stahlke, Ewalda von Rosen] Hlth State Dept Parana, Curitiba, Parana, Brazil; [Velavan, Thirumalaisamy P.] Univ Klinikum Tubingen, Inst Trop Med, Tubingen, Germany; [Velavan, Thirumalaisamy P.] Vietnamese German Ctr Med Res, Hanoi, Vietnam; [Velavan, Thirumalaisamy P.] Duy Tan Univ, Fac Med, Da Nang, Vietnam; [Thiel, Steffen] Aarhus Univ, Dept Biomed, Aarhus, Denmark; [Weinschutz Mendes, Hellen] Yale Sch Med, Ctr Child Study, New Haven, CT USA; [Goncalves, Leticia Boslooper] Univ Fed Parana, Genet Dept, LIGH Immunogenet & Histocompatibil, Curitiba, Parana, Brazil; [Braga, Anna Carolina de Moraes] Sci Police Parana, Lab Forens Mol Genet, Curitiba, Parana, Brazil	Universidade Federal do Parana; Universidade Federal do Parana; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Duy Tan University; Aarhus University; Yale University; Universidade Federal do Parana	Boldt, ABW (corresponding author), Univ Fed Parana, Postgrad Program Genet, Dept Genet, Lab Human Mol Genet, Curitiba, Parana, Brazil.; Boldt, ABW (corresponding author), Univ Fed Parana, Postgrad Program Internal Med & Hlth Sci, Lab Mol Immunopathol, Dept Clin Pathol,Hosp Clin, Curitiba, Parana, Brazil.	angelicaboldt@gmail.com	Kretzschmar, Gabriela Canalli/AAV-8554-2020; Kretzschmar, Gabriela/AAB-5370-2022; Velavan, Thirumalaisamy P/C-1223-2010; Boldt, Angelica/G-3630-2012	Kretzschmar, Gabriela Canalli/0000-0002-0539-7612; Velavan, Thirumalaisamy P/0000-0002-9809-9883; , Valeria Bumiller-Bini Hoch/0000-0003-4000-2417; Boslooper Goncalves, Leticia/0000-0002-6144-5471; Andrade, Fabiana/0000-0003-4116-2324; Thiel, Steffen/0000-0002-4817-155X; Jose de Messias Reason, Iara/0000-0002-5573-260X	CAPES (Coordenacao de Aperfeicoamento de Pessoal Superior) [01/2007, 518/2010 PRODOC]; CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico) [034/2008]; Fundacao Araucaria; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES/PROAP) [001, CAPES-40001016006P1, CAPES40001016006P1, CAPES-40001016012P1]; CNPq [141955/2020-1, 314288/2018-0]; CAPES-PRINT scholarship [41/2017]; Danish Research Council; Tubingen University	CAPES (Coordenacao de Aperfeicoamento de Pessoal Superior)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao Araucaria(Fundacao Araucaria de Apoio ao Desenvolvimento Cientifico e Tecnologico do Estado do Parana FAFundacao de Amparo a Pesquisa e Inovacoo Estado de Santa Catarina (FAPESC)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES/PROAP)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); CAPES-PRINT scholarship; Danish Research Council(Det Frie Forskningsrad (DFF)); Tubingen University	This work was supported by the 01/2007 and 518/2010 PRODOC grants of CAPES (Coordenacao de Aperfeicoamento de Pessoal Superior, http://www.capes.gov.br/bolsas/bolsasno-pais/prodoc) for AB and by the 034/2008 CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, http://www.cnpq.br/web/guest/bolsas-e-auxilios) and Fundacao Araucaria (http://www.fappr.pr.gov.br/) grants for IM. We thank the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES/PROAPFinance Code 001) for financial support and for the scholarships provided to GK (CAPES-40001016006P1), VB (CAPES40001016006P1), CT (CAPES-40001016012P1), and HM (CAPES-40001016012P1). LG receives a CNPq scholarship (141955/2020-1). AB currently receives a research productivity scholarship from CNPq (314288/2018-0). She also received a CAPES-PRINT scholarship (41/2017) to enable the collaboration with TV from the Tubingen University, also fostering the collaboration with ST from the Aarhus University. FA was a PNPD (Programa Nacional de Pos Doutorado)/CAPES post-doc fellow. ST was funded by the Danish Research Council. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alves HV, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007696; Andrade FA, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005409; [Anonymous], 2006, Rev. Assoc. Med. Bras., V52, P288; [Anonymous], 2017, GLOBAL HEPATITIS REP; Vieira MCA, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006788; Auer ED, 2020, INT J INFECT DIS, V96, P541, DOI 10.1016/j.ijid.2020.05.033; Bellamy R, 1998, QJM-INT J MED, V91, P13, DOI 10.1093/qjmed/91.1.13; Beltrame MH, 2015, MOL IMMUNOL, V67, P85, DOI 10.1016/j.molimm.2015.03.245; Benjamini Y., 1995, J R STAT SOC B, V57, P289; Bessone F, 2014, LIVER INT, V34, P991, DOI 10.1111/liv.12499; Boldt ABW, 2006, GENES IMMUN, V7, P393, DOI 10.1038/sj.gene.6364312; Boldt ABW, 2002, HUM MUTAT, V19, P296, DOI 10.1002/humu.10051; Boldt ABW, 2017, ENCY SIGNALING MOL, P1, DOI [10.1007/978-1-4614-6438-9_101714-1, DOI 10.1007/978-1-4614-6438-9_101714-1]; Boldt ABW, 2013, J CLIN IMMUNOL, V33, P210, DOI 10.1007/s10875-012-9770-4; Boldt ABW, 2012, ADV CLIN CHEM, V56, P105, DOI 10.1016/B978-0-12-394317-0.00012-1; Boldt ABW, 2010, BMC GENET, V11, DOI 10.1186/1471-2156-11-38; Boldt ABW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069054; Braga ACD, 2006, ACTA TROP, V97, P88, DOI 10.1016/j.actatropica.2005.09.003; Broker K, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-018-1752-8; Chen TL, 2015, VIROL SIN, V30, P249, DOI 10.1007/s12250-015-3605-4; de Messias-Reason IJ, 2007, J INFECT DIS, V196, P1379, DOI 10.1086/521627; Degn SE, 2010, J IMMUNOL METHODS, V361, P37, DOI 10.1016/j.jim.2010.07.006; Dornelles LN, 2006, CLIN EXP IMMUNOL, V145, P463, DOI 10.1111/j.1365-2249.2006.03161.x; El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; Moura TCF, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/3718451; Garred P, 2003, MOL IMMUNOL, V40, P73, DOI 10.1016/S0161-5890(03)00104-4; Guo S, 2010, CLIN IMMUNOL, V136, P282, DOI 10.1016/j.clim.2010.03.007; Ramos JMH, 2011, MEM I OSWALDO CRUZ, V106, P632, DOI 10.1590/S0074-02762011000500019; Hohler T, 1998, EXP CLIN IMMUNOGENET, V15, P130, DOI 10.1159/000019064; Jarduli LR, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/989837; Juliger S, 2000, BIOCHEM BIOPH RES CO, V275, P617, DOI 10.1006/bbrc.2000.3343; Kretzschmar GC, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006705; Larsen F, 2004, J BIOL CHEM, V279, P21302, DOI 10.1074/jbc.M400520200; Leitao C, 2014, BRAZ J INFECT DIS, V18, P8, DOI 10.1016/j.bjid.2013.04.003; Luo JR, 2019, GENE, V688, P107, DOI 10.1016/j.gene.2018.11.082; Madsen HO, 1998, J IMMUNOL, V161, P3169; Magalhaes R, 2010, VIRAL IMMUNOL, V23, P449, DOI 10.1089/vim.2009.0105; Mendes HW, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0007534; Messias-Reason IJ, 2009, CLIN EXP IMMUNOL, V157, P395, DOI 10.1111/j.1365-2249.2009.03975.x; Mira MT, 2006, MICROBES INFECT, V8, P1124, DOI 10.1016/j.micinf.2005.10.024; Ning G, 2020, J VIRAL HEPATITIS, V27, P1071, DOI 10.1111/jvh.13319; Oluyinka OO, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131912; Osthoff M, 2014, VACCINE, V32, P4772, DOI 10.1016/j.vaccine.2014.06.023; Qu ZH, 2009, MOL IMMUNOL, V47, P283, DOI 10.1016/j.molimm.2009.09.022; Razavi-Shearer D, 2018, LANCET GASTROENTEROL, V3, P383, DOI 10.1016/S2468-1253(18)30056-6; Reibel F, 2015, MED MALADIES INFECT, V45, P383, DOI 10.1016/j.medmal.2015.09.002; Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255; Risitano AM, 2020, NAT REV IMMUNOL, V20, P343, DOI 10.1038/s41577-020-0320-7; ROSA H, 1992, REV I MED TROP, V34, P421, DOI 10.1590/S0036-46651992000500008; Rosa PS, 2020, CLIN INFECT DIS, V70, P2054, DOI 10.1093/cid/ciz570; Sarvari J, 2014, HEPAT MON, V14, DOI 10.5812/hepatmon.13103; Schweitzer A., 2015, LANCET, V386, P1546, DOI [DOI 10.1016/S0140-6736(15)61412-X, 10.1016/S0140-6736(15)61412-X]; Segat L, 2008, J VIRAL HEPATITIS, V15, P387, DOI [10.1111/j.1365-2893.2008.00965.x, 10.1111/j.1365-2893.2007.00965.x]; Song LH, 2003, MUTAT RES-FUND MOL M, V522, P119, DOI 10.1016/S0027-5107(02)00284-1; Steel LF, 2003, PROTEOMICS, V3, P601, DOI 10.1002/pmic.200300399; Sun ZY, 2019, THERANOSTICS, V9, P1200, DOI 10.7150/thno.31991; Talhari C, 2010, J INFECT DIS, V202, P345, DOI 10.1086/653839; Thiel S, 2012, CLIN EXP IMMUNOL, V169, P38, DOI 10.1111/j.1365-2249.2012.04584.x; Thomas HC, 1996, LANCET, V348, P1417, DOI 10.1016/S0140-6736(96)05409-8; Tong HV, 2013, J VIRAL HEPATITIS, V20, P687, DOI 10.1111/jvh.12089; Vinay K, 2009, J CLIN MICROBIOL, V47, P2998, DOI 10.1128/JCM.00876-09; Vogt L, 2006, J CLIN INVEST, V116, P2817, DOI 10.1172/JCI25673; Wallis R, 2005, J IMMUNOL, V175, P6846, DOI 10.4049/jimmunol.175.10.6846; Boldt ABW, 2016, MOL IMMUNOL, V78, P48, DOI 10.1016/j.molimm.2016.08.015; Xu HD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075371; Yuen MF, 1999, HEPATOLOGY, V29, P1248, DOI 10.1002/hep.510290417; Zhang GL, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/3524842; Zhu CL, 2018, ONCOL LETT, V15, P7459, DOI 10.3892/ol.2018.8223	68	0	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2021	11								574457	10.3389/fimmu.2020.574457	http://dx.doi.org/10.3389/fimmu.2020.574457			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QL8XQ	33643280	gold, Green Published			2022-12-18	WOS:000621364300001
J	Sesti-Costa, R; Borges, MD; Lanaro, C; de Albuquerque, DM; Saad, STO; Costa, FF				Sesti-Costa, Renata; Borges, Marina Dorigatti; Lanaro, Carolina; de Albuquerque, Dulcineia Martins; Olalla Saad, Sara Terezinha; Costa, Fernando Ferreira			Inflammatory Dendritic Cells Contribute to Regulate the Immune Response in Sickle Cell Disease	FRONTIERS IN IMMUNOLOGY			English	Article						dendritic cell; sickle cell disease; heme oxygenase; inflammation; monocyte		Sickle cell disease (SCD), one of the most common hemoglobinopathies worldwide, is characterized by a chronic inflammatory component, with systemic release of inflammatory cytokines, due to hemolysis and vaso-occlusive processes. Patients with SCD demonstrate dysfunctional T and B lymphocyte responses, and they are more susceptible to infection. Although dendritic cells (DCs) are the main component responsible for activating and polarizing lymphocytic function, and are able to produce pro-inflammatory cytokines found in the serum of patients with SCD, minimal studies have thus far been devoted to these cells. In the present study, we identified the subpopulations of circulating DCs in patients with SCD, and found that the bloodstream of the patients showed higher numbers and percentages of DCs than that of healthy individuals. Among all the main DCs subsets, inflammatory DCs (CD14(+) DCs) were responsible for this rise and correlated with higher reticulocyte count. The patients had more activated monocyte-derived DCs (mo-DCs), which produced MCP-1, IL-6, and IL-8 in culture. We found that a CD14(+) mo-DC subset present in culture from some of the patients was the more activated subset and was mainly responsible for cytokine production, and this subset was also responsible for IL-17 production in co-culture with T lymphocytes. Finally, we suggest an involvement of heme oxygenase in the upregulation of CD14 in mo-DCs from the patients, indicating a potential mechanism for inducing inflammatory DC differentiation from circulating monocytes in the patients, which correlated with inflammatory cytokine production, T lymphocyte response skewing, and reticulocyte count.	[Sesti-Costa, Renata; Borges, Marina Dorigatti; Lanaro, Carolina; de Albuquerque, Dulcineia Martins; Olalla Saad, Sara Terezinha; Costa, Fernando Ferreira] Univ Estadual Campinas, UNICAMP, Hematol & Hemotherapy Ctr, Campinas, Brazil	Universidade Estadual de Campinas	Sesti-Costa, R (corresponding author), Univ Estadual Campinas, UNICAMP, Hematol & Hemotherapy Ctr, Campinas, Brazil.	renata.sesti@gmail.com	Costa, Fernando F/D-1566-2012; Sesti-Costa, Renata/H-9115-2012	Costa, Fernando F/0000-0002-4632-572X; Sesti-Costa, Renata/0000-0002-7098-2850	FAPESP [2017/21892-8, 2014/00984-3]	FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	We acknowledge the participants that agreed to contribute to this work; Irene Santos, for the assistance with flow cytometry; and FAPESP for financial support (process numbers: 2017/21892-8 and 2014/00984-3).	Alcantara-Hernandez M, 2017, IMMUNITY, V47, P1037, DOI 10.1016/j.immuni.2017.11.001; Ambrosi A, 2012, EUR J IMMUNOL, V42, P2274, DOI 10.1002/eji.201242653; Anyaegbu CC, 1998, EUR J HAEMATOL, V60, P267; Balandya E, 2016, AM J HEMATOL, V91, P938, DOI 10.1002/ajh.24438; Belcher JD, 2000, BLOOD, V96, P2451, DOI 10.1182/blood.V96.7.2451.h8002451_2451_2459; Booth C, 2010, INT J INFECT DIS, V14, pE2, DOI 10.1016/j.ijid.2009.03.010; Brawley Otis W, 2008, NIH Consens State Sci Statements, V25, P1; Brousse V, 2014, BRIT J HAEMATOL, V166, P165, DOI 10.1111/bjh.12950; Charache S, 1995, CONTROL CLIN TRIALS, V16, P432, DOI 10.1016/S0197-2456(95)00098-4; Chu CC, 2011, SEMIN IMMUNOL, V23, P28, DOI 10.1016/j.smim.2011.01.006; Conran N, 2007, ANN HEMATOL, V86, P255, DOI 10.1007/s00277-006-0246-6; Coutant F, 2016, NAT REV RHEUMATOL, V12, P703, DOI 10.1038/nrrheum.2016.147; CROIZAT H, 1994, BRIT J HAEMATOL, V87, P592, DOI 10.1111/j.1365-2141.1994.tb08318.x; Durai V, 2016, IMMUNITY, V45, P719, DOI 10.1016/j.immuni.2016.10.010; Dutertre CA, 2019, IMMUNITY, V51, P573, DOI 10.1016/j.immuni.2019.08.008; Dutra FF, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00115; ElAlfy MS, 2018, IMMUNOL RES, V66, P480, DOI 10.1007/s12026-018-9010-y; Finnegan EM, 2007, AM J HEMATOL, V82, P266, DOI 10.1002/ajh.20819; Godefroy E, 2016, HAEMATOLOGICA, V101, P1028, DOI 10.3324/haematol.2016.147181; Guarda CC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51339-x; Hoshino H, 2000, J ALLERGY CLIN IMMUN, V105, P143, DOI 10.1016/S0091-6749(00)90189-1; HUMBERT JR, 1990, BIOMED PHARMACOTHER, V44, P153, DOI 10.1016/0753-3322(90)90002-Q; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; Kasten KR, 2010, INFECT IMMUN, V78, P4714, DOI 10.1128/IAI.00456-10; Kato GJ, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.10; Kato GJ, 2017, J CLIN INVEST, V127, P750, DOI 10.1172/JCI89741; Keikhaei B, 2013, EUR CYTOKINE NETW, V24, P45, DOI 10.1684/ecn.2013.0328; Koffi K Gustave, 2003, Hematol J, V4, P363, DOI 10.1038/sj.thj.6200310; Lanaro C, 2009, J LEUKOCYTE BIOL, V85, P235, DOI 10.1189/jlb.0708445; Liu YF, 2019, BLOOD, V134, P579, DOI 10.1182/blood.2019000172; Liu YF, 2018, BLOOD, V131, P1600, DOI 10.1182/blood-2017-12-819870; MacDonald KPA, 2002, BLOOD, V100, P4512, DOI 10.1182/blood-2001-11-0097; Madigan Catherine, 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406010659; McGeachy MJ, 2008, IMMUNITY, V28, P445, DOI 10.1016/j.immuni.2008.03.001; Mildner A, 2014, IMMUNITY, V40, P642, DOI 10.1016/j.immuni.2014.04.016; Miossec P, 2009, MICROBES INFECT, V11, P625, DOI 10.1016/j.micinf.2009.04.003; Murphy TL, 2016, ANNU REV IMMUNOL, V34, P93, DOI 10.1146/annurev-immunol-032713-120204; Musa BOP, 2010, CLIN VACCINE IMMUNOL, V17, P602, DOI 10.1128/CVI.00145-09; Patente TA, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03176; Raghupathy R, 2000, ACTA HAEMATOL-BASEL, V103, P197, DOI 10.1159/000041049; Ramakrishnan M, 2010, LANCET INFECT DIS, V10, P329, DOI 10.1016/S1473-3099(10)70055-4; RAUTONEN N, 1992, IMMUNOL LETT, V34, P207, DOI 10.1016/0165-2478(92)90215-A; Satpathy AT, 2012, NAT IMMUNOL, V13, P1145, DOI 10.1038/ni.2467; Schraml BU, 2015, CURR OPIN IMMUNOL, V32, P13, DOI 10.1016/j.coi.2014.11.001; Shale M, 2009, GUT, V58, P1291, DOI 10.1136/gut.2006.098475; Singhal R, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/1409383; Steinberg MH, 2009, THESCIENTIFICWORLDJO, V9, P46, DOI 10.1100/tsw.2009.10; Steinberg MH, 2003, JAMA-J AM MED ASSOC, V289, P1645, DOI 10.1001/jama.289.13.1645; Steinberg MH, 2001, SEMIN HEMATOL, V38, P299, DOI 10.1053/shem.2001.27570; STEINMAN RM, 1983, J EXP MED, V157, P613, DOI 10.1084/jem.157.2.613; Swiecki M, 2015, NAT REV IMMUNOL, V15, P471, DOI 10.1038/nri3865; Swiecki M, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003728; Villani AC, 2017, SCIENCE, V356, DOI 10.1126/science.aah4573; Vingert B, 2014, AM J HEMATOL, V89, P261, DOI 10.1002/ajh.23629; Wing K, 2010, NAT IMMUNOL, V11, P7, DOI 10.1038/ni.1818; Zhong H, 2014, J IMMUNOL, V193, P102, DOI 10.4049/jimmunol.1400105	56	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 4	2021	11								617962	10.3389/fimmu.2020.617962	http://dx.doi.org/10.3389/fimmu.2020.617962			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QI5FT	33613546	Green Published, gold			2022-12-18	WOS:000619003900001
J	Chao, M; Liu, N; Sun, ZC; Jiang, YL; Jiang, TT; Xv, M; Jia, LT; Tu, YY; Wang, L				Chao, Min; Liu, Nan; Sun, Zhichuan; Jiang, Yongli; Jiang, Tongtong; Xv, Meng; Jia, Lintao; Tu, Yanyang; Wang, Liang			TGF-beta Signaling Promotes Glioma Progression Through Stabilizing Sox9	FRONTIERS IN IMMUNOLOGY			English	Article						glioma; Sox9; transforming growth factor-&#946; migration; invasion		Gliomas are brain and spinal cord malignancies characterized by high malignancy, high recurrence and poor prognosis, the underlying mechanisms of which remain largely elusive. Here, we found that the Sry-related high mobility group box (Sox) family transcription factor, Sox9, was upregulated and correlated with poor prognosis of clinical gliomas. Sox9 promotes migration and invasion of glioma cells and in vivo development of xenograft tumors from inoculated glioma cells. Sox9 functions downstream of the transforming growth factor-beta (TGF-beta) pathway, in which TGF-beta signaling prevent proteasomal degradation of the Sox9 protein in glioma cells. These findings provide novel insight into the wide interplay between TGF-beta signaling and oncogenic transcription factors, and have implications for targeted therapy and prognostic assessment of gliomas.	[Chao, Min; Sun, Zhichuan; Xv, Meng; Wang, Liang] Fourth Mil Med Univ, Tangdu Hosp, Dept Neurosurg, Xian, Peoples R China; [Liu, Nan; Tu, Yanyang] Fourth Mil Med Univ, Tangdu Hosp, Dept Expt Surg, Xian, Peoples R China; [Jiang, Yongli] Fourth Mil Med Univ, Xijing Hosp, Dept Neurol, Xian, Peoples R China; [Jiang, Tongtong; Jia, Lintao] Fourth Mil Med Univ, Dept Biochem & Mol Biol, State Key Lab Canc Biol, Xian, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University	Wang, L (corresponding author), Fourth Mil Med Univ, Tangdu Hosp, Dept Neurosurg, Xian, Peoples R China.; Tu, YY (corresponding author), Fourth Mil Med Univ, Tangdu Hosp, Dept Expt Surg, Xian, Peoples R China.	tufmmu@188.com; Drwangliang@126.com	wang, liang/GXH-6755-2022	wang, liang/0000-0002-5247-6727	National Natural Science Foundation of China [81702458, 81772661, 81572983]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the following: 1. The National Natural Science Foundation of China, grant no. 81702458, Recipient: NL. 2. The National Natural Science Foundation of China, grant no. 81772661, Recipient: LW. 3. The National Natural Science Foundation of China, grant no. 81572983, Recipient: YT.		0	0	0	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 3	2021	11								592080	10.3389/fimmu.2020.592080	http://dx.doi.org/10.3389/fimmu.2020.592080			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QI0RP	33613515	Green Published, gold			2022-12-18	WOS:000618683100001
J	Gibson, KM; Kain, R; Luqmani, RA; Ross, CJ; Cabral, DA; Brown, KL				Gibson, Kristen M.; Kain, Renate; Luqmani, Raashid A.; Ross, Colin J.; Cabral, David A.; Brown, Kelly L.		PedVas Investigators Network	Autoantibodies Against Lysosome Associated Membrane Protein-2 (LAMP-2) in Pediatric Chronic Primary Systemic Vasculitis	FRONTIERS IN IMMUNOLOGY			English	Article						anti-neutrophil cytoplasmic antibody; ANCA-associated vasculitis; LAMP-2; lysosome-associated membrane protein-2; pediatric; systemic vasculitis		Background Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small vessel vasculitis in adults and children that commonly affects the kidneys. Although the frequent antigenic, and presumed pathogenic, targets of ANCA in AAV are proteinase-3 (PR3) and myeloperoxidase (MPO), ANCA against lysosome associated membrane protein-2 (LAMP-2), a lesser known ANCA antigen that is expressed on the glomerular endothelium, are present in some adults with AAV-associated renal disease. LAMP-2-ANCA has not been assessed in children with chronic systemic vasculitis, and, if present, would be a potentially valuable biomarker given that treatment decisions for these pediatric patients at diagnosis are largely informed by kidney function. Methods A custom ELISA, using commercially available reagents, was designed to detect autoantibodies to human LAMP-2 in serum. Sera obtained from 51 pediatric patients at the time of diagnosis of chronic primary systemic vasculitis (predominantly AAV) were screened. LAMP-2-ANCA titers were evaluated for correlation with clinical metrics of disease activity (pediatric vasculitis activity score [pVAS], C-reactive protein [CRP] concentration, and erythrocyte sedimentation rate [ESR]), MPO- and PR3-ANCA titers, and renal function (glomerular filtration rate [GFR], renal-specific pVAS, and serum creatinine concentration). Results LAMP-2-ANCA (>1,000 ng/ml) were detected in 35% (n = 18) of pediatric systemic vasculitis patients, of which, 10 (20% of all patients) were found to have high positive titers (>1,500 ng/ml). Undetectable or negative titres (<500 ng/ml) were identified in 12% (n = 6) of patients, those with titers between 500 and 1,000 ng/ml were considered low with unknown clinical relevance (53%, n = 27). Although LAMP-2-ANCA titers did not significantly differ between patients with AAV versus ANCA-negative vasculitis, only AAV patients had high concentrations (>1,500 ng/ml) of LAMP-2-ANCA. LAMP-2-ANCA titers did not correlate with measures of disease activity (pVAS, CRP, or ESR) at the time of diagnosis. In contrast, for patients with 12-month post diagnosis follow-up, a negative correlation was observed between the change in GFR (from diagnosis to 12-month follow-up) and LAMP-2-ANCA titer at diagnosis. Conclusions Moderate to high LAMP-2-ANCA titers were detected in 35% (18/51) of children with chronic systemic vasculitis affecting small-to-medium vessels. Although the highest concentrations of LAMP-2-ANCA in this population were observed in individuals positive for classic ANCA (MPO- or PR3-ANCA), similar to previous reports on adult patients, LAMP-2-ANCA titers do not correlate with classic ANCA titers or with overall disease activity at diagnosis. Renal disease is a common manifestation in systemic small-medium vessel vasculitis (both in adults and children, though more severe in children) and our preliminary data suggest LAMP-2-ANCA at diagnosis may be a risk factor for more severe renal disease.	[Gibson, Kristen M.] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada; [Gibson, Kristen M.; Brown, Kelly L.] BC Childrens Hosp Res Inst, Vancouver, BC, Canada; [Kain, Renate] Med Univ Vienna, Dept Pathol, Vienna, Austria; [Luqmani, Raashid A.] Univ Oxford, Nuffield Dept Orthoped Rheumatol & Musculoskeleta, Oxford, England; [Ross, Colin J.] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada; [Cabral, David A.; Brown, Kelly L.] Univ British Columbia, Dept Pediat, Vancouver, BC, Canada; [Cabral, David A.] BC Childrens Hosp, Div Rheumatol, Vancouver, BC, Canada; [Brown, Kelly L.] Univ British Columbia, Ctr Blood Res, Vancouver, BC, Canada	University of British Columbia; Medical University of Vienna; University of Oxford; University of British Columbia; University of British Columbia; BC Childrens Hospital; University of British Columbia; University of British Columbia	Brown, KL (corresponding author), BC Childrens Hosp Res Inst, Vancouver, BC, Canada.; Brown, KL (corresponding author), Univ British Columbia, Dept Pediat, Vancouver, BC, Canada.; Brown, KL (corresponding author), Univ British Columbia, Ctr Blood Res, Vancouver, BC, Canada.	kbrown@bcchr.ca	Kain, Renate/ACR-4709-2022	Kain, Renate/0000-0002-2428-543X; Brown, Kelly/0000-0001-5385-3582; Cabral, David A./0000-0003-1840-9210	Canadian Institutes of Health Research [TR2-119188]; Michael Smith Foundation for Health Research Awards; University of British Columbia; The Arthritis Society (TAS) Canada through the Ross Petty Arthritis Society Chair	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Michael Smith Foundation for Health Research Awards; University of British Columbia; The Arthritis Society (TAS) Canada through the Ross Petty Arthritis Society Chair	This study has been supported by a Canadian Institutes of Health Research grant for the PedVas Initiative [TR2-119188 to DC]. KB and CR are supported by Michael Smith Foundation for Health Research Awards. KG is supported by the University of British Columbia Four Year Fellowship for PhD Students. DC is supported by The Arthritis Society (TAS) Canada through the Ross Petty Arthritis Society Chair.	Abdulkader R, 2013, ANN RHEUM DIS, V72, P1888, DOI 10.1136/annrheumdis-2013-203511; Bohm M, 2014, PEDIATR RHEUMATOL, V12, DOI 10.1186/1546-0096-12-18; Borregaard N, 2007, TRENDS IMMUNOL, V28, P340, DOI 10.1016/j.it.2007.06.002; Brown KL, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00341; Bulanov NM, 2018, TERAPEVT ARKH, V90, P15, DOI [10.26442/terarkh201890615-21, https//doi.org/10.26442/terarkh201890615-21]; Cabral DA, 2016, ARTHRITIS RHEUMATOL, V68, P2514, DOI 10.1002/art.39729; Cabral DA, 2009, ARTHRITIS RHEUM-US, V60, P3413, DOI 10.1002/art.24876; DAVIES DJ, 1982, BMJ-BRIT MED J, V285, P606, DOI 10.1136/bmj.285.6342.606; Van Wijngaarden RAFD, 2006, J AM SOC NEPHROL, V17, P2264, DOI 10.1681/ASN.2005080870; Dolezalova P, 2013, ANN RHEUM DIS, V72, P1628, DOI 10.1136/annrheumdis-2012-202111; FALK RJ, 1988, NEW ENGL J MED, V318, P1651, DOI 10.1056/NEJM198806233182504; Hilhorst M, 2015, J AM SOC NEPHROL, V26, P2314, DOI 10.1681/ASN.2014090903; KAIN R, 1995, J EXP MED, V181, P585, DOI 10.1084/jem.181.2.585; Kain R, 2008, NAT MED, V14, P1088, DOI 10.1038/nm.1874; Kain R, 2013, PRESSE MED, V42, P584, DOI 10.1016/j.lpm.2013.01.029; Kain R, 2013, CURR OPIN RHEUMATOL, V25, P26, DOI 10.1097/BOR.0b013e32835b4f8f; Kain R, 2012, J AM SOC NEPHROL, V23, P556, DOI 10.1681/ASN.2011090920; Kawakami T, 2013, ACTA DERM-VENEREOL, V93, P70, DOI 10.2340/00015555-1418; Lionaki S, 2012, ARTHRITIS RHEUM-US, V64, P3452, DOI 10.1002/art.34562; Morishita KA, 2017, ARTHRITIS RHEUMATOL, V69, P1470, DOI 10.1002/art.40112; Rhee RL, 2016, ARTHRITIS RHEUMATOL, V68, P1711, DOI 10.1002/art.39614; Roth AJ, 2012, J AM SOC NEPHROL, V23, P545, DOI 10.1681/ASN.2011030273; Sinico RA, 2013, AUTOIMMUN REV, V12, P477, DOI 10.1016/j.autrev.2012.08.006; Sundqvist M, 2020, J LEUKOCYTE BIOL, V108, P617, DOI 10.1002/JLB.3VMR0220-438RR; Tan EM, 1997, ARTHRITIS RHEUM-US, V40, P1601, DOI 10.1002/art.1780400909; Tervaert JWC, 2019, NEPHROL DIAL TRANSPL, V34, P384, DOI 10.1093/ndt/gfy406; VANDERWOUDE FJ, 1985, LANCET, V1, P425; Yamaguchi M, 2015, J RHEUMATOL, V42, P1853, DOI 10.3899/jrheum.141622	28	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 3	2021	11								624758	10.3389/fimmu.2020.624758	http://dx.doi.org/10.3389/fimmu.2020.624758			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QJ3JF	33613565	gold, Green Published			2022-12-18	WOS:000619587800001
J	Davidov, V; Jensen, G; Mai, S; Chen, SH; Pan, PY				Davidov, Vitaliy; Jensen, Garrett; Mai, Sunny; Chen, Shu-Hsia; Pan, Ping-Ying			Analyzing One Cell at a TIME: Analysis of Myeloid Cell Contributions in the Tumor Immune Microenvironment (vol 11, 1842, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						MDSC; TAM; TIME; sc-RNAseq; reprogram			[Davidov, Vitaliy; Jensen, Garrett; Chen, Shu-Hsia; Pan, Ping-Ying] Texas A&M Coll Med, Bryan, TX 77807 USA; [Davidov, Vitaliy; Jensen, Garrett; Mai, Sunny; Chen, Shu-Hsia; Pan, Ping-Ying] Houston Methodist Res Inst, Canc Ctr Excellence, Ctr Immunotherapy Res, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; The Methodist Hospital System; The Methodist Hospital - Houston	Chen, SH; Pan, PY (corresponding author), Texas A&M Coll Med, Bryan, TX 77807 USA.; Chen, SH; Pan, PY (corresponding author), Houston Methodist Res Inst, Canc Ctr Excellence, Ctr Immunotherapy Res, Houston, TX 77030 USA.	schen3@houstonmethodist.org; ppan@houstonmethodist.org			Texas A&M Open Access to Knowledge Fund (OAKFund); University Libraries [R01 CA127483, R01 CA204191, R01 CA208703]; NIH [R01 CA188610]	Texas A&M Open Access to Knowledge Fund (OAKFund); University Libraries; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	In the original article, we neglected to include the funder Texas A&M Open Access to Knowledge Fund (OAKFund), supported by the University Libraries, to VD; NIH R01 CA127483, R01 CA204191, R01 CA208703 to S-HC; and NIH R01 CA188610 to P-YP. S-HC is the Emily Hermann Chair in Immunology Research and this work was supported in part by that endowment.	Davidov V, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01842	1	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 1	2021	11								645213	10.3389/fimmu.2020.645213	http://dx.doi.org/10.3389/fimmu.2020.645213			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QH1EC	33597955	gold, Green Published			2022-12-18	WOS:000618018200001
J	Hubenthal, M; Loscher, BS; Erdmann, J; Franke, A; Gola, D; Konig, IR; Emmert, H				Huebenthal, Matthias; Loescher, Britt-Sabina; Erdmann, Jeanette; Franke, Andre; Gola, Damian; Koenig, Inke R.; Emmert, Hila			Current Developments of Clinical Sequencing and the Clinical Utility of Polygenic Risk Scores in Inflammatory Diseases	FRONTIERS IN IMMUNOLOGY			English	Review						inflammation; atopic dermatitis; inflammatory bowel disease; coronary artery disease; genome-wide association studies; polygenic risk score; whole-exome sequencing	GENOME-WIDE ASSOCIATION; CORONARY-ARTERY-DISEASE; ATOPIC-DERMATITIS; HEART-DISEASE; SUSCEPTIBILITY LOCI; CROHNS-DISEASE; BOWEL-DISEASE; PREDICTION; VARIANTS; ADULTS	In this mini-review, we highlight selected research by the Deutsche Forschungsgemeinschaft (DFG) Cluster of Excellence "Precision Medicine in Chronic Inflammation" focusing on clinical sequencing and the clinical utility of polygenic risk scores as well as its implication on precision medicine in the field of the inflammatory diseases inflammatory bowel disease, atopic dermatitis and coronary artery disease. Additionally, we highlight current developments and discuss challenges to be faced in the future. Exemplary, we point to residual challenges in detecting disease-relevant variants resulting from difficulties in the interpretation of candidate variants and their potential interactions. While polygenic risk scores represent promising tools for the stratification of patient groups, currently, polygenic risk scores are not accurate enough for clinical setting. Precision medicine, incorporating additional data from genomics, transcriptomics and proteomics experiments, may enable the identification of distinct disease pathogeneses. In the future, data-intensive biomedical innovation will hopefully lead to improved patient stratification for personalized medicine.	[Huebenthal, Matthias; Emmert, Hila] Univ Hosp Schleswig Holstein, Quincke Res Ctr, Dept Dermatol, Kiel, Germany; [Loescher, Britt-Sabina; Franke, Andre] Christian Albrechts Univ Kiel, Inst Clin Mol Biol, Kiel, Germany; [Loescher, Britt-Sabina; Franke, Andre] Univ Hosp Schleswig Holstein, Kiel, Germany; [Erdmann, Jeanette] Univ Lubeck, Inst Cardiogenet, Lubeck, Germany; [Gola, Damian; Koenig, Inke R.] Univ Lubeck, Inst Med Biometry & Stat, Lubeck, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Kiel; University of Kiel; Schleswig Holstein University Hospital; University of Lubeck; University of Lubeck	Emmert, H (corresponding author), Univ Hosp Schleswig Holstein, Quincke Res Ctr, Dept Dermatol, Kiel, Germany.	hemmert@dermatology.uni-kiel.de	König, Inke R/A-4544-2009; Erdmann, Jeanette/P-7513-2014; Emmert, Hila/AAT-1086-2020; Franke, Andre/B-2151-2010	König, Inke R/0000-0003-0504-6465; Erdmann, Jeanette/0000-0002-4486-6231; Emmert, Hila/0000-0002-7051-7350; Franke, Andre/0000-0003-1530-5811	Deutsche Forschungsgemeinschaft (DFG) Cluster of Excellence "Precision Medicine in Chronic Inflammation" (PMI) [EXC2167]	Deutsche Forschungsgemeinschaft (DFG) Cluster of Excellence "Precision Medicine in Chronic Inflammation" (PMI)(German Research Foundation (DFG))	This review covers research that has been funded by the Deutsche Forschungsgemeinschaft (DFG) Cluster of Excellence "Precision Medicine in Chronic Inflammation" (PMI, EXC2167).	Abraham G, 2016, EUR HEART J, V37, P3267, DOI 10.1093/eurheartj/ehw450; Abraham S, 2020, BRIT J DERMATOL, V183, P382, DOI 10.1111/bjd.18958; Abuabara K, 2020, J ALLERGY CLIN IMMUN, V145, P192, DOI 10.1016/j.jaci.2019.06.044; Ananthakrishnan AN, 2014, AM J GASTROENTEROL, V109, P395, DOI 10.1038/ajg.2013.464; Andersen YMF, 2017, J AM ACAD DERMATOL, V76, P274, DOI 10.1016/j.jaad.2016.08.047; Asad S, 2016, J EUR ACAD DERMATOL, V30, P1939, DOI 10.1111/jdv.13806; Beaney KE, 2017, CLIN CHEM LAB MED, V55, P1605, DOI 10.1515/cclm-2016-0984; Bieber T, 2010, ANN DERMATOL, V22, P125, DOI 10.5021/ad.2010.22.2.125; Biondi RB, 2020, CLIN EXP GASTROENTER, V13, P107, DOI 10.2147/CEG.S243478; Bogari NM, 2020, J INFECT PUBLIC HEAL, V13, P27, DOI 10.1016/j.jiph.2019.05.020; Borg-Bartolo Simon P, 2020, F1000Res, V9, DOI 10.12688/f1000research.20928.1; Braenne I, 2016, EUR J HUM GENET, V24, P191, DOI 10.1038/ejhg.2015.100; Brnne I, 2014, BMC CARDIOVASC DISOR, V14, DOI 10.1186/1471-2261-14-108; Chen GB, 2017, BMC MED GENET, V18, DOI 10.1186/s12881-017-0451-2; Clark H, 2019, CLIN EXP ALLERGY, V49, P1475, DOI 10.1111/cea.13485; Cleynen I, 2016, LANCET, V387, P156, DOI 10.1016/S0140-6736(15)00465-1; Cutler DJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128074; Ellinghaus D, 2013, NAT GENET, V45, P808, DOI 10.1038/ng.2642; Engelhardt KR, 2013, J ALLERGY CLIN IMMUN, V131, P825, DOI 10.1016/j.jaci.2012.09.025; Erdmann J, 2018, CARDIOVASC RES, V114, P1241, DOI 10.1093/cvr/cvy084; Erdmann J, 2013, NATURE, V504, P432, DOI 10.1038/nature12722; Esparza-Gordillo J, 2013, J ALLERGY CLIN IMMUN, V132, P371, DOI 10.1016/j.jaci.2013.01.057; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Evans DM, 2011, NAT GENET, V43, P761, DOI 10.1038/ng.873; Giudicessi JR, 2017, MAYO CLIN PROC, V92, P642, DOI 10.1016/j.mayocp.2017.01.015; Glocker EO, 2011, ANN NY ACAD SCI, V1246, P102, DOI 10.1111/j.1749-6632.2011.06339.x; Gola D, 2020, GENET EPIDEMIOL, V44, P125, DOI 10.1002/gepi.22279; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Goudey B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172826; Goyette P, 2015, NAT GENET, V47, P172, DOI 10.1038/ng.3176; Green RC, 2013, GENET MED, V15, P565, DOI 10.1038/gim.2013.73; Guttman-Yassky E, 2020, JAMA DERMATOL, V156, P411, DOI 10.1001/jamadermatol.2020.0079; Guttman-Yassky E, 2019, J ALLERGY CLIN IMMUN, V143, P155, DOI 10.1016/j.jaci.2018.08.022; Hirota T, 2012, NAT GENET, V44, P1222, DOI 10.1038/ng.2438; Inouye M, 2018, J AM COLL CARDIOL, V72, P1883, DOI 10.1016/j.jacc.2018.07.079; Jansen PR, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111582; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Jung ES, 2018, EUR J GASTROEN HEPAT, V30, P1491, DOI 10.1097/MEG.0000000000001247; Kessler T, 2014, HERZ, V39, P186, DOI 10.1007/s00059-013-4048-z; Khera AV, 2018, NAT GENET, V50, P1219, DOI 10.1038/s41588-018-0183-z; Kim M, 2017, J AM ACAD DERMATOL, V76, P40, DOI 10.1016/j.jaad.2016.08.022; Kotlarz D, 2012, GASTROENTEROLOGY, V143, P347, DOI 10.1053/j.gastro.2012.04.045; Krarup NT, 2015, ATHEROSCLEROSIS, V240, P305, DOI 10.1016/j.atherosclerosis.2015.03.022; Lenz TL, 2015, NAT GENET, V47, P1085, DOI 10.1038/ng.3379; Lipinski S, 2019, CSH MOL CASE STUD, V5, DOI 10.1101/mcs.a002428; Liu JZ, 2015, NAT GENET, V47, P979, DOI 10.1038/ng.3359; Manz J, 2016, J INVEST DERMATOL, V136, P2380, DOI 10.1016/j.jid.2016.07.009; Margolis DJ, 2014, J INVEST DERMATOL, V134, P2272, DOI 10.1038/jid.2014.126; Margolis DJ, 2014, J ALLERGY CLIN IMMUN, V133, P784, DOI 10.1016/j.jaci.2013.09.015; Marigorta UM, 2017, NAT GENET, V49, P1517, DOI 10.1038/ng.3936; Moyle M, 2019, EXP DERMATOL, V28, P756, DOI 10.1111/exd.13911; Mucha S, 2020, J ALLERGY CLIN IMMUN, V145, P1208, DOI 10.1016/j.jaci.2019.10.030; Nevulis MG, 2018, CARDIOL REV, V26, P287, DOI 10.1097/CRD.0000000000000214; Paternoster L, 2015, NAT GENET, V47, P1449, DOI 10.1038/ng.3424; Paternoster L, 2012, NAT GENET, V44, P187, DOI 10.1038/ng.1017; Reisberg S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179238; Ripatti S, 2010, LANCET, V376, P1393, DOI 10.1016/S0140-6736(10)61267-6; Schicho R, 2015, CURR DRUG TARGETS, V16, P181, DOI 10.2174/1389450116666150202161500; Schmitt J, 2016, J ALLERGY CLIN IMMUN, V137, P130, DOI 10.1016/j.jaci.2015.06.029; Schunkert H, 2008, CIRCULATION, V117, P1675, DOI 10.1161/CIRCULATIONAHA.107.730614; Serra EG, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14275-y; Shapiro MD, 2018, CIRC RES, V122, P1420, DOI 10.1161/CIRCRESAHA.118.311227; Sharp SA, 2019, DIABETES CARE, V42, P200, DOI 10.2337/dc18-1785; Somineni HK, 2019, CLIN GASTROENTEROL H, V17, P243, DOI 10.1016/j.cgh.2018.08.078; Steyers CM, 2014, INT J MOL SCI, V15, P11324, DOI 10.3390/ijms150711324; Stitziel NO, 2016, NEW ENGL J MED, V375, P2306, DOI 10.1056/NEJMc1607380; Sun LD, 2011, NAT GENET, V43, P690, DOI 10.1038/ng.851; Tada H, 2016, EUR HEART J, V37, P561, DOI 10.1093/eurheartj/ehv462; Taylan F, 2015, J ALLERGY CLIN IMMUN, V136, P507, DOI 10.1016/j.jaci.2015.02.010; Thomsen T, 2005, EUR J CARDIOV PREV R, V12, P424, DOI 10.1097/01.hjr.0000186617.29992.11; Tregouet DA, 2009, NAT GENET, V41, P283, DOI 10.1038/ng.314; Versmissen J, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2423; Webb TR, 2017, J AM COLL CARDIOL, V69, P823, DOI 10.1016/j.jacc.2016.11.056; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Weidinger S, 2013, HUM MOL GENET, V22, P4841, DOI 10.1093/hmg/ddt317; WILSON PWF, 1987, AM J CARDIOL, V59, pG91, DOI 10.1016/0002-9149(87)90165-2; Wollenberg A, 2019, J ALLERGY CLIN IMMUN, V143, P135, DOI 10.1016/j.jaci.2018.05.029; Worthey EA, 2011, GENET MED, V13, P255, DOI 10.1097/GIM.0b013e3182088158; Zeissig Y, 2015, GUT, V64, P66, DOI 10.1136/gutjnl-2013-306520	79	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 29	2021	11								577677	10.3389/fimmu.2020.577677	http://dx.doi.org/10.3389/fimmu.2020.577677			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QF7AU	33633722	gold, Green Published			2022-12-18	WOS:000617045900001
J	Alotaibi, F; Vincent, M; Min, WP; Koropatnick, J				Alotaibi, Faizah; Vincent, Mark; Min, Wei-Ping; Koropatnick, James			Reduced CD5 on CD8(+) T Cells in Tumors but Not Lymphoid Organs Is Associated With Increased Activation and Effector Function	FRONTIERS IN IMMUNOLOGY			English	Article						tumor-infiltrating lymphocytes (TILs); CD5; CD8(+) T cells; CD4(+) T cells; activation; exhaustion	RECEPTOR; EXPRESSION; ANTIGENS	CD5, a member of the scavenger receptor cysteine-rich superfamily, is a marker for T cells and a subset of B cells (B1a). CD5 associates with T-cell and B-cell receptors and increased CD5 is an indication of B cell activation. In tumor-infiltrating lymphocytes (TILs) isolated from lung cancer patients, CD5 levels were negatively correlated with anti-tumor activity and tumor-mediated activation-induced T cell death, suggesting that CD5 could impair activation of anti-tumor T cells. We determined CD5 levels in T cell subsets in different organs in mice bearing syngeneic 4T1 breast tumor homografts and assessed the relationship between CD5 and increased T cell activation and effector function by flow cytometry. We report that T cell CD5 levels were higher in CD4(+) T cells than in CD8(+) T cells in 4T1 tumor-bearing mice, and that high CD5 levels on CD4(+) T cells were maintained in peripheral organs (spleen and lymph nodes). However, both CD4(+) and CD8(+) T cells recruited to tumors had reduced CD5 compared to CD4(+) and CD8(+) T cells in peripheral organs. In addition, CD5(high)/CD4(+) T cells and CD5(high)/CD8(+) T cells from peripheral organs exhibited higher levels of activation and associated effector function compared to CD5(low)/CD4(+) T cell and CD5(low)/CD8(+) T cell from the same organs. Interestingly, CD8(+) T cells among TILs and downregulated CD5 were activated to a higher level, with concomitantly increased effector function markers, than CD8(+)/CD5(high) TILs. Thus, differential CD5 levels among T cells in tumors and lymphoid organs can be associated with different levels of T cell activation and effector function, suggesting that CD5 may be a therapeutic target for immunotherapeutic activation in cancer therapy.	[Alotaibi, Faizah; Koropatnick, James] Univ Western Ontario, Dept Microbiol & Immunol, London, ON, Canada; [Alotaibi, Faizah; Koropatnick, James] Lawson Hlth Res Inst, Canc Res Lab Program, London Reg Canc Program, London, ON, Canada; [Vincent, Mark; Min, Wei-Ping; Koropatnick, James] Univ Western Ontario, Dept Oncol, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Koropatnick, J (corresponding author), Univ Western Ontario, Dept Microbiol & Immunol, London, ON, Canada.; Koropatnick, J (corresponding author), Lawson Hlth Res Inst, Canc Res Lab Program, London Reg Canc Program, London, ON, Canada.; Koropatnick, J (corresponding author), Univ Western Ontario, Dept Oncol, London, ON, Canada.	jkoropat@uwo.ca		Alotaibi, Faizah/0000-0002-3282-1845	Canadian Institutes of Health Research (CIHR); London Regional Cancer Program; King Abdullah Scholarship	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); London Regional Cancer Program; King Abdullah Scholarship	This research has been funded by grants to JK from the Canadian Institutes of Health Research (CIHR) and the London Regional Cancer Program, and a King Abdullah Scholarship to FA.	Agata Y, 1996, INT IMMUNOL, V8, P765, DOI 10.1093/intimm/8.5.765; Ahn E, 2018, P NATL ACAD SCI USA, V115, P4749, DOI 10.1073/pnas.1718217115; Alotaibi F, 2020, EUR J IMMUNOL, V50, P695, DOI 10.1002/eji.201948309; ARIIZUMI K, 1995, J IMMUNOL, V154, P6031; Aruffo A, 1997, IMMUNOL TODAY, V18, P498, DOI 10.1016/S0167-5699(97)01130-4; Azzam HS, 1998, J EXP MED, V188, P2301, DOI 10.1084/jem.188.12.2301; Azzam HS, 2001, J IMMUNOL, V166, P5464, DOI 10.4049/jimmunol.166.9.5464; Betts MR, 2004, METHOD CELL BIOL, V75, P497; Bondada S, 2000, CURR TOP MICROBIOL, V252, P141; Bourque J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01163; BOYSE EA, 1968, P NATL ACAD SCI USA, V60, P886, DOI 10.1073/pnas.60.3.886; Cantor GH, 2001, J VIROL, V75, P1689, DOI 10.1128/JVI.75.4.1689-1696.2001; CANTOR H, 1975, J EXP MED, V141, P1376, DOI 10.1084/jem.141.6.1376; Cibrian D, 2017, EUR J IMMUNOL, V47, P946, DOI 10.1002/eji.201646837; CRON RQ, 1989, J IMMUNOL, V143, P3769; De Cicco P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01680; Dorothee G, 2005, J IMMUNOL, V174, P6888, DOI 10.4049/jimmunol.174.11.6888; Freeman BE, 2012, P NATL ACAD SCI USA, V109, P9971, DOI 10.1073/pnas.1203543109; FREEMAN GJ, 1992, J IMMUNOL, V149, P3795; Friedlein G, 2007, J IMMUNOL, V178, P6821, DOI 10.4049/jimmunol.178.11.6821; Fry TJ, 2005, J IMMUNOL, V174, P6571, DOI 10.4049/jimmunol.174.11.6571; Martinez VG, 2011, PHARMACOL REV, V63, P967, DOI 10.1124/pr.111.004523; Gagnon J, 2010, IMMUNOL CELL BIOL, V88, P451, DOI 10.1038/icb.2009.109; Garrido F, 2010, INT J CANCER, V127, P249, DOI 10.1002/ijc.25270; Gupta R, 2004, AM J CLIN PATHOL, V121, P368, DOI 10.1309/T5EM98QUB9CM8F57; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Hippen KL, 2000, J EXP MED, V191, P883, DOI 10.1084/jem.191.5.883; Jeong YI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046553; Kieper WC, 2004, J IMMUNOL, V172, P40, DOI 10.4049/jimmunol.172.1.40; Kim K, 2014, P NATL ACAD SCI USA, V111, P11774, DOI 10.1073/pnas.1410626111; LEDBETTER JA, 1980, J EXP MED, V152, P280, DOI 10.1084/jem.152.2.280; Martinez-Florensa M, 2014, J INFECT DIS, V209, P1077, DOI 10.1093/infdis/jit624; Mizoguchi A, 2003, INT IMMUNOL, V15, P97, DOI 10.1093/intimm/dxg006; Mumberg D, 1999, P NATL ACAD SCI USA, V96, P8633, DOI 10.1073/pnas.96.15.8633; Ordonez-Rueda D, 2009, EUR J IMMUNOL, V39, P2233, DOI 10.1002/eji.200839053; Sinha P, 2008, J IMMUNOL, V181, P4666, DOI 10.4049/jimmunol.181.7.4666; Spolski R, 2008, ANNU REV IMMUNOL, V26, P57, DOI 10.1146/annurev.immunol.26.021607.090316; Stamou P, 2003, J IMMUNOL, V171, P1278, DOI 10.4049/jimmunol.171.3.1278; Tabbekh M, 2011, J IMMUNOL, V187, P102, DOI 10.4049/jimmunol.1004145; Takahashi K, 1998, AM J PATHOL, V152, P445; Voisinne G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02900; WERNERFAVRE C, 1989, EUR J IMMUNOL, V19, P1209, DOI 10.1002/eji.1830190709; Wolfl M, 2007, BLOOD, V110, P201, DOI 10.1182/blood-2006-11-056168; Xu H, 2015, J IMMUNOL, V194	44	0	0	3	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 28	2021	11								584937	10.3389/fimmu.2020.584937	http://dx.doi.org/10.3389/fimmu.2020.584937			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QF3QT	33584650	gold, Green Published			2022-12-18	WOS:000616813300001
J	Garcia-Perez, L; van Eggermond, MCJA; Maietta, E; Van der Hoorn, MLP; Pike-Overzet, K; Staal, FJT				Garcia-Perez, Laura; van Eggermond, Marla C. J. A.; Maietta, Elisa; Van der Hoorn, Marie-Louise P.; Pike-Overzet, Karin; Staal, Frank J. T.			A Novel Branched DNA-Based Flowcytometric Method for Single-Cell Characterization of Gene Therapy Products and Expression of Therapeutic Genes	FRONTIERS IN IMMUNOLOGY			English	Article						hematopoietic stem and progenitor cell; transgene; branched DNA; vector copy number; quantitative polymerase chain reaction; gene therapy; single cell; flow cytometry		Many preclinical and clinical studies of hematopoietic stem cell-based gene therapy (GT) are based on the use of lentiviruses as the vector of choice. Assessment of the vector titer and transduction efficiency of the cell product is critical for these studies. Efficacy and safety of the modified cell product are commonly determined by assessing the vector copy number (VCN) using qPCR. However, this optimized and well-established method in the GT field is based on bulk population averages, which can lead to misinterpretation of the actual VCN per transduced cell. Therefore, we introduce here a single cell-based method that allows to unmask cellular heterogeneity in the GT product, even when antibodies are not available. We use Invitrogen's flow cytometry-based PrimeFlow (TM) RNA Assay with customized probes to determine transduction efficiency of transgenes of interest, promoter strength, and the cellular heterogeneity of murine and human stem cells. The assay has good specificity and sensitivity to detect the transgenes, as shown by the high correlations between PrimeFlow (TM)-positive cells and the VCN. Differences in promoter strengths can readily be detected by differences in percentages and fluorescence intensity. Hence, we show a customizable method that allows to determine the number of transduced cells and the actual VCN per transduced cell in a GT product. The assay is suitable for all therapeutic genes for which antibodies are not available or too cumbersome for routine flow cytometry. The method also allows co-staining of surface markers to analyze differential transduction efficiencies in subpopulations of target cells.	[Garcia-Perez, Laura; van Eggermond, Marla C. J. A.; Maietta, Elisa; Pike-Overzet, Karin; Staal, Frank J. T.] Leiden Univ Med Ctr LUMC, Dept Immunol, Leiden, Netherlands; [Van der Hoorn, Marie-Louise P.] Leiden Univ Med Ctr LUMC, Dept Obstet, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)	Staal, FJT (corresponding author), Leiden Univ Med Ctr LUMC, Dept Immunol, Leiden, Netherlands.	f.j.t.staal@lumc.nl	Pike-Overzet, Karin/AAT-3716-2021	Pike-Overzet, Karin/0000-0002-8827-246X; Garcia Perez, Laura/0000-0002-3862-165X; van der Hoorn, Marie-Louise/0000-0002-7781-7815	ZonMW E-RARE grant [40-419000-98-020]; European Union's Horizon 2020 research and innovation program [666908, 755170]	ZonMW E-RARE grant; European Union's Horizon 2020 research and innovation program	This work was supported in part by ZonMW E-RARE grant (40-419000-98-020) and received funding from the European Union's Horizon 2020 research and innovation program under grant agreements No. 666908 (SCIDNET) and No. 755170 (RECOMB).	Abina SHB, 2015, JAMA-J AM MED ASSOC, V313, P1550, DOI 10.1001/jama.2015.3253; Ailles L, 2002, MOL THER, V6, P615, DOI 10.1006/mthe.2002.0720; Aiuti A, 2017, EMBO MOL MED, V9, P737, DOI 10.15252/emmm.201707573; Aiuti A, 2013, SCIENCE, V341, P865, DOI 10.1126/science.1233151; Benjelloun F, 2008, MOL THER, V16, P1490, DOI 10.1038/mt.2008.118; Biasco L, 2017, HEMATOL ONCOL CLIN N, V31, P737, DOI 10.1016/j.hoc.2017.06.009; Braun CJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007280; Brendel C, 2018, HUM GENE THER CL DEV, V29, P69, DOI 10.1089/humc.2017.245; Carbonaro DA, 2014, MOL THER, V22, P607, DOI 10.1038/mt.2013.265; Carriglio N, 2017, HUM GENE THER CL DEV, V28, P17, DOI 10.1089/humc.2016.191; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Charrier S, 2011, GENE THER, V18, P479, DOI 10.1038/gt.2010.163; Charrier S, 2019, MOL THER-METH CLIN D, V15, P232, DOI 10.1016/j.omtm.2019.08.014; Cicalese MP, 2016, BLOOD, V128, P45, DOI 10.1182/blood-2016-01-688226; Cowan MJ, 2020, BIOL BLOOD MARROW TR, V26, pS88; De Ravin SS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8856; Diez IA, 2011, MOL PHARMACEUT, V8, P1525, DOI 10.1021/mp200132u; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Fehse B, 2004, GENE THER, V11, P879, DOI 10.1038/sj.gt.3302270; Ferrua F, 2019, LANCET HAEMATOL, V6, pE239, DOI 10.1016/S2352-3026(19)30021-3; Ferrua F, 2017, HUM GENE THER, V28, P972, DOI 10.1089/hum.2017.175; Forte D, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/5974613; Garcia-Gomez M, 2016, MOL THER, V24, P1187, DOI 10.1038/mt.2016.87; Garcia-Perez L, 2020, MOL THER-METH CLIN D, V17, P666, DOI 10.1016/j.omtm.2020.03.016; Gaspar HB, 2004, LANCET, V364, P2181, DOI 10.1016/S0140-6736(04)17590-9; Halene S, 1999, BLOOD, V94, P3349, DOI 10.1182/blood.V94.10.3349.422k05_3349_3357; Invitrogen, 2016, PIMEFLOW RNA ASSAY M; Knight S, 2012, J VIROL, V86, P9088, DOI 10.1128/JVI.00485-12; Kohn DB, 2020, NAT MED, V26, P200, DOI 10.1038/s41591-019-0735-5; Mamcarz E, 2019, NEW ENGL J MED, V380, P1525, DOI 10.1056/NEJMoa1815408; Marktel S, 2019, NAT MED, V25, P234, DOI 10.1038/s41591-018-0301-6; Morris EC, 2017, BLOOD, V130, P1327, DOI 10.1182/blood-2017-04-777136; Pike-Overzet K, 2011, LEUKEMIA, V25, P1471, DOI 10.1038/leu.2011.106; Pike-Overzet K, 2007, GENE THERAPY RAG DEF; Poletti V, 2018, MOL THER-METH CLIN D, V9, P257, DOI 10.1016/j.omtm.2018.03.002; Punwani D, 2017, HUM GENE THER, V28, P112, DOI 10.1089/hum.2016.064; Ribeil JA, 2017, NEW ENGL J MED, V376, P848, DOI 10.1056/NEJMoa1609677; Rio P, 2019, NAT MED, V25, P1396, DOI 10.1038/s41591-019-0550-z; Rosler ES, 2000, BLOOD, V96, P3414; Santilli G, 2011, MOL THER, V19, P122, DOI 10.1038/mt.2010.226; Sastry L, 2002, GENE THER, V9, P1155, DOI 10.1038/sj.gt.3301731; Schambach A, 2006, MOL THER, V13, P391, DOI 10.1016/j.ymthe.2005.08.012; Schiroli G, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan0820; Schuesler T., 2009, COPY NUMBER DETERMIN, P281, DOI [10.1007/978-1-59745-409-4_19, DOI 10.1007/978-1-59745-409-4_19]; Soh KT, 2018, METHODS MOL BIOL, V1678, P49, DOI 10.1007/978-1-4939-7346-0_4; Staal FJT, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00443; Tanavde VM, 2002, EXP HEMATOL, V30, P816, DOI 10.1016/S0301-472X(02)00818-4; Thermofisher, 2017, PRIMEFLOW RNA ASS EN; Theunissen K, 2005, EXP HEMATOL, V33, P165, DOI 10.1016/j.exphem.2004.10.016; Thompson AA, 2018, NEW ENGL J MED, V378, P1479, DOI 10.1056/NEJMoa1705342; Villella AD, 2005, MOL THER, V11, P483, DOI 10.1016/j.ymthe.2004.10.017; Wang JCY, 1997, BLOOD, V89, P3919, DOI 10.1182/blood.V89.11.3919	52	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 28	2021	11								607991	10.3389/fimmu.2020.607991	http://dx.doi.org/10.3389/fimmu.2020.607991			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QF5RL	33584681	gold, Green Published			2022-12-18	WOS:000616951000001
J	Lee, GW; Lee, SW; Kim, J; Ju, YJ; Kim, HO; Yun, CH; Cho, JH				Lee, Gil-Woo; Lee, Sung-Woo; Kim, Juhee; Ju, Young-Jun; Kim, Hee-Ok; Yun, Cheol-Heui; Cho, Jae-Ho			Supraphysiological Levels of IL-2 in Jak3-Deficient Mice Promote Strong Proliferative Responses of Adoptively Transferred Naive CD8(+) T Cells	FRONTIERS IN IMMUNOLOGY			English	Article						interleukin-2; naive CD8(+) T cells; antigen-independent proliferation; Janus kinase 3; activated CD4(+) T cells; CD4(+) regulatory T cells		The antigen-independent, strong proliferative responses of naive CD8(+) T cells have been well demonstrated in a particular strain of mice lacking IL-2 receptors. This type of proliferation is mainly driven by common gamma-chain (gamma(c)) cytokines, such as IL-2, IL-7, and IL-15, present at abnormally high levels in these mice. Similarly, in the present study, we showed that mice lacking Janus kinase 3 (Jak3), a tyrosine kinase crucial for gamma(c) cytokine signaling, could induce strong proliferation of adoptively transferred naive CD8(+) T cells. This proliferation was also independent of antigenic stimulation, but heavily dependent on IL-2, as evidenced by the failure of proliferation of adoptively transferred IL-2 receptor alpha- and beta-chain-deficient naive CD8(+) T cells. Consistent with this, Jak3 (-/-) mice showed elevated serum levels of IL-2 compared to wild-type mice, and interestingly, IL-2 production was due to high levels of accumulation of activated CD4(+) T cells in Jak3 (-/-) mice along with defective CD4(+) T regulatory cells. Collectively, these findings reveal previously unidentified unique immune contexts of Jak3 (-/-) mice that cause robust IL-2-driven T cell expansion and have a clinical implication for designing a treatment strategy for human patients with loss-of-function genetic mutations of Jak3.	[Lee, Gil-Woo; Lee, Sung-Woo; Kim, Juhee] Pohang Univ Sci & Technol, Div Integrat Biosci & Biotechnol, Pohang, South Korea; [Lee, Gil-Woo; Lee, Sung-Woo; Cho, Jae-Ho] Chonnam Natl Univ, Med Res Ctr Combinatorial Tumor Immunotherapy, Dept Microbiol & Immunol, Med Sch, Jeonnam, South Korea; [Lee, Gil-Woo; Lee, Sung-Woo; Kim, Hee-Ok; Cho, Jae-Ho] Chonnam Natl Univ, Hwasun Hosp, Immunotherapy Innovat Ctr, Med Sch, Jeonnam, South Korea; [Ju, Young-Jun; Yun, Cheol-Heui] Seoul Natl Univ, Dept Agr Biotechnol, Seoul, South Korea; [Ju, Young-Jun; Yun, Cheol-Heui] Seoul Natl Univ, Res Inst Agr & Life Sci, Seoul, South Korea	Pohang University of Science & Technology (POSTECH); Chonnam National University; Chonnam National University; Seoul National University (SNU); Seoul National University (SNU)	Cho, JH (corresponding author), Chonnam Natl Univ, Med Res Ctr Combinatorial Tumor Immunotherapy, Dept Microbiol & Immunol, Med Sch, Jeonnam, South Korea.; Cho, JH (corresponding author), Chonnam Natl Univ, Hwasun Hosp, Immunotherapy Innovat Ctr, Med Sch, Jeonnam, South Korea.	jh_cho@chonnam.ac.kr	YUN, Cheol-Heui/AAR-2775-2020	YUN, Cheol-Heui/0000-0002-0041-2887	National Research Foundation - Korean Ministry of Science and ICT [2018R1A5A2024181, 2020M3A9G3080281]	National Research Foundation - Korean Ministry of Science and ICT	This work was supported by National Research Foundation funded by the Korean Ministry of Science and ICT (2018R1A5A2024181 and 2020M3A9G3080281 for J-HC).	Azzam HS, 1998, J EXP MED, V188, P2301, DOI 10.1084/jem.188.12.2301; Baird AM, 1998, J LEUKOCYTE BIOL, V63, P669, DOI 10.1002/jlb.63.6.669; Bosco N, 2005, J IMMUNOL, V175, P162, DOI 10.4049/jimmunol.175.1.162; Candotti F, 1997, BLOOD, V90, P3996, DOI 10.1182/blood.V90.10.3996; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; Casanova JL, 2012, IMMUNITY, V36, P515, DOI 10.1016/j.immuni.2012.03.016; Cattaneo F, 2013, J ALLERGY CLIN IMMUN, V131, P1136, DOI 10.1016/j.jaci.2012.12.667; Chinen T, 2016, NAT IMMUNOL, V17, P1322, DOI 10.1038/ni.3540; Cho JH, 2007, J EXP MED, V204, P1787, DOI 10.1084/jem.20070740; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; Fontenot JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/ni1263; Frucht DM, 2001, GENES IMMUN, V2, P422, DOI 10.1038/sj.gene.6363802; Ghoreschi K, 2009, IMMUNOL REV, V228, P273, DOI 10.1111/j.1600-065X.2008.00754.x; Goldrath AW, 1999, IMMUNITY, V11, P183, DOI 10.1016/S1074-7613(00)80093-X; Hosking MP, 2014, J IMMUNOL, V193, P1873, DOI 10.4049/jimmunol.1400348; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Kieper WC, 2004, J IMMUNOL, V172, P40, DOI 10.4049/jimmunol.172.1.40; Kim J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01907; Leonard WJ, 1995, IMMUNOL REV, V148, P97, DOI 10.1111/j.1600-065X.1995.tb00095.x; Leonard WJ, 2001, INT J HEMATOL, V73, P271, DOI 10.1007/BF02981951; Lin JX, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028449; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Mandl JN, 2013, IMMUNITY, V38, P263, DOI 10.1016/j.immuni.2012.09.011; Min B, 2005, J IMMUNOL, V174, P6039, DOI 10.4049/jimmunol.174.10.6039; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; Pandiyan P, 2007, NAT IMMUNOL, V8, P1353, DOI 10.1038/ni1536; Park SY, 1995, IMMUNITY, V3, P771, DOI 10.1016/1074-7613(95)90066-7; Ramsey C, 2008, J IMMUNOL, V180, P5320, DOI 10.4049/jimmunol.180.8.5320; Roberts JL, 2004, BLOOD, V103, P2009, DOI 10.1182/blood-2003-06-2104; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; Schmidt A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00051; Seddon B, 2002, J IMMUNOL, V169, P3752, DOI 10.4049/jimmunol.169.7.3752; Surh CD, 2008, IMMUNITY, V29, P848, DOI 10.1016/j.immuni.2008.11.002; SUZUKI H, 1995, SCIENCE, V268, P1472, DOI 10.1126/science.7770771; Thomis DC, 1997, CURR OPIN IMMUNOL, V9, P541, DOI 10.1016/S0952-7915(97)80108-2; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9; Yao Z, 2007, BLOOD, V109, P4368, DOI 10.1182/blood-2006-11-055756	38	0	0	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 28	2021	11								616898	10.3389/fimmu.2020.616898	http://dx.doi.org/10.3389/fimmu.2020.616898			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QF3LO	33584707	gold, Green Published			2022-12-18	WOS:000616799700001
J	Madrid, M; Brianza-Padilla, M; Echeverria, JC; Rivera-Gonzalez, R; Bojalil, R				Madrid, Miriam; Brianza-Padilla, Malinalli; Echeverria, Juan C.; Rivera-Gonzalez, Rolando; Bojalil, Rafael			The Severity of Neurological Dysfunction in Preschool Children, Secondary to Damage Generated During the Perinatal Period, is Associated With a Pro-Inflammatory Pattern of Serum Molecules	FRONTIERS IN IMMUNOLOGY			English	Article						perinatal risks; inflammation; sequelae; neurological signs; neurodevelopment		Disorders in the child's neurological development caused by perinatal risks can lead to long-term altered neurological signs that begin at an early age and involve persistent functional disorders. Recent data suggest that tissue dysfunction, not just acute damage, may initiate or perpetuate an inflammatory response. The aim of this study was to find out if any neurological dysfunction in preschool children secondary to damage generated during the perinatal period is associated with the magnitude of perinatal risks and long-term modifications in the serum concentrations of inflammatory molecules. The participants, aged 1-4 years, were on neurodevelopmental follow-up and rehabilitation therapy from the first three months of life and had no acute disease data. We classified the children into three groups according to the importance of their perinatal risks: low, medium, and high. The results show that 1) the magnitude of perinatal risks correlated with the severity of neurological dysfunction; 2) the greatest changes in the concentrations of the molecules of the inflammatory process were associated with the most altered neurological signs. This suggests that persistent nervous system dysfunction keeps inflammatory responses active even in the absence of an acute process of infection or damage.	[Madrid, Miriam] Univ Autonoma Metropolitana, Ciencias Biol & Salud, Mexico City, DF, Mexico; [Brianza-Padilla, Malinalli; Bojalil, Rafael] Inst Nacl Cardiol Ignacio Chavez, Dept Immunol, Mexico City, DF, Mexico; [Echeverria, Juan C.] Univ Autonoma Metropolitana Iztapalapa, Dept Elect Engn, Mexico City, DF, Mexico; [Rivera-Gonzalez, Rolando] Inst Nacl Pediat, Neurodev Monitoring Lab, Mexico City, DF, Mexico; [Bojalil, Rafael] Univ Autonoma Metropolitana Xochimilco, Dept Hlth Care, Mexico City, DF, Mexico	Universidad Autonoma Metropolitana - Mexico; National Institute of Cardiology - Mexico; Universidad Autonoma Metropolitana - Mexico; Universidad Autonoma Metropolitana - Mexico	Bojalil, R (corresponding author), Inst Nacl Cardiol Ignacio Chavez, Dept Immunol, Mexico City, DF, Mexico.; Rivera-Gonzalez, R (corresponding author), Inst Nacl Pediat, Neurodev Monitoring Lab, Mexico City, DF, Mexico.; Bojalil, R (corresponding author), Univ Autonoma Metropolitana Xochimilco, Dept Hlth Care, Mexico City, DF, Mexico.	rolandorivera66@gmail.com; rafaelbojalil@gmail.com	Echeverria, JC/AAZ-1573-2020; Rivera Gonzalez, Rolando/ADT-8884-2022	Rivera Gonzalez, Rolando/0000-0002-8312-0248	National Council of Science and Technology (CONACyT), Mexico	National Council of Science and Technology (CONACyT), Mexico(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	MM has received a scholarship from the National Council of Science and Technology (CONACyT), Mexico.	Alvarado G., 2010, EVALUACI N NEURODESA; Andersson U, 2012, ANNU REV IMMUNOL, V30, P313, DOI 10.1146/annurev-immunol-020711-075015; Arreola-Ramirez G., 2005, PERINATOLOG A REPROD, V19, P141; Bojalil R., 2016, INMUNOLOG A MOL CELU, P106; Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R; Cervantes-Villagrana RD, 2014, GAC MED MEX, V150, P440; De la Cruz D., 2011, ARCH NEUROCIEN MEX, V16, P209; Delfino A., 2010, ARCH PEDIATR URUG, V81; Diaz R., 2016, REV M D 150 N CONDES, V27, P441, DOI [10.1016/j.rmclc.2016.07.005, DOI 10.1016/J.RMCLC.2016.07.005]; DIPIETRO JA, 1991, PEDIATR RES, V29, P231, DOI 10.1203/00006450-199103000-00003; Edmond K, 2016, J TROP PEDIATRICS, V62, P83, DOI 10.1093/tropej/fmw018; Evans SH, 2017, CURR PROB PEDIATR AD, V47, P161, DOI 10.1016/j.cppeds.2017.06.005; Feldman R, 2009, CHILD DEV, V80, P544, DOI 10.1111/j.1467-8624.2009.01278.x; Canton SBF, 2012, B MED HOSP INFANT M, V69, P144; Geva R, 2008, J CHILD PSYCHOL PSYC, V49, P1031, DOI 10.1111/j.1469-7610.2008.01918.x; Gold PW, 2013, MOL PSYCHIATR, V18, P154, DOI 10.1038/mp.2012.167; Gómez-López Simón, 2013, Arch Venez Puer Ped, V76, P30; Grijalba-Uche Miguel, 2015, pers.bioét., V19, P80, DOI 10.5294/PEBI.2015.19.1.7; Hernandez ME., 2007, SALUD MENT, V30; Inder T E, 2000, Semin Neonatol, V5, P3, DOI 10.1053/siny.1999.0112; Lasry A, 2017, CANCER RES, V77, P3740, DOI 10.1158/0008-5472.CAN-16-3383; Lopez-Antunez M., 2000, ANATOM A FUNCIONAL S, P437; Medina Alva Maria del Pilar, 2015, Rev Peru Med Exp Salud Publica, V32, P565; Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201; Moxon SG, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/1471-2393-15-S2-S8; Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029; National Scientific Council on the Developing Child, 2014, EXCESSIVE STRESS DIS; Nuysink J, 2008, EUR J PEDIATR, V167, P613, DOI 10.1007/s00431-008-0686-1; Okin D, 2012, CURR BIOL, V22, pR733, DOI 10.1016/j.cub.2012.07.029; Okubo M, 2010, GLIA, V58, P599, DOI 10.1002/glia.20948; Papocsek M, 2011, INFANT MENT HEALTH J, V32, P29, DOI 10.1002/imhj.20282; Patankar V C, 2012, Indian J Psychiatry, V54, P159, DOI 10.4103/0019-5545.99540; Pavlov VA, 2017, NAT NEUROSCI, V20, P156, DOI 10.1038/nn.4477; Porges SW., 2017, TEOR A POLIVAGAL FUN; Ramirez BY., 2008, ARCH NEUROCIEN, V13; Rivera R., 2020, NUTRICI N MATERNO IN; Romero G., 2004, ARCH NEUROCIEN MEX D, V9, P143; Sanchez-Perez C, 2015, ACTA PEDIATR MEX, V36, P480, DOI 10.18233/APM36No6pp480-496; Secretaria de Salud, 2016, NORMA OFICIAL MEXICA; Sparks SE, 2015, CLIN PERINATOL, V42, P363, DOI 10.1016/j.clp.2015.02.008; Steinman L, 2004, NAT IMMUNOL, V5, P575, DOI 10.1038/ni1078; Torres P., 2013, ENF NEUROL MEX, V12, P128; Uemura K, 2007, AM J PHYSIOL-HEART C, V293, pH2254, DOI 10.1152/ajpheart.00490.2007; Vargas-Garcia C., 2007, SISTEMA DETECCI N EV; Vericat A, 2017, ACTA PEDIATR MEX, V38, P255, DOI 10.18233/apm38no4pp255-2661434; WEDMORE CV, 1981, NATURE, V289, P646, DOI 10.1038/289646a0; World Health Organization, 2018, INT CLASS DIS MORT M	47	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 28	2021	11								595309	10.3389/fimmu.2020.595309	http://dx.doi.org/10.3389/fimmu.2020.595309			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology	QF3TP	33584663	Green Published, gold			2022-12-18	WOS:000616820700001
J	Park, J; Sohn, JH; Han, SM; Park, YJ; Huh, JY; Choe, SS; Kim, JB				Park, Jeu; Sohn, Jee Hyung; Han, Sang Mun; Park, Yoon Jeong; Huh, Jin Young; Choe, Sung Sik; Kim, Jae Bum			Adipocytes Are the Control Tower That Manages Adipose Tissue Immunity by Regulating Lipid Metabolism	FRONTIERS IN IMMUNOLOGY			English	Review						adipocytes; lipid metabolite; invariant natural killer cell; adipose tissue remodeling; adipose tissue inflammation	INSULIN-RESISTANCE; CELLS; OBESITY; INNATE	Accumulating evidence reveals that adipose tissue is an immunologically active organ that exerts multiple impacts on the regulation of systemic energy metabolism. Adipose tissue immunity is modulated by the interactions between adipocytes and various immune cells. Nevertheless, the underlying mechanisms that control inter-cellular interactions between adipocytes and immune cells in adipose tissue have not been thoroughly elucidated. Recently, it has been demonstrated that adipocytes utilize lipid metabolites as a key mediator to initiate and mediate diverse adipose tissue immune responses. Adipocytes present lipid antigens and secrete lipid metabolites to determine adipose immune tones. In addition, the interactions between adipocytes and adipose immune cells are engaged in the control of adipocyte fate and functions upon metabolic stimuli. In this review, we discuss an integrated view of how adipocytes communicate with adipose immune cells using lipid metabolites. Also, we briefly discuss the newly discovered roles of adipose stem cells in the regulation of adipose tissue immunity.	[Park, Jeu; Sohn, Jee Hyung; Han, Sang Mun; Park, Yoon Jeong; Huh, Jin Young; Choe, Sung Sik; Kim, Jae Bum] Seoul Natl Univ, Natl Creat Res Initiat Ctr Adipocyte Struct & Fun, Seoul, South Korea; [Park, Jeu; Sohn, Jee Hyung; Han, Sang Mun; Park, Yoon Jeong; Huh, Jin Young; Choe, Sung Sik; Kim, Jae Bum] Seoul Natl Univ, Inst Mol Biol & Genet, Seoul, South Korea; [Park, Jeu; Sohn, Jee Hyung; Han, Sang Mun; Park, Yoon Jeong; Huh, Jin Young; Choe, Sung Sik; Kim, Jae Bum] Seoul Natl Univ, Sch Biol Sci, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Kim, JB (corresponding author), Seoul Natl Univ, Natl Creat Res Initiat Ctr Adipocyte Struct & Fun, Seoul, South Korea.; Kim, JB (corresponding author), Seoul Natl Univ, Inst Mol Biol & Genet, Seoul, South Korea.; Kim, JB (corresponding author), Seoul Natl Univ, Sch Biol Sci, Seoul, South Korea.	jaebkim@snu.ac.kr		KIM, Jae Bum/0000-0003-2337-6935; Sohn, Jee Hyung/0000-0003-2739-134X; Huh, Jin Young/0000-0002-0980-7199	National Research Foundation of Korea (NRF) - Korea government (MSIT) [NRF-2020R1A3B2078617]	National Research Foundation of Korea (NRF) - Korea government (MSIT)	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. NRF-2020R1A3B2078617).	Alexaki A, 2017, J BIOL CHEM, V292, P3929, DOI 10.1074/jbc.M116.756460; Barral DC, 2007, NAT REV IMMUNOL, V7, P929, DOI 10.1038/nri2191; Brestoff JR, 2015, CELL, V161, P146, DOI 10.1016/j.cell.2015.02.022; Burl RB, 2018, CELL METAB, V28, P300, DOI 10.1016/j.cmet.2018.05.025; Camell CD, 2019, CELL METAB, V30, P1024, DOI 10.1016/j.cmet.2019.10.006; Camell CD, 2017, NATURE, V550, P119, DOI 10.1038/nature24022; Cao HM, 2008, CELL, V134, P933, DOI 10.1016/j.cell.2008.07.048; Castoldi A, 2016, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00637; Ceccarelli S, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00236; Chan KL, 2015, J BIOL CHEM, V290, P16979, DOI 10.1074/jbc.M115.646992; Chaurasia B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.576347; Chawla A, 2011, NAT REV IMMUNOL, V11, P738, DOI 10.1038/nri3071; Choe SS, 2020, POSTGRAD MED J, V96, P451, DOI 10.1136/postgradmedj-2019-136428; Choe SS, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00030; Choe SS, 2014, DIABETES, V63, P3359, DOI 10.2337/db13-1965; Cimen I, 2019, MOL METAB, V28, P58, DOI 10.1016/j.molmet.2019.08.004; Deutsch A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134773; Domingo P, 1999, AIDS, V13, P2261, DOI 10.1097/00002030-199911120-00008; Donath MY, 2011, NAT REV IMMUNOL, V11, P98, DOI 10.1038/nri2925; Doran AC, 2020, NAT REV IMMUNOL, V20, P254, DOI 10.1038/s41577-019-0240-6; Ferrero R, 2020, TRENDS CELL BIOL, V30, P937, DOI 10.1016/j.tcb.2020.09.007; Fischer-Posovszky P, 2006, J CLIN ENDOCR METAB, V91, P1129, DOI 10.1210/jc.2005-0737; Fischer-Posovszky P, 2011, ENDOCRINOLOGY, V152, P3074, DOI 10.1210/en.2011-1031; Freigang S, 2010, J CLIN INVEST, V120, P1873, DOI 10.1172/JCI40451; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gandotra S, 2011, NEW ENGL J MED, V364, P740, DOI 10.1056/NEJMoa1007487; Ganeshan K, 2014, ANNU REV IMMUNOL, V32, P609, DOI 10.1146/annurev-immunol-032713-120236; Gao H, 2020, CELL METAB, V32, P1, DOI 10.1016/j.cmet.2020.06.007; Gartung A, 2016, J BIOL CHEM, V291, P16001, DOI 10.1074/jbc.M116.725937; Ghaben AL, 2019, NAT REV MOL CELL BIO, V20, P242, DOI 10.1038/s41580-018-0093-z; Goldberg EL, 2020, NAT METAB, V2, P50, DOI 10.1038/s42255-019-0160-6; Green DR, 2001, NAT REV MOL CELL BIO, V2, P917, DOI 10.1038/35103104; Haluzik M, 2011, EXPERT REV ENDOCRINO, V6, P5, DOI [10.1586/eem.10.69, 10.1586/EEM.10.69]; Ham M, 2016, DIABETES, V65, P2624, DOI 10.2337/db16-0060; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; Henriques F, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107998; Hepler C, 2018, ELIFE, V7, DOI 10.7554/eLife.39636; Herrero L, 2010, P NATL ACAD SCI USA, V107, P240, DOI 10.1073/pnas.0905310107; Hu B, 2020, NATURE, V578, P610, DOI 10.1038/s41586-020-2028-z; Hu XQ, 2016, J LIPID RES, V57, P663, DOI 10.1194/jlr.M066530; Huang-Doran I, 2010, J ENDOCRINOL, V207, P245, DOI 10.1677/JOE-10-0272; Huh JY, 2018, ADIPOCYTE, V7, P129, DOI 10.1080/21623945.2018.1440928; Huh JY, 2017, DIABETES, V66, P835, DOI 10.2337/db16-1122; Huh JY, 2014, MOL CELLS, V37, P365, DOI 10.14348/molcells.2014.0074; Huh JY, 2013, MOL CELL BIOL, V33, P328, DOI 10.1128/MCB.00552-12; Hussain I, 2016, ENDOCRIN METAB CLIN, V45, P783, DOI 10.1016/j.ecl.2016.06.012; Hwang I, 2019, DIABETES METAB J, V43, P752, DOI 10.4093/dmj.2019.0174; Hwang I, 2019, P NATL ACAD SCI USA, V116, P11936, DOI 10.1073/pnas.1822067116; Jackson-Jones LH, 2020, IMMUNITY, V52, P700, DOI 10.1016/j.immuni.2020.03.011; Jaitin DA, 2019, CELL, V178, P686, DOI 10.1016/j.cell.2019.05.054; Ji YW, 2012, J BIOL CHEM, V287, P24378, DOI 10.1074/jbc.M112.371807; Johnson JA, 2004, AM J PHYSIOL-ENDOC M, V286, pE261, DOI 10.1152/ajpendo.00056.2003; Johnson MD, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030686; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kim JI, 2015, MOL CELL BIOL, V35, P1686, DOI 10.1128/MCB.01321-14; Kohlgruber AC, 2018, NAT IMMUNOL, V19, P464, DOI 10.1038/s41590-018-0094-2; Lagathu C, 2007, ANTIVIR THER, V12, P489; LaMarche NM, 2020, CELL METAB, V32, P243, DOI 10.1016/j.cmet.2020.05.017; Lee YS, 2011, DIABETES, V60, P2474, DOI 10.2337/db11-0194; Li P, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-1044-5; Li SZ, 2009, CIRC RES, V105, P1072, DOI 10.1161/CIRCRESAHA.109.199570; Luo BW, 2019, BBA-MOL BASIS DIS, V1865, P339, DOI 10.1016/j.bbadis.2018.10.005; Luoma AM, 2014, TRENDS IMMUNOL, V35, P613, DOI 10.1016/j.it.2014.09.003; Luoma AM, 2013, IMMUNITY, V39, P1032, DOI 10.1016/j.immuni.2013.11.001; Lynch L, 2015, NAT IMMUNOL, V16, P85, DOI 10.1038/ni.3047; Lynch L, 2012, IMMUNITY, V37, P574, DOI 10.1016/j.immuni.2012.06.016; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Marcelin G, 2017, CELL METAB, V25, P673, DOI 10.1016/j.cmet.2017.01.010; Martin S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046242; Masoodi M, 2015, BBA-MOL CELL BIOL L, V1851, P503, DOI 10.1016/j.bbalip.2014.09.023; Mazid MA, 2006, FEBS LETT, V580, P6885, DOI 10.1016/j.febslet.2006.11.049; McLaughlin T, 2017, J CLIN INVEST, V127, P5, DOI 10.1172/JCI88876; Olefsky JM, 2010, ANNU REV PHYSIOL, V72, P219, DOI 10.1146/annurev-physiol-021909-135846; Park J, 2019, GENE DEV, V33, P1657, DOI 10.1101/gad.329557.119; Park YJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01311; PRINS JB, 1994, BIOCHEM BIOPH RES CO, V205, P625, DOI 10.1006/bbrc.1994.2711; Ralchshandehroo M, 2019, BBA-MOL CELL BIOL L, V1864, P1157, DOI 10.1016/j.bbalip.2019.04.016; Satoh M, 2016, SCI REP-UK, V6, DOI 10.1038/srep28473; Savage DB, 2009, DIS MODEL MECH, V2, P554, DOI 10.1242/dmm.002907; Schwalie PC, 2018, NATURE, V559, P103, DOI 10.1038/s41586-018-0226-8; Shan B, 2020, NAT METAB, V2, DOI 10.1038/s42255-020-00301-7; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; Shimizu T, 2009, ANNU REV PHARMACOL, V49, P123, DOI 10.1146/annurev.pharmtox.011008.145616; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shin KC, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01232-w; Sohn JH, 2018, J BIOL CHEM, V293, P13974, DOI 10.1074/jbc.RA118.003541; Somnay-Wadgaonkar K, 1999, INT IMMUNOL, V11, P383, DOI 10.1093/intimm/11.3.383; Spalding KL, 2008, NATURE, V453, P783, DOI 10.1038/nature06902; Spallanzani RG, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw3658; Strissel KJ, 2007, DIABETES, V56, P2910, DOI 10.2337/db07-0767; Summers SA, 2019, NAT METAB, V1, P1051, DOI 10.1038/s42255-019-0134-8; Sun WF, 2020, NATURE, V587, P98, DOI 10.1038/s41586-020-2856-x; Talbot NA, 2014, MOL CELL ENDOCRINOL, V393, P129, DOI 10.1016/j.mce.2014.06.010; Tessaro FHG, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/568408; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; van den Elzen P, 2005, NATURE, V437, P906, DOI 10.1038/nature04001; van Eijkeren RJ, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00479; van Eijkeren RJ, 2018, IMMUNOLOGY, V153, P179, DOI 10.1111/imm.12839; Ververs FA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01192; Vijay J, 2020, NAT METAB, V2, P97, DOI 10.1038/s42255-019-0152-6; Vijayakumar A, 2017, CELL REP, V21, P1021, DOI 10.1016/j.celrep.2017.09.091; Vishvanath L, 2019, J CLIN INVEST, V129, P4022, DOI 10.1172/JCI129191; Wang HD, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11270-1; Wang Q, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02509; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yeh YS, 2018, ISCIENCE, V9, P175, DOI 10.1016/j.isci.2018.10.019; Zmora N, 2017, CELL METAB, V25, P506, DOI 10.1016/j.cmet.2017.02.006	108	0	0	5	18	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 28	2021	11								598566	10.3389/fimmu.2020.598566	http://dx.doi.org/10.3389/fimmu.2020.598566			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QF3JJ	33584664	gold, Green Published			2022-12-18	WOS:000616794000001
J	Wang, GH; Chai, Q; Xiao, YJ; Peng, WY; Teng, M; Wang, JY; Lin, HQ; Su, XF; Wu, L				Wang, Guihua; Chai, Qin; Xiao, Yajie; Peng, Wenying; Teng, Miao; Wang, Jingyi; Lin, Hanqing; Su, Xiaofan; Wu, Lin			Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers	FRONTIERS IN IMMUNOLOGY			English	Article						large cell lung carcinoma; PD-L1 expression; tumor mutational burden; CD8(+) tumor-infiltrating lymphocytes; chemo-immunotherapy; predictive biomarker		Immune checkpoint inhibitors have revolutionized the treatments of lung cancers, and multiple predictive biomarkers alone or in combination help clinicians with the appropriate therapeutic selections. Recently, chemo-immunotherapy has been recommended for treating advanced non-small cell lung cancers in patients without driver mutations. However, the clinical relevance of predictive biomarkers and the treatment efficacy of chemo-immunotherapy in large cell lung carcinoma (LCLC) remain unclear. Here, we reported a rare case of LCLC with none driver gene mutations and low values of multiple predictive biomarkers. These biomarkers included a low PD-L1 expression of 5-10%, a low tumor mutational burden (TMB) of 2.5 muts/mb, a low CD8(+) tumor-infiltrating lymphocyte density of 147.91 psc/mm(2). After one-cycle chemotherapy, the patient progressed rapidly and then was switched to pembrolizumab combining paclitaxel plus cisplatin. Interestingly, he achieved a partial response after two cycles of chemo-immunotherapy, showing multiple lymph nodes obviously shrunk on CT scan, and other clinical symptoms were relieved when compared with the baseline findings. After five cycles of chemo-immunotherapy, this advanced patient still benefited and was changed to maintenance immunotherapy monotherapy. This case suggests that chemo-immunotherapy may provide an effective therapeutic option for those LCLC patients with low values of multiple predictive biomarkers, particularly for those who progressed from first-line classical treatments.	[Wang, Guihua; Chai, Qin] Changsha Cent Hosp, Dept Oncol, Changsha, Peoples R China; [Xiao, Yajie; Teng, Miao; Lin, Hanqing; Su, Xiaofan] YuceBio Technol Co Ltd, Shenzhen, Peoples R China; [Peng, Wenying; Wang, Jingyi; Wu, Lin] Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Dept Thorac Oncol 2,Xiangya Sch Med, Changsha, Peoples R China; [Peng, Wenying] Yunnan Canc Hosp, Dept Oncol 2, Kunming, Yunnan, Peoples R China	Central South University	Wu, L (corresponding author), Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Dept Thorac Oncol 2,Xiangya Sch Med, Changsha, Peoples R China.	wulin-calf@vip.163.com	Wang, Jin/GYA-2019-2022; WANG, JINGYI/GSJ-1241-2022; wang, jing/GVT-8700-2022	XIAO, Yajie/0000-0002-0954-267X	Hunan Cancer Hospital Climb Plan [ZX2020005-5]; Hunan Province Health Commission Foundation	Hunan Cancer Hospital Climb Plan; Hunan Province Health Commission Foundation	This study was kindly funded by Hunan Cancer Hospital Climb Plan (NO. ZX2020005-5) and Hunan Province Health Commission Foundation (NO.B2019090).	Arbour KC, 2019, JAMA-J AM MED ASSOC, V322, P764, DOI 10.1001/jama.2019.11058; Bassanelli M, 2018, ANTICANCER RES, V38, P3789, DOI 10.21873/anticanres.12662; Brambilla E, 2001, EUR RESPIR J, V18, P1059, DOI 10.1183/09031936.01.00275301; Camidge DR, 2019, NAT REV CLIN ONCOL, V16, P341, DOI 10.1038/s41571-019-0173-9; Chan AW, 2019, J THORAC ONCOL, V14, P1213, DOI 10.1016/j.jtho.2019.03.021; Chan TA, 2019, ANN ONCOL, V30, P44, DOI 10.1093/annonc/mdy495; Duffy MJ, 2019, CLIN CHEM, V65, P1228, DOI 10.1373/clinchem.2019.303644; Galluzzi L, 2015, CANCER CELL, V28, P690, DOI 10.1016/j.ccell.2015.10.012; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Han Y, 2020, ANN PALLIAT MED, V9, P3705, DOI 10.21037/apm-20-1667; Hu-Lieskovan S, 2019, CLIN CANCER RES, V25, P5061, DOI 10.1158/1078-0432.CCR-18-4275; Jiang T, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0762-1; Koomen BM, 2020, HISTOPATHOLOGY, V76, P793, DOI 10.1111/his.14040; Langer CJ, 2016, LANCET ONCOL, V17, P1497, DOI 10.1016/S1470-2045(16)30498-3; Mauclet C, 2019, LUNG CANCER, V128, P53, DOI 10.1016/j.lungcan.2018.12.006; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Meng XJ, 2019, CLIN LUNG CANCER, V20, P48, DOI 10.1016/j.cllc.2018.09.012; Mok TSK, 2019, LANCET, V393, P1819, DOI 10.1016/S0140-6736(18)32409-7; Ock CY, 2016, CLIN CANCER RES, V22, P2261, DOI 10.1158/1078-0432.CCR-15-2834; Osipov A, 2020, CLIN CANCER RES, V26, P4842, DOI 10.1158/1078-0432.CCR-20-0458; Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865; Peng J, 2015, CANCER RES, V75, P5034, DOI 10.1158/0008-5472.CAN-14-3098; Prasad V, 2020, ANN ONCOL, V31, P1112, DOI 10.1016/j.annonc.2020.07.001; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Samstein RM, 2019, NAT GENET, V51, P202, DOI 10.1038/s41588-018-0312-8; Schulze AB, 2020, J THORAC DIS, V12, P1824, DOI 10.21037/jtd-19-3414a; Shen X, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k3529; Subbiah V, 2020, ANN ONCOL, V31, P1115, DOI 10.1016/j.annonc.2020.07.002; Teng MWL, 2015, CANCER RES, V75, P2139, DOI 10.1158/0008-5472.CAN-15-0255; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Tsao MS, 2018, J THORAC ONCOL, V13, P1302, DOI 10.1016/j.jtho.2018.05.013; Wang VE, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0281-y; Yu YF, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.6879	33	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 28	2021	11								607416	10.3389/fimmu.2020.607416	http://dx.doi.org/10.3389/fimmu.2020.607416			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QF3OE	33584678	Green Published, gold			2022-12-18	WOS:000616806500001
J	Duhan, V; Khairnar, V; Kitanovski, S; Hamdan, TA; Klein, AD; Lang, J; Ali, M; Adomati, T; Bhat, H; Friedrich, SK; Li, FH; Krebs, P; Futerman, AH; Addo, MM; Hardt, C; Hoffmann, D; Lang, PA; Lang, KS				Duhan, Vikas; Khairnar, Vishal; Kitanovski, Simo; Hamdan, Thamer A.; Klein, Andres D.; Lang, Judith; Ali, Murtaza; Adomati, Tom; Bhat, Hilal; Friedrich, Sarah-Kim; Li, Fanghui; Krebs, Philippe; Futerman, Anthony H.; Addo, Marylyn M.; Hardt, Cornelia; Hoffmann, Daniel; Lang, Philipp A.; Lang, Karl S.			Integrin Alpha E (CD103) Limits Virus-Induced IFN-I Production in Conventional Dendritic Cells	FRONTIERS IN IMMUNOLOGY			English	Article						GWAS; genome wide association screen; Itgae; CD103; vesicular stomatitis virus; IFN-I; AKT; mTOR		Early and strong production of IFN-I by dendritic cells is important to control vesicular stomatitis virus (VSV), however mechanisms which explain this cell-type specific innate immune activation remain to be defined. Here, using a genome wide association study (GWAS), we identified Integrin alpha-E (Itgae, CD103) as a new regulator of antiviral IFN-I production in a mouse model of vesicular stomatitis virus (VSV) infection. CD103 was specifically expressed by splenic conventional dendritic cells (cDCs) and limited IFN-I production in these cells during VSV infection. Mechanistically, CD103 suppressed AKT phosphorylation and mTOR activation in DCs. Deficiency in CD103 accelerated early IFN-I in cDCs and prevented death in VSV infected animals. In conclusion, CD103 participates in regulation of cDC specific IFN-I induction and thereby influences immune activation after VSV infection.	[Duhan, Vikas; Khairnar, Vishal; Hamdan, Thamer A.; Lang, Judith; Ali, Murtaza; Adomati, Tom; Bhat, Hilal; Friedrich, Sarah-Kim; Li, Fanghui; Hardt, Cornelia; Lang, Karl S.] Univ Duisburg Essen, Inst Immunol, Med Fac, Essen, Germany; [Duhan, Vikas] QIMR Berghofer Med Res Inst, Immunol Canc & Infect Lab, Herston, Qld, Australia; [Khairnar, Vishal] Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA; [Kitanovski, Simo; Hoffmann, Daniel] Univ Duisburg Essen, Fac Biol, Bioinformat & Computat Biophys, Essen, Germany; [Hamdan, Thamer A.] Amer Univ Madaba, Fac Hlth Sci, Dept Med Labs, Amman, Jordan; [Klein, Andres D.; Futerman, Anthony H.] Weizmann Inst Sci, Dept Biomol Sci, Rehovot, Israel; [Klein, Andres D.] Univ Desarrollo, Ctr Genet & Genom, Clin Alemana Santiago, Santiago, Chile; [Bhat, Hilal] Univ Cologne, Univ Hosp Cologne, Ctr Mol Med Cologne, Cologne, Germany; [Krebs, Philippe] Univ Bern, Inst Pathol, Bern, Switzerland; [Addo, Marylyn M.] Univ Med Ctr Hamburg Eppendorf, Div Infect Dis, Dept Med 1, Hamburg, Germany; [Addo, Marylyn M.] Partner Site Hamburg Lubeck Borstel Riemse, German Ctr Infect Res, Hamburg, Germany; [Addo, Marylyn M.] Bernhard Nocht Inst Trop Med, Dept Clin Immunol Infect Dis, Hamburg, Germany; [Lang, Philipp A.] Heinrich Heine Univ Dusseldorf, Fac Med, Dept Mol Med 2, Dusseldorf, Germany	University of Duisburg Essen; QIMR Berghofer Medical Research Institute; Harvard University; Dana-Farber Cancer Institute; University of Duisburg Essen; Weizmann Institute of Science; Clinica Alemana; Universidad del Desarrollo; University of Cologne; University of Bern; University of Hamburg; University Medical Center Hamburg-Eppendorf; German Center for Infection Research; Bernhard Nocht Institut fur Tropenmedizin; Heinrich Heine University Dusseldorf	Duhan, V; Lang, KS (corresponding author), Univ Duisburg Essen, Inst Immunol, Med Fac, Essen, Germany.; Duhan, V (corresponding author), QIMR Berghofer Med Res Inst, Immunol Canc & Infect Lab, Herston, Qld, Australia.	vikas.duhan08@gmail.com; karlsebastian.lang@uk-essen.de	Addo, Marylyn M./GNP-2548-2022; Hoffmann, Daniel/P-5624-2019; Krebs, Philippe/A-3449-2012; Duhan, Vikas/J-7163-2019; Khairnar, Vishal/AAM-3008-2020	Hoffmann, Daniel/0000-0003-2973-7869; Krebs, Philippe/0000-0003-4918-6654; Duhan, Vikas/0000-0002-6337-8225; Khairnar, Vishal/0000-0002-3584-7530; KLEIN, ANDRES/0000-0002-9951-2174	Deutsche Forschungsgemeinschaft (DFG) [LA1419/7-1, LA1419/10-1, LA1558/5-1, 715 SI1558/3-1]; Jurgen Manchot Foundation (MOI); FONDECYT [1180337];  [Sonderforschungsbereich SFB974];  [Transregio TRR60];  [RTG1949/1];  [RTG2098]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Jurgen Manchot Foundation (MOI); FONDECYT(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); ; ; ; 	This study was funded by Deutsche Forschungsgemeinschaft (DFG) grants LA1419/7-1, LA1419/10-1, LA1558/5-1, and 715 SI1558/3-1. This study was further supported by the Sonderforschungsbereich SFB974, the Transregio TRR60, and the Research Training Groups RTG1949/1 and RTG2098, the Jurgen Manchot Foundation (MOI) and FONDECYT 1180337.	Agnandji ST, 2016, NEW ENGL J MED, V374, P1647, DOI 10.1056/NEJMoa1502924; Anz D, 2011, INT J CANCER, V129, P2417, DOI 10.1002/ijc.25902; Bao MS, 2013, PROTEIN CELL, V4, P40, DOI 10.1007/s13238-012-2104-8; Bronson PG, 2012, CURR OPIN IMMUNOL, V24, P530, DOI 10.1016/j.coi.2012.07.008; Cao WP, 2008, NAT IMMUNOL, V9, P1157, DOI 10.1038/ni.1645; Carpenter B, 2017, J STAT SOFTW, V76, P1, DOI 10.18637/jss.v076.i01; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; Colonna M, 2007, EUR J IMMUNOL, V37, P306, DOI 10.1002/eji.200637009; Diebold SS, 2003, NATURE, V424, P324, DOI 10.1038/nature01783; Garrigan K, 1996, BLOOD, V88, P3508, DOI 10.1182/blood.V88.9.3508.bloodjournal8893508; Haller O, 2007, BIOCHIMIE, V89, P812, DOI 10.1016/j.biochi.2007.04.015; HWANG SY, 1995, P NATL ACAD SCI USA, V92, P11284, DOI 10.1073/pnas.92.24.11284; Ivanov S, 2012, J INFECT DIS, V206, P723, DOI 10.1093/infdis/jis413; Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581; Kang HM, 2008, GENETICS, V178, P1709, DOI 10.1534/genetics.107.080101; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kaur S, 2008, P NATL ACAD SCI USA, V105, P4808, DOI 10.1073/pnas.0710907105; Kirby A, 2010, GENETICS, V185, P1081, DOI 10.1534/genetics.110.115014; Klein AD, 2016, CELL REP, V16, P2546, DOI 10.1016/j.celrep.2016.07.085; Le Floc'h A, 2007, J EXP MED, V204, P559, DOI 10.1084/jem.20061524; Le Floc'h A, 2011, CANCER RES, V71, P328, DOI 10.1158/0008-5472.CAN-10-2457; Lee HK, 2007, SCIENCE, V315, P1398, DOI 10.1126/science.1136880; Moltedo B, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002345; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Muzaki ARBM, 2016, MUCOSAL IMMUNOL, V9, P336, DOI 10.1038/mi.2015.64; Na YR, 2016, MOL CELLS, V39, P734, DOI 10.14348/molcells.2016.0160; Pantel A, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001759; Pauls K, 2001, J INVEST DERMATOL, V117, P569, DOI 10.1046/j.0022-202x.2001.01481.x; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; ROBERTS WK, 1976, NATURE, V264, P477, DOI 10.1038/264477a0; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Schabbauer G, 2008, MOL IMMUNOL, V45, P2790, DOI 10.1016/j.molimm.2008.02.001; Schneider WM, 2014, ANNU REV IMMUNOL, V32, P513, DOI 10.1146/annurev-immunol-032713-120231; Schon MP, 2000, J IMMUNOL, V165, P6583, DOI 10.4049/jimmunol.165.11.6583; Shaabani N, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.350; Shekhar S, 2020, CELL MOL IMMUNOL, V17, P670, DOI 10.1038/s41423-020-0397-8; Silverman RH, 2007, J VIROL, V81, P12720, DOI 10.1128/JVI.01471-07; Spanier J, 2014, J IMMUNOL, V193, P3045, DOI 10.4049/jimmunol.1400959; Sun QM, 2006, IMMUNITY, V24, P633, DOI 10.1016/j.immuni.2006.04.004; Swiecki M, 2010, IMMUNITY, V33, P955, DOI 10.1016/j.immuni.2010.11.020; Takaki H, 2018, MUCOSAL IMMUNOL, V11, P82, DOI 10.1038/mi.2017.48; Teijaro JR, 2013, SCIENCE, V340, P207, DOI 10.1126/science.1235214; Uematsu S, 2007, J BIOL CHEM, V282, P15319, DOI 10.1074/jbc.R700009200; Van den Bossche J, 2012, BLOOD, V119, P1623, DOI 10.1182/blood-2011-10-384289; Van Prooyen N, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005749; Weichhart T, 2008, ANN RHEUM DIS, V67, P70, DOI 10.1136/ard.2008.098459; Yeon SH, 2015, IMMUNOLOGY, V144, P312, DOI 10.1111/imm.12373	47	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 27	2021	11								607889	10.3389/fimmu.2020.607889	http://dx.doi.org/10.3389/fimmu.2020.607889			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QE9NB	33584680	gold, Green Published			2022-12-18	WOS:000616529200001
J	Piconese, S; Walker, LSK; Dominguez-Villar, M				Piconese, Silvia; Walker, Lucy S. K.; Dominguez-Villar, Margarita			Editorial: Control of Regulatory T Cell Stability, Plasticity, and Function in Health and Disease	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						regulatory T cell (T reg); plasticity; autoimmunity; cancer; metabolism	TH1-LIKE TREG GENERATION; INSTABILITY		[Piconese, Silvia] Sapienza Univ Rome, Dept Internal Clin Sci Anaesthesiol & Cardiovasc, Rome, Italy; [Piconese, Silvia] Ist Pasteur Italia, Fdn Cenci Bolognetti, Lab, Rome, Italy; [Walker, Lucy S. K.] UCL, Inst Immun & Transplantat, Div Infect & Immun, Royal Free Campus, London, England; [Dominguez-Villar, Margarita] Imperial Coll London, Fac Med, Dept Infect Dis, London, England	Sapienza University Rome; Fondazione Cenci Bolognetti; University of London; University College London; Imperial College London	Dominguez-Villar, M (corresponding author), Imperial Coll London, Fac Med, Dept Infect Dis, London, England.	m.dominguez-villar@imperial.ac.uk						Bailey-Bucktrout SL, 2013, IMMUNITY, V39, P949, DOI 10.1016/j.immuni.2013.10.016; Chaudhary B, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4030028; Dominguez-Villar M, 2018, NAT IMMUNOL, V19, P665, DOI 10.1038/s41590-018-0120-4; Dominguez-Villar M, 2011, NAT MED, V17, P673, DOI 10.1038/nm.2389; Huynh A, 2015, NAT IMMUNOL, V16, P188, DOI 10.1038/ni.3077; Kitz A, 2017, CELL MOL LIFE SCI, V74, P4059, DOI 10.1007/s00018-017-2569-y; Kitz A, 2016, EMBO REP, V17, P1169, DOI 10.15252/embr.201541905; Lucca LE, 2020, NAT REV IMMUNOL, V20, P680, DOI 10.1038/s41577-020-0296-3; McClymont SA, 2011, J IMMUNOL, V186, P3918, DOI 10.4049/jimmunol.1003099; Pacella I, 2018, P NATL ACAD SCI USA, V115, pE6546, DOI 10.1073/pnas.1720113115; Panduro M, 2016, ANNU REV IMMUNOL, V34, P609, DOI 10.1146/annurev-immunol-032712-095948; Sakaguchi S, 2020, ANNU REV IMMUNOL, V38, P541, DOI 10.1146/annurev-immunol-042718-041717; Zhou XY, 2009, NAT IMMUNOL, V10, P1000, DOI 10.1038/ni.1774	13	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 27	2021	11								611591	10.3389/fimmu.2020.611591	http://dx.doi.org/10.3389/fimmu.2020.611591			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QE9PD	33584690	gold, Green Published			2022-12-18	WOS:000616534600001
J	Zhang, RL; Feng, S; Xie, XC; Huang, ZD; Wan, Q; Wang, SM; Zhang, Z				Zhang, Ruiling; Feng, Shuo; Xie, Xiaochen; Huang, Zhendong; Wan, Qing; Wang, Shumin; Zhang, Zhong			Dysbacteriosis of the Intestinal Flora Is an Important Reason for the Death of Adult House Flies Caused by Beauveria bassiana	FRONTIERS IN IMMUNOLOGY			English	Article						Beauveria bassiana; Musca domestica; intestinal flora; dysbacteriosis; pathogenic fungi		Beauveria bassiana is one of the most widespread insect pathogens and can be used in the biological control of agricultural, forestry and medical pests. The mechanisms by which B. bassiana leads to mortality in different host insects are also different. For house flies, B. bassiana has strong virulence, but its microecological mechanism is not clear. In this paper, the virulence of three strains of B. bassiana (TB, CB and BB) isolated from different hosts to house flies was studied. The results showed that the three strains of B. bassiana had strong pathogenicity to house fly adults. Specifically, TB was the strongest, CB was the second strongest, and BB was the weakest, with maximum lethal effects on house fly populations 5, 6, and 7 days after infection, respectively. Further study showed that the intestinal flora of house flies was disordered 3, 4, and 5 days after B. bassiana TB, CB and BB strain infection, respectively. Intestinal flora dysbacteriosis may be an important reason for the death of house flies caused by B. bassiana. After infection, the negative interaction ratio of bacteria in the house fly intestine decreased, and the stronger the virulence was, the lower the negative interaction ratio was. The time from B. bassiana infection to intestinal flora dysbacteriosis was not fixed. We named this period the "spring stage". The stronger the virulence of the B. bassiana strain was, the shorter the "spring stage" was. Therefore, the "spring stage" can be used as a virulence marker for evaluating the pathogenicity of different B. bassiana strains.	[Zhang, Ruiling; Feng, Shuo; Xie, Xiaochen; Huang, Zhendong; Wan, Qing; Zhang, Zhong] Shandong First Med Univ & Shandong Acad Med Sci, Collaborat Innovat Ctr Origin & Control Emerging, Tai An, Shandong, Peoples R China; [Zhang, Ruiling; Feng, Shuo; Xie, Xiaochen; Huang, Zhendong; Wan, Qing; Wang, Shumin; Zhang, Zhong] Shandong First Med Univ & Shandong Acad Med Sci, Sch Basic Med Sci, Tai An, Shandong, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences	Zhang, Z (corresponding author), Shandong First Med Univ & Shandong Acad Med Sci, Collaborat Innovat Ctr Origin & Control Emerging, Tai An, Shandong, Peoples R China.; Wang, SM; Zhang, Z (corresponding author), Shandong First Med Univ & Shandong Acad Med Sci, Sch Basic Med Sci, Tai An, Shandong, Peoples R China.	wshmfly@163.com; nasonia@163.com			National Natural Science Foundation of China [81572028, 81871686]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (nos. 81572028 and 81871686). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbas N, 2015, NEOTROP ENTOMOL, V44, P402, DOI 10.1007/s13744-015-0290-9; Akami M, 2019, BMC MICROBIOL, V19, DOI 10.1186/s12866-019-1607-3; Anderson RD, 2011, J INVERTEBR PATHOL, V107, P179, DOI 10.1016/j.jip.2011.04.004; Apiwathnasorn C, 2012, SE ASIAN J TROP MED, V43, P48; Bokulich NA, 2013, NAT METHODS, V10, P57, DOI [10.1038/NMETH.2276, 10.1038/nmeth.2276]; Boucias D, 2016, J INVERTEBR PATHOL, V136, P100, DOI 10.1016/j.jip.2016.03.013; Boucias DG, 2018, APPL MICROBIOL BIOT, V102, P5873, DOI 10.1007/s00253-018-9089-z; Burgess ER, 2018, J MED ENTOMOL, V55, P1237, DOI 10.1093/jme/tjy083; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; DILLON RJ, 1986, J INVERTEBR PATHOL, V47, P350, DOI 10.1016/0022-2011(86)90106-0; Dillon RJ, 2000, NATURE, V403, P851, DOI 10.1038/35002669; DILLON RJ, 1995, J INVERTEBR PATHOL, V66, P72, DOI 10.1006/jipa.1995.1063; Edgar RC, 2013, NAT METHODS, V10, P996, DOI [10.1038/NMETH.2604, 10.1038/nmeth.2604]; Farooq M, 2016, BRAZ J MICROBIOL, V47, P807, DOI 10.1016/j.bjm.2016.06.002; Graczyk TK, 2001, MICROBES INFECT, V3, P231, DOI 10.1016/S1286-4579(01)01371-5; Heiden SE, 2020, ANTIMICROB RESIST IN, V9, DOI 10.1186/s13756-020-0696-y; Hosokawa T, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2015.11, 10.1038/nmicrobiol.2015.11]; Huang ZD, 2019, EXP APPL ACAROL, V77, P83, DOI 10.1007/s10493-018-0329-9; Johnson DM, 2019, J MED ENTOMOL, V56, P774, DOI 10.1093/jme/tjy218; Khamesipour F, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5934-3; Khan HAA, 2019, PEST MANAG SCI, V75, P2969, DOI 10.1002/ps.5409; Li X, 2020, WATER RES, V177, DOI 10.1016/j.watres.2020.115769; Maccollom GB, 2009, ENVIRON ENTOMOL, V38, P116, DOI 10.1603/022.038.0114; Machtinger ET, 2016, BIOCONTROL SCI TECHN, V26, P1444, DOI 10.1080/09583157.2016.1210085; Machtinger ET, 2016, J INSECT SCI, V16, DOI 10.1093/jisesa/iew032; Malik A, 2007, J ENVIRON SCI HEAL B, V42, P453, DOI 10.1080/03601230701316481; MILLER RW, 1993, J AGR ENTOMOL, V10, P189; Mishra Sapna, 2017, Journal of Parasitic Diseases, V41, P543, DOI 10.1007/s12639-016-0848-4; Mishra Sapna, 2015, Journal of Parasitic Diseases, V39, P697, DOI 10.1007/s12639-013-0408-0; Mishra S, 2011, PARASITOL RES, V108, P1483, DOI 10.1007/s00436-010-2203-5; Park R, 2019, MICROBIOME, V7, DOI 10.1186/s40168-019-0748-9; Robacker DC, 2004, J CHEM ECOL, V30, P1329, DOI 10.1023/B:JOEC.0000037743.98703.43; Smith CC, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00801; STEINKRAUS DC, 1990, J MED ENTOMOL, V27, P309, DOI 10.1093/jmedent/27.3.309; Sukontason K, 2000, J VECTOR ECOL, V25, P114; Tan SQ, 2021, INSECT SCI, V28, P347, DOI 10.1111/1744-7917.12776; Walterson AM, 2015, FEMS MICROBIOL REV, V39, P968, DOI 10.1093/femsre/fuv027; Wan Qing, 2020, Zhongguo Meijieshengwuxue Ji Kongzhi Zazhi, V31, P36, DOI 10.11853/j.issn.1003.8280.2020.01.008; Wanchoo A, 2009, MICROBIOL-SGM, V155, P3121, DOI 10.1099/mic.0.029157-0; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Wang SB, 2012, P NATL ACAD SCI USA, V109, P12734, DOI 10.1073/pnas.1204158109; WATSON DW, 1995, BIOL CONTROL, V5, P405, DOI 10.1006/bcon.1995.1048; Watson DW, 1996, BIOL CONTROL, V7, P221, DOI 10.1006/bcon.1996.0087; Weeks ENI, 2017, MED VET ENTOMOL, V31, P15, DOI 10.1111/mve.12201; Wei G, 2017, P NATL ACAD SCI USA, V114, P5994, DOI 10.1073/pnas.1703546114; Wu MH, 2014, J INSECT SCI, V14, DOI 10.1093/jis/14.1.129; Zhang F, 2018, PEST MANAG SCI, V74, P438, DOI 10.1002/ps.4726; Zhang J., 2018, SCI SERICULT, V44, P678; Zhou FY, 2019, PEST MANAG SCI, V75, P170, DOI 10.1002/ps.5084	50	0	0	6	21	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 26	2021	11								589338	10.3389/fimmu.2020.589338	http://dx.doi.org/10.3389/fimmu.2020.589338			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QE5TA	33574812	Green Published, gold			2022-12-18	WOS:000616268400001
J	Lacroix-Desmazes, S; Pratt, KP				Lacroix-Desmazes, Sebastien; Pratt, Kathleen P.			Editorial: Tolerating Factor VIII: Novel Strategies to Prevent and Reverse Neutralizing Anti-FVIII Antibodies	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						factor VIII; protein immunogenicity; hemophilia A; immune tolerance induction; anti-drug antibodies	HEMOPHILIA-A; INHIBITORS		[Lacroix-Desmazes, Sebastien] Univ Paris, Sorbonne Univ, INSERM, Ctr Rech Cordeliers, Paris, France; [Pratt, Kathleen P.] Uniformed Serv Univ Hlth Sci, Dept Med, Room A3060, Bethesda, MD 20814 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Uniformed Services University of the Health Sciences - USA	Lacroix-Desmazes, S (corresponding author), Univ Paris, Sorbonne Univ, INSERM, Ctr Rech Cordeliers, Paris, France.; Pratt, KP (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Med, Room A3060, Bethesda, MD 20814 USA.	sebastien.lacroix-desmazes@crc.jussieu.fr; Kathleen.pratt@usuhs.edu		Pratt, Kathleen/0000-0001-6837-6133	Grifols, Inc.; NIH [R01 HL 130448, R01 HL 126727B, IAAA-A-HL-007.001]; INSERM; Agence Nationale de la Recherche [ANR-10-BLAN-1118, ANR-18-CE17-0010]; European Community [859974 EDUC8]; Centre National de la Recherche Scientifique; Sorbonne Universite (Paris, France)	Grifols, Inc.; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Agence Nationale de la Recherche(French National Research Agency (ANR)); European Community(European Commission); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Sorbonne Universite (Paris, France)	Publication charges for this collection were subsidized by an unrestricted, investigator-initiated educational grant from Grifols, Inc. to KP. KP is also funded by NIH R01 HL 130448, R01 HL 126727B, and IAAA-A-HL-007.001 to the Collaborative Health Sciences Research Program of the Uniformed Services University of the Health Sciences. Grifols was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. SL-D is supported by INSERM, Centre National de la Recherche Scientifique and Sorbonne Universite '(Paris, France) and by grants from Agence Nationale de la Recherche (ANR-10-BLAN-1118 and ANR-18-CE17-0010) and from the European Community (H2020-MSCA-ITN-2019 project 859974 EDUC8).	Aledort L, 2019, BLOOD TRANSFUS-ITALY, V17, P479, DOI 10.2450/2019.0211-19; Astermark J, 2007, BLOOD, V109, P546, DOI 10.1182/blood-2006-04-017988; Bournazos S, 2017, ANNU REV IMMUNOL, V35, P285, DOI 10.1146/annurev-immunol-051116-052433; D'Angiolella LS, 2018, EUR J HAEMATOL, V101, P435, DOI 10.1111/ejh.13108; Dimitrov JD, 2013, J IMMUNOL, V191, P993, DOI 10.4049/jimmunol.1300880; EHRENFORTH S, 1992, LANCET, V339, P594, DOI 10.1016/0140-6736(92)90874-3; Flajnik MF, 2018, NAT REV IMMUNOL, V18, P438, DOI 10.1038/s41577-018-0003-9; Hay CRM, 2012, BLOOD, V119, P1335, DOI 10.1182/blood-2011-08-369132; Heyman B, 2000, ANNU REV IMMUNOL, V18, P709, DOI 10.1146/annurev.immunol.18.1.709; Kitazawa T, 2012, NAT MED, V18, P1570, DOI 10.1038/nm.2942; Leissinger C, 2011, NEW ENGL J MED, V365, P1684, DOI 10.1056/NEJMoa1104435; Lu LL, 2018, NAT REV IMMUNOL, V18, P46, DOI 10.1038/nri.2017.106; Rocino A, 2017, J CLIN MED, V6, DOI 10.3390/jcm6040046; Schroeder HW, 2010, J ALLERGY CLIN IMMUN, V125, pS41, DOI 10.1016/j.jaci.2009.09.046; van den Berg HM, 2020, THROMB HAEMOSTASIS, V120, P1166, DOI 10.1055/s-0040-1713097; Walshl CE, 2016, THROMB HAEMOSTASIS, V116, pS10, DOI 10.1160/TH16-01-0049; Weyand AC, 2019, BLOOD, V133, P389, DOI 10.1182/blood-2018-08-872291	17	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 25	2021	11								639386	10.3389/fimmu.2020.639386	http://dx.doi.org/10.3389/fimmu.2020.639386			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QD9BP	33569066	Green Published, gold			2022-12-18	WOS:000615805600001
J	Portoles, JM; Jimenez, C; Janeiro, D; Lopez-Oliva, MO; Ortega-Carrion, A; Blanquez, D; Arribas, L; Gomez, C; Diez, T; Pascual, J; Portero, I				Portoles, Jose Maria; Jimenez, Carlos; Janeiro, Dario; Lopez-Oliva, Maria O.; Ortega-Carrion, Alvaro; Blanquez, Daniel; Arribas, Luis; Gomez, Carlos; Diez, Teresa; Pascual, Julio; Portero, Isabel			The Immunobiogram, a Novel In Vitro Assay to Evaluate Treatment Resistance in Patients Receiving Immunosuppressive Therapy	FRONTIERS IN IMMUNOLOGY			English	Article						cellular pharmacodynamics; immune cell assay; immunosuppressive therapy monitoring; transplant rejection; personalized medicine	SENSITIVITY	Immunosuppressive drugs are widely used to treat several autoimmune disorders and prevent rejection after organ transplantation. However, intra-individual variations in the pharmacological response to immunosuppressive therapy critically influence its efficacy, often resulting in poor treatment responses and serious side effects. Effective diagnostic tools that help clinicians to tailor immunosuppressive therapy to the needs and immunological profile of the individual patient thus constitute a major unmet clinical need. In vitro assays that measure immune cell responses to immunosuppressive drugs constitute a promising approach to individualized immunosuppressive therapy. Here, we present the Immunobiogram, a functional pharmacodynamic immune cell-based assay for simultaneous quantitative measurement of a patient's immune response to a battery of immunosuppressive drugs. Peripheral blood mononuclear cells collected from patients are immunologically stimulated to induce activation and proliferation and embedded in a hydrogel mixture in which they are exposed to a concentration gradient of the immunosuppressants of interest. Analysis of samples from kidney transplant patients using this procedure revealed an association between the sensitivity of individual patients to the immunosuppressive regimen and their immunological risk of transplant rejection. Incorporation of the Immunobiogram assay into clinical settings could greatly facilitate personalized optimization and monitoring of immunosuppressive therapy, and study of the mechanisms underlying resistance to immunosuppressants.	[Portoles, Jose Maria; Janeiro, Dario] Hosp Univ Puerta Hierro, Dept Nephrol, Madrid, Spain; [Portoles, Jose Maria; Jimenez, Carlos; Janeiro, Dario; Lopez-Oliva, Maria O.; Pascual, Julio] Inst Salud Carlos III, Res Net REDInREN 016 0009, Madrid, Spain; [Jimenez, Carlos; Lopez-Oliva, Maria O.] Hosp La Paz, Dept Nephrol, Madrid, Spain; [Ortega-Carrion, Alvaro; Gomez, Carlos; Diez, Teresa; Portero, Isabel] BIOHOPE Sci SL, Dept R D, Madrid, Spain; [Blanquez, Daniel; Arribas, Luis] Adamas Engn Consulting, Madrid, Spain; [Pascual, Julio] Hosp Mar, Inst Mar Med Res, Dept Nephrol, Barcelona, Spain	Hospital Puerta de Hierro-Majadahonda; Instituto de Salud Carlos III; Hospital Universitario La Paz; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar	Portoles, JM (corresponding author), Hosp Univ Puerta Hierro, Dept Nephrol, Madrid, Spain.; Portoles, JM (corresponding author), Inst Salud Carlos III, Res Net REDInREN 016 0009, Madrid, Spain.; Portero, I (corresponding author), BIOHOPE Sci SL, Dept R D, Madrid, Spain.	josem.portoles@salud.madrid.org; isabel.portero@biohope.eu	Portoles, Jose/C-3337-2013	Portoles, Jose/0000-0002-2114-1385; Lopez-Oliva, Maria Ovidia/0000-0003-3503-3518; Diez, Teresa/0000-0001-7649-8907; Portero Sanchez, Isabel/0000-0003-4770-8332	European Commission [733248]	European Commission(European CommissionEuropean Commission Joint Research Centre)	Research was funded by a competitive grant from the European Commission (SME Instrument - Phase II), Project: TRANSBIO (Id 733248) "Cellular BIOtechnology for prognosis and monitoring in renal TRANSplantation" (https://cordis.europa.eu/project/id/733248).	ALVAREZ J, 1992, J ALLERGY CLIN IMMUN, V89, P714, DOI 10.1016/0091-6749(92)90379-G; Baker BM, 2012, J CELL SCI, V125, P3015, DOI 10.1242/jcs.079509; Bergmann TK, 2012, CLIN PHARMACOKINET, V51, P711, DOI 10.1007/s40262-012-0007-8; Braun F, 2006, EXPERT OPIN INV DRUG, V15, P267, DOI 10.1517/13543784.15.3.267; Charfeddine K, 2005, TRANSPL P, V37, P2823, DOI 10.1016/j.transproceed.2005.05.009; Choi J, 2019, CLIN LAB MED, V39, P643, DOI 10.1016/j.cll.2019.07.010; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1016, DOI 10.1164/ajrccm/144.5.1016; Danger R, 2016, EUR J IMMUNOL, V46, P2695, DOI 10.1002/eji.201545963; Davidova Natalya V, 2002, Russ J Immunol, V7, P335; de la Zerda A, 2018, APL BIOENG, V2, DOI 10.1063/1.5006599; Doan T, 2005, J CLIN PHARMACOL, V45, P751, DOI 10.1177/0091270005277938; Eckardt KU, 2009, AM J TRANSPLANT, V9, pS1, DOI 10.1111/j.1600-6143.2009.02834.x; FRANCIS DMA, 1988, TRANSPLANTATION, V46, P853, DOI 10.1097/00007890-198812000-00012; Hirano T, 1998, CLIN PHARMACOL THER, V63, P465, DOI 10.1016/S0009-9236(98)90042-X; Hirano T, 2007, INT IMMUNOPHARMACOL, V7, P3, DOI 10.1016/j.intimp.2006.09.020; Hui KL, 2015, MOL BIOL CELL, V26, P685, DOI 10.1091/mbc.E14-03-0830; Husson J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019680; Jouve T, 2019, EXPERT OPIN DRUG SAF, V18, P285, DOI 10.1080/14740338.2019.1599858; Kalamasz D, 2004, J IMMUNOTHER, V27, P405, DOI 10.1097/00002371-200409000-00010; Kihara Y, 2009, CELL TRANSPLANT, V18, P639, DOI 10.1177/096368970901805-620; Kumar R, 2019, INFECT DIS CLIN N AM, V33, P1143, DOI 10.1016/j.idc.2019.05.008; Kurata Y, 2009, CLIN PHARMACOL THER, V86, P285, DOI 10.1038/clpt.2009.61; Kushihara H, 2016, BIOL PHARM BULL, V39, P1085, DOI 10.1248/bpb.b15-00690; Kuypers DRJ, 2005, TRANSPL INT, V18, P140, DOI 10.1111/j.1432-2277.2004.00041.x; Muhetaer G, 2014, CLIN THER, V36, P1264, DOI 10.1016/j.clinthera.2014.06.019; Murakami N, 2014, AM J TRANSPLANT, V14, P2317, DOI 10.1111/ajt.12852; Nam K, 2004, INT J PHARMACEUT, V275, P259, DOI 10.1016/j.ijpharm.2004.02.009; Neurauter AA, 2007, ADV BIOCHEM ENG BIOT, V106, P41, DOI 10.1007/10_2007_072; Pascual J, 2019, TRANSPLANT REV-ORLAN, V33, P191, DOI 10.1016/j.trre.2019.07.001; Ponticelli C, 2019, J NEPHROL, V32, P851, DOI 10.1007/s40620-019-00602-5; Ramamoorthy S, 2013, ENDOCR DEV, V24, P41, DOI 10.1159/000342502; Ritz C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0146021; Staatz CE, 2014, ARCH TOXICOL, V88, P1351, DOI 10.1007/s00204-014-1247-1; Stout DA, 2015, JOVE-J VIS EXP, DOI 10.3791/52948; Sugiyama K, 2006, J IMMUNOASS IMMUNOCH, V27, P195, DOI 10.1080/15321810600595443; Sugiyama K, 2011, INT J CLIN PHARM TH, V49, P145, DOI 10.5414/CPP49145; Takeuchi H, 2015, CELL MED, V7, P51, DOI 10.3727/215517914X681802; Tonelli M, 2011, AM J TRANSPLANT, V11, P2093, DOI 10.1111/j.1600-6143.2011.03686.x; Ventura-Aguiar P, 2016, EXPERT OPIN DRUG SAF, V15, P303, DOI 10.1517/14740338.2016.1132698; Wiseman AC, 2016, CLIN J AM SOC NEPHRO, V11, P332, DOI 10.2215/CJN.08570814; Yang Xue-Qin, 2018, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V26, P1765, DOI 10.7534/j.issn.1009-2137.2018.06.031; Yu M, 2018, CURR DRUG METAB, V19, P513, DOI 10.2174/1389200219666180129151948; Zaza G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02978	43	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 25	2021	11								618202	10.3389/fimmu.2020.618202	http://dx.doi.org/10.3389/fimmu.2020.618202			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QD9DA	33569062	Green Published, gold			2022-12-18	WOS:000615809300001
J	Wiening, V; Schmidt, T; Dahmen, M; Siam, S; Reuter, S; Pavenstadt, HJ; Sester, M; Suwelack, B				Wiening, Vanessa; Schmidt, Tina; Dahmen, Maximilian; Siam, Sami; Reuter, Stefan; Pavenstadt, Hermann-Joseph; Sester, Martina; Suwelack, Barbara			Case Report: Management of a Multidrug-Resistant CMV-Strain in a Renal Transplant Recipient by High-Dose CMV-Specific Immunoglobulins, Modulation in Immunosuppression, and Induction of CMV-Specific Cellular Immunity	FRONTIERS IN IMMUNOLOGY			English	Article						multidrug-resistant cytomegalovirus; high dose immunoglobulins; renal transplant; case report; cytomegalovirus-specific cellular immunity		The management of multidrug-resistant strains of cytomegalovirus after solid organ transplantation is challenging. This case report demonstrates the successful treatment of a multidrug-resistant strain of cytomegalovirus that may represent a valuable option for problematic cases. This report illustrates the emergence of a multidrug-resistant cytomegalovirus (CMV) UL54 mutant strain in a renal transplant recipient with severe lymphopenia and thrombocytopenia. We show that the combined treatment with high-dose intravenous cytomegalovirus-specific immunoglobulins (CMV-IVIG) after the switch to a mammalian target of rapamycin (mTOR)-inhibitor and cyclosporine A was a successful treatment alternative to direct antiviral treatment with high-dose ganciclovir and foscarnet. This treatment was associated with a quantitative induction of CMV-specific CD4 and CD8 T cells that showed maturation in phenotype and functionality with decreasing viral load. Our case report illustrates that high-dose CMV-IVIG and conversion of immunosuppressive drugs to mTOR inhibitors and cyclosporine A can be a successful treatment in a situation where the use of direct antiviral drugs was considered insufficient.	[Wiening, Vanessa; Dahmen, Maximilian; Siam, Sami; Reuter, Stefan; Pavenstadt, Hermann-Joseph; Suwelack, Barbara] Westphalian Wilhelms Univ Munster, Univ Hosp Munster, Transplant Nephrol Dept Internal Med D, Munster, Germany; [Schmidt, Tina; Sester, Martina] Saarland Univ, Dept Transplant & Infect Immunol, Homburg, Germany; [Dahmen, Maximilian] Univ Hosp Munster, Clin Child & Adolescent Psychiat Psychosomat & Ps, Munster, Germany	University of Munster; Universitatsklinikum des Saarlandes; University of Munster	Suwelack, B (corresponding author), Westphalian Wilhelms Univ Munster, Univ Hosp Munster, Transplant Nephrol Dept Internal Med D, Munster, Germany.	Barbara.Suwelack@ukmuenster.de	Sester, Martina/AAA-3383-2022					Eiz-Vesper B, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00410; Ferrer IR, 2011, AM J TRANSPLANT, V11, P654, DOI 10.1111/j.1600-6143.2011.03473.x; Ferrer IR, 2010, J IMMUNOL, V185, P2004, DOI 10.4049/jimmunol.1001176; Fleming JN, 2017, TRANSPL INFECT DIS, V19, DOI 10.1111/tid.12779; Gurkan S, 2010, AM J TRANSPLANT, V10, P2132, DOI 10.1111/j.1600-6143.2010.03210.x; Havenith SHC, 2013, TRANSPLANTATION, V95, P184, DOI 10.1097/TP.0b013e318276a1ef; Jarque M, 2020, CLIN INFECT DIS, V71, P2375, DOI 10.1093/cid/ciz1209; Jarque M, 2018, TRANSPLANTATION, V102, pE472, DOI 10.1097/TP.0000000000002421; Kaminski H, 2020, MICROBIOL IMMUNOL, V64, P520, DOI 10.1111/1348-0421.12794; Kaminski H, 2019, J INFECT DIS, V220, P761, DOI 10.1093/infdis/jiz194; Kotton CN, 2018, TRANSPLANTATION, V102, P900, DOI 10.1097/TP.0000000000002191; Lepore M, 2021, TRANSPL INFECT DIS, V23, DOI 10.1111/tid.13495; Maertens J, 2019, NEW ENGL J MED, V381, P1136, DOI 10.1056/NEJMoa1714656; Nashan B, 2012, TRANSPLANTATION, V93, P1075, DOI 10.1097/TP.0b013e31824810e6; Sabe N, 2012, TRANSPL INT, V25, pe78, DOI 10.1111/j.1432-2277.2012.01489.x; Schmidt T, 2013, METHODS MOL BIOL, V1064, P267, DOI 10.1007/978-1-62703-601-6_19; Scott GM, 2007, ANTIMICROB AGENTS CH, V51, P89, DOI 10.1128/AAC.00633-06; Sester M, 2016, AM J TRANSPLANT, V16, P1697, DOI 10.1111/ajt.13684; Sester U, 2008, AM J TRANSPLANT, V8, P1486, DOI 10.1111/j.1600-6143.2008.02279.x; Sommerer C, 2019, KIDNEY INT, V96, P231, DOI 10.1016/j.kint.2019.01.041; Stoelben S, 2014, TRANSPL INT, V27, P77, DOI 10.1111/tri.12225; Tedesco-Silva H, 2015, AM J TRANSPLANT, V15, P2655, DOI 10.1111/ajt.13327; Tha-In T, 2008, TRENDS IMMUNOL, V29, P608, DOI 10.1016/j.it.2008.08.004; Tischer S, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0336-5; Walker S, 2007, TRANSPL INFECT DIS, V9, P165, DOI 10.1111/j.1399-3062.2006.00199.x	25	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 25	2021	11								623178	10.3389/fimmu.2020.623178	http://dx.doi.org/10.3389/fimmu.2020.623178			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QD9CA	33569064	Green Published, gold			2022-12-18	WOS:000615806700001
J	Chen, YCE; Burgess, M; Mapp, S; Mollee, P; Gill, D; Blumenthal, A; Saunders, NA				Chen, Yu-Chen Enya; Burgess, Melinda; Mapp, Sally; Mollee, Peter; Gill, Devinder; Blumenthal, Antje; Saunders, Nicholas A.			SIRP alpha Suppresses Response to Therapeutic Antibodies by Nurse Like Cells From Chronic Lymphocytic Leukemia Patients	FRONTIERS IN IMMUNOLOGY			English	Article						nurse-like-cells; chronic lymphocytic leukemia; macrophages; antibody dependent phagocytosis; antibody resistance 2; macrophage		Targeted antibody therapies improve outcomes for chronic lymphocytic leukemia (CLL) patients. However, resistance often develops. We have previously shown that resistance to therapeutic antibodies, by monocyte derived macrophages (referred to as nurse like cells, NLCs), from CLL patients is characterized by suppression of antibody dependent phagocytosis (ADP). The mechanism(s) contributing to the muted ADP responses remain unresolved. In this regard, an innate immune checkpoint was recently described that uses the CD47:SIRP alpha axis to suppress phagocytic responses by macrophages. In this study we examine whether the SIRP alpha axis regulates ADP responses to the anti-CD20 antibody, obinutuzumab, by NLCs. Using siRNA depletion strategies we show that SIRP alpha is a suppressor of ADP responses. Moreover, we show that this innate immune checkpoint contributes to the resistance phenotype in NLCs derived from CLL patients. Finally, we show that SIRP alpha suppression is mediated via the phosphatase, Shp1, which in turn suppresses SYK-dependent activation of ADP. Thus, we identify a druggable pathway that could be exploited to enhance sensitivity to existing therapeutic antibodies used in CLL. This is the first study to show that activation of the CD47:SIRP alpha innate immune checkpoint contributes to ADP resistance in NLCs from CLL patients.	[Chen, Yu-Chen Enya; Burgess, Melinda; Blumenthal, Antje; Saunders, Nicholas A.] Univ Queensland, Diamantina Inst, Woolloongabba, Qld, Australia; [Burgess, Melinda; Mapp, Sally; Mollee, Peter; Gill, Devinder] Princess Alexandra Hosp, Dept Haematol, Canc Serv Unit, Woolloongabba, Qld, Australia; [Mapp, Sally; Saunders, Nicholas A.] Univ Queensland, Sch Med, Translat Res Inst, Woolloongabba, Qld, Australia	University of Queensland; University of Queensland	Saunders, NA (corresponding author), Univ Queensland, Diamantina Inst, Woolloongabba, Qld, Australia.; Saunders, NA (corresponding author), Univ Queensland, Sch Med, Translat Res Inst, Woolloongabba, Qld, Australia.	nsaunders@uq.edu.au		Chen, Yu Chen Enya/0000-0003-4223-5054				Advani R, 2018, NEW ENGL J MED, V379, P1711, DOI 10.1056/NEJMoa1807315; Barclay AN, 2006, NAT REV IMMUNOL, V6, P457, DOI 10.1038/nri1859; Betancur PA, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14802; Bewarder N, 1996, MOL CELL BIOL, V16, P4735; Bosch F, 2020, LEUKEMIA, V34, P441, DOI 10.1038/s41375-019-0554-1; Burger JA, 2000, BLOOD, V96, P2655; Burgess M, 2020, ONCOGENE, V39, P5756, DOI 10.1038/s41388-020-01394-w; Burgess M, 2017, ONCOGENE, V36, P2366, DOI 10.1038/onc.2016.387; Burgess M, 2020, LEUKEMIA LYMPHOMA, V61, P2738, DOI 10.1080/10428194.2020.1775211; Cabrales P, 2019, TRANSL ONCOL, V12, P626, DOI 10.1016/j.tranon.2018.12.001; Chao MP, 2011, CANCER RES, V71, P1374, DOI 10.1158/0008-5472.CAN-10-2238; Chao MP, 2010, CELL, V142, P699, DOI 10.1016/j.cell.2010.07.044; Chen J, 2017, NATURE, V544, P493, DOI 10.1038/nature22076; Chen YCE, 2017, BBA-REV CANCER, V1868, P176, DOI 10.1016/j.bbcan.2017.03.006; Chen YCE, 2020, LEUKEMIA, V34, P451, DOI 10.1038/s41375-019-0556-z; Church AK, 2016, CLIN EXP IMMUNOL, V183, P90, DOI 10.1111/cei.12697; Feng MY, 2019, NAT REV CANCER, V19, P568, DOI 10.1038/s41568-019-0183-z; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Goede V, 2013, LEUKEMIA, V27, P1172, DOI 10.1038/leu.2012.252; Goede V, 2015, DRUG AGING, V32, P877, DOI 10.1007/s40266-015-0308-3; Gul N, 2014, J CLIN INVEST, V124, P812, DOI 10.1172/JCI66776; Hallek M, 2018, BLOOD, V131, P2745, DOI 10.1182/blood-2017-09-806398; Hogarth PM, 2012, NAT REV DRUG DISCOV, V11, P311, DOI 10.1038/nrd2909; Kant AM, 2002, BLOOD, V100, P1852; KELTON JG, 1985, BLOOD, V66, P490; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kiefer F, 1998, MOL CELL BIOL, V18, P4209, DOI 10.1128/MCB.18.7.4209; Kundu S, 2010, J IMMUNOL, V184, P6529, DOI 10.4049/jimmunol.0903562; Lefebvre ML, 2006, J IMMUNOTHER, V29, P388, DOI 10.1097/01.cji.0000203081.43235.d7; Li Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14102-4; Moogk D, 2016, J IMMUNOL, V197, P644, DOI 10.4049/jimmunol.1600178; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Okazawa H, 2005, J IMMUNOL, V174, P2004, DOI 10.4049/jimmunol.174.4.2004; Oldenborg PA, 2001, J EXP MED, V193, P855, DOI 10.1084/jem.193.7.855; Piccione EC, 2016, CLIN CANCER RES, V22, P5109, DOI 10.1158/1078-0432.CCR-15-2503; Pirich Theo, 2018, Oncotarget, V9, P29944, DOI 10.18632/oncotarget.25714; Ribas A, 2015, CANCER DISCOV, V5, P915, DOI 10.1158/2159-8290.CD-15-0563; Roghanian A, 2015, CANCER CELL, V27, P473, DOI 10.1016/j.ccell.2015.03.005; Sobota A, 2005, J IMMUNOL, V175, P4450, DOI 10.4049/jimmunol.175.7.4450; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; Tsukada N, 2002, BLOOD, V99, P1030, DOI 10.1182/blood.V99.3.1030; van Mirre E, 2004, J IMMUNOL, V173, P332, DOI 10.4049/jimmunol.173.1.332; VanDerMeid KR, 2018, CANCER IMMUNOL RES, V6, P1150, DOI 10.1158/2326-6066.CIR-18-0319; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; Weiskopf K, 2015, MABS-AUSTIN, V7, P303, DOI 10.1080/19420862.2015.1011450; Wierda WG, 2019, J NATL COMPR CANC NE, V17, P12, DOI 10.6004/jnccn.2019.0002; Woyach JA, 2019, BLOOD, V134, P1796, DOI 10.1182/blood.2019001321; Ysebaert L, 2011, LEUKEMIA LYMPHOMA, V52, P1404, DOI 10.3109/10428194.2011.568078; Zhang WT, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00018	49	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 21	2021	11								610523	10.3389/fimmu.2020.610523	http://dx.doi.org/10.3389/fimmu.2020.610523			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QB8KV	33552071	Green Published, gold			2022-12-18	WOS:000614387100001
J	Ngwa, DN; Singh, SK; Agrawal, A				Ngwa, Donald N.; Singh, Sanjay K.; Agrawal, Alok			C-Reactive Protein-Based Strategy to Reduce Antibiotic Dosing for the Treatment of Pneumococcal Infection	FRONTIERS IN IMMUNOLOGY			English	Article						C-reactive protein; clarithromycin; pneumococcal infection; Streptococcus pneumoniae; combination therapy		C-reactive protein (CRP) is a component of innate immunity. The concentration of CRP in serum increases in microbial infections including Streptococcus pneumoniae infection. Employing a mouse model of pneumococcal infection, it has been shown that passively administered human wild-type CRP protects mice against infection, provided that CRP is injected into mice within two hours of administering pneumococci. Engineered CRP (E-CRP) molecules have been reported recently; unlike wild-type CRP, passively administered E-CRP protected mice against infection even when E-CRP was injected into mice after twelve hours of administering pneumococci. The current study was aimed at comparing the protective capacity of E-CRP with that of an antibiotic clarithromycin. We established a mouse model of pneumococcal infection in which both E-CRP and clarithromycin, when used alone, provided minimal but equal protection against infection. In this model, the combination of E-CRP and clarithromycin drastically reduced bacteremia and increased survival of mice when compared to the protective effects of either E-CRP or clarithromycin alone. E-CRP was more effective in reducing bacteremia in mice treated with clarithromycin than in untreated mice. Also, there was 90% reduction in antibiotic dosing by including E-CRP in the antibiotic-treatment for maximal protection of infected mice. These findings provide an example of cooperation between the innate immune system and molecules that prevent multiplication of bacteria, and that should be exploited to develop novel combination therapies for infections against multidrug-resistant pneumococci. The reduction in antibiotic dosing by including E-CRP in the combination therapy might also resolve the problem of developing antibiotic resistance.	[Ngwa, Donald N.; Singh, Sanjay K.; Agrawal, Alok] East Tennessee State Univ, Dept Biomed Sci, James H Quillen Coll Med, Johnson City, TN 37614 USA	East Tennessee State University	Agrawal, A (corresponding author), East Tennessee State Univ, Dept Biomed Sci, James H Quillen Coll Med, Johnson City, TN 37614 USA.	agrawal@etsu.edu			National Institutes of Health [AR068787, AI117730, AI151561]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the National Institutes of Health grants AR068787, AI117730. and AI151561.	Agrawal A, 2005, MOL IMMUNOL, V42, P927, DOI 10.1016/j.molimm.2004.09.028; Alvarez-Elcoro S, 1999, MAYO CLIN PROC, V74, P613, DOI 10.4065/74.6.613; Caballero J, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-48; Ejim L, 2011, NAT CHEM BIOL, V7, P348, DOI [10.1038/NCHEMBIO.559, 10.1038/nchembio.559]; Gang TB, 2015, INFECT IMMUN, V83, P1845, DOI 10.1128/IAI.03058-14; Gang TB, 2012, J BIOL CHEM, V287, P43116, DOI 10.1074/jbc.M112.427310; Giamarellos-Bourboulis EJ, 2004, ANTIMICROB AGENTS CH, V48, P93, DOI 10.1128/AAC.48.1.93-99.2004; Hammond DJ, 2010, J BIOL CHEM, V285, P36235, DOI 10.1074/jbc.M110.142026; Ianaro A, 2000, J PHARMACOL EXP THER, V292, P156; KAKEGAWA T, 1990, Chemotherapy, V38, P317; KAPLAN MH, 1974, J IMMUNOL, V112, P2135; LIU TY, 1963, J BIOL CHEM, V238, P1928; Majhi A, 2014, ANTIMICROB AGENTS CH, V58, P5164, DOI 10.1128/AAC.03245-14; Martinez JA, 2003, CLIN INFECT DIS, V36, P389, DOI 10.1086/367541; Mold C, 2002, J IMMUNOL, V168, P6375, DOI 10.4049/jimmunol.168.12.6375; MOLD C, 1981, J EXP MED, V154, P1703, DOI 10.1084/jem.154.5.1703; NAKAYAMA S, 1983, CLIN EXP IMMUNOL, V54, P319; Ngwa DN, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.586669; Ngwa DN, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00166; Pathak A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01780; Ramos-Sevillano E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044135; Schneider EK, 2017, ESSAYS BIOCHEM, V61, P115, DOI 10.1042/EBC20160058; Shrive AK, 1996, NAT STRUCT BIOL, V3, P346, DOI 10.1038/nsb0496-346; Simons JP, 2014, IMMUNOLOGY, V142, P414, DOI 10.1111/imm.12266; Singh SK, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01812; Singh SK, 2017, J BIOL CHEM, V292, P3129, DOI 10.1074/jbc.M116.773176; Singh SK, 2012, J BIOL CHEM, V287, P3550, DOI 10.1074/jbc.M111.310011; Suresh MV, 2007, J IMMUNOL, V178, P1158, DOI 10.4049/jimmunol.178.2.1158; Suresh MV, 2006, J IMMUNOL, V176, P4369, DOI 10.4049/jimmunol.176.7.4369; Szalai AJ, 1996, INFECT IMMUN, V64, P4850, DOI 10.1128/IAI.64.11.4850-4853.1996; SZALAI AJ, 1995, J IMMUNOL, V155, P2557; Tessier PR, 2002, ANTIMICROB AGENTS CH, V46, P1425, DOI 10.1128/AAC.46.5.1425-1434.2002; Thompson D, 1999, STRUCTURE, V7, P169, DOI 10.1016/S0969-2126(99)80023-9; VOLANAKI.JE, 1971, P SOC EXP BIOL MED, V136, P612; VOLANAKIS JE, 1982, ANN NY ACAD SCI, V389, P235, DOI 10.1111/j.1749-6632.1982.tb22140.x; Waterer GW, 2005, EUR J CLIN MICROBIOL, V24, P691, DOI 10.1007/s10096-005-0019-5; Worthington RJ, 2013, TRENDS BIOTECHNOL, V31, P177, DOI 10.1016/j.tibtech.2012.12.006; Yanagihara K, 2000, CLIN EXP IMMUNOL, V122, P67, DOI 10.1046/j.1365-2249.2000.01343.x; YOTHER J, 1982, J IMMUNOL, V128, P2374; Yuste J, 2001, J ANTIMICROB CHEMOTH, V48, P594, DOI 10.1093/jac/48.4.594; Zuckerman JM, 2000, INFECT DIS CLIN N AM, V14, P449, DOI 10.1016/S0891-5520(05)70257-9	41	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 20	2021	11								620784	10.3389/fimmu.2020.620784	http://dx.doi.org/10.3389/fimmu.2020.620784			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QB3VI	33552084	Green Published, gold			2022-12-18	WOS:000614069500001
J	Johnson, DK; Magoffin, W; Myers, SJ; Finnell, JG; Hancock, JC; Orton, TS; Persaud, SP; Christensen, KA; Weber, KS				Johnson, Deborah K.; Magoffin, Wyatt; Myers, Sheldon J.; Finnell, Jordan G.; Hancock, John C.; Orton, Taylor S.; Persaud, Stephen P.; Christensen, Kenneth A.; Weber, K. Scott			CD4 Inhibits Helper T Cell Activation at Lower Affinity Threshold for Full-Length T Cell Receptors Than Single Chain Signaling Constructs	FRONTIERS IN IMMUNOLOGY			English	Article						CD4; T cell receptor; affinity; chimeric antigen receptor; Lck; helper T cell	TELOMERASE PEPTIDE VACCINATION; RECOGNITION SPECIFICITY; CRYSTAL-STRUCTURE; TERNARY COMPLEX; PHASE-I/II; ALPHA-BETA; TCR-ALPHA; IN-VITRO; ANTIGEN; MHC	CD4(+) T cells are crucial for effective repression and elimination of cancer cells. Despite a paucity of CD4(+) T cell receptor (TCR) clinical studies, CD4(+) T cells are primed to become important therapeutics as they help circumvent tumor antigen escape and guide multifactorial immune responses. However, because CD8(+) T cells directly kill tumor cells, most research has focused on the attributes of CD8(+) TCRs. Less is known about how TCR affinity and CD4 expression affect CD4(+) T cell activation in full length TCR (flTCR) and TCR single chain signaling (TCR-SCS) formats. Here, we generated an affinity panel of TCRs from CD4(+) T cells and expressed them in flTCR and three TCR-SCS formats modeled after chimeric antigen receptors (CARs) to understand the contributions of TCR-pMHCII affinity, TCR format, and coreceptor CD4 interactions on CD4(+) T cell activation. Strikingly, the coreceptor CD4 inhibited intermediate and high affinity TCR-construct activation by Lck-dependent and -independent mechanisms. These inhibition mechanisms had unique affinity thresholds dependent on the TCR format. Intracellular construct formats affected the tetramer staining for each TCR as well as IL-2 production. IL-2 production was promoted by increased TCR-pMHCII affinity and the flTCR format. Thus, CD4(+) T cell therapy development should consider TCR affinity, CD4 expression, and construct format.	[Johnson, Deborah K.; Magoffin, Wyatt; Myers, Sheldon J.; Hancock, John C.; Orton, Taylor S.; Weber, K. Scott] Brigham Young Univ, Dept Microbiol & Mol Biol, Provo, UT 84602 USA; [Finnell, Jordan G.; Christensen, Kenneth A.] Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA; [Persaud, Stephen P.] Washington Univ, Div Lab & Genom Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Brigham Young University; Brigham Young University; Washington University (WUSTL)	Weber, KS (corresponding author), Brigham Young Univ, Dept Microbiol & Mol Biol, Provo, UT 84602 USA.	scott_weber@byu.edu	Johnson, Deborah K/AAK-3809-2021; Weber, Scott/O-1022-2014	Weber, Scott/0000-0003-3688-2191; Persaud, Stephen/0000-0002-7733-5509; Hancock, John/0000-0002-7747-7814	R15 grant from the National Institutes of Health [R0102063]; Simmons Center for Cancer Research Summer Fellowships; Brigham Young University	R15 grant from the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Simmons Center for Cancer Research Summer Fellowships; Brigham Young University	This work was supported by a R15 grant toKW(R0102063) from the National Institutes of Health, Simmons Center for Cancer Research Summer Fellowships and Graduate Student Fellowship grants at Brigham Young University to DJ.	Aggen DH, 2012, GENE THER, V19, P365, DOI 10.1038/gt.2011.104; Aleksic M, 2012, EUR J IMMUNOL, V42, P3174, DOI 10.1002/eji.201242606; [Anonymous], 2019, CLIN TRANSL IMMUNOL, DOI DOI 10.1158/1078-0432.Ccr-18-2559; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; Benatuil L, 2010, PROTEIN ENG DES SEL, V23, P155, DOI 10.1093/protein/gzq002; Bendle GM, 2010, NAT MED, V16, P565, DOI 10.1038/nm.2128; Bonnard M, 1999, J IMMUNOL, V162, P1252; Borst J, 2018, NAT REV IMMUNOL, V18, P635, DOI 10.1038/s41577-018-0044-0; Bowerman NA, 2009, MOL IMMUNOL, V46, P3000, DOI 10.1016/j.molimm.2009.06.012; Brunsvig PF, 2006, CANCER IMMUNOL IMMUN, V55, P1553, DOI 10.1007/s00262-006-0145-7; Brunsvig PF, 2011, CLIN CANCER RES, V17, P6847, DOI 10.1158/1078-0432.CCR-11-1385; Chao G, 2006, NAT PROTOC, V1, P755, DOI 10.1038/nprot.2006.94; Chervin AS, 2009, J IMMUNOL, V183, P7639, DOI 10.4049/jimmunol.0901664; Chlewicki LK, 2005, J MOL BIOL, V346, P223, DOI 10.1016/j.jmb.2004.11.057; Corse E, 2011, J IMMUNOL, V186, P5039, DOI 10.4049/jimmunol.1003650; Corse E, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000481; da Silva DG, 2016, BLOOD, V128; Daniels MA, 2006, NATURE, V444, P724, DOI 10.1038/nature05269; Deniger DC, 2016, MOL THER, V24, P1078, DOI 10.1038/mt.2016.51; Donermeyer DL, 2006, J IMMUNOL, V177, P6911, DOI 10.4049/jimmunol.177.10.6911; Filipp D, 2004, MOL IMMUNOL, V41, P645, DOI 10.1016/j.molimm.2004.04.011; Fragoso R, 2003, J IMMUNOL, V170, P913, DOI 10.4049/jimmunol.170.2.913; Gai SA, 2007, CURR OPIN STRUC BIOL, V17, P467, DOI 10.1016/j.sbi.2007.08.012; Garrido F, 2010, INT J CANCER, V127, P249, DOI 10.1002/ijc.25270; Gascoigne NRJ, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00072; Ghorashian S, 2019, NAT MED, V25, P1408, DOI 10.1038/s41591-019-0549-5; Glassman CR, 2018, CELL REP, V22, P1263, DOI 10.1016/j.celrep.2017.12.104; Gros A, 2016, NAT MED, V22, P433, DOI 10.1038/nm.4051; Haga-Friedman A, 2012, J IMMUNOL, V188, P5538, DOI 10.4049/jimmunol.1103020; Harris DT, 2018, J IMMUNOL, V200, P1088, DOI 10.4049/jimmunol.1700236; Harris DT, 2016, STRUCTURE, V24, P1142, DOI 10.1016/j.str.2016.04.011; Harris DT, 2016, TRENDS PHARMACOL SCI, V37, P220, DOI 10.1016/j.tips.2015.11.004; HAUGHN L, 1992, NATURE, V358, P328, DOI 10.1038/358328a0; Hebeisen M, 2013, J CLIN INVEST, V123, P1044, DOI 10.1172/JCI65325; Holler PD, 2000, P NATL ACAD SCI USA, V97, P5387, DOI 10.1073/pnas.080078297; Holler PD, 2003, IMMUNITY, V18, P255, DOI 10.1016/S1074-7613(03)00019-0; Holst J, 2006, NAT PROTOC, V1, P406, DOI 10.1038/nprot.2006.61; Horkova V, 2020, CELL REP, V30, P1504, DOI 10.1016/j.celrep.2020.01.008; Huang J, 2013, IMMUNITY, V39, P846, DOI 10.1016/j.immuni.2013.08.036; Inderberg EM, 2020, CANCER IMMUNOL IMMUN, V69, P859, DOI 10.1007/s00262-019-02468-9; Irvine DJ, 2002, NATURE, V419, P845, DOI 10.1038/nature01076; Irving M, 2012, J BIOL CHEM, V287, P23068, DOI 10.1074/jbc.M112.357673; James JR, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aan1088; Jiang N, 2011, IMMUNITY, V34, P13, DOI 10.1016/j.immuni.2010.12.017; Kalergis AM, 2001, NAT IMMUNOL, V2, P229, DOI 10.1038/85286; Kersh GJ, 1998, IMMUNITY, V9, P817, DOI 10.1016/S1074-7613(00)80647-0; KILLEEN N, 1993, NATURE, V364, P729, DOI 10.1038/364729a0; Kim JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018556; Knies D, 2016, ONCOTARGET, V7, P21199, DOI 10.18632/oncotarget.8385; Kofler DM, 2011, MOL THER, V19, P760, DOI 10.1038/mt.2011.9; Krogsgaard M, 2003, MOL CELL, V12, P1367, DOI 10.1016/S1097-2765(03)00474-X; Kyte JA, 2011, CLIN CANCER RES, V17, P4568, DOI 10.1158/1078-0432.CCR-11-0184; Laugel B, 2007, J BIOL CHEM, V282, P23799, DOI 10.1074/jbc.M700976200; Long AH, 2015, NAT MED, V21, P581, DOI 10.1038/nm.3838; Love PE, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002485; Lu YC, 2017, J CLIN ONCOL, V35, P3322, DOI 10.1200/JCO.2017.74.5463; Mandl JN, 2013, IMMUNITY, V38, P263, DOI 10.1016/j.immuni.2012.09.011; Matsuzaki J, 2015, SCI REP-UK, V5, DOI 10.1038/srep14896; McMahan RH, 2006, J CLIN INVEST, V116, P2543, DOI 10.1172/JCI26936; Mensali N, 2019, EBIOMEDICINE, V40, P106, DOI 10.1016/j.ebiom.2019.01.031; Midelfort KS, 2004, J MOL BIOL, V343, P685, DOI 10.1016/j.jmb.2004.08.019; MORITZ D, 1994, P NATL ACAD SCI USA, V91, P4318, DOI 10.1073/pnas.91.10.4318; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; Parrish HL, 2016, P NATL ACAD SCI USA, V113, P3000, DOI 10.1073/pnas.1518499113; Parrish HL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132333; Persaud SP, 2014, NAT IMMUNOL, V15, P266, DOI 10.1038/ni.2822; Persaud SP, 2010, MOL IMMUNOL, V47, P1793, DOI 10.1016/j.molimm.2010.02.013; Presotto D, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01564; Quezada SA, 2010, J EXP MED, V207, P637, DOI 10.1084/jem.20091918; Ramos CA, 2018, MOL THER, V26, P2727, DOI 10.1016/j.ymthe.2018.09.009; Richman Sarah A., 2009, V504, P323, DOI 10.1007/978-1-60327-569-9_19; Richman SA, 2009, MOL IMMUNOL, V46, P902, DOI 10.1016/j.molimm.2008.09.021; Riquelme E, 2009, EUR J IMMUNOL, V39, P2259, DOI 10.1002/eji.200939341; Robbins PF, 2008, J IMMUNOL, V180, P6116, DOI 10.4049/jimmunol.180.9.6116; Salter AI, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aat6753; Savage PA, 1999, IMMUNITY, V10, P485, DOI 10.1016/S1074-7613(00)80048-5; Schmid DA, 2010, J IMMUNOL, V184, P4936, DOI 10.4049/jimmunol.1000173; Sebestyen Z, 2008, J IMMUNOL, V180, P7736, DOI 10.4049/jimmunol.180.11.7736; Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601.141107; Stepanek O, 2014, CELL, V159, P333, DOI 10.1016/j.cell.2014.08.042; Stone JD, 2014, CANCER IMMUNOL IMMUN, V63, P1163, DOI 10.1007/s00262-014-1586-z; Stone JD, 2012, METHOD ENZYMOL, V503, P189, DOI 10.1016/B978-0-12-396962-0.00008-2; Suso EMI, 2011, CANCER IMMUNOL IMMUN, V60, P809, DOI 10.1007/s00262-011-0991-9; Tan MP, 2017, CLIN EXP IMMUNOL, V187, P124, DOI 10.1111/cei.12828; Tavano R, 2006, NAT CELL BIOL, V8, P1270, DOI 10.1038/ncb1492; Thomas S, 2011, BLOOD, V118, P319, DOI 10.1182/blood-2010-12-326736; Tian S, 2007, J IMMUNOL, V179, P2952, DOI 10.4049/jimmunol.179.5.2952; van der Merwe PA, 2011, IMMUNITY, V34, P1, DOI 10.1016/j.immuni.2011.01.001; van der Merwe PA, 2003, ANNU REV IMMUNOL, V21, P659, DOI 10.1146/annurev.immunol.21.120601.141036; Van Laethem F, 2013, CELL, V154, P1326, DOI 10.1016/j.cell.2013.08.009; Van Laethem F, 2012, TRENDS IMMUNOL, V33, P437, DOI 10.1016/j.it.2012.05.006; Varela-Rohena A, 2008, NAT MED, V14, P1390, DOI 10.1038/nm.1779; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; Viola A, 1997, J EXP MED, V186, P1775, DOI 10.1084/jem.186.10.1775; Voss RH, 2008, J IMMUNOL, V180, P391, DOI 10.4049/jimmunol.180.1.391; Voss RH, 2010, BLOOD, V115, P5154, DOI 10.1182/blood-2009-11-254078; Wang JH, 2001, P NATL ACAD SCI USA, V98, P10799, DOI 10.1073/pnas.191124098; Wang Q, 2001, J EXP MED, V194, P1721, DOI 10.1084/jem.194.12.1721; Weber KS, 2012, P NATL ACAD SCI USA, V109, P9511, DOI 10.1073/pnas.1202408109; Weber KS, 2005, P NATL ACAD SCI USA, V102, P19033, DOI 10.1073/pnas.0507554102; Wei QR, 2020, P NATL ACAD SCI USA, V117, P15809, DOI 10.1073/pnas.1913334117; Weinkove R, 2019, CLIN TRANSL IMMUNOL, V8, DOI 10.1002/cti2.1049; Xie Y, 2010, J EXP MED, V207, P651, DOI 10.1084/jem.20091921; Yin YY, 2012, P NATL ACAD SCI USA, V109, P5405, DOI 10.1073/pnas.1118801109; Zehn D, 2009, NATURE, V458, P211, DOI 10.1038/nature07657; Zhong S, 2013, P NATL ACAD SCI USA, V110, P6973, DOI 10.1073/pnas.1221609110	106	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 19	2021	11								561889	10.3389/fimmu.2020.561889	http://dx.doi.org/10.3389/fimmu.2020.561889			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QA5WT	33542711	gold, Green Published			2022-12-18	WOS:000613516800001
J	Borchers, MT; Lau, GW; Dela Cruz, CS				Borchers, Michael T.; Lau, Gee W.; Dela Cruz, Charles S.			Editorial: Outsmarting the Host: How Bacterial Pathogens Modulate Immune Responses in the Lung	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						bacteria; pathogen; host response; lung; immune response			[Borchers, Michael T.] Univ Cincinnati, Coll Med, Div Pulm Crit Care & Sleep Med, Cincinnati, OH USA; [Borchers, Michael T.] Cincinnati VA Hosp, Dept Vet Affairs, Cincinnati, OH USA; [Lau, Gee W.] Univ Illinois, Dept Pathobiol, Urbana, IL USA; [Dela Cruz, Charles S.] Yale Univ, Ctr Pulm Infect Res & Treatment, Dept Internal Med, New Haven, CT 06520 USA	University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; University of Illinois System; University of Illinois Urbana-Champaign; Yale University	Dela Cruz, CS (corresponding author), Yale Univ, Ctr Pulm Infect Res & Treatment, Dept Internal Med, New Haven, CT 06520 USA.	charles.delacruz@yale.edu			NIH [HL119538, AI080710, HL142626, HL126094]; Veteran's Administration [I01BX002347, I01BX004661]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veteran's Administration(US Department of Veterans Affairs)	This work was funded in part by the support from the NIH (HL119538 to MTB, AI080710 and HL142626 to GWL; and HL126094 to CDC) and the Veteran's Administration (I01BX002347 to MTB and I01BX004661 to CDC).		0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 18	2021	11								629491	10.3389/fimmu.2020.629491	http://dx.doi.org/10.3389/fimmu.2020.629491			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QA2IR	33537037	Green Published, gold			2022-12-18	WOS:000613272500001
J	Eckert, IN; Ribechini, E; Jarick, KJ; Strozniak, S; Potter, SJ; Beilhack, A; Lutz, MB				Eckert, Ina N.; Ribechini, Eliana; Jarick, Katja J.; Strozniak, Sandra; Potter, Sarah J.; Beilhack, Andreas; Lutz, Manfred B.			VLA-1 Binding to Collagen IV Controls Effector T Cell Suppression by Myeloid-Derived Suppressor Cells in the Splenic Red Pulp	FRONTIERS IN IMMUNOLOGY			English	Article						myeloid-derived suppressor cells (MDSCs); T cells; VLA-1; homing; spleen	ALPHA-1-BETA-1 INTEGRIN; EXPRESSION; MONOCYTES; SUBSETS; SPLEEN; SUBPOPULATIONS; IDENTIFICATION; LOCALIZATION; INFILTRATION; LYMPHOCYTES	Myeloid-derived suppressor cells (MDSCs) represent a major population controlling T cell immune responses. However, little is known about their molecular requirements for homing and T cell interaction to mediate suppression. Here, we investigated the functional role of the homing and collagen IV receptor VLA-1 (alpha 1 beta 1-integrin) on in vitro GM-CSF generated murine MDSCs from wild-type (WT) and CD49a/alpha 1-integrin (Itga1 (-/-)) gene-deficient mice. Here, we found that effector (Teff) but not naive (Tn) CD4(+) T cells express VLA-1 and monocytes further up-regulated their expression after culture in GM-CSF when they differentiated into the monocytic subset of resting MDSCs (R-MDSCs). Subsequent activation of R-MDSCs by LPS+IFN-gamma (A-MDSCs) showed increased in vitro suppressor potential, which was independent of VLA-1. Surprisingly, VLA-1 deficiency did not influence A-MDSC motility or migration on collagen IV in vitro. However, interaction times of Itga1 (-/-) A-MDSCs with Teff were shorter than with WT A-MDSCs on collagen IV but not on fibronectin substrate in vitro. After injection, A-MDSCs homed to the splenic red pulp where they co-localized with Teff and showed immediate suppression already after 6 h as shown by inhibition of T cell proliferation and induction of apoptosis. Injection of A-MDSCs from Itga1(-/-) mice showed equivalent homing into the spleen but a reduced suppressive effect. Interaction studies of A-MDSCs with Teff in the subcapsular red pulp with intravital two-photon microscopy revealed also here that MDSC motility and migration parameters were not altered by VLA-1 deficiency, but the interaction times with Teff were reduced. Together, our data point to a new role of VLA-1 adhesion to collagen IV as a prerequisite for extended contact times with Teff required for suppression.	[Eckert, Ina N.; Ribechini, Eliana; Strozniak, Sandra; Potter, Sarah J.; Lutz, Manfred B.] Univ Wurzburg, Inst Virol & Immunobiol, Wurzburg, Germany; [Jarick, Katja J.; Beilhack, Andreas] Univ Hosp Wurzburg, Dept Internal Med 2, Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Lutz, MB (corresponding author), Univ Wurzburg, Inst Virol & Immunobiol, Wurzburg, Germany.	m.lutz@vim.uni-wuerzburg.de		Lutz, Manfred B./0000-0001-9193-1772; Jarick, Katja/0000-0001-5162-7266	DFG [LU851/6-2]; University of Wurzburg	DFG(German Research Foundation (DFG)); University of Wurzburg	This project was supported by the DFG (LU851/6-2) and the University of Wurzburg in the funding programme Open Access Publishing.	Asimakopoulos G, 2000, ANN THORAC SURG, V69, P1192, DOI 10.1016/S0003-4975(99)01553-2; Bajenoff M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011524; Becker HM, 2013, J IMMUNOL, V190, P4305, DOI 10.4049/jimmunol.1202097; Beilhack A, 2005, BLOOD, V106, P1113, DOI 10.1182/blood-2005-02-0509; Ben-Horin S, 2004, CLIN IMMUNOL, V113, P119, DOI 10.1016/j.clim.2004.06.007; BRADLEY LM, 1992, J IMMUNOL, V148, P324; Bronte V, 2013, IMMUNITY, V39, P806, DOI 10.1016/j.immuni.2013.10.010; Chapman TJ, 2010, J IMMUNOL, V184, P3841, DOI 10.4049/jimmunol.0902281; Chopra M, 2013, CARCINOGENESIS, V34, P1296, DOI 10.1093/carcin/bgt038; Conrad C, 2007, NAT MED, V13, P836, DOI 10.1038/nm1605; Cortez-Retamozo V, 2013, IMMUNITY, V38, P296, DOI 10.1016/j.immuni.2012.10.015; Cortez-Retamozo V, 2012, P NATL ACAD SCI USA, V109, P2491, DOI 10.1073/pnas.1113744109; Delano MJ, 2007, J EXP MED, V204, P1463, DOI 10.1084/jem.20062602; Dennis J, 2010, AM J PATHOL, V177, P2527, DOI 10.2353/ajpath.2010.100017; Dorhoi A, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01895; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; Endl E, 2001, METHOD CELL BIOL, V63, P399; Fiorucci S, 2002, IMMUNITY, V17, P769, DOI 10.1016/S1074-7613(02)00476-4; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gardner H, 1996, DEV BIOL, V175, P301, DOI 10.1006/dbio.1996.0116; Gardner H, 2014, ADV EXP MED BIOL, V819, P21, DOI 10.1007/978-94-017-9153-3_2; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Goldstein I, 2003, J CLIN INVEST, V112, P1444, DOI 10.1172/JCI200319607; Greifenberg V, 2009, EUR J IMMUNOL, V39, P2865, DOI 10.1002/eji.200939486; Haile LA, 2010, J IMMUNOL, V185, P203, DOI 10.4049/jimmunol.0903573; HEMLER ME, 1985, EUR J IMMUNOL, V15, P502, DOI 10.1002/eji.1830150515; Hutchinson JA, 2011, METHODS MOL BIOL, V677, P181, DOI 10.1007/978-1-60761-869-0_13; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jung YW, 2010, J IMMUNOL, V185, P5315, DOI 10.4049/jimmunol.1001948; Krieglstein CF, 2002, J CLIN INVEST, V110, P1773, DOI 10.1172/JCI200215256; Lee YS, 2019, INNATE IMMUN-LONDON, V25, P46, DOI 10.1177/1753425918820427; Lesokhin AM, 2012, CANCER RES, V72, P876, DOI 10.1158/0008-5472.CAN-11-1792; LIAKKA A, 1995, CELL TISSUE RES, V282, P117; Lokmic Z, 2008, SEMIN IMMUNOL, V20, P4, DOI 10.1016/j.smim.2007.12.009; Makarenkova VP, 2006, J IMMUNOL, V176, P2085, DOI 10.4049/jimmunol.176.4.2085; Mondanelli G, 2017, CURR OPIN PHARMACOL, V35, P30, DOI 10.1016/j.coph.2017.05.002; Movahedi K, 2008, BLOOD, V111, P4233, DOI 10.1182/blood-2007-07-099226; Pirila L, 1996, J RHEUMATOL, V23, P1691; Ray SJ, 2004, IMMUNITY, V20, P167, DOI 10.1016/S1074-7613(04)00021-4; Ribechini E, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.128664; Ribechini E, 2017, BLOOD ADV, V1, P947, DOI 10.1182/bloodadvances.2017006858; Roberts AI, 1999, IMMUNOLOGY, V97, P679; Rossner S, 2005, EUR J IMMUNOL, V35, P3533, DOI 10.1002/eji.200526172; RUBIO MA, 1995, EUR J IMMUNOL, V25, P2701, DOI 10.1002/eji.1830250945; Sevko A, 2012, J IMMUNOTOXICOL, V9, P275, DOI 10.3109/1547691X.2012.655343; Siracusa F, 2019, EUR J IMMUNOL, V49, P966, DOI 10.1002/eji.201847982; STEMME S, 1992, ARTERIOSCLER THROMB, V12, P206, DOI 10.1161/01.ATV.12.2.206; Swirski FK, 2009, SCIENCE, V325, P612, DOI 10.1126/science.1175202; Ugel S, 2012, CELL REP, V2, P628, DOI 10.1016/j.celrep.2012.08.006; Unsoeld H, 2004, J IMMUNOL, V173, P3013, DOI 10.4049/jimmunol.173.5.3013; Veglia F, 2018, NAT IMMUNOL, V19, P108, DOI 10.1038/s41590-017-0022-x; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791; ZAL T, 1994, J EXP MED, V180, P2089, DOI 10.1084/jem.180.6.2089	54	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 18	2021	11								616531	10.3389/fimmu.2020.616531	http://dx.doi.org/10.3389/fimmu.2020.616531			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QA2LW	33584706	Green Published, gold			2022-12-18	WOS:000613280900001
J	Spilleboudt, C; De Wilde, V; Lewalle, P; Cabanne, L; Leclerc, M; Beckerich, F; Bories, D; Cardoso, S; Soares, MP; Vokaer, B; Hougardy, JM; Flamand, V; Racape, J; Abramowicz, M; Maury, S; Le Moine, A				Spilleboudt, Chloe; De Wilde, Virginie; Lewalle, Philippe; Cabanne, Ludovic; Leclerc, Mathieu; Beckerich, Florence; Bories, Dominique; Cardoso, Silvia; Soares, Miguel P.; Vokaer, Benoit; Hougardy, Jean-Michel; Flamand, Veronique; Racape, Judith; Abramowicz, Marc; Maury, Sebastien; Le Moine, Alain			Donor-Derived Myeloid Heme Oxygenase-1 Controls the Development of Graft-Versus-Host Disease	FRONTIERS IN IMMUNOLOGY			English	Article						Heme oxygenase-1; graft-versus-host disease; transplantation; hematopoeietic stem cell transplantation; polymorphism; myeloid-derived suppressor cells	REGULATORY T-CELLS; MICROSATELLITE POLYMORPHISM; SUPPRESSOR-CELLS; CARBON-MONOXIDE; GENE PROMOTER; ACTIVATION; TRANSPLANTATION; SUSCEPTIBILITY; INDUCTION; SURVIVAL	Graft-versus-host disease (GVHD) remains a major clinical drawback of allogeneic hematopoietic stem cell transplantation (HSCT). Here, we investigated how the stress responsive heme catabolizing enzyme heme oxygenase-1 (HO-1, encoded by HMOX1) regulates GVHD in response to allogeneic hematopoietic stem cell transplantation in mice and humans. We found that deletion of the Hmox1 allele, specifically in the myeloid compartment of mouse donor bone marrow, promotes the development of aggressive GVHD after allogeneic transplantation. The mechanism driving GVHD in mice transplanted with allogeneic bone marrow lacking HO-1 expression in the myeloid compartment involves enhanced T cell alloreactivity. The clinical relevance of these observations was validated in two independent cohorts of HSCT patients. Individuals transplanted with hematopoietic stem cells from donors carrying a long homozygous (GT)(n) repeat polymorphism (L/L) in the HMOX1 promoter, which is associated with lower HO-1 expression, were at higher risk of developing severe acute GVHD as compared to donors carrying a short (GT)(n) repeat (S/L or S/S) polymorphism associated with higher HO-1 expression. In this study, we showed the unique importance of donor-derived myeloid HO-1 in the prevention of lethal experimental GVHD and we corroborated this observation by demonstrating the association between human HMOX1 (GT)(n) microsatellite polymorphisms and the incidence of severe acute GVHD in two independent HSCT patient cohorts. Donor-derived myeloid HO-1 constitutes a potential therapeutic target for HSCT patients and large-scale prospective studies in HSCT patients are necessary to validate the HO-1 L/L genotype as an independent risk factor for developing severe acute GVHD.	[Spilleboudt, Chloe; De Wilde, Virginie; Vokaer, Benoit; Flamand, Veronique; Le Moine, Alain] Univ Libre Bruxelles, Inst Med Immunol, Gosselies, Belgium; [De Wilde, Virginie] Univ Libre Bruxelles, Erasme Hosp, Hematol Dept, Brussels, Belgium; [Lewalle, Philippe] Univ Libre Bruxelles, Jules Bordet Inst, Hematol Dept, Brussels, Belgium; [Cabanne, Ludovic; Leclerc, Mathieu; Beckerich, Florence; Bories, Dominique; Maury, Sebastien] Hop Henri Mondor, AP HP, Dept Hematol, Creteil, France; [Cabanne, Ludovic; Leclerc, Mathieu; Beckerich, Florence; Bories, Dominique; Maury, Sebastien] Univ Paris Est Creteil UPEC, Creteil, France; [Cardoso, Silvia; Soares, Miguel P.] Inst Gulbenkian Ciencias, Oeiras, Portugal; [Hougardy, Jean-Michel; Racape, Judith; Le Moine, Alain] Univ Libre Bruxelles, Erasme Hosp, Nephrol & Internal Med Dept, Brussels, Belgium; [Racape, Judith] Univ Libre Bruxelles, Ecole Sante Publ, Ctr Rech Epidemiol Biostat & Rech Clin, Brussels, Belgium; [Abramowicz, Marc] Univ Geneva, Fac Med, Dept Genet Med & Dev, Geneva, Switzerland	Universite Libre de Bruxelles; Universite Libre de Bruxelles; Institut Jules Bordet; Universite Libre de Bruxelles; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Instituto Gulbenkian de Ciencia; Universite Libre de Bruxelles; Universite Libre de Bruxelles; University of Geneva	Spilleboudt, C; Le Moine, A (corresponding author), Univ Libre Bruxelles, Inst Med Immunol, Gosselies, Belgium.; Le Moine, A (corresponding author), Univ Libre Bruxelles, Erasme Hosp, Nephrol & Internal Med Dept, Brussels, Belgium.	chloe.spilleboudt@bordet.be; alemoine@ulb.ac.be		Cardoso, Silvia/0000-0003-4639-698X; spilleboudt, chloe/0000-0002-8009-403X; Flamand, Veronique/0000-0002-8906-3758	Societe Francophone de Transplantation (France); Alice and David Van Buuren Foundation; Fonds Carine Vyghen pour le don d'organes; Fundacao Calouste Gulbenkian; Fundacao para a Ciencia e Tecnologia [PTDC/SAU TOX/116627/2010, HMSP-ICT/0022/2010]; European Community 7th Framework Grant [ERC-2011-AdG. 294709]	Societe Francophone de Transplantation (France); Alice and David Van Buuren Foundation; Fonds Carine Vyghen pour le don d'organes; Fundacao Calouste Gulbenkian(European Commission); Fundacao para a Ciencia e Tecnologia(Portuguese Foundation for Science and TechnologyEuropean Commission); European Community 7th Framework Grant	CS was also funded by the Societe Francophone de Transplantation (France), the Alice and David Van Buuren Foundation, and the Fonds Carine Vyghen pour le don d'organes. MS is supported by Fundacao Calouste Gulbenkian and by competitive grants from the Fundacao para a Ciencia e Tecnologia (PTDC/SAU TOX/116627/2010, HMSP-ICT/0022/2010) and by the European Community 7th Framework Grant ERC-2011-AdG. 294709.	Al-Huseini LMA, 2014, J BIOL CHEM, V289, P16442, DOI 10.1074/jbc.M113.532069; Alaluf E, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.133929; Allie N, 2013, SCI REP-UK, V3, DOI 10.1038/srep01809; Andersen MH, 2009, J CLIN INVEST, V119, P2245, DOI 10.1172/JCI38739; Baan C, 2004, AM J TRANSPLANT, V4, P811, DOI 10.1111/j.1600-6143.2004.00420.x; Blazar BR, 2012, NAT REV IMMUNOL, V12, P443, DOI 10.1038/nri3212; Bluestone JA, 2018, SCIENCE, V362, P154, DOI 10.1126/science.aau2688; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Brouard S, 2002, J BIOL CHEM, V277, P17950, DOI 10.1074/jbc.M108317200; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Budhwar S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02776; Chen YH, 2004, EUR HEART J, V25, P39, DOI 10.1016/j.ehj.2003.10.009; Chen YH, 2002, HUM GENET, V111, P1, DOI 10.1007/s00439-002-0769-4; Chen YH, 2014, J AM SOC NEPHROL, V25, P2669, DOI 10.1681/ASN.2013111205; Colson YL, 2004, BLOOD, V104, P3829, DOI 10.1182/blood-2004-01-0393; De Wilde V, 2009, AM J TRANSPLANT, V9, P2034, DOI 10.1111/j.1600-6143.2009.02757.x; Dilek N, 2010, CURR OPIN ORGAN TRAN, V15, P765, DOI 10.1097/MOT.0b013e3283401742; Ewing P, 2007, INT J MOL MED, V20, P301; Exner M, 2004, FREE RADICAL BIO MED, V37, P1097, DOI 10.1016/j.freeradbiomed.2004.07.008; Ferrandiz ML, 2008, CURR PHARM DESIGN, V14, P473, DOI 10.2174/138161208783597399; Funes SC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01467; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Garcia-Santos D, 2010, MED HYPOTHESES, V74, P807, DOI 10.1016/j.mehy.2009.12.010; Garza R, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000710; Gerbitz A, 2004, BIOL BLOOD MARROW TR, V10, P461, DOI 10.1016/j.bbmt.2004.04.001; Gerbitz A, 2008, BIOL BLOOD MARROW TR, V14, P1180, DOI 10.1016/j.bbmt.2008.08.002; Gill AJ, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1102-z; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600; Graca L, 2004, P NATL ACAD SCI USA, V101, P10122, DOI 10.1073/pnas.0400084101; Guenegou A, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.039743; Highfill SL, 2010, BLOOD, V116, P5738, DOI 10.1182/blood-2010-06-287839; Hirai H, 2003, BLOOD, V102, P1619, DOI 10.1182/blood-2002-12-3733; Hoffmann P, 2002, J EXP MED, V196, P389, DOI 10.1084/jem.20020399; Horio T, 2020, CANCERS, V12, DOI 10.3390/cancers12020424; Hsu LA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108773; Jagasia M, 2012, BLOOD, V119, P296, DOI 10.1182/blood-2011-06-364265; Jais A, 2014, CELL, V158, P25, DOI 10.1016/j.cell.2014.04.043; Koehn BH, 2017, J LEUKOCYTE BIOL, V102, P335, DOI 10.1189/jlb.5MR1116-464R; Kollgaard T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168210; Kovtunovych G, 2010, BLOOD, V116, P6054, DOI 10.1182/blood-2010-03-272138; Larsen R, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001118; Leaf DE, 2016, J AM SOC NEPHROL, V27, P3291, DOI 10.1681/ASN.2016010038; Mamiya T, 2008, TOHOKU J EXP MED, V216, P331, DOI 10.1620/tjem.216.331; McDaid J, 2005, FASEB J, V19, P458, DOI 10.1096/fj.04-2217fje; Morecki S, 2008, BIOL BLOOD MARROW TR, V14, P973, DOI 10.1016/j.bbmt.2008.06.018; Mougiakakos D, 2013, LEUKEMIA, V27, P377, DOI 10.1038/leu.2012.215; Naito Y, 2014, ARCH BIOCHEM BIOPHYS, V564, P83, DOI 10.1016/j.abb.2014.09.005; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Ozaki KS, 2008, CLIN TRANSPLANT, V22, P609, DOI 10.1111/j.1399-0012.2008.00832.x; Pechlaner R, 2015, ARTERIOSCL THROM VAS, V35, P229, DOI 10.1161/ATVBAHA.114.304729; Romano M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01625; Rosborough BR, 2012, J LEUKOCYTE BIOL, V91, P701, DOI 10.1189/jlb.0311119; Rueda B, 2007, ARTHRITIS RHEUM-US, V56, P3953, DOI 10.1002/art.23048; Ryter SW, 2016, TRANSL RES, V167, P7, DOI 10.1016/j.trsl.2015.06.011; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Soares MP, 2016, IMMUNITY, V44, P492, DOI 10.1016/j.immuni.2016.02.016; Soares MP, 2016, CURR OPIN IMMUNOL, V38, P94, DOI 10.1016/j.coi.2015.11.006; Soares MP, 2009, CURR OPIN PHARMACOL, V9, P482, DOI 10.1016/j.coph.2009.05.008; Soares MP, 2001, IMMUNOL REV, V184, P275, DOI 10.1034/j.1600-065x.2001.1840124.x; Terry CM, 1999, AM J PHYSIOL-HEART C, V276, pH1493, DOI 10.1152/ajpheart.1999.276.5.H1493; THOMAS ED, 1975, NEW ENGL J MED, V292, P895, DOI 10.1056/NEJM197504242921706; Ugel S, 2015, J CLIN INVEST, V125, P3365, DOI 10.1172/JCI80006; Vigorito AC, 2009, BLOOD, V114, P702, DOI 10.1182/blood-2009-03-208983; Vijayan V, 2018, BIOCHEM PHARMACOL, V153, P159, DOI 10.1016/j.bcp.2018.02.010; Walther M, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002579; Wegiel B, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.97; Weis N, 2009, MOL BIOL CELL, V20, P1280, DOI 10.1091/mbc.E08-10-1005; Woo J, 2000, TRANSPLANTATION, V69, P623, DOI 10.1097/00007890-200002270-00026; Yamada N, 2000, AM J HUM GENET, V66, P187, DOI 10.1086/302729; Yamashita K, 2006, FASEB J, V20, P776, DOI 10.1096/fj.05-4791fje; Yet SF, 1999, J CLIN INVEST, V103, pR23, DOI 10.1172/JCI6163; Yu MS, 2016, TRANSPL IMMUNOL, V37, P10, DOI 10.1016/j.trim.2016.05.002; Zeiser R, 2017, NEW ENGL J MED, V377, P2167, DOI 10.1056/NEJMra1609337; Zhang M, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120596; Zhou HB, 2017, J CELL MOL MED, V21, P894, DOI 10.1111/jcmm.13028	76	0	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 18	2021	11								579151	10.3389/fimmu.2020.579151	http://dx.doi.org/10.3389/fimmu.2020.579151			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QA4TX	33537027	gold, Green Published			2022-12-18	WOS:000613438400001
J	Jimenez, M; Pastor, L; Urrea, V; de la Concepcion, MLR; Parker, E; Fuente-Soro, L; Jairoce, C; Mandomando, I; Carrillo, J; Naniche, D; Blanco, J				Jimenez, Montse; Pastor, Lucia; Urrea, Victor; Rodriguez de la Concepcion, Maria Luisa; Parker, Erica; Fuente-Soro, Laura; Jairoce, Chenjerai; Mandomando, Inacio; Carrillo, Jorge; Naniche, Denise; Blanco, Julia			A Longitudinal Analysis Reveals Early Activation and Late Alterations in B Cells During Primary HIV Infection in Mozambican Adults	FRONTIERS IN IMMUNOLOGY			English	Article						B-cell activation; plasmablasts; marginal zone (MZ) B cell; transitional B cell; PD-1	RESPONSES; MEMORY; CD4(+); VACCINATION; MECHANISMS; EXHAUSTION; DEPLETION; DISEASE; VIREMIA; HAART	Primary HIV infection (PHI) and subsequent chronic infection alter B-cell compartment. However, longitudinal analysis defining the dynamics of B-cell alterations are still limited. We longitudinally studied B-cell subsets in individuals followed for 1 year after PHI (n = 40). Treated and untreated chronic HIV infected (n = 56) and HIV-uninfected individuals (n = 58) were recruited as reference groups at the Manhica District in Mozambique. B cells were analyzed by multicolor flow-cytometry. Anti-HIV humoral response and plasma cytokines were assessed by ELISA or Luminex-based technology. A generalized activation of B cells induced by HIV occurs early after infection and is characterized by increases in Activated and Tissue-like memory cells, decreases in IgM-IgD- (switched) and IgM-only B cells. These alterations remain mostly stable until chronic infection and are reverted in part by ART. In contrast, other parameters followed particular dynamics: PD-1 expression in memory cells decreases progressively during the first year of infection, Transitional B cells expand at month 3-4 after infection, and Marginal zone-like B cells show a late depletion. Plasmablasts expand 2 months after infection linked to plasma viral load and anti-p24 IgG3 responses. Most of well-defined changes induced by HIV in B-cell activation and memory subsets are readily observed after PHI, lasting until ART initiation. However, subsequent changes occur after sustained viral infection. These data indicate that HIV infection impacts B cells in several waves over time, and highlight that early treatment would result in beneficial effects on the B-cell compartment.	[Jimenez, Montse; Pastor, Lucia; Urrea, Victor; Rodriguez de la Concepcion, Maria Luisa; Carrillo, Jorge; Blanco, Julia] Univ Autonoma Barcelona, AIDS Res Inst IrsiCaixa, Inst Germans Trias & Pujol IGTP, Hosp Germans Trias & Pujol, Badalona, Spain; [Pastor, Lucia; Fuente-Soro, Laura; Naniche, Denise] Hosp Clin Univ Barcelona, ISGlobal, Barcelona Inst Global Hlth, Barcelona, Spain; [Pastor, Lucia; Fuente-Soro, Laura; Jairoce, Chenjerai; Mandomando, Inacio; Naniche, Denise] Ctr Invest Saude Manhica CISM, Maputo, Mozambique; [Parker, Erica] Univ Western Australia, Fac Hlth & Med Sci, Perth, WA, Australia; [Blanco, Julia] Univ Vic, Univ Cent Catalunya UVIC UCC, Vic, Spain	Autonomous University of Barcelona; Fundacio Institut d'Investigacio en Ciencies de la Salut Germans Trias i Pujol (IGTP); Hospital Germans Trias i Pujol; Institut de Recerca de la Sida - IrsiCaixa; ISGlobal; University of Barcelona; Hospital Clinic de Barcelona; Centro de Investigacao em Saude de Manhica; University of Western Australia; Universitat de Vic - Universitat Central de Catalunya (UVic-UCC)	Blanco, J (corresponding author), Univ Autonoma Barcelona, AIDS Res Inst IrsiCaixa, Inst Germans Trias & Pujol IGTP, Hosp Germans Trias & Pujol, Badalona, Spain.; Blanco, J (corresponding author), Univ Vic, Univ Cent Catalunya UVIC UCC, Vic, Spain.	jblanco@irsicaixa.es	Urrea, Victor/ABF-9634-2021; Jairoce, Chenjerai/AAD-3231-2020; Carrillo, Jorge/AAL-9481-2021; Palomo, Lucía Pastor/AAV-4303-2020; Blanco, Julià/A-5347-2008; Naniche, Denise/S-1814-2018	Jairoce, Chenjerai/0000-0001-6060-8673; Carrillo, Jorge/0000-0003-0221-5948; Palomo, Lucía Pastor/0000-0002-8346-514X; Blanco, Julià/0000-0002-2225-0217; Fuente-Soro, Laura/0000-0002-8580-5857; Parker, Erica/0000-0003-0555-382X; Naniche, Denise/0000-0002-4495-6325; Rodriguez de la Concepcion/0000-0002-6944-3462	Spanish Ministry of Science (Mineco) [SAF-2011-27901]; Bill and Melinda Gates Foundation [OPP1068252]; Spanish Ministry of Health through the Institute of Health Carlos III (ISCIII) [FI12/00096, DTS15/00185]	Spanish Ministry of Science (Mineco)(Spanish Government); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Spanish Ministry of Health through the Institute of Health Carlos III (ISCIII)	This work was supported by The Spanish Ministry of Science (Mineco) (SAF-2011-27901) to DN; Bill and Melinda Gates Foundation (OPP1068252) to DN and The Spanish Ministry of Health through the Institute of Health Carlos III (ISCIII) (FI12/00096) to LP and (DTS15/00185) to JB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amu S, 2016, AIDS, V30, P2169, DOI 10.1097/QAD.0000000000001182; Amu S, 2014, RETROVIROLOGY, V11, DOI 10.1186/s12977-014-0076-x; Boliar S, 2012, J VIROL, V86, P8031, DOI 10.1128/JVI.00771-12; Cagigi A, 2010, LANCET INFECT DIS, V10, P499, DOI 10.1016/S1473-3099(10)70117-1; Carrillo J, 2018, AIDS, V32, P149, DOI 10.1097/QAD.0000000000001686; Cerutti A, 2013, NAT REV IMMUNOL, V13, P118, DOI 10.1038/nri3383; Chung JB, 2003, TRENDS IMMUNOL, V24, P343, DOI 10.1016/S1471-4906(03)00119-4; De Milito A, 2004, BLOOD, V103, P2180, DOI 10.1182/blood-2003-07-2375; Deeks SG, 2011, ANNU REV MED, V62, P141, DOI 10.1146/annurev-med-042909-093756; Demberg T, 2015, VIROLOGY, V484, P323, DOI 10.1016/j.virol.2015.06.022; Farooq PD, 2019, CURR HIV-AIDS REP, V16, P395, DOI 10.1007/s11904-019-00461-6; Fink K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00078; Kardava L, 2014, J CLIN INVEST, V124, P3252, DOI 10.1172/JCI74351; Kazer SW, 2020, NAT MED, V26, P511, DOI 10.1038/s41591-020-0799-2; Kerneis S, 2014, CLIN INFECT DIS, V58, P1130, DOI 10.1093/cid/cit937; Liechti T, 2019, J EXP MED, V216, P2071, DOI 10.1084/jem.20181124; Mabuka JM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01104; Malaspina A, 2006, P NATL ACAD SCI USA, V103, P2262, DOI 10.1073/pnas.0511094103; Malaspina A, 2007, BLOOD, V109, P2086, DOI 10.1182/blood-2006-06-031385; Massanella M, 2013, EXPERT REV CLIN IMMU, V9, P1135, DOI 10.1586/1744666X.2013.842897; McCune JM, 2001, NATURE, V410, P974, DOI 10.1038/35073648; Moens L, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00065; Moir S, 2008, J EXP MED, V205, P1797, DOI 10.1084/jem.20072683; Moir S, 2017, IMMUNOL REV, V275, P33, DOI 10.1111/imr.12502; Moir S, 2014, CURR OPIN HIV AIDS, V9, P472, DOI 10.1097/COH.0000000000000092; Moir S, 2011, ANNU REV PATHOL-MECH, V6, P223, DOI 10.1146/annurev-pathol-011110-130254; Moir S, 2010, BLOOD, V116, P5571, DOI 10.1182/blood-2010-05-285528; Negredo E, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/5897298; Pastor L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218000; Pastor L, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01925; Pastor L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08218-0; Pastor L, 2017, JAIDS-J ACQ IMM DEF, V74, P459, DOI 10.1097/QAI.0000000000001272; Pensierosoa S, 2009, P NATL ACAD SCI USA, V106, P7939, DOI 10.1073/pnas.0901702106; Rethi B, 2013, AIDS, V27, P155, DOI 10.1097/QAD.0b013e32835b8c5e; Robb ML, 2016, NEW ENGL J MED, V374, P2120, DOI 10.1056/NEJMoa1508952; Roberts L, 2010, AIDS, V24, P819, DOI 10.1097/QAD.0b013e3283367836; Samuelsson A, 1997, VIROLOGY, V238, P180, DOI 10.1006/viro.1997.8790; Shan MM, 2018, IMMUNITY, V49, P709, DOI 10.1016/j.immuni.2018.08.013; Titanji K, 2006, BLOOD, V108, P1580, DOI 10.1182/blood-2005-11-013383; Titanji K, 2010, J CLIN INVEST, V120, P3878, DOI 10.1172/JCI43271; Yates NL, 2011, AIDS, V25, P2089, DOI 10.1097/QAD.0b013e32834b348e	41	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 15	2021	11								614319	10.3389/fimmu.2020.614319	http://dx.doi.org/10.3389/fimmu.2020.614319			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PZ3RW	33519823	Green Published, gold			2022-12-18	WOS:000612657300001
J	Guerrouahen, B; Elnaggar, M; Al-Mohannadi, A; Kizhakayil, D; Bonini, C; Benjamin, R; Brentjens, R; Buchholz, CJ; Casorati, G; Ferrone, S; Locke, FL; Martin, F; Schambach, A; Turtle, C; Veys, P; van der Vliet, HJ; Maccalli, C				Guerrouahen, Bella; Elnaggar, Muhammad; Al-Mohannadi, Anjud; Kizhakayil, Dhanya; Bonini, Chiara; Benjamin, Reuben; Brentjens, Renier; Buchholz, Christian J.; Casorati, Giulia; Ferrone, Soldano; Locke, Frederick L.; Martin, Francisco; Schambach, Axel; Turtle, Cameron; Veys, Paul; van der Vliet, Hans J.; Maccalli, Cristina		EICCI Faculty Grp	Proceedings From the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development", 15(th)-16(th) February 2019, Doha, Qatar	FRONTIERS IN IMMUNOLOGY			English	Review						cancer; immunotherapy; CAR-T cells; TCR engineered lymphocytes; CAR-NK cells; monoclonal antibody; clinical trial; off-the-shelf development	CHIMERIC-ANTIGEN-RECEPTOR; MONOCLONAL-ANTIBODY MK2-23; MODIFIED T-CELLS; B-CELL; AXICABTAGENE CILOLEUCEL; ANTITUMOR EFFICACY; MALIGNANT ASCITES; PHASE II/III; STEM-CELLS; CD19 CAR	The progress in the isolation and characterization of tumor antigen (TA)-specific T lymphocytes and in the genetic modification of immune cells allowed the clinical development of adoptive cell therapy (ACT). Several clinical studies highlighted the striking clinical activity of T cells engineered to express either Chimeric Antigen (CAR) or T Cell (TCR) Receptors to target molecularly defined antigens expressed on tumor cells. The breakthrough of immunotherapy is represented by the approval of CAR-T cells specific for advanced or refractory CD19(+) B cell malignancies by both the Food and Drug Administration (FDA) and the European Medicinal Agency (EMA). Moreover, advances in the manufacturing and gene editing of engineered immune cells contributed to the selection of drug products with desired phenotype, refined specificity and decreased toxicity. An important step toward the optimization of CAR-T cell therapy is the development of "off-the shelf" T cell products that allow to reduce the complexity and the costs of the manufacturing and to render these drugs available for a broad number of cancer patients. The Engineered Immune Cells in Cancer Immunotherapy (EICCI) workshop hosted in Doha, Qatar, renowned experts, from both academia and industry, to present and discuss the progress on both pre-clinical and clinical development of genetically modified immune cells, including advances in the "off-the-shelf" manufacturing. These experts have addressed also organizational needs and hurdles for the clinical grade production and application of these biological drugs.	[Guerrouahen, Bella; Elnaggar, Muhammad; Al-Mohannadi, Anjud; Kizhakayil, Dhanya; Maccalli, Cristina] Sidra Med, Res Dept, Doha, Qatar; [Bonini, Chiara] Univ Vita Salute San Raffaele, Expt Hematol Unit, Milan, Italy; [Bonini, Chiara; Casorati, Giulia] Hosp San Raffaele Sci Inst, Milan, Italy; [Benjamin, Reuben] Kings Coll Hosp London, Div Canc Studies, London, England; [Brentjens, Renier] Mem Sloan Kettering Canc Ctr, Dept Med, Cellular Therapeut, 1275 York Ave, New York, NY 10021 USA; [Buchholz, Christian J.] Paul Ehrlich Inst, Res Unit Mol Biotechnol & Gene Therapy, Langen, Germany; [Casorati, Giulia] Univ Vita Salute San Raffaele, Expt Immunol Unit, Milan, Italy; [Ferrone, Soldano] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02115 USA; [Locke, Frederick L.] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA; [Martin, Francisco] Univ Granada, Andalusian Reg Govt, Pfizer, Genom Med Dept, Granada, Spain; [Schambach, Axel] Hannover Med Sch, Inst Expt Hematol, Hannover, Germany; [Schambach, Axel] Harvard Med Sch, Boston Childrens Hosp, Div Hematol Oncol, Boson, MA USA; [Turtle, Cameron] Fred Hutchinson Canc Ctr, Clin Res Div, Seattle, WA USA; [Veys, Paul] Great Ormond St GOS Hosp, Bone Marrow Transplant Unit, London, England; [Veys, Paul] UCL, GOS Inst Child Hlth, London, England; [van der Vliet, Hans J.] Vrije Univ Amsterdam, Amsterdam UMC, Dept Med Oncol, Amsterdam, Netherlands; [van der Vliet, Hans J.] Canc Ctr, Amsterdam, Netherlands; [van der Vliet, Hans J.] Lava Therapeut, Utrecht, Netherlands	Sidra Medical & Research Center; Vita-Salute San Raffaele University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; King's College Hospital NHS Foundation Trust; King's College Hospital; Memorial Sloan Kettering Cancer Center; Paul Ehrlich Institute; Vita-Salute San Raffaele University; Harvard University; Harvard Medical School; Massachusetts General Hospital; H Lee Moffitt Cancer Center & Research Institute; Pfizer; University of Granada; Hannover Medical School; Harvard University; Boston Children's Hospital; Fred Hutchinson Cancer Center; University of London; University College London; University of Amsterdam; Vrije Universiteit Amsterdam	Maccalli, C (corresponding author), Sidra Med, Res Dept, Doha, Qatar.	cmaccalli@sidra.org	Schambach, Axel/C-5491-2011; Martin, Francisco/K-8763-2014; Casorati, Giulia/J-7141-2018	Martin, Francisco/0000-0003-1961-8612; Casorati, Giulia/0000-0002-5102-4112; Al-Mohannadi, Anjud/0000-0001-8719-0860; Benjamin, Reuben/0000-0003-1434-0594; Roelands, Jessica/0000-0003-3631-2041; ponterio, eleonora/0000-0003-4779-2028	Qatar National Research Fund (QNRF)-Conference Workshop Sponsorship Program [CWSP15-W-0911-18001]; AIRC [Ig 18458]; AIRC 5 per Mille [22737]; Italian Ministry of Research and University [PRIN 2017WC8499]; Italian Ministry of Health (Research project on CAR T cells for hematological malignancies and solid tumors)	Qatar National Research Fund (QNRF)-Conference Workshop Sponsorship Program; AIRC(Fondazione AIRC per la ricerca sul cancro); AIRC 5 per Mille(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Research and University(Ministry of Education, Universities and Research (MIUR)); Italian Ministry of Health (Research project on CAR T cells for hematological malignancies and solid tumors)	The EICCI workshop was funded by the Qatar National Research Fund (QNRF)-Conference Workshop Sponsorship Program grant CWSP15-W-0911-18001 (Doha, Qatar). CBo received funding from AIRC (Ig 18458) and AIRC 5 per Mille, Rif. 22737, Italian Ministry of Research and University (PRIN 2017WC8499) and Italian Ministry of Health (Research project on CAR T cells for hematological malignancies and solid tumors).	Abramson JS, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.7505; Abramson JS, 2017, NEW ENGL J MED, V377, P783, DOI 10.1056/NEJMc1704610; Admiraal R, 2016, BONE MARROW TRANSPL, V51, P1376, DOI 10.1038/bmt.2016.116; Agarwal S, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1671761; Altrock PM, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-1791; Anderson KG, 2019, CANCER IMMUNOL RES, V7, P1412, DOI 10.1158/2326-6066.CIR-19-0258; [Anonymous], 2017, NEW ENGL J MED, DOI [DOI 10.1182/BLOOD-2018-99-114152, DOI 10.1056/NEJMoa1708566]; Avanzi MP, 2018, CELL REP, V23, P2130, DOI 10.1016/j.celrep.2018.04.051; Beard RE, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/2051-1426-2-25; Benjamin R, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-111356; Bertucci F, 2018, BRIT J CANCER, V119, P1383, DOI 10.1038/s41416-018-0309-1; Beyar-Katz O, 2020, CURR OPIN HEMATOL, V27, P368, DOI 10.1097/MOH.0000000000000614; Bokemeyer C, 2015, GASTRIC CANCER, V18, P833, DOI 10.1007/s10120-014-0423-6; Boyiadzis MM, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0460-5; Brenner MK, 2019, MOL THER, V27, P693, DOI 10.1016/j.ymthe.2019.02.017; Buchholz CJ, 2015, TRENDS BIOTECHNOL, V33, P777, DOI 10.1016/j.tibtech.2015.09.008; Campoli M, 2010, ADV CANCER RES, V109, P73, DOI 10.1016/B978-0-12-380890-5.00003-X; Cany J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064384; Chapuis AG, 2019, NAT MED, V25, P1064, DOI 10.1038/s41591-019-0472-9; Chaussabel D, 2014, NAT REV IMMUNOL, V14, P271, DOI 10.1038/nri3642; Chavez JC, 2018, BEST PRACT RES CL HA, V31, P135, DOI 10.1016/j.beha.2018.04.001; Cieri N, 2015, BLOOD, V125, P2865, DOI 10.1182/blood-2014-11-608539; Clynes RA, 2019, ANNU REV MED, V70, P437, DOI 10.1146/annurev-med-062617-035821; Consonni M, 2017, CYTOKINE GROWTH F R, V36, P117, DOI 10.1016/j.cytogfr.2017.06.007; Curran KJ, 2015, MOL THER, V23, P769, DOI 10.1038/mt.2015.4; Depil S, 2020, NAT REV DRUG DISCOV, V19, P185, DOI 10.1038/s41573-019-0051-2; Dolstra H, 2017, CLIN CANCER RES, V23, P4107, DOI 10.1158/1078-0432.CCR-16-2981; Downing JR, 2012, NAT GENET, V44, P619, DOI 10.1038/ng.2287; ESHHAR Z, 1993, P NATL ACAD SCI USA, V90, P720, DOI 10.1073/pnas.90.2.720; Eyquem J, 2017, NATURE, V543, P113, DOI 10.1038/nature21405; Fischer J, 2017, J IMMUNOTHER, V40, P187, DOI 10.1097/CJI.0000000000000169; Gattinoni L, 2011, NAT MED, V17, P1290, DOI 10.1038/nm.2446; Geldres C, 2014, CLIN CANCER RES, V20, P962, DOI 10.1158/1078-0432.CCR-13-2218; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Graham C, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7100155; Greco R, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00095; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Grupp SA, 2011, CURR TOP MICROBIOL, V344, P149, DOI 10.1007/82_2010_94; Gupta B, 2012, J IMMUNOTHER, V35, P488, DOI 10.1097/CJI.0b013e31826183a7; Hartmann J, 2018, MOL THER-METH CLIN D, V10, P128, DOI 10.1016/j.omtm.2018.07.001; Hay KA, 2019, BLOOD, V133, P1652, DOI 10.1182/blood-2018-11-883710; Hay KA, 2017, DRUGS, V77, P237, DOI 10.1007/s40265-017-0690-8; Heiss MM, 2010, INT J CANCER, V127, P2209, DOI 10.1002/ijc.25423; Hendrickx W, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1253654; Hinrichs CS, 2014, IMMUNOL REV, V257, P56, DOI 10.1111/imr.12132; Hirayama AV, 2019, BLOOD, V133, P1876, DOI 10.1182/blood-2018-11-887067; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Kaech SM, 2012, NAT REV IMMUNOL, V12, P749, DOI 10.1038/nri3307; Kalos M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002842; Kansagra AJ, 2019, BONE MARROW TRANSPL, V54, P1868, DOI 10.1038/s41409-019-0451-2; Kantarjian H, 2017, NEW ENGL J MED, V376, P836, DOI 10.1056/NEJMoa1609783; Kaufmann KB, 2013, MOL THER, V21, P648, DOI 10.1038/mt.2012.249; Kershaw MH, 2006, CLIN CANCER RES, V12, P6106, DOI 10.1158/1078-0432.CCR-06-1183; Kohn DB, 2011, MOL THER, V19, P432, DOI 10.1038/mt.2011.1; Kosti P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01104; Krooss SA, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2019.100764; Kuhn NF, 2019, CANCER CELL, V35, P473, DOI 10.1016/j.ccell.2019.02.006; Labrijn AF, 2019, NAT REV DRUG DISCOV, V18, P585, DOI 10.1038/s41573-019-0028-1; Legut M, 2015, CELL MOL IMMUNOL, V12, P656, DOI 10.1038/cmi.2015.28; Lepore M, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/21624011.2014.970463; Lepore M, 2014, J EXP MED, V211, P1360, DOI 10.1084/jem.20140410; Li ZX, 2002, SCIENCE, V296, P497, DOI 10.1126/science.1068893; Liu XJ, 2018, CURR RES TRANSL MED, V66, P39, DOI 10.1016/j.retram.2018.04.003; Lock D, 2017, HUM GENE THER, V28, P914, DOI 10.1089/hum.2017.111; Locke FL, 2020, BLOOD ADV, V4, P4898, DOI 10.1182/bloodadvances.2020002394; Locke FL, 2019, LANCET ONCOL, V20, P31, DOI 10.1016/S1470-2045(18)30864-7; Locke FL, 2018, CLIN ADV HEMATOL ONC, V16, P19; Locke FL, 2017, MOL THER, V25, P285, DOI 10.1016/j.ymthe.2016.10.020; Maciag PC, 2008, CANCER RES, V68, P8066, DOI 10.1158/0008-5472.CAN-08-0287; MacLeod DT, 2017, MOL THER, V25, P949, DOI 10.1016/j.ymthe.2017.02.005; Mau-Sorensen M, 2015, CANCER CHEMOTH PHARM, V75, P1065, DOI 10.1007/s00280-015-2728-5; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Melero I, 2014, NAT REV CLIN ONCOL, V11, P509, DOI 10.1038/nrclinonc.2014.111; MITTELMAN A, 1992, P NATL ACAD SCI USA, V89, P466, DOI 10.1073/pnas.89.2.466; Morgan RA, 2013, J IMMUNOTHER, V36, P133, DOI 10.1097/CJI.0b013e3182829903; Morgan RA, 2012, HUM GENE THER, V23, P1043, DOI 10.1089/hum.2012.041; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Neelapu SS, 2020, BLOOD, V135, P2106, DOI 10.1182/blood.2019004162; Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, P47, DOI 10.1038/nrclinonc.2017.148; Neelapu SS, 2017, CLIN ADV HEMATOL ONC, V15, P117; Oliveira G, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac8265; Oluwole OO, 2020, BIOL BLOOD MARROW TR, V26, P1581, DOI 10.1016/j.bbmt.2020.06.008; Osborn MJ, 2016, MOL THER, V24, P570, DOI 10.1038/mt.2015.197; Park JR, 2007, MOL THER, V15, P825, DOI 10.1038/sj.mt.6300104; Parmiani G, 2014, HUM VACC IMMUNOTHER, V10, P3175, DOI 10.4161/hv.29418; Pegram HJ, 2012, BLOOD, V119, P4133, DOI 10.1182/blood-2011-12-400044; Pellegatta S, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao2731; Pfeiffer A, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201809158; Philip B, 2014, BLOOD, V124, P1277, DOI 10.1182/blood-2014-01-545020; PHILIP T, 1995, NEW ENGL J MED, V333, P1540, DOI 10.1056/NEJM199512073332305; PHILIP T, 1991, ANN ONCOL, V2, P57, DOI 10.1093/annonc/2.suppl_1.57; Ponterio E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.565631; Porter DL, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5415; Price MA, 2011, PIGM CELL MELANOMA R, V24, P1148, DOI 10.1111/j.1755-148X.2011.00929.x; Provasi E, 2012, NAT MED, V18, P807, DOI 10.1038/nm.2700; Qasim W, 2019, AM J HEMATOL, V94, pS50, DOI 10.1002/ajh.25399; Qasim W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaj2013; Quintas-Cardama A, 2018, NEW ENGL J MED, V378, P1065, DOI 10.1056/NEJMc1800913; Rafiq S, 2018, NAT BIOTECHNOL, V36, P847, DOI 10.1038/nbt.4195; Ren JT, 2017, PROTEIN CELL, V8, P634, DOI 10.1007/s13238-017-0410-x; Ren JT, 2017, CLIN CANCER RES, V23, P2255, DOI 10.1158/1078-0432.CCR-16-1300; Rezvani K, 2019, BONE MARROW TRANSPL, V54, P785, DOI 10.1038/s41409-019-0601-6; Rice J, 2008, EUR J IMMUNOL, V38, P2118, DOI 10.1002/eji.200838213; Robbins PF, 2015, CLIN CANCER RES, V21, P1019, DOI 10.1158/1078-0432.CCR-14-2708; Robbins PF, 2013, NAT MED, V19, P747, DOI 10.1038/nm.3161; Roelands J, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000617; Roelands J, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102229; Rosenberg SA, 2015, SCIENCE, V348, P62, DOI 10.1126/science.aaa4967; Ruella M, 2018, NAT MED, V24, P1499, DOI 10.1038/s41591-018-0201-9; Sadelain M, 2009, CURR OPIN IMMUNOL, V21, P215, DOI 10.1016/j.coi.2009.02.009; Schmitt TM, 2017, NAT BIOTECHNOL, V35, P1188, DOI 10.1038/nbt.4004; Schott JW, 2019, MOL THER-METH CLIN D, V14, P134, DOI 10.1016/j.omtm.2019.05.015; Schuster SJ, 2019, NEW ENGL J MED, V380, P1586, DOI 10.1056/NEJMc1901464; Schuster SJ, 2019, NEW ENGL J MED, V380, P45, DOI 10.1056/NEJMoa1804980; Shah NN, 2019, NAT REV CLIN ONCOL, V16, P372, DOI 10.1038/s41571-019-0184-6; Shah NN, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00146; Sharma P, 2019, CRIT REV IMMUNOL, V39, P105, DOI 10.1615/CritRevImmunol.2019030788; Singh N, 2017, CURR HEMATOL MALIG R, V12, P522, DOI 10.1007/s11899-017-0417-7; Sotillo E, 2015, CANCER DISCOV, V5, P1282, DOI 10.1158/2159-8290.CD-15-1020; Suerth JD, 2012, MOL THER, V20, P1022, DOI 10.1038/mt.2011.309; Sugiyama H, 2010, JPN J CLIN ONCOL, V40, P377, DOI 10.1093/jjco/hyp194; Tang J, 2018, ANN ONCOL, V29, P84, DOI 10.1093/annonc/mdx755; Till BG, 2008, BLOOD, V112, P2261, DOI 10.1182/blood-2007-12-128843; Tilly H, 2015, ANN ONCOL, V26, pV116, DOI 10.1093/annonc/mdv304; Topp MS, 2015, LANCET ONCOL, V16, P57, DOI 10.1016/S1470-2045(14)71170-2; Torikai H, 2012, BLOOD, V119, P5697, DOI 10.1182/blood-2012-01-405365; Tran E, 2014, ONCOTARGET, V5, P4579, DOI 10.18632/oncotarget.2234; Turtle CJ, 2016, CLIN PHARMACOL THER, V100, P252, DOI 10.1002/cpt.392; Turtle CJ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf8621; Turtle CJ, 2016, EXPERT REV HEMATOL, V9, P719, DOI 10.1080/17474086.2016.1203251; Turtle CJ, 2016, J CLIN INVEST, V126, P2123, DOI 10.1172/JCI85309; Vakulskas CA, 2018, NAT MED, V24, P1216, DOI 10.1038/s41591-018-0137-0; van Brummelen Emilie M J, 2018, Oncotarget, V9, P24737, DOI 10.18632/oncotarget.25343; Veluchamy JP, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00087; Wang XH, 2005, CANCER RES, V65, P6976, DOI 10.1158/0008-5472.CAN-04-2328; Wang XH, 2011, CANCER RES, V71, P7410, DOI 10.1158/0008-5472.CAN-10-1134; Wang XH, 2010, JNCI-J NATL CANCER I, V102, P1496, DOI 10.1093/jnci/djq343; Wang YY, 2015, EXPERT OPIN THER TAR, V19, P1339, DOI 10.1517/14728222.2015.1068759; Wiebking V, 2021, HAEMATOLOGICA, V106, P847, DOI 10.3324/haematol.2019.233882; Wimberger P, 2012, ANN ONCOL, V23, P1979, DOI 10.1093/annonc/mds178; Yang JC, 2016, ADV IMMUNOL, V130, P279, DOI 10.1016/bs.ai.2015.12.006; Zacharakis N, 2018, NAT MED, V24, P724, DOI 10.1038/s41591-018-0040-8; Zhang YP, 2017, J GENET GENOMICS, V44, P415, DOI 10.1016/j.jgg.2017.09.002; Zhao JJ, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0677-2; Zimmermann K, 2020, CANCERS, V12, DOI 10.3390/cancers12020375	145	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 14	2021	11								589381	10.3389/fimmu.2020.589381	http://dx.doi.org/10.3389/fimmu.2020.589381			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PY8UW	33584653	gold, Green Published			2022-12-18	WOS:000612317500001
J	Franzin, R; Stasi, A; Fiorentino, M; Stallone, G; Cantaluppi, V; Gesualdo, L; Castellano, G				Franzin, Rossana; Stasi, Alessandra; Fiorentino, Marco; Stallone, Giovanni; Cantaluppi, Vincenzo; Gesualdo, Loreto; Castellano, Giuseppe			Inflammaging and Complement System: A Link Between Acute Kidney Injury and Chronic Graft Damage (vol 11, 734, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						renal aging; complement system; AKI-to-CKD transition; cellular senescence and SASP; complement; inhibition therapy			[Franzin, Rossana; Stasi, Alessandra; Fiorentino, Marco; Gesualdo, Loreto; Castellano, Giuseppe] Univ Bari Aldo Moro, Dept Emergency & Organ Transplantat, Nephrol Dialysis & Transplantat Unit, Bari, Italy; [Franzin, Rossana; Cantaluppi, Vincenzo] Univ Piemonte Orientale, Dept Translat Med, Novara, Italy; [Stallone, Giovanni; Castellano, Giuseppe] Univ Foggia, Dept Med & Surg Sci, Nephrol Dialysis & Transplantat Unit, Foggia, Italy	Universita degli Studi di Bari Aldo Moro; University of Eastern Piedmont Amedeo Avogadro; University of Foggia	Franzin, R; Castellano, G (corresponding author), Univ Bari Aldo Moro, Dept Emergency & Organ Transplantat, Nephrol Dialysis & Transplantat Unit, Bari, Italy.; Franzin, R (corresponding author), Univ Piemonte Orientale, Dept Translat Med, Novara, Italy.	rossanafranzin@hotmail.it; giuseppe.castellano@unifg.it	Fiorentino, Marco/K-3771-2018; Franzin, Rossana/AAO-7099-2021; Franzin, Rossana/AHH-5631-2022; stasi, alessandra/K-5023-2016	Fiorentino, Marco/0000-0001-7334-8372; Franzin, Rossana/0000-0001-7907-7614; Stasi, Alessandra/0000-0003-3652-3623				Franzin R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00734	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 8	2021	11								630855	10.3389/fimmu.2020.630855	http://dx.doi.org/10.3389/fimmu.2020.630855			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PU9NU	33488634	Green Published, gold			2022-12-18	WOS:000609625800001
J	Weinstein-Marom, H; Gross, G; Levi, M; Brayer, H; Schachter, J; Itzhaki, O; Besser, MJ				Weinstein-Marom, Hadas; Gross, Gideon; Levi, Michal; Brayer, Hadar; Schachter, Jacob; Itzhaki, Orit; Besser, Michal J.			Genetic Modification of Tumor-Infiltrating Lymphocytes via Retroviral Transduction	FRONTIERS IN IMMUNOLOGY			English	Article						adoptive cell therapy; rapid expansion protocol; T cell subsets; T cell differentiation status; chimeric antigen receptors	ADOPTIVE CELL THERAPY; METASTATIC MELANOMA; IMMUNOTHERAPY; EFFICACY; RESPONSES; SUBSETS; CD8(+); MEMORY	Adoptive T cell therapy (ACT) holds great promise for cancer treatment. One approach, which has regained wide interest in recent years, employs antitumor T cells isolated from tumor lesions ("tumor-infiltrating lymphocytes" or TIL). It is now appreciated that a considerable proportion of anti-melanoma TIL recognize new HLA-binding peptides resulting from somatic mutations, which occurred during tumor progression. The clinical efficacy of TIL can potentially be improved via their genetic modification, designed to enhance their survival, homing capacity, resistance to suppression, tumor killing ability and additional properties of clinical relevance. Successful implementation of such gene-based strategies critically depends on efficient and reproducible protocols for gene delivery into clinical TIL preparations. Here we describe an optimized protocol for the retroviral transduction of TIL. As the experimental system we employed anti-melanoma TIL cultures prepared from four patients, recombinant retrovirus encoding an anti-CD19 chimeric antigen receptor (CAR) as a model gene of interest and CD19+ and CD19- human cell lines serving as target cells. Transduction on day 7 of the rapid expansion protocol (REP) resulted in 69 +/- 8% CAR positive TIL. Transduced, but not untransduced TIL, from the four patients responded robustly to CD19+, but not CD19- cell lines, as judged by substantial secretion of IFN-gamma following co-culture. In light of the rekindled interest in antitumor TIL, this protocol can be incorporated into a broad range of gene-based approaches for improving the in-vivo survival and functionality of TIL in the clinical setting.	[Weinstein-Marom, Hadas; Levi, Michal; Brayer, Hadar; Schachter, Jacob; Itzhaki, Orit; Besser, Michal J.] Sheba Med Ctr, Ella Lemelbaum Inst Immunooncol, Ramat Gan, Israel; [Weinstein-Marom, Hadas; Gross, Gideon] MIGAL Galilee Res Inst, Lab Immunol, Kiryat Shmona, Israel; [Weinstein-Marom, Hadas; Gross, Gideon] Tel Hai Coll, Dept Biotechnol, Upper Galilee, Israel; [Weinstein-Marom, Hadas; Besser, Michal J.] Tel Aviv Univ, Sackler Sch Med, Dept Clin Microbiol & Immunol, Tel Aviv, Israel	Chaim Sheba Medical Center; Tel Hai Academy College; Tel Aviv University; Sackler Faculty of Medicine	Itzhaki, O; Besser, MJ (corresponding author), Sheba Med Ctr, Ella Lemelbaum Inst Immunooncol, Ramat Gan, Israel.; Besser, MJ (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Clin Microbiol & Immunol, Tel Aviv, Israel.	orit.itzhaki@sheba.health.gov.il; Michal.besser@sheba.health.gov.il			Israel Science Foundation [1804/18]	Israel Science Foundation(Israel Science Foundation)	This study was supported by a research grant from the Israel Science Foundation (grant 1804/18).	Barrett DM, 2014, CYTOTHERAPY, V16, P619, DOI 10.1016/j.jcyt.2013.10.013; Berger C, 2008, J CLIN INVEST, V118, P294, DOI 10.1172/JCI32103; Besser MJ, 2020, MOL CARCINOGEN, V59, P736, DOI 10.1002/mc.23193; Besser MJ, 2015, CANCER J, V21, P465, DOI 10.1097/PPO.0000000000000154; Besser MJ, 2013, CLIN CANCER RES, V19, P4792, DOI 10.1158/1078-0432.CCR-13-0380; Besser MJ, 2010, CLIN CANCER RES, V16, P2646, DOI 10.1158/1078-0432.CCR-10-0041; Besser MJ, 2009, J IMMUNOTHER, V32, P415, DOI 10.1097/CJI.0b013e31819c8bda; Besser MJ, 2006, ISR MED ASSOC J, V8, P164; Bianchi V, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01215; Dafni U, 2019, ANN ONCOL, V30, P1902, DOI 10.1093/annonc/mdz398; Forget MA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00908; Heemskerk B, 2008, HUM GENE THER, V19, P496, DOI 10.1089/hum.2007.0171; Itzhaki O, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000148; Itzhaki O, 2013, IMMUNOTHERAPY-UK, V5, P79, DOI 10.2217/imt.12.143; Itzhaki O, 2011, J IMMUNOTHER, V34, P212, DOI 10.1097/CJI.0b013e318209c94c; Jacoby E, 2018, AM J HEMATOL, V93, P1485, DOI 10.1002/ajh.25274; Klebanoff CA, 2012, J IMMUNOTHER, V35, P651, DOI 10.1097/CJI.0b013e31827806e6; Levin N, 2018, J IMMUNOL, V201, P2959, DOI 10.4049/jimmunol.1701725; Levin N, 2017, J IMMUNOTHER, V40, P39, DOI 10.1097/CJI.0000000000000150; Li YF, 2010, J IMMUNOL, V184, P452, DOI 10.4049/jimmunol.0901101; Pato A, 2015, CLIN EXP IMMUNOL, V182, P220, DOI 10.1111/cei.12688; Phan GQ, 2013, CANCER CONTROL, V20, P289, DOI 10.1177/107327481302000406; Rasoulouniriana D, 2019, J CLIN INVEST, V129, P4151, DOI 10.1172/JCI127590; Restifo NP, 2012, NAT REV IMMUNOL, V12, P269, DOI 10.1038/nri3191; Robertson Jane, 2019, Immunooncol Technol, V3, P1, DOI 10.1016/j.iotech.2019.09.003; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; Rosenberg SA, 2011, CLIN CANCER RES, V17, P4550, DOI 10.1158/1078-0432.CCR-11-0116; Sommermeyer D, 2016, LEUKEMIA, V30, P492, DOI 10.1038/leu.2015.247; Tran KQ, 2008, J IMMUNOTHER, V31, P742, DOI 10.1097/CJI.0b013e31818403d5; van den Berg JH, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000848; Weinstein-Marom H, 2019, J IMMUNOTHER, V42, P43, DOI 10.1097/CJI.0000000000000252; Weinstein-Marom H, 2016, J IMMUNOTHER, V39, P60, DOI 10.1097/CJI.0000000000000109; Xu Y, 2014, BLOOD, V123, P3750, DOI 10.1182/blood-2014-01-552174; Zhang L, 2015, CLIN CANCER RES, V21, P2278, DOI 10.1158/1078-0432.CCR-14-2085; Zikich D, 2016, IMMUNOTHERAPY-UK, V8, P35, DOI 10.2217/imt.15.99	35	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 7	2021	11								584148	10.3389/fimmu.2020.584148	http://dx.doi.org/10.3389/fimmu.2020.584148			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PU2KN	33488585	gold, Green Published			2022-12-18	WOS:000609135000001
J	Thomassen, MJ; Judson, MA; Barna, BP				Thomassen, Mary Jane; Judson, Marc A.; Barna, Barbara P.			Editorial: Novel Insights Into the Immunology of Pulmonary Granulomatous Diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						granulomatous disease; sarcoidosis; Th17; matrix metalloproteinase 12; environmental and occupational exposures			[Thomassen, Mary Jane; Barna, Barbara P.] East Carolina Univ, Div Pulm Crit Care & Sleep Med, Greenville, NC 27858 USA; [Judson, Marc A.] Albany Med Coll, Div Pulm, Crit Care, Albany, NY 12208 USA	University of North Carolina; East Carolina University; Albany Medical College	Thomassen, MJ (corresponding author), East Carolina Univ, Div Pulm Crit Care & Sleep Med, Greenville, NC 27858 USA.	thomassenm@ecu.edu			 [ES025191];  [CHHE P30 ES025128]	; 	This study was funded by grants ES025191 to MT and CHHE P30 ES025128.		0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 5	2021	11								633103	10.3389/fimmu.2020.633103	http://dx.doi.org/10.3389/fimmu.2020.633103			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PT6HJ	33584732	gold, Green Published			2022-12-18	WOS:000608714200001
J	Jorgensen, TN; Kovats, S; Lotter, H				Jorgensen, Trine N.; Kovats, Susan; Lotter, Hanna			Editorial: Effects of Androgens on Immunity to Self and Foreign	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						androgen; sex differences; immune cells; cancer; infection; autoimmunity			[Jorgensen, Trine N.] Cleveland Clin, Lerner Res Inst, Dept Inflammat & Immun, Cleveland, OH 44106 USA; [Kovats, Susan] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA; [Lotter, Hanna] Bernhard Nocht Inst Trop Med BMITM, Dept Mol Parasitol & Immunol, Hamburg, Germany	Cleveland Clinic Foundation; Oklahoma Medical Research Foundation	Jorgensen, TN (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Inflammat & Immun, Cleveland, OH 44106 USA.	jorgent@ccf.org						Cole SW, 2020, P NATL ACAD SCI USA, V117, P4601, DOI 10.1073/pnas.1821367117; Cutolo M, 2006, ANN NY ACAD SCI, V1089, P538, DOI 10.1196/annals.1386.043; Dominguez-Andres J, 2019, TRENDS IMMUNOL, V40, P1105, DOI 10.1016/j.it.2019.10.001; Narayanan R, 2018, MOL CELL ENDOCRINOL, V465, P134, DOI 10.1016/j.mce.2017.06.013; vom Steeg LG, 2019, SEMIN IMMUNOPATHOL, V41, P189, DOI 10.1007/s00281-018-0718-5	5	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 21	2020	11								630066	10.3389/fimmu.2020.630066	http://dx.doi.org/10.3389/fimmu.2020.630066			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PN2AR	33408721	Green Published, gold			2022-12-18	WOS:000604287900001
J	Bacsa, B; Graziani, A; Krivic, D; Wiedner, P; Malli, R; Rauter, T; Tiapko, O; Groschner, K				Bacsa, Bernadett; Graziani, Annarita; Krivic, Denis; Wiedner, Patrick; Malli, Roland; Rauter, Thomas; Tiapko, Oleksandra; Groschner, Klaus			Pharmaco-Optogenetic Targeting of TRPC Activity Allows for Precise Control Over Mast Cell NFAT Signaling	FRONTIERS IN IMMUNOLOGY			English	Article						canonical transient receptor potential channels; mast cells; opto-chemical immunomodulation; NFAT nuclear translocation; photopharmacology; OptoBI-1	CALCIUM-ENTRY; CHANNEL; CA2+; DEGRANULATION; INNATE; INFLUX	Canonical transient receptor potential (TRPC) channels are considered as elements of the immune cell Ca2+ handling machinery. We therefore hypothesized that TRPC photopharmacology may enable uniquely specific modulation of immune responses. Utilizing a recently established TRPC3/6/7 selective, photochromic benzimidazole agonist OptoBI-1, we set out to test this concept for mast cell NFAT signaling. RBL-2H3 mast cells were found to express TRPC3 and TRPC7 mRNA but lacked appreciable Ca2+/NFAT signaling in response to OptoBI-1 photocycling. Genetic modification of the cells by introduction of single recombinant TRPC isoforms revealed that exclusively TRPC6 expression generated OptoBI-1 sensitivity suitable for opto-chemical control of NFAT1 activity. Expression of any of three benzimidazole-sensitive TRPC isoforms (TRPC3/6/7) reconstituted plasma membrane TRPC conductances in RBL cells, and expression of TRPC6 or TRPC7 enabled light-mediated generation of temporally defined Ca2+ signaling patterns. Nonetheless, only cells overexpressing TRPC6 retained essentially low basal levels of NFAT activity and displayed rapid and efficient NFAT nuclear translocation upon OptoBI-1 photocycling. Hence, genetic modification of the mast cells' TRPC expression pattern by the introduction of TRPC6 enables highly specific opto-chemical control over Ca2+ transcription coupling in these immune cells.	[Bacsa, Bernadett; Graziani, Annarita; Krivic, Denis; Wiedner, Patrick; Tiapko, Oleksandra; Groschner, Klaus] Med Univ Graz, Gottfried Schatz Res Ctr Biophys, Graz, Austria; [Malli, Roland; Rauter, Thomas] Med Univ Graz, Gottfried Schatz Res Ctr Mol Biol & Biochem, Graz, Austria	Medical University of Graz; Medical University of Graz	Groschner, K (corresponding author), Med Univ Graz, Gottfried Schatz Res Ctr Biophys, Graz, Austria.	klaus.groschner@medunigraz.at		Bacsa, Bernadett/0000-0003-2201-4721; Tiapko, Oleksandra/0000-0001-7360-4823; Krivic, Denis/0000-0002-2852-4522	FWF [P3326]	FWF(Austrian Science Fund (FWF))	This research was funded by FWF P3326 (KG). DK is a member of the PhD program (DK) "Metabolic and Cardiovascular Disease" [W1226].	Ankenbruck N, 2018, ANGEW CHEM INT EDIT, V57, P2768, DOI 10.1002/anie.201700171; Aponte-Lopez A, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/2584243; Berry CT, 2018, CELL CALCIUM, V74, P131, DOI 10.1016/j.ceca.2018.07.003; Bohineust A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14810-2; Cohen R, 2009, J IMMUNOL, V183, P6478, DOI 10.4049/jimmunol.0901615; Curcic S, 2019, PHARMACOL THERAPEUT, V200, P13, DOI 10.1016/j.pharmthera.2019.04.003; Dietrich A, 2003, J BIOL CHEM, V278, P47842, DOI 10.1074/jbc.M302983200; Fehrentz T, 2011, ANGEW CHEM INT EDIT, V50, P12156, DOI 10.1002/anie.201103236; Feske S, 2015, ANNU REV IMMUNOL, V33, P291, DOI 10.1146/annurev-immunol-032414-112212; Freichel M, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00150; Graziani A, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030556; He L, 2015, ELIFE, V4, DOI 10.7554/eLife.10024; Kaesler S, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125057; Kar P, 2015, MOL CELL, V58, P232, DOI 10.1016/j.molcel.2015.02.027; Kar P, 2011, J BIOL CHEM, V286, P14795, DOI 10.1074/jbc.M111.220582; Khalil M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00174; Komi DEA, 2020, CLIN REV ALLERG IMMU, V58, P313, DOI 10.1007/s12016-019-08753-w; Lichtenegger M, 2018, NAT CHEM BIOL, V14, P396, DOI 10.1038/s41589-018-0015-6; Lievremont JP, 2004, AM J PHYSIOL-CELL PH, V287, pC1709, DOI 10.1152/ajpcell.00350.2004; Linde CI, 2012, AM J PHYSIOL-HEART C, V302, pH611, DOI 10.1152/ajpheart.00950.2011; Ma HT, 2008, J IMMUNOL, V180, P2233, DOI 10.4049/jimmunol.180.4.2233; Panyi G, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0106; Parenti A, 2016, BRIT J PHARMACOL, V173, P953, DOI 10.1111/bph.13392; Poburko D, 2007, CIRC RES, V101, P1030, DOI 10.1161/CIRCRESAHA.107.155531; Poteser M, 2011, P NATL ACAD SCI USA, V108, P13876, DOI 10.1073/pnas.1111388108; Poteser M, 2011, P NATL ACAD SCI USA, V108, P10556, DOI 10.1073/pnas.1106183108; Rivera J, 2006, J ALLERGY CLIN IMMUN, V117, P1214, DOI 10.1016/j.jaci.2006.04.015; Ryu KA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08520-x; Sanchez-Miranda E, 2010, BIOCHEM BIOPH RES CO, V391, P1714, DOI 10.1016/j.bbrc.2009.12.139; Suzuki R, 2010, J LEUKOCYTE BIOL, V88, P863, DOI 10.1189/jlb.0510253; Svobodova B, 2019, CELL CALCIUM, V79, P27, DOI 10.1016/j.ceca.2019.02.007; Tan P, 2017, TRENDS BIOTECHNOL, V35, P215, DOI 10.1016/j.tibtech.2016.09.002; Tiapko O, 2019, CHEM SCI, V10, P2837, DOI 10.1039/c8sc05536j; Tsvilovskyy V, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00564; Velema WA, 2014, J AM CHEM SOC, V136, P2178, DOI 10.1021/ja413063e; Wajdner HE, 2017, PHYSIOL REP, V5, DOI 10.14814/phy2.13166; Wedemeyer J, 2000, CURR OPIN IMMUNOL, V12, P624, DOI 10.1016/S0952-7915(00)00154-0; Xu JY, 2018, CANCER RES, V78, P2564, DOI 10.1158/0008-5472.CAN-17-2061	38	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 18	2020	11								613194	10.3389/fimmu.2020.613194	http://dx.doi.org/10.3389/fimmu.2020.613194			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PM7LY	33391284	gold, Green Published			2022-12-18	WOS:000603976900001
J	Bajana, S; Thomas, K; Georgescu, C; Zhao, Y; Wren, JD; Kovats, S; Sun, XH				Bajana, Sandra; Thomas, Kevin; Georgescu, Constantin; Zhao, Ying; Wren, Jonathan D.; Kovats, Susan; Sun, Xiao-Hong			Augmenting E Protein Activity Impairs cDC2 Differentiation at the Pre-cDC Stage	FRONTIERS IN IMMUNOLOGY			English	Article						E protein; cDC1; cDC2; pre-cDC; IRF4; IRF8	TRANSCRIPTION FACTOR E2-2; DENDRITIC CELLS; IN-VITRO; PROGENITORS; IRF8; IDENTIFICATION; MAINTAINS; MOUSE; FATE	Dendritic cell (DC) specification and differentiation are controlled by a circuit of transcription factors, which regulate the expression of DC effector genes as well as the transcription factors themselves. E proteins are a widely expressed basic helix-loop-helix family of transcription factors whose activity is suppressed by their inhibitors, ID proteins. Loss-of-function studies have demonstrated the essential role of both E and ID proteins in different aspects of DC development. In this study, we employed a gain-of-function approach to illustrate the importance of the temporal control of E protein function in maintaining balanced differentiation of conventional DC (cDC) subsets, cDC1 and cDC2. We expressed an E protein mutant, ET2, which dimerizes with endogenous E proteins to overcome inhibition by ID proteins and activate the transcription of E protein targets. Induction of ET2 expression at the hematopoietic progenitor stage led to a dramatic reduction in cDC2 precursors (pre-cDC2s) with little impact on pre-cDC1s. Consequently, we observed decreased numbers of cDC2s in the spleen and lung, as well as in FLT3L-driven bone marrow-derived DC cultures. Furthermore, in mice bearing ET2, we detected increased expression of the IRF8 transcription factor in cDC2s, in which IRF8 is normally down-regulated and IRF4 up-regulated. This aberrant expression of IRF8 induced by ET2 may contribute to the impairment of cDC2 differentiation. In addition, analyses of the transcriptomes of splenic cDC1s and cDC2s revealed that ET2 expression led to a shift, at least in part, of the transcriptional profile characteristic of cDC2s to that of cDC1. Together, these results suggest that a precise control of E protein activity is crucial for balanced DC differentiation.	[Bajana, Sandra; Thomas, Kevin; Zhao, Ying; Kovats, Susan; Sun, Xiao-Hong] Oklahoma Med Res Fdn, Program Arthrit & Clin Immunol, 825 NE 13th St, Oklahoma City, OK 73104 USA; [Georgescu, Constantin; Wren, Jonathan D.] Oklahoma Med Res Fdn, Program Genes & Human Dis, 825 NE 13th St, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation; Oklahoma Medical Research Foundation	Sun, XH (corresponding author), Oklahoma Med Res Fdn, Program Arthrit & Clin Immunol, 825 NE 13th St, Oklahoma City, OK 73104 USA.	sunx@omrf.org			NIH [1P20 GM103636-07, HL119501]; Presbyterian Health Foundation; Lew and Mira Ward Chair in Biomedical Research at the Oklahoma Medical Research Foundation	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Presbyterian Health Foundation; Lew and Mira Ward Chair in Biomedical Research at the Oklahoma Medical Research Foundation	This work was supported by grants from the NIH (1P20 GM103636-07) to X-HS and JW and (HL119501) to SK, and from the Presbyterian Health Foundation to X-HS. X-HS holds the Lew and Mira Ward Chair in Biomedical Research at the Oklahoma Medical Research Foundation.	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Bagadia P, 2019, NAT IMMUNOL, V20, P1174, DOI 10.1038/s41590-019-0449-3; Bajana S, 2016, J IMMUNOL, V196, P1666, DOI 10.4049/jimmunol.1501870; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Briseno CG, 2018, P NATL ACAD SCI USA, V115, P10726, DOI 10.1073/pnas.1809925115; Cisse B, 2008, CELL, V135, P37, DOI 10.1016/j.cell.2008.09.016; Cochrane SW, 2009, BLOOD, V113, P1016, DOI 10.1182/blood-2008-06-164996; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Durai V, 2019, NAT IMMUNOL, V20, P1161, DOI 10.1038/s41590-019-0450-x; Durai V, 2016, IMMUNITY, V45, P719, DOI 10.1016/j.immuni.2016.10.010; Gao Y, 2013, IMMUNITY, V39, P722, DOI 10.1016/j.immuni.2013.08.028; Ghosh HS, 2010, IMMUNITY, V33, P905, DOI 10.1016/j.immuni.2010.11.023; Grajales-Reyes GE, 2015, NAT IMMUNOL, V16, P708, DOI 10.1038/ni.3197; Guermonprez P, 2019, INT REV CEL MOL BIO, V349, P1, DOI 10.1016/bs.ircmb.2019.08.002; Hacker C, 2003, NAT IMMUNOL, V4, P380, DOI 10.1038/ni903; Hu TS, 2013, J IMMUNOL, V191, P5065, DOI 10.4049/jimmunol.1301546; Kim S, 2020, IMMUNITY, V53, P759, DOI 10.1016/j.immuni.2020.07.018; Ling F, 2014, CURR TOP DEV BIOL, V110, P189, DOI 10.1016/B978-0-12-405943-6.00005-1; Lugt BV, 2014, NAT IMMUNOL, V15, P161, DOI 10.1038/ni.2795; Ma WJ, 2019, BMC MOL CELL BIOL, V20, DOI 10.1186/s12860-019-0199-y; Murphy KM, 2013, ADV IMMUNOL, V120, P239, DOI 10.1016/B978-0-12-417028-5.00009-0; Murphy TL, 2016, ANNU REV IMMUNOL, V34, P93, DOI 10.1146/annurev-immunol-032713-120204; Murre C, 2005, NAT IMMUNOL, V6, P1079, DOI 10.1038/ni1260; Naik SH, 2007, NAT IMMUNOL, V8, P1217, DOI 10.1038/ni1522; Naik SH, 2010, METHODS MOL BIOL, V595, P167, DOI 10.1007/978-1-60761-421-0_10; Nakano H, 2015, J IMMUNOL, V194, P3808, DOI 10.4049/jimmunol.1402195; Nie L, 2003, EMBO J, V22, P5780, DOI 10.1093/emboj/cdg567; Nie L, 2008, MOL CELL BIOL, V28, P2078, DOI 10.1128/MCB.00844-07; Nold MF, 2010, NAT IMMUNOL, V11, P1014, DOI 10.1038/ni.1944; Onai N, 2007, NAT IMMUNOL, V8, P1207, DOI 10.1038/ni1518; Park ST, 1999, J EXP MED, V189, P501, DOI 10.1084/jem.189.3.501; Park ST, 1998, J BIOL CHEM, V273, P7030, DOI 10.1074/jbc.273.12.7030; Peng V, 2020, J BIOL CHEM, V295, P14866, DOI 10.1074/jbc.RA120.013806; Roberts AB, 2003, ANN NY ACAD SCI, V995, P1, DOI 10.1111/j.1749-6632.2003.tb03205.x; Rodrigues PF, 2018, NAT IMMUNOL, V19, P711, DOI 10.1038/s41590-018-0136-9; Roquilly A, 2017, IMMUNITY, V47, P135, DOI 10.1016/j.immuni.2017.06.021; Satpathy AT, 2012, NAT IMMUNOL, V13, P1145, DOI 10.1038/ni.2467; Schlitzer A, 2015, NAT IMMUNOL, V16, P718, DOI 10.1038/ni.3200; Schlitzer A, 2014, CURR OPIN IMMUNOL, V26, P90, DOI 10.1016/j.coi.2013.11.002; Sichien D, 2017, MUCOSAL IMMUNOL, V10, P831, DOI 10.1038/mi.2017.8; Sichien D, 2016, IMMUNITY, V45, P626, DOI 10.1016/j.immuni.2016.08.013; Williams JW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3990	42	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 18	2020	11								577718	10.3389/fimmu.2020.577718	http://dx.doi.org/10.3389/fimmu.2020.577718			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PM7MT	33391258	gold, Green Published			2022-12-18	WOS:000603979000001
J	Lavelle, EC; Carsetti, R; Pickl, WF; Wiedermann, U				Lavelle, Ed C.; Carsetti, Rita; Pickl, Winfried F.; Wiedermann, Ursula			Editorial: Challenges in Vaccinology	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						vaccine; systems biology; adjuvant; emerging infectious diseases; nosocomial infections; demographic changes; microbiome			[Lavelle, Ed C.] Trinity Coll Dublin, Trinity Biomed Sci Inst, Sch Biochem & Immunol, Adjuvant Res Grp, Dublin, Ireland; [Carsetti, Rita] Bambino Gesu Children Hosp, Immunol Res Area B Cell Dev Unit, Immunol Diag Unit, Rome, Italy; [Pickl, Winfried F.] Med Univ Vienna, Inst Immunol, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria; [Wiedermann, Ursula] Med Univ Vienna, Inst Specif Prophylaxis & Trop Med, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria	Trinity College Dublin; IRCCS Bambino Gesu; Medical University of Vienna; Medical University of Vienna	Wiedermann, U (corresponding author), Med Univ Vienna, Inst Specif Prophylaxis & Trop Med, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria.	ursula.wiedermann@meduniwien.ac.at		Pickl, Winfried F./0000-0003-0430-4952; Wiedermann, Ursula/0000-0002-1302-3223					0	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 17	2020	11								632537	10.3389/fimmu.2020.632537	http://dx.doi.org/10.3389/fimmu.2020.632537			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PM2HI	33391292	Green Published, gold			2022-12-18	WOS:000603626800001
J	Sadiq, A; Bostan, N				Sadiq, Asma; Bostan, Nazish			Comparative Analysis of G1P[8] Rotaviruses Identified Prior to Vaccine Implementation in Pakistan With Rotarix (TM) and RotaTeq (TM) Vaccine Strains (vol 11, 562282, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						G1P[8]; rotavirus; genotype; antigenic epitopes; emergence			[Sadiq, Asma; Bostan, Nazish] COMSATS Univ CUI, Dept Biosci, Islamabad, Pakistan	COMSATS University Islamabad (CUI)	Bostan, N (corresponding author), COMSATS Univ CUI, Dept Biosci, Islamabad, Pakistan.	nazishbostan@comsats.edu.pk	Bostan, Nazish/AAU-3262-2021	Bostan, Nazish/0000-0003-2226-5440				Sadiq A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.562282	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 16	2020	11								625157	10.3389/fimmu.2020.625157	http://dx.doi.org/10.3389/fimmu.2020.625157			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PL9VA	33391290	Green Published, gold			2022-12-18	WOS:000603459000001
J	Carvelli, J; Le Saux, A; Bourenne, J; Gainnier, M; Kaplanski, G				Carvelli, Julien; Le Saux, Audrey; Bourenne, Jeremy; Gainnier, Marc; Kaplanski, Gilles			Evolution Toward Severe Covid-19 From Biological Monitoring to Therapeutic Considerations	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						COVID-19; SARS-CoV-2; C reactive protein; IL-6; cytokine storm	IL-18		[Carvelli, Julien; Le Saux, Audrey; Bourenne, Jeremy; Gainnier, Marc] Aix Marseille Univ, Reanimat Urgences, CHU Timone, AP HM, Marseille, France; [Carvelli, Julien] CHU Timone, AP HM, Marseille Immunopole, Marseille, France; [Kaplanski, Gilles] Aix Marseille Univ, CHU Conception, AP HM, Med Interne & Immunol Clin, Marseille, France	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Carvelli, J (corresponding author), Aix Marseille Univ, Reanimat Urgences, CHU Timone, AP HM, Marseille, France.; Carvelli, J (corresponding author), CHU Timone, AP HM, Marseille Immunopole, Marseille, France.	Julien.CARVELLI@ap-hm.fr						Cao B., 2020, NEW ENGL J MED, V382, pe68, DOI [10.1056/NEJMc2008043, DOI 10.1084/jem.189.3.599]; Carvelli J, 2020, NATURE, V588, P146, DOI 10.1038/s41586-020-2600-6; Cauchois R, 2020, P NATL ACAD SCI USA, V117, P18951, DOI 10.1073/pnas.2009017117; Dinarello CA, 2018, J LEUKOCYTE BIOL, V104, P237, DOI 10.1002/JLB.CE0118-025RR; Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2022926, 10.1056/NEJMoa2021436]; Lucas C, 2020, NATURE, V584, P463, DOI 10.1038/s41586-020-2588-y; Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007; Park JH, 2020, LANCET GLOB HEALTH, V8, pE1249, DOI 10.1016/S2214-109X(20)30365-X; Roumier M, 2021, J CLIN IMMUNOL, V41, P303, DOI 10.1007/s10875-020-00911-6; Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012; Urwyler P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02072; van de Veerdonk FL, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.17708; Zalinger ZB, 2017, J NEUROVIROL, V23, P845, DOI 10.1007/s13365-017-0574-4; Zhang HJ, 2020, AM J RESP CRIT CARE, V202, P219, DOI 10.1164/rccm.202003-0541OC; Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041	17	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 15	2020	11								562038	10.3389/fimmu.2020.562038	http://dx.doi.org/10.3389/fimmu.2020.562038			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PL3YA	33384683	Green Published, gold			2022-12-18	WOS:000603060400001
J	Chalvon, NB; Orquevaux, P; Giusti, D; Gatouillat, G; Tabary, T; Libyh, MT; Chrusciel, J; Drame, M; Stockton-Bliard, G; Amoura, Z; Arnaud, L; Lorenz, HM; Blaison, G; Bonnotte, B; Magy-Bertrand, N; Revuz, S; Voll, RE; Hinschberger, O; Schwarting, A; Pham, BN; Martin, T; Pennaforte, JL; Servettaz, A				Chalvon, Nellie Bourse; Orquevaux, Pauline; Giusti, Delphine; Gatouillat, Gregory; Tabary, Thierry; Libyh, Marcelle Tonye; Chrusciel, Jan; Drame, Moustapha; Stockton-Bliard, Grace; Amoura, Zahir; Arnaud, Laurent; Lorenz, Hanns-Martin; Blaison, Gilles; Bonnotte, Bernard; Magy-Bertrand, Nadine; Revuz, Sabine; Voll, Reinhard Edmund; Hinschberger, Oliver; Schwarting, Andreas; Pham, Bach Nga; Martin, Thierry; Pennaforte, Jean-Loup; Servettaz, Amelie			Absence of Anti-Glomerular Basement Membrane Antibodies in 200 Patients With Systemic Lupus Erythematosus With or Without Lupus Nephritis: Results of the GOODLUPUS Study	FRONTIERS IN IMMUNOLOGY			English	Article						anti-glomerular basement membrane antibodies; lupus nephritis; Goodpasture disease; anti-GBM antibodies; anti-GBM glomerulonephritis; systemic lupus erythematosus	ANTINEUTROPHIL CYTOPLASMIC ANTIBODY; CHINESE PATIENTS; GBM ANTIBODIES; CLASSIFICATION; DISEASE; GLOMERULONEPHRITIS; AUTOANTIBODIES; DERIVATION; DIAGNOSIS; FEATURES	Introduction Anti-glomerular basement membrane (GBM) antibodies are pathogenic antibodies first detected in renal-limited anti-GBM disease and in Goodpasture disease, the latter characterized by rapidly progressive crescentic glomerulonephritis combined with intra-alveolar hemorrhage. Studies have suggested that anti-GBM antibody positivity may be of interest in lupus nephritis (LN). Moreover, severe anti-GBM vasculitis cases in patients with systemic lupus erythematosus (SLE) have been described in the literature, but few studies have assessed the incidence of anti-GBM antibodies in SLE patients. Objective The main study objective was to determine if positive anti-GBM antibodies were present in the serum of SLE patients with or without proliferative renal damage and compared to a healthy control group. Methodology This retrospective study was performed on SLE patients' sera from a Franco-German European biobank, developed between 2011 and 2014, from 17 hospital centers in the Haut-Rhin region. Patients were selected according to their renal involvement, and matched by age and gender. The serum from healthy voluntary blood donors was also tested. Anti-GBM were screened by fluorescence enzyme immunoassay (FEIA), and then by indirect immunofluorescence (IIF) in case of low reactivity detection (titer >6 U/ml). Results The cohort was composed of 100 SLE patients with proliferative LN (27% with class III, 67% with class IV, and 6% with class V), compared to 100 SLE patients without LN and 100 controls. Patients were mostly Caucasian and met the ACR 1997 criteria and/or the SLICC 2012 criteria. Among the 300 tested sera, no significant levels of anti-GBM antibodies were detected (>10 U/ml) by the automated technique, three sera were found "ambivalent" (>7 U/ml): one in the SLE with LN group and two in the SLE without LN group. Subsequent IIF assays did not detect anti-GBM antibodies. Conclusion Anti-GBM antibodies were not detected in the serum of Caucasian patients with SLE, even in case of renal involvement, a situation favoring the antigenic exposure of glomerular basement membranes. Our results reaffirm the central role of anti-GBM antibodies as a specific diagnostic biomarker for Goodpasture vasculitis and therefore confirm that anti-GBM antibody must not be carried out in patients with SLE (with or without LN) in the absence of disease-suggestive symptoms.	[Chalvon, Nellie Bourse; Orquevaux, Pauline; Pennaforte, Jean-Loup; Servettaz, Amelie] CHU Reims, Dept Med Interne, Reims, France; [Giusti, Delphine; Gatouillat, Gregory; Tabary, Thierry; Libyh, Marcelle Tonye; Pham, Bach Nga] CHU Reims, Dept Immunol Biol, Lab Immunol, Reims, France; [Chrusciel, Jan] Ctr Hosp Troyes, Dept Informat Med & Evaluat Performances, Sante Publ, Troyes, France; [Drame, Moustapha] Univ Hosp Martinique, Dept Delegat Rech Clin & Innovat, Fort De France, Martinique, France; [Stockton-Bliard, Grace] Univ Reims, Commiss Rech, Reims, France; [Amoura, Zahir] AP HP, Serv Med Interne, Paris, France; [Arnaud, Laurent] Hop Univ Strasbourg, Serv Rhumatol, Strasbourg, France; [Lorenz, Hanns-Martin] Univ Hosp Heidelberg, Dept Internal Med 5, Div Rheumatol, Clint Hematol Oncol & Rhaurnatol, Heidelberg, Germany; [Blaison, Gilles] Hop Louis Pasteur, Dept Med Interne, Colmar, France; [Bonnotte, Bernard] Ctr Hosp Reg Univ Dijon, Dept Med Interne & Immunol Clin, Dijon, France; [Magy-Bertrand, Nadine] CHU Besancon, Dept Med Interne, Besancon, France; [Revuz, Sabine] Hop Belle Isle, Dept Med Interne, Metz, France; [Voll, Reinhard Edmund] Univ Freiburg, Med Ctr, Dept Rheumatol & Clin Immunol, Freiburg, Germany; [Hinschberger, Oliver] Grp Hosp Reg Mulhouse & Sud Alsace GHRMSA, Dept Med Interne, Mulhouse, France; [Schwarting, Andreas] Johannes Gutenberg Univ Mainz, Univ Ctr Autoimmunitat Mainz, Mainz, Germany; [Martin, Thierry] Hop Univ Strasbourg, Immunol Clin & Med Interne, Strasbourg, France	CHU de Reims; Universite de Reims Champagne-Ardenne; CHU de Reims; Universite de Reims Champagne-Ardenne; Institute of Public Health Surveillance; CHU Martinique; Universite de Reims Champagne-Ardenne; Assistance Publique Hopitaux Paris (APHP); CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Ruprecht Karls University Heidelberg; CHU Dijon Bourgogne; Universite de Franche-Comte; CHU Besancon; University of Freiburg; Johannes Gutenberg University of Mainz; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Chalvon, NB (corresponding author), CHU Reims, Dept Med Interne, Reims, France.	nbourse@chu.reims.fr	Bonnotte, Bernard/ABA-2525-2021; Magy-Bertrand, Nadine/ABE-1285-2021	Bonnotte, Bernard/0000-0002-1098-4598; Magy-Bertrand, Nadine/0000-0003-1117-5079; GIUSTI, Delphine/0000-0001-6857-4842; ARNAUD, Laurent/0000-0002-8077-8394; Martin, Thierry/0000-0002-2776-2641				Alba P, 2003, ANN RHEUM DIS, V62, P556, DOI 10.1136/ard.62.6.556; Amoura Z, 2010, HAUTE AUTORITE SANTE; Bajema IM, 2018, KIDNEY INT, V93, P789, DOI 10.1016/j.kint.2017.11.023; Bentow C, 2015, IMMUNOL RES, V61, P110, DOI 10.1007/s12026-014-8601-5; BOMBARDIER C, 1992, ARTHRITIS RHEUM, V35, P630, DOI 10.1002/art.1780350606; CASAGRANDE JT, 1978, BIOMETRICS, V34, P483, DOI 10.2307/2530613; Chalvon N, 2017, REV MED INTERNE, V38, pA175, DOI [10.1016/j.revmed.2017.03.245, DOI 10.1016/J.REVMED.2017.03.245]; Faurschou M, 2010, ARTHRIT CARE RES, V62, P873, DOI 10.1002/acr.20116; Gavand P-E, 2017, REV MED INTERNE, V38, pA78, DOI [10.1016/j.revmed.2017.10.368, DOI 10.1016/J.REVMED.2017.10.368]; Ghali JR, 2016, NEPHROLOGY, V21, P86, DOI 10.1111/nep.12574; Greco A, 2015, AUTOIMMUN REV, V14, P246, DOI 10.1016/j.autrev.2014.11.006; Guillevin L, 2015, TRAITE MALADIES SYND; Hahn BH, 2012, ARTHRIT CARE RES, V64, P797, DOI 10.1002/acr.21664; Hellmark T, 1997, J AM SOC NEPHROL, V8, P376; Hellmark T, 2014, J AUTOIMMUN, V48-49, P108, DOI 10.1016/j.jaut.2014.01.024; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; Huong DLT, 1999, MEDICINE, V78, P148; Jarrot PA, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003748; Jaskowski TD, 2002, J CLIN LAB ANAL, V16, P143, DOI 10.1002/jcla.10034; Zhao J, 2007, NEPHRON CLIN PRACT, V107, pC56, DOI 10.1159/000107803; Korbet SM, 2007, J AM SOC NEPHROL, V18, P244, DOI 10.1681/ASN.2006090992; LEE SS, 1993, LUPUS, V2, P105, DOI 10.1177/096120339300200207; LERNER RA, 1967, J EXP MED, V126, P989, DOI 10.1084/jem.126.6.989; Levy JB, 2004, KIDNEY INT, V66, P1535, DOI 10.1111/j.1523-1755.2004.00917.x; Li CH, 2006, SCAND J RHEUMATOL, V35, P201, DOI 10.1080/03009740500303181; Li C, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015668; Liang Y, 2017, RHEUMATOL INT, V37, P305, DOI 10.1007/s00296-016-3630-0; Liu K, 2009, J CLIN INVEST, V119, P911, DOI 10.1172/JCI36728; Liu XX, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-277; McAdoo SP, 2017, KIDNEY INT, V92, P693, DOI 10.1016/j.kint.2017.03.014; Mok MY, 2010, LUPUS, V19, P1384, DOI 10.1177/0961203310375832; Park Se Jin, 2013, Saudi J Kidney Dis Transpl, V24, P596; Pedchenko V, 2010, NEW ENGL J MED, V363, P343, DOI 10.1056/NEJMoa0910500; Petri M, 2012, ARTHRITIS RHEUM-US, V64, P2677, DOI 10.1002/art.34473; Philip R, 2020, REV MED INTERNE, V41, P21, DOI 10.1016/j.revmed.2019.10.334; Rutgers A, 2005, AM J KIDNEY DIS, V46, P253, DOI 10.1053/j.ajkd.2005.05.003; SAVAGE COS, 1986, BRIT MED J, V292, P301, DOI 10.1136/bmj.292.6516.301; SEGONDS A, 1981, Revue de Medecine Interne, V2, P143, DOI 10.1016/S0248-8663(81)80057-4; Sharman A, 2004, NEPHROL DIAL TRANSPL, V19, P1420, DOI 10.1093/ndt/gfh139; SHAYAKUL C, 1995, AM J KIDNEY DIS, V26, P300, DOI 10.1016/0272-6386(95)90650-9; Sinico RA, 2006, NEPHROL DIAL TRANSPL, V21, P397, DOI 10.1093/ndt/gfi230; Soliman S, 2017, CLIN IMMUNOL, V185, P10, DOI 10.1016/j.clim.2016.08.001; STEBLAY RW, 1962, J EXP MED, V116, P253, DOI 10.1084/jem.116.2.253; Tamirou F, 2018, RMD OPEN, V4, DOI 10.1136/rmdopen-2018-000793; Taylor DM, 2012, INTERN MED J, V42, P672, DOI 10.1111/j.1445-5994.2011.02621.x; Tikly M, 2008, BEST PRACT RES CL RH, V22, P643, DOI 10.1016/j.berh.2008.05.003; Turner-Stokes T, 2017, KIDNEY INT, V92, P1223, DOI 10.1016/j.kint.2017.04.029; Weening JJ, 2004, J AM SOC NEPHROL, V15, P241, DOI 10.1097/01.ASN.0000108969.21691.5D; Wu HJ, 2016, AUTOIMMUN REV, V15, P684, DOI 10.1016/j.autrev.2016.03.002; Yadla M, 2011, SAUDI J KIDNEY DIS T, V22, P349; Yamada T, 2018, J NIPPON MED SCH, V85, P138, DOI 10.1272/jnms.2018_85-21; Yamazaki K, 1993, Nihon Kyobu Shikkan Gakkai Zasshi, V31, P251; Yang R, 2009, NEPHROL DIAL TRANSPL, V24, P1838, DOI 10.1093/ndt/gfn761; Zhao J, 2009, KIDNEY INT, V76, P1108, DOI 10.1038/ki.2009.348	54	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 14	2020	11								597863	10.3389/fimmu.2020.597863	http://dx.doi.org/10.3389/fimmu.2020.597863			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PK7FH	33381119	Green Published, gold			2022-12-18	WOS:000602605400001
J	Kramer, J; Glaser, F; Hasselblatt, M; Brand, E; Pogoda, C; Lenders, M; Wiendl, H; Meuth, SG; Duning, T				Kramer, Julia; Glaser, Felix; Hasselblatt, Martin; Brand, Eva; Pogoda, Christian; Lenders, Malte; Wiendl, Heinz; Meuth, Sven G.; Duning, Thomas			Case Report: A Spinal Ischemic Lesion in a 24-Year-Old Patient With Fabry Disease	FRONTIERS IN IMMUNOLOGY			English	Article						Fabry disease; spinal lesion; multiple sclerosis; spinal ischemia; case report; MRI		Background While cerebral lesions are common in Fabry disease (FD), spinal lesions have not been described, and their presence was suggested to be indicative of multiple sclerosis. Here, we present a FD patient with histopathological confirmed spinal ischemic stroke. Case presentation A patient with genetically and biochemically diagnosed FD and characteristic manifestations (acroparesthesia, angiokeratomas, hypohidrosis, microalbuminuria, myocardial hypertrophy) presented with paraplegia, loss of all sensory modalities below Th9, and loss of bowel and bladder function. While cranial MRI was inconspicuous, spinal MRI showed a T2 hyperintense, non-contrast-enhancing lesion of the thoracic spinal cord. Lumbar puncture revealed mild pleocytosis, increased total protein and lactate levels, decreased glucose ratio, and negative oligoclonal bands. Rheumatic, neoplastic, and infectious disorders were excluded. The patient received intravenous and intrathecal methylprednisolone, plasmapheresis, intravenous immunoglobulins, and cyclophosphamide without clinical improvement. A biopsy of the thoracic lesion was performed. A histopathological examination revealed necrotic tissue consistent with spinal cord ischemia. Diagnostic work-up for stroke etiology clarification was not conspicuous. Two years onward, the patient suffered from a pontine infarction and a transient ischemic attack. Conclusion The current case highlights the possible occurrence of spinal ischemic lesions in FD. Thus, the diagnosis of FD should not be prematurely discarded in the presence of spinal lesions.	[Kramer, Julia; Glaser, Felix; Wiendl, Heinz; Meuth, Sven G.; Duning, Thomas] Univ Hosp Munster, Dept Neurol, Inst Translat Neurol, Munster, Germany; [Hasselblatt, Martin] Univ Hosp Munster, Inst Neuropathol, Munster, Germany; [Brand, Eva; Lenders, Malte] Univ Hosp Munster, Dept Internal Med D, Munster, Germany; [Brand, Eva; Lenders, Malte] Univ Hosp Munster, Interdisciplinary Fabry Ctr IFAZ, Munster, Germany; [Pogoda, Christian] Univ Hosp Munster, Dept Cardiol 1, Coronary & Peripheral Vasc Dis & Heart Failure &, Munster, Germany; [Meuth, Sven G.] Univ Hosp Dusseldorf, Dept Neurol, Dusseldorf, Germany	University of Munster; University of Munster; University of Munster; University of Munster; University of Munster; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital	Kramer, J (corresponding author), Univ Hosp Munster, Dept Neurol, Inst Translat Neurol, Munster, Germany.	julia.kraemer@ukmuenster.de	Meuth, Sven G/HHM-8941-2022; Wiendl, Heinz/AAX-6041-2021	Meuth, Sven G/0000-0003-2571-3501; Pogoda, Christian/0000-0003-3669-7789	Sanofi Genzyme; Novartis; Shire/Takeda; Amicus Therapeutics; Bayer Healthcare; Bayer Vital; Biogen Idec; Merck Serono; Sanofi US; Teva; German Ministry for Education and Research (BMBF); Deutsche Forschungsgemeinschaft (DFG); Else Kroner Fresenius Foundation; German Academic Exchange Service; Hertie Foundation; Interdisciplinary Center for Clinical Studies (IZKF) Muenster; German Foundation Neurology; Almirall; Amicus Therapeutics Germany; Biogen; Diamed; Fresenius Medical Care; Genzyme; ONO Pharma; Roche; Shire; Actelion; Merz Pharma	Sanofi Genzyme(Sanofi-AventisGenzyme Corporation); Novartis(Novartis); Shire/Takeda; Amicus Therapeutics; Bayer Healthcare(Bayer AGBayer Healthcare Pharmaceuticals); Bayer Vital(Bayer AG); Biogen Idec(Biogen); Merck Serono(Merck & Company); Sanofi US; Teva(Teva Pharmaceutical Industries); German Ministry for Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Else Kroner Fresenius Foundation; German Academic Exchange Service(Deutscher Akademischer Austausch Dienst (DAAD)); Hertie Foundation; Interdisciplinary Center for Clinical Studies (IZKF) Muenster; German Foundation Neurology; Almirall(Almirall); Amicus Therapeutics Germany; Biogen(Biogen); Diamed; Fresenius Medical Care; Genzyme(Sanofi-AventisGenzyme Corporation); ONO Pharma; Roche(Roche Holding); Shire; Actelion; Merz Pharma	JK: received honoraria for lecturing from Biogen, Novartis, Genzyme, Merck, Mylan, and Teva and financial research support from Sanofi Genzyme and Novartis. EB: received research grants and speaker honoraria from Sanofi Genzyme, Shire/Takeda, and Amicus Therapeutics. ML: received speaker honoraria from Amicus Therapeutics, Sanofi Genzyme, and Shire/Takeda and advisory board honoraria from Sanofi Genzyme. HW: received compensation for serving on Scientific Advisory Boards/Steering Committees for Bayer Healthcare, Biogen Idec, Sanofi Genzyme, Merck Serono, and Novartis. He has received speaker honoraria and travel support from Bayer Vital GmbH, Bayer Schering AG, Biogen, CSL Behring, EMD Serono, Fresenius Medical Care, Genzyme, Merck Serono, Omniamed, Novartis, and Sanofi Aventis. He has received compensation as a consultant from Biogen Idec, Merck Serono, Novartis, Roche, and SanofiGenzyme. HW also received research support from Bayer Healthcare, Bayer Vital, Biogen Idec, Merck Serono, Novartis, Sanofi Genzyme, Sanofi US, and Teva. SM: received honoraria for lecturing and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS, and Teva. His research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Else Kroner Fresenius Foundation, German Academic Exchange Service, Hertie Foundation, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology, and by Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, Merck Serono, Novartis, ONO Pharma, Roche, and Teva. TD: received honoraria and travel expenses from Genzyme, Shire, Bristol-Myers Squibb, Boehringer-Ingelheim Pharma, Sanofi Aventis, Wisai, Novartis, Bayer Vital, Merz Pharma, Actelion, and Lundbeck for serving as a speaker and consultant. He received research support from Genzyme, Shire, and Actelion and grants from Novartis and Merz Pharma for conducting dementia studies.	Bottcher T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071894; Burlina Alessandro, 2016, J. inborn errors metab. screen., V4, pe160039, DOI 10.1177/2326409816661361; Cocozza S, 2018, INSIGHTS IMAGING, V9, P1077, DOI 10.1007/s13244-018-0664-8; Eng CM, 2007, J INHERIT METAB DIS, V30, P184, DOI 10.1007/s10545-007-0521-2; Fellgiebel A, 2009, NEUROLOGY, V72, P63, DOI 10.1212/01.wnl.0000338566.54190.8a; Invernizzi P, 2008, MULT SCLER J, V14, P1003, DOI 10.1177/1352458508092355; Lidove O, 2010, GENET MED, V12, P668, DOI 10.1097/GIM.0b013e3181f13b75; Rost NS, 2016, NEUROLOGY, V86, P1880, DOI 10.1212/WNL.0000000000002673; Yagita Y, 2019, STROKE, V50, P2571, DOI 10.1161/STROKEAHA.119.025528	9	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 14	2020	11								595514	10.3389/fimmu.2020.595514	http://dx.doi.org/10.3389/fimmu.2020.595514			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PK7RD	33381118	Green Published, gold			2022-12-18	WOS:000602636200001
J	Chelombitko, MA; Chernyak, BV; Fedorov, AV; Zinovkin, RA; Razin, E; Paruchuru, LB				Chelombitko, Maria A.; Chernyak, Boris V.; Fedorov, Artem V.; Zinovkin, Roman A.; Razin, Ehud; Paruchuru, Lakhsmi Bhargavi			The Role Played by Mitochondria in Fc epsilon RI-Dependent Mast Cell Activation (vol 11, 584210, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						mast cell; mitochondria; Fc epsilon RI-dependent activation; IgE; allergy			[Chelombitko, Maria A.; Chernyak, Boris V.; Zinovkin, Roman A.] Lomonosov Moscow State Univ, Belozersky Inst Physicochem Biol, Moscow, Russia; [Fedorov, Artem V.] Lomonosov Moscow State Univ, Biol Fac, Dept Cell Biol & Histol, Moscow, Russia; [Zinovkin, Roman A.] IM Sechenov First Moscow State Med Univ, Inst Mol Med, Moscow, Russia; [Razin, Ehud; Paruchuru, Lakhsmi Bhargavi] Hebrew Univ Jerusalem, Sch Med, Dept Biochem & Mol Biol, Jerusalem, Israel	Lomonosov Moscow State University; Lomonosov Moscow State University; Sechenov First Moscow State Medical University; Hebrew University of Jerusalem	Chelombitko, MA (corresponding author), Lomonosov Moscow State Univ, Belozersky Inst Physicochem Biol, Moscow, Russia.; Paruchuru, LB (corresponding author), Hebrew Univ Jerusalem, Sch Med, Dept Biochem & Mol Biol, Jerusalem, Israel.	chelombitko@mail.bio.msu.ru; bhargavi.lakshmi@mail.huji.ac.il	Zinovkin, Roman/J-2500-2013	Zinovkin, Roman/0000-0001-5337-4346				Chelombitko MA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.584210; Herb M, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aar5926; Park J, 2015, NEUROSCI LETT, V584, P191, DOI 10.1016/j.neulet.2014.10.016; Zinovkin RA, 2014, AGING-US, V6, P661, DOI 10.18632/aging.100685	4	0	0	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 11	2020	11								620293	10.3389/fimmu.2020.620293	http://dx.doi.org/10.3389/fimmu.2020.620293			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PJ6ZZ	33362803				2022-12-18	WOS:000601914300001
J	Lu, XJ; Deng, Q; Thompson, KD				Lu, Xin-Jiang; Deng, Qing; Thompson, Kim Dawn			Editorial: The Function of Phagocytes in Non-Mammals	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						phagocytes; non-mammals; macrophages; neutrophils; B cells; macrophage polarization; hemocytes; teleost			[Lu, Xin-Jiang] Ningbo Univ, State Key Lab Managing Biot & Chem Threats Qual &, Ningbo, Peoples R China; [Lu, Xin-Jiang] Ningbo Univ, Sch Marine Sci, Lab Biochem & Mol Biol, Ningbo, Peoples R China; [Lu, Xin-Jiang] Ningbo Univ, Key Lab Appl Marine Biotechnol, Minist Educ, Ningbo, Peoples R China; [Lu, Xin-Jiang] Pilot Natl Lab Marine Sci & Technol, Lab Marine Biol & Biotechnol, Qingdao, Peoples R China; [Deng, Qing] Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; [Thompson, Kim Dawn] Moredun Res Inst, Aquaculture Res Grp, Penicuik, Midlothian, Scotland	Ningbo University; Ningbo University; Ningbo University; Qingdao National Laboratory for Marine Science & Technology; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Moredun Research Institute	Lu, XJ (corresponding author), Ningbo Univ, State Key Lab Managing Biot & Chem Threats Qual &, Ningbo, Peoples R China.; Lu, XJ (corresponding author), Ningbo Univ, Sch Marine Sci, Lab Biochem & Mol Biol, Ningbo, Peoples R China.; Lu, XJ (corresponding author), Ningbo Univ, Key Lab Appl Marine Biotechnol, Minist Educ, Ningbo, Peoples R China.; Lu, XJ (corresponding author), Pilot Natl Lab Marine Sci & Technol, Lab Marine Biol & Biotechnol, Qingdao, Peoples R China.; Deng, Q (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.; Thompson, KD (corresponding author), Moredun Res Inst, Aquaculture Res Grp, Penicuik, Midlothian, Scotland.	lxj711043@163.com; deng67@purdue.edu; kim.thompson@moredun.ac.uk	Thompson, Kimberly/O-7707-2015; Deng, Qing/AAC-1123-2020; Thompson, Kim/GLU-8547-2022	Thompson, Kimberly/0000-0003-3550-4842; Deng, Qing/0000-0002-9254-9951; 	Programfor the Natural Science Foundation of China [41776151, 31972821]; Zhejiang Provincial Natural Science Foundation of China [LR18C040001, LZ18C190001, SJLZ2020002]; National Institutes of Health [R35GM119787]	Programfor the Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Natural Science Foundation of China(Natural Science Foundation of Zhejiang Province); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This project was supported by the Programfor the Natural Science Foundation of China (41776151; 31972821), the Zhejiang Provincial Natural Science Foundation of China (LR18C040001; LZ18C190001), theFundamentalResearchFunds for theProvincial Universities ofZhejiang (SJLZ2020002), and the National Institutes of Health (Grant R35GM119787 to QD).	Akula MK, 2016, NAT IMMUNOL, V17, P922, DOI 10.1038/ni.3487; Bleriot C, 2020, IMMUNITY, V52, P957, DOI 10.1016/j.immuni.2020.05.014; Delano MJ, 2016, J CLIN INVEST, V126, P23, DOI 10.1172/JCI82224; Li J, 2006, NAT IMMUNOL, V7, P1116, DOI 10.1038/ni1389; Lu XJ, 2017, J IMMUNOL, V198, P4692, DOI 10.4049/jimmunol.1700101; Muench DE, 2020, NATURE, V582, P109, DOI 10.1038/s41586-020-2227-7; Nagasawa T, 2015, FRONT IMMUNOL, V6, DOI [10.3389/fimmu.2015.00301, 10.3389/fimmu.2014.00445]; Robb CT, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5627; Saralahti AK, 2020, DIS MODEL MECH, V13, DOI 10.1242/dmm.045716	9	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 11	2020	11								628847	10.3389/fimmu.2020.628847	http://dx.doi.org/10.3389/fimmu.2020.628847			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PJ2BJ	33362804	Green Published, gold			2022-12-18	WOS:000601579900001
J	Zechendorf, E; Vassen, P; Zhang, JY; Hallawa, A; Martincuks, A; Krenkel, O; Muller-Newen, G; Schuerholz, T; Simon, TP; Marx, G; Ascheid, G; Schmeink, A; Dartmann, G; Thiemermann, C; Martin, L				Zechendorf, Elisabeth; Vassen, Phillip; Zhang, Jieyi; Hallawa, Ahmed; Martincuks, Antons; Krenkel, Oliver; Mueller-Newen, Gerhard; Schuerholz, Tobias; Simon, Tim-Philipp; Marx, Gernot; Ascheid, Gerd; Schmeink, Anke; Dartmann, Guido; Thiemermann, Christoph; Martin, Lukas			Heparan Sulfate Induces Necroptosis in Murine Cardiomyocytes: A Medical-in-Silico Approach Combining In Vitro Experiments and Machine Learning (vol 9, 393, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						septic cardiomyopathy; necroptosis; apoptosis; Petri nets; modeling; optimization; small data			[Zechendorf, Elisabeth; Krenkel, Oliver; Simon, Tim-Philipp; Marx, Gernot; Martin, Lukas] Univ Hosp RWTH Aachen, Dept Intens Care & Intermediate Care, Aachen, Germany; [Vassen, Phillip; Zhang, Jieyi; Schmeink, Anke] Rhein Westfal TH Aachen, Res Area Informat Theory & Systemat Design Commun, Aachen, Germany; [Hallawa, Ahmed; Ascheid, Gerd] Rhein Westfal TH Aachen, Chair Integrated Signal Proc Syst, Aachen, Germany; [Martincuks, Antons; Mueller-Newen, Gerhard] Rhein Westfal TH Aachen, Inst Biochem & Mol Biol, Aachen, Germany; [Krenkel, Oliver] Univ Hosp RWTH Aachen, Dept Med 3, Aachen, Germany; [Schuerholz, Tobias] Univ Hosp Rostock, Dept Anesthesia & Intens Care, Rostock, Germany; [Dartmann, Guido] Trier Univ Appl Sci, Res Area Distributed Syst, Trier, Germany; [Thiemermann, Christoph; Martin, Lukas] Queen Mary Univ London, William Harvey Res Inst, London, England	RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University; RWTH Aachen University; RWTH Aachen University; RWTH Aachen University Hospital; University of Rostock; University of London; Queen Mary University London	Martin, L (corresponding author), Univ Hosp RWTH Aachen, Dept Intens Care & Intermediate Care, Aachen, Germany.; Schmeink, A (corresponding author), Rhein Westfal TH Aachen, Res Area Informat Theory & Systemat Design Commun, Aachen, Germany.; Dartmann, G (corresponding author), Trier Univ Appl Sci, Res Area Distributed Syst, Trier, Germany.; Martin, L (corresponding author), Queen Mary Univ London, William Harvey Res Inst, London, England.	anke.schmeink@rwth-aachen.de; g.dartmann@umwelt-campus.de; lmartin@ukaachen.de		Thiemermann, Christoph/0000-0003-4228-9722				Zechendorf E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00393	1	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 10	2020	11								630463	10.3389/fimmu.2020.630463	http://dx.doi.org/10.3389/fimmu.2020.630463			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PI9IU	33362805	Green Submitted, Green Published, gold			2022-12-18	WOS:000601396200001
J	Liu, XL; Zhao, J; Shi, C; Liu, ZY; Shen, HT; Dang, JL; Li, Y; Yang, DG; Wei, J; Kang, LQ; Zhou, J; Cao, FL; Zheng, SG; Wang, ZK				Liu, Xiaolong; Zhao, Jun; Shi, Ce; Liu, Zhiyu; Shen, Hongtao; Dang, Junlong; Li, Yang; Yang, Dongguang; Wei, Jia; Kang, Liqing; Zhou, Jin; Cao, Fenglin; Zheng, Song Guo; Wang, Zhenkun			Construction of CII-Specific CAR-T to Explore the Cytokine Cascades Between Cartilage-Reactive T Cells and Chondrocytes	FRONTIERS IN IMMUNOLOGY			English	Article						cytokine cascade; type II collagen; chimeric antigen receptor T cell; inflammatory arthritis; cartilage	COLONY-STIMULATING FACTOR; RHEUMATOID-ARTHRITIS; TGF-BETA; EXPRESSION; COLLAGEN	Cytokine cascades exist in many autoimmune disorders which amplify and sustain the autoimmune process and lead to chronic inflammatory injury to the host tissues. Increasing evidence indicates that chondrocytes can interact with T cells, which may be a crucial event in inflammatory arthritis. To address the reciprocal influences of cartilage-reactive T cells and chondrocytes, we constructed cartilage-reactive T cells by developing a type II collagen-specific chimeric antigen receptor (CII-CAR). An in vitro co-culture model of CII-CAR-T cells and fresh cartilage was developed, in which CII-CAR-T displayed specific proliferative capacity and cytokine release against fresh cartilage samples, and chondrocytes could respond to CII-CAR-T cells by secreting IL-6. The proposed model will help us to explore the possible cytokine cascades between cartilage-reactive T cells and cartilage.	[Liu, Xiaolong; Shi, Ce; Liu, Zhiyu; Li, Yang; Yang, Dongguang; Wei, Jia; Cao, Fenglin; Wang, Zhenkun] Harbin Med Univ, Affiliated Hosp 1, Cent Lab, Harbin, Peoples R China; [Liu, Xiaolong] Northeast Agr Univ, Coll Life Sci, Harbin, Peoples R China; [Zhao, Jun; Dang, Junlong] Sun Yat Sen Univ, Hosp 3, Dept Clin Immunol, Guangzhou, Peoples R China; [Shen, Hongtao] Harbin Med Univ, Affiliated Hosp 1, Dept Orthoped Surg, Harbin, Peoples R China; [Dang, Junlong] Penn State Coll Med, Dept Med, Div Rheumatol, Hershey, PA USA; [Kang, Liqing] East China Normal Univ, Sch Chem & Mol Engn, Shanghai Engn Res Ctr Mol Therapeut & New Drug De, Inst Biomed Engn & Technol, Shanghai, Peoples R China; [Zhou, Jin] Harbin Med Univ, Affiliated Hosp 1, Dept Hematol, Harbin, Peoples R China; [Zheng, Song Guo] Ohio State Univ, Coll Med, Dept Internal Med, Columbus, OH 43210 USA	Harbin Medical University; Northeast Agricultural University - China; Sun Yat Sen University; Harbin Medical University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; East China Normal University; Harbin Medical University; University System of Ohio; Ohio State University	Wang, ZK (corresponding author), Harbin Med Univ, Affiliated Hosp 1, Cent Lab, Harbin, Peoples R China.; Zheng, SG (corresponding author), Ohio State Univ, Coll Med, Dept Internal Med, Columbus, OH 43210 USA.	Zheng.1771@osu.edu; wzkcc@163.com		Liu, Xiaolong/0000-0002-1359-4376; Liu, Zhiyu/0000-0001-8351-1268; Zhao, Jun/0000-0001-9724-7226	Natural Science Foundation of Heilongjiang Province [QC2017099]	Natural Science Foundation of Heilongjiang Province(Natural Science Foundation of Heilongjiang Province)	We thank Qiang Liu and David Cram for critical reading and English editing of the manuscript. This work was in part supported by Grant QC2017099 from Natural Science Foundation of Heilongjiang Province (QZ).	ALVAROGRACIA JM, 1991, J IMMUNOL, V146, P3365; Auger I, 2020, ARTHRITIS RHEUMATOL, V72, P903, DOI 10.1002/art.41189; Bi X, 2019, EBIOMEDICINE, V50, P408, DOI 10.1016/j.ebiom.2019.11.024; Brennan FM, 2008, J CLIN INVEST, V118, P3537, DOI 10.1172/JCI36389; Busch R, 2019, NAT REV RHEUMATOL, V15, P364, DOI 10.1038/s41584-019-0219-5; Butler DM, 1995, EUR CYTOKINE NETW, V6, P225; Chen MG, 2014, CYTOKINE GROWTH F R, V25, P301, DOI 10.1016/j.cytogfr.2013.12.011; Clements KM, 2001, OSTEOARTHR CARTILAGE, V9, P499, DOI 10.1053/joca.2000.0417; Conde J, 2018, CELL PHYSIOL BIOCHEM, V45, P2401, DOI 10.1159/000488227; Cook AD, 1996, ARTHRITIS RHEUM, V39, P1720, DOI 10.1002/art.1780391015; Cope AP, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2412; Dayer JM, 2010, RHEUMATOLOGY, V49, P15, DOI 10.1093/rheumatology/kep329; Fang Q, 2000, INT IMMUNOL, V12, P659, DOI 10.1093/intimm/12.5.659; Feldmann M, 2002, NAT REV IMMUNOL, V2, P364, DOI 10.1038/nri802; Firestein GS, 2017, IMMUNITY, V46, P183, DOI 10.1016/j.immuni.2017.02.006; Fox AJS, 2009, SPORTS HEALTH, V1, P461, DOI 10.1177/1941738109350438; HAWORTH C, 1991, EUR J IMMUNOL, V21, P2575, DOI 10.1002/eji.1830211039; Hay KA, 2018, BRIT J HAEMATOL, V183, P364, DOI 10.1111/bjh.15644; Hu XX, 2019, INT IMMUNOPHARMACOL, V70, P428, DOI 10.1016/j.intimp.2019.03.008; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Komatsu N, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00077; Kong N, 2012, ANN RHEUM DIS, V71, P1567, DOI 10.1136/annrheumdis-2011-201052; Koskinen A, 2011, CLIN EXP RHEUMATOL, V29, P57; Li N, 2013, INT J CLIN EXP PATHO, V6, P1375; Lu L, 2014, P NATL ACAD SCI USA, V111, pE3432, DOI 10.1073/pnas.1408780111; Luo Y, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00604; Murakami M, 2012, INT J BIOL SCI, V8, P1267, DOI 10.7150/ijbs.4828; Murakami M, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00022; Musters A, 2018, J IMMUNOL, V201, P417, DOI 10.4049/jimmunol.1800421; Nandakumar KS, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030677; Noack M, 2017, SEMIN IMMUNOPATHOL, V39, P365, DOI 10.1007/s00281-017-0619-z; Ogata A, 2019, MOD RHEUMATOL, V29, P258, DOI [10.1080/14397595.2018.1546357, 10.1080/14397595.2018.1533514]; Ota M, 2020, ARTHRITIS RHEUMATOL, V72, P931, DOI 10.1002/art.41182; Otero M, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2292; OUTERBRIDGE RE, 1961, J BONE JOINT SURG BR, V43, P752; Pereira RC, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00415; Perretti M, 2017, NAT REV RHEUMATOL, V13, P87, DOI 10.1038/nrrheum.2016.193; Ramalingam R, 2012, J IMMUNOL, V189, P3878, DOI 10.4049/jimmunol.1201029; Roybal KT, 2018, SCIENCE, V359, P1112, DOI 10.1126/science.aat0962; SAKLATVALA J, 1986, NATURE, V322, P547, DOI 10.1038/322547a0; Schinnerling K, 2017, CLIN EXP IMMUNOL, V189, P12, DOI 10.1111/cei.12966; Smilek DE, 2014, DIS MODEL MECH, V7, P503, DOI 10.1242/dmm.015099; Terrando N, 2010, P NATL ACAD SCI USA, V107, P20518, DOI 10.1073/pnas.1014557107; Tseng CC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21031071; Wang LX, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010455; Wang ZK, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00792; Xu AP, 2016, J IMMUNOL, V196, P3631, DOI 10.4049/jimmunol.1501740; Yang Mengru, 2019, Cell Physiol Biochem, V52, P1178, DOI 10.33594/000000080; Yang SJ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1266-6; Yap HY, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7100161; Zhang QF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02359; Zheng SG, 2008, J IMMUNOL, V180, P7112, DOI 10.4049/jimmunol.180.11.7112; Zheng ZL, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-29; Zhou C, 2016, OSTEOARTHR CARTILAGE, V24, P1648, DOI 10.1016/j.joca.2016.04.016; Zhou L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00178; Zhou SH, 2016, J ORTHOP RES, V34, P454, DOI 10.1002/jor.23043; Zou YY, 2018, J CLIN INVEST, V128, P4510, DOI 10.1172/JCI97965	57	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 4	2020	11								568741	10.3389/fimmu.2020.568741	http://dx.doi.org/10.3389/fimmu.2020.568741			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PG2XO	33343563	gold, Green Published			2022-12-18	WOS:000599604100001
J	Masaud, SM; Szasz, O; Szasz, AM; Ejaz, H; Anwar, RA; Szasz, A				Masaud, Syed Muzzammil; Szasz, Oliver; Szasz, A. Marcell; Ejaz, Hume; Anwar, Rana Attique; Szasz, Andras			A Potential Bioelectromagnetic Method to Slow Down the Progression and Prevent the Development of Ultimate Pulmonary Fibrosis by COVID-19	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-21; rehabilitation; electric field; immune-effect; heat-shock protein; modulated electro-hyperthermia	HEAT-SHOCK PROTEINS; ACUTE RESPIRATORY SYNDROME; PROGRAMMED CELL-DEATH; HYPERTHERMIC TREATMENT; SARS-CORONAVIRUS; IMMUNE-RESPONSES; GENOME SEQUENCE; LIPID RAFTS; LUNG INJURY; APOPTOSIS	Introduction Right now, we are facing a global pandemic caused by the coronavirus SARS-CoV-2 that causes the highly contagious human disease COVID-19. The number of COVID-19 cases is increasing at an alarming rate, more and more people suffer from it, and the death toll is on the rise since December 2019, when COVID-19 has presumably appeared. We need an urgent solution for the prevention, treatment, and recovery of the involved patients. Methods Modulated electro-hyperthermia (mEHT) is known as an immuno-supportive therapy in oncology. Our proposal is to apply this method to prevent the progression of the disease after its identification, to provide treatment when necessary, and deliver rehabilitation to diminish the fibrotic-often fatal-consequences of the infection. Hypothesis The effects of mEHT, which are proven for oncological applications, could be utilized for the inactivation of the virus or for treating the fibrotic consequences. The hypothesized mEHT effects, which could have a role in the antiviral treatment, it could be applied for viral-specific immune-activation and for anti-fibrotic treatments.	[Masaud, Syed Muzzammil] OncoTreatments Pvt Ltd, Karachi, Pakistan; [Szasz, Oliver; Szasz, Andras] St Istvan Univ, Biotech Dept, Godollo, Hungary; [Szasz, A. Marcell] Semmelweis Univ, Dept Internal Med & Oncol, Budapest, Hungary; [Ejaz, Hume] Univ Turku, Dept Biochem, Turku, Finland; [Anwar, Rana Attique] Nishtar Med Coll Multan, Dept Oncol, Multan, Pakistan	Hungarian University of Agriculture & Life Sciences; Semmelweis University; Finland National Institute for Health & Welfare; University of Turku	Szasz, A (corresponding author), St Istvan Univ, Biotech Dept, Godollo, Hungary.	Szasz.Andras@gek.szie.hu	Szász, András/AAG-7730-2022; Szász, András/AEB-7956-2022					Andocs G, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.39; Andocs G, 2015, CELL STRESS CHAPERON, V20, P37, DOI 10.1007/s12192-014-0523-6; Andocs G, 2009, STRAHLENTHER ONKOL, V185, P120, DOI 10.1007/s00066-009-1903-1; [Anonymous], HUM COR TYP; Asai A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082839; Azhar EI, 2019, INFECT DIS CLIN N AM, V33, P891, DOI 10.1016/j.idc.2019.08.001; Azkur AK, 2020, ALLERGY, V75, P1564, DOI 10.1111/all.14364; Baglivo Mirko, 2020, Acta Biomed, V91, P161, DOI 10.23750/abm.v91i1.9402; Ballerini M, 2013, ANDROTHERM APPL PEYR, DOI 10.1155/2013/962349; Banoun H, 2020, EVOLUTION SARS COV 2, DOI [10.2139/ssrn.3637909, DOI 10.2139/SSRN.3637909]; Barry CA, 1983, PARETO DISTRIBUTIONS; Batawi S, 2019, HEALTH QUAL LIFE OUT, V17, DOI 10.1186/s12955-019-1165-2; Cabrera-Benitez NE, 2012, CRIT CARE MED, V40, P510, DOI 10.1097/CCM.0b013e31822f09d7; Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x; Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09; Chi K.-H., 2020, CHALLENGES SOLUTIONS, P206; Cohen Marc, 2020, F1000Res, V9, P292, DOI [10.12688/f1000research.23299.1, 10.12688/f1000research.23299.2]; Conti C, 1999, ANTIMICROB AGENTS CH, V43, P822, DOI 10.1128/AAC.43.4.822; Cunha L, 2014, DRUG DISCOV TODAY, V19, P936, DOI 10.1016/j.drudis.2014.01.003; Dank M, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.e14571; de Araujo AR, 2015, AN BRAS DERMATOL, V90, P707, DOI 10.1590/abd1806-4841.20153605; DEMARCO A, 1993, J GEN VIROL, V74, P1685, DOI 10.1099/0022-1317-74-8-1685; Dezso Z, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.055103; Evans SS, 2015, NAT REV IMMUNOL, V15, P335, DOI 10.1038/nri3843; Feder ME, 1999, ANNU REV PHYSIOL, V61, P243, DOI 10.1146/annurev.physiol.61.1.243; Feys BJ, 2000, TRENDS GENET, V16, P449, DOI 10.1016/S0168-9525(00)02107-7; Fischer H, 2004, P NATL ACAD SCI USA, V101, P3691, DOI 10.1073/pnas.0308393100; Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4; Fung TS, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00296; Gabriella H, 2017, CLIN PRACT, V14, P73, DOI DOI 10.4172/CLINICAL-PRACTICE.100098; Galvani AP, 2005, NATURE, V438, P293, DOI 10.1038/438293a; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; George PM, 2020, LANCET RESP MED, V8, P807, DOI 10.1016/S2213-2600(20)30225-3; Goldberg A, 2020, ACE2 COVID 19 IS IT; Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310; Gurkan OU, 2003, AM J PHYSIOL-LUNG C, V285, pL710, DOI 10.1152/ajplung.00044.2003; Hagiwara S, 2007, LUNG, V185, P287, DOI 10.1007/s00408-007-9018-x; He JH, 2008, CHAOS SOLITON FRACT, V38, P1390, DOI 10.1016/j.chaos.2008.04.018; Hegyi G., 2012, OPEN J BIOPHYS, V02, DOI [10.4236/ojbiphy.2012.23009, DOI 10.4236/OJBIPHY.2012.23009]; Hegyi G, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/672873; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Huang QC, 2014, J HEPATOL, V61, P859, DOI 10.1016/j.jhep.2014.04.035; Hui DSC, 2019, INFECT DIS CLIN N AM, V33, P869, DOI 10.1016/j.idc.2019.07.001; Hui DS, 2005, THORAX, V60, P401, DOI 10.1136/thx.2004.030205; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jansen MAA, 2018, IMMUNOLOGY, V153, P51, DOI 10.1111/imm.12811; Jeung TS, 2015, CASE REP CLIN MED, V4, P157, DOI [10.4236/crcm.2015.45033, DOI 10.4236/crcm.2015.45033]; Kang D, 2020, ROLE TEMPERATURE COV, DOI [10.20944/preprints202005.0070.v12020, DOI 10.20944/PREPRINTS202005.0070.V12020]; Kendrick AA, 2017, ONCOTARGET, V8, P6742, DOI 10.18632/oncotarget.14272; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kregel KC, 2002, J APPL PHYSIOL, V92, P2177, DOI 10.1152/japplphysiol.01267.2001; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924; Lee K, 2012, INT REV CEL MOL BIO, V294, P171, DOI 10.1016/B978-0-12-394305-7.00004-5; Lee YN, 2005, J VIROL METHODS, V129, P152, DOI 10.1016/j.jviromet.2005.05.022; Lei JQ, 2020, RADIOLOGY, V295, P18, DOI 10.1148/radiol.2020200236; Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685; Li GM, 2007, MICROBES INFECT, V9, P96, DOI 10.1016/j.micinf.2006.10.015; Li XD, 2012, INT J HYPERTHER, V28, P451, DOI 10.3109/02656736.2012.677929; Li XF, 2020, CANCER IMMUNOL IMMUN, V69, P535, DOI 10.1007/s00262-019-02457-y; Lionetti V, 2005, CURR OPIN CRIT CARE, V11, P82, DOI 10.1097/00075198-200502000-00013; Liu AD, 2020, CLIN MICROBIOL INFEC, V26, P1703, DOI 10.1016/j.cmi.2020.07.009; Liu L, 2020, MICROBES INFECT, V22, P206, DOI 10.1016/j.micinf.2020.05.008; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; LWOFF A, 1969, BACTERIOL REV, V33, P390, DOI 10.1128/MMBR.33.3.390-403.1969; LWOFF A, 1959, BACTERIOL REV, V23, P109, DOI 10.1128/MMBR.23.3.109-124.1959; Ma T, 2015, DISTRIBUTION HUMAN R, DOI [10.1002/cplx.21666, DOI 10.1002/CPLX.21666]; Mahmudpour M, 2020, CYTOKINE, V133, DOI 10.1016/j.cyto.2020.155151; Manes S, 2003, NAT REV IMMUNOL, V3, P557, DOI 10.1038/nri1129; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Maruyama H, 2018, VIRUS RES, V257, P94, DOI 10.1016/j.virusres.2018.09.011; Mate A, 2017, ACUPUNCTURE ELECTRO, V42, P121, DOI 10.3727/036012917X15004036818267; Matricardi PM, 2020, PEDIAT ALLERG IMM-UK, V31, P454, DOI 10.1111/pai.13271; Mayer KA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01533; Meggyeshazi N, 2014, STRAHLENTHER ONKOL, V190, P815, DOI 10.1007/s00066-014-0617-1; Meggyeshazi N, 2015, THESIS; Meggyeshazi N, 2013, PROGRAMMED CELL DEAT; MIKKELSEN RB, 1981, CANCER RES, V41, P209; Milani A, 2019, IMMUNOTHERAPY-UK, V11, P215, DOI 10.2217/imt-2018-0105; Minnaar CA, 2020, INT J HYPERTHER, V37, P263, DOI 10.1080/02656736.2020.1737253; Mo HY, 2006, RESPIROLOGY, V11, P49, DOI 10.1111/j.1440-1843.2006.00783.x; Nagy G, 2013, DEEP TEMPERATURE MEA, DOI 10.1155/2013/685264; Ngai JC, 2010, RESPIROLOGY, V15, P543, DOI 10.1111/j.1440-1843.2010.01720.x; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Oei AL, 2015, CANCER RES, V75, P5120, DOI 10.1158/0008-5472.CAN-15-0816; Ortiz-Prado E, 2020, DIAGN MICR INFEC DIS, V98, DOI 10.1016/j.diagmicrobio.2020.115094; Ou JW, 2020, INTEGR CANCER THER, V19, DOI 10.1177/1534735419895591; Papp E., 2017, OPEN J BIOPHYS, V7, P216, DOI [DOI 10.4236/OJBIPHY.2017.74016, 10.4236/ojbiphy.2017.74016]; Pathak N, 2020, GREAT IMITATOR COVID; PENNYPACKER C, 1995, J ACQ IMMUN DEF SYND, V8, P321; Prasad B, 2018, J THERM BIOL, V74, P281, DOI 10.1016/j.jtherbio.2018.04.007; Qin W, 2014, ONCOL REP, V32, P2373, DOI 10.3892/or.2014.3500; Qing EY, 2020, MBIO, V11, DOI 10.1128/mBio.02764-19; Rajendran L, 2005, J CELL SCI, V118, P1099, DOI 10.1242/jcs.01681; Raoult D, 2020, CELL STRESS; Ren LL, 2005, DNA CELL BIOL, V24, P496, DOI 10.1089/dna.2005.24.496; Ren Y, 2015, INT J HYPERTHER, V31, P5, DOI 10.3109/02656736.2014.993339; Ritchie H, 2020, MORTALITY RISK COVID; Rokni M, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2107; Ruan YJ, 2003, LANCET, V361, P1779, DOI 10.1016/S0140-6736(03)13414-9; Sanchez EL, 2015, VIROLOGY, V479, P609, DOI 10.1016/j.virol.2015.02.038; Sethuraman N, 2020, JAMA-J AM MED ASSOC, V323, P2249, DOI 10.1001/jama.2020.8259; Shatizadeh Malekshahi S, 2016, INFECT DIS-NOR, V5, DOI [10.5812/pedinfect.36953., DOI 10.1093/CID/CIAA344, DOI 10.1093/cid/ciaa344]; Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3; Singanayagam A, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-27; Sun PF, 2020, J MED VIROL, V92, P612, DOI 10.1002/jmv.25735; Suzuki T, 2009, OPEN DERMATOL J, V3, P178, DOI [10.2174/1874372200903010178, DOI 10.2174/1874372200903010178]; Szasz A, 2003, ELECTROMAGN BIOL MED, V22, P103, DOI 10.1081/JBC-120024620; Szasz A., 2019, J RADIAT CANCER RES, V10, P1, DOI DOI 10.4103/JRCR.JRCR_25_18; Szasz A, 2020, BOOK CHALLENGES SOLU, P377; Szasz A, 2020, PREFACE BOOK CHALLEN; Szasz A, 2017, J ADV BIOL, V10, P2061, DOI [10.24297/jab.v10i2.6328, DOI 10.24297/JAB.V10I2.6328]; Szasz A, 2014, 31 URSI GEN ASS SCI, DOI [10.1109/URSIGASS.2014.6930100, DOI 10.1109/URSIGASS.2014.6930100]; Szasz A, 2015, BIOELECTROMAGNETIC S, P323; Szasz A, 2011, ONCOTHERMIA: PRINCIPLES AND PRACTICES, P1, DOI 10.1007/978-90-481-9498-8; Szasz AM, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01012; Szasz O, 2017, ADV BIOSCI BIOTECHNO, V8, P434, DOI [10.4236/abb.2017.811032, DOI 10.4236/ABB.2017.811032]; Szasz O, 2017, OPEN J BIOPHYS, V7, P183, DOI [10.4236/ojbiphy.2017.74014, DOI 10.4236/OJBIPHY.2017.74014]; Szasz O., 2018, OPEN J BIOPHYS, V8, P31, DOI DOI 10.4236/ojbiphy.2018.81004; Szasz O., 2013, HYPERTHERMIA, DOI [10.5772/52208, DOI 10.5772/52208]; Szasz O, 2018, OJBIPHY, V8, P49, DOI [10.4236/ojbiphy.2018.82005, DOI 10.4236/OJBIPHY.2018.82005]; Szasz O, 2017, OPEN J BIOPHYS, V7, P116, DOI [10.4236/ojbiphy.2017.73010, DOI 10.4236/OJBIPHY.2017.73010]; Szasz O, 2014, J CANC SCI THER, V6, P4, DOI [10.4172/1948-5956.1000259, DOI 10.4172/1948-5956.1000259]; Szasz O, 2018, MED HYPOTHESES, V116, P74, DOI 10.1016/j.mehy.2018.03.015; Szasz O, 2015, J CLIN ONCOL, V33; Szigeti K, 2016, BMC MED IMAGING, V16, DOI 10.1186/s12880-016-0118-z; Taha EA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184588; Tan YX, 2007, J VIROL, V81, P6346, DOI 10.1128/JVI.00090-07; Thaker SK, 2019, BMC BIOL, V17, DOI 10.1186/s12915-019-0678-9; Tharakan S, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03045-8; Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010; Tsan MF, 2004, CELL MOL IMMUNOL, V1, P274; Tsang YW, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1690-2; Ulrich H, 2020, STEM CELL REV REP, V16, P434, DOI 10.1007/s12015-020-09976-7; da Silva RMV, 2013, DERMAT RES PRACT, V2013, DOI 10.1155/2013/715829; van Dorp L, 2020, INFECT GENET EVOL, V83, DOI 10.1016/j.meegid.2020.104351; Van Gool SW., 2018, AUSTIN ONCOL CASE RE, V3, P1; Vancsik T, 2019, CANCER MED-US, V8, P4292, DOI 10.1002/cam4.2330; Vancsik T, 2018, J CANCER, V9, P41, DOI 10.7150/jca.21520; Verdecchia P, 2020, EUR J INTERN MED, V76, P14, DOI 10.1016/j.ejim.2020.04.037; Vincze G, 2016, J ADV BIOL, V9, P1872, DOI DOI 10.24297/jab.v9i2.4059; Vincze GY, 2015, BIOL MED, V7, P249, DOI DOI 10.4172/0974-8369.1000249; Vincze GY, 2015, J ADV BIOL, V8, P1514; Voronov S, 2002, FEBS LETT, V522, P77, DOI 10.1016/S0014-5793(02)02888-0; Wada Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035069; Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585; Wang F, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137799; [王科雯 Wang Kewen], 2020, [测绘通报, Bulletin of Surveying and Mapping], P1; Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045; Wang T., 2020, MEDRXIV, DOI [10.1101/2020.04.29.20085498, DOI 10.1101/2020.04.29.20085498]; Wang XL, 2020, CELL MOL IMMUNOL, V17, P894, DOI 10.1038/s41423-020-0498-4; Watanabe T, 1999, J PHYSIOL-LONDON, V515, P881, DOI 10.1111/j.1469-7793.1999.881ab.x; Weinrauch Y, 1999, ANNU REV MICROBIOL, V53, P155, DOI 10.1146/annurev.micro.53.1.155; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Xiong LJ, 2014, INT J MOL SCI, V15, P17411, DOI 10.3390/ijms151017411; Xu YH, 2020, J INFECTION, V80, P394, DOI 10.1016/j.jinf.2020.02.017; Yang KL, 2016, ONCOTARGET, V7, P84082, DOI 10.18632/oncotarget.11444; Yang XM, 2020, EMERG MICROBES INFEC, V9, P1287, DOI 10.1080/22221751.2020.1773745; YERUSHALMI A, 1982, P NATL ACAD SCI-BIOL, V79, P4766, DOI 10.1073/pnas.79.15.4766; Zhang W, 2020, EMERG MICROBES INFEC, V9, DOI 10.1080/22221751.2020.1729071; Zhou P, 2020, NATURE, V588, pE6, DOI [10.1038/s41586-020-2012-7, 10.1038/s41586-020-2951-z]; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	162	0	0	1	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 4	2020	11								556335	10.3389/fimmu.2020.556335	http://dx.doi.org/10.3389/fimmu.2020.556335			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PG2OC	33343561	Green Published, gold			2022-12-18	WOS:000599579000001
J	Yang, J; Zhang, JY; Fan, RF; Zhao, W; Han, T; Duan, K; Li, XG; Zeng, PY; Deng, JL; Zhang, JK; Yang, XM				Yang, Jing; Zhang, Jiayou; Fan, Renfeng; Zhao, Wei; Han, Tian; Duan, Kai; Li, Xinguo; Zeng, Peiyu; Deng, Jinglong; Zhang, Jikai; Yang, Xiaoming			Identifying Potential Candidate Hub Genes and Functionally Enriched Pathways in the Immune Responses to Quadrivalent Inactivated Influenza Vaccines in the Elderly Through Co-Expression Network Analysis	FRONTIERS IN IMMUNOLOGY			English	Article						weighted gene co-expression network analysis (WGCNA); hub genes; quadrivalent inactivated influenza vaccines (QIVs); MCEMP1; SPARC; reactogenicity	ANTIBODY-RESPONSES; SYSTEMS BIOLOGY; SPARC; VACCINATION; PROTEIN; CYSTEINE; RICH; EXPRESSION; CELLS; ADULTS	Insights into the potential candidate hub genes may facilitate the generation of safe and effective immunity against seasonal influenza as well as the development of personalized influenza vaccines for the elderly at high risk of influenza virus infection. This study aimed to identify the potential hub genes related to the immune induction process of the 2018/19 seasonal quadrivalent inactivated influenza vaccines (QIVs) in the elderly >= 60 years by using weighted gene co-expression network analysis (WGCNA). From 63 whole blood samples from16 elderly individuals, a total of 13,345 genes were obtained and divided into eight co-expression modules, with two modules being significantly correlated with vaccine-induced immune responses. After functional enrichment analysis, genes under GO terms of vaccine-associated immunity were used to construct the sub-network for identification and functional validation of hub genes. MCEMP1 and SPARC were confirmed as the hub genes with an obvious effect on QIVs-induced immunity. The MCEMP1 expression was shown to be negatively correlated with the QIVs-associated reactogenicity within 7 days after vaccination, which could be suppressed by the CXCL 8/IL-8 and exacerbated by the Granzyme-B cytotoxic mediator. Meanwhile, the SPARC expression was found to increase the immune responses to the QIVs and contribute to the persistence of protective humoral antibody titers. These two genes can be used to predict QIVs-induced adverse reaction, the intensity of immune responses, and the persistence of humoral antibody against influenza. This work has shed light on further research on the development of personalized QIVs with appropriate immune responses and long-lasting immunity against the forthcoming seasonal influenza.	[Yang, Jing; Zhang, Jiayou; Zhao, Wei; Han, Tian; Duan, Kai; Li, Xinguo; Yang, Xiaoming] Natl Inst Engn Technol Res Combinat Vaccine, Wuhan, Peoples R China; [Yang, Jing; Zhang, Jiayou; Zhao, Wei; Han, Tian; Duan, Kai; Li, Xinguo] Wuhan Inst Biol Prod Co Ltd, Wuhan, Peoples R China; [Fan, Renfeng; Zhang, Jikai] Guangdong Prov Inst Biol Prod & Mat Med, Guangzhou, Peoples R China; [Zeng, Peiyu; Deng, Jinglong] Gaozhou Ctr Dis Control & Prevent, Maoming City, Peoples R China; [Yang, Xiaoming] China Biotechnol Co Ltd, Beijing, Peoples R China		Yang, XM (corresponding author), Natl Inst Engn Technol Res Combinat Vaccine, Wuhan, Peoples R China.; Yang, XM (corresponding author), China Biotechnol Co Ltd, Beijing, Peoples R China.	yangxiaomingzs@hotmail.com	Yang, Jing/ABD-6821-2021	Yang, Jing/0000-0001-7729-3452				Alvarez MJ, 2005, CANCER RES, V65, P5123, DOI 10.1158/0008-5472.CAN-04-1102; Bentebibel SE, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005191; Boultwood J, 2000, HUM GENET, V106, P127, DOI 10.1007/s004390051020; Bradshaw AD, 2012, INT J BIOCHEM CELL B, V44, P480, DOI 10.1016/j.biocel.2011.12.021; Bucasas KL, 2011, J INFECT DIS, V203, P921, DOI 10.1093/infdis/jiq156; Chang CH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071556; Chen JX, 2019, IUBMB LIFE, V71, P956, DOI 10.1002/iub.2033; Chen WH, 2011, VACCINE, V29, P2865, DOI 10.1016/j.vaccine.2011.02.017; Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-S4-S11; Chlenski A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023880; Crooke SN, 2019, EXP GERONTOL, V124, DOI 10.1016/j.exger.2019.110632; Deist MS, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00011; Doyle JD, 2019, MMWR-MORBID MORTAL W, V68, P135, DOI 10.15585/mmwr.mm6806a2; Dyda A, 2015, VACCINE, V33, P3299, DOI 10.1016/j.vaccine.2015.05.046; Furman D, 2014, P NATL ACAD SCI USA, V111, P869, DOI 10.1073/pnas.1321060111; Garcia-Sastre A, 2016, P NATL ACAD SCI USA, V113, P1689, DOI 10.1073/pnas.1525361113; GOLDBLUM SE, 1994, P NATL ACAD SCI USA, V91, P3448, DOI 10.1073/pnas.91.8.3448; Hansen KD, 2012, BIOSTATISTICS, V13, P204, DOI 10.1093/biostatistics/kxr054; Haralambieva IH, 2016, VACCINE, V34, P3993, DOI 10.1016/j.vaccine.2016.06.034; Haralambieva IH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122282; Haralambieva IH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062149; Henry C, 2019, CELL HOST MICROBE, V25, P357, DOI 10.1016/j.chom.2019.01.002; Herati RS, 2014, J IMMUNOL, V193, P3528, DOI 10.4049/jimmunol.1302503; Inoue M, 2010, INT J CANCER, V127, P1393, DOI 10.1002/ijc.25160; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Kennedy RB, 2013, GENES IMMUN, V14, P277, DOI 10.1038/gene.2013.14; Kim A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051707; Klein SL, 2015, T ROY SOC TROP MED H, V109, P9, DOI 10.1093/trstmh/tru167; Kositanont U, 2012, VIRAL IMMUNOL, V25, P471, DOI 10.1089/vim.2012.0024; Kovats S, 2015, CELL IMMUNOL, V294, P63, DOI 10.1016/j.cellimm.2015.01.018; Lambert ND, 2012, EXPERT REV VACCINES, V11, P985, DOI [10.1586/erv.12.61, 10.1586/ERV.12.61]; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lee D, 2017, IMMUNOL RES, V65, P1009, DOI 10.1007/s12026-017-8940-0; Lee N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026050; Lever M, 2017, CURR ISSUES MOL BIOL, V22, P1, DOI 10.21775/cimb.022.001; Li K, 2005, GENOMICS, V86, P68, DOI 10.1016/j.ygeno.2005.03.006; Liu XS, 2017, J CELL BIOCHEM, V118, P3953, DOI 10.1002/jcb.26050; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Luo Z, 2014, J LEUKOCYTE BIOL, V96, P73, DOI 10.1189/jlb.1A0713-415RR; McElhaney JE, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00041; McElhaney JE, 2015, METHODS MOL BIOL, V1343, P121, DOI 10.1007/978-1-4939-2963-4_11; Nakaya HI, 2016, P NATL ACAD SCI USA, V113, P1853, DOI 10.1073/pnas.1519690113; National Bureau of Statistics, 2019 STAT B NAT EC S; Organization WH, 2018, INFL SEAS WHO WHO; Patel SS, 2019, INT J INFECT DIS, V85, pS26, DOI 10.1016/j.ijid.2019.05.009; Pei G, 2017, METHOD ENZYMOL, V585, P135, DOI 10.1016/bs.mie.2016.09.016; Puig-Barbera J, 2017, VACCINE, V35, P5799, DOI 10.1016/j.vaccine.2017.09.035; Ramakrishnan A, 2012, CYTOKINE, V60, P661, DOI 10.1016/j.cyto.2012.08.004; Raman K, 2016, STROKE, V47, P652, DOI 10.1161/STROKEAHA.115.011854; Ravindran R, 2014, SCIENCE, V343, P313, DOI 10.1126/science.1246829; Reber AJ, 2012, AGING DIS, V3, P68; Rempel SA, 2007, GENES IMMUN, V8, P262, DOI 10.1038/sj.gene.6364388; Riley HJ, 2020, ANAT REC, V303, P1624, DOI 10.1002/ar.24133; Rotta G, 2008, J EXP MED, V205, P657, DOI 10.1084/jem.20071734; Shahid Z, 2010, VACCINE, V28, P6145, DOI 10.1016/j.vaccine.2010.07.036; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Strbian D, 2006, J CEREBR BLOOD F MET, V26, P605, DOI 10.1038/sj.jcbfm.9600228; Tanaka M, 2018, J GASTROEN HEPATOL, V33, P671, DOI 10.1111/jgh.13842; Toba H, 2015, AM J PHYSIOL-CELL PH, V308, pC972, DOI 10.1152/ajpcell.00402.2014; Voigt EA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-17735-x; Wang B, 2014, MOL MED REP, V10, P1461, DOI 10.3892/mmr.2014.2339; WHO, 2011, MAN LAB DIAGN VIR SU; Xie WF, 2020, INFLAMM RES, V69, P179, DOI 10.1007/s00011-019-01306-z; Yao QM, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.01142; Young B, 2017, VACCINE, V35, P212, DOI 10.1016/j.vaccine.2016.11.013; Zhang B, 2005, STAT APPL GENET MOL, V4, DOI 10.2202/1544-6115.1128	67	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 4	2020	11								603337	10.3389/fimmu.2020.603337	http://dx.doi.org/10.3389/fimmu.2020.603337			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PG2PW	33343577	gold, Green Published			2022-12-18	WOS:000599583600001
J	Sack, U; Tarnok, A; Preijers, F; Kohl, U; Na, IK				Sack, Ulrich; Tarnok, Attila; Preijers, Frank; Kohl, Ulrike; Na, Il-Kang			Editorial: Modulation of Human Immune Parameters by Anticancer Therapies	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						immunoncology; flow cytometry; checkpoint inhibition; blockade; immune modulation; tumor-immune cell interaction			[Sack, Ulrich; Kohl, Ulrike] Univ Leipzig, Inst Clin Immunol, Med Fac, Leipzig, Germany; [Tarnok, Attila; Kohl, Ulrike] Fraunhofer Inst Cell Therapy & Immunol IZI, Leipzig, Germany; [Tarnok, Attila] Univ Leipzig, Inst Med Informat Stat & Epidemiol IMISE, Leipzig, Germany; [Tarnok, Attila] Tsinghua Univ, Dept Precis Instruments, Beijing, Peoples R China; [Preijers, Frank] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands; [Kohl, Ulrike] Hannover Med Sch, Inst Cellular Therapeut, Hannover, Germany; [Na, Il-Kang] Charite Univ Med Berlin, Dept Hematol & Oncol, Berlin, Germany; [Na, Il-Kang] Free Univ Berlin, Berlin, Germany; [Na, Il-Kang] Humboldt Univ, Berlin, Germany; [Na, Il-Kang] Berlin Inst Hlth, Berlin, Germany; [Na, Il-Kang] Expt & Clin Res Ctr ECRC, Berlin, Germany; [Na, Il-Kang] German Canc Consortium DKTK, Partner Site Berlin, Heidelberg, Germany	Leipzig University; Fraunhofer Gesellschaft; Leipzig University; Tsinghua University; Radboud University Nijmegen; Hannover Medical School; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Helmholtz Association; German Cancer Research Center (DKFZ)	Sack, U (corresponding author), Univ Leipzig, Inst Clin Immunol, Med Fac, Leipzig, Germany.	ulrich.sack@medizin.uni-leipzig.de		Na, Il-Kang/0000-0001-9902-5424				Arnaud-Sampaio VF, 2020, CYTOM PART A, V97, P1109, DOI 10.1002/cyto.a.24035; Frolich S, 2020, CYTOM PART A, V97, P378, DOI 10.1002/cyto.a.23988; Hofer E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00745; Huang YM, 2020, CYTOM PART A, V97, P61, DOI 10.1002/cyto.a.23953; Kloess S, 2019, TRANSFUS MED HEMOTH, V46, P4, DOI 10.1159/000495771; Kloess S, 2019, HUM GENE THER, V30, P381, DOI 10.1089/hum.2018.247; Kloss S, 2017, HUM GENE THER, V28, P897, DOI 10.1089/hum.2017.157; Kohl U, 2018, HUM GENE THER, V29, P559, DOI 10.1089/hum.2017.254; Koehl U, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00351; Laskowski TJ, 2020, CYTOM PART A, V97, P116, DOI 10.1002/cyto.a.23882; Li R, 2020, CYTOM PART A, V97, P528, DOI 10.1002/cyto.a.23872; Lisselstelin ME, 2019, J PATHOL CLIN RES, V5, P3, DOI 10.1002/cjp2.113; Muller S, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03123; Xu MX, 2020, CYTOM PART A, V97, P46, DOI 10.1002/cyto.a.23902; Yu Q, 2020, CYTOM PART A, V97, P900, DOI 10.1002/cyto.a.24014; Zhang J, 2020, CYTOM PART A, V97, P70, DOI 10.1002/cyto.a.23869	16	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 2	2020	11								621556	10.3389/fimmu.2020.621556	http://dx.doi.org/10.3389/fimmu.2020.621556			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PF1OJ	33343586	Green Published, gold			2022-12-18	WOS:000598831600001
J	Wang, HX; Pan, WR; Zheng, L; Zhong, XP; Tan, L; Liang, ZF; He, J; Feng, PF; Zhao, Y; Qiu, YR				Wang, Hong-Xia; Pan, Wenrong; Zheng, Lei; Zhong, Xiao-Ping; Tan, Liang; Liang, Zhanfeng; He, Jing; Feng, Pingfeng; Zhao, Yong; Qiu, Yu-Rong			Thymic Epithelial Cells Contribute to Thymopoiesis and T Cell Development (vol 10, 3099, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						thymic epithelial cells (TECs); medullary thymic epithelial cells (mTECs); thymopoiesis; tissue-restricted antigens (TRAs); tolerance			[Wang, Hong-Xia; Zheng, Lei; He, Jing; Feng, Pingfeng; Qiu, Yu-Rong] Southern Med Univ, Nanfang Hosp, Lab Med Ctr, Guangzhou, Peoples R China; [Wang, Hong-Xia; Liang, Zhanfeng; Zhao, Yong] Chinese Acad Sci, Inst Zool, State Key Lab Membrane Biol, Beijing, Peoples R China; [Pan, Wenrong] Southern Med Univ, Taihe Branch, Dept Gen Surg, Nanfang Hosp, Guangzhou, Peoples R China; [Zhong, Xiao-Ping] Duke Univ, Med Ctr, Dept Pediat, Div Allergy & Immunol, Durham, NC 27710 USA; [Tan, Liang] Cent South Univ, Dept Urol Organ Transplantat, Ctr Organ Transplantat, Xiangya Hosp 2, Changsha, Peoples R China	Southern Medical University - China; Chinese Academy of Sciences; Institute of Zoology, CAS; Southern Medical University - China; Duke University; Central South University	Qiu, YR (corresponding author), Southern Med Univ, Nanfang Hosp, Lab Med Ctr, Guangzhou, Peoples R China.; Zhao, Y (corresponding author), Chinese Acad Sci, Inst Zool, State Key Lab Membrane Biol, Beijing, Peoples R China.	zhaoy@ioz.ac.cn; qyr@smu.edu.cn			 [81801390];  [31800754]	; 	In the original article, there was an error in the Funding statement. The correct numbers for National Nature Science Foundation of China are 81801390 to H-XW and 31800754 to ZL.	Wang HX, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03099	1	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 30	2020	11								628464	10.3389/fimmu.2020.628464	http://dx.doi.org/10.3389/fimmu.2020.628464			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PE2UZ	33329618	gold, Green Published			2022-12-18	WOS:000598225300001
J	Brands, X; Haak, BW; Klarenbeek, AM; Otto, NA; Faber, DR; Lutter, R; Scicluna, BP; Wiersinga, WJ; van der Poll, T				Brands, Xanthe; Haak, Bastiaan W.; Klarenbeek, Augustijn M.; Otto, Natasja A.; Faber, Daniel R.; Lutter, Rene; Scicluna, Brendon P.; Wiersinga, W. Joost; van der Poll, Tom			Concurrent Immune Suppression and Hyperinflammation in Patients With Community-Acquired Pneumonia (vol 11, 796, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						community-acquired pneumonia; immune suppression; systemic inflammation; sepsis; lipopolysaccharide			[Brands, Xanthe; Haak, Bastiaan W.; Klarenbeek, Augustijn M.; Otto, Natasja A.; Scicluna, Brendon P.; Wiersinga, W. Joost; van der Poll, Tom] Univ Amsterdam, Locat AMC, Ctr Expt & Mol Med CEMM, Amsterdam Univ,Med Ctr, Amsterdam, Netherlands; [Faber, Daniel R.] BovenIJ Hosp, Dept Internal Med, Amsterdam, Netherlands; [Lutter, Rene] Univ Amsterdam, Locat AMC, Amsterdam Univ, Resp Med & Expt Immunol,Med Ctr, Amsterdam, Netherlands; [Scicluna, Brendon P.] Univ Amsterdam, Locat AMC, Amsterdam Univ, Dept Clin Epidemiol Biostat & Bioinformat,Med Ctr, Amsterdam, Netherlands; [Wiersinga, W. Joost; van der Poll, Tom] Univ Amsterdam, Locat AMC, Div Infect Dis, Amsterdam Univ,Med Ctr, Amsterdam, Netherlands	University of Amsterdam; University of Amsterdam; University of Amsterdam; University of Amsterdam	Brands, X (corresponding author), Univ Amsterdam, Locat AMC, Ctr Expt & Mol Med CEMM, Amsterdam Univ,Med Ctr, Amsterdam, Netherlands.	x.brands@amsterdamumc.nl	Scicluna, Brendon/T-8112-2018	Scicluna, Brendon/0000-0003-2826-0341; Wiersinga, Willem/0000-0003-2277-1343				Brands X, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00796	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 27	2020	11								626667	10.3389/fimmu.2020.626667	http://dx.doi.org/10.3389/fimmu.2020.626667			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PD9QK	33329617				2022-12-18	WOS:000598010000001
J	Liu, PP; Pan, ZZ; Gu, CY; Cao, XD; Liu, XW; Zhang, JJ; Xiao, Z; Wang, XP; Guo, HB; Ju, DW; Deng, SJ				Liu, Peipei; Pan, Zhongzong; Gu, Chunyin; Cao, Xiaodan; Liu, Xiaowu; Zhang, Jianjian; Xiao, Zheng; Wang, Xueping; Guo, Haibing; Ju, Dianwen; Deng, Su-Jun			An Omalizumab Biobetter Antibody With Improved Stability and Efficacy for the Treatment of Allergic Diseases	FRONTIERS IN IMMUNOLOGY			English	Article						IgE; allergic diseases; biobetter; affinity; stability; half-life; efficacy	FC-EPSILON-RI; ANTIIMMUNOGLOBULIN-E; MONOCLONAL-ANTIBODY; IMMUNOGLOBULIN-E; HUMAN BASOPHILS; IGE; ASTHMA; RECEPTOR; PHARMACODYNAMICS; AFFINITY	The critical role of IgE in allergic diseases is well-documented and clinically proven. Omalizumab, a humanized anti-IgE antibody, was the first approved antibody for the treatment of allergic diseases. Nevertheless, omalizumab still has some limitations, such as product instability and dosage restriction in clinical application. In this study, we attempted to develop an omalizumab biobetter antibody with the potential to overcome its limitations. We removed two aspartic acid isomerization hotspots in CDRs of omalizumab to improve antibody candidate's stability. Meanwhile, several murine amino acids in the framework region of omalizumab were replaced with human source to reduce the potential immunogenicity. Yeast display technology was then applied to screen antibody candidates with high binding affinity to IgE. Moreover, YTE mutation in Fc fragment was introduced into the candidates for extending their serum half-life. A lead candidate, AB1904Am15, was screened out, which showed desired biophysical properties and improved stability, high binding affinity and elevated potency in vitro, prolonged half-life in human FcRn transgenic mouse, and enhanced in vivo efficacy in cynomolgus monkey asthma model. Overall, our study developed a biobetter antibody of omalizumab, AB1904Am15, which has the potential to show improved clinical benefit in the treatment of allergic diseases.	[Liu, Peipei; Ju, Dianwen] Fudan Univ, Dept Biol Med, Sch Pharm, Shanghai, Peoples R China; [Liu, Peipei; Ju, Dianwen] Fudan Univ, Shanghai Engn Res Ctr Immunotherapeut, Sch Pharm, Shanghai, Peoples R China; [Liu, Peipei; Pan, Zhongzong; Gu, Chunyin; Cao, Xiaodan; Liu, Xiaowu; Zhang, Jianjian; Xiao, Zheng; Wang, Xueping; Guo, Haibing; Deng, Su-Jun] Shanghai Jemincare Pharmaceut Co Ltd, Shanghai, Peoples R China	Fudan University; Fudan University	Ju, DW (corresponding author), Fudan Univ, Dept Biol Med, Sch Pharm, Shanghai, Peoples R China.; Ju, DW (corresponding author), Fudan Univ, Shanghai Engn Res Ctr Immunotherapeut, Sch Pharm, Shanghai, Peoples R China.; Guo, HB; Deng, SJ (corresponding author), Shanghai Jemincare Pharmaceut Co Ltd, Shanghai, Peoples R China.	guohaibing@jemincare.com; dianwenju@fudan.edu.cn; dengsujun@jemincare.com						Aswad DW, 2000, J PHARMACEUT BIOMED, V21, P1129, DOI 10.1016/S0731-7085(99)00230-7; Balbino B, 2018, PHARMACOL THERAPEUT, V191, P50, DOI 10.1016/j.pharmthera.2018.05.015; Barnes PJ, 2012, SEMIN RESP CRIT CARE, V33, P685, DOI 10.1055/s-0032-1326965; Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019; Cacia J, 1996, BIOCHEMISTRY-US, V35, P1897, DOI 10.1021/bi951526c; Chang TW, 2007, ADV IMMUNOL, V93, P63, DOI 10.1016/S0065-2776(06)93002-8; Chang TW, 2015, J ALLERGY CLIN IMMUN, V135, P337, DOI 10.1016/j.jaci.2014.04.036; Chang TW, 2000, NAT BIOTECHNOL, V18, P157, DOI 10.1038/72601; Cherf GM, 2015, METHODS MOL BIOL, V1319, P155, DOI 10.1007/978-1-4939-2748-7_8; Chu SY, 2012, J ALLERGY CLIN IMMUN, V129, P1102, DOI 10.1016/j.jaci.2011.11.029; Cooper AM, 2012, J IMMUNOL, V188, P3199, DOI 10.4049/jimmunol.1102689; D'Amato G, 2014, MULTIDISCIP RESP MED, V9, DOI 10.1186/2049-6958-9-23; D'Amato Gennaro, 2007, Ther Clin Risk Manag, V3, P613; Dall'Acqua WF, 2006, J BIOL CHEM, V281, P23514, DOI 10.1074/jbc.M604292200; Dreyfus DH, 2006, ANN ALLERG ASTHMA IM, V96, P624, DOI 10.1016/S1081-1206(10)63560-0; Garman SC, 2000, NATURE, V406, P259, DOI 10.1038/35018500; Gasser P, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13815-w; Gasser P, 2018, CURR OPIN IMMUNOL, V54, P86, DOI 10.1016/j.coi.2018.05.015; Gauvreau GM, 2016, J ALLERGY CLIN IMMUN, V138, P1051, DOI 10.1016/j.jaci.2016.02.027; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; Griffin MP, 2020, NEW ENGL J MED, V383, P415, DOI 10.1056/NEJMoa1913556; Guntern P, 2020, ALLERGY, V75, P2491, DOI 10.1111/all.14308; Harris RJ, 2001, J CHROMATOGR B, V752, P233, DOI 10.1016/S0378-4347(00)00548-X; Hochhaus G, 2003, CURR MED RES OPIN, V19, P491, DOI 10.1185/030079903125002171; Iwashita K, 2008, J PHARMACOL SCI, V106, P92, DOI 10.1254/jphs.FP0071523; Kuriakose A, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/1298473; Lanier BQ, 2005, ALLERGY ASTHMA PROC, V26, P435; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Lowe PJ, 2009, BRIT J CLIN PHARMACO, V68, P61, DOI 10.1111/j.1365-2125.2009.03401.x; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372; Nadeau KC, 2012, IMMUNOL ALLERGY CLIN, V32, P111, DOI 10.1016/j.iac.2011.11.004; Nowak C, 2017, MABS-AUSTIN, V9, P1217, DOI 10.1080/19420862.2017.1368602; Nowak D, 2006, RESP MED, V100, P1907, DOI 10.1016/j.rmed.2005.10.004; Okada H, 2010, CLIN EXP IMMUNOL, V160, P1, DOI 10.1111/j.1365-2249.2010.04139.x; Oliver JM, 2010, INT ARCH ALLERGY IMM, V151, P275, DOI 10.1159/000250436; Owen CE, 2007, PHARMACOL THERAPEUT, V113, P121, DOI 10.1016/j.pharmthera.2006.07.003; Pharmaceuticals and Medical Devices Agency (PMDA), 2008, XOL REP DEL RES; PRESTA L, 1994, J BIOL CHEM, V269, P26368; Robbie GJ, 2013, ANTIMICROB AGENTS CH, V57, P6147, DOI 10.1128/AAC.01285-13; Sheldon E, 2016, ADV THER, V33, P225, DOI 10.1007/s12325-016-0287-8; Sreedhara A, 2012, PHARM RES-DORDR, V29, P187, DOI 10.1007/s11095-011-0534-2; Sutton BJ, 2015, IMMUNOL REV, V268, P222, DOI 10.1111/imr.12340; Wakankar AA, 2007, J PHARM SCI-US, V96, P1708, DOI 10.1002/jps.20823; Walker S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003559.pub3; Wilcock LK, 2006, IMMUNOL ALLERGY CLIN, V26, P333, DOI 10.1016/j.iac.2006.02.004; Yalcin AD, 2021, IMMUNOPHARM IMMUNOT, V43, P1, DOI 10.1080/08923973.2020.1818770; Yalcin AD, 2016, IMMUNOPHARM IMMUNOT, V38, P253, DOI 10.3109/08923973.2016.1173057; Yalcin AD, 2013, EXPERT OPIN BIOL TH, V13, P1335, DOI 10.1517/14712598.2013.819338	52	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 27	2020	11								596908	10.3389/fimmu.2020.596908	http://dx.doi.org/10.3389/fimmu.2020.596908			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PC8VG	33329588	gold, Green Published			2022-12-18	WOS:000597276400001
J	Ikeda, T; Takeuchi, H; Takahashi, K; Nakamura, H; Kunii, M; Katsumoto, A; Tada, M; Higashiyama, Y; Hibiya, T; Suzuki, S; Nishino, I; Koyano, S; Doi, H; Tanaka, F				Ikeda, Takuya; Takeuchi, Hideyuki; Takahashi, Keita; Nakamura, Haruko; Kunii, Misako; Katsumoto, Atsuko; Tada, Mikiko; Higashiyama, Yuichi; Hibiya, Takashi; Suzuki, Shigeaki; Nishino, Ichizo; Koyano, Shigeru; Doi, Hiroshi; Tanaka, Fumiaki			Tonsillectomy Improved Therapeutic Response in Anti-SRP Myopathy With Chronic Tonsillitis	FRONTIERS IN IMMUNOLOGY			English	Article						anti-SRP myopathy; chronic tonsillitis; IgA nephritis; intravenous immunoglobulin; tonsillectomy	IGA NEPHROPATHY; IMMUNOGLOBULIN	Chronic tonsillitis has been attracted attention as a source of abnormal immune responses and a possible trigger of autoimmune diseases such as IgA nephritis, IgA vasculitis, palmoplantar pustulosis, psoriasis, rheumatoid arthritis, Behcet's disease, and myositis. Here we present the first report of anti-signal recognition particle antibody-associated necrotizing myopathy (anti-SRP myopathy) with IgA nephropathy and chronic tonsillitis in which the therapeutic response to intravenous immunoglobulin (IVIG) treatment was dramatically improved after tonsillectomy and accompanied by a rapid increase in Delta IgG, defined as the change in serum IgG levels 2 weeks after the start of IVIG treatment relative to pre-treatment levels. Moreover, serum anti-SRP antibody titers became undetectable after tonsillectomy even though the resected tonsils did not produce anti-SRP antibodies. Tonsillectomy should be considered when chronic tonsillitis is observed in patients with autoimmune diseases showing poor response to treatment, including anti-SRP myopathy.	[Ikeda, Takuya; Takeuchi, Hideyuki; Takahashi, Keita; Nakamura, Haruko; Kunii, Misako; Katsumoto, Atsuko; Tada, Mikiko; Higashiyama, Yuichi; Koyano, Shigeru; Doi, Hiroshi; Tanaka, Fumiaki] Yokohama City Univ, Dept Neurol & Stroke Med, Grad Sch Med, Yokohama, Kanagawa, Japan; [Hibiya, Takashi] Yokohama City Univ Med, Dept Pathol, Yokohama, Kanagawa, Japan; [Suzuki, Shigeaki] Keio Univ, Dept Neurol, Sch Med, Tokyo, Japan; [Nishino, Ichizo] Natl Ctr Neurol & Psychiat, Med Genome Ctr, Natl Inst Neurosci, Dept Neuromuscular Res, Tokyo, Japan; [Nishino, Ichizo] Natl Ctr Neurol & Psychiat, Med Genome Ctr, Dept Genome Med Dev, Tokyo, Japan	Yokohama City University; Yokohama City University; Keio University; National Center for Neurology & Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan	Takeuchi, H; Tanaka, F (corresponding author), Yokohama City Univ, Dept Neurol & Stroke Med, Grad Sch Med, Yokohama, Kanagawa, Japan.	htake@yokohama-cu.ac.jp; ftanaka@yokohama-cu.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan; Ministry of Health, Labour and Welfare of Japan; Yokohama City University; National Center of Neurology and Psychiatry [29-4]	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Yokohama City University; National Center of Neurology and Psychiatry(National Center for Neurology & Psychiatry - Japan)	This study was supported partly by grants-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan; grants from the Ministry of Health, Labour and Welfare of Japan; a grant for Strategic Research Promotion from Yokohama City University; and an Intramural Research Grant (29-4) for Neurological and Psychiatric Disorders from the National Center of Neurology and Psychiatry.	Allenbach Y, 2018, NEUROMUSCULAR DISORD, V28, P87, DOI 10.1016/j.nmd.2017.09.016; Feriozzi S, 2016, J NEPHROL, V29, P13, DOI 10.1007/s40620-015-0247-4; Furman D, 2019, NAT MED, V25, P1822, DOI 10.1038/s41591-019-0675-0; Harabuchi Y, 2019, IMMUN INFLAMM DIS, V7, P86, DOI 10.1002/iid3.248; KAWAGUCHI M, 1993, ACTA OTO-LARYNGOL, P36; Kuitwaard K, 2009, ANN NEUROL, V66, P597, DOI 10.1002/ana.21737; Lai KN, 2012, NAT REV NEPHROL, V8, P275, DOI 10.1038/nrneph.2012.58; Liu LL, 2015, AM J KIDNEY DIS, V65, P80, DOI 10.1053/j.ajkd.2014.06.036; Sato Y, 1996, NEPHRON, V74, P301, DOI 10.1159/000189325; Suzuki S, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0277-y; Takechi H, 2013, NEPHROL DIAL TRANSPL, V28, P3004, DOI 10.1093/ndt/gft399; Xie YS, 2004, KIDNEY INT, V65, P1135, DOI 10.1111/j.1523-1755.2004.00486.x	12	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2020	11								595480	10.3389/fimmu.2020.595480	http://dx.doi.org/10.3389/fimmu.2020.595480			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PC1FW	33329585	Green Published, gold			2022-12-18	WOS:000596755500001
J	Jia, ZK; Li, HY; Liang, YL; Potempa, LA; Ji, SR; Wu, Y				Jia, Zhe-Kun; Li, Hai-Yun; Liang, Yu-Lin; Potempa, Lawrence A.; Ji, Shang-Rong; Wu, Yi			Monomeric C-Reactive Protein Binds and Neutralizes Receptor Activator of NF-kappa B Ligand-Induced Osteoclast Differentiation (vol 9, 234, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						inflammation; rheumatoid arthritis; osteoclast; receptor activator of NF-&#954; B ligand; C-reactive protein			[Jia, Zhe-Kun; Liang, Yu-Lin; Ji, Shang-Rong] Lanzhou Univ, Sch Life Sci, MOE Key Lab Cell Act & Stress Adaptat, Lanzhou, Peoples R China; [Li, Hai-Yun; Wu, Yi] Xi An Jiao Tong Univ, Sch Basic Med Sci, MOE Key Lab Environm & Genes Related Dis, Xian, Peoples R China; [Potempa, Lawrence A.] Roosevelt Univ, Coll Pharm, Schaumburg, IL USA; [Wu, Yi] Xi An Jiao Tong Univ, Affiliated Childrens Hosp, Xian, Peoples R China	Lanzhou University; Xi'an Jiaotong University; Xi'an Jiaotong University	Ji, SR (corresponding author), Lanzhou Univ, Sch Life Sci, MOE Key Lab Cell Act & Stress Adaptat, Lanzhou, Peoples R China.; Wu, Y (corresponding author), Xi An Jiao Tong Univ, Sch Basic Med Sci, MOE Key Lab Environm & Genes Related Dis, Xian, Peoples R China.; Wu, Y (corresponding author), Xi An Jiao Tong Univ, Affiliated Childrens Hosp, Xian, Peoples R China.	jsr@lzu.edu.cn; wuy@lzu.edu.cn						Jia ZK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00234	1	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2020	11								619847	10.3389/fimmu.2020.619847	http://dx.doi.org/10.3389/fimmu.2020.619847			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PB5RR	33329615	Green Published, gold			2022-12-18	WOS:000596378500001
J	Materne, EC; Lilleri, D; Garofoli, F; Lombardi, G; Furione, M; Zavattoni, M; Gibson, L				Materne, Emma C.; Lilleri, Daniele; Garofoli, Francesca; Lombardi, Giuseppina; Furione, Milena; Zavattoni, Maurizio; Gibson, Laura			Cytomegalovirus-Specific T Cell Epitope Recognition in Congenital Cytomegalovirus Mother-Infant Pairs	FRONTIERS IN IMMUNOLOGY			English	Article						cytomegalovirus; T cell; immune escape; epitope; congenital infection; mother-infant pairs; immunology	I ALLELE PROMISCUITY; FUNCTIONAL EXHAUSTION; ESCAPE MUTATIONS; RESPONSES; CD8(+); VIRUS; INFECTION; CMV; EVOLUTION; CD4(+)	Background: Congenital cytomegalovirus (cCMV) infection is the most common infection acquired before birth and from which about 20% of infants develop permanent neurodevelopmental effects regardless of presence or absence of symptoms at birth. Viral escape from host immune control may be a mechanism of CMV transmission and infant disease severity. We sought to identify and compare CMV epitopes recognized by mother-infant pairs. We also hypothesized that if immune escape were occurring, then one pattern of longitudinal CD8 T cell responses restricted by shared HLA alleles would be maternal loss (by viral escape) and infant gain (by viral reversion to wildtype) of CMV epitope recognition. Methods: The study population consisted of 6 women with primary CMV infection during pregnancy and their infants with cCMV infection. CMV UL83 and UL123 peptides with known or predicted restriction by maternal MHC class I alleles were identified, and a subset was selected for testing based on several criteria. Maternal or infant cells were stimulated with CMV peptides in the IFN-gamma ELISpot assay. Results: Overall, 14 of 25 (56%; 8 UL83 and 6 UL123) peptides recognized by mother-infant pairs were not previously reported as CD8 T cell epitopes. Of three pairs with longitudinal samples, one showed maternal loss and infant gain of responses to a CMV epitope restricted by a shared HLA allele. Conclusions: CD8 T cell responses to multiple novel CMV epitopes were identified, particularly in infants. Moreover, the hypothesized pattern of CMV immune escape was observed in one mother-infant pair. These findings emphasize that knowledge of paired CMV epitope recognition allows exploration of viral immune escape that may operate within the maternal-fetal system. Our work provides rationale for future studies of this potential mechanism of CMV transmission during pregnancy or clinical outcomes of infants with cCMV infection.	[Materne, Emma C.; Gibson, Laura] Univ Massachusetts, Sch Med, Worcester, MA 01605 USA; [Lilleri, Daniele] Fdn Ist Ricovero & Cura Carattere Sci IRCCS Polic, Unita Operat Complessa, Lab Genet Trapiantol & Malattie Cardiovasc, Pavia, Italy; [Garofoli, Francesca; Lombardi, Giuseppina] Fdn Ist Ricovero & Cura Carattere Sci IRCCS Polic, Neonatal Unit, Pavia, Italy; [Garofoli, Francesca; Lombardi, Giuseppina] Fdn Ist Ricovero & Cura Carattere Sci IRCCS Polic, Neonatal Intens Care Unit, Pavia, Italy; [Furione, Milena; Zavattoni, Maurizio] Fdn Ist Ricovero & Cura Carattere Sci IRCCS Polic, Mol Virol Unit, Microbiol & Virol Dept, Pavia, Italy; [Gibson, Laura] UMass Mem Med Ctr, Dept Med, Worcester, MA 01605 USA; [Gibson, Laura] UMass Mem Med Ctr, Dept Pediat, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Materne, EC; Gibson, L (corresponding author), Univ Massachusetts, Sch Med, Worcester, MA 01605 USA.; Gibson, L (corresponding author), UMass Mem Med Ctr, Dept Med, Worcester, MA 01605 USA.; Gibson, L (corresponding author), UMass Mem Med Ctr, Dept Pediat, Worcester, MA 01605 USA.	ecmaterne@mgh.harvard.edu; laura.gibson@umassmed.edu	Garofoli, Francesca/P-9052-2019; de Lima, Antonio Marcos Oliveira/AAT-2148-2021; Furione, Milena/AAC-1945-2022	Garofoli, Francesca/0000-0003-3710-966X; 	NIH [U19-AI-109858]; Ministero della Salute, Ricerca Corrente [08053618]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministero della Salute, Ricerca Corrente(Ministry of Health, Italy)	This work was partially funded by NIH U19-AI-109858 and Ministero della Salute, Ricerca Corrente (grant no. 08053618). The funders had no role in study design, data collection, and interpretation.	Alfaro-Murillo JA, 2016, VACCINE, V34, P225, DOI 10.1016/j.vaccine.2015.11.039; Angelosanto JM, 2012, J VIROL, V86, P8161, DOI 10.1128/JVI.00889-12; Antoine P, 2012, J IMMUNOL, V189, P2665, DOI 10.4049/jimmunol.1101165; Arcia D, 2017, VIRAL IMMUNOL, V30, P3, DOI 10.1089/vim.2016.0095; Borchers S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050248; Bull RA, 2015, J VIROL, V89, P5478, DOI 10.1128/JVI.03717-14; Burrows SR, 2003, J IMMUNOL, V171, P1407, DOI 10.4049/jimmunol.171.3.1407; Camargo JF, 2019, BLOOD, V133, P867, DOI 10.1182/blood-2018-10-878918; Chen SF, 2016, J PEDIAT INF DIS SOC, V5, P14, DOI 10.1093/jpids/piu089; Choi YJ, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.146; Du YS, 2017, MBIO, V8, DOI 10.1128/mBio.01050-17; Elkington R, 2003, J VIROL, V77, P5226, DOI 10.1128/JVI.77.9.5226-5240.2003; Frahm N, 2007, EUR J IMMUNOL, V37, P2419, DOI 10.1002/eji.200737365; Gerna G, 2019, NEW MICROBIOL, V42, P1; Gibson L, 2004, J IMMUNOL, V172, P2256, DOI 10.4049/jimmunol.172.4.2256; Gibson L, 2007, J INFECT DIS, V195, P1789, DOI 10.1086/518042; Gibson L, 2015, J CLIN IMMUNOL, V35, P289, DOI 10.1007/s10875-015-0139-3; Gliga S, 2018, J CLIN VIROL, V105, P91, DOI 10.1016/j.jcv.2018.06.009; Gordon CL, 2017, J EXP MED, V214, P651, DOI 10.1084/jem.20160758; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; Huygens A, 2015, J INFECT DIS, V212, P484, DOI 10.1093/infdis/jiv071; Jones N, 2003, J IMMUNOL METHODS, V274, P139, DOI 10.1016/S0022-1759(02)00510-0; Karimzadeh H, 2019, GASTROENTEROLOGY, V156, P1820, DOI 10.1053/j.gastro.2019.02.003; Kefalakes H, 2019, GASTROENTEROLOGY, V156, P1805, DOI 10.1053/j.gastro.2019.01.035; Larsson M, 1999, AIDS, V13, P767, DOI 10.1097/00002030-199905070-00005; Lee H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189488; Leitman EM, 2017, J EXP MED, V214, P3239, DOI 10.1084/jem.20162123; Lidehall AK, 2013, SCAND J IMMUNOL, V77, P135, DOI 10.1111/sji.12013; Lilleri D, 2008, J INFECT DIS, V198, P536, DOI 10.1086/590118; Liu MKP, 2013, J CLIN INVEST, V123, P380, DOI 10.1172/JCI65330; Marchant A, 2003, J CLIN INVEST, V111, P1747, DOI 10.1172/JCI200317470; Marsico C, 2017, ITAL J PEDIATR, V43, DOI 10.1186/s13052-017-0358-8; McLane LM, 2019, ANNU REV IMMUNOL, V37, P457, DOI 10.1146/annurev-immunol-041015-055318; Miles DJC, 2007, J VIROL, V81, P5766, DOI 10.1128/JVI.00052-07; Nelson CS, 2020, J INFECT DIS, V221, P45, DOI 10.1093/infdis/jiz428; Olbrich H, 2020, HUM GENE THER, V31, P423, DOI 10.1089/hum.2019.149; Ould MAE, 2004, PEDIATR RES, V55, P280, DOI 10.1203/01.PDR.0000104150.85437.FE; Pedron B, 2007, J INFECT DIS, V196, P1033, DOI 10.1086/521196; PELLOQUIN F, 1986, IN VITRO CELL DEV B, V22, P689; Rao XY, 2011, IMMUNOGENETICS, V63, P691, DOI 10.1007/s00251-011-0552-6; Renzette N, 2017, J VIROL, V91, DOI 10.1128/JVI.01976-16; Renzette N, 2015, P NATL ACAD SCI USA, V112, pE4120, DOI 10.1073/pnas.1501880112; Renzette N, 2014, CURR OPIN VIROL, V8, P109, DOI 10.1016/j.coviro.2014.08.001; Renzette N, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003735; Renzette N, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001344; Sackman AM, 2018, PATHOGENS, V7, DOI 10.3390/pathogens7010016; Sanchez-Merino V, 2005, J IMMUNOL, V175, P6976, DOI 10.4049/jimmunol.175.10.6976; Sanchez-Merino V, 2008, J INFECT DIS, V197, P300, DOI 10.1086/524845; Schneidewind A, 2009, J VIROL, V83, P8616, DOI 10.1128/JVI.00730-09; Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1; Sood S, 2018, TRANSPL INFECT DIS, V20, DOI 10.1111/tid.12934; Thobakgale CF, 2009, J VIROL, V83, P10234, DOI 10.1128/JVI.00921-09; Walker S, 2007, TRANSPL INFECT DIS, V9, P165, DOI 10.1111/j.1399-3062.2006.00199.x; Wherry EJ, 2007, IMMUNITY, V27, P670, DOI 10.1016/j.immuni.2007.09.006; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862	55	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2020	11								568217	10.3389/fimmu.2020.568217	http://dx.doi.org/10.3389/fimmu.2020.568217			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PB5KZ	33329532	gold, Green Published			2022-12-18	WOS:000596360800001
J	Piekarska, A; Wisniewski, P; Lewandowski, K; Gil, L; Trzonkowski, P; Bieniaszewska, M; Zaucha, JM				Piekarska, Agnieszka; Wisniewski, Piotr; Lewandowski, Krzysztof; Gil, Lidia; Trzonkowski, Piotr; Bieniaszewska, Maria; Zaucha, Jan Maciej			Immune Status Against Hepatitis B in Patients After Allogeneic Hematopoietic Cell Transplantation-Factors Affecting Early and Long-Lasting Maintenance of Protective Anti-HBs Titers	FRONTIERS IN IMMUNOLOGY			English	Article						hepatitis B vaccine; vaccination schedule; donor vaccination; hematopoietic cell transplantation (HCT); chronic graft versus host disease (GVHD)	VERSUS-HOST-DISEASE; TH2 CYTOKINE PRODUCTION; T-CELL; INFECTIOUS COMPLICATIONS; MARROW-TRANSPLANTATION; RECIPIENTS; VACCINATION; RECONSTITUTION; GUIDELINES; VIRUS	The immunization of allogeneic hematopoietic cell transplantation (HCT) recipients against vaccine-preventable diseases is a part of posttransplantation guidelines. We conducted a prospective study to assess clinical and immunological parameters that would determine the response and long-term maintenance of protective antibody titers upon the hepatitis B virus (HBV) vaccination after HCT. The investigated variables included: vaccination of the HCT recipients and their donors prior to HCT, chronic graft versus host disease (cGVHD) and the timing of post-HCT vaccination, and B- and T-cell subtype status. Forty-two patients were immunized with three or more doses of recombinant hepatitis B surface antigen (rHBsAg) administered according to the individualized schedule of 0-1-2-6-(12) months. After vaccination, seroconversion was achieved in the whole group. The vaccines were categorized according to the antibody (Ab) titers as weak (WRs; 28.7%), good (GRs; 38%) or very good responders (VGRs; 3.3%). In multivariate logistic regression, severe cGVHD (OR= 15.5), and preceding donor immunization (OR= 0.13) were independent predictors of a weak response to vaccination. A prior belonging to the WR group impaired the durability of protection (OR= 0.17) at a median follow-up of 11.5 years. Patients with severe cGVHD showed a trend toward lower median Ab titers, although they required a higher rate of booster vaccine doses. All VGRs had CD4+ cells > 0.2 x 10(6)/L. There was a lower mean rate of CD4+IL2+ lymphocytes in WRs. Vaccination demonstrated the immunomodulatory effect on B-cell and T-cell subsets and a Th1/Th2 cytokine profile, while shifts depended on a history of severe cGVHD and the type of vaccine responder. To conclude, vaccination of HCT donors against HBV allows a better response to vaccination in the respective HCT recipients. Double doses of rHBsAg should be considered in patients with cGVHD and in those not immunized before HCT. A dedicated intensified vaccination schedule should be administered to WRs.	[Piekarska, Agnieszka; Bieniaszewska, Maria; Zaucha, Jan Maciej] Med Univ Gdansk, Dept Hematol & Transplantol, Gdansk, Poland; [Wisniewski, Piotr] Med Univ Gdansk, Dept Endocrinol & Internal Dis, Gdansk, Poland; [Lewandowski, Krzysztof] Med Univ Gdansk, Dept Lab Med, Gdansk, Poland; [Gil, Lidia] Poznan Univ Med Sci, Dept Hematol & Stem Cell Transplantat, Poznan, Poland; [Trzonkowski, Piotr] Med Univ Gdansk, Dept Clin Immunol, Gdansk, Poland	Fahrenheit Universities; Medical University Gdansk; Fahrenheit Universities; Medical University Gdansk; Fahrenheit Universities; Medical University Gdansk; Poznan University of Medical Sciences; Fahrenheit Universities; Medical University Gdansk	Piekarska, A (corresponding author), Med Univ Gdansk, Dept Hematol & Transplantol, Gdansk, Poland.	agnieszka.piekarska@gumed.edu.pl	Bieniaszewska, Maria/GZL-8270-2022; Wisniewski, Piotr/H-2646-2017	Wisniewski, Piotr/0000-0002-4411-577X	Ministry of Science and Higher Education [2 PO5B 080 26]; French Government; French Embassy in Poland; French Government Scholarship [385816B/P361471J]	Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland); French Government; French Embassy in Poland; French Government Scholarship	The laboratory analyses (immunophenotype of lymphocyte subsets and cytokine expression) were financed by a grant from the Ministry of Science and Higher Education (Mentorship Grant number 2 PO5B 080 26). This work was supported by the French Government and the French Embassy in Poland(science.varsovieamba@diplomatie.gouv.fr).The competence to assess Th1 and Th2 cytokine expression was gained thanks to the French Government Scholarship (Number 385816B/P361471J) taking place in Laboratoire d'Immunology CHU Rangueil, Toulouse, France, in 2003.	Avigan D, 2001, BIOL BLOOD MARROW TR, V7, P171, DOI 10.1053/bbmt.2001.v7.pm11302551; Bauer T, 2006, VACCINE, V24, P572, DOI 10.1016/j.vaccine.2005.08.058; Bosch M, 2012, CURR OPIN HEMATOL, V19, P324, DOI 10.1097/MOH.0b013e328353bc7d; Carpenter PA, 2016, BLOOD, V127, P2824, DOI 10.1182/blood-2015-12-550475; Clave E, 2009, BLOOD, V113, P6477, DOI 10.1182/blood-2008-09-176594; Conrad A, 2018, EXPERT REV VACCINES, V17, P299, DOI 10.1080/14760584.2018.1449649; Cordonnier C, 2019, LANCET INFECT DIS, V19, pE200, DOI 10.1016/S1473-3099(18)30600-5; CUTHBERT RJG, 1995, J CLIN PATHOL, V48, P257, DOI 10.1136/jcp.48.3.257; D'Orsogna L, 2009, BIOL BLOOD MARROW TR, V15, P795, DOI 10.1016/j.bbmt.2008.11.024; Gratwohl A, 2005, BONE MARROW TRANSPL, V36, P757, DOI 10.1038/sj.bmt.1705140; Hamaguchi M, 2002, INT J HEMATOL, V75, P324, DOI 10.1007/BF02982051; Harris AE, 2015, BONE MARROW TRANSPL, V50, P899, DOI 10.1038/bmt.2015.49; Hauri-Hohl MM, 2007, BLOOD, V109, P4080, DOI 10.1182/blood-2006-07-034157; Hilgendorf Inken, 2011, Vaccine, V29, P2825, DOI 10.1016/j.vaccine.2011.02.018; Jaffe D, 2006, BLOOD, V108, P2470, DOI 10.1182/blood-2006-04-006981; Jagasia MH, 2015, BIOL BLOOD MARROW TR, V21, P389, DOI 10.1016/j.bbmt.2014.12.001; JUNG T, 1993, J IMMUNOL METHODS, V159, P197, DOI 10.1016/0022-1759(93)90158-4; Kaloyannidis P, 2007, BIOL BLOOD MARROW TR, V13, P1049, DOI 10.1016/j.bbmt.2007.05.009; Kardar GA, 2002, SCAND J IMMUNOL, V55, P311, DOI 10.1046/j.1365-3083.2002.01057.x; Koff RS, 2002, VACCINE, V20, P3695, DOI 10.1016/S0264-410X(02)00405-X; Krenger W, 2008, SEMIN IMMUNOPATHOL, V30, P439, DOI 10.1007/s00281-008-0131-6; Kulkarni S, 2000, BLOOD, V95, P3683; Ljungman P, 2012, CLIN MICROBIOL INFEC, V18, P93, DOI 10.1111/j.1469-0691.2012.03971.x; Martorana A, 2014, IMMUNOL LETT, V162, P303, DOI 10.1016/j.imlet.2014.06.003; Mikulska M, 2014, CLIN MICROBIOL INFEC, V20, pO694, DOI 10.1111/1469-0691.12611; Parkkali T, 1996, APMIS, V104, P383, DOI 10.1111/j.1699-0463.1996.tb00731.x; Passweg JR, 2016, BONE MARROW TRANSPL, V51, P786, DOI 10.1038/bmt.2016.20; Perez-Simon JA, 2006, DRUGS, V66, P1041; Rostaing L, 1999, CYTOMETRY, V35, P318, DOI 10.1002/(SICI)1097-0320(19990401)35:4<318::AID-CYTO4>3.0.CO;2-4; Roux E, 2000, BLOOD, V96, P2299; Rubin LG, 2014, CLIN INFECT DIS, V58, P309, DOI [10.1093/cid/cit684, 10.1093/cid/cit816]; Seggewiss R, 2010, BLOOD, V115, P3861, DOI 10.1182/blood-2009-12-234096; Small TN, 2011, EXPERT REV CLIN IMMU, V7, P193, DOI [10.1586/eci.10.103, 10.1586/ECI.10.103]; Storek J, 2001, BLOOD, V98, P3505, DOI 10.1182/blood.V98.13.3505; Storek J, 2001, BLOOD, V97, P3380, DOI 10.1182/blood.V97.11.3380; Svegliati S, 2007, BLOOD, V110, P237, DOI 10.1182/blood-2007-01-071043; Tomblyn M, 2009, BIOL BLOOD MARROW TR, V15, P1143, DOI 10.1016/j.bbmt.2009.06.019; Ullmann AJ, 2016, ANN HEMATOL, V95, P1435, DOI 10.1007/s00277-016-2711-1; Vigano M, 2011, BONE MARROW TRANSPL, V46, P125, DOI 10.1038/bmt.2010.70; Walayat S, 2015, WORLD J HEPATOL, V7, P2503, DOI 10.4254/wjh.v7.i24.2503; Weinberg K, 2001, BLOOD, V97, P1458, DOI 10.1182/blood.V97.5.1458; WITHERSPOON RP, 1981, BLOOD, V58, P360; Zeiser R, 2017, NEW ENGL J MED, V377, P2565, DOI 10.1056/NEJMra1703472	43	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2020	11								586523	10.3389/fimmu.2020.586523	http://dx.doi.org/10.3389/fimmu.2020.586523			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PE6CM	33335530	gold, Green Published			2022-12-18	WOS:000598451600001
J	Coffelt, SB; Kabelitz, D; Silva-Santos, B; Kuball, J; Born, W; Bank, I				Coffelt, Seth B.; Kabelitz, Dieter; Silva-Santos, Bruno; Kuball, Jurgen; Born, Willi; Bank, Ilan			Editorial: gamma delta T Cells in Cancer	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						gamma delta T cells; cancer; butyrophilin; immunotherapy; bisphoshonates	TCR		[Coffelt, Seth B.] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland; [Coffelt, Seth B.] Canc Res UK Beatson Inst, Glasgow, Lanark, Scotland; [Kabelitz, Dieter] Univ Kiel, Inst Immunol, Kiel, Germany; [Silva-Santos, Bruno] Univ Lisbon, Fac Med, Inst Med Mol, Lisbon, Portugal; [Kuball, Jurgen] Utrecht Med Ctr, Dept Hematol, Utrecht, Netherlands; [Kuball, Jurgen] Utrecht Med Ctr, Ctr Translat Immunol, Utrecht, Netherlands; [Born, Willi] Natl Jewish Hlth, Dept Immunol & Genom Med, Denver, CO USA; [Bank, Ilan] Sheba Med Ctr, Div Med, Rheumatol Unit, Tel Hashomer, Israel	University of Glasgow; Beatson Institute; University of Kiel; Universidade de Lisboa; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; National Jewish Health; Chaim Sheba Medical Center	Coffelt, SB (corresponding author), Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland.; Coffelt, SB (corresponding author), Canc Res UK Beatson Inst, Glasgow, Lanark, Scotland.; Kabelitz, D (corresponding author), Univ Kiel, Inst Immunol, Kiel, Germany.; Silva-Santos, B (corresponding author), Univ Lisbon, Fac Med, Inst Med Mol, Lisbon, Portugal.; Kuball, J (corresponding author), Utrecht Med Ctr, Dept Hematol, Utrecht, Netherlands.; Kuball, J (corresponding author), Utrecht Med Ctr, Ctr Translat Immunol, Utrecht, Netherlands.; Born, W (corresponding author), Natl Jewish Hlth, Dept Immunol & Genom Med, Denver, CO USA.; Bank, I (corresponding author), Sheba Med Ctr, Div Med, Rheumatol Unit, Tel Hashomer, Israel.	seth.coffelt@glasgow.ac.uk; dietrich.kabelitz@uksh.de; bssantos@medicina.ulisboa.pt; J.H.E.Kuball@umcutrecht.nl; bornw@njhealth.org; ibank@tauex.tau.ac.il	Kabelitz, Dieter/AAB-4199-2021	Coffelt, Seth/0000-0003-2257-2862	Cancer Research UK Glasgow Centre [A25142]; Wellcome Trust [208990/Z/17/Z]; Medical Research Council [MR/R502327/1]; Breast Cancer Now [2018JulPR1101, 2019DecPhD1349]; Tenovus Scotland [S17-17]; Deutsche Forschungsgemeinschaft [Ka 502/19-2]; Wilhelm Sander Foundation [2018.045.1]; "la Caixa" Banking Foundation [HR18-00069]; Dutch Research Council [NWO ZonMW 43400003]; Dutch Cancer Society [KWF UU 2014-6790, UU 2015-7601, UU 2018-11393, UU 2018-11979, UU 2019-12586]	Cancer Research UK Glasgow Centre; Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Breast Cancer Now; Tenovus Scotland; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Wilhelm Sander Foundation; "la Caixa" Banking Foundation(La Caixa Foundation); Dutch Research Council; Dutch Cancer Society(KWF Kankerbestrijding)	The authors acknowledge funding from the Cancer Research UK Glasgow Centre (A25142 to SBC), the Wellcome Trust (208990/Z/17/Z to SBC), the Medical Research Council (MR/R502327/1 to SBC), Breast Cancer Now (2018JulPR1101 and 2019DecPhD1349 to SBC), Tenovus Scotland (S17-17 to SBC), the Deutsche Forschungsgemeinschaft (Ka 502/19-2 to DK), the Wilhelm Sander Foundation (2018.045.1 to DK), "la Caixa" Banking Foundation (HR18-00069 to BS-S), the Dutch Research Council (NWO ZonMW 43400003 to JK), the Dutch Cancer Society (KWF UU 2014-6790, UU 2015-7601, UU 2018-11393, UU 2018-11979, UU 2019-12586, UU 2020-13043 to JK).	BANK I, 1986, NATURE, V322, P179, DOI 10.1038/322179a0; BORN W, 1987, NATURE, V330, P572, DOI 10.1038/330572a0; BORST J, 1987, NATURE, V325, P683, DOI 10.1038/325683a0; BRENNER MB, 1986, NATURE, V322, P145, DOI 10.1038/322145a0; CHIEN YH, 1987, NATURE, V327, P677, DOI 10.1038/327677a0; Harly C, 2012, BLOOD, V120, P2269, DOI 10.1182/blood-2012-05-430470; Hayday AC, 2019, J IMMUNOL, V203, P311, DOI 10.4049/jimmunol.1800934; Kabelitz D, 2020, CELL MOL IMMUNOL, V17, P925, DOI 10.1038/s41423-020-0504-x; Karunakaran MM, 2020, IMMUNITY, V52, P487, DOI 10.1016/j.immuni.2020.02.014; SAITO H, 1984, NATURE, V309, P757, DOI 10.1038/309757a0; Sebestyen Z, 2020, NAT REV DRUG DISCOV, V19, P169, DOI 10.1038/s41573-019-0038-z; Silva-Santos B, 2019, NAT REV CANCER, V19, P392, DOI 10.1038/s41568-019-0153-5; Willcox BE, 2019, NAT IMMUNOL, V20, P121, DOI 10.1038/s41590-018-0304-y	13	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 20	2020	11								602411	10.3389/fimmu.2020.602411	http://dx.doi.org/10.3389/fimmu.2020.602411			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PA1RD	33329597	Green Published, Green Accepted, gold			2022-12-18	WOS:000595402300001
J	Zhou, Y; Wang, YC; Ni, HQ; Deng, WF; Liu, D; Xu, J; Cui, NQ; Wu, YH; Fu, SJ; Xiao, LL; Liu, HL; Qi, K; Wang, SQ; Xiong, F; Miao, Y				Zhou, Yi; Wang, Yuchen; Ni, Haiqiang; Deng, Wenfeng; Liu, Ding; Xu, Jian; Cui, Naiqian; Wu, Yihan; Fu, Shaojie; Xiao, Lulu; Liu, Hailiang; Qi, Ka; Wang, Shaoqing; Xiong, Fu; Miao, Yun			The Potential Significance of ABO Genotyping for Donor Selection in Kidney Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						ABO subtype; genotype; donor selection; serologic testing; kidney transplantation	MOLECULAR-GENETIC ANALYSIS; BLOOD-GROUP ANTIGEN; GROUP-A; SUBGROUP; LEWIS; POPULATION; SEQUENCE	Background The ABO blood group system is clinically important in kidney transplantation, but ABO genotyping fails to attract sufficient attention in some countries and regions. We identified one case of early graft dysfunction due to an ABO genotype mismatch. Here, we performed ABO genotyping in blood samples, analyzed grouping discrepancies, and investigated the weak A subgroup frequency in kidney transplantation candidates. Methods Blood samples from 302 uremic patients with grouping discrepancies and 356 uremic patients with type A blood were analyzed using standard serologic serotyping techniques. The ABO genotypes and alleles were analyzed by polymerase chain reaction sequence-specific primer (PCR-SSP) and sequence-based typing (PCR-SBT). Results All 302 uremic patients with grouping discrepancies carried weak ABO subgroup alleles and 77.48% carried irregular ABO antibodies. The discrepancy rate between serotyping and genotyping was 42.38%, and the mismatching rate of donor selection according to serotype reached 88.74%. And 2.53% of 356 uremic patients with type A blood were determined to be in the weak A subgroup, which was a higher percentage than that observed in the healthy Chinese population (0.53%) by serological screening, but much lower than that observed in Caucasians (20%). Conclusion We revealed the high risk of blood type misjudgment and genetically ABO-mismatched transplantation if serological test was performed only in blood-group typing. Improved precision of ABO genotyping is crucial for successful kidney transplantation and reasonable organ allocation.	[Zhou, Yi; Wang, Yuchen; Ni, Haiqiang; Deng, Wenfeng; Xu, Jian; Cui, Naiqian; Wu, Yihan; Fu, Shaojie; Xiao, Lulu; Miao, Yun] Southern Med Univ, Nanfang Hosp, Div Transplantat, Guangzhou, Peoples R China; [Liu, Ding] Southern Med Univ, Zhujiang Hosp, Div Transplantat, Guangzhou, Peoples R China; [Liu, Hailiang; Xiong, Fu] Southern Med Univ, Sch Basic Med Sci, Dept Med Genet, Guangzhou, Peoples R China; [Qi, Ka] Qinhuangdao Char Hosp, Hemodialysis Ctr, Qinhuangdao, Hebei, Peoples R China; [Wang, Shaoqing] Chengdu Med Coll, Affiliated Hosp 1, Nephrol Dept, Chengdu, Peoples R China	Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Chengdu Medical College	Miao, Y (corresponding author), Southern Med Univ, Nanfang Hosp, Div Transplantat, Guangzhou, Peoples R China.; Xiong, F (corresponding author), Southern Med Univ, Sch Basic Med Sci, Dept Med Genet, Guangzhou, Peoples R China.	wongfu@smu.edu.cn; miaoyunecho@126.com			Science and Technology Planning Project of Guangzhou [201803010109]; Natural Science Foundation of Guangdong Province [2020A1515010674]; President Funding of Nanfang Hospital [2018B009, 2018C003]; College Students' Innovative Entrepreneurial Training Plan Program [201812121148, X202012121239, 202012121046]	Science and Technology Planning Project of Guangzhou; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); President Funding of Nanfang Hospital; College Students' Innovative Entrepreneurial Training Plan Program	This study was funded by the Science and Technology Planning Project of Guangzhou (Grant No. 201803010109), Natural Science Foundation of Guangdong Province (Grant No. 2020A1515010674), the President Funding of Nanfang Hospital (Grant No. 2018B009, 2018C003) and College Students' Innovative Entrepreneurial Training Plan Program (Grant No. 201812121148, X202012121239, 202012121046).	Anstee DJ, 2010, BLOOD, V115, P4635, DOI 10.1182/blood-2010-01-261859; Anstee DJ, 2009, BLOOD, V114, P248, DOI 10.1182/blood-2008-11-146860; BARIETY J, 1980, KIDNEY INT, V17, P820, DOI 10.1038/ki.1980.94; Bianco T, 2001, BLOOD, V97, P3633, DOI 10.1182/blood.V97.11.3633; BREIMER ME, 1986, TRANSPLANTATION, V42, P88; Breimer ME, 2006, TRANSPLANTATION, V82, P479, DOI 10.1097/01.tp.0000231697.15817.51; Bryan CF, 2004, CLIN TRANSPLANT, V18, P12, DOI 10.1111/j.1399-0012.2004.00211; Chang CS, 2008, INT J HEMATOL, V88, P127, DOI 10.1007/s12185-008-0136-x; Chen Y, 2016, J CLIN HEMATOL CHINA, V29, P773, DOI [10.13201/j.issn.1004-2806-b.2016.10.001, DOI 10.13201/J.ISSN.1004-2806-B.2016.10.001]; CORDONCARDO C, 1989, CANCER RES, V49, P212; Daniels G., 2002, HUMAN BLOOD GROUPS; Dashkova N. G., 2009, Anesteziologiya i Reanimatologiya, P62; de Weerd AE, 2018, CLIN J AM SOC NEPHRO, V13, P1234, DOI 10.2215/CJN.00540118; Du Z, 2012, CHINA MODERN MED, V19, P175, DOI [10.3969/j.issn.1674-4721.2012.25.092, DOI 10.3969/J.ISSN.1674-4721.2012.25.092]; Eiz-Vesper B, 2005, TRANSFUSION, V45, P960, DOI 10.1111/j.1537-2995.2005.04370.x; Flechner SM, 2018, AM J TRANSPLANT, V18, P2730, DOI 10.1111/ajt.14744; Gassner C, 1996, BLOOD, V88, P1852, DOI 10.1182/blood.V88.5.1852.bloodjournal8851852; Gloor JM, 2003, TRANSPLANTATION, V75, P971, DOI 10.1097/01.TP.0000058226.397.32; GOODWIN WE, 1963, J UROLOGY, V89, P349, DOI 10.1016/S0022-5347(17)64556-7; Hakomori S, 1999, BBA-GEN SUBJECTS, V1473, P247, DOI 10.1016/S0304-4165(99)00183-X; Holscher CM, 2020, AM J KIDNEY DIS, V75, P114, DOI 10.1053/j.ajkd.2019.04.025; Hosoi E, 2008, J MED INVESTIG, V55, P174, DOI 10.2152/jmi.55.174; Huang HB, 2019, BLOOD TRANSFUS-ITALY, V17, P217, DOI 10.2450/2018.0091-18; Kawase T, 2002, TRANSPLANT P, V34, P2773, DOI 10.1016/S0041-1345(02)03405-X; Kluger MD, 2012, TRANSPLANTATION, V94, P526, DOI 10.1097/TP.0b013e31825c591e; NELSON PW, 1988, TRANSPLANTATION, V45, P316, DOI 10.1097/00007890-198802000-00013; Ogasawara K, 1996, BLOOD, V88, P2732, DOI 10.1182/blood.V88.7.2732.bloodjournal8872732; Olsson ML, 2001, BLOOD, V98, P1585, DOI 10.1182/blood.V98.5.1585; TRICKETT LP, 1983, BRIT J EXP PATHOL, V64, P137; Ushigome H, 2010, CLIN TRANSPLANT, V24, P16, DOI 10.1111/j.1399-0012.2010.01278.x; Wang ML, 2021, NEPHROL DIAL TRANSPL, V36, P288, DOI 10.1093/ndt/gfz171; Weng FL, 2017, CLIN TRANSPLANT, V31, DOI 10.1111/ctr.12978; Westhoff CM, 2019, BLOOD, V133, P1814, DOI 10.1182/blood-2018-11-833954; Xie J, 2016, CHIN J BLOOD TRANSFU, V29, P381, DOI [10.13303/j.cjbt.issn.1004-549x.2016.04.014, DOI 10.13303/J.CJBT.ISSN.1004-549X.2016.04.014]; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMAMOTO F, 1992, BIOCHEM BIOPH RES CO, V187, P366, DOI 10.1016/S0006-291X(05)81502-5; YAMAMOTO F, 1995, GLYCOBIOLOGY, V5, P51, DOI 10.1093/glycob/5.1.51; Ying YL, 2013, TRANSFUS APHER SCI, V48, P67, DOI 10.1016/j.transci.2012.08.002; [于立新 Yu Lixin], 2010, [中华泌尿外科杂志, Chinese Journal of Urology], V31, P814	39	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 19	2020	11								608716	10.3389/fimmu.2020.608716	http://dx.doi.org/10.3389/fimmu.2020.608716			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OZ7XY	33329606	Green Published, gold			2022-12-18	WOS:000595135500001
J	Han, JH; Cai, MM; Grein, J; Perera, S; Wang, HM; Bigler, M; Ueda, R; Rosahl, TW; Pinheiro, E; LaFace, D; Seghezzi, W; Williams, SMG				Han, Jin-Hwan; Cai, Mingmei; Grein, Jeffery; Perera, Samanthi; Wang, Hongmei; Bigler, Mike; Ueda, Roenna; Rosahl, Thomas W.; Pinheiro, Elaine; LaFace, Drake; Seghezzi, Wolfgang; Williams, Sybil M. Genther			Effective Anti-tumor Response by TIGIT Blockade Associated With Fc gamma R Engagement and Myeloid Cell Activation (vol 11, 573405, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						TIGIT; Fc gamma R; myeloid cells; combination cancer immunotherapy; costimulatory molecules; immune checkpoint blockade			[Han, Jin-Hwan; Cai, Mingmei; Grein, Jeffery; Perera, Samanthi; Wang, Hongmei; Bigler, Mike; Ueda, Roenna; Rosahl, Thomas W.; Pinheiro, Elaine; LaFace, Drake; Seghezzi, Wolfgang; Williams, Sybil M. Genther] Merck & Co Inc, Kenilworth, NJ 07033 USA	Merck & Company	Williams, SMG (corresponding author), Merck & Co Inc, Kenilworth, NJ 07033 USA.	sybil_williams@merck.com						Han JH, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.573405	1	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 18	2020	11								615755	10.3389/fimmu.2020.615755	http://dx.doi.org/10.3389/fimmu.2020.615755			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OZ7NR	33329611	Green Published, gold			2022-12-18	WOS:000595108700001
J	Zhou, JO; Zaidi, HA; Ton, T; Fera, D				Zhou, Jeffrey O.; Zaidi, Hussain A.; Ton, Therese; Fera, Daniela			The Effects of Framework Mutations at the Variable Domain Interface on Antibody Affinity Maturation in an HIV-1 Broadly Neutralizing Antibody Lineage (vol 11, 1529, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						human immunodeficiency virus; antibody; evolution; crystal structure; somatic hypermutation; framework			[Zhou, Jeffrey O.; Zaidi, Hussain A.; Fera, Daniela] Swarthmore Coll, Dept Chem & Biochem, Swarthmore, PA 19081 USA; [Ton, Therese] Swarthmore Coll, Dept Biol, Swarthmore, PA 19081 USA	Swarthmore College; Swarthmore College	Fera, D (corresponding author), Swarthmore Coll, Dept Chem & Biochem, Swarthmore, PA 19081 USA.	dfera1@swarthmore.edu			Meyer Davidson '57 Summer Research Fellowship Grant; amfAR [109502-61-RKVA]; Swarthmore College; NIGMS from the NIH [P30 GM124165]; NIH-ORIP HEI grant [S10OD021527]; DOE Office of Science [DE-AC02-06CH11357]	Meyer Davidson '57 Summer Research Fellowship Grant; amfAR; Swarthmore College; NIGMS from the NIH; NIH-ORIP HEI grant; DOE Office of Science(United States Department of Energy (DOE))	JZ was supported by the Meyer Davidson '57 Summer Research Fellowship Grant. DF acknowledges support from the Mathilde Krim Fellowship in Basic Biomedical Research (109502-61-RKVA) from amfAR and Swarthmore College Startup and Faculty Research Funds. This work is based upon research conducted at NE-CAT beamlines, which are funded by the NIGMS from the NIH (P30 GM124165). The Eiger 16M detector on the 24-ID-E beam line is funded by a NIH-ORIP HEI grant (S10OD021527). This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357.	Zhou JO, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01529	1	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 18	2020	11								620518	10.3389/fimmu.2020.620518	http://dx.doi.org/10.3389/fimmu.2020.620518			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OZ7NB	33312180	gold, Green Published			2022-12-18	WOS:000595107100001
J	Alberici, F; Emmi, G; Kronbichler, A				Alberici, Federico; Emmi, Giacomo; Kronbichler, Andreas			Editorial: "Toward Precision Medicine in Vasculitis"	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis; biomarkers; Behcet's syndrome; uveitis; treatment	RITUXIMAB		[Alberici, Federico] Univ Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Brescia, Italy; [Alberici, Federico] ASST Spedali Civili Brescia, Spedali Civili Hosp, Nephrol Unit, Brescia, Italy; [Emmi, Giacomo] Univ Firenze, Dept Expt & Clin Med, Florence, Italy; [Emmi, Giacomo] Careggi Univ Hosp Firenze, Internal Interdisciplinary Med Unit, Florence, Italy; [Kronbichler, Andreas] Med Univ Innsbruck, Dept Internal Med Nephrol & Hypertens 4, Innsbruck, Austria	University of Brescia; Hospital Spedali Civili Brescia; University of Florence; Medical University of Innsbruck	Alberici, F (corresponding author), Univ Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Brescia, Italy.; Alberici, F (corresponding author), ASST Spedali Civili Brescia, Spedali Civili Hosp, Nephrol Unit, Brescia, Italy.	federico.alberici@unibs.it	Alberici, Federico/AAC-5289-2022; Kronbichler, Andreas/ABD-1235-2021	Alberici, Federico/0000-0002-1686-5709; Kronbichler, Andreas/0000-0002-2945-2946; Emmi, Giacomo/0000-0001-9575-8321				Alberici F, 2017, J ALLERGY CLIN IMMUN, V139, P1684, DOI 10.1016/j.jaci.2016.08.051; Alberici F, 2015, RHEUMATOLOGY, V54, P1153, DOI 10.1093/rheumatology/keu452; Alberici F, 2014, NEPHROL DIAL TRANSPL, V29, P1151, DOI 10.1093/ndt/gft318; Charles P, 2018, ANN RHEUM DIS, V77, P1144, DOI 10.1136/annrheumdis-2017-212878; Jennette JC, 2013, ARTHRITIS RHEUM-US, V65, P1, DOI 10.1002/art.37715; Tedesco M, 2019, J NEPHROL, V32, P871, DOI 10.1007/s40620-019-00628-9	6	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 17	2020	11								616221	10.3389/fimmu.2020.616221	http://dx.doi.org/10.3389/fimmu.2020.616221			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OZ6AW	33281833	gold, Green Published			2022-12-18	WOS:000595007600001
J	Pearson, JA; Li, YY; Majewska-Szczepanik, M; Guo, JH; Zhang, L; Liu, Y; Wong, FS; Wen, L				Pearson, James A.; Li, Yangyang; Majewska-Szczepanik, Monika; Guo, Junhua; Zhang, Li; Liu, Yu; Wong, F. Susan; Wen, Li			Insulin-Reactive T Cells Convert Diabetogenic Insulin-Reactive VH125 B Cells Into Tolerogenic Cells by Reducing Germinal Center T:B Cell Interactions in NOD Mice	FRONTIERS IN IMMUNOLOGY			English	Article						insulin; Type 1 diabetes; B cells; T cells; TGF&#946; germinal center	CXC CHEMOKINE RECEPTOR-5; HUMAN THYMUS; BETA-CELLS; EXPRESSION; INTERLEUKIN-21; AUTOIMMUNITY; SPECIFICITY; ACTIVATION; MECHANISMS; TOLERANCE	Insulin is a key autoantigen in Type 1 Diabetes (T1D), targeted by both T and B cells. Therefore, understanding insulin-specific T:B cell interactions is important. We have previously reported an insulin-reactive CD4+ T cell, (designated 2H6). Unlike other insulin-reactive T cells, 2H6 cells protect non-obese diabetic (NOD) mice from T1D development, mediated by TGF beta. To investigate insulin-specific T:B cell interactions, we bred 2H6 alpha beta T cell receptor transgenic NOD mice (2H6) with the insulin-reactive B cell receptor transgenic NOD mice (VH125), generating 2H6VH125 NOD mice. Similar to 2H6 mice, 2H6VH125 mice are protected from T1D development. Interestingly, VH125 B cells did not alter the phenotype of 2H6 T cells; however, 2H6 T cells significantly altered the VH125 B cells by reducing the insulin-reactive non-germinal center (GC) and GC B cells, as well as MHC and costimulatory molecule expression on the B cells. Furthermore, the B cells in 2H6VH125 NOD mice exhibited increased non-insulin-specific and a class switched IgG isotype, which can be recapitulated in vivo in Rag-deficient NOD mice by adoptive transfer. In vitro, VH125 B cells from 2H6VH125 mice suppressed the proliferation of 2H6 T cells to insulin antigen but enhanced TGF beta secretion by 2H6 T cells from 2H6VH125 mice compared to 2H6 mice. In summary, our data showed that 2H6 CD4+ T cells alter the phenotype and function of insulin-reactive B cells from pathogenic to tolerogenic cells. In turn, VH125 B cells also modulate the function of the 2H6 T cells. Thus, promoting the interactions between antigen-specific regulatory T cells and B cells may lead to protection from T1D.	[Pearson, James A.; Li, Yangyang; Majewska-Szczepanik, Monika; Guo, Junhua; Zhang, Li; Wen, Li] Yale Univ, Sch Med, Endocrinol Sect, New Haven, CT 06520 USA; [Pearson, James A.; Wong, F. Susan] Cardiff Univ, Sch Med, Div Infect & Immun, Diabet Res Grp, Cardiff, Wales; [Li, Yangyang; Liu, Yu] Nanjing Med Univ, Sir Run Run Shaw Hosp, Dept Endocrinol, Nanjing, Peoples R China; [Majewska-Szczepanik, Monika] Jagiellonian Univ Med Coll, Dept Med Biol, Krakow, Poland; [Guo, Junhua] Peoples Liberat Army PLA, Dept Rheumatol, Gen Hosp, Beijing, Peoples R China	Yale University; Cardiff University; Nanjing Medical University; Jagiellonian University; Collegium Medicum Jagiellonian University	Wen, L (corresponding author), Yale Univ, Sch Med, Endocrinol Sect, New Haven, CT 06520 USA.	li.wen@yale.edu		Pearson, James/0000-0002-2867-2269	JDRF Postdoctoral Fellowship [3-PDF-2016-197-A-N]; MRC [MR/K021141/1]; MRC Career Development Award [MR/T010525/1]; Molecular & Genetic Mouse Core of NIH P30 [DK 045735]; Diabetes Research Connection; NIH [RO1HD097808]; MRC [MR/T010525/1] Funding Source: UKRI	JDRF Postdoctoral Fellowship(Juvenile Diabetes Research Foundation); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC Career Development Award(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Molecular & Genetic Mouse Core of NIH P30(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Diabetes Research Connection; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was funded by a JDRF Postdoctoral Fellowship (3-PDF-2016-197-A-N) and more recently a MRC Career Development Award (MR/T010525/1) to JP, MRC research grant MR/K021141/1 to FW and by the Molecular & Genetic Mouse Core of NIH P30 (DK 045735), Diabetes Research Connection and NIH RO1HD097808 to LW.	Acevedo-Suarez CA, 2005, J IMMUNOL, V174, P827, DOI 10.4049/jimmunol.174.2.827; Attridge K, 2014, J IMMUNOL, V192, P2195, DOI 10.4049/jimmunol.1302082; Bingley PJ, 1997, DIABETES, V46, P1701, DOI 10.2337/diabetes.46.11.1701; Boldison J, 2019, DIABETOLOGIA, V62, P2052, DOI 10.1007/s00125-019-04974-y; Breitfeld D, 2000, J EXP MED, V192, P1545, DOI 10.1084/jem.192.11.1545; Bulek AM, 2012, NAT IMMUNOL, V13, P283, DOI 10.1038/ni.2206; Chentoufi AA, 2002, DIABETES, V51, P1383, DOI 10.2337/diabetes.51.5.1383; Cole DK, 2016, J CLIN INVEST, V126, P3626, DOI 10.1172/JCI89919; DANIEL D, 1995, EUR J IMMUNOL, V25, P1056, DOI 10.1002/eji.1830250430; Du W, 2006, J CLIN INVEST, V116, P1360, DOI 10.1172/JCI27030; Ferreira RC, 2015, DIABETOLOGIA, V58, P781, DOI 10.1007/s00125-015-3509-8; HASKINS K, 1988, DIABETES, V37, P1444, DOI 10.2337/diabetes.37.10.1444; Heninger AK, 2013, DIABETES, V62, P2059, DOI 10.2337/db12-0942; Hulbert C, 2001, J IMMUNOL, V167, P5535, DOI 10.4049/jimmunol.167.10.5535; Hummel S, 2011, DIABETES CARE, V34, P1301, DOI 10.2337/dc10-2456; Khan AR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6997; Lamont D, 2014, J IMMUNOL, V193, P2135, DOI 10.4049/jimmunol.1400997; Linterman MA, 2010, J EXP MED, V207, P353, DOI 10.1084/jem.20091738; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nakayama M, 2005, J AUTOIMMUN, V25, P193, DOI 10.1016/j.jaut.2005.09.014; Nakayama M, 2005, NATURE, V435, P220, DOI 10.1038/nature03523; Pugliese A, 1997, NAT GENET, V15, P293, DOI 10.1038/ng0397-293; Rojas M, 2001, J IMMUNOL, V166, P3194, DOI 10.4049/jimmunol.166.5.3194; Schaerli P, 2000, J EXP MED, V192, P1553, DOI 10.1084/jem.192.11.1553; Schloot NC, 1998, J AUTOIMMUN, V11, P169, DOI 10.1006/jaut.1997.0183; Semana G, 1999, J AUTOIMMUN, V12, P259, DOI 10.1006/jaut.1999.0282; Skowera A, 2008, J CLIN INVEST, V118, P3390, DOI 10.1172/JCI35449; Spolski R, 2008, P NATL ACAD SCI USA, V105, P14028, DOI 10.1073/pnas.0804358105; SRIKANTA S, 1986, DIABETES, V35, P139, DOI 10.2337/diabetes.35.2.139; Sutherland APR, 2009, DIABETES, V58, P1144, DOI 10.2337/db08-0882; Thayer TC, 2016, DIABETES, V65, P3429, DOI 10.2337/db15-1649; Vafiadis P, 1997, NAT GENET, V15, P289, DOI 10.1038/ng0397-289; VARDI P, 1988, DIABETES CARE, V11, P736, DOI 10.2337/diacare.11.9.736; Viisanen T, 2017, DIABETES, V66, P437, DOI 10.2337/db16-0714; Vogelzang A, 2008, IMMUNITY, V29, P127, DOI 10.1016/j.immuni.2008.06.001; Wan XX, 2016, J EXP MED, V213, P967, DOI 10.1084/jem.20151869; WEGMANN DR, 1994, J AUTOIMMUN, V7, P833, DOI 10.1006/jaut.1994.1066; WEGMANN DR, 1994, EUR J IMMUNOL, V24, P1853, DOI 10.1002/eji.1830240820; Williams JM, 2015, J IMMUNOL, V195, P853, DOI 10.4049/jimmunol.1403114; Wong FS, 1999, NAT MED, V5, P1026, DOI 10.1038/12465; Zekzer D, 1997, DIABETES, V46, P1124, DOI 10.2337/diabetes.46.7.1124; ZIEGLER AG, 1989, DIABETES, V38, P1320, DOI 10.2337/diabetes.38.10.1320	42	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 12	2020	11								585886	10.3389/fimmu.2020.585886	http://dx.doi.org/10.3389/fimmu.2020.585886			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OV4XU	33262765	Green Published, gold, Green Accepted			2022-12-18	WOS:000592215600001
J	Isenberg, DA; Kao, AH; Aydemir, A; Merrill, JT				Isenberg, David A.; Kao, Amy H.; Aydemir, Aida; Merrill, Joan T.			Commentary: Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						BAFF; APRIL; TACI; B cell; monoclonal antibody; multiple sclerosis; rheumatoid arthritis; systemic lupus erythematosus	PHASE-II; DOUBLE-BLIND; RHEUMATOID-ARTHRITIS; INADEQUATE RESPONSE; TRIAL; ANIFROLUMAB; BELIMUMAB		[Isenberg, David A.] UCL, Div Med, Ctr Rheumatol, London, England; [Kao, Amy H.] EMD Serono Res & Dev Inst Inc, Global Clin Dev, Billerica, MA USA; [Kao, Amy H.; Aydemir, Aida] Merck KGaA, Darmstadt, Germany; [Aydemir, Aida] EMD Serono Res & Dev Inst Inc, Global Biostat, Billerica, MA USA; [Merrill, Joan T.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Program, 825 NE 13th St, Oklahoma City, OK 73104 USA	University of London; University College London; Merck KGaA; EMD Serono Inc.; Merck KGaA; Merck KGaA; EMD Serono Inc.; Oklahoma Medical Research Foundation	Isenberg, DA (corresponding author), UCL, Div Med, Ctr Rheumatol, London, England.	d.isenberg@ucl.ac.uk	Merrill, Joan/HDL-9141-2022		Bioscript Science, Macclesfield, UK - Merck KGaA, Darmstadt, Germany	Bioscript Science, Macclesfield, UK - Merck KGaA, Darmstadt, Germany	The development of this article included medical writing support, provided by Bioscript Science, Macclesfield, UK and funded by Merck KGaA, Darmstadt, Germany.	Furie RA, 2015, ANN RHEUM DIS, V74, P1667, DOI 10.1136/annrheumdis-2013-205144; Furie R, 2011, ARTHRITIS RHEUM-US, V63, P3918, DOI 10.1002/art.30613; Furie RA, 2019, LANCET RHEUMATOL, V1, pE208, DOI 10.1016/S2665-9913(19)30076-1; Genovese MC, 2011, ARTHRITIS RHEUM-US, V63, P1793, DOI 10.1002/art.30373; Ginzler EM, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3738; Gordon C, 2019, RHEUMATOL ADV PRACT, V3, DOI 10.1093/rap/rkz021; Isenberg D, 2015, ANN RHEUM DIS, V74, P2006, DOI 10.1136/annrheumdis-2013-205067; Kappos L, 2014, LANCET NEUROL, V13, P353, DOI 10.1016/S1474-4422(14)70028-6; Luhder F, 2014, LANCET NEUROL, V13, P340, DOI 10.1016/S1474-4422(14)70050-X; Merrill JT, 2018, ARTHRITIS RHEUMATOL, V70, P266, DOI 10.1002/art.40360; Morand EF, 2020, RHEUMATOLOGY, V59, P2930, DOI 10.1093/rheumatology/keaa029; Morand EF, 2020, NEW ENGL J MED, V382, P211, DOI 10.1056/NEJMoa1912196; Pena-Rossi C, 2009, LUPUS, V18, P547, DOI 10.1177/0961203309102803; Rosman Z, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-88; Sergott RC, 2015, J NEUROL SCI, V351, P174, DOI 10.1016/j.jns.2015.02.019; Tak PP, 2008, ARTHRITIS RHEUM-US, V58, P61, DOI 10.1002/art.23178; van Vollenhoven RF, 2015, ARTHRITIS RHEUMATOL, V67, P2828, DOI 10.1002/art.39262; van Vollenhoven RF, 2011, ARTHRITIS RHEUM-US, V63, P1782, DOI 10.1002/art.30372; Wallace DJ, 2009, ARTHRIT RHEUM-ARTHR, V61, P1168, DOI 10.1002/art.24699	19	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 11	2020	11								592639	10.3389/fimmu.2020.592639	http://dx.doi.org/10.3389/fimmu.2020.592639			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OV4RX	33262771	gold, Green Published			2022-12-18	WOS:000592200300001
J	Leborgne, NGF; Taddeo, A; Freigang, S; Benarafa, C				Leborgne, Nathan G. F.; Taddeo, Adriano; Freigang, Stefan; Benarafa, Charaf			Serpinb1a Is Dispensable for the Development and Cytokine Response of Invariant Natural Killer T Cell Subsets	FRONTIERS IN IMMUNOLOGY			English	Article						invariant NKT; serpin; &#945; -galactosylceramide; cytokine response; innate immunity	STREPTOCOCCUS-PNEUMONIAE INFECTION; NEUTROPHIL SURVIVAL; IFN-GAMMA; INHIBITION; DEFENSE; PATHWAY; LINEAGE	Invariant natural killer T (iNKT) cells are innate-like T lymphocytes. They quickly respond to antigenic stimulation by producing copious amounts of cytokines and chemokines. iNKT precursors differentiate into three subsets iNKT1, iNKT2, and iNKT17 with specific cytokine production signatures. While key transcription factors drive subset differentiation, factors that regulate iNKT subset homeostasis remain incompletely defined. Transcriptomic analyses of thymic iNKT subsets indicate that Serpinb1a is one of the most specific transcripts for iNKT17 cells suggesting that iNKT cell maintenance and function may be regulated by Serpinb1a. Serpinb1a is a major survival factor in neutrophils and prevents cell death in a cell-autonomous manner. It also controls inflammation in models of bacterial and viral infection as well as in LPS-driven inflammation. Here, we examined the iNKT subsets in neutropenic Serpinb1a (-/-) mice as well as in Serpinb1a (-/-) mice with normal neutrophil counts due to transgenic re-expression of SERPINB1 in neutrophils. In steady state, we found no significant effect of Serpinb1a-deficiency on the proliferation and numbers of iNKT subsets in thymus, lymph nodes, lung, liver and spleen. Following systemic activation with alpha-galactosylceramide, the prototypic glycolipid agonist of iNKT cells, we observed similar serum levels of IFN-gamma and IL-4 between genotypes. Moreover, splenic dendritic cells showed normal upregulation of maturation markers following iNKT cell activation with alpha-galactosylceramide. Finally, lung instillation of alpha-galactosylceramide induced a similar recruitment of neutrophils and production of iNKT-derived cytokines IL-17, IFN-gamma, and IL-4 in wild-type and Serpinb1a (-/-) mice. Taken together, our results indicate that Serpinb1a, while dominantly expressed in iNKT17 cells, is not essential for iNKT cell homeostasis, subset differentiation and cytokine release.	[Leborgne, Nathan G. F.; Taddeo, Adriano; Benarafa, Charaf] Inst Virol & Immunol, Mittelhausern, Switzerland; [Leborgne, Nathan G. F.; Taddeo, Adriano; Benarafa, Charaf] Univ Bern, Vetsuisse Fac, Dept Infect Dis & Pathobiol, Bern, Switzerland; [Leborgne, Nathan G. F.] Univ Bern, Grad Sch Cellular & Biomed Sci, Bern, Switzerland; [Freigang, Stefan] Univ Bern, Inst Pathol, Bern, Switzerland	University of Bern; University of Bern; University of Bern	Benarafa, C (corresponding author), Inst Virol & Immunol, Mittelhausern, Switzerland.; Benarafa, C (corresponding author), Univ Bern, Vetsuisse Fac, Dept Infect Dis & Pathobiol, Bern, Switzerland.	charaf.benarafa@vetsuisse.unibe.ch	Taddeo, Adriano/AAW-3861-2021	Taddeo, Adriano/0000-0003-3281-1548; Benarafa, Charaf/0000-0002-2049-7769	Swiss National Science Foundation [310030-173137]; Novartis foundation for medical-biological research	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Novartis foundation for medical-biological research(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This project was funded by grants from the Swiss National Science Foundation (310030-173137) and the Novartis foundation for medical-biological research.	Baumann M, 2013, BLOOD, V121, P3900, DOI 10.1182/blood-2012-09-455022; Benarafa C, 2007, J EXP MED, V204, P1901, DOI 10.1084/jem.20070494; Benarafa C, 2011, J LEUKOCYTE BIOL, V90, P21, DOI 10.1189/jlb.0810461; Bendelac A, 2007, ANNU REV IMMUNOL, V25, P297, DOI 10.1146/annurev.immunol.25.022106.141711; Bennstein SB, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01950; Brennan PJ, 2013, NAT REV IMMUNOL, V13, P101, DOI 10.1038/nri3369; Burgener SS, 2016, BIOL CHEM, V397, P897, DOI 10.1515/hsz-2016-0132; Burgener SS, 2019, CELL REP, V27, P3646, DOI 10.1016/j.celrep.2019.05.065; Cameron G, 2018, IMMUNOL CELL BIOL, V96, P759, DOI 10.1111/imcb.12034; Choi YJ, 2019, NAT IMMUNOL, V20, P276, DOI 10.1038/s41590-018-0303-z; Constantinides MG, 2013, CURR OPIN IMMUNOL, V25, P161, DOI 10.1016/j.coi.2013.01.003; Crowe NY, 2002, J EXP MED, V196, P119, DOI 10.1084/jem.20020092; Dai H, 2015, EUR J IMMUNOL, V45, P3045, DOI 10.1002/eji.201545532; Dashtsoodol N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00841; Dashtsoodol N, 2017, NAT IMMUNOL, V18, P274, DOI 10.1038/ni.3668; Egawa T, 2005, IMMUNITY, V22, P705, DOI 10.1016/j.immuni.2005.03.011; Engel I, 2016, NAT IMMUNOL, V17, P728, DOI 10.1038/ni.3437; Georgiev H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13116; Gong DP, 2011, J INFECT DIS, V204, P592, DOI 10.1093/infdis/jir352; Hayakawa Y, 2002, BLOOD, V100, P1728; Ivanov S, 2012, J INFECT DIS, V206, P723, DOI 10.1093/infdis/jis413; Kim EY, 2015, SEMIN IMMUNOL, V27, P26, DOI 10.1016/j.smim.2015.02.005; Koay HF, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aay6039; Kovalovsky D, 2008, NAT IMMUNOL, V9, P1055, DOI 10.1038/ni.1641; Lee KA, 2008, CELL IMMUNOL, V251, P50, DOI 10.1016/j.cellimm.2008.03.004; Lee YJ, 2015, IMMUNITY, V43, P566, DOI 10.1016/j.immuni.2015.06.025; Liew PX, 2017, IMMUNITY, V47, P752, DOI 10.1016/j.immuni.2017.09.016; Michel ML, 2007, J EXP MED, V204, P995, DOI 10.1084/jem.20061551; Michel ML, 2008, P NATL ACAD SCI USA, V105, P19845, DOI 10.1073/pnas.0806472105; Nakamatsu M, 2007, MICROBES INFECT, V9, P364, DOI 10.1016/j.micinf.2006.12.003; Park JY, 2019, CELL REP, V27, P2548, DOI 10.1016/j.celrep.2019.05.012; Salou M, 2019, J EXP MED, V216, P133, DOI 10.1084/jem.20181483; Savage AK, 2008, IMMUNITY, V29, P391, DOI 10.1016/j.immuni.2008.07.011; Shissler SC, 2019, MOL IMMUNOL, V105, P116, DOI 10.1016/j.molimm.2018.09.023; Tsagaratou A, 2019, MOL IMMUNOL, V105, P55, DOI 10.1016/j.molimm.2018.11.013; Venken K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07911-6; Victor JR, 2020, CLIN REV ALLERG IMMU, V59, P371, DOI 10.1007/s12016-020-08784-8; Wang HG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01450	38	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 11	2020	11								562587	10.3389/fimmu.2020.562587	http://dx.doi.org/10.3389/fimmu.2020.562587			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OV0GM	33262755	gold, Green Published			2022-12-18	WOS:000591899600001
J	Zhang, J; Chen, N; Chen, ZY; Liu, YL; Zheng, K; Qiu, YD; Zhang, N; Zhu, JP; Yu, HB; He, QS				Zhang, Jing; Chen, Ning; Chen, Zhiyun; Liu, Yali; Zheng, Kai; Qiu, Yundong; Zhang, Nan; Zhu, Junping; Yu, Haibin; He, Qiushui			Low Mannose Binding Lectin, but Not L-Ficolin, Is Associated With Spontaneous Clearance of Hepatitis C Virus After Infection	FRONTIERS IN IMMUNOLOGY			English	Article						hepatitis C virus; spontaneous clearance; mannose-binding lectin; L-ficolin; cytokine profile; genotyping; China; cytokine	HEPATOCELLULAR-CARCINOMA; GENE POLYMORPHISMS; CYTOKINES; BIOMARKERS; IMPACT	Some individuals can spontaneously clear the hepatitis C virus (HCV) after infection, whereas others develop a chronic infection. The exact mechanism of this phenomenon is unknown. We aimed to evaluate the association of plasma levels of MBL, L-ficolin, and cytokines with outcome of HCV infections in two groups of patients who cleared HCV spontaneously (CHS), and who developed chronic HCV infections (CHC). Altogether, 86 patients and 183 healthy controls were included. Of 86 patients, 36 had CHS and 50 had CHC. Concentrations of plasma MBL and L-ficolin were measured in patients and controls. Twenty plasma cytokines and adhesion molecules, including GM-CSF, ICAM-1, IFN-gamma, IFN-alpha, IL-1 alpha, IL-1 beta, IL-10, IL-12p70, IL-13, IL-17A, IL-4, IL-8, IP-10, MCP-1, IL-6, MIP-1 alpha, MIP-1 beta, sE-Selectin, sP-Selectin, and TNF-alpha, were determined in all patients and randomly selected 45 controls. The level of MBL was significantly lower in subjects with CHS than in healthy controls (median: 293.10 vs. 482.64 ng/ml, p = 0.008), whereas the level of MBL was significantly higher in patients with CHC than in controls (median: 681.32 vs. 482.64 ng/ml, p = 0.001). No such differences in plasma L-ficolin were observed. Plasma levels of all cytokines and adhesion molecules, except ICAM-1, were significantly higher in patients than in controls. Moreover, patients with CHC had significantly higher levels of IFN-gamma, IFN-alpha, IL-1 alpha, IL-10, IL-13, IL-4, IL-6, and TNF-alpha than those with CHS. These findings implicate that lower levels of plasma MBL, together with lower levels of above mentioned cytokines may play a part in virus clearance of HCV infection.	[Zhang, Jing; Liu, Yali; Yu, Haibin] Capital Med Univ, Beijing Youan Hosp, Unit 3, Dept Hepatol, Beijing, Peoples R China; [Chen, Ning; Chen, Zhiyun; Zheng, Kai; Zhang, Nan; Zhu, Junping; He, Qiushui] Capital Med Univ, Dept Med Microbiol, Beijing, Peoples R China; [Qiu, Yundong] Guan Hosp Tradit Chinese Med, Dept Tradit Chinese Med, Guan, Peoples R China; [He, Qiushui] Univ Turku, Dept Med Microbiol, Turku, Finland	Capital Medical University; Capital Medical University; University of Turku	Yu, HB (corresponding author), Capital Med Univ, Beijing Youan Hosp, Unit 3, Dept Hepatol, Beijing, Peoples R China.; He, QS (corresponding author), Capital Med Univ, Dept Med Microbiol, Beijing, Peoples R China.; He, QS (corresponding author), Univ Turku, Dept Med Microbiol, Turku, Finland.	xiaobenyu2002@163.com; Qiushui.he@utu.fi			National 13th five-year Plan Major Infectious Diseases Prevention and Control Science and Technology Major Project [2018ZX10715005-004-006]; Beijing Municipal Administration of Hospitals Incubation Program [PX2018058]; Capital's Funds for Health Improvement and Research [2020-1-3011]	National 13th five-year Plan Major Infectious Diseases Prevention and Control Science and Technology Major Project; Beijing Municipal Administration of Hospitals Incubation Program; Capital's Funds for Health Improvement and Research	This work was partly supported by the National 13th five-year Plan Major Infectious Diseases Prevention and Control Science and Technology Major Project (2018ZX10715005-004-006, Beijing Municipal Administration of Hospitals Incubation Program (PX2018058) and Capital's Funds for Health Improvement and Research (2020-1-3011). The funding body had no role in study design, data collection, data analysis or interpretation, or writing of the report. All authors report no conflicts of interest relevant to this article.	Baskic D, 2017, CYTOKINE, V96, P185, DOI 10.1016/j.cyto.2017.04.008; Blackburn SD, 2007, TRENDS MICROBIOL, V15, P143, DOI 10.1016/j.tim.2007.02.006; Chen N, 2019, CLIN MICROBIOL INFEC, V25, DOI 10.1016/j.cmi.2018.10.003; Cribier B, 1998, J MED VIROL, V55, P89, DOI 10.1002/(SICI)1096-9071(199806)55:2&lt;89::AID-JMV1&gt;3.0.CO;2-J; Fan XG, 1998, MEDIAT INFLAMM, V7, P295, DOI 10.1080/09629359890992; Garred P, 2016, IMMUNOL REV, V274, P74, DOI 10.1111/imr.12468; Garred P, 2010, J INNATE IMMUN, V2, P3, DOI 10.1159/000242419; Garred P, 2008, BIOCHEM SOC T, V36, P1461, DOI 10.1042/BST0361461; Gauthiez E, 2017, LIVER INT, V37, P1431, DOI 10.1111/liv.13401; Hammad LN, 2013, J IMMUNOTOXICOL, V10, P380, DOI 10.3109/1547691X.2012.758198; Hummelshoj T, 2005, HUM MOL GENET, V14, P1651, DOI 10.1093/hmg/ddi173; Jalal PJ, 2019, J MED MICROBIOL, V68, P642, DOI 10.1099/jmm.0.000935; Jalal PJ, 2019, VIROLOGY, V530, P99, DOI 10.1016/j.virol.2019.02.002; Janiak M, 2018, ADV EXP MED BIOL, V1039, P45, DOI 10.1007/5584_2017_76; Kazmierczak J, 2016, ARCH IMMUNOL THER EX, V64, P101, DOI 10.1007/s00005-015-0364-8; Koutsounaki E, 2008, J CLIN IMMUNOL, V28, P495, DOI 10.1007/s10875-008-9201-8; Lapa D, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040305; Malaguarnera M, 1997, BIOMED PHARMACOTHER, V51, P391, DOI 10.1016/S0753-3322(97)89432-2; Matsushita M, 2013, MOL IMMUNOL, V55, P22, DOI 10.1016/j.molimm.2012.08.017; Munthe-Fog L, 2007, SCAND J IMMUNOL, V65, P383, DOI 10.1111/j.1365-3083.2007.01915.x; Qin QQ, 2015, J VIRAL HEPATITIS, V22, P238, DOI 10.1111/jvh.12295; Ramos Juliene Antonio, 2012, BMC Res Notes, V5, P508, DOI 10.1186/1756-0500-5-508; Sarvari J, 2016, J CLIN LAB ANAL, V30, P301, DOI 10.1002/jcla.21855; Shah S, 2015, AIDS, V29, P1325, DOI 10.1097/QAD.0000000000000654; Sofian M, 2012, HEPAT MON, V12, DOI 10.5812/hepatmon.6156; Thrift AP, 2017, NAT REV GASTRO HEPAT, V14, P122, DOI 10.1038/nrgastro.2016.176; Tilg H, 2000, NEW ENGL J MED, V343, P1467, DOI 10.1056/NEJM200011163432007; Wright H, 2005, DIGEST DIS SCI, V50, P1793, DOI 10.1007/s10620-005-2940-y; Yousef Laila M, 2017, Egypt J Immunol, V24, P89; Zhao N, 2017, FASEB J, V31, P2405, DOI 10.1096/fj.201601200RR; Zhao YL, 2014, J IMMUNOL, V193, P783, DOI 10.4049/jimmunol.1302563	31	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 11	2020	11								587669	10.3389/fimmu.2020.587669	http://dx.doi.org/10.3389/fimmu.2020.587669			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OV0BB	33262767	Green Published, gold			2022-12-18	WOS:000591885500001
J	Santos, IKFD; Costa, CHN				Santos, Isabel Kinney Ferreira De Miranda; Costa, Carlos Henrique Nery			Impact of Hydroxychloroquine on Antibody Responses to the SARS-CoV-2 Coronavirus (vol 11, 1739, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						COVID-19; Sars-CoV-2; coronavirus; antibodies; hydroxychloroquine			[Santos, Isabel Kinney Ferreira De Miranda] Univ Sao Paulo, Ribeirao Preto Sch Med, Sao Paulo, Brazil; [Costa, Carlos Henrique Nery] Univ Fed Piaui, Nathan Portela Inst Trop Med, Teresina, Brazil	Universidade de Sao Paulo; Universidade Federal do Piaui	Santos, IKFD (corresponding author), Univ Sao Paulo, Ribeirao Preto Sch Med, Sao Paulo, Brazil.	imsantos@fmrp.usp.br						DEMIRANDA SIKF, 2020, FRONT IMMUNOL, V11	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 2	2020	11								615628	10.3389/fimmu.2020.615628	http://dx.doi.org/10.3389/fimmu.2020.615628			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OX5AO	33224154	gold, Green Published			2022-12-18	WOS:000593577300001
J	Sood, AK; Nemeth, M; Wang, JM; Wu, Y; Gandhi, S				Sood, Ashwani K.; Nemeth, Michael; Wang, Jianmin; Wu, Yun; Gandhi, Shipra			Opportunities for Antigen Discovery in Metastatic Breast Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						CDK4; 6 inhibition; in situ anti-tumor immunity; synergizing TAA and TNA; increased tumor immunity; decreased autoimmunity	REGULATORY T-CELLS; NEOANTIGEN LANDSCAPE; CDK4/6 INHIBITION; IMMUNE-RESPONSES; SELF-ANTIGENS; IMMUNOTHERAPY; TOLERANCE; LYMPHOCYTES; INDUCTION; EVOLUTION	Immune checkpoint inhibitor-based immunotherapy (ICI) of breast cancer is currently efficacious in a fraction of triple negative breast cancers (TNBC) as these cancers generally carry high tumor mutation burden (TMB) and show increased tumor infiltration by CD8(+) T cells. However, most estrogen receptor positive breast cancers (ERBC) have low TMB and/or are infiltrated with immunosuppressive regulatory T cells (Tregs) and thus fail to induce a significant anti-tumor immune response. Our understanding of the immune underpinning of the anti-tumor effects of CDK4/6 inhibitor (CDKi) treatment coupled with new knowledge about the mechanisms of tolerance to self-antigens suggests a way forward, specifically via characterizing and exploiting the repertoire of tumor antigens expressed by metastatic ERBC. These treatment-associated tumor antigens (TATA) may include the conventional tumor neoantigens (TNA) encoded by single nucleotide mutations, TNA encoded by tumor specific aberrant RNA transcription, splicing and DNA replication induced frameshift (FS) events as well as the shared tumor antigens. The latter may include the conventional tumor associated antigens (TAA), cancer-testis antigens (CTA) and antigens encoded by the endogenous retroviral (ERV) like sequences and repetitive DNA sequences induced by ET and CDKi treatment. An approach to identifying these antigens is outlined as this will support the development of a multi-antigen-based immunotherapy strategy for improved targeting of metastatic disease with potential for minimal autoimmune toxicity against normal tissues.	[Sood, Ashwani K.; Nemeth, Michael] Roswell Park Comprehens Canc Ctr, Dept Immunol, Buffalo, NY USA; [Nemeth, Michael; Gandhi, Shipra] Roswell Park Comprehens Canc Ctr, Dept Med, Buffalo, NY USA; [Wang, Jianmin] Roswell Park Comprehens Canc Ctr, Dept Biostat & Bioinformat, Buffalo, NY USA; [Wu, Yun] SUNY Buffalo, Dept Biomed Engn, Buffalo, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Sood, AK (corresponding author), Roswell Park Comprehens Canc Ctr, Dept Immunol, Buffalo, NY USA.	Ashwani.sood@roswellpark.org	Sood, Anoop Kumar/A-7344-2013; wang, jian/GVS-0711-2022; Gandhi, Shipra/HDO-0135-2022	Sood, Anoop Kumar/0000-0001-5702-4108; 	Breast Cancer Coalition of Rochester NY; National Center for Advancing Translational Sciences of the National Institute of Health [5KL2TR0013-05, UL1TR0012-05]	Breast Cancer Coalition of Rochester NY; National Center for Advancing Translational Sciences of the National Institute of Health	This work was supported by a grant from Breast Cancer Coalition of Rochester NY (to AS) and grants from National Center for Advancing Translational Sciences of the National Institute of Health under award number 5KL2TR0013-05 and UL1TR0012-05 (to SG).	Adams S, 2014, J CLIN ONCOL, V32, P2959, DOI 10.1200/JCO.2013.55.0491; Ahrends T, 2017, IMMUNITY, V47, P848, DOI 10.1016/j.immuni.2017.10.009; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alspach E, 2019, NATURE, V574, P696, DOI 10.1038/s41586-019-1671-8; Anagnostou V, 2017, CANCER DISCOV, V7, P264, DOI 10.1158/2159-8290.CD-16-0828; Bates GJ, 2006, J CLIN ONCOL, V24, P5373, DOI 10.1200/JCO.2006.05.9584; Baumgaertner P, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1216290; Borst J, 2018, NAT REV IMMUNOL, V18, P635, DOI 10.1038/s41577-018-0044-0; Bos R, 2010, CANCER RES, V70, P8368, DOI 10.1158/0008-5472.CAN-10-1322; Brocks D, 2017, NAT GENET, V49, P1052, DOI 10.1038/ng.3889; Brown SD, 2014, GENOME RES, V24, P743, DOI 10.1101/gr.165985.113; Buchwalter G, 2013, CANCER CELL, V23, P753, DOI 10.1016/j.ccr.2013.04.026; Budczies J, 2015, J PATHOL CLIN RES, V1, P225, DOI 10.1002/cjp2.25; Cao L, 2019, CANCER CHEMOTH PHARM, V84, P609, DOI 10.1007/s00280-019-03891-6; Chatani PD, 2020, CLIN CANCER RES, V26, P537, DOI 10.1158/1078-0432.CCR-19-2138; Cheever MA, 2009, CLIN CANCER RES, V15, P5323, DOI 10.1158/1078-0432.CCR-09-0737; Contreras A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0358-2; Coombes RC, 2019, CLIN CANCER RES, V25, P4255, DOI 10.1158/1078-0432.CCR-18-3663; Coser KR, 2003, P NATL ACAD SCI USA, V100, P13994, DOI 10.1073/pnas.2235866100; Criscitiello C, 2012, BREAST CARE, V7, P262, DOI 10.1159/000342164; De Mattos-Arruda L, 2019, CELL REP, V27, P2690, DOI 10.1016/j.celrep.2019.04.098; Deng JH, 2018, CANCER DISCOV, V8, P216, DOI 10.1158/2159-8290.CD-17-0915; Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370; Garcia-Murillas I, 2019, JAMA ONCOL, V5, P1473, DOI 10.1001/jamaoncol.2019.1838; Goel S, 2017, NATURE, V548, P471, DOI 10.1038/nature23465; Goodyear O, 2010, BLOOD, V116, P1908, DOI 10.1182/blood-2009-11-249474; Griffiths EA, 2018, CLIN CANCER RES, V24, P1019, DOI 10.1158/1078-0432.CCR-17-1792; Guenther LM, 2019, CLIN CANCER RES, V25, P1343, DOI 10.1158/1078-0432.CCR-18-0372; Heylmann D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083384; Hilf N, 2019, NATURE, V565, P240, DOI 10.1038/s41586-018-0810-y; Hinrichs CS, 2013, NAT BIOTECHNOL, V31, P999, DOI 10.1038/nbt.2725; Im SA, 2019, NEW ENGL J MED, V381, P307, DOI 10.1056/NEJMoa1903765; Jayasinghe RG, 2018, CELL REP, V23, P270, DOI 10.1016/j.celrep.2018.03.052; Johnston S, 2019, NPJ BREAST CANCER, V5, DOI 10.1038/s41523-018-0097-z; Keskin DB, 2019, NATURE, V565, P234, DOI 10.1038/s41586-018-0792-9; Kong Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13035-2; Kreiter S, 2015, NATURE, V520, P692, DOI 10.1038/nature14426; Laidlaw BJ, 2016, NAT REV IMMUNOL, V16, P102, DOI 10.1038/nri.2015.10; Lee HJ, 2017, ONCOTARGET, V8, P113345, DOI 10.18632/oncotarget.23007; Legoux FP, 2015, IMMUNITY, V43, P896, DOI 10.1016/j.immuni.2015.10.011; Lei Jonathan T, 2019, J Cancer Metastasis Treat, V5, DOI 10.20517/2394-4722.2019.12; Leonard JP, 2012, BLOOD, V119, P4597, DOI 10.1182/blood-2011-10-388298; Li YF, 2017, CANCER LETT, V399, P64, DOI 10.1016/j.canlet.2017.02.031; Liu C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18966-9; Liu QJ, 2020, PROTEIN CELL, V11, P549, DOI 10.1007/s13238-020-00707-9; Liu SZ, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0432-8; Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902; Narang P, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5402-1; Nelson CE, 2019, CELL REP, V28, P3092, DOI 10.1016/j.celrep.2019.08.038; Niesvizky R, 2015, LEUKEMIA LYMPHOMA, V56, P3320, DOI 10.3109/10428194.2015.1030641; Odunsi K, 2014, CANCER IMMUNOL RES, V2, P37, DOI 10.1158/2326-6066.CIR-13-0126; Olmez I, 2018, CANCER RES, V78, P4360, DOI 10.1158/0008-5472.CAN-17-3124; Ono M, 2012, BREAST CANCER RES TR, V132, P793, DOI 10.1007/s10549-011-1554-7; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Pan J, 2017, ONCOTARGET, V8, P82689, DOI 10.18632/oncotarget.19831; Pandey A, 2012, INT REV IMMUNOL, V31, P302, DOI 10.3109/08830185.2012.723511; Parylo S, 2019, J ONCOL PHARM PRACT, V25, P110, DOI 10.1177/1078155218770904; Paul MR, 2020, J CLIN INVEST, V130, P4252, DOI 10.1172/JCI129941; Purbhoo MA, 2004, NAT IMMUNOL, V5, P524, DOI 10.1038/ni1058; Razavi P, 2018, CANCER CELL, V34, P427, DOI 10.1016/j.ccell.2018.08.008; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; Rubio C, 2019, CLIN CANCER RES, V25, P390, DOI 10.1158/1078-0432.CCR-18-0685; Rugo HS, 2019, BREAST CANCER RES TR, V174, P719, DOI 10.1007/s10549-018-05125-4; Sabbatini P, 2012, CLIN CANCER RES, V18, P6497, DOI 10.1158/1078-0432.CCR-12-2189; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Savas P, 2018, NAT MED, V24, P986, DOI 10.1038/s41591-018-0078-7; Schaer DA, 2018, CELL REP, V22, P2978, DOI 10.1016/j.celrep.2018.02.053; Schmid P, 2018, NEW ENGL J MED, V379, P2108, DOI 10.1056/NEJMoa1809615; Schmid P, 2020, LANCET ONCOL, V21, P44, DOI 10.1016/S1470-2045(19)30689-8; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shen LH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50738-4; Sledge GW, 2020, JAMA ONCOL, V6, P116, DOI 10.1001/jamaoncol.2019.4782; Smart AC, 2018, NAT BIOTECHNOL, V36, P1056, DOI 10.1038/nbt.4239; Sood AK, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317691688; Sood AK, 2010, IMMUNOL RES, V46, P206, DOI 10.1007/s12026-009-8129-2; Soussi T, 2015, CELL DEATH DIFFER, V22, P1239, DOI 10.1038/cdd.2015.53; Tanaka T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177019; Thomas A, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1490854; Tran E, 2017, NAT IMMUNOL, V18, P255, DOI 10.1038/ni.3682; Turajlic S, 2017, LANCET ONCOL, V18, P1009, DOI 10.1016/S1470-2045(17)30516-8; Verdegaal EME, 2016, NATURE, V536, P91, DOI 10.1038/nature18945; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Ward JP, 2016, ADV IMMUNOL, V130, P25, DOI 10.1016/bs.ai.2016.01.001; Yates LR, 2017, CANCER CELL, V32, P169, DOI 10.1016/j.ccell.2017.07.005; Yu W, 2015, IMMUNITY, V42, P929, DOI 10.1016/j.immuni.2015.05.001; Zacharakis N, 2018, NAT MED, V24, P724, DOI 10.1038/s41591-018-0040-8; Zaidi N, 2019, NATURE, V565, P170, DOI 10.1038/d41586-018-07728-9; Zhang XL, 2017, CANCER IMMUNOL RES, V5, P516, DOI 10.1158/2326-6066.CIR-16-0264; Zhao J, 2010, CANCER RES, V70, P4850, DOI 10.1158/0008-5472.CAN-10-0283	94	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 30	2020	11								570049	10.3389/fimmu.2020.570049	http://dx.doi.org/10.3389/fimmu.2020.570049			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OQ3KZ	33193348	Green Published, gold			2022-12-18	WOS:000588687400001
J	Bonney, EA; Krebs, K; Kim, J; Prakash, K; Torrance, BL; Haynes, L; Rincon, M				Bonney, Elizabeth Ann; Krebs, Kendall; Kim, Jihye; Prakash, Kirtika; Torrance, Blake L.; Haynes, Laura; Rincon, Mercedes			Protective Intranasal Immunization Against Influenza Virus in Infant Mice Is Dependent on IL-6	FRONTIERS IN IMMUNOLOGY			English	Article						infant; influenza; mouse; vaccination; lung	T-CELLS; UNITED-STATES; CHILDREN; INTERLEUKIN-6; INDUCTION; NEWBORN; VACCINE; EXPRESSION; INFECTION; CD4(+)	Respiratory diseases adversely affect infants and are the focus of efforts to develop vaccinations and other modalities to prevent disease. The infant immune system differs from that of older children and adults in many ways that are as yet ill understood. We have used a C57BL/6 mouse model of infection with a laboratory- adapted strain of influenza (PR8) to delineate the importance of the cytokine IL-6 in the innate response to primary infection and in the development of protective immunity in adult mice. Herein, we used this same model in infant (14 days of age) mice to determine the effect of IL-6 deficiency. Infant wild type mice are more susceptible than older mice to infection, similar to the findings in humans. IL-6 is expressed in the lung in the early response to PR8 infection. While intramuscular immunization does not protect against lethal challenge, intranasal administration of heat inactivated virus is protective and correlates with expression of IL-6 in the lung, activation of lung CD8 cells, and development of an influenza-specific antibody response. In IL-6 deficient mice, this response is abrogated, and deficient mice are not protected against lethal challenge. These studies support the importance of the role of the tissue environment in infant immunity, and further suggest that IL-6 may be helpful in the generation of protective immune responses in infants.	[Bonney, Elizabeth Ann; Krebs, Kendall; Prakash, Kirtika] Univ Vermont, Larner Coll Med, Dept Obstet Gynecol & Reprod Sci, Burlington, VT 05405 USA; [Kim, Jihye] Univ Colorado, Dept Med, Div Med Oncol, Anschutz Med Campus, Aurora, CO USA; [Torrance, Blake L.; Haynes, Laura] Univ Connecticut, Ctr Aging, Dept Immunol, Farmington, CT USA; [Rincon, Mercedes] Univ Vermont, Dept Med, Larner Coll Med, Div Immunobiol, Burlington, VT USA; [Rincon, Mercedes] Univ Colorado, Dept Immunol & Microbiol, Anschutz Med Campus, Aurora, CO USA	University of Vermont; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Connecticut; University of Vermont; University of Colorado System; University of Colorado Anschutz Medical Campus	Bonney, EA (corresponding author), Univ Vermont, Larner Coll Med, Dept Obstet Gynecol & Reprod Sci, Burlington, VT 05405 USA.	elizabeth.bonney@med.uvm.edu		Torrance, Blake/0000-0001-8647-2436	NIH [P30CA046934, P30GM118228, P30GM103532, R56 AI116255, R01 AI051454]; University of Vermont College of Medicine New Research Initiative Program; UVM Flow Cytometry and Cell Sorting Facility; Department of Obstetrics, Gynecology and Reproductive Sciences; University of Connecticut Center on Aging; University of Colorado Cancer Center Bioinformatics/Biostatistics Shared Resources; National Institute of General Medical Sciences of the National Institutes of Health [P20GM103449]; Vermont Genetics Network	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Vermont College of Medicine New Research Initiative Program; UVM Flow Cytometry and Cell Sorting Facility; Department of Obstetrics, Gynecology and Reproductive Sciences; University of Connecticut Center on Aging; University of Colorado Cancer Center Bioinformatics/Biostatistics Shared Resources; National Institute of General Medical Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Vermont Genetics Network	Support for this work came from NIH P30GM118228 to the Vermont Center for Immunology and Infectious Disease, P30GM103532 to the Vermont Lung Center, the University of Vermont College of Medicine New Research Initiative Program, the UVM Flow Cytometry and Cell Sorting Facility, and the Department of Obstetrics, Gynecology and Reproductive Sciences. MR was also supported by NIH R56 AI116255 and R01 AI051454. LH and BT are supported by the University of Connecticut Center on Aging. JK is supported by the University of Colorado Cancer Center Bioinformatics/Biostatistics Shared Resources, supported by NIH P30CA046934. Research reported herein was also supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P20GM103449, The Vermont Genetics Network.	Agarkhedkar S, 2019, HUM VACC IMMUNOTHER, V15, P973, DOI 10.1080/21645515.2019.1565259; Arulanandam BP, 2000, J IMMUNOL, V164, P3698, DOI 10.4049/jimmunol.164.7.3698; Belshe RB, 2007, NEW ENGL J MED, V356, P685, DOI 10.1056/NEJMoa065368; Bergen R, 2004, PEDIATR INFECT DIS J, V23, P138, DOI 10.1097/01.inf.0000109392.96411.4f; Blanton L, 2019, MMWR-MORBID MORTAL W, V68, P125, DOI 10.15585/mmwr.mm6806a1; Bot A, 1996, VIRAL IMMUNOL, V9, P207, DOI 10.1089/vim.1996.9.207; Briassoulis G, 2007, CLIN BIOCHEM, V40, P299, DOI 10.1016/j.clinbiochem.2006.11.015; Carbone G, 2013, INT J BIOL SCI, V9, P279, DOI 10.7150/ijbs.5996; Caspard H, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-023118; Chilvers MA, 2003, THORAX, V58, P333, DOI 10.1136/thorax.58.4.333; Clay CC, 2014, J VIROL, V88, P7412, DOI 10.1128/JVI.00188-14; Cohn M, 2017, SCAND J IMMUNOL, V86, P124, DOI 10.1111/sji.12579; Debock I, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00393; Denney L, 2018, BIOMED J, V41, P218, DOI 10.1016/j.bj.2018.08.004; Diehl S, 2002, J EXP MED, V196, P39, DOI 10.1084/jem.20020026; Dienz O, 2012, MUCOSAL IMMUNOL, V5, P258, DOI 10.1038/mi.2012.2; Dienz O, 2009, J EXP MED, V206, P69, DOI 10.1084/jem.20081571; EICHELBERGER M, 1991, J EXP MED, V174, P875, DOI 10.1084/jem.174.4.875; Fadel SA, 2006, INT IMMUNOL, V18, P249, DOI 10.1093/intimm/dxh360; Fike AJ, 2019, J LEUKOCYTE BIOL, V105, P539, DOI 10.1002/JLB.4A0518-191R; Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728; Grohskopf LA, 2018, MMWR RECOMM REP, V67, DOI 10.15585/mmwr.rr6703a1; Grohskopf LA, 2018, MMWR-MORBID MORTAL W, V67, P643, DOI 10.15585/mmwr.mm6722a5; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Huygens A, 2015, J INFECT DIS, V212, P484, DOI 10.1093/infdis/jiv071; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jonges M, 2010, J CLIN MICROBIOL, V48, P928, DOI 10.1128/JCM.02045-09; Kanehisa M, 2010, NUCLEIC ACIDS RES, V38, pD355, DOI 10.1093/nar/gkp896; Kollmann TR, 2017, IMMUNITY, V46, P350, DOI 10.1016/j.immuni.2017.03.009; Lang VR, 2012, RHEUMATOLOGY, V51, P852, DOI 10.1093/rheumatology/ker223; Lartey S, 2020, J INFECT DIS, V221, P21, DOI 10.1093/infdis/jiz321; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; Liao XH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138684; Liu SS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01843; Maldonado YA, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-2478; Mandelboim M, 2016, ONCOTARGET, V7, P1185, DOI 10.18632/oncotarget.6746; Marchesi S, 2005, ATHEROSCLEROSIS, V178, P345, DOI 10.1016/j.atherosclerosis.2004.08.036; Mariani TJ, 2015, CLIN PERINATOL, V42, P685, DOI 10.1016/j.clp.2015.08.001; Matsukura S, 1996, J ALLERGY CLIN IMMUN, V98, P1080, DOI 10.1016/S0091-6749(96)80195-3; Matzinger P, 2007, NAT IMMUNOL, V8, P11, DOI 10.1038/ni0107-11; McDonald JU, 2017, IMMUNOLOGY, V151, P451, DOI 10.1111/imm.12742; Misra RS, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8040265; Mohn KGI, 2020, J INFECT DIS, V221, P1528, DOI 10.1093/infdis/jiz583; Mold JE, 2008, SCIENCE, V322, P1562, DOI 10.1126/science.1164511; Mold JE, 2010, SCIENCE, V330, P1695, DOI 10.1126/science.1196509; Neveu WA, 2011, AM J RESP CELL MOL, V45, P1133, DOI 10.1165/rcmb.2011-0054OC; Ohtsuka Y, 2015, PEDIATR INT, V57, P22, DOI 10.1111/ped.12546; Poehling KA, 2018, CLIN INFECT DIS, V66, P665, DOI 10.1093/cid/cix869; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; Preaud E, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-813; Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723; Rincon M, 2012, TRENDS IMMUNOL, V33, P571, DOI 10.1016/j.it.2012.07.003; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; Rose-John S, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028415; Scheltema NM, 2017, LANCET GLOB HEALTH, V5, pE984, DOI 10.1016/S2214-109X(17)30344-3; SCHOLTISSEK C, 1969, J GEN VIROL, V5, P283, DOI 10.1099/0022-1317-5-2-283; SCHWARTZ DH, 1984, INFECT IMMUN, V43, P202, DOI 10.1128/IAI.43.1.202-205.1984; Shinjoh M, 2018, VACCINE, V36, P5510, DOI 10.1016/j.vaccine.2018.07.065; Sinnott BD, 2016, J IMMUNOL, V197, P68, DOI 10.4049/jimmunol.1501297; Smith LS, 2013, PEDIATR CRIT CARE ME, V14, P631, DOI 10.1097/PCC.0b013e318291753f; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Turner PJ, 2020, J ALLERGY CLIN IMMUN, V145, P1157, DOI 10.1016/j.jaci.2019.12.010; Valdin HL, 2017, VACCINE, V35, P4088, DOI 10.1016/j.vaccine.2017.06.050; Velazquez-Salinas L, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01057; Wang Q, 2020, PEDIATR RES, V87, P511, DOI 10.1038/s41390-019-0340-9; Wu W, 2014, CRIT CARE, V18, DOI 10.1186/cc13788; Yang J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03049; Yang ML, 2017, SCI REP-UK, V7, DOI 10.1038/srep43829; Yang R, 2016, J EXP MED, V213, P2281, DOI 10.1084/jem.20160417; Yoshikawa T, 2009, J VIROL, V83, P3039, DOI 10.1128/JVI.01792-08	70	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 28	2020	11								568978	10.3389/fimmu.2020.568978	http://dx.doi.org/10.3389/fimmu.2020.568978			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OP3YM	33193346	gold, Green Published			2022-12-18	WOS:000588017400001
J	Mestre, L; Carrillo-Salinas, FJ; Mecha, M; Feliu, A; Espejo, C; Alvarez-Cermeno, JC; Villar, LM; Guaza, C				Mestre, L.; Carrillo-Salinas, F. J.; Mecha, M.; Feliu, A.; Espejo, C.; Alvarez-Cermeno, J. C.; Villar, L. M.; Guaza, C.		Frontiers Editorial Off	Manipulation of Gut Microbiota Influences Immune Responses, Axon Preservation, and Motor Disability in a Model of Progressive Multiple Sclerosis	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						Theiler's virus model; gut microbiota; Treg and Breg cells; neuroinflammation; multiple sclerosis			[Frontiers Editorial Off] Frontiers Media SA, Lausanne, Switzerland									Mestre L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01374	1	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 27	2020	11								614941	10.3389/fimmu.2020.614941	http://dx.doi.org/10.3389/fimmu.2020.614941			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OO9HN		gold, Green Published			2022-12-18	WOS:000587684500001
J	van Oers, NSC; Su, DM; Chidgey, AP; Dudakov, J				van Oers, Nicolai S. C.; Su, Dong-Ming; Chidgey, Ann P.; Dudakov, Jarrod			Editorial: New Insights Into Thymic Functions During Stress, Aging, and in Disease Settings	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						thymus; thymic tissue regeneration; thymic involution; severe combined immunodeficiency; tissue regeneration; FoxN1 gene; thymic epithelial cell (TEC)			[van Oers, Nicolai S. C.] Univ Texas Southwestern Med Ctr Dallas, Dept Immunol, Dallas, TX 75390 USA; [van Oers, Nicolai S. C.] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [van Oers, Nicolai S. C.] Univ Texas Southwestern Med Ctr Dallas, Dept Microbiol, Dallas, TX 75390 USA; [Su, Dong-Ming] Univ North Texas, Hlth Sci Ctr, Microbiol Immunol & Genet, Ft Worth, TX USA; [Chidgey, Ann P.] Monash Univ, Dept Anat & Dev Biol, Melbourne, Vic, Australia; [Dudakov, Jarrod] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA; [Dudakov, Jarrod] Univ Washington, Seattle, WA 98195 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of North Texas System; University of North Texas Denton; Monash University; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	van Oers, NSC (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Immunol, Dallas, TX 75390 USA.; van Oers, NSC (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA.; van Oers, NSC (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Microbiol, Dallas, TX 75390 USA.	nicolai.vanoers@utsouthwestern.edu	Van+Oers, Nicolai/ABA-2437-2021	van Oers, Nicolai/0000-0002-6545-8405	National Institutes of Health R01 [R01 AI114523, R21 AI144140]	National Institutes of Health R01(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported in part by grants from the National Institutes of Health R01 (R01 AI114523, R21 AI144140 NvO).	Dally A, 1997, MED HIST, V41, P70, DOI 10.1017/S0025727300062049; Jacobs MT, 1999, RADIOLOGY, V210, P11, DOI 10.1148/radiology.210.1.r99ja4511; Miller JF, 2019, CELL, V179, P21, DOI 10.1016/j.cell.2019.08.023	3	0	0	2	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 22	2020	11								591936	10.3389/fimmu.2020.591936	http://dx.doi.org/10.3389/fimmu.2020.591936			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OL2QK	33193434	Green Published, gold			2022-12-18	WOS:000585186400001
J	Lee, FEH; Wrammert, J; Cenci, S				Lee, F. Eun-Hyung; Wrammert, Jens; Cenci, Simone			Editorial: Advances in Plasma Cells in Health and Disease	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						niche; bone marrow; allergy; serological memory; plasma cell; multiple myeloma; immunoglobulin; antibody			[Lee, F. Eun-Hyung] Emory Univ, Dept Med, Div Pulm Allergy Crit Care & Sleep Med, Atlanta, GA 30322 USA; [Lee, F. Eun-Hyung] Emory Univ, Lowance Ctr Human Immunol, Atlanta, GA 30322 USA; [Lee, F. Eun-Hyung; Wrammert, Jens] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA; [Wrammert, Jens] Emory Univ, Sch Med, Dept Pediat, Div Infect Dis, Atlanta, GA 30322 USA; [Cenci, Simone] Osped San Raffaele, Div Genet & Cell Biol, Unit Age Related Dis, Milan, Italy; [Cenci, Simone] Univ Vita Salute San Raffaele, Milan, Italy	Emory University; Emory University; Emory University; Emory University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University	Lee, FEH (corresponding author), Emory Univ, Dept Med, Div Pulm Allergy Crit Care & Sleep Med, Atlanta, GA 30322 USA.; Lee, FEH (corresponding author), Emory Univ, Lowance Ctr Human Immunol, Atlanta, GA 30322 USA.; Lee, FEH; Wrammert, J (corresponding author), Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA.; Wrammert, J (corresponding author), Emory Univ, Sch Med, Dept Pediat, Div Infect Dis, Atlanta, GA 30322 USA.; Cenci, S (corresponding author), Osped San Raffaele, Div Genet & Cell Biol, Unit Age Related Dis, Milan, Italy.; Cenci, S (corresponding author), Univ Vita Salute San Raffaele, Milan, Italy.	f.e.lee@emory.edu; jwramme@emory.edu; cenci.simone@hsr.it			NIH/NIAID [R01AI121252, P01AI125180, U19AI1109962, U01AI1993, R01AI137127, U01AI144673, 5U19AI057266]; Gates Innovations Technology [INV-002351]; Fondazione AIRC [23245]; Fondazione Cariplo [2018-0541]	NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Gates Innovations Technology; Fondazione AIRC(Fondazione AIRC per la ricerca sul cancro); Fondazione Cariplo(Fondazione Cariplo)	The authors' work is supported, in part, by grants from the NIH/NIAID (R01AI121252; P01AI125180; U19AI1109962; U01AI1993) and Gates Innovations Technology (INV-002351) to FE-HL, from NIH/NIAID (R01AI137127; U01AI144673; 5U19AI057266) to JW, and from Fondazione AIRC (Investigator Grant 23245) and Fondazione Cariplo (2018-0541) to SC.	Cavalli G, 2020, J MOL BIOL, V432, P2525, DOI 10.1016/j.jmb.2020.01.015; Cenci S, 2011, CURR OPIN CELL BIOL, V23, P216, DOI 10.1016/j.ceb.2010.11.004; COOPER MD, 1965, NATURE, V205, P143, DOI 10.1038/205143a0; D'Souza L, 2019, IMMUNOL REV, V288, P161, DOI 10.1111/imr.12732; FAGRAEUS A, 1947, NATURE, V159, P499, DOI 10.1038/159499a0; Halliley JL, 2015, IMMUNITY, V43, P132, DOI 10.1016/j.immuni.2015.06.016; Hammarlund E, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01901-w; Kumar SK, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.46; Manz RA, 1997, NATURE, V388, P133, DOI 10.1038/40540; Manz RA, 2005, ANNU REV IMMUNOL, V23, P367, DOI 10.1146/annurev.immunol.23.021704.115723; Nutt SL, 2015, NAT REV IMMUNOL, V15, P160, DOI 10.1038/nri3795; Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442; Pioli PD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02768; Radbruch A, 2006, NAT REV IMMUNOL, V6, P741, DOI 10.1038/nri1886; Slifka MK, 1998, IMMUNITY, V8, P363, DOI 10.1016/S1074-7613(00)80541-5	15	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 21	2020	11								606737	10.3389/fimmu.2020.606737	http://dx.doi.org/10.3389/fimmu.2020.606737			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OL9DT	33193457	gold, Green Published			2022-12-18	WOS:000585631600001
J	Huang, WC; Fang, LW; Liou, CJ				Huang, Wen-Chung; Fang, Li-Wen; Liou, Chian-Jiun			Phloretin Attenuates Allergic Airway Inflammation and Oxidative Stress in Asthmatic Mice (vol 8, 134, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						asthma; cytokine; eosinophil; oxidative stress; phloretin			[Huang, Wen-Chung] Chang Gung Univ Sci & Technol, Grad Inst Hlth Ind Technol, Res Ctr Chinese Herbal Med, Res Ctr Ind Human Ecol,Coll Human Ecol, Taoyuan, Taiwan; [Huang, Wen-Chung; Liou, Chian-Jiun] Chang Gung Mem Hosp, Div Allergy Asthma & Rheumatol, Dept Pediat, Taoyuan, Taiwan; [Fang, Li-Wen] I Shou Univ, Dept Nutr, Kaohsiung, Taiwan; [Liou, Chian-Jiun] Chang Gung Univ Sci & Technol, Dept Nursing, Res Ctr Chinese Herbal Med, Taoyuan, Taiwan	Chang Gung University of Science & Technology; Chang Gung Memorial Hospital; I Shou University; Chang Gung University of Science & Technology	Liou, CJ (corresponding author), Chang Gung Mem Hosp, Div Allergy Asthma & Rheumatol, Dept Pediat, Taoyuan, Taiwan.; Liou, CJ (corresponding author), Chang Gung Univ Sci & Technol, Dept Nursing, Res Ctr Chinese Herbal Med, Taoyuan, Taiwan.	ccliu@mail.cgust.edu.tw						Huang WC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00134	1	0	0	4	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 19	2020	11								582838	10.3389/fimmu.2020.582838	http://dx.doi.org/10.3389/fimmu.2020.582838			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OI6QA	33193395	Green Published, gold			2022-12-18	WOS:000583399500001
J	Song, Y; Zhu, Y; Hu, B; Liu, YH; Lin, DD; Jin, ZQ; Yin, ZN; Dong, C; Wu, DP; Liu, HY				Song, Yuan; Zhu, Ying; Hu, Bo; Liu, Yonghao; Lin, Dandan; Jin, Ziqi; Yin, Zhinan; Dong, Chen; Wu, Depei; Liu, Haiyan			Donor gamma delta T Cells Promote GVL Effect and Mitigate aGVHD in Allogeneic Hematopoietic Stem Cell Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						&#947; &#948; T cells; IL-17; graft-versus-host disease; graft-versus-leukemia; hematopoietic stem cell transplantation	BONE-MARROW-TRANSPLANTATION; VERSUS-HOST-DISEASE; LEUKEMIA PATIENTS; TUMOR; CYTOTOXICITY; LYMPHOCYTES; REACTIVITY; EXPANSION; IMPACT; ROLES	Disease relapse and graft-versus-host disease (GVHD) are the major complications affecting the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT). While the functions of alpha beta T cells are extensively studied, the role of donor gamma delta T cells in allo-HSCT is less well defined. Using TCR delta(-/-) donors lacking gamma delta T cells, we demonstrated that donor gamma delta T cells were critical in mediating graft-versus-leukemia (GVL) effect during allo-HSCT. In the absence of donor gamma delta T cells, IFN-gamma production by CD8(+) T cells was severely impaired. V gamma 4 subset was the major gamma delta T cell subset mediating the GVL effect in vivo, which was partially dependent on IL-17A. Meanwhile, donor gamma delta T cells could mitigate acute GVHD in a murine allo-HSCT model by suppressing CD4(+) T cell activation and the major gamma delta T cell subset that exerted this protective function was also V gamma 4 gamma delta T cells. Therefore, our findings provide evidence that donor gamma delta T cells, especially V gamma 4 subset, can enhance GVL effect and mitigate aGVHD during allo-HSCT.	[Song, Yuan; Zhu, Ying; Liu, Yonghao; Liu, Haiyan] Natl Univ Singapore, Yong Loo Lin Sch Med, Immunol Programme, Life Sci Inst, Singapore, Singapore; [Song, Yuan; Zhu, Ying; Liu, Yonghao; Liu, Haiyan] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol & Immunol, Singapore, Singapore; [Hu, Bo; Lin, Dandan; Jin, Ziqi; Wu, Depei] Soochow Univ, Affiliated Hosp 1, Natl Clin Res Ctr Hematol Dis,Collaborat Innovat, Inst Blood & Marrow Transplantat,Jiangsu Inst Hem, Suzhou, Peoples R China; [Yin, Zhinan] Jinan Univ, Zhuhai Hosp, Zhuhai Peoples Hosp, Zhuhai Precis Med Ctr, Zhuhai, Peoples R China; [Yin, Zhinan] Jinan Univ, Fac Med Sci, Biomed Translat Res Inst, Guangzhou, Peoples R China; [Dong, Chen] Tsinghua Univ, Inst Immunol, Beijing, Peoples R China; [Dong, Chen] Tsinghua Univ, Sch Med, Beijing, Peoples R China	National University of Singapore; National University of Singapore; Soochow University - China; Jinan University; Jinan University; Tsinghua University; Tsinghua University	Liu, HY (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Immunol Programme, Life Sci Inst, Singapore, Singapore.; Liu, HY (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol & Immunol, Singapore, Singapore.; Hu, B; Wu, DP (corresponding author), Soochow Univ, Affiliated Hosp 1, Natl Clin Res Ctr Hematol Dis,Collaborat Innovat, Inst Blood & Marrow Transplantat,Jiangsu Inst Hem, Suzhou, Peoples R China.	hubo82428@163.com; wudepei@suda.edu.cn; micliuh@nus.edu.sg	dong, chen/B-3181-2009; Lin, Dandan/GRJ-2233-2022; Liu, Haiyan/ABD-8689-2021	dong, chen/0000-0002-0084-9130; Liu, Haiyan/0000-0002-4652-469X	National Key R&D Program of China [2017YFA0104502, 2016YFC0902800]; National Natural Science Foundation of China [81571556, 81730003, 81470346]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); National University of Singapore	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); National University of Singapore(National University of Singapore)	This work has been supported by National Key R&D Program of China (2017YFA0104502, 2016YFC0902800), National Natural Science Foundation of China (81571556, 81730003, and 81470346), Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), and start-up grant of National University of Singapore.	Abdelhakim H, 2017, BIOMEDICINES, V5, DOI 10.3390/biomedicines5030035; Arruda LCM, 2019, BLOOD ADV, V3, P3436, DOI 10.1182/bloodadvances.2019000682; Arruda LCM, 2019, J IMMUNOL, V202, P1859, DOI 10.4049/jimmunol.1801448; Benchetrit F, 2002, BLOOD, V99, P2114, DOI 10.1182/blood.V99.6.2114; BERAN M, 1987, LEUKEMIA, V1, P52; Bertaina A, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1216291; Bhat P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.67; Blazar BR, 1996, BLOOD, V87, P4463, DOI 10.1182/blood.V87.10.4463.bloodjournal87104463; Blazar BR, 2012, NAT REV IMMUNOL, V12, P443, DOI 10.1038/nri3212; Blink SE, 2014, CELL IMMUNOL, V290, P39, DOI 10.1016/j.cellimm.2014.04.013; Bonneville M, 2010, NAT REV IMMUNOL, V10, P467, DOI 10.1038/nri2781; Born WK, 2013, CELL MOL IMMUNOL, V10, P13, DOI 10.1038/cmi.2012.45; Brandes M, 2009, P NATL ACAD SCI USA, V106, P2307, DOI 10.1073/pnas.0810059106; Cai YF, 2018, CELL MOL IMMUNOL, V15, P233, DOI 10.1038/cmi.2016.37; Cela ME, 1996, BONE MARROW TRANSPL, V17, P243; Coffelt SB, 2015, NATURE, V522, P345, DOI 10.1038/nature14282; Cooke KR, 1996, BLOOD, V88, P3230, DOI 10.1182/blood.V88.8.3230.bloodjournal8883230; Drobyski W R, 1999, Biol Blood Marrow Transplant, V5, P222, DOI 10.1053/bbmt.1999.v5.pm10465102; Drobyski WR, 2000, J IMMUNOL, V165, P1634, DOI 10.4049/jimmunol.165.3.1634; ELLISON CA, 1995, J IMMUNOL, V155, P4189; Gaballa A, 2019, BONE MARROW TRANSPL, V54, P1562, DOI 10.1038/s41409-019-0462-z; Gertner-Dardenne J, 2012, J IMMUNOL, V188, P4701, DOI 10.4049/jimmunol.1103710; Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916; Godder KT, 2007, BONE MARROW TRANSPL, V39, P751, DOI 10.1038/sj.bmt.1705650; Gooley TA, 2010, NEW ENGL J MED, V363, P2091, DOI 10.1056/NEJMoa1004383; Guo BL, 2005, BREAST CANCER RES TR, V93, P169, DOI 10.1007/s10549-005-4792-8; Halary F, 2005, J EXP MED, V201, P1567, DOI 10.1084/jem.20041851; He WF, 2010, J IMMUNOL, V185, P126, DOI 10.4049/jimmunol.0903767; Huang YM, 2001, TRANSPLANTATION, V72, P1907, DOI 10.1097/00007890-200112270-00007; Kalyan S, 2013, CELL MOL IMMUNOL, V10, P21, DOI 10.1038/cmi.2012.44; Kersey JH, 2010, NEW ENGL J MED, V363, P2158, DOI 10.1056/NEJMe1010818; Knight A, 2010, BLOOD, V116, P2164, DOI 10.1182/blood-2010-01-255166; Kunzmann V, 2005, LEUKEMIA LYMPHOMA, V46, P671, DOI 10.1080/10428190500051893; Kunzmann V, 2000, BLOOD, V96, P384; Liu Y, 2015, LEUKEMIA, V29, P939, DOI 10.1038/leu.2014.310; Ma SB, 2014, CANCER RES, V74, P1969, DOI 10.1158/0008-5472.CAN-13-2534; Ma YT, 2011, J EXP MED, V208, P491, DOI 10.1084/jem.20100269; McCallion O, 2018, TRANSPLANTATION, V102, P1983, DOI 10.1097/TP.0000000000002335; Minculescu L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01997; Muranski P, 2008, BLOOD, V112, P362, DOI 10.1182/blood-2007-11-120998; Pasquini Marcelo C, 2010, Clin Transpl, P87; Radestad E, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/578741; Ravens S, 2017, NAT IMMUNOL, V18, P393, DOI 10.1038/ni.3686; Saitoh A, 2008, MED ONCOL, V25, P137, DOI 10.1007/s12032-007-9004-4; Silva-Santos B, 2015, NAT REV IMMUNOL, V15, P683, DOI 10.1038/nri3904; Song Y, 2018, EUR J IMMUNOL, V48, P670, DOI 10.1002/eji.201747177; VIALE M, 1992, BONE MARROW TRANSPL, V10, P249; Wu P, 2014, IMMUNITY, V40, P785, DOI 10.1016/j.immuni.2014.03.013; Xiang Z, 2014, CANCER CELL, V26, P565, DOI 10.1016/j.ccr.2014.07.026; ZOCCHI MR, 1990, EUR J IMMUNOL, V20, P2685	50	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 16	2020	11								558143	10.3389/fimmu.2020.558143	http://dx.doi.org/10.3389/fimmu.2020.558143			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OK6OT	33178187	Green Published, gold			2022-12-18	WOS:000584768100001
J	Yang, M; Wang, YW; Zhang, YH; Li, YJ; Li, QF; Tan, JT				Yang, Min; Wang, Yiwen; Zhang, Yonghong; Li, Yanjun; Li, Qifeng; Tan, Jintong			Role of Interleukin-33 in Staphylococcus epidermidis-Induced Septicemia	FRONTIERS IN IMMUNOLOGY			English	Article						IL-33; septicemia; Staphylococcus epidermidis; prostaglandin E2; interleukin-17A; interleukin-22	INFLAMMATION; ST2; EXPRESSION; RESPONSES; IL-17A	Interleukin (IL)-33 is a member of the IL-1 family, which plays an important role in inflammatory response. In this study, we evaluated the effect of IL-33 on septicemia and the underlying mechanisms by establishing a Staphylococcus epidermidis (S. epidermidis)-induced septicemic mouse model. The expression of IL-33, IL-1 alpha, IL-1 beta, IL-6, IL-17A, IL-22, and PGE2 were measured by double antibody sandwich enzyme-linked immunosorbent assay, and bacterial colony formation in peripheral blood and kidneys were counted postinfection. The percentages of neutrophils, eosinophils, and inflammatory monocytes were evaluated by flow cytometry, and tissue damage was assessed by hematoxylin and eosin (H&E) staining. The survival of septicemic mice was monitored daily. IL-33 expression was significantly augmented following S. epidermidis infection. High IL-33 expression significantly decreased the survival of model mice, and aggravated the damage of lung, liver, and kidney tissues. However, administration of ST2 (receptor for IL-33) to the S. epidermidis-infected mice blocked the IL-33 signaling pathway, which elevated PGE2, IL-17A, and IL-22, and promoted healing of organ damage. In addition, ST2 suppressed the mobilization of inflammatory monocytes, but promoted the accumulation of neutrophils and eosinophils in S. epidermidis-infected mice. Inhibition of PGE2, IL-17A, and IL-22 facilitated the development of septicemia and organ damage in S. epidermidis-infected mice, as well as reducing their survival. Our findings reveal that IL-33 aggravates organ damage in septicemic mice by inhibiting PGE2, IL-17A, and IL-22 production.	[Yang, Min] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Neurosurg, Sch Med, Shanghai, Peoples R China; [Wang, Yiwen; Zhang, Yonghong; Li, Yanjun; Tan, Jintong] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Neonatol, Sch Med, Shanghai, Peoples R China; [Li, Qifeng] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Pediat Neurosurg, Sch Med, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Tan, JT (corresponding author), Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Neonatol, Sch Med, Shanghai, Peoples R China.; Li, QF (corresponding author), Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Pediat Neurosurg, Sch Med, Shanghai, Peoples R China.	lqf989@163.com; tanjintong@xinhuamed.com.cn						Alsulaiman D, 2017, CURR EMERG HOSP ME R, V5, P28, DOI 10.1007/s40138-017-0125-6; Artru F, 2020, J HEPATOL, V72, P1052, DOI 10.1016/j.jhep.2019.12.017; Babic ZM, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0455-z; Balasubramanian S, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01473; Blaschke U, 2017, J INNATE IMMUN, V9, P587, DOI 10.1159/000479153; Brockmann L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051033; Chan LNC, 2015, INFECT IMMUN, V83, P4427, DOI 10.1128/IAI.01061-15; Chang KK, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.95; Chizzolini C, 2008, BLOOD, V112, P3696, DOI 10.1182/blood-2008-05-155408; Cho JS, 2010, J CLIN INVEST, V120, P1762, DOI 10.1172/JCI40891; Ding XB, 2019, SHOCK, V52, pE1, DOI 10.1097/SHK.0000000000001260; Drechsler Susanne, 2015, Intensive Care Med Exp, V3, P48, DOI 10.1186/s40635-015-0048-z; Dudakov JA, 2015, ANNU REV IMMUNOL, V33, P747, DOI 10.1146/annurev-immunol-032414-112123; Duffin R, 2016, SCIENCE, V351, P1333, DOI 10.1126/science.aad9903; Fagundes CT, 2007, J LEUKOCYTE BIOL, V81, P492, DOI 10.1189/jlb.0606422; Garth JM, 2017, J IMMUNOL, V199, P3381, DOI 10.4049/jimmunol.1701301; Gauvreau GM, 1999, AM J RESP CRIT CARE, V159, P31, DOI 10.1164/ajrccm.159.1.9804030; Ghorbani MG, 2009, J GUILAN U MED SCI, V18, P25; HAN M, 2017, J IMMUNOL, V0199; Hoogerwerf JJ, 2010, INTENS CARE MED, V36, P630, DOI 10.1007/s00134-010-1773-0; Kim Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178567; Krychtiuk KA, 2018, CYTOKINE, V103, P109, DOI 10.1016/j.cyto.2017.09.017; Lange H, 2002, J CELL MOL MED, V6, P653, DOI 10.1111/j.1582-4934.2002.tb00464.x; Lefrancais E, 2012, P NATL ACAD SCI USA, V109, P1673, DOI 10.1073/pnas.1115884109; Lohning M, 1998, P NATL ACAD SCI USA, V95, P6930, DOI 10.1073/pnas.95.12.6930; Moulin D, 2007, CYTOKINE, V40, P216, DOI 10.1016/j.cyto.2007.09.013; Nanzer AM, 2013, THORAX, V68, pA163, DOI 10.1136/thoraxjnl-2013-204457.345; Napolitani G, 2009, EUR J IMMUNOL, V39, P1301, DOI 10.1002/eji.200838969; Olson RM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217440; Oshikawa K, 2002, CLIN EXP ALLERGY, V32, P1520, DOI 10.1046/j.1365-2745.2002.01494.x; Talabot-Ayer D, 2012, JOINT BONE SPINE, V79, P32, DOI 10.1016/j.jbspin.2011.02.011; Valdez PA, 2012, IMMUNITY, V36, P668, DOI 10.1016/j.immuni.2012.02.013; Vancheri C, 2004, TRENDS IMMUNOL, V25, P40, DOI 10.1016/j.it.2003.11.001; Wondimu Z, 2010, AM J PATHOL, V177, P2334, DOI 10.2353/ajpath.2010.100028; Yao CC, 2009, NAT MED, V15, P633, DOI 10.1038/nm.1968; Yin H, 2006, BIOCHEM BIOPH RES CO, V351, P940, DOI 10.1016/j.bbrc.2006.10.166; Yuan Li, 2016, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V32, P1623; Zhu JF, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/1827901	38	0	0	4	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 15	2020	11								534099	10.3389/fimmu.2020.534099	http://dx.doi.org/10.3389/fimmu.2020.534099			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OK6BF	33178181	gold, Green Published			2022-12-18	WOS:000584732900001
J	Yong, KSM; Her, ZS; Tan, SY; Tan, WWS; Liu, M; Lai, F; Heng, SM; Fan, Y; Chang, KTE; Wang, CI; Chan, JKY; Chen, JZ; Chen, QF				Yong, Kylie Su Mei; Her, Zhisheng; Tan, Sue Yee; Tan, Wilson Wei Sheng; Liu, Min; Lai, Fritz; Heng, Shi Min; Fan, Yong; Chang, Kenneth Tou En; Wang, Cheng-, I; Chan, Jerry Kok Yen; Chen, Jianzhu; Chen, Qingfeng			Humanized Mouse as a Tool to Predict Immunotoxicity of Human Biologics	FRONTIERS IN IMMUNOLOGY			English	Article						cytokine storm; biologic testing; humanized mice; immunotoxicity; inflammation	REGULATORY T-CELLS; CD28 SUPERAGONIST TGN1412; MONOCLONAL-ANTIBODIES; PULMONARY-EDEMA; INTERLEUKIN-2 THERAPY; ANIMAL-MODELS; IL-2 THERAPY; EXPRESSION; MICE; TREG	Advancements in science enable researchers to constantly innovate and create novel biologics. However, the use of non-human animal models during the development of biologics impedes identification of precise in vivo interactions between the human immune system and treatments. Due to lack of this understanding, adverse effects are frequently observed in healthy volunteers and patients exposed to potential biologics during clinical trials. In this study, we evaluated and compared the effects of known immunotoxic biologics, Proleukin (R)/IL-2 and OKT3 in humanized mice (reconstituted with human fetal cells) to published clinical outcomes. We demonstrated that humanized mice were able to recapitulate in vivo pathological changes and human-specific immune responses, such as elevated cytokine levels and modulated lymphocytes and myeloid subsets. Given the high similarities of immunological side effects observed between humanized mice and clinical studies, this model could be used to assess immunotoxicity of biologics at a pre-clinical stage, without placing research participants and/or patients at risk.	[Yong, Kylie Su Mei; Her, Zhisheng; Tan, Sue Yee; Tan, Wilson Wei Sheng; Liu, Min; Lai, Fritz; Heng, Shi Min; Chen, Qingfeng] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore; [Fan, Yong] Guangzhou Med Univ, Key Lab Major Obstetr Dis Guangdong Prov, Affiliated Hosp 3, Guangzhou, Peoples R China; [Chang, Kenneth Tou En; Chen, Qingfeng] KK Womens & Childrens Hosp, Dept Pathol & Lab Med, Singapore, Singapore; [Chang, Kenneth Tou En] Duke NUS Grad Med Sch, Dept Pathol, Singapore, Singapore; [Wang, Cheng-, I] ASTAR, Singapore Immunol Network, Singapore, Singapore; [Chan, Jerry Kok Yen] KK Womens & Childrens Hosp, Dept Reprod Med, Singapore, Singapore; [Chan, Jerry Kok Yen] Natl Univ Singapore, Yong Loo Lin Sch Med, Expt Fetal Med Grp, Singapore, Singapore; [Chen, Jianzhu] Singapore Massachusetts Inst Technol Alliance Res, Interdisciplinary Res Grp Infect Dis, Singapore, Singapore; [Chen, Jianzhu] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Chen, Jianzhu] MIT, Dept Biol, Cambridge, MA USA; [Chen, Qingfeng] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol & Immunol, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Guangzhou Medical University; KK Women's & Children's Hospital; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN); KK Women's & Children's Hospital; National University of Singapore; Massachusetts Institute of Technology (MIT); Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National University of Singapore; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); National University of Singapore	Chen, QF (corresponding author), ASTAR, Inst Mol & Cell Biol, Singapore, Singapore.; Chen, QF (corresponding author), KK Womens & Childrens Hosp, Dept Pathol & Lab Med, Singapore, Singapore.; Chen, QF (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol & Immunol, Singapore, Singapore.	qchen@imcb.a-star.edu.sg			National Medical Research Council Singapore [NMRC/OFLCG/003/2018]; CS-IRG [CIRG19may-0051]; A*STAR IAF-PP IMPACT programme [H18/01/a0/022]; National Research Foundation Fellowship Singapore [NRF-NRFF2017-03, NRF2016-CRP001-103, NRF2019-NRF-ISF003-3127]	National Medical Research Council Singapore(National Medical Research Council, SingaporeUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); CS-IRG; A*STAR IAF-PP IMPACT programme; National Research Foundation Fellowship Singapore(National Research Foundation, Singapore)	This work was supported by the following grants: National Medical Research Council Singapore, VICTORY programme (NMRC/OFLCG/003/2018) and CS-IRG (CIRG19may-0051), A*STAR IAF-PP IMPACT programme (H18/01/a0/022) and National Research Foundation Fellowship Singapore NRF-NRFF2017-03, Competitive Research Programme NRF2016-CRP001-103 and NRF2019-NRF-ISF003-3127 to QC.	Abraham S, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00276; Adair John R., 1994, Human Antibodies and Hybridomas, V5, P41; Alcantar-Orozco EM, 2013, HUM GENE THER METHOD, V24, P310, DOI 10.1089/hgtb.2013.022; Amaria RN, 2015, IMMUNOTARGETS THER, V4, P79, DOI 10.2147/ITT.S61590; Antony GK, 2010, CURR MED CHEM, V17, P3297; Arenas-Ramirez N, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag3187; Arenas-Ramirez N, 2015, TRENDS IMMUNOL, V36, P763, DOI 10.1016/j.it.2015.10.003; Arrowsmith J, 2011, NAT REV DRUG DISCOV, V10, P1, DOI 10.1038/nrd3439; Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; Attarwala H, 2010, J Young Pharm, V2, P332, DOI 10.4103/0975-1483.66810; Begley CG, 2012, NATURE, V483, P531, DOI 10.1038/483531a; BERTHIAUME Y, 1995, AM J RESP CRIT CARE, V152, P329, DOI 10.1164/ajrccm.152.1.7599842; Beyersdorf N, 2015, IMMUNOTARGETS THER, V4, P111, DOI 10.2147/ITT.S61647; Billerbeck E, 2011, BLOOD, V117, P3076, DOI 10.1182/blood-2010-08-301507; Borsellino G, 2007, BLOOD, V110, P1225, DOI 10.1182/blood-2006-12-064527; Boyman O, 2019, SWISS MED WKLY, V149, DOI 10.4414/smw.2019.14697; Boyman O, 2012, NAT REV IMMUNOL, V12, P180, DOI 10.1038/nri3156; Brady JL, 2014, CLIN TRANSL IMMUNOL, V3, DOI 10.1038/cti.2014.28; Brehm MA, 2010, CURR OPIN ENDOCRINOL, V17, P120, DOI 10.1097/MED.0b013e328337282f; Cacev T, 2008, CARCINOGENESIS, V29, P1572, DOI 10.1093/carcin/bgn164; Campbell DJ, 2011, NAT REV IMMUNOL, V11, P119, DOI 10.1038/nri2916; Carpenter PA, 2000, J IMMUNOL, V165, P6205, DOI 10.4049/jimmunol.165.11.6205; Chapman K, 2009, MABS-AUSTIN, V1, P505, DOI 10.4161/mabs.1.5.9676; CHATENOUD L, 1982, EUR J IMMUNOL, V12, P979, DOI 10.1002/eji.1830121116; Chen Q, 2013, BIO-PROTOCOL, V3, pe992, DOI DOI 10.21769/BioProtoc.992; Chen QF, 2009, P NATL ACAD SCI USA, V106, P21783, DOI 10.1073/pnas.0912274106; Clark IA, 2007, IMMUNOL CELL BIOL, V85, P271, DOI 10.1038/sj.icb.7100062; Dansette PM, 1998, EUR J DRUG METAB PH, V23, P443, DOI 10.1007/BF03189993; Debure A, 1989, J UROL, V45, P546, DOI [10.1097/00007890-198803000-00009, DOI 10.1097/00007890-198803000-00009]; Denayer T, 2014, NEW HORIZ TRANSL MED, V2, P5, DOI 10.1016/j.nhtm.2014.08.001; Descotes J, 2005, DRUG SAFETY, V28, P127, DOI 10.2165/00002018-200528020-00004; Durost P, 2014, J IMMUNOL, V192; Eastwood D, 2010, BRIT J PHARMACOL, V161, P512, DOI 10.1111/j.1476-5381.2010.00922.x; FERRO TJ, 1989, J IMMUNOL, V142, P1916; Fletcher JM, 2009, J IMMUNOL, V183, P7602, DOI 10.4049/jimmunol.0901881; Fukuchi Y, 1998, LEUKEMIA RES, V22, P837, DOI 10.1016/S0145-2126(98)00084-8; Fyfe GA, 1996, J CLIN ONCOL, V14, P2410, DOI 10.1200/JCO.1996.14.8.2410; GASTON RS, 1991, KIDNEY INT, V39, P141, DOI 10.1038/ki.1991.18; Halloran PF, 2004, NEW ENGL J MED, V351, P2715, DOI 10.1056/NEJMra033540; Harrison RK, 2016, NAT REV DRUG DISCOV, V15, P817, DOI 10.1038/nrd.2016.184; Henson PM, 2005, NAT IMMUNOL, V6, P1179, DOI 10.1038/ni1205-1179; Hunig T, 2016, FEBS J, V283, P3325, DOI 10.1111/febs.13754; Hunig T, 2012, NAT REV IMMUNOL, V12, P317, DOI 10.1038/nri3192; Ilan Y, 2010, J CLIN IMMUNOL, V30, P167, DOI 10.1007/s10875-009-9323-7; Isaacs JD, 2008, RHEUMATOLOGY, V47, P1461, DOI 10.1093/rheumatology/ken163; Ito R, 2013, J IMMUNOL, V191, P2890, DOI 10.4049/jimmunol.1203543; Ito S, 2014, MOL THER, V22, P1388, DOI 10.1038/mt.2014.50; Jolliffe L K, 1993, Int Rev Immunol, V10, P241, DOI 10.3109/08830189309061699; Katano I, 2015, J IMMUNOL, V194, P3513, DOI 10.4049/jimmunol.1401323; Kola I, 2008, CLIN PHARMACOL THER, V83, P227, DOI 10.1038/sj.clpt.6100479; Krieg C, 2010, P NATL ACAD SCI USA, V107, P11906, DOI 10.1073/pnas.1002569107; Kryczek I, 2009, CANCER RES, V69, P3995, DOI 10.1158/0008-5472.CAN-08-3804; Kuhn C, 2016, IMMUNOTHERAPY-UK, V8, P889, DOI 10.2217/imt-2016-0049; Levin AM, 2012, NATURE, V484, P529, DOI 10.1038/nature10975; Li Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01570-9; Li ZY, 2015, CELL MOL IMMUNOL, V12, P558, DOI 10.1038/cmi.2015.10; Lim AI, 2017, CELL, V168, P1086, DOI 10.1016/j.cell.2017.02.021; Loisel S, 2007, CRIT REV ONCOL HEMAT, V62, P34, DOI 10.1016/j.critrevonc.2006.11.010; Malcolm SL, 2012, J IMMUNOL METHODS, V384, P33, DOI 10.1016/j.jim.2012.07.001; Mandapathil M, 2009, J IMMUNOL METHODS, V346, P55, DOI 10.1016/j.jim.2009.05.004; Martin A, 2013, CLIN IMMUNOL, V148, P136, DOI 10.1016/j.clim.2013.04.011; Martin-Orozco N, 2010, CANCER RES, V70, P9581, DOI 10.1158/0008-5472.CAN-10-1379; Meloni G, 2002, LEUKEMIA, V16, P2016, DOI 10.1038/sj.leu.2402566; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976-0105.177703; Ohira M, 2013, TRANSPL P, V45, P2045, DOI 10.1016/j.transproceed.2013.01.046; Oosting M, 2014, P NATL ACAD SCI USA, V111, pE4478, DOI 10.1073/pnas.1410293111; Otto MW, 2002, PSYCHOTHER PSYCHOSOM, V71, P241, DOI 10.1159/000064813; Pearson Todd, 2008, Curr Protoc Immunol, VChapter 15, DOI 10.1002/0471142735.im1521s81; Roayaie S, 2000, MEDIAT INFLAMM, V9, P141, DOI 10.1080/09629350020002877; Rongvaux A, 2014, NAT BIOTECHNOL, V32, P364, DOI 10.1038/nbt.2858; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; Sakaguchi S, 2007, EUR J IMMUNOL, V37, pS116, DOI 10.1002/eji.200737593; SAXON RR, 1991, AM J ROENTGENOL, V156, P281, DOI 10.2214/ajr.156.2.1898799; Shablak A, 2011, J IMMUNOTHER, V34, P107, DOI 10.1097/CJI.0b013e3181fb659f; Sheu TT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089379; Shiheido H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094324; Shultz LD, 2012, NAT REV IMMUNOL, V12, P786, DOI 10.1038/nri3311; Sim GC, 2014, J CLIN INVEST, V124, P99, DOI 10.1172/JCI46266; Stegall MD, 2016, AM J TRANSPLANT, V16, P1094, DOI 10.1111/ajt.13582; Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842; Taneja V, 1998, J CLIN INVEST, V101, P921, DOI 10.1172/JCI2860; Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11; Tranter E, 2013, BRIT J CLIN PHARMACO, V76, P164, DOI 10.1111/bcp.12096; van Wijk Femke, 2006, Drug Discov Today Technol, V3, P103, DOI 10.1016/j.ddtec.2006.03.003; Venken K, 2008, J IMMUNOL, V180, P6411, DOI 10.4049/jimmunol.180.9.6411; Waldron-Lynch F, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003401; Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435; Wei S, 2007, CANCER RES, V67, P7487, DOI 10.1158/0008-5472.CAN-07-0565; Weissmuller S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149093; Yong KSM, 2018, ARCH IMMUNOL THER EX, V66, P245, DOI 10.1007/s00005-018-0506-x; Yong KSM, 2016, CELL MOL IMMUNOL, V13, P605, DOI 10.1038/cmi.2015.40; Ziegler SF, 2007, EUR J IMMUNOL, V37, P21, DOI 10.1002/eji.200636929	94	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 15	2020	11								553362	10.3389/fimmu.2020.553362	http://dx.doi.org/10.3389/fimmu.2020.553362			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OI4TN	33193321	gold, Green Published			2022-12-18	WOS:000583273100001
J	Rodriguez-Fernandez, JL; Mellado, M; Thelen, M; Murphy, PM				Rodriguez-Fernandez, Jose Luis; Mellado, Mario; Thelen, Marcus; Murphy, Philip M.			Editorial: Atypical Functions of Leukocyte Chemoattractant Receptors	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						chemotaxis; chemokine; atypical chemokine receptor; G protein-coupled receptor; signaling; arrestin; GPCR			[Rodriguez-Fernandez, Jose Luis] CSIC, Ctr Invest Biol Margarita Salas, Dept Mol Cell Biol, Madrid, Spain; [Mellado, Mario] CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Madrid, Spain; [Thelen, Marcus] Univ Svizzera Italiana, Inst Res Biomed, Fac Biomed Sci, Bellinzona, Switzerland; [Murphy, Philip M.] NIAID, Lab Mol Immunol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Universita della Svizzera Italiana; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Rodriguez-Fernandez, JL (corresponding author), CSIC, Ctr Invest Biol Margarita Salas, Dept Mol Cell Biol, Madrid, Spain.; Mellado, M (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Madrid, Spain.; Thelen, M (corresponding author), Univ Svizzera Italiana, Inst Res Biomed, Fac Biomed Sci, Bellinzona, Switzerland.; Murphy, PM (corresponding author), NIAID, Lab Mol Immunol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	rodrifer@cib.csic.es; mmellado@cnb.csic.es; marcus.thelen@irb.usi.ch; pmm@nih.gov	Mellado, Mario/M-9893-2014; Rodriguez-Fernandez, Jose Luis/Q-5021-2019; Mellado, Mario/Q-4752-2019	Mellado, Mario/0000-0001-6325-1630; Rodriguez-Fernandez, Jose Luis/0000-0001-8874-1425; Mellado, Mario/0000-0001-6325-1630	MICIU [SAF2017-83306-R]; RIER (RETICS Program/ISCIII) [RD08/0075]; AEI/FEDER, UE [SAF2017-82940-R]; RETICS Program/ISCIII [RD12/0012/0006]; SNSF [310030_163336/1]; SNSF (Sinergia) [CRSII3_160719]; Helmut Horten Foundation; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH	MICIU; RIER (RETICS Program/ISCIII); AEI/FEDER, UE; RETICS Program/ISCIII; SNSF(Swiss National Science Foundation (SNSF)); SNSF (Sinergia); Helmut Horten Foundation; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We acknowledge all authors that contributed to this collection. Work supported by grants SAF2017-83306-R (MICIU) and RIER (RETICS Program/ISCIII) (RD08/0075) (JLR-F); grants SAF2017-82940-R AEI/FEDER, UE and RD12/0012/0006 (RETICS Program/ISCIII) (MM); grants from the SNSF (310030_163336/1 and Sinergia CRSII3_160719) and Helmut Horten Foundation (MT); and supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH (PMM).	BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; D'Agostino G, 2020, BIOCHEM BIOPH RES CO, V528, P347, DOI 10.1016/j.bbrc.2020.02.120; Di Liberto D, 2008, J EXP MED, V205, P2075, DOI 10.1084/jem.20070608; Legler Daniel F, 2018, F1000Res, V7, P95, DOI 10.12688/f1000research.13130.1; Lopez-Cotarelo P, 2017, TRENDS IMMUNOL, V38, P927, DOI 10.1016/j.it.2017.08.004; Murphy PM, 2018, CYTOKINE, V109, P2, DOI 10.1016/j.cyto.2017.12.022; Pan M, 2016, DEV CELL, V36, P428, DOI 10.1016/j.devcel.2016.01.012; Teijeira A, 2020, IMMUNITY, V52, P856, DOI 10.1016/j.immuni.2020.03.001; Zabel BA, 2015, ANNU REV PATHOL-MECH, V10, P51, DOI 10.1146/annurev-pathol-012513-104640; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	10	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 9	2020	11								596902	10.3389/fimmu.2020.596902	http://dx.doi.org/10.3389/fimmu.2020.596902			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OF5QV	33163007	gold, Green Published			2022-12-18	WOS:000581262900001
J	Kallenius, G; Nigou, J; Cooper, A; Correia-Neves, M				Kallenius, Gunilla; Nigou, Jerome; Cooper, Andrea; Correia-Neves, Margarida			Editorial: Mycobacterial Glycolipids-Role in Immunomodulation and Targets for Vaccine Development	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						Mycobacterium tuberculosis; Mycobacterium leprae; glycolipid; lipoarabinomannan; Mycobacterium ulcerans; immunomodulation; vaccine			[Kallenius, Gunilla; Correia-Neves, Margarida] Karolinska Inst, Div Infect Dis, Dept Med Solna, Stockholm, Sweden; [Nigou, Jerome] Univ Paul Sabatier, Inst Pharmacol & Biol Struct, Univ Toulouse, Ctr Natl Rech Sci CNRS, Toulouse, France; [Cooper, Andrea] Univ Leicester, Leicester TB Res Grp LTBRG, Dept Resp Sci, Leicester, Leics, England; [Correia-Neves, Margarida] Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Med, Braga, Portugal; [Correia-Neves, Margarida] Portugal PT Govt Associate Lab, ICVS Biomat Biodegradables & Biomimet 3Bs, Braga, Portugal	Karolinska Institutet; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); University of Leicester; Universidade do Minho	Kallenius, G (corresponding author), Karolinska Inst, Div Infect Dis, Dept Med Solna, Stockholm, Sweden.	gunilla.kallenius@ki.se	Källenius, Gunilla/AGZ-3956-2022; Correia-Neves, Margarida/AAH-4636-2020	Correia-Neves, Margarida/0000-0002-2202-5431				Andersen P, 2019, NAT REV IMMUNOL, V19, P550, DOI 10.1038/s41577-019-0174-z; Berti F, 2020, CURR OPIN IMMUNOL, V65, P42, DOI 10.1016/j.coi.2020.03.015; Correia-Neves M, 2019, ERJ OPEN RES, V5, DOI 10.1183/23120541.00115-2018; Gilleron M, 2008, MYCOBACTERIAL CELL ENVELOPE, P75; Ishikawa E, 2017, TRENDS IMMUNOL, V38, P66, DOI 10.1016/j.it.2016.10.009; Kasmar AG, 2014, ART SCI TUBERCULOSIS, P123; Layre E, 2015, ELS; Lienhardt C, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001965; Minnick D, 2021, SUBST ABUS, V42, P587, DOI 10.1080/08897077.2020.1803181; Moody D Branch, 2017, F1000Res, V6, P1909, DOI 10.12688/f1000research.12178.1; Oldenburg R, 2017, BIOCHIMIE, V141, P3, DOI 10.1016/j.biochi.2017.03.012; Orme IM, 2015, NAT IMMUNOL, V16, P57, DOI 10.1038/ni.3048; Vergne I, 2015, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00187; World Health Organization, 2019, GLOB TUB REP 2019; World Health Organization, 2014, GLOB STRAT TARG TUB	15	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 8	2020	11								603900	10.3389/fimmu.2020.603900	http://dx.doi.org/10.3389/fimmu.2020.603900			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OE5QQ	33133110	Green Published, gold			2022-12-18	WOS:000580585100001
J	Rogers, SW; Myers, EJ; Gahring, LC				Rogers, Scott W.; Myers, Elizabeth J.; Gahring, Lorise C.			Age-Associated Tooth Loss and Oral Microbial Dysbiosis in a Mouse Genetic Model of Chronic Nicotine Exposure	FRONTIERS IN IMMUNOLOGY			English	Article						nicotinic receptor alpha7; mouse; microbiome; tooth loss; aging	ACETYLCHOLINE-RECEPTOR; INTESTINAL MICROBIOTA; BONE LOSS; T-CELLS; OSTEONECROSIS; ALPHA-7; EXPRESSION; DIAGNOSIS; DISEASE; HEALTH	Nicotine acts as a potent modulator of normal cellular responses through the nicotinic acetylcholine receptor subtype alpha7. In a mouse genetic model of alpha7 receptor dysfunction, alpha7(E260A:G), 85 percent of 18 month-old mice exhibit an age-associated spontaneous loosening or complete loss of 3rd molars that was not present in the control mice. The adjacent soft tissues appeared largely unaffected. Further analysis including micro-CT revealed evidence of bone loss surrounding the 3rd molars with areas of cavitation and/or sponge-like (cancellous) bone remodeling in the mandible. The mandible microbiome was examined using 16S-rRNA sequencing. The results show the alpha7(E260A:G)oral microbiome included increased landscape complexity indicative of dysbiosis, and a significant increase of some bacteria, particularlyStaphylococcus. These results suggest that normal alpha7 function plays a relevant role in maintaining normal gene expression and oral microbiome stasis. Consequently, this mouse model suggests there are consequences to ongoing alpha7 receptor dysfunction and oral health, as can occur from chronic exposure to nicotine as expected from electronic nicotine delivery systems (ENDS or "vaping"), that may not be seen until older age.	[Rogers, Scott W.; Gahring, Lorise C.] Salt Lake City Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Salt Lake City, UT 84148 USA; [Rogers, Scott W.] Univ Utah, Sch Med, Dept Neurobiol, Salt Lake City, UT 84112 USA; [Myers, Elizabeth J.; Gahring, Lorise C.] Univ Utah, Sch Med, Dept Internal Med, Div Geriatr, Salt Lake City, UT USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Rogers, SW (corresponding author), Salt Lake City Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Salt Lake City, UT 84148 USA.; Rogers, SW (corresponding author), Univ Utah, Sch Med, Dept Neurobiol, Salt Lake City, UT 84112 USA.	Scott.Rogers@hsc.utah.edu			National Institutes of Health, Heart Lung and Blood Institute [R01 HL135610]; Veterans Administration (VA Merit Grant) [I01BX004637]	National Institutes of Health, Heart Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Veterans Administration (VA Merit Grant)(US Department of Veterans Affairs)	This work was supported by grants National Institutes of Health, Heart Lung and Blood Institute (R01 HL135610 to LG and SR) and from the Veterans Administration (VA Merit Grant No. I01BX004637 to LG).	Albuquerque EX, 2009, PHYSIOL REV, V89, P73, DOI 10.1152/physrev.00015.2008; Arredondo J, 2007, LIFE SCI, V80, P2191, DOI 10.1016/j.lfs.2007.01.013; Baker PJ, 1999, INFECT IMMUN, V67, P2804, DOI 10.1128/IAI.67.6.2804-2809.1999; Becattini S, 2016, TRENDS MOL MED, V22, P458, DOI 10.1016/j.molmed.2016.04.003; Broide RS, 2019, FRONT NEUROANAT, V13, DOI 10.3389/fnana.2019.00076; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Conti-Fine BM, 2000, EUR J PHARMACOL, V393, P279, DOI 10.1016/S0014-2999(00)00036-4; de Jonge WJ, 2007, BRIT J PHARMACOL, V151, P915, DOI 10.1038/sj.bjp.0707264; Eid HM, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00387; Enioutina EY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121128; Fenollar F, 2006, J CLIN MICROBIOL, V44, P1018, DOI 10.1128/JCM.44.3.1018-1028.2006; Foucault-Fruchard L, 2017, NEURAL REGEN RES, V12, P1418, DOI 10.4103/1673-5374.215244; Gaetti-Jardim E, 2010, BRAZ J MICROBIOL, V41, P1056, DOI [10.1590/S1517-83822010000400025, 10.1590/S1517-838220100004000025]; Gahring LC, 2005, AAPS J, V7, pE885, DOI 10.1208/aapsj070486; Gahring LC, 2020, AM J PHYSIOL-LUNG C, V319, pL683, DOI 10.1152/ajplung.00227.2020; Gahring LC, 2018, AM J PHYSIOL-LUNG C, V315, pL553, DOI 10.1152/ajplung.00230.2018; Gahring LC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187773; Gahring LC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175367; Gahring LC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057481; Glowacki AJ, 2013, P NATL ACAD SCI USA, V110, P18525, DOI 10.1073/pnas.1302829110; Gomez A, 2017, CELL HOST MICROBE, V22, P269, DOI 10.1016/j.chom.2017.08.013; Hajiasgharzadeh K, 2019, J CELL PHYSIOL, V234, P14666, DOI 10.1002/jcp.28220; Ji X, 2012, ORAL DIS, V18, P85, DOI 10.1111/j.1601-0825.2011.01848.x; Khan A, 2016, OSTEOPOROSIS INT, V27, P853, DOI 10.1007/s00198-015-3335-3; Kishibe M, 2015, INT IMMUNOPHARMACOL, V29, P63, DOI 10.1016/j.intimp.2015.05.047; Malhotra Ranjan, 2010, J Indian Soc Periodontol, V14, P72, DOI 10.4103/0972-124X.65442; Pandiyan P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00426; Papke RL, 2014, BIOCHEM PHARMACOL, V89, P1, DOI 10.1016/j.bcp.2014.01.029; Park S, 2015, J BIOL CHEM, V290, P17349, DOI 10.1074/jbc.M115.652305; Persoon IF, 2017, CLIN ORAL INVEST, V21, P1871, DOI 10.1007/s00784-016-1980-3; Rogers SW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036467; Rogers SW, 2012, AM J MED GENET A, V158A, P1135, DOI 10.1002/ajmg.a.35372; Rosas-Ballina M, 2009, J INTERN MED, V265, P663, DOI 10.1111/j.1365-2796.2009.02098.x; Shiba T, 2016, SCI REP-UK, V6, DOI 10.1038/srep30997; Taur Y, 2014, NAT MED, V20, P246, DOI 10.1038/nm.3492; Ubeda C, 2010, J CLIN INVEST, V120, P4332, DOI 10.1172/JCI43918; Wade WG, 2013, PHARMACOL RES, V69, P137, DOI 10.1016/j.phrs.2012.11.006; Wongtrakool C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109602; WONNACOTT S, 1990, TRENDS PHARMACOL SCI, V11, P216, DOI 10.1016/0165-6147(90)90242-Z; Wright JA, 2010, INT J MED MICROBIOL, V300, P193, DOI 10.1016/j.ijmm.2009.10.003	40	0	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 7	2020	11								575200	10.3389/fimmu.2020.575200	http://dx.doi.org/10.3389/fimmu.2020.575200			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OD4OF	33117372	gold, Green Published			2022-12-18	WOS:000579831100001
J	Harris, KM; Horn, SE; Grant, ML; Lang, HL; Sani, G; Jensen-Wachspress, MA; Kankate, VV; Datar, A; Lazarski, CA; Bollard, CM; Keller, MD				Harris, Katherine M.; Horn, Sarah E.; Grant, Melanie L.; Lang, Haili; Sani, Gelina; Jensen-Wachspress, Mariah A.; Kankate, Vaishnavi V.; Datar, Anushree; Lazarski, Christopher A.; Bollard, Catherine M.; Keller, Michael D.			T-Cell Therapeutics Targeting Human Parainfluenza Virus 3 Are Broadly Epitope Specific and Are Cross Reactive With Human Parainfluenza Virus 1	FRONTIERS IN IMMUNOLOGY			English	Article						parainfluenza; immunotherapy; T-cell; bone marrow transplant; anti-viral	INFECTIONS; CYTOMEGALOVIRUS; TYPE-3; TRANSPLANTATION; LYMPHOCYTES; THERAPY; VACCINE; PROTEIN	Human Parainfluenza Virus-3 (HPIV3) causes severe respiratory illness in immunocompromised patients and lacks approved anti-viral therapies. A phase I study of adoptively transferred virus-specific T-cells (VSTs) targeting HPIV3 following bone marrow transplantation is underway (NCT03180216). We sought to identify immunodominant epitopes within HPIV3 Matrix protein and their cross-reactivity against related viral proteins. VSTs were generated from peripheral blood of healthy donors by ex-vivo expansion after stimulation with a 15-mer peptide library encompassing HPIV3 matrix protein. Epitope mapping was performed using IFN-gamma ELIspot with combinatorial peptide pools. Flow cytometry was used to characterize products with intracellular cytokine staining. In 10 VST products tested, we discovered 12 novel immunodominant epitopes. All products recognized an epitope at the C-terminus. On IFN-gamma ELISpot, individual peptides eliciting activity demonstrated mean IFN-gamma spot forming units per well (SFU)/1x10(5)cells of 115.5 (range 24.5-247.5). VST products were polyfunctional, releasing IFN-gamma and TNF-alpha in response to identified epitopes, which were primarily HLA Class II restricted. Peptides from Human Parainfluenza Virus-1 corresponding to the HPIV3 epitopes showed cross-reactivity for HPIV1 in 11 of 12 tested epitopes (mean cross reactivity index: 1.19). Characterization of HPIV3 epitopes may enable development of third-party VSTs to treat immune suppressed patients with HPIV infection.	[Harris, Katherine M.; Horn, Sarah E.; Grant, Melanie L.; Lang, Haili; Sani, Gelina; Jensen-Wachspress, Mariah A.; Kankate, Vaishnavi V.; Datar, Anushree; Lazarski, Christopher A.; Bollard, Catherine M.; Keller, Michael D.] Childrens Natl Hosp, Ctr Canc & Immunol Res, Washington, DC 20010 USA; [Harris, Katherine M.; Bollard, Catherine M.] Childrens Natl Hosp, Ctr Canc & Blood Disorders, Washington, DC 20010 USA; [Bollard, Catherine M.; Keller, Michael D.] George Washington Univ, GW Canc Ctr, Washington, DC 20052 USA; [Keller, Michael D.] Childrens Natl Hosp, Div Allergy & Immunol, Washington, DC USA	Children's National Health System; Children's National Health System; George Washington University; Children's National Health System	Bollard, CM (corresponding author), Childrens Natl Hosp, Ctr Canc & Immunol Res, Washington, DC 20010 USA.; Bollard, CM (corresponding author), Childrens Natl Hosp, Ctr Canc & Blood Disorders, Washington, DC 20010 USA.; Bollard, CM (corresponding author), George Washington Univ, GW Canc Ctr, Washington, DC 20052 USA.	cbollard@childrensnational.org		Jensen-Wachspress, Mariah/0000-0002-4384-1374; Bollard, Catherine M./0000-0001-5140-9090	National Institutes of Health [K23-HL136783-01]; Jeffrey Modell Foundation; Board of Visitors of the Children's National Health System	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Jeffrey Modell Foundation; Board of Visitors of the Children's National Health System	This work was supported by grants from the National Institutes of Health (K23-HL136783-01 to MK), the Jeffrey Modell Foundation, and the Board of Visitors of the Children's National Health System.	Boeckh M, 2008, BRIT J HAEMATOL, V143, P455, DOI 10.1111/j.1365-2141.2008.07295.x; DAVE VP, 1994, VIROLOGY, V199, P376, DOI 10.1006/viro.1994.1135; Ding BB, 2017, CELL HOST MICROBE, V21, P538, DOI 10.1016/j.chom.2017.03.004; Englund JA, 2013, VACCINE, V31, P5706, DOI 10.1016/j.vaccine.2013.09.046; Falsey Ann R, 2012, Infect Drug Resist, V5, P121, DOI 10.2147/IDR.S25874; Feuchtinger T, 2008, J IMMUNOTHER, V31, P199, DOI 10.1097/CJI.0b013e31815ef862; Gerdemann U, 2012, MOL THER, V20, P1622, DOI 10.1038/mt.2012.130; Henrickson KJ, 2003, CLIN MICROBIOL REV, V16, P242, DOI 10.1128/CMR.16.2.242-264.2003; Leen AM, 2008, J VIROL, V82, P546, DOI 10.1128/JVI.01689-07; Leen AM, 2006, NAT MED, V12, P1160, DOI 10.1038/nm1475; Leen AM, 2013, BLOOD, V121, P5113, DOI 10.1182/blood-2013-02-486324; Leen AM, 2009, BLOOD, V114, P4283, DOI 10.1182/blood-2009-07-232454; Mclaughlin LP, 2016, CYTOTHERAPY, V18, P1515, DOI 10.1016/j.jcyt.2016.08.010; Nichols WG, 2001, BLOOD, V98, P573, DOI 10.1182/blood.V98.3.573; Olive M, 2002, HUM GENE THER, V13, P1167, DOI 10.1089/104303402320138952; Papadopoulou A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008825; Peggs KS, 2003, LANCET, V362, P1375, DOI 10.1016/S0140-6736(03)14634-X; Prockop S, 2020, J CLIN INVEST, V130, P733, DOI 10.1172/JCI121127; Srinivasan A, 2011, BIOL BLOOD MARROW TR, V17, P1520, DOI 10.1016/j.bbmt.2011.03.001; STOKES A, 1992, VIRUS RES, V25, P91, DOI 10.1016/0168-1702(92)90102-F; Tzannou I, 2019, BLOOD ADV, V3, P2571, DOI 10.1182/bloodadvances.2019000371; Tzannou I, 2017, J CLIN ONCOL, V35, P3547, DOI [10.1200/JCO.2017.73.0655, 10.1200/jco.2017.73.0655]; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Withers B, 2017, BLOOD ADV, V1, P2193, DOI 10.1182/bloodadvances.2017010223; Ziola B, 1987, Viral Immunol, V1, P111	25	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 5	2020	11								575977	10.3389/fimmu.2020.575977	http://dx.doi.org/10.3389/fimmu.2020.575977			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OC9PI	33123159	gold, Green Published			2022-12-18	WOS:000579486700001
J	Hodl, I; Bosch, P; Dreo, B; Stradner, MH				Hodl, Isabel; Bosch, Philipp; Dreo, Barbara; Stradner, Martin H.			Case Report: Extensive Phosphorylation of Interleukin-1 Receptor-Associated Kinase 4 in a Patient With Schnitzler Syndrome	FRONTIERS IN IMMUNOLOGY			English	Article						Schnitzler syndrome; autoinflammatory disease; interleukin-1 receptor associated kinase 4; flow cytometry; interleukin 1; Castleman disease	DIAGNOSTIC-CRITERIA; CASTLEMAN; DISEASE	Schnitzler syndrome (SchS) is a rare autoinflammatory disease, characterized by urticarial rash, recurrent fever, osteo-articular pain/arthritis with bone condensation, and monoclonal gammopathy. Diagnosis may be difficult due to overlapping signs with other diseases. Here, we describe the case of a 62-year-old man with SchS, who was initially misdiagnosed with multicentric Castleman disease (MCD). As excessive release of IL-6 is characteristic of MCD, in contrast to IL-1 in SchS, we measured the phosphorylation of intracellular signaling proteins of the respective pathways by flow cytometry. We found a distinct increase of phosphorylated IRAK-4 in our patient's B cells and monocytes while phosphorylation of STAT-3 was low, suggesting predominant IL-1 signaling. In accordance with these results and the classification criteria, we established the diagnosis of SchS instead of MCD and commenced therapy with the IL-1 receptor antagonist anakinra. We observed a rapid remission of signs accompanied by a reduction of phosphorylated IRAK-4 to normal levels. In conclusion, we propose phosphorylated IRAK-4 in B cells and monocytes as a potential marker for diagnosis of SchS and for treatment response to IL-1 blockade.	[Hodl, Isabel; Bosch, Philipp; Dreo, Barbara; Stradner, Martin H.] Med Univ Graz, Dept Internal Med, Div Rheumatol & Immunol, Graz, Austria	Medical University of Graz	Stradner, MH (corresponding author), Med Univ Graz, Dept Internal Med, Div Rheumatol & Immunol, Graz, Austria.	martin.stradner@medunigraz.at		Stradner, Martin/0000-0002-7884-6626; Hodl, Isabel/0000-0003-4044-0046				Bahia MS, 2015, CELL SIGNAL, V27, P1039, DOI 10.1016/j.cellsig.2015.02.025; Cabral-Marques O, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02742; Fajgenbaum DC, 2017, BLOOD, V129, P1646, DOI 10.1182/blood-2016-10-746933; Gavasso S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088632; Gellrich FF, 2019, Z RHEUMATOL, V78, P43, DOI 10.1007/s00393-019-0591-1; Gusdorf L, 2017, CURR RHEUMATOL REP, V19, DOI 10.1007/s11926-017-0673-5; Gusdorf L, 2017, ALLERGY, V72, P177, DOI 10.1111/all.13035; Kanegane H, 2018, ALLERGOL INT, V67, P43, DOI 10.1016/j.alit.2017.06.003; Kuuliala K, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1278-0; Kuuliala K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167975; Kuuliala K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137385; Lipsker D, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-38; Liu AY, 2016, LANCET HAEMATOL, V3, pE163, DOI 10.1016/S2352-3026(16)00006-5; Munshi N, 2015, LEUKEMIA LYMPHOMA, V56, P1252, DOI 10.3109/10428194.2014.953145; Nikfar S, 2018, RHEUMATOL INT, V38, P1363, DOI 10.1007/s00296-018-4041-1; Picard C, 2011, CLIN MICROBIOL REV, V24, P490, DOI 10.1128/CMR.00001-11; Polizzotto MN, 2013, BLOOD, V122, P4189, DOI 10.1182/blood-2013-08-519959; Post GR, 2016, ANN CLIN LAB SCI, V46, P474; Rowczenio DM, 2018, BLOOD, V131, P974, DOI 10.1182/blood-2017-10-810366; Schaper F, 2015, CYTOKINE GROWTH F R, V26, P475, DOI 10.1016/j.cytogfr.2015.07.004; Soudet S, 2018, CURR RES TRANSL MED, V66, P83, DOI 10.1016/j.retram.2018.06.001; van de Donk NWCJ, 2014, HAEMATOLOGICA, V99, P984, DOI 10.3324/haematol.2013.100552; van Leersum FS, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-019-1117-2; Villarreal-Villarreal CD, 2016, ACTAS DERMO-SIFILOGR, V107, P369, DOI 10.1016/j.ad.2015.12.001; von Bernuth H, 2012, EUR J IMMUNOL, V42, P3126, DOI 10.1002/eji.201242683; Wiese MD, 2020, EXPERT OPIN INV DRUG, V29, P475, DOI 10.1080/13543784.2020.1752660; Wu S, 2010, EXPERT REV VACCINES, V9, P631, DOI 10.1586/ERV.10.59	27	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 30	2020	11								576200	10.3389/fimmu.2020.576200	http://dx.doi.org/10.3389/fimmu.2020.576200			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OC5WQ	33123160	Green Published, gold			2022-12-18	WOS:000579226700001
J	Probert, L; Quintana, FJ; Bar-Or, A				Probert, Lesley; Quintana, Francisco J.; Bar-Or, Amit			Editorial: Update on Translational Neuroimmunology-Research of ISNI 2018	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						neuroimmunology; central nervous system; translational medicine; multiple sclerosis; neurodegeneration; immune system; biomarkers; immunotherapeutics	BRAIN		[Probert, Lesley] Hellenic Pasteur Inst, Dept Immunol, Athens, Greece; [Quintana, Francisco J.] Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, 75 Francis St, Boston, MA 02115 USA; [Quintana, Francisco J.] Harvard Med Sch, Boston, MA 02115 USA; [Bar-Or, Amit] Univ Penn, Dept Neurol, Ctr Neuroinflammat & Expt Therapeut, Philadelphia, PA 19104 USA; [Bar-Or, Amit] Univ Penn, Dept Neurol, Multiple Sclerosis Div, Philadelphia, PA 19104 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Pennsylvania; University of Pennsylvania	Probert, L (corresponding author), Hellenic Pasteur Inst, Dept Immunol, Athens, Greece.	lesley.probert@gmail.com	Bar-Or, Amit/AIC-1416-2022					Akkermann R, 2017, GLIA, V65, P581, DOI 10.1002/glia.23113; Bar-Or A, 2016, NEUROLOGY, V87, pS12, DOI 10.1212/WNL.0000000000002821; Baruch K, 2016, NAT MED, V22, P135, DOI 10.1038/nm.4022; Chao CC, 2019, CELL, V179, P1483, DOI 10.1016/j.cell.2019.11.016; Cox LM, 2018, NEUROTHERAPEUTICS, V15, P135, DOI 10.1007/s13311-017-0598-8; Dias MC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215372; Galli E, 2019, NAT MED, V25, P1290, DOI 10.1038/s41591-019-0521-4; Hawkins RFW, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.96882; Jelcic I, 2018, CELL, V175, P85, DOI 10.1016/j.cell.2018.08.011; Jhaveri DJ, 2012, DEV NEUROBIOL, V72, P1044, DOI 10.1002/dneu.22027; Jiang SH, 2020, IMMUNOL CELL BIOL, V98, P490, DOI 10.1111/imcb.12339; Kebir H, 2018, J CLIN INVEST, V128, P2000, DOI 10.1172/JCI97098; Knier B, 2018, NAT IMMUNOL, V19, P1341, DOI 10.1038/s41590-018-0237-5; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Mitsdoerffer M, 2013, ANN NY ACAD SCI, V1283, P57, DOI 10.1111/nyas.12118; Miyake S, 2019, J NEUROIMMUNOL, V329, P20, DOI 10.1016/j.jneuroim.2018.07.015; Mohebiany AN, 2020, CELL REP, V30, P1585, DOI 10.1016/j.celrep.2019.12.097; Rothhammer V, 2019, NAT REV IMMUNOL, V19, P184, DOI 10.1038/s41577-019-0125-8; Sagan SA, 2017, JOVE-J VIS EXP, DOI 10.3791/56185; Stephenson EL, 2019, ACS CENTRAL SCI, V5, P1223, DOI 10.1021/acscentsci.9b00327; Wang CH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15508; Wekerle H, 2019, BRAIN, V142, P838, DOI 10.1093/brain/awz068	22	0	0	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 30	2020	11								2012	10.3389/fimmu.2020.02012	http://dx.doi.org/10.3389/fimmu.2020.02012			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OB9FU	33101268	Green Published, gold			2022-12-18	WOS:000578769300001
J	Levinson, M; Khass, M; Burrows, PD; Schroeder, HW				Levinson, Michael; Khass, Mohamed; Burrows, Peter D.; Schroeder, Harry W., Jr.			Replacement of TCR D beta With Immunoglobulin D(H)DSP2.3 Imposes a Tyrosine-Enriched TCR Repertoire and Adversely Affects T Cell Development	FRONTIERS IN IMMUNOLOGY			English	Article						germline selection; CDR-B3; TCRB diversity; Db1; immunoglobulin DSP2; 3	RECEPTOR REPERTOIRES; ANTIGEN; SEQUENCES; SELECTION; MEMBRANE; REQUIRES; AFFINITY	Enrichment for tyrosine in immunoglobulin CDR-H3 is due in large part to natural selection of germline immunoglobulin D(H)sequence. We have previously shown that when D(H)sequence is modified to reduce the contribution of tyrosine codons, epitope recognition is altered and B cell development, antibody production, autoantibody production, and morbidity and mortality following pathogen challenge are adversely affected. TCR beta diversity (D beta) gene segment sequences are even more highly conserved than D-H, with trout D beta 1 identical to human and mouse D beta 1. We hypothesized that natural selection of D beta sequence also shapes CDR-B3 diversity and influences T cell development and T cell function. To test this, we used a mouse strain that lacked D beta 2 and contained a novel D beta 1 allele (D beta YTL) that replaces D beta 1 with an immunoglobulin D-H, DSP2.3. Unlike D beta 1, wherein glycine predominates in all three reading frames (RFs), in DSP2.3 there is enrichment for tyrosine in RF1, threonine in RF2, and leucine in RF3. Mature T cells usingD beta YTLexpressed TCRs enriched at particular CDR-B3 positions for tyrosine but depleted of leucine. Changing D beta sequence altered thymocyte and peripheral T cell numbers and the T cell response to an ovalbumin immunodominant epitope. The differences in tyrosine content might explain, at least in part, why TCRs are more polyspecific and of lower affinity for their cognate antigens than their immunoglobulin counterparts.	[Levinson, Michael; Khass, Mohamed; Schroeder, Harry W., Jr.] Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA; [Khass, Mohamed] Natl Res Ctr, Div Genet Engn & Biotechnol, Cairo, Egypt; [Burrows, Peter D.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; Egyptian Knowledge Bank (EKB); National Research Centre (NRC); University of Alabama System; University of Alabama Birmingham	Schroeder, HW (corresponding author), Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.	hschroeder@uabmc.edu		Schroeder, Harry/0000-0002-3767-6878	 [AI090902];  [AI117703]	; 	This work was supported in part, by AI090902 and AI117703.	Bassing CH, 2000, NATURE, V405, P583, DOI 10.1038/35014635; Batista FD, 1998, IMMUNITY, V8, P751, DOI 10.1016/S1074-7613(00)80580-4; Capra J.D., 2002, THE ANTIBODIES, P43; CIBOTTI R, 1994, J EXP MED, V180, P861, DOI 10.1084/jem.180.3.861; Cohn M., 2008, EUR J IMMUNOL, V38, P1179; Coombs D, 2004, BIOPHYS J, V86, P1408, DOI 10.1016/S0006-3495(04)74211-3; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Ippolito GC, 2006, J EXP MED, V203, P1567, DOI 10.1084/jem.20052217; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; Kabat EA, 1991, SEQUENCES PROTEINS I, P1; Khass M, 2016, EUR J IMMUNOL, V46, P1141; KHASS M, 2020, FRONT IMMUNOL, V0011; Khass M, 2018, IMMUNOL REV, V284, P106, DOI 10.1111/imr.12669; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lam KP, 1999, J EXP MED, V190, P471, DOI 10.1084/jem.190.4.471; Lefranc MP, 2002, DEV COMP IMMUNOL, V26, P697, DOI 10.1016/S0145-305X(02)00026-5; Letunic I, 2016, NUCLEIC ACIDS RES, V44, pW242, DOI 10.1093/nar/gkw290; Ma L, 2016, SCI REP-UK, V6, DOI 10.1038/srep29544; Madi A, 2014, GENOME RES, V24, P1603, DOI 10.1101/gr.170753.113; Nguyen HH, 2007, J VIROL, V81, P9331, DOI 10.1128/JVI.00751-07; Ou JH, 2018, NAT METHODS, V15, P8, DOI 10.1038/nmeth.4555; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; Rudolph MG, 2006, ANNU REV IMMUNOL, V24, P419, DOI 10.1146/annurev.immunol.23.021704.115658; Schelonka RL, 2005, J IMMUNOL, V175, P6624, DOI 10.4049/jimmunol.175.10.6624; Schelonka RL, 2007, EUR J IMMUNOL, V37, P1010, DOI 10.1002/eji.200636569; Schelonka RL, 2008, J IMMUNOL, V181, P8409, DOI 10.4049/jimmunol.181.12.8409; Shah DK, 2014, J IMMUNOL, V192, P4017, DOI 10.4049/jimmunol.1302259; Sleckman BP, 2000, P NATL ACAD SCI USA, V97, P7975, DOI 10.1073/pnas.130190597; Stadinski BD, 2016, NAT IMMUNOL, V17, P946, DOI 10.1038/ni.3491; Teague TK, 2010, INT IMMUNOL, V22, P387, DOI 10.1093/intimm/dxq020; TJOELKER LW, 1990, P NATL ACAD SCI USA, V87, P7856, DOI 10.1073/pnas.87.20.7856; Tsourkas PK, 2012, CELL MOL IMMUNOL, V9, P62, DOI 10.1038/cmi.2011.29; Vale AM, 2013, J EXP MED, V210, P875, DOI 10.1084/jem.20121861; Wang CL, 2010, P NATL ACAD SCI USA, V107, P1518, DOI 10.1073/pnas.0913939107; Wang YY, 2016, PROCEEDINGS OF THE SECOND SUMMIT FORUM OF CHINA'S CULTURAL PSYCHOLOGY, P68; Wong HSC, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0349-5; Yoshida R, 2000, IMMUNOGENETICS, V52, P35, DOI 10.1007/s002510000248; Zemlin M, 2008, J IMMUNOL, V181, P8416, DOI 10.4049/jimmunol.181.12.8416	40	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 29	2020	11								573413	10.3389/fimmu.2020.573413	http://dx.doi.org/10.3389/fimmu.2020.573413			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OB7BI	33133088	gold, Green Published			2022-12-18	WOS:000578622200001
J	Mathur, R; Murugaiyan, G; Khan, MN				Mathur, Ramkumar; Murugaiyan, Gopal; Khan, M. Nadeem			Editorial: Cross-Talk Between Inflammation and Barrier Framework at Mucosal Surfaces in the Lung: Implications for Infections and Pathology	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						lung infection and pathology; mucosal inflammation; epithelial barrier function; mucosal immune response; therapeutic interventions			[Mathur, Ramkumar] Univ North Dakota, Sch Med & Hlth Sci, Dept Geriatr, Grand Forks, ND USA; [Murugaiyan, Gopal] Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, 75 Francis St, Boston, MA 02115 USA; [Murugaiyan, Gopal] Harvard Med Sch, Boston, MA 02115 USA; [Khan, M. Nadeem] Univ North Dakota, Sch Med & Hlth Sci, Dept Biomed Sci, Grand Forks, ND 58202 USA	University of North Dakota Grand Forks; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of North Dakota Grand Forks	Khan, MN (corresponding author), Univ North Dakota, Sch Med & Hlth Sci, Dept Biomed Sci, Grand Forks, ND 58202 USA.	nadeem.khan@und.edu		mathur, Ramkumar/0000-0002-9317-2631	National Institute of Health (NIH) [1 RO1A143741-01A1]	National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the National Institute of Health (NIH) grant 1 RO1A143741-01A1 to MK.		0	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 29	2020	11								598533	10.3389/fimmu.2020.598533	http://dx.doi.org/10.3389/fimmu.2020.598533			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NZ1OR	33133108	Green Published, gold			2022-12-18	WOS:000576861200001
J	Menon, M; Budhwar, R; Shukla, RN; Bankar, K; Vasudevan, M; Ranga, U				Menon, Malini; Budhwar, Roli; Shukla, Rohit Nandan; Bankar, Kiran; Vasudevan, Madavan; Ranga, Udaykumar			The Signature Amino Acid Residue Serine 31 of HIV-1C Tat Potentiates an Activated Phenotype in Endothelial Cells	FRONTIERS IN IMMUNOLOGY			English	Article						HIV-1C; genetic subtypes; Tat; signature amino acid residue; CCL2; endothelial cells; angiogenesis	CLADE-SPECIFIC DIFFERENCES; IN-VITRO; KAPOSIS-SARCOMA; GENE-EXPRESSION; T-CELLS; PROTEIN; PATHOGENESIS; MONOCYTES; INDUCTION; VIVO	The natural cysteine to serine variation at position 31 of Tat in HIV-1C disrupts the dicysteine motif attenuating the chemokine function of Tat. We ask if there exists a trade-off in terms of a gain of function for HIV-1C Tat due to this natural variation. We constructed two Tat-expression vectors encoding Tat proteins discordant for the serine 31 residue (CS-Tat vs. CC-Tat), expressed the proteins in Jurkat cells under doxycycline control, and performed the whole transcriptome analysis to compare the early events of Tat-induced host gene expression. Our analysis delineated a significant enrichment of pathways and gene ontologies associated with the angiogenic signaling events in CS-Tat stable cells. Subsequently, we validated and compared angiogenic signaling events induced by CS- vs. CC-Tat using human umbilical vein endothelial cells (HUVEC) and the human cerebral microvascular endothelial cell line (hCMEC/D3). CS-Tat significantly enhanced the production of CCL2 from HUVEC and induced an activated phenotype in endothelial cells conferring on them enhanced migration, invasion, andin vitromorphogenesis potential. The ability of CS-Tat to induce the activated phenotype in endothelial cells could be of significance, especially in the context of HIV-associated cardiovascular and neuronal disorders. The findings from the present study are likely to help appreciate the functional significance of the SAR (signature amino acid residues) influencing the unique biological properties.	[Menon, Malini; Ranga, Udaykumar] Jawaharlal Nehru Ctr Adv Sci Res, Bangalore, Karnataka, India; [Budhwar, Roli; Shukla, Rohit Nandan; Bankar, Kiran; Vasudevan, Madavan] Bionivid Pvt Ltd, Bangalore, Karnataka, India	Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Ranga, U (corresponding author), Jawaharlal Nehru Ctr Adv Sci Res, Bangalore, Karnataka, India.	udaykumar@jncasr.ac.in		Budhwar, Roli/0000-0001-8494-1606	Department of Biotechnology, Government of India [BT/INF/22/SP27679/2018]; Council of Scientific and Industrial Research [27/320/16-EMR-II]; JNCASR	Department of Biotechnology, Government of India(Department of Biotechnology (DBT) India); Council of Scientific and Industrial Research(Council of Scientific & Industrial Research (CSIR) - India); JNCASR	This work was supported by grants to JNCASR from The Department of Biotechnology, Government of India (Grant No. BT/INF/22/SP27679/2018), the Council of Scientific and Industrial Research (Grant No. 27/320/16-EMR-II), and intramural funds from JNCASR. The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.	Agarwala Manoj Kumar, 2015, Indian Dermatol Online J, V6, P280, DOI 10.4103/2229-5178.160271; Ajasin DO, 2019, ELIFE, V8, DOI 10.7554/eLife.35546; Albini A, 2007, NAT PROTOC, V2, P504, DOI 10.1038/nprot.2006.466; Arese M, 2001, J IMMUNOL, V166, P1380, DOI 10.4049/jimmunol.166.2.1380; Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6; Barillari G, 2002, CLIN MICROBIOL REV, V15, P310, DOI 10.1128/CMR.15.2.310-326.2002; Bonnet F, 2002, HIV Med, V3, P195, DOI 10.1046/j.1468-1293.2002.00117.x; Cantaluppi V, 2001, AIDS RES HUM RETROV, V17, P965, DOI 10.1089/088922201750290087; Chang JR, 2011, J BIOL CHEM, V286, P41125, DOI 10.1074/jbc.M111.268466; Chiozzini C, 2016, CURR DRUG TARGETS, V17, P33, DOI 10.2174/1389450116666150825110658; Coiras M, 2006, PROTEOMICS, V6, pS63, DOI 10.1002/pmic.200500437; Cota-Gomez A, 2002, J BIOL CHEM, V277, P14390, DOI 10.1074/jbc.M108591200; de la Fuente C, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-14; Duan M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060170; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; Eugenin EA, 2006, J NEUROSCI, V26, P1098, DOI 10.1523/JNEUROSCI.3863-05.2006; Fiala Milan, 2004, Cardiovasc Toxicol, V4, P97, DOI 10.1385/CT:4:2:097; Gandhi N, 2009, AIDS RES HUM RETROV, V25, P691, DOI 10.1089/aid.2008.0299; Gibellini D, 2002, VIRUS RES, V90, P337, DOI 10.1016/S0168-1702(02)00253-8; Guidolin D, 2010, MICROSCOPY SCI TECHN, V2, P876; Hemelaar J, 2011, AIDS, V25, P679, DOI 10.1097/QAD.0b013e328342ff93; Hu DJ, 1999, AIDS, V13, P873, DOI 10.1097/00002030-199905280-00002; Huigen MCDG, 2004, EUR J CLIN INVEST, V34, P57, DOI 10.1111/j.1365-2362.2004.01282.x; Ismail M, 2006, EUR J HAEMATOL, V77, P157, DOI 10.1111/j.1600-0609.2006.00682.x; Izmailova E, 2003, NAT MED, V9, P191, DOI 10.1038/nm822; Johri MK, 2011, EXPERT OPIN BIOL TH, V11, P269, DOI 10.1517/14712598.2011.546339; Kedzierska Katherine, 2001, Antiviral Chemistry and Chemotherapy, V12, P133; Kim Jeehyoung, 2016, Dent Hypotheses, V7, P73; KORBER B, 1992, AIDS RES HUM RETROV, V8, P1549, DOI 10.1089/aid.1992.8.1549; Lafrenie RM, 1996, J IMMUNOL, V156, P1638; Lafrenie RM, 1997, J IMMUNOL, V159, P4077; Lee E, 2014, SCI REP-UK, V4, DOI 10.1038/srep07139; Li JCB, 2010, AIDS, V24, P1609, DOI 10.1097/QAD.0b013e32833ac6a0; Li L, 2012, ADV VIROL, V2012, DOI 10.1155/2012/123605; Li WX, 2008, J NEUROSCI, V28, P12190, DOI 10.1523/JNEUROSCI.3019-08.2008; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Ma Chaoyu, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot5034; Matzen K, 2004, VIRUS RES, V104, P145, DOI 10.1016/j.virusres.2004.04.001; Mazzuca P, 2016, NEW MICROBIOL, V39, P163; Mischiati C, 1999, AIDS, V13, P1637, DOI 10.1097/00002030-199909100-00006; Mishra M, 2008, ANN NEUROL, V63, P366, DOI 10.1002/ana.21292; O'Brien J, 2016, JOVE-J VIS EXP, DOI 10.3791/54719; Park IW, 2001, BLOOD, V97, P352, DOI 10.1182/blood.V97.2.352; Paul RH, 2014, J NEUROVIROL, V20, P627, DOI 10.1007/s13365-014-0293-z; Peeters M, 2000, AIDS, V14, pS129; Pugliese A, 2005, CELL BIOCHEM FUNCT, V23, P223, DOI 10.1002/cbf.1147; Ranga U, 2004, J VIROL, V78, P2586, DOI 10.1128/JVI.78.5.2586-2590.2004; Ranjbar S, 2006, J IMMUNOL, V176, P4182, DOI 10.4049/jimmunol.176.7.4182; Rao VR, 2008, J NEUROSCI, V28, P10010, DOI 10.1523/JNEUROSCI.2955-08.2008; Rao VR, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-61; Rayne F, 2010, EMBO J, V29, P1348, DOI 10.1038/emboj.2010.32; Roberts TK, 2012, LAB INVEST, V92, P1213, DOI 10.1038/labinvest.2012.80; Romani B, 2010, J GEN VIROL, V91, P1, DOI 10.1099/vir.0.016303-0; Samikkannu T, 2014, CURR HIV RES, V12, P397; Satishchandra P, 2000, INDIAN J MED RES, V111, P14; SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961; Staton CA, 2009, INT J EXP PATHOL, V90, P195, DOI 10.1111/j.1365-2613.2008.00633.x; Verma A, 2016, J VIROL, V90, P7046, DOI 10.1128/JVI.00308-16; Wadia R S, 2001, J Assoc Physicians India, V49, P343; Weinberger LS, 2005, CELL, V122, P169, DOI 10.1016/j.cell.2005.06.006; Williams DW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069270; Wong JK, 2010, J BIOL CHEM, V285, P18319, DOI 10.1074/jbc.M110.120840; Zhao XC, 2016, VIRUS GENES, V52, P179, DOI 10.1007/s11262-015-1267-9; Zhou F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053145; Zidovetzki R, 1998, AIDS RES HUM RETROV, V14, P825, DOI 10.1089/aid.1998.14.825	66	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 25	2020	11								529614	10.3389/fimmu.2020.529614	http://dx.doi.org/10.3389/fimmu.2020.529614			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OA8EI	33101270	Green Published, gold			2022-12-18	WOS:000578012700001
J	Horman, WSJ; Nguyen, THO; Kedzierska, K; Butler, J; Shan, SH; Layton, R; Bingham, J; Payne, J; Bean, AGD; Layton, DS				Horman, William S. J.; Nguyen, Thi H. O.; Kedzierska, Katherine; Butler, Jeffrey; Shan, Songhua; Layton, Rachel; Bingham, John; Payne, Jean; Bean, Andrew G. D.; Layton, Daniel S.			The Dynamics of the Ferret Immune Response During H7N9 Influenza Virus Infection	FRONTIERS IN IMMUNOLOGY			English	Article						influenza; ferrets; antigen presenting cells; animal model; zoonoses	PRO-INFLAMMATORY CYTOKINE; DENDRITIC CELL SUBSETS; H5N1; INTERFERON; APOPTOSIS; PATHOLOGY; CHARACTERIZE; TRANSMISSION; PATHOGENESIS; SEVERITY	As the recent outbreak of SARS-CoV-2 has highlighted, the threat of a pandemic event from zoonotic viruses, such as the deadly influenza A/H7N9 virus subtype, continues to be a major global health concern. H7N9 virus strains appear to exhibit greater disease severity in mammalian hosts compared to natural avian hosts, though the exact mechanisms underlying this are somewhat unclear. Knowledge of the H7N9 host-pathogen interactions have mainly been constrained to natural sporadic human infections. To elucidate the cellular immune mechanisms associated with disease severity and progression, we used a ferret model to closely resemble disease outcomes in humans following influenza virus infection. Intriguingly, we observed variable disease outcomes when ferrets were inoculated with the A/Anhui/1/2013 (H7N9) strain. We observed relatively reduced antigen-presenting cell activation in lymphoid tissues which may be correlative with increased disease severity. Additionally, depletions in CD8(+)T cells were not apparent in sick animals. This study provides further insight into the ways that lymphocytes maturate and traffic in response to H7N9 infection in the ferret model.	[Horman, William S. J.; Nguyen, Thi H. O.; Kedzierska, Katherine] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Parkville, Vic, Australia; [Horman, William S. J.; Bean, Andrew G. D.; Layton, Daniel S.] Australian Ctr Dis Prevent, Commonwealth Sci & Ind Res Org Hlth & Biosecur, East Geelong, Vic, Australia; [Butler, Jeffrey; Shan, Songhua; Layton, Rachel; Bingham, John; Payne, Jean] Australian Ctr Dis Prevent, Commonwealth Sci & Ind Res Org, East Geelong, Vic, Australia	University of Melbourne; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Layton, DS (corresponding author), Australian Ctr Dis Prevent, Commonwealth Sci & Ind Res Org Hlth & Biosecur, East Geelong, Vic, Australia.	daniel.layton@csiro.au	Layton, Daniel S/J-6117-2017; Bingham, John/H-8591-2013; Nguyen, Thi Hoang Oanh/AAM-6827-2021	Bingham, John/0000-0003-2360-3827; Nguyen, Thi Hoang Oanh/0000-0002-9294-7693; Horman, William/0000-0001-9836-8521; Butler, Jeff/0000-0001-7971-9904	joint CSIRO/University of Melbourne OneHealth Scholarship; CSIRO strategic funding	joint CSIRO/University of Melbourne OneHealth Scholarship; CSIRO strategic funding	WH was supported by a joint CSIRO/University of Melbourne OneHealth Scholarship. This project was supported by CSIRO strategic funding.	Arilahti V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096350; Barman S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002791; Belser JA, 2013, NATURE, V501, P556, DOI 10.1038/nature12391; Belser JA, 2011, DIS MODEL MECH, V4, P575, DOI 10.1242/dmm.007823; Belser JA, 2011, J INFECT DIS, V203, P40, DOI 10.1093/infdis/jiq018; Boonnak K, 2014, J IMMUNOL, V192, P5906, DOI 10.4049/jimmunol.1302992; Butler J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162375; Carolan LA, 2016, J VIROL, V90, P2838, DOI 10.1128/JVI.02797-15; Carolan LA, 2014, J VIROL METHODS, V205, P38, DOI 10.1016/j.jviromet.2014.04.014; Chen Y, 2013, LANCET, V381, P1916, DOI 10.1016/S0140-6736(13)60903-4; Chi Y, 2013, J INFECT DIS, V208, P1962, DOI 10.1093/infdis/jit440; de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477; DiPiazza A, 2016, J VIROL, V90, P7991, DOI 10.1128/JVI.01001-16; Duan M, 2012, J IMMUNOL, V189, P946, DOI 10.4049/jimmunol.1200660; Edenborough KM, 2016, J VIROL, V90, P1888, DOI 10.1128/JVI.01878-15; Friesenhagen J, 2012, J LEUKOCYTE BIOL, V92, P11, DOI 10.1189/jlb.0911479; Hao XL, 2008, J VIROL, V82, P4908, DOI 10.1128/JVI.02367-07; Horman WSJ, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2018.01812; Imai M, 2017, CELL HOST MICROBE, V22, P615, DOI 10.1016/j.chom.2017.09.008; Kuchipudi SV, 2014, VET RES, V45, DOI 10.1186/s13567-014-0118-3; Laurie KL, 2018, J INFECT DIS, V217, P548, DOI 10.1093/infdis/jix509; Layton DS, 2017, J IMMUNOL METHODS, V444, P29, DOI 10.1016/j.jim.2017.02.009; Lee ACY, 2017, J GEN VIROL, V98, P922, DOI 10.1099/jgv.0.000751; Lee ACY, 2015, CLIN VACCINE IMMUNOL, V22, P1235, DOI 10.1128/CVI.00443-15; Misharin AV, 2013, AM J RESP CELL MOL, V49, P503, DOI 10.1165/rcmb.2013-0086MA; Moore IN, 2014, J VIROL, V88, P13879, DOI 10.1128/JVI.02341-14; Morrison J, 2014, J VIROL, V88, P10556, DOI 10.1128/JVI.00570-14; Music N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157903; Nichols JE, 2001, J VIROL, V75, P5921, DOI 10.1128/JVI.73.13.5921-5929.2001; REED L. J., 1938, AMER JOUR HYG, V27, P493; Ryan KA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202675; Shinya K, 2012, J VIROL, V86, P6055, DOI 10.1128/JVI.00365-12; Smith JH, 2011, J VIROL, V85, P7572, DOI 10.1128/JVI.00512-11; Svitek N, 2008, VIROLOGY, V376, P53, DOI 10.1016/j.virol.2008.02.035; Sweet C, 1999, HDB ANIMAL MODELS IN, P989; To KKW, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0498-2; Wang C, 2014, CLIN INFECT DIS, V58, P1095, DOI 10.1093/cid/ciu053; Wang JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029879; Wang YM, 2012, CELL HOST MICROBE, V11, P631, DOI 10.1016/j.chom.2012.05.003; Wang ZF, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7833; Wang ZF, 2014, P NATL ACAD SCI USA, V111, P769, DOI 10.1073/pnas.1321748111; Watanabe T, 2013, NATURE, V501, P551, DOI 10.1038/nature12392; Wibawa H, 2013, COMP IMMUNOL MICROB, V36, P175, DOI 10.1016/j.cimid.2012.12.001; World Health Organization, 2019, INFL HUM AN INT SUMM; Xu LL, 2014, J INFECT DIS, V209, P551, DOI 10.1093/infdis/jit474; Zaynagetdinov R, 2013, AM J RESP CELL MOL, V49, P180, DOI 10.1165/rcmb.2012-0366MA; Zhao CH, 2016, J GEN VIROL, V97, P299, DOI 10.1099/jgv.0.000357; Zhu H, 2013, SCIENCE, V341, P183, DOI 10.1126/science.1239844; Zitzow LA, 2002, J VIROL, V76, P4420, DOI 10.1128/JVI.76.9.4420-4429.2002	49	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 24	2020	11								559113	10.3389/fimmu.2020.559113	http://dx.doi.org/10.3389/fimmu.2020.559113			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NX7TJ	33072098	Green Published, gold			2022-12-18	WOS:000575908400001
J	Cagnazzo, TD; Nogueira, CT; de Castro, CA; Neris, DM; Fattori, ACM; Correia, RD; Albuquerque, YR; Fragelli, BDD; Mendes, TMF; Allegretti, SM; Soares, EG; Romanello, L; Torini, JR; Pereira, HD; Anibal, FD				Cagnazzo, Tulio di Orlando; Nogueira, Camila Tita; de Castro, Cynthia Aparecida; Neris, Debora Meira; Fattori, Ana Carolina Maragno; Correia, Ricardo de Oliveira; Albuquerque, Yulli Roxenne; Fragelli, Bruna Dias de Lima; Mendes, Tiago Manuel Fernandes; Allegretti, Silmara Marques; Soares, Edson Garcia; Romanello, Larissa; Torini, Juliana Roberta; Pereira, Humberto D'Muniz; Anibal, Fernanda de Freitas			Investigating Immunization With Nucleotide Enzymes ofSchistosoma mansoni: Nucleoside Diphosphate Kinase and Adenylosuccinate Lyase as New Antigenic Targets Against Schistosomiasis	FRONTIERS IN IMMUNOLOGY			English	Article						schistosomiasis; Schistosoma mansoni; Nucleoside Diphosphate Kinase; Adenylosuccinate Lyase; immunization	VACCINE CANDIDATE; GENE STRUCTURE; IFN-GAMMA; TNF-ALPHA; RESPONSES; EOSINOPHILS; IMMUNITY; PRAZIQUANTEL; JAPONICUM; GRANULOMA	Schistosomiasis, caused bySchistosoma mansonitrematode worm, affects more than 1.5 million people in Brazil. The current treatment consists in the administration of Praziquantel, the only medicine used for treatment for more than 40 years. Some of the limitations of this drug consist in its inactivity against schistosomula and parasite eggs, the appearance of resistant strains and non-prevention against reinfection. Thus, the objective of this study was to evaluate the effect of immunization with recombinant functional enzymes of the purine salvage pathway ofS. mansoni, Nucleoside Diphosphate Kinase (NDPK) and Adenylosuccinate Lyase (ADSL), to evaluate the host immune response, as well as the parasite load after vaccination. For this, Balb/c mice were divided into 5 groups: control (uninfected and untreated), non-immunized/infected, NDPK infected, ADSL infected, and NDPK + ADSL infected. Immunized groups received three enzyme dosages, with a 15-day interval between each dose, and after 15 days of the last application the animals were infected with 80 cercariae ofS. mansoni. On the 47th day after the infection, fecal eggs were counted and, on the 48th day after the infection, the evaluation of leukocyte response, parasite load, antibody production, cytokines quantification, and histopathological analysis were performed. The results showed that immunizations with NDPK, ADSL or NDPK + ADSL promoted a discreet reduction in eosinophil counts in lavage of peritoneal cavity. All immunized animals showed increased production and secretion of IgG1, IgG2a, and IgE antibodies. Increased production of IL-4 was observed in the group immunized with the combination of both enzymes (NDPK + ADSL). In addition, in all immunized groups there were reductions in egg counts in the liver and intestine, such as reductions in liver granulomas. Thus, we suggest that immunizations with these enzymes could contribute to the reduction of schistosomiasis transmission, besides being important in immunopathogenesis control of the disease.	[Cagnazzo, Tulio di Orlando; Nogueira, Camila Tita; de Castro, Cynthia Aparecida; Neris, Debora Meira; Fattori, Ana Carolina Maragno; Correia, Ricardo de Oliveira; Albuquerque, Yulli Roxenne; Fragelli, Bruna Dias de Lima; Anibal, Fernanda de Freitas] Univ Fed Sao Carlos UFSCar, Dept Morfol & Patol, Lab Inflamacao & Doencas Infecciosas, Sao Carlos, Brazil; [Mendes, Tiago Manuel Fernandes; Allegretti, Silmara Marques] Univ Estadual Campinas, Inst Biol, Dept Biol Anim, Campinas, Brazil; [Soares, Edson Garcia] Univ Sao Paulo, Dept Patol & Med Legal, Lab Citopatol, Ribeirao Preto, Brazil; [Romanello, Larissa; Torini, Juliana Roberta; Pereira, Humberto D'Muniz] Univ Sao Paulo, Inst Fis Sao Carlos, Lab Biol Estrutural, Sao Carlos, Brazil	Universidade Federal de Sao Carlos; Universidade de Sao Paulo; Universidade Estadual de Campinas; Universidade de Sao Paulo; Universidade de Sao Paulo	de Castro, CA; Anibal, FD (corresponding author), Univ Fed Sao Carlos UFSCar, Dept Morfol & Patol, Lab Inflamacao & Doencas Infecciosas, Sao Carlos, Brazil.	cynthiaefi2004@yahoo.com.br; ffanibal@ufscar.br	Fragelli, Bruna Dias de Lima/AIC-8817-2022; Castro, Cynthia Aparecida/GPW-8379-2022; de Castro, Cynthia Aparecida/AIE-5723-2022; Albuquerque, Yulli Roxenne/AAU-4380-2021; de Oliveira Correia, Ricardo/AAU-4391-2021; Castro, Cynthia Aparecida/GQP-6823-2022; Mendes, Tiago/F-7281-2016; Anibal, Fernanda de Freitas/H-5528-2013	Castro, Cynthia Aparecida/0000-0002-2675-8069; de Castro, Cynthia Aparecida/0000-0002-2675-8069; de Oliveira Correia, Ricardo/0000-0003-4498-2440; Castro, Cynthia Aparecida/0000-0002-2675-8069; Dias de Lima Fragelli, Bruna/0000-0002-3970-7834; Albuquerque, Yulli Roxenne/0000-0001-8501-4695; Mendes, Tiago/0000-0002-3630-9099; Anibal, Fernanda de Freitas/0000-0002-7211-0626	FAPESP [2012/05532-8, 202/10213-9, 2014/07331-5, 2012/14223-9]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) [001]	FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	FAPESP 2014/07331-5; FAPESP 2012/14223-9; FAPESP 2012/05532-8; and FAPESP 202/10213-9. TM was financed partially by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) - Finance Code 001.	Abreu PAE, 2004, INFECT IMMUN, V72, P5931, DOI 10.1128/IAI.72.10.5931-5937.2004; Al-Sherbiny M, 2003, ACTA TROP, V88, P117, DOI 10.1016/S0001-706X(03)00195-5; Alebie G., 2014, J BACTERIOL PARASITO, V5, DOI [10.4172/2155-9597.1000189, DOI 10.4172/2155-9597.1000189]; Allen JE, 2011, NAT REV IMMUNOL, V11, P375, DOI 10.1038/nri2992; Brunet LR, 1997, J IMMUNOL, V159, P777; Butterworth AE, 1998, BRIT MED BULL, V54, P357, DOI 10.1093/oxfordjournals.bmb.a011693; Cardoso FC, 2006, CLIN EXP IMMUNOL, V144, P382, DOI 10.1111/j.1365-2249.2006.03081.x; Cioli D, 2004, INT J PARASITOL, V34, P979, DOI 10.1016/j.ijpara.2004.05.001; Colley DG, 2014, PARASITE IMMUNOL, V36, P347, DOI 10.1111/pim.12087; de Moira AP, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000820; Fraga LAD, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-56; DELGADO VS, 1992, PARASITOL RES, V78, P648, DOI 10.1007/BF00931515; DOVEY HF, 1984, MOL BIOCHEM PARASIT, V11, P157, DOI 10.1016/0166-6851(84)90062-8; Farias LP, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000597; Feitosa KA, 2018, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.01000; Fitzsimmons CM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00061; Foulk BW, 2002, INT J PARASITOL, V32, P1487, DOI 10.1016/S0020-7519(02)00161-3; Gause WC, 2013, NAT REV IMMUNOL, V13, P607, DOI 10.1038/nri3476; Gryseels B, 2012, INFECT DIS CLIN N AM, V26, P383, DOI 10.1016/j.idc.2012.03.004; Hall SL, 2011, MOL BIOCHEM PARASIT, V179, P18, DOI 10.1016/j.molbiopara.2011.05.002; Hams E, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00089; Helmy MMF, 2009, EXP PARASITOL, V122, P310, DOI 10.1016/j.exppara.2009.04.006; Henri S, 2002, J IMMUNOL, V169, P929, DOI 10.4049/jimmunol.169.2.929; Hogan SP, 2013, CURR OPIN GASTROEN, V29, P7, DOI 10.1097/MOG.0b013e32835ab29a; Jankovic D, 1999, J IMMUNOL, V162, P345; Jiz M, 2009, INFECT IMMUN, V77, P2051, DOI 10.1128/IAI.00012-09; Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397; Kmoch S, 2000, HUM MOL GENET, V9, P1501, DOI 10.1093/hmg/9.10.1501; McCormick ML, 1996, J IMMUNOL, V157, P5009; Merrifield M, 2016, VACCINE, V34, P2988, DOI 10.1016/j.vaccine.2016.03.079; Ministerio da Saude, 2019, ESQ CAUS SINT TRAT D; Molehin AJ, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-0621-y; Neris DM, 2013, INT TRENDS IMMUN, V1, P49; Neris DM., 2012, EFEITO IMUNIZACAO CO; Oliveira CR, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001894; OLIVIER L, 1952, J PARASITOL, V38, P19, DOI 10.2307/3274166; Olveda DU, 2013, TROP MED SURG, V1, P135; Othman AA, 2015, ACTA TROP, V148, P179, DOI 10.1016/j.actatropica.2015.04.016; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; PELLEGRINO J., 1956, REV BRASIL MALARIOL E DOENCAS TROP, V8, P589; Peng Hong-juan, 2004, Chinese Journal of Parasitology and Parasitic Diseases, V22, P46; Pereira TC, 2008, EXP PARASITOL, V118, P619, DOI 10.1016/j.exppara.2007.11.017; Rezende CMF, 2011, IMMUNOL LETT, V141, P123, DOI 10.1016/j.imlet.2011.09.003; Rofatto HK, 2011, REV BIOL, V6, P54; Romanello L, 2017, MOL BIOCHEM PARASIT, V214, P27, DOI 10.1016/j.molbiopara.2017.03.006; Schramm G, 2010, MICROBES INFECT, V12, P881, DOI 10.1016/j.micinf.2010.06.001; Schwartz C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02492; Senft A W, 1972, Int J Parasitol, V2, P249, DOI 10.1016/0020-7519(72)90013-6; Siddiqui AA, 2011, HUM VACCINES, V7, P1192, DOI 10.4161/hv.7.11.17017; Swartz JM, 2006, BLOOD, V108, P2420, DOI 10.1182/blood-2006-04-015933; de Melo TT, 2010, PARASITE IMMUNOL, V32, P749, DOI 10.1111/j.1365-3024.2010.01244.x; Torini JR, 2019, MOL BIOCHEM PARASIT, V231, DOI 10.1016/j.molbiopara.2019.111187; Tran MH, 2006, NAT MED, V12, P835, DOI 10.1038/nm1430; Tweyongyere R, 2016, PARASITE IMMUNOL, V38, P516, DOI 10.1111/pim.12336; Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2; Wilson RA, 2006, MEM I OSWALDO CRUZ, V101, P13, DOI 10.1590/S0074-02762006000900004; World Health Organization, 2019, NEGLECTED TROPICAL D; World Health Organization, 2020, WHAT IS SCHIST; World Health Organization, 2019, SCHISTOSOMIASIS; Wynn TA, 2000, PARASITOL TODAY, V16, P497, DOI 10.1016/S0169-4758(00)01788-9; Yan YT, 2005, VET PARASITOL, V131, P53, DOI 10.1016/j.vetpar.2005.04.038; Zheng B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00061	62	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 23	2020	11								569988	10.3389/fimmu.2020.569988	http://dx.doi.org/10.3389/fimmu.2020.569988			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NX2EB	33072110	gold, Green Published			2022-12-18	WOS:000575526900001
J	Baratelli, M; Morgan, S; Hemmink, JD; Reid, E; Carr, BV; Lefevre, E; Montaner-Tarbes, S; Charleston, B; Fraile, L; Tchilian, E; Montoya, M				Baratelli, Massimiliano; Morgan, Sophie; Hemmink, Johanneke Dinie; Reid, Elizabeth; Carr, Brigid Veronica; Lefevre, Eric; Montaner-Tarbes, Sergio; Charleston, Bryan; Fraile, Lorenzo; Tchilian, Elma; Montoya, Maria			Identification of a Newly Conserved SLA-II Epitope in a Structural Protein of Swine Influenza Virus	FRONTIERS IN IMMUNOLOGY			English	Article						swine influenza; class II epitopes; swine; IFN gamma; nucleoprotein	MULTIPLE SEQUENCE ALIGNMENT; A VIRUS; T-CELLS; PIGS; CD4(+); INDUCTION	Despite the role of pigs as a source of new Influenza A Virus viruses (IAV) potentially capable of initiating human pandemics, immune responses to swine influenza virus (SwIV) in pigs are not fully understood. Several SwIV epitopes presented by swine MHC (SLA) class I have been identified using different approaches either in outbred pigs or in Babraham large white inbred pigs, which are 85% identical by genome wide SNP analysis. On the other hand, some class II SLA epitopes were recently described in outbred pigs. In this work, Babraham large white inbred pigs were selected to identify SLA II epitopes from SwIV H1N1. PBMCs were screened for recognition of overlapping peptides covering the NP and M1 proteins from heterologous IAV H1N1 in IFN gamma ELISPOT. A novel SLA class II restricted epitope was identified in NP from swine H1N1. This conserved novel epitope could be the base for further vaccine approaches against H1N1 in pigs.	[Baratelli, Massimiliano; Montoya, Maria] Univ Autonoma Barcelona, Ctr Recerca Sanitat Anim CReSA, UAB IRTA, Bellaterra, Spain; [Morgan, Sophie; Hemmink, Johanneke Dinie; Reid, Elizabeth; Carr, Brigid Veronica; Lefevre, Eric; Charleston, Bryan; Tchilian, Elma; Montoya, Maria] Pirbright Inst, Surrey, England; [Montaner-Tarbes, Sergio] Innovex Therapeut SL, Badalona, Spain; [Montaner-Tarbes, Sergio; Fraile, Lorenzo] Univ Lleida, Anim Hlth Dept, Lleida, Spain; [Montoya, Maria] CSIC, CIB, Ctr Invest Biol Margarita Salas, Madrid, Spain	Autonomous University of Barcelona; IRTA; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; Universitat de Lleida; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Montoya, M (corresponding author), Univ Autonoma Barcelona, Ctr Recerca Sanitat Anim CReSA, UAB IRTA, Bellaterra, Spain.; Montoya, M (corresponding author), Pirbright Inst, Surrey, England.; Montoya, M (corresponding author), CSIC, CIB, Ctr Invest Biol Margarita Salas, Madrid, Spain.	maria.montoya@cib.csic.es	Fraile, Lorenzo/A-1142-2009; hemmink, Johanneke Dinie/AAX-5023-2021; Fraile, Lorenzo/AGE-2172-2022; Fraile, Lorenzo/GQQ-8989-2022; Tchilian, Elma/Q-5976-2017	Fraile, Lorenzo/0000-0002-8980-5862; hemmink, Johanneke Dinie/0000-0001-8764-4156; Fraile, Lorenzo/0000-0002-8980-5862; Fraile, Lorenzo/0000-0002-8980-5862; Montaner Tarbes, Sergio/0000-0002-7664-3382; Tchilian, Elma/0000-0002-4869-5118	European Community [FP7-228393]; Spanish Ministry of Science and Innovation [AGL2010-22200-C02-01]; UK's BBSRC grant [BBS/E/I/00002014]; BBSRC [BBS/E/I/00007031, BBS/E/I/00002014, BBS/E/I/00001932] Funding Source: UKRI	European Community(European Commission); Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); UK's BBSRC grant(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	The research leading to these results has received funding from the European Community's Seventh Framework Program (FP7, 2007-2013), the Research Infrastructures Action under grant FP7-228393 (a NADIR project); from the project AGL2010-22200-C02-01 from the Spanish Ministry of Science and Innovation; the UK's BBSRC grant BBS/E/I/00002014.	Baratelli M, 2017, J GEN VIROL, V98, P895, DOI 10.1099/jgv.0.000748; Baratelli M, 2014, RES VET SCI, V96, P380, DOI 10.1016/j.rvsc.2013.12.006; Blanco E, 2000, J VIROL, V74, P4902, DOI 10.1128/JVI.74.10.4902-4907.2000; Chen L, 2014, J VIROL, V88, P11760, DOI 10.1128/JVI.01631-14; Crisci E, 2013, MOL IMMUNOL, V55, P200, DOI 10.1016/j.molimm.2013.02.008; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Fox A, 2018, DRUGS, V78, P1297, DOI 10.1007/s40265-018-0958-7; Gerner W, 2015, MOL IMMUNOL, V66, P3, DOI 10.1016/j.molimm.2014.10.025; Gutierrez AH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159237; Hu YM, 2017, CURR TOP MED CHEM, V17, P2271, DOI 10.2174/1568026617666170224122508; Ito T, 1998, J VIROL, V72, P7367, DOI 10.1128/JVI.72.9.7367-7373.1998; Jensen KK, 2018, IMMUNOLOGY, V154, P394, DOI 10.1111/imm.12889; Katoh K, 2019, BRIEF BIOINFORM, V20, P1160, DOI 10.1093/bib/bbx108; Lefevre EA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032400; Nicholls S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152155; Olson ZF, 2017, VET IMMUNOL IMMUNOP, V185, P57, DOI 10.1016/j.vetimm.2017.01.009; Powell TJ, 2012, J VIROL, V86, P13397, DOI 10.1128/JVI.01820-12; Sant AJ, 2018, IMMUNOL REV, V284, P91, DOI 10.1111/imr.12662; Schwartz JC, 2018, HLA, V92, P40, DOI 10.1111/tan.13281; Smith GJD, 2009, NATURE, V459, P1122, DOI 10.1038/nature08182; Sridhar S, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00195; Swain SL, 2012, NAT REV IMMUNOL, V12, P136, DOI 10.1038/nri3152; Talker SC, 2016, J VIROL, V90, P9364, DOI 10.1128/JVI.01211-16; Talker SC, 2015, VET RES, V46, DOI 10.1186/s13567-015-0182-3; Tungatt K, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007017; Van Reeth K., 2019, DIS SWINE, P576, DOI [10.1002/9781119350927.ch36, DOI 10.1002/9781119350927.CH36]; Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033; Westgeest KB, 2014, J VIROL, V88, P2844, DOI 10.1128/JVI.02163-13; Zhang Y, 2017, NUCLEIC ACIDS RES, V45, pD466, DOI 10.1093/nar/gkw857	29	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 16	2020	11								2083	10.3389/fimmu.2020.02083	http://dx.doi.org/10.3389/fimmu.2020.02083			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NY3DL	33042120	Green Published, gold			2022-12-18	WOS:000576274600001
J	Chen, X; Zhao, MZ; Miao, BP; Liu, ZQ; Yang, G; Liu, JQ; Yang, PC; Song, JP				Chen, Xiao; Zhao, Mei-Zhen; Miao, Bei-Ping; Liu, Zhi-Qiang; Yang, Gui; Liu, Jiang-Qi; Yang, Ping-Chang; Song, Jiang-Ping			Inhibition of Bcl2L12 Attenuates Eosinophilia-Related Inflammation in the Heart	FRONTIERS IN IMMUNOLOGY			English	Article						eosinophilia; heart; myocarditis; inflammation	BCL2-LIKE PROTEIN 12; B-CELLS; APOPTOSIS; EXPRESSION; MYOCARDITIS	Background:The eosinophilic inflammation plays a critical role in myocarditis (Mcd); its underlying mechanism remains to be further elucidated. This study aims to investigate the role of Bcl2-like protein 12 (Bcl2L12) in inducing the defects of apoptosis in eosinophils (Eos) of the heart tissues. Methods:Human explant heart samples were collected. Eosinophilia and myocarditis (Mcd)-like inflammation were induced in the mouse heart by immunizing with murine cardiac alpha-myosin heavy chain (MyHC alpha) peptides. Results:Markedly more Eos were observed in heart tissues from patients with Mcd than those from patients with dilated cardiomyopathy. Eos isolated from Mcd hearts showed the signs of apoptosis defects. The Eo counts in the Mcd heart tissues were positively correlated with the Bcl2L12 expression in Eos isolated from the heart tissues. Exposure to interleukin 5 in the culture induced the expression of Bcl2L12 in Eos. Bcl2L12 bound c-Myc, the transcription factor of Fas ligand (FasL), to prevent c-Myc from binding to the FasL promoter, to restrict the FasL gene transcription in Eos. Inhibition of Bcl2L12 prevented the induction of eosinophilia and Mcd-like inflammation in the mouse heart. Conclusions:The Bcl2L12 expression contributes to apoptosis defects in Eos of the Mcd heart. Blocking Bcl2L12 prevents the eosinophilia induction and alleviates Mcd-like inflammation in mice.	[Chen, Xiao; Song, Jiang-Ping] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Cardiovasc Dis, Natl Ctr Cardiovasc Dis, Pima Hosp, Beijing, Peoples R China; [Zhao, Mei-Zhen; Liu, Zhi-Qiang; Liu, Jiang-Qi; Yang, Ping-Chang] Shenzhen Univ, Res Ctr Allergy & Immunol, Sch Med, Shenzhen, Peoples R China; [Miao, Bei-Ping] Shenzhen Univ, Affiliated Hosp 1, Dept Otolaryngol, Shenzhen, Peoples R China; [Yang, Gui] Longgang Cent Hosp, Dept Otolaryngol, Shenzhen, Peoples R China; [Yang, Ping-Chang] Guangdong Prov Key Lab Reg Immun & Dis, Shenzhen, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Peking Union Medical College; Shenzhen University; Shenzhen University	Song, JP (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Cardiovasc Dis, Natl Ctr Cardiovasc Dis, Pima Hosp, Beijing, Peoples R China.; Yang, PC (corresponding author), Shenzhen Univ, Res Ctr Allergy & Immunol, Sch Med, Shenzhen, Peoples R China.	pcy2356@szu.edu.cn; fwsongjiangping@hotmail.com			Shanghai Municipal Science and Technology Major Project [2017SHZDZX01]; CAMS In-Novation Fund for Medical Sciences (CIFMS) [2016-I2M-1-015]; National Nature and Science Foundation of China [81870706, 31570932, 81700888, 81701589]; Guangdong Provincial Key Laboratory of Regional Immunity and Diseases [2019B030301009]; Shenzhen science, technology and innovation committee [KQTD20170331145453160, KQJSCX20180328095619081]	Shanghai Municipal Science and Technology Major Project; CAMS In-Novation Fund for Medical Sciences (CIFMS); National Nature and Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Provincial Key Laboratory of Regional Immunity and Diseases; Shenzhen science, technology and innovation committee	This study was supported by grants of Shanghai Municipal Science and Technology Major Project (Grant No. 2017SHZDZX01), CAMS In-Novation Fund for Medical Sciences (CIFMS, 2016-I2M-1-015), the National Nature and Science Foundation of China (81870706, 31570932, 81700888, and 81701589), Guangdong Provincial Key Laboratory of Regional Immunity and Diseases (2019B030301009) and Shenzhen science, technology and innovation committee (KQTD20170331145453160 and KQJSCX20180328095619081). The open access publication fee will be paid by the grants of CAMS In-Novation Fund for Medical Sciences (CIFMS, 2016-I2M-1-015).	Agarwal Ritesh, 2011, J Infect Public Health, V4, P235, DOI 10.1016/j.jiph.2011.08.006; Arakaki R, 2014, CRIT REV IMMUNOL, V34, P301, DOI 10.1615/CritRevImmunol.2014009988; Bandeira-Melo C, 2002, J IMMUNOL, V168, P4756, DOI 10.4049/jimmunol.168.9.4756; Blyszczuk P, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00064; Brambatti M, 2017, J AM COLL CARDIOL, V70, P2363, DOI 10.1016/j.jacc.2017.09.023; Busse W, 2019, J ALLERGY CLIN IMMUN, V143, P190, DOI 10.1016/j.jaci.2018.08.031; Chen L, 2019, EUR HEART J, V40, P1690, DOI 10.1093/eurheartj/ehz172; Chen X, 2018, CIRCULATION, V138, P2559, DOI 10.1161/CIRCULATIONAHA.118.033890; Chen X, 2017, INT J CARDIOL, V229, P75, DOI 10.1016/j.ijcard.2016.11.263; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Filippone RT, 2019, INFLAMM BOWEL DIS, V25, P1140, DOI 10.1093/ibd/izz024; Fulkerson PC, 2014, J IMMUNOL, V193, P4043, DOI 10.4049/jimmunol.1400732; Fung G, 2016, CIRC RES, V118, P496, DOI 10.1161/CIRCRESAHA.115.306573; Guo XT, 2017, CELL BIOCHEM FUNCT, V35, P77, DOI 10.1002/cbf.3250; Hirasawa M, 2003, INT ARCH ALLERGY IMM, V130, P73, DOI 10.1159/000068371; Ilmarinen P, 2014, BASIC CLIN PHARMACOL, V114, P109, DOI 10.1111/bcpt.12163; Ishihara K, 2000, BBA-MOL BASIS DIS, V1501, P25, DOI 10.1016/S0925-4439(00)00002-8; Jayaraman S, 1999, J IMMUNOL, V162, P1717; Johnson-Weaver BT, 2018, J ALLERGY CLIN IMMUN, V141, P791, DOI 10.1016/j.jaci.2017.07.043; Kandikattu HK, 2019, CYTOKINE GROWTH F R, V47, P83, DOI 10.1016/j.cytogfr.2019.05.003; Kankaanranta H, 2000, J ALLERGY CLIN IMMUN, V106, P77; Klion AD, 2015, HEMATOL-AM SOC HEMAT, P92, DOI 10.1182/asheducation-2015.1.92; Kuchynka P, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/2829583; Li MG, 2018, J IMMUNOL, V201, P725, DOI 10.4049/jimmunol.1800139; Lu W, 2016, SCI REP-UK, V6, DOI 10.1038/srep21620; NEU N, 1987, J IMMUNOL, V139, P3630; Nussinovitch U, 2010, CURR PHARM DESIGN, V16, P3574, DOI 10.2174/138161210793797870; Real LM, 2014, LIVER INT, V34, P558, DOI 10.1111/liv.12330; Reddy J, 2013, CURR OPIN RHEUMATOL, V25, P502, DOI 10.1097/BOR.0b013e3283620036; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Scorilas A, 2001, GENOMICS, V72, P217, DOI 10.1006/geno.2000.6455; Song Tengyao, 2017, BMJ Case Rep, V2017, DOI 10.1136/bcr-2016-218992; Stegh AH, 2007, GENE DEV, V21, P98, DOI 10.1101/gad.1480007; Stegh AH, 2011, CELL CYCLE, V10, P33, DOI 10.4161/cc.10.1.14365; Timmer T, 2002, J PATHOL, V196, P125, DOI 10.1002/path.1028; Xue JM, 2017, ALLERGY, V72, P1704, DOI 10.1111/all.13186; Zhang H, 2013, J CLIN INVEST, V123, P2306, DOI 10.1172/JCI67554; Zhang SW, 2018, BIOMED PHARMACOTHER, V97, P1189, DOI 10.1016/j.biopha.2017.11.002	38	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 11	2020	11								1955	10.3389/fimmu.2020.01955	http://dx.doi.org/10.3389/fimmu.2020.01955			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NX9DW	33013849	gold, Green Published			2022-12-18	WOS:000576003400001
J	Khass, M; Levinson, M; Schelonka, RL; Kapoor, P; Burrows, PD; Schroeder, HW				Khass, Mohamed; Levinson, Michael; Schelonka, Robert L.; Kapoor, Pratibha; Burrows, Peter D.; Schroeder, Harry W., Jr.			Preimmune Control of the Variance of TCR CDR-B3: Insights Gained From Germline Replacement of a TCR D beta Gene Segment With an Ig D(H)Gene Segment	FRONTIERS IN IMMUNOLOGY			English	Article						germline; T cell receptor; gene segment; immunoglobulin; D gene segment	B-CELL DEVELOPMENT; H READING FRAME; BONE-MARROW; REPERTOIRE; DIVERSITY; SELECTION	We have previously shown that the sequence of the immunoglobulin diversity gene segment (D-H) helps dictate the structure and composition of complementarity determining region 3 of the immunoglobulin heavy chain (CDR-H3). In order to test the role of germline D sequence on the diversity of the preimmune TCR beta repertoire of T cells, we generated a mouse with a mutant TCR beta DJC locus wherein the D beta 2-J beta 2 gene segment cluster was deleted and the remaining diversity gene segment, D beta 1 (IMGT:TRDB1), was replaced with DSP2.3 (IMGT:IGHD2-02), a commonly used B cell immunoglobulin D(H)gene segment. Crystallographic studies have shown that the length and thus structure of TCR CDR-B3 places amino acids at the tip of CDR-B3 in a position to directly interact with peptide bound to an MHC molecule. The length distribution of complementarity determining region 3 of the T cell receptor beta chain (CDR-B3) has been proposed to be restricted largely by MHC-specific selection, disfavoring CDR-B3 that are too long or too short. Here we show that the mechanism of control of CDR-B3 length depends on the D beta sequence, which in turn dictates exonucleolytic nibbling. By contrast, the extent of N addition and the variance of created CDR3 lengths are regulated by the cell of origin, the thymocyte. We found that the sequence of the D and control of N addition collaborate to bias the distribution of CDR-B3 lengths in the pre-immune TCR repertoire and to focus the diversity provided by N addition and the sequence of the D on that portion of CDR-B3 that is most likely to interact with the peptide that is bound to the presenting MHC.	[Khass, Mohamed; Levinson, Michael; Kapoor, Pratibha] Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA; [Khass, Mohamed] Natl Res Ctr, Div Genet Engn & Biotechnol, Cairo, Egypt; [Schelonka, Robert L.] Oregon Hlth & Sci Univ, Div Neonatol, Dept Pediat, Portland, OR USA; [Burrows, Peter D.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; [Schroeder, Harry W., Jr.] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Dept Med Microbiol & Genet, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; Egyptian Knowledge Bank (EKB); National Research Centre (NRC); Oregon Health & Science University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Schroeder, HW (corresponding author), Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Dept Med Microbiol & Genet, Birmingham, AL 35294 USA.	hschroeder@uabmc.edu		Schroeder, Harry/0000-0002-3767-6878	 [AI090902];  [AI117703]	; 	This work was supported, in part, by AI090902 and AI117703.	Bassing CH, 2000, NATURE, V405, P583, DOI 10.1038/35014635; BOGUE M, 1992, P NATL ACAD SCI USA, V89, P11011, DOI 10.1073/pnas.89.22.11011; FEENEY AJ, 1992, J IMMUNOL, V149, P222; GU H, 1991, IMMUNOL TODAY, V12, P420, DOI 10.1016/0167-5699(91)90146-K; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; Kabat EA, 1991, SEQUENCES PROTEINS I, P1; Khass M, 2018, IMMUNOL REV, V284, P106, DOI 10.1111/imr.12669; Khass M, 2013, EUR J IMMUNOL, V43, P629, DOI 10.1002/eji.201242936; Lefranc MP, 2002, DEV COMP IMMUNOL, V26, P697, DOI 10.1016/S0145-305X(02)00026-5; LU J, 2019, NAT COMMUN, V10; Motea EA, 2010, BBA-PROTEINS PROTEOM, V1804, P1151, DOI 10.1016/j.bbapap.2009.06.030; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Schelonka RL, 2010, J IMMUNOL, V185, P6075, DOI 10.4049/jimmunol.1001419; Schroeder HW, 2010, CRIT REV IMMUNOL, V30, P327; Silva-Sanchez A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118171; Sleckman BP, 2000, P NATL ACAD SCI USA, V97, P7975, DOI 10.1073/pnas.130190597; Teague TK, 2010, INT IMMUNOL, V22, P387, DOI 10.1093/intimm/dxq020; Trad A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00385; Vale AM, 2015, ANN NY ACAD SCI, V1362, P48, DOI 10.1111/nyas.12808; Vale AM, 2013, J EXP MED, V210, P875, DOI 10.1084/jem.20121861; Vale AM, 2010, J IMMUNOL, V185, P6085, DOI 10.4049/jimmunol.1001423; Wong HSC, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0349-5; Zemlin M, 2002, IMMUNOL RES, V26, P265, DOI 10.1385/IR:26:1-3:265; Zemlin M, 2008, J IMMUNOL, V181, P8416, DOI 10.4049/jimmunol.181.12.8416	24	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 11	2020	11								2079	10.3389/fimmu.2020.02079	http://dx.doi.org/10.3389/fimmu.2020.02079			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NX8AI	33042119	gold, Green Published			2022-12-18	WOS:000575926500001
J	Frade-Barros, AF; Ianni, BM; Cabantous, S; Pissetti, CW; Saba, B; Lin-Wang, HT; Buck, P; Marin-Neto, JA; Schmidt, A; Dias, F; Hirata, MH; Sampaio, M; Fragata, A; Pereira, AC; Donadi, E; Rodrigues, V; Kalil, J; Chevillard, C; Cunha-Neto, E				Farage Frade-Barros, Amanda; Ianni, Barbara Maria; Cabantous, Sandrine; Pissetti, Cristina Wide; Saba, Bruno; Lin-Wang, Hui Tzu; Buck, Paula; Marin-Neto, Jose Antonio; Schmidt, Andre; Dias, Fabricio; Hirata, Mario Hiroyuki; Sampaio, Marcelo; Fragata, Abilio; Pereira, Alexandre Costa; Donadi, Eduardo; Rodrigues, Virmondes; Kalil, Jorge; Chevillard, Christophe; Cunha-Neto, Edecio			Polymorphisms in Genes Affecting Interferon-gamma Production and Th1 T Cell Differentiation Are Associated With Progression to Chagas Disease Cardiomyopathy (vol 11, 1386, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						Chagas disease; cardiomyopathy; susceptibility; IL12; IL 10; IFN; IL4			[Farage Frade-Barros, Amanda; Ianni, Barbara Maria; Buck, Paula; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med FMUSP, Heart Inst InCor, Sao Paulo, Brazil; [Farage Frade-Barros, Amanda; Kalil, Jorge; Cunha-Neto, Edecio] INCT, Inst Invest Immunol 3, Sao Paulo, Brazil; [Farage Frade-Barros, Amanda; Cabantous, Sandrine] Aix Marseille Univ, INSERM, GIMP UMR S906, Marseille, France; [Farage Frade-Barros, Amanda; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil; [Farage Frade-Barros, Amanda; Kalil, Jorge] Univ Brasil, Inst Tecnol, Bioengn Program, Sao Paulo, Brazil; [Pissetti, Cristina Wide; Rodrigues, Virmondes] Univ Fed Triangulo Mineiro UFTM, Immunol Lab, Uberaba, Brazil; [Saba, Bruno; Lin-Wang, Hui Tzu; Sampaio, Marcelo; Fragata, Abilio] Inst Cardiol Dante Pazzanese IDPC, Lab Invest Mol Cardiol, Sao Paulo, Brazil; [Marin-Neto, Jose Antonio; Schmidt, Andre; Dias, Fabricio; Donadi, Eduardo] Univ Sao Paulo, Sch Med Ribeirao Preto FMRP, Ribeirao Preto, Brazil; [Hirata, Mario Hiroyuki] Univ Sao Paulo, Fac Pharmaceut Sci, Dept Clin & Toxicol Anal, Sao Paulo, Brazil; [Chevillard, Christophe] Aix Marseille Univ, INSERM, UMR 1090, TAGC Theories & Approaches Genom Complex, Marseille, France	Universidade de Sao Paulo; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Universidade de Sao Paulo; Universidade Brasil; Universidade Federal do Triangulo Mineiro; Universidade de Sao Paulo; Universidade de Sao Paulo; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Frade-Barros, AF (corresponding author), Univ Sao Paulo, Sch Med FMUSP, Heart Inst InCor, Sao Paulo, Brazil.; Frade-Barros, AF (corresponding author), INCT, Inst Invest Immunol 3, Sao Paulo, Brazil.; Frade-Barros, AF (corresponding author), Aix Marseille Univ, INSERM, GIMP UMR S906, Marseille, France.; Frade-Barros, AF (corresponding author), Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.; Frade-Barros, AF (corresponding author), Univ Brasil, Inst Tecnol, Bioengn Program, Sao Paulo, Brazil.	amanda.frade@universidadebrasil.edu.br	Cunha-Neto, Edecio/B-4157-2009; Inserm U1090, TAGC/ABE-9980-2021; Chevillard, Christophe/A-7087-2015; Hirata, Mario Hiroyuki/C-9718-2013; Schmidt, André/G-1569-2011; Pereira, Alexandre/HHN-1038-2022	Cunha-Neto, Edecio/0000-0002-3699-3345; Chevillard, Christophe/0000-0002-5269-8813; Hirata, Mario Hiroyuki/0000-0002-9521-7979; Schmidt, André/0000-0002-1090-8165; 				Frade-Barros AF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01386	1	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 10	2020	11								593759	10.3389/fimmu.2020.593759	http://dx.doi.org/10.3389/fimmu.2020.593759			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NW7AX		gold, Green Published			2022-12-18	WOS:000575170100001
J	Di Rosa, F				Di Rosa, F.			Editorial: Serafino Zappacosta and the Ceppellini School: A Pioneer Model for Nurturing Education in Immunology (vol 11, 1524, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						education; innate immunity; adaptive immunity; MHC; vaccination												Di Rosa F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01524	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 8	2020	11								600832	10.3389/fimmu.2020.600832	http://dx.doi.org/10.3389/fimmu.2020.600832			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NV3VT		Green Published, gold			2022-12-18	WOS:000574254400001
J	Feinberg, MW				Feinberg, Mark W.			Editorial: The Role of Oxidative Stress, Epigenetics and Non-coding RNA in Regulating Trained Immunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						trained immunity; epigenetics; oxidative stress; non-coding RNA; stem cells			[Feinberg, Mark W.] Brigham & Womens Hosp, Dept Med, Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA; [Feinberg, Mark W.] Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Feinberg, MW (corresponding author), Brigham & Womens Hosp, Dept Med, Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA.; Feinberg, MW (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	mfeinberg@bwh.harvard.edu		Feinberg, Mark/0000-0001-9523-3859	National Institutes of Health [HL115141, HL134849, HL148207, HL148355]; American Heart Association [18SFRN33900144, 20SFRN35200163]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association)	This work was supported by the National Institutes of Health (HL115141, HL134849, HL148207, HL148355) and the American Heart Association (18SFRN33900144 and 20SFRN35200163).	Bekkering S, 2016, ATHEROSCLEROSIS, V254, P228, DOI 10.1016/j.atherosclerosis.2016.10.019; Bekkering S, 2014, ARTERIOSCL THROM VAS, V34, P1731, DOI 10.1161/ATVBAHA.114.303887; Christ A, 2018, CELL, V172, P162, DOI 10.1016/j.cell.2017.12.013; Gourbal B, 2018, IMMUNOL REV, V283, P21, DOI 10.1111/imr.12647; Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109; Mai JT, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-61; Mitroulis I, 2018, CELL, V172, P147, DOI 10.1016/j.cell.2017.11.034; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6; Schnack L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00013	9	0	0	3	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 8	2020	11								2114	10.3389/fimmu.2020.02114	http://dx.doi.org/10.3389/fimmu.2020.02114			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NV3VQ	33013891	gold, Green Published			2022-12-18	WOS:000574254100001
J	Pereira, AL; Jouhault, Q; Lopez, EM; Cosma, A; Lambotte, O; Le Grand, R; Lehmann, MH; Tchitchek, N				Leite Pereira, Adrien; Jouhault, Quentin; Marcos Lopez, Ernesto; Cosma, Antonio; Lambotte, Olivier; Le Grand, Roger; Lehmann, Michael H.; Tchitchek, Nicolas			Modulation of Cell Surface Receptor Expression by Modified Vaccinia Virus Ankara in Leukocytes of Healthy and HIV-Infected Individuals	FRONTIERS IN IMMUNOLOGY			English	Article						AIDS; chemokine; cytokine; mass cytometry; modified vaccinia virus Ankara; poxvirus; surface marker; vaccination	DENDRITIC CELLS; CHEMOKINE RECEPTORS; GENE-EXPRESSION; ADVERSE EVENTS; CYTOMETRY DATA; CCR5; VACCINATION; MATURATION; SAFETY; MVA	Viral vectors are increasingly used as delivery means to induce a specific immunity in humans and animals. However, they also impact the immune system, and it depends on the given context whether this is beneficial or not. The attenuated vaccinia virus strain modified vaccinia virus Ankara (MVA) has been used as a viral vector in clinical studies intended to treat and prevent cancer and infectious diseases. The adjuvant property of MVA is thought to be due to its capability to stimulate innate immunity. Here, we confirmed that MVA induces interleukin-8 (IL-8), and this chemokine was upregulated significantly more in monocytes and HLA-DR(bright)dendritic cells (DCs) of HIV-infected patients on combined antiretroviral therapy (ART) than in cells of healthy persons. The effect of MVA on cell surface receptors is mostly unknown. Using mass cytometry profiling, we investigated the expression of 17 cell surface receptors in leukocytes afterex vivoinfection of human whole-blood samples with MVA. We found that MVA downregulates most of the characteristic cell surface markers in particular types of leukocytes. In contrast, C-X-C motif chemokine receptor 4 (CXCR4) was significantly upregulated in each leukocyte type of healthy persons. Additionally, we detected a relative higher cell surface expression of the HIV-1 co-receptors C-C motif chemokine receptor 5 (CCR5) and CXCR4 in leukocytes of HIV-ART patients than in healthy persons. Importantly, we showed that MVA infection significantly downregulated CCR5 in CD4+ T cells, CD8+ T cells, B cells, and three different DC populations. CD86, a costimulatory molecule for T cells, was significantly upregulated in HLA-(DRDCs)-D-bright after MVA infection of whole blood from HIV-ART patients. However, MVA was unable to downregulate cell surface expression of CD11b and CD32 in monocytes and neutrophils of HIV-ART patients to the same extent as in monocytes and neutrophils of healthy persons. In summary, MVA modulates the expression of many different kinds of cell surface receptors in leukocytes, which can vary in cells originating from persons previously infected with other pathogens.	[Leite Pereira, Adrien; Jouhault, Quentin; Marcos Lopez, Ernesto; Cosma, Antonio; Lambotte, Olivier; Le Grand, Roger; Tchitchek, Nicolas] Univ Paris Sud 11, CEA, IDMIT Infrastruct, INSERM U1184,Immunol Viral Infect & Autoimmune Di, Fontenay Aux Roses, France; [Lambotte, Olivier] Ctr Immunol Viral Infect & Autoimmune Dis, INSERM U1184, Le Kremlin Bicetre, France; [Lambotte, Olivier] Hop Univ Paris Saclay, AP HP, Serv Med Interne & Immunol Clin, Le Kremlin Bicetre, France; [Lehmann, Michael H.] Ludwig Maximilians Univ Munchen, Inst Infect Dis & Zoonoses, Munich, Germany	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; University of Munich	Tchitchek, N (corresponding author), Univ Paris Sud 11, CEA, IDMIT Infrastruct, INSERM U1184,Immunol Viral Infect & Autoimmune Di, Fontenay Aux Roses, France.; Lehmann, MH (corresponding author), Ludwig Maximilians Univ Munchen, Inst Infect Dis & Zoonoses, Munich, Germany.	Michael.Lehmann@lmu.de; nicolas.tchitchek@sorbonne-universite.fr	Lehmann, Michael H./A-1983-2013; Lambotte, Olivier/GRT-0160-2022	Lehmann, Michael H./0000-0002-1037-8600; Tchitchek, Nicolas/0000-0003-3307-0446; Cosma, Antonio/0000-0002-3686-8034	French Government "Programme d'Investissements d'Avenir" (PIA) [ANR-11-INBS-0008, ANR-10-EQPX-0201]; ANRS (France Recherche Nord & Sud Sida-hiv Hepatites)	French Government "Programme d'Investissements d'Avenir" (PIA)(French National Research Agency (ANR)); ANRS (France Recherche Nord & Sud Sida-hiv Hepatites)(French National Research Agency (ANR))	The IDMIT infrastructure was supported by the French Government "Programme d'Investissements d'Avenir" (PIA) under Grant ANR-11-INBS-0008 and grant ANR-10-EQPX-0201 (FlowCyTech facility). NT was supported by fellowships from the ANRS (France Recherche Nord & Sud Sida-hiv Hepatites).	Afonso P, 2017, ANTIVIR THER, V22, P645, DOI 10.3851/IMP3160; Altenburg AF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08719-y; Amato RJ, 2012, FUTURE ONCOL, V8, P231, DOI [10.2217/FON.12.7, 10.2217/fon.12.7]; Bachelerie F, 2014, PHARMACOL REV, V66, P1, DOI 10.1124/pr.113.007724; Baden LR, 2018, J INFECT DIS, V218, P633, DOI 10.1093/infdis/jiy212; Blanchard TJ, 1998, J GEN VIROL, V79, P1159, DOI 10.1099/0022-1317-79-5-1159; Brandler S, 2010, J VIROL, V84, P5314, DOI 10.1128/JVI.02329-09; Casey CG, 2005, JAMA-J AM MED ASSOC, V294, P2734, DOI 10.1001/jama.294.21.2734; Chen B, 2019, TRENDS MICROBIOL, V27, P878, DOI 10.1016/j.tim.2019.06.002; Chen LP, 2013, NAT REV IMMUNOL, V13, P227, DOI 10.1038/nri3405; Condit RC, 2016, VACCINE, V34, P6610, DOI 10.1016/j.vaccine.2016.04.060; Cosma A, 2003, VACCINE, V22, P21, DOI 10.1016/S0264-410X(03)00538-3; Dai Y, 2003, CELL CYCLE, V2, P467, DOI 10.4161/cc.2.5.465; De Pablo C, 2012, ANTIVIR THER, V17, P1615, DOI 10.3851/IMP2357; Drexler I, 1998, J GEN VIROL, V79, P347, DOI 10.1099/0022-1317-79-2-347; Drillien R, 2004, J GEN VIROL, V85, P2167, DOI 10.1099/vir.0.79998-0; Duffy D, 2012, IMMUNITY, V37, P917, DOI 10.1016/j.immuni.2012.07.015; Gomez CE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141456; Elhmouzi-Younes J, 2017, CYTOM PART A, V91A, P969, DOI 10.1002/cyto.a.23107; Finck R, 2013, CYTOM PART A, V83A, P483, DOI 10.1002/cyto.a.22271; Gilbert SC, 2013, VACCINE, V31, P4241, DOI 10.1016/j.vaccine.2013.03.020; Greenough TC, 2008, VACCINE, V26, P6883, DOI 10.1016/j.vaccine.2008.09.084; Guerra S, 2007, J VIROL, V81, P8707, DOI 10.1128/JVI.00444-07; Gupta RK, 2019, NATURE, V568, P244, DOI 10.1038/s41586-019-1027-4; Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905; Iyer SS, 2014, VACCINES, V2, P160, DOI 10.3390/vaccines2010160; Kastenmuller W, 2006, VIROLOGY, V350, P276, DOI 10.1016/j.virol.2006.02.039; Kochhar S, 2019, VACCINE, V37, P5796, DOI 10.1016/j.vaccine.2018.08.085; Kreijtz JHCM, 2014, LANCET INFECT DIS, V14, P1196, DOI [10.1016/s1473-3099(14)70963-6, 10.1016/S1473-3099(14)70963-6]; Kremer Melanie, 2012, Methods Mol Biol, V890, P59, DOI 10.1007/978-1-61779-876-4_4; Kretzschmar M, 2006, PLOS MED, V3, P1341, DOI 10.1371/journal.pmed.0030272; Kutscher S, 2010, GENE THER, V17, P1372, DOI 10.1038/gt.2010.90; Lehmann MH, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0252-1; Lehmann MH, 2009, J VIROL, V83, P2540, DOI 10.1128/JVI.01884-08; Lemaitre J, 2020, J INNATE IMMUN, V12, P170, DOI 10.1159/000499841; Liu L, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-15; Lopalco L, 2010, VIRUSES-BASEL, V2, P574, DOI 10.3390/v2020574; MAHNEL H, 1994, BERL MUNCH TIERARZTL, V107, P253; MAYR A, 1964, ZENTBL BAKTERIOLOG P, V195, P24; McFadden G, 2005, NAT REV MICROBIOL, V3, P201, DOI 10.1038/nrmicro1099; Medina-Echeverz J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12998-6; Moss B, 1996, Adv Exp Med Biol, V397, P7; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Norder M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011400; Palgen JL, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0175-8; Pascutti MF, 2011, J VIROL, V85, P5532, DOI 10.1128/JVI.02267-10; Pereira AL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01777; Pereira AL, 2018, CYTOKINE, V111, P97, DOI 10.1016/j.cyto.2018.08.018; Pittman PR, 2019, NEW ENGL J MED, V381, P1897, DOI 10.1056/NEJMoa1817307; Ponnan SM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213911; Price PJR, 2013, VACCINE, V31, P4231, DOI 10.1016/j.vaccine.2013.03.017; Qiu P, 2011, NAT BIOTECHNOL, V29, P886, DOI 10.1038/nbt.1991; Roszer T, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7080103; Rosati M, 2001, J IMMUNOL, V167, P1654, DOI 10.4049/jimmunol.167.3.1654; Routy JP, 2017, AIDS RES THER, V14, DOI 10.1186/s12981-017-0164-9; Royo S, 2014, J VIROL, V88, P5511, DOI 10.1128/JVI.00468-14; Sanchez-Ramon S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02936; Shalekoff S, 2001, J CLIN IMMUNOL, V21, P390, DOI 10.1023/A:1013121625962; SOKOLOSKI JA, 1993, BLOOD, V82, P625; Topfer E, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/478408; Viegas EO, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206838; Wilen CB, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006866; WYATT LS, 1995, VIROLOGY, V210, P202, DOI 10.1006/viro.1995.1332; Zicari S, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030200	64	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 8	2020	11								2096	10.3389/fimmu.2020.02096	http://dx.doi.org/10.3389/fimmu.2020.02096			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NV3VD	33013882	Green Accepted, gold, Green Published			2022-12-18	WOS:000574252800001
J	Skevaki, C; Thornton, CA				Skevaki, Chrysanthi; Thornton, Catherine A.			Editorial: Early Life Origins of Immune-Mediated Disease	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						pregnancy; infancy; microbiome; breast milk; fetal programming			[Skevaki, Chrysanthi] Philipps Univ Marburg, Inst Lab Med, Univ Giessen & Marburg Lung Ctr UGMLC, German Ctr Lung Res DZL, Marburg, Germany; [Thornton, Catherine A.] Swansea Univ, Sch Med, Inst Life Sci, Swansea, W Glam, Wales	Philipps University Marburg; Swansea University	Thornton, CA (corresponding author), Swansea Univ, Sch Med, Inst Life Sci, Swansea, W Glam, Wales.	c.a.thornton@swansea.ac.uk			Universities Giessen and Marburg Lung Center (UGMLC); German Center for Lung Research (DZL); University Hospital Giessen and Marburg (UKGM); Deutsche Forschungsgemeinschaft (DFG) [SFB 1021, KFO 309, SK 317/1-1, 428518790]; Diabetes UK; Welsh Government Ser Cymru Programme	Universities Giessen and Marburg Lung Center (UGMLC); German Center for Lung Research (DZL); University Hospital Giessen and Marburg (UKGM); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Diabetes UK(Diabetes UK); Welsh Government Ser Cymru Programme	CS was supported by the Universities Giessen and Marburg Lung Center (UGMLC), the German Center for Lung Research (DZL), University Hospital Giessen and Marburg (UKGM) research funding according to article 2, section 3 cooperation agreement, and the Deutsche Forschungsgemeinschaft (DFG)-funded SFB 1021 (C04), KFO 309 (P10), and SK 317/1-1 (Project No. 428518790). CT was supported by Diabetes UK and Welsh Government Ser Cymru Programme.		0	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 3	2020	11								2050	10.3389/fimmu.2020.02050	http://dx.doi.org/10.3389/fimmu.2020.02050			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NQ0FZ	33013866	gold, Green Published			2022-12-18	WOS:000570546000001
J	Soria-Juan, B; Escacena, N; Capilla-Gonzalez, V; Aguilera, Y; Llanos, L; Tejedo, JR; Bedoya, FJ; Juan, V; De la Cuesta, A; Ruiz-Salmeron, R; Andreu, E; Grochowicz, L; Prosper, F; Sanchez-Guijo, F; Lozano, FS; Miralles, M; Del Rio-Sola, L; Castellanos, G; Moraleda, JM; Sackstein, R; Garcia-Arranz, M; Garcia-Olmo, D; Martin, F; Hmadcha, A; Soria, B				Soria-Juan, Barbara; Escacena, Natalia; Capilla-Gonzalez, Vivian; Aguilera, Yolanda; Llanos, Lucia; Tejedo, Juan R.; Bedoya, Francisco J.; Juan, Veronica; De la Cuesta, Antonio; Ruiz-Salmeron, Rafael; Andreu, Enrique; Grochowicz, Lukas; Prosper, Felipe; Sanchez-Guijo, Fermin; Lozano, Francisco S.; Miralles, Manuel; Del Rio-Sola, Lourdes; Castellanos, Gregorio; Moraleda, Jose M.; Sackstein, Robert; Garcia-Arranz, Mariano; Garcia-Olmo, Damian; Martin, Franz; Hmadcha, Abdelkrim; Soria, Bernat		Collaborative Working Grp Noma Pr	Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus (vol 10, 1151, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						cellular medicaments; cell-based therapy; clinical trials; diabetes; critical limb ischemia; cost-effective			[Soria-Juan, Barbara; Llanos, Lucia; Garcia-Arranz, Mariano; Garcia-Olmo, Damian] Fdn Jimenez Diaz, Hlth Res Inst, Madrid, Spain; [Escacena, Natalia; Capilla-Gonzalez, Vivian; Aguilera, Yolanda; Tejedo, Juan R.; Bedoya, Francisco J.; Martin, Franz; Hmadcha, Abdelkrim; Soria, Bernat] Univ Seville, Univ Pablo Olavide, Andalusian Ctr Mol Biol & Regenerat Med CABIMER, Dept Regenerat & Cell Therapy,CSIC, Seville, Spain; [Tejedo, Juan R.; Bedoya, Francisco J.; Martin, Franz; Hmadcha, Abdelkrim; Soria, Bernat] Spanish Biomed Res Ctr Diabet & Associated Metab, Madrid, Spain; [Juan, Veronica] Andalusian eHlth Lib, Seville, Spain; [De la Cuesta, Antonio] Hosp Victoria Eugenia Cruz Roja, Unidad Isquemia Cron Miembros Inferiores, Seville, Spain; [Ruiz-Salmeron, Rafael] Hosp Univ Virgen Macarena, Serv Cardiol, Seville, Spain; [Andreu, Enrique; Grochowicz, Lukas; Prosper, Felipe] Clin Univ Navarra, Pamplona, Spain; [Sanchez-Guijo, Fermin; Lozano, Francisco S.] IBSAL Hosp Univ Salamanca, Salamanca, Spain; [Miralles, Manuel] Univ Valencia, Dept Surg, Valencia, Spain; [Del Rio-Sola, Lourdes] Hosp Univ Valladolid, Cirugia Vasc, Valladolid, Spain; [Castellanos, Gregorio; Moraleda, Jose M.] Hosp Clin Univ Virgen Arrixaca, Serv Hematol Hemoterapia, Murcia, Spain; [Sackstein, Robert] Florida Int Univ, Herbert Wertheim Coll Med, Miami, FL 33199 USA; [Soria, Bernat] Univ Miguel Hernandez Elche, ISABIAL, Alicante, Spain; [Soria, Bernat] Univ Miguel Hernandez Elche, Inst Bioengn, Alicante, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; University of Sevilla; CSIC - Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); Hospital Universitario Virgen Macarena; University of Navarra; University of Valencia; Hospital Clinico Universitario Virgen de la Arrixaca; State University System of Florida; Florida International University; General University Hospital of Alicante; Universidad Miguel Hernandez de Elche; Universitat d'Alacant; Instituto de Investigacion Sanitaria y Biomedica de Alicante (ISABIAL); Universidad Miguel Hernandez de Elche	Hmadcha, A; Soria, B (corresponding author), Univ Seville, Univ Pablo Olavide, Andalusian Ctr Mol Biol & Regenerat Med CABIMER, Dept Regenerat & Cell Therapy,CSIC, Seville, Spain.; Hmadcha, A; Soria, B (corresponding author), Spanish Biomed Res Ctr Diabet & Associated Metab, Madrid, Spain.; Soria, B (corresponding author), Univ Miguel Hernandez Elche, ISABIAL, Alicante, Spain.; Soria, B (corresponding author), Univ Miguel Hernandez Elche, Inst Bioengn, Alicante, Spain.	khmadcha@gmail.com; bernat.soria@umh.es	Sanchez-Guijo, Fermin/D-8542-2018; Martin, Franz/K-4197-2014; Prosper, Felipe/H-6859-2017; Tejedo, Juan R./AAN-8865-2021; , Bernat/AAL-6470-2021; Andreu, Enrique J/F-9813-2016; Aguilera, Yolanda/C-2177-2017; Bedoya, Francisco/AAX-8812-2021; Bedoya, Francisco J/R-4871-2018; Hmadcha, Abdelkrim/T-1173-2019	Sanchez-Guijo, Fermin/0000-0002-7076-7739; Martin, Franz/0000-0002-5745-8704; Prosper, Felipe/0000-0001-6115-8790; Tejedo, Juan R./0000-0002-8434-7516; Andreu, Enrique J/0000-0001-5317-9989; Aguilera, Yolanda/0000-0001-6601-8324; Bedoya, Francisco/0000-0003-0262-7029; Bedoya, Francisco J/0000-0003-0262-7029; Hmadcha, Abdelkrim/0000-0002-4105-3702; Soria, Bernat/0000-0002-2356-0380				George MJ, 2018, STEM CELL TRANSL MED, V7, P731, DOI 10.1002/sctm.18-0015; Moll G, 2019, TRENDS MOL MED, V25, P149, DOI 10.1016/j.molmed.2018.12.006; Moll G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085040; Soria-Juan B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01151	4	0	0	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 2	2020	11								2029	10.3389/fimmu.2020.02029	http://dx.doi.org/10.3389/fimmu.2020.02029			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NQ0TW	32983148	gold, Green Published			2022-12-18	WOS:000570582200001
J							Frontiers Prod Off	Editorial: NKT Cells in Cancer Immunotherapy (vol 11, 1314, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						iNKT; CD1d; dendritic cells; alpha-GalCer; cancer; immunotherapy			[Frontiers Prod Off] Frontiers Media SA, Lausanne, Switzerland		Frontiers Media SA, Lausanne, Switzerland.							Webb TJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01314	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 31	2020	11								594504	10.3389/fimmu.2020.594504	http://dx.doi.org/10.3389/fimmu.2020.594504			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NQ3ZF	32983185	gold, Green Published			2022-12-18	WOS:000570802300001
J	Litjens, NHR; Langerak, AW; van der List, ACJ; Klepper, M; de Bie, M; Azmani, Z; den Dekker, AT; Brouwer, RWW; Betjes, MGH; Van IJcken, WFJ				Litjens, Nicolle H. R.; Langerak, Anton W.; van der List, Amy C. J.; Klepper, Mariska; de Bie, Maaike; Azmani, Zakia; den Dekker, Alexander T.; Brouwer, Rutger W. W.; Betjes, Michiel G. H.; Van IJcken, Wilfred F. J.			Validation of a Combined Transcriptome and T Cell Receptor Alpha/Beta (TRA/TRB) Repertoire Assay at the Single Cell Level for Paucicellular Samples	FRONTIERS IN IMMUNOLOGY			English	Article						single cell transcriptomics; single T cell receptor repertoire analysis; cDNA; combined transcriptome and T cell receptor repertoire assay; low cell number	FLOW-CYTOMETRIC ANALYSIS; SEQUENCE; LINKING	Transcriptomics can be combined with TRA and TRB clonotype analysis at the single cell level. The aim of this study was to validate this approach on the ICELL8 Single-Cell system and to evaluate its usefulness to analyse clinical paucicellular samples. For this purpose, we carefully selected T cell lines with defined TRA/TRB clonotypes as well as clinical samples enriched for CD3(+)T cells that possess a complex TCR repertoire. Low cell numbers of the different samples were dispensed in a chip on the ICELL8 Single-Cell System. Two sequencing libraries were generated from each single cell cDNA preparation, one for the TRA/TRB repertoire and one for the 5 ' ends of transcripts, and subsequently sequenced. Transcriptome analysis revealed that the cell lines on average express 2,268 unique genes/cell and T cells of clinical samples 770 unique genes/cell. The expected combined TRA/TRB clonotype was determined for on average 71% of the cells of the cell lines. In the clinical samples the TRA/TRB repertoire was more complex than those of the cell lines. Furthermore, the TRB clonotype distribution of the clinical samples was positively correlated to frequencies of TCRV beta families in CD3(+)T cells obtained by a flow cytometry-based approach (Spearman's Rho correlation coefficient 0.81,P= 6.49*10(-7)). Combined analyses showed that transcriptome-based cell type-specific clusters in clinical samples corresponded to clinical features such as CMV status. In conclusion, we showed that the ICELL8 Single-Cell System enabled combined interrogation of both TRA/TRB repertoire and transcriptome of paucicellular clinical samples. This opens the way to study the response of single T cells within heterogeneous samples for both their transcriptome and TRA/TRB clonotypes in disease or upon treatment.	[Litjens, Nicolle H. R.; van der List, Amy C. J.; Klepper, Mariska; Betjes, Michiel G. H.] Erasmus MC, Univ Med Ctr, Dept Internal Med, Sect Nephrol & Transplantat, Rotterdam, Netherlands; [Langerak, Anton W.; de Bie, Maaike] Erasmus MC, Univ Med Ctr, Dept Immunol, Lab Med Immunol, Rotterdam, Netherlands; [Azmani, Zakia; den Dekker, Alexander T.; Brouwer, Rutger W. W.; Van IJcken, Wilfred F. J.] Erasmus MC, Univ Med Ctr, Ctr Biom, Rotterdam, Netherlands; [Azmani, Zakia; den Dekker, Alexander T.; Brouwer, Rutger W. W.; Van IJcken, Wilfred F. J.] Erasmus MC, Univ Med Ctr, Dept Cell Biol, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Litjens, NHR (corresponding author), Erasmus MC, Univ Med Ctr, Dept Internal Med, Sect Nephrol & Transplantat, Rotterdam, Netherlands.; Van IJcken, WFJ (corresponding author), Erasmus MC, Univ Med Ctr, Ctr Biom, Rotterdam, Netherlands.; Van IJcken, WFJ (corresponding author), Erasmus MC, Univ Med Ctr, Dept Cell Biol, Rotterdam, Netherlands.	n.litjens@erasmusmc.nl; w.vanijcken@erasmusmc.nl	Brouwer, Rutger/AAI-4731-2021; van ijcken, willem/N-9805-2018	van ijcken, willem/0000-0002-0421-8301; den Dekker, Alexander/0000-0002-3353-8101; Brouwer, Rutger/0000-0001-7524-6230; van der List, Amy/0000-0002-4163-2317				Aarts M, 2017, GENE DEV, V31, P2085, DOI 10.1101/gad.297796.117; Bergiers I, 2018, ELIFE, V7, DOI [10.7554/elife.29312, 10.7554/eLife.29312]; Betjes MGH, 2011, KIDNEY INT, V80, P209, DOI 10.1038/ki.2011.110; Betjes MGH, 2009, J AM SOC NEPHROL, V20, P2661, DOI 10.1681/ASN.2009040400; Cunningham F, 2019, NUCLEIC ACIDS RES, V47, pD745, DOI 10.1093/nar/gky1113; De Simone M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01638; Eltahla AA, 2016, IMMUNOL CELL BIOL, V94, P604, DOI 10.1038/icb.2016.16; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; Goldstein LD, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3893-1; Han A, 2014, NAT BIOTECHNOL, V32, P684, DOI 10.1038/nbt.2938; Hester J., 2019, J OPEN SOURCE SOFTW, V4, P1686, DOI [10.21105/joss.01686, DOI 10.21105/JOSS.01686]; Huang H, 2019, P NATL ACAD SCI USA, V116, P8995, DOI 10.1073/pnas.1902649116; Huang L, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01826; Huang L, 2015, IMMUN AGEING, V12, DOI 10.1186/s12979-015-0055-7; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kohler S, 2005, EUR J IMMUNOL, V35, P1987, DOI 10.1002/eji.200526181; Laks E, 2019, CELL, V179, P1207, DOI 10.1016/j.cell.2019.10.026; Langerak AW, 2001, BLOOD, V98, P165, DOI 10.1182/blood.V98.1.165; Legut M, 2015, CELL MOL IMMUNOL, V12, P656, DOI 10.1038/cmi.2015.28; Li B, 2016, NAT GENET, V48, P725, DOI 10.1038/ng.3581; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Litjens NHR, 2013, CLIN EXP IMMUNOL, V174, P179, DOI 10.1111/cei.12152; Litjens NHR, 2008, J IMMUNOL METHODS, V330, P1, DOI 10.1016/j.jim.2007.10.013; Litjens NHR, 2011, IMMUN AGEING, V8, DOI 10.1186/1742-4933-8-2; Litjens NHR, 2009, BLOOD, V114, P3947, DOI 10.1182/blood-2009-03-211896; Marie-Paule leFranc GL, 2001, T CELL RECEPTOR FACT; Meijers RWJ, 2013, CLIN EXP IMMUNOL, V174, P424, DOI 10.1111/cei.12188; Meijers RWJ, 2012, IMMUN AGEING, V9, DOI 10.1186/1742-4933-9-19; Miles JJ, 2011, IMMUNOL CELL BIOL, V89, P375, DOI 10.1038/icb.2010.139; Nikolich-Zugich J, 2004, NAT REV IMMUNOL, V4, P123, DOI 10.1038/nri1292; Papalexi E, 2018, NAT REV IMMUNOL, V18, P35, DOI 10.1038/nri.2017.76; Quinlan Aaron R, 2014, Curr Protoc Bioinformatics, V47, DOI 10.1002/0471250953.bi1112s47; Regev Aviv, 2017, Elife, V6, DOI 10.7554/eLife.27041; Sandberg Y, 2007, LEUKEMIA, V21, P230, DOI 10.1038/sj.leu.2404486; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Valihrach L, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030807; van der Maaten L, 2008, J MACH LEARN RES, V9, P2579; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Ye J, 2013, NUCLEIC ACIDS RES, V41, pW34, DOI 10.1093/nar/gkt382; Zhang JJ, 2014, BIOINFORMATICS, V30, P614, DOI 10.1093/bioinformatics/btt593	40	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 28	2020	11								1999	10.3389/fimmu.2020.01999	http://dx.doi.org/10.3389/fimmu.2020.01999			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NU4HQ	33013853	Green Published, gold			2022-12-18	WOS:000573603900001
J	Riis, JL; Ahmadi, H; Silke, O; Granger, SW; Bryce, CI; Granger, DA				Riis, Jenna L.; Ahmadi, Hedyeh; Silke, Olivia; Granger, Steve W.; Bryce, Crystal I.; Granger, Douglas A.			Correspondence Between Cytomegalovirus Immunoglobulin-G Levels Measured in Saliva and Serum	FRONTIERS IN IMMUNOLOGY			English	Article						cytomegalovirus; saliva; serum; immunoglobulin-G; antibody; cytokine	SOCIOECONOMIC DISPARITIES; INFECTION; MUCOSAL; MARKERS; STRESS; SEROPREVALENCE; REACTIVATION; STUDENTS	Human cytomegalovirus (HCMV) infects more than 80% of the global population. While mostly asymptomatic, HCMV infection can be serious among the immunocompromised, and it is implicated in chronic disease pathophysiology in adulthood. Large-scale minimally invasive HCMV screening could advance research and public health efforts to monitor infection prevalence and prevent or mitigate downstream risks associated with infection. We examine the utility of measuring HCMV immunoglobulin-G (IgG) levels in saliva as an index of serum levels. Matched serum and saliva samples from healthy adults (N= 98; 44% female; 51% white) were assayed for HCMV IgG, total salivary protein, and salivary markers related to oral inflammation, blood, and tissue integrity. We examine the serum-saliva association for HCMV IgG and assess the influence of participant characteristics and factors specific to the oral compartment (e.g., oral inflammation) on HCMV IgG levels and cross-specimen relations. We found a robust serum-saliva association for HCMV IgG with serum antibody levels accounting for >60% of the variance in salivary levels. This relation remained after adjusting for key demographic and oral immune-related variables. Compared to the serum test, the salivary HCMV IgG test had 51% sensitivity and 97% specificity. With improvements in assay performance and sample optimization, HCMV antibody levels in oral fluids may be a useful proxy for serum levels.	[Riis, Jenna L.; Ahmadi, Hedyeh; Bryce, Crystal I.; Granger, Douglas A.] Univ Calif Irvine, Inst Interdisciplinary Salivary Biosci Res, Irvine, CA 92697 USA; [Riis, Jenna L.; Silke, Olivia; Granger, Douglas A.] Univ Calif Irvine, Dept Psychol Sci, Irvine, CA 92697 USA; [Granger, Steve W.; Granger, Douglas A.] Salimetr Res & Technol Ctr, Carlsbad, CA USA; [Bryce, Crystal I.] Arizona State Univ, T Denny Sanford Sch Social & Family Dynam, Tempe, AZ USA; [Granger, Douglas A.] Johns Hopkins Univ, Sch Nursing, Dept Acute & Chron Care, Baltimore, MD USA; [Granger, Douglas A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Granger, Douglas A.] Univ Nebraska, Dept Psychol, Salivary Biosci Lab, Lincoln, NE 68588 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; Arizona State University; Arizona State University-Tempe; Johns Hopkins University; Johns Hopkins University; University of Nebraska System; University of Nebraska Lincoln	Riis, JL (corresponding author), Univ Calif Irvine, Inst Interdisciplinary Salivary Biosci Res, Irvine, CA 92697 USA.; Riis, JL (corresponding author), Univ Calif Irvine, Dept Psychol Sci, Irvine, CA 92697 USA.	jriis@uci.edu		Silke, Olivia/0000-0002-2452-1498	National Institutes of Health [LOI2-BIO-19]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the National Institutes of Health: LOI2-BIO-19.	Amin MM, 2018, CLIN INFECT DIS, V67, P587, DOI 10.1093/cid/ciy143; [Anonymous], 2013, EPIDEMIOLOGY; [Anonymous], 2017, CTR DIS CONTROL PREV; Bate SL, 2010, CLIN INFECT DIS, V50, P1439, DOI 10.1086/652438; Bishop NC, 2009, FRONT BIOSCI-LANDMRK, V14, P4444, DOI 10.2741/3540; Brandtzaeg P, 2007, ANN NY ACAD SCI, V1098, P288, DOI 10.1196/annals.1384.012; Brandtzaeg P, 2013, J ORAL MICROBIOL, V5, DOI 10.3402/jom.v5i0.20401; Burgdorf KS, 2019, BRAIN BEHAV IMMUN, V79, P152, DOI 10.1016/j.bbi.2019.01.026; Burgener B, 2010, J ENDODONT, V36, P1307, DOI 10.1016/j.joen.2010.04.018; Cannon MJ, 2010, REV MED VIROL, V20, P202, DOI 10.1002/rmv.655; Colugnati FAB, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-71; Dollard Sheila C, 2014, BMC Res Notes, V7, P776, DOI 10.1186/1756-0500-7-776; Dowd JB, 2009, EPIDEMIOL INFECT, V137, P58, DOI 10.1017/S0950268808000551; Dowd JB, 2013, EXP GERONTOL, V48, P385, DOI 10.1016/j.exger.2013.01.016; Dowd JB, 2012, HEALTH PSYCHOL, V31, P5, DOI 10.1037/a0025337; Elwenspoek MMC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01263; Feinstein L, 2016, MECH AGEING DEV, V158, P53, DOI 10.1016/j.mad.2016.06.001; Goodrum F, 2016, ANNU REV VIROL, V3, P333, DOI 10.1146/annurev-virology-110615-042422; Granger DA., 2020, SALIVARY BIOSCIENCE; Heaney JLJ, 2018, BIOMARKERS, V23, P115, DOI 10.1080/1354750X.2016.1265009; Hettegger P, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218456; Huang Y, 2018, J INFECT DIS, V217, P1069, DOI 10.1093/infdis/jix679; Kivlighan KT, 2004, HORM BEHAV, V46, P39, DOI 10.1016/j.yhbeh.2004.01.006; Kuo CP, 2008, CLIN MICROBIOL INFEC, V14, P221, DOI 10.1111/j.1469-0691.2007.01895.x; La Rosa C, 2012, FUTURE VIROL, V7, P279, DOI 10.2217/FVL.12.8; Lee JY, 2007, ORAL DIS, V13, P550, DOI 10.1111/j.1601-0825.2006.01332.x; LI F, 2017, PLOS ONE, V0012; Manicklal S, 2013, CLIN MICROBIOL REV, V26, P86, DOI 10.1128/CMR.00062-12; Mehta SK, 2000, J INFECT DIS, V182, P1761, DOI 10.1086/317624; Melnick M, 2012, EXP MOL PATHOL, V92, P118, DOI 10.1016/j.yexmp.2011.10.011; Morrison KM, 2019, J VIROL, V93, DOI 10.1128/JVI.01608-18; Naucler Cecilia Soderberg, 2019, Oncotarget, V10, P4333, DOI 10.18632/oncotarget.27016; Nishanian P, 1998, CLIN DIAGN LAB IMMUN, V5, P507, DOI 10.1128/CDLI.5.4.507-512.1998; Prince HE, 2014, CLIN VACCINE IMMUNOL, V21, P1377, DOI 10.1128/CVI.00487-14; Prosch S, 2000, VIROLOGY, V272, P357, DOI 10.1006/viro.2000.0367; Reed RG, 2019, BRAIN BEHAV IMMUN, V80, P266, DOI 10.1016/j.bbi.2019.03.018; Riis J.L., 2020, SALIVARY BIOSCIENCE; Riis Jenna L, 2020, Brain Behav Immun Health, V1, DOI 10.1016/j.bbih.2019.100014; Riis JL, 2017, PEPTIDES, V91, P58, DOI 10.1016/j.peptides.2017.03.006; Roberts ET, 2010, AM J EPIDEMIOL, V172, P363, DOI 10.1093/aje/kwq177; Ross S A, 2011, Infect Disord Drug Targets, V11, P466; Sarid O, 2004, RES NURS HEALTH, V27, P370, DOI 10.1002/nur.20028; Sarid O, 2003, Psychol Health Med, V8, P106, DOI 10.1080/1354850021000059313; Schwartz EB, 2004, CLIN CHEM, V50, P654, DOI 10.1373/clinchem.2003.028266; Shenk T, 2008, HUMAN CYTOMEGALOVIRU, DOI [10.1007/978-3-540-77349-8_1, DOI 10.1007/978-3-540-77349-8_1]; Simanek AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016103; Sorsa T, 2004, ORAL DIS, V10, P311, DOI 10.1111/j.1601-0825.2004.01038.x; Trueba AF, 2012, PHYSIOL BEHAV, V105, P841, DOI 10.1016/j.physbeh.2011.10.014; U.S. Department of Health and Human Services, 2000, ORAL HLTH AM A, V44, P16, DOI [10.1089/pop.2013.0038, DOI 10.1089/POP.2013.0038]; Zhang J, 2015, MED SCI MONITOR, V21, P4102, DOI 10.12659/MSM.896071; Zuhair M, 2019, REV MED VIROL, V29, DOI 10.1002/rmv.2034	51	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 28	2020	11								2095	10.3389/fimmu.2020.02095	http://dx.doi.org/10.3389/fimmu.2020.02095			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NQ0DL	32983163	Green Published, gold			2022-12-18	WOS:000570539300001
J	Serrano, A; Cervera, R; Gris, JC				Serrano, Antonio; Cervera, Ricard; Gris, Jean Christophe			Editorial: Primary Antiphospholipid Syndrome	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						PAPS; APS; thrombosis; B2GP1; PS/PT; cardiolipin			[Serrano, Antonio] Hosp Univ 12 Octubre, Dept Immunol, Madrid, Spain; [Cervera, Ricard] Hosp Clin Barcelona, Dept Autoimmune Dis, Barcelona, Spain; [Gris, Jean Christophe] CHU Nimes, Dept Haematol, Nimes, France; [Gris, Jean Christophe] Univ Montpellier, Nimes, France; [Gris, Jean Christophe] IM Sechenov First Moscow State Med Univ, Moscow, Russia	Hospital Universitario 12 de Octubre; University of Barcelona; Hospital Clinic de Barcelona; Universite de Montpellier; CHU de Nimes; Universite de Montpellier; Sechenov First Moscow State Medical University	Serrano, A (corresponding author), Hosp Univ 12 Octubre, Dept Immunol, Madrid, Spain.	autoimmunity.transplant@gmail.com		Serrano, Antonio/0000-0003-1993-640X	Fondo de Investigaciones Sanitarias. Instituto de Salud Carlos III [P117-0147]; European Regional Development Fund	Fondo de Investigaciones Sanitarias. Instituto de Salud Carlos III(Instituto de Salud Carlos III); European Regional Development Fund(European Commission)	AS was funded in part by Grant P117-0147 from Fondo de Investigaciones Sanitarias. Instituto de Salud Carlos III (Cofunded with European Regional Development Fund).	ALARCONSEGOVIA D, 1989, J RHEUMATOL, V16, P482; ASHERSON RA, 1988, J RHEUMATOL, V15, P1742; FONT J, 1988, MED CLIN-BARCELONA, V91, P736; Ruffatti A, 2009, ANN RHEUM DIS, V68, P397, DOI 10.1136/ard.2008.096669; Sciascia S, 2017, NAT REV RHEUMATOL, V13, DOI 10.1038/nrrheum.2017.124	5	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 28	2020	11								1993	10.3389/fimmu.2020.01993	http://dx.doi.org/10.3389/fimmu.2020.01993			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NQ0AY	32983139	gold, Green Published			2022-12-18	WOS:000570532600001
J	Zhou, YB; Meng, ZR; Ying, BW				Zhou, Yanbing; Meng, Zirui; Ying, Binwu			Commentary: Epidemiology of Antibody-Positive Autoimmune Encephalitis in Southwest China: A Multicenter Study	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						autoimmune encephalitis; epidemiology; neuronal autoantibodies; thyroid peroxidase antibodies; glasgow outcome scale; modified rankin scale; response to immunotherapy in epilepsy and encephalopathy score	NMDA RECEPTOR ENCEPHALITIS; AUTOANTIBODIES; DIAGNOSIS		[Zhou, Yanbing; Meng, Zirui; Ying, Binwu] Sichuan Univ, West China Hosp, Dept Lab Med, Chengdu, Peoples R China	Sichuan University	Ying, BW (corresponding author), Sichuan Univ, West China Hosp, Dept Lab Med, Chengdu, Peoples R China.	binwuying@126.com						BATES D, 1977, ANN NEUROL, V2, P211, DOI 10.1002/ana.410020306; Beers SR, 2012, J NEUROTRAUM, V29, P1126, DOI 10.1089/neu.2011.2272; Bien CI, 2019, J NEUROIMMUNOL, V334, DOI 10.1016/j.jneuroim.2019.576975; Dubey D, 2018, J NEUROIMMUNOL, V323, P62, DOI 10.1016/j.jneuroim.2018.07.009; Ferracci F, 2003, NEUROLOGY, V60, P712, DOI 10.1212/01.WNL.0000048660.71390.C6; Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9; Gresa-Arribas N, 2014, LANCET NEUROL, V13, P167, DOI 10.1016/S1474-4422(13)70282-5; Gu YX, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02611; Huang XQ, 2015, INT J CLIN EXP MED, V8, P18927; Husari KS, 2019, NEUROTHERAPEUTICS, V16, P685, DOI 10.1007/s13311-019-00750-3; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; LANGFITT TW, 1978, J NEUROSURG, V48, P673, DOI 10.3171/jns.1978.48.5.0673; Lee WJ, 2016, NEUROLOGY, V86, P1683, DOI 10.1212/WNL.0000000000002635; Li J, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00440; Lim JA, 2019, ANN NEUROL, V85, P352, DOI 10.1002/ana.25421; Liu TN, 2019, MULT SCLER RELAT DIS, V28, P177, DOI 10.1016/j.msard.2018.12.036; McMillan T, 2016, NAT REV NEUROL, V12, P477, DOI 10.1038/nrneurol.2016.89; Ricken G, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00841; Titulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1	19	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 28	2020	11								1976	10.3389/fimmu.2020.01976	http://dx.doi.org/10.3389/fimmu.2020.01976			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NP9YR	32983134	gold, Green Published			2022-12-18	WOS:000570526500001
J	Zeng, C; Shao, ZB; Li, JW; Pan, H; Xing, FY				Zeng, Chong; Shao, Zhongbao; Li, Jiwei; Pan, Hao; Xing, Feiyue			Commentary: Metabolites released from apoptotic cells act as tissue messengers	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						metabolites; apoptosis; pannexin 1; neighboring cell; gene expression	FIND-ME SIGNAL; MOLECULAR-MECHANISMS; DEATH		[Zeng, Chong] Southern Med Univ, Peoples Hosp Shunde 1, Shunde Hosp, Med Res Ctr, Foshan, Peoples R China; [Shao, Zhongbao] Guangzhou Coll Technol & Business, Dept Elect Informat Engn, Guangzhou, Peoples R China; [Li, Jiwei] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Peoples R China; [Pan, Hao] Guangzhou Univ Chinese Med, Sch Basic Med Sci, Res Ctr Integrat Med, Guangzhou, Peoples R China; [Xing, Feiyue] Jinan Univ, Dept Immunobiol, Inst Tissue Transplantat & Immunol, Guangzhou, Peoples R China; [Xing, Feiyue] Jinan Univ, MOE Key Lab Tumor Mol Biol, Key Lab Funct Prot Res Guangdong Higher Educ Inst, Guangzhou, Peoples R China	Southern Medical University - China; Zhengzhou University; Guangzhou University of Chinese Medicine; Jinan University; Jinan University	Zeng, C (corresponding author), Southern Med Univ, Peoples Hosp Shunde 1, Shunde Hosp, Med Res Ctr, Foshan, Peoples R China.; Xing, FY (corresponding author), Jinan Univ, Dept Immunobiol, Inst Tissue Transplantat & Immunol, Guangzhou, Peoples R China.; Xing, FY (corresponding author), Jinan Univ, MOE Key Lab Tumor Mol Biol, Key Lab Funct Prot Res Guangdong Higher Educ Inst, Guangzhou, Peoples R China.	wonder10@126.com; tfyxing@jnu.edu.cn	潘, 浩/AAZ-6693-2020	潘, 浩/0000-0002-2049-1842	Scientific Research Star plan of Shunde Hospital, Southern Medical University (The First People's Hospital) (Foshan) [SRSP2019012]; Medical Scientific Research Foundation of Guangdong Province [A2020175]	Scientific Research Star plan of Shunde Hospital, Southern Medical University (The First People's Hospital) (Foshan); Medical Scientific Research Foundation of Guangdong Province	This work was supported by grants from the Scientific Research Star plan of Shunde Hospital, Southern Medical University (The First People's Hospital) (Foshan) (Grant No. SRSP2019012) and the Medical Scientific Research Foundation of Guangdong Province (A2020175).	Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Chekeni FB, 2010, NATURE, V467, P863, DOI 10.1038/nature09413; Elliott MR, 2009, NATURE, V461, P282, DOI 10.1038/nature08296; Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4; Galluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI 10.1038/nri.2016.107; Jaime-Sanchez P, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000528; Leite CA, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000129; Martins I, 2014, CELL DEATH DIFFER, V21, P79, DOI 10.1038/cdd.2013.75; Medina CB, 2020, NATURE, V580, P130, DOI 10.1038/s41586-020-2121-3; Nagata S, 2017, NAT REV IMMUNOL, V17, P333, DOI 10.1038/nri.2016.153; Vandenabeele P, 2016, ADV EXP MED BIOL, V930, P133, DOI 10.1007/978-3-319-39406-0_6	11	0	0	3	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 20	2020	11								1878	10.3389/fimmu.2020.01878	http://dx.doi.org/10.3389/fimmu.2020.01878			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NM1WO	32973777	gold, Green Published			2022-12-18	WOS:000567894700001
J	Karim, MY				Karim, Mohammed Yousuf			Using Clinical Cases to Restore Basic Science Immunology Knowledge in Physicians and Senior Medical Students	FRONTIERS IN IMMUNOLOGY			English	Article						postgraduate; education; rheumatology; immunodeficiency; interactive; case-based learning	CURRICULUM; RETENTION; BACK	The majority of medical students and many physicians find basic science immunology confusing and the teaching of immunology to be uninteresting. Physicians undergoing training in a range of disciplines treat patients with immunological disease, including allergy/immunology and rheumatology. It is essential for senior medical students and physicians to understand the pathology of immune diseases and the pharmacology of immune interventions. In order to optimize this learning, underlying concepts of basic immunology need to be revised, or sometimes learned for the first time. Teachers may need to overcome baseline attitudinal negativity. Medical students and postgraduates are more able to relate to basic immunology if approached through a clinical route. Case presentations and case-based discussions are a familiar format for medical students and physicians, though typically utilized to enhance understanding of clinical presentation, investigation, and treatment. Hence, they may be more receptive to "difficult" immunology concepts when presented in a familiar teaching framework. Although there is data supporting case-based learning for basic immunology in medical students, there is little data in physicians. Extrapolating from the medical student literature, I devised a program of clinical cases for physicians whereby understanding the immunopathological basis of the condition and/or its immunological treatment was employed as a platform to appreciate the basic science immunology in more depth. A variety of cases were selected to illustrate different immunological topics. The sessions were small group and highly interactive in nature. As this programme has only recently been introduced, formal evaluation has yet to be concluded.	[Karim, Mohammed Yousuf] Sidra Med, Hematopathol, Doha, Qatar; [Karim, Mohammed Yousuf] Weill Cornell Med Qatar, Clin Pathol & Lab Med, Ar Rayyan, Qatar	Sidra Medical & Research Center; Qatar Foundation (QF); Weill Cornell Medical College Qatar	Karim, MY (corresponding author), Sidra Med, Hematopathol, Doha, Qatar.; Karim, MY (corresponding author), Weill Cornell Med Qatar, Clin Pathol & Lab Med, Ar Rayyan, Qatar.	mkarim@sidra.org	Karim, Mohammed Yousuf/AAI-6771-2020	Karim, Mohammed Yousuf/0000-0003-0912-1629				Alam A, 2011, ANN SAUDI MED, V31, P58, DOI 10.4103/0256-4947.75780; [Anonymous], 2016, J MED EDUC CURRIC DE; Bacchetta R, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00077; Bandiera G, 2018, MED EDUC, V52, P78, DOI 10.1111/medu.13386; Bansal AS, 1997, ACAD MED, V72, P662, DOI 10.1097/00001888-199708000-00006; Bousfiha A, 2020, J CLIN IMMUNOL, V40, P66, DOI 10.1007/s10875-020-00758-x; Bousfiha A, 2018, J CLIN IMMUNOL, V38, P129, DOI 10.1007/s10875-017-0465-8; Brauer DG, 2015, MED TEACH, V37, P312, DOI 10.3109/0142159X.2014.970998; Custers EJFM, 2011, MED EDUC, V45, P422, DOI 10.1111/j.1365-2923.2010.03889.x; D'Eon Marcel F, 2006, BMC Med Educ, V6, P5, DOI 10.1186/1472-6920-6-5; Gupta Shalini, 2014, Int J Appl Basic Med Res, V4, P16, DOI 10.4103/2229-516X.125675; Haidaris CG, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02548; Klavdianou K, 2020, BIODRUGS, V34, P133, DOI 10.1007/s40259-020-00405-2; Kulasegaram KM, 2017, MED EDUC, V51, P184, DOI 10.1111/medu.13145; Ling Y, 2008, ACAD MED, V83, pS82, DOI 10.1097/ACM.0b013e318183e2fc; Lo B, 2015, SCIENCE, V349, P436, DOI 10.1126/science.aaa1663; Mathew G, 2018, MED TEACH, V40, P755, DOI 10.1080/0142159X.2018.1440073; Morand EF, 2020, NEW ENGL J MED, V382, P211, DOI 10.1056/NEJMoa1912196; Norman G, 2013, ACAD MED, V88, P151, DOI [10.1097/ACM.0b013e31827c953e, 10.1097/ACM.0b013e31827c9465, 10.1097/ACM.0b013e3182a45def]; Norman G, 2009, MED TEACH, V31, P807, DOI 10.1080/01421590903049814; Novack JP, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00995; PATEL VL, 1991, ACAD MED, V66, P380, DOI 10.1097/00001888-199107000-00002; Petrizzo MC, 2019, BMC MED EDUC, V19, DOI 10.1186/s12909-019-1786-5; Sannathimmappa M, 2020, IMPLEMENTATION EVALU; Schmidt RE, 2018, NAT REV RHEUMATOL, V14, P7, DOI 10.1038/nrrheum.2017.198; Semianchuk VB, 2015, GALICIAN MED J, V22, P18; SHULMAN LS, 1970, J MED EDUC, V45, P90; Spencer AL, 2008, ACAD MED, V83, P662, DOI 10.1097/ACM.0b013e318178356b; Stuart Melissa K, 2018, Mo Med, V115, P66; Weiler T, 2019, MED TEACH, V41, P847, DOI 10.1080/0142159X.2018.1533244; Weston W Wayne, 2018, Can Med Educ J, V9, pe109; Wilkerson L, 2009, MED TEACH, V31, P812, DOI 10.1080/01421590903049806; Woods NN, 2007, ADV HEALTH SCI EDUC, V12, P417, DOI 10.1007/s10459-006-9054-y; Zante B, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228257; Zhang ZR, 2013, BMC MED EDUC, V13, DOI 10.1186/1472-6920-13-11	35	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 19	2020	11								1756	10.3389/fimmu.2020.01756	http://dx.doi.org/10.3389/fimmu.2020.01756			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NM1SZ	32973743	Green Published, gold			2022-12-18	WOS:000567885400001
J	Na, HS; Park, JS; Cho, KH; Kwon, JY; Choi, J; Jhun, J; Kim, SJ; Park, SH; Cho, ML				Na, Hyun Sik; Park, Jin-Sil; Cho, Keun-Hyung; Kwon, Ji Ye; Choi, JeongWon; Jhun, Jooyeon; Kim, Seok Jung; Park, Sung-Hwan; Cho, Mi-La			Interleukin-1-Interleukin-17 Signaling Axis Induces Cartilage Destruction and Promotes Experimental Osteoarthritis (vol 11, 730, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						osteoarthritis; inflammation; interleukin-17; IL-1 receptor antagonist knockout; intestinal homeostasis			[Na, Hyun Sik; Park, Jin-Sil; Cho, Keun-Hyung; Kwon, Ji Ye; Choi, JeongWon; Jhun, Jooyeon; Park, Sung-Hwan; Cho, Mi-La] Catholic Univ Korea, Catholic Res Inst Med Sci, Coll Med, Rheumatism Res Ctr, Seoul, South Korea; [Kim, Seok Jung] Catholic Univ Korea, Uijeongbu St Marys Hosp, Dept Orthoped Surg, Coll Med, Seoul, South Korea; [Park, Sung-Hwan] Catholic Univ Korea, Seoul St Marys Hosp, Div Rheumatol, Dept Internal Med,Coll Med, Seoul, South Korea; [Cho, Mi-La] Catholic Univ Korea, Dept Med Lifesci, Coll Med, Seoul, South Korea; [Cho, Mi-La] Catholic Univ Korea, Dept Biomed & Hlth Sci, Coll Med, Seoul, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Seoul St. Mary's Hospital; Catholic University of Korea; Catholic University of Korea	Cho, ML (corresponding author), Catholic Univ Korea, Catholic Res Inst Med Sci, Coll Med, Rheumatism Res Ctr, Seoul, South Korea.; Cho, ML (corresponding author), Catholic Univ Korea, Dept Med Lifesci, Coll Med, Seoul, South Korea.; Cho, ML (corresponding author), Catholic Univ Korea, Dept Biomed & Hlth Sci, Coll Med, Seoul, South Korea.	iammila@catholic.ac.kr			Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI15C1062]; Ministry of Health & Welfare, Republic of Korea [HI15C3062]; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [NRF-2018R1D1A1B07048554]	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea; Ministry of Health & Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education(National Research Foundation of Korea)	"This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI15C1062), funded by the Ministry of Health & Welfare, Republic of Korea (HI15C3062), and Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (grant number NRF-2018R1D1A1B07048554)."	Na HS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00730	1	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 19	2020	11								1862	10.3389/fimmu.2020.01862	http://dx.doi.org/10.3389/fimmu.2020.01862			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NM1RO	32973769	gold, Green Published			2022-12-18	WOS:000567881700001
J	Kumar, V; Baruah, K; Nguyen, DV; Smagghe, G; Vossen, E; Bossier, P				Kumar, Vikash; Baruah, Kartik; Nguyen, Dung Viet; Smagghe, Guy; Vossen, Els; Bossier, Peter			Phloroglucinol-Mediated Hsp70 Production in Crustaceans: Protection against Vibrio parahaemolyticus in Artemia franciscana and Macrobrachium rosenbergii (vol 9, 1091, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						gnotobioticArtemia; Vibrio parahaemolyticus; phloroglucinol; heat shock protein 70; Macrobrachium rosenbergii			[Kumar, Vikash; Baruah, Kartik; Nguyen, Dung Viet; Bossier, Peter] Univ Ghent, Fac Biosci Engn, Dept Anim Sci & Aquat Ecol, Lab Aquaculture, Ghent, Belgium; [Kumar, Vikash; Baruah, Kartik; Nguyen, Dung Viet; Bossier, Peter] Univ Ghent, Dept Anim Sci & Aquat Ecol, Artemia Reference Ctr, Fac Biosci Engn, Ghent, Belgium; [Kumar, Vikash] ICAR Res Complex, Cent Inland Fisheries Res Inst CIFRI, Barakpur, India; [Smagghe, Guy] Univ Ghent, Fac Biosci Engn, Dept Crop Protect, Ghent, Belgium; [Vossen, Els] Univ Ghent, Lab Anim Nutr & Anim Prod Qual, Dept Anim Sci & Aquat Ecol, Fac Biosci Engn, Ghent, Belgium; [Baruah, Kartik] Swedish Univ Agr Sci, Dept Anim Nutr & Management, Fac Vet Med & Anim Sci, Uppsala, Sweden	Ghent University; Ghent University; Ghent University; Ghent University; Swedish University of Agricultural Sciences	Baruah, K (corresponding author), Univ Ghent, Fac Biosci Engn, Dept Anim Sci & Aquat Ecol, Lab Aquaculture, Ghent, Belgium.; Baruah, K (corresponding author), Univ Ghent, Dept Anim Sci & Aquat Ecol, Artemia Reference Ctr, Fac Biosci Engn, Ghent, Belgium.; Baruah, K (corresponding author), Swedish Univ Agr Sci, Dept Anim Nutr & Management, Fac Vet Med & Anim Sci, Uppsala, Sweden.	kartik.baruah@slu.se	Baruah, Kartik/ABG-1532-2020	Baruah, Kartik/0000-0002-2060-4982				Kumar V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01091	1	0	0	6	18	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 18	2020	11								1860	10.3389/fimmu.2020.01860	http://dx.doi.org/10.3389/fimmu.2020.01860			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NM2NT	32973767	Green Published, gold			2022-12-18	WOS:000567939400001
J	Wang, QL; Oryoji, D; Mitoma, H; Kimoto, Y; Koyanagi, M; Yokoyama, K; Ayano, M; Akahoshi, M; Arinobu, Y; Niiro, H; Akashi, K; Horiuchi, T				Wang, Qiaolei; Oryoji, Daisuke; Mitoma, Hiroki; Kimoto, Yasutaka; Koyanagi, Masamichi; Yokoyama, Kana; Ayano, Masahiro; Akahoshi, Mitsuteru; Arinobu, Yojiro; Niiro, Hiroaki; Akashi, Koichi; Horiuchi, Takahiko			Methotrexate Enhances Apoptosis of Transmembrane TNF-Expressing Cells Treated With Anti-TNF Agents	FRONTIERS IN IMMUNOLOGY			English	Article						anti-TNF agent; methotrexate; rheumatoid arthritis; transmembrane TNF; apoptosis; cytotoxicity	RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; CERTOLIZUMAB PEGOL; PLUS METHOTREXATE; PHASE-III; ALPHA; INFLIXIMAB; IMMUNOGENICITY; ETANERCEPT; THERAPY	Background Concomitant use of methotrexate (MTX) improves the clinical efficacy of anti-TNF agents in the treatment of rheumatoid arthritis (RA). We aimed to clarify the cytotoxic effect of MTX on transmembrane TNF (tmTNF)-expressing cells treated with anti-TNF agents. Methods Jurkat T cells stably expressing tmTNF were used for the following experiments. Cytotoxicity induced by an anti-TNF agent (infliximab, adalimumab, or certolizumab pegol) with concomitant MTX were compared with that by MTX alone or by an anti-TNF agent alone using flow cytometry. Apoptosis-induction mediated by reverse signal through tmTNF, complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP) were evaluated. Folic acid and Y-27632, a Rho kinase inhibitor, were used as inhibitors to study intracellular signaling pathway in apoptosis induced by MTX and anti-TNF agents. Results Apoptosis of tmTNF-expressing cells was significantly increased by the concomitant administration of MTX and an anti-TNF agent, compared with MTX alone or an anti-TNF agent alone. The apoptosis induction by concomitant MTX was most pronounced in infliximab-treatment. Reverse signal transduction, but not CDC or ADCC/ADCP, was responsible for the coordinate effect of MTX and an anti-TNF agent on tmTNF-expressing cells. Folic acid inhibited MTX-mediated apoptosis, while Y-27632 suppressed JNK activation and infliximab-induced apoptosis via revere signal through tmTNF. Conclusion The apoptotic effect was enhanced by combination of MTX and an anti-TNF agent in tmTNF-expressing cells. The intracellular pathways induced by MTX and anti-TNF agents seem to be independent. These findings might explain at least in part improved the clinical response upon co-therapy of MTX and an anti-TNF agent in RA.	[Wang, Qiaolei; Oryoji, Daisuke; Kimoto, Yasutaka; Koyanagi, Masamichi; Horiuchi, Takahiko] Kyushu Univ, Beppu Hosp, Dept Internal Med, Beppu, Oita, Japan; [Wang, Qiaolei; Mitoma, Hiroki; Yokoyama, Kana; Ayano, Masahiro; Akahoshi, Mitsuteru; Arinobu, Yojiro; Niiro, Hiroaki; Akashi, Koichi] Kyushu Univ, Grad Sch Med Sci, Dept Med & Biosyst Sci, Fukuoka, Japan	Kyushu University; Kyushu University	Mitoma, H (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Med & Biosyst Sci, Fukuoka, Japan.	mitoma@intmed1.med.kyushu-u.ac.jp	Ayano, Masahiro/GSE-5333-2022; Horiuchi, Takahiko/ABH-1481-2021	Horiuchi, Takahiko/0000-0002-1770-1087	JSPS KAKENHI [JP19K08911]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by the JSPS KAKENHI Grant Number JP19K08911.	Bradley JR, 2008, J PATHOL, V214, P149, DOI 10.1002/path.2287; Breedveld FC, 2006, ARTHRITIS RHEUM-US, V54, P26, DOI 10.1002/art.21519; Brown PM, 2016, NAT REV RHEUMATOL, V12, P731, DOI 10.1038/nrrheum.2016.175; Catrina AI, 2005, ARTHRITIS RHEUM-US, V52, P61, DOI 10.1002/art.20764; Fairbanks LD, 1999, BIOCHEM J, V342, P143, DOI 10.1042/0264-6021:3420143; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Genestier L, 1998, J CLIN INVEST, V102, P322, DOI 10.1172/JCI2676; Gerards AH, 2003, RHEUMATOLOGY, V42, P1189, DOI 10.1093/rheumatology/keg323; Harashima S, 2001, J IMMUNOL, V166, P130, DOI 10.4049/jimmunol.166.1.130; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Horiuchi T, 2010, RHEUMATOLOGY, V49, P1215, DOI 10.1093/rheumatology/keq031; Jani M, 2014, RHEUMATOLOGY, V53, P213, DOI 10.1093/rheumatology/ket260; Keystone E, 2008, ARTHRITIS RHEUM, V58, P3319, DOI 10.1002/art.23964; Klareskog L, 2004, LANCET, V363, P675, DOI 10.1016/S0140-6736(04)15640-7; Lopez-Olivo MA, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000957.pub2; Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140-6736(99)05246-0; Mitoma H, 2004, GASTROENTEROLOGY, V126, P934, DOI 10.1053/j.gastro.2004.01.036; Mitoma H, 2005, GASTROENTEROLOGY, V128, P376, DOI 10.1053/j.gastro.2004.11.060; Mitoma H, 2008, ARTHRITIS RHEUM-US, V58, P1248, DOI 10.1002/art.23447; Mitoma H, 2018, CYTOKINE, V101, P56, DOI 10.1016/j.cyto.2016.08.014; Murdaca G, 2019, EXPERT OPIN DRUG SAF, V18, P343, DOI 10.1080/14740338.2019.1602117; Murdaca G, 2016, EXPERT OPIN DRUG SAF, V15, P43, DOI 10.1517/14740338.2016.1112375; Nishina N, 2013, CLIN RHEUMATOL, V32, P1661, DOI 10.1007/s10067-013-2309-0; Ruderman EM, 2013, BULL HOSP JT DIS, V71, P214; Saoudi Abdelhadi, 2014, Small GTPases, V5, DOI 10.4161/sgtp.28208; Singh JA, 2016, ARTHRITIS RHEUMATOL, V68, P1, DOI 10.1002/art.39480; Smolen JS, 2013, ANN RHEUM DIS, V72, P1432, DOI 10.1136/annrheumdis-2012-201620corr1; Smolen JS, 2009, ANN RHEUM DIS, V68, P823, DOI 10.1136/ard.2008.090019; Smolen JS, 2017, ANN RHEUM DIS, V76, P960, DOI 10.1136/annrheumdis-2016-210715; Steeland S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051442; Strand V, 2017, BIODRUGS, V31, P299, DOI 10.1007/s40259-017-0231-8; Tian HH, 2007, BULL HOSP JT DIS, V65, P168; Ueda N, 2013, INFLAMM BOWEL DIS, V19, P1224, DOI 10.1097/MIB.0b013e318280b169; Zhang M, 2017, ONCOTARGET, V8, P63799, DOI 10.18632/oncotarget.19124	34	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 14	2020	11								2042	10.3389/fimmu.2020.02042	http://dx.doi.org/10.3389/fimmu.2020.02042			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NJ5PW	32922407	Green Published, gold			2022-12-18	WOS:000566095900001
J	Gao, K; Chen, LY; Zhang, YW; Zhao, Y; Wan, ZY; Wu, JH; Lin, LY; Kuang, YS; Lu, JH; Zhang, XQ; Tian, L; Liu, X; Qiu, X				Gao, Kai; Chen, Lingyan; Zhang, Yuanwei; Zhao, Yi; Wan, Ziyun; Wu, Jinghua; Lin, Liya; Kuang, Yashu; Lu, Jinhua; Zhang, Xiuqing; Tian, Lei; Liu, Xiao; Qiu, Xiu			Germline-Encoded TCR-MHC Contacts Promote TCR V Gene Bias in Umbilical Cord Blood T Cell Repertoire (vol 10, 2064, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						TRBV gene usage; MHC genetic variations; quantitative trait locus mapping; umbilical cord blood; TCR-MHC co-evolution			[Gao, Kai; Zhang, Xiuqing; Liu, Xiao] Univ Chinese Acad Sci, BGI Educ Ctr, Shenzhen, Peoples R China; [Gao, Kai; Chen, Lingyan; Zhang, Yuanwei; Zhao, Yi; Wan, Ziyun; Wu, Jinghua; Lin, Liya; Zhang, Xiuqing; Tian, Lei; Liu, Xiao] BGI Shenzhen, Shenzhen, Peoples R China; [Gao, Kai; Kuang, Yashu; Lu, Jinhua; Qiu, Xiu] Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Div Birth Cohort Study, Guangzhou, Peoples R China; [Zhao, Yi] South China Univ Technol, Sch Biol & Biol Engn, Guangzhou, Peoples R China; [Lu, Jinhua; Qiu, Xiu] Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Dept Women & Childrens Hlth Care, Guangzhou, Peoples R China; [Qiu, Xiu] Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Dept Obstet & Gynecol, Guangzhou, Peoples R China	Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Beijing Genomics Institute (BGI); Guangzhou Medical University; South China University of Technology; Guangzhou Medical University; Guangzhou Medical University	Liu, X (corresponding author), Univ Chinese Acad Sci, BGI Educ Ctr, Shenzhen, Peoples R China.; Tian, L; Liu, X (corresponding author), BGI Shenzhen, Shenzhen, Peoples R China.; Qiu, X (corresponding author), Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Div Birth Cohort Study, Guangzhou, Peoples R China.; Qiu, X (corresponding author), Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Dept Women & Childrens Hlth Care, Guangzhou, Peoples R China.; Qiu, X (corresponding author), Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Dept Obstet & Gynecol, Guangzhou, Peoples R China.	tianlei1@genomics.cn; liuxiao@genomics.cn; qxiu0161@163.com	tian, lei/HGU-7245-2022; Liu, Xiao/P-2732-2015	Liu, Xiao/0000-0002-8073-0534				Gao K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02064	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 13	2020	11								1752	10.3389/fimmu.2020.01752	http://dx.doi.org/10.3389/fimmu.2020.01752			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NJ3YX	32903811	gold, Green Published			2022-12-18	WOS:000565984100001
J	Rosen, BC; Pedreno-Lopez, N; Ricciardi, MJ; Reed, JS; Sacha, JB; Rakasz, EG; Watkins, DI				Rosen, Brandon C.; Pedreno-Lopez, Nuria; Ricciardi, Michael J.; Reed, Jason S.; Sacha, Jonah B.; Rakasz, Eva G.; Watkins, David I.			Rhesus Cytomegalovirus-Specific CD8(+)Cytotoxic T Lymphocytes Do Not Become Functionally Exhausted in Chronic SIVmac239 Infection	FRONTIERS IN IMMUNOLOGY			English	Article						simian immunodeficiency virus; cytotoxic T lymphocytes; cytomegalovirus; rhesus macaques; human immunodeficiency virus	CLASS-I MOLECULE; VIRAL REPLICATION; CELLS; ESCAPE; HIV; EXPRESSION; PD-1; VIREMIA; MEMORY; MAMU-A-ASTERISK-02	CD8(+)cytotoxic T lymphocytes (CTLs) exert potent antiviral activity after HIV/SIV infection. However, efforts to harness the antiviral efficacy of CTLs for HIV/SIV prophylaxis and therapy have been severely hindered by two major problems: viral escape and exhaustion. By contrast, CTLs directed against human cytomegalovirus (HCMV), a ubiquitous chronic herpesvirus, seldom select for escape mutations and remain functional and refractory to exhaustion during chronic HCMV and HIV infection. Recently, attempts have been made to retarget HCMV-specific CTLs for cancer immunotherapy. We speculate that such a strategy may also be beneficial in the context of HIV/SIV infection, facilitating CTL-mediated control of HIV/SIV replication. As a preliminary assessment of the validity of this approach, we investigated the phenotypes and functionality of rhesus CMV (RhCMV)-specific CTLs in SIVmac239-infected Indian rhesus macaques (RMs), a crucial HIV animal model system. We recently identified two immunodominant,Mamu-A*02-restricted CTL epitopes derived from RhCMV proteins and sought to evaluate the phenotypic and functional characteristics of these CTL populations in chronic SIVmac239 infection. We analyzed and directly compared RhCMV- and SIVmac239-specific CTLs during SIVmac239 infection in a cohort ofMamu-A*01(+)andMamu-A*02(+)RMs. CTL populations specific for at least one of the RhCMV-derived CTL epitopes were detected in ten of elevenMamu-A*02(+)animals tested, and both populations were detected in five of these animals. Neither RhCMV-specific CTL population exhibited significant changes in frequency, memory phenotype, granzyme B expression, exhaustion marker (PD-1 and CTLA-4) expression, or polyfunctionality between pre- and chronic SIVmac239 infection timepoints. In chronic SIVmac239 infection, RhCMV-specific CTLs exhibited higher levels of granzyme B expression and polyfunctionality, and lower levels of exhaustion marker expression, than SIVmac239-specific CTLs. Additionally, compared to SIVmac239-specific CTLs, greater proportions of RhCMV-specific CTLs were of the terminally differentiated effector memory phenotype (CD28(-)CCR7(-)) during chronic SIVmac239 infection. These results suggest that, in contrast to SIVmac239-specific CTLs, RhCMV-specific CTLs maintain their phenotypes and cytolytic effector functions during chronic SIVmac239 infection, and that retargeting RhCMV-specific CTLs might be a promising SIV immunotherapeutic strategy.	[Rosen, Brandon C.] Univ Miami, Miller Sch Med, Med Scientist Training Program, Miami, FL 33136 USA; [Rosen, Brandon C.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA; [Pedreno-Lopez, Nuria; Ricciardi, Michael J.; Watkins, David I.] George Washington Univ, Sch Med, Dept Pathol, Washington, DC USA; [Reed, Jason S.; Sacha, Jonah B.] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Beaverton, OR USA; [Reed, Jason S.; Sacha, Jonah B.] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Beaverton, OR USA; [Rakasz, Eva G.] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI USA	University of Miami; University of Miami; George Washington University; Oregon Health & Science University; Oregon Health & Science University; Oregon National Primate Research Center; University of Wisconsin System; University of Wisconsin Madison	Rosen, BC (corresponding author), Univ Miami, Miller Sch Med, Med Scientist Training Program, Miami, FL 33136 USA.; Rosen, BC (corresponding author), Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA.	bcr54@med.miami.edu	Lopez, Nuria Pedreno/AAG-9496-2021	Lopez, Nuria Pedreno/0000-0001-6927-2301	National Institutes of Health (NIH) [R01 AI052056, R01 AI108421, P01 AI094420, F30 AI147881]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was supported by National Institutes of Health (NIH) grants R01 AI052056, R01 AI108421, and P01 AI094420 to DW, and F30 AI147881 to BR. The funders had no role in study design, data collection and analysis, decision to publish, or manuscript preparation.	Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Allen TM, 1998, J IMMUNOL, V160, P6062; Allen TM, 2001, J VIROL, V75, P738, DOI 10.1128/JVI.75.2.738-749.2001; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Bronke C, 2005, J INFECT DIS, V191, P873, DOI 10.1086/427828; Brozy J, 2018, J VIROL, V92, DOI 10.1128/JVI.00491-18; Cecchinato V, 2008, J IMMUNOL, V180, P5439, DOI 10.4049/jimmunol.180.8.5439; Cline AN, 2005, J MED PRIMATOL, V34, P303; Curran MA, 2010, P NATL ACAD SCI USA, V107, P4275, DOI 10.1073/pnas.0915174107; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; Derhovanessian E, 2011, J GEN VIROL, V92, P2746, DOI 10.1099/vir.0.036004-0; Friese C, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60738-4; Gonzalez-Nieto L, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008015; Goonetilleke N, 2009, J EXP MED, V206, P1253, DOI 10.1084/jem.20090365; Goulder PJR, 2004, NAT REV IMMUNOL, V4, P630, DOI 10.1038/nri1417; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Harper J, 2020, NAT MED, V26, P519, DOI 10.1038/s41591-020-0782-y; Hosie L, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01776; Hryniewicz A, 2006, BLOOD, V108, P3834, DOI 10.1182/blood-2006-04-010637; Huang RR, 2011, CLIN CANCER RES, V17, P4101, DOI 10.1158/1078-0432.CCR-11-0407; Kaufmann DE, 2009, J IMMUNOL, V182, P5891, DOI 10.4049/jimmunol.0803771; Kaul Artur, 2019, Primate Biol, V6, P1, DOI 10.5194/pb-6-1-2019; Kaur A, 2003, J VIROL, V77, P5749, DOI 10.1128/JVI.77.10.5749-5758.2003; Khan N, 2004, J IMMUNOL, V173, P7481, DOI 10.4049/jimmunol.173.12.7481; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Koup RA, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a007252; Loffredo JT, 2007, J VIROL, V81, P8827, DOI 10.1128/JVI.00895-07; Loffredo JT, 2004, J IMMUNOL, V173, P5064, DOI 10.4049/jimmunol.173.8.5064; Martins MA, 2019, J VIROL, V93, DOI 10.1128/JVI.01626-18; Martins MA, 2018, J VIROL, V92, DOI 10.1128/JVI.00690-18; Martins MA, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006529; Martins MA, 2014, J VIROL, V88, P7493, DOI 10.1128/JVI.00601-14; Nakamoto N, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000313; National Research Council of the National Academy of Sciences, 2011, GUIDE CARE USE LAB A; O'Connor DH, 2002, NAT MED, V8, P493, DOI 10.1038/nm0502-493; Pedicord VA, 2011, P NATL ACAD SCI USA, V108, P266, DOI 10.1073/pnas.1016791108; Petrovas C, 2007, BLOOD, V110, P928, DOI 10.1182/blood-2007-01-069112; Petrovas C, 2006, J EXP MED, V203, P2281, DOI 10.1084/jem.20061496; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; Picker LJ, 2006, J CLIN INVEST, V116, P1514, DOI 10.1172/JCI27564; Pomplun NL, 2021, CYTOM PART A, V99, P278, DOI 10.1002/cyto.a.24197; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Schmittnaegel M, 2016, MOL CANCER THER, V15, P2130, DOI 10.1158/1535-7163.MCT-16-0207; Schmittnaegel M, 2015, CANCER IMMUNOL RES, V3, P764, DOI 10.1158/2326-6066.CIR-15-0037; Sloan DD, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005233; Steiner K, 1999, CLIN EXP IMMUNOL, V115, P451; Trautmann L, 2006, NAT MED, V12, P1198, DOI 10.1038/nm1482; Trautmann L, 2012, BLOOD, V120, P3466, DOI 10.1182/blood-2012-04-422550; Vogel TU, 2002, J VIROL, V76, P11623, DOI 10.1128/JVI.76.22.11623-11636.2002; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; Weatherall D, 2020, MOLECULAR HEMATOLOGY, 4TH EDITION, P1; Wills MR, 2002, J IMMUNOL, V168, P5455, DOI 10.4049/jimmunol.168.11.5455; Yant LJ, 2006, J VIROL, V80, P5074, DOI 10.1128/JVI.80.10.5074-5077.2006	53	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 12	2020	11								1960	10.3389/fimmu.2020.01960	http://dx.doi.org/10.3389/fimmu.2020.01960			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NK1OW	32922404	gold, Green Published			2022-12-18	WOS:000566509600001
J	Riesner, K; Cordes, S; Peczynski, C; Kalupa, M; Schwarz, C; Shi, Y; Mertlitz, S; Mengwasser, J; van der Werf, S; Peric, Z; Koenecke, C; Schoemans, H; Duarte, RF; Basak, GW; Penack, O				Riesner, Katarina; Cordes, Steffen; Peczynski, Christophe; Kalupa, Martina; Schwarz, Constanze; Shi, Yu; Mertlitz, Sarah; Mengwasser, Joerg; van der Werf, Steffie; Peric, Zinaida; Koenecke, Christian; Schoemans, Helene; Duarte, Rafael F.; Basak, Grzegorz W.; Penack, Olaf			Reduced Calcium Signaling Is Associated With Severe Graft-Versus-Host Disease: Results From Preclinical Models and From a Prospective EBMT Study	FRONTIERS IN IMMUNOLOGY			English	Article						graft-versus-host-disease; stem cell transplantation; calcium; GPRC6a; GVHD mouse models; EBMT study	ACUTE GVHD; GPRC6A; RECEPTOR	Despite its involvement in various immune functions, including the allogeneic activation of T-lymphocytes, the relevance of calcium (Ca2+) for GVHD pathobiology is largely unknown. To elucidate a potential association between Ca(2+)and GVHD, we analyzed Ca2+-sensing G-protein coupled receptor 6a (GPRC6a) signaling in preclinical GVHD models and conducted a prospective EBMT study on Ca(2+)serum levels prior alloSCT including 363 matched sibling allogeneic peripheral blood stem cell transplantations (alloSCTs). In experimental models, we found decreasedGprc6aexpression during intestinal GVHD. GPRC6a deficient alloSCT recipients had higher clinical and histopathological GVHD scores leading to increased mortality. As possible underlying mechanism, we found increased antigen presentation potential in GPRC6a(-/-)alloSCT recipients demonstrated by higher proliferation rates of T-lymphocytes. In patients with low Ca(2+)serum levels (<= median 2.2 mmol/l) before alloSCT, we found a higher incidence of acute GVHD grades II-IV (HR = 2.3 Cl = 1.45-3.85p= 0.0006), severe acute GVHD grades III-IV (HR = 3.3 CI = 1.59-7.14,p= 0.002) and extensive chronic GVHD (HR = 2.0 Cl = 1.04-3.85p= 0.04). In conclusion, experimental and clinical data suggest an association of reduced Ca(2+)signaling with increased severity of GVHD. Future areas of interest include the in depth analysis of involved molecular pathways and the investigation of Ca(2+)signaling as a therapeutic target during GVHD.	[Riesner, Katarina; Cordes, Steffen; Kalupa, Martina; Schwarz, Constanze; Shi, Yu; Mertlitz, Sarah; Mengwasser, Joerg; Penack, Olaf] Charite Univ Med Berlin, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany; [Peczynski, Christophe; Peric, Zinaida; Koenecke, Christian; Schoemans, Helene; Duarte, Rafael F.; Basak, Grzegorz W.; Penack, Olaf] EBMT Transplant Complicat Working Party, Paris, France; [Peczynski, Christophe] EBMT Stat Unit, Paris, France; [Mengwasser, Joerg] Charite Univ Med Berlin, Dept Surg, Campus Charite Mitte, Campus Virchow Clin, Berlin, Germany; [van der Werf, Steffie] EBMT Data Off, Leiden, Netherlands; [Peric, Zinaida] Univ Hosp Ctr Rebro, Zagreb, Croatia; [Koenecke, Christian] Hannover Med Sch, Hannover, Germany; [Schoemans, Helene] UZ Leuven, Leuven, Belgium; [Duarte, Rafael F.] Hosp Univ Puerta de Hierro, Madrid, Spain; [Basak, Grzegorz W.] Med Univ Warsaw, Warsaw, Poland; [Penack, Olaf] Berlin Inst Hlth, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Hannover Medical School; KU Leuven; Hospital Puerta de Hierro-Majadahonda; Medical University of Warsaw; Berlin Institute of Health	Riesner, K (corresponding author), Charite Univ Med Berlin, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany.	katarina.riesner@charite.de	DUARTE, Rafael F./Q-5884-2018; Penack, Olaf/L-1068-2016	DUARTE, Rafael F./0000-0002-5240-9815; Riesner, Katarina/0000-0001-5745-8184; Penack, Olaf/0000-0003-4876-802X; Basak, Grzegorz/0000-0003-3858-8180; Schoemans, Helene/0000-0002-7568-8239; Peczynski, Christophe/0000-0002-3829-0088	Jose Carreras LeukamieStiftung [DJCLS 03 FN/2017]; Deutsche Krebshilfe [70113055, 70113519]; DKMS [DKMS-SLS-MHG-2019-04]; Jose Carreras Leukamie-Stiftung [11R2016, 3R/2019]; Deutsche Forschungsgemeinschaft [PE 1450/7-1]	Jose Carreras LeukamieStiftung; Deutsche Krebshilfe(Deutsche Krebshilfe); DKMS; Jose Carreras Leukamie-Stiftung; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	KR acknowledges the support of Jose Carreras LeukamieStiftung (DJCLS 03 FN/2017), Deutsche Krebshilfe (70113055), and DKMS (DKMS-SLS-MHG-2019-04). OP acknowledges the support of Jose Carreras Leukamie-Stiftung (11R2016, 3R/2019), Deutsche Krebshilfe (70113519), and Deutsche Forschungsgemeinschaft (PE 1450/7-1). The Charite Medical Library covers Article Processing Costs.	Bhatt N, 2017, EXP CLIN TRANSPLANT, V15, P567, DOI 10.6002/ect.2016.0180; Chen S, 2015, BLOOD, V126, P103, DOI 10.1182/blood-2014-12-617258; Clemmensen C, 2014, BRIT J PHARMACOL, V171, P1129, DOI 10.1111/bph.12365; Dehghan A, 2011, CIRCULATION, V123, P731, DOI 10.1161/CIRCULATIONAHA.110.948570; Feske S, 2007, NAT REV IMMUNOL, V7, P690, DOI 10.1038/nri2152; Jankovic D, 2013, J EXP MED, V210, P1899, DOI 10.1084/jem.20130084; Kharfan-Dabaja MA, 2018, BRIT J HAEMATOL, V180, P854, DOI 10.1111/bjh.15105; Koehn BH, 2015, ONCOTARGET, V6, P38444, DOI 10.18632/oncotarget.6307; Lee SJ, 2003, BIOL BLOOD MARROW TR, V9, P215, DOI 10.1053/bbmt.2003.50026; Manes TD, 2018, J IMMUNOL, V201, P3167, DOI 10.4049/jimmunol.1800223; Mengwasser J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00203; Mertlitz S, 2017, BLOOD, V129, P1865, DOI 10.1182/blood-2016-08-734210; Nogai A, 2016, HAEMATOLOGICA, V101, pE344, DOI 10.3324/haematol.2016.144519; Pi M, 2017, MOL METAB, V6, DOI 10.1016/j.molmet.2016.12.006; Pi M, 2010, J BIOL CHEM, V285, P39953, DOI 10.1074/jbc.M110.158063; Pi M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003858; Piper C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00163; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; Riesner K, 2016, BONE MARROW TRANSPL, V51, P410, DOI 10.1038/bmt.2015.279; Riesner K, 2017, BLOOD, V129, P2021, DOI 10.1182/blood-2016-08-736314; Rossol M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2339; Smajilovic S, 2013, AMINO ACIDS, V44, P383, DOI 10.1007/s00726-012-1341-8; Takahashi H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13506-w; Thangavelu G, 2020, BLOOD, V135, P28, DOI 10.1182/blood.2019000032; Vaeth M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14714; Vaughn JE, 2015, BIOL BLOOD MARROW TR, V21, P1418, DOI 10.1016/j.bbmt.2015.04.002; Wellendorph P, 2009, J MOL ENDOCRINOL, V42, P215, DOI 10.1677/JME-08-0149; Wilhelm K, 2010, NAT MED, V16, P1434, DOI 10.1038/nm.2242	28	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 11	2020	11								1983	10.3389/fimmu.2020.01983	http://dx.doi.org/10.3389/fimmu.2020.01983			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NI4ON	32849661	Green Published, gold			2022-12-18	WOS:000565333300001
J	Harb, J; Wilson, BS; Hermouet, S				Harb, Jean; Wilson, Bridget S.; Hermouet, Sylvie			Structure, Isotypes, Targets, and Post-translational Modifications of Immunoglobulins and Their Role in Infection, Inflammation and Autoimmunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						immunoglobulins; glycosylation; targets; inflammation; infection; autoimmunity	CHRONIC LYMPHOCYTIC-LEUKEMIA; HEPATITIS-C VIRUS; ANTIINFLAMMATORY ACTIVITY; RHEUMATOID-ARTHRITIS; SIALIC-ACID; DISEASE; GLYCOSYLATION; ANTIBODIES; CELLS		[Harb, Jean] Univ Nantes, Inserm, UMR1064, Ctr Rech Transplantat & Immunol, Nantes, France; [Harb, Jean; Hermouet, Sylvie] Univ Angers, Univ Nantes, Inserm, CRCINA, Nantes, France; [Harb, Jean] CHU Nantes, Lab Biochim, Nantes, France; [Wilson, Bridget S.] Univ New Mexico, Ctr Comprehens Canc, Albuquerque, NM 87131 USA; [Wilson, Bridget S.] Univ New Mexico, Sch Med, Dept Pathol, Albuquerque, NM 87131 USA; [Hermouet, Sylvie] CHU Nantes, Lab Hematol, Nantes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Universite d'Angers; Nantes Universite; CHU de Nantes; University of New Mexico; University of New Mexico; Nantes Universite; CHU de Nantes	Hermouet, S (corresponding author), Univ Angers, Univ Nantes, Inserm, CRCINA, Nantes, France.; Hermouet, S (corresponding author), CHU Nantes, Lab Hematol, Nantes, France.	sylvie.hermouet@univ-nantes.fr						Ackerman ME, 2013, J CLIN INVEST, V123, P2183, DOI 10.1172/JCI65708; Anthony RM, 2008, SCIENCE, V320, P373, DOI 10.1126/science.1154315; Anthony RM, 2008, P NATL ACAD SCI USA, V105, P19571, DOI 10.1073/pnas.0810163105; Bigot-Corbel E, 2008, BLOOD, V112, P4357, DOI 10.1182/blood-2008-07-167569; Bosseboeuf A, 2020, CANCERS, V12, DOI 10.3390/cancers12051254; Bosseboeuf A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01347; Bosseboeuf A, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.95367; Catera R, 2008, MOL MED, V14, P665, DOI 10.2119/2008-00102.Catera; Chiorazzi N, 2005, ANN NY ACAD SCI, V1062, P1, DOI 10.1196/annals.1358.002; Dalziel M, 2014, SCIENCE, V343, P37, DOI 10.1126/science.1235681; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; Gasdaska JR, 2012, MOL IMMUNOL, V50, P134, DOI 10.1016/j.molimm.2012.01.001; Hamblin TJ, 1999, BLOOD, V94, P1848, DOI 10.1182/blood.V94.6.1848; Hermouet S, 2003, NEW ENGL J MED, V348, P178, DOI 10.1056/NEJM200301093480219; Hwang KK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090725; Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594; Myhrinder AL, 2008, BLOOD, V111, P3838, DOI 10.1182/blood-2007-11-125450; Nair S, 2020, MOL GENET METAB, V129, P286, DOI 10.1016/j.ymgme.2020.01.009; Nair S, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98259; Nair S, 2016, NEW ENGL J MED, V374, P555, DOI 10.1056/NEJMoa1508808; Nimmerjahn F, 2005, SCIENCE, V310, P1510, DOI 10.1126/science.1118948; Nimmerjahn F, 2006, SPRINGER SEMIN IMMUN, V28, P305, DOI 10.1007/s00281-006-0052-1; Novak J, 2018, SEMIN NEPHROL, V38, P461, DOI 10.1016/j.semnephrol.2018.05.016; Panfilio Sara, 2013, Leuk Res Rep, V2, P39, DOI 10.1016/j.lrr.2013.01.002; PAREKH RB, 1988, LANCET, V1, P966; PAREKH RB, 1985, NATURE, V316, P452, DOI 10.1038/316452a0; Preuss KD, 2019, BRIT J HAEMATOL, V184, P384, DOI 10.1111/bjh.15659; Quast I, 2015, J CLIN INVEST, V125, P4160, DOI 10.1172/JCI82695; Garcia AR, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-112842; Scallon BJ, 2007, MOL IMMUNOL, V44, P1524, DOI 10.1016/j.molimm.2006.09.005; Schwab I, 2014, EUR J IMMUNOL, V44, P1444, DOI 10.1002/eji.201344230; Schwab I, 2012, EUR J IMMUNOL, V42, P826, DOI 10.1002/eji.201142260; Umana P, 1999, NAT BIOTECHNOL, V17, P176, DOI 10.1038/6179; van de Geijn FE, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2892; Wang TT, 2017, SCIENCE, V355, P395, DOI 10.1126/science.aai8128; Washburn N, 2015, P NATL ACAD SCI USA, V112, pE4339, DOI 10.1073/pnas.1512309112	36	0	0	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 7	2020	11								1761	10.3389/fimmu.2020.01761	http://dx.doi.org/10.3389/fimmu.2020.01761			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NF6AM	32849630	Green Published, gold			2022-12-18	WOS:000563377800001
J	Oliveira, SC; Delpino, MV; Giambartolomei, GH; Quarleri, J; Splitter, G				Oliveira, Sergio C.; Delpino, M. Victoria; Giambartolomei, Guillermo Hernan; Quarleri, Jorge; Splitter, Gary			Editorial: Advances in Liver Inflammation and Fibrosis Due to Infectious Diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						fibrosis; HSC; liver; inflammasome; kupffer	INJURY		[Oliveira, Sergio C.] Univ Fed Minas Gerais, Dept Biochem & Immunol, Belo Horizonte, MG, Brazil; [Delpino, M. Victoria; Giambartolomei, Guillermo Hernan] Univ Buenos Aires, Fac Farm & Bioquim, Inst Inmunol Genet & Metab INIGEM, Buenos Aires, DF, Argentina; [Delpino, M. Victoria; Giambartolomei, Guillermo Hernan; Quarleri, Jorge] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina; [Quarleri, Jorge] Univ Buenos Aires UBA, Fac Med, Inst Invest Biomed Retrovirus & Sida INBIRS, Buenos Aires, DF, Argentina; [Splitter, Gary] Univ Wisconsin Madison, Dept Pathobiol Sci, Madison, WI 53706 USA	Universidade Federal de Minas Gerais; University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; University of Wisconsin System; University of Wisconsin Madison	Oliveira, SC (corresponding author), Univ Fed Minas Gerais, Dept Biochem & Immunol, Belo Horizonte, MG, Brazil.; Delpino, MV; Giambartolomei, GH (corresponding author), Univ Buenos Aires, Fac Farm & Bioquim, Inst Inmunol Genet & Metab INIGEM, Buenos Aires, DF, Argentina.; Delpino, MV; Giambartolomei, GH; Quarleri, J (corresponding author), Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina.; Quarleri, J (corresponding author), Univ Buenos Aires UBA, Fac Med, Inst Invest Biomed Retrovirus & Sida INBIRS, Buenos Aires, DF, Argentina.; Splitter, G (corresponding author), Univ Wisconsin Madison, Dept Pathobiol Sci, Madison, WI 53706 USA.	scozeus1@gmail.com; mdelpino@ffyb.uba.ar; ggiambart@ffyb.uba.ar; quarleri@fmed.uba.ar; gary.splitter@wisc.edu	Oliveira, Sergio Costa/AAG-5408-2021; Quarleri, Jorge/AFR-0308-2022	Oliveira, Sergio Costa/0000-0003-4062-5577; Quarleri, Jorge/0000-0001-5110-8773	NIAID NIH HHS [R01 AI116453] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Colmenero JD, 1996, MEDICINE, V75, P195, DOI 10.1097/00005792-199607000-00003; Gong J, 2019, HEPATOLOGY, V69, P524, DOI 10.1002/hep.29820; Puche JE, 2013, COMPR PHYSIOL, V3, P1473, DOI 10.1002/cphy.c120035; Rockey DC, 2015, NEW ENGL J MED, V372, P1138, DOI 10.1056/NEJMra1300575; Tacke F, 2014, J HEPATOL, V60, P1090, DOI 10.1016/j.jhep.2013.12.025; Tsochatzis EA, 2014, LANCET, V383, P1749, DOI 10.1016/S0140-6736(14)60121-5; Zhangdi HJ, 2019, WORLD J GASTROENTERO, V25, P4835, DOI 10.3748/wjg.v25.i33.4835	8	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 5	2020	11								1760	10.3389/fimmu.2020.01760	http://dx.doi.org/10.3389/fimmu.2020.01760			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NF3OO	32849629	Green Published, gold			2022-12-18	WOS:000563207900001
J	Bansal, R; Mandrekar, P; Mohanty, SK; Weiskirchen, R				Bansal, Ruchi; Mandrekar, Pranoti; Mohanty, Sujit K.; Weiskirchen, Ralf			Editorial: Macrophages in Liver Disease	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						liver diseases; macrophage phenotypes; therapeutic targets; treatment strategies; innate immunity			[Bansal, Ruchi] Univ Twente, Fac Sci & Technol, Tech Med Ctr, Translat Liver Res,Dept Med Cell BioPhys, Enschede, Netherlands; [Mandrekar, Pranoti] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA; [Mohanty, Sujit K.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat & Thorac Surg, Cincinnati, OH 45229 USA; [Weiskirchen, Ralf] RWTH Univ Hosp Aachen, Inst Mol Pathobiochem Expt Gene Therapy & Clin Ch, Aachen, Germany	University of Twente; University of Massachusetts System; University of Massachusetts Worcester; Cincinnati Children's Hospital Medical Center; RWTH Aachen University; RWTH Aachen University Hospital	Bansal, R (corresponding author), Univ Twente, Fac Sci & Technol, Tech Med Ctr, Translat Liver Res,Dept Med Cell BioPhys, Enschede, Netherlands.	r.bansal@utwente.nl	; Weiskirchen, Ralf/O-1734-2018; Bansal, Ruchi/D-4796-2016	Mohanty, Sujit/0000-0001-9559-4638; Weiskirchen, Ralf/0000-0003-3888-0931; Bansal, Ruchi/0000-0003-2470-5876					0	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 4	2020	11								1754	10.3389/fimmu.2020.01754	http://dx.doi.org/10.3389/fimmu.2020.01754			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ND8SP	32849626	Green Published, gold			2022-12-18	WOS:000562172800001
J	Lewis, MC; Childs, CE; Perez-Cano, FJ				Lewis, Marie C.; Childs, Caroline E.; Perez-Cano, Francisco J.			Editorial: Sustained Effects of Early Nutrition on Immune Development and Microbiome-Immune Crosstalk	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						early nutrition; microbiota; immune development; developmental programming; metabolic profiles	HUMAN-MILK		[Lewis, Marie C.] Univ Reading, Sch Chem Food & Pharm, Food & Nutr Sci, Reading, Berks, England; [Childs, Caroline E.] Univ Southampton, Sch Human Dev & Hlth, Fac Med, Southampton, Hants, England; [Childs, Caroline E.] Univ Southampton, Inst Life Sci, Southampton, Hants, England; [Perez-Cano, Francisco J.] Univ Barcelona UB, Fac Pharm & Food Sci, Physiol Sect, Dept Biochem & Physiol, Barcelona, Spain; [Perez-Cano, Francisco J.] Nutr & Food Safety Res Inst INSA UB, Santa Coloma De Gramenet, Spain	University of Reading; University of Southampton; University of Southampton; University of Barcelona	Lewis, MC (corresponding author), Univ Reading, Sch Chem Food & Pharm, Food & Nutr Sci, Reading, Berks, England.	marie.lewis@reading.ac.uk	Perez-Cano, Francisco J/G-6516-2019	Perez-Cano, Francisco J/0000-0001-6243-9164; Childs, Caroline/0000-0001-6832-224X				Al Nabhani Z, 2020, MUCOSAL IMMUNOL, V13, P183, DOI 10.1038/s41385-020-0257-y; Cheng LH, 2021, CRIT REV FOOD SCI, V61, P1184, DOI 10.1080/10408398.2020.1754756; Field CJ, 2005, J NUTR, V135, P1; Gensollen T, 2017, J ALLERGY CLIN IMMUN, V139, P1084, DOI 10.1016/j.jaci.2017.02.011; Gensollen T, 2016, SCIENCE, V352, P539, DOI 10.1126/science.aad9378; Lee Khui Hung, 2020, Clin Mol Allergy, V18, P5, DOI 10.1186/s12948-020-00120-x; Ruiz L, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00696	7	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 31	2020	11								1687	10.3389/fimmu.2020.01687	http://dx.doi.org/10.3389/fimmu.2020.01687			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NC9UX	32903783	Green Published, gold			2022-12-18	WOS:000561556800001
J	Liu, X; Li, F; Niu, HX; Ma, L; Chen, JZ; Zhang, Y; Peng, L; Gan, C; Ma, XM; Zhu, BD				Liu, Xun; Li, Fei; Niu, Hongxia; Ma, Lan; Chen, Jianzhu; Zhang, Ying; Peng, Liang; Gan, Chao; Ma, Xingming; Zhu, Bingdong			IL-2 Restores T-Cell Dysfunction Induced by Persistent Mycobacterium tuberculosis Antigen Stimulation (vol 10, 2350, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						Mycobacterium tuberculosis; T cell exhaustion; T cell dysfunction; antigen persistence; IL-2			[Liu, Xun; Li, Fei; Niu, Hongxia; Ma, Lan; Gan, Chao; Ma, Xingming; Zhu, Bingdong] Lanzhou Univ, Sch Basic Med Sci, Gansu Prov Key Lab Evidence Based Med & Clin Tran, Lanzhou, Peoples R China; [Liu, Xun; Li, Fei; Niu, Hongxia; Ma, Lan; Gan, Chao; Ma, Xingming; Zhu, Bingdong] Lanzhou Univ, Sch Basic Med Sci, Lanzhou Ctr TB Res, Lanzhou, Peoples R China; [Liu, Xun; Li, Fei; Niu, Hongxia; Ma, Lan; Gan, Chao; Zhu, Bingdong] Lanzhou Univ, Inst Pathogen Biol, Sch Basic Med Sci, Lanzhou, Peoples R China; [Chen, Jianzhu] MIT, Koch Inst Integrat Canc Res, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Zhang, Ying] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD USA; [Peng, Liang] Lanzhou Univ, Sch Life Sci, Ctr Life Sci, Lanzhou, Peoples R China	Lanzhou University; Lanzhou University; Lanzhou University; Massachusetts Institute of Technology (MIT); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Lanzhou University	Zhu, BD (corresponding author), Lanzhou Univ, Sch Basic Med Sci, Gansu Prov Key Lab Evidence Based Med & Clin Tran, Lanzhou, Peoples R China.; Zhu, BD (corresponding author), Lanzhou Univ, Sch Basic Med Sci, Lanzhou Ctr TB Res, Lanzhou, Peoples R China.; Zhu, BD (corresponding author), Lanzhou Univ, Inst Pathogen Biol, Sch Basic Med Sci, Lanzhou, Peoples R China.	bdzhu@lzu.edu.cn						Liu X, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02350	1	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 31	2020	11								1671	10.3389/fimmu.2020.01671	http://dx.doi.org/10.3389/fimmu.2020.01671			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NC9UF	32849579	gold, Green Published			2022-12-18	WOS:000561555000001
J	Chen, HM; Liu, HZ; Lu, CN; Wang, MJ; Li, X; Zhao, H; Yan, YH; Yu, WL; Han, L; Dai, ZH				Chen, Haiming; Liu, Huazhen; Lu, Chuanjian; Wang, Maojie; Li, Xiong; Zhao, Hui; Yan, Yuhong; Yu, Wanling; Han, Ling; Dai, Zhenhua			PSORI-CM02 Formula Increases CD4+ Foxp3+ Regulatory T Cell Frequency and Ameliorates Imiquimod-Induced Psoriasis in Mice (vol 8, 1767, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						psoriasis; inflammation; immunoregulation; regulatory T cell; PSORI-CM02			[Chen, Haiming; Liu, Huazhen; Lu, Chuanjian; Wang, Maojie; Li, Xiong; Yan, Yuhong; Yu, Wanling; Han, Ling; Dai, Zhenhua] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangzhou, Peoples R China; [Chen, Haiming] Guangzhou Univ Chinese Med, Postdoctoral Programme, Guangzhou, Peoples R China; [Chen, Haiming; Liu, Huazhen; Lu, Chuanjian; Wang, Maojie; Li, Xiong; Yan, Yuhong; Yu, Wanling; Han, Ling; Dai, Zhenhua] Guangdong Prov Hosp Chinese Med, Guangzhou, Peoples R China; [Chen, Haiming; Liu, Huazhen; Lu, Chuanjian; Wang, Maojie; Li, Xiong; Yu, Wanling; Han, Ling; Dai, Zhenhua] Guangdong Prov Acad Chinese Med Sci, Guangzhou, Peoples R China; [Lu, Chuanjian; Han, Ling] Guangdong Prov Key Lab Clin Res Tradit Chinese Me, Guangzhou, Peoples R China; [Zhao, Hui] Chinese Univ Hong Kong, Sch Biomed Sci, Key Lab Regenerat Med, Minist Educ,Fac Med, Hong Kong, Peoples R China; [Zhao, Hui] Chinese Acad Sci Chinese Univ Hong Kong Joint Lab, Kunming Inst Zool, Hong Kong, Peoples R China	Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Chinese University of Hong Kong; Chinese Academy of Sciences; Kunming Institute of Zoology	Lu, CN; Han, L; Dai, ZH (corresponding author), Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangzhou, Peoples R China.; Lu, CN; Han, L; Dai, ZH (corresponding author), Guangdong Prov Hosp Chinese Med, Guangzhou, Peoples R China.; Lu, CN; Han, L; Dai, ZH (corresponding author), Guangdong Prov Acad Chinese Med Sci, Guangzhou, Peoples R China.; Lu, CN; Han, L (corresponding author), Guangdong Prov Key Lab Clin Res Tradit Chinese Me, Guangzhou, Peoples R China.	luchuanjian888@vip.sina.com; linghan36@163.com; zdai2009@hotmail.com		Wang, Maojie/0000-0003-1417-416X				Chen HM, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01767	1	0	0	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 29	2020	11								1650	10.3389/fimmu.2020.01650	http://dx.doi.org/10.3389/fimmu.2020.01650			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NC9AW	32849567	gold, Green Published			2022-12-18	WOS:000561504300001
J	Hart, DP				Hart, Daniel P.			FVIII Immunogenicity-Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A	FRONTIERS IN IMMUNOLOGY			English	Review						inhibitor; in silico; risk; non-severe hemophilia; prediction	COMPLEX CLASS-II; T-CELL-CLONES; FACTOR-VIII; IMMUNE TOLERANCE; RANDOMIZED-TRIAL; MUTATION; POLYMORPHISMS; PROPHYLAXIS; RESPONSES; PEPTIDES	The life-long inhibitor risk in non-severe hemophilia A has been an important clinical and research focus in recent years. Non-severe hemophilia A is most commonly caused by point mutation, missenseF8genotypes, of which over 500 variants are described. The immunogenic potential of just a single amino acid change within a complex 2,332 amino acid protein is an important reminder of the challenges of protein replacement therapies in diverse, global populations. Although someF8genotypes have been identified as "high risk" mutations in non-severe hemophilia A (e.g., R593C), this is likely, in part at least, a reporting bias and oversimplification of the underlying immunological mechanism. Bioinformatic approaches offer a strategy to dissect the contribution ofF8genotype in the context of the wider HLA diversity through which antigenic peptides will necessarily be presented. Extensive modeling of all permutations of FVIII-derived fifteen-mer peptides straddling all reportedF8genotype positions demonstrate the likely heterogeneity of peptide binding affinity to different HLA II grooves. For the majority ofF8genotypes it is evident that inhibitor risk prediction is dependent on the combination ofF8genotype and available HLA II. Only a minority of FVIII-derived peptides are predicted to bind to all candidate HLA molecules.In silicopredictions still over call the risk of inhibitor occurrence, suggestive of mechanisms of "protection" against clinically meaningful inhibitor events. The structural homology between FVIII and FV provides an attractive mechanism by which someF8genotypes may be afforded co-incidental tolerance through homology of FV and FVIII primary amino sequence.In silicostrategies enable the extension of this hypothesis to analyse the extent to which co-incidental cross-matching exists between FVIII-derived primary peptide sequences and any other protein in the entire human proteome and thus potential central tolerance. This review of complimentaryin vitro, in silico, and clinical epidemiology data documents incremental insights into immunological mechanism of inhibitor occurrence in non-severe hemophilia A over the last decade. However, complex questions remain about antigenic processing and presentation to truly understand and predict an individual person with hemophilia risk of inhibitor occurrence.	[Hart, Daniel P.] Queen Mary Univ London, Dept Immunobiol, Barts & London Sch Med & Dent, Blizard Inst, London, England	University of London; Queen Mary University London	Hart, DP (corresponding author), Queen Mary Univ London, Dept Immunobiol, Barts & London Sch Med & Dent, Blizard Inst, London, England.	d.hart@qmul.ac.uk						ALY AM, 1990, BRIT J HAEMATOL, V76, P238, DOI 10.1111/j.1365-2141.1990.tb07878.x; Astermark J, 2006, BLOOD, V108, P3739, DOI 10.1182/blood-2006-05-024711; Astermark J, 2013, BLOOD, V121, P1446, DOI 10.1182/blood-2012-06-434803; Batty P, 2018, INT J LAB HEMATOL, V40, P561, DOI 10.1111/ijlh.12862; Batty P, 2017, BRIT J HAEMATOL, V176, P796, DOI 10.1111/bjh.14543; BIGGS R, 1959, Sang, V30, P340; Collins PW, 2014, BLOOD, V124, P3389, DOI 10.1182/blood-2014-07-580498; DiMichele DM, 2006, J THROMB HAEMOST, V4, P2271, DOI 10.1111/j.1538-7836.2006.02127.x; Dong GQ, 2013, BIOINFORMATICS, V29, P3158, DOI 10.1093/bioinformatics/btt560; Earnshaw SR, 2015, HAEMOPHILIA, V21, P310, DOI 10.1111/hae.12621; Eckhardt CL, 2015, J THROMB HAEMOST, V13, P1217, DOI 10.1111/jth.12990; Eckhardt CL, 2009, J THROMB HAEMOST, V7, P930, DOI 10.1111/j.1538-7836.2009.03357.x; Eckhardt CL, 2013, BLOOD, V122, P1954, DOI 10.1182/blood-2013-02-483263; Ettinger RA, 2009, BLOOD, V114, P1423, DOI 10.1182/blood-2009-01-200725; Gouw SC, 2013, NEW ENGL J MED, V368, P231, DOI 10.1056/NEJMoa1208024; Hart DP, 2019, HAEMATOLOGICA, V104, P599, DOI 10.3324/haematol.2018.195669; Hartman IZ, 2010, NAT MED, V16, P1333, DOI 10.1038/nm.2248; Hay CRM, 1997, THROMB HAEMOSTASIS, V77, P234; Jacquemin M, 2003, BLOOD, V101, P1351, DOI 10.1182/blood-2002-05-1369; James EA, 2011, J THROMB HAEMOST, V9, P689, DOI 10.1111/j.1538-7836.2011.04202.x; Kempton CL, 2018, BLOOD ADV, V2, P1750, DOI 10.1182/bloodadvances.2018019323; Nielsen M, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-296; NILSSON IM, 1970, BIBL HAEMATOL, P111; O'Donoghue AJ, 2012, NAT METHODS, V9, P1095, DOI [10.1038/nmeth.2182, 10.1038/NMETH.2182]; Oldenburg J, 1997, THROMB HAEMOSTASIS, V77, P238; Pashov AD, 2014, HAEMOPHILIA, V20, P176, DOI 10.1111/hae.12276; Pavlova A, 2009, J THROMB HAEMOST, V7, P2006, DOI 10.1111/j.1538-7836.2009.03636.x; Peyron I, 2018, HAEMATOLOGICA, V103, P172, DOI 10.3324/haematol.2017.175083; Peyvandi F, 2016, NEW ENGL J MED, V374, P2054, DOI 10.1056/NEJMoa1516437; POOL JG, 1965, NEW ENGL J MED, V273, P1443, DOI 10.1056/NEJM196512302732701; POOL JG, 1964, NATURE, V203, P312, DOI 10.1038/203312a0; Schneidman-Duhovny D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206654; Schwaab R, 1995, THROMB HAEMOSTASIS, V74, P1402; Shepherd AJ, 2015, BRIT J HAEMATOL, V168, P413, DOI 10.1111/bjh.13131; van Haren SD, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002246; van Velzen AS, 2015, THROMB HAEMOSTASIS, V114, P46, DOI 10.1160/TH14-11-0940; Whelan SFJ, 2013, BLOOD, V121, P1039, DOI 10.1182/blood-2012-07-444877; WHITE GC, 1989, NEW ENGL J MED, V320, P166, DOI 10.1056/NEJM198901193200307; White GC, 2001, THROMB HAEMOSTASIS, V85, P560, DOI 10.1055/s-0037-1615621	39	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 28	2020	11								1498	10.3389/fimmu.2020.01498	http://dx.doi.org/10.3389/fimmu.2020.01498			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NC6ZR	32849511	Green Published, gold			2022-12-18	WOS:000561366000001
J	Jergovic, M; Thompson, HL; Renkema, KR; Smithey, MJ; Nikolich-Zugich, J				Jergovic, Mladen; Thompson, Heather L.; Renkema, Kristin R.; Smithey, Megan J.; Nikolich-Zugich, Janko			Defective Transcriptional Programming of Effector CD8 T Cells in Aged Mice Is Cell-Extrinsic and Can Be Corrected by Administration of IL-12 and IL-18 (vol 10, 2206, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						aging; cytotoxic T cells; inflammation; cytokines; bacterial infection			[Jergovic, Mladen; Thompson, Heather L.; Renkema, Kristin R.; Smithey, Megan J.; Nikolich-Zugich, Janko] Univ Arizona, Coll Med, Dept Immunobiol, Tucson, AZ 85721 USA; [Jergovic, Mladen; Thompson, Heather L.; Renkema, Kristin R.; Smithey, Megan J.; Nikolich-Zugich, Janko] Univ Arizona, Coll Med, Ctr Aging, Tucson, AZ 85721 USA; [Renkema, Kristin R.] Grand Valley State Univ, Biomed Sci Dept, Allendale, MI 49401 USA	University of Arizona; University of Arizona; Grand Valley State University	Nikolich-Zugich, J (corresponding author), Univ Arizona, Coll Med, Dept Immunobiol, Tucson, AZ 85721 USA.; Nikolich-Zugich, J (corresponding author), Univ Arizona, Coll Med, Ctr Aging, Tucson, AZ 85721 USA.	jnikolich@medadmin.arizona.edu			USPHS awards from the National Institute of Health [NIH/NIAID HHSN27220110017C, R01 AG020719, P01 052359]; NATIONAL INSTITUTE ON AGING [R37AG020719] Funding Source: NIH RePORTER	USPHS awards from the National Institute of Health; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by USPHS awards NIH/NIAID HHSN27220110017C, R01 AG020719, and P01 052359 to JN-Z from the National Institute of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Jergovic M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02206	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 28	2020	11								1367	10.3389/fimmu.2020.01367	http://dx.doi.org/10.3389/fimmu.2020.01367			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NC7KY	32849497	Green Published, gold			2022-12-18	WOS:000561395300001
J	Maria, LD; Marcello, C; Monica, V				Maria, Leite-de-Moraesko; Marcello, Chieppa; Monica, Vermeulen			Editorial: Innate Immune Cells and Inflammatory Mediators in Mucosal Pathologies	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						inflammation; innate cells; mucosal pathology; mediators; homeostasis			[Maria, Leite-de-Moraesko] CNRS, INEM, Lab Immunoregulat & Immunopathol, UMR8253, Paris, France; [Maria, Leite-de-Moraesko] INSERM, UMR1151, Paris, France; [Marcello, Chieppa] Natl Inst Gastroenterol S Bellis, Res Hosp, Castellana Grotte, Italy; [Monica, Vermeulen] Acad Nacl Med Buenos Aires, CONICET, Lab Celulas Presentadoras Antigeno & Respuesta In, IMEX Inst Med Expt, Buenos Aires, DF, Argentina	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Buenos Aires National Academy of Medicine; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Monica, V (corresponding author), Acad Nacl Med Buenos Aires, CONICET, Lab Celulas Presentadoras Antigeno & Respuesta In, IMEX Inst Med Expt, Buenos Aires, DF, Argentina.	mvermeulen@hematologia.anm.edu.ar	Chieppa, Marcello/I-8447-2018	Chieppa, Marcello/0000-0001-9819-0823	Consejo de Investigaciones cientificas y tecnologicas (CONICET) [PIP 2017-0950]	Consejo de Investigaciones cientificas y tecnologicas (CONICET)(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET))	Funded by grants from Consejo de Investigaciones cientificas y tecnologicas (CONICET) PIP 2017-0950.		0	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 28	2020	11								1679	10.3389/fimmu.2020.01679	http://dx.doi.org/10.3389/fimmu.2020.01679			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NC7CB	32849584	Green Published, gold			2022-12-18	WOS:000561372200001
J	Sautto, GA; Diotti, RA				Sautto, Giuseppe A.; Diotti, Roberta A.			Editorial: Immunotherapeutic and Immunoprophylactic Strategies for Infectious Diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						infectious diseases; vaccines; antiviral drugs; monoclonal antibodies; chimeric antigen receptor (CAR)	ANTIBODIES; THERAPY		[Sautto, Giuseppe A.] Univ Georgia, Ctr Vaccines & Immunol, Athens, GA 30602 USA; [Diotti, Roberta A.] Univ Vita Salute San Raffaele, Microbiol & Virol Unit, Milan, Italy	University System of Georgia; University of Georgia; Vita-Salute San Raffaele University	Sautto, GA (corresponding author), Univ Georgia, Ctr Vaccines & Immunol, Athens, GA 30602 USA.	gasautto@uga.edu						Andreano E, 2019, CURR OPIN IMMUNOL, V59, P130, DOI 10.1016/j.coi.2019.07.005; Cohen J, 2020, SCIENCE, V368, P564, DOI 10.1126/science.368.6491.564; Mancini N, 2015, FUTURE MICROBIOL, V10, P665, DOI [10.2217/FMB.14.122, 10.2217/fmb.14.122]; Setliff I, 2019, CELL, V179, P1636, DOI 10.1016/j.cell.2019.11.003	4	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 28	2020	11								1670	10.3389/fimmu.2020.01670	http://dx.doi.org/10.3389/fimmu.2020.01670			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NC7AB	32849578	gold, Green Published			2022-12-18	WOS:000561367000001
J							Frontiers Editorial Off	RETRACTION: The Increase in IL-1 beta in the Early Stage of Heatstroke Might Be Caused by Splenic Lymphocyte Pyroptosis Induced by mtROS-Mediated Activation of the NLRP3 Inflammasome (Retraction of Vol 10, art no 2862, 2019)	FRONTIERS IN IMMUNOLOGY			English	Retraction																		Wang G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02862	1	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 24	2020	11								1863	10.3389/fimmu.2020.01863	http://dx.doi.org/10.3389/fimmu.2020.01863			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NB5WJ		gold, Green Published			2022-12-18	WOS:000560581900001
J	Vanmierlo, T; van Horssen, J; Hellings, N; Broux, B				Vanmierlo, Tim; van Horssen, Jack; Hellings, Niels; Broux, Bieke			Editorial: Neuro-Immune Connections to Enable Repair in CNS Disorders	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						neuroimmunology; central nervous system; immune system; CNS repair; CNS disorders			[Vanmierlo, Tim; Hellings, Niels; Broux, Bieke] Hasselt Univ, Biomed Res Inst, Neuroimmune Connect & Repair Lab, Dept Immunol & Infect,Univ MS Ctr, Hasselt, Belgium; [Vanmierlo, Tim] Maastricht Univ, Sch Mental Hlth & Neurosci, Div Translat Neurosci, Maastricht, Netherlands; [van Horssen, Jack] Vrije Univ Amsterdam, Amsterdam UMC, Amsterdam Neurosci, Dept Mol Cell Biol & Immunol,MS Ctr Amsterdam, Amsterdam, Netherlands; [Broux, Bieke] Maastricht Univ, Cardiovasc Res Inst Maastricht, Dept Internal Med, Maastricht, Netherlands	Hasselt University; Maastricht University; University of Amsterdam; Vrije Universiteit Amsterdam; Maastricht University	Broux, B (corresponding author), Hasselt Univ, Biomed Res Inst, Neuroimmune Connect & Repair Lab, Dept Immunol & Infect,Univ MS Ctr, Hasselt, Belgium.; Broux, B (corresponding author), Maastricht Univ, Cardiovasc Res Inst Maastricht, Dept Internal Med, Maastricht, Netherlands.	Bieke.broux@uhasselt.be	Broux, Bieke/AAK-3721-2021; Vanmierlo, Tim/C-7773-2013	Vanmierlo, Tim/0000-0003-2912-0578; Broux, Bieke/0000-0001-8509-2415; van Horssen, Jack/0000-0003-4078-7402	Fonds voor Wetenschappelijk Onderzoek (FWO); Belgian Charcot Stichting; Stichting MS Research; MS International Foundation; MoveS	Fonds voor Wetenschappelijk Onderzoek (FWO)(FWO); Belgian Charcot Stichting; Stichting MS Research; MS International Foundation; MoveS	The editors of this Research Topic are funded by Fonds voor Wetenschappelijk Onderzoek (FWO), the Belgian Charcot Stichting, Stichting MS Research, MS International Foundation, and MoveS.		0	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 24	2020	11								1425	10.3389/fimmu.2020.01425	http://dx.doi.org/10.3389/fimmu.2020.01425			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NB5WL	32793198	Green Published, gold			2022-12-18	WOS:000560582100001
J	Xu, CL; Lu, YP; Zheng, X; Feng, XM; Yang, XC; Timm, J; Wu, J; Wang, BJ; Lu, MJ; Yang, DL; Liu, J				Xu, Chunli; Lu, Yinping; Zheng, Xin; Feng, Xuemei; Yang, Xuecheng; Timm, Joerg; Wu, Jun; Wang, Baoju; Lu, Mengji; Yang, Dongliang; Liu, Jia			TLR2 Expression in Peripheral CD4+ T Cells Promotes Th17 Response and Is Associated with Disease Aggravation of Hepatitis B Virus-Related Acute-On-Chronic Liver Failure (vol 8, 1609, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						toll-like receptor 2; chronic hepatitis B; chronic hepatitis B-related liver failure; T helper cell 17; CD4+T cells			[Xu, Chunli; Lu, Yinping; Zheng, Xin; Feng, Xuemei; Yang, Xuecheng; Wu, Jun; Wang, Baoju; Yang, Dongliang; Liu, Jia] Huazhong Univ Sci & Technol Wuhan, Union Hosp, Dept Infect Dis, Tongji Med Coll, Wuhan, Peoples R China; [Xu, Chunli] Huazhong Univ Sci & Technol Wuhan, Union Hosp, Dept Anesthesiol, Tongji Med Coll, Wuhan, Peoples R China; [Timm, Joerg] Heinrich Heine Univ Dusseldorf, Univ Hosp, Inst Virol, Dusseldorf, Germany; [Lu, Mengji] Univ Duisburg Essen, Univ Hosp Essen, Inst Virol, Essen, Germany	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Heinrich Heine University Dusseldorf; University of Duisburg Essen	Liu, J (corresponding author), Huazhong Univ Sci & Technol Wuhan, Union Hosp, Dept Infect Dis, Tongji Med Coll, Wuhan, Peoples R China.	jialiu77@hotmail.com	Lu, Mengji/ABF-9410-2020					Xu CL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01609	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 24	2020	11								1566	10.3389/fimmu.2020.01566	http://dx.doi.org/10.3389/fimmu.2020.01566			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NB5WH	32793220	Green Published, gold			2022-12-18	WOS:000560581700001
J	Carmo, AM; Love, PE; Marshall, AJ				Carmo, Alexandre M.; Love, Paul E.; Marshall, Aaron J.			Editorial: Inhibitory Receptors and Pathways of Lymphocytes	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						lymphocyte; inhibitory receptor; inhibitory signaling; checkpoint blockade; immunotherapy; autoimmunity; cancer			[Carmo, Alexandre M.] IBMC Inst Biol Mol & Celular, Porto, Portugal; [Carmo, Alexandre M.] Univ Porto, I3S Inst Invest & Inovacao Saude, Porto, Portugal; [Love, Paul E.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Hematopoiesis & Lymphocyte Biol, NIH, Bethesda, MD USA; [Marshall, Aaron J.] Univ Manitoba, Rady Fac Hlth Sci, Dept Immunol, Winnipeg, MB, Canada	Universidade do Porto; Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Manitoba	Marshall, AJ (corresponding author), Univ Manitoba, Rady Fac Hlth Sci, Dept Immunol, Winnipeg, MB, Canada.	aaron.marshall@umanitoba.ca	Carmo, Alexandre M./B-5191-2011	Carmo, Alexandre M./0000-0002-2508-9799	FEDER through the Operacional Programme for Competitiveness and Internationalization (POCI); Portuguese funds through FCT [PTDC/MEDIMU/32296/2017]; Canadian Institutes of Health Research [PJT-162268]	FEDER through the Operacional Programme for Competitiveness and Internationalization (POCI); Portuguese funds through FCT(Portuguese Foundation for Science and Technology); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	AC was funded by FEDER through the Operacional Programme for Competitiveness and Internationalization (POCI) and by Portuguese funds through FCT, grant PTDC/MEDIMU/32296/2017. AM was funded by the Canadian Institutes of Health Research (PJT-162268).		0	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 22	2020	11								1552	10.3389/fimmu.2020.01552	http://dx.doi.org/10.3389/fimmu.2020.01552			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MZ7ZD	32793215	Green Published, gold			2022-12-18	WOS:000559344400001
J	Rosini, R; Nicchi, S; Pizza, M; Rappuoli, R				Rosini, Roberto; Nicchi, Sonia; Pizza, Mariagrazia; Rappuoli, Rino			Vaccines Against Antimicrobial Resistance (vol 11, 1048, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						vaccines; infectious diseases; antimicrobial resistance (AMR); vaccine development; vaccinology; mechanisms of antibiotic resistance			[Rosini, Roberto; Nicchi, Sonia; Pizza, Mariagrazia; Rappuoli, Rino] GSK, Siena, Italy; [Nicchi, Sonia] Univ Bologna, Dept Pharm & Biotechnol FaBiT, Bologna, Italy; [Rappuoli, Rino] VAMRes Lab, Toscana Life Sci, Siena, Italy; [Rappuoli, Rino] Imperial Coll London, Fac Med, London, England	GlaxoSmithKline; University of Bologna; Imperial College London	Rappuoli, R (corresponding author), GSK, Siena, Italy.; Rappuoli, R (corresponding author), VAMRes Lab, Toscana Life Sci, Siena, Italy.; Rappuoli, R (corresponding author), Imperial Coll London, Fac Med, London, England.	rino.r.rappuoli@gsk.com						Rosini R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01048	1	0	0	2	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 21	2020	11								1578	10.3389/fimmu.2020.01578	http://dx.doi.org/10.3389/fimmu.2020.01578			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NA4QW	32849536				2022-12-18	WOS:000559803900001
J	Attaf, N; Cervera-Marzal, I; Dong, C; Gil, L; Renand, A; Spinelli, L; Milpied, P				Attaf, Noudjoud; Cervera-Marzal, Inaki; Dong, Chuang; Gil, Laurine; Renand, Amedee; Spinelli, Lionel; Milpied, Pierre			FB5P-seq: FACS-Based 5-Prime End Single-Cell RNA-seq for Integrative Analysis of Transcriptome and Antigen Receptor Repertoire in B and T Cells (vol 11, 216, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						single-cell RNA sequencing; transcriptome; antigen receptor; B cells; T cells			[Attaf, Noudjoud; Cervera-Marzal, Inaki; Dong, Chuang; Gil, Laurine; Spinelli, Lionel; Milpied, Pierre] Aix Marseille Univ, CNRS, INSERM, Ctr Immunol Marseille Luminy, Marseille, France; [Renand, Amedee] Univ Nantes, INSERM, UMR1064, Ctr Rech Transplantat & Immunol, Nantes, France; [Cervera-Marzal, Inaki] Eura Nova, Marseille, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite	Milpied, P (corresponding author), Aix Marseille Univ, CNRS, INSERM, Ctr Immunol Marseille Luminy, Marseille, France.	milpied@ciml.univ-mrs.fr	Milpied, Pierre J/Q-1380-2015	Milpied, Pierre J/0000-0003-1873-5358; ATTAF, Noudjoud/0000-0001-7254-7679				Attaf N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00216	1	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 17	2020	11								1521	10.3389/fimmu.2020.01521	http://dx.doi.org/10.3389/fimmu.2020.01521			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MW1RP	32765526	Green Published, gold			2022-12-18	WOS:000556823500001
J	Liu, YC; Li, L				Liu, Yangchun; Li, Li			Commentary: Proinflammatory role of blister fluid-derived exosomes in bullous pemphigoid	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						exosome; bullous pemphigoid; skin disorder; immunology; inflammation	EXPRESSION; CELLS; SERUM		[Liu, Yangchun; Li, Li] Peking Union Med Coll & Chinese Acad Med Sci, Dept Dermatol, Peking Union Med Coll Hosp, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital	Li, L (corresponding author), Peking Union Med Coll & Chinese Acad Med Sci, Dept Dermatol, Peking Union Med Coll Hosp, Beijing, Peoples R China.	lilipumch2007@sina.com			National Key Research and Development Program of China [2016YFC0901500]; National Natural Science Foundation of China [81972945]; Milstein Medical Asian American Partnership Foundation and Education Reform Projects of Peking Union Medical College [2016zlgc0106]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Milstein Medical Asian American Partnership Foundation and Education Reform Projects of Peking Union Medical College	This work was supported by the National Key Research and Development Program of China Grant No. 2016YFC0901500, National Natural Science Foundation of China (81972945), and Milstein Medical Asian American Partnership Foundation and Education Reform Projects of Peking Union Medical College (2016zlgc0106).	Admyre C, 2006, EUR J IMMUNOL, V36, P1772, DOI 10.1002/eji.200535615; Amber KT, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00201; Amber KT, 2018, CLIN REV ALLERG IMMU, V54, P26, DOI 10.1007/s12016-017-8633-4; Ameglio F, 1998, BRIT J DERMATOL, V138, P611; Bagci IS, 2017, AUTOIMMUN REV, V16, P445, DOI 10.1016/j.autrev.2017.03.010; Bonciani D, 2017, J DERMATOL SCI, V87, P210, DOI 10.1016/j.jdermsci.2017.04.008; Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326; Fang H, 2018, J PATHOL, V245, P114, DOI 10.1002/path.5061; Fang H, 2016, J DERMATOL SCI, V83, P116, DOI 10.1016/j.jdermsci.2016.04.009; Gunther C, 2011, CLIN EXP IMMUNOL, V166, P145, DOI 10.1111/j.1365-2249.2011.04464.x; Plee J, 2015, SCI REP-UK, V5, DOI 10.1038/srep18001; Selmaj I, 2017, J NEUROIMMUNOL, V306, P1, DOI 10.1016/j.jneuroim.2017.02.002; Skokos D, 2003, J IMMUNOL, V170, P3037, DOI 10.4049/jimmunol.170.6.3037; Tan LN, 2016, AUTOIMMUNITY, V49, P357, DOI 10.1080/08916934.2016.1191477; Tukaj S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070496; Turpin D, 2016, AUTOIMMUN REV, V15, P174, DOI 10.1016/j.autrev.2015.11.004; Zhu T, 2019, ANN MED, V51, P101, DOI 10.1080/07853890.2019.1592215	17	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 16	2020	11								1506	10.3389/fimmu.2020.01506	http://dx.doi.org/10.3389/fimmu.2020.01506			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MW0XM	32765519	gold, Green Published			2022-12-18	WOS:000556770900001
J	Chatterjea, D				Chatterjea, Devavani			Teaching Immunology as a Liberal Art	FRONTIERS IN IMMUNOLOGY			English	Article						immunology education; undergraduate; liberal arts; storytelling; metaphor		A complex, rapidly evolving biomedical field that is of critical relevance to human health and well-being, immunology provides important and substantive opportunities to practice and teach the central tenets of a liberal arts curriculum.	[Chatterjea, Devavani] Macalester Coll, Dept Biol, St Paul, MN 55105 USA	Macalester College	Chatterjea, D (corresponding author), Macalester Coll, Dept Biol, St Paul, MN 55105 USA.	chatterjead@macalester.edu						Auerbach RP, 2018, J ABNORM PSYCHOL, V127, P623, DOI 10.1037/abn0000362; Buchsbaum D, 2012, PHILOS T R SOC B, V367, P2202, DOI 10.1098/rstb.2012.0122; DeKruif P, 1926, MICROBE HUNTERS REIS; Hooks B ., 1994, TEACHING COMMUNITY P; hooks bell, 1994, TEACHING TRANSGRESS, P59; Intergovernmental Panel on Climate Change, 2018, GLOB WARM 1 5 0 C GLOB WARM 1 5 0 C; Kaufmann SHE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00684; Muscatell KA, 2020, MOL PSYCHIATR, V25, P2189, DOI 10.1038/s41380-018-0259-2; Ngozi AC, 2009, DANGER SINGLE STORY; Only Connect, 1998, AM SCHOLAR, V67, P4	10	0	0	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 14	2020	11								1462	10.3389/fimmu.2020.01462	http://dx.doi.org/10.3389/fimmu.2020.01462			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MV8WV	32765506	gold, Green Published			2022-12-18	WOS:000556631900001
J	Sitnicka, E; Bryceson, Y; Freud, AG; Mace, EM				Sitnicka, Ewa; Bryceson, Yenan; Freud, Aharon G.; Mace, Emily M.			Editorial: Molecular and Cellular Pathways in NK Cell Development	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						NK cells; developmental and maturation stages; regulatory pathways; disease-induced defects; clinical applications			[Sitnicka, Ewa] Lund Univ, Dept Lab Med, Div Mol Hematol, Lund, Sweden; [Bryceson, Yenan] Karolinska Inst, Dept Med, Ctr Hematol & Regenerat Med, Stockholm, Sweden; [Bryceson, Yenan] Univ Bergen, Dept Clin Sci, Broegelmann Res Lab, Bergen, Norway; [Freud, Aharon G.] Ohio State Univ, Dept Pathol, James Canc Hosp, Columbus, OH 43210 USA; [Freud, Aharon G.] Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA; [Freud, Aharon G.] Ohio State Univ, Comprehens Canc Ctr, James Canc Hosp, Columbus, OH 43210 USA; [Mace, Emily M.] Columbia Univ, Dept Pediat, Irving Med Ctr, New York, NY 10027 USA	Lund University; Karolinska Institutet; University of Bergen; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Columbia University; NewYork-Presbyterian Hospital	Sitnicka, E (corresponding author), Lund Univ, Dept Lab Med, Div Mol Hematol, Lund, Sweden.	ewa.sitnicka_quinn@med.lu.se	Bryceson, Yenan/D-2121-2018	Bryceson, Yenan/0000-0002-7783-9934	Swedish Research Council; Swedish Foundation for Cancer Research; Lund University Medical Faculty; Swedish Foundation for Childhood Cancer; Center for Innovative Medicine; USA National Institutes of Health/National Cancer Institute [CA199447, CA208353]; NIH-NIAID [R01AI137073, R0AI137275]; Stem Therapy Program	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Foundation for Cancer Research; Lund University Medical Faculty; Swedish Foundation for Childhood Cancer; Center for Innovative Medicine; USA National Institutes of Health/National Cancer Institute; NIH-NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Stem Therapy Program	ES was supported by funding provided by the Swedish Research Council including the Stem Therapy Program, the Swedish Foundation for Cancer Research and the Lund University Medical Faculty. YB was supported by the Swedish Research Council, the Swedish Foundation for Cancer Research, the Swedish Foundation for Childhood Cancer, and the Center for Innovative Medicine. AF was supported by funding from the USA National Institutes of Health/National Cancer Institute (CA199447 and CA208353). EM was supported by NIH-NIAID R01AI137073 and R0AI137275.		0	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 14	2020	11								1448	10.3389/fimmu.2020.01448	http://dx.doi.org/10.3389/fimmu.2020.01448			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MV3XA	32760398	gold, Green Published			2022-12-18	WOS:000556293300001
J	Piconese, S; Campello, S; Natalini, A				Piconese, Silvia; Campello, Silvia; Natalini, Ambra			Recirculation and Residency of T Cells and Tregs: Lessons Learnt in Anacapri (vol 11, 682, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						T cells; Tregs; cell migration; cell cycle; recirculation			[Piconese, Silvia] Sapienza Univ Roma, Dipartimento Sci Clin Internist Anestesiol & Card, Rome, Italy; [Piconese, Silvia] Fdn Cenci Bolognetti, Ist Pasteur Italia, Rome, Italy; [Campello, Silvia] Univ Roma Tor Vergata, Dept Biol, Rome, Italy; [Natalini, Ambra] CNR, Natl Res Council, Inst Mol Biol & Pathol, Rome, Italy; [Natalini, Ambra] Sapienza Univ Roma, Dipartimento Med Mol DMM, Rome, Italy	Sapienza University Rome; Fondazione Cenci Bolognetti; University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome	Natalini, A (corresponding author), CNR, Natl Res Council, Inst Mol Biol & Pathol, Rome, Italy.; Natalini, A (corresponding author), Sapienza Univ Roma, Dipartimento Med Mol DMM, Rome, Italy.	ambra.natalini@uniroma1.it		Natalini, Ambra/0000-0002-7618-493X; Piconese, Silvia/0000-0002-9685-5227				Piconese S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00682	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 9	2020	11								1401	10.3389/fimmu.2020.01401	http://dx.doi.org/10.3389/fimmu.2020.01401			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MU3NC	32742268	Green Published, gold			2022-12-18	WOS:000555578100001
J	Valero-Pacheco, N; Beaulieu, AM				Valero-Pacheco, Nuriban; Beaulieu, Aimee M.			Transcriptional Regulation of Mouse Tissue-Resident Natural Killer Cell Development (vol 11, 309, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						natural killer cells; tissue-resident NK cells; transcriptional regulation; transcription factors; group 1 innate lymphoid cells			[Valero-Pacheco, Nuriban; Beaulieu, Aimee M.] Rutgers State Univ, New Jersey Med Sch, Ctr Immun & Inflammat, Rutgers Biomed & Hlth Sci, Newark, NJ 07102 USA; [Valero-Pacheco, Nuriban; Beaulieu, Aimee M.] Rutgers State Univ, New Jersey Med Sch, Dept Microbiol Biochem & Mol Genet, Rutgers Biomed & Hlth Sci, Newark, NJ 07102 USA	Rutgers State University Newark; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University Newark; Rutgers State University New Brunswick; Rutgers State University Medical Center	Beaulieu, AM (corresponding author), Rutgers State Univ, New Jersey Med Sch, Ctr Immun & Inflammat, Rutgers Biomed & Hlth Sci, Newark, NJ 07102 USA.; Beaulieu, AM (corresponding author), Rutgers State Univ, New Jersey Med Sch, Dept Microbiol Biochem & Mol Genet, Rutgers Biomed & Hlth Sci, Newark, NJ 07102 USA.	ab1550@njms.rutgers.edu	Valero-Pacheco, Nuriban/GPS-5781-2022	Valero-Pacheco, Nuriban/0000-0001-6091-6043				Valero-Pacheco N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00309	1	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 8	2020	11								1355	10.3389/fimmu.2020.01355	http://dx.doi.org/10.3389/fimmu.2020.01355			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MT5AP	32733452	Green Published, gold			2022-12-18	WOS:000554984300001
J	Mane-Damas, M; Vinke, A; Hoffmann, C; Zong, SH; Losen, M; Molenaar, PC; Damoiseaux, J; Koudijs, S; Rouhl, RPW; Martinez-Martinez, P				Mane-Damas, Marina; Vinke, Anita; Hoffmann, Carolin; Zong, Shenghua; Losen, Mario; Molenaar, Peter C.; Damoiseaux, Jan; Koudijs, Suzanne; Rouhl, Rob P. W.; Martinez-Martinez, Pilar			Unidentified Neuronal Surface IgG Autoantibodies in a Case of Hashimoto's Encephalopathy	FRONTIERS IN IMMUNOLOGY			English	Article						Hashimoto encephalopathy; autoimmune encephalitis; autoantibodies; case report; pathogenicity	THYROID ANTIBODIES; ENCEPHALITIS; RECEPTOR	Hashimoto's encephalopathy is an encephalitis of presumed autoimmune origin characterized by the presence of autoantibodies against thyroid proteins. We present a case of a young patient with pre-existing Hashimoto's thyroiditis and progressive cognitive complaints, absence-like episodes, and sporadic bilateral epileptiform frontal and frontotemporal activity. No abnormalities were observed during the neurological examination and on MRI. Antibodies to thyroid peroxidase (TPO) were elevated and remained positive while the symptoms were present. Levothyroxine and methylprednisolone did not ameliorate the complaints. Subsequent treatment with high-dose intravenous immunoglobulins (IVIG) led to improved cognitive functions and to the disappearance of the absence-like-episodes. Patient's serum, but not CSF, gave a characteristic IgG-specific hippocampal pattern in rat brain immunohistochemistry; this immunoreactivity was maintained after specific and complete depletion of TPO antibodies. Serum IgG bound to primary neurons in cell culture, likely targeting a yet unidentified neuronal surface antigen. The clinical response to IVIG suggests but does not prove, that the circulating novel autoantibodies may induce the encephalopathy. It would be of interest to investigate more patients with Hashimoto's encephalopathy for the presence of neuronal surface autoantibodies, to define their role in the disease and their target antigen(s).	[Mane-Damas, Marina; Hoffmann, Carolin; Zong, Shenghua; Losen, Mario; Molenaar, Peter C.; Martinez-Martinez, Pilar] Maastricht Univ, Dept Psychiat & Neuropsychol, Maastricht, Netherlands; [Mane-Damas, Marina; Hoffmann, Carolin; Zong, Shenghua; Losen, Mario; Molenaar, Peter C.; Rouhl, Rob P. W.; Martinez-Martinez, Pilar] Maastricht Univ, Fac Hlth Med & Life Sci, Sch Mental Hlth & Neurosci, Maastricht, Netherlands; [Vinke, Anita; Koudijs, Suzanne; Rouhl, Rob P. W.] Maastricht UMC, Dept Neurol, Maastricht, Netherlands; [Damoiseaux, Jan] Maastricht UMC, Cent Diagnost Lab, Maastricht, Netherlands; [Rouhl, Rob P. W.] Acad Ctr Epileptol Kempenhaeghe MUMC, Heeze, Netherlands; [Rouhl, Rob P. W.] Acad Ctr Epileptol Kempenhaeghe MUMC, Maastricht, Netherlands	Maastricht University; Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC)	Martinez-Martinez, P (corresponding author), Maastricht Univ, Dept Psychiat & Neuropsychol, Maastricht, Netherlands.; Martinez-Martinez, P (corresponding author), Maastricht Univ, Fac Hlth Med & Life Sci, Sch Mental Hlth & Neurosci, Maastricht, Netherlands.	p.martinez@maastrichtuniversity.nl	Damoiseaux, Jan/B-8993-2009	Damoiseaux, Jan/0000-0003-4007-6985	Netherlands Organization for Scientific Research (NWO) Graduate School of Translational Neuroscience Program [022005019]; Brain Foundation of the Netherlands [KS2012(1)-157]; ZonMW NWO Program Translationeel onderzoek [40-127 41200-98-9257]; China Scholarship Council [201507720015]	Netherlands Organization for Scientific Research (NWO) Graduate School of Translational Neuroscience Program(Netherlands Organization for Scientific Research (NWO)); Brain Foundation of the Netherlands; ZonMW NWO Program Translationeel onderzoek; China Scholarship Council(China Scholarship Council)	This study has been supported by the Netherlands Organization for Scientific Research (NWO) Graduate School of Translational Neuroscience Program(022005019), the Brain Foundation of the Netherlands [KS2012(1)-157] and the ZonMW NWO Program Translationeel onderzoek (40-127 41200-98-9257) and the China Scholarship Council (201507720015).	Armangue T, 2020, LANCET NEUROL, V19, P234, DOI 10.1016/S1474-4422(19)30488-0; Castillo-Gomez E, 2016, ANN NEUROL, V79, P144, DOI 10.1002/ana.24545; Chen KA, 2017, EUR J PAEDIATR NEURO, V21, P898, DOI 10.1016/j.ejpn.2017.06.002; Chong JY, 2003, ARCH NEUROL-CHICAGO, V60, P164, DOI 10.1001/archneur.60.2.164; Ferracci F, 2003, NEUROLOGY, V60, P712, DOI 10.1212/01.WNL.0000048660.71390.C6; Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9; Hoffmann C, 2020, JAMA PSYCHIAT, V77, P322, DOI 10.1001/jamapsychiatry.2019.3679; Hollowell JG, 2002, J CLIN ENDOCR METAB, V87, P489, DOI 10.1210/jc.87.2.489; Laurent C, 2016, AUTOIMMUN REV, V15, P1129, DOI 10.1016/j.autrev.2016.09.008; Mane-Damas M, 2019, AUTOIMMUN REV, V18, DOI 10.1016/j.autrev.2019.102348; Napthali K, 2014, DEMENT GER COGN D EX, V4, P140, DOI 10.1159/000362716; Oide T, 2004, J NEUROL SCI, V217, P7, DOI 10.1016/j.jns.2003.08.005; Petit-Pedrol M, 2014, LANCET NEUROL, V13, P276, DOI 10.1016/S1474-4422(13)70299-0; Tuzun E, 2011, NEUROL INDIA, V59, P47, DOI 10.4103/0028-3886.76857	14	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 7	2020	11								1358	10.3389/fimmu.2020.01358	http://dx.doi.org/10.3389/fimmu.2020.01358			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MR1TM	32733453	gold, Green Published			2022-12-18	WOS:000553374200001
J	Russell, MW; Gray-Owen, SD; Jerse, AE				Russell, Michael W.; Gray-Owen, Scott D.; Jerse, Ann E.			Editorial: Immunity to Neisseria gonorrhoeae	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						Neisseria gonorrhoeae; immunity; vaccine; immune evasion; immunopathogenesis	RESISTANCE; INFECTION; RESPONSES		[Russell, Michael W.] SUNY Buffalo, Dept Microbiol & Immunol, Buffalo, NY 14260 USA; [Gray-Owen, Scott D.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada; [Jerse, Ann E.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Microbiol & Immunol, Bethesda, MD USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Toronto; Uniformed Services University of the Health Sciences - USA	Russell, MW (corresponding author), SUNY Buffalo, Dept Microbiol & Immunol, Buffalo, NY 14260 USA.	russellm@buffalo.edu	Gray-Owen, Scott/AFL-7380-2022; Gray-Owen, Scott/AAG-7337-2022; Russell, Michael W./H-4456-2019	Russell, Michael W./0000-0002-1303-4061; Gray-Owen, Scott D./0000-0002-1477-3616	National Institutes of Health [U19 AI144180, R44-AI104067, R44-AI115877, R01-AI125421-01A1, 2R01-AI103400-05]; Canadian Institutes of Health Research [PJT-153177, PJT-392076]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Studies in the authors' laboratories were supported by the following research grants: MR: R44-AI104067 and R44-AI115877 from the National Institutes of Health; SG-O: R01-AI125421-01A1 and 2R01-AI103400-05 from the National Institutes of Health and PJT-153177 and PJT-392076 from the Canadian Institutes of Health Research; and AJ: U19 AI144180 from the National Institutes of Health.	Cornelissen CN, 1998, MOL MICROBIOL, V27, P611, DOI 10.1046/j.1365-2958.1998.00710.x; Criss AK, 2012, NAT REV MICROBIOL, V10, P178, DOI 10.1038/nrmicro2713; Jerse AE, 2014, VACCINE, V32, P1579, DOI 10.1016/j.vaccine.2013.08.067; Liu Y, 2017, MUCOSAL IMMUNOL, V10, P1594, DOI 10.1038/mi.2017.11; Petousis-Harris H, 2017, LANCET, V390, P1603, DOI 10.1016/S0140-6736(17)31449-6; Rice PA, 2017, ANNU REV MICROBIOL, V71, P665, DOI 10.1146/annurev-micro-090816-093530; Shafer WM, 1998, P NATL ACAD SCI USA, V95, P1829, DOI 10.1073/pnas.95.4.1829; Song WX, 2008, VACCINE, V26, P5741, DOI 10.1016/j.vaccine.2008.08.020; Suay-Garcia B, 2018, ANTIBIOTICS-BASEL, V7, DOI 10.3390/antibiotics7020049; Warner DM, 2008, MOL MICROBIOL, V70, P462, DOI 10.1111/j.1365-2958.2008.06424.x; WHO, 2019, REPORT GLOBAL SEXUAL	11	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 2	2020	11								1375	10.3389/fimmu.2020.01375	http://dx.doi.org/10.3389/fimmu.2020.01375			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MQ5VH	32714334	Green Published, gold			2022-12-18	WOS:000552961600001
J	Osier, F; Uzonna, JE				Osier, Faith; Uzonna, Jude E.			Editorial: Regulation of Immunity to Parasitic Infections Endemic to Africa	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						parasitic infections; immune response; malaria; trypanosomiasis; leishmaniasis; toxoplasmosis; fascioliasis			[Osier, Faith] Heidelberg Univ Hosp, Ctr Infect Dis, Heidelberg, Germany; [Osier, Faith] Ctr Geog Med Res, KEMRI Wellcome Trust Res Programme, Kilifi, Kenya; [Uzonna, Jude E.] Univ Manitoba, Max Rady Coll Med, Dept Immunol, Rady Fac Hlth Sci, Winnipeg, MB, Canada	Ruprecht Karls University Heidelberg; University of Manitoba	Uzonna, JE (corresponding author), Univ Manitoba, Max Rady Coll Med, Dept Immunol, Rady Fac Hlth Sci, Winnipeg, MB, Canada.	jude.uzonna@umanitoba.ca						Cummings RD, ESSENTIALS GLYCOBIOL, V3rd; Geiger A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00212; Hotez PJ, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008001; Hotez PJ, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002570; McFarlane E, 2011, J INFECT DIS, V204, P36, DOI 10.1093/infdis/jir080; Mischlinger J, 2020, CLIN MICROBIOL REV, V33, DOI 10.1128/CMR.00104-19; Stager S, 2003, INFECT IMMUN, V71, P4804, DOI 10.1128/IAI.71.8.4804-4807.2003; Vanaerschot M, 2014, FEMS MICROBIOL REV, V38, P41, DOI 10.1111/1574-6976.12032	8	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 12	2020	11								1159	10.3389/fimmu.2020.01159	http://dx.doi.org/10.3389/fimmu.2020.01159			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MD3CI	32595637	Green Published, gold			2022-12-18	WOS:000543848900001
J	Choi, EY; Choi, K; Nam, G; Kim, W; Chung, M				Choi, Eun Young; Choi, Kyungho; Nam, Giri; Kim, Woojin; Chung, Minho			H60: A Unique Murine Hematopoietic Cell-Restricted Minor Histocompatibility Antigen for Graft-versus-Leukemia Effect	FRONTIERS IN IMMUNOLOGY			English	Review						H60; minor histocompatibility antigen; graft-versus-leukemia; graft-versus-host-disease; hematopoieic cell-restricted antigen	CD4(+) T-CELLS; HOST-DISEASE; NEGATIVE SELECTION; CENTRAL TOLERANCE; DENDRITIC CELLS; NKG2D RECEPTOR; IN-VIVO; EXPRESSION; PEPTIDE; TRANSPLANTATION	Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important treatment for many types of hematological malignancies. Matching of donor and recipient for the major histocompatibility complex (MHC) improves the HSCT reconstitution, but donor-derived T cells reactive to non-MHC encoded minor histocompatibility antigens (MiHAs) can induce graft-versus-host disease (GVHD) while also being needed for graft-versus-leukemia (GVL) effects. MiHAs are allelically variant self-peptides presented conventionally on MHC molecules, but are alloantigenic in transplantation settings. Immunodominant MiHAs are most strongly associated with GVHD and GVL. There is need for mouse paradigms to understand these contradictory effects. H60 is a highly immunodominant mouse MiHA with hematopoietic cell-restricted expression. Immunodominance of H60 is tightly associated with its allelic nature (presence vs. absence of the transcripts), and the qualitative (TCR diversity) and quantitative (frequency) traits of the reactive T cells. The identity as a hematopoietic cell-restricted antigen (HRA) of H60 assists the appearance of the immunodominace in allo-HSCT circumstances, and generation of GVL effects without induction of serious GVHD after adoptive T cell transfer. Also it allows the low avidity T cells to escape thymic negative selection and exert GVL effect in the periphery, which is a previously unevaluated finding related to HRAs. In this review, we describe the molecular features and immunobiology in detail through which H60 selectively exerts its potent GVL effect. We further describe how lessons learned can be extrapolated to human allo-HCST.	[Choi, Eun Young; Choi, Kyungho; Nam, Giri; Kim, Woojin; Chung, Minho] Seoul Natl Univ, Dept Biomed Sci, Coll Med, Seoul, South Korea; [Choi, Eun Young] Seoul Natl Univ, Inst Human Environm Interface Biol, Coll Med, Seoul, South Korea; [Choi, Kyungho] Seoul Natl Univ, Dept Biochem & Mol Biol, Coll Med, Seoul, South Korea; [Choi, Kyungho] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Choi, EY (corresponding author), Seoul Natl Univ, Dept Biomed Sci, Coll Med, Seoul, South Korea.; Choi, EY (corresponding author), Seoul Natl Univ, Inst Human Environm Interface Biol, Coll Med, Seoul, South Korea.	eycii@snu.ac.kr		Choi, Kyungho/0000-0003-1635-173X	National Research Foundation - Ministry of Science and ICT (Basic Research Laboratory) [2017R1A4A1015745]; Seoul National University Hospital, Republic of Korea; National Research Foundation - Ministry of Science and ICT (Basic Research Program) [2019R1A2C3004336]	National Research Foundation - Ministry of Science and ICT (Basic Research Laboratory); Seoul National University Hospital, Republic of Korea; National Research Foundation - Ministry of Science and ICT (Basic Research Program)	This work was supported by grants from the National Research Foundation funded by the Ministry of Science and ICT (Basic Research Laboratory 2017R1A4A1015745; Basic Research Program 2019R1A2C3004336) and Seoul National University Hospital, Republic of Korea.	Blazar BR, 1996, TRANSPLANTATION, V61, P619, DOI 10.1097/00007890-199602270-00017; Bleakley M, 2004, NAT REV CANCER, V4, P371, DOI 10.1038/nrc1365; Bui JD, 2006, J IMMUNOL, V176, P905, DOI 10.4049/jimmunol.176.2.905; Cerwenka A, 2000, IMMUNITY, V12, P721, DOI 10.1016/S1074-7613(00)80222-8; Cerwenka A, 2002, J IMMUNOL, V168, P3131, DOI 10.4049/jimmunol.168.7.3131; Choi EY, 2002, BLOOD, V100, P4259, DOI 10.1182/blood-2002-05-1299; Choi EY, 2002, IMMUNITY, V17, P593, DOI 10.1016/S1074-7613(02)00428-4; Choi EY, 2001, J IMMUNOL, V166, P4370, DOI 10.4049/jimmunol.166.7.4370; Choi JH, 2009, TRANSPLANTATION, V87, P1609, DOI 10.1097/TP.0b013e3181a52dc4; de Witte MA, 2007, BLOOD, V109, P3830, DOI 10.1182/blood-2006-07-037713; DEBUEGER M, 1992, J IMMUNOL, V149, P1788; den Haan JMM, 1998, SCIENCE, V279, P1054, DOI 10.1126/science.279.5353.1054; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; Derbinski J, 2001, NAT IMMUNOL, V2, P1032, DOI 10.1038/ni723; Dertschnig S, 2015, BLOOD, V125, P2720, DOI 10.1182/blood-2014-08-597245; Diefenbach A, 2000, NAT IMMUNOL, V1, P119, DOI 10.1038/77793; Dossa RG, 2018, BLOOD, V131, P108, DOI 10.1182/blood-2017-07-791608; Eden PA, 1999, J IMMUNOL, V162, P4502; Enouz S, 2012, J EXP MED, V209, P1769, DOI 10.1084/jem.20120905; FERRARA JLM, 1991, NEW ENGL J MED, V324, P667; Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916; Goulmy E, 1996, NEW ENGL J MED, V334, P281, DOI 10.1056/NEJM199602013340501; Goulmy E, 2004, CANCER J, V10, P1, DOI 10.1097/00130404-200401000-00001; GRAFF RJ, 1978, IMMUNOGENETICS, V7, P367, DOI 10.1007/BF01844026; Granados DP, 2016, LEUKEMIA, V30, P1344, DOI 10.1038/leu.2016.22; Greenfield A, 1996, NAT GENET, V14, P474, DOI 10.1038/ng1296-474; Grufman P, 1999, EUR J IMMUNOL, V29, P2197, DOI 10.1002/(SICI)1521-4141(199907)29:07<2197::AID-IMMU2197>3.0.CO;2-B; Hombrink P, 2015, CLIN CANCER RES, V21, P2177, DOI 10.1158/1078-0432.CCR-14-2188; HOROWITZ MM, 1990, BLOOD, V75, P555; Hubert FX, 2011, BLOOD, V118, P2462, DOI 10.1182/blood-2010-06-286393; Jeon Ji Yeong, 2011, Immune Netw, V11, P100, DOI 10.4110/in.2011.11.2.100; Ju JM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02665-z; Ju JM, 2015, IMMUNE NETW, V15, P222, DOI 10.4110/in.2015.15.5.222; Jung KM, 2007, IMMUNENETWORK, V7, P6, DOI 10.4110/in.2007.7.4.173; Kedl RM, 2000, J EXP MED, V192, P1105, DOI 10.1084/jem.192.8.1105; Kim J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8994; Kircher B, 2002, BRIT J HAEMATOL, V117, P935, DOI 10.1046/j.1365-2141.2002.03536.x; Klein CA, 2002, J EXP MED, V196, P359, DOI 10.1084/jem.20011838; Klein L, 2014, NAT REV IMMUNOL, V14, P377, DOI 10.1038/nri3667; Klein L, 2009, NAT REV IMMUNOL, V9, P833, DOI 10.1038/nri2669; Kloosterboer FM, 2004, LEUKEMIA, V18, P798, DOI 10.1038/sj.leu.2403297; Koble C, 2009, J EXP MED, V206, P1505, DOI 10.1084/jem.20082449; Kowalewski DJ, 2015, P NATL ACAD SCI USA, V112, pE166, DOI 10.1073/pnas.1416389112; Kroger N, 2010, BIOL BLOOD MARROW TR, V16, P1187, DOI 10.1016/j.bbmt.2010.06.008; Kwun J, 2011, J IMMUNOL, V187, P3997, DOI 10.4049/jimmunol.1003918; Li N, 2011, BLOOD, V118, P5965, DOI 10.1182/blood-2011-07-367011; Luedtke B, 2003, IMMUNOGENETICS, V55, P284, DOI 10.1007/s00251-003-0581-x; Mackall CL, 1997, IMMUNOL REV, V157, P61, DOI 10.1111/j.1600-065X.1997.tb00974.x; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; Malarkannan S, 2000, IMMUNITY, V13, P333, DOI 10.1016/S1074-7613(00)00033-9; Malarkannan S, 1998, J IMMUNOL, V161, P3501; Malhotra D, 2016, NAT IMMUNOL, V17, P187, DOI 10.1038/ni.3327; Marijt WAE, 2003, P NATL ACAD SCI USA, V100, P2742, DOI 10.1073/pnas.0530192100; Matte-Martone C, 2017, J CLIN INVEST, V127, P2765, DOI 10.1172/JCI85736; McBride K, 2002, IMMUNOGENETICS, V54, P562, DOI 10.1007/s00251-002-0502-4; McCaughtry TM, 2008, SEMIN IMMUNOPATHOL, V30, P399, DOI 10.1007/s00281-008-0137-0; Melichar HJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004400; Mendoza LM, 1997, IMMUNITY, V7, P461, DOI 10.1016/S1074-7613(00)80368-4; Muller AMS, 2019, BIOL BLOOD MARROW TR, V25, P2338, DOI 10.1016/j.bbmt.2019.08.001; Ostrov DA, 2002, J IMMUNOL, V168, P283, DOI 10.4049/jimmunol.168.1.283; Perreault C, 1998, IMMUNOL TODAY, V19, P69, DOI 10.1016/S0167-5699(97)01185-7; Reinbold CJA, 2008, MOL IMMUNOL, V45, P1318, DOI 10.1016/j.molimm.2007.09.017; Roopenian D, 2002, IMMUNOL REV, V190, P86, DOI 10.1034/j.1600-065X.2002.19007.x; Russell PS, 2011, TRANSPLANTATION, V91, P847, DOI 10.1097/TP.0b013e3182122f82; Ryu SJ, 2012, MOL CELLS, V33, P393, DOI 10.1007/s10059-012-0008-3; Ryu SJ, 2009, BLOOD, V113, P4273, DOI 10.1182/blood-2008-09-181263; Scott D, 2000, IMMUNITY, V12, P711, DOI 10.1016/S1074-7613(00)80221-6; Song MG, 2012, MOL CELLS, V33, P79, DOI 10.1007/s10059-012-2228-y; Spierings E, 2004, TRENDS IMMUNOL, V25, P56, DOI 10.1016/j.it.2003.12.002; Takada A, 2008, J IMMUNOL, V180, P1678, DOI 10.4049/jimmunol.180.3.1678; Teshima T, 2003, BLOOD, V102, P429, DOI 10.1182/blood-2003-01-0266; van Bergen CAM, 2017, J CLIN INVEST, V127, P517, DOI 10.1172/JCI86175; van der Torren CR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119595; VANBLEEK GM, 1990, NATURE, V348, P213; Wang XJ, 2011, BLOOD, V118, P6426, DOI 10.1182/blood-2011-06-358747; Wilke Martina, 2003, Hematol J, V4, P315, DOI 10.1038/sj.thj.6200318; Wu T, 2013, J IMMUNOL, V191, P488, DOI 10.4049/jimmunol.1300657; Xu P, 2017, J DERMATOL SCI, V88, P216, DOI 10.1016/j.jdermsci.2017.07.004; Yoo KI, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.107; Yoshimura Y, 2004, J IMMUNOL, V172, P6666, DOI 10.4049/jimmunol.172.11.6666; Yu W, 2015, IMMUNITY, V42, P929, DOI 10.1016/j.immuni.2015.05.001; Zehn D, 2006, IMMUNITY, V25, P261, DOI 10.1016/j.immuni.2006.06.009; Zhang H, 2011, MOL IMMUNOL, V48, P539, DOI 10.1016/j.molimm.2010.10.015; Zuberi AR, 1998, IMMUNITY, V9, P687, DOI 10.1016/S1074-7613(00)80666-4	84	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 10	2020	11								1163	10.3389/fimmu.2020.01163	http://dx.doi.org/10.3389/fimmu.2020.01163			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MD3RR	32587590	gold, Green Published			2022-12-18	WOS:000543888800001
J	Jiang, JJ; Hu, X; Li, WW; Liu, J; Liang, BY; Chen, H; Huang, JG; Zang, N; Ning, CY; Liao, YY; Chen, RF; Lai, JZ; Chu, JM; Pan, PJ; Cui, P; Tang, Q; Chen, X; Liang, H; Ye, L				Jiang, Junjun; Hu, Xi; Li, Wenwei; Liu, Jie; Liang, Bingyu; Chen, Hui; Huang, Jiegang; Zang, Ning; Ning, Chuanyi; Liao, Yanyan; Chen, Rongfeng; Lai, Jingzhen; Chu, Jiemei; Pan, Peijiang; Cui, Ping; Tang, Qiao; Chen, Xiu; Liang, Hao; Ye, Li			Enhanced Signaling Through the TLR9 Pathway Is Associated With Resistance to HIV-1 Infection in Chinese HIV-1-Exposed Seronegative Individuals	FRONTIERS IN IMMUNOLOGY			English	Article						HIV-1; HIV-1-exposed seronegative; innate immunity; TLR9; China	EXPOSED UNINFECTED INDIVIDUALS; SEX WORKERS; T-CELLS; ACTIVATION; RESPONSES; POLYMORPHISMS; INTERFERONS; EXPRESSION; INDUCTION; IMMUNITY	Innate immunity is the first line of defense against invading pathogens and may mediate HIV-1 resistance in HIV-1-exposed seronegative (HESN) individuals. This study aims to identify components of innate immunity that confer natural HIV-1 resistance in Chinese HESN individuals. Specifically, we compared the expression levels of Toll-like receptors (TLRs) and associated pathway molecules in peripheral blood mononuclear cells (PBMCs), monocytes/macrophages, and plasma obtained from HESN and control individuals. HESN individuals had higher expression of TLR9, IRF7, IFN-alpha/beta, RANTES, and MIP-1 alpha/1 beta in PBMCs and plasma than control subjects. Upon TLR9 stimulation, significantly higher expression of TLR9 and IRF7, as well as higher production of IFN-alpha/beta, RANTES, and MIP-1 alpha/1 beta, was observed in PBMCs and monocytes/macrophages from HESN individuals than in the corresponding cells from control individuals. More importantly, both with and without TLR9 stimulation, the levels of HIV-1 replication in monocyte-derived macrophages (MDMs) from HESN individuals were significantly lower than those in MDMs from control individuals. These data suggest that increased TLR9 activity and subsequent release of antiviral factors contribute to protection against HIV-1 in HESN individuals.	[Jiang, Junjun; Hu, Xi; Liu, Jie; Liang, Bingyu; Chen, Hui; Huang, Jiegang; Ning, Chuanyi; Liao, Yanyan; Chen, Rongfeng; Pan, Peijiang; Tang, Qiao; Chen, Xiu; Liang, Hao; Ye, Li] Guangxi Med Univ, Sch Publ Hlth, Guangxi Key Lab AIDS Prevent & Treatment, Nanning, Peoples R China; [Jiang, Junjun; Li, Wenwei; Liu, Jie; Liang, Bingyu; Chen, Hui; Huang, Jiegang; Zang, Ning; Ning, Chuanyi; Liao, Yanyan; Chen, Rongfeng; Lai, Jingzhen; Chu, Jiemei; Pan, Peijiang; Cui, Ping; Tang, Qiao; Chen, Xiu; Liang, Hao; Ye, Li] Guangxi Med Univ, Guangxi Collaborat Innovat Ctr Biomed, Life Sci Inst, Nanning, Peoples R China	Guangxi Medical University; Guangxi Medical University	Jiang, JJ; Liang, H; Ye, L (corresponding author), Guangxi Med Univ, Sch Publ Hlth, Guangxi Key Lab AIDS Prevent & Treatment, Nanning, Peoples R China.; Jiang, JJ; Liang, H; Ye, L (corresponding author), Guangxi Med Univ, Guangxi Collaborat Innovat Ctr Biomed, Life Sci Inst, Nanning, Peoples R China.	jiangjunjun@gxmu.edu.cn; lianghao@gxmu.edu.cn; yeli@gxmu.edu.cn			National Natural Science Foundation of China (NSFC) [81971935, 81703275, 81960602, 31860040]; Guangxi Science Fund for Distinguished Young Scholars [2018GXNSFFA281001]; China Postdoctoral Science Foundation [2018M640890, 2019T120798]; Guangxi Bagui Scholar; Natural Science Foundation of Guangxi Province [2018GXNSFAA138002]; Thousands of Young and Middle-aged Key Teachers Training Program in Guangxi Colleges and Universities	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Guangxi Science Fund for Distinguished Young Scholars(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Guangxi Bagui Scholar; Natural Science Foundation of Guangxi Province(National Natural Science Foundation of Guangxi Province); Thousands of Young and Middle-aged Key Teachers Training Program in Guangxi Colleges and Universities	This study was supported by the National Natural Science Foundation of China (NSFC; 81971935, 81703275, 81960602, and 31860040), Guangxi Science Fund for Distinguished Young Scholars (2018GXNSFFA281001), China Postdoctoral Science Foundation (2018M640890, 2019T120798), Guangxi Bagui Scholar (to JJ), Natural Science Foundation of Guangxi Province (2018GXNSFAA138002), and Thousands of Young and Middle-aged Key Teachers Training Program in Guangxi Colleges and Universities (to JJ).	Altfeld M, 2015, NAT IMMUNOL, V16, P554, DOI 10.1038/ni.3157; Serna-Ortega PA, 2020, MICROBES INFECT, V22, P371, DOI 10.1016/j.micinf.2019.11.002; Biasin M, 2010, J IMMUNOL, V184, P2710, DOI 10.4049/jimmunol.0902463; Boulet S, 2008, AIDS, V22, P595, DOI 10.1097/QAD.0b013e3282f56b23; Campbell LA, 2015, NEUROPHARMACOLOGY, V92, P98, DOI 10.1016/j.neuropharm.2015.01.009; Cervantes CAC, 2016, SCI REP-UK, V6, DOI 10.1038/srep25875; Doyle T, 2015, NAT REV MICROBIOL, V13, P403, DOI 10.1038/nrmicro3449; Espindola MS, 2016, IMMUNOL RES, V64, P1118, DOI 10.1007/s12026-016-8862-2; Fourcade L, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10040215; Fulcher JA, 2017, AIDS RES HUM RETROV, V33, P788, DOI [10.1089/aid.2017.0014, 10.1089/AID.2017.0014]; Furci L, 1997, J EXP MED, V186, P455, DOI 10.1084/jem.186.3.455; Guardo AC, 2015, AIDS, V29, P1309, DOI 10.1097/QAD.0000000000000728; Harper MS, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005254; Hasselrot K, 2010, AIDS, V24, P1569, DOI 10.1097/QAD.0b013e32833ac646; Herrero R, 2015, GENES IMMUN, V16, P134, DOI 10.1038/gene.2014.71; Huo YL, 2017, J ALLERGY CLIN IMMUN, V140, P605, DOI 10.1016/j.jaci.2017.01.033; Italiani P, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00514; Jaumdally SZ, 2017, IMMUNOLOGY, V151, P464, DOI 10.1111/imm.12743; Jennes W, 2006, J IMMUNOL, V177, P6588, DOI 10.4049/jimmunol.177.10.6588; Joas S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03762-3; Kaczorowski DJ, 2012, MOL MED, V18, P851, DOI 10.2119/molmed.2012.00011; Kallas E, 2016, MED MICROBIOL IMMUN, V205, P231, DOI 10.1007/s00430-015-0444-8; Lajoie J, 2014, J INFECT DIS, V210, P319, DOI 10.1093/infdis/jiu023; Liao YY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12066-3; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Liu Xun, 2014, Sci Rep, V4, P4450, DOI 10.1038/srep04450; Methy N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171493; Nahrendorf M, 2013, CIRC RES, V112, P1624, DOI 10.1161/CIRCRESAHA.113.300890; Ning S, 2011, GENES IMMUN, V12, P399, DOI 10.1038/gene.2011.21; Oganesyan G, 2006, NATURE, V439, P208, DOI 10.1038/nature04374; Okoko NA, 2017, INT J STD AIDS, V28, P1215, DOI 10.1177/0956462417693735; Ortega PAS, 2018, AIDS, V32, P2453, DOI [10.1097/QAD.0000000000001938, 10.1097/qad.0000000000001938]; Palsson-McDermott EM, 2007, BIOCHEM SOC T, V35, P1437, DOI 10.1042/BST0351437; Parrish NF, 2013, P NATL ACAD SCI USA, V110, P6626, DOI 10.1073/pnas.1304288110; Perkins DJ, 2015, CYTOKINE, V74, P171, DOI 10.1016/j.cyto.2015.03.001; Rajan R, 2017, AIDS CARE, V29, P1404, DOI 10.1080/09540121.2017.1300629; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; SCHON MR, 1991, TRANSPL P, V23, P2456; Stacey AR, 2009, J VIROL, V83, P3719, DOI 10.1128/JVI.01844-08; Suresh P, 2007, AIDS RES HUM RETROV, V23, P261, DOI 10.1089/aid.2006.0146; Suresh P, 2006, J CLIN IMMUNOL, V26, P476, DOI 10.1007/s10875-006-9036-0; Thibodeau V, 2017, SCI REP-UK, V7, DOI 10.1038/srep43857; Tomescu C, 2011, CLIN EXP IMMUNOL, V164, P158, DOI 10.1111/j.1365-2249.2011.04379.x; Tomescu C, 2010, AIDS, V24, P2151, DOI 10.1097/QAD.0b013e32833dfc20; Wang L, 2016, EUR J IMMUNOL, V46, P2409, DOI 10.1002/eji.201646491; Wasik TJ, 1999, J IMMUNOL, V162, P4355; Were WA, 2006, JAIDS-J ACQ IMM DEF, V43, P91, DOI 10.1097/01.qai.0000225021.81384.28; Yahyaei S, 2016, JAIDS-J ACQ IMM DEF, V73, P11, DOI 10.1097/QAI.0000000000001070; Yao XD, 2014, MUCOSAL IMMUNOL, V7, P268, DOI 10.1038/mi.2013.44; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780	50	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 29	2020	11								1050	10.3389/fimmu.2020.01050	http://dx.doi.org/10.3389/fimmu.2020.01050			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MB1HA	32547554	gold, Green Published			2022-12-18	WOS:000542356700001
J	Butenko, S; Satyanarayanan, SK; Assi, S; Schif-Zuck, S; Barkan, D; Sher, N; Ariel, A				Butenko, Sergei; Satyanarayanan, Senthil K.; Assi, Simaan; Schif-Zuck, Sagie; Barkan, Dalit; Sher, Noa; Ariel, Amiram			Transcriptomic Analysis of Monocyte-Derived Non-Phagocytic Macrophages Favors a Role in Limiting Tissue Repair and Fibrosis (vol 11, 405, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						inflammation; macrophages; efferocytosis; transcriptional profiling; fibrosis			[Butenko, Sergei; Satyanarayanan, Senthil K.; Assi, Simaan; Schif-Zuck, Sagie; Barkan, Dalit; Ariel, Amiram] Univ Haifa, Dept Human Biol, Haifa, Israel; [Sher, Noa] Univ Haifa, Tauber Bioinformat Ctr, Haifa, Israel	University of Haifa; University of Haifa	Ariel, A (corresponding author), Univ Haifa, Dept Human Biol, Haifa, Israel.	amiram@research.haifa.ac.il	Satyanarayanan, Senthil Kumaran/AAE-8015-2019	Schif-Zuck, Sagie/0000-0001-5415-9488				Butenko S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00405	1	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 20	2020	11								1003	10.3389/fimmu.2020.01003	http://dx.doi.org/10.3389/fimmu.2020.01003			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LW8RI	32508846	gold, Green Published			2022-12-18	WOS:000539410700001
J	Mancusi, A; Kanakry, CG; Pierini, A				Mancusi, Antonella; Kanakry, Christopher G.; Pierini, Antonio			Editorial: The Immunobiology of HLA-Haploidentical Hematopoietic Cell Transplantation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						haploidentical transplantation; T-cell depleted grafts; T-cell-replete grafts; post-transplantation cyclophosphamide; immune reconstitution; adoptive cell therapy; regulatory T cells; immune evasion			[Mancusi, Antonella; Pierini, Antonio] Univ Perugia, Dept Med, Hematol & Clin Immunol & Bone Marrow Transplant P, Perugia, Italy; [Kanakry, Christopher G.] NCI, Expt Transplantat & Immunotherapy Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	University of Perugia; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Mancusi, A; Pierini, A (corresponding author), Univ Perugia, Dept Med, Hematol & Clin Immunol & Bone Marrow Transplant P, Perugia, Italy.; Kanakry, CG (corresponding author), NCI, Expt Transplantat & Immunotherapy Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	antonella.mancusi@unipg.it; christopher.kanakry@nih.gov; antonio.pierini@unipg.it			Associazione Italiana per la Ricerca sul Cancro (AIRC) [20456]; Intramural Research Program of the National Cancer Institute of the National Institutes of Health	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Intramural Research Program of the National Cancer Institute of the National Institutes of Health	The preparation of the article was funded by Associazione Italiana per la Ricerca sul Cancro (AIRC), Start-Up Grant 2017, project code: 20456 (AM and AP), and the Intramural Research Program of the National Cancer Institute of the National Institutes of Health (CK).		0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 20	2020	11								1031	10.3389/fimmu.2020.01031	http://dx.doi.org/10.3389/fimmu.2020.01031			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LW7DC	32508848	gold, Green Published			2022-12-18	WOS:000539302900001
J	Market, M; Tennakoon, G; Ng, J; Scaffidi, M; de Souza, CT; Kennedy, MA; Auer, RC				Market, Marisa; Tennakoon, Gayashan; Ng, Juliana; Scaffidi, Marlena; de Souza, Christiano Tanese; Kennedy, Michael A.; Auer, Rebecca C.			A Method of Assessment of Human Natural Killer Cell Phenotype and Function in Whole Blood	FRONTIERS IN IMMUNOLOGY			English	Article						natural killer cells; whole blood; flow cytometry; cytokine stimulation; interferon gamma; NKG2D	NK CELLS; T-CELLS; MONONUCLEAR-CELLS; ACTIVATION; CRYOPRESERVATION; EXPRESSION; RECEPTOR; DISEASE; INNATE; KINASE	The majority of data on human Natural Killer (NK) cell phenotype and function has been generated using cryopreserved peripheral blood mononuclear cells (PBMCs). However, cryopreservation can have adverse effects on PBMCs. In contrast, investigating immune cells in whole blood can reduce the time, volume of blood required, and potential artefacts associated with manipulation of the cells. Whole blood collected from healthy donors and cancer patients was processed by three separate protocols that can be used independently or in parallel to assess extracellular receptors, intracellular signaling protein phosphorylation, and intracellular and extracellular cytokine production in human NK cells. To assess extracellular receptor expression, 200 mu L of whole blood was incubated with an extracellular staining (ECS) mix and cells were subsequently fixed and RBCs lysed prior to analysis. The phosphorylation status of signaling proteins was assessed in 500 mu L of whole blood following co-incubation with interleukin (IL)-2/12 and an ECS mix for 20 min prior to cell fixation, RBC lysis, and subsequent permeabilization for staining with an intracellular staining (ICS) mix. Cytokine production (IFN gamma) was similarly assessed by incubating 1 mL of whole blood with PMA-ionomycin or IL-2/12 prior to incubation with ECS and subsequent ICS antibodies. In addition, plasma was collected from stimulated samples prior to ECS for quantification of secreted IFN gamma by ELISA. Results were consistent, despite inherent inter-patient variability. Although we did not investigate an exhaustive list of targets, this approach enabled quantification of representative ECS surface markers including activating (NKG2D and DNAM-1) and inhibitory (NKG2A, PD-1, TIGIT, and TIM-3) receptors, cytokine receptors (CD25, CD122, CD132, and CD212) and ICS markers associated with NK cell activation following stimulation, including signaling protein phosphorylation (p-STAT4, p-STAT5, p-p38 MAPK, p-S6) and IFN gamma in both healthy donors and cancer patients. In addition, we compared extracellular receptor expression using whole blood vs. cryopreserved PBMCs and observed a significant difference in the expression of almost all receptors. The methods presented permit a relatively rapid parallel assessment of immune cell receptor expression, signaling protein activity, and cytokine production in a minimal volume of whole blood from both healthy donors and cancer patients.	[Market, Marisa; Scaffidi, Marlena] Univ Ottawa, Ottawa, ON, Canada; [Tennakoon, Gayashan; Ng, Juliana; de Souza, Christiano Tanese; Kennedy, Michael A.; Auer, Rebecca C.] Ottawa Hosp, Canc Therapeut Program, Res Inst, Ottawa, ON, Canada; [Auer, Rebecca C.] Univ Ottawa, Ottawa Hosp, Dept Surg, Ottawa, ON, Canada	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute	Auer, RC (corresponding author), Ottawa Hosp, Canc Therapeut Program, Res Inst, Ottawa, ON, Canada.; Auer, RC (corresponding author), Univ Ottawa, Ottawa Hosp, Dept Surg, Ottawa, ON, Canada.	rauer@ohri.ca	Kennedy, Michael/K-5969-2019	Kennedy, Michael/0000-0002-1071-3624	Cancer Research Society; Terry Fox Foundation [1073]; Canadian Institute of Healthy Research; Ontario Graduate Scholarship; Queen Elizabeth II Graduate scholarship	Cancer Research Society; Terry Fox Foundation; Canadian Institute of Healthy Research; Ontario Graduate Scholarship(Ontario Graduate Scholarship); Queen Elizabeth II Graduate scholarship	The authors received funding from the following agencies: Cancer Research Society, Terry Fox Foundation (#1073), Canadian Institute of Healthy Research, Ontario Graduate Scholarship, Queen Elizabeth II Graduate scholarship.	Agaugue S, 2008, BLOOD, V112, P1776, DOI 10.1182/blood-2008-02-135871; Amano K, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/747680; Angka L, 2018, ANN SURG ONCOL, V25, P3747, DOI 10.1245/s10434-018-6691-3; Apodaca MC, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0674-1; Bachmann MF, 2007, EMBO REP, V8, P1142, DOI 10.1038/sj.embor.7401099; Chan CJ, 2014, CELL DEATH DIFFER, V21, P5, DOI 10.1038/cdd.2013.26; Chester C, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00601; Claus M, 2009, J IMMUNOL METHODS, V341, P154, DOI 10.1016/j.jim.2008.11.006; Costantini C, 2011, J LEUKOCYTE BIOL, V89, P221, DOI 10.1189/jlb.0510250; Dominguez E, 1997, BIOCHEM SOC T, V25, pS175, DOI 10.1042/bst025175s; Domogala A, 2016, CYTOTHERAPY, V18, P754, DOI 10.1016/j.jcyt.2016.02.008; Dunne J, 2001, J IMMUNOL, V167, P3129, DOI 10.4049/jimmunol.167.6.3129; Ebbo M, 2016, EBIOMEDICINE, V6, P222, DOI 10.1016/j.ebiom.2016.02.025; Fogel LA, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4232; Han B, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6248590; Hatton O, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00607; Jonjic S, 2008, CURR OPIN IMMUNOL, V20, P30, DOI 10.1016/j.coi.2007.11.002; KASAHARA T, 1983, J IMMUNOL, V130, P1784; KIESSLING R, 1975, EUR J IMMUNOL, V5, P117, DOI 10.1002/eji.1830050209; Kutscher S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076215; Lazarevic V, 2013, NAT REV IMMUNOL, V13, P777, DOI 10.1038/nri3536; Long EO, 2013, ANNU REV IMMUNOL, V31, P227, DOI 10.1146/annurev-immunol-020711-075005; Marais A, 2014, NAT IMMUNOL, V15, P749, DOI 10.1038/ni.2936; MARTI F, 1993, TRANSFUSION, V33, P651, DOI 10.1046/j.1537-2995.1993.33893342746.x; Mata MM, 2014, J IMMUNOL METHODS, V406, P1, DOI 10.1016/j.jim.2014.01.017; Mavropoulos A, 2005, BLOOD, V105, P282, DOI 10.1182/blood-2004-07-2782; Naranbhai V, 2011, J IMMUNOL METHODS, V366, P28, DOI 10.1016/j.jim.2011.01.001; Orange JS, 2006, CLIN IMMUNOL, V118, P1, DOI 10.1016/j.clim.2005.10.011; Ouyang W, 1999, P NATL ACAD SCI USA, V96, P3888, DOI 10.1073/pnas.96.7.3888; Paust S, 2010, IMMUNOL REV, V235, P286, DOI 10.1111/j.0105-2896.2010.00906.x; Posevitz-Fejfar A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115920; Ramachandran Hari, 2012, Cells, V1, P313, DOI 10.3390/cells1030313; Ruitenberg JJ, 2006, BMC IMMUNOL, V7, DOI 10.1186/1471-2172-7-11; Saito H, 2012, GASTRIC CANCER, V15, P27, DOI 10.1007/s10120-011-0059-8; Schulze TJ, 2018, TRANSFUS MED HEMOTH, V45, P288, DOI 10.1159/000494035; Sim GC, 2016, ONCOTARGET, V7, P36074, DOI 10.18632/oncotarget.8683; Tai LH, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1431082; Tai LH, 2013, CANCER RES, V73, P97, DOI 10.1158/0008-5472.CAN-12-1993; Wang L, 2016, CYTOM PART A, V89A, P246, DOI 10.1002/cyto.a.22813; Weinberg A, 2009, CLIN VACCINE IMMUNOL, V16, P1176, DOI 10.1128/CVI.00342-08; Yang J, 2016, BMC IMMUNOL, V17, DOI 10.1186/s12865-016-0144-1; Yin XW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02341; Zhang SM, 2000, J IMMUNOL, V165, P1374, DOI 10.4049/jimmunol.165.3.1374; Zhang W, 2016, J IMMUNOL METHODS, V431, P31, DOI 10.1016/j.jim.2016.02.004	44	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 20	2020	11								963	10.3389/fimmu.2020.00963	http://dx.doi.org/10.3389/fimmu.2020.00963			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LW7CW	32508837	Green Published, gold			2022-12-18	WOS:000539302200001
J	Anel, A; Pardo, J; Villalba, M				Anel, Alberto; Pardo, Julian; Villalba, Martin			Editorial: The Natural Killer Cell Interactome in the Tumor Microenvironment: Basic Concepts and Clinical Application	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						NK cell; adoptive cell immunotherapy; off-the-shelf NK cells; ovarian cancer; pediatric tumors; checkpoint inhibitors; NK cell metabolism			[Anel, Alberto] Univ Zaragoza, Aragon Hlth Res Inst IIS Aragon, Dept Biochem & Mol & Cell Biol, Apoptosis Immun & Canc Grp, Zaragoza, Spain; [Pardo, Julian] Aragon Hlth Res Inst IIS Aragon, Immunotherapy Inflammat & Canc Grp, Zaragoza, Spain; [Pardo, Julian] Govt Aragon, Aragon i D Fdn ARAID, Zaragoza, Spain; [Villalba, Martin] CHU Montpellier, IRMB, Montpellier, France; [Villalba, Martin] Univ Montpellier, CHU Montpellier, CNRS, IRMB,INSERM, Montpellier, France	University of Zaragoza; Universite de Montpellier; CHU de Montpellier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier	Anel, A (corresponding author), Univ Zaragoza, Aragon Hlth Res Inst IIS Aragon, Dept Biochem & Mol & Cell Biol, Apoptosis Immun & Canc Grp, Zaragoza, Spain.	anel@unizar.es							0	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2020	11								872	10.3389/fimmu.2020.00872	http://dx.doi.org/10.3389/fimmu.2020.00872			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LW1CY	32508819	Green Published, gold			2022-12-18	WOS:000538884800001
J	Xu, S; Yang, H; Zhuo, Y; Yu, YS; Liao, HY; Li, S; Yue, YS; Su, KH; Zhang, ZX				Xu, Shu; Yang, Hong; Zhuo, Yue; Yu, Yangsheng; Liao, Hongyan; Li, Song; Yue, Yinshi; Su, Kaihong; Zhang, Zhixin			Production of Autoreactive Heavy Chain-Only Antibodies in Systemic Lupus Erythematosus	FRONTIERS IN IMMUNOLOGY			English	Article						B cell; plasmablast; heavy chain antibody; polyreactive antibody; autoreactive antibody; somatic hypermutation	LIGHT-CHAIN; SECRETION; DISEASE; DEPOSITION; FUSION	Systemic lupus erythematosus (SLE) is characterized by the overproduction of high-affinity autoreactive antibodies. Here, we show that more than 65.8% of 222 recombinant antibodies derived from 8 SLE patients can be secreted as heavy chain-only antibodies (HCAbs) when expressed in HEK-293T cells. The secretion of HCAbs follows the conventional endoplasmic reticulum-Golgi apparatus pathway, despite triggering a weaker unfolded protein response (UPR). Many of the purified SLE HCAbs remain autoreactive and have an even higher affinity for dsDNA, Sm, nucleosome, and cardiolipin than HCAbs from healthy individuals. Extended analyses of the CDR3 region and the heavy chain variable (VH) region of HCAb F3 show that the VH region is responsible for IgH secretion, while the CDR3 region determines its reactivity. Such a high frequency of HCAb secretion cannot fully concur with our current understanding of antibody assembly and secretion. The presence of a large proportion of autoreactive HCAbs in SLE reveals a novel mechanism for the generation of autoreactive antibodies in lupus.	[Xu, Shu; Yang, Hong] Sichuan Univ, State Key Lab Biotherapy, Chengdu, Peoples R China; [Zhuo, Yue; Zhang, Zhixin] Univ Elect Sci & Technol China, Hlth Management Ctr, Inst Hlth Management, Sichuan Prov Peoples Hosp, Chengdu, Peoples R China; [Yu, Yangsheng; Yue, Yinshi] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA; [Liao, Hongyan] Sichuan Univ, West China Hosp, Dept Lab Med, Chengdu, Peoples R China; [Li, Song] Shandong Univ, Qilu Hosp, Dept Med Oncol, Canc Ctr, Jinan, Peoples R China; [Su, Kaihong] Calif Univ Sci & Med, Dept Med Educ, Educ Microbiol Immunol, San Bernardino, CA 92408 USA	Sichuan University; Sichuan Provincial People's Hospital; University of Electronic Science & Technology of China; University of Nebraska System; University of Nebraska Medical Center; Sichuan University; Shandong University	Zhang, ZX (corresponding author), Univ Elect Sci & Technol China, Hlth Management Ctr, Inst Hlth Management, Sichuan Prov Peoples Hosp, Chengdu, Peoples R China.; Su, KH (corresponding author), Calif Univ Sci & Med, Dept Med Educ, Educ Microbiol Immunol, San Bernardino, CA 92408 USA.	suk@cusm.org; zhangzhixin@scu.edu.cn		Xu, Shu/0000-0002-9709-5290; Zhang, Zhixin/0000-0003-3924-1082	NIH [AI073174, AI098576, AR059351]; National Natural Science Foundation of China [31540073]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported in part by NIH [(grant number AI073174 to ZZ), (grant number AI098576 to ZZ), and (grant number to AR059351 to KS)] and National Natural Science Foundation of China (grant number 31540073 to ZZ).	ALEXANDER A, 1988, J CLIN INVEST, V82, P1244, DOI 10.1172/JCI113722; Behnke J, 2015, J MOL BIOL, V427, P1589, DOI 10.1016/j.jmb.2015.02.011; Blanc MR, 2009, BIOTECHNOL APPL BIOC, V54, P207, DOI 10.1042/BA20090208; Buxbaum JN, 2001, AMYLOID, V8, P84, DOI 10.3109/13506120109007349; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; Cheng Z, 2016, MOL SYST BIOL, V12, DOI 10.15252/msb.20156423; Clarke SC, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03037; Dul JL, 1996, J IMMUNOL, V157, P2969; Ellgaard L, 2016, TRAFFIC, V17, P615, DOI 10.1111/tra.12392; Feige MJ, 2010, TRENDS BIOCHEM SCI, V35, P189, DOI 10.1016/j.tibs.2009.11.005; Feige MJ, 2009, MOL CELL, V34, P569, DOI 10.1016/j.molcel.2009.04.028; FRANKLIN EC, 1964, AM J MED, V37, P332, DOI 10.1016/0002-9343(64)90191-3; FRANKLIN EC, 1976, J IMMUNOL, V116, P1194; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; Han J, 2013, NAT CELL BIOL, V15, P481, DOI 10.1038/ncb2738; Iijima M, 2016, INTERNAL MED, V55, P399, DOI 10.2169/internalmedicine.55.5042; KOHLER G, 1976, EUR J IMMUNOL, V6, P292, DOI 10.1002/eji.1830060411; Kyttaris VC, 2010, METHODS MOL BIOL, V662, P265, DOI 10.1007/978-1-60761-800-3_13; LEACH IH, 1987, BRIT J RHEUMATOL, V26, P460; Lee JG, 2016, NAT CELL BIOL, V18, P765, DOI 10.1038/ncb3372; Li S, 2016, ARTHRITIS RHEUMATOL, V68, P614, DOI 10.1002/art.39455; Liao HY, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01691; MAINS PE, 1983, J BIOL CHEM, V258, P5027; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; Muyldermans S, 2001, J Biotechnol, V74, P277; Muyldermans S, 2013, ANNU REV BIOCHEM, V82, P775, DOI 10.1146/annurev-biochem-063011-092449; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Pisetsky DS, 2016, NAT REV RHEUMATOL, V12, P102, DOI 10.1038/nrrheum.2015.151; SELIGMANN M, 1979, IMMUNOL REV, V48, P145, DOI 10.1111/j.1600-065X.1979.tb00302.x; Shusta EV, 1999, J MOL BIOL, V292, P949, DOI 10.1006/jmbi.1999.3130; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; SONENSHEIN GE, 1978, J EXP MED, V148, P301, DOI 10.1084/jem.148.1.301; Wahner-Roedler DL, 2016, WILLIAMS HEMATOLOGY, P1803; Wardemann H, 2004, J EXP MED, V200, P191, DOI 10.1084/jem.20040818; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907	35	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 5	2020	11								632	10.3389/fimmu.2020.00632	http://dx.doi.org/10.3389/fimmu.2020.00632			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LS4KT	32431693	Green Published, gold			2022-12-18	WOS:000536355200001
J	Knight, JS; Jain, R; Cassatella, MA; Lood, C				Knight, Jason S.; Jain, Rohit; Cassatella, Marco A.; Lood, Christian			Editorial: Neutrophil Communication	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						neutrophil; malignancy; platelet; autoimmunity; infection; inflammation; cell-cell interaction; neutrophil extracellular traps			[Knight, Jason S.] Univ Michigan, Dept Internal Med, Div Rheumatol, Ann Arbor, MI 48109 USA; [Jain, Rohit] Univ Sydney, Fac Med & Hlth, Centenary Inst, Camperdown, NSW, Australia; [Cassatella, Marco A.] Univ Verona, Sect Gen Pathol, Dept Med, Verona, Italy; [Lood, Christian] Univ Washington, Dept Med, Div Rheumatol, Seattle, WA 98195 USA	University of Michigan System; University of Michigan; University of Sydney; Centenary Institute; University of Verona; University of Washington; University of Washington Seattle	Lood, C (corresponding author), Univ Washington, Dept Med, Div Rheumatol, Seattle, WA 98195 USA.	Loodc@uw.edu	Cassatella, M A/B-8037-2013; Jain, Rohit/O-2015-2019	Cassatella, M A/0000-0001-7824-1806; Jain, Rohit/0000-0002-4905-462X	Lupus Research Alliance [519414]; Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG-20339]; Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR-PRIN) [20177J4E75_004]; National Health and Medical Research Council Australia [1126403]; NIH [R01HL115138]; Lupus Research Alliance; Burroughs Wellcome Fund	Lupus Research Alliance; Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR-PRIN)(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); National Health and Medical Research Council Australia(National Health and Medical Research Council (NHMRC) of Australia); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lupus Research Alliance; Burroughs Wellcome Fund(Burroughs Wellcome Fund)	This study was funded by Lupus Research Alliance (519414) to CL, Associazione Italiana per la Ricerca sul Cancro (AIRC, IG-20339), Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR-PRIN 2015YYKPNN and 20177J4E75_004) to MC. RJ was supported by grant 1126403 from National Health and Medical Research Council Australia. JK was supported by grants from NIH (R01HL115138), Lupus Research Alliance, and Burroughs Wellcome Fund.	Warnatsch A, 2015, SCIENCE, V349, P316, DOI 10.1126/science.aaa8064	1	0	0	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 30	2020	11								871	10.3389/fimmu.2020.00871	http://dx.doi.org/10.3389/fimmu.2020.00871			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LS1XH	32425954	Green Published, gold			2022-12-18	WOS:000536184000001
J	Krieger, E; Toor, AA				Krieger, Elizabeth; Toor, Amir Ahmed			Can Graft vs. Leukemia Effect Be Uncoupled From Graft vs. Host Disease? An Examination of Proportions	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						hematopoietic cell transplantation; graft vs; host disease; graft vs; leukemia effect; whole exome sequencing; tumor vaccination	HEMATOPOIETIC-CELL TRANSPLANTATION; MINOR HISTOCOMPATIBILITY ANTIGENS; RELAPSE-FREE SURVIVAL; INDEPENDENT PREDICTOR; GVHD PROPHYLAXIS; T-CELLS; CANCER; RECIPIENTS; NEOANTIGENS; REPERTOIRE		[Krieger, Elizabeth] Virginia Commonwealth Univ, Dept Pediat, Richmond, VA USA; [Toor, Amir Ahmed] Virginia Commonwealth Univ, Massey Canc Ctr, Dept Internal Med, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Toor, AA (corresponding author), Virginia Commonwealth Univ, Massey Canc Ctr, Dept Internal Med, Richmond, VA 23298 USA.	amir.toor@vcuhealth.org			NIH-NCI Cancer Center Support Grant [P30-CA016059]	NIH-NCI Cancer Center Support Grant	AT was supported by research funding from the NIH-NCI Cancer Center Support Grant (P30-CA016059; PI: Gordon Ginder, MD).	Al-Homsi AS, 2015, BIOL BLOOD MARROW TR, V21, P604, DOI 10.1016/j.bbmt.2014.08.014; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alpdogan O, 2012, SEMIN ONCOL, V39, P629, DOI 10.1053/j.seminoncol.2012.10.001; Behjati S, 2013, ARCH DIS CHILDHOOD-E, V98, P236, DOI 10.1136/archdischild-2013-304340; Binkert L, 2015, BONE MARROW TRANSPL, V50, P1331, DOI 10.1038/bmt.2015.148; Bleakley M, 2004, NAT REV CANCER, V4, P371, DOI 10.1038/nrc1365; Bykova NA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01819; Campesato LF, 2015, ONCOTARGET, V6, P34221, DOI 10.18632/oncotarget.5950; Chen YB, 2013, BONE MARROW TRANSPL, V48, P755, DOI 10.1038/bmt.2012.143; Chiappinelli KB, 2015, CELL, V162, P974, DOI 10.1016/j.cell.2015.07.011; Claiborne J, 2019, LEUKEMIA LYMPHOMA, V60, P2733, DOI 10.1080/10428194.2019.1605066; Fleischhauer K, 2012, LANCET ONCOL, V13, P366, DOI 10.1016/S1470-2045(12)70004-9; Goodman AM, 2017, MOL CANCER THER, V16, P2598, DOI 10.1158/1535-7163.MCT-17-0386; Goulmy E, 1992, TISSUE DISTRIBUTION; Grimm J, 1998, BONE MARROW TRANSPL, V21, P29, DOI 10.1038/sj.bmt.1701041; Grove CS, 2014, DIS MODEL MECH, V7, P941, DOI 10.1242/dmm.015974; Gubin MM, 2015, J CLIN INVEST, V125, P3413, DOI 10.1172/JCI80008; Harvey J, 2012, BONE MARROW TRANSPL, V47, P1294, DOI 10.1038/bmt.2012.8; Ho VT, 2001, BLOOD, V98, P3192, DOI 10.1182/blood.V98.12.3192; HOROWITZ MM, 1990, BLOOD, V75, P555; Jameson-Lee M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00529; Jelinek T, 2017, IMMUNOLOGY, V152, P357, DOI 10.1111/imm.12788; Johnson DB, 2016, CANCER IMMUNOL RES, V4, P959, DOI 10.1158/2326-6066.CIR-16-0143; Kaiser T, 2004, BLOOD, V104, P340, DOI 10.1182/blood-2004-02-0518; Karas M, 2016, ANTICANCER RES, V36, P5487, DOI 10.21873/anticanres.11130; Koparde V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187771; Lai LS, 2016, TRANSPL IMMUNOL, V39, P34, DOI 10.1016/j.trim.2016.08.006; Lansford JL, 2018, BLOOD ADV, V2, P2052, DOI 10.1182/bloodadvances.2018022475; Larsen ME, 2010, BIOL BLOOD MARROW TR, V16, P1370, DOI 10.1016/j.bbmt.2010.03.022; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lee SJ, 2007, BLOOD, V110, P4576, DOI 10.1182/blood-2007-06-097386; Lennerz V, 2005, P NATL ACAD SCI USA, V102, P16013, DOI 10.1073/pnas.0500090102; Levine JE, 2011, INT J HEMATOL, V93, P571, DOI 10.1007/s12185-011-0803-1; Martin PJ, 2017, BLOOD, V129, P791, DOI 10.1182/blood-2016-09-737700; Meier J, 2013, BIOL BLOOD MARROW TR, V19, P366, DOI 10.1016/j.bbmt.2012.12.004; Miller A, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.94; Molldrem JJ, 2000, NAT MED, V6, P1018, DOI 10.1038/79526; Mutis T, 2003, INT J HEMATOL, V78, P208, DOI 10.1007/BF02983796; Nazha A, 2016, BONE MARROW TRANSPL, V51, P1642, DOI 10.1038/bmt.2016.254; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Park SS, 2019, BIOL BLOOD MARROW TR, V25, P63, DOI 10.1016/j.bbmt.2018.08.004; Pianko MJ, 2018, CANCER J, V24, P31, DOI 10.1097/PPO.0000000000000297; Proll J, 2011, DNA RES, V18, P201, DOI 10.1093/dnares/dsr008; Rajasagi M, 2014, BLOOD, V124, P453, DOI 10.1182/blood-2014-04-567933; Ratanatharathorn V, 2015, BONE MARROW TRANSPL, V50, P106, DOI 10.1038/bmt.2014.203; Razzaq BA, 2016, BIOL BLOOD MARROW TR, V22, P850, DOI 10.1016/j.bbmt.2015.11.1103; Ren XJ, 2018, ACS CENTRAL SCI, V4, P680, DOI 10.1021/acscentsci.8b00081; Ritari J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01625; Sahin U, 2018, ANN HEMATOL, V97, P1027, DOI 10.1007/s00277-018-3274-0; Salman A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02284; Sampson JK, 2014, BRIT J HAEMATOL, V166, P566, DOI 10.1111/bjh.12898; Solomon SR, 2017, BIOL BLOOD MARROW TR, V23, P1208, DOI 10.1016/j.bbmt.2017.02.022; Spierings E, 2014, TISSUE ANTIGENS, V84, P347, DOI 10.1111/tan.12445; Spierings E, 2013, BIOL BLOOD MARROW TR, V19, P1244, DOI 10.1016/j.bbmt.2013.06.001; Stringaris K, 2016, BLOOD, V128, P2819, DOI 10.1182/blood-2016-05-713099; Toor AA, 2015, BIOL BLOOD MARROW TR, V21, P1237, DOI 10.1016/j.bbmt.2015.03.011; Toor AA, 2012, BRIT J HAEMATOL, V158, P700, DOI 10.1111/j.1365-2141.2012.09225.x; uksza M, 2017, NATURE, V176, P139, DOI [10.1038/nature24462, DOI 10.1038/NATURE24462]; van der Lee DI, 2019, J CLIN INVEST, V129, P774, DOI 10.1172/JCI97482; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang W, 2018, BLOOD ADV, V2, P2419, DOI 10.1182/bloodadvances.2018019513; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333	62	0	1	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 28	2020	11								777	10.3389/fimmu.2020.00777	http://dx.doi.org/10.3389/fimmu.2020.00777			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LO0QX	32425947	gold, Green Published			2022-12-18	WOS:000533335700001
J	Owoicho, O; Olwal, CO; Quaye, O				Owoicho, Oloche; Olwal, Charles Ochieng'; Quaye, Osbourne			Commentary: An enzymatic pathway in the human gut microbiome that converts A to universal O type blood	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						blood transfusion; HLA-I; platelet transfusion; thrombocytopenia; platelet transfusion refractoriness; epithelial cells	REFRACTORINESS; GENERATION; PLATELETS; ANTIGENS		[Owoicho, Oloche; Olwal, Charles Ochieng'; Quaye, Osbourne] Univ Ghana, West African Ctr Cell Biol Infect Pathogens, Dept Biochem Cell & Mol Biol, Accra, Ghana	University of Ghana	Quaye, O (corresponding author), Univ Ghana, West African Ctr Cell Biol Infect Pathogens, Dept Biochem Cell & Mol Biol, Accra, Ghana.	oquaye@ug.edu.gh		Olwal, Charles Ochieng'/0000-0003-1747-2963	WACCBIP-World Bank ACE PhD fellowship [ACE02-WACCBIP]; DELTAS Africa grant [DEL-15-007]; New Partnership for Africa's Development, Planning and Coordinating Agency (NEPARD Agency); Wellcome Trust [107755/Z15/Z]	WACCBIP-World Bank ACE PhD fellowship; DELTAS Africa grant; New Partnership for Africa's Development, Planning and Coordinating Agency (NEPARD Agency); Wellcome Trust(Wellcome TrustEuropean Commission)	OO and CO were supported by a WACCBIP-World Bank ACE PhD fellowship (ACE02-WACCBIP: Awandare) and a DELTAS Africa grant (DEL-15-007: Awandare). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development, Planning and Coordinating Agency (NEPARD Agency) with funding from the Wellcome Trust (107755/Z15/Z: Awandare).	Benamu E, 2016, CURR OPIN INFECT DIS, V29, P319, DOI 10.1097/QCO.0000000000000279; BLUMBERG N, 1984, BLOOD, V63, P448; Borger AK, 2016, MOL MED, V22, P274, DOI 10.2119/molmed.2015.00235; Feng Q, 2014, STEM CELL REP, V3, P817, DOI 10.1016/j.stemcr.2014.09.010; Geng J, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007171; Izak Marina, 2014, F1000Prime Rep, V6, P45, DOI 10.12703/P6-45; Jin Y, 2018, HUM GENOMICS, V12, DOI 10.1186/s40246-018-0175-1; Juskewitch JE, 2017, TRANSFUSION, V57, P2828, DOI 10.1111/trf.14316; KURATA Y, 1989, VOX SANG, V57, P199, DOI 10.1111/j.1423-0410.1989.tb00823.x; Lawrence M, 2019, EMERG TOP LIFE SCI, V3, P301, DOI 10.1042/ETLS20180153; Rahfeld P, 2019, NAT MICROBIOL, V4, P1475, DOI 10.1038/s41564-019-0469-7; Vo PT, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.3840.3840	12	0	0	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 28	2020	11								772	10.3389/fimmu.2020.00772	http://dx.doi.org/10.3389/fimmu.2020.00772			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LO0QL	32411149	gold, Green Published			2022-12-18	WOS:000533334500001
J	Becerril-Garcia, MA; Yam-Puc, JC; Maqueda-Alfaro, R; Beristain-Covarrubias, N; Heras-Chavarria, M; Gallegos-Hernandez, IA; Calderon-Amador, J; Munguia-Fuentes, R; Donis-Maturano, L; Flores-Langarica, A; Flores-Romo, L				Becerril-Garcia, Miguel Angel; Yam-Puc, Juan Carlos; Maqueda-Alfaro, Raul; Beristain-Covarrubias, Nonantzin; Heras-Chavarria, Monica; Gallegos-Hernandez, Isis Amara; Calderon-Amador, Juana; Munguia-Fuentes, Rosario; Donis-Maturano, Luis; Flores-Langarica, Adriana; Flores-Romo, Leopoldo			Langerhans Cells From Mice at Birth Express Endocytic- and Pattern Recognition-Receptors, Migrate to Draining Lymph Nodes Ferrying Antigen and Activate Neonatal T Cells in vivo	FRONTIERS IN IMMUNOLOGY			English	Article						neonates; immunization at birth; T cell activation; in vivo immune response; CD204; CD14; TLR-4	DERMAL DENDRITIC CELLS; ONTOGENY; FETAL; INDUCTION; IMMUNITY; SKIN; TOLERANCE; EPIDERMIS; DISTINCT; INNATE	Antigen capturing at the periphery is one of the earliest, crucial functions of antigen-presenting cells (APCs) to initiate immune responses. Langerhans cells (LCs), the epidermal APCs migrate to draining lymph nodes (DLNs) upon acquiring antigens. An arsenal of endocytic molecules is available to this end, including lectins and pathogen recognition receptors (PRRs). However, cutaneous LCs are poorly defined in the early neonatal period. We assessed endocytic molecules expression in situ: Mannose (CD206)-, Scavenger (SRA/CD204)-, Complement (CD2l, CDllb)-, and Fc-Receptors (CD16/32, CD23) as well as CD1d, CD14, CD205, Langerin (CD207), MHCII, and TLR4 in unperturbed epidermal LCs from both adult and early neonatal mice. As most of these markers were negative at birth (day 0), LC presence was revealed with the conspicuous, epidermal LC-restricted ADPase (and confirmed with CD45) staining detecting that they were as numerous as adult ones. Unexpectedly, most LCs at day 0 expressed CD14 and CD204 while very few were MHCII+ and TLR4+. In contrast, adult LCs lacked all these markers except Langerin, CD205, CD11b, MHCII and TLR4. Intriguingly, the CD204+ and CD14+ LCs predominant at day 0, apparently disappeared by day 4. Upon cutaneous FITC application, LCs were reduced in the skin and a CD204+MHCII+FITC+ population with high levels of CD86 subsequently appeared in DLNs, with a concomitant increased percentage of CD3+CD69+ T cells, strongly suggesting that neonatal LCs were able both to ferry the cutaneous antigen into DLNs and to activate neonatal T cells in vivo. Cell cycle analysis indicated that neonatal T cells in DLNs responded with proliferation. Our study reveals that epidermal LCs are present at birth, but their repertoire of endocytic molecules and PRRs differs to that of adult ones. We believe this to be the first description of CDl4, CD204 and TLR4 in neonatal epidermal LCs in situ. Newborns' LCs express molecules to detect antigens during early postnatal periods, are able to take up local antigens and to ferry them into DLNs conveying the information to responsive neonatal T cells.	[Becerril-Garcia, Miguel Angel; Yam-Puc, Juan Carlos; Maqueda-Alfaro, Raul; Heras-Chavarria, Monica; Gallegos-Hernandez, Isis Amara; Calderon-Amador, Juana; Munguia-Fuentes, Rosario; Donis-Maturano, Luis; Flores-Romo, Leopoldo] Cinvestav IPN, Natl Polytech Inst, Ctr Adv Res, Dept Cell Biol, Mexico City, DF, Mexico; [Yam-Puc, Juan Carlos; Beristain-Covarrubias, Nonantzin; Flores-Langarica, Adriana] Univ Birmingham, Coll Med & Dent Sci, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England; [Becerril-Garcia, Miguel Angel] Univ Autonoma Nuevo Leon, Sch Med, Dept Microbiol, Monterrey, Mexico; [Donis-Maturano, Luis] Natl Autonomous Univ Mexico UNAM, Fac Higher Studies FES Iztacala, Mexico City, DF, Mexico	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; University of Birmingham; Universidad Autonoma de Nuevo Leon; Universidad Nacional Autonoma de Mexico	Yam-Puc, JC (corresponding author), Cinvestav IPN, Natl Polytech Inst, Ctr Adv Res, Dept Cell Biol, Mexico City, DF, Mexico.; Yam-Puc, JC (corresponding author), Univ Birmingham, Coll Med & Dent Sci, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England.	jcyampuc@gmail.com	Yam-Puc, Juan C/CAF-4325-2022	Yam-Puc, Juan C/0000-0003-4395-8844; Flores-Langarica, Adriana/0000-0003-2183-4437; Donis Maturano, Luis/0000-0001-8430-5669; Beristain-Covarrubias, Nonantzin/0000-0002-4828-5282; Maqueda-Alfaro, Raul Antonio/0000-0003-3538-1176; Becerril-Garcia, Miguel Angel/0000-0003-1329-7918; Munguia-Fuentes, Rosario/0000-0003-2021-6274	National Council for Science and Technology-CONACYT Mexico [221102]	National Council for Science and Technology-CONACYT Mexico(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	This work was supported by a grant from the National Council for Science and Technology-CONACYT Mexico (221102) to LF-R.	ADKINS B, 1992, J IMMUNOL, V149, P3448; Adkins B, 2004, NAT REV IMMUNOL, V4, P553, DOI 10.1038/nri1394; ADKINS B, 1993, J IMMUNOL, V151, P6617; Adkins B, 2000, Int Rev Immunol, V19, P157, DOI 10.3109/08830180009088503; BAKER KW, 1983, J INVEST DERMATOL, V80, P104, DOI 10.1111/1523-1747.ep12531712; Barrios C, 1996, EUR J IMMUNOL, V26, P1489, DOI 10.1002/eji.1830260713; Bennett CL, 2005, J CELL BIOL, V169, P569, DOI 10.1083/jcb.200501071; Chang-Rodriguez S, 2005, J LEUKOCYTE BIOL, V77, P352, DOI 10.1189/jlb.1004584; Chorro L, 2009, J EXP MED, V206, P3089, DOI 10.1084/jem.20091586; Deckers J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00093; DEPPER JM, 1983, J IMMUNOL, V131, P690; Dewar AL, 2001, IMMUNOLOGY, V103, P61, DOI 10.1046/j.1365-2567.2001.01221.x; Doebel T, 2017, TRENDS IMMUNOL, V38, P817, DOI 10.1016/j.it.2017.06.008; Douillard P, 2005, J INVEST DERMATOL, V125, P983, DOI 10.1111/j.0022-202X.2005.23951.x; Durai V, 2016, IMMUNITY, V45, P719, DOI 10.1016/j.immuni.2016.10.010; ELBE A, 1989, J IMMUNOL, V143, P2431; Flacher V, 2008, IMMUNOLOGY, V123, P339, DOI 10.1111/j.1365-2567.2007.02785.x; Flores-Maldonado OE, 2019, MYCOPATHOLOGIA, V184, P747, DOI 10.1007/s11046-019-00398-9; Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728; FOSTER CA, 1986, J INVEST DERMATOL, V86, P240, DOI 10.1111/1523-1747.ep12285201; Fukunaga A, 2004, J IMMUNOL, V172, P4091, DOI 10.4049/jimmunol.172.7.4091; Garcia AM, 2000, IMMUNOL RES, V22, P177, DOI 10.1385/IR:22:2-3:177; GILLIS S, 1981, J EXP MED, V154, P983, DOI 10.1084/jem.154.3.983; Ginhoux F, 2010, IMMUNOL CELL BIOL, V88, P387, DOI 10.1038/icb.2010.38; Guilliams M, 2016, IMMUNITY, V45, P669, DOI 10.1016/j.immuni.2016.08.015; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; Hoeffel G, 2012, J EXP MED, V209, P1167, DOI 10.1084/jem.20120340; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kaplan DH, 2017, NAT IMMUNOL, V18, P1068, DOI 10.1038/ni.3815; KATZ SI, 1979, NATURE, V282, P324, DOI 10.1038/282324a0; Kissenpfennig A, 2005, IMMUNITY, V22, P643, DOI 10.1016/j.immuni.2005.04.004; KOBAYASHI M, 1987, CELL TISSUE RES, V248, P315; KRIPKE ML, 1990, J IMMUNOL, V145, P2833; Liu YJ, 2001, CELL, V106, P259, DOI 10.1016/S0092-8674(01)00456-1; MACATONIA SE, 1987, J EXP MED, V166, P1654, DOI 10.1084/jem.166.6.1654; MALEK TR, 1984, J IMMUNOL, V133, P1976; Mass E, 2016, SCIENCE, V353, DOI 10.1126/science.aaf4238; McGovern N, 2017, NATURE, V546, P662, DOI 10.1038/nature22795; McGovern N, 2014, IMMUNITY, V41, P465, DOI 10.1016/j.immuni.2014.08.006; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Merad M, 2008, NAT REV IMMUNOL, V8, P935, DOI 10.1038/nri2455; Moodycliffe AM, 2000, J EXP MED, V191, P2011, DOI 10.1084/jem.191.11.2011; Munguia-Fuentes R, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00013; Nagao K, 2009, P NATL ACAD SCI USA, V106, P3312, DOI 10.1073/pnas.0807126106; Quesada-Pascual F, 2008, VET IMMUNOL IMMUNOP, V124, P220, DOI 10.1016/j.vetimm.2008.03.011; Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723; ROMANI N, 1986, J INVEST DERMATOL, V86, P129, DOI 10.1111/1523-1747.ep12284135; Rudd BD, 2020, ANNU REV IMMUNOL, V38, P229, DOI 10.1146/annurev-immunol-091319-083608; Sarzotti M, 1996, SCIENCE, V271, P1726, DOI 10.1126/science.271.5256.1726; Schuster C, 2009, J EXP MED, V206, P169, DOI 10.1084/jem.20081747; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Siegrist C A, 2000, Int Rev Immunol, V19, P195, DOI 10.3109/08830180009088505; Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411; Tajpara P, 2018, FASEB J, V32, P4132, DOI 10.1096/fj.201701090R; Tripp CH, 2004, J INVEST DERMATOL, V122, P670, DOI 10.1111/j.0022-202X.2004.22337.x; van der Aar AMG, 2007, J IMMUNOL, V178, P1986, DOI 10.4049/jimmunol.178.4.1986; van der Aar AMG, 2013, J INVEST DERMATOL, V133, P1240, DOI 10.1038/jid.2012.500; Wu XD, 2016, J EXP MED, V213, P2553, DOI 10.1084/jem.20160600	58	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 27	2020	11								744	10.3389/fimmu.2020.00744	http://dx.doi.org/10.3389/fimmu.2020.00744			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LO1RF	32395120	Green Published, gold			2022-12-18	WOS:000533404500001
J	Pelayo, R; Garcia, LF; Santos-Argumedo, L				Pelayo, Rosana; Garcia, Luis F.; Santos-Argumedo, Leopoldo			Editorial: Immunopathology of Chronic Bacterial and Viral Diseases Prevalent in Latin America	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						immunopathology; chronic; bacterial; viral; infections; Latin America			[Pelayo, Rosana] Mexican Inst Social Secur, Eastern Biomed Res Ctr CIBIOR, Puebla, Mexico; [Garcia, Luis F.] Univ Antioquia, Grp Cellular Immunol & Immunogenet, Medellin, Colombia; [Santos-Argumedo, Leopoldo] Natl Polytech Inst, CINVESTAV, Ctr Res & Adv Studies, Dept Mol Biomed,IPN, Mexico City, DF, Mexico	Instituto Mexicano del Seguro Social; Universidad de Antioquia; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico	Pelayo, R (corresponding author), Mexican Inst Social Secur, Eastern Biomed Res Ctr CIBIOR, Puebla, Mexico.; Garcia, LF (corresponding author), Univ Antioquia, Grp Cellular Immunol & Immunogenet, Medellin, Colombia.; Santos-Argumedo, L (corresponding author), Natl Polytech Inst, CINVESTAV, Ctr Res & Adv Studies, Dept Mol Biomed,IPN, Mexico City, DF, Mexico.	rosana.pelayo.c@gmail.com; lfgarcia@une.net.co; lesantos@cinvestav.mx		Jaramillo Garcia, Luis Fernando/0000-0003-2909-9318	International Union of Immunological Societies (IUIS); Latin American Association of Immunology (ALAI); Mexican Society of Immunology (SMI); National Council of Science and Technology (CONACYT Mexico); Mexican Institute for Social Security (FIS IMSS); American Association of Immunologists (AAI)	International Union of Immunological Societies (IUIS); Latin American Association of Immunology (ALAI); Mexican Society of Immunology (SMI); National Council of Science and Technology (CONACYT Mexico)(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Mexican Institute for Social Security (FIS IMSS); American Association of Immunologists (AAI)	This funding granted by the International Union of Immunological Societies (IUIS), the Latin American Association of Immunology (ALAI), the Mexican Society of Immunology (SMI), and the National Council of Science and Technology (CONACYT Mexico), was of crucial relevance for the mission fulfillment at the Latin American Immunology Meeting, including the cutting-edge scientific program and our remarkable regional interaction and knowledge dissemination. LS-A and RP were supported by the National Council of Science and Technology (CONACYT Mexico). RP was supported by the Mexican Institute for Social Security (FIS IMSS). LG was supported by the American Association of Immunologists (AAI).		0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 22	2020	11								749	10.3389/fimmu.2020.00749	http://dx.doi.org/10.3389/fimmu.2020.00749			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LN9VM	32425940	Green Published, gold			2022-12-18	WOS:000533278700001
J	Kathamuthu, GR; Munisankar, S; Banurekha, VV; Nair, D; Sridhar, R; Babu, S				Kathamuthu, Gokul Raj; Munisankar, Saravanan; Banurekha, Vaithilingam V.; Nair, Dina; Sridhar, Rathinam; Babu, Subash			Filarial Coinfection Is Associated With Higher Bacterial Burdens and Altered Plasma Cytokine and Chemokine Responses in Tuberculous Lymphadenitis	FRONTIERS IN IMMUNOLOGY			English	Article						tuberculosis; lymphadenitis; filariasis; cytokines; chemokines	IL-33; IMMUNITY; INTERLEUKIN-12; INNATE; IL-18; MICE	Filarial infections are known to modulate cytokine responses in pulmonary tuberculosis by their propensity to induce Type 2 and regulatory cytokines. However, very little is known about the effect of filarial infections on extra-pulmonary forms of tuberculosis. Thus, we have examined the effect of filarial infections on the plasma levels of various families of (IL-1, IL-12, gamma C, and regulatory) cytokines and (CC and CXC) chemokines in tuberculous lymphadenitis coinfection. We also measured lymph node culture grades in order to assess the burden of Mycobacterium tuberculosis in the two study groups [Fil+ (n = 67) and Fil- (n = 109)]. Our data reveal that bacterial burden was significantly higher in Fil+ compared to Fil- individuals. Plasma levels of IL-1 family (IL-1 alpha, IL-beta, IL-18) cytokines were significantly lower with the exception of IL-33 in Fil+ compared to Fil- individuals. Similarly, plasma levels of IL-12 family cytokines -IL-12 and IL-23 were significantly reduced, while IL-35 was significantly elevated in Fil+ compared to Fil- individuals. Filarial infection was also associated with diminished levels of IL-2, IL-9 and enhanced levels of IL-4, IL-10, and IL-1Ra. Similarly, the Fil+ individuals were linked to elevated levels of different CC (CCL-1, CCL-2, CCL-3, CCL-11) and CXC (CXCL-2, CXCL-8, CXCL-9, CXCL-11) chemokines. Therefore, we conclude that filarial infections exert powerful bystander effects on tuberculous lymphadenitis, effects including modulation of protective cytokines and chemokines with a direct impact on bacterial burdens.	[Kathamuthu, Gokul Raj; Munisankar, Saravanan; Babu, Subash] Natl Inst Hlth, NIRT, Int Ctr Excellence Res, Chennai, Tamil Nadu, India; [Kathamuthu, Gokul Raj; Banurekha, Vaithilingam V.; Nair, Dina] NIRT, Chennai, Tamil Nadu, India; [Sridhar, Rathinam] Govt Stanley Med Hosp, Chennai, Tamil Nadu, India; [Babu, Subash] NIAID, Lab Parasit Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Babu, Subash] NCI, Frederick Natl Lab Canc Res, Frederick, MD 21701 USA	Indian Council of Medical Research (ICMR); ICMR - National Institute for Research in Tuberculosis (NIRT); Indian Council of Medical Research (ICMR); ICMR - National Institute for Research in Tuberculosis (NIRT); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kathamuthu, GR (corresponding author), Natl Inst Hlth, NIRT, Int Ctr Excellence Res, Chennai, Tamil Nadu, India.; Kathamuthu, GR (corresponding author), NIRT, Chennai, Tamil Nadu, India.	gokul.r@nirt.res.in	Babu, Subash/GXG-4746-2022		National Institutes of Health	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This research was supported [in part] by the National Institutes of Health.	Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; [Anonymous], 2019, GLOB TUB REP 2018; Babu S, 2016, TRENDS IMMUNOL, V37, P597, DOI 10.1016/j.it.2016.07.005; Banchereau J, 2012, NAT IMMUNOL, V13, P925, DOI 10.1038/ni.2406; Boisson-Dupuis S, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aau8714; Booty MG, 2016, SCI REP-UK, V6, DOI 10.1038/srep36720; Cooper AM, 2011, MUCOSAL IMMUNOL, V4, P252, DOI 10.1038/mi.2011.13; COOPER AM, 1995, IMMUNOLOGY, V84, P423; Cooper AM, 2008, IMMUNOL REV, V226, P191, DOI 10.1111/j.1600-065X.2008.00702.x; Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098; Dorhoi A, 2016, SEMIN IMMUNOPATHOL, V38, P153, DOI 10.1007/s00281-015-0531-3; FLYNN JL, 1995, J IMMUNOL, V155, P2515; Handa U, 2012, J INFECT DEV COUNTR, V6, P6, DOI 10.3855/jidc.2090; Ji DX, 2019, NAT MICROBIOL, V4, P2128, DOI 10.1038/s41564-019-0578-3; Kathamuthu GR, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007265; Kathamuthu GR, 2017, CYTOKINE, V90, P66, DOI 10.1016/j.cyto.2016.10.013; Khader SA, 2007, NAT IMMUNOL, V8, P369, DOI 10.1038/ni1449; Kumar NP, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54803-w; Kumar NP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176495; LEVETON C, 1989, INFECT IMMUN, V57, P390, DOI 10.1128/IAI.57.2.390-395.1989; Liew FY, 2010, NAT REV IMMUNOL, V10, P103, DOI 10.1038/nri2692; Mantovani A, 2019, IMMUNITY, V50, P778, DOI 10.1016/j.immuni.2019.03.012; Martinez-Barricarte R, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aau6759; Mayer-Barber KD, 2015, IMMUNOL REV, V264, P264, DOI 10.1111/imr.12249; Mayer-Barber KD, 2011, IMMUNITY, V35, P1023, DOI 10.1016/j.immuni.2011.12.002; Monin L, 2014, SEMIN IMMUNOL, V26, P552, DOI 10.1016/j.smim.2014.09.004; Moussion C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003331; O'Garra A, 2013, ANNU REV IMMUNOL, V31, P475, DOI 10.1146/annurev-immunol-032712-095939; Pichery M, 2012, J IMMUNOL, V188, P3488, DOI 10.4049/jimmunol.1101977; Pineros AR, 2017, SCI REP-UK, V7, DOI 10.1038/srep41240; Rajamanickam A, 2019, J IMMUNOL, V202, P1494, DOI 10.4049/jimmunol.1801190; Redford PS, 2011, MUCOSAL IMMUNOL, V4, P261, DOI 10.1038/mi.2011.7; Robinson CM, 2008, J INFECT DIS, V198, P359, DOI 10.1086/589774; Rook GAW, 2007, CURR MOL MED, V7, P327; Salgame P, 2013, NAT IMMUNOL, V14, P1118, DOI 10.1038/ni.2736; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Slight SR, 2013, CYTOKINE GROWTH F R, V24, P105, DOI 10.1016/j.cytogfr.2012.10.002; Specht S, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.k5198; Sugawara I, 1999, INFECT IMMUN, V67, P2585, DOI 10.1128/IAI.67.5.2585-2589.1999; Taylor MJ, 2010, LANCET, V376, P1175, DOI 10.1016/S0140-6736(10)60586-7; Wood IS, 2009, BIOCHEM BIOPH RES CO, V384, P105, DOI 10.1016/j.bbrc.2009.04.081	41	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 21	2020	11								706	10.3389/fimmu.2020.00706	http://dx.doi.org/10.3389/fimmu.2020.00706			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LM5QL	32373129	gold, Green Published, Green Accepted			2022-12-18	WOS:000532303500001
J	Pal, L; Bujdoso, O; McKee, M; Sandor, J; Szucs, S				Pal, Laszlo; Bujdoso, Orsolya; McKee, Martin; Sandor, Janos; Szucs, Sandor			Commentary: Short-Chain Alcohols Upregulate GILZ Gene Expression and Attenuate LPS-Induced Septic Immune Response	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						short chain alcohols; aliphatic alcohols; granulocytes; monocytes; phagocytosis; immunosuppression; immunotoxicity; alcohol abuse	SPIRITS INHIBIT PHAGOCYTOSIS; ILLEGALLY PRODUCED SPIRITS; ALIPHATIC-ALCOHOLS; MAIN SOURCE; CONSUMPTION; EXPOSURE; BEVERAGES; QUALITY; DISEASE; LINK		[Pal, Laszlo; Bujdoso, Orsolya; Sandor, Janos; Szucs, Sandor] Univ Debrecen, Fac Publ Hlth, Dept Prevent Med, Debrecen, Hungary; [McKee, Martin] London Sch Hyg & Trop Med, European Ctr Hlth Soc Transit, London, England	University of Debrecen; University of London; London School of Hygiene & Tropical Medicine	Szucs, S (corresponding author), Univ Debrecen, Fac Publ Hlth, Dept Prevent Med, Debrecen, Hungary.	szucs.sandor@sph.unideb.hu						Arnyas EM, 2016, ALCOHOL ALCOHOLISM, V51, P388, DOI 10.1093/alcalc/agv132; Arnyas EM, 2012, IMMUNOPHARM IMMUNOT, V34, P844, DOI 10.3109/08923973.2012.663387; Beaulieu E, 2011, NAT REV RHEUMATOL, V7, P340, DOI 10.1038/nrrheum.2011.59; Bereshchenko O, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00308; Bujdoso O, 2019, REGUL TOXICOL PHARM, V106, P334, DOI 10.1016/j.yrtph.2019.05.020; Chousterman BG, 2017, SEMIN IMMUNOPATHOL, V39, P517, DOI 10.1007/s00281-017-0639-8; Corrao G, 1999, ADDICTION, V94, P1551, DOI 10.1046/j.1360-0443.1999.9410155111.x; Gilg T, 2012, VERKEHRSMEDIZIN FAHR, P480; Goral J, 2008, ALCOHOL, V42, P237, DOI 10.1016/j.alcohol.2008.02.003; Lachenmeier D.W., 2004, RECHTSMED, V14, P454, DOI [10.1007/s00194-004-0292-0, DOI 10.1007/S00194-004-0292-0]; Lachenmeier DW, 2008, REGUL TOXICOL PHARM, V50, P313, DOI 10.1016/j.yrtph.2007.12.008; Lachenmeier DW, 2013, IMMUNOPHARM IMMUNOT, V35, P451, DOI 10.3109/08923973.2013.794147; Lau AH, 2009, TRENDS IMMUNOL, V30, P13, DOI 10.1016/j.it.2008.09.005; McKee M, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e1146; Molina PE, 2010, ALCOHOL RES HEALTH, V33, P97; Nelson S, 2002, NAT REV IMMUNOL, V2, P205, DOI 10.1038/nri744; Ng HP, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00053; Pal L, 2015, IMMUNOPHARM IMMUNOT, V37, P193, DOI 10.3109/08923973.2015.1009998; Pal L, 2013, IMMUNOPHARM IMMUNOT, V35, P627, DOI 10.3109/08923973.2013.822510; Pal L, 2013, IMMUNOPHARM IMMUNOT, V35, P251, DOI 10.3109/08923973.2012.759962; Rehm J, 2010, DRUG ALCOHOL REV, V29, P426, DOI 10.1111/j.1465-3362.2009.00140.x; Rehm J, 2010, ADDICTION, V105, P817, DOI 10.1111/j.1360-0443.2010.02899.x; Szabo G, 1999, ALCOHOL ALCOHOLISM, V34, P830, DOI 10.1093/alcalc/34.6.830; Szabo G, 2009, ALCOHOL CLIN EXP RES, V33, P220, DOI 10.1111/j.1530-0277.2008.00842.x; Szucs S, 2005, ADDICTION, V100, P536, DOI 10.1111/j.1360-0443.2005.01009.x; World Health Organization, 2018, AIR POLL CHILD HLTH	26	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 21	2020	11								728	10.3389/fimmu.2020.00728	http://dx.doi.org/10.3389/fimmu.2020.00728			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LM5RT	32373133	Green Published, gold			2022-12-18	WOS:000532307100001
J	Heymans, C; de Lange, IH; Hutten, MC; Lenaerts, K; de Ruijter, NJE; Kessels, LCGA; Rademakers, G; Melotte, V; Boesmans, W; Saito, M; Usuda, H; Stock, SJ; Spiller, OB; Beeton, ML; Payne, MS; Kramer, BW; Newnham, JP; Jobe, AH; Kemp, MW; van Gemert, WG; Wolfs, TGAM				Heymans, Cathelijne; de Lange, Ilse H.; Huetten, Matthias C.; Lenaerts, Kaatje; de Ruijter, Nadine J. E.; Kessels, Lilian C. G. A.; Rademakers, Glenn; Melotte, Veerle; Boesmans, Werend; Saito, Masatoshi; Usuda, Haruo; Stock, Sarah J.; Spiller, Owen B.; Beeton, Michael L.; Payne, Matthew S.; Kramer, Boris W.; Newnham, John P.; Jobe, Alan H.; Kemp, Matthew W.; van Gemert, Wim G.; Wolfs, Tim G. A. M.			Chronic Intra-Uterine Ureaplasma parvum Infection Induces Injury of the Enteric Nervous System in Ovine Fetuses (vol 11, 189, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						Ureaplasma parvum; intra-amniotic infection; chorioamnionitis; enteric nervous system; sheep; preterm birth; necrotizing enterocolitis			[Heymans, Cathelijne; de Lange, Ilse H.; Lenaerts, Kaatje; van Gemert, Wim G.] Maastricht Univ, NUTRIM Sch Nutr & Translat Res Metab, Dept Surg, Maastricht, Netherlands; [de Lange, Ilse H.; Huetten, Matthias C.; de Ruijter, Nadine J. E.; Kessels, Lilian C. G. A.; Kramer, Boris W.; Wolfs, Tim G. A. M.] Maastricht Univ, Sch Oncol & Dev Biol GROW, Dept Pediat, Maastricht, Netherlands; [Huetten, Matthias C.; Kramer, Boris W.] Maastricht Univ, Med Ctr, Dept Pediat, Neonatol, Maastricht, Netherlands; [Huetten, Matthias C.] Univ Hosp Aachen, Dept Pediat, Neonatol, Aachen, Germany; [Huetten, Matthias C.] Univ Childrens Hosp Wurzburg, Dept Pediat, Neonatol, Wurzburg, Germany; [Rademakers, Glenn; Melotte, Veerle; Boesmans, Werend] Maastricht Univ, Sch Oncol & Dev Biol GROW, Dept Pathol, Med Ctr, Maastricht, Netherlands; [Boesmans, Werend] Hasselt Univ, Biomed Res Inst BIOMED, Hasselt, Belgium; [Saito, Masatoshi; Usuda, Haruo; Payne, Matthew S.; Newnham, John P.; Jobe, Alan H.; Kemp, Matthew W.] Univ Western Australia, Div Obstet & Gynecol, Perth, WA, Australia; [Saito, Masatoshi; Usuda, Haruo; Kemp, Matthew W.] Tohoku Univ Hosp, Ctr Perinatal & Neonatal Med, Sendai, Miyagi, Japan; [Stock, Sarah J.] Univ Edinburgh, Usher Inst, Edinburgh, Midlothian, Scotland; [Spiller, Owen B.] Cardiff Univ, Sch Med, Div Infect & Immun, Cardiff, Wales; [Beeton, Michael L.] Cardiff Metropolitan Univ, Cardiff Sch Sport & Hlth Sci, Cardiff, Wales; [Jobe, Alan H.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Perinatal Inst, Div Neonatol Pulm, Cincinnati, OH USA; [Kemp, Matthew W.] Murdoch Univ, Sch Vet & Life Sci, Perth, WA, Australia; [van Gemert, Wim G.] Maastricht Univ, Dept Surg, Med Ctr, Pediat Surg, Maastricht, Netherlands; [van Gemert, Wim G.] Univ Hosp Aachen, Dept Surg, Aachen, Germany; [Wolfs, Tim G. A. M.] Maastricht Univ, Sch Cardiovasc Dis CARIM, Dept Biomed Engn BMT, Maastricht, Netherlands	Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University; RWTH Aachen University; RWTH Aachen University Hospital; University of Wurzburg; Maastricht University; Hasselt University; University of Western Australia; Tohoku University; University of Edinburgh; Cardiff University; Cardiff Metropolitan University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Murdoch University; Maastricht University; RWTH Aachen University; RWTH Aachen University Hospital; Maastricht University	Wolfs, TGAM (corresponding author), Maastricht Univ, Sch Oncol & Dev Biol GROW, Dept Pediat, Maastricht, Netherlands.; Wolfs, TGAM (corresponding author), Maastricht Univ, Sch Cardiovasc Dis CARIM, Dept Biomed Engn BMT, Maastricht, Netherlands.	tim.wolfs@maastrichtuniversity.nl	Kramer, Boris/AAO-3183-2021; Lenaerts, Kaatje/B-9614-2008	Lenaerts, Kaatje/0000-0002-9858-0538; Beeton, Michael/0000-0002-6292-0772; melotte, veerle/0000-0002-9459-123X; Heymans, Cathelijne/0000-0001-9373-1360; de Lange, Ilse Hilligje/0000-0002-7780-9399; Usuda, Haruo/0000-0002-9334-8086				Heymans C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00189	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 15	2020	11								672	10.3389/fimmu.2020.00672	http://dx.doi.org/10.3389/fimmu.2020.00672			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LJ9RH	32351513	Green Published, gold			2022-12-18	WOS:000530497300001
J	Matino, D; Afraz, S; Zhao, G; Tieu, P; Gargaro, M; Fallarino, F; Iorio, A				Matino, Davide; Afraz, Sajjad; Zhao, George; Tieu, Paul; Gargaro, Marco; Fallarino, Francesca; Iorio, Alfonso			Tolerance to FVIII: Role of the Immune Metabolic Enzymes Indoleamine 2,3 Dyoxigenase-1 and Heme Oxygenase-1	FRONTIERS IN IMMUNOLOGY			English	Review						hemophilia; inhibitor; danger model; FVIII; IDO; HO-1; tolerance	SEVERE HEMOPHILIA-A; ARYL-HYDROCARBON RECEPTOR; THERAPEUTIC FACTOR-VIII; REGULATORY T-CELLS; PREVIOUSLY UNTREATED PATIENTS; ENVIRONMENTAL RISK-FACTORS; COAGULATION-FACTOR-VIII; VON-WILLEBRAND-FACTOR; INHIBITOR DEVELOPMENT; DENDRITIC CELLS	The occurrence of neutralizing anti-FVIII antibodies is a major complication in the treatment of patients affected by hemophilia A. The immune response to FVIII is a complex, multi-factorial process that has been extensively studied for the past two decades. The reasons why only a proportion of hemophilic patients treated with FVIII concentrates develop a clinically significant immune response is incompletely understood. The "danger theory" has been proposed as a possible explanation to interpret the findings of some observational clinical studies highlighting the possible detrimental impact of inflammatory stimuli at the time of replacement therapy on inhibitor development. The host immune system is often challenged to react to FVIII under steady state or inflammatory conditions (e.g., bleeding, infections) although fine tuning of mechanisms of immune tolerance can control this reactivity and promote long-term unresponsiveness to the therapeutically administered factor. Recent studies have provided evidence that multiple interactions involving central and peripheral mechanisms of tolerance are integrated by the host immune system with the environmental conditions at the time of FVIII exposure and influence the balance between immunity and tolerance to FVIII. Here we review evidences showing the involvement of two key immunoregulatory oxygenase enzymes (IDO1, HO-1) that have been studied in hemophilia patients and pre-clinical models, showing that the ability of the host immune system to induce such regulatory proteins under inflammatory conditions can play important roles in the balance between immunity and tolerance to exogenous FVIII.	[Matino, Davide] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Matino, Davide; Afraz, Sajjad; Tieu, Paul] Thrombosis & Atherosclerosis Res Inst, Hamilton, ON, Canada; [Zhao, George; Tieu, Paul] McMaster Univ, McMaster Fac Hlth Sci, Hamilton, ON, Canada; [Gargaro, Marco; Fallarino, Francesca] Univ Perugia, Dept Expt Med, Perugia, Italy; [Iorio, Alfonso] Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada	McMaster University; McMaster University; McMaster University; University of Perugia	Iorio, A (corresponding author), Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.	iorioa@mcmaster.ca	Gargaro, Marco/K-7077-2016; Fallarino, Francesca/O-3358-2013	Gargaro, Marco/0000-0003-0645-9800; Fallarino, Francesca/0000-0002-8501-2136	Italian Association for Cancer Research [AIRC 19903]; Telethon [GGP17094]; research projects of National Interest [Prin 2017BZEREZ]	Italian Association for Cancer Research; Telethon; research projects of National Interest	This work was supported by the Italian Association for Cancer Research (AIRC 19903 to FF) and Telethon (GGP17094 to FF), and the research projects of National Interest (Prin 2017BZEREZ to FF).	Abraham NG, 2008, PHARMACOL REV, V60, P79, DOI 10.1124/pr.107.07104; Agaugue S, 2006, J IMMUNOL, V177, P2061, DOI 10.4049/jimmunol.177.4.2061; Alexander AM, 2002, DIABETES, V51, P356, DOI 10.2337/diabetes.51.2.356; Allacher P, 2011, BLOOD, V117, P259, DOI 10.1182/blood-2010-06-289009; Astermark J, 2010, HAEMOPHILIA, V16, P747, DOI 10.1111/j.1365-2516.2010.02231.x; Auerswald G, 2015, HAEMOPHILIA, V21, P622, DOI 10.1111/hae.12666; Ball HJ, 2014, AMINO ACIDS, V46, P2155, DOI [10.1007/s00726-014-1766-3, DOI 10.1007/S00726-014-1766-3]; Basran J, 2016, BIOCHEMISTRY-US, V55, P6743, DOI 10.1021/acs.biochem.6b01005; Bessede A, 2014, NATURE, V511, P184, DOI 10.1038/nature13323; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Blancou P, 2010, SUPPRESSION REGULATI, V677; Brydun A, 2007, HYPERTENS RES, V30, P341, DOI 10.1291/hypres.30.341; Campbell NK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28488-6; Castaman G, 2019, HAEMATOLOGICA, V104, P1702, DOI 10.3324/haematol.2019.221093; Chauveau C, 2005, BLOOD, V106, P1694, DOI 10.1182/blood-2005-02-0494; Chen W, 2007, BLOOD, V110, p404A, DOI 10.1182/blood.V110.11.1344.1344; Chora AA, 2007, J CLIN INVEST, V117, P438, DOI 10.1172/JCI28844; Delignat S, 2018, SEMIN THROMB HEMOST, V44, P517, DOI 10.1055/s-0038-1657777; Dimitrov JD, 2010, BLOOD, V115, P2682, DOI 10.1182/blood-2009-04-216408; Eckhardt CL, 2011, J THROMB HAEMOST, V9, P1948, DOI 10.1111/j.1538-7836.2011.04467.x; Fallarino F, 2003, NAT IMMUNOL, V4, P1206, DOI 10.1038/ni1003; Fallarino F, 2006, J IMMUNOL, V176, P6752, DOI 10.4049/jimmunol.176.11.6752; Gangadharan B, 2014, J THROMB HAEMOST, V12, P2065, DOI 10.1111/jth.12740; Gargaro M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01973; Gouw SC, 2007, J THROMB HAEMOST, V5, P1383, DOI 10.1111/j.1538-7836.2007.02595.x; Gouw SC, 2007, BLOOD, V109, P4648, DOI 10.1182/blood-2006-11-056291; Gouw SC, 2013, BLOOD, V121, P4046, DOI 10.1182/blood-2012-09-457036; Gouw SC, 2012, BLOOD, V119, P2922, DOI 10.1182/blood-2011-09-379453; Grohmann U, 2003, TRENDS IMMUNOL, V24, P242, DOI 10.1016/S1471-4906(03)00072-3; Grohmann U, 2007, NAT MED, V13, P579, DOI 10.1038/nm1563; Grohmann U, 2017, CYTOKINE GROWTH F R, V35, P37, DOI 10.1016/j.cytogfr.2017.05.004; Gurtner GJ, 2003, GASTROENTEROLOGY, V125, P1762, DOI 10.1053/j.gastro.2003.08.031; Hofbauer CJ, 2015, BLOOD, V125, P1180, DOI 10.1182/blood-2014-09-598268; Hu GL, 2003, J THROMB HAEMOST, V1, P2159, DOI 10.1046/j.1538-7836.2003.00366.x; Iorio A, 2019, ANN INTERN MED, V171, P540, DOI 10.7326/M19-1208; Jacquemin M, 2003, BLOOD, V101, P1351, DOI 10.1182/blood-2002-05-1369; Kapturczak MH, 2004, AM J PATHOL, V165, P1045, DOI 10.1016/S0002-9440(10)63365-2; Kolodziej LR, 2011, AMINO ACIDS, V41, P1173, DOI 10.1007/s00726-010-0787-9; Kurnik K, 2010, HAEMOPHILIA, V16, P256, DOI 10.1111/j.1365-2516.2009.02122.x; Lacroix-Desmazes S, 2008, BLOOD, V112, P240, DOI 10.1182/blood-2008-02-124941; Lacroix-Desmazes S, 2017, BLOOD TRANSFUS-ITALY, V15, P568, DOI 10.2450/2016.0252-16; Lai JD, 2016, BLOOD, V127, P3439, DOI 10.1182/blood-2015-11-679282; Listopad J, 2007, EXP DERMATOL, V16, P661, DOI 10.1111/j.1600-0625.2007.00581.x; Liu L, 2009, GENE THER, V16, P724, DOI 10.1038/gt.2009.13; Lovgren KM, 2016, HAEMOPHILIA, V22, P657, DOI 10.1111/hae.13075; Maclean PS, 2011, HAEMOPHILIA, V17, P282, DOI 10.1111/j.1365-2516.2010.02422.x; Madoiwa S, 2009, J THROMB HAEMOST, V7, P811, DOI 10.1111/j.1538-7836.2009.03314.x; Mathis D, 2004, IMMUNITY, V20, P509, DOI 10.1016/S1074-7613(04)00111-6; Matino D, 2015, J CLIN INVEST, V125, P3766, DOI 10.1172/JCI81859; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Medzhitov R, 2000, SEMIN IMMUNOL, V12, P185, DOI 10.1006/smim.2000.0230; Meeks SL, 2012, BLOOD, V120, P2512, DOI 10.1182/blood-2012-02-412361; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Meunier Sylvain, 2017, Blood Adv, V1, P1842, DOI 10.1182/bloodadvances.2017008706; Mezrich JD, 2010, J IMMUNOL, V185, P3190, DOI 10.4049/jimmunol.0903670; Miller L, 2015, THROMB HAEMOSTASIS, V114, P268, DOI 10.1160/TH14-09-0789; Moorehead P.C., 2012, BLOOD, V120, P627; Moreau A, 2000, BLOOD, V95, P3435, DOI 10.1182/blood.V95.11.3435.011k32_3435_3441; Mueller DL, 2010, NAT IMMUNOL, V11, P21, DOI 10.1038/ni.1817; Munn DH, 2005, IMMUNITY, V22, P633, DOI 10.1016/j.immuni.2005.03.013; Navarrete A, 2009, J THROMB HAEMOST, V7, P1816, DOI 10.1111/j.1538-7836.2009.03571.x; Nguyen NT, 2010, P NATL ACAD SCI USA, V107, P19961, DOI 10.1073/pnas.1014465107; Ohnmacht C, 2009, J EXP MED, V206, P549, DOI 10.1084/jem.20082394; Pallotta MT, 2011, NAT IMMUNOL, V12, P870, DOI 10.1038/ni.2077; Pearce EJ, 2018, NAT REV IMMUNOL, V18, P81, DOI 10.1038/nri.2017.139; Peyron I, 2015, HAEMOPHILIA, V21, pE94, DOI 10.1111/hae.12579; Peyvandi F, 2018, RES PRACT THROMB HAE, V2, P220, DOI 10.1002/rth2.12094; Pfistershammer K, 2006, THROMB HAEMOSTASIS, V96, P309, DOI 10.1160/TH05-11-0729; Platokouki H, 2018, HAEMOPHILIA, V24, P283, DOI 10.1111/hae.13387; Platten M, 2019, NAT REV DRUG DISCOV, V18, P379, DOI 10.1038/s41573-019-0016-5; Popov A, 2008, J MOL MED, V86, P145, DOI 10.1007/s00109-007-0262-6; Puccetti P, 2007, NAT REV IMMUNOL, V7, P817, DOI 10.1038/nri2163; Puccetti P, 2007, EUR J IMMUNOL, V37, P876, DOI 10.1002/eji.200737184; Reding MT, 2000, THROMB HAEMOSTASIS, V84, P643, DOI 10.1055/s-0037-1614081; Remy S, 2009, J IMMUNOL, V182, P1877, DOI 10.4049/jimmunol.0802436; Repesse Y, 2013, HAEMATOLOGICA, V98, P1650, DOI 10.3324/haematol.2013.084665; Romani L, 2008, NATURE, V451, P211, DOI 10.1038/nature06471; Russo S, 2003, PSYCHOSOM MED, V65, P665, DOI 10.1097/01.PSY.0000078188.74020.CC; Santagostino E, 2005, BRIT J HAEMATOL, V130, P422, DOI 10.1111/j.1365-2141.2005.05605.x; Santagostino E, 2019, HAEMOPHILIA, V25, P656, DOI 10.1111/hae.13756; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Skupsky J, 2009, BLOOD, V114, P4741, DOI 10.1182/blood-2008-10-186452; Terness P, 2002, J EXP MED, V196, P447, DOI 10.1084/jem.20020052; Theate I, 2015, CANCER IMMUNOL RES, V3, P161, DOI 10.1158/2326-6066.CIR-14-0137; Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934; van Baren N, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00034; Van Helden PMW, 2010, HAEMOPHILIA, V16, P35, DOI 10.1111/j.1365-2516.2010.02215.x; van Schooten CJ, 2008, BLOOD, V112, P1704, DOI 10.1182/blood-2008-01-133181; Varthaman A, 2019, HAEMATOLOGICA, V104, P236, DOI 10.3324/haematol.2018.206383; Volpi C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2874; Walshl CE, 2016, THROMB HAEMOSTASIS, V116, pS10, DOI 10.1160/TH16-01-0049; Whelan SFJ, 2013, BLOOD, V121, P1039, DOI 10.1182/blood-2012-07-444877; Wroblewska A, 2013, J THROMB HAEMOST, V11, P47, DOI 10.1111/jth.12065; Xia ZW, 2007, AM J PATHOL, V171, P1904, DOI 10.2353/ajpath.2007.070096; Xia ZW, 2006, J IMMUNOL, V177, P5936, DOI 10.4049/jimmunol.177.9.5936; Xie FT, 2015, TRANSPL IMMUNOL, V33, P69, DOI 10.1016/j.trim.2015.05.003; Xing Y, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006957; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; Yan YP, 2010, J IMMUNOL, V185, P5953, DOI 10.4049/jimmunol.1001628	99	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 15	2020	11								620	10.3389/fimmu.2020.00620	http://dx.doi.org/10.3389/fimmu.2020.00620			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LJ9NC	32351505	Green Published, gold			2022-12-18	WOS:000530486400001
J	Rana, A; de Almeida, FC; Montero, HPA; Carazas, MGM; Bortoluci, KR; Sad, S; Amarante-Mendes, GP				Rana, Aamir; de Almeida, Felipe Campos; Paico Montero, Henry A.; Gonzales Carazas, Maryanne M.; Bortoluci, Karina R.; Sad, Subash; Amarante-Mendes, Gustavo P.			RIPK3 and Caspase-1/11 Are Necessary for Optimal Antigen-Specific CD8 T Cell Response Elicited by Genetically Modified Listeria monocytogenes	FRONTIERS IN IMMUNOLOGY			English	Article						Effector CD8(+) T cells; Listeria monocytogenes; ovalbumin; RIPK3; Casp-1; 11	EXPRESSING MESOTHELIN CRS-207; DENDRITIC CELLS; VACCINE; DIFFERENTIATION; IMMUNOTHERAPY; MAGNITUDE; INFECTION; SURVIVAL; SAFETY	Efficient induction of effector and long-term protective antigen-specific CD8(+) T memory response by vaccination is essential to eliminate malignant and pathogen-infected cells. Intracellular infectious bacteria, including Listeria monocytogenes, have been considered potent vectors to carry multiple therapeutic proteins and generate antigen-specific CD8(+) T cell responses. Although the role of molecules involved in inflammatory cell death pathways, such as necroptosis (RIPK3-mediated) and pyroptosis (Caspase-1/11-mediated), as effectors of immune response against intracellular bacteria are relatively well understood, their contribution to the adjuvant effect of recombinant bacterial vectors in the context of antigen-specific CD8(+) T cell response remained obscure. Therefore, we evaluated the impact of RIPK3 and Caspase-1/11 (Casp-1/11) individual and combined deficiencies on the modulation of antigen-specific CD8(+) T cell response during vaccination of mice with ovalbumin-expressing L. monocytogenes (LM-OVA). We observed that Casp-1/11 but not RIPK3 deficiency negatively impacts the capacity of mice to clear LM-OVA. Importantly, both RIPK3 and Casp-1/11 are necessary for optimal LM-OVA-mediated antigen-specific CD8(+) T cell response, as measured by in vivo antigen-specific CD8(+) T cell proliferation, target cell elimination, and cytokine production. Furthermore, Casp-1/11 and Casp-1/11/RIPK3 combined deficiencies restrict the early initiation of antigen-specific CD8(+) T cell memory response. Taken together, our findings demonstrate that RIPK3 and Casp-1/11 influence the quality of CD8(+) T cell responses induced by recombinant L. monocytogenes vectors.	[Rana, Aamir; de Almeida, Felipe Campos; Paico Montero, Henry A.; Gonzales Carazas, Maryanne M.; Amarante-Mendes, Gustavo P.] Univ Sao Paulo, Inst Ciencias Biomed, Sao Paulo, Brazil; [Rana, Aamir; de Almeida, Felipe Campos; Amarante-Mendes, Gustavo P.] INCT, Inst Invest Imunol, Sao Paulo, Brazil; [Bortoluci, Karina R.] Univ Fed Sao Paulo, Dept Ciencias Biol, Ctr Terapia Celular & Mol CTC Mol, Sao Paulo, Brazil; [Sad, Subash] Univ Ottawa, Dept Biochem Microbiol & Immunol, Fac Med, Ottawa, ON, Canada	Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); University of Ottawa	Amarante-Mendes, GP (corresponding author), Univ Sao Paulo, Inst Ciencias Biomed, Sao Paulo, Brazil.; Amarante-Mendes, GP (corresponding author), INCT, Inst Invest Imunol, Sao Paulo, Brazil.	gpam@usp.br	Bortoluci, Karina/P-9296-2019; Mendes, Gustavo P Amarante/C-8187-2012; Bortoluci, Karina R/C-6018-2012; Rana, Aamir/G-3749-2015	Bortoluci, Karina/0000-0001-6780-5397; Mendes, Gustavo P Amarante/0000-0002-7851-6205; Bortoluci, Karina R/0000-0001-6780-5397; Paico Montero, Henry Alonso/0000-0002-4521-3312; Rana, Aamir/0000-0003-4421-5225	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Sao Paulo, Brazil [2015/12977-4, 2018/01627-0]; FAPESP; CNPq	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Sao Paulo, Brazil(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Sao Paulo, Brazil, Grant Nos. 2015/12977-4 and 2018/01627-0. FAPESP also provided Ph.D. fellowship to AR and MSc fellowships to FA and MG. HP was a recipient of MSC fellowship from CNPq.	Badovinac VP, 2007, IMMUNITY, V26, P827, DOI 10.1016/j.immuni.2007.04.013; Basu P, 2018, INT J GYNECOL CANCER, V28, P764, DOI 10.1097/IGC.0000000000001235; Broz P, 2019, MICROBIOL SPECTR, V7, DOI 10.1128/microbiolspec.BAI-0003-2019; Busch DH, 1998, IMMUNITY, V8, P353, DOI 10.1016/S1074-7613(00)80540-3; Chandra D, 2013, BRIT J CANCER, V108, P2281, DOI 10.1038/bjc.2013.206; Clemente T, 2013, METHODS, V61, P105, DOI 10.1016/j.ymeth.2013.02.007; Comber Joseph D, 2014, Ther Adv Vaccines, V2, P77, DOI 10.1177/2051013614525375; Darji A, 2000, FEMS IMMUNOL MED MIC, V27, P341; Denham JD, 2018, INT J INFECT DIS, V72, P1, DOI 10.1016/j.ijid.2018.04.004; Dillinger B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01152; Dudani R, 2002, J IMMUNOL, V168, P5737, DOI 10.4049/jimmunol.168.11.5737; Farhood B, 2019, J CELL PHYSIOL, V234, P8509, DOI 10.1002/jcp.27782; Feng HP, 2005, J IMMUNOL, V175, P421, DOI 10.4049/jimmunol.175.1.421; Flickinger JC, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030048; Foulds KE, 2002, J IMMUNOL, V168, P1528, DOI 10.4049/jimmunol.168.4.1528; Gerlach C, 2013, SCIENCE, V340, P635, DOI 10.1126/science.1235487; Hamon M, 2006, NAT REV MICROBIOL, V4, P423, DOI 10.1038/nrmicro1413; Jia YY, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00279; Kaech SM, 2001, NAT IMMUNOL, V2, P415, DOI 10.1038/87720; Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541; Khanna KM, 2007, SCIENCE, V318, P116, DOI 10.1126/science.1146291; Kolb-Maurer A, 2000, INFECT IMMUN, V68, P3680, DOI 10.1128/IAI.68.6.3680-3688.2000; Krummey SM, 2016, J IMMUNOL, V196, P2838, DOI 10.4049/jimmunol.1500639; Le DT, 2015, J CLIN ONCOL, V33, P1325, DOI 10.1200/JCO.2014.57.4244; Le DT, 2012, CLIN CANCER RES, V18, P858, DOI 10.1158/1078-0432.CCR-11-2121; Newton K, 2004, MOL CELL BIOL, V24, P1464, DOI 10.1128/MCB.24.4.1464-1469.2004; Pamer EG, 1997, IMMUNOL REV, V158, P129, DOI 10.1111/j.1600-065X.1997.tb00999.x; Patel R, 2017, CELL DEATH DIFFER, V24, P1900, DOI 10.1038/cdd.2017.112; Pearce VQ, 2015, J IMMUNOL, V195, P3206, DOI 10.4049/jimmunol.1501227; Poirier N, 2016, J IMMUNOL, V197, P4593, DOI 10.4049/jimmunol.1601538; Poirier N, 2016, J IMMUNOL, V196, P274, DOI 10.4049/jimmunol.1501810; Porter BB, 2006, INFECT IMMUN, V74, P1528, DOI 10.1128/IAI.74.3.1528-1536.2006; Qiu ZJ, 2018, PATHOGENS, V7, DOI 10.3390/pathogens7020055; Sacco JJ, 2016, HUM VACC IMMUNOTHER, V12, P1085, DOI 10.1080/21645515.2015.1121338; Sad S, 2008, J IMMUNOL, V180, P5853, DOI 10.4049/jimmunol.180.9.5853; Safran H, 2018, INT J RADIAT ONCOL, V100, P1175, DOI 10.1016/j.ijrobp.2018.01.004; Sai K, 2019, J CELL BIOL, V218, P1994, DOI 10.1083/jcb.201810014; Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514; Stark FC, 2009, CANCER RES, V69, P4327, DOI 10.1158/0008-5472.CAN-08-3160; Tsuji NM, 2004, INT IMMUNOL, V16, P335, DOI 10.1093/intimm/dxh041; Vitiello M, 2019, ONCOGENE, V38, P3756, DOI 10.1038/s41388-019-0681-1; Warren SE, 2011, EUR J IMMUNOL, V41, P1934, DOI 10.1002/eji.201041214	42	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 9	2020	11								536	10.3389/fimmu.2020.00536	http://dx.doi.org/10.3389/fimmu.2020.00536			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LI4CA	32328060	Green Published, gold			2022-12-18	WOS:000529432000001
J	More-Bayona, JA; Torrealba, D; Thomson, C; Wakaruk, J; Barreda, DR				More-Bayona, Juan A.; Torrealba, Debora; Thomson, Caitlin; Wakaruk, Jeremy; Barreda, Daniel R.			Differential Effects of Drinking Water Quality on Phagocyte Responses of Broiler Chickens Against Fungal and Bacterial Challenges	FRONTIERS IN IMMUNOLOGY			English	Article						drinking water quality; phagocyte function; acute inflammation; fungal and bacterial challenges; comparative immunology	ACUTE INFLAMMATORY RESPONSE; ZYMOSAN-INDUCED PERITONITIS; SALMONELLA-ENTERITIDIS; CYTOKINE EXPRESSION; RESOLUTION; CELLS; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; TYPHIMURIUM; LEUKOCYTES; SYSTEM	Combinatorial effects of xenobiotics in water on health may occur even at levels within current acceptable guidelines for individual chemicals. Herein, we took advantage of the sensitivity of the immune system and an avian animal model to examine the impact of xenobiotic mixtures on animal health. Water was derived from an underground well in Alberta, Canada and met guidelines for consumption, but contained a number of contaminants. Changes to chicken immunity were evaluated following acute (7d) exposure to contaminated water under basal and immune challenged conditions. An increase in resident macrophages and a decrease in CD8+ lymphocytes were identified in the abdominal cavity, which served as a relevant site where immune leukocytes could be examined. Subsequent intra-abdominal immune stimulation detected differential in vivo acute inflammatory responses to fungal and bacterial challenges. Leukocyte recruitment into the challenge site and activation of phagocyte antimicrobial responses were affected. These functional responses paralleled molecular changes in the expression for pro-inflammatory and regulatory genes. In all, this study primarily highlights dysregulation of phagocyte responses following acute (7d) exposure of poultry to contaminated water. Given that production food animals hold a unique position at the interface of animal, environmental and human health, this emphasizes the need to consider the impact of xenobiotic mixtures in our assessments of water quality.	[More-Bayona, Juan A.; Torrealba, Debora; Thomson, Caitlin; Barreda, Daniel R.] Univ Alberta, Dept Biol Sci, Lab Immunol & Anim Hlth, Edmonton, AB, Canada; [Wakaruk, Jeremy; Barreda, Daniel R.] Univ Alberta, Dept Agr Food & Nutr Sci, Edmonton, AB, Canada	University of Alberta; University of Alberta	Barreda, DR (corresponding author), Univ Alberta, Dept Biol Sci, Lab Immunol & Anim Hlth, Edmonton, AB, Canada.; Barreda, DR (corresponding author), Univ Alberta, Dept Agr Food & Nutr Sci, Edmonton, AB, Canada.	d.barreda@ualberta.ca	Barreda, Daniel/A-2613-2014; More-Bayona, Juan Anderson/R-3728-2016	Barreda, Daniel/0000-0003-4630-2840; More-Bayona, Juan Anderson/0000-0002-6089-2886; Torrealba, Debora/0000-0003-0807-4234	Natural Sciences and Engineering Council of Canada (NSERC) [RGPIN-201805768]; Alberta Livestock and Meat Agency (ALMA) [2015R036R]; National Fund for Innovation in Science and Technology (FINCyT/Innovate-Peru); Department of Biological Sciences at the University of Alberta; CONICYT-Chile (Becas Chile) [74170029]	Natural Sciences and Engineering Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Alberta Livestock and Meat Agency (ALMA); National Fund for Innovation in Science and Technology (FINCyT/Innovate-Peru); Department of Biological Sciences at the University of Alberta(University of Alberta); CONICYT-Chile (Becas Chile)	This work was supported by Natural Sciences and Engineering Council of Canada (NSERC grant number RGPIN-201805768) and Alberta Livestock and Meat Agency (ALMA grant number 2015R036R) grants to DB. JM-B was supported by a National Fund for Innovation in Science and Technology (FINCyT/Innovate-Peru) scholarship and a Graduate Teaching Assistantship by the Department of Biological Sciences at the University of Alberta. DT was supported by a CONICYT-Chile postdoctoral fellowship (Becas Chile N: 74170029).	Agricultural and Agri-Food Canada, 2001, CHEM EXP IND AGR AR; Agricultural and Agri-Food Canada, 2001, FERT EXP IND AGR AR; Alberta Environment and Sustainable Resource Development, 2011, PEST IND; Alberta Environment and Sustainable Resource Development, 2013, IMP LAND US WAT; Alberta Municipal Affairs, 2012, MUN CENS POP LISTS; Alberta Treasury Board and Finance, 2013, EC STAT; Alexander J, 2008, SCI COMM FOOD SAF, P1; Anderson A-M, 1997, PESTICIDES ALBERTA S; Ball P, 2017, P NATL ACAD SCI USA, V114, P13327, DOI 10.1073/pnas.1703781114; Bayona JAM, 2017, DEV COMP IMMUNOL, V74, P167, DOI 10.1016/j.dci.2017.04.018; Bayona JAM, 2017, METHODS, V112, P167, DOI 10.1016/j.ymeth.2016.06.013; Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470; Carr RM, 2004, WATER SCI TECHNOL, V50, P31, DOI 10.2166/wst.2004.0081; Cash JL, 2009, METHOD ENZYMOL, V461, P379, DOI 10.1016/S0076-6879(09)05417-2; Chadzinska M, 2008, DEV COMP IMMUNOL, V32, P509, DOI 10.1016/j.dci.2007.08.008; Cuzzocrea S, 1997, SHOCK, V8, P268, DOI 10.1097/00024382-199710000-00006; EC, 2001, FACT SHEET DIOX FEED; Eilers W, 2010, AGRIENVIRONMENTAL IN; Escher BI, 2011, ENVIRON SCI TECHNOL, V45, P3835, DOI 10.1021/es1030799; Freire MO, 2013, PERIODONTOL 2000, V63, P149, DOI 10.1111/prd.12034; Frisbie SH, 2015, ENVIRON HEALTH-GLOB, V14, DOI 10.1186/s12940-015-0050-7; Gilroy D, 2015, SEMIN IMMUNOL, V27, P161, DOI 10.1016/j.smim.2015.05.003; Goossens KE, 2013, DEV COMP IMMUNOL, V41, P370, DOI 10.1016/j.dci.2013.05.020; Hrudey SE, 2008, CAN MED ASSOC J, V178, P975, DOI 10.1503/cmaj.080374; Ipinza F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111062; Jokinen CC, 2012, J ENVIRON QUAL, V41, P242, DOI 10.2134/jeq2011.0203; Kaiser P, 2000, MICROBIOL-UK, V146, P3217, DOI 10.1099/00221287-146-12-3217; Khakhria R, 1994, SALMONELLA SHIGELLAE; Klecka G, 2010, REV ENVIRON CONTAM T, V207, P1, DOI 10.1007/978-1-4419-6406-9_1; KOGUT MH, 1995, POULTRY SCI, V74, P8, DOI 10.3382/ps.0740008; Kolaczkowska E, 2008, INFLAMM RES, V57, P272, DOI 10.1007/s00011-007-7131-1; Koning CW, 2006, WATER SCI TECHNOL, V53, P153, DOI 10.2166/wst.2006.308; Lamb CL, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/5309328; Leypoldt John K, 2007, Adv Perit Dial, V23, P66; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MacDonald D, 1999, CAN COUNC MINIST ENV, P1; Magor KE, 2013, DEV COMP IMMUNOL, V41, P377, DOI 10.1016/j.dci.2013.04.010; Mast J, 1998, VET IMMUNOL IMMUNOP, V61, P343, DOI 10.1016/S0165-2427(97)00152-9; Moe Christine L., 2006, Journal of Water and Health, V4, P41; MOOS AB, 1994, TOXICOL APPL PHARM, V127, P331, DOI 10.1006/taap.1994.1169; Peterson H, 2008, CAN MED ASSOC J, V179, P55, DOI 10.1503/cmaj.1080061; Phelan C., 2012, PESTICIDES ALBERTAS; RAO TS, 1994, J PHARMACOL EXP THER, V269, P917; Riber U, 1999, VET IMMUNOL IMMUNOP, V67, P259, DOI 10.1016/S0165-2427(98)00233-5; Rieger AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047070; Robert J, 2019, SCI TOTAL ENVIRON, V671, P644, DOI 10.1016/j.scitotenv.2019.03.395; Robert J, 2018, TOXICOL SCI, V166, P39, DOI 10.1093/toxsci/kfy179; Sansbury BE, 2016, CIRC RES, V119, P113, DOI 10.1161/CIRCRESAHA.116.307308; Sobsey Mark D, 2003, Forum Nutr, V56, P396; Sousa JCG, 2018, J HAZARD MATER, V344, P146, DOI 10.1016/j.jhazmat.2017.09.058; Staines K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110330; Stewart CR, 2013, DEV COMP IMMUNOL, V41, P463, DOI 10.1016/j.dci.2013.05.011; VANDERSLICE RR, 1989, TOXICOL IND HEALTH, V5, P747, DOI 10.1177/074823378900500512; Vogel C, 1997, ARCH TOXICOL, V71, P372, DOI 10.1007/s002040050401; Vogel CFA, 2007, ARCH BIOCHEM BIOPHYS, V461, P169, DOI 10.1016/j.abb.2007.01.015; WHO (World Health Organization), 2002, WHO FOOD ADDITIVES S, V48; WIGGINS PM, 1990, MICROBIOL REV, V54, P432, DOI 10.1128/MMBR.54.4.432-449.1990	57	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 7	2020	11								584	10.3389/fimmu.2020.00584	http://dx.doi.org/10.3389/fimmu.2020.00584			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LH8LO	32318069	Green Published, gold			2022-12-18	WOS:000529034400001
J	Walter, L; Bontrop, R				Walter, Lutz; Bontrop, Ronald			Editorial: Comparative Genetics of NK Cell Receptor Families in Relation to MHC Class I Ligands and Their Function	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						NK receptors; MHC; genomics; NHP; animal model; livestock			[Walter, Lutz] Leibniz Inst Primate Res, Primate Genet Lab, German Primate Ctr, Gottingen, Germany; [Bontrop, Ronald] Biomed Primate Res Ctr, Comparat Genet & Refinement, Rijswijk, Netherlands	Deutsches Primatenzentrum (DPZ)	Walter, L (corresponding author), Leibniz Inst Primate Res, Primate Genet Lab, German Primate Ctr, Gottingen, Germany.	walter@dpz.eu	Bontrop, Ronald E/J-3628-2012; Walter, Lutz/I-2606-2017	Bontrop, Ronald E/0000-0003-0874-6467; Walter, Lutz/0000-0001-9408-3131				Albrecht C, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00600; Hellmann I, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002436; Parham P, 2018, ANNU REV IMMUNOL, V36, P519, DOI 10.1146/annurev-immunol-042617-053149	3	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 1	2020	11								561	10.3389/fimmu.2020.00561	http://dx.doi.org/10.3389/fimmu.2020.00561			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PC3LI	32296444	Green Published, gold			2022-12-18	WOS:000596906800001
J	Crofts, KF; Holbrook, BC; Soto-Pantoja, DR; Ornelles, DA; Alexander-Miller, MA				Crofts, Kali F.; Holbrook, Beth C.; Soto-Pantoja, David R.; Ornelles, David A.; Alexander-Miller, Martha A.			TCR Dependent Metabolic Programming Regulates Autocrine IL-4 Production Resulting in Self-Tuning of the CD8(+) T Cell Activation Setpoint	FRONTIERS IN IMMUNOLOGY			English	Article						IL-4; metabolism; functional avidity; CD8(+) T cell; NFAT; activation	LIPID RAFT INTEGRITY; HIGH-AVIDITY; TRANSCRIPTION FACTOR; SELECTIVE EXPANSION; LYMPHOCYTE RESPONSE; INTERFERON-GAMMA; DOWN-REGULATION; CUTTING EDGE; IN-VIVO; CTL	The ability of T cells to sense and respond to environmental cues by altering their functional capabilities is critical for a safe and optimally protective immune response. One of the important properties that contributes to this goal is the activation set-point of the T cell. Here we report a new pathway through which TCR transgenic OT-I CD8(+) T cells can self-tune their activation threshold. We find that in the presence of a strong TCR engagement event there is a shift in the metabolic programming of the cell where both glycolysis and oxidative phosphorylation are significantly increased. This diverges from the switch to a predominantly glycolytic profile that would be predicted following naive T cell activation. Our data suggest this altered metabolic program results in the production of autocrine IL-4. Both metabolic pathways are required for this cytokine to be made. IL-4 signaling in the activated OT-I CD8(+) T cell results in modulation of the sensitivity of the cell, establishing a higher activation setpoint that is maintained over time. Together these data demonstrate a novel mechanism for the regulation of IL-4 production in CD8(+) T cells. Further, they reveal a new pathway for the self-tuning of peptide sensitivity. Finally, these studies uncover an unexpected role for oxidative phosphorylation in regulating differentiation in these cells.	[Crofts, Kali F.; Holbrook, Beth C.; Ornelles, David A.; Alexander-Miller, Martha A.] Wake Forest Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27101 USA; [Soto-Pantoja, David R.] Wake Forest Sch Med, Ctr Comprehens Canc, Dept Canc Biol, Winston Salem, NC 27101 USA; [Soto-Pantoja, David R.] Wake Forest Sch Med, Dept Surg, Winston Salem, NC 27101 USA	Wake Forest University; Wake Forest University; Wake Forest University	Alexander-Miller, MA (corresponding author), Wake Forest Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27101 USA.	Martha.Alexander-Miller@wakehealth.edu	Pantoja, David Soto/ABB-3764-2020	Holbrook, Beth/0000-0001-6026-695X	NCI [P30 CA012197]; ASTRO-BCRF Early Career Development Award (DS-P)	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ASTRO-BCRF Early Career Development Award (DS-P)	We acknowledge services provided by the Cell and Viral Vector Core and the Flow Cytometry Core Laboratories of the Wake Forest Comprehensive Cancer Center, supported in part by NCI P30 CA012197. We thank Dr. Jason Grayson, Dr. Yong Lu, and Dr. Xuewei Zhu for helpful comments regarding the manuscript. The authors wish to acknowledge the support of the ASTRO-BCRF Early Career Development Award (DS-P).	ALEXANDER MA, 1991, J EXP MED, V173, P849, DOI 10.1084/jem.173.4.849; AlexanderMiller MA, 1996, J EXP MED, V184, P485, DOI 10.1084/jem.184.2.485; AlexanderMiller MA, 1996, P NATL ACAD SCI USA, V93, P4102, DOI 10.1073/pnas.93.9.4102; Amoah S, 2012, J IMMUNOL, V189, P638, DOI 10.4049/jimmunol.1102579; Apte SH, 2008, P NATL ACAD SCI USA, V105, P17475, DOI 10.1073/pnas.0809549105; Baek HJ, 2008, RHEUMATOLOGY, V47, P795, DOI 10.1093/rheumatology/ken089; Busch DH, 1999, J EXP MED, V189, P701, DOI 10.1084/jem.189.4.701; Cawthon AG, 2004, CELL IMMUNOL, V227, P148, DOI 10.1016/j.cellimm.2004.03.001; Cawthon AG, 2002, J IMMUNOL, V169, P3492, DOI 10.4049/jimmunol.169.7.3492; Cawthon AG, 2001, J IMMUNOL, V167, P2577, DOI 10.4049/jimmunol.167.5.2577; Chang CH, 2013, CELL, V153, P1239, DOI 10.1016/j.cell.2013.05.016; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Derby MA, 2001, J IMMUNOL, V166, P1690, DOI 10.4049/jimmunol.166.3.1690; Drake DR, 2001, J IMMUNOL, V166, P7009, DOI 10.4049/jimmunol.166.12.7009; Dura B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6940; Dutoit V, 2001, CANCER RES, V61, P5850; ERARD F, 1993, SCIENCE, V260, P1802, DOI 10.1126/science.8511588; Gallimore A, 1998, J EXP MED, V187, P1647; Gerriets VA, 2015, J CLIN INVEST, V125, P194, DOI 10.1172/JCI76012; Gray PM, 2001, J VIROL, V75, P10065, DOI 10.1128/JVI.75.21.10065-10072.2001; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Jackson RJ, 2014, VACCINE, V32, P5703, DOI 10.1016/j.vaccine.2014.08.023; Jones N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01516; Kang YJ, 2007, J IMMUNOL, V179, P4598, DOI 10.4049/jimmunol.179.7.4598; Kelso A, 1997, P NATL ACAD SCI USA, V94, P8070, DOI 10.1073/pnas.94.15.8070; Kiani A, 1997, IMMUNITY, V7, P849, DOI 10.1016/S1074-7613(00)80403-3; Kiani A, 2001, BLOOD, V98, P1480, DOI 10.1182/blood.V98.5.1480; Kienzle N, 2005, J IMMUNOL, V174, P2021, DOI 10.4049/jimmunol.174.4.2021; Klein-Hessling S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00612-6; Kroger CJ, 2007, J IMMUNOL, V179, P748, DOI 10.4049/jimmunol.179.2.748; Lamouse-Smith ESN, 1999, J IMMUNOL, V163, P4160; Le KS, 2018, BLOOD ADV, V2, P1889, DOI 10.1182/bloodadvances.2018017244; Maciolek JA, 2014, CURR OPIN IMMUNOL, V27, P60, DOI 10.1016/j.coi.2014.01.006; Menk AV, 2018, CELL REP, V22, P1509, DOI 10.1016/j.celrep.2018.01.040; Messaoudi I, 2002, SCIENCE, V298, P1797, DOI 10.1126/science.1076064; Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613; Morris SC, 2009, J IMMUNOL, V182, P1429, DOI 10.4049/jimmunol.182.3.1429; Nakamura K, 2005, BONE MARROW TRANSPL, V36, P639, DOI 10.1038/sj.bmt.1705107; Noble A, 2016, EUR J IMMUNOL, V46, P1438, DOI 10.1002/eji.201545939; Oakes SA, 2007, P NATL ACAD SCI USA, V104, P15171, DOI 10.1073/pnas.0707798104; Oh S, 2004, P NATL ACAD SCI USA, V101, P15154, DOI 10.1073/pnas.0406649101; Pau G, 2010, BIOINFORMATICS, V26, P979, DOI 10.1093/bioinformatics/btq046; Pearce Erika L, 2013, Science, V342, P1242454, DOI 10.1126/science.1242454; Priyadharshini B, 2018, J IMMUNOL, V201, P2215, DOI 10.4049/jimmunol.1800311; Ranasinghe C, 2007, J IMMUNOL, V178, P2370, DOI 10.4049/jimmunol.178.4.2370; Ranasinghe C, 2009, EUR J IMMUNOL, V39, P1819, DOI 10.1002/eji.200838995; Ranger AM, 1998, IMMUNITY, V8, P125, DOI 10.1016/S1074-7613(00)80465-3; Redmond WL, 2005, J IMMUNOL, V174, P2046, DOI 10.4049/jimmunol.174.4.2046; Renkema KR, 2016, J EXP MED, V213, P1319, DOI 10.1084/jem.20151359; Roehrl MHA, 2004, P NATL ACAD SCI USA, V101, P7554, DOI 10.1073/pnas.0401835101; SEDER RA, 1992, J IMMUNOL, V148, P1652; Sedlik C, 2000, J VIROL, V74, P5769, DOI 10.1128/JVI.74.13.5769-5775.2000; Sena LA, 2013, IMMUNITY, V38, P225, DOI 10.1016/j.immuni.2012.10.020; Sharma SK, 2011, IMMUNOLOGY, V133, P307, DOI 10.1111/j.1365-2567.2011.03440.x; Shen J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02287; Snyder JT, 2003, CURR HIV RES, V1, P287, DOI 10.2174/1570162033485230; Team,R.C, 2018, R LANG ENV STAT COMP; Teixeira LK, 2005, J IMMUNOL, V175, P5931, DOI 10.4049/jimmunol.175.9.5931; Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923; Vaeth M, 2017, IMMUNITY, V47, P664, DOI 10.1016/j.immuni.2017.09.003; Wijesundara DK, 2013, VACCINE, V31, P4548, DOI 10.1016/j.vaccine.2013.07.062; Wijesundara DK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055788; Yee C, 1999, J IMMUNOL, V162, P2227; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1	65	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 31	2020	11								540	10.3389/fimmu.2020.00540	http://dx.doi.org/10.3389/fimmu.2020.00540			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LE5GO	32300344	Green Published, gold			2022-12-18	WOS:000526747300001
J	Schneidawind, D; Meyer, E				Schneidawind, Dominik; Meyer, Everett			Editorial: Immune Tolerance Post Allogeneic Hematopoietic Cell Transplantation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						allogeneic HCT; GvHD; immune tolerance; GVL effects; graft engineering			[Schneidawind, Dominik] Univ Tubingen Hosp, Dept Med 2, Tubingen, Germany; [Meyer, Everett] Stanford Univ, Sch Med, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Stanford University	Schneidawind, D (corresponding author), Univ Tubingen Hosp, Dept Med 2, Tubingen, Germany.	dominik.schneidawind@med.uni-tuebingen.de							0	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 24	2020	11								523	10.3389/fimmu.2020.00523	http://dx.doi.org/10.3389/fimmu.2020.00523			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PC3JX	32265940	Green Published, gold			2022-12-18	WOS:000596903100001
J	Olive, D; Vivier, E; Romagnani, C				Olive, Daniel; Vivier, Eric; Romagnani, Chiara			Editorial: In Memoriam of Professor Alessandro Moretta	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						natural kill cell; transplanation; immune deficiency; infection; immunology; cancer biology			[Olive, Daniel] Inst Paoli Calmettes, INSERM, UMR1068, CNRS,UMR7258, Marseille, France; [Vivier, Eric] Innate Pharma, Marseille, France; [Romagnani, Chiara] Deutsch Rheuma Forschungszentrum DRFZ, Berlin, Germany	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC)	Olive, D (corresponding author), Inst Paoli Calmettes, INSERM, UMR1068, CNRS,UMR7258, Marseille, France.	daniel.olive@inserm.fr	Vivier, Eric/F-8939-2010; Romagnani, Chiara/E-4708-2016	Vivier, Eric/0000-0001-7022-8287; Romagnani, Chiara/0000-0002-5167-7463					0	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 13	2020	11								439	10.3389/fimmu.2020.00439	http://dx.doi.org/10.3389/fimmu.2020.00439			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LE6PG		Green Accepted, gold			2022-12-18	WOS:000526844900001
J	Mastroianni-Kirsztajn, G; Hornig, N; Schlumberger, W				Mastroianni-Kirsztajn, Gianna; Hornig, Nora; Schlumberger, Wolfgang			Autoantibodies in renal diseases - clinical significance and recent developments in serological detection (vol 6, 221, 2015)	FRONTIERS IN IMMUNOLOGY			English	Correction						autoantibodies; renal autoimmune diseases; anti-PLA2R; anti-THSD7A; anti-nucleosomes; anti-dsDNA; ANCA; anti-PR3			[Mastroianni-Kirsztajn, Gianna] Univ Fed Sao Paulo, Dept Med, Div Nephrol, Sao Paulo, Brazil; [Hornig, Nora; Schlumberger, Wolfgang] EUROIMMUN Med Labordiagnost AG, Inst Expt Immunol, Lubeck, Germany	Universidade Federal de Sao Paulo (UNIFESP); EUROIMMUN	Schlumberger, W (corresponding author), EUROIMMUN Med Labordiagnost AG, Inst Expt Immunol, Lubeck, Germany.	w.schlumberger@euroimmun.de	Mastroianni Kirsztajn, Gianna/D-9596-2013	Mastroianni Kirsztajn, Gianna/0000-0003-1317-4109				Mastroianni-Kirsztajn G, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00221	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 11	2020	11								424	10.3389/fimmu.2020.00424	http://dx.doi.org/10.3389/fimmu.2020.00424			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LC7UH	32218788	Green Published, gold			2022-12-18	WOS:000525537900001
J	Vlasova, AN; Butler, JE				Vlasova, Anastasia N.; Butler, John E.			Editorial: Porcine Anti-Viral Immunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						swine; viruses; immune response; vaccines; immune evasion; emerging	VIRUSES; FUTURE; IMPACT		[Vlasova, Anastasia N.] Ohio State Univ, Ohio Agr Res & Dev Ctr, Food Anim Hlth Res Program, Dept Vet Prevent Med,CFAES, Wooster, OH 44691 USA; [Butler, John E.] Univ Iowa, Carver Coll Med, Dept Microbiol & Immunol, Iowa, IA 52242 USA	University System of Ohio; Ohio State University; University of Iowa	Vlasova, AN (corresponding author), Ohio State Univ, Ohio Agr Res & Dev Ctr, Food Anim Hlth Res Program, Dept Vet Prevent Med,CFAES, Wooster, OH 44691 USA.; Butler, JE (corresponding author), Univ Iowa, Carver Coll Med, Dept Microbiol & Immunol, Iowa, IA 52242 USA.	vlasova.1@osu.edu; john-butler@uiowa.edu						Brumm MC, 2002, J ANIM SCI, V80, P309; Cornelison AS, 2018, TRANSL ANIM SCI, V2, P50, DOI 10.1093/tas/txx005; Gerber PF, 2012, CAN J VET RES, V76, P38; Holtkamp DJ, 2013, J SWINE HEALTH PROD, V21, P72; Lu G, 2020, J INFECTION, V80, P365, DOI 10.1016/j.jinf.2019.11.011; Mandl JN, 2015, CELL, V160, P20, DOI 10.1016/j.cell.2014.12.003; McGlone John J, 2013, Animals (Basel), V3, P401, DOI 10.3390/ani3020401; MENGELING WL, 1980, ARCH VIROL, V65, P55, DOI 10.1007/BF01340540; Moelling K, 2013, ARCH VIROL, V158, P1833, DOI 10.1007/s00705-013-1679-6; Orzalli MH, 2017, TRENDS CELL BIOL, V27, P810, DOI 10.1016/j.tcb.2017.05.007; Perry BD, 2013, P NATL ACAD SCI USA, V110, P20871, DOI 10.1073/pnas.1012953108; Thomson BJ, 2001, INT J EXP PATHOL, V82, P65, DOI 10.1111/j.1365-2613.2001.iep195.x; Wang QH, 2019, CURR OPIN VIROL, V34, P39, DOI 10.1016/j.coviro.2018.12.001; Wang Z, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0183-1	14	0	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 6	2020	11								399	10.3389/fimmu.2020.00399	http://dx.doi.org/10.3389/fimmu.2020.00399			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LC0RU	32210972	Green Published, gold			2022-12-18	WOS:000525038700001
J	Li, K; Wang, S; Cao, YM; Bao, HF; Li, PH; Sun, P; Bai, XW; Fu, YF; Ma, XQ; Zhang, J; Li, D; Chen, YL; Liu, XR; An, FL; Wu, FJ; Lu, ZJ; Liu, ZX				Li, Kun; Wang, Sheng; Cao, Yimei; Bao, Huifang; Li, Pinghua; Sun, Pu; Bai, Xingwen; Fu, Yuanfang; Ma, Xueqing; Zhang, Jing; Li, Dong; Chen, Yingli; Liu, Xuerong; An, Fanglan; Wu, Faju; Lu, Zengjun; Liu, Zaixin			Development of Foot-and-Mouth Disease Virus-Neutralizing Monoclonal Antibodies Derived From Plasmablasts of Infected Cattle and Their Germline Gene Usage (vol 10, 2870, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						cattle; foot-and-mouth disease virus; broadly neutralizing antibodies; antigenic character; single B cell antibody			[Li, Kun; Wang, Sheng; Cao, Yimei; Bao, Huifang; Li, Pinghua; Sun, Pu; Bai, Xingwen; Fu, Yuanfang; Ma, Xueqing; Zhang, Jing; Li, Dong; Chen, Yingli; Lu, Zengjun; Liu, Zaixin] Chinese Acad Agr Sci, Lanzhou Vet Res Inst, State Key Lab Vet Etiol Biol, Lanzhou, Peoples R China; [Liu, Xuerong; An, Fanglan; Wu, Faju] China Agr Vet Biol & Technol Co Ltd, Lanzhou, Peoples R China	Chinese Academy of Agricultural Sciences; Lanzhou Veterinary Research Institute, CAAS	Cao, YM; Lu, ZJ; Liu, ZX (corresponding author), Chinese Acad Agr Sci, Lanzhou Vet Res Inst, State Key Lab Vet Etiol Biol, Lanzhou, Peoples R China.	caoyimei@caas.cn; luzengjun@caas.cn; liuzaixin@caas.cn	Li, Ping/GYV-4914-2022					Kenney M, 2017, J IMMUNOL METHODS, V450, P1, DOI 10.1016/j.jim.2017.07.001; Li K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02870	2	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 21	2020	11								286	10.3389/fimmu.2020.00286	http://dx.doi.org/10.3389/fimmu.2020.00286			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LA1XB	32153589	Green Published, gold			2022-12-18	WOS:000523746700001
J	Pascutti, MF; Martinez, GJ; Quiroga, MF				Pascutti, Maria Fernanda; Martinez, Gustavo Javier; Quiroga, Maria Florencia			Editorial: Strategies for Modulating T Cell Responses in Autoimmunity and Infection	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						T cells; animal studies; human studies; immunemodulation; health; disease	THERAPIES		[Pascutti, Maria Fernanda] Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Leiden, Netherlands; [Martinez, Gustavo Javier] Rosalind Franklin Univ Med & Sci, Ctr Canc Cell Biol Immunol & Infect, Discipline Microbiol & Immunol, N Chicago, IL USA; [Quiroga, Maria Florencia] Univ Buenos Aires, Consejo Nacl Invest Cient & Tecn, Inst Invest Biomed Retrovirus & Sida, Buenos Aires, DF, Argentina	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Rosalind Franklin University Medical & Science; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Quiroga, MF (corresponding author), Univ Buenos Aires, Consejo Nacl Invest Cient & Tecn, Inst Invest Biomed Retrovirus & Sida, Buenos Aires, DF, Argentina.	florenciaquiroga@gmail.com						Boer MC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00217; Grant ML, 2018, BLOOD REV, V32, P203, DOI 10.1016/j.blre.2017.11.004; Ha NY, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.106; Ketelhuth DFJ, 2013, CURR PHARM DESIGN, V19, P5850; Nakajima M, 2019, ADV EXP MED BIOL, V1189, P313, DOI 10.1007/978-981-32-9717-3_11; Raffin C, 2020, NAT REV IMMUNOL, V20, P158, DOI 10.1038/s41577-019-0232-6; Teijeira A, 2019, CANCER IMMUNOL RES, V7, P1564, DOI 10.1158/2326-6066.CIR-19-0115; Topper MJ, 2020, NAT REV CLIN ONCOL, V17, P75, DOI 10.1038/s41571-019-0266-5	8	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 20	2020	11								208	10.3389/fimmu.2020.00208	http://dx.doi.org/10.3389/fimmu.2020.00208			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KT4HQ	32153569	gold, Green Published			2022-12-18	WOS:000518976200001
J	Wu, X; Li, Y; Song, CB; Chen, YL; Fu, YJ; Jiang, YJ; Ding, HB; Shang, H; Zhang, ZN				Wu, Xian; Li, Yao; Song, Cheng-Bo; Chen, Ya-Li; Fu, Ya-Jing; Jiang, Yong-Jun; Ding, Hai-Bo; Shang, Hong; Zhang, Zi-Ning			Increased Expression of sST2 in Early HIV Infected Patients Attenuated the IL-33 Induced T Cell Responses (vol 9, 2850, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						IL-33; ST2; T cell response; IFN-gamma; HIV infection			[Wu, Xian; Li, Yao; Song, Cheng-Bo; Chen, Ya-Li; Fu, Ya-Jing; Jiang, Yong-Jun; Ding, Hai-Bo; Shang, Hong; Zhang, Zi-Ning] China Med Univ, Dept Lab Med, NHC Key Lab AIDS Immunol, Affiliated Hosp 1, Shenyang, Peoples R China; [Wu, Xian] Xiamen Univ, Dept Lab Med, Affiliated Hosp 1, Xiamen, Peoples R China; [Li, Yao] Shanxi Med Univ, Hosp 1, Clin & Emergency Med Lab Dept, Taiyuan, Peoples R China; [Song, Cheng-Bo; Chen, Ya-Li; Fu, Ya-Jing; Jiang, Yong-Jun; Ding, Hai-Bo; Shang, Hong; Zhang, Zi-Ning] Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Peoples R China; [Song, Cheng-Bo; Chen, Ya-Li; Fu, Ya-Jing; Jiang, Yong-Jun; Ding, Hai-Bo; Shang, Hong; Zhang, Zi-Ning] China Med Univ, Key Lab AIDS Immunol Liaoning Prov, Affiliated Hosp 1, Shenyang, Peoples R China; [Song, Cheng-Bo; Chen, Ya-Li; Fu, Ya-Jing; Jiang, Yong-Jun; Ding, Hai-Bo; Shang, Hong; Zhang, Zi-Ning] Chinese Acad Med Sci, Key Lab AIDS Immunol, Shenyang, Peoples R China	China Medical University; Xiamen University; Shanxi Medical University; Collaborative Innovation Center for Diagnosis & Treatment of Infectious Diseases; China Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College	Shang, H; Zhang, ZN (corresponding author), China Med Univ, Dept Lab Med, NHC Key Lab AIDS Immunol, Affiliated Hosp 1, Shenyang, Peoples R China.; Shang, H; Zhang, ZN (corresponding author), Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Peoples R China.; Shang, H; Zhang, ZN (corresponding author), China Med Univ, Key Lab AIDS Immunol Liaoning Prov, Affiliated Hosp 1, Shenyang, Peoples R China.; Shang, H; Zhang, ZN (corresponding author), Chinese Acad Med Sci, Key Lab AIDS Immunol, Shenyang, Peoples R China.	hongshang100@hotmail.com; zi_ning101@hotmail.com	Song, Chengbo/AAJ-2087-2021					Wu X, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02850	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 18	2020	11								88	10.3389/fimmu.2020.00088	http://dx.doi.org/10.3389/fimmu.2020.00088			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KS9JF	32132992	Green Published, gold			2022-12-18	WOS:000518623700001
J	Silva, RDE; de Oliveira, BC; da Silva, AA; de Castro, MCAB; Ferreira, LFGR; Hernandes, MZ; de Brito, MEF; de-Melo-Neto, OP; Rezende, AM; Pereira, VRA				de Freitas e Silva, Rafael; de Oliveira, Beatriz Coutinho; da Silva, Ailton Alvaro; Accioly Brelaz de Castro, Maria Carolina; Gomes Rebello Ferreira, Luiz Felipe; Hernandes, Marcelo Zaldini; Felinto de Brito, Maria Edileuza; de-Melo-Neto, Osvaldo Pompilio; Rezende, Antonio Mauro; Alves Pereira, Valeria Rego			Immunogenicity of Potential CD4(+) and CD8(+) T Cell Epitopes Derived From the Proteome of Leishmania braziliensis	FRONTIERS IN IMMUNOLOGY			English	Article						neglected diseases; cutaneous leishmaniasis; Leishmania (Viannia) braziliensis; immunogenicity; CD4(+) CD8(+) T cell epitopes	AMERICAN CUTANEOUS LEISHMANIASIS; VACCINE CANDIDATES; IMMUNE-RESPONSES; MAJOR INFECTION; CROSS-IMMUNITY; REGULATORY T; MICE LACKING; EXPRESSION; MACROPHAGES; MECHANISMS	Background: A safe and effective vaccine against human leishmaniasis still requires the identification of better antigens for immunization and adequate models to evaluate the immune response. To support vaccine development, this work tested the immunogenicity of 10 different peptides derived from the proteome of Leishmania braziliensis, which were selected by their in silico affinity to MHC complexes. Research design and Methods: Comparative cell proliferation assays were performed by culturing, in the presence of each peptide, PBMC cells from subclinical subjects (SC), cutaneous leishmaniasis patients with active disease (AD), post-treatment (PT) individuals, and healthy controls. Culture supernatants were then used for Th1, Th2, and Th17 cytokine measurements. Cells from selected PT samples were also used to assess the expression, by T cells, of the T-bet Th1 transcription factor. Results: A robust cell proliferation was observed for the SC group, for all the tested peptides. The levels of Th1 cytokines were peptide-dependent and had substantial variations between groups, where, for instance, IFN-gamma and TNF levels were some of the highest, particularly on PT cultures, when compared to IL-2. On the other hand, Th2 cytokines displayed much less variation. IL-6 was the most abundant among all the evaluated cytokines while IL-4 and IL-10 could be found at much lower concentrations. IL-17 was also detected with variations in SC and AD groups. T-bet was up-regulated in CD4(+) and CD8(+) T cells from the PT group after stimulation with all peptides. Conclusions: The peptide epitopes can differentially stimulate cells from SC, AD, and PT individuals, leading to distinct immune responses.	[de Freitas e Silva, Rafael] Univ Pernambuco, Dept Nat Sci, Garanhuns, Brazil; [de Freitas e Silva, Rafael; de Oliveira, Beatriz Coutinho; da Silva, Ailton Alvaro; Accioly Brelaz de Castro, Maria Carolina; Felinto de Brito, Maria Edileuza; Alves Pereira, Valeria Rego] Fundacao Oswaldo Cruz, Dept Immunol, Recife, PE, Brazil; [Accioly Brelaz de Castro, Maria Carolina] Univ Fed Pernambuco, Parasitol Lab, Vitoria De Santo Antao, Brazil; [Gomes Rebello Ferreira, Luiz Felipe; Hernandes, Marcelo Zaldini] Univ Fed Pernambuco, Dept Pharmaceut Sci, Recife, PE, Brazil; [de-Melo-Neto, Osvaldo Pompilio; Rezende, Antonio Mauro] Fundacao Oswald Cruz, Dept Microbiol, Recife, PE, Brazil	Universidade de Pernambuco (UPE); Fundacao Oswaldo Cruz; Universidade Federal de Pernambuco; Universidade Federal de Pernambuco; Fundacao Oswaldo Cruz	Pereira, VRA (corresponding author), Fundacao Oswaldo Cruz, Dept Immunol, Recife, PE, Brazil.	valeria@cpqam.fiocruz.br	de Freitas e Silva, Rafael/AAH-6028-2020; de Castro, Maria Carolina Accioly Brelaz/AAV-5606-2020; Rezende, Antonio Mauro/S-2126-2018	de Freitas e Silva, Rafael/0000-0001-7343-5986; de Castro, Maria Carolina Accioly Brelaz/0000-0003-2205-0618; de Melo Neto, Osvaldo/0000-0001-5402-7346; Hernandes, Marcelo Zaldini/0000-0002-3624-474X; Rezende, Antonio Mauro/0000-0003-4775-1779	State of Pernambuco Funding Agency (FACEPE); Brazilian Research Council CNPq; Chamada MCTI/CNPq/MS-SCTIE -Decit [40/2012, 404259/2012];  [400325/2019-5]	State of Pernambuco Funding Agency (FACEPE); Brazilian Research Council CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Chamada MCTI/CNPq/MS-SCTIE -Decit; 	BO and LF are recipients of fellowships from the State of Pernambuco Funding Agency (FACEPE). MH, OM-N, and VP acknowledge research fellowships received from the Brazilian Research Council CNPq. This study was supported by: Chamada MCTI/CNPq/MS-SCTIE -Decit No. 40/2012 - Pesquisa em Doeneas Negligenciadas. Processo No.: 404259/2012; and by Edital 39/2018 - Proep - IAM(faixa B). Processo: 400325/2019-5.	Aebischer T, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00260; Agallou M, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005311; Alexander J, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00080; Bacon KM, 2013, VACCINE, V31, P480, DOI 10.1016/j.vaccine.2012.11.032; BARRAL A, 1995, AM J TROP MED HYG, V53, P256, DOI 10.4269/ajtmh.1995.53.256; Bertholet S, 2009, VACCINE, V27, P7036, DOI 10.1016/j.vaccine.2009.09.066; BOGDAN C, 1990, EUR J IMMUNOL, V20, P1131, DOI 10.1002/eji.1830200528; Carrion J, 2011, COMP IMMUNOL MICROB, V34, P381, DOI 10.1016/j.cimid.2011.06.002; Costa DL, 2013, HUM IMMUNOL, V74, P1491, DOI 10.1016/j.humimm.2013.08.269; Coutinho SG, 1996, EXP PARASITOL, V84, P144, DOI 10.1006/expr.1996.0100; Silva RDE, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00327; de Jesus AR, 2008, INT IMMUNOPHARMACOL, V8, P1344, DOI 10.1016/j.intimp.2008.03.020; De Luca PM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00151; De Luca PM, 2001, ACTA TROP, V80, P251, DOI 10.1016/S0001-706X(01)00181-4; Freitas-Silva R, 2016, THESIS; Garner-Spitzer E, 2013, J IMMUNOL, V191, P2426, DOI 10.4049/jimmunol.1300293; Garner-Spitzer E, 2009, VACCINE, V27, P197, DOI 10.1016/j.vaccine.2008.10.045; Gillespie PM, 2016, VACCINE, V34, P2992, DOI 10.1016/j.vaccine.2015.12.071; Gollob KJ, 2014, PARASITE IMMUNOL, V36, P367, DOI 10.1111/pim.12100; Gorelik L, 2002, J EXP MED, V195, P1499, DOI 10.1084/jem.20012076; GREEN SJ, 1990, J IMMUNOL, V145, P4290; Hotez PJ, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002570; Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153; Iborra S, 2018, EXPERT REV VACCINES, V17, P323, DOI 10.1080/14760584.2018.1459191; Inaba K, 2000, J EXP MED, V191, P927, DOI 10.1084/jem.191.6.927; Kaye P, 2011, NAT REV MICROBIOL, V9, P604, DOI 10.1038/nrmicro2608; Kedzierski L, 2011, HUM VACCINES, V7, P1204, DOI 10.4161/hv.7.11.17752; Kimura A, 2010, EUR J IMMUNOL, V40, P1830, DOI 10.1002/eji.201040391; Kostka SL, 2009, J IMMUNOL, V182, P3039, DOI 10.4049/jimmunol.0713598; LAINSON R, 1977, J TROP MED HYG, V80, P29; Lazarevic V, 2013, NAT REV IMMUNOL, V13, P777, DOI 10.1038/nri3536; Mayrink W, 2013, T ROY SOC TROP MED H, V107, P212, DOI 10.1093/trstmh/trt006; MELBY PC, 1994, INFECT IMMUN, V62, P837, DOI 10.1128/IAI.62.3.837-842.1994; Moll H, 2004, INT J MED MICROBIOL, V294, P337, DOI 10.1016/j.ijmm.2004.03.003; Moll H, 2006, HDB DENDRITIC CELLS, P669, DOI [10.1002/9783527619696.ch32, DOI 10.1002/9783527619696.CH32]; Nagill R, 2011, INT IMMUNOPHARMACOL, V11, P1464, DOI 10.1016/j.intimp.2011.05.008; Costa CHN, 2011, PLOS NEGLECT TROP D, V5, DOI [10.1371/journal.pntd.0000965, 10.1371/journal.pntd.0000943]; Pakpour N, 2008, J IMMUNOL, V180, P8299, DOI 10.4049/jimmunol.180.12.8299; Porrozzi R, 2004, AM J TROP MED HYG, V71, P297, DOI 10.4269/ajtmh.2004.71.297; Ravindran R, 2005, J IMMUNOL, V175, P4603, DOI 10.4049/jimmunol.175.7.4603; Rodriguez-Pinto D, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001627; Sacks DL, 2014, NAT IMMUNOL, V15, P403, DOI 10.1038/ni.2853; Schroeder J, 2011, HUM VACCINES, V7, P10, DOI 10.4161/hv.7.0.14556; Scott P, 2016, NAT REV IMMUNOL, V16, P581, DOI 10.1038/nri.2016.72; Shin H, 2013, IMMUNOL REV, V255, P165, DOI 10.1111/imr.12087; Soong L, 2012, SEMIN IMMUNOPATHOL, V34, P735, DOI 10.1007/s00281-012-0350-8; Srivastava S, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1553-y; Vargas-Inchaustegui DA, 2008, J IMMUNOL, V180, P7537, DOI 10.4049/jimmunol.180.11.7537; Vieira LQ, 1996, J IMMUNOL, V157, P827; WHO, 2015, LEISHMANIASIS; Wiedermann U, 2016, HUM VACC IMMUNOTHER, V12, P239, DOI 10.1080/21645515.2015.1093263; Wilhelm P, 2001, J IMMUNOL, V166, P4012, DOI 10.4049/jimmunol.166.6.4012	52	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 14	2020	10								3145	10.3389/fimmu.2019.03145	http://dx.doi.org/10.3389/fimmu.2019.03145			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KR2YJ	32117204	Green Published, gold			2022-12-18	WOS:000517485300001
J	Li, JT; Zhang, J; Guo, HX; Yang, SM; Fan, WP; Ye, N; Tian, ZQ; Yu, TT; Ai, GP; Shen, ZG; He, HY; Yan, P; Lin, H; Luo, X; Li, HL; Wu, YZ				Li, Jintao; Zhang, Ji; Guo, Hongxia; Yang, Shimin; Fan, Weiping; Ye, Nan; Tian, Zhiqiang; Yu, Tiantian; Ai, Guoping; Shen, Zigang; He, Haiyang; Yan, Ping; Lin, Hui; Luo, Xue; Li, Hongli; Wu, Yuzhang			Critical Role of Alternative M2 Skewing in miR-155 Deletion-Mediated Protection of Colitis (vol 9, 904, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						M2 macrophages; miR-155; colitis; C; EBP beta; SOCS1			[Li, Jintao; Guo, Hongxia; Ye, Nan; Yu, Tiantian; Ai, Guoping; Lin, Hui; Luo, Xue] Army Med Univ, Inst Trop Med, Chongqing, Peoples R China; [Li, Jintao; Guo, Hongxia] Army Med Univ, Coll Basic Med, Dept MicroBiol, Chongqing, Peoples R China; [Zhang, Ji; Tian, Zhiqiang; Shen, Zigang; He, Haiyang; Wu, Yuzhang] Army Med Univ, Inst Immunol, PLA, Chongqing, Peoples R China; [Yang, Shimin] Army Med Univ, Xinqiao Hosp, Dept Gastroenterol, Chongqing, Peoples R China; [Fan, Weiping] Shanxi Med Univ, Dept Microbiol & Immunol, Taiyuan, Peoples R China; [Yan, Ping] Army Med Univ, Southwest Hosp, Dept Obstet & Gynecol, Chongqing, Peoples R China; [Li, Hongli] Army Med Univ, Coll Basic Med, Dept Histol & Embryol, Chongqing, Peoples R China	Army Medical University; Army Medical University; Army Medical University; Army Medical University; Shanxi Medical University; Army Medical University; Army Medical University	Li, JT (corresponding author), Army Med Univ, Inst Trop Med, Chongqing, Peoples R China.; Li, JT (corresponding author), Army Med Univ, Coll Basic Med, Dept MicroBiol, Chongqing, Peoples R China.; Wu, YZ (corresponding author), Army Med Univ, Inst Immunol, PLA, Chongqing, Peoples R China.; Li, HL (corresponding author), Army Med Univ, Coll Basic Med, Dept Histol & Embryol, Chongqing, Peoples R China.	ljtqms@qq.com; wuyuzhang@tmmu.edu.cn; lihongli@tmmu.edu.cn	Fan, Weiping/ABC-7405-2021	li, jintao/0000-0003-3637-2386; Wu, Yuzhang/0000-0002-4049-0214				Li JT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00904	1	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 13	2020	10								3153	10.3389/fimmu.2019.03153	http://dx.doi.org/10.3389/fimmu.2019.03153			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KR2KK	32117209	gold, Green Published			2022-12-18	WOS:000517448500001
J	Muhammad, A; Kassmannhuber, J; Rauscher, M; Falcon, AA; Wheeler, DW; Zhang, AA; Lubitz, P; Lubitz, W				Muhammad, Abbas; Kassmannhuber, Johannes; Rauscher, Mascha; Falcon, Alaric A.; Wheeler, David W.; Zhang, Alan A.; Lubitz, Petra; Lubitz, Werner			Subcutaneous Immunization of Dogs With Bordetella bronchiseptica Bacterial Ghost Vaccine (vol 10, 1377, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						Bordetella; Bacterial Ghosts (BGs); whooping cough; immunization (vaccination); dog model			[Muhammad, Abbas; Kassmannhuber, Johannes; Rauscher, Mascha; Lubitz, Petra; Lubitz, Werner] BIRD C GmbH & Co KG, Vienna, Austria; [Kassmannhuber, Johannes; Rauscher, Mascha] Univ Vienna, Ctr Mol Biol, Vienna, Austria; [Falcon, Alaric A.; Wheeler, David W.; Zhang, Alan A.] ELANCO Anim Hlth, Greenfield, IN USA	University of Vienna	Muhammad, A (corresponding author), BIRD C GmbH & Co KG, Vienna, Austria.	abbas.muhammad@bird-c.at						Muhammad A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01377	1	0	0	0	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 12	2020	11								193	10.3389/fimmu.2020.00193	http://dx.doi.org/10.3389/fimmu.2020.00193			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KR4MQ	32117311	Green Published, gold			2022-12-18	WOS:000517594500001
J	Zakas, PM; Healey, JF; Smith, IW; Lillicrap, D; Lollar, P				Zakas, Philip M.; Healey, John F.; Smith, Ian W.; Lillicrap, David; Lollar, Pete			Sedimentation Velocity Analytical Ultracentrifugation of Oxidized Recombinant Full-Length Factor VIII	FRONTIERS IN IMMUNOLOGY			English	Article						hemophilia A; factor VIII; oxidation; immunogenicity; analytical ultracentrifugation	SEVERE HEMOPHILIA-A; PREVIOUSLY UNTREATED PATIENTS; NONGENETIC RISK-FACTORS; INHIBITOR DEVELOPMENT; IMMUNOGENICITY; PRODUCTS; MODEL; MICE; CHILDREN; DOMAIN	Anti-drug antibodies to coagulation factor VIII (fVIII), often termed inhibitors, present the greatest economical and treatment related obstacle in the management of hemophilia A. Although several genetic and environmental risk factors associated with inhibitor development have been identified, the precise mechanisms responsible for the immune response to exogenous fVIII therapies remain undefined. Clinical trials suggest there is an increased immunogenic potential of recombinant fVIII compared to plasma-derived products. Additional biochemical and immunological studies have demonstrated that changes in recombinant fVIII production and formulation can alter fVIII structure and immunogenicity. Recently, one study demonstrated increased immunogenicity of the recombinant fVIII product Helixate in hemophilia A mice following oxidation with hypochlorite (ClO-). It is widely reported that protein aggregates within drug products can induce adverse immune reactions in patients. Several studies have therefore investigated the prevalence of molecular aggregates in commercial recombinant products with and without use-relevant stress and agitation. To investigate the potential link between oxidation-induced immunogenicity and molecular aggregation, we analyzed the recombinant fVIII product, Helixate, via sedimentation velocity analytical ultracentrifugation following oxidation with ClO-. At 80 mu M ClO-, a concentration that reduced the specific-activity by 67%, no detectable increase in large molecular aggregates (s > 12 S) was observed when compared to non-oxidized fVIII. This lack of aggregates was demonstrated both in commercial excipient as well as a HEPES buffered saline formulation. These data suggest that oxidation induced immunogenicity is independent of aggregate-mediated immune response. Therefore, our data support multiple, independent mechanisms underlying fVIII immunogenicity.	[Zakas, Philip M.; Lillicrap, David] Queens Univ, Dept Pathol & Mol Med, Kingston, ON, Canada; [Healey, John F.; Smith, Ian W.; Lollar, Pete] Emory Univ, Childrens Healthcare Atlanta, Aflac Canc & Blood Disorders Ctr, Dept Pediat, Atlanta, GA 30322 USA	McMaster University; Queens University - Canada; Children's Healthcare of Atlanta (CHOA); Emory University	Lollar, P (corresponding author), Emory Univ, Childrens Healthcare Atlanta, Aflac Canc & Blood Disorders Ctr, Dept Pediat, Atlanta, GA 30322 USA.	jlollar@emory.edu		Smith, Ian/0000-0002-1424-6832	National Institutes of Health/National Heart, Lung and Blood Institute [U54HL141981]; Canadian Institute of Health Research [FDN 154285]	National Institutes of Health/National Heart, Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by the National Institutes of Health/National Heart, Lung and Blood Institute (award number U54HL141981 to PL) and the Canadian Institute of Health Research (award number FDN 154285 to DL).	Alom-Ruiz SP, 2008, ANTIOXID REDOX SIGN, V10, P1089, DOI 10.1089/ars.2007.2007; Alvarez T, 2015, EUR J HAEMATOL, V94, P2, DOI 10.1111/ejh.12494; Anzengruber J, 2018, J THROMB HAEMOST, V16, P1176, DOI 10.1111/jth.14125; Astermark J, 2010, HAEMOPHILIA, V16, P747, DOI 10.1111/j.1365-2516.2010.02231.x; Bardi E, 2015, EUR J HAEMATOL, V94, P7, DOI 10.1111/ejh.12495; Batsuli G, 2018, J THROMB HAEMOST, V16, P1779, DOI 10.1111/jth.14233; Brautigam CA, 2015, METHOD ENZYMOL, V562, P109, DOI 10.1016/bs.mie.2015.05.001; Calvez T, 2018, HAEMATOLOGICA, V103, P179, DOI 10.3324/haematol.2017.174706; Calvez T, 2014, BLOOD, V124, P3398, DOI 10.1182/blood-2014-07-586347; Canis K, 2018, J THROMB HAEMOST, V16, P1592, DOI 10.1111/jth.14204; Collins PW, 2014, BLOOD, V124, P3389, DOI 10.1182/blood-2014-07-580498; Dam J, 2004, METHOD ENZYMOL, V384, P185; De Cristofaro Raimondo, 2019, TH Open, V3, pe123, DOI 10.1055/s-0039-1688413; Gangadharan B, 2014, J THROMB HAEMOST, V12, P2065, DOI 10.1111/jth.12740; Goudemand J, 2006, BLOOD, V107, P46, DOI 10.1182/blood-2005-04-1371; Gouw SC, 2013, BLOOD, V121, P4046, DOI 10.1182/blood-2012-09-457036; Gouw SC, 2013, NEW ENGL J MED, V368, P231, DOI 10.1056/NEJMoa1208024; Gouw SC, 2012, BLOOD, V119, P2922, DOI 10.1182/blood-2011-09-379453; Healey JF, 2018, J THROMB HAEMOST, V16, P303, DOI 10.1111/jth.13917; Hermeling S, 2006, J PHARM SCI-US, V95, P1084, DOI 10.1002/jps.20599; Lovgren KM, 2016, HAEMOPHILIA, V22, P772, DOI 10.1111/hae.13014; LUSHER JM, 1993, NEW ENGL J MED, V328, P453, DOI 10.1056/NEJM199302183280701; Markovitz RC, 2013, BLOOD, V121, P2785, DOI 10.1182/blood-2012-09-456582; Meeks SL, 2007, BLOOD, V110, P4234, DOI 10.1182/blood-2007-06-096842; Meeks SL, 2012, BLOOD, V120, P2512, DOI 10.1182/blood-2012-02-412361; Mosesson MW, 1990, J CLIN INVEST, V145, P1310, DOI [10.1172/JCI114662, DOI 10.1172/JCI114662]; Moussa EM, 2016, J PHARM SCI-US, V105, P417, DOI 10.1016/j.xphs.2015.11.002; Palla R, 2015, BLOOD, V125, P2052, DOI 10.1182/blood-2014-08-532820; Peyron I, 2018, CELL IMMUNOL, V325, P64, DOI 10.1016/j.cellimm.2018.01.008; Pipe SW, 2016, BLOOD, V128, P2007, DOI 10.1182/blood-2016-04-713289; Pisal DS, 2012, J PHARM SCI-US, V101, P2055, DOI 10.1002/jps.23091; Prokopowicz ZM, 2010, J IMMUNOL, V184, P824, DOI 10.4049/jimmunol.0902606; Roberts CJ, 2014, TRENDS BIOTECHNOL, V32, P372, DOI 10.1016/j.tibtech.2014.05.005; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Shahab U, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031199; Svedberg T, 1940, THE ULTRACENTRIFUGE; van Beers MMC, 2011, PHARM RES-DORDR, V28, P2393, DOI 10.1007/s11095-011-0451-4; Wight J, 2003, HAEMOPHILIA, V9, P418, DOI 10.1046/j.1365-2516.2003.00780.x; Zhao Huaying, 2013, Curr Protoc Protein Sci, VChapter 20, DOI 10.1002/0471140864.ps2012s71	39	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 7	2020	11								150	10.3389/fimmu.2020.00150	http://dx.doi.org/10.3389/fimmu.2020.00150			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KR0CN	32117290	Green Published, gold			2022-12-18	WOS:000517288600001
J	Cox, ST; Danby, R; Hernandez, D; Laza-Briviesca, R; Pearson, H; Madrigal, JA; Saudemont, A				Cox, Steven T.; Danby, Robert; Hernandez, Diana; Laza-Briviesca, Raquel; Pearson, Hayley; Madrigal, J. Alejandro; Saudemont, Aurore			Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma (vol 9, 1282, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						NK cell; pregnancy; tolerance; NKG2D; ligand; luciferase; MICA; ULBP1			[Cox, Steven T.; Danby, Robert; Hernandez, Diana; Laza-Briviesca, Raquel; Pearson, Hayley; Madrigal, J. Alejandro; Saudemont, Aurore] Royal Free Hosp, Anthony Nolan Res Inst, London, England; [Cox, Steven T.; Hernandez, Diana; Madrigal, J. Alejandro; Saudemont, Aurore] UCL, Inst Canc, London, England; [Danby, Robert] Oxford Univ Hosp NHS Fdn Trust, Churchill Hosp, Oxford, England; [Saudemont, Aurore] GSK, Med Res Ctr, Stevenage, Herts, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Oxford University Hospitals NHS Foundation Trust; University of Oxford; GlaxoSmithKline	Cox, ST (corresponding author), Royal Free Hosp, Anthony Nolan Res Inst, London, England.; Cox, ST (corresponding author), UCL, Inst Canc, London, England.	steven.cox@anthonynolan.org	Cox, Steve Thomas/AAE-5408-2021; Danby, Robert/AAE-7955-2021; Hernandez, Diana/AAE-4613-2021	Cox, Steve Thomas/0000-0003-0590-1281; Laza Briviesca, Raquel/0000-0003-2369-567X				Cox ST, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01282	1	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 4	2020	11								87	10.3389/fimmu.2020.00087	http://dx.doi.org/10.3389/fimmu.2020.00087			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KO5DE	32117247	Green Published, gold			2022-12-18	WOS:000515569200001
J	Pei, XL; Earley, LF; He, Y; Chen, XJ; Hall, NE; Samulski, RJ; Li, CW				Pei, Xiaolei; Earley, Lauriel Freya; He, Yi; Chen, Xiaojing; Hall, Nikita Elexa; Samulski, Richard Jude; Li, Chengwen			Efficient Capsid Antigen Presentation From Adeno-Associated Virus Empty Virions In Vivo (vol 9, 844, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						adeno-associated virus; capsid; antigen presentation; CD8+T cells; empty virions			[Pei, Xiaolei; He, Yi] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China; [Pei, Xiaolei; Earley, Lauriel Freya; He, Yi; Chen, Xiaojing; Hall, Nikita Elexa; Samulski, Richard Jude; Li, Chengwen] Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27515 USA; [Samulski, Richard Jude] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27515 USA; [Li, Chengwen] Univ N Carolina, Dept Pediat, Chapel Hill, NC 27515 USA	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital - CAMS; Peking Union Medical College; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Li, CW (corresponding author), Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27515 USA.; Li, CW (corresponding author), Univ N Carolina, Dept Pediat, Chapel Hill, NC 27515 USA.	chengwen@med.unc.edu						Pei XL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00844	1	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 4	2020	10								3076	10.3389/fimmu.2019.03076	http://dx.doi.org/10.3389/fimmu.2019.03076			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KO5CK	32117195	Green Published, gold			2022-12-18	WOS:000515567200001
J	Mandal, A; Das, S; Kumar, A; Roy, S; Verma, S; Ghosh, AK; Singh, R; Abhishek, K; Saini, S; Sardar, A; Purkait, B; Kumar, A; Mandal, C; Das, P				Mandal, Abhishek; Das, Sushmita; Kumar, Ajay; Roy, Saptarshi; Verma, Sudha; Ghosh, Ayan Kumar; Singh, Ruby; Abhishek, Kumar; Saini, Savita; Sardar, Abul Hasan; Purkait, Bidyut; Kumar, Ashish; Mandal, Chitra; Das, Pradeep			L-Arginine Uptake by Cationic Amino Acid Transporter Promotes Intra-Macrophage Survival of Leishmania donovani by Enhancing Arginase-Mediated Polyamine Synthesis (vol 8, 839, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						macrophage; Leishmania; L-arginine; CAT-2; arginase; nitric oxide; polyamine; cytokine			[Mandal, Abhishek; Kumar, Ajay; Verma, Sudha; Ghosh, Ayan Kumar; Singh, Ruby; Abhishek, Kumar; Saini, Savita; Sardar, Abul Hasan; Purkait, Bidyut; Kumar, Ashish; Das, Pradeep] Rajendra Mem Res Inst Med Sci ICMR, Dept Mol Biol, Patna, Bihar, India; [Das, Sushmita] AIIMS, Dept Microbiol, Patna, Bihar, India; [Roy, Saptarshi; Mandal, Chitra] CSIR Indian Inst Chem Biol, Canc Biol & Inflammatory Disorder Div, Kolkata, India; [Saini, Savita] Natl Inst Pharmaceut Educ & Res, Dept Biotechnol, Hajipur, India; [Sardar, Abul Hasan] Sarsuna Coll, Dept Microbiol, Kolkata, India	Indian Council of Medical Research (ICMR); ICMR - Rajendra Memorial Research Institute of Medical Sciences (RMRI); All India Institute of Medical Sciences (AIIMS) Patna; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB); National Institute of Pharmaceutical Education & Research (NIPER)	Das, P (corresponding author), Rajendra Mem Res Inst Med Sci ICMR, Dept Mol Biol, Patna, Bihar, India.	drpradeep.das@gmail.com	GHOSH, AYAN/GYV-5906-2022					Mandal A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00839	1	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 31	2020	10								3101	10.3389/fimmu.2019.03101	http://dx.doi.org/10.3389/fimmu.2019.03101			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KK3YF	32082300	Green Published, gold			2022-12-18	WOS:000512681000001
J	Colucci, F				Colucci, Francesco			Sharing Knowledge With Young and Established Students of Immunology by the Neapolitan Gulf at the Ruggero Ceppellini Advanced School	FRONTIERS IN IMMUNOLOGY			English	Article						pregnancy; immunity; transplantation; cancer; collaborations	ZIKA VIRUS; PREGNANCY; KIR; RECEPTORS; LIGANDS; WOMEN		[Colucci, Francesco] Univ Cambridge, Sch Clin Med, Dept Obstet & Gynaecol, Natl Inst Hlth Res,Cambridge Biomed Res Ctr, Cambridge, England; [Colucci, Francesco] Univ Cambridge, Ctr Trophoblast Res, Cambridge, England	University of Cambridge; University of Cambridge	Colucci, F (corresponding author), Univ Cambridge, Sch Clin Med, Dept Obstet & Gynaecol, Natl Inst Hlth Res,Cambridge Biomed Res Ctr, Cambridge, England.; Colucci, F (corresponding author), Univ Cambridge, Ctr Trophoblast Res, Cambridge, England.	fc287@medschl.cam.ac.uk			 [200841/Z/16/Z]		Work in the Colucci laboratory is funded by theWellcome Trust (Grant Number 200841/Z/16/Z).	Aghaeepour N, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan2946; Bodmer W, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01280; Colucci F, 2019, EUR J IMMUNOL, V49, P2123, DOI 10.1002/eji.201970125; Colucci F, 2019, SCIENCE, V365, P862, DOI 10.1126/science.aaw1300; Colucci F, 2014, EUR J IMMUNOL, V44, P1883, DOI 10.1002/eji.201470065; de Goffau MC, 2019, NATURE, V572, P329, DOI 10.1038/s41586-019-1451-5; Di Giacomo A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01494; Doisne JM, 2015, J IMMUNOL, V195, P3937, DOI 10.4049/jimmunol.1500689; Estes ML, 2016, SCIENCE, V353, P772, DOI 10.1126/science.aag3194; Filipovic I, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06918-3; Huhn O, 2019, NAT COMMUN, DOI [10.17863/CAM.47154, DOI 10.17863/CAM.47154]; Jiang W, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0358-0; Jiang XX, 2018, CELL MOL IMMUNOL, V15, P1027, DOI 10.1038/s41423-018-0008-0; Kourtis AP, 2014, NEW ENGL J MED, V370, P2211, DOI 10.1056/NEJMra1213566; Le Gars M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02469; Lei YM, 2016, J CLIN INVEST, V126, P2736, DOI 10.1172/JCI85295; Luty AJF, 2016, LANCET INFECT DIS, V16, P137, DOI 10.1016/S1473-3099(15)00379-5; McIntosh CM, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0474-8; Moffett A, 2015, IMMUNOL REV, V267, P283, DOI 10.1111/imr.12323; Musso D, 2019, NEW ENGL J MED, V381, P1444, DOI 10.1056/NEJMra1808246; Nakimuli A, 2015, P NATL ACAD SCI USA, V112, P845, DOI 10.1073/pnas.1413453112; Nakimuli A, 2014, AM J OBSTET GYNECOL, V210, P510, DOI 10.1016/j.ajog.2013.10.879; Namara B, 2017, PEDIAT ALLERG IMM-UK, V28, P784, DOI 10.1111/pai.12804; Norman PJ, 2016, AM J HUM GENET, V99, P375, DOI 10.1016/j.ajhg.2016.06.023; Parham P, 2013, NAT REV IMMUNOL, V13, P133, DOI 10.1038/nri3370; Pierson TC, 2018, NATURE, V560, P573, DOI 10.1038/s41586-018-0446-y; Salvany-Celades M, 2019, CELL REP, V27, P2537, DOI 10.1016/j.celrep.2019.04.109; Sharkey AM, 2015, J IMMUNOL, V195, P3026, DOI 10.4049/jimmunol.1501229; Shreeve N., 2019, SSRN ELECT J, DOI [10.2139/ssrn.3477575, DOI 10.2139/SSRN.3477575]; Surani MA, 2002, NATURE, V416, P491, DOI 10.1038/416491a; Turco MY, 2018, NATURE, V564, P263, DOI 10.1038/s41586-018-0753-3; Vento-Tormo R, 2018, NATURE, V563, P347, DOI 10.1038/s41586-018-0698-6; Zitvogel L, 2018, SCIENCE, V359, P1366, DOI 10.1126/science.aar6918	33	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 28	2020	11								43	10.3389/fimmu.2020.00043	http://dx.doi.org/10.3389/fimmu.2020.00043			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KM8FS	32047501	Green Published, Green Submitted, gold			2022-12-18	WOS:000514376600001
J	Pilon, C; Bigot, J; Grondin, C; Thiolat, A; Lang, PL; Cohen, JL; Grimbert, P; Matignon, M				Pilon, Caroline; Bigot, Jeremy; Grondin, Cynthia; Thiolat, Allan; Lang, Philippe; Cohen, Jose L.; Grimbert, Philippe; Matignon, Marie			Phenotypic and Transcriptomic Lymphocytes Changes in Allograft Recipients After Intravenous Immunoglobulin Therapy in Kidney Transplant Recipients	FRONTIERS IN IMMUNOLOGY			English	Article						kidney transplantation; high-dose intravenous immunoglobulin; donor specific antibodies; lymphocytes phenotype; immunomodulation	DONOR-SPECIFIC ANTIBODIES; IMMUNE GLOBULIN; RENAL-DISEASE; B-CELLS; DESENSITIZATION; REJECTION; MEMORY; CLASSIFICATION; AUTOIMMUNE; RITUXIMAB	High dose intravenous immunoglobulin (IVIG) are widely used after kidney transplantation and its biological effect on T and B cell phenotype in the context of maintenance immunosuppression was not documented yet. We designed a monocentric prospective cohort study of kidney allograft recipients with anti-HLA donor specific antibodies (DSA) without acute rejection on screening biopsies treated with prophylactic high-dose IVIG (2 g/kg) monthly for 2 months. Any previous treatment with Rituximab was an exclusion criterion. We performed an extensive analysis of phenotypic and transcriptomic T and B lymphocytes changes and serum cytokines after treatment (day 60). Twelve kidney transplant recipients who completed at least two courses of high-dose IVIG (2 g/kg) were included in a median time of 45 (12-132) months after transplant. Anti-HLA DSA characteristics were similar before and after treatment. At D60, PBMC population distribution was similar to the day before the first infusion. CD8(+) CD45RA(+) T cells and naive B-cells (Bm2(+)) decreased (P = 0.03 and P = 0.012, respectively) whereas Bm1 (mature B-cells) increased (P = 0.004). ROR gamma t serum mRNA transcription factor and CD3 serum mRNA increased 60 days after IVIG (P = 0.02 for both). Among the 25 cytokines tested, only IL-18 serum concentration significantly decreased at D60 (P = 0.03). In conclusion, high dose IVIG induced limited B cell and T cell phenotype modifications that could lead to anti-HLA DSA decrease. However, no clinical effect has been isolated and the real benefit of prophylactic use of IVIG after kidney transplantation merits to be questioned.	[Pilon, Caroline; Grondin, Cynthia; Cohen, Jose L.; Grimbert, Philippe; Matignon, Marie] Hop H Mondor A Chenevier, AP HP, Ctr Invest Clin Biotherapie, Creteil, France; [Pilon, Caroline; Bigot, Jeremy; Thiolat, Allan; Lang, Philippe; Cohen, Jose L.; Grimbert, Philippe; Matignon, Marie] Univ Paris Est, UMR S955, UPEC, Creteil, France; [Pilon, Caroline; Bigot, Jeremy; Thiolat, Allan; Lang, Philippe; Cohen, Jose L.; Grimbert, Philippe; Matignon, Marie] INSERM, U955, Equipe 21, Creteil, France; [Lang, Philippe; Grimbert, Philippe; Matignon, Marie] Hop H Mondor A Chenevier, AP HP, Nephrol & Transplantat Dept, Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Matignon, M (corresponding author), Hop H Mondor A Chenevier, AP HP, Ctr Invest Clin Biotherapie, Creteil, France.; Matignon, M (corresponding author), Univ Paris Est, UMR S955, UPEC, Creteil, France.; Matignon, M (corresponding author), INSERM, U955, Equipe 21, Creteil, France.; Matignon, M (corresponding author), Hop H Mondor A Chenevier, AP HP, Nephrol & Transplantat Dept, Creteil, France.	marie.matignon@aphp.fr	Cohen, José/Q-4816-2018; JEREMY, BIGOT/D-2465-2018	Cohen, José/0000-0002-5077-6726; JEREMY, BIGOT/0000-0002-0968-9102	CSL Behring	CSL Behring	The authors declare that this study received funding from CSL Behring. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	Anglicheau D, 2007, AM J TRANSPLANT, V7, P1185, DOI 10.1111/j.1600-6143.2007.01752.x; Aubert O, 2017, J AM SOC NEPHROL, V28, P1912, DOI 10.1681/ASN.2016070797; Banham GD, 2018, LANCET, V391, P2619, DOI 10.1016/S0140-6736(18)30984-X; Bayry J, 2011, J AUTOIMMUN, V36, P9, DOI 10.1016/j.jaut.2010.09.006; Bohnhorst JO, 2001, J IMMUNOL, V167, P3610, DOI 10.4049/jimmunol.167.7.3610; Bollee G, 2008, CLIN J AM SOC NEPHRO, V3, P1461, DOI 10.2215/CJN.00500108; Chen WH, 2015, TRANSPLANTATION, V99, P2029, DOI 10.1097/TP.0000000000000802; Galeotti C, 2017, INT IMMUNOL, V29, P491, DOI 10.1093/intimm/dxx039; Gelfand EW, 2012, NEW ENGL J MED, V367, P2015, DOI 10.1056/NEJMra1009433; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Jordan S, 2003, AM J TRANSPLANT, V3, P653, DOI 10.1034/j.1600-6143.2003.00121.x; Jordan SC, 2004, J AM SOC NEPHROL, V15, P3256, DOI 10.1097/01.ASN.0000145878.92906.9F; Jordan SC, 2015, IMMUNOTHERAPY-UK, V7, P377, DOI [10.2217/IMT.15.10, 10.2217/imt.15.10]; Jordan SC, 2014, CURR OPIN ORGAN TRAN, V19, P591, DOI 10.1097/MOT.0000000000000128; Lefaucheur C, 2010, J AM SOC NEPHROL, V21, P1398, DOI 10.1681/ASN.2009101065; Leibler C, 2014, AM J TRANSPLANT, V14, P1173, DOI 10.1111/ajt.12721; Levey AS, 2007, CLIN CHEM, V53, P766, DOI 10.1373/clinchem.2006.077180; Liu C, 2018, EUR CYTOKINE NETW, V29, P48, DOI 10.1684/ecn.2018.0410; Loupy A, 2017, AM J TRANSPLANT, V17, P28, DOI 10.1111/ajt.14107; Loupy A, 2010, TRANSPLANTATION, V89, P1403, DOI 10.1097/TP.0b013e3181da1cc3; Luque Y, 2016, TRANSPL INT, V29, P1205, DOI 10.1111/tri.12833; Matignon M, 2015, AM J TRANSPLANT, V15, P2718, DOI 10.1111/ajt.13304; Matignon M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178572; Mitchell P, 2009, CURR OPIN ORGAN TRAN, V14, P326, DOI 10.1097/MOT.0b013e32832ce88e; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; Montgomery RA, 2011, NEW ENGL J MED, V365, P318, DOI 10.1056/NEJMoa1012376; Pallier A, 2010, KIDNEY INT, V78, P503, DOI 10.1038/ki.2010.162; Ritter C, 2014, J NEUROIMMUNOL, V274, P225, DOI 10.1016/j.jneuroim.2014.06.007; Schaenman JM, 2018, HUM IMMUNOL, V79, P659, DOI 10.1016/j.humimm.2018.06.006; Snanoudj R, 2014, TRANSPLANTATION, V97, P917, DOI 10.1097/01.TP.0000438211.34842.5e; Todeschini M, 2013, J IMMUNOL, V191, P2818, DOI 10.4049/jimmunol.1203261; Vo AA, 2008, NEW ENGL J MED, V359, P242, DOI 10.1056/NEJMoa0707894; Vo AA, 2014, TRANSPLANTATION, V98, P312, DOI 10.1097/TP.0000000000000064; Xu C, 1998, AM J PATHOL, V153, P1257, DOI 10.1016/S0002-9440(10)65670-2; Yabu JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153355; Zhang QW, 2006, J IMMUNOL, V176, P770, DOI 10.4049/jimmunol.176.2.770	36	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 24	2020	11								34	10.3389/fimmu.2020.00034	http://dx.doi.org/10.3389/fimmu.2020.00034			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KJ2EC	32038663	Green Published, gold			2022-12-18	WOS:000511870000001
J	Pouw, RB; Delgado, IG; Lera, AL; de Cordoba, SR; Wouters, D; Kuijpers, TW; Sanchez-Corral, P				Pouw, Richard B.; Gomez Delgado, Irene; Lopez Lera, Alberto; Rodriguez de Cordoba, Santiago; Wouters, Diana; Kuijpers, Taco W.; Sanchez-Corral, Pilar			High Complement Factor H-Related (FHR)-3 Levels Are Associated With the Atypical Hemolytic-Uremic Syndrome-Risk Allele CFHR3*B (vol 9, 848, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						complement; factor H; factor H-related protein 3; CFHR3 gene; atypical hemolytic-uremic syndrome			[Pouw, Richard B.; Wouters, Diana] Univ Amsterdam, Dept Immunopathol, Sanquin Res & Landsteiner Lab, Acad Med Ctr, Amsterdam, Netherlands; [Pouw, Richard B.; Kuijpers, Taco W.] Emma Childrens Hosp, Dept Pediat Hematol Immunol & Infect Dis, Acad Med Ctr, Amsterdam, Netherlands; [Gomez Delgado, Irene; Sanchez-Corral, Pilar] La Paz Univ Hosp, Complement Res Grp, Hosp La Paz Inst Hlth Res IdiPAZ, Ctr Biomed Network Res Rare Dis CIBERER, Madrid, Spain; [Lopez Lera, Alberto] La Paz Univ Hosp, Immunol Unit, Hosp La Paz Inst Hlth Res IdiPAZ, Ctr Biomed Network Res Rare Dis CIBERER, Madrid, Spain; [Rodriguez de Cordoba, Santiago] CSIC, Biol Res Ctr CIB, Ctr Biomed Network Res Rare Dis CIBERER, Madrid, Spain; [Kuijpers, Taco W.] Univ Amsterdam, Dept Blood Cell Res, Sanquin Res & Landsteiner Lab, Acad Med Ctr, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Hospital Universitario La Paz; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Hospital Universitario La Paz; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Consejo Superior de Investigaciones Cientificas (CSIC); University of Amsterdam; Academic Medical Center Amsterdam	Sanchez-Corral, P (corresponding author), La Paz Univ Hosp, Complement Res Grp, Hosp La Paz Inst Hlth Res IdiPAZ, Ctr Biomed Network Res Rare Dis CIBERER, Madrid, Spain.	pilar.sanchez-corral@idipaz.es	Sánchez-Corral, Pilar/GLR-0387-2022; Pouw, Richard/AAE-1042-2020	Pouw, Richard/0000-0003-3469-8454				Pouw RB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00848	1	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 24	2020	10								3073	10.3389/fimmu.2019.03073	http://dx.doi.org/10.3389/fimmu.2019.03073			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KJ1YQ	32038624	Green Published, gold			2022-12-18	WOS:000511855500001
J							Frontiers Editorial Off	RETRACTION: Plumbagin Ameliorates Collagen-Induced Arthritis by Regulating Treg/Th17 Cell Imbalances and Suppressing Osteoclastogenesis (Retraction of Vol 9, art no 3102, 2019)	FRONTIERS IN IMMUNOLOGY			English	Retraction																		Wang TY, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03102	1	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 23	2020	11								112	10.3389/fimmu.2020.00112	http://dx.doi.org/10.3389/fimmu.2020.00112			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KJ2ET		Green Published, gold			2022-12-18	WOS:000511871700001
J	King, IL; Divangahi, M				King, Irah L.; Divangahi, Maziar			Editorial: Evolving Mechanisms of Disease Tolerance	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						host defense; infection; immunity; disease tolerance; tissue damage	PROTECTION; DEFENSE		[King, Irah L.; Divangahi, Maziar] McGill Univ, Hlth Ctr, Dept Med, Meakins Christie Labs, Montreal, PQ, Canada; [King, Irah L.; Divangahi, Maziar] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada; [Divangahi, Maziar] McGill Univ, Hlth Ctr, McGill Int TB Ctr, Montreal, PQ, Canada	McGill University; McGill University; McGill University	King, IL; Divangahi, M (corresponding author), McGill Univ, Hlth Ctr, Dept Med, Meakins Christie Labs, Montreal, PQ, Canada.; King, IL; Divangahi, M (corresponding author), McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada.; Divangahi, M (corresponding author), McGill Univ, Hlth Ctr, McGill Int TB Ctr, Montreal, PQ, Canada.	irah.king@mcgill.ca; maziar.divangahi@mcgill.ca			CIHR operating grant [MOP-130579]; CIHR Foundation [FDN-143273]; J. T. Costello Memorial Research Fund; Richard and Edith Strauss Canada Foundation; LIoyd Carr-Harris Foundation	CIHR operating grant(Canadian Institutes of Health Research (CIHR)); CIHR Foundation(Canadian Institutes of Health Research (CIHR)); J. T. Costello Memorial Research Fund; Richard and Edith Strauss Canada Foundation; LIoyd Carr-Harris Foundation	This work was supported by a CIHR operating grant (MOP-130579) to IK, a CIHR Foundation Grant (FDN-143273) to MD, the generous support of J. T. Costello Memorial Research Fund, the Richard and Edith Strauss Canada Foundation and the LIoyd Carr-Harris Foundation. IK was a Canada Research Chair in Barrier Immunity and MD holds a Strauss Chair in Respiratory Diseases.	Ayres JS, 2008, GENETICS, V178, P1807, DOI 10.1534/genetics.107.083782; Ayres JS, 2008, PLOS BIOL, V6, P2764, DOI 10.1371/journal.pbio.0060305; CALDWELL RM, 1958, SCIENCE, V128, P714, DOI 10.1126/science.128.3326.714; Cobb NA., 1894, CONTRIBUTIONS EC KNO; Lederberg J, 2000, SCIENCE, V288, P287, DOI 10.1126/science.288.5464.287; Medzhitov R, 2012, SCIENCE, V335, P936, DOI 10.1126/science.1214935; Raberg L, 2007, SCIENCE, V318, P812, DOI 10.1126/science.1148526; Seixas E, 2009, P NATL ACAD SCI USA, V106, P15837, DOI 10.1073/pnas.0903419106; Soares MP, 2017, NAT REV IMMUNOL, V17, P83, DOI 10.1038/nri.2016.136; Xing Y, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006957	10	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 20	2019	10								2974	10.3389/fimmu.2019.02974	http://dx.doi.org/10.3389/fimmu.2019.02974			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KA3PS	31921211	Green Published, gold			2022-12-18	WOS:000505711400001
J	Muthukuru, M				Muthukuru, Manoj			Commentary: Is the developmentally immature immune response in paediatric sepsis a recapitulation of immune tolerance?	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						immune system; endotoxins; Toll-like receptors; inflammation; neonatal sepsis; immune tolerance	TRENDS		[Muthukuru, Manoj] Univ Washington, Hlth Sci Ctr, Seattle, WA 98195 USA; [Muthukuru, Manoj] Holist Hlth Orat LLC, Centereach, NY 11720 USA	University of Washington; University of Washington Seattle	Muthukuru, M (corresponding author), Univ Washington, Hlth Sci Ctr, Seattle, WA 98195 USA.; Muthukuru, M (corresponding author), Holist Hlth Orat LLC, Centereach, NY 11720 USA.	manojm@u.washington.edu			Holistic Health Oration LLC	Holistic Health Oration LLC	The publication cost of this article was supported by Holistic Health Oration LLC.	Basha S, 2014, EXPERT REV CLIN IMMU, V10, P1171, DOI 10.1586/1744666X.2014.942288; Cavaillon JM, 2006, CRIT CARE, V10, DOI 10.1186/cc5055; Fu Y, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002526; Hartman ME, 2013, PEDIATR CRIT CARE ME, V14, P686, DOI 10.1097/PCC.0b013e3182917fad; Hibbert JE, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00357; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Jaramillo-Bustamante JC, 2012, PEDIATR CRIT CARE ME, V13, P501, DOI 10.1097/PCC.0b013e31823c980f; Kan B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07215-9; Kollmann TR, 2017, IMMUNITY, V46, P350, DOI 10.1016/j.immuni.2017.03.009; Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1; Maddux AB, 2015, IMMUNOLOGY, V145, P1, DOI 10.1111/imm.12454; Muthukuru M, 2006, INFECT IMMUN, V74, P1431, DOI 10.1128/IAI.74.2.1431-1435.2006; Muthukuru M, 2005, INFECT IMMUN, V73, P687, DOI 10.1128/IAI.73.2.687-694.2005; Muthukuru M, 2008, INFECT IMMUN, V76, P477, DOI 10.1128/IAI.00100-07; Muthukuru M, 2020, MED HYPOTHESES, V134, DOI 10.1016/j.mehy.2019.109418; Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098; Raymond SL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184159; Seeley JJ, 2018, NATURE, V559, P114, DOI 10.1038/s41586-018-0253-5; Vachharajani V, 2019, INNATE IMMUN-LONDON, V25, P267, DOI 10.1177/1753425919842320; Vamadevan AS, 2010, INNATE IMMUN-LONDON, V16, P93, DOI 10.1177/1753425909339231; Wynn JL, 2011, MOL MED, V17, P1146, DOI 10.2119/molmed.2011.00169	21	0	0	9	19	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 19	2019	10								2932	10.3389/fimmu.2019.02932	http://dx.doi.org/10.3389/fimmu.2019.02932			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JZ5YA	31921186	Green Published, gold			2022-12-18	WOS:000505177400001
J	Calzas, C; Descamps, D; Chignard, M; Chevalier, C				Calzas, Cynthia; Descamps, Delphyne; Chignard, Michel; Chevalier, Christophe			Editorial: Innovative Therapeutic and Vaccine Approaches Against Respiratory Pathogens	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						vaccine; therapeutics; innovative delivery system; adjuvant; drug repurposing; antimicrobial peptide; respiratory pathogen			[Calzas, Cynthia; Descamps, Delphyne; Chevalier, Christophe] Univ Paris Saclay, INRAE, VIM, Jouy En Josas, France; [Chignard, Michel] UPMC Univ, Sorbonne Univ, INSERM, Ctr Rech St Antoine,Paris 06, Paris, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Chevalier, C (corresponding author), Univ Paris Saclay, INRAE, VIM, Jouy En Josas, France.	christophe.chevalier@inra.fr	Chevalier, Christophe/AAK-4461-2020; Chevalier, Christophe/AAW-5560-2020; Chevalier, Christophe/C-2575-2009	Chevalier, Christophe/0000-0003-3231-9027	Livestock Vaccine Innovation Fund (LVIF) (Canada's International Development Research Centre); Livestock Vaccine Innovation Fund (LVIF) (Bill & Melinda Gates Foundation); Livestock Vaccine Innovation Fund (LVIF) (Global Affairs Canada)	Livestock Vaccine Innovation Fund (LVIF) (Canada's International Development Research Centre); Livestock Vaccine Innovation Fund (LVIF) (Bill & Melinda Gates Foundation); Livestock Vaccine Innovation Fund (LVIF) (Global Affairs Canada)	This work was supported by a grant from the Livestock Vaccine Innovation Fund (LVIF) (Canada's International Development Research Centre, Bill & Melinda Gates Foundation, Global Affairs Canada).	Li S, 2014, NAT IMMUNOL, V15, P195, DOI 10.1038/ni.2789; O'Brien KL, 2019, LANCET, V394, P757, DOI 10.1016/S0140-6736(19)30721-4	2	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 17	2019	10								2960	10.3389/fimmu.2019.02960	http://dx.doi.org/10.3389/fimmu.2019.02960			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JZ3RM	31921201	gold, Green Published			2022-12-18	WOS:000505019000001
J	Gil, L; Martin, A; Lazo, L				Gil, Lazaro; Martin, Alejandro; Lazo, Laura			Wanted Dead or Alive: A Correlate of Protection Against Dengue Virus	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						dengue virus; vaccines; antibodies; cell-mediate immunity; protection; antibody-dependent enhancement of infection	T-CELL RESPONSES; NUCLEOCAPSID-LIKE PARTICLES; ANTIBODY-DEPENDENT ENHANCEMENT; HEMORRHAGIC-FEVER; IMMUNE-RESPONSE; INFECTION; VACCINE; RECOMBINANT; CD4(+); LIVE		[Gil, Lazaro; Martin, Alejandro; Lazo, Laura] Ctr Genet Engn & Biotechnol, Havana, Cuba	Centro de Ingenieria Genetica y Biotecnologia	Gil, L (corresponding author), Ctr Genet Engn & Biotechnol, Havana, Cuba.	lazaro.gil@cigb.edu.cu	Lazo, Laura/ABF-4912-2022					Balsitis SJ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000790; Bernardo L, 2008, CLIN VACCINE IMMUNOL, V15, P439, DOI 10.1128/CVI.00208-07; Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060; Blanc G, 1929, B ACAD MED, V102, P40; Borges MB, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007721; Dejnirattisai W, 2010, SCIENCE, V328, P745, DOI 10.1126/science.1185181; Duangchinda T, 2010, P NATL ACAD SCI USA, V107, P16922, DOI 10.1073/pnas.1010867107; Durbin AP, 2010, CURR TOP MICROBIOL, V338, P129, DOI 10.1007/978-3-642-02215-9_10; Forshey BM, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004398; Gil L, 2016, J IMMUNOL, V197, P3597, DOI 10.4049/jimmunol.1600927; Gil L, 2014, VIROLOGY, V456, P70, DOI 10.1016/j.virol.2014.03.011; Gil L, 2012, J GEN VIROL, V93, P1204, DOI 10.1099/vir.0.037721-0; Gil L, 2009, INT IMMUNOL, V21, P1175, DOI 10.1093/intimm/dxp082; Goncalvez AP, 2007, P NATL ACAD SCI USA, V104, P9422, DOI 10.1073/pnas.0703498104; Grifoni A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01309; Gubler DJ, 2002, ARCH MED RES, V33, P330, DOI 10.1016/S0188-4409(02)00378-8; Guirakhoo F, 2006, HUM VACCINES, V2, P60, DOI 10.4161/hv.2.2.2555; Gunther VJ, 2011, VACCINE, V29, P3895, DOI 10.1016/j.vaccine.2011.03.038; Halstead SB, 2002, EMERG INFECT DIS, V8, P1474, DOI 10.3201/eid0812.020170; HALSTEAD SB, 1969, AM J TROP MED HYG, V18, P997, DOI 10.4269/ajtmh.1969.18.997; HALSTEAD SB, 1979, J INFECT DIS, V140, P527, DOI 10.1093/infdis/140.4.527; Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0; Halstead SB, 2007, LANCET, V369, P1410, DOI 10.1016/S0140-6736(07)60645-X; Halstead SB, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00075; Hatch S, 2011, J INFECT DIS, V203, P1282, DOI 10.1093/infdis/jir012; Hung NT, 2004, J INFECT DIS, V189, P221, DOI 10.1086/380762; Jentes ES, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw062; Juraska M, 2018, P NATL ACAD SCI USA, V115, pE8378, DOI 10.1073/pnas.1714250115; Kirkpatrick BD, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1517; KLIKS SC, 1988, AM J TROP MED HYG, V38, P411, DOI 10.4269/ajtmh.1988.38.411; Lazo L, 2019, EXPERT REV VACCINES, V18, P161, DOI 10.1080/14760584.2019.1574575; Lobigs M, 2003, IMMUNOL CELL BIOL, V81, P217, DOI 10.1046/j.1440-1711.2003.01161.x; MASON RA, 1973, APPL MICROBIOL, V25, P539, DOI 10.1128/AEM.25.4.539-544.1973; Mehlhop E, 2007, CELL HOST MICROBE, V2, P417, DOI 10.1016/j.chom.2007.09.015; Monath TP, 2002, VACCINE, V20, P1004, DOI 10.1016/S0264-410X(01)00457-1; Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887; Mongkolsapaya J, 2006, J IMMUNOL, V176, P3821, DOI 10.4049/jimmunol.176.6.3821; Murphy BR, 2011, ANNU REV IMMUNOL, V29, P587, DOI 10.1146/annurev-immunol-031210-101315; Nguyen TPD, 2010, J IMMUNOL, V184, P7281, DOI 10.4049/jimmunol.0903262; Pierson Theodore C., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000665; Rivino L, 2016, EXPERT REV VACCINES, V15, P443, DOI 10.1586/14760584.2016.1116948; Rivino L, 2013, J VIROL, V87, P2693, DOI 10.1128/JVI.02675-12; Russell PK, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004854; Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7; Slifka MK, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00195; Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820; Valdes I, 2016, ARCH VIROL, V161, P465, DOI 10.1007/s00705-015-2681-y; Vannice KS, 2018, VACCINE, V36, P3411, DOI 10.1016/j.vaccine.2018.02.062; Watson AM, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005786; Weiskopf D, 2016, J INFECT DIS, V214, P1117, DOI 10.1093/infdis/jiw309; Weiskopf D, 2015, J VIROL, V89, P120, DOI 10.1128/JVI.02129-14; Weiskopf D, 2014, J VIROL, V88, P11383, DOI 10.1128/JVI.01108-14; Weiskopf D, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00093; Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110; Wilder-Smith A, 2019, LANCET, V393, P350, DOI 10.1016/S0140-6736(18)32560-1; Yachi PP, 2006, IMMUNITY, V25, P203, DOI 10.1016/j.immuni.2006.05.015; Yauch LE, 2010, J IMMUNOL, V185, P5405, DOI 10.4049/jimmunol.1001709; Yauch LE, 2009, J IMMUNOL, V182, P4865, DOI 10.4049/jimmunol.0801974; Zellweger RM, 2015, J VIROL, V89, P6494, DOI 10.1128/JVI.00036-15; Zellweger RM, 2014, J IMMUNOL, V193, P4117, DOI 10.4049/jimmunol.1401597; Zellweger RM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003723; Zellweger RM, 2010, CELL HOST MICROBE, V7, P128, DOI 10.1016/j.chom.2010.01.004	62	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 16	2019	10								2946	10.3389/fimmu.2019.02946	http://dx.doi.org/10.3389/fimmu.2019.02946			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JZ3NF	31921194	gold, Green Published			2022-12-18	WOS:000505007900001
J	Smith, AM; Buss, F; Munitic, I				Smith, Andrew M.; Buss, Folma; Munitic, Ivana			Editorial: The Role of Optineurin in Immunity and Immune-Mediated Diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						optineurin; innate immunity; inflammation; autophagy; vesicle trafficking	KAPPA-B ACTIVATION; SALMONELLA; EXPRESSION; PROTEIN; NEMO		[Smith, Andrew M.] UCL, Eastman Dent Inst, Microbial Dis, London, England; [Buss, Folma] Univ Cambridge, Cambridge Inst Med Res, Cambridge, England; [Munitic, Ivana] Univ Rijeka, Dept Biotechnol, Lab Mol Immunol, Rijeka, Croatia	University of London; University College London; University of Cambridge; University of Rijeka	Munitic, I (corresponding author), Univ Rijeka, Dept Biotechnol, Lab Mol Immunol, Rijeka, Croatia.	ivana.munitic@biotech.uniri.hr	Munitic, Ivana/S-3197-2018	Munitic, Ivana/0000-0002-5171-9950; Smith, Andrew/0000-0002-4691-5973; Buss, Folma/0000-0003-4457-3479	Medical Research Council [MR/K000888/1, MR/N000048/1, MR/L000261/1]; BBSRC [BB/R001316/1]; Croatian Science Foundation [IP-2018-01-8563]; University of Rijeka [18-211-1369]; MRC [MR/S007776/1, MR/N000048/1] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Croatian Science Foundation; University of Rijeka; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	AS thanks the Medical Research Council (MR/L000261/1) for financial support. FB thanks the Medical Research Council (MR/K000888/1 and MR/N000048/1) and the BBSRC (BB/R001316/1). IM thanks the Croatian Science Foundation (IP-2018-01-8563) and the support of the University of Rijeka (18-211-1369).	Albagha OME, 2010, NAT GENET, V42, P520, DOI 10.1038/ng.562; Gleason CE, 2011, J BIOL CHEM, V286, P35663, DOI 10.1074/jbc.M111.267567; Li YG, 1998, MOL CELL BIOL, V18, P1601, DOI 10.1128/MCB.18.3.1601; Markovinovic A, 2018, NEUROSCIENCE, V388, P139, DOI 10.1016/j.neuroscience.2018.07.007; Markovinovic A, 2017, PROG NEUROBIOL, V154, P1, DOI 10.1016/j.pneurobio.2017.04.005; Munitic I, 2013, J IMMUNOL, V191, P6231, DOI 10.4049/jimmunol.1301696; Schwamborn K, 2000, J BIOL CHEM, V275, P22780, DOI 10.1074/jbc.M001500200; Segal Anthony W, 2016, F1000Res, V5, P2510, DOI 10.12688/f1000research.9699.1; Slowicka K, 2016, EUR J IMMUNOL, V46, P971, DOI 10.1002/eji.201545863; Smith AM, 2015, IMMUNOLOGY, V144, P45, DOI 10.1111/imm.12338; Tumbarello DA, 2012, NAT CELL BIOL, V14, P1024, DOI 10.1038/ncb2589; Wild P, 2011, SCIENCE, V333, P228, DOI 10.1126/science.1205405; Zhu G, 2007, CURR BIOL, V17, P1438, DOI 10.1016/j.cub.2007.07.041	13	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 11	2019	10								2803	10.3389/fimmu.2019.02803	http://dx.doi.org/10.3389/fimmu.2019.02803			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JY2AB	31921108	Green Published, gold			2022-12-18	WOS:000504222100001
J	Saulle, I; Ibba, SV; Torretta, E; Vittori, C; Fenizia, C; Piancone, F; Minisci, D; Lori, EM; Trabattoni, D; Gelfi, C; Clerici, M; Biasin, M				Saulle, Irma; Ibba, Salome Valentina; Torretta, Enrica; Vittori, Cecilia; Fenizia, Claudio; Piancone, Federica; Minisci, Davide; Lori, Elisa Maria; Trabattoni, Daria; Gelfi, Cecilia; Clerici, Mario; Biasin, Mara			Endoplasmic Reticulum Associated Aminopeptidase 2 (ERAP2) Is Released in the Secretome of Activated MDMs and Reduces in vitro HIV-1 Infection (vol 10, 1648, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						ERAP2; haplotype; HIV-1; MDM; secretion; immune system; CTL; IFN gamma			[Saulle, Irma; Ibba, Salome Valentina; Vittori, Cecilia; Lori, Elisa Maria; Trabattoni, Daria; Biasin, Mara] Univ Milan, Dept Biomed & Clin Sci L Sacco, Milan, Italy; [Torretta, Enrica; Gelfi, Cecilia] Univ Milan, Dept Biomed Sci Hlth, Milan, Italy; [Fenizia, Claudio; Clerici, Mario] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy; [Piancone, Federica; Clerici, Mario] Don C Gnocchi Fdn IRCCS, Milan, Italy; [Minisci, Davide] ASST Fatebenefratelli Sacco, Dept Infect Dis, Milan, Italy; [Gelfi, Cecilia] IRCCS Orthopaed Inst Galeazzi, Milan, Italy	University of Milan; Luigi Sacco Hospital; University of Milan; University of Milan; IRCCS Fondazione Don Carlo Gnocchi Onlus	Saulle, I (corresponding author), Univ Milan, Dept Biomed & Clin Sci L Sacco, Milan, Italy.	irma.saulle@unimi.it	biasin, mara/AAD-1578-2022; torretta, enrica/I-8793-2012; piancone, federica/K-5893-2016	biasin, mara/0000-0003-3671-4235; torretta, enrica/0000-0002-6374-3325; piancone, federica/0000-0001-7951-1169; Saulle, Irma/0000-0002-8600-2503				Saulle I, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01648	1	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 6	2019	10								2838	10.3389/fimmu.2019.02838	http://dx.doi.org/10.3389/fimmu.2019.02838			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JX5XT	31853242	gold, Green Published			2022-12-18	WOS:000503808200001
J	Raman, SC; Mejias-Perez, E; Gomez, CE; Garcia-Arriaza, J; Perdiguero, B; Vijayan, A; Perez-Ruiz, M; Cuervo, A; Santiago, C; Sorzano, COS; Sanchez-Corzo, C; Moog, C; Burger, JA; Schorcht, A; Sanders, RW; Carrascosa, JL; Esteban, M				Raman, Suresh C.; Mejias-Perez, Ernesto; Gomez, Carmen E.; Garcia-Arriaza, Juan; Perdiguero, Beatriz; Vijayan, Aneesh; Perez-Ruiz, Mar; Cuervo, Ana; Santiago, Cesar; Sorzano, Carlos Oscar S.; Sanchez-Corzo, Cristina; Moog, Christiane; Burger, Judith A.; Schorcht, Anna; Sanders, Rogier W.; Carrascosa, Jose L.; Esteban, Mariano			The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1	FRONTIERS IN IMMUNOLOGY			English	Article						VACV 14K protein; MVA-HIV vaccine; CD8 T cells; GC B cells; Tfh cells; SOSIPs; HIV-1 neutralizing antibodies	VACCINIA VIRUS ANKARA; HUMAN MONOCLONAL-ANTIBODIES; N-GLYCAN RECOGNITION; IMMUNE-RESPONSES; TFH CELLS; VIREMIA; ACTIVATION; INFECTION; DOMAIN; IMMUNOGENICITY	There is an urgent need for the development of potent vaccination regimens that are able to induce specific T and B cell responses against human immunodeficiency virus type 1 (HIV-1). Here, we describe the generation and characterization of a fusion antigen comprised of the HIV-1 envelope GP120 glycoprotein from clade C (GP120C) fused at its C-terminus, with the modified vaccinia virus (VACV) 14K protein (A27L gene) (termed GP120C14K). The design is directed toward improving the immunogenicity of the GP120C protein through its oligomerization facilitated by the fused VACV 14K protein that results in hexamer-like structures. Two different immunogens were generated: a recombinant GP120C14K fusion protein (purified from a stable CHO-K1 cell line) and a recombinant modified vaccinia virus Ankara (MVA) poxvirus vector expressing the GP120C14K fusion protein (termed MVA-GP120C14K). The GP120C14K fusion protein is recognized by broadly neutralizing antibodies (bNAbs) against HIV-1. In a murine model, a heterologous prime/boost immunization regimen with MVA-GP120C14K prime followed by adjuvanted GP120C14K protein boost generated stronger and polyfunctional HIV-1 Env-specific CD8 T cell responses when compared with the delivery of the monomeric GP120C form. Furthermore, the immunization protocol MVA-GP120C14K/GP120C14K elicited higher HIV-1 Env-specific T follicular helper cells, germinal center B cells and antibody responses than monomeric GP120. In addition, a similar MVA-GP120C14K prime/GP120C14K protein boost regimen performed in rabbits triggered high HIV-1-Env-specific IgG binding antibody titers that were capable of neutralizing HIV-1 pseudoviruses. The extent of HIV-1 neutralization was comparable to that elicited by the current standard GP140 SOSIP trimers from clades B and C when immunized as MVA-SOSIP prime/SOSIP protein boost regimen. Overall, the novel fusion antigen and the corresponding immunization scheme provided in this report can therefore be considered as potential vaccine strategies against HIV-1.	[Raman, Suresh C.; Mejias-Perez, Ernesto; Gomez, Carmen E.; Garcia-Arriaza, Juan; Perdiguero, Beatriz; Vijayan, Aneesh; Sanchez-Corzo, Cristina; Esteban, Mariano] CSIC, CNB, Dept Mol & Cellular Biol, Madrid, Spain; [Perez-Ruiz, Mar; Cuervo, Ana; Carrascosa, Jose L.] CSIC, CNB, Dept Struct Macromol, Madrid, Spain; [Santiago, Cesar] CSIC, CNB, Xray Crystallizat Unit, Madrid, Spain; [Sorzano, Carlos Oscar S.] CSIC, CNB, Biocomp Unit, Madrid, Spain; [Moog, Christiane] Univ Strasbourg, FMTS, OMICARE, FHU,INSERM U1109, Strasbourg, France; [Burger, Judith A.; Schorcht, Anna; Sanders, Rogier W.] Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Med Microbiol, Amsterdam, Netherlands; [Sanders, Rogier W.] Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA; [Mejias-Perez, Ernesto] LMU, Max von Pettenkofer Inst, Munich, Germany; [Vijayan, Aneesh] Janssen Vaccines & Prevent BV, Leiden, Netherlands	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Amsterdam; Cornell University; University of Munich	Esteban, M (corresponding author), CSIC, CNB, Dept Mol & Cellular Biol, Madrid, Spain.	mesteban@cnb.csic.es	VIJAYAN, ANEESH/K-1961-2014; Gomez, Carmen Elena/K-1940-2014; C, Moog/E-3962-2016; Perdiguero, Beatriz/K-6587-2017; Sorzano, Carlos Oscar S S./F-2639-2016; Esteban, Mariano/ABG-5375-2020; Vijayan, Aneesh/AAH-5640-2019; S. Sorzano, Carlos Oscar/ABE-4884-2021; Santiago, Cesar/K-4240-2014	VIJAYAN, ANEESH/0000-0002-2828-5285; Gomez, Carmen Elena/0000-0002-5414-7935; C, Moog/0000-0002-0916-156X; Perdiguero, Beatriz/0000-0001-6276-7766; Sorzano, Carlos Oscar S S./0000-0002-9473-283X; Esteban, Mariano/0000-0003-0846-2827; Vijayan, Aneesh/0000-0002-2828-5285; S. Sorzano, Carlos Oscar/0000-0002-9473-283X; Perez-Ruiz, Mar/0000-0001-5776-1650; Santiago, Cesar/0000-0002-5149-1722; Mejias Perez, Ernesto/0000-0002-5208-8177; Schorcht, Anna/0000-0003-1548-790X; Cuervo, Ana/0000-0001-9414-503X	EU H2020 EHVA grant [REP-681032-2]; Spanish AIDS Research Network - FEDER [RD16/0025/0014-ISCIII]; Horizon 2020 program of the European Union; La Caixa fellowship;  [SAF2013-45232R];  [SAF-2017-88089R]	EU H2020 EHVA grant; Spanish AIDS Research Network - FEDER; Horizon 2020 program of the European Union; La Caixa fellowship(La Caixa Foundation); ; 	This investigation was supported by Spanish grants SAF2013-45232R and SAF-2017-88089R and, in part, by EU H2020 EHVA grant REP-681032-2. This research was also supported by Spanish AIDS Research Network RD16/0025/0014-ISCIII - FEDER. Structural studies were carried out with the help of iNEXT Structural Audit grant PID: 2023, funded by the Horizon 2020 program of the European Union. SR was supported by a La Caixa fellowship.	Abrishami V, 2013, BIOINFORMATICS, V29, P2460, DOI 10.1093/bioinformatics/btt429; Bannard O, 2017, CURR OPIN IMMUNOL, V45, P21, DOI 10.1016/j.coi.2016.12.004; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Binley JM, 2000, J VIROL, V74, P627, DOI 10.1128/JVI.74.2.627-643.2000; Blattner C, 2014, IMMUNITY, V40, P669, DOI 10.1016/j.immuni.2014.04.008; Boivin S, 2013, PROTEIN EXPRES PURIF, V91, P192, DOI 10.1016/j.pep.2013.08.002; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Capucci S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181886; CARROLL MW, 1995, BIOTECHNIQUES, V19, P352; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; Chang TH, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003563; Claireaux M, 2018, MBIO, V9, DOI 10.1128/mBio.00317-18; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; de la Pena AT, 2017, CELL REP, V20, P1805, DOI 10.1016/j.celrep.2017.07.077; de la Rosa-Trevin JM, 2013, J STRUCT BIOL, V184, P321, DOI 10.1016/j.jsb.2013.09.015; ESTEBAN M, 1984, VIROLOGY, V133, P220, DOI 10.1016/0042-6822(84)90443-4; Garces F, 2014, CELL, V159, P69, DOI 10.1016/j.cell.2014.09.009; Garcia-Arriaza J, 2014, HUM VACC IMMUNOTHER, V10, P2235, DOI 10.4161/hv.28974; Garcia-Arriaza J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012395; Gomez CE, 2013, J VIROL, V87, P7282, DOI 10.1128/JVI.03246-12; Gomez CE, 2007, VACCINE, V25, P2863, DOI 10.1016/j.vaccine.2006.09.090; Gomez CE, 2001, ARCH VIROL, V146, P875, DOI 10.1007/s007050170122; GORNY MK, 1993, J IMMUNOL, V150, P635; GORNY MK, 1991, P NATL ACAD SCI USA, V88, P3238, DOI 10.1073/pnas.88.8.3238; Havenar-Daughton C, 2017, IMMUNOL REV, V275, P49, DOI 10.1111/imr.12512; Havenar-Daughton C, 2016, J IMMUNOL, V197, P994, DOI 10.4049/jimmunol.1600320; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; JOKLIK WK, 1962, VIROLOGY, V18, P9, DOI 10.1016/0042-6822(62)90172-1; Julien JP, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003342; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Lee JH, 2017, IMMUNITY, V46, P690, DOI 10.1016/j.immuni.2017.03.017; Li YX, 2011, J VIROL, V85, P8954, DOI 10.1128/JVI.00754-11; Locci M, 2013, IMMUNITY, V39, P758, DOI 10.1016/j.immuni.2013.08.031; Malyala P, 2008, J PHARM SCI-US, V97, P2041, DOI 10.1002/jps.21152; McLellan JS, 2011, NATURE, V480, P336, DOI 10.1038/nature10696; Mesin L, 2016, IMMUNITY, V45, P471, DOI 10.1016/j.immuni.2016.09.001; Mouquet H, 2012, P NATL ACAD SCI USA, V109, pE3268, DOI 10.1073/pnas.1217207109; Moysi E, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0437-y; Pancera M, 2013, NAT STRUCT MOL BIOL, V20, P804, DOI 10.1038/nsmb.2600; Papa I, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01858; Perdiguero B, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020160; Ramirez JC, 2000, J VIROL, V74, P7651, DOI 10.1128/JVI.74.16.7651-7655.2000; Ramirez JC, 2000, J VIROL, V74, P923, DOI 10.1128/JVI.74.2.923-933.2000; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; RODRIGUEZ JF, 1985, J VIROL, V56, P482, DOI 10.1128/JVI.56.2.482-488.1985; Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104; Sanders RW, 2015, SCIENCE, V349, DOI 10.1126/science.aac4223; Sanders RW, 2017, IMMUNOL REV, V275, P161, DOI 10.1111/imr.12481; Scheres SHW, 2008, NAT PROTOC, V3, P977, DOI 10.1038/nprot.2008.62; Scheres SHW, 2012, J STRUCT BIOL, V180, P519, DOI 10.1016/j.jsb.2012.09.006; Scheres SHW, 2012, J MOL BIOL, V415, P406, DOI 10.1016/j.jmb.2011.11.010; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Stark H, 2010, METHOD ENZYMOL, V481, P109, DOI 10.1016/S0076-6879(10)81005-5; Suan D, 2017, CURR OPIN IMMUNOL, V45, P97, DOI 10.1016/j.coi.2017.03.006; van Dijk JAPP, 2000, J CHROMATOGR A, V867, P105, DOI 10.1016/S0021-9673(99)01161-9; van Gils MJ, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2016.199; Vargas J, 2014, BIOINFORMATICS, V30, P2891, DOI 10.1093/bioinformatics/btu404; Vijayan A, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00494-16, 10.1128/cvi.00494-16]; Vijayan A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133595; Vijayan A, 2012, J IMMUNOL, V188, P6407, DOI 10.4049/jimmunol.1102492; Wild J, 2009, VIRAL IMMUNOL, V22, P309, DOI 10.1089/vim.2009.0038; Yamamoto T, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3964	62	0	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 4	2019	10								2793	10.3389/fimmu.2019.02793	http://dx.doi.org/10.3389/fimmu.2019.02793			22	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JW8BO	31867001	Green Published, gold			2022-12-18	WOS:000503272300001
J	Crispin, JC; Morel, L				Crispin, Jose C.; Morel, Laurence			Editorial: Mechanisms by Which SLE-Associated Genetic Variants Contribute to SLE Pathogenesis	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						lupus (SLE); SNP; genetic variant; pathogenesis; autoimmunity			[Crispin, Jose C.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Immunol & Rheumatol, Mexico City, DF, Mexico; [Crispin, Jose C.] Escuela Med & Ciencias Salud, Tecnol Monterrey, Mexico City, DF, Mexico; [Morel, Laurence] Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL 32611 USA	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Tecnologico de Monterrey; State University System of Florida; University of Florida	Crispin, JC (corresponding author), Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Immunol & Rheumatol, Mexico City, DF, Mexico.; Crispin, JC (corresponding author), Escuela Med & Ciencias Salud, Tecnol Monterrey, Mexico City, DF, Mexico.; Morel, L (corresponding author), Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL 32611 USA.	carlos.crispina@incmnsz.mx; morel@ufl.edu		Crispin, Jose/0000-0002-7590-3621	NIH [RO1 AI045050]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	LM supported by a grant from the NIH RO1 AI045050.	Graham DSC, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002341; Juang YT, 2005, J CLIN INVEST, V115, P996, DOI 10.1172/JCI200522854; Maeda K, 2018, J CLIN INVEST, V128, P3445, DOI 10.1172/JCI99507; Manson JJ, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-6; Morel L, 2000, P NATL ACAD SCI USA, V97, P6670, DOI 10.1073/pnas.97.12.6670; Morel L, 2001, P NATL ACAD SCI USA, V98, P1787, DOI 10.1073/pnas.031336098; Rosetti F, 2019, CURR OPIN RHEUMATOL, V31, P185, DOI 10.1097/BOR.0000000000000572	7	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 3	2019	10								2808	10.3389/fimmu.2019.02808	http://dx.doi.org/10.3389/fimmu.2019.02808			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JW4QP	31849982	Green Published, gold			2022-12-18	WOS:000503038200001
J	Buckley, PR; Alden, K; Coccia, M; Chalon, A; Collignon, C; Temmerman, ST				Buckley, P. R.; Alden, K.; Coccia, M.; Chalon, A.; Collignon, C.; Temmerman, S. T.		Frontiers Prod Off	Application of Modeling Approaches to Explore Vaccine Adjuvant Mode-of-Action (vol 10, 2150, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						vaccines; adjuvants; mathematical modeling; computational biology; systems biology; mechanistic modeling; AS01			[Buckley, P. R.] Frontiers Media SA, Lausanne, Switzerland		Buckley, PR (corresponding author), Frontiers Media SA, Lausanne, Switzerland.							Buckley PR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02150	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 2	2019	10								2905	10.3389/fimmu.2019.02905	http://dx.doi.org/10.3389/fimmu.2019.02905			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JX9TB		Green Published, gold			2022-12-18	WOS:000504068400001
J	D'Antoni, ML; Kallianpur, KJ; Premeaux, TA; Corley, MJ; Fujita, T; Laws, EI; Ogata-Arakaki, D; Chow, DC; Khadka, VS; Shikuma, CM; Ndhlovu, LC				D'Antoni, Michelle L.; Kallianpur, Kalpana J.; Premeaux, Thomas A.; Corley, Michael J.; Fujita, Tsuyoshi; Laws, Elizabeth, I; Ogata-Arakaki, Debra; Chow, Dominic C.; Khadka, Vedbar S.; Shikuma, Cecilia M.; Ndhlovu, Lishomwa C.			Lower Interferon Regulatory Factor-8 Expression in Peripheral Myeloid Cells Tracks With Adverse Central Nervous System Outcomes in Treated HIV Infection	FRONTIERS IN IMMUNOLOGY			English	Article						HIV-1; IRF-8; interferon; monocytes; dendritic cells; cognition; central nervous system; anti-retroviral therapy	SEQUENCE-BINDING-PROTEIN; SURFACE-BASED ANALYSIS; TRANSCRIPTION FACTOR; NEUROCOGNITIVE IMPAIRMENT; DENDRITIC CELLS; MACROPHAGES; ACTIVATION; DISEASE; CNS; SEGMENTATION	Cognitive dysfunction persists in 30-50% of chronically HIV-infected individuals despite combination antiretroviral therapy (ART). Although monocytes are implicated in poor cognitive performance, distinct biological mechanisms associated with cognitive dysfunction in HIV infection are unclear. We previously showed that a regulatory region of the interferon regulatory factor-8 (IRF8) gene is hyper-methylated in HIV-infected individuals with cognitive impairment compared to those with normal cognition. Here, we investigated IRF-8 protein expression and assessed relationships with multiple parameters associated with brain health. Intracellular IRF-8 expression was measured in cryopreserved peripheral blood mononuclear cells from chronically HIV-infected individuals on ART using flow cytometry. Neuropsychological performance was assessed by generating domain-specific standardized (NPZ) scores, with a global score defined by aggregating individual domain scores. Regional brain volumes were obtained by magnetic resonance imaging and soluble inflammatory factors were assessed by immunosorbent assays. Non-parametric analyses were conducted and statistical significance was defined as p < 0.05. Twenty aviremic (HIV RNA<50 copies/ml) participants, 84% male, median age 51 [interquartile range (IQR) 46, 55], median CD4 count 548 [439, 700] were evaluated. IRF-8 expression was highest in plasmacytoid dendritic cells (pDCs). Assessing cognitive function, lower IRF-8 density in classical monocytes significantly correlated with worse NPZ_learning memory (LM; rho = 0.556) and NPZ_working memory (WM; rho = 0.612) scores, in intermediate monocytes with worse NPZ_LM (rho = 0.532) scores, and in non-classical monocytes, lower IRF-8 correlated with worse global NPZ (rho = 0.646), NPZ_LM (rho = 0.536), NPZ_WM (rho = 0.647), and NPZ_executive function (rho = 0.605) scores. In myeloid DCs (mDCs) lower IRF-8 correlated with worse NPZ_WM (rho = 0.48) scores and in pDCs with worse NPZ_WM (rho = 0.561) scores. Declines in IRF-8 in classical monocytes significantly correlated with smaller hippocampal volume (rho = 0.573) and in intermediate and non-classical monocytes with smaller cerebral white matter volume (rho = 0.509 and rho = 0.473, respectively). IRF-8 density in DCs did not significantly correlate with brain volumes. Among biomarkers tested, higher soluble ICAM-1 levels significantly correlated with higher IRF-8 in all monocyte and DC subsets. These data may implicate IRF-8 as a novel transcription factor in the neuropathophysiology of brain abnormalities in treated HIV and serve as a potential therapeutic target to decrease the burden of cognitive dysfunction in this population.	[D'Antoni, Michelle L.; Kallianpur, Kalpana J.; Premeaux, Thomas A.; Fujita, Tsuyoshi; Laws, Elizabeth, I; Ndhlovu, Lishomwa C.] Univ Hawaii, Dept Trop Med, Honolulu, HI 96822 USA; [D'Antoni, Michelle L.; Kallianpur, Kalpana J.; Ogata-Arakaki, Debra; Chow, Dominic C.; Shikuma, Cecilia M.; Ndhlovu, Lishomwa C.] Univ Hawaii, Hawaii Ctr AIDS, Honolulu, HI 96822 USA; [Corley, Michael J.] Univ Hawaii, Dept Nat Hawaiian Hlth, Honolulu, HI 96822 USA; [Khadka, Vedbar S.] Univ Hawaii, John A Burns Sch Med, Off Biostat & Quantitat Hlth Sci, Honolulu, HI 96822 USA	University of Hawaii System; University of Hawaii System; University of Hawaii System; University of Hawaii System	Ndhlovu, LC (corresponding author), Univ Hawaii, Dept Trop Med, Honolulu, HI 96822 USA.; Ndhlovu, LC (corresponding author), Univ Hawaii, Hawaii Ctr AIDS, Honolulu, HI 96822 USA.	lndhlovu@hawaii.edu	n, l/AAX-3992-2020	Chow, Dominic/0000-0001-7395-038X	University of Washington/Fred Hutch Center for AIDS Research, an NIH [AI027757]; NIAID; NCI; NIMH; NIDA; NICHD; NHLBI; NIA; NIGMS; NIDDK; National Institute of Mental Health [R01MH104141]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K01HL140271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM113134] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [U54MD007584, U54MD007601] Funding Source: NIH RePORTER	University of Washington/Fred Hutch Center for AIDS Research, an NIH; NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	This work was funded in part by a 2018 New Investigator award (to MD'A) from the University of Washington/Fred Hutch Center for AIDS Research, an NIH funded program under award number AI027757 which was supported by the following NIH Institutes and Centers: NIAID, NCI, NIMH, NIDA, NICHD, NHLBI, NIA, NIGMS, NIDDK. LN receives support from the National Institute of Mental Health (award R01MH104141).	Anthony IC, 2005, J NEUROPATH EXP NEUR, V64, P529, DOI 10.1093/jnen/64.6.529; Antinori A, 2007, NEUROLOGY, V69, P1789, DOI 10.1212/01.WNL.0000287431.88658.8b; Apostolova LG, 2006, ARCH NEUROL-CHICAGO, V63, P693, DOI 10.1001/archneur.63.5.693; Becker AM, 2012, BLOOD, V119, P2003, DOI 10.1182/blood-2011-06-364976; Brickman AM, 2006, BIOL PSYCHIAT, V60, P444, DOI 10.1016/j.biopsych.2006.01.011; Buckner RL, 2004, NEUROIMAGE, V23, P724, DOI 10.1016/j.neuroimage.2004.06.018; Burdo TH, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000842; Cassol E, 2013, J NEUROIMMUNE PHARM, V8, P1087, DOI 10.1007/s11481-013-9512-2; Corley MJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep33310; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DIEZRUIZ A, 1993, INT ARCH ALLERGY IMM, V102, P56, DOI 10.1159/000236550; Ellis RJ, 1997, ARCH NEUROL-CHICAGO, V54, P416, DOI 10.1001/archneur.1997.00550160054016; Eming SA, 2017, SCIENCE, V356, P1026, DOI 10.1126/science.aam7928; Fastenau PS, 1999, CLIN NEUROPSYCHOL, V13, P30, DOI 10.1076/clin.13.1.30.1976; Fields RD, 2010, SCIENCE, V330, P768, DOI 10.1126/science.1199139; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Gadani SP, 2015, NEURON, V85, P703, DOI 10.1016/j.neuron.2015.01.013; Gartner S, 2000, SCIENCE, V287, P602, DOI 10.1126/science.287.5453.602; Giese NA, 1997, J EXP MED, V186, P1535, DOI 10.1084/jem.186.9.1535; Goldmann T, 2016, NAT IMMUNOL, V17, P797, DOI 10.1038/ni.3423; Gongvatana A, 2014, J NEUROIMMUNE PHARM, V9, P740, DOI 10.1007/s11481-014-9567-8; Gonzalez-Scarano F, 2005, NAT REV IMMUNOL, V5, P69, DOI 10.1038/nri1527; Guo YY, 2017, INFLAMMATION, V40, P68, DOI 10.1007/s10753-016-0454-8; Gupta M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7379; Hambleton S, 2011, NEW ENGL J MED, V365, P127, DOI 10.1056/NEJMoa1100066; Heaton RK, 2010, NEUROLOGY, V75, P2087, DOI 10.1212/WNL.0b013e318200d727; Heaton RK, 2004, J INT NEUROPSYCH SOC, V10, P317, DOI 10.1017/S1355617704102130; Henault J, 2012, IMMUNITY, V37, P986, DOI 10.1016/j.immuni.2012.09.014; Henderson APD, 2009, ANN NEUROL, V66, P739, DOI 10.1002/ana.21800; Herz J, 2017, IMMUNITY, V46, P943, DOI 10.1016/j.immuni.2017.06.007; Ickovics JR, 2001, JAMA-J AM MED ASSOC, V285, P1466, DOI 10.1001/jama.285.11.1466; Ikushima H, 2013, COLD SH Q B, V78, P105, DOI 10.1101/sqb.2013.78.020321; Jensen SS, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-37; Karki R, 2018, CELL, V173, P920, DOI 10.1016/j.cell.2018.02.055; Kusao I, 2012, J NEUROPSYCH CLIN N, V24, P71, DOI 10.1176/appi.neuropsych.11050109; Li HG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034566; Lin Q, 2015, NUCLEIC ACIDS RES, V43, P9680, DOI 10.1093/nar/gkv1056; Maxwell JR, 2015, IMMUNITY, V43, P739, DOI 10.1016/j.immuni.2015.08.019; Mortimer JA, 2004, NEUROLOGY, V62, P428, DOI 10.1212/01.WNL.0000106463.66966.65; Munier S, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-73; Olafsdottir HF, 2018, CURR BIOL, V28, pR37, DOI 10.1016/j.cub.2017.10.073; Oriss TB, 2014, J IMMUNOL, V192, P5471, DOI 10.4049/jimmunol.1303183; Pohlack ST, 2014, BRAIN STRUCT FUNCT, V219, P255, DOI 10.1007/s00429-012-0497-z; Prinz M, 2017, NAT NEUROSCI, V20, P136, DOI 10.1038/nn.4475; Qiu YG, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01249-7; Robert K, 1991, COMPREHENSIVE NORMS; Savitsky D, 2010, CANCER IMMUNOL IMMUN, V59, P489, DOI 10.1007/s00262-009-0804-6; Scheller M, 1999, BLOOD, V94, P3764, DOI 10.1182/blood.V94.11.3764.423k03_3764_3771; Schiavoni G, 2002, J EXP MED, V196, P1415, DOI 10.1084/jem.20021263; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Sevigny JJ, 2004, NEUROLOGY, V63, P2084, DOI 10.1212/01.WNL.0000145763.68284.15; Sgarbanti M, 2002, J EXP MED, V195, P1359, DOI 10.1084/jem.20010753; Shapshak P, 2011, AIDS, V25, P123, DOI 10.1097/QAD.0b013e328340fd42; Shechter R, 2013, IMMUNITY, V38, P555, DOI 10.1016/j.immuni.2013.02.012; Shikuma CM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090330; Shikuma CM, 2012, AIDS RES HUM RETROV, V28, P793, DOI [10.1089/aid.2011.0086, 10.1089/AID.2011.0086]; Sichien D, 2016, IMMUNITY, V45, P626, DOI 10.1016/j.immuni.2016.08.013; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Tamura T, 2005, J IMMUNOL, V174, P2573, DOI 10.4049/jimmunol.174.5.2573; Tamura T, 2002, J INTERF CYTOK RES, V22, P145, DOI 10.1089/107999002753452755; Thames AD, 2015, AIDS, V29, P1483, DOI 10.1097/QAD.0000000000000706; Tozzi V, 2009, JAIDS-J ACQ IMM DEF, V52, P56, DOI 10.1097/QAI.0b013e3181af83d6; Tsujimura H, 2004, J IMMUNOL, V172, P6820, DOI 10.4049/jimmunol.172.11.6820; Twum DYF, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.124267; Valcour VG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070164; Wang IM, 2000, J IMMUNOL, V165, P271, DOI 10.4049/jimmunol.165.1.271; Wang Y, 2016, ONCOL REP, V36, P3522, DOI 10.3892/or.2016.5171; Wechsler D, 2012, WAIS 4 WECHSLER ADUL; Yuan L, 2017, AGING DIS, V8, P250, DOI 10.14336/AD.2016.0918; Zeng QG, 2017, J MOL NEUROSCI, V63, P159, DOI 10.1007/s12031-017-0966-1; Zhou JX, 2009, J IMMUNOL, V183, P3188, DOI 10.4049/jimmunol.0803693; Zhou MY, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/4273108	74	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 29	2019	10								2789	10.3389/fimmu.2019.02789	http://dx.doi.org/10.3389/fimmu.2019.02789			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JW0VI	31849969	gold, Green Published			2022-12-18	WOS:000502777400001
J	Tripp, RA; Bakre, A; Stambas, J				Tripp, Ralph A.; Bakre, Abhijeet; Stambas, John			Editorial: Understanding the Limitations of Current Influenza Vaccine Strategies and Future Development of More Efficacious Preventative and Therapeutic Interventions	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						influenza virus; vaccine; efficacy; therapeutics; prevention			[Tripp, Ralph A.; Bakre, Abhijeet] Univ Georgia, Anim Hlth Res Ctr, Dept Infect Dis, Athens, GA 30602 USA; [Stambas, John] Deakin Univ, Sch Med, Geelong, Vic, Australia	University System of Georgia; University of Georgia; Deakin University	Tripp, RA (corresponding author), Univ Georgia, Anim Hlth Res Ctr, Dept Infect Dis, Athens, GA 30602 USA.	ratripp@uga.edu	Bakre, Abhijeet A./A-4632-2013	Bakre, Abhijeet A./0000-0002-6755-5233					0	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 29	2019	10								2804	10.3389/fimmu.2019.02804	http://dx.doi.org/10.3389/fimmu.2019.02804			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JW0WR	31849978	Green Published, gold			2022-12-18	WOS:000502780900001
J	Pinheiro, AJMCR; Mendes, ARS; Neves, MDFD; Prado, CM; Bittencourt-Mernak, MI; Santana, FPR; Lago, JHG; de Sa, JC; da Rocha, CQ; de Sousa, EM; Fontes, VC; Grisoto, MAG; Falcai, A; Lima-Neto, LG				Pinheiro, Aruana Joaquim Matheus Costa Rodrigues; Mendes, Aleff Ricardo Santos; Neves, Milena Dara Farias de Jesus; Prado, Carla Maximo; Bittencourt-Mernak, Marcia Isabel; Santana, Fernanda Paula Roncon; Lago, Joao Henrique G.; de Sa, Joicy Cortez; da Rocha, Claudia Quintino; de Sousa, Eduardo Martins; Fontes, Valeria Costa; Grisoto, Marco Augusto Gregolin; Falcai, Angela; Lima-Neto, Lidio Goncalves			Galloyl-Hexahydroxydiphenoyl (HHDP)-Glucose Isolated From Punica granatum L. Leaves Protects Against Lipopolysaccharide (LPS)-Induced Acute Lung Injury in BALB/c Mice (vol 10, 1978, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						pomegranate; galloyl-HHDP-glucose; acute lung injury; anti-inflammatory effects; cytokines; leukocytes			[Pinheiro, Aruana Joaquim Matheus Costa Rodrigues; Mendes, Aleff Ricardo Santos; Neves, Milena Dara Farias de Jesus; de Sousa, Eduardo Martins; Fontes, Valeria Costa; Grisoto, Marco Augusto Gregolin; Lima-Neto, Lidio Goncalves] Univ Ceuma, Programa Posgrad, Sao Luis, Maranhao, Brazil; [Pinheiro, Aruana Joaquim Matheus Costa Rodrigues; de Sousa, Eduardo Martins; Lima-Neto, Lidio Goncalves] Univ Estadual Maranhao, Programa Posgrad Rede BIONORTE, Sao Luis, Maranhao, Brazil; [Prado, Carla Maximo; Bittencourt-Mernak, Marcia Isabel; Santana, Fernanda Paula Roncon] Univ Fed Sao Paulo, Dept Biosci, Santos, SP, Brazil; [Prado, Carla Maximo; Bittencourt-Mernak, Marcia Isabel; Santana, Fernanda Paula Roncon] Univ Sao Paulo, Sch Med, Dept Med, Sao Paulo, SP, Brazil; [Lago, Joao Henrique G.] Univ Fed ABC, Ctr Ciencias Nat & Humanas, Santo Andre, SP, Brazil; [de Sa, Joicy Cortez; Lima-Neto, Lidio Goncalves] Univ Ceuma, Dept Curso Med, Sao Luis, Maranhao, Brazil; [da Rocha, Claudia Quintino] Univ Fed Maranhao, Dept Quim, Sao Luis, Maranhao, Brazil; [Falcai, Angela] Univ Ceuma, Programa Posgrad, Mestrado Meio Ambiente, Sao Luis, Maranhao, Brazil	Universidade Ceuma; Universidade Estadual do Maranhao; Universidade Federal de Sao Paulo (UNIFESP); Universidade de Sao Paulo; Universidade Federal do ABC (UFABC); Universidade Ceuma; Universidade Federal do Maranhao; Universidade Ceuma	Lima-Neto, LG (corresponding author), Univ Ceuma, Programa Posgrad, Sao Luis, Maranhao, Brazil.; Lima-Neto, LG (corresponding author), Univ Estadual Maranhao, Programa Posgrad Rede BIONORTE, Sao Luis, Maranhao, Brazil.; Lima-Neto, LG (corresponding author), Univ Ceuma, Dept Curso Med, Sao Luis, Maranhao, Brazil.	lidio.neto@ceuma.br	Prado, Carla M/G-3327-2012; Pinheiro, Aruana/GPF-9255-2022; da Rocha, Claudia Quintino/U-8013-2019; de Sousa, Eduardo Martins/AAT-9294-2020; Falcai, Angela/E-2082-2016	Prado, Carla M/0000-0003-1160-0442; da Rocha, Claudia Quintino/0000-0002-3578-1869; de Sousa, Eduardo Martins/0000-0002-2506-169X; Lima Neto, Lidio/0000-0001-7696-0882; Falcai, Angela/0000-0002-6036-7504				Pinheiro AJMCR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01978	1	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 27	2019	10								2727	10.3389/fimmu.2019.02727	http://dx.doi.org/10.3389/fimmu.2019.02727			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JV1HP	31819743	Green Published, gold			2022-12-18	WOS:000502118700001
J	Trottein, F; Alcorn, JF				Trottein, Francois; Alcorn, John F.			Editorial: Secondary Respiratory Infections in the Context of Acute and Chronic Pulmonary Diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						respiratory viruses; influenza; COPD; cystic fibrosis; sepsis; pneumonia; innate immune response; immunotherapy			[Trottein, Francois] Univ Lille, CHU Lille, Inst Pasteur Lille, Ctr Infect & Immunite Lille,CNRS,INSERM,U1019,UMR, Lille, France; [Alcorn, John F.] UPMC Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; CHU Lille; Universite de Lille; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Trottein, F (corresponding author), Univ Lille, CHU Lille, Inst Pasteur Lille, Ctr Infect & Immunite Lille,CNRS,INSERM,U1019,UMR, Lille, France.	francois.trottein@pasteur-lille.fr			NHLBI NIH HHS [R01 HL107380] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL107380] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))			0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 27	2019	10								2764	10.3389/fimmu.2019.02764	http://dx.doi.org/10.3389/fimmu.2019.02764			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JV1HB	31827474	gold, Green Published			2022-12-18	WOS:000502117200001
J	Silva, SL; Fonseca, M; Pereira, MLM; Silva, SP; Barbosa, RR; Serra-Caetano, A; Blanco, E; Rosmaninho, P; Perez-Andres, M; Sousa, AB; Raposo, AASF; Gama-Carvalho, M; Victorino, RM; Hammarstrom, L; de Sousa, AE				Silva, Susana L.; Fonseca, Mariana; Pereira, Marcelo L. M.; Silva, Sara P.; Barbosa, Rita R.; Serra-Caetano, Ana; Blanco, Elena; Rosmaninho, Pedro; Perez-Andres, Martin; Sousa, Ana Berta; Raposo, Alexandre A. S. F.; Gama-Carvalho, Margarida; Victorino, Rui M.; Hammarstrom, Lennart; de Sousa, Ana E.			Monozygotic Twins Concordant for Common Variable Immunodeficiency: Strikingly Similar Clinical and Immune Profile Associated With a Polygenic Burden	FRONTIERS IN IMMUNOLOGY			English	Article						CVID; flow-cytometry; polygenic disease; genetics; WES; monozygotic twins	ICAM-1 GENE; DISEASE; CD45; ACTIVATION; SYSTEM; SUSCEPTIBILITY; DEFICIENCY; SUBGROUPS; DIAGNOSIS; PATHWAYS	Monozygotic twins provide a unique opportunity to better understand complex genetic diseases and the relative contribution of heritable factors in shaping the immune system throughout life. Common Variable Immunodeficiency Disorders (CVID) are primary antibody defects displaying wide phenotypic and genetic heterogeneity, with monogenic transmission accounting for only a minority of the cases. Here, we report a pair of monozygotic twins concordant for CVID without a family history of primary immunodeficiency. They featured a remarkably similar profile of clinical manifestations and immunological alterations at diagnosis (established at age 37) and along the subsequent 15 years of follow-up. Interestingly, whole-exome sequencing failed to identify a monogenic cause for CVID, but unraveled a combination of heterozygous variants, with a predicted deleterious impact. These variants were found in genes involved in relevant immunological pathways, such as JUN, PTPRC, TLR1, ICAM1, and JAK3. The potential for combinatorial effects translating into the observed disease phenotype is inferred from their roles in immune pathways, namely in T and B cell activation. The combination of these genetic variants is also likely to impose a significant constraint on environmental influences, resulting in a similar immunological phenotype in both twins, despite exposure to different living conditions. Overall, these cases stress the importance of integrating NGS data with clinical and immunological phenotypes at the single-cell level, as provided by multi-dimensional flow-cytometry, in order to understand the complex genetic landscape underlying the vast majority of patients with CVID, as well as those with other immunodeficiencies.	[Silva, Susana L.; Fonseca, Mariana; Silva, Sara P.; Barbosa, Rita R.; Serra-Caetano, Ana; Rosmaninho, Pedro; Sousa, Ana Berta; Raposo, Alexandre A. S. F.; Victorino, Rui M.; de Sousa, Ana E.] Univ Lisbon, Inst Med Mol Joao Lobo Antunes, Fac Med, Lisbon, Portugal; [Silva, Susana L.; Fonseca, Mariana; Silva, Sara P.; Serra-Caetano, Ana; Rosmaninho, Pedro; Sousa, Ana Berta; Raposo, Alexandre A. S. F.; Victorino, Rui M.; de Sousa, Ana E.] Ctr Hosp Univ Lisboa Norte, Ctr Acad Med Lisboa, Ctr Imunodeficiencias Primarias, Lisbon, Portugal; [Silva, Susana L.; Fonseca, Mariana; Silva, Sara P.; Serra-Caetano, Ana; Rosmaninho, Pedro; Sousa, Ana Berta; Raposo, Alexandre A. S. F.; Victorino, Rui M.; de Sousa, Ana E.] Univ Lisbon, Fac Med, Lisbon, Portugal; [Silva, Susana L.; Fonseca, Mariana; Silva, Sara P.; Serra-Caetano, Ana; Rosmaninho, Pedro; Sousa, Ana Berta; Raposo, Alexandre A. S. F.; Victorino, Rui M.; de Sousa, Ana E.] Inst Med Mol, Lisbon, Portugal; [Silva, Susana L.; Silva, Sara P.; Sousa, Ana Berta; Victorino, Rui M.] Ctr Hosp Univ Lisboa Norte, Hosp Santa Maria, Lisbon, Portugal; [Pereira, Marcelo L. M.; Gama-Carvalho, Margarida] Univ Lisbon, Fac Sci, BioISI Biosyst & Integrat Sci Inst, Lisbon, Portugal; [Blanco, Elena; Perez-Andres, Martin] Univ Salamanca USAL, Inst Biomed Res Salamanca IBSAL, Cytometry Serv NUCLEUS, Dept Med,Canc Res Ctr,IBMCC,USAL CSIC, Salamanca, Spain; [Blanco, Elena; Perez-Andres, Martin] Inst Hlth Carlos III, Biomed Res Networking Ctr Canc CIBER CIBERONC CB1, Madrid, Spain; [Hammarstrom, Lennart] Karolinska Inst, Dept Lab Med, Stockholm, Sweden	Universidade de Lisboa; Universidade de Lisboa; Universidade de Lisboa; Universidade de Lisboa; Hospital Santa Maria; BIOISI; Universidade de Lisboa; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Karolinska Institutet	Silva, SL (corresponding author), Univ Lisbon, Inst Med Mol Joao Lobo Antunes, Fac Med, Lisbon, Portugal.; Silva, SL (corresponding author), Ctr Hosp Univ Lisboa Norte, Ctr Acad Med Lisboa, Ctr Imunodeficiencias Primarias, Lisbon, Portugal.; Silva, SL (corresponding author), Univ Lisbon, Fac Med, Lisbon, Portugal.; Silva, SL (corresponding author), Inst Med Mol, Lisbon, Portugal.; Silva, SL (corresponding author), Ctr Hosp Univ Lisboa Norte, Hosp Santa Maria, Lisbon, Portugal.	susanasilva@medicina.ulisboa.pt	Perez-Andres, Martin/B-3692-2019; Gama-Carvalho, Margarida/E-6180-2012; Silva, Sara/GXM-8709-2022; Carvalho, Margarida/GZA-4406-2022; Pereira, Marcelo/U-9099-2017; Sousa, Ana E./L-2642-2014	Perez-Andres, Martin/0000-0003-4599-0776; Gama-Carvalho, Margarida/0000-0002-0365-6916; Rosmaninho, Pedro/0000-0002-9964-3908; Raposo, Alexandre/0000-0002-2794-0508; Pereira, Marcelo/0000-0002-1424-9275; Sousa, Ana Berta/0000-0001-5889-2492; Blanco Alvarez, Elena/0000-0002-8150-5646; Sousa, Ana E./0000-0002-4618-9799; Caetano, Ana/0000-0002-1626-4364	FEDER through POR Lisboa 2020 - Programa Operacional Regional de Lisboa PORTUGAL 2020; Fundacao para a Ciencia e a Tecnologia; Fundacao para a Ciencia e a Tecnologia (FCT)/Ministerio da Ciencia, Tecnologia e Ensino Superior (MCTES) through Fundos do Orcamento de Estado [UID/BIM/50005/2019]; FCT, Portugal [UID/MULTI/04046/2019]; FCT [PTDC/BIA-CEL/29257/2017];  [PAC - PRECISE - LISBOA-01-0145-FEDER-016394]	FEDER through POR Lisboa 2020 - Programa Operacional Regional de Lisboa PORTUGAL 2020; Fundacao para a Ciencia e a Tecnologia(Portuguese Foundation for Science and TechnologyEuropean Commission); Fundacao para a Ciencia e a Tecnologia (FCT)/Ministerio da Ciencia, Tecnologia e Ensino Superior (MCTES) through Fundos do Orcamento de Estado; FCT, Portugal(Portuguese Foundation for Science and TechnologyEuropean Commission); FCT(Portuguese Foundation for Science and TechnologyEuropean Commission); 	This work received funding from PAC - PRECISE - LISBOA-01-0145-FEDER-016394, co-funded by FEDER through POR Lisboa 2020 - Programa Operacional Regional de Lisboa PORTUGAL 2020 and Fundacao para a Ciencia e a Tecnologia; and UID/BIM/50005/2019, project funded by Fundacao para a Ciencia e a Tecnologia (FCT)/Ministerio da Ciencia, Tecnologia e Ensino Superior (MCTES) through Fundos do Orcamento de Estado. Work in MG-C lab is supported by UID/MULTI/04046/2019 Research Unit grant from FCT, Portugal (to BioISI) and FCT research grant PTDC/BIA-CEL/29257/2017.	Abel M, 2006, HUM IMMUNOL, V67, P612, DOI 10.1016/j.humimm.2006.04.011; Abolhassani H, 2019, GENET MED, V21, P243, DOI 10.1038/s41436-018-0012-x; Abolhassani H, 2014, J ALLERGY CLIN IMMUN, V134, P1375, DOI 10.1016/j.jaci.2014.04.042; Ameratunga R, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00415; Ban SA, 2014, J CLIN IMMUNOL, V34, P941, DOI 10.1007/s10875-014-0088-2; Barbosa RR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022848; Berbers RM, 2017, TRENDS IMMUNOL, V38, P206, DOI 10.1016/j.it.2016.11.008; Blanco E, 2019, J ALLERGY CLIN IMMUN, V144, P809, DOI 10.1016/j.jaci.2019.02.017; Blanco E, 2018, J ALLERGY CLIN IMMUN, V141, P2208, DOI 10.1016/j.jaci.2018.02.017; Bonilla FA, 2016, J ALLER CL IMM-PRACT, V4, P38, DOI 10.1016/j.jaip.2015.07.025; Braun C, 2001, CLIN IMMUNOL, V101, P357, DOI 10.1006/clim.2001.5118; Brodin P, 2017, NAT REV IMMUNOL, V17, P21, DOI 10.1038/nri.2016.125; Brodin P, 2015, CELL, V160, P37, DOI 10.1016/j.cell.2014.12.020; Carr EJ, 2016, NAT IMMUNOL, V17, P461, DOI 10.1038/ni.3371; Conley ME, 2009, ANNU REV IMMUNOL, V27, P199, DOI 10.1146/annurev.immunol.021908.132649; de Valles-Ibanez G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00636; del Pino-Molina L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00878; DePaolo RW, 2012, J EXP MED, V209, P1437, DOI 10.1084/jem.20112339; Do HT, 2006, J IMMUNOL, V176, P931, DOI 10.4049/jimmunol.176.2.931; Driessen GJ, 2011, BLOOD, V118, P6814, DOI 10.1182/blood-2011-06-361881; Eisen DP, 2003, CLIN INFECT DIS, V37, P1496, DOI 10.1086/379324; Fang MY, 2016, J CLIN IMMUNOL, V36, pS68, DOI 10.1007/s10875-016-0260-y; Flores-Montero J, 2017, LEUKEMIA, V31, P2094, DOI 10.1038/leu.2017.29; Foletta VC, 1998, J LEUKOCYTE BIOL, V63, P139, DOI 10.1002/jlb.63.2.139; Gil J, 2005, MED CLIN-BARCELONA, V125, P10, DOI 10.1157/13076408; Gil-Krzewska A, 2016, J ALLERGY CLIN IMMUN, V137, P1165, DOI 10.1016/j.jaci.2015.08.039; Jolles S, 2013, J ALLER CL IMM-PRACT, V1, P545, DOI 10.1016/j.jaip.2013.09.015; Jorgensen SF, 2019, J CLIN IMMUNOL, V39, P30, DOI 10.1007/s10875-018-0574-z; Kalina T, 2012, LEUKEMIA, V26, P1986, DOI 10.1038/leu.2012.122; KAMIN RM, 1968, P NATL ACAD SCI USA, V60, P881, DOI 10.1073/pnas.60.3.881; Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092; Kienzler AK, 2017, CLIN EXP IMMUNOL, V188, P326, DOI 10.1111/cei.12947; Kojima D, 2016, J ALLERGY CLIN IMMUN, V138, P303, DOI 10.1016/j.jaci.2016.01.012; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Lancioni CL, 2011, INFECT IMMUN, V79, P663, DOI 10.1128/IAI.00806-10; Li J, 2016, BBA-GEN SUBJECTS, V1860, P2656, DOI 10.1016/j.bbagen.2016.06.014; Liston A, 2016, TRENDS IMMUNOL, V37, P637, DOI 10.1016/j.it.2016.08.002; Lvovs D, 2012, ACTA NATURAE, V4, P59, DOI 10.32607/20758251-2012-4-3-59-71; Maffucci P, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00220; Nishihara H, 2002, BIOCHEM BIOPH RES CO, V296, P716, DOI 10.1016/S0006-291X(02)00931-2; Ochtrop MLG, 2011, BLOOD, V118, P309, DOI 10.1182/blood-2010-11-321695; Orange JS, 2011, J ALLERGY CLIN IMMUN, V127, P1360, DOI 10.1016/j.jaci.2011.02.039; Picard C, 2018, J CLIN IMMUNOL, V38, P96, DOI 10.1007/s10875-017-0464-9; Rodriguez-Cortez VC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8335; Romano R, 2017, CLIN IMMUNOL, V176, P71, DOI 10.1016/j.clim.2017.01.006; Sanui T, 2003, BLOOD, V102, P2948, DOI 10.1182/blood-2003-01-0173; Sousa AE, 2001, J INFECT DIS, V184, P552, DOI 10.1086/322804; Stray-Pedersen A, 2017, J ALLERGY CLIN IMMUN, V139, P232, DOI 10.1016/j.jaci.2016.05.042; Sunyaev S, 2001, HUM MOL GENET, V10, P591, DOI 10.1093/hmg/10.6.591; Tchilian EZ, 2006, CLIN EXP IMMUNOL, V146, P448, DOI 10.1111/j.1365-2249.2006.03230.x; Tchilian EZ, 2006, TRENDS IMMUNOL, V27, P146, DOI 10.1016/j.it.2006.01.001; van de Ven AAJM, 2011, CRIT REV IMMUNOL, V31, P85, DOI 10.1615/CritRevImmunol.v31.i2.10; van der Burg M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00246; van der Velden VHJ, 2019, J IMMUNOL METHODS, V475, DOI 10.1016/j.jim.2017.03.011; van Schouwenburg PA, 2015, CLIN IMMUNOL, V160, P301, DOI 10.1016/j.clim.2015.05.020; Verma NK, 2017, J IMMUNOL, V199, P1213, DOI 10.4049/jimmunol.1700495; von Spee-Mayer C, 2019, CLIN IMMUNOL, V203, P59, DOI 10.1016/j.clim.2019.04.001; Vorechovsky I, 2001, NAT GENET, V29, P22, DOI 10.1038/ng723; Warnatz K, 2002, BLOOD, V99, P1544, DOI 10.1182/blood.V99.5.1544; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Whitmore LC, 2016, J IMMUNOL, V196, P1376, DOI 10.4049/jimmunol.1500856; Wingren AG, 2017, CRIT REV IMMUNOL, V37, P463, DOI 10.1615/CritRevImmunol.v37.i2-6.130; Wu L, 2015, J MED GENET, V52, P10, DOI 10.1136/jmedgenet-2014-102697; Wu ZP, 2010, J IMMUNOL, V185, P231, DOI 10.4049/jimmunol.0903625; Yazdani R, 2019, J ALLER CL IMM-PRACT, V7, P864, DOI 10.1016/j.jaip.2018.09.004; Zikherman J, 2008, IMMUNITY, V29, P839, DOI 10.1016/j.immuni.2008.12.005	66	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 22	2019	10								2503	10.3389/fimmu.2019.02503	http://dx.doi.org/10.3389/fimmu.2019.02503			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JT8OV	31824477	Green Published, gold			2022-12-18	WOS:000501243800001
J	dos Santos, EJM; Barber, GN; Ishak, R; Vallinoto, ACR				Melo dos Santos, Eduardo Jose; Barber, Glen N.; Ishak, Ricardo; Rosario Vallinoto, Antonio Carlos			Editorial: Immuno-Epigenetic Markers for Infectious Diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						immuno-epigenetic; biomarkers; infectious disease; host; immune response			[Melo dos Santos, Eduardo Jose] Fed Univ Para, Inst Biol Sci, Human & Med Genet Lab, Belem, Para, Brazil; [Barber, Glen N.] Univ Miami, Dept Cell Biol, Miami, FL USA; [Ishak, Ricardo; Rosario Vallinoto, Antonio Carlos] Fed Univ Para, Inst Biol Sci, Virus Lab, Belem, Para, Brazil	Universidade Federal do Para; University of Miami; Universidade Federal do Para	Vallinoto, ACR (corresponding author), Fed Univ Para, Inst Biol Sci, Virus Lab, Belem, Para, Brazil.	vallinoto@ufpa.br	Vallinoto, Antonio Carlos/AAL-9501-2020	Vallinoto, Antonio Carlos/0000-0003-1135-6507					0	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 19	2019	10								2719	10.3389/fimmu.2019.02719	http://dx.doi.org/10.3389/fimmu.2019.02719			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JT5KF	31824503	Green Published, gold			2022-12-18	WOS:000501027900001
J	Gray, PE; McCarthy, H; Siggs, OM; Saleem, MA; O'Brien, T; Frith, K; Ziegler, JB; Kitching, AR; Fogo, AB; Hudson, BG; Pedchenko, V				Gray, Paul E.; McCarthy, Hugh; Siggs, Owen M.; Saleem, Moin A.; O'Brien, Tracy; Frith, Katie; Ziegler, John B.; Kitching, A. Richard; Fogo, Agnes B.; Hudson, Billy G.; Pedchenko, Vadim			Molecular Analysis of Goodpasture's Disease Following Hematopoietic Stem Cell Transplant in a Pediatric Patient, Recalls the Conformeropathy of Wild-Type Anti-GBM Disease	FRONTIERS IN IMMUNOLOGY			English	Article						Goodpastures; glomerular basement membrane; conformeropathy; GvHD; anti-GBM; alloimmunity; autoimmunity	BASEMENT-MEMBRANE; AUTOIMMUNE GLOMERULONEPHRITIS; NONCOLLAGENOUS DOMAIN; COLLAGEN-IV; AUTOANTIBODIES; ALPHA-3(IV)NC1; AUTOANTIGEN; VASCULITIS; EPITOPES; MODEL	Background: Goodpasture's disease (GP) is mediated by autoantibodies that bind the glomerular and alveolar basement membrane, causing rapidly progressive glomerulonephritis with or without pulmonary hemorrhage. The autoantibodies bind neoepitopes formed upon disruption of the quaternary structure of alpha 345NC1 hexamer, a critical structural domain of alpha 345 collagen IV scaffolds. Hexamer disruption leads to a conformational changes that transitions alpha 3 and alpha 5NC1 subunits into immunogens, however, the trigger remains unknown. This contrasts with another anti-GBM disease, Alports' post-transplant nephritis (APTN), where the pathogenic alloantibody binds directly to native NC1 hexamer. The current report includes the first study of antigenic specificity and allo-incompatability in anti-GBM disease occurring after allogeneic haematopoietic stem cell transplant (HSCT). Results: The anti-GBM antibodies were found to be directed predominantly against the E-A epitope of the alpha 3 NC1 monomer of collagen IV and developed rapidly in patient serum reaching peak level within 5 weeks. Autoantibody binding to native alpha 345NC1 hexamer was minimal; however, binding was greatly increased upon dissociation of the native hexamer. There were no polymorphic genetic differences between donor and recipient collagen IV genes which would be predicted to cause a significant NC1 conformational change or to provide a target for antibody binding. Both patient and donor possessed the Goodpasture's susceptibility HLA-allele DRB1*1501. Conclusions: The current report includes the first in-depth study of allo-incompatability and antigenic specificity in anti-GBM disease occurring after allogeneic haematopoietic stem cell transplant (HSCT). No polymorphic genetic differences were identified between donor and recipient collagen IV genes which would be predicted to provide a target for antibody binding. Furthermore, autoantibody binding to native alpha 345NC1 hexamer was minimal, increasing greatly upon dissociation of the native hexamer, resembling wild-type GP diseases and marking this as the first example of a post-HSCT conformeropathy.	[Gray, Paul E.; Frith, Katie; Ziegler, John B.] Sydney Childrens Hosp, Dept Immunol & Infect Dis, Sydney, NSW, Australia; [Gray, Paul E.; O'Brien, Tracy; Ziegler, John B.] Univ New South Wales, Sch Womens & Childrens Hlth, Fac Med, Sydney, NSW, Australia; [McCarthy, Hugh] Sydney Childrens Hosp, Dept Nephrol, Sydney, NSW, Australia; [Siggs, Owen M.] Garvan Inst Med Res, Div Immunol, Darlinghurst, NSW, Australia; [Saleem, Moin A.] Univ Bristol, Bristol Med Sch, Fac Hlth Sci, Bristol, Avon, England; [O'Brien, Tracy] Sydney Childrens Hosp, Kids Canc Ctr, Sydney, NSW, Australia; [Kitching, A. Richard] Monash Univ, Ctr Inflammatory Dis, Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia; [Fogo, Agnes B.] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA; [Fogo, Agnes B.; Hudson, Billy G.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA; [Fogo, Agnes B.; Hudson, Billy G.; Pedchenko, Vadim] Vanderbilt Univ, Med Ctr, Dept Pediat, Div Nephrol, Nashville, TN 37232 USA; [Hudson, Billy G.] Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA	University of Sydney; University of New South Wales Sydney; University of Sydney; Garvan Institute of Medical Research; University of Bristol; University of Sydney; Monash University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Gray, PE (corresponding author), Sydney Childrens Hosp, Dept Immunol & Infect Dis, Sydney, NSW, Australia.; Gray, PE (corresponding author), Univ New South Wales, Sch Womens & Childrens Hlth, Fac Med, Sydney, NSW, Australia.	paul.gray1@health.nsw.gov.au	Kitching, A Richard/B-6947-2013	Kitching, A Richard/0000-0002-2713-2391; Saleem, Moin/0000-0002-9808-4518; Siggs, Owen/0000-0003-2840-4851; Gray, Paul/0000-0003-2057-3968	National Institutes of Health [R01 DK18381]; MRC [MR/R013942/1, G0800200, MR/L002418/1, MR/R003017/1, MR/P024297/1, G0800571] Funding Source: UKRI	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the grant R01 DK18381 from the National Institutes of Health to BH.	BOLTON WK, 1993, KIDNEY INT, V44, P294, DOI 10.1038/ki.1993.244; BOMBASSEI GJ, 1992, AM J IND MED, V21, P141, DOI 10.1002/ajim.4700210204; Brinkerhoff BT, 2016, MODERN PATHOL, V29, P637, DOI 10.1038/modpathol.2016.61; Chen LL, 2003, KIDNEY INT, V64, P2108, DOI 10.1046/j.1523-1755.2003.00332.x; Cui Z, 2016, J AUTOIMMUN, V70, P1, DOI 10.1016/j.jaut.2016.04.001; Deenick EK, 2010, IMMUNITY, V33, P241, DOI 10.1016/j.immuni.2010.07.015; DONAGHY M, 1983, LANCET, V2, P1390; Goodnow CC, 2007, CELL, V130, P25, DOI 10.1016/j.cell.2007.06.033; Gray PE, 2015, J CLIN IMMUNOL, V35, P604, DOI 10.1007/s10875-015-0194-9; GUNWAR S, 1991, AM J RESP CELL MOL, V5, P107, DOI 10.1165/ajrcmb/5.2.107; Hellmark T, 1999, J BIOL CHEM, V274, P25862, DOI 10.1074/jbc.274.36.25862; Hirayama K, 2008, CLIN EXP NEPHROL, V12, P339, DOI 10.1007/s10157-008-0051-8; Holbro A, 2015, HEMATOL-AM SOC HEMAT, P378, DOI 10.1182/asheducation-2015.1.378; Hou HA, 2007, J FORMOS MED ASSOC, V106, P779, DOI 10.1016/S0929-6646(08)60040-6; KALLURI R, 1994, P NATL ACAD SCI USA, V91, P6201, DOI 10.1073/pnas.91.13.6201; Kang JS, 2007, J BIOL CHEM, V282, P10670, DOI 10.1074/jbc.M611892200; Meyer D, 2013, MULT SCLER RELAT DIS, V2, P60, DOI 10.1016/j.msard.2012.07.002; Moratto D, 2011, BLOOD, V118, P1675, DOI 10.1182/blood-2010-11-319376; Netzer KO, 1999, J BIOL CHEM, V274, P11267, DOI 10.1074/jbc.274.16.11267; Ooi JD, 2017, NATURE, V545, P243, DOI 10.1038/nature22329; Ooi JD, 2013, J AM SOC NEPHROL, V24, P419, DOI 10.1681/ASN.2012070705; Pedchenko V, 2010, NEW ENGL J MED, V363, P343, DOI 10.1056/NEJMoa0910500; Persson U, 2004, NEPHROL DIAL TRANSPL, V19, P2030, DOI 10.1093/ndt/gfh355; Phelps RG, 1999, KIDNEY INT, V56, P1638, DOI 10.1046/j.1523-1755.1999.00720.x; Sado Y, 1998, KIDNEY INT, V53, P664, DOI 10.1046/j.1523-1755.1998.00795.x; Shetty HB, 2002, NEPHROL DIAL TRANSPL, V17, P2280, DOI 10.1093/ndt/17.12.2280; Singh P, 2011, CLIN NEPHROL, V76, P74, DOI 10.5414/CN106607; Wang KS, 2017, BLOOD, V130, P2889, DOI 10.1182/blood-2017-08-801001; Wang XP, 2005, J AM SOC NEPHROL, V16, P3563, DOI 10.1681/ASN.2005060670; Yanir AD, 2018, BIOL BLOOD MARROW TR, V24, P1643, DOI 10.1016/j.bbmt.2018.03.029	30	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 14	2019	10								2659	10.3389/fimmu.2019.02659	http://dx.doi.org/10.3389/fimmu.2019.02659			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JR1RM	31798588	Green Published, gold			2022-12-18	WOS:000499411100001
J	Meijerink, M; van den Broek, TJ; Dulos, R; Garthoff, J; Knippels, L; Knipping, K; Harthoorn, L; Houben, G; Verschuren, L; van Bilsen, J				Meijerink, Marjolein; van den Broek, Tim J.; Dulos, Remon; Garthoff, Jossie; Knippels, Leon; Knipping, Karen; Harthoorn, Lucien; Houben, Geert; Verschuren, Lars; van Bilsen, Jolanda			Network-Based Selection of Candidate Markers and Assays to Assess the Impact of Oral Immune Interventions on Gut Functions	FRONTIERS IN IMMUNOLOGY			English	Article						gut assays; biomarkers; safety assessment; efficacy assessment; systems biology; immune intervention; network databases	IRRITABLE-BOWEL-SYNDROME; SMOOTH-MUSCLE; INTESTINAL PERMEABILITY; BARRIER FUNCTION; MAST-CELLS; ULCERATIVE-COLITIS; TIGHT JUNCTIONS; IMMUNOTHERAPY; EXPRESSION; MOTILITY	To assess the safety and efficacy of oral immune interventions, it is important and required by regulation to assess the impact of those interventions not only on the immune system, but also on other organs such as the gut as the porte d'entree. Despite clear indications that the immune system interacts with several physiological functions of the gut, it is still unknown which pathways and molecules are crucial to assessing the impact of nutritional immune interventions on gut functioning. Here we used a network-based systems biology approach to clarify the molecular relationships between immune system and gut functioning and to identify crucial biomarkers to assess effects on gut functions upon nutritional immune interventions. First, the different gut functionalities were categorized based on literature and EFSA guidance documents. Moreover, an overview of the current assays and methods to measure gut function was generated. Secondly, gut-function related biological processes and adverse events were selected and subsequently linked to the physiological functions of the GI tract. Thirdly, database terms and annotations from the Gene ontology database and the Comparative Toxicogenomics Database (CTD) related to the previously selected gut-function related processes were selected. Next, database terms and annotations were used to identify the pathways and genes involved in those gut functionalities. In parallel, information from CTD was used to identify immune disease related genes. The resulting lists of both gut and immune function genes showed an overlap of 753 genes out of 1,296 gut-function related genes indicating the close gut-immune relationship. Using bioinformatics enrichment tools DAVID and Panther, the identified gut-immune markers were predicted to be involved in motility, barrier function, the digestion and absorption of vitamins and fat, regulation of the digestive system and gastric acid, and protection from injurious or allergenic material. Concluding, here we provide a promising systems biology approach to identify genes that help to clarify the relationships between immune system and gut functioning, with the aim to identify candidate biomarkers to monitor nutritional immune intervention assays for safety and efficacy in the general population. This knowledge helps to optimize future study designs to predict effects of nutritional immune intervention on gut functionalities.	[Meijerink, Marjolein; van den Broek, Tim J.; Dulos, Remon; Houben, Geert; Verschuren, Lars; van Bilsen, Jolanda] TNO, Zeist, Netherlands; [Garthoff, Jossie] Danone Food Safety Ctr, Utrecht, Netherlands; [Knippels, Leon; Knipping, Karen; Harthoorn, Lucien] Danone Nutricia Res, Utrecht, Netherlands; [Knippels, Leon; Knipping, Karen] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Utrecht, Netherlands	Netherlands Organization Applied Science Research; Danone Nutricia; Danone Nutricia; Utrecht University	Meijerink, M (corresponding author), TNO, Zeist, Netherlands.	marjolein.meijerink@tno.nl		Houben, Geert/0000-0001-7261-3912; Garthoff, Jossie A./0000-0003-1195-4494; van Bilsen, Jolanda/0000-0003-3439-5445	Dutch Governmental TNO Research Cooperation Funds; Danone Nutricia Research and Food Safety center	Dutch Governmental TNO Research Cooperation Funds; Danone Nutricia Research and Food Safety center(Danone Nutricia)	This research was financially supported by the Dutch Governmental TNO Research Cooperation Funds and Danone Nutricia Research and Food Safety center.	Adam B, 2005, ALIMENT PHARM THER, V22, P357, DOI 10.1111/j.1365-2036.2005.02572.x; Adriaanse MPM, 2013, ALIMENT PHARM THER, V37, P482, DOI 10.1111/apt.12194; Akiho H, 2002, AM J PHYSIOL-GASTR L, V282, pG226, DOI 10.1152/ajpgi.2002.282.2.G226; Akiho Hirotada, 2011, World J Gastrointest Pathophysiol, V2, P72; Akiho Hirotada, 2010, World J Gastrointest Pathophysiol, V1, P97, DOI 10.4291/wjgp.v1.i3.97; ALAM AN, 1994, GUT, V35, P1707, DOI 10.1136/gut.35.12.1707; Albers R, 2005, BRIT J NUTR, V94, P452, DOI 10.1079/BJN20051469; [Anonymous], 2011, EFSA J, V9, DOI 10.2903/j.efsa.2011.2424; [Anonymous], 2014, GUT MICROBES, V5, P1, DOI 10.4161/jkst.25530; Bertiaux-Vandaele N, 2011, AM J GASTROENTEROL, V106, P2165, DOI 10.1038/ajg.2011.257; Bettolli M, 2012, J PEDIATR SURG, V47, P1891, DOI 10.1016/j.jpedsurg.2012.05.006; Bittar A, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0046-8; Bresson JL, 2016, EFSA J, V14, DOI 10.2903/j.efsa.2016.4369; Buckley MJ, 1997, ITAL J GASTROENTEROL, V29, P495; Carbon S, 2019, NUCLEIC ACIDS RES, V47, pD330, DOI 10.1093/nar/gky1055; Caspi RR, 2008, NAT REV IMMUNOL, V8, P970, DOI 10.1038/nri2438; Chan KKW, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010341.pub2; Chassaing B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044328; Costa F, 2005, GUT, V54, P364, DOI 10.1136/gut.2004.043406; Costa F, 2003, DIGEST LIVER DIS, V35, P642, DOI 10.1016/S1590-8658(03)00381-5; Dalton JE, 2006, GASTROENTEROLOGY, V131, P818, DOI 10.1053/j.gastro.2006.06.003; Dey N, 2015, CELL, V163, P95, DOI 10.1016/j.cell.2015.08.059; El-Salhy M, 2012, DIGEST DIS SCI, V57, P873, DOI 10.1007/s10620-011-1948-8; Farhadi A, 2003, J CHROMATOGR B, V784, P145, DOI 10.1016/S1570-0232(02)00787-0; Farro G, 2016, NEUROGASTROENT MOTIL, V28, P934, DOI 10.1111/nmo.12796; Fasano A, 2012, ANN NY ACAD SCI, V1258, P25, DOI 10.1111/j.1749-6632.2012.06538.x; Furuta GT, 2005, AM J PHYSIOL-GASTR L, V289, pG890, DOI 10.1152/ajpgi.00015.2005; Gagnon J, 2011, LIFE SCI, V88, P212, DOI 10.1016/j.lfs.2010.11.010; Gasbarrini A, 2008, EUR REV MED PHARMACO, V12, P111; Gibbons SJ, 2009, NEUROGASTROENT MOTIL, V21, P85, DOI 10.1111/j.1365-2982.2008.01185.x; Grootjans J, 2010, WORLD J GASTRO SURG, V2, P61, DOI 10.4240/wjgs.v2.i3.61; Groschwitz KR, 2009, J ALLERGY CLIN IMMUN, V124, P3, DOI 10.1016/j.jaci.2009.05.038; Heron A, 2013, J NEUROIMMUNOL, V264, P1, DOI 10.1016/j.jneuroim.2013.09.018; Herrmann JR, 2016, AM J PHYSIOL-CELL PH, V310, pC423, DOI 10.1152/ajpcell.00348.2015; Honzawa Y, 2010, INFLAMM BOWEL DIS, V16, P2004, DOI 10.1002/ibd.21243; Hu WH, 2007, AM J PHYSIOL-CELL PH, V293, pC1991, DOI 10.1152/ajpcell.00300.2007; Huang HH, 2016, WORLD J GASTROENTERO, V22, P10140, DOI 10.3748/wjg.v22.i46.10140; Jacob C, 2005, J BIOL CHEM, V280, P31936, DOI 10.1074/jbc.M506338200; Jacob P, 2007, LANGENBECK ARCH SURG, V392, P267, DOI 10.1007/s00423-007-0168-3; James C, 2017, CURR OPIN ALLERGY CL, V17, P55, DOI 10.1097/ACI.0000000000000335; Johansson MEV, 2012, METHODS MOL BIOL, V842, P229, DOI 10.1007/978-1-61779-513-8_13; Johnston RL, 2009, DIGEST DIS SCI, V54, P2538, DOI 10.1007/s10620-008-0641-z; JONES SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI DOI 10.1016/j.jaci.2009.05.022; Kostadinova AI, 2013, PEDIAT ALLERG IMM-UK, V24, P633, DOI 10.1111/pai.12122; Krystel-Whittemore M, 2016, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00620; Lee H, 2013, J NEUROGASTROENTEROL, V19, P244, DOI 10.5056/jnm.2013.19.2.244; Lighton JRB, 2017, EUR J CLIN NUTR, V71, P301, DOI 10.1038/ejcn.2016.265; Liu HJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023072; Lotito A, 2017, NUTRIENTS, V9, DOI 10.3390/nu9030241; Lund P, 2012, EUR J CLIN NUTR, V66, P1059, DOI 10.1038/ejcn.2012.93; Lutgens LCHW, 2005, CANCER, V103, P191, DOI 10.1002/cncr.20733; Madsen KL, 1999, INFLAMM BOWEL DIS, V5, P262, DOI 10.1097/00054725-199911000-00004; Mankertz J, 2000, J CELL SCI, V113, P2085; Martin GR, 2005, AM J PHYSIOL-GASTR L, V288, pG431, DOI 10.1152/ajpgi.00242.2004; Meddings JB, 1999, AM J PHYSIOL-GASTR L, V276, pG951, DOI 10.1152/ajpgi.1999.276.4.G951; Meijerink M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00231; Michot JM, 2016, EUR J CANCER, V54, P139, DOI 10.1016/j.ejca.2015.11.016; Mobs C, 2012, J ALLERGY CLIN IMMUN, V130, P1108, DOI 10.1016/j.jaci.2012.07.056; Murch S, 2006, CURR OPIN GASTROEN, V22, P664, DOI 10.1097/01.mog.0000245546.18279.7e; Nikaki K, 2016, BEST PRACT RES CL GA, V30, P225, DOI 10.1016/j.bpg.2016.03.003; Ohama T, 2003, J BIOL CHEM, V278, P48794, DOI 10.1074/jbc.M310166200; Ohama T, 2008, J GASTROENTEROL, V43, P858, DOI 10.1007/s00535-008-2241-2; Ohama T, 2007, AM J PHYSIOL-GASTR L, V292, pG1429, DOI 10.1152/ajpgi.00315.2006; Oliveros J.C., 2007, INTERACTIVE TOOL COM; Panigrahi MK, 2013, J NEUROGASTROENTEROL, V19, P374, DOI 10.5056/jnm.2013.19.3.374; Parsons M. S., 2008, Endocrine Metabolic & Immune Disorders-Drug Targets, V8, P184, DOI 10.2174/187153008785700073; Peacock M, 2010, CLIN J AM SOC NEPHRO, V5, pS23, DOI 10.2215/CJN.05910809; Peck BCE, 2016, J BIOL CHEM, V291, P15975, DOI 10.1074/jbc.M116.733733; Peeters TL, 2005, GUT, V54, P1638, DOI 10.1136/gut.2004.062604; Pinier M, 2012, GASTROENTEROLOGY, V142, P316, DOI 10.1053/j.gastro.2011.10.038; Poole DP, 2010, NEUROGASTROENT MOTIL, V22, DOI 10.1111/j.1365-2982.2010.01487.x; Rasmussen SO, 2016, AM J PHYSIOL-GASTR L, V311, pG480, DOI 10.1152/ajpgi.00139.2016; Reed DE, 2014, NEUROGASTROENT MOTIL, V26, P1663, DOI 10.1111/nmo.12442; Reisinger KW, 2013, PEDIATR RES, V73, P209, DOI 10.1038/pr.2012.160; Relja B, 2010, ACAD EMERG MED, V17, P729, DOI 10.1111/j.1553-2712.2010.00792.x; Robinson AM, 2014, AM J PHYSIOL-GASTR L, V307, pG1115, DOI 10.1152/ajpgi.00174.2014; Romantsik O, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010638.pub2; Samedy L, 2018, AM J RESP CRIT CARE, V197; Sanders KM, 2012, NAT REV GASTRO HEPAT, V9, P633, DOI 10.1038/nrgastro.2012.168; Santos J, 2005, SCAND J GASTROENTERO, V40, P129, DOI 10.1080/00365520410009410; Sapone A, 2006, DIABETES, V55, P1443, DOI 10.2337/db05-1593; Singer P, 2016, NUTR CLIN PRACT, V31, P30, DOI 10.1177/0884533615622536; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Spain L, 2016, CANCER TREAT REV, V44, P51, DOI 10.1016/j.ctrv.2016.02.001; Sundaresan S, 2013, FASEB J, V27, P1191, DOI 10.1096/fj.12-217703; Tam H, 2016, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858; van Nieuwenhoven MA, 2000, CLIN SCI, V98, P349, DOI 10.1042/CS19990274; Vazquez-Ortiz M, 2016, PEDIAT ALLERG IMM-UK, V27, P117, DOI 10.1111/pai.12510; Vilz TO, 2012, JOVE-J VIS EXP, DOI 10.3791/4086; Volynets V, 2016, DIGEST DIS SCI, V61, P737, DOI 10.1007/s10620-015-3935-y; Wang LR, 2015, J IMMUNOL METHODS, V421, P44, DOI 10.1016/j.jim.2014.12.015; Wang Zhiming, 2009, Current Zoology, V55, P67; Wilcz-Villega E, 2014, NEUROGASTROENT MOTIL, V26, P316, DOI 10.1111/nmo.12262; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Yan GW, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008821; Yang M, 2017, AM J PHYSIOL-GASTR L, V312, pG367, DOI 10.1152/ajpgi.00232.2016; Yang ZH, 2013, AM J PHYSIOL-GASTR L, V304, pG381, DOI 10.1152/ajpgi.00357.2012; Yeung JP, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009542.pub2; Yu LCH, 2001, IMMUNOL REV, V179, P61, DOI 10.1034/j.1600-065X.2001.790107.x; Zhang JW, 2012, AM J MED SCI, V343, P199, DOI 10.1097/MAJ.0b013e31823aace6; Zhang L, 2016, J NEUROGASTROENTEROL, V22, P181, DOI 10.5056/jnm15137; Zheng XJ, 2013, METABOLOMICS, V9, P818, DOI 10.1007/s11306-013-0500-6; Zolotarevsky Y, 2002, GASTROENTEROLOGY, V123, P163, DOI 10.1053/gast.2002.34235	103	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 13	2019	10								2672	10.3389/fimmu.2019.02672	http://dx.doi.org/10.3389/fimmu.2019.02672			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JR1IZ	31798593	Green Published, gold			2022-12-18	WOS:000499388900001
J	Shekhar, S; Petersen, FC; Yang, X				Shekhar, Sudhanshu; Petersen, Fernanda Cristina; Yang, Xi			Editorial: Understanding and Exploiting Host-Commensal Interactions to Combat Pathogens	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						commensal; host; immunity; pathogen; vaccine; therapeutics	GUT MICROBIOTA; IMMUNITY		[Shekhar, Sudhanshu; Petersen, Fernanda Cristina] Univ Oslo, Inst Oral Biol, Fac Dent, Oslo, Norway; [Yang, Xi] Univ Manitoba, Max Rady Coll Med, Dept Immunol, Winnipeg, MB, Canada	University of Oslo; University of Manitoba	Shekhar, S (corresponding author), Univ Oslo, Inst Oral Biol, Fac Dent, Oslo, Norway.	sudhanshu.shekhar@odont.uio.no	Petersen, Fernanda Cristina/AAQ-1107-2020	Petersen, Fernanda Cristina/0000-0003-4649-247X; Yang, Xi/0000-0002-8831-7488	Norwegian Research Council [241011]; Canadian Institutes of Health Research [MOP-130423]	Norwegian Research Council(Research Council of NorwayEuropean Commission); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	SS and FP received the funding from the Norwegian Research Council (241011), whereas XY received financial support from the Canadian Institutes of Health Research (MOP-130423).	Abt MC, 2014, CURR OPIN IMMUNOL, V29, P16, DOI 10.1016/j.coi.2014.03.003; Carding Simon, 2015, Microbial Ecology in Health and Disease, V26, P26191, DOI 10.3402/mehd.v26.26191; Cerf-Bensussan N, 2010, NAT REV IMMUNOL, V10, P735, DOI 10.1038/nri2850; Gevers D, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001377; Henriques-Normark B, 2010, EXP CELL RES, V316, P1408, DOI 10.1016/j.yexcr.2010.03.003; Hugenholtz F, 2018, CELL MOL LIFE SCI, V75, P149, DOI 10.1007/s00018-017-2693-8; Kamada N, 2013, NAT REV IMMUNOL, V13, P321, DOI 10.1038/nri3430; Samuelson DR, 2015, FRONT MICROBIOL, V6, DOI [10.5389/fmicb.2015.01085, 10.3389/fmicb.2015.01085]; Turnbaugh PJ, 2007, NATURE, V449, P804, DOI 10.1038/nature06244	9	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 12	2019	10								2645	10.3389/fimmu.2019.02645	http://dx.doi.org/10.3389/fimmu.2019.02645			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JQ8NZ	31781125	gold, Green Published			2022-12-18	WOS:000499196500001
J	Mika, J; Kabacik, S; Badie, C; Polanska, J; Candeias, SM				Mika, Justyna; Kabacik, Sylwia; Badie, Christophe; Polanska, Joanna; Candeias, Serge M.			Germline DNA Retention in Murine and Human Rearranged T Cell Receptor Gene Coding Joints: Alternative Recombination Signal Sequences and V(D)J Recombinase Errors	FRONTIERS IN IMMUNOLOGY			English	Article						T cell receptor genes; V(D)J recombination; RSS; errors; translocations; lymphoid neoplasms	CHROMOSOMAL TRANSLOCATIONS; RAG; MECHANISMS; IDENTIFICATION; ORGANIZATION; CLEAVAGE; DATABASE; COMPLEX; REPAIR; BETA	The genes coding for the antigenic T cell receptor (TR) subunits are assembled in thymocytes from discrete V, D, and J genes by a site-specific recombination process. A tight control of this activity is required to prevent potentially detrimental recombination events. V, D, and J genes are flanked by semi-conserved nucleotide motives called recombination signal sequences (RSSs). V(D)J recombination is initiated by the precise introduction of a DNA double-strand break exactly at the border of the genes and their RSSs by the RAG recombinase. RSSs are therefore physically separated from the coding region of the genes before assembly of a rearranged TR gene. During a high throughput profiling of TRB genes in mice, we identified rearranged TRB genes in which part or all of a flanking RSS was retained in V-D or D-J coding joints. In some instances, this retention of germline DNA resulted from the use of an upstream alternative RSS. However, we also identified TRB sequences where retention of germline DNA occurred in the absence of alternative RSS, suggesting that RAG activity was mis-targeted during recombination. Similar events were also identified in human rearranged TRB and TRG genes. The use of alternative RSSs during V(D)J recombination illustrates the complexity of RAG-RSSs interactions during V(D)J recombination. While the frequency of errors resulting from mis-targeted RAG activity is very low, we believe that these RAG errors may be at the origin of oncogenic translocations and are a threat for genetic stability in developing lymphocytes.	[Mika, Justyna; Polanska, Joanna] Silesian Tech Univ, Data Min Div, Gliwice, Poland; [Kabacik, Sylwia; Badie, Christophe] Ctr Radiat Chem & Environm Hazards Ftibl Hlth Eng, Radiat Effects Dept, Canc Mech & Biomarkers Grp, Didcot, Oxon, England; [Candeias, Serge M.] Univ Grenoble Alpes, IRIG LCBM, CNRS, CEA, Grenoble, France	Silesian University of Technology; CEA; Centre National de la Recherche Scientifique (CNRS); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Candeias, SM (corresponding author), Univ Grenoble Alpes, IRIG LCBM, CNRS, CEA, Grenoble, France.	serge.candeias@cea.fr	Polanska, Joanna/H-4513-2013	Polanska, Joanna/0000-0001-8004-9864; Mika, Justyna/0000-0003-4615-784X; Candeias, Serge/0000-0003-2257-5529	European Commissions [DoReMi, European Atomic Energy Community's Seventh Framework Program (FP7/2007-2011)] [249689]; European Social Fund [POWR.03.02.00-00-I029]; Polish National Science Centre grant OPUS [2015/19/B/ST6/01736]; Silesian University of Technology [02/010/BK19/0143]	European Commissions [DoReMi, European Atomic Energy Community's Seventh Framework Program (FP7/2007-2011)]; European Social Fund(European Social Fund (ESF)); Polish National Science Centre grant OPUS; Silesian University of Technology	This work has been supported by the European Commissions [DoReMi, European Atomic Energy Community's Seventh Framework Program (FP7/2007-2011) under Grant Agreement No. 249689], in part through the European Social Fund grant POWR.03.02.00-00-I029 (JM), and the Polish National Science Centre grant OPUS no. 2015/19/B/ST6/01736 and Silesian University of Technology grant no. 02/010/BK19/0143 (JP). Calculations were carried out using infrastructure of GeCONiI (POIG.02.03.01-24-099/13).	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bailin T, 1999, MOL CELL BIOL, V19, P4664; Candeias S, 1996, J EXP MED, V184, P1919, DOI 10.1084/jem.184.5.1919; Candeias SM, 2017, CELL MOL LIFE SCI, V74, P4339, DOI 10.1007/s00018-017-2581-2; Chaumeil J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3231; Chaumeil J, 2013, CELL REP, V3, P359, DOI 10.1016/j.celrep.2013.01.024; Ciubotaru M, 2013, NUCLEIC ACIDS RES, V41, P2437, DOI 10.1093/nar/gks1294; Cowell LG, 2003, J EXP MED, V197, P207, DOI 10.1084/jem.20020250; Cowell LG, 2002, GENOME BIOL, V3; Deriano L, 2011, NATURE, V471, P119, DOI 10.1038/nature09755; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; Grundy GJ, 2009, MOL CELL, V35, P217, DOI 10.1016/j.molcel.2009.06.022; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; Kim MS, 2018, MOL CELL, V70, P358, DOI 10.1016/j.molcel.2018.03.008; Kim MS, 2015, NATURE, V518, P507, DOI 10.1038/nature14174; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; Le Noir S, 2012, BLOOD, V120, P3298, DOI 10.1182/blood-2012-04-425488; Lee AI, 2003, PLOS BIOL, V1, P56, DOI 10.1371/journal.pbio.0000001; Lee GS, 2004, CELL, V117, P171, DOI 10.1016/S0092-8674(04)00301-0; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; Lieber MR, 2016, NAT REV CANCER, V16, P387, DOI 10.1038/nrc.2016.40; LIEBER MR, 1988, P NATL ACAD SCI USA, V85, P8588, DOI 10.1073/pnas.85.22.8588; Marculescu R, 2006, DNA REPAIR, V5, P1246, DOI 10.1016/j.dnarep.2006.05.015; McGuire HM, 2018, IMMUNOL CELL BIOL, V96, P642, DOI 10.1111/imcb.12033; Merelli I, 2010, NUCLEIC ACIDS RES, V38, pW262, DOI 10.1093/nar/gkq391; NADEL B, 1995, J IMMUNOL, V155, P4322; Nadel B, 1997, MOL CELL BIOL, V17, P3768, DOI 10.1128/MCB.17.7.3768; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; RAMSDEN DA, 1994, NUCLEIC ACIDS RES, V22, P1785, DOI 10.1093/nar/22.10.1785; Ru H, 2018, NAT STRUCT MOL BIOL, V25, P732, DOI 10.1038/s41594-018-0098-5; Ru H, 2015, CELL, V163, P1138, DOI 10.1016/j.cell.2015.10.055; SAKANO H, 1979, NATURE, V280, P288, DOI 10.1038/280288a0; Schatz DG, 2011, ANNU REV GENET, V45, P167, DOI 10.1146/annurev-genet-110410-132552; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Touvrey C, 2006, IMMUNOBIOLOGY, V211, P741, DOI 10.1016/j.imbio.2006.04.001; Wilson EB, 1927, J AM STAT ASSOC, V22, P209, DOI 10.2307/2276774; Zar JH, 2014, BIOSTAT ANAL, V5	37	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 8	2019	10								2637	10.3389/fimmu.2019.02637	http://dx.doi.org/10.3389/fimmu.2019.02637			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JQ4SJ	31781122	Green Published, gold			2022-12-18	WOS:000498937200001
J	Zangari, P; Cifaldi, C; Di Cesare, S; Di Matteo, G; Chiriaco, M; Amodio, D; Cotugno, N; De Luca, M; Surace, C; Ladogana, S; Gardini, S; Merli, P; Algeri, M; Rossi, P; Palma, P; Cancrini, C; Finocchi, A				Zangari, Paola; Cifaldi, Cristina; Di Cesare, Silvia; Di Matteo, Gigliola; Chiriaco, Maria; Amodio, Donato; Cotugno, Nicola; De Luca, Maia; Surace, Cecilia; Ladogana, Saverio; Gardini, Simone; Merli, Pietro; Algeri, Mattia; Rossi, Paolo; Palma, Paolo; Cancrini, Caterina; Finocchi, Andrea			Novel Compound Heterozygous Mutations in IL-7 Receptor alpha Gene in a 15-Month-Old Girl Presenting With Thrombocytopenia, Normal T Cell Count and Maternal Engraftment	FRONTIERS IN IMMUNOLOGY			English	Article						SCID; IL-7R alpha gene; novel compound heterozygous mutations; atypical onset; maternal engraftment	SEVERE COMBINED IMMUNODEFICIENCY; OMENN-SYNDROME; RECEPTOR; MANIFESTATIONS; DEFICIENCY; EXPRESSION; INFANT	Patients with severe combined immunodeficiency (SCID) exhibit T lymphopenia and profound impairments in cellular and humoral immunity. IL-7 receptor alpha (IL-7R alpha) deficiency is a rare form of SCID that usually presents in the first months of life with severe and opportunistic infections, failure to thrive and high risk of mortality unless treated. Here, we reported an atypical and delayed onset of IL7R alpha-SCID in a 15-month-old girl presenting with thrombocytopenia. Immunological investigations showed a normal lymphocyte count with isolated CD4-penia, absence of naive T cells, marked hypergammaglobulinemia, and maternal T cell engraftment. Targeted next generation sequencing (NGS) revealed two novel compound heterozygous mutations in the IL-7R alpha gene: c.160T>C (p.S54P) and c.245G>T (p.C82F). The atypical onset and the unusual immunological phenotype expressed by our patient highlights the diagnostic challenge in the field of primary immunodeficiencies (PID) and in particular in SCID patients where prompt diagnosis and therapy greatly affects survival.	[Zangari, Paola; Cifaldi, Cristina; Di Cesare, Silvia; Di Matteo, Gigliola; Chiriaco, Maria; Amodio, Donato; De Luca, Maia; Rossi, Paolo; Cancrini, Caterina; Finocchi, Andrea] Bambino Gesu Pediat Hosp, IRCCS, Acad Dept Pediat, Unit Immune & Infect Dis, Rome, Italy; [Di Cesare, Silvia; Di Matteo, Gigliola; Amodio, Donato; Cotugno, Nicola; Rossi, Paolo; Cancrini, Caterina; Finocchi, Andrea] Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy; [Cotugno, Nicola; Palma, Paolo] Osped Pediat Bambino Gesu, IRCCS, Acad Dept Pediat, Res Unit Congenital & Perinatal Infect,Unit Immun, Rome, Italy; [Surace, Cecilia] Bambino Gesu Pediat Hosp, IRCCS, Lab Med Genet Unit, Rome, Italy; [Ladogana, Saverio] Casa Sollievo Sofferenza Hosp, IRCCS, Paediat Oncohaematol Unit, San Giovanni Rotondo, Italy; [Gardini, Simone] GenomeUp SRL, Rome, Italy; [Merli, Pietro; Algeri, Mattia] Bambino Gesu Pediat Hosp, IRCCS, Dept Pediat Hematol & Oncol, Rome, Italy	IRCCS Bambino Gesu; University of Rome Tor Vergata; IRCCS Bambino Gesu; IRCCS Bambino Gesu; IRCCS Casa Sollievo Della Sofferenza; IRCCS Bambino Gesu	Zangari, P; Di Matteo, G (corresponding author), Bambino Gesu Pediat Hosp, IRCCS, Acad Dept Pediat, Unit Immune & Infect Dis, Rome, Italy.; Di Matteo, G (corresponding author), Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy.	paola.zangari@opbg.net; di.matteo@med.uniroma2.it	Palma, Paolo/K-3379-2016; Zangari, Paola/AAA-6406-2020; Surace, Cecilia/AAA-9163-2020; Surace, Cecilia/AAA-8657-2020; Palma, Paolo/AAK-9275-2020; Algeri, Mattia/AAB-8965-2019; Amodio, Donato/AAA-9016-2019; Finocchi, Andrea/K-5926-2016; De Luca, Maia/AAI-1048-2019; DI CESARE, SILVIA/AAB-5754-2020; Merli, Pietro/K-3132-2018; DI MATTEO, GIGLIOLA/AAB-5968-2020	Surace, Cecilia/0000-0003-2344-6948; Palma, Paolo/0000-0002-3066-4719; Algeri, Mattia/0000-0002-6673-2664; Amodio, Donato/0000-0003-4550-3018; Finocchi, Andrea/0000-0003-0958-8536; De Luca, Maia/0000-0001-7549-3514; DI CESARE, SILVIA/0000-0002-9912-7997; Merli, Pietro/0000-0001-6426-4046; DI MATTEO, GIGLIOLA/0000-0001-8344-5635; Cotugno, Nicola/0000-0002-7748-1581	Italian TELETHON foundation [GGP15109]; Italian Ministero della Salute [NET-2011-02350069]; Ospedale Pediatrico Bambino Gesu Ricerca Corrente [201702P003966, RC2019.1.6_FINOCCHI]	Italian TELETHON foundation(Fondazione Telethon); Italian Ministero della Salute(Ministry of Health, Italy); Ospedale Pediatrico Bambino Gesu Ricerca Corrente	This work was funded by the Italian TELETHON foundation (grant number GGP15109), the Italian Ministero della Salute (NET-2011-02350069), and Ospedale Pediatrico Bambino Gesu Ricerca Corrente (201702P003966) and (RC2019.1.6_FINOCCHI).	Azizi G, 2016, CELL IMMUNOL, V310, P14, DOI 10.1016/j.cellimm.2016.08.012; Bayer DK, 2014, CLIN EXP IMMUNOL, V178, P459, DOI 10.1111/cei.12421; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Buckley RH, 2004, J CLIN INVEST, V114, P1409, DOI 10.1172/JCI200423571; Cifaldi C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00316; DeLano W.L., 2002, CCP4 NEWSL PROTEIN C, V40, P82; Fischer A, 2000, CLIN EXP IMMUNOL, V122, P143, DOI 10.1046/j.1365-2249.2000.01359.x; Giliani S, 2006, J PEDIATR-US, V148, P272, DOI 10.1016/j.jpeds.2005.10.004; Giliani S, 2005, IMMUNOL REV, V203, P110, DOI 10.1111/j.0105-2896.2005.00234.x; Khanolkar A, 2015, J ALLERGY CLIN IMMUN, V135, P1093, DOI 10.1016/j.jaci.2015.02.012; Leiding JW, 2015, ANN ALLERG ASTHMA IM, V115, P1, DOI 10.1016/j.anai.2015.04.024; Mazzucchelli R, 2007, NAT REV IMMUNOL, V7, P144, DOI 10.1038/nri2023; Muller SM, 2001, BLOOD, V98, P1847, DOI 10.1182/blood.V98.6.1847; Palmer K, 2007, J ALLERGY CLIN IMMUN, V120, P423, DOI 10.1016/j.jaci.2007.02.047; Pires DEV, 2014, BIOINFORMATICS, V30, P335, DOI 10.1093/bioinformatics/btt691; Renaux A, 2018, NUCLEIC ACIDS RES, V46, P2699, DOI 10.1093/nar/gky092; Wahlstrom J, 2017, J ALLERGY CLIN IMMUN, V139, P628, DOI 10.1016/j.jaci.2016.04.049; Zago CA, 2014, HUM IMMUNOL, V75, P662, DOI 10.1016/j.humimm.2014.04.006; Zaunders JJ, 2014, CYTOKINE GROWTH F R, V25, P391, DOI 10.1016/j.cytogfr.2014.07.012	19	0	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 30	2019	10								2471	10.3389/fimmu.2019.02471	http://dx.doi.org/10.3389/fimmu.2019.02471			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JM3ZO	31736942	Green Published, gold			2022-12-18	WOS:000496156800001
J	da Costa-Rocha, IA; Campi-Azevedo, AC; Peruhype-Magalhaes, V; Coelho-dos-Reis, JG; Fradico, JRB; Souza-Lopes, T; Reis, LR; Freire, LC; Costa-Pereira, C; Mambrini, JVD; Maia, MDD; de Lima, SMB; de Noronha, TG; Xavier, JR; Camacho, LAB; de Albuquerque, EM; Farias, RHG; de Castro, TD; Homma, A; Romano, APM; Domingues, CM; Martins, RD; Teixeira-Carvalho, A; Martins, OA				da Costa-Rocha, Ismael Artur; Campi-Azevedo, Ana Carolina; Peruhype-Magalhaes, Vanessa; Coelho-dos-Reis, Jordana Grazziela; Barbosa Fradico, Jordana Rodrigues; Souza-Lopes, Thalles; Reis, Laise Rodrigues; Freire, Larissa Chaves; Costa-Pereira, Christiane; de Melo Mambrini, Juliana Vaz; de Sousa Maia, Maria de Lourdes; Barbosa de Lima, Sheila Maria; de Noronha, Tatiana Guimaraes; Xavier, Janaina Reis; Bastos Camacho, Luiz Antonio; de Albuquerque, Elizabeth Maciel; Guedes Farias, Roberto Henrique; de Castro, Thalita da Matta; Homma, Akira; Martins Romano, Alessandro Pecego; Domingues, Carla Magda; Martins, Reinaldo de Menezes; Teixeira-Carvalho, Andrea; Martins-Filho, Olindo Assis			Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine (vol 10, 1211, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						Yellow Fever; 17DD vaccine; subdoses; neutralizing antibodies; cellular memory			[da Costa-Rocha, Ismael Artur; Campi-Azevedo, Ana Carolina; Peruhype-Magalhaes, Vanessa; Coelho-dos-Reis, Jordana Grazziela; Barbosa Fradico, Jordana Rodrigues; Souza-Lopes, Thalles; Reis, Laise Rodrigues; Freire, Larissa Chaves; Costa-Pereira, Christiane; Teixeira-Carvalho, Andrea; Martins-Filho, Olindo Assis] FIOCRUZ Minas, Fundacao Oswaldo Cruz, Inst Rene Rachou, Grp Integrado Pesquisas Biomarcadores, Belo Horizonte, MG, Brazil; [Coelho-dos-Reis, Jordana Grazziela] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Lab Virol Basica & Aplicada, Belo Horizonte, MG, Brazil; [de Melo Mambrini, Juliana Vaz] FIOCRUZ Minas, Fundacao Oswaldo Cruz, Inst Rene Rachou, Nucleo Estudos Saude Publ & Envelhecimento, Belo Horizonte, MG, Brazil; [de Sousa Maia, Maria de Lourdes; de Noronha, Tatiana Guimaraes; Xavier, Janaina Reis; de Albuquerque, Elizabeth Maciel; de Castro, Thalita da Matta; Homma, Akira; Martins, Reinaldo de Menezes] Fiocruz MS, Inst Tecnol Imunobiol Biomanguinhos, Assessoria Clin, Rio De Janeiro, Brazil; [Barbosa de Lima, Sheila Maria] Fiocruz MS, Inst Tecnol Imunobiol Biomanguinhos, Lab Tecnol Virol, Rio De Janeiro, Brazil; [Bastos Camacho, Luiz Antonio] Fiocruz MS, Escola Nacl Saude Publ, Dept Epidemiol & Metodos Quantitat Saude, Rio De Janeiro, Brazil; [Guedes Farias, Roberto Henrique] Inst Biol Exercito, Rio De Janeiro, Brazil; [Martins Romano, Alessandro Pecego; Domingues, Carla Magda] Minist Saude, Secretaria Vigilancia Saude, Dept Vigilancia Doencas Transmissiveis, Brasilia, DF, Brazil	Fundacao Oswaldo Cruz; Universidade Federal de Minas Gerais; Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz	Campi-Azevedo, AC; Martins, OA (corresponding author), FIOCRUZ Minas, Fundacao Oswaldo Cruz, Inst Rene Rachou, Grp Integrado Pesquisas Biomarcadores, Belo Horizonte, MG, Brazil.	campiazevedo@gmail.com; oassismartins@gmail.com	Martins-Filho, Olindo Assis/ABE-6278-2021; Campi-Azevedo, Ana Carolina/ABE-8321-2021; Souza-Lopes, Thalles/AAG-8975-2021; de Melo Mambrini, Juliana Vaz/AAO-9462-2021; Noronha, Tatiana/HDO-7158-2022; Coelho-dos-Reis, Jordana/HGU-6453-2022	Martins-Filho, Olindo Assis/0000-0002-5494-4889; Campi-Azevedo, Ana Carolina/0000-0001-6306-3605; Souza-Lopes, Thalles/0000-0003-2923-6335; Rodrigues Reis, Laise/0000-0003-0580-916X				da Costa-Rocha IA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01211	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 22	2019	10								2433	10.3389/fimmu.2019.02433	http://dx.doi.org/10.3389/fimmu.2019.02433			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JJ9AP	31695694	Green Published, gold			2022-12-18	WOS:000494443900001
J	Migotto, MA; Mardon, K; Orian, J; Weckbecker, G; Kneuer, R; Bhalla, R; Reutens, DC				Migotto, Mary-Anne; Mardon, Karine; Orian, Jacqueline; Weckbecker, Gisbert; Kneuer, Rainer; Bhalla, Rajiv; Reutens, David C.			Efficient Distribution of a Novel Zirconium-89 Labeled Anti-cd20 Antibody Following Subcutaneous and Intravenous Administration in Control and Experimental Autoimmune Encephalomyelitis-Variant Mice	FRONTIERS IN IMMUNOLOGY			English	Article						radiolabeling; positron emission tomography imaging; monoclonal antibody; neuroimaging; biodistribution; experimental autoimmune encephalomyelitis; subcutaneous; intravenous	REMITTING MULTIPLE-SCLEROSIS; B-CELL FOLLICLES; CORTICAL DEMYELINATION; OCRELIZUMAB; THERAPIES; DISEASE; TRAFFICKING; RITUXIMAB; TRANSPORT; ANTIGEN	Objective: To investigate the imaging and biodistribution of a novel zirconium-89 (Zr-89)-labeled mouse anti-cd20 monoclonal antibody (mAb) in control and experimental autoimmune encephalomyelitis (EAE) mice following subcutaneous (s. c.) and intravenous (i.v.) administration. Background: Anti-cd20-mediated B-cell depletion using mAbs is a promising therapy for multiple sclerosis. Recombinant human myelin oligodendrocyte glycoprotein (rhMOG)-induced EAE involves B-cell-mediated inflammation and demyelination in mice. Design/Methods: C57BL/6J mice (n = 39) were EAE-induced using rhMOG. On Day 14 post EAE induction, Zr-89-labeled-anti-cd20 mAb was injected in control and EAE mice in the right lower flank (s.c.) or tail vein (i.v.). Positron emission tomography/computed tomography (PET/CT) imaging and gamma counting (ex vivo) were performed on Days 1, 3, and 7 to quantify tracer accumulation in the major organs, lymphatics, and central nervous system (CNS). A preliminary study was conducted in healthy mice to elucidate full and early kinetics of the tracer that were subsequently applied in the EAE and control mice study. Results: Zr-89-labeled anti-cd20 mAb was effectively absorbed from s.c. and i.v. injection sites and distributed to all major organs in the EAE and control mice. There was a good correlation between in vivo PET/CT data and ex vivo quantification of biodistribution of the tracer. From gamma counting studies, initial tracer uptake within the lymphatic system was found to be higher in the draining lymph nodes (inguinal or subiliac and sciatic) following s.c. vs. i.v. administration; within the CNS a significantly higher tracer uptake was observed at 24 h in the cerebellum, cerebrum, and thoracic spinal cord (p < 0.05 for all) following s.c. vs. i.v. administration. Conclusions: The preclinical data suggest that initial tracer uptake was significantly higher in the draining lymph nodes (subiliac and sciatic) and parts of CNS (the cerebellum and cerebrum) when administered s.c. compared with i.v in EAE mice.	[Migotto, Mary-Anne; Mardon, Karine; Bhalla, Rajiv; Reutens, David C.] Univ Queensland, Ctr Adv Imaging, Brisbane, Qld, Australia; [Mardon, Karine] Univ Queensland, Natl Imaging Facil, Brisbane, Qld, Australia; [Orian, Jacqueline] La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem & Genet, Melbourne, Vic, Australia; [Weckbecker, Gisbert; Kneuer, Rainer] Novartis Pharma AG, Novartis Inst BioMed Res, Basel, Switzerland; [Bhalla, Rajiv; Reutens, David C.] ARC Training Ctr Innovat Biomed Imaging Technol, Brisbane, Qld, Australia	University of Queensland; University of Queensland; La Trobe University; Novartis	Bhalla, R; Reutens, DC (corresponding author), Univ Queensland, Ctr Adv Imaging, Brisbane, Qld, Australia.; Bhalla, R; Reutens, DC (corresponding author), ARC Training Ctr Innovat Biomed Imaging Technol, Brisbane, Qld, Australia.	r.bhalla@uq.edu.au; d.reutens@uq.edu.au	Mardon, Karine/B-8437-2016; Bhalla, Rajiv/P-5502-2014	Mardon, Karine/0000-0002-0889-9052; Bhalla, Rajiv/0000-0003-1421-3667	Novartis Pharma AG, Basel, Switzerland	Novartis Pharma AG, Basel, Switzerland	The study was funded by Novartis Pharma AG, Basel, Switzerland.	Agahozo MC, 2016, MULT SCLER RELAT DIS, V9, P110, DOI 10.1016/j.msard.2016.07.011; Antel J, 2012, ACTA NEUROPATHOL, V123, P627, DOI 10.1007/s00401-012-0953-0; Aung LL, 2015, MULT SCLER J, V21, P1131, DOI 10.1177/1352458514560923; Bar-Or A, 2008, ANN NEUROL, V63, P395, DOI 10.1002/ana.21363; Bar-Or A, 2018, NEUROLOGY, V90, pE1805, DOI 10.1212/WNL.0000000000005516; Baxter AG, 2007, NAT REV IMMUNOL, V7, P904, DOI 10.1038/nri2190; Caravagna C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22872-y; Dahlberg AM, 2014, MOL PHARMACEUT, V11, P496, DOI 10.1021/mp400464s; Dang PT, 2015, CURR TOP BEHAV NEURO, V26, P143, DOI 10.1007/7854_2015_378; de Vos AF, 2002, J IMMUNOL, V169, P5415, DOI 10.4049/jimmunol.169.10.5415; Gelfand JM, 2017, NEUROTHERAPEUTICS, V14, P835, DOI 10.1007/s13311-017-0557-4; Gonzalez SF, 2011, ANNU REV IMMUNOL, V29, P215, DOI 10.1146/annurev-immunol-031210-101255; Greenfield AL, 2018, ANN NEUROL, V83, P13, DOI 10.1002/ana.25119; Harp CT, 2010, EUR J IMMUNOL, V40, P2942, DOI 10.1002/eji.201040516; Hauser SL, 2017, NEW ENGL J MED, V376, P221, DOI 10.1056/NEJMoa1601277; Hauser SL, 2017, AM AC NEUR ANN M 18; Hauser SL, 2017, NEW ENGL J MED, V376, P1694, DOI 10.1056/NEJMc1702076; Hawker K, 2009, ANN NEUROL, V66, P460, DOI 10.1002/ana.21867; Jelcic I, 2018, CELL, V175, P85, DOI 10.1016/j.cell.2018.08.011; Kinzel S, 2016, CNS DRUGS, V30, P1137, DOI 10.1007/s40263-016-0396-6; Kutzelnigg A, 2005, BRAIN, V128, P2705, DOI 10.1093/brain/awh641; Kutzelnigg A, 2007, BRAIN PATHOL, V17, P38, DOI 10.1111/j.1750-3639.2006.00041.x; Lehmann-Horn K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102048; Lehmann-Horn K, 2013, THER ADV NEUROL DISO, V6, P161, DOI 10.1177/1756285612474333; Magliozzi R, 2007, BRAIN, V130, P1089, DOI 10.1093/brain/awm038; Merkler D, 2006, BRAIN, V129, P1972, DOI 10.1093/brain/awl135; Michel L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00636; Migotto MA., EUROPEAN COMMITTEE T; Mix E, 2010, PROG NEUROBIOL, V92, P386, DOI 10.1016/j.pneurobio.2010.06.005; Pacheco-Fernandez T, 2018, AM AC NEUR ANN M 27; Phelps ME, 2000, J NUCL MED, V41, P661; Rahmanzadeh R, 2018, ACTA NEUROL SCAND, V137, P544, DOI 10.1111/ane.12915; Sabatino JJ, 2019, CSH PERSPECT MED, V9, DOI 10.1101/cshperspect.a032037; Savelieva M., 2016, EUROPEAN COMMITTEE T; Serafini B, 2004, BRAIN PATHOL, V14, P164, DOI 10.1111/j.1750-3639.2004.tb00049.x; Smith P., 2016, EUROPEAN COMMITTEE T; Smith P, 2017, AM AC NEUR ANN M 18; Spijker S, 2011, NEUROMETHODS, V57, P13, DOI 10.1007/978-1-61779-111-6_2; Steinman L, 2005, TRENDS IMMUNOL, V26, P565, DOI 10.1016/j.it.2005.08.014; Stern JNH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008879; Thomas SN, 2015, CURR OPIN CHEM ENG, V7, P65, DOI 10.1016/j.coche.2014.11.003; Tillema JM, 2013, THER ADV NEUROL DISO, V6, P249, DOI 10.1177/1756285613478870; van Zwam M, 2009, J MOL MED, V87, P273, DOI 10.1007/s00109-008-0421-4; von Budingen HC, 2015, EUR NEUROL, V73, P238, DOI 10.1159/000377675; Vosjan MJWD, 2010, NAT PROTOC, V5, P739, DOI 10.1038/nprot.2010.13; Wang WR, 2012, DRUG METAB DISPOS, V40, P952, DOI 10.1124/dmd.111.043604; Wu F, 2012, PHARM RES-DORDR, V29, P1843, DOI 10.1007/s11095-012-0708-6	47	0	0	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 18	2019	10								2437	10.3389/fimmu.2019.02437	http://dx.doi.org/10.3389/fimmu.2019.02437			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JJ7GG	31681317	gold, Green Published			2022-12-18	WOS:000494321100001
J	Jiang, TF; Li, G; Xu, J; Gao, SN; Chen, X				Jiang, Tianfang; Li, Gen; Xu, Jun; Gao, Shane; Chen, Xu			The Challenge of the Pathogenesis of Parkinson's Disease: Is Autoimmunity the Culprit? (vol 9, 2047, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						autoimmunity; Parkinson's disease; alpha-synuclein; autoimmune diseases; neuroimmunology			[Jiang, Tianfang; Chen, Xu] Jiang Su Univ, Shanghai Peoples Hosp 8, Dept Neurol, Shanghai, Peoples R China; [Li, Gen] Shanghai Jiao Tong Univ, Rui Jin Hosp, Sch Med, Dept Neurol, Shanghai, Peoples R China; [Li, Gen] Shanghai Jiao Tong Univ, Rui Jin Hosp, Sch Med, Inst Neurol, Shanghai, Peoples R China; [Xu, Jun; Gao, Shane] Tongji Univ, Sch Med, East Hosp, Shanghai, Peoples R China	Jiangsu University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Tongji University	Chen, X (corresponding author), Jiang Su Univ, Shanghai Peoples Hosp 8, Dept Neurol, Shanghai, Peoples R China.; Gao, SN (corresponding author), Tongji Univ, Sch Med, East Hosp, Shanghai, Peoples R China.	gaoshan2009@tongji.edu.cn; cxwp65@163.com						Jiang TF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02047; Singh Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep17723	2	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 16	2019	10								2242	10.3389/fimmu.2019.02242	http://dx.doi.org/10.3389/fimmu.2019.02242			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JO1FC	31681258	Green Published, gold			2022-12-18	WOS:000497329900001
J	Carreras-Planella, L; Monguio-Tortajada, M; Borras, FE; Franquesa, M				Carreras-Planella, Laura; Monguio-Tortajada, Marta; Enric Borras, Francesc; Franquesa, Marcella			Immunomodulatory Effect of MSC on B Cells Is Independent of Secreted Extracellular Vesicles (vol 10, 1288, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						mesenchymal stromal cells; exosome; regulatory B cell; immunosuppression; memory B cell; Ev isolation			[Carreras-Planella, Laura; Monguio-Tortajada, Marta; Enric Borras, Francesc; Franquesa, Marcella] Germans Trias & Pujol Hlth Sci Res Inst, REMAR IVECAT Grp, Badalona, Spain; [Carreras-Planella, Laura; Enric Borras, Francesc] Autonomous Univ Barcelona, Dept Cell Biol Physiol & Immunol, Barcelona, Spain; [Monguio-Tortajada, Marta] Germans Trias & Pujol Hlth Sci Res Inst, ICREC Res Program, Badalona, Spain; [Enric Borras, Francesc; Franquesa, Marcella] Germans Trias & Pujol Univ Hosp, Serv Nephrol, Badalona, Spain	Autonomous University of Barcelona	Franquesa, M (corresponding author), Germans Trias & Pujol Hlth Sci Res Inst, REMAR IVECAT Grp, Badalona, Spain.; Franquesa, M (corresponding author), Germans Trias & Pujol Univ Hosp, Serv Nephrol, Badalona, Spain.	mfranquesa@igtp.cat	Borràs, Francesc E/P-2287-2017	Borràs, Francesc E/0000-0003-4038-1912	Fundacio La Marato de TV3 [201516-10, 201502-30]; SGR programme of Generalitat de Catalunya [2017-SGR-301]; ISCIII-REDinREN [RD16/0009]; Instituto Carlos III [PI17/00335]; ISCIII; European Regional Development Fund; Spanish Government [FPU17/01444]; PERIS from the Generalitat de Catalunya [SLT002/16/00234]; Health Department of the Catalan Government (Direccio General de Recerca i Innovacio, Department Salut, Generalitat de Catalunya); Catalan Health Department (Generalitat de Catalunya) [SLT002/16/00069]	Fundacio La Marato de TV3; SGR programme of Generalitat de Catalunya; ISCIII-REDinREN; Instituto Carlos III(Instituto de Salud Carlos III); ISCIII(Instituto de Salud Carlos III); European Regional Development Fund(European Commission); Spanish Government(Spanish GovernmentEuropean Commission); PERIS from the Generalitat de Catalunya; Health Department of the Catalan Government (Direccio General de Recerca i Innovacio, Department Salut, Generalitat de Catalunya)(Generalitat de Catalunya); Catalan Health Department (Generalitat de Catalunya)(Generalitat de Catalunya)	This work was supported in part by Fundacio La Marato de TV3 (201516-10, 201502-30), SGR programme of Generalitat de Catalunya (2017-SGR-301 REMAR Group), ISCIII-REDinREN (RD16/0009 Feder Funds) and Instituto Carlos III project PI17/00335, integrated in the National R+ D+ I and funded by the ISCIII and the European Regional Development Fund. LC-P by the Spanish Government FPU grant (Formacion de Personal Universitario, FPU17/01444); MM-T is sponsored by the PERIS (SLT002/16/00234) from the Generalitat de Catalunya; FB is a researcher from Fundacio Institut de Recerca en Ciencies de la Salut Germans Trias i Pujol, supported by the Health Department of the Catalan Government (Direccio General de Recerca i Innovacio, Department Salut, Generalitat de Catalunya) and MF is funded by the Catalan Health Department (Generalitat de Catalunya) contract PERIS (SLT002/16/00069); the authors also want to thank Miriam Moron-Font for the graphical art help.	CARRERASPLANELL, 2019, FRONT IMMUNOL, V10	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 15	2019	10								2413	10.3389/fimmu.2019.02413	http://dx.doi.org/10.3389/fimmu.2019.02413			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JO1DA	31660058	Green Published, gold			2022-12-18	WOS:000497324400002
J	Zimmer, J				Zimmer, Jacques			Alessandro Moretta and Transporter Associated With Antigen Processing (TAP) Deficiency: On Giant's Shoulders	FRONTIERS IN IMMUNOLOGY			English	Article						TAP deficiency; natural killer cells; HLA class I; cytotoxicity; antibodies	HLA-CLASS-I; NATURAL-KILLER-CELLS; NK CELLS; EXPRESSION; MUTATION; RECEPTORS; MOLECULES; GENE; REPERTOIRE; LYSIS	The laboratory hosting me for my Ph.D. described in 1994 the first human cases of TAP deficiency in two siblings with recurrent bacterial airway infections and a negative Human Leukocyte Antigen class I (HLA) serotyping. At this time, it became clear that natural killer (NK) cells interact with HLA class I molecules which inhibit them. Inhibitory receptors were postulated, and Alessandro Moretta was the first to generate monoclonal anti-human NK cell antibodies that bound to such molecules, which he characterized in detail (Killer Immunoglobulin-like receptors-KIR). Natural killer cells from healthy donors preferentially kill targets with absent HLA class I molecules ("missing self" concept), whereas we observed that the NK cells from the TAP-deficient patients were hypo-responsive and did not lyse the HLA class I-negative leukemia cell line K562. Moreover, they were not very active in antibody-dependent cellular cytotoxicity assays. To address the question if such NK cells would express KIR or not, my thesis supervisor requested the anti-KIR antibodies from Alessandro Moretta, who was kind enough to provide us generously with aliquots. It turned out that the NK cells from the TAP-deficient individuals expressed most of these inhibitory receptors normally. We then had the privilege to receive almost every new antibody generated in the Moretta lab and to complete the phenotypic studies of the NK cells from our patients. I had the great chance to meet Alessandro Moretta at several occasions. He deeply impressed me each time and strongly influenced my way of thinking.	[Zimmer, Jacques] Luxembourg Inst Hlth, Dept Infect & Immun, Lab Innate Cellular Immun & Chron Inflammat, Esch Sur Alzette, Luxembourg	Luxembourg Institute of Health	Zimmer, J (corresponding author), Luxembourg Inst Hlth, Dept Infect & Immun, Lab Innate Cellular Immun & Chron Inflammat, Esch Sur Alzette, Luxembourg.	jacques.zimmer@lih.lu		Zimmer, Jacques/0000-0002-7118-6944				Amand M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00699; Beziat V, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00507; Bottino C, 2000, HUM IMMUNOL, V61, P1, DOI 10.1016/S0198-8859(99)00162-7; De la Salle H, 2002, CLIN EXP IMMUNOL, V128, P525, DOI 10.1046/j.1365-2249.2002.01862.x; de la Salle H, 1999, J CLIN INVEST, V103, pR9, DOI 10.1172/JCI5687; DELASALLE H, 1994, SCIENCE, V265, P237, DOI 10.1126/science.7517574; Dogu F, 2006, PARASITOL INT, V55, P219, DOI 10.1016/j.parint.2006.02.003; DONATO L, 1995, J PEDIATR-US, V127, P895, DOI 10.1016/S0022-3476(95)70024-2; Espana A, 2010, ARCH DERMATOL, V146, P96, DOI 10.1001/archdermatol.2009.354; Freud AG, 2017, IMMUNITY, V47, P820, DOI 10.1016/j.immuni.2017.10.008; Gauthier L, 2019, CELL, V177, P1701, DOI 10.1016/j.cell.2019.04.041; Hanalioglu D, 2017, CLIN IMMUNOL, V178, P74, DOI 10.1016/j.clim.2017.01.011; Hanna J, 2005, BLOOD, V106, P3465, DOI 10.1182/blood-2005-03-0855; Hoglund P, 1998, EUR J IMMUNOL, V28, P370, DOI 10.1002/(SICI)1521-4141(199801)28:01<370::AID-IMMU370>3.0.CO;2-W; Konstantinou P, 2013, PEDIATR DERMATOL, V30, pE223, DOI 10.1111/pde.12151; Law-Ping-Man S, 2018, PEDIATR DERMATOL, V35, pE375, DOI 10.1111/pde.13676; Li SS, 2019, INT IMMUNOL, V31, P385, DOI 10.1093/intimm/dxz016; LJUNGGREN HG, 1994, P NATL ACAD SCI USA, V91, P6520, DOI 10.1073/pnas.91.14.6520; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; Matamoros N, 2001, CLIN EXP IMMUNOL, V125, P274, DOI 10.1046/j.1365-2249.2001.01595.x; Moins-Teisserenc HT, 1999, LANCET, V354, P1598, DOI 10.1016/S0140-6736(99)04206-3; MORETTA A, 1990, J EXP MED, V172, P1589, DOI 10.1084/jem.172.6.1589; MORETTA A, 1994, J EXP MED, V180, P545, DOI 10.1084/jem.180.2.545; Parissiadis A, 2005, BRIT J OPHTHALMOL, V89, P1661, DOI 10.1136/bjo.2005.078097; Pende D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01179; PERUSSIA B, 1987, NAT IMMUN CELL GROW, V6, P171; Poli A, 2018, TRENDS IMMUNOL, V39, P460, DOI 10.1016/j.it.2018.01.011; Ruggeri L, 2005, J IMMUNOTHER, V28, P175, DOI 10.1097/01.cji.0000161395.88959.1f; Sim MJW, 2019, P NATL ACAD SCI USA, V116, P12964, DOI 10.1073/pnas.1903781116; Sleiman M, 2014, J IMMUNOL, V192, P2602, DOI 10.4049/jimmunol.1302843; Souza-Fonseca-Guimaraes F, 2012, MOL MED, V18, P270, DOI 10.2119/molmed.2011.00201; Villa-Forte A, 2008, ARTHRITIS RHEUM-US, V58, P2579, DOI 10.1002/art.23675; Vitale M, 2002, BLOOD, V99, P1723, DOI 10.1182/blood.V99.5.1723; Vitale M, 1996, P NATL ACAD SCI USA, V93, P1453, DOI 10.1073/pnas.93.4.1453; Whitters D, 2013, THORAX, V68, P491, DOI 10.1136/thoraxjnl-2012-203138; Zimmer J, 2005, QJM-INT J MED, V98, P719, DOI 10.1093/qjmed/hci112; Zimmer J, 1998, J EXP MED, V187, P117, DOI 10.1084/jem.187.1.117; Zimmer J, 1999, EUR J IMMUNOL, V29, P1286, DOI 10.1002/(SICI)1521-4141(199904)29:04<1286::AID-IMMU1286>3.0.CO;2-L; Zimmer J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001033	39	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 15	2019	10								2404	10.3389/fimmu.2019.02404	http://dx.doi.org/10.3389/fimmu.2019.02404			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JO1CU	31681294	gold, Green Published			2022-12-18	WOS:000497323800002
